PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Cao, SB; Ma, TF; Ungerleider, N; Roberts, C; Kobelski, M; Jin, LJ; Concha, M; Wang, X; Baddoo, M; Nguyen, HM; Corey, E; Fazli, L; Ledet, E; Zhang, RB; Silberstein, JL; Zhang, WS; Zhang, K; Sartor, O; Dong, XS; Flemington, EK; Dong, Y				Cao, Subing; Ma, Tianfang; Ungerleider, Nathan; Roberts, Claire; Kobelski, Margaret; Jin, Lianjin; Concha, Monica; Wang, Xia; Baddoo, Melody; Nguyen, Holly M.; Corey, Eva; Fazli, Ladan; Ledet, Elisa; Zhang, Rubin; Silberstein, Jonathan L.; Zhang, Wensheng; Zhang, Kun; Sartor, Oliver; Dong, Xuesen; Flemington, Erik K.; Dong, Yan			Circular RNAs add diversity to androgen receptor isoform repertoire in castration-resistant prostate cancer	ONCOGENE			English	Article							TRANSLATION; EXPRESSION; PROGRESSION; LANDSCAPE	Deregulated expression of circular RNAs (circRNAs) is associated with various human diseases, including many types of cancer. Despite their growing links to cancer, there has been limited characterization of circRNAs in metastatic castration-resistant prostate cancer, the major cause of prostate cancer mortality. Here, through the analysis of an exome-capture RNA-seq dataset from 47 metastatic castration-resistant prostate cancer samples and ribodepletion and RNase R RNA-sequencing of patient-derived xenografts (PDXs) and cell models, we identified 13 circRNAs generated from the key prostate cancer driver gene-androgen receptor (AR). We validated and characterized the top four most abundant, clinically relevant AR circRNAs. Expression of these AR circRNAs was upregulated during castration-resistant progression of PDXs. The upregulation was not due to global increase of circRNA formation in these tumors. Instead, the levels of AR circRNAs correlated strongly with that of the linear AR transcripts (both AR and AR variants) in clinical samples and PDXs, indicating a transcriptional mechanism of regulation. In cultured cells, androgen suppressed the expression of these AR circRNAs and the linear AR transcripts, and the suppression was attenuated by an antiandrogen. Using nuclear/cytoplasmic fractionation and RNA in-situ hybridization assays, we demonstrated predominant cytoplasmic localization of these AR circRNAs, indicating likely cytoplasmic functions. Overall, this is the first comprehensive characterization of circRNAs arising from the AR gene. With greater resistance to exoribonuclease compared to the linear AR transcripts and detectability of AR circRNAs in patient plasma, these AR circRNAs may serve as surrogate circulating markers for AR/AR-variant expression and castration-resistant prostate cancer progression.	[Cao, Subing; Ma, Tianfang; Kobelski, Margaret; Jin, Lianjin; Dong, Yan] Tulane Univ, Sch Med, Dept Struct & Cellular Biol, Tulane Canc Ctr, 1430 Tulane Ave, New Orleans, LA 70112 USA; [Ungerleider, Nathan; Roberts, Claire; Concha, Monica; Wang, Xia; Baddoo, Melody; Flemington, Erik K.] Tulane Univ, Sch Med, Dept Pathol, Tulane Canc Ctr, New Orleans, LA 70112 USA; [Nguyen, Holly M.; Corey, Eva] Univ Washington, Dept Urol, Seattle, WA 98195 USA; [Fazli, Ladan; Dong, Xuesen] Univ British Columbia, Vancouver Prostate Ctr, Dept Urol Sci, Vancouver, BC, Canada; [Ledet, Elisa; Zhang, Rubin; Silberstein, Jonathan L.; Sartor, Oliver] Tulane Univ, Sch Med, Dept Med, Tulane Canc Ctr, New Orleans, LA 70112 USA; [Zhang, Wensheng; Zhang, Kun] Xavier Univ Louisiana, Dept Comp Sci, Bioinformat Facil, Xavier RCMI Ctr Canc Res, New Orleans, LA USA	Tulane University; Tulane University; University of Washington; University of Washington Seattle; University of British Columbia; Tulane University; Xavier University of Louisiana	Dong, Y (corresponding author), Tulane Univ, Sch Med, Dept Struct & Cellular Biol, Tulane Canc Ctr, 1430 Tulane Ave, New Orleans, LA 70112 USA.; Flemington, EK (corresponding author), Tulane Univ, Sch Med, Dept Pathol, Tulane Canc Ctr, New Orleans, LA 70112 USA.	erik@tulane.edu; ydong@tulane.edu	Dong, Xuesen/AGF-9228-2022	Dong, Yan/0000-0003-1622-5354; Ma, Tianfang/0000-0003-4161-882X; Kobelski, Margaret/0000-0002-8829-4562	National Institutes of Health [R01CA188609, R01AI101046, R01AI106676, P01CA214091]; PNW Prostate Cancer SPORE [P50CA097186, P01CA163227, RCMI 2U54MD007595, 5P20GM103424-17]; Department of Defense [W81XWH-15-10439, W81XWH-16-1-0317, W81XWH-16-1-0318]; Prostate Cancer Foundation; NATIONAL CANCER INSTITUTE [R01CA243793, R21CA236549, P01CA214091, P01CA163227, R01CA188609, P50CA097186] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI106676, R01AI101046] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103424] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [U54MD007595] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); PNW Prostate Cancer SPORE; Department of Defense(United States Department of Defense); Prostate Cancer Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	This work was supported by the following grants: the National Institutes of Health grants R01CA188609, R01AI101046, R01AI106676, P01CA214091, PNW Prostate Cancer SPORE P50CA097186, P01CA163227, RCMI 2U54MD007595, and 5P20GM103424-17; Department of Defense grants W81XWH-15-10439, W81XWH-16-1-0317, and W81XWH-16-1-0318; The Prostate Cancer Foundation. The Richard M. Lucas Foundation supported the development of the LuCaP models. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.	Abdelmohsen K, 2017, RNA BIOL, V14, P361, DOI 10.1080/15476286.2017.1279788; Abe N, 2015, SCI REP-UK, V5, DOI 10.1038/srep16435; Abe N, 2013, ANGEW CHEM INT EDIT, V52, P7004, DOI 10.1002/anie.201302044; Ashwal-Fluss R, 2014, MOL CELL, V56, P55, DOI 10.1016/j.molcel.2014.08.019; Bach DH, 2019, MOL THER-NUCL ACIDS, V16, P118, DOI 10.1016/j.omtn.2019.02.005; Burd CE, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001233; Burnstein KL, 2005, J CELL BIOCHEM, V95, P657, DOI 10.1002/jcb.20460; Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001; Cao SB, 2016, ENDOCR-RELAT CANCER, V23, pT199, DOI 10.1530/ERC-16-0298; Chen S, 2019, CANCER CELL, V176, pe822; Dai YQ, 2018, MED SCI MONITOR, V24, P3462, DOI 10.12659/MSM.908009; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dong Y, 2004, CANCER RES, V64, P19, DOI 10.1158/0008-5472.CAN-03-2789; Egan A, 2014, CANCER TREAT REV, V40, P426, DOI 10.1016/j.ctrv.2013.09.011; Hamilton MP, 2016, NEOPLASIA, V18, P356, DOI 10.1016/j.neo.2016.04.008; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Holdt LM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12429; Huang H, 2002, CRIT REV EUKAR GENE, V12, P193, DOI 10.1615/CritRevEukaryotGeneExpr.v12.i3.30; Jie ST, 2019, INT J BIOL MACROMOL, V122, P1235, DOI 10.1016/j.ijbiomac.2018.09.076; Kahn B, 2014, INT J BIOL SCI, V10, P588, DOI 10.7150/ijbs.8671; Kong Z, 2017, BIOCHEM BIOPH RES CO, V493, P1217, DOI 10.1016/j.bbrc.2017.07.162; Kotake Y, 2011, ONCOGENE, V30, P1956, DOI 10.1038/onc.2010.568; Kristensen LS, 2018, ONCOGENE, V37, P555, DOI 10.1038/onc.2017.361; Legnini I, 2017, MOL CELL, V66, P22, DOI 10.1016/j.molcel.2017.02.017; Li SL, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0629-7; Li Y, 2012, ONCOGENE, V31, P4759, DOI 10.1038/onc.2011.637; Li Y, 2015, CELL RES, V25, P981, DOI 10.1038/cr.2015.82; Li ZY, 2015, NAT STRUCT MOL BIOL, V22, P256, DOI 10.1038/nsmb.2959; Liang DM, 2014, GENE DEV, V28, P2233, DOI 10.1101/gad.251926.114; Markowski MC, 2017, JCO PRECIS ONCOL, V1; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Nyquist MD, 2013, P NATL ACAD SCI USA, V110, P17492, DOI 10.1073/pnas.1308587110; Pamudurti NR, 2017, MOL CELL, V66, P9, DOI 10.1016/j.molcel.2017.02.021; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Shand RL, 2006, CURR OPIN UROL, V16, P123, DOI 10.1097/01.mou.0000193384.39351.64; Ungerleider N, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-2865-7; Ungerleider N, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007206; Ungerleider NA, 2019, J VIROL, V93, DOI 10.1128/JVI.01952-18; Vo JN, 2019, CELL, V176, P869, DOI 10.1016/j.cell.2018.12.021; Xia QL, 2018, CELL PHYSIOL BIOCHEM, V50, P1903, DOI 10.1159/000494870; Xu HY, 2015, SCI REP-UK, V5, DOI 10.1038/srep12453; Yang Y, 2017, CELL RES, V27, P626, DOI 10.1038/cr.2017.31; Yuan X, 2014, ONCOGENE, V33, P2815, DOI 10.1038/onc.2013.235; Zhang Y, 2013, MOL CELL, V51, P792, DOI 10.1016/j.molcel.2013.08.017; Zheng QP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11215	45	23	24	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2019	38	45					7060	7072		10.1038/s41388-019-0947-7	http://dx.doi.org/10.1038/s41388-019-0947-7			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JL9XI	31409897	Green Accepted			2022-12-28	WOS:000495878400003
J	Zhang, YJ; Yan, LB; Zeng, J; Zhou, H; Liu, HR; Yu, G; Yao, WM; Chen, K; Ye, ZQ; Xu, H				Zhang, Yangjun; Yan, Libin; Zeng, Jin; Zhou, Hui; Liu, Haoran; Yu, Gan; Yao, Weimin; Chen, Ke; Ye, Zhangqun; Xu, Hua			Pan-cancer analysis of clinical relevance of alternative splicing events in 31 human cancers	ONCOGENE			English	Article							MESSENGER-RNA DECAY; FUNCTIONAL CONSEQUENCES; PROSTATE-CANCER; GENE; PROTEIN; TRANSCRIPTOME; REGULATOR; IMPACT; EXONS; PBRM1	Alternative splicing represents a critical posttranscriptional regulation of gene expression, which contributes to the protein complexity and mRNA processing. Defects of alternative splicing including genetic alteration and/or altered expression of both pre-mRNA and trans-acting factors give rise to many cancers. By integrally analyzing clinical data and splicing data from TCGA and SpliceSeq databases, a number of splicing events were found clinically relevant in tumor samples. Alternative splicing of KLK2 (KLK2_51239) was found as a potential inducement of nonsense-mediated mRNA decay and associated with poor survival in prostate cancer. Consensus K-means clustering analysis indicated that alternative splicing events could be potentially used for molecular subtype classification of cancers. By random forest survival algorithm, prognostic prediction signatures with well performances were constructed for 31 cancers by using survival-associated alternative splicing events. Furthermore, an online tool for visualization of Kaplan-Meier plots of splicing events in 31 cancers was explored. Briefly, alternative splicing was found of significant clinical relevance with cancers.	[Zhang, Yangjun; Yan, Libin; Zeng, Jin; Zhou, Hui; Liu, Haoran; Yu, Gan; Yao, Weimin; Chen, Ke; Ye, Zhangqun; Xu, Hua] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Urol, Wuhan 430030, Hubei, Peoples R China; [Zhang, Yangjun; Yan, Libin; Zeng, Jin; Zhou, Hui; Liu, Haoran; Yu, Gan; Yao, Weimin; Chen, Ke; Ye, Zhangqun; Xu, Hua] Inst Urol Hubei Prov, Wuhan 430030, Hubei, Peoples R China	Huazhong University of Science & Technology	Xu, H (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Urol, Wuhan 430030, Hubei, Peoples R China.; Xu, H (corresponding author), Inst Urol Hubei Prov, Wuhan 430030, Hubei, Peoples R China.	xuhuawhu@163.com	Zhou, Hui/AAV-2680-2020		National Natural Science Foundation of China [81702522, 81602236]; National Major Scientific and Technological Special Project for Significant New Drugs Development [2017ZX09304022]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Major Scientific and Technological Special Project for Significant New Drugs Development	The authors would like to thank Xudong Zhang of Genek Company for helpful advices of data processing. This work was funded by the National Natural Science Foundation of China (81702522, 81602236) and National Major Scientific and Technological Special Project for Significant New Drugs Development (2017ZX09304022).	Arzalluz-Luque A, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1496-z; Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-2; Baralle FE, 2017, NAT REV MOL CELL BIO, V18, P437, DOI 10.1038/nrm.2017.27; Bates DO, 2017, PHARMACOL REV, V69, P63, DOI 10.1124/pr.115.011239; Bauman JA, 2010, NUCLEIC ACIDS RES, V38, P8348, DOI 10.1093/nar/gkq731; Blencowe BJ, 2017, TRENDS BIOCHEM SCI, V42, P407, DOI 10.1016/j.tibs.2017.04.001; Chang YF, 2007, ANNU REV BIOCHEM, V76, P51, DOI 10.1146/annurev.biochem.76.050106.093909; Chen FJ, 2018, CLIN CANCER RES, V24, P2182, DOI 10.1158/1078-0432.CCR-17-3378; Climente-Gonzalez H, 2017, CELL REP, V20, P2215, DOI 10.1016/j.celrep.2017.08.012; da Costa PJ, 2017, INT J BIOCHEM CELL B, V91, P168, DOI 10.1016/j.biocel.2017.07.013; Davuluri RV, 2008, TRENDS GENET, V24, P167, DOI 10.1016/j.tig.2008.01.008; Eilertsen IA, 2019, INT J CANCER, V144, P841, DOI 10.1002/ijc.31809; Fu XD, 2014, NAT REV GENET, V15, P689, DOI 10.1038/nrg3778; Gao WH, 2017, P NATL ACAD SCI USA, V114, P1027, DOI 10.1073/pnas.1619726114; Ge Y, 2014, BIOESSAYS, V36, P236, DOI 10.1002/bies.201300156; Gerstberger S, 2014, NAT REV GENET, V15, P829, DOI 10.1038/nrg3813; Green RE, 2003, BIOINFORMATICS, V19, pi118, DOI 10.1093/bioinformatics/btg1015; Guo ZQ, 2016, CANCER CELL, V30, P474, DOI 10.1016/j.ccell.2016.08.003; Han L, 2015, CANCER CELL, V28, DOI 10.1016/j.ccell.2015.08.013; Han T, 2017, SCIENCE, V356, DOI 10.1126/science.aal3755; Hoadley KA, 2014, CELL, V158, P929, DOI 10.1016/j.cell.2014.06.049; Hogner A, 2018, UROL ONCOL, V36, pe1, DOI DOI 10.1016/J.UR0L0NC.2017.10.027; Hong SK, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/526341; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Jayasinghe RG, 2018, CELL REP, V23, P270, DOI 10.1016/j.celrep.2018.03.052; Kahles A, 2018, CANCER CELL, V34, P211, DOI 10.1016/j.ccell.2018.07.001; Kahles A, 2016, BIOINFORMATICS, V32, P1840, DOI 10.1093/bioinformatics/btw076; Karpinski P, 2017, EPIGENOMICS-UK, V9, P1341, DOI 10.2217/epi-2017-0070; Kelemen O, 2013, GENE, V514, P1, DOI 10.1016/j.gene.2012.07.083; Kim JY, 2015, J UROLOGY, V194, DOI 10.1016/j.juro.2015.04.114; Ladomery MR, 2007, CANCER LETT, V249, P133, DOI 10.1016/j.canlet.2006.08.015; Li H, 2018, MODERN PATHOL, V31, P198, DOI 10.1038/modpathol.2017.74; Li Y, 2017, CANCER LETT, V393, P40, DOI 10.1016/j.canlet.2017.02.016; Lindeboom RGH, 2016, NAT GENET, V48, P1112, DOI 10.1038/ng.3664; Lu JW, 2016, J CLIN INVEST, V126, P3058, DOI 10.1172/JCI86508; Miller MB, 2017, J NEUROCHEM, V140, P889, DOI 10.1111/jnc.13749; Nam RK, 2006, CLIN CANCER RES, V12, P6452, DOI 10.1158/1078-0432.CCR-06-1485; Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259; Popp MWL, 2013, ANNU REV GENET, V47, P139, DOI 10.1146/annurev-genet-111212-133424; Prinos P, 2011, NAT STRUCT MOL BIOL, V18, P673, DOI 10.1038/nsmb.2040; Ryan MC, 2012, BIOINFORMATICS, V28, P2385, DOI 10.1093/bioinformatics/bts452; Schafer Sebastian, 2015, Curr Protoc Hum Genet, V87, DOI 10.1002/0471142905.hg1116s87; Sebestyen E, 2016, GENOME RES, V26, P732, DOI 10.1101/gr.199935.115; Shum EY, 2016, CELL, V165, P382, DOI 10.1016/j.cell.2016.02.046; Stros M, 2007, CELL MOL LIFE SCI, V64, P2590, DOI 10.1007/s00018-007-7162-3; Tabrez SS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00370-5; Taliaferro JM, 2016, MOL CELL, V61, P821, DOI 10.1016/j.molcel.2016.01.020; Tian JB, 2019, NUCLEIC ACIDS RES, V47, pD909, DOI 10.1093/nar/gky954; Tien JF, 2017, NUCLEIC ACIDS RES, V45, P6698, DOI 10.1093/nar/gkx187; Tilgner H, 2018, GENOME RES, V28, P231, DOI 10.1101/gr.230516.117; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Traunmuller L, 2016, SCIENCE, V352, P982, DOI 10.1126/science.aaf2397; Ushijima T, 2017, CELL, V171, P1316, DOI 10.1016/j.cell.2017.10.018; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Vuong CK, 2016, NAT REV NEUROSCI, V17, P265, DOI 10.1038/nrn.2016.27; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Wollerton MC, 2004, MOL CELL, V13, P91, DOI 10.1016/S1097-2765(03)00502-1; Yan QH, 2015, P NATL ACAD SCI USA, V112, P3445, DOI 10.1073/pnas.1502849112; Ylitalo EB, 2017, EUR UROL, V72, pE147, DOI 10.1016/j.eururo.2017.07.043; Zhang Y, 2014, J NEUROSCI, V34, P11929, DOI [10.1523/JNEUROSCI.1860-14.2014, 10.11772/j.issn.1001-9081.2014.07.1929]	60	34	35	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2019	38	40					6678	6695		10.1038/s41388-019-0910-7	http://dx.doi.org/10.1038/s41388-019-0910-7			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JC0EY	31391553				2022-12-28	WOS:000488953500003
J	Wang, S; Wang, N; Yu, B; Cao, MX; Wang, YL; Guo, YQ; Zhang, YL; Zhang, P; Yu, X; Wang, SJ; Zeng, L; Liang, B; Li, X; Wu, YJ				Wang, Shuang; Wang, Ning; Yu, Bin; Cao, Mingxing; Wang, Yanlong; Guo, Yuqi; Zhang, Yanli; Zhang, Ping; Yu, Xiao; Wang, Shujing; Zeng, Li; Liang, Bin; Li, Xin; Wu, Yingjie			Circulating IGF-1 promotes prostate adenocarcinoma via FOXO3A/BIM signaling in a double-transgenic mouse model	ONCOGENE			English	Article							CANCER CELLS; TRANSCRIPTIONAL REGULATION; GROWTH-FACTORS; I RECEPTOR; EXPRESSION; APOPTOSIS; BIM; PROGRESSION; RISK; FOXO	High circulating insulin-like growth factor-1 (IGF-1) levels increase the risk of prostate cancer. However, whether circulating IGF-1 levels directly aggravate prostate cancer remains elusive. In this study, we crossed a transgenic prostate adenocarcinoma mouse model, Hi-Myc mice, with a liver-specific IGF-1 transgenic mouse model (HIT) to increase their circulating IGF-1 levels to investigate the impact of the elevated circulating IGF-1 on prostate cancer development in vivo. The Hi-Myc/HIT mice had increased incidence and invasiveness of prostate cancer. IGF-1 elevation led to the accumulation of FOXO3A in the cytosol of prostate tumor cells and downregulation of its target gene Bien, which resulted in the apoptosis inhibition and prostate cancer overgrowth. The differential expressions of IGF-1R, FOXO3A, and BIM in the benign versus malignant prostate tissues supported a negative association between the FOXO3A/BIM axis and IGF-1R expression in human prostate adenocarcinoma. Our findings suggest that targeting the IGF-1/FOXO3A/BIM signaling axis could be an attractive strategy for prostate cancer prevention or treatment.	[Wang, Shuang; Wang, Ning; Yu, Bin; Cao, Mingxing; Zeng, Li; Wu, Yingjie] Dalian Med Univ, Inst Genome Engn Anim Models Human Dis, Dalian 116044, Liaoning, Peoples R China; [Wang, Shuang; Wang, Ning; Yu, Bin; Cao, Mingxing; Zeng, Li; Wu, Yingjie] Dalian Med Univ, Natl Ctr Genet Engn Anim Models Int Res, Dalian 116044, Liaoning, Peoples R China; [Wang, Shuang; Wang, Ning; Wu, Yingjie] Dalian Med Univ, Coll Integrat Med, Dalian 116044, Liaoning, Peoples R China; [Cao, Mingxing] Mudanjiang Normal Univ, Coll Life Sci & Technol, Mudanjiang 157011, Heilongjiang, Peoples R China; [Wang, Yanlong] Dalian Med Univ, Dalian Municipal Cent Hosp, Dept Urol Surg, Dalian 116033, Liaoning, Peoples R China; [Guo, Yuqi; Zhang, Yanli; Li, Xin; Wu, Yingjie] NYU, Coll Dent, Dept Basic Sci & Craniofacial Biol, New York, NY 10010 USA; [Zhang, Ping] Dalian Med Univ, Affiliated Hosp 2, Dept Endocrinol, Dalian 116027, Liaoning, Peoples R China; [Yu, Xiao] Dalian Med Univ, Dept Pathol, Dalian 116044, Liaoning, Peoples R China; [Wang, Shujing] Dalian Med Univ, Dept Biochem & Mol Biol, Dalian 116044, Liaoning, Peoples R China; [Liang, Bin] Chinese Acad Sci, Kunming Inst Zool, CAS Ctr Excellence Anim Evolut & Genet, Key Lab Anim Models & Human Dis Mech,Chinese Acad, Kunming 650223, Yunnan, Peoples R China; [Li, Xin] NYU, Langone Med Ctr, Dept Urol, New York, NY 10016 USA; [Li, Xin] NYU, Langone Med Ctr, Perlmutter Canc Inst, New York, NY 10016 USA; [Wu, Yingjie] Icahn Sch Med Mt Sinai, Dept Med, Div Endocrinol Diabet & Bone Dis, New York, NY 10029 USA	Dalian Medical University; Dalian Medical University; Dalian Medical University; Mudanjiang Normal University; Dalian Medical University; New York University; Dalian Medical University; Dalian Medical University; Dalian Medical University; Chinese Academy of Sciences; Kunming Institute of Zoology; New York University; NYU Langone Medical Center; New York University; NYU Langone Medical Center; Icahn School of Medicine at Mount Sinai	Wu, YJ (corresponding author), Dalian Med Univ, Inst Genome Engn Anim Models Human Dis, Dalian 116044, Liaoning, Peoples R China.; Wu, YJ (corresponding author), Dalian Med Univ, Natl Ctr Genet Engn Anim Models Int Res, Dalian 116044, Liaoning, Peoples R China.; Wu, YJ (corresponding author), Dalian Med Univ, Coll Integrat Med, Dalian 116044, Liaoning, Peoples R China.; Li, X; Wu, YJ (corresponding author), NYU, Coll Dent, Dept Basic Sci & Craniofacial Biol, New York, NY 10010 USA.; Liang, B (corresponding author), Chinese Acad Sci, Kunming Inst Zool, CAS Ctr Excellence Anim Evolut & Genet, Key Lab Anim Models & Human Dis Mech,Chinese Acad, Kunming 650223, Yunnan, Peoples R China.; Li, X (corresponding author), NYU, Langone Med Ctr, Dept Urol, New York, NY 10016 USA.; Li, X (corresponding author), NYU, Langone Med Ctr, Perlmutter Canc Inst, New York, NY 10016 USA.; Wu, YJ (corresponding author), Icahn Sch Med Mt Sinai, Dept Med, Div Endocrinol Diabet & Bone Dis, New York, NY 10029 USA.	liangb@mail.kiz.ac.cn; xl15@nyu.edu; yingjiewu@dmu.edu.cn		Li, Xin/0000-0002-7414-5734	Nature Science Foundation of China (NSFC) [81471000, 31871163]; Ministry of Science and Technology [2014DFA32120]	Nature Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea)	This study was supported by the Nature Science Foundation of China (NSFC) No. 81471000, No. 31871163, and Ministry of Science and Technology (No. 2014DFA32120) to Yingjie Wu.	Ali TZ, 2008, AM J SURG PATHOL, V32, P1890, DOI 10.1097/PAS.0b013e31817ce994; Bonilla C, 2016, INT J CANCER, V139, P1520, DOI 10.1002/ijc.30206; Butler AA, 1998, CANCER RES, V58, P3021; Cannata D, 2010, ENDOCRINOLOGY, V151, P5751, DOI 10.1210/en.2010-0792; Cao Y, 2015, INT J CANCER, V136, P2418, DOI 10.1002/ijc.29295; Dansen TB, 2008, TRENDS CELL BIOL, V18, P421, DOI 10.1016/j.tcb.2008.07.004; Das TP, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.403; Dey P, 2014, ONCOGENE, V33, P4213, DOI 10.1038/onc.2013.384; DiGiovanni J, 2000, P NATL ACAD SCI USA, V97, P3455, DOI 10.1073/pnas.97.7.3455; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Essafi A, 2005, ONCOGENE, V24, P2317, DOI 10.1038/sj.onc.1208421; Grabowska MM, 2014, CANCER METAST REV, V33, P377, DOI 10.1007/s10555-013-9487-8; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross DN, 2009, CURR DIABETES REP, V9, P208, DOI 10.1007/s11892-009-0034-5; Imada K, 2017, PROSTATE, V77, P145, DOI 10.1002/pros.23254; Jin RJ, 2014, CANCER RES, V74, P2763, DOI 10.1158/0008-5472.CAN-13-2543; Kaplan-Lefko PJ, 2008, ONCOGENE, V27, P2868, DOI 10.1038/sj.onc.1210943; Le Roith Derek, 2003, Exp Diabesity Res, V4, P205, DOI 10.1155/EDR.2003.205; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Lynch RL, 2005, MOL CANCER RES, V3, P163, DOI 10.1158/1541-7786.MCR-04-0163; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; Nandana S, 2010, PROSTATE, V70, P591, DOI 10.1002/pros.21093; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Osuka S, 2013, STEM CELLS, V31, P627, DOI 10.1002/stem.1328; Powell WC, 2003, CURR DRUG TARGETS, V4, P263, DOI 10.2174/1389450033491145; Rinner O, 2007, NAT BIOTECHNOL, V25, P345, DOI 10.1038/nbt1289; Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001; Sarwar S, 2017, PROSTATE CANCER, V2017, DOI 10.1155/2017/5687212; Shappell SB, 2004, CANCER RES, V64, P2270, DOI 10.1158/0008-5472.CAN-03-0946; Shariat SF, 2000, UROLOGY, V56, P423, DOI 10.1016/S0090-4295(00)00648-8; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Stan SD, 2008, CANCER RES, V68, P7661, DOI 10.1158/0008-5472.CAN-08-1510; Sun JJ, 2018, BBA-MOL BASIS DIS, V1864, P1873, DOI 10.1016/j.bbadis.2018.03.004; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Sutherland BW, 2008, CANCER RES, V68, P3495, DOI 10.1158/0008-5472.CAN-07-6531; Travis RC, 2016, CANCER RES, V76, P2288, DOI 10.1158/0008-5472.CAN-15-1551; Wang X, 2009, NATURE, V461, P495, DOI 10.1038/nature08361; Weiss JM, 2007, INT J CANCER, V121, P2267, DOI 10.1002/ijc.22921; Wu YJ, 2009, ENDOCRINOLOGY, V150, P4395, DOI 10.1210/en.2009-0272; Wu YP, 2002, CANCER RES, V62, P1030; Yakar S, 2004, NOVART FDN SYMP, V262; Yakar S, 2004, NOVART FDN SYMP, V262, P9; Yakar Shoshana, 2004, Novartis Found Symp, V262, P3; Yang L, 2005, J BIOL CHEM, V280, P33558, DOI 10.1074/jbc.M504461200	45	13	13	2	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2019	38	36					6338	6353		10.1038/s41388-019-0880-9	http://dx.doi.org/10.1038/s41388-019-0880-9			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IX6EX	31312023				2022-12-28	WOS:000485776800002
J	Wei, T; Weiler, SME; Toth, M; Sticht, C; Lutz, T; Thomann, S; De La Torre, C; Straub, B; Merker, S; Ruppert, T; Marquardt, J; Singer, S; Gretz, N; Schirmacher, P; Breuhahn, K				Wei, Teng; Weiler, Sofia Maria Elisabeth; Toth, Marcell; Sticht, Carsten; Lutz, Teresa; Thomann, Stefan; De La Torre, Carolina; Straub, Beate; Merker, Sabine; Ruppert, Thomas; Marquardt, Jens; Singer, Stephan; Gretz, Norbert; Schirmacher, Peter; Breuhahn, Kai			YAP-dependent induction of UHMK1 supports nuclear enrichment of the oncogene MYBL2 and proliferation in liver cancer cells	ONCOGENE			English	Article							YES-ASSOCIATED PROTEIN; ORGAN SIZE CONTROL; HIPPO PATHWAY; EXPRESSION; KINASE; GENE; KIS; HOMEOSTASIS; INSTABILITY; ACTIVATION	The oncogene yes-associated protein (YAP) is a key modifier of liver homeostasis and regulates mitosis in hepatocytes as well as in malignantly transformed cells. However, the question of how YAP supports cell proliferation in hepatocellular carcinoma (HCC) is not well understood. Here we identified U2AF momology motif kinase 1 (UHMK1) as a direct transcriptional target of YAP and the transcription factor forkhead box M1 (FOXM1), which supports HCC cell proliferation but not migration. Indeed, UHMK1 stimulates the expression of genes that are specific for cell cycle regulation and which are known downstream effectors of YAP. By using BioID labeling and mass spectrometry, the dimerization partner, RB-like, E2F and multi-vulval class B (DREAM) complex constituent MYB proto-oncogene like 2 (MYBL2, B-MYB) was identified as a direct UHMK1 interaction partner. Like YAP, UHMK1 stimulates nuclear enrichment of MYBL2, which is associated HCC cell proliferation and the expression of the cell cycle regulators CCNB1, CCNB2, KIF20A, and MAD2L1. The association between YAP, UHMK1, MYBL2, and proliferation was confirmed in YAP(s127A)-transgenic mice and human HCC tissues. In summary, we provide a model by which YAP supports cell proliferation through the induction of important cell cycle regulators in a UHMK1- and MYBL2-dependent manner.	[Wei, Teng; Weiler, Sofia Maria Elisabeth; Toth, Marcell; Lutz, Teresa; Thomann, Stefan; Schirmacher, Peter; Breuhahn, Kai] Univ Hosp Heidelberg, Inst Pathol, Heidelberg, Germany; [Sticht, Carsten; De La Torre, Carolina; Gretz, Norbert] Heidelberg Univ, Med Fac Mannheim, Med Res Ctr, Mannheim, Germany; [Straub, Beate] Johannes Gutenberg Univ Mainz, Inst Pathol, Mainz, Germany; [Merker, Sabine; Ruppert, Thomas] Univ Heidelberg ZMBH, DKFZ ZMBH Alliance, Zentrum Mol Biol, Heidelberg, Germany; [Marquardt, Jens] Johannes Gutenberg Univ Mainz, Dept Med 1, Mainz, Germany; [Singer, Stephan] Univ Med Greifswald, Inst Pathol, Greifswald, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Johannes Gutenberg University of Mainz; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Johannes Gutenberg University of Mainz; Greifswald Medical School	Breuhahn, K (corresponding author), Univ Hosp Heidelberg, Inst Pathol, Heidelberg, Germany.	kai.breuhahn@med.uni-heidelberg.de	Ruppert, Thomas/AAC-2467-2021	Ruppert, Thomas/0000-0001-9152-2266; Thomann, Stefan/0000-0002-3500-0014; wei, teng/0000-0001-7560-2848	German Cancer Aid (Deutsche Krebshilfe) [DKH 111524]; China Scholarship Council/CSC; German Research Foundation [MA 4443/2-2]; Volkswagen Foundation (Lichtenberg program);  [SFB/TR 209];  [SPP1782/2]	German Cancer Aid (Deutsche Krebshilfe)(Deutsche Krebshilfe); China Scholarship Council/CSC(China Scholarship Council); German Research Foundation(German Research Foundation (DFG)); Volkswagen Foundation (Lichtenberg program); ; 	We thank M. Bissinger and J. Schmitt for excellent technical assistance, Dr. A. Ori for providing us with the BirA vector, as well as T. R. Brummelkamp and F. D. Camargo for providing Col1A1-YAPS127A transgenic mice. Tissue samples were provided by the tissue bank of the National Center of Tumor Diseases (Heidelberg, Germany) in accordance with the regulations of the tissue bank and the approval of the Ethics Committee of Heidelberg University. We also thank the Center of Model System and Comparative Pathology (CMCP; Dr. F. Lasitschka, Dr. T. Poth) and H. Conrad for their support. This study was supported by a grant from the German Cancer Aid (Deutsche Krebshilfe/Dr. Mildred Scheel Stiftung, to K.B., DKH 111524), the SFB/TR 209 "Liver Cancer" (to K.B., S.S., and P.S.), the priority program SPP1782/2 (to K. B.), and the China Scholarship Council/CSC (to T.W.). J.U.M. is supported by grants from the German Research Foundation (MA 4443/2-2) and the Volkswagen Foundation (Lichtenberg program).	Ally A, 2017, CELL, V169, P1327, DOI 10.1016/j.cell.2017.05.046; Benhamouche S, 2010, GENE DEV, V24, P1718, DOI 10.1101/gad.1938710; Bieche I, 2003, MOL BRAIN RES, V114, P55, DOI 10.1016/S0169-328X(03)00132-3; Boehm M, 2002, EMBO J, V21, P3390, DOI 10.1093/emboj/cdf343; Calvisi DF, 2011, HEPATOLOGY, V53, P1226, DOI 10.1002/hep.24174; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Eisinger-Mathason TSK, 2015, P NATL ACAD SCI USA, V112, pE3402, DOI 10.1073/pnas.1420005112; Guan Z, 2018, CURR RES TRANSL MED, V66, P27, DOI 10.1016/j.retram.2017.11.002; Guiley KZ, 2015, GENE DEV, V29, P961, DOI 10.1101/gad.257568.114; Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161; Langenickel TH, 2008, J CLIN INVEST, V118, P3848, DOI 10.1172/JCI33206; Manceau V, 2006, FEBS J, V273, P577, DOI 10.1111/j.1742-4658.2005.05091.x; Manceau V, 2008, J MOL BIOL, V381, P748, DOI 10.1016/j.jmb.2008.06.026; Manceau V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043946; MAUCUER A, 1995, P NATL ACAD SCI USA, V92, P3100, DOI 10.1073/pnas.92.8.3100; Panciera T, 2017, NAT REV MOL CELL BIO, V18, P758, DOI 10.1038/nrm.2017.87; Petrovic V, 2008, J BIOL CHEM, V283, P453, DOI 10.1074/jbc.M705792200; Qiao YT, 2017, CELL REP, V19, P1495, DOI 10.1016/j.celrep.2017.04.075; Roux KJ, 2012, J CELL BIOL, V196, P801, DOI 10.1083/jcb.201112098; Sadasivam S, 2013, NAT REV CANCER, V13, P585, DOI 10.1038/nrc3556; Schopp IM, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15690; Song H, 2010, P NATL ACAD SCI USA, V107, P1431, DOI 10.1073/pnas.0911409107; Tschaharganeh DF, 2013, GASTROENTEROLOGY, V144, P1530, DOI 10.1053/j.gastro.2013.02.009; Weiler SME, 2017, GASTROENTEROLOGY, V152, P2037, DOI 10.1053/j.gastro.2017.02.018; Xu MZ, 2011, ONCOGENE, V30, P1229, DOI 10.1038/onc.2010.504; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408	29	33	35	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2019	38	27					5541	5550		10.1038/s41388-019-0801-y	http://dx.doi.org/10.1038/s41388-019-0801-y			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IG5KR	30936457				2022-12-28	WOS:000473842500015
J	Dayan, A; Fleminger, G; Ashur-Fabian, O				Dayan, Avraham; Fleminger, Gideon; Ashur-Fabian, Osnat			Targeting the Achilles' heel of cancer cells via integrin-mediated delivery of ROS-generating dihydrolipoamide dehydrogenase	ONCOGENE			English	Article							ALPHA-KETOGLUTARATE DEHYDROGENASE; LIPOAMIDE DEHYDROGENASE; COMPLEX; STRATEGIES; SUBSTRATE; SEQUENCE; SUBUNIT; IMPORT; STRAIN	Cancer cells frequently exhibit higher levels of reactive oxygen species (ROS) than normal cells and when ROS levels increase beyond a cellular tolerability threshold, cancer cell death is enhanced. The mitochondrial dihydrolipoamide dehydrogenase (DLDH) is an enzyme which produces ROS in association with its oxidoreductive activity and may be thus utilized as an exogenous anticancer agent. As cancer cells often overexpress integrins that recognize RGD-containing proteins, we have bioengineered the human DLDH with RGD motifs (DLDHRGD) for integrin-mediated drug delivery. The modified protein fully retained its enzyme activity and ROS-production capability. DLDHRGD uptake by cells was shown to depend on the presence of cell-associated integrin alpha v beta 3, as comparatively demonstrated with normal kidney cells (HEK293) transfected with either beta 1 (alpha v beta 1 positive) or beta 3 integrins (alpha v beta 3 positive). The interaction with beta 3 integrins was shown to be competitively inhibited by an RGD peptide. In mice melanoma cells (B16F10), which highly express an endogenous alpha v beta 3 integrin, fast cellular uptake of DLDHRGD which resulted in cell number reduction, apoptosis induction, and a parallel intracellular ROS production was shown. Similar results were obtained with additional human melanoma cell models (A375, WM3314, and WM3682). In contrast, HEK293 beta 3 cells remained intact following DLDHRGD uptake. The high pharmacological safety profile of DLDHRGD has been observed by several modes of administrations in BALB/C or C57B1/6 mouse strains. Treatments with DLDHRGD in a subcutaneous melanoma mice model resulted in significant tumor inhibition. Our study demonstrated, in vitro and in vivo, the development of a unique platform, which targets cancer cells via integrin-mediated drug delivery of an exogenous ROS-generating drug.	[Dayan, Avraham; Fleminger, Gideon] Tel Aviv Univ, George S Wise Fac Life Sci, Sch Mol Cell Biol & Biotechnol, Tel Aviv, Israel; [Ashur-Fabian, Osnat] Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, Tel Aviv, Israel	Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine	Ashur-Fabian, O (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, Tel Aviv, Israel.	osnataf@gmail.com	Ashur, Osnat/AAC-1417-2020	Ashur-Fabian, Osnat/0000-0001-8624-3182	Israeli Ministry of Economics [52679, 55869]	Israeli Ministry of Economics	The authors wish to thank Mrs. Ronit Hollander for the graphics assistance and the table of contents illustration. This research was supported by the Israeli Ministry of Economics (Projects 52679 and 55869).	Ambrus A, 2018, NEUROCHEM INT, V117, P5, DOI 10.1016/j.neuint.2017.05.018; Ambrus A, 2013, ARCH BIOCHEM BIOPHYS, V538, P145, DOI 10.1016/j.abb.2013.08.015; Babu A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15012-5; Bender T, 2016, BBA-MOL CELL RES, V1863, P2436, DOI 10.1016/j.bbamcr.2016.01.017; Bolley J, 2013, NANOSCALE, V5, P11478, DOI 10.1039/c3nr03763k; Bui T, 2006, CANCER CELL, V9, P419, DOI 10.1016/j.ccr.2006.05.012; Caswell P, 2008, TRENDS CELL BIOL, V18, P257, DOI 10.1016/j.tcb.2008.03.004; Chen W, 2017, SMALL, V13, DOI 10.1002/smll.201601997; Chiarugi A, 2012, NAT REV CANCER, V12, P741, DOI 10.1038/nrc3340; CUNNINGHAM ML, 1985, PHOTOCHEM PHOTOBIOL, V42, P125, DOI 10.1111/j.1751-1097.1985.tb01549.x; DAHL HHM, 1987, J BIOL CHEM, V262, P7398; Danhier F, 2012, MOL PHARMACEUT, V9, P2961, DOI 10.1021/mp3002733; Dayan A, 2018, RSC ADV, V8, P9112, DOI 10.1039/c7ra13777j; Dayan A, 2017, J MOL RECOGNIT, V30, DOI 10.1002/jmr.2617; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Diebold L, 2016, FREE RADICAL BIO MED, V100, P86, DOI 10.1016/j.freeradbiomed.2016.04.198; FLEMINGER G, 1995, APPL ENVIRON MICROB, V61, P4357, DOI 10.1128/AEM.61.12.4357-4361.1995; Fu Q, 2016, INT J EXP PATHOL, V97, P351, DOI 10.1111/iep.12192; Galadari S, 2017, FREE RADICAL BIO MED, V104, P144, DOI 10.1016/j.freeradbiomed.2017.01.004; Gandioso A, 2016, J ORG CHEM, V81, P11556, DOI 10.1021/acs.joc.6b02415; Hu ZW, 2000, P NATL ACAD SCI USA, V97, P9221, DOI 10.1073/pnas.97.16.9221; Jezek J, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7010013; Kapp TG, 2017, SCI REP-UK, V7, DOI 10.1038/srep39805; Klyachko NL, 2005, J BIOL CHEM, V280, P16106, DOI 10.1074/jbc.M414285200; Masoud GN, 2015, ACTA PHARM SIN B, V5, P378, DOI 10.1016/j.apsb.2015.05.007; McCartney RG, 1998, J BIOL CHEM, V273, P24158, DOI 10.1074/jbc.273.37.24158; Nicco C, 2018, MOLECULES, V23, DOI 10.3390/molecules23010084; Nogueira V, 2013, CLIN CANCER RES, V19, P4309, DOI 10.1158/1078-0432.CCR-12-1424; Omura T, 1998, J BIOCHEM-TOKYO, V123, P1010; Poprac P, 2017, TRENDS PHARMACOL SCI, V38, P592, DOI 10.1016/j.tips.2017.04.005; Ralph SJ, 2011, PHARM RES-DORDR, V28, P2695, DOI 10.1007/s11095-011-0566-7; Raza MH, 2017, J CANCER RES CLIN, V143, P1789, DOI 10.1007/s00432-017-2464-9; Schaffner P, 2003, CELL MOL LIFE SCI, V60, P119, DOI 10.1007/s000180300008; Schiffelers RM, 2003, J CONTROL RELEASE, V91, P115, DOI 10.1016/S0168-3659(03)00240-2; Schito L, 2016, TRENDS CANCER, V2, P758, DOI 10.1016/j.trecan.2016.10.016; Schumacker PT, 2006, CANCER CELL, V10, P175, DOI 10.1016/j.ccr.2006.08.015; Sheldrake HM, 2014, J MED CHEM, V57, P6301, DOI 10.1021/jm5000547; STAMBAUGH R, 1966, J BIOL CHEM, V241, P1462; Starkov AA, 2004, J NEUROSCI, V24, P7779, DOI 10.1523/JNEUROSCI.1899-04.2004; Sun Y, 2017, DRUG DEVELOP RES, V78, P283, DOI 10.1002/ddr.21399; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Tretter L, 2004, J NEUROSCI, V24, P7771, DOI 10.1523/JNEUROSCI.1842-04.2004; TSAI CS, 1981, ARCH BIOCHEM BIOPHYS, V206, P77, DOI 10.1016/0003-9861(81)90068-0; Vanderperre B, 2015, CURR OPIN CELL BIOL, V33, P35, DOI 10.1016/j.ceb.2014.10.008; Wang J, 2008, CANCER BIOL THER, V7, P1875, DOI 10.4161/cbt.7.12.7067; Wang YC, 2007, J BIOMED SCI, V14, P203, DOI 10.1007/s11373-006-9136-0; Yu YP, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-78; Zhou ZH, 2001, P NATL ACAD SCI USA, V98, P14802, DOI 10.1073/pnas.011597698; Zundorf G, 2009, NEUROSCIENCE, V158, P610, DOI 10.1016/j.neuroscience.2008.10.015	49	23	23	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2019	38	25					5050	5061		10.1038/s41388-019-0775-9	http://dx.doi.org/10.1038/s41388-019-0775-9			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IE1KY	30872792				2022-12-28	WOS:000472145900012
J	Alessandrini, F; Menotti, L; Avitabile, E; Appolloni, I; Ceresa, D; Marubbi, D; Campadelli-Fiume, G; Malatesta, P				Alessandrini, Francesco; Menotti, Laura; Avitabile, Elisa; Appolloni, Irene; Ceresa, Davide; Marubbi, Daniela; Campadelli-Fiume, Gabriella; Malatesta, Paolo			Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model	ONCOGENE			English	Article							HERPES-SIMPLEX-VIRUS; PHASE-I; EXPRESSING IL-12; VIRAL THERAPY; STEM-CELLS; GLIOMA; GROWTH; MUTANT; EFFICACY; TUMOR	Oncolytic herpes simplex viruses are proving to be effective in clinical trials against a number of cancers. Here, R-115, an oncolytic herpes simplex virus retargeted to human erbB-2, fully virulent in its target cells, and armed with murine interleukin-12 was evaluated in a murine model of glioblastoma. We show that a single R-115 injection in established tumors resulted, in about 30% of animals, in the complete eradication of the tumor, otherwise invariably lethal. The treatment also induced a significant improvement in the overall median survival time of mice and a resistance to recurrence from the same neoplasia. Such a high degree of protection was unprecedented; it was not observed before following treatments with the commonly used, mutated/attenuated oncolytic viruses. This is the first study providing the evidence of benefits offered by a fully virulent, retargeted, and armed herpes simplex virus in the treatment of glioblastoma and paves the way for clinical translation.	[Alessandrini, Francesco; Appolloni, Irene; Ceresa, Davide; Marubbi, Daniela; Malatesta, Paolo] Univ Genoa, Dept Expt Med, Genoa, Italy; [Menotti, Laura; Avitabile, Elisa] Univ Bologna, Dept Pharm & Biotechnol, Bologna, Italy; [Marubbi, Daniela; Malatesta, Paolo] Osped Policlin San Martino, IRCCS Oncol, Genoa, Italy; [Campadelli-Fiume, Gabriella] Univ Bologna, Dept Expt Diagnost & Specialty Med, Bologna, Italy	University of Genoa; University of Bologna; University of Bologna	Malatesta, P (corresponding author), Univ Genoa, Dept Expt Med, Genoa, Italy.; Malatesta, P (corresponding author), Osped Policlin San Martino, IRCCS Oncol, Genoa, Italy.	paolo.malatesta@unige.it	Appolloni, Irene/AAC-1629-2019; Malatesta, Paolo/J-3570-2012; Ceresa, Davide/AAB-8518-2019	Malatesta, Paolo/0000-0003-3045-3361; Alessandrini, Francesco/0000-0002-8450-848X; MENOTTI, LAURA/0000-0003-3277-5399; AVITABILE, ELISA/0000-0003-0328-2544	European Research Council (ERC) [340060]; Compagnia di San Paolo, Turin, Italy [2015.9834]; RFO (University of Bologna)	European Research Council (ERC)(European Research Council (ERC)); Compagnia di San Paolo, Turin, Italy(Compagnia di San Paolo); RFO (University of Bologna)	This work was supported by European Research Council (ERC) advanced grant number 340060 to GCF and PM; by Compagnia di San Paolo, Turin, Italy (grant no 2015.9834) "Terapie innovative per il glioblastoma" to PM; by RFO (University of Bologna) to LM and EA. We would like to thank Dr. Antonio Daga for providing human glioma-initiating cells.	Ahmed N, 2010, CLIN CANCER RES, V16, P474, DOI 10.1158/1078-0432.CCR-09-1322; Alessandrini F, 2016, J CANCER, V7, P1791, DOI 10.7150/jca.15564; Andtbacka RHI, 2015, J CLIN ONCOL, V33, P2780, DOI 10.1200/JCO.2014.58.3377; [Anonymous], R LANG ENV STAT COMP; Appolloni I, 2019, CANCER LETT, V442, P213, DOI 10.1016/j.canlet.2018.10.006; Banelli B, 2015, CELL CYCLE, V14, P3418, DOI 10.1080/15384101.2015.1090063; BYSTRYN JC, 1978, J IMMUNOL, V120, P96; Campadelli-Fiume G, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8030063; Campadelli-Fiume G, 2011, REV MED VIROL, V21, P213, DOI 10.1002/rmv.691; Cheema TA, 2013, P NATL ACAD SCI USA, V110, P12006, DOI 10.1073/pnas.1307935110; Cody JJ, 2012, INT J BREAST CANCER, V2012, DOI 10.1155/2012/628697; Coffin RS, 2015, CURR OPIN VIROL, V13, P93, DOI 10.1016/j.coviro.2015.06.005; Delman KA, 2000, HUM GENE THER, V11, P2465, DOI 10.1089/10430340050207957; Dobin Alexander, 2015, Curr Protoc Bioinformatics, V51, DOI 10.1002/0471250953.bi1114s51; Duhem-Tonnelle V, 2010, J NEUROPATH EXP NEUR, V69, P606, DOI 10.1097/NEN.0b013e3181e00579; Edelstein Arthur, 2010, Curr Protoc Mol Biol, VChapter 14, DOI 10.1002/0471142727.mb1420s92; Favaro R, 2014, CANCER RES, V74, P1833, DOI 10.1158/0008-5472.CAN-13-1942; Gambini E, 2012, MOL THER, V20, P994, DOI 10.1038/mt.2012.22; Gulati S, 2010, DIAGN PATHOL, V5, DOI 10.1186/1746-1596-5-18; Guo HY, 2015, MED MICROBIOL IMMUN, V204, P439, DOI 10.1007/s00430-015-0410-5; Hausler SFM, 2011, CANCER IMMUNOL IMMUN, V60, P1405, DOI 10.1007/s00262-011-1040-4; Hellums EK, 2005, NEURO-ONCOLOGY, V7, P213, DOI 10.1215/S1152851705000074; HIESIGER EM, 1993, J NEURO-ONCOL, V16, P93, DOI 10.1007/BF01324695; Hunter WD, 1999, J VIROL, V73, P6319, DOI 10.1128/JVI.73.8.6319-6326.1999; Kambara H, 2005, CANCER RES, V65, P2832, DOI 10.1158/0008-5472.CAN-04-3227; Kemeny N, 2006, HUM GENE THER, V17, P1214, DOI 10.1089/hum.2006.17.1214; Kimata H, 2006, ANN SURG ONCOL, V13, P1078, DOI 10.1245/ASO.2006.08.035; Korn T, 2017, NAT REV IMMUNOL, V17, P179, DOI 10.1038/nri.2016.144; Lambright ES, 2000, MOL THER, V2, P387, DOI 10.1006/mthe.2000.0133; Leoni V, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007209; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Liu BL, 2003, GENE THER, V10, P292, DOI 10.1038/sj.gt.3301885; Louis DN., 2016, WHO CLASSIFICATION T; Louyeau A, 2015, TRENDS IMMUNOL, V36, P569, DOI 10.1016/j.it.2015.08.006; Markert JM, 2000, GENE THER, V7, P867, DOI 10.1038/sj.gt.3301205; MARTUZA RL, 1991, SCIENCE, V252, P854, DOI 10.1126/science.1851332; Menotti L, 2008, J VIROL, V82, P10153, DOI 10.1128/JVI.01133-08; Menotti L, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10070352; Mineo JF, 2007, J NEURO-ONCOL, V85, P281, DOI 10.1007/s11060-007-9424-1; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; MOSMANN TR, 1989, ADV IMMUNOL, V46, P111, DOI 10.1016/S0065-2776(08)60652-5; Nabika Shinya, 2010, Hiroshima Journal of Medical Sciences, V59, P65; Nakao A, 2011, CANCER GENE THER, V18, P167, DOI 10.1038/cgt.2010.65; Parker JN, 2000, P NATL ACAD SCI USA, V97, P2208, DOI 10.1073/pnas.040557897; Patel DM, 2016, HUM GENE THER CL DEV, V27, P69, DOI 10.1089/humc.2016.031; Pritchard CC, 2001, P NATL ACAD SCI USA, V98, P13266, DOI 10.1073/pnas.221465998; Reisoli E, 2012, CANCER GENE THER, V19, P788, DOI 10.1038/cgt.2012.62; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Saha D, 2017, CANCER CELL, V32, P253, DOI 10.1016/j.ccell.2017.07.006; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Thomas ED, 2016, J OVARIAN RES, V9, DOI 10.1186/s13048-016-0282-3; Toda M, 1998, J IMMUNOL, V160, P4457; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Uchida H, 2013, MOL THER, V21, P561, DOI 10.1038/mt.2012.211; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; van der Woude LL, 2017, TRENDS CANCER, V3, P797, DOI 10.1016/j.trecan.2017.09.006; Veinalde R, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1285992	58	36	36	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2019	38	23					4467	4479		10.1038/s41388-019-0737-2	http://dx.doi.org/10.1038/s41388-019-0737-2			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IB4KM	30755732				2022-12-28	WOS:000470240300003
J	Hepburn, AC; Steele, RE; Veeratterapillay, R; Wilson, L; Kounatidou, EE; Barnard, A; Berry, P; Cassidy, JR; Moad, M; El-Sherif, A; Gaughan, L; Mills, IG; Robson, CN; Heer, R				Hepburn, A. C.; Steele, R. E.; Veeratterapillay, R.; Wilson, L.; Kounatidou, E. E.; Barnard, A.; Berry, P.; Cassidy, J. R.; Moad, M.; El-Sherif, A.; Gaughan, L.; Mills, I. G.; Robson, C. N.; Heer, R.			The induction of core pluripotency master regulators in cancers defines poor clinical outcomes and treatment resistance	ONCOGENE			English	Article							ANDROGEN-RECEPTOR; PROSTATE-CANCER; STEM-CELLS; MESENCHYMAL TRANSITION; SERUM TRIIODOTHYRONINE; THYROID-HORMONE; TUMOR-GROWTH; METASTASIS; PLASTICITY; DIFFERENTIATION	Stem cell characteristics have been associated with treatment resistance and poor prognosis across many cancer types. The ability to induce and regulate the pathways that sustain these characteristic hallmarks of lethal cancers in a novel in vitro model would greatly enhance our understanding of cancer progression and treatment resistance. In this work, we present such a model, based simply on applying standard pluripotency/embryonic stem cell media alone. Core pluripotency stem cell master regulators (OCT4, SOX2 and NANOG) along with epithelial-mesenchymal transition (EMT) markers (Snail, Slug, vimentin and N-cadherin) were induced in human prostate, breast, lung, bladder, colorectal, and renal cancer cells. RNA sequencing revealed pathways activated by pluripotency inducing culture that were shared across all cancers examined. These pathways highlight a potential core mechanism of treatment resistance. With a focus on prostate cancer, the culture-based induction of core pluripotent stem cell regulators was shown to promote survival in castrate conditions-mimicking first line treatment resistance with hormonal therapies. This acquired phenotype was shown to be mediated through the upregulation of iodothyronine deiodinase DIO2, a critical modulator of the thyroid hormone signalling pathway. Subsequent inhibition of DIO2 was shown to supress expression of prostate specific antigen, the cardinal clinical biomarker of prostate cancer progression and highlighted a novel target for clinical translation in this otherwise fatal disease. This study identifies a new and widely accessible simple preclinical model to recreate and explore underpinning pathways of lethal disease and treatment resistance.	[Hepburn, A. C.; Wilson, L.; Kounatidou, E. E.; Barnard, A.; Berry, P.; Cassidy, J. R.; Moad, M.; Gaughan, L.; Robson, C. N.; Heer, R.] Newcastle Univ, Northern Inst Canc Res, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Steele, R. E.; Mills, I. G.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Prostate Canc UK Movember Ctr Excellence Prostate, Belfast BT9 7AE, Antrim, North Ireland; [Veeratterapillay, R.; Heer, R.] Newcastle Upon Tyne Hosp NHS Fdn Trust, Freeman Hosp, Dept Urol, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England; [El-Sherif, A.] Newcastle Tyne Hosp NHS Fdn Trust, Royal Victoria Infirm, Dept Pathol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; [Mills, I. G.] Univ Oxford, Nuffield Dept Surg Sci, Oxford OX3 9DU, England	Newcastle University - UK; Queens University Belfast; Newcastle Freeman Hospital; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; University of Oxford	Hepburn, AC; Robson, CN; Heer, R (corresponding author), Newcastle Univ, Northern Inst Canc Res, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.; Heer, R (corresponding author), Newcastle Upon Tyne Hosp NHS Fdn Trust, Freeman Hosp, Dept Urol, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England.	anastasia.hepburn@newcastle.ac.uk; c.n.robson@newcastle.ac.uk; rakesh.heer@newcastle.ac.uk	Mills, Ian/AAK-9292-2020	Mills, Ian/0000-0001-5347-5083	Prostate Cancer UK [PG12-24]; Cancer Research UK ECMC [C9380/A25138]; European Union [721746]	Prostate Cancer UK; Cancer Research UK ECMC; European Union(European Commission)	We are grateful for financial support by Prostate Cancer UK (PG12-24) and Cancer Research UK ECMC (C9380/A25138). This project also received funding from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No721746.	Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Agudo J, 2018, IMMUNITY, V48, P271, DOI 10.1016/j.immuni.2018.02.001; Arora VK, 2013, CELL, V155, P1309, DOI 10.1016/j.cell.2013.11.012; Baccelli I, 2013, NAT BIOTECHNOL, V31, P539, DOI 10.1038/nbt.2576; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bishop JL, 2017, CANCER DISCOV, V7, P54, DOI 10.1158/2159-8290.CD-15-1263; Bluemn EG, 2017, CANCER CELL, V32, P474, DOI 10.1016/j.ccell.2017.09.003; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Fagnocchi L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11903; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Gao D, 2014, CELL, V159, P176, DOI 10.1016/j.cell.2014.08.016; Glinsky GV, 2008, J CLIN ONCOL, V26, P2846, DOI 10.1200/JCO.2008.17.0266; Grillet F, 2017, GUT, V66, P1802, DOI 10.1136/gutjnl-2016-311447; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; Harner-Foreman N, 2017, SCI REP-UK, V7, DOI 10.1038/srep40633; Hassan KA, 2009, CLIN CANCER RES, V15, P6386, DOI 10.1158/1078-0432.CCR-09-1105; Hepburn AC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050690; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Jeter CR, 2011, ONCOGENE, V30, P3833, DOI 10.1038/onc.2011.114; Jeter CR, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.41; Jeter CR, 2015, STEM CELLS, V33, P2381, DOI 10.1002/stem.2007; Khan A, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1708-7; Kolijn K, 2018, CANCER RES, V78, P4671, DOI 10.1158/0008-5472.CAN-17-3752; Korpal M, 2013, CANCER DISCOV, V3, P1030, DOI 10.1158/2159-8290.CD-13-0142; Krebs AM, 2017, NAT CELL BIOL, V19, P518, DOI 10.1038/ncb3513; Kregel S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053701; Lehrer S, 2001, PROSTATE CANCER P D, V4, P232, DOI 10.1038/sj.pcan.4500542; Lehrer S, 2002, J UROLOGY, V168, P2431, DOI 10.1016/S0022-5347(05)64161-4; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Li P, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-55; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Malinowska K, 2009, PROSTATE, V69, P1109, DOI 10.1002/pros.20956; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marinho PA, 2015, SCI REP-UK, V5, DOI 10.1038/srep09834; Mathieu J, 2011, CANCER RES, V71, P4640, DOI 10.1158/0008-5472.CAN-10-3320; Moad M, 2013, EUR UROL, V64, P753, DOI 10.1016/j.eururo.2013.03.054; Moeller LC, 2013, ENDOCR-RELAT CANCER, V20, pR19, DOI 10.1530/ERC-12-0219; Mondul AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047730; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Mukherjee R, 2011, BRIT J CANCER, V104, P1920, DOI 10.1038/bjc.2011.163; Murgai M, 2017, NAT MED, V23, P1176, DOI 10.1038/nm.4400; Navone NM, 2018, PROSTATE, V78, P1262, DOI 10.1002/pros.23701; PASCUAL A, 1987, ENDOCRINOLOGY, V120, P1089, DOI 10.1210/endo-120-3-1089; Poli V, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03264-2; Rosene ML, 2010, ENDOCRINOLOGY, V151, P5961, DOI 10.1210/en.2010-0553; Schmidinger M, 2011, CANCER-AM CANCER SOC, V117, P534, DOI 10.1002/cncr.25422; Schoenhals M, 2009, BIOCHEM BIOPH RES CO, V383, P157, DOI 10.1016/j.bbrc.2009.02.156; Sedelaar JPM, 2009, PROSTATE, V69, P1724, DOI 10.1002/pros.21028; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Theodossiou C, 2000, AM J MED SCI, V319, P96, DOI 10.1097/00000441-200002000-00005; Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001; Tran HD, 2014, CANCER RES, V74, P6330, DOI 10.1158/0008-5472.CAN-14-0923; van de Wetering M, 2015, CELL, V161, P933, DOI 10.1016/j.cell.2015.03.053; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Williamson SC, 2013, BRIT J CANCER, V109, P950, DOI 10.1038/bjc.2013.399; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	60	36	36	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2019	38	22					4412	4424		10.1038/s41388-019-0712-y	http://dx.doi.org/10.1038/s41388-019-0712-y			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IA1RB	30742096	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000469339100015
J	Rua, WM; Venkatachalam, G; Sobota, RM; Chen, LY; Wang, LC; Jacobson, A; Paramasivam, K; Surana, U				Rua, Weimei; Venkatachalam, Gireedhar; Sobota, Radoslaw Mikolaj; Chen, Liyan; Wang, Loo Chien; Jacobson, Alena; Paramasivam, Kathirvel; Surana, Uttam			Resistance to anti-microtubule drug-induced cell death is determined by regulation of BimEL expression	ONCOGENE			English	Article							APOPTOSIS RESISTANCE; DEGRADATION; PHOSPHORYLATION; TRANSCRIPTION; MECHANISMS; TAXOL; B1	Anti-microtubule agents are frequently used as anticancer therapeutics. Cell death induced by these agents is considered to be due to sustained mitotic arrest caused by the activation of spindle assembly checkpoint (SAC). However, some cell types are resistant to mitotic cell death. Cells' ability to escape mitotic arrest (mitotic slippage) is thought to be a major mechanism contributing to this resistance. Here, we show that resistance to cell death induced by anti-mitotic agents is not linked to cells' capacity to undergo mitotic slippage as generally believed but is dependent on the state of BimEL regulation during mitosis. While transcriptional repression of BimEL in the mitotic death-resistant cells involves polycomb repressive complex 2 (PRC2)-mediated histone trimethylation, the BimEL protein is destabilized by cullin 1/4A-beta TrCP-dependent degradation involving activation of cullin 1/4A by neddylation. These results imply that pharmacological augmentation of BimEL activity in anti-microtubule drug-resistant tumors may have important therapeutic implications.	[Rua, Weimei; Venkatachalam, Gireedhar; Sobota, Radoslaw Mikolaj; Chen, Liyan; Wang, Loo Chien; Jacobson, Alena; Paramasivam, Kathirvel; Surana, Uttam] ASTAR, Inst Mol & Cell Biol, 61 Biopolis Dr, Singapore 138673, Singapore; [Surana, Uttam] ASTAR, Bioproc Technol Inst, Singapore, Singapore; [Surana, Uttam] Natl Univ Singapore, Dept Pharmacol, Singapore, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Agency for Science Technology & Research (A*STAR); A*STAR - Bioprocessing Technology Institute (BTI); National University of Singapore	Surana, U (corresponding author), ASTAR, Inst Mol & Cell Biol, 61 Biopolis Dr, Singapore 138673, Singapore.; Surana, U (corresponding author), ASTAR, Bioproc Technol Inst, Singapore, Singapore.; Surana, U (corresponding author), Natl Univ Singapore, Dept Pharmacol, Singapore, Singapore.	mcbucs@imcb.a-star.edu.sg		Surana, Uttam/0000-0002-4785-6514; Ruan, Weimei/0000-0002-3459-5837; Sobota, Radoslaw/0000-0002-2455-2526; Chen, Liyan/0000-0002-5255-0296	Biomedical Research Council of A* STAR (Agency for Science, Technology and Research), Singapore	Biomedical Research Council of A* STAR (Agency for Science, Technology and Research), Singapore(Agency for Science Technology & Research (A*STAR))	We thank the members of the US laboratory for helpful discussions and the mouse model unit (IMCB, Singapore) for kindly providing the PLKO. 1 vector and lentiviral packaging vectors. The U.S. lab is supported by the Biomedical Research Council of A* STAR (Agency for Science, Technology and Research), Singapore.	Bah N, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.251; Balachandran RS, 2016, J CELL BIOL, V215, P151, DOI 10.1083/jcb.201601083; Brito DA, 2009, CELL MOTIL CYTOSKEL, V66, P437, DOI 10.1002/cm.20316; Chan KS, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.148; Cheung CHA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012564; Chumduri C, 2015, J MOL MED, V93, P559, DOI 10.1007/s00109-014-1242-2; Dehan E, 2009, MOL CELL, V33, P109, DOI 10.1016/j.molcel.2008.12.020; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Goncalves A, 2001, P NATL ACAD SCI USA, V98, P11737, DOI 10.1073/pnas.191388598; Harley ME, 2010, EMBO J, V29, P2407, DOI 10.1038/emboj.2010.112; Haschka MD, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7891; He YJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157558; Huang S, 2016, ONCOTARGET, V7, P38718, DOI 10.18632/oncotarget.9586; Jiang LY, 2011, J BIOL CHEM, V286, P6971, DOI 10.1074/jbc.M110.186494; KNEHR M, 1995, EXP CELL RES, V217, P546, DOI 10.1006/excr.1995.1121; Kutuk O, 2010, CELL DEATH DIFFER, V17, P1624, DOI 10.1038/cdd.2010.41; Li R, 2005, CELL DEATH DIFFER, V12, P292, DOI 10.1038/sj.cdd.4401554; Manchado E, 2012, CELL DEATH DIFFER, V19, P369, DOI 10.1038/cdd.2011.197; Orr GA, 2003, ONCOGENE, V22, P7280, DOI 10.1038/sj.onc.1206934; Pathan N, 2001, NEOPLASIA, V3, P550, DOI 10.1038/sj.neo.7900213; Ridinger-Saison M, 2013, CELL DEATH DIFFER, V20, P1268, DOI 10.1038/cdd.2013.88; Rieder CL, 2004, DEV CELL, V7, P637, DOI 10.1016/j.devcel.2004.09.002; Sinnott R, 2014, CANCER RES, V74, P3857, DOI 10.1158/0008-5472.CAN-13-3398; Terrano DT, 2010, MOL CELL BIOL, V30, P640, DOI 10.1128/MCB.00882-09; Thomas Y, 2010, CELL CYCLE, V9, P4338, DOI 10.4161/cc.9.21.13593; Vitale I, 2011, NAT REV MOL CELL BIO, V12, P384, DOI 10.1038/nrm3115; Wan LX, 2014, DEV CELL, V29, P377, DOI 10.1016/j.devcel.2014.04.022; Wu N, 2017, ONCOL LETT, V13, P1826, DOI 10.3892/ol.2017.5660; Xu ZJ, 2017, ONCOL LETT, V14, P345, DOI 10.3892/ol.2017.6149; Yamaguchi H, 2004, J BIOL CHEM, V279, P39431, DOI 10.1074/jbc.M401530200; Zhang WZ, 2008, J BIOL CHEM, V283, P16416, DOI 10.1074/jbc.M802360200	31	1	1	2	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2019	38	22					4352	4365		10.1038/s41388-019-0727-4	http://dx.doi.org/10.1038/s41388-019-0727-4			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IA1RB	30770899				2022-12-28	WOS:000469339100011
J	El Kharbili, M; Agaesse, G; Barbollat-Boutrand, L; Pommier, RM; de la Fouchardiere, A; Larue, L; Caramel, J; Puisieux, A; Berthier-Vergnes, O; Masse, I				El Kharbili, Manale; Agaesse, Gweltaz; Barbollat-Boutrand, Laetitia; Pommier, Roxane M.; de la Fouchardiere, Arnaud; Larue, Lionel; Caramel, Julie; Puisieux, Alain; Berthier-Vergnes, Odile; Masse, Ingrid			Tspan8-beta-catenin positive feedback loop promotes melanoma invasion	ONCOGENE			English	Article							BETA-CATENIN EXPRESSION; TETRASPANIN CO-029; CELL MOTILITY; METASTASIS; TUMORS; OVEREXPRESSION; ASSOCIATION; PROGRESSION; CADHERIN; PATHWAY	Due to its high proclivity to metastasize, and despite the recent development of targeted and immune therapy strategies, melanoma is still the deadliest form of skin cancer. Therefore, understanding the molecular mechanisms underlying melanoma invasion remains crucial. We previously characterized Tspan8 for its ability to prompt melanoma cell detachment from their microenvironment and trigger melanoma cell invasiveness, but the signaling events by which Tspan8 regulates the invasion process still remain unknown. Here, we demonstrated that beta-catenin stabilization is a molecular signal subsequent to the onset of Tspan8 expression, and that, in turn, beta-catenin triggers the direct transcriptional activation of Tspan8 expression, leading to melanoma invasion. Moreover, we showed that beta-catenin activation systematically correlates with a high expression of Tspan8 protein in melanoma lesions from transgenic Nras; bcat* mice, as well as in deep penetrating naevi, a type of human pre-melanoma neoplasm characterized by a combined activation of beta-catenin and MAP kinase signaling. Overall, our data suggest that beta-catenin and Tspan8 are part of a positive feedback loop, which sustains a high Tspan8 expression level, conferring to melanoma cells the invasive properties required for tumor progression and dissemination.	[El Kharbili, Manale; Agaesse, Gweltaz; Barbollat-Boutrand, Laetitia; Berthier-Vergnes, Odile; Masse, Ingrid] Univ Lyon, F-69003 Lyon, France; [El Kharbili, Manale; Agaesse, Gweltaz; Barbollat-Boutrand, Laetitia; Berthier-Vergnes, Odile; Masse, Ingrid] Univ Lyon 1, F-69003 Lyon, France; [El Kharbili, Manale; Agaesse, Gweltaz; Barbollat-Boutrand, Laetitia; Berthier-Vergnes, Odile; Masse, Ingrid] CNRS, UMR5534, Ctr Genet & Physiol Mol & Cellulaires, F-69622 Villeurbanne, France; [Pommier, Roxane M.; de la Fouchardiere, Arnaud; Caramel, Julie; Puisieux, Alain] Univ Lyon 1, Univ Lyon, Ctr Rech Cancerol Lyon, CNRS,UMR5286,Inserm,U1052, F-69000 Lyon, France; [de la Fouchardiere, Arnaud] Ctr Leon Berard, Dept Biopathol, Lyon, France; [Larue, Lionel] PSL Res Univ, Normal & Pathol Dev Melanocytes, Inst Curie, INSERM,U1021, Orsay, France; [Larue, Lionel] Univ Paris Saclay, Univ Paris Sud, CNRS, UMR 3347, Orsay, France; [Larue, Lionel] Equipe Labellisee Ligue Canc, Orsay, France; [El Kharbili, Manale] Univ Colorado, Dept Dermatol, Anschutz Med Campus,12800 E 19th Ave,P18-8132, Aurora, CO 80045 USA; [Barbollat-Boutrand, Laetitia; Masse, Ingrid] Univ Lyon 1, Univ Lyon, Ctr Rech Cancerol Lyon, CNRS,UMR5286,Inserm,U1052, F-69000 Lyon, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UNICANCER; Centre Leon Berard; UNICANCER; Centre Leon Berard; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Saclay; University of Colorado System; University of Colorado Anschutz Medical Campus; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UNICANCER; Centre Leon Berard	Masse, I (corresponding author), Univ Lyon, F-69003 Lyon, France.; Masse, I (corresponding author), Univ Lyon 1, F-69003 Lyon, France.; Masse, I (corresponding author), CNRS, UMR5534, Ctr Genet & Physiol Mol & Cellulaires, F-69622 Villeurbanne, France.; Masse, I (corresponding author), Univ Lyon 1, Univ Lyon, Ctr Rech Cancerol Lyon, CNRS,UMR5286,Inserm,U1052, F-69000 Lyon, France.	ingrid.masse@univ-lyon1.fr		Caramel, Julie/0000-0002-8883-918X; POMMIER, Roxane/0000-0002-5351-7367; MASSE, Ingrid/0000-0003-3193-970X; PUISIEUX, Alain/0000-0002-9938-3798	French Society for Dermatological Research (SRD); La Ligue Contre le Cancer (Comite Ardeche); association "Vaincre le Melanome"	French Society for Dermatological Research (SRD); La Ligue Contre le Cancer (Comite Ardeche); association "Vaincre le Melanome"	This work was supported by a grant from the French Society for Dermatological Research (SRD), a grant from La Ligue Contre le Cancer (Comite Ardeche) and a grant from the association "Vaincre le Melanome".	Abe M, 2008, CANCER LETT, V266, P163, DOI 10.1016/j.canlet.2008.02.058; Agaesse G, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.11; Agaesse G, 2017, ONCOGENE, V36, P446, DOI 10.1038/onc.2016.219; Ailane N, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00364; Aktary Z, 2016, PIGM CELL MELANOMA R, V29, P524, DOI 10.1111/pcmr.12501; Arozarena I, 2011, ONCOGENE, V30, P4531, DOI 10.1038/onc.2011.162; Bachmann IM, 2005, CLIN CANCER RES, V11, P8606, DOI 10.1158/1078-0432.CCR-05-0011; Berthier-Vergnes O, 2011, BRIT J CANCER, V104, P155, DOI 10.1038/sj.bjc.6605994; Bhansali M, 2016, MOL ENDOCRINOL, V30, P13, DOI 10.1210/me.2015-1075; Cavard C, 2006, ONCOGENE, V25, P599, DOI 10.1038/sj.onc.1208860; Chien AJ, 2009, P NATL ACAD SCI USA, V106, P1193, DOI 10.1073/pnas.0811902106; Claas C, 1998, J CELL BIOL, V141, P267, DOI 10.1083/jcb.141.1.267; Conde-Perez A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9093; Damsky WE, 2011, CANCER CELL, V20, P741, DOI 10.1016/j.ccr.2011.10.030; Delmas V, 2003, GENESIS, V36, P73, DOI 10.1002/gene.10197; Delmas V, 2007, GENE DEV, V21, P2923, DOI 10.1101/gad.450107; Eichhoff OM, 2011, PIGM CELL MELANOMA R, V24, P631, DOI 10.1111/j.1755-148X.2011.00871.x; El Kharbili M, 2017, ONCOTARGET, V8, P17140, DOI 10.18632/oncotarget.15084; Gallagher SJ, 2013, ONCOGENE, V32, P2230, DOI 10.1038/onc.2012.229; Gesierich S, 2005, CLIN CANCER RES, V11, P2840, DOI 10.1158/1078-0432.CCR-04-1935; Gesierich S, 2006, CANCER RES, V66, P7083, DOI 10.1158/0008-5472.CAN-06-0391; Greco C, 2010, CANCER RES, V70, P7674, DOI 10.1158/0008-5472.CAN-09-4482; Grossmann AH, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003398; Guo Q, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053523; Hemler ME, 2014, NAT REV CANCER, V14, P49, DOI 10.1038/nrc3640; Herlevsen M, 2003, J CELL SCI, V116, P4373, DOI 10.1242/jcs.00760; Kageshita T, 2001, BRIT J DERMATOL, V145, P210, DOI 10.1046/j.1365-2133.2001.04336.x; Kanetaka K, 2003, J GASTROEN HEPATOL, V18, P1309, DOI 10.1046/j.1440-1746.2003.03182.x; Kanetaka K, 2001, J HEPATOL, V35, P637, DOI 10.1016/S0168-8278(01)00183-0; Larue L, 2006, FRONT BIOSCI-LANDMRK, V11, P733, DOI 10.2741/1831; Le Naour F, 2006, MOL CELL PROTEOMICS, V5, P845, DOI 10.1074/mcp.M500330-MCP200; Li L, 2018, INT J ONCOL, V52, P473, DOI 10.3892/ijo.2017.4231; Luke JJ, 2017, NAT REV CLIN ONCOL, V14, P463, DOI 10.1038/nrclinonc.2017.43; Maelandsmo GM, 2003, CLIN CANCER RES, V9, P3383; Maisonial-Besset A, 2017, ONCOTARGET, V8, P22034, DOI 10.18632/oncotarget.15787; Masse I, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.62; Murakami T, 2001, BIOCHEM BIOPH RES CO, V288, P8, DOI 10.1006/bbrc.2001.5719; Nazarenko I, 2010, CANCER RES, V70, P1668, DOI 10.1158/0008-5472.CAN-09-2470; Pan SJ, 2015, INT J MOL SCI, V16, P5363, DOI 10.3390/ijms16035363; Pan SJ, 2015, BIOCHEM BIOPH RES CO, V458, P476, DOI 10.1016/j.bbrc.2015.01.128; Park CS, 2016, ONCOGENE, V35, P4540, DOI 10.1038/onc.2015.520; Rodia MT, 2016, ONCOTARGET, V7, P30295, DOI 10.18632/oncotarget.8108; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Seubert B, 2015, INT J CANCER, V136, P2304, DOI 10.1002/ijc.29296; Shain AH, 2016, NEW ENGL J MED, V374, P995, DOI 10.1056/NEJMc1515834; Sinnberg T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023429; SZALA S, 1990, P NATL ACAD SCI USA, V87, P3542, DOI 10.1073/pnas.87.9.3542; Yeh I, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00758-3; Yue SJ, 2015, ONCOTARGET, V6, P2366, DOI 10.18632/oncotarget.2958; Zhou Z, 2008, CLIN EXP METASTAS, V25, P537, DOI 10.1007/s10585-008-9168-0; Zoller M, 2009, NAT REV CANCER, V9, P40, DOI 10.1038/nrc2543	51	16	16	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2019	38	20					3781	3793		10.1038/s41388-019-0691-z	http://dx.doi.org/10.1038/s41388-019-0691-z			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HY3OI	30679790				2022-12-28	WOS:000468035600002
J	Huang, JJ; Corona, AL; Dunn, BP; Cai, EM; Prakken, JN; Blobe, GC				Huang, Jennifer J.; Corona, Armando L.; Dunn, Brian P.; Cai, Elise M.; Prakken, Jesse N.; Blobe, Gerard C.			Increased type III TGF-beta receptor shedding decreases tumorigenesis through induction of epithelial-to-mesenchymal transition	ONCOGENE			English	Article							SIGNALING PATHWAY; PEPTIDE INHIBITORS; CANCER; BETAGLYCAN; ACTIVATION; METASTASIS; MECHANISMS; APOPTOSIS; RIII; ERK	The type III TGF-beta receptor (T beta RIII) is a TGF-beta co-receptor that presents ligand to the type II TGF-beta receptor to initiate signaling. T beta RIII also undergoes ectodomain shedding to release a soluble form (sT beta RIII) that can bind ligand, sequestering it away from cell surface receptors. We have previously identified a T beta RIII extracellular mutant that has enhanced ectodomain shedding ("super shedding (SS)"-T beta RIII-SS). Here, we utilize T beta RIII-SS to study the balance of cell surface and soluble T beta RIII in the context of lung cancer. We demonstrate that expressing T beta RIII-SS in lung cancer cell models induces epithelial-to-mesenchymal transition (EMT) and that these T beta RIII-SS (EMT) cells are less migratory, invasive and adhesive and more resistant to gemcitabine. Moreover, T beta RIII-SS (EMT) cells exhibit decreased tumorigenicity but increased growth rate in vitro and in vivo. These studies suggest that the balance of cell surface and soluble T beta RIII may regulate a dichotomous role for T beta RIII during cancer progression.	[Huang, Jennifer J.; Corona, Armando L.; Blobe, Gerard C.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27708 USA; [Dunn, Brian P.; Cai, Elise M.; Prakken, Jesse N.; Blobe, Gerard C.] Duke Univ, Med Ctr, Dept Med, Div Med Oncol, Durham, NC 27710 USA	Duke University; Duke University	Blobe, GC (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27708 USA.; Blobe, GC (corresponding author), Duke Univ, Med Ctr, Dept Med, Div Med Oncol, Durham, NC 27710 USA.	gerard.blobe@duke.edu	Blobe, Gerard/AAJ-5945-2020	Blobe, Gerard/0000-0002-4274-8901; Cai, Elise/0000-0002-6650-8208	National Institutes of Health/National Cancer Institute [F30CA196162, T32-GM007171, R01CA135006]; NATIONAL CANCER INSTITUTE [F30CA196162] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007171] Funding Source: NIH RePORTER	National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the following grants from the National Institutes of Health/National Cancer Institute: F30CA196162 (J.J.H.), T32-GM007171 (Medical Scientist Training Program; J.J.H), and R01CA135006 (G.C.B).	Akhurst RJ, 2012, NAT REV DRUG DISCOV, V11, P790, DOI 10.1038/nrd3810; Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Cagnol S, 2010, FEBS J, V277, P2, DOI 10.1111/j.1742-4658.2009.07366.x; Campeau E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006529; Chambard JC, 2007, BBA-MOL CELL RES, V1773, P1299, DOI 10.1016/j.bbamcr.2006.11.010; Dong M, 2007, J CLIN INVEST, V117, P206, DOI 10.1172/JCI29293; Dotor J, 2007, CYTOKINE, V39, P106, DOI 10.1016/j.cyto.2007.06.004; Elderbroom JL, 2014, MOL BIOL CELL, V25, P2320, DOI 10.1091/mbc.E13-09-0524; Finger EC, 2008, CARCINOGENESIS, V29, P528, DOI 10.1093/carcin/bgm289; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Gallo-Oller G, 2016, CANCER LETT, V381, P67, DOI 10.1016/j.canlet.2016.07.029; Gatza CE, 2010, CELL SIGNAL, V22, P1163, DOI 10.1016/j.cellsig.2010.01.016; Greenberg AK, 2002, AM J RESP CELL MOL, V26, P558, DOI 10.1165/ajrcmb.26.5.4689; Guan XM, 2015, ACTA PHARM SIN B, V5, P402, DOI 10.1016/j.apsb.2015.07.005; Hanks BA, 2013, J CLIN INVEST, V123, P3925, DOI 10.1172/JCI65745; Hempel N, 2007, CANCER RES, V67, P5231, DOI 10.1158/0008-5472.CAN-07-0035; Huang JJ, 2016, BIOCHEM SOC T, V44, P1441, DOI 10.1042/BST20160065; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; Jurisic D, 2015, GROWTH FACTORS, V33, P200, DOI 10.3109/08977194.2015.1055740; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Llopiz D, 2009, INT J CANCER, V125, P2614, DOI 10.1002/ijc.24656; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Skrypek N, 2017, TRENDS GENET, V33, P943, DOI 10.1016/j.tig.2017.08.004; Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x; Stamenkovic I, 2003, J PATHOL, V200, P448, DOI 10.1002/path.1400; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492; Treffers LW, 2016, IMMUNOL REV, V273, P312, DOI 10.1111/imr.12444; Turley RS, 2007, CANCER RES, V67, P1090, DOI 10.1158/0008-5472.CAN-06-3117; Valcourt U, 2005, MOL BIOL CELL, V16, P1987, DOI 10.1091/mbc.e04-08-0658; Velasco-Loyden G, 2004, J BIOL CHEM, V279, P7721, DOI 10.1074/jbc.M306499200; Vilchis-Landeros MM, 2001, BIOCHEM J, V355, P215, DOI 10.1042/0264-6021:3550215; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	40	8	8	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2019	38	18					3402	3414		10.1038/s41388-018-0672-7	http://dx.doi.org/10.1038/s41388-018-0672-7			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HW3RI	30643193	Green Accepted			2022-12-28	WOS:000466610000006
J	Knudsen, ES; Kumarasamy, V; Ruiz, A; Sivinski, J; Chung, SJ; Grant, A; Vail, P; Chauhan, SS; Jie, T; Riall, TS; Witkiewicz, AK				Knudsen, Erik S.; Kumarasamy, Vishnu; Ruiz, Amanda; Sivinski, Jared; Chung, Sejin; Grant, Adam; Vail, Paris; Chauhan, Shailender S.; Jie, Tun; Riall, Taylor S.; Witkiewicz, Agnieszka K.			Cell cycle plasticity driven by MTOR signaling: integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer	ONCOGENE			English	Article							BREAST-CANCER; CDK6; PROLIFERATION; COMBINATION; PATHWAY; SENSITIVITY; ABERRATIONS; PROGRESSION; MECHANISMS; SENESCENCE	Pancreatic ductal adenocarcinoma (PDAC), like many KRAS-driven tumors, preferentially loses CDKN2A that encodes an endogenous CDK4/6 inhibitor to bypass the RB-mediated cell cycle suppression. Analysis of a panel of patient-derived cell lines and matched xenografts indicated that many pancreatic cancers have intrinsic resistance to CDK4/6 inhibition that is not due to any established mechanism or published biomarker. Rather, there is a KRAS-dependent rapid adaptive response that leads to the upregulation of cyclin proteins, which participate in functional complexes to mediate resistance. In vivo, the degree of response is associated with the suppression of a gene expression signature that is strongly prognostic in pancreatic cancer. Resistance is associated with an adaptive gene expression signature that is common to multiple kinase inhibitors, but is attenuated with MTOR inhibitors. Combination treatment with MTOR and CDK4/6 inhibitors had potent activity across a large number of patient-derived models of PDAC underscoring the potential clinical efficacy.	[Knudsen, Erik S.; Kumarasamy, Vishnu; Ruiz, Amanda; Chung, Sejin; Grant, Adam; Vail, Paris; Witkiewicz, Agnieszka K.] Roswell Pk Canc Inst, Ctr Personalized Med, Buffalo, NY 14263 USA; [Knudsen, Erik S.; Kumarasamy, Vishnu; Ruiz, Amanda; Chung, Sejin; Grant, Adam; Vail, Paris] Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; [Sivinski, Jared] Univ Arizona, Dept Pharmacol, Tucson, AZ USA; [Chauhan, Shailender S.] Univ Arizona, Cellular & Mol Med, Tucson, AZ USA; [Jie, Tun; Riall, Taylor S.] Univ Arizona, Dept Surg, Tucson, AZ USA; [Witkiewicz, Agnieszka K.] Roswell Pk Canc Inst, Dept Pathol, Buffalo, NY 14263 USA	Roswell Park Cancer Institute; Roswell Park Cancer Institute; University of Arizona; University of Arizona; University of Arizona; Roswell Park Cancer Institute	Knudsen, ES; Witkiewicz, AK (corresponding author), Roswell Pk Canc Inst, Ctr Personalized Med, Buffalo, NY 14263 USA.; Knudsen, ES (corresponding author), Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA.; Witkiewicz, AK (corresponding author), Roswell Pk Canc Inst, Dept Pathol, Buffalo, NY 14263 USA.	Erik.Knudsen@roswellpark.org; Agnieszka.Witkiewicz@roswellpark.org	Kumarasamy, Vishnu/AAV-8896-2021; Chauhan, Shailender Singh/AAM-5269-2020	Chauhan, Shailender Singh/0000-0002-1975-2734; Sivinski, Jared/0000-0003-2696-6279	NCI; NATIONAL CANCER INSTITUTE [R01CA211878] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank all members of the laboratory group and colleagues in the discussion and preparation of this paper. The research was supported by a grant to AKW from the NCI.	Aguirre AJ, 2017, CANCER CELL, V32, P185, DOI 10.1016/j.ccell.2017.07.007; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Asghar U, 2015, NAT REV DRUG DISCOV, V14, P130, DOI 10.1038/nrd4504; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Cheema AR, 2016, SURG CLIN N AM, V96, P1391, DOI 10.1016/j.suc.2016.07.011; Chou A, 2018, GUT, V67, P2142, DOI 10.1136/gutjnl-2017-315144; Collisson EA, 2011, NAT MED, V17, P500, DOI 10.1038/nm.2344; Cowan RW, 2014, CANCER J, V20, P80, DOI 10.1097/PPO.0000000000000011; Driscoll DR, 2016, CANCER RES, V76, P6911, DOI 10.1158/0008-5472.CAN-16-0810; Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053; Duronio RJ, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008904; Franco J, 2016, CELL REP, V14, P979, DOI 10.1016/j.celrep.2015.12.094; Franco J, 2014, ONCOTARGET, V5, P6512, DOI 10.18632/oncotarget.2270; Gao H, 2015, NAT MED, V21, P1318, DOI 10.1038/nm.3954; Gao SQ, 2017, ONCOTARGET, V8, P98233, DOI 10.18632/oncotarget.21004; Gelbert LM, 2014, INVEST NEW DRUG, V32, P825, DOI 10.1007/s10637-014-0120-7; Goel S, 2016, CANCER CELL, V29, P255, DOI 10.1016/j.ccell.2016.02.006; Gong XQ, 2017, CANCER CELL, V32, P761, DOI 10.1016/j.ccell.2017.11.006; Heilmann AM, 2014, CANCER RES, V74, P3947, DOI 10.1158/0008-5472.CAN-13-2923; Herrera-Abreu MT, 2016, CANCER RES, V76, P2301, DOI 10.1158/0008-5472.CAN-15-0728; Johnson GL, 2014, CLIN CANCER RES, V20, P2516, DOI 10.1158/1078-0432.CCR-13-1081; Kleeff J, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.22; Knudsen ES, 2018, GUT, V67, P508, DOI 10.1136/gutjnl-2016-313133; Knudsen ES, 2017, TRENDS CANCER, V3, P39, DOI 10.1016/j.trecan.2016.11.006; Knudsen ES, 2016, GASTROENTEROLOGY, V150, P48, DOI 10.1053/j.gastro.2015.08.056; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; Kwong LN, 2012, NAT MED, V18, P1503, DOI 10.1038/nm.2941; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Ono H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096060; Ottaiano A, 2017, ACTA ONCOL, V56, P377, DOI 10.1080/0284186X.2017.1288922; Patel P, 2018, MOL CANCER RES, V16, P361, DOI 10.1158/1541-7786.MCR-17-0602; Patnaik A, 2016, CANCER DISCOV, V6, P740, DOI 10.1158/2159-8290.CD-16-0095; Raspe E, 2017, EMBO MOL MED, V9, P1052, DOI 10.15252/emmm.201607084; Rodrik-Outmezguine VS, 2011, CANCER DISCOV, V1, P248, DOI 10.1158/2159-8290.CD-11-0085; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Sherr CJ, 2016, CANCER DISCOV, V6, P353, DOI 10.1158/2159-8290.CD-15-0894; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Teh JLF, 2018, CANCER DISCOV, V8, P568, DOI 10.1158/2159-8290.CD-17-0699; Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0; Witkiewicz AK, 2016, CELL REP, V16, P2017, DOI 10.1016/j.celrep.2016.07.023; Witkiewicz AK, 2015, ONCOTARGET, V6, P15788, DOI 10.18632/oncotarget.3819; Witkiewicz AK, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7744; Witkiewicz AK, 2011, CELL CYCLE, V10, P2497, DOI 10.4161/cc.10.15.16776; Yoshida A, 2016, CANCER RES, V76, P2990, DOI 10.1158/0008-5472.CAN-15-2931; Yuan TL, 2018, CELL REP, V22, P1889, DOI 10.1016/j.celrep.2018.01.051; Zhang JF, 2016, MOL CELL, V62, P929, DOI 10.1016/j.molcel.2016.04.023; 2004, MOL CANC THER, V3, P1427	51	30	30	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2019	38	18					3355	3370		10.1038/s41388-018-0650-0	http://dx.doi.org/10.1038/s41388-018-0650-0			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HW3RI	30696953	Green Accepted			2022-12-28	WOS:000466610000003
J	Cai, L; Lin, SY; Girard, L; Zhou, YY; Yang, L; Ci, B; Zhou, QB; Luo, DN; Yao, B; Tang, H; Allen, J; Huffman, K; Gazdar, A; Heymach, J; Wistuba, I; Xiao, GH; Minna, J; Xie, Y				Cai, Ling; Lin, ShinYi; Girard, Luc; Zhou, Yunyun; Yang, Lin; Ci, Bo; Zhou, Qinbo; Luo, Danni; Yao, Bo; Tang, Hao; Allen, Jeffrey; Huffman, Kenneth; Gazdar, Adi; Heymach, John; Wistuba, Ignacio; Xiao, Guanghua; Minna, John; Xie, Yang			LCE: an open web portal to explore gene expression and clinical associations in lung cancer	ONCOGENE			English	Article							PUBLIC REPOSITORY; KLOTHO; CLASSIFICATION; ARRAYEXPRESS; BLOCKADE; MICE	We constructed a lung cancer-specific database housing expression data and clinical data from over 6700 patients in 56 studies. Expression data from 23 genome-wide platforms were carefully processed and quality controlled, whereas clinical data were standardized and rigorously curated. Empowered by this lung cancer database, we created an open access web resource-the Lung Cancer Explorer (LCE), which enables researchers and clinicians to explore these data and perform analyses. Users can perform meta-analyses on LCE to gain a quick overview of the results on tumor vs non-malignant tissue (normal) differential gene expression and expression-survival association. Individual dataset-based survival analysis, comparative analysis, and correlation analysis are also provided with flexible options to allow for customized analyses from the user.	[Cai, Ling; Zhou, Yunyun; Yang, Lin; Ci, Bo; Yao, Bo; Tang, Hao; Allen, Jeffrey; Xiao, Guanghua; Xie, Yang] UT Southwestern Med Ctr, Quantitat Biomed Res Ctr, Dept Clin Sci, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Cai, Ling] UT Southwestern Med Ctr, Childrens Med Ctr, Res Inst, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Lin, ShinYi; Zhou, Qinbo; Luo, Danni; Yao, Bo; Xiao, Guanghua; Xie, Yang] UT Southwestern Med Ctr, Bioinformat Core Facil, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Girard, Luc; Huffman, Kenneth; Gazdar, Adi; Minna, John] Univ Texas Southwestern Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Zhou, Yunyun] Univ Mississippi, Med Ctr, Dept Data Sci, 2500N State St, Jackson, MS 39216 USA; [Yang, Lin] Chinese Acad Med Sci, Dept Pathol, Natl Canc Ctr, Canc Hosp, Beijing 100021, Peoples R China; [Yang, Lin] Peking Union Med Coll, Beijing 100021, Peoples R China; [Gazdar, Adi] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Heymach, John] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77005 USA; [Wistuba, Ignacio] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Xiao, Guanghua; Minna, John; Xie, Yang] Univ Texas Southwestern Med Ctr Dallas, Simmons Canc Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Minna, John] Univ Texas Southwestern Med Ctr Dallas, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Minna, John] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Mississippi; University of Mississippi Medical Center; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Xiao, GH; Xie, Y (corresponding author), UT Southwestern Med Ctr, Quantitat Biomed Res Ctr, Dept Clin Sci, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.; Xiao, GH; Xie, Y (corresponding author), UT Southwestern Med Ctr, Bioinformat Core Facil, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.; Minna, J (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.; Xiao, GH; Minna, J; Xie, Y (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Simmons Canc Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.; Minna, J (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.; Minna, J (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Guanghua.Xiao@UTSouthwestern.edu; John.Minna@UTSouthwestern.edu; Yang.Xie@UTSouthwestern.edu	Heymach, John/AAG-2361-2019; Yang, Lin/J-6807-2019	Heymach, John/0000-0001-9068-8942; Yang, Lin/0000-0002-7594-3770	National Institutes of Health [5R01CA152301, P50CA70907, 5P30CA142543, 1R01GM115473, 1R01CA172211]; Cancer Prevention and Research Institute of Texas [RP120732, RP180805, RP150596]; NATIONAL CANCER INSTITUTE [P30CA142543, R01CA172211, P50CA070907] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM115473] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention and Research Institute of Texas; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was partially supported by grants from the National Institutes of Health [5R01CA152301, P50CA70907, 5P30CA142543, 1R01GM115473, and 1R01CA172211], and the Cancer Prevention and Research Institute of Texas [RP120732, RP180805, and RP150596]. We thank Jessie Norris for proofreading the manuscript.	Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Bai J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059772; Brazma A, 2003, NUCLEIC ACIDS RES, V31, P68, DOI 10.1093/nar/gkg091; Broad Institute TCGA Genome Data Analysis Center, 2016, AN READ STAND TCGA B, DOI [10.7908/C11G0KM9, DOI 10.7908/C11G0KM9]; Cheng WC, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-421; Croft D, 2014, NUCLEIC ACIDS RES, V42, pD472, DOI 10.1093/nar/gkt1102; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Feichtinger J, 2012, DATABASE-OXFORD, DOI 10.1093/database/bas055; Fraley C, 2002, J AM STAT ASSOC, V97, P611, DOI 10.1198/016214502760047131; Fukuoka J, 2004, CLIN CANCER RES, V10, P4314, DOI 10.1158/1078-0432.CCR-03-0489; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Girard L, 2016, CLIN CANCER RES, V22, P4880, DOI 10.1158/1078-0432.CCR-15-2900; Goswami Chirayu Pankaj, 2013, J Clin Bioinforma, V3, P22, DOI 10.1186/2043-9113-3-22; Gray KA, 2015, NUCLEIC ACIDS RES, V43, pD1079, DOI 10.1093/nar/gku1071; Greene CS, 2015, NAT GENET, V47, P569, DOI 10.1038/ng.3259; Hellmann Matthew D, 2018, N Engl J Med, V378, P2093, DOI 10.1056/NEJMoa1801946; Hellmann MD, 2018, CANCER CELL, V33, P853, DOI 10.1016/j.ccell.2018.04.001; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Kang DD, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gkr1071; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kilpinen S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r139; Kris MG, 2014, JAMA-J AM MED ASSOC, V311, P1998, DOI 10.1001/jama.2014.3741; Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Mizuno H, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-18; Morishita K, 2001, J NUTR, V131, P3182, DOI 10.1093/jn/131.12.3182; Nicholson Andrew G, 2018, G048 DATASET HISTOPA; Niehrs C, 1999, NATURE, V402, P483, DOI 10.1038/990025; NORDENBERG D, 1990, JAMA-J AM MED ASSOC, V264, P1556, DOI 10.1001/jama.264.12.1556; Omberg L, 2013, NAT GENET, V45, P1121, DOI 10.1038/ng.2761; Orvis T, 2014, CANCER RES, V74, P6486, DOI 10.1158/0008-5472.CAN-14-0061; Parkinson H, 2005, NUCLEIC ACIDS RES, V33, pD553; Parmigiani G, 2004, CLIN CANCER RES, V10, P2922, DOI 10.1158/1078-0432.CCR-03-0490; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Rizvi H, 2018, J CLIN ONCOL, V36, P633, DOI 10.1200/JCO.2017.75.3384; Schabath MB, 2016, ONCOGENE, V35, P3209, DOI 10.1038/onc.2015.375; Schwarzer G., 2007, R NEWS, V7, P40; Shedden K, 2008, NAT MED, V14, P822, DOI 10.1038/nm.1790; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Szasz AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337; Therneau TM, 2000, MODELING SURVIVAL DA; Thorsson V, 2018, IMMUNITY, V48, P812, DOI [10.1016/j.immuni.2018.03.023, 10.1016/j.immuni.2019.08.004]; Torres PU, 2007, KIDNEY INT, V71, P730, DOI 10.1038/sj.ki.5002163; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03; Xie B, 2013, PATHOL ONCOL RES, V19, P611, DOI 10.1007/s12253-013-9663-8; Zappasodi R, 2018, CANCER CELL, V33, P581, DOI 10.1016/j.ccell.2018.03.005; Zhang A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110052; Zhu YL, 2008, BIOINFORMATICS, V24, P2798, DOI 10.1093/bioinformatics/btn520; Zoubarev A, 2012, BIOINFORMATICS, V28, P2272, DOI 10.1093/bioinformatics/bts430	50	54	55	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2019	38	14					2551	2564		10.1038/s41388-018-0588-2	http://dx.doi.org/10.1038/s41388-018-0588-2			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HR7LI	30532070	Green Published, hybrid			2022-12-28	WOS:000463335200008
J	Xu, C; Wang, YF; Tu, Q; Zhang, ZY; Chen, MR; Mwangi, J; Li, YX; Jin, Y; Zhao, XD; Lai, R				Xu, Cheng; Wang, Yunfei; Tu, Qiu; Zhang, Zhiye; Chen, Mengrou; Mwangi, James; Li, Yaxiong; Jin, Yang; Zhao, Xudong; Lai, Ren			Targeting surface nucleolin induces autophagy-dependent cell death in pancreatic cancer via AMPK activation	ONCOGENE			English	Article							DEFENSE PEPTIDE LL-37; IN-VIVO; GROWTH; GEMCITABINE; THERAPY; PROLIFERATION; MECHANISMS; RESISTANCE; APOPTOSIS; PROMOTES	Pancreatic cancer remains one of the deadliest human cancers despite current advances in conventional therapeutics including surgery and adjuvant therapies. Here, we showed that LZ1, a peptide derived from a snake venom cathelicidin, significantly inhibited growth of pancreatic cancer cells by inducing autophagy-dependent cell death both in vitro and in vivo. The LZ1-induced cell death was blocked by pharmacological or genetic inhibition of autophagy. In orthotopic model of pancreatic cancer, systemic administration of LZ1 (1-4 mg/kg) exhibited remarkable antitumor efficacy, significantly prolonged mice survival, and showed negligible adverse effects by comparison with gemcitabine (20 mg/kg). Mechanistic studies revealed that LZ1 acts through binding to nucleolin, whose expression on cell surface is frequently increased in pancreatic cancer cells. LZ1 binding triggers degradation of surface-expressed nucleolin. This leads to activation of 5'-AMP kinase which results in suppression of mTORC1 activity and induction of autophagic flux. These data suggest that LZ1, targeting nucleolin-AMPK-autophagy axis, is a promising lead for the development of therapeutic agents against pancreatic cancer.	[Xu, Cheng; Wang, Yunfei; Tu, Qiu; Zhang, Zhiye; Mwangi, James; Zhao, Xudong; Lai, Ren] Chinese Acad Sci, Key Lab Anim Models & Human Dis Mech, Key Lab Bioact Peptides Yunnan Prov, Kunming Inst Zool, Kunming 650223, Yunnan, Peoples R China; [Xu, Cheng; Wang, Yunfei; Mwangi, James] Univ Chinese Acad Sci, Kunming Coll Life Sci, Kunming 650204, Yunnan, Peoples R China; [Chen, Mengrou; Lai, Ren] Nanjing Agr Univ, Life Sci Coll, Nanjing 210095, Jiangsu, Peoples R China; [Mwangi, James; Lai, Ren] Chinese Acad Sci, Sino African Joint Res Ctr, Kunming Inst Zool, Kunming 650223, Yunnan, Peoples R China; [Li, Yaxiong] Kunming Med Univ, Yanan Affiliated Hosp, Dept Cardiovasc Surg, Kunming 650041, Yunnan, Peoples R China; [Jin, Yang] Oslo Univ Hosp, Inst Canc Genet & Informat, Oslo, Norway	Chinese Academy of Sciences; Kunming Institute of Zoology; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Nanjing Agricultural University; Chinese Academy of Sciences; Kunming Institute of Zoology; Kunming Medical University; University of Oslo	Zhao, XD; Lai, R (corresponding author), Chinese Acad Sci, Key Lab Anim Models & Human Dis Mech, Key Lab Bioact Peptides Yunnan Prov, Kunming Inst Zool, Kunming 650223, Yunnan, Peoples R China.; Lai, R (corresponding author), Nanjing Agr Univ, Life Sci Coll, Nanjing 210095, Jiangsu, Peoples R China.; Lai, R (corresponding author), Chinese Acad Sci, Sino African Joint Res Ctr, Kunming Inst Zool, Kunming 650223, Yunnan, Peoples R China.; Jin, Y (corresponding author), Oslo Univ Hosp, Inst Canc Genet & Informat, Oslo, Norway.	yangj@ibv.uio.no; zhaoxudong@mail.kiz.ac.cn; rlai@mail.kiz.ac.cn	Jin, Yang/GXF-7896-2022	Jin, Yang/0000-0002-7996-048X; Zhang, Zhiye/0000-0002-1661-2277; zhao, zhao xu dong/0000-0001-9126-7365	National Natural Science Foundation of China [21761142002, 81770464]; Ministry of Science and Technology [2018ZX09301043-003]; Chinese Academy of Science [QYZDJ-SSWSMC012, SAJC201606]; Chinese Academy of Science (West Light Foundation); Chinese Academy of Science (Youth Innovation Promotion Association) [2017432]; Yunnan Provincial Science and Technology Department [2017FB038, 2015BC005]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Chinese Academy of Science(Chinese Academy of Sciences); Chinese Academy of Science (West Light Foundation); Chinese Academy of Science (Youth Innovation Promotion Association); Yunnan Provincial Science and Technology Department	This work was supported by National Natural Science Foundation of China (21761142002 and 81770464), Ministry of Science and Technology (2018ZX09301043-003), Chinese Academy of Science (QYZDJ-SSWSMC012, SAJC201606, the West Light Foundation and Youth Innovation Promotion Association (2017432)) and Yunnan Provincial Science and Technology Department (2017FB038, 2015BC005).	Benedetti E, 2015, ONCOTARGET, V6, P42091, DOI 10.18632/oncotarget.5990; Berger CM, 2015, BIOCHIMIE, V113, P78, DOI 10.1016/j.biochi.2015.03.023; Cavalcante LD, 2014, EUR J PHARMACOL, V741, P8, DOI [10.1016/j.ejphar.2014.07.041, 10.1010/j.ejphar.2014.07.041]; CHEN CM, 1991, J BIOL CHEM, V266, P7754; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Destouches D, 2011, CANCER RES, V71, P3296, DOI 10.1158/0008-5472.CAN-10-3459; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; FANG SH, 1993, EXP CELL RES, V208, P48, DOI 10.1006/excr.1993.1221; Farin K, 2011, CANCER RES, V71, P2140, DOI 10.1158/0008-5472.CAN-10-2887; Galzio R, 2012, J CELL BIOCHEM, V113, P571, DOI 10.1002/jcb.23381; Gilles ME, 2016, CANCER RES, V76, P7181, DOI 10.1158/0008-5472.CAN-16-0300; Goldshmit Y, 2014, ONCOTARGET, V5, P8602, DOI 10.18632/oncotarget.2343; Hamma-Kourbali Y, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-212; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; He XQ, 2016, EBIOMEDICINE, V13, P248, DOI 10.1016/j.ebiom.2016.10.022; Hidalgo M, 2015, PANCREATOLOGY, V15, P8, DOI 10.1016/j.pan.2014.10.001; Hovanessian AG, 2006, CELL RES, V16, P174, DOI 10.1038/sj.cr.7310024; Huang Y, 2006, BLOOD, V107, P3564, DOI 10.1182/blood-2005-07-2961; Khanbolooki S, 2006, MOL CANCER THER, V5, P2251, DOI 10.1158/1535-7163.MCT-06-0075; Kim MP, 2008, CLIN CANCER RES, V14, P1284, DOI 10.1158/1078-0432.CCR-07-2247; Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035; Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529; Krust B, 2001, P NATL ACAD SCI USA, V98, P14090, DOI 10.1073/pnas.221467298; Krust B, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-333; Li FF, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01565-6; Liu Y, 2015, CELL DEATH DIFFER, V22, P367, DOI 10.1038/cdd.2014.143; Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; Mongelard F, 2007, TRENDS CELL BIOL, V17, P80, DOI 10.1016/j.tcb.2006.11.010; Nazli O, 2000, HEPATO-GASTROENTEROL, V47, P1750; Nikoletopoulou V, 2013, BBA-MOL CELL RES, V1833, P3448, DOI 10.1016/j.bbamcr.2013.06.001; Paglin S, 2001, CANCER RES, V61, P439; Palmieri D, 2015, P NATL ACAD SCI USA, V112, P9418, DOI 10.1073/pnas.1507087112; Qin JY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9471; Ren SX, 2012, CANCER RES, V72, P6512, DOI 10.1158/0008-5472.CAN-12-2359; Reyes-Reyes EM, 2010, CANCER RES, V70, P8617, DOI 10.1158/0008-5472.CAN-10-0920; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Said EA, 2005, FEBS J, V272, P4646, DOI 10.1111/j.1742-4658.2005.04870.x; Said EA, 2002, J BIOL CHEM, V277, P37492, DOI 10.1074/jbc.M201194200; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; Shen SS, 2012, AUTOPHAGY, V8, P1, DOI 10.4161/auto.8.1.16618; Shi S, 2012, CANCER LETT, V317, P127, DOI 10.1016/j.canlet.2011.11.029; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Soundararajan S, 2008, CANCER RES, V68, P2358, DOI 10.1158/0008-5472.CAN-07-5723; Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0; Wang H, 2013, EUR J PHARMACOL, V707, P1, DOI 10.1016/j.ejphar.2013.03.028; Wu WKK, 2010, INT J CANCER, V127, P1741, DOI 10.1002/ijc.25489; Yang AN, 2018, CANCER DISCOV, V8, P276, DOI 10.1158/2159-8290.CD-17-0952; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Zhou ST, 2012, CANCER LETT, V323, P115, DOI 10.1016/j.canlet.2012.02.017	50	28	29	6	34	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2019	38	11					1832	1844		10.1038/s41388-018-0556-x	http://dx.doi.org/10.1038/s41388-018-0556-x			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HO7XX	30356139				2022-12-28	WOS:000461164400004
J	Buffiere, A; Uzan, B; Aucagne, R; Hermetet, F; Mas, M; Nassurdine, S; Aznague, A; Carmignac, V; Tournier, B; Bouchot, O; Ballerini, P; Barata, JT; Bastie, JN; Delva, L; Pflumio, F; Quere, R				Buffiere, Anne; Uzan, Benjamin; Aucagne, Romain; Hermetet, Francois; Mas, Manon; Nassurdine, Sandra; Aznague, Aziza; Carmignac, Virginie; Tournier, Benjamin; Bouchot, Olivier; Ballerini, Paola; Barata, Joao T.; Bastie, Jean-Noel; Delva, Laurent; Pflumio, Francoise; Quere, Ronan			T-cell acute lymphoblastic leukemia displays autocrine production of Interleukin-7	ONCOGENE			English	Article							OF-FUNCTION MUTATIONS; IL-7; PROGRESSION; ACTIVATION; SURVIVAL; ISLANDS; GROWTH; IL7R	T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy characterized by an accumulation of immature T cells. Although patient outcomes have improved, novel targeted therapies are needed to reduce the intensity of chemotherapy and improve the prognosis of high-risk patients. Interleukin-7 (IL-7) modulates the survival and proliferation of normal and malignant T cells. Targeting the IL-7 signaling pathway is thus a potentially effective therapeutic strategy. To achieve such aim, it is essential to first understand how the IL-7 signaling pathway is activated. Although IL-7 production has been observed from multiple stromal tissues, T-ALL autocrine IL-7 secretion has not yet been described. Interestingly, using T-ALL cell lines, primary and patient-derived xenotransplanted (PDX) T-ALL cells, we demonstrate that T-ALL cells produce IL-7 whereas normal T cells do not. Finally, using knock down of IL7 gene in T-ALL cells, we describe to what extent IL-7 autocrine secretion is involved in the T-ALL cells propagation in bone marrow and how it affects the number of leukemia-initiating cells in PDX mice. Together, these results demonstrate how the autocrine production of the IL-7 cytokine mediated by T-ALL cells can be involved in the oncogenic development of T-ALL and offer novel insights into T-ALL spreading.	[Buffiere, Anne; Aucagne, Romain; Hermetet, Francois; Mas, Manon; Nassurdine, Sandra; Aznague, Aziza; Carmignac, Virginie; Bastie, Jean-Noel; Delva, Laurent; Quere, Ronan] Univ Bourgogne Franche Comte, Inserm, UMR1231, Dijon, France; [Buffiere, Anne; Aucagne, Romain; Hermetet, Francois; Aznague, Aziza; Bastie, Jean-Noel; Delva, Laurent; Quere, Ronan] LipSTIC Lab, Dijon, France; [Uzan, Benjamin; Pflumio, Francoise] Univ Paris 11, Univ Paris 7, CEA, Inserm,UMR967, Fontenay Aux Roses, France; [Uzan, Benjamin; Pflumio, Francoise] CEA, IRCM, LSHL, Fontenay Aux Roses, France; [Tournier, Benjamin] Hop Univ Francois Mitterrand, Serv Genet Canc, Dijon, France; [Bouchot, Olivier] Hop Univ Francois Mitterrand, Chirurg Cardiovasc, Dijon, France; [Ballerini, Paola] Hop Trousseau, AP HP, Lab Hematol, Paris, France; [Barata, Joao T.] Univ Lisbon, Fac Med, Inst Med Mol, Lisbon, Portugal; [Bastie, Jean-Noel] Hop Univ Francois Mitterrand, Serv Hematol Clin, Dijon, France; [Bastie, Jean-Noel] Hop Univ Francois Mitterrand, CRB Ferdinand Cabanne, BB 0033-00044, Dijon, France	Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; CHU Dijon Bourgogne; CHU Dijon Bourgogne; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; Universidade de Lisboa; CHU Dijon Bourgogne; CHU Dijon Bourgogne	Quere, R (corresponding author), Univ Bourgogne Franche Comte, Inserm, UMR1231, Dijon, France.; Quere, R (corresponding author), LipSTIC Lab, Dijon, France.	ronan.quere@inserm.fr	Hermetet, François/GPF-8614-2022; Quere, Ronan/C-6178-2017	Pflumio, Francoise/0000-0001-8995-596X; Aucagne, Romain/0000-0002-5644-3287; DELVA, Laurent/0000-0002-1086-3964; Quere, Ronan/0000-0002-1615-6769; Hermetet, Francois/0000-0001-5549-1992; Tournier, Benjamin/0000-0001-6609-8096	Association Laurette Fugain; Conference de Coordination Interregionale du Grand Est - Bourgogne Franche-Comte (CCIRGE-BFC) de la Ligue contre le Cancer; National Research Agency under the program "Investissements d'Avenir" [ANR-11-LABX-0021]; (LipSTIC Labex); Conseil Regional de Bourgogne through the plan d'action regional pour l'innovation (PARI); European Union through the PO FEDER-FSE Bourgogne; French Ministere de la Recherche et de l'Enseignement Superieur (MRES); Ligue contre le Cancer; INSERM; Universite Paris Diderot	Association Laurette Fugain; Conference de Coordination Interregionale du Grand Est - Bourgogne Franche-Comte (CCIRGE-BFC) de la Ligue contre le Cancer; National Research Agency under the program "Investissements d'Avenir"(French National Research Agency (ANR)); (LipSTIC Labex); Conseil Regional de Bourgogne through the plan d'action regional pour l'innovation (PARI); European Union through the PO FEDER-FSE Bourgogne; French Ministere de la Recherche et de l'Enseignement Superieur (MRES); Ligue contre le Cancer(Ligue nationale contre le cancer); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Universite Paris Diderot	The authors express their gratitude to the animal housing facility and cytometry platform staff at the University of Burgundy (Dijon, France), especially Valerie Saint-Giorgio, David Lheraud, Sebastien Lapipe, Anabelle Sequeira, and Serge Monier, for their excellent suggestions and valuable technical support. The authors also thank Julien Guy for providing information on T-ALL immune data that helped in the EGIL characterization, as well as Antonio Vitobello for providing insight about DNA methylation. The authors are also grateful to Suzanne Rankin (CHU Dijon) for editing and proofreading this paper. This study was supported by grants from the Association Laurette Fugain (RQ), the Conference de Coordination Interregionale du Grand Est - Bourgogne Franche-Comte (CCIRGE-BFC) de la Ligue contre le Cancer (RQ), by the National Research Agency under the program "Investissements d'Avenir" (reference ANR-11-LABX-0021, LipSTIC Labex), by the Conseil Regional de Bourgogne through the plan d'action regional pour l'innovation (PARI), and the European Union through the PO FEDER-FSE Bourgogne 2014/2020 programs. AB was supported by fellowships from the French Ministere de la Recherche et de l'Enseignement Superieur (MRES) and the Ligue contre le Cancer. FP and BU have grants from LNCC, INSERM, CEA, and Universite Paris Diderot.	Alves NL, 2009, P NATL ACAD SCI USA, V106, P1512, DOI 10.1073/pnas.0809559106; Barata JT, 2006, EXP HEMATOL, V34, P1133, DOI 10.1016/j.exphem.2006.05.001; Barata JT, 2004, J EXP MED, V200, P659, DOI 10.1084/jem.20040789; Barata JT, 2001, BLOOD, V98, P1524, DOI 10.1182/blood.V98.5.1524; Black KL, 2018, NUCLEIC ACIDS RES, V46, P11357, DOI 10.1093/nar/gky946; Buffiere A, 2018, LEUKEMIA, V32, P2062, DOI 10.1038/s41375-018-0081-5; Cai YJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058647; Cramer SD, 2016, BLOOD, V128, P473, DOI 10.1182/blood-2016-03-679209; Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511; Freyer DR, 2011, BLOOD, V117, P3010, DOI 10.1182/blood-2010-07-294678; Fry TJ, 2002, BLOOD, V99, P3892, DOI 10.1182/blood.V99.11.3892; FUNK PE, 1995, BLOOD, V86, P2661; Girardi T, 2017, BLOOD, V129, P1113, DOI 10.1182/blood-2016-10-706465; Hunger SP, 2015, NEW ENGL J MED, V373, P1541, DOI 10.1056/NEJMra1400972; Jacobs SR, 2010, J IMMUNOL, V184, P3461, DOI 10.4049/jimmunol.0902593; Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230; Karawajew L, 2000, BLOOD, V96, P297, DOI 10.1182/blood.V96.1.297.013k24_297_306; Laouar Y, 2004, BLOOD, V103, P1985, DOI 10.1182/blood-2003-06-2126; Liu Y, 2017, NAT GENET, V49, P1211, DOI 10.1038/ng.3909; Marks DI, 2009, BLOOD, V114, P5136, DOI 10.1182/blood-2009-08-231217; Oosterwegel MA, 1997, IMMUNITY, V6, P351, DOI 10.1016/S1074-7613(00)80337-4; Oshima S, 2004, MOL CELL BIOL, V24, P6298, DOI 10.1128/MCB.24.14.6298-6310.2004; Poglio S, 2015, LEUKEMIA, V29, P977, DOI 10.1038/leu.2014.317; RICH BE, 1993, J EXP MED, V177, P305, DOI 10.1084/jem.177.2.305; Richter-Pechanska P, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201809443; Scupoli MT, 2007, HAEMATOLOGICA, V92, P264, DOI 10.3324/haematol.10356; Scupoli MT, 2003, HAEMATOLOGICA, V88, P1229; Shochat C, 2011, J EXP MED, V208, P901, DOI 10.1084/jem.20110580; Silva A, 2011, CANCER RES, V71, P4780, DOI 10.1158/0008-5472.CAN-10-3606; Thomas X, 2004, J CLIN ONCOL, V22, P4075, DOI 10.1200/JCO.2004.10.050; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Zenatti PP, 2011, NAT GENET, V43, P932, DOI 10.1038/ng.924	32	7	7	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2019	38	48					7357	7365		10.1038/s41388-019-0921-4	http://dx.doi.org/10.1038/s41388-019-0921-4			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JR4XX	31417180				2022-12-28	WOS:000499631000006
J	Koh, XY; Koh, XH; Hwang, LA; Ferrer, FJ; Rahmat, SAB; Lama, D; Lane, DP				Koh, Xin Yu; Koh, Xiao Hui; Hwang, Le-ann; Ferrer, Fernando Jose; Rahmat, Siti Aishah Binte; Lama, Dilraj; Lane, David P.			Therapeutic anti-cancer activity of antibodies targeting sulfhydryl bond constrained epitopes on unglycosylated RON receptor tyrosine kinase	ONCOGENE			English	Article							MACROPHAGE-STIMULATING PROTEIN; N-LINKED GLYCOSYLATION; C-MET; MONOCLONAL-ANTIBODY; CANCER-CELLS; GROWTH; PATHOGENESIS; ACTIVATION; PHENOTYPES; HALLMARKS	Recepteur d'origine nantais (RON) receptor tyrosine kinase (RTK) and its ligand, serum macrophage-stimulating protein (MSP), are well-established oncogenic drivers for tumorigenesis and metastasis. RON is often found to be alternatively spliced resulting in various isoforms that are constitutively active. RON is therefore an attractive target for cancer therapeutics, including small molecular inhibitors and monoclonal antibodies. While small molecule inhibitors of RON may inhibit other protein kinases including the highly similar MET kinase, monoclonal antibodies targeting RON are more specific, potentially inducing fewer side effects. Although anti-RON monoclonal antibody therapies have been developed and tested in clinical trials, they were met with limited success. Cancer cells have been associated with aberrant glycosylation mechanisms. Notably for RON, the loss of N-bisected glycosylation is a direct cause for tumorigenesis and poorer prognosis in cancer patients. Particularly in gastric cancer, aberrant RON glycosylation augments RON activation. Here, we present a novel panel of monoclonal antibodies which potentially widens the specific targeting of not only the glycosylated RON, but also unglycosylated and aberrantly glycosylated RON. Our antibodies can bind strongly to deglycosylated RON from tunicamycin treated cells, recognise RON in IHC/IF and possess superior therapeutic efficacy in RON expressing xenograft tumours. Our most potent antibody in xenograft assays, is directed to the RON alpha chain and targets a sulfhydryl bond constrained epitope that appears to be cryptic in the crystal structure. This establishes the paradigm that such constrained and cryptic epitopes represent good targets for therapeutic antibodies.	[Koh, Xin Yu; Koh, Xiao Hui; Hwang, Le-ann; Ferrer, Fernando Jose; Rahmat, Siti Aishah Binte; Lane, David P.] ASTAR, P53 Lab, Singapore, Singapore; [Lama, Dilraj] ASTAR, Bioinformat Inst, Singapore, Singapore	Agency for Science Technology & Research (A*STAR); Agency for Science Technology & Research (A*STAR); A*STAR - Bioinformatics Institute (BII)	Lane, DP (corresponding author), ASTAR, P53 Lab, Singapore, Singapore.	dplane@p53Lab.a-star.edu.sg	Lama, Dilraj/ABG-9950-2020	Lama, Dilraj/0000-0001-8603-9368; Lane, David/0000-0003-0551-3545	A*STAR	A*STAR(Agency for Science Technology & Research (A*STAR))	This work was supported by A*STAR.	Andrade K, 2017, SCI TRANSL MED, V9, P1, DOI 10.1126/scitranslmed.aai9338; Angeloni D, 2004, J BIOL CHEM, V279, P3726, DOI 10.1074/jbc.M309342200; Beers SA, 2016, BLOOD, V127, P1097, DOI 10.1182/blood-2015-09-625343; Benham AM, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a012872; Benz I, 2002, MOL MICROBIOL, V45, P267, DOI 10.1046/j.1365-2958.2002.03030.x; Case VB DA, 2014, AMBER 14; Catenacci DVT, 2011, CANCER BIOL THER, V12, P9, DOI 10.4161/cbt.12.1.15747; Cazet A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2577; Chakedis J, 2016, ONCOTARGET, V7, P45959, DOI 10.18632/oncotarget.10009; Chang K, 2015, ONCOTARGET, V6, P3507, DOI 10.18632/oncotarget.3420; Chao KLL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041912; Chen JF, 2017, ONCOL REP, V37, P721, DOI 10.3892/or.2017.5356; de-Freitas JCM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091921; Dussault I, 2009, ANTI-CANCER AGENT ME, V9, P221, DOI 10.2174/187152009787313792; Ellis CR, 2012, J AM CHEM SOC, V134, P8184, DOI 10.1021/ja301005f; Ferreira IG, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020580; Gomes C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066737; Gorlatova N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027269; Greenbaum A, 2016, HELIYON, V2, DOI 10.1016/j.heliyon.2016.e00153; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Haynes PA, 1998, GLYCOBIOLOGY, V8, P1, DOI 10.1093/glycob/8.1.1; Ho WL, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0334-6; Itkonen HM, 2015, METHODS MOL BIOL, V1233, P103, DOI 10.1007/978-1-4939-1789-1_10; Johns TG, 2004, J BIOL CHEM, V279, P30375, DOI 10.1074/jbc.M401218200; Kang JG, 2011, BMB REP, V44, P765, DOI 10.5483/BMBRep.2011.44.12.765; Kaszuba K, 2015, P NATL ACAD SCI USA, V112, P4334, DOI 10.1073/pnas.1503262112; Krishnaswamy S, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3747-x; Lama D, 2013, SCI REP-UK, V3, DOI 10.1038/srep03451; Ling Y, 2017, ONCOTARGET, V8, P39101, DOI 10.18632/oncotarget.16603; LoRusso PM, 2017, INVEST NEW DRUG, V35, P442, DOI 10.1007/s10637-016-0413-0; Mereiter S, 2016, BBA-GEN SUBJECTS, V1860, P1795, DOI 10.1016/j.bbagen.2015.12.016; Meyer SE, 2009, DEV BIOL, V333, P173, DOI 10.1016/j.ydbio.2009.06.028; Morrison AC, 2004, J IMMUNOL, V172, P1825, DOI 10.4049/jimmunol.172.3.1825; Munkley J, 2016, ONCOTARGET, V7, P35478, DOI 10.18632/oncotarget.8155; Phuc Vinh Nguyen Lam, 2013, Genomics Proteomics & Bioinformatics, V11, P96, DOI 10.1016/j.gpb.2012.11.003; RONSIN C, 1993, ONCOGENE, V8, P1195; Sarabipour S, 2013, BIOPHYS J, V105, P165, DOI 10.1016/j.bpj.2013.05.053; Very N, 2018, ONCOTARGET, V9, P1380, DOI 10.18632/oncotarget.22377; Wagh PK, 2008, ADV CANCER RES, V100, P1, DOI 10.1016/S0065-230X(08)00001-8; Wang MH, 2007, J PATHOL, V213, P402, DOI 10.1002/path.2245; Wang MH, 2013, J BIOMED RES, V27, P345, DOI 10.7555/JBR.27.20130038; Wong CH, 2005, J ORG CHEM, V70, P4219, DOI 10.1021/jo050278f; Wong JS, 2013, ONCOTARGET, V4, P1019, DOI 10.18632/oncotarget.1075; Yao HP, 2013, NAT REV CANCER, V13, P466, DOI 10.1038/nrc3545; Yao HP, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-82; Yao HP, 2006, CANCER BIOL THER, V5, P1179, DOI 10.4161/cbt.5.9.3073; Zhang K, 2010, INT J ONCOL, V36, P255, DOI 10.3892/ijo_00000496; Zou Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069992	48	9	11	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2019	38	48					7342	7356		10.1038/s41388-019-0946-8	http://dx.doi.org/10.1038/s41388-019-0946-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JR4XX	31417186	hybrid			2022-12-28	WOS:000499631000005
J	Berg, KCG; Sveen, A; Holand, M; Alagaratnam, S; Berg, M; Danielsen, SA; Nesbakken, A; Soreide, K; Lothel, RA				Berg, Kaja C. G.; Sveen, Anita; Holand, Maren; Alagaratnam, Sharmini; Berg, Marianne; Danielsen, Stine A.; Nesbakken, Arild; Soreide, Kjetil; Lothel, Ragnhild A.			Gene expression profiles of CMS2-epithelial/canonical colorectal cancers are largely driven by DNA copy number gains	ONCOGENE			English	Article							CONSENSUS MOLECULAR SUBTYPES; ANNEXIN A11	About 80% of colorectal cancers (CRCs) have chromosomal instability, which is an integral part of aggressive malignancy development, but the importance of specific copy number aberrations (CNAs) in modulating gene expression, particularly within the framework of clinically relevant molecular subtypes, remains mostly elusive. We performed DNA copy number profiling of 257 stage I-IV primary CRCs and integrative gene expression analysis in 151 microsatellite stable (MSS) tumors, focusing on high-level amplifications and the effect of CNAs on the characteristics of the gene expression-based consensus molecular subtypes (CMS). The results were validated in 323 MSS tumors from TCGA. Novel recurrent high-level amplifications (>= 15 additional copies) with a major impact on gene expression were found for TOX3 (16q) at 1.5% frequency, as well as for CCND2 (12p) and ANXA11 (10q) at 1% frequency, in addition to the well-known targets ERBB2 (17q) and MYC (8q). Focal amplifications with >= 15 or >= 5 additional copies of at least one of these regions were associated with a poor overall survival among patients with stage I-III MSS CRCs (multivariable hazard ratio >= 3.2, p <= 0.01). All highlevel amplifications were focal and had a more consistent relationship with gene expression than lower amplitude and/or broad-range amplifications, suggesting specific targeting during carcinogenesis. Genome-wide, copy number driven gene expression was enriched for pathways characteristic of the CMS2-epithelial/canonical subtype, including DNA repair and cell cycle progression. Furthermore, 50% of upregulated genes in CMS2-epithelial/canonical MSS CRCs were driven by CNAs, an enrichment compared with the other CMS groups, and associated with the stronger correspondence between CNAs and gene expression in malignant epithelial cells than in the cells of the tumor microenvironment (fibroblasts, endothelial cells, leukocytes). In conclusion, we identify novel recurrent amplifications with impact on gene expression in CRC and provide the first evidence that CMS2 may have a stronger copy-number related genetic basis than subtypes more heavily influenced by gene expression signals from the tumor microenvironment.	[Berg, Kaja C. G.; Sveen, Anita; Holand, Maren; Alagaratnam, Sharmini; Berg, Marianne; Danielsen, Stine A.; Lothel, Ragnhild A.] Oslo Univ Hosp, Inst Canc Res, Dept Mol Oncol, POB 4953, NO-0424 Oslo, Norway; [Berg, Kaja C. G.; Sveen, Anita; Holand, Maren; Alagaratnam, Sharmini; Danielsen, Stine A.; Nesbakken, Arild; Lothel, Ragnhild A.] Oslo Univ Hosp, KG Jebsen Colorectal Canc Res Ctr, POB 4953, NO-0424 Oslo, Norway; [Berg, Kaja C. G.; Sveen, Anita; Holand, Maren; Nesbakken, Arild; Lothel, Ragnhild A.] Univ Oslo, Fac Med, Inst Clin Med, POB 4950, NO-0424 Oslo, Norway; [Nesbakken, Arild] Oslo Univ Hosp, Dept Gastrointestinal Surg, POB 4950, NO-0424 Oslo, Norway; [Berg, Marianne; Soreide, Kjetil] Stavanger Univ Hosp, Gastrointestinal Translat Res Unit, Lab Mol Biol, POB 8100, NO-4011 Stavanger, Norway; [Soreide, Kjetil] Stavanger Univ Hosp, Dept Gastrointestinal Surg, POB 8100, NO-4011 Stavanger, Norway; [Soreide, Kjetil] Univ Bergen, Dept Clin Med, POB 7804, NO-5020 Bergen, Norway	University of Oslo; University of Oslo; University of Oslo; University of Oslo; Stavanger University Hospital; Stavanger University Hospital; University of Bergen	Lothel, RA (corresponding author), Oslo Univ Hosp, Inst Canc Res, Dept Mol Oncol, POB 4953, NO-0424 Oslo, Norway.; Lothel, RA (corresponding author), Oslo Univ Hosp, KG Jebsen Colorectal Canc Res Ctr, POB 4953, NO-0424 Oslo, Norway.; Lothel, RA (corresponding author), Univ Oslo, Fac Med, Inst Clin Med, POB 4950, NO-0424 Oslo, Norway.	rlothe@rr-research.no		Lothe, Ragnhild A./0000-0002-1693-1032; Sveen, Anita/0000-0001-8219-6251	Norwegian Cancer Society [6824048-2016, 72190-PR-2006-0442/182759-2016]; Southern and Eastern Norway Regional Health Authority; foundation "Stiftelsen Kristian Gerhard Jebsen"; Research Council of Norway ("Toppforsk" project) [250993]	Norwegian Cancer Society(Norwegian Cancer Society); Southern and Eastern Norway Regional Health Authority; foundation "Stiftelsen Kristian Gerhard Jebsen"; Research Council of Norway ("Toppforsk" project)(Research Council of Norway)	The authors are grateful to Dr Oddmund Nordgard, Dept of Haematology and Oncology, Stavanger University Hospital, for providing the DNA from the Stavanger series. The study was supported by the Norwegian Cancer Society (project number 6824048-2016 to A. Sveen and project numbers 72190-PR-2006-0442/182759-2016 to R.A. Lothe), the Southern and Eastern Norway Regional Health Authority, the foundation "Stiftelsen Kristian Gerhard Jebsen", the Research Council of Norway ("Toppforsk" project number 250993).	Agesen TH, 2012, GUT, V61, P1560, DOI 10.1136/gutjnl-2011-301179; Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35; Berg KCG, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0691-y; Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013; Carter JH, 2017, COLD SPRING HARB MOL, V3, P1; Cha Y, 2018, MOL ONCOL, V12, P993, DOI 10.1002/1878-0261.12194; Crockford A, 2017, ANN ONCOL, V28, P149, DOI 10.1093/annonc/mdw612; Danielsen HE, 2016, NAT REV CLIN ONCOL, V13, P291, DOI 10.1038/nrclinonc.2015.208; Dittmer S, 2011, J CELL SCI, V124, P252, DOI 10.1242/jcs.068759; Domingo E, 2016, LANCET GASTROENTEROL, V1, P207, DOI 10.1016/S2468-1253(16)30014-0; Duncan R, 2008, BRIT J CANCER, V98, P426, DOI 10.1038/sj.bjc.6604128; Fehrmann RSN, 2015, NAT GENET, V47, P115, DOI 10.1038/ng.3173; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Alonso MH, 2017, BRIT J CANCER, V117, P421, DOI 10.1038/bjc.2017.208; Hua KL, 2018, MED SCI MONITOR, V24, P149, DOI 10.12659/MSM.905372; HUGO gene Nomenclature Committee, MULT CHECK; Lee AJX, 2011, CANCER RES, V71, P1858, DOI 10.1158/0008-5472.CAN-10-3604; Mi HY, 2017, NUCLEIC ACIDS RES, V45, pD183, DOI 10.1093/nar/gkw1138; Nilsen G, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-591; Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9; Shan JX, 2013, CANCER RES, V73, P2840, DOI 10.1158/0008-5472.CAN-12-4313; Sveen A, 2018, CLIN CANCER RES, V24, P794, DOI 10.1158/1078-0432.CCR-17-1234; Sveen A, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006225; Valtorta E, 2013, INT J CANCER, V133, P1259, DOI 10.1002/ijc.28106; Van Loo P, 2010, P NATL ACAD SCI USA, V107, P16910, DOI 10.1073/pnas.1009843107; Wang H, 2016, ONCOGENE, V35, P2011, DOI 10.1038/onc.2015.304; Wang JS, 2014, CLIN CHIM ACTA, V431, P164, DOI 10.1016/j.cca.2014.01.031	27	16	16	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2019	38	33					6109	6122		10.1038/s41388-019-0868-5	http://dx.doi.org/10.1038/s41388-019-0868-5			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IR6TP	31308487	Green Published, hybrid			2022-12-28	WOS:000481572400003
J	Hardy, LR; Pergande, MR; Esparza, K; Heath, KN; Onyuksel, H; Cologna, SM; Burdette, JE				Hardy, Laura R.; Pergande, Melissa R.; Esparza, Karina; Heath, Kimberly N.; Onyuksel, Hayat; Cologna, Stephanie M.; Burdette, Joanna E.			Proteomic analysis reveals a role for PAX8 in peritoneal colonization of high grade serous ovarian cancer that can be targeted with micelle encapsulated thiostrepton	ONCOGENE			English	Article							GROWTH; FOXM1; EXPRESSION; CELLS; TRANSITION; TISSUES	High grade serous ovarian cancer (HGSOC) is the fifth leading cause of cancer deaths among women yet effective targeted therapies against this disease are limited. The heterogeneity of HGSOC, including few shared oncogenic drivers and origination from both the fallopian tube epithelium (FTE) and ovarian surface epithelium (OSE), has hampered development of targeted drug therapies. PAX8 is a lineage-specific transcription factor expressed in the FTE that is also ubiquitously expressed in HGSOC where it is an important driver of proliferation, migration, and cell survival. PAX8 is not normally expressed in the OSE, but it is turned on after malignant transformation. In this study, we use proteomic and transcriptomic analysis to examine the role of PAX8 leading to increased migratory capabilities in a human ovarian cancer model, as well as in tumor models derived from the OSE and FTE. We find that PAX8 is a master regulator of migration with unique downstream transcriptional targets that are dependent on the cell's site of origin. Importantly, we show that targeting PAX8, either through CRISPR genomic alteration or through drug treatment with micelle encapsulated thiostrepton, leads to a reduction in tumor burden. These findings suggest PAX8 is a unifying protein driving metastasis in ovarian tumors that could be developed as an effective drug target to treat HGSOC derived from both the OSE and FTE.	[Hardy, Laura R.; Heath, Kimberly N.; Burdette, Joanna E.] Univ Illinois, Dept Pharmaceut Sci, Chicago, IL 60607 USA; [Pergande, Melissa R.; Cologna, Stephanie M.] Univ Illinois, Dept Chem, Chicago, IL USA; [Esparza, Karina; Onyuksel, Hayat] Univ Illinois, Dept Biopharmaceut Sci, Chicago, IL USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Burdette, JE (corresponding author), Univ Illinois, Dept Pharmaceut Sci, Chicago, IL 60607 USA.	joannab@uic.edu		Pergande, Melissa/0000-0003-1197-4057	Department of Defense Ovarian Cancer Fund [160076]; National Cancer Institute [F30CA224986]; National Cancer Center for Research Resources Facilities Improvement Program [C06RR15482]; University of Illinois-Chicago Department of Chemistry; Ara Parsegian Medical Research Foundation; Abraham Lincoln Fellowship; NATIONAL CANCER INSTITUTE [F30CA224986] Funding Source: NIH RePORTER	Department of Defense Ovarian Cancer Fund(United States Department of Defense); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Cancer Center for Research Resources Facilities Improvement Program; University of Illinois-Chicago Department of Chemistry; Ara Parsegian Medical Research Foundation; Abraham Lincoln Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the Department of Defense Ovarian Cancer Fund 160076, the National Cancer Institute F30CA224986, the National Cancer Center for Research Resources Facilities Improvement Program C06RR15482, the University of Illinois-Chicago Department of Chemistry, the Ara Parsegian Medical Research Foundation, and the Abraham Lincoln Fellowship.	Adler EK, 2017, ONCOTARGET, V8, P108316, DOI 10.18632/oncotarget.22718; Adusumilli R, 2017, METHODS MOL BIOL, V1550, P339, DOI 10.1007/978-1-4939-6747-6_23; Ashok B, 2004, J PHARM SCI-US, V93, P2476, DOI 10.1002/jps.20150; Batth TS, 2014, J PROTEOME RES, V13, P6176, DOI 10.1021/pr500893m; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Cheung HW, 2011, P NATL ACAD SCI USA, V108, P12372, DOI 10.1073/pnas.1109363108; de Cristofaro T, 2016, ONCOTARGET, V7, P41929, DOI 10.18632/oncotarget.9740; de Cristofaro T, 2009, J MOL ENDOCRINOL, V42, P35, DOI 10.1677/JME-08-0100; Di Palma T, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-292; Eddie SL, 2015, ONCOTARGET, V6, P20500, DOI 10.18632/oncotarget.3985; Elias KM, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87988; Endsley MP, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00154; Esparza K, 2019, INT J PHARMACEUT, V556, P21, DOI 10.1016/j.ijpharm.2018.12.001; Ghannam-Shahbari D, 2018, ONCOGENE, V37, P2213, DOI 10.1038/s41388-017-0040-z; Gokce E, 2011, J CHROMATOGR B, V879, P610, DOI 10.1016/j.jchromb.2011.01.032; Grassi ML, 2017, J PROTEOMICS, V151, P2, DOI 10.1016/j.jprot.2016.06.009; Haley J, 2016, ONCOTARGET, V7, P32810, DOI 10.18632/oncotarget.9053; Harms JM, 2008, MOL CELL, V30, P26, DOI 10.1016/j.molcel.2008.01.009; Hegde NS, 2011, NAT CHEM, V3, P725, DOI [10.1038/NCHEM.1114, 10.1038/nchem.1114]; Jiang LZ, 2015, J CANCER RES CLIN, V141, P971, DOI 10.1007/s00432-014-1872-3; Ke N, 2011, METHODS MOL BIOL, V740, P33, DOI 10.1007/978-1-61779-108-6_6; King SM, 2013, CARCINOGENESIS, V34, P1125, DOI 10.1093/carcin/bgt003; King SM, 2011, ENDOCR-RELAT CANCER, V18, P627, DOI 10.1530/ERC-11-0107; Kurman RJ, 2011, HUM PATHOL, V42, P918, DOI 10.1016/j.humpath.2011.03.003; Labidi-Galy SI, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00962-1; Laury AR, 2010, AM J SURG PATHOL, V34, P627, DOI 10.1097/PAS.0b013e3181da7687; Li CG, 2011, ONCOGENE, V30, P4824, DOI 10.1038/onc.2011.190; Lim SB, 2012, J CONTROL RELEASE, V163, P34, DOI 10.1016/j.jconrel.2012.06.002; Mansouri A, 1998, NAT GENET, V19, P87, DOI 10.1038/ng0598-87; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; McCloskey CW, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00053; Musrap N, 2015, J BIOL CHEM, V290, P17218, DOI 10.1074/jbc.M115.639773; Ong SE, 2006, NAT PROTOC, V1, P2650, DOI 10.1038/nprot.2006.427; Ozcan A, 2011, MODERN PATHOL, V24, P751, DOI 10.1038/modpathol.2011.3; Piek JMJ, 2001, J PATHOL, V195, P451, DOI 10.1002/path.1000; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Rodgers LH, 2016, ONCOTARGET, V7, P32785, DOI 10.18632/oncotarget.9051; Russo A, 2018, ONCOGENE, V37, P1976, DOI 10.1038/s41388-017-0097-8; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Tanwar PS, 2014, CARCINOGENESIS, V35, P546, DOI 10.1093/carcin/bgt357; Waldemarson S, 2012, J PROTEOME RES, V11, P2876, DOI 10.1021/pr201258q; Wang LN, 2012, J CELL BIOCHEM, V113, P3762, DOI 10.1002/jcb.24250; Wang M, 2011, MOL CANCER THER, V10, P2287, DOI 10.1158/1535-7163.MCT-11-0536; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/nmeth.1322, 10.1038/NMETH.1322]; Zhang X, 2014, ONCOTARGET, V5, P11365, DOI 10.18632/oncotarget.2497	45	17	17	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2019	38	32					6003	6016		10.1038/s41388-019-0842-2	http://dx.doi.org/10.1038/s41388-019-0842-2			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IP8XH	31296958	Green Accepted			2022-12-28	WOS:000480329900001
J	Xu, ZL; Li, LC; Qian, YY; Song, Y; Qin, LP; Duan, YY; Wang, ML; Li, PS; Jiang, BC; Ma, CH; Shao, CS; Gong, YQ				Xu, Zhiliang; Li, Linchuan; Qian, Yanyan; Song, Yu; Qin, Liping; Duan, Yuyao; Wang, Molin; Li, Peishan; Jiang, Baichun; Ma, Chunhong; Shao, Changshun; Gong, Yaoqin			Upregulation of IL-6 in CUL4B-deficient myeloid-derived suppressive cells increases the aggressiveness of cancer cells	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; TUMOR PROGRESSION; METHYLATION; TUMORIGENESIS; INTERLEUKIN-6; DYSREGULATION; PROMOTER; PATHWAY; CUL4A; STAT3	Cancer progression depends on a tumor-supportive microenvironment. Myeloid-derived suppressor cells (MDSCs) represent key cellular components in tumor microenvironment and have been demonstrated to facilitate tumor progression by restricting host immune responses and by sustaining the malignancy of cancer cells. CUL4B, which assembles the CUL4B-RING E3 ligase complex (CRL4B), possesses a potent oncogenic property in cancer cells by epigenetically inactivating many tumor suppressors. However, CUL4B in hematopoietic cells exerts tumor-suppressive effect by restricting the accumulation and function of MDSCs. How CUL4B regulates the function of MDSCs is not fully characterized. In the present study, we demonstrate that the enhanced growth and metastasis of transplanted tumor cells in hematopoietic or myeloid cell-specific Cul4b knockout recipient mice is mediated by increased production of IL-6 in MDSCs. CUL4B complex epigenetically represses IL-6 transcription in myeloid cells. The IL-6 produced by MDSCs renders cancer cells stem cell-like properties by activating IL-6/STAT3 signaling. This crosstalk was effectively blocked either by blocking IL-6 in MDSCs or by inhibition of STAT3 activation in tumor cells. These findings provide a new mechanistic insight into the cancer-promoting property of MDSCs.	[Xu, Zhiliang; Li, Linchuan; Qian, Yanyan; Song, Yu; Qin, Liping; Duan, Yuyao; Wang, Molin; Li, Peishan; Jiang, Baichun; Gong, Yaoqin] Shandong Univ, Key Lab Expt Teratol, Inst Mol Med & Genet, Minist Educ,Sch Basic Med Sci, Jinan, Shandong, Peoples R China; [Ma, Chunhong] Shandong Univ, Key Lab Expt Teratol, Minist Educ, Dept Immunol,Sch Basic Med Sci, Jinan, Shandong, Peoples R China; [Shao, Changshun] Soochow Univ, Inst Translat Med, State Key Lab Radiat Med & Protect, Suzhou, Jiangsu, Peoples R China	Shandong University; Shandong University; Soochow University - China	Gong, YQ (corresponding author), Shandong Univ, Key Lab Expt Teratol, Inst Mol Med & Genet, Minist Educ,Sch Basic Med Sci, Jinan, Shandong, Peoples R China.	yxg8@sdu.edu.cn	ma, chunhong/C-6043-2008; Shao, Changshun/AAD-8977-2022	ma, chunhong/0000-0002-8121-4718; Shao, Changshun/0000-0003-2618-9342; Qian, Yanyan/0000-0002-1759-5835	National Natural Science Foundation of China [81330050, 81571523]; Natural Science Foundation of Shandong Province [ZR2016HZ01]; Key Research and Development Program of Shandong Province [2016ZDJS07A08]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province); Key Research and Development Program of Shandong Province	This work was supported by the National Natural Science Foundation of China (81330050 and 81571523), the Natural Science Foundation of Shandong Province (ZR2016HZ01), and the Key Research and Development Program of Shandong Province (2016ZDJS07A08).	Albini A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00527; Chen Z, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01344-9; Chin AR, 2014, MOL CELL ENDOCRINOL, V382, P598, DOI 10.1016/j.mce.2013.03.024; Dandrea M, 2009, NUCLEIC ACIDS RES, V37, P6681, DOI 10.1093/nar/gkp723; Gabrilovich DI, 2017, CANCER IMMUNOL RES, V5, P3, DOI 10.1158/2326-6066.CIR-16-0297; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Hannah J, 2015, GENE, V573, P33, DOI 10.1016/j.gene.2015.08.064; He YM, 2018, J CELL BIOCHEM, V119, P5308, DOI 10.1002/jcb.26643; Hu HL, 2012, CANCER CELL, V22, P781, DOI 10.1016/j.ccr.2012.10.024; Ishida K, 2012, J PERIODONTOL, V83, P917, DOI 10.1902/jop.2011.110356; Ji QH, 2014, J CELL SCI, V127, P4679, DOI 10.1242/jcs.154245; Jia L, 2017, J BIOL CHEM, V292, P2966, DOI 10.1074/jbc.M116.765230; Jiang BC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037070; Jiang T, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0534-7; Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8; Khoshbin AP, 2019, ARCH IMMUNOL THER EX, V67, P89, DOI 10.1007/s00005-018-0531-9; Kishimoto T, 2005, ANNU REV IMMUNOL, V23, P1, DOI 10.1146/annurev.immunol.23.021704.115806; Kumar V, 2016, TRENDS IMMUNOL, V37, P208, DOI 10.1016/j.it.2016.01.004; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; Mi J, 2017, MOL ONCOL, V11, P305, DOI 10.1002/1878-0261.12038; Murdoch C, 2008, NAT REV CANCER, V8, P618, DOI 10.1038/nrc2444; Nile CJ, 2008, ARTHRITIS RHEUM, V58, P2686, DOI 10.1002/art.23758; Peng DJ, 2016, CANCER RES, V76, P3156, DOI 10.1158/0008-5472.CAN-15-2528; Qian YY, 2015, CANCER RES, V75, P5070, DOI 10.1158/0008-5472.CAN-15-0898; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Safarzadeh E, 2018, J CELL PHYSIOL, V233, P3024, DOI 10.1002/jcp.26075; Tang BK, 2011, MOL IMMUNOL, V48, P1001, DOI 10.1016/j.molimm.2011.01.003; Umansky V, 2013, CANCER MICROENVIRON, V6, P169, DOI 10.1007/s12307-012-0126-7; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Wang SW, 2014, INT J ONCOL, V44, P1032, DOI 10.3892/ijo.2014.2259; Xiong S, 2018, AM J CANCER RES, V8, P302; Yang Y, 2015, ONCOGENE, V34, P104, DOI 10.1038/onc.2013.522; Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995; Yuan JP, 2015, J PATHOL, V235, P784, DOI 10.1002/path.4492	35	15	16	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 25	2019	38	30					5860	5872		10.1038/s41388-019-0847-x	http://dx.doi.org/10.1038/s41388-019-0847-x			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IT3FY	31235785				2022-12-28	WOS:000482739300002
J	Yamaguchi, T; Hayashi, M; Ida, L; Yamamoto, M; Lu, C; Kajino, T; Cheng, JL; Nakatochi, M; Isomura, H; Yamazaki, M; Suzuki, M; Fujimoto, T; Takahashi, T				Yamaguchi, Tomoya; Hayashi, Miyu; Ida, Lisa; Yamamoto, Masatoshi; Lu, Can; Kajino, Taisuke; Cheng, Jinglei; Nakatochi, Masahiro; Isomura, Hisanori; Yamazaki, Masaya; Suzuki, Motoshi; Fujimoto, Toyoshi; Takahashi, Takashi			ROR1-CAVIN3 interaction required for caveolae-dependent endocytosis and pro-survival signaling in lung adenocarcinoma	ONCOGENE			English	Article							PLASMA-MEMBRANE; PROTEINS; NKX2-1/TTF-1; ONCOGENE; ROR1	The receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a transcriptional target of the lineage-survival oncogene NKX2-1/TTF-1 in lung adenocarcinomas. In addition to its kinase-dependent role, ROR1 functions as a scaffold protein to facilitate interaction between caveolin-1 (CAV1) and CAVIN1, and consequently maintains caveolae formation, which in turn sustains pro-survival signaling toward AKT from multiple receptor tyrosine kinases (RTKs), including epidermal growth factor receptor (EGFR), MET (proto-oncogene, receptor tyrosine kinase), and IGF-IR (insulin-like growth factor receptor 1). Therefore, ROR1 is an attractive target for overcoming EGFR-TKI resistance due to various mechanisms such as EGFR T790M double mutation and bypass signaling from other RTKs. Here, we report that ROR1 possesses a novel scaffold function indispensable for efficient caveolae-dependent endocytosis. CAVIN3 was found to bind with ROR1 at a site distinct from sites for CAV1 and CAVIN1, a novel function required for proper CAVIN3 subcellular localization and caveolae-dependent endocytosis, but not caveolae formation itself. Furthermore, evidence of a mechanistic link between ROR1-CAVIN3 interaction and consequential caveolae trafficking, which was found to utilize a binding site distinct from those for ROR1 interactions with CAV1 and CAVIN1, with RTK-mediated pro-survival signaling towards AKT in early endosomes in lung adenocarcinoma cells was also obtained. The present findings warrant future study to enable development of novel therapeutic strategies for inhibiting the multifaceted scaffold functions of ROR1 in order to reduce the intolerable death toll from this devastating cancer.	[Yamaguchi, Tomoya; Hayashi, Miyu; Ida, Lisa; Lu, Can; Kajino, Taisuke; Isomura, Hisanori; Suzuki, Motoshi; Takahashi, Takashi] Nagoya Univ, Grad Sch Med, Ctr Neurol Dis & Canc, Div Mol Carcinogenesis, Nagoya, Aichi 4668550, Japan; [Yamaguchi, Tomoya; Yamamoto, Masatoshi; Yamazaki, Masaya] Kumamoto Univ, Grad Sch Med Sci, Dept Canc Biol, Kumamoto 8608556, Japan; [Yamaguchi, Tomoya; Yamamoto, Masatoshi] Kumamoto Univ, Ctr Metab Regulat Hlth Aging, Kumamoto 8608556, Japan; [Kajino, Taisuke; Isomura, Hisanori] Aichi Canc Ctr, Res Inst, Div Mol Therapeut, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan; [Cheng, Jinglei; Fujimoto, Toyoshi] Nagoya Univ, Grad Sch Med, Dept Anat & Mol Cell Biol, Nagoya, Aichi 4668550, Japan; [Nakatochi, Masahiro] Nagoya Univ Hosp, Ctr Adv Med & Clin Res, Nagoya, Aichi 4668550, Japan; [Takahashi, Takashi] Aichi Canc Ctr, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan	Nagoya University; Kumamoto University; Kumamoto University; Aichi Cancer Center; Nagoya University; Nagoya University; Aichi Cancer Center	Takahashi, T (corresponding author), Nagoya Univ, Grad Sch Med, Ctr Neurol Dis & Canc, Div Mol Carcinogenesis, Nagoya, Aichi 4668550, Japan.; Takahashi, T (corresponding author), Aichi Canc Ctr, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	tak@aichi-cc.jp	Takahashi, Takashi/I-7262-2014; Fujimoto, Toyoshi/ABH-9058-2020; Nakatochi, Masahiro/Q-1247-2015; Yamaguchi, Tomoya/AAN-7524-2020	Takahashi, Takashi/0000-0003-0615-7001; Fujimoto, Toyoshi/0000-0002-3601-7977; Nakatochi, Masahiro/0000-0002-1838-4837; Yamaguchi, Tomoya/0000-0001-6933-543X; Yamazaki, Masaya/0000-0003-4151-4983	Japan Society for the Promotion of Science (JSPS); Project for Cancer Research and Therapeutic Evolution (P-CREATE) program of the Japan Agency for Medical Research and Development (AMED); Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan	Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Project for Cancer Research and Therapeutic Evolution (P-CREATE) program of the Japan Agency for Medical Research and Development (AMED); Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Yukako Shimada and Naoe Hotta for their technical support, and Kiyoshi Yanagisawa for the valuable discussion regarding this study. We are also grateful for the expert assistance from N Tsurumaki for image analysis. This work was supported in part by grants-in-aid for Scientific Research (A) and (C) from the Japan Society for the Promotion of Science (JSPS), the Project for Cancer Research and Therapeutic Evolution (P-CREATE) program of the Japan Agency for Medical Research and Development (AMED), and a grant-in-aid for Scientific Research on Innovative Areas from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan.	Briand N, 2011, BIOCHIMIE, V93, P71, DOI 10.1016/j.biochi.2010.03.022; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Chaudhary N, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001832; Cheng JPX, 2016, TRENDS CELL BIOL, V26, P177, DOI 10.1016/j.tcb.2015.10.010; Choudhury A, 2006, NAT CELL BIOL, V8, P317, DOI 10.1038/ncb1380; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Echarri A, 2015, J CELL SCI, V128, P2747, DOI 10.1242/jcs.153940; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; Gambin Y, 2014, ELIFE, V3, DOI 10.7554/eLife.01434; Hansen CG, 2010, TRENDS CELL BIOL, V20, P177, DOI 10.1016/j.tcb.2010.01.005; Hansen CG, 2009, NAT CELL BIOL, V11, P807, DOI 10.1038/ncb1887; Hernandez VJ, 2013, ELIFE, V2, DOI 10.7554/eLife.00905; Ida L, 2016, CANCER SCI, V107, P155, DOI 10.1111/cas.12858; Kirkham M, 2005, BBA-MOL CELL RES, V1746, P349, DOI 10.1016/j.bbamcr.2005.11.005; Kovtun O, 2015, J CELL SCI, V128, P1269, DOI 10.1242/jcs.167866; Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571; Lievens S, 2006, NAT METHODS, V3, P971, DOI 10.1038/nmeth1206-971; Liu LB, 2008, J BIOL CHEM, V283, P4314, DOI 10.1074/jbc.M707890200; McMahon HT, 2011, NAT REV MOL CELL BIO, V12, P517, DOI 10.1038/nrm3151; McMahon KA, 2009, EMBO J, V28, P1001, DOI 10.1038/emboj.2009.46; Mohan J, 2015, J CELL SCI, V128, P979, DOI 10.1242/jcs.161463; Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521; Nichols B, 2003, J CELL SCI, V116, P4707, DOI 10.1242/jcs.00840; Palfy M, 2012, TRENDS CELL BIOL, V22, P447, DOI 10.1016/j.tcb.2012.06.004; Parton RG, 2007, NAT REV MOL CELL BIO, V8, P185, DOI 10.1038/nrm2122; Parton RG, 2013, NAT REV MOL CELL BIO, V14, P98, DOI 10.1038/nrm3512; Pelkmans L, 2002, TRAFFIC, V3, P311, DOI 10.1034/j.1600-0854.2002.30501.x; Schermelleh L, 2010, J CELL BIOL, V190, P165, DOI 10.1083/jcb.201002018; Shvets E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7867; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; Sorkin A, 2009, NAT REV MOL CELL BIO, V10, P609, DOI 10.1038/nrm2748; Xu XL, 2001, CANCER RES, V61, P7943; Yamaguchi T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10060; Yamaguchi T, 2013, CANCER CELL, V23, P718, DOI 10.1016/j.ccr.2013.04.002; Yamaguchi T, 2012, CANCER CELL, V21, P348, DOI 10.1016/j.ccr.2012.02.008; Zochbauer-Muller S, 2005, ONCOGENE, V24, P6249, DOI 10.1038/sj.onc.1208775	36	11	11	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2019	38	26					5142	5157		10.1038/s41388-019-0785-7	http://dx.doi.org/10.1038/s41388-019-0785-7			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IF4AX	30894682				2022-12-28	WOS:000473025300003
J	Bao, DK; Zhao, J; Zhou, XC; Yang, Q; Chen, YB; Zhu, JJ; Yuan, P; Yang, J; Qin, T; Wan, SG; Xing, JL				Bao, Dengke; Zhao, Jing; Zhou, Xingchun; Yang, Qi; Chen, Yibing; Zhu, Jianjun; Yuan, Peng; Yang, Jin; Qin, Tao; Wan, Shaogui; Xing, Jinliang			Mitochondrial fission-induced mtDNA stress promotes tumor-associated macrophage infiltration and HCC progression	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; MESENCHYMAL TRANSITION; DYNAMICS; DRP1; MICROENVIRONMENT; CONTRIBUTES; INHIBITION; EXPRESSION; SURVIVAL; RELEASE	Tumor-associated macrophages (TAMs) contribute to hepatocellular carcinoma (HCC) progression. However, the molecular mechanism underlying the infiltration of TAMs into HCC microenvironment is largely unclear. Recent studies have reported that alteration of mitochondrial nucleoid structures induces mitochondrial DNA (mtDNA) release into the cytosol, which is recognized as mtDNA stress, and consequently regulates innate immunity. Here we aimed to investigate whether mitochondrial fission induces mtDNA stress and then promotes TAM infiltration and HCC progression. Confocal microscopy and real-time PCR were used to detect cytosolic mtDNA content in HCC cells. The relationship between the expression of mitochondrial fission key regulator dynamin-related protein 1 (Drp1) and the percentage of CD163 (a marker of TAMs)-positive cells was investigated in HCC tissues using immunohistochemistry. Finally, the effect of Drp1 overexpression in HCC cells on recruitment and polarization of TAMs was investigated. Our data showed that increased Drp1 expression was positively correlated with the infiltration of TAMs into HCC tissues. Drp1-mediated mitochondrial fission induced the cytosolic mtDNA stress to enhance the CCL2 secretion from HCC cells by TLR9-mediated NF-kappa B signaling pathway, and thus promoted the TAM recruitment and polarization. Depleting cytosolic mtDNA using DNase I or blocking TLR9 pathway by TLR9 antagonist, siRNA for TLR9 or p65 in HCC cells with Drp1 overexpression significantly decreased the recruitment and polarization of TAMs. Blocking CCR2 by antagonist significantly reduced TAM infiltration and suppressed HCC progression in mouse model. In conclusion, our findings reveal a novel mechanism of TAM infiltration in HCC by mitochondrial fission-induced mtDNA stress.	[Bao, Dengke; Zhao, Jing; Yang, Qi; Wan, Shaogui] Gannan Med Univ, Affiliated Hosp 1, Ctr Mol Pathol, Ganzhou 341000, Jiangxi, Peoples R China; [Bao, Dengke; Zhao, Jing; Zhou, Xingchun; Zhu, Jianjun; Yuan, Peng; Xing, Jinliang] Fourth Mil Med Univ, State Key Lab Canc Biol, Xian 710032, Shanxi, Peoples R China; [Bao, Dengke; Zhao, Jing; Zhou, Xingchun; Zhu, Jianjun; Yuan, Peng; Xing, Jinliang] Fourth Mil Med Univ, Expt Teaching Ctr Basic Med, Xian 710032, Shanxi, Peoples R China; [Bao, Dengke; Qin, Tao] Henan Univ, Henan Prov Peoples Hosp, Dept Hepatobiliary Pancreat Surg, Zhengzhou 450002, Henan, Peoples R China; [Chen, Yibing] Zhengzhou Univ, Affiliated Hosp 1, Genet & Prenatal Diag Ctr, Dept Gynecol & Obstet, Zhengzhou 450052, Henan, Peoples R China; [Yang, Jin] Northwest Univ, Sch Life Sci, Institue Prevent Genom Med, Xian 710069, Shaanxi, Peoples R China	Gannan Medical University; Air Force Military Medical University; Air Force Military Medical University; Henan University; Zhengzhou University; Zhengzhou University; Northwest University Xi'an	Wan, SG (corresponding author), Gannan Med Univ, Affiliated Hosp 1, Ctr Mol Pathol, Ganzhou 341000, Jiangxi, Peoples R China.; Xing, JL (corresponding author), Fourth Mil Med Univ, State Key Lab Canc Biol, Xian 710032, Shanxi, Peoples R China.; Xing, JL (corresponding author), Fourth Mil Med Univ, Expt Teaching Ctr Basic Med, Xian 710032, Shanxi, Peoples R China.	wansg@gmu.edu.cn; xingjl@fmmu.edu.cn			National Natural Science Foundation of China [81320108021, U1604167]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (grants No. 81320108021 and U1604167). We also thank Dr. Fanglin Zhang of Department of Microbiology, Fourth Military Medical University for providing the THP-1 cell line.	Bamboat ZM, 2010, HEPATOLOGY, V51, P621, DOI 10.1002/hep.23365; Ban-Ishihara R, 2013, P NATL ACAD SCI USA, V110, P11863, DOI 10.1073/pnas.1301951110; Bao DK, 2016, CANCER CHEMOTH PHARM, V78, P791, DOI 10.1007/s00280-016-3128-1; Capece D, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/187204; Castanier C, 2010, EMBO REP, V11, P133, DOI 10.1038/embor.2009.258; Chan DC, 2006, ANNU REV CELL DEV BI, V22, P79, DOI 10.1146/annurev.cellbio.22.010305.104638; Chen HC, 2010, CELL, V141, P280, DOI 10.1016/j.cell.2010.02.026; Hernandez-Gea V, 2013, GASTROENTEROLOGY, V144, P512, DOI 10.1053/j.gastro.2013.01.002; Huang QC, 2016, AUTOPHAGY, V12, P999, DOI 10.1080/15548627.2016.1166318; Ishihara N, 2009, NAT CELL BIOL, V11, P958, DOI 10.1038/ncb1907; Ishihara T, 2015, MOL CELL BIOL, V35, P211, DOI 10.1128/MCB.01054-14; Kim H, 2011, MOL CELL, V44, P532, DOI 10.1016/j.molcel.2011.08.045; Krysko DV, 2011, TRENDS IMMUNOL, V32, P157, DOI 10.1016/j.it.2011.01.005; Lahiri A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013772; Lee JG, 2008, CELL SIGNAL, V20, P105, DOI 10.1016/j.cellsig.2007.09.003; Li XG, 2017, GUT, V66, P157, DOI 10.1136/gutjnl-2015-310514; Liu Y, 2015, J HEPATOL, V63, P114, DOI 10.1016/j.jhep.2015.02.009; Mantovani A, 2017, NAT REV CLIN ONCOL, V14, P399, DOI 10.1038/nrclinonc.2016.217; Montessuit S, 2010, CELL, V142, P889, DOI 10.1016/j.cell.2010.08.017; Nakahira K, 2015, ANTIOXID REDOX SIGN, V23, P1329, DOI 10.1089/ars.2015.6407; Park S, 2015, SCI REP-UK, V5, DOI 10.1038/srep15489; Rehman J, 2012, FASEB J, V26, P2175, DOI 10.1096/fj.11-196543; Sahin H, 2010, NAT REV GASTRO HEPAT, V7, P682, DOI 10.1038/nrgastro.2010.168; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sierra-Filardi E, 2014, J IMMUNOL, V192, P3858, DOI 10.4049/jimmunol.1302821; Sun XC, 2018, LIVER INT, V38, P1263, DOI 10.1111/liv.13660; Tripathi C, 2014, ONCOTARGET, V5, P5350, DOI 10.18632/oncotarget.2110; Vilaysane A, 2009, SEMIN IMMUNOL, V21, P208, DOI 10.1016/j.smim.2009.05.006; Vyas S, 2016, CELL, V166, P555, DOI 10.1016/j.cell.2016.07.002; Wan YY, 2014, ONCOL REP, V32, P619, DOI 10.3892/or.2014.3235; Weinberg SE, 2015, IMMUNITY, V42, P406, DOI 10.1016/j.immuni.2015.02.002; West AP, 2015, NATURE, V520, P553, DOI 10.1038/nature14156; Wu J, 2011, ONCOGENE, V30, P4410, DOI 10.1038/onc.2011.149; Wu WX, 2016, AUTOPHAGY, V12, P1675, DOI 10.1080/15548627.2016.1193656; Yasukawa K, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000287; Ye LY, 2016, CANCER RES, V76, P818, DOI 10.1158/0008-5472.CAN-15-0977; Zhang JZ, 2014, INT J MOL MED, V33, P817, DOI 10.3892/ijmm.2014.1650; Zhang JY, 2018, HEPATOLOGY, V67, P1872, DOI 10.1002/hep.29681; Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780; Zhang Z, 2009, CANCER LETT, V286, P223, DOI 10.1016/j.canlet.2009.05.023; Zhao J, 2013, ONCOGENE, V32, P4814, DOI 10.1038/onc.2012.494; Zhao YX, 2018, EXP CELL RES, V363, P171, DOI 10.1016/j.yexcr.2017.12.030; Zhou J, 2009, INT J CANCER, V125, P1640, DOI 10.1002/ijc.24556; Zong WX, 2016, MOL CELL, V61, P667, DOI 10.1016/j.molcel.2016.02.011	44	61	63	5	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2019	38	25					5007	5020		10.1038/s41388-019-0772-z	http://dx.doi.org/10.1038/s41388-019-0772-z			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IE1KY	30894684	Green Published, hybrid			2022-12-28	WOS:000472145900009
J	Claeys, S; Denecker, G; Durinck, K; Decaesteker, B; Mus, LM; Loontiens, S; Vanhauwaert, S; Althoff, K; Wigerup, C; Bexell, D; Dolman, E; Henrich, KO; Wehrmann, L; Westerhout, EM; Demoulin, JB; Kumps, C; Van Maerken, T; Laureys, G; Van Neste, C; De Wilde, B; De Wever, O; Westermann, F; Versteeg, R; Molenaar, JJ; Pahlman, S; Schulte, JH; De Preter, K; Speleman, F				Claeys, Shana; Denecker, Geertrui; Durinck, Kaat; Decaesteker, Bieke; Mus, Liselot M.; Loontiens, Siebe; Vanhauwaert, Suzanne; Althoff, Kristina; Wigerup, Caroline; Bexell, Daniel; Dolman, Emmy; Henrich, Kai-Oliver; Wehrmann, Lea; Westerhout, Ellen M.; Demoulin, Jean-Baptiste; Kumps, Candy; Van Maerken, Tom; Laureys, Genevieve; Van Neste, Christophe; De Wilde, Bram; De Wever, Olivier; Westermann, Frank; Versteeg, Rogier; Molenaar, Jan J.; Pahlman, Sven; Schulte, Johannes H.; De Preter, Katleen; Speleman, Frank			ALK positively regulates MYCN activity through repression of HBP1 expression	ONCOGENE			English	Article							LARGE-CELL LYMPHOMA; TRANSCRIPTIONAL REPRESSOR; NEURONAL DIFFERENTIATION; ACTIVATING MUTATIONS; BET INHIBITORS; TARGET GENES; CANCER CELLS; NEUROBLASTOMA; KINASE; RESISTANCE	ALK mutations occur in 10% of primary neuroblastomas and represent a major target for precision treatment. In combination with MYCN amplification, ALK mutations infer an ultra-high-risk phenotype resulting in very poor patient prognosis. To open up opportunities for future precision drugging, a deeper understanding of the molecular consequences of constitutive ALK signaling and its relationship to MYCN activity in this aggressive pediatric tumor entity will be essential. We show that mutant ALK downregulates the 'HMG-box transcription factor 1' (HBP1) through the PI3K-AKT-FOXO3a signaling axis. HBP1 inhibits both the transcriptional activating and repressing activity of MYCN, the latter being mediated through PRC2 activity. HBP1 itself is under negative control of MYCN through miR-17 similar to 92. Combined targeting of HBP1 by PI3K antagonists and MYCN signaling by BET- or HDAC-inhibitors blocks MYCN activity and significantly reduces tumor growth, suggesting a novel targeted therapy option for high-risk neuroblastoma.	[Claeys, Shana; Denecker, Geertrui; Durinck, Kaat; Decaesteker, Bieke; Mus, Liselot M.; Loontiens, Siebe; Vanhauwaert, Suzanne; Kumps, Candy; Van Maerken, Tom; Van Neste, Christophe; De Wilde, Bram; De Preter, Katleen; Speleman, Frank] Univ Ghent, CMGG, Ghent, Belgium; [Claeys, Shana; Denecker, Geertrui; Durinck, Kaat; Decaesteker, Bieke; Mus, Liselot M.; Loontiens, Siebe; Vanhauwaert, Suzanne; Van Maerken, Tom; Laureys, Genevieve; Van Neste, Christophe; De Wilde, Bram; De Wever, Olivier; De Preter, Katleen; Speleman, Frank] Univ Ghent, CRIG, Ghent, Belgium; [Althoff, Kristina] Univ Childrens Hosp Essen, Dept Pediat Oncol & Hematol, Essen, Germany; [Wigerup, Caroline; Bexell, Daniel; Pahlman, Sven] Lund Univ, Translat Canc Res, Canc Ctr Medicon Village, Lund, Sweden; [Dolman, Emmy; Molenaar, Jan J.] Princess Maxima Ctr Pediat Canc, Utrecht, Netherlands; [Henrich, Kai-Oliver; Wehrmann, Lea; Westermann, Frank] German Canc Res Ctr, Neuroblastoma Genom B087, Heidelberg, Germany; [Westerhout, Ellen M.; Versteeg, Rogier] Acad Med Ctr, Dept Oncogen, Amsterdam, Netherlands; [Demoulin, Jean-Baptiste] Catholic Univ Louvain, De Duve Inst, Brussels, Belgium; [Kumps, Candy] Ghent Univ Hosp, Dept Urogynaecol, Ghent, Belgium; [Laureys, Genevieve; De Wilde, Bram] Ghent Univ Hosp, Dept Pediat Oncol & Hematol, Ghent, Belgium; [De Wever, Olivier] Univ Ghent, LECR, Ghent, Belgium; [Schulte, Johannes H.] Charite, Dept Pediat Oncol Hematol, Berlin, Germany; [Schulte, Johannes H.] BIH, Berlin, Germany; [Schulte, Johannes H.] German Translat Canc Res Consortium DKTK, Berlin, Germany; [Schulte, Johannes H.] German Translat Canc Res Consortium DKFZ, Heidelberg, Germany	Ghent University; Ghent University; University of Duisburg Essen; Lund University; Helmholtz Association; German Cancer Research Center (DKFZ); University of Amsterdam; Academic Medical Center Amsterdam; Universite Catholique Louvain; Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital; Ghent University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Berlin Institute of Health	Speleman, F (corresponding author), Univ Ghent, CMGG, Ghent, Belgium.; Speleman, F (corresponding author), Univ Ghent, CRIG, Ghent, Belgium.	franki.speleman@ugent.be	speleman, frank/AAR-5184-2020; Durinck, Kaat/AFN-5192-2022; de wever, olivier/J-3094-2013; Versteeg, Rogier/AAQ-1765-2020; Mus, Liselot/FCB-1557-2022; Van Neste, Christophe/AAE-5505-2020; laureys, genevieve/AAG-2390-2021; Westermann, Frank/F-7509-2013	speleman, frank/0000-0002-6628-8559; de wever, olivier/0000-0002-5453-760X; Mus, Liselot/0000-0001-5738-0639; Vanhauwaert, Suzanne/0000-0002-7768-4549; Schulte, Johannes Hubertus/0000-0003-0671-1201; De Wilde, Bram/0000-0003-0213-1322; Dolman, Emmy/0000-0002-0567-5918; Loontiens, Siebe/0000-0002-4602-4580; Decaesteker, Bieke/0000-0003-2264-781X; Durinck, Kaat/0000-0003-1762-5739; Bexell, Daniel/0000-0001-9426-9550	Research Foundation-Flanders (FWO) [11J8313N, 18B1716N, 12N6917N, 1803115 N]; Emmanuel van der Schueren grant ('Kom op tegen Kanker'); VLK (Flemish League against cancer); FWO Research Foundation-Flanders (FWO); Ghent University (BOF) [BOF16/PDO/043]; Belgian Foundation against Cancer [2014-175]; Ghent University [BOF10/GOA/019, BOF16/GOA/23]; Belgian Program of Interuniversity Poles of Attraction (IUAP) [VII-P7/03]; fund for Scientific Research Flanders [G053012N, G050712N, G051516N]; Stichting Villa Joep	Research Foundation-Flanders (FWO)(FWO); Emmanuel van der Schueren grant ('Kom op tegen Kanker'); VLK (Flemish League against cancer); FWO Research Foundation-Flanders (FWO)(FWO); Ghent University (BOF)(Ghent University); Belgian Foundation against Cancer; Ghent University(Ghent University); Belgian Program of Interuniversity Poles of Attraction (IUAP); fund for Scientific Research Flanders(FWO); Stichting Villa Joep	S.C. is supported by a pre-doctoral fellowship of the Research Foundation-Flanders (FWO; 11J8313N) and an Emmanuel van der Schueren grant ('Kom op tegen Kanker'). S.V. is funded by the VLK (Flemish League against cancer) and 'Stichting Villa Joep'. B.D. and S.L. are supported by a pre-doctoral fellowship of the FWO Research Foundation-Flanders (FWO). K.D. is supported by Ghent University (BOF; BOF16/PDO/043). C.V., B.D.W. and T.V.M. are senior clinical investigators of the Research Foundation-Flanders (FWO; 18B1716N (B.D.W.), 12N6917N (C.V.), 1803115 N (T.V.M.)). We would further like to thank the following funding agencies: the Belgian Foundation against Cancer (project 2014-175) to F.S., Ghent University (BOF10/GOA/019, BOF16/GOA/23) to F.S., the Belgian Program of Interuniversity Poles of Attraction (IUAP Phase VII-P7/03) to F.S., the fund for Scientific Research Flanders (Research projects G053012N, G050712N, G051516N to F.S) and 'Stichting Villa Joep' to F.S.	Althoff K, 2015, ONCOGENE, V34, P3357, DOI 10.1038/onc.2014.269; Amin AD, 2016, ONCOTARGET, V7, P23715, DOI 10.18632/oncotarget.8173; Berry T, 2012, CANCER CELL, V22, P117, DOI 10.1016/j.ccr.2012.06.001; Bollaert E, 2018, CELL SIGNAL, V44, P158, DOI 10.1016/j.cellsig.2018.01.014; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Braekeveldt N, 2015, INT J CANCER, V136, pE252, DOI 10.1002/ijc.29217; Bresler SC, 2014, CANCER CELL, V26, P682, DOI 10.1016/j.ccell.2014.09.019; Bresler SC, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002950; Cage TA, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00111; Carpenter EL, 2012, NAT REV CLIN ONCOL, V9, P391, DOI 10.1038/nrclinonc.2012.72; Chen YY, 2008, NATURE, V455, P971, DOI 10.1038/nature07399; Chesler L, 2006, CANCER RES, V66, P8139, DOI 10.1158/0008-5472.CAN-05-2769; Cheung NKV, 2013, NAT REV CANCER, V13, P397, DOI 10.1038/nrc3526; CHOU TC, 1983, TRENDS PHARMACOL SCI, V4, P450, DOI 10.1016/0165-6147(83)90490-X; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Cortes C, 2015, CELL ONCOL, V38, P341, DOI 10.1007/s13402-015-0233-9; Corvetta D, 2013, J BIOL CHEM, V288, P8332, DOI 10.1074/jbc.M113.454280; de Brachene AC, 2014, BIOCHEM J, V460, P25, DOI 10.1042/BJ20131467; De Brouwer S, 2010, CLIN CANCER RES, V16, P4353, DOI 10.1158/1078-0432.CCR-09-2660; Debruyne DN, 2016, ONCOGENE, V35, P3681, DOI 10.1038/onc.2015.434; Ferreira ACD, 2016, J LEUKOCYTE BIOL, V99, P569, DOI 10.1189/jlb.2A0415-162R; Duffy DJ, 2014, MOL CANCER THER, V13, P454, DOI 10.1158/1535-7163.MCT-13-0560-T; Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Escamilla-Powers JR, 2010, J BIOL CHEM, V285, P4847, DOI 10.1074/jbc.M109.074856; Fredlund E, 2008, P NATL ACAD SCI USA, V105, P14094, DOI 10.1073/pnas.0804455105; Frumm SM, 2013, CHEM BIOL, V20, P713, DOI 10.1016/j.chembiol.2013.03.020; George RE, 2008, NATURE, V455, P975, DOI 10.1038/nature07397; Gu TL, 2004, BLOOD, V103, P4622, DOI 10.1182/blood-2003-03-0820; Guan J, 2016, DIS MODEL MECH, V9, P941, DOI 10.1242/dmm.024448; Hasan MK, 2013, SCI REP-UK, V3, DOI 10.1038/srep03450; Hellemans J, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-2-r19; Henrich KO, 2016, CANCER RES, V76, P5523, DOI 10.1158/0008-5472.CAN-15-2507; Heuckmann JM, 2011, CLIN CANCER RES, V17, P7394, DOI 10.1158/1078-0432.CCR-11-1648; Heukamp LC, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003967; Isozaki H, 2016, CANCER RES, V76, P1506, DOI 10.1158/0008-5472.CAN-15-1010; Janky R, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003731; Janoueix-Lerosey I, 2008, NATURE, V455, P967, DOI 10.1038/nature07398; Kim JY, 2006, J BIOL CHEM, V281, P10865, DOI 10.1074/jbc.M513378200; Kim YH, 2006, ONCOGENE, V25, P130, DOI 10.1038/sj.onc.1208997; Lambertz I, 2015, CLIN CANCER RES, V21, P3327, DOI 10.1158/1078-0432.CCR-14-2024; Li HL, 2011, BREAST CANCER RES TR, V126, P565, DOI 10.1007/s10549-010-0954-4; Li YL, 2014, CANCER CELL, V26, P262, DOI 10.1016/j.ccr.2014.06.014; Louis CU, 2015, ANNU REV MED, V66, P49, DOI 10.1146/annurev-med-011514-023121; Lovly CM, 2014, CLIN CANCER RES, V20, P2249, DOI 10.1158/1078-0432.CCR-13-1610; Mestdagh P, 2010, ONCOGENE, V29, P1394, DOI 10.1038/onc.2009.429; Molenaar JJ, 2012, NATURE, V483, P589, DOI 10.1038/nature10910; Moore NF, 2014, ONCOTARGET, V5, P8737, DOI 10.18632/oncotarget.2372; Mosse YP, 2008, NATURE, V455, P930, DOI 10.1038/nature07261; Mosse YP, 2013, LANCET ONCOL, V14, P472, DOI 10.1016/S1470-2045(13)70095-0; Pall G, 2015, CURR OPIN ONCOL, V27, P118, DOI 10.1097/CCO.0000000000000165; Passoni L, 2009, CANCER RES, V69, P7338, DOI 10.1158/0008-5472.CAN-08-4419; Pei YX, 2016, CANCER CELL, V29, P311, DOI 10.1016/j.ccell.2016.02.011; Persson CU, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09662-8; Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159-8290.CD-12-0418; Sakamoto H, 2011, CANCER CELL, V19, P679, DOI 10.1016/j.ccr.2011.04.004; Santo EE, 2013, CANCER RES, V73, P2189, DOI 10.1158/0008-5472.CAN-12-3767; Schonerr C, 2012, ONCOGENE, V31, P5193, DOI 10.1038/onc.2012.12; Schubbert S, 2014, CANCER RES, V74, P7048, DOI 10.1158/0008-5472.CAN-14-1470; Stratikopoulos EE, 2016, CLIN CANCER RES, V22, P2605, DOI 10.1158/1078-0432.CCR-15-2389; Stratikopoulos EE, 2015, CANCER CELL, V27, P837, DOI 10.1016/j.ccell.2015.05.006; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; Toyokawa G, 2015, ONCOL RES TREAT, V38, P291, DOI 10.1159/000430852; Umapathy G, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005470; Valentijn LJ, 2012, P NATL ACAD SCI USA, V109, P19190, DOI 10.1073/pnas.1208215109; Vaughan L, 2016, ONCOTARGET, V7, P57525, DOI 10.18632/oncotarget.10544; Watanabe N, 2015, DEVELOPMENT, V142, P2278, DOI 10.1242/dev.120477; Yan Xiaocai, 2011, Genes Cancer, V2, P538, DOI 10.1177/1947601911416003; Yao CJ, 2005, LEUKEMIA, V19, P1958, DOI 10.1038/sj.leu.2403918; Yu DN, 2005, ANN NY ACAD SCI, V1059, P145, DOI 10.1196/annals.1339.047; Zeller K, 2003, GENOME BIOL, V4, P1; Zhu SZ, 2012, CANCER CELL, V21, P362, DOI 10.1016/j.ccr.2012.02.010	73	8	9	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2019	38	15					2690	2705		10.1038/s41388-018-0595-3	http://dx.doi.org/10.1038/s41388-018-0595-3			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HS8LQ	30538293				2022-12-28	WOS:000464121600002
J	Paroni, G; Bolis, M; Zanetti, A; Ubezio, P; Helin, K; Staller, P; Gerlach, LO; Fratelli, M; Neve, RM; Terao, M; Garattini, E				Paroni, Gabriela; Bolis, Marco; Zanetti, Adriana; Ubezio, Paolo; Helin, Kristian; Staller, Peter; Gerlach, Lars Ole; Fratelli, Maddalena; Neve, Richard M.; Terao, Mineko; Garattini, Enrico			HER2-positive breast-cancer cell lines are sensitive to KDM5 inhibition: definition of a gene-expression model for the selection of sensitive cases	ONCOGENE			English	Article							HISTONE DEMETHYLASE RBP2; EMERGING ROLE; RESISTANCE; PROLIFERATION; MECHANISMS; LAPATINIB; SURVIVAL; LANGUAGE	Targeting of histone methylation has therapeutic potential in oncology. Here, we provide proof-of-principle that pharmacological inhibition of KDM5 histone-demethylases is a new strategy for the personalized treatment of HER2(+) breast cancer. The anti-proliferative effects of the prototype of a new class of selective KDM5-inhibitors (KDM5-inhl) are evaluated in 40 cell lines, recapitulating the heterogeneity of breast cancer. This analysis demonstrates that HER2(+) cells are particularly sensitive to KDM5 inhibition. The results are confirmed in an appropriate in vivo model with a close structural analog (KDM5-inhlA). RNA-seq data obtained in HER2(+) BT-474 cells exposed to KDM5-Inhl indicate that the compound alters expression of numerous genes downstream of the ERBB2 gene-product, HER2. In selected HER2-positive breast-cancer cells, we demonstrate synergistic interactions between KDM5-inhl and HER2-targeting agents (trastuzumab and lapatinib). In addition, HER2(+) cell lines with innate and acquired resistance to trastuzumab show sensitivity to KDM5-inhl. The levels of KDM5A/B/C proteins, which are selectively targeted by the agent, have no significant association with KDM5-inhl responsiveness across our panel of breast-cancer cell lines, suggesting the existence of other determinants of sensitivity. Using RNA-seq data of the breast-cancer cell lines we generate a gene-expression model that is a robust predictor of KDM5-inhl sensitivity. In a test set of breast cancers, this model predicts sensitivity to the compound in a large fraction of HER2(+) tumors. In conclusion, KDM5 inhibition has potential in the treatment of HER2(+) breast cancer and our gene-expression model can be developed into a diagnostic tool for the selection of patients.	[Paroni, Gabriela; Bolis, Marco; Zanetti, Adriana; Fratelli, Maddalena; Terao, Mineko; Garattini, Enrico] Ist Ric Farmacol Mario Negri IRCCS, Mol Biol Lab, Via La Masa 19, I-20157 Milan, Italy; [Ubezio, Paolo] Ist Ric Farmacol Mario Negri IRCCS, Dept Oncol, Via La Masa 19, I-20157 Milan, Italy; [Helin, Kristian] Univ Copenhagen, BRIC, Ole Maaloes Vej 5, DK-2200 Copenhagen, Denmark; [Helin, Kristian] Univ Copenhagen, Novo Nordisk Fdn Stem Cell Biol, Blegdamsvej 3, DK-2200 Copenhagen, Denmark; [Staller, Peter] Bayer AG, Drug Discovery, Mullerstr 178, D-13353 Berlin, Germany; [Gerlach, Lars Ole] Global Drug Discovery, CV Res, Novo Nordisk, Denmark; [Neve, Richard M.] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Copenhagen; University of Copenhagen; Bayer AG; Gilead Sciences	Garattini, E (corresponding author), Ist Ric Farmacol Mario Negri IRCCS, Mol Biol Lab, Via La Masa 19, I-20157 Milan, Italy.	enrico.garattini@marionegri.it	adriana, zanetti/ABA-1189-2020; Helin, Kristian/HDM-8306-2022; Paroni, Gabriela/J-4848-2018; Ubezio, Paolo/AAA-6455-2020; Bolis, Marco/AAC-2379-2019; Garattini, Enrico/AAI-1998-2019; terao, mineko/AAU-8089-2020; Fratelli, Maddalena/AAA-6446-2020; Terao, Mineko/AAA-6415-2020; ubezio, paolo/AAA-6704-2020	adriana, zanetti/0000-0002-5825-9707; Helin, Kristian/0000-0003-1975-6097; Paroni, Gabriela/0000-0003-0132-0869; Ubezio, Paolo/0000-0003-0412-9891; Bolis, Marco/0000-0003-4377-5079; Fratelli, Maddalena/0000-0002-1769-3427; Terao, Mineko/0000-0002-9976-9869; Garattini, Enrico/0000-0001-8983-886X	Associazione Italiana per la Ricerca contro il Cancro (AIRC); Fondazione Italo Monzino	Associazione Italiana per la Ricerca contro il Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Italo Monzino	Grants from the Associazione Italiana per la Ricerca contro il Cancro (AIRC) and the Fondazione Italo Monzino to Enrico Garattini were fundamental for the completion of this work. We would like to acknowledge the help of Mr. Alessandro Soave for the artwork and Laura Pasetto for the densitometric analyses.	Akimoto C, 2008, GENES CELLS, V13, P623, DOI 10.1111/j.1365-2443.2008.01193.x; Araki K, 2018, BREAST CANCER-TOKYO, V25, P392, DOI 10.1007/s12282-017-0812-x; Barrett A, 2007, INT J CANCER, V121, P265, DOI 10.1002/ijc.22673; Basse C, 2015, INT J CANCER, V137, P2785, DOI 10.1002/ijc.29347; Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Bolis M, 2017, ANN ONCOL, V28, P611, DOI 10.1093/annonc/mdw660; Brustel J, 2011, TRENDS CELL BIOL, V21, P452, DOI 10.1016/j.tcb.2011.04.006; Calabrich A, 2008, ONCOLOGY-NY, V22, p[1263, 1259]; Calabrich A, 2008, ONCOLOGY-NY, V22, p[1259, 1263]; Calabrich A, 2008, ONCOLOGY-NY, V22, P1250; Cao J, 2014, CELL REP, V6, P868, DOI 10.1016/j.celrep.2014.02.004; Catchpole S, 2011, INT J ONCOL, V38, P1267, DOI 10.3892/ijo.2011.956; Cejalvo JM, 2017, CANCER RES, V77, P2213, DOI 10.1158/0008-5472.CAN-16-2717; Centritto F, 2015, EMBO MOL MED, V7, P950, DOI 10.15252/emmm.201404670; Citri A, 2004, EMBO REP, V5, P1165, DOI 10.1038/sj.embor.7400300; Esteva FJ, 2010, AM J PATHOL, V177, P1647, DOI 10.2353/ajpath.2010.090885; Fabi A, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0380-5; Gajria D, 2011, EXPERT REV ANTICANC, V11, P263, DOI 10.1586/ERA.10.226; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Guo XQ, 2017, J KIDNEY CANCER VHL, V4, P1, DOI 10.15586/jkcvhl.2017.56; Hou JL, 2012, AM J TRANSL RES, V4, P247; Kennedy JM, 2014, J EXP MED, V211, P2519, DOI 10.1084/jem.20140455; Kute T, 2004, CYTOM PART A, V57A, P86, DOI 10.1002/cyto.a.10095; Labbe RM, 2014, AM J TRANSL RES, V6, P1; Li N, 2016, CANCER RES, V76, P831, DOI 10.1158/0008-5472.CAN-15-0906; Moldovan L, 2013, J Med Life, V6, P14; Paroni G, 2012, ONCOGENE, V31, P3431, DOI 10.1038/onc.2011.506; Pasini D, 2008, GENE DEV, V22, P1345, DOI 10.1101/gad.470008; Pedersen MT, 2010, TRENDS CELL BIOL, V20, P662, DOI 10.1016/j.tcb.2010.08.011; Perou CM, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a003293; Regan MM, 2011, LANCET ONCOL, V12, P1101, DOI 10.1016/S1470-2045(11)70270-4; Rodrigues Loreta M, 2012, BMC Res Notes, V5, P250, DOI 10.1186/1756-0500-5-250; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Rosenfeld JA, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-143; Sahlberg KK, 2013, MOL ONCOL, V7, P392, DOI 10.1016/j.molonc.2012.10.012; Sarter K, 2016, J EXP MED, V213, P177, DOI 10.1084/jem.20150435; Schulz R, 2012, J EXP MED, V209, P275, DOI 10.1084/jem.20111117; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Taylor-Papadimitriou J, 2017, EXPERT OPIN THER TAR, V21, P5, DOI 10.1080/14728222.2017.1263616; Teng YC, 2013, CANCER RES, V73, P4711, DOI 10.1158/0008-5472.CAN-12-3165; Tumber A, 2017, CELL CHEM BIOL, V24, P371, DOI 10.1016/j.chembiol.2017.02.006; Valabrega G, 2011, BREAST CANCER RES TR, V130, P29, DOI 10.1007/s10549-010-1281-5; Wang GG, 2009, NATURE, V459, P847, DOI 10.1038/nature08036; Wang Q, 2015, BIOCHEM BIOPH RES CO, V464, P659, DOI 10.1016/j.bbrc.2015.07.049; Yamamoto S, 2014, CANCER CELL, V25, P762, DOI 10.1016/j.ccr.2014.04.024; Zeng JP, 2010, GASTROENTEROLOGY, V138, P981, DOI 10.1053/j.gastro.2009.10.004	46	12	12	5	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2019	38	15					2675	2689		10.1038/s41388-018-0620-6	http://dx.doi.org/10.1038/s41388-018-0620-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HS8LQ	30538297				2022-12-28	WOS:000464121600001
J	Kolb, R; Kluz, P; Tan, ZW; Borcherding, N; Bormann, N; Vishwakarma, A; Balcziak, L; Zhu, PC; Davies, BSJ; Gourronc, F; Liu, LZ; Ge, X; Jiang, BH; Gibson-Corley, K; Klingelhutz, A; Tan, NS; Zhu, YW; Sutterwala, FS; Shen, X; Zhang, Wz				Kolb, Ryan; Kluz, Paige; Tan, Zhen Wei; Borcherding, Nicholas; Bormann, Nicholas; Vishwakarma, Ajaykumar; Balcziak, Louis; Zhu, Pengcheng; Davies, Brandon S. J.; Gourronc, Francoise; Liu, Ling-Zhi; Ge, Xin; Jiang, Bing-Hua; Gibson-Corley, Katherine; Klingelhutz, Aloysius; Tan, Nguan Soon; Zhu, Yuwen; Sutterwala, Fayyaz S.; Shen, Xian; Zhang, Weizhou			Obesity-associated inflammation promotes angiogenesis and breast cancer via angiopoietin-like 4	ONCOGENE			English	Article							CELL-LINE; ANGPTL4; METASTASIS; BEVACIZUMAB; PROGRESSION; MIGRATION; BETA-1; TUMORS; VEGF	Obesity is a risk factor for breast cancer and also predicts poor clinical outcomes regardless of menopausal status. Contributing to the poor clinical outcomes is the suboptimal efficacy of standard therapies due to dose limiting toxicities and obesity-related complications, highlighting the need to develop novel therapeutic approaches for treating obese patients. We recently found that obesity leads to an increase in tumor-infiltrating macrophages with activated NLRC4 inflammasome and increased interleukin (IL)-1 beta production. IL-1 beta, in turn, leads to increased angiogenesis and cancer progression. Using Next Generation RNA sequencing, we identified an NLRC4/IL-1 beta-dependent upregulation of angiopoietin-like 4 (ANGPTL4), a known angiogenic factor in cancer, in tumors from obese mice. ANGPTL4-deficiency by genetic knockout or treatment with a neutralizing antibody led to a significant reduction in obesity-induced angiogenesis and tumor growth. At a mechanistic level, ANGPTL4 expression is induced by IL-1 beta from primary adipocytes in a manner dependent on NF-kappa B- and MAP kinase-activation, which is further enhanced by hypoxia. This report shows that adipocyte-derived ANGPTL4 drives disease progression under obese conditions and is a potential therapeutic target for treating obese breast cancer patients.	[Kolb, Ryan; Kluz, Paige; Borcherding, Nicholas; Vishwakarma, Ajaykumar; Liu, Ling-Zhi; Ge, Xin; Jiang, Bing-Hua; Gibson-Corley, Katherine; Zhang, Weizhou] Univ Iowa, Dept Pathol, Carver Coll Med, Iowa City, IA 52242 USA; [Kolb, Ryan; Zhang, Weizhou] Univ Florida, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA; [Kluz, Paige; Zhang, Weizhou] Univ Iowa, Free Rad & Radiat Biol, Carver Coll Med, Iowa City, IA 52242 USA; [Tan, Zhen Wei; Zhu, Pengcheng; Tan, Nguan Soon] Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore; [Borcherding, Nicholas; Zhang, Weizhou] Univ Iowa, Med Scientist Training Program, Carver Coll Med, Iowa City, IA 52242 USA; [Borcherding, Nicholas; Vishwakarma, Ajaykumar; Zhang, Weizhou] Univ Iowa, Canc Biol Grad Program, Carver Coll Med, Iowa City, IA 52242 USA; [Bormann, Nicholas] Univ Iowa, Dept Psychiat, Carver Coll Med, Iowa City, IA 52242 USA; [Balcziak, Louis] Univ Iowa, Interdisciplinary Neurosci Grad Program, Carver Coll Med, Iowa City, IA 52242 USA; [Davies, Brandon S. J.] Univ Iowa, Dept Biochem, Fraternal Order Eagles Diabet Res Ctr, Iowa City, IA 52242 USA; [Davies, Brandon S. J.] Univ Iowa, Obes Res & Educ Initiat, Iowa City, IA 52242 USA; [Gourronc, Francoise; Klingelhutz, Aloysius] Univ Iowa, Dept Microbiol & Immunol, Carver Coll Med, Iowa City, IA 52242 USA; [Tan, Nguan Soon] Nanyang Technol Univ, Lee Kong Chian Sch Med, 50 Nanyang Dr, Singapore 639798, Singapore; [Tan, Nguan Soon] Agcy Sci Technol & Res, Inst Mol Cell Biol, Proteos, 61 Biopolis Dr, Singapore 138673, Singapore; [Tan, Nguan Soon] KK Womens & Children Hosp, KK Res Ctr, 100 Bukit Timah Rd, Singapore 229899, Singapore; [Zhu, Yuwen] Univ Colorado, Dept Surg, Denver Anschutz Med Campus, Aurora, CO 80045 USA; [Sutterwala, Fayyaz S.] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA; [Shen, Xian] Wenzhou Med Univ, Div Gastrointestinal Surg, Affiliated Hosp 2, Wenzhou 325035, Zhejiang, Peoples R China	University of Iowa; State University System of Florida; University of Florida; University of Iowa; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; University of Iowa; University of Iowa; University of Iowa; University of Iowa; University of Iowa; University of Iowa; University of Iowa; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); KK Women's & Children's Hospital; University of Colorado System; University of Colorado Anschutz Medical Campus; Cedars Sinai Medical Center; Wenzhou Medical University	Kolb, R; Zhang, Wz (corresponding author), Univ Iowa, Dept Pathol, Carver Coll Med, Iowa City, IA 52242 USA.; Kolb, R; Zhang, Wz (corresponding author), Univ Florida, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA.; Zhang, Wz (corresponding author), Univ Iowa, Free Rad & Radiat Biol, Carver Coll Med, Iowa City, IA 52242 USA.; Zhang, Wz (corresponding author), Univ Iowa, Med Scientist Training Program, Carver Coll Med, Iowa City, IA 52242 USA.; Zhang, Wz (corresponding author), Univ Iowa, Canc Biol Grad Program, Carver Coll Med, Iowa City, IA 52242 USA.; Shen, X (corresponding author), Wenzhou Med Univ, Div Gastrointestinal Surg, Affiliated Hosp 2, Wenzhou 325035, Zhejiang, Peoples R China.	ryankolb@ufl.edu; shenxian1120@126.com; zhangw@ufl.edu	Bormann, Nicholas/AAF-7338-2022; Tan, Nguan Soon/A-2220-2011; Sutterwala, Fayyaz/AAH-5859-2021; Bormann, Nicholas/AFK-0303-2022; Kluz, Paige/AAT-4892-2021; Cassel, Suzanne/AAI-3947-2021; Klingelhutz, Aloysius/L-9081-2018	Tan, Nguan Soon/0000-0003-0136-7341; Cassel, Suzanne/0000-0003-2492-1923; Gibson-Corley, Katherine/0000-0002-1846-1580; Kolb, Ryan/0000-0001-6305-2885; Klingelhutz, Aloysius/0000-0003-4258-5046; Hartl, Carla/0000-0001-9769-7462; Bormann, Nicholas/0000-0001-8847-8727; Liu, Ling-Zhi/0000-0001-9234-457X; Borcherding, Nicholas/0000-0003-1427-6342; Jiang, Bing-Hua/0000-0003-4526-2031; Davies, Brandon/0000-0002-7168-8522	NIH [CA200673, CA203834, T32 AI007260, F30 CA206255, R01HL130146, R01 AI118719]; Oberley Award (National Cancer Institute Award) from Holden Comprehensive Cancer Center at the University of Iowa [P30CA086862]; Department of Microbiology, University of Iowa; Ministry of Education, Singapore [MOE2014-T2-1-012]; NATIONAL CANCER INSTITUTE [F30CA206255, R01CA193511, P30CA086862, R01CA203834, R01CA200673] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL130146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI118719, R01AI104706, T32AI007260] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES005605] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007337] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Oberley Award (National Cancer Institute Award) from Holden Comprehensive Cancer Center at the University of Iowa; Department of Microbiology, University of Iowa; Ministry of Education, Singapore(Ministry of Education, Singapore); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	RK: NIH T32 AI007260; WZ: NIH R01 grants CA200673 and CA203834, Oberley Award (National Cancer Institute Award P30CA086862) from Holden Comprehensive Cancer Center at the University of Iowa; NB: NIH F30 CA206255; AK: Mark Stinski Developmental Grant from the Department of Microbiology, University of Iowa; BD: NIH R01HL130146; NST: grant from Ministry of Education, Singapore (MOE2014-T2-1-012); FSS: NIH R01 AI118719.	Arendt LM, 2013, CANCER RES, V73, P6080, DOI 10.1158/0008-5472.CAN-13-0926; Bai L, 2015, SCI REP-UK, V5, DOI 10.1038/srep17717; Biswas T, 2014, CANCER LETT, V346, P129, DOI 10.1016/j.canlet.2013.12.018; Blankenberg Daniel, 2010, Curr Protoc Mol Biol, VChapter 19, DOI 10.1002/0471142727.mb1910s89; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Choi J, 2018, PROG LIPID RES, V69, P11, DOI 10.1016/j.plipres.2017.11.002; DeCicco-Skinner KL, 2014, JOVE-J VIS EXP, DOI 10.3791/51312; Fukumura D, 2016, MICROCIRCULATION, V23, P191, DOI 10.1111/micc.12270; Gealekman O, 2008, AM J PHYSIOL-ENDOC M, V295, pE1056, DOI 10.1152/ajpendo.90345.2008; Giardine B, 2005, GENOME RES, V15, P1451, DOI 10.1101/gr.4086505; Goecks J, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r86; Goh YY, 2010, AM J PATHOL, V177, P2791, DOI 10.2353/ajpath.2010.100129; Gu JW, 2011, CANCER BIOL THER, V11, P910, DOI 10.4161/cbt.11.10.15473; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hata S, 2017, ONCOL REP, V38, P120, DOI 10.3892/or.2017.5669; Hu K, 2016, ONCOTARGET, V7, P7816, DOI 10.18632/oncotarget.6868; Huang ZQ, 2016, ARCH ORAL BIOL, V71, P144, DOI 10.1016/j.archoralbio.2016.07.011; Incio J, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aag0945; Jain RK, 2014, CANCER CELL, V26, P605, DOI 10.1016/j.ccell.2014.10.006; Kim SH, 2011, CANCER RES, V71, P7010, DOI 10.1158/0008-5472.CAN-11-1262; Kolb R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13007; Kolb R, 2016, CURR OPIN PHARMACOL, V29, P77, DOI 10.1016/j.coph.2016.07.005; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Lara-Tejero M, 2006, J EXP MED, V203, P1407, DOI 10.1084/jem.20060206; Lei X, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.217638; Li H, 2011, HEPATOLOGY, V54, P910, DOI 10.1002/hep.24479; Li L, 2015, CELL REP, V10, P654, DOI 10.1016/j.celrep.2015.01.011; Lichtenstein L, 2010, CELL METAB, V12, P580, DOI 10.1016/j.cmet.2010.11.002; Lohmann AE, 2012, CURR TREAT OPTION ON, V13, P249, DOI 10.1007/s11864-012-0181-9; Malinda Katherine M., 2009, V467, P287, DOI 10.1007/978-1-59745-241-0_17; Markan KR, 2014, DIABETES, V63, P4057, DOI 10.2337/db14-0595; OCONNELL KA, 1990, J IMMUNOL, V144, P521; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; SUGIURA K, 1952, CANCER, V5, P382, DOI 10.1002/1097-0142(195203)5:2<382::AID-CNCR2820050229>3.0.CO;2-3; Tan MJ, 2012, MOL CANCER RES, V10, P677, DOI 10.1158/1541-7786.MCR-11-0519; Tan W, 2011, NATURE, V470, P548, DOI 10.1038/nature09707; Tolaney SM, 2015, P NATL ACAD SCI USA, V112, P14325, DOI 10.1073/pnas.1518808112; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Vu BG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077988; Zhu PC, 2012, BIOSCIENCE REP, V32, P211, DOI 10.1042/BSR20110102; Zudaire E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027385	42	59	60	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2019	38	13					2351	2363		10.1038/s41388-018-0592-6	http://dx.doi.org/10.1038/s41388-018-0592-6			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ7GN	30518876	Green Accepted			2022-12-28	WOS:000462588000009
J	Pai, VC; Hsu, CC; Chan, TS; Liao, WY; Chuu, CP; Chen, WY; Li, CR; Lin, CY; Huang, SP; Chen, LT; Tsai, KK				Pai, Vincent C.; Hsu, Chung-Chi; Chan, Tze-Sian; Liao, Wen-Ying; Chuu, Chih-Pin; Chen, Wei-Yu; Li, Chi-Rong; Lin, Ching-Yu; Huang, Shu-Pin; Chen, Li-Tzong; Tsai, Kelvin K.			ASPM promotes prostate cancer stemness and progression by augmenting Wnt-Dvl-3-beta-catenin signaling (vol 38, pg 1340, 2018)	ONCOGENE			English	Correction									[Pai, Vincent C.; Hsu, Chung-Chi; Chan, Tze-Sian; Tsai, Kelvin K.] Taipei Med Univ, Grad Inst Clin Med, Coll Med, Taipei 11031, Taiwan; [Hsu, Chung-Chi; Chan, Tze-Sian; Tsai, Kelvin K.] Taipei Med Univ, Wan Fang Hosp, Div Gastroenterol, Dept Internal Med,Lab Adv Mol Therapeut, Taipei 11696, Taiwan; [Pai, Vincent C.; Liao, Wen-Ying; Chen, Li-Tzong; Tsai, Kelvin K.] Natl Hlth Res Inst, Natl Inst Canc Res, Zhunan 35053, Miaoli County, Taiwan; [Chuu, Chih-Pin; Lin, Ching-Yu] Natl Hlth Res Inst, Inst Cellular & Syst Med, Zhunan 35053, Miaoli County, Taiwan; [Chen, Wei-Yu] Taipei Med Univ, Wan Fang Hosp, Dept Pathol, Taipei 11696, Taiwan; [Li, Chi-Rong] Minist Hlth & Welf, Dept Teaching & Res, Taichung Hosp, Taichung 40343, Taiwan; [Huang, Shu-Pin] Kaohsiung Med Univ, Dept Urol, Chung Ho Mem Hosp, Kaohsiung 80756, Taiwan	Taipei Medical University; Taipei Medical University; Taipei Municipal WanFang Hospital; National Health Research Institutes - Taiwan; National Health Research Institutes - Taiwan; Taipei Medical University; Taipei Municipal WanFang Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital	Tsai, KK (corresponding author), Taipei Med Univ, Grad Inst Clin Med, Coll Med, Taipei 11031, Taiwan.; Tsai, KK (corresponding author), Taipei Med Univ, Wan Fang Hosp, Div Gastroenterol, Dept Internal Med,Lab Adv Mol Therapeut, Taipei 11696, Taiwan.; Tsai, KK (corresponding author), Natl Hlth Res Inst, Natl Inst Canc Res, Zhunan 35053, Miaoli County, Taiwan.	tsaik@tmu.edu.tw		Tsai, Kelvin/0000-0002-1612-2868; Li, Chi-Rong/0000-0002-0314-8284				Pai VC, 2019, ONCOGENE, V38, P1340, DOI 10.1038/s41388-018-0497-4	1	7	9	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2019	38	8					1354	1354		10.1038/s41388-018-0561-0	http://dx.doi.org/10.1038/s41388-018-0561-0			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HM1XR	30390070	Bronze			2022-12-28	WOS:000459249800015
J	Park, SH; Jeong, S; Kim, BR; Jeong, YA; Kim, JL; Na, YJ; Jo, MJ; Yun, HK; Kim, DY; Kim, BG; Lee, DH; Oh, SC				Park, Seong Hye; Jeong, Soyeon; Kim, Bo Ram; Jeong, Yoon A.; Kim, Jung Lim; Na, Yoo Jin; Jo, Min Jee; Yun, Hye Kyeong; Kim, Dae Yeong; Kim, Bu Gyeom; Lee, Dae-Hee; Oh, Sang Cheul			Activating CCT2 triggers Gli-1 activation during hypoxic condition in colorectal cancer	ONCOGENE			English	Article							ER STRESS; CHAPERONIN; CELLS; INHIBITOR; PROTEINS; TRIC/CCT; SURVIVAL; COMPLEX; GROWTH; HSP90	Hypoxia, or the deficiency of oxygen, in solid tumors is majorly responsible for the progression of cancer and remains unaffected by chemotherapy, but still requires definitive definition of the hypoxia signaling. Hypoxia disrupts the complete folding of mitochondrial proteins, leading to several diseases. The present study confirms that hypoxia activates the Hedgehog pathway in colorectal cancer (CRC), considering its role in cancer epithelial to mesenchymal transition, migration, and invasion. The activity of hypoxia-mediated Gli-1, a Hedgehog signaling factor in hypoxia, was confirmed by in vitro western blotting, immunofluorescence staining, wound-healing assay, and matrigel invasion assay, as well as by in vivo xenograft models (n = 5 per group). The Gli-1 mechanism in hypoxia was analyzed via mass spectrometry. Hypoxia enhanced the interaction of Gli-1 and T-complex protein 1 subunit beta (CCT2), as observed in the mass spectrometric analysis. We observed that reduction in CCT2 inhibits tumor induction by Gli-1. Ubiquitination-mediated Gli-1 degradation by beta-TrCP occurs during incomplete folding of Gli-1 in hypoxia. The human CRC tissues revealed greater CCT2 expression than did the normal colon tissues, indicating that higher CCT2 expression in tumor tissues from CRC patients reduced their survival rate. Moreover, we suggest that CCT2 correlates with Gli-1 expression and is an important determinant of survival in the CRC patients. The results reveal that CCT2 can regulate the folding of Gli-1 in relation to hypoxia in CRC.	[Park, Seong Hye; Jeong, Yoon A.; Na, Yoo Jin; Jo, Min Jee; Yun, Hye Kyeong; Kim, Dae Yeong; Kim, Bu Gyeom; Lee, Dae-Hee; Oh, Sang Cheul] Korea Univ, Coll Med, Grad Sch Med, Seoul, South Korea; [Jeong, Soyeon; Kim, Bo Ram; Kim, Jung Lim; Lee, Dae-Hee; Oh, Sang Cheul] Korea Univ, Guro Hosp, Dept Oncol, Seoul 152703, South Korea	Korea University; Korea University Medicine (KU Medicine); Korea University; Korea University Medicine (KU Medicine)	Lee, DH; Oh, SC (corresponding author), Korea Univ, Coll Med, Grad Sch Med, Seoul, South Korea.; Lee, DH; Oh, SC (corresponding author), Korea Univ, Guro Hosp, Dept Oncol, Seoul 152703, South Korea.	neogene@korea.ac.kr; sachoh@korea.ac.kr			National Research Foundation (NRF) of Korea - Korean government (MSIP) [NRF-2017R1A2B2011684, NRF-2018M3A9G1075561]	National Research Foundation (NRF) of Korea - Korean government (MSIP)	This work was supported by grant from the National Research Foundation (NRF) of Korea and funded by the Korean government (MSIP) (NRF-2017R1A2B2011684, NRF-2018M3A9G1075561).	Altaba ARI, 1999, TRENDS GENET, V15, P418, DOI 10.1016/S0168-9525(99)01840-5; Boudiaf-Benmammar C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060895; Briscoe J, 2013, NAT REV MOL CELL BIO, V14, P416, DOI 10.1038/nrm3598; Calderwood SK, 2006, TRENDS BIOCHEM SCI, V31, P164, DOI 10.1016/j.tibs.2006.01.006; Carr AC, 2017, ONCOTARGET, V8, P110273, DOI 10.18632/oncotarget.22681; Feldman DE, 2005, MOL CANCER RES, V3, P597, DOI 10.1158/1541-7786.MCR-05-0221; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Flamment M, 2012, TRENDS ENDOCRIN MET, V23, P381, DOI 10.1016/j.tem.2012.06.003; Gao Q, 2015, ONCOL LETT, V9, P2381, DOI 10.3892/ol.2015.2988; Guest ST, 2015, EXP CELL RES, V332, P223, DOI 10.1016/j.yexcr.2015.02.005; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Huntzicker EG, 2006, GENE DEV, V20, P276, DOI 10.1101/gad.1380906; Kalisman N, 2012, P NATL ACAD SCI USA, V109, P2884, DOI 10.1073/pnas.1119472109; Kasembeli M, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001844; Kim BR, 2017, ONCOTARGET, V8, P101952, DOI 10.18632/oncotarget.21882; Koumenis C, 2006, CURR MOL MED, V6, P55, DOI 10.2174/156652406775574604; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; Lei JJ, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-66; Leitner A, 2012, STRUCTURE, V20, P814, DOI 10.1016/j.str.2012.03.007; Leu JIJ, 2009, MOL CELL, V36, P15, DOI 10.1016/j.molcel.2009.09.023; Melki R, 1997, BIOCHEMISTRY-US, V36, P5817, DOI 10.1021/bi962830o; Michieli P, 2009, CELL CYCLE, V8, P3291, DOI 10.4161/cc.8.20.9741; Morimoto RI, 2008, GENE DEV, V22, P1427, DOI 10.1101/gad.1657108; Pandolfi S, 2015, EXPERT REV MOL MED, V17, DOI 10.1017/erm.2015.3; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Qualtrough D, 2015, CANCERS, V7, P1885, DOI 10.3390/cancers7030867; Roh SH, 2015, INT J MOL SCI, V16, P26706, DOI 10.3390/ijms161125975; Sergeeva OA, 2013, J BIOL CHEM M, VM112, P443929; SHUIN T, 1994, CANCER RES, V54, P2852; Teglund S, 2010, BBA-REV CANCER, V1805, P181, DOI 10.1016/j.bbcan.2010.01.003; Trinidad AG, 2013, MOL CELL, V50, P805, DOI 10.1016/j.molcel.2013.05.002; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; Varnat F, 2009, EMBO MOL MED, V1, P338, DOI 10.1002/emmm.200900039; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Won KA, 1998, MOL CELL BIOL, V18, P7584, DOI 10.1128/MCB.18.12.7584; Workman P, 2007, NAT CHEM BIOL, V3, P455, DOI 10.1038/nchembio0807-455; Zhang K, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0368-y	38	16	16	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	1					136	150		10.1038/s41388-019-0972-6	http://dx.doi.org/10.1038/s41388-019-0972-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG3NM	31462707				2022-12-28	WOS:000509849200009
J	Dupain, C; Gracia, C; Harttrampf, AC; Riviere, J; Geoerger, B; Massaad-Massade, L				Dupain, Celia; Gracia, Celine; Harttrampf, Anne C.; Riviere, Julie; Geoerger, Birgit; Massaad-Massade, Liliane			Newly identified LMO3-BORCS5 fusion oncogene in Ewing sarcoma at relapse is a driver of tumor progression	ONCOGENE			English	Article							GENE FUSIONS; GENOMIC LANDSCAPE; QUANTITATIVE PCR; CANCER; CELL; EXPRESSION; BORC; RHABDOMYOSARCOMAS; TUMORIGENICITY; PROLIFERATION	Recently, we detected a new fusion transcript LMO3-BORCS5 in a patient with Ewing sarcoma within a cohort of relapsed pediatric cancers. LMO3-BORCS5 was as highly expressed as the characteristic fusion oncogene EWS/FLI1. However, the expression level of LMO3-BORCS5 at diagnosis was very low. Sanger sequencing depicted two LMO3-BORCS5 variants leading to loss of the functional domain LIM2 in LMO3 gene, and disruption of BORCS5. In vitro studies showed that LMO3-BORCS5 (i) increases proliferation, (ii) decreases expression of apoptosis-related genes and treatment sensitivity, and (iii) downregulates genes involved in differentiation and upregulates proliferative and extracellular matrix-related pathways. Remarkably, in vivo LMO3-BORCS5 demonstrated its high oncogenic potential by inducing tumors in mouse fibroblastic NIH-3T3 cell line. Moreover, BORCS5 probably acts, in vivo, as a tumor-suppressor gene. In conclusion, functional studies of fusion oncogenes at relapse are of great importance to define mechanisms involved in tumor progression and resistance to conventional treatments.	[Dupain, Celia; Gracia, Celine; Harttrampf, Anne C.; Geoerger, Birgit; Massaad-Massade, Liliane] Univ Paris Sud 11, CNRS UMR 8203, Gustave Roussy Canc Ctr, Lab Vectorol & Therapeut Anticanc, F-94805 Villejuif, France; [Riviere, Julie] Gustave Roussy Canc Ctr, INSERM U1170, Villejuif, France; [Geoerger, Birgit] Gustave Roussy, Dept Pediat & Adolescent Oncol, Villejuif, France; [Massaad-Massade, Liliane] U1195 INSERM, 20 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm)	Massaad-Massade, L (corresponding author), Univ Paris Sud 11, CNRS UMR 8203, Gustave Roussy Canc Ctr, Lab Vectorol & Therapeut Anticanc, F-94805 Villejuif, France.; Massaad-Massade, L (corresponding author), U1195 INSERM, 20 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France.	liliane.massade@inserm.fr	; Massade, Liliane/O-7226-2017	Gracia, Celine/0000-0002-3312-6465; Massade, Liliane/0000-0002-9636-4559	Universite Paris-Sud; CNRS	Universite Paris-Sud; CNRS(Centre National de la Recherche Scientifique (CNRS))	This study was supported by Universite Paris-Sud (CD) and CNRS and microarray analysis was supported by the "Taxe d'apprentissage Gustave Roussy - 2017 - CD". We acknowledge Drs Nathalie Gaspar and Estelle Daudigeos-Dubus as well as the ITCC (Innovative Therapies for Children with Cancer) consortium for providing the pediatric cell lines and antineoplastic molecules used in the study, as well as Catherine Richon (technical assistance). We acknowledge Dr Giorgia Urbinati and Pr. Karim Benihoud for the valuable comments as well as Lena Zig and Linda Ramdani for their precious technical help for the cloning of LMO3-BORCS5. We also acknowledge Dr Guillaume Meurice for the analysis of microarray data. The animal studies were performed within the animal facility of Gustave Roussy and authors gratefully thank the technical support of Olivia Bawa and expertize of Dr Paule Opolon (histocytopathology platform) for the preparation and analysis of histological slides.	Abate F, 2014, BMC SYST BIOL, V8, DOI 10.1186/s12918-014-0097-z; Albanese A, 2012, ANNU REV BIOMED ENG, V14, P1, DOI [10.1146/annurev-bioeng-071811-150124, 10.1146/annurev.bioeng-071811-150124]; Ali HM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095964; Alves IT, 2015, ONCOGENE, V34, P568, DOI 10.1038/onc.2013.591; Anderson ND, 2018, SCIENCE, V361, DOI 10.1126/science.aam8419; Aoyama M, 2005, CANCER RES, V65, P4587, DOI 10.1158/0008-5472.CAN-04-4630; Arpinati M, 2013, BIOL BLOOD MARROW TR, V19, P735, DOI 10.1016/j.bbmt.2013.01.007; Bao JX, 2000, DEVELOPMENT, V127, P425; Barr FG, 2001, ONCOGENE, V20, P5736, DOI 10.1038/sj.onc.1204599; Benjamini Y, 2008, BIOMETRICS, V64, P1215, DOI 10.1111/j.1541-0420.2007.00984.x; Bridge JA, 2013, BRAIN PATHOL, V23, P121, DOI 10.1111/j.1750-3639.2012.00612.x; Brouwer-Visser J, 2015, CYTOKINE GROWTH F R, V26, P371, DOI 10.1016/j.cytogfr.2015.01.002; Buart S, 2017, ONCOTARGET, V8, P108786, DOI 10.18632/oncotarget.22150; Cachia D, 2015, BRAIN TUMOR PATHOL, V32, P105, DOI 10.1007/s10014-014-0205-1; Chaudhary B, 2014, CANCER IMMUNOL IMMUN, V63, P81, DOI 10.1007/s00262-013-1500-0; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; Cooper GM, 2000, DEV CAUSES CANC CELL; Crompton BD, 2014, CANCER DISCOV, V4, P1326, DOI 10.1158/2159-8290.CD-13-1037; Dancey JE, 2012, CELL, V148, P409, DOI 10.1016/j.cell.2012.01.014; Daudigeos-Dubus E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142612; Duan C, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0521-3; Dupain C, 2019, MOL THER, V27, P200, DOI 10.1016/j.ymthe.2018.10.022; Dupain C, 2017, MOL THER-NUCL ACIDS, V6, P315, DOI 10.1016/j.omtn.2017.01.005; Dupain C, 2016, INT J ONCOL, V49, P1248, DOI 10.3892/ijo.2016.3617; Frenkel-Morgenstern M, 2012, GENOME RES, V22, P1231, DOI 10.1101/gr.130062.111; Gao QS, 2018, CELL REP, V23, P227, DOI 10.1016/j.celrep.2018.03.050; Goel RK, 2016, CANCER METAST REV, V35, P179, DOI 10.1007/s10555-016-9623-3; Graham RP, 2015, MODERN PATHOL, V28, P822, DOI 10.1038/modpathol.2015.4; Haeussler M, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1012-2; Han SM, 2013, NEOPLASIA, V15, P1193, DOI 10.1593/neo.131604; Hartmaier RJ, 2018, ANN ONCOL, V29, P872, DOI 10.1093/annonc/mdy025; Harttrampf AC, 2017, CLIN CANCER RES, V23, P6101, DOI 10.1158/1078-0432.CCR-17-0381; Isogai E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019297; Jeanmougin M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012336; Justilien V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035040; Kalinova M, 2008, LEUKEMIA RES, V32, P25, DOI 10.1016/j.leukres.2007.01.002; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Kim C, 2016, J CANCER, V7, P1550, DOI 10.7150/jca.15578; Kumar-Sinha C, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0252-1; Langemeyer L, 2015, DEV CELL, V33, P121, DOI 10.1016/j.devcel.2015.04.008; Larsen S, 2010, BIOCHEM BIOPH RES CO, V392, P252, DOI 10.1016/j.bbrc.2009.12.010; Latysheva NS, 2016, NUCLEIC ACIDS RES, V44, P4487, DOI 10.1093/nar/gkw282; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Li J, 2015, HUM PATHOL, V46, P1821, DOI 10.1016/j.humpath.2015.07.022; Lin PP, 2008, CANCER RES, V68, P8968, DOI 10.1158/0008-5472.CAN-08-0573; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Man JH, 2014, CELL REP, V9, P1812, DOI 10.1016/j.celrep.2014.10.055; Massard C, 2017, CANCER DISCOV, V7, P586, DOI 10.1158/2159-8290.CD-16-1396; Mertens F, 2015, NAT REV CANCER, V15, P371, DOI 10.1038/nrc3947; Mitelman F, 2007, NAT REV CANCER, V7, P233, DOI 10.1038/nrc2091; Montpetit A, 2002, EUR J HUM GENET, V10, P62, DOI 10.1038/sj.ejhg.5200766; Niwa S, 2017, CURR BIOL, V27, P2569, DOI 10.1016/j.cub.2017.07.013; Okada T, 2013, SCI REP-UK, V3, DOI 10.1038/srep02899; Panagopoulos I, 2014, ONCOL REP, V32, P40, DOI 10.3892/or.2014.3180; Parveen A, 2016, CRIT REV EUKAR GENE, V26, P49, DOI 10.1615/CritRevEukaryotGeneExpr.v26.i1.60; Pu J, 2015, DEV CELL, V33, P176, DOI 10.1016/j.devcel.2015.02.011; Qiu YS, 2018, INT J MOL MED, V41, P2755, DOI 10.3892/ijmm.2018.3476; Rekhi B, 2016, MODERN PATHOL, V29, P1532, DOI 10.1038/modpathol.2016.144; Sang MX, 2014, MOL BIOL REP, V41, P1067, DOI 10.1007/s11033-013-2952-1; Shugay M, 2013, BIOINFORMATICS, V29, P2539, DOI 10.1093/bioinformatics/btt445; Shugay M, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002797; Song YF, 2015, AM J TRANSL RES, V7, P1271; Stransky N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5846; Teranoa T, 2005, EXP HEMATOL, V33, P641, DOI 10.1016/j.exphem.2005.01.018; Tirode F, 2014, CANCER DISCOV, V4, P1342, DOI 10.1158/2159-8290.CD-14-0622; Tsubota Shoma, 2017, Oncoscience, V4, P70, DOI 10.18632/oncoscience.360; Urbinati G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125277; Vaishnavi A, 2013, NAT MED, V19, P1469, DOI 10.1038/nm.3352; Yau NKM, 2015, CURR CANCER DRUG TAR, V15, P327; Zhang L, 2015, INT J CLIN EXP PATHO, V8, P11421; Zhao YB, 2013, SCI REP-UK, V3, DOI 10.1038/srep03120; Zhou W, 2015, CANCER LETT, V360, P68, DOI 10.1016/j.canlet.2015.02.004	72	4	4	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2019	38	47					7200	7215		10.1038/s41388-019-0914-3	http://dx.doi.org/10.1038/s41388-019-0914-3			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP0UL	31488873	Green Published, hybrid			2022-12-28	WOS:000497989400002
J	Liang, YR; Song, XJ; Li, YM; Su, P; Han, DW; Ma, TT; Guo, RB; Chen, B; Zhao, WJ; Sang, YT; Zhang, N; Li, XY; Zhang, HW; Liu, Y; Duan, Y; Wang, LJ; Yang, QF				Liang, Yiran; Song, Xiaojin; Li, Yaming; Su, Peng; Han, Dianwen; Ma, Tingting; Guo, Renbo; Chen, Bing; Zhao, Wenjing; Sang, Yuting; Zhang, Ning; Li, Xiaoyan; Zhang, Hanwen; Liu, Ying; Duan, Yi; Wang, Lijuan; Yang, Qifeng			circKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating miR-548p/PBLD axis in breast cancer	ONCOGENE			English	Article							OSTEOSARCOMA CELLS; WNT/BETA-CATENIN; RNA; CHEMORESISTANCE; METASTASIS; EXPRESSION; CIRCHIPK3; CIRCPVT1; ABUNDANT; MARKER	Increasing evidence has indicated that circular RNAs (circRNAs) play a critical role in cancer development. However, only a small number of circRNAs have been experimentally validated and functionally annotated. In this study, using a high-throughput microarray assay, we identified a novel circRNA, circKDM4C, which was downregulated in breast cancer tissues with metastasis. Furthermore, we analyzed a cohort of breast cancer patients and found that circKDM4C expression was decreased in breast cancer tissues, and lower circKDM4C expression was associated with poor prognosis and metastasis in breast cancer. Functionally, we demonstrated that circKDM4C significantly repressed breast cancer proliferation, metastasis, and doxorubicin resistance in vitro and in vivo. Mechanistically, using a dual-luciferase activity assay and AGO2 RNA immunoprecipitation, circKDM4C was identified as a miR-548p sponge. We also found that PBLD was a direct target of miR-548p, which functioned as a tumor suppressor in breast cancer. Moreover, miR-548p overexpression was able to reverse the circKDM4C-induced attenuation of malignant phenotypes and elevated expression of PBLD in breast cancer cells. Taken together, our data indicate that circKDM4C might have considerable potential as a prognostic biomarker in breast cancer, and support the notion that therapeutic targeting of circKDM4C/miR-548p/PBLD axis may be a promising treatment approach for breast cancer patients.	[Liang, Yiran; Song, Xiaojin; Li, Yaming; Han, Dianwen; Ma, Tingting; Sang, Yuting; Zhang, Ning; Li, Xiaoyan; Zhang, Hanwen; Liu, Ying; Duan, Yi; Yang, Qifeng] Shandong Univ, Qilu Hosp, Dept Breast Surg, Jinan 250012, Shandong, Peoples R China; [Su, Peng] Shandong Univ, Qilu Hosp, Dept Pathol, Jinan 250012, Shandong, Peoples R China; [Guo, Renbo] Shandong Univ, Shandong Canc Hosp, Dept Urol, Jinan 250117, Shandong, Peoples R China; [Chen, Bing; Zhao, Wenjing; Wang, Lijuan; Yang, Qifeng] Shandong Univ, Qilu Hosp, Pathol Tissue Bank, Jinan 250012, Shandong, Peoples R China	Shandong University; Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University; Shandong University	Yang, QF (corresponding author), Shandong Univ, Qilu Hosp, Dept Breast Surg, Jinan 250012, Shandong, Peoples R China.; Yang, QF (corresponding author), Shandong Univ, Qilu Hosp, Pathol Tissue Bank, Jinan 250012, Shandong, Peoples R China.	qifengy_sdu@163.com	yang, qiang/GYJ-0971-2022; Zhang, Ning/GOJ-8058-2022; Zhang, Ning/GNP-1966-2022; Zhang, Hanwen/CAG-1998-2022	Zhang, Ning/0000-0002-6430-4236; Yang, Qifeng/0000-0003-0576-8513	National Natural Science Foundation of China [81272903, 81672613, 81502285, 81602329]; China Postdoctoral Science Foundation [2018M630787]; Key Research and Development Program of Shandong Province [2015GSF118093, 2016GSF201119]; Natural Science Foundation of Shandong Province [ZR2014HQ078]; Shandong Science and Technology Development Plan [2016CYJS01A02]; Special Support Plan for National High Level Talents ("Ten Thousand Talents Program")	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Key Research and Development Program of Shandong Province; Natural Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province); Shandong Science and Technology Development Plan; Special Support Plan for National High Level Talents ("Ten Thousand Talents Program")	This work was supported by the National Natural Science Foundation of China (No. 81272903; No. 81672613; No. 81502285; No. 81602329), China Postdoctoral Science Foundation to NZ (2018M630787), the Key Research and Development Program of Shandong Province (No. 2015GSF118093, No. 2016GSF201119), the Natural Science Foundation of Shandong Province (ZR2014HQ078), the Shandong Science and Technology Development Plan (2016CYJS01A02), and the Special Support Plan for National High Level Talents ("Ten Thousand Talents Program") to QY.	Barrett SP, 2015, ELIFE, V4, DOI 10.7554/eLife.07540; Bray F, 2018, CA CANC J CLIN; Cai JC, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15870; Chen GW, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0204-3; Chen J, 2017, CANCER LETT, V388, P208, DOI 10.1016/j.canlet.2016.12.006; Chen LL, 2015, RNA BIOL, V12, P381, DOI 10.1080/15476286.2015.1020271; COCQUERELLE C, 1993, FASEB J, V7, P155, DOI 10.1096/fasebj.7.1.7678559; Du WW, 2016, NUCLEIC ACIDS RES, V44, P2846, DOI 10.1093/nar/gkw027; Gao DF, 2017, EPIGENOMICS-UK, V9, P1175, DOI 10.2217/epi-2017-0055; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Huang GL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131225; Huang SL, 2019, CIRCULATION, V139, P2857, DOI 10.1161/CIRCULATIONAHA.118.038361; Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112; Jones SE, 2008, CLIN BREAST CANCER, V8, P224, DOI 10.3816/CBC.2008.n.025; Ke ZY, 2019, J CELL PHYSIOL, V234, P1699, DOI 10.1002/jcp.27041; Kim C, 2018, CELL, V173, P879, DOI 10.1016/j.cell.2018.03.041; Li AM, 2016, ONCOTARGET, V7, P524, DOI 10.18632/oncotarget.6358; Li DM, 2013, WORLD J GASTROENTERO, V19, P2781, DOI 10.3748/wjg.v19.i18.2781; Li DM, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1637-7; Li F, 2015, ONCOTARGET, V6, P6001, DOI 10.18632/oncotarget.3469; Li RC, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0852-y; Li YW, 2017, EMBO REP, V18, P1646, DOI 10.15252/embr.201643581; Long JA, 2010, HEPATOB PANCREAT DIS, V9, P296; Maishman T, 2017, ANN SURG, V266, P165, DOI 10.1097/SLA.0000000000001930; O'Reilly EA, 2015, BBA CLIN, V3, P257, DOI 10.1016/j.bbacli.2015.03.003; Salzman J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030733; Sang MX, 2018, CANCER LETT, V426, P37, DOI 10.1016/j.canlet.2018.03.049; Shi L, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.556; Shi ZM, 2017, FEBS J, V284, P1096, DOI 10.1111/febs.14045; Tan SY, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0887-9; Wan L, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/1579490; Wang KF, 2017, CANCER LETT, V394, P1, DOI 10.1016/j.canlet.2016.12.036; Wang L., 2018, JOULE, V2, P1, DOI DOI 10.1016/j.mtnano.2018.04.007; Wang Y, 2016, CANCER LETT, V382, P137, DOI 10.1016/j.canlet.2016.08.024; Wei XF, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.541; Xie F., 2018, AXIS, V17, P144, DOI DOI 10.1186/S12943-018-0892-Z; Xiong W, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/8421614; Xu H, 2018, CANCER LETT, V412, P69, DOI 10.1016/j.canlet.2017.09.030; Zeng KX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0454-8; Zhang J, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0719-3; Zhang J, 2007, J PROTEOME RES, V6, P4423, DOI 10.1021/pr0703425; Zheng QP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11215; Zhong ZY, 2016, SCI REP-UK, V6, DOI 10.1038/srep30919; Zhu KP, 2018, INT J BIOL SCI, V14, P321, DOI 10.7150/ijbs.24360	44	93	95	3	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2019	38	42					6850	6866		10.1038/s41388-019-0926-z	http://dx.doi.org/10.1038/s41388-019-0926-z			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE5UU	31406252				2022-12-28	WOS:000490758200004
J	Thakur, VS; Aguila, B; Brett-Morris, A; Creighton, CJ; Welford, SM				Thakur, Vijay S.; Aguila, Brittany; Brett-Morris, Adina; Creighton, Chad J.; Welford, Scott M.			Spermidine/spermine N1-acetyltransferase 1 is a gene-specific transcriptional regulator that drives brain tumor aggressiveness	ONCOGENE			English	Article							CELL-MIGRATION; PROLIFERATION; GLIOBLASTOMA; EXPRESSION; BINDING; GROWTH	Spermidine/spermine N1-acetyltransferase 1 (SAT1), the rate-limiting enzyme in polyamine catabolism, has broad regulatory roles due to near ubiquitous polyamine binding. We describe a novel function of SAT1 as a gene-specific transcriptional regulator through local polyamine acetylation. SAT1 expression is elevated in aggressive brain tumors and promotes resistance to radiotherapy. Expression profiling in glioma cells identified SAT1 target genes that distinguish high-and low-grade tumors, in support of the prognostic utility of SAT1 expression. We further discovered mechanisms of SAT1-driven tumor aggressiveness through promotion of expression of both DNA damage response pathways as well as cell cycle regulatory genes. Mechanistically, SAT1 associates specifically with the promoter of the MELK gene, which functionally controls other SAT1 targets, and leads biologically to maintenance of neurosphere stemness in conjunction with FOXM1 and EZH2. CRISPR knockin mutants demonstrate the essentiality of the polyamine acetyltransferase activity of SAT1 for its function as a transcriptional regulator. Together, the data demonstrate that gene-specific polyamine removal is a major transcriptional regulatory mechanism active in high-grade gliomas that drives poor outcomes.	[Thakur, Vijay S.; Welford, Scott M.] Univ Miami, Miller Sch Med, Dept Radiat Oncol, Miami, FL 33136 USA; [Aguila, Brittany] Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; [Brett-Morris, Adina] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; [Creighton, Chad J.] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA; [Creighton, Chad J.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Welford, Scott M.] Univ Miami, Sylvester Comprehens Canc Ctr, Miller Sch Med, Miami, FL 33136 USA	University of Miami; Case Western Reserve University; Case Western Reserve University; Baylor College of Medicine; Baylor College of Medicine; University of Miami	Welford, SM (corresponding author), Univ Miami, Miller Sch Med, Dept Radiat Oncol, Miami, FL 33136 USA.; Welford, SM (corresponding author), Univ Miami, Sylvester Comprehens Canc Ctr, Miller Sch Med, Miami, FL 33136 USA.	scott.welford@med.miami.edu			 [P30CA125123];  [R01CA187053]; NATIONAL CANCER INSTITUTE [R01CA187053, P30CA125123] Funding Source: NIH RePORTER	; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by P30CA125123 (CJC); and R01CA187053 (SMW).	Baek JH, 2007, J BIOL CHEM, V282, P33358, DOI 10.1074/jbc.M705627200; Brett-Morris A, 2014, CANCER RES, V74, P6925, DOI 10.1158/0008-5472.CAN-14-1249; Ceccarelli M, 2016, CELL, V164, P550, DOI 10.1016/j.cell.2015.12.028; Chen X, 2013, MOL CELL BIOL, V33, P227, DOI 10.1128/MCB.00881-12; Coleman CS, 1996, BIOCHEM J, V316, P697, DOI 10.1042/bj3160697; Dehart GW, 2008, P NATL ACAD SCI USA, V105, P7188, DOI 10.1073/pnas.0708044105; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Holst CM, 2008, CELL BIOL INT, V32, P39, DOI 10.1016/j.cellbi.2007.08.008; Huang L, 2017, BIOCHEM BIOPH RES CO, V490, P707, DOI 10.1016/j.bbrc.2017.06.105; Joshi K, 2013, STEM CELLS, V31, P1051, DOI 10.1002/stem.1358; Kim SH, 2015, STEM CELL REP, V4, P226, DOI 10.1016/j.stemcr.2014.12.006; Krieg AJ, 2006, MOL CELL BIOL, V26, P7030, DOI 10.1128/MCB.00322-06; Lee SB, 2011, BIOCHEM J, V433, P205, DOI 10.1042/BJ20101322; Pegg AE, 2008, AM J PHYSIOL-ENDOC M, V294, pE995, DOI 10.1152/ajpendo.90217.2008; Pegg AE, 2011, METHODS MOL BIOL, V720, P3, DOI 10.1007/978-1-61779-034-8_1; Santos JS, 2010, DEV DYNAM, V239, P1010, DOI 10.1002/dvdy.22228; Sharma V, 2017, CARCINOGENESIS, V38, P152, DOI 10.1093/carcin/bgw126; Takeuchi H, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006441; Uemura T, 2008, J BIOL CHEM, V283, P26428, DOI 10.1074/jbc.M804714200; Veeravalli KK, 2012, CELL SIGNAL, V24, P272, DOI 10.1016/j.cellsig.2011.09.011; Wang J, 2017, J CLIN INVEST, V127, P3075, DOI 10.1172/JCI89092; Yoo J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11045	22	16	16	3	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2019	38	41					6794	6800		10.1038/s41388-019-0917-0	http://dx.doi.org/10.1038/s41388-019-0917-0			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JC8UZ	31399646	Green Accepted			2022-12-28	WOS:000489552900007
J	Tan, BS; Yang, MC; Singh, S; Chou, YC; Chen, HY; Wang, MY; Wang, YC; Chen, RH				Tan, Boon-Shing; Yang, Min-Chi; Singh, Shaifali; Chou, Yu-Chi; Chen, Hsin-Yi; Wang, Ming-Yang; Wang, Yi-Ching; Chen, Ruey-Hwa			LncRNA NORAD is repressed by the YAP pathway and suppresses lung and breast cancer metastasis by sequestering S100P	ONCOGENE			English	Article							LONG NONCODING RNAS; HIPPO PATHWAY; CELL CONTACT; CO-REPRESSOR; YAP/TAZ; GROWTH; DISRUPTION; THERAPY; PUMILIO	Metastasis is responsible for most cancer mortality, but its molecular mechanism has not been completely understood. In addition to coding genes and miRNAs, the contribution of long noncoding RNAs (lncRNAs) to tumor metastatic dissemination and the mechanisms controlling their expression are areas of intensive investigation. Here, we show that lncRNA NORAD is downregulated in lung and breast cancers, and that NORAD low expression in these cancer types is associated with lymph node metastasis and poor prognosis. NORAD is transcriptionally repressed by the Hippo pathway transducer YAP/TAZ-TEAD complex in conjunction with the action of NuRD complex. Functionally, NORAD elicits potent inhibitory effects on migration and invasion of multiple lung and breast cancer cell lines, and repression of NORAD expression participates in the migration- and invasion-stimulatory effects of the YAP pathway. Mechanistically, NORAD exploits its multiple repeated sequences to function as a multivalent platform for binding and sequestering S100P, thereby suppressing S100P-elicited pro-metastatic signaling network. Using cell and mouse models, we show that the S100P decoy function of NORAD suppresses lung and breast cancer migration, invasion, and metastasis. Together, our study identifies NORAD as a novel metastasis suppressor, elucidates its regulatory and functional mechanisms, and highlights its prognostic value.	[Tan, Boon-Shing; Yang, Min-Chi; Singh, Shaifali; Chen, Ruey-Hwa] Acad Sinica, Inst Biol Chem, Taipei, Taiwan; [Yang, Min-Chi; Chen, Ruey-Hwa] Natl Taiwan Univ, Inst Biochem Sci, Coll Life Sci, Taipei, Taiwan; [Singh, Shaifali; Chen, Ruey-Hwa] Acad Sinica, Chem Biol & Mol Biophys Program, Taiwan Int Grad Program, Taipei, Taiwan; [Singh, Shaifali] Natl Tsing Hua Univ, Inst Bioinformat & Struct Biol, Hsinchu, Taiwan; [Chou, Yu-Chi] Acad Sinica, Genom Res Ctr, Taipei, Taiwan; [Chen, Hsin-Yi] Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Coll Med Sci & Technol, Taipei, Taiwan; [Wang, Ming-Yang] Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan; [Wang, Yi-Ching] Natl Cheng Kung Univ, Inst Basic Med Sci, Coll Med, Tainan, Taiwan; [Wang, Yi-Ching] Natl Cheng Kung Univ, Dept Pharmacol, Coll Med, Tainan, Taiwan	Academia Sinica - Taiwan; National Taiwan University; Academia Sinica - Taiwan; National Tsing Hua University; Academia Sinica - Taiwan; Taipei Medical University; National Taiwan University; National Taiwan University Hospital; National Cheng Kung University; National Cheng Kung University	Chen, RH (corresponding author), Acad Sinica, Inst Biol Chem, Taipei, Taiwan.; Chen, RH (corresponding author), Natl Taiwan Univ, Inst Biochem Sci, Coll Life Sci, Taipei, Taiwan.; Chen, RH (corresponding author), Acad Sinica, Chem Biol & Mol Biophys Program, Taiwan Int Grad Program, Taipei, Taiwan.	rhchen@gate.sinica.edu.tw	Wang, Yi-Ching/J-8702-2019; Tan, Boon Shing/C-7715-2014	Wang, Yi-Ching/0000-0002-7694-2067; Tan, Boon Shing/0000-0002-3789-8673	National Health Research Institute [NHRI-EX107-10708BI]; Institute of Biological Chemistry, Academia Sinica	National Health Research Institute(National Health Research Institutes - Taiwan); Institute of Biological Chemistry, Academia Sinica(Academia Sinica - Taiwan)	We thank Sherry Hsueh-Chi Yen and Pan-Chyr Yang for reagents, Suh-Yuen Liang for TCGA analysis, National RNAi Core Facility for shRNA constructs and CRISPR vectors and constructs, Academia Sinica Animal Core Facility for IVIS analysis, Institute of Biological Chemistry Histopathology Core Facility for tissue processing and histology, Academia Sinica Common Mass Spectrometry Facilities for MS analysis, Human Biobank, Research Center of Clinical Medicine, and Cancer Data Bank of National Cheng Kung University Hospital for patient's specimens. This work is supported by National Health Research Institute Grant NHRI-EX107-10708BI and intramural fund from Institute of Biological Chemistry, Academia Sinica.	Arumugam T, 2011, AMINO ACIDS, V41, P893, DOI 10.1007/s00726-010-0496-4; Austermann J, 2008, J BIOL CHEM, V283, P29331, DOI 10.1074/jbc.M806145200; Brunner AL, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-8-r75; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Das A, 2016, J BIOL CHEM, V291, P6096, DOI 10.1074/jbc.M115.708313; de Andres-Pablo A, 2017, CURR GENET, V63, P29, DOI 10.1007/s00294-016-0615-1; Du M, 2012, J BIOL CHEM, V287, P15330, DOI 10.1074/jbc.M112.349787; Elster D, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05370-7; Geisler S, 2013, NAT REV MOL CELL BIO, V14, P699, DOI 10.1038/nrm3679; Gibadulinova A, 2016, ONCOTARGET, V7, P22508, DOI 10.18632/oncotarget.7999; Gutschner T, 2012, RNA BIOL, V9, P703, DOI 10.4161/rna.20481; Heil A, 2011, J BIOL CHEM, V286, P7227, DOI 10.1074/jbc.M110.135095; Hu BR, 2017, INT J BIOCHEM CELL B, V92, P34, DOI 10.1016/j.biocel.2017.09.008; Iyer MK, 2015, NAT GENET, V47, P199, DOI 10.1038/ng.3192; Jiao S, 2014, CANCER CELL, V25, P166, DOI 10.1016/j.ccr.2014.01.010; Kawasaki N, 2018, CANCER SCI, V109, P2211, DOI 10.1111/cas.13626; Kim JK, 2009, INT J ONCOL, V35, P1257, DOI 10.3892/ijo_00000442; Kim M, 2015, CELL REP, V11, P270, DOI 10.1016/j.celrep.2015.03.015; Kim T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10186; Kugel JF, 2012, TRENDS BIOCHEM SCI, V37, P144, DOI 10.1016/j.tibs.2011.12.003; Laugesen A, 2014, CELL STEM CELL, V14, P735, DOI 10.1016/j.stem.2014.05.006; Lee JT, 2012, SCIENCE, V338, P1435, DOI 10.1126/science.1231776; Lee S, 2016, CELL, V164, P69, DOI 10.1016/j.cell.2015.12.017; Li HM, 2017, MOL CANCER, V16, DOI 10.1186/s12943-016-0576-5; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Mercer TR, 2013, NAT STRUCT MOL BIOL, V20, P300, DOI 10.1038/nsmb.2480; Moroishi T, 2016, CELL, V167, P1525, DOI 10.1016/j.cell.2016.11.005; Munschauer M, 2018, NATURE, V561, P132, DOI 10.1038/s41586-018-0453-z; Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014; Prica F, 2016, AM J CANCER RES, V6, P562; Santamaria-Kisiel L, 2006, BIOCHEM J, V396, P201, DOI 10.1042/BJ20060195; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Sun M, 2015, ENDOCR REV, V36, P25, DOI 10.1210/er.2014-1034; Tichon A, 2018, GENE DEV, V32, P70, DOI 10.1101/gad.309138.117; Tichon A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12209; Valencia-Sama I, 2015, J BIOL CHEM, V290, P16906, DOI 10.1074/jbc.M115.642363; von Eyss B, 2015, CANCER CELL, V28, P743, DOI 10.1016/j.ccell.2015.10.013; Whiteman HJ, 2007, CANCER RES, V67, P8633, DOI 10.1158/0008-5472.CAN-07-0545; Wilusz JE, 2016, BBA-GENE REGUL MECH, V1859, P128, DOI 10.1016/j.bbagrm.2015.06.003; Wu HC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4214; Wu XL, 2017, ONCOL RES TREAT, V40, P370, DOI 10.1159/000464465; Yan XH, 2015, CANCER CELL, V28, P529, DOI 10.1016/j.ccell.2015.09.006; Yuan WC, 2014, MOL CELL, V54, P586, DOI 10.1016/j.molcel.2014.03.035; Yuan WC, 2011, CANCER CELL, V20, P214, DOI 10.1016/j.ccr.2011.07.008; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zhang ZK, 2019, MOL CELL, V73, P7, DOI 10.1016/j.molcel.2018.10.030; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210; Zhou YH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010138	49	71	71	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2019	38	28					5612	5626		10.1038/s41388-019-0812-8	http://dx.doi.org/10.1038/s41388-019-0812-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IH9RW	30967631				2022-12-28	WOS:000474845100005
J	Ishikawa, M; Osaki, M; Yamagishi, M; Onuma, K; Ito, H; Okada, F; Endo, H				Ishikawa, Mizuho; Osaki, Mitsuhiko; Yamagishi, Makoto; Onuma, Kunishige; Ito, Hisao; Okada, Futoshi; Endo, Hideya			Correlation of two distinct metastasis-associated proteins, MTA1 and S100A4, in angiogenesis for promoting tumor growth	ONCOGENE			English	Article							BREAST-CANCER METASTASIS; HUMAN ENDOTHELIAL-CELLS; HEAVY-CHAIN; EXPRESSION; HYPOXIA; GENE; MTS1; OVEREXPRESSION; MOTILITY; BINDING	Extensive studies on metastasis-associated proteins, S100A4 and MTA1, have been carried out for over two decades, but correlation of both proteins remains obscure. Here we show evidence for the correlation in angiogenesis. First, silencing of each protein by siRNA-mediated knockdown in mouse endothelial MSS31 cells resulted in the inhibition of tube formation. Unexpectedly, the knockdown of MTA1 affected not only its own expression but also the expression of S100A4, whereas silencing of S100A4 did not affect the MTA1 expression. Additionally, non-muscle myosin IIA (NMIIA) phosphorylation, which was partly controlled by S100A4, was found to be upregulated by knockdown of both proteins in MSS31 cells. Moreover, cycloheximide treatment of MSS31 cells revealed that the rate of S100A4 degradation was accelerated by MTA1 knockdown. This finding, together with our observation that cytoplasmic MTA1, but not nuclear MTA1, was colocalized with S100A4, suggested the involvement of MTA1 in S100A4 stability. The direct in vivo angiogenesis assay showed that both protein siRNAs provoked a significant inhibition of new blood vessel formation induced by angiogenic factors, indicating their anti-angiogenic activities. Treatment of human pancreatic tumor (PANC-1) xenograft in mice with mMTA1 siRNA resulted in tumor regression via suppression of angiogenesis in vivo, as also observed in the case of human prostate cancer xenograft treated with mS100A4 siRNA. Taken together, these data led us to conclude that the MTA1-S100A4-NMIIA axis exists in endothelial cells as a novel pathway in promoting tumor vascular formation and could be a target for suppressing tumor growth and metastasis.	[Ishikawa, Mizuho; Osaki, Mitsuhiko; Onuma, Kunishige; Ito, Hisao; Okada, Futoshi] Tottori Univ, Fac Med, Dept Biomed Sci, Div Pathol Biochem, 86 Nishi Cho, Yonago, Tottori 6838503, Japan; [Osaki, Mitsuhiko; Okada, Futoshi] Tottori Univ, Chromosome Engn Res Ctr, 86 Nishi Cho, Yonago, Tottori 6838503, Japan; [Yamagishi, Makoto] Univ Tokyo, Grad Sch Frontier Sci, Dept Computat Biol & Med Sci, Lab Tumor Cell Biol,Minato Ku, Tokyo 1088639, Japan; [Endo, Hideya] Univ Tokyo, Inst Med Sci, Dept Canc Biol, Div Cellular & Mol Biol,Minato Ku, Tokyo 1088639, Japan	Tottori University; Tottori University; University of Tokyo; University of Tokyo	Endo, H (corresponding author), Univ Tokyo, Inst Med Sci, Dept Canc Biol, Div Cellular & Mol Biol,Minato Ku, Tokyo 1088639, Japan.	endoh@ims.u-tokyo.ac.jp		Onuma, Kunishige/0000-0002-1034-5796; Okada, Futoshi/0000-0003-4733-1037	Arteriosclerosis Research Foundation, Tokyo, Japan	Arteriosclerosis Research Foundation, Tokyo, Japan	We are grateful to Dr. K. Takenaga (Chiba Cancer Center Research Institute, Chiba, Japan) for valuable comments and critical reading of the manuscript. We also thank to Dr. Y. Toh (National Kyushu Cancer Center, Fukuoka, Japan) for valuable information on the MTA1 studies. This work was supported by a grant from the Arteriosclerosis Research Foundation, Tokyo, Japan.	Ambartsumian N, 2001, ONCOGENE, V20, P4685, DOI 10.1038/sj.onc.1204636; Bartoszewska S, 2015, FASEB J, V29, P1467, DOI 10.1096/fj.14-267054; Dannenmann C, 2008, CANCER BIOL THER, V7, P1462, DOI 10.4161/cbt.7.9.6427; Dulyaninova NG, 2005, BIOCHEMISTRY-US, V44, P6867, DOI 10.1021/bi0500776; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014; FORD HL, 1995, ONCOGENE, V11, P2067; Garrett SC, 2006, J BIOL CHEM, V281, P677, DOI 10.1074/jbc.R500017200; Ghosh G, 2010, J CLIN INVEST, V120, P4141, DOI 10.1172/JCI42980; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Hunter K, 2006, NAT REV CANCER, V6, P141, DOI 10.1038/nrc1803; Jang KS, 2006, CANCER SCI, V97, P374, DOI 10.1111/j.1349-7006.2006.00186.x; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Kriajevska M, 2000, BBA-MOL CELL RES, V1498, P252, DOI 10.1016/S0167-4889(00)00100-2; Li DQ, 2009, P NATL ACAD SCI USA, V106, P17493, DOI 10.1073/pnas.0908027106; Liu TL, 2015, EUR J MED RES, V20, DOI 10.1186/s40001-015-0084-x; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Meinert C, 2017, DATA BRIEF, V10, P354, DOI 10.1016/j.dib.2016.12.004; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Moon HE, 2006, ONCOL REP, V16, P929; Ochiya T, 2014, ANGIOGENESIS, V17, P17, DOI 10.1007/s10456-013-9372-7; Oida Y, 2006, ONCOL REP, V16, P457; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Riker AI, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-13; Rudland SDS, 2006, CLIN CANCER RES, V12, P1192, DOI 10.1158/1078-0432.CCR-05-1580; Schmidt-Hansen B, 2004, ONCOGENE, V23, P5487, DOI 10.1038/sj.onc.1207720; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; Takenaga K, 1997, CLIN CANCER RES, V3, P2309; TAKENAGA K, 1994, JPN J CANCER RES, V85, P831, DOI 10.1111/j.1349-7006.1994.tb02955.x; Toh Y, 2000, J EXP CLIN CANC RES, V19, P105; Toh Y, 1999, BRIT J CANCER, V79, P1723, DOI 10.1038/sj.bjc.6690274; TOH Y, 1994, J BIOL CHEM, V269, P22958; Wang YY, 2010, ANN SURG ONCOL, V17, P89, DOI 10.1245/s10434-009-0722-z; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yoo YG, 2006, EMBO J, V25, P1231, DOI 10.1038/sj.emboj.7601025; Zhu XX, 2010, J THORAC ONCOL, V5, P1159, DOI 10.1097/JTO.0b013e3181e04d98	38	11	11	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2019	38	24					4715	4728		10.1038/s41388-019-0748-z	http://dx.doi.org/10.1038/s41388-019-0748-z			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IC7ND	30745574	Green Submitted			2022-12-28	WOS:000471160500005
J	Johnson, CE; Dunlop, EA; Seifan, S; McCann, HD; Hay, T; Parfitt, GJ; Jones, AT; Giles, PJ; Shen, MH; Sampson, JR; Errington, RJ; Davies, DM; Tee, AR				Johnson, Charlotte E.; Dunlop, Elaine A.; Seifan, Sara; McCann, Henry D.; Hay, Trevor; Parfitt, Geraint J.; Jones, Ashley T.; Giles, Peter J.; Shen, Ming H.; Sampson, Julian R.; Errington, Rachel J.; Davies, D. Mark; Tee, Andrew R.			Loss of tuberous sclerosis complex 2 sensitizes tumors to nelfinavir-bortezomib therapy to intensify endoplasmic reticulum stress-induced cell death (vol 37, pg 5913, 2019)	ONCOGENE			English	Correction									[Johnson, Charlotte E.; Dunlop, Elaine A.; Seifan, Sara; McCann, Henry D.; Jones, Ashley T.; Giles, Peter J.; Shen, Ming H.; Sampson, Julian R.; Errington, Rachel J.; Davies, D. Mark; Tee, Andrew R.] Cardiff Univ, Div Canc & Genet, Heath Pk, Cardiff CF14 4XN, S Glam, Wales; [Hay, Trevor; Parfitt, Geraint J.] Cardiff Univ, European Canc Stem Cell Res Inst, Hadyn Ellis Bldg,Maindy Rd, Cardiff CF24 4HQ, S Glam, Wales; [Davies, D. Mark] Singleton Hosp, Dept Oncol, South West Wales Canc Ctr, Swansea SA2 8QA, W Glam, Wales	Cardiff University; Cardiff University; Singleton Hospital	Tee, AR (corresponding author), Cardiff Univ, Div Canc & Genet, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.	teea@cardiff.ac.uk						Johnson CE, 2018, ONCOGENE, V37, P5913, DOI 10.1038/s41388-018-0381-2	1	0	0	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2019	38	16					3102	3102		10.1038/s41388-018-0598-0	http://dx.doi.org/10.1038/s41388-018-0598-0			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU3IV	30622341	Green Published, hybrid			2022-12-28	WOS:000465167600016
J	Zhao, H; Martin, E; Matalkah, F; Shah, N; Ivanov, A; Ruppert, JM; Lockman, PR; Agazie, YM				Zhao, Hua; Martin, Elisha; Matalkah, Fatimah; Shah, Neal; Ivanov, Alexey; Ruppert, J. Michael; Lockman, Paul R.; Agazie, Yehenew M.			Conditional knockout of SHP2 in ErbB2 transgenic mice or inhibition in HER2-amplified breast cancer cell lines blocks oncogene expression and tumorigenesis	ONCOGENE			English	Article							EPIDERMAL-GROWTH-FACTOR; CRYSTAL-STRUCTURE; TYROSINE PHOSPHATASE; MOLECULAR-MECHANISM; BASAL-LIKE; MAMMARY; LEADS; PHOSPHORYLATION; TRANSITION; COMPLEX	Overexpression of the human epidermal growth factor receptor 2 (HER2) is the cause of HER2-positive breast cancer (BC). Although HER2-inactivating therapies have benefited BC patients, development of resistance and disease recurrence have been the major clinical problems, pointing to a need for alternative therapeutic strategies. For that to happen, proteins that play critical roles in the biology of HER2-induced tumorigenesis have to be identified and characterized. Here, we show that the Src homology phosphotyrosyl phosphatase 2 (Shp2) encoded by the Ptpn11 gene is a requisite for ErbB2-induced tumorigenesis. We report that conditional knockout of Shp2 alleles in the ErbB2 BC model mice abrogates mammary tumorigenesis by blocking the expression of the ErbB2 transgene. We also show that inhibition of SHP2 encoded by the PTPN11 gene in the HER2-amplified BC cells induces a normal-like cellular phenotype and suppresses tumorigenesis and metastasis by blocking HER2 overexpression. These findings demonstrate that ErbB2-induced tumors in mice or xenograft tumors induced by transplantation of HER2-amplified BC cells are vulnerable to SHP2 inhibition since it abrogates the expression of the very oncogene that causes of the disease. This report paves the way for developing SHP2-targeting therapies for BC treatment in the future.	[Zhao, Hua; Martin, Elisha; Matalkah, Fatimah; Ivanov, Alexey; Ruppert, J. Michael; Agazie, Yehenew M.] West Virginia Univ, Sch Med, Dept Biochem, Morgantown, WV 26506 USA; [Shah, Neal; Lockman, Paul R.] West Virginia Univ, Sch Med, Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA; [Ivanov, Alexey; Ruppert, J. Michael; Agazie, Yehenew M.] West Virginia Univ, Sch Med, WVU Canc Inst, Morgantown, WV 26506 USA	West Virginia University; West Virginia University; West Virginia University	Agazie, YM (corresponding author), West Virginia Univ, Sch Med, Dept Biochem, Morgantown, WV 26506 USA.; Agazie, YM (corresponding author), West Virginia Univ, Sch Med, WVU Canc Inst, Morgantown, WV 26506 USA.	yagazie@hsc.wvu.edu		Ivanov, Alexey/0000-0002-8617-4604; Ruppert, John/0000-0001-6004-6527; Lockman, Paul/0000-0002-6995-9944; Matalkah, Fatimah/0000-0002-0160-3757	National Cancer Institute (NCI), a component of the National Institute of Health (NIH) [CA124940]; NIH [GM103488, GM104842, GM103434, P20RR016440, P30RR032138/P30GM103488]; NATIONAL CANCER INSTITUTE [R01CA124940] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM104942] Funding Source: NIH RePORTER	National Cancer Institute (NCI), a component of the National Institute of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by a grant (CA124940) from the National Cancer Institute (NCI), a component of the National Institute of Health (NIH) to YMA. The Flow Core and Imaging facilities are supported by grants from NIH (GM103488, GM104842, GM103434, P20RR016440, and P30RR032138/P30GM103488.). We would like to thank Dr. Benjamin Neel and Dr. Timothy Lane for providing the SHP2-floxed and the MMTV-Cre mice, respectively. Also, we thank Dr. Karen Martin, Dr. Amanda Ammer, and Mrs. Sarah McLaughlin for their support in microscopic and ultrasound imaging and Dr. Katherine Brundage for her support in FACS analyses.	Agazie YM, 2003, MOL CELL BIOL, V23, P7875, DOI 10.1128/MCB.23.21.7875-7886.2003; Ahmed Z, 2010, CELL SIGNAL, V22, P23, DOI 10.1016/j.cellsig.2009.08.011; Bentires-Alj M, 2006, NAT MED, V12, P114, DOI 10.1038/nm1341; Brandt BH, 1999, FASEB J, V13, P1939, DOI 10.1096/fasebj.13.14.1939; Burks J, 2006, ONCOGENE, V25, P7166, DOI 10.1038/sj.onc.1209728; Cleghon V, 1998, MOL CELL, V2, P719, DOI 10.1016/S1097-2765(00)80287-7; Deblois G, 2010, CANCER RES, V70, P10277, DOI 10.1158/0008-5472.CAN-10-2840; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dent S, 2013, CANCER TREAT REV, V39, P622, DOI 10.1016/j.ctrv.2013.01.002; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; FENG GS, 1994, ONCOGENE, V9, P1545; Fornaro M, 2006, J CELL BIOL, V175, P87, DOI 10.1083/jcb.200602029; Frearson JA, 1998, J EXP MED, V187, P1417, DOI 10.1084/jem.187.9.1417; Garrett TPJ, 2003, MOL CELL, V11, P495, DOI 10.1016/S1097-2765(03)00048-0; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hartman Z, 2013, ONCOGENE, V32, P4169, DOI 10.1038/onc.2012.418; Hartman ZR, 2013, MOL CANCER RES, V11, P651, DOI 10.1158/1541-7786.MCR-12-0578; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Ke YH, 2006, J BIOL CHEM, V281, P34374, DOI 10.1074/jbc.M607325200; Kim YS, 2014, J BREAST CANCER, V17, P121, DOI 10.4048/jbc.2014.17.2.121; Lan LX, 2015, EMBO J, V34, P1493, DOI 10.15252/embj.201489004; Li G, 2002, DEVELOPMENT, V129, P4159; Matalkah F, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-015-0659-z; Muenst S, 2013, HISTOPATHOLOGY, V63, P74, DOI 10.1111/his.12140; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Pegram M D, 2000, Cancer Treat Res, V103, P57; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Verma S, 2012, NEW ENGL J MED, V367, P1783, DOI 10.1056/NEJMoa1209124; Zhao H, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1131-2; Zhou X, 2008, HISTOPATHOLOGY, V53, P389, DOI 10.1111/j.1365-2559.2008.03103.x; Zhou XD, 2008, CELL DEATH DIFFER, V15, P988, DOI 10.1038/cdd.2008.54; Zhou XD, 2009, J BIOL CHEM, V284, P12226, DOI 10.1074/jbc.M900020200	38	15	15	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2019	38	13					2275	2290		10.1038/s41388-018-0574-8	http://dx.doi.org/10.1038/s41388-018-0574-8			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ7GN	30467378	Green Submitted, Green Accepted			2022-12-28	WOS:000462588000004
J	Su, F; Ahn, S; Saha, A; DiGiovanni, J; Kolonin, MG				Su, Fei; Ahn, Songyeon; Saha, Achinto; DiGiovanni, John; Kolonin, Mikhail G.			Adipose stromal cell targeting suppresses prostate cancer epithelial-mesenchymal transition and chemoresistance	ONCOGENE			English	Article							TUMOR PROGRESSION; TISSUE; OBESITY	Fat tissue, overgrowing in obesity, promotes the progression of various carcinomas. Clinical and animal model studies indicate that adipose stromal cells (ASC), the progenitors of adipocytes, are recruited by tumors and promote tumor growth as tumor stromal cells. Here, we investigated the role of ASC in cancer chemoresistance and invasiveness, the attributes of tumor aggressiveness. By using human cell co-culture models, we demonstrate that ASC induce epithelial-mesenchymal transition (EMT) in prostate cancer cells. Our results for the first time demonstrate that ASC interaction renders cancer cells more migratory and resistant to docetaxel, cabazitaxel, and cisplatin chemotherapy. To confirm these findings in vivo, we compared cancer aggressiveness in lean and obese mice grafted with prostate tumors. We show that obesity promotes EMT in cancer cells and tumor invasion into the surrounding fat tissue. A hunter-killer peptide D-CAN, previously developed for targeted ASC ablation, suppressed the obesity-associated EMT and cancer progression. Importantly, cisplatin combined with D-CAN was more effective than cisplatin alone in suppressing growth of mouse prostate cancer allografts and xenografts even in non-obese mice. Our data demonstrate that ASC promote tumor aggressiveness and identify them as a target of combination cancer therapy.	[Su, Fei; Kolonin, Mikhail G.] Univ Texas Hlth Sci Ctr Houston, Inst Mol Med Prevent Dis, Brown Fdn, Houston, TX 77030 USA; [Ahn, Songyeon; Saha, Achinto; DiGiovanni, John] Univ Texas Austin, Dell Pediat Res Inst, Div Pharmacol & Toxicol, Austin, TX 78723 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Austin	Kolonin, MG (corresponding author), Univ Texas Hlth Sci Ctr Houston, Inst Mol Med Prevent Dis, Brown Fdn, Houston, TX 77030 USA.	mikhail.g.kolonin@uth.tmc.edu		Kolonin, Mikhail/0000-0002-3743-7869; SU, FEI/0000-0001-5834-4074	NIH [R01 CA196259, R21 CA216745]; Harry E. Bovay, Jr. Foundation; NATIONAL CANCER INSTITUTE [R21CA216745, R01CA196259] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Harry E. Bovay, Jr. Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by NIH grant R01 CA196259 (to JD and MK), R21 CA216745 (to MK) and the Harry E. Bovay, Jr. Foundation.	Daquinag AC, 2015, CELL DEATH DIFFER, V22, P351, DOI 10.1038/cdd.2014.148; Daquinag AC, 2017, MOL THER-ONCOLYTICS, V6, P1, DOI 10.1016/j.omto.2017.05.003; Daquinag AC, 2016, MOL THER, V24, P34, DOI 10.1038/mt.2015.155; Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022; Eheman C, 2012, CANCER-AM CANCER SOC, V118, P2338, DOI 10.1002/cncr.27514; Jung YH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2766; Kandul NP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13100; Lengyel E, 2018, TRENDS CANCER, V4, P374, DOI 10.1016/j.trecan.2018.03.004; Lu YS, 2017, BIOCHEM BIOPH RES CO, V494, P719, DOI 10.1016/j.bbrc.2017.10.118; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Duong MN, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0569-0; Nowicka A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081859; Orecchioni S, 2013, CANCER RES, V73, P5880, DOI 10.1158/0008-5472.CAN-13-0821; Park J, 2014, NAT REV ENDOCRINOL, V10, P455, DOI 10.1038/nrendo.2014.94; Rowan BG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089595; Saha A, 2017, CANCER RES, V77, P5158, DOI [10.1158/0008-5472.CAN-17-0284, 10.1158/0008-5472.can-17-0284]; Saha A, 2016, ONCOTARGET, V7, P25194, DOI 10.18632/oncotarget.7535; Sun K, 2011, J CLIN INVEST, V121, P2094, DOI 10.1172/JCI45887; Tan EHP, 2018, ONCOGENE, V37, P2067, DOI 10.1038/s41388-017-0109-8; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Zhang Y, 2012, CANCER RES, V72, P5198, DOI 10.1158/0008-5472.CAN-12-0294; Zhang Y, 2009, CANCER RES, V69, P5259, DOI 10.1158/0008-5472.CAN-08-3444	22	45	46	5	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2019	38	11					1979	1988		10.1038/s41388-018-0558-8	http://dx.doi.org/10.1038/s41388-018-0558-8			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HO7XX	30361686	Green Accepted			2022-12-28	WOS:000461164400014
J	Toppaldoddi, KR; Cacemiro, MD; Bluteau, O; Panneau-Schmaltz, B; Pioch, A; Muller, D; Villeval, JL; Raslova, H; Constantinescu, SN; Plo, I; Vainchenker, W; Marty, C				Toppaldoddi, Katte Rao; Cacemiro, Maira da Costa; Bluteau, Olivier; Panneau-Schmaltz, Barbara; Pioch, Amelie; Muller, Delphine; Villeval, Jean-Luc; Raslova, Hana; Constantinescu, Stefan N.; Plo, Isabelle; Vainchenker, William; Marty, Caroline			Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice	ONCOGENE			English	Article							THROMBOPOIETIN RECEPTOR; ESSENTIAL THROMBOCYTHEMIA; CALR MUTATIONS; MYELOFIBROSIS; ACTIVATION	Frameshift mutations in the calreticulin (CALR) gene are present in 30% of essential thrombocythemia and myelofibrosis patients. The two most frequent mutations are CALR del52 (type 1, approximately 60%) and CALR ins5 (type 2, around 30%), but many other rarer mutations exist accounting each for less than 2% of all CALR mutations. Most of them are structurally classified as type 1-like and type 2-like CALR mutations according to the absence or presence of a residual wild-type calcium-binding motif and the modification of the alpha-helix structure. Yet, several key questions remain unanswered, especially the reason of such low frequencies of these other mutations. In an attempt to investigate specific pathogenic differences between type 1-like and type 2-like CALR mutations and del52 and ins5, we modeled two type 1-like (del34 and del46) and one type 2-like (dell9) mutations in cell lines and in mice. All CALR mutants constitutively activate JAK2 and STAT5/3/1 in a similar way in the presence of the thrombopoietin receptor (MPL) and induced cytokine-independent cell growth but to a lesser extent with rare mutants over time. This correlates with reduced expression levels of rare CALR mutants compared to del52 and ins5. Lethally irradiated mice that were engrafted with bone marrow transduced with the different CALR mutations developed thrombocytosis, but to a much lesser extent with ins5 and the type 2-like CALR mutation. In contrast to type 2-like mice, type 1-like mice developed marked myelofibrosis and splenomegaly 10 months after engraftment. Similar to del52, type 1-like CALR mutations induced an expansion at an early stage of hematopoiesis compared to ins5 and type 2-like mutation. Thus, type 1-like and type 2-like CALR mutants structurally and functionally resemble del52 and ins5 mutants, respectively.	[Toppaldoddi, Katte Rao; Cacemiro, Maira da Costa; Bluteau, Olivier; Pioch, Amelie; Muller, Delphine; Villeval, Jean-Luc; Raslova, Hana; Plo, Isabelle; Vainchenker, William; Marty, Caroline] INSERM, UMR 1170, Gustave Roussy, Villejuif, France; [Toppaldoddi, Katte Rao; Cacemiro, Maira da Costa; Bluteau, Olivier; Panneau-Schmaltz, Barbara; Pioch, Amelie; Muller, Delphine; Villeval, Jean-Luc; Raslova, Hana; Plo, Isabelle; Vainchenker, William; Marty, Caroline] Univ Paris Saclay, UMR 1170, Gustave Roussy, Villejuif, France; [Toppaldoddi, Katte Rao; Cacemiro, Maira da Costa; Bluteau, Olivier; Panneau-Schmaltz, Barbara; Pioch, Amelie; Muller, Delphine; Villeval, Jean-Luc; Raslova, Hana; Plo, Isabelle; Vainchenker, William; Marty, Caroline] Gustave Roussy, UMR 1170, Villejuif, France; [Cacemiro, Maira da Costa] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Clin Anal Toxicol & Food Sci, Ribeirao Preto, SP, Brazil; [Constantinescu, Stefan N.] Ludwig Inst Canc Res, Brussels, Belgium; [Constantinescu, Stefan N.] Catholic Univ Louvain, de Duve Inst, Brussels, Belgium	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Universidade de Sao Paulo; Ludwig Institute for Cancer Research; Universite Catholique Louvain	Marty, C (corresponding author), INSERM, UMR 1170, Gustave Roussy, Villejuif, France.; Marty, C (corresponding author), Univ Paris Saclay, UMR 1170, Gustave Roussy, Villejuif, France.; Marty, C (corresponding author), Gustave Roussy, UMR 1170, Villejuif, France.	caroline.marty@gustaveroussy.fr	Plo, Isabelle/C-9056-2017; MARTY, Caroline/I-1721-2017; Plo, Isabelle/AAT-6742-2021; Raslova, Hana/N-3562-2018; da Costa Cacemiro, Maira/S-4458-2017	Plo, Isabelle/0000-0002-5915-6910; MARTY, Caroline/0000-0003-4350-2302; Raslova, Hana/0000-0001-8846-5299; da Costa Cacemiro, Maira/0000-0002-4170-2063; Vainchenker, William/0000-0003-4705-202X; Villeval, Jean-Luc/0000-0002-0562-925X	Ligue Nationale Contre le Cancer ("Equipe labellisee 2016"); Institut National du Cancer (PLBIO-2015); MPN Research Foundation; Agence Nationale de la Recherche (ANR-DFG 2014, JAK-POT); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut de Medecine Moleculaire Personnalisee du Cancer (MMO, ANR); Agence Nationale de la Recherche; Ludwig Institute for Cancer Research; Salus Sanguinis; Fondation contre le Cancer; Action de Recherche Concertee; Belgian Genetic Medical Initiative Interuniversity Attraction Pole, Belspo	Ligue Nationale Contre le Cancer ("Equipe labellisee 2016"); Institut National du Cancer (PLBIO-2015); MPN Research Foundation; Agence Nationale de la Recherche (ANR-DFG 2014, JAK-POT)(French National Research Agency (ANR)); Institut National de la Sante et de la Recherche Medicale (Inserm)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Institut de Medecine Moleculaire Personnalisee du Cancer (MMO, ANR)(French National Research Agency (ANR)); Agence Nationale de la Recherche(French National Research Agency (ANR)); Ludwig Institute for Cancer Research; Salus Sanguinis; Fondation contre le Cancer; Action de Recherche Concertee; Belgian Genetic Medical Initiative Interuniversity Attraction Pole, Belspo	This work was supported by grants from Ligue Nationale Contre le Cancer ("Equipe labellisee 2016", H.R.), Institut National du Cancer (PLBIO-2015, I.P.), MPN Research Foundation (I.P.), Agence Nationale de la Recherche (ANR-DFG 2014, JAK-POT, J.L.V.) and Institut National de la Sante et de la Recherche Medicale (Inserm). B. P-S. was funded by Institut de Medecine Moleculaire Personnalisee du Cancer (MMO, ANR). O.B. was supported by Agence Nationale de la Recherche. Support to S.N.C. was from Ludwig Institute for Cancer Research, Salus Sanguinis, Fondation contre le Cancer, Action de Recherche Concertee and Belgian Genetic Medical Initiative Interuniversity Attraction Pole, Belspo. We thank O. Bawa for histology, the staff of the animal facilities of Gustave Roussy directed by P. Gonin, and P. Rameau and Y. Lecluse at the Imaging and Cytometry Platform.	Araki M, 2016, BLOOD, V127, P1307, DOI 10.1182/blood-2015-09-671172; Balligand T, 2016, LEUKEMIA, V30, P1775, DOI 10.1038/leu.2016.47; Barbui T, 2016, BLOOD REV, V30, P453, DOI 10.1016/j.blre.2016.06.001; Cabagnols X, 2015, LEUKEMIA, V29, P249, DOI 10.1038/leu.2014.270; Chachoua I, 2016, BLOOD, V127, P1325, DOI 10.1182/blood-2015-11-681932; Eder-Azanza L, 2014, LEUKEMIA, V28, P2106, DOI 10.1038/leu.2014.190; Elala YC, 2016, AM J HEMATOL, V91, P503, DOI 10.1002/ajh.24338; Elf S, 2016, CANCER DISCOV, V6, P368, DOI 10.1158/2159-8290.CD-15-1434; Klampfl T, 2013, NEW ENGL J MED, V369, P2379, DOI 10.1056/NEJMoa1311347; Li J, 2018, BLOOD, V131, P649, DOI 10.1182/blood-2017-09-806356; Marty C, 2016, BLOOD, V127, P1317, DOI 10.1182/blood-2015-11-679571; Nangalia J, 2013, NEW ENGL J MED, V369, P2391, DOI 10.1056/NEJMoa1312542; Pietra D, 2016, LEUKEMIA, V30, P431, DOI 10.1038/leu.2015.277; Shide K, 2017, LEUKEMIA, V31, P1136, DOI 10.1038/leu.2016.308; Tefferi A, 2014, BLOOD, V124, P2465, DOI 10.1182/blood-2014-07-588426; Tefferi A, 2014, AM J HEMATOL, V89, pE121, DOI 10.1002/ajh.23743; Vainchenker W, 2017, BLOOD, V129, P667, DOI 10.1182/blood-2016-10-695940	17	6	6	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2019	38	10					1651	1660		10.1038/s41388-018-0538-z	http://dx.doi.org/10.1038/s41388-018-0538-z			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN8DD	30846848				2022-12-28	WOS:000460423800006
J	Schaefer, T; Lengerke, C				Schaefer, Thorsten; Lengerke, Claudia			SOX2 protein biochemistry in stemness, reprogramming, and cancer: the PI3K/AKT/SOX2 axis and beyond	ONCOGENE			English	Review							INHIBITS CELL-PROLIFERATION; CYCLIN-DEPENDENT KINASES; MOBILITY-GROUP DOMAIN; DNA-BINDING; HELICOBACTER-PYLORI; S6 PHOSPHORYLATION; SIGNALING PATHWAY; NUCLEAR EXPORT; MOUSE; AKT	Research of the past view years expanded our understanding of the various physiological functions the cell-fate determining transcription factor SOX2 exerts in ontogenesis, reprogramming, and cancer. However, while scientific reports featuring novel and exciting aspects of SOX2-driven biology are published in near weekly routine, investigations in the underlying protein-biochemical processes that transiently tailor SOX2 activity to situational demand are underrepresented and have not yet been comprehensively summarized. Largely unrecognizable to modern array or sequencing-based technology, various protein secondary modifications and concomitant function modulations have been reported for SOX2. The chemical modifications imposed onto SOX2 are inherently heterogeneous, comprising singular or clustered events of phosphorylation, methylation, acetylation, ubiquitination, SUMOylation, PARPylation, and O-glycosylation that reciprocally affect each other and critically impact SOX2 functionality, often in a tissue and species-specific manner. One recurring regulatory principle though is the canonical PI3K/AKT signaling axis to which SOX2 relates in various entangled, albeit not exclusive ways. Here we provide a comprehensive review of the current knowledge on SOX2 protein modifications, their proposed relationship to the PI3K/AKT pathway, and regulatory influence on SOX2 with regards to stemness, reprogramming, and cancer.	[Schaefer, Thorsten; Lengerke, Claudia] Univ Basel, Basel, Switzerland; [Schaefer, Thorsten; Lengerke, Claudia] Univ Hosp Basel, Dept Biomed, Basel, Switzerland; [Lengerke, Claudia] Univ Hosp Basel, Div Hematol, Basel, Switzerland	University of Basel; University of Basel; University of Basel	Schaefer, T (corresponding author), Univ Basel, Basel, Switzerland.; Schaefer, T (corresponding author), Univ Hosp Basel, Dept Biomed, Basel, Switzerland.	thorsten.schaefer@unibas.ch	Lengerke, Claudia/AAV-8745-2021	Lengerke, Claudia/0000-0001-5442-2805; Schaefer, Thorsten/0000-0003-4867-8374	University of Basel Forschungsfonds [DMS-2351]	University of Basel Forschungsfonds	We acknowledge funding assigned to TS through the University of Basel Forschungsfonds (Grant No. DMS-2351) and apologize to authors whose work could not be cited or laid out in further detail due to reference or space limitations.	Arnold K, 2011, CELL STEM CELL, V9, P317, DOI 10.1016/j.stem.2011.09.001; Asanuma K, 2016, GUT, V65, P1416, DOI 10.1136/gutjnl-2015-309272; Asonuma S, 2009, AM J PHYSIOL-GASTR L, V297, pG312, DOI 10.1152/ajpgi.00518.2007; Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Baltus GA, 2009, STEM CELLS, V27, P2175, DOI 10.1002/stem.168; Bareiss PM, 2013, CANCER RES, V73, P5544, DOI 10.1158/0008-5472.CAN-12-4177; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Biernaskie J, 2009, CELL STEM CELL, V5, P610, DOI 10.1016/j.stem.2009.10.019; Blanco S, 2016, NATURE, V534, P335, DOI 10.1038/nature18282; Boucher J, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a009191; Boumahdi S, 2014, NATURE, V511, P246, DOI 10.1038/nature13305; Bowles J, 2000, DEV BIOL, V227, P239, DOI 10.1006/dbio.2000.9883; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Carrasco-Garcia E, 2016, AM J CANCER RES, V6, P701; Driskell RR, 2009, DEVELOPMENT, V136, P2815, DOI 10.1242/dev.038620; Fang L, 2014, MOL CELL, V55, P537, DOI 10.1016/j.molcel.2014.06.018; Fang XF, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-11; Fang XF, 2011, PROTEOMICS, V11, P921, DOI 10.1002/pmic.201000419; Feng RP, 2015, BIOL CHEM, V396, P883, DOI 10.1515/hsz-2014-0317; Fernandes KJL, 2004, NAT CELL BIOL, V6, P1082, DOI 10.1038/ncb1181; Foulk R A, 2001, Early Pregnancy, V5, P61; Gao FR, 2009, J BIOL CHEM, V284, P22263, DOI 10.1074/jbc.M109.033118; Gargini R, 2015, STEM CELLS, V33, P646, DOI 10.1002/stem.1904; Garros-Regulez L, 2016, EXPERT OPIN THER TAR, V20, P393, DOI 10.1517/14728222.2016.1151002; Gasca S, 2002, P NATL ACAD SCI USA, V99, P11199, DOI 10.1073/pnas.172383099; Gaullier G, 2017, MOL CELL, V65, P581, DOI 10.1016/j.molcel.2017.02.001; Gen Y, 2013, CANCER SCI, V104, P810, DOI 10.1111/cas.12155; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Golden BDO, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076345; GRANA X, 1995, ONCOGENE, V11, P211; Grimm D, 2020, SEMIN CANCER BIOL, V67, P122, DOI 10.1016/j.semcancer.2019.03.004; Gunawardena J, 2010, SCIENCE, V328, P581, DOI 10.1126/science.1188974; Guth SIE, 2008, CELL MOL LIFE SCI, V65, P3000, DOI 10.1007/s00018-008-8138-7; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hietakangas V, 2006, P NATL ACAD SCI USA, V103, P45, DOI 10.1073/pnas.0503698102; Hori N, 2012, J BIOL CHEM, V287, P44006, DOI 10.1074/jbc.M112.424580; Hossini AM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154770; Hou LL, 2017, SEMIN CELL DEV BIOL, V63, P2, DOI 10.1016/j.semcdb.2016.08.005; Ikushima H, 2011, J BIOL CHEM, V286, P41434, DOI 10.1074/jbc.M111.300863; Jang H, 2012, CELL STEM CELL, V11, P62, DOI 10.1016/j.stem.2012.03.001; Jeong CH, 2010, STEM CELLS, V28, P2141, DOI 10.1002/stem.540; Jeong HC, 2017, STEM CELLS, V35, P2037, DOI 10.1002/stem.2642; Josse L, 2016, BIOCHEM J, V473, P4651, DOI 10.1042/BCJ20160845; Juuri E, 2013, DEVELOPMENT, V140, P1424, DOI 10.1242/dev.089599; Kamachi Y, 2000, TRENDS GENET, V16, P182, DOI 10.1016/S0168-9525(99)01955-1; Kamachi Y, 2001, GENE DEV, V15, P1272, DOI 10.1101/gad.887101; Kamachi Y, 2013, DEVELOPMENT, V140, P4129, DOI 10.1242/dev.091793; Kim BR, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002581; Knauss JL, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0840-2; Kopp JL, 2008, STEM CELLS, V26, P903, DOI 10.1634/stemcells.2007-0951; Koren S, 2015, NATURE, V525, P114, DOI 10.1038/nature14669; Korkaya H, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000121; Krol I, 2018, BRIT J CANCER, V119, P487, DOI 10.1038/s41416-018-0186-7; Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338; Lengerke C, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-42; Li J, 2007, J BIOL CHEM, V282, P19481, DOI 10.1074/jbc.M702056200; Liao CH, 2018, STEM CELLS, V36, P1514, DOI 10.1002/stem.2862; Liao XH, 2008, AMINO ACIDS, V35, P761, DOI 10.1007/s00726-008-0100-3; Liu TH, 2016, SCI REP-UK, V6, DOI 10.1038/srep28946; Liu ZY, 2017, MOL CELL, V65, P589, DOI 10.1016/j.molcel.2017.01.017; Luo JF, 2018, AM J TRANSL RES, V10, P639; Mackenzie RWA, 2014, DIABETES METAB SYNDR, V7, P55, DOI 10.2147/DMSO.S48260; Maier S, 2011, HUM PATHOL, V42, P1078, DOI 10.1016/j.humpath.2010.11.010; Malak PN, 2015, CELL CYCLE, V14, P3748, DOI 10.1080/15384101.2015.1104444; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Mansouri Sheila, 2016, CNS Oncol, V5, P159, DOI 10.2217/cns-2016-0001; Mao J, 2014, STEM CELLS DEV, V23, P779, DOI 10.1089/scd.2013.0325; Martelli AM, 2011, CURR MED CHEM, V18, P2715; Martini M, 2014, ANN MED, V46, P372, DOI 10.3109/07853890.2014.912836; Masui S, 2007, NAT CELL BIOL, V9, P625, DOI 10.1038/ncb1589; Matsuda K, 2008, SCAND J GASTROENTERO, V43, P25, DOI 10.1080/00365520701579795; Matsushima D, 2011, DEVELOPMENT, V138, P443, DOI 10.1242/dev.055178; Mehta GA, 2017, BREAST CANCER RES TR, V162, P439, DOI 10.1007/s10549-017-4139-2; Meyuhas O, 2015, INT REV CEL MOL BIO, V320, P41, DOI 10.1016/bs.ircmb.2015.07.006; Miinea CP, 2005, BIOCHEM J, V391, P87, DOI 10.1042/BJ20050887; Myers SA, 2016, ELIFE, V5, DOI 10.7554/eLife.10647; Nakagawa M, 2008, NAT BIOTECHNOL, V26, P101, DOI 10.1038/nbt1374; Nicoletti F, 2007, TRENDS PHARMACOL SCI, V28, P206, DOI 10.1016/j.tips.2007.03.008; Nowling TK, 2000, J BIOL CHEM, V275, P3810, DOI 10.1074/jbc.275.6.3810; Otsubo T, 2008, BRIT J CANCER, V98, P824, DOI 10.1038/sj.bjc.6604193; Pham DL, 2013, INT J GYNECOL PATHOL, V32, P358, DOI 10.1097/PGP.0b013e31826a642b; Porta C, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00064; Qin J, 2015, ONCOTARGET, V6, P6944, DOI 10.18632/oncotarget.3128; Que J, 2007, DEVELOPMENT, V134, P2521, DOI 10.1242/dev.003855; Ren CM, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0321-3; Rigbolt KTG, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001570; Ruvinsky I, 2006, TRENDS BIOCHEM SCI, V31, P342, DOI 10.1016/j.tibs.2006.04.003; Sarkar A, 2016, CELL REP, V16, P1929, DOI 10.1016/j.celrep.2016.07.034; Schaefer T, 2019, BRAIN PATHOL, V29, P336, DOI 10.1111/bpa.12670; Schaefer T, 2015, ONCOTARGET, V6, P43540, DOI 10.18632/oncotarget.6183; Schaefer T, 2015, CELL CYCLE, V14, P3784, DOI 10.1080/15384101.2015.1115642; Schepers GE, 2002, DEV CELL, V3, P167, DOI 10.1016/S1534-5807(02)00223-X; Schneider A, 2009, AM J MED GENET A, V149A, P2706, DOI 10.1002/ajmg.a.33098; Schrock A, 2014, CARCINOGENESIS, V35, P1636, DOI 10.1093/carcin/bgu094; Schrock A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059201; Semple BD, 2013, PROG NEUROBIOL, V106, P1, DOI 10.1016/j.pneurobio.2013.04.001; Sendoel A, 2017, NATURE, V541, P494, DOI 10.1038/nature21036; Sharma NS, O GLCNAC MODIFICATIO, DOI 10.1101/345223; Siddle K, 2011, J MOL ENDOCRINOL, V47, pR1, DOI 10.1530/JME-11-0022; Signer RAJ, 2014, NATURE, V509, P49, DOI 10.1038/nature13035; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tang JM, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0074-2; Taranova OV, 2006, GENE DEV, V20, P1187, DOI 10.1101/gad.1407906; Thevenet L, 2004, EMBO J, V23, P3336, DOI 10.1038/sj.emboj.7600352; Tripathi SC, 2017, CANCER RES, V77, P4414, DOI 10.1158/0008-5472.CAN-16-2874; Tsuruzoe S, 2006, BIOCHEM BIOPH RES CO, V351, P920, DOI 10.1016/j.bbrc.2006.10.130; Van Hoof D, 2009, CELL STEM CELL, V5, P214, DOI 10.1016/j.stem.2009.05.021; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Velcheti V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061427; Wahl GM, 2017, NPJ BREAST CANCER, V3, DOI 10.1038/s41523-017-0012-z; Wang K, 2018, ORGANOMETALLICS, V37, P1, DOI 10.1021/acs.organomet.7b00657; Wang SM, 2015, CANCER LETT, V358, P210, DOI 10.1016/j.canlet.2014.12.045; Wang Z, 2019, ONCOGENE, V38, P5250, DOI 10.1038/s41388-019-0790-x; Wilbertz T, 2011, MODERN PATHOL, V24, P944, DOI 10.1038/modpathol.2011.49; Williamson KA, 2006, HUM MOL GENET, V15, P1413, DOI 10.1093/hmg/ddl064; Wilson M, 2002, CURR OPIN GENET DEV, V12, P441, DOI 10.1016/S0959-437X(02)00323-4; Wissmuller S, 2006, NUCLEIC ACIDS RES, V34, P1735, DOI 10.1093/nar/gkl105; Wuebben EL, 2017, ONCOTARGET, V8, P44917, DOI 10.18632/oncotarget.16570; Yesudhas D, 2017, FEBS OPEN BIO, V7, P1750, DOI 10.1002/2211-5463.12316; Zhang JC, 2012, CANCER RES, V72, P4597, DOI 10.1158/0008-5472.CAN-12-1045; Zhang J, 2014, BMC NEUROL, V14, DOI 10.1186/s12883-014-0207-y; Zhao HY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027026; Zhao SL, 2004, MOL CELL NEUROSCI, V27, P332, DOI 10.1016/j.mcn.2004.08.002	124	66	68	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	2					278	292		10.1038/s41388-019-0997-x	http://dx.doi.org/10.1038/s41388-019-0997-x			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KD3JY	31477842	hybrid, Green Published			2022-12-28	WOS:000507766400003
J	Wei, TT; Lin, YT; Tang, SP; Luo, CK; Tsai, CT; Shun, CT; Chen, CC				Wei, Tzu-Tang; Lin, Yi-Ting; Tang, Shao-Pu; Luo, Cong-Kai; Tsai, Chiou-Tsun; Shun, Chia-Tung; Chen, Ching-Chow			Metabolic targeting of HIF-1 alpha potentiates the therapeutic efficacy of oxaliplatin in colorectal cancer	ONCOGENE			English	Article							HYPOXIA-INDUCIBLE FACTORS; TUMOR HYPOXIA; HISTONE DEACETYLASE; DRUG-RESISTANCE; HIF-1; INFLAMMATION; CHEMORESISTANCE; ANGIOGENESIS; CHEMOTHERAPY; VASCULATURE	Drug resistance is a major problem limiting the efficacy of chemotherapy in cancer treatment, and the hypoxia-induced stabilization of HIF-1 alpha plays a role in this process. HIF-1 alpha overexpression has been observed in a variety of human cancers, including colorectal cancer (CRC). Therefore, targeting HIF-1 alpha is a promising strategy for overcoming chemoresistance to enhance the efficacy of chemotherapies in CRC. Here, we show that DNMT inhibitors can induce HIF-1 alpha degradation to overcome oxaliplatin resistance and enhance anti-CRC therapy. We found that a low-toxicity DNMT inhibitor, zebularine, could downregulate HIF-1 alpha expression and overcome hypoxia-induced oxaliplatin resistance in HCT116 cells and showed efficacy in HCT116 xenograft models and AOM/DSS-induced CRC mouse models. Zebularine could induce the degradation of HIF-1 alpha protein through hydroxylation. LC-MS analysis showed a decrease in succinate in various CRC cells under hypoxia and in colon tissues of AOM/DSS-induced CRC mice. The decrease was reversed by zebularine. Tumor angiogenesis was also reduced by zebularine. Furthermore, zebularine potentiated the anticancer effect of oxaliplatin in AOM/DSS-induced CRC models. This finding provides a new strategy in which an increase in HIF-1 alpha hydroxylation could overcome oxaliplatin resistance to enhance anti-CRC therapy.	[Wei, Tzu-Tang; Lin, Yi-Ting; Tang, Shao-Pu; Luo, Cong-Kai; Tsai, Chiou-Tsun; Chen, Ching-Chow] Natl Taiwan Univ, Dept Pharmacol, Coll Med, Taipei 100, Taiwan; [Wei, Tzu-Tang; Lin, Yi-Ting; Tang, Shao-Pu; Luo, Cong-Kai; Tsai, Chiou-Tsun; Shun, Chia-Tung; Chen, Ching-Chow] Natl Taiwan Univ, Grad Inst Forens Med, Coll Med, Taipei 100, Taiwan; [Shun, Chia-Tung] Natl Taiwan Univ Hosp, Dept Pathol, Taipei 106, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University Hospital	Chen, CC (corresponding author), Natl Taiwan Univ, Dept Pharmacol, Coll Med, Taipei 100, Taiwan.; Chen, CC (corresponding author), Natl Taiwan Univ, Grad Inst Forens Med, Coll Med, Taipei 100, Taiwan.	chingchowchen@ntu.edu.tw	WEI, TZU-TANG/AAT-8447-2020; Tsai, Chiou-Tsun/AAO-6782-2021	SHUN, CHIA-TUNG/0000-0002-0468-4468	National Science Council of Taiwan; Institute of Biomedical Sciences, Academia Sinica [IBMS-CRC103-P02]	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan); Institute of Biomedical Sciences, Academia Sinica(Academia Sinica - Taiwan)	This work was supported by a research grant from the National Science Council of Taiwan and the Institute of Biomedical Sciences, Academia Sinica (IBMS-CRC103-P02).	Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912; Berchner-Pfannschmidt U, 2008, J BIOL CHEM, V283, P31745, DOI 10.1074/jbc.M804390200; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bokemeyer C, 2009, J CLIN ONCOL, V27, P663, DOI 10.1200/JCO.2008.20.8397; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Chan DA, 2005, MOL CELL BIOL, V25, P6415, DOI 10.1128/MCB.25.15.6415-6426.2005; Chan DA, 2009, CANCER CELL, V15, P527, DOI 10.1016/j.ccr.2009.04.010; Chen CC, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0248-3; Cheng JC, 2004, CANCER CELL, V6, P151, DOI 10.1016/j.ccr.2004.06.023; Colgan SP, 2010, NAT REV GASTRO HEPAT, V7, P281, DOI 10.1038/nrgastro.2010.39; Fong GH, 2008, CELL DEATH DIFFER, V15, P635, DOI 10.1038/cdd.2008.10; Foxler DE, 2012, NAT CELL BIOL, V14, P201, DOI 10.1038/ncb2424; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Kim MS, 2010, CANCER METAST REV, V29, P181, DOI 10.1007/s10555-010-9207-6; Kong XG, 2006, MOL CELL BIOL, V26, P2019, DOI 10.1128/MCB.26.6.2019-2028.2006; Lee K, 2009, P NATL ACAD SCI USA, V106, P17910, DOI 10.1073/pnas.0909353106; Lendahl U, 2009, NAT REV GENET, V10, P821, DOI 10.1038/nrg2665; Liu LL, 2008, CANCER SCI, V99, P121, DOI 10.1111/j.1349-7006.2007.00643.x; Ma J, 2008, MOL CANCER THER, V7, P3670, DOI 10.1158/1535-7163.MCT-08-0715; Mabjeesh NJ, 2003, CANCER CELL, V3, P363, DOI 10.1016/S1535-6108(03)00077-1; Meneses AM, 2016, HYPOXIA, V4, P53, DOI 10.2147/HP.S53576; Pientka FK, 2012, J CELL SCI, V125, P5168, DOI 10.1242/jcs.109041; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Rapisarda A, 2012, NAT REV CLIN ONCOL, V9, P378, DOI 10.1038/nrclinonc.2012.64; Remels AHV, 2015, ENDOCRINOLOGY, V156, P1770, DOI 10.1210/en.2014-1591; Rohwer N, 2011, DRUG RESIST UPDATE, V14, P191, DOI 10.1016/j.drup.2011.03.001; Samanta D, 2014, P NATL ACAD SCI USA, V111, pE5429, DOI 10.1073/pnas.1421438111; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230; Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; Thienpont B, 2016, NATURE, V537, P63, DOI 10.1038/nature19081; Tredan O, 2007, J NATL CANCER I, V99, P1441, DOI 10.1093/jnci/djm135; Ullman TA, 2011, GASTROENTEROLOGY, V140, P1807, DOI 10.1053/j.gastro.2011.01.057; Wei TT, 2016, EBIOMEDICINE, V10, P124, DOI 10.1016/j.ebiom.2016.07.019; Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988; Wilson TR, 2006, ANN ONCOL, V17, pX315, DOI 10.1093/annonc/mdl280; Yang PM, 2013, SCI REP-UK, V3, DOI 10.1038/srep03219; Zhong H, 1999, CANCER RES, V59, P5830	47	23	29	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	2					414	427		10.1038/s41388-019-0999-8	http://dx.doi.org/10.1038/s41388-019-0999-8			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KD3JY	31477841				2022-12-28	WOS:000507766400012
J	Svensmark, JH; Brakebusch, C				Svensmark, Julius H.; Brakebusch, Cord			Rho GTPases in cancer: friend or foe?	ONCOGENE			English	Review							SKIN TUMOR-FORMATION; MUTATIONS; RAC1; PROTEINS; INVASION; LYMPHOMA; KINASE; FAMILY; SHAPE; MOUSE	The Rho GTPases RhoA, Rac1, and Cdc42 are important regulators of cytoskeletal dynamics. Although many in vitro and in vivo data indicate tumor-promoting effects of activated Rho GTPases, also tumor suppressive functions have been described, suggesting either highly cell-type-specific functions for Rho GTPases in cancer or insufficient cancer models. The availability of a large number of cancer genome-sequencing data by The Cancer Genome Atlas (TCGA) allows for the investigation of Rho GTPase function in human cancers in silico. This information should be used to improve our in vitro and in vivo cancer models, which are essential for a molecular understanding of Rho GTPase function in malignant tumors and for the potential development of cancer drugs targeting Rho GTPase signaling.	[Svensmark, Julius H.; Brakebusch, Cord] Univ Copenhagen, BRIC, Ole Maaloes Vej 5, DK-2200 Copenhagen, Denmark	University of Copenhagen	Brakebusch, C (corresponding author), Univ Copenhagen, BRIC, Ole Maaloes Vej 5, DK-2200 Copenhagen, Denmark.	cord.brakebusch@bric.ku.dk						Araiza-Olivera D, 2018, ONCOGENE, V37, P944, DOI 10.1038/onc.2017.400; Aspenstrom P, 2007, EXP CELL RES, V313, P3673, DOI 10.1016/j.yexcr.2007.07.022; Aspenstrom Pontus, 2020, Small GTPases, V11, P248, DOI 10.1080/21541248.2017.1391365; Bagrodia A, 2016, J CLIN ONCOL, V34, P4000, DOI 10.1200/JCO.2016.68.7798; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Bos JL, 2007, CELL, V129, P865, DOI 10.1016/j.cell.2007.05.018; Bustelo XR, 2007, BIOESSAYS, V29, P356, DOI 10.1002/bies.20558; Bustelo XR, 2018, BIOCHEM SOC T, V46, P741, DOI 10.1042/BST20170531; Cardama GA, 2017, INT J ONCOL, V51, P1025, DOI 10.3892/ijo.2017.4093; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chang MT, 2016, NAT BIOTECHNOL, V34, P155, DOI 10.1038/nbt.3391; Chauhan BK, 2011, P NATL ACAD SCI USA, V108, P18289, DOI 10.1073/pnas.1108993108; Cortes JR, 2018, CANCER CELL, V33, P259, DOI 10.1016/j.ccell.2018.01.001; Davis MJ, 2013, P NATL ACAD SCI USA, V110, P912, DOI 10.1073/pnas.1220895110; Dubash AD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017380; Garcia-Mariscal A, 2018, ONCOGENE, V37, P847, DOI 10.1038/onc.2017.333; Garcia-Mata R, 2011, NAT REV MOL CELL BIO, V12, P493, DOI 10.1038/nrm3153; Hakem A, 2005, GENE DEV, V19, P1974, DOI 10.1101/gad.1310805; Hodge RG, 2016, NAT REV MOL CELL BIO, V17, P496, DOI 10.1038/nrm.2016.67; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Humphries B, 2017, CANCER RES, V77, P4051, DOI 10.1158/0008-5472.CAN-16-3141; Hurst CD, 2017, CANCER CELL, V32, P701, DOI 10.1016/j.ccell.2017.08.005; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Ju JA, 2018, GENES-BASEL, V9, DOI 10.3390/genes9020067; Kakiuchi M, 2014, NAT GENET, V46, P583, DOI 10.1038/ng.2984; Karlsson R, 2009, BBA-REV CANCER, V1796, P91, DOI 10.1016/j.bbcan.2009.03.003; Kazanietz MG, 2017, CANCER RES, V77, P5445, DOI 10.1158/0008-5472.CAN-17-1456; Kissil JL, 2007, CANCER RES, V67, P8089, DOI 10.1158/0008-5472.CAN-07-2300; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lawson CD, 2018, J CELL BIOL, V217, P447, DOI 10.1083/jcb.201612069; Li H, 2019, CANCER RES, V79, P2167, DOI 10.1158/0008-5472.CAN-18-1253; Li H, 2014, BIOFACTORS, V40, P226, DOI 10.1002/biof.1155; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; Michaelson D, 2008, J CELL BIOL, V181, P485, DOI 10.1083/jcb.200801047; Mizukawa B, 2017, BLOOD, V130, P1336, DOI 10.1182/blood-2016-12-758458; Nagata Y, 2016, BLOOD, V127, P596, DOI 10.1182/blood-2015-06-644948; Navarro-Lerida I, 2015, DEV CELL, V32, P318, DOI 10.1016/j.devcel.2014.12.019; Nishizawa Takashi, 2018, Oncotarget, V9, P23198, DOI 10.18632/oncotarget.25269; Nobis M, 2017, CELL REP, V21, P274, DOI 10.1016/j.celrep.2017.09.022; O'Hayre M, 2016, ONCOGENE, V35, P3771, DOI 10.1038/onc.2015.442; Palomero T, 2014, NAT GENET, V46, P166, DOI 10.1038/ng.2873; Peck J, 2002, FEBS LETT, V528, P27, DOI 10.1016/S0014-5793(02)03331-8; Pedersen E, 2012, EXP CELL RES, V318, P1779, DOI 10.1016/j.yexcr.2012.05.004; Porter Andrew P, 2016, Small GTPases, V7, P123, DOI 10.1080/21541248.2016.1173767; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Rane CK, 2019, SEMIN CANCER BIOL, V54, P40, DOI 10.1016/j.semcancer.2018.01.006; Ridley AJ, 2013, J MICROSC-OXFORD, V251, P242, DOI 10.1111/jmi.12025; Roberts PJ, 2008, J BIOL CHEM, V283, P25150, DOI 10.1074/jbc.M800882200; Rodrigues P, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6458; Rohde M, 2014, GENE CHROMOSOME CANC, V53, P911, DOI 10.1002/gcc.22202; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Sakata-Yanagimoto M, 2014, NAT GENET, V46, P171, DOI 10.1038/ng.2872; Schaefer Antje, 2014, Small GTPases, V5, P6, DOI 10.4161/21541248.2014.968004; Tomino T, 2018, BIOCHEM BIOPH RES CO, V497, P298, DOI 10.1016/j.bbrc.2018.02.073; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Van Hengel J, 2008, GASTROENTEROLOGY, V134, P781, DOI 10.1053/j.gastro.2008.01.002; Vega Francisco M, 2018, Small GTPases, V9, P384, DOI 10.1080/21541248.2016.1253528; Vennin Claire, 2020, Small GTPases, V11, P45, DOI 10.1080/21541248.2017.1345712; Wang Z, 2010, ONCOGENE, V29, P3362, DOI 10.1038/onc.2010.95; Wu CY, 2014, GASTROENTEROLOGY, V147, P143, DOI 10.1053/j.gastro.2014.03.048; Yang JQ, 2016, J ALLERGY CLIN IMMUN, V137, P231, DOI 10.1016/j.jaci.2015.05.004; Yoo HY, 2014, NAT GENET, V46, P371, DOI 10.1038/ng.2916; Zandvakili I, 2017, ONCOGENE, V36, P3213, DOI 10.1038/onc.2016.473; Zandvakili I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127923; Zuo Y, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-0966-2	67	68	68	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2019	38	50					7447	7456		10.1038/s41388-019-0963-7	http://dx.doi.org/10.1038/s41388-019-0963-7			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JV7GY	31427738				2022-12-28	WOS:000502530500001
J	Secker, KA; Keppeler, H; Duerr-Stoerzer, S; Schmid, H; Schneidawind, D; Hentrich, T; Schulze-Hentrich, JM; Mankel, B; Fend, F; Schneidawind, C				Secker, Kathy-Ann; Keppeler, Hildegard; Duerr-Stoerzer, Silke; Schmid, Hannes; Schneidawind, Dominik; Hentrich, Thomas; Schulze-Hentrich, Julia M.; Mankel, Barbara; Fend, Falko; Schneidawind, Corina			Inhibition of DOT1L and PRMT5 promote synergistic anti-tumor activity in a human MLL leukemia model induced by CRISPR/Cas9	ONCOGENE			English	Article							HEMATOPOIETIC PROGENITOR CELLS; GENE-EXPRESSION PROFILE; ACUTE MYELOID-LEUKEMIA; STEM-CELLS; ARGININE METHYLATION; PROTEIN; TRANSLOCATIONS; MURINE; IDENTIFICATION; MAINTENANCE	MLL rearrangements play a crucial role in leukemogenesis and comprise a poor prognosis. Therefore, new treatment strategies are urgently needed. We used the CRISPR/Cas9 system to generate an innovative leukemia model based on 100% pure MLL-AF4 or -AF9 rearranged cells derived from umbilical cord blood with indefinite growth in cell culture systems. Our model shared phenotypical, morphological and molecular features of patient cells faithfully mimicking the nature of the disease. Thus, it serves as a fundamental basis for pharmacological studies: inhibition of histone methyltransferase disruptor of telomeric silencing 1-like (DOT1L) is one specific therapeutic approach currently tested in clinical trials. However, success was limited by restricted response warranting further investigation of drug combinations. Recently, it has been shown that the inhibition of protein arginine methyltransferase 5 (PRMT5) exhibits anti-tumoral activity against human cell lines and in MLL mouse models. Here, we used DOT1L and PRMT5 inhibitors in our human MLL-rearranged model demonstrating dose-dependent reduced proliferation, impairment of cell cycle, increasing differentiation, apoptosis, downregulation of target genes and sensitization to chemotherapy. Strikingly, the combination of both compounds led to synergistic anti-tumoral effects. Our study provides a strong rationale for novel targeted combination therapies to improve the outcome of MLL-rearranged leukemias.	[Secker, Kathy-Ann; Keppeler, Hildegard; Duerr-Stoerzer, Silke; Schmid, Hannes; Schneidawind, Dominik; Schneidawind, Corina] Univ Hosp Tuebingen, Dept Hematol & Oncol, Tubingen, Germany; [Hentrich, Thomas; Schulze-Hentrich, Julia M.] Univ Tubingen, Inst Med Genet & Appl Genom, Tubingen, Germany; [Mankel, Barbara; Fend, Falko] Univ Tubingen, Inst Pathol & Neuropathol, Tubingen, Germany; [Mankel, Barbara; Fend, Falko] Univ Hosp Tuebingen, Ctr Comprehens Canc, Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Schneidawind, C (corresponding author), Univ Hosp Tuebingen, Dept Hematol & Oncol, Tubingen, Germany.	corina.schneidawind@med.uni-tuebingen.de	Schulze-Hentrich, Julia M./C-1830-2017; Schneidawind, Dominik/AAR-4509-2020; Hentrich, Thomas/N-9336-2019	Schulze-Hentrich, Julia M./0000-0002-9242-2096; Hentrich, Thomas/0000-0002-1488-9096; Fend, Falko/0000-0002-5496-293X	Junior Research Group Grant of the Interdisciplinary Centre for Clinical Research (IZKF) [2383-0-0, 2386-0-0, 2316-0-0]; Wuerttembergischer Krebspreis; Clinician Scientist Program of the Faculty of Medicine Tuebingen; Max Eder Junior Research Group Grant from the Deutsche Krebshilfe; American Society for Blood and Marrow Transplantation (ASBMT); Margarete-von-Wrangell fellowship through the Ministry of Science, Research and the Arts Baden-Wuerttemberg; decipherPD transnational consortium on Epigenomics of Complex Diseases (BMBF) [01KU1503]	Junior Research Group Grant of the Interdisciplinary Centre for Clinical Research (IZKF); Wuerttembergischer Krebspreis; Clinician Scientist Program of the Faculty of Medicine Tuebingen; Max Eder Junior Research Group Grant from the Deutsche Krebshilfe; American Society for Blood and Marrow Transplantation (ASBMT); Margarete-von-Wrangell fellowship through the Ministry of Science, Research and the Arts Baden-Wuerttemberg; decipherPD transnational consortium on Epigenomics of Complex Diseases (BMBF)(Federal Ministry of Education & Research (BMBF))	We thank the Flow Cytometry Core Facility Berg of the University Hospital Tuebingen for their excellent technical support. Likewise, we would like to thank the Department of Obstetrics and Gynecology of the University Hospital Tuebingen for providing human cord blood, and the core facility c.ATG of the University Hospital Tuebingen for preparing the RNA-seq libraries, sequencing the samples and data quality control. Furthermore, we thank Dr. Johan Jeong for his technical support in the analysis of the RNA-seq data. CS was supported by a Junior Research Group Grant of the Interdisciplinary Centre for Clinical Research (IZKF, 2383-0-0), the Wuerttembergischer Krebspreis and the Clinician Scientist Program of the Faculty of Medicine Tuebingen. DS was supported by a Max Eder Junior Research Group Grant from the Deutsche Krebshilfe, a New Investigator Award of the American Society for Blood and Marrow Transplantation (ASBMT), a Junior Research Group Grant of the Interdisciplinary Centre for Clinical Research (IZKF, 2316-0-0) and the Clinician Scientist Program of the Faculty of Medicine Tuebingen. JMSH was supported by a Margarete-von-Wrangell fellowship through the Ministry of Science, Research and the Arts Baden-Wuerttemberg, a Junior Research Group Grant of the Interdisciplinary Centre for Clinical Research (IZKF, 2386-0-0) and, together with TH, received funding from the decipherPD transnational consortium on Epigenomics of Complex Diseases (BMBF grant number 01KU1503).	Andersson AK, 2015, NAT GENET, V47, P330, DOI 10.1038/ng.3230; Andrews S., 2010, FASTQC QUALITY CONTR; Aoki Y, 2015, BLOOD, V125, P967, DOI 10.1182/blood-2014-03-563304; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Baer MR, 1998, LEUKEMIA, V12, P317, DOI 10.1038/sj.leu.2400933; Barabe F, 2007, SCIENCE, V316, P600, DOI 10.1126/science.1139851; Bouchlaka MN, 2013, J EXP MED, V210, P2223, DOI 10.1084/jem.20131219; Breese EH, 2013, BLOOD, V122, P3722; Breese EH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136644; Brinkmann KO, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13938; Buechele C, 2015, BLOOD, V126, P1683, DOI 10.1182/blood-2015-05-646398; Bueno C, 2012, CELL RES, V22, P986, DOI 10.1038/cr.2012.4; Bursen A, 2010, BLOOD, V115, P3570, DOI 10.1182/blood-2009-06-229542; Chen W, 2008, CANCER CELL, V13, P432, DOI 10.1016/j.ccr.2008.03.005; Chen W, 2011, BLOOD, V117, P3474, DOI 10.1182/blood-2010-11-317529; Choi PS, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4728; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Daigle SR, 2013, BLOOD, V122, P1017, DOI 10.1182/blood-2013-04-497644; Daigle SR, 2011, CANCER CELL, V20, P53, DOI 10.1016/j.ccr.2011.06.009; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Gundry MC, 2016, CELL REP, V17, P1453, DOI 10.1016/j.celrep.2016.09.092; Jansson M, 2008, NAT CELL BIOL, V10, P1431, DOI 10.1038/ncb1802; Kaushik S, 2018, LEUKEMIA, V32, P499, DOI 10.1038/leu.2017.206; Kerbel RS, 2003, CANCER BIOL THER, V2, pS134; Krivtsov AV, 2008, CANCER CELL, V14, P355, DOI 10.1016/j.ccr.2008.10.001; Langer T, 2003, GENE CHROMOSOME CANC, V36, P393, DOI 10.1002/gcc.10167; Lavallee VP, 2015, NAT GENET, V47, P1030, DOI 10.1038/ng.3371; Leek JT, 2012, BIOINFORMATICS, V28, P882, DOI 10.1093/bioinformatics/bts034; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Lin S, 2016, CANCER CELL, V30, P737, DOI 10.1016/j.ccell.2016.10.008; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Meyer C, 2018, LEUKEMIA, V32, P273, DOI 10.1038/leu.2017.213; Meyer C, 2013, LEUKEMIA, V27, P2165, DOI 10.1038/leu.2013.135; Mongiardi MP, 2015, SCI REP-UK, V5, DOI 10.1038/srep15494; Montes R, 2011, BLOOD, V117, P4746, DOI 10.1182/blood-2010-12-322230; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Moreno-Mateos MA, 2015, NAT METHODS, V12, P982, DOI [10.1038/NMETH.3543, 10.1038/nmeth.3543]; Moriya K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037892; Mullighan CG, 2007, LEUKEMIA, V21, P2000, DOI 10.1038/sj.leu.2404808; Muntean AG, 2012, ANNU REV PATHOL-MECH, V7, P283, DOI 10.1146/annurev-pathol-011811-132434; Okada Y, 2005, CELL, V121, P167, DOI 10.1016/j.cell.2005.02.020; Piganeau M, 2013, GENOME RES, V23, P1182, DOI 10.1101/gr.147314.112; Reichel M, 2001, ONCOGENE, V20, P2900, DOI 10.1038/sj.onc.1204401; Reimer J, 2017, HAEMATOLOGICA, V102, P1558, DOI 10.3324/haematol.2017.164046; Schneidawind C, 2018, BLOOD ADV, V2, P832, DOI 10.1182/bloodadvances.2017013748; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Serio J, 2018, ONCOGENE, V37, P450, DOI 10.1038/onc.2017.337; Shi JW, 2015, NAT BIOTECHNOL, V33, P661, DOI 10.1038/nbt.3235; Slany RK, 2009, HAEMATOL-HEMATOL J, V94, P984, DOI 10.3324/haematol.2008.002436; Somervaille TCP, 2006, CANCER CELL, V10, P257, DOI 10.1016/j.ccr.2006.08.020; Somervaille TCP, 2009, CELL STEM CELL, V4, P129, DOI 10.1016/j.stem.2008.11.015; Srinivasan K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11295; Stam RW, 2010, BLOOD, V115, P2835, DOI 10.1182/blood-2009-07-233049; Stein EM, 2018, BLOOD, V131, P2661, DOI 10.1182/blood-2017-12-818948; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Torres R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4964; Wei J, 2008, CANCER CELL, V13, P483, DOI 10.1016/j.ccr.2008.04.020; Yang YZ, 2013, NAT REV CANCER, V13, P37, DOI 10.1038/nrc3409; Zhang BL, 2015, ONCOTARGET, V6, P22799, DOI 10.18632/oncotarget.4332	59	15	17	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2019	38	46					7181	7195		10.1038/s41388-019-0937-9	http://dx.doi.org/10.1038/s41388-019-0937-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JN5HX	31417187				2022-12-28	WOS:000496930500005
J	Kim, EH; Jo, Y; Sai, S; Park, MJ; Kim, JY; Kim, JS; Lee, YJ; Cho, JM; Kwak, SY; Baek, JH; Jeong, YK; Song, JY; Yoon, M; Hwang, SG				Kim, Eun Ho; Jo, Yunhui; Sai, Sei; Park, Mung-Jin; Kim, Jeong-Yub; Kim, Jin Su; Lee, Yeon-Joo; Cho, Jae-Min; Kwak, Seo-Young; Baek, Jeong-Hwa; Jeong, Youn Kyoung; Song, Jie-Young; Yoon, Myonggeun; Hwang, Sang-Gu			Tumor-treating fields induce autophagy by blocking the Akt2/miR29b axis in glioblastoma cells	ONCOGENE			English	Article							CANCER; PROLIFERATION; EXPRESSION; SURVIVAL; PATHWAY	Tumor-treating fields (TTFs) - a type of electromagnetic field-based therapy using low-intensity electrical fields - has recently been characterized as a potential anticancer therapy for glioblastoma multiforme (GBM). However, the molecular mechanisms involved remain poorly understood. Our results show that the activation of autophagy contributes to the TTF-induced anti-GBM activity in vitro or in vivo and GBM patient stem cells or primary in vivo culture systems. TTF-treatment upregulated several autophagy-related genes (similar to 2-fold) and induced cytomorphological changes. TTF-induced autophagy in GBM was associated with decreased Akt2 expression, not Akt1 or Akt3, via the mTOR/p70S6K pathway. An Affymetrix GeneChip miRNA 4.0 Array analysis revealed that TTFs altered the expression of many microRNAs (miRNAs). TTF-induced autophagy upregulated miR-29b, which subsequently suppressed the Akt signaling pathway. A luciferase reporter assay confirmed that TTFs induced miR-29b to target Akt2, negatively affecting Akt2 expression thereby triggering autophagy. TTF-induced autophagy suppressed tumor growth in GBM mouse models subjected to TTFs as determined by positron emission tomography and computed tomography (PET-CT). GBM patient stem cells and a primary in vivo culture system with high Akt2 levels also showed TTF-induced inhibition. Taken together, our results identified autophagy as a critical cell death pathway triggered by TTFs in GBM and indicate that TTF is a potential treatment option for GBM.	[Kim, Eun Ho; Jo, Yunhui; Park, Mung-Jin; Kim, Jeong-Yub; Lee, Yeon-Joo; Cho, Jae-Min; Baek, Jeong-Hwa; Song, Jie-Young; Hwang, Sang-Gu] Korea Inst Radiol & Med Sci, Div Radiat Biomed Res, Seoul 01812, South Korea; [Jo, Yunhui; Yoon, Myonggeun] Korea Univ, Dept Bioconvergence Engn, Seoul 02842, South Korea; [Sai, Sei] Natl Inst Radiol Sci, Dept Basic Med Sci Radiat Damages, Chiba, Japan; [Kim, Jin Su] Korea Inst Radiol & Med Sci, Div RI Convergence Res, Seoul 01812, South Korea; [Kwak, Seo-Young] Korea Inst Sci & Technol, Ctr Theragnosis, Biomed Res Inst, Seoul 02792, South Korea; [Jeong, Youn Kyoung] Korea Inst Radiol & Med Sci, Radiat Nonclin Ctr, Div Radiat Res Infrastruct Operat, Seoul 01812, South Korea	Korea Institute of Radiological & Medical Sciences; Korea University; National Institutes for Quantum Science & Technology; Korea Institute of Radiological & Medical Sciences; Korea Institute of Science & Technology (KIST); Korea Institute of Radiological & Medical Sciences	Hwang, SG (corresponding author), Korea Inst Radiol & Med Sci, Div Radiat Biomed Res, Seoul 01812, South Korea.; Yoon, M (corresponding author), Korea Univ, Dept Bioconvergence Engn, Seoul 02842, South Korea.	radioyoon@korea.ac.kr; sgh63@kcch.re.kr	KIM, JIN SU/U-2112-2019; Song, Jie-Young/AAG-6684-2019; Song, Jie-Young/AAH-1254-2019	KIM, JIN SU/0000-0001-8965-9538; Song, Jie-Young/0000-0002-5769-3886; baeg, jeonghwa/0000-0001-5364-0026; Lee, Yeon-Joo/0000-0002-6605-8761	National Research Foundation of Korea (NRF) [NRF-2017R1D1A1B03028923]; Korea Institute of Radiological and Medical Sciences (KIRAMS) - Ministry of Science, ICT (MSIP) Republic of Korea [50531-2018, 50538-2019]	National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Korea Institute of Radiological and Medical Sciences (KIRAMS) - Ministry of Science, ICT (MSIP) Republic of Korea	This work was supported by a National Research Foundation of Korea (NRF) grant (no. NRF-2017R1D1A1B03028923) and a grant from the Korea Institute of Radiological and Medical Sciences (KIRAMS), which was funded by the Ministry of Science, ICT (MSIP) Republic of Korea (50531-2018, 50538-2019).	[Anonymous], 2011, NOVOTTF 100A SYST PR; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Boya P, 2013, NAT CELL BIOL, V15, P713, DOI 10.1038/ncb2788; Constantinescu CC, 2009, PHYS MED BIOL, V54, P2885, DOI 10.1088/0031-9155/54/9/020; Davies AM, 2013, ANN NY ACAD SCI, V1291, P86, DOI 10.1111/nyas.12112; Fohlin H, 2013, EUR J CANCER, V49, P1196, DOI 10.1016/j.ejca.2012.12.006; Ganapathy B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155456; Ghobrial IM, 2005, CA-CANCER J CLIN, V55, P178, DOI 10.3322/canjclin.55.3.178; Giladi M, 2017, RADIAT ONCOL, V12, DOI 10.1186/s13014-017-0941-6; Hippert MM, 2006, CANCER RES, V66, P9349, DOI 10.1158/0008-5472.CAN-06-1597; Jeong H, 2014, APPL PHYS LETT, V105, DOI 10.1063/1.4902112; Jo Y, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113684; Johnson DR, 2012, CANCER-AM CANCER SOC, V118, P5608, DOI 10.1002/cncr.27590; Kessler AF, 2018, CELL DEATH DISCOV, V4, DOI 10.1038/s41420-018-0079-9; Kim EH, 2016, ONCOTARGET, V7, P65125, DOI 10.18632/oncotarget.11372; Kim EH, 2016, ONCOTARGET, V7, P62267, DOI 10.18632/oncotarget.11407; Kirson ED, 2004, CANCER RES, V64, P3288, DOI 10.1158/0008-5472.CAN-04-0083; Kirson ED, 2007, P NATL ACAD SCI USA, V104, P10152, DOI 10.1073/pnas.0702916104; Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356; Kreisberg JI, 2004, CANCER RES, V64, P5232, DOI 10.1158/0008-5472.CAN-04-0272; Li Y, 2016, J ANIM SCI BIOTECHNO, V7, DOI 10.1186/s40104-016-0093-9; Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254; Mott JL, 2007, ONCOGENE, V26, P6133, DOI 10.1038/sj.onc.1210436; Plastaras JP, 2008, CANCER BIOL THER, V7, P2047, DOI 10.4161/cbt.7.12.7570; Populo H, 2012, INT J MOL SCI, V13, P1886, DOI 10.3390/ijms13021886; Rivas S, 2018, BIOMEDICINES, V6, DOI 10.3390/biomedicines6010029; Sanai N, 2008, NEUROSURGERY, V62, P753, DOI 10.1227/01.neu.0000318159.21731.cf; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Stupp R., 2015, JCO, V33, P2000; Stupp R, 2017, JAMA-J AM MED ASSOC, V318, P2306, DOI 10.1001/jama.2017.18718; Stupp R, 2015, JAMA-J AM MED ASSOC, V314, P2535, DOI 10.1001/jama.2015.16669; Stupp R, 2012, EUR J CANCER, V48, P2192, DOI 10.1016/j.ejca.2012.04.011; Toms SA, 2019, J NEURO-ONCOL, V141, P467, DOI 10.1007/s11060-018-03057-z; Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777; Walter BA, 2013, J CANCER, V4, P350, DOI 10.7150/jca.6394; Wang Y, 2013, EUR J CELL BIOL, V92, P123, DOI 10.1016/j.ejcb.2012.11.004; Yin J, 2017, CANCER RES, V77, P4973, DOI 10.1158/0008-5472.CAN-17-0388; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054	39	30	31	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2019	38	39					6630	6646		10.1038/s41388-019-0882-7	http://dx.doi.org/10.1038/s41388-019-0882-7			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JA5AQ	31375748				2022-12-28	WOS:000487856000005
J	Ou, WB; Ni, N; Zuo, R; Zhuang, WH; Zhu, MJ; Kyriazoglou, A; Wu, DL; Eilers, G; Demetri, GD; Qiu, HB; Li, B; Marino-Enriquez, A; Fletcher, JA				Ou, Wen-Bin; Ni, Nan; Zuo, Rui; Zhuang, Weihao; Zhu, Meijun; Kyriazoglou, Anastasios; Wu, Duolin; Eilers, Grant; Demetri, George D.; Qiu, Haibo; Li, Bin; Marino-Enriquez, Adrian; Fletcher, Jonathan A.			Cyclin D1 is a mediator of gastrointestinal stromal tumor KIT-independence	ONCOGENE			English	Article							KINASE-C-THETA; CANCER-CELL-GROWTH; IMATINIB MESYLATE; ADIPOCYTIC DIFFERENTIATION; PKC-THETA; EXPRESSION; PROLIFERATION; RESISTANCE; MUTATIONS; OVEREXPRESSION	Oncogenic KIT or PDGFRA tyrosine kinase mutations are compelling therapeutic targets in most gastrointestinal stromal tumors (GISTs), and the KIT inhibitor, imatinib, is therefore standard of care for patients with metastatic GIST. However, some GISTs lose expression of KIT oncoproteins, and therefore become KIT-independent and are consequently resistant to KIT-inhibitor drugs. We identified distinctive biologic features in KIT-independent, imatinib-resistant GISTs as a step towards identifying drug targets in these poorly understood tumors. We developed isogenic GIST lines in which the parental forms were KIT oncoprotein-dependent, whereas sublines had loss of KIT oncoprotein expression, accompanied by markedly downregulated expression of the GIST biomarker, protein kinase C-theta (PRKCQ). Biologic mechanisms unique to KIT-independent GISTs were identified by transcriptome sequencing, qRT-PCR, immunoblotting, protein interaction studies, knockdown and expression assays, and dual-luciferase assays. Transcriptome sequencing showed that cyclin D1 expression was extremely low in two of three parental KIT-dependent GIST lines, whereas cyclin D1 expression was high in each of the KIT-independent GIST sublines. Cyclin D1 inhibition in KIT-independent GISTs had anti-proliferative and pro-apoptotic effects, associated with Rb activation and p27 upregulation. PRKCQ, but not KIT, was a negative regulator of cyclin D1 expression, whereas JUN and Hippo pathway effectors YAP and TAZ were positive regulators of cyclin D1 expression. PRKCQ, JUN, and the Hippo pathway coordinately regulate GIST cyclin D1 expression. These findings highlight the roles of PRKCQ, JUN, Hippo, and cyclin D1 as oncogenic mediators in GISTs that have converted, during TKI-therapy, to a KIT-independent state. Inhibitors of these pathways could be effective therapeutically for these now untreatable tumors.	[Ou, Wen-Bin; Ni, Nan; Zuo, Rui; Zhuang, Weihao; Wu, Duolin] Zhejiang Sci Tech Univ, Coll Life Sci & Med, Zhejiang Prov Key Lab Silkworm Bioreactor & Biome, Hangzhou, Zhejiang, Peoples R China; [Ou, Wen-Bin; Zhu, Meijun; Kyriazoglou, Anastasios; Eilers, Grant; Qiu, Haibo; Li, Bin; Marino-Enriquez, Adrian; Fletcher, Jonathan A.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Ou, Wen-Bin; Zhu, Meijun; Kyriazoglou, Anastasios; Eilers, Grant; Demetri, George D.; Marino-Enriquez, Adrian; Fletcher, Jonathan A.] Harvard Med Sch, Boston, MA 02115 USA; [Demetri, George D.] Dana Farber Harvard Canc Ctr, Ludwig Ctr Dana Farber, Boston, MA 02115 USA; [Demetri, George D.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Qiu, Haibo] Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [Li, Bin] Cent S Univ, Xiangya Hosp, Div Oncol, Changsha, Hunan, Peoples R China	Zhejiang Sci-Tech University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; State Key Lab Oncology South China; Sun Yat Sen University; Central South University	Ou, WB (corresponding author), Zhejiang Sci Tech Univ, Coll Life Sci & Med, Zhejiang Prov Key Lab Silkworm Bioreactor & Biome, Hangzhou, Zhejiang, Peoples R China.; Ou, WB; Fletcher, JA (corresponding author), Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.; Ou, WB; Fletcher, JA (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	ouwenbin@tsinghua.org.cn; jfletcher@partners.org		, Wenbin/0000-0002-6311-9442; Marino-Enriquez, Adrian/0000-0002-7680-9901	NIH [1P50CA127003, 1P50CA168512]; GIST Cancer Research Fund; David Foundation; National Natural Science Foundation of China [81728012, 81602061]; Natural Science Foundation of Zhejiang Province [LY18H160065]; Zhejiang medical and health science and technology plan project [2018KY651]; Zhejiang Xinmiao Talents Program [2017R406050]; National Undergraduate Training Program for Innovation and Entrepreneurship, Science Foundation of Zhejiang Sci-Tech University [14042107-Y]; Graduate research and innovation projects of Zhejiang Sci-Tech University, China; SARC; NATIONAL CANCER INSTITUTE [P50CA127003] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); GIST Cancer Research Fund; David Foundation; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Zhejiang Province(Natural Science Foundation of Zhejiang Province); Zhejiang medical and health science and technology plan project; Zhejiang Xinmiao Talents Program; National Undergraduate Training Program for Innovation and Entrepreneurship, Science Foundation of Zhejiang Sci-Tech University; Graduate research and innovation projects of Zhejiang Sci-Tech University, China; SARC; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH grants 1P50CA127003 and 1P50CA168512, and by the GIST Cancer Research Fund, SARC and David Foundation. This research was also supported by National Natural Science Foundation of China (81728012, 81602061), the Natural Science Foundation of Zhejiang Province (LY18H160065), Zhejiang medical and health science and technology plan project (2018KY651), Zhejiang Xinmiao Talents Program (2017R406050), National Undergraduate Training Program for Innovation and Entrepreneurship, Science Foundation of Zhejiang Sci-Tech University (14042107-Y), Graduate research and innovation projects of Zhejiang Sci-Tech University, China. We thank Adalis Maisonet, Terry Haley, and Edward Fox for technical and biostatistical support in the whole transcriptome sequencing.	Barbash O, 2008, CELL CYCLE, V7, P2983, DOI 10.4161/cc.7.19.6775; Barbash O, 2008, CANCER CELL, V14, P68, DOI 10.1016/j.ccr.2008.05.017; Bauer S, 2007, ONCOGENE, V26, P7560, DOI 10.1038/sj.onc.1210558; Blay JY, 2005, ANN ONCOL, V16, P566, DOI 10.1093/annonc/mdi127; Blay P, 2004, CLIN CANCER RES, V10, P4089, DOI 10.1158/1078-0432.CCR-04-0630; Casimiro MC, 2017, CANCER RES, V77, P3391, DOI 10.1158/0008-5472.CAN-16-0425; Coqueret O, 2002, GENE, V299, P35, DOI 10.1016/S0378-1119(02)01055-7; Corless CL, 2004, J CLIN ONCOL, V22, P3813, DOI 10.1200/JCO.2004.05.140; Debiec-Rychter M, 2005, GASTROENTEROLOGY, V128, P270, DOI 10.1053/j.gastro.2004.11.020; DeMatteo RP, 2009, LANCET, V373, P1097, DOI 10.1016/S0140-6736(09)60500-6; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Demetri GD, 2009, CLIN CANCER RES, V15, P5902, DOI 10.1158/1078-0432.CCR-09-0482; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Draper N, 2008, HUM PATHOL, V39, P1784, DOI 10.1016/j.humpath.2008.05.007; Duensing A, 2004, CANCER RES, V64, P5127, DOI 10.1158/0008-5472.CAN-04-0559; Essat M, 2011, INT J CANCER, V128, P2202, DOI 10.1002/ijc.25827; Fernando R, 2007, J BIOL CHEM, V282, P28864, DOI 10.1074/jbc.M700785200; Fletcher CDM, 2002, HUM PATHOL, V33, P459, DOI 10.1053/hupa.2002.123545; Fletcher J.A., 2003, P AM SOC CLIN ONCOL, V22, P815; Guan LJ, 2007, J BIOL CHEM, V282, P14213, DOI 10.1074/jbc.M610513200; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Heinrich MC, 2006, J CLIN ONCOL, V24, P4764, DOI 10.1200/JCO.2006.06.2265; Heinrich MC, 2008, J CLIN ONCOL, V26, P5352, DOI 10.1200/JCO.2007.15.7461; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hizli AA, 2006, J BIOL CHEM, V281, P14596, DOI 10.1074/jbc.M601959200; Huang SF, 1996, AM J PATHOL, V149, P1565; Husson H, 2002, BLOOD, V99, P282, DOI 10.1182/blood.V99.1.282; Jean S, 2001, BBA-GENE STRUCT EXPR, V1522, P89, DOI 10.1016/S0167-4781(01)00326-8; Jirawatnotai S, 2011, NATURE, V474, P230, DOI 10.1038/nature10155; Landis MW, 2006, CANCER CELL, V9, P13, DOI 10.1016/j.ccr.2005.12.019; Lee YM, 2006, CELL CYCLE, V5, P2110, DOI 10.4161/cc.5.18.3218; Li HY, 2006, CANCER RES, V66, P11399, DOI 10.1158/0008-5472.CAN-06-2386; Li ZP, 2006, CELL CYCLE, V5, P2440, DOI 10.4161/cc.5.21.3428; Liegl B, 2008, J PATHOL, V216, P64, DOI 10.1002/path.2382; Mariani O, 2007, CANCER CELL, V11, P361, DOI 10.1016/j.ccr.2007.02.007; Mizuno T, 2012, ONCOGENE, V31, P5117, DOI 10.1038/onc.2012.5; Motegi A, 2005, PATHOL INT, V55, P106, DOI 10.1111/j.1440-1827.2005.01806.x; Ou WB, 2008, ONCOGENE, V27, P5624, DOI 10.1038/onc.2008.177; Page K, 2002, AM J RESP CELL MOL, V27, P204, DOI 10.1165/ajrcmb.27.2.20010016oc; Pruneri G, 2003, MODERN PATHOL, V16, P886, DOI 10.1097/01.MP.0000085026.38856.B9; Rubin BP, 2001, CANCER RES, V61, P8118; Serrano C, 2015, J CLIN ONCOL, V33, pE93, DOI 10.1200/JCO.2013.48.7488; Shan J, 2009, MOL CELL, V36, P469, DOI 10.1016/j.molcel.2009.10.018; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shen Q, 2008, ONCOGENE, V27, P366, DOI 10.1038/sj.onc.1210643; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Siegmund K, 2015, CELL COMMUN SIGNAL, V13, DOI 10.1186/s12964-015-0100-3; Snyder EL, 2009, J PATHOL, V218, P292, DOI 10.1002/path.2564; Tashiro E, 2007, CANCER SCI, V98, P629, DOI 10.1111/j.1349-7006.2007.00449.x; Thomazy VA, 2002, J MOL DIAGN, V4, P201, DOI 10.1016/S1525-1578(10)60704-0; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; Vikhanskaya F, 2007, NAT CELL BIOL, V9, P698, DOI 10.1038/ncb1598; Yang PP, 2016, ONCOTARGET, V7, P32652, DOI 10.18632/oncotarget.8999; Zhu MJ, 2007, ONCOGENE, V26, P6386, DOI 10.1038/sj.onc.1210464	54	18	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2019	38	39					6615	6629		10.1038/s41388-019-0894-3	http://dx.doi.org/10.1038/s41388-019-0894-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JA5AQ	31371779				2022-12-28	WOS:000487856000004
J	Rohwer, N; Jumpertz, S; Erdem, M; Egners, A; Warzecha, KT; Fragoulis, A; Kuhl, AA; Kramann, R; Neuss, S; Rudolph, I; Endermann, T; Zasada, C; Apostolova, I; Gerling, M; Kempa, S; Hughes, R; Lewis, CE; Brenner, W; Malinowski, MB; Stockmann, M; Schomburg, L; Faller, W; Sansom, OJ; Tacke, F; Morkel, M; Cramer, T				Rohwer, Nadine; Jumpertz, Sandra; Erdem, Merve; Egners, Antje; Warzecha, Klaudia T.; Fragoulis, Athanassios; Kuehl, Anja A.; Kramann, Rafael; Neuss, Sabine; Rudolph, Ines; Endermann, Tobias; Zasada, Christin; Apostolova, Ivayla; Gerling, Marco; Kempa, Stefan; Hughes, Russell; Lewis, Claire E.; Brenner, Winfried; Malinowski, Maciej B.; Stockmann, Martin; Schomburg, Lutz; Faller, William; Sansom, Owen J.; Tacke, Frank; Morkel, Markus; Cramer, Thorsten			Non-canonical HIF-1 stabilization contributes to intestinal tumorigenesis	ONCOGENE			English	Article							HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; CARCINOMA-ASSOCIATED FIBROBLASTS; TUMOR-ASSOCIATED MACROPHAGES; TARGETED CANCER-THERAPY; DENDRITIC CELLS; POOR-PROGNOSIS; MURINE MODEL; MOUSE MODEL; STEM-CELLS; FACTOR-I	The hypoxia-inducible transcription factor HIF-1 is appreciated as a promising target for cancer therapy. However, conditional deletion of HIF-1 and HIF-1 target genes in cells of the tumor microenvironment can result in accelerated tumor growth, calling for a detailed characterization of the cellular context to fully comprehend HIF-1's role in tumorigenesis. We dissected cell type-specific functions of HIF-1 for intestinal tumorigenesis by lineage-restricted deletion of the Hif1a locus. Intestinal epithelial cell-specific Hif1a loss reduced activation of Wnt/beta-catenin, tumor-specific metabolism and inflammation, significantly inhibiting tumor growth. Deletion of Hif1a in myeloid cells reduced the expression of fibroblast-activating factors in tumor-associated macrophages resulting in decreased abundance of tumor-associated fibroblasts (TAF) and robustly reduced tumor formation. Interestingly, hypoxia was detectable only sparsely and without spatial association with HIF-1 alpha, arguing for an importance of hypoxia-independent, i.e., non-canonical, HIF-1 stabilization for intestinal tumorigenesis that has not been previously appreciated. This adds a further layer of complexity to the regulation of HIF-1 and suggests that hypoxia and HIF-1 alpha stabilization can be uncoupled in cancer. Collectively, our data show that HIF-1 is a pivotal pro-tumorigenic factor for intestinal tumor formation, controlling key oncogenic programs in both the epithelial tumor compartment and the tumor microenvironment.	[Rohwer, Nadine; Rudolph, Ines] Charite Univ Med Berlin, Hepatol & Gastroenterol, Augustenburger Pl 1, D-13353 Berlin, Germany; [Jumpertz, Sandra; Erdem, Merve; Egners, Antje; Fragoulis, Athanassios; Cramer, Thorsten] RWTH Univ Hosp, Mol Tumor Biol, Dept Gen Visceral & Transplantat Surg, Pauwelsstr 30, D-52074 Aachen, Germany; [Warzecha, Klaudia T.; Tacke, Frank] RWTH Univ Hosp, Med 3, Pauwelsstr 30, D-52074 Aachen, Germany; [Kuehl, Anja A.] Charite Univ Med Berlin, Res Ctr Immunosci, Hindenburgdamm 30, D-12200 Berlin, Germany; [Kramann, Rafael] RWTH Univ Hosp, Med 2, Pauwelsstr 30, D-52074 Aachen, Germany; [Neuss, Sabine] RWTH Univ Hosp, Pathol, Pauwelsstr 30, D-52074 Aachen, Germany; [Endermann, Tobias; Schomburg, Lutz] Charite Univ Med Berlin, Expt Endocrinol, Augustenburger Pl 1, D-13353 Berlin, Germany; [Zasada, Christin; Kempa, Stefan] Max Delbruck Ctr, Robert Rossle Str 10, D-13125 Berlin, Germany; [Apostolova, Ivayla; Brenner, Winfried] Charite Univ Med Berlin, Nucl Med, Augustenburger Pl 1, D-13353 Berlin, Germany; [Gerling, Marco] Karolinska Inst, Biosci & Nutr, Alfred Nobels Alle 8, S-17177 Stockholm, Sweden; [Hughes, Russell; Lewis, Claire E.] Univ Sheffield, Med Sch, Oncol & Metab, Sheffield S10 2RX, S Yorkshire, England; [Malinowski, Maciej B.; Stockmann, Martin] Charite Univ Med Berlin, Surg, Augustenburger Pl 1, D-13353 Berlin, Germany; [Faller, William; Sansom, Owen J.] Canc Res UK Beatson Inst, Glasgow G61 1BD, Lanark, Scotland; [Morkel, Markus] Charite Univ Med Berlin, Inst Pathol, Charitepl 1, D-10117 Berlin, Germany; [Cramer, Thorsten] Maastricht Univ, NUTRIM Sch Nutr & Translat Res Metab, Maastricht, Netherlands; [Cramer, Thorsten] ESCAM, Aachen, Germany; [Cramer, Thorsten] ESCAM, Maastricht, Netherlands; [Malinowski, Maciej B.] Saarland Univ Hosp, Dept Gen Visceral Vasc & Pediat Surg, Homburg, Germany; [Faller, William] Netherlands Canc Inst, Amsterdam, Netherlands	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Karolinska Institutet; University of Sheffield; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Beatson Institute; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Maastricht University; Maastricht University Medical Centre (MUMC); Universitatsklinikum des Saarlandes; Netherlands Cancer Institute	Cramer, T (corresponding author), RWTH Univ Hosp, Mol Tumor Biol, Dept Gen Visceral & Transplantat Surg, Pauwelsstr 30, D-52074 Aachen, Germany.; Cramer, T (corresponding author), Maastricht Univ, NUTRIM Sch Nutr & Translat Res Metab, Maastricht, Netherlands.; Cramer, T (corresponding author), ESCAM, Aachen, Germany.; Cramer, T (corresponding author), ESCAM, Maastricht, Netherlands.	tcramer@ukaachen.de	Tacke, Frank/ABF-2212-2020; Erdem, Merve/H-1563-2015; Cramer, Thorsten/S-2479-2016; Erdem, Merve/HGB-3063-2022; Schomburg, Lutz/D-8096-2013; Kramann, Rafael/K-7995-2013	Cramer, Thorsten/0000-0002-6462-239X; Schomburg, Lutz/0000-0001-9445-1555; Fragoulis, Athanassios/0000-0002-6973-3080; Rohwer, Nadine/0000-0001-6170-1327; Morkel, Markus/0000-0002-2553-9999; Kuhl, Anja/0000-0003-2293-5387; Sansom, Owen J./0000-0001-9540-3010; Kramann, Rafael/0000-0003-4048-6351; Faller, William James/0000-0002-0738-2254; Brenner, Winfried/0000-0003-2478-6004	Deutsche Krebshilfe [109160]; Deutsche Forschungsgemeinschaft [CR 133/2-1, CR 133/2-2, CR 133/2-3, CR 133/2-4]; BMBF (MAPTor-NET) [031A426A]	Deutsche Krebshilfe(Deutsche Krebshilfe); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); BMBF (MAPTor-NET)(Federal Ministry of Education & Research (BMBF))	Research in the Cramer lab was supported by grants from Deutsche Krebshilfe (109160) and Deutsche Forschungsgemeinschaft (CR 133/2-1 until 2-4). NR was supported by a grant from the BMBF (MAPTor-NET (031A426A)). We are indebted to Ralf Weiskirchen (University Hospital Aachen) for help regarding the MLEC assay. We are grateful to Christine Sers (Charite, Berlin) and Florian R. Greten (Georg-Speyer-Haus, Frankfurt) for helpful discussions and to Ilia N. Buhtoiarov (Children's Hospital of New Jersey, USA), Glenn S. Belinsky, Daniel W. Rosenberg (University of Connecticut Health Center, Farmington, USA), and Takuji Tanaka (Gifu Municipal Hospital, Japan) for providing control reagents. We are grateful to Deborah Gumucio (University of Michigan, USA) for providing Villin-Cre mice. The excellent technical assistance of Birgit Bogdanoff and Simone Spiekermann is highly appreciated. Parts of this work were granted the "Best Poster Award" at the 2015 CELL symposium "Cancer, Inflammation and Immunity" in Sitges, Spain.	Baba Y, 2010, AM J PATHOL, V176, P2292, DOI 10.2353/ajpath.2010.090972; Backer V, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0190074; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Biswas SK, 2013, SEMIN IMMUNOPATHOL, V35, P585, DOI 10.1007/s00281-013-0367-7; BUCALA R, 1994, MOL MED, V1, P71, DOI 10.1007/bf03403533; Calon A, 2015, NAT GENET, V47, P320, DOI 10.1038/ng.3225; COOPER HS, 1993, LAB INVEST, V69, P238; Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5; Crawford JR, 2010, J IMMUNOL METHODS, V363, P9, DOI 10.1016/j.jim.2010.09.025; Cummins EP, 2008, GASTROENTEROLOGY, V134, P156, DOI 10.1053/j.gastro.2007.10.012; Dilly AK, 2016, TRANSL RES, V169, P19, DOI 10.1016/j.trsl.2015.10.006; Doedens AL, 2010, CANCER RES, V70, P7465, DOI 10.1158/0008-5472.CAN-10-1439; Eichele DD, 2017, WORLD J GASTROENTERO, V23, P6016, DOI 10.3748/wjg.v23.i33.6016; Farrall AL, 2012, INT J CANCER, V131, P2242, DOI 10.1002/ijc.27500; Fluck K, 2016, MUCOSAL IMMUNOL, V9, P379, DOI 10.1038/mi.2015.67; Gascard P, 2016, GENE DEV, V30, P1002, DOI 10.1101/gad.279737.116; Hammerich L, 2015, HEPATOLOGY, V61, P990, DOI 10.1002/hep.27571; Heijmans J, 2012, BBA-MOL BASIS DIS, V1822, P9, DOI 10.1016/j.bbadis.2010.12.001; Hoebler C, 2006, DIGEST DIS SCI, V51, P381, DOI 10.1007/s10620-006-3142-y; Hu J, 1998, BIOCHEM BIOPH RES CO, V245, P894, DOI 10.1006/bbrc.1998.8543; Huang M, 2014, TRENDS PHARMACOL SCI, V35, P41, DOI 10.1016/j.tips.2013.11.004; Hung SP, 2013, CELL TRANSPLANT, V22, P1869, DOI 10.3727/096368912X657954; Imamura T, 2009, INT J CANCER, V124, P763, DOI 10.1002/ijc.24032; Isella C, 2015, NAT GENET, V47, P312, DOI 10.1038/ng.3224; Janakiram NB, 2014, ADV EXP MED BIOL, V816, P25, DOI 10.1007/978-3-0348-0837-8_2; Kaidi A, 2006, CANCER RES, V66, P6683, DOI 10.1158/0008-5472.CAN-06-0425; Karhausen J, 2004, J CLIN INVEST, V114, P1098, DOI 10.1172/JCI200421086; Kim JW, 2012, CANCER RES, V72, P3187, DOI 10.1158/0008-5472.CAN-12-0534; Kim YE, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.033241; Kohne CH, 2014, PROG TUMOR RES, V41, P36, DOI 10.1159/000356436; Kramann R, 2015, CELL STEM CELL, V16, P51, DOI 10.1016/j.stem.2014.11.004; Krishnamachary B, 2003, CANCER RES, V63, P1138; LaGory EL, 2016, NAT CELL BIOL, V18, P356, DOI 10.1038/ncb3330; Louis NA, 2006, J CELL BIOCHEM, V99, P1616, DOI 10.1002/jcb.20947; Madison BB, 2002, J BIOL CHEM, V277, P33275, DOI 10.1074/jbc.M204935200; Mahler M, 1998, AM J PHYSIOL-GASTR L, V274, pG544, DOI 10.1152/ajpgi.1998.274.3.G544; Mantovani A, 2010, CURR OPIN IMMUNOL, V22, P231, DOI 10.1016/j.coi.2010.01.009; Mazumdar J, 2010, NAT CELL BIOL, V12, P1007, DOI 10.1038/ncb2102; Mikami Y, 2009, BIOCHEM BIOPH RES CO, V379, P1060, DOI 10.1016/j.bbrc.2009.01.002; Mitchem JB, 2013, CANCER RES, V73, P1128, DOI 10.1158/0008-5472.CAN-12-2731; Mizukami Y, 2005, NAT MED, V11, P992, DOI 10.1038/nm1294; Mladenova DN, 2015, DIS MODEL MECH, V8, P1093, DOI 10.1242/dmm.019000; Neufert C, 2013, J CLIN INVEST, V123, P1428, DOI 10.1172/JCI63748; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Okayasu I, 1996, GUT, V39, P87, DOI 10.1136/gut.39.1.87; Palazon A, 2017, CANCER CELL, V32, P669, DOI 10.1016/j.ccell.2017.10.003; Palazon A, 2014, IMMUNITY, V41, P518, DOI 10.1016/j.immuni.2014.09.008; Peterson LW, 2014, NAT REV IMMUNOL, V14, P141, DOI 10.1038/nri3608; Pradere JP, 2013, HEPATOLOGY, V58, P1461, DOI 10.1002/hep.26429; Raffaghello L, 2015, IMMUNOL LETT, V168, P175, DOI 10.1016/j.imlet.2015.06.016; Ragusa S, 2014, CELL REP, V8, P1957, DOI 10.1016/j.celrep.2014.08.041; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Riemer P, 2017, J CELL BIOL, V216, P1567, DOI 10.1083/jcb.201610058; Robinson A, 2008, GASTROENTEROLOGY, V134, P145, DOI 10.1053/j.gastro.2007.09.033; ROSS R, 1961, J BIOPHYS BIOCHEM CY, V11, P677, DOI 10.1083/jcb.11.3.677; Ryan HE, 2000, CANCER RES, V60, P4010; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230; Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005; Shah YM, 2008, GASTROENTEROLOGY, V134, P2036, DOI 10.1053/j.gastro.2008.03.009; Shay JES, 2014, CARCINOGENESIS, V35, P1067, DOI 10.1093/carcin/bgu004; Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395; Stockmann C, 2008, NATURE, V456, P814, DOI 10.1038/nature07445; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Travis MA, 2014, ANNU REV IMMUNOL, V32, P51, DOI 10.1146/annurev-immunol-032713-120257; Trottier MD, 2012, P NATL ACAD SCI USA, V109, P16594, DOI 10.1073/pnas.1213854109; Tymoszuk P, 2014, EUR J IMMUNOL, V44, P2247, DOI 10.1002/eji.201344304; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Waldner MJ, 2012, INT J BIOL SCI, V8, P1248, DOI 10.7150/ijbs.4614; Wynn TA, 2016, IMMUNITY, V44, P450, DOI 10.1016/j.immuni.2016.02.015; Wynn TA, 2010, SEMIN LIVER DIS, V30, P245, DOI 10.1055/s-0030-1255354; Xue J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8158; Xue X, 2014, AM J PHYSIOL-GASTR L, V307, pG187, DOI 10.1152/ajpgi.00112.2014; Xue X, 2013, GASTROENTEROLOGY, V145, P831, DOI 10.1053/j.gastro.2013.07.010; Yoshimura H, 2004, CLIN CANCER RES, V10, P8554, DOI 10.1158/1078-0432.CCR-0946-03; Zhong H, 1999, CANCER RES, V59, P5830	79	14	14	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2019	38	28					5670	5685		10.1038/s41388-019-0816-4	http://dx.doi.org/10.1038/s41388-019-0816-4			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IH9RW	31043706	Green Submitted, Green Accepted			2022-12-28	WOS:000474845100009
J	John, B; Naczki, C; Patel, C; Ghoneum, A; Qasem, S; Salih, Z; Said, N				John, Bincy; Naczki, Christine; Patel, Chirayu; Ghoneum, Alia; Qasem, Shadi; Salih, Ziyan; Said, Neveen			Regulation of the bi-directional cross-talk between ovarian cancer cells and adipocytes by SPARC	ONCOGENE			English	Article							BINDING PROTEIN BETA; ADIPOSE TRIGLYCERIDE LIPASE; C/EBP-BETA; CHEMOKINE GENES; EXPRESSION; INFLAMMATION; METASTASIS; LIPOLYSIS; PATHWAYS; SURVIVAL	Ovarian cancer (OvCa) exhibits a specific predilection for metastasis to the omentum. Our earlier studies highlighted the tumour-suppressor effect of secreted protein acidic and rich in cysteine (SPARC) in OvCa through multi-faceted roles inhibiting cancer cell interactions within the peritoneal milieu. The goal of this study is to investigate the role of SPARC in OvCa interactions with omental adipocytes and its role in OvCa colonization in the omentum. We employed multi-pronged approach using primary omental adipocytes from Sparc knockout mice, genetically engineered human omental adipocytes in 3D co-cultures with OvCa cells, as well as treatment with recombinant SPARC protein. We show that SPARC suppresses multistep cascade in OvCa omental metastasis. SPARC inhibited in vivo and adipocyte-induced homing, proliferation, and invasion of OvCa cells. SPARC suppressed metabolic programming of both adipocytes and OvCa cells and exerted an inhibitory effect of adipocyte differentiation and their phenotypic switch to cancer-associated phenotype. Mechanistic studies revealed that this effect is mediated through inhibition of cEBP beta-NFkB-AP-1 transcription machinery. These findings define a novel and functionally important role of SPARC in OvCa and not only bridge the knowledge gap but highlight the need to consider SPARC protein expression in therapeutic development.	[John, Bincy; Naczki, Christine; Patel, Chirayu; Ghoneum, Alia; Said, Neveen] Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC 27109 USA; [Qasem, Shadi; Salih, Ziyan; Said, Neveen] Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Winston Salem, NC 27103 USA; [Said, Neveen] Wake Forest Univ, Bowman Gray Sch Med, Dept Urol, Winston Salem, NC 27103 USA; [Qasem, Shadi] Univ Kentucky, Coll Med, Surg Pathol, Lexington, KY USA; [Salih, Ziyan] Univ Louisville, Sch Med, Dept Pathol & Lab Med, Louisville, KY 40202 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; University of Kentucky; University of Louisville	Said, N (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC 27109 USA.; Salih, Z; Said, N (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Winston Salem, NC 27103 USA.; Said, N (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Urol, Winston Salem, NC 27103 USA.; Salih, Z (corresponding author), Univ Louisville, Sch Med, Dept Pathol & Lab Med, Louisville, KY 40202 USA.	ziyan.salih@louisville.edu; nsaid@wakehealth.edu		Patel, Chirayu/0000-0003-0649-0090	Marsha Rivkin Pilot Award; WFBMC Department of Pathology Research Pilot Funds;  [R01 CA193437];  [P30CA012197]; NATIONAL CANCER INSTITUTE [P30CA012197, R01CA193437] Funding Source: NIH RePORTER	Marsha Rivkin Pilot Award; WFBMC Department of Pathology Research Pilot Funds; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported by Marsha Rivkin Pilot Award, WFBMC Department of Pathology Research Pilot Funds and R01 CA193437 (NS) and P30CA012197 to the Wake Forest Baptist Comprehensive Cancer Center (WFBCCC).	Al-Hassan NN, 2012, NEOPLASIA, V14, P259, DOI 10.1593/neo.12442; Barbolina MV, 2009, CANCER TREAT RES, V149, P319, DOI 10.1007/978-0-387-98094-2_15; Bowtell DD, 2015, NAT REV CANCER, V15, P668, DOI 10.1038/nrc4019; Bradshaw AD, 2003, P NATL ACAD SCI USA, V100, P6045, DOI 10.1073/pnas.1030790100; Cheville NF, 2014, VET PATHOL, V51, P28, DOI 10.1177/0300985813505114; Chinnaiyan P, 2012, CANCER RES, V72, P5878, DOI 10.1158/0008-5472.CAN-12-1572-T; Currie E, 2013, CELL METAB, V18, P153, DOI 10.1016/j.cmet.2013.05.017; Das SK, 2011, SCIENCE, V333, P233, DOI 10.1126/science.1198973; De Pergola G, 2013, J OBES, V2013, DOI 10.1155/2013/291546; Delany AM, 2003, ENDOCRINOLOGY, V144, P2588, DOI 10.1210/en.2002-221044; Delany AM, 2009, J CELL COMMUN SIGNAL, V3, P227, DOI 10.1007/s12079-009-0076-0; Dirat B, 2011, CANCER RES, V71, P2455, DOI 10.1158/0008-5472.CAN-10-3323; Doerstling SS, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00216; Ebadi M, 2014, NUTRIENTS, V6, P5280, DOI 10.3390/nu6115280; Esteves CL, 2014, J CLIN ENDOCR METAB, V99, pE160, DOI 10.1210/jc.2013-1708; Ewing SJ, 2008, CELL DEATH DIFFER, V15, P1734, DOI 10.1038/cdd.2008.105; Fontana L, 2007, DIABETES, V56, P1010, DOI 10.2337/db06-1656; Gharpure KM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04987-y; Grisouard J, 2012, INNATE IMMUN-LONDON, V18, P25, DOI 10.1177/1753425910386632; Guo L, 2012, CELL DEATH DIFFER, V19, P1917, DOI 10.1038/cdd.2012.75; Guo L, 2015, J BIOL CHEM, V290, P755, DOI 10.1074/jbc.R114.619957; Harjes U, 2017, ONCOGENE, V36, P912, DOI 10.1038/onc.2016.256; Hein S, 2009, ONCOL REP, V22, P177, DOI 10.3892/or_00000422; Hernandez L, 2010, CANCER RES, V70, P4005, DOI 10.1158/0008-5472.CAN-09-3912; Hotamisligil GS, 2017, NATURE, V542, P177, DOI 10.1038/nature21363; House CD, 2017, CANCER RES, V77, P6927, DOI 10.1158/0008-5472.CAN-17-0366; Howe LR, 2013, CLIN CANCER RES, V19, P6074, DOI 10.1158/1078-0432.CCR-12-2603; Huber R, 2012, CELL SIGNAL, V24, P1287, DOI 10.1016/j.cellsig.2012.02.007; Iyengar P, 2003, ONCOGENE, V22, P6408, DOI 10.1038/sj.onc.1206737; Jakobs A, 2016, J BIOL CHEM, V291, P26098, DOI 10.1074/jbc.M116.748129; Ji CB, 2011, J BIOENERG BIOMEMBR, V43, P367, DOI 10.1007/s10863-011-9361-8; Kulbe H, 2012, CANCER RES, V72, P66, DOI 10.1158/0008-5472.CAN-11-2178; Ladanyi A, 2018, ONCOGENE, V37, P2285, DOI 10.1038/s41388-017-0093-z; Lengyel E, 2014, ONCOGENE, V33, P3619, DOI 10.1038/onc.2013.321; Liu D, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03590-5; Miranda F, 2016, CANCER CELL, V30, P273, DOI 10.1016/j.ccell.2016.06.020; Naczki C, 2018, CANCERS, V10, DOI 10.3390/cancers10100385; Nie J, 2011, CONNECT TISSUE RES, V52, P99, DOI 10.3109/03008207.2010.483747; Nie J, 2009, J CELL COMMUN SIGNAL, V3, P247, DOI 10.1007/s12079-009-0064-4; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Oyesanya RA, 2008, FASEB J, V22, P2639, DOI 10.1096/fj.07-101428; Piconese S, 2011, J AUTOIMMUN, V37, P300, DOI 10.1016/j.jaut.2011.09.002; Pradeep S, 2014, CANCER CELL, V26, P77, DOI 10.1016/j.ccr.2014.05.002; Rahman SM, 2012, J BIOL CHEM, V287, P34349, DOI 10.1074/jbc.M112.410613; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; Roby KF, 2000, CARCINOGENESIS, V21, P585, DOI 10.1093/carcin/21.4.585; Rozenberg JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078179; Said N, 2005, AM J PATHOL, V167, P1739, DOI 10.1016/S0002-9440(10)61255-2; Said N, 2013, J CARCINOGENE MUTAGE, V4, P151; Said N, 2007, MOL CANCER RES, V5, P1015, DOI 10.1158/1541-7786.MCR-07-0001; Said N, 2007, AM J PATHOL, V170, P1054, DOI 10.2353/ajpath.2007.060903; Said N, 2013, J CLIN INVEST, V123, P4089, DOI 10.1172/JCI71241; Said N, 2012, J CLIN INVEST, V122, P1503, DOI 10.1172/JCI61392; Said N, 2011, J CLIN INVEST, V121, P132, DOI 10.1172/JCI42912; Said NA, 2008, NEOPLASIA, V10, P1092, DOI 10.1593/neo.08672; Said NA, 2007, NEOPLASIA, V9, P23, DOI 10.1593/neo.06658; Schweiger M, 2006, J BIOL CHEM, V281, P40236, DOI 10.1074/jbc.M608048200; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Tucker SL, 2014, CLIN CANCER RES, V20, P3280, DOI 10.1158/1078-0432.CCR-14-0445; Vaysse C, 2017, NPJ BREAST CANCER, V3, DOI 10.1038/s41523-017-0015-9; Yeung TL, 2015, AM J PHYSIOL-CELL PH, V309, pC444, DOI 10.1152/ajpcell.00188.2015; Zhang WL, 2014, J BIOL CHEM, V289, P32178, DOI 10.1074/jbc.M114.601096; Zhang ZQ, 2010, J BIOL CHEM, V285, P33092, DOI 10.1074/jbc.M110.130377; Zhang ZJ, 2014, INT J MOL SCI, V15, P17242, DOI 10.3390/ijms151017242	64	27	29	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2019	38	22					4366	4383		10.1038/s41388-019-0728-3	http://dx.doi.org/10.1038/s41388-019-0728-3			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IA1RB	30765860	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000469339100012
J	Ghoshal, A; Rodrigues, LC; Gowda, CP; Elcheva, IA; Liu, ZQ; Abraham, T; Spiegelman, VS				Ghoshal, Archita; Rodrigues, Lucas C.; Gowda, Chethana P.; Elcheva, Irina A.; Liu, Zhenqiu; Abraham, Thomas; Spiegelman, Vladimir S.			Extracellular vesicle-dependent effect of RNA-binding protein IGF2BP1 on melanoma metastasis	ONCOGENE			English	Article							MYC MESSENGER-RNA; CRD-BP; CODING REGION; C-MYC; NICHE FORMATION; EXPRESSION; CELLS; TRANSCRIPTION; BETA-TRCP1; PHENOTYPE	Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) is a multifunctional RNA-binding protein with an oncofetal pattern of expression shown to be implicated in the development of a variety of malignancies. In this study, we explored the role and mechanisms of IGF2BP1 in melanoma development and progression. In two different in vivo models, we showed that although genetic deletion or shRNA-mediated suppression of IGF2BP1 did not affect primary tumor formation, it drastically suppressed lung metastasis. Here we demonstrated that extracellular vesicles (EVs) secreted by melanoma cells mediate the effects of IGF2BP1 on metastasis: EVs from the IGF2BP1 knockdown melanoma cells failed to promote metastasis, whereas EVs isolated from IGF2BP1-overexpressed melanoma cells further accelerated EV-induced metastasis. Moreover, the EVs from IGF2BP1 knockdown melanoma cells inhibited fibronectin deposition and accumulation of CD45(+) cells in the lungs compared with control EVs, thus blocking the pre-metastatic niche formation potential of EVs. IGF2BP1 knockdown did not affect size, number, or protein/RNA concentration of secreted EVs or their uptake by recipient cells in vitro or in vivo. However, RNA-sequencing and proteomics analysis of the EVs revealed differential expression in a number of mRNA, proteins, and miRNAs. This suggested that IGF2BP1 is intimately involved in the regulation of the cargo of EVs, thereby affecting the pro-metastatic function of melanoma-derived EVs. To the best of our knowledge, this is the first study that demonstrates the role of RNA-binding protein IGF2BP1 in EV-mediated promotion of melanoma metastasis and may provide novel avenues for the development of metastatic inhibitors.	[Ghoshal, Archita; Rodrigues, Lucas C.; Gowda, Chethana P.; Elcheva, Irina A.; Liu, Zhenqiu; Spiegelman, Vladimir S.] Penn State Univ, Coll Med, Dept Pediat, Div Pediat Hematol Oncol, Hershey, PA 17033 USA; [Abraham, Thomas] Penn State Univ, Coll Med, Dept Neural & Behav Sci, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Spiegelman, VS (corresponding author), Penn State Univ, Coll Med, Dept Pediat, Div Pediat Hematol Oncol, Hershey, PA 17033 USA.	vspiegelman@pennstatehealth.psu.edu	Abraham, Thomas/AAJ-7950-2020; Abraham, Thomas/J-7080-2014	Spiegelman, Vladimir S/0000-0003-4847-155X; Abraham, Thomas/0000-0003-0750-8774; Ghoshal, Archita/0000-0002-9210-3140	NIH [R01 AR063361]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR063361] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This study was supported in part by the NIH grant R01 AR063361 (VSS). We thank Dr Ze'ev Ronai for the generous gift of reagents and Dr JM Sundstrom for the help with Nanosight (TM) analysis of EVs. We thank Penn State Cancer Institute Genomics Sciences, Penn State College of Medicine Imaging Core, Flow Cytometry Core, and Molecular and Histopathology Core Facilities for help with respective data acquisition and analysis.	Azmi AS, 2013, CANCER METAST REV, V32, P623, DOI 10.1007/s10555-013-9441-9; Bell JL, 2015, J CLIN ONCOL, V33, P1285, DOI 10.1200/JCO.2014.55.9880; Bosenberg M, 2006, GENESIS, V44, P262, DOI 10.1002/dvg.20205; Chen Y, 2017, ONCOGENE, V36, P4692, DOI 10.1038/onc.2017.100; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Craig EA, 2012, PIGM CELL MELANOMA R, V25, P83, DOI 10.1111/j.1755-148X.2011.00921.x; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Dimitriadis E, 2007, INT J CANCER, V121, P486, DOI 10.1002/ijc.22716; Dorayappan KDP, 2018, ONCOGENE, V37, P3806, DOI 10.1038/s41388-018-0189-0; Elcheva I, 2008, ONCOGENE, V27, P5069, DOI 10.1038/onc.2008.141; Elcheva I, 2009, MOL CELL, V35, P240, DOI 10.1016/j.molcel.2009.06.007; Ghoshal A, 2016, MOL CELL BIOCHEM, V418, P119, DOI 10.1007/s11010-016-2738-6; Goswami S, 2015, J BIOL CHEM, V290, P384, DOI 10.1074/jbc.M114.590158; Gupta S, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-0923-0; Hamilton KE, 2013, CARCINOGENESIS, V34, P2647, DOI 10.1093/carcin/bgt217; Hood JL, 2011, CANCER RES, V71, P3792, DOI 10.1158/0008-5472.CAN-10-4455; Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756; Iyer SC, 2015, MOL CELL BIOCHEM, V407, P223, DOI 10.1007/s11010-015-2471-6; Jao CY, 2008, P NATL ACAD SCI USA, V105, P15779, DOI 10.1073/pnas.0808480105; Kim T, 2018, MOL CARCINOGEN, V57, P678, DOI 10.1002/mc.22786; Leeds P, 1997, ONCOGENE, V14, P1279, DOI 10.1038/sj.onc.1201093; Li WH, 2014, APMIS, V122, P1080, DOI 10.1111/apm.12261; Liu YF, 2016, CANCER CELL, V30, P243, DOI 10.1016/j.ccell.2016.06.021; Lobb RJ, 2017, SEMIN CELL DEV BIOL, V67, P3, DOI 10.1016/j.semcdb.2017.01.004; Meerbrey KL, 2011, P NATL ACAD SCI USA, V108, P3665, DOI 10.1073/pnas.1019736108; Noubissi FK, 2006, NATURE, V441, P898, DOI 10.1038/nature04839; Noubissi FK, 2009, CANCER RES, V69, P8572, DOI 10.1158/0008-5472.CAN-09-1500; Oberman F, 2007, RNA, V13, P1558, DOI 10.1261/rna.559507; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Peinado H, 2011, SEMIN CANCER BIOL, V21, P139, DOI 10.1016/j.semcancer.2011.01.002; Psaila B, 2009, NAT REV CANCER, V9, P285, DOI 10.1038/nrc2621; Sparanese D, 2007, NUCLEIC ACIDS RES, V35, P1209, DOI 10.1093/nar/gkl1148; Stohr N, 2012, CELL ADHES MIGR, V6, P312, DOI 10.4161/cam.20628; Su YL, 2016, ONCOTARGET, V7, P68397, DOI 10.18632/oncotarget.11722; Vikesaa J, 2006, EMBO J, V25, P1456, DOI 10.1038/sj.emboj.7601039; Wang RJ, 2015, J BIOL CHEM, V290, P8938, DOI 10.1074/jbc.M114.624700; Weidle UH, 2017, CANCER GENOM PROTEOM, V14, P1, DOI 10.21873/cgp.20015; Wen SW, 2016, CANCER RES, V76, P6816, DOI 10.1158/0008-5472.CAN-16-0868	38	22	22	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2019	38	21					4182	4196		10.1038/s41388-019-0797-3	http://dx.doi.org/10.1038/s41388-019-0797-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ3HX	30936459	Green Accepted			2022-12-28	WOS:000468740200015
J	Jang, D; Kwon, H; Choi, M; Lee, J; Pak, Y				Jang, Donghwan; Kwon, Hayeong; Choi, Moonjeong; Lee, Jaewoong; Pak, Yunbae			Sumoylation of Flotillin-1 promotes EMT in metastatic prostate cancer by suppressing Snail degradation	ONCOGENE			English	Article							RENAL-CELL CARCINOMA; NUCLEAR TRANSLOCATION; SIGNALING PATHWAY; BREAST-CANCER; UP-REGULATION; ACTIVATION; KINASE; CAVEOLIN-2; PROTEIN; MEMBRANE	Flotillin-1 (Flot-1) has been shown to regulate cancer progression, but the regulatory role of post-translational modifications of Flot-1 on cancers remains elusive. Herein, we show that up-regulated E2 conjugating enzyme UBC9 sumoylates Flot-1 at Lys-51 and Lys-195 with small ubiquitin-like modifier (SUMO)-2/3 modification in metastatic prostate cancer. Mitogen induced the sumoylation and nuclear translocation of Flot-1. The nuclear-targeted Flot-1 physically interacted with Snail, and inhibited Snail degradation through the proteasome in a sumoylation-dependent manner, thereby promoting epithelial-to-mesenchymal transition (EMT). Sumoylation of Flot-1 by up-regulated UBC9 in human metastatic prostate cancer tissues and prostate cancer cells with high metastatic potential positively correlated with the stabilization of Snail and the induction of Snail-mediated EMT genes in the metastatic prostate cancer. Our study reveals a new mechanism of sumoylated Flot-1-mediating Snail stabilization, and identifies a novel sumoylated Flot-1-Snail signaling axis in EMT of metastatic prostate cancer.	[Jang, Donghwan; Kwon, Hayeong; Choi, Moonjeong; Lee, Jaewoong; Pak, Yunbae] Gyeongsang Natl Univ, BK21 Plus Program, Div Life Sci, Grad Sch Appl Life Sci,PMBBRC, Jinju 52828, South Korea	Gyeongsang National University	Pak, Y (corresponding author), Gyeongsang Natl Univ, BK21 Plus Program, Div Life Sci, Grad Sch Appl Life Sci,PMBBRC, Jinju 52828, South Korea.	ybpak@gnu.ac.kr	Pak, Yunbae/Q-5783-2019	Pak, Yunbae/0000-0002-8594-5673; Kwon, Hayeong/0000-0002-8828-6060; Jang, Donghwan/0000-0002-4639-1102	National Research Foundation of Korea [NRF-2015R1D1A3A01016537, NRF-2018R1D1A1B07045995, NRF-2015R1D1A4A01017437, NRF-2018R1C1B6006816]; National R&D Program for Cancer Control of Korea [1631090]; Next-Generation BioGreen 21 Program of Korea SSAC [PJ01317301]; Global Ph.D. Fellowship Program [NRF-2013H1A2A1034489]; the BK21 Plus Program	National Research Foundation of Korea(National Research Foundation of Korea); National R&D Program for Cancer Control of Korea; Next-Generation BioGreen 21 Program of Korea SSAC; Global Ph.D. Fellowship Program; the BK21 Plus Program	This work was supported by grants from the National Research Foundation of Korea (NRF-2015R1D1A3A01016537 and NRF-2018R1D1A1B07045995 to YP and NRF-2015R1D1A4A01017437 and NRF-2018R1C1B6006816 to HK), the National R&D Program for Cancer Control of Korea (1631090 to HK), and the Next-Generation BioGreen 21 Program of Korea SSAC, Project No. PJ01317301 to HK. DJ is a recipient of the Global Ph.D. Fellowship Program (NRF-2013H1A2A1034489). MC was supported by a scholarship from the BK21 Plus Program.	Amaddii M, 2012, J BIOL CHEM, V287, P7265, DOI 10.1074/jbc.M111.287599; Baulida J, 2015, BBA-REV CANCER, V1856, P55, DOI 10.1016/j.bbcan.2015.05.005; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Bettermann K, 2012, CANCER LETT, V316, P113, DOI 10.1016/j.canlet.2011.10.036; Chaffer CL, 2016, CANCER METAST REV, V35, P645, DOI 10.1007/s10555-016-9648-7; Christofori G, 2003, EMBO J, V22, P2318, DOI 10.1093/emboj/cdg228; Du C, 2010, CANCER RES, V70, P7810, DOI 10.1158/0008-5472.CAN-09-4481; Escriva M, 2008, MOL CELL BIOL, V28, P1528, DOI 10.1128/MCB.02061-07; Garbis SD, 2008, J PROTEOME RES, V7, P3146, DOI 10.1021/pr800060r; Glebov OO, 2006, NAT CELL BIOL, V8, P46, DOI 10.1038/ncb1342; Gomez V, 2010, J BIOL CHEM, V285, P20683, DOI 10.1074/jbc.M110.130591; Green J. R, 2006, CAN MED BIOL ENG C, DOI [10.13140/2.1.1621.3446, DOI 10.13140/2.1.1621.3446]; Guillaume E, 2013, J CELL SCI, V126, P5293, DOI 10.1242/jcs.133975; Jang D, 2015, J CELL SCI, V128, P2179, DOI 10.1242/jcs.169409; Jeong K, 2012, TRAFFIC, V13, P1218, DOI 10.1111/j.1600-0854.2012.01378.x; Kaufhold S, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0062-0; Koh M, 2016, INT J CANCER, V138, P1232, DOI 10.1002/ijc.29869; Kuhne S, 2015, INT J MOL SCI, V16, P6447, DOI 10.3390/ijms16036447; Kwon H, 2015, BBA-MOL CELL RES, V1853, P1022, DOI 10.1016/j.bbamcr.2015.02.002; Kwon H, 2013, BBA-MOL CELL RES, V1833, P2176, DOI 10.1016/j.bbamcr.2013.05.003; Kwon H, 2011, J CELL MOL MED, V15, P888, DOI 10.1111/j.1582-4934.2010.01079.x; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Limpert AS, 2007, MOL CELL BIOL, V27, P5686, DOI 10.1128/MCB.01109-06; Lin CY, 2011, CLIN CANCER RES, V17, P3089, DOI 10.1158/1078-0432.CCR-10-3068; Liu J, 2005, J BIOL CHEM, V280, P1432, DOI 10.1074/jbc.M409740200; Meister M, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.47; Morrow IC, 2002, J BIOL CHEM, V277, P48834, DOI 10.1074/jbc.M209082200; Neumann-Giesen C, 2004, BIOCHEM J, V378, P509, DOI 10.1042/BJ20031100; Osorio LA, 2016, MOL MED REP, V13, P778, DOI 10.3892/mmr.2015.4585; Poblete CE, 2014, INT J ONCOL, V44, P647, DOI 10.3892/ijo.2014.2254; Pulukuri SM, 2005, J BIOL CHEM, V280, P36529, DOI 10.1074/jbc.M503111200; Randle DD, 2013, ONCOL LETT, V6, P1767, DOI 10.3892/ol.2013.1635; Ren ZX, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150070; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Santamaria A, 2005, MOL CELL BIOL, V25, P1900, DOI 10.1128/MCB.25.5.1900-1911.2005; Sehat B, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000628; Song LB, 2012, GASTROENTEROLOGY, V143, P995, DOI 10.1053/j.gastro.2012.06.033; Tomasovic A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029739; Tulloch LB, 2011, J BIOL CHEM, V286, P36020, DOI 10.1074/jbc.M111.282145; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Yan Y, 2014, TUMOR BIOL, V35, P10479, DOI 10.1007/s13277-014-2343-9; Zhang YY, 2014, MOL MED REP, V10, P860, DOI 10.3892/mmr.2014.2310; Zhao Q, 2014, NUCLEIC ACIDS RES, V42, pW325, DOI 10.1093/nar/gku383; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	44	23	24	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2019	38	17					3248	3260		10.1038/s41388-018-0641-1	http://dx.doi.org/10.1038/s41388-018-0641-1			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU8RI	30631151	hybrid, Green Published			2022-12-28	WOS:000465557200010
J	Tripathi, V; Shin, JH; Stuelten, CH; Zhang, YE				Tripathi, Veenu; Shin, Jee-Hye; Stuelten, Christina H.; Zhang, Ying E.			TGF-beta-induced alternative splicing of TAK1 promotes EMT and drug resistance	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; TO-MESENCHYMAL TRANSITION; CANCER; MAPKKK; TRAF6; P38; PHOSPHORYLATION; METASTASIS; REGULATOR	Transforming growth factor-beta (TGF-beta) is major inducer of epithelial-to-mesenchymal transition (EMT), which associates with cancer cell metastasis and resistance to chemotherapy and targeted drugs, through both transcriptional and non-transcriptional mechanisms. We previously reported that, in cancer cells, heightened mitogenic signaling allows TGF-beta-activated Smad3 to interact with poly(RC) binding protein 1 (PCBP1) and together they regulate many alternative splicing events that favors expression of protein isoforms essential for EMT, cytoskeletal rearrangement, and adherens junction signaling. Here we show that the exclusion of TGF-beta-activated kinase 1 (TAK1) variable exon 12 requires another RNA-binding protein, Fox-1 homolog 2 (Rbfox2), which binds intronic sequences in front of exon 12 independently of the Smad3-PCBP1 complex. Functionally, exon 12-excluded TAK1 Delta E12 and full-length TAK1FL are distinct. The short isoform TAK1 Delta E12 is constitutively active and supports TGF-beta-induced EMT and nuclear factor kappa B (NF-kappa B) signaling, whereas the full-length isoform TAK1FL promotes TGF-beta-induced apoptosis. These observations offer a harmonious explanation for how a single TAK1 kinase can mediate the opposing responses of cell survival and apoptosis in response to TGF-beta. They also reveal a propensity of the alternatively spliced TAK1 isoform TAK1 Delta E12 to cause drug resistance due to its activity in supporting EMT and NF-kappa B survival signaling.	[Tripathi, Veenu; Shin, Jee-Hye; Stuelten, Christina H.; Zhang, Ying E.] NCI, Lab Cellular & Mol Biol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Zhang, YE (corresponding author), NCI, Lab Cellular & Mol Biol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.	zhangyin@mail.nih.gov	Zhang, Ying E/G-3657-2015	Zhang, Ying E/0000-0003-2753-7601	NIH, National Cancer Institute, Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC010419] Funding Source: NIH RePORTER	NIH, National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr. K. Matsumoto for providing HATAK1 (Delta E12) plasmids; Dr. ZG Liu for NF kappa B-Luc reporter construct; Dr. K Hunter, Dr. L. Yang, and Dr. T. Misteli for Met-1, 4T1, and hMSC cells, respectively. This research was supported by the intramural research program of the NIH, National Cancer Institute, Center for Cancer Research.	Akhurst RJ, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022301; Alcorn JF, 2008, J CELL SCI, V121, P1036, DOI 10.1242/jcs.019455; Arsura M, 2003, ONCOGENE, V22, P412, DOI 10.1038/sj.onc.1206132; Bakin AV, 2002, J CELL SCI, V115, P3193; Bianchini G, 2016, NAT REV CLIN ONCOL, V13, P674, DOI 10.1038/nrclinonc.2016.66; Borowsky AD, 2005, CLIN EXP METASTAS, V22, P47, DOI 10.1007/s10585-005-2908-5; Brown K, 2005, J MOL BIOL, V354, P1013, DOI 10.1016/j.jmb.2005.09.098; Brown M, 2008, EXPERT OPIN THER TAR, V12, P1109, DOI 10.1517/14728222.12.9.1109 ; Dempsey CE, 2000, BBA-GENE STRUCT EXPR, V1517, P46, DOI 10.1016/S0167-4781(00)00258-X; Derynck R, 2014, CURR OPIN CELL BIOL, V31, P56, DOI 10.1016/j.ceb.2014.09.001; Disterer P, 2014, HUM GENE THER, V25, P587, DOI 10.1089/hum.2013.234; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Gingery A, 2008, EXP CELL RES, V314, P2725, DOI 10.1016/j.yexcr.2008.06.006; Hamidi A, 2012, J BIOL CHEM, V287, P123, DOI 10.1074/jbc.M111.285122; Hata A, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a022061; Hirata Y, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010205; Huang SD, 2012, CELL, V151, P937, DOI 10.1016/j.cell.2012.10.035; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Ishitani T, 2003, EMBO J, V22, P6277, DOI 10.1093/emboj/cdg605; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Ouyang C, 2014, J BIOL CHEM, V289, P24226, DOI 10.1074/jbc.M114.559963; Sakurai H, 2000, FEBS LETT, V474, P141, DOI 10.1016/S0014-5793(00)01588-X; Scholz R, 2010, J BIOL CHEM, V285, P25753, DOI 10.1074/jbc.M109.093468; Seoane J, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022277; Shapiro IM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002218; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Sorrentino A, 2008, NAT CELL BIOL, V10, P1199, DOI 10.1038/ncb1780; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Tang LY, 2017, J BIOL CHEM, V292, P4302, DOI 10.1074/jbc.M116.773085; Tripathi V, 2016, MOL CELL, V64, P549, DOI 10.1016/j.molcel.2016.09.013; Venables JP, 2013, MOL CELL BIOL, V33, P396, DOI 10.1128/MCB.01174-12; Venables JP, 2012, MOL BIOL EVOL, V29, P260, DOI 10.1093/molbev/msr193; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamashita M, 2008, MOL CELL, V31, P918, DOI 10.1016/j.molcel.2008.09.002; Yeo GW, 2009, NAT STRUCT MOL BIOL, V16, P130, DOI 10.1038/nsmb.1545; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zhang CL, 2008, GENE DEV, V22, P2550, DOI 10.1101/gad.1703108; Zhang YE, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022129; Zhou DH, 2018, BIOCHEM BIOPH RES CO, V497, P1018, DOI 10.1016/j.bbrc.2018.02.160	43	42	46	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2019	38	17					3185	3200		10.1038/s41388-018-0655-8	http://dx.doi.org/10.1038/s41388-018-0655-8			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU8RI	30626936	Green Accepted			2022-12-28	WOS:000465557200006
J	Sayed, ME; Yuan, L; Robin, JD; Tedone, E; Batten, K; Dahlson, N; Wright, WE; Shay, JW; Ludlow, AT				Sayed, Mohammed E.; Yuan, Laura; Robin, Jerome D.; Tedone, Enzo; Batten, Kimberly; Dahlson, Nicole; Wright, Woodring E.; Shay, Jerry W.; Ludlow, Andrew T.			NOVA1 directs PTBP1 to hTERT pre-mRNA and promotes telomerase activity in cancer cells	ONCOGENE			English	Article							REVERSE-TRANSCRIPTASE HTERT; CATALYTIC SUBUNIT GENE; SPLICING PATTERNS; ALIGNMENT; HALLMARKS; ROLES	Alternative splicing is dysregulated in cancer cells, driving the production of isoforms that allow tumor cells to survive and continuously proliferate. Part of the reactivation of telomerase involves the splicing of hTERT transcripts to produce full-length (FL) TERT. Very few splicing factors to date have been described to interact with hTERT and promote the production of FL TERT. We recently described one such splicing factor, NOVA1, that acts as an enhancer of FL hTERT splicing, increases telomerase activity, and promotes telomere maintenance in cancer cells. NOVA1 is expressed primarily in neurons and is involved in neurogenesis. In the present studies, we describe that polypyrimidine-tract binding proteins (PTBPs), which are also typically involved in neurogenesis, are also participating in the splicing of hTERT to FL in cancer. Knockdown experiments of PTBP1 in cancer cells indicate that PTBP1 reduces hTERT FL splicing and telomerase activity. Stable knockdown of PTBP1 results in progressively shortened telomere length in H1299 and H920 lung cancer cells. RNA pulldown experiments reveal that PTBP1 interacts with hTERT pre-mRNA in a NOVA1 dependent fashion. Knockdown of PTBP1 increases the expression of PTBP2 which also interacts with NOVA1, potentially preventing the association of NOVA1 with hTERT pre-mRNA. These new data highlight that splicing in cancer cells is regulated by competition for splice sites and that combinations of splicing factors interact at cis regulatory sites on pre-mRNA transcripts. By employing hTERT as a model gene, we show the coordination of the splicing factors NOVA1 and PTBP1 in cancer by regulating telomerase that is expressed in the vast majority of cancer cell types.	[Sayed, Mohammed E.; Ludlow, Andrew T.] Univ Michigan, Sch Kinesiol, 401 Washtenaw Ave, Ann Arbor, MI 48109 USA; [Yuan, Laura; Tedone, Enzo; Batten, Kimberly; Dahlson, Nicole; Wright, Woodring E.; Shay, Jerry W.] UT Southwestern Med Ctr, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Robin, Jerome D.] Aix Marseille Univ, UMR125, MMG, F-13385 Marseille, France	University of Michigan System; University of Michigan; University of Texas System; University of Texas Southwestern Medical Center Dallas; UDICE-French Research Universities; Aix-Marseille Universite	Ludlow, AT (corresponding author), Univ Michigan, Sch Kinesiol, 401 Washtenaw Ave, Ann Arbor, MI 48109 USA.	atludlow@umich.edu	Robin, Jerome/AAD-4309-2019	Robin, Jerome/0000-0001-5865-8372; Ludlow, Andrew/0000-0003-0423-4800; Wright, Woodring/0000-0001-6838-6665	NIH [C06 RR30414]; National Institute on Aging [AG01228]; T32 Training Grant [CA124334]; Pathway to Independence award (National Cancer Institute (NCI)) [K99/R00 CA197672-01A1]; Harold Simmons NCI Designated Comprehensive Cancer Center Support Grant [CA142543]; NCI SPORE [CA070907]; NATIONAL CANCER INSTITUTE [P50CA070907, P30CA142543, K99CA197672, R00CA197672, T32CA124334] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG001228] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); T32 Training Grant; Pathway to Independence award (National Cancer Institute (NCI)); Harold Simmons NCI Designated Comprehensive Cancer Center Support Grant; NCI SPORE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Drs. John Minna and Adi Gazdar for cell lines. We acknowledge Henrietta Lacks and her family members for the important contributions "HeLa" cells have made to this work. This work was performed in laboratories constructed with support from NIH Grant C06 RR30414. This work was supported by AG01228 from the National Institute on Aging (WEW and JWS) and by a T32 Training Grant CA124334 (JWS). A Pathway to Independence award to ATL (K99/R00 CA197672-01A1, National Cancer Institute (NCI)). We also acknowledge the Harold Simmons NCI Designated Comprehensive Cancer Center Support Grant (CA142543), the NCI SPORE (CA070907), and the Southland Financial Corporation Distinguished Chair in Geriatric Research (JWS and WEW).	Avilion AA, 1996, CANCER RES, V56, P645; Aviv A, 2017, TRENDS CANCER, V3, P253, DOI 10.1016/j.trecan.2017.02.005; Gomes NMV, 2011, AGING CELL, V10, P761, DOI 10.1111/j.1474-9726.2011.00718.x; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He X, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2013.47; Holohan B, 2014, J CELL BIOL, V205, P289, DOI 10.1083/jcb.201401012; Hrdlickova R, 2012, MOL CELL BIOL, V32, P4283, DOI 10.1128/MCB.00550-12; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim W, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.2000016; Lai TP, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01291-z; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Linares AJ, 2015, ELIFE, V4, DOI 10.7554/eLife.09268; Ludlow AT, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05582-x; Ludlow AT, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku439; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Monaghan P, 2018, PHILOS T R SOC B, V373, DOI 10.1098/rstb.2016.0435; Oltean S, 2014, ONCOGENE, V33, P5311, DOI 10.1038/onc.2013.533; Polydorides AD, 2000, P NATL ACAD SCI USA, V97, P6350, DOI 10.1073/pnas.110128397; Ramirez RD, 2004, CANCER RES, V64, P9027, DOI 10.1158/0008-5472.CAN-04-3703; Romanelli MG, 2013, INT J MOL SCI, V14, P22906, DOI 10.3390/ijms141122906; Saito Y, 2016, ELIFE, V5, DOI 10.7554/eLife.14371; Seluanov A, 2007, AGING CELL, V6, P45, DOI 10.1111/j.1474-9726.2006.00262.x; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Ulaner GA, 1998, CANCER RES, V58, P4168; Ulaner GA, 2000, INT J CANCER, V85, P330, DOI 10.1002/(SICI)1097-0215(20000201)85:3<330::AID-IJC6>3.0.CO;2-U; Withers JB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048016; Wong MS, 2014, TRENDS GENET, V30, P430, DOI 10.1016/j.tig.2014.07.006; Wong MS, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4306; Wong MS, 2013, CELL REP, V3, P1028, DOI 10.1016/j.celrep.2013.03.011; Wright WE, 1996, EMBO J, V15, P1734, DOI 10.1002/j.1460-2075.1996.tb00519.x; Wu TD, 2005, BIOINFORMATICS, V21, P1859, DOI 10.1093/bioinformatics/bti310; Yi XM, 2000, NEOPLASIA, V2, P433, DOI 10.1038/sj.neo.7900113; Yi XM, 2001, NUCLEIC ACIDS RES, V29, P4818, DOI 10.1093/nar/29.23.4818; Young AJ, 2018, PHILOS T R SOC B, V373, DOI 10.1098/rstb.2016.0452; Zhang J, 2013, CANCER DISCOV, V3, P1228, DOI 10.1158/2159-8290.CD-13-0253	37	29	31	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2019	38	16					2937	2952		10.1038/s41388-018-0639-8	http://dx.doi.org/10.1038/s41388-018-0639-8			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU3IV	30568224	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000465167600005
J	Hirano, D; Hayakawa, F; Yasuda, T; Tange, N; Yamamoto, H; Kojima, Y; Morishita, T; Imoto, N; Tsuzuki, S; Mano, H; Naoe, T; Kiyoi, H				Hirano, Daiki; Hayakawa, Fumihiko; Yasuda, Takahiko; Tange, Naoyuki; Yamamoto, Hideyuki; Kojima, Yuki; Morishita, Takanobu; Imoto, Naoto; Tsuzuki, Shinobu; Mano, Hiroyuki; Naoe, Tomoki; Kiyoi, Hitoshi			Chromosomal translocation-mediated evasion from miRNA induces strong MEF2D fusion protein expression, causing inhibition of PAX5 transcriptional activity	ONCOGENE			English	Article							LYMPHOBLASTIC-LEUKEMIA; CELL; PHOSPHORYLATION; TARGET; GENES; DIFFERENTIATION; OVEREXPRESSION; REPRESSION; MYOGENESIS; REGULATOR	MEF2D fusion genes are newly discovered recurrent gene abnormalities that are detected in approximately 5% of acute lymphoblastic leukemia cases. We previously demonstrated that the vector-driven expression of MEF2D fusion proteins was markedly stronger than that of wild-type MEF2D; however, the underlying mechanisms and significance of this expression have yet to be clarified. We herein showed that the strong expression of MEF2D fusion proteins was caused by the loss of the target site of miRNA due to gene translocation. We identified the target region of miRNA located in the coding region and selected miR-122 as a candidate of the responsible miRNA. Mutations at a putative binding site of miR-122 increased MEF2D expression, while the transfection of its miRNA mimic reduced the expression of wild-type MEF2D, but not MEF2D fusion proteins. We also found that MEF2D fusion proteins inhibited the transcriptional activity of PAX5, a B-cell differentiation regulator in a manner that depended on fusion-specific strong expression and an association with histone deacetylase 4, which may lead to the differentiation disorders of B cells. Our results provide novel insights into the mechanisms underlying leukemia development by MEF2D fusion genes and the involvement of the deregulation of miRNA-mediated repression in cancer development.	[Hirano, Daiki; Hayakawa, Fumihiko; Tange, Naoyuki; Yamamoto, Hideyuki; Kojima, Yuki; Morishita, Takanobu; Kiyoi, Hitoshi] Nagoya Univ, Dept Hematol & Oncol, Grad Sch Med, Nagoya, Aichi, Japan; [Hayakawa, Fumihiko] Nagoya Univ, Grad Sch Med, Dept Pathophysiol Lab Sci, Nagoya, Aichi, Japan; [Yasuda, Takahiko] Natl Hosp Org, Nagoya Med Ctr, Clin Res Ctr, Nagoya, Aichi, Japan; [Imoto, Naoto] Ogaki Municipal Hosp, Dept Hematol, Ogaki, Japan; [Tsuzuki, Shinobu] Aichi Med Univ, Sch Med, Dept Biochem, Nagakute, Aichi, Japan; [Mano, Hiroyuki] Univ Tokyo, Dept Cellular Signaling, Grad Sch Med, Tokyo, Japan; [Naoe, Tomoki] Nagoya Med Ctr, Nagoya, Aichi, Japan	Nagoya University; Nagoya University; Nagoya Medical Center; Ogaki Municipal Hospital; Aichi Medical University; University of Tokyo; Nagoya Medical Center	Hayakawa, F (corresponding author), Nagoya Univ, Dept Hematol & Oncol, Grad Sch Med, Nagoya, Aichi, Japan.; Hayakawa, F (corresponding author), Nagoya Univ, Grad Sch Med, Dept Pathophysiol Lab Sci, Nagoya, Aichi, Japan.	bun-hy@med.nagoya-u.ac.jp	Naoe, Tomoki/I-1888-2012; Yasuda, Takahiko/AGQ-5448-2022; Imoto, Naoto/AAB-7504-2022	Yasuda, Takahiko/0000-0002-4686-0976; Imoto, Naoto/0000-0003-0567-8761; Tsuzuki, Shinobu/0000-0002-3209-3550	Japan Agency for Medical Research and Development; JSPS KAKENHI	Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED)); JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We are very grateful to Yoko Matsuyama and Chika Wakamatsu for their technical assistance. We would thank to Yukie Konishi, Manami Kira, Rie Kojima, Yuko Kojima, Youko Okada, and Saori Kanamori for their secretarial assistance. This study was supported in part by grants for Practical Research for Innovative Cancer Control (to FH, HM, and HK), for Programs for Development of Innovative Research on Cancer Therapeutics (P-DIRECT) (to TN), for Project for Cancer Research And Therapeutic Evolution (P-CREATE) (to TY), and for Leading Advanced Projects for Medical Innovation (LEAP) (to HM) from the Japan Agency for Medical Research and Development. This work was also supported by JSPS KAKENHI (to FH, TY, and HK).	Arnold MA, 2007, DEV CELL, V12, P377, DOI 10.1016/j.devcel.2007.02.004; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Chen JJ, 2010, NAT REV CANCER, V10, P23, DOI 10.1038/nrc2765; Gaudilliere B, 2002, J BIOL CHEM, V277, P46442, DOI 10.1074/jbc.M206653200; Gregoire S, 2005, MOL CELL BIOL, V25, P2273, DOI 10.1128/MCB.25.6.2273-2287.2005; Gregoire S, 2006, J BIOL CHEM, V281, P4423, DOI 10.1074/jbc.M509471200; Gu Z, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13331; Hao NB, 2017, ONCOTARGET, V8, P81572, DOI 10.18632/oncotarget.19197; Hausser J, 2013, GENOME RES, V23, P604, DOI 10.1101/gr.139758.112; Hayakawa F, 2004, CANCER CELL, V5, P389, DOI 10.1016/S1535-6108(04)00082-0; Hayashi M, 2004, J CLIN INVEST, V113, P1138, DOI 10.1172/JCI200419890; Homminga I, 2011, CANCER CELL, V19, P484, DOI 10.1016/j.ccr.2011.02.008; Hong SH, 2000, MOL CELL BIOL, V20, P6612, DOI 10.1128/MCB.20.17.6612-6625.2000; Imoto N, 2016, J BIOL CHEM, V291, P4723, DOI 10.1074/jbc.M115.637835; Kataoka K, 2016, NATURE, V534, P402, DOI 10.1038/nature18294; Kurahashi S, 2011, ONCOGENE, V30, P1822, DOI 10.1038/onc.2010.554; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; Liu YF, 2016, EBIOMEDICINE, V8, P173, DOI 10.1016/j.ebiom.2016.04.038; Loher P, 2012, BIOINFORMATICS, V28, P3322, DOI 10.1093/bioinformatics/bts615; Lujambio A, 2012, NATURE, V482, P347, DOI 10.1038/nature10888; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; Ma LN, 2014, CANCER RES, V74, P1452, DOI 10.1158/0008-5472.CAN-13-2171; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Nebbioso A, 2020, EMBO REP, V21, DOI [10.1038/embor.2009.88, 10.15252/embr.202051028]; Parker BC, 2013, J CLIN INVEST, V123, P855, DOI 10.1172/JCI67144; Persson M, 2009, P NATL ACAD SCI USA, V106, P18740, DOI 10.1073/pnas.0909114106; Potthoff MJ, 2007, DEVELOPMENT, V134, P4131, DOI 10.1242/dev.008367; Schwieger M, 2009, BLOOD, V114, P2476, DOI 10.1182/blood-2008-05-158196; Suzuki K, 2016, J CLIN ONCOL, V34, P3451, DOI 10.1200/JCO.2016.66.5547; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Tay Y, 2011, CELL, V147, P344, DOI 10.1016/j.cell.2011.09.029; Watamoto K, 2003, ONCOGENE, V22, P9176, DOI 10.1038/sj.onc.1206902; Yang Q, 2009, SCIENCE, V323, P124, DOI 10.1126/science.1166088; Yasuda T, 2016, NAT GENET, V48, P569, DOI 10.1038/ng.3535; Yasuda T, 2012, J IMMUNOL, V188, P6127, DOI 10.4049/jimmunol.1103039; Zhao YY, 2015, J NEUROSCI RES, V93, P1891, DOI 10.1002/jnr.23628	37	10	10	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2019	38	13					2263	2274		10.1038/s41388-018-0573-9	http://dx.doi.org/10.1038/s41388-018-0573-9			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ7GN	30478446				2022-12-28	WOS:000462588000003
J	Smirnov, A; Lena, AM; Cappello, A; Panatta, E; Anemona, L; Bischetti, S; Annicchiarico-Petruzzelli, M; Mauriello, A; Melino, G; Candi, E				Smirnov, Artem; Lena, Anna Maria; Cappello, Angela; Panatta, Emanuele; Anemona, Lucia; Bischetti, Simone; Annicchiarico-Petruzzelli, Margherita; Mauriello, Alessandro; Melino, Gerry; Candi, Eleonora			ZNF185 is a p63 target gene critical for epidermal differentiation and squamous cell carcinoma development	ONCOGENE			English	Article							E-CADHERIN; LIM DOMAIN; P53 HOMOLOG; ADHESION; EXPRESSION; REVEALS; TRANSCRIPTION; PROTEIN; SKIN; PROLIFERATION	Development and maintenance of healthy stratified epithelia require the coordination of complex transcriptional programmes. The transcription factor p63, a member of the p53 family, plays a crucial role in epithelial development and homeostasis. Analysis of the p63-dependent transcriptome indicated that one important aspect of p63 functions in epithelial development is the regulation of cell-cell and cell-matrix adhesion programmes. However, limited knowledge exists on the relevant cell-cell adhesion molecules involved in physiological epithelial formation. Similarly, limited data are available to understand if deregulation of the cell-cell adhesion programme is important in tumour formation. Here, using the epidermis as an experimental model with the RNA sequencing approach, we identify a novel p63-regulated gene induced during differentiation, ZNF185. ZNF185 is an actin-cytoskeleton-associated Lin-l 1, Isl-1 and Mec-3 (LIM) domain containing protein, whose function is poorly known. We found that p63 binds to a specific enhancer region, promoting its expression to sustain epithelial differentiation. ZNF185 silencing strongly impaired keratinocyte differentiation according to gene array analysis. ZNF185 is detected at the cell-cell periphery where it physically interacts with E-cadherin, indicating that it is important to maintain epithelial integrity beyond its pro-differentiation role. Interestingly, poorly differentiated, including head and neck, cervical and oesophageal, squamous cell carcinomas display loss of ZNF185 expression. Together, these studies reinforce that p63 is a crucial gene for maintaining epithelial tissue integrity and support the deregulation of the cell-cell adhesion programme,which plays a critical role in carcinoma development.	[Smirnov, Artem; Lena, Anna Maria; Cappello, Angela; Panatta, Emanuele; Anemona, Lucia; Bischetti, Simone; Mauriello, Alessandro; Melino, Gerry; Candi, Eleonora] Univ Roma Tor Vergata, Dept Expt Med & Surg, Via Montpellier 1, I-00133 Rome, Italy; [Annicchiarico-Petruzzelli, Margherita; Candi, Eleonora] Ist Dermopat Immacolata IRCCS, Via Monti Creta 104, I-00163 Rome, Italy; [Melino, Gerry] Univ Cambridge, MRC Toxicol Unit, Hodgkin Bldg,Lancaster Rd, Leicester LE1 9HN, Leics, England	University of Rome Tor Vergata; IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Cambridge	Melino, G; Candi, E (corresponding author), Univ Roma Tor Vergata, Dept Expt Med & Surg, Via Montpellier 1, I-00133 Rome, Italy.; Candi, E (corresponding author), Ist Dermopat Immacolata IRCCS, Via Monti Creta 104, I-00163 Rome, Italy.; Melino, G (corresponding author), Univ Cambridge, MRC Toxicol Unit, Hodgkin Bldg,Lancaster Rd, Leicester LE1 9HN, Leics, England.	gerry.melino@uniroma2.it; candi@uniroma2.it	Lena, Anna Maria/AAI-5042-2020; Smirnov, Artem/AAB-3496-2020; Annicchiarico-Petruzzelli, Margherita/AAG-7746-2020; Cappello, Angela/AAL-6109-2021; Anemona, lucia/AAB-3491-2022	Smirnov, Artem/0000-0002-1575-8725; Annicchiarico-Petruzzelli, Margherita/0000-0002-4717-4740; Anemona, lucia/0000-0002-3711-2714; Panatta, Emanuele/0000-0001-8723-9564	AIRC [IG-15653]; IDI-IRCCS;  [RF-2016-02362541]; MRC [MC_U132670600, MC_UU_00025/2] Funding Source: UKRI	AIRC(Fondazione AIRC per la ricerca sul cancro); IDI-IRCCS; ; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The authors thank Dr. Ivano Amelio for his assistance with the gene microarray analysis, Dr. Alessandro Terrinoni for his assistance with RNA seq experiment, and Dr. Alessandra Gambacurta for reagents and scientific discussion. The authors also thank all laboratory members for their helpful discussion. This work has been partially supported by AIRC Grant IG-15653 to GM. This work has been mainly supported by IDI-IRCCS (RC to EC and GM) and RF-2016-02362541 (to EC).	Amelio I, 2012, J CELL BIOL, V199, P347, DOI 10.1083/jcb.201203134; Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; Bao XM, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0840-9; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Beaudry VG, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001168; Beck Tim N, 2016, Cancers Head Neck, V1, DOI 10.1186/s41199-016-0003-z; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Carroll DK, 2007, CELL CYCLE, V6, P255, DOI 10.4161/cc.6.3.3799; Carroll DK, 2006, NAT CELL BIOL, V8, P551, DOI 10.1038/ncb1420; Cassandri M, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2017.71; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Cavazza A, 2016, STEM CELL REP, V6, P618, DOI 10.1016/j.stemcr.2016.03.003; Davis MA, 2006, DEV CELL, V10, P21, DOI 10.1016/j.devcel.2005.12.004; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; Ferone G, 2013, HUM MOL GENET, V22, P531, DOI 10.1093/hmg/dds464; Fuchs E, 2002, NAT REV GENET, V3, P199, DOI 10.1038/nrg758; Fuchs E, 2007, NATURE, V445, P834, DOI 10.1038/nature05659; Gallant-Behm CL, 2013, CELL CYCLE, V12, P409, DOI 10.4161/cc.23593; Gonzalez HE, 2003, ARCH OTOLARYNGOL, V129, P754, DOI 10.1001/archotol.129.7.754; Guo ZH, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005473; Hatzfeld M, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a029157; Heiss NS, 1997, GENOMICS, V43, P329, DOI 10.1006/geno.1997.4810; Ihrie RA, 2005, CELL, V120, P843, DOI 10.1016/j.cell.2005.01.008; Kadrmas JL, 2004, NAT REV MOL CELL BIO, V5, P920, DOI 10.1038/nrm1499; Koster MI, 2006, DEV BIOL, V289, P253, DOI 10.1016/j.ydbio.2005.10.041; Kouwenhoven EN, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001065; Kroigard AB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0189887; Laurikkala J, 2006, DEVELOPMENT, V133, P1553, DOI 10.1242/dev.02325; Luxenburg C, 2015, NAT CELL BIOL, V17, P592, DOI 10.1038/ncb3146; McDade SS, 2014, NUCLEIC ACIDS RES, V42, P6270, DOI 10.1093/nar/gku299; Medina PP, 2005, HUM MOL GENET, V14, P973, DOI 10.1093/hmg/ddi091; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Nguyen BC, 2006, GENE DEV, V20, P1028, DOI 10.1101/gad.1406006; Niessen CM, 2008, BBA-BIOMEMBRANES, V1778, P562, DOI 10.1016/j.bbamem.2007.12.015; Niessen CM, 2007, J INVEST DERMATOL, V127, P2525, DOI 10.1038/sj.jid.5700865; Osada M, 2005, MOL CELL BIOL, V25, P6077, DOI 10.1128/MCB.25.14.6077-6089.2005; Osada M, 2005, J INVEST DERMATOL, V125, P52, DOI 10.1111/j.0022-202X.2005.23801.x; Oti M, 2015, GENOM DATA, V5, P159, DOI 10.1016/j.gdata.2015.06.002; Perez-Moreno M, 2008, P NATL ACAD SCI USA, V105, P15399, DOI 10.1073/pnas.0807301105; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Saladi SV, 2017, CANCER CELL, V31, P35, DOI 10.1016/j.ccell.2016.12.001; Shalom-Feuerstein R, 2011, CELL DEATH DIFFER, V18, P887, DOI 10.1038/cdd.2010.159; Shimomura Y, 2008, DEVELOPMENT, V135, P743, DOI 10.1242/dev.006718; Vaezi A, 2002, DEV CELL, V3, P367, DOI 10.1016/S1534-5807(02)00259-9; van Roy F, 2014, NAT REV CANCER, V14, P121, DOI 10.1038/nrc3647; Vanaja DK, 2003, CANCER RES, V63, P3877; Vasilaki E, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aag3232; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Warner SMB, 2013, AM J RESP CELL MOL, V49, P978, DOI 10.1165/rcmb.2012-0447OC; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; Wu N, 2012, J BIOL CHEM, V287, P5627, DOI 10.1074/jbc.M111.328120; Xu JF, 1998, NAT GENET, V20, P175, DOI 10.1038/2477; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zarnegar BJ, 2012, AM J HUM GENET, V91, P435, DOI 10.1016/j.ajhg.2012.07.007; Zhang JS, 2007, ONCOGENE, V26, P111, DOI 10.1038/sj.onc.1209769	57	23	24	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2019	38	10					1625	1638		10.1038/s41388-018-0509-4	http://dx.doi.org/10.1038/s41388-018-0509-4			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN8DD	30337687	Green Published, hybrid			2022-12-28	WOS:000460423800004
J	Wagner, S; Vlachogiannis, G; Brandon, AD; Valenti, M; Box, G; Jenkins, L; Mancusi, C; Self, A; Manodoro, F; Assiotis, I; Robinson, P; Chauhan, R; Rust, AG; Matthews, N; Eason, K; Khan, K; Starling, N; Cunningham, D; Sadanandam, A; Isacke, CM; Kirkin, V; Valeri, N; Whittaker, SR				Wagner, Steve; Vlachogiannis, Georgios; Brandon, Alexis De Haven; Valenti, Melanie; Box, Gary; Jenkins, Liam; Mancusi, Caterina; Self, Annette; Manodoro, Floriana; Assiotis, Ioannis; Robinson, Penny; Chauhan, Ritika; Rust, Alistair G.; Matthews, Nik; Eason, Kate; Khan, Khurum; Starling, Naureen; Cunningham, David; Sadanandam, Anguraj; Isacke, Clare M.; Kirkin, Vladimir; Valeri, Nicola; Whittaker, Steven R.			Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer	ONCOGENE			English	Article							NF-KAPPA-B; INTRINSIC RESISTANCE; PLUS IRINOTECAN; DOSE-ESCALATION; INFLAMMATION; DRIVEN; COLON; FLUOROURACIL; ACTIVATION; LEUCOVORIN	Despite showing clinical activity in BRAF-mutant melanoma, the MEK inhibitor (MEKi) trametinib has failed to show clinical benefit in KRAS-mutant colorectal cancer. To identify mechanisms of resistance to MEKi, we employed a pharmacogenomic analysis of MEKi-sensitive versus MEKi-resistant colorectal cancer cell lines. Strikingly, interferon- and inflammatory-related gene sets were enriched in cell lines exhibiting intrinsic and acquired resistance to MEK inhibition. The bromodomain inhibitor JQ1 suppressed interferon-stimulated gene (ISG) expression and in combination with MEK inhibitors displayed synergistic effects and induced apoptosis in MEKi-resistant colorectal cancer cell lines. ISG expression was confirmed in patient-derived organoid models, which displayed resistance to trametinib and were resensitized by JQ1 co-treatment. In in vivo models of colorectal cancer, combination treatment significantly suppressed tumor growth. Our findings provide a novel explanation for the limited response to MEK inhibitors in KRAS-mutant colorectal cancer, known for its inflammatory nature. Moreover, the high expression of ISGs was associated with significantly reduced survival of colorectal cancer patients. Excitingly, we have identified novel therapeutic opportunities to overcome intrinsic and acquired resistance to MEK inhibition in colorectal cancer.	[Wagner, Steve; Brandon, Alexis De Haven; Valenti, Melanie; Box, Gary; Mancusi, Caterina; Self, Annette; Kirkin, Vladimir; Whittaker, Steven R.] Inst Canc Res, Div Canc Therapeut, London, England; [Vlachogiannis, Georgios; Eason, Kate; Sadanandam, Anguraj; Valeri, Nicola] Inst Canc Res, Div Mol Pathol, London, England; [Jenkins, Liam; Isacke, Clare M.] Inst Canc Res, Breast Canc Now Res Ctr, London, England; [Manodoro, Floriana; Assiotis, Ioannis; Robinson, Penny; Chauhan, Ritika; Rust, Alistair G.; Matthews, Nik] Inst Canc Res, Tumour Profiling Unit, London, England; [Khan, Khurum; Starling, Naureen; Cunningham, David; Valeri, Nicola] Royal Marsden NHS Fdn Trust, Dept Med, London, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust	Whittaker, SR (corresponding author), Inst Canc Res, Div Canc Therapeut, London, England.	steven.whittaker@icr.ac.uk	Whittaker, Steven/AAS-9874-2020	Rust, Alistair/0000-0001-7287-192X; Sadanandam, Anguraj/0000-0001-8485-5150; valeri, nicola/0000-0002-5426-5683; Starling, Naureen/0000-0002-1496-6792; Eason, Katherine/0000-0001-6903-9067; Cunningham, David/0000-0001-5158-1069; Kirkin, Vladimir/0000-0002-8049-3663; Isacke, Clare/0000-0002-9222-3345; Whittaker, Steven/0000-0001-9062-7947; Jenkins, Liam/0000-0002-0560-0182	Institute of Cancer Research start-up funds; Cancer Research UK (Cancer Research UK) [C2739/A22897]; Biotechnology and Biological Sciences Research Council (BBSRC CASE Studentship) [1650206]; National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at the Royal Marsden NHS Foundation Trust; Institute of Cancer Research [A62, A100, A101, A159]; Cancer Research UK [CEA A18052]; European Union FP7 [CIG 334261]; NIHR BRC at the Royal Marsden NHS Foundation Trust; BBSRC [1650206] Funding Source: UKRI	Institute of Cancer Research start-up funds; Cancer Research UK (Cancer Research UK); Biotechnology and Biological Sciences Research Council (BBSRC CASE Studentship)(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at the Royal Marsden NHS Foundation Trust; Institute of Cancer Research; Cancer Research UK(Cancer Research UK); European Union FP7(European Commission); NIHR BRC at the Royal Marsden NHS Foundation Trust; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This work has been funded by the Institute of Cancer Research start-up funds (to SRW), Cancer Research UK (Cancer Research UK grant number C2739/A22897 to VK, Cancer Research UK Cancer Therapeutics Unit), Biotechnology and Biological Sciences Research Council (BBSRC CASE Studentship 1650206 to LJ and CMI), by the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at the Royal Marsden NHS Foundation Trust, and the Institute of Cancer Research (grant numbers A62, A100, A101, A159), Cancer Research UK (grant number CEA A18052) and the European Union FP7 (grant number CIG 334261) to NV. KE, AS, KK, NS, and DC acknowledge support from the NIHR BRC at the Royal Marsden NHS Foundation Trust, and the Institute of Cancer Research.	Ancrile B, 2007, GENE DEV, V21, P1714, DOI 10.1101/gad.1549407; Ancrile BB, 2008, MOL INTERV, V8, P22, DOI 10.1124/mi.8.1.6; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Berthon C, 2016, LANCET HAEMATOL, V3, pE186, DOI 10.1016/S2352-3026(15)00247-1; Blagg J, 2017, CANCER CELL, V32, P9, DOI 10.1016/j.ccell.2017.06.005; Boutin AT, 2017, GENE DEV, V31, P370, DOI 10.1101/gad.293449.116; Brown JD, 2014, MOL CELL, V56, P219, DOI 10.1016/j.molcel.2014.08.024; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Clevers H, 2004, CELL, V118, P671, DOI 10.1016/j.cell.2004.09.005; Crusz SM, 2015, NAT REV CLIN ONCOL, V12, P584, DOI 10.1038/nrclinonc.2015.105; De Raedt T, 2014, NATURE, V514, P247, DOI 10.1038/nature13561; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gelfo V, 2016, ONCOTARGET, V7, P72167, DOI 10.18632/oncotarget.12354; Gilmartin AG, 2011, CLIN CANCER RES, V17, P989, DOI 10.1158/1078-0432.CCR-10-2200; Golay HG, 2014, EXPERT REV ANTICANC, V14, P869, DOI 10.1586/14737140.2014.928596; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X; Hickish T, 2017, LANCET ONCOL, V18, P192, DOI 10.1016/S1470-2045(17)30006-2; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Infante JR, 2012, LANCET ONCOL, V13, P773, DOI 10.1016/S1470-2045(12)70270-X; Jamieson T, 2012, J CLIN INVEST, V122, P3127, DOI 10.1172/JCI61067; KNIGHT DM, 1993, MOL IMMUNOL, V30, P1443, DOI 10.1016/0161-5890(93)90106-L; Lewin J, 2018, J CLIN ONCOL, V36, P3007, DOI 10.1200/JCO.2018.78.2292; Lito P, 2014, CANCER CELL, V25, P697, DOI 10.1016/j.ccr.2014.03.011; Luo WJ, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-161; Ma YF, 2017, CLIN CANCER RES, V23, P2027, DOI 10.1158/1078-0432.CCR-16-0453; Manchado E, 2016, NATURE, V534, P647, DOI 10.1038/nature18600; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; NAGARKATTI M, 1990, J IMMUNOL, V144, P4898; Nicodeme E, 2010, NATURE, V468, P1119, DOI 10.1038/nature09589; Romano M, 2016, ANTICANCER RES, V36, P1447; Roumeliotis TI, 2017, CELL REP, V20, P2201, DOI 10.1016/j.celrep.2017.08.010; Sadanandam A, 2013, NAT MED, V19, P619, DOI 10.1038/nm.3175; Sakamoto K, 2009, CLIN CANCER RES, V15, P2248, DOI 10.1158/1078-0432.CCR-08-1383; Samatar AA, 2014, NAT REV DRUG DISCOV, V13, P928, DOI 10.1038/nrd4281; Shouval DS, 2016, GASTROENTEROLOGY, V151, P1100, DOI 10.1053/j.gastro.2016.08.055; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; Sun C, 2014, CELL REP, V7, P86, DOI 10.1016/j.celrep.2014.02.045; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; Van Cutsem E, 2007, J CLIN ONCOL, V25, P1658, DOI 10.1200/JCO.2006.08.1620; Van Cutsem E, 2011, J CLIN ONCOL, V29, P2011, DOI 10.1200/JCO.2010.33.5091; Vlachogiannis G, 2018, SCIENCE, V359, P920, DOI 10.1126/science.aao2774; Whittaker SR, 2004, CANCER RES, V64, P262, DOI 10.1158/0008-5472.CAN-03-0110; Whittaker SR, 2013, CANCER DISCOV, V3, P350, DOI 10.1158/2159-8290.CD-12-0470; Wislez M, 2006, CANCER RES, V66, P4198, DOI 10.1158/0008-5472.CAN-05-3842; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Workman P, 2010, BRIT J CANCER, V102, P1555, DOI 10.1038/sj.bjc.6605642; Zawistowski JS, 2017, CANCER DISCOV, V7, P302, DOI 10.1158/2159-8290.CD-16-0653; Zou Z, 2014, ONCOGENE, V33, P2395, DOI 10.1038/onc.2013.179	53	22	22	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2019	38	10					1717	1733		10.1038/s41388-018-0554-z	http://dx.doi.org/10.1038/s41388-018-0554-z			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN8DD	30353166	Green Published, hybrid			2022-12-28	WOS:000460423800011
J	Chen, JB; Chou, FJ; Yeh, SY; Ou, ZY; Shyr, C; Huang, CP; Xiang, ZD; Sun, Y; Messing, E; Zu, XB; Chang, CS				Chen, Jinbo; Chou, Fuju; Yeh, Shuyuan; Ou, Zhenyu; Shyr, Chihrong; Huang, Chiping; Xiang, Zhendong; Sun, Yin; Messing, Edward; Zu, Xiongbing; Chang, Chawnshang			Androgen dihydrotestosterone (DHT) promotes the bladder cancer nuclear AR-negative cell invasion via a newly identified membrane androgen receptor (mAR-SLC39A9)-mediated G alpha i protein/MAPK/MMP9 intracellular signaling	ONCOGENE			English	Article							PROTEIN-COUPLED RECEPTOR; ZINC TRANSPORTER; THERAPEUTIC TARGETS; HUMAN ZIP9; PROSTATE; METASTASIS; CALCIUM; STATES	While androgens may function via nuclear androgen receptor (nAR) to increase bladder cancer (BCa) progression, the impact of androgens on muscle invasive BCa, which contains nearly 80% nAR-negative cells, remains unclear. To dissect the androgens potential impacts on these nAR-negative muscle invasive BCa, we first found that the androgens, dihydrotestosterone (DHT) might function via a novel membrane AR (mAR-SLC39A9) to increase nAR-negative BCa cell migration and invasion. Mechanism dissection revealed that DHT/mAR-SLC39A9 might function by altering G(alpha i) protein-mediated MAPK/MMP9 intracellular signaling to increase nAR-negative BCa cell migration and invasion. Preclinical studies using multiple in vitro nAR-negative BCa cell lines and an in vivo mouse model all demonstrated that targeting this newly identified DHT/mAR-SLC39A9/G(alpha i)/MAPK/MMP9 signaling with small molecules mAR-SLC39A9-shRNA or G(alpha i)-shRNA, and not the classic antiandrogens including enzalutamide, bicalutamide, or hydroxyflutamide, could suppress nAR-negative BCa cell invasion. Results from human clinical samples surveys also indicated the positive correlation of this newly identified DHT/mAR signaling with BCa progression and prognosis. Together, these results suggest that androgens may not only function via the classic nAR to increase the nAR-positive BCa cell invasion, they may also function via this newly identified mAR-SLC39A9 to increase the nAR-negative/mAR-positive BCa cell invasion.	[Chen, Jinbo; Ou, Zhenyu; Zu, Xiongbing] Cent South Univ, Xiangya Hosp, Dept Urol, Changsha 410008, Peoples R China; [Chen, Jinbo; Chou, Fuju; Yeh, Shuyuan; Ou, Zhenyu; Xiang, Zhendong; Sun, Yin; Messing, Edward; Chang, Chawnshang] Univ Rochester, Dept Pathol, Med Inst, George Whipple Lab Canc Res, Rochester, NY 14627 USA; [Chen, Jinbo; Chou, Fuju; Yeh, Shuyuan; Ou, Zhenyu; Xiang, Zhendong; Sun, Yin; Messing, Edward; Chang, Chawnshang] Univ Rochester, Dept Urol, Med Inst, George Whipple Lab Canc Res, Rochester, NY USA; [Chen, Jinbo; Chou, Fuju; Yeh, Shuyuan; Ou, Zhenyu; Xiang, Zhendong; Sun, Yin; Messing, Edward; Chang, Chawnshang] Univ Rochester, Dept Radiat Oncol, Med Inst, George Whipple Lab Canc Res, Rochester, NY 14627 USA; [Chen, Jinbo; Chou, Fuju; Yeh, Shuyuan; Ou, Zhenyu; Xiang, Zhendong; Sun, Yin; Messing, Edward; Chang, Chawnshang] Univ Rochester, Wilmot Canc Ctr, Med Inst, Rochester, NY 14627 USA; [Shyr, Chihrong; Huang, Chiping; Chang, Chawnshang] China Med Univ Hosp, Sex Hormone Res Ctr, Dept Urol, Taichung 404, Taiwan; [Shyr, Chihrong; Huang, Chiping; Chang, Chawnshang] China Med Univ Hosp, Sex Hormone Res Ctr, Dept Med Technol, Taichung 404, Taiwan	Central South University; University of Rochester; University of Rochester; University of Rochester; University of Rochester; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan	Zu, XB (corresponding author), Cent South Univ, Xiangya Hosp, Dept Urol, Changsha 410008, Peoples R China.; Chang, CS (corresponding author), Univ Rochester, Dept Pathol, Med Inst, George Whipple Lab Canc Res, Rochester, NY 14627 USA.; Chang, CS (corresponding author), Univ Rochester, Dept Radiat Oncol, Med Inst, George Whipple Lab Canc Res, Rochester, NY 14627 USA.; Chang, CS (corresponding author), Univ Rochester, Wilmot Canc Ctr, Med Inst, Rochester, NY 14627 USA.; Chang, CS (corresponding author), China Med Univ Hosp, Sex Hormone Res Ctr, Dept Urol, Taichung 404, Taiwan.; Chang, CS (corresponding author), China Med Univ Hosp, Sex Hormone Res Ctr, Dept Med Technol, Taichung 404, Taiwan.	whzuxb@163.com; chang@urmc.rochester.edu		Chang, Chawnshang/0000-0001-8510-3516	NIH [CA155477]; Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence [MOHW104-TDU-B-212-113002]; National Natural Science Foundation of China [81572523]; Hunan Province Funds for Distinguished Young Scientists of China [2016JJ1026]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Hunan Province Funds for Distinguished Young Scientists of China	This work was supported by NIH grant (CA155477), in part by Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW104-TDU-B-212-113002), the National Natural Science Foundation of China (81572523), and the Hunan Province Funds for Distinguished Young Scientists of China (2016JJ1026).	Antoni S, 2017, EUR UROL, V71, P96, DOI 10.1016/j.eururo.2016.06.010; Berg AH, 2014, ENDOCRINOLOGY, V155, P4237, DOI 10.1210/en.2014-1198; Carneiro BA, 2015, CANCER TREAT REV, V41, P170, DOI 10.1016/j.ctrv.2014.11.003; Chang C, 2014, ONCOGENE, V33, P3225, DOI 10.1038/onc.2013.274; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; De Toni L, 2016, ENDOCRINOLOGY, V157, P4473, DOI 10.1210/en.2016-1312; Dobruch J, 2016, EUR UROL, V69, P300, DOI 10.1016/j.eururo.2015.08.037; Foradori CD, 2008, FRONT NEUROENDOCRIN, V29, P169, DOI 10.1016/j.yfrne.2007.10.005; Gao ZG, 2016, BIOCHEM PHARMACOL, V107, P59, DOI 10.1016/j.bcp.2016.03.003; Goldsmith ZG, 2007, ONCOGENE, V26, P3122, DOI 10.1038/sj.onc.1210407; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Huang B, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0408-7; Ide H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174746; Izumi K, 2014, ONCOTARGET, V5, P12665, DOI 10.18632/oncotarget.2851; Kamat AM, 2016, LANCET, V388, P2796, DOI 10.1016/S0140-6736(16)30512-8; Li P, 2017, CANCERS, V9, DOI 10.3390/cancers9020020; LIEBERHERR M, 1994, J BIOL CHEM, V269, P7217; Liu Q, 2015, J CELL BIOCHEM, V116, P1213, DOI 10.1002/jcb.25073; Milowsky MI, 2016, J CLIN ONCOL, V34, P1945, DOI 10.1200/JCO.2015.65.9797; Miyamoto H, 2012, CURR CANCER DRUG TAR, V12, P14, DOI 10.2174/156800912798888965; Miyamoto H, 2007, J NATL CANCER I, V99, P558, DOI 10.1093/jnci/djk113; Munnich N, 2016, BIOMETALS, V29, P995, DOI 10.1007/s10534-016-9971-z; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12182, DOI 10.1073/pnas.0804700105; Ou ZY, 2015, ONCOTARGET, V6, P26065, DOI 10.18632/oncotarget.4569; Pi M, 2012, PROSTATE, V72, P399, DOI 10.1002/pros.21442; Pi M, 2010, J BIOL CHEM, V285, P39953, DOI 10.1074/jbc.M110.158063; Rosner W, 1999, STEROIDS, V64, P100, DOI 10.1016/S0039-128X(98)00108-1; Sen A, 2011, STEROIDS, V76, P822, DOI 10.1016/j.steroids.2011.02.016; Shiota M, 2015, ONCOTARGET, V6, P14710, DOI 10.18632/oncotarget.3817; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sun YH, 2006, J ANDROL, V27, P671, DOI 10.2164/jandrol.106.000554; Tan WS, 2016, CANCER TREAT REV, V47, P22, DOI 10.1016/j.ctrv.2016.05.002; Tang XL, 2013, CANCER RES, V73, P6206, DOI 10.1158/0008-5472.CAN-13-1049; Thal DM, 2018, NATURE, V559, P45, DOI 10.1038/s41586-018-0259-z; Thomas P, 2018, GEN COMP ENDOCR, V257, P130, DOI 10.1016/j.ygcen.2017.04.016; Thomas P, 2017, MOL CELL ENDOCRINOL, V447, P23, DOI 10.1016/j.mce.2017.02.025; Thomas P, 2014, ENDOCRINOLOGY, V155, P4250, DOI 10.1210/en.2014-1201; Tuygun C, 2011, UROL ONCOL-SEMIN ORI, V29, P43, DOI 10.1016/j.urolonc.2009.01.033; Wang JL, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0720-8	40	13	13	2	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					574	586		10.1038/s41388-019-0964-6	http://dx.doi.org/10.1038/s41388-019-0964-6			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31506605				2022-12-28	WOS:000509718300007
J	Timaner, M; Kotsofruk, R; Raviv, Z; Magidey, K; Shechter, D; Kan, T; Nevelsky, A; Daniel, S; de Vries, EGE; Zhang, TW; Kaidar-Person, O; Kerbel, RS; Shaked, Y				Timaner, Michael; Kotsofruk, Ruslana; Raviv, Ziv; Magidey, Ksenia; Shechter, Dvir; Kan, Tal; Nevelsky, Alexander; Daniel, Shahar; de Vries, Elisabeth G. E.; Zhang, Tongwu; Kaidar-Person, Orit; Kerbel, Robert S.; Shaked, Yuval			Microparticles from tumors exposed to radiation promote immune evasion in part by PD-L1	ONCOGENE			English	Article							CANCER-THERAPY; RADIOTHERAPY; CELLS; MECHANISMS; EXPRESSION; MEDIATORS; RESPONSES; ASSAY; MICROENVIRONMENT; MICROVESICLES	Radiotherapy induces immune-related responses in cancer patients by various mechanisms. Here, we investigate the immunomodulatory role of tumor-derived microparticles (TMPs)-extracellular vesicles shed from tumor cells-following radiotherapy. We demonstrate that breast carcinoma cells exposed to radiation shed TMPs containing elevated levels of immune-modulating proteins, one of which is programmed death-ligand 1 (PD-L1). These TMPs inhibit cytotoxic T lymphocyte (CTL) activity both in vitro and in vivo, and thus promote tumor growth. Evidently, adoptive transfer of CTLs pre-cultured with TMPs from irradiated breast carcinoma cells increases tumor growth rates in mice recipients in comparison with control mice receiving CTLs pre-cultured with TMPs from untreated tumor cells. In addition, blocking the PD-1-PD-L1 axis, either genetically or pharmacologically, partially alleviates TMP-mediated inhibition of CTL activity, suggesting that the immunomodulatory effects of TMPs in response to radiotherapy is mediated, in part, by PD-L1. Overall, our findings provide mechanistic insights into the tumor immune surveillance state in response to radiotherapy and suggest a therapeutic synergy between radiotherapy and immune checkpoint inhibitors.	[Timaner, Michael; Kotsofruk, Ruslana; Raviv, Ziv; Magidey, Ksenia; Shechter, Dvir; Kan, Tal; Shaked, Yuval] Technion, Cell Biol & Canc Sci, Rappaport Fac Med, Haifa, Israel; [Nevelsky, Alexander; Daniel, Shahar; Kaidar-Person, Orit] Rambam Hlth Care Campus, Radiat Oncol Unit, Oncol Inst, Haifa, Israel; [de Vries, Elisabeth G. E.] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, Groningen, Netherlands; [Zhang, Tongwu] NCI, Div Canc Epidemiol & Genet, Integrat Tumor Epidemiol Branch, NIH, Bethesda, MD USA; [Kerbel, Robert S.] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Rambam Health Care Campus; University of Groningen; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Shaked, Y (corresponding author), Technion, Cell Biol & Canc Sci, Rappaport Fac Med, Haifa, Israel.	yshaked@tx.technion.ac.il		Zhang, Tongwu/0000-0003-2124-2706; Kaidar-Person, Orit/0000-0003-4023-1869; de Vries, Elisabeth/0000-0002-8949-7425	Israel Cancer Research Fund; European Research Council [771112]; Rappaport funds	Israel Cancer Research Fund; European Research Council(European Research Council (ERC)European Commission); Rappaport funds	This study was supported by grants from the Israel Cancer Research Fund supported the Buckstein Family to YS and RSK, the European Research Council (no. 771112) and Rappaport funds to YS.	Ahn GO, 2008, CANCER CELL, V13, P193, DOI 10.1016/j.ccr.2007.11.032; Al-Nedawi K, 2009, CELL CYCLE, V8, P2014, DOI 10.4161/cc.8.13.8988; Barcellos-Hoff MH, 2005, NAT REV CANCER, V5, P867, DOI 10.1038/nrc1735; Barcellos-Hoff MH, 2005, SEMIN CANCER BIOL, V15, P138, DOI 10.1016/j.semcancer.2004.08.010; Barker HE, 2015, NAT REV CANCER, V15, P409, DOI 10.1038/nrc3958; Chen G, 2018, NATURE, V560, P382, DOI 10.1038/s41586-018-0392-8; Cox J, 2014, MOL CELL PROTEOMICS, V13, P2513, DOI 10.1074/mcp.M113.031591; De Palma M, 2013, CANCER CELL, V23, P277, DOI 10.1016/j.ccr.2013.02.013; Deng LF, 2014, J CLIN INVEST, V124, P687, DOI 10.1172/JCI67313; Dovedi SJ, 2014, CANCER RES, V74, P5458, DOI 10.1158/0008-5472.CAN-14-1258; EHLERS G, 1973, BRIT J RADIOL, V46, P220, DOI 10.1259/0007-1285-46-543-220; Formenti SC, 2009, LANCET ONCOL, V10, P718, DOI 10.1016/S1470-2045(09)70082-8; Fremder E, 2014, INT J CANCER, V135, P270, DOI 10.1002/ijc.28678; FU YX, 1990, CANCER RES, V50, P227; GENOVESI EV, 1984, CANCER RES, V44, P1489; Hutchinson Lisa, 2011, Nat Rev Clin Oncol, V8, P508, DOI 10.1038/nrclinonc.2011.112; Issman L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083680; Jaiswal R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061515; Kang J, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0156-7; Keklikoglou I, 2019, NAT CELL BIOL, V21, P190, DOI 10.1038/s41556-018-0256-3; Koller KM, 2017, CANCER BIOL THER, V18, P36, DOI 10.1080/15384047.2016.1264543; Lee TH, 2011, SEMIN IMMUNOPATHOL, V33, P455, DOI 10.1007/s00281-011-0250-3; Ma RH, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1118599; Makinde AY, 2016, SEMIN RADIAT ONCOL, V26, P254, DOI 10.1016/j.semradonc.2016.07.001; Matsumura S, 2008, J IMMUNOL, V181, P3099, DOI 10.4049/jimmunol.181.5.3099; Mege D, 2018, METHODS MOL BIOL, V1765, P271, DOI 10.1007/978-1-4939-7765-9_17; Mell LK, 2017, INT J RADIAT ONCOL, V97, P536, DOI 10.1016/j.ijrobp.2016.11.027; Meng YR, 2010, MOL THER, V18, P912, DOI 10.1038/mt.2010.18; Palayoor ST, 2014, MOL CANCER RES, V12, P1002, DOI 10.1158/1541-7786.MCR-13-0623; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Peinado H, 2017, NAT REV CANCER, V17, P302, DOI 10.1038/nrc.2017.6; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Postow MA, 2015, J CLIN ONCOL, V33, P1974, DOI 10.1200/JCO.2014.59.4358; Rak J, 2010, SEMIN THROMB HEMOST, V36, P888, DOI 10.1055/s-0030-1267043; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Reynders K, 2015, PROG TUMOR RES, V42, P67, DOI 10.1159/000437185; Ricklefs FL, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aar2766; Rose B, 2017, PRACT RADIAT ONCOL, V7, pE291, DOI 10.1016/j.prro.2017.03.008; Russell JS, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00157; Shaked Y, 2016, NAT REV CLIN ONCOL, V13, P611, DOI 10.1038/nrclinonc.2016.57; Sharabi AB, 2015, LANCET ONCOL, V16, pE498, DOI 10.1016/S1470-2045(15)00007-8; Sharma P, 2015, CELL, V161, P205, DOI 10.1016/j.cell.2015.03.030; STONE HB, 1979, JNCI-J NATL CANCER I, V63, P1229; Tang K, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2282; Timaner Michael, 2016, Curr Protoc Cell Biol, V70, DOI 10.1002/0471143030.cb1918s70; Timaner M, 2015, ONCOTARGET, V6, P27537, DOI 10.18632/oncotarget.4826; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Tyanova S, 2018, METHODS MOL BIOL, V1711, P133, DOI 10.1007/978-1-4939-7493-1_7; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Voloshin T, 2014, CANCER MICROENVIRON, V7, P11, DOI 10.1007/s12307-014-0144-8; Wargo JA, 2015, SEMIN ONCOL, V42, P601, DOI 10.1053/j.seminoncol.2015.05.007; Wersall PJ, 2006, ACTA ONCOL, V45, P493, DOI 10.1080/02841860600604611; WINN HJ, 1961, J IMMUNOL, V86, P228; Wolford CC, 2013, J CLIN INVEST, V123, P2893, DOI 10.1172/JCI64410; Zhao LL, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0328-9	55	23	25	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	1					187	203		10.1038/s41388-019-0971-7	http://dx.doi.org/10.1038/s41388-019-0971-7			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG3NM	31467431	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000509849200013
J	Rajabi, H; Hata, T; Li, W; Long, MD; Hu, Q; Liu, S; Raina, D; Kui, L; Yasumizu, Y; Hong, DL; Samur, M; Kufe, D				Rajabi, Hasan; Hata, Tsuyoshi; Li, Wei; Long, Mark D.; Hu, Qiang; Liu, Song; Raina, Deepak; Kui, Ling; Yasumizu, Yota; Hong, Deli; Samur, Mehmet; Kufe, Donald			MUC1-C represses the RASSF1A tumor suppressor in human carcinoma cells	ONCOGENE			English	Article							DNA METHYLATION; IMMUNE EVASION; MST2 PATHWAY; ONCOPROTEIN; RAS; ASSOCIATION; DOMAIN; GENE; TRANSCRIPTION; ACTIVATION	RASSF1A encodes a tumor suppressor that inhibits the RAS -> RAF -> MEK -> ERK pathway and is one of the most frequently inactivated genes in human cancers. MUC1-C is an oncogenic effector of the cancer cell epigenome that is overexpressed in diverse carcinomas. We show here that MUC1-C represses RASSF1A expression in KRAS wild-type and mutant cancer cells. Mechanistically, MUC1-C occupies the RASSF1A promoter in a complex with the ZEB1 transcriptional repressor. In turn, MUC1-C/ZEB1 complexes recruit DNA methyltransferase 3b (DNMT3b) to the CpG island in the RASSF1A promoter. Targeting MUC1-C, ZEB1, and DNMT3b thereby decreases methylation of the CpG island and derepresses RASSF1A transcription. We also show that targeting MUC1-C regulates KRAS signaling, as evidenced by RNA-seq analysis, and decreases MEK/ERK activation, which is of importance for RAS-mediated tumorigenicity. These findings define a previously unrecognized role for MUC1-C in suppression of RASSF1A and support targeting MUC1-C as an approach for inhibiting MEK -> ERK signaling.	[Rajabi, Hasan; Hata, Tsuyoshi; Li, Wei; Raina, Deepak; Kui, Ling; Yasumizu, Yota; Hong, Deli; Samur, Mehmet; Kufe, Donald] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA; [Long, Mark D.; Hu, Qiang; Liu, Song] Roswell Pk Comprehens Canc Ctr, Dept Biostat & Bioinformat, Buffalo, NY USA; [Raina, Deepak] Genus Oncol, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kufe, D (corresponding author), Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu	wei, li/GSD-3630-2022; Hong, Deli/AAG-2565-2021; Wei, Li/AAE-9938-2020	Li, Wei/0000-0001-6728-1300; Hu, Qiang/0000-0002-4090-5539; Samur, Mehmet/0000-0002-9978-5682; Long, Mark/0000-0003-1120-8176	National Cancer Institute of the National Institutes of Health [CA97098, CA166480, CA216553, CA233084, U24CA232979]; NATIONAL CANCER INSTITUTE [R01CA166480, U01CA233084, R21CA216553, R01CA097098, U24CA232979] Funding Source: NIH RePORTER	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Grants from the National Cancer Institute of the National Institutes of Health under award numbers CA97098, CA166480, CA216553, CA233084, and U24CA232979.	Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088; Ahmad R, 2012, J BIOL CHEM, V287, P20866, DOI 10.1074/jbc.M112.357293; Ahmad R, 2009, CANCER RES, V69, P7013, DOI 10.1158/0008-5472.CAN-09-0523; Alam M, 2016, MOL CANCER RES, V14, P1266, DOI 10.1158/1541-7786.MCR-16-0233; Baksh S, 2005, MOL CELL, V18, P637, DOI 10.1016/j.molcel.2005.05.010; Bouillez A, 2016, CANCER RES, V76, P1538, DOI 10.1158/0008-5472.CAN-15-1804; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; Cox Adrienne D, 2010, Small GTPases, V1, P2; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann RH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102160; Donninger H, 2007, J CELL SCI, V120, P3163, DOI 10.1242/jcs.010389; Donninger H, 2016, SEMIN CELL DEV BIOL, V58, P86, DOI 10.1016/j.semcdb.2016.06.007; Dubois F, 2016, CANCER RES, V76, P1627, DOI 10.1158/0008-5472.CAN-15-1008; Guo C, 2011, J BIOL CHEM, V286, P6253, DOI 10.1074/jbc.M110.178210; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Hiraki M, 2017, ONCOGENE, V36, P2791, DOI 10.1038/onc.2016.439; Huang L, 2005, CANCER RES, V65, P10413, DOI 10.1158/0008-5472.CAN-05-2474; Kazanets A, 2016, BBA-REV CANCER, V1865, P275, DOI 10.1016/j.bbcan.2016.04.001; Kidger AM, 2018, PHARMACOL THERAPEUT, V187, P45, DOI 10.1016/j.pharmthera.2018.02.007; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Kufe DW, 2013, ONCOGENE, V32, P1073, DOI 10.1038/onc.2012.158; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Li YQ, 2003, ONCOGENE, V22, P6107, DOI 10.1038/sj.onc.1206732; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Maeda T, 2018, CANCER RES, V78, P205, DOI 10.1158/0008-5472.CAN-17-1636; Martin-Belmonte F, 2012, NAT REV CANCER, V12, P23, DOI 10.1038/nrc3169; Matallanas D, 2007, MOL CELL, V27, P962, DOI 10.1016/j.molcel.2007.08.008; Matallanas D, 2011, MOL CELL, V44, P893, DOI 10.1016/j.molcel.2011.10.016; O'Neill E, 2004, SCIENCE, V306, P2267, DOI 10.1126/science.1103233; Oh HJ, 2006, CANCER RES, V66, P2562, DOI 10.1158/0008-5472.CAN-05-2951; Palakurthy RK, 2009, MOL CELL, V36, P219, DOI 10.1016/j.molcel.2009.10.009; Panchamoorthy G, 2011, HYBRIDOMA, V30, P531, DOI 10.1089/hyb.2011.0070; PANDEY P, 1995, CANCER RES, V55, P4000; Papaspyropoulos A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02786-5; Raina D, 2004, J BIOL CHEM, V279, P20607, DOI 10.1074/jbc.M310538200; Rajabi H, 2016, ONCOGENE, V35, P6439, DOI 10.1038/onc.2016.180; Rajabi H, 2014, ONCOGENE, V33, P1680, DOI 10.1038/onc.2013.114; Rajabi H, 2018, ONCOGENE, V37, P2079, DOI 10.1038/s41388-017-0096-9; Rajabi H, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07850-0; Rajabi H, 2017, BBA-REV CANCER, V1868, P117, DOI 10.1016/j.bbcan.2017.03.003; Rajabi H, 2012, J BIOL CHEM, V287, P10703, DOI 10.1074/jbc.M111.323311; Ram RR, 2014, MOL CELL BIOL, V34, P2350, DOI 10.1128/MCB.01506-13; Richter AM, 2009, BBA-REV CANCER, V1796, P114, DOI 10.1016/j.bbcan.2009.03.004; Romano D, 2014, NAT CELL BIOL, V16, P673, DOI 10.1038/ncb2986; Schmidt ML, 2018, CANCER RES, V78, P2614, DOI 10.1158/0008-5472.CAN-17-2466; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Strunnikova M, 2005, MOL CELL BIOL, V25, P3923, DOI 10.1128/MCB.25.10.3923-3933.2005; Tagde A, 2016, ONCOTARGET, V7, P38974, DOI 10.18632/oncotarget.9777; Takahashi H, 2015, ONCOGENE, V34, P5187, DOI 10.1038/onc.2014.442; Teng IW, 2011, CANCER RES, V71, P4653, DOI 10.1158/0008-5472.CAN-10-3418; Thaler S, 2009, CANCER RES, V69, P1748, DOI 10.1158/0008-5472.CAN-08-1377; Tolcher AW, 2018, MOL CANCER THER, V17, P3, DOI 10.1158/1535-7163.MCT-17-0349; van der Weyden L, 2007, BBA-REV CANCER, V1776, P58, DOI 10.1016/j.bbcan.2007.06.003; Vaseva AV, 2018, CANCER CELL, V34, P807, DOI 10.1016/j.ccell.2018.10.001; Vlahov N, 2015, CURR BIOL, V25, P3019, DOI 10.1016/j.cub.2015.09.072; Vos MD, 2006, J BIOL CHEM, V281, P4557, DOI 10.1074/jbc.M512128200; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Wei XL, 2005, CANCER CELL, V7, P167, DOI 10.1016/j.ccr.2005.01.008; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Zhou C, 2017, ONCOTARGET, V8, P54388, DOI 10.18632/oncotarget.17077; Zhou CX, 2017, ONCOTARGET, V8, P49534, DOI 10.18632/oncotarget.17743	62	12	12	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2019	38	47					7266	7277		10.1038/s41388-019-0940-1	http://dx.doi.org/10.1038/s41388-019-0940-1			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP0UL	31435022	hybrid, Green Accepted			2022-12-28	WOS:000497989400006
J	Han, Y; Kim, B; Cho, U; Park, IS; Kim, SI; Dhanasekaran, DN; Tsang, BK; Song, YS				Han, Youngjin; Kim, Boyun; Cho, Untack; Park, In Sil; Kim, Se Ik; Dhanasekaran, Danny N.; Tsang, Benjamin K.; Song, Yong Sang			Mitochondrial fission causes cisplatin resistance under hypoxic conditions via ROS in ovarian cancer cells	ONCOGENE			English	Article							INDUCED MIGRATION; DYNAMICS; DRP1; PHOSPHORYLATION; METASTASIS; SURVIVAL; P53; TRAFFICKING; STRESS; FUSION	Mitochondria undergo fission and fusion continually for survival through the course of cellular adaption processes in response to changes in the surrounding environment. Dysregulated mitochondria' dynamics has been reported in various diseases including cancer. Under hypoxic conditions (<1% O-2), the relationship between mitochondrial dynamics and sensitivity to cisplatin (CDDP) was examined in ovarian cancer cells. We found that hypoxia promoted mitochondria' fission and CDDP resistance in ovarian cancer cells. Hypoxia-induced reactive oxygen species (ROS) caused an increase in mitochondrial fission, a response abolished by free radical scavenging with N-acetylcysteine (NAC) and Trolox. Also, treatment of hydrogen peroxide (H2O2) decreased inhibitory p-Drp1 (Ser637) content and increased mitochondrial fission. Suppression of mitochondrial fission enhanced the CDDP sensitivity of hypoxic ovarian cancer cells. Lastly, in tumor spheroids from malignant ascites or tissues of patients with advanced-stage ovarian cancer, pretreatment with Mdivi-1 increased the CDDP sensitivity. Taken together, our results implicate that hypoxia-induced ROS trigger mitochondrial fission and CDDP resistance through downregulation of p-Drpl (Ser637) and Mfn1 in ovarian cancer cells. Inhibition of Drp1 by Mdivi-1 treatment or si-Drpl transfection increased CDDP sensitivity of ovarian cancer cells under hypoxia. Therefore, mitochondrial dynamics of cancer cells adapting to the hypoxic tumor microenvironment could be a potential target for anticancer therapy.	[Han, Youngjin; Song, Yong Sang] Seoul Natl Univ, Dept Agr Biotechnol, WCU Biomodulat, Seoul 08826, South Korea; [Han, Youngjin; Kim, Boyun; Cho, Untack; Park, In Sil; Song, Yong Sang] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul 03080, South Korea; [Kim, Boyun] Univ Texas Hlth Sci Ctr Houston, Dept Anesthesiol, McGovern Med Sch, Houston, TX 77030 USA; [Cho, Untack; Song, Yong Sang] Seoul Natl Univ, Interdisciplinary Program Canc Biol, Seoul 03080, South Korea; [Park, In Sil] Seoul Natl Univ, Dept Agr Biotechnol, Seoul 08826, South Korea; [Kim, Se Ik; Song, Yong Sang] Seoul Natl Univ, Coll Med, Dept Obstet & Gynecol, Seoul 03080, South Korea; [Dhanasekaran, Danny N.] Univ Oklahoma, Hlth Sci Ctr, Stephenson Canc Ctr, Oklahoma City, OK 73012 USA; [Tsang, Benjamin K.] Univ Ottawa, Dept Obstet & Gynecol, Ottawa, ON K1H 8L6, Canada; [Tsang, Benjamin K.] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8L6, Canada; [Tsang, Benjamin K.] Ottawa Hosp Res Inst, Chron Dis Program, Ottawa, ON K1H 8L6, Canada; [Tsang, Benjamin K.] Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Macau Inst Appl Res Med & Hlth, Macau, Peoples R China	Seoul National University (SNU); Seoul National University (SNU); University of Texas System; University of Texas Health Science Center Houston; Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Ottawa; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; Macau University of Science & Technology	Song, YS (corresponding author), Seoul Natl Univ, Dept Agr Biotechnol, WCU Biomodulat, Seoul 08826, South Korea.; Song, YS (corresponding author), Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul 03080, South Korea.; Song, YS (corresponding author), Seoul Natl Univ, Interdisciplinary Program Canc Biol, Seoul 03080, South Korea.; Song, YS (corresponding author), Seoul Natl Univ, Coll Med, Dept Obstet & Gynecol, Seoul 03080, South Korea.	yssong@snu.ac.kr		SONG, YONGSANG/0000-0001-7115-4021; Han, Youngjin/0000-0002-3778-2056; Kim, Se Ik/0000-0002-9790-6735	BK21 Plus Program of the Department of Agricultural Biotechnology, Seoul National University (Seoul, Korea); Korea Health Technology R&D Project through the Korea Health Industry Development R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI16C2037]; Seoul National University Hospital (SNUH) research fund [04-2017-0530]; Canadian Institutes of Health Research [MOP-126144]	BK21 Plus Program of the Department of Agricultural Biotechnology, Seoul National University (Seoul, Korea); Korea Health Technology R&D Project through the Korea Health Industry Development R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea; Seoul National University Hospital (SNUH) research fund; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This research was supported by the BK21 Plus Program of the Department of Agricultural Biotechnology, Seoul National University (Seoul, Korea), a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea [grant number HI16C2037], and Seoul National University Hospital (SNUH) research fund [grant number 04-2017-0530], as well as a grant from the Canadian Institutes of Health Research [grant number MOP-126144]. Also, we would like to thank Prof. Woo Ho Kim (Seoul National University, Republic of Korea) and his lab members for technical assistance in this study.	Akbarzadeh M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16940-y; Altieri DC, 2017, BRIT J CANCER, V117, P301, DOI 10.1038/bjc.2017.201; Archer SL, 2013, NEW ENGL J MED, V369, P2236, DOI 10.1056/NEJMra1215233; Braicu EI, 2014, ONCOTARGETS THER, V7, P1563, DOI 10.2147/OTT.S65373; Caino MC, 2015, P NATL ACAD SCI USA, V112, P8638, DOI 10.1073/pnas.1500722112; Capriglione S, 2017, MED ONCOL, V34, DOI 10.1007/s12032-017-1026-y; Carreau A, 2011, J CELL MOL MED, V15, P1239, DOI 10.1111/j.1582-4934.2011.01258.x; Casciello F, 2017, P NATL ACAD SCI USA, V114, P7077, DOI 10.1073/pnas.1618706114; Chaitanya GV, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-31; Chen Y, 2012, INT J MOL SCI, V13, P13264, DOI 10.3390/ijms131013264; Cheng CT, 2016, CANCER RES, V76, P5006, DOI 10.1158/0008-5472.CAN-15-2921; Cho U, 2018, MOL CARCINOGEN, V57, P235, DOI 10.1002/mc.22750; Coburn SB, 2017, INT J CANCER, V140, P2451, DOI 10.1002/ijc.30676; Cocola C, 2017, J CELL BIOCHEM, V118, P570, DOI 10.1002/jcb.25737; Eales KL, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.50; Farrand L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074008; Ferree A, 2012, ADV EXP MED BIOL, V748, P13, DOI 10.1007/978-1-4614-3573-0_2; Ferreira-da-Silva A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122308; Girda E, 2017, INT J GYNECOL CANCER, V27, P1701, DOI 10.1097/IGC.0000000000001061; Gjorevski N, 2016, NATURE, V539, P359, DOI 10.1038/nature20168; Han XJ, 2015, INT J ONCOL, V46, P691, DOI 10.3892/ijo.2014.2781; Han Y, 2018, FREE RADICAL RES, V52, P1271, DOI 10.1080/10715762.2018.1459594; Hong YH, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00167; Humpton TJ, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026146; Itoh K, 2013, TRENDS CELL BIOL, V23, P64, DOI 10.1016/j.tcb.2012.10.006; Jabs J, 2017, MOL SYST BIOL, V13, DOI 10.15252/msb.20177697; Kang J, 2018, CANCER RES, V78, P1184, DOI 10.1158/0008-5472.CAN-17-2506; Kim B, 2013, AM J PHYSIOL-REG I, V305, pR927, DOI 10.1152/ajpregu.00502.2012; Kim B, 2017, ONCOTARGET, V8, P60299, DOI 10.18632/oncotarget.19140; Kim B, 2017, CANCER RES TREAT, V49, P338, DOI 10.4143/crt.2016.175; Kim S, 2018, NPJ PRECIS ONCOL, V2, DOI 10.1038/s41698-018-0063-0; Kim S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31097-y; Kong B, 2015, ANN NY ACAD SCI, V1350, P1, DOI 10.1111/nyas.12883; Lee JH, 2012, J BIOL CHEM, V287, P20898, DOI 10.1074/jbc.M111.336875; Lee JY, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1077-4; Li PY, 2016, SCI REP-UK, V6, DOI 10.1038/srep22831; Matz M, 2017, GYNECOL ONCOL, V144, P396, DOI 10.1016/j.ygyno.2016.11.019; Oettinghaus B, 2016, BBA-BIOENERGETICS, V1857, P1267, DOI 10.1016/j.bbabio.2016.03.016; Otera H, 2016, J CELL BIOL, V212, P531, DOI 10.1083/jcb.201508099; Panieri E, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.105; Park HK, 2017, CANCER EPIDEM BIOMAR, V26, P1511, DOI 10.1158/1055-9965.EPI-17-0290; Parone PA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003257; Pletjushkina OY, 2006, BBA-BIOENERGETICS, V1757, P518, DOI 10.1016/j.bbabio.2006.03.018; Ren YA, 2016, CANCER RES, V76, P2206, DOI 10.1158/0008-5472.CAN-15-1046; Seo JA, 2016, CANCER LETT, V371, P30, DOI 10.1016/j.canlet.2015.11.021; Shen YL, 2018, INT J MOL MED, V41, P2317, DOI 10.3892/ijmm.2018.3385; Soragni A, 2016, CANCER CELL, V29, P90, DOI 10.1016/j.ccell.2015.12.002; Taguchi N, 2007, J BIOL CHEM, V282, P11521, DOI 10.1074/jbc.M607279200; Turco MY, 2017, NAT CELL BIOL, V19, P568, DOI 10.1038/ncb3516; Wan YY, 2014, ONCOL REP, V32, P619, DOI 10.3892/or.2014.3235; Xie Q, 2015, NAT NEUROSCI, V18, P501, DOI 10.1038/nn.3960; Xu SC, 2016, J PINEAL RES, V60, P291, DOI 10.1111/jpi.12310; Zhang D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197266	53	77	78	3	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2019	38	45					7089	7105		10.1038/s41388-019-0949-5	http://dx.doi.org/10.1038/s41388-019-0949-5			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JL9XI	31409904				2022-12-28	WOS:000495878400005
J	Hu, X; Xiang, DX; Xie, Y; Tao, LW; Zhang, Y; Jin, Y; Pinello, L; Wan, YZ; Yuan, GC; Li, Z				Hu, Xin; Xiang, Dongxi; Xie, Ying; Tao, Luwei; Zhang, Yu; Jin, Yue; Pinello, Luca; Wan, Youzhong; Yuan, Guo-Cheng; Li, Zhe			LSD1 suppresses invasion, migration and metastasis of luminal breast cancer cells via activation of GATA3 and repression of TRIM37 expression	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; MOLECULAR PORTRAITS; MAMMARY-GLAND; DIFFERENTIATION; DEMETHYLATION; INHIBITION; PROGRAMS; TARGETS; GENOME; EMT	LSD1 (KDM1A) is a histone demethylase that plays both oncogenic and tumor suppressor roles in breast cancer. However, the exact contexts under which it plays these opposite functions remain largely elusive. By characterizing its role in luminal breast epithelial cells, here we show that inhibition of LSD1 by both genetic and pharmacological approaches increases their invasion and migration, whereas its inhibition by genetic approach, but not by pharmacological approach, impairs their proliferation/survival. Induced loss of LSD1 in luminal cells in a mouse model of luminal breast cancer, MMTV-PyMT, leads to a profound increase in lung metastasis. Mechanistically, LSD1 interacts with GATA3, a key luminal-specific transcription factor (TF), and their common target genes are highly related to breast cancer. LSD1 positively regulates GATA3 expression. It also represses expression of TRIM37, a breast epithelial oncogene encoding a histone H2A ubiquitin ligase, and ELF5, a key TF gene for luminal progenitors and alveolar luminal cells. LSD1-loss also leads to reduced expression of several cell-cell adhesion genes (e.g., CDH1, VCL, CTNNA1), possibly via TRIM37-upregulation and subsequently TRIM37-mediated repression. Collectively, our data suggest LSD1 largely plays a tumor suppressor role in luminal breast cancer and the oncogenic program associated with LSD1-inhibition may be suppressed via TRIM37-inhibition.	[Hu, Xin; Zhang, Yu; Jin, Yue; Wan, Youzhong] Jilin Univ, Sch Life Sci, Changchun, Jilin, Peoples R China; [Hu, Xin; Xiang, Dongxi; Xie, Ying; Tao, Luwei; Li, Zhe] Harvard Med Sch, Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA; [Hu, Xin; Xiang, Dongxi; Xie, Ying; Tao, Luwei; Li, Zhe] Harvard Med Sch, Dept Med, Boston, MA 02115 USA; [Pinello, Luca; Yuan, Guo-Cheng] Harvard Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostatist & Computat Biol, Boston, MA 02115 USA	Jilin University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard T.H. Chan School of Public Health	Li, Z (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA.; Li, Z (corresponding author), Harvard Med Sch, Dept Med, Boston, MA 02115 USA.	zli4@rics.bwh.harvard.edu		HU, XIN/0000-0002-5105-8929; Li, Zhe/0000-0002-3434-0885	U.S. Department of Defense [W81XWH-15-1-0100]; NCI/NIH [SG-0062-10, CA126980, CA222560]; Harvard Stem Cell Institute [DP-0137-13-00]; Brigham and Women's Hospital; National Natural Science Foundation of China [NSFC31471356]; Jilin Province Science and Technology Development Project [20180101240JC, 20190701005GH]; NATIONAL CANCER INSTITUTE [R01CA222560] Funding Source: NIH RePORTER	U.S. Department of Defense(United States Department of Defense); NCI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Harvard Stem Cell Institute; Brigham and Women's Hospital; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jilin Province Science and Technology Development Project; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr. Stuart Orkin for the Lsd1<SUP>L/L</SUP> conditional knockout mouse line, and Drs. Alan Cantor, Hui Huang, and Andrew Woo (Boston Children's Hospital) for help with gel filtration chromatography. This research was supported by Breakthrough Award from U.S. Department of Defense (W81XWH-15-1-0100), Pathway-to-Independence K99/R00 grant (CA126980) and R01 grant (CA222560) from NCI/NIH, Seed Grant (SG-0062-10) and Cancer Program Pilot Grant (DP-0137-13-00) from Harvard Stem Cell Institute, and Start-up Fund from Brigham and Women's Hospital to ZL. This work was also supported by National Natural Science Foundation of China (NSFC31471356) and Jilin Province Science and Technology Development Project (20180101240JC, 20190701005GH) to XH.	Ahuja N, 2014, J CLIN INVEST, V124, P56, DOI 10.1172/JCI69736; Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Asselin-Labat ML, 2011, MOL CELL BIOL, V31, P4609, DOI 10.1128/MCB.05766-11; Benner C, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003906; Bhatnagar S, 2014, NATURE, V516, P116, DOI 10.1038/nature13955; Choi HJ, 2015, EMBO REP, V16, P1288, DOI 10.15252/embr.201540244; Choi YS, 2009, DEV BIOL, V329, P227, DOI 10.1016/j.ydbio.2009.02.032; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; Feng JX, 2016, BREAST CANCER RES TR, V159, P443, DOI 10.1007/s10549-016-3959-9; Gallego-Ortega D, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002330; Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038; Hu X, 2009, P NATL ACAD SCI USA, V106, P10141, DOI 10.1073/pnas.0900437106; Huang J, 2007, NATURE, V449, P105, DOI 10.1038/nature06092; Huang Y, 2012, BREAST CANCER RES TR, V131, P777, DOI 10.1007/s10549-011-1480-8; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kouros-Mehr H, 2008, CANCER CELL, V13, P141, DOI 10.1016/j.ccr.2008.01.011; Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Lee JY, 2014, ONCOGENE, V33, P1325, DOI 10.1038/onc.2013.53; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Li Q, 2011, CANCER RES, V71, P6899, DOI 10.1158/0008-5472.CAN-11-1523; Lim E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2560; Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324; Lin YW, 2010, EMBO J, V29, P1803, DOI 10.1038/emboj.2010.63; Lynch JT, 2012, EXPERT OPIN THER TAR, V16, P1239, DOI 10.1517/14728222.2012.722206; Maes T, 2018, CANCER CELL, V33, P495, DOI 10.1016/j.ccell.2018.02.002; McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Mould DP, 2015, MED RES REV, V35, P586, DOI 10.1002/med.21334; Oakes SR, 2008, GENE DEV, V22, P581, DOI 10.1101/gad.1614608; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Serce N, 2012, BMC CLIN PATHOL, V12, DOI 10.1186/1472-6890-12-13; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shen H, 2013, CELL, V153, P38, DOI 10.1016/j.cell.2013.03.008; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Si WZ, 2015, CANCER CELL, V27, P822, DOI 10.1016/j.ccell.2015.04.011; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tao LW, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14431; Tao LW, 2015, STEM CELL REP, V5, P60, DOI 10.1016/j.stemcr.2015.05.014; Tao LW, 2014, STEM CELL REP, V2, P770, DOI 10.1016/j.stemcr.2014.04.004; Wang J, 2009, NAT GENET, V41, P125, DOI 10.1038/ng.268; Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050; Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546; Woo AJ, 2008, MOL CELL BIOL, V28, P2675, DOI 10.1128/MCB.01945-07; Wu YD, 2013, CELL REP, V5, P224, DOI 10.1016/j.celrep.2013.08.030; Wu ZQ, 2012, P NATL ACAD SCI USA, V109, P16654, DOI 10.1073/pnas.1205822109; Yan W, 2010, J BIOL CHEM, V285, P14042, DOI 10.1074/jbc.M110.105262; Zhang XM, 2013, CELL REP, V5, P445, DOI 10.1016/j.celrep.2013.09.018; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	53	35	35	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2019	38	44					7017	7034		10.1038/s41388-019-0923-2	http://dx.doi.org/10.1038/s41388-019-0923-2			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ1AO	31409898	Green Accepted			2022-12-28	WOS:000493892900005
J	Mongiardi, MP; Radice, G; Piras, M; Stagni, V; Pacioni, S; Re, A; Putti, S; Ferre, F; Farsetti, A; Pallini, R; Barila, D; Levi, A; Falchetti, ML				Mongiardi, Maria Patrizia; Radice, Giulia; Piras, Maurizia; Stagni, Venturina; Pacioni, Simone; Re, Agnese; Putti, Sabrina; Ferre, Fabrizio; Farsetti, Antonella; Pallini, Roberto; Barila, Daniela; Levi, Andrea; Falchetti, Maria Laura			Axitinib exposure triggers endothelial cells senescence through ROS accumulation and ATM activation	ONCOGENE			English	Article							RECEPTOR TYROSINE KINASES; GROWTH-FACTOR; INHIBITOR; AG-013736; ANTIANGIOGENESIS; ANGIOGENESIS; SECRETION; TARGET; LINES; P53	Inhibitors of Vascular Endothelial Growth Factor target both tumor vasculature and cancer cells that have hijacked VEGF Receptors (VEGFRs) signaling for tumor growth-promoting activities. It is important to get precise insight in the specificity of cell responses to these antiangiogenic drugs to maximize their efficiency and minimize off-target systemic toxicity. Here we report that Axitinib, an inhibitor of VEGFRs currently in use as a second line treatment for advanced renal cell carcinoma, promotes senescence of human endothelial cells in vitro. A one-hour pulse of Axitinib is sufficient for triggering cell senescence. Mechanistically, this requires oxidative stress-dependent activation of the Ataxia Telangiectasia Mutated (ATM) kinase. Axitinib-mediated senescence promoting action is prevented by short-term treatment with antioxidants or ATM inhibitors, which conversely fail to prevent senescence induced by the DNA-damaging drug doxorubicin. Coherently, induction of oxidative stress-related genes distinguishes the response of endothelial cells to Axitinib from that to doxorubicin. Importantly, an Axitinib pulse causes cell senescence in glioblastoma cells. However, neither antioxidants nor ATM inhibitors can reverse this phenotype. Thus, antioxidants may selectively protect endothelial cells from Axitinib by decreasing systemic toxicity and maintaining a functional vascularization necessary for efficient delivery of chemotherapeutic drugs within the tumor mass.	[Mongiardi, Maria Patrizia; Radice, Giulia; Piras, Maurizia; Pacioni, Simone; Re, Agnese; Putti, Sabrina; Farsetti, Antonella; Levi, Andrea; Falchetti, Maria Laura] CNR, Inst Cell Biol & Neurobiol, Rome, Italy; [Stagni, Venturina; Barila, Daniela] Univ Roma Tor Vergata, Dept Biol, Rome, Italy; [Stagni, Venturina; Barila, Daniela] Ist Ricovero & Cura Carattere Sci IRCCS Fdn Santa, Lab Cell Signaling, Rome, Italy; [Pacioni, Simone; Pallini, Roberto] Fdn Policlin Univ A Gemelli, Inst Neurosurg, Rome, Italy; [Ferre, Fabrizio] Univ Bologna Alma Mater, Dept Pharm & Biotechnol, I-40126 Bologna, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia Cellulare e Neurobiologia (IBCN-CNR); University of Rome Tor Vergata; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Bologna	Farsetti, A; Falchetti, ML (corresponding author), CNR, Inst Cell Biol & Neurobiol, Rome, Italy.	antonella.farsetti@cnr.it; marialaura.falchetti@cnr.it	falchetti, maria laura/AAA-5586-2019; Pallini, Roberto/AAA-3760-2019; PALLINI, Roberto/AAA-3747-2019; Farsetti, Antonella/I-8710-2018; Mongiardi, Maria Patrizia/AAA-4668-2019; BARILA', DANIELA/K-8506-2016; PUTTI, SABRINA/H-2574-2019	PALLINI, Roberto/0000-0002-4611-8827; Farsetti, Antonella/0000-0002-8603-7925; mongiardi, maria patrizia/0000-0002-5578-1751; BARILA', DANIELA/0000-0002-6192-1562; PUTTI, SABRINA/0000-0003-3335-043X; stagni, venturina/0000-0002-3971-0398	MIUR-CNR Flagship Invecchiamento [DSB.AD009.001.004]; Associazione Italiana per la Ricerca sul Cancro-AIRC IG2016 [19069]; MIUR-JPI HDHL NUTRICOG MiTyrAge [PRIN_2015LZE9944_005, RF-2016-02362022]; AIRC IG2016 [19069];  [RF-2016-02363460]	MIUR-CNR Flagship Invecchiamento; Associazione Italiana per la Ricerca sul Cancro-AIRC IG2016(Fondazione AIRC per la ricerca sul cancro); MIUR-JPI HDHL NUTRICOG MiTyrAge; AIRC IG2016(Fondazione AIRC per la ricerca sul cancro); 	The study was supported by research grants from: MIUR-CNR Flagship Invecchiamento #DSB.AD009.001.004 to AL and MLF; Associazione Italiana per la Ricerca sul Cancro-AIRC IG2016-n.19069, MIUR-JPI HDHL NUTRICOG MiTyrAge, PRIN_2015LZE9944_005 and RF-2016-02362022 to DB; by RF-2016-02363460 to VS. VS has also been supported by AIRC IG2016-n.19069. We thank Dr Silvia Soddu and Prof Carlo Gaetano for their suggestions on p53 protein detection and ROS measurement, respectively.	Amantini C, 2016, ONCOTARGET, V7, P50180, DOI 10.18632/oncotarget.10326; Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Bellesoeur A, 2017, DRUG DES DEV THER, V11, P2801, DOI 10.2147/DDDT.S109640; Bonello-Palot N, 2014, ATHEROSCLEROSIS, V237, P45, DOI 10.1016/j.atherosclerosis.2014.08.036; Chang MWF, 2005, EXP CELL RES, V309, P121, DOI 10.1016/j.yexcr.2005.05.002; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Davalli P, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3565127; Demaria M, 2017, CANCER DISCOV, V7, P165, DOI 10.1158/2159-8290.CD-16-0241; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Elmore LW, 2002, J BIOL CHEM, V277, P35509, DOI 10.1074/jbc.M205477200; Ewald JA, 2010, JNCI-J NATL CANCER I, V102, P1536, DOI 10.1093/jnci/djq364; Ferrara N, 2004, ONCOLOGIST, V9, P2, DOI 10.1634/theoncologist.9-suppl_1-2; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Freund A, 2012, MOL BIOL CELL, V23, P2066, DOI 10.1091/mbc.E11-10-0884; Goel HL, 2013, NAT REV CANCER, V13, P871, DOI 10.1038/nrc3627; Guo Z, 2010, SCIENCE, V330, P517, DOI 10.1126/science.1192912; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; He SH, 2017, CELL, V169, P1000, DOI 10.1016/j.cell.2017.05.015; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Hovinga KE, 2005, J NEURO-ONCOL, V74, P99, DOI 10.1007/s11060-004-4204-7; Hu-Lowe DD, 2008, CLIN CANCER RES, V14, P7272, DOI 10.1158/1078-0432.CCR-08-0652; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Kang HT, 2017, NAT CHEM BIOL, V13, P616, DOI 10.1038/nchembio.2342; Klaeger S, 2017, SCIENCE, V358, DOI 10.1126/science.aan4368; Lenain C, 2015, CARCINOGENESIS, V36, P1263, DOI 10.1093/carcin/bgv124; Liang YX, 2002, J BIOL CHEM, V277, P20087, DOI 10.1074/jbc.M201766200; Menendez D, 2007, MOL CELL BIOL, V27, P2590, DOI 10.1128/MCB.01742-06; Morelli MB, 2015, ONCOTARGET, V6, P36245, DOI 10.18632/oncotarget.5768; Nair RR, 2015, J CELL SCI, V128, P342, DOI 10.1242/jcs.159517; Passos JF, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.5; Pawlikowski JS, 2013, J CELL SCI, V126, P4061, DOI 10.1242/jcs.109728; Perrigue PM, 2015, MOL CANCER RES, V13, P636, DOI 10.1158/1541-7786.MCR-13-0268; Przybylska D, 2016, ONCOTARGET, V7, P66429, DOI 10.18632/oncotarget.12079; Rugo HS, 2005, J CLIN ONCOL, V23, P5474, DOI 10.1200/JCO.2005.04.192; Song YS, 2005, MECH AGEING DEV, V126, P580, DOI 10.1016/j.mad.2004.11.008; Welti J, 2013, J CLIN INVEST, V123, P3190, DOI 10.1172/JCI70212; White RR, 2016, MOL CELL, V63, P729, DOI 10.1016/j.molcel.2016.08.004; Wilmes LJ, 2007, MAGN RESON IMAGING, V25, P319, DOI 10.1016/j.mri.2006.09.041	39	24	25	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2019	38	27					5413	5424		10.1038/s41388-019-0798-2	http://dx.doi.org/10.1038/s41388-019-0798-2			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IG5KR	30967634				2022-12-28	WOS:000473842500006
J	Wang, YC; Li, X; Liu, W; Li, BJ; Chen, DQ; Hu, FP; Wang, LZ; Liu, XGM; Cui, RJ; Liu, RH				Wang, Yicun; Li, Xin; Liu, Wei; Li, Bingjin; Chen, Dongquan; Hu, Fengping; Wang, Lizhong; Liu, Xiaoguang M.; Cui, Ranji; Liu, Runhua			MicroRNA-1205, encoded on chromosome 8q24, targets EGLN3 to induce cell growth and contributes to risk of castration-resistant prostate cancer	ONCOGENE			English	Article							GENOME-WIDE ASSOCIATION; LONG-RANGE INTERACTION; IN-SITU HYBRIDIZATION; PROLYL HYDROXYLASE; NEURONAL APOPTOSIS; C-MYC; PROMOTES; BREAST; EXPRESSION; GENES	The chromosome 8q24.21 locus, which contains the proto-oncogene c-MYC, long non-coding RNA PVT1, and microRNAs (miRs), is the most commonly amplified region in human prostate cancer. A long-range interaction of genetic variants with c-MYC or long non-coding PVT1 at this locus contributes to the genetic risk of prostate cancer. At this locus is a cluster of genes for six miRs (miR-1204, -1205, -1206, -1207-3p, -1207-5p, and -1208), but their functional role remains elusive. Here the copy numbers and expression levels of miRs-1204-1208 were investigated using quantitative PCR for prostate cancer cell lines and primary tumors. The data revealed that copy numbers and expression of miR-1205 were increased in both castration-resistant prostate cancer cell lines and in primary tumors. In castration-resistant prostate cancer specimens, the copy number at the miR-1205 locus correlated with the expression of miR-1205. Furthermore, functional analysis with an miR-1205 mimic, an miR-1205 inhibitor, and CRISPR/Cas9 knockout revealed that, in human prostate cancer cells, miR-1205 promoted cell proliferation and cell cycle progression and inhibited hydrogen peroxide-induced apoptosis. In these cells, miR-1205 downregulated the expression of the Egl-9 family hypoxia inducible factor 3(EGLN3) gene and targeted a site in its 3'-untranslated region to downregulate its transcriptional activity. Thus, by targeting EGLN3, miR-1205 has an oncogenic role and may contribute to the genetic risk of castration-resistant prostate cancer.	[Wang, Yicun; Li, Xin; Liu, Wei; Li, Bingjin; Cui, Ranji] Jilin Univ, Prov Key Lab Mol & Chem Genet, Hosp 2, Changchun, Jilin, Peoples R China; [Wang, Yicun; Li, Xin; Liu, Wei; Hu, Fengping; Wang, Lizhong; Liu, Runhua] Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA; [Chen, Dongquan] Univ Alabama Birmingham, Div Prevent Med, Birmingham, AL USA; [Chen, Dongquan; Wang, Lizhong; Liu, Runhua] Univ Alabama Birmingham, Comprehens Canc Ctr, Birmingham, AL 35294 USA; [Liu, Xiaoguang M.] Univ Alabama Birmingham, Dept Biomed Engn, Birmingham, AL USA	Jilin University; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Cui, RJ (corresponding author), Jilin Univ, Prov Key Lab Mol & Chem Genet, Hosp 2, Changchun, Jilin, Peoples R China.; Liu, RH (corresponding author), Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA.; Liu, RH (corresponding author), Univ Alabama Birmingham, Comprehens Canc Ctr, Birmingham, AL 35294 USA.	cuiranji@jlu.edu.cn; runhua@uab.edu	cui, ranji/AAV-6234-2021	Wang, Yicun/0000-0001-6497-3387; Liu, Xiaoguang (Margaret)/0000-0002-4617-9750	National Institutes of Health/National Cancer Institute [CA118948, CA179282, CA013148]; Department of Defense [BC160808, PC130594, PC140308]; Mike Slive Foundation for Prostate Cancer Research; Natural Science Foundation of China [31571126, 31571342, 81772757]; NATIONAL CANCER INSTITUTE [P30CA013148, U54CA118638, U54CA118948] Funding Source: NIH RePORTER	National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defense(United States Department of Defense); Mike Slive Foundation for Prostate Cancer Research; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr. Donald L Hill for editorial assistance in preparing this manuscript. This work was supported by grants from the National Institutes of Health/National Cancer Institute (CA118948, CA179282, and CA013148 to LW and RL), the Department of Defense (BC160808, PC130594, and PC140308 to LW and RL), the Mike Slive Foundation for Prostate Cancer Research (to LW), and the Natural Science Foundation of China (Nos. 31571126, 31571342, and 81772757 to XL, BL, and RC). Results are based, in part, on data generated by the TCGA Research Network: http://ca ncergenome. nih. gov/.	Ahmadiyeh N, 2010, P NATL ACAD SCI USA, V107, P9742, DOI 10.1073/pnas.0910668107; [Anonymous], 2018, CANCER DISCOV, V8, pOF15; Bae S, 2014, BIOINFORMATICS, V30, P1473, DOI 10.1093/bioinformatics/btu048; Barsotti AM, 2012, J BIOL CHEM, V287, P2509, DOI 10.1074/jbc.M111.322875; Bawa P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122143; Beck-Engeser GB, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-4; CHER ML, 1994, GENE CHROMOSOME CANC, V11, P153, DOI 10.1002/gcc.2870110304; Cho SW, 2018, CELL, V173, P1398, DOI 10.1016/j.cell.2018.03.068; Das DK, 2016, EXP CELL RES, V348, P190, DOI 10.1016/j.yexcr.2016.09.021; Eeles RA, 2008, NAT GENET, V40, P316, DOI 10.1038/ng.90; Fu J, 2013, MOL CELL BIOL, V33, P3050, DOI 10.1128/MCB.00273-13; Gao S, 2017, ONCOTARGET, V8, P41451, DOI 10.18632/oncotarget.17816; Garvalov BK, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6577; Gerber SA, 2009, ARTERIOSCL THROM VAS, V29, P1363, DOI 10.1161/ATVBAHA.109.192542; Gudmundsson J, 2007, NAT GENET, V39, P631, DOI 10.1038/ng1999; Henze AT, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6582; Hogel H, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0410-5; Hogel H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027112; Huppi K, 2008, MOL CANCER RES, V6, P212, DOI 10.1158/1541-7786.MCR-07-0105; Huppi Konrad, 2012, Frontiers in Genetics, V3, P69, DOI 10.3389/fgene.2012.00069; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kim T, 2014, P NATL ACAD SCI USA, V111, P4173, DOI 10.1073/pnas.1400350111; Lapointe J, 2007, CANCER RES, V67, P8504, DOI 10.1158/0008-5472.CAN-07-0673; Lee S, 2005, CANCER CELL, V8, P155, DOI 10.1016/j.ccr.2005.06.015; Lipscomb EA, 1999, J NEUROCHEM, V73, P429, DOI 10.1046/j.1471-4159.1999.0730429.x; Liu RH, 2015, CANCER RES, V75, P1714, DOI 10.1158/0008-5472.CAN-14-2109; Liu RH, 2015, CANCER RES, V75, P1703, DOI 10.1158/0008-5472.CAN-14-2108; Liu RH, 2009, CANCER RES, V69, P2252, DOI 10.1158/0008-5472.CAN-08-3717; Liu XY, 2018, ONCOGENE, V37, P3426, DOI 10.1038/s41388-018-0215-2; Luo WB, 2014, MOL BIOL CELL, V25, P2788, DOI 10.1091/mbc.E14-02-0775; Luo YZ, 2018, J CANCER, V9, P1096, DOI 10.7150/jca.23909; Ma Lijiang, 2014, Curr Protoc Hum Genet, V80, DOI 10.1002/0471142905.hg0721s80; Madden SL, 1996, CANCER RES, V56, P5384; Meyer KB, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002165; Min H, 2010, EXP MOL MED, V42, P233, DOI 10.3858/emm.2010.42.4.032; Peng XW, 2015, CANCER BIOL THER, V16, P261, DOI 10.1080/15384047.2014.1001287; Place TL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014617; Riquelme E, 2014, J THORAC ONCOL, V9, P998, DOI 10.1097/JTO.0000000000000202; Rodriguez J, 2018, CELL REP, V24, P1316, DOI 10.1016/j.celrep.2018.06.108; Sato H, 2006, INT J UROL, V13, P761, DOI 10.1111/j.1442-2042.2006.01399.x; Sato K, 1999, JNCI-J NATL CANCER I, V91, P1574, DOI 10.1093/jnci/91.18.1574; Schlisio S, 2009, J CELL MOL MED, V13, P4104, DOI 10.1111/j.1582-4934.2009.00881.x; Shi HL, 2015, ONCOL REP, V33, P1185, DOI 10.3892/or.2014.3695; Shi YX, 2017, MED SCI MONITOR, V23, P2042, DOI 10.12659/MSM.901191; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sotelo J, 2010, P NATL ACAD SCI USA, V107, P3001, DOI 10.1073/pnas.0906067107; Tang JM, 2018, ONCOGENE, V37, P4723, DOI 10.1038/s41388-018-0310-4; Thomas G, 2008, NAT GENET, V40, P310, DOI 10.1038/ng.91; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Tseng YY, 2014, NATURE, V512, P82, DOI 10.1038/nature13311; VANDENBERG C, 1995, CLIN CANCER RES, V1, P11; Vergara R, 2012, J EXP BOT, V63, P4123, DOI 10.1093/jxb/ers094; VISAKORPI T, 1995, CANCER RES, V55, P342; Wang LZ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6909; Wang LZ, 2009, CANCER CELL, V16, P336, DOI 10.1016/j.ccr.2009.08.016; Wasserman NF, 2010, GENOME RES, V20, P1191, DOI 10.1101/gr.105361.110; WEIJERMAN PC, 1994, CANCER RES, V54, P5579; Wong N, 2015, NUCLEIC ACIDS RES, V43, pD146, DOI 10.1093/nar/gku1104; Wu GY, 2015, ONCOTARGET, V6, P28882, DOI 10.18632/oncotarget.4921; Yan C, 2017, CANCER SCI, V108, P868, DOI 10.1111/cas.13212; Yeager M, 2007, NAT GENET, V39, P645, DOI 10.1038/ng2022; Zhang GX, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0858-x; Zhang W, 2016, CLIN CANCER RES, V22, P2545, DOI 10.1158/1078-0432.CCR-15-1927; Zhao J, 2018, ONCOGENE, V37, P4094, DOI 10.1038/s41388-018-0250-z	64	28	29	1	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2019	38	24					4820	4834		10.1038/s41388-019-0760-3	http://dx.doi.org/10.1038/s41388-019-0760-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IC7ND	30808975	Green Accepted			2022-12-28	WOS:000471160500012
J	Huang, JF; Jiang, HY; Cai, H; Liu, Y; Zhu, YQ; Lin, SS; Hu, TT; Wang, TT; Yang, WJ; Xiao, B; Sun, SH; Ma, LY; Yin, HR; Wang, F				Huang, Jin-Feng; Jiang, Hong-Yue; Cai, Hui; Liu, Yan; Zhu, Yi-Qing; Lin, Sha-Sha; Hu, Ting-Ting; Wang, Tian-Tian; Yang, Wen-Jun; Xiao, Bang; Sun, Shu-Han; Ma, Li-Ye; Yin, Hui-Rong; Wang, Fang			Genome-wide screening identifies oncofetal lncRNA Ptn-dt promoting the proliferation of hepatocellular carcinoma cells by regulating the Ptn receptor	ONCOGENE			English	Article							LONG NONCODING RNA; ANAPLASTIC LYMPHOMA KINASE; MESSENGER-RNA; FETAL LIVER; PROTEIN HUR; CANCER; PLEIOTROPHIN; EXPRESSION; GROWTH; BETA	Oncofetal genes are genes that express abundantly in both fetal and tumor tissues yet downregulated or undetected in adult tissues, and can be used as tumor markers for cancer diagnosis and treatment. Meanwhile, long noncoding RNAs (lncRNAs) are known to play crucial roles in the pathogenesis of hepatocellular carcinoma (HCC), including tumor growth, proliferation, metastasis, invasion, and recurrence. We performed a genome-wide screening using microarrays to detect the lncRNA expression profiles in fetal livers, adult livers, and liver cancer tissues from mice to identify oncofetal lncRNAs in HCC. From the microarray data analysis, we identified lncRNA Ptn-dt as a possible oncofetal gene. Both in vitro and in vivo experiments results confirmed that overexpression of Ptn-dt significantly promoted the proliferation of mouse HCC cells. RNA pulldown assay showed that Ptn-dt could interact with the HuR protein. Interestingly, miR-96 binds with HuR to maintain its stability as well. Overexpression of lncRNA Ptn-dt led to the downregulation of miR-96, which might be due to the interaction between Ptn-dt and HuR. Meanwhile, previous studies have reported that Ptn can promote tumor growth and vascular abnormalization via anaplastic lymphoma kinase (Alk) signaling. In our study, we found that overexpression of Ptn-dt could promote the expression of Alk through repressing miR-96 via interacting with HuR, thus enhancing the biologic function of Ptn. In summary, a new oncofetal lncRNA Ptn-dt is identified, and it can promote the proliferation of HCC cells by regulating the HuR/miR-96/Alk pathway and Ptn-Alk axis.	[Huang, Jin-Feng; Liu, Yan; Zhu, Yi-Qing; Wang, Tian-Tian; Yang, Wen-Jun; Xiao, Bang; Sun, Shu-Han; Wang, Fang] Second Mil Med Univ, Dept Med Genet, Shanghai 200433, Peoples R China; [Huang, Jin-Feng; Wang, Tian-Tian; Sun, Shu-Han; Wang, Fang] Second Mil Med Univ, Changhai Hosp, Dept Clin Genet, Shanghai 200433, Peoples R China; [Jiang, Hong-Yue] Fudan Univ, Zhongshan Hosp, Dept Gastroenterol, Shanghai 200032, Peoples R China; [Cai, Hui; Ma, Li-Ye] Second Mil Med Univ, Changhai Hosp, Dept Gen Surg, Shanghai 200433, Peoples R China; [Lin, Sha-Sha; Hu, Ting-Ting; Yin, Hui-Rong] Second Mil Med Univ, Changhai Hosp, Ctr Reprod Med, Shanghai 200433, Peoples R China	Naval Medical University; Naval Medical University; Fudan University; Naval Medical University; Naval Medical University	Wang, F (corresponding author), Second Mil Med Univ, Dept Med Genet, Shanghai 200433, Peoples R China.; Wang, F (corresponding author), Second Mil Med Univ, Changhai Hosp, Dept Clin Genet, Shanghai 200433, Peoples R China.; Ma, LY (corresponding author), Second Mil Med Univ, Changhai Hosp, Dept Gen Surg, Shanghai 200433, Peoples R China.; Yin, HR (corresponding author), Second Mil Med Univ, Changhai Hosp, Ctr Reprod Med, Shanghai 200433, Peoples R China.	malydr@163.com; topyin@126.com; wfsjz@163.com		, Jin-Feng/0000-0002-4757-3418; Jiang, Hongyue/0000-0001-8783-7759	National Key Basic Research Program (973 project) from the Ministry of Science and Technology of China [2015CB554004]; National Natural Science Foundation of China [81672775, 81330037]; Natural Science Foundation of Shanghai [15XD1504500]	National Key Basic Research Program (973 project) from the Ministry of Science and Technology of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai)	We thank Dr. Li Su for the help in flow cytometry technique, and the Institutional Animal Care and Use Committee (the Second Military Medical University, Shanghai, China) for the ethics approval of animal studies. Some elements of Fig. 6 are from LES LABORATOIRES SERVIER. This work was supported by grants from the National Key Basic Research Program (973 project) (2015CB554004) from the Ministry of Science and Technology of China, the National Natural Science Foundation of China (81672775 and 81330037) and the Natural Science Foundation of Shanghai (15XD1504500).	BECKER D, 2012, MOL CANCER, V11; BERGSTRAND CG, 1956, SCAND J CLIN LAB INV, V8, P174, DOI 10.3109/00365515609049266; Boyerinas B, 2008, CANCER RES, V68, P2587, DOI 10.1158/0008-5472.CAN-08-0264; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Cao CH, 2015, GASTROENTEROLOGY, V148, P415, DOI 10.1053/j.gastro.2014.10.012; Cooper C, 2009, NUCLEIC ACIDS RES, V37, P4518, DOI 10.1093/nar/gkp441; Coulouarn C, 2005, J HEPATOL, V42, P860, DOI 10.1016/j.jhep.2005.01.027; Filipowicz W, 2011, PROG DRUG RES, V67, P221, DOI 10.1007/978-3-7643-8989-5_11; Grzelinski M, 2009, NEOPLASIA, V11, P145, DOI 10.1593/neo.81040; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Hashiguchi Y, 2012, INT J ONCOL, V40, P1477, DOI 10.3892/ijo.2012.1363; Hu M, 2005, CANCER RES, V65, P8715, DOI 10.1158/0008-5472.CAN-05-0700; Huang JF, 2013, HEPATOLOGY, V57, P1882, DOI 10.1002/hep.26195; Iavarone M, 2015, HEPATOLOGY, V62, P784, DOI 10.1002/hep.27729; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kaur K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175471; Kong DS, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm121; Kotake Y, 2011, ONCOGENE, V30, P1956, DOI 10.1038/onc.2010.568; Koutsioumpa M, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0287-3; Liu HY, 2006, PLOS MED, V3, P1090, DOI 10.1371/journal.pmed.0030232; Ma YL, 2010, J CELL MOL MED, V14, P2697, DOI 10.1111/j.1582-4934.2010.01191.x; Majumdar A, 2012, NAT REV GASTRO HEPAT, V9, P530, DOI 10.1038/nrgastro.2012.114; Martens-Uzunova ES, 2014, EUR UROL, V65, P1140, DOI 10.1016/j.eururo.2013.12.003; Michelotti GA, 2016, GUT, V65, P683, DOI 10.1136/gutjnl-2014-308176; Papadimitriou E, 2009, EUR CYTOKINE NETW, V20, P180, DOI 10.1684/ecn.2009.0172; Park TJ, 2008, MOL CARCINOGEN, V47, P784, DOI 10.1002/mc.20438; Perez-Pinera P, 2008, CURR OPIN HEMATOL, V15, P210, DOI 10.1097/MOH.0b013e3282fdc69e; Powers C, 2002, J BIOL CHEM, V277, P14153, DOI 10.1074/jbc.M112354200; Prensner JR, 2011, NAT BIOTECHNOL, V29, P742, DOI 10.1038/nbt.1914; Quinn JJ, 2016, NAT REV GENET, V17, P47, DOI 10.1038/nrg.2015.10; Raveh E, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0458-2; Rosenfield SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047876; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Srikantan S, 2012, CURR PROTEIN PEPT SC, V13, P372, DOI 10.2174/138920312801619394; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; Venook AP, 2010, ONCOLOGIST, V15, P5, DOI 10.1634/theoncologist.2010-S4-05; Vishwamitra D, 2012, AM J PATHOL, V180, P1772, DOI 10.1016/j.ajpath.2012.01.008; Wang F, 2014, HEPATOLOGY, V60, P1278, DOI 10.1002/hep.27239; Wang L, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt006; Wang SB, 2016, FEBS LETT, V590, P559, DOI 10.1002/1873-3468.12078; Wilusz CJ, 2012, MOL CELL, V47, P495, DOI 10.1016/j.molcel.2012.08.005; Xu D, 2013, HEPATOLOGY, V58, P739, DOI 10.1002/hep.26361; Xu F, 2010, J CELL BIOCHEM, V111, P727, DOI 10.1002/jcb.22762; Yamauchi N, 2005, MODERN PATHOL, V18, P1591, DOI 10.1038/modpathol.3800436; Yong KJ, 2013, NEW ENGL J MED, V368, P2266, DOI 10.1056/NEJMoa1300297; Yoon JH, 2012, MOL CELL, V47, P648, DOI 10.1016/j.molcel.2012.06.027; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010; Zhang L, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2016.1141087; Zhang YM, 2015, INT J CLIN EXP MED, V8, P11683; Zheng L, 2014, TUMOR BIOL, V35, P4095, DOI 10.1007/s13277-013-1535-z	51	17	17	0	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2019	38	18					3428	3445		10.1038/s41388-018-0643-z	http://dx.doi.org/10.1038/s41388-018-0643-z			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HW3RI	30643194				2022-12-28	WOS:000466610000008
J	Wang, C; Wang, G; Feng, X; Shepherd, P; Zhang, J; Tang, MF; Chen, Z; Srivastava, M; McLaughlin, ME; Navone, NM; Hart, GT; Chen, JJ				Wang, Chao; Wang, Gang; Feng, Xu; Shepherd, Peter; Zhang, Jie; Tang, Mengfan; Chen, Zhen; Srivastava, Mrinal; McLaughlin, Megan E.; Navone, Nora M.; Hart, Glen Traver; Chen, Junjie			Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition	ONCOGENE			English	Article							AICARDI-GOUTIERES-SYNDROME; CANCER-CELLS; REPLICATION STRESS; PROTEIN-KINASE; DNA-DAMAGE; H2; MUTATIONS; SENSITIVITY; PATHWAY; LEADS	Ataxia telangiectasia mutated and RAD3 related (ATR) protein kinase plays critical roles in ensuring DNA replication, DNA repair, and cell cycle control in response to replication stress, making ATR inhibition a promising therapeutic strategy for cancer treatment. To identify genes whose loss makes tumor cells hypersensitive to ATR inhibition, we performed CRISPR/ Cas9-based whole-genome screens in 3 independent cell lines treated with a highly selective ATR inhibitor, AZD6738. These screens uncovered a comprehensive genome-wide profile of ATR inhibitor sensitivity. From the candidate genes, we demonstrated that RNASEH2 deficiency is synthetic lethal with ATR inhibition both in vitro and in vivo. RNASEH2-deficient cells exhibited elevated levels of DNA damage and, when treated with AZD6738, underwent apoptosis (short-time treated) or senescence (long-time treated). Notably, RNASEH2 deficiency is frequently found in prostate adenocarcinoma; we found decreased RNASEH2B protein levels in prostate adenocarcinoma patient-derived xenograft (PDX) samples. Our findings suggest that ATR inhibition may be beneficial for cancer patients with reduced levels of RNASEH2 and that RNASEH2 merits further exploration as a potential biomarker for ATR inhibitor-based therapy.	[Wang, Chao; Feng, Xu; Zhang, Jie; Tang, Mengfan; Chen, Zhen; Srivastava, Mrinal; Chen, Junjie] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; [Wang, Gang; McLaughlin, Megan E.; Hart, Glen Traver] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Shepherd, Peter; Navone, Nora M.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Chen, JJ (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA.	jchen8@mdanderson.org	Srivastava, Mrinal/AAM-5013-2020	Wang, Andy/0000-0001-6798-1032; Feng, Xu/0000-0003-1603-7070; Wang, Chao/0000-0001-6191-5261	CPRIT [RP160667]; NIH [CA157448, CA193124, CA210929, CA216911, CA216437]; MD Anderson's NIH Cancer Center Support Grant [CA016672]; NATIONAL CANCER INSTITUTE [R01CA216911, R01CA216437, P01CA193124, P30CA016672, R01CA157448, P01CA160032, R01CA210929] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R35GM130119] Funding Source: NIH RePORTER	CPRIT; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MD Anderson's NIH Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the members of Dr. Junjie Chen's lab for their kind help and Dr. Lei Li for his suggestions regarding the experimental design. We also thank Amy Ninetto from the Department of Scientific Publications at MD Anderson for editing the manuscript. This work was supported in part by CPRIT (RP160667) and NIH grants (CA157448, CA193124, CA210929, CA216911, and CA216437) to JC and MD Anderson's NIH Cancer Center Support Grant (CA016672).	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Bartsch K, 2017, HUM MOL GENET, V26, P3960, DOI 10.1093/hmg/ddx283; Brown EJ, 2000, GENE DEV, V14, P397; Charrier JD, 2011, J MED CHEM, V54, P2320, DOI 10.1021/jm101488z; Checkley S, 2015, SCI REP-UK, V5, DOI 10.1038/srep13545; Chon H, 2013, NUCLEIC ACIDS RES, V41, P3130, DOI 10.1093/nar/gkt027; Crow YJ, 2006, NAT GENET, V38, P910, DOI 10.1038/ng1842; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; Fokas E, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.181; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Guichard SM, 2013, CANCER RES, V73, DOI 10.1158/1538-7445.AM2013-3343; Hall AB, 2014, ONCOTARGET, V5, P5674, DOI 10.18632/oncotarget.2158; Hart T, 2017, G3-GENES GENOM GENET, V7, P2719, DOI 10.1534/g3.117.041277; Hart T, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-1015-8; Hart T, 2015, CELL, V163, DOI 10.1016/j.cell.2015.11.015; Hart T, 2014, MOL SYST BIOL, V10, DOI 10.15252/msb.20145216; He T, 2017, EPIGENOMICS-UK, V9, P849, DOI 10.2217/epi-2017-0019; Hiller B, 2012, J EXP MED, V209, P1419, DOI 10.1084/jem.20120876; Huang SD, 2012, CELL, V151, P937, DOI 10.1016/j.cell.2012.10.035; Keszthelyi A, 2016, GENES-BASEL, V7, DOI 10.3390/genes7120134; Kim H, 2017, CLIN CANCER RES, V23, P3097, DOI 10.1158/1078-0432.CCR-16-2273; Kim H, 2016, CLIN CANCER RES, V22, DOI 10.1158/1557-3265.OVCA15-A08; Kumar A, 2016, NAT MED, V22, P369, DOI 10.1038/nm.4053; Kwok M, 2016, BLOOD, V127, P582, DOI 10.1182/blood-2015-05-644872; Li T, 2018, J EXP MED, V215, P1287, DOI 10.1084/jem.20180139; Mackenzie KJ, 2016, EMBO J, V35, P831, DOI 10.15252/embj.201593339; McElhinny SAN, 2010, NAT CHEM BIOL, V6, P774, DOI [10.1038/NCHEMBIO.424, 10.1038/nchembio.424]; Mohni KN, 2014, CANCER RES, V74, P2835, DOI 10.1158/0008-5472.CAN-13-3229; Mu YH, 2016, EMBO REP, V17, P94, DOI 10.15252/embr.201540964; Pendergraft WF, 2015, J CLIN INVEST, V125, P102, DOI 10.1172/JCI78533; Perrino FW, 2009, J MOL MED-JMM, V87, P25, DOI 10.1007/s00109-008-0422-3; Pizzi S, 2015, HUM MOL GENET, V24, P649, DOI 10.1093/hmg/ddu485; Pokatayev V, 2016, J EXP MED, V213, P329, DOI 10.1084/jem.20151464; Prevo R, 2012, CANCER BIOL THER, V13, P1072, DOI 10.4161/cbt.21093; Reaper PM, 2011, NAT CHEM BIOL, V7, P428, DOI [10.1038/NCHEMBIO.573, 10.1038/nchembio.573]; Reijns MAM, 2012, CELL, V149, DOI 10.1016/j.cell.2012.04.011; Rice GI, 2013, HUM MUTAT, V34, P1066, DOI 10.1002/humu.22336; Robinson D, 2015, CELL, V162, P454, DOI 10.1016/j.cell.2015.06.053; Ruiz S, 2016, MOL CELL, V62, P307, DOI 10.1016/j.molcel.2016.03.006; Rundle S, 2017, CANCERS, V9, DOI 10.3390/cancers9050041; Saldivar JC, 2017, NAT REV MOL CELL BIO, V18, P622, DOI 10.1038/nrm.2017.67; Sidik SM, 2016, CELL, V166, P1423, DOI 10.1016/j.cell.2016.08.019; Steinhart Z, 2017, NAT MED, V23, P60, DOI 10.1038/nm.4219; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Techer H, 2017, NAT REV GENET, V18, P535, DOI 10.1038/nrg.2017.46; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Williams JS, 2017, DNA REPAIR, V53, P52, DOI 10.1016/j.dnarep.2017.02.016; Williamson CT, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13837; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; Yang H, 2017, P NATL ACAD SCI USA, V114, pE4612, DOI 10.1073/pnas.1705499114; Zeman MK, 2014, NAT CELL BIOL, V16, P2, DOI 10.1038/ncb2897; Zhu SY, 2017, METHODS MOL BIOL, V1656, P175, DOI 10.1007/978-1-4939-7237-1_11; Zimmermann M, 2018, NATURE, V559, P285, DOI 10.1038/s41586-018-0291-z	54	64	64	3	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2019	38	14					2451	2463		10.1038/s41388-018-0606-4	http://dx.doi.org/10.1038/s41388-018-0606-4			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HR7LI	30532030	Green Accepted			2022-12-28	WOS:000463335200002
J	Vantaku, V; Putluri, V; Bader, DA; Maity, S; Ma, J; Arnold, JM; Rajapakshe, K; Donepudi, SR; von Rundstedt, FC; Devarakonda, V; Dubrulle, J; Karanam, B; McGuire, SE; Stossi, F; Jain, AK; Coarfa, C; Cao, Q; Sikora, AG; Villanueva, H; Kavuri, SM; Lotan, Y; Sreekumar, A; Putluri, N				Vantaku, Venkatrao; Putluri, Vasanta; Bader, David A.; Maity, Suman; Ma, Jing; Arnold, James M.; Rajapakshe, Kimal; Donepudi, Sri Ramya; von Rundstedt, Friedrich-Carl; Devarakonda, Vaishnavi; Dubrulle, Julien; Karanam, Balasubramanyam; McGuire, Sean E.; Stossi, Fabio; Jain, Abhinav K.; Coarfa, Cristian; Cao, Qi; Sikora, Andrew G.; Villanueva, Hugo; Kavuri, Shyam M.; Lotan, Yair; Sreekumar, Arun; Putluri, Nagireddy			Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression	ONCOGENE			English	Article							GROUP PROTEIN EZH2; BREAST-CANCER; DNA METHYLATION; CELLULAR FUNCTIONS; METASTASIS; PROSTATE; GENES; HYPERMETHYLATION; IDENTIFICATION; SUPPRESSOR	Advanced Bladder Cancer (BLCA) remains a clinical challenge that lacks effective therapeutic measures. Here, we show that distinct, stage-wise metabolic alterations in BLCA are associated with the loss of function of aldehyde oxidase (AOX1). AOX1 associated metabolites have a high predictive value for advanced BLCA and our findings demonstrate that AOX1 is epigenetically silenced during BLCA progression by the methyltransferase activity of EZH2. Knockdown (KD) of AOX1 in normal bladder epithelial cells re-wires the tryptophan-kynurenine pathway resulting in elevated NADP levels which may increase metabolic flux through the pentose phosphate (PPP) pathway, enabling increased nucleotide synthesis, and promoting cell invasion. Inhibition of NADP synthesis rescues the metabolic effects of AOX1 KD. Ectopic AOX1 expression decreases NADP production, PPP flux and nucleotide synthesis, while decreasing invasion in cell line models and suppressing growth in tumor xenografts. Further gain and loss of AOX1 confirm the EZH2-dependent activation, metabolic deregulation, and tumor growth in BLCA. Our findings highlight the therapeutic potential of AOX1 and provide a basis for the development of prognostic markers for advanced BLCA.	[Vantaku, Venkatrao; Bader, David A.; Rajapakshe, Kimal; Dubrulle, Julien; McGuire, Sean E.; Stossi, Fabio; Coarfa, Cristian; Sreekumar, Arun; Putluri, Nagireddy] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Putluri, Vasanta; Donepudi, Sri Ramya; Dubrulle, Julien; McGuire, Sean E.; Stossi, Fabio; Coarfa, Cristian; Sikora, Andrew G.; Villanueva, Hugo; Sreekumar, Arun; Putluri, Nagireddy] Baylor Coll Med, Dan L Duncan Canc Ctr, Alkek Ctr Mol Discovery, Adv Technol Core, Houston, TX 77030 USA; [Maity, Suman] Univ Texas Houston, Sch Publ Hlth, Dept Biostat, Houston, TX USA; [Ma, Jing] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1124 Columbia St, Seattle, WA 98104 USA; [Arnold, James M.; Sreekumar, Arun] Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; [von Rundstedt, Friedrich-Carl] Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA; [von Rundstedt, Friedrich-Carl] Friedrich Schiller Univ, Jena Univ Hosp, Dept Urol, Jena, Germany; [Devarakonda, Vaishnavi; Kavuri, Shyam M.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Karanam, Balasubramanyam] Tuskegee Univ, Dept Biol, Tuskegee, AL 36088 USA; [Karanam, Balasubramanyam] Tuskegee Univ, Ctr Canc Res, Tuskegee, AL 36088 USA; [Jain, Abhinav K.] Univ Texas MD Anderson Canc Ctr, Dept Epigenet & Mol Carcinogenesis, Ctr Canc Epigenet, Houston, TX 77030 USA; [Cao, Qi] Houston Methodist Res Inst, Inst Acad Med, Ctr Inflammat & Epigenet, Houston, TX USA; [Sikora, Andrew G.; Villanueva, Hugo] Baylor Coll Med, Dept Otolaryngol Head Neck Surg, Houston, TX 77030 USA; [Lotan, Yair] Univ Texas SouthWestern, Dept Urol, Dallas, TX USA	Baylor College of Medicine; Baylor College of Medicine; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; Fred Hutchinson Cancer Center; Baylor College of Medicine; Baylor College of Medicine; Friedrich Schiller University of Jena; Baylor College of Medicine; Tuskegee University; Tuskegee University; University of Texas System; UTMD Anderson Cancer Center; The Methodist Hospital System; The Methodist Hospital - Houston; Baylor College of Medicine; University of Texas System; University of Texas Southwestern Medical Center Dallas	Putluri, N (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.; Putluri, N (corresponding author), Baylor Coll Med, Dan L Duncan Canc Ctr, Alkek Ctr Mol Discovery, Adv Technol Core, Houston, TX 77030 USA.	putluri@bcm.edu	; Cao, Qi/A-5517-2010	Putluri, Nagireddy/0000-0003-4488-7400; Cao, Qi/0000-0002-5140-3681; Ma, Jing/0000-0001-6294-227X; Bader, David/0000-0003-0514-7346; Donepudi, Sri Ramya/0000-0002-2845-1212				Ablain J, 2014, INT J CANCER, V135, P2262, DOI 10.1002/ijc.29081; Agledal L, 2010, REDOX REP, V15, P2, DOI 10.1179/174329210X12650506623122; [Anonymous], 2018, CANCER DISCOV, V8, pOF15, DOI [10.1158/2159-8290.CD-RW2018-067, DOI 10.1158/2159-8290.CD-RW2018-067]; Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180; Baylin SB, 1998, ADV CANCER RES, V72, P141; BEACONSFIELD P, 1964, Dev Med Child Neurol, V6, P469; Bhowmik SK, 2015, ONCOTARGET, V6, P42651, DOI 10.18632/oncotarget.4765; Blecher-Gonen R, 2013, NAT PROTOC, V8, P539, DOI 10.1038/nprot.2013.023; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Chalkiadaki A, 2015, NAT REV CANCER, V15, DOI 10.1038/nrc3985; Chen YG, 2009, INT J COMPUT INT SYS, V2, P1, DOI 10.2991/jnmp.2009.2.1.1; Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009; D'Amato NC, 2015, CANCER RES, V75, P4651, DOI 10.1158/0008-5472.CAN-15-2011; Davidson B, 2014, HUM PATHOL, V45, P691, DOI 10.1016/j.humpath.2013.11.003; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Deryugina EI, 2008, HISTOCHEM CELL BIOL, V130, P1119, DOI 10.1007/s00418-008-0536-2; Di Croce L, 2013, NAT STRUCT MOL BIOL, V20, P1147, DOI 10.1038/nsmb.2669; Dudziec E, 2011, EPIGENOMICS-UK, V3, P35, DOI 10.2217/EPI.10.71; Estecio MRH, 2007, GENOME RES, V17, P1529, DOI 10.1101/gr.6417007; Esteller M, 2000, CANCER RES, V60, P129; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Garattini E, 2008, CELL MOL LIFE SCI, V65, P1019, DOI 10.1007/s00018-007-7398-y; Garattini Enrico, 2009, Human Genomics, V4, P119; Haldrup C, 2013, J CLIN ONCOL, V31, P3250, DOI 10.1200/JCO.2012.47.1847; Hurst CD, 2017, CANCER CELL, V32, P701, DOI 10.1016/j.ccell.2017.08.005; Hussain M, 2009, CANCER RES, V69, P3570, DOI 10.1158/0008-5472.CAN-08-2807; Icard P, 2012, BBA-REV CANCER, V1825, P111, DOI 10.1016/j.bbcan.2011.10.007; Jin F, 2017, CANCER PREV RES, V10, P588, DOI [10.1158/1940-6207.CAPR-17-0198, 10.1158/1940-6207.capr-17-0198]; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Kim WJ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-3; Kitamura S, 2006, DRUG METAB PHARMACOK, V21, P83, DOI 10.2133/dmpk.21.83; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kompier LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013821; Li M, 2015, JOVE-J VIS EXP, DOI 10.3791/52411; Ma J, 2016, BIOINFORMATICS, V32, P3165, DOI 10.1093/bioinformatics/btw410; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Opitz CA, 2011, NATURE, V478, P197, DOI 10.1038/nature10491; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Oster B, 2011, INT J CANCER, V129, P2855, DOI 10.1002/ijc.25951; Ozturk S, 2016, P NATL ACAD SCI USA, V113, P638, DOI 10.1073/pnas.1514663113; Park JS, 2014, IEEE ENG MED BIO, P3430, DOI 10.1109/EMBC.2014.6944360; Piyarathna DWB, 2018, EUR UROL FOCUS, V4, P907, DOI 10.1016/j.euf.2017.04.005; Platten M, 2012, CANCER RES, V72, P5435, DOI 10.1158/0008-5472.CAN-12-0569; Prendergast GC, 2011, NATURE, V478, P192, DOI 10.1038/478192a; Putluri N, 2014, NEOPLASIA, V16, P390, DOI 10.1016/j.neo.2014.05.007; Putluri N, 2011, CANCER RES, V71, P7376, DOI 10.1158/0008-5472.CAN-11-1154; Putluri N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021417; Reinert T, 2011, CLIN CANCER RES, V17, P5582, DOI 10.1158/1078-0432.CCR-10-2659; SALTER M, 1985, BIOCHEM J, V229, P499, DOI 10.1042/bj2290499; Sanchez-Carbayo M, 2006, J CLIN ONCOL, V24, P778, DOI 10.1200/JCO.2005.03.2375; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sievert KD, 2009, WORLD J UROL, V27, P295, DOI 10.1007/s00345-009-0395-z; Sudo T, 2005, BRIT J CANCER, V92, P1754, DOI 10.1038/sj.bjc.6602531; Sun SS, 2016, CELL SIGNAL, V28, P481, DOI 10.1016/j.cellsig.2016.02.004; Tan JZ, 2014, ACTA PHARMACOL SIN, V35, P161, DOI 10.1038/aps.2013.161; Terunuma A, 2014, J CLIN INVEST, V124, P398, DOI 10.1172/JCI71180; Thoma C, 2018, NAT REV UROL, V15, P1, DOI 10.1038/nrurol.2017.207; Vantaku V, 2019, CLIN CANCER RES, V25, P3689, DOI 10.1158/1078-0432.CCR-18-1515; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Wolff EM, 2010, CANCER RES, V70, P8169, DOI 10.1158/0008-5472.CAN-10-1335; Yan JL, 2013, BLOOD, V121, P4512, DOI 10.1182/blood-2012-08-450494; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yang M, 2013, CANCER CELL, V23, P709, DOI 10.1016/j.ccr.2013.05.015; Ying WH, 2008, ANTIOXID REDOX SIGN, V10, P179, DOI 10.1089/ars.2007.1672; Zhai LJ, 2015, CLIN CANCER RES, V21, P5427, DOI 10.1158/1078-0432.CCR-15-0420	69	23	23	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2020	39	40					6265	6285		10.1038/s41388-019-0902-7	http://dx.doi.org/10.1038/s41388-019-0902-7			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NV5JK	31383940	Green Accepted			2022-12-28	WOS:000574357500001
J	Cebria-Costa, JP; Pascual-Reguant, L; Gonzalez-Perez, A; Serra-Bardenys, G; Querol, J; Cosin, M; Verde, G; Cigliano, RA; Sanseverino, W; Segura-Bayona, S; Iturbide, A; Andreu, D; Nuciforo, P; Bernado-Morales, C; Rodilla, V; Arribas, J; Yelamos, J; de Herreros, AG; Stracker, TH; Peiro, S				Cebria-Costa, J. P.; Pascual-Reguant, L.; Gonzalez-Perez, A.; Serra-Bardenys, G.; Querol, J.; Cosin, M.; Verde, G.; Cigliano, R. A.; Sanseverino, W.; Segura-Bayona, S.; Iturbide, A.; Andreu, D.; Nuciforo, P.; Bernado-Morales, C.; Rodilla, V.; Arribas, J.; Yelamos, J.; Garcia de Herreros, A.; Stracker, T. H.; Peiro, S.			LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells	ONCOGENE			English	Article							OXIDASE-LIKE 2; DOUBLE-STRAND BREAKS; TO-MESENCHYMAL TRANSITION; DNA-DAMAGE RESPONSE; LYSYL OXIDASE; GENOMIC INSTABILITY; E-CADHERIN; LOXL2; EXPRESSION; TRANSCRIPTION	Oxidation of H3 at lysine 4 (H3K4ox) by lysyl oxidase-like 2 (LOXL2) generates an H3 modification with an unknown physiological function. We find that LOXL2 and H3K4ox are higher in triple-negative breast cancer (TNBC) cell lines and patient-derived xenografts (PDXs) than those from other breast cancer subtypes. ChIP-seq revealed that H3K4ox is located primarily in heterochromatin, where it is involved in chromatin compaction. Knocking down LOXL2 reduces H3K4ox levels and causes chromatin decompaction, resulting in a sustained activation of the DNA damage response (DDR) and increased susceptibility to anticancer agents. This critical role that LOXL2 and oxidized H3 play in chromatin compaction and DDR suggests that functionally targeting LOXL2 could be a way to sensitize TNBC cells to conventional therapy.	[Cebria-Costa, J. P.; Pascual-Reguant, L.; Serra-Bardenys, G.; Querol, J.; Cosin, M.; Verde, G.; Nuciforo, P.; Bernado-Morales, C.; Rodilla, V.; Arribas, J.; Peiro, S.] Vall dHebron Inst Oncol VHIO, Barcelona 08035, Spain; [Gonzalez-Perez, A.; Segura-Bayona, S.; Stracker, T. H.] Barcelona Inst Sci & Technol, Inst Res Biomed IRB Barcelona, Barcelona 08028, Spain; [Verde, G.] Univ Int Catalunya, Fac Med & Hlth Sci, Barcelona, Spain; [Cigliano, R. A.; Sanseverino, W.] Sequentia Biotech SL, Comte Urgell 240, Barcelona, Spain; [Iturbide, A.] Helmoholtz Zentrum Munchen, Inst Epigenet & Stem Cells, D-81377 Munich, Germany; [Andreu, D.; Garcia de Herreros, A.] Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Barcelona, Spain; [Bernado-Morales, C.; Arribas, J.] Ctr Invest Biomed Red Oncol CIBERONC, Barcelona 08035, Spain; [Arribas, J.] ICREA, Barcelona, Spain; [Arribas, J.] Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Bellaterra, Spain; [Yelamos, J.; Garcia de Herreros, A.] Inst Hosp del Mar Invest Med IMIM, Programa Recerca Canc, Barcelona, Spain	Vall d'Hebron Institut d'Oncologia (VHIO); Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; Universitat Internacional de Catalunya (UIC); Pompeu Fabra University; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; ICREA; Autonomous University of Barcelona; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar	Peiro, S (corresponding author), Vall dHebron Inst Oncol VHIO, Barcelona 08035, Spain.	speiro@vhio.net	Benito, Verónica Rodilla/A-5171-2018; Yelamos, Jose/N-2842-2016; Sanseverino, Walter/AAX-5254-2021; Reguant, Laura Pascual/AAB-6274-2019; Segura-Bayona, Sandra/W-8156-2019; Arribas, Joaquin/M-4482-2014; Verde, Gaetano/U-2749-2017	Benito, Verónica Rodilla/0000-0003-0512-4179; Sanseverino, Walter/0000-0003-3324-5912; Reguant, Laura Pascual/0000-0003-2361-1392; Segura-Bayona, Sandra/0000-0001-7788-9889; Bernado Morales, Cristina/0000-0003-1376-0407; Arribas, Joaquin/0000-0002-0504-0664; Peiro, Sandra/0000-0001-9519-3877; Yelamos, Jose/0000-0003-1195-1496; Verde, Gaetano/0000-0003-4768-0165; Cebria Costa, Joan Pau/0000-0002-3628-2973; Gonzalez-Perez, Abel/0000-0002-8582-4660	Instituto de Salud Carlos III (ISCIII) FIS/FEDER [PI12/01250, CP08/00223, PI16/00253, CB16/12/00449]; MINECO [SAF201348849-C2-1-R]; Breast Cancer Research Foundation [BCRF-17-008]; Worldwide Cancer Research; Red Tematica de Investigacion Cooperativa en Cancer [RD012/0036/005]; Fundacion Cientifica de la Asociacion Espanola contra el Cancer; Fundacio La Marato TV3; institutional funding (MINECO) through the Centres of Excellence Severo Ochoa award; CERCA Programme of the Catalan Government; Fundacio La Caixa fellowship; MINECO ("Juan de la Cierva Incorporation" fellowship) [IJCI-2014-20723]; Miguel Servet contract (ISCIII/FIS); Fundacio FERO; FI Fellowship from the Generalitat de Catalunya;  [BFU2015-68354];  [AGL2014-52395-C2-2-R]	Instituto de Salud Carlos III (ISCIII) FIS/FEDER; MINECO(Spanish Government); Breast Cancer Research Foundation; Worldwide Cancer Research; Red Tematica de Investigacion Cooperativa en Cancer; Fundacion Cientifica de la Asociacion Espanola contra el Cancer; Fundacio La Marato TV3; institutional funding (MINECO) through the Centres of Excellence Severo Ochoa award; CERCA Programme of the Catalan Government; Fundacio La Caixa fellowship; MINECO ("Juan de la Cierva Incorporation" fellowship); Miguel Servet contract (ISCIII/FIS); Fundacio FERO; FI Fellowship from the Generalitat de Catalunya(Generalitat de Catalunya); ; 	We would like to thank R. Pena and J. Valle for technical assistance, V.A. Raker for manuscript editing, G. Gil for manuscript reading and advice, A. Jordan for H1-GFP constructs, T. Jenuwein for SUV-39 constructs, and H. Galvez-Garcia for ATAC protocol implementation. This work was supported by grants from Instituto de Salud Carlos III (ISCIII) FIS/FEDER (PI12/01250; CP08/00223; PI16/00253; and CB16/12/00449), MINECO (SAF201348849-C2-1-R) to SP, BFU2015-68354 to THS, Breast Cancer Research Foundation (BCRF-17-008) to JA, AGL2014-52395-C2-2-R to DA, Worldwide Cancer Research, Red Tematica de Investigacion Cooperativa en Cancer (RD012/0036/005), Fundacion Cientifica de la Asociacion Espanola contra el Cancer, and Fundacio La Marato TV3. THS was supported by institutional funding (MINECO) through the Centres of Excellence Severo Ochoa award and the CERCA Programme of the Catalan Government, and SS-B, by a Fundacio La Caixa fellowship. We thank La Caixa Foundation and Cellex Foundation for provide research facilities and equipment. GV has received funding from the MINECO (a "Juan de la Cierva Incorporation" fellowship; IJCI-2014-20723). SP was a recipient of a Miguel Servet contract (ISCIII/FIS), and AI, JPC-C, LP-G, and GS-B are supported by contracts from Worldwide Cancer Research, Fundacio La Marato TV3, Fundacio FERO, and a FI Fellowship from the Generalitat de Catalunya, respectively.	Ahn SG, 2013, BREAST CANCER RES TR, V141, P89, DOI 10.1007/s10549-013-2662-3; Almendro V, 2014, CELL REP, V6, P514, DOI 10.1016/j.celrep.2013.12.041; Ayrapetov MK, 2014, P NATL ACAD SCI USA, V111, P9169, DOI 10.1073/pnas.1403565111; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Baldeyron C, 2011, J CELL BIOL, V193, P81, DOI 10.1083/jcb.201101030; Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Barker HE, 2012, NAT REV CANCER, V12, P540, DOI 10.1038/nrc3319; Bayona-Feliu A, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00338-5; Bekker-Jensen S, 2006, J CELL BIOL, V173, P195, DOI 10.1083/jcb.200510130; Bonilla CY, 2008, MOL CELL, V30, P267, DOI 10.1016/j.molcel.2008.03.023; Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/NMETH.2688, 10.1038/nmeth.2688]; Burgess RC, 2015, CELL, V162, P944, DOI 10.1016/j.cell.2015.08.006; Burgess RC, 2014, CELL REP, V9, P1703, DOI 10.1016/j.celrep.2014.10.060; Cano A, 2012, FUTURE ONCOL, V8, P1095, DOI [10.2217/FON.12.105, 10.2217/fon.12.105]; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Ernst J, 2012, NAT METHODS, V9, P215, DOI 10.1038/nmeth.1906; Escriva M, 2008, MOL CELL BIOL, V28, P1528, DOI 10.1128/MCB.02061-07; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Fong SFT, 2007, GENE CHROMOSOME CANC, V46, P644, DOI 10.1002/gcc.20444; Gan WJ, 2011, GENE DEV, V25, P2041, DOI 10.1101/gad.17010011; Garcia-Rubio ML, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005674; Goodarzi AA, 2008, MOL CELL, V31, P167, DOI 10.1016/j.molcel.2008.05.017; Guelen L, 2008, NATURE, V453, P948, DOI 10.1038/nature06947; Gursoy-Yuzugullu O, 2016, J MOL BIOL, V428, P1846, DOI 10.1016/j.jmb.2015.11.021; Herranz N, 2008, MOL CELL BIOL, V28, P4772, DOI 10.1128/MCB.00323-08; Herranz N, 2016, FEBS J, V283, P4263, DOI 10.1111/febs.13922; Holliday DL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2889; Iturbide A, 2015, MOL CELL, V58, P755, DOI 10.1016/j.molcel.2015.04.012; Iturbide A, 2015, FEBS J, V282, P1768, DOI 10.1111/febs.12961; Kaidi A, 2013, NATURE, V498, DOI 10.1038/nature12201; Khurana S, 2014, CELL REP, V8, P1049, DOI 10.1016/j.celrep.2014.07.024; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lerat E, 2017, NUCLEIC ACIDS RES, V45, DOI 10.1093/nar/gkw953; Martin A, 2015, EMBO J, V34, P1090, DOI 10.15252/embj.201489975; McDonald OG, 2011, NAT STRUCT MOL BIOL, V18, P867, DOI 10.1038/nsmb.2084; Millanes-Romero A, 2013, MOL CELL, V52, P746, DOI 10.1016/j.molcel.2013.10.015; Moreno-Bueno G, 2011, EMBO MOL MED, V3, P528, DOI 10.1002/emmm.201100156; Murga M, 2007, J CELL BIOL, V178, P1101, DOI 10.1083/jcb.200704140; Peinado H, 2005, EMBO J, V24, P3446, DOI 10.1038/sj.emboj.7600781; Peinado H, 2008, CANCER RES, V68, P4541, DOI 10.1158/0008-5472.CAN-07-6345; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Schietke R, 2010, J BIOL CHEM, V285, P6658, DOI 10.1074/jbc.M109.042424; Soria G, 2012, MOL CELL, V46, P722, DOI 10.1016/j.molcel.2012.06.002; Soutoglou E, 2008, SCIENCE, V320, P1507, DOI [10.1126/science.1159051, 10.1126/science.ll59051]; Tarazona S, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv711; Torres S, 2015, CLIN CANCER RES, V21, P4892, DOI 10.1158/1078-0432.CCR-14-3096; Toth KF, 2004, J CELL SCI, V117, P4277, DOI 10.1242/jcs.01293; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Tsompana M, 2014, EPIGENET CHROMATIN, V7, DOI 10.1186/1756-8935-7-33; Tuduri S, 2009, NAT CELL BIOL, V11, P1315, DOI 10.1038/ncb1984; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Voloshenyuk TG, 2011, CYTOKINE, V55, P90, DOI 10.1016/j.cyto.2011.03.024; WILLIAMSON PR, 1986, J BIOL CHEM, V261, P9477; Wong CCL, 2014, HEPATOLOGY, V60, P1645, DOI 10.1002/hep.27320; Wu M, 2008, MOL CELL BIOL, V28, P7337, DOI 10.1128/MCB.00976-08; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064; Ziv Y, 2006, NAT CELL BIOL, V8, P870, DOI 10.1038/ncb1446	61	16	16	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	1					79	121		10.1038/s41388-019-0969-1	http://dx.doi.org/10.1038/s41388-019-0969-1			43	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG3NM	31462706	hybrid, Green Published			2022-12-28	WOS:000509849200007
J	Rabinovich, S; Silberman, A; Adler, L; Agron, S; Levin-Zaidman, S; Bahat, A; Porat, Z; Ben-Zeev, E; Geva, I; Itkin, M; Malitsky, S; Buchaklian, A; Helbling, D; Dimmock, D; Erez, A				Rabinovich, Shiran; Silberman, Alon; Adler, Lital; Agron, Shani; Levin-Zaidman, Smadar; Bahat, Amir; Porat, Ziv; Ben-Zeev, Efrat; Geva, Inbal; Itkin, Maxim; Malitsky, Sergey; Buchaklian, Adam; Helbling, Daniel; Dimmock, David; Erez, Ayelet			The mitochondrial carrier Citrin plays a role in regulating cellular energy during carcinogenesis	ONCOGENE			English	Article							DEFICIENCY; CANCER; EXPERIENCE; ASPARTATE	Citrin, encoded by SLC25A13 gene, is an inner mitochondrial transporter that is part of the malate-aspartate shuttle, which regulates the NAD+/NADH ratio between the cytosol and mitochondria. Citrullinemia type II (CTLN-II) is an inherited disorder caused by germline mutations in SLC25A13, manifesting clinically in growth failure that can be alleviated by dietary restriction of carbohydrates. The association of citrin with glycolysis and NAD+/NADH ratio led us to hypothesize that it may play a role in carcinogenesis. Indeed, we find that citrin is upregulated in multiple cancer types and is essential for supplementing NAD+ for glycolysis and NADH for oxidative phosphorylation. Consequently, citrin deficiency associates with autophagy, whereas its overexpression in cancer cells increases energy production and cancer invasion. Furthermore, based on the human deleterious mutations in citrin, we found a potential inhibitor of citrin that restricts cancerous phenotypes in cells. Collectively, our findings suggest that targeting citrin may be of benefit for cancer therapy.	[Rabinovich, Shiran; Silberman, Alon; Adler, Lital; Agron, Shani; Bahat, Amir; Erez, Ayelet] Weizmann Inst Sci, Dept Biol Regulat, Rehovot, Israel; [Levin-Zaidman, Smadar] Weizmann Inst Sci, Dept Chem Res Support, Rehovot, Israel; [Porat, Ziv] Weizmann Inst Sci, Dept Cell Sorting, Rehovot, Israel; [Ben-Zeev, Efrat; Geva, Inbal] Weizmann Inst Sci, Grand Israel Natl Ctr Personalized Med, Rehovot, Israel; [Itkin, Maxim; Malitsky, Sergey] Weizmann Inst Sci, Dept Life Sci Core Facil, Rehovot, Israel; [Buchaklian, Adam; Helbling, Daniel; Dimmock, David] Med Coll Wisconsin, Human & Mol Genet & Biochem Ctr, Milwaukee, WI 53226 USA; [Dimmock, David] Rady Childrens Inst Genom Med, San Diego, CA USA	Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science; Medical College of Wisconsin	Erez, A (corresponding author), Weizmann Inst Sci, Dept Biol Regulat, Rehovot, Israel.	ayelet.erez@weizmann.ac.il	Itkin, Maxim/AFU-5181-2022; Malitsky, Sergey/ABC-2545-2020; Itkin, Maxim/ABB-9183-2020; Porat, Ziv/K-1672-2012	Itkin, Maxim/0000-0003-1348-2814; Malitsky, Sergey/0000-0003-4619-7219; Porat, Ziv/0000-0003-3059-181X	European research program [CIG618113, ERC614204]; Israel Science Foundation [1343/13, 1952/13]; Minerva grant [711730]; Adelis Foundation; Henry S. and Anne S. Reich Research Fund; Dukler Fund for Cancer Research; Paul Sparr Foundation; Saul and Theresa Esman Foundation; estate of Fannie Sherr; Weizmann Institute	European research program(European Commission); Israel Science Foundation(Israel Science Foundation); Minerva grant; Adelis Foundation; Henry S. and Anne S. Reich Research Fund; Dukler Fund for Cancer Research; Paul Sparr Foundation; Saul and Theresa Esman Foundation; estate of Fannie Sherr; Weizmann Institute	We acknowledge and thank the Weizmann Institute for providing financial and infrastructural support. We thank Tomer Shlomi and his student Won Dong-Lee, Gad Asher, Zvulun Elazar and his student Adi Abada, Yoav Shaul, Irit Sagi, Ron Rotkopf, and Sivan Galai for the intellectual and technical assistance. AE is incumbent of the Leah Omenn Career Development Chair and is supported by research grants from the European research program (CIG618113, ERC614204), the Israel Science Foundation (1343/13; 1952/13), and from the Minerva grant award (711730). AE received additional support from the Adelis Foundation, the Henry S. and Anne S. Reich Research Fund, the Dukler Fund for Cancer Research, the Paul Sparr Foundation, the Saul and Theresa Esman Foundation, from Joseph Piko Baruch, and from the estate of Fannie Sherr. The authors declare applying for a patent for citrin inhibition as cancer therapy.	Amoedo ND, 2016, BBA-MOL CELL RES, V1863, P2394, DOI 10.1016/j.bbamcr.2016.04.011; Bartolome Fernando, 2015, Methods Mol Biol, V1264, P263, DOI 10.1007/978-1-4939-2257-4_23; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Chang KW, 2011, MOL GENET METAB, V103, P293, DOI 10.1016/j.ymgme.2011.03.013; Chung HY, 2017, J CANCER PREV, V22, P127, DOI 10.15430/JCP.2017.22.3.127; Corbet C, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03525-0; Dimmock D, 2009, MOL GENET METAB, V96, P44, DOI 10.1016/j.ymgme.2008.10.007; Dimmock D, 2007, PEDIATRICS, V119, pE773, DOI 10.1542/peds.2006-1950; Dimmock D, 2010, CLIN CHEM, V56, P1119, DOI 10.1373/clinchem.2009.141549; Erez A, 2015, NAT REV CANCER, V15, P440, DOI 10.1038/nrc3949; Fass E, 2006, J BIOL CHEM, V281, P36303, DOI 10.1074/jbc.M607031200; Fiermonte G, 2011, MOL GENET METAB, V104, P501, DOI 10.1016/j.ymgme.2011.08.022; Garcia-Bermudez J, 2018, NAT CELL BIOL, V20, P775, DOI 10.1038/s41556-018-0118-z; Gaude E, 2018, MOL CELL, V69, P581, DOI 10.1016/j.molcel.2018.01.034; Hollinshead KER, 2016, WIRES SYST BIOL MED, V8, P272, DOI 10.1002/wsbm.1334; Kimura N, 2013, TRANSPL P, V45, P3432, DOI 10.1016/j.transproceed.2013.06.016; Kluza J, 2012, CANCER RES, V72, P5035, DOI 10.1158/0008-5472.CAN-12-0979; Komatsu M, 2010, FEBS LETT, V584, P1374, DOI 10.1016/j.febslet.2010.02.017; Malitsky S, 2016, NEW PHYTOL, V210, P88, DOI 10.1111/nph.13852; Porporato PE, 2014, CELL REP, V8, P754, DOI 10.1016/j.celrep.2014.06.043; Rabinovich S, 2015, NATURE, V527, P379, DOI 10.1038/nature15529; Revollo JR, 2007, CURR OPIN GASTROEN, V23, P164, DOI 10.1097/MOG.0b013e32801b3c8f; ROBINSON BH, 1985, AM J HUM GENET, V37, P938; Saheki T, 2010, MOL GENET METAB, V100, pS59, DOI 10.1016/j.ymgme.2010.02.014; Salem M, 2017, JOVE-J VIS EXP, V1, P124; Satrustegui J, 2007, PHYSIOL REV, V87, P29, DOI 10.1152/physrev.00005.2006; Shaul YD, 2016, NUCLEIC ACIDS RES, V44, pD560, DOI 10.1093/nar/gkv1337; Shinohara M, 2010, J BIOL CHEM, V285, P4481, DOI 10.1074/jbc.M109.071779; Song YZ, 2011, INT J MOL MED, V28, P33, DOI 10.3892/ijmm.2011.653; Sullivan LB, 2018, NAT CELL BIOL, V20, P782, DOI 10.1038/s41556-018-0125-0; Takeuchi S, 2015, PEDIATRICS, V136, pE530, DOI 10.1542/peds.2014-4172; Torrano V, 2016, NAT CELL BIOL, V18, P645, DOI 10.1038/ncb3357; van Niekerk G, 2018, CELL ONCOL, V41, P343, DOI 10.1007/s13402-018-0383-7; Xian ZY, 2015, TUMOR BIOL, V36, P8093, DOI 10.1007/s13277-015-3540-x; Hung YP, 2011, CELL METAB, V14, P545, DOI 10.1016/j.cmet.2011.08.012; Zheng L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7001	36	11	11	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	1					164	175		10.1038/s41388-019-0976-2	http://dx.doi.org/10.1038/s41388-019-0976-2			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG3NM	31462712				2022-12-28	WOS:000509849200011
J	Chen, DC; Li, YC; Zhang, XW; Wu, HY; Wang, Q; Cai, J; Cui, YM; Liu, HL; Lan, P; Wang, JP; Yang, ZH; Wang, L				Chen, Daici; Li, Yichen; Zhang, Xiaowen; Wu, Haiyong; Wang, Qian; Cai, Jian; Cui, Yanmei; Liu, Huanliang; Lan, Ping; Wang, Jianping; Yang, Zihuan; Wang, Lei			Ubiquitin ligase TRIM65 promotes colorectal cancer metastasis by targeting ARHGAP35 for protein degradation	ONCOGENE			English	Article							TO-MESENCHYMAL TRANSITION; TUMOR-CELL-MIGRATION; GENETICS; POLARITY; FASCIN; RHOA	Tripartite motif-containing protein 65 (TRIM65) is an E3 ubiquitin ligase and a critical regulator of a variety of cellular processes as well as tumor progression. Therefore, more substrates must be identified in the physiology or disease context. Here, we found that TRIM65 is upregulated and associated with poor survival in colorectal cancer (CRC). More specifically, high expression of TRIM65 is associated with CRC metastasis and recurrence. Ectopic overexpression of TRIM65 in CRC cell lines enhanced proliferation, invasion, and migration, while knockdown of TRIM65 expression had the opposite effects. Furthermore, we identified a new substrate of TRIM65, namely ARHGAP35, a Rho GTPase-activating protein (GAP) that is involved in polarized cell migration. Phenotypically, forced expression of TRIM65 induces increased production of migration-related structures, focal adhesions, and/or filopodia and enhances CRC metastasis to the liver or the lung in a mouse model. Mechanistic studies revealed that TRIM65 mediates ubiquitination of ARHGAP35, whose degradation leads to elevated Rho GTPase activity. In addition, we identified several phosphorylation sites on TRIM65. In sum, we reveal a novel TRIM65-GAP-Rho regulatory axis that modulates the actin cytoskeleton and the migration behavior of CRC cells, and the TRIM65-ARHGAP35 interaction might be a valuable therapeutic target in CRC.	[Chen, Daici; Li, Yichen; Zhang, Xiaowen; Wu, Haiyong; Wang, Qian; Cui, Yanmei; Liu, Huanliang; Lan, Ping; Wang, Jianping; Yang, Zihuan; Wang, Lei] Sun Yat Sen Univ, Affiliated Hosp 6, Guangdong Prov Key Lab Colorectal & Pelv Floor Di, Guangzhou, Guangdong, Peoples R China; [Chen, Daici; Li, Yichen; Zhang, Xiaowen; Wu, Haiyong; Wang, Qian; Cui, Yanmei; Liu, Huanliang; Lan, Ping; Wang, Jianping; Yang, Zihuan; Wang, Lei] Guangdong Inst Gastroenterol, Guangzhou, Guangdong, Peoples R China; [Cai, Jian; Lan, Ping; Wang, Jianping; Wang, Lei] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Colorectal Surg, Guangzhou, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University	Chen, DC; Yang, ZH; Wang, L (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 6, Guangdong Prov Key Lab Colorectal & Pelv Floor Di, Guangzhou, Guangdong, Peoples R China.; Chen, DC; Yang, ZH; Wang, L (corresponding author), Guangdong Inst Gastroenterol, Guangzhou, Guangdong, Peoples R China.; Wang, L (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 6, Dept Colorectal Surg, Guangzhou, Guangdong, Peoples R China.	chendc3@mail.sysu.edu.cn; yzhuan@mail.sysu.edu.cn; wangl9@mail.sysu.edu.cn	Chen, Daici/AAI-7285-2020	Chen, Daici/0000-0002-8872-0592; Liu, Huanliang/0000-0002-1006-6666; Cai, Jian/0000-0001-5687-2009	Natural Science Foundation of China [81573078, 81872386]; Natural Science Foundation of Guangdong Province [2017A030313805, 2016A030311021]; Guangzhou Science and Technology Program Key Projects [201604020174, 201604020005]; National Key Clinical Discipline	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Guangzhou Science and Technology Program Key Projects; National Key Clinical Discipline	This work was financially supported by Natural Science Foundation of China (Grant No. 81573078 and 81872386), Natural Science Foundation of Guangdong Province (Grant No. 2017A030313805 and 2016A030311021), and Guangzhou Science and Technology Program Key Projects (Grant No. 201604020174 and 201604020005). The authors thank group members of Professor Lei Wang for inspirational discussion, and support by National Key Clinical Discipline and the Program of Introducing Talents of Discipline to Universities in general.	Ali MRK, 2017, P NATL ACAD SCI USA, V114, pE5655, DOI 10.1073/pnas.1703151114; Bartolome RA, 2008, CANCER RES, V68, P8221, DOI 10.1158/0008-5472.CAN-08-0561; Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9; Chen L, 2010, NATURE, V464, P1062, DOI 10.1038/nature08978; Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fang LK, 2015, CANCER CELL, V28, P183, DOI 10.1016/j.ccell.2015.07.004; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Fornage M, 2011, ANN NEUROL, V69, P928, DOI 10.1002/ana.22403; Freudenberger P, 2012, J NEUROL SCI, V322, P82, DOI 10.1016/j.jns.2012.06.016; Han SQ, 2016, MOL ONCOL, V10, P966, DOI 10.1016/j.molonc.2016.03.006; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Kamanova J, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005552; Keck JM, 2011, SCIENCE, V332, P1557, DOI 10.1126/science.1205193; Lang XT, 2017, J EXP MED, V214, P459, DOI 10.1084/jem.20160592; Li ST, 2014, P NATL ACAD SCI USA, V111, P6970, DOI 10.1073/pnas.1322545111; Li Y, 2016, BIOCHEM BIOPH RES CO, V473, P278, DOI 10.1016/j.bbrc.2016.03.093; Pathan M, 2015, PROTEOMICS, V15, P2597, DOI 10.1002/pmic.201400515; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Schmidt H, 2012, EXP GERONTOL, V47, P873, DOI 10.1016/j.exger.2012.06.003; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; Short KM, 2006, J BIOL CHEM, V281, P8970, DOI 10.1074/jbc.M512755200; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Wei WS, 2018, CANCER LETT, V435, P10, DOI 10.1016/j.canlet.2018.07.036; William WN, 2009, NAT REV DRUG DISCOV, V8, P213, DOI 10.1038/nrd2663; Yang SY, 2009, CANCER CELL, V15, P124, DOI 10.1016/j.ccr.2008.12.019; Yang YF, 2017, J CELL SCI, V130, P3108, DOI 10.1242/jcs.206623; Zajac O, 2018, NAT CELL BIOL, V20, P296, DOI 10.1038/s41556-017-0027-6; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	29	26	26	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2019	38	37					6429	6444		10.1038/s41388-019-0891-6	http://dx.doi.org/10.1038/s41388-019-0891-6			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IX6FR	31332286	Green Published, hybrid			2022-12-28	WOS:000485778800003
J	Sicari, D; Fantuz, M; Bellazzo, A; Valentino, E; Apollonio, M; Pontisso, I; Di Cristino, F; Dal Ferro, M; Bicciato, S; Del Salf, G; Collavin, L				Sicari, Dania; Fantuz, Marco; Bellazzo, Arianna; Valentino, Elena; Apollonio, Mattia; Pontisso, Ilaria; Di Cristino, Francesca; Dal Ferro, Marco; Bicciato, Silvio; Del Salf, Giannino; Collavin, Licio			Mutant p53 improves cancer cells' resistance to endoplasmic reticulum stress by sustaining activation of the UPR regulator ATF6	ONCOGENE			English	Article							TRANSMEMBRANE PROTEIN; SURVIVAL; ER; TRANSLATION; PROTEOLYSIS; METASTASIS; APOPTOSIS	Missense mutations in the TP53 gene are frequent in human cancers, giving rise to mutant p53 proteins that can acquire oncogenic properties. Gain of function mutant p53 proteins can enhance tumour aggressiveness by promoting cell invasion, metastasis and chemoresistance. Accumulating evidences indicate that mutant p53 proteins can also modulate cell homeostatic processes, suggesting that missense p53 mutation may increase resistance of tumour cells to intrinsic and extrinsic cancer-related stress conditions, thus offering a selective advantage. Here we provide evidence that mutant p53 proteins can modulate the Unfolded Protein Response (UPR) to increase cell survival upon Endoplasmic Reticulum (ER) stress, a condition to which cancer cells are exposed during tumour formation and progression, as well as during therapy. Mechanistically, this action of mutant p53 is due to enhanced activation of the pro-survival UPR effector ATF6, coordinated with inhibition of the pro-apoptotic UPR effectors JNK and CHOP. In a triple-negative breast cancer cell model with missense TP53 mutation, we found that ATF6 activity is necessary for viability and invasion phenotypes. Together, these findings suggest that ATF6 inhibitors might be combined with mutant p53-targeting drugs to specifically sensitise cancer cells to endogenous or chemotherapy-induced ER stress.	[Sicari, Dania; Fantuz, Marco; Bellazzo, Arianna; Valentino, Elena; Apollonio, Mattia; Pontisso, Ilaria; Di Cristino, Francesca; Del Salf, Giannino; Collavin, Licio] Natl Lab CIB LNCIB, Area Sci Pk, I-34149 Trieste, Italy; [Sicari, Dania; Fantuz, Marco; Bellazzo, Arianna; Valentino, Elena; Apollonio, Mattia; Pontisso, Ilaria; Di Cristino, Francesca; Dal Ferro, Marco; Del Salf, Giannino; Collavin, Licio] Univ Trieste, Dept Life Sci, I-34127 Trieste, Italy; [Fantuz, Marco] Int Sch Adv Studies SISSA, Trieste, Italy; [Bicciato, Silvio] Univ Modena & Reggio Emilia, Dept Life Sci, I-41100 Modena, Italy; [Del Salf, Giannino] FIRC Inst Mol Oncol, IFOM, Trieste, Italy	University of Trieste; International School for Advanced Studies (SISSA); Universita di Modena e Reggio Emilia; IFOM - FIRC Institute of Molecular Oncology	Del Salf, G; Collavin, L (corresponding author), Natl Lab CIB LNCIB, Area Sci Pk, I-34149 Trieste, Italy.; Del Salf, G; Collavin, L (corresponding author), Univ Trieste, Dept Life Sci, I-34127 Trieste, Italy.; Del Salf, G (corresponding author), FIRC Inst Mol Oncol, IFOM, Trieste, Italy.	giannino.delsal@Lncib.it; collavin@Lncib.it	Collavin, Licio/A-5312-2010; Bicciato, Silvio/C-9825-2009	Collavin, Licio/0000-0001-6815-5381; Bicciato, Silvio/0000-0002-1944-7078; Fantuz, Marco/0000-0001-7758-3660; Pontisso, Ilaria/0000-0002-4167-6539; Sicari, Daria/0000-0003-3847-129X	AIRC (Italian Association for Cancer Research) Investigator Grant [IG 14173]; AIRC Special Program Molecular Clinical Oncology "5 per mille" [10016]; Regione FVG [LR 17/2014]; FIRC (Fondazione Italiana Ricerca sul Cancro); Fondazione Umberto Veronesi postdoctoral fellowship; FIRC	AIRC (Italian Association for Cancer Research) Investigator Grant(Fondazione AIRC per la ricerca sul cancro); AIRC Special Program Molecular Clinical Oncology "5 per mille"(Fondazione AIRC per la ricerca sul cancro); Regione FVG(Regione Friuli Venezia Giulia); FIRC (Fondazione Italiana Ricerca sul Cancro)(Fondazione AIRC per la ricerca sul cancro); Fondazione Umberto Veronesi postdoctoral fellowship(Fondazione Umberto Veronesi); FIRC(Fondazione AIRC per la ricerca sul cancro)	We thank Giada Pastore (LNCIB, Trieste) for assistance with tissue culture. We thank Ciara Gallagher and Peter Walter (UCSF, USA) for kindly providing Ceapin-A7. We thank all people from LNCIB (Trieste) for advice and discussion. This work was funded by AIRC (Italian Association for Cancer Research) Investigator Grant (IG 14173) to LC, and AIRC Special Program Molecular Clinical Oncology "5 per mille" (Grant no. 10016) to GDS. This work was also funded by Regione FVG (LR 17/2014; project acronym RIFT) to GDS. AB was supported by a "G. Lucatello e G. Mazzega" postdoctoral fellowship from FIRC (Fondazione Italiana Ricerca sul Cancro), and by a Fondazione Umberto Veronesi postdoctoral fellowship. MF was supported by a "L. Fontana and M. Lionello" fellowship from FIRC. EV was supported by a "G. Lucatello e G. Mazzega" postdoctoral fellowship from FIRC.	Adachi Y, 2008, CELL STRUCT FUNCT, V33, P75, DOI 10.1247/csf.07044; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Bourougaa K, 2010, MOL CELL, V38, P78, DOI 10.1016/j.molcel.2010.01.041; Chevet E, 2015, CANCER DISCOV, V5, P586, DOI 10.1158/2159-8290.CD-14-1490; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Clarke HJ, 2014, CANCER CELL, V25, P563, DOI 10.1016/j.ccr.2014.03.015; Cooks T, 2013, CANCER CELL, V23, P634, DOI 10.1016/j.ccr.2013.03.022; Cunha DA, 2012, DIABETES, V61, P2763, DOI 10.2337/db12-0123; Di Minin G, 2014, MOL CELL, V56, P617, DOI 10.1016/j.molcel.2014.10.013; Gallagher CM, 2016, ELIFE, V5, DOI 10.7554/eLife.11880; Guan M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09698; Guan M, 2011, CLIN CANCER RES, V17, P1796, DOI 10.1158/1078-0432.CCR-10-3216; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Ingallina E, 2018, NAT CELL BIOL, V20, P28, DOI 10.1038/s41556-017-0009-8; Kim MP, 2018, CELL DEATH DIFFER, V25, P161, DOI 10.1038/cdd.2017.185; Li C, 2018, EXP CELL RES, V367, P170, DOI 10.1016/j.yexcr.2018.03.033; Li D, 2011, CELL DEATH DIFFER, V18, P1904, DOI 10.1038/cdd.2011.71; Liu JF, 2018, CELL, V173, P400, DOI 10.1016/j.cell.2018.02.052; Mantovani F, 2019, CELL DEATH DIFFER, V26, P199, DOI 10.1038/s41418-018-0246-9; Montibeller L, 2018, CELL STRESS CHAPERON, V23, P897, DOI 10.1007/s12192-018-0897-y; Namba T, 2015, ONCOTARGET, V6, P19990, DOI 10.18632/oncotarget.4598; Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Prischi F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4554; Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027; Sabapathy K, 2018, NAT REV CLIN ONCOL, V15, P13, DOI 10.1038/nrclinonc.2017.151; Schewe DM, 2008, P NATL ACAD SCI USA, V105, P10519, DOI 10.1073/pnas.0800939105; Senft D, 2016, TRENDS CANCER, V2, P429, DOI 10.1016/j.trecan.2016.06.004; Silwal-Pandit L, 2014, CLIN CANCER RES, V20, P3569, DOI 10.1158/1078-0432.CCR-13-2943; Tay KH, 2014, CELL SIGNAL, V26, P287, DOI 10.1016/j.cellsig.2013.11.008; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Urra H, 2016, TRENDS CANCER, V2, P252, DOI 10.1016/j.trecan.2016.03.007; Vogiatzi F, 2016, P NATL ACAD SCI USA, V113, pE8433, DOI 10.1073/pnas.1612711114; Walerych D, 2016, NAT CELL BIOL, V18, P897, DOI 10.1038/ncb3380; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Wang M, 2014, NAT REV CANCER, V14, P581, DOI 10.1038/nrc3800; Wang Y, 2000, J BIOL CHEM, V275, P27013; Wu J, 2007, DEV CELL, V13, P351, DOI 10.1016/j.devcel.2007.07.005; Yao XL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125634; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Zeng LF, 2004, EMBO J, V23, P950, DOI 10.1038/sj.emboj.7600106	42	37	37	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2019	38	34					6184	6195		10.1038/s41388-019-0878-3	http://dx.doi.org/10.1038/s41388-019-0878-3			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IS5RM	31312025	Green Submitted			2022-12-28	WOS:000482210100003
J	Fletcher, CE; Sulpice, E; Combe, S; Shibakawa, A; Leach, DA; Hamilton, MP; Chrysostomou, SL; Sharp, A; Welti, J; Yuan, W; Dart, DA; Knight, E; Ning, J; Francis, JC; Kounatidou, EE; Gaughan, L; Swain, A; Lupold, SE; de Bono, JS; McGuire, SE; Gidrol, X; Bevan, CL				Fletcher, Claire E.; Sulpice, Eric; Combe, Stephanie; Shibakawa, Akifumi; Leach, Damien A.; Hamilton, Mark P.; Chrysostomou, Stelios L.; Sharp, Adam; Welti, Jon; Yuan, Wei; Dart, Dafydd A.; Knight, Eleanor; Ning, Jian; Francis, Jeffrey C.; Kounatidou, Evangelia E.; Gaughan, Luke; Swain, Amanda; Lupold, Shawn E.; de Bono, Johann S.; McGuire, Sean E.; Gidrol, Xavier; Bevan, Charlotte L.			Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer	ONCOGENE			English	Article							EXPRESSION SIGNATURE; CELLS; GENE; PROLIFERATION; PROHIBITIN; VARIANTS; IDENTIFICATION; REGIONS; PROTEIN; TUMORS	Androgen receptor (AR) signalling is a key prostate cancer (PC) driver, even in advanced 'castrate-resistant' disease (CRPC). To systematically identify microRNAs (miRs) modulating AR activity in lethal disease, hormone-responsive and -resistant PC cells expressing a luciferase-based AR reporter were transfected with a miR inhibitor library; 78 inhibitors significantly altered AR activity. Upon validation, miR-346, miR-361-3p and miR-197 inhibitors markedly reduced AR transcriptional activity, mRNA and protein levels, increased apoptosis, reduced proliferation, repressed EMT, and inhibited PC migration and invasion, demonstrating additive effects with AR inhibition. Corresponding miRs increased AR activity through a novel and anti-dogmatic mechanism of direct association with AR 6.9 kb 3' UTR and transcript stabilisation. In addition, miR-346 and miR-361-3p modulation altered levels of constitutively active AR variants, and inhibited variantdriven PC cell proliferation, so may contribute to persistent AR signalling in CRPC in the absence of circulating androgens. Pathway analysis of AGO-PAR-CLIP-identified miR targets revealed roles in DNA replication and repair, cell cycle, signal transduction and immune function. Silencing these targets, including tumour suppressors ARHGDIA and TAGLN2, phenocopied miR effects, demonstrating physiological relevance. MiR-346 additionally upregulated the oncogene, YWHAZ, which correlated with grade, biochemical relapse and metastasis in patients. These AR-modulatory miRs and targets correlated with AR activity in patient biopsies, and were elevated in response to long-term enzalutamide treatment of patient-derived CRPC xenografts. In summary, we identified miRs that modulate AR activity in PC and CRPC, via novel mechanisms, and may represent novel PC therapeutic targets.	[Fletcher, Claire E.; Shibakawa, Akifumi; Leach, Damien A.; Chrysostomou, Stelios L.; Dart, Dafydd A.; Bevan, Charlotte L.] Hammersmith Hosp, Imperial Ctr Translat & Expt Med, Dept Surg & Canc, Imperial Coll London, Du Cane Rd, London W12 0NN, England; [Sulpice, Eric; Combe, Stephanie; Knight, Eleanor; Gidrol, Xavier] Univ Grenoble Alpes, CEA, INSERM, BIG,BGE, 17 Ave Martyrs, F-38054 Grenoble, France; [Hamilton, Mark P.] Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza Houston M822, Houston, TX 77030 USA; [Sharp, Adam; Welti, Jon; Yuan, Wei; de Bono, Johann S.] Inst Canc Res, Prostate Canc Target Therapy Grp, Sutton, Surrey, England; [Sharp, Adam; Welti, Jon; Yuan, Wei; de Bono, Johann S.] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England; [Ning, Jian; Francis, Jeffrey C.; Swain, Amanda] Inst Canc Res, Tumour Profiling Unit, London SW3 6JB, England; [Kounatidou, Evangelia E.; Gaughan, Luke] Newcastle Univ, Northern Inst Canc Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Lupold, Shawn E.] Johns Hopkins Univ, Sch Med, James Buchanan Brady Urol Inst, Baltimore, MD USA; [McGuire, Sean E.] Med Hosp, Dept Mol & Cell Biol, Baylor Coll, Houston, TX USA; [McGuire, Sean E.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA; [McGuire, Sean E.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA	Imperial College London; CEA; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); Baylor College of Medicine; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Newcastle University - UK; Johns Hopkins University; Baylor College of Medicine; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Bevan, CL (corresponding author), Hammersmith Hosp, Imperial Ctr Translat & Expt Med, Dept Surg & Canc, Imperial Coll London, Du Cane Rd, London W12 0NN, England.	charlotte.bevan@imperial.ac.uk	Bevan, Charlotte L/K-2276-2012	Bevan, Charlotte L/0000-0002-7533-0552; Gidrol, Xavier/0000-0002-4233-3749; Sulpice, Eric/0000-0001-7695-0561; de Bono, Johann S/0000-0002-2034-595X; Fletcher, Claire/0000-0003-2083-2798; Sharp, Adam/0000-0002-3740-1612; Leach, Damien/0000-0003-3203-9826	Prostate Cancer UK; Movember Foundation through the London Movember Centre of Excellence [CEO13_2-002]; Prostate Cancer Foundation; Movember; MRC [MR/M018318/1] Funding Source: UKRI	Prostate Cancer UK; Movember Foundation through the London Movember Centre of Excellence; Prostate Cancer Foundation; Movember; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We are grateful for the assistance of Laurent Guyon and Kristina Skare with statistical analysis of screening data. This work was supported by Prostate Cancer UK and the Movember Foundation through the London Movember Centre of Excellence (CEO13_2-002). We also gratefully acknowledge funding from Movember, Prostate Cancer UK and also the Prostate Cancer Foundation, and infrastructure support from the Cancer Research UK Imperial Centre, the Imperial Experimental Cancer Medicine Centre and the National Institute for Health Research Imperial Biomedical Research Centre.	Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144; Brideau C, 2003, J BIOMOL SCREEN, V8, P634, DOI 10.1177/1087057103258285; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Cheng HL, 2011, METHODS MOL BIOL, V776, P95, DOI 10.1007/978-1-61779-243-4_7; Dart DA, 2009, ENDOCR-RELAT CANCER, V16, P1157, DOI 10.1677/ERC-09-0028; Epis MR, 2009, J BIOL CHEM, V284, P24696, DOI 10.1074/jbc.M109.030098; Gamble SC, 2007, ONCOGENE, V26, P1757, DOI 10.1038/sj.onc.1209967; Gamble SC, 2004, ONCOGENE, V23, P2996, DOI 10.1038/sj.onc.1207444; Gandellini P, 2010, DISCOV MED, V9, P212; Goc A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040594; Guo JF, 2015, J BIOL CHEM, V290, P30342, DOI 10.1074/jbc.M115.691857; Guzel E, 2015, INT J CANCER, V136, P875, DOI 10.1002/ijc.29054; Hagman Z, 2013, BRIT J CANCER, V108, P1668, DOI 10.1038/bjc.2013.131; Hamilton MP, 2016, NEOPLASIA, V18, P356, DOI 10.1016/j.neo.2016.04.008; Hu R, 2011, PROSTATE, V71, P1656, DOI 10.1002/pros.21382; James ND, 2017, NEW ENGL J MED, V377, P338, DOI 10.1056/NEJMoa1702900; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kashat M, 2012, AM J TRANSL RES, V4, P432; Kim D, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r72; Koivisto P, 1998, AM J PATHOL, V152, P1; Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843; Kumar A, 2016, NAT MED, V22, P369, DOI 10.1038/nm.4053; Kumar B, 2016, ONCOTARGET, V7, P72593, DOI 10.18632/oncotarget.12241; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Larne O, 2015, EUR UROL, V68, P581, DOI 10.1016/j.eururo.2014.12.025; Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016; Mellinghoff IK, 2004, CANCER CELL, V6, P517, DOI 10.1016/j.ccr.2004.09.031; Murata T, 2012, CLIN CANCER RES, V18, P5617, DOI 10.1158/1078-0432.CCR-12-0281; Nadiminty N, 2012, J BIOL CHEM, V287, P1527, DOI 10.1074/jbc.M111.278705; Nyquist MD, 2013, P NATL ACAD SCI USA, V110, P17492, DOI 10.1073/pnas.1308587110; Ostling P, 2011, CANCER RES, V71, P1956, DOI 10.1158/0008-5472.CAN-10-2421; Ozen M, 2008, ONCOGENE, V27, P1788, DOI 10.1038/sj.onc.1210809; Pang YX, 2010, ACTA BIOCH BIOPH SIN, V42, P363, DOI 10.1093/abbs/gmq038; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; Qu FJ, 2013, MOL CELL BIOCHEM, V377, P121, DOI 10.1007/s11010-013-1576-z; Ribas J, 2009, CANCER RES, V69, P7165, DOI 10.1158/0008-5472.CAN-09-1448; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Shenouda SK, 2009, CANCER METAST REV, V28, P369, DOI 10.1007/s10555-009-9188-5; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sikand Kavleen, 2011, Mol Cell Pharmacol, V3, P107; Sikand K, 2011, INT J CANCER, V129, P810, DOI 10.1002/ijc.25753; Song G, 2015, SCI REP-UK, V5, DOI 10.1038/srep15793; Takkunen M, 2006, J HISTOCHEM CYTOCHEM, V54, P1263, DOI 10.1369/jhc.6A6958.2006; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Van Etten JL, 2017, CANCER RES, V77, P5228, DOI 10.1158/0008-5472.CAN-17-0320; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wadosky KM, 2016, ONCOTARGET, V7, P64447, DOI 10.18632/oncotarget.10901; Waltering KK, 2006, PROSTATE, V66, P1585, DOI 10.1002/pros.20387; Wang G, 2006, ONCOGENE, V25, P7311, DOI 10.1038/sj.onc.1209715; Ware KE, 2014, ENDOCR-RELAT CANCER, V21, pT87, DOI 10.1530/ERC-13-0470; Yang ZM, 2007, MOL ENDOCRINOL, V21, P343, DOI 10.1210/me.2006-0104; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897; Zhang BL, 2005, CANCER RES, V65, P6054, DOI 10.1158/0008-5472.CAN-05-0175; Zhang ZW, 2010, ASIAN J ANDROL, V12, P186, DOI 10.1038/aja.2009.76; Zhu YZ, 2013, PROSTATE, V73, P1614, DOI 10.1002/pros.22615; Zohn IE, 2006, CELL, V125, P957, DOI 10.1016/j.cell.2006.03.048	56	38	41	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2019	38	28					5700	5724		10.1038/s41388-019-0823-5	http://dx.doi.org/10.1038/s41388-019-0823-5			25	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IH9RW	31043708	Green Published, hybrid			2022-12-28	WOS:000474845100011
J	He, MJ; Jin, QN; Chen, C; Liu, YF; Ye, XS; Jiang, YL; Ji, FH; Qian, HS; Gan, DL; Yue, SJ; Zhu, W; Chen, TM				He, Mengjia; Jin, Qianni; Chen, Cong; Liu, Yifeng; Ye, Xiangsen; Jiang, Yulin; Ji, Feihu; Qian, Husun; Gan, Delu; Yue, Shujun; Zhu, Wei; Chen, Tingmei			The miR-186-3p/EREG axis orchestrates tamoxifen resistance and aerobic glycolysis in breast cancer cells	ONCOGENE			English	Article							COLORECTAL-CANCER; MICRORNA; GROWTH; EPIREGULIN; SENSITIVITY; ACTIVATION; MECHANISMS; EXPRESSION; PATHWAY; GENE	Tamoxifen resistance is one of the major challenges for its medical uses in estrogen receptor (ER)-positive breast cancer. Aerobic glycolysis, an anomalous characteristic of glucose metabolism in cancer cells, has been shown to associate with the resistance to chemotherapeutic agents. It remains, however, largely unclear whether and how tamoxifen resistance contributes to aerobic glycolysis in breast cancer. Here, we report that tamoxifen resistance is associated with enhanced glycolysis in ER-positive breast cancer cells. We demonstrate that EREG, an agonist of EGFR, has an important role in enhancing glycolysis via activating EGFR signaling and its downstream glycolytic genes in tamoxifen-resistant breast cancer cells. We further show that EREG is a direct target of miR-186-3p and that downregulation of miR-186-3p by tamoxifen results in EREG upregulation in tamoxifen-resistant breast cancer cells. Importantly, systemic delivery of cholesterolmodified agomiR-186-3p to mice bearing tamoxifen-resistant breast tumors effectively attenuates both tumor growth and [F-18]-fluoro-deoxyglucose ([F-18]-FDG) uptake. Together, our results reveal a novel molecular mechanism of resistance to hormone therapies in which the miR-186-3p/EREG axis orchestrates tamoxifen resistance and aerobic glycolysis in ER-positive breast cancer, suggesting targeting miR-186-3p as a promising strategy for therapeutic intervention in endocrineresistant breast tumors.	[He, Mengjia] Chongqing Med Univ, Coll Clin Med, Chongqing 400016, Peoples R China; [Jin, Qianni; Liu, Yifeng; Ye, Xiangsen; Jiang, Yulin; Ji, Feihu; Qian, Husun; Gan, Delu; Yue, Shujun; Chen, Tingmei] Chongqing Med Univ, Minist Educ, Key Lab Diagnost Med Designated, Chongqing 400016, Peoples R China; [Jin, Qianni; Liu, Yifeng; Ye, Xiangsen; Jiang, Yulin; Ji, Feihu; Qian, Husun; Gan, Delu; Yue, Shujun; Chen, Tingmei] Chongqing Med Univ, Dept Lab Med, Chongqing 400016, Peoples R China; [Chen, Cong; Zhu, Wei] Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Shanghai 200032, Peoples R China	Chongqing Medical University; Chongqing Medical University; Chongqing Medical University; Fudan University	Chen, TM (corresponding author), Chongqing Med Univ, Minist Educ, Key Lab Diagnost Med Designated, Chongqing 400016, Peoples R China.; Chen, TM (corresponding author), Chongqing Med Univ, Dept Lab Med, Chongqing 400016, Peoples R China.; Zhu, W (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Shanghai 200032, Peoples R China.	zhu.wei1@zs-hospital.sh.cn; tingmeichen@cqmu.edu.cn	liu, yi/GXE-9662-2022	Chen, Tingmei/0000-0003-4250-674X	National Natural Science Foundation of China [81272544, 81502267]; Foundation and frontier science and technology project of Yuzhong district science and technology commission, Chongqing, China [20150121]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Foundation and frontier science and technology project of Yuzhong district science and technology commission, Chongqing, China	We thank members of the Chen's and Zhu's labs for helpful comments. This work was supported by grants from the National Natural Science Foundation of China (81272544 and 81502267) and Foundation and frontier science and technology project of Yuzhong district science and technology commission, Chongqing, China (20150121).	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; [Anonymous], ASN00022011 ANSIATCC; Bhattacharya B, 2016, BRIT J PHARMACOL, V173, P970, DOI 10.1111/bph.13422; Connor CE, 2001, CANCER RES, V61, P2917; Daurio NA, 2016, CANCER RES, V76, P3295, DOI 10.1158/0008-5472.CAN-15-2197; Fischer K, 2007, BLOOD, V109, P3812, DOI 10.1182/blood-2006-07-035972; Gambhir SS, 2000, P NATL ACAD SCI USA, V97, P2785, DOI 10.1073/pnas.97.6.2785; Gee JMW, 2003, ENDOCRINOLOGY, V144, P5105, DOI 10.1210/en.2003-0705; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Iorns E, 2009, BIOCHEM J, V417, P361, DOI 10.1042/BJ20081682; JAIYESIMI IA, 1995, J CLIN ONCOL, V13, P513, DOI 10.1200/JCO.1995.13.2.513; Jiang S, 2012, EMBO J, V31, P1985, DOI 10.1038/emboj.2012.45; Johnston SRD, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv212; Knowlden JM, 2003, ENDOCRINOLOGY, V144, P1032, DOI 10.1210/en.2002-220620; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li CF, 2017, BIOCHEM BIOPH RES CO, V491, P552, DOI 10.1016/j.bbrc.2017.03.042; Lim SO, 2016, CANCER RES, V76, P1284, DOI 10.1158/0008-5472.CAN-15-2478; Lin SB, 2015, NAT REV CANCER, V15, P321, DOI 10.1038/nrc3932; Liu L, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.35; Ma CX, 2009, ONCOLOGY-NY, V23, P133; Ma J, 2010, CANCER GENE THER, V17, P523, DOI 10.1038/cgt.2010.18; Massarweh S, 2008, CANCER RES, V68, P826, DOI 10.1158/0008-5472.CAN-07-2707; Miao Y, 2016, MOL THER-NUCL ACIDS, V5, DOI 10.1038/mtna.2016.72; Mills JN, 2018, CURR OPIN PHARMACOL, V41, P59, DOI 10.1016/j.coph.2018.04.009; Mishra S, 2016, CRIT REV ONCOL HEMAT, V98, P12, DOI 10.1016/j.critrevonc.2015.10.003; Morandi A, 2017, BBA-REV CANCER, V1868, P1, DOI 10.1016/j.bbcan.2016.12.004; Park WC, 2005, INT J ONCOL, V27, P1459; Peifer Christian, 2009, Biochem J, V417, pe5, DOI 10.1042/BJ20082243; Poliakova M, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0798-9; Qu X, 2016, ONCOGENE, V35, P6403, DOI 10.1038/onc.2016.170; Revillion F, 2008, ANN ONCOL, V19, P73, DOI 10.1093/annonc/mdm431; Santen RJ, 2009, STEROIDS, V74, P586, DOI 10.1016/j.steroids.2008.11.020; Schneider MR, 2009, J CELL PHYSIOL, V218, P460, DOI 10.1002/jcp.21635; Shelly M, 1998, J BIOL CHEM, V273, P10496, DOI 10.1074/jbc.273.17.10496; Sun P, 2014, ASIAN PAC J CANCER P, V15, P4245, DOI 10.7314/APJCP.2014.15.10.4245; Sunaga N, 2013, ONCOGENE, V32, P4034, DOI 10.1038/onc.2012.402; Swietach P, 2007, CANCER METAST REV, V26, P299, DOI 10.1007/s10555-007-9064-0; Thrane S, 2015, ONCOGENE, V34, P4199, DOI 10.1038/onc.2014.351; Torres-Arzayus MI, 2004, CANCER CELL, V6, P263, DOI 10.1016/j.ccr.2004.06.027; Torring N, 2000, ANTICANCER RES, V20, P91; Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Wang L, 2014, CANCER RES, V74, P4720, DOI 10.1158/0008-5472.CAN-14-0960; Ye JJ, 2016, MOL BIOSYST, V12, P3417, DOI 10.1039/c6mb00576d; Zhang LF, 2017, CELL MOL LIFE SCI, V74, P2929, DOI 10.1007/s00018-017-2508-y; Zhang LF, 2015, EMBO J, V34, P2671, DOI 10.15252/embj.201591803; Zhao S, 2009, SCI CHINA SER C, V52, P1111, DOI 10.1007/s11427-009-0152-y; Zhu X, 2016, ONCOGENE, V35, P323, DOI 10.1038/onc.2015.84; Zhu ZW, 2000, BIOCHEM BIOPH RES CO, V273, P1019, DOI 10.1006/bbrc.2000.3033	50	52	53	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2019	38	28					5551	5565		10.1038/s41388-019-0817-3	http://dx.doi.org/10.1038/s41388-019-0817-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IH9RW	30967627				2022-12-28	WOS:000474845100001
J	Casado-Medrano, V; Barrio-Real, L; Wang, A; Cooke, M; Lopez-Haber, C; Kazanietz, MG				Casado-Medrano, Victoria; Barrio-Real, Laura; Wang, Anita; Cooke, Mariana; Lopez-Haber, Cynthia; Kazanietz, Marcelo G.			Distinctive requirement of PKC epsilon in the control of Rho GTPases in epithelial and mesenchymally transformed lung cancer cells	ONCOGENE			English	Article							PROTEIN-KINASE-C; DOWN-REGULATION; PROSTATE-CANCER; BREAST-CANCER; CONSTITUTIVE ACTIVATION; ESSENTIAL MEDIATOR; EXPRESSION; GEF; PHOSPHORYLATION; DIFFERENTIATION	Diacylglycerol (DAG)/phorbol ester-regulated protein kinase C (PKC) isozymes have been widely linked to tumor promotion and the development of a metastatic phenotype. PKC epsilon, an oncogenic member of the PKC family, is abnormally overexpressed in lung cancer and other cancer types. This kinase plays significant roles in proliferation, survival, and migration; however, its role in epithelial-to-mesenchymal transition (EMT) has been scarcely studied. Silencing experiments in non-small lung cancer (NSCLC) cells revealed that PKC epsilon or other DAG-regulated PKCs (PKC alpha and PKC delta) were dispensable for the acquisition of a mesenchymal phenotype induced by transforming growth factor beta (TGF-beta. Unexpectedly, we found a nearly complete down-regulation of PKC epsilon expression in TGF-beta-mesenchymally transformed NSCLC cells. PMA and AJH-836 (a DAG-mimetic that preferentially activates PKC epsilon) promote ruffle formation in NSCLC cells via Racl, however they fail to induce these morphological changes in TGF-beta-mesenchymally transformed cells despite their elevated Racl activity. Several Rac guanine nucleotide exchange-factors (Rac-GEFs) were also up-regulated in TGF-beta-treated NSCLC cells, including Trio and Tiam2, which were required for cell motility. Lastly, we found that silencing or inhibiting PKC epsilon enhances RhoA activity and stress fiber formation, a phenotype also observed in TGF-beta-transformed cells. Our studies established a distinctive involvement of PKC in epithelial and mesenchymal NSCLC cells, and identified a complex interplay between PKC epsilon and small GTPases that contributes to regulation of NSCLC cell morphology and motile activity.	[Casado-Medrano, Victoria; Barrio-Real, Laura; Wang, Anita; Cooke, Mariana; Lopez-Haber, Cynthia; Kazanietz, Marcelo G.] Univ Penn, Perelman Sch Med, Dept Syst Pharmacol & Translat Therapeut, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Kazanietz, MG (corresponding author), Univ Penn, Perelman Sch Med, Dept Syst Pharmacol & Translat Therapeut, Philadelphia, PA 19104 USA.	marcelog@upenn.edu	Cooke, Mariana/ABD-5051-2021; Casado-Medrano, Victoria/ABE-6429-2021	Casado-Medrano, Victoria/0000-0002-6929-4559; Cooke, Mariana/0000-0001-9300-8447; Lopez Haber, Cynthia/0000-0001-9106-543X	National Institutes of Health [R01-ES026023, R01-ES026023-S1]; NATIONAL CANCER INSTITUTE [R01CA196232] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES026023] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by grant R01-ES026023 and R01-ES026023-S1 from the National Institutes of Health to M.G.K.	Aziz MH, 2007, CANCER RES, V67, P8828, DOI 10.1158/0008-5472.CAN-07-1604; Bae KM, 2007, CANCER RES, V67, P6053, DOI 10.1158/0008-5472.CAN-06-4037; Barrio-Real Laura, 2018, Oncotarget, V9, P28612, DOI 10.18632/oncotarget.25584; Bassini A, 1999, BLOOD, V93, P1178, DOI 10.1182/blood.V93.4.1178.404k28_1178_1188; Basu A, 2007, CELL SIGNAL, V19, P1633, DOI 10.1016/j.cellsig.2007.04.008; Benavides F, 2011, CELL CYCLE, V10, P268, DOI 10.4161/cc.10.2.14469; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Bin Hafeez B, 2011, CANCER RES, V71, P2318, DOI 10.1158/0008-5472.CAN-10-4170; Brown KA, 2004, BREAST CANCER RES, V6, pR215, DOI 10.1186/bcr778; Burgos M, 2007, GLIA, V55, P1437, DOI 10.1002/glia.20555; Bustelo XR, 2018, BIOCHEM SOC T, V46, P741, DOI 10.1042/BST20170531; Caino MC, 2012, ONCOGENE, V31, P2593, DOI 10.1038/onc.2011.428; Caino MC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031714; Chang MT, 2016, NAT BIOTECHNOL, V34, P155, DOI 10.1038/nbt.3391; Cook Danielle R, 2011, Genes Cancer, V2, P932, DOI 10.1177/1947601912437035; Cooke M, 2018, J BIOL CHEM, V293, P8330, DOI 10.1074/jbc.RA117.000235; David CJ, 2016, CELL, V164, P1015, DOI 10.1016/j.cell.2016.01.009; Di Marcantonio D, 2015, EXP CELL RES, V339, P10, DOI 10.1016/j.yexcr.2015.09.017; Fleming IN, 1997, J BIOL CHEM, V272, P33105, DOI 10.1074/jbc.272.52.33105; Gaboardi GC, 2010, CELL SIGNAL, V22, P629, DOI 10.1016/j.cellsig.2009.11.017; Galli D, 2015, EXP CELL RES, V330, P277, DOI 10.1016/j.yexcr.2014.11.011; Gandellini P, 2009, CANCER RES, V69, P2287, DOI 10.1158/0008-5472.CAN-08-2894; Gao S, 2009, MOL CELL, V36, P457, DOI 10.1016/j.molcel.2009.09.043; Garcia-Mata R, 2007, TRENDS CELL BIOL, V17, P36, DOI 10.1016/j.tcb.2006.11.004; Garg R, 2014, ONCOGENE, V33, P5225, DOI 10.1038/onc.2013.524; Garg R, 2018, ONCOGENE, V37, P4735, DOI 10.1038/s41388-018-0318-9; Garg R, 2017, CELL REP, V19, P375, DOI 10.1016/j.celrep.2017.03.042; Garg R, 2012, J BIOL CHEM, V287, P37570, DOI 10.1074/jbc.M112.398925; Garofalo M, 2011, ANNU REV PHARMACOL, V51, P25, DOI 10.1146/annurev-pharmtox-010510-100517; Gobbi G, 2007, STEM CELLS, V25, P2322, DOI 10.1634/stemcells.2006-0839; Gobbi G, 2013, BLOOD, V122, P1305, DOI 10.1182/blood-2013-04-490599; Gobbi G, 2012, J CELL PHYSIOL, V227, P630, DOI 10.1002/jcp.22765; Gobbi G, 2010, INT J ONCOL, V37, P719, DOI 10.3892/ijo_00000721; Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189; Gorin MA, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-9; Gorshkova I, 2008, J BIOL CHEM, V283, P11794, DOI 10.1074/jbc.M800250200; Griner EM, 2007, NAT REV CANCER, V7, P281, DOI 10.1038/nrc2110; Griner EM, 2010, J BIOL CHEM, V285, P16931, DOI 10.1074/jbc.M109.099036; Guilluy C, 2011, NAT PROTOC, V6, P2050, DOI 10.1038/nprot.2011.411; Gutierrez-Uzquiza A, 2015, MOL CANCER RES, V13, P1336, DOI 10.1158/1541-7786.MCR-15-0111; Hafeez Bilal Bin, 2015, Cancer Prev Res (Phila), V8, P375, DOI 10.1158/1940-6207.CAPR-14-0231; Hall A, 2005, BIOCHEM SOC T, V33, P891, DOI 10.1042/BST0330891; Hill KS, 2014, ONCOGENE, V33, P2134, DOI 10.1038/onc.2013.147; Isakov N, 2018, SEMIN CANCER BIOL, V48, P36, DOI 10.1016/j.semcancer.2017.04.012; Iyengar PV, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040877; Jain K, 2014, CANCERS, V6, P860, DOI 10.3390/cancers6020860; Jain K, 2014, BREAST CANCER-BASIC, V8, P61, DOI 10.4137/BCBCR.S13640; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Leask A, 2008, J CELL SCI, V121, P3459, DOI 10.1242/jcs.029215; Leontieva OV, 2004, J BIOL CHEM, V279, P5788, DOI 10.1074/jbc.M308375200; Levay M, 2009, BIOCHEMISTRY-US, V48, P8615, DOI 10.1021/bi900667y; Lopez-Haber C, 2016, MOL CELL BIOL, V36, P2011, DOI 10.1128/MCB.00180-16; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Meshki J, 2010, J BIOL CHEM, V285, P26033, DOI 10.1074/jbc.M110.128371; Mochly-Rosen D, 2012, NAT REV DRUG DISCOV, V11, P937, DOI 10.1038/nrd3871; Montero JC, 2016, ONCOTARGET, V7, P77937, DOI 10.18632/oncotarget.12846; Newton AC, 2017, TRENDS PHARMACOL SCI, V38, P438, DOI 10.1016/j.tips.2017.02.002; Ong ST, 2014, J BIOL CHEM, V289, P19420, DOI 10.1074/jbc.M113.545863; Pan Q, 2005, CANCER RES, V65, P8366, DOI 10.1158/0008-5472.CAN-05-0553; Pan Q, 2006, CANCER RES, V66, P9379, DOI 10.1158/0008-5472.CAN-06-2646; Pang MF, 2016, ONCOGENE, V35, P748, DOI 10.1038/onc.2015.133; Pardo OE, 2006, EMBO J, V25, P3078, DOI 10.1038/sj.emboj.7601198; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Shankar E, 2008, ONCOGENE, V27, P3957, DOI 10.1038/onc.2008.39; Slupsky JR, 2007, AM J PATHOL, V170, P745, DOI 10.2353/ajpath.2007.060557; Sosa MS, 2010, MOL CELL, V40, P877, DOI 10.1016/j.molcel.2010.11.029; Sun XW, 2018, J CELL PHYSIOL, V233, P596, DOI 10.1002/jcp.25920; Symonds JM, 2011, CANCER RES, V71, P2087, DOI 10.1158/0008-5472.CAN-10-1511; Ungefroren H, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061568; Ungefroren H, 2018, DEV DYNAM, V247, P451, DOI 10.1002/dvdy.24505; Wang HB, 2014, J BIOL CHEM, V289, P19823, DOI 10.1074/jbc.M114.548446; Wang LY, 2017, PEPTIDES, V96, P44, DOI 10.1016/j.peptides.2017.08.006; Wang YY, 2015, CELL PHYSIOL BIOCHEM, V36, P179, DOI 10.1159/000374062; Wu-Zhang AX, 2013, BIOCHEM J, V452, P195, DOI 10.1042/BJ20130220; Yu JR, 2015, GENE DEV, V29, P250, DOI 10.1101/gad.248963.114; Zeidman R, 2002, MOL BIOL CELL, V13, P12, DOI 10.1091/mbc.01-04-0210; Zhang HT, 2009, BIOL REPROD, V80, P440, DOI 10.1095/biolreprod.108.072983; Zhang XP, 2014, INT J CANCER, V134, P257, DOI 10.1002/ijc.28141; Zhao W, 2015, MOL BIOL CELL, V26, P1786, DOI 10.1091/mbc.E14-10-1474	81	8	11	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2019	38	27					5396	5412		10.1038/s41388-019-0796-4	http://dx.doi.org/10.1038/s41388-019-0796-4			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IG5KR	30923343	Green Accepted			2022-12-28	WOS:000473842500005
J	Wu, MQ; Sheng, L; Cheng, MS; Zhang, HJ; Jiang, YZ; Lin, SB; Liang, Y; Zhu, FY; Liu, ZQ; Zhang, YY; Zhang, XH; Gao, Q; Chen, DM; Li, J; Li, Y				Wu, Mingqing; Sheng, Lu; Cheng, Maosheng; Zhang, Haojie; Jiang, Yizhou; Lin, Shuibin; Liang, Yu; Zhu, Fengyu; Liu, Zhenqing; Zhang, Yingyin; Zhang, Xiuhong; Gao, Qian; Chen, Demeng; Li, Jiong; Li, Yang			Low doses of decitabine improve the chemotherapy efficacy against basal-like bladder cancer by targeting cancer stem cells	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; DNA METHYLATION; UROTHELIAL CARCINOMA; MOLECULAR CHARACTERIZATION; AGENT DECITABINE; INITIATING CELLS; PROGRESSION; DIFFERENTIATION; IDENTIFICATION; COMBINATION	Low dose treatment with the DNA methylation inhibitor decitabine has been shown to be applicable for the management of certain types of cancer. However, its antitumor effect and mechanisms are context dependent and its activity has never been systematically studied in bladder cancer treatment. We used mouse models, cultured cell lines and patient-derived xenografts to demonstrate that low dose decitabine treatment remarkably enhanced the effects of cisplatin and gemcitabine on basal-like bladder cancer both in vivo and in vitro. Genetic lineage tracing revealed that the stemness of a bladder cancer stem cell population was inhibited by decitabine treatment in mice. These effects were accompanied by decreases in genome-wide DNA methylation, gene re-expression, and changes in key cellular regulatory pathways such as STAT3 signaling. These results indicate that this DNA-demethylating reagent is a promising therapeutic approach for basal-like bladder cancer treatment.	[Wu, Mingqing; Cheng, Maosheng; Liang, Yu; Zhu, Fengyu; Zhang, Yingyin; Zhang, Xiuhong; Gao, Qian; Li, Yang] Anhui Med Univ, Sch Life Sci, Dept Genet, Hefei 230031, Anhui, Peoples R China; [Sheng, Lu; Zhang, Haojie] Fudan Univ, Huadong Hosp, Dept Urol, Shanghai 200040, Peoples R China; [Jiang, Yizhou] Shenzhen Univ, Inst Adv Study, Shenzhen 518060, Guangdong, Peoples R China; [Lin, Shuibin; Chen, Demeng] Sun Yat Sen Univ, Affiliated Hosp 1, Ctr Translat Med, Guangzhou 510080, Guangdong, Peoples R China; [Liu, Zhenqing; Li, Jiong] Univ Calif Los Angeles, Lab Mol Signaling, Div Oral Biol & Med, Sch Dent, Los Angeles, CA 90095 USA; [Liu, Zhenqing; Li, Jiong] Univ Calif Los Angeles, Broad Stem Cell Res Ctr, Los Angeles, CA 90095 USA; [Li, Jiong] Virginia Commonwealth Univ, Inst Struct Biol Drug Discovery & Dev, Dept Med Chem, Sch Pharm, 800 E Leigh St, Richmond, VA 23284 USA	Anhui Medical University; Fudan University; Shenzhen University; Sun Yat Sen University; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Virginia Commonwealth University	Li, Y (corresponding author), Anhui Med Univ, Sch Life Sci, Dept Genet, Hefei 230031, Anhui, Peoples R China.; Chen, DM (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Ctr Translat Med, Guangzhou 510080, Guangdong, Peoples R China.; Li, J (corresponding author), Univ Calif Los Angeles, Lab Mol Signaling, Div Oral Biol & Med, Sch Dent, Los Angeles, CA 90095 USA.; Li, J (corresponding author), Univ Calif Los Angeles, Broad Stem Cell Res Ctr, Los Angeles, CA 90095 USA.; Li, J (corresponding author), Virginia Commonwealth Univ, Inst Struct Biol Drug Discovery & Dev, Dept Med Chem, Sch Pharm, 800 E Leigh St, Richmond, VA 23284 USA.	chendm29@mail.sysu.edu.cn; jli29@vcu.edu; liyang@ahmu.edu.cn			National Natural Science Foundation of China [81872313, 81672776, 31501838]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (81872313 and 81672776 to YL, 31501838 to XHZ).	Alcazar O, 2012, INT J CANCER, V131, P18, DOI 10.1002/ijc.26320; Anastasiadis A, 2012, THER ADV UROL, V4, P13, DOI 10.1177/1756287211431976; Babjuk M, 2013, EUR UROL, V64, P639, DOI 10.1016/j.eururo.2013.06.003; BECCI PJ, 1978, CANCER RES, V38, P4463; Beck B, 2013, NAT REV CANCER, V13, P727, DOI 10.1038/nrc3597; Blum W, 2007, J CLIN ONCOL, V25, P3884, DOI 10.1200/JCO.2006.09.4169; Cashen AF, 2010, J CLIN ONCOL, V28, P556, DOI 10.1200/JCO.2009.23.9178; Chan KS, 2009, P NATL ACAD SCI USA, V106, P14016, DOI 10.1073/pnas.0906549106; Chen MX, 2018, INT J CANCER, V143, P1530, DOI 10.1002/ijc.31531; Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009; Deng WK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111988; Felsenstein KM, 2018, NAT REV UROL, V15, P92, DOI 10.1038/nrurol.2017.179; Ferguson AT, 1997, J BIOL CHEM, V272, P32260, DOI 10.1074/jbc.272.51.32260; Flotho C, 2009, LEUKEMIA, V23, P1019, DOI 10.1038/leu.2008.397; Fu XY, 2015, CURR PROTEIN PEPT SC, V16, P329, DOI 10.2174/138920371604150429155740; Ghoshal K, 2005, MOL CELL BIOL, V25, P4727, DOI 10.1128/MCB.25.11.4727-4741.2005; Hagemann S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017388; Ho PL, 2012, NAT REV UROL, V9, P583, DOI 10.1038/nrurol.2012.142; Ho PL, 2012, CANCER RES, V72, P3135, DOI 10.1158/0008-5472.CAN-11-3195; Huang HY, 2007, HUM PATHOL, V38, P1703, DOI 10.1016/j.humpath.2007.04.003; Issa JPJ, 2004, BLOOD, V103, P1635, DOI 10.1182/blood-2003-03-0687; Juergens RA, 2011, CANCER DISCOV, V1, P598, DOI 10.1158/2159-8290.CD-11-0214; Kahn SL, 2008, CANCER CYTOPATHOL, V114, P57, DOI 10.1002/cncr.23258; Kandimalla R, 2013, NAT REV UROL, V10, P327, DOI 10.1038/nrurol.2013.89; Khandelwal M, 2018, MOL CELL BIOCHEM, V446, P105, DOI 10.1007/s11010-018-3278-z; Kurtova AV, 2015, NATURE, V517, P209, DOI 10.1038/nature14034; Li LM, 2018, ONCOTARGETS THER, V11, P6863, DOI 10.2147/OTT.S161919; Li X, 2017, CLIN CANCER RES, V23, P6031, DOI 10.1158/1078-0432.CCR-17-1201; Li Y, 2015, ONCOTARGET, V6, P10195, DOI 10.18632/oncotarget.3555; Li Y, 2011, CANCER SCI, V102, P2043, DOI 10.1111/j.1349-7006.2011.02061.x; Liang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep29479; Licht JD, 2015, CELL, V162, P938, DOI 10.1016/j.cell.2015.08.005; Lv L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.367; Malik P, 2014, CANCER MANAG RES, V6, P53, DOI 10.2147/CMAR.S40600; Momparler RL, 2005, SEMIN HEMATOL, V42, pS9, DOI 10.1053/j.seminhematol.2005.05.002; O'Flaherty JD, 2012, J THORAC ONCOL, V7, P1880, DOI 10.1097/JTO.0b013e31826bfbc6; Oz S, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku775; Oing C, 2016, J UROLOGY, V195, P254, DOI 10.1016/j.juro.2015.06.115; Paner GP, 2014, HUM PATHOL, V45, P1473, DOI 10.1016/j.humpath.2014.02.024; Papafotiou G, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11914; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pei M, 2009, DIFFERENTIATION, V78, P260, DOI 10.1016/j.diff.2009.08.001; Peng D, 2018, EPIGENOMICS-UK, V10, P1189, DOI 10.2217/epi-2018-0017; Rebouissou S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008970; Ribas A, 2014, CLIN CANCER RES, V20, P4982, DOI 10.1158/1078-0432.CCR-14-0933; Saito R, 2018, CANCER RES, V78, P3954, DOI 10.1158/0008-5472.CAN-18-0173; Schulz WA, 2016, EPIGENOMICS-UK, V8, P1415, DOI 10.2217/epi-2016-0064; Shah JB, 2011, CLIN CANCER RES, V17, P2608, DOI 10.1158/1078-0432.CCR-10-2770; Shang DH, 2008, UROLOGY, V71, P1220, DOI 10.1016/j.urology.2007.11.029; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sonpavde G, 2016, J CLIN ONCOL, V34, P780, DOI 10.1200/JCO.2015.65.4442; Su Y, 2010, CANCER EPIDEM BIOMAR, V19, P327, DOI 10.1158/1055-9965.EPI-09-0865; Timp W, 2013, NAT REV CANCER, V13, P497, DOI 10.1038/nrc3486; Triozzi PL, 2012, CANCER IMMUNOL IMMUN, V61, P1441, DOI 10.1007/s00262-012-1204-x; Tsai HC, 2012, CANCER CELL, V21, P430, DOI 10.1016/j.ccr.2011.12.029; Van Batavia J, 2014, NAT CELL BIOL, V16, P982, DOI 10.1038/ncb3038; Volkmer JP, 2012, P NATL ACAD SCI USA, V109, P2078, DOI 10.1073/pnas.1120605109; von der Maase H, 2005, J CLIN ONCOL, V23, P4602, DOI 10.1200/JCO.2005.07.757; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Williams PD, 2008, NEOPLASIA, V10, P838, DOI 10.1593/neo.08432; Xylinas E, 2016, BIOMOLECULES, V6, DOI 10.3390/biom6030037; Yan P, 2012, BLOOD, V120, P2466, DOI 10.1182/blood-2012-05-429175; Yang YM, 2008, CANCER INVEST, V26, P725, DOI 10.1080/07357900801941845; Yu GJ, 2019, CELL MOL IMMUNOL, V16, P401, DOI 10.1038/s41423-018-0026-y; Zhao D, 2015, ONCOGENE, V34, P3107, DOI 10.1038/onc.2014.257; Zhu FY, 2017, STEM CELL REP, V9, P429, DOI 10.1016/j.stemcr.2017.07.004	66	15	16	3	26	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2019	38	27					5425	5439		10.1038/s41388-019-0799-1	http://dx.doi.org/10.1038/s41388-019-0799-1			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IG5KR	30918330				2022-12-28	WOS:000473842500007
J	Rossa, C; D'Silva, NJ				Rossa, Carlos, Jr.; D'Silva, Nisha J.			Non-murine models to investigate tumor-immune interactions in head and neck cancer	ONCOGENE			English	Review							SQUAMOUS-CELL CARCINOMA; FUNCTIONAL-CHARACTERIZATION; KNOCKOUT PIGS; EXPRESSION; SURVIVAL; SYSTEM; GENOME; CATS; DOG; IMMUNOTHERAPY	The immune response has important roles in the biology of solid tumors, including oncogenesis, tumor growth, invasion and metastasis, and response to treatment. Improved understanding of tumor-immune system interactions has provided promising therapeutic options that are based on the rescue and enhancement of the anti-tumoral host response. Immunebased treatments have been approved for clinical use in various types of cancer, including head and neck cancer (HNC); other strategies involving combination therapies are currently in development. These novel therapies were developed based on knowledge derived from in vitro, in silico, and in vivo pre-clinical studies. However, clinical trials seldom replicate the efficacy observed in pre-clinical animal studies. This lack of correlation between pre-clinical studies and clinical trials may be related to limitations of the models used; which highlights the relevance of considering immune-related aspects of different pre-clinical models. Murine models are the most frequently used pre-clinical models of HNC and are discussed elsewhere. Non-murine models have characteristics that offer unique opportunities for the study of HNC etiology, therapeutic strategies, and tumor-immune system interactions. The current review focuses on immune-related aspects of nonmurine models, including dog, cat, pig, zebrafish, and frog, that could be used to investigate tumor-immune interactions in HNC.	[Rossa, Carlos, Jr.] State Univ Sao Paulo, UNESP, Sch Dent Araraquara, Dept Diag & Surg, Araraquara, SP, Brazil; [Rossa, Carlos, Jr.; D'Silva, Nisha J.] Univ Michigan, Sch Dent, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA; [D'Silva, Nisha J.] Univ Michigan, Dept Pathol, Med Sch, Ann Arbor, MI 48109 USA	Universidade Estadual Paulista; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Rossa, C (corresponding author), State Univ Sao Paulo, UNESP, Sch Dent Araraquara, Dept Diag & Surg, Araraquara, SP, Brazil.; Rossa, C; D'Silva, NJ (corresponding author), Univ Michigan, Sch Dent, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA.; D'Silva, NJ (corresponding author), Univ Michigan, Dept Pathol, Med Sch, Ann Arbor, MI 48109 USA.	c.rossa@unesp.br; njdsilva@umich.edu	Rossa, Carlos/D-8328-2012	Rossa, Carlos/0000-0003-1705-5481; D'Silva, Nisha/0000-0001-7030-3187	NIH/NIDCR [DE027551, DE022567]; University of Michigan; FAPESP [2017/14283-5, 2014/50312-4]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE022567, R35DE027551] Funding Source: NIH RePORTER	NIH/NIDCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); University of Michigan(University of Michigan System); FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work was supported by grants from NIH/NIDCR DE027551 (NJD), DE022567 (NJD), FAPESP 2017/14283-5 (CRJ), and University of Michigan and FAPESP 2014/50312-4 (NJD and CRJ)	Adam SJ, 2007, ONCOGENE, V26, P1038, DOI 10.1038/sj.onc.1209892; Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923; Alves AM, 2018, J ORAL PATHOL MED, V47, P460, DOI 10.1111/jop.12643; Arnold CR, 2017, OR SURG OR MED OR PA, V123, P536, DOI 10.1016/j.oooo.2016.11.017; Bergeron LM, 2014, VET IMMUNOL IMMUNOP, V157, P31, DOI 10.1016/j.vetimm.2013.10.018; Bergkvist GT, 2011, VET COMP ONCOL, V9, P106, DOI 10.1111/j.1476-5829.2010.00239.x; Bordignon V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064613; Borovansky J, 2003, MELANOMA RES, V13, P543, DOI 10.1097/01.cmr.0000056276.15046.21; Callesen MM, 2017, MOL ONCOL, V11, P1616, DOI 10.1002/1878-0261.12136; Cannon Claire M, 2015, Vet Sci, V2, P111, DOI 10.3390/vetsci2030111; Choi YJ, 2017, ONCOTARGET, V8, P69398, DOI 10.18632/oncotarget.20626; Curry JM, 2007, OTOLARYNG HEAD NECK, V137, P735, DOI 10.1016/j.otohns.2007.07.019; Day M.J., 2014, VET IMMUNOLOGY PRINC; Day MJ, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1798-5; de Almeida EMP, 2001, J HISTOCHEM CYTOCHEM, V49, P867, DOI 10.1177/002215540104900707; De Pelsmaeker S, 2018, J LEUKOCYTE BIOL, V103, P129, DOI 10.1002/JLB.4A0417-163RR; de Ruiter EJ, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1356148; Dobson J. M., 2013, ISRN VET SCI, V2013, DOI DOI 10.1155/2013/941275); Ferris RL, 2018, ORAL ONCOL, V81, P45, DOI 10.1016/j.oraloncology.2018.04.008; Ferris RL, 2015, J CLIN ONCOL, V33, P3293, DOI 10.1200/JCO.2015.61.1509; Fulton AJ, 2013, JAVMA-J AM VET MED A, V243, P696, DOI 10.2460/javma.243.5.696; Gooden MJM, 2011, BRIT J CANCER, V105, P93, DOI 10.1038/bjc.2011.189; Groenen MAM, 2012, NATURE, V491, P393, DOI 10.1038/nature11622; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hanna GJ, 2017, ORAL ONCOL, V67, P61, DOI 10.1016/j.oraloncology.2017.02.005; Harley R, 2011, J COMP PATHOL, V144, P239, DOI 10.1016/j.jcpa.2010.09.173; Hassan BB, 2017, VET PATHOL, V54, P32, DOI 10.1177/0300985816650243; Hayes A, 2006, J COMP PATHOL, V135, P93, DOI 10.1016/j.jcpa.2006.06.001; Hirano F, 2005, CANCER RES, V65, P1089; Howe K, 2013, NATURE, V496, P498, DOI 10.1038/nature12111; Hu L, 2017, ORAL DIS, V23, P801, DOI 10.1111/odi.12667; Huang J, 2014, J IMMUNOL, V193, P1496, DOI 10.4049/jimmunol.1400915; Ito T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113833; Iwai Y, 2002, P NATL ACAD SCI USA, V99, P12293, DOI 10.1073/pnas.192461099; Kamb A, 2005, NAT REV DRUG DISCOV, V4, P161, DOI 10.1038/nrd1635; Karo JM, 2014, CELL, V159, P94, DOI 10.1016/j.cell.2014.08.026; Khanna C, 2006, NAT BIOTECHNOL, V24, P1065, DOI 10.1038/nbt0906-1065b; Khoshnevis M, 2017, J NEUROSCI METH, V282, P61, DOI 10.1016/j.jneumeth.2017.03.007; Klobukowska HJ, 2016, VET PATHOL, V53, P1124, DOI 10.1177/0300985816629713; Lam SH, 2004, DEV COMP IMMUNOL, V28, P9, DOI 10.1016/S0145-305X(03)00103-4; Lei SH, 2016, SCI REP-UK, V6, DOI 10.1038/srep25222; Leroy G, 2009, ANIM GENET, V40, P333, DOI 10.1111/j.1365-2052.2008.01843.x; Li S, 2015, TRANSGENIC RES, V24, P509, DOI 10.1007/s11248-015-9866-8; Li X, 2006, CARDIOVASC INTER RAD, V29, P420, DOI 10.1007/s00270-005-0099-8; Li YJ, 2017, CELL MOL IMMUNOL, V14, P80, DOI 10.1038/cmi.2016.50; Lieschke GJ, 2001, BLOOD, V98, P3087, DOI 10.1182/blood.V98.10.3087; Lillico SG, 2013, SCI REP-UK, V3, DOI 10.1038/srep02847; Lindblad-Toh K, 2005, NATURE, V438, P803, DOI 10.1038/nature04338; Liu DL, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005277; Lunney JK, 2009, DEV COMP IMMUNOL, V33, P362, DOI 10.1016/j.dci.2008.07.002; Mair KH, 2014, DEV COMP IMMUNOL, V45, P321, DOI 10.1016/j.dci.2014.03.022; Martano M, 2016, ONCOL LETT, V11, P399, DOI 10.3892/ol.2015.3847; Martin CK, 2011, VET PATHOL, V48, P302, DOI 10.1177/0300985810384414; Mas A, 2011, J SMALL ANIM PRACT, V52, P359, DOI 10.1111/j.1748-5827.2011.01075.x; McAnulty PA, 2012, MINIPIG IN BIOMEDICAL RESEARCH, P1; Mestrinho LA, 2017, J VET DENT, V34, P92, DOI 10.1177/0898756417713979; Meurens F, 2012, TRENDS MICROBIOL, V20, P50, DOI 10.1016/j.tim.2011.11.002; Miyazawa J, 2004, CANCER RES, V64, P2024, DOI 10.1158/0008-5472.CAN-03-1855; Mochizuki H, 2017, VET COMP ONCOL, V15, P1598, DOI 10.1111/vco.12275; Montague MJ, 2014, P NATL ACAD SCI USA, V111, P17230, DOI 10.1073/pnas.1410083111; Munday JS, 2015, VET J, V204, P223, DOI 10.1016/j.tvjl.2015.03.002; Munday JS, 2011, RES VET SCI, V90, P280, DOI 10.1016/j.rvsc.2010.06.014; Nemec A, 2012, J COMP PATHOL, V147, P111, DOI 10.1016/j.jcpa.2011.11.198; Popovic A, 2018, J CLIN INVEST, V128, P3209, DOI 10.1172/JCI120775; Rathore K, 2014, TRANSL RES, V164, P158, DOI 10.1016/j.trsl.2014.02.002; Reymond MA, 2000, EUR J SURG ONCOL, V26, P393, DOI 10.1053/ejso.1999.0905; Rossa C, 2019, ONCOGENE, V38, P3973, DOI 10.1038/s41388-019-0686-9; Rothkotter HJ, 2009, DEV COMP IMMUNOL, V33, P267, DOI 10.1016/j.dci.2008.06.016; Sanz R, 2017, EUR J PHARM BIOPHARM, V117, P203, DOI 10.1016/j.ejpb.2017.04.019; Schachtschneider KM, 2017, ONCOTARGET, V8, P63620, DOI 10.18632/oncotarget.18872; Schachtschneider KM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02912-9; Schook LB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128864; Schook LB, 2015, ANNU REV ANIM BIOSCI, V3, P219, DOI 10.1146/annurev-animal-022114-110815; Seoane J, 2013, MED ORAL PATOL ORAL, V18, pE246, DOI 10.4317/medoral.17998; Shield KD, 2017, CA-CANCER J CLIN, V67, P51, DOI 10.3322/caac.21384; Sieren JC, 2014, J CLIN INVEST, V124, P4052, DOI 10.1172/JCI75447; Sinkora M, 2009, DEV COMP IMMUNOL, V33, P273, DOI 10.1016/j.dci.2008.07.011; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Snyder LA, 2004, VET PATHOL, V41, P209, DOI 10.1354/vp.41-3-209; Soltero-Rivera MM, 2014, J FELINE MED SURG, V16, P164, DOI 10.1177/1098612X13502975; STEBBINS KE, 1989, VET PATHOL, V26, P121, DOI 10.1177/030098588902600204; Sterenczak KA, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-694; Stramandinoli-Zanicotti RT, 2013, INT ARCH OTORHINOLAR, V17, P163, DOI 10.7162/S1809-97772013000200008; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Strietzel CJ, 2014, VET IMMUNOL IMMUNOP, V158, P214, DOI 10.1016/j.vetimm.2014.01.012; Supsavhad Wachiraphan, 2016, Vet Sci, V3, DOI 10.3390/vetsci3030018; Supsavhad W, 2016, VET J, V210, P7, DOI 10.1016/j.tvjl.2015.11.006; Suzuki S, 2016, VET IMMUNOL IMMUNOP, V178, P37, DOI 10.1016/j.vetimm.2016.06.011; Suzuki S, 2012, CELL STEM CELL, V10, P753, DOI 10.1016/j.stem.2012.04.021; TODOROFF RJ, 1979, J AM VET MED ASSOC, V175, P567; Wakshlag JJ, 2011, AM J VET RES, V72, P1369, DOI 10.2460/ajvr.72.10.1369; Walters Eric M, 2013, Mo Med, V110, P212; Watson AL, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00078; Wiles V, 2017, J FELINE MED SURG, V19, P185, DOI 10.1177/1098612X15622237; Wypij J. M., 2013, PATHOL RES INT, V2013, DOI DOI 10.1155/2013/502197; Yamakawa Hirohito, 1999, Journal of Reproduction and Development, V45, P111, DOI 10.1262/jrd.45.111; Yoshikawa H, 2012, AM J VET RES, V73, P1801, DOI 10.2460/ajvr.73.11.1801; Yuhki N, 2007, J HERED, V98, P390, DOI 10.1093/jhered/esm056; Zhang C, 2008, CYTOTHERAPY, V10, P711, DOI 10.1080/14653240802320237; 2011, GENETICS PIG, P1	100	8	8	3	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2019	38	25					4902	4914		10.1038/s41388-019-0776-8	http://dx.doi.org/10.1038/s41388-019-0776-8			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IE1KY	30872793	Green Accepted			2022-12-28	WOS:000472145900002
J	Recio, C; Guerra, B; Guerra-Rodriguez, M; Aranda-Tavio, H; Martin-Rodriguez, P; de Mirecki-Garrido, M; Brito-Casillas, Y; Garcia-Castellano, JM; Estevez-Braun, A; Fernandez-Perez, L				Recio, Carlota; Guerra, Borja; Guerra-Rodriguez, Miguel; Aranda-Tavio, Haidee; Martin-Rodriguez, Patricia; de Mirecki-Garrido, Mercedes; Brito-Casillas, Yeray; Garcia-Castellano, Jose M.; Estevez-Braun, Ana; Fernandez-Perez, Leandro			Signal transducer and activator of transcription (STAT)-5: an opportunity for drug development in oncohematology	ONCOGENE			English	Review							CHRONIC MYELOID-LEUKEMIA; HODGKIN LYMPHOMA; JANUS KINASES; STAT PROTEINS; SELF-RENEWAL; BCR-ABL; CELLS; IMATINIB; MUTATION; PATHWAY	The signal transducer and activator of transcription (STAT) are transcription factors that work via JAK/STAT pathway regulating the expression of genes involved in cell survival, proliferation, differentiation, development, immune response, and, among other essential biological functions, hematopoiesis. JAK/STAT signaling is strictly regulated under normal physiological conditions. However, a large group of diverse diseases has been associated to an aberrant regulation of STAT factors. Erroneous modulation of the pathway leads to constitutive STAT activation, thereby driving proliferation, inflammation, and an uncontrolled immune response. Deregulated STAT5 activation has been found in the development of many hematopoietic tumors, including chronic and acute leukemias, polycythemia vera, and lymphoma. Mutations in the kinases that phosphorylate STAT5, and/or overexpression of the upstream receptor-associated tyrosine kinases have been suggested as the main drivers of constitutive STAT5 activation. Hyper-activated STAT5 leads to the aberrant expression of its target genes including antiapoptotic, proliferative, and pro-inflammatory genes, favouring tumorigenesis. In this review, we intent to discuss the biology of JAK/STAT pathway, with particular focus on STAT5 and its crucial role in the development and progression of hematologic malignancies. Furthermore, we provide a synopsis of potential therapeutic strategies based on STAT5 activity inhibition that may represent an excellent opportunity for drug development in oncohematology.	[Recio, Carlota; Guerra, Borja; Guerra-Rodriguez, Miguel; Aranda-Tavio, Haidee; Martin-Rodriguez, Patricia; de Mirecki-Garrido, Mercedes; Brito-Casillas, Yeray; Garcia-Castellano, Jose M.; Fernandez-Perez, Leandro] Univ Las Palmas Gran Canaria, IUIBS, Farmacol Mol & Traslac BIOPharm, Las Palmas De Gc 35016, Las Palmas, Spain; [Estevez-Braun, Ana] Univ La Laguna, Inst Univ Bioorgan CIBICAN, Dept Quim Organ, E-38206 Tenerife, Spain	Universidad de Las Palmas de Gran Canaria; Universidad de la Laguna	Recio, C (corresponding author), Univ Las Palmas Gran Canaria, IUIBS, Farmacol Mol & Traslac BIOPharm, Las Palmas De Gc 35016, Las Palmas, Spain.	carlota.recio@ulpgc.es	Casillas, Yeray Brito/U-6954-2018; Guerra, Borja/G-9739-2015; Recio, Carlota/ABF-5850-2021; Guerra, Borja/ABE-1138-2021; Patricia, Martín Rodríguez/H-3238-2015; Estevez-Braun, Ana/A-8122-2015; Guerra Rodriguez, Miguel/R-4283-2018; Recio, Carlota/D-2984-2019; Fernandez-Perez, Leandro/H-1493-2015	Casillas, Yeray Brito/0000-0002-0707-7444; Guerra, Borja/0000-0003-4355-5682; Guerra, Borja/0000-0003-4355-5682; Patricia, Martín Rodríguez/0000-0002-2378-3242; Estevez-Braun, Ana/0000-0001-5279-7099; Guerra Rodriguez, Miguel/0000-0002-0047-1131; Recio, Carlota/0000-0002-8832-2826; Fernandez-Perez, Leandro/0000-0001-7802-465X	Spanish Ministry of Economy and Competitivity (MINECO); European Regional Development Fund-European Social Fund [SAF2015-65113-C2-2-R]; Alfredo Martin-Reyes Foundation (Arehucas) - FICIC; MINECO - Juan de la Cierva 2017 program; ULPGC 2017	Spanish Ministry of Economy and Competitivity (MINECO); European Regional Development Fund-European Social Fund; Alfredo Martin-Reyes Foundation (Arehucas) - FICIC; MINECO - Juan de la Cierva 2017 program; ULPGC 2017	We thank all the authors that contributed to the understanding of the role of STAT5 in hematopoiesis and oncohematology. We apologize to those whose work deserves to be cited but unfortunately are not quoted because of space restriction. The research program in the author's lab was supported by grants-in-aid from Spanish Ministry of Economy and Competitivity (MINECO) with the funding of European Regional Development Fund-European Social Fund (SAF2015-65113-C2-2-R) and Alfredo Martin-Reyes Foundation (Arehucas) -FICIC. CR and MMG were supported by postdoctoral grants-in-aid from MINECO - Juan de la Cierva 2017 program and ULPGC 2017, respectively.	Able AA, 2017, BIOLOGY-BASEL, V6, DOI 10.3390/biology6010020; Bibi S, 2014, HAEMATOLOGICA, V99, P417, DOI 10.3324/haematol.2013.098442; Braunstein J, 2003, J BIOL CHEM, V278, P34133, DOI 10.1074/jbc.M304531200; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Campia I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126159; Chatain N, 2013, ONCOGENE, V32, P3587, DOI 10.1038/onc.2012.369; Chun JN, 2018, ONCOTARGET, V9, P3121, DOI 10.18632/oncotarget.23213; Cumaraswamy AA, 2014, ACS MED CHEM LETT, V5, P1202, DOI 10.1021/ml500165r; de Lavallade H, 2008, J CLIN ONCOL, V26, P3358, DOI 10.1200/JCO.2007.15.8154; Dolznig H, 2006, ONCOGENE, V25, P2890, DOI 10.1038/sj.onc.1209308; Dorritie KA, 2014, LEUKEMIA, V28, P248, DOI 10.1038/leu.2013.192; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; Fernandez-Perez L, 2016, RESTRICTED GROWTH CL, P125; Fievez L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000727; Ghoreschi K, 2009, IMMUNOL REV, V228, P273, DOI 10.1111/j.1600-065X.2008.00754.x; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Guerra B, 2017, ONCOTARGET, V8, P29679, DOI 10.18632/oncotarget.11425; Haura EB, 2005, NAT CLIN PRACT ONCOL, V2, P315, DOI 10.1038/ncponc0195; Heltemes-Harris LM, 2012, CURR OPIN IMMUNOL, V24, P146, DOI 10.1016/j.coi.2012.01.015; Hochhaus A, 2009, LEUKEMIA, V23, P1054, DOI 10.1038/leu.2009.38; Hoelbl A, 2006, BLOOD, V107, P4898, DOI 10.1182/blood-2005-09-3596; Hospital MA, 2017, ONCOTARGETS THER, V10, P607, DOI 10.2147/OTT.S103790; Hu XY, 2013, P NATL ACAD SCI USA, V110, P10213, DOI 10.1073/pnas.1221243110; Hughes Katherine, 2012, JAKSTAT, V1, P151, DOI 10.4161/jkst.19691; Joliot V, 2006, ONCOGENE, V25, P4573, DOI 10.1038/sj.onc.1209480; Jona A, 2013, EXP HEMATOL, V41, P995, DOI 10.1016/j.exphem.2013.09.014; Kaymaz BT, 2013, AM J BLOOD RES, V3, P58; Kayser S, 2014, LEUKEMIA LYMPHOMA, V55, P243, DOI 10.3109/10428194.2013.800198; Kemp RA, 2010, IMMUNOL CELL BIOL, V88, P213, DOI 10.1038/icb.2009.95; Kerenyi MA, 2008, BLOOD, V112, P3878, DOI 10.1182/blood-2008-02-138339; Kiu H, 2012, GROWTH FACTORS, V30, P88, DOI 10.3109/08977194.2012.660936; Kosova B, 2010, LEUKEMIA LYMPHOMA, V51, P1895, DOI 10.3109/10428194.2010.507830; Kuppers R, 2002, ADV CANCER RES, V84, P277, DOI 10.1016/S0065-230X(02)84009-X; Linher-Melville K, 2017, MOL CELL ENDOCRINOL, V451, P40, DOI 10.1016/j.mce.2017.02.014; Trung LQ, 2015, MOL NUTR FOOD RES, V59, P2143, DOI 10.1002/mnfr.201500166; Malin S, 2010, NAT IMMUNOL, V11, P171, DOI 10.1038/ni.1827; Martin-Rodriguez P, 2019, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01546; Martin-Subero JI, 2002, BLOOD, V99, P1474, DOI 10.1182/blood.V99.4.1474; Melo JV, 2004, HEMATOL ONCOL CLIN N, V18, P545, DOI 10.1016/j.hoc.2004.03.008; Miklossy G, 2013, NAT REV DRUG DISCOV, V12, P611, DOI 10.1038/nrd4088; Moslehi JJ, 2015, J CLIN ONCOL, V33, P4210, DOI 10.1200/JCO.2015.62.4718; Murray PJ, 2007, J IMMUNOL, V178, P2623, DOI 10.4049/jimmunol.178.5.2623; Nelson Erik A, 2012, Genes Cancer, V3, P503, DOI 10.1177/1947601912466555; Nelson EA, 2011, BLOOD, V117, P3421, DOI 10.1182/blood-2009-11-255232; O'Shea JJ, 2015, ANNU REV MED, V66, P311, DOI 10.1146/annurev-med-051113-024537; O'Sullivan LA, 2007, MOL IMMUNOL, V44, P2497, DOI 10.1016/j.molimm.2006.11.025; Papaemmanuil E, 2016, NEW ENGL J MED, V374, P2209, DOI 10.1056/NEJMoa1516192; Park JH, 2010, NAT IMMUNOL, V11, P257, DOI 10.1038/ni.1840; Peixoto F, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.01233; Quentmeier H, 2006, LEUKEMIA, V20, P471, DOI 10.1038/sj.leu.2404081; Rawlings JS, 2004, J CELL SCI, V117, P1281, DOI 10.1242/jcs.00963; Re D, 2005, BLOOD, V105, P4553, DOI 10.1182/blood-2004-12-4750; Reich Nancy C, 2013, JAKSTAT, V2, pe27080, DOI 10.4161/jkst.27080; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; Rosenwald A, 2003, J EXP MED, V198, P851, DOI 10.1084/jem.20031074; Scheeren FA, 2005, NAT IMMUNOL, V6, P303, DOI 10.1038/ni1172; Scheeren FA, 2008, BLOOD, V111, P4706, DOI 10.1182/blood-2007-08-105643; Schepers H, 2007, BLOOD, V110, P2880, DOI 10.1182/blood-2006-08-039073; Schindler C, 2007, J BIOL CHEM, V282, P20059, DOI 10.1074/jbc.R700016200; Schindler C, 2008, SEMIN CELL DEV BIOL, V19, P311, DOI 10.1016/j.semcdb.2008.08.010; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; Socolovsky M, 2001, BLOOD, V98, P3261, DOI 10.1182/blood.V98.12.3261; Sonkin D, 2015, CANCER BIOMARK, V15, P79, DOI 10.3233/CBM-140434; Spivak JL, 2018, CURR TREAT OPTION ON, V19, DOI 10.1007/s11864-018-0529-x; Stark GR, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028555; Sun JP, 2011, LEUKEMIA RES, V35, P1402, DOI 10.1016/j.leukres.2011.06.018; Swaminathan S, 2015, NAT IMMUNOL, V16, P766, DOI 10.1038/ni.3160; Szelag M, 2016, CURR PROTEIN PEPT SC, V17, P135, DOI 10.2174/1389203716666151102103706; Tasian SK, 2012, BLOOD, V120, P833, DOI 10.1182/blood-2011-12-389932; Tsatsanis C, 2000, INT J MOL MED, V5, P583; Tsuruyama T, 2002, P NATL ACAD SCI USA, V99, P8253, DOI 10.1073/pnas.112202899; Vainchenker W, 2008, SEMIN CELL DEV BIOL, V19, P385, DOI 10.1016/j.semcdb.2008.07.002; Van Etten RA, 2007, ONCOGENE, V26, P6738, DOI 10.1038/sj.onc.1210758; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Walters DK, 2006, CANCER CELL, V10, P65, DOI 10.1016/j.ccr.2006.06.002; Walz C, 2012, BLOOD, V119, P3550, DOI 10.1182/blood-2011-12-397554; Wang XF, 2017, MOL CANCER, V16, DOI 10.1186/s12943-016-0574-7; Wang Zhengqi, 2013, JAKSTAT, V2, pe27159, DOI 10.4161/jkst.27159; Warsch W, 2013, CELL CYCLE, V12, P1813, DOI 10.4161/cc.25116; Warsch W, 2012, ONCOTARGET, V3, P1669; Warsch W, 2011, BLOOD, V117, P3409, DOI 10.1182/blood-2009-10-248211; Wierenga ATJ, 2008, MOL CELL BIOL, V28, P6668, DOI 10.1128/MCB.01025-08; Wingelhofer B, 2018, LEUKEMIA, V32, P1135, DOI 10.1038/s41375-017-0005-9; Wiwi CA, 2004, GROWTH FACTORS, V22, P79, DOI 10.1080/08977190410001715172; Xiao WB, 2008, J CLIN INVEST, V118, P924, DOI 10.1172/JCI34013; Yan DQ, 2012, BLOOD, V119, P3539, DOI 10.1182/blood-2011-03-345215; Yanga S, 2008, EXP CELL RES, V314, P413, DOI 10.1016/j.yexcr.2007.09.002; Yao Z, 2007, BLOOD, V109, P4368, DOI 10.1182/blood-2006-11-055756; Zahn M, 2017, BLOOD, V129, P1480, DOI 10.1182/blood-2016-06-720516; Zhao RX, 2005, J BIOL CHEM, V280, P22788, DOI 10.1074/jbc.C500138200	90	24	24	3	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2019	38	24					4657	4668		10.1038/s41388-019-0752-3	http://dx.doi.org/10.1038/s41388-019-0752-3			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IC7ND	30783189				2022-12-28	WOS:000471160500001
J	Chu, Y; Elrod, N; Wang, CJ; Li, L; Chen, T; Routh, A; Xia, Z; Li, W; Wagner, EJ; Ji, P				Chu, Yuan; Elrod, Nathan; Wang, Chaojie; Li, Lei; Chen, Tao; Routh, Andrew; Xia, Zheng; Li, Wei; Wagner, Eric J.; Ji, Ping			Nudt21 regulates the alternative polyadenylation of Pak1 and is predictive in the prognosis of glioblastoma patients	ONCOGENE			English	Article							CLEAVAGE FACTOR IM; BREAST-CANCER; UNTRANSLATED REGIONS; RNA; CELLS; EXPRESSION; GROWTH; ASSOCIATION; RESISTANCE; MELANOMA	Alternative polyadenylation (APA) has emerged as a prevalent feature associated with cancer development and progression. The advantage of APA to tumor progression is to induce oncogenes through 3'-UTR shortening, and to inactivate tumor suppressor genes via the re-routing of microRNA competition. We previously identified the Mammalian Cleavage Factor I-25 (CFIm25) (encoded by Nudt21 gene) as a master APA regulator whose expression levels directly impact the tumorigenicity of glioblastoma (GBM) in vitro and in vivo. Despite its importance, the role of Nudt21 in GBM development is not known and the genes subject to Nudt21 APA regulation that contribute to GBM progression have not been identified. Here, we find that Nudt21 is reduced in low grade glioma (LGG) and all four subtypes of high grade glioma (GBM). Reduced expression of Nudt21 associates with worse survival in TCGA LGG cohorts and two TCGA GBM cohorts. Moreover, although CFIm25 was initially identified as biochemically associated with both CFIm59 and CFIm68, we observed three CFIm distinct subcomplexes exist and CFIm59 protein level is dependent on Nudt21 expression in GBM cells, but CFIm68 is not, and that only CFIm59 predicts prognosis of GBM patients similar to Nudt21. Through the use of Poly(A)-Click-Seq to characterize APA, we define the mRNAs subject to 3'-UTR shortening upon Nudt21 depletion in GBM cells and observed enrichment in genes important in the Ras signaling pathway, including Pak1. Remarkably, we find that Pak1 expression is regulated by Nudt21 through its 3'-UTR APA, and the combination of Pak1 and Nudt21 expression generates an even stronger prognostic indicator of GBM survival versus either value used alone. Collectively, our data uncover Nudt21 and its downstream target Pak1 as a potential "combination biomarker" for predicting prognosis of GBM patients.	[Chu, Yuan; Elrod, Nathan; Routh, Andrew; Wagner, Eric J.; Ji, Ping] Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA; [Chu, Yuan; Chen, Tao] Fudan Univ, Zhongshan Hosp, Endoscopy Ctr, Shanghai, Peoples R China; [Chu, Yuan; Chen, Tao] Fudan Univ, Endoscopy Res Inst, Shanghai, Peoples R China; [Wang, Chaojie; Xia, Zheng] OHSU, Dept Mol Microbiol & Immunol, Computat Biol Program, Portland, OR 97273 USA; [Li, Lei; Li, Wei] Baylor Coll Med, Daniel Duncan Canc Ctr, Houston, TX 77030 USA; [Routh, Andrew; Wagner, Eric J.] Univ Texas Med Branch, Sealy Ctr Struct Biol & Mol Biophys, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; Fudan University; Fudan University; Oregon Health & Science University; Baylor College of Medicine; University of Texas System; University of Texas Medical Branch Galveston	Wagner, EJ; Ji, P (corresponding author), Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA.; Wagner, EJ (corresponding author), Univ Texas Med Branch, Sealy Ctr Struct Biol & Mol Biophys, Galveston, TX 77555 USA.	ejwagner@utmb.edu; piji@utmb.edu	Wang, Chaojie/AAX-3167-2021; Routh, Andrew/J-7486-2019; Elrod, Nathan/Q-5610-2019; Xia, Zheng/AAC-5360-2022; Elrod, Nathan/N-5956-2016; Li, Lei/S-9028-2016	Wang, Chaojie/0000-0002-5865-1397; Routh, Andrew/0000-0002-2874-5990; Xia, Zheng/0000-0003-3364-8324; Elrod, Nathan/0000-0003-1310-6026; Li, Lei/0000-0003-3924-2544; Ji, Ping/0000-0001-7103-1507	US National Institutes of Health (NIH) [R01CA193466-01]; Cancer Prevention Research Institute of Texas grant [CPRIT RP140800]; NIH [R03 CA223893-01]; NATIONAL CANCER INSTITUTE [R01CA193466, R03CA223893, P30CA016672] Funding Source: NIH RePORTER	US National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention Research Institute of Texas grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the US National Institutes of Health (NIH) grants R01CA193466-01 to W.L. and E.J.W., the Cancer Prevention Research Institute of Texas grant CPRIT RP140800 to E.J.W., and NIH R03 CA223893-01 to P.J.	Akman BH, 2012, NUCLEIC ACIDS RES, V40, P10679, DOI 10.1093/nar/gks855; Aoki H, 2007, CLIN CANCER RES, V13, P6603, DOI 10.1158/1078-0432.CCR-07-0145; Bagheri-Yarmand R, 2001, J BIOL CHEM, V276, P29403, DOI 10.1074/jbc.M103129200; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Brown KM, 2003, MOL CELL, V12, P1467, DOI 10.1016/S1097-2765(03)00453-2; Brumbaugh J, 2018, CELL, V172, P629, DOI 10.1016/j.cell.2017.12.035; Brumbaugh J, 2018, CELL, V172, P106, DOI 10.1016/j.cell.2017.11.023; Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Cornett AL, 2014, METHODS MOL BIOL, V1125, P157, DOI 10.1007/978-1-62703-971-0_14; Creemers EE, 2016, CIRC RES, V118, P433, DOI 10.1161/CIRCRESAHA.115.307082; Denysenko T, 2010, CELL BIOCHEM FUNCT, V28, P343, DOI 10.1002/cbf.1666; Diederichs S, 2016, EMBO MOL MED, V8, P442, DOI 10.15252/emmm.201506055; Edlinger L, 2017, BRIT J HAEMATOL, V179, P229, DOI 10.1111/bjh.14833; Elkon R, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-7-r59; Fu YG, 2011, GENOME RES, V21, P741, DOI 10.1101/gr.115295.110; Giubellino A, 2008, EXPERT OPIN THER TAR, V12, P1021, DOI 10.1517/14728222.12.8.1021 ; Gruber AR, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6465; Gruber AR, 2012, RNA BIOL, V9, P1405, DOI 10.4161/rna.22570; Han T, 2014, CELL RES, V24, P1023, DOI 10.1038/cr.2014.88; Hardy JG, 2016, BIOCHEM SOC T, V44, P1051, DOI 10.1042/BST20160078; Holm C, 2006, JNCI-J NATL CANCER I, V98, P671, DOI 10.1093/jnci/djj185; JASONNI VM, 1995, ANTICANCER RES, V15, P1327; Ji Z, 2009, P NATL ACAD SCI USA, V106, P7028, DOI 10.1073/pnas.0900028106; Johnson DB, 2014, CLIN CANCER RES, V20, P4186, DOI 10.1158/1078-0432.CCR-13-3270; Kang TW, 2014, SCI REP-UK, V4, DOI 10.1038/srep05546; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Kim S, 2010, GENES CELLS, V15, P1003, DOI 10.1111/j.1365-2443.2010.01436.x; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Larson KC, 2010, INFLAMM RES, V59, P15, DOI 10.1007/s00011-009-0062-2; Li TF, 2015, ONCOL REP, V34, P2357, DOI 10.3892/or.2015.4226; Masamha CP, 2018, CARCINOGENESIS, V39, P2, DOI 10.1093/carcin/bgx096; Masamha CP, 2016, RNA, V22, P830, DOI 10.1261/rna.055939.116; Masamha CP, 2014, NATURE, V510, P412, DOI 10.1038/nature13261; Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016; Muller S, 2014, DATABASE-OXFORD, DOI 10.1093/database/bau076; Nagarajan P, 2010, J CELL SCI, V123, P3566, DOI 10.1242/jcs.062240; Ozsolak F, 2010, CELL, V143, P1018, DOI 10.1016/j.cell.2010.11.020; Park HJ, 2018, NAT GENET, V50, P783, DOI 10.1038/s41588-018-0118-8; Peng H, 2016, SCI REP-UK, V6, DOI 10.1038/srep22000; Riemann K, 2009, ANTICANCER RES, V29, P1271; Routh A, 2017, NUCLEIC ACIDS RES, V45, DOI 10.1093/nar/gkx286; Routh A, 2015, J MOL BIOL, V427, P2610, DOI 10.1016/j.jmb.2015.06.011; Ruegsegger U, 1996, J BIOL CHEM, V271, P6107; Shao JF, 2013, OMICS, V17, P136, DOI 10.1089/omi.2012.0098; Singh P, 2009, CANCER RES, V69, P9422, DOI 10.1158/0008-5472.CAN-09-2236; Sowd GA, 2016, P NATL ACAD SCI USA, V113, pE1054, DOI 10.1073/pnas.1524213113; Sun M, 2017, CANCER LETT, V410, P158, DOI 10.1016/j.canlet.2017.09.026; Tian B, 2005, NUCLEIC ACIDS RES, V33, P201, DOI 10.1093/nar/gki158; Tian B, 2017, NAT REV MOL CELL BIO, V18, P18, DOI 10.1038/nrm.2016.116; Wagner EJ, 2002, MOL CELL, V10, P943, DOI 10.1016/S1097-2765(02)00645-7; Walker-Daniels J, 2003, AM J PATHOL, V162, P1037, DOI 10.1016/S0002-9440(10)63899-0; Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Xia Z, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6274; Yajima I, 2014, AM J CANCER RES, V4, P182; Yang Q, 2011, STRUCTURE, V19, P368, DOI 10.1016/j.str.2010.12.021; Yang Q, 2010, P NATL ACAD SCI USA, V107, P10062, DOI 10.1073/pnas.1000848107; Zhu Y, 2018, MOL CELL, V69, P62, DOI 10.1016/j.molcel.2017.11.031; Zimmermannova O, 2017, ONCOGENE, V36, P5985, DOI 10.1038/onc.2017.210	60	34	35	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2019	38	21					4154	4168		10.1038/s41388-019-0714-9	http://dx.doi.org/10.1038/s41388-019-0714-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ3HX	30705404	Green Accepted			2022-12-28	WOS:000468740200013
J	Seoane, M; Buhs, S; Iglesias, P; Strauss, J; Puller, AC; Muller, J; Gerull, H; Feldhaus, S; Alawi, M; Brandner, JM; Eggert, D; Du, JY; Thomale, J; Wild, PJ; Zimmermann, M; Sternsdorf, T; Schumacher, U; Nollau, P; Fisher, DE; Horstmann, MA				Seoane, Marcos; Buhs, Sophia; Iglesias, Pablo; Strauss, Julia; Puller, Ann-Christin; Mueller, Juergen; Gerull, Helwe; Feldhaus, Susanne; Alawi, Malik; Brandner, Johanna M.; Eggert, Dennis; Du, Jinyan; Thomale, Juergen; Wild, Peter J.; Zimmermann, Martin; Sternsdorf, Thomas; Schumacher, Udo; Nollau, Peter; Fisher, David E.; Horstmann, Martin A.			Lineage-specific control of TFIIH by MITF determines transcriptional homeostasis and DNA repair	ONCOGENE			English	Article							NUCLEOTIDE EXCISION-REPAIR; CELL-CYCLE ARREST; XERODERMA-PIGMENTOSUM; MASTER REGULATOR; MELANOMA; MICROPHTHALMIA; MELANOCYTES; ACTIVATION; MYC; EXPRESSION	The melanocytic lineage, which is prominently exposed to ultraviolet radiation (UVR) and radiation-independent oxidative damage, requires specific DNA-damage response mechanisms to maintain genomic and transcriptional homeostasis. The coordinate lineage-specific regulation of intricately intertwined DNA repair and transcription is incompletely understood. Here we demonstrate that the Microphthalmia-associated transcription factor (MITF) directly controls general transcription and UVR-induced nucleotide excision repair by transactivation of GTF2H1 as a core element of TFIIH. Thus, MITF ensures the rapid resumption of transcription after completion of strand repair and maintains transcriptional output, which is indispensable for survival of the melanocytic lineage including melanoma in vitro and in vivo. Moreover, MITF controls c-MYC implicated in general transcription by transactivation of far upstream binding protein 2 (FUBP2/KSHRP), which induces c-MYC pulse regulation through TFIIH, and experimental depletion of MITF results in consecutive loss of CDK7 in the TFIIH-CAK subcomplex. Targeted for proteasomal degradation, CDK7 is dependent on transactivation by MITF or c-MYC to maintain a steady state. The dependence of TFIIH-CAK on sequence-specific MITF and c-MYC constitutes a previously unrecognized mechanism feeding into super-enhancer-driven or other oncogenic transcriptional circuitries, which supports the concept of a transcription-directed therapeutic intervention in melanoma.	[Seoane, Marcos; Buhs, Sophia; Iglesias, Pablo; Strauss, Julia; Puller, Ann-Christin; Mueller, Juergen; Gerull, Helwe; Sternsdorf, Thomas; Nollau, Peter; Horstmann, Martin A.] Childrens Canc Ctr Hamburg, Res Inst, D-20246 Hamburg, Germany; [Seoane, Marcos; Buhs, Sophia; Iglesias, Pablo; Strauss, Julia; Puller, Ann-Christin; Mueller, Juergen; Gerull, Helwe; Sternsdorf, Thomas; Nollau, Peter; Horstmann, Martin A.] Univ Med Ctr Hamburg, Dept Pediat Hematol & Oncol, D-20246 Hamburg, Germany; [Feldhaus, Susanne; Schumacher, Udo] Univ Med Ctr Hamburg, Inst Anat & Expt Morphol, D-20246 Hamburg, Germany; [Alawi, Malik] Univ Med Ctr Hamburg, Bioinformat Serv Facil, D-20246 Hamburg, Germany; [Alawi, Malik; Eggert, Dennis] Leibniz Inst Expt Virol, Heinrich Pette Inst, D-20251 Hamburg, Germany; [Brandner, Johanna M.] Univ Med Ctr Hamburg, Dept Dermatol, D-20246 Hamburg, Germany; [Eggert, Dennis] Max Planck Inst Struct & Dynam Matter, D-22761 Hamburg, Germany; [Du, Jinyan] Harvard Med Sch, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; [Thomale, Juergen] Univ Duisburg Essen, Inst Cell Biol, D-45122 Essen, Germany; [Wild, Peter J.] Univ Hosp Zurich, Inst Surg Pathol, CH-8091 Zurich, Switzerland; [Zimmermann, Martin] Med Sch Hannover, Dept Pediat Hematol & Oncol, D-30625 Hannover, Germany; [Fisher, David E.] Harvard Med Sch, Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Dept Dermatol, Boston, MA 02115 USA; [Du, Jinyan] Merrimack Pharmaceut, Cambridge, MA 02139 USA	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; Heinrich Pette Institute; University of Hamburg; University Medical Center Hamburg-Eppendorf; Max Planck Society; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Duisburg Essen; University of Zurich; University Zurich Hospital; Hannover Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital	Horstmann, MA (corresponding author), Childrens Canc Ctr Hamburg, Res Inst, D-20246 Hamburg, Germany.; Horstmann, MA (corresponding author), Univ Med Ctr Hamburg, Dept Pediat Hematol & Oncol, D-20246 Hamburg, Germany.	horstman@uke.de	, Malik/AAB-7437-2021; Fisher, David/AAH-2878-2019	, Malik/0000-0002-5993-7709; Iglesias Vazquez, Pablo/0000-0003-2506-5313; Wild, Peter Johannes/0000-0002-1017-3744	Deutsche Forschungsgemeinschaft (DFG) [Ho2176/3-1/2]; Fordergemeinschaft Kinderkrebs-Zentrum Hamburg; Rudiger Colditz Stiftung; NATIONAL CANCER INSTITUTE [R01CA222871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043369] Funding Source: NIH RePORTER	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Fordergemeinschaft Kinderkrebs-Zentrum Hamburg; Rudiger Colditz Stiftung; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Deutsche Forschungsgemeinschaft (DFG) grants to M.A.H. (Ho2176/3-1/2), Fordergemeinschaft Kinderkrebs-Zentrum Hamburg and the Rudiger Colditz Stiftung. We gratefully acknowledge help from members of the Grundhoff lab for technical support and members of the microscopy and imaging group, both at the Heinrich-Pette-Institute, Hamburg. We also thank Ewa Wladykowski, Christine Knies, and Tobias Gosau for technical assistance.	Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Beerens N, 2005, J BIOL CHEM, V280, P4722, DOI 10.1074/jbc.M409147200; Bertolotto C, 2011, NATURE, V480, P94, DOI 10.1038/nature10539; Bushnell DA, 1996, J BIOL CHEM, V271, P20170, DOI 10.1074/jbc.271.33.20170; Carreira S, 2005, NATURE, V433, P764, DOI 10.1038/nature03269; Chen J, 2003, NATURE, V424, P228, DOI 10.1038/nature01746; Chymkowitch P, 2011, EMBO J, V30, P468, DOI 10.1038/emboj.2010.337; Coin F, 2008, MOL CELL, V31, P9, DOI 10.1016/j.molcel.2008.04.024; Compe E, 2012, NAT REV MOL CELL BIO, V13, P343, DOI 10.1038/nrm3350; Cui RT, 2007, CELL, V128, P853, DOI 10.1016/j.cell.2006.12.045; Davis IJ, 2006, CANCER CELL, V9, P473, DOI 10.1016/j.ccr.2006.04.021; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Development Core Team, 2013, R LANG ENV STAT COMP; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; Drapkin R, 1996, P NATL ACAD SCI USA, V93, P6488, DOI 10.1073/pnas.93.13.6488; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; Eliades P, 2018, J INVEST DERMATOL, V138, P1582, DOI 10.1016/j.jid.2017.09.056; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; Ganuza M, 2012, EMBO J, V31, P2498, DOI 10.1038/emboj.2012.94; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Garrett S, 2001, MOL CELL BIOL, V21, P88, DOI 10.1128/MCB.21.1.88-99.2001; Gervais V, 2004, NAT STRUCT MOL BIOL, V11, P616, DOI 10.1038/nsmb782; Hachiya A, 2001, J INVEST DERMATOL, V116, P578, DOI 10.1046/j.1523-1747.2001.01290.x; Hanawalt PC, 2002, ONCOGENE, V21, P8949, DOI 10.1038/sj.onc.1206096; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; Iben S, 2002, CELL, V109, P297, DOI 10.1016/S0092-8674(02)00729-8; James L, 2002, P NATL ACAD SCI USA, V99, P10429, DOI 10.1073/pnas.162369299; Jao CY, 2008, P NATL ACAD SCI USA, V105, P15779, DOI 10.1073/pnas.0808480105; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; King R, 1999, AM J PATHOL, V155, P731, DOI 10.1016/S0002-9440(10)65172-3; Kraemer KH, 2007, NEUROSCIENCE, V145, P1388, DOI 10.1016/j.neuroscience.2006.12.020; Kwiatkowski N, 2014, NATURE, V511, P616, DOI 10.1038/nature13393; Larochelle S, 2012, NAT STRUCT MOL BIOL, V19, P1108, DOI 10.1038/nsmb.2399; Levy C, 2006, TRENDS MOL MED, V12, P406, DOI 10.1016/j.molmed.2006.07.008; Liedert B, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl051; Limsirichaikul S, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp023; Liu JH, 2006, EMBO J, V25, P2119, DOI 10.1038/sj.emboj.7601101; Loercher AE, 2005, J CELL BIOL, V168, P35, DOI 10.1083/jcb.200410115; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Loven J, 2012, CELL, V151, P476, DOI 10.1016/j.cell.2012.10.012; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; Miller AJ, 2004, CANCER RES, V64, P509, DOI 10.1158/0008-5472.CAN-03-2440; Muller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6712; Price ER, 1998, J BIOL CHEM, V273, P33042, DOI 10.1074/jbc.273.49.33042; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; Singleton KR, 2017, CELL REP, V21, P2796, DOI 10.1016/j.celrep.2017.11.022; Steingrimsson E, 2004, ANNU REV GENET, V38, P365, DOI 10.1146/annurev.genet.38.072902.092717; Strub T, 2011, ONCOGENE, V30, P2319, DOI 10.1038/onc.2010.612; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691; Wellbrock C, 2015, PIGM CELL MELANOMA R, V28, P390, DOI 10.1111/pcmr.12370; Xia M, 2017, CELL REP, V20, P1794, DOI 10.1016/j.celrep.2017.07.056; Yokoi M, 2000, J BIOL CHEM, V275, P9870, DOI 10.1074/jbc.275.13.9870; Yokoyama S, 2011, NATURE, V480, P99, DOI 10.1038/nature10630; Zhuang D, 2008, ONCOGENE, V27, P6623, DOI 10.1038/onc.2008.258; 2004, CANC CELL, V6, P565	57	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2019	38	19					3616	3635		10.1038/s41388-018-0661-x	http://dx.doi.org/10.1038/s41388-018-0661-x			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HX4OU	30651597	Green Published, hybrid			2022-12-28	WOS:000467379600005
J	Laouirem, S; Sannier, A; Norkowski, E; Cauchy, F; Doblas, S; Rautou, PE; Albuquerque, M; Garteiser, P; Sognigbe, L; Raffenne, J; van Beers, BE; Soubrane, O; Bedossa, P; Cros, J; Paradis, V				Laouirem, Samira; Sannier, Aurelie; Norkowski, Emma; Cauchy, Francois; Doblas, Sabrina; Rautou, Pierre Emmanuel; Albuquerque, Miguel; Garteiser, Philippe; Sognigbe, Laura; Raffenne, Jerome; van Beers, Bernard E.; Soubrane, Olivier; Bedossa, Pierre; Cros, Jerome; Paradis, Valerie			Endothelial fatty liver binding protein 4: a new targetable mediator in hepatocellular carcinoma related to metabolic syndrome	ONCOGENE			English	Article							UNITED-STATES; PPAR-GAMMA; CANCER; ADIPOCYTES; DISEASE; OBESITY; PROMOTE; EXPRESSION; METFORMIN; LEPTIN	Metabolic syndrome (MS) is becoming the leading risk factor for hepatocellular carcinoma (HCC). HCC development related to MS may occur in advanced or non-advanced liver fibrosis, suggesting specific molecular pathways. Among these pathways, basal inflammatory state and adipokines production are involved. The aim of this study was to evaluate the role of fatty acid-binding protein 4 (FABP4). In this study, we demonstrate the specific overexpression of FABP4 in human HCC samples from patients with MS compared to other risk factors for chronic liver disease with FABP4 expression restricted to peritumoral endothelial cells. In vitro, glucose, insulin, VEGFA and hypoxia upregulated endothelial FABP4, which was reversed by metformin through mTOR pathway inhibition. FABP4 exerts oncogenic effects on hepatoma cell lines by upregulating the angiogenesis gene signature and pathways involved in the cell cycle, leading to increased cell proliferation and migration, and downregulating HIF1 pathway; effects were reversed in the presence of a specific FABP4 inhibitor (BMS309403). We showed the role of microvesicles as FABP4 vectors between endothelial and tumor cells. In vivo, BMS309403 significantly reduces tumor growth in heterotopic and orthotopic xenografted mice model. In conclusion, this study demonstrates the emerging oncogenic role of liver endothelial cells through FABP4 in HCC related to MS, and highlights new anti-neoplastic mechanism of metformin.	[Laouirem, Samira; Sannier, Aurelie; Norkowski, Emma; Cauchy, Francois; Doblas, Sabrina; Garteiser, Philippe; Sognigbe, Laura; Raffenne, Jerome; van Beers, Bernard E.; Bedossa, Pierre; Cros, Jerome; Paradis, Valerie] INSERM UMR 1149, Ctr Rech Inflammat, Paris, France; [Cauchy, Francois; Soubrane, Olivier] Beaujon Hosp, Hepatobiliary Surg Dept, Clichy, France; [Rautou, Pierre Emmanuel] Beaujon Hosp, Hepatol Dept, 100 Bd Gen Leclerc, F-92110 Clichy, France; [Albuquerque, Miguel; Cros, Jerome; Paradis, Valerie] Beaujon Hosp, Pathol Dept, Clichy, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite	Paradis, V (corresponding author), INSERM UMR 1149, Ctr Rech Inflammat, Paris, France.; Paradis, V (corresponding author), Beaujon Hosp, Pathol Dept, Clichy, France.	vparadis@teaser.fr	Paradis, Valerie/X-9097-2019; François, Cauchy/J-7031-2019; Van Beers, Bernard/N-2816-2016; raffenne, jerome/AAD-1601-2020; Soubrane, Olivier/ABB-4434-2021; Cros, Jerome/X-7677-2019; Garteiser, Philippe/P-5719-2017	François, Cauchy/0000-0002-4997-3730; Van Beers, Bernard/0000-0001-6429-1140; raffenne, jerome/0000-0002-5344-5674; Cros, Jerome/0000-0002-4935-3865; Rautou, Pierre-Emmanuel/0000-0001-9567-1859; Garteiser, Philippe/0000-0003-0157-8851	la Ligue Nationale de la Recherche Contre le Cancer; 2la Fondation de la Recherche Medicale	la Ligue Nationale de la Recherche Contre le Cancer; 2la Fondation de la Recherche Medicale	The study was supported by "la Ligue Nationale de la Recherche Contre le Cancer." A. Sannier received a research grant from "2la Fondation de la Recherche Medicale".	Baffy G, 2012, J HEPATOL, V56, P1384, DOI 10.1016/j.jhep.2011.10.027; Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201; Bedossa P, 2012, HEPATOLOGY, V56, P1751, DOI 10.1002/hep.25889; Ben Sahra I, 2011, CANCER RES, V71, P4366, DOI 10.1158/0008-5472.CAN-10-1769; Boord JB, 2004, CIRCULATION, V110, P1492, DOI 10.1161/01.CIR.0000141735.13202.B6; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Cao H, 2006, DIABETES, V55, P1915, DOI 10.2337/db05-1496; Cauchy F, 2017, CLIN SCI, V131, P27, DOI 10.1042/CS20160438; Cauchy F, 2015, GUT, V64, P1498, DOI 10.1136/gutjnl-2015-310069; Das R, 2001, CLIN CANCER RES, V7, P1706; Dirat B, 2011, CANCER RES, V71, P2455, DOI 10.1158/0008-5472.CAN-10-3323; Eckel RH, 2010, LANCET, V375, P181, DOI 10.1016/S0140-6736(09)61794-3; El-Serag HB, 2001, AM J GASTROENTEROL, V96, P2462, DOI 10.1111/j.1572-0241.2001.04054.x; Elmasri H, 2012, ANGIOGENESIS, V15, P457, DOI 10.1007/s10456-012-9274-0; Ertunc ME, 2015, J LIPID RES, V56, P423, DOI 10.1194/jlr.M055798; Furuhashi M, 2008, NAT REV DRUG DISCOV, V7, P489, DOI 10.1038/nrd2589; Garin-Shkolnik T, 2014, DIABETES, V63, P900, DOI 10.2337/db13-0436; Guaita-Esteruelas S, 2017, MOL CARCINOGEN, V56, P208, DOI 10.1002/mc.22485; Hammamieh Rasha, 2004, J Exp Ther Oncol, V4, P195; Hancke K, 2010, BREAST CANCER RES TR, V119, P367, DOI 10.1007/s10549-009-0577-9; Harjes U, 2014, J BIOL CHEM, V289, P23168, DOI 10.1074/jbc.M114.576512; Herroon MK, 2013, ONCOTARGET, V4, P2108, DOI 10.18632/oncotarget.1482; Hotamisligil GS, 1996, SCIENCE, V274, P1377, DOI 10.1126/science.274.5291.1377; Hu BF, 2015, J HEPATOL, V63, P855, DOI 10.1016/j.jhep.2015.05.030; Queipo-Ortuno MI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048605; Kaess BM, 2012, J CLIN ENDOCR METAB, V97, pE1943, DOI 10.1210/jc.2012-1458; Kim YC, 2011, J NUTR BIOCHEM, V22, P289, DOI 10.1016/j.jnutbio.2010.02.007; Koh JH, 2009, DIABETES CARE, V32, P147, DOI 10.2337/dc08-1379; Larsson SC, 2007, BRIT J CANCER, V97, P1005, DOI 10.1038/sj.bjc.6603932; Lee D, 2014, ONCOL REP, V31, P1116, DOI 10.3892/or.2014.2975; Lemoinne S, 2015, HEPATOLOGY, V61, P1041, DOI 10.1002/hep.27318; Maeda K, 2005, CELL METAB, V1, P107, DOI 10.1016/j.cmet.2004.12.008; Manabe Y, 2003, J PATHOL, V201, P221, DOI 10.1002/path.1430; Marra F, 2009, HEPATOLOGY, V50, P957, DOI 10.1002/hep.23046; Milner KL, 2009, HEPATOLOGY, V49, P1926, DOI 10.1002/hep.22896; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Pais R, 2016, J HEPATOL, V65, P1245, DOI 10.1016/j.jhep.2016.07.033; Paradis V, 2009, HEPATOLOGY, V49, P851, DOI 10.1002/hep.22734; Pelton PD, 1999, BIOCHEM BIOPH RES CO, V261, P456, DOI 10.1006/bbrc.1999.1071; Saavedra P, 2015, BBA-MOL CELL RES, V1853, P2966, DOI 10.1016/j.bbamcr.2015.09.002; Saxena NK, 2007, CANCER RES, V67, P2497, DOI 10.1158/0008-5472.CAN-06-3075; Sharma D, 2010, HEPATOLOGY, V52, P1713, DOI 10.1002/hep.23892; Starley BQ, 2010, HEPATOLOGY, V51, P1820, DOI 10.1002/hep.23594; Thompson KJ, 2017, LIVER INT, DOI [10.1111/liv, DOI 10.1111/LIV]; Wang Y, 2014, J CHEM INF MODEL, V54, P3046, DOI 10.1021/ci500503b; Wang Y, 2017, BIOMED PHARMACOTHER, V85, P272, DOI 10.1016/j.biopha.2016.11.021; Welzel TM, 2011, HEPATOLOGY, V54, P463, DOI 10.1002/hep.24397; Westerbacka J, 2007, DIABETES, V56, P2759, DOI 10.2337/db07-0156; Wong RJ, 2015, GASTROENTEROLOGY, V148, P547, DOI 10.1053/j.gastro.2014.11.039; Xu AM, 2006, CLIN CHEM, V52, P405, DOI 10.1373/clinchem.2005.062463	51	30	30	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2019	38	16					3033	3046		10.1038/s41388-018-0597-1	http://dx.doi.org/10.1038/s41388-018-0597-1			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU3IV	30575815	Green Published, hybrid			2022-12-28	WOS:000465167600012
J	Hald, OH; Olsen, L; Gallo-Oller, G; Elfman, LHM; Lokke, C; Kogner, P; Sveinbjornsson, B; Flaegstad, T; Johnsen, JI; Einvik, C				Hald, Oyvind H.; Olsen, Lotte; Gallo-Oller, Gabriel; Elfman, Lotta Helena Maria; Lokke, Cecilie; Kogner, Per; Sveinbjornsson, Baldur; Flaegstad, Trond; Johnsen, John Inge; Einvik, Christer			Inhibitors of ribosome biogenesis repress the growth of MYCN-amplified neuroblastoma	ONCOGENE			English	Article							RNA-POLYMERASE I; N-MYC; THERAPEUTIC STRATEGY; G-QUADRUPLEXES; EXPRESSION; CANCER; P53; CX-5461; TARGET; PATHWAYS	Abnormal increases in nucleolar size and number caused by dysregulation of ribosome biogenesis has emerged as a hallmark in the majority of spontaneous cancers. The observed ribosome hyperactivity can be directly induced by the MYC transcription factors controlling the expression of RNA and protein components of the ribosome. Neuroblastoma, a highly malignant childhood tumor of the sympathetic nervous system, is frequently characterized by MYCN gene amplification and high expression of MYCN and c-MYC signature genes. Here, we show a strong correlation between high-risk disease, MYCN expression, poor survival, and ribosome biogenesis in neuroblastoma patients. Treatment of neuroblastoma cells with quarfloxin or CX-5461, two small molecule inhibitors of RNA polymerase I, suppressed MycN expression, induced DNA damage, and activated p53 followed by cell cycle arrest or apoptosis. CX-5461 repressed the growth of established MYCN-amplified neuroblastoma xenograft tumors in nude mice. These findings suggest that inhibition of ribosome biogenesis represent new therapeutic opportunities for children with high-risk neuroblastomas expressing high levels of Myc.	[Hald, Oyvind H.; Flaegstad, Trond; Einvik, Christer] UNN Univ Hosp North Norway, Dept Pediat, Div Child & Adolescent Hlth, NO-9038 Tromso, Norway; [Olsen, Lotte; Lokke, Cecilie; Flaegstad, Trond; Einvik, Christer] Arctic Univ Norway UiT, Pediat Res Grp, Dept Clin Med, Fac Hlth Sci, NO-9037 Tromso, Norway; [Gallo-Oller, Gabriel; Elfman, Lotta Helena Maria; Kogner, Per; Sveinbjornsson, Baldur; Johnsen, John Inge] Karolinska Inst, Childhood Canc Res Unit, Dept Womens & Childrens Hlth, S-17176 Stockholm, Sweden; [Sveinbjornsson, Baldur] Arctic Univ Norway UiT, Mol Inflammat Res Grp, Dept Med Biol, Fac Hlth Sci, NO-9037 Tromso, Norway	UiT The Arctic University of Tromso; University Hospital of North Norway; UiT The Arctic University of Tromso; Karolinska Institutet; UiT The Arctic University of Tromso	Einvik, C (corresponding author), UNN Univ Hosp North Norway, Dept Pediat, Div Child & Adolescent Hlth, NO-9038 Tromso, Norway.; Einvik, C (corresponding author), Arctic Univ Norway UiT, Pediat Res Grp, Dept Clin Med, Fac Hlth Sci, NO-9037 Tromso, Norway.	christer.einvik@uit.no	; Gallo-Oller, Gabriel/D-6825-2019	Johnsen, John Inge/0000-0003-1277-812X; Gallo-Oller, Gabriel/0000-0002-3864-1941	Norwegian Childhood Cancer Society (Barnekreftforeningen); Northern-Norwegian Health Authorities (Helse Nord); Simon Fougner Hartmanns Familiefond; Swedish Childhood Cancer Foundation; Swedish Cancer Foundation; Swedish Foundation for Strategic Research; Cancer Research Foundations of Radiumhemmet	Norwegian Childhood Cancer Society (Barnekreftforeningen); Northern-Norwegian Health Authorities (Helse Nord); Simon Fougner Hartmanns Familiefond; Swedish Childhood Cancer Foundation(European Commission); Swedish Cancer Foundation; Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research); Cancer Research Foundations of Radiumhemmet	This work was supported by the Norwegian Childhood Cancer Society (Barnekreftforeningen), The Northern-Norwegian Health Authorities (Helse Nord), the Simon Fougner Hartmanns Familiefond, the Swedish Childhood Cancer Foundation, the Swedish Cancer Foundation, the Swedish Foundation for Strategic Research (www.nnbcr.se) and The Cancer Research Foundations of Radiumhemmet. We wish to thank Dr. Emma Bell for kindly providing the siMYCN IMR-32 microarray data.	Bell E, 2007, CELL CYCLE, V6, P1249, DOI 10.4161/cc.6.10.4222; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Bykov VJN, 2018, NAT REV CANCER, V18, P89, DOI 10.1038/nrc.2017.109; Bywater MJ, 2012, CANCER CELL, V22, P51, DOI 10.1016/j.ccr.2012.05.019; Cole KA, 2012, CLIN CANCER RES, V18, P2423, DOI 10.1158/1078-0432.CCR-11-1409; Drygin D, 2011, CANCER RES, V71, P1418, DOI 10.1158/0008-5472.CAN-10-1728; Drygin D, 2009, CANCER RES, V69, P7653, DOI 10.1158/0008-5472.CAN-09-1304; EGAN M, 1988, J CLIN PATHOL, V41, P527, DOI 10.1136/jcp.41.5.527; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Goldschneider D, 2006, NUCLEIC ACIDS RES, V34, P5603, DOI 10.1093/nar/gkl619; Gonin-Laurent N, 2006, CARCINOGENESIS, V27, P1266, DOI 10.1093/carcin/bgi356; Hein N, 2013, TRENDS MOL MED, V19, P643, DOI 10.1016/j.molmed.2013.07.005; Henriksen JR, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-1; Johnsen JI, 2018, PHARMACOL RES, V131, P164, DOI 10.1016/j.phrs.2018.02.023; Karahan G, 2015, ONCOL REP, V33, P3131, DOI 10.3892/or.2015.3940; Keshelava N, 2001, CANCER RES, V61, P6185; Kitade S, 2016, CANCER SCI, V107, P1399, DOI 10.1111/cas.13026; Kobayashi C, 2005, CANCER-AM CANCER SOC, V103, P174, DOI 10.1002/cncr.20717; Lee HC, 2017, BRIT J HAEMATOL, V177, P80, DOI 10.1111/bjh.14525; Li LM, 2016, ONCOTARGETS THER, V9, P5985, DOI 10.2147/OTT.S104513; Lutz W, 1996, ONCOGENE, V13, P803; Maris JM, 2010, NEW ENGL J MED, V362, P2202, DOI 10.1056/NEJMra0804577; Negi SS, 2015, ONCOTARGET, V6, P18094, DOI 10.18632/oncotarget.4093; Niemas-Teshiba Risa, 2018, Oncotarget, V9, P6416, DOI 10.18632/oncotarget.23740; Otto T, 2009, CANCER CELL, V15, P67, DOI 10.1016/j.ccr.2008.12.005; Pelletier J, 2018, NAT REV CANCER, V18, P51, DOI 10.1038/nrc.2017.104; Popov A, 2013, NUCLEUS-AUSTIN, V4, P134, DOI 10.4161/nucl.23985; Quin J, 2016, ONCOTARGET, V7, P49800, DOI 10.18632/oncotarget.10452; Rhodes D, 2015, NUCLEIC ACIDS RES, V43, P8627, DOI 10.1093/nar/gkv862; Roth Sarah Andrea, 2018, Oncotarget, V9, P18160, DOI 10.18632/oncotarget.24793; Ruiz-Perez MV, 2017, GENES-BASEL, V8, DOI 10.3390/genes8040113; Scaife JE, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.7_suppl.94; Schroeder U, 2003, BLOOD, V102, P246, DOI 10.1182/blood-2002-07-2268; Siddiqui-Jain A, 2002, P NATL ACAD SCI USA, V99, P11593, DOI 10.1073/pnas.182256799; Singhal J, 2011, CANCER PREV RES, V4, P879, DOI 10.1158/1940-6207.CAPR-11-0025; Smith J, 2010, ADV CANCER RES, V108, P73, DOI [10.1016/B978-0-12-380888-2.00003-0, 10.1016/S0065.230X(10)08002.4]; Suenaga Y, 2009, BIOCHEM BIOPH RES CO, V390, P21, DOI 10.1016/j.bbrc.2009.09.044; Trajkovski M, 2012, J AM CHEM SOC, V134, P4132, DOI 10.1021/ja208483v; van Riggelen J, 2010, NAT REV CANCER, V10, P301, DOI 10.1038/nrc2819; Wang LL, 2013, CANCER-AM CANCER SOC, V119, P3718, DOI 10.1002/cncr.28251; Westermann F, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-10-r150; Xu H, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14432; Xue C, 2007, CANCER RES, V67, P10351, DOI 10.1158/0008-5472.CAN-06-4345; Yokobori T, 2009, CANCER RES, V69, P3788, DOI 10.1158/0008-5472.CAN-08-2846	44	28	30	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2019	38	15					2800	2813		10.1038/s41388-018-0611-7	http://dx.doi.org/10.1038/s41388-018-0611-7			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HS8LQ	30542116	hybrid, Green Published			2022-12-28	WOS:000464121600010
J	Liu, SM; Yin, P; Kujawa, SA; Coon, JS; Okeigwe, I; Bulun, SE				Liu, Shimeng; Yin, Ping; Kujawa, Stacy A.; Coon, John S.; Okeigwe, Ijeoma; Bulun, Serdar E.			Progesterone receptor integrates the effects of mutated MED12 and altered DNA methylation to stimulate RANKL expression and stem cell proliferation in uterine leiomyoma	ONCOGENE			English	Article							OSTEOCLAST DIFFERENTIATION; TRANSCRIPTIONAL REGULATION; MEDIATOR; LIGAND; GENE; MUTATIONS; PATHWAY; CANCER	Progesterone and its receptor, PR, are essential for uterine leiomyoma (LM, a.k.a., fibroid) tumorigenesis, but the underlying cellular and molecular mechanisms remain unclear. The receptor activator of NF-kappa B (RANKL) was recently identified as a novel progesterone/PR-responsive gene that plays an important role in promoting LM growth. Here, we used RANKL as a representative gene to investigate how steroid hormone, genetic, and epigenetic signals are integrated to regulate LM stem cell (LSC) function. We demonstrated that RANKL specifically upregulates LSC proliferation through activation of Cyclin D1. RANKL gene transcription was robustly induced by the progesterone agonist R5020, leading to a dramatically higher RANKL expression in LM compared to adjacent myometrial (MM) tissue. MethylCap-Seq revealed a differentially methylated region (DMR) adjacent to the distal PR-binding site (PRBS) 87 kb upstream of the RANKL transcription start site. Hypermethylation of the DMR inhibited recruitment of PR to the adjacent PRBS. Luciferase assays indicated that the DMR and distal PRBS constitute a novel RANKL distal regulatory element that actively regulates RANKL expression. Furthermore, MED12 physically interacts with PR in LM tissue. The interaction between MED12 and PR, binding of PR and MED12 to PRBS, and RANKL gene expression are significantly higher in LM containing a distinct MED12 mutation (G44D) than in LM with wild-type MED12. In summary, our findings suggest that DNA methylation and MED12 mutation together constitute a complex regulatory network that affects progesterone/PR-mediated RANKL gene expression, with an important role in activating stem cell proliferation and fibroid tumor development.	[Liu, Shimeng; Yin, Ping; Kujawa, Stacy A.; Coon, John S.; Okeigwe, Ijeoma; Bulun, Serdar E.] Northwestern Univ, Div Reprod Sci Med, Dept Obstet & Gynecol, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Bulun, SE (corresponding author), Northwestern Univ, Div Reprod Sci Med, Dept Obstet & Gynecol, Feinberg Sch Med, Chicago, IL 60611 USA.	s-bulun@northwestern.edu			NIH [P01 HD057877]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD057877] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA060553] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by NIH grant P01 HD057877 to SB.	Acevedo ML, 2003, MOL CELL BIOL, V23, P335, DOI 10.1128/MCB.23.1.335-348.2003; Aranda-Orgilles B, 2016, CELL STEM CELL, V19, P784, DOI 10.1016/j.stem.2016.08.004; Asselin-Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027; Banaganapalli B, 2016, J CELL BIOCHEM, V117, P2023, DOI 10.1002/jcb.25499; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Bonifacino Juan S, 2016, CURR PROTOC CELL BIO, V71; Borahay MA, 2015, MOL MED, V21, P242, DOI 10.2119/molmed.2014.00053; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; Bulun SE, 2013, NEW ENGL J MED, V369, P1344, DOI 10.1056/NEJMra1209993; Catherino WH, 2011, FERTIL STERIL, V95, P9, DOI 10.1016/j.fertnstert.2010.08.049; Chen W, 2007, NUCLEIC ACIDS RES, V35, P6161, DOI 10.1093/nar/gkm661; Delgado-Calle J, 2012, EPIGENETICS-US, V7, P83, DOI 10.4161/epi.7.1.18753; Flaque MCD, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3587; Dyson MT, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004158; Faivre EJ, 2008, MOL ENDOCRINOL, V22, P823, DOI 10.1210/me.2007-0437; Fan X, 2004, J CELL BIOCHEM, V93, P807, DOI 10.1002/jcb.20217; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Gonzalez-Suarez E, 2010, NATURE, V468, P103, DOI 10.1038/nature09495; Hagege H, 2007, NAT PROTOC, V2, P1722, DOI 10.1038/nprot.2007.243; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hsu PY, 2016, ONCOGENE, V35, P2379, DOI 10.1038/onc.2015.298; Hu H, 2014, BREAST CANCER RES TR, V146, P515, DOI 10.1007/s10549-014-3049-9; Hu Y, 2008, BIOCHEM BIOPH RES CO, V370, P440, DOI 10.1016/j.bbrc.2008.03.106; Ikhena DE, 2018, J CLIN ENDOCR METAB, V103, P1842, DOI 10.1210/jc.2017-01585; Ishikawa H, 2010, ENDOCRINOLOGY, V151, P2433, DOI 10.1210/en.2009-1225; Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091; Kiesel L, 2016, MATURITAS, V86, P10, DOI 10.1016/j.maturitas.2016.01.001; Kim JJ, 2013, ENDOCR REV, V34, P130, DOI 10.1210/er.2012-1043; Klug M., 2014, EPIGENETICS, V1, P127, DOI DOI 10.4161/EPI.1.3.3327; Klug M, 2006, EPIGENETICS-US, V1, P127, DOI 10.4161/epi.1.3.3327; Li Y, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1412-9; Makinen N, 2011, SCIENCE, V334, P252, DOI 10.1126/science.1208930; Malik M, 2012, MATRIX BIOL, V31, P389, DOI 10.1016/j.matbio.2012.09.005; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; Mittal P, 2015, J CLIN INVEST, V125, P3280, DOI 10.1172/JCI81534; Navarro A, 2014, J CLIN ENDOCR METAB, V99, pE2437, DOI 10.1210/jc.2014-2264; Navarro A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033284; Nishikawa K, 2015, NAT MED, V21, P281, DOI 10.1038/nm.3774; Nolan E, 2016, NAT MED, V22, P933, DOI 10.1038/nm.4118; Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972; Ono M, 2013, P NATL ACAD SCI USA, V110, P17053, DOI 10.1073/pnas.1313650110; Ooi SKT, 2007, NATURE, V448, P714, DOI 10.1038/nature05987; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; Renema N, 2016, BIOSCIENCE REP, V36, DOI 10.1042/BSR20160150; Schramek D, 2010, NATURE, V468, P98, DOI 10.1038/nature09387; Shen L, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-284; Tanos T, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005654; Turunen M, 2014, CELL REP, V7, P654, DOI 10.1016/j.celrep.2014.03.047; Yin P, 2015, J CLIN ENDOCR METAB, V100, pE601, DOI 10.1210/jc.2014-2134; Yin P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029021	50	21	22	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2019	38	15					2722	2735		10.1038/s41388-018-0612-6	http://dx.doi.org/10.1038/s41388-018-0612-6			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HS8LQ	30538295	hybrid, Green Accepted, Green Published			2022-12-28	WOS:000464121600004
J	Flood, B; Manils, J; Nulty, C; Flis, E; Kenealy, S; Barber, G; Fay, J; Mills, KHG; Kay, EW; Creagh, EM				Flood, Brian; Manils, Joan; Nulty, Ciara; Flis, Ewelina; Kenealy, Sinead; Barber, Gillian; Fay, Joanna; Mills, Kingston H. G.; Kay, Elaine W.; Creagh, Emma M.			Caspase-11 regulates the tumour suppressor function of STAT1 in a murine model of colitis-associated carcinogenesis	ONCOGENE			English	Article							NONCANONICAL INFLAMMASOME ACTIVATION; CELL-PROLIFERATION; INTERFERON-ALPHA; COLON; ANGIOGENESIS; EXPRESSION; LIPOPOLYSACCHARIDE; TUMORIGENESIS; PYROPTOSIS; INNATE	Murine inflammatory caspase-11 has an important role in intestinal epithelial inflammation and barrier function. Activation of the non-canonical inflammasome, mediated by caspase-11, serves as a regulatory pathway for the production of the proinflammatory cytokines IL-1 beta and IL-18, and has a key role in pyroptotic cell death. We have previously demonstrated a protective role for caspase-11 during dextran sulphate sodium (DSS)-induced colitis, however the importance of caspase-11 during colorectal tumour development remains unclear. Here, we show that Casp11(-1-) mice are highly susceptible to the azoxymethane (AOM)-DSS model of colitis-associated cancer (CAC), compared to their wild type (WT) littermates. We show that deficient IL-18 production occurs at initial inflammation stages of disease, and that IL-1 beta production is more significantly impaired in Casp11(-1-) colons during established CAC. We identify defective STAT1 activation in Casp11(-)(1-) colons during disease progression, and show that IL-1 beta signalling induces caspase-11 expression and STAT1 activation in primary murine macrophages and intestinal epithelial cells. These findings uncover an anti-tumour role for the caspase-11 and the non-canonical inflammasome during CAC, and suggest a critical role for caspase-11, linking IL-1 beta and STAT1 signalling pathways.	[Flood, Brian; Manils, Joan; Nulty, Ciara; Flis, Ewelina; Kenealy, Sinead; Barber, Gillian; Mills, Kingston H. G.; Creagh, Emma M.] Trinity Coll Dublin, Trinity Biomed Sci Inst, Sch Biochem & Immunol, Dublin 2, Ireland; [Fay, Joanna; Kay, Elaine W.] Royal Coll Surgeons Ireland, Dublin 9, Ireland; [Fay, Joanna; Kay, Elaine W.] Beaumont Hosp, Dublin 9, Ireland	Trinity College Dublin; Royal College of Surgeons - Ireland	Creagh, EM (corresponding author), Trinity Coll Dublin, Trinity Biomed Sci Inst, Sch Biochem & Immunol, Dublin 2, Ireland.	ecreagh@tcd.ie	Manils, Joan/ABC-7884-2021; Manils, Joan/I-1258-2015; Mills, Kingston H/F-5684-2013; Creagh, Emma/AAX-1064-2021	Manils, Joan/0000-0001-8429-1295; Manils, Joan/0000-0001-8429-1295; Mills, Kingston H/0000-0003-3646-8222; Creagh, Emma/0000-0001-7631-4370; Barber, Gillian/0000-0002-6909-6042	Enterprise Ireland [CF-2015-0061P]; Government of Ireland PRTLI PhD programme [201921, 12259]; EU [721906]; SFI Investigator programme [12/IP/1400]	Enterprise Ireland; Government of Ireland PRTLI PhD programme; EU(European Commission); SFI Investigator programme(Science Foundation Ireland)	We thank the J. Yuan laboratory (Harvard Medical School) for the provision of Caspase-11<SUP>-/-</SUP> mice; and the technical staff of the Comparative Medicine Unit, TCD for their assistance in the backcrossing and breeding of these mice. This study was supported by Enterprise Ireland (CF-2015-0061P). B.F. was supported by a Government of Ireland PRTLI PhD programme (scheme #201921, award #12259). E.F. is an Early Stage Researcher of the EU Horizon 2020 Research and Innovation Programme, TRACT (Marie Sklodowska-Curie grant agreement No 721906). S.K. is funded by an SFI Investigator programme grant (12/IP/1400).	Aachoui Y, 2013, SCIENCE, V339, P975, DOI 10.1126/science.1230751; Allen IC, 2010, J EXP MED, V207, P1045, DOI 10.1084/jem.20100050; Asquith M, 2010, J EXP MED, V207, P1573, DOI 10.1084/jem.20101330; Barker N, 2014, NAT REV MOL CELL BIO, V15, P19, DOI 10.1038/nrm3721; Bhattacharyya S, 2011, P NATL ACAD SCI USA, V108, P9554, DOI 10.1073/pnas.1017296108; BIASCO G, 1990, CANCER RES, V50, P1156; Boucher D, 2018, J EXP MED, V215, P827, DOI 10.1084/jem.20172222; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Broz P, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003144; Carmi Y, 2011, J IMMUNOL, V186, P3462, DOI 10.4049/jimmunol.1002901; Case CL, 2013, P NATL ACAD SCI USA, V110, P1851, DOI 10.1073/pnas.1211521110; Chan SR, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3100; Chen GY, 2011, J IMMUNOL, V186, P7187, DOI 10.4049/jimmunol.1100412; Creagh EM, 2014, TRENDS IMMUNOL, V35, P631, DOI 10.1016/j.it.2014.10.004; Crncec I, 2018, MOL ONCOL, V12, P514, DOI 10.1002/1878-0261.12178; Demon D, 2014, MUCOSAL IMMUNOL, V7, P1504, DOI 10.1038/mi.2014.83; Dempoya J, 2012, J VIROL, V86, P12760, DOI 10.1128/JVI.01881-12; Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612; Dupaul-Chicoine J, 2010, IMMUNITY, V32, P367, DOI 10.1016/j.immuni.2010.02.012; Elinav E, 2011, CELL, V145, P745, DOI 10.1016/j.cell.2011.04.022; Fink SL, 2006, CELL MICROBIOL, V8, P1812, DOI 10.1111/j.1462-5822.2006.00751.x; Flood B, 2015, CLIN EXP IMMUNOL, V181, P39, DOI 10.1111/cei.12617; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Fung KYC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120425; Ghiringhelli F, 2009, NAT MED, V15, P1170, DOI 10.1038/nm.2028; Gkouskou KK, 2016, ONCOGENE, V35, P2496, DOI 10.1038/onc.2015.307; Gurung P, 2012, J BIOL CHEM, V287, P16955; Hagar JA, 2013, SCIENCE, V341, P1250, DOI 10.1126/science.1240988; Hou J, 2014, CANCER CELL, V25, P49, DOI 10.1016/j.ccr.2013.11.011; Hu B, 2013, P NATL ACAD SCI USA, V110, P9862, DOI 10.1073/pnas.1307575110; Hu B, 2010, P NATL ACAD SCI USA, V107, P21635, DOI 10.1073/pnas.1016814108; Huang SY, 2002, ONCOGENE, V21, P2504, DOI 10.1038/sj.onc.1205341; Hur J, 2001, FEBS LETT, V507, P157, DOI 10.1016/S0014-5793(01)02975-1; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kalerl P, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00088; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kayagaki N, 2015, NATURE, V526, P666, DOI 10.1038/nature15541; Kayagaki N, 2013, SCIENCE, V341, P1246, DOI 10.1126/science.1240248; Kayagaki N, 2011, NATURE, V479, P117, DOI 10.1038/nature10558; Lopez-Pastrana J, 2015, J BIOL CHEM, V290, P17485, DOI 10.1074/jbc.M115.641191; Ma YH, 2016, ONCOTARGET, V7, P73003, DOI 10.18632/oncotarget.12193; Man SM, 2015, CELL, V162, P45, DOI 10.1016/j.cell.2015.06.001; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516; Mattarollo SR, 2011, CANCER RES, V71, P4809, DOI 10.1158/0008-5472.CAN-11-0753; Neurath MF, 2014, NAT REV IMMUNOL, V14, P329, DOI 10.1038/nri3661; Nivarthi H, 2016, ONCOTARGET, V7, P51096, DOI 10.18632/oncotarget.9315; Normand S, 2011, P NATL ACAD SCI USA, V108, P9601, DOI 10.1073/pnas.1100981108; Oficjalska K, 2015, J IMMUNOL, V194, P1252, DOI 10.4049/jimmunol.1400501; Perse M, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/718617; Peterson JE, 2012, ANGIOGENESIS, V15, P265, DOI 10.1007/s10456-012-9259-z; Rathinam VAK, 2012, CELL, V150, P606, DOI 10.1016/j.cell.2012.07.007; Salcedo R, 2010, J EXP MED, V207, P1625, DOI 10.1084/jem.20100199; Schauvliege R, 2002, J BIOL CHEM, V277, P41624, DOI 10.1074/jbc.M207852200; Simpson JAD, 2010, GUT, V59, P926, DOI 10.1136/gut.2009.194472; Tattoli I, 2016, CELL REP, V14, P2576, DOI 10.1016/j.celrep.2016.02.065; Williams TM, 2015, J IMMUNOL, V194, P3369, DOI 10.4049/jimmunol.1402098; Williams TM, 2015, AM J PHYSIOL-GASTR L, V308, pG139, DOI 10.1152/ajpgi.00234.2014; Wilson JE, 2015, NAT MED, V21, P906, DOI 10.1038/nm.3908; Wu XL, 2014, WORLD J GASTROENTERO, V20, P10440, DOI 10.3748/wjg.v20.i30.10440; Yuasa K, 2016, GENES CELLS, V21, P25, DOI 10.1111/gtc.12316; Zaki MH, 2010, J IMMUNOL, V185, P4912, DOI 10.4049/jimmunol.1002046	62	18	20	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2019	38	14					2658	2674		10.1038/s41388-018-0613-5	http://dx.doi.org/10.1038/s41388-018-0613-5			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HR7LI	30538296	Green Published, hybrid			2022-12-28	WOS:000463335200015
J	Pearson, SJ; Sarkar, TR; McQueen, CM; Elswood, J; Schmitt, EE; Wall, SW; Scribner, KC; Wyatt, G; Barhoumi, R; Behbod, F; Rijnkels, M; Porter, WW				Pearson, Scott J.; Sarkar, Tapasree Roy; McQueen, Cole M.; Elswood, Jessica; Schmitt, Emily E.; Wall, Steven W.; Scribner, Kelly C.; Wyatt, Garhett; Barhoumi, Rola; Behbod, Fariba; Rijnkels, Monique; Porter, Weston W.			ATM-dependent activation of SIM2s regulates homologous recombination and epithelial-mesenchymal transition	ONCOGENE			English	Article							CARCINOMA IN-SITU; SURGICAL ADJUVANT BREAST; DNA-DAMAGE; GENOMIC INSTABILITY; LOCAL RECURRENCE; CELL-CYCLE; C-MET; CANCER; REPAIR; BRCA1	There is increasing evidence that genomic instability is a prerequisite for cancer progression. Here we show that SIM2s, a member of the bHLH/PAS family of transcription factors, regulates DNA damage repair through enhancement of homologous recombination (HR), and prevents epithelial-mesenchymal transitions (EMT) in an Ataxia-telangiectasia mutated (ATM)-dependent manner. Mechanistically, we found that SIM2s interacts with ATM and is stabilized through ATM-dependent phosphorylation in response to IR. Once stabilized, SIM2s interacts with BRCA1 and supports RAD51 recruitment to the site of DNA damage. Loss of SIM2s through the introduction of shSIM2 or the mutation of SIM2s at one of the predicted ATM phosphorylation sites (S115) reduces HR efficiency through disruption of RAD51 recruitment, resulting in genomic instability and induction of EMT. The EMT induced by the mutation of S115 is characterized by a decrease in E-cadherin and an induction of the basal marker, K14, resulting in increased invasion and metastasis. Together, these results identify a novel player in the DNA damage repair pathway and provides a link in ductal carcinoma in situ progression to invasive ductal carcinoma through loss of SIM2s, increased genomic instability, EMT, and metastasis.	[Pearson, Scott J.; Sarkar, Tapasree Roy; McQueen, Cole M.; Elswood, Jessica; Schmitt, Emily E.; Wall, Steven W.; Scribner, Kelly C.; Wyatt, Garhett; Barhoumi, Rola; Rijnkels, Monique; Porter, Weston W.] Texas A&M Univ, Coll Vet Med, Dept Integrat Biosci, College Stn, TX 77843 USA; [Behbod, Fariba] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66160 USA; [Porter, Weston W.] Texas A&M Univ, Vet Integrat Biosci, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; University of Kansas; University of Kansas Medical Center; Texas A&M University System; Texas A&M University College Station	Porter, WW (corresponding author), Texas A&M Univ, Coll Vet Med, Dept Integrat Biosci, College Stn, TX 77843 USA.; Porter, WW (corresponding author), Texas A&M Univ, Vet Integrat Biosci, College Stn, TX 77843 USA.	wporter@cvm.tamu.edu	Schmitt, Emily/GOP-0896-2022	Wall, Steven/0000-0002-4813-9920; Epps (Elswood), Jessica/0000-0003-1966-1557; Wyatt, Garhett/0000-0001-7402-6404	National Cancer Institute [R21CA190941, R01HD083952, R21CA185460]; Department of Defense (DOD-CDMRP) [W81XWH-11-1-0158]; American Association for Cancer Research (AACR)-2014 Breast Cancer Research Foundation-Translational Breast Cancer research; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD083952] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R21CA190941] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES026568] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defense (DOD-CDMRP)(United States Department of Defense); American Association for Cancer Research (AACR)-2014 Breast Cancer Research Foundation-Translational Breast Cancer research; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	National Cancer Institute R21CA190941 (WP); R01HD083952 (CO-PI WP, MR); R21CA185460 (FB) Department of Defense (DOD-CDMRP) W81XWH-11-1-0158 (KCS) American Association for Cancer Research (AACR)-2014 Breast Cancer Research Foundation-Translational Breast Cancer research (FB)	Aleman MJ, 2005, P NATL ACAD SCI USA, V102, P12765, DOI 10.1073/pnas.0505484102; [Anonymous], 2018, SOC AC CANC FACTS FI; Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005; Bardos JI, 2005, BBA-REV CANCER, V1755, P107, DOI 10.1016/j.bbcan.2005.05.001; Behbod F, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2358; Bergamaschi A, 2006, GENE CHROMOSOME CANC, V45, P1033, DOI 10.1002/gcc.20366; Bersten DC, 2013, NAT REV CANCER, V13, P827, DOI 10.1038/nrc3621; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Blom N, 2004, PROTEOMICS, V4, P1633, DOI 10.1002/pmic.200300771; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Burgess M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00019; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Burstein HJ, 2004, NEW ENGL J MED, V350, P1430, DOI 10.1056/NEJMra031301; Chapman JR, 2012, J CELL SCI, V125, P3529, DOI 10.1242/jcs.105353; Cowell CF, 2013, MOL ONCOL, V7, P859, DOI 10.1016/j.molonc.2013.07.005; Cowell CF, 2013, MOL ONCOL; Denison MS, 2011, TOXICOL SCI, V124, P1, DOI 10.1093/toxsci/kfr218; Du Y, 2016, NAT MED, V22, P194, DOI 10.1038/nm.4032; Elsarraj HS, 2017, CANCER RES, V77, P3802, DOI 10.1158/0008-5472.CAN-16-2794; Epstein DJ, 2000, DEVELOPMENT, V127, P4701; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fisher B, 1999, LANCET, V353, P1993, DOI 10.1016/S0140-6736(99)05036-9; Fisher ER, 1999, CANCER-AM CANCER SOC, V86, P429, DOI 10.1002/(SICI)1097-0142(19990801)86:3<429::AID-CNCR11>3.0.CO;2-Y; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Fridlyand J, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-96; Gatz SA, 2006, CELL DEATH DIFFER, V13, P1003, DOI 10.1038/sj.cdd.4401903; George WD, 2003, LANCET, V362, P95, DOI 10.1016/S0140-6736(03)13859-7; Golding SE, 2004, J BIOL CHEM, V279, P15402, DOI 10.1074/jbc.M314191200; Goodarzi AA, 2008, MOL CELL, V31, P167, DOI 10.1016/j.molcel.2008.05.017; Gustafson TL, 2009, ONCOGENE, V28, P1561, DOI 10.1038/onc.2008.497; Halvorsen OJ, 2007, CLIN CANCER RES, V13, P892, DOI 10.1158/1078-0432.CCR-06-1207; Heyer WD, 2010, ANNU REV GENET, V44, P113, DOI 10.1146/annurev-genet-051710-150955; Hilton JL, 2002, JNCI-J NATL CANCER I, V94, P1396; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Jonsson G, 2005, CANCER RES, V65, P7612, DOI 10.1158/0008-5472.CAN-05-0570; Kim TM, 2012, MOL CELL BIOL, V32, P3663, DOI 10.1128/MCB.00406-12; Kumar Gaurav, 2005, Mo Med, V102, P138; Kwak HI, 2007, CARCINOGENESIS, V28, P259, DOI 10.1093/carcin/bgl122; Kwei KA, 2010, MOL ONCOL, V4, P255, DOI 10.1016/j.molonc.2010.04.001; Laffin B, 2008, MOL CELL BIOL, V28, P1936, DOI 10.1128/MCB.01701-07; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Loeb LA, 2001, CANCER RES, V61, P3230; Lorkovic ZJ, 2017, NUCLEUS-PHILA, V8, P583, DOI 10.1080/19491034.2017.1384893; Mavaddat N, 2012, CANCER EPIDEM BIOMAR, V21, P134, DOI 10.1158/1055-9965.EPI-11-0775; Metz RP, 2006, J BIOL CHEM, V281, P10839, DOI 10.1074/jbc.M508858200; Morrison C, 2000, EMBO J, V19, P463, DOI 10.1093/emboj/19.3.463; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P3044, DOI 10.1073/pnas.85.9.3044; Okui M, 2005, EXP CELL RES, V309, P220, DOI 10.1016/j.yexcr.2005.05.018; PAGE DL, 1995, CANCER, V76, P1197, DOI 10.1002/1097-0142(19951001)76:7<1197::AID-CNCR2820760715>3.0.CO;2-0; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Renwick A, 2006, NAT GENET, V38, P873, DOI 10.1038/ng1837; Rudloff U, 2010, J CLIN ONCOL, V28, P3762, DOI 10.1200/JCO.2009.26.8847; Rugo HS, 2016, NEW ENGL J MED, V375, P23, DOI 10.1056/NEJMoa1513749; Ryu T, 2015, NAT CELL BIOL, V17, P1401, DOI 10.1038/ncb3258; Sanders ME, 2005, CANCER, V103, P2481, DOI 10.1002/cncr.21069; Savage KI, 2014, MOL CELL, V54, P445, DOI 10.1016/j.molcel.2014.03.021; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Scribner KC, 2013, ONCOGENE, V32, P2631, DOI 10.1038/onc.2012.286; Scribner KC, 2011, MOL ENDOCRINOL, V25, P635, DOI 10.1210/me.2010-0423; Shook D, 2003, MECH DEVELOP, V120, P1351, DOI 10.1016/j.mod.2003.06.005; SILVERSTEIN MJ, 1995, LANCET, V345, P1154; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; Thompson D, 2005, JNCI-J NATL CANCER I, V97, P813, DOI 10.1093/jnci/dji141; Tirkkonen M, 1997, CANCER RES, V57, P1222; Trenz K, 2005, MUTAGENESIS, V20, P131, DOI 10.1093/mutage/gei018; Tsouroula K, 2016, MOL CELL, V63, P293, DOI 10.1016/j.molcel.2016.06.002; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6; Valdez KE, 2011, J PATHOL, V225, P565, DOI 10.1002/path.2969; Van Cleef A, 2014, FACTS VIEWS VIS OBGY, V6, P210; Wang Haibo, 2014, Jacobs J Radiat Oncol, V1; Wang JH, 2016, ONCOTARGET, V7, P7701, DOI 10.18632/oncotarget.6715; Wellberg E, 2010, DEVELOPMENT, V137, P945, DOI 10.1242/dev.041657; Woods SL, 2002, J BIOL CHEM, V277, P10236, DOI 10.1074/jbc.M110752200; Yang RL, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0698-3; Yoshida K, 2004, CANCER SCI, V95, P866, DOI 10.1111/j.1349-7006.2004.tb02195.x; Zamborszky J, 2017, ONCOGENE, V36, P746, DOI 10.1038/onc.2016.243; Zhou CY, 2003, ONCOGENE, V22, P2396, DOI 10.1038/sj.onc.1206319	78	10	10	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2019	38	14					2611	2626		10.1038/s41388-018-0622-4	http://dx.doi.org/10.1038/s41388-018-0622-4			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HR7LI	30531838	Green Accepted			2022-12-28	WOS:000463335200012
J	Fan, ZY; Yang, J; Zhang, D; Zhang, XL; Ma, X; Kang, L; Liu, Y; Yan, X; Ji, QB; Wang, JL; Li, Y; Zhang, SJ; Zhu, X; Hu, Y; Xu, XJ; Ye, QN; Jiao, SC				Fan, Zhongyi; Yang, Jing; Zhang, Dong; Zhang, Xuelin; Ma, Xiaoyan; Kang, Lei; Liu, Ying; Yan, Xiang; Ji, Quanbo; Wang, Jinliang; Li, Ying; Zhang, Sujie; Zhu, Xiang; Hu, Yi; Xu, Xiaojie; Ye, Qinong; Jiao, Shunchang			The risk variant rs884225 within EGFR impairs miR-103a-3p's anti-tumourigenic function in non-small cell lung cancer	ONCOGENE			English	Article							GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE INHIBITORS; GENE COPY NUMBER; AMERICAN SOCIETY; EXPRESSION; POLYMORPHISM; STATISTICS; MUTATIONS; PROLIFERATION; PROGRESSION	Epidermal growth factor receptor (EGFR) status is the major determinant of non-small cell lung cancer (NSCLC) therapy selection. Studies have hinted that EGFR antibodies or tyrosine kinase inhibitors were beneficial in patients with EGFR mutation-negative but EGFR-overexpressing of NSCLC. However, the mechanisms underlying EGFR amplification and overexpression in NSCLC remain largely unknown. Here, we report that rs884225, a single nucleotide polymorphism in the EGFR 3'-terminal untranslated region, was significantly associated with EGFR expression level and contributed to NSCLC susceptibility. Mechanistically, the rs884225 C allele enhanced EGFR expression by altering the miR-103a-3p binding site, thus impairing miR-103a-3p's anti-tumourigenic function. As a tumour suppressor gene, miR-103a-3p expression correlated with overall and recurrence-free survival in NSCLC patients. Furthermore, miR-103a-3p inhibited growth and metastasis via effects on the KRAS pathway and epithelial-to-mesenchymal transition in EGFR wild-type NSCLC cell lines, respectively, which substantially reduced EGFR expression and activity. Thus, rs884225 may be a biomarker for NSCLC susceptibility, and miR-103a-3p may be a potential therapeutic target in NSCLC.	[Fan, Zhongyi; Yan, Xiang; Ji, Quanbo; Wang, Jinliang; Li, Ying; Zhang, Sujie; Hu, Yi; Jiao, Shunchang] Peoples Liberat Army Gen Hosp, Dept Oncol, Beijing, Peoples R China; [Yang, Jing; Zhang, Dong] Peoples Liberat Army Gen Hosp, Dept Nanlou Oncol, Beijing, Peoples R China; [Zhang, Xuelin] Peoples Liberat Army Gen Hosp, Dept Nanlou Respirat, Beijing, Peoples R China; [Ma, Xiaoyan] Changchun Univ Chinese Med, Sch Chinese Med, Dept Cardiovasc Dis, Changchun, Jilin, Peoples R China; [Kang, Lei] Peking Univ, Dept Nucl Med, Hosp 1, Beijing, Peoples R China; [Liu, Ying] Peoples Liberat Army Gen Hosp, Dept Ophthalmol, Beijing, Peoples R China; [Zhu, Xiang; Xu, Xiaojie; Ye, Qinong] Beijing Inst Biotechnol, Dept Med Mol Biol, Beijing, Peoples R China	Chinese People's Liberation Army General Hospital; Chinese People's Liberation Army General Hospital; Chinese People's Liberation Army General Hospital; Changchun University of Chinese Medicine; Peking University; Chinese People's Liberation Army General Hospital	Jiao, SC (corresponding author), Peoples Liberat Army Gen Hosp, Dept Oncol, Beijing, Peoples R China.; Xu, XJ; Ye, QN (corresponding author), Beijing Inst Biotechnol, Dept Med Mol Biol, Beijing, Peoples R China.	miraclexxj@126.com; yeqn66@yahoo.com; jiaosc301@163.com	yan, Xiang/ABI-1846-2020; wang, jinliang/AAA-2799-2021	yan, Xiang/0000-0002-3683-474X; wang, jinliang/0000-0001-6427-3487; Jiao, Shunchang/0000-0002-9120-5233; Kang, Lei/0000-0001-8729-4547	National Natural Science Foundation of China [81702936, 81672602, 81822037, 81472589, 81630067]; Scientific Research Project of Health Care [15BJZ43]; Natural Science Foundation of Beijing [7172199]; Logistics Scientific Research Project [BWS16J010]; Postdoctoral Science Foundation of China [2017M613389, 2018T111142, 2017T100809]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Scientific Research Project of Health Care; Natural Science Foundation of Beijing(Beijing Natural Science Foundation); Logistics Scientific Research Project; Postdoctoral Science Foundation of China(China Postdoctoral Science Foundation)	This work was supported by the National Natural Science Foundation of China (81702936, 81672602, 81822037, 81472589 and 81630067), Scientific Research Project of Health Care (15BJZ43), the Natural Science Foundation of Beijing (7172199), Logistics Scientific Research Project (BWS16J010) and General Financial Grant from the Postdoctoral Science Foundation of China (2017M613389, 2018T111142 and 2017T100809). The PLA General Hospital and Beijing Institute of Biotechnology made equal contributions to this work.	Avraham R, 2011, NAT REV MOL CELL BIO, V12, P104, DOI 10.1038/nrm3048; Barlesi F, 2013, J CLIN ONCOL, V31, p486s; Baumgart A, 2010, CANCER RES, V70, P5368, DOI 10.1158/0008-5472.CAN-09-3763; Bradley JD, 2015, LANCET ONCOL, V16, P187, DOI 10.1016/S1470-2045(14)71207-0; Burstein HJ, 2017, J CLIN ONCOL, V35, P1341, DOI 10.1200/JCO.2016.71.5292; Cappuzzo F, 2010, LANCET ONCOL, V11, P521, DOI 10.1016/S1470-2045(10)70112-1; Cavalleri T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176680; Chang JTH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168284; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Chiyomaru T, 2015, INT J ONCOL, V46, P487, DOI 10.3892/ijo.2014.2752; Chu HY, 2013, MUTAGENESIS, V28, P49, DOI 10.1093/mutage/ges051; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Datta D, 2003, CHEST, V123, P2096, DOI 10.1378/chest.123.6.2096; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Goldstraw P, 2011, LANCET, V378, P1727, DOI 10.1016/S0140-6736(10)62101-0; Grandis JR, 2004, PHARMACOL THERAPEUT, V102, P37, DOI 10.1016/j.pharmthera.2004.01.002; Hart S, 2004, CANCER RES, V64, P1943, DOI 10.1158/0008-5472.CAN-03-3720; Hirsch FR, 2005, J CLIN ONCOL, V23, P6838, DOI 10.1200/JCO.2005.01.2823; Izar B, 2014, J THORAC ONCOL, V9, P1363, DOI 10.1097/JTO.0000000000000266; Jiang XM, 2016, ONCOTARGET, V7, P36733, DOI 10.18632/oncotarget.9166; Jokinen E, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-612; Lee Y, 2012, CLIN CANCER RES, V18, P1760, DOI 10.1158/1078-0432.CCR-11-2582; Li YW, 2010, CANCER RES, V70, P1486, DOI 10.1158/0008-5472.CAN-09-2792; Liang JL, 2015, CELL PROLIFERAT, V48, P78, DOI 10.1111/cpr.12159; Lin YX, 2014, AM J CANCER RES, V4, P411; Liu WQ, 2005, CANCER RES, V65, P46; Liu XM, 2017, ONCOTARGET, V8, P50209, DOI 10.18632/oncotarget.16854; Merrick DT, 2006, CLIN CANCER RES, V12, P2281, DOI 10.1158/1078-0432.CCR-05-2291; Milas L, 2004, INT J RADIAT ONCOL, V58, P966, DOI 10.1016/j.ijrobp.2003.08.035; Morgillo F, 2016, ESMO OPEN, V1, DOI 10.1136/esmoopen-2016-000060; Nomura M, 2007, PLOS MED, V4, P715, DOI 10.1371/journal.pmed.0040125; Ohe Y, 2008, CLIN CANCER RES, V14, P4206, DOI 10.1158/1078-0432.CCR-07-5143; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Patel JD, 2014, J CLIN ONCOL, V32, P129, DOI 10.1200/JCO.2013.53.7076; Pirker R, 2012, LANCET ONCOL, V13, P33, DOI 10.1016/S1470-2045(11)70318-7; Qin Q, 2016, J CELL MOL MED, V20, P1974, DOI 10.1111/jcmm.12889; Rizvi NA, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.tps8123; Ruan YF, 2016, SCI REP-UK, V6, DOI 10.1038/srep23368; RUSCH V, 1993, CANCER RES, V53, P2379; Santos GD, 2011, ANNU REV PATHOL-MECH, V6, P49, DOI 10.1146/annurev-pathol-011110-130206; Shelton JG, 2005, CELL CYCLE, V4, P822, DOI 10.4161/cc.4.6.1724; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; van Meerbeeck JP, 2011, LANCET, V378, P1741, DOI 10.1016/S0140-6736(11)60165-7; Wang F, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-90; Weber DG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114483; Xu NQ, 2016, ONCOTARGET, V7, P3884, DOI 10.18632/oncotarget.6461; Yu MJ, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0677-9; Yuan ZQ, 2009, CANCER RES, V69, P7811, DOI 10.1158/0008-5472.CAN-09-0986; Zhong ZY, 2016, SCI REP-UK, V6, DOI 10.1038/srep30919; Zhou SJ, 2015, CELL PHYSIOL BIOCHEM, V36, P166, DOI 10.1159/000374061	52	11	11	2	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2019	38	13					2291	2304		10.1038/s41388-018-0576-6	http://dx.doi.org/10.1038/s41388-018-0576-6			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ7GN	30470824				2022-12-28	WOS:000462588000005
J	Fedorova, O; Petukhov, A; Daks, A; Shuvalov, O; Leonova, T; Vasileva, E; Aksenov, N; Melino, G; Barlev, NA				Fedorova, Olga; Petukhov, Alexey; Daks, Alexandra; Shuvalov, Oleg; Leonova, Tatyana; Vasileva, Elena; Aksenov, Nikolai; Melino, Gerry; Barlev, Nikolai A.			Orphan receptor NR4A3 is a novel target of p53 that contributes to apoptosis	ONCOGENE			English	Article							TUMOR-SUPPRESSOR P53; NUCLEAR RECEPTORS; MESSENGER-RNA; CANCER-CELLS; BCL-2; EXPRESSION; TRANSCRIPTION; PROTEASOME; FAMILY; GENES	Major tumor suppressor and transcription factor p53 coordinates expression of many genes hence affecting critical cellular functions including cell cycle, senescence, and apoptosis. The NR4A family of orphan receptors (NR4A1-3) belongs to the superfamily of nuclear receptors. They regulate genes involved in proliferation, cell migration, and apoptosis. In this study, we report an identification of NR4A3 as a direct transcriptional target of p53. Using various techniques, we showed that p53 directly bound the promoter of NR4A3 gene and induced its transcription. Functionally, over-expression of NR4A3 attenuated proliferation of cancer cells and promoted apoptosis by augmenting the expression of pro-apoptotic genes, PUMA and Bax. Knockdown of NR4A3 reversed these phenotypes. Importantly, NR4A3 exhibited tumor suppressive functions both in p53-dependent and independent manner. In addition, NR4A3 physically interacted with an anti-apoptotic Bcl-2 protein hence sequestering it from blunting apoptosis. These observations were corroborated by the bioinformatics analysis, which demonstrated a correlation between high levels of NR4A3 expression and better survival of breast and lung cancer patients. Collectively, our studies revealed a novel transcriptional target of p53, NR4A3, which triggers apoptosis and thus likely has a tumor suppressive role in breast and lung cancers.	[Fedorova, Olga; Petukhov, Alexey; Daks, Alexandra; Shuvalov, Oleg; Leonova, Tatyana; Vasileva, Elena; Aksenov, Nikolai; Barlev, Nikolai A.] Inst Cytol, Gene Express Program, St Petersburg 194064, Russia; [Petukhov, Alexey] Almazov Natl Med Res Ctr, St Petersburg 197341, Russia; [Melino, Gerry] MRC Toxicol Unit, Leicester LE1 9HN, Leics, England; [Barlev, Nikolai A.] Moscow Inst Technol & Phys, Dolgoprudnyi 141700, Moscow Region, Russia	Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS; Almazov National Medical Research Centre; Moscow Institute of Physics & Technology	Barlev, NA (corresponding author), Inst Cytol, Gene Express Program, St Petersburg 194064, Russia.; Barlev, NA (corresponding author), Moscow Inst Technol & Phys, Dolgoprudnyi 141700, Moscow Region, Russia.	nick.a.barlev@gmail.com	Daks, Alexandra/F-1191-2017; Shuvalov, Oleg/AAF-3535-2021; Petukhov, Alexey/ABA-7903-2020; Barlev, Nikolai A/K-5268-2017; Fedorova, Olga/ABI-4862-2020; Leonova, Tatiana/V-3589-2019	Daks, Alexandra/0000-0003-0495-1244; Petukhov, Alexey/0000-0002-7298-5238; Barlev, Nikolai A/0000-0001-7111-2446; Fedorova, Olga/0000-0003-1382-4204	RCF [18-75-10076]; RFBR [18-29-09144]; MRC [MC_UU_00025/2, MC_U132670600] Funding Source: UKRI	RCF; RFBR(Russian Foundation for Basic Research (RFBR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	O.F., A.P. and E.V. carried out chromatin immunoprecipitation, Luciferase assay, quantitative PCR, cell-cycle analysis, colony formation assay, immunofluorescence, wound-healing and real-time cell migration assay and acknowledge the support from RCF grant 18-75-10076. A.D., O.S., N.B. carried out annexin V, coimmunoprecipitation interaction assay and the bioinformatics analysis and acknowledge the support from RFBR grant 18-29-09144. We appreciate Dr Mikhal Maliewitz (MRC Toxicology, Leicester) for a gift of NR4A1 and NR4A2 antibodies.	Althubiti M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.489; Amelio I, 2016, CELL DEATH DIFFER, V23, P912, DOI 10.1038/cdd.2016.12; Amelio I, 2015, TRENDS BIOCHEM SCI, V40, P425, DOI 10.1016/j.tibs.2015.04.007; Angeloni SV, 2004, J ENDOCRINOL, V180, P497, DOI 10.1677/joe.0.1800497; Antonov AV, 2011, NUCLEIC ACIDS RES, V39, pW323, DOI 10.1093/nar/gkr372; Barlev NA, 2010, CELL DEATH DIFFER, V17, P373, DOI 10.1038/cdd.2009.73; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Beard JA, 2016, SCI REP-UK, V6, DOI 10.1038/srep25108; Charni M, 2016, CELL DEATH DIFFER, V23, P509, DOI 10.1038/cdd.2015.119; Cronauer MV, 2004, ONCOGENE, V23, P3541, DOI 10.1038/sj.onc.1207346; Deutsch AJA, 2017, CANCER RES, V77, P2375, DOI 10.1158/0008-5472.CAN-16-2320; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elias A, 2013, MOL PHARMACOL, V83, P1229, DOI 10.1124/mol.113.085092; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Fedorova OA, 2011, BIOCHEM BIOPH RES CO, V416, P258, DOI 10.1016/j.bbrc.2011.10.126; Feng ZH, 2011, J MOL CELL BIOL, V3, P44, DOI 10.1093/jmcb/mjq040; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Gao WN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091462; Gibson LF, 1999, BREAST CANCER RES TR, V55, P107, DOI 10.1023/A:1006175811676; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hamroun D, 2006, HUM MUTAT, V27, P14, DOI 10.1002/humu.20269; Hermeking H, 2007, CANCER CELL, V12, P414, DOI 10.1016/j.ccr.2007.10.028; Innocente SA, 2005, FEBS LETT, V579, P1001, DOI 10.1016/j.febslet.2004.12.073; Iwano S, 2006, FEBS LETT, V580, P890, DOI 10.1016/j.febslet.2006.01.009; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kitagawa H, 2007, MOL CELL BIOL, V27, P7486, DOI 10.1128/MCB.00409-07; Kurakula K, 2014, BBA-MOL CELL RES, V1843, P2543, DOI 10.1016/j.bbamcr.2014.06.010; Lee SO, 2011, EXPERT OPIN THER TAR, V15, P195, DOI 10.1517/14728222.2011.547481; Levrero M, 2000, J CELL SCI, V113, P1661; Lezina L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.483; Lezina L, 2015, ONCOTARGET, V6, P25843, DOI 10.18632/oncotarget.4584; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Malewicz M, 2011, GENE DEV, V25, P2031, DOI 10.1101/gad.16872411; Marouco D, 2013, ONCOTARGET, V4, P1556, DOI 10.18632/oncotarget.1436; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Moiseeva TN, 2013, ONCOTARGET, V4, P1338, DOI 10.18632/oncotarget.1060; Murray-Zmijewski F, 2008, NAT REV MOL CELL BIO, V9, P702, DOI 10.1038/nrm2451; Olefsky JM, 2001, J BIOL CHEM, V276, P36863, DOI 10.1074/jbc.R100047200; Pant V, 2014, GENE DEV, V28, P1739, DOI 10.1101/gad.247452.114; Shibue T, 2006, EMBO J, V25, P4952, DOI 10.1038/sj.emboj.7601359; Stark AM, 2006, NEUROL RES, V28, P787, DOI 10.1179/016164106X110364; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Yeh CM, 2016, SCI REP-UK, V6, DOI 10.1038/srep31690; Yu CL, 1997, BIOCHEM BIOPH RES CO, V239, P617, DOI 10.1006/bbrc.1997.7522; Yu CL, 1997, CANCER LETT, V116, P191, DOI 10.1016/S0304-3835(97)00186-9; Yu J, 2008, ONCOGENE, V27, pS71, DOI 10.1038/onc.2009.45; Zhao BX, 2006, EMBO J, V25, P5703, DOI 10.1038/sj.emboj.7601435; Zhao Y, 2010, ARTERIOSCL THROM VAS, V30, P1535, DOI 10.1161/ATVBAHA.109.191163; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060	54	23	23	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2019	38	12					2108	2122		10.1038/s41388-018-0566-8	http://dx.doi.org/10.1038/s41388-018-0566-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP6UR	30455429				2022-12-28	WOS:000461822600008
J	Jung, SH; Hwang, HJ; Kang, D; Park, HA; Lee, HC; Jeong, D; Lee, K; Park, HJ; Ko, YG; Lee, JS				Jung, Seung Hee; Hwang, Hyun Jung; Kang, Donghee; Park, Hyun A.; Lee, Hyung Chul; Jeong, Daecheol; Lee, Keunwook; Park, Heon Joo; Ko, Young-Gyu; Lee, Jae-Seon			mTOR kinase leads to PTEN-loss-induced cellular senescence by phosphorylating p53	ONCOGENE			English	Article							ONCOGENE-INDUCED SENESCENCE; BINDING PARTNER; AKT; GROWTH; CELLS; ACTIVATION; RICTOR; RAPTOR; TOR	Loss of PTEN, the major negative regulator of the PI3K/AKT pathway induces a cellular senescence as a failsafe mechanism to defend against tumorigenesis, which is called PTEN-loss-induced cellular senescence (PICS). Although many studies have indicated that the mTOR pathway plays a critical role in cellular senescence, the exact functions of mTORC1 and mTORC2 in PICS are not well understood. In this study, we show that mTOR acts as a critical relay molecule downstream of PI3K/AKT and upstream of p53 in PICS. We found that PTEN depletion induces cellular senescence via p53-p21 signaling without triggering DNA damage response. mTOR kinase, a major component of mTORC1 and mTORC2, directly binds p53 and phosphorylates it at serine 15. mTORC1 and mTORC2 compete with MDM2 and increase the stability of p53 to induce cellular senescence via accumulation of the cell cycle inhibitor, p21. In embryonic fibroblasts of PTEN-knockout mice, PTEN deficiency also induces mTORC1 and mTORC2 to bind to p53 instead of MDM2, leading to cellular senescence. These results collectively demonstrate for the first time that mTOR plays a critical role in switching cells from proliferation signaling to senescence signaling via a direct link between the growth-promoting activity of AKT and the growth-suppressing activity of p53.	[Jung, Seung Hee; Hwang, Hyun Jung; Kang, Donghee; Park, Hyun A.; Lee, Hyung Chul; Lee, Jae-Seon] Inha Univ, Dept Mol Med, Coll Med, Incheon 22212, South Korea; [Jung, Seung Hee; Hwang, Hyun Jung; Kang, Donghee; Park, Hyun A.; Lee, Hyung Chul; Park, Heon Joo; Lee, Jae-Seon] Inha Univ, Coll Med, Hypoxia Related Dis Res Ctr, Incheon 22212, South Korea; [Jeong, Daecheol; Lee, Keunwook] Hallym Univ, Dept Biomed Sci, Chunchon 24252, Gangwon Do, South Korea; [Park, Heon Joo] Inha Univ, Dept Microbiol, Coll Med, Incheon 22212, South Korea; [Ko, Young-Gyu] Korea Univ, Div Life Sci, Seoul 02841, South Korea	Inha University; Inha University; Hallym University; Inha University; Korea University	Lee, JS (corresponding author), Inha Univ, Dept Mol Med, Coll Med, Incheon 22212, South Korea.; Lee, JS (corresponding author), Inha Univ, Coll Med, Hypoxia Related Dis Res Ctr, Incheon 22212, South Korea.	jaeslee@inha.ac.kr			National Research Foundation (NRF) - Korean government (MSIT) [MRC 2014R1A5A2009392, 2017R1A2B2007542, 2017M2A2A7A01070591]	National Research Foundation (NRF) - Korean government (MSIT)	The pcDNA3-Flag mTOR WT and mTOR KD constructs were generously gifted by Jie Chen (University of Illinois, Illinois, USA). We acknowledge Korea Mouse Phenotyping Center (KMPC) for providing mouse embryonic fibroblasts. This work was supported by grants to JSL (MRC 2014R1A5A2009392, 2017R1A2B2007542, and 2017M2A2A7A01070591) through the National Research Foundation (NRF) funded by the Korean government (MSIT).	Alimonti A, 2010, J CLIN INVEST, V120, P681, DOI 10.1172/JCI40535; Astle MV, 2012, ONCOGENE, V31, P1949, DOI 10.1038/onc.2011.394; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bhaskar PT, 2007, DEV CELL, V12, P487, DOI 10.1016/j.devcel.2007.03.020; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Courtois-Cox S, 2008, ONCOGENE, V27, P2801, DOI 10.1038/sj.onc.1210950; di Fagagna FD, 2003, NATURE, V426, P194, DOI 10.1038/nature02118; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Di Mitri D, 2016, TRENDS CELL BIOL, V26, P215, DOI 10.1016/j.tcb.2015.10.005; Facchinetti V, 2008, EMBO J, V27, P1932, DOI 10.1038/emboj.2008.120; Fujita K, 2009, NAT CELL BIOL, V11, P1135, DOI 10.1038/ncb1928; Garcia-Martinez JM, 2008, BIOCHEM J, V416, P375, DOI 10.1042/BJ20081668; Gorgoulis VG, 2010, CURR OPIN CELL BIOL, V22, P816, DOI 10.1016/j.ceb.2010.07.013; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Humphrey SJ, 2013, CELL METAB, V17, P1009, DOI 10.1016/j.cmet.2013.04.010; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Jung SH, 2016, CELL DEATH DIFFER, V23, P417, DOI 10.1038/cdd.2015.107; Kolesnichenko M, 2012, CELL CYCLE, V11, P2391, DOI 10.4161/cc.20683; Korotchkina LG, 2010, AGING-US, V2, P344, DOI 10.18632/aging.100160; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Lee GH, 2016, J CELL BIOL, V215, P705, DOI 10.1083/jcb.201605121; Lee JJ, 2011, CELL DEATH DIFFER, V18, P666, DOI 10.1038/cdd.2010.139; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Miyauchi H, 2004, EMBO J, V23, P212, DOI 10.1038/sj.emboj.7600045; Moral M, 2009, CANCER RES, V69, P1099, DOI 10.1158/0008-5472.CAN-08-3240; Nogueira V, 2008, CANCER CELL, V14, P458, DOI 10.1016/j.ccr.2008.11.003; Perez-Mancera PA, 2014, NAT REV CANCER, V14, P547, DOI 10.1038/nrc3773; Puzio-Kuter AM, 2009, GENE DEV, V23, P675, DOI 10.1101/gad.1772909; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.03.035, 10.1016/j.cell.2017.02.004]; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Vilella-Bach M, 1999, J BIOL CHEM, V274, P4266, DOI 10.1074/jbc.274.7.4266; Xie JL, 2013, NAT CELL BIOL, V15, P1263, DOI 10.1038/ncb2877; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	37	55	56	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2019	38	10					1639	1650		10.1038/s41388-018-0521-8	http://dx.doi.org/10.1038/s41388-018-0521-8			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN8DD	30337688	Green Published, hybrid			2022-12-28	WOS:000460423800005
J	Vargas, G; Bouchet, M; Bouazza, L; Reboul, P; Boyault, C; Gervais, M; Kan, C; Benetollo, C; Brevet, M; Croset, M; Mazel, M; Cayrefourcq, L; Geraci, S; Vacher, S; Pantano, F; Filipits, M; Driouch, K; Bieche, I; Gnant, M; Jacot, W; Aubin, JE; Duterque-Coquillaud, M; Alix-Panabieres, C; Clezardin, P; Bonnelye, E				Vargas, G.; Bouchet, M.; Bouazza, L.; Reboul, P.; Boyault, C.; Gervais, M.; Kan, C.; Benetollo, C.; Brevet, M.; Croset, M.; Mazel, M.; Cayrefourcq, L.; Geraci, S.; Vacher, S.; Pantano, F.; Filipits, M.; Driouch, K.; Bieche, I.; Gnant, M.; Jacot, W.; Aubin, J. E.; Duterque-Coquillaud, M.; Alix-Panabieres, C.; Clezardin, P.; Bonnelye, E.			ERR alpha promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors	ONCOGENE			English	Article							ESTROGEN-RELATED RECEPTOR; OSTEOCLAST DIFFERENTIATION; METASTASIS; ORPHAN; GAMMA; IDENTIFICATION; GENE; PGC-1-ALPHA; BIOMARKERS; ACTIVATOR	Bone is the most common metastatic site for breast cancer. Estrogen-related-receptor alpha (ERR alpha) has been implicated in cancer cell invasiveness. Here, we established that ERR alpha promotes spontaneous metastatic dissemination of breast cancer cells from primary mammary tumors to the skeleton. We carried out cohort studies, pharmacological inhibition, gain-of-function analyses in vivo and cellular and molecular studies in vitro to identify new biomarkers in breast cancer metastases. Meta-analysis of human primary breast tumors revealed that high ERR alpha expression levels were associated with bone but not lung metastases. ERR alpha expression was also detected in circulating tumor cells from metastatic breast cancer patients. ERR alpha overexpression in murine 4T1 breast cancer cells promoted spontaneous bone micro-metastases formation when tumor cells were inoculated orthotopically, whereas lung metastases occurred irrespective of ERR alpha expression level. In vivo, Rank was identified as a target for ERR alpha. That was confirmed in vitro in Rankl stimulated tumor cell invasion, in mTOR/pS6K phosphorylation, by transactivation assay, ChIP and bioinformatics analyses. Moreover, pharmacological inhibition of ERR alpha reduced primary tumor growth, bone micro-metastases formation and Rank expression in vitro and in vivo. Transcriptomic studies and meta-analysis confirmed a positive association between metastases and ERR alpha/RANK in breast cancer patients and also revealed a positive correlation between ERR alpha and BRCA1(mut) carriers. Taken together, our results reveal a novel ERR alpha/RANK axis by which ERR alpha in primary breast cancer promotes early dissemination of cancer cells to bone. These findings suggest that ERR alpha may be a useful therapeutic target to prevent bone metastases.	[Vargas, G.; Bouchet, M.; Bouazza, L.; Gervais, M.; Kan, C.; Brevet, M.; Croset, M.; Geraci, S.; Clezardin, P.; Bonnelye, E.] INSERM, UMR1033, Lyon, France; [Vargas, G.; Bouchet, M.; Bouazza, L.; Gervais, M.; Kan, C.; Benetollo, C.; Croset, M.; Geraci, S.; Clezardin, P.; Bonnelye, E.] Univ Lyon 1, Lyon, France; [Bouchet, M.] IGFL, Lyon, France; [Reboul, P.] Univ Lorraine, CNRS, UMR7365, Nancy, France; [Boyault, C.] Inst Adv Biosci, Grenoble, France; [Kan, C.] Univ Sydney, Ctr Canc Res, Sydney, NSW, Australia; [Benetollo, C.] CNRS, INSERM, U1028, UMR5292, Lyon, France; [Brevet, M.] Ctr Biol & Pathol Est, Bron, France; [Mazel, M.; Cayrefourcq, L.; Alix-Panabieres, C.] Inst Univ Rech Clin, EA2415, Montpellier, France; [Vacher, S.; Driouch, K.; Bieche, I.] Inst Curie, Dept Genet, Paris, France; [Pantano, F.] Univ Campus Biomed, I-00128 Rome, Italy; [Filipits, M.; Gnant, M.] Med Univ Vienna, Dept Surg, Vienna, Austria; [Filipits, M.; Gnant, M.] Med Univ Vienna, Ctr Comprehens Canc, Vienna, Austria; [Jacot, W.] Montpellier Canc Inst, Montpellier, France; [Aubin, J. E.] Univ Toronto, Toronto, ON, Canada; [Duterque-Coquillaud, M.] Inst Biol Lille, CNRS, UMR8161, Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Engineering & Systems Sciences (INSIS); Universite de Lorraine; University of Sydney; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Lyon; Universite de Montpellier; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University Campus Bio-Medico - Rome Italy; Medical University of Vienna; Medical University of Vienna; Universite de Montpellier; University of Toronto; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille	Bonnelye, E (corresponding author), INSERM, UMR1033, Lyon, France.; Bonnelye, E (corresponding author), Univ Lyon 1, Lyon, France.	edith.bonnelye@inserm.fr	Gnant, Michael/AAN-7054-2020; Pantano, Francesco/D-8459-2012; Clezardin, Philippe/M-8071-2014; Bonnelye, Edith/AAT-9134-2021; Croset, Martine/S-4784-2019; REBOUL, Pascal/ABA-3774-2021	Gnant, Michael/0000-0003-1002-2118; Pantano, Francesco/0000-0002-2894-9686; Clezardin, Philippe/0000-0003-0149-4463; REBOUL, Pascal/0000-0003-3546-2152; Duterque-Coquillaud, Martine/0000-0003-3943-5629; Filipits, Martin/0000-0003-2847-4534; BREVET, Marie/0000-0003-2275-691X; VACHER, Sophie/0000-0002-0042-6023; Boyault, Cyril/0000-0001-9614-4292; Cayrefourcq, Laure/0000-0002-6124-7029; Bouazza, Lamia/0000-0001-8487-2655	National Center for Scientific Research (CNRS); National Institute of Health and Medical Research (INSERM); University of Lyon1, La Ligue Nationale (Drome), Inserm-Transfert; Labex DEVweCAN; French National Cancer Institute (INCa); Marie-Curie-Individual-Fellowship [655777-miR-OMeS]; CANCER-ID (FP7/2007-2013); EFPIA	National Center for Scientific Research (CNRS)(Centre National de la Recherche Scientifique (CNRS)); National Institute of Health and Medical Research (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); University of Lyon1, La Ligue Nationale (Drome), Inserm-Transfert; Labex DEVweCAN; French National Cancer Institute (INCa)(Institut National du Cancer (INCA) France); Marie-Curie-Individual-Fellowship; CANCER-ID (FP7/2007-2013); EFPIA	This work was supported by the National Center for Scientific Research (CNRS) to EB, the National Institute of Health and Medical Research (INSERM), the University of Lyon1, La Ligue Nationale (Drome), Inserm-Transfert (EB). GV was supported by the Labex DEVweCAN, MG, MB by the French National Cancer Institute (INCa), CK by the Marie-Curie-Individual-Fellowship (655777-miR-OMeS). CAP, LC, and MM by CANCER-ID (FP7/2007-2013) and EFPIA.	Ariazi EA, 2002, CANCER RES, V62, P6510; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Audet-Walsh E, 2015, ACTA PHARMACOL SIN, V36, P51, DOI 10.1038/aps.2014.121; Bae S, 2017, J CLIN INVEST, V127, P2555, DOI 10.1172/JCI89935; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bartkowiak K, 2015, CANCER RES, V75, P5367, DOI 10.1158/0008-5472.CAN-14-3728; Benoit G, 2006, PHARMACOL REV, V58, P798, DOI 10.1124/pr.58.4.10; Bieche I, 2001, CANCER RES, V61, P1652; Blake ML, 2014, CLIN EXP METASTAS, V31, P233, DOI 10.1007/s10585-013-9624-3; Bonnelye E, 2013, J BONE MINER RES, V28, P225, DOI 10.1002/jbmr.1836; Bonnelye E, 2010, J MOL ENDOCRINOL, V45, P365, DOI 10.1677/JME-10-0024; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Brodowicz T, 2017, CANCER TREAT REV, V61, P23, DOI 10.1016/j.ctrv.2017.09.008; Campbell JP, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001363; Carnesecchi J, 2017, P NATL ACAD SCI USA, V114, P3909, DOI 10.1073/pnas.1614664114; Castet A, 2006, MOL ENDOCRINOL, V20, P1035, DOI 10.1210/me.2005-0227; Chaveroux C, 2013, CELL METAB, V17, P586, DOI 10.1016/j.cmet.2013.03.003; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; D'Oronzo S, 2017, J BONE ONCOL, V9, P1, DOI 10.1016/j.jbo.2017.09.001; David M, 2012, INT J ONCOL, V40, P1133, DOI 10.3892/ijo.2011.1309; Deblois G, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12156; Deblois G, 2013, NAT REV CANCER, V13, P27, DOI 10.1038/nrc3396; Delhon I, 2009, ENDOCRINOLOGY, V150, P4463, DOI 10.1210/en.2009-0121; Delliaux C, 2018, CANCER LETT, V438, P32, DOI 10.1016/j.canlet.2018.08.027; Dirckx N, 2018, J CLIN INVEST, V128, P1087, DOI 10.1172/JCI97794; Dwyer MA, 2010, CANCER RES, V70, P9298, DOI 10.1158/0008-5472.CAN-10-0226; Fradet A, 2016, ONCOTARGET, V7, P77071, DOI 10.18632/oncotarget.12787; Fradet A, 2011, CANCER RES, V71, P5728, DOI 10.1158/0008-5472.CAN-11-1431; GARCIA CMS, 2014, BRAZ J VET PATHOL, V7, P158; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; Hong EJ, 2013, P NATL ACAD SCI USA, V110, P17975, DOI 10.1073/pnas.1315319110; Ishibashi H, 2003, J CLIN ENDOCR METAB, V88, P2309, DOI 10.1210/jc.2002-021353; Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524; Kan C, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101674; Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Nolan E, 2016, NAT MED, V22, P933, DOI 10.1038/nm.4118; PANTEL K, 1995, JNCI-J NATL CANCER I, V87, P1162, DOI 10.1093/jnci/87.15.1162; Patch RJ, 2011, J MED CHEM, V54, P788, DOI 10.1021/jm101063h; Rakha EA, 2008, J CLIN ONCOL, V26, P3153, DOI 10.1200/JCO.2007.15.5986; Salatino S, 2016, MOL ENDOCRINOL, V30, P809, DOI 10.1210/me.2016-1036; Santini D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019234; Schmid M, 2003, J CLIN ONCOL, V21, P984, DOI 10.1200/JCO.2003.01.138; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Sigl V, 2016, CELL RES, V26, P761, DOI 10.1038/cr.2016.69; Stark C, 2006, NUCLEIC ACIDS RES, V34, pD535, DOI 10.1093/nar/gkj109; Stein RA, 2009, J STEROID BIOCHEM, V114, P106, DOI 10.1016/j.jsbmb.2009.02.010; Sumi D, 2005, BIOCHEM BIOPH RES CO, V328, P165, DOI 10.1016/j.bbrc.2004.12.165; Takeno A, 2018, AM J PHYSIOL-ENDOC M, V314, pE115, DOI 10.1152/ajpendo.00159.2017; Tam IS, 2016, J STEROID BIOCHEM, V157, P13, DOI 10.1016/j.jsbmb.2015.06.009; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Wei W, 2010, CELL METAB, V11, P503, DOI 10.1016/j.cmet.2010.04.015; Willy PJ, 2004, P NATL ACAD SCI USA, V101, P8912, DOI 10.1073/pnas.0401420101; Wu DL, 2016, BBA-REV CANCER, V1866, P23, DOI 10.1016/j.bbcan.2016.06.001; Yevshin I, 2017, NUCLEIC ACIDS RES, V45, pD61, DOI 10.1093/nar/gkw951; Zeng R, 2015, J BONE MINER RES, V30, P2287, DOI 10.1002/jbmr.2584; Zhang LY, 2012, J CLIN PATHOL, V65, P36, DOI 10.1136/jclinpath-2011-200312; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017	61	22	23	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2019	38	7					950	964		10.1038/s41388-018-0579-3	http://dx.doi.org/10.1038/s41388-018-0579-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HL3OH	30478447	Green Published, Green Accepted			2022-12-28	WOS:000458624900003
J	Tsompana, M; Gluck, C; Sethi, I; Joshi, I; Bard, J; Nowak, NJ; Sinha, S; Buck, MJ				Tsompana, Maria; Gluck, Christian; Sethi, Isha; Joshi, Ishita; Bard, Jonathan; Nowak, Norma J.; Sinha, Satrajit; Buck, Michael J.			Reactivation of super-enhancers by KLF4 in human Head and Neck Squamous Cell Carcinoma	ONCOGENE			English	Article							PLURIPOTENT STEM-CELLS; CHIP-SEQ; GENOMIC CHARACTERIZATION; HOMEOBOX GENES; HOX GENES; EXPRESSION; CANCER; TRANSCRIPTION; P63; DISCOVERY	Head and neck squamous cell carcinoma (HNSCC) is a disease of significant morbidity and mortality and rarely diagnosed in early stages. Despite extensive genetic and genomic characterization, targeted therapeutics and diagnostic markers of HNSCC are lacking due to the inherent heterogeneity and complexity of the disease. Herein, we have generated the global histone mark based epigenomic and transcriptomic cartogram of SCC25, a representative cell type of mesenchymal HNSCC and its normal oral keratinocyte counterpart. Examination of genomic regions marked by differential chromatin states and associated with misregulated gene expression led us to identify SCC25 enriched regulatory sequences and transcription factors (TF) motifs. These findings were further strengthened by ATAC-seq based open chromatin and TF footprint analysis which unearthed Kruppel-like Factor 4 (KLF4) as a potential key regulator of the SCC25 cistrome. We reaffirm the results obtained from in silico and chromatin studies in SCC25 by ChIP-seq of KLF4 and identify Delta Np63 as a co-oncogenic driver of the cancer-specific gene expression milieu. Taken together, our results lead us to propose a model where elevated KLF4 levels sustains the oncogenic state of HNSCC by reactivating repressed chromatin domains at key downstream genes, often by targeting super-enhancers.	[Tsompana, Maria; Gluck, Christian; Sethi, Isha; Joshi, Ishita; Bard, Jonathan; Nowak, Norma J.; Sinha, Satrajit; Buck, Michael J.] SUNY Buffalo, Ctr Excellence Bioinformat & Life Sci, Dept Biochem, Buffalo, NY 14260 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Sinha, S; Buck, MJ (corresponding author), SUNY Buffalo, Ctr Excellence Bioinformat & Life Sci, Dept Biochem, Buffalo, NY 14260 USA.	ssinha2@buffalo.edu; mjbuck@buffalo.edu	Gluck, Christian/HHC-5073-2022	Bard, Jonathan/0000-0001-7433-0086; Tsompana, Maria/0000-0001-7546-3198	Community Foundation for Greater Buffalo	Community Foundation for Greater Buffalo	We thank University at Buffalo Genomics and Bioinformatics Core facility for Next-generation sequencing and analysis support. These studies were supported, in part, by grants from the Community Foundation for Greater Buffalo to NJN.	Alorabi M, 2016, CRIT REV ONCOL HEMAT, V99, P170, DOI 10.1016/j.critrevonc.2015.12.006; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Andrews S., 2010, FASTQC QUALITY CONTR; [Anonymous], PIC SET COMM LIN TOO; Bailey TL, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks433; Bailey TL, 2009, NUCLEIC ACIDS RES, V37, pW202, DOI 10.1093/nar/gkp335; Bishop JA, 2012, MODERN PATHOL, V25, P405, DOI 10.1038/modpathol.2011.173; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Botchkarev VA, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a015248; Boudreau NJ, 2004, J BIOL CHEM, V279, P4862, DOI 10.1074/jbc.M305190200; Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/NMETH.2688, 10.1038/nmeth.2688]; Buganim Y, 2013, NAT REV GENET, V14, P427, DOI 10.1038/nrg3473; Candi E, 2015, CELL DEATH DIFFER, V22, P12, DOI 10.1038/cdd.2014.113; Care A, 1996, MOL CELL BIOL, V16, P4842; Chapuy B, 2013, CANCER CELL, V24, P777, DOI 10.1016/j.ccr.2013.11.003; Chen YJ, 2008, CANCER BIOL THER, V7, P777, DOI 10.4161/cbt.7.5.5768; Cui Rutao, 2005, Biochem Biophys Res Commun, V336, P339; Destro MFDS, 2010, INT J ONCOL, V36, P141, DOI 10.3892/ijo_00000485; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Ernst J, 2012, NAT METHODS, V9, P215, DOI 10.1038/nmeth.1906; Evans PM, 2008, ACTA BIOCH BIOPH SIN, V40, P554, DOI 10.1111/j.1745-7270.2008.00439.x; Evans PM, 2007, J BIOL CHEM, V282, P33994, DOI 10.1074/jbc.M701847200; Feng JX, 2012, NAT PROTOC, V7, P1728, DOI 10.1038/nprot.2012.101; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; Foster KW, 2005, ONCOGENE, V24, P1491, DOI 10.1038/sj.onc.1208307; Foster KW, 1999, CELL GROWTH DIFFER, V10, P423; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Grant CE, 2011, BIOINFORMATICS, V27, P1017, DOI 10.1093/bioinformatics/btr064; Hassan NMM, 2006, ONCOL RES, V16, P217, DOI 10.3727/000000006783981080; He HH, 2014, NAT METHODS, V11, P73, DOI [10.1038/NEMTH.2762, 10.1038/nmeth.2762]; Huang CC, 2005, CANCER BIOL THER, V4, P1401, DOI 10.4161/cbt.4.12.2355; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Iglesias-Bartolome R, 2013, CANCER DISCOV, V3, P722, DOI 10.1158/2159-8290.CD-13-0239; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jiang W, 2008, CANCER BIOL THER, V7, P783, DOI 10.4161/cbt.7.5.6110; Jimenez L, 2015, ARCH PATHOL LAB MED, V139, P1349, DOI 10.5858/arpa.2014-0471-OA; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2086, DOI 10.1073/pnas.89.6.2086; Kaichi S, 2010, CARDIOVASC RES, V88, P314, DOI 10.1093/cvr/cvq189; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kheradpour P, 2014, NUCLEIC ACIDS RES, V42, P2976, DOI 10.1093/nar/gkt1249; Lai WKM, 2012, BIOINFORMATICS, V28, P1021, DOI 10.1093/bioinformatics/bts063; Landt SG, 2012, GENOME RES, V22, P1813, DOI 10.1101/gr.136184.111; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li QH, 2011, ANN APPL STAT, V5, P1752, DOI 10.1214/11-AOAS466; Linder S, 2011, ANNU REV CELL DEV BI, V27, P185, DOI 10.1146/annurev-cellbio-092910-154216; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lui VWY, 2013, CANCER DISCOV, V3, P761, DOI 10.1158/2159-8290.CD-13-0103; Machanick P, 2011, BIOINFORMATICS, V27, P1696, DOI 10.1093/bioinformatics/btr189; Mao ZB, 2003, ONCOGENE, V22, P4434, DOI 10.1038/sj.onc.1206508; Marcinkiewicz KM, 2014, J CELL PHYSIOL, V229, P1405, DOI 10.1002/jcp.24577; Marcinkiewicz KM, 2014, EXP CELL RES, V320, P128, DOI 10.1016/j.yexcr.2013.09.011; Marinov GK, 2014, G3-GENES GENOM GENET, V4, P209, DOI 10.1534/g3.113.008680; Molinolo AA, 2007, CLIN CANCER RES, V13, P4964, DOI 10.1158/1078-0432.CCR-07-1041; Nakatake Y, 2006, MOL CELL BIOL, V26, P7772, DOI 10.1128/MCB.00468-06; Nichols AC, 2012, ARCH OTOLARYNGOL, V138, P732, DOI 10.1001/archoto.2012.1558; Pandya AY, 2004, CLIN CANCER RES, V10, P2709, DOI 10.1158/1078-0432.CCR-03-0484; Pickering CR, 2013, CANCER DISCOV, V3, P770, DOI 10.1158/2159-8290.CD-12-0537; Pique-Regi R, 2011, GENOME RES, V21, P447, DOI 10.1101/gr.112623.110; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Rahman M, 2015, BIOINFORMATICS, V31, P3666, DOI 10.1093/bioinformatics/btv377; Ramirez F, 2014, NUCLEIC ACIDS RES, V42, pW187, DOI 10.1093/nar/gku365; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Sethi I, 2017, NUCLEIC ACIDS RES, V45, P8208, DOI 10.1093/nar/gkx416; Sethi I, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1793-9; Sethi I, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-1042; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Tai SK, 2011, CANCER SCI, V102, P895, DOI 10.1111/j.1349-7006.2011.01859.x; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Tetreault MP, 2010, GASTROENTEROLOGY, V139, P2124, DOI 10.1053/j.gastro.2010.08.048; Thomas-Chollier M, 2012, NAT PROTOC, V7, P1551, DOI 10.1038/nprot.2012.088; Tomov ML, 2016, SCI REP-UK, V6, DOI 10.1038/srep37637; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Walter V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056823; Yamatoji M, 2010, ONCOL REP, V23, P61, DOI 10.3892/or_00000606; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0	80	11	12	3	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	2					262	277		10.1038/s41388-019-0990-4	http://dx.doi.org/10.1038/s41388-019-0990-4			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KD3JY	31477832				2022-12-28	WOS:000507766400002
J	Green, NH; Galvan, DL; Badal, SS; Chang, BH; LeBleu, VS; Long, JY; Jonasch, E; Danesh, FR				Green, Nathanael H.; Galvan, Daniel L.; Badal, Shawn S.; Chang, Benny H.; LeBleu, Valerie S.; Long, Jianyin; Jonasch, Eric; Danesh, Farhad R.			MTHFD2 links RNA methylation to metabolic reprogramming in renal cell carcinoma	ONCOGENE			English	Article							ONE-CARBON METABOLISM; CANCER; SERINE; TRANSLATION; GLYCINE; HIF-2; N-6-METHYLADENOSINE	One-carbon metabolism plays a central role in a broad array of metabolic processes required for the survival and growth of tumor cells. However, the molecular basis of how one-carbon metabolism may influence RNA methylation and tumorigenesis remains largely unknown. Here we show MTHFD2, a mitochondrial enzyme involved in one-carbon metabolism, contributes to the progression of renal cell carcinoma (RCC) via a novel epitranscriptomic mechanism that involves HIF-2 alpha. We found that expression of MTHFD2 was significantly elevated in human RCC tissues, and MTHFD2 knockdown strongly reduced xenograft tumor growth. Mechanistically, using an unbiased methylated RNA immunoprecipitation sequencing (meRIP-Seq) approach, we found that MTHFD2 plays a critical role in controlling global N-6-methyladenosine (m(6)A) methylation levels, including the m(6)A methylation of HIF-2 alpha mRNA, which results in enhanced translation of HIF-2 alpha. Enhanced HIF-2 alpha translation, in turn, promotes the aerobic glycolysis, linking one-carbon metabolism to HIF-2 alpha-dependent metabolic reprogramming through RNA methylation. Our findings also suggest that MTHFD2 and HIF-2 alpha form a positive feedforward loop in RCC, promoting metabolic reprograming and tumor growth. Taken together, our results suggest that MTHFD2 links RNA methylation status to the metabolic state of tumor cells in RCC.	[Green, Nathanael H.; Danesh, Farhad R.] Baylor Coll Med, Dept Pharmacol & Chem Biol, Houston, TX 77030 USA; [Green, Nathanael H.; Galvan, Daniel L.; Badal, Shawn S.; Long, Jianyin; Danesh, Farhad R.] Univ Texas MD Anderson Canc Ctr, Sect Nephrol, Houston, TX 77030 USA; [Chang, Benny H.] Baylor Coll Med, Dept Med & Mol & Cellular Biol, Houston, TX 77030 USA; [LeBleu, Valerie S.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; [Jonasch, Eric] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Oncol, Houston, TX 77030 USA	Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Danesh, FR (corresponding author), Baylor Coll Med, Dept Pharmacol & Chem Biol, Houston, TX 77030 USA.; Danesh, FR (corresponding author), Univ Texas MD Anderson Canc Ctr, Sect Nephrol, Houston, TX 77030 USA.	fdanesh@mdanderson.org	Galvan, Daniel L./L-2768-2019	Galvan, Daniel L./0000-0001-7541-6252; Danesh, Farhad/0000-0001-6849-5239	 [R01-DK078900];  [R01-DK091310]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK078900, R01DK091310] Funding Source: NIH RePORTER	; ; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	FRD: R01-DK078900; R01-DK091310	American Cancer Society, 2018, CANC FACTS FIG 2018; Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Ben-Sahra I, 2016, SCIENCE, V351, P728, DOI 10.1126/science.aad0489; Chen WF, 2016, NATURE, V539, P112, DOI 10.1038/nature19796; Cho H, 2016, NATURE, V539, P107, DOI 10.1038/nature19795; Choueiri TK, 2017, NEW ENGL J MED, V376, P354, DOI 10.1056/NEJMra1601333; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Dengler VL, 2014, CRIT REV BIOCHEM MOL, V49, P1, DOI 10.3109/10409238.2013.838205; Di Pietro E, 2002, MOL CELL BIOL, V22, P4158, DOI 10.1128/MCB.22.12.4158-4166.2002; Dominissini D, 2013, NAT PROTOC, V8, P176, DOI 10.1038/nprot.2012.148; Dominissini D, 2012, NATURE, V485, P201, DOI 10.1038/nature11112; Ducker GS, 2016, CELL METAB, V23, P1140, DOI 10.1016/j.cmet.2016.04.016; Fu Y, 2014, NAT REV GENET, V15, P293, DOI 10.1038/nrg3724; GEBHARD RL, 1987, J LIPID RES, V28, P1177; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Hakimi AA, 2016, CANCER CELL, V29, P104, DOI 10.1016/j.ccell.2015.12.004; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hsieh JJ, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.9; Kaelin WG, 2007, CLIN CANCER RES, V13, p680S, DOI 10.1158/1078-0432.CCR-06-1865; Komata M, 2014, METHODS MOL BIOL, V1164, P33, DOI 10.1007/978-1-4939-0805-9_4; Koufaris C, 2016, J PROTEOME RES, V15, P2618, DOI 10.1021/acs.jproteome.6b00188; Labuschagne CF, 2014, CELL REP, V7, P1248, DOI 10.1016/j.celrep.2014.04.045; Lenburg ME, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-31; Li B, 2014, NATURE, V513, P251, DOI 10.1038/nature13557; Lin SB, 2016, MOL CELL, V62, P335, DOI 10.1016/j.molcel.2016.03.021; Locasale JW, 2013, NAT REV CANCER, V13, P572, DOI 10.1038/nrc3557; Long JY, 2010, J BIOL CHEM, V285, P23455, DOI 10.1074/jbc.M110.136168; Mack FA, 2003, CANCER CELL, V3, P75, DOI 10.1016/S1535-6108(02)00240-4; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; Martinez-Saez O, 2017, CRIT REV ONCOL HEMAT, V111, P117, DOI 10.1016/j.critrevonc.2017.01.013; Massari F, 2015, CANCER TREAT REV, V41, P767, DOI 10.1016/j.ctrv.2015.07.002; Meyer KD, 2012, CELL, V149, P1635, DOI 10.1016/j.cell.2012.05.003; Moore LE, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002312; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morscher RJ, 2018, NATURE, V554, P128, DOI 10.1038/nature25460; Nickerson ML, 2008, CLIN CANCER RES, V14, P4726, DOI 10.1158/1078-0432.CCR-07-4921; Noone AM, 2018, SEER CANC STAT REV 1; Pikman Y, 2016, J EXP MED, V213, P1285, DOI 10.1084/jem.20151574; Qiu B, 2015, CANCER DISCOV, V5, P652, DOI 10.1158/2159-8290.CD-14-1507; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Sheppard NG, 2015, SCI REP-UK, V5, DOI 10.1038/srep15029; Shimba S, 2004, J BIOL CHEM, V279, P40946, DOI 10.1074/jbc.M400840200; Tedeschi PM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.393; Tibbetts AS, 2010, ANNU REV NUTR, V30, P57, DOI 10.1146/annurev.nutr.012809.104810; Tun HW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010696; Wang X, 2015, CELL, V161, P1388, DOI 10.1016/j.cell.2015.05.014; Wettersten HI, 2017, NAT REV NEPHROL, V13, P410, DOI 10.1038/nrneph.2017.59; Yan Q, 2007, MOL CELL BIOL, V27, P2092, DOI 10.1128/MCB.01514-06; Yang M, 2016, NAT REV CANCER, V16, P650, DOI 10.1038/nrc.2016.81; Ye JB, 2014, CANCER DISCOV, V4, P1406, DOI 10.1158/2159-8290.CD-14-0250; Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001	51	50	50	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2019	38	34					6211	6225		10.1038/s41388-019-0869-4	http://dx.doi.org/10.1038/s41388-019-0869-4			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IS5RM	31289360	Green Accepted			2022-12-28	WOS:000482210100005
J	Scalia, P; Pandini, G; Carnevale, V; Giordano, A; Williams, SJ				Scalia, Pierluigi; Pandini, Giuseppe; Carnevale, Vincenzo; Giordano, Antonio; Williams, Stephen J.			Identification of a novel EphB4 phosphodegron regulated by the autocrine IGFII/IRA axis in malignant mesothelioma	ONCOGENE			English	Article							GROWTH-FACTOR-II; INSULIN-RECEPTOR ISOFORM; IGF-II; TYROSINE-KINASE; BIOLOGICAL SIGNIFICANCE; VASCULAR MORPHOGENESIS; BREAST CANCERS; CELL MIGRATION; MELANOMA-CELLS; EXPRESSION	Malignant mesothelioma is a deadly disease with limited therapeutic options. EphB4 is an oncogenic tyrosine kinase receptor expressed in malignant mesothelioma as well as in a variety of cancers. It is involved in tumor microenvironment mediating angiogenesis and invasive cellular effects via both EphrinB2 ligand-dependent and independent mechanisms. The molecular network underlying EphB4 oncogenic effects is still unclear. Here we show that EphB4 expression in malignant mesothelioma cells is markedly decreased upon neutralization of cancer-secreted IGF-II. In particular, we demonstrate that EphB4 protein expression in malignant mesothelioma cells depend upon a degradation rescue mechanism controlled by the autocrine IGF-II-insulin receptor-A specific signaling axis. We show that the regulation of EphB4 expression is linked to a competing post-translational modification of its carboxy-terminal tail via phosphorylation of its tyrosine 987 by the Insulin receptor isoform-A kinase-associated activity in response to the autocrine IGF-II stimuli. Neutralization of this autocrine-induced EphB4-phosphorylation by IGF-II associates with the increased ubiquitination of EphB4 carboxy-terminal tail and with its rapid degradation. We also describe a novel Ubiquitin binding motif in the targeted region as part of the identified EphB4 phosphodegron and provide 3D modeling data supporting a possible model for the acute EphB4 PTM-driven regulation by IGF-II. Altogether, these findings disclose a novel molecular mechanism for the maintenance of EphB4-expression in malignant mesothelioma cells and other IGF-II-secreting cancers (IGF2omas).	[Scalia, Pierluigi; Giordano, Antonio; Williams, Stephen J.] Temple Univ, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; [Scalia, Pierluigi; Giordano, Antonio; Williams, Stephen J.] Temple Univ, Ctr Biotechnol, Biol Dept, Philadelphia, PA 19122 USA; [Scalia, Pierluigi; Williams, Stephen J.] ISOPROG, Ist Somatogene Ric Oncogenom, I-93100 Caltanissetta, Italy; [Scalia, Pierluigi; Williams, Stephen J.] Somatolink Res Fdn, Philadelphia, PA 19102 USA; [Pandini, Giuseppe] Univ Catania, Garibaldi Nesima Med Ctr, Dept Clin & Expt Med, Endocrinol, I-95122 Catania, Italy; [Carnevale, Vincenzo] Temple Univ, Coll Sci & Technol, Inst Computat Mol Sci, Philadelphia, PA 19122 USA; [Giordano, Antonio] Univ Siena, Dept Med Biotechnol, I-53100 Siena, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Presidio Ospedaliero Garibaldi-Nesima; University of Catania; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Siena	Scalia, P (corresponding author), Temple Univ, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA.; Scalia, P (corresponding author), Temple Univ, Ctr Biotechnol, Biol Dept, Philadelphia, PA 19122 USA.; Scalia, P (corresponding author), ISOPROG, Ist Somatogene Ric Oncogenom, I-93100 Caltanissetta, Italy.; Scalia, P (corresponding author), Somatolink Res Fdn, Philadelphia, PA 19102 USA.	pscalia@isoprog.org	Scalia, Pierluigi/AAH-8443-2019; Pandini, Giuseppe/AAB-9650-2019; Giordano, Antonio/F-1927-2010	Scalia, Pierluigi/0000-0002-5911-1640; Pandini, Giuseppe/0000-0003-3747-7649; Giordano, Antonio/0000-0002-5959-016X	ASEM srl (Treviso, Italy); GianAmico Alessandrini Family	ASEM srl (Treviso, Italy); GianAmico Alessandrini Family	We thank Dr. Steven Albelda (University of Pennsylvania, USA) for providing the MSTO211H cell line and his constructive criticism during the manuscript preparation; Dr Veronica Vella (University of Catania, Italy) for IR system expression data in colorectal cancer cell lines; Dr Parkash S Gill (USC, Los Angeles, CA) for critical insights in manuscript revision. We also thank ASEM srl (Treviso, Italy) and the GianAmico Alessandrini Family for supporting PS research.	Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; Atapattu L, 2014, CELL ADHES MIGR, V8, P294, DOI 10.4161/19336918.2014.970026; Baserga R, 2013, J CELL PHYSIOL, V228, P675, DOI 10.1002/jcp.24217; Becerikli M, 2015, INT J CANCER, V136, P1781, DOI 10.1002/ijc.29244; BENNETT BD, 1994, J BIOL CHEM, V269, P14211; Bussi G, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2408420; Chen T, 2013, TUMOR BIOL, V34, P379, DOI 10.1007/s13277-012-0560-7; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; DAUGHADAY WH, 1993, P NATL ACAD SCI USA, V90, P5823, DOI 10.1073/pnas.90.12.5823; Dynkevich Y, 2013, ENDOCR REV, V34, P798, DOI 10.1210/er.2012-1033; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; Erber R, 2006, EMBO J, V25, P628, DOI 10.1038/sj.emboj.7600949; Ferguson BD, 2015, SCI REP-UK, V5, DOI 10.1038/srep10641; Frasca F, 1999, MOL CELL BIOL, V19, P3278, DOI 10.1128/mcb.19.5.3278; Greenall SA, 2018, TRANSL ONCOL, V11, P971, DOI 10.1016/j.tranon.2018.05.011; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hornbeck PV, 2015, NUCLEIC ACIDS RES, V43, pD512, DOI 10.1093/nar/gku1267; Huang X, 2007, CANCER RES, V67, P9800, DOI 10.1158/0008-5472.CAN-07-0531; Hunter T, 2007, MOL CELL, V28, P730, DOI 10.1016/j.molcel.2007.11.019; Janes PW, 2005, CELL, V123, P291, DOI 10.1016/j.cell.2005.08.014; Kim KW, 1998, CANCER RES, V58, P348; Kumar SR, 2009, CANCER RES, V69, P3736, DOI 10.1158/0008-5472.CAN-08-3232; Liu R, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-269; Louvi A, 1997, DEV BIOL, V189, P33, DOI 10.1006/dbio.1997.8666; Marks AG, 2011, ENDOCRINOLOGY, V152, P922, DOI 10.1210/en.2010-0784; Martiny-Baron G, 2010, ANGIOGENESIS, V13, P259, DOI 10.1007/s10456-010-9183-z; Morcavallo A, 2011, MOL ENDOCRINOL, V25, P1456, DOI 10.1210/me.2010-0484; Noren NK, 2006, NAT CELL BIOL, V8, P815, DOI 10.1038/ncb1438; Noren NK, 2009, BIOCHEM J, V422, P433, DOI 10.1042/BJ20090014; Nussbaum T, 2008, HEPATOLOGY, V48, P146, DOI 10.1002/hep.22297; Pandini G, 1999, CLIN CANCER RES, V5, P1935; Pandini G, 2002, J BIOL CHEM, V277, P39684, DOI 10.1074/jbc.M202766200; Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806; Pundir S, 2017, METHODS MOL BIOL, V1558, P41, DOI 10.1007/978-1-4939-6783-4_2; Ritter MR, 2002, P NATL ACAD SCI USA, V99, P7455, DOI 10.1073/pnas.102185799; ROGLER CE, 1994, J BIOL CHEM, V269, P13779; Rutkowski R, 2012, INT J CANCER, V131, pE614, DOI 10.1002/ijc.27392; RUTTEN AAJJL, 1995, CANCER RES, V55, P3634; Salgia R, 2018, BBA-REV CANCER, V1869, P128, DOI 10.1016/j.bbcan.2018.01.003; Scalia P, 2001, J CELL BIOCHEM, V82, P610, DOI 10.1002/jcb.1196; Sciacca L, 1999, ONCOGENE, V18, P2471, DOI 10.1038/sj.onc.1202600; Sciacca L, 2002, ONCOGENE, V21, P8240, DOI 10.1038/sj.onc.1206058; SINHA UK, 2003, ENT-EAR NOSE THROAT, V82, P887; Stapleton D, 1999, NAT STRUCT BIOL, V6, P44; Steinle JJ, 2002, J BIOL CHEM, V277, P43830, DOI 10.1074/jbc.M207221200; Swatek KN, 2016, CELL RES, V26, P399, DOI 10.1038/cr.2016.39; Tawo R, 2017, CELL, V169, P470, DOI 10.1016/j.cell.2017.04.003; Vihanto MM, 2005, FASEB J, V19, P1689, DOI 10.1096/fj.04-3647fje; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Xia GB, 2005, CLIN CANCER RES, V11, P4305, DOI 10.1158/1078-0432.CCR-04-2109; Xia GB, 2005, CANCER RES, V65, P4623, DOI 10.1158/0008-5472.CAN-04-2667; Xu WW, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14399; Yang NY, 2006, J BIOL CHEM, V281, P32574, DOI 10.1074/jbc.M604338200; Zhao SK, 2010, P NATL ACAD SCI USA, V107, P7704, DOI 10.1073/pnas.0908764107	55	8	8	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2019	38	31					5987	6001		10.1038/s41388-019-0854-y	http://dx.doi.org/10.1038/s41388-019-0854-y			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IT3GE	31270394	hybrid, Green Published			2022-12-28	WOS:000482740000006
J	Coleman, DJ; Gao, L; King, CJ; Schwartzman, J; Urrutia, J; Sehrawat, A; Tayou, J; Balter, A; Burchard, J; Chiotti, KE; Derrick, DS; Sun, DC; Xia, Z; Heiser, LM; Alumkal, JJ				Coleman, Daniel J.; Gao, Lina; King, Carly J.; Schwartzman, Jacob; Urrutia, Joshua; Sehrawat, Archana; Tayou, Junior; Balter, Ariel; Burchard, Julja; Chiotti, Kami E.; Derrick, Daniel S.; Sun, Duanchen; Xia, Zheng; Heiser, Laura M.; Alumkal, Joshi J.			BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer	ONCOGENE			English	Article							CASTRATION-RESISTANT; ANDROGEN RECEPTOR; MCM PROTEINS; EXPRESSION; VARIANTS	BET bromodomain inhibitors block prostate cancer cell growth at least in part through c-Myc and androgen receptor (AR) suppression. However, little is known about other transcriptional regulators whose suppression contributes to BET bromodomain inhibitor anti-tumor activity. Moreover, the anti-tumor activity of BET bromodomain inhibition in AR-independent castration-resistant prostate cancers (CRPC), whose frequency is increasing, is also unknown. Herein, we demonstrate that BET bromodomain inhibition blocks growth of a diverse set of CRPC cell models, including those that are AR-independent or in which c-Myc is not suppressed. To identify transcriptional regulators whose suppression accounts for these effects, we treated multiple CRPC cell lines with the BET bromodomain inhibitor JQ1 and then performed RNA-sequencing followed by Master Regulator computational analysis. This approach identified several previously unappreciated transcriptional regulators that are highly expressed in CRPC and whose suppression, via both transcriptional or post-translational mechanisms, contributes to the anti-tumor activity of BET bromodomain inhibitors.	[Coleman, Daniel J.; Gao, Lina; King, Carly J.; Schwartzman, Jacob; Urrutia, Joshua; Sehrawat, Archana; Tayou, Junior; Chiotti, Kami E.; Derrick, Daniel S.; Heiser, Laura M.; Alumkal, Joshi J.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97239 USA; [King, Carly J.; Derrick, Daniel S.; Sun, Duanchen; Xia, Zheng; Heiser, Laura M.] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97239 USA; [Balter, Ariel; Burchard, Julja] Oregon Hlth & Sci Univ, Computat Biol Program, Portland, OR 97239 USA; [Chiotti, Kami E.; Alumkal, Joshi J.] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Heiser, LM; Alumkal, JJ (corresponding author), Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97239 USA.; Heiser, LM (corresponding author), Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97239 USA.; Alumkal, JJ (corresponding author), Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97239 USA.	heiserl@ohsu.edu; alumkalj@ohsu.edu	Xia, Zheng/AAC-5360-2022	Xia, Zheng/0000-0003-3364-8324; Urrutia, Joshua/0000-0003-2171-0936; Coleman, Daniel/0000-0002-3414-3160; Schwartzman, Jacob/0000-0002-2640-8181	National Institutes of Health (NIH)/National Cancer Institute (NCI) R01 award [CA178610]; Pacific Northwest Prostate Cancer SPORE/NCI [P50 CA097186]; Cancer Center Support Grant (CCSG) [P30 CA069533]; Oregon Clinical and Translational Research Institute (OCTRI) from the National Center for Advancing Translational Sciences (NCATS), NIH [UL1TR000128]; Department of Defense Synergistic Idea Award [W81XWH-13-1-0420]; Department of Defense Impact Awards [W81XWH-16-1-0597, W81XWH-16-1-1601]; Prospect Creek Foundation; Hope Foundation Award; Stand Up to Cancer-Prostate Cancer Foundation-Prostate Dream Team Translational Cancer Research Grant [SU2C-AACR-DT0409]; Movember Foundation; Wayne D. Kuni and Joan E. Kuni Foundation; Stand Up To Cancer is a program of the Entertainment Industry Foundation [7465sc]; NATIONAL CANCER INSTITUTE [P30CA069533, P50CA097186, R01CA178610] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [K01LM012877] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/National Cancer Institute (NCI) R01 award; Pacific Northwest Prostate Cancer SPORE/NCI; Cancer Center Support Grant (CCSG); Oregon Clinical and Translational Research Institute (OCTRI) from the National Center for Advancing Translational Sciences (NCATS), NIH; Department of Defense Synergistic Idea Award; Department of Defense Impact Awards; Prospect Creek Foundation; Hope Foundation Award; Stand Up to Cancer-Prostate Cancer Foundation-Prostate Dream Team Translational Cancer Research Grant; Movember Foundation; Wayne D. Kuni and Joan E. Kuni Foundation; Stand Up To Cancer is a program of the Entertainment Industry Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	This research was supported by: National Institutes of Health (NIH)/National Cancer Institute (NCI) R01 award CA178610; the Pacific Northwest Prostate Cancer SPORE/NCI (P50 CA097186); Cancer Center Support Grant (CCSG) (P30 CA069533); the Oregon Clinical and Translational Research Institute (OCTRI) (UL1TR000128) from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH; Department of Defense Synergistic Idea Award (W81XWH-13-1-0420); Department of Defense Impact Awards (W81XWH-16-1-0597 and W81XWH-16-1-1601). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or DOD. Other support includes: Wayne D. Kuni and Joan E. Kuni Foundation, Prospect Creek Foundation, a Hope Foundation Award, and a Stand Up to Cancer-Prostate Cancer Foundation-Prostate Dream Team Translational Cancer Research Grant (SU2C-AACR-DT0409); this research grant is made possible by the generous support of the Movember Foundation. Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research (7465sc). We thank Dr. James Bradner at Dana-Farber Cancer Institute for providing the JQ1 compound used in in vivo studies.	Aggarwal R, 2018, J CLIN ONCOL, V36, P2492, DOI 10.1200/JCO.2017.77.6880; Alvarez MJ, 2016, NAT GENET, V48, P838, DOI 10.1038/ng.3593; Alvarez MJ, 2014, BIOCONDUCTOR, P1; Alvarez MJ, 2013, BIOCONDUCTOR; American Cancer Society, 2019, CANC FACTS FIG 2019; Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229; Aytes A, 2014, CANCER CELL, V25, P638, DOI 10.1016/j.ccr.2014.03.017; Bandopadhayay P, 2014, CLIN CANCER RES, V20, P912, DOI 10.1158/1078-0432.CCR-13-2281; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Bishop JL, 2015, ONCOTARGET, V6, P234, DOI 10.18632/oncotarget.2703; Bluemn EG, 2017, CANCER CELL, V32, P474, DOI 10.1016/j.ccell.2017.09.003; Chan SC, 2015, NUCLEIC ACIDS RES, V43, P5880, DOI 10.1093/nar/gkv262; Coleman DJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40518-5; Coleman DJ, 2016, ONCOTARGET, V7, P40690, DOI 10.18632/oncotarget.9816; Culig Z, 1999, BRIT J CANCER, V81, P242, DOI 10.1038/sj.bjc.6690684; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Fong CY, 2015, NATURE, V525, P538, DOI 10.1038/nature14888; Forsburg SL, 2004, MICROBIOL MOL BIOL R, V68, P109, DOI 10.1128/MMBR.68.1.109-131.2004; Gao LB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070739; Gertz J, 2013, MOL CELL, V52, P25, DOI 10.1016/j.molcel.2013.08.037; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313; Hafner M, 2016, NAT METHODS, V13, P521, DOI [10.1038/NMETH.3853, 10.1038/nmeth.3853]; Hu R, 2012, CANCER RES, V72, P3457, DOI 10.1158/0008-5472.CAN-11-3892; Ibarra A, 2008, P NATL ACAD SCI USA, V105, P8956, DOI 10.1073/pnas.0803978105; Jang MK, 2005, MOL CELL, V19, P523, DOI 10.1016/j.molcel.2005.06.027; Kuruma H, 2013, MOL CANCER THER, V12, P567, DOI 10.1158/1535-7163.MCT-12-0798; Lefebvre C, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.31; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; Pruitt SC, 2007, STEM CELLS, V25, P3121, DOI 10.1634/stemcells.2007-0483; Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159-8290.CD-12-0418; Rathert P, 2015, NATURE, V525, P543, DOI 10.1038/nature14898; Shima N, 2007, NAT GENET, V39, P93, DOI 10.1038/ng1936; Shu SK, 2016, NATURE, V529, P413, DOI 10.1038/nature16508; Smallwood A, 2012, GENOME RES, V22, P1426, DOI 10.1101/gr.124818.111; Snoek R, 2009, CLIN CANCER RES, V15, P39, DOI 10.1158/1078-0432.CCR-08-1726; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Valensin S, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-196; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Wyce A, 2013, ONCOTARGET, V4, P2419, DOI 10.18632/oncotarget.1572; Yankulov K, 1999, MOL CELL BIOL, V19, P6154; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963	46	15	15	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2019	38	28					5658	5669		10.1038/s41388-019-0815-5	http://dx.doi.org/10.1038/s41388-019-0815-5			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IH9RW	30996246	Green Accepted			2022-12-28	WOS:000474845100008
J	Hounjet, J; Habets, R; Schaaf, MB; Hendrickx, TC; Barbeau, LMO; Yahyanejad, S; Rouschop, KM; Groot, AJ; Vooijs, M				Hounjet, Judith; Habets, Roger; Schaaf, Marco B.; Hendrickx, Tessa C.; Barbeau, Lydie M. O.; Yahyanejad, Sanaz; Rouschop, Kasper M.; Groot, Arjan J.; Vooijs, Marc			The anti-malarial drug chloroquine sensitizes oncogenic NOTCH1 driven human T-ALL to gamma-secretase inhibition	ONCOGENE			English	Article							GENE-EXPRESSION; CELL-DEATH; AUTOPHAGY; ACTIVATION; RESISTANCE; MUTATIONS; REGULATOR; PROTEIN; CANCER; CYTOTOXICITY	T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive cancer arising from T-cell progenitors. Although current treatments, including chemotherapy and glucocorticoids, have significantly improved survival, T-ALL remains a fatal disease and new treatment options are needed. Since more than 60% of T-ALL cases bear oncogenic NOTCH1 mutations, small molecule inhibitors of NOTCH1 signalling; gamma-secretase inhibitors (GSI), are being actively investigated for the treatment of T-ALL. Unfortunately, GSI have shown limited clinical efficacy and dose-limiting toxicities. We hypothesized that by combining known drugs, blocking NOTCH activity through another mechanism, may synergize with GSI enabling equal efficacy at a lower concentration. Here, we show that the clinically used anti-malarial drug chloroquine (CQ), an inhibitor of lysosomal function and autophagy, decreases T-ALL cell viability and proliferation. This effect of CQ was not observed in GSI-resistant T-ALL cell lines. Mechanistically, CQ impairs the redox balance, induces ds DNA breaks and activates the DNA damage response. CQ also interferes with intracellular trafficking and processing of oncogenic NOTCH1. Interestingly, we show for the first time that the addition of CQ to gamma-secretase inhibition has a synergistic therapeutic effect on T-ALL and reduces the concentration of GSI required to obtain a reduction in cell viability and a block of proliferation. Overall, our results suggest that CQ may be a promising repurposed drug in the treatment of T-ALL, as a single treatment or in combination with GSI, increasing the therapeutic ratio.	[Hounjet, Judith; Habets, Roger; Schaaf, Marco B.; Hendrickx, Tessa C.; Barbeau, Lydie M. O.; Yahyanejad, Sanaz; Rouschop, Kasper M.; Groot, Arjan J.; Vooijs, Marc] Maastricht Univ, Sch Dev Biol & Oncol, Dept Radiotherapy GROW, Maastricht, Netherlands; [Hounjet, Judith; Habets, Roger; Schaaf, Marco B.; Hendrickx, Tessa C.; Barbeau, Lydie M. O.; Yahyanejad, Sanaz; Rouschop, Kasper M.; Groot, Arjan J.; Vooijs, Marc] Maastricht Univ, Comprehens Canc Ctr Maastricht MUMC, Maastricht, Netherlands; [Hounjet, Judith] MAASTRO Clin, Maastricht, Netherlands	Maastricht University; Maastricht University; Maastricht University; Maastricht University Medical Centre (MUMC)	Vooijs, M (corresponding author), Maastricht Univ, Sch Dev Biol & Oncol, Dept Radiotherapy GROW, Maastricht, Netherlands.; Vooijs, M (corresponding author), Maastricht Univ, Comprehens Canc Ctr Maastricht MUMC, Maastricht, Netherlands.	marc.vooijs@maastrichtuniversity.nl		Rouschop, Kasper/0000-0002-4208-5415; Barbeau, Lydie/0000-0003-4556-9789	European Research Council (ERC) under the European Community Seventh Framework Program (FP7/2007-13) ERC starting Grant [208259]; Kootstra-Talent Fellowship Program from Maastricht-UMC + [2016-7]	European Research Council (ERC) under the European Community Seventh Framework Program (FP7/2007-13) ERC starting Grant; Kootstra-Talent Fellowship Program from Maastricht-UMC +	This work was supported by the European Research Council (ERC) under the European Community Seventh Framework Program (FP7/2007-13) ERC starting Grant 208259 and the Kootstra-Talent Fellowship Program 2016-7 from Maastricht-UMC +.	Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Burikhanov R, 2017, CELL REP, V18, P508, DOI 10.1016/j.celrep.2016.12.051; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Chen PJ, 2017, FREE RADICAL BIO MED, V104, P280, DOI 10.1016/j.freeradbiomed.2017.01.033; Childress JL, 2006, CURR BIOL, V16, P2228, DOI 10.1016/j.cub.2006.09.031; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Ding ZB, 2011, CLIN CANCER RES, V17, P6229, DOI 10.1158/1078-0432.CCR-11-0816; Eng CH, 2016, P NATL ACAD SCI USA, V113, P182, DOI 10.1073/pnas.1515617113; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Gupta-Rossi N, 2004, J CELL BIOL, V166, P73, DOI 10.1083/jcb.200310098; Herranz D, 2015, NAT MED, V21, P1182, DOI 10.1038/nm.3955; Hori YS, 2015, J NEURO-ONCOL, V122, P11, DOI 10.1007/s11060-014-1686-9; Hu T, 2016, ONCOL REP, V35, P43, DOI 10.3892/or.2015.4380; Jaekel R, 2006, DEV CELL, V11, P655, DOI 10.1016/j.devcel.2006.09.019; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kaether C, 2006, NEURODEGENER DIS, V3, P275, DOI 10.1159/000095267; Kim SB, 2007, CELL DEATH DIFFER, V14, P982, DOI 10.1038/sj.cdd.4402083; Liang X, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-10; Loehberg CR, 2007, CANCER RES, V67, P12026, DOI 10.1158/0008-5472.CAN-07-3058; Maclean KH, 2008, J CLIN INVEST, V118, P79, DOI 10.1172/JCI33700; Maes H, 2014, CANCER CELL, V26, P190, DOI 10.1016/j.ccr.2014.06.025; Maes H, 2013, TRENDS MOL MED, V19, P428, DOI 10.1016/j.molmed.2013.04.005; Malecki MJ, 2006, MOL CELL BIOL, V26, P4642, DOI 10.1128/MCB.01655-05; Man JH, 2018, CELL STEM CELL, V22, P104, DOI 10.1016/j.stem.2017.10.005; Mansour MR, 2006, LEUKEMIA, V20, P537, DOI 10.1038/sj.leu.2404101; Marks DI, 2009, BLOOD, V114, P5136, DOI 10.1182/blood-2009-08-231217; Mathews JA, 2010, J BIOL CHEM, V285, P37531, DOI 10.1074/jbc.M110.141556; Mauvezin C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8007; Milano J, 2004, TOXICOL SCI, V82, P341, DOI 10.1093/toxsci/kfh254; Natsumeda M, 2016, BRAIN PATHOL, V26, P713, DOI 10.1111/bpa.12343; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Pasternak SH, 2003, J BIOL CHEM, V278, P26687, DOI 10.1074/jbc.M304009200; Qu XZ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173712; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Ratikan JA, 2013, INT J RADIAT ONCOL, V87, P761, DOI 10.1016/j.ijrobp.2013.07.024; Roti G, 2013, CANCER CELL, V23, P390, DOI 10.1016/j.ccr.2013.01.015; Rouschop KMA, 2010, J CLIN INVEST, V120, P127, DOI 10.1172/JCI40027; Rouschop KMA, 2009, RADIOTHER ONCOL, V92, P411, DOI 10.1016/j.radonc.2009.06.029; Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370; Schneider M, 2013, J CELL SCI, V126, P645, DOI 10.1242/jcs.116590; Sethi N, 2010, J BIOL CHEM, V285, P34757, DOI 10.1074/jbc.M110.158634; Shi TT, 2017, CANCER CHEMOTH PHARM, V79, P287, DOI 10.1007/s00280-016-3197-1; Tagami S, 2008, MOL CELL BIOL, V28, P165, DOI 10.1128/MCB.00863-07; Vaccari T, 2010, DEVELOPMENT, V137, P1825, DOI 10.1242/dev.045484; Valapala M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2624; van Tetering G, 2009, J BIOL CHEM, V284, P31018, DOI 10.1074/jbc.M109.006775; Verbaanderd C, 2017, ECANCERMEDICALSCIENC, V11, DOI 10.3332/ecancer.2017.781; Vermezovic J, 2015, NAT STRUCT MOL BIOL, V22, P417, DOI 10.1038/nsmb.3013; Wakabayashi N, 2014, MOL CELL BIOL, V34, P653, DOI 10.1128/MCB.01408-13; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wong GT, 2004, J BIOL CHEM, V279, P12876, DOI 10.1074/jbc.M311652200; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; Zhang BB, 2015, FAM CANCER, V14, P19, DOI 10.1007/s10689-014-9757-9	54	19	19	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2019	38	27					5457	5468		10.1038/s41388-019-0802-x	http://dx.doi.org/10.1038/s41388-019-0802-x			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IG5KR	30967635				2022-12-28	WOS:000473842500009
J	Marchand, B; Pitarresi, JR; Reichert, M; Suzuki, K; Laczko, D; Rustgi, AK				Marchand, Benoit; Pitarresi, Jason R.; Reichert, Maximilian; Suzuki, Kensuke; Laczko, Dorottya; Rustgi, Anil K.			PRRX1 isoforms cooperate with FOXM1 to regulate the DNA damage response in pancreatic cancer cells	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; HOMEOBOX GENE; TRANSCRIPTION FACTORS; METASTATIC COLONIZATION; BREAST-CANCER; COMET ASSAY; EXPRESSION; PRX2; INHIBITION; REPAIR	PRRX1 is a homeodomain transcriptional factor, which has two isoforms, PRXX1A and PRRX1B. The PRRX1 isoforms have been demonstrated to be important in pancreatic cancer, especially in the regulation of epithelial-to-mesenchymal transition (EMT) in Pancreatic Ductal Adenocarcinoma (PDAC) and of mesenchymal-to-epithelial transition (MET) in liver metastasis. In order to determine the functional underpinnings of PRRX1 and its isoforms, we have unraveled a new interplay between PRRX1 and the FOXM1 transcriptional factors. Our detailed biochemical analysis reveals the direct physical interaction between PRRX1 and FOXM1 proteins that requires the PRRX1A/B 200-222/217 amino acid (aa) region and the FOXM1 Forkhead domain. Additionally, we demonstrate the cooperation between PRRX1 and FOXM1 in the regulation of FOXM1-dependent transcriptional activity. Moreover, we establish FOXM1 as a critical downstream target of PRRX1 in pancreatic cancer cells. We demonstrate a novel role for PRRX1 in the regulation of genes involved in DNA repair pathways. Indeed, we show that expression of PRRX1 isoforms may limit the induction of DNA damage in pancreatic cancer cells. Finally, we demonstrate that targeting FOXM1 with the small molecule inhibitor FDI6 suppress pancreatic cancer cell proliferation and induces their apoptotic cell death. FDI6 sensitizes pancreatic cancer cells to Etoposide and Gemcitabine induced apoptosis. Our data provide new insights into PRRX1's involvement in regulating DNA damage and provide evidence of a possible PRRX1-FOXM1 axis that is critical for PDAC cells.	[Marchand, Benoit; Pitarresi, Jason R.; Reichert, Maximilian; Suzuki, Kensuke; Laczko, Dorottya; Rustgi, Anil K.] Univ Penn, Perelman Sch Med, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA; [Marchand, Benoit; Pitarresi, Jason R.; Suzuki, Kensuke; Laczko, Dorottya; Rustgi, Anil K.] Univ Penn, Abramson Canc Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA; [Reichert, Maximilian] Tech Univ Munich, Med Klin 2, D-81675 Munich, Germany; [Reichert, Maximilian; Rustgi, Anil K.] Univ Penn, Perelman Sch Med, Dept Genet, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Technical University of Munich; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; University of Pennsylvania; Pennsylvania Medicine	Rustgi, AK (corresponding author), Univ Penn, Perelman Sch Med, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA.; Rustgi, AK (corresponding author), Univ Penn, Abramson Canc Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA.; Rustgi, AK (corresponding author), Univ Penn, Perelman Sch Med, Dept Genet, Philadelphia, PA 19104 USA.	anil2@pennmedicine.upenn.edu	Reichert, Maximilian/GOH-1246-2022	Marchand, Benoit/0000-0001-9302-6688	NIH/NIDDK [R01 DK060694]; Center for Molecular Studies in Digestive and Liver Diseases [NIH P30 DK050306]; American Cancer Society; Fonds de recherche en sante du Quebec [P-Marchand-35978]; National Pancreas Foundation; German Cancer Aid Foundation (Max Eder Program, Deutsche Krebshilfe) [111273]; AGA-Actavis Research Award in Pancreatic Disorders; NIH loan repayment program; NCI [F32 CA221094]; NATIONAL CANCER INSTITUTE [F32CA221094] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007066, R01DK060694, P30DK050306] Funding Source: NIH RePORTER	NIH/NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Center for Molecular Studies in Digestive and Liver Diseases; American Cancer Society(American Cancer Society); Fonds de recherche en sante du Quebec(Fonds de la Recherche en Sante du Quebec); National Pancreas Foundation; German Cancer Aid Foundation (Max Eder Program, Deutsche Krebshilfe); AGA-Actavis Research Award in Pancreatic Disorders; NIH loan repayment program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We are grateful to Dr. Zheng Fu (Virginia Commonwealth University) for providing the 6xFOXM1 luciferase reporter construct. We thank Dr. Kaori Ihida-Stansbury (University of Pennsylvania) for the PRRX1 wild type and Knockout mouse embryonic fibroblasts (MEFs). The Tenascin-C (TN7) luciferase construct was kindly provided by Dr. Edward E. Morrisey (University of Pennsylvania). We are thankful to the Molecular Pathology and Imaging Core, the Cell Culture and iPS Core and the HumanMicrobial Analytic and Repository Core Facilities. This work was supported by the NIH/NIDDK R01 DK060694 (BM, MR, JRP, AKR), the Center for Molecular Studies in Digestive and Liver Diseases (NIH P30 DK050306), the American Cancer Society, Fonds de recherche en sante du Quebec P-Marchand-35978 (BM), National Pancreas Foundation (MR), German Cancer Aid Foundation (Max Eder Program, Deutsche Krebshilfe 111273 to MR), AGA-Actavis Research Award in Pancreatic Disorders (MR), NCI F32 CA221094 (JRP) and the NIH loan repayment program (JRP).	American Cancer Society, 2018, CANC FACTS FIG 2018; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Baranski OA, 2015, CELL PROLIFERAT, V48, P105, DOI 10.1111/cpr.12153; Bergwerff M, 2000, VIRCHOWS ARCH, V436, P12, DOI 10.1007/PL00008193; Berry FB, 2006, HUM MOL GENET, V15, P905, DOI 10.1093/hmg/ddl008; Bhat UG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006593; Bhat UG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005592; Copertino DW, 1997, P NATL ACAD SCI USA, V94, P1846, DOI 10.1073/pnas.94.5.1846; Ewald B, 2007, MOL CANCER THER, V6, P1239, DOI 10.1158/1535-7163.MCT-06-0633; Foucher I, 2003, DEVELOPMENT, V130, P1867, DOI 10.1242/dev.00414; Gartel AL, 2017, CANCER RES, V77, P3135, DOI 10.1158/0008-5472.CAN-16-3566; Golson ML, 2016, DEVELOPMENT, V143, P4558, DOI 10.1242/dev.112672; Gormally MV, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6165; Guo JB, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0393-x; Guo Y, 2002, P NATL ACAD SCI USA, V99, P3663, DOI 10.1073/pnas.062041099; Gyori BM, 2014, REDOX BIOL, V2, P457, DOI 10.1016/j.redox.2013.12.020; Halasi M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031761; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Huang C, 2014, CLIN CANCER RES, V20, P1477, DOI 10.1158/1078-0432.CCR-13-2311; Huang C, 2012, CANCER RES, V72, P655, DOI 10.1158/0008-5472.CAN-11-3102; Ihida-Stansbury K, 2004, CIRC RES, V94, P1507, DOI 10.1161/01.RES.0000130656.72424.20; Jones FS, 2001, CIRC RES, V89, P131, DOI 10.1161/hh1401.093582; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; KERN MJ, 1992, NUCLEIC ACIDS RES, V20, P5189, DOI 10.1093/nar/20.19.5189; KERN MJ, 1994, GENOMICS, V19, P334, DOI 10.1006/geno.1994.1066; Khongkow P, 2014, ONCOGENE, V33, P4144, DOI 10.1038/onc.2013.457; Kong XY, 2013, CANCER RES, V73, P3987, DOI 10.1158/0008-5472.CAN-12-3859; Kwok JMM, 2010, MOL CANCER RES, V8, P24, DOI 10.1158/1541-7786.MCR-09-0432; Laczko D, 2017, AM J PATHOL, V187, P1787, DOI 10.1016/j.ajpath.2017.04.013; Lu MF, 1999, DEV BIOL, V205, P145, DOI 10.1006/dbio.1998.9116; Lu MF, 1999, DEVELOPMENT, V126, P495; Major ML, 2004, MOL CELL BIOL, V24, P2649, DOI 10.1128/MCB.24.7.2649-2661.2004; Marchand B, 2015, J BIOL CHEM, V290, P5592, DOI 10.1074/jbc.M114.616714; Marchand B, 2012, CARCINOGENESIS, V33, P529, DOI 10.1093/carcin/bgr309; Marshak S, 2000, MOL CELL BIOL, V20, P7583, DOI 10.1128/MCB.20.20.7583-7590.2000; MARTIN JF, 1995, GENE DEV, V9, P1237, DOI 10.1101/gad.9.10.1237; Monteiro LJ, 2013, ONCOGENE, V32, P4634, DOI 10.1038/onc.2012.491; Norris RA, 2001, DNA CELL BIOL, V20, P89, DOI 10.1089/104454901750070292; Norris RA, 2001, J BIOL CHEM, V276, P26829, DOI 10.1074/jbc.M100239200; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Olive PL, 2006, NAT PROTOC, V1, P23, DOI 10.1038/nprot.2006.5; Park YY, 2012, CARCINOGENESIS, V33, P1843, DOI 10.1093/carcin/bgs167; Qu SM, 1999, DEVELOPMENT, V126, P359; Radhakrishnan SK, 2006, CANCER RES, V66, P9731, DOI 10.1158/0008-5472.CAN-06-1576; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Reichert M, 2013, GENE DEV, V27, P288, DOI 10.1101/gad.204453.112; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takahashi Y, 2013, BRIT J CANCER, V109, P307, DOI 10.1038/bjc.2013.339; Takano S, 2016, GENE DEV, V30, P233, DOI 10.1101/gad.263327.115; Tan YJ, 2007, MOL CELL BIOL, V27, P1007, DOI 10.1128/MCB.01068-06; ten Berge D, 1998, DEVELOPMENT, V125, P3831; Tucker SC, 1999, J BIOL CHEM, V274, P32325, DOI 10.1074/jbc.274.45.32325; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Zhang N, 2012, CLIN CANCER RES, V18, P5961, DOI 10.1158/1078-0432.CCR-12-0039; Zhang N, 2011, CANCER CELL, V20, P427, DOI 10.1016/j.ccr.2011.08.016; Zhang YH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023069; Zheng L, 2015, INT J CLIN EXP PATHO, V8, P10534; Zona S, 2014, BBA-GENE REGUL MECH, V1839, P1316, DOI 10.1016/j.bbagrm.2014.09.016	60	17	17	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2019	38	22					4325	4339		10.1038/s41388-019-0725-6	http://dx.doi.org/10.1038/s41388-019-0725-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IA1RB	30705403	Green Accepted			2022-12-28	WOS:000469339100009
J	Lu, P; Geng, J; Zhang, L; Wang, Y; Niu, NN; Fang, Y; Liu, F; Shi, JJ; Zhang, ZG; Sun, YW; Wang, LW; Tang, YJ; Xue, J				Lu, Ping; Geng, Jing; Zhang, Lei; Wang, Yu; Niu, Ningning; Fang, Yuan; Liu, Fang; Shi, Juanjuan; Zhang, Zhi-Gang; Sun, Yong-Wei; Wang, Li-Wei; Tang, Yujie; Xue, Jing			THZ1 reveals CDK7-dependent transcriptional addictions in pancreatic cancer	ONCOGENE			English	Article							TARGETING TRANSCRIPTION; EXPRESSION; INHIBITION; THERAPY; GROWTH	Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with high mortality. Lack of effective treatment makes novel therapeutic discovery an urgent demand in PDAC research. By screening an epigenetic-related compound library, we identified THZ1, a covalent inhibitor of CDK7, as a promising candidate. Multiple long-established and patient-derived PDAC cell lines (PDC) were used to validate the efficacy of THZ1 in vitro. In addition, patient-derived xenograft (PDX) models and animal models of PDAC were utilized for examining THZ1 efficacy in vivo. Furthermore, RNA-Seq analyse was performed to reveal the molecular mechanism of THZ1 treatment. Finally, PDAC cell lines with primary or acquired resistance to THZ1 were investigated to explore the potential mechanism of THZ1 susceptibility. CDK7 inhibition was identified as a selective and potent therapeutic strategy for PDAC progression in multiple preclinical models. Mechanistic analyses revealed that CDK7 inhibition led to a pronounced downregulation of gene transcription, with a preferential repression of mitotic cell cycle and NF-kappa B signaling-related transcripts. MYC transcriptional was found to be involved in susceptibility of PDAC cells to CDK7 inhibition. In conclusion, Identification of CDK7-dependent transcriptional addiction in PDACs provides a potent therapeutic strategy that targets highly aggressive pancreatic cancer.	[Lu, Ping; Geng, Jing; Niu, Ningning; Shi, Juanjuan; Xue, Jing] Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Stem Cell Res Ctr, Renji Hosp,Sch Med, Shanghai, Peoples R China; [Zhang, Lei; Liu, Fang; Tang, Yujie] Shanghai Jiao Tong Univ, Key Lab Cell Differentiat & Apoptosis, Natl Minist Educ, Dept Pathophysiol,Sch Med, Shanghai, Peoples R China; [Wang, Yu; Wang, Li-Wei] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Oncol, Shanghai, Peoples R China; [Fang, Yuan] Shanghai Jiao Tong Univ, Ruijin Hosp, Res Inst Pancreat Dis, Sch Med, Shanghai, Peoples R China; [Zhang, Zhi-Gang; Wang, Li-Wei] Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst, Renji Hosp,Sch Med, Shanghai, Peoples R China; [Sun, Yong-Wei] Shanghai Jiao Tong Univ, Dept Biliary Pancreat Surg, Renji Hosp, Sch Med, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Xue, J (corresponding author), Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Stem Cell Res Ctr, Renji Hosp,Sch Med, Shanghai, Peoples R China.; Tang, YJ (corresponding author), Shanghai Jiao Tong Univ, Key Lab Cell Differentiat & Apoptosis, Natl Minist Educ, Dept Pathophysiol,Sch Med, Shanghai, Peoples R China.; Wang, LW (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Oncol, Shanghai, Peoples R China.; Wang, LW (corresponding author), Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst, Renji Hosp,Sch Med, Shanghai, Peoples R China.	liweiwang@shsmu.edu.cn; yujietang@shsmu.edu.cn; jingxue@sjtu.edu.cn		Sun, Yongwei/0000-0002-5937-634X; Zhang, Zhi-gang/0000-0001-8965-223X	Program for professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning [TP2015007, TP2015017]; National Natural Science Foundation of China [81702938, 81770628, 81572761, 81772655]; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support [20161312]; Recruitment Program of Global Experts of China (National 1000-Youth Talents Program); Shanghai Rising-Star Program	Program for professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support; Recruitment Program of Global Experts of China (National 1000-Youth Talents Program); Shanghai Rising-Star Program	This work was supported by the Program for professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning No. TP2015007 to J.X., TP2015017 to Y.T.), National Natural Science Foundation of China (81702938 and 81770628 to J.X.; 81572761 and 81772655 to Y.T.), Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support No. 20161312 (J.X.), The Recruitment Program of Global Experts of China (National 1000-Youth Talents Program to Y.T.), Shanghai Rising-Star Program (Y.T.).	Aguirre AJ, 2017, CANCER CELL, V32, P185, DOI 10.1016/j.ccell.2017.07.007; Cao KX, 2014, CANCER CELL, V26, P158, DOI 10.1016/j.ccr.2014.07.020; Chipumuro E, 2014, CELL, V159, P1126, DOI 10.1016/j.cell.2014.10.024; Christensen CL, 2014, CANCER CELL, V26, P909, DOI 10.1016/j.ccell.2014.10.019; Corcoran RB, 2015, CANCER RES, V71, P5020; Franco HL, 2015, CELL, V163, P28, DOI 10.1016/j.cell.2015.09.013; Gao Y, 2018, CELL CHEM BIOL, V25, P135, DOI 10.1016/j.chembiol.2017.11.007; Garcia PL, 2016, ONCOGENE, V35, P833, DOI 10.1038/onc.2015.126; Guerra C, 2011, CANCER CELL, V19, P728, DOI 10.1016/j.ccr.2011.05.011; Guo JC, 2004, ONCOGENE, V23, P71, DOI 10.1038/sj.onc.1206926; Hessmann E, 2017, GUT, V66, P168, DOI 10.1136/gutjnl-2016-312539; Hidalgo M, 2014, CANCER DISCOV, V4, P998, DOI 10.1158/2159-8290.CD-14-0001; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Jiang YY, 2017, GUT, V66, P1358, DOI 10.1136/gutjnl-2016-311818; Kwiatkowski N, 2014, NATURE, V511, P616, DOI 10.1038/nature13393; Ling JH, 2012, CANCER CELL, V21, P105, DOI 10.1016/j.ccr.2011.12.006; Loven J, 2012, CELL, V151, P476, DOI 10.1016/j.cell.2012.10.012; Mazur PK, 2015, NAT MED, V21, P1163, DOI 10.1038/nm.3952; Ochiai Takanori, 2008, J Med Dent Sci, V55, P49; Prabhu L, 2014, ONCOTARGET, V5, P10969, DOI 10.18632/oncotarget.2624; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Wang JQ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11363; Wang XJ, 2016, ONCOTARGET, V7, P21441, DOI 10.18632/oncotarget.7375; Wang YB, 2015, CELL, V163, P174, DOI 10.1016/j.cell.2015.08.063; Witkiewicz AK, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7744; Wong MH, 2014, CLIN CANCER RES, V20, P4047, DOI 10.1158/1078-0432.CCR-13-3377; Wong RWJ, 2017, BLOOD, V130, P2326, DOI 10.1182/blood-2017-06-792184; Wu CY, 2014, GASTROENTEROLOGY, V147, P143, DOI 10.1053/j.gastro.2014.03.048; Yadav D, 2013, GASTROENTEROLOGY, V144, P1252, DOI 10.1053/j.gastro.2013.01.068; Yuan J, 2017, CANCER RES, V77, P6614, DOI 10.1158/0008-5472.CAN-17-1143; Zhang ZF, 2017, MOL CANCER THER, V16, P1739, DOI 10.1158/1535-7163.MCT-17-0078	34	29	30	4	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2019	38	20					3932	3945		10.1038/s41388-019-0701-1	http://dx.doi.org/10.1038/s41388-019-0701-1			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HY3OI	30692639				2022-12-28	WOS:000468035600012
J	Williams, KC; Cepeda, MA; Javed, S; Searle, K; Parkins, KM; Makela, AV; Hamilton, AM; Soukhtehzari, S; Kim, Y; Tuck, AB; Ronald, JA; Foster, PJ; Chambers, AF; Leong, HS				Williams, Karla C.; Cepeda, Mario A.; Javed, Sumreen; Searle, Karlee; Parkins, Katie M.; Makela, Ashley V.; Hamilton, Amanda M.; Soukhtehzari, Sepideh; Kim, Yohan; Tuck, Alan B.; Ronald, John A.; Foster, Paula J.; Chambers, Ann F.; Leong, Hon S.			Invadopodia are chemosensing protrusions that guide cancer cell extravasation to promote brain tropism in metastasis	ONCOGENE			English	Article							BREAST-CANCER; THERAPEUTIC TARGET; LIGHT-CHAIN; PROSTATE-CANCER; IN-VIVO; PHOSPHORYLATION; INVASION; KINASE; PAK1; ACTIVATION	Invadopodia are cell protrusions that mediate cancer cell extravasation but the microenvironmental cues and signaling factors that induce invadopodia formation during extravasation remain unclear. Using intravital imaging and loss of function experiments, we determined invadopodia contain receptors involved in chemotaxis, namely GABA receptor and EGFR. These chemotaxis capabilities are mediated in part by PAK1 which controls invadopodia responsiveness to ligands such as GABA and EGF via assembly, stability, and turnover of invadopodia in vivo. PAK1 knockdown rendered cells unresponsive to chemotactic stimuli present in the stroma, resulting in dramatically lower rates of cancer cell extravasation and metastatic colony formation compared to stimulated cancer cells. In an experimental mouse model of brain metastasis, inhibition of PAK1 significantly reduced overall tumor burden and reduced the average size of brain metastases. In summary, invadopodia contain chemotaxis receptors that can respond to microenvironmental cues to guide cancer cell extravasation, and when PAK1 is depleted, brain tropism of metastatic breast cancer cells is significantly reduced, blocking secondary colony growth at sites otherwise permissive for metastatic outgrowth.	[Williams, Karla C.; Cepeda, Mario A.; Searle, Karlee; Kim, Yohan; Leong, Hon S.] Western Univ, Schulich Sch Med & Dent, Dept Surg, Div Urol, London, ON, Canada; [Williams, Karla C.; Cepeda, Mario A.; Leong, Hon S.] Lawson Hlth Res Inst, Translat Prostate Canc Res Lab, London, ON, Canada; [Williams, Karla C.; Tuck, Alan B.; Chambers, Ann F.] Lawson Hlth Res Inst, Translat Breast Canc Res Unit, London, ON, Canada; [Williams, Karla C.; Javed, Sumreen; Searle, Karlee; Soukhtehzari, Sepideh] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada; [Cepeda, Mario A.; Leong, Hon S.] Mayo Clin, Dept Urol, Rochester, MN 55905 USA; [Parkins, Katie M.; Makela, Ashley V.; Hamilton, Amanda M.; Ronald, John A.; Foster, Paula J.] Western Univ, Schulich Sch Med & Dent, Dept Med Biophys, London, ON, Canada; [Parkins, Katie M.; Makela, Ashley V.; Hamilton, Amanda M.; Ronald, John A.; Foster, Paula J.] Western Univ, Robarts Res Inst, London, ON, Canada; [Tuck, Alan B.; Chambers, Ann F.] Western Univ, Schulich Sch Med & Dent, Dept Oncol, London, ON, Canada; [Tuck, Alan B.; Chambers, Ann F.] Western Univ, Schulich Sch Med & Dent, Dept Pathol & Lab Med, London, ON, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); University of British Columbia; Mayo Clinic; Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Williams, KC; Leong, HS (corresponding author), Western Univ, Schulich Sch Med & Dent, Dept Surg, Div Urol, London, ON, Canada.; Williams, KC; Leong, HS (corresponding author), Lawson Hlth Res Inst, Translat Prostate Canc Res Lab, London, ON, Canada.; Williams, KC (corresponding author), Lawson Hlth Res Inst, Translat Breast Canc Res Unit, London, ON, Canada.; Williams, KC (corresponding author), Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada.; Leong, HS (corresponding author), Mayo Clin, Dept Urol, Rochester, MN 55905 USA.	karla.williams@ubc.ca; leong.hon@mayo.edu	Ronald, John A/B-7123-2008	Ronald, John A/0000-0003-3665-173X; Williams, Karla/0000-0003-2954-2869; Leong, Hon/0000-0001-7801-1402	OICR High Impact Grant [SPS 0613-03]; Movember/PCC Rising Star Grants [RS-2013-55, RS-2016-1011]; CIHR Postdoctoral Fellowship [140880]; Breast Cancer Society of Canada	OICR High Impact Grant; Movember/PCC Rising Star Grants; CIHR Postdoctoral Fellowship(Canadian Institutes of Health Research (CIHR)); Breast Cancer Society of Canada	This work was supported by an OICR High Impact Grant (SPS 0613-03), Movember/PCC Rising Star Grants (RS-2013-55 and RS-2016-1011) awarded to H.S.L., CIHR Postdoctoral Fellowship (140880) awarded to K.C.W., and the Breast Cancer Society of Canada (K.C.W., K.P., A.M.).	Artym VV, 2015, J CELL BIOL, V208, P331, DOI 10.1083/jcb.201405099; Artym Vira V., 2009, V522, P211, DOI 10.1007/978-1-59745-413-1_15; Badowski C, 2008, MOL BIOL CELL, V19, P633, DOI 10.1091/mbc.E06-01-0088; BAND V, 1990, CANCER RES, V50, P7351; Barry DJ, 2015, J CELL BIOL, V209, P163, DOI 10.1083/jcb.201501081; Beach JR, 2011, BMC CELL BIOL, V12, DOI 10.1186/1471-2121-12-52; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Burger KL, 2014, PROSTATE, V74, P134, DOI 10.1002/pros.22735; Calle Y, 2006, J CELL SCI, V119, P2375, DOI 10.1242/jcs.02939; Cepeda MA, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0547-x; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chew TL, 1998, J MUSCLE RES CELL M, V19, P839, DOI 10.1023/A:1005417926585; Coniglio SJ, 2008, MOL CELL BIOL, V28, P4162, DOI 10.1128/MCB.01532-07; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Gligorijevic B, 2012, J CELL SCI, V125, P724, DOI 10.1242/jcs.092726; Goicoechea SM, 2017, J CELL SCI, V130, P1064, DOI 10.1242/jcs.195552; Heyn C, 2006, MAGN RESON MED, V56, P1001, DOI 10.1002/mrm.21029; Jeannot P, 2017, ELIFE, V6, DOI [10.7554/eLife.22207, 10.7554/eLife.22207.001]; Kienast Y, 2010, NAT MED, V16, P116, DOI 10.1038/nm.2072; Kim Y, 2016, NAT PROTOC, V11, P937, DOI 10.1038/nprot.2016.050; KOOP S, 1995, CANCER RES, V55, P2520; Koop S, 1996, P NATL ACAD SCI USA, V93, P11080, DOI 10.1073/pnas.93.20.11080; Leong HS, 2014, CELL REP, V8, P1558, DOI 10.1016/j.celrep.2014.07.050; Li Z, 2003, CELL, V114, P215, DOI 10.1016/S0092-8674(03)00559-2; Lohmer LL, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005786; Lohmer LL, 2014, CELL ADHES MIGR, V8, P246, DOI 10.4161/cam.28406; MORRIS VL, 1994, CLIN EXP METASTAS, V12, P357, DOI 10.1007/BF01755879; Moshfegh Y, 2014, NAT CELL BIOL, V16, P571, DOI 10.1038/ncb2972; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; Murrell DH, 2015, TRANSL ONCOL, V8, P176, DOI 10.1016/j.tranon.2015.03.009; Neman J, 2014, P NATL ACAD SCI USA, V111, P984, DOI 10.1073/pnas.1322098111; Nicholas NS, 2016, ONCOTARGET, V7, P70881, DOI 10.18632/oncotarget.12282; Parkins KM, 2016, SCI REP-UK, V6, DOI 10.1038/srep35889; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Sharma VP, 2013, CURR BIOL, V23, P2079, DOI 10.1016/j.cub.2013.08.044; Sizemore GM, 2014, J BIOL CHEM, V289, P24102, DOI 10.1074/jbc.M114.593582; Souter LH, 2010, LAB INVEST, V90, P1247, DOI 10.1038/labinvest.2010.97; Steffen A, 2008, CURR BIOL, V18, P926, DOI 10.1016/j.cub.2008.05.044; Stoletov K, 2015, EXPERT REV ANTICANC, V15, P733, DOI 10.1586/14737140.2015.1058711; Stoletov K, 2014, AM J CLIN EXP UROL, V2, P45; Stylli SS, 2009, J CELL SCI, V122, P2727, DOI 10.1242/jcs.046680; Takizawa N, 2002, BIOCHEM BIOPH RES CO, V297, P773, DOI 10.1016/S0006-291X(02)02302-1; van den Dries K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2402; Viaud J, 2009, MOL CANCER THER, V8, P2559, DOI 10.1158/1535-7163.MCT-09-0102; Williams KC, 2016, CONVERG SCI PHYS ONC, V2, DOI 10.1088/2057-1739/2/2/023001; Williams KC, 2014, MOL BIOL CELL, V25, P2061, DOI 10.1091/mbc.E13-10-0582; Williams KC, 2014, J CELL SCI, V127, P1712, DOI 10.1242/jcs.134734; Wirth A, 2003, J PHYSIOL-LONDON, V549, P489, DOI 10.1113/jphysiol.2002.033167; Yamaguchi H, 2005, J CELL BIOL, V168, P441, DOI 10.1083/jcb.200407076; Yamauchi K, 2006, CANCER RES, V66, P4208, DOI 10.1158/0008-5472.CAN-05-3927; Zhang QB, 2010, INT J CANCER, V126, P2534, DOI 10.1002/ijc.24979; 2006, CANCER RES, V66, P3034, DOI DOI 10.1158/0008-5472.CAN-05-2177	53	31	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2019	38	19					3598	3615		10.1038/s41388-018-0667-4	http://dx.doi.org/10.1038/s41388-018-0667-4			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HX4OU	30651600	hybrid, Green Published			2022-12-28	WOS:000467379600004
J	Huang, CC; Cheng, SH; Wu, CH; Li, WY; Wang, JS; Kung, ML; Chu, TH; Huang, ST; Feng, CT; Huang, SC; Tai, MH				Huang, Chao-Cheng; Cheng, Shih-Hsuan; Wu, Chen-Hsuan; Li, Wen-Yuan; Wang, Jiang-Shiang; Kung, Mei-Lang; Chu, Tian-Huei; Huang, Shih-Tsung; Feng, Chien-Ting; Huang, Shih-Chung; Tai, Ming-Hong			Delta-like 1 homologue promotes tumorigenesis and epithelial-mesenchymal transition of ovarian high-grade serous carcinoma through activation of Notch signaling	ONCOGENE			English	Article							STEM-CELLS; GROWTH-FACTOR; DLK1; EXPRESSION; CANCER; GENE; PROTEIN; INHIBITOR; PATHWAY; PREF-1	Ovarian carcinoma is the most lethal type of gynecologic malignancies. Alterations of Notch pathway are prevalent in ovarian carcinogenesis. This study investigated the expression profile and function of delta-like 1 homolog (DLK1), a non-canonical Notch ligand, during ovarian carcinogenesis. Tissue microarray (TMA) consisting of surgically resected samples from 221 patients with ovarian carcinoma was constructed for DLK1 expression. DLK1 overexpression or knockdown was achieved by adenovirus gene delivery to evaluate the effect of DLK1 on the oncogenic behaviors in ovarian cancer cells and in xenografted tumors. TMA analysis revealed that elevated DLK1 expression was correlated with stages, lymph node metastasis and E-cadherin downregulation. Despite no influence on survival among ovarian carcinoma patients, DLK1 overexpression was specially associated with overall survival and progression free survival in high-grade serous carcinoma (HGSC) patients, constituting an independent prognostic factor for these patients. By adenovirus gene delivery, it was found modulation of cellular DLK1 level regulated the tumorigenic behaviors and epithelial-mesenchymal transition (EMT) in vitro and in vivo. Immunohistochemical analysis further showed that DLK1 overexpression resulted in escalated proliferation, angiogenesis, EMT and Notch activities. Application of recombinant DLK1 extracellular domain (rDLK1-EC) recapitulated the tumorigenic behaviors of DLK1 in ovarian cancer cells. By using neutralizing antibody or pharmaceutical inhibitor, blockade of Notch signaling attenuated the tumorigenic behaviors evoked by DLK1 overexpression. The present study indicates that DLK1 overexpression participates in ovarian carcinogenesis through Notch activation and EMT induction. Moreover, DLK1 may constitute a novel diagnostic biomarker and therapeutic target for HGSC.	[Huang, Chao-Cheng; Cheng, Shih-Hsuan; Wang, Jiang-Shiang] Kaohsiung Chang Gung Mem Hosp, Dept Pathol, Kaohsiung, Taiwan; [Huang, Chao-Cheng; Cheng, Shih-Hsuan; Wu, Chen-Hsuan; Wang, Jiang-Shiang] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan; [Huang, Chao-Cheng; Wang, Jiang-Shiang] Kaohsiung Chang Gung Mem Hosp, Biobank & Tissue Bank, Kaohsiung, Taiwan; [Cheng, Shih-Hsuan; Chu, Tian-Huei; Feng, Chien-Ting; Huang, Shih-Chung; Tai, Ming-Hong] Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung, Taiwan; [Wu, Chen-Hsuan] Kaohsiung Chang Gung Mem Hosp, Dept Obstet & Gynecol, Kaohsiung, Taiwan; [Wu, Chen-Hsuan] Chang Gung Univ, Grad Inst Clin Med Sci, Coll Med, Tao Yuan, Taiwan; [Li, Wen-Yuan] Fooyin Univ Hosp, Dept Pathol, Pingtung, Taiwan; [Li, Wen-Yuan; Tai, Ming-Hong] Natl Sun Yat Sen Univ, Dept Biol Sci, Kaohsiung, Taiwan; [Kung, Mei-Lang] Natl Sun Yat Sen Univ, Dept Chem, Kaohsiung, Taiwan; [Chu, Tian-Huei; Tai, Ming-Hong] Natl Sun Yat Sen Univ, Ctr Neurosci, Kaohsiung, Taiwan; [Huang, Shih-Tsung] Natl Sun Yat Sen Univ, Doctoral Degree Program Marine Biotechnol, Kaohsiung, Taiwan; [Huang, Shih-Tsung] Acad Sinica, Doctoral Degree Program Marine Biotechnol, Taipei, Taiwan; [Huang, Shih-Chung] Kaohsiung Armed Forces Gen Hosp, Dept Internal Med, Kaohsiung, Taiwan; [Tai, Ming-Hong] Kaohsiung Med Univ, Grad Inst Clin Sci, Kaohsiung 807, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; National Sun Yat Sen University; Chang Gung Memorial Hospital; Chang Gung University; National Sun Yat Sen University; National Sun Yat Sen University; National Sun Yat Sen University; National Sun Yat Sen University; Academia Sinica - Taiwan; Kaohsiung Medical University	Huang, CC (corresponding author), Kaohsiung Chang Gung Mem Hosp, Dept Pathol, Kaohsiung, Taiwan.; Huang, CC (corresponding author), Chang Gung Univ, Coll Med, Kaohsiung, Taiwan.; Huang, CC (corresponding author), Kaohsiung Chang Gung Mem Hosp, Biobank & Tissue Bank, Kaohsiung, Taiwan.; Tai, MH (corresponding author), Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung, Taiwan.; Tai, MH (corresponding author), Natl Sun Yat Sen Univ, Dept Biol Sci, Kaohsiung, Taiwan.; Tai, MH (corresponding author), Natl Sun Yat Sen Univ, Ctr Neurosci, Kaohsiung, Taiwan.; Tai, MH (corresponding author), Kaohsiung Med Univ, Grad Inst Clin Sci, Kaohsiung 807, Taiwan.	huangcc@cgmh.org.tw; minghongtai@gmail.com		Chu, Tian-Huei/0000-0003-1197-5754	Ministry of Science and Technology, Taiwan [NSC101-2320-B-182-009, NSC102-2320-B-182-011, MOST103-2320-B-182-005-MY3, MOST105-2325-B-110-001]; Chang Gung Medical Foundation Kaohsiung Chang Gung Memorial Hospital Tissue Bank [CLRPG8E0161, CLRPG8F1701]; Kaohsiung Armed Forces General Hospital, Taiwan [107-10]	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan); Chang Gung Medical Foundation Kaohsiung Chang Gung Memorial Hospital Tissue Bank; Kaohsiung Armed Forces General Hospital, Taiwan	This work was supported by grants from the Ministry of Science and Technology, Taiwan (NSC101-2320-B-182-009, NSC102-2320-B-182-011, MOST103-2320-B-182-005-MY3 to C.C.H., and MOST105-2325-B-110-001 to M.H.T.). We thank Chang Gung Medical Foundation Kaohsiung Chang Gung Memorial Hospital Tissue Bank (CLRPG8E0161 and CLRPG8F1701), and the Kaohsiung Armed Forces General Hospital, Taiwan (107-10) for technical support.	Abdallah BM, 2007, J BIOL CHEM, V282, P7339, DOI 10.1074/jbc.M607530200; Baladron V, 2005, EXP CELL RES, V303, P343, DOI 10.1016/j.yexcr.2004.10.001; Baladron V, 2001, FRONT BIOSCI-LANDMRK, V6, pA25, DOI 10.2741/baladron; Benetatos L, 2013, CELL MOL LIFE SCI, V70, P795, DOI 10.1007/s00018-012-1080-8; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Ceder JA, 2008, EUR UROL, V54, P1344, DOI 10.1016/j.eururo.2008.03.006; Chen X, 2012, CANCER RES, V72, P2294, DOI 10.1158/0008-5472.CAN-11-2181; Chen X, 2010, ONCOTARGET, V1, P210, DOI 10.18632/oncotarget.127; Choi JH, 2008, CANCER RES, V68, P5716, DOI 10.1158/0008-5472.CAN-08-0001; Deng JL, 2016, ONCOTARGET, V7, P55771, DOI 10.18632/oncotarget.9908; EUHUS DM, 1986, J SURG ONCOL, V31, P229, DOI 10.1002/jso.2930310402; Falix FA, 2012, BBA-MOL BASIS DIS, V1822, P988, DOI 10.1016/j.bbadis.2012.02.003; Gasperowicz M, 2008, PLACENTA, V29, P651, DOI 10.1016/j.placenta.2008.06.004; Guseh JS, 2009, DEVELOPMENT, V136, P1751, DOI 10.1242/dev.029249; Haga CL, 2012, J BIOL CHEM, V287, P42695, DOI 10.1074/jbc.M112.387761; Haslehurst AM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-91; Hu TH, 2003, CANCER-AM CANCER SOC, V98, P1444, DOI 10.1002/cncr.11653; Hu W, 2014, CANCER RES, V74, P3282, DOI 10.1158/0008-5472.CAN-13-2066; Huang CC, 2018, ANGIOGENESIS, V21, P901, DOI 10.1007/s10456-018-9615-8; Huang CC, 2018, ANGIOGENESIS, V21, P299, DOI 10.1007/s10456-018-9596-7; Huang J, 2007, CARCINOGENESIS, V28, P1094, DOI 10.1093/carcin/bgl215; Jung JG, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004751; Kawakami T, 2006, HUM MOL GENET, V15, P821, DOI 10.1093/hmg/ddl001; Kim YS, 2016, BIOCHEM BIOPH RES CO, V480, P254, DOI 10.1016/j.bbrc.2016.10.041; Kim Y, 2009, CANCER RES, V69, P9271, DOI 10.1158/0008-5472.CAN-09-1605; Klymenko Y, 2017, CANCERS, V9, P1; Kurman RJ, 2016, AM J PATHOL, V186, P733, DOI 10.1016/j.ajpath.2015.11.011; Kurman RJ, 2010, AM J SURG PATHOL, V34, P433, DOI 10.1097/PAS.0b013e3181cf3d79; Laborda J, 2000, HISTOL HISTOPATHOL, V15, P119, DOI 10.14670/HH-15.119; Li L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095912; Liu GY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142680; Liu Yu, 2010, Zhongguo Fei Ai Za Zhi, V13, P923, DOI 10.3779/j.issn.1009-3419.2010.10.12; Ma Z, 2017, BIOCHEM BIOPH RES CO, V490, P309, DOI 10.1016/j.bbrc.2017.06.041; Nueda ML, 2008, J MOL BIOL, V379, P428, DOI 10.1016/j.jmb.2008.03.070; Nueda ML, 2017, FASEB J, V31, P3484, DOI 10.1096/fj.201601341RRR; Nueda ML, 2014, BBA-MOL CELL RES, V1843, P2674, DOI 10.1016/j.bbamcr.2014.07.015; Park JT, 2008, CANCER RES, V68, P8852, DOI 10.1158/0008-5472.CAN-08-0517; Park JT, 2006, CANCER RES, V66, P6312, DOI 10.1158/0008-5472.CAN-05-3610; Park JT, 2010, AM J PATHOL, V177, P1087, DOI 10.2353/ajpath.2010.100316; Peters JM, 2012, NAT REV CANCER, V12, P181, DOI 10.1038/nrc3214; Rodriguez P, 2012, CARDIOVASC RES, V93, P232, DOI 10.1093/cvr/cvr296; Shih IM, 2007, CANCER RES, V67, P1879, DOI 10.1158/0008-5472.CAN-06-3958; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Smas CM, 1997, MOL CELL BIOL, V17, P977, DOI 10.1128/MCB.17.2.977; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; Smas CM, 1997, CRIT REV EUKAR GENE, V7, P281, DOI 10.1615/CritRevEukarGeneExpr.v7.i4.10; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Wang YH, 2006, MOL CELL BIOL, V26, P5421, DOI 10.1128/MCB.02437-05; Wu JC, 2016, PROSTATE, V76, P1469, DOI 10.1002/pros.23230; Xu J, 2016, AM J CANCER RES, V6, P2700; Yanai H, 2010, J BIOCHEM, V148, P85, DOI 10.1093/jb/mvq034; Yin D, 2006, ONCOGENE, V25, P1852, DOI 10.1038/sj.onc.1209219; Zhang L, 2008, P NATL ACAD SCI USA, V105, P7004, DOI 10.1073/pnas.0801615105; Zhang S S, 2016, Zhonghua Zhong Liu Za Zhi, V38, P510, DOI 10.3760/cma.j.issn.0253-3766.2016.07.006	54	26	26	2	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2019	38	17					3201	3215		10.1038/s41388-018-0658-5	http://dx.doi.org/10.1038/s41388-018-0658-5			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU8RI	30626939				2022-12-28	WOS:000465557200007
J	Yoshino, Y; Qi, HC; Kanazawa, R; Sugamata, M; Suzuki, K; Kobayashi, A; Shindo, K; Matsuzawa, A; Shibata, S; Endo, S; Miyanishi, Y; Shimaoka, T; Ishioka, C; Kanno, S; Yasui, A; Chiba, N				Yoshino, Yuki; Qi, Huicheng; Kanazawa, Ryo; Sugamata, Mami; Suzuki, Kenta; Kobayashi, Akihiro; Shindo, Kazuha; Matsuzawa, Ayako; Shibata, Shun; Endo, Shino; Miyanishi, Yutaro; Shimaoka, Tatsuro; Ishioka, Chikashi; Kanno, Shin-ichiro; Yasui, Akira; Chiba, Natsuko			RACK1 regulates centriole duplication by controlling localization of BRCA1 to the centrosome in mammary tissue-derived cells	ONCOGENE			English	Article							PROTEIN; IDENTIFICATION; ASSOCIATION; INHIBITION; DOMAIN; CYCLE; OLA1	Breast cancer gene 1 (BRCA1) is a tumor suppressor that is associated with hereditary breast and ovarian cancer. BRCA1 functions in DNA repair and centrosome regulation together with BRCA1-associated RING domain protein (BARD1), a heterodimer partner of BRCA1. Obg-like ATPase 1 (OLA1) was identified as a protein that interacts with BARD1. OLA1 regulates the centrosome by binding to and collaborating with BRCA1 and BARD1. We identified receptor for activated C kinase (RACK1) as a protein that interacts with OLA1. RACK1 directly bound to OLA1, the N-terminal region of BRCA1, and gamma-tubulin, associated with BARD1, and localized the centrosomes throughout the cell cycle. Knockdown of RACK1 caused abnormal centrosomal localization of BRCA1 and abrogated centriole duplication. Overexpression of RACK1 increased the centrosomal localization of BRCA1 and caused centrosome amplification due to centriole overduplication. The number of centrioles in cells with two gamma-tubulin spots was higher in cell lines derived from mammary tissue compared to those derived from other tissues. The effects of aberrant RACK1 expression level on centriole duplication were observed in cell lines derived from mammary tissue, but not in those derived from other tissues. Two BRCA1 variants, R133H and E143K, and a RACK1 variant, K280E, associated with cancer, which weakened the BRCA1-RACK1 interaction, interfered with the centrosomal localization of BRCA1 and reduced centrosome amplification induced by overexpression of RACK1. These results suggest that RACK1 regulates centriole duplication by controlling the centrosomal localization of BRCA1 in mammary tissue-derived cells and that this is dependent on the BRCA1-RACK1 interaction.	[Yoshino, Yuki; Qi, Huicheng; Kanazawa, Ryo; Sugamata, Mami; Suzuki, Kenta; Kobayashi, Akihiro; Shindo, Kazuha; Endo, Shino; Miyanishi, Yutaro; Chiba, Natsuko] Tohoku Univ, IDAC, Dept Canc Biol, Sendai, Miyagi, Japan; [Matsuzawa, Ayako; Shibata, Shun] Tohoku Univ, IDAC, Dept Mol Immunol, Sendai, Miyagi, Japan; [Shimaoka, Tatsuro] Tokyo Univ Sci, Res Inst Biomed Sci, Div Mol Pathol, Noda, Chiba, Japan; [Ishioka, Chikashi] Tohoku Univ, IDAC, Dept Clin Oncol, Sendai, Miyagi, Japan; [Kanno, Shin-ichiro; Yasui, Akira] Tohoku Univ, IDAC, Div Dynam Proteome Aging & Canc, Sendai, Miyagi, Japan	Tohoku University; Tohoku University; Tokyo University of Science; Tohoku University; Tohoku University	Chiba, N (corresponding author), Tohoku Univ, IDAC, Dept Canc Biol, Sendai, Miyagi, Japan.	natsuko.chiba.c7@tohoku.ac.jp	Kanno, Shin-ichiro/AAE-4549-2019; Yoshino, Yuki/AAQ-9620-2021	Shibata, Shun/0000-0002-9081-1370; Ishioka, Chikashi/0000-0002-3023-1227	JSPS KAKENHI [JP24300327, JP16H04690, JP16K18409]; Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT); Program for Interdisciplinary Research in Frontier Research Institute for Interdisciplinary Sciences (FRIS), Tohoku University; Astellas Foundation for Research on Metabolic Disorders; Yasuda Medical Foundation; Princess Takamatsu Cancer Research Fund [1424621]; Daiwa Securities Health Foundation; Kobayashi Foundation for Cancer Research; Kobayashi International Scholarship Foundation; Friends of Leukemia Research Fund; Research Program of the Smart-Aging Research Center, Tohoku University; Foundation for Promotion of Cancer Research in Japan	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT); Program for Interdisciplinary Research in Frontier Research Institute for Interdisciplinary Sciences (FRIS), Tohoku University; Astellas Foundation for Research on Metabolic Disorders; Yasuda Medical Foundation; Princess Takamatsu Cancer Research Fund; Daiwa Securities Health Foundation; Kobayashi Foundation for Cancer Research(Kobayashi Foundation for Cancer Research); Kobayashi International Scholarship Foundation; Friends of Leukemia Research Fund; Research Program of the Smart-Aging Research Center, Tohoku University; Foundation for Promotion of Cancer Research in Japan	We thank Satoko Aoki for technical assistance. This study was supported by grants-in-aid from JSPS KAKENHI Grant numbers JP24300327 (to N.C.), JP16H04690 (to N.C and Y.Y.), JP16K18409 (to Y.Y.), Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT) (to C.I. and N.C.), Program for Interdisciplinary Research in Frontier Research Institute for Interdisciplinary Sciences (FRIS), Tohoku University, Astellas Foundation for Research on Metabolic Disorders, the Yasuda Medical Foundation, the Princess Takamatsu Cancer Research Fund (1424621), Daiwa Securities Health Foundation, Kobayashi Foundation for Cancer Research, Kobayashi International Scholarship Foundation, Friends of Leukemia Research Fund, Research Program of the Smart-Aging Research Center, Tohoku University (to N.C.), and Foundation for Promotion of Cancer Research in Japan (to Y.Y.).	Adams DR, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-22; Ai E, 2009, MOL BIOL CELL, V20, P1629, DOI 10.1091/mbc.E08-09-0917; Al-Reefy S, 2010, BREAST CANCER RES TR, V123, P911, DOI 10.1007/s10549-010-1020-y; Bai L, 2016, ONCOTARGET, V7, P10402, DOI 10.18632/oncotarget.7224; Bettencourt-Dias M, 2011, TRENDS GENET, V27, P307, DOI 10.1016/j.tig.2011.05.004; Brodie KM, 2012, J BIOL CHEM, V287, P7701, DOI 10.1074/jbc.M111.327296; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; Cao XX, 2010, BREAST CANCER RES TR, V123, P375, DOI 10.1007/s10549-009-0657-x; Cao XX, 2010, INT J CANCER, V127, P1172, DOI 10.1002/ijc.25120; Clark SL, 2012, COMPUT STRUCT BIOTEC, V1, DOI 10.5936/csbj.201204005; Ding ZH, 2016, MOL CELL BIOL, V36, P2568, DOI 10.1128/MCB.00137-16; Duff D, 2017, CELL SIGNAL, V35, P250, DOI 10.1016/j.cellsig.2017.03.005; Fujita H, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2015.1075643; Gandin Valentina, 2013, Genes Cancer, V4, P369, DOI 10.1177/1947601913486348; Godinho SA, 2014, NATURE, V510, P167, DOI 10.1038/nature13277; Guarguaglini G, 2005, MOL BIOL CELL, V16, P1095, DOI 10.1091/mbc.E04-10-0939; Guichard P, 2018, BIOESSAYS, V40, DOI 10.1002/bies.201700241; Hsu LC, 2001, CANCER RES, V61, P7713; Kais Z, 2012, ONCOGENE, V31, P799, DOI 10.1038/onc.2011.271; Kershner L, 2017, NEURAL REGEN RES, V12, P1036, DOI 10.4103/1673-5374.211175; Ko MJ, 2006, ONCOGENE, V25, P298, DOI 10.1038/sj.onc.1209028; Lacombe J, 2013, INT J CANCER, V132, P1105, DOI 10.1002/ijc.27766; Leipe DD, 2002, J MOL BIOL, V317, P41, DOI 10.1006/jmbi.2001.5378; Li JJ, 2015, ONCOGENE, V34, P1890, DOI 10.1038/onc.2014.127; Matsuzawa A, 2014, MOL CELL, V53, P101, DOI 10.1016/j.molcel.2013.10.028; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Sankaran S, 2006, CANCER RES, V66, P4100, DOI 10.1158/0008-5472.CAN-05-4430; Sankaran S, 2005, MOL CELL BIOL, V25, P8656, DOI 10.1128/MCB.25.19.8656-8668.2005; Shimomura A, 2009, J CANCER RES CLIN, V135, P421, DOI 10.1007/s00432-008-0472-5; Skop AR, 2004, SCIENCE, V305, P61, DOI 10.1126/science.1097931; Starita LM, 2004, MOL CELL BIOL, V24, P8457, DOI 10.1128/MCB.24.19.8457-8466.2004; Sun H, 2010, MOL CANCER RES, V8, P57, DOI 10.1158/1541-7786.MCR-09-0278; Takaoka M, 2018, INT J CLIN ONCOL, V23, P36, DOI 10.1007/s10147-017-1182-2; Towler WI, 2013, HUM MUTAT, V34, P439, DOI 10.1002/humu.22251; Verstraeten N, 2011, MICROBIOL MOL BIOL R, V75, P507, DOI 10.1128/MMBR.00009-11; Watanabe G, 2018, CANCER SCI, V109, P2027, DOI 10.1111/cas.13595; Wei LZ, 2008, MOL CELL BIOL, V28, P7380, DOI 10.1128/MCB.01075-08; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yoshino Y, 2018, MOL CANCER RES, V16, P1499, DOI 10.1158/1541-7786.MCR-18-0269	40	19	19	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2019	38	16					3077	3092		10.1038/s41388-018-0647-8	http://dx.doi.org/10.1038/s41388-018-0647-8			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IB2GE	30617304				2022-12-28	WOS:000470086900001
J	Kessler, BE; Mishall, KM; Kellett, MD; Clark, EG; Pugazhenthi, U; Pozdeyev, N; Kim, J; Tan, AC; Schweppe, RE				Kessler, Brittelle E.; Mishall, Katie M.; Kellett, Meghan D.; Clark, Erin G.; Pugazhenthi, Umarani; Pozdeyev, Nikita; Kim, Jihye; Tan, Aik Choon; Schweppe, Rebecca E.			Resistance to Src inhibition alters the BRAF-mutant tumor secretome to promote an invasive phenotype and therapeutic escape through a FAK>p130Cas>c-Jun signaling axis	ONCOGENE			English	Article							FOCAL-ADHESION-KINASE; TARGETED THERAPIES; THYROID-CARCINOMA; GROWTH-FACTOR; PHASE-II; CANCER; FAK; DASATINIB; MIGRATION; SURVIVAL	Few therapy options exist for patients with advanced papillary and anaplastic thyroid cancer. We and others have previously identified c-Src as a key mediator of thyroid cancer pro-tumorigenic processes and a promising therapeutic target for thyroid cancer. To increase the efficacy of targeting Src in the clinic, we sought to define mechanisms of resistance to the Src inhibitor, dasatinib, to identify key pathways to target in combination. Using a panel of thyroid cancer cell lines expressing clinically relevant mutations in BRAF or RAS, which were previously developed to be resistant to dasatinib, we identified a switch to a more invasive phenotype in the BRAF-mutant cells as a potential therapy escape mechanism. This phenotype switch is driven by FAK kinase activity, and signaling through the p130Cas>c-Jun signaling axis. We have further shown this more invasive phenotype is accompanied by alterations in the secretome through the increased expression of pro-inflammatory cytokines, including IL-1 beta, and the pro-invasive metalloprotease, MMP-9. Furthermore, IL-1 beta signals via a feedforward autocrine loop to promote invasion through a FAK>p130Cas>c-Jun>MMP-9 signaling axis. We further demonstrate that upfront combined inhibition of FAK and Src synergistically inhibits growth and invasion, and induces apoptosis in a panel of BRAF- and RAS-mutant thyroid cancer cell lines. Together our data demonstrate that acquired resistance to single-agent Src inhibition promotes a more invasive phenotype through an IL-1 beta>FAK>p130Cas>c-Jun >MMP signaling axis, and that combined inhibition of FAK and Src has the potential to block this inhibitor-induced phenotype switch.	[Kessler, Brittelle E.; Mishall, Katie M.; Kellett, Meghan D.; Clark, Erin G.; Pugazhenthi, Umarani; Pozdeyev, Nikita; Schweppe, Rebecca E.] Univ Colorado, Sch Med, Div Endocrinol Metab & Diabet, Dept Med, Aurora, CO 80045 USA; [Kim, Jihye; Tan, Aik Choon] Univ Colorado, Sch Med, Canc Ctr, Aurora, CO 80045 USA; [Kim, Jihye; Tan, Aik Choon; Schweppe, Rebecca E.] Univ Colorado, Sch Med, Dept Med, Div Med Oncol, Aurora, CO 80045 USA; [Pozdeyev, Nikita] Div Bioinformat & Personalized Med, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Schweppe, RE (corresponding author), Univ Colorado, Sch Med, Div Endocrinol Metab & Diabet, Dept Med, Aurora, CO 80045 USA.; Schweppe, RE (corresponding author), Univ Colorado, Sch Med, Dept Med, Div Med Oncol, Aurora, CO 80045 USA.	Rebecca.Schweppe@ucdenver.edu	Tan, Aik Choon/A-3135-2011	Tan, Aik Choon/0000-0003-2955-8369; Kim, Jihye/0000-0002-0338-2329; Schweppe, Rebecca/0000-0001-7502-0151	NIH/NCI [1RO1CA164193, 1R01CA222299]; American Cancer Society [RSG-13-060-01-TBE]; Cancer League of Colorado; Front Range Cancer Challenge Fellowship; NCI Cancer Center support grant [P30CA046934]; NATIONAL CANCER INSTITUTE [P30CA046934, R01CA164193, R01CA222299] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008497] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); Cancer League of Colorado; Front Range Cancer Challenge Fellowship; NCI Cancer Center support grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr. Christopher Korch, UCCC, and Randall Wong at the B. Davis Center BioResources Core Facility for STR profiling of the cell lines. We thank Dr. Rytis Prekeris for assistance with the zymography assays. This work was supported by NIH/NCI grant 1RO1CA164193 (RES), 1R01CA222299 (RES), American Cancer Society RSG-13-060-01-TBE (RES), the Cancer League of Colorado (RES), and the Front Range Cancer Challenge Fellowship (KMM). The UCCC DNA Sequencing, Flow Cytometry, and Protein Production/Mab/Tissue Culture Shared Resources are supported by NCI Cancer Center support grant, P30CA046934.	Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Antonelli A, 2011, CURR GENOMICS, V12, P626, DOI 10.2174/138920211798120808; Apte RN, 2006, CANCER METAST REV, V25, P387, DOI 10.1007/s10555-006-9004-4; Barderas R, 2013, MOL CELL PROTEOMICS, V12, P1602, DOI 10.1074/mcp.M112.022848; Beadnell TC, 2016, MOL CANCER THER, V15, P1952, DOI 10.1158/1535-7163.MCT-15-0702; Bolos V, 2010, ONCOTARGETS THER, V3, P83; Caillou B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022567; Carneiro RM, 2015, CANCER TREAT REV, V41, P690, DOI 10.1016/j.ctrv.2015.06.002; Chan CM, 2012, CLIN CANCER RES, V18, P3580, DOI 10.1158/1078-0432.CCR-11-3359; Chan D, 2012, ONCOL LETT, V3, P807, DOI 10.3892/ol.2012.579; Chen GM, 2018, MOL CANCER THER, V17, P806, DOI 10.1158/1535-7163.MCT-17-0561; Chen XL, 2012, DEV CELL, V22, P146, DOI 10.1016/j.devcel.2011.11.002; Chen YF, 2011, ACTA PHARM SIN B, V1, P197, DOI 10.1016/j.apsb.2011.10.007; Chen YJ, 2005, NUCLEIC ACIDS RES, V33, pD169; Chow AKM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078675; Defilippi P, 2006, TRENDS CELL BIOL, V16, P257, DOI 10.1016/j.tcb.2006.03.003; Fallahi-Sichani M, 2017, MOL SYST BIOL, V13, DOI 10.15252/msb.20166796; Fallahi-Sichani M, 2015, MOL SYST BIOL, V11, DOI 10.15252/msb.20145877; Finn RS, 2011, CLIN CANCER RES, V17, P6905, DOI 10.1158/1078-0432.CCR-11-0288; Gelfo V, 2016, ONCOTARGET, V7, P72167, DOI 10.18632/oncotarget.12354; Glickman MS, 2012, CELL, V148, P1089, DOI 10.1016/j.cell.2012.02.015; Golubovskaya VM, 2003, MOL CANCER RES, V1, P755; Hauck CR, 2000, J BIOL CHEM, V275, P41092, DOI 10.1074/jbc.M005450200; Hayes DN, 2012, CLIN CANCER RES, V18, P2056, DOI 10.1158/1078-0432.CCR-11-0563; Hirata E, 2015, CANCER CELL, V27, P574, DOI 10.1016/j.ccell.2015.03.008; Ilic D, 1998, J CELL BIOL, V143, P547; Johnson FM, 2010, J CLIN ONCOL, V28, P4609, DOI 10.1200/JCO.2010.30.5474; Kebebew E, 2005, CANCER-AM CANCER SOC, V103, P1330, DOI 10.1002/cncr.20936; Kemper K, 2014, CANCER RES, V74, P5937, DOI 10.1158/0008-5472.CAN-14-1174; Kessler BEBE, 2016, MOL CANCER RES, P14869; Kim WG, 2012, CLIN CANCER RES, V18, P1281, DOI 10.1158/1078-0432.CCR-11-2892; Lee BY, 2015, PHARMACOL THERAPEUT, V146, P132, DOI 10.1016/j.pharmthera.2014.10.001; Lee CR, 2016, FEBS LETT, V590, P358, DOI 10.1002/1873-3468.12057; Leight JL, 2015, P NATL ACAD SCI USA, V112, P5366, DOI 10.1073/pnas.1505662112; Lu HB, 2013, MOL CANCER THER, V12, P2864, DOI 10.1158/1535-7163.MCT-13-0233; McCulloch CA, 2006, NAT REV DRUG DISCOV, V5, P864, DOI 10.1038/nrd2109; Michailidi C, 2010, PATHOL ONCOL RES, V16, P497, DOI 10.1007/s12253-010-9269-3; Mishall KM, 2017, ONCOTARGET IMPACT J, V8; Mon NN, 2017, ONCOL LETT, V13, P955, DOI 10.3892/ol.2016.5521; Montero-Conde C, 2013, CANCER DISCOV, V3, P520, DOI 10.1158/2159-8290.CD-12-0531; Ng M, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.2584; Obenauf AC, 2015, NATURE, V520, P368, DOI 10.1038/nature14336; Owens LV, 1996, ANN SURG ONCOL, V3, P100, DOI 10.1007/BF02409059; Paraiso KHT, 2015, CANCER DISCOV, V5, P264, DOI 10.1158/2159-8290.CD-14-0293; Qiao YC, 2016, J BIOL CHEM, V291, P5068, DOI 10.1074/jbc.M115.702571; Ramsdale R, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aab1111; Ryder M, 2008, ENDOCR-RELAT CANCER, V15, P1069, DOI 10.1677/ERC-08-0036; Sandri S, 2016, PHARMACOL RES, V111, P523, DOI 10.1016/j.phrs.2016.07.017; Santarpia L, 2012, EXPERT OPIN THER TAR, V16, P103, DOI 10.1517/14728222.2011.645805; Schweppe RE, 2009, J CLIN ENDOCR METAB, V94, P2199, DOI 10.1210/jc.2008-2511; Segarra M, 2005, FASEB J, V19, P1875, DOI 10.1096/fj.04-3574fje; Shah MH, 2017, J CLIN ONCOL, V32, P6022; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Sipos Jennifer A, 2010, Ther Adv Med Oncol, V2, P3, DOI 10.1177/1758834009352667; Stanam A, 2016, ONCOTARGET, V7, P76087, DOI 10.18632/oncotarget.12590; Taylor KN, 2018, MOL CANCER THER, V17, P719, DOI 10.1158/1535-7163.MCT-17-1177; Titz B, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.28; Ware KE, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.4; Weber A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3105cm1; Wilson C, 2014, ONCOTARGET, V5, P7328, DOI 10.18632/oncotarget.2397; Wu XY, 2005, DEV CELL, V9, P185, DOI 10.1016/j.devcel.2005.06.006; Wynn TA, 2011, J EXP MED, V208, P1339, DOI 10.1084/jem.20110551; Zhang P, 2015, EUR J ORAL SCI, V123, P249, DOI 10.1111/eos.12191; Zhao W, 2014, J BIOMOL SCREEN, V19, P817, DOI 10.1177/1087057114521867; Zubrilov I, 2015, CANCER LETT, V361, P86, DOI 10.1016/j.canlet.2015.02.041	65	10	11	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2019	38	14					2565	2579		10.1038/s41388-018-0617-1	http://dx.doi.org/10.1038/s41388-018-0617-1			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HR7LI	30531837	Green Accepted			2022-12-28	WOS:000463335200009
J	Stylianou, N; Lehman, ML; Wang, CW; Fard, AT; Rockstroh, A; Fazli, L; Jovanovic, L; Ward, M; Sadowski, MC; Kashyap, AS; Buttyan, R; Gleave, ME; Westbrook, TF; Williams, ED; Gunter, JH; Nelson, CC; Hollier, BG				Stylianou, Nataly; Lehman, Melanie L.; Wang, Chenwei; Fard, Atefeh Taherian; Rockstroh, Anja; Fazli, Ladan; Jovanovic, Lidija; Ward, Micheal; Sadowski, Martin C.; Kashyap, Abhishek S.; Buttyan, Ralph; Gleave, Martin E.; Westbrook, Thomas F.; Williams, Elizabeth D.; Gunter, Jennifer H.; Nelson, Colleen C.; Hollier, Brett G.			A molecular portrait of epithelial-mesenchymal plasticity in prostate cancer associated with clinical outcome (vol 38, pg 913, 2019)	ONCOGENE			English	Correction									[Stylianou, Nataly; Lehman, Melanie L.; Wang, Chenwei; Fard, Atefeh Taherian; Rockstroh, Anja; Jovanovic, Lidija; Sadowski, Martin C.; Williams, Elizabeth D.; Gunter, Jennifer H.; Nelson, Colleen C.; Hollier, Brett G.] Queensland Univ Technol, Australian Prostate Canc Res Ctr Queensland, Princess Alexandra Hosp, Fac Hlth,Sch Biomed Sci,Translat Res Inst,Inst Hl, Brisbane, Qld, Australia; [Lehman, Melanie L.; Fazli, Ladan; Buttyan, Ralph; Gleave, Martin E.] Univ British Columbia, Dept Urol Sci, Vancouver Prostate Ctr, Vancouver, BC, Canada; [Ward, Micheal] Univ Queensland, Sch Med, Glycat & Diabet Complicat Grp, Mater Res Inst,Translat Res Inst, Brisbane, Qld, Australia; [Kashyap, Abhishek S.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Tissue Repair & Regenerat Program, Brisbane, Qld, Australia; [Westbrook, Thomas F.] Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA	Queensland University of Technology (QUT); University of British Columbia; Mater Research; University of Queensland; Queensland University of Technology (QUT); Baylor College of Medicine	Hollier, BG (corresponding author), Queensland Univ Technol, Australian Prostate Canc Res Ctr Queensland, Princess Alexandra Hosp, Fac Hlth,Sch Biomed Sci,Translat Res Inst,Inst Hl, Brisbane, Qld, Australia.	b.hollier@qut.edu.au	Gunter, Jennifer H/B-8960-2016; Williams, Elizabeth D/B-1538-2008; Stylianou, Nataly/GOP-1782-2022; Fard, Ati/AAX-4092-2021	Gunter, Jennifer H/0000-0003-2447-5732; Williams, Elizabeth D/0000-0002-3364-6655; Sadowski, Martin/0000-0002-5267-1442; Stylianou, Nataly/0000-0002-8006-5730; Gleave, Martin/0000-0003-4235-0167				Stylianou N, 2019, ONCOGENE, V38, P913, DOI 10.1038/s41388-018-0488-5	1	3	3	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2019	38	13					2436	2436		10.1038/s41388-018-0587-3	http://dx.doi.org/10.1038/s41388-018-0587-3			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ7GN	30510231	hybrid, Green Published			2022-12-28	WOS:000462588000017
J	Marques, M; Jangal, M; Wang, LC; Kazanets, A; da Silva, SD; Zhao, TJ; Lovato, A; Yu, H; Jie, S; del Rincon, S; MacKey, J; Damaraju, S; Alaoui-Jamali, M; Witcher, M				Marques, Maud; Jangal, Maika; Wang, Li-Chun; Kazanets, Anna; da Silva, Sabrina Daniela; Zhao, Tiejun; Lovato, Amanda; Yu, Henry; Jie, Su; del Rincon, Sonia; MacKey, John; Damaraju, Sambasivarao; Alaoui-Jamali, Moulay; Witcher, Michael			Oncogenic activity of poly (ADP-ribose) glycohydrolase	ONCOGENE			English	Article							BREAST-CANCER; POLY(ADP-RIBOSE) POLYMERASE; MAMMARY TUMORIGENESIS; MOLECULAR PORTRAITS; DNA-DAMAGE; CELLS; GROWTH; PARP; TUMORS	Poly (ADP-ribosylation), known as PARylation, is a post-translational modification catalyzed by poly (ADP-ribose) polymerases (PARP) and primarily removed by the enzyme poly (ADP-ribose) glycohydrolase (PARG). While the aberrant removal of post-translation modifications including phosphorylation and methylation has known tumorigenic effects, deregulation of PARylation has not been widely studied. Increased hydrolysis of PARylation chains facilitates cancer growth through enhancing estrogen receptor (ER)-driven proliferation, but oncogenic transformation has not been linked to increased PARG expression. In this study, we find that elevated PARG levels are associated with a poor prognosis in breast cancers, especially in HER2-positive and triple-negative subtypes. Using both in vitro and in vivo models, we demonstrate that heightened expression of catalytically active PARG facilitates cell transformation and invasion of normal mammary epithelial cells. Catalytically inactive PARG mutants did not recapitulate these phenotypes. Consistent with clinical data showing elevated PARG predicts poor outcomes in HER2+ patients, we observed that PARG acts in synergy with HER2 to promote neoplastic growth of immortalized mammary cells. In contrast, PARG depletion significantly impairs the growth and metastasis of triple-negative breast tumors. Mechanistically, we find that PARG interacts with SMAD2/3 and significantly decreases their PARylation in non-transformed cells, leading to enhanced expression of SMAD target genes. Further linking SMAD-mediated transcription to the oncogenicity of PARG, we show that PARG-mediated anchorage-independent growth and invasion are dependent, at least in part, on SMAD expression. Overall, our study underscores the oncogenic impact of aberrant protein PARylation and highlights the therapeutic potential of PARG inhibition in breast cancer.	[Marques, Maud; Jangal, Maika; Wang, Li-Chun; Kazanets, Anna; da Silva, Sabrina Daniela; Zhao, Tiejun; Lovato, Amanda; Yu, Henry; Jie, Su; del Rincon, Sonia; Alaoui-Jamali, Moulay; Witcher, Michael] McGill Univ, Dept Oncol, Lady Davis Inst, Jewish Gen Hosp, Montreal, PQ, Canada; [Marques, Maud; Jangal, Maika; Wang, Li-Chun; Kazanets, Anna; da Silva, Sabrina Daniela; Zhao, Tiejun; Lovato, Amanda; Yu, Henry; Jie, Su; del Rincon, Sonia; Alaoui-Jamali, Moulay; Witcher, Michael] McGill Univ, Dept Expt Med, Lady Davis Inst, Jewish Gen Hosp, Montreal, PQ, Canada; [da Silva, Sabrina Daniela] McGill Univ, Dept Otolaryngol Head & Neck Surg, Sir Mortimer B Davis Jewish Gen Hosp, Montreal, PQ, Canada; [MacKey, John] Univ Alberta, Dept Oncol, Div Med Oncol, Cross Canc Inst, Edmonton, AB, Canada; [Damaraju, Sambasivarao] Univ Alberta, Dept Lab Med & Pathol, Cross Canc Inst, Edmonton, AB, Canada	Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; McGill University; University of Alberta; University of Alberta	Witcher, M (corresponding author), McGill Univ, Dept Oncol, Lady Davis Inst, Jewish Gen Hosp, Montreal, PQ, Canada.; Witcher, M (corresponding author), McGill Univ, Dept Expt Med, Lady Davis Inst, Jewish Gen Hosp, Montreal, PQ, Canada.	Michael.Witcher@mcgill.ca	Wurzba, Sabrina/ABF-5002-2020	Wurzba, Sabrina/0000-0002-3742-2819	Quebec Breast Cancer Foundation (QBCF); Canadian Institute of Health Research (CIHR); Fonds de recherche du Quebec Sante (FRQS); FRQS; McGill Integrated Cancer Research Training Program; CIHR studentship; MITACS; Institute NEOMED	Quebec Breast Cancer Foundation (QBCF); Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Fonds de recherche du Quebec Sante (FRQS); FRQS; McGill Integrated Cancer Research Training Program; CIHR studentship(Canadian Institutes of Health Research (CIHR)); MITACS; Institute NEOMED	This work was supported by grants from the Quebec Breast Cancer Foundation (QBCF), the Canadian Institute of Health Research (CIHR) and Fonds de recherche du Quebec Sante (FRQS) to MW, FRQS postdoctoral fellowship to MM and McGill Integrated Cancer Research Training Program fellowships to MM and MJ. AL was supported by a CIHR studentship. LCW was supported by a MITACS postdoctoral fellowship in collaboration with Institute NEOMED.	ALBINI A, 1987, CANCER RES, V47, P3239; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Bruna A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2039; Canto C, 2015, CELL METAB, V22, P31, DOI 10.1016/j.cmet.2015.05.023; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chang CH, 2017, ONCOTARGET, V8, P31199, DOI 10.18632/oncotarget.16105; Chiou SH, 2013, J EXP MED, V210, P85, DOI 10.1084/jem.20121044; Dahl M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103651; Docquier F, 2009, CLIN CANCER RES, V15, P5762, DOI 10.1158/1078-0432.CCR-09-0329; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Feng XX, 2013, INT REV CEL MOL BIO, V304, P227, DOI 10.1016/B978-0-12-407696-9.00005-1; Frizzell KM, 2009, J BIOL CHEM, V284, P33926, DOI 10.1074/jbc.M109.023879; Gupta PB, 2007, CANCER RES, V67, P2062, DOI 10.1158/0008-5472.CAN-06-3895; Gupte R, 2017, GENE DEV, V31, P101, DOI 10.1101/gad.291518.116; Hilmi K, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1601898; Ishizawa K, 2010, CELL STEM CELL, V7, P279, DOI 10.1016/j.stem.2010.08.009; Kasimir-Bauer S, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3099; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kowanetz M, 2010, P NATL ACAD SCI USA, V107, P21248, DOI 10.1073/pnas.1015855107; Kraus WL, 2008, CURR OPIN CELL BIOL, V20, P294, DOI 10.1016/j.ceb.2008.03.006; Le May N, 2012, MOL CELL, V48, P785, DOI 10.1016/j.molcel.2012.09.021; Lee SW, 2000, MOL CELL BIOL, V20, P1723, DOI 10.1128/MCB.20.5.1723-1732.2000; Li F, 2005, DIABETES, V54, P1514, DOI 10.2337/diabetes.54.5.1514; Liu HP, 2010, P NATL ACAD SCI USA, V107, P18115, DOI 10.1073/pnas.1006732107; Livraghi L, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0425-1; Lonn P, 2010, MOL CELL, V40, P521, DOI 10.1016/j.molcel.2010.10.029; Luo X, 2012, GENE DEV, V26, P417, DOI 10.1101/gad.183509.111; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marcato P, 2011, STEM CELLS, V29, P32, DOI 10.1002/stem.563; Marques M, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0454-9; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Masutani M, 2013, MOL ASPECTS MED, V34, P1202, DOI 10.1016/j.mam.2013.05.003; Morrison C, 1997, NAT GENET, V17, P479, DOI 10.1038/ng1297-479; Mortusewicz O, 2011, NUCLEIC ACIDS RES, V39, P5045, DOI 10.1093/nar/gkr099; Moynihan KA, 2005, CELL METAB, V2, P105, DOI 10.1016/j.cmet.2005.07.001; Muraoka RS, 2003, MOL CELL BIOL, V23, P8691, DOI 10.1128/MCB.23.23.8691-8703.2003; Patra KC, 2013, CANCER CELL, V24, P213, DOI 10.1016/j.ccr.2013.06.014; Pena-Hernandez R, 2015, P NATL ACAD SCI USA, V112, pE677, DOI 10.1073/pnas.1416674112; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Ramadoss S, 2017, ONCOGENE, V36, P47, DOI 10.1038/onc.2016.174; Redig AJ, 2013, J INTERN MED, V274, P113, DOI 10.1111/joim.12084; Robson M, 2017, NEW ENGL J MED, V377, P523, DOI 10.1056/NEJMoa1706450; Roux Kyle J, 2013, Curr Protoc Protein Sci, V74, DOI 10.1002/0471140864.ps1923s74; Schmierer B, 2007, NAT REV MOL CELL BIO, V8, P970, DOI 10.1038/nrm2297; Shirai H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.133; Shirai H, 2013, BIOCHEM BIOPH RES CO, V435, P100, DOI 10.1016/j.bbrc.2013.04.048; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Tong WM, 2007, ONCOGENE, V26, P3857, DOI 10.1038/sj.onc.1210156; Tong WM, 2002, CANCER RES, V62, P6990; Tsutsumi M, 2001, CARCINOGENESIS, V22, P1, DOI 10.1093/carcin/22.1.1; Verdone L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144287; Ward TM, 2013, ONCOGENE, V32, P2463, DOI 10.1038/onc.2012.256; Witt AE, 2017, ONCOGENE, V36, P1707, DOI 10.1038/onc.2016.337; Wright RHG, 2016, SCIENCE, V352, P1221, DOI 10.1126/science.aad9335; Xu YJ, 2010, J EXP MED, V207, P2421, DOI 10.1084/jem.20100433; Zhang YJ, 2013, NAT METHODS, V10, P981, DOI 10.1038/nmeth.2603; Zhao TJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092853	59	20	20	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2019	38	12					2177	2191		10.1038/s41388-018-0568-6	http://dx.doi.org/10.1038/s41388-018-0568-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP6UR	30459355	Green Published, hybrid			2022-12-28	WOS:000461822600013
J	Frazier, NM; Brand, T; Gordan, JD; Grandis, J; Jura, N				Frazier, Nicole Michael; Brand, Toni; Gordan, John D.; Grandis, Jennifer; Jura, Natalia			Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; SCATTER FACTOR-RECEPTOR; C-MET; LUNG-CANCER; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; GENE AMPLIFICATION; CRYSTAL-STRUCTURE; PROGNOSTIC-SIGNIFICANCE; NUCLEAR MET	Ligand-dependent oligomerization of receptor tyrosine kinases (RTKs) results in their activation through highly specific conformational changes in the extracellular and intracellular receptor domains. These conformational changes are unique for each RTK subfamily, limiting cross-activation between unrelated RTKs. The proto-oncogene MET receptor tyrosine kinase overcomes these structural constraints and phosphorylates unrelated RTKs in numerous cancer cell lines. The molecular basis for these interactions is unknown. We investigated the mechanism by which MET phosphorylates the human epidermal growth factor receptor-3 (HER3 or ERBB3), a catalytically impaired RTK whose phosphorylation by MET has been described as an essential component of drug resistance to inhibitors targeting EGFR and HER2. We find that in untransformed cells, HER3 is not phosphorylated by MET in response to ligand stimulation, but rather to increasing levels of MET expression, which results in ligand-independent MET activation. Phosphorylation of HER3 by its canonical coreceptors, EGFR and HER2, is achieved by engaging an allosteric site on the HER3 kinase domain, but this site is not required when HER3 is phosphorylated by MET. We also observe that HER3 preferentially interacts with MET during its maturation along the secretory pathway, before MET is post translationally processed by cleavage within its extracellular domain. This results in accumulation of phosphorylated HER3 in the Golgi apparatus. We further show that in addition to HER3, MET phosphorylates other RTKs in the Golgi, suggesting that this mechanism is not limited to HER3 phosphorylation. These data demonstrate a link between MET overexpression and its aberrant activation in the Golgi endomembranes and suggest that non-canonical interactions between MET and other RTKs occur during maturation of receptors. Our study highlights a novel aspect of MET signaling in cancer that would not be accessible to inhibition by therapeutic antibodies.	[Frazier, Nicole Michael; Jura, Natalia] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94158 USA; [Brand, Toni; Grandis, Jennifer] Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA 94113 USA; [Gordan, John D.] Univ Calif San Francisco, Div Hematol & Oncol, San Francisco, CA 94158 USA; [Jura, Natalia] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Jura, N (corresponding author), Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94158 USA.	natalia.jura@ucsf.edu		Frazier, Nicole/0000-0002-9499-1938	National Institute of General Medical Sciences [R01 GM109176]; Susan G. Komen Foundation [CCR14299947]; Lung Cancer Research Foundation; National Institute of Dental and Craniofacial Research [R01 DE023685]; NATIONAL CANCER INSTITUTE [R35CA231998, R01CA098372] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE023685] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007810, R01GM109176] Funding Source: NIH RePORTER	National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Susan G. Komen Foundation(Susan G. Komen Breast Cancer Foundation); Lung Cancer Research Foundation; National Institute of Dental and Craniofacial Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank M. Moasser for insightful discussions and members of the Jura lab for valuable discussions and input on experimental design and execution. This work was supported partially by the grant from the National Institute of General Medical Sciences to N.J. (R01 GM109176), Susan G. Komen Foundation Career Catalyst Research Grant to N.J. (CCR14299947), Lung Cancer Research Foundation Grant to N.J. and the grant from National Institute of Dental and Craniofacial Research to J.G. (R01 DE023685).	Agarwal S, 2009, BRIT J CANCER, V100, P941, DOI 10.1038/sj.bjc.6604937; Beji A, 2012, CLIN CANCER RES, V18, P956, DOI 10.1158/1078-0432.CCR-11-1186; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Bougherara H, 2009, MOL CANCER RES, V7, P1525, DOI 10.1158/1541-7786.MCR-09-0138; Casadevall D, 2015, ONCOTARGET, V6, P16215, DOI 10.18632/oncotarget.3976; Chen R, 2013, J CELL BIOCHEM, V114, P816, DOI 10.1002/jcb.24420; Chirgadze DY, 1999, NAT STRUCT BIOL, V6, P72; Choudhary C, 2009, MOL CELL, V36, P326, DOI 10.1016/j.molcel.2009.09.019; Christensen JG, 2005, CANCER LETT, V225, P1, DOI 10.1016/j.canlet.2004.09.044; Cignetto S, 2016, MOL ONCOL, V10, P938, DOI 10.1016/j.molonc.2016.03.004; Citores L, 2007, J CELL PHYSIOL, V212, P148, DOI 10.1002/jcp.21014; Coleman DT, 2016, ONCOTARGET, V7, P32664, DOI 10.18632/oncotarget.8706; Dawson JP, 2005, MOL CELL BIOL, V25, P7734, DOI 10.1128/MCB.25.17.7734-7742.2005; Dieras V, 2015, ANN ONCOL, V26, P1904, DOI 10.1093/annonc/mdv263; Dimou A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107677; Du ZQ, 2016, MOL CANCER THER, V15, P1227, DOI 10.1158/1535-7163.MCT-15-0745; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Favelyukis S, 2001, NAT STRUCT BIOL, V8, P1058, DOI 10.1038/nsb721; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; Gherardi E, 2003, P NATL ACAD SCI USA, V100, P12039, DOI 10.1073/pnas.2034936100; Guo A, 2008, P NATL ACAD SCI USA, V105, P692, DOI 10.1073/pnas.0707270105; Jura N, 2009, P NATL ACAD SCI USA, V106, P21608, DOI 10.1073/pnas.0912101106; Jura N, 2009, CELL, V137, P1293, DOI 10.1016/j.cell.2009.04.025; Kataoka Y, 2012, INVEST NEW DRUG, V30, P1352, DOI 10.1007/s10637-011-9699-0; Kavran JM, 2014, ELIFE, V3, DOI 10.7554/eLife.03772; Kermorgant S, 2003, J BIOL CHEM, V278, P28921, DOI 10.1074/jbc.M302116200; Kermorgant S, 2008, J CELL BIOL, V182, P855, DOI 10.1083/jcb.200806076; KIM HH, 1994, J BIOL CHEM, V269, P24747; Kim KH, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.17; Kim SM, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.48; KOMADA M, 1993, FEBS LETT, V328, P25, DOI 10.1016/0014-5793(93)80958-W; Lefebvre J, 2012, FASEB J, V26, P1387, DOI 10.1096/fj.11-197723; Li AN, 2015, LUNG CANCER, V90, P375, DOI 10.1016/j.lungcan.2015.10.021; Li YQ, 2015, ONCOTARGET, V6, P13309, DOI 10.18632/oncotarget.3751; Liu SY, 2016, ONCOTARGET, V7, P11251, DOI 10.18632/oncotarget.7081; Liu XD, 2011, CLIN CANCER RES, V17, P7127, DOI 10.1158/1078-0432.CCR-11-1157; Mazot P, 2011, ONCOGENE, V30, P2017, DOI 10.1038/onc.2010.595; McKern NM, 2006, NATURE, V443, P218, DOI 10.1038/nature05106; Menting JG, 2013, NATURE, V493, P241, DOI 10.1038/nature11781; MONDINO A, 1991, MOL CELL BIOL, V11, P6084, DOI 10.1128/MCB.11.12.6084; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; Rosen LS, 2017, CLIN CANCER RES, V23, P1910, DOI 10.1158/1078-0432.CCR-16-1418; Ruco LP, 1996, J PATHOL, V180, P266, DOI 10.1002/(SICI)1096-9896(199611)180:3<266::AID-PATH658>3.0.CO;2-Q; Schmidt-Arras DE, 2005, MOL CELL BIOL, V25, P3690, DOI 10.1128/MCB.25.9.3690-3703.2005; Seiwert TY, 2009, CANCER RES, V69, P3021, DOI 10.1158/0008-5472.CAN-08-2881; Shah MA, 2017, JAMA ONCOL, V3, P620, DOI 10.1001/jamaoncol.2016.5580; Shah MA, 2016, ONCOLOGIST, V21, P1085, DOI 10.1634/theoncologist.2016-0038; Shi PY, 2016, CANCER LETT, V380, P494, DOI 10.1016/j.canlet.2016.07.021; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Song ZB, 2017, CLIN LUNG CANCER, V18, P213, DOI 10.1016/j.cllc.2016.09.011; Stamos J, 2004, EMBO J, V23, P2325, DOI 10.1038/sj.emboj.7600243; Steinway SN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128159; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Tabone-Eglinger S, 2008, CLIN CANCER RES, V14, P2285, DOI 10.1158/1078-0432.CCR-07-4102; Tang ZY, 2004, J CANCER RES CLIN, V130, P187, DOI 10.1007/s00432-003-0511-1; Tanizaki J, 2011, BRIT J CANCER, V105, P807, DOI 10.1038/bjc.2011.322; TEMPEST PR, 1988, BRIT J CANCER, V58, P3, DOI 10.1038/bjc.1988.150; Tey SK, 2017, CANCER LETT, V411, P150, DOI 10.1016/j.canlet.2017.09.047; Xie YQ, 2014, MOL ENDOCRINOL, V28, P1629, DOI 10.1210/me.2014-1078; Yan SC, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0296-y; Yun C, 2015, MOL CARCINOGEN, V54, P1700, DOI 10.1002/mc.22241; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013; ZHU H, 1994, J BIOL CHEM, V269, P29943; Zhu LY, 2016, J CELL SCI, V129, P4238, DOI 10.1242/jcs.191684	69	18	18	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2019	38	11					1936	1950		10.1038/s41388-018-0537-0	http://dx.doi.org/10.1038/s41388-018-0537-0			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HO7XX	30390071	Green Accepted			2022-12-28	WOS:000461164400011
J	Patel, Y; Soni, M; Awgulewitsch, A; Kern, MJ; Liu, S; Shah, N; Singh, UP; Chen, H				Patel, Y.; Soni, M.; Awgulewitsch, A.; Kern, M. J.; Liu, S.; Shah, N.; Singh, U. P.; Chen, H.			Overexpression of miR-489 derails mammary hierarchy structure and inhibits HER2/neu-induced tumorigenesis (vol 38, pg 445, 2018)	ONCOGENE			English	Correction									[Patel, Y.; Soni, M.; Liu, S.; Shah, N.; Chen, H.] Univ South Carolina, Dept Biol Sci, Columbia, SC 29208 USA; [Patel, Y.; Soni, M.; Liu, S.; Shah, N.; Chen, H.] Univ South Carolina, Ctr Colon Canc Res, Columbia, SC 29208 USA; [Awgulewitsch, A.] Med Univ South Carolina, Dept Med, Charleston, SC 29425 USA; [Awgulewitsch, A.] Med Univ South Carolina, Dept Regenerat Med & Cell Biol, Transgen & Genome Editing Core, Charleston, SC 29425 USA; [Kern, M. J.] Med Univ South Carolina, Dept Regenerat Med & Cell Biol, Gene Funct Core, Charleston, SC 29425 USA; [Singh, U. P.] Univ South Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC 29208 USA	University of South Carolina System; University of South Carolina Columbia; University of South Carolina System; University of South Carolina Columbia; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Chen, H (corresponding author), Univ South Carolina, Dept Biol Sci, Columbia, SC 29208 USA.; Chen, H (corresponding author), Univ South Carolina, Ctr Colon Canc Res, Columbia, SC 29208 USA.	hchen@biol.sc.edu	chen, hexin/F-1714-2011	Chen, Hexin/0000-0001-9300-0859; Singh, Udai/0000-0002-7048-4325	U.S. Department of Health &amp; Human Services | NIH | National Institute of General Medical Sciences (NIGMS) [4P30 GM103342-05] Funding Source: Medline; U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute (NCI) [4R01 CA178386-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA178386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM103342] Funding Source: NIH RePORTER	U.S. Department of Health &amp; Human Services | NIH | National Institute of General Medical Sciences (NIGMS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute (NCI); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Patel Y, 2019, ONCOGENE, V38, P445, DOI 10.1038/s41388-018-0439-1	1	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2019	38	3					454	454		10.1038/s41388-018-0559-7	http://dx.doi.org/10.1038/s41388-018-0559-7			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HH6OP	30375491	Bronze			2022-12-28	WOS:000455851200011
J	Ji, DH; Zhang, PS; Ma, WJ; Fei, YW; Xue, W; Wang, Y; Zhang, XY; Zhou, HX; Zhao, Y				Ji, Dehuan; Zhang, Pengshan; Ma, Wenjuan; Fei, Yiwen; Xue, Wen; Wang, Yu; Zhang, Xiuyan; Zhou, Haixia; Zhao, Yun			Oncogenic heterogeneous nuclear ribonucleoprotein D-like modulates the growth and imatinib response of human chronic myeloid leukemia CD34(+) cells via pre-B-cell leukemia homeobox 1	ONCOGENE			English	Article							HEMATOPOIETIC STEM-CELLS; GENE-EXPRESSION; HNRNP PROTEINS; MESSENGER-RNA; PROLIFERATION; JKTBP1; PBX1; MICRODELETION; INSIGHTS; CLONING	Chronic myeloid leukemia (CML) originates from normal hematopoietic stem cells acquiring BCR-ABL fusion gene, specific BCR-ABL inhibitors (e.g., imatinib mesylate, IM) have greatly improved patient management. However, some patients are still suffering from relapse and drug resistance, which urges better understanding of the growth/survival mechanisms of CML stem/progenitor cells. In the present study, the role and its underlying mechanism of heterogeneous nuclear ribonucleoprotein D-like (HNRPDL) in CML cells were investigated. Firstly, overexpression of HNRPDL promoted the growth of murine BaF3 cells in vitro and induced leukemia in vivo, which was enhanced by co-expression of BCR-ABL. Conversely, HNRPDL silencing inhibited colony-forming cell (CFC) production of CML CD34(+) cells and attenuated BCR-ABL induced leukemia. In addition, HNRPDL modulated imatinib response of K562 cells and HNRPDL silencing sensitized CML CD34(+) cells to imatinib treatment. Mechanistically, we found the stability of pre-B-cell leukemia homeobox 1 (PBX1) mRNA was sustained by HNRPDL through its binding to a specific motif (ACUAGC) in 3 '-untranslated region (3 '-UTR) of PBX1. The expression of PBX1 was significantly higher in CML CD34(+) cells than that in control cells and PBX silencing inhibited the growth of CML cells and sensitized them to imatinib treatment. In contrast, overexpression of PBX1 elevated the CFC production of normal hematopoietic CD34(+) cells and "rescued" HNRPDL silencing induced growth inhibition and imatinib sensitization. Taken together, our data have demonstrated that HNRPDL transforms hematopoietic cells and a novel HNRPDL/PBX1 axis plays an important role in human CML CD34(+) cells.	[Ji, Dehuan; Zhang, Pengshan; Ma, Wenjuan; Fei, Yiwen; Xue, Wen; Wang, Yu; Zhang, Xiuyan; Zhao, Yun] Soochow Univ, Natl Clin Res Ctr Hematol Dis, Cyrus Tang Hematol Ctr, Suzhou 215123, Peoples R China; [Zhou, Haixia] Soochow Univ, Affiliated Hosp 1, Natl Clin Res Ctr Hematol Dis, Suzhou 215006, Peoples R China; [Zhao, Yun] Soochow Univ, Collaborat Innovat Ctr Hematol, Suzhou 215006, Peoples R China	Soochow University - China; Soochow University - China; Soochow University - China	Zhao, Y (corresponding author), Soochow Univ, Natl Clin Res Ctr Hematol Dis, Cyrus Tang Hematol Ctr, Suzhou 215123, Peoples R China.; Zhou, HX (corresponding author), Soochow Univ, Affiliated Hosp 1, Natl Clin Res Ctr Hematol Dis, Suzhou 215006, Peoples R China.; Zhao, Y (corresponding author), Soochow Univ, Collaborat Innovat Ctr Hematol, Suzhou 215006, Peoples R China.	zhouhaixia@suda.edu.cn; zhaoy@suda.edu.cn		, Yun/0000-0002-0065-4675	National Natural Science Foundation of China [31771579, 31371392, 81400113, 81500119, 81800151]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Innovation Capability Development Project of Jiangsu Province [BM2015004]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Innovation Capability Development Project of Jiangsu Province	This work was supported by National Natural Science Foundation of China (Nos. 31771579, 31371392 to YZ, 81400113 to HZ, 81500119 to XZ, and 81800151 to WM), the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), and the Innovation Capability Development Project of Jiangsu Province (No. BM2015004).	Akindahunsi AA, 2005, COMPUT BIOL CHEM, V29, P13, DOI 10.1016/j.compbiolchem.2004.11.002; Al-Ghoul M, 2008, J PROTEOME RES, V7, P4107, DOI 10.1021/pr800174k; Bandiera A, 2003, ARCH BIOCHEM BIOPHYS, V409, P305, DOI 10.1016/S0003-9861(02)00413-7; Bertagnolo V, 2011, J PROTEOMICS, V75, P398, DOI 10.1016/j.jprot.2011.08.005; Bonnet C, 2010, J MED GENET, V47, P377, DOI 10.1136/jmg.2009.071902; Boopathi E, 2004, J BIOL CHEM, V279, P35242, DOI 10.1074/jbc.M403160200; Corbin AS, 2011, J CLIN INVEST, V121, P396, DOI 10.1172/JCI35721; de Wit M, 2014, J PROTEOMICS, V99, P26, DOI 10.1016/j.jprot.2014.01.001; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; Deneault E, 2009, CELL, V137, P369, DOI 10.1016/j.cell.2009.03.026; Doi A, 1998, BBA-GENE STRUCT EXPR, V1396, P51, DOI 10.1016/S0167-4781(97)00223-6; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Ficara F, 2008, CELL STEM CELL, V2, P484, DOI 10.1016/j.stem.2008.03.004; Geuens T, 2016, HUM GENET, V135, P851, DOI 10.1007/s00439-016-1683-5; Golan-Gerstl R, 2011, CANCER RES, V71, P4464, DOI 10.1158/0008-5472.CAN-10-4410; Guo X, 2006, ONCOGENE, V25, P4241, DOI 10.1038/sj.onc.1209452; Hamilton A, 2012, BLOOD, V119, P1501, DOI 10.1182/blood-2010-12-326843; Hu XY, 2017, AM J MED GENET A, V173, P120, DOI 10.1002/ajmg.a.37965; HUNGER SP, 1991, BLOOD, V77, P687; Imasaki T, 2007, MOL CELL, V28, P57, DOI 10.1016/j.molcel.2007.08.006; Ito T, 2010, NATURE, V466, P765, DOI 10.1038/nature09171; Jiang XY, 2010, BLOOD, V116, P2112, DOI 10.1182/blood-2009-05-222471; Kamei D, 2002, GENE, V298, P49, DOI 10.1016/S0378-1119(02)00926-5; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; Kawamura H, 2002, J BIOL CHEM, V277, P2732, DOI 10.1074/jbc.M108477200; Kurokawa Y, 2003, J HEPATOL, V39, P1004, DOI 10.1016/S0168-8278(03)00473-2; Lai CK, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2017.86; Omnus DJ, 2011, J MOL BIOL, V407, P492, DOI 10.1016/j.jmb.2011.01.050; Peng XC, 2011, MOL CELL BIOCHEM, V351, P233, DOI 10.1007/s11010-011-0730-8; Perrotti D, 1998, EMBO J, V17, P4442, DOI 10.1093/emboj/17.15.4442; Perrotti D, 2007, CLIN CANCER RES, V13, P1638, DOI 10.1158/1078-0432.CCR-06-2320; Radich JP, 2006, P NATL ACAD SCI USA, V103, P2794, DOI 10.1073/pnas.0510423103; Reboll MR, 2007, RNA, V13, P1328, DOI 10.1261/rna.545407; Sherbenou DW, 2007, J CLIN INVEST, V117, P2067, DOI 10.1172/JCI31988; Shimabe M, 2009, ONCOGENE, V28, P4364, DOI 10.1038/onc.2009.288; Sloma I, 2010, LEUKEMIA, V24, P1823, DOI 10.1038/leu.2010.159; Trotta R, 2003, CANCER CELL, V3, P145, DOI 10.1016/S1535-6108(03)00020-5; Tsuchiya N, 1998, J BIOCHEM-TOKYO, V123, P499; van Erk MJ, 2005, EUR J NUTR, V44, P143, DOI 10.1007/s00394-004-0503-1; Vegi NM, 2016, CELL REP, V16, P498, DOI 10.1016/j.celrep.2016.05.094; Vieira NM, 2014, HUM MOL GENET, V23, P4103, DOI 10.1093/hmg/ddu127; Wang Y, 2013, NAT STRUCT MOL BIOL, V20, P36, DOI 10.1038/nsmb.2459; Wu YY, 2008, CELL BIOCHEM FUNCT, V26, P467, DOI 10.1002/cbf.1468; Xu X, 2016, J BIOL CHEM, V291, P9617, DOI 10.1074/jbc.M115.701979; Zhang PS, 2018, ACTA BIOCH BIOPH SIN, V50, P880, DOI 10.1093/abbs/gmy085; Zhang X, 2015, ONCOGENE, V34, P3000, DOI 10.1038/onc.2014.241; Zhou HC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107606	47	4	4	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	2					443	453		10.1038/s41388-019-0998-9	http://dx.doi.org/10.1038/s41388-019-0998-9			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KD3JY	31488872				2022-12-28	WOS:000507766400014
J	Zhu, S; Zhao, DY; Li, C; Li, QQ; Jiang, WH; Liu, QP; Wang, R; Fazli, L; Li, YA; Zhang, LL; Yi, Y; Meng, QS; Wang, WY; Wang, GY; Zhang, M; Zu, XB; Zhao, W; Deng, T; Yu, JD; Dong, XS; Chen, KF; Cao, Q				Zhu, Sen; Zhao, Dongyu; Li, Chao; Li, Qiaqia; Jiang, Weihua; Liu, Qipeng; Wang, Rui; Fazli, Ladan; Li, Yinan; Zhang, Lili; Yi, Yang; Meng, Qingshu; Wang, Wanyi; Wang, Guangyu; Zhang, Min; Zu, Xiongbing; Zhao, Wei; Deng, Tuo; Yu, Jindan; Dong, Xuesen; Chen, Kaifu; Cao, Qi			BMI1 is directly regulated by androgen receptor to promote castration-resistance in prostate cancer	ONCOGENE			English	Article							CELL; PROGRESSION; EZH2	B lymphoma Mo-MLV insertion region 1 (BMI1) has been reported to be an oncoprotein. BMI1 represses tumor suppressors to promote cell proliferation, epithelial-mesenchymal transition (EMT), and cancer progression. Although it is known that the expression of BMI1 is increased in many cancer types, the mechanism of BMI1 upregulation is not yet clear. We performed integrative analysis for 3 sets of prostate cancer (PCa) genomic data, and found that BMI1 and androgen receptor (AR) were positively correlated, suggesting that AR might regulate BMI1. Next, we showed that dihydrotestosterone (DHT) upregulated both mRNA and protein levels of BMI1 and that BMI1 was increased in castration-resistant prostate cancer (CRPC) from both human patients and a mouse xenograph model. We further identified an AR binding site in the promoter/enhancer region of BMI1, and confirmed BMI1 as the direct target of AR using gene-editing technology. We also demonstrated that high expression of BMI1 is critical for the development of castration-resistance. Our data also suggest that BMI1-specific inhibitors could be an effective treatment of CRPC.	[Zhu, Sen; Li, Chao; Li, Qiaqia; Jiang, Weihua; Liu, Qipeng; Wang, Rui; Zhang, Lili; Yi, Yang; Meng, Qingshu; Cao, Qi] Houston Methodist Res Inst, Ctr Inflammat & Epigenet, Houston, TX 77030 USA; [Zhao, Dongyu; Wang, Guangyu; Chen, Kaifu] Houston Methodist Res Inst, Ctr Bioinformat & Computat Biol, Houston, TX 77030 USA; [Zhao, Dongyu; Wang, Guangyu; Chen, Kaifu] Cornell Univ, Weill Cornell Med, Dept Cardiothorac Surg, New York, NY 10065 USA; [Li, Chao; Li, Qiaqia; Yi, Yang; Meng, Qingshu; Cao, Qi] Northwestern Univ, Feinberg Sch Med, Dept Urol, Chicago, IL 60611 USA; [Li, Chao; Zu, Xiongbing] Cent S Univ, Xiangya Hosp, Dept Urol, Changsha 410008, Peoples R China; [Li, Qiaqia; Liu, Qipeng] Cent S Univ, Xiangya Sch Med, Changsha 410008, Peoples R China; [Fazli, Ladan; Li, Yinan; Dong, Xuesen] Vancouver Gen Hosp, Vancouver Prostate Ctr, Vancouver, BC V6H 3Z6, Canada; [Fazli, Ladan; Li, Yinan; Dong, Xuesen] Univ British Columbia, Dept Urol Sci, Vancouver, BC V6H 3Z6, Canada; [Wang, Wanyi] Texas Womans Univ, Off Res & Sponsored Programs, Ctr Res Design & Anal, Houston, TX 77030 USA; [Zhang, Min] Houston Methodist Res Inst, Dept Cardiovasc Sci, Ctr Cardiovasc Regenerat, Houston, TX USA; [Zhao, Wei] Sun Yat Sen Univ, Zhongshan Sch Med, Guangzhou 510080, Peoples R China; [Deng, Tuo] Cent S Univ, Minist Educ, Xiangya Hosp 2, Dept Endocrinol & Metab, Changsha 410011, Peoples R China; [Deng, Tuo] Cent S Univ, Minist Educ, Key Lab Diabet Immunol, Changsha 410011, Peoples R China; [Yu, Jindan] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA; [Yu, Jindan; Cao, Qi] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; [Cao, Qi] Houston Methodist Res Inst, Houston Methodist Canc Ctr, Houston, TX 77030 USA	The Methodist Hospital System; The Methodist Hospital - Houston; The Methodist Hospital System; The Methodist Hospital - Houston; Cornell University; Northwestern University; Feinberg School of Medicine; Central South University; Central South University; University of British Columbia; University of British Columbia; Texas Womans University; The Methodist Hospital System; The Methodist Hospital - Houston; Sun Yat Sen University; Central South University; Central South University; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; The Methodist Hospital System; The Methodist Hospital - Houston	Cao, Q (corresponding author), Houston Methodist Res Inst, Ctr Inflammat & Epigenet, Houston, TX 77030 USA.; Chen, KF (corresponding author), Houston Methodist Res Inst, Ctr Bioinformat & Computat Biol, Houston, TX 77030 USA.; Chen, KF (corresponding author), Cornell Univ, Weill Cornell Med, Dept Cardiothorac Surg, New York, NY 10065 USA.; Cao, Q (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Urol, Chicago, IL 60611 USA.; Cao, Q (corresponding author), Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.; Cao, Q (corresponding author), Houston Methodist Res Inst, Houston Methodist Canc Ctr, Houston, TX 77030 USA.	kchen2@houstonmethodist.org; qi.cao@northwestern.edu	Wang, Guangyu/AAM-5940-2021; Dong, Xuesen/AGF-9228-2022; Zhao, Dongyu/ABA-2574-2020; Cao, Qi/A-5517-2010	Wang, Guangyu/0000-0003-4803-7200; Cao, Qi/0000-0002-5140-3681; Wang, Wanyi/0000-0001-9482-9968	Houston Methodist Research Institute; Prostate Cancer Foundation [13YOUN007]; U.S. Department of Defense [W81XWH-15-1-0639, W81XWH-17-1-0357]; American Cancer Society [RSG-15-192-01-TBE]; NIH/NCI [R01CA208257, R01CA172384]; NIH/NIGMS [R01GM125632]; NIH/NHLBI [R01HL133254]; US Department of Defense [W81XWH-17-1-0405, W81XWH-17-1-0362, W81XWH-17-1-0578]; Canadian Institute of Health Research [MOP-137007]; TFRI New Frontier Grant [1062]; National Natural Science Foundation of China [81572766, 81972651, 31771630, 81770868, 91742103]; Guangdong Innovative and Entrepreneurial Research Team Program [2016ZT06S029]; Natural Science Foundation of Guangdong Province [2017A030312009]; China Scholarship Council [201706370147]; Innovation-driven Project of Central South University [2017CX011]; CPRIT [RP120348, RP170002]	Houston Methodist Research Institute; Prostate Cancer Foundation; U.S. Department of Defense(United States Department of Defense); American Cancer Society(American Cancer Society); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); US Department of Defense(United States Department of Defense); Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); TFRI New Frontier Grant; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Innovative and Entrepreneurial Research Team Program; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); China Scholarship Council(China Scholarship Council); Innovation-driven Project of Central South University; CPRIT	This work is supported, in part, by grants from Houston Methodist Research Institute, Prostate Cancer Foundation (13YOUN007 to QC), U.S. Department of Defense (W81XWH-15-1-0639 and W81XWH-17-1-0357 to QC), American Cancer Society (Research Scholar Grant RSG-15-192-01-TBE to QC), and NIH/NCI (R01CA208257 to QC); KC is supported in part by grants from NIH/NIGMS (R01GM125632 to KC) and NIH/NHLBI (R01HL133254 to KC); JY is supported by NIH/NCI (R01CA172384), US Department of Defense (W81XWH-17-1-0405, W81XWH-17-1-0362, and W81XWH-17-1-0578). XD is supported by the Canadian Institute of Health Research (#MOP-137007) and TFRI New Frontier Grant #1062. WZ is supported by the National Natural Science Foundation of China (81572766,81972651 and 31771630), Guangdong Innovative and Entrepreneurial Research Team Program (2016ZT06S029), and Natural Science Foundation of Guangdong Province (2017A030312009); CL is supported by the China Scholarship Council (201706370147). TD is supported by National Natural Science Foundation of China (81770868 and 91742103), and Innovation-driven Project of Central South University (2017CX011). The University of Texas MD Anderson Cancer Center Science Park Next-Generation Sequencing (NGS) Facility is supported by CPRIT grants RP120348 and RP170002.	Bansal N, 2016, CLIN CANCER RES, V22, P6176, DOI 10.1158/1078-0432.CCR-15-3107; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen KF, 2013, GENOME RES, V23, P341, DOI 10.1101/gr.142067.112; Clyne Melanie, 2011, Nat Rev Urol, V9, P4, DOI 10.1038/nrurol.2011.208; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Grant CE, 2011, BIOINFORMATICS, V27, P1017, DOI 10.1093/bioinformatics/btr064; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Ji Q, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006816; Jin X, 2017, NAT MED, V23, P1352, DOI 10.1038/nm.4415; Kassi E, 2011, CANCER LETT, V302, P1, DOI 10.1016/j.canlet.2010.10.020; Kent WJ, 2010, BIOINFORMATICS, V26, P2204, DOI 10.1093/bioinformatics/btq351; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kreso A, 2014, NAT MED, V20, P29, DOI 10.1038/nm.3418; Kron KJ, 2017, NAT GENET, V49, P1336, DOI 10.1038/ng.3930; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Li HL, 2016, CANCER RES, V76, P6701, DOI 10.1158/0008-5472.CAN-16-1518; Mounir Z, 2016, ELIFE, V5, DOI 10.7554/eLife.13964; Mourgues L, 2015, LEUKEMIA, V29, P1993, DOI 10.1038/leu.2015.112; Nishida Y, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2017.8; Ren H, 2016, J CANCER, V7, P1074, DOI 10.7150/jca.14031; Siddique HR, 2012, STEM CELLS, V30, P372, DOI 10.1002/stem.1035; Song LB, 2009, J CLIN INVEST, V119, P3626, DOI 10.1172/JCI39374; Takayama K, 2014, CANCER RES, V74, P6542, DOI 10.1158/0008-5472.CAN-14-1030; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; van Leenders GJLH, 2007, EUR UROL, V52, P455, DOI 10.1016/j.eururo.2006.11.020; Wang W, 2008, AM J SURG PATHOL, V32, P65, DOI 10.1097/PAS.0b013e318058a96b; Yong KJ, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad6066; Yoo YA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12943; Yu Y, 2015, PROSTATE, V75, P1043, DOI 10.1002/pros.22988; Zhu S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02863-3	31	19	19	4	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	1					17	29		10.1038/s41388-019-0966-4	http://dx.doi.org/10.1038/s41388-019-0966-4			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG3NM	31462713	Green Accepted			2022-12-28	WOS:000509849200002
J	Gomez, ML; Shah, N; Kenny, TC; Jenkins, EC; Germain, D				Gomez, Maria L.; Shah, Nagma; Kenny, Timothy C.; Jenkins, Edmund C., Jr.; Germain, Doris			SOD1 is essential for oncogene-driven mammary tumor formation but dispensable for normal development and proliferation	ONCOGENE			English	Article							SUPEROXIDE-DISMUTASE 1; TRANSGENIC MICE; ESTROGEN-RECEPTOR; CANCER; BREAST; UPRMT; NEU; ADENOCARCINOMA; IDENTIFICATION; ACTIVATION	We previously reported that the dismutase SOD1 is overexpressed in breast cancer. However, whether SOD1 plays an active role in tumor formation in vivo has never been demonstrated. Further, as luminal cells of normal breast epithelial cells are enriched in SOD1, whether SOD1 is essential for normal mammary gland development has never been determined. We initiated this study to investigate the role of SOD1 in mammary gland tumorigenesis as well as in normal mammary gland development. We crossed the inducible erbB2 (MMTV-iErbB2) and Wnt (MMTV-Wnt) transgenic mice to the SOD1 heterozygote or knockout mice. Our results show that SOD1 is essential for oncogene-driven proliferation, but not normal proliferation of the mammary gland associated with pregnancy or other normal proliferative tissues such as skin and intestines. We show that activation of the oncogene ErbB2 is associated with increased ROS and that high ROS subpopulation of ErbB2 cancer cells show elevated SOD1. In the same cells, decrease in SOD1 is associated with an elevation in both apoptosis as well as oncogene-induced senescence. Based on these results, we suggest that SOD1 carries a housekeeping function that maintains ROS levels below a threshold that supports oncogene-dependent proliferation, while allowing escape from oncogene-induced senescence, independently of the oncogene driving tumor formation. These results identify SOD1 as an ideal target for cancer therapy as SOD1 inhibitors hold the potential to prevent the growth of cancers cells of diverse genotypes, activate multiple modes of cell death therefore making acquired resistance more difficult, while sparing normal tissues.	[Gomez, Maria L.; Shah, Nagma; Kenny, Timothy C.; Jenkins, Edmund C., Jr.; Germain, Doris] Icahn Sch Med Mt Sinai, Dept Med, Div Hematol Oncol, Tisch Canc Inst, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Germain, D (corresponding author), Icahn Sch Med Mt Sinai, Dept Med, Div Hematol Oncol, Tisch Canc Inst, New York, NY 10029 USA.	doris.germain@mssm.edu		Jenkins, Edmund/0000-0002-6448-090X; Gomez, Maria Lucia/0000-0003-3682-9219; Kenny, Timothy Cole/0000-0001-8258-5716	NIH [R01CA172046]; NIH; P30 grant [CA196521]; NATIONAL CANCER INSTITUTE [F31CA228259, P30CA196521, R01CA172046] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); P30 grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank all members of the Germain lab and of the Mount Sinai Flow Cytometry Core, Microscopy Core and Biorepository Core Facility. This study was supported by the NIH R01CA172046 to DG and the NIH supplement to MG. The core facilities used in this study are supported by P30 grant CA196521.	Bae J, 2000, MCL 1S SPLICING VARI, DOI [10.1074/JBC.M909826199, DOI 10.1074/JBC.M909826199]; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; Elster N, 2015, BREAST CANCER RES TR, V149, P5, DOI 10.1007/s10549-014-3250-x; Finley LWS, 2011, CANCER CELL, V19, P416, DOI 10.1016/j.ccr.2011.02.014; Germain D, 2017, J BIOENERG BIOMEMBR, V49, P291, DOI 10.1007/s10863-017-9716-x; Glasauer A, 2014, J CLIN INVEST, V124, P117, DOI 10.1172/JCI71714; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hart PC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7053; He CX, 2016, TRENDS BIOCHEM SCI, V41, P568, DOI 10.1016/j.tibs.2016.04.004; Hempel N, 2011, ANTI-CANCER AGENT ME, V11, P191, DOI 10.2174/187152011795255911; Ho YS, 1998, J BIOL CHEM, V273, P7765, DOI 10.1074/jbc.273.13.7765; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Kannan N, 2014, P NATL ACAD SCI USA, V111, P7789, DOI 10.1073/pnas.1403813111; Kenny TC, 2017, ONCOGENE, V36, P4393, DOI 10.1038/onc.2017.52; Kenny TC, 2017, J BIOENERG BIOMEMBR, V49, P297, DOI 10.1007/s10863-017-9722-z; Kenny TC, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00159; Kenny TC, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00037; Li S., 2018, INT J CHEM REACT ENG, V16, P1; Li Y, 2000, ONCOGENE, V19, P1002, DOI 10.1038/sj.onc.1203273; Lombard David B, 2011, Handb Exp Pharmacol, V206, P163, DOI 10.1007/978-3-642-21631-2_8; Matzuk MM, 1998, ENDOCRINOLOGY, V139, P4008, DOI 10.1210/en.139.9.4008; Moody SE, 2002, CANCER CELL, V2, P451, DOI 10.1016/S1535-6108(02)00212-X; Moullan N, 2015, CELL REP, V10, P1681, DOI 10.1016/j.celrep.2015.02.034; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; OBERLEY LW, 1979, CANCER RES, V39, P1141; Okado-Matsumoto A, 2001, J BIOL CHEM, V276, P38388, DOI 10.1074/jbc.M105395200; Palechor-Ceron N, 2013, AM J PATHOL, V183, P1862, DOI 10.1016/j.ajpath.2013.08.009; Papa Luena, 2014, Genes Cancer, V5, P15; Papa L, 2014, J BIOL CHEM, V289, P5412, DOI 10.1074/jbc.C113.526475; Papa L, 2014, MOL CELL BIOL, V34, P699, DOI 10.1128/MCB.01337-13; Papa L, 2011, J CELL SCI, V124, P1396, DOI 10.1242/jcs.078220; Pelicano H, 2006, J CELL BIOL, V175, P913, DOI 10.1083/jcb.200512100; Reddi AR, 2013, CELL, V152, P224, DOI 10.1016/j.cell.2012.11.046; Riar AK, 2017, HUM MOL GENET, V26, P1318, DOI 10.1093/hmg/ddx049; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Sabharwal SS, 2014, NAT REV CANCER, V14, P709, DOI 10.1038/nrc3803; Sajesh BV, 2015, ONCOTARGET, V6, P27907, DOI 10.18632/oncotarget.4875; Sarkisian CJ, 2007, NAT CELL BIOL, V9, P493, DOI 10.1038/ncb1567; Schieber M, 2014, CURR BIOL, V24, pR453, DOI 10.1016/j.cub.2014.03.034; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Somwar R, 2011, P NATL ACAD SCI USA, V108, P16375, DOI 10.1073/pnas.1113554108; Somwar R, 2009, J BIOMOL SCREEN, V14, P1176, DOI 10.1177/1087057109350919; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; Tao RD, 2010, MOL CELL, V40, P893, DOI 10.1016/j.molcel.2010.12.013; Tsang CK, 2018, MOL CELL, V70, P502, DOI 10.1016/j.molcel.2018.03.029; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Wang Y, 2018, J CELL BIOL, V217, P1915, DOI 10.1083/jcb.201708007; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107	50	21	22	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	2019	38	29					5751	5765		10.1038/s41388-019-0839-x	http://dx.doi.org/10.1038/s41388-019-0839-x			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IQ4WS	31222103	Green Accepted			2022-12-28	WOS:000480752800001
J	Ippolito, L; Morandi, A; Taddei, ML; Parri, M; Comito, G; Iscaro, A; Raspollini, MR; Magherini, F; Rapizzi, E; Masquelier, J; Muccioli, GG; Sonveaux, P; Chiarugi, P; Giannoni, E				Ippolito, Luigi; Morandi, Andrea; Taddei, Maria Letizia; Parri, Matteo; Comito, Giuseppina; Iscaro, Alessandra; Raspollini, Maria Rosaria; Magherini, Francesca; Rapizzi, Elena; Masquelier, Julien; Muccioli, Giulio G.; Sonveaux, Pierre; Chiarugi, Paola; Giannoni, Elisa			Cancer-associated fibroblasts promote prostate cancer malignancy via metabolic rewiring and mitochondrial transfer	ONCOGENE			English	Article							TUMOR MICROENVIRONMENT; LACTATE METABOLISM; CELLS; PGC-1-ALPHA; MUSCLE; HOMEOSTASIS; SUPEROXIDE; ACTIVATION; SIRTUINS; KINASE	Cancer-associated fibroblasts (CAFs) are the major cellular stromal component of many solid tumors. In prostate cancer (PCa), CAFs establish a metabolic symbiosis with PCa cells, contributing to cancer aggressiveness through lactate shuttle. In this study, we report that lactate uptake alters the NAD(+)/NADH ratio in the cancer cells, which culminates with SIRT1-dependent PGC-1 alpha activation and subsequent enhancement of mitochondrial mass and activity. The high exploitation of mitochondria results in tricarboxylic acid cycle deregulation, accumulation of oncometabolites and in the altered expression of mitochondrial complexes, responsible for superoxide generation. Additionally, cancer cells hijack CAF-derived functional mitochondria through the formation of cellular bridges, a phenomenon that we observed in both in vitro and in vivo PCa models. Our work reveals a crucial function of tumor mitochondria as the energy sensors and transducers of CAF-dependent metabolic reprogramming and underscores the reliance of PCa cells on CAF catabolic activity and mitochondria trading.	[Ippolito, Luigi; Morandi, Andrea; Parri, Matteo; Comito, Giuseppina; Iscaro, Alessandra; Magherini, Francesca; Chiarugi, Paola; Giannoni, Elisa] Univ Florence, Dept Expt & Clin Biomed Sci, I-50134 Florence, Italy; [Taddei, Maria Letizia; Rapizzi, Elena] Univ Florence, Dept Expt & Clin Med, I-50134 Florence, Italy; [Raspollini, Maria Rosaria] Univ Hosp Careggi, Histopathol & Mol Diagnost, Largo Brambilla 3, I-50134 Florence, Italy; [Masquelier, Julien; Muccioli, Giulio G.] UCL, LDRI, Bioanal & Pharmacol Bioact Lipids Res Grp, B-1200 Brussels, Belgium; [Sonveaux, Pierre] UCL, IREC, Pole Pharmacol, B-1200 Brussels, Belgium; [Chiarugi, Paola] Tuscany Tumour Inst ITT, Florence, Italy; [Chiarugi, Paola] Excellence Ctr Res Transfer & High Educ DenoTHE, Florence, Italy	University of Florence; University of Florence; University of Florence; Azienda Ospedaliero Universitaria Careggi; Universite Catholique Louvain; Universite Catholique Louvain	Chiarugi, P; Giannoni, E (corresponding author), Univ Florence, Dept Expt & Clin Biomed Sci, I-50134 Florence, Italy.; Chiarugi, P (corresponding author), Tuscany Tumour Inst ITT, Florence, Italy.; Chiarugi, P (corresponding author), Excellence Ctr Res Transfer & High Educ DenoTHE, Florence, Italy.	paola.chiarugi@unifi.it; elisa.giannoni@unifi.it	Giannoni, Elisa/AAE-2092-2020; Morandi, Andrea/AAC-1901-2022; Chiarugi, Paola/CDD-7988-2022	Morandi, Andrea/0000-0002-9222-5332; Chiarugi, Paola/0000-0001-7655-2969; Muccioli, Giulio/0000-0002-1600-9259; Ippolito, Luigi/0000-0001-7927-8555	Fondazione Umberto Veronesi; Associazione Italiana Ricerca sul Cancro (AIRC) [8797]; AIRC; Fondazione Cassa di Risparmio di Firenze [19515]; Istituto Toscano Tumori [0203607]; Interuniversity Attraction Pole from Belspo [UP7-03]; Action de Recherche Concertee from the Communaute Francaise de Belgique [ARC 14/19-058]; Belgian Fonds National de la Recherche Scientifique (F.R.S. FNRS); Programma operativo regionale Obiettivo "Competitivita regionale e occupazione" della Regione Toscana cofinanziato dal Fondo europeo di sviluppo regionale 2007-2013 (POR CReO FESR 2007-2013)	Fondazione Umberto Veronesi(Fondazione Umberto Veronesi); Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); AIRC(Fondazione AIRC per la ricerca sul cancro); Fondazione Cassa di Risparmio di Firenze(Fondazione Cassa Risparmio Firenze); Istituto Toscano Tumori; Interuniversity Attraction Pole from Belspo; Action de Recherche Concertee from the Communaute Francaise de Belgique; Belgian Fonds National de la Recherche Scientifique (F.R.S. FNRS)(Fonds de la Recherche Scientifique - FNRS); Programma operativo regionale Obiettivo "Competitivita regionale e occupazione" della Regione Toscana cofinanziato dal Fondo europeo di sviluppo regionale 2007-2013 (POR CReO FESR 2007-2013)	The work was supported by Fondazione Umberto Veronesi to AM, Associazione Italiana Ricerca sul Cancro (AIRC) (grant 8797 to PC), AIRC and Fondazione Cassa di Risparmio di Firenze (grant 19515 to PC and AM), Istituto Toscano Tumori (grant 0203607 to PC), Programma operativo regionale Obiettivo "Competitivita regionale e occupazione" della Regione Toscana cofinanziato dal Fondo europeo di sviluppo regionale 2007-2013 (POR CReO FESR 2007-2013, grant to PC), Interuniversity Attraction Pole from Belspo (grant #UP7-03 to PS), an Action de Recherche Concertee from the Communaute Francaise de Belgique (ARC 14/19-058 to PS), and the Belgian Fonds National de la Recherche Scientifique (F.R.S. FNRS, to PS). The authors thank: Dr Paolo E. Porporato (University of Turin, Italy) for providing mitochondria-targeted plasmids mt-HA-eGFP, AT-F001-D and mtDsRed, AT-F002-D (Aequotech srl); Dr Andrea Rasola (University of Padua, Italy) for providing pLJM1-EGFP plasmid for lentiviral infection; Dr Barbara Stecca (Istituto Toscano Tumori, Florence, Italy) for providing pCMV-dR8.91 packaging plasmid and pMD2G envelope plasmid; Dr. Nicla Lorito and Dr. Lavinia Ferrone for technical support. PS is a F.R.S.-FNRS Senior Research Associate. The MASSMET platform (https://www.uclouvain.be/en-massmet.html) is acknowledged for the access to the HLPC-MS.	Andrzejewski S, 2017, CELL METAB, V26, P778, DOI 10.1016/j.cmet.2017.09.006; Aspuria PJP, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-21; Benton CR, 2008, PHYSIOL GENOMICS, V35, P45, DOI 10.1152/physiolgenomics.90217.2008; Brauer HA, 2013, CLIN CANCER RES, V19, P571, DOI 10.1158/1078-0432.CCR-12-2123; Caicedo A, 2015, SCI REP-UK, V5, DOI 10.1038/srep09073; Cannito S, 2010, ANTIOXID REDOX SIGN, V12, P1383, DOI 10.1089/ars.2009.2737; Chandel NS, 2015, CELL METAB, V22, P204, DOI 10.1016/j.cmet.2015.05.013; Chen EI, 2007, CANCER RES, V67, P1472, DOI 10.1158/0008-5472.CAN-06-3137; Chen YJ, 2016, NAT CHEM BIOL, V12, P937, DOI [10.1038/NCHEMBIO.2172, 10.1038/nchembio.2172]; Dikalova AE, 2010, CIRC RES, V107, P106, DOI 10.1161/CIRCRESAHA.109.214601; Dong LF, 2017, ELIFE, V6, DOI 10.7554/eLife.22187; Faubert B, 2017, CELL, V171, P358, DOI 10.1016/j.cell.2017.09.019; Fiaschi T, 2012, CANCER RES, V72, P5130, DOI 10.1158/0008-5472.CAN-12-1949; Frezza C, 2007, NAT PROTOC, V2, P287, DOI 10.1038/nprot.2006.478; Gambini J, 2011, ARCH BIOCHEM BIOPHYS, V512, P24, DOI 10.1016/j.abb.2011.04.020; Giannoni E, 2005, MOL CELL BIOL, V25, P6391, DOI 10.1128/MCB.25.15.6391-6403.2005; Giannoni E, 2009, ONCOGENE, V28, P2074, DOI 10.1038/onc.2009.77; Giannoni E, 2015, ONCOTARGET, V6, P24061, DOI 10.18632/oncotarget.4448; Giannoni E, 2011, ANTIOXID REDOX SIGN, V14, P2361, DOI 10.1089/ars.2010.3727; Giannoni E, 2010, CANCER RES, V70, P6945, DOI 10.1158/0008-5472.CAN-10-0785; Guarente L, 2013, GENE DEV, V27, P2072, DOI 10.1101/gad.227439.113; Houtkooper RH, 2012, NAT REV MOL CELL BIO, V13, P225, DOI 10.1038/nrm3293; Ippolito L, 2016, ONCOTARGET, V7, P61890, DOI 10.18632/oncotarget.11301; Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906; Kong XX, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011707; Le Gal K, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad3740; LeBleu VS, 2014, NAT CELL BIOL, V16, P992, DOI 10.1038/ncb3039; Lou E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033093; MacKenzie ED, 2007, MOL CELL BIOL, V27, P3282, DOI 10.1128/MCB.01927-06; Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P3515, DOI 10.4161/cc.9.17.12928; Morandi A, 2016, TRENDS CANCER, V2, P736, DOI 10.1016/j.trecan.2016.11.001; Nazarewicz RR, 2013, ANTIOXID REDOX SIGN, V19, P344, DOI 10.1089/ars.2013.5185; Nemoto S, 2005, J BIOL CHEM, V280, P16456, DOI 10.1074/jbc.M501485200; Pasquier J, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-94; Pavlides S, 2009, CELL CYCLE, V8, P3984, DOI 10.4161/cc.8.23.10238; Pittelli M, 2011, MOL PHARMACOL, V80, P1136, DOI 10.1124/mol.111.073916; Porporato PE, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723548.2014.968043; Porporato PE, 2014, CELL REP, V8, P754, DOI 10.1016/j.celrep.2014.06.043; Rabinovitch RC, 2017, CELL REP, V21, P1, DOI 10.1016/j.celrep.2017.09.026; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Rogers RS, 2013, PHYSIOLOGY, V28, P414, DOI 10.1152/physiol.00032.2013; Rustom A, 2004, SCIENCE, V303, P1007, DOI 10.1126/science.1093133; Salem AF, 2012, CELL CYCLE, V11, P2545, DOI 10.4161/cc.20920; Santi A, 2015, BBA-MOL CELL RES, V1853, P3211, DOI 10.1016/j.bbamcr.2015.09.013; Sciacovelli M, 2016, NATURE, V537, P544, DOI 10.1038/nature19353; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Spees JL, 2006, P NATL ACAD SCI USA, V103, P1283, DOI 10.1073/pnas.0510511103; Summermatter S, 2013, P NATL ACAD SCI USA, V110, P8738, DOI 10.1073/pnas.1212976110; Tan AS, 2015, CELL METAB, V21, P81, DOI 10.1016/j.cmet.2014.12.003; Torrano V, 2016, NAT CELL BIOL, V18, P645, DOI 10.1038/ncb3357; Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Weinberg F, 2009, ANN NY ACAD SCI, V1177, P66, DOI 10.1111/j.1749-6632.2009.05039.x	53	97	99	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2019	38	27					5339	5355		10.1038/s41388-019-0805-7	http://dx.doi.org/10.1038/s41388-019-0805-7			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IG5KR	30936458	Green Submitted			2022-12-28	WOS:000473842500001
J	Azam, SH; Porrello, A; Harrison, EB; Leslie, PL; Liu, XA; Waugh, TA; Belanger, A; Mangala, LS; Lopez-Berestein, G; Wilson, HL; McCann, JV; Kim, WY; Sood, AK; Liu, JZ; Dudley, AC; Pecot, CV				Azam, Salma H.; Porrello, Alessandro; Harrison, Emily B.; Leslie, Patrick L.; Liu, Xinan; Waugh, Trent A.; Belanger, Adam; Mangala, Lingegowda S.; Lopez-Berestein, Gabriel; Wilson, Harper L.; McCann, James V.; Kim, William Y.; Sood, Anil K.; Liu, Jinze; Dudley, Andrew C.; Pecot, Chad V.			Quaking orchestrates a post-transcriptional regulatory network of endothelial cell cycle progression critical to angiogenesis and metastasis	ONCOGENE			English	Article							MIR-200 FAMILY; MESSENGER-RNA; ANTIANGIOGENIC THERAPY; TUMOR ANGIOGENESIS; CANCER-CELLS; GROWTH; DIFFERENTIATION; PROTEINS; PROMOTES; ZEB1	Angiogenesis is critical to cancer development and metastasis. However, anti-angiogenic agents have only had modest therapeutic success, partly due to an incomplete understanding of tumor endothelial cell (EC) biology. We previously reported that the microRNA (miR)-200 family inhibits metastasis through regulation of tumor angiogenesis, but the underlying molecular mechanisms are poorly characterized. Here, using integrated bioinformatics approaches, we identified the RNA-binding protein (RBP) quaking (QKI) as a leading miR-200b endothelial target with previously unappreciated roles in the tumor microenvironment in lung cancer. In lung cancer samples, both miR-200b suppression and QKI overexpression corresponded with tumor ECs relative to normal ECs, and QKI silencing phenocopied miR-200b-mediated inhibition of sprouting. Additionally, both cancer cell and endothelial QKI expression in patient samples significantly corresponded with poor survival and correlated with angiogenic indices. QKI supported EC function by stabilizing cyclin D1 (CCND1) mRNA to promote EC Gl/S cell cycle transition and proliferation. Both nanoparticle-mediated RNA interference of endothelial QKI expression and palbociclib blockade of CCND1 function potently inhibited metastasis in concert with significant effects on tumor vasculature. Altogether, this work demonstrates the clinical relevance and therapeutic potential of a novel, actionable miR/RBP axis in tumor angiogenesis and metastasis.	[Azam, Salma H.] Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; [Porrello, Alessandro; Leslie, Patrick L.; Waugh, Trent A.; Belanger, Adam; Wilson, Harper L.; Kim, William Y.; Pecot, Chad V.] Univ N Carolina, UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Harrison, Emily B.] Univ N Carolina, Eshelman Sch Pharm, Ctr Nanotechnol Drug Delivery, Chapel Hill, NC 27599 USA; [Liu, Xinan; Liu, Jinze] Univ Kentucky, Dept Comp Sci, Lexington, KY 40506 USA; [Belanger, Adam] Univ N Carolina, Div Pulm & Crit Care, Chapel Hill, NC 27599 USA; [Mangala, Lingegowda S.; Sood, Anil K.] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA; [Mangala, Lingegowda S.; Lopez-Berestein, Gabriel; Sood, Anil K.] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNA, Houston, TX 77030 USA; [Lopez-Berestein, Gabriel] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [McCann, James V.] Univ N Carolina, Dept Cell Biol & Physiol, Chapel Hill, NC 27599 USA; [Kim, William Y.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA; [Kim, William Y.; Pecot, Chad V.] Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; [Sood, Anil K.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; [Dudley, Andrew C.] Univ Virginia, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA 22908 USA; [Dudley, Andrew C.] Univ Virginia, Emily Couric Canc Ctr, Charlottesville, VA 22908 USA; [Pecot, Chad V.] Univ N Carolina, Div Hematol & Oncol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Kentucky; University of North Carolina; University of North Carolina Chapel Hill; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Texas System; UTMD Anderson Cancer Center; University of Virginia; University of Virginia; University of North Carolina; University of North Carolina Chapel Hill	Pecot, CV (corresponding author), Univ N Carolina, UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.; Pecot, CV (corresponding author), Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA.; Pecot, CV (corresponding author), Univ N Carolina, Div Hematol & Oncol, Chapel Hill, NC 27599 USA.	pecot@email.unc.edu	Sood, Anoop Kumar/A-7344-2013; , UNC Flow Cytometry Core/AGU-9839-2022; , Animal Studies Core/ADK-4234-2022; , Animal Studies Core/AAF-4432-2022; Harrison, Emily B./AAW-1826-2021; , Pathology Services Core/CEZ-2246-2022	Sood, Anoop Kumar/0000-0001-5702-4108; Harrison, Emily B./0000-0002-6934-3875; Wilson, Harper/0000-0002-6093-4767	National Institutes of Health [R01-CA215075, R01-CA042978, U54-CA198999, MRSG-14-222-01-RMC]; American Cancer Society; Jimmy V Foundation Scholar award; UCRF Innovator Award; Stuart Scott V Foundation/Lung Cancer Initiative Award for Clinical Research; University Cancer Research Fund; Lung Cancer Research Foundation; Free to Breathe Metastasis Research Award; Susan G. Komen Career Catalyst Award; National Institute of General Medical Sciences [5T32 GM007092]; National Cancer Institute of the National Institutes of Health [T32CA196589]; American Cancer Society Research Professor Award; National Cancer Institute [P50 CA217685, R35 CA209904]; National Cancer Institute Center Core Support Grant [CA016086]; North Carolina Biotech Center Institutional Support Grant [2012-IDG-1006]; NATIONAL CANCER INSTITUTE [P50CA217685, R01CA042978, P30CA016086, R35CA209904, U54CA198999, T32CA196589, R01CA215075] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007092] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Jimmy V Foundation Scholar award; UCRF Innovator Award; Stuart Scott V Foundation/Lung Cancer Initiative Award for Clinical Research; University Cancer Research Fund; Lung Cancer Research Foundation; Free to Breathe Metastasis Research Award; Susan G. Komen Career Catalyst Award(Susan G. Komen Breast Cancer Foundation); National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society Research Professor Award(American Cancer Society); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Cancer Institute Center Core Support Grant; North Carolina Biotech Center Institutional Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors would like to especially thank members of the Victoria Bautch laboratory for their advice on performing the endothelial sprouting assay, the UNC Animal Histopathology Core, the UNC Biomedical Research Imaging Center, Janet Dow from the UNC Flow Cytometry Core Facility, and the Tissue Pathology Lab Core. The authors would also like to thank Adolfo Alfonso for providing the ZsGreen fluorescent labeled 10T1/2 (pericyte) cells used in the pericyte-coated sprouting assay. C.V.P. was supported in part by the National Institutes of Health R01-CA215075, R01-CA042978 and U54-CA198999, a Mentored Research Scholar Grants in Applied and Clinical Research (MRSG-14-222-01-RMC) from the American Cancer Society, the Jimmy V Foundation Scholar award, the UCRF Innovator Award, the Stuart Scott V Foundation/Lung Cancer Initiative Award for Clinical Research, the University Cancer Research Fund, the Lung Cancer Research Foundation, the Free to Breathe Metastasis Research Award and the Susan G. Komen Career Catalyst Award. S.H.A. was supported in part by a grant from the National Institute of General Medical Sciences under award 5T32 GM007092. E.B.H. was supported in part by a grant from the National Cancer Institute of the National Institutes of Health under award number T32CA196589. AKS was supported in part by The American Cancer Society Research Professor Award and grants from the National Cancer Institute (P50 CA217685 and R35 CA209904). The UNC Flow Cytometry Core Facility and Lineberger Comprehensive Cancer Center Animal Histopathology and Animal Studies Cores are all supported in part by a National Cancer Institute Center Core Support Grant (CA016086) to the UNC Lineberger Comprehensive Cancer Center. The UNC Flow Cytometry Core Facility is also supported in part by the North Carolina Biotech Center Institutional Support Grant 2012-IDG-1006.	Akerman M, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r30; Azam SH, 2018, JOVE-J VIS EXP, DOI 10.3791/57309; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Bohnsack BL, 2006, GENESIS, V44, P93, DOI 10.1002/gene.20189; Bottsford-Miller JN, 2012, J CLIN ONCOL, V30, P4026, DOI 10.1200/JCO.2012.41.9242; Carmeliet P, 2011, NAT REV DRUG DISCOV, V10, P417, DOI 10.1038/nrd3455; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chan YC, 2012, ARTERIOSCL THROM VAS, V32, P1372, DOI 10.1161/ATVBAHA.112.248583; Chan YC, 2011, J BIOL CHEM, V286, P2047, DOI 10.1074/jbc.M110.158790; Chen AJ, 2012, GENE DEV, V26, P1459, DOI 10.1101/gad.189001.112; Cochrane A, 2017, STEM CELLS, V35, P952, DOI 10.1002/stem.2594; Conn SJ, 2015, CELL, V160, P1125, DOI 10.1016/j.cell.2015.02.014; de Bruin RG, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10846; de Bruin RG, 2016, SCI REP-UK, V6, DOI 10.1038/srep21643; Ding YZ, 2017, LIFE SCI, V191, P245, DOI 10.1016/j.lfs.2017.09.001; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Fry DW, 2004, MOL CANCER THER, V3, P1427; Gibbons DL, 2009, GENE DEV, V23, P2140, DOI 10.1101/gad.1820209; Gill JG, 2012, STEM CELLS DEV, V21, P167, DOI 10.1089/scd.2011.0194; Goel S, 2013, JNCI-J NATL CANCER I, V105, P1188, DOI 10.1093/jnci/djt164; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; GRIFFIN MJ, 1976, IN VITRO CELL DEV B, V12, P393, DOI 10.1007/BF02796317; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hardy RJ, 1996, J NEUROSCI, V16, P7941; Harrison EB, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00307; Hlatky L, 2002, JNCI-J NATL CANCER I, V94, P883; Jain RK, 2014, CANCER CELL, V26, P605, DOI 10.1016/j.ccell.2014.10.006; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Kondo T, 1999, MAMM GENOME, V10, P662; Lamprecht MR, 2007, BIOTECHNIQUES, V42, P71, DOI 10.2144/000112257; Landen CN, 2005, CANCER RES, V65, P6910, DOI 10.1158/0008-5472.CAN-05-0530; Larocque D, 2005, NAT NEUROSCI, V8, P27, DOI 10.1038/nn1359; Larocque D, 2002, NEURON, V36, P815, DOI 10.1016/S0896-6273(02)01055-3; Li ZH, 2003, DEV GROWTH DIFFER, V45, P449; Li ZZ, 2000, J NEUROSCI, V20, P4944; Lu CH, 2010, CANCER CELL, V18, P185, DOI 10.1016/j.ccr.2010.06.016; Magenta A, 2011, CELL DEATH DIFFER, V18, P1628, DOI 10.1038/cdd.2011.42; Nakatsu Martin N, 2007, J Vis Exp, P186, DOI 10.3791/186; Noguera-Troise I, 2006, NATURE, V444, P1032, DOI 10.1038/nature05355; Noveroske JK, 2002, GENESIS, V32, P218, DOI 10.1002/gene.10060; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Pecot CV, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3427; Pillman KA, 2018, EMBO J, V37, DOI 10.15252/embj.201899016; Saccomanno L, 1999, P NATL ACAD SCI USA, V96, P12605, DOI 10.1073/pnas.96.22.12605; Santo L, 2015, SEMIN ONCOL, V42, P788, DOI 10.1053/j.seminoncol.2015.09.024; Teplova M, 2013, GENE DEV, V27, P928, DOI 10.1101/gad.216531.113; van Mil A, 2012, CARDIOVASC RES, V93, P655, DOI 10.1093/cvr/cvs003; Vasudev NS, 2014, ANGIOGENESIS, V17, P471, DOI 10.1007/s10456-014-9420-y; Welch-Reardon KM, 2015, ARTERIOSCL THROM VAS, V35, P303, DOI 10.1161/ATVBAHA.114.303220; Winkler F, 2004, CANCER CELL, V6, P553, DOI 10.1016/j.ccr.2004.10.011; Wong PP, 2016, CURR BIOL, V26, pR1161, DOI 10.1016/j.cub.2016.09.043; Wong PP, 2015, CANCER CELL, V27, P123, DOI 10.1016/j.ccell.2014.10.015; Wu J, 1999, J BIOL CHEM, V274, P29202, DOI 10.1074/jbc.274.41.29202; Wu JI, 2002, P NATL ACAD SCI USA, V99, P4233, DOI 10.1073/pnas.072090399; Zearfoss NR, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001269; Zhang YY, 2003, EMBO J, V22, P1801, DOI 10.1093/emboj/cdg171; Zhou X, 2017, ONCOTARGET, V8, P82174, DOI 10.18632/oncotarget.19066; Zong FY, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004289	60	12	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2019	38	26					5191	5210		10.1038/s41388-019-0786-6	http://dx.doi.org/10.1038/s41388-019-0786-6			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IF4AX	30918328	Green Accepted			2022-12-28	WOS:000473025300006
J	Maric, G; Annis, MG; MacDonald, PA; Russo, C; Perkins, D; Siwak, DR; Mills, GB; Siegel, PM				Maric, Gordana; Annis, Matthew G.; MacDonald, Patricia A.; Russo, Caterina; Perkins, Dru; Siwak, Doris R.; Mills, Gordon B.; Siegel, Peter M.			GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and beta-catenin activity	ONCOGENE			English	Article							GLYCOPROTEIN NONMETASTATIC B; WNT/BETA-CATENIN; TRANSGENIC MICE; MAMMARY-TUMORS; BASAL-LIKE; GLEMBATUMUMAB VEDOTIN; THERAPEUTIC TARGET; CANCER; EXPRESSION; PROMOTES	Glycoprotein Nmb (GPNMB) is overexpressed in triple-negative and basal-like breast cancers and its expression is predictive of poor prognosis within this aggressive breast cancer subtype. GPNMB promotes breast cancer growth, invasion, and metastasis; however, its role in mammary tumor initiation remains unknown. To address this question, we overexpressed GPNMB in the mammary epithelium to generate MMTV/GPNMB transgenic mice and crossed these animals to the MMTV/Wnt-1 mouse model, which is known to recapitulate features of human basal breast cancers. We show that GPNMB alone does not display oncogenic properties; however, its expression dramatically accelerates tumor onset in MMTV/Wnt-1 mice. MMTV/Wnt-1 x MMTV/GPNMB bigenic mice also exhibit a significant increase in the growth rate of established primary tumors, which is attributable to increased proliferation and decreased apoptosis. To elucidate molecular mechanisms underpinning the tumor-promoting effects of GPNMB in this context, we interrogated activated pathways in tumors derived from the MMTV/Wnt-1 and MMTV/Wnt-1 x MMTV/GPNMB mice using RPPA analysis. These data revealed that MMTV/Wnt-1 x MMTV/GPNMB bigenic tumors exhibit a pro-growth signature characterized by elevated PI3K/AKT/mTOR signaling and increased beta-catenin activity. Furthermore, we extended these observations to an independent Wnt-1 expressing model of aggressive breast cancer, and confirmed that GPNMB enhances canonical Wnt pathway activation, as evidenced by increased beta-catenin transcriptional activity, in breast cancer cells and tumors co-expressing Wnt-1 and GPNMB. GPNMB-dependent engagement of beta-catenin occurred, in part, through AKT activation. Taken together, these data ascribe a novel, pro-growth role for GPNMB in Wnt-1 expressing basal breast cancers.	[Maric, Gordana; Annis, Matthew G.; MacDonald, Patricia A.; Russo, Caterina; Perkins, Dru; Siegel, Peter M.] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ, Canada; [Maric, Gordana; Annis, Matthew G.; MacDonald, Patricia A.; Russo, Caterina; Siegel, Peter M.] McGill Univ, Dept Med, Montreal, PQ, Canada; [Siwak, Doris R.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Mills, Gordon B.] Oregon Hlth & Sci Univ, Knight Canc Inst, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA; [Siegel, Peter M.] McGill Univ, Dept Biochem, Montreal, PQ, Canada	McGill University; McGill University; University of Texas System; UTMD Anderson Cancer Center; Oregon Health & Science University; McGill University	Siegel, PM (corresponding author), McGill Univ, Goodman Canc Res Ctr, Montreal, PQ, Canada.; Siegel, PM (corresponding author), McGill Univ, Dept Med, Montreal, PQ, Canada.; Siegel, PM (corresponding author), McGill Univ, Dept Biochem, Montreal, PQ, Canada.	peter.siegel@mcgill.ca		Annis, Matthew/0000-0002-8776-004X; Mills, Gordon/0000-0002-0144-9614	Canadian Institutes for Health Research (CIHR); CIHR [MOP-119401, PJT-153327]	Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); CIHR(Canadian Institutes of Health Research (CIHR))	We acknowledge the Goodman Cancer Research Centre (GCRC) transgenic facility (McGill University) for generation of the MMTV/GPNMB mice, the GCRC histology core facility (McGill University) for routine histological services and Zhifeng Dong for some Immunohistochemical staining. We thank members of the Siegel laboratory for thoughtful discussions and critical reading of the manuscript. GM acknowledges studentship support from the Canadian Institutes for Health Research (CIHR). PMS is currently a McGill University William Dawson Scholar. This research was supported solely by grants from the CIHR (MOP-119401; PJT-153327).	Bankfalvi A, 2004, MODERN PATHOL, V17, P1051, DOI 10.1038/modpathol.3800082; Bao G, 2016, EXP BIOL MED, V241, P1968, DOI 10.1177/1535370216654224; Bianchini G, 2016, NAT REV CLIN ONCOL, V13, P674, DOI 10.1038/nrclinonc.2016.66; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Bocker W, 2002, LAB INVEST, V82, P737, DOI 10.1097/01.LAB.0000017371.72714.C5; Cadigan KM, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007906; Chen C, 2018, CANCER RES, V78, P6424, DOI 10.1158/0008-5472.CAN-18-0599; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Davies BR, 2012, MOL CANCER THER, V11, P873, DOI 10.1158/1535-7163.MCT-11-0824-T; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Failor KL, 2007, MOL ENDOCRINOL, V21, P2403, DOI 10.1210/me.2007-0143; Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Howe LR, 2004, CANCER BIOL THER, V3, P36, DOI 10.4161/cbt.3.1.561; Hu TH, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-236; Huang S, 2005, GENOME BIOL, V6, P1; Huang SX, 2008, NEOPLASIA, V10, P118, DOI 10.1593/neo.07637; Iadevaia S, 2010, CANCER RES, V70, P6704, DOI 10.1158/0008-5472.CAN-10-0460; Jin R, 2018, ONCOL REP, V39, P3034, DOI 10.3892/or.2018.6346; Kanematsu M, 2015, CANCER MED-US, V4, P1344, DOI 10.1002/cam4.480; Kapoun AM, 1997, ONCOGENE, V14, P2985, DOI 10.1038/sj.onc.1201146; Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Korkaya H, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000121; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; Li SG, 2014, TUMOR BIOL, V35, P7693, DOI 10.1007/s13277-014-1975-0; Li Y, 2000, ONCOGENE, V19, P1002, DOI 10.1038/sj.onc.1203273; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Li Y, 2001, BMC Mol Biol, V2, P2, DOI 10.1186/1471-2199-2-2; Lim E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2560; Lin AF, 2016, NAT CELL BIOL, V18, P213, DOI 10.1038/ncb3295; Lin J, 2013, CLIN CANCER RES, V19, P1760, DOI 10.1158/1078-0432.CCR-12-3072; Lopez-Knowles E, 2010, INT J CANCER, V126, P1121, DOI 10.1002/ijc.24831; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Maric G, 2015, ONCOGENE, V34, P5494, DOI 10.1038/onc.2015.8; Maric G, 2013, ONCOTARGETS THER, V6, P839, DOI 10.2147/OTT.S44906; Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261; Maubant S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122333; Mulholland DJ, 2006, ONCOGENE, V25, P329, DOI 10.1038/sj.onc.1209020; Musgrove EA, 2004, BREAST CANCER RES, V6, P65, DOI 10.1186/bcr737; Nagahara Y, 2017, J NEUROSCI RES, V95, P1647, DOI 10.1002/jnr.23999; Nieto AI, 2003, COMPARATIVE MED, V53, P433; Northey JJ, 2008, MOL CELL BIOL, V28, P3162, DOI 10.1128/MCB.01734-07; Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016; Okita Y, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aak9397; Ono Y, 2016, BIOCHEM BIOPH RES CO, V481, P7, DOI 10.1016/j.bbrc.2016.11.034; Perry JM, 2011, GENE DEV, V25, P1928, DOI 10.1101/gad.17421911; Pfefferle AD, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-11-r125; Podsypanina K, 2004, BMC MED, V2, DOI 10.1186/1741-7015-2-24; Prat A, 2013, ONCOLOGIST, V18, P123, DOI 10.1634/theoncologist.2012-0397; Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Robles AI, 2008, CHEM-BIOL INTERACT, V171, P159, DOI 10.1016/j.cbi.2007.01.014; Rose AAN, 2007, MOL CANCER RES, V5, P1001, DOI 10.1158/1541-7786.MCR-07-0119; Rose AAN, 2017, PHARMACOL THERAPEUT, V179, P127, DOI 10.1016/j.pharmthera.2017.05.010; Rose AAN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012093; Rose AAN, 2010, CLIN CANCER RES, V16, P2147, DOI 10.1158/1078-0432.CCR-09-1611; Schroeder JA, 2000, ONCOGENE, V19, P3193, DOI 10.1038/sj.onc.1203652; Schroeder JA, 2002, J BIOL CHEM, V277, P22692, DOI 10.1074/jbc.M201975200; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; Sharma P, 2016, ONCOLOGIST, V21, P1050, DOI 10.1634/theoncologist.2016-0067; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Taelman VF, 2010, CELL, V143, P1136, DOI 10.1016/j.cell.2010.11.034; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Vargo-Gogola T, 2007, NAT REV CANCER, V7, P659, DOI 10.1038/nrc2193; Wakefield LM, 2003, COMPARATIVE MED, V53, P424; Watanabe K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092317; Xu JH, 2016, MOL CARCINOGEN, V55, P431, DOI 10.1002/mc.22292; Yardley DA, 2015, J CLIN ONCOL, V33, P1609, DOI 10.1200/JCO.2014.56.2959; Yu B, 2016, J CELL BIOCHEM, V117, P1511, DOI 10.1002/jcb.25394; Yuan HD, 1999, J BIOL CHEM, V274, P30419, DOI 10.1074/jbc.274.43.30419; Zhang YX, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317699119	75	16	16	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2019	38	26					5294	5307		10.1038/s41388-019-0793-7	http://dx.doi.org/10.1038/s41388-019-0793-7			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IF4AX	30914799				2022-12-28	WOS:000473025300013
J	Comito, G; Iscaro, A; Bacci, M; Morandi, A; Ippolito, L; Parri, M; Montagnani, I; Raspollini, MR; Serni, S; Simeoni, L; Giannoni, E; Chiarugi, P				Comito, G.; Iscaro, A.; Bacci, M.; Morandi, A.; Ippolito, L.; Parri, M.; Montagnani, I.; Raspollini, M. R.; Serni, S.; Simeoni, L.; Giannoni, E.; Chiarugi, P.			Lactate modulates CD4(+) T-cell polarization and induces an immunosuppressive environment, which sustains prostate carcinoma progression via TLR8/miR21 axis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CANCER-ASSOCIATED FIBROBLASTS; FACTOR-KAPPA-B; LACTIC-ACID; TGF-BETA; TUMOR; METABOLISM; ACTIVATION; EXPRESSION; GLUTAMINE	Leukocyte infiltration plays an active role in controlling tumor development. In the early stages of carcinogenesis, T cells counteract tumor growth. However, in advanced stages, cancer cells and infiltrating stromal components interfere with the immune control and instruct immune cells to support, rather than counteract, tumor malignancy, via cell-cell contact or soluble mediators. In particular, metabolites are emerging as active players in driving immunosuppression. Here we demonstrate that in a prostate cancer model lactate released by glycolytic cancer-associated fibroblasts (CAFs) acts on CD4(+) T cells, shaping T-cell polarization. In particular, CAFs exposure (i) reduces the percentage of the antitumoral Th1 subset, inducing a lactate-dependent, SIRT1-mediated deacetylation/degradation of T-bet transcription factor; (ii) increases T-reg cells, driving naive T cells polarization, through a lactate-based NF-kB activation and FoxP3 expression. In turn, this metabolic-based CAF-immunomodulated environment exerts a pro-invasive effect on prostate cancer cells, by activating a previously unexplored miR21/TLR8 axis that sustains cancer malignancy.	[Comito, G.; Bacci, M.; Morandi, A.; Ippolito, L.; Parri, M.; Giannoni, E.; Chiarugi, P.] Univ Florence, Dept Expt & Clin Biomed Sci, I-50134 Florence, Italy; [Iscaro, A.] Univ Sheffield, Med Sch, Dept Oncol & Metab, Beech Hill Rd, Sheffield, S Yorkshire, England; [Montagnani, I.; Raspollini, M. R.] Univ Hosp Careggi, Histopathol & Mol Diagnost, Largo Brambilla 3, I-50134 Florence, Italy; [Serni, S.] Univ Florence, Careggi Hosp, Dept Urol Robot Surg & Renal Transplantat, I-50134 Florence, Italy; [Simeoni, L.] Otto Von Guericke Univ, Inst Mol & Clin Immunol, Leipziger Str 44, D-39120 Magdeburg, Germany; [Chiarugi, P.] Tuscany Tumor Inst ITT, I-50134 Florence, Italy; [Chiarugi, P.] Excellence Ctr Res Transfer & High Educ DenoTHE, I-50134 Florence, Italy	University of Florence; University of Sheffield; University of Florence; Azienda Ospedaliero Universitaria Careggi; University of Florence; Azienda Ospedaliero Universitaria Careggi; Otto von Guericke University; ISPRO Istituto per lo studio, la prevenzione e la rete oncologica	Giannoni, E (corresponding author), Univ Florence, Dept Expt & Clin Biomed Sci, I-50134 Florence, Italy.	elisa.giannoni@unifi.it	Chiarugi, Paola/CDD-7988-2022; Bacci, Marina/AFN-8715-2022; Giannoni, Elisa/AAE-2092-2020; Morandi, Andrea/AAC-1901-2022	Morandi, Andrea/0000-0002-9222-5332; Ippolito, Luigi/0000-0001-7927-8555; Chiarugi, Paola/0000-0001-7655-2969	Fondazione Umberto Veronesi; Associazione Italiana Ricerca sul Cancro (AIRC) [8797]; AIRC; Fondazione Cassa di Risparmio di Firenze [19515]; Istituto Toscano Tumori [0203607]; Programma operativo regionale Obiettivo "Competitivita regionale e occupazione" della Regione Toscana cofinanziato dal Fondo europeo di sviluppo regionale 2007-2013 (POR CReO FESR 2007-2013)	Fondazione Umberto Veronesi(Fondazione Umberto Veronesi); Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); AIRC(Fondazione AIRC per la ricerca sul cancro); Fondazione Cassa di Risparmio di Firenze(Fondazione Cassa Risparmio Firenze); Istituto Toscano Tumori; Programma operativo regionale Obiettivo "Competitivita regionale e occupazione" della Regione Toscana cofinanziato dal Fondo europeo di sviluppo regionale 2007-2013 (POR CReO FESR 2007-2013)	The work was supported by Fondazione Umberto Veronesi to GC and AM, Associazione Italiana Ricerca sul Cancro (AIRC) (grant 8797 to PC), AIRC and Fondazione Cassa di Risparmio di Firenze (grant 19515 to PC and AM), Istituto Toscano Tumori (grant 0203607 to PC), Programma operativo regionale Obiettivo "Competitivita regionale e occupazione" della Regione Toscana cofinanziato dal Fondo europeo di sviluppo regionale 2007-2013 (POR CReO FESR 2007-2013, grant to PC). The authors thank Dr. Lavinia Ferrone for technical support.	Alsaab HO, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00561; Anari F, 2018, FUTURE ONCOL, V14, P1409, DOI 10.2217/fon-2017-0585; Angelin A, 2017, CELL METAB, V25, P1282, DOI 10.1016/j.cmet.2016.12.018; Biswas SK, 2015, IMMUNITY, V43, P435, DOI 10.1016/j.immuni.2015.09.001; Brand A, 2016, CELL METAB, V24, P657, DOI 10.1016/j.cmet.2016.08.011; Buck MD, 2017, CELL, V169, P570, DOI 10.1016/j.cell.2017.04.004; Calcinotto A, 2012, CANCER RES, V72, P2746, DOI 10.1158/0008-5472.CAN-11-1272; Carr EL, 2010, J IMMUNOL, V185, P1037, DOI 10.4049/jimmunol.0903586; Chang CH, 2015, CELL, V162, P1229, DOI 10.1016/j.cell.2015.08.016; Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490; Costa A, 2018, CANCER CELL, V33, P463, DOI 10.1016/j.ccell.2018.01.011; Eidelman E, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00131; Fabbri M, 2012, P NATL ACAD SCI USA, V109, pE2110, DOI 10.1073/pnas.1209414109; Fang DF, 2017, J EXP MED, V214, P1861, DOI 10.1084/jem.20170494; Fiaschi Tania, 2012, Int J Cell Biol, V2012, P762825, DOI 10.1155/2012/762825; Fiaschi T, 2012, CANCER RES, V72, P5130, DOI 10.1158/0008-5472.CAN-12-1949; Fischer K, 2007, BLOOD, V109, P3812, DOI 10.1182/blood-2006-07-035972; Flammiger A, 2013, EUR J CANCER, V49, P1273, DOI 10.1016/j.ejca.2012.11.035; Gambini J, 2011, ARCH BIOCHEM BIOPHYS, V512, P24, DOI 10.1016/j.abb.2011.04.020; Geltink RIK, 2018, ANNU REV IMMUNOL, V36, P461, DOI 10.1146/annurev-immunol-042617-053019; Giannoni E, 2015, ONCOTARGET, V6, P24061, DOI 10.18632/oncotarget.4448; Giannoni E, 2011, ANTIOXID REDOX SIGN, V14, P2361, DOI 10.1089/ars.2010.3727; Giannoni E, 2010, CANCER RES, V70, P6945, DOI 10.1158/0008-5472.CAN-10-0785; Gottfried E, 2006, BLOOD, V107, P2013, DOI 10.1182/blood-2005-05-1795; Guarente L, 2013, GENE DEV, V27, P2072, DOI 10.1101/gad.227439.113; Ha Tai-You, 2009, Immune Netw, V9, P209, DOI 10.4110/in.2009.9.6.209; Haas R, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002202; Hatley ME, 2010, CANCER CELL, V18, P282, DOI 10.1016/j.ccr.2010.08.013; Hensley CT, 2013, J CLIN INVEST, V123, P3678, DOI 10.1172/JCI69600; Houtkooper RH, 2012, NAT REV MOL CELL BIO, V13, P225, DOI 10.1038/nrm3293; Huber V, 2017, SEMIN CANCER BIOL, V43, P74, DOI 10.1016/j.semcancer.2017.03.001; Hude I, 2017, HAEMATOLOGICA, V102, P30, DOI 10.3324/haematol.2016.150656; Husain Z, 2013, J IMMUNOL, V191, P1486, DOI 10.4049/jimmunol.1202702; Johnston CJC, 2016, CELL IMMUNOL, V299, P14, DOI 10.1016/j.cellimm.2015.10.006; Krichevsky AM, 2009, J CELL MOL MED, V13, px, DOI 10.1111/j.1582-4934.2008.00556.x; Levine BL, 1997, J IMMUNOL, V159, P5921; Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001; Lim S, 2017, CANCER RES, V77, P1245, DOI 10.1158/0008-5472.CAN-16-1647; Long MX, 2009, IMMUNITY, V31, P921, DOI 10.1016/j.immuni.2009.09.022; Ludin A, 2017, NATURE, V552, P41, DOI 10.1038/nature24759; Lyssiotis CA, 2017, TRENDS CELL BIOL, V27, P873, DOI 10.1016/j.tcb.2017.06.003; Macintyre AN, 2014, CELL METAB, V20, P61, DOI 10.1016/j.cmet.2014.05.004; MacIver NJ, 2013, ANNU REV IMMUNOL, V31, P259, DOI 10.1146/annurev-immunol-032712-095956; Mendler AN, 2012, INT J CANCER, V131, P633, DOI 10.1002/ijc.26410; Metzler B, 2016, J IMMUNOL, V196, P3618, DOI 10.4049/jimmunol.1501756; Michalek RD, 2011, J IMMUNOL, V186, P3299, DOI 10.4049/jimmunol.1003613; Mishra R, 2018, J CLIN INVEST, V128, P4472, DOI 10.1172/JCI99397; Montanari M, 2017, ONCOTARGET, V8, P35376, DOI 10.18632/oncotarget.15686; Morrot A, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00081; Murray CM, 2005, NAT CHEM BIOL, V1, P371, DOI 10.1038/nchembio744; Neuzillet C, 2015, PHARMACOL THERAPEUT, V147, P22, DOI 10.1016/j.pharmthera.2014.11.001; Pavlides S, 2009, CELL CYCLE, V8, P3984, DOI 10.4161/cc.8.23.10238; Pearce EL, 2010, CURR OPIN IMMUNOL, V22, P314, DOI 10.1016/j.coi.2010.01.018; Pfeffer SR, 2015, DRUG DEVELOP RES, V76, P270, DOI 10.1002/ddr.21257; Polet F, 2013, J INTERN MED, V273, P156, DOI 10.1111/joim.12016; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Renner K, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00248; Romero-Garcia S, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00052; Ruan QG, 2012, ADV EXP MED BIOL, V946, P207, DOI 10.1007/978-1-4614-0106-3_12; Saada A, 2014, INT J BIOCHEM CELL B, V48, P60, DOI 10.1016/j.biocel.2013.12.010; Shime H, 2008, J IMMUNOL, V180, P7175, DOI 10.4049/jimmunol.180.11.7175; Siska PJ, 2015, TRENDS IMMUNOL, V36, P257, DOI 10.1016/j.it.2015.02.007; Sonveaux P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033418; Sotgia F, 2012, CELL CYCLE, V11, P1445, DOI 10.4161/cc.19841; Su SC, 2017, CELL RES, V27, P461, DOI 10.1038/cr.2017.34; Sugiura A, 2018, J IMMUNOL, V200, P400, DOI 10.4049/jimmunol.1701041; Thompson ED, 2010, J EXP MED, V207, P1791, DOI 10.1084/jem.20092454; van Loosdregt J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019047; Vegran F, 2011, CANCER RES, V71, P2550, DOI 10.1158/0008-5472.CAN-10-2828; Wang F, 2012, ONCOGENE, V31, P1546, DOI 10.1038/onc.2011.347; Wang X, 2016, ONCOTARGETS THER, V9, P5023, DOI 10.2147/OTT.S105862; Wong N, 2014, CANCER INVEST, V32, P330, DOI 10.3109/07357907.2014.919306; Yoshida GJ, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0221-y; Zhang Q, 2009, CLIN CANCER RES, V15, P3557, DOI 10.1158/1078-0432.CCR-08-1656; Ziani L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00414	75	85	87	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2019	38	19					3681	3695		10.1038/s41388-019-0688-7	http://dx.doi.org/10.1038/s41388-019-0688-7			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HX4OU	30664688				2022-12-28	WOS:000467379600009
J	Das, S; Nair, RS; Mishra, R; Sondarva, G; Viswakarma, N; Abdelkarim, H; Gaponenko, V; Rana, B; Rana, A				Das, Subhasis; Nair, Rakesh Sathish; Mishra, Rajakishore; Sondarva, Gautam; Viswakarma, Navin; Abdelkarim, Hazem; Gaponenko, Vadim; Rana, Basabi; Rana, Ajay			Mixed lineage kinase 3 promotes breast tumorigenesis via phosphorylation and activation of p21-activated kinase 1	ONCOGENE			English	Article							I-TASSER; SIGNALING PATHWAYS; PROTEIN-STRUCTURE; PAK1 KINASE; CANCER; TRANSLOCATION; LOCALIZATION; EXPRESSION; MECHANISM; APOPTOSIS	Mixed lineage kinase 3 (MLK3), a MAP3K member has been envisioned as a viable drug target in cancer, yet its detailed function and signaling is not fully elucidated. We identified that MLK3 tightly associates with an oncogene, PAK1. Mammalian PAK1 being a Ste20 (MAP4K) member, we tested whether it is an upstream regulator of MLK3. In contrast to our hypothesis, MLK3 activated PAK1 kinase activity directly, as well as in the cells. Although, MLK3 can phosphorylate PAK1 on Ser133 and Ser204 sites, PAK1S133A mutant is constitutively active, whereas, PAK1S204A is not activated by MLK3. Stable overexpression of PAK1S204A in breast cancer cells, impedes migration, invasion, and NF kappa B activity. In vivo breast cancer cell tumorigenesis is significantly reduced in tumors expressing PAK1S204A mutant. These results suggest that mammalian PAK1 does not act as a MAP4K and MLK3-induced direct activation of PAK1 plays a key role in breast cancer tumorigenesis.	[Das, Subhasis; Nair, Rakesh Sathish; Sondarva, Gautam; Viswakarma, Navin; Rana, Basabi; Rana, Ajay] Univ Illinois, Div Surg Oncol, Dept Surg, Chicago, IL 60612 USA; [Mishra, Rajakishore] Cent Univ Jharkhand, Sch Nat Sci, Ctr Life Sci, Ranchi 835205, Jharkhand, India; [Abdelkarim, Hazem; Gaponenko, Vadim] Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA; [Rana, Basabi; Rana, Ajay] Univ Illinois, Univ Illinois Hosp, Chicago, IL 60612 USA; [Rana, Basabi; Rana, Ajay] Univ Illinois, Hlth Sci Syst Canc Ctr, Chicago, IL 60612 USA; [Rana, Basabi; Rana, Ajay] Jesse Brown VA Med Ctr, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Central University of Jharkhand; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center	Rana, A (corresponding author), Univ Illinois, Div Surg Oncol, Dept Surg, Chicago, IL 60612 USA.; Rana, A (corresponding author), Univ Illinois, Univ Illinois Hosp, Chicago, IL 60612 USA.; Rana, A (corresponding author), Univ Illinois, Hlth Sci Syst Canc Ctr, Chicago, IL 60612 USA.; Rana, A (corresponding author), Jesse Brown VA Med Ctr, Chicago, IL 60612 USA.	arana@uic.edu	Mishra, Rajakishore/ABC-3550-2020; Rana, Ajay/ABE-3739-2020; Das, Subhasis/O-8421-2017	Rana, Ajay/0000-0003-0951-2566; Das, Subhasis/0000-0003-1032-4407; Gaponenko, Vadim/0000-0002-7891-9223	National Cancer Institute [CA 176846, CA 216410, CA 178063, CA 188427]; Veteran Administration Merit Awards [BX002703, BX003296]; NIH shared instrument grant [S100D018445]; NATIONAL CANCER INSTITUTE [R01CA176846, R01CA178063, R01CA188427] Funding Source: NIH RePORTER; Veterans Affairs [I01BX003296] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veteran Administration Merit Awards; NIH shared instrument grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs(US Department of Veterans Affairs)	We acknowledge funding support from National Cancer Institute to A.R. (CA 176846 and CA 216410), B.R. (CA 178063) and V.G. (CA 188427). Additional support came from Veteran Administration Merit Awards to A.R. (BX002703) and B.R. (BX003296). We also acknowledge the NIH shared instrument grant # S100D018445, awarded to U.A.M.S. Proteomics Core Lab, Little Rock, Arkansas, USA.	Bodner A, 2002, J NEUROCHEM, V82, P1424, DOI 10.1046/j.1471-4159.2002.01088.x; Chen RE, 2007, BBA-MOL CELL RES, V1773, P1311, DOI 10.1016/j.bbamcr.2007.05.003; Chong C, 2001, J BIOL CHEM, V276, P17347, DOI 10.1074/jbc.M009316200; French JD, 2013, AM J HUM GENET, V92, P489, DOI 10.1016/j.ajhg.2013.01.002; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Heo L, 2016, SCI REP-UK, V6, DOI 10.1038/srep32153; Holm C, 2006, JNCI-J NATL CANCER I, V98, P671, DOI 10.1093/jnci/djj185; Jha RK, 2011, J MOL BIOL, V413, P513, DOI 10.1016/j.jmb.2011.08.022; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; Kumar R, 2002, J CELL PHYSIOL, V193, P133, DOI 10.1002/jcp.10167; Lee BN, 1999, P NATL ACAD SCI USA, V96, P12679, DOI 10.1073/pnas.96.22.12679; Letessier A, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-245; Lu WG, 1999, ONCOGENE, V18, P797, DOI 10.1038/sj.onc.1202361; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Mao K, 2008, J MOL CELL CARDIOL, V44, P429, DOI 10.1016/j.yjmcc.2007.10.016; Mayhew MW, 2007, J CELL SCI, V120, P3911, DOI 10.1242/jcs.008177; Misek SA, 2017, MOL CANCER RES, V15, P1085, DOI 10.1158/1541-7786.MCR-16-0318; Mishra P, 2010, MOL ENDOCRINOL, V24, P598, DOI 10.1210/me.2009-0387; Nayal A, 2006, J CELL BIOL, V173, P587, DOI 10.1083/jcb.200509075; Nheu TV, 2002, CANCER J, V8, P328, DOI 10.1097/00130404-200207000-00009; Ong CC, 2011, P NATL ACAD SCI USA, V108, P7177, DOI 10.1073/pnas.1103350108; Parrini MC, 2002, MOL CELL, V9, P73, DOI 10.1016/S1097-2765(01)00428-2; Pierce BG, 2014, BIOINFORMATICS, V30, P1771, DOI 10.1093/bioinformatics/btu097; Qing HT, 2012, TUMOR BIOL, V33, P985, DOI 10.1007/s13277-012-0327-1; Radu M, 2014, NAT REV CANCER, V14, P13, DOI 10.1038/nrc3645; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Rana Ajay, 2013, Genes Cancer, V4, P334, DOI 10.1177/1947601913485415; Rangasamy V, 2012, P NATL ACAD SCI USA, V109, P8149, DOI 10.1073/pnas.1200804109; Rangasamy V, 2010, CANCER RES, V70, P1731, DOI 10.1158/0008-5472.CAN-09-3492; Rattanasinchai C, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.44; Rider L, 2013, MOL ENDOCRINOL, V27, P1048, DOI 10.1210/me.2012-1322; Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5; Sancho D, 2002, J IMMUNOL, V169, P292, DOI 10.4049/jimmunol.169.1.292; Sathyanarayana P, 2002, MOL CELL, V10, P1527, DOI 10.1016/S1097-2765(02)00734-7; Shoulson I, 2007, NEUROLOGY, V69, P1480, DOI 10.1212/01.wnl.0000277648.63931.c0; Smith CM, 1997, GENOME RES, V7, P835, DOI 10.1101/gr.7.8.835; Tabusa H, 2013, MOL CANCER RES, V11, P109, DOI 10.1158/1541-7786.MCR-12-0466; Wang RA, 2002, EMBO J, V21, P5437, DOI 10.1093/emboj/cdf543; Wang ZP, 2013, J BIOL CHEM, V288, P20093, DOI 10.1074/jbc.M112.426023; Yang JY, 2015, NUCLEIC ACIDS RES, V43, pW174, DOI 10.1093/nar/gkv342; Yang JY, 2015, NAT METHODS, V12, P7, DOI 10.1038/nmeth.3213; Zhang Y, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-40; Zhou L, 2009, BMC IMMUNOL, V10, DOI 10.1186/1471-2172-10-15; 2015, J BIOL CHEM, V290, P2170, DOI DOI 10.1074/JBC.M115.655563	46	10	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2019	38	19					3569	3584		10.1038/s41388-019-0690-0	http://dx.doi.org/10.1038/s41388-019-0690-0			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HX4OU	30664689	Green Accepted			2022-12-28	WOS:000467379600002
J	Marusiak, AA; Prelowska, MK; Mehlich, D; Lazniewski, M; Kaminska, K; Gorczynski, A; Korwat, A; Sokolowska, O; Kedzierska, H; Golab, J; Biernat, W; Plewczynski, D; Brognard, J; Nowis, D				Marusiak, Anna A.; Prelowska, Monika K.; Mehlich, Dawid; Lazniewski, Michal; Kaminska, Klaudia; Gorczynski, Adam; Korwat, Aleksandra; Sokolowska, Olga; Kedzierska, Hanna; Golab, Jakub; Biernat, Wojciech; Plewczynski, Dariusz; Brognard, John; Nowis, Dominika			Upregulation of MLK4 promotes migratory and invasive potential of breast cancer cells	ONCOGENE			English	Article							NF-KAPPA-B; EPITHELIAL-MESENCHYMAL TRANSITION; KINASE MLK4; SUBTYPES; METASTASIS; MLK4-BETA; CULTURE; JNK	Metastasis to distant organs is a major cause for solid cancer mortality, and the acquisition of migratory and invasive phenotype is a key factor in initiation of malignancy. In this study we investigated the contribution of Mixed-Lineage Kinase 4 (MLK4) to aggressive phenotype of breast cancer cells. Our TCGA cancer genomic data analysis revealed that amplification or mRNA upregulation of MLK4 occurred in 23% of invasive breast carcinoma cases. To find the association between MLK4 expression and the specific subtype of breast cancer, we performed a transcriptomic analysis of multiple datasets, which showed that MLK4 is highly expressed in triple-negative breast cancer compared to other molecular subtypes. Depletion of MLK4 in cell lines with high MLK4 expression impaired proliferation and anchorage-dependent colony formation. Moreover, silencing of MLK4 expression significantly reduced the migratory potential and invasiveness of breast cancer cells as well as the number of spheroids formed in 3D cultures. These in vitro findings translate into slower rate of tumor growth in mice upon MLK4 knock-down. Furthermore, we established that MLK4 activates NF-kappa B signaling and promotes a mesenchymal phenotype in breast cancer cells. Immunohistochemical staining of samples obtained from breast cancer patients revealed a strong positive correlation between high expression of MLK4 and metastatic potential of tumors, which was predominantly observed in TNBC subgroup. Taken together, our results show that high expression of MLK4 promotes migratory and invasive phenotype of breast cancer and may represent a novel target for anticancer treatment.	[Marusiak, Anna A.; Prelowska, Monika K.; Mehlich, Dawid; Kaminska, Klaudia; Sokolowska, Olga; Kedzierska, Hanna; Nowis, Dominika] Univ Warsaw, Ctr New Technol, Expt Med Lab, Warsaw, Poland; [Prelowska, Monika K.; Sokolowska, Olga] Med Univ Warsaw, Postgrad Sch Mol Med, Warsaw, Poland; [Mehlich, Dawid; Nowis, Dominika] Med Univ Warsaw, Genom Med, Warsaw, Poland; [Lazniewski, Michal; Plewczynski, Dariusz] Univ Warsaw, Ctr New Technol, Lab Funct & Struct Genom, Warsaw, Poland; [Lazniewski, Michal] Med Univ Warsaw, Dept Phys Chem, Fac Pharm, Warsaw, Poland; [Gorczynski, Adam; Korwat, Aleksandra; Biernat, Wojciech] Med Univ Gdansk, Dept Pathomorphol, Gdansk, Poland; [Sokolowska, Olga; Golab, Jakub; Nowis, Dominika] Med Univ Warsaw, Dept Immunol, Warsaw, Poland; [Golab, Jakub] Med Univ Warsaw, Ctr Preclin Res & Technol, Warsaw, Poland; [Plewczynski, Dariusz] Warsaw Univ Technol, Fac Math & Informat Sci, Warsaw, Poland; [Brognard, John] NCI, Frederick, MD 21701 USA	University of Warsaw; Medical University of Warsaw; Medical University of Warsaw; University of Warsaw; Medical University of Warsaw; Fahrenheit Universities; Medical University Gdansk; Medical University of Warsaw; Medical University of Warsaw; Warsaw University of Technology; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Marusiak, AA (corresponding author), Univ Warsaw, Ctr New Technol, Expt Med Lab, Warsaw, Poland.	a.marusiak@cent.uw.edu.pl	Nowis, Dominika/P-1213-2017; Golab, Jakub/K-6974-2013; Brognard, John/T-5099-2019; Nowis, Dominika/P-6866-2019; Marusiak, Anna/AAN-7020-2020	Nowis, Dominika/0000-0003-2748-9523; Golab, Jakub/0000-0002-2830-5100; Brognard, John/0000-0002-9243-6615; Nowis, Dominika/0000-0003-2748-9523; Gorczynski, Adam/0000-0002-1950-452X; Plewczynski, Dariusz/0000-0002-3840-7610; Korwat, Aleksandra/0000-0002-7418-1698; Lazniewski, Michal/0000-0003-0436-404X; Marusiak, Anna/0000-0001-8907-3131	European Union under the European Regional Development Fund; Polish National Science Centre [2013/10/E/NZ5/00778, 2014/15/B/ST6/05082, 015/16/S/NZ5/00088]; Foundation for Polish Science; Ministry of Science and Higher Education, Republic of Poland [DI2017 016 747]; NATIONAL CANCER INSTITUTE [ZIABC011691] Funding Source: NIH RePORTER	European Union under the European Regional Development Fund; Polish National Science Centre; Foundation for Polish Science(Foundation for Polish ScienceEuropean Commission); Ministry of Science and Higher Education, Republic of Poland(Ministry of Science and Higher Education, Poland); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Dr. J. Chlebowska-Tuz, Dr. S. Fawdar, Dr. P. Gaj, Dr. Z. Koledova, Dr. T. Stoklosa, M. Sobczak for technical help and insightful comments. The research was carried out within HOMING program of The Foundation for Polish Science co-financed by the European Union under the European Regional Development Fund (to AAM) and Polish National Science Centre (015/16/S/NZ5/00088 to AAM). The research was also supported by The Foundation for Polish Science (TEAM to DP) and Polish National Science Centre (2013/10/E/NZ5/00778 to DN, 2014/15/B/ST6/05082 to DP) and Ministry of Science and Higher Education, Republic of Poland (DI2017 016 747 to DM).	Bardelli A, 2003, SCIENCE, V300, P949, DOI 10.1126/science.1082596; Blessing NA, 2017, CELL SIGNAL, V39, P66, DOI 10.1016/j.cellsig.2017.07.021; Breslin S, 2013, DRUG DISCOV TODAY, V18, P240, DOI 10.1016/j.drudis.2012.10.003; Burstein MD, 2015, CLIN CANCER RES, V21, P1688, DOI 10.1158/1078-0432.CCR-14-0432; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Gandalovicova A, 2017, TRENDS CANCER, V3, P391, DOI 10.1016/j.trecan.2017.04.008; Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304; Guedj M, 2012, ONCOGENE, V31, P1196, DOI 10.1038/onc.2011.301; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Haffty BG, 2006, J CLIN ONCOL, V24, P5652, DOI 10.1200/JCO.2006.06.5664; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huang CY, 2017, J CELL PHYSIOL, V232, P1337, DOI 10.1002/jcp.25610; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Kalimutho M, 2015, TRENDS PHARMACOL SCI, V36, P822, DOI 10.1016/j.tips.2015.08.009; Kim SH, 2016, CANCER CELL, V29, P201, DOI 10.1016/j.ccell.2016.01.005; Kumar P, 2016, ARCH GYNECOL OBSTET, V293, P247, DOI 10.1007/s00404-015-3859-y; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Li CW, 2012, CANCER RES, V72, P1290, DOI 10.1158/0008-5472.CAN-11-3123; Martini M, 2013, CANCER RES, V73, P1912, DOI 10.1158/0008-5472.CAN-12-3074; Marusiak AA, 2016, CANCER RES, V76, P724, DOI 10.1158/0008-5472.CAN-15-0701-T; Marusiak AA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4901; Maubant S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122333; Neil JR, 2008, CANCER RES, V68, P1462, DOI 10.1158/0008-5472.CAN-07-3094; Pal A, 2014, JOVE-J VIS EXP, DOI 10.3791/51311; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Pires BRB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169622; Prat A, 2015, BREAST, V24, pS26, DOI 10.1016/j.breast.2015.07.008; Saab WFA, 2012, ONCOGENESIS, V1, DOI 10.1038/oncsis.2012.6; Sabatier R, 2011, BREAST CANCER RES TR, V126, P407, DOI 10.1007/s10549-010-0897-9; Seit-Nebi A, 2012, CELL MOL IMMUNOL, V9, P27, DOI 10.1038/cmi.2011.15; Sleeman J, 2010, EUR J CANCER, V46, P1177, DOI 10.1016/j.ejca.2010.02.039; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Wu Y, 2009, CANCER CELL, V15, P416, DOI 10.1016/j.ccr.2009.03.016; Yersal O, 2014, WORLD J CLIN ONCOL, V5, P412, DOI 10.5306/wjco.v5.i3.412	38	12	12	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2019	38	15					2860	2875		10.1038/s41388-018-0618-0	http://dx.doi.org/10.1038/s41388-018-0618-0			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HS8LQ	30552384	hybrid, Green Published			2022-12-28	WOS:000464121600014
J	Renziehausen, A; Wang, HX; Rao, B; Weir, L; Lo Nigro, C; Lattanzio, L; Merlano, M; Vega-Rioja, A; Fernandez-Carranco, MD; Hajji, N; Matin, R; Harwood, C; Li, S; Sim, VR; O'Neill, K; Evans, A; Thompson, A; Szlosarek, P; Fleming, C; Stebbing, J; Proby, C; Tzakos, AG; Syed, N; Crook, T				Renziehausen, Alexander; Wang, Hexiao; Rao, Bhavya; Weir, Lynda; Lo Nigro, Cristiana; Lattanzio, Laura; Merlano, Marco; Vega-Rioja, Antonio; del Carmen Fernandez-Carranco, Maria; Hajji, Nabil; Matin, Rubeta; Harwood, Catherine; Li, Su; Sim, Van Ren; O'Neill, Kevin; Evans, Alan; Thompson, Alastair; Szlosarek, Peter; Fleming, Colin; Stebbing, Justin; Proby, Charlotte; Tzakos, Andreas G.; Syed, Nelofer; Crook, Tim			The renin angiotensin system (RAS) mediates bifunctional growth regulation in melanoma and is a novel target for therapeutic intervention	ONCOGENE			English	Article							CONVERTING-ENZYME-INHIBITORS; II TYPE-1 RECEPTOR; IMPROVED SURVIVAL; BREAST-CANCER; SERUM; TUMOR; ANGIOGENESIS; ANTAGONIST; BIOMARKER; AGTR1	Despite emergence of new systemic therapies, metastatic melanoma remains a challenging and often fatal form of skin cancer. The renin-angiotensin system (RAS) is a major physiological regulatory pathway controlling salt-water equilibrium, intravascular volume and blood pressure. Biological effects of the RAS are mediated by the vasoactive hormone angiotensin II (AngII) via two receptor subtypes, AT1R (encoded by AGTR1) and AT2R (encoded by AGTR2). We report decreasing expression and increasing CpG island methylation of AGTR1 in metastatic versus primary melanoma and detection in serum of methylated genomic DNA from the AGTR1 CpG island in metastatic melanoma implying that AGTR1 encodes a tumour suppressor function in melanoma. Consistent with this hypothesis, antagonism of AT1R using losartan or shRNA-mediated knockdown in melanoma cell lines expressing AGTR1 resulted in acquisition of the ability to proliferate in serum-free conditions. Conversely, ectopic expression of AGTR1 in cell lines lacking endogenous expression inhibits proliferation irrespective of the presence of AngII implying a ligand-independent suppressor function for AT1R. Treatment of melanoma cell lines expressing endogenous AT2R with either AngII or the AT2R-selective agonist Y6AII induces proliferation in serum-free conditions whereas the AT2R-specific antagonists PD123319 and EMA401 inhibit melanoma growth and angiogenesis and potentiate inhibitors of BRAF and MEK in cells with BRAF V600 mutations. Our results demonstrate that the RAS has both oncogenic and tumour suppressor functions in melanoma. Pharmacological inhibition of AT2R may provide therapeutic opportunities in melanomas expressing this receptor and AGTR1 CpG island methylation in serum may serve as a novel biomarker of metastatic melanoma.	[Renziehausen, Alexander; Hajji, Nabil; Syed, Nelofer] Imperial Coll London, Div Brain Sci, John Fulcher Neurooncol Lab, London, England; [Wang, Hexiao] China Med Univ, Dept Dermatol, Hosp 1, Shenyang, Liaoning, Peoples R China; [Rao, Bhavya; Weir, Lynda; Proby, Charlotte] Ninewells Hosp, Med Res Inst, Dundee, Scotland; [Rao, Bhavya; Weir, Lynda; Proby, Charlotte] Med Sch, Dundee, Scotland; [Lo Nigro, Cristiana; Lattanzio, Laura; Merlano, Marco] Osped San Croce & Carle, Dept Oncol, Cuneo, Italy; [Vega-Rioja, Antonio; del Carmen Fernandez-Carranco, Maria] Hosp Univ Virgen Macarena, Seville, Spain; [Matin, Rubeta; Harwood, Catherine] Barts & London Queen Marys Sch Med & Dent, London, England; [Li, Su] Royal Marsden Hosp, Fulham Rd, London, England; [Sim, Van Ren] Maidstone Hlth Author, Kent Oncol Ctr, Maidstone ME16 9QQ, Kent, England; [O'Neill, Kevin] Charing Cross Hosp, Dept Neurosurg, London, England; [Evans, Alan] Ninewells Hosp, Dept Pathol, Dundee, Scotland; [Thompson, Alastair] MD Anderson Canc Ctr, Breast Surg Oncol, Houston, TX USA; [Szlosarek, Peter] Barts Canc Ctr, Dept Med Oncol, London, England; [Fleming, Colin; Proby, Charlotte] Ninewells Hosp, Dept Dermatol, Dundee, Scotland; [Stebbing, Justin] Imperial Coll, London, England; [Tzakos, Andreas G.] Univ Ioannina, Dept Chem, Ioannina, Greece; [Crook, Tim] St Lukes Canc Ctr, Guildford, Surrey, England	Imperial College London; China Medical University; University of Dundee; University of Dundee; Hospital Universitario Virgen Macarena; University of London; Queen Mary University London; Royal Marsden NHS Foundation Trust; Imperial College London; University of Dundee; University of Texas System; UTMD Anderson Cancer Center; University of Dundee; Imperial College London; University of Ioannina	Syed, N (corresponding author), Imperial Coll London, Div Brain Sci, John Fulcher Neurooncol Lab, London, England.; Crook, T (corresponding author), St Lukes Canc Ctr, Guildford, Surrey, England.	N.syed@imperial.ac.uk; timothycrook@nhs.net	Matin, Rubeta/AAB-1515-2019; merlano, marco/HHS-9397-2022; hajji, nabil/AAV-1435-2020; tzakos, Andreas/V-9624-2019; Renziehausen, Alexander/AAE-4907-2020	Matin, Rubeta/0000-0002-9695-5412; Stebbing, Justin/0000-0002-1117-6947; Tzakos, Andreas/0000-0001-6391-0288; Vega Rioja, Antonio/0000-0003-4698-9697	Anonymous Trust; Tenovus Scotland; Melanoma Focus; Leng Foundation; Brain Tumour Research Campaign; Economica y Competitividad [SAF2014-60649-JN]; Fondo Europeo de Regional-FEDER	Anonymous Trust; Tenovus Scotland; Melanoma Focus; Leng Foundation; Brain Tumour Research Campaign; Economica y Competitividad; Fondo Europeo de Regional-FEDER	The work was supported by They The Anonymous Trust, Tenovus Scotland (to Dr. T.C.), Melanoma Focus (to C.P.), The Leng Foundation (to C.P.) and The Brain Tumour Research Campaign (to N.S.). Antonio Vega-Rioja is under contract Proyectos I + D + I para jovenes investigadores from de Economica y Competitividad (SAF2014-60649-JN) and co-funded by Fondo Europeo de Regional-FEDER. Tim Crook is a Scottish Senior Clinical Fellow in Medical Oncology.	Anand U, 2013, EUR J PAIN, V17, P1012, DOI 10.1002/j.1532-2149.2012.00269.x; Ateeq B, 2009, CELL CYCLE, V8, P3794, DOI 10.4161/cc.8.23.9976; Bar J, 2015, CLIN LUNG CANCER, V16, pE189, DOI 10.1016/j.cllc.2015.05.002; Beaumont KA, 2014, HEALTHCARE-BASEL, V2, P27, DOI 10.3390/healthcare2010027; Brunner D, 2010, ALTEX-ALTERN ANIM EX, V27, P53; Campbell DJ, 1996, CLIN EXP PHARMACOL P, V23, pS125, DOI 10.1111/j.1440-1681.1996.tb03073.x; Carpentier AF, 2012, EUR J NEUROL, V19, P1337, DOI 10.1111/j.1468-1331.2012.03766.x; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chen XS, 2013, CANCER LETT, V328, P318, DOI 10.1016/j.canlet.2012.10.006; Corkery DP, 2011, BRIT J HAEMATOL, V153, P786, DOI 10.1111/j.1365-2141.2011.08661.x; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Flaherty Keith T, 2011, F1000 Med Rep, V3, P8, DOI 10.3410/M3-8; Guo RD, 2015, IUBMB LIFE, V67, P42, DOI 10.1002/iub.1342; Hanaizi Z, 2012, EUR J CANCER, V48, P237, DOI 10.1016/j.ejca.2011.09.018; Hatzimichael E, 2014, EXPERT REV MOL DIAGN, V14, P639, DOI 10.1586/14737159.2014.928204; Hesselink JMK, 2017, J PAIN RES, V10, P439, DOI 10.2147/JPR.S128520; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hoshimoto S, 2012, J INVEST DERMATOL, V132, P1689, DOI 10.1038/jid.2012.36; Karnik SS, 2015, PHARMACOL REV, V67, P754, DOI 10.1124/pr.114.010454; Lo Nigro C, 2013, J INVEST DERMATOL, V133, P1278, DOI 10.1038/jid.2012.493; Magnani F, 2014, ACS CHEM BIOL, V9, P1420, DOI 10.1021/cb500063y; Miura S, 2005, J BIOL CHEM, V280, P18237, DOI 10.1074/jbc.M500639200; Moreno BH, 2015, SEMIN ONCOL, V42, P466, DOI 10.1053/j.seminoncol.2015.02.008; Moreno-Munoz D, 2015, EUR J CLIN INVEST, V45, P1325, DOI 10.1111/eci.12557; Nussberger J, 2002, HYPERTENSION, V39, pE1, DOI 10.1161/hy0102.102293; Otake AH, 2010, CANCER CHEMOTH PHARM, V66, P79, DOI 10.1007/s00280-009-1136-0; Patton EE, 2010, PIGM CELL MELANOMA R, V23, P314, DOI 10.1111/j.1755-148X.2010.00693.x; Reis IM, 2015, BRIT J CANCER, V113, P460, DOI 10.1038/bjc.2015.240; Rhodes DR, 2009, P NATL ACAD SCI USA, V106, P10284, DOI 10.1073/pnas.0900351106; Shah R, 2009, BRIT J CANCER, V100, P1687, DOI 10.1038/sj.bjc.6605042; Sullivan RJ, 2015, CLIN CANCER RES, V21, P2424, DOI 10.1158/1078-0432.CCR-14-1650; Syed N, 2006, BLOOD, V107, P250, DOI 10.1182/blood-2005-03-1194; Wolchok JD, 2015, CELL, V162, P937, DOI 10.1016/j.cell.2015.07.045; Yoon C, 2011, CAN MED ASSOC J, V183, pE1073, DOI 10.1503/cmaj.101497; Zou YZ, 2004, NAT CELL BIOL, V6, P499, DOI 10.1038/ncb1137	35	26	26	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2019	38	13					2320	2336		10.1038/s41388-018-0563-y	http://dx.doi.org/10.1038/s41388-018-0563-y			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ7GN	30478450	Green Accepted			2022-12-28	WOS:000462588000007
J	Wei, N; Li, J; Fang, C; Chang, J; Xirou, V; Syrigos, NK; Marks, BJ; Chu, E; Schmitz, JC				Wei, Ning; Li, Jun; Fang, Cheng; Chang, Jin; Xirou, Vasiliki; Syrigos, Nick K.; Marks, Benjamin J.; Chu, Edward; Schmitz, John C.			Targeting colon cancer with the novel STAT3 inhibitor bruceantinol	ONCOGENE			English	Article							PROTEIN-KINASE-D; COMBINATION; METASTASIS; EXPRESSION; BRUSATOL; TRIAL	STAT3, a transcriptional mediator of oncogenic signaling, is constitutively active in similar to 70% of human cancers. The development of STAT3 inhibitors remains an active area of research as no inhibitors have yet to be approved for the treatment of human cancer. Herein, we revealed that bruceantinol (BOL) is a novel STAT3 inhibitor demonstrating potent antitumor activity in in vitro and in vivo human colorectal cancer (CRC) models. BOL strongly inhibited STAT3 DNA-binding ability (IC50 = 2.4 pM), blocked the constitutive and IL-6-induced STAT3 activation in a dose- and time-dependent manner, and suppressed transcription of STAT3 target genes encoding anti-apoptosis factors (MCL-1, PTTG1, and survivin) and cell-cycle regulators (c-Myc). Structure-activity relationship studies demonstrated that the C15 side chain on BOL affected its ability to bind STAT3. Administration of 4 mg/kg BOL significantly inhibited CRC tumor xenografts [p < 0.001], but no effect was observed in a STAT3(-/-) tumor model. Additional studies showed that BOL effectively sensitized MEK inhibitors through repression of p-STAT3 and MCL-1 induction, known resistance mechanisms of MEK inhibition. Taken together, our findings suggest BOL is a novel therapeutic STAT3 inhibitor that can be used either alone or in combination with MEK inhibitors for the treatment of human CRC.	[Wei, Ning; Marks, Benjamin J.; Chu, Edward; Schmitz, John C.] Univ Pittsburgh, Sch Med, Dept Med, Div Hematol Oncol, Pittsburgh, PA 15213 USA; [Wei, Ning; Marks, Benjamin J.; Chu, Edward; Schmitz, John C.] Univ Pittsburgh, UPMC Hillman Canc Ctr, Canc Therapeut Program, Pittsburgh, PA 15260 USA; [Li, Jun] Liaoning Univ Tradit Chinese Med, Basic Med Sci Coll, Shenyang, Liaoning, Peoples R China; [Fang, Cheng] Univ Pittsburgh, Computat Modeling & Simulat Program, Pittsburgh, PA USA; [Chang, Jin] Taishan Med Univ, Dept Oncol, Tai An, Shandong, Peoples R China; [Xirou, Vasiliki; Syrigos, Nick K.] Univ Athens, Med Sch, Athens, Greece	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Liaoning University of Traditional Chinese Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Shandong First Medical University & Shandong Academy of Medical Sciences; National & Kapodistrian University of Athens	Wei, N; Schmitz, JC (corresponding author), Univ Pittsburgh, Sch Med, Dept Med, Div Hematol Oncol, Pittsburgh, PA 15213 USA.; Wei, N; Schmitz, JC (corresponding author), Univ Pittsburgh, UPMC Hillman Canc Ctr, Canc Therapeut Program, Pittsburgh, PA 15260 USA.	chinaweining@yahoo.com; schmitzjc@upmc.edu	FANG, CHENG/B-6718-2016; WEI, NING/AAF-8368-2020; SYRIGOS, NIKOLAOS/ABB-6880-2021; WEI, NING/P-8505-2019; Syrigos, Nick/ABC-6339-2021	FANG, CHENG/0000-0002-9767-2043; WEI, NING/0000-0003-2723-4061; WEI, NING/0000-0003-2723-4061; Syrigos, Nick/0000-0001-8082-594X	UPCI NCI Cancer Center Support Grant Developmental Funds [P30CA047904]; China National Natural Sciences Foundation [81202556]; Pennsylvania Department of Health	UPCI NCI Cancer Center Support Grant Developmental Funds; China National Natural Sciences Foundation(National Natural Science Foundation of China (NSFC)); Pennsylvania Department of Health	This project was supported, in part, by funds from the UPCI NCI Cancer Center Support Grant Developmental Funds (P30CA047904). This project used the UPCI Cytometry Facility and the UPCI Animal Facility, which are supported, in part, by P30CA047904. This project also was supported, in part, by Grants (No. 81202556) from the China National Natural Sciences Foundation. This project is funded, in part, under a grant with the Pennsylvania Department of Health.	Arseneau J C, 1983, Invest New Drugs, V1, P239; Bhattacharya S, 2005, BIOCHEM J, V392, P335, DOI 10.1042/BJ20050465; Bibbins-Domingo K, 2016, JAMA-J AM MED ASSOC, V315, P2564, DOI 10.1001/jama.2016.5989; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Castelletti D, 2010, MOL CANCER THER, V9, P3145, DOI 10.1158/1535-7163.MCT-10-0539; Cragg GM, 2013, BBA-GEN SUBJECTS, V1830, P3670, DOI 10.1016/j.bbagen.2013.02.008; Cuendet M, 2004, CLIN CANCER RES, V10, P1170, DOI 10.1158/1078-0432.CCR-0362-3; Demain AL, 2011, MICROB BIOTECHNOL, V4, P687, DOI 10.1111/j.1751-7915.2010.00221.x; Gurel G, 2009, J MOL BIOL, V389, P146, DOI 10.1016/j.jmb.2009.04.005; Huang W, 2016, ONCOGENE, V35, P783, DOI 10.1038/onc.2015.215; Jung KH, 2017, CLIN CANCER RES, V23, P5537, DOI 10.1158/1078-0432.CCR-16-2253; Kohne CH, 2009, ONCOLOGIST, V14, P478, DOI 10.1634/theoncologist.2008-0202; Lam W, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001270; Lee HJ, 2014, CANCER CELL, V26, P207, DOI 10.1016/j.ccr.2014.05.019; Li YZ, 2015, P NATL ACAD SCI USA, V112, P1839, DOI 10.1073/pnas.1424171112; LIAO LL, 1976, MOL PHARMACOL, V12, P167; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Mata-Greenwood E, 2002, LEUKEMIA, V16, P2275, DOI 10.1038/sj.leu.2402696; Morikawa T, 2011, CLIN CANCER RES, V17, P1452, DOI 10.1158/1078-0432.CCR-10-2694; Oh SB, 2014, CANCER LETT, V353, P95, DOI 10.1016/j.canlet.2014.07.007; Sen M, 2012, CANCER DISCOV, V2, P694, DOI 10.1158/2159-8290.CD-12-0191; Vartanian S, 2016, MOL CELL PROTEOMICS, V15, P1220, DOI 10.1074/mcp.M115.055509; Vultur A, 2014, ONCOGENE, V33, P1850, DOI 10.1038/onc.2013.131; Wei N, 2015, ONCOTARGET, V6, P4745, DOI 10.18632/oncotarget.2938; Wei N, 2014, MOL CANCER THER, V13, P1130, DOI 10.1158/1535-7163.MCT-13-0880; WISEMAN CL, 1982, AM J CLIN ONCOL-CANC, V5, P389, DOI 10.1097/00000421-198208000-00007; Wu SY, 2015, ONCOTARGET, V6, P40866, DOI 10.18632/oncotarget.5885; Yan Z, 2017, CHIN J INTEGR MED, V23, P153, DOI 10.1007/s11655-016-2501-6; Yang JH, 2013, J ETHNOPHARMACOL, V147, P442, DOI 10.1016/j.jep.2013.03.034; Zhao CG, 2015, ONCOTARGET, V6, P14472, DOI 10.18632/oncotarget.3991; Zhao C, 2016, ONCOTARGET, V7, P12917, DOI 10.18632/oncotarget.7338; Zhao M, 2011, PHYTOTHER RES, V25, P1796, DOI 10.1002/ptr.3477; Zhou C, 2014, ONCOGENE, V33, P851, DOI 10.1038/onc.2013.16	33	42	42	1	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2019	38	10					1676	1687		10.1038/s41388-018-0547-y	http://dx.doi.org/10.1038/s41388-018-0547-y			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN8DD	30348989				2022-12-28	WOS:000460423800008
J	Esteves, P; Dard, L; Brillac, A; Hubert, C; Sarlak, S; Rousseau, B; Dumon, E; Izotte, J; Bonneu, M; Lacombe, D; Dupuy, JW; Amoedo, N; Rossignol, R				Esteves, Pauline; Dard, Laetitia; Brillac, Aurelia; Hubert, Christophe; Sarlak, Saharnaz; Rousseau, Benoit; Dumon, Elodie; Izotte, Julien; Bonneu, Marc; Lacombe, Didier; Dupuy, Jean-William; Amoedo, Nivea; Rossignol, Rodrigue			Nuclear control of lung cancer cells migration, invasion and bioenergetics by eukaryotic translation initiation factor 3F	ONCOGENE			English	Article							METASTASIS; HALLMARKS; INDUCTION; PHENOTYPE; APOPTOSIS; PATHWAY; GROWTH; STAT3	The basic understanding of the biological effects of eukaryotic translation initiation factors (EIFs) remains incomplete, notably for their roles independent of protein translation. Different EIFs exhibit nuclear localization and DNA-related functions have been proposed, but the understanding of EIFs novel functions beyond protein translation lacks of integrative analyses between the genomic and the proteomic levels. Here, the noncanonical function of EIF3F was studied in human lung adenocarcinoma by combining methods that revealed both the protein-protein and the protein-DNA interactions of this factor. We discovered that EIF3F promotes cell metastasis in vivo. The underpinning molecular mechanisms involved the regulation of a cluster of 34 metastasis-promoting genes including Snail2, as revealed by proteomics combined with immuno-affinity purification of EIF3F and ChIP-seq/Q-PCR analyses. The interaction between EIF3F and signal transducer and activator of transcription 3 (STAT3) controlled the EIF3F-mediated increase in Snail2 expression and cellular invasion, which were specifically abrogated using the STAT3 inhibitor Nifuroxazide or knockdown approaches. Furthermore, EIF3F overexpression reprogrammed energy metabolism through the activation of AMP-activated protein kinase and the stimulation of oxidative phosphorylation. Our findings demonstrate the role of EIF3F in the molecular control of cell migration, invasion, bioenergetics, and metastasis. The discovery of a role for EIF3F-STAT3 interaction in the genetic control of cell migration and metastasis in human lung adenocarcinoma could lead to the development of diagnosis and therapeutic strategies.	[Esteves, Pauline; Dard, Laetitia; Brillac, Aurelia; Hubert, Christophe; Sarlak, Saharnaz; Rousseau, Benoit; Dumon, Elodie; Izotte, Julien; Bonneu, Marc; Lacombe, Didier; Dupuy, Jean-William; Rossignol, Rodrigue] Bordeaux Univ, 146 Rue Leo Saignat, F-33000 Bordeaux, France; [Esteves, Pauline; Dard, Laetitia; Brillac, Aurelia; Hubert, Christophe; Sarlak, Saharnaz; Dumon, Elodie; Lacombe, Didier; Rossignol, Rodrigue] INSERM U1211, F-33000 Bordeaux, France; [Rousseau, Benoit; Izotte, Julien] Univ Bordeaux, Transgen Anim Facil A2, F-33000 Bordeaux, France; [Bonneu, Marc; Dupuy, Jean-William] Funct Genom Ctr CGFB, Prote Facil, 146 Rue Leo Saignat, F-33076 Bordeaux, France; [Bonneu, Marc] Bordeaux INP, Ave Fac, F-33405 Talence, France; [Amoedo, Nivea; Rossignol, Rodrigue] Funct Genom Ctr CGFB, CELLOMET, 146 Rue Leo Saignat, F-33000 Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux	Rossignol, R (corresponding author), Bordeaux Univ, 146 Rue Leo Saignat, F-33000 Bordeaux, France.; Rossignol, R (corresponding author), INSERM U1211, F-33000 Bordeaux, France.; Rossignol, R (corresponding author), Funct Genom Ctr CGFB, CELLOMET, 146 Rue Leo Saignat, F-33000 Bordeaux, France.	rodrigue.rossignol@u-bordeaux.fr	Dupuy, Jean-William JWD/F-5335-2012	Dupuy, Jean-William JWD/0000-0002-2448-4797; sarlak, saharnaz/0000-0001-6949-3753; Esteves, Pauline/0000-0002-4787-339X	French National Institute for Scientific and Medical Research (INSERM); Brazilian National Council for Scientific and Technological Development (CnPq); CAPES-COFECUB; Fondation ARC; French National Institute against Cancer (Inca); Ligue Regionale contre le cancer; Plan Cancer;  [H2020-MSCA-ITN-2016/722605]	French National Institute for Scientific and Medical Research (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Brazilian National Council for Scientific and Technological Development (CnPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); CAPES-COFECUB(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Fondation ARC; French National Institute against Cancer (Inca); Ligue Regionale contre le cancer(Ligue nationale contre le cancer); Plan Cancer; 	This work was supported, in part, by the French National Institute for Scientific and Medical Research (INSERM), the Brazilian National Council for Scientific and Technological Development (CnPq), CAPES-COFECUB, Plan Cancer, Fondation ARC (N.A), French National Institute against Cancer (Inca), Ligue Regionale contre le cancer, and H2020-MSCA-ITN-2016/722605 - TRANSMIT (Translating the Role of Mitochondria in Tumorigenesis).	Aguilar E, 2016, STEM CELLS, V34, P1163, DOI 10.1002/stem.2286; Aitken CE, 2012, NAT STRUCT MOL BIOL, V19, P568, DOI 10.1038/nsmb.2303; Anjomshoaa A, 2009, BRIT J CANCER, V101, P822, DOI 10.1038/sj.bjc.6605229; Benard G, 2006, AM J PHYSIOL-CELL PH, V291, pC1172, DOI 10.1152/ajpcell.00195.2006; BERNDTSON WE, 1991, J ANIM SCI, V69, P67; Casas E, 2011, CANCER RES, V71, P245, DOI 10.1158/0008-5472.CAN-10-2330; Chu J, 2016, TRENDS CELL BIOL, V26, P918, DOI 10.1016/j.tcb.2016.06.005; Deutsch EW, 2017, NUCLEIC ACIDS RES, V45, pD1100, DOI 10.1093/nar/gkw936; Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022; Faubert B, 2017, CELL, V171, P358, DOI 10.1016/j.cell.2017.09.019; Gao BC, 2015, BBA-GENE REGUL MECH, V1849, P753, DOI 10.1016/j.bbagrm.2014.11.006; Giese A, 1996, INT J CANCER, V67, P275, DOI 10.1002/(SICI)1097-0215(19960717)67:2<275::AID-IJC20>3.0.CO;2-9; Grossman RL, 2016, NEW ENGL J MED, V375, P1109, DOI 10.1056/NEJMp1607591; Han SY, 2018, INT J MOL MED, V42, P1644, DOI 10.3892/ijmm.2018.3733; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Henriet E, 2017, HEPATOLOGY, V66, P2016, DOI 10.1002/hep.29336; Hensley CT, 2016, CELL, V164, P681, DOI 10.1016/j.cell.2015.12.034; Higareda-Mendoza AE, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-10; Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906; Gutierrez-Fernandez MJ, 2015, BMC BIOCHEM, V16, DOI 10.1186/s12858-015-0054-5; Jia DY, 2017, PHYS BIOL, V14, DOI 10.1088/1478-3975/aa6f90; Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8; Kall L, 2007, NAT METHODS, V4, P923, DOI 10.1038/NMETH1113; Kathagen-Buhmann A, 2016, NEURO-ONCOLOGY, V18, P1219, DOI 10.1093/neuonc/now024; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Liu MH, 2019, J CLIN MED, V8, DOI 10.3390/jcm8060822; Melser S, 2013, CELL METAB, V17, P719, DOI 10.1016/j.cmet.2013.03.014; Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329; Moretti J, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000545; Mori S, 2009, ONCOGENE, V28, P2796, DOI 10.1038/onc.2009.139; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Pecqueur C, 2001, J BIOL CHEM, V276, P8705, DOI 10.1074/jbc.M006938200; Perego M, 2018, ONCOGENE, V37, P302, DOI 10.1038/onc.2017.341; Porporato PE, 2014, CELL REP, V8, P754, DOI 10.1016/j.celrep.2014.06.043; Rodrigues MF, 2016, BIOCHEM J, V473, P703, DOI 10.1042/BJ20150645; Rosland GV, 2019, CANCER METAB, V7, DOI 10.1186/s40170-019-0197-8; Shi J, 2006, ONCOGENE, V25, P4923, DOI 10.1038/sj.onc.1209495; Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477; Sinnberg T, 2016, EBIOMEDICINE, V8, P132, DOI 10.1016/j.ebiom.2016.04.037; Strudwick S, 2002, DIFFERENTIATION, V70, P10, DOI 10.1046/j.1432-0436.2002.700102.x; Stuelten CH, 2018, NAT REV CANCER, V18, P296, DOI 10.1038/nrc.2018.15; Tamura T, 2015, MOL CLIN ONCOL, V3, P217, DOI 10.3892/mco.2014.410; Taylor CA, 2007, EXP CELL RES, V313, P437, DOI 10.1016/j.yexcr.2006.09.030; Vaklavas C, 2015, CANCER BIOL THER, V16, P1471, DOI 10.1080/15384047.2015.1071729; Wegrzyn J, 2009, SCIENCE, V323, P793, DOI 10.1126/science.1164551; Wen FS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034194; Williams D, 2019, CLIN EXP METASTAS, V36, P211, DOI 10.1007/s10585-019-09967-0; Wu KL, 2015, LUNG CANCER, V88, P187, DOI 10.1016/j.lungcan.2015.02.012; Zhu YX, 2016, SCI REP-UK, V6, DOI 10.1038/srep20253	51	9	9	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					617	636		10.1038/s41388-019-1009-x	http://dx.doi.org/10.1038/s41388-019-1009-x			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31527668	Green Published, hybrid			2022-12-28	WOS:000509718300010
J	Liu, YY; Li, XY; Zhang, YP; Wang, HX; Rong, XM; Peng, JL; He, L; Peng, Y				Liu, Yunyun; Li, Xiaoyu; Zhang, Yuanpei; Wang, Hongxuan; Rong, Xiongming; Peng, Jialing; He, Lei; Peng, Ying			An miR-340-5p-macrophage feedback loop modulates the progression and tumor microenvironment of glioblastoma multiforme	ONCOGENE			English	Article							CANCER STEM-CELLS; MACROPHAGE POLARIZATION; TGF-BETA; GROWTH; REGULATORS; PREDICTS; AGGRESSIVENESS; PROLIFERATION; INFILTRATION; SUPPRESSES	MicroRNAs (miRNAs) have been shown to be involved in the progression and tumor microenvironment of glioblastoma multiforme (GBM). Our previous research has indicated that miR-340-5p has an antitumor effect in vitro. However, the role of miR-340-5p in GBM has not been fully elucidated. Here, we show that downregulation of miR-340-5p in GBM is correlated with tumor size, recurrence, and poor survival. Moreover, we found that miR-340-5p levels are correlated with the density of tumor-associated macrophages (TAMs) and M2-polarized TAMs in GBM. Biofunctional investigations revealed that downregulation of miR-340-5p promoted TAM recruitment and M2-TAMs polarization in vitro and in vivo. In addition, we found that upregulation of miR-340-5p inhibited tumor growth and was associated with good prognosis in vivo. Through gene expression profiles and bioinformatics analysis, we showed that miR-340-5p directly targets POSTN, which recruited TAMs through integrin alpha v beta 3. Downregulation of miR-340-5p in GBM did not induce the differentiation of TAMs into polarized M2 cells but was able to promote the M2 polarization of TAMs through directly targeting LTBP-1. Furthermore, we found that M2-TAMs promoted tumorigenesis and were associated with a poor prognosis in vivo. In an in vitro study, we demonstrated that M2-TAMs inhibited miR-340-5p expression in GBM cells by upregulation of TGF beta-1, which increased HMGA-2 expression in GBM. A ChIP assay confirmed that HMGA-2 transcriptionally suppressed miR-340-5p expression. Patients with low-miR-340-5p expression, high CD163, high POSTN, high LIBP1 levels, and high HMGA-2 had a poor prognosis with shorter overall survival, confirming data from the TCGA database. These findings suggest that an miR-340-5p-macrophage feedback loop modulates the progression and tumor microenvironment of GBM and may represent a prognostic biomarker and therapeutic strategy for GBM.	[Liu, Yunyun; Li, Xiaoyu; Zhang, Yuanpei; Wang, Hongxuan; Rong, Xiongming; Peng, Jialing; He, Lei; Peng, Ying] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Neurol, Guangzhou 510120, Guangdong, Peoples R China; [Liu, Yunyun; Li, Xiaoyu; Zhang, Yuanpei; Wang, Hongxuan; Rong, Xiongming; Peng, Jialing; He, Lei; Peng, Ying] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou 510120, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University	Peng, Y (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Neurol, Guangzhou 510120, Guangdong, Peoples R China.; Peng, Y (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou 510120, Guangdong, Peoples R China.	docpengy123@163.com			National Natural Science Foundation of China [81572481, 81502167, 81502552]; key point program of Science & Technique plan for production, study, and research of Guangzhou city [201508020058]; Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun Yat-sen University [KLB09001]; Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology [[2013]163]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); key point program of Science & Technique plan for production, study, and research of Guangzhou city; Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun Yat-sen University; Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology	We thank and acknowledge the patients for tumor tissue donation. We also thank SWQ and BH for their scientific support in some experiments. This work was supported by the National Natural Science Foundation of China (No. 81572481 to YP, 81502167 to XMR and 81502552 to LH), the key point program of Science & Technique plan for production, study, and research of Guangzhou city (201508020058). Grant KLB09001 from the Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun Yat-sen University and Grant [2013]163 from Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology.	Baer C, 2016, NAT CELL BIOL, V18, P790, DOI 10.1038/ncb3371; Chen DG, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03225-9; Chen H, 2017, ONCOGENE, V36, P4415, DOI 10.1038/onc.2017.73; Chen XW, 2017, ONCOGENE, V36, P5045, DOI 10.1038/onc.2017.118; Chi JQ, 2015, VIROLOGY, V476, P72, DOI 10.1016/j.virol.2014.11.027; Chiou GY, 2013, MOL CELL, V52, P693, DOI 10.1016/j.molcel.2013.11.009; Cui TT, 2019, ONCOGENE, V38, P2923, DOI 10.1038/s41388-018-0601-9; Da FA, 2013, CLIN DEV IMMUNOL, V2013; Fabbri M, 2012, P NATL ACAD SCI USA, V109, pE2110, DOI 10.1073/pnas.1209414109; Fernandez S, 2015, ONCOGENE, V34, P3240, DOI 10.1038/onc.2014.267; Fiore D, 2016, ONCOTARGET, V7, P19531, DOI 10.18632/oncotarget.6968; Forstreuter F, 2002, J NEUROIMMUNOL, V132, P93, DOI 10.1016/S0165-5728(02)00315-6; Gargiulo G, 2013, CANCER CELL, V23, P660, DOI 10.1016/j.ccr.2013.03.030; Garris C, 2013, NAT MED, V19, P1207, DOI 10.1038/nm.3355; Gordon SR, 2017, NATURE, V545, P495, DOI 10.1038/nature22396; Hambardzumyan D, 2016, NAT NEUROSCI, V19, P20, DOI 10.1038/nn.4185; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Held-Feindt J, 2010, EXP CELL RES, V316, P1553, DOI 10.1016/j.yexcr.2010.02.018; Heusinkveld M, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-216; Huang DQ, 2015, ONCOTARGET, V6, P9257, DOI 10.18632/oncotarget.3288; Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644; Komohara Y, 2008, J PATHOL, V216, P15, DOI 10.1002/path.2370; Lathia JD, 2011, CELL STEM CELL, V8, P482, DOI 10.1016/j.stem.2011.04.013; Lee J, 2015, NEURO-ONCOLOGY, V17, P685, DOI 10.1093/neuonc/nou302; Li H, 2006, CELL RES, V16, P169, DOI 10.1038/sj.cr.7310023; Liu B, 2014, HUM PATHOL, V45, P1752, DOI 10.1016/j.humpath.2014.02.028; Luo H, 2015, BRAIN, V138, P3654, DOI 10.1093/brain/awv287; Mellman I, 2011, NATURE, V480, P480, DOI 10.1038/nature10673; Mikheev AM, 2015, NEURO-ONCOLOGY, V17, P372, DOI 10.1093/neuonc/nou161; Ngambenjawong C, 2017, ADV DRUG DELIVER REV, V114, P206, DOI 10.1016/j.addr.2017.04.010; Okada M, 2009, INT J ONCOL, V34, P1621, DOI 10.3892/ijo_00000292; Platten M, 2003, ANN NEUROL, V54, P388, DOI 10.1002/ana.10679; Ponomarev ED, 2013, GLIA, V61, P91, DOI 10.1002/glia.22363; Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Qian Y, 2017, ACS NANO, V11, P9536, DOI 10.1021/acsnano.7b05465; Rape A, 2014, ADV DRUG DELIVER REV, V79-80, P172, DOI 10.1016/j.addr.2014.08.012; Rong XM, 2016, ONCOTARGET, V7, P83976, DOI 10.18632/oncotarget.6930; Roth P, 2013, BRAIN, V136, P564, DOI 10.1093/brain/aws351; Saha D, 2017, CANCER CELL, V32, P253, DOI 10.1016/j.ccell.2017.07.006; Schwarm FP, 2016, INT J ONCOL, V48, P1485, DOI 10.3892/ijo.2016.3397; Shi Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15080; Simon T, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0878-x; Squadrito ML, 2013, TRENDS IMMUNOL, V34, P350, DOI 10.1016/j.it.2013.02.003; Thuault S, 2006, J CELL BIOL, V174, P175, DOI 10.1083/jcb.200512110; Wang SC, 2012, LAB INVEST, V92, P151, DOI 10.1038/labinvest.2011.128; Wu A, 2010, NEURO-ONCOLOGY, V12, P1113, DOI 10.1093/neuonc/noq082; Wu ZS, 2011, CANCER-AM CANCER SOC, V117, P2842, DOI 10.1002/cncr.25860; Xiong QS, 2017, CELL BIOSCI, V7, DOI 10.1186/s13578-017-0144-8; Yamashita D, 2015, CANCER RES, V75, P1123, DOI 10.1158/0008-5472.CAN-14-0938; Zheng F, 2012, GUT, V61, P278, DOI 10.1136/gut.2011.239145; Zhou WC, 2015, NAT CELL BIOL, V17, P170, DOI 10.1038/ncb3090; Zhuang XQ, 2017, NAT CELL BIOL, V19, P1274, DOI 10.1038/ncb3613	53	36	36	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2019	38	49					7399	7415		10.1038/s41388-019-0952-x	http://dx.doi.org/10.1038/s41388-019-0952-x			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JT4BN	31427735				2022-12-28	WOS:000500936600003
J	Zheng, J; Zhang, H; Ma, RR; Liu, HT; Gao, P				Zheng, Jie; Zhang, Hui; Ma, Ranran; Liu, Haiting; Gao, Peng			Long non-coding RNA KRT19P3 suppresses proliferation and metastasis through COPS7A-mediated NF-kappa B pathway in gastric cancer	ONCOGENE			English	Article							COP9 SIGNALOSOME; BREAST-CANCER; EXPRESSION; DEGRADATION; HOMOLOG; P53	Long non-coding RNAs (lncRNAs) have emerged as critical regulators in gastric cancer (GC). LncRNA expression microarray data indicate that KRT19P3 (Keratin 19 Pseudogene 3) is downregulated in GC samples. However, the expression pattern and molecular mechanism of KRT19P3 in GC have not been characterized. The present study confirmed the downregulation of KRT19P3 in GC tissues and cells. Decreased expression of KRT19P3 was correlated with larger tumor size, advanced TNM stage, Lauren's classification, positive lymph node metastasis, and poor prognosis. Enforced expression of KRT19P3 significantly inhibited cell proliferation, migration, and invasion in vitro, as well as tumorigenesis and metastasis in vivo. Conversely, KRT19P3 knockdown had opposite effects. Mechanistically, RNA pull-down and RNA immunoprecipitation assay revealed that KRT19P3 could directly bind COPS7A. KRT19P3 enhanced COPS7A protein stability in GC cells, and KRT19P3 suppressed GC cell proliferation and metastasis partly through regulation of COPS7A expression. COPS7A could promote deubiquitinylation of I kappa B alpha, which was executed by CSN-associated deubiquitinylase USP15, and then KRT19P3 inactivated nuclear factor kappa-B (NF-kappa B) signaling pathway in a COPS7A-dependent manner. For the first time, we revealed that KRT19P3 could suppress tumor growth and metastasis through COPS7A-mediated NF-kappa B pathway, which may serve as potential targets for treatment of GC in the future.	[Zheng, Jie; Zhang, Hui; Ma, Ranran; Liu, Haiting; Gao, Peng] Shandong Univ, Minist Educ, Key Lab Expt Teratol, Jinan, Shandong, Peoples R China; [Zheng, Jie; Zhang, Hui; Ma, Ranran; Liu, Haiting; Gao, Peng] Shandong Univ, Sch Med, Dept Pathol, Jinan, Shandong, Peoples R China; [Zheng, Jie] Weifang Med Univ, Dept Pathol, Weifang, Shandong, Peoples R China; [Zhang, Hui; Ma, Ranran; Liu, Haiting; Gao, Peng] Shandong Univ, Qilu Hosp, Dept Pathol, Jinan, Shandong, Peoples R China	Shandong University; Shandong University; Weifang Medical University; Shandong University	Gao, P (corresponding author), Shandong Univ, Minist Educ, Key Lab Expt Teratol, Jinan, Shandong, Peoples R China.; Gao, P (corresponding author), Shandong Univ, Sch Med, Dept Pathol, Jinan, Shandong, Peoples R China.; Gao, P (corresponding author), Shandong Univ, Qilu Hosp, Dept Pathol, Jinan, Shandong, Peoples R China.	gaopeng@sdu.edu.cn			National Science Foundation of China [81672842, 81802474]; Taishan Scholars Program of Shandong Province [ts201511096]; Natural Scientific Foundation of Shandong Province [ZR2015HL091]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Taishan Scholars Program of Shandong Province; Natural Scientific Foundation of Shandong Province(Natural Science Foundation of Shandong Province)	This study was supported by the National Science Foundation of China (Grant No. 81672842 and 81802474), the Taishan Scholars Program of Shandong Province (Grant No. ts201511096), the Natural Scientific Foundation of Shandong Province (ZR2015HL091).	Alves KH, 2002, FEBS LETT, V527, P15, DOI 10.1016/S0014-5793(02)03147-2; Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Chen RB, 2017, NUCLEIC ACIDS RES, V45, P9947, DOI 10.1093/nar/gkx600; de Groen FLM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132495; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Gong CG, 2011, NATURE, V470, P284, DOI 10.1038/nature09701; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Hou J, 2017, ONCOGENE, V36, P1134, DOI 10.1038/onc.2016.280; Hsu MC, 2008, MODERN PATHOL, V21, P609, DOI [10.1038/modpathol.2008.23, 10.1038/mpath.2008.23]; Hu Y, 2014, CANCER RES, V74, P6890, DOI 10.1158/0008-5472.CAN-14-0686; Kouvaraki MA, 2003, CANCER RES, V63, P2977; Liu TY, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0873-2; Lu MH, 2016, ONCOGENE, V35, P3524, DOI 10.1038/onc.2015.413; Mao LX, 2019, EXP CELL RES, V374, P274, DOI 10.1016/j.yexcr.2018.10.012; Qi FZ, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0420-4; Sasaki N, 2001, CLIN CANCER RES, V7, P4136; Schweitzer K, 2007, EMBO J, V26, P1532, DOI 10.1038/sj.emboj.7601600; Shackleford TJ, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2902; Shi XF, 2013, CANCER LETT, V339, P159, DOI 10.1016/j.canlet.2013.06.013; Sokolova O, 2017, TOXINS, V9, DOI 10.3390/toxins9040119; Uhle S, 2003, EMBO J, V22, P1302, DOI 10.1093/emboj/cdg127; Wang H, 2018, THERANOSTICS, V8, P2814, DOI 10.7150/thno.23012; Wang YL, 2002, BIOCHEM J, V366, P79, DOI 10.1042/bj20020211; Wicker CA, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-3313-y; Yang F, 2011, HEPATOLOGY, V54, P1679, DOI 10.1002/hep.24563; Zhao RY, 2011, J CLIN INVEST, V121, P851, DOI 10.1172/JCI44111; Zhu YP, 2014, ONCOL LETT, V7, P1197, DOI 10.3892/ol.2014.1843	28	38	41	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2019	38	45					7073	7088		10.1038/s41388-019-0934-z	http://dx.doi.org/10.1038/s41388-019-0934-z			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JL9XI	31409899				2022-12-28	WOS:000495878400004
J	Raimondi, F; Inoue, A; Kadji, FMN; Shuai, N; Gonzalez, JC; Singh, G; de la Vega, AA; Sotillo, R; Fischer, B; Aoki, J; Gutkind, JS; Russell, RB				Raimondi, Francesco; Inoue, Asuka; Kadji, Francois M. N.; Shuai, Ni; Gonzalez, Juan-Carlos; Singh, Gurdeep; de la Vega, Alicia Alonso; Sotillo, Rocio; Fischer, Bernd; Aoki, Junken; Gutkind, J. Silvio; Russell, Robert B.			Rare, functional, somatic variants in gene families linked to cancer genes: GPCR signaling as a paradigm	ONCOGENE			English	Article							PROTEIN-COUPLED RECEPTORS; MUTATIONAL LANDSCAPE; ADENOSINE RECEPTOR; TUMOR-SUPPRESSOR; PATHWAY; PROLIFERATION; ACTIVATION; EXPRESSION; MECHANISM; DATABASE	Oncodriver genes are usually identified when mutations recur in multiple tumours. Different drivers often converge in the activation or repression of key cancer-relevant pathways. However, as many pathways contain multiple members of the same gene family, individual mutations might be overlooked, as each family member would necessarily have a lower mutation frequency and thus not identified as significant in any one-gene-at-a-time analysis. Here, we looked for mutated, functional sequence positions in gene families that were mutually exclusive (in patients) with another gene in the same pathway, which identified both known and new candidate oncodrivers. For instance, many inactivating mutations in multiple G-protein (particularly G(i/o)) coupled receptors, are mutually exclusive with G alpha(s) oncogenic activating mutations, both of which ultimately enhance cAMP signalling. By integrating transcriptomics and interaction data, we show that the G(s) pathway is upregulated in multiple cancer types, even those lacking known GNAS activating mutations. This suggests that cancer cells may develop alternative strategies to activate adenylate cyclase signalling in multiple cancer types. Our study provides a mechanistic interpretation for several rare somatic mutations in multi-gene oncodrivers, and offers possible explanations for known and potential off-label cancer treatments, suggesting new therapeutic opportunities.	[Raimondi, Francesco; Gonzalez, Juan-Carlos; Singh, Gurdeep; Russell, Robert B.] Heidelberg Univ, BioQuant, Neuenheimer Feld 267, D-69120 Heidelberg, Germany; [Raimondi, Francesco; Gonzalez, Juan-Carlos; Singh, Gurdeep; Russell, Robert B.] Heidelberg Univ, Biochem Ctr BZH, Neuenheimer Feld 328, D-69120 Heidelberg, Germany; [Inoue, Asuka; Kadji, Francois M. N.; Aoki, Junken] Tohoku Univ, Grad Sch Pharmaceut Sci, Sendai, Miyagi 9808578, Japan; [Inoue, Asuka; Kadji, Francois M. N.; Aoki, Junken] Japan Agcy Med Res & Dev AMED, Adv Res & Dev Programs Med Innovat PRIME, Chiyoda Ku, Tokyo 1000004, Japan; [Shuai, Ni; Fischer, Bernd] German Canc Res Ctr, Computat Genome Biol, D-69120 Heidelberg, Germany; [de la Vega, Alicia Alonso; Sotillo, Rocio] German Canc Res Ctr, TLRC, Div Mol Thorac Oncol, D-69120 Heidelberg, Germany; [de la Vega, Alicia Alonso; Sotillo, Rocio] German Ctr Lung Res DZL, D-69120 Heidelberg, Germany; [Gutkind, J. Silvio] Univ San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Tohoku University; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of San Diego	Raimondi, F; Russell, RB (corresponding author), Heidelberg Univ, BioQuant, Neuenheimer Feld 267, D-69120 Heidelberg, Germany.; Raimondi, F; Russell, RB (corresponding author), Heidelberg Univ, Biochem Ctr BZH, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	francesco.raimondi@bioquant.uni-heidelberg.de; robert.russell@bioquant.uni-heidelberg.de	Russell, Robert/GWU-6389-2022; Raimondi, Francesco/AAB-8586-2019; Francois, Kadji/ABF-2484-2021; Gutkind, J. Silvio/J-1201-2016; Ngako KADJI, Francois Marie/ABF-8093-2021; Russell, Rob/AAH-9145-2019	Russell, Robert/0000-0002-7213-1398; Francois, Kadji/0000-0002-9187-4584; Gutkind, J. Silvio/0000-0002-5150-4482; Russell, Rob/0000-0002-1905-4717; Sotillo, Rocio/0000-0002-0855-7917; RAIMONDI, Francesco/0000-0002-6891-3178; Alonso de la Vega, Alicia/0000-0002-4898-6871; Gonzalez-Sanchez, Juan Carlos/0000-0002-7493-3669	Cell Networks Excellence initiative of the Germany Research Foundation (DFG); Alexander Von Humboldt post-doctoral fellowship; Michael J. Fox Foundation; Japan Science and Technology Agency (JST) [JPMJPR1331]; Japan Agency for Medical Research and Development (AMED) [JP17gm5910013]; Japan Society for the Promotion of Science (JSPS) KAKENHI [17K08264]; AMED [JP17gm0710001]	Cell Networks Excellence initiative of the Germany Research Foundation (DFG)(German Research Foundation (DFG)); Alexander Von Humboldt post-doctoral fellowship(Alexander von Humboldt Foundation); Michael J. Fox Foundation; Japan Science and Technology Agency (JST)(Japan Science & Technology Agency (JST)); Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Japan Society for the Promotion of Science (JSPS) KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); AMED	FR, JCG, GS and RBR are supported by the Cell Networks Excellence initiative of the Germany Research Foundation (DFG). FR was supported by an Alexander Von Humboldt post-doctoral fellowship and a Michael J. Fox Foundation research grant. RBR is part of the DFG SFB/TPR186 Molecular Switches in the Spatio-Temporal Control of Cellular Signal Transmission, and a member of the BMBF German Network for Bioinfomatics Infrastructure (de. NBI). AI was funded by Japan Science and Technology Agency (JST) Grant Number JPMJPR1331, Japan Agency for Medical Research and Development (AMED) Grant Number JP17gm5910013 and Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number 17K08264. JA received funding from AMED Grant Number JP17gm0710001. The authors thank Ayumi Inoue, Naoko Kuroda and Yuko Sugamura (Tohoku University) for plasmid construction and cell culture experiments. We also thank a reviewer for the helpful suggestion to explore the wider set of genes potentially affecting cAMP in cancer.	Audet M, 2012, CELL, V151, P14, DOI 10.1016/j.cell.2012.09.003; Bailey MH, 2018, CELL, V173, P371, DOI [10.1016/j.cell.2018.02.060, 10.1016/j.cell.2018.07.034]; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Bateman A, 2017, NUCLEIC ACIDS RES, V45, pD158, DOI 10.1093/nar/gkw1099; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Betts MJ, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gku1094; Choy C, 2016, ONCOL REP, V35, P3135, DOI 10.3892/or.2016.4710; Cives M, 2015, ENDOCR-RELAT CANCER, V22, P1, DOI 10.1530/ERC-14-0360; Cohen S, 2011, J CELL PHYSIOL, V226, P2438, DOI 10.1002/jcp.22593; De Giorgi V, 2018, JAMA ONCOL, V4, DOI 10.1001/jamaoncol.2017.2908; Demir H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109897; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Eddy Sean R, 2009, Genome Inform, V23, P205; Fabregat A, 2016, NUCLEIC ACIDS RES, V44, pD481, DOI 10.1093/nar/gkv1351; Finn RD, 2016, NUCLEIC ACIDS RES, V44, pD279, DOI 10.1093/nar/gkv1344; Fishman P, 2002, ANTI-CANCER DRUG, V13, P437, DOI 10.1097/00001813-200206000-00001; Flock T, 2015, NATURE, V524, P173, DOI 10.1038/nature14663; Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Gelis L, 2017, EXP DERMATOL, V26, P569, DOI 10.1111/exd.13316; Gelis L, 2016, J BIOL CHEM, V291, P17772, DOI 10.1074/jbc.M116.734517; Gonzalez-Sanchez JC, 2018, FEBS LETT, V592, P463, DOI 10.1002/1873-3468.12988; Gordon S, 2006, ONCOGENE, V25, P1125, DOI 10.1038/sj.onc.1209080; Gussow AB, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0869-4; Han H, 2015, SCI REP-UK, V5, DOI 10.1038/srep11432; Ideno N, 2018, GASTROENTEROLOGY, V155, P1593, DOI 10.1053/j.gastro.2018.08.006; Inoue A, 2012, NAT METHODS, V9, P1021, DOI [10.1038/nmeth.2172, 10.1038/NMETH.2172]; Jiang C, 2007, NUCLEIC ACIDS RES, V35, pD137, DOI 10.1093/nar/gkl1041; Johannessen CM, 2013, NATURE, V504, P138, DOI 10.1038/nature12688; Jose J, 2017, ACS MED CHEM LETT, V8, P1072, DOI 10.1021/acsmedchemlett.7b00282; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kucuk C, 2011, P NATL ACAD SCI USA, V108, P20119, DOI 10.1073/pnas.1115128108; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Leiserson MDM, 2015, NAT GENET, V47, P106, DOI 10.1038/ng.3168; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Marbach D, 2016, NAT METHODS, V13, P366, DOI [10.1038/NMETH.3799, 10.1038/nmeth.3799]; Martincorena I, 2017, CELL, V171, P1029, DOI 10.1016/j.cell.2017.09.042; Marx V, 2016, NAT METHODS, V134, P2016; Menigatti M, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.21; Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984; Miller ML, 2015, CELL SYST, V1, P197, DOI 10.1016/j.cels.2015.08.014; Moore AR, 2016, NAT GENET, V48, P675, DOI 10.1038/ng.3549; Mu JS, 2017, ONCOL LETT, V13, P1223, DOI 10.3892/ol.2017.5573; Muppidi JR, 2014, NATURE, V516, P254, DOI 10.1038/nature13765; Nairismagi ML, 2016, LEUKEMIA, V30, P1311, DOI 10.1038/leu.2016.13; Neph S, 2012, CELL, V150, P1274, DOI 10.1016/j.cell.2012.04.040; Neuhaus EM, 2009, J BIOL CHEM, V284, P16218, DOI 10.1074/jbc.M109.012096; Nilsson MB, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aao4307; O'Hayre M, 2016, ONCOGENE, V35, P3771, DOI 10.1038/onc.2015.442; O'Hayre M, 2013, NAT REV CANCER, V13, P412, DOI 10.1038/nrc3521; Patra KC, 2018, NAT CELL BIOL, V20, P811, DOI 10.1038/s41556-018-0122-3; Petrovski S, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003709; Porta-Pardo E, 2017, NAT METHODS, V14, P782, DOI [10.1038/NMETH.4364, 10.1038/nmeth.4364]; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Raimondi F, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12971-7; Raimondi F, 2016, SCI REP-UK, V6, DOI 10.1038/srep34490; Reimand J, 2016, NUCLEIC ACIDS RES, V44, pW83, DOI 10.1093/nar/gkw199; Rochdi MD, 2010, MOL PHARMACOL, V77, P836, DOI 10.1124/mol.109.061804; Rosenbaum DM, 2009, NATURE, V459, P356, DOI 10.1038/nature08144; Rovati GE, 2007, MOL PHARMACOL, V71, P959, DOI 10.1124/mol.106.029470; Samyn B, 2015, NAT METHODS, V2, P1; Sarnataro D, 2006, MOL PHARMACOL, V70, P1298, DOI 10.1124/mol.106.025601; Scheer A, 2000, MOL PHARMACOL, V57, P219; Southan C, 2016, NUCLEIC ACIDS RES, V44, pD1054, DOI 10.1093/nar/gkv1037; Tuominen I, 2015, ONCOGENE, V34, P1174, DOI 10.1038/onc.2014.50; Turan S, 2015, CURR OSTEOPOROS REP, V13, P146, DOI 10.1007/s11914-015-0268-x; Velazquez EF, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-2; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wang LW, 2003, CLIN CANCER RES, V9, P6371; Wang YM, 2015, MOL MED REP, V11, P1925, DOI 10.3892/mmr.2014.2944; White C, 2016, ONCOTARGET, V7, P23106, DOI 10.18632/oncotarget.7145; Yates A, 2016, NUCLEIC ACIDS RES, V44, pD710, DOI 10.1093/nar/gkv1157; Yu J, 2013, ONCOGENE, V32, P307, DOI 10.1038/onc.2012.54; Zatelli MC, 2007, ENDOCR-RELAT CANCER, V14, P91, DOI 10.1677/ERC-06-0026; Zhang D, 2010, CANCER BIOL THER, V10, P19, DOI 10.4161/cbt.10.1.11944; Zheng GY, 2008, BIOINFORMATICS, V24, P2416, DOI 10.1093/bioinformatics/btn439	78	8	8	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2019	38	38					6491	6506		10.1038/s41388-019-0895-2	http://dx.doi.org/10.1038/s41388-019-0895-2			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IY7XR	31337866	Green Published, hybrid			2022-12-28	WOS:000486609000002
J	Zhang, YH; Feng, XL; Zhang, J; Chen, MY; Huang, E; Chen, XB				Zhang, Yanhong; Feng, Xiuli; Zhang, Jin; Chen, Minyi; Huang, Eric; Chen, Xinbin			Iron regulatory protein 2 is a suppressor of mutant p53 in tumorigenesis	ONCOGENE			English	Article							FERREDOXIN REDUCTASE; MITOCHONDRIAL FERREDOXIN; BINDING PROTEIN; MOUSE MODELS; CELL-GROWTH; CANCER; GAIN; MUTATION; GENE; FERROPTOSIS	p53 is known to play a role in iron homeostasis and is required for FDXR-mediated iron metabolism via iron regulatory protein 2 (IRP2). Interestingly, p53 is frequently mutated in tumors wherein iron is often accumulated, suggesting that mutant p53 may exert its gain of function by altering iron metabolism. In this study, we found that FDXR deficiency decreased mutant p53 expression along with altered iron metabolism in p53(R270H)(/-) MEFs and cancer cells carrying mutant p53. Consistently, we found that decreased expression of mutant p53 by FDXR deficiency inhibited mutant p53-R270H to induce carcinoma and high grade pleomorphic sarcoma in FDXR+/-; p53(R270H)(/-) mice as compared with p53(R270H)(/-) mice. Moreover, we found that like its effect on wild-type p53, loss of IRP2 increased mutant p53 expression. However, unlike its effect to suppress cell growth in cells carrying wild-type p53, loss of IRP2 promoted cell growth in cancer cells expressing mutant p53. Finally, we found that ectopic expression of IRP2 suppressed cell growth in a mutant p53-dependent manner. Together, our data indicate that mutant p53 gain-of-function can be suppressed by IRP2 and FDXR deficiency, both of which may be explored to target tumors carrying mutant p53.	[Zhang, Yanhong; Feng, Xiuli; Zhang, Jin; Chen, Xinbin] Univ Calif Davis, Sch Med, Comparat Oncol Lab, Davis, CA 95616 USA; [Zhang, Yanhong; Feng, Xiuli; Zhang, Jin; Chen, Xinbin] Univ Calif Davis, Sch Vet Med, Comparat Oncol Lab, Davis, CA 95616 USA; [Feng, Xiuli] Nanjing Agr Univ, Coll Vet Med, Nanjing 210095, Jiangsu, Peoples R China; [Chen, Minyi] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; [Huang, Eric] Univ Washington, Dept Pathol, Seattle, WA 98104 USA	University of California System; University of California Davis; University of California System; University of California Davis; Nanjing Agricultural University; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Washington; University of Washington Seattle	Chen, XB (corresponding author), Univ Calif Davis, Sch Med, Comparat Oncol Lab, Davis, CA 95616 USA.; Chen, XB (corresponding author), Univ Calif Davis, Sch Vet Med, Comparat Oncol Lab, Davis, CA 95616 USA.	xbchen@ucdavis.edu		chen, xinbin/0000-0002-4582-6506	National Institutes of Health [CA224433-01]; NATIONAL CANCER INSTITUTE [R01CA224433] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by the National Institutes of Health grants CA224433-01. The authors would like to thank Dr. Elizabeth Leibold and Dr. Kuanyu Li for their generous gifts of IRP2 antibodies.	Bertout JA, 2009, CANCER RES, V69, P3213, DOI 10.1158/0008-5472.CAN-08-4223; Beutler E, 2006, ANNU REV MED, V57, P331, DOI 10.1146/annurev.med.57.121304.131310; BRANDT ME, 1992, ARCH BIOCHEM BIOPHYS, V294, P735, DOI 10.1016/0003-9861(92)90749-M; Butt J, 1996, P NATL ACAD SCI USA, V93, P4345, DOI 10.1073/pnas.93.9.4345; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Edmondson DA, 2016, RADIAT RES, V186, P235, DOI 10.1667/RR14263.1; Elbendary AA, 1996, CLIN CANCER RES, V2, P1571; Fonseca-Nunes A, 2014, CANCER EPIDEM BIOMAR, V23, P12, DOI 10.1158/1055-9965.EPI-13-0733; Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112; Gunshin H, 2001, FEBS LETT, V509, P309, DOI 10.1016/S0014-5793(01)03189-1; GUO B, 1994, J BIOL CHEM, V269, P24252; Guzman C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092444; Hanel W, 2013, CELL DEATH DIFFER, V20, P898, DOI 10.1038/cdd.2013.17; HANN HWL, 1990, HEPATOLOGY, V11, P566, DOI 10.1002/hep.1840110407; Henderson ER, 1996, J BIOL CHEM, V271, P4900; Hentze MW, 2010, CELL, V142, P24, DOI 10.1016/j.cell.2010.06.028; HENTZE MW, 1989, NUCLEIC ACIDS RES, V17, P6103, DOI 10.1093/nar/17.15.6103; HERSHKO C, 1991, BLOOD, V77, P2049; Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111; Jiang L, 2015, NATURE, V520, P57, DOI 10.1038/nature14344; Kwok JC, 2002, CRIT REV ONCOL HEMAT, V42, P65, DOI 10.1016/S1040-8428(01)00213-X; Lacombe J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198851; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lange H, 2000, P NATL ACAD SCI USA, V97, P1050, DOI 10.1073/pnas.97.3.1050; Lawen A, 2013, ANTIOXID REDOX SIGN, V18, P2473, DOI 10.1089/ars.2011.4271; Lee MK, 2012, CANCER CELL, V22, P751, DOI 10.1016/j.ccr.2012.10.022; Liu G, 2002, ONCOGENE, V21, P7195, DOI 10.1038/sj.onc.1205862; Muller JJ, 2001, J BIOL CHEM, V276, P2786, DOI 10.1074/jbc.M008501200; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; O'Brien G, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-19043-w; Okumura H, 2015, ANTICANCER RES, V35, P6471; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Oren M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001107; Porter JB, 1996, BLOOD, V88, P705, DOI 10.1182/blood.V88.2.705.bloodjournal882705; ROUAULT TA, 1990, P NATL ACAD SCI USA, V87, P7958, DOI 10.1073/pnas.87.20.7958; Rouault TA, 2006, NAT CHEM BIOL, V2, P406, DOI 10.1038/nchembio807; Sauer L, 2010, ONCOGENE, V29, P2628, DOI 10.1038/onc.2010.24; Shaheen NJ, 2003, JNCI-J NATL CANCER I, V95, P154, DOI 10.1093/jnci/95.2.154; Sheftel AD, 2010, P NATL ACAD SCI USA, V107, P11775, DOI 10.1073/pnas.1004250107; Shi YB, 2012, BBA-MOL CELL RES, V1823, P484, DOI 10.1016/j.bbamcr.2011.11.002; Simcox JA, 2013, CELL METAB, V17, P329, DOI 10.1016/j.cmet.2013.02.007; Smith AG, 1995, TOXICOL LETT, V82-3, P945, DOI 10.1016/0378-4274(95)03530-3; Torti SV, 2013, NAT REV CANCER, V13, P342, DOI 10.1038/nrc3495; Wang JA, 2011, BIOCHEM J, V434, P365, DOI 10.1042/BJ20101825; Xie YC, 2017, CELL REP, V20, P1692, DOI 10.1016/j.celrep.2017.07.055; Yan WS, 2010, J BIOL CHEM, V285, P14229, DOI 10.1074/jbc.M109.097253; Yang HJ, 2017, P NATL ACAD SCI USA, V114, P11500, DOI 10.1073/pnas.1711814114; Yu JS, 2003, CANCER RES, V63, P6170; Zhang F, 2008, J BIOL CHEM, V283, P33911, DOI 10.1074/jbc.M806432200; Zhang J, 2018, CANCER RES, V78, P1511, DOI 10.1158/0008-5472.CAN-17-2457; Zhang J, 2015, EMBO J, V34, P2953, DOI 10.15252/embj.201591437; Zhang YH, 2017, GENE DEV, V31, P1243, DOI 10.1101/gad.299388.117; Zhou G, 2014, MOL CELL, V54, P960, DOI 10.1016/j.molcel.2014.04.024	54	6	6	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2019	38	35					6256	6269		10.1038/s41388-019-0876-5	http://dx.doi.org/10.1038/s41388-019-0876-5			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IU9RZ	31332290	Green Accepted			2022-12-28	WOS:000483919400002
J	Khoshchehreh, R; Totonchi, M; Ramirez, JC; Torres, R; Baharvand, H; Aicher, A; Ebrahimi, M; Heeschen, C				Khoshchehreh, Reyhaneh; Totonchi, Mehdi; Carlos Ramirez, Juan; Torres, Raul; Baharvand, Hossein; Aicher, Alexandra; Ebrahimi, Marzieh; Heeschen, Christopher			Epigenetic reprogramming of primary pancreatic cancer cells counteracts their in vivo tumourigenicity	ONCOGENE			English	Article							STEM-CELLS; INHIBITION; DEDIFFERENTIATION; PLURIPOTENCY; TECHNOLOGY; DOT1L	Pancreatic ductal adenocarcinoma (PDAC) arises through accumulation of multiple genetic alterations. However, cancer cells also acquire and depend on cancer-specific epigenetic changes. To conclusively demonstrate the crucial relevance of the epigenetic programme for the tumourigenicity of the cancer cells, we used cellular reprogramming technology to reverse these epigenetic changes. We reprogrammed human PDAC cultures using three different techniques - (1) lentivirally via induction of Yamanaka Factors (OSKM), (2) the pluripotency-associated gene OCT4 and the microRNA mir-302, or (3) using episomal vectors as a safer alternative without genomic integration. We found that induction with episomal vectors was the most efficient method to reprogram primary human PDAC cultures as well as primary human fibroblasts that served as positive controls. Successful reprogramming was evidenced by immunostaining, alkaline phosphatase staining, and real-time PCR. Intriguingly, reprogramming of primary human PDAC cultures drastically reduced their in vivo tumourigenicity, which appeared to be driven by the cells' enhanced differentiation and loss of stemness upon transplantation. Our study demonstrates that reprogrammed primary PDAC cultures are functionally distinct from parental PDAC cells resulting in drastically reduced tumourigenicity in vitro and in vivo. Thus, epigenetic alterations account at least in part for the tumourigenicity and aggressiveness of pancreatic cancer, supporting the notion that epigenetic modulators could be a suitable approach to improve the dismal outcome of patients with pancreatic cancer.	[Khoshchehreh, Reyhaneh; Totonchi, Mehdi; Baharvand, Hossein; Ebrahimi, Marzieh] ACECR, Royan Inst Stern Cell Biol & Technol, Cell Sci Res Ctr, Dept Stern Cells & Dev Biol, Tehran, Iran; [Khoshchehreh, Reyhaneh; Baharvand, Hossein; Ebrahimi, Marzieh] Univ Sci & Culture, Dept Dev Biol, Tehran, Iran; [Totonchi, Mehdi] ACECR, Royan Inst Reprod Biomed, Reprod Biomed Res Ctr, Dept Genet, Tehran, Iran; [Carlos Ramirez, Juan] VIVEBioTECH, San Sebastian 20009, Spain; [Torres, Raul] CNIO, Human Canc Genet Program, Mol Cytogenet & Genome Editing Unit, Madrid 28029, Spain; [Torres, Raul] Univ Barcelona, Sch Med, Josep Carreras Leukemia Res Inst, Barcelona 08036, Spain; [Torres, Raul] Univ Barcelona, Sch Med, Dept Biomed, Barcelona 08036, Spain; [Aicher, Alexandra] Univ Sydney, Centenary Inst, Gene & Stem Cell Therapy Program, Camperdown, NSW 2050, Australia; [Aicher, Alexandra; Heeschen, Christopher] Spanish Natl Canc Res Ctr CNIO, Mol Pathol Programme, Madrid 28029, Spain	Academic Center for Education, Culture & Research (ACECR); Academic Center for Education, Culture & Research (ACECR); Centro Nacional de Investigaciones Oncologicas (CNIO); Institut de Recerca Contra la Leucemia Josep Carreras (IJC); University of Barcelona; University of Barcelona; University of Sydney; Centenary Institute; Centro Nacional de Investigaciones Oncologicas (CNIO)	Ebrahimi, M (corresponding author), ACECR, Royan Inst Stern Cell Biol & Technol, Cell Sci Res Ctr, Dept Stern Cells & Dev Biol, Tehran, Iran.; Ebrahimi, M (corresponding author), Univ Sci & Culture, Dept Dev Biol, Tehran, Iran.; Aicher, A (corresponding author), Univ Sydney, Centenary Inst, Gene & Stem Cell Therapy Program, Camperdown, NSW 2050, Australia.; Aicher, A; Heeschen, C (corresponding author), Spanish Natl Canc Res Ctr CNIO, Mol Pathol Programme, Madrid 28029, Spain.	aicher_a@yahoo.com; Mebrahimi@royaninstitute.org; christopher.heeschen@icloud.com	ebrahimi, marzieh/AAO-2659-2020; Ruiz, Raul Torres/J-1649-2018; Aicher, Alexandra/GZK-8031-2022	ebrahimi, marzieh/0000-0003-1140-0379; Ruiz, Raul Torres/0000-0001-9606-0398; Aicher, Alexandra/0000-0002-8920-9577	ERC [Pa-CSC 233460]; European Community [602783]; Royan Institute [91000413]	ERC(European Research Council (ERC)European Commission); European Community(European Commission); Royan Institute	The research was supported by the ERC Advanced Investigator Grant (Pa-CSC 233460, to C.H.), the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement no 602783 (CAM-PaC, to CH) and funding provided by the Royan Institute (#91000413 to ME).	Blelloch RH, 2004, P NATL ACAD SCI USA, V101, P13985, DOI 10.1073/pnas.0405015101; Carette JE, 2010, BLOOD, V115, P4039, DOI 10.1182/blood-2009-07-231845; Carey BW, 2009, P NATL ACAD SCI USA, V106, P157, DOI 10.1073/pnas.0811426106; Chen CW, 2015, NAT MED, V21, P335, DOI 10.1038/nm.3832; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cioffi M, 2015, CLIN CANCER RES, V21, P2325, DOI 10.1158/1078-0432.CCR-14-1399; Daigle SR, 2013, BLOOD, V122, P1017, DOI 10.1182/blood-2013-04-497644; Duan HY, 2017, GYNECOL ONCOL, V147, P408, DOI 10.1016/j.ygyno.2017.08.010; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Friedlander SYG, 2009, CANCER CELL, V16, P379, DOI 10.1016/j.ccr.2009.09.027; Hermann PC, 2014, GASTROENTEROLOGY, V147, P1119, DOI 10.1053/j.gastro.2014.08.002; Hochedlinger K, 2004, GENE DEV, V18, P1875, DOI 10.1101/gad.1213504; Kim J, 2015, EMBO J, V34, P739, DOI 10.15252/embj.201490736; Krstic M, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2697-z; Kumano K, 2012, BLOOD, V119, P6234, DOI 10.1182/blood-2011-07-367441; Lee JJ, 2014, LAB INVEST, V94, P822, DOI 10.1038/labinvest.2014.87; Li L, 2003, CANCER RES, V63, P2733; Lonardo E, 2011, CELL STEM CELL, V9, P433, DOI 10.1016/j.stem.2011.10.001; De Bonis ML, 2014, STEM CELL REP, V2, P690, DOI 10.1016/j.stemcr.2014.03.002; Matsuda Y, 2014, PATHOL INT, V64, P299, DOI 10.1111/pin.12180; Matsui T, 2012, STEM CELLS, V30, P1109, DOI 10.1002/stem.1091; MCKINNELL RG, 1969, SCIENCE, V165, P394, DOI 10.1126/science.165.3891.394; Miyoshi N, 2010, P NATL ACAD SCI USA, V107, P40, DOI 10.1073/pnas.0912407107; Morandi A, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00040; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Rubio-Viqueira B, 2006, CLIN CANCER RES, V12, P4652, DOI 10.1158/1078-0432.CCR-06-0113; Sainz B, 2014, CANCER RES, V74, P7309, DOI 10.1158/0008-5472.CAN-14-1354; Schlaeger TM, 2015, NAT BIOTECHNOL, V33, P58, DOI 10.1038/nbt.3070; Semi K, 2015, CANCER SCI, V106, P1251, DOI 10.1111/cas.12758; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Wang H, 2017, ONCOTARGET, V8; Yamada Y, 2014, STEM CELL TRANSL MED, V3, P1182, DOI 10.5966/sctm.2014-0090; Zagorac S, 2016, CANCER RES, V76, P4546, DOI 10.1158/0008-5472.CAN-15-3268; Zhang X, 2013, ONCOGENE, V32, P2249, DOI 10.1038/onc.2012.237; Zhou Z, 2018, J CELL PHYSIOL, V233, P1359, DOI 10.1002/jcp.26012	37	17	17	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2019	38	34					6226	6239		10.1038/s41388-019-0871-x	http://dx.doi.org/10.1038/s41388-019-0871-x			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IS5RM	31308488	Green Published, hybrid			2022-12-28	WOS:000482210100006
J	Seshacharyulu, P; Rachagani, S; Muniyan, S; Siddiqui, JA; Cruz, E; Sharma, S; Krishnan, R; Killips, BJ; Sheinin, Y; Lele, SM; Smith, LM; Talmon, GA; Ponnusamy, MP; Datta, K; Batra, SK				Seshacharyulu, Parthasarathy; Rachagani, Satyanarayana; Muniyan, Sakthivel; Siddiqui, Jawed A.; Cruz, Eric; Sharma, Sunandini; Krishnan, Ramakrishnan; Killips, Brigham J.; Sheinin, Yuri; Lele, Subodh M.; Smith, Lynette M.; Talmon, Geoffrey A.; Ponnusamy, Moorthy P.; Datta, Kaustubh; Batra, Surinder K.			FDPS cooperates with PTEN loss to promote prostate cancer progression through modulation of small GTPases/AKT axis	ONCOGENE			English	Article							FARNESYL PYROPHOSPHATE SYNTHASE; ZOLEDRONIC ACID; IN-VITRO; CELL-PROLIFERATION; ISOPRENOID PATHWAY; BINDING; INHIBITION; EXPRESSION; TARGET; BISPHOSPHONATE	Farnesyl diphosphate synthase (FDPS), a mevalonate pathway enzyme, is highly expressed in several cancers, including prostate cancer (PCa). To date, the mechanistic, functional, and clinical significance of FDPS in cancer remains unexplored. We evaluated the FDPS expression and its cancer-associated phenotypes using in vitro and in vivo methods in PTEN-deficient and sufficient human and mouse PCa cells and tumors. Interestingly, FDPS overexpression synergizes with PTEN deficiency in PTEN conditionally knockout mice (P < 0.05) and expressed significantly higher in human (P < 0.001) PCa tissues, cell lines, and murine tumoroids compared to respective controls. In silico analysis revealed that FDPS is associated with increasing Gleason score, PTEN functionally deficient status, and poor survival of PCa. Ectopic overexpression of FDPS promotes oncogenic phenotypes such as colony formation (P < 0.01) and proliferation (P < 0.01) through activation of AKT and ERK signaling by prenylating Rho A, Rho G, and CDC42 small GTPases. Of interest, knockdown of FDPS in PCa cells exhibits decreased colony growth and proliferation (P < 0.001) by modulating AKT and ERK pathways. Further, genetic and pharmacological inhibition of PI3K but not AKT reduced FDPS expression. Pharmacological targeting of FDPS by zoledronic acid (ZOL), which is already in clinics, exhibit reduced growth and clonogenicity of human and murine PCa cells (P < 0.01) and 3D tumoroids (P < 0.02) by disrupting AKT and ERK signaling through direct interference of small GTPases protein prenylation. Thus, FDPS plays an oncogenic role in PTEN-deficient PCa through GTPase/AKT axis. Identifying mevalonate pathway proteins could serve as a therapeutic target in PTEN dysregulated tumors.	[Seshacharyulu, Parthasarathy; Rachagani, Satyanarayana; Muniyan, Sakthivel; Siddiqui, Jawed A.; Cruz, Eric; Sharma, Sunandini; Krishnan, Ramakrishnan; Killips, Brigham J.; Ponnusamy, Moorthy P.; Datta, Kaustubh; Batra, Surinder K.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Sheinin, Yuri; Lele, Subodh M.; Talmon, Geoffrey A.; Batra, Surinder K.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; [Smith, Lynette M.] Univ Nebraska Med Ctr, Dept Stat, Omaha, NE USA; [Ponnusamy, Moorthy P.; Datta, Kaustubh; Batra, Surinder K.] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Batra, SK (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.; Batra, SK (corresponding author), Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA.; Batra, SK (corresponding author), Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA.	sbatra@unmc.edu	Krishnan, Ramakrishnan/AAX-6627-2020; Siddiqui, Jawed/G-9258-2017; Muniyan, Sakthivel/L-3868-2019; Seshacharyulu, Parthasarathy/AGL-7648-2022	Siddiqui, Jawed/0000-0003-1287-3004; Muniyan, Sakthivel/0000-0001-9405-7857; Seshacharyulu, Parthasarathy/0000-0002-2348-3901	United States Department of Defense [PC170891]; National Institutes of Health [P01 CA217798, UO1 CA185148, 1R01CA182435-01A1, P30 GM106397]; NATIONAL CANCER INSTITUTE [P01CA217798, U01CA185148] Funding Source: NIH RePORTER	United States Department of Defense(United States Department of Defense); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work/authors are supported, in parts, by the grants from the United States Department of Defense Grant PC170891, National Institutes of Health (P01 CA217798, UO1 CA185148 and 1R01CA182435-01A1) and P30 GM106397.	Abate M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14495-6; Algur E, 2005, INT J RADIAT ONCOL, V61, P535, DOI 10.1016/j.ijrobp.2004.09.065; Allott EH, 2014, CANCER EPIDEM BIOMAR, V23, P2349, DOI 10.1158/1055-9965.EPI-14-0458; Bastian PJ, 2012, EUR UROL, V61, P1096, DOI 10.1016/j.eururo.2012.02.031; Beier F, 2010, J CELL BIOCHEM, V110, P573, DOI 10.1002/jcb.22604; Bifulco M, 2005, LIFE SCI, V77, P1740, DOI 10.1016/j.lfs.2005.05.017; Castellano Esther, 2011, Genes Cancer, V2, P261, DOI 10.1177/1947601911408079; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen M, 2018, NAT GENET, V50, P206, DOI 10.1038/s41588-017-0027-2; COX A D, 1992, Critical Reviews in Oncogenesis, V3, P365; Dhar MK, 2013, NEW BIOTECHNOL, V30, P114, DOI 10.1016/j.nbt.2012.07.001; Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Ettinger SL, 2004, CANCER RES, V64, P2212, DOI 10.1158/0008-5472.CAN-2148-2; Ferraldeschi R, 2015, EUR UROL, V67, P795, DOI 10.1016/j.eururo.2014.10.027; Fraser M, 2017, NATURE, V541, P359, DOI 10.1038/nature20788; Gao D, 2014, CELL, V159, P176, DOI 10.1016/j.cell.2014.08.016; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Gritzalis D, 2015, BIOORG MED CHEM LETT, V25, P1117, DOI 10.1016/j.bmcl.2014.12.089; Hatziieremia S, 2016, MOL CARCINOGEN, V55, P1667, DOI 10.1002/mc.22417; Heemers H, 2001, MOL ENDOCRINOL, V15, P1817, DOI 10.1210/me.15.10.1817; Hein AL, 2016, CANCER RES, V76, P2243, DOI 10.1158/0008-5472.CAN-15-2119; Hirschey MD, 2015, SEMIN CANCER BIOL, V35, pS129, DOI 10.1016/j.semcancer.2015.10.002; Ishimoto K, 2010, BIOCHEM J, V429, P347, DOI 10.1042/BJ20091511; Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727; Karabulut B, 2009, CELL BIOL INT, V33, P239, DOI 10.1016/j.cellbi.2008.11.011; Kaushik G, 2018, STEM CELLS, V36, P1329, DOI 10.1002/stem.2852; Kijima T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064615; Kwak MK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053476; Lakshmanan I, 2016, ONCOGENE, V35, P4112, DOI 10.1038/onc.2015.478; Leon CG, 2010, PROSTATE, V70, P390, DOI 10.1002/pros.21072; Li L, 2010, BIOCHEM PHARMACOL, V79, P399, DOI 10.1016/j.bcp.2009.08.033; Liao Chun-Peng, 2010, Hormones & Cancer, V1, P44, DOI 10.1007/s12672-009-0005-y; Long Q, 2014, CANCER RES, V74, P3228, DOI 10.1158/0008-5472.CAN-13-2699; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; Muniyan S, 2015, CELL SIGNAL, V27, P2261, DOI 10.1016/j.cellsig.2015.08.002; Neville-Webbe HL, 2010, BRIT J CANCER, V102, P1010, DOI 10.1038/sj.bjc.6605579; Ottewell PD, 2008, JNCI-J NATL CANCER I, V100, P1167, DOI 10.1093/jnci/djn240; Ozturk OH, 2007, CELL BIOL INT, V31, P1069, DOI 10.1016/j.cellbi.2007.02.004; Reilly JE, 2017, CANCER BIOL THER, V18, P872, DOI 10.1080/15384047.2016.1219817; Sharon C, 2015, ONCOTARGET, V6, P15332, DOI 10.18632/oncotarget.3684; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Souchek JJ, 2014, BRIT J CANCER, V111, P1139, DOI 10.1038/bjc.2014.385; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Taylor LG, 2009, CANCER-AM CANCER SOC, V115, P2388, DOI 10.1002/cncr.24283; Todenhofer T, 2013, WORLD J UROL, V31, P345, DOI 10.1007/s00345-012-0844-y; Ullen A, 2005, ACTA ONCOL, V44, P644, DOI 10.1080/02841860510029617; Wang J, 2008, J PROTEOME RES, V7, P3879, DOI 10.1021/pr8001645; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Yue SH, 2014, CELL METAB, V19, P393, DOI 10.1016/j.cmet.2014.01.019	50	18	20	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2019	38	26					5265	5280		10.1038/s41388-019-0791-9	http://dx.doi.org/10.1038/s41388-019-0791-9			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IF4AX	30914801	Green Accepted			2022-12-28	WOS:000473025300011
J	Yang, F; Jin, H; Que, B; Chao, YH; Zhang, HQ; Ying, XL; Zhou, ZY; Yuan, ZS; Su, JL; Wu, B; Zhang, WJ; Qi, DF; Chen, DM; Min, W; Lin, SB; Ji, WD				Yang, Fan; Jin, Huan; Que, Biao; Chao, Yinghui; Zhang, Haiqing; Ying, Xiaoling; Zhou, Zhongyang; Yuan, Zusen; Su, Jialin; Wu, Bin; Zhang, Wenjuan; Qi, Defeng; Chen, Demeng; Min, Wang; Lin, Shuibin; Ji, Weidong			Dynamic m(6)A mRNA methylation reveals the role of METTL3-m(6)A-CDCP1 signaling axis in chemical carcinogenesis	ONCOGENE			English	Article							INDUCED MALIGNANT-TRANSFORMATION; STEM-LIKE CELLS; EPITHELIAL-CELLS; NUCLEAR-RNA; N-6-METHYLADENOSINE; CDCP1; GENE; N6-METHYLADENOSINE; TRANSLATION; DEMETHYLASE	N6-methyladenosine (m(6)A) is the most abundant internal modification in mammalian mRNAs. Despite its functional importance in various physiological events, the role of m(6)A in chemical carcinogenesis remains largely unknown. Here we profiled the dynamic m(6)A mRNA modification during cellular transformation induced by chemical carcinogens and identified a subset of cell transformation-related, concordantly modulated m(6)A sites. Notably, the increased m(6)A in 3'-UTR mRNA of oncogene CDCP1 was found in malignant transformed cells. Mechanistically, the m(6)A methyltransferase METTL3 and demethylases ALKBH5 mediate the m(6)A modification in 3'-UTR of CDCP1 mRNA. METTL3 and m(6)A reader YTHDF1 preferentially recognize m(6)A residues on CPCP1 3'-UTR and promote CDCP1 translation. We further showed that METTL3 and CDCP1 are upregulated in the bladder cancer patient samples and the expression of METTL3 and CDCP1 is correlated with the progression status of the bladder cancers. Inhibition of the METTL3-m(6)A-CDCP1 axis resulted in decreased growth and progression of chemical-transformed cells and bladder cancer cells. Most importantly, METTL3-m(6)A-CDCP1 axis has synergistic effect with chemical carcinogens in promoting malignant transformation of uroepithelial cells and bladder cancer tumorigenesis in vitro and in vivo. Taken together, our results identify dynamic m(6)A modification in chemical-induced malignant transformation and provide insight into critical roles of the METTL3-m(6)A-CDCP1 axis in chemical carcinogenesis.	[Yang, Fan; Jin, Huan; Que, Biao; Chao, Yinghui; Zhang, Haiqing; Ying, Xiaoling; Zhou, Zhongyang; Su, Jialin; Chen, Demeng; Min, Wang; Lin, Shuibin; Ji, Weidong] Sun Yat Sen Univ, Affiliated Hosp 1, Ctr Translat Med, Guangzhou 510080, Guangdong, Peoples R China; [Jin, Huan] Zunyi Med Coll, Dept Physiol, Zunyi 563000, Guizhou, Peoples R China; [Que, Biao; Yuan, Zusen; Qi, Defeng] Guangzhou Med Univ, Affiliated Hosp 1, Minimally Invas Surg Ctr, Guangdong Key Lab Urol,Dept Urol, Guangzhou 510230, Guangdong, Peoples R China; [Wu, Bin] Guangzhou Univ Chinese Med, Affiliated Hosp 2, Guangzhou 510080, Guangdong, Peoples R China; [Zhang, Wenjuan] Jinan Univ, Sch Med, Dept Prevent Med, Guangzhou 510632, Guangdong, Peoples R China; [Min, Wang] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06519 USA; [Min, Wang] Yale Univ, Sch Med, Vasc Biol & Therapeut Program, New Haven, CT 06519 USA	Sun Yat Sen University; Zunyi Medical University; Guangzhou Medical University; Guangzhou University of Chinese Medicine; Jinan University; Yale University; Yale University	Min, W; Lin, SB; Ji, WD (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Ctr Translat Med, Guangzhou 510080, Guangdong, Peoples R China.; Min, W (corresponding author), Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06519 USA.; Min, W (corresponding author), Yale Univ, Sch Med, Vasc Biol & Therapeut Program, New Haven, CT 06519 USA.	wang.min@yale.edu; linshb6@mail.sysu.edu.cn; jiweidong@mail.sysu.edu.cn	ji, weidong/AAX-7397-2020	Lin, Shuibin/0000-0002-7065-614X	National Natural Science Foundation of China [81472999, 81772699, 81772999, 81473014, 81272350]; Key Natural Science Foundation of Guangdong [8151012003000011]; Guangzhou People's Livelihood Science and Technology Project [201803010052]; Key projects of Guangzhou Scientific Research [201804020023]; National Key Research and Development Program of China [2016YFC1300600]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Natural Science Foundation of Guangdong; Guangzhou People's Livelihood Science and Technology Project; Key projects of Guangzhou Scientific Research; National Key Research and Development Program of China	This work was supported by grants from National Natural Science Foundation of China (Number 81472999, Number 81772699, Number 81772999, Number 81473014, and Number 81272350), Key Natural Science Foundation of Guangdong (Number 8151012003000011), Guangzhou People's Livelihood Science and Technology Project (201803010052), Key projects of Guangzhou Scientific Research (201804020023), National Key Research and Development Program of China (2016YFC1300600).	Achanzar WE, 2001, CANCER RES, V61, P455; Batista PJ, 2014, CELL STEM CELL, V15, P707, DOI 10.1016/j.stem.2014.09.019; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Clark SJ, 2017, CANCER CELL, V32, P278, DOI 10.1016/j.ccell.2017.08.016; Cui Q, 2017, CELL REP, V18, P2622, DOI 10.1016/j.celrep.2017.02.059; Dominissini D, 2013, NAT PROTOC, V8, P176, DOI 10.1038/nprot.2012.148; Dominissini D, 2012, NATURE, V485, P201, DOI 10.1038/nature11112; Dunn SJ, 2014, SCIENCE, V344, P1156, DOI 10.1126/science.1248882; Feinberg AP, 2016, NAT REV GENET, V17, P284, DOI 10.1038/nrg.2016.13; Fu Y, 2014, NAT REV GENET, V15, P293, DOI 10.1038/nrg3724; Haussmann IU, 2016, NATURE, V540, P301, DOI 10.1038/nature20577; He Y, 2016, ONCOGENE, V35, P468, DOI 10.1038/onc.2015.101; HEIDELBERGER C, 1975, ANNU REV BIOCHEM, V44, P79, DOI 10.1146/annurev.bi.44.070175.000455; Ji WD, 2006, BIOMED ENVIRON SCI, V19, P277; Ji WD, 2008, CARCINOGENESIS, V29, P1267, DOI 10.1093/carcin/bgn012; Jia GF, 2011, NAT CHEM BIOL, V7, P885, DOI [10.1038/NCHEMBIO.687, 10.1038/nchembio.687]; Lence T, 2016, NATURE, V540, P242, DOI 10.1038/nature20568; Li ZJ, 2017, CANCER CELL, V31, P127, DOI 10.1016/j.ccell.2016.11.017; Lin SB, 2018, MOL CELL, V71, P244, DOI 10.1016/j.molcel.2018.06.001; Lin SB, 2016, MOL CELL, V62, P335, DOI 10.1016/j.molcel.2016.03.021; Liu JZ, 2014, NAT CHEM BIOL, V10, P93, DOI 10.1038/nchembio.1432; Luch A, 2005, NAT REV CANCER, V5, P113, DOI 10.1038/nrc1546; Ma JZ, 2017, HEPATOLOGY, V65, P529, DOI 10.1002/hep.28885; Meng J, 2014, METHODS, V69, P274, DOI 10.1016/j.ymeth.2014.06.008; Meyer KD, 2017, ANNU REV CELL DEV BI, V33, P319, DOI 10.1146/annurev-cellbio-100616-060758; Meyer KD, 2012, CELL, V149, P1635, DOI 10.1016/j.cell.2012.05.003; Ping XL, 2014, CELL RES, V24, P177, DOI 10.1038/cr.2014.3; Ravegnini G, 2015, TOXICOL SCI, V148, P2, DOI 10.1093/toxsci/kfv165; REZNIKOFF CA, 1988, CARCINOGENESIS, V9, P1427, DOI 10.1093/carcin/9.8.1427; Roundtree IA, 2017, ELIFE, V6, DOI 10.7554/eLife.31311; Roundtree IA, 2016, CURR OPIN CHEM BIOL, V30, P46, DOI 10.1016/j.cbpa.2015.10.024; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Scherl-Mostageer M, 2001, ONCOGENE, V20, P4402, DOI 10.1038/sj.onc.1204566; Sens DA, 2004, TOXICOL SCI, V79, P56, DOI 10.1093/toxsci/kfh086; Tuck MT, 1996, CANCER LETT, V103, P107, DOI 10.1016/0304-3835(96)04203-6; Uekita T, 2014, MOL CANCER RES, V12, P1449, DOI 10.1158/1541-7786.MCR-13-0587; Vaz M, 2017, CANCER CELL, V32, P360, DOI 10.1016/j.ccell.2017.08.006; Visvanathan A, 2018, ONCOGENE, V37, P522, DOI 10.1038/onc.2017.351; Vu LP, 2017, NAT MED, V23, P1369, DOI 10.1038/nm.4416; Wang X, 2015, CELL, V161, P1388, DOI 10.1016/j.cell.2015.05.014; Wang X, 2014, NATURE, V505, P117, DOI 10.1038/nature12730; Wang Y, 2014, NAT CELL BIOL, V16, P191, DOI 10.1038/ncb2902; Wortmann A, 2009, IUBMB LIFE, V61, P723, DOI 10.1002/iub.198; Wright HJ, 2016, ONCOGENE, V35, P4762, DOI 10.1038/onc.2016.7; Xiao W, 2016, MOL CELL, V61, P507, DOI 10.1016/j.molcel.2016.01.012; Yoon KJ, 2017, CELL, V171, P877, DOI 10.1016/j.cell.2017.09.003; Zhang CZ, 2016, P NATL ACAD SCI USA, V113, pE2047, DOI 10.1073/pnas.1602883113; Zhang SC, 2017, CANCER CELL, V31, P591, DOI 10.1016/j.ccell.2017.02.013; Zheng GQ, 2013, MOL CELL, V49, P18, DOI 10.1016/j.molcel.2012.10.015	49	101	103	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2019	38	24					4755	4772		10.1038/s41388-019-0755-0	http://dx.doi.org/10.1038/s41388-019-0755-0			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IC7ND	30796352	hybrid, Green Published			2022-12-28	WOS:000471160500008
J	Chen, YL; Wu, WL; Jang, CW; Yen, YC; Wang, SH; Tsai, FY; Shen, YY; Chen, YW				Chen, Yu-Lin; Wu, Wan-Lin; Jang, Chuan-Wei; Yen, Yi-Chen; Wang, Ssu-Han; Tsai, Fang-Yu; Shen, Ying-Ying; Chen, Ya-Wen			Interferon-stimulated gene 15 modulates cell migration by interacting with Rac1 and contributes to lymph node metastasis of oral squamous cell carcinoma cells	ONCOGENE			English	Article							BREAST-CANCER; RHO FAMILY; ISG15; EXPRESSION; PROTEIN; BINDING; TUMORIGENESIS; ISGYLATION; PROTEOMICS; INVASION	In an effort to understand the underlying mechanisms of lymph node metastasis in oral squamous cell carcinoma (OSCC), through in vivo selection, LN1-1 cells were previously established from OEC-M1 cells and showed enhanced lymphangiogenesis and lymphatic metastasis capabilities. In the current study, we use a stable isotope labeling with amino acids in cell culture (SILAC) and liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based proteomic platform to compare LN1-1 to OEC-M1 cells. Interferon-stimulated gene 15 (ISG15) was found highly expressed in LN1-1 cells Immunohistochemical analysis and meta-analysis of publicly available microarray datasets revealed that the ISG15 level was increased in human OSCC tissues and associated with poor disease outcome. Knockdown of ISG15 had minimal effects on tumor growth but did decrease tumor lymphangiogenesis and lymphatic metastasis of LN1-1 cells. Consistent with the in vivo assay, ISG15 knockdown did not impair cell growth but diminished cell migration, invasion, and transendothelial migration in vitro. ISG15-induced cell migration was independent of ISGylation and associated with membrane protrusion. Ectopic expression of ISG15 increased Rac1 activity and knockdown of Rac1 impaired ISG15-enhanced migration. Furthermore, Rac1 colocalized with ISG15 to a region of membrane protrusion and ISG15 coimmunoprecipitated with Rac1, especially with the Rac1-GDP form. Importantly, as shown by proximity ligation assays, ISG15 and Rac1 physically interacted with each other. Our results indicated that ISG15 affects cell migration by interacting with Rac1 and regulating Rac1 activity and contributes to lymphatic metastasis in OSCC.	[Chen, Yu-Lin; Wu, Wan-Lin; Jang, Chuan-Wei; Yen, Yi-Chen; Wang, Ssu-Han; Tsai, Fang-Yu; Chen, Ya-Wen] Natl Hlth Res Inst, Natl Inst Canc Res, Miaoli, Taiwan; [Shen, Ying-Ying] Natl Hlth Res Inst, Pathol Core Lab, Miaoli, Taiwan; [Chen, Ya-Wen] China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan	National Health Research Institutes - Taiwan; National Health Research Institutes - Taiwan; China Medical University Taiwan	Chen, YW (corresponding author), Natl Hlth Res Inst, Natl Inst Canc Res, Miaoli, Taiwan.; Chen, YW (corresponding author), China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan.	ywc@nhri.org.tw	Chen, Ya-Wen/AAG-7549-2019	Chen, Ya-Wen/0000-0002-6080-8859; Chen, Yu-Lin/0000-0001-9564-3997	National Health Research Institutes, Taiwan [NHRI CA-107-PP-04, MOST 106-2314-B-400-026-MY3]; Ministry of Science and Technology, Taiwan [NHRI CA-107-PP-04, MOST 106-2314-B-400-026-MY3]	National Health Research Institutes, Taiwan(National Health Research Institutes - Taiwan); Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan)	This study was supported by grants NHRI CA-107-PP-04 and MOST 106-2314-B-400-026-MY3 from National Health Research Institutes and Ministry of Science and Technology, Taiwan.	Ahmad Y, 2014, TRENDS CELL BIOL, V24, P257, DOI 10.1016/j.tcb.2013.10.010; Andersen JB, 2006, CYTOKINE GROWTH F R, V17, P411, DOI 10.1016/j.cytogfr.2006.10.001; Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI 10.1093/nar/gkh131; Boureux A, 2007, MOL BIOL EVOL, V24, P203, DOI 10.1093/molbev/msl145; Burks J, 2015, ONCOTARGET, V6, P7221, DOI 10.18632/oncotarget.3372; Cajee UF, 2012, INT J MOL SCI, V13, P11804, DOI 10.3390/ijms130911804; Castillo-Lluva S, 2013, ONCOGENE, V32, P1735, DOI 10.1038/onc.2012.189; Castillo-Lluva S, 2010, NAT CELL BIOL, V12, P1078, DOI 10.1038/ncb2112; Charras G, 2014, NAT REV MOL CELL BIO, V15, P813, DOI 10.1038/nrm3897; Chen RH, 2016, ONCOTARGET, V7, P16910, DOI 10.18632/oncotarget.7626; Chen YW, 2008, CANCER RES, V68, P476, DOI 10.1158/0008-5472.CAN-07-1960; Chen YW, 2007, CANCER RES, V67, P7589, DOI 10.1158/0008-5472.CAN-07-0381; Chen YW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069389; Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j; Desai SD, 2012, EXP BIOL MED, V237, P38, DOI 10.1258/ebm.2011.011236; dos Santos PF, 2017, J INTERF CYTOK RES, V37, P246, DOI 10.1089/jir.2016.0103; Durfee LA, 2012, METHODS MOL BIOL, V832, P141, DOI 10.1007/978-1-61779-474-2_9; Estilo CL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-11; Festing Michael F W, 2002, ILAR J, V43, P244; Friedl P, 2012, NAT CELL BIOL, V14, P777, DOI 10.1038/ncb2548; Gardel ML, 2010, ANNU REV CELL DEV BI, V26, P315, DOI 10.1146/annurev.cellbio.011209.122036; Graziano BR, 2014, CURR OPIN CELL BIOL, V30, P60, DOI 10.1016/j.ceb.2014.06.007; Hermann MR, 2016, J CELL SCI, V129, P1391, DOI 10.1242/jcs.177592; Hishiki T, 2014, BIOCHEM BIOPH RES CO, V448, P95, DOI 10.1016/j.bbrc.2014.04.081; Jeon YJ, 2010, BBA-MOL BASIS DIS, V1802, P485, DOI 10.1016/j.bbadis.2010.02.006; Kim KI, 2006, MOL CELL BIOL, V26, P472, DOI 10.1128/MCB.26.2.472-479.2006; Kuriakose MA, 2004, CELL MOL LIFE SCI, V61, P1372, DOI 10.1007/s00018-004-4069-0; Laljee RP, 2013, ASIAN PAC J CANCER P, V14, P1147, DOI 10.7314/APJCP.2013.14.2.1147; Lee CH, 2013, J PATHOL, V230, P298, DOI 10.1002/path.4173; Li C, 2014, ONCOTARGET, V5, P8429, DOI 10.18632/oncotarget.2316; Liao CT, 2009, INT J RADIAT ONCOL, V73, P764, DOI 10.1016/j.ijrobp.2008.05.004; LOEB KR, 1992, J BIOL CHEM, V267, P7806; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; Peng CH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023452; Pyeon D, 2007, CANCER RES, V67, P4605, DOI 10.1158/0008-5472.CAN-06-3619; Qin A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034132; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Sainz B, 2014, CANCER RES, V74, P7309, DOI 10.1158/0008-5472.CAN-14-1354; Sgorbissa A, 2012, CYTOKINE GROWTH F R, V23, P307, DOI 10.1016/j.cytogfr.2012.07.003; Spano D, 2012, SEMIN CANCER BIOL, V22, P234, DOI 10.1016/j.semcancer.2012.03.006; Symons M, 2000, TRENDS CELL BIOL, V10, P415, DOI 10.1016/S0962-8924(00)01832-8; Talbot SG, 2005, CANCER RES, V65, P3063, DOI 10.1158/0008-5472.CAN-04-1985; Toruner GA, 2004, CANCER GENET CYTOGEN, V154, P27, DOI 10.1016/j.cancergencyto.2004.01.026; Tyanova S, 2014, METHODS MOL BIOL, V1188, P351, DOI 10.1007/978-1-4939-1142-4_24; UEDA T, 1990, J BIOL CHEM, V265, P9373; Um K, 2014, DEV CELL, V29, P701, DOI 10.1016/j.devcel.2014.05.011; Walther TC, 2010, J CELL BIOL, V190, P491, DOI 10.1083/jcb.201004052; Wang SH, 2018, INT J CANC; Wong TY, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/2809192; Yamaguchi H, 2007, BBA-MOL CELL RES, V1773, P642, DOI 10.1016/j.bbamcr.2006.07.001; Ye H, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-69; Yeh YH, 2013, CLIN CANCER RES, V19, P5927, DOI 10.1158/1078-0432.CCR-13-0018; Yen YC, 2015, ONCOTARGET, V6, P41837, DOI 10.18632/oncotarget.5995; Yen YC, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-6; Zhang QM, 2017, EXP THER MED, V14, P2329, DOI 10.3892/etm.2017.4720; Zhang X, 2002, CANCER-AM CANCER SOC, V95, P1663, DOI 10.1002/cncr.10837; Zhang XQ, 2015, NATURE, V517, P89, DOI 10.1038/nature13801	58	19	19	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2019	38	23					4480	4495		10.1038/s41388-019-0731-8	http://dx.doi.org/10.1038/s41388-019-0731-8			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IB4KM	30765861				2022-12-28	WOS:000470240300004
J	Tew, BY; Legendre, C; Gooden, GC; Johnson, KN; Martinez, RA; Kiefer, J; Bernstein, M; Glen, J; Butry, L; Hinek, A; Toms, SA; Salhia, B				Tew, Ben Yi; Legendre, Christophe; Gooden, Gerald C.; Johnson, Kyle N.; Martinez, Rae Anne; Kiefer, Jeff; Bernstein, Mark; Glen, Jennifer; Butry, Loren; Hinek, Aleksander; Toms, Steven A.; Salhia, Bodour			Isolation and characterization of patient-derived CNS metastasis-associated stromal cell lines	ONCOGENE			English	Article							MESENCHYMAL STEM-CELLS; BREAST-CANCER; BRAIN METASTASES; EXPRESSION; CARCINOMA; FIBROBLASTS; GENERATION; TUMORS; NICHE	The functional role of human derived stromal cells in the tumor microenviornment of CNS metastases (CM) remain understudied. The purpose of the current study was to isolate and characterize stromal cells of the tumor microenvironment in CM. Four different patient-derived cell lines (PDCs) of stromal and one PDC of tumorigenic origin were generated from breast or lung CM. PDCs were analyzed by DNA/RNA sequencing, DNA methylation profiling, and immunophenotypic assays. The stromal derived PDCs were termed CNS metastasis-associated stromal cells (cMASCs). Functional analysis of cMASCs was tested by co-implanting them with tumorigenic cells in mice. cMASCs displayed normal genotypes compared with tumorigenic cell lines. RNA-seq and DNA methylation analyses demonstrated that cMASCs highly resembled each other, suggesting a common cell of origin. Additionally, cMASCs revealed gene expression signatures associated with cancer associated fibroblasts (CAFs), epithelial to mesenchymal transition, mesenchymal stem cells and expressed high levels of collagen. Functionally, cMASCs restricted tumor growth, and induced desmoplasia in vivo, suggesting that cMASCs may promote a protective host response to impede tumor growth. In summary, we demonstrated the isolation, molecular characterization and functional role of human derived cMASCs, a subpopulation of cells in the microenvironment of CM that have tumor inhibitory functions.	[Tew, Ben Yi; Gooden, Gerald C.; Salhia, Bodour] Univ Southern Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Dept Translat Genom, Los Angeles, CA 90033 USA; [Legendre, Christophe; Gooden, Gerald C.; Johnson, Kyle N.; Martinez, Rae Anne; Kiefer, Jeff; Salhia, Bodour] Translat Genom Res Inst, Phoenix, AZ 85004 USA; [Bernstein, Mark; Glen, Jennifer] Univ Hlth Network, Div Neurosurg, Toronto, ON, Canada; [Hinek, Aleksander] Hosp Sickkids, Peter Gilgan Ctr Res & Learning, Toronto, ON, Canada; [Butry, Loren] Geisinger Hlth Syst, Dept Neurosurg, Danville, PA USA; [Toms, Steven A.] Brown Univ, Lifespan Hlth Syst, Dept Neurosurg, Providence, RI 02912 USA; [Toms, Steven A.] Brown Univ, Warren Alpert Sch Med, Providence, RI 02912 USA	University of Southern California; Translational Genomics Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Geisinger Health System; Brown University; Brown University	Salhia, B (corresponding author), Univ Southern Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Dept Translat Genom, Los Angeles, CA 90033 USA.; Salhia, B (corresponding author), Translat Genom Res Inst, Phoenix, AZ 85004 USA.	salhia@usc.edu	Hinek, Aleksander/V-8790-2019	HINEK, Aleksander/0000-0002-5498-6261; Martinez, Rae Anne M./0000-0003-0262-1049	Avon Foundation; Avon Foundation for Women grant [02-2014-064]; National Center for Research Resources [C06RR030524]	Avon Foundation; Avon Foundation for Women grant; National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This work was supported in part by a grant from the Avon Foundation (BS). Avon Foundation for Women grant#02-2014-064. Animal studies in this work were performed at the University of Arizona Phoenix Campus Vivarium. The University of Arizona Phoenix Campus Vivarium was supported by Award Number C06RR030524 from the National Center for Research Resources. The content of this paper is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. The authors would also like to thank the patients who contributed their tumors for our study.	Amakye D, 2013, NAT MED, V19, P1410, DOI 10.1038/nm.3389; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Cheng JC, 2011, CANCER LETT, V304, P107, DOI 10.1016/j.canlet.2011.02.008; Christoforides A, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-302; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Cirri P, 2011, AM J CANCER RES, V1, P482; Cook D, 2013, ADV EXP MED BIOL, V786, P213, DOI 10.1007/978-94-007-6621-1_12; Daginakatte GC, 2007, HUM MOL GENET, V16, P1098, DOI 10.1093/hmg/ddm059; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; GOMORI G, 1950, AM J CLIN PATHOL, V20, P661, DOI 10.1093/ajcp/20.7_ts.661; Hasebe T, 2002, MODERN PATHOL, V15, P502, DOI 10.1038/modpathol.3880555; Huijbers IJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009808; Kauppila S, 1998, J PATHOL, V186, P262, DOI 10.1002/(SICI)1096-9896(1998110)186:3<262::AID-PATH191>3.0.CO;2-3; Kim HM, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0587-9; Kim J, 2013, THORAC CANCER, V4, P167, DOI 10.1111/j.1759-7714.2012.00164.x; Kim LS, 2004, CLIN EXP METASTAS, V21, P107, DOI 10.1023/B:CLIN.0000024761.00373.55; Kupershmidt I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013066; Langley RR, 2011, INT J CANCER, V128, P2527, DOI 10.1002/ijc.26031; Legendre CR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150629; Li AQ, 2010, ONCOL REP, V23, P1247, DOI 10.3892/or_00000757; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Lillie RD, 1940, STAIN TECHNOL, V15, P17, DOI 10.3109/10520294009110327; Lojewski X, 2015, STEM CELL TRANSL MED, V4, P1223, DOI 10.5966/sctm.2015-0057; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Maher Elizabeth A, 2009, Cancer Res, V69, P6015, DOI 10.1158/0008-5472.CAN-08-4347; Mao Y, 2013, CANCER METAST REV, V32, P303, DOI 10.1007/s10555-012-9415-3; Miller KD, 2003, ANN ONCOL, V14, P1072, DOI 10.1093/annonc/mdg300; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Quail DF, 2017, CANCER CELL, V31, P326, DOI 10.1016/j.ccell.2017.02.009; Salgado AJ, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00249; Salhia B, 2005, CANCER RES, V65, P8792, DOI 10.1158/0008-5472.CAN-05-0160; Saunders CT, 2012, BIOINFORMATICS, V28, P1811, DOI 10.1093/bioinformatics/bts271; Sekar S, 2015, NEUROBIOL AGING, V36, P583, DOI 10.1016/j.neurobiolaging.2014.09.027; Tosoni A, 2008, CRIT REV ONCOL HEMAT, V68, P212, DOI 10.1016/j.critrevonc.2008.04.004; Stormo Gary D, 2013, Curr Protoc Bioinformatics, V43, DOI [10.1002/0471250953.bi1110s43, 10.1002/0471250953.bi1201s43]; Weil RJ, 2005, AM J PATHOL, V167, P913, DOI 10.1016/S0002-9440(10)61180-7; Yoneda T, 2001, J BONE MINER RES, V16, P1486, DOI 10.1359/jbmr.2001.16.8.1486	42	7	9	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2019	38	21					4002	4014		10.1038/s41388-019-0680-2	http://dx.doi.org/10.1038/s41388-019-0680-2			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ3HX	30700832	Green Published, hybrid			2022-12-28	WOS:000468740200003
J	Palmbos, PL; Wang, Y; Bankhead, A; Kelleher, AJ; Wang, LD; Yang, HB; Ahmet, ML; Gumkowski, ER; Welling, SD; Magnuson, B; Leflein, J; Hiles, GL; Abel, EV; Dziubinski, ML; Urs, S; Day, ML; Ljungman, ME; Simeone, DM				Palmbos, Phillip L.; Wang, Yin; Bankhead, Armand, III; Kelleher, Alan J.; Wang, Lidong; Yang, Huibin; Ahmet, McKenzie L.; Gumkowski, Erica R.; Welling, Samuel D.; Magnuson, Brian; Leflein, Jacob; Hiles, Guadalupe Lorenzatti; Abel, Ethan V.; Dziubinski, Michele L.; Urs, Sumithra; Day, Mark L.; Ljungman, Mats E.; Simeone, Diane M.			ATDC mediates a TP63-regulated basal cancer invasive program	ONCOGENE			English	Article							BLADDER-CANCER; MOLECULAR CLASSIFICATION; TRIM29; GENOME; SUBTYPES; PROGNOSIS; MIGRATION; TAXONOMY; ISOFORMS; REQUIRES	Basal subtype cancers are deadly malignancies but the molecular events driving tumor lethality are not completely understood. Ataxia-telangiectasia group D complementing gene (ATDC, also known as TRIM29), is highly expressed and drives tumor formation and invasion in human bladder cancers but the factor(s) regulating its expression in bladder cancer are unknown. Molecular subtyping of bladder cancer has identified an aggressive basal subtype, which shares molecular features of basal/squamous tumors arising in other organs and is defined by activation of a TP63-driven gene program. Here, we demonstrate that ATDC is linked with expression of TP63 and highly expressed in basal bladder cancers. We find that TP63 binds to transcriptional regulatory regions of ATDC and KRT14 directly, increasing their expression, and that ATDC and KRT14 execute a TP63-driven invasive program. In vivo, ATDC is required for TP63-induced bladder tumor invasion and metastasis. These results link TP63 and the basal gene expression program to ATDC and to aggressive tumor behavior. Defining ATDC as a molecular determinant of aggressive, basal cancers may lead to improved biomarkers and therapeutic approaches.	[Palmbos, Phillip L.; Wang, Yin; Kelleher, Alan J.; Ahmet, McKenzie L.; Gumkowski, Erica R.] Univ Michigan, Med Ctr, Dept Internal Med, Ann Arbor, MI 48109 USA; [Palmbos, Phillip L.; Wang, Yin; Bankhead, Armand, III; Welling, Samuel D.; Magnuson, Brian; Leflein, Jacob; Hiles, Guadalupe Lorenzatti; Abel, Ethan V.; Dziubinski, Michele L.; Urs, Sumithra; Ljungman, Mats E.] Univ Michigan, Med Ctr, Rogel Canc Ctr, Ann Arbor, MI 48109 USA; [Bankhead, Armand, III; Magnuson, Brian] Univ Michigan, Med Ctr, Dept Biostat, Ann Arbor, MI 48109 USA; [Bankhead, Armand, III] Univ Michigan, Med Ctr, Dept Computat Med & Bioinformat, Ann Arbor, MI 48109 USA; [Wang, Lidong; Simeone, Diane M.] NYU Langone Hlth, Dept Surg, New York, NY 10016 USA; [Wang, Lidong; Simeone, Diane M.] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY 10016 USA; [Yang, Huibin; Ljungman, Mats E.] Univ Michigan, Med Ctr, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; [Hiles, Guadalupe Lorenzatti; Day, Mark L.] Univ Michigan, Med Ctr, Dept Urol, Ann Arbor, MI 48109 USA; [Dziubinski, Michele L.] Univ Michigan, Med Ctr, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; [Simeone, Diane M.] NYU Langone Hlth, Dept Pathol, New York, NY 10016 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; NYU Langone Medical Center; NYU Langone Medical Center; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; NYU Langone Medical Center	Palmbos, PL (corresponding author), Univ Michigan, Med Ctr, Dept Internal Med, Ann Arbor, MI 48109 USA.; Palmbos, PL (corresponding author), Univ Michigan, Med Ctr, Rogel Canc Ctr, Ann Arbor, MI 48109 USA.	ppalmbos@med.umich.edu		Lorenzatti, Guadalupe/0000-0002-8423-3279	University of Michigan Cancer Center Core Grant [CA046592-26S3]; NIH [K08 CA201335, R01 CA17483601]; BCAN YIA; ASCO YIA; NATIONAL CANCER INSTITUTE [K08CA201335, P30CA046592] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR002240] Funding Source: NIH RePORTER	University of Michigan Cancer Center Core Grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); BCAN YIA; ASCO YIA; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This work was funded by grants from the University of Michigan Cancer Center Core Grant CA046592-26S3, NIH K08 CA201335 (PLP), BCAN YIA (PLP), ASCO YIA (PLP), and NIH R01 CA17483601 (DMS).	Cai BH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041742; Candi E, 2006, CELL DEATH DIFFER, V13, P1037, DOI 10.1038/sj.cdd.4401926; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Choi W, 2017, EUR UROL, V72, P354, DOI 10.1016/j.eururo.2017.03.010; Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009; Choi W, 2012, PLOS ONE, V7, P453, DOI 10.1371/journal.pone.0030206; Damrauer JS, 2014, P NATL ACAD SCI USA, V111, P3110, DOI 10.1073/pnas.1318376111; Dukel M, 2016, J BIOL CHEM, V291, P21541, DOI 10.1074/jbc.M116.730960; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gaya JM, 2015, J UROLOGY, V193, P1144, DOI 10.1016/j.juro.2014.10.098; Guo GC, 2017, CELL ONCOL, V40, P157, DOI 10.1007/s13402-016-0312-6; Guo GW, 2013, NAT GENET, V45, P1459, DOI 10.1038/ng.2798; Han AL, 2017, ONCOGENE, V36, P5243, DOI 10.1038/onc.2017.149; Hedegaard J, 2016, CANCER CELL, V30, P27, DOI 10.1016/j.ccell.2016.05.004; Hoadley KA, 2014, CELL, V158, P929, DOI 10.1016/j.cell.2014.06.049; Hovelson DH, 2018, EUR UROL, V74, P741, DOI 10.1016/j.eururo.2018.06.047; Karni-Schmidt O, 2011, AM J PATHOL, V178, P1350, DOI 10.1016/j.ajpath.2010.11.061; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Lai W, 2013, DIS ESOPHAGUS, V26, P817, DOI 10.1111/j.1442-2050.2012.01400.x; Lee SH, 2015, J EXP MED, V212, P1061, DOI 10.1084/jem.20141601; Leivo MZ, 2016, PATHOLOGY, V48, P543, DOI 10.1016/j.pathol.2016.05.008; Lerner SP, 2016, BLADDER CANCER, V2, P37, DOI 10.3233/BLC-150037; Masuda Y, 2015, BBA-MOL CELL RES, V1853, P2296, DOI 10.1016/j.bbamcr.2015.05.035; McDade SS, 2012, NUCLEIC ACIDS RES, V40, P7190, DOI 10.1093/nar/gks389; Murray-Zmijewski F, 2006, CELL DEATH DIFFER, V13, P962, DOI 10.1038/sj.cdd.4401914; Palmbos PL, 2015, CANCER RES, V75, P5155, DOI 10.1158/0008-5472.CAN-15-0603; Qiu F, 2015, INT J CLIN EXP PATHO, V8, P5053; Robertson AG, 2017, CELL, V171, P540, DOI 10.1016/j.cell.2017.09.007; Seiler Roland, 2017, Eur Urol, V72, P544, DOI 10.1016/j.eururo.2017.03.030; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sjodahl G, 2017, J PATHOL, V242, P113, DOI 10.1002/path.4886; Sjodahl G, 2012, CLIN CANCER RES, V18, P3377, DOI 10.1158/1078-0432.CCR-12-0077-T; Su XH, 2013, NAT REV CANCER, V13, P136, DOI 10.1038/nrc3446; Tamura S, 2018, BLADDER CANCER, V4, P77, DOI 10.3233/BLC-170144; Tang ZP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063676; Velez-delValle C, 2016, SCI REP-UK, V6, DOI 10.1038/srep24389; Wang FR, 2018, J CELL BIOL, V217, P4314, DOI 10.1083/jcb.201712130; Wang LD, 2015, GENE DEV, V29, P171, DOI 10.1101/gad.253591.114; Wang LD, 2009, CANCER CELL, V15, P207, DOI 10.1016/j.ccr.2009.01.018; Wang Y, 2018, JOVE-J VIS EXP, DOI 10.3791/58345; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Xu WH, 2016, ONCOL REP, V36, P1411, DOI 10.3892/or.2016.4941; 2010, MOL CELL BIOL, V30, P3004, DOI DOI 10.1128/MCB.01023-09	44	9	10	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2019	38	18					3340	3354		10.1038/s41388-018-0646-9	http://dx.doi.org/10.1038/s41388-018-0646-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HW3RI	30643195	Green Accepted			2022-12-28	WOS:000466610000002
J	Khan, I; Spencer-Smith, R; O'Bryan, JP				Khan, Imran; Spencer-Smith, Russell; O'Bryan, John P.			Targeting the alpha 4-alpha 5 dimerization interface of K-RAS inhibits tumor formation in vivo	ONCOGENE			English	Article							FORMS DIMERS; H-RAS; N-RAS; PROTEINS; KRAS; GAPS; GEFS	RAS genes are the most commonly mutated oncogenes in human cancers. Despite tremendous efforts over the past several decades, however, RAS-specific inhibitors remain elusive. Thus, targeting RAS remains a highly sought-after goal of cancer research. Previously, we have reported a new approach to inhibit RAS-dependent signaling and transformation in vitro by targeting the alpha 4-alpha 5 dimerization interface with a novel RAS-specific monobody termed NS1. Expression of NS1 inhibits oncogenic K-RAS and H-RAS signaling and transformation in vitro. Here, we evaluated the efficacy of targeting RAS dimerization as an approach to inhibit tumor formation in vivo. Using a doxycycline (DOX)-regulated NS1 expression system, we demonstrate that DOX-induced NS1 inhibited oncogenic K-RAS-driven tumor growth in vivo. Furthermore, we observed context-specific effects of NS1 on RAS-mediated signaling in 2D vs 3D growth conditions. Finally, our results highlight the potential therapeutic efficacy of targeting the alpha 4-alpha 5 dimerization interface as an approach to inhibit RAS-driven tumors in vivo.	[Khan, Imran; Spencer-Smith, Russell; O'Bryan, John P.] Univ Illinois, Canc Ctr, Dept Pharmacol, Chicago, IL 60612 USA; [Khan, Imran; Spencer-Smith, Russell; O'Bryan, John P.] Jesse Brown VA Med Ctr, Chicago, IL 60612 USA; [Khan, Imran; O'Bryan, John P.] Med Univ South Carolina, Hollings Canc Ctr, Dept Cell & Mol Pharmacol & Expt Therapeut, Charleston, SC 29425 USA; [Khan, Imran; O'Bryan, John P.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	O'Bryan, JP (corresponding author), Univ Illinois, Canc Ctr, Dept Pharmacol, Chicago, IL 60612 USA.; O'Bryan, JP (corresponding author), Jesse Brown VA Med Ctr, Chicago, IL 60612 USA.; O'Bryan, JP (corresponding author), Med Univ South Carolina, Hollings Canc Ctr, Dept Cell & Mol Pharmacol & Expt Therapeut, Charleston, SC 29425 USA.; O'Bryan, JP (corresponding author), Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA.	obryanjo@musc.edu		Spencer-Smith, Russell/0000-0002-8865-0520; O'Bryan, John/0000-0001-5386-1080	NIH [CA192822, CA212608, CA201717]; US Department of Veterans Affairs Biomedical Laboratory Research and Development Service [1I01BX002095]; NATIONAL CANCER INSTITUTE [R21CA201717, F31CA192822, R01CA212608] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002095] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Department of Veterans Affairs Biomedical Laboratory Research and Development Service; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs(US Department of Veterans Affairs)	The authors wish to thank Drs. Andrei Karginov, Todd Waldman, Gregory Thatcher, Bernard Weisman, and Robert Winn for providing various cell lines. In addition, we wish to thank Drs. Shohei Koide and Andrei Karginov along with the O'Bryan and Karginov labs for many helpful discussions. R.S.S. was supported by an NIH F31 Predoctoral Award (CA192822). This work was supported in part by a Merit Review Award (1I01BX002095) from the US Department of Veterans Affairs Biomedical Laboratory Research and Development Service and NIH awards (CA212608 and CA201717) to J.P.O. The contents of this article do not represent the views of the U.S. Department of Veterans Affairs or the United States Government.	Ambrogio C, 2018, CELL, V172, P857, DOI 10.1016/j.cell.2017.12.020; Cherfils J, 2013, PHYSIOL REV, V93, P269, DOI 10.1152/physrev.00003.2012; Chung JK, 2018, BIOPHYS J, V114, P137, DOI 10.1016/j.bpj.2017.10.042; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; Cox Adrienne D, 2010, Small GTPases, V1, P2; Guldenhaupt J, 2012, BIOPHYS J, V103, P1585, DOI 10.1016/j.bpj.2012.08.043; Janes MR, 2018, CELL, V172, P578, DOI 10.1016/j.cell.2018.01.006; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Kim JS, 2004, CANCER RES, V64, P1932, DOI 10.1158/0008-5472.CAN-03-3862; Kovrigina EA, 2015, BIOPHYS J, V109, P1000, DOI 10.1016/j.bpj.2015.07.020; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; Lin WC, 2014, P NATL ACAD SCI USA, V111, P2996, DOI 10.1073/pnas.1321155111; Muzumdar MD, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00942-5; Nan XL, 2015, P NATL ACAD SCI USA, V112, P7996, DOI 10.1073/pnas.1509123112; Ostrem JM, 2013, NATURE, V503, P548, DOI 10.1038/nature12796; Plowman SJ, 2005, P NATL ACAD SCI USA, V102, P15500, DOI 10.1073/pnas.0504114102; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Santos E, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005318; Simanshu DK, 2017, CELL, V170, P17, DOI 10.1016/j.cell.2017.06.009; Spencer-Smith R, 2019, SEMIN CANCER BIOL, V54, P138, DOI 10.1016/j.semcancer.2017.12.005; Spencer-Smith Russell, 2019, Small GTPases, V10, P378, DOI 10.1080/21541248.2017.1333188; Spencer-Smith R, 2017, NAT CHEM BIOL, V13, P62, DOI [10.1038/nchembio.2231, 10.1038/NCHEMBIO.2231]; Vartanian S, 2013, J BIOL CHEM, V288, P2403, DOI 10.1074/jbc.M112.394130; Vigil D, 2010, NAT REV CANCER, V10, P842, DOI 10.1038/nrc2960; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459	26	32	32	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2019	38	16					2984	2993		10.1038/s41388-018-0636-y	http://dx.doi.org/10.1038/s41388-018-0636-y			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU3IV	30573767	Green Accepted			2022-12-28	WOS:000465167600008
J	Li, L; Cao, BR; Liang, XH; Lu, S; Luo, HC; Wang, ZH; Wang, SX; Jiang, J; Lang, JY; Zhu, GQ				Li, Ling; Cao, Bangrong; Liang, Xinhua; Lu, Shun; Luo, Huaichao; Wang, Zhaohui; Wang, Shaoxin; Jiang, Jian; Lang, Jinyi; Zhu, Guiquan			Microenvironmental oxygen pressure orchestrates an anti- and pro-tumoral gamma delta T cell equilibrium via tumor-derived exosomes	ONCOGENE			English	Article							SUPPRESSOR-CELLS; CARCINOMA-CELLS; EXPANSION; HYPOXIA; PROMOTE; ELICIT; REGULATORS; RESPONSES; PROTEINS; GROWTH	gamma delta T cells are a unique lymphocyte population that have been reported to have either anti- or pro-tumoral functions in several cancer types, but the mechanisms are underinvestigated. Exosomes, initially considered to be cellular "garbage dumpsters," are now implicated in mediating interactions with the cellular environment. Hypoxia is a common feature of solid tumors and is believed to alter tumor-derived exosomes (TEXs), which mediate the hypoxic evolution of the tumor microenvironment in return. This study sought to investigate whether TEXs mediate the anti- and pro-tumoral equilibrium of gamma delta T cells under different oxygen pressures in the tumor microenvironment. We show that TEXs can alter the expansion and cytotoxicity of gamma delta T cells in an HSP70-dependent but dendritic cell-independent manner. The stimulating effects of normoxic TEXs on gamma delta T-cell activity were absent from hypoxic TEXs, which enhanced the suppressive effect of myeloid-derived suppressor cells (MDSCs) on gamma delta T cells through a miR-21/PTEN/PD-L1 regulation axis. Finally, the therapeutic outcome benefited from combined miR-21 and PD-Ll targeting in oral squamous cell carcinoma (OSCC)-bearing immunocompetent mice. We conclude that oxygen pressure in the tumor microenvironment orchestrates an anti- and protumoral gamma delta T-cell equilibrium by altering TEX content, which subsequently regulates MDSC function in a miR-21/PTEN/PD-L1 -axis-dependent manner. Our results should prompt further investigation into integrated exosomal miRNA inhibition and immune checkpoint inhibitor therapeutic modalities for patients with OSCC.	[Li, Ling; Wang, Zhaohui; Wang, Shaoxin; Jiang, Jian; Zhu, Guiquan] Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Dept Head & Neck Surg, Sichuan Canc Ctr,Sch Med, Chengdu, Sichuan, Peoples R China; [Cao, Bangrong] Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Dept Basic Res, Sichuan Canc Ctr,Sch Med, Chengdu, Sichuan, Peoples R China; [Liang, Xinhua] Sichuan Univ, State Key Lab Oral Dis, West China Hosp Stomatol, Chengdu, Sichuan, Peoples R China; [Lu, Shun; Lang, Jinyi] Univ Elect Sci & Technol China, Dept Radiat Oncol, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr,Sch Med, Chengdu, Peoples R China; [Luo, Huaichao] Univ Elect Sci & Technol China, Dept Clin Lab, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr,Sch Med, Chengdu, Sichuan, Peoples R China	University of Electronic Science & Technology of China; University of Electronic Science & Technology of China; Sichuan University; University of Electronic Science & Technology of China; University of Electronic Science & Technology of China	Zhu, GQ (corresponding author), Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Dept Head & Neck Surg, Sichuan Canc Ctr,Sch Med, Chengdu, Sichuan, Peoples R China.; Lang, JY (corresponding author), Univ Elect Sci & Technol China, Dept Radiat Oncol, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr,Sch Med, Chengdu, Peoples R China.	langjy610@163.com; zgq@sichuancancer.org	Lu, Shun/ABF-8341-2021; , 曹邦荣/AAN-3604-2020	Zhu, Guiquan/0000-0002-8316-5809; Cao, Bangrong/0000-0002-3865-3563; lang, jinyi/0000-0002-5406-8671	National Natural Science Foundation of China [81672690, 81772900, 81872196, 81302375]; Department of Science and Technology of Sichuan Province [2015SZ0053, 2017JQ0040]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Department of Science and Technology of Sichuan Province	This work was supported by the National Natural Science Foundation of China (grant nos. 81672690, 81772900, 81872196, and 81302375) and the Department of Science and Technology of Sichuan Province (grant nos. 2015SZ0053 and 2017JQ0040).	Castella B, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1047580; Chalmin F, 2010, J CLIN INVEST, V120, P457, DOI 10.1172/JCI40483; Chen TY, 2011, J IMMUNOL, V186, P2219, DOI 10.4049/jimmunol.1002991; Chen WL, 2006, EUR J IMMUNOL, V36, P1598, DOI 10.1002/eji.200535501; Daley D, 2016, CELL, V166, P1485, DOI 10.1016/j.cell.2016.07.046; Desiderio V, 2015, ONCOTARGET, V6, P71, DOI 10.18632/oncotarget.2698; Florcken A, 2015, IMMUNOL LETT, V168, P260, DOI 10.1016/j.imlet.2015.10.001; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Gu XY, 2015, INT J CANCER, V136, pE74, DOI 10.1002/ijc.29100; Hasan MS, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/705831; Hood JL, 2011, CANCER RES, V71, P3792, DOI 10.1158/0008-5472.CAN-10-4455; King HW, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-421; Kondo M, 2008, CYTOTHERAPY, V10, P842, DOI 10.1080/14653240802419328; Kondo M, 2011, JOVE-J VIS EXP, V55, P3182; Kucharzewska P, 2013, P NATL ACAD SCI USA, V110, P7312, DOI 10.1073/pnas.1220998110; Li LM, 2014, J IMMUNOL, V192, P1034, DOI 10.4049/jimmunol.1301309; Li L, 2016, CANCER RES, V76, P1770, DOI 10.1158/0008-5472.CAN-15-1625; Liu CR, 2006, J IMMUNOL, V176, P1375, DOI 10.4049/jimmunol.176.3.1375; Liu YF, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1027472; Lo Presti E, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00607; Lu X, 2010, CLIN CANCER RES, V16, P5928, DOI 10.1158/1078-0432.CCR-10-1360; Ludwig S, 2017, CLIN CANCER RES, V23, P4843, DOI 10.1158/1078-0432.CCR-16-2819; Lv LH, 2012, J BIOL CHEM, V287, P15874, DOI 10.1074/jbc.M112.340588; Ma SB, 2014, CANCER RES, V74, P1969, DOI 10.1158/0008-5472.CAN-13-2534; Martins VR, 2013, CURR OPIN ONCOL, V25, P66, DOI 10.1097/CCO.0b013e32835b7c81; Marvel D, 2015, J CLIN INVEST, V125, P3356, DOI 10.1172/JCI80005; Mathivanan S, 2010, J PROTEOMICS, V73, P1907, DOI 10.1016/j.jprot.2010.06.006; Noman MZ, 2014, J EXP MED, V211, P781, DOI 10.1084/jem.20131916; O'Loughlin AJ, 2012, CURR GENE THER, V12, P262, DOI 10.2174/156652312802083594; Park JE, 2010, MOL CELL PROTEOMICS, V9, P1085, DOI 10.1074/mcp.M900381-MCP200; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Peinado H, 2011, SEMIN CANCER BIOL, V21, P139, DOI 10.1016/j.semcancer.2011.01.002; Plebanek MP, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01433-3; Rao Q, 2016, HEPATOLOGY, V64, P456, DOI 10.1002/hep.28549; Robbins PD, 2014, NAT REV IMMUNOL, V14, P195, DOI 10.1038/nri3622; Schorey JS, 2008, TRAFFIC, V9, P871, DOI 10.1111/j.1600-0854.2008.00734.x; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Silva-Santos B, 2015, NAT REV IMMUNOL, V15, P683, DOI 10.1038/nri3904; Song MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055761; Warnakulasuriya S, 2009, ORAL ONCOL, V45, P309, DOI 10.1016/j.oraloncology.2008.06.002; Webber J, 2010, CANCER RES, V70, P9621, DOI 10.1158/0008-5472.CAN-10-1722; Whiteside TL, 2016, J CLIN INVEST, V126, P1216, DOI 10.1172/JCI81136; Wolfers J, 2001, NAT MED, V7, P297, DOI 10.1038/85438; Wu D, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.992749; Wu P, 2014, IMMUNITY, V40, P785, DOI 10.1016/j.immuni.2014.03.013; Xiang XY, 2010, AM J PATHOL, V177, P1606, DOI 10.2353/ajpath.2010.100245; Zhu GQ, 2014, NEOPLASIA, V16, P168, DOI 10.1593/neo.132034	48	87	90	1	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2019	38	15					2830	2843		10.1038/s41388-018-0627-z	http://dx.doi.org/10.1038/s41388-018-0627-z			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HS8LQ	30546089				2022-12-28	WOS:000464121600012
J	Nie, E; Miao, F; Jin, X; Wu, WN; Zhou, X; Zeng, AL; Yu, TF; Zhi, TL; Shi, ZM; Wang, YY; Zhang, JX; Liu, N; You, YP				Nie, Er; Miao, Faan; Jin, Xin; Wu, Weining; Zhou, Xu; Zeng, Ailiang; Yu, Tianfu; Zhi, Tongle; Shi, Zhumei; Wang, Yingyi; Zhang, Junxia; Liu, Ning; You, Yongping			Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma	ONCOGENE			English	Article							FOLLISTATIN-LIKE 1; GENE O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; HISTONE DEACETYLATION; PROMOTER METHYLATION; BINDING-PROTEIN; EXPRESSION; MGMT; REPAIR; FSTL1; HDAC2	Temozolomide was recognized as the first-line therapy for glioblastoma to prolong the survival of patients noticeably, while recent clinical studies found that some patients were not sensitive to temozolomide treatment. The possible mechanisms seemed to be methylguanine-DNA-methyltransferase (MGMT), mismatch repair, PARP, etc. And the abnormal expression of MGMT might be the most direct factor. In this study, we provide evidence that Fstl1 plays a vital role in temozolomide resistance by sequentially regulating DIP2A protein distribution, H3K9 acetylation (H3K9Ac), and MGMT transcription. As a multifunctional protein widely distributed in cells, DIP2A cooperates with the HDAC2-DMAP1 complex to enhance H3K9Ac deacetylation, prevent MGMT transcription, and increase temozolomide sensitivity. Fstl1, a glycoprotein highly expressed in glioblastoma, competitively binds DIP2A to block DIP2A nuclear translocation, so as to hinder DIP2A from binding the HDAC2-DMAP1 complex. The overexpression of Fstl1 promoted the expression of MGMT in association with increased promoter H3K9Ac. Upregulation of Fstl1 enhanced temozolomide resistance, whereas Fstl1 silencing obviously sensitized GBM cells to temozolomide both in vivo and in vitro. Moreover, DIP2A depletion abolished the effects of Fstl1 on MGMT expression and temozolomide resistance. These findings highlight an important role of Fstl1 in the regulation of temozolomide resistance by modulation of DIP2A/MGMT signaling.	[Nie, Er; Miao, Faan; Jin, Xin; Wu, Weining; Zhou, Xu; Zeng, Ailiang; Yu, Tianfu; Zhi, Tongle; Shi, Zhumei; Wang, Yingyi; Zhang, Junxia; Liu, Ning; You, Yongping] Nanjing Med Univ, Dept Neurosurg, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China; [Shi, Zhumei] Nanjing Med Univ, State Key Lab Reprod Med, Collaborat Innovat Ctr Canc Personalized Med, Dept Pathol,Canc Ctr, Nanjing 210029, Jiangsu, Peoples R China; [Liu, Ning; You, Yongping] CGCG, Nanjing 210029, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing Medical University	Liu, N; You, YP (corresponding author), Nanjing Med Univ, Dept Neurosurg, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China.; Liu, N; You, YP (corresponding author), CGCG, Nanjing 210029, Jiangsu, Peoples R China.	liuning0853@126.com; yypl9@njmu.edu.cn	zeng, ailiang/AAF-4498-2020	Zeng, Ailiang/0000-0003-2869-9899	Research Special Fund for Public Welfare Industry of Health [201402008]; National Key Research and Development Plan [2016YFC0902500]; National Natural Science Foundation of China [81672501, 81472362, 81372709]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	Research Special Fund for Public Welfare Industry of Health; National Key Research and Development Plan; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	This work was supported by grants from the Research Special Fund for Public Welfare Industry of Health (201402008), the National Key Research and Development Plan (2016YFC0902500), National Natural Science Foundation of China (81672501, 81472362, and 81372709), and the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).	Bae K, 2016, ONCOTARGET, V7, P18076, DOI 10.18632/oncotarget.6729; Bhakat KK, 2000, J BIOL CHEM, V275, P34197, DOI 10.1074/jbc.M005447200; Boldogh I, 1998, CANCER RES, V58, P3950; Bradshaw AD, 2012, INT J BIOCHEM CELL B, V44, P480, DOI 10.1016/j.biocel.2011.12.021; Chan QKY, 2009, CARCINOGENESIS, V30, P114, DOI 10.1093/carcin/bgn215; Choi YB, 2004, J BIOL CHEM, V279, P50930, DOI 10.1074/jbc.M406831200; COSTELLO JF, 1994, MOL CELL BIOL, V14, P6515, DOI 10.1128/MCB.14.10.6515; Danam RP, 2005, MOL CANCER THER, V4, P61; Esteller M, 1999, CANCER RES, V59, P793; Fiskus W, 2014, MOL CANCER THER, V13, P1142, DOI 10.1158/1535-7163.MCT-13-0770; Friedman HS, 2000, CLIN CANCER RES, V6, P2585; Geng Y, 2011, P NATL ACAD SCI USA, V108, P7058, DOI 10.1073/pnas.1007293108; Gerace E, 2015, METHOD ENZYMOL, V559, P99, DOI 10.1016/bs.mie.2014.11.010; Gerson SL, 2002, J CLIN ONCOL, V20, P2388, DOI 10.1200/JCO.2002.06.110; Gerson SL, 2004, NAT REV CANCER, V4, P296, DOI 10.1038/nrc1319; Hambrock HO, 2004, J BIOL CHEM, V279, P11727, DOI 10.1074/jbc.M309318200; Hambrock HO, 2003, J BIOL CHEM, V278, P11351, DOI 10.1074/jbc.M212291200; Hegi ME, 2004, CLIN CANCER RES, V10, P1871, DOI 10.1158/1078-0432.CCR-03-0384; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Hegi ME, 2008, J CLIN ONCOL, V26, P4189, DOI 10.1200/JCO.2007.11.5964; Hodgson G, 2001, NAT GENET, V29, P459, DOI 10.1038/ng771; Kim HJ, 2016, CELL SIGNAL, V28, P1137, DOI 10.1016/j.cellsig.2016.05.018; Kitange GJ, 2016, CELL REP, V14, P2587, DOI 10.1016/j.celrep.2016.02.045; Kitange GJ, 2012, CLIN CANCER RES, V18, P4070, DOI 10.1158/1078-0432.CCR-12-0560; Kramer OH, 2009, TRENDS PHARMACOL SCI, V30, P647, DOI 10.1016/j.tips.2009.09.007; Kudo-Saito C, 2013, CANCER RES, V73, P6185, DOI 10.1158/0008-5472.CAN-13-1364; Lacroix M, 2001, J NEUROSURG, V95, P190, DOI 10.3171/jns.2001.95.2.0190; Lavon I, 2007, CANCER RES, V67, P8952, DOI 10.1158/0008-5472.CAN-06-3820; Liu S, 2006, EXP MOL PATHOL, V80, P132, DOI 10.1016/j.yexmp.2005.07.005; Liu S, 2010, AM J PHYSIOL-ENDOC M, V299, pE351, DOI 10.1152/ajpendo.00005.2010; Luo H, 2015, BRAIN, V138, P3654, DOI 10.1093/brain/awv287; Ma XY, 2009, J CLIN NEUROSCI, V16, P1595, DOI 10.1016/j.jocn.2009.02.036; Mukhopadhyay M, 2002, GENE, V293, P59, DOI 10.1016/S0378-1119(02)00694-7; Murakami K, 2012, FEBS LETT, V586, P319, DOI 10.1016/j.febslet.2012.01.010; Nakagawachi T, 2003, ONCOGENE, V22, P8835, DOI 10.1038/sj.onc.1207183; Nie E, 2017, J NEURO-ONCOL, V133, P59, DOI 10.1007/s11060-017-2425-9; Nie E, 2016, SCI REP-UK, V6, DOI 10.1038/srep39743; Oshima Y, 2008, CIRCULATION, V117, P3099, DOI 10.1161/CIRCULATIONAHA.108.767673; Ouchi N, 2010, J BIOL CHEM, V285, P7127, DOI 10.1074/jbc.M109.069468; Park HG, 2014, INT J NEUROPSYCHOPH, V17, P1487, DOI 10.1017/S1461145714000248; Pistollato F, 2010, STEM CELLS, V28, P851, DOI 10.1002/stem.415; Poelmans G, 2011, MOL PSYCHIATR, V16, P365, DOI 10.1038/mp.2010.105; Reddy SP, 2008, CLIN CANCER RES, V14, P2978, DOI 10.1158/1078-0432.CCR-07-4821; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Sarkaria JN, 2008, CLIN CANCER RES, V14, P2900, DOI 10.1158/1078-0432.CCR-07-1719; Serao NVL, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-49; SHIBANUMA M, 1993, EUR J BIOCHEM, V217, P13, DOI 10.1111/j.1432-1033.1993.tb18212.x; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Sundaram GM, 2013, NATURE, V495, P103, DOI 10.1038/nature11890; Tai IT, 2008, DRUG RESIST UPDATE, V11, P231, DOI 10.1016/j.drup.2008.08.005; Tanaka M, 2010, FEBS J, V277, P4278, DOI 10.1111/j.1742-4658.2010.07816.x; Torres S, 2013, CLIN CANCER RES, V19, P6006, DOI 10.1158/1078-0432.CCR-13-1130; Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866; Turtoi A, 2012, J PROTEOME RES, V11, P5011, DOI 10.1021/pr3005698; Vannahme C, 2003, BIOCHEM J, V373, P805, DOI 10.1042/BJ20030532; Venneti S, 2013, BRAIN PATHOL, V23, P558, DOI 10.1111/bpa.12042; Wilting RH, 2012, DRUG RESIST UPDATE, V15, P21, DOI 10.1016/j.drup.2012.01.008; Yang JH, 2016, ONCOL REP, V35, P3566, DOI 10.3892/or.2016.4757	58	23	23	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2019	38	15					2706	2721		10.1038/s41388-018-0596-2	http://dx.doi.org/10.1038/s41388-018-0596-2			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HS8LQ	30542120	Green Published, hybrid			2022-12-28	WOS:000464121600003
J	He, YF; Hooker, E; Yu, EJ; Cunha, GR; Liao, L; Xu, JM; Earl, A; Wu, HQ; Gonzalgo, ML; Sun, ZJ				He, Yongfeng; Hooker, Erika; Yu, Eun-Jeong; Cunha, Gerald R.; Liao, Lan; Xu, Jianming; Earl, Andrew; Wu, Huiqing; Gonzalgo, Michael L.; Sun, Zijie			Androgen signaling is essential for development of prostate cancer initiated from prostatic basal cells	ONCOGENE			English	Article							EPITHELIAL STEM-CELLS; BETA-CATENIN; MURINE PROSTATE; P53 HOMOLOG; RECEPTOR; ORIGIN; P63; REGENERATION; ACTIVATION; POLYPOSIS	Emerging evidence has shown that both prostatic basal and luminal cells are able to initiate oncogenic transformation. However, despite the diversity of tumor-initiating cells, most prostate cancer cells express the androgen receptor (AR) and depend on androgens for their growth and expansion, implicating an essential role of androgen signaling in prostate tumorigenesis. Prostatic basal cells express p63 and are able to differentiate into luminal, neuroendocrine, and basal cells. Here, we directly assessed the essential role of androgen signaling in prostatic p63-expressing cell initiated oncogenic transformation and tumor formation. Using novel and relevant mouse models, we demonstrated that, with stabilized beta-catenin expression, prostatic p63-expressing cells possess the ability to initiate oncogenic transformation and, in the presence of androgens, they further transdifferentiate into luminal-like tumor cells and develop adenocarcinomas. Castration prior to activating stabilized beta-catenin sensitizes p63-expressing cells and increases their sensitivity to androgens, resulting in aggressive and fast growing tumor phenotypes. These findings are consistent with what have been observed in human prostate cancers, demonstrating an essential role for androgen signaling in prostate cancer initiation and progression. This study also provides fresh insight into developing new therapeutic strategies for better treating prostate cancer patients.	[He, Yongfeng; Hooker, Erika; Yu, Eun-Jeong; Earl, Andrew; Sun, Zijie] Beckman Res Inst & Canc Ctr, Dept Canc Biol, Duarte, CA 91010 USA; [He, Yongfeng; Hooker, Erika; Yu, Eun-Jeong; Sun, Zijie] Stanford Univ, Sch Med, Dept Urol, Stanford, CA 94305 USA; [Cunha, Gerald R.] Univ Calif San Francisco, Dept Urol, Sch Med, San Francisco, CA 94143 USA; [Liao, Lan; Xu, Jianming] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Wu, Huiqing] Beckman Res Inst & Canc Ctr, Dept Pathol, Duarte, CA 91010 USA; [Gonzalgo, Michael L.] Univ Miami, Dept Urol, Sylvester Comprehens Canc Ctr, Sch Med, Miami, FL 33136 USA	Stanford University; University of California System; University of California San Francisco; Baylor College of Medicine; University of Miami	Sun, ZJ (corresponding author), Beckman Res Inst & Canc Ctr, Dept Canc Biol, Duarte, CA 91010 USA.; Sun, ZJ (corresponding author), Stanford Univ, Sch Med, Dept Urol, Stanford, CA 94305 USA.	zjsun@coh.org	He, Yongfeng/AAR-8257-2020	Hooker, Erika/0000-0002-4515-4041; Earl, Andrew/0000-0002-5732-954X	NIH [R01CA070297, R01CA151623, R01CA166894, R21CA190021, R01DK104941, R01CA193455, R01CA112403]; NATIONAL CANCER INSTITUTE [R01CA070297, R01CA166894, R01CA112403, R01CA193455, R21CA190021, R01CA151623] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK104941] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by NIH grants R01CA070297 (Z.S.), R01CA151623 (Z.S.), R01CA166894 (Z.S.), R21CA190021 (Z.S.), R01DK104941 (Z.S.), R01CA193455 (J.X.), and R01CA112403 (J.X.).	Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5; Beliakoff J, 2008, MOL CELL BIOL, V28, P282, DOI 10.1128/MCB.00771-07; Bierie B, 2003, ONCOGENE, V22, P3875, DOI 10.1038/sj.onc.1206426; Bruxvoort KJ, 2007, CANCER RES, V67, P2490, DOI 10.1158/0008-5472.CAN-06-3028; Choi N, 2012, CANCER CELL, V21, P253, DOI 10.1016/j.ccr.2012.01.005; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018; Goldstein AS, 2010, SCIENCE, V329, P568, DOI 10.1126/science.1189992; Guo XC, 2009, NAT CELL BIOL, V11, P1451, DOI 10.1038/ncb1988; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Ittmann M, 2013, CANCER RES, V73, P2718, DOI 10.1158/0008-5472.CAN-12-4213; KYPRIANOU N, 1988, ENDOCRINOLOGY, V122, P552, DOI 10.1210/endo-122-2-552; Lawson DA, 2007, J CLIN INVEST, V117, P2044, DOI 10.1172/JCI32810; Lawson DA, 2010, P NATL ACAD SCI USA, V107, P2610, DOI 10.1073/pnas.0913873107; Lee DK, 2014, INT J BIOL SCI, V10, P1007, DOI 10.7150/ijbs.9997; Lee SH, 2016, ONCOGENE, V35, P702, DOI 10.1038/onc.2015.117; Lee SH, 2015, STEM CELLS, V33, P3356, DOI 10.1002/stem.2096; Locke JA, 2008, CANCER RES, V68, P6407, DOI 10.1158/0008-5472.CAN-07-5997; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Mulholland DJ, 2002, J BIOL CHEM, V277, P17933, DOI 10.1074/jbc.M200135200; Murillo-Garzon V, 2017, NAT REV UROL, V14, P683, DOI 10.1038/nrurol.2017.144; Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335; Peng Y, 2011, J BIOL CHEM, V286, P40331, DOI 10.1074/jbc.M111.302059; Pignon JC, 2013, P NATL ACAD SCI USA, V110, P8105, DOI 10.1073/pnas.1221216110; Placencio VR, 2008, CANCER RES, V68, P4709, DOI 10.1158/0008-5472.CAN-07-6289; Sartor O, 2002, UROLOGY, V60, P138; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Signoretti S, 2000, AM J PATHOL, V157, P1769, DOI 10.1016/S0002-9440(10)64814-6; SUGIMURA Y, 1986, BIOL REPROD, V34, P973, DOI 10.1095/biolreprod34.5.973; Sun Y, 2012, NAT MED, V18, P1359, DOI 10.1038/nm.2890; Truica CI, 2000, CANCER RES, V60, P4709; Truica CI, 2001, AACR ANN M P, V42, P693; Tsujimura A, 2002, J CELL BIOL, V157, P1257, DOI 10.1083/jcb.200202067; Verras M, 2006, CANCER LETT, V237, P22, DOI 10.1016/j.canlet.2005.06.004; Wang X, 2009, NATURE, V461, P495, DOI 10.1038/nature08361; Wang YZ, 2001, DIFFERENTIATION, V68, P270, DOI 10.1046/j.1432-0436.2001.680414.x; Wang ZA, 2011, ONCOGENE, V30, P1261, DOI 10.1038/onc.2010.530; Wang ZA, 2013, NAT CELL BIOL, V15, P274, DOI 10.1038/ncb2697; Weischenfeldt J, 2013, CANCER CELL, V23, P159, DOI 10.1016/j.ccr.2013.01.002; Wissmann C, 2003, J PATHOL, V201, P204, DOI 10.1002/path.1449; Xin L, 2003, P NATL ACAD SCI USA, V100, P11896, DOI 10.1073/pnas.1734139100; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200; Yu X, 2011, ONCOGENE, V30, P1868, DOI 10.1038/onc.2010.560; Zhu CF, 2011, J BIOL CHEM, V286, P33478, DOI 10.1074/jbc.M111.269894	46	11	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2019	38	13					2337	2350		10.1038/s41388-018-0583-7	http://dx.doi.org/10.1038/s41388-018-0583-7			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ7GN	30510232	Green Submitted, Green Accepted			2022-12-28	WOS:000462588000008
J	Zhao, LJ; Wang, W; Xu, L; Yi, T; Zhao, X; Wei, YQ; Vermeulen, L; Goel, A; Zhou, ST; Wang, X				Zhao, Linjie; Wang, Wei; Xu, Lian; Yi, Tao; Zhao, Xia; Wei, Yuquan; Vermeulen, Louis; Goel, Ajay; Zhou, Shengtao; Wang, Xin			Integrative network biology analysis identifies miR-508-3p as the determinant for the mesenchymal identity and a strong prognostic biomarker of ovarian cancer	ONCOGENE			English	Article							MOLECULAR SUBTYPES; EARLY RELAPSE; EXPRESSION; PROGRESSION; TRANSITION; SIGNATURE; DISTINCT; CARCINOMA; APOPTOSIS; TARGETS	Ovarian cancer is a heterogeneous malignancy that poses tremendous clinical challenge. Based on unsupervised classification of whole-genome gene expression profiles, four molecular subtypes of ovarian cancer were recently identified. However, single-driver molecular events specific to these subtypes have not been clearly elucidated. We aim to characterize the regulatory mechanisms underlying the poor prognosis mesenchymal subtype of ovarian cancer using a systems biology approach, involving a variety of molecular modalities including gene and microRNA expression profiles. miR-508-3p emerged as the most powerful determinant that regulates a cascade of dysregulated genes in the mesenchymal subtype, including core genes involved in epithelial-mesenchymal transition (EMT) program. Moreover, miR-508-3p down-regulation, due to promoter hypermethylation, was directly correlated with metastatic behaviors in vitro and in vivo. Taken together, our multidimensional network analysis identified miR-508-3p as a master regulator that defines the mesenchymal subtype and provides a novel prognostic biomarker to improve management of this disease.	[Zhao, Linjie; Yi, Tao; Zhao, Xia; Wei, Yuquan; Zhou, Shengtao] Sichuan Univ, Key Lab Birth Defects & Related Dis Women & Child, Dept Obstet & Gynecol, Chengdu, Sichuan, Peoples R China; [Zhao, Linjie; Yi, Tao; Zhao, Xia; Wei, Yuquan; Zhou, Shengtao] Sichuan Univ, State Key Lab Biotherapy, West China Second Univ Hosp, Chengdu, Sichuan, Peoples R China; [Zhao, Linjie; Yi, Tao; Zhao, Xia; Wei, Yuquan; Zhou, Shengtao] Collaborat Innovat Ctr, Chengdu, Sichuan, Peoples R China; [Wang, Wei; Wang, Xin] City Univ Hong Kong, Dept Biomed Sci, Kowloon Tong, Hong Kong, Peoples R China; [Xu, Lian] Sichuan Univ, Dept Pathol, West China Second Univ Hosp, Chengdu, Sichuan, Peoples R China; [Vermeulen, Louis] Univ Amsterdam, Ctr Expt Mol Med, Acad Med Ctr, Lab Expt Oncol & Radiobiol LEXOR, NL-1105 AZ Amsterdam, Netherlands; [Goel, Ajay] Baylor Univ, Med Ctr, Ctr Gastrointestinal Res, Dallas, TX USA; [Goel, Ajay] Baylor Univ, Med Ctr, Ctr Translat Genom & Oncol, Baylor Scott & White Res Inst, Dallas, TX USA; [Goel, Ajay] Baylor Univ, Med Ctr, Charles A Sammons Canc Ctr, Dallas, TX USA; [Wang, Xin] City Univ Hong Kong, Shenzhen Res Inst, Shenzhen, Peoples R China	Sichuan University; Sichuan University; City University of Hong Kong; Sichuan University; University of Amsterdam; Academic Medical Center Amsterdam; Baylor University; Baylor University Medical Center; Baylor Health Care System; Baylor University; Baylor University Medical Center; Baylor University; Baylor University Medical Center; City University of Hong Kong	Zhou, ST (corresponding author), Sichuan Univ, Key Lab Birth Defects & Related Dis Women & Child, Dept Obstet & Gynecol, Chengdu, Sichuan, Peoples R China.; Zhou, ST (corresponding author), Sichuan Univ, State Key Lab Biotherapy, West China Second Univ Hosp, Chengdu, Sichuan, Peoples R China.; Zhou, ST (corresponding author), Collaborat Innovat Ctr, Chengdu, Sichuan, Peoples R China.; Wang, X (corresponding author), City Univ Hong Kong, Dept Biomed Sci, Kowloon Tong, Hong Kong, Peoples R China.; Wang, X (corresponding author), City Univ Hong Kong, Shenzhen Res Inst, Shenzhen, Peoples R China.	taotaovip2005@163.com; xin.wang@cityu.edu.hk	Wang, Xin/A-1130-2012	Wang, Xin/0000-0002-5122-2418; Vermeulen, Louis/0000-0002-6066-789X; Zhou, Shengtao/0000-0001-8322-5536	National Natural Science Foundation of China [81822034, 81773119, 81402396]; National Key Research and Development Program of China [2018YFA0109200, 2017YFA0106800]; Sichuan Science-Technology Soft Sciences Project [2016ZR0086]; West China Second Hospital, Sichuan University [KS021]; Research Grants Council of the Hong Kong Special Administrative Region, China [CityU 21101115, 11102317, 11103718]; Science Technology and Innovation Committee of Shenzhen Municipality [JCYJ20170307091256048]; Shenzhen Research Institute, City University of Hong Kong	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program of China; Sichuan Science-Technology Soft Sciences Project; West China Second Hospital, Sichuan University; Research Grants Council of the Hong Kong Special Administrative Region, China(Hong Kong Research Grants Council); Science Technology and Innovation Committee of Shenzhen Municipality; Shenzhen Research Institute, City University of Hong Kong(City University of Hong Kong)	This work was supported by grants from the National Natural Science Foundation of China (grant#81822034, grant #81773119, and grant #81402396), National Key Research and Development Program of China (2018YFA0109200 and 2017YFA0106800), Sichuan Science-Technology Soft Sciences Project (grant #2016ZR0086), Direct Scientific Research Grants from West China Second Hospital, Sichuan University (grant #KS021) awarded to Shengtao Zhou and a grant from the Research Grants Council of the Hong Kong Special Administrative Region, China (Project No. CityU 21101115, 11102317, 11103718), as well as a grant from The Science Technology and Innovation Committee of Shenzhen Municipality (JCYJ20170307091256048) awarded to Xin Wang, and partially supported by the Shenzhen Research Institute, City University of Hong Kong.	Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Bagnoli M, 2016, LANCET ONCOL, V17, P1137, DOI 10.1016/S1470-2045(16)30108-5; Bagnoli M, 2011, ONCOTARGET, V2, P1265, DOI 10.18632/oncotarget.401; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bilyk O, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00145; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Bonome T, 2008, CANCER RES, V68, P5478, DOI 10.1158/0008-5472.CAN-07-6595; Bowtell DD, 2015, NAT REV CANCER, V15, P668, DOI 10.1038/nrc4019; Cairo S, 2008, CANCER CELL, V14, P471, DOI 10.1016/j.ccr.2008.11.002; Ceppi P, 2014, ONCOGENE, V33, P269, DOI 10.1038/onc.2013.55; Chaisaingmongkol J, 2017, CANCER CELL, V32, P57, DOI 10.1016/j.ccell.2017.05.009; Chan CK, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.160275; De Sousa E Melo F, 2013, NAT MED, V19, P614, DOI 10.1038/nm.3174; Di Stefano V, 2016, AM J PATHOL, V186, P2473, DOI 10.1016/j.ajpath.2016.05.019; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Fletcher MNC, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3464; Floor S, 2011, ONCOGENE, V30, P4609, DOI 10.1038/onc.2011.184; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Huang TT, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0493-7; Jiang JW, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.36; Karnezis AN, 2017, NAT REV CANCER, V17, P65, DOI 10.1038/nrc.2016.113; Konecny GE, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju249; Kossai M, 2018, PATHOBIOLOGY, V85, P41, DOI 10.1159/000479006; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lin CY, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5620; Liu N, 2017, ONCOTARGET, V8, P60015, DOI 10.18632/oncotarget.9623; Martin M., 2011, EMBNET J, V17, P10, DOI [10.14806/ej.17.1.200, DOI 10.14806/EJ.17.1.200]; Mateescu B, 2011, NAT MED, V17, P1627, DOI 10.1038/nm.2512; Matulonis UA, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.61; Nam EJ, 2016, ONCOTARGET, V7, P70524, DOI 10.18632/oncotarget.12045; Northcott PA, 2017, NATURE, V547, P311, DOI 10.1038/nature22973; Pan YH, 2017, ONCOTARGET, V8, P17406, DOI 10.18632/oncotarget.15921; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246; Sean D, 2007, BIOINFORMATICS, V23, P1846, DOI 10.1093/bioinformatics/btm254; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tan TZ, 2013, EMBO MOL MED, V5, P1051, DOI 10.1002/emmm.201201823; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Vang S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058226; Wang X, 2011, BIOINFORMATICS, V27, P879, DOI 10.1093/bioinformatics/btr028; Way GP, 2016, G3-GENES GENOM GENET, V6, P4097, DOI 10.1534/g3.116.033514; Wong N, 2015, NUCLEIC ACIDS RES, V43, pD146, DOI 10.1093/nar/gku1104; Yang D, 2013, CANCER CELL, V23, P186, DOI 10.1016/j.ccr.2012.12.020; Yu XT, 2013, TUMOR BIOL, V34, P3501, DOI 10.1007/s13277-013-0928-3; Yu Y, 2013, CELL, V152, P248, DOI 10.1016/j.cell.2012.12.006; Zhai QN, 2012, BIOCHEM BIOPH RES CO, V419, P621, DOI 10.1016/j.bbrc.2012.02.060; Zhao L, 2017, ONCOGENE, V36, P3384, DOI 10.1038/onc.2016.487; Zhao LJ, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1412-6; Zhao LJ, 2017, CANCER RES, V77, P1369, DOI 10.1158/0008-5472.CAN-16-1615; Zhao LJ, 2013, HUM REPROD, V28, P1324, DOI 10.1093/humrep/det042; Zhao M, 2015, SCI REP-UK, V5, DOI 10.1038/srep11459; Zhou ST, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M112.017988; Zhou ST, 2012, CANCER LETT, V318, P14, DOI 10.1016/j.canlet.2011.10.038	55	37	37	4	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2019	38	13					2305	2319		10.1038/s41388-018-0577-5	http://dx.doi.org/10.1038/s41388-018-0577-5			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ7GN	30478449	Green Published, hybrid			2022-12-28	WOS:000462588000006
J	Asnaghi, L; Whiten, DT; Key, N; Choi, JH; Mahale, A; Alkatan, H; Edward, DP; Elkhamary, SM; Al-Mesfer, S; Maktabi, A; Hurtado, CG; Leen, GY; Carcaboso, AM; Mumm, JS; Abu Safieh, L; Eberhart, CG				Asnaghi, Laura; Whiten, David T.; Key, Nolan; Choi, Joshua; Mahale, Alka; Alkatan, Hind; Edward, Deepak P.; Elkhamary, Sahar M.; Al-Mesfer, Saleh; Maktabi, Azza; Hurtado, Christopher G.; Leen, Grace Y.; Carcaboso, Angel M.; Mumm, Jeff S.; Abu Safieh, Leen; Eberhart, Charles G.			ACVR1C/SMAD2 signaling promotes invasion and growth in retinoblastoma	ONCOGENE			English	Article							TGF-BETA; TUMORIGENIC PHENOTYPE; CELL-GROWTH; ACTIVIN-A; CANCER; RECEPTOR; PROTEINS; DIFFERENTIATION; EXPRESSION; REVEALS	Retinoblastoma is the most common intraocular cancer in children. While the primary tumor can often be treated by local or systemic chemotherapy, metastatic dissemination is generally resistant to therapy and remains a leading cause of pediatric cancer death in much of the world. In order to identify new therapeutic targets in aggressive tumors, we sequenced RNA transcripts in five snap frozen retinoblastomas which invaded the optic nerve and five which did not. A three-fold increase was noted in mRNA levels of ACVR1C/ALK7, a type I receptor of the TGF-beta family, in invasive retinoblastomas, while downregulation of DACT2 and LEFTY2, negative modulators of the ACVR1C signaling, was observed in most invasive tumors. A two-to three-fold increase in ACVR1C mRNA was also found in invasive WERI Rb1 and Y79 cells as compared to non-invasive cells in vitro. Transcripts of ACVR1C receptor and its ligands (Nodal, Activin A/B, and GDF3) were expressed in six retinoblastoma lines, and evidence of downstream SMAD2 signaling was present in all these lines. Pharmacological inhibition of ACVR1C signaling using SB505124, or genetic downregulation of the receptor using shRNA potently suppressed invasion, growth, survival, and reduced the protein levels of the mesenchymal markers ZEB1 and Snail. The inhibitory effects on invasion, growth, and proliferation were recapitulated by knocking down SMAD2, but not SMAD3. Finally, in an orthotopic zebrafish model of retinoblastoma, a 55% decrease in tumor spread was noted (p = 0.0026) when larvae were treated with 3 mu M of SB505124, as compared to DMSO. Similarly, knockdown of ACVR1C in injected tumor cells using shRNA also resulted in a 54% reduction in tumor dissemination in the zebrafish eye as compared to scrambled shRNA control (p = 0.0005). Our data support a role for the ACVR1C/SMAD2 pathway in promoting invasion and growth of retinoblastoma.	[Asnaghi, Laura; Key, Nolan; Choi, Joshua; Eberhart, Charles G.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Whiten, David T.; Edward, Deepak P.; Hurtado, Christopher G.; Leen, Grace Y.; Mumm, Jeff S.; Eberhart, Charles G.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA; [Mahale, Alka; Alkatan, Hind; Edward, Deepak P.; Elkhamary, Sahar M.; Al-Mesfer, Saleh; Maktabi, Azza; Abu Safieh, Leen] King Khalid Eye Specialist Hosp, Riyadh, Saudi Arabia; [Edward, Deepak P.] Univ Illinois, Eye & Ear Infirm, Chicago, IL 60612 USA; [Elkhamary, Sahar M.] Mansoura Fac Med, Dept Diagnost Radiol, Mansoura, Egypt; [Carcaboso, Angel M.] Inst Rec St Joan de Deu, Barcelona, Spain; [Eberhart, Charles G.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; [Alkatan, Hind] King Saud Univ, Coll Med, Dept Ophthalmol, Riyadh, Saudi Arabia	Johns Hopkins University; Johns Hopkins University; King Khaled Eye Specialist Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Egyptian Knowledge Bank (EKB); Mansoura University; Johns Hopkins University; King Saud University	Eberhart, CG (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.; Eberhart, CG (corresponding author), Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA.; Abu Safieh, L (corresponding author), King Khalid Eye Specialist Hosp, Riyadh, Saudi Arabia.; Eberhart, CG (corresponding author), Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA.	leensafieh@yahoo.co.uk; ceberha@jhmi.edu	Elkhamary, Sahar M/AAR-6991-2020; ALKATAN, HIND M/AAU-3752-2021; Elkhamary, Sahar M/R-2021-2017; Mumm, Jeff S/F-3125-2013; Elkhamary, Sahar M/Z-1797-2018	Elkhamary, Sahar M/0000-0001-8694-4376; ALKATAN, HIND M/0000-0002-9968-4099; Elkhamary, Sahar M/0000-0001-8694-4376; Elkhamary, Sahar M/0000-0001-8694-4376; Mumm, Jeff/0000-0002-2575-287X; Lee, Grace/0000-0003-1999-0836; Carcaboso, Angel/0000-0002-8485-426X	King Khaled Eye Specialist Hospital (KKESH)-Wilmer Eye Institute (WEI) Collaborative Research Grant; NIH [R21CA229919]; Jenny Fund; ISCIII-FEDER [CP13/00189]; MINECO (Retos program; Cure4RB project) [RTC-2015-4319-1];  [EY001765]; NATIONAL CANCER INSTITUTE [R21CA229919] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY001765, T32EY007143] Funding Source: NIH RePORTER	King Khaled Eye Specialist Hospital (KKESH)-Wilmer Eye Institute (WEI) Collaborative Research Grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Jenny Fund; ISCIII-FEDER; MINECO (Retos program; Cure4RB project); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	King Khaled Eye Specialist Hospital (KKESH)-Wilmer Eye Institute (WEI) Collaborative Research Grant, NIH Grant R21CA229919, the core grant EY001765, and The Jenny Fund. AMC acknowledges funding from ISCIII-FEDER (CP13/00189) and MINECO (Retos program; Cure4RB project RTC-2015-4319-1).	Arima Y, 2012, J BIOL CHEM, V287, P7896, DOI 10.1074/jbc.M111.313759; Asnaghi L, 2016, ONCOTARGET, V7, P70028, DOI 10.18632/oncotarget.12142; Asnaghi L, 2013, INVEST OPHTH VIS SCI, V54, P295, DOI 10.1167/iovs.12-10209; Badhu B, 2005, CLIN EXP OPHTHALMOL, V33, P386, DOI 10.1111/j.1442-9071.2005.01010.x; Bashir M, 2015, NPJ BREAST CANCER, V1, DOI 10.1038/npjbcancer.2015.7; Bertacchi M, 2015, STEM CELL REP, V5, P532, DOI 10.1016/j.stemcr.2015.08.011; Bondestam J, 2001, CYTOGENET CELL GENET, V95, P157, DOI 10.1159/000059339; Busch M, 2018, ONCOL REP, V39, P160, DOI 10.3892/or.2017.6100; Byfield SD, 2004, MOL PHARMACOL, V65, P744, DOI 10.1124/mol.65.3.744; Chantada GL, 2011, PEDIATR BLOOD CANCER, V56, P341, DOI 10.1002/pbc.22843; Chawla B, 2016, OPHTHALMOLOGY, V123, P1933, DOI 10.1016/j.ophtha.2016.05.034; Chen XY, 2015, SCI REP-UK, V5, DOI 10.1038/srep10351; Chung IC, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-348; Condro MC, 2016, J COMP NEUROL, V524, P3827, DOI 10.1002/cne.24035; Gong WC, 2016, ONCOTARGET, V7, P70152, DOI 10.18632/oncotarget.12161; Gray PC, 2012, FEBS LETT, V586, P1836, DOI 10.1016/j.febslet.2012.01.051; Gregory PA, 2011, MOL BIOL CELL, V22, P1686, DOI 10.1091/mbc.E11-02-0103; Hamilton L, 2016, ZEBRAFISH, V13, P523, DOI 10.1089/zeb.2016.1339; Honavar Santosh G, 2005, Ophthalmol Clin North Am, V18, P65, DOI 10.1016/j.ohc.2004.09.001; Hu TT, 2017, ANTICANCER RES, V37, P3441, DOI 10.21873/anticanres.11712; James D, 2005, DEVELOPMENT, V132, P1273, DOI 10.1242/dev.01706; Joseph JV, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.395; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kanno C, 2009, CURR EYE RES, V34, P652, DOI 10.1080/02713680903007147; Kirsammer G, 2014, SEMIN CANCER BIOL, V29, P40, DOI 10.1016/j.semcancer.2014.07.007; Lawrence MG, 2011, PROSTATE, V71, P1198, DOI 10.1002/pros.21335; Leal-Leal Carlos A, 2006, Clin Transl Oncol, V8, P39, DOI 10.1007/s12094-006-0093-x; Liu CH, 2003, J BIOL CHEM, V278, P11721, DOI 10.1074/jbc.M207728200; Liu Y, 2017, INT J MOL MED, V40, P1172, DOI 10.3892/ijmm.2017.3102; Liu YQ, 2013, J BIOL CHEM, V288, P11572, DOI 10.1074/jbc.M112.434951; Lonardo E, 2011, CELL STEM CELL, V9, P433, DOI 10.1016/j.stem.2011.10.001; Loomans HA, 2016, AM J CANCER RES, V6, P2431; Lv FZ, 2015, INT J IMMUNOPATH PH, V28, P77, DOI 10.1177/0394632015572557; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; MCFALL RC, 1977, CANCER RES, V37, P1003; Morini M, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-649; Pacifici M, 2016, CYTOKINE GROWTH F R, V27, P93, DOI 10.1016/j.cytogfr.2015.12.007; Pascual-Pasto G, 2016, CANCER LETT, V380, P10, DOI 10.1016/j.canlet.2016.06.012; Peng L, 2017, ONCOTARGET, V8, P34387, DOI 10.18632/oncotarget.16166; Postovit LM, 2008, P NATL ACAD SCI USA, V105, P4329, DOI 10.1073/pnas.0800467105; REID TW, 1974, J NATL CANCER I, V53, P347, DOI 10.1093/jnci/53.2.347; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Sakami S, 2008, MECH DEVELOP, V125, P106, DOI 10.1016/j.mod.2007.10.001; Schmierer B, 2003, J BIOL CHEM, V278, P21197, DOI 10.1074/jbc.M212425200; Schubert FR, 2014, BMC EVOL BIOL, V14, DOI 10.1186/1471-2148-14-157; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Strizzi Luigi, 2009, Expert Rev Dermatol, V4, P67, DOI 10.1586/17469872.4.1.67; Tanaka K, 2007, ONCOGENE, V26, P6456, DOI 10.1038/sj.onc.1210459; Teng Y, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-453; Theodoropoulou S, 2010, FASEB J, V24, P2620, DOI 10.1096/fj.09-152546; Topczewska JM, 2006, NAT MED, V12, P925, DOI 10.1038/nm1448; Tsuchida K, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-15; Villegas VM, 2013, CURR OPIN OPHTHALMOL, V24, P581, DOI 10.1097/ICU.0000000000000002; Weingart MF, 2015, ONCOTARGET, V6, P3165, DOI 10.18632/oncotarget.3078; White CD, 2009, FEBS LETT, V583, P1817, DOI 10.1016/j.febslet.2009.05.007; White DT, 2017, P NATL ACAD SCI USA, V114, pE3719, DOI 10.1073/pnas.1617721114; Wickham H., 2016, GGPLOT2 ELEGANT GRAP; Yang Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097578; Yoshinaga K, 2004, CLIN CANCER RES, V10, P5702, DOI 10.1158/1078-0432.CCR-03-0262	59	24	24	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2019	38	12					2056	2075		10.1038/s41388-018-0543-2	http://dx.doi.org/10.1038/s41388-018-0543-2			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP6UR	30401983	Green Accepted			2022-12-28	WOS:000461822600005
J	Kohler, M; Ehrenfeld, S; Halbach, S; Lauinger, M; Burk, U; Reischmannl, N; Cheng, SF; Spohr, C; Uhl, FM; Kohler, N; Ringwald, K; Braun, S; Peters, C; Zeiser, R; Reinheckel, T; Brummer, T				Koehler, Martin; Ehrenfeld, Sophia; Halbach, Sebastian; Lauinger, Manuel; Burk, Ulrike; Reischmannl, Nadine; Cheng, Shuofei; Spohr, Corinna; Uhl, Franziska Maria; Koehler, Natalie; Ringwald, Kathrin; Braun, Sandra; Peters, Christoph; Zeiser, Robert; Reinheckel, Thomas; Brummer, Tilman			B-Raf deficiency impairs tumor initiation and progression in a murine breast cancer model	ONCOGENE			English	Article							ERK ACTIVATION; MAPK PATHWAY; CATHEPSIN-B; BRAF; INHIBITORS; PHOSPHORYLATION; METASTASIS; EXPRESSION; CELLS; GENE	Copy number gains, point mutations and epigenetic silencing events are increasingly observed in genes encoding elements of the Ras/Raf/MEK/ERK signaling axis in human breast cancer. The three Raf kinases A-Raf, B-Raf, and Raf-1 have an important role as gatekeepers in ERK pathway activation and are often dysregulated by somatic alterations of their genes or by the aberrant activity of receptor tyrosine kinases (RTKs) and Ras-GTPases. B-Raf represents the most potent Raf isoform and a critical effector downstream of RTKs and RAS proteins. Aberrant RTK signaling is mimicked by the polyoma middle T antigen (PyMT), which activates various oncogenic signaling pathways, incl. the RAS/ERK axis, in a similar manner as RTKs in human breast cancer. Mammary epithelial cell directed expression of PyMT in mice by the MMTV-PyMT transgene induces mammary hyperplasia progressing over adenoma to metastatic breast cancer with an almost complete penetrance. To understand the functional role of B-Raf in this model for luminal type B breast cancer, we crossed MMTV-PyMT mice with animals that either lack B-Raf expression in the mammary gland or express the signaling impaired B-Raf(AVKA) mutant. The AVKA mutation prevents phosphorylation of T599 and S602 in the B-Raf activation loop and thereby activation of the kinase by upstream signals. We demonstrate for the first time that B-Raf expression and activation is important for tumor initiation in vivo as well as for lung metastasis. Isogenic tumor cell lines generated from conditional Braf knock-out or knock-in mice displayed a reduction in EGF-induced ERK pathway activity as well as in proliferation and invasive growth in three-dimensional matrigel cultures. Our results suggest that B-Raf, which has been hardly studied in the context of breast cancer, represents a critical effector of the PyMT oncoprotein and invite for an assessment of its functional role in human breast cancer.	[Koehler, Martin; Ehrenfeld, Sophia; Halbach, Sebastian; Lauinger, Manuel; Burk, Ulrike; Reischmannl, Nadine; Cheng, Shuofei; Spohr, Corinna; Ringwald, Kathrin; Braun, Sandra; Peters, Christoph; Reinheckel, Thomas; Brummer, Tilman] Univ Freiburg, Fac Med, Inst Mol Med & Cell Res, Freiburg, Germany; [Koehler, Martin; Halbach, Sebastian; Reischmannl, Nadine; Spohr, Corinna; Koehler, Natalie] Univ Freiburg, Spemann Grad Sch Biol & Med, Freiburg, Germany; [Koehler, Martin; Ehrenfeld, Sophia; Halbach, Sebastian; Lauinger, Manuel; Reischmannl, Nadine; Spohr, Corinna; Uhl, Franziska Maria; Koehler, Natalie; Ringwald, Kathrin] Univ Freiburg, Fac Biol, Freiburg, Germany; [Ehrenfeld, Sophia; Lauinger, Manuel; Peters, Christoph; Zeiser, Robert; Reinheckel, Thomas; Brummer, Tilman] German Consortium Translat Canc Res DKTK, Partner Site Freiburg, Heidelberg, Germany; [Ehrenfeld, Sophia; Lauinger, Manuel; Peters, Christoph; Zeiser, Robert; Reinheckel, Thomas; Brummer, Tilman] German Canc Res Ctr, Heidelberg, Germany; [Burk, Ulrike; Peters, Christoph; Zeiser, Robert; Reinheckel, Thomas; Brummer, Tilman] Univ Freiburg, Ctr Biol Signalling Studies BIOSS, Freiburg, Germany; [Uhl, Franziska Maria; Koehler, Natalie; Zeiser, Robert] Univ Freiburg, Univ Med Ctr, Fac Med, Dept Hematol & Oncol, Freiburg, Germany; [Peters, Christoph; Zeiser, Robert; Reinheckel, Thomas; Brummer, Tilman] Comprehens Canc Ctr Freiburg, Freiburg, Germany	University of Freiburg; University of Freiburg; University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of Freiburg; University of Freiburg	Reinheckel, T; Brummer, T (corresponding author), Univ Freiburg, Fac Med, Inst Mol Med & Cell Res, Freiburg, Germany.; Reinheckel, T; Brummer, T (corresponding author), German Consortium Translat Canc Res DKTK, Partner Site Freiburg, Heidelberg, Germany.; Reinheckel, T; Brummer, T (corresponding author), German Canc Res Ctr, Heidelberg, Germany.; Reinheckel, T; Brummer, T (corresponding author), Univ Freiburg, Ctr Biol Signalling Studies BIOSS, Freiburg, Germany.; Reinheckel, T; Brummer, T (corresponding author), Comprehens Canc Ctr Freiburg, Freiburg, Germany.	thomas.reinheckel@mol-med.uni-freiburg.de; tilman.brummer@mol-med.uni-freiburg.de	Halbach, Sebastian/G-4021-2012; Brummer, Tilman/AAA-9428-2020; Köhler, Natalie/AAG-1712-2019; Brummer, Tilman/B-6218-2016; Reinheckel, Thomas/AAL-9761-2021	Halbach, Sebastian/0000-0002-6827-8178; Brummer, Tilman/0000-0003-4387-7905; Köhler, Natalie/0000-0002-7502-0431; Brummer, Tilman/0000-0003-4387-7905; Reinheckel, Thomas/0000-0001-9866-9105; Zeiser, Robert/0000-0001-6565-3393; Kohler, Martin/0000-0002-7248-6084	Deutsche Forschungsgemeinschaft (DFG) via the Collaborative Research Centre 850; Excellence Initiative of the German Federal and State Governments [EXC 294 BIOSS]; German Cancer Consortium (DKTK) [L627]; Spemann Graduate School for Biology and Medicine (SGBM) [GSC-4]; Emmy-Noether program of the DFG; Heisenberg program of the DFG	Deutsche Forschungsgemeinschaft (DFG) via the Collaborative Research Centre 850(German Research Foundation (DFG)); Excellence Initiative of the German Federal and State Governments; German Cancer Consortium (DKTK); Spemann Graduate School for Biology and Medicine (SGBM); Emmy-Noether program of the DFG(German Research Foundation (DFG)); Heisenberg program of the DFG	This work was funded by the Deutsche Forschungsgemeinschaft (DFG) via the Collaborative Research Centre 850 (projects B4; B7, and C6), the Excellence Initiative of the German Federal and State Governments (EXC 294 BIOSS), the German Cancer Consortium (DKTK, L627) and the Spemann Graduate School for Biology and Medicine (GSC-4; SGBM) via fellowships to MK, SH, NK, CK. and NR. TB was also supported by the Emmy-Noether and Heisenberg programs of the DFG. We would also like to thank Chris Ormandy for helpful discussions, Ricarda Herr for advice, and Nicole Klemm and Ulrike Reif for expert technical assistance.	Aceto N, 2012, NAT MED, V18, P529, DOI 10.1038/nm.2645; Adeyinka A, 2002, CLIN CANCER RES, V8, P1747; Ali NA, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0437-3; Balko JM, 2014, CANCER DISCOV, V4, P232, DOI 10.1158/2159-8290.CD-13-0286; Beliveau A, 2010, GENE DEV, V24, P2800, DOI 10.1101/gad.1990410; Ben-David U, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12160; Bengsch F, 2014, ONCOGENE, V33, P4474, DOI 10.1038/onc.2013.395; Bentires-Alj M, 2006, NAT MED, V12, P114, DOI 10.1038/nm1341; Calleja V, 2007, PLOS BIOL, V5, P780, DOI 10.1371/journal.pbio.0050095; Chen AP, 2006, J NEUROSCI RES, V83, P28, DOI 10.1002/jnr.20703; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; Desideri E, 2015, CELL, V161, P967, DOI 10.1016/j.cell.2015.04.045; Dilworth SM, 2002, NAT REV CANCER, V2, P951, DOI 10.1038/nrc946; Dow LE, 2012, NAT PROTOC, V7, P374, DOI 10.1038/nprot.2011.446; Fantozzi A, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1530; Fluck MM, 2009, MICROBIOL MOL BIOL R, V73, P542, DOI 10.1128/MMBR.00009-09; Galabova-Kovacs G, 2006, P NATL ACAD SCI USA, V103, P1325, DOI 10.1073/pnas.0507399103; Galabova-Kovacs G, 2008, J CELL BIOL, V180, P947, DOI 10.1083/jcb.200709069; Gillies TE, 2017, CELL SYST, V5, P549, DOI 10.1016/j.cels.2017.10.019; Girotti MR, 2015, CANCER CELL, V27, P85, DOI 10.1016/j.ccell.2014.11.006; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Ha JR, 2016, J CELL BIOCHEM, V117, P1971, DOI 10.1002/jcb.25561; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Haug S, 2015, INT J CANCER, V136, P2328, DOI 10.1002/ijc.29289; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Herr R, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-17; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Hillebrand LE, 2016, ONCOTARGET, V7, P58244, DOI 10.18632/oncotarget.11309; Holderfield M, 2014, NAT REV CANCER, V14, P455, DOI 10.1038/nrc3760; Hu JC, 2013, CELL, V154, P1036, DOI 10.1016/j.cell.2013.07.046; Jacob LS, 2015, CANCER RES, V75, P3713, DOI 10.1158/0008-5472.CAN-15-0562; Kamata T, 2010, CANCER RES, V70, P8475, DOI 10.1158/0008-5472.CAN-10-0603; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kohler M, 2016, CELL CYCLE, V15, P1171, DOI 10.1080/15384101.2016.1159111; Kohler M, 2016, EMBO J, V35, P143, DOI 10.15252/embj.201592097; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lan LX, 2015, EMBO J, V34, P1493, DOI 10.15252/embj.201489004; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Little AS, 2013, ONCOGENE, V32, P1207, DOI 10.1038/onc.2012.160; Liu H, 2018, CANCER DISCOV, V8, P354, DOI 10.1158/2159-8290.CD-17-0679; Marcotte R, 2012, P NATL ACAD SCI USA, V109, P2808, DOI 10.1073/pnas.1018861108; McLaughlin SK, 2013, CANCER CELL, V24, P365, DOI 10.1016/j.ccr.2013.08.004; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Nieto P, 2017, NATURE, V548, P239, DOI 10.1038/nature23297; O'Toole SA, 2013, J CLIN PATHOL, V66, P530, DOI 10.1136/jclinpath-2012-201361; Olsen SN, 2017, CANCER DISCOV, V7, P202, DOI 10.1158/2159-8290.CD-16-0520; Pearson GW, 2007, J CELL BIOL, V179, P1555, DOI 10.1083/jcb.200706099; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; Roring M, 2012, EMBO J, V31, P2629, DOI 10.1038/emboj.2012.100; Roering Michael, 2012, Critical Reviews in Oncogenesis, V17, P97; Samatar AA, 2014, NAT REV DRUG DISCOV, V13, P928, DOI 10.1038/nrd4281; Santarpia L, 2012, BREAST CANCER RES TR, V134, P333, DOI 10.1007/s10549-012-2035-3; Sears R, 2017, CANCER DISCOV, V7, P131, DOI 10.1158/2159-8290.CD-16-1423; Sevenich L, 2011, ONCOGENE, V30, P54, DOI 10.1038/onc.2010.387; Sevenich L, 2010, P NATL ACAD SCI USA, V107, P2497, DOI 10.1073/pnas.0907240107; Smith Brittni A, 2012, Genes Cancer, V3, P550, DOI 10.1177/1947601913475359; Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017; Thevakumaran N, 2015, NAT STRUCT MOL BIOL, V22, P37, DOI 10.1038/nsmb.2924; Tilch E, 2014, BREAST CANCER RES TR, V143, P385, DOI 10.1007/s10549-013-2798-1; Varga A, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aai8482; Wagner KU, 2002, DEVELOPMENT, V129, P1377; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Whyte J, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2361; Wojnowski L, 2000, MECH DEVELOP, V91, P97, DOI 10.1016/S0925-4773(99)00276-2; Yaktapour N, 2014, J CLIN INVEST, V124, P5074, DOI 10.1172/JCI76539; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429; Zhang C, 2015, NATURE, V526, P583, DOI 10.1038/nature14982; Zhong J, 2007, NAT NEUROSCI, V10, P598, DOI 10.1038/nn1898; Zuber J, 2011, NAT BIOTECHNOL, V29, P79, DOI 10.1038/nbt.1720	71	8	8	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2019	38	8					1324	1339		10.1038/s41388-018-0663-8	http://dx.doi.org/10.1038/s41388-018-0663-8			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HM1XR	30659267				2022-12-28	WOS:000459249800013
J	Son, B; Lee, S; Kim, H; Kang, H; Jeon, J; Jo, S; Seong, KM; Lee, SJ; Youn, H; Youn, B				Son, Beomseok; Lee, Sungmin; Kim, Hyunwoo; Kang, Hyunkoo; Jeon, Jaewan; Jo, Sunmi; Seong, Ki Moon; Lee, Su-Jae; Youn, HyeSook; Youn, BuHyun			Decreased FBP1 expression rewires metabolic processes affecting aggressiveness of glioblastoma	ONCOGENE			English	Article							IN-VIVO; CANCER; GLIOMA; THERAPY; RADIORESISTANCE; GLYCOLYSIS; STRESS; EMODIN; BRAIN; CELLS	Radiotherapy is a standard treatment option for patients with glioblastoma (GBM). Although it has high therapeutic efficacy, some proportion of the tumor cells that survive after radiotherapy may cause side effects. In this study, we found that fructose 1,6-bisphosphatase 1 (FBP1), a rate-limiting enzyme in gluconeogenesis, was downregulated upon treatment with ionizing radiation (IR). Ets1, which was found to be overexpressed in IR-induced infiltrating GBM, was suggested to be a transcriptional repressor of FBP1. Furthermore, glucose uptake and extracellular acidification rates were increased upon FBP1 downregulation, which indicated an elevated glycolysis level. We found that emodin, an inhibitor of phosphoglycerate mutase 1 derived from natural substances, significantly suppressed the glycolysis rate and IR-induced GBM migration in in vivo orthotopic xenograft mouse models. We propose that the reduced FBP1 level reprogrammed the metabolic state of GBM cells, and thus, FBP1 is a potential therapeutic target regulating GBM metabolism following radiotherapy.	[Son, Beomseok; Lee, Sungmin; Kim, Hyunwoo; Kang, Hyunkoo; Jeon, Jaewan; Youn, BuHyun] Pusan Natl Univ, Dept Integrated Biol Sci, Busan 46241, South Korea; [Jo, Sunmi] Inje Univ, Sch Med, Haeundae Paik Hosp, Dept Radiat Oncol, Busan 48108, South Korea; [Seong, Ki Moon] Korea Inst Radiol & Med Sci, Natl Radiat Emergency Med Ctr, Lab Low Dose Risk Assessment, Seoul 01812, South Korea; [Lee, Su-Jae] Hanyang Univ, Res Inst Nat Sci, Dept Life Sci, Seoul 04763, South Korea; [Youn, HyeSook] Sejong Univ, Dept Integrat Biosci & Biotechnol, Seoul 05006, South Korea; [Youn, BuHyun] Pusan Natl Univ, Dept Biol Sci, Busan 46241, South Korea	Pusan National University; Inje University; Korea Institute of Radiological & Medical Sciences; Hanyang University; Sejong University; Pusan National University	Youn, B (corresponding author), Pusan Natl Univ, Dept Integrated Biol Sci, Busan 46241, South Korea.; Youn, B (corresponding author), Pusan Natl Univ, Dept Biol Sci, Busan 46241, South Korea.	bhyoun72@pusan.ac.kr		Jo, Sunmi/0000-0002-1761-8953	Nuclear Safety Research Program through the Korea Foundation Of Nuclear Safety (KoFONS); Nuclear Safety and Security Commission (NSSC) of the Republic of Korea [1805019]	Nuclear Safety Research Program through the Korea Foundation Of Nuclear Safety (KoFONS); Nuclear Safety and Security Commission (NSSC) of the Republic of Korea	This work was supported by the Nuclear Safety Research Program through the Korea Foundation Of Nuclear Safety (KoFONS) using the financial resource granted by the Nuclear Safety and Security Commission (NSSC) of the Republic of Korea (No. 1805019). We thank Dr. Akio Soeda (Gifu University) for providing patient-derived X01 GBM cells.	Abbadi S, 2014, MOL CANCER RES, V12, P1547, DOI 10.1158/1541-7786.MCR-14-0106-T; Bhat KPL, 2013, CANCER CELL, V24, P331, DOI 10.1016/j.ccr.2013.08.001; Brady ST, 2012, BASIC NEUROCHEMISTRY: PRINCIPLES OF MOLECULAR, CELLULAR, AND MEDICAL NEUROBIOLOGY, 8THEDITION, P1; Chang L, 2004, MOL MED, V10, P65, DOI 10.2119/2005-00029.Saltiel; Chen J, 2011, ONCOGENE, V30, P4297, DOI 10.1038/onc.2011.137; Cong Jingjing, 2018, CELL METAB, V28, P243; Cooper LAD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012548; Desvergne B, 2006, PHYSIOL REV, V86, P465, DOI 10.1152/physrev.00025.2005; Ferrer VP, 2018, GLIA, V66, P1542, DOI 10.1002/glia.23309; Graziose Rocky, 2010, Curr Drug Discov Technol, V7, P2; Halliday J, 2014, P NATL ACAD SCI USA, V111, P5248, DOI 10.1073/pnas.1321014111; Han TY, 2013, CELL ADHES MIGR, V7, P395, DOI 10.4161/cam.26345; Han XT, 2017, ONCOTARGET, V8, P100931, DOI 10.18632/oncotarget.21753; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Haris K, 2014, ASIAN PAC J CANCER P, V15, P4499, DOI 10.7314/APJCP.2014.15.11.4499; Hitosugi T, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2759; Hitosugi T, 2012, CANCER CELL, V22, P585, DOI 10.1016/j.ccr.2012.09.020; Husain SR, 2015, CANCER GENE THER, V22, P554, DOI 10.1038/cgt.2015.58; Huse JT, 2011, GLIA, V59, P1190, DOI 10.1002/glia.21165; Jiang XL, 2014, INT J CANCER, V135, P1991, DOI 10.1002/ijc.28637; Kanehisa M, 2014, NUCLEIC ACIDS RES, V42, pD199, DOI 10.1093/nar/gkt1076; Kang J, 2017, ONCOGENE, V36, P1585, DOI 10.1038/onc.2016.328; Ke C, 2014, ONCOTARGET, V5, P1657, DOI 10.18632/oncotarget.1823; Kim MS, 2005, INT J ONCOL, V27, P839; Kim W, 2011, RADIAT RES, V176, P539, DOI 10.1667/RR2609.1; Le A, 2010, P NATL ACAD SCI USA, V107, P2037, DOI 10.1073/pnas.0914433107; Lee E, 2018, SEMIN CANCER BIOL, V53, P201, DOI 10.1016/j.semcancer.2018.07.006; Lee S, 2018, CELL PHYSIOL BIOCHEM, V47, P2233, DOI 10.1159/000491535; Lee S, 2017, CELL PHYSIOL BIOCHEM, V42, P1684, DOI 10.1159/000479418; Li B, 2014, NATURE, V513, P251, DOI 10.1038/nature13557; Li J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167857; Li SN, 2016, SCI REP-UK, V6, DOI 10.1038/srep28479; Li XG, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00325; Li YH, 2015, NAT CELL BIOL, V17, P1327, DOI 10.1038/ncb3240; Liu H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189353; Lu CL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121046; Martinez-Outschoorn UE, 2017, NAT REV CLIN ONCOL, V14, P11, DOI 10.1038/nrclinonc.2016.60; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Ostrom QT, 2013, NEURO-ONCOLOGY, V15, P1, DOI 10.1093/neuonc/not151; Parekh HS, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-21; Peterson CW, 2010, MOL CELL BIOL, V30, P2887, DOI 10.1128/MCB.01613-09; Rahman SA, 2009, J CHEMINFORMATICS, V1, DOI 10.1186/1758-2946-1-12; Robinson DR, 2017, NATURE, V548, P297, DOI 10.1038/nature23306; Seyfried TN, 2015, CANCER LETT, V356, P289, DOI 10.1016/j.canlet.2014.07.015; Shi WK, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0435-y; Soeda A, 2009, ONCOGENE, V28, P3949, DOI 10.1038/onc.2009.252; Son B, 2017, AM J PHYSIOL-LUNG C, V313, pL916, DOI 10.1152/ajplung.00144.2017; Thakkar JP, 2014, CANCER EPIDEM BIOMAR, V23, P1985, DOI 10.1158/1055-9965.EPI-14-0275; Tran B, 2010, J CLIN NEUROSCI, V17, P417, DOI 10.1016/j.jocn.2009.09.004; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Verschoor ML, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013565; Wang CY, 2007, EUR J PHARMACOL, V577, P58, DOI 10.1016/j.ejphar.2007.08.033; Wang YL, 2005, BIOCHEM BIOPH RES CO, V331, P1207, DOI 10.1016/j.bbrc.2005.03.243; Weller M, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.17; Winter SF, 2017, CRIT REV ONCOL HEMAT, V112, P41, DOI 10.1016/j.critrevonc.2017.02.016; Wolf A, 2010, ONCOTARGET, V1, P552, DOI 10.18632/oncotarget.190; Xie Q, 2014, NEURO-ONCOLOGY, V16, P1575, DOI 10.1093/neuonc/nou147; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zhang WW, 2006, J BIOL CHEM, V281, P10105, DOI 10.1074/jbc.M600272200; Zuccoli G, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-33	61	19	19	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	1					36	49		10.1038/s41388-019-0974-4	http://dx.doi.org/10.1038/s41388-019-0974-4			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG3NM	31444412				2022-12-28	WOS:000509849200004
J	Zeng, YT; Liu, XF; Yang, WT; Zheng, PS				Zeng, Yu-Ting; Liu, Xiao-Fang; Yang, Wen-Ting; Zheng, Peng-Sheng			REX1 promotes EMT-induced cell metastasis by activating the JAK2/STAT3-signaling pathway by targeting SOCS1 in cervical cancer	ONCOGENE			English	Article							SIGNAL TRANSDUCER; DNA METHYLATION; GENE-EXPRESSION; YY1; PROTEIN; MARKER; CLASSIFICATION; ASSOCIATION; SUPPRESSOR; CARCINOMA	ZFP42 zinc finger protein (REX1), a pluripotency marker in mouse pluripotent stem cells, has been identified as a tumor suppressor in several human cancers. However, the function of REX1 in cervical cancer remains unknown. Both IHC and western blot assays demonstrated that the expression of REX1 protein in cervical cancer tissue was much higher than that in normal cervical tissue. A xenograft assay showed that REX1 overexpression in SiHa and HeLa cells facilitated distant metastasis but did not significantly affect tumor formation in vivo. In addition, in vitro cell migration and invasion capabilities were also promoted by REX1. Mechanistically, REX1 overexpression induced epithelial-to-mesenchymal transition (EMT) by upregulating VIMENTIN and downregulating E-CADHERIN. Furthermore, the JAK2/STAT3-signaling pathway was activated in REX1-overexpressing cells, which also exhibited increased levels of p-STAT3 and p-JAK2, as well as downregulated expression of SOCS1, which is an inhibitor of the JAK2/STAT3-signaling pathway, at both the transcriptional and translational levels. A dual-luciferase reporter assay and qChIP assays confirmed that REX1 trans-suppressed the expression of SOCS1 by binding to two specific regions of the SOCS1 promoter. Therefore, all our data suggest that REX1 overexpression could play a crucial role in the metastasis and invasion of cervical cancer by upregulating the activity of the JAK2/STAT3 pathway by trans-suppressing SOCS1 expression.	[Zeng, Yu-Ting; Yang, Wen-Ting; Zheng, Peng-Sheng] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Reprod Med, Xian 710061, Shaanxi, Peoples R China; [Liu, Xiao-Fang; Zheng, Peng-Sheng] Minist Educ Peoples Republ China, Key Lab Environm & Genes Related Dis, Sect Canc Stem Cell Res, Xian 710061, Shaanxi, Peoples R China	Xi'an Jiaotong University; Ministry of Education, China	Yang, WT; Zheng, PS (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Reprod Med, Xian 710061, Shaanxi, Peoples R China.; Zheng, PS (corresponding author), Minist Educ Peoples Republ China, Key Lab Environm & Genes Related Dis, Sect Canc Stem Cell Res, Xian 710061, Shaanxi, Peoples R China.	04203031@stu.xjtu.edu.cn; zpsheng@mail.xjtu.edu.cn			National Natural Science Foundation of China [81802946, 81472728, 81672910]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by a to grant Dr XiaoFang Liu from the National Natural Science Foundation of China (No. 81802946) and Prof. Peng-Sheng Zheng from the National Natural Science Foundation of China (Nos. 81472728 and 81672910).	Anzai E, 2017, BIOL PHARM BULL, V40, P1483, DOI 10.1248/bpb.b17-00307; Aoyama T, 2010, J BIOL CHEM, V285, P29842, DOI 10.1074/jbc.M110.116319; Arai E, 2012, CARCINOGENESIS, V33, P1487, DOI 10.1093/carcin/bgs177; Astudillo H, 2004, J CLIN ONCOL, V22, p466S; Berkopec A, 2007, J DISCRET ALGORITHMS, V5, P341, DOI 10.1016/j.jda.2006.01.001; Boxberg M, 2019, AM J SURG PATHOL, V43, P303, DOI 10.1097/PAS.0000000000001178; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brivanlou AH, 2003, SCIENCE, V300, P913, DOI 10.1126/science.1082940; Chan EM, 2009, NAT BIOTECHNOL, V27, P1033, DOI 10.1038/nbt.1580; Chen Q, 2016, ONCOTARGET, V7, P36115, DOI 10.18632/oncotarget.8741; Cui N, 2016, ONCOTARGET, V7, P26152, DOI 10.18632/oncotarget.8434; Cui Y, 2016, ONCOL REP, V36, P108, DOI 10.3892/or.2016.4822; de Sanjose S, 2010, LANCET ONCOL, V11, P1048, DOI 10.1016/S1470-2045(10)70230-8; Do Kim J, 2009, NUCLEIC ACIDS RES, V37, P5656, DOI 10.1093/nar/gkp613; Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027; Garcia-Tunon I, 2011, STEM CELL RES, V7, P1, DOI 10.1016/j.scr.2011.02.005; Henderson JK, 2002, STEM CELLS, V20, P329, DOI 10.1634/stemcells.20-4-329; Huang SY, 2007, CLIN CANCER RES, V13, P1362, DOI 10.1158/1078-0432.CCR-06-2313; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Karpathiou G, 2019, HEAD NECK-J SCI SPEC, V41, P1918, DOI 10.1002/hed.25629; Kim BS, 2011, HUM GENE THER, V22, P1551, DOI 10.1089/hum.2011.096; Kim MH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123133; Kumar L, 2007, BIOINFORMATION, V2, P5, DOI 10.6026/97320630002005; Lee MY, 2010, J CELL PHYSIOL, V224, P17, DOI 10.1002/jcp.22071; Liu XF, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0359-6; Mongan NP, 2006, MOL CARCINOGEN, V45, P887, DOI 10.1002/mc.20186; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; Oka D, 2009, CANCER-AM CANCER SOC, V115, P3412, DOI 10.1002/cncr.24394; Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934; Palko L, 2004, J CELL SCI, V117, P465, DOI 10.1242/jcs.00870; Qin HW, 2012, P NATL ACAD SCI USA, V109, P5004, DOI 10.1073/pnas.1117218109; Qureshi R, 2015, CANCER LETT, V356, P321, DOI 10.1016/j.canlet.2014.09.021; Raman JD, 2006, CARCINOGENESIS, V27, P499, DOI 10.1093/carcin/bgi299; Rizvi MMA, 2011, J CANCER RES CLIN, V137, P1255, DOI 10.1007/s00432-011-0994-0; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Sobti RC, 2011, CELL ONCOL, V34, P533, DOI 10.1007/s13402-011-0056-2; Suzuki A, 2001, J EXP MED, V193, P471, DOI 10.1084/jem.193.4.471; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Takemoto S, 2009, BRIT J CANCER, V101, P967, DOI 10.1038/sj.bjc.6605212; Tarazona S, 2011, GENOME RES, V21, P2213, DOI 10.1101/gr.124321.111; Tewari KS, 2014, NEW ENGL J MED, V370, P734, DOI 10.1056/NEJMoa1309748; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; Toyooka Y, 2008, DEVELOPMENT, V135, P909, DOI 10.1242/dev.017400; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Wang HY, 2015, ONCOTARGET, V6, P20711, DOI 10.18632/oncotarget.4133; Wu YZ, 2004, ONCOGENE, V23, P168, DOI 10.1038/sj.onc.1207003; Yang WT, 2012, CANCER-AM CANCER SOC, V118, P3691, DOI 10.1002/cncr.26698; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Zhang JJ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-130; Zhao GW, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0177-y; Zhou XC, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0911-3	52	36	38	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2019	38	43					6940	6957		10.1038/s41388-019-0906-3	http://dx.doi.org/10.1038/s41388-019-0906-3			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JH4GX	31409905	hybrid			2022-12-28	WOS:000492728000005
J	Cui, Y; Groth, S; Troutman, S; Carlstedt, A; Sperka, T; Riecken, LB; Kissil, JL; Jin, HC; Morrison, H				Cui, Yan; Groth, Susann; Troutman, Scott; Carlstedt, Annemarie; Sperka, Tobias; Riecken, Lars Bjorn; Kissil, Joseph L.; Jin, Hongchuan; Morrison, Helen			The NF2 tumor suppressor merlin interacts with Ras and RasGAP, which may modulate Ras signaling	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEIN; ANCHORAGE-INDEPENDENT GROWTH; NEUROFIBROMATOSIS TYPE-2; PLECKSTRIN HOMOLOGY; STRUCTURAL BASIS; GENE-PRODUCT; P120 RASGAP; FERM DOMAIN; CELLS; INHIBITION	Inactivation of the tumor suppressor NF2/merlin underlies neurofibromatosis type 2 (NF2) and some sporadic tumors. Previous studies have established that merlin mediates contact inhibition of proliferation; however, the exact mechanisms remain obscure and multiple pathways have been implicated. We have previously reported that merlin inhibits Ras and Rac activity during contact inhibition, but how merlin regulates Ras activity has remained elusive. Here we demonstrate that merlin can directly interact with both Ras and p120RasGAP (also named RasGAP). While merlin does not increase the catalytic activity of RasGAP, the interactions with Ras and RasGAP may fine-tune Ras signaling. In vivo, loss of RasGAP in Schwann cells, unlike the loss of merlin, failed to promote tumorigenic growth in an orthotopic model. Therefore, modulation of Ras signaling through RasGAP likely contributes to, but is not sufficient to account for, merlin's tumor suppressor activity. Our study provides new insight into the mechanisms of merlin-dependent Ras regulation and may have additional implications for merlin-dependent regulation of other small GTPases.	[Cui, Yan; Groth, Susann; Carlstedt, Annemarie; Sperka, Tobias; Riecken, Lars Bjorn; Morrison, Helen] Leibniz Inst Aging, Fritz Lipmann Inst, Beutenbergstr 11, D-07745 Jena, Germany; [Troutman, Scott; Kissil, Joseph L.] Scripps Res Inst, Dept Mol Med, 130 Scripps Way, Jupiter, FL 33458 USA; [Jin, Hongchuan] Zhejiang Univ, Med Sch, Sir Run Run Shaw Hosp, Lab Canc Biol,Key Lab Biotherapy, Hangzhou 310016, Zhejiang, Peoples R China	Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI); Scripps Research Institute; Zhejiang University	Cui, Y; Morrison, H (corresponding author), Leibniz Inst Aging, Fritz Lipmann Inst, Beutenbergstr 11, D-07745 Jena, Germany.	yan.cui@leibniz-fli.de; Helen.Morrison@leibniz-fli.de	Morrison, Helen/F-9748-2014	Morrison, Helen/0000-0003-4938-1409; Jin, Hongchuan/0000-0002-6697-3097; Cui, Yan/0000-0002-6522-8343; Riecken, Lars Bjorn/0000-0002-1992-4591	Deutsche Forschungsgemeinschaft [MO 1421/2-1, MO 1421/5-1]; Deutsche Krebshilfe [612000]; National Natural Science Foundation of China [81761138047]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported in part by grants from Deutsche Forschungsgemeinschaft (MO 1421/2-1 and MO 1421/5-1) and Deutsche Krebshilfe (612000) to HM, and from National Natural Science Foundation of China (81761138047) to HJ.	Ahronowitz I, 2007, HUM MUTAT, V28, P1, DOI 10.1002/humu.20393; Ammoun S, 2008, CANCER RES, V68, P5236, DOI 10.1158/0008-5472.CAN-07-5849; BANSAL R, 1987, J NEUROCHEM, V49, P1902, DOI 10.1111/j.1471-4159.1987.tb02453.x; Bayrak-Toydemir P., 1993, GENEREVIEWS; Bondeva T, 2002, MOL BIOL CELL, V13, P2323, DOI 10.1091/mbc.E02-01-0019; Chadee DN, 2006, P NATL ACAD SCI USA, V103, P4463, DOI 10.1073/pnas.0510651103; Chinthalapudi K, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03648-4; Clucas J, 2014, J CELL SCI, V127, P267, DOI 10.1242/jcs.133108; COLBURN NH, 1978, CANCER RES, V38, P624; Cole BK, 2008, MOL CELL BIOL, V28, P1274, DOI 10.1128/MCB.01139-07; Coll MAL, 2005, ONCOGENE, V24, P1727, DOI 10.1038/sj.onc.1208379; Curto M, 2007, J CELL BIOL, V177, P893, DOI 10.1083/jcb.200703010; Drugan JK, 2000, J BIOL CHEM, V275, P35021, DOI 10.1074/jbc.M004386200; Eerola I, 2003, AM J HUM GENET, V73, P1240, DOI 10.1086/379793; Evans DGR, 2009, GENET MED, V11, P599, DOI 10.1097/GIM.0b013e3181ac9a27; Fehon RG, 2010, NAT REV MOL CELL BIO, V11, P276, DOI 10.1038/nrm2866; Garcia-Rendueles MER, 2015, CANCER DISCOV, V5, P1178, DOI 10.1158/2159-8290.CD-15-0330; Geissler KJ, 2013, P NATL ACAD SCI USA, V110, P20587, DOI 10.1073/pnas.1222078110; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; Gusella JF, 1999, BBA-REV CANCER, V1423, pM29, DOI 10.1016/S0304-419X(99)00005-0; Hayashi T, 2018, CLIN CANCER RES, V24, P1436, DOI 10.1158/1078-0432.CCR-17-2343; Hennigan RF, 2010, MOL CELL BIOL, V30, P54, DOI 10.1128/MCB.00248-09; Hirokawa Y, 2004, CANCER J, V10, P20, DOI 10.1097/00130404-200401000-00006; HOSHINO M, 1988, MOL CELL BIOL, V8, P4169, DOI 10.1128/MCB.8.10.4169; Kang BS, 2002, ACTA CRYSTALLOGR D, V58, P381, DOI 10.1107/S0907444901021175; Kim DI, 2016, MOL BIOL CELL, V27, P1188, DOI 10.1091/mbc.E15-12-0844; Koehler JA, 2001, CELL GROWTH DIFFER, V12, P551; Li QZ, 2007, J MOL BIOL, V365, P1446, DOI 10.1016/j.jmb.2006.10.075; Li W, 2010, CELL, V140, P477, DOI 10.1016/j.cell.2010.01.029; Li YJ, 2015, CELL RES, V25, P801, DOI 10.1038/cr.2015.69; Lim JY, 2006, BIOCHEM BIOPH RES CO, V340, P1151, DOI 10.1016/j.bbrc.2005.12.122; Lin TH, 1997, J BIOL CHEM, V272, P8849; Lobsiger CS, 2000, GLIA, V30, P290, DOI 10.1002/(SICI)1098-1136(200005)30:3<290::AID-GLIA8>3.0.CO;2-6; Lubeck BA, 2015, J IMMUNOL, V195, P31, DOI 10.4049/jimmunol.1402639; Maertens Ophelia, 2014, Advances in Biological Regulation, V55, P1, DOI 10.1016/j.jbior.2014.04.002; Meier C, 1999, J NEUROSCI, V19, P3847; Mo SP, 2018, BIOCHEM SOC T, V46, P1325, DOI 10.1042/BST20180173; Monje PV, 2009, GLIA, V57, P947, DOI 10.1002/glia.20819; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Morrison H, 2007, CANCER RES, V67, P520, DOI 10.1158/0008-5472.CAN-06-1608; Newlaczyl AU, 2017, SCI REP-UK, V7, DOI 10.1038/srep41297; Orthaus S, 2009, NUCLEIC ACIDS RES, V37, P3391, DOI 10.1093/nar/gkp199; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Petrilli AM, 2016, ONCOGENE, V35, P537, DOI 10.1038/onc.2015.125; Riecken LB, 2015, HUM MUTAT, V36, P270, DOI 10.1002/humu.22737; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Sher I, 2012, DEV CELL, V22, P703, DOI 10.1016/j.devcel.2012.03.008; Shimizu T, 2002, J BIOL CHEM, V277, P10332, DOI 10.1074/jbc.M109979200; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; Shyu YJ, 2006, BIOTECHNIQUES, V40, P61, DOI 10.2144/000112036; Simanshu DK, 2017, CELL, V170, P17, DOI 10.1016/j.cell.2017.06.009; Sperka T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027511; Suarez-Cabrera C, 2017, CANCER RES, V77, P1357, DOI 10.1158/0008-5472.CAN-16-1586; TIKOO A, 1994, J BIOL CHEM, V269, P23387; vanderGeer P, 1997, MOL CELL BIOL, V17, P1840, DOI 10.1128/MCB.17.4.1840; Wiederhold T, 2004, ONCOGENE, V23, P8815, DOI 10.1038/sj.onc.1208110; Yang JY, 2001, MOL CELL BIOL, V21, P5346, DOI 10.1128/MCB.21.16.5346-5358.2001; Zhou L, 2016, ONCOGENE, V35, P3443, DOI 10.1038/onc.2015.404	58	22	23	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2019	38	36					6370	6381		10.1038/s41388-019-0883-6	http://dx.doi.org/10.1038/s41388-019-0883-6			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IX6EX	31312020	hybrid, Green Published			2022-12-28	WOS:000485776800004
J	Yuan, XT; Larsson, C; Xu, DW				Yuan, Xiaotian; Larsson, Catharina; Xu, Dawei			Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players	ONCOGENE			English	Review							CATALYTIC SUBUNIT HTERT; PROMOTER MUTATIONS; INSERTIONAL MUTAGENESIS; BLADDER-CANCER; MESSENGER-RNA; GENE PROMOTER; LIFE-SPAN; EXPRESSION; REARRANGEMENTS; MAINTENANCE	Long-lived species Homo sapiens have evolved robust protection mechanisms against cancer by repressing telomerase and maintaining short telomeres, thereby delaying the onset of the majority of cancer types until post-reproductive age. Indeed, telomerase is silent in most differentiated human cells, predominantly due to the transcriptional repression of its catalytic component telomerase reverse transcriptase (TERT) gene. The lack of telomerase/TERT expression leads to progressive telomere erosion in dividing human cells, whereas critically shortened telomere length induces a permanent growth arrest stage named replicative senescence. TERT/telomerase activation has been experimentally shown to be essential to cellular immortalization and malignant transformation by stabilizing telomere length and erasing the senescence barrier. Consistently, TERT expression/telomerase activity is detectable in up to 90% of human primary cancers. Compelling evidence has also accumulated that TERT contributes to cancer development and progression via multiple activities beyond its canonical telomere-lengthening function. Given these key roles of telomerase and TERT in oncogenesis, great efforts have been made to decipher mechanisms underlying telomerase activation and TERT induction. In the last two decades since the TERT gene and promoter were cloned, the derepression of the TERT gene has been shown to be achieved typically at a transcriptional level through dysregulation of oncogenic factors or signaling, post-transcriptional/translational regulation and genomic amplification. However, advances in high-throughput next-generation sequencing technologies have prompted a revolution in cancer genomics, which leads to the recent discovery that genomic alterations take center stage in activating the TERT gene. In this review article, we summarize critical mechanisms activating TERT transcription, with special emphases on the contribution of TERT promoter mutations and structural alterations at the TERT locus, and briefly discuss the underlying implications of these genomic events-driven TERT hyperactivity in cancer initiation/progression and potential clinical applications as well.	[Yuan, Xiaotian] Shandong Univ, Sch Med, Jinan 250012, Shandong, Peoples R China; [Yuan, Xiaotian; Xu, Dawei] Karolinska Inst, CMM, Dept Med, S-17164 Solna, Sweden; [Yuan, Xiaotian; Larsson, Catharina; Xu, Dawei] Karolinska Inst, Bioclinicum, S-17164 Solna, Sweden; [Yuan, Xiaotian; Larsson, Catharina; Xu, Dawei] Karolinska Univ Hosp Solna, S-17164 Solna, Sweden; [Larsson, Catharina] Karolinska Inst, Dept Oncol Pathol, S-17164 Solna, Sweden	Shandong University; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	Yuan, XT (corresponding author), Shandong Univ, Sch Med, Jinan 250012, Shandong, Peoples R China.; Yuan, XT; Xu, DW (corresponding author), Karolinska Inst, CMM, Dept Med, S-17164 Solna, Sweden.; Yuan, XT; Xu, DW (corresponding author), Karolinska Inst, Bioclinicum, S-17164 Solna, Sweden.; Yuan, XT; Xu, DW (corresponding author), Karolinska Univ Hosp Solna, S-17164 Solna, Sweden.	Xiaotian.Yan@ki.se; Dawei.Xu@ki.se		Xu, Dawei/0000-0003-3141-4524	China Postdoctoral Science Foundation [2019M652404]; Swedish Cancer Society; Swedish Research Council; Cancer Society in Stockholm; Karolinska Institutet Foundation; Swedish Foundation for International Cooperation in Research and Higher Education (STINT); Nanna Svartz Foundation; Ruth and Richard Julin Foundation	China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Cancer Society in Stockholm; Karolinska Institutet Foundation(Karolinska Institutet); Swedish Foundation for International Cooperation in Research and Higher Education (STINT); Nanna Svartz Foundation; Ruth and Richard Julin Foundation	This work was supported by grants from China Postdoctoral Science Foundation Grant (2019M652404), the Swedish Cancer Society, Swedish Research Council, the Cancer Society in Stockholm, Karolinska Institutet Foundation, Swedish Foundation for International Cooperation in Research and Higher Education (STINT), Ruth and Richard Julin Foundation and Nanna Svartz Foundation.	Ackermann S, 2018, SCIENCE, V362, P1165, DOI 10.1126/science.aat6768; Barthel FP, 2017, NAT GENET, V49, P349, DOI 10.1038/ng.3781; Bayard Q, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07552-9; Bell RJA, 2016, MOL CANCER RES, V14, P315, DOI 10.1158/1541-7786.MCR-16-0003; Bell RJA, 2015, SCIENCE, V348, P1036, DOI 10.1126/science.aab0015; Bellon M, 2008, JNCI-J NATL CANCER I, V100, P98, DOI 10.1093/jnci/djm269; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bougel S, 2013, CLIN CANCER RES, V19, P2216, DOI 10.1158/1078-0432.CCR-12-1246; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Casillas MA, 2003, GENE, V316, P57, DOI 10.1016/S0378-1119(03)00739-X; Cassar L, 2008, CANCER RES, V68, P9157, DOI 10.1158/0008-5472.CAN-08-1323; Castelo-Branco P, 2013, LANCET ONCOL, V14, P534, DOI 10.1016/S1470-2045(13)70110-4; Chang KP, 2017, HEAD NECK-J SCI SPEC, V39, P1131, DOI 10.1002/hed.24728; Chen X, 2019, GENOME RES, V29, P819, DOI 10.1101/gr.242529.118; Chiba K, 2017, SCIENCE, V357, P1416, DOI 10.1126/science.aao0535; Chiba K, 2015, ELIFE, V4, DOI 10.7554/eLife.07918; Chou WC, 2001, J CLIN INVEST, V108, P1541, DOI 10.1172/JCI14064; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Dahlstrom J, 2016, ANN HEMATOL, V95, P1825, DOI 10.1007/s00277-016-2787-7; Davis CF, 2014, CANCER CELL, V26, P319, DOI 10.1016/j.ccr.2014.07.014; Ding DQ, 2013, FASEB J, V27, P4375, DOI 10.1096/fj.13-230904; Diplas BH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04448-6; Drevytska TI, 2014, CELL BIOCHEM FUNCT, V32, P565, DOI 10.1002/cbf.3051; Dwight T, 2018, ENDOCR-RELAT CANCER, V25, P1, DOI 10.1530/ERC-17-0306; Fan YD, 2005, CLIN CANCER RES, V11, P4331, DOI 10.1158/1078-0432.CCR-05-0099; Ge Z, 2006, MOL CELL BIOL, V26, P230, DOI 10.1128/MCB.26.1.230-237.2006; Gewin L, 2004, GENE DEV, V18, P2269, DOI 10.1101/gad.1214704; Gomes NMV, 2011, AGING CELL, V10, P761, DOI 10.1111/j.1474-9726.2011.00718.x; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; Horikawa I, 2001, J NATL CANCER I, V93, P1171, DOI 10.1093/jnci/93.15.1171; Horn S, 2013, SCIENCE, V339, P959, DOI 10.1126/science.1230062; Hu CJ, 2017, GUT, V66, P31, DOI 10.1136/gutjnl-2015-309322; Huang FW, 2013, SCIENCE, V339, P957, DOI 10.1126/science.1229259; Hurst CD, 2014, EUR UROL, V65, P367, DOI 10.1016/j.eururo.2013.08.057; Im E, 2017, J CELL PHYSIOL, V232, P2083, DOI 10.1002/jcp.25607; Juratli TA, 2018, ACTA NEUROPATHOL, V136, P779, DOI 10.1007/s00401-018-1899-7; Juratli TA, 2018, CLIN CANCER RES, V24, P5282, DOI 10.1158/1078-0432.CCR-17-3717; Kim W, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.2000016; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Labgaa I, 2018, ONCOGENE, V37, P3740, DOI 10.1038/s41388-018-0206-3; Lassmann T, 2015, INT J MOL SCI, V16, P1192, DOI 10.3390/ijms16011192; Lee DD, 2019, J CLIN INVEST, V129, P223, DOI 10.1172/JCI121303; Levine M, 2014, CELL, V157, P13, DOI 10.1016/j.cell.2014.02.009; Li C, 2015, ONCOTARGET, V6, P19542, DOI 10.18632/oncotarget.4295; Li WJ, 2008, CANCER LETT, V260, P28, DOI 10.1016/j.canlet.2007.10.018; Li YY, 2010, FASEB J, V24, P1442, DOI 10.1096/fj.09-149328; Lin YB, 2018, J CLIN PATHOL, V71, P832, DOI 10.1136/jclinpath-2018-205132; Liu C, 2007, CANCER RES, V67, P2626, DOI 10.1158/0008-5472.CAN-06-4126; Liu L, 2017, ONCOLOGIST, V22, P1178, DOI 10.1634/theoncologist.2017-0064; Liu N, 2016, NUCLEIC ACIDS RES, V44, P8693, DOI 10.1093/nar/gkw549; Liu T, 2014, ONCOGENE, V33, P4978, DOI 10.1038/onc.2013.446; Liu TT, 2016, GENES-BASEL, V7, DOI 10.3390/genes7070038; Liu Z, 2013, ONCOGENE, V32, P4203, DOI 10.1038/onc.2012.441; Ma RZ, 2019, UROL ONCOL-SEMIN ORI, V37, DOI 10.1016/j.urolonc.2019.01.014; Maida Y, 2015, CANCER SCI, V106, P1486, DOI 10.1111/cas.12806; Mancini A, 2018, CANCER CELL, V34, P513, DOI 10.1016/j.ccell.2018.08.003; Maryoung L, 2017, J CLIN INVEST, V127, P982, DOI 10.1172/JCI91161; Masutomi K, 2005, P NATL ACAD SCI USA, V102, P8222, DOI 10.1073/pnas.0503095102; Mitchell TJ, 2018, CELL, V173, P611, DOI 10.1016/j.cell.2018.02.020; Nault JC, 2015, NAT GENET, V47, P1187, DOI 10.1038/ng.3389; Park JI, 2009, NATURE, V460, P66, DOI 10.1038/nature08137; Paterlini-Brechot P, 2003, ONCOGENE, V22, P3911, DOI 10.1038/sj.onc.1206492; Peifer M, 2015, NATURE, V526, P700, DOI 10.1038/nature14980; Sahm F, 2015, JNCI-J NATL CANCER I, V108, P108, DOI 10.1093/jnci/djv1377; Saretzki G, 2014, CURR PHARM DESIGN, V20, P6386, DOI 10.2174/1381612820666140630095606; Schilling G, 2013, LEUKEMIA RES, V37, P280, DOI 10.1016/j.leukres.2012.10.009; Seluanov A, 2018, NAT REV CANCER, V18, P433, DOI 10.1038/s41568-018-0004-9; Shay JW, 2019, NAT REV GENET, V20, P299, DOI 10.1038/s41576-019-0099-1; Sizemore GM, 2017, NAT REV CANCER, V17, P337, DOI 10.1038/nrc.2017.20; Stern JL, 2015, GENE DEV, V29, P2219, DOI 10.1101/gad.269498.115; Straat K, 2009, JNCI-J NATL CANCER I, V101, P488, DOI 10.1093/jnci/djp031; Sung WK, 2012, NAT GENET, V44, P765, DOI 10.1038/ng.2295; Svahn F, 2018, CLIN ENDOCRINOL, V88, P343, DOI 10.1111/cen.13513; Takakura M, 1999, CANCER RES, V59, P551; Takakura M, 2001, NUCLEIC ACIDS RES, V29, P3006, DOI 10.1093/nar/29.14.3006; Valentijn LJ, 2015, NAT GENET, V47, P1411, DOI 10.1038/ng.3438; Vogelstein B, 2015, NEW ENGL J MED, V373, P1895, DOI 10.1056/NEJMp1508811; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wang K, 2015, ONCOLOGIST, V20, P263, DOI 10.1634/theoncologist.2014-0391; Wang N, 2014, J CLIN ENDOCR METAB, V99, pE1571, DOI 10.1210/jc.2014-1158; Wang XG, 2016, MOL NEUROBIOL, V53, P2726, DOI 10.1007/s12035-015-9400-2; Wong MS, 2014, TRENDS GENET, V30, P430, DOI 10.1016/j.tig.2014.07.006; Xie H, 2014, ONCOTARGET, V5, P10048, DOI 10.18632/oncotarget.2491; Xing MZ, 2014, J CLIN ONCOL, V32, P2718, DOI 10.1200/JCO.2014.55.5094; Xu DK, 2008, J BIOL CHEM, V283, P23567, DOI 10.1074/jbc.M800790200; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; Yu JY, 2018, CANCER LETT, V434, P33, DOI 10.1016/j.canlet.2018.07.013; Yuan XT, 2019, ONCOGENE, V38, P965, DOI 10.1038/s41388-018-0483-x; Yuan XT, 2017, ONCOTARGET, V8, P23120, DOI 10.18632/oncotarget.15498; Zeng JP, 2009, J PATHOL, V218, P419, DOI 10.1002/path.2530; Zhang AJ, 2000, CANCER RES, V60, P6230; Zhang AJ, 2003, AM J HUM GENET, V72, P940, DOI 10.1086/374565; Zhang K, 2017, CANCER RES, V77, P2534, DOI 10.1158/0008-5472.CAN-16-1887; Zhao JQ, 2000, NEOPLASIA, V2, P531, DOI 10.1038/sj.neo.7900114; Zhao YJ, 2009, GENE CHROMOSOME CANC, V48, P963, DOI 10.1002/gcc.20698; Zhou JZ, 2014, AGING CELL, V13, P197, DOI 10.1111/acel.12161	98	171	172	12	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2019	38	34					6172	6183		10.1038/s41388-019-0872-9	http://dx.doi.org/10.1038/s41388-019-0872-9			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IS5RM	31285550	Green Published, hybrid			2022-12-28	WOS:000482210100002
J	Zhu, SM; Soutto, M; Chen, Z; Piazuelo, MB; Washington, MK; Belkhiri, A; Zaika, A; Peng, DF; El, WERA				Zhu, Shoumin; Soutto, Mohammed; Chen, Zheng; Piazuelo, M. Blanca; Washington, M. Kay; Belkhiri, Abbes; Zaika, Alexander; Peng, Dunfa; El-Rifai, Wael			Activation of IGF1R by DARPP-32 promotes STAT3 signaling in gastric cancer cells	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; NF-KAPPA-B; NEGATIVE REGULATION; INSULIN; EXPRESSION; INFLAMMATION; BLOCKADE; PATHWAY; GENE; OVEREXPRESSION	Dopamine and cAMP-regulated phosphoprotein, Mr 32000 (DARPP-32), is frequently overexpressed in early stages of gastric cancers. We utilized in vitro assays, 3D gastric gland organoid cultures, mouse models, and human tissue samples to investigate the biological and molecular impact of DARPP-32 on activation of IGF1R and STAT3 signaling and gastric tumorigenesis. DARPP-32 enhanced phosphorylation of IGF1R (Y1135), a step that was critical for STAT3 phosphorylation at Y705, nuclear localization, and transcription activation. By using proximity ligation and co-immunoprecipitation assays, we found that IGF1R and DARPP-32 co-existed in the same protein complex. Binding of DARPP-32 to IGF1R promoted IGF1R phosphorylation with subsequent activation of downstream SRC and STAT3. Analysis of gastric tissues from the TFF1 knockout (KO) mouse model of gastric neoplasia, demonstrated phosphorylation of STAT3 in the early stages of gastric tumorigenesis. By crossing the TFF1 KO mice with DARPP-32 (DP) knockout (KO) mice, that have normal stomach, we obtained double knockout (TFF1 KO/DP KO). The gastric mucosa from the double KO mice did not show phosphorylation of IGF1R or STAT3. In addition, the TFF1 KO/DP KO mice had a significant delay in developing neoplastic gastric lesions. Analysis of human gastric cancer tissue microarrays, showed high levels of DARPP-32 and positive immunostaining for nuclear STAT3 in cancer tissues, as compared to non-cancer histologically normal tissues. In summary, the DARPP-32-IGF1R signaling axis plays a key role in regulating the STAT3 signaling, a critical step in gastric tumorigenesis.	[Zhu, Shoumin; Soutto, Mohammed; Chen, Zheng; Zaika, Alexander; Peng, Dunfa; El-Rifai, Wael] Univ Miami, Miller Sch Med, Dept Surg, Miami, FL 33136 USA; [Soutto, Mohammed; Chen, Zheng; Zaika, Alexander; El-Rifai, Wael] Miami Healthcare Syst, Dept Vet Affairs, Miami, FL 33125 USA; [Zaika, Alexander; Peng, Dunfa; El-Rifai, Wael] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA; [Piazuelo, M. Blanca] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA; [Washington, M. Kay] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; [Belkhiri, Abbes] Vanderbilt Univ, Dept Surg, Med Ctr, Nashville, TN 37240 USA	University of Miami; University of Miami; Vanderbilt University; Vanderbilt University; Vanderbilt University	El, WERA (corresponding author), Univ Miami, Miller Sch Med, Dept Surg, Miami, FL 33136 USA.; El, WERA (corresponding author), Miami Healthcare Syst, Dept Vet Affairs, Miami, FL 33125 USA.; El, WERA (corresponding author), Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.	wxe45@miami.edu			U.S. National Institutes of Health [R01CA93999]; U.S. Department of Veterans affairs [I01BX001179, 1IK6BX003787]; NATIONAL CANCER INSTITUTE [R01CA138833, R01CA093999] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK058404] Funding Source: NIH RePORTER; Veterans Affairs [IK6BX003787, I01BX002115, I01BX001179] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. Department of Veterans affairs(US Department of Veterans Affairs); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Veterans Affairs(US Department of Veterans Affairs)	This study was supported by the U.S. National Institutes of Health (R01CA93999), Research Career Scientist award (1IK6BX003787), and a merit award (I01BX001179) from the U.S. Department of Veterans affairs (W. El-Rifai). The contents of this work are solely the responsibility of the authors and do not necessarily represent the official views of the Department of Veterans Affairs, National Institutes of Health, or the University of Miami.	Adachi Y, 2014, TUMOR BIOL, V35, P973, DOI 10.1007/s13277-013-1131-2; Adachi Y, 2009, CARCINOGENESIS, V30, P1305, DOI 10.1093/carcin/bgp134; Ahn JH, 2015, MOL HUM REPROD, V21, P792, DOI 10.1093/molehr/gav039; Beckler A, 2003, CANCER, V98, P1547, DOI 10.1002/cncr.11654; Belkhiri A, 2005, CANCER RES, V65, P6583, DOI 10.1158/0008-5472.CAN-05-1433; Cafferkey C, 2016, EXPERT OPIN INV DRUG, V25, P1023, DOI 10.1080/13543784.2016.1195807; Carboni JM, 2005, CANCER RES, V65, P3781, DOI 10.1158/0008-5472.CAN-04-4602; Chen Z, 2017, GENE CHROMOSOME CANC, V56, P535, DOI 10.1002/gcc.22456; Chen Z, 2016, GUT, V65, P925, DOI 10.1136/gutjnl-2014-308416; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; El-Rifai W, 2002, CANCER RES, V62, P4061; Fienberg AA, 1998, SCIENCE, V281, P838, DOI 10.1126/science.281.5378.838; Ge J, 2015, MOL MED REP, V11, P633, DOI 10.3892/mmr.2014.2746; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Grivennikov SI, 2010, CYTOKINE GROWTH F R, V21, P11, DOI 10.1016/j.cytogfr.2009.11.005; Gryko M, 2014, POL J PATHOL, V65, P135, DOI 10.5114/PJP.2014.42678; He GB, 2011, CELL RES, V21, P159, DOI 10.1038/cr.2010.183; Jones SA, 2011, J CLIN INVEST, V121, P3375, DOI 10.1172/JCI57158; Lefebvre O, 1996, SCIENCE, V274, P259, DOI 10.1126/science.274.5285.259; Li CJ, 2013, J CANCER RES THER, V9, pS67, DOI 10.4103/0973-1482.119100; Li SL, 2015, TUMOR BIOL, V36, P4519, DOI 10.1007/s13277-015-3096-9; Ma YF, 2016, CLIN CANCER RES, V22, P1767, DOI 10.1158/1078-0432.CCR-15-1677; Menting JG, 2015, STRUCTURE, V23, P1271, DOI 10.1016/j.str.2015.04.016; Mitchell TJ, 2005, IMMUNOLOGY, V114, P301, DOI 10.1111/j.1365-2567.2005.02091.x; Mukherjee K, 2010, SURGERY, V148, P354, DOI 10.1016/j.surg.2010.05.011; Numata K, 2016, J CANCER RES CLIN, V142, P415, DOI 10.1007/s00432-015-2039-6; O'Shea JJ, 2012, IMMUNITY, V36, P542, DOI 10.1016/j.immuni.2012.03.014; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Soutto M, 2011, J CLIN INVEST, V121, P1753, DOI 10.1172/JCI43922; Szasz AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Vangamudi B, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-240; Wang MSJ, 2005, INT J CLIN PRACT, V59, P58, DOI 10.1111/j.1742-1241.2004.00305.x; Werner H, 2012, ONCOGENE, V31, P2703, DOI 10.1038/onc.2011.447; Yadav A, 2005, J BIOL CHEM, V280, P31830, DOI 10.1074/jbc.M501316200; Yoshimura A, 2003, CURR OPIN IMMUNOL, V15, P704, DOI 10.1016/j.coi.2003.09.004; Yoshimura A, 2005, ARTHRITIS RES THER, V7, P100, DOI 10.1186/ar1741; Zhao GB, 2016, ONCOL REP, V35, P1787, DOI 10.3892/or.2016.4544; Zhou JD, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0386-9; Zhu SM, 2017, GUT, V66, P802, DOI 10.1136/gutjnl-2016-312141; Zhu SM, 2011, GASTROENTEROLOGY, V141, P1738, DOI 10.1053/j.gastro.2011.06.070	41	13	14	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	2019	38	29					5805	5816		10.1038/s41388-019-0843-1	http://dx.doi.org/10.1038/s41388-019-0843-1			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IQ4WS	31235784	Green Accepted			2022-12-28	WOS:000480752800005
J	Tiessen, I; Abildgaard, MH; Lubas, M; Gylling, HM; Steinhauer, C; Pietras, EJ; Diederichs, S; Frankel, LB; Lund, AH				Tiessen, Imke; Abildgaard, Marie H.; Lubas, Michal; Gylling, Helene M.; Steinhauer, Cornelia; Pietras, Elin J.; Diederichs, Sven; Frankel, Lisa B.; Lund, Anders H.			A high-throughput screen identifies the long non-coding RNA DRAIC as a regulator of autophagy	ONCOGENE			English	Article							SELECTIVE AUTOPHAGY; ACTIVATES AUTOPHAGY; CELL-PROLIFERATION; MECHANISMS; EXPRESSION; COMPLEX; LC3; TRANSCRIPTION; DISCOVERY; MIR-21	Autophagy is a conserved degradation process that occurs in all eukaryotic cells and its dysfunction has been associated with various diseases including cancer. While a number of large-scale attempts have recently identified new molecular players in autophagy regulation, including proteins and microRNAs, little is known regarding the function of long non-coding RNAs (lncRNAs) in the regulation of this process. To identify new long non-coding RNAs with functional implications in autophagy, we performed a high-throughput RNAi screen targeting more than 600 lncRNA transcripts and monitored their effects on autophagy in MCF-7 cells. We identified 63 lncRNAs that affected GFP-LC3B puncta numbers significantly. We validated the strongest hit, the lncRNA DRAIC previously shown to impact cell proliferation, and revealed a novel role for this lncRNA in the regulation of autophagic flux. Interestingly, we find DRAIC's pro-proliferative effects to be autophagy-independent. This study serves as a valuable resource for researchers from both the lncRNA and autophagy fields as it advances the current understanding of autophagy regulation by non-coding RNAs.	[Tiessen, Imke; Abildgaard, Marie H.; Lubas, Michal; Gylling, Helene M.; Steinhauer, Cornelia; Pietras, Elin J.; Frankel, Lisa B.; Lund, Anders H.] Univ Copenhagen, BRIC, DK-2200 Copenhagen, Denmark; [Abildgaard, Marie H.; Frankel, Lisa B.] Danish Canc Soc Res Ctr DCRC, DK-2100 Copenhagen, Denmark; [Diederichs, Sven] German Canc Res Ctr, Div RNA Biol & Canc, D-69120 Heidelberg, Germany; [Diederichs, Sven] Univ Freiburg, Fac Med, Med Ctr, Dept Thorac Surg,Div Canc Res, D-79106 Freiburg, Germany; [Diederichs, Sven] Univ Freiburg, German Canc Consortium DKTK, Partner Site Freiburg, D-79106 Freiburg, Germany	University of Copenhagen; Danish Cancer Society; Helmholtz Association; German Cancer Research Center (DKFZ); University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); University of Freiburg	Frankel, LB; Lund, AH (corresponding author), Univ Copenhagen, BRIC, DK-2200 Copenhagen, Denmark.; Frankel, LB (corresponding author), Danish Canc Soc Res Ctr DCRC, DK-2100 Copenhagen, Denmark.	frankel@cancer.dk; anders.lund@bric.ku.dk	Lund, Anders H./F-4786-2014; Diederichs, Sven/J-6237-2012	Lund, Anders H./0000-0002-7407-3398; Gylling, Helene Maria/0000-0002-6875-2845; Frankel, Lisa/0000-0001-7249-3607; Diederichs, Sven/0000-0001-7901-4752; Abildgaard, Marie Holm/0000-0002-6354-6102	European Union [607720]; Danish Council for Independent Research (Sapere Aude program); Novo Nordisk Foundation; Lundbeck Foundation; Danish Cancer Society; EU COST Action Transautophagy [CA15138]	European Union(European Commission); Danish Council for Independent Research (Sapere Aude program); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Lundbeck Foundation(Lundbeckfonden); Danish Cancer Society(Danish Cancer Society); EU COST Action Transautophagy	We thank Sudeep Sahadevan for analysis of RNA-seq data, Bettina Mentz for technical assistance, Kevin Ryan for providing pLenti-CRISPR NTC, ATG5, and ATG7 constructs [44], W Lee Kraus for providing PInducer20-DRAIC and -EV constructs [34]. Imke Tiessen was supported by the People Program (Marie Sklodowska-Curie Actions) of the European Union's Seventh Framework Program FP7-PEOPLE-2013-ITN (Grant agreement no.: 607720). Work in the Lund laboratory was supported by the Danish Council for Independent Research (Sapere Aude program), the Novo Nordisk Foundation, the Lundbeck Foundation, the Danish Cancer Society and the EU COST Action Transautophagy (CA15138).	Abada A, 2014, EMBO REP, V15, P839, DOI 10.15252/embr.201439076; Alers S, 2012, MOL CELL BIOL, V32, P2, DOI 10.1128/MCB.06159-11; Bertoli C, 2013, NAT REV MOL CELL BIO, V14, P518, DOI 10.1038/nrm3629; Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Boutros M, 2008, NAT REV GENET, V9, P554, DOI 10.1038/nrg2364; Capparelli C, 2012, CELL CYCLE, V11, P3599, DOI 10.4161/cc.21884; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen CL, 2015, BIOMATERIALS, V44, P71, DOI 10.1016/j.biomaterials.2014.12.023; Chen YN, 2016, ONCOTARGET, V7, P52673, DOI 10.18632/oncotarget.10170; Dengjel J, 2005, P NATL ACAD SCI USA, V102, P7922, DOI 10.1073/pnas.0501190102; Deretic V, 2009, CELL HOST MICROBE, V5, P527, DOI 10.1016/j.chom.2009.05.016; Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233; Doria A, 2013, NEW ENGL J MED, V368, P1845, DOI [10.1056/NEJMc1303158, 10.1056/NEJMra1205406]; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Farkas T, 2009, AUTOPHAGY, V5, P1018, DOI 10.4161/auto.5.7.9443; Figueiredo VC, 2017, CELL MOL LIFE SCI, V74, P2537, DOI 10.1007/s00018-017-2481-5; Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200; Frankel LB, 2017, AUTOPHAGY, V13, P3, DOI 10.1080/15548627.2016.1222992; Frankel LB, 2012, CARCINOGENESIS, V33, P2018, DOI 10.1093/carcin/bgs266; Frankel LB, 2011, EMBO J, V30, P4628, DOI 10.1038/emboj.2011.331; Fulda S, 2015, ONCOGENE, V34, P5105, DOI 10.1038/onc.2014.458; Ge D, 2014, AUTOPHAGY, V10, P957, DOI 10.4161/auto.28363; Geisler S, 2013, NAT REV MOL CELL BIO, V14, P699, DOI 10.1038/nrm3679; Gomez-Sanchez R, 2016, DATA BRIEF, V7, P641, DOI 10.1016/j.dib.2016.02.085; Green DR, 2014, CELL, V157, P65, DOI 10.1016/j.cell.2014.02.049; Guo SJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21106-5; Hosokawa N, 2006, FEBS LETT, V580, P2623, DOI 10.1016/j.febslet.2006.04.008; Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248; Hoyer-Hansen M, 2007, MOL CELL, V25, P193, DOI 10.1016/j.molcel.2006.12.009; Hu YR, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0743-3; Huang FT, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0845-6; Huang SY, 2015, AUTOPHAGY, V11, P2172, DOI 10.1080/15548627.2015.1106663; Jiang H, 2010, CANCER RES, V70, P7882, DOI 10.1158/0008-5472.CAN-10-1604; Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; Klingenberg M, 2018, HEPATOLOGY, V68, P1817, DOI 10.1002/hep.30102; Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356; Konig R, 2007, NAT METHODS, V4, P847, DOI 10.1038/NMETH1089; Lamark T, 2009, CELL CYCLE, V8, P1986, DOI 10.4161/cc.8.13.8892; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Lipinski MM, 2010, DEV CELL, V18, P1041, DOI 10.1016/j.devcel.2010.05.005; Litovchick L, 2007, MOL CELL, V26, P539, DOI 10.1016/j.molcel.2007.04.015; Liu CH, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0619-z; Liu XW, 2016, NAT CELL BIOL, V18, P431, DOI 10.1038/ncb3328; Loayza-Puch F, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r32; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lubas M, 2018, EMBO REP, V19, DOI 10.15252/embr.201846072; McKnight NC, 2012, EMBO J, V31, P1931, DOI 10.1038/emboj.2012.36; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Mizushima N, 2010, NAT CELL BIOL, V12, P823, DOI 10.1038/ncb0910-823; Musiwaro P, 2013, AUTOPHAGY, V9, P1407, DOI 10.4161/auto.25455; Nakatogawa H, 2009, NAT REV MOL CELL BIO, V10, P458, DOI 10.1038/nrm2708; Notzold L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02357-0; O'Prey J, 2017, METHOD ENZYMOL, V588, P79, DOI 10.1016/bs.mie.2016.09.076; Orvedahl A, 2011, NATURE, V480, P113, DOI 10.1038/nature10546; Pawar K, 2016, SCI REP-UK, V6, DOI 10.1038/srep19416; Polycarpou-Schwarz M, 2018, ONCOGENE, V37, P4750, DOI 10.1038/s41388-018-0281-5; Poulsen EG, 2016, METHODS MOL BIOL, V1449, P421, DOI 10.1007/978-1-4939-3756-1_28; Quinn JJ, 2016, NAT REV GENET, V17, P47, DOI 10.1038/nrg.2015.10; Sakurai K, 2015, MOL CANCER RES, V13, P828, DOI 10.1158/1541-7786.MCR-15-0016-T; Seiler J, 2017, NUCLEIC ACIDS RES, V45, P5458, DOI 10.1093/nar/gkx076; Song J, 2014, J ORTHOP RES, V32, P1628, DOI 10.1002/jor.22718; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun M, 2015, MOL CELL, V59, P698, DOI 10.1016/j.molcel.2015.06.023; Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; van Beek N, 2018, BBA-MOL CELL RES, V1865, P803, DOI 10.1016/j.bbamcr.2018.03.002; Viereck J, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1475; Wang Y, 2014, ONCOL LETT, V8, P1947, DOI 10.3892/ol.2014.2487; White E, 2015, CLIN CANCER RES, V21, P5037, DOI 10.1158/1078-0432.CCR-15-0490; Xu ZJ, 2017, ONCOL REP, V37, P1359, DOI 10.3892/or.2017.5416; Yang L, 2016, MOL BIOSYST, V12, P2605, DOI 10.1039/c6mb00114a; Yang LX, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.464; Ying L, 2013, MOL BIOSYST, V9, P407, DOI 10.1039/c2mb25386k; Zhang J, 2017, AUTOPHAGY, V13, P1004, DOI 10.1080/15548627.2017.1312041; Zhao Dan, 2018, Non-Coding RNA, V4, P39, DOI 10.3390/ncrna4040039; Zhao YG, 2018, CURR OPIN CELL BIOL, V53, P29, DOI 10.1016/j.ceb.2018.04.003; Zhao ZS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7212	81	25	28	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2019	38	26					5127	5141		10.1038/s41388-019-0783-9	http://dx.doi.org/10.1038/s41388-019-0783-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IF4AX	30872794				2022-12-28	WOS:000473025300002
J	Clarke, PA; Roe, T; Swabey, K; Hobbs, SM; McAndrew, C; Tomlin, K; Westwood, I; Burke, R; van Montfort, R; Workman, P				Clarke, Paul A.; Roe, Toby; Swabey, Kate; Hobbs, Steve M.; McAndrew, Craig; Tomlin, Kathy; Westwood, Isaac; Burke, Rosemary; van Montfort, Robert; Workman, Paul			Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer	ONCOGENE			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE INHIBITION; MUTATIONS CONFER RESISTANCE; MEK INHIBITION; ACQUIRED-RESISTANCE; ERK1/2 INHIBITOR; COMBINED BRAF; CLINICAL DEVELOPMENT; APOPTOTIC RESPONSE; TUMOR-GROWTH; PI3 KINASE	Genomic alterations in cancer cells result in vulnerabilities that clinicians can exploit using molecularly targeted drugs, guided by knowledge of the tumour genotype. However, the selective activity of these drugs exerts an evolutionary pressure on cancers that can result in the outgrowth of resistant clones. Use of rational drug combinations can overcome resistance to targeted drugs, but resistance may eventually develop to combinatorial therapies. We selected MAPK- and PI3K-pathway inhibition in colorectal cancer as a model system to dissect out mechanisms of resistance. We focused on these signalling pathways because they are frequently activated in colorectal tumours, have well-characterised mutations and are clinically relevant. By treating a panel of 47 human colorectal cancer cell lines with a combination of MEK- and PI3K-inhibitors, we observe a synergistic inhibition of growth in almost all cell lines. Cells with KRAS mutations are less sensitive to PI3K inhibition, but are particularly sensitive to the combined treatment. Colorectal cancer cell lines with inherent or acquired resistance to monotherapy do not show a synergistic response to the combination treatment. Cells that acquire resistance to an MEK-PI3K inhibitor combination treatment still respond to an ERK-PI3K inhibitor regimen, but subsequently also acquire resistance to this combination treatment. Importantly, the mechanisms of resistance to MEK and PI3K inhibitors observed, MEK1/2 mutation or loss of PTEN, are similar to those detected in the clinic. ERK inhibitors may have clinical utility in overcoming resistance to MEK inhibitor regimes; however, we find a recurrent active site mutation of ERK2 that drives resistance to ERK inhibitors in mono- or combined regimens, suggesting that resistance will remain a hurdle. Importantly, we find that the addition of low concentrations of the BCL2-family inhibitor navitoclax to the MEK-PI3K inhibitor regimen improves the synergistic interaction and blocks the acquisition of resistance.	[Clarke, Paul A.; Roe, Toby; Swabey, Kate; Hobbs, Steve M.; McAndrew, Craig; Tomlin, Kathy; Westwood, Isaac; Burke, Rosemary; van Montfort, Robert; Workman, Paul] Inst Canc Res, Canc Res UK Canc Therapeut Unit, London SM2 5NG, England	Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Clarke, PA (corresponding author), Inst Canc Res, Canc Res UK Canc Therapeut Unit, London SM2 5NG, England.	paul.clarke@icr.ac.uk		Clarke, Paul/0000-0001-9342-1290	Cancer Research UK [C309/A11566, C368/A6743, A368/A7990]; Cancer Research UK; Kidani Memorial fund	Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK); Kidani Memorial fund	This work was supported by Cancer Research UK (grant numbers C309/A11566, C368/A6743, and A368/A7990). We acknowledge Cancer Research UK funding to the Cancer Research UK Unit at The Institute of Cancer Research. Paul Workman is a Cancer Research UK Life Fellow. We thank the Kidani Memorial fund for supporting KS. We thank Julian Blagg and Peter Sheldrake for synthesis of CCT245731, and Nicky Evans for editorial assistance.	Aronov AM, 2007, J MED CHEM, V50, P1280, DOI 10.1021/jm061381f; Bean GR, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003483; Blake JF, 2016, J MED CHEM, V59, P5650, DOI 10.1021/acs.jmedchem.6b00389; Chaikuad A, 2014, NAT CHEM BIOL, V10, P853, DOI [10.1038/NCHEMBIO.1629, 10.1038/nchembio.1629]; CHOU TC, 1983, TRENDS PHARMACOL SCI, V4, P450, DOI 10.1016/0165-6147(83)90490-X; Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471; Corcoran RB, 2013, CANCER CELL, V23, P121, DOI 10.1016/j.ccr.2012.11.007; de Castro DG, 2013, CLIN PHARMACOL THER, V93, P252, DOI 10.1038/clpt.2012.237; Dreyling M, 2017, J CLIN ONCOL, V35, P3898, DOI 10.1200/JCO.2017.75.4648; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Faber AC, 2014, CANCER DISCOV, V4, P42, DOI 10.1158/2159-8290.CD-13-0315; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Folkes AJ, 2008, J MED CHEM, V51, P5522, DOI 10.1021/jm800295d; Garcia-Garcia C, 2015, CLIN CANCER RES, V21, P5499, DOI 10.1158/1078-0432.CCR-14-3091; Garraway LA, 2012, CANCER DISCOV, V2, P214, DOI 10.1158/2159-8290.CD-12-0012; Garrison Erik, 12073907 ARXIV; Germann UA, 2017, MOL CANCER THER, V16, P2351, DOI 10.1158/1535-7163.MCT-17-0456; Goetz EM, 2014, CANCER RES, V74, P7079, DOI 10.1158/0008-5472.CAN-14-2073; Guillard S, 2009, CELL CYCLE, V8, P443, DOI 10.4161/cc.8.3.7643; Haagensen EJ, 2012, BRIT J CANCER, V106, P1386, DOI 10.1038/bjc.2012.70; Hatzivassiliou G, 2012, MOL CANCER THER, V11, P1143, DOI 10.1158/1535-7163.MCT-11-1010; Hayakawa M, 2006, BIOORGAN MED CHEM, V14, P6847, DOI 10.1016/j.bmc.2006.06.046; Herrero A, 2015, CANCER CELL, V28, P170, DOI 10.1016/j.ccell.2015.07.001; Hobbs S, 1998, BIOCHEM BIOPH RES CO, V252, P368, DOI 10.1006/bbrc.1998.9646; Hoeflich KP, 2012, CANCER RES, V72, P210, DOI 10.1158/0008-5472.CAN-11-1515; Holford J, 1998, BRIT J CANCER, V77, P366, DOI 10.1038/bjc.1998.59; Jaiswal BS, 2018, CLIN CANCER RES, V24, P4044, DOI 10.1158/1078-0432.CCR-17-3674; Jha S, 2016, MOL CANCER THER, V15, P548, DOI 10.1158/1535-7163.MCT-15-0172; Johnson DB, 2014, J CLIN ONCOL, V32, P3697, DOI 10.1200/JCO.2014.57.3535; Jokinen E, 2015, THER ADV MED ONCOL, V7, P170, DOI 10.1177/1758834015571111; Juric D, 2015, NATURE, V518, P240, DOI 10.1038/nature13948; Kaserer T, 2018, CELL CHEM BIOL, V25, P1359, DOI 10.1016/j.chembiol.2018.07.013; Konieczkowski DJ, 2018, CANCER CELL, V33, P801, DOI 10.1016/j.ccell.2018.03.025; Kumar R, 2016, J PHARMACEUT BIOMED, V125, P140, DOI 10.1016/j.jpba.2016.03.036; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; Mancini M, 2016, SEMIN CELL DEV BIOL, V50, P164, DOI 10.1016/j.semcdb.2015.09.018; Martinelli E, 2013, INT J CANCER, V133, P2089, DOI 10.1002/ijc.28236; Migliardi G, 2012, CLIN CANCER RES, V18, P2515, DOI 10.1158/1078-0432.CCR-11-2683; Morris EJ, 2013, CANCER DISCOV, V3, P742, DOI 10.1158/2159-8290.CD-13-0070; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Oddo D, 2016, CANCER RES, V76, P4504, DOI 10.1158/0008-5472.CAN-16-0396; Petigny-Lechartier C, 2017, MOL CANCER THER, V16, P102, DOI 10.1158/1535-7163.MCT-16-0342; Raynaud FI, 2007, CANCER RES, V67, P5840, DOI 10.1158/0008-5472.CAN-06-4615; Raynaud FI, 2009, MOL CANCER THER, V8, P1725, DOI 10.1158/1535-7163.MCT-08-1200; Ren DC, 2010, SCIENCE, V330, P1390, DOI 10.1126/science.1190217; ROY S, 2010, J MOL SIGNAL, V5, DOI DOI 10.1186/1750-2187-5-10; Sale MJ, 2013, BIOCHEM J, V450, P285, DOI 10.1042/BJ20121212; Samatar AA, 2014, NAT REV DRUG DISCOV, V13, P928, DOI 10.1038/nrd4281; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Sullivan RJ, 2018, CANCER DISCOV, V8, P184, DOI 10.1158/2159-8290.CD-17-1119; Wagle N, 2014, CANCER DISCOV, V4, P61, DOI 10.1158/2159-8290.CD-13-0631; Workman P, 2013, CURR OPIN PHARMACOL, V13, P486, DOI 10.1016/j.coph.2013.06.004; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Yang WS, 2008, NAT CELL BIOL, V10, P125, DOI 10.1038/ncb0208-125; Yap TA, 2012, ANNU REV PHARMACOL, V52, P549, DOI 10.1146/annurev-pharmtox-010611-134532; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhao YJ, 2014, NAT REV CLIN ONCOL, V11, P385, DOI 10.1038/nrclinonc.2014.83; Zunder ER, 2008, CANCER CELL, V14, P180, DOI 10.1016/j.ccr.2008.06.014	62	17	17	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2019	38	25					5076	5090		10.1038/s41388-019-0780-z	http://dx.doi.org/10.1038/s41388-019-0780-z			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IE1KY	30905967	Green Published, hybrid			2022-12-28	WOS:000472145900014
J	Schwiebs, A; San Juan, MH; Schmidt, KG; Wiercinska, E; Anlauf, M; Ottenlinger, F; Thomas, D; Elwakeel, E; Weigert, A; Farin, HF; Bonig, H; Scholich, K; Geisslinger, G; Pfeilschifter, JM; Radeke, HH				Schwiebs, Anja; San Juan, Martina Herrero; Schmidt, Katrin G.; Wiercinska, Eliza; Anlauf, Martin; Ottenlinger, Florian; Thomas, Dominique; Elwakeel, Eiman; Weigert, Andreas; Farin, Henner F.; Bonig, Halvard; Scholich, Klaus; Geisslinger, Gerd; Pfeilschifter, Josef M.; Radeke, Heinfried H.			Cancer-induced inflammation and inflammation-induced cancer in colon: a role for S1P lyase	ONCOGENE			English	Article							PERSISTENT STAT3 ACTIVATION; SPHINGOSINE KINASE 1; BOWEL-DISEASE; INTESTINAL INFLAMMATION; COLORECTAL-CANCER; LYMPHOCYTE EGRESS; TUMOR PROGRESSION; DOWN-REGULATION; SPHINGOSINE-1-PHOSPHATE; RECEPTOR	A role of sphingolipids for inflammatory bowel disease and cancer is evident. However, the relative and separate contribution of sphingolipid deterioration in inflammation versus carcinogenesis for the pathophysiology of colitis-associated colon cancer (CAC) was unknown and therefore examined in this study. We performed isogenic bone marrow transplantation of inducible sphingosine-1-phosphate (S1P) lyase knockout mice to specifically modulate sphingolipids and associated genes and proteins in a compartment-specific way in a DSS/AOM mediated CAC model. 3D organoid cultures were used in vitro. S1P lyase (SGPL1) knockout in either immune cells or tissue, caused local sphingolipid accumulation leading to a dichotomic development of CAC: Immune cell SGPL1 knockout (I-SGPL(-/-)) augmented massive immune cell infiltration initiating colitis with lesions and calprotectin increase. Pathological crypt remodeling plus extracellular S1P-signaling caused delayed tumor formation characterized by S1P receptor 1, STAT3 mRNA increase, as well as programmed cell death ligand 1 expression, accompanied by a putatively counter regulatory STAT1(S727) phosphorylation. In contrast, tissue SGPL1 knockout (T-SGPL(-/-)) provoked immediate occurrence of epithelial-driven tumors with upregulated sphingosine kinase 1, S1P receptor 2 and epidermal growth factor receptor. Here, progressing carcinogenesis was accompanied by an IL-12 to IL-23 shift with a consecutive development of a Th2/GATA3-driven, tumor-favoring microenvironment. Moreover, the knockout models showed distinct lymphopenia and neutrophilia, different from the full SGPL1 knockout. This study shows that depending on the initiating cellular S1P source, the pathophysiology of inflammation-induced cancer versus cancer-induced inflammation develops through separate, discernible molecular steps.	[Schwiebs, Anja; San Juan, Martina Herrero; Schmidt, Katrin G.; Ottenlinger, Florian; Pfeilschifter, Josef M.; Radeke, Heinfried H.] Hosp Goethe Univ, ZAFES, Pharmazentrum Frankfurt, Inst Gen Pharmacol & Toxicol, Frankfurt, Germany; [Wiercinska, Eliza; Bonig, Halvard] German Red Cross Blood Serv Inst, Frankfurt, Germany; [Wiercinska, Eliza; Bonig, Halvard] Goethe Univ, Inst Transfus Med & Immunohematol, Frankfurt, Germany; [Anlauf, Martin] St Vincenz Hosp, Inst Pathol & Cytol, Limburg, Germany; [Thomas, Dominique; Scholich, Klaus; Geisslinger, Gerd] Hosp Goethe Univ, Pharmazentrum Frankfurt, Inst Clin Pharmacol, Frankfurt, Germany; [Elwakeel, Eiman; Weigert, Andreas] Hosp Goethe Univ, Pharmazentrum Frankfurt, Inst Biochem 1, Frankfurt, Germany; [Farin, Henner F.] Inst Tumor Biol & Expt Therapy, Georg Speyer Haus, Frankfurt, Germany; [Farin, Henner F.] German Canc Consortium DKTK, Heidelberg, Germany; [Farin, Henner F.] German Canc Res Ctr, Heidelberg, Germany; [Bonig, Halvard] Univ Washington, Dept Med Hematol, Seattle, WA 98195 USA; [Geisslinger, Gerd] Fraunhofer Inst Mol Biol & Appl Ecol IME, Project Grp Translat Med & Pharmacol TMP, Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Goethe University Frankfurt; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of Washington; University of Washington Seattle; Fraunhofer Gesellschaft	Schwiebs, A; Radeke, HH (corresponding author), Hosp Goethe Univ, ZAFES, Pharmazentrum Frankfurt, Inst Gen Pharmacol & Toxicol, Frankfurt, Germany.	schwiebs@med.uni-frankfurt.de; radeke@em.uni-frankfurt.de	Bönig, Halvard/AAG-3029-2021; Weigert, Andreas/E-6540-2010; Radeke, Heinfried H/E-3772-2013; Farin, Henner/AAC-2574-2021	Bönig, Halvard/0000-0003-0088-2675; Weigert, Andreas/0000-0002-7529-1952; Radeke, Heinfried H/0000-0002-4499-2510; Farin, Henner/0000-0003-1558-5366; Elwakeel, Eiman/0000-0002-0219-9653; Wiercinska, Eliza/0000-0002-8434-6492	Deutsche Forschungsgemeinschaft [SFB1039]; Else-Kroner-Fresenius-Graduiertenkolleg; Translational Research Innovation Pharma graduate school - Else-Kroner-Fresenius Foundation; LOEWE Cell and Gene Therapy Frankfurt faculty [III L 4 518/17.004]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Else-Kroner-Fresenius-Graduiertenkolleg; Translational Research Innovation Pharma graduate school - Else-Kroner-Fresenius Foundation; LOEWE Cell and Gene Therapy Frankfurt faculty	This work was supported by the Deutsche Forschungsgemeinschaft (grant number: SFB1039) to (HHR, AS, KGS, DT, EE, AW, KS, GG, JMP). We also acknowledge the support of the Else-Kroner-Fresenius-Graduiertenkolleg for (FO), the Translational Research Innovation Pharma graduate school for (KGS) funded by the Else-Kroner-Fresenius Foundation both awarded to (HHR), and the LOEWE Cell and Gene Therapy Frankfurt faculty (grant number: III L 4 518/17.004) for EW, awarded to HB.	Allende ML, 2011, J BIOL CHEM, V286, P7348, DOI 10.1074/jbc.M110.171819; Alvarez SE, 2010, NATURE, V465, P1084, DOI 10.1038/nature09128; [Anonymous], 2010, WOODHEAD PUBL MATER; Arlt O, 2014, CELL PHYSIOL BIOCHEM, V34, P27, DOI 10.1159/000362982; Becker C, 2004, IMMUNITY, V21, P491, DOI 10.1016/j.immuni.2004.07.020; Begagne E, 2014, J CLIN INVEST, V124, P5368, DOI 10.1172/JCI74188; Bernstein CN, 2001, CANCER-AM CANCER SOC, V91, P854, DOI 10.1002/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z; Beswick EJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01125; Billich A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059630; Brizuela L, 2012, MOL CANCER THER, V11, P1841, DOI 10.1158/1535-7163.MCT-12-0227; Caini S, 2016, DIGEST LIVER DIS, V48, P1162, DOI 10.1016/j.dld.2016.07.008; Chumanevich AA, 2010, CARCINOGENESIS, V31, P1787, DOI 10.1093/carcin/bgq158; Cyster JG, 2012, ANNU REV IMMUNOL, V30, P69, DOI 10.1146/annurev-immunol-020711-075011; Daniel C, 2007, MOL IMMUNOL, V44, P3305, DOI 10.1016/j.molimm.2007.02.026; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Degagne E, 2014, CLIN EXP GASTROENTER, V7, P205, DOI 10.2147/CEG.S43453; Dillmann C, 2016, J IMMUNOL, V196, P1579, DOI 10.4049/jimmunol.1403168; Doll F, 2005, BBA-MOL CELL BIOL L, V1738, P72, DOI 10.1016/j.bbalip.2005.12.001; Duan RD, 2009, PROG LIPID RES, V48, P62, DOI 10.1016/j.plipres.2008.04.003; Foerster S, 2013, PROTEOMICS, V13, P3131, DOI 10.1002/pmic.201300154; Gandy KAO, 2013, FASEB J, V27, P3155, DOI 10.1096/fj.13-228460; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Gu YP, 2011, J CELL BIOL, V193, P667, DOI 10.1083/jcb.201010075; Helbling M, 2014, ONCOTARGET, V5, P4671, DOI 10.18632/oncotarget.2069; Jonker DJ, 2007, NEW ENGL J MED, V357, P2040, DOI 10.1056/NEJMoa071834; Kawamori T, 2009, FASEB J, V23, P405, DOI 10.1096/fj.08-117572; Kim JJ, 2012, JOVE-J VIS EXP, DOI 10.3791/3678; Kroemer G, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1058597; Kumar A, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/7685142; Lee H, 2010, NAT MED, V16, P1421, DOI 10.1038/nm.2250; Liang J, 2013, CANCER CELL, V23, P107, DOI 10.1016/j.ccr.2012.11.013; Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537; Linke B, 2009, J PROTEOME RES, V8, P4851, DOI 10.1021/pr900106v; Liu SQ, 2013, INT J ONCOL, V42, P617, DOI 10.3892/ijo.2012.1733; Minn AJ, 2016, CELL, V165, P272, DOI 10.1016/j.cell.2016.03.031; Monteleone G, 2012, INT J MOL SCI, V13, P11071, DOI 10.3390/ijms130911071; Nitulescu II, 2017, EBIOMEDICINE, V26, P112, DOI 10.1016/j.ebiom.2017.11.013; Oskouian B, 2006, P NATL ACAD SCI USA, V103, P17384, DOI 10.1073/pnas.0600050103; Ottenlinger FM, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00412; Pathria P, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2014.998529; Patmanathan SN, 2017, CELL SIGNAL, V34, P66, DOI 10.1016/j.cellsig.2017.03.002; Richter C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00044; Rizzo A, 2011, WORLD J GASTROENTERO, V17, P3092, DOI 10.3748/wjg.v17.i26.3092; Rosen H, 2003, P NATL ACAD SCI USA, V100, P10907, DOI 10.1073/pnas.1832725100; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Schwab SR, 2005, SCIENCE, V309, P1735, DOI 10.1126/science.1113640; Schwab SR, 2007, NAT IMMUNOL, V8, P1295, DOI 10.1038/ni1545; Schwiebs A, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00094; Shalapour S, 2015, J CLIN INVEST, V125, P3347, DOI 10.1172/JCI80007; Sharma P, 2015, CELL, V161, P205, DOI 10.1016/j.cell.2015.03.030; Shida D, 2004, FEBS LETT, V577, P333, DOI 10.1016/j.febslet.2004.10.024; Siso S, 2010, PRION, V4, P134; Snider AJ, 2009, FASEB J, V23, P143, DOI 10.1096/fj.08-118109; Suh JH, 2015, TRANSL CANCER RES, V4, P469, DOI 10.3978/j.issn.221-676X.2015.10.06; Tanaka T, 2003, CANCER SCI, V94, P965, DOI 10.1111/j.1349-7006.2003.tb01386.x; Timofeeva OA, 2006, ONCOGENE, V25, P7555, DOI 10.1038/sj.onc.1209742; Uddin S, 2002, J BIOL CHEM, V277, P14408, DOI 10.1074/jbc.M109671200; Vogel P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004112; Wang KP, 2015, ADV CANCER RES, V128, P173, DOI 10.1016/bs.acr.2015.04.014; Zamora-Pineda J, 2016, J EXP MED, V213, P2773, DOI 10.1084/jem.20160287; Zhang WW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01699; Zhong ZY, 2016, CELL, V166, P288, DOI 10.1016/j.cell.2016.05.051	62	23	27	3	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2019	38	24					4788	4803		10.1038/s41388-019-0758-x	http://dx.doi.org/10.1038/s41388-019-0758-x			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IC7ND	30816345				2022-12-28	WOS:000471160500010
J	Zhang, J; Jia, L; Liu, TF; Yip, YL; Tang, WC; Lin, WT; Deng, W; Lo, KW; You, CP; Lung, ML; Lung, HL; Cheung, ALM; Tsao, SW; Tsang, CM				Zhang, Jun; Jia, Lin; Liu, Tengfei; Yip, Yim Ling; Tang, Wing Chung; Lin, Weitao; Deng, Wen; Lo, Kwok Wai; You, Chanping; Lung, Maria Li; Lung, Hong Lok; Cheung, Annie Lai-Man; Tsao, Sai Wah; Tsang, Chi Man			mTORC2-mediated PDHE1 alpha nuclear translocation links EBV-LMP1 reprogrammed glucose metabolism to cancer metastasis in nasopharyngeal carcinoma	ONCOGENE			English	Article							EPSTEIN-BARR-VIRUS; EPITHELIAL-CELLS; EXPRESSION; SNAIL; IMMORTALIZATION; TRANSCRIPTION; GLYCOLYSIS; ACTIVATION; INFECTION; GROWTH	EBV infection of preinvasive nasopharyngeal epithelium is believed to be an initiation step during pathogenesis of nasopharyngeal carcinoma (NPC), but the mechanisms remain poorly understood. Here we report a novel mechanism driving NPC metastasis through the EBV-encoded LMP1-mediated metabolic reprogramming, via activation of IGF1-mTORC2 signaling and nuclear acetylation of the Snail promoter by the PDHE1 alpha, an enzyme involved in glucose metabolism. Mechanistically, EBV-LMP1 increases the cellular secretion of IGF1 which promotes phosphorylation of IGF1R to activate mTORC2/AKT signaling linking glucose metabolism to cell motility. LMP1 expression facilitates translocation of mitochondrial PDHE1a into the nucleus in a phosphorylation-dependent manner at Ser(293) residue. Functionally, nuclear PDHE1a promotes H3K9 acetylation on the Snail promoter to enhance cell motility, thereby driving cancer metastasis. Importantly, the IGF1/mTORC2/PDHE1 alpha/Snail axis correlates significantly with disease progression and poor prognosis in NPC patients. This study highlights the functional importance of IGF1-mTORC2-PDHE1 alpha signaling mediated by EBV-LMP1 in NPC pathogenesis.	[Zhang, Jun; Jia, Lin; Liu, Tengfei; Yip, Yim Ling; Tang, Wing Chung; Lin, Weitao; Deng, Wen; You, Chanping; Cheung, Annie Lai-Man; Tsao, Sai Wah; Tsang, Chi Man] Univ Hong Kong, Sch Biomed Sci, Li Ka Shing Fac Med, Hong Kong, Peoples R China; [Deng, Wen] Univ Hong Kong, Sch Nursing, Li Ka Shing Fac Med, Hong Kong, Peoples R China; [Lo, Kwok Wai] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, State Key Lab Translat Oncol, Hong Kong, Peoples R China; [Lung, Maria Li] Univ Hong Kong, Li Ka Shing Fac Med, Dept Clin Oncol, Hong Kong, Peoples R China; [Lung, Maria Li; Tsao, Sai Wah] Univ Hong Kong, Ctr Canc Res, Hong Kong, Peoples R China; [Lung, Hong Lok] Hong Kong Baptist Univ, Dept Biol, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; Chinese University of Hong Kong; University of Hong Kong; University of Hong Kong; Hong Kong Baptist University	Tsao, SW; Tsang, CM (corresponding author), Univ Hong Kong, Sch Biomed Sci, Li Ka Shing Fac Med, Hong Kong, Peoples R China.; Tsao, SW (corresponding author), Univ Hong Kong, Ctr Canc Res, Hong Kong, Peoples R China.	gswtsao@hku.hk; annatsan@hku.hk	ZHANG, Jun/V-5275-2018	ZHANG, Jun/0000-0002-6523-7573; Lin, Weitao/0000-0003-4385-9897	Research Grants Council, Area of Excellence NPC [AoE/M 06/08]; Theme-Based Research Scheme [T12-401/13-R]; Collaborative Research Fund [C7027-16G, C4001-18GF, C1013-15G]; General Research Fund [14117316, 17161116, 17120814, 779713, 779312, 17110315, 17111516]; Health and Medical Research Fund [04151726, 05162386, 13142201]	Research Grants Council, Area of Excellence NPC; Theme-Based Research Scheme; Collaborative Research Fund; General Research Fund; Health and Medical Research Fund	We acknowledge the Faculty Core Facility members of HKU and Mr. Tony Chan for technical supports. SWT and KWL are funded by the Research Grants Council, Area of Excellence NPC (Grant No. AoE/M 06/08), Theme-Based Research Scheme (T12-401/13-R), Collaborative Research Fund (C7027-16G, C4001-18GF and C1013-15G), General Research Fund (14117316, 17161116, 17120814, 779713, and 779312), and Health and Medical Research Fund (04151726). CMT is funded by the Health and Medical Research Fund (05162386 and 13142201) and General Research Fund (17110315 and 17111516).	Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Cai TT, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006503; Chae YC, 2016, CANCER CELL, V30, P257, DOI 10.1016/j.ccell.2016.07.004; Chua MLK, 2016, LANCET, V387, P1012, DOI 10.1016/S0140-6736(15)00055-0; Dimauro Ivan, 2012, BMC Res Notes, V5, P513, DOI 10.1186/1756-0500-5-513; EPSTEIN MA, 1964, LANCET, V1, P702, DOI 10.1016/s0140-6736(64)91524-7; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hamabe A, 2014, P NATL ACAD SCI USA, V111, P15526, DOI 10.1073/pnas.1407717111; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hecht I, 2015, SCI REP-UK, V5, DOI 10.1038/srep13538; Horikawa T, 2011, BRIT J CANCER, V104, P1160, DOI 10.1038/bjc.2011.38; Levy P, 2016, ONCOGENE, V35, P4155, DOI 10.1038/onc.2015.479; Li HM, 2006, INT J CANCER, V119, P1567, DOI 10.1002/ijc.22032; Li Y., 2017, NAT COMMUN, V8; Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001; Lin WT, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06889-5; Liu HP, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002690; Lo AKF, 2018, J PATHOL, V246, P180, DOI 10.1002/path.5130; Lo AKF, 2015, J PATHOL, V237, P238, DOI 10.1002/path.4575; McFadden K, 2016, P NATL ACAD SCI USA, V113, pE782, DOI 10.1073/pnas.1517141113; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; Nagaraj R, 2017, CELL, V168, P210, DOI 10.1016/j.cell.2016.12.026; Niedobitek G, 1992, Diagn Mol Pathol, V1, P103, DOI 10.1097/00019606-199203000-00016; PATHMANATHAN R, 1995, NEW ENGL J MED, V333, P693, DOI 10.1056/NEJM199509143331103; Ren XY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14053; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.03.035, 10.1016/j.cell.2017.02.004]; Shair KHY, 2009, CANCER RES, V69, P5734, DOI 10.1158/0008-5472.CAN-09-0468; Sommermann TG, 2011, CANCER RES, V71, P7291, DOI 10.1158/0008-5472.CAN-11-1715; Stacpoole PW, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx071; Sutendra G, 2014, CELL, V158, P84, DOI 10.1016/j.cell.2014.04.046; Tsang CM, 2012, P NATL ACAD SCI USA, V109, pE3473, DOI 10.1073/pnas.1202637109; Tsang CM, 2010, INT J CANCER, V127, P1570, DOI 10.1002/ijc.25173; Tsao SW, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0270; Tsao SW, 2015, J PATHOL, V235, P323, DOI 10.1002/path.4448; Tsao SW, 2002, SEMIN CANCER BIOL, V12, P473, DOI 10.1016/S1044579X02000901; Tsao SW, 2002, BBA-MOL CELL RES, V1590, P150, DOI 10.1016/S0167-4889(02)00208-2; Tworkoski K, 2015, J VIROL, V89, P2590, DOI 10.1128/JVI.02921-14; Wang XM, 2016, CELL RES, V26, P1, DOI 10.1038/cr.2015.134; Wang YF, 2013, CURR CANCER DRUG TAR, V13, P963, DOI 10.2174/15680096113136660102; Xiao L, 2014, ONCOGENE, V33, P4568, DOI 10.1038/onc.2014.32; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Zhang D, 2017, ONCOGENE, V36, P2900, DOI 10.1038/onc.2016.446; Zhang J, 2017, ADV EXP MED BIOL, V1018, P75, DOI 10.1007/978-981-10-5765-6_6; Zhang J, 2017, J VIROL, V91, DOI 10.1128/JVI.02168-16; Zhu DD, 2016, INT J CANCER, V138, P1175, DOI 10.1002/ijc.29850	46	25	26	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2019	38	24					4669	4684		10.1038/s41388-019-0749-y	http://dx.doi.org/10.1038/s41388-019-0749-y			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IC7ND	30745576	Green Published, hybrid			2022-12-28	WOS:000471160500002
J	Aasen, T; Leithe, E; Graham, SV; Kameritsch, P; Mayan, MD; Mesnil, M; Pogoda, K; Tabernero, A				Aasen, Trond; Leithe, Edward; Graham, Sheila V.; Kameritsch, Petra; Mayan, Maria D.; Mesnil, Marc; Pogoda, Kristin; Tabernero, Arantxa			Connexins in cancer: bridging the gap to the clinic	ONCOGENE			English	Review							TRANS-RETINOIC ACID; SUICIDE-GENE-THERAPY; JUNCTIONAL INTERCELLULAR COMMUNICATION; HUMAN PROSTATE-CANCER; TUMOR-CELLS; BREAST-CANCER; UP-REGULATION; IN-VITRO; SPONTANEOUS METASTASIS; MONOCLONAL-ANTIBODIES	Gap junctions comprise arrays of intercellular channels formed by connexin proteins and provide for the direct communication between adjacent cells. This type of intercellular communication permits the coordination of cellular activities and plays key roles in the control of cell growth and differentiation and in the maintenance of tissue homoeostasis. After more than 50 years, deciphering the links among connexins, gap junctions and cancer, researchers are now beginning to translate this knowledge to the clinic. The emergence of new strategies for connexin targeting, combined with an improved understanding of the molecular bases underlying the dysregulation of connexins during cancer development, offers novel opportunities for clinical applications. However, different connexin isoforms have diverse channel-dependent and -independent functions that are tissue and stage specific. This can elicit both pro- and anti-tumorigenic effects that engender significant challenges in the path towards personalised medicine. Here, we review the current understanding of the role of connexins and gap junctions in cancer, with particular focus on the recent progress made in determining their prognostic and therapeutic potential.	[Aasen, Trond] Autonomous Univ Barcelona, CIBERONC, Vall dHebron Inst Res VHIR, Translat Mol Pathol, Barcelona, Spain; [Leithe, Edward] Oslo Univ Hosp, Inst Canc Res, Dept Mol Oncol, Oslo, Norway; [Leithe, Edward] Oslo Univ Hosp, KG Jebsen Colorectal Canc Res Ctr, Oslo, Norway; [Graham, Sheila V.] Univ Glasgow, Coll Med Vet & Life Sci, Inst Infect Immun & Inflammat, MRC,Ctr Virus Res, Glasgow, Lanark, Scotland; [Kameritsch, Petra; Pogoda, Kristin] Ludwig Maximilians Univ Munchen, Walter Brendel Ctr Expt Med, Munich, Germany; [Kameritsch, Petra; Pogoda, Kristin] Munich Univ Hosp, Munich, Germany; [Mayan, Maria D.] Univ A Coruna, Serv Galego Saude SERGAS, Inst Invest Biomed A Coruna INIBIC, CellCOM Res Grp, La Coruna, Spain; [Mesnil, Marc] Univ Poitiers, Fac Sci Fondamentales & Appl, STIM Lab, Poitiers, France; [Tabernero, Arantxa] Univ Salamanca, INCYL, Dept Bioquim & Biol Mol, Salamanca, Spain	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; University of Oslo; University of Oslo; University of Glasgow; University of Munich; University of Munich; Complejo Hospitalario Universitario A Coruna; Universidade da Coruna; Instituto de Investigacion Biomedica de A Coruna (INIBIC); Universite de Poitiers; University of Salamanca	Aasen, T (corresponding author), Autonomous Univ Barcelona, CIBERONC, Vall dHebron Inst Res VHIR, Translat Mol Pathol, Barcelona, Spain.; Tabernero, A (corresponding author), Univ Salamanca, INCYL, Dept Bioquim & Biol Mol, Salamanca, Spain.	trond.aasen@vhir.org; ataber@usal.es	Mayan, Maria D./C-8813-2012; Mayán, María D./AAR-9227-2021; Tabernero, Arantxa/K-5950-2014; Aasen, Trond/B-5279-2013	Mayan, Maria D./0000-0002-5809-9440; Mayán, María D./0000-0002-5809-9440; Tabernero, Arantxa/0000-0001-6302-6134; Aasen, Trond/0000-0003-0763-2695; Mesnil, Marc/0000-0003-4922-0365	Instituto de Salud Carlos III [PI16/00772, CPII16/00042]; European Regional Development Fund (ERDF); Norwegian Cancer Society [709125]; South-Eastern Norway Regional Health Authority [2016013]; Kristian Gerhard Jebsen Foundation; Ministerio de Economia y Competitividad, Spain; Consejeria de Educacion, Junta de Castilla y Leon, Spain [FEDER BFU2015-70040-R]; FEDER [SA026U16]; Fundacion Ramon Areces; Spanish Foundation for Research on Bone and Mineral Metabolism (FEIOMM); FECYT-Ministerio de Economia y Competitividad [PRECIPITA-2015-000139]; Xunta de Galicia [IN607B 2017/21]; Instituto de Salud Carlos III (ISCIII, Spain) [PI16/00035]; European Regional Development Fund, 'A way of making Europe' from the European Union; Worldwide Cancer research grant [08-0159]; Medical Research Council; Ligue contre le Cancer (Comites de la Charente-Maritime et de la Vienne); MRC [MC_UU_12014/3] Funding Source: UKRI	Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); European Regional Development Fund (ERDF)(European Commission); Norwegian Cancer Society(Norwegian Cancer Society); South-Eastern Norway Regional Health Authority; Kristian Gerhard Jebsen Foundation; Ministerio de Economia y Competitividad, Spain(Spanish Government); Consejeria de Educacion, Junta de Castilla y Leon, Spain(Junta de Castilla y Leon); FEDER(European Commission); Fundacion Ramon Areces; Spanish Foundation for Research on Bone and Mineral Metabolism (FEIOMM); FECYT-Ministerio de Economia y Competitividad; Xunta de Galicia(Xunta de GaliciaEuropean Commission); Instituto de Salud Carlos III (ISCIII, Spain)(Instituto de Salud Carlos III); European Regional Development Fund, 'A way of making Europe' from the European Union; Worldwide Cancer research grant; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Ligue contre le Cancer (Comites de la Charente-Maritime et de la Vienne); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The authors are members of The European Consortium for Research on Connexins and Cancer. We apologise to authors whose work could not be cited due to space limitations. Trond Aasen acknowledges the support from Instituto de Salud Carlos III (grants PI16/00772 and CPII16/00042), co-financed by the European Regional Development Fund (ERDF). Edward Leithe acknowledges the support from the Norwegian Cancer Society (grant number 709125), the South-Eastern Norway Regional Health Authority (grant number 2016013) and the Kristian Gerhard Jebsen Foundation. Arantxa Tabernero acknowledges the support from the Ministerio de Economia y Competitividad, Spain; FEDER BFU2015-70040-R, Consejeria de Educacion, Junta de Castilla y Leon, Spain; FEDER SA026U16 and Fundacion Ramon Areces. Maria D Mayan acknowledges the support from the Spanish Foundation for Research on Bone and Mineral Metabolism (FEIOMM), grant PRECIPITA-2015-000139 from the FECYT-Ministerio de Economia y Competitividad, grant IN607B 2017/21 from Xunta de Galicia and grant PI16/00035 from the Instituto de Salud Carlos III (ISCIII, Spain), and the European Regional Development Fund, 'A way of making Europe' from the European Union. Sheila Graham acknowledges the support from Worldwide Cancer research grant 08-0159 and from the Medical Research Council as core funding for the MRC University of Glasgow Centre for Virus Research. Marc Mesnil acknowledges the support from Ligue contre le Cancer (Comites de la Charente-Maritime et de la Vienne).	Aasen T, 2003, ONCOGENE, V22, P7969, DOI 10.1038/sj.onc.1206709; Aasen T, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-31; Aasen T, 2016, NAT REV CANCER, V16, P775, DOI 10.1038/nrc.2016.105; Aasen T, 2015, CELL TISSUE RES, V360, P685, DOI 10.1007/s00441-014-2078-3; Ablasser A, 2013, NATURE, V503, P530, DOI 10.1038/nature12640; Gleisner MA, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01067; Alonso F, 2016, ONCOTARGET, V7, P14015, DOI 10.18632/oncotarget.7370; Ariazi J, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00333; Artesi M, 2015, NEURO-ONCOLOGY, V17, P392, DOI 10.1093/neuonc/nou215; Aucher A, 2013, J IMMUNOL, V191, P6250, DOI 10.4049/jimmunol.1301728; Balla P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125316; Benko G, 2011, PROSTATE CANCER P D, V14, P90, DOI 10.1038/pcan.2010.51; Bennett MVL, 2003, TRENDS NEUROSCI, V26, P610, DOI 10.1016/j.tins.2003.09.008; Bijnsdorp IV, 2012, BRIT J CANCER, V107, P1963, DOI 10.1038/bjc.2012.500; Brockmeyer P, 2014, INT J ONCOL, V45, P273, DOI 10.3892/ijo.2014.2394; Buhrmann C, 2015, BIOCHEM PHARMACOL, V98, P51, DOI 10.1016/j.bcp.2015.08.105; Bui Marilyn M., 2011, Sarcoma, V2011, P971050, DOI 10.1155/2011/971050; Busby M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030693; Carystinos GD, 2001, CANCER CHEMOTH PHARM, V47, P126, DOI 10.1007/s002800000231; Castellana B, 2012, J CANCER, V3, P175, DOI 10.7150/jca.4120; Chasampalioti M, 2018, BREAST CANC RES TREA; Chekhonin VP, 2012, NANOMED-NANOTECHNOL, V8, P63, DOI 10.1016/j.nano.2011.05.011; Chen JT, 2003, CLIN CANCER RES, V9, P4200; Chen Q, 2016, NATURE, V533, P493, DOI 10.1038/nature18268; Chen WL, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0487-0; Chen Y, 2005, INT J CANCER, V113, P14, DOI 10.1002/ijc.20498; Chi Y, 2014, J CELL SCI, V127, P1487, DOI 10.1242/jcs.139089; Crespin S, 2016, CANCER MED-US, V5, P1742, DOI 10.1002/cam4.730; Dahle J, 2000, RADIAT RES, V154, P10; Dai P, 2007, MOL BIOL CELL, V18, P2264, DOI 10.1091/mbc.E06-12-1064; Danos K, 2016, APPL IMMUNOHISTO M M, V24, P476, DOI 10.1097/PAI.0000000000000212; de Martel C, 2017, INT J CANCER, V141, P664, DOI 10.1002/ijc.30716; de Wit C, 2006, ADV CARDIOL, V42, P268, DOI 10.1159/000092575; Defamie N, 2014, FEBS LETT, V588, P1331, DOI 10.1016/j.febslet.2014.01.012; Delvaeye T, 2018, TRENDS MOL MED, V24, P1036, DOI 10.1016/j.molmed.2018.10.005; Dilber MS, 1997, CANCER RES, V57, P1523; Du GJ, 2013, CANCER CHEMOTH PHARM, V71, P893, DOI 10.1007/s00280-013-2080-6; Dubina MV, 2002, ONCOGENE, V21, P4992, DOI 10.1038/sj.onc.1205630; Duffy HS, 2007, J BIOL CHEM, V282, P9789, DOI 10.1074/jbc.M605261200; Duflot-Dancer A, 1998, GENE THER, V5, P1372, DOI 10.1038/sj.gt.3300734; EGHBALI B, 1991, P NATL ACAD SCI USA, V88, P10701, DOI 10.1073/pnas.88.23.10701; ELSABBAN ME, 1991, J CELL BIOL, V115, P1375, DOI 10.1083/jcb.115.5.1375; Elshami AA, 1996, GENE THER, V3, P85; Elzarrad MK, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-20; Ezumi K, 2008, CLIN CANCER RES, V14, P677, DOI 10.1158/1078-0432.CCR-07-1184; Falk S, 2018, PAIN, V159, P1127, DOI 10.1097/j.pain.0000000000001197; FICK J, 1995, P NATL ACAD SCI USA, V92, P11071, DOI 10.1073/pnas.92.24.11071; Fukushima M, 2007, INT J ONCOL, V30, P225; Gartner C, 2012, PHARMACOL RES, V65, P347, DOI 10.1016/j.phrs.2011.11.012; Gangoso E, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.560; Gielen PR, 2013, NEUROPHARMACOLOGY, V75, P539, DOI 10.1016/j.neuropharm.2013.05.002; Gilleron J, 2018, BBA-BIOMEMBRANES, V1860, P182, DOI 10.1016/j.bbamem.2017.06.004; Glass AM, 2015, CELL MOL LIFE SCI, V72, P2899, DOI 10.1007/s00018-015-1966-3; Gonzalez-Sanchez A, 2016, ONCOTARGET, V7, P49819, DOI 10.18632/oncotarget.10454; Greco R, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00095; Grek CL, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1229-6; Haass NK, 2010, HISTOCHEM CELL BIOL, V133, P113, DOI 10.1007/s00418-009-0654-5; Haefliger JA, 2017, ARTERIOSCL THROM VAS, V37, P2136, DOI 10.1161/ATVBAHA.117.310072; Harikumar KB, 2010, INT J CANCER, V127, P257, DOI 10.1002/ijc.25041; Harris LD, 2008, MOL CARCINOGEN, V47, P678, DOI 10.1002/mc.20420; Hellmann P, 1999, EXP CELL RES, V246, P480, DOI 10.1006/excr.1998.4332; Herrero-Gonzalez S, 2010, ONCOGENE, V29, P5712, DOI 10.1038/onc.2010.299; Hirschi KK, 1996, CELL GROWTH DIFFER, V7, P861; Hitomi M, 2015, CELL REP, V11, P1031, DOI 10.1016/j.celrep.2015.04.021; Hong XT, 2015, ONCOTARGET, V6, P15566, DOI 10.18632/oncotarget.3904; Huang RP, 2001, INT J CANCER, V92, P130, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1165>3.0.CO;2-G; Hunter AW, 2005, MOL BIOL CELL, V16, P5686, DOI 10.1091/mbc.E05-08-0737; Inose T, 2009, ANN SURG ONCOL, V16, P1704, DOI 10.1245/s10434-009-0443-3; Ito A, 2006, CANCER LETT, V234, P239, DOI 10.1016/j.canlet.2005.03.049; Ito A, 2004, CARCINOGENESIS, V25, P2015, DOI 10.1093/carcin/bgh208; Ito A, 2000, J CLIN INVEST, V105, P1189, DOI 10.1172/JCI8257; James CC, 2018, MOL BIOL CELL, V29, P797, DOI 10.1091/mbc.E17-06-0406; Jaraiz-Rodriguez M, 2017, STEM CELL REP, V9, P451, DOI 10.1016/j.stemcr.2017.06.007; Jin Z, 2013, CELL MOL NEUROBIOL, V33, P1143, DOI 10.1007/s10571-013-9980-1; Jing YM, 2012, ASIAN PAC J CANCER P, V13, P2363, DOI 10.7314/APJCP.2012.13.5.2363; Kameritsch P, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.105; Kameritsch P, 2015, BBA-MOL CELL RES, V1853, P2907, DOI 10.1016/j.bbamcr.2015.08.004; Karpinich NO, 2015, ARTERIOSCL THROM VAS, V35, P1147, DOI 10.1161/ATVBAHA.114.304752; Kawasaki Y, 2011, INT J CANCER, V128, P51, DOI 10.1002/ijc.25308; Khan Z, 2014, CARCINOGENESIS, V35, P145, DOI 10.1093/carcin/bgt292; Khoo NKS, 1998, INT J CANCER, V77, P440; King TJ, 2005, BBA-BIOMEMBRANES, V1719, P146, DOI 10.1016/j.bbamem.2005.08.012; Klymenko T, 2017, J VIROL, V91, DOI 10.1128/JVI.01001-17; Knosel T, 2005, NEOPLASIA, V7, P741, DOI 10.1593/neo.05178; Kong H, 2016, ONCOL REP, V35, P1868, DOI 10.3892/or.2015.4535; Kotini M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06368-x; Kotini M, 2015, DEV BIOL, V401, P143, DOI 10.1016/j.ydbio.2014.12.023; Krutovskikh VA, 2002, ONCOGENE, V21, P1989, DOI 10.1038/sj.onc.1205187; Krutovskikh VA, 2000, ONCOGENE, V19, P505, DOI 10.1038/sj.onc.1203340; Kyo N, 2008, ONCOL REP, V19, P627; Lai SW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010127; Laird DW, 2018, NAT REV DRUG DISCOV, V17, P905, DOI 10.1038/nrd.2018.138; Laird DW, 2006, BIOCHEM J, V394, P527, DOI 10.1042/BJ20051922; Lampe PD, 2004, INT J BIOCHEM CELL B, V36, P1171, DOI 10.1016/S1357-2725(03)00264-4; Lazar I, 2015, PIGM CELL MELANOMA R, V28, DOI 10.1111/pcmr.12380; Leithe E, 2018, BBA-BIOMEMBRANES, V1860, P48, DOI 10.1016/j.bbamem.2017.05.008; Leithe E, 2016, BBA-REV CANCER, V1865, P133, DOI 10.1016/j.bbcan.2016.02.001; Li SY, 2011, NEUROSCI LETT, V503, P115, DOI 10.1016/j.neulet.2011.08.019; Li X, 2012, CANCER BIOL THER, V13, P890, DOI 10.4161/cbt.20841; Liang QL, 2010, MED ONCOL, V27, P1164, DOI 10.1007/s12032-009-9354-1; Lin JHC, 2002, J NEUROSCI, V22, P4302, DOI 10.1523/JNEUROSCI.22-11-04302.2002; Lin QT, 2016, MOL MED REP, V13, P1329, DOI 10.3892/mmr.2015.4680; Lin QT, 2010, NEOPLASIA, V12, P748, DOI 10.1593/neo.10602; Lin YP, 2019, ONCOGENE, V38, P822, DOI 10.1038/s41388-018-0471-1; Liu D, 2015, GENE, V574, P217, DOI 10.1016/j.gene.2015.08.052; Liu LX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143438; Liu XL, 2010, INT J MOL MED, V25, P709, DOI 10.3892/ijmm_00000395; LOEWENSTEIN WR, 1966, NATURE, V209, P1248, DOI 10.1038/2091248a0; MacDonald AI, 2012, BIOCHEM J, V446, P9, DOI 10.1042/BJ20111144; Martins-Marques T, 2016, J EXTRACELL VESICLES, V5, DOI 10.3402/jev.v5.32538; McLachlan E, 2006, CANCER RES, V66, P9886, DOI 10.1158/0008-5472.CAN-05-4302; MCNUTT NS, 1969, SCIENCE, V165, P597, DOI 10.1126/science.165.3893.597; Mehta P, 1999, DEV GENET, V24, P91, DOI 10.1002/(SICI)1520-6408(1999)24:1/2<91::AID-DVG10>3.0.CO;2-#; MEHTA PP, 1986, CELL, V44, P187, DOI 10.1016/0092-8674(86)90497-6; Melo SA, 2014, CANCER CELL, V26, P707, DOI 10.1016/j.ccell.2014.09.005; Menachem A, 2016, ONCOTARGET, V7, P12489, DOI 10.18632/oncotarget.7273; Mendoza-Naranjo A, 2007, J IMMUNOL, V178, P6949, DOI 10.4049/jimmunol.178.11.6949; Mesnil M, 2000, CANCER RES, V60, P3989; MESNIL M, 1995, CANCER RES, V55, P629; Mesnil M, 1996, P NATL ACAD SCI USA, V93, P1831, DOI 10.1073/pnas.93.5.1831; Mesnil M, 2018, BBA-BIOMEMBRANES, V1860, P237, DOI 10.1016/j.bbamem.2017.06.015; Miura D, 2007, FEBS LETT, V581, P2541, DOI 10.1016/j.febslet.2007.04.080; Mothersill C, 2004, NAT REV CANCER, V4, P158, DOI 10.1038/nrc1277; Mulkearns-Hubert EE, 2018, DEV CX46 TARGETING S; Munoz JL, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.111; Murphy SF, 2016, CANCER RES, V76, P139, DOI 10.1158/0008-5472.CAN-15-1286; Naoi Y, 2008, CANCER LETT, V262, P248, DOI 10.1016/j.canlet.2007.12.008; Naoi Y, 2007, BREAST CANCER RES TR, V106, P11, DOI 10.1007/s10549-006-9465-8; Naus CC, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1089-0; Nomura S, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-79; Nukolova NV, 2014, B EXP BIOL MED+, V157, P524, DOI 10.1007/s10517-014-2606-x; OELZE I, 1995, J VIROL, V69, P4489, DOI 10.1128/JVI.69.7.4489-4494.1995; Ohba Y, 2007, INT J CANCER, V121, P47, DOI 10.1002/ijc.22608; Olbina G, 2003, MOL CANCER RES, V1, P690; Oliveira R, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-7; Osswald M, 2016, NEURO-ONCOLOGY, V18, P479, DOI 10.1093/neuonc/now014; Osswald M, 2015, NATURE, V528, P93, DOI 10.1038/nature16071; Park SY, 2010, CLIN CANCER RES, V16, P876, DOI 10.1158/1078-0432.CCR-09-1532; Pasquier J, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-94; PITTS JD, 1994, MOL CARCINOGEN, V11, P127, DOI 10.1002/mc.2940110302; Pogoda K, 2016, BMC CELL BIOL, V17, DOI 10.1186/s12860-016-0099-3; Polak R, 2015, BLOOD, V126, P2404, DOI 10.1182/blood-2015-03-634238; Pollmann MA, 2005, BREAST CANCER RES, V7, pR522, DOI 10.1186/bcr1042; Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039; Poyet C, 2015, J CLIN PATHOL, V68, P819, DOI 10.1136/jclinpath-2015-202898; Prise KM, 2009, NAT REV CANCER, V9, P351, DOI 10.1038/nrc2603; Qin H, 2002, J BIOL CHEM, V277, P29132, DOI 10.1074/jbc.M200797200; Raza A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08058-y; Rhett JM, 2011, MOL BIOL CELL, V22, P1516, DOI 10.1091/mbc.E10-06-0548; Riquelme MA, 2013, NEUROPHARMACOLOGY, V75, P525, DOI 10.1016/j.neuropharm.2013.02.021; Ryu CH, 2012, BIOCHEM BIOPH RES CO, V421, P585, DOI 10.1016/j.bbrc.2012.04.050; Saccheri F, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000739; Saez CG, 2003, J CELL BIOCHEM, V89, P450, DOI 10.1002/jcb.10519; Saez JC, 2014, FEBS LETT, V588, P1205, DOI 10.1016/j.febslet.2014.03.004; Saito-Katsuragi M, 2007, CANCER, V110, P1162, DOI 10.1002/cncr.22894; Salat-Canela C, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/1478-811X-12-31; Sato H, 2007, MOL CARCINOGEN, V46, P215, DOI 10.1002/mc.20267; Segal SS, 2015, J VASC RES, V52, P136, DOI 10.1159/000439112; Sentani K, 2010, PATHOBIOLOGY, V77, P241, DOI 10.1159/000314966; Shao Q, 2005, CANCER RES, V65, P2705, DOI 10.1158/0008-5472.CAN-04-2367; Shen YM, 2018, INT J ONCOL, V52, P872, DOI 10.3892/ijo.2018.4263; Shi Q, 2015, DEV CELL, V35, P483, DOI 10.1016/j.devcel.2015.10.014; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Shishido SN, 2014, INT J CANCER, V134, P1474, DOI 10.1002/ijc.28461; Shishido SN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044963; Sin WC, 2016, ONCOGENE, V35, P1504, DOI 10.1038/onc.2015.210; Sirnes S, 2012, INT J CANCER, V131, P570, DOI 10.1002/ijc.26392; Sirnes S, 2011, EPIGENETICS-US, V6, P602, DOI 10.4161/epi.6.5.15237; Smyth JW, 2013, CELL REP, V5, P611, DOI 10.1016/j.celrep.2013.10.009; Soares AR, 2015, SCI REP-UK, V5, DOI 10.1038/srep13243; Soung YH, 2017, CANCERS, V9, DOI 10.3390/cancers9010008; Stoletov K, 2013, J CELL SCI, V126, P904, DOI 10.1242/jcs.112748; Sun P, 2015, VIRUSES-BASEL, V7, P5243, DOI 10.3390/v7102871; Tabernero A, 2016, NEUROSCIENCE, V323, P183, DOI 10.1016/j.neuroscience.2015.02.029; Tan LW, 2002, CARCINOGENESIS, V23, P231, DOI 10.1093/carcin/23.2.231; Tanaka M, 2004, ONCOL REP, V11, P537; Tanaka M, 2001, HUM GENE THER, V12, P2225, DOI 10.1089/10430340152710568; Tanaka T, 2016, MOL CLIN ONCOL, V4, P989, DOI 10.3892/mco.2016.828; Tang B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074527; Teleki I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112541; Teleki I, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-50; Thayanithy V, 2014, TRANSL RES, V164, P359, DOI 10.1016/j.trsl.2014.05.011; Thiagarajan PS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02938-1; Thuringer D, 2016, ONCOTARGET, V7, P73925, DOI 10.18632/oncotarget.12136; Thuringer D, 2016, ONCOTARGET, V7, P28160, DOI 10.18632/oncotarget.8583; Thuringer D, 2015, ONCOTARGET, V6, P28800, DOI 10.18632/oncotarget.4894; Tittarelli A, 2015, J BIOL CHEM, V290, P23670, DOI 10.1074/jbc.M115.651547; Tittarelli A, 2014, J IMMUNOL, V192, P1313, DOI 10.4049/jimmunol.1301297; Touraine RL, 1998, GENE THER, V5, P1705, DOI 10.1038/sj.gt.3300784; Touraine RL, 1998, HUM GENE THER, V9, P2385, DOI 10.1089/hum.1998.9.16-2385; Uhlen M, 2017, SCIENCE, V357, P660, DOI 10.1126/science.aan2507; Ul-Hussain M, 2014, J BIOL CHEM, V289, P20979, DOI 10.1074/jbc.M113.540187; Villares GJ, 2009, CANCER RES, V69, P6730, DOI 10.1158/0008-5472.CAN-09-0300; Vrionis FD, 1997, GENE THER, V4, P577, DOI 10.1038/sj.gt.3300438; Wang H, 2018, CANCER CELL, V34, P823, DOI 10.1016/j.ccell.2018.10.002; Wang LZ, 2015, ONCOL REP, V34, P2133, DOI 10.3892/or.2015.4192; Wang LZ, 2013, TOXICOLOGY, V312, P149, DOI 10.1016/j.tox.2013.08.013; Wang N, 2013, BBA-BIOMEMBRANES, V1828, P35, DOI 10.1016/j.bbamem.2012.07.002; Wang WK, 2015, INT J MOL SCI, V16, P439, DOI 10.3390/ijms16010439; Wang X, 2010, P NATL ACAD SCI USA, V107, P17194, DOI 10.1073/pnas.1006785107; Wang YJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01480-2; Wang ZS, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-306; Willebrords J, 2017, PHARMACOL THERAPEUT, V180, P144, DOI 10.1016/j.pharmthera.2017.07.001; Wu JF, 2016, ONCOL REP, V36, P3251, DOI 10.3892/or.2016.5156; Wu L, 2016, MOL MED REP, V13, P3213, DOI 10.3892/mmr.2016.4895; Wygoda MR, 1997, CANCER RES, V57, P1699; Xu N, 2016, ONCOTARGET, V7, P67476, DOI 10.18632/oncotarget.11231; Yang J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.197; Yu ML, 2012, BIOL PHARM BULL, V35, P1230, DOI 10.1248/bpb.b110535; Yu SC, 2012, STEM CELLS, V30, P108, DOI 10.1002/stem.1685; Yulyana Y, 2013, STEM CELLS DEV, V22, P1870, DOI 10.1089/scd.2012.0529; Yusubalieva GM, 2014, B EXP BIOL MED+, V157, P510, DOI 10.1007/s10517-014-2603-0; Yusubalieva GM, 2012, B EXP BIOL MED+, V153, P163, DOI 10.1007/s10517-012-1667-y; Zhang YW, 2003, J BIOL CHEM, V278, P44852, DOI 10.1074/jbc.M305072200; Zhang YW, 2001, ONCOGENE, V20, P4138, DOI 10.1038/sj.onc.1204563; Zhang YW, 2003, CANCER RES, V63, P1623; Zhou JZ, 2016, ONCOGENE, V35, P5597, DOI 10.1038/onc.2016.101; Zhou JZ, 2015, ONCOGENE, V34, P1831, DOI 10.1038/onc.2014.113; ZHU DG, 1992, P NATL ACAD SCI USA, V89, P10218, DOI 10.1073/pnas.89.21.10218; Zhu T, 2017, ONCOTARGET, V8, P21281, DOI 10.18632/oncotarget.15068; Zibara K, 2015, SCI REP-UK, V5, DOI 10.1038/srep12598; zur Hausen H, 2009, VIROLOGY, V384, P260, DOI 10.1016/j.virol.2008.11.046	222	87	88	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2019	38	23					4429	4451		10.1038/s41388-019-0741-6	http://dx.doi.org/10.1038/s41388-019-0741-6			23	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IB4KM	30814684	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000470240300001
J	Zhao, GX; Xu, YY; Weng, SQ; Zhang, S; Chen, Y; Shen, XZ; Dong, L; Chen, S				Zhao, Guang-Xi; Xu, Ying-Ying; Weng, Shu-Qiang; Zhang, Si; Chen, Ying; Shen, Xi-Zhong; Dong, Ling; Chen, She			CAPS1 promotes colorectal cancer metastasis via Snail mediated epithelial mesenchymal transformation	ONCOGENE			English	Article							CA2+-DEPENDENT ACTIVATOR PROTEIN; E-CADHERIN; CELLS REVEALS; TUMOR-CELLS; SECRETION; TRANSITION; EXPRESSION; INVASION; SYSTEM; EMT	Colorectal cancer (CRC) is a common gastrointestinal cancer with high mortality rate mostly due to metastasis. Ca2+-dependent activator protein for secretion 1 (CAPS1) was originally identified as a soluble factor that reconstitutes Ca2+-dependent secretion. In this study, we discovered a novel role of CAPS1 in CRC metastasis. CAPS1 is frequently up-regulated in CRC tissues. Increased CAPS1 expression is associated with frequent metastasis and poor prognosis of CRC patients. Overexpression of CAPS1 promotes CRC cell migration and invasion in vitro, as well as liver metastasis in vivo, without affecting cell proliferation. CAPS1 induces epithelial-mesenchymal transition (EMT), including decreased E-cadherin and ZO-1, epithelial marker expression, and increased N-cadherin and Snail, mesenchymal marker expression. Snail knockdown reversed CAPS1-induced EMT, cell migration and invasion. This result indicates that Snail is required for CAPS1-mediated EMT process and metastasis in CRC. Furthermore, CAPS1 can bind with Septin2 and p85 (subunit of PI3K). LY294002 and wortmanin, PI3K/Akt inhibitors, can abolish CAPS1-induced increase of Akt/GSK3 beta activity, as well as increase of Snail protein level. Taken together, CAPS1 promotes colorectal cancer metastasis through PI3K/Akt/GSK3 beta/Snail signal pathway-mediated EMT process.	[Zhao, Guang-Xi; Weng, Shu-Qiang; Shen, Xi-Zhong; Dong, Ling] Fudan Univ, Zhongshan Hosp, Shanghai Inst Liver Dis, Dept Gastroenterol & Hepatol, Shanghai 200032, Peoples R China; [Zhao, Guang-Xi; Xu, Ying-Ying; Zhang, Si; Chen, She] Fudan Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Key Lab Glycoconjugate Res,Minist Publ Hlth, Shanghai 200032, Peoples R China; [Chen, Ying] Fudan Univ, Sch Basic Med Sci, Dept Physiol & Pathophysiol, Shanghai 200032, Peoples R China	Fudan University; Fudan University; Fudan University	Shen, XZ; Dong, L (corresponding author), Fudan Univ, Zhongshan Hosp, Shanghai Inst Liver Dis, Dept Gastroenterol & Hepatol, Shanghai 200032, Peoples R China.; Chen, S (corresponding author), Fudan Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Key Lab Glycoconjugate Res,Minist Publ Hlth, Shanghai 200032, Peoples R China.	shen.xizhong@zs-hospital.sh.cn; dong.ling@zs-hospital.sh.cn; shechen@fudan.edu.cn	zhang, si/AAG-9094-2021	zhang, Si/0000-0002-5682-4995	National Natural Science Foundation of China (NSFC) [81672334, 81772615, 81572686, 81772968, 81573423, 81770137, 81672720]; Shanghai Science and Technology Commission [15410710100, 16ZR1406100]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Shanghai Science and Technology Commission(Shanghai Science & Technology CommitteeScience & Technology Commission of Shanghai Municipality (STCSM))	This work was supported by the National Natural Science Foundation of China (NSFC) (81672334, 81772615, 81572686, 81772968, 81573423, 81770137, 81672720) and Shanghai Science and Technology Commission (15410710100, 16ZR1406100).	Abbey M, 2016, SCI REP-UK, V6, DOI 10.1038/srep20007; Agarwal E, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-145; Angelis D, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00122; Ann K, 1997, J BIOL CHEM, V272, P19637, DOI 10.1074/jbc.272.32.19637; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Tang BL, 2015, MOL MEMBR BIOL, V32, P120, DOI 10.3109/09687688.2015.1079934; Cao H, 2015, PATHOL RES PRACT, V211, P557, DOI 10.1016/j.prp.2015.05.010; Cao LQ, 2015, CANCER LETT, V359, P127, DOI 10.1016/j.canlet.2015.01.004; Chen L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0534-9; Chen T, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01024-2; Chen XF, 2012, MOL BIOL REP, V39, P3549, DOI 10.1007/s11033-011-1128-0; Garcia Z, 2006, EMBO J, V25, P4740, DOI 10.1038/sj.emboj.7601324; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Hahn S, 2013, EMBO J, V32, P3079, DOI 10.1038/emboj.2013.236; Hawk ET, 2005, J CLIN ONCOL, V23, P378, DOI 10.1200/JCO.2005.08.097; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; Hosono M, 2016, NEUROSCI LETT, V617, P232, DOI 10.1016/j.neulet.2016.02.035; Huang XT, 2018, CELL PHYSIOL BIOCHEM, V47, P590, DOI 10.1159/000490015; Huang YW, 2006, FEBS J, V273, P3248, DOI 10.1111/j.1742-4658.2006.05333.x; Im HJ, 2016, CANCER RES, V76, P1698, DOI 10.1158/0008-5472.CAN-15-2114; James DJ, 2009, P NATL ACAD SCI USA, V106, P17308, DOI 10.1073/pnas.0900755106; Do K, 2015, INVEST NEW DRUG, V33, P720, DOI 10.1007/s10637-015-0212-z; Koch H, 2000, BIOCHEM J, V349, P247, DOI 10.1042/0264-6021:3490247; Leipe DD, 2002, J MOL BIOL, V317, P41, DOI 10.1006/jmbi.2001.5378; Liu TT, 2011, ACTA BIOCH BIOPH SIN, V43, P542, DOI 10.1093/abbs/gmr044; Lu LL, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/5874127; Luo W, 2018, PHYTOTHER RES, V32, P2009, DOI 10.1002/ptr.6132; Mali AV, 2018, CANCER BIOL MED, V15, P137, DOI 10.20892/j.issn.2095-3941.2018.0012; Mathias RA, 2009, J PROTEOME RES, V8, P2827, DOI 10.1021/pr8010974; Miller S, 2011, NEURO-ONCOLOGY, V13, P866, DOI 10.1093/neuonc/nor070; Mundade Rasika, 2014, Oncoscience, V1, P400; Nagano K, 2015, INT J BIOCHEM CELL B, V62, P62, DOI 10.1016/j.biocel.2015.02.013; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pemberton JG, 2014, GEN COMP ENDOCR, V205, P268, DOI 10.1016/j.ygcen.2014.03.011; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Price TJ, 2014, LANCET ONCOL, V15, P569, DOI 10.1016/S1470-2045(14)70118-4; Rettig J, 2002, SCIENCE, V298, P781, DOI 10.1126/science.1075375; Rokavec M, 2014, J CLIN INVEST, V124, P1853, DOI 10.1172/JCI73531; Sadakata T, 2007, J HISTOCHEM CYTOCHEM, V55, P301, DOI 10.1369/jhc.6A7033.2006; Sanchez-Tillo E, 2012, CELL MOL LIFE SCI, V69, P3429, DOI 10.1007/s00018-012-1122-2; Shiozaki H, 1996, CANCER, V77, P1605, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1605::AID-CNCR4>3.3.CO;2-R; Smit MA, 2009, MOL CELL BIOL, V29, P3722, DOI 10.1128/MCB.01164-08; Tanaka T, 2017, J CELL PHYSIOL, V232, P939, DOI 10.1002/jcp.25619; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thuault S, 2008, J BIOL CHEM, V283, P33437, DOI 10.1074/jbc.M802016200; Vu T, 2017, CANCERS, V9, DOI 10.3390/cancers9120171; VanSaun MN, 2009, AM J PATHOL, V175, P355, DOI 10.2353/ajpath.2009.080703; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WALENT JH, 1992, CELL, V70, P765, DOI 10.1016/0092-8674(92)90310-9; Wang JM, 2015, ONCOTARGET, V6, P27427, DOI 10.18632/oncotarget.4861; Wang YD, 2018, EUR J PHARMACOL, V834, P45, DOI 10.1016/j.ejphar.2018.07.006; Wu LG, 2014, ANNU REV PHYSIOL, V76, P301, DOI 10.1146/annurev-physiol-021113-170305; Xu DC, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0547-4; Xue RY, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101626; Zhang Y, 2017, MOL CARCINOGEN, V56, P272, DOI 10.1002/mc.22491; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	57	17	19	0	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2019	38	23					4574	4589		10.1038/s41388-019-0740-7	http://dx.doi.org/10.1038/s41388-019-0740-7			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IB4KM	30742066				2022-12-28	WOS:000470240300010
J	Echizen, K; Horiuchi, K; Aoki, Y; Yamada, Y; Minamoto, T; Oshima, H; Oshima, M				Echizen, Kanae; Horiuchi, Keigo; Aoki, Yayoi; Yamada, Yoichi; Minamoto, Toshinari; Oshima, Hiroko; Oshima, Masanobu			NF-kappa B-induced NOX1 activation promotes gastric tumorigenesis through the expansion of SOX2-positive epithelial cells	ONCOGENE			English	Article							OXIDATIVE STRESS; ROS GENERATION; STEM; INFLAMMATION; EXPRESSION; PHOSPHORYLATION; DIFFERENTIATION; SURVIVAL; OXIDASES; STOMACH	We previously showed that NADPH oxidase organizer 1 (Noxol), a component of NADPH oxidase 1 (NOX1), is a TNF-alpha-induced tumor-promoting factor in gastric tumorigenesis. However, the mechanism of NOX1-induced reactive oxygen species (ROS) signaling for the gastric tumorigenesis has not been understood. Here, we showed that expression of NOX1 complex components, including Noxol, but not other NOX family members was significantly upregulated in both mouse models for gastritis and gastric tumors, which was associated with increased ROS levels. We also found that NF-kB directly regulated NOXO1 expression in TNF-a-stimulated gastric cancer cells, suggesting that inflammation induces NOX1 complex activation through TNF-alpha/NF-kappa B pathway. Notably, in situ hybridization indicated that Noxol mRNA was detected in proliferating cells of gastritis and gastric tumors, and pharmacological inhibition of NOX activity significantly suppressed the proliferation of MKN45 gastric cancer cells and gastric hyperplasia of K19-C2mE mice. These results suggest that NOX1/ROS signaling has an important role in increased proliferation of stomach epithelial cells in the inflamed mucosa. Moreover, we found that expression of SOX2, a marker of gastric epithelial stem cells, was increased by NOX1/ROS signaling. Furthermore, disruption of Noxol in K19-C2mE mice significantly suppressed gastritis-associated metaplastic hyperplasia, a potent preneoplastic lesion, which was associated with decreased number of SOX2-positive cells. These results indicate that inflammation-induced Noxol expression is responsible for development of metaplastic hyperplasia in the stomach through an increase in SOX2-expressing undifferentiated epithelial cells. Therefore, inhibition of the NOX1/ROS signaling pathway is a possible strategy for prevention and therapy for gastric cancer development.	[Echizen, Kanae; Horiuchi, Keigo; Aoki, Yayoi; Oshima, Hiroko; Oshima, Masanobu] Kanazawa Univ, Canc Res Inst, Div Genet, Kanazawa, Ishikawa 9201192, Japan; [Echizen, Kanae; Oshima, Masanobu] Japan Agcy Med Res & Dev, AMED, AMED CREST, Tokyo 1000004, Japan; [Yamada, Yoichi] Kanazawa Univ, Fac Elect & Comp Engn, Inst Sci & Engn, Kanazawa, Ishikawa 9201192, Japan; [Minamoto, Toshinari] Kanazawa Univ, Canc Res Inst, Div Translat & Clin Oncol, Kanazawa, Ishikawa 9208640, Japan; [Oshima, Hiroko; Oshima, Masanobu] Kanazawa Univ, WPI Nano Life Sci Inst, Kanazawa, Ishikawa 9201192, Japan	Kanazawa University; Kanazawa University; Kanazawa University; Kanazawa University	Oshima, M (corresponding author), Kanazawa Univ, Canc Res Inst, Div Genet, Kanazawa, Ishikawa 9201192, Japan.; Oshima, M (corresponding author), Japan Agcy Med Res & Dev, AMED, AMED CREST, Tokyo 1000004, Japan.; Oshima, M (corresponding author), Kanazawa Univ, WPI Nano Life Sci Inst, Kanazawa, Ishikawa 9201192, Japan.	oshimam@staff.kanazawa-u.ac.jp	Minamoto, Toshinari/D-8442-2015; Oshima, Masanobu/F-9958-2014	Minamoto, Toshinari/0000-0003-4168-996X; Oshima, Masanobu/0000-0002-3304-0004; Oshima, Hiroko/0000-0001-6855-4008	AMEDCREST [JP17gm0410014]; AMED [JP18ck0106259]; Japan Agency for Medical Research and Development, Japan [JP15H02362, JP15K18405]; Ministry of Education, Culture, Sports, Science and Technology of Japan; Takeda Foundation; Mitsubishi Foundation	AMEDCREST; AMED(Japan Agency for Medical Research and Development (AMED)); Japan Agency for Medical Research and Development, Japan(Japan Agency for Medical Research and Development (AMED)); Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Takeda Foundation(Takeda Science Foundation (TSF)); Mitsubishi Foundation	We thank Ayako Tsuda and Manami Watanabe for their technical assistance. This work was supported by AMEDCREST (JP17gm0410014) and AMED (JP18ck0106259), Japan Agency for Medical Research and Development, Japan; Grants-in-Aid for Scientific Research (A) (JP15H02362), and Grants-in-Aid for Young Scientists (B) (JP15K18405) from the Ministry of Education, Culture, Sports, Science and Technology of Japan; and Takeda Foundation and The Mitsubishi Foundation.	Adachi Y, 2008, ONCOGENE, V27, P4921, DOI 10.1038/onc.2008.133; Arnold K, 2011, CELL STEM CELL, V9, P317, DOI 10.1016/j.stem.2011.09.001; Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Block K, 2012, NAT REV CANCER, V12, P627, DOI 10.1038/nrc3339; Butcher LD, 2017, CELL MOL GASTROENTER, V3, P316, DOI 10.1016/j.jcmgh.2017.02.002; Debbabi M, 2013, FASEB J, V27, P1733, DOI 10.1096/fj.12-216432; Echizen K, 2016, CANCER SCI, V107, P391, DOI 10.1111/cas.12901; El-Omar EM, 2003, GASTROENTEROLOGY, V124, P1193, DOI 10.1016/S0016-5085(03)00157-4; Goldenring JR, 2006, AM J PHYSIOL-GASTR L, V291, pG999, DOI 10.1152/ajpgi.00187.2006; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Joo JH, 2016, CANCER RES, V76, P855, DOI 10.1158/0008-5472.CAN-15-1512; Kamata T, 2009, CANCER SCI, V100, P1382, DOI 10.1111/j.1349-7006.2009.01207.x; Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002; Kennedy CL, 2014, ONCOGENE, V33, P2540, DOI 10.1038/onc.2013.205; Machado JC, 2003, GASTROENTEROLOGY, V125, P364, DOI 10.1016/S0016-5085(03)00899-0; Maeda Y, 2016, CANCER PREV RES, V9, P253, DOI 10.1158/1940-6207.CAPR-15-0315; Morgan MJ, 2011, CELL RES, V21, P103, DOI 10.1038/cr.2010.178; Morgan MJ, 2010, MOL CELLS, V30, P1, DOI 10.1007/s10059-010-0105-0; Myant KB, 2013, CELL STEM CELL, V12, P761, DOI 10.1016/j.stem.2013.04.006; Oshima H, 2014, ONCOGENE, V33, P3820, DOI 10.1038/onc.2013.356; Oshima H, 2004, EMBO J, V23, P1669, DOI 10.1038/sj.emboj.7600170; Oshima H, 2006, GASTROENTEROLOGY, V131, P1086, DOI 10.1053/j.gastro.2006.07.014; Oshima H, 2011, CANCER SCI, V102, P713, DOI 10.1111/j.1349-7006.2011.01847.x; Oshima M, 2005, CANCER RES, V65, P9147, DOI 10.1158/0008-5472.CAN-05-1936; Park MT, 2014, CELL DEATH DIFFER, V21, P1185, DOI 10.1038/cdd.2014.34; Polk DB, 2010, NAT REV CANCER, V10, P403, DOI 10.1038/nrc2857; Ristimaki A, 1997, CANCER RES, V57, P1276; Roy K, 2015, CLIN SCI, V128, P863, DOI 10.1042/CS20140542; Sarkar A, 2016, CELL REP, V16, P1929, DOI 10.1016/j.celrep.2016.07.034; Scheeren FA, 2014, NAT CELL BIOL, V16, P1238, DOI 10.1038/ncb3058; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Tan P, 2015, GASTROENTEROLOGY, V149, P1153, DOI 10.1053/j.gastro.2015.05.059; Terashima M, 2012, CLIN CANCER RES, V18, P5992, DOI 10.1158/1078-0432.CCR-12-1318; Tye H, 2012, CANCER CELL, V22, P466, DOI 10.1016/j.ccr.2012.08.010; Van Cutsem E, 2016, LANCET, V388, P2654, DOI 10.1016/S0140-6736(16)30354-3; Wang D, 2010, ONCOGENE, V29, P781, DOI 10.1038/onc.2009.421	38	35	36	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2019	38	22					4250	4263		10.1038/s41388-019-0702-0	http://dx.doi.org/10.1038/s41388-019-0702-0			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IA1RB	30700829	Green Published, hybrid			2022-12-28	WOS:000469339100004
J	Li, ZP; Jiao, XM; Di Sante, G; Ertel, A; Casimiro, MC; Wang, M; Katiyar, S; Ju, XM; Klopfenstein, DV; Tozeren, A; Dampier, W; Chepelev, I; Jeltsch, A; Pestell, RG				Li, Zhiping; Jiao, Xuanmao; Di Sante, Gabriele; Ertel, Adam; Casimiro, Mathew C.; Wang, Min; Katiyar, Sanjay; Ju, Xiaoming; Klopfenstein, D., V; Tozeren, Aydin; Dampier, William; Chepelev, Iouri; Jeltsch, Albert; Pestell, Richard G.			Cyclin D1 integrates G9a-mediated histone methylation	ONCOGENE			English	Article							NUCLEAR LAMINA INTERACTIONS; METHYLTRANSFERASE G9A; LYSINE METHYLTRANSFERASE; CHROMOSOMAL INSTABILITY; NEGATIVE REGULATION; CHROMATIN DYNAMICS; PROTEIN FAMILIES; DI-METHYLATION; CELLS; CANCER	Lysine methylation of histones and non-histone substrates by the SET domain containing protein lysine methyltransferase (KMT) G9a/EHMT2 governs transcription contributing to apoptosis, aberrant cell growth, and pluripotency. The positioning of chromosomes within the nuclear three-dimensional space involves interactions between nuclear lamina (NL) and the lamina-associated domains (LAD). Contact of individual LADs with the NL are dependent upon H3K9me2 introduced by G9a. The mechanisms governing the recruitment of G9a to distinct subcellular sites, into chromatin or to LAD, is not known. The cyclin D1 gene product encodes the regulatory subunit of the holoenzyme that phosphorylates pRB and NRF1 thereby governing cell-cycle progression and mitochondrial metabolism. Herein, we show that cyclin D1 enhanced H3K9 dimethylation though direct association with G9a. Endogenous cyclin D1 was required for the recruitment of G9a to target genes in chromatin, for G9a-induced H3K9me2 of histones, and for NL-LAD interaction. The finding that cyclin D1 is required for recruitment of G9a to target genes in chromatin and for H3K9 dimethylation, identifies a novel mechanism coordinating protein methylation.	[Li, Zhiping; Jiao, Xuanmao; Di Sante, Gabriele; Casimiro, Mathew C.; Wang, Min; Katiyar, Sanjay; Pestell, Richard G.] Penn Biotechnol Ctr, Baruch S Blumberg Inst, Penn Canc & Regenerat Med Res Ctr, 3805 Old Easton Rd, Doylestown, PA 18902 USA; [Ertel, Adam; Ju, Xiaoming] Thomas Jefferson Univ, Dept Canc Biol, 233 South 10th St, Philadelphia, PA 19107 USA; [Klopfenstein, D., V; Tozeren, Aydin] Drexel Univ, Ctr Integrated Bioinformat, Sch Biomed Engn, Philadelphia, PA 19104 USA; [Dampier, William] Drexel Univ, Dept Microbiol & Immunol, Coll Med, Philadelphia, PA 19104 USA; [Chepelev, Iouri] Cincinnati Childrens Hosp Med Ctr, Ctr Autoimmune Genom & Etiol, Cincinnati, OH 45229 USA; [Chepelev, Iouri] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45267 USA; [Jeltsch, Albert] Univ Stuttgart, Inst Biochem & Tech Biochem, Dept Biochem, Allmandring 31, D-70569 Stuttgart, Germany; [Pestell, Richard G.] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore 637551, Singapore	Jefferson University; Drexel University; Drexel University; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of Stuttgart; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Pestell, RG (corresponding author), Penn Biotechnol Ctr, Baruch S Blumberg Inst, Penn Canc & Regenerat Med Res Ctr, 3805 Old Easton Rd, Doylestown, PA 18902 USA.; Pestell, RG (corresponding author), Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore 637551, Singapore.	richard.pestell@bblumberg.org	Jeltsch, Albert/O-7404-2014	Jeltsch, Albert/0000-0001-6113-9290; Chepelev, Iouri/0000-0002-2121-8805; Klopfenstein, DV/0000-0003-0161-7603	Breast Cancer Research Foundation; Pennsylvania Department of Health; Dr. Ralph and Marian C. Falk Medical Research Trust;  [R01CA70896];  [R01CA75503];  [R01CA86072]	Breast Cancer Research Foundation; Pennsylvania Department of Health; Dr. Ralph and Marian C. Falk Medical Research Trust; ; ; 	This work was supported in part by R01CA70896, R01CA75503, and R01CA86072 (RGP). This project was funded in part from the Dr. Ralph and Marian C. Falk Medical Research Trust (RGP), a grant from the Breast Cancer Research Foundation (RGP), and a grant from the Pennsylvania Department of Health (RGP).	Aggarwal P, 2010, CANCER CELL, V18, P329, DOI 10.1016/j.ccr.2010.08.012; Amendola M, 2015, EMBO REP, V16, P610, DOI 10.15252/embr.201439789; Banaszynski LA, 2006, CELL, V126, P995, DOI 10.1016/j.cell.2006.07.025; Bizen N, 2014, STEM CELLS, V32, P1602, DOI 10.1002/stem.1613; Casimiro MC, 2015, ONCOTARGET, V6, P8525, DOI 10.18632/oncotarget.3267; Casimiro MC, 2013, MOL ENDOCRINOL, V27, P1415, DOI 10.1210/me.2013-1065; Casimiro MC, 2012, J CLIN INVEST, V122, P833, DOI 10.1172/JCI60256; Chen WL, 2017, CURR CANCER DRUG TAR, V17, P555, DOI 10.2174/1568009616666160512145303; Cho HS, 2011, NEOPLASIA, V13, P676, DOI 10.1593/neo.11512; Collins RE, 2005, J BIOL CHEM, V280, P5563, DOI 10.1074/jbc.M410483200; Collins R, 2010, NUCLEIC ACIDS RES, V38, P3503, DOI 10.1093/nar/gkq081; Czimmerer Z, 2018, IMMUNITY, V48, P75, DOI 10.1016/j.immuni.2017.12.010; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; Deimling S.J., 2017, NEUROGENESIS AUSTIN, V4; Ding J, 2013, CELL METAB, V18, P896, DOI 10.1016/j.cmet.2013.11.004; Esteve PO, 2006, GENE DEV, V20, P3089, DOI 10.1101/gad.1463706; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Fang TC, 2012, J EXP MED, V209, P661, DOI 10.1084/jem.20112343; Fu MF, 2005, J BIOL CHEM, V280, P16934, DOI 10.1074/jbc.M500403200; Fu MF, 2005, J BIOL CHEM, V280, P29728, DOI 10.1074/jbc.M503188200; Gong Z, 2018, GENET MOL BIOL, V41, P488, DOI [10.1590/1678-4685-GMB-2017-0164, 10.1590/1678-4685-gmb-2017-0164]; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Huang J, 2010, J BIOL CHEM, V285, P9636, DOI 10.1074/jbc.M109.062588; Huang TH, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.65; Hulit J, 2004, MOL CELL BIOL, V24, P7598, DOI 10.1128/MCB.24.17.7598-7611.2004; Ju XM, 2014, CANCER RES, V74, P508, DOI 10.1158/0008-5472.CAN-13-1313; Kind J, 2015, CELL, V163, P134, DOI 10.1016/j.cell.2015.08.040; Kind J, 2013, CELL, V153, P178, DOI 10.1016/j.cell.2013.02.028; Kubicek S, 2007, MOL CELL, V25, P473, DOI 10.1016/j.molcel.2007.01.017; Lee JS, 2010, MOL CELL, V39, P71, DOI 10.1016/j.molcel.2010.06.008; Li Y, 2016, NUCLEIC ACIDS RES, V44, P7173, DOI 10.1093/nar/gkw327; Li ZP, 2006, MOL CELL BIOL, V26, P4240, DOI 10.1128/MCB.02124-05; Li ZP, 2010, CANCER RES, V70, P8802, DOI 10.1158/0008-5472.CAN-10-0312; Lindsay J, 2008, CTS-CLIN TRANSL SCI, V1, P107, DOI 10.1111/j.1752-8062.2008.00041.x; Lukaszewicz AI, 2011, P NATL ACAD SCI USA, V108, P11632, DOI 10.1073/pnas.1106230108; Marampon F, 2008, MOL BIOL CELL, V19, P2566, DOI 10.1091/mbc.E06-12-1110; Mi HY, 2005, NUCLEIC ACIDS RES, V33, pD284, DOI 10.1093/nar/gki078; Mozzetta C, 2014, MOL CELL, V53, P277, DOI 10.1016/j.molcel.2013.12.005; Nishio H, 2004, P NATL ACAD SCI USA, V101, P11257, DOI 10.1073/pnas.0401343101; Nozawa RS, 2010, NAT CELL BIOL, V12, P719, DOI 10.1038/ncb2075; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Peric-Hupkes D, 2010, COLD SH Q B, V75, P517, DOI 10.1101/sqb.2010.75.014; Peric-Hupkes D, 2010, MOL CELL, V38, P603, DOI 10.1016/j.molcel.2010.03.016; Pestell RG, 2013, AM J PATHOL, V183, P3, DOI 10.1016/j.ajpath.2013.03.001; Plaisier SB, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq636; Prokocimer M, 2009, J CELL MOL MED, V13, P1059, DOI [10.1111/j.1582-4934.2009.00676.x, 10.1111/j.1582-4934.2008.00676.x]; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Ramagopalan SV, 2010, GENOME RES, V20, P1352, DOI 10.1101/gr.107920.110; Rathert P, 2008, NAT CHEM BIOL, V4, P344, DOI 10.1038/nchembio.88; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Reutens AT, 2001, MOL ENDOCRINOL, V15, P797, DOI 10.1210/me.15.5.797; Roopra A, 2004, MOL CELL, V14, P727, DOI 10.1016/j.molcel.2004.05.026; Sakamaki T, 2006, MOL CELL BIOL, V26, P5449, DOI 10.1128/MCB.02074-05; Sampath SC, 2007, MOL CELL, V27, P596, DOI 10.1016/j.molcel.2007.06.026; Shambaugh GE, 1996, J NEUROPATH EXP NEUR, V55, P1009, DOI 10.1097/00005072-199609000-00008; Shinkai Y, 2011, GENE DEV, V25, P781, DOI 10.1101/gad.2027411; Stahl M, 2006, CANCER RES, V66, P7562, DOI 10.1158/0008-5472.CAN-06-0974; Strickfaden H, 2010, NUCLEUS-PHILA, V1, P284, DOI 10.4161/nucl.1.3.11969; Tachibana M, 2005, GENE DEV, V19, P815, DOI 10.1101/gad.1284005; Takahashi A, 2012, MOL CELL, V45, P123, DOI 10.1016/j.molcel.2011.10.018; Takawa M, 2011, CANCER SCI, V102, P1298, DOI 10.1111/j.1349-7006.2011.01958.x; Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403; Towbin BD, 2012, CELL, V150, P934, DOI 10.1016/j.cell.2012.06.051; Walter J, 2003, J CELL BIOL, V160, P685, DOI 10.1083/jcb.200211103; Wang CG, 2003, MOL CELL BIOL, V23, P6159, DOI 10.1128/MCB.23.17.6159-6173.2003; Wang CG, 2006, P NATL ACAD SCI USA, V103, P11567, DOI 10.1073/pnas.0603363103; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wozniak RJ, 2007, ONCOGENE, V26, P77, DOI 10.1038/sj.onc.1209763; Zullo JM, 2012, CELL, V149, P1474, DOI 10.1016/j.cell.2012.04.035; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	71	16	17	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2019	38	22					4232	4249		10.1038/s41388-019-0723-8	http://dx.doi.org/10.1038/s41388-019-0723-8			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IA1RB	30718920	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000469339100003
J	Cui, TT; Bell, EH; McElroy, J; Becker, AP; Gulati, PM; Geurts, M; Mladkova, N; Gray, A; Liu, K; Yang, LL; Liu, ZY; Fleming, JL; Haque, SJ; Barnholtz-Sloan, JS; Ligon, KL; Beroukhim, R; Robe, P; Chakravarti, A				Cui, Tiantian; Bell, Erica H.; McElroy, Joseph; Becker, Aline Paixao; Gulati, Pooja Manchanda; Geurts, Marjolein; Mladkova, Nikol; Gray, Ashley; Liu, Kevin; Yang, Linlin; Liu, Ziyan; Fleming, Jessica L.; Haque, S. Jaharul; Barnholtz-Sloan, Jill S.; Ligon, Keith L.; Beroukhim, Rameen; Robe, Pierre; Chakravarti, Arnab			miR-4516 predicts poor prognosis and functions as a novel oncogene via targeting PTPN14 in human glioblastoma	ONCOGENE			English	Article							ORGAN SIZE CONTROL; MICRORNA EXPRESSION; HIPPO PATHWAY; PROLIFERATION; CANCER; YAP; TUMORIGENICITY; TEMOZOLOMIDE; HOMEOSTASIS; APOPTOSIS	Glioblastomas (GBMs) are the most aggressive primary brain tumors, with an average survival of less than 15 months. Therefore, there is a critical need to develop novel therapeutic strategies for GBM. This study aimed to assess the prognostic value of miR-4516 and investigate its oncogenic functions and the underlying cellular and molecular mechanisms in GBM. To determine the correlation between miR-4516 expression and overall survival of patients with GBM, total RNAs were isolated from 268 FFPE tumor samples, miR expression was assayed (simultaneously) using the nCounter human miRNA v3a assay followed by univariable and multivariable survival analyses. Further, in vitro and in vivo studies were conducted to define the role of miR-4516 in GBM tumorigenesis and the underlying molecular mechanisms. Upon multivariable analysis, miR-4516 was correlated with poor prognosis in GBM patients (HR = 1.49, 95%CI: 1.12-1.99, P = 0.01). Interestingly, the significance of miR-4516 was retained including MGMT methylation status. Overexpression of miR-4516 significantly enhanced cell proliferation and invasion of GBM cells both in vitro and in vivo. While conducting downstream targeting studies, we found that the tumor-promoting function of miR-4516, in part, was mediated by direct targeting of PTPN14 (protein tyrosine phosphatase, non-receptor type 14) which, in turn, regulated the Hippo pathway in GBM. Taken together, our data suggest that miR-4516 represents an independent negative prognostic factor in GBM patients and acts as a novel oncogene in GBM, which regulates the PTPN14/Hippo pathway. Thus, this newly identified miR-4516 may serve as a new potential therapeutic target for GBM treatment.	[Cui, Tiantian; Bell, Erica H.; Becker, Aline Paixao; Gulati, Pooja Manchanda; Yang, Linlin; Liu, Ziyan; Fleming, Jessica L.; Haque, S. Jaharul; Chakravarti, Arnab] Arthur G James Hosp, Dept Radiat Oncol, Ohio State Comprehens Canc Ctr, Columbus, OH 43210 USA; [McElroy, Joseph] Ohio State Univ, Dept Biomed Informat, Ctr Biostat, Columbus, OH 43210 USA; [Geurts, Marjolein; Robe, Pierre] Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Dept Neurol & Neurosurg, Utrecht, Netherlands; [Mladkova, Nikol] Columbia Univ, Dept Internal Med, Div Nephrol, New York, NY 10032 USA; [Gray, Ashley] Ohio State Univ, Columbus, OH 43210 USA; [Liu, Kevin] Ohio State Univ, Coll Med, Columbus, OH 43210 USA; [Barnholtz-Sloan, Jill S.] Case Western Reserve Univ, Sch Med, Case Comprehens Canc Ctr, Cleveland, OH USA; [Ligon, Keith L.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Ligon, Keith L.; Beroukhim, Rameen] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Beroukhim, Rameen] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Utrecht University; Utrecht University Medical Center; Columbia University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Case Western Reserve University; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute	Chakravarti, A (corresponding author), Arthur G James Hosp, Dept Radiat Oncol, Ohio State Comprehens Canc Ctr, Columbus, OH 43210 USA.	Chakravarti.7@osu.edu	Becker, Aline/AAD-2209-2021; Geurts, Marjolein/AAP-4148-2020; Barnholtz-Sloan, Jill/A-4817-2011	Barnholtz-Sloan, Jill/0000-0001-6190-9304	National Cancer Institute [R01CA169368, R01CA11522358, R01CA1145128, R01CA108633, R01CA188228, 1RC2CA148190, U10CA180850-01]; Brain Tumor Funders Collaborative Grant; Ohio State University Comprehensive Cancer Center Award; NATIONAL CANCER INSTITUTE [P30CA016058, U10CA180850, UG1CA233331, R01CA188228, R01CA169368] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Brain Tumor Funders Collaborative Grant; Ohio State University Comprehensive Cancer Center Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by National Cancer Institute [R01CA169368 (to A.C.), R01CA11522358 (to A.C.), R01CA1145128 (to A.C.), R01CA108633 (to A.C.), R01CA188228 (to A.C., R.B., K.L., and J.B.), 1RC2CA148190 (to A.C.), and U10CA180850-01 (to A.C.)]; A Brain Tumor Funders Collaborative Grant (to A.C.); Ohio State University Comprehensive Cancer Center Award (to A.C.).	Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005; Bady P, 2012, ACTA NEUROPATHOL, V124, P547, DOI 10.1007/s00401-012-1016-2; Bell EH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118745; Belle L, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005547; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Borrelli N, 2017, MODERN PATHOL, V30, P39, DOI [10.1038/nnodpathol.2016.157, 10.1038/modpathol.2016.157]; Chang WH, 2016, TUMOR BIOL, V37, P14813, DOI 10.1007/s13277-016-5295-4; Chowdhari S, 2014, J CELL PHYSIOL, V229, P1630, DOI 10.1002/jcp.24608; Cui TT, 2015, ONCOTARGET, V6, P10060, DOI 10.18632/oncotarget.3542; Cui TT, 2012, CARCINOGENESIS, V33, P2326, DOI 10.1093/carcin/bgs273; Du WZ, 2015, NEURO-ONCOLOGY, V17, P243, DOI 10.1093/neuonc/nou217; Fortin JP, 2017, BIOINFORMATICS, V33, P558, DOI 10.1093/bioinformatics/btw691; Garzon R, 2006, TRENDS MOL MED, V12, P580, DOI 10.1016/j.molmed.2006.10.006; Han CH, 2014, MOL CANCER RES, V12, P784, DOI 10.1158/1541-7786.MCR-13-0638; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Hsu SD, 2011, NUCLEIC ACIDS RES, V39, pD163, DOI 10.1093/nar/gkq1107; Laczmanska I, 2011, ACTA BIOCHIM POL, V58, P467; Lenos K, 2012, CANCER RES, V72, P4074, DOI 10.1158/0008-5472.CAN-12-0215; Li SW, 2017, NEURO-ONCOLOGY, V19, P55, DOI 10.1093/neuonc/now129; Liu X, 2013, ONCOGENE, V32, P1266, DOI 10.1038/onc.2012.147; Losman JA, 2013, GENE DEV, V27, P836, DOI 10.1101/gad.217406.113; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Maksimovic J, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-6-r44; McNamara Mairead G, 2013, Cancers (Basel), V5, P1103, DOI 10.3390/cancers5031103; Michaloglou C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061916; Ostrom QT, 2015, NEURO-ONCOLOGY, V17, P1, DOI [10.1093/neuonc/nov189, 10.1093/neuonc/noaa200, 10.1093/neuonc/noab200]; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Shenouda SK, 2009, CANCER METAST REV, V28, P369, DOI 10.1007/s10555-009-9188-5; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Team RC, 2016, R LANG ENV STAT COMP; Varelas X, 2014, DEVELOPMENT, V141, P1614, DOI 10.1242/dev.102376; Wang LJ, 2015, ONCOTARGET, V6, P5932, DOI 10.18632/oncotarget.3465; Wang WQ, 2012, GENE DEV, V26, P1959, DOI 10.1101/gad.192955.112; Wilson KE, 2014, J BIOL CHEM, V289, P23693, DOI 10.1074/jbc.M113.534701; Wong N, 2015, NUCLEIC ACIDS RES, V43, pD146, DOI 10.1093/nar/gku1104; Xia HP, 2013, NEURO-ONCOLOGY, V15, P413, DOI 10.1093/neuonc/nos296; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210; Zougman A, 2013, EUR J CANCER, V49, P531, DOI 10.1016/j.ejca.2012.07.031	41	37	37	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2019	38	16					2923	2936		10.1038/s41388-018-0601-9	http://dx.doi.org/10.1038/s41388-018-0601-9			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU3IV	30559405	Green Accepted			2022-12-28	WOS:000465167600004
J	Zhao, ZQ; Hao, DP; Wang, L; Li, JJ; Meng, Y; Li, PP; Wang, Y; Zhang, C; Zhou, HS; Gardner, K; Di, LJ				Zhao, Zhiqiang; Hao, Dapeng; Wang, Li; Li, Jingjing; Meng, Yuan; Li, Peipei; Wang, Yuan; Zhang, Chao; Zhou, Haisheng; Gardner, Kevin; Di, Li-Jun			CtBP promotes metastasis of breast cancer through repressing cholesterol and activating TGF-beta signaling	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; TERMINAL BINDING-PROTEIN; COREPRESSOR CTBP; TRANSCRIPTIONAL REGULATION; E-CADHERIN; CELLS; PROGRESSION; EXPRESSION; RECEPTOR; SURVIVAL	Metastasis is the process through which the primary cancer cells spread beyond the primary tumor and disseminate to other organs. Most cancer patients die of metastatic disease. EMT is proposed to be the initial event associated with cancer metastasis and how it occurred is still a mystery. CtBP is known as a co-repressor abundantly expressed in many types of cancer and regulates genes involved in cancer initiation, progression, and metastasis. We found that CtBP regulates intracellular cholesterol homeostasis in breast cancer cells by forming a complex with ZEB1 and transcriptionally repressing SREBF2 expression. Importantly, CtBP repression of intracellular cholesterol abundance leads to increased EMT and cell migration. The reason is that cholesterol negatively regulates the stability of TGF-beta receptors on the cell membrane. Interestingly, TGF-beta is also capable of reducing intracellular cholesterol relying on the increased recruitment of ZEB1 and CtBP complex to SREBF2 promoter. Thus, we propose a feedback loop formed by CtBP, cholesterol, and TGF-beta signaling pathway, through which TGF-beta triggers the cascade that mobilizes the cancer cells for metastasis. Consistently, the intravenous injection of breast cancer cells with ectopically CtBP expression show increased lung metastasis depending on the reduction of intracellular cholesterol. Finally, we analyzed the public breast cancer datasets and found that CtBP expression negatively correlates with SREBF2 and HMGCR expressions. High expression of CtBP and low expression of SREBF2 and HMGCR significantly correlates with high EMT of the primary tumors.	[Zhao, Zhiqiang; Hao, Dapeng; Wang, Li; Li, Jingjing; Meng, Yuan; Li, Peipei; Wang, Yuan; Zhang, Chao; Di, Li-Jun] Univ Macau, Fac Hlth Sci, Canc Ctr, Macau, Peoples R China; [Wang, Li] Univ Macau, Fac Hlth Sci, Metabol Core, Macau, Peoples R China; [Zhou, Haisheng] Anhui Med Univ, Dept Biochem & Mol Biol, Hefei, Anhui, Peoples R China; [Gardner, Kevin] Columbia Univ, Dept Pathol & Cell Biol, Irving Med Ctr, New York, NY USA; [Hao, Dapeng] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA	University of Macau; University of Macau; Anhui Medical University; Columbia University; NewYork-Presbyterian Hospital; Baylor College of Medicine	Di, LJ (corresponding author), Univ Macau, Fac Hlth Sci, Canc Ctr, Macau, Peoples R China.	lijundi@um.edu.mo	Li, Jing/GYU-5036-2022		Science and Technology Development Fund (FDCT) of Macao SAR [FDCT 014/2018/A1]; Multi-Year Research Grant from the University of Macau [MYRG2018-00158-FHS, MYRG2016-00251-FHS]; National Natural Science Foundation of China [31701153, 81772980, 81372911, 81772909]	Science and Technology Development Fund (FDCT) of Macao SAR; Multi-Year Research Grant from the University of Macau; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	DL is supported by the Science and Technology Development Fund (FDCT) of Macao SAR (FDCT 014/2018/A1), the Multi-Year Research Grant from the University of Macau (MYRG2018-00158-FHS), and National Natural Science Foundation of China (grant no. 81772980). LW is supported by the Multi-Year Research Grant from the University of Macau (MYRG2016-00251-FHS). HZ is supported by National Natural Science Foundation of China (grant no. 81372911, 81772909). DH is supported by National Natural Science Foundation of China (grant no. 31701153).	Ahmad A, 2011, CANCER RES, V71, P3400, DOI 10.1158/0008-5472.CAN-10-0965; Barcelo-Coblijn G, 2011, P NATL ACAD SCI USA, V108, P19569, DOI 10.1073/pnas.1115484108; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bizama C, 2014, INT J CANCER, V134, P755, DOI 10.1002/ijc.28405; Bjarnadottir O, 2015, CLIN CANCER RES, V21, P3402, DOI 10.1158/1078-0432.CCR-14-1403; Cardwell CR, 2014, J CLIN ONCOL, V32, P3177, DOI 10.1200/JCO.2013.54.4569; Chang TI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109628; Chen CL, 2008, J CELL PHYSIOL, V215, P223, DOI 10.1002/jcp.21303; Chen CL, 2007, J CELL SCI, V120, P3509, DOI 10.1242/jcs.006916; Chen YG, 2009, CELL RES, V19, P58, DOI 10.1038/cr.2008.315; Chiarugi P, 2008, BIOCHEM PHARMACOL, V76, P1352, DOI 10.1016/j.bcp.2008.07.023; Chinnadurai G, 2009, CANCER RES, V69, P731, DOI 10.1158/0008-5472.CAN-08-3349; Debiais- Delpech C, 2013, UROL ONCOL, V32, P426; Deng H, 2013, J INVEST DERMATOL, V133, P1294, DOI 10.1038/jid.2012.487; Deng Y, 2012, MOL CARCINOGEN, V51, P500, DOI 10.1002/mc.20813; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Di LJ, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2438; Di LJ, 2010, NAT STRUCT MOL BIOL, V17, P1406, DOI 10.1038/nsmb.1941; Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022; Drabsch Y, 2012, CANCER METAST REV, V31, P553, DOI 10.1007/s10555-012-9375-7; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Funasaka T, 2009, CANCER RES, V69, P5349, DOI 10.1158/0008-5472.CAN-09-0488; Furusawa T, 1999, MOL CELL BIOL, V19, P8581; Ginestier C, 2012, STEM CELLS, V30, P1327, DOI 10.1002/stem.1122; Goluszko P, 2005, INFECT IMMUN, V73, P7791, DOI 10.1128/IAI.73.12.7791-7796.2005; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Halldorsson S, 2017, CANCER LETT, V396, P117, DOI 10.1016/j.canlet.2017.03.019; Hamabe A, 2014, P NATL ACAD SCI USA, V111, P15526, DOI 10.1073/pnas.1407717111; Hamada F, 2004, DEV CELL, V7, P677, DOI 10.1016/j.devcel.2004.08.022; Hayes S, 2002, J CELL BIOL, V158, P1239, DOI 10.1083/jcb.200204088; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Izutsu K, 2001, BLOOD, V97, P2815, DOI 10.1182/blood.V97.9.2815; Jacobs EJ, 2011, CANCER RES, V71, P1763, DOI 10.1158/0008-5472.CAN-10-2953; Jiang FJ, 2016, BIOCHEM BIOPH RES CO, V469, P985, DOI 10.1016/j.bbrc.2015.12.078; Jiang L, 2015, ONCOGENE, V34, P3908, DOI 10.1038/onc.2014.321; Kojima K, 1993, Nagoya J Med Sci, V56, P1; Kuzu OF, 2016, CANCER RES, V76, P2063, DOI 10.1158/0008-5472.CAN-15-2613; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lee S, 2011, BBA-MOL CELL RES, V1813, P713, DOI 10.1016/j.bbamcr.2011.01.035; Lin X, 2003, MOL CELL BIOL, V23, P9081, DOI 10.1128/MCB.23.24.9081-9093.2003; Liu KY, 2017, INT J ONCOL, V50, P252, DOI 10.3892/ijo.2016.3774; Liu Y, 2012, CANCER SCI, V103, P1420, DOI 10.1111/j.1349-7006.2012.02347.x; Mahammad S, 2015, METHODS MOL BIOL, V1232, P91, DOI 10.1007/978-1-4939-1752-5_8; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Maxfield FR, 2002, J CLIN INVEST, V110, P891, DOI 10.1172/JCI200216500; Maxfield FR, 2012, METHOD CELL BIOL, V108, P367, DOI 10.1016/B978-0-12-386487-1.00017-1; Morrison CD, 2013, CANCER LETT, V341, P30, DOI 10.1016/j.canlet.2013.02.048; Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349-7006.2007.00550.x; Nath A, 2015, SCI REP-UK, V5, DOI 10.1038/srep14752; Nelson ER, 2013, SCIENCE, V342, P1094, DOI 10.1126/science.1241908; Paliwal Seema, 2012, Genes Cancer, V3, P481, DOI 10.1177/1947601912463695; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pena C, 2006, INT J CANCER, V119, P2098, DOI 10.1002/ijc.22083; Phelps RA, 2009, CELL, V137, P623, DOI 10.1016/j.cell.2009.02.037; Postigo AA, 2003, EMBO J, V22, P2453, DOI 10.1093/emboj/cdg226; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; Renkawitz J, 2009, NAT CELL BIOL, V11, P1438, DOI 10.1038/ncb1992; Rios Garcia M, 2017, CELL METAB, V26; Sanchez-Tillo E, 2012, CELL MOL LIFE SCI, V69, P3429, DOI 10.1007/s00018-012-1122-2; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Steeg PS, 2016, NAT REV CANCER, V16, P201, DOI 10.1038/nrc.2016.25; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tan TZ, 2014, EMBO MOL MED, V6, P1279, DOI 10.15252/emmm.201404208; Turajlic S, 2016, SCIENCE, V352, P169, DOI 10.1126/science.aaf2784; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; van Grunsven LA, 2003, J BIOL CHEM, V278, P26135, DOI 10.1074/jbc.M300597200; Wang L, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.587; Wang R, 2012, NEOPLASIA, V14, P905, DOI 10.1593/neo.121192; Warita K, 2014, SCI REP-UK, V4, DOI 10.1038/srep07593; Yang T, 2013, CELL PHYSIOL BIOCHEM, V31, P863, DOI 10.1159/000350104; Yang WH, 2012, NAT CELL BIOL, V14, P366, DOI 10.1038/ncb2455; Zadran S, 2014, P NATL ACAD SCI USA, V111, P13235, DOI 10.1073/pnas.1414714111; Zhang QH, 2007, P NATL ACAD SCI USA, V104, P829, DOI 10.1073/pnas.0610590104; Zhang QH, 2006, P NATL ACAD SCI USA, V103, P9029, DOI 10.1073/pnas.0603269103; Zhang XL, 2013, ONCOL REP, V30, P809, DOI 10.3892/or.2013.2537; Zhao WN, 2016, CANCER RES, V76, P2037, DOI 10.1158/0008-5472.CAN-15-1970; Zhou HJ, 2014, BIOMATERIALS, V35, P1597, DOI 10.1016/j.biomaterials.2013.11.020; Zhuang LY, 2005, J CLIN INVEST, V115, P959	81	46	48	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2019	38	12					2076	2091		10.1038/s41388-018-0570-z	http://dx.doi.org/10.1038/s41388-018-0570-z			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP6UR	30442980				2022-12-28	WOS:000461822600006
J	Azad, T; Nouri, K; van Rensburg, HJJ; Maritan, SM; Wu, LQ; Hao, YW; Montminy, T; Yu, JH; Khanal, P; Mulligan, LM; Yang, XL				Azad, Taha; Nouri, Kazem; van Rensburg, Helena J. Janse; Maritan, Sarah M.; Wu, Liqing; Hao, Yawei; Montminy, Tess; Yu, Jihang; Khanal, Prem; Mulligan, Lois M.; Yang, Xiaolong			A gain-of-functional screen identifies the Hippo pathway as a central mediator of receptor tyrosine kinases during tumorigenesis	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; NUCLEAR TRANSLOCATION; CELL-PROLIFERATION; CONTACT INHIBITION; RET PROTOONCOGENE; PANCREATIC-CANCER; YAP; GROWTH; DROSOPHILA; APOPTOSIS	The Hippo pathway has emerged as a key signaling pathway that regulates various biological functions. Dysregulation of the Hippo pathway has been implicated in a broad range of human cancer types. While a number of stimuli affecting the Hippo pathway have been reported, its upstream kinase and extracellular regulators remain largely unknown. Here we performed the first comprehensive gain-of-functional screen for receptor tyrosine kinases (RTKs) regulating the Hippo pathway using an RTK overexpression library and a Hippo signaling activity biosensor. Surprisingly, we found that the majority of RTKs could regulate the Hippo signaling activity. We further characterized several of these novel relationships [TAM family members (TYRO3, AXL, METRK), RET, and FGFR family members (FGFR1 and FGFR2)] and found that the Hippo effectors YAP/TAZ are central mediators of the tumorigenic phenotypes (e.g., increased cell proliferation, transformation, increased cell motility, and angiogenesis) induced by these RTKs and their extracellular ligands (Gas6, GDNF, and FGF) through either PI3K or MAPK signaling pathway. Significantly, we identify FGFR, RET, and MERTK as the first RTKs that can directly interact with and phosphorylate YAP/TAZ at multiple tyrosine residues independent of upstream Hippo signaling, thereby activating their functions in tumorigenesis. In conclusion, we have identified several novel kinases and extracellular stimuli regulating the Hippo pathway. Our findings also highlight the pivotal role of the Hippo pathway in mediating Gas6/GDNF/FGF-TAM/RET/FGFR-MAPK/PI3K signaling during tumorigenesis and provide a compelling rationale for targeting YAP/TAZ in RTK-driven cancers.	[Azad, Taha; Nouri, Kazem; van Rensburg, Helena J. Janse; Maritan, Sarah M.; Wu, Liqing; Hao, Yawei; Montminy, Tess; Yu, Jihang; Khanal, Prem; Mulligan, Lois M.; Yang, Xiaolong] Queens Univ, Dept Pathol & Mol Med, Kingston, ON K7L 3N6, Canada	McMaster University; Queens University - Canada	Yang, XL (corresponding author), Queens Univ, Dept Pathol & Mol Med, Kingston, ON K7L 3N6, Canada.	yangx@queensu.ca	Mulligan, Lois/D-1893-2010	Maritan, Sarah/0000-0002-9703-7429; Azad, Taha/0000-0002-9498-0657; Janse van Rensburg, Helena/0000-0002-4066-7489; Mulligan, Lois/0000-0002-9308-8245; Nouri, Kazem/0000-0001-7787-1304	Canadian Institute of Health Research (CIHR) [119325, 148629]; Canadian Breast Cancer Foundation; CIHR [142303]; Vanier Canada Graduate Scholarship; Ontario International Graduate Scholarship; Queen Elizabeth II Graduate Scholarship in Science and Technology; Master's CIHR award; Terry Fox Research Institute Training Program in Transdisciplinary Cancer Research	Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); CIHR(Canadian Institutes of Health Research (CIHR)); Vanier Canada Graduate Scholarship; Ontario International Graduate Scholarship; Queen Elizabeth II Graduate Scholarship in Science and Technology; Master's CIHR award; Terry Fox Research Institute Training Program in Transdisciplinary Cancer Research	This work was supported by grants from Canadian Institute of Health Research (CIHR#119325, 148629), Canadian Breast Cancer Foundation to XY and CIHR (CIHR#142303) to LMM. TA is supported by the Vanier Canada Graduate Scholarship and Ontario International Graduate Scholarship. HJJvR was supported by a Queen Elizabeth II Graduate Scholarship in Science and Technology. SMM was supported by a Master's CIHR award. SMM, TM, PK, and TA are supported by studentships from the Terry Fox Research Institute Training Program in Transdisciplinary Cancer Research. We thank Dr David Lillicrap and Dr Paula James for providing the HUVEC, Telo-HEC, and BOEC cells; Dr Camargo for STBS-luc reporter plasmid; Mina Ghahremani for help in making figures; Dr Abdi Ghafari for Aortic ring angiogenesis assay; Elham Ghourbanpour and Dr Lillicrap for helping in Nucleofection transfection; Dr Guan for providing us with HEK293A-LATS knockout cells, and Carrie Wei for help in analyzing motility assay; and Dr Peter Greer for reading the manuscript.	Alvarez H, 2010, CANCER BIOL THER, V10, P1009, DOI 10.4161/cbt.10.10.13248; Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; Attisano Liliana, 2013, F1000Prime Rep, V5, P17, DOI 10.12703/P5-17; Axelrod H, 2014, ONCOTARGET, V5, P1, DOI 10.18632/oncotarget.2422; Azad T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03278-w; Azad T, 2018, JOVE-J VIS EXP, V139, P11; Azad T, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050407; Calses PC, 2019, TRENDS CANCER, V5, P297, DOI 10.1016/j.trecan.2019.04.001; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Chen LM, 2010, GENE DEV, V24, P290, DOI 10.1101/gad.1865310; Chioni AM, 2012, J CELL BIOL, V197, P801, DOI 10.1083/jcb.201108077; Choura M, 2011, J RECEPT SIG TRANSD, V31, P387, DOI 10.3109/10799893.2011.625425; Coleman SJ, 2014, EMBO MOL MED, V6, P467, DOI 10.1002/emmm.201302698; Edwards DN, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aan4667; Fan R, 2013, P NATL ACAD SCI USA, V110, P2569, DOI 10.1073/pnas.1216462110; Gainor JF, 2013, ONCOLOGIST, V2, P13; Gorelik R, 2014, NAT PROTOC, V9, P1931, DOI 10.1038/nprot.2014.131; Gumbiner BM, 2014, J CELL SCI, V127, P709, DOI 10.1242/jcs.140103; Hao YW, 2008, J BIOL CHEM, V283, P5496, DOI 10.1074/jbc.M709037200; Haskins JW, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005770; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Huang SM, 2014, ENDOCR-RELAT CANCER, V21, P73, DOI 10.1530/ERC-13-0351; Ishida M, 2007, CANCER SCI, V98, P815, DOI 10.1111/j.1349-7006.2007.00457.x; Jang EJ, 2012, MOL CELL BIOL, V32, P4925, DOI 10.1128/MCB.00392-12; Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Keshet R, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723556.2014.995006; Koorstra JBM, 2009, CANCER BIOL THER, V8, P618, DOI 10.4161/cbt.8.7.7923; Lai ZC, 2005, CELL, V120, P675, DOI 10.1016/j.cell.2004.12.036; Lee YW, 2012, J CELL BIOCHEM, V113, P2920, DOI 10.1002/jcb.24170; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Levy D, 2008, MOL CELL, V29, P350, DOI 10.1016/j.molcel.2007.12.022; Li P, 2016, GENE DEV, V30, P798, DOI 10.1101/gad.274951.115; Lian EY, 2017, ENDOCR-RELAT CANCER, V24, P53, DOI 10.1530/ERC-16-0393; Liu AM, 2012, BBA-REV CANCER, V1826, P357, DOI 10.1016/j.bbcan.2012.05.006; Meng ZP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9357; Mohseni M, 2014, NAT CELL BIOL, V16, P108, DOI 10.1038/ncb2884; Moroishi T, 2015, GENE DEV, V29, P1271, DOI 10.1101/gad.262816.115; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; Mulligan LM, 2014, NAT REV CANCER, V14, P173, DOI 10.1038/nrc3680; Reddy BVVG, 2013, DEV CELL, V24, P459, DOI 10.1016/j.devcel.2013.01.020; Rizvi S, 2016, J BIOL CHEM, V115, P72; Robinson DR, 2000, ONCOGENE, V19, P5548, DOI 10.1038/sj.onc.1203957; Romano D, 2014, NAT CELL BIOL, V16, P673, DOI 10.1038/ncb2986; Romei C, 2016, NAT REV ENDOCRINOL, V12, P192, DOI 10.1038/nrendo.2016.11; Saucedo LJ, 2007, NAT REV MOL CELL BIO, V8, P613, DOI 10.1038/nrm2221; Schlessinger J, 2014, COLD SPRING HARB PER, V6, P89; Sugihara T, 2018, MOL CANCER RES, V2, P158; Taha Z, 2018, CANCERS, V10, DOI 10.3390/cancers10040094; Tamm C, 2011, J CELL SCI, V124, P1136, DOI 10.1242/jcs.075796; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; van Rensburg HJJ, 2018, CELL SIGNAL, V52, P12, DOI 10.1016/j.cellsig.2018.08.012; Vasudevan HN, 2016, CURR TOP DEV BIOL, V117, P393, DOI 10.1016/bs.ctdb.2015.10.016; Wang WQ, 2014, MOL CELL PROTEOMICS, V13, P119, DOI 10.1074/mcp.M113.030049; Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X; Xu MZ, 2011, ONCOGENE, V30, P1229, DOI 10.1038/onc.2010.504; Yang XP, 2011, NAT METHODS, V8, P659, DOI [10.1038/NMETH.1638, 10.1038/nmeth.1638]; Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Zhang XM, 2009, CANCER RES, V69, P6033, DOI 10.1158/0008-5472.CAN-08-4592; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao YL, 2018, MOL CANCER RES, V16, P1046, DOI 10.1158/1541-7786.MCR-17-0593	64	36	37	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	2					334	355		10.1038/s41388-019-0988-y	http://dx.doi.org/10.1038/s41388-019-0988-y			22	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KD3JY	31477837				2022-12-28	WOS:000507766400007
J	Hwang, BJ; Zhang, Y; Brozowski, JM; Liu, Z; Burette, S; Lough, K; Smith, CC; Shan, Y; Chen, JB; Li, N; Williams, S; Su, M; Googe, P; Thomas, NE; Liu, Z				Hwang, Bin-Jin; Zhang, Yang; Brozowski, Jaime M.; Liu, Zhen; Burette, Susan; Lough, Kendall; Smith, Christof C.; Shan, Yue; Chen, Jinbo; Li, Ning; Williams, Scott; Su, Maureen; Googe, Paul; Thomas, Nancy E.; Liu, Zhi			The dysfunction of BP180/collagen XVII in keratinocytes promotes melanoma progression	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMA; SUPPRESSOR-CELLS; EPIDERMOLYSIS-BULLOSA; COLLAGEN-XVII; MYELOID CELLS; BP180; INFLAMMATION; EXPRESSION; METASTASIS; CHEMOKINE	BP180, also termed collagen XVII, is a hemidesmosomal transmembrane glycoprotein expressed in basal keratinocytes, and functions as a cell-matrix adhesion molecule in the dermal-epidermal junction of the skin. Its function, other than cell-matrix adhesion, remains unclear. We generated a mouse strain with BP180 dysfunction (termed Delta NC16A), which develops spontaneous skin inflammation accompanied by an influx of myeloid derived suppressor cells (MDSCs). We used the B16 mouse melanoma model to demonstrate that BP180 dysfunction in either skin or basal keratinocytes promotes MDSC influx into skin and tumor progression. MDSC depletion reduced tumor progression in Delta NC16A mice, demonstrating a critical role for BP180 dysfunction-driven MDSCs in melanoma progression. This study provides the first direct evidence that BP180, a cell-cell matrix adhesion molecule, possesses antitumor function through modulating infiltration of MDSCs. Basal keratinocytes actively participate in skin microenvironment changes caused by BP180 dysfunction. Delta NC16A mice could be a new animal model to study the melanoma microenvironment.	[Hwang, Bin-Jin; Brozowski, Jaime M.; Smith, Christof C.; Liu, Zhi] Univ N Carolina, Dept Microbiol & Immunol, Sch Med, Chapel Hill, NC 27515 USA; [Zhang, Yang; Liu, Zhen; Burette, Susan; Li, Ning; Googe, Paul; Thomas, Nancy E.; Liu, Zhi] Univ N Carolina, Dept Dermatol, Sch Med, Chapel Hill, NC 27515 USA; [Zhang, Yang] Xi An Jiao Tong Univ, Hosp 2, Sch Med, Dept Dermatol, Xian, Shaanxi, Peoples R China; [Brozowski, Jaime M.] Duke Univ, Sch Med, Dept Med Rheumatol & Immunol, Durham, NC USA; [Liu, Zhen] Guangdong Ctr Adverse Drug React Monitoring, Guangzhou, Guangdong, Peoples R China; [Lough, Kendall; Williams, Scott] Univ N Carolina, Dept Pathol & Lab Med, Sch Med, Chapel Hill, NC 27515 USA; [Shan, Yue] Univ N Carolina, Dept Biostat, Sch Publ Hlth, Chapel Hill, NC 27515 USA; [Chen, Jinbo] Huazhong Univ Sci & Technol, Wuhan 1 Hosp, Tongji Med Coll, Dept Dermatol, Wuhan, Hubei, Peoples R China; [Su, Maureen] Univ N Carolina, Dept Pediat, Sch Med, Chapel Hill, NC 27515 USA; [Su, Maureen; Thomas, Nancy E.; Liu, Zhi] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Xi'an Jiaotong University; Duke University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; Huazhong University of Science & Technology; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill	Liu, Z (corresponding author), Univ N Carolina, Dept Microbiol & Immunol, Sch Med, Chapel Hill, NC 27515 USA.; Liu, Z (corresponding author), Univ N Carolina, Dept Dermatol, Sch Med, Chapel Hill, NC 27515 USA.; Liu, Z (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA.	zhi_liu@med.unc.edu	, UNC Flow Cytometry Core/AGU-9839-2022	Su, Maureen/0000-0002-3680-9982; Chen, Jinbo/0000-0002-9665-8506; Williams, Scott/0000-0001-9975-7334	Cancer Center Core Support Grant [P30 CA016086]; NIH [R01 AI40768, R01 AR072694]; 15 UNC Cancer Center Research Award; UNC Graduate School Dissertation 16 Completion Fellowship;  [P01CA206980]; NATIONAL CANCER INSTITUTE [P01CA206980, P30CA016086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR072694] Funding Source: NIH RePORTER	Cancer Center Core Support Grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); 15 UNC Cancer Center Research Award; UNC Graduate School Dissertation 16 Completion Fellowship; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank Dr. Dennis Loop for providing the Krt-14 promoter driven Cre mice. We thank Dr. Donna Culton and Susan McCray for assistance in Flow Cytometry. We thank Dr. Yisong Wan and Dr. Jenny PY Ting for their assistance. We thank the UNC Flow Cytometry Core Facility, which is supported in part by P30 CA016086 Cancer Center Core Support Grant to the UNC Lineberger Comprehensive Cancer Center, for their assistance in flow cytometry analyses. This work was supported by the NIH (R01 AI40768 and R01 AR072694 to ZL), the 15 UNC Cancer Center Research Award (to ZL) and UNC Graduate School Dissertation 16 Completion Fellowship (to BJH) and P01CA206980 (to NT).	Aho S, 1999, 180 KD BULLOUS PEMPH, V367, P356; Bangert C, 2011, CLIN DERMATOL, V29, P360, DOI 10.1016/j.clindermatol.2011.01.006; Bleehen S., 1998, TXB DERMATOLOGY, P1765; Bobek V, 2010, ANTICANCER RES, V30, P4799; Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150; Bruce DW, 2017, J CLIN INVEST, V127, P1813, DOI 10.1172/JCI91816; Bubier JA, 2010, J INVEST DERMATOL, V130, P1819, DOI 10.1038/jid.2010.46; Chen RY, 2002, J IMMUNOL, V169, P3987, DOI 10.4049/jimmunol.169.7.3987; Chen RY, 2001, J CLIN INVEST, V108, P1151, DOI 10.1172/jci11494; Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127; Condamine T, 2015, ANNU REV MED, V66, P97, DOI 10.1146/annurev-med-051013-052304; Di Meglio P, 2011, IMMUNITY, V35, P857, DOI 10.1016/j.immuni.2011.12.003; Fine JD, 2012, J AM ACAD DERMATOL, V66, P856, DOI 10.1016/j.jaad.2012.01.045; Fine JD, 2010, ORPHANET J RARE DIS, V5, DOI 10.1186/1750-1172-5-12; Fine JD, 2010, ANN NY ACAD SCI, V1194, P213, DOI 10.1111/j.1749-6632.2010.05463.x; Fine JD, 2009, J AM ACAD DERMATOL, V60, P203, DOI 10.1016/j.jaad.2008.09.035; GIUDICE GJ, 1992, J INVEST DERMATOL, V99, P243, DOI 10.1111/1523-1747.ep12616580; Golan T, 2015, MOL CELL, V59, P664, DOI 10.1016/j.molcel.2015.06.028; Hammers CM, 2016, ANNU REV PATHOL-MECH, V11, P175, DOI 10.1146/annurev-pathol-012615-044313; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hopkinson SB, 2000, MOL BIOL CELL, V11, P277, DOI 10.1091/mbc.11.1.277; Hurskainen T, 2014, J INVEST DERMATOL, P1; Hurskainen T, 2012, CELL TISSUE RES, V348, P579, DOI 10.1007/s00441-012-1368-x; Jonkman MF, 1982, 180 KD BULLOUS PEMPH, P1345; Kiritsi D, 2011, J MED GENET, V48, P450, DOI 10.1136/jmg.2010.086751; Koster J, 2003, J CELL SCI, V116, P387, DOI 10.1242/jcs.00241; Krenacs T, 2012, HISTOCHEM CELL BIOL, V138, P653, DOI 10.1007/s00418-012-0981-9; Kumar V, 2016, TRENDS IMMUNOL, V37, P208, DOI 10.1016/j.it.2016.01.004; Leighty L, 2007, ARCH DERMATOL RES, V299, P417, DOI 10.1007/s00403-007-0790-5; Liu Z, 2008, J AUTOIMMUN, V31, P331, DOI 10.1016/j.jaut.2008.08.009; Lund AW, 2016, CANCER DISCOV, V6, P22, DOI 10.1158/2159-8290.CD-15-0023; Mabuchi E, 2007, BRIT J DERMATOL, V157, P596, DOI 10.1111/j.1365-2133.2007.08046.x; Mallipeddi R, 2002, CLIN EXP DERMATOL, V27, P616, DOI 10.1046/j.1365-2230.2002.01130.x; Margadant C, 2008, CURR OPIN CELL BIOL, V20, P589, DOI 10.1016/j.ceb.2008.05.001; Matsumura H, 2016, SCIENCE, V351, DOI 10.1126/science.aad4395; MCGRATH JA, 1995, NAT GENET, V11, P83, DOI 10.1038/ng0995-83; Murdoch C, 2008, NAT REV CANCER, V8, P618, DOI 10.1038/nrc2444; Nishie W, 2007, NAT MED, V13, P378, DOI 10.1038/nm1496; Ortiz ML, 2015, J EXP MED, V212, P351, DOI 10.1084/jem.20140835; Ostrand-Rosenberg S, 2009, J IMMUNOL, V182, P4499, DOI 10.4049/jimmunol.0802740; Parikka M, 2006, EXP CELL RES, V312, P1431, DOI 10.1016/j.yexcr.2006.01.015; Parikka M, 2003, J HISTOCHEM CYTOCHEM, V51, P921, DOI 10.1177/002215540305100707; Parikka M, 2001, J ORAL PATHOL MED, V30, P589, DOI 10.1034/j.1600-0714.2001.301003.x; Rozenberg GI, 2010, MELANOMA RES, V20, P361, DOI 10.1097/CMR.0b013e328336ee17; Sawanobori Y, 2008, BLOOD, V111, P5457, DOI 10.1182/blood-2008-01-136895; Silvers WK, 1979, INBRED GENETICALLY 1, P1979; Stelkovics E, 2008, APPL IMMUNOHISTO M M, V16, P433, DOI 10.1097/PAI.0b013e318162f8aa; Talmadge JE, 2013, NAT REV CANCER, V13, P739, DOI 10.1038/nrc3581; Tang L., 2016, J MOL SIGNAL, V11, P1; Tanimura S, 2011, CELL STEM CELL, V8, P177, DOI 10.1016/j.stem.2010.11.029; Van den Bergh F, 2012, EXP DERMATOL, V21, P605, DOI 10.1111/j.1600-0625.2012.01529.x; van Deventer HW, 2010, CANCER RES, V70, P10161, DOI 10.1158/0008-5472.CAN-10-1921; Van Kilsdonk JWJ, 2010, MELANOMA RES, V20, P372, DOI 10.1097/CMR.0b013e32833d8d70; Williams SE, 2011, NATURE, V470, P353, DOI 10.1038/nature09793; Youn JI, 2008, J IMMUNOL, V181, P5791, DOI 10.4049/jimmunol.181.8.5791; Youn JI, 2010, EUR J IMMUNOL, V40, P2969, DOI 10.1002/eji.201040895; Zhang Y, 2018, P NATL ACAD SCI USA, V115, P6434, DOI 10.1073/pnas.1721805115	57	8	8	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2019	38	50					7491	7503		10.1038/s41388-019-0961-9	http://dx.doi.org/10.1038/s41388-019-0961-9			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JV7GY	31435021	Green Accepted			2022-12-28	WOS:000502530500004
J	Yang, R; Liu, N; Chen, L; Jiang, YQ; Shi, Y; Mao, C; Liu, YT; Wang, M; Lai, WW; Tang, HS; Gao, MH; Xiao, DS; Wang, X; Zhou, H; Tang, CE; Liu, WL; Yu, FL; Cao, Y; Yan, Q; Liu, S; Tao, YG				Yang, Rui; Liu, Na; Chen, Ling; Jiang, Yiqun; Shi, Ying; Mao, Chao; Liu, Yating; Wang, Min; Lai, Weiwei; Tang, Haosheng; Gao, Menghui; Xiao, Desheng; Wang, Xiang; Zhou, Hu; Tang, Can-e; Liu, Wenliang; Yu, Fenglei; Cao, Ya; Yan, Qin; Liu, Shuang; Tao, Yongguang			GIAT4RA functions as a tumor suppressor in non-small cell lung cancer by counteracting Uchl3-mediated deubiquitination of LSH	ONCOGENE			English	Article							LONG NONCODING RNA; LYMPHOID-SPECIFIC HELICASE; GENE-EXPRESSION; METHYLATION PATTERNS; DNA METHYLATION; BINDING-SITE; GINS COMPLEX; AXIS; PHOSPHORYLATION; PROLIFERATION	Elucidating mechanisms in tumor suppressors and epigenetic modifiers are needed to gain insights into the etiology and treatment of cancer, the interplay between long intergenic non-coding RNAs (lncRNAs) and chromatin remodeling remains unclear. Here, we showed that GIAT4RA, a poorly characterized lncRNA LOC102723729, was significantly decreased in lung cancer cells and tissues; while no association was observed with clinical risk factors, expression was linked with clinical stage and lymphatic metastasis. Higher expression of GIAT4RA was linked with overall survival in NSCLC. GIAT4RA inhibited many characteristics of tumorigenesis including cell growth, clonal formation, migration and invasion, epithelial-mesenchymal transition, tumor sphere and tumor growth in vivo. Mechanistically, GIAT4RA was essential for the degradation of chromatin modifier lymphoid-specific helicase (LSH) by counteracting the deubiquintination in proteasome pathway by binding to 227-589 AA of LSH. GIAT4RA interfered with ubiquitin hydrolase Uchl3-mediated interaction and stabilization of LSH. LSH knockdown rescued GIAT4RA-promoted features, and LSH overexpression prevented GIAT4RA-induced phenotypes. Taken together, lncRNA GIAT4RA plays a critical role in NSCLC adenocarcinoma as a ubiquitination regulator and tumor suppressor.	[Yang, Rui; Liu, Na; Chen, Ling; Jiang, Yiqun; Shi, Ying; Mao, Chao; Liu, Yating; Wang, Min; Lai, Weiwei; Tang, Haosheng; Gao, Menghui; Cao, Ya; Tao, Yongguang] Cent S Univ, Xiangya Hosp, Dept Pathol, Key Lab Carcinogenesis & Canc Invas,Minist Educ, Changsha 410078, Hunan, Peoples R China; [Yang, Rui; Liu, Na; Chen, Ling; Jiang, Yiqun; Shi, Ying; Mao, Chao; Liu, Yating; Wang, Min; Lai, Weiwei; Tang, Haosheng; Gao, Menghui; Cao, Ya; Tao, Yongguang] Cent S Univ, Sch Basic Med, Canc Res Inst, Key Lab Carcinogenesis,Minist Hlth, Changsha 410078, Hunan, Peoples R China; [Jiang, Yiqun; Xiao, Desheng] Cent S Univ, Xiangya Hosp, Dept Pathol, Changsha 410008, Hunan, Peoples R China; [Wang, Xiang; Liu, Wenliang; Yu, Fenglei; Tao, Yongguang] Cent S Univ, Xiangya Hosp 2, Dept Thorac Surg, Hunan Key Lab Tumor Models & Individualized Med, Changsha, Hunan, Peoples R China; [Zhou, Hu] Chinese Acad Sci, Shanghai Inst Mat Med, 555 Zu Chongzhi Rd,Zhangjiang Hitech Pk, Shanghai 201203, Peoples R China; [Tang, Can-e; Liu, Shuang] Cent S Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Dept Oncol,Inst Med Sci, Changsha 410008, Hunan, Peoples R China; [Yan, Qin] Yale Sch Med, Dept Pathol, New Haven, CT 06520 USA	Central South University; Central South University; Central South University; Central South University; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Central South University; Yale University	Tao, YG (corresponding author), Cent S Univ, Xiangya Hosp, Dept Pathol, Key Lab Carcinogenesis & Canc Invas,Minist Educ, Changsha 410078, Hunan, Peoples R China.; Tao, YG (corresponding author), Cent S Univ, Sch Basic Med, Canc Res Inst, Key Lab Carcinogenesis,Minist Hlth, Changsha 410078, Hunan, Peoples R China.; Tao, YG (corresponding author), Cent S Univ, Xiangya Hosp 2, Dept Thorac Surg, Hunan Key Lab Tumor Models & Individualized Med, Changsha, Hunan, Peoples R China.; Liu, S (corresponding author), Cent S Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Dept Oncol,Inst Med Sci, Changsha 410008, Hunan, Peoples R China.	shuangliu2016@csu.edu.cn; taoyong@csu.edu.cn	Mao, Chao/AAM-6358-2020	Jiang, Yiqun/0000-0003-3262-9498; , chao/0000-0002-8685-8539	National Natural Science Foundation of China [81672787, 81672991, 81874139, 81728014, 81672308]; National Basic Research Program of China [2015CB553903]; Fundamental Research Funds for the Central Universities [2017zzts828, 2017zzts206]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China(National Basic Research Program of China); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This work was supported by the National Natural Science Foundation of China (81672787 [YT], 81672991 and 81874139 [SL], 81728014 [QY], 81672308 [XW]), the National Basic Research Program of China (2015CB553903 [YT]), and the Fundamental Research Funds for the Central Universities (2017zzts828 [RY] and 2017zzts206 [NL]).	Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012; Bhan A, 2017, CANCER RES, V77, P3965, DOI 10.1158/0008-5472.CAN-16-2634; Brunner AL, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-8-r75; Burrage J, 2012, J CELL SCI, V125, P5524, DOI 10.1242/jcs.111252; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Fan T, 2003, CANCER RES, V63, P4677; Feinberg AP, 2016, NAT REV GENET, V17, P284, DOI 10.1038/nrg.2016.13; Forde PM, 2014, CLIN CANCER RES, V20, P2244, DOI 10.1158/1078-0432.CCR-13-2088; Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672; He XZ, 2016, CANCER RES, V76, P5743, DOI 10.1158/0008-5472.CAN-16-0268; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040; Jia JT, 2017, THERANOSTICS, V7, P3920, DOI 10.7150/thno.21389; Jiang Y, 2015, ONCOGENE, V34, P6079, DOI 10.1038/onc.2015.53; Jiang YQ, 2017, THERANOSTICS, V7, P3293, DOI 10.7150/thno.19988; Kamada K, 2007, NAT STRUCT MOL BIOL, V14, P388, DOI 10.1038/nsmb1231; Keren I, 2017, EPIGENETICS-US, V12, P584, DOI 10.1080/15592294.2017.1348446; Keyes WM, 2011, CELL STEM CELL, V8, P164, DOI 10.1016/j.stem.2010.12.009; Kim JY, 2011, FEBS LETT, V585, P1121, DOI 10.1016/j.febslet.2011.03.053; Kong LY, 2006, BIOCHEM BIOPH RES CO, V339, P1204, DOI 10.1016/j.bbrc.2005.11.136; Labib K, 2007, TRENDS CELL BIOL, V17, P271, DOI 10.1016/j.tcb.2007.04.002; Leveille N, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7520; Liao CY, 2018, CELL REP, V23, P3352, DOI 10.1016/j.celrep.2018.05.033; Liu S, 2016, CHIN J CANCER, V35, DOI 10.1186/s40880-016-0138-7; Luo KT, 2016, GENE DEV, V30, P2581, DOI 10.1101/gad.289439.116; Mao C, 2018, CANCER RES, V78, P3484, DOI 10.1158/0008-5472.CAN-17-3454; Materne P, 2016, ELIFE, V5, DOI 10.7554/eLife.13500; Myant K, 2011, GENOME RES, V21, P83, DOI 10.1101/gr.108498.110; Reck M, 2013, LANCET, V382, P709, DOI 10.1016/S0140-6736(13)61502-0; Ren JK, 2015, NUCLEIC ACIDS RES, V43, P1444, DOI 10.1093/nar/gku1371; Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Shi Y, 2012, CARCINOGENESIS, V33, P1468, DOI 10.1093/carcin/bgs171; Shi Y, 2018, CANCER LETT, V422, P81, DOI 10.1016/j.canlet.2018.02.028; Taniue K, 2016, P NATL ACAD SCI USA, V113, P1273, DOI 10.1073/pnas.1500992113; Tao YG, 2011, NUCLEIC ACIDS RES, V39, P9508, DOI 10.1093/nar/gkr611; Tao YG, 2011, P NATL ACAD SCI USA, V108, P5626, DOI 10.1073/pnas.1017000108; Tao YG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009163; von Eyss B, 2012, EMBO J, V31, P972, DOI 10.1038/emboj.2011.451; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Xiao DS, 2017, THERANOSTICS, V7, P132, DOI 10.7150/thno.17032; Yan B, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0542-9; Yoon JH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3939; Yu WS, 2014, GENOME RES, V24, P1613, DOI 10.1101/gr.172015.114; Yu WS, 2014, P NATL ACAD SCI USA, V111, P5890, DOI 10.1073/pnas.1320945111; Zemach A, 2013, CELL, V153, P193, DOI 10.1016/j.cell.2013.02.033; Zhang H, 2015, CANCER RES, V75, P2363, DOI 10.1158/0008-5472.CAN-14-2928; Zhang KC, 2017, THERANOSTICS, V7, P213, DOI 10.7150/thno.16044; Zhang PF, 2016, EMBO REP, V17, P1204, DOI 10.15252/embr.201642067; Zhao D, 2017, NATURE, V542, P484, DOI 10.1038/nature21357; Zheng J, 2016, NAT GENET, V48, P747, DOI 10.1038/ng.3568	51	32	34	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2019	38	46					7133	7145		10.1038/s41388-019-0909-0	http://dx.doi.org/10.1038/s41388-019-0909-0			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JN5HX	31417184				2022-12-28	WOS:000496930500002
J	Pique, L; de Paz, AM; Pineyro, D; Martinez-Cardus, A; de Moura, MC; Llinas-Arias, P; Setien, F; Gomez-Miragaya, J; Gonzalez-Suarez, E; Sigurdsson, S; Jonasson, JG; Villanueva, A; Vidal, A; Davalos, V; Esteller, M				Pique, Laia; Martinez de Paz, Alexia; Pineyro, David; Martinez-Cardus, Anna; Castro de Moura, Manuel; Llinas-Arias, Pere; Setien, Fernando; Gomez-Miragaya, Jorge; Gonzalez-Suarez, Eva; Sigurdsson, Stefan; Jonasson, Jon G.; Villanueva, Alberto; Vidal, August; Davalos, Veronica; Esteller, Manel			Epigenetic inactivation of the splicing RNA-binding protein CELF2 in human breast cancer	ONCOGENE			English	Article							TUMOR; IDENTIFICATION; ACTIVATION	Human tumors show altered patterns of protein isoforms that can be related to the dysregulation of messenger RNA alternative splicing also observed in transformed cells. Although somatic mutations in core spliceosome components and their associated factors have been described in some cases, almost nothing is known about the contribution of distorted epigenetic patterns to aberrant splicing. Herein, we show that the splicing RNA-binding protein CELF2 is targeted by promoter hypermethylation-associated transcriptional silencing in human cancer. Focusing on the context of breast cancer, we also demonstrate that CELF2 restoration has growth-inhibitory effects and that its epigenetic loss induces an aberrant downstream pattern of alternative splicing, affecting key genes in breast cancer biology such as the autophagy factor ULK1 and the apoptotic protein CARD10. Furthermore, the presence of CELF2 hypermethylation in the clinical setting is associated with shorter overall survival of the breast cancer patients carrying this epigenetic lesion.	[Pique, Laia; Martinez de Paz, Alexia; Pineyro, David; Martinez-Cardus, Anna; Castro de Moura, Manuel; Llinas-Arias, Pere; Setien, Fernando; Gomez-Miragaya, Jorge; Gonzalez-Suarez, Eva; Davalos, Veronica; Esteller, Manel] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Lhospitalet Barcelona, Catalonia, Spain; [Sigurdsson, Stefan] Biomed Ctr, Dept Biochem & Mol Biol, Vatnsmyrarvegur 16, IS-101 Reykjavik, Iceland; [Jonasson, Jon G.] Univ Iceland, Fac Med, Sturlugata 8, IS-101 Reykjavik, Iceland; [Jonasson, Jon G.] Landspitali Univ Hosp, Dept Pathol, Reykjavik, Iceland; [Villanueva, Alberto] IDIBELL Inst Catala Oncol, Translat Res Lab, Barcelona, Catalonia, Spain; [Vidal, August] Bellvitge Univ Hosp, Dept Pathol, Barcelona, Catalonia, Spain; [Esteller, Manel] Ctr Invest Biomed Red Canc CIBERONC, Madrid 28029, Spain; [Esteller, Manel] ICREA, Barcelona, Catalonia, Spain; [Esteller, Manel] UB, Sch Med & Hlth Sci, Physiol Sci Dept, Barcelona, Catalonia, Spain; [Esteller, Manel] Josep Carreras Leukaemia Res Inst IJC, Barcelona, Catalonia, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Iceland; Landspitali National University Hospital; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; ICREA; University of Barcelona; Institut de Recerca Contra la Leucemia Josep Carreras (IJC)	Esteller, M (corresponding author), Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Lhospitalet Barcelona, Catalonia, Spain.; Esteller, M (corresponding author), Ctr Invest Biomed Red Canc CIBERONC, Madrid 28029, Spain.; Esteller, M (corresponding author), ICREA, Barcelona, Catalonia, Spain.; Esteller, M (corresponding author), UB, Sch Med & Hlth Sci, Physiol Sci Dept, Barcelona, Catalonia, Spain.; Esteller, M (corresponding author), Josep Carreras Leukaemia Res Inst IJC, Barcelona, Catalonia, Spain.	mesteller@carrerasresearch.org	Davalos, Veronica/AAR-8547-2020; Llinàs-Arias, Pere/AAB-8254-2022; Llinàs-Arias, Pere/M-4501-2014; Gonzalez-Suarez, Eva/L-6298-2014; Martinez, Anna/AAA-4939-2020; Esteller, Manel/L-5956-2014; Sigurdsson, Stefan/L-9820-2015; Castro de Moura, Manuel/L-4259-2017; Davalos, Veronica/S-1668-2016	Llinàs-Arias, Pere/0000-0002-3666-0532; Gonzalez-Suarez, Eva/0000-0003-0858-8171; Esteller, Manel/0000-0003-4490-6093; Sigurdsson, Stefan/0000-0002-5284-0058; Jonasson, Jon G./0000-0002-2635-5032; Martinez Cardus, Anna/0000-0002-3937-8794; Pineyro, David/0000-0001-5633-3339; Castro de Moura, Manuel/0000-0002-8488-5306; Martinez de Paz, Alexia/0000-0003-0808-1389; Davalos, Veronica/0000-0003-4077-5137	Health Department PERIS-project of the Catalan Government (Generalitat de Catalunya) [SLT/002/16/00374]; AGAUR of the Catalan Government (Generalitat de Catalunya) [2017SGR1080, 2014SGR633, 2009SGR1315]; Spanish Institute of Health Carlos III (ISCIII) [DTS16/00153]; Ministerio de Economia y Competitividad (MINECO) [SAF2014-55000-R]; European Development Regional Fund, "A way to achieve Europe" ERDF; Cellex Foundation; "la Caixa" Banking Foundation [LCF/PR/PR15/11100003]	Health Department PERIS-project of the Catalan Government (Generalitat de Catalunya); AGAUR of the Catalan Government (Generalitat de Catalunya); Spanish Institute of Health Carlos III (ISCIII)(Instituto de Salud Carlos III); Ministerio de Economia y Competitividad (MINECO); European Development Regional Fund, "A way to achieve Europe" ERDF; Cellex Foundation(Foundation CELLEX); "la Caixa" Banking Foundation(La Caixa Foundation)	We thank CERCA Program/Generalitat de Catalunya for institutional support. This work was supported by the Health Department PERIS-project no. SLT/002/16/00374 and AGAUR-projects nos. 2017SGR1080, 2014SGR633, and 2009SGR1315 of the Catalan Government (Generalitat de Catalunya); the Spanish Institute of Health Carlos III (ISCIII) project no. DTS16/00153 and Ministerio de Economia y Competitividad (MINECO) project no. SAF2014-55000-R, co-financed by the European Development Regional Fund, "A way to achieve Europe" ERDF; the Cellex Foundation; and "la Caixa" Banking Foundation (LCF/PR/PR15/11100003).	Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Carey KT, 2018, TRENDS GENET, V34, P279, DOI 10.1016/j.tig.2017.12.012; Dasgupta T, 2012, WIRES RNA, V3, P104, DOI 10.1002/wrna.107; Dvinge H, 2016, NAT REV CANCER, V16, P413, DOI 10.1038/nrc.2016.51; Dvinge H, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0168-9; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Feinberg AP, 2018, NEW ENGL J MED, V378, P1323, DOI [10.1056/NEJMra1402513, 10.1056/nejmra1402513]; Gomez-Miragaya J, 2017, STEM CELL REP, V8, P1392, DOI 10.1016/j.stemcr.2017.03.026; Han J, 2005, NUCLEIC ACIDS RES, V33, P2769, DOI 10.1093/nar/gki561; Hosur V, 2014, P NATL ACAD SCI USA, V111, pE2200, DOI 10.1073/pnas.1323908111; Iorio F, 2016, CELL, V166, P740, DOI 10.1016/j.cell.2016.06.017; Johnson KC, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0094-0; Jung- H, 2015, NAT GENET, V47, P1242, DOI 10.1038/ng.3414; Kalsotra A, 2011, NAT REV GENET, V12, P715, DOI 10.1038/nrg3052; Kuchay S, 2017, NATURE, V546, P554, DOI 10.1038/nature22965; Nilsen TW, 2010, NATURE, V463, P457, DOI 10.1038/nature08909; Pan D, 2016, MOL CANCER RES, V14, P93, DOI 10.1158/1541-7786.MCR-15-0229-T; Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259; Papasaikas P, 2016, TRENDS BIOCHEM SCI, V41, P33, DOI 10.1016/j.tibs.2015.11.003; Rodriguez-Pinto D, 2009, CANCER IMMUNOL IMMUN, V58, P221, DOI 10.1007/s00262-008-0543-0; Sandoval J, 2011, EPIGENETICS-US, V6, P692, DOI 10.4161/epi.6.6.16196; Sveen A, 2016, ONCOGENE, V35, P2413, DOI 10.1038/onc.2015.318; Vlasova IA, 2008, RNA BIOL, V5, P201, DOI 10.4161/rna.7056; Zhang L, 2018, J MED CHEM, V61, P6491, DOI 10.1021/acs.jmedchem.7b01684	24	34	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2019	38	45					7106	7112		10.1038/s41388-019-0936-x	http://dx.doi.org/10.1038/s41388-019-0936-x			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JL9XI	31409895	hybrid, Green Published			2022-12-28	WOS:000495878400006
J	Ritchey, L; Ha, T; Otsuka, A; Kabashima, K; Wang, DR; Wang, YY; Lowy, DR; Tosato, G				Ritchey, Lisa; Ha, Taekyu; Otsuka, Atsushi; Kabashima, Kenji; Wang, Dunrui; Wang, Yuyi; Lowy, Douglas R.; Tosato, Giovanna			DLC1 deficiency and YAP signaling drive endothelial cell contact inhibition of growth and tumorigenesis	ONCOGENE			English	Article							FOCAL ADHESION KINASE; GTPASE-ACTIVATING PROTEIN; ORGAN SIZE CONTROL; HIPPO PATHWAY; TUMOR-SUPPRESSOR; RHO; ANGIOGENESIS; THERAPY; COMPLEX; SRC	Deleted in Liver Cancer 1 (DLC1) is a tumor suppressor gene deleted in many cancers, including angiosarcoma, an aggressive malignancy of endothelial cell derivation. DLC1-deficiency in primary endothelial cells causes the loss of cell contact inhibition of growth through incompletely defined mechanisms. We report that DLC1 is a regulator of YAP, a transcriptional coactivator of proliferation-promoting and tumor-promoting genes; when confluent, active/nuclear YAP was significantly more abundant in DLC1-deficient endothelial cells compared with control cells. We also found that YAP is a required effector of the loss of cell contact inhibition of growth manifested by DLC1-deficient endothelial cells, as the silencing of YAP prevents this loss. Consistently, human angiosarcomas specimens contained a significantly greater proportion of DLC1(-) tumor cells with nuclear YAP compared with the DLC1(+) normal cells in the adjacent tissue. Verteporfin, an inhibitor of YAP, significantly reduced angiosarcoma growth in mice. These results identify YAP as a previously unrecognized effector of DLC1 deficiency-associated loss of cell contact growth inhibition in endothelial cells and a potential therapeutic target in angiosarcoma.	[Ritchey, Lisa; Ha, Taekyu; Wang, Dunrui; Wang, Yuyi; Lowy, Douglas R.; Tosato, Giovanna] NCI, Lab Cellular Oncol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Otsuka, Atsushi; Kabashima, Kenji] Kyoto Univ, Grad Sch Med, Dept Dermatol, Kyoto, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Kyoto University	Tosato, G (corresponding author), NCI, Lab Cellular Oncol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.	tosatog@mail.nih.gov		Otsuka, Atsushi/0000-0001-7365-947X; Tosato, Giovanna/0000-0003-1663-3227	Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research; Japan Society for the Promotion of Science KAKENHI [15H05790]; NATIONAL CANCER INSTITUTE [ZIASC010355] Funding Source: NIH RePORTER	Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Japan Society for the Promotion of Science KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Michael Kruhlak, Langston Lim, and Andy Tran for helping with confocal imaging and images quantification; Ms. Luowei Li, M. DiPrima, Drs. R. Yarchoan, D. Sanchez-Martin, H. Ohnuki, M. Potente, H. Gerhard and Jing-xin Feng; and members of the Laboratory of Cellular Oncology for contributing in various aspects of this work. This work was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research (DSM, XQ, DRL, GT) and by the Japan Society for the Promotion of Science KAKENHI, Grants-in-Aid for Scientific Research 15H05790 (AO, KK).	Azzolin L, 2014, CELL, V158, P157, DOI 10.1016/j.cell.2014.06.013; Behjati S, 2014, NAT GENET, V46, P376, DOI 10.1038/ng.2921; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Braun AC, 2015, CELL SIGNAL, V27, P1643, DOI 10.1016/j.cellsig.2015.04.003; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; Chalmers ZR, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0424-2; Choi HJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7943; Coxon A, 2010, MOL CANCER THER, V9, P2641, DOI 10.1158/1535-7163.MCT-10-0213; da Costa A, 2017, CLIN EXP DERMATOL, V42, P645, DOI 10.1111/ced.13149; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Durkin ME, 2007, J CELL MOL MED, V11, P1185, DOI 10.1111/j.1582-4934.2007.00098.x; EAGLE H, 1967, NATURE, V213, P1102, DOI 10.1038/2131102a0; Edwards DN, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aan4667; Feng XD, 2014, CANCER CELL, V25, P831, DOI 10.1016/j.ccr.2014.04.016; Gao YJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5629; Golubovskaya VM, 2008, J MED CHEM, V51, P7405, DOI 10.1021/jm800483v; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Huggett MT, 2014, BRIT J CANCER, V110, P1698, DOI 10.1038/bjc.2014.95; Ishida Y, 2018, CURR OPIN ONCOL, V30, P107, DOI 10.1097/CCO.0000000000000427; Jiao S, 2014, CANCER CELL, V25, P166, DOI 10.1016/j.ccr.2014.01.010; Khan JA, 2018, J CLIN ONCOL, V36, P194, DOI 10.1200/JCO.2017.74.9812; Kim TY, 2007, BIOCHEM BIOPH RES CO, V355, P72, DOI 10.1016/j.bbrc.2007.01.121; Li GR, 2011, P NATL ACAD SCI USA, V108, P17129, DOI 10.1073/pnas.1112122108; Liao YC, 2008, INT J BIOCHEM CELL B, V40, P843, DOI 10.1016/j.biocel.2007.04.008; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Masuzawa M, 1998, J DERMATOL SCI, V16, P91, DOI 10.1016/S0923-1811(97)00032-7; Mohseni M, 2014, NAT CELL BIOL, V16, P108, DOI 10.1038/ncb2884; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; Murga M, 2004, STEM CELLS, V22, P385, DOI 10.1634/stemcells.22-3-385; Neto F, 2018, ELIFE, V7, DOI 10.7554/eLife.31037; Nguyen LT, 2015, CANCER CELL, V27, P797, DOI 10.1016/j.ccell.2015.05.005; OBESO J, 1990, LAB INVEST, V63, P259; Pang A, 2016, JAMA ONCOL, V2, P941, DOI 10.1001/jamaoncol.2016.0241; Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014; Qian XL, 2009, CANCER CELL, V16, P246, DOI 10.1016/j.ccr.2009.07.031; Rosenbluh J, 2012, CELL, V151, P1457, DOI 10.1016/j.cell.2012.11.026; Salvucci O, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7576; Sanchez-Martin D, 2018, JNCI-J NATL CANCER I, V110, P390, DOI 10.1093/jnci/djx219; Shih YP, 2010, CANCER RES, V70, P8270, DOI 10.1158/0008-5472.CAN-10-1174; Shimozono N, 2015, CANCER RES, V75, P4458, DOI 10.1158/0008-5472.CAN-15-0418; Song SM, 2014, CANCER RES, V74, P4170, DOI 10.1158/0008-5472.CAN-13-3569; Sorrentino G, 2014, NAT CELL BIOL, V16, P357, DOI 10.1038/ncb2936; Stein C, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005465; STOKER MGP, 1973, NATURE, V246, P200, DOI 10.1038/246200a0; Taniguchi K, 2015, NATURE, V519, P57, DOI 10.1038/nature14228; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; Totaro A, 2018, NAT CELL BIOL, V20, P888, DOI 10.1038/s41556-018-0142-z; Tripathi BK, 2019, J CELL BIOL, V218, P3060, DOI 10.1083/jcb.201810098; Tsuneki M, 2017, CANCER SCI, V108, P2295, DOI 10.1111/cas.13379; Wu L, 1999, Curr Opin Ophthalmol, V10, P217, DOI 10.1097/00055735-199906000-00011; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Yu FX, 2014, CANCER CELL, V25, P822, DOI 10.1016/j.ccr.2014.04.017; Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112; Zhang HB, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aac5418; Zhang H, 2014, J BIOL CHEM, V289, P18681, DOI 10.1074/jbc.M114.554584; Zhang JM, 2008, CANCER RES, V68, P2789, DOI 10.1158/0008-5472.CAN-07-6205; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2011, NAT CELL BIOL, V13, P877, DOI 10.1038/ncb2303; Ziemssen F, 2012, EXPERT OPIN DRUG MET, V8, P1023, DOI 10.1517/17425255.2012.701617	60	7	8	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2019	38	45					7046	7059		10.1038/s41388-019-0944-x	http://dx.doi.org/10.1038/s41388-019-0944-x			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JL9XI	31409902	Green Accepted			2022-12-28	WOS:000495878400002
J	Gregory, PA				Gregory, Philip A.			The miR-200-Quaking axis functions in tumour angiogenesis	ONCOGENE			English	Editorial Material							RNA-BINDING PROTEINS; MIR-200 FAMILY; QUAKING; METASTASIS; PROMOTES; CANCER; ZEB1; REPRESSION; INVASION; EMT		[Gregory, Philip A.] Univ South Australia, Ctr Canc Biol, Adelaide, SA 5000, Australia; [Gregory, Philip A.] SA Pathol, Adelaide, SA 5000, Australia; [Gregory, Philip A.] Univ Adelaide, Discipline Med, Adelaide, SA 5005, Australia	Centre for Cancer Biology; University of South Australia; SA Pathology; University of Adelaide	Gregory, PA (corresponding author), Univ South Australia, Ctr Canc Biol, Adelaide, SA 5000, Australia.; Gregory, PA (corresponding author), SA Pathol, Adelaide, SA 5000, Australia.; Gregory, PA (corresponding author), Univ Adelaide, Discipline Med, Adelaide, SA 5005, Australia.	philip.gregory@unisa.edu.au			Cancer Council's Beat Cancer Project; State Government through the Department of Health	Cancer Council's Beat Cancer Project; State Government through the Department of Health	This work was undertaken with the financial support of Cancer Council's Beat Cancer Project on behalf of its donors and the State Government through the Department of Health.	Azam SH, 2019, ONCOGENE, V38, P5191, DOI 10.1038/s41388-019-0786-6; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Bracken CP, 2014, EMBO J, V33, P2040, DOI 10.15252/embj.201488641; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Chan YC, 2012, ARTERIOSCL THROM VAS, V32, P1372, DOI 10.1161/ATVBAHA.112.248583; Chan YC, 2011, J BIOL CHEM, V286, P2047, DOI 10.1074/jbc.M110.158790; Chen AJ, 2012, GENE DEV, V26, P1459, DOI 10.1101/gad.189001.112; Cochrane A, 2017, STEM CELLS, V35, P952, DOI 10.1002/stem.2594; Conn SJ, 2015, CELL, V160, P1125, DOI 10.1016/j.cell.2015.02.014; Darbelli L, 2016, WIRES RNA, V7, P399, DOI 10.1002/wrna.1344; de Bruin RG, 2016, SCI REP-UK, V6, DOI 10.1038/srep21643; Ding YZ, 2017, LIFE SCI, V191, P245, DOI 10.1016/j.lfs.2017.09.001; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; Gibbons DL, 2009, GENE DEV, V23, P2140, DOI 10.1101/gad.1820209; Gill JG, 2012, STEM CELLS DEV, V21, P167, DOI 10.1089/scd.2011.0194; Goel S, 2018, TRENDS CELL BIOL, V28, P911, DOI 10.1016/j.tcb.2018.07.002; Gregory PA, 2008, CELL CYCLE, V7, P3112, DOI 10.4161/cc.7.20.6851; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Harrison EB, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00307; Hoefert JE, 2018, J CELL BIOL, V217, P2185, DOI 10.1083/jcb.201708173; Kim EJ, 2019, INT J CANCER, V145, P1585, DOI 10.1002/ijc.32372; Larocque D, 2005, NAT NEUROSCI, V8, P27, DOI 10.1038/nn1359; Liu TZ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13923; Lupo G, 2017, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00519; Magenta A, 2011, CELL DEATH DIFFER, V18, P1628, DOI 10.1038/cdd.2011.42; Noveroske JK, 2002, GENESIS, V32, P218, DOI 10.1002/gene.10060; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Pecot CV, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3427; Pillman KA, 2018, EMBO J, V37, DOI 10.15252/embj.201899016; Schettini F, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00608; van Mil A, 2012, CARDIOVASC RES, V93, P655, DOI 10.1093/cvr/cvs003; Zhou X, 2017, ONCOTARGET, V8, P82174, DOI 10.18632/oncotarget.19066; Zong FY, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004289	33	2	2	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2019	38	41					6767	6769		10.1038/s41388-019-0916-1	http://dx.doi.org/10.1038/s41388-019-0916-1			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JC8UZ	31406253				2022-12-28	WOS:000489552900004
J	Delespaul, L; Merle, C; Lesluyes, T; Lagarde, P; Le Guellec, S; Perot, G; Baud, J; Carlotti, M; Danet, C; Fevre, M; Rousseau, B; Durrieu, S; Teichmann, M; Coindre, JM; Lartigue, L; Chibon, F				Delespaul, Lucile; Merle, Candice; Lesluyes, Tom; Lagarde, Pauline; Le Guellec, Sophie; Perot, Gaelle; Baud, Jessica; Carlotti, Martina; Danet, Coralie; Fevre, Murielle; Rousseau, Benoit; Durrieu, Stephanie; Teichmann, Martin; Coindre, Jean-Michel; Lartigue, Lydia; Chibon, Frederic			Fusion-mediated chromosomal instability promotes aneuploidy patterns that resemble human tumors	ONCOGENE			English	Article							MARROW-DERIVED CELLS; SOFT-TISSUE SARCOMAS; PURKINJE NEURONS; LARGE SERIES; CANCER; BONE; DNA; METASTASIS; MUSCLE; CONDENSATION	Oncogenesis is considered to result from chromosomal instability, in addition to oncogene and tumor-suppressor alterations. Intermediate to aneuploidy and chromosomal instability, genome doubling is a frequent event in tumor development but the mechanisms driving tetraploidization and its impact remain unexplored. Cell fusion, one of the pathways to tetraploidy, is a physiological process involved in mesenchymal cell differentiation. Besides simple genome doubling, cell fusion results in the merging of two different genomes that can be destabilized upon proliferation. By testing whether cell fusion is involved in mesenchymal oncogenesis, we provide evidence that it induces genomic instability and mediates tumor initiation. After a latency period, the tumor emerges with the cells most suited for its development. Furthermore, hybrid tumor genomes were stabilized after this selection process and were very close to those of human pleomorphic mesenchymal tumors. Thus genome restructuring triggered by cell fusion may account for the chromosomal instability involved in oncogenesis.	[Delespaul, Lucile; Merle, Candice; Lesluyes, Tom; Le Guellec, Sophie; Perot, Gaelle; Chibon, Frederic] CRCT, INSERM U1037, F-31037 Toulouse, France; [Delespaul, Lucile; Lesluyes, Tom; Lagarde, Pauline; Baud, Jessica; Lartigue, Lydia] INSERM U1218, 229 Cours Argonne, F-33076 Bordeaux, France; [Delespaul, Lucile; Lesluyes, Tom; Coindre, Jean-Michel; Lartigue, Lydia] Univ Bordeaux, 146 Rue Leo Saignat, F-33000 Bordeaux, France; [Merle, Candice] Univ Toulouse, 3 Paul Sabatier,118 Route Narbonne, F-31062 Toulouse 9, France; [Merle, Candice; Lesluyes, Tom] IUCT Oncopole, Inst Claudius Regaud, Toulouse, France; [Lagarde, Pauline; Baud, Jessica; Coindre, Jean-Michel] Bergonie Inst, Dept Biopathol, 229 Cours Argonne, F-33076 Bordeaux, France; [Le Guellec, Sophie; Perot, Gaelle; Chibon, Frederic] IUCT Oncopole, Inst Claudius Regaud, Dept Pathol, Toulouse, France; [Carlotti, Martina] INSERM U1053, 146 Rue Leo Saignat, F-33000 Bordeaux, France; [Danet, Coralie; Fevre, Murielle; Rousseau, Benoit] Bordeaux Univ, Anim Facil A2, 146 Rue Leo Saignat, F-33000 Bordeaux, France; [Durrieu, Stephanie; Teichmann, Martin] ARNA Lab, CNRS UMR 5320, INSERM U1212, F-33000 Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; UNICANCER; Institut Claudius Regaud; UNICANCER; Institut Bergonie; UNICANCER; Institut Claudius Regaud; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Chibon, F (corresponding author), CRCT, INSERM U1037, F-31037 Toulouse, France.; Chibon, F (corresponding author), IUCT Oncopole, Inst Claudius Regaud, Dept Pathol, Toulouse, France.	frederic.chibon@inserm.fr	Delespaul, Lucile/AAZ-1073-2021; Pérot, Gaëlle/W-8038-2019; Lesluyes, Tom/GSD-4621-2022; Lesluyes, Tom/AAB-6229-2019; Teichmann, Martin/M-7407-2014	Lesluyes, Tom/0000-0003-2251-5884; Lesluyes, Tom/0000-0003-2251-5884; chibon, Frederic/0000-0002-6548-2181; Delespaul, Lucile/0000-0002-9509-6425; Teichmann, Martin/0000-0002-5257-0510	Fondation ARC pour la Recherche Contre le Cancer; Fondation Recherche Medicale	Fondation ARC pour la Recherche Contre le Cancer; Fondation Recherche Medicale	This work was supported by the Fondation ARC pour la Recherche Contre le Cancer (to T.L.) and the Fondation Recherche Medicale (to L.L. and L.D.). We acknowledge personnel of CREFRE US006 for technical assistance.	Aichel O., 1911, VORTRAGE AUFSATZE EN, P92; Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Bakhoum SF, 2018, NATURE, V553, P467, DOI 10.1038/nature25432; Bielski CM, 2018, NAT GENET, V50, P1189, DOI 10.1038/s41588-018-0165-1; Camargo FD, 2003, NAT MED, V9, P1520, DOI 10.1038/nm963; Chakraborty A, 2004, BONE MARROW TRANSPL, V34, P183, DOI 10.1038/sj.bmt.1704547; Chen EH, 2005, SCIENCE, V308, P369, DOI 10.1126/science.1104799; Chibon F, 2000, CANCER RES, V60, P6339; Clawson GA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184451; Clawson GA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134320; Clawson GA, 2013, SCIENCE, V342, P699, DOI 10.1126/science.1244270; Clawson GA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041052; Commo F, 2016, BIOINFORMATICS, V32, P1402, DOI 10.1093/bioinformatics/btv718; Davoli T, 2017, SCIENCE, V355, DOI 10.1126/science.aaf8399; Davoli T, 2013, CELL, V155, P948, DOI 10.1016/j.cell.2013.10.011; Davoli T, 2011, ANNU REV CELL DEV BI, V27, P585, DOI 10.1146/annurev-cellbio-092910-154234; Davoli T, 2010, CELL, V141, P81, DOI 10.1016/j.cell.2010.01.031; Ding JX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041942; Dittmar T, 2015, INT J MOL SCI, V16, P30362, DOI 10.3390/ijms161226240; Dodd RD, 2010, DIS MODEL MECH, V3, P557, DOI 10.1242/dmm.005223; Duelli D, 2003, CANCER CELL, V3, P445, DOI 10.1016/S1535-6108(03)00114-4; Duelli D, 2007, NAT REV CANCER, V7, P968, DOI 10.1038/nrc2272; Duelli DM, 2007, CURR BIOL, V17, P431, DOI 10.1016/j.cub.2007.01.049; Durrieu-Gaillard S, 2018, CELL CYCLE, V17, P605, DOI 10.1080/15384101.2017.1405881; Elinav E, 2013, NAT REV CANCER, V13, P759, DOI 10.1038/nrc3611; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Fletcher CD, 2012, WHO CLASSIFICATION T; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011; Gast CE, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aat7828; Gibault L, 2011, J PATHOL, V223, P64, DOI 10.1002/path.2787; Giroux V, 2017, NAT REV CANCER, V17, P594, DOI 10.1038/nrc.2017.68; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Johansson CB, 2008, NAT CELL BIOL, V10, P575, DOI 10.1038/ncb1720; JOHNSON RT, 1970, NATURE, V226, P717, DOI 10.1038/226717a0; Kemeny LV, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060826; Kirsch DG, 2007, NAT MED, V13, P992, DOI 10.1038/nm1602; KOVACS G, 1985, LANCET, V1, P350; KOVACS G, 1985, INT J CANCER, V36, P637, DOI 10.1002/ijc.2910360602; Kurgyis Z, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060980; Kwon M, 2008, GENE DEV, V22, P2189, DOI 10.1101/gad.1700908; LaBerge GS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0168581; Lazar AJ, 2017, CELL, V171, P950, DOI 10.1016/j.cell.2017.10.014; Lazebnik Y, 2014, CELL CYCLE, V13, P2323, DOI 10.4161/cc.29704; Lazova R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066731; Li GH, 2013, STEM CELLS, V31, P2304, DOI 10.1002/stem.1491; Lu X, 2009, P NATL ACAD SCI USA, V106, P9385, DOI 10.1073/pnas.0900108106; Luo F, 2016, ONCOTARGET, V7, P30924, DOI 10.18632/oncotarget.9045; Margolis RL, 2005, CANCER CELL, V8, P353, DOI 10.1016/j.ccr.2005.10.017; Martincorena I, 2018, SCIENCE, V362, P911, DOI 10.1126/science.aau3879; Martincorena I, 2015, SCIENCE, V348, P880, DOI 10.1126/science.aaa6806; MUKHOPADHYAY KD, 2011, PLOS ONE, V0006; Nygren JM, 2008, NAT CELL BIOL, V10, P584, DOI 10.1038/ncb1721; Ogle BM, 2005, NAT REV MOL CELL BIO, V6, P567, DOI 10.1038/nrm1678; Pawelek JM, 2005, LANCET ONCOL, V6, P988, DOI 10.1016/S1470-2045(05)70466-6; Pawelek JM, 2008, NAT REV CANCER, V8, P377, DOI 10.1038/nrc2371; Perot G, 2010, AM J PATHOL, V177, P2080, DOI 10.2353/ajpath.2010.100104; Perot G, 2009, CANCER RES, V69, P2269, DOI 10.1158/0008-5472.CAN-08-1443; Powell AE, 2011, CANCER RES, V71, P1497, DOI 10.1158/0008-5472.CAN-10-3223; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; Rizvi AZ, 2006, P NATL ACAD SCI USA, V103, P6321, DOI 10.1073/pnas.0508593103; Santaguida S, 2015, NAT REV MOL CELL BIO, V16, P473, DOI 10.1038/nrm4025; Targa A, 2018, CURR OPIN CELL BIOL, V52, P136, DOI 10.1016/j.ceb.2018.03.007; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Turajlic S, 2018, CELL, V173, P581, DOI 10.1016/j.cell.2018.03.057; Van Mater D, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.123687; Vignery A, 2005, J EXP MED, V202, P337, DOI 10.1084/jem.20051123; Vitale I, 2011, CELL DEATH DIFFER, V18, P1403, DOI 10.1038/cdd.2010.145; Vitale I, 2011, NAT REV MOL CELL BIO, V12, P384, DOI 10.1038/nrm3115; Walsh S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027500; Weimann JM, 2003, NAT CELL BIOL, V5, P959, DOI 10.1038/ncb1053; Yano T, 2010, INT J MOL MED, V25, P153, DOI 10.3892/ijmm_00000325; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760; Zhou XF, 2015, AM J PATHOL, V185, P2049, DOI 10.1016/j.ajpath.2015.03.014	75	16	16	0	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2019	38	33					6083	6094		10.1038/s41388-019-0859-6	http://dx.doi.org/10.1038/s41388-019-0859-6			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IR6TP	31270395				2022-12-28	WOS:000481572400001
J	Qian, JY; Gao, J; Sun, X; Cao, MD; Shi, L; Xia, TS; Zhou, WB; Wang, S; Ding, Q; Wei, JF				Qian, Jia-Yi; Gao, Jian; Sun, Xi; Cao, Meng-Da; Shi, Liang; Xia, Tian-Song; Zhou, Wen-Bin; Wang, Shui; Ding, Qiang; Wei, Ji-Fu			KIAA1429 acts as an oncogenic factor in breast cancer by regulating CDK1 in an N6-methyladenosine-independent manner	ONCOGENE			English	Article							METHYLTRANSFERASE METTL3 PROMOTES; STEM-LIKE CELLS; RNA-METHYLATION; M(6)A; EXPRESSION; N-6-METHYLADENOSINE; TRANSLATION; IDENTIFICATION; PROGRESSION; KEGG	Most N6-methyladenosine (m(6)A) associated regulatory proteins (i.e., m(6)A writer, eraser, and reader proteins) are involved in the pathogenesis of various cancers, mostly in m(6)A-dependent manners. As a component in the m(6)A 'writers', KIAA1429 is reported to be an RNA-binding protein and involved in the m(6)A modification, mRNA splicing and processing. Till now, the functions of KIAA1429 in tumorigenesis and related mechanism have not been reported. In the present study, we found KIAA1429 was highly expressed in breast cancer tissues, but frequently down-regulated in non-cancerous breast tissues. The overall survival of breast cancer patients with high-expression KIAA1429 was significantly shorter than those with low-expression KIAA1429. Then, we demonstrated that KIAA1429 was associated with breast cancer proliferation and metastasis in vivo and in vitro. The potential targeting genes of KIAA1429 in breast cancer were identified by RNA immunoprecipitation sequencing. One of these genes is cyclin-dependent kinase 1 (CDK1), which plays an oncogenic role in cancers. Furthermore, we confirmed that KIAA1429 played its oncogenic role in breast cancer by regulating CDK1 by an m(6)A-independent manner. 5'-fluorouracil was found to be very effective in reducing the expression of KIAA1429 and CDK1 in breast cancer. These findings indicated that KIAA1429 could promote breast cancer progression and was correlated with pathogenesis. It may represent a promising therapeutic strategy on breast cancer, especially in combination with CDK1 treatment.	[Qian, Jia-Yi; Sun, Xi; Shi, Liang; Xia, Tian-Song; Zhou, Wen-Bin; Wang, Shui; Ding, Qiang] Nanjing Med Univ, Affiliated Hosp 1, Jiangsu Breast Dis Ctr, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China; [Gao, Jian] Nanjing Univ, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, Nanjing 210093, Jiangsu, Peoples R China; [Cao, Meng-Da; Wei, Ji-Fu] Nanjing Med Univ, Affiliated Hosp 1, Res Div Clin Pharmacol, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing University; Nanjing Medical University	Wang, S; Ding, Q (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Jiangsu Breast Dis Ctr, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.; Wei, JF (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Res Div Clin Pharmacol, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.	ws0801@hotmail.com; dingqiang@njmu.edu.cn; weijifu@hotmail.com	Gao, Jian/AAU-8293-2021	Gao, Jian/0000-0002-2722-7067	National Natural Science Foundation of China [81572595, 81572607, 81602336]; Project of the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Project of the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	This work was supported by the National Natural Science Foundation of China [grant numbers 81572595, 81572607, 81602336], and the Project of the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).	Barbieri I, 2017, NATURE, V552, P126, DOI 10.1038/nature24678; Cai XL, 2018, CANCER LETT, V415, P11, DOI 10.1016/j.canlet.2017.11.018; Chen MN, 2018, HEPATOLOGY, V67, P2254, DOI 10.1002/hep.29683; Chen X, 2015, MED ORAL PATOL ORAL, V20, pE7, DOI 10.4317/medoral.19841; Cui Q, 2017, CELL REP, V18, P2622, DOI 10.1016/j.celrep.2017.02.059; Dai DJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0129-x; Dassi E, 2017, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00067; Dominissini D, 2013, NAT PROTOC, V8, P176, DOI 10.1038/nprot.2012.148; Fry Nate J, 2018, Oncotarget, V9, P31231, DOI 10.18632/oncotarget.25782; Fu Y, 2014, NAT REV GENET, V15, P293, DOI 10.1038/nrg3724; Fustin JM, 2013, CELL, V155, P793, DOI 10.1016/j.cell.2013.10.026; Gao SY, 2014, ASIAN PAC J CANCER P, V15, P6437, DOI 10.7314/APJCP.2014.15.15.6437; Garcia-Maurino SM, 2017, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00071; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Haussmann IU, 2016, NATURE, V540, P301, DOI 10.1038/nature20577; Hong S, 2017, J CANCER PREV, V22, P203, DOI 10.15430/JCP.2017.22.4.203; Jiang GL, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2911-z; Jiang HS, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-182; Jiao XL, 2012, BIOINFORMATICS, V28, P1805, DOI 10.1093/bioinformatics/bts251; Kanehisa M, 2008, NUCLEIC ACIDS RES, V36, pD480, DOI 10.1093/nar/gkm882; Kim SJ, 2008, ANN ONCOL, V19, P68, DOI 10.1093/annonc/mdm358; Knuckles P, 2018, GENE DEV, V32, P415, DOI 10.1101/gad.309146.117; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li ZJ, 2017, CANCER CELL, V31, P127, DOI 10.1016/j.ccell.2016.11.017; Lin SB, 2016, MOL CELL, V62, P335, DOI 10.1016/j.molcel.2016.03.021; Ma JZ, 2017, HEPATOLOGY, V65, P529, DOI 10.1002/hep.28885; Malumbres M, 2005, TRENDS BIOCHEM SCI, V30, P630, DOI 10.1016/j.tibs.2005.09.005; Malumbres M, 2014, GENOME BIOL, V15, DOI 10.1186/gb4184; Mao XZ, 2005, BIOINFORMATICS, V21, P3787, DOI 10.1093/bioinformatics/bti430; Niessen M, 2001, GENETICS, V157, P679; Pan YT, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0590-8; Panneerdoss S, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aar8263; Patil DP, 2016, NATURE, V537, P369, DOI 10.1038/nature19342; Payton M, 2006, CANCER RES, V66, P4299, DOI 10.1158/0008-5472.CAN-05-2507; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Roundtree IA, 2017, CELL, V169, P1187, DOI 10.1016/j.cell.2017.05.045; Santamaria D, 2007, NATURE, V448, P811, DOI 10.1038/nature06046; Schwartz S, 2014, CELL REP, V8, P284, DOI 10.1016/j.celrep.2014.05.048; Su R, 2018, CELL, V172, P90, DOI 10.1016/j.cell.2017.11.031; Tang C, 2018, P NATL ACAD SCI USA, V115, pE325, DOI 10.1073/pnas.1717794115; Tang JY, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0706-6; Tsai WC, 2008, DIS MARKERS, V24, P89, DOI 10.1155/2008/945197; Visvanathan A, 2018, ONCOGENE, V37, P522, DOI 10.1038/onc.2017.351; Wang SW, 2017, CANCER LETT, V408, P112, DOI 10.1016/j.canlet.2017.08.030; Wang X, 2015, CELL, V161, P1388, DOI 10.1016/j.cell.2015.05.014; Wang X, 2014, NATURE, V505, P117, DOI 10.1038/nature12730; Wen J, 2018, MOL CELL, V69, P1028, DOI 10.1016/j.molcel.2018.02.015; Xiao W, 2016, MOL CELL, V61, P507, DOI 10.1016/j.molcel.2016.01.012; Yue YA, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-018-0019-0; Yue YN, 2015, GENE DEV, V29, P1343, DOI 10.1101/gad.262766.115; Zhang CZ, 2016, ONCOTARGET, V7, P64527, DOI 10.18632/oncotarget.11743; Zhang CZ, 2016, P NATL ACAD SCI USA, V113, pE2047, DOI 10.1073/pnas.1602883113; Zhang SC, 2017, CANCER CELL, V31, P591, DOI 10.1016/j.ccell.2017.02.013; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhao BXS, 2017, NAT REV MOL CELL BIO, V18, P31, DOI 10.1038/nrm.2016.132	56	105	106	4	43	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2019	38	33					6123	6141		10.1038/s41388-019-0861-z	http://dx.doi.org/10.1038/s41388-019-0861-z			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IR6TP	31285549				2022-12-28	WOS:000481572400004
J	Kim, M; Gwak, J; Hwang, S; Yang, S; Jeong, SM				Kim, Minjoong; Gwak, Jihye; Hwang, Sunsook; Yang, Seungyeon; Jeong, Seung Min			Mitochondrial GPT2 plays a pivotal role in metabolic adaptation to the perturbation of mitochondrial glutamine metabolism	ONCOGENE			English	Article							PANCREATIC-CANCER GROWTH; UP-REGULATION; SUPPRESSION; INHIBITION; SURVIVAL; PATHWAY	Cancer cells exhibit metabolic dependence on mitochondrial glutamine metabolism that provides them with the substrates required for rapid proliferation. Despite the extensive efforts to target this glutamine addiction for therapeutic purposes, the adaptive metabolic responses and the mechanisms whereby cells maintain their unlimited growth remain areas of active investigation. Here we report that mitochondrial glutamate-pyruvate transaminase 2 (GPT2) contributes to cell survival and growth by sustaining the tricarboxylic acid (TCA) cycle anaplerosis after the inhibition of glutaminase (GLS), the first enzyme for mitochondrial glutamine metabolism. We found that elevated reactive oxygen species upon GLS inhibition induce GPT2 expression via activating transcription factor 4. Moreover, inhibition of GPT2 synergized with suppression of GLS activity to induce a pronounced reduction in proliferation and an increase in cell death of cancer cells. Our data uncover GPT2 as an important component of the adaptive metabolic response for glutamine deprivation and indicate that targeting this pathway in combination with GLS inhibition may be an effective therapeutic approach for cancer treatment.	[Kim, Minjoong; Gwak, Jihye; Hwang, Sunsook; Yang, Seungyeon; Jeong, Seung Min] Catholic Univ Korea, Coll Med, Dept Biochem, 222 Banpo Daero, Seoul 06591, South Korea; [Kim, Minjoong; Gwak, Jihye; Hwang, Sunsook; Yang, Seungyeon; Jeong, Seung Min] Catholic Univ Korea, Coll Med, Dept Biomed & Hlth Sci, 222 Banpo Daero, Seoul 06591, South Korea; [Kim, Minjoong; Gwak, Jihye; Hwang, Sunsook; Yang, Seungyeon; Jeong, Seung Min] Catholic Univ Korea, Coll Med, Inst Aging & Metab Dis, 222 Banpo Daero, Seoul 06591, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea	Jeong, SM (corresponding author), Catholic Univ Korea, Coll Med, Dept Biochem, 222 Banpo Daero, Seoul 06591, South Korea.; Jeong, SM (corresponding author), Catholic Univ Korea, Coll Med, Dept Biomed & Hlth Sci, 222 Banpo Daero, Seoul 06591, South Korea.; Jeong, SM (corresponding author), Catholic Univ Korea, Coll Med, Inst Aging & Metab Dis, 222 Banpo Daero, Seoul 06591, South Korea.	smjeong@catholic.ac.kr		Kim, Minjoong/0000-0003-1065-7914	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education [2015R1C1A1A01052548, 2018R1D1A1B07040961]	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education	This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2015R1C1A1A01052548 and 2018R1D1A1B07040961).	Altman BJ, 2016, NAT REV CANCER, V16, P619, DOI 10.1038/nrc.2016.71; Biancur DE, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15965; Byun JK, 2017, CELL REP, V20, P586, DOI 10.1016/j.celrep.2017.06.066; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Ferguson J, 2017, ONCOTARGET, V8, P32946, DOI 10.18632/oncotarget.16514; Gross MI, 2014, MOL CANCER THER, V13, P890, DOI 10.1158/1535-7163.MCT-13-0870; Hao YJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11971; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Jeong SM, 2016, SCI REP-UK, V6, DOI 10.1038/srep30767; Jeong SM, 2013, CANCER CELL, V23, P450, DOI 10.1016/j.ccr.2013.02.024; Lu SC, 2009, MOL ASPECTS MED, V30, P42, DOI 10.1016/j.mam.2008.05.005; Panieri E, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.105; Patel D, 2016, J BIOL CHEM, V291, P9322, DOI 10.1074/jbc.M115.710145; Polet F, 2016, ONCOTARGET, V7, P1765, DOI 10.18632/oncotarget.6426; Robinson MM, 2007, BIOCHEM J, V406, P407, DOI 10.1042/BJ20070039; Salgado MC, 2014, BBA-GENE REGUL MECH, V1839, P288, DOI 10.1016/j.bbagrm.2014.01.005; Shanware NP, 2011, J MOL MED, V89, P229, DOI 10.1007/s00109-011-0731-9; Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040; Sun LC, 2015, CELL RES, V25, P429, DOI 10.1038/cr.2015.33; Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817; Toda K, 2016, NEOPLASIA, V18, P654, DOI 10.1016/j.neo.2016.09.004; Wang SF, 2016, ONCOTARGET, V7, P74132, DOI 10.18632/oncotarget.12356; Wise DR, 2010, TRENDS BIOCHEM SCI, V35, P427, DOI 10.1016/j.tibs.2010.05.003; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Wong D T, 1973, Adv Enzyme Regul, V11, P139, DOI 10.1016/0065-2571(73)90013-7; Yang S, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0089-1; Ye JB, 2010, EMBO J, V29, P2082, DOI 10.1038/emboj.2010.81; Zhang J, 2014, MOL CELL, V56, P205, DOI 10.1016/j.molcel.2014.08.018	28	21	21	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2019	38	24					4729	4738		10.1038/s41388-019-0751-4	http://dx.doi.org/10.1038/s41388-019-0751-4			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IC7ND	30765862				2022-12-28	WOS:000471160500006
J	Zang, GX; Mu, YB; Gao, LL; Bergh, A; Landstrom, M				Zang, Guangxiang; Mu, Yabing; Gao, Linlin; Bergh, Anders; Landstrom, Marene			PKC sigma facilitates lymphatic metastatic spread of prostate cancer cells in a mice xenograft model	ONCOGENE			English	Article							KINASE-C-ZETA; TUMOR-ASSOCIATED MACROPHAGES; NODE METASTASIS; GROWTH; LYMPHANGIOGENESIS; MECHANISMS; MIGRATION; INVASION; HYALURONAN; PHOSPHORYLATION	Prostate cancer disseminates primarily into the adjacent lymph nodes, which is related to a poor outcome. Atypical protein kinase C sigma (PKC sigma) is highly expressed in aggressive prostate cancer and correlates with Gleason score, clinical stage, and poor prognosis. Here, we report the molecular mechanisms of PKC sigma in lymphatic metastasis during prostate cancer progression. Using zinc-finger nuclease technology or PKC shRNA lentiviral particles, and orthotopic mouse xenografts, we show that PKC sigma-knockout or knockdown from aggressive prostate cancer (PC3 and PC3U) cells, decreasesd tumor growth and lymphatic metastasis in vivo. Intriguingly, PKC sigma-knockout or knockdown impaired the activation of AKT, ERK, and NF-kappa B signaling in prostate cancer cells, thereby impairing the expression of lymphangiogenic factors and macrophage recruitment, resulting in aberrant lymphangiogenesis. Moreover, PKC sigma regulated the expression of hyaluronan synthase enzymes, which is important for hyaluronan-mediated lymphatic drainage and tumor dissemination. Thus, PKC sigma plays a crucial oncogenic role in the lymphatic metastasis of prostate cancer and is predicted to be a novel therapeutic target for prostate cancer.	[Zang, Guangxiang; Mu, Yabing; Gao, Linlin; Bergh, Anders; Landstrom, Marene] Umea Univ, Dept Med Biosci, Bldg 6M,2nd Floor, SE-90185 Umea, Sweden; [Gao, Linlin] Natl Inst Biol Sci, 7 Sci Pk Rd ZGC Life Sci Pk, Beijing 102206, Peoples R China	Umea University; National Institute of Biological Sciences, Beijing	Landstrom, M (corresponding author), Umea Univ, Dept Med Biosci, Bldg 6M,2nd Floor, SE-90185 Umea, Sweden.	Marene.Landstrom@umu.se		Landstrom, Marene/0000-0001-6737-7230	RFI/VR and Science for Life Laboratory, Sweden; Bioinformatics Infrastructure for Life Sciences (BILS); Swedish Medical Research Council [K2016-02513]; Swedish Cancer Society [CAN 2017/544, 2016/387]; Knut and Alice Wallenberg Foundation [2012.0090]; Cancer Research Foundation in Northern Sweden; Lion's Cancer Research Foundation; Umea University;  [ALF-VLL464591];  [ALF-VLL-738911]	RFI/VR and Science for Life Laboratory, Sweden; Bioinformatics Infrastructure for Life Sciences (BILS); Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Swedish Cancer Society(Swedish Cancer Society); Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Cancer Research Foundation in Northern Sweden; Lion's Cancer Research Foundation; Umea University; ; 	We would like to acknowledge the National Genomics Infrastructure (NGI)/Uppsala Genome Center and UPPMAX for providing assistance in massive parallel sequencing and computational infrastructure. Work performed at the NGI/Uppsala Genome Center was funded by the RFI/VR and Science for Life Laboratory, Sweden. We would like to thank Dr. Jeanette Tangrot for the exome sequencing analysis and support from the Bioinformatics Infrastructure for Life Sciences (BILS) and Dr. Xiaolian Gu for valuable advices on data achieved from whole genome sequencing of PC3 and PC3U cells. We acknowledge the skillful technical assistance performed by Pernilla Andersson and Susanne Gidlund at Department of Medical Bioscience, Umea University. This work was supported by grants from the Swedish Medical Research Council (K2016-02513), the Swedish Cancer Society (CAN 2017/544; 2016/387), ALF-VLL464591 and ALF-VLL-738911, the Knut and Alice Wallenberg Foundation (2012.0090), the Cancer Research Foundation in Northern Sweden, Lion's Cancer Research Foundation, and Umea University.	Avraamides CJ, 2008, NAT REV CANCER, V8, P604, DOI 10.1038/nrc2353; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; Brown AJ, 2013, NAT METHODS, V10, P638, DOI 10.1038/nmeth.2516; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Dadras SS, 2003, AM J PATHOL, V162, P1951, DOI 10.1016/S0002-9440(10)64328-3; Daneshmand S, 2004, J UROLOGY, V172, P2252, DOI 10.1097/01.ju.0000143448.04161.cc; Datta K, 2010, FUTURE ONCOL, V6, P823, DOI 10.2217/FON.10.33; Diaz-Meco MT, 2001, MOL CELL BIOL, V21, P1218, DOI 10.1128/MCB.21.4.1218-1227.2001; Esteve PO, 2002, J BIOL CHEM, V277, P35150, DOI 10.1074/jbc.M108600200; Evans JD, 2003, AM J CLIN PATHOL, V119, P392, DOI 10.1309/BKPC9DX98R781B87; FRANZEN P, 1993, EXP CELL RES, V207, P1, DOI 10.1006/excr.1993.1156; Guo H, 2009, J NEUROCHEM, V109, P203, DOI 10.1111/j.1471-4159.2009.05946.x; Hagemann T, 2009, BLOOD, V113, P3139, DOI 10.1182/blood-2008-12-172825; Halin S, 2009, NEOPLASIA, V11, P177, DOI 10.1593/neo.81338; Hamidi A, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aal4186; Hirai T, 2003, J BIOCHEM, V133, P1, DOI 10.1093/jb/mvg017; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Izumi K, 2016, ONCOTARGET, V7, P8389, DOI 10.18632/oncotarget.6690; Jiang D, 2007, ANNU REV CELL DEV BI, V23, P435, DOI 10.1146/annurev.cellbio.23.090506.123337; Josefsson A, 2011, AM J PATHOL, V179, P1961, DOI 10.1016/j.ajpath.2011.06.005; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kim JY, 2013, P NATL ACAD SCI USA, V110, P6418, DOI 10.1073/pnas.1221799110; Kyzas PA, 2005, J PATHOL, V206, P170, DOI 10.1002/path.1776; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; Lissbrant IF, 2000, INT J ONCOL, V17, P445; Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033; Monslow J, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00231; Mu Y, 2015, BRIT J CANCER, V112, P1223, DOI 10.1038/bjc.2015.71; Nguyen DP, 2014, BJU INT, V114, P168, DOI [10.1111/bju.12488, 10.1111/j.1464-410X.2013.11397_10.x]; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Pang MF, 2016, ONCOGENE, V35, P748, DOI 10.1038/onc.2015.133; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Sato K, 2016, CELL STEM CELL, V19, P127, DOI 10.1016/j.stem.2016.06.003; Shayan R, 2006, CARCINOGENESIS, V27, P1729, DOI 10.1093/carcin/bgl031; Shiao SL, 2016, CANCER LETT, V380, P340, DOI 10.1016/j.canlet.2015.12.022; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Stacker SA, 2014, NAT REV CANCER, V14, P159, DOI 10.1038/nrc3677; Sun RH, 2005, CANCER RES, V65, P1433, DOI 10.1158/0008-5472.CAN-04-1163; Tammela T, 2010, CELL, V140, P460, DOI 10.1016/j.cell.2010.01.045; Vigetti D, 2010, J BIOL CHEM, V285, P24639, DOI 10.1074/jbc.M110.134536; Yang MJ, 2011, J EXP MED, V208, P2099, DOI 10.1084/jem.20102667; Yao Sheng, 2010, Genes Cancer, V1, P444, DOI 10.1177/1947601910376079; Yokoyama Y, 2003, BRIT J CANCER, V88, P237, DOI 10.1038/sj.bjc.6600701; Zeng YP, 2005, PROSTATE, V65, P222, DOI 10.1002/pros.20288; Zheng W, 2014, J CLIN INVEST, V124, P878, DOI 10.1172/JCI71603	45	8	8	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2019	38	22					4215	4231		10.1038/s41388-019-0722-9	http://dx.doi.org/10.1038/s41388-019-0722-9			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IA1RB	30705401	Green Published, hybrid			2022-12-28	WOS:000469339100002
J	Tenvooren, I; Jenks, MZ; Rashid, H; Cook, KL; Muhlemann, JK; Sistrunk, C; Holmes, J; Wang, K; Bonin, K; Hodges, K; Lo, HW; Shaikh, A; Camarillo, IG; Lelievre, SA; Seewaldt, V; Vidi, PA				Tenvooren, Iliana; Jenks, Monica Z.; Rashid, Hamza; Cook, Katherine L.; Muhlemann, Joelle K.; Sistrunk, Christopher; Holmes, Julia; Wang, Kevin; Bonin, Keith; Hodges, Kurt; Lo, Hui-Wen; Shaikh, Ayaz; Camarillo, Ignacio G.; Lelievre, Sophie A.; Seewaldt, Victoria; Vidi, Pierre-Alexandre			Elevated leptin disrupts epithelial polarity and promotes premalignant alterations in the mammary gland	ONCOGENE			English	Article							BREAST-CANCER RISK; CELL POLARITY; GROWTH-FACTOR; NUCLEAR-ORGANIZATION; SIGNALING PATHWAYS; CIRCULATING LEVELS; NORMAL-WEIGHT; OBESITY; ADIPONECTIN; AFADIN	Obesity is a highly prevalent and modifiable breast cancer risk factor. While the role of obesity in fueling breast cancer progression is well established, the mechanisms linking obesity to breast cancer initiation are poorly understood. A hallmark of breast cancer initiation is the disruption of apical polarity in mammary glands. Here we show that mice with diet-induced obesity display mislocalization of Par3, a regulator of cellular junctional complexes defining mammary epithelial polarity. We found that epithelial polarity loss also occurs in a 3D coculture system that combines acini with human mammary adipose tissue, and establish that a paracrine effect of the tissue adipokine leptin causes loss of polarity by overactivation of the PI3K/Akt pathway. Leptin sensitizes non-neoplastic cells to proliferative stimuli, causes mitotic spindle misalignment, and expands the pool of cells with stem/progenitor characteristics, which are early steps for cancer initiation. We also found that normal breast tissue samples with high leptin/adiponectin transcript ratio characteristic of obesity have an altered distribution of apical polarity markers. This effect is associated with increased epithelial cell layers. Our results provide a molecular basis for early alterations in epithelial architecture during obesity-mediated cancer initiation.	[Tenvooren, Iliana; Jenks, Monica Z.; Rashid, Hamza; Holmes, Julia; Lo, Hui-Wen; Vidi, Pierre-Alexandre] Wake Forest Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA; [Cook, Katherine L.] Wake Forest Sch Med, Dept Surg, Winston Salem, NC 27157 USA; [Cook, Katherine L.; Vidi, Pierre-Alexandre] Wake Forest Univ, Ctr Comprehens Canc, Winston Salem, NC 27109 USA; [Muhlemann, Joelle K.] Wake Forest Univ, Dept Biol, Winston Salem, NC 27109 USA; [Sistrunk, Christopher; Seewaldt, Victoria] City Hope Natl Med Ctr, Dept Populat Sci, Duarte, CA 91010 USA; [Wang, Kevin; Bonin, Keith] Wake Forest Univ, Dept Phys, Winston Salem, NC 27109 USA; [Hodges, Kurt] Univ Cincinnati, Dept Pathol & Lab Med, Cincinnati, OH 45219 USA; [Shaikh, Ayaz] Indiana Univ Sch Med, IU Hlth Arnett Hosp, Lafayette, IN 47905 USA; [Camarillo, Ignacio G.] Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; [Lelievre, Sophie A.] Purdue Univ, Dept Basic Med Sci, W Lafayette, IN 47907 USA	Wake Forest University; Wake Forest University; Wake Forest University; Wake Forest University; City of Hope; Wake Forest University; University System of Ohio; University of Cincinnati; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Vidi, PA (corresponding author), Wake Forest Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA.; Vidi, PA (corresponding author), Wake Forest Univ, Ctr Comprehens Canc, Winston Salem, NC 27109 USA.	pvidi@wakehealth.edu		LELIEVRE, Sophie/0000-0001-6606-2501; Muhlemann, Joelle/0000-0003-2431-4357; Sistrunk, Christopher/0000-0002-5951-1361; Cook, Katherine/0000-0001-6241-0214	National Institute of Health [R00CA163957]; Walther Cancer Foundation; Wake Forest Center for Molecular Signaling (CMS); National Cancer Institute's Cancer Center Support Grant [P30CA012197]; NATIONAL CANCER INSTITUTE [R01CA158668, R01CA192914, P30CA012197, R00CA163957] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Walther Cancer Foundation; Wake Forest Center for Molecular Signaling (CMS); National Cancer Institute's Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Kenneth Grant for assistance with electron microscopy and Dr. Fei Xing for assistance with stem cell analyses. The CA-Akt construct was a gift from Dr. Mong-Hong Lee (MD Anderson Cancer Center). NuMA B1C11 antibodies were kindly provided by Dr. J. Nickerson (University of Massachusetts). This work was funded by the National Institute of Health (R00CA163957 to PAV), the Walther Cancer Foundation (to SAL, PAV, and IGC), the Wake Forest Center for Molecular Signaling (CMS; to PAV and KB), and the National Cancer Institute's Cancer Center Support Grant award number P30CA012197 issued to the Wake Forest Baptist Comprehensive Cancer Center. SAL, VS, and PAV are members of the International Breast Cancer & Nutrition (IBCN) program.	Ando S, 2012, NAT REV ENDOCRINOL, V8, P263, DOI 10.1038/nrendo.2011.184; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Balda MS, 2000, EMBO J, V19, P2024, DOI 10.1093/emboj/19.9.2024; Bartella V, 2008, CANCER RES, V68, P4919, DOI 10.1158/0008-5472.CAN-08-0642; Bissell MJ, 1999, CANCER RES, V59, p1757S; BRIAND P, 1987, IN VITRO CELL DEV B, V23, P181, DOI 10.1007/BF02623578; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Carminati M, 2016, NAT STRUCT MOL BIOL, V23, P155, DOI 10.1038/nsmb.3152; Carpenter RL, 2015, ONCOGENE, V34, P546, DOI 10.1038/onc.2013.582; Cecchini RS, 2012, CANCER PREV RES, V5, P583, DOI 10.1158/1940-6207.CAPR-11-0482; Chandramouly G, 2007, J CELL SCI, V120, P1596, DOI 10.1242/jcs.03439; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Dietze EC, 2015, NAT REV CANCER, V15, P248, DOI 10.1038/nrc3896; Dubois V, 2014, NUTR CANCER, V66, P645, DOI 10.1080/01635581.2014.894104; Elloul S, 2014, MOL CANCER RES, V12, P464, DOI 10.1158/1541-7786.MCR-13-0398; Esper RM, 2015, CANCER PREV RES, V8, P1174, DOI 10.1158/1940-6207.CAPR-14-0334; Fan Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120775; Fang LH, 2007, CELL RES, V17, P100, DOI 10.1038/sj.cr.7310145; Feigin ME, 2014, CANCER RES, V74, P3180, DOI 10.1158/0008-5472.CAN-13-3415; Grafton MMG, 2011, INTEGR BIOL-UK, V3, P451, DOI [10.1039/c0ib00132e, 10.1039/c0ib00132c]; Grossmann ME, 2012, BIOCHIMIE, V94, P2164, DOI 10.1016/j.biochi.2012.06.013; Gunter MJ, 2009, JNCI-J NATL CANCER I, V101, P48, DOI 10.1093/jnci/djn415; Hao Y, 2010, CURR BIOL, V20, P1809, DOI 10.1016/j.cub.2010.09.032; Hu X, 2002, J NATL CANCER I, V94, P1704, DOI 10.1093/jnci/94.22.1704; Hursting SD, 2012, CANCER PREV RES, V5, P1260, DOI 10.1158/1940-6207.CAPR-12-0140; Ibarra-Drendall C, 2012, BREAST CANCER RES TR, V132, P487, DOI 10.1007/s10549-011-1609-9; Kim CS, 2006, INT J OBESITY, V30, P1347, DOI 10.1038/sj.ijo.0803259; Lelievre SA, 2010, J MAMMARY GLAND BIOL, V15, P49, DOI 10.1007/s10911-010-9168-y; Macara IG, 2014, CURR BIOL, V24, pR815, DOI 10.1016/j.cub.2014.06.068; Macis D, 2014, INT J EPIDEMIOL, V43, P1226, DOI 10.1093/ije/dyu088; Martin-Belmonte F, 2007, CELL, V128, P383, DOI 10.1016/j.cell.2006.11.051; Martin-Belmonte F, 2012, NAT REV CANCER, V12, P23, DOI 10.1038/nrc3169; Matsubara M, 2002, EUR J ENDOCRINOL, V147, P173, DOI 10.1530/eje.0.1470173; McCaffrey LM, 2012, CANCER CELL, V22, P601, DOI 10.1016/j.ccr.2012.10.003; Millikan RC, 2008, BREAST CANCER RES TR, V109, P123, DOI 10.1007/s10549-007-9632-6; Niu DH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067456; Ogden Cynthia L, 2015, NCHS Data Brief, P1; Ooshio T, 2010, J BIOL CHEM, V285, P5003, DOI 10.1074/jbc.M109.043760; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; Pierobon M, 2013, BREAST CANCER RES TR, V137, P307, DOI 10.1007/s10549-012-2339-3; Rangel MC, 2016, BREAST CANCER RES TR, V156, P211, DOI 10.1007/s10549-016-3746-7; Ray A, 2017, CYTOKINE GROWTH F R, V38, P80, DOI 10.1016/j.cytogfr.2017.11.002; Renehan AG, 2015, NAT REV CANCER, V15, P484, DOI 10.1038/nrc3967; Roignot J, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a013789; Royer C, 2011, CELL DEATH DIFFER, V18, P1470, DOI 10.1038/cdd.2011.60; Saxena NK, 2013, J MAMMARY GLAND BIOL, V18, P309, DOI 10.1007/s10911-013-9308-2; Schwartz GF, 2008, CANCER, V113, P2627, DOI 10.1002/cncr.23903; Sumis A, 2016, ENDOCR-RELAT CANCER, V23, P839, DOI 10.1530/ERC-16-0359; Takai Y, 2008, ANNU REV CELL DEV BI, V24, P309, DOI 10.1146/annurev.cellbio.24.110707.175339; Teixeira TFS, 2012, NUTR RES, V32, P637, DOI 10.1016/j.nutres.2012.07.003; Vidi Pierre-Alexandre, 2013, Methods Mol Biol, V945, P193, DOI 10.1007/978-1-62703-125-7_13; Vidi PA, 2012, J CELL SCI, V125, P350, DOI 10.1242/jcs.089177; Wang F, 2002, JNCI-J NATL CANCER I, V94, P1494, DOI 10.1093/jnci/94.19.1494; Wheatley KE, 2011, J OBES, V2011, DOI 10.1155/2011/265417; Wu MH, 2009, BRIT J CANCER, V100, P578, DOI 10.1038/sj.bjc.6604913; Xue GD, 2013, JNCI-J NATL CANCER I, V105, P393, DOI 10.1093/jnci/djs648; Zeidan A, 2007, J PHARMACOL EXP THER, V322, P1110, DOI 10.1124/jpet.107.122440	57	27	27	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2019	38	20					3855	3870		10.1038/s41388-019-0687-8	http://dx.doi.org/10.1038/s41388-019-0687-8			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HY3OI	30670780	Green Accepted			2022-12-28	WOS:000468035600007
J	Woosley, AN; Dalton, AC; Hussey, GS; Howley, BV; Mohanty, BK; Grelet, S; Dincman, T; Bloos, S; Olsen, SK; Howe, PH				Woosley, Alec N.; Dalton, Annamarie C.; Hussey, George S.; Howley, Breege V.; Mohanty, Bidyut K.; Grelet, Simon; Dincman, Toros; Bloos, Sean; Olsen, Shaun K.; Howe, Philip H.			TGF beta promotes breast cancer stem cell self-renewal through an ILEI/LIFR signaling axis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; METASTASIS SUPPRESSOR; TUMOR CELLS; IN-VITRO; LIFR; EMT; CARCINOMA; EVOLUTION; ILEI; IDENTIFICATION	FAM3C/Interleukin-like EMT Inducer (ILEI) is an oncogenic member of the FAM3 cytokine family and serves essential roles in both epithelial-mesenchymal transition (EMT) and breast cancer metastasis. ILEI expression levels are regulated through a non-canonical TGF beta signaling pathway by 3'-UTR-mediated translational silencing at the mRNA level by hnRNP E1. TGF beta stimulation or silencing of hnRNP E1 increases ILEI translation and induces an EMT program that correlates with enhanced invasion and migration. Recently, EMT has been linked to the formation of breast cancer stem cells (BCSCs) that confer both tumor cell heterogeneity as well as chemoresistant properties. Herein, we demonstrate that hnRNP E1 knockdown significantly shifts normal mammary epithelial cells to mesenchymal BCSCs in vitro and in vivo. We further validate that modulating ILEI protein levels results in the abrogation of these phenotypes, promoting further investigation into the unknown mechanism of ILEI signaling that drives tumor progression. We identify LIFR as the receptor for ILEI, which mediates signaling through STAT3 to drive both EMT and BCSC formation. Reduction of either ILEI or LIFR protein levels results in reduced tumor growth, fewer tumor initiating cells and reduced metastasis within the hnRNP E1 knockdown cell populations in vivo. These results reveal a novel ligand-receptor complex that drives the formation of BCSCs and represents a unique target for the development of metastatic breast cancer therapies.	[Woosley, Alec N.; Dalton, Annamarie C.; Hussey, George S.; Howley, Breege V.; Mohanty, Bidyut K.; Grelet, Simon; Dincman, Toros; Bloos, Sean; Olsen, Shaun K.; Howe, Philip H.] Med Univ South Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Charleston, SC 29425 USA	Medical University of South Carolina	Howe, PH (corresponding author), Med Univ South Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Charleston, SC 29425 USA.	howep@musc.edu	Bloos, Sean/AAD-4630-2021	Dincman, Toros/0000-0002-4449-0510; Olsen, Shaun/0000-0002-1265-7101; Howe, Philip/0000-0002-1358-1313; Bloos, Sean/0000-0002-1044-4823	DOD BCRP [BC170301]; NIH NCI [RO1CA154663, T32 CA193201, F31 CA213627]; Office of the Assistant Secretary of Defense for Health Affairs through the Breast Cancer Research Program [W81XWH-18-1-0003]; U.S. Army Medical Research Acquisition Activity, Chandler Street, Fort Detrick MD; NATIONAL CANCER INSTITUTE [T32CA193201, R01CA154663, F31CA213627] Funding Source: NIH RePORTER	DOD BCRP(United States Department of Defense); NIH NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Office of the Assistant Secretary of Defense for Health Affairs through the Breast Cancer Research Program; U.S. Army Medical Research Acquisition Activity, Chandler Street, Fort Detrick MD; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Ken Noguchi and the Howe laboratory members for their helpful discussions and critical reading of the manuscript. The SUM cell lines and HMLE cell lines were a generous gift from Dr. Steven Ethier and Dr. Juan Massague, respectively. Funding for this project was provided by DOD BCRP BC170301 to ACD, NIH NCI T32 CA193201 to ACD, NIH NCI F31 CA213627 to ANW, and NIH NCI RO1CA154663 to PHH. Cores at MUSC used for this project include the shRNA Shared Technology Resource, Flow Cytometry and Cell Sorting Unit, Laboratory Core in the Center for Oral Health Research, Cell and Molecular Imaging Core and the Biorepository and Tissue Analysis Shared Resource. The U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick MD 21702-5014 is the awarding and administering acquisition office for ACD. This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Breast Cancer Research Program, under Award No. W81XWH-18-1-0003. Opinions, interpretations, conclusions, and recommendations are those of the author and are not necessarily endorsed by the Department of Defense. In conducting research using animals, the investigators adhere to the laws of the United States and regulations of the Department of Agriculture.	Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Asiedu MK, 2011, CANCER RES, V71, P4707, DOI 10.1158/0008-5472.CAN-10-4554; Brill B, 2008, LAB ANIM-UK, V42, P104, DOI 10.1258/la.2007.06003e; Chaudhury A, 2010, NAT CELL BIOL, V12, P286, DOI 10.1038/ncb2029; Chen DH, 2012, NAT MED, V18, P1511, DOI 10.1038/nm.2940; Chiou SH, 2008, CLIN CANCER RES, V14, P4085, DOI 10.1158/1078-0432.CCR-07-4404; Csiszar A, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0433-7; Forozan F, 1999, BRIT J CANCER, V81, P1328, DOI 10.1038/sj.bjc.6695007; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Ginestier C, 2010, J CLIN INVEST, V120, P485, DOI 10.1172/JCI39397; Grelet S, 2017, NAT CELL BIOL, V19, P1105, DOI 10.1038/ncb3595; Guo HW, 2015, ONCOTARGET, V6, P25484, DOI 10.18632/oncotarget.4688; Hasegawa H, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4917; Hirai H, 2011, BIOCHEM J, V438, P11, DOI 10.1042/BJ20102152; Howley BV, 2016, ONCOGENE, V35, P1725, DOI 10.1038/onc.2015.238; Howley BV, 2018, ONCOGENE, V37, P1308, DOI 10.1038/s41388-017-0023-0; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Hussey GS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052624; Hussey GS, 2011, MOL CELL, V41, P419, DOI 10.1016/j.molcel.2011.02.003; Ishihara K, 2002, BBA-MOL CELL RES, V1592, P281, DOI 10.1016/S0167-4889(02)00321-X; James P, 1996, GENETICS, V144, P1425; Johnson RW, 2016, NAT CELL BIOL, V18, P1078, DOI 10.1038/ncb3408; Junk DJ, 2017, ONCOGENE, V36, P4001, DOI 10.1038/onc.2017.33; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Katahira T, 2010, BIOCHEM BIOPH RES CO, V392, P301, DOI 10.1016/j.bbrc.2009.12.180; Kim SY, 2013, CELL SIGNAL, V25, P961, DOI 10.1016/j.cellsig.2013.01.007; Korkaya H, 2012, MOL CELL, V47, P570, DOI 10.1016/j.molcel.2012.06.014; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Lahsnig C, 2009, ONCOGENE, V28, P638, DOI 10.1038/onc.2008.418; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Lebrun Jean-Jacques, 2012, ISRN Mol Biol, V2012, P381428, DOI 10.5402/2012/381428; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Li XY, 2014, ONCOTARGET, V5, P788, DOI 10.18632/oncotarget.1772; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Liu F, 2016, ONCOL LETT, V12, P4869, DOI 10.3892/ol.2016.5369; Luo Q, 2015, CARCINOGENESIS, V36, P1201, DOI 10.1093/carcin/bgv108; Lv SD, 2018, ONCOGENE, V37, P1354, DOI 10.1038/s41388-017-0026-x; Ma D, 2016, ONCOL REP, V36, P827, DOI 10.3892/or.2016.4865; Maatta JA, 2016, BONEKEY REP, V5, DOI 10.1038/bonekey.2016.14; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; MATSUI WH, 2016, MEDICINE S1, V95, DOI DOI 10.1097/MD.0000000000004765; Nicola NA, 2015, CYTOKINE GROWTH F R, V26, P533, DOI 10.1016/j.cytogfr.2015.07.001; Port MD, 2007, J NEUROCHEM, V101, P782, DOI 10.1111/j.1471-4159.2007.04471.x; Richards EJ, 2015, J BIOL CHEM, V290, P6857, DOI 10.1074/jbc.M114.610915; Schust J, 2006, CHEM BIOL, V13, P1235, DOI 10.1016/j.chembiol.2006.09.018; Thomas SJ, 2015, BRIT J CANCER, V113, P365, DOI 10.1038/bjc.2015.233; Tomita H, 2016, ONCOTARGET, V7, P11018, DOI 10.18632/oncotarget.6920; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Underhill-Day N, 2006, CANCER RES, V66, P10891, DOI 10.1158/0008-5472.CAN-06-1766; Velasco-Velazquez MA, 2012, INT J BIOCHEM CELL B, V44, P573, DOI 10.1016/j.biocel.2011.12.020; Waerner T, 2006, CANCER CELL, V10, P227, DOI 10.1016/j.ccr.2006.07.020; Wahl GM, 2017, NPJ BREAST CANCER, V3, DOI 10.1038/s41523-017-0012-z; Wang TY, 2018, CELL METAB, V27, P136, DOI 10.1016/j.cmet.2017.11.001; Wang XY, 2012, J BIOMED RES, V26, P325, DOI 10.7555/JBR.26.20110050; Yates LR, 2017, CANCER CELL, V32, P169, DOI 10.1016/j.ccell.2017.07.005; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522; Yue Xuetian, 2015, Cancer Cell Microenviron, V2; Zhu Y, 2002, GENOMICS, V80, P144, DOI 10.1006/geno.2002.6816	60	42	43	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2019	38	20					3794	3811		10.1038/s41388-019-0703-z	http://dx.doi.org/10.1038/s41388-019-0703-z			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HY3OI	30692635	Green Accepted			2022-12-28	WOS:000468035600003
J	Gunaratna, RT; Santos, A; Luo, LJ; Nagi, C; Lambertz, I; Spier, M; Conti, CJ; Fuchs-Young, RS				Gunaratna, Ramesh T.; Santos, Andres; Luo, Linjie; Nagi, Chandandeep; Lambertz, Isabel; Spier, Madison; Conti, Claudio J.; Fuchs-Young, Robin S.			Dynamic role of the codon 72 p53 single-nucleotide polymorphism in mammary tumorigenesis in a humanized mouse model	ONCOGENE			English	Article							NF-KAPPA-B; BREAST-CANCER; CELLULAR SENESCENCE; R72P POLYMORPHISM; ANGIOGENIC SWITCH; TUMOR SUPPRESSION; ARGININE ALLELE; INFLAMMATION; EXPRESSION; ASSOCIATION	Female breast cancer (BrCa) is the most common noncutaneous cancer among women in the United States. Human epidemiological studies reveal that a p53 single-nucleotide polymorphism (SNP) at codon 72, encoding proline (P72) or arginine (R72), is associated with differential risk of several cancers, including BrCa. However, the molecular mechanisms by which these variants affect mammary tumorigenesis remain unresolved. To investigate the effects of this polymorphism on susceptibility to mammary cancer, we used a humanized p53 mouse model, homozygous for either P72 or R72. Our studies revealed that R72 mice had a significantly higher mammary tumor incidence and reduced latency in both DMBAinduced and MMTV-Erbb2/Neu mouse mammary tumor models compared to P72 mice. Analyses showed that susceptible mammary glands from E-R72 (R72 x MMTV-Erbb2/Neu) mice developed a senescence-associated secretory phenotype (SASP) with influx of proinflammatory macrophages, ultimately resulting in chronic, protumorigenic inflammation. Mammary tumors arising in E-R72 mice also had an increased influx of tumor-associated macrophages, contributing to angiogenesis and elevated tumor growth rates. These results demonstrate that the p53 R72 variant increased susceptibility to mammary tumorigenesis through chronic inflammation.	[Gunaratna, Ramesh T.; Fuchs-Young, Robin S.] Texas A&M Univ, Interdisciplinary Program Genet, College Stn, TX 77843 USA; [Gunaratna, Ramesh T.; Santos, Andres; Luo, Linjie; Lambertz, Isabel; Spier, Madison; Conti, Claudio J.; Fuchs-Young, Robin S.] Texas A&M Hlth Sci Ctr, Coll Med, Dept Mol & Cellular Med, College Stn, TX 77807 USA; [Gunaratna, Ramesh T.] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; [Santos, Andres] Texas Tech Univ, Hlth Sci Ctr, Paul L Foster Sch Med, El Paso, TX USA; [Nagi, Chandandeep] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA; [Conti, Claudio J.] Univ Carlos III Madrid, Dept Bioingn, Madrid, Spain; [Conti, Claudio J.] Fdn Jimenez Diaz IIS FJD, Fdn Inst Invest Sanitaria, Madrid, Spain; [Conti, Claudio J.] Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid, Spain	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Princeton University; Texas Tech University System; Texas Tech University; Baylor College of Medicine; Universidad Carlos III de Madrid; Fundacion Jimenez Diaz; CIBER - Centro de Investigacion Biomedica en Red; CIBERER	Fuchs-Young, RS (corresponding author), Texas A&M Univ, Interdisciplinary Program Genet, College Stn, TX 77843 USA.; Fuchs-Young, RS (corresponding author), Texas A&M Hlth Sci Ctr, Coll Med, Dept Mol & Cellular Med, College Stn, TX 77807 USA.	fuchs-young@medicine.tamhsc.edu	Gunaratna, Ramesh/B-2256-2016	Gunaratna, Ramesh/0000-0002-8872-9984	National Institutes of Health [R01MD006228]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was funded by the National Institutes of Health grant R01MD006228 (to RF-Y).	Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784; Aizat AAA, 2011, ASIAN PAC J CANCER P, V12, P2909; Alawadi S, 2011, MED ONCOL, V28, P709, DOI 10.1007/s12032-010-9505-4; Andrechek ER, 2003, CANCER RES, V63, P4920; Arendt LM, 2013, CANCER RES, V73, P6080, DOI 10.1158/0008-5472.CAN-13-0926; Azzam GA, 2011, CELL CYCLE, V10, P1352, DOI 10.4161/cc.10.9.15344; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Bieging KT, 2014, NAT REV CANCER, V14, P359, DOI 10.1038/nrc3711; Bonafe M, 2003, CLIN CANCER RES, V9, P4860; Brady NJ, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/4549676; Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653; Capell BC, 2016, GENE DEV, V30, P321, DOI 10.1101/gad.271882.115; Carron EC, 2017, ONCOTARGET, V8, P50731, DOI 10.18632/oncotarget.14913; Catena CS, 2015, FRONT MED-LAUSANNE, V2, DOI 10.3389/fmed.2015.00085; Cha YJ, 2018, BREAST CANCER RES TR, V170, P15, DOI 10.1007/s10549-018-4722-1; Chang SH, 2004, P NATL ACAD SCI USA, V101, P591, DOI 10.1073/pnas.2535911100; Costa Carla, 2007, Angiogenesis, V10, P149, DOI 10.1007/s10456-007-9074-0; Crespi E, 2016, CURR OPIN PHARMACOL, V31, P114, DOI 10.1016/j.coph.2016.11.004; Dakouras A, 2008, ANTICANCER RES, V28, P1039; Dastjerdi Mehdi Nikbahkt, 2011, Acta Med Iran, V49, P71; de Ostrovich KK, 2008, AM J PATHOL, V173, P824, DOI 10.2353/ajpath.2008.071005; Denisov EV, 2012, TUMOR SUPPRESSOR GEN; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Ehling J, 2014, GUT, V63, P1960, DOI 10.1136/gutjnl-2013-306294; Eren F, 2010, PATHOL ONCOL RES, V16, P563, DOI 10.1007/s12253-010-9255-9; Fitzmaurice C, 2017, JAMA ONCOL, V3, P524, DOI 10.1001/jamaoncol.2016.5688; Frank AK, 2011, MOL CELL BIOL, V31, P1201, DOI 10.1128/MCB.01136-10; Gage M, 2012, J SURG ONCOL, V105, P444, DOI 10.1002/jso.21856; Garcia PB, 2014, SEMIN CELL DEV BIOL, V27, P74, DOI 10.1016/j.semcdb.2013.12.014; Georgakopoulou EA, 2013, AGING-US, V5, P37; Grochola LF, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001032; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Howe LR, 2005, CANCER RES, V65, P10113, DOI 10.1158/0008-5472.CAN-05-1524; Hursting SD, 2011, CANCER PREV RES, V4, P285, DOI 10.1158/1940-6207.CAPR-11-0056; Jackson JG, 2006, CANCER RES, V66, P8356, DOI 10.1158/0008-5472.CAN-06-1752; Jiang XG, 2014, MOL CELL ENDOCRINOL, V382, P673, DOI 10.1016/j.mce.2013.06.003; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kortlever RM, 2006, NAT CELL BIOL, V8, P877, DOI 10.1038/ncb1448; Koutras A, 2015, PHARMACOGENOMICS, V16, P79, DOI [10.2217/PGS.14.148, 10.2217/pgs.14.148]; Kung CP, 2016, CELL REP, V14, P2413, DOI 10.1016/j.celrep.2016.02.037; Kung CP, 2015, MOL CANCER RES, V13, P250, DOI 10.1158/1541-7786.MCR-14-0385; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; Lin EY, 2006, CANCER RES, V66, P11238, DOI 10.1158/0008-5472.CAN-06-1278; Lopez-Arribillaga E, 2015, DEVELOPMENT, V142, P41, DOI 10.1242/dev.107714; Martinez FO, 2006, J IMMUNOL, V177, P7303, DOI 10.4049/jimmunol.177.10.7303; MEDINA D, 1974, J NATL CANCER I, V53, P213, DOI 10.1093/jnci/53.1.213; Morris PG, 2011, CANCER PREV RES, V4, P1021, DOI 10.1158/1940-6207.CAPR-11-0110; Movahedi K, 2010, CANCER RES, V70, P5728, DOI 10.1158/0008-5472.CAN-09-4672; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; Padala C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184448; Papadakis ED, 2002, BRIT J CANCER, V87, P1013, DOI 10.1038/sj.bjc.6600595; Park SW, 2011, LAB INVEST, V91, P63, DOI 10.1038/labinvest.2010.151; Perez LO, 2006, WORLD J GASTROENTERO, V12, P1426, DOI 10.3748/wjg.v12.i9.1426; Pim D, 2004, INT J CANCER, V108, P196, DOI 10.1002/ijc.11548; Pusztaszeri MP, 2006, J HISTOCHEM CYTOCHEM, V54, P385, DOI 10.1369/jhc.4A6514.2005; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Rijnkels M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053270; Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094; Rogler A, 2011, PATHOBIOLOGY, V78, P193, DOI 10.1159/000326767; Salminen A, 2012, CELL SIGNAL, V24, P835, DOI 10.1016/j.cellsig.2011.12.006; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schneider-Stock R, 2004, NEOPLASIA, V6, P529, DOI 10.1593/neo.04178; Shaked H, 2012, P NATL ACAD SCI USA, V109, P14007, DOI 10.1073/pnas.1211509109; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Siddique M, 2006, ONCOGENE, V25, P3489, DOI 10.1038/sj.onc.1209405; Surekha D, 2011, ASIAN PAC J CANCER P, V12, P1893; Svensson S, 2015, CLIN CANCER RES, V21, P3794, DOI 10.1158/1078-0432.CCR-15-0204; Takeuchi S, 2010, CANCER RES, V70, P9381, DOI 10.1158/0008-5472.CAN-10-0801; Volodko N, 2015, WORLD J GASTROENTERO, V21, P10358, DOI 10.3748/wjg.v21.i36.10358; Yoshimura T, 2017, CYTOKINE, V98, P71, DOI 10.1016/j.cyto.2017.02.001; You W, 2018, ADV BREAST CANC RES, V7, P1, DOI DOI 10.4236/ABCR.2018.71001; Zhang ZZ, 2010, BREAST CANCER RES TR, V120, P509, DOI 10.1007/s10549-009-0480-4; Zhu F, 2010, CANCER RES, V70, P5851, DOI 10.1158/0008-5472.CAN-09-4646	76	10	10	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2019	38	18					3535	3550		10.1038/s41388-018-0630-4	http://dx.doi.org/10.1038/s41388-018-0630-4			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HW3RI	30651598	hybrid, Green Published			2022-12-28	WOS:000466610000015
J	Li, M; Tang, Y; Li, QS; Xiao, M; Yang, YY; Wang, YL				Li, Ming; Tang, Yi; Li, Qingshu; Xiao, Ming; Yang, Yaying; Wang, Yalan			Mono-ADP-ribosylation of H3R117 traps 5mC hydroxylase TET1 to impair demethylation of tumor suppressor gene TFPI2	ONCOGENE			English	Article							COLORECTAL-CANCER; DNA METHYLATION; 5-HYDROXYMETHYLCYTOSINE; EXPRESSION; 5-CARBOXYLCYTOSINE; 5-FORMYLCYTOSINE; HYPERMETHYLATION; 5-METHYLCYTOSINE; TRANSCRIPTION; INHIBITORS	Recently, nuclear poly-ADP-ribosylation had aroused research interest in epigenetics, but little attempt to explore functions of mono-ADP-ribosylation of histone, the major formation of histone ADP-ribosylated modification. We have previously reported a novel mono-ADP-ribosylation of H3R117, which promoted proliferation of LoVo cells. Here we showed that mono-ADP-ribosylated H3R117 of LoVo cells depressed demethylation of tumor suppressor TFPI2 promoter by suppressing TET1 expression and adjusting H3K9me3 enrichment of TFPI2 promoter to attenuate affinity of TET1, besides, since high H3K27me3 level was associated with hypermethylation, mono-ADP-ribosylated-H3R117-depended-H3K27me3 of TFPI2 promoter may contribute to hypermethylation of TFPI2. However, H3R117A mutation increased poly-ADPribosylated modification of TET1 promoter not TFPI2 promoter, which resulted in boosting transcription and expression of TET1 by altering DNA methylated modification, chromatin accessibility, and histone-methylated modification of TET1 promoter, while knockout TET1 of H3R117A LoVo cells directly led to hypermethylation of TFPI2 promoter and depression of TFPI2 secretion as well as enhanced proliferation, suggested that TET1 played a key role in demethylation of TFPI2, production of TFPI2, and cell proliferation. Bioinformatics analyses reveal prevalent hypermethylation of TFPI2 was an early event in tumorigenesis of colorectal caner, and expression of TET1 and TFPI2 was positive correlation in colorectal cancer and normal tissue. These data suggested that mono-ADP-ribosylation of H3R117 upregulated methylation of TFPI2 by impact TET1, since hypermethyaltion of TFPI2 was an early event in tumorigenesis, selectively target mono-ADP-ribosylation of H3R117 deficiency could be a feasible way to block tumorigenesis of colorectal cancer.	[Li, Ming; Tang, Yi; Li, Qingshu; Xiao, Ming; Yang, Yaying; Wang, Yalan] Chongqing Med Univ, Dept Pathol, Mol Med & Canc Res Ctr, Chongqing 400016, Peoples R China	Chongqing Medical University	Wang, YL (corresponding author), Chongqing Med Univ, Dept Pathol, Mol Med & Canc Res Ctr, Chongqing 400016, Peoples R China.	wangyalan074@126.com			Science and Technology Plan Projects of Yuzhong District in Chongqing [20170409, 20140106]; Scientific Research Foundation of Chongqing Medical University [201413]	Science and Technology Plan Projects of Yuzhong District in Chongqing; Scientific Research Foundation of Chongqing Medical University	We gratefully acknowledge Professor Wei-Xue Tang (Chongqing, China) for his gift of LoVo cell line. This work was supported by the Science and Technology Plan Projects of Yuzhong District in Chongqing [grant numbers 20170409 and 20140106], and the Scientific Research Foundation of Chongqing Medical University [grant number 201413].	BURZIO LO, 1979, J BIOL CHEM, V254, P3029; Ciccarone F, 2014, ONCOTARGET, V5, P10356, DOI 10.18632/oncotarget.1905; Gao Shenglan, 2017, Cell Cycle, V16, P2249, DOI 10.1080/15384101.2017.1373223; Glockner SC, 2009, CANCER RES, V69, P4691, DOI 10.1158/0008-5472.CAN-08-0142; He YF, 2011, SCIENCE, V333, P1303, DOI 10.1126/science.1210944; Hibi K, 2012, ANTICANCER RES, V32, P787; Hibi K, 2011, CANCER LETT, V311, P96, DOI 10.1016/j.canlet.2011.07.006; Hottiger MO, 2015, ANNU REV BIOCHEM, V84, P227, DOI 10.1146/annurev-biochem-060614-034506; Huang WY, 2015, NUCLEIC ACIDS RES, V43, pD856, DOI 10.1093/nar/gku1151; Ichimura N, 2015, CANCER PREV RES, V8, P702, DOI 10.1158/1940-6207.CAPR-14-0306; Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597; Krishnakumar R, 2010, MOL CELL, V39, P736, DOI 10.1016/j.molcel.2010.08.014; Kroeze LI, 2015, BBA-REV CANCER, V1855, P144, DOI 10.1016/j.bbcan.2015.01.001; Kudo Y, 2012, CANCER SCI, V103, P670, DOI 10.1111/j.1349-7006.2012.02213.x; Li YF, 2015, EPIGENETICS-US, V10, P229, DOI 10.1080/15592294.2015.1006506; Ling F, 2017, ONCOTARGET, V8, P72773, DOI 10.18632/oncotarget.20347; Liu ZJ, 2014, CLIN CANCER RES, V20, P4598, DOI 10.1158/1078-0432.CCR-13-3380; Maiti A, 2011, J BIOL CHEM, V286, P35334, DOI 10.1074/jbc.C111.284620; Martinez-Zamudio R, 2012, MOL CELL BIOL, V32, P2490, DOI 10.1128/MCB.06667-11; McInnes T, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3226-4; Neri F, 2015, ONCOGENE, V34, P4168, DOI 10.1038/onc.2014.356; Neri F, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-8-r91; Nocchi L, 2011, J BIOL CHEM, V286, P19478, DOI 10.1074/jbc.M110.217331; Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972; Putiri EL, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-6-r81; Rasmussen SL, 2016, COLORECTAL DIS, V18, P549, DOI 10.1111/codi.13336; Rawluszko-Wieczorek AA, 2015, J CANCER RES CLIN, V141, P1379, DOI 10.1007/s00432-014-1901-2; Robertson J, 2011, BIOCHEM BIOPH RES CO, V411, P40, DOI 10.1016/j.bbrc.2011.06.077; Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Thomson JP, 2016, CANCER RES, V76, P3097, DOI 10.1158/0008-5472.CAN-15-1910; Wu H, 2011, GENE DEV, V25, P679, DOI 10.1101/gad.2036011; Xu YF, 2011, MOL CELL, V42, P451, DOI 10.1016/j.molcel.2011.04.005; Yamaguchi H, 2018, ONCOGENE, V37, P208, DOI 10.1038/onc.2017.311; Yuan XX, 2016, SCI REP-UK, V6, DOI 10.1038/srep20005; Zampieri M, 2012, BIOCHEM J, V441, P645, DOI 10.1042/BJ20111417; Zampieri M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004717; Zhou Z, 2018, J CELL PHYSIOL, V233, P1359, DOI 10.1002/jcp.26012; 1999, BIOL CHEM, V274, P1786	40	6	7	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2019	38	18					3488	3503		10.1038/s41388-018-0671-8	http://dx.doi.org/10.1038/s41388-018-0671-8			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HW3RI	30651599	hybrid, Green Published			2022-12-28	WOS:000466610000012
J	Hong, SY; Xu, JF; Li, Y; Andrade, J; Hoover, P; Kaminski, PJ; Laimins, LA				Hong, Shiyuan; Xu, Junfen; Li, Yan; Andrade, Jorge; Hoover, Paul; Kaminski, Paul J.; Laimins, Laimonis A.			Topoisomerase II beta-binding protein 1 activates expression of E2F1 and p73 in HPV-positive cells for genome amplification upon epithelial differentiation	ONCOGENE			English	Article							HUMAN-PAPILLOMAVIRUS TYPE-16; DNA-DAMAGE RESPONSE; LIFE-CYCLE; IN-VIVO; REPLICATION; TOPBP1; E6; P53; STABILITY; CANCER	High-risk human papillomaviruses (HPVs) constitutively activate ataxia telangiectasia mutated (ATM) and ataxia telangiectasia- and Rad3-related (ATR) DNA damage repair pathways for viral genome amplification. HPVs activate these pathways through the immune regulator STAT-5. For the ATR pathway, STAT-5 increases expression of the topoisomerase II beta-binding protein 1 (TopBP1), a scaffold protein that binds ATR and recruits it to sites of DNA damage. TopBP1 also acts as a transcriptional regulator, and we investigated how this activity influenced the HPV life cycle. We determined that TopBP1 levels are increased in cervical intraepithelial neoplasias as well as cervical carcinomas, consistent with studies in HPV-positive cell lines. Suppression of TopBP1 by shRNAs impairs HPV genome amplification and activation of the ATR pathway but does not affect the total levels of ATR and CHK1. In contrast, knockdown reduces the expression of other DNA damage factors such as RAD51 and Mre11 but not BRCA2 or NBS1. Interestingly, TopBP1 positively regulates the expression of E2F1, a TopBP1-binding partner, and p73 in HPV-positive cells in contrast to its effects in other cell types. TopBP1 transcriptional activity is regulated by AKT, and treatment with AKT inhibitors suppresses expression of E2F1 and p73 without interfering with ATR signaling. Importantly, the levels of p73 are elevated in HPV-positive cells and its knockdown impairs HPV genome amplification. This demonstrates that p73, like p63 and p53, is an important regulator of the HPV life cycle that is controlled by the transcriptional activating properties of the multifunctional TopBP1 protein.	[Hong, Shiyuan; Hoover, Paul; Kaminski, Paul J.; Laimins, Laimonis A.] Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA; [Xu, Junfen] Zhejiang Univ, Womens Hosp, Sch Med, Dept Gynecol Oncol, Hangzhou 310006, Zhejiang, Peoples R China; [Li, Yan; Andrade, Jorge] Univ Chicago, Ctr Res Informat, Chicago, IL 60637 USA	Northwestern University; Feinberg School of Medicine; Zhejiang University; University of Chicago	Hong, SY; Laimins, LA (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA.	shiyuan-hong@northwestern.edu; l-laimins@northwestern.edu	Fan, Qing/AAI-8294-2021	Kaminski, Paul/0000-0002-5513-2962; Andrade, Jorge/0000-0003-3210-2186	NCI [CA059655, CA142861]; ACS [IRG-15-173-21]; National Natural Scientific Foundation of China [81702552]; NATIONAL CANCER INSTITUTE [R01CA059655, R01CA142861] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ACS(American Cancer Society); National Natural Scientific Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported by grants from NCI (CA059655 and CA142861) to L.A.L., ACS grant IRG-15-173-21 to S.H., and National Natural Scientific Foundation of China (No. 81702552) to J.X.	Accardi R, 2006, EMBO REP, V7, P334, DOI 10.1038/sj.embor.7400615; Andrews S., 2010, FASTQC QUALITY CONTR; Chappell WH, 2016, J VIROL, V90, P2639, DOI 10.1128/JVI.02495-15; Concin N, 2004, CANCER RES, V64, P2449, DOI 10.1158/0008-5472.CAN-03-1060; Connell C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032442; Conway MJ, 2009, J DENT RES, V88, P307, DOI 10.1177/0022034509333446; DiMaio D, 2013, VIROLOGY, V445, P99, DOI 10.1016/j.virol.2013.05.006; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Donaldson MM, 2012, J VIROL, V86, P12806, DOI 10.1128/JVI.01002-12; Doorbar J, 2013, VIROLOGY, V445, P80, DOI 10.1016/j.virol.2013.07.008; Doorbar J, 2012, VACCINE, V30, pF55, DOI 10.1016/j.vaccine.2012.06.083; Edwards TG, 2013, J VIROL, V87, P3979, DOI 10.1128/JVI.03473-12; Fang YF, 2014, CANCER BIOL THER, V15, P1268, DOI 10.4161/cbt.29691; Fehrmann Frauke, 2005, Methods Mol Biol, V292, P317; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Gunasekharan V, 2012, J VIROL, V86, P5393, DOI 10.1128/JVI.07239-11; Gunasekharan VK, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005747; Habiger C, 2016, J VIROL, V90, P694, DOI 10.1128/JVI.02137-15; Hartley KA, 2002, J VIROL, V76, P5014, DOI 10.1128/JVI.76.10.5014-5023.2002; Hebner CM, 2006, REV MED VIROL, V16, P83, DOI 10.1002/rmv.488; Herold S, 2008, EMBO J, V27, P2851, DOI 10.1038/emboj.2008.200; Hong SY, 2017, J ZHEJIANG UNIV-SC B, V18, P215, DOI 10.1631/jzus.B1600306; Hong SY, 2015, MBIO, V6, DOI 10.1128/mBio.02006-15; Hong SY, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003295; Hong SY, 2011, J VIROL, V85, P9486, DOI 10.1128/JVI.05007-11; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; JEON S, 1995, P NATL ACAD SCI USA, V92, P1654, DOI 10.1073/pnas.92.5.1654; Kidiyoor GR, 2016, DNA REPAIR, V44, P143, DOI 10.1016/j.dnarep.2016.05.020; Kumagai A, 2006, CELL, V124, P943, DOI 10.1016/j.cell.2005.12.041; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Liu K, 2003, MOL CELL BIOL, V23, P3287, DOI 10.1128/MCB.23.9.3287-3304.2003; Liu K, 2006, EMBO J, V25, P4795, DOI 10.1038/sj.emboj.7601355; Liu K, 2013, MOL CELL BIOL, V33, P4685, DOI 10.1128/MCB.00373-13; Liu K, 2011, MOL CELL BIOL, V31, P4464, DOI 10.1128/MCB.05574-11; Liu K, 2009, MOL CELL BIOL, V29, P2673, DOI 10.1128/MCB.01140-08; Lorenz LD, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003717; McBride AA, 2013, VIROLOGY, V445, P57, DOI 10.1016/j.virol.2013.06.006; McCarthy DJ, 2012, NUCLEIC ACIDS RES, V40, P4288, DOI 10.1093/nar/gks042; Mehta K, 2018, MBIO, V9, DOI 10.1128/mBio.00064-18; Melar-New M, 2010, J VIROL, V84, P5212, DOI 10.1128/JVI.00078-10; Mighty KK, 2011, J VIROL, V85, P8863, DOI 10.1128/JVI.00750-11; Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886; Moody CA, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000605; Morrison C, 2000, EMBO J, V19, P463, DOI 10.1093/emboj/19.3.463; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Niklison-Chirou MV, 2016, MOL NEUROBIOL, V53, P4509, DOI 10.1007/s12035-015-9381-1; OCONNOR M, 1995, VIROLOGY, V207, P77, DOI 10.1006/viro.1995.1053; OFFORD EA, 1990, J VIROL, V64, P4792, DOI 10.1128/JVI.64.10.4792-4798.1990; Pacini L, 2015, J VIROL, V89, P11396, DOI 10.1128/JVI.02151-15; Reiser J, 2011, J VIROL, V85, P11372, DOI 10.1128/JVI.05279-11; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Sedman J, 1995, EMBO J, V14, P6218, DOI 10.1002/j.1460-2075.1995.tb00312.x; Spurgeon ME, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9080219; Stiewe T, 2002, CELL DEATH DIFFER, V9, P237, DOI 10.1038/sj.cdd.4400995; Stunkel W, 1999, J VIROL, V73, P1918; Thomas JT, 1999, P NATL ACAD SCI USA, V96, P8449, DOI 10.1073/pnas.96.15.8449; Thomas M, 2008, ONCOGENE, V27, P7018, DOI 10.1038/onc.2008.351; Wallace NA, 2015, ANNU REV VIROL, V2, P403, DOI 10.1146/annurev-virology-100114-055021; Wang LG, 2012, BIOINFORMATICS, V28, P2184, DOI 10.1093/bioinformatics/bts356; Wise-Draper TM, 2008, FRONT BIOSCI-LANDMRK, V13, P1003, DOI 10.2741/2739; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Yuan X, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.69; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798; J VIROL, V74, P5198	68	6	6	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2019	38	17					3274	3287		10.1038/s41388-018-0633-1	http://dx.doi.org/10.1038/s41388-018-0633-1			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU8RI	30631149	Green Accepted			2022-12-28	WOS:000465557200012
J	Louault, K; Bonneaud, TL; Seveno, C; Gomez-Bougie, P; Nguyen, F; Gautier, F; Bourgeois, N; Loussouarn, D; Kerdraon, O; Barille-Nion, S; Jezequel, P; Campone, M; Amiot, M; Juin, PP; Souaze, F				Louault, K.; Bonneaud, T. L.; Seveno, C.; Gomez-Bougie, P.; Nguyen, F.; Gautier, F.; Bourgeois, N.; Loussouarn, D.; Kerdraon, O.; Barille-Nion, S.; Jezequel, P.; Campone, M.; Amiot, M.; Juin, P. P.; Souaze, F.			Interactions between cancer-associated fibroblasts and tumor cells promote MCL-1 dependency in estrogen receptor-positive breast cancers	ONCOGENE			English	Article							BCL-2; CARCINOMA; DETERMINANT; SENSITIVITY; APOPTOSIS; FEATURES; IMPACT; IL-6	Selective inhibition of BCL-2 is expected to enhance therapeutic vulnerability in luminal estrogen receptor-positive breast cancers. We show here that the BCL-2 dependency of luminal tumor cells is nevertheless mitigated by breast cancer-associated fibroblasts (bCAFs) in a manner that defines MCL-1 as another critical therapeutic target. bCAFs favor MCL-1 expression and apoptotic resistance in luminal cancer cells in a IL-6 dependent manner while their own, robust, survival also relies on MCL-1. Studies based on ex vivo cultures of human luminal breast cancer tissues further argue that the contribution of stroma-derived signals to MCL-1 expression shapes BCL-2 dependency. Thus, MCL-1 inhibitors are beneficial for targeted apoptosis of breast tumor ecosystems, even in a subtype where MCL-1 dependency is not intrinsically driven by oncogenic pathways.	[Louault, K.; Bonneaud, T. L.; Seveno, C.; Nguyen, F.; Gautier, F.; Bourgeois, N.; Barille-Nion, S.; Jezequel, P.; Campone, M.; Juin, P. P.; Souaze, F.] Univ Nantes, Univ Angers, INSERM, CRCINA,Team 8, Nantes, France; [Louault, K.; Bonneaud, T. L.; Seveno, C.; Gomez-Bougie, P.; Gautier, F.; Bourgeois, N.; Kerdraon, O.; Barille-Nion, S.; Jezequel, P.; Campone, M.; Amiot, M.; Juin, P. P.; Souaze, F.] SIRIC ILIAD, Nantes, France; [Gomez-Bougie, P.; Amiot, M.] Univ Nantes, Univ Angers, INSERM, CRCINA,Team 10, Nantes, France; [Nguyen, F.] Nantes Atlantic Coll Vet Med Food Sci & Engn, ONIRIS, Anim Canc, Nantes, France; [Gautier, F.; Kerdraon, O.; Jezequel, P.; Campone, M.; Juin, P. P.] ICO Rene Gauducheau, St Herblain, France; [Loussouarn, D.] CHU Nantes, Serv Anat Pathol, Nantes, France; [Juin, P. P.; Souaze, F.] CNRS GDR3697 Micronit, Tours, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; Universite d'Angers; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; Universite d'Angers; Ecole Nationale Veterinaire, Agroalimentaire et de l'Alimentation Nantes-Atlantique; UNICANCER; Institut de Cancerologie de l'Ouest (ICO); Nantes Universite; CHU de Nantes	Juin, PP; Souaze, F (corresponding author), Univ Nantes, Univ Angers, INSERM, CRCINA,Team 8, Nantes, France.; Juin, PP; Souaze, F (corresponding author), SIRIC ILIAD, Nantes, France.; Juin, PP (corresponding author), ICO Rene Gauducheau, St Herblain, France.; Juin, PP; Souaze, F (corresponding author), CNRS GDR3697 Micronit, Tours, France.	philippe.juin@univ-nantes.fr; frederique.souaze@univ-nantes.fr	JUIN, Philippe/Q-1338-2019; JUIN, Philippe P/H-3636-2014; Barille-nion, sophie/W-8103-2019; souazé, frédérique/AAE-6478-2021	JUIN, Philippe/0000-0002-4997-3888; JUIN, Philippe P/0000-0002-4997-3888; Barille-nion, sophie/0000-0001-5171-9937; Louault, Kevin/0000-0002-2325-5757; Gomez Bougie, Patricia/0000-0002-4846-4782; Nguyen, Frederique/0000-0001-7203-2982; Frederique, Souaze/0000-0003-0476-2603	CIFRE grant (ANRT contract) [20150995]; Ligue contre le cancer; Odyssea; Canceropole Grand Ouest (MATURE project 2017-18); ARC [R15083NN]; ANR [15-CE18-0008]; INCa; DGOS (SIRIC ILIAD, INCa-DGOS Inserm) [12558]	CIFRE grant (ANRT contract)(French National Research Agency (ANR)); Ligue contre le cancer(Ligue nationale contre le cancer); Odyssea; Canceropole Grand Ouest (MATURE project 2017-18); ARC(Australian Research Council); ANR(French National Research Agency (ANR)); INCa(Institut National du Cancer (INCA) France); DGOS (SIRIC ILIAD, INCa-DGOS Inserm)	This research was performed within the framework of a CIFRE grant (ANRT contract #20150995) for K. Louault at CRCINA and ONCOTHEREX. T.L Bonneaud was supported by a fellowship from Ligue contre le cancer. This work was supported by Odyssea, Canceropole Grand Ouest (MATURE project 2017-18), ARC (R15083NN), ANR (15-CE18-0008), INCa and DGOS (SIRIC ILIAD, INCa-DGOS Inserm-12558).	Campbell KJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0035-2; Campone M, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-110; Costa A, 2018, CANCER CELL, V33, P463, DOI 10.1016/j.ccell.2018.01.011; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Denys H, 2008, CANCER LETT, V266, P263, DOI 10.1016/j.canlet.2008.02.068; Dousset C, 2017, BRIT J HAEMATOL, V179, P684, DOI 10.1111/bjh.14251; Foight GW, 2014, ACS CHEM BIOL, V9, P1962, DOI 10.1021/cb500340w; Gascard P, 2016, GENE DEV, V30, P1002, DOI 10.1101/gad.279737.116; Hendrayani SF, 2016, ONCOTARGET, V7, P41974, DOI 10.18632/oncotarget.9633; Holliday DL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2889; Jezequel P, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0550-y; Juin P, 2013, NAT REV CANCER, V13, P455, DOI 10.1038/nrc3538; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kotschy A, 2016, NATURE, V538, P477, DOI 10.1038/nature19830; Kumar S, 2017, BLOOD, V130, P2401, DOI 10.1182/blood-2017-06-788786; Labovsky V, 2016, TUMOR BIOL, V37, P13377, DOI 10.1007/s13277-016-5268-7; Lagares D, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3765; Leu CM, 2003, ONCOGENE, V22, P7809, DOI 10.1038/sj.onc.1207084; Ma YF, 2017, ADV CLIN EXP MED, V26, P421, DOI 10.17219/acem/62120; Marusyk A, 2016, CANCER RES, V76, P6495, DOI 10.1158/0008-5472.CAN-16-1457; Merino D, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam7049; Mertens JC, 2013, CANCER RES, V73, P897, DOI 10.1158/0008-5472.CAN-12-2130; Montero J, 2018, CELL DEATH DIFFER, V25, P56, DOI 10.1038/cdd.2017.183; Oakes SR, 2012, P NATL ACAD SCI USA, V109, P2766, DOI 10.1073/pnas.1104778108; Perillo B, 2000, MOL CELL BIOL, V20, P2890, DOI 10.1128/MCB.20.8.2890-2901.2000; Qiao AX, 2016, FRONT MED-PRC, V10, P33, DOI 10.1007/s11684-016-0431-5; Romagnoli M, 2007, LEUKEMIA, V21, P1070, DOI 10.1038/sj.leu.2404602; Ryan J, 2013, METHODS, V61, P156, DOI 10.1016/j.ymeth.2013.04.006; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Sansone P, 2017, CANCER RES, V77, P1927, DOI 10.1158/0008-5472.CAN-16-2129; Sansone P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10442; Seveno C, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3214; Trecesson SD, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01079-1; Vaillant F, 2013, CANCER CELL, V24, P120, DOI 10.1016/j.ccr.2013.06.002; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Winslow S, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0530-2; Xiao Y, 2015, MOL CANCER THER, V14, P1837, DOI 10.1158/1535-7163.MCT-14-0928; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Young AIJ, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0781-6	39	28	29	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2019	38	17					3261	3273		10.1038/s41388-018-0635-z	http://dx.doi.org/10.1038/s41388-018-0635-z			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU8RI	30631150	Green Published, hybrid			2022-12-28	WOS:000465557200011
J	Khater, F; Langlois, S; Cassart, P; Roy, AM; Lajoie, M; Healy, J; Richer, C; St-Onge, P; Piche, N; Perreault, S; Cellot, S; Marzouki, M; Jabado, N; Sinnett, D				Khater, Fida; Langlois, Sylvie; Cassart, Pauline; Roy, Anne-Marie; Lajoie, Mathieu; Healy, Jasmine; Richer, Chantal; St-Onge, Pascal; Piche, Nelson; Perreault, Sebastien; Cellot, Sonia; Marzouki, Monia; Jabado, Nada; Sinnett, Daniel			Recurrent somatic BRAF insertion (p.V504_R506dup): a tumor marker and a potential therapeutic target in pilocytic astrocytoma	ONCOGENE			English	Article							MAPK PATHWAY ACTIVATION; B-RAF; KINASE; INHIBITORS; CLASSIFICATION; DIMERIZATION; PROGRESSION; CHILDHOOD; DELETIONS; ALIGNMENT	Pilocytic astrocytoma (PA) is emerging as a tumor entity with dysregulated RAS/RAF/MEK/ERK signaling. In this study, we report the identification of a novel recurrent BRAF insertion (p.V504_R506dup) in five PA cases harboring exclusively this somatic tandem duplication. This recurrent alteration leads to an addition of three amino acids in the kinase domain of BRAF and has functional impact on activating MAPK phosphorylation. Importantly, we show that this mutation confers resistance to RAF inhibitors without changing effectiveness while downstream MEK inhibitors remain effective. Our results further emphasize the importance of BRAF alterations in PA and the need to characterize them in a given tumor as this can affect therapeutic strategies and their potential use as tumor marker in molecular diagnostics.	[Khater, Fida; Langlois, Sylvie; Cassart, Pauline; Roy, Anne-Marie; Lajoie, Mathieu; Healy, Jasmine; Richer, Chantal; St-Onge, Pascal; Cellot, Sonia; Marzouki, Monia; Sinnett, Daniel] CHU St Justine, Div Hematol Oncol, Charles Bruneau Canc Ctr, Montreal, PQ, Canada; [Khater, Fida; Cellot, Sonia; Marzouki, Monia; Sinnett, Daniel] Univ Montreal, Fac Med, Dept Pediat, Montreal, PQ, Canada; [Piche, Nelson] CHU St Justine, Dept Pediat Surg, Montreal, PQ, Canada; [Perreault, Sebastien] CHU St Justine, Div Neurol, Montreal, PQ, Canada; [Jabado, Nada] McGill Univ, Fac Med, Dept Pediat, Montreal, PQ, Canada	Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; Universite de Montreal; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; McGill University	Sinnett, D (corresponding author), CHU St Justine, Div Hematol Oncol, Charles Bruneau Canc Ctr, Montreal, PQ, Canada.; Sinnett, D (corresponding author), Univ Montreal, Fac Med, Dept Pediat, Montreal, PQ, Canada.	daniel.sinnett@umontreal.ca	sinnett, daniel/S-4589-2017; Jabado, Nada/AAN-4026-2020	sinnett, daniel/0000-0003-3625-6676; KHATER, Fida/0000-0003-2810-3928	Ministere de l'Economie, de la Science et de l'Innovation du Quebec; Charles-Bruneau Cancer Center Foundation; RMGA/Fonds de recherche du Quebec-Sante; Canadian Institutes of Health Research; Cole Foundation Fellowship	Ministere de l'Economie, de la Science et de l'Innovation du Quebec; Charles-Bruneau Cancer Center Foundation; RMGA/Fonds de recherche du Quebec-Sante; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Cole Foundation Fellowship	The authors are indebted to the personal involvement of the patient and his parents who fully participated in this study. Patient tissue samples were provided by the CHU Sainte-Justine Pediatric Cancer biobank. Whole-exome sequencing was performed at the Integrated Clinical Genomics Centre in Pediatrics, CHU SainteJustine; Sanger sequencing and targeted ultra-deep re-sequencing were performed at the McGill University and Genome Quebec Innovation Centre; Computations were made on the supercomputer Briaree from Universite de Montreal, managed by Calcul Quebec and Compute Canada. This study was supported by research funds provided by the Ministere de l'Economie, de la Science et de l'Innovation du Quebec, the Charles-Bruneau Cancer Center Foundation, RMGA/Fonds de recherche du Quebec-Sante and the Canadian Institutes of Health Research (D.S.). F.K. is the recipient of a Cole Foundation Fellowship. D.S. holds the Francois-Karl-Viau Research Chair in Pediatric Oncogenomics.	Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Baccichet A, 1997, LEUKEMIA RES, V21, P817, DOI 10.1016/S0145-2126(97)00075-1; Belirgen M, 2012, CHILD NERV SYST, V28, P375, DOI 10.1007/s00381-011-1676-6; Bergthold G, 2014, BBA-REV CANCER, V1845, P294, DOI 10.1016/j.bbcan.2014.02.004; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; BUDKA H, 1975, ACTA NEUROCHIR, V32, P139, DOI 10.1007/BF01405911; Chen SH, 2016, CANCER DISCOV, V6, P300, DOI 10.1158/2159-8290.CD-15-0896; Choi J, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12197; Collins VP, 2015, ACTA NEUROPATHOL, V129, P775, DOI 10.1007/s00401-015-1410-7; Freeman AK, 2013, MOL CELL, V49, P751, DOI 10.1016/j.molcel.2012.12.018; Gajjar A, 2014, CLIN CANCER RES, V20, P5630, DOI 10.1158/1078-0432.CCR-14-0833; Garnett MJ, 2004, CANCER CELL, V6, P313, DOI 10.1016/j.ccr.2004.09.022; Haling JR, 2014, CANCER CELL, V26, P402, DOI 10.1016/j.ccr.2014.07.007; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Heritier S, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0690-z; Jones DTW, 2006, J NEUROPATH EXP NEUR, V65, P1049, DOI 10.1097/01.jnen.0000240465.33628.87; Jones DTW, 2013, NAT GENET, V45, P927, DOI 10.1038/ng.2682; Jones DTW, 2012, CELL MOL LIFE SCI, V69, P1799, DOI 10.1007/s00018-011-0898-9; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Karoulia Z, 2016, CANCER CELL, V30, P501, DOI 10.1016/j.ccell.2016.08.008; KATSETOS CD, 1994, CLIN NEUROPATHOL, V13, P295; Koboldt DC, 2009, BIOINFORMATICS, V25, P2283, DOI 10.1093/bioinformatics/btp373; Krieger MD, 1997, PEDIATR NEUROSURG, V27, P1, DOI 10.1159/000121218; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Ma JZ, 2013, BIOINFORMATICS, V29, P257, DOI 10.1093/bioinformatics/btt210; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Orr LC, 2002, MED PEDIATR ONCOL, V38, P173, DOI 10.1002/mpo.1305; Pfister S, 2008, J CLIN INVEST, V118, P1739, DOI 10.1172/JCI33656; Potter N, 2008, NEOPLASIA, V10, P757, DOI 10.1593/neo.07914; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Rahman MA, 2014, CRIT REV ONCOL HEMAT, V90, P220, DOI 10.1016/j.critrevonc.2013.12.008; Ramos AH, 2015, HUM MUTAT, V36, pE2423, DOI 10.1002/humu.22771; Rodriguez FJ, 2010, AM J SURG PATHOL, V34, P147, DOI 10.1097/PAS.0b013e3181c75238; Roskoski R, 2016, PHARMACOL RES, V103, P26, DOI 10.1016/j.phrs.2015.10.021; Ross JS, 2016, INT J CANCER, V138, P881, DOI 10.1002/ijc.29825; Sanoudou D, 2000, BRIT J CANCER, V82, P1218; Schwarz JM, 2014, NAT METHODS, V11, P361, DOI 10.1038/nmeth.2890; Spinella JF, 2016, ONCOTARGET, V7, P65485, DOI 10.18632/oncotarget.11796; Stuer C, 2007, CANCER-AM CANCER SOC, V110, P2799, DOI 10.1002/cncr.23148; Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105; Wagenaar TR, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12171; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Zhang JH, 2013, NAT GENET, V45, P602, DOI 10.1038/ng.2611	46	9	9	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2019	38	16					2994	3002		10.1038/s41388-018-0623-3	http://dx.doi.org/10.1038/s41388-018-0623-3			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU3IV	30575814	Green Published, hybrid			2022-12-28	WOS:000465167600009
J	Motohara, T; Masuda, K; Morotti, M; Zheng, YY; El-Sahhar, S; Chong, KY; Wietek, N; Alsaadi, A; Karaminejadranjbar, M; Hu, ZY; Artibani, M; Gonzalez, LS; Katabuchi, H; Saya, H; Ahmed, AA				Motohara, Takeshi; Masuda, Kenta; Morotti, Matteo; Zheng, Yiyan; El-Sahhar, Salma; Chong, Kay Yi; Wietek, Nina; Alsaadi, Abdulkhaliq; Karaminejadranjbar, Mohammad; Hu, Zhiyuan; Artibani, Mara; Gonzalez, Laura Santana; Katabuchi, Hidetaka; Saya, Hideyuki; Ahmed, Ahmed Ashour			An evolving story of the metastatic voyage of ovarian cancer cells: cellular and molecular orchestration of the adipose-rich metastatic microenvironment	ONCOGENE			English	Review							MESENCHYMAL STEM-CELLS; TUMOR-ASSOCIATED MACROPHAGES; INDUCIBLE KINASE 2; CD44 VARIANT 6; MILKY SPOTS; TRANSCOELOMIC METASTASIS; PROGRESSION; FIBROBLASTS; PATHOGENESIS; CARCINOMA	Metastasis is a complex multistep process that involves critical interactions between cancer cells and a variety of stromal components in the tumor microenvironment, which profoundly influence the different aspects of the metastatic cascade and organ tropism of disseminating cancer cells. Ovarian cancer is the most lethal gynecological malignancy and is characterized by peritoneal disseminated metastasis. Evidence has demonstrated that ovarian cancer possesses specific metastatic tropism for the adipose-rich omentum, which has a pivotal role in the creation of the metastatic tumor microenvironment in the intraperitoneal cavity. Considering the distinct biology of ovarian cancer metastasis, the elucidation of the cellular and molecular mechanisms underlying the reciprocal interplay between ovarian cancer cells and surrounding stromal cell types in the adipose-rich metastatic microenvironment will provide further insights into the development of novel therapeutic approaches for patients with advanced ovarian cancer. Herein, we review the biological mechanisms that regulate the highly orchestrated crosstalk between ovarian cancer cells and various cancer-associated stromal cells in the metastatic tumor microenvironment with regard to the omentum by illustrating how different stromal cells concertedly contribute to the development of ovarian cancer metastasis and metastatic tropism for the omentum.	[Motohara, Takeshi; Masuda, Kenta; Morotti, Matteo; Zheng, Yiyan; El-Sahhar, Salma; Chong, Kay Yi; Wietek, Nina; Alsaadi, Abdulkhaliq; Karaminejadranjbar, Mohammad; Hu, Zhiyuan; Artibani, Mara; Gonzalez, Laura Santana; Ahmed, Ahmed Ashour] Univ Oxford, Ovarian Canc Cell Lab, Weatherall Inst Mol Med, Oxford OX3 9DS, England; [Motohara, Takeshi; Masuda, Kenta; Morotti, Matteo; Zheng, Yiyan; El-Sahhar, Salma; Chong, Kay Yi; Wietek, Nina; Alsaadi, Abdulkhaliq; Karaminejadranjbar, Mohammad; Hu, Zhiyuan; Artibani, Mara; Gonzalez, Laura Santana; Ahmed, Ahmed Ashour] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Womens & Reprod Hlth, Womens Ctr, Oxford OX3 9DU, England; [Katabuchi, Hidetaka] Kumamoto Univ, Fac Life Sci, Dept Obstet & Gynecol, Chuo Ku, 1-1-1 Honjo, Kumamoto, Kumamoto 8608556, Japan; [Saya, Hideyuki] Keio Univ, Sch Med, Inst Adv Med Res, Div Gene Regulat,Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan	University of Oxford; University of Oxford; Kumamoto University; Keio University	Ahmed, AA (corresponding author), Univ Oxford, Ovarian Canc Cell Lab, Weatherall Inst Mol Med, Oxford OX3 9DS, England.; Ahmed, AA (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Womens & Reprod Hlth, Womens Ctr, Oxford OX3 9DU, England.	ahmed.ahmed@wrh.ox.ac.uk	Morotti, Matteo/AAE-8922-2020; Hu, Zhiyuan/U-1990-2019; Hu, Zhiyuan/GRY-2701-2022	Morotti, Matteo/0000-0002-1790-1185; Hu, Zhiyuan/0000-0002-1688-6032; Hu, Zhiyuan/0000-0002-1688-6032; Alsaadi, Abdulkhaliq/0000-0003-1732-0740; Saya, Hideyuki/0000-0001-6610-1902	Ovarian Cancer Action; National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC); Helen Clarke Fund; Wellbeing of Women Scholarship; Japan Society for the Promotion of Science; BCSRC studentship; MRC [G0902418] Funding Source: UKRI	Ovarian Cancer Action(Ovarian Cancer Action); National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC)(National Institute for Health Research (NIHR)); Helen Clarke Fund; Wellbeing of Women Scholarship; Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); BCSRC studentship; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was funded by Ovarian Cancer Action, National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), and the Helen Clarke Fund. NW is supported by a Wellbeing of Women Scholarship. KM is supported by a fellowship from the Japan Society for the Promotion of Science. LG is supported by a BCSRC studentship.	Agarwal R, 2003, NAT REV CANCER, V3, P502, DOI 10.1038/nrc1123; Ahmed AA, 2012, BJOG-INT J OBSTET GY, V119, P134, DOI 10.1111/j.1471-0528.2011.03149.x; Ahmed AA, 2010, CANCER CELL, V18, P109, DOI 10.1016/j.ccr.2010.06.018; Ahmed N, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00256; Aras S, 2017, BRIT J CANCER, V117, P1583, DOI 10.1038/bjc.2017.356; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Bon H, 2015, MOL CANCER RES, V13, P620, DOI 10.1158/1541-7786.MCR-13-0182-T; Borovski T, 2011, CANCER RES, V71, P634, DOI 10.1158/0008-5472.CAN-10-3220; Bowtell DD, 2015, NAT REV CANCER, V15, P668, DOI 10.1038/nrc4019; Buys SS, 2011, JAMA-J AM MED ASSOC, V305, P2295, DOI 10.1001/jama.2011.766; Cai J, 2012, CARCINOGENESIS, V33, P20, DOI 10.1093/carcin/bgr230; Carroll MJ, 2016, ONCOTARGET, V7, P86608, DOI 10.18632/oncotarget.13474; Casey RC, 2001, AM J PATHOL, V159, P2071, DOI 10.1016/S0002-9440(10)63058-1; Castells M, 2012, CANCER LETT, V326, P59, DOI 10.1016/j.canlet.2012.07.020; Chanmee T, 2014, CANCERS, V6, P1670, DOI 10.3390/cancers6031670; Chau YY, 2014, NAT CELL BIOL, V16, P367, DOI 10.1038/ncb2922; Chen F, 2017, BJOG-INT J OBSTET GY, V124, P872, DOI 10.1111/1471-0528.14543; Cho JA, 2011, GYNECOL ONCOL, V123, P379, DOI 10.1016/j.ygyno.2011.08.005; Chu YJ, 2015, EXP CELL RES, V337, P16, DOI 10.1016/j.yexcr.2015.07.020; Clark R, 2013, AM J PATHOL, V183, P576, DOI 10.1016/j.ajpath.2013.04.023; Coffelt SB, 2009, P NATL ACAD SCI USA, V106, P3806, DOI 10.1073/pnas.0900244106; Cuiffo BG, 2012, CELL ADHES MIGR, V6, P220, DOI 10.4161/cam.20875; Curtis M, 2018, CELL METAB, V28, P1; Dirat B, 2010, ENDOCR DEV, V19, P45, DOI 10.1159/000316896; Duluc D, 2007, BLOOD, V110, P4319, DOI 10.1182/blood-2007-02-072587; Esselen KM, 2016, JAMA ONCOL, V2, P1427, DOI 10.1001/jamaoncol.2016.1842; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Furuhashi M, 2008, NAT REV DRUG DISCOV, V7, P489, DOI 10.1038/nrd2589; Furuya Mitsuko, 2012, Cancers (Basel), V4, P701, DOI 10.3390/cancers4030701; Gusky HC, 2016, OBES REV, V17, P1015, DOI 10.1111/obr.12450; Hagemann T, 2006, J IMMUNOL, V176, P5023, DOI 10.4049/jimmunol.176.8.5023; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hansen JM, 2016, EUR J CANCER, V56, P131, DOI 10.1016/j.ejca.2015.12.016; Harjes U, 2017, ONCOGENE, V36, P912, DOI 10.1038/onc.2016.256; Hellner K, 2016, EBIOMEDICINE, V10, P137, DOI 10.1016/j.ebiom.2016.06.048; Hill BS, 2017, ONCOTARGET, V8, P73296, DOI 10.18632/oncotarget.20265; Jeon ES, 2008, STEM CELLS, V26, P789, DOI 10.1634/stemcells.2007-0742; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Kamdje AHN, 2017, CANCER BIOL MED, V14, P129, DOI 10.20892/j.issn.2095-3941.2016.0033; Kenny HA, 2007, INT J CANCER, V121, P1463, DOI 10.1002/ijc.22874; Klopp AH, 2012, CLIN CANCER RES, V18, P771, DOI 10.1158/1078-0432.CCR-11-1916; Ko SY, 2012, J CLIN INVEST, V122, P3603, DOI 10.1172/JCI62229; Krishnan V, 2018, GYNECOL ONCOL, V149, P205, DOI 10.1016/j.ygyno.2018.01.014; Krishnan V, 2015, JOVE-J VIS EXP, DOI 10.3791/52721; KRIST LFG, 1995, ANAT REC, V241, P163, DOI 10.1002/ar.1092410204; Kurman RJ, 2010, AM J SURG PATHOL, V34, P433, DOI 10.1097/PAS.0b013e3181cf3d79; Langley RR, 2011, INT J CANCER, V128, P2527, DOI 10.1002/ijc.26031; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Lau TS, 2017, ONCOGENE, V36, P3576, DOI 10.1038/onc.2016.509; Lengyel E, 2014, ONCOGENE, V33, P3619, DOI 10.1038/onc.2013.321; Lim D, 2013, PATHOLOGY, V45, P229, DOI 10.1097/PAT.0b013e32835f2264; Lis R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038340; Liu JY, 2016, TUMOR BIOL, V37, P5715, DOI 10.1007/s13277-016-4887-3; Liu J, 2014, CLIN CANCER RES, V20, P5150, DOI 10.1158/1078-0432.CCR-14-1312; Liu Y, 2016, CANCER CELL, V30, P668, DOI 10.1016/j.ccell.2016.09.011; Luo ZY, 2016, CANCER LETT, V377, P174, DOI 10.1016/j.canlet.2016.04.038; Massague J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038; McLean K, 2011, J CLIN INVEST, V121, P3206, DOI 10.1172/JCI45273; Mebius RE, 2009, IMMUNITY, V30, P670, DOI 10.1016/j.immuni.2009.04.005; Meleshina AV, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0003-7; Meza-Perez S, 2017, TRENDS IMMUNOL, V38, P526, DOI 10.1016/j.it.2017.03.002; Mills Kathryn, 2017, F1000Res, V6, P84, DOI 10.12688/f1000research.9977.1; Miranda F, 2017, CELL CYCLE, V16, P15, DOI 10.1080/15384101.2016.1235846; Miranda F, 2016, CANCER CELL, V30, P273, DOI 10.1016/j.ccell.2016.06.020; Mitra AK, 2012, CANCER DISCOV, V2, P1100, DOI 10.1158/2159-8290.CD-12-0206; Motohara T, 2016, OBSTET GYNECOL, V127, P1003, DOI 10.1097/AOG.0000000000001420; Motohara T, 2011, CARCINOGENESIS, V32, P1597, DOI 10.1093/carcin/bgr183; Motohara T, 2010, CANCER SCI, V101, P1550, DOI 10.1111/j.1349-7006.2010.01556.x; Muraoka M, 2009, AM J PHYSIOL-ENDOC M, V296, pE1430, DOI 10.1152/ajpendo.00024.2009; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Nieman KM, 2013, BBA-MOL CELL BIOL L, V1831, P1533, DOI 10.1016/j.bbalip.2013.02.010; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Nowicka A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081859; Olson OC, 2013, CELL RES, V23, P179, DOI 10.1038/cr.2012.123; Orbay H, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/461718; PAGET S, 1989, CANCER METAST REV, V8, P98; Patch AM, 2015, NATURE, V521, P489, DOI 10.1038/nature14410; Pearce OMT, 2018, CANCER DISCOV, V8, P304, DOI 10.1158/2159-8290.CD-17-0284; Petrillo M, 2016, GYNECOL ONCOL, V142, P176, DOI 10.1016/j.ygyno.2016.03.037; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Pradeep S, 2014, CANCER CELL, V26, P77, DOI 10.1016/j.ccr.2014.05.002; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Reagan MR, 2011, STEM CELLS, V29, P920, DOI 10.1002/stem.645; Reinartz S, 2014, INT J CANCER, V134, P32, DOI 10.1002/ijc.28335; Rizi BS, 2015, CANCER RES, V75, P456, DOI 10.1158/0008-5472.CAN-14-1337; Robinson-Smith TM, 2007, CANCER RES, V67, P5708, DOI 10.1158/0008-5472.CAN-06-4375; Romero IL, 2015, CLIN CANCER RES, V21, P680, DOI 10.1158/1078-0432.CCR-14-2198; Schild T, 2018, CANCER CELL, V33, P347, DOI 10.1016/j.ccell.2018.02.001; Shih IM, 2004, AM J PATHOL, V164, P1511, DOI 10.1016/S0002-9440(10)63708-X; SHIMOTSUMA M, 1992, CANCER RES, V52, P5400; Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003; Suh DH, 2014, BIOCHEM PHARMACOL, V92, P43, DOI 10.1016/j.bcp.2014.08.011; Takaishi K, 2010, CANCER SCI, V101, P2128, DOI 10.1111/j.1349-7006.2010.01652.x; Tan DSP, 2006, LANCET ONCOL, V7, P925, DOI 10.1016/S1470-2045(06)70939-1; Tayama S, 2017, ONCOTARGET, V8, P44312, DOI 10.18632/oncotarget.17871; Thibault B, 2014, CANCER METAST REV, V33, P17, DOI 10.1007/s10555-013-9456-2; Tjhay F, 2015, CANCER SCI, V106, P1421, DOI 10.1111/cas.12765; Tucker SL, 2014, CLIN CANCER RES, V20, P3280, DOI 10.1158/1078-0432.CCR-14-0445; Ullah I, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150025; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Wan LL, 2013, NAT MED, V19, P1450, DOI 10.1038/nm.3391; Worzfeld T, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00024; Yap TA, 2009, NAT REV CANCER, V9, P167, DOI 10.1038/nrc2583; Yeung TL, 2016, BIOMOLECULES, V6, DOI 10.3390/biom6010003; Yeung TL, 2015, AM J PHYSIOL-CELL PH, V309, pC444, DOI 10.1152/ajpcell.00188.2015; Yeung TL, 2013, CANCER RES, V73, P5016, DOI 10.1158/0008-5472.CAN-13-0023; Yin MZ, 2016, J CLIN INVEST, V126, P4157, DOI 10.1172/JCI87252; Zhang YL, 2017, ONCOTARGETS THER, V10, P1655, DOI 10.2147/OTT.S129502; Zhang YA, 2011, CANCER LETT, V303, P47, DOI 10.1016/j.canlet.2011.01.011; Zhou JH, 2017, CLIN CANCER RES, V23, P1945, DOI 10.1158/1078-0432.CCR-16-1562	112	94	96	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2019	38	16					2885	2898		10.1038/s41388-018-0637-x	http://dx.doi.org/10.1038/s41388-018-0637-x			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU3IV	30568223	Green Published, hybrid			2022-12-28	WOS:000465167600001
J	Umakoshi, M; Takahashi, S; Itoh, G; Kuriyama, S; Sasaki, Y; Yanagihara, K; Yashiro, M; Maeda, D; Goto, A; Tanaka, M				Umakoshi, Michinobu; Takahashi, So; Itoh, Go; Kuriyama, Sei; Sasaki, Yuto; Yanagihara, Kazuyoshi; Yashiro, Masakazu; Maeda, Daichi; Goto, Akiteru; Tanaka, Masamitsu			Macrophage-mediated transfer of cancer-derived components to stromal cells contributes to establishment of a pro-tumor microenvironment	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CARCINOMA-ASSOCIATED-FIBROBLASTS; MESOTHELIAL CELLS; INVASION; EXOSOMES; PROMOTE; METASTASIS; ROLES; BETA	Tumor-derived extracellular vesicles (TEVs) secreted into the blood create a pre-metastatic niche in distant organs; however, it is unclear how TEVs are delivered and how they affect stromal cells in the tumor microenvironment. Tumor-associated macrophages (TAMs) have pivotal roles in cancer progression by interacting with cancer cells and other stromal cells. Here, we report a novel function of TAMs: delivery and transmission of TEV contents. TEV-incorporating macrophages (TEV-M Phi s) showed increased invasiveness and were disseminated widely. Upon contact with host stromal cells (peritoneal mesothelial cells (PMCs), fibroblasts, and endothelial cells), TEV-MFs released membrane blebs containing TEVs, a process dependent upon localized activation of caspase-3 in M Phi s. Scattered blebs were incorporated into stromal cells, leading to transfer of cancer-derived RNA and proteins such as TGF-beta, activated Src, Wnt3, and HIF1 alpha. TEV-M Phi-secreted blebs containing cancer-derived components contributed to myofibroblastic changes in recipient stromal cells. TEVs delivered by M Phi s penetrated deep into the parenchyma of the stomach in TEV-injected mice, and transmitted TEVs to PMCs lining the stomach surface; this process induced PMCs to undergo mesothelial-mesenchymal transition. PMCs infiltrated the gastric wall and created a niche, thereby promoting tumor invasion. Depletion of M Phi s prevented these events. Moreover, TEV-M Phi s created a pro-metastatic niche. Taken together, these results suggest a novel function for TAMs: transfer of cancer-derived components to surrounding stromal cells and induction of a pro-tumor microenvironment via an increase in the number of CAF-like cells.	[Umakoshi, Michinobu; Takahashi, So; Itoh, Go; Kuriyama, Sei; Sasaki, Yuto; Tanaka, Masamitsu] Akita Univ, Dept Mol Med & Biochem, Grad Sch Med, 1-1-1 Hondo, Akita 0108543, Japan; [Umakoshi, Michinobu; Maeda, Daichi; Goto, Akiteru] Akita Univ, Grad Sch Med, Dept Cellular & Organ Pathol, 1-1-1 Hondo, Akita 0108543, Japan; [Takahashi, So] Akita Univ, Grad Sch Med, Dept Gastroenterol & Neurol, 1-1-1 Hondo, Akita 0108543, Japan; [Sasaki, Yuto] Akita Univ, Fac & Grad Sch Engn & Resource Sci, Dept Life Sci, 1-1 Tegata Gakuenmachi, Akita 0108502, Japan; [Yanagihara, Kazuyoshi] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Div Pathol, 6-5-1 Kashiwashi, Chiba 2770882, Japan; [Yashiro, Masakazu] Osaka City Univ, Dept Surg Oncol, Grad Sch Med, Abeno Ku, 1-4-3 Asahimachi, Osaka 5458545, Japan; [Maeda, Daichi] Osaka Univ, Grad Sch Med, Dept Clin Genom, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan	Akita University; Akita University; Akita University; Akita University; National Cancer Center - Japan; Osaka Metropolitan University; Osaka University	Tanaka, M (corresponding author), Akita Univ, Dept Mol Med & Biochem, Grad Sch Med, 1-1-1 Hondo, Akita 0108543, Japan.; Goto, A (corresponding author), Akita Univ, Grad Sch Med, Dept Cellular & Organ Pathol, 1-1-1 Hondo, Akita 0108543, Japan.	akigoto@med.akita-u.ac.jp; mastanak@med.akita-u.ac.jp	Goto, Akiteru/P-5775-2014; Kuriyama, Sei/AAV-2368-2020	Kuriyama, Sei/0000-0002-5502-7177; Goto, Akiteru/0000-0001-8776-9004; Takahashi, So/0000-0002-0321-2784	JSPS KAKENHI Grants [17K19579, 16H04691]; Princess Takamatsu Cancer Research Fund [14-24620]; Takeda Science Foundation; Project Mirai Cancer Research	JSPS KAKENHI Grants; Princess Takamatsu Cancer Research Fund; Takeda Science Foundation(Takeda Science Foundation (TSF)); Project Mirai Cancer Research	This work was supported by JSPS KAKENHI Grants (Nos. 17K19579 and 16H04691 to M. Tanaka), a Research Grant from the Princess Takamatsu Cancer Research Fund (14-24620 to M. Tanaka), the Takeda Science Foundation, and Project Mirai Cancer Research grants to M. Tanaka.	Antwi-Baffour SS, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929-015-0174-7; Bao XL, 2012, MOL VIS, V18, P1983; Barile L, 2017, PHARMACOL THERAPEUT, V174, P63, DOI 10.1016/j.pharmthera.2017.02.020; Che DH, 2017, MOL IMMUNOL, V90, P197, DOI 10.1016/j.molimm.2017.06.018; Chen R, 2012, BIO PROTOC, V2, pISS3; Ciardiello C, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020175; Crescitelli R, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.20677; Fackler OT, 2008, J CELL BIOL, V181, P879, DOI 10.1083/jcb.200802081; Feng D, 2010, TRAFFIC, V11, P675, DOI 10.1111/j.1600-0854.2010.01041.x; Fuyuhiro Y, 2011, BRIT J CANCER, V105, P996, DOI 10.1038/bjc.2011.330; Genard G, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00828; Hashimoto O, 2016, J PATHOL, V240, P211, DOI 10.1002/path.4769; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Itoh G, 2017, ONCOGENE, V36, P4434, DOI 10.1038/onc.2017.49; Lin SS, 2017, ONCOTARGET, V8, P110426, DOI 10.18632/oncotarget.22786; Liu CY, 2013, LAB INVEST, V93, P844, DOI 10.1038/labinvest.2013.69; Lv ZD, 2013, MOL CELL BIOCHEM, V377, P177, DOI 10.1007/s11010-013-1583-0; Maia J, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00018; Mulcahy LA, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.24641; Naito Y, 2017, CELL MOL LIFE SCI, V74, P697, DOI 10.1007/s00018-016-2346-3; Nakase I, 2015, SCI REP-UK, V5, DOI 10.1038/srep10300; Patel A, 2016, LIFE SCI, V157, P52, DOI 10.1016/j.lfs.2016.05.036; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Qian ZR, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/649161; Roh-Johnson M, 2017, DEV CELL, V43, P549, DOI 10.1016/j.devcel.2017.11.003; Rothschild PR, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07329-y; Rynne-Vidal A, 2015, CANCERS, V7, P1994, DOI 10.3390/cancers7040872; Sandoval P, 2013, J PATHOL, V231, P517, DOI 10.1002/path.4281; Satoyoshi R, 2015, ONCOGENE, V34, P3176, DOI 10.1038/onc.2014.246; Shan B, 2008, J BIOL CHEM, V283, P21065, DOI 10.1074/jbc.M802786200; Shimoda M, 2017, BBA-MOL CELL RES, V1864, P1989, DOI 10.1016/j.bbamcr.2017.05.027; Song WZ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01106; Steinbichler TB, 2017, SEMIN CANCER BIOL, V44, P170, DOI 10.1016/j.semcancer.2017.02.006; Syn N, 2016, TRENDS PHARMACOL SCI, V37, P606, DOI 10.1016/j.tips.2016.04.006; Takahashi H, 2017, ONCOTARGET, V8, P8633, DOI 10.18632/oncotarget.14374; Tanaka M, 2017, CANCER RES, V77, P684, DOI 10.1158/0008-5472.CAN-16-0964; Wang S, 2016, ONCOTARGET, V7, P8809, DOI 10.18632/oncotarget.6604; Yanagihara K, 2004, CANCER SCI, V95, P575, DOI 10.1111/j.1349-7006.2004.tb02489.x; Yuyama K, 2012, J BIOL CHEM, V287, P10977, DOI 10.1074/jbc.M111.324616; Zhang Q, 2013, CARCINOGENESIS, V34, P962, DOI 10.1093/carcin/bgt027; Zhou B, 2008, NATURE, V454, P109, DOI 10.1038/nature07060	42	35	36	0	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2019	38	12					2162	2176		10.1038/s41388-018-0564-x	http://dx.doi.org/10.1038/s41388-018-0564-x			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP6UR	30459356				2022-12-28	WOS:000461822600012
J	Zhou, PJ; Wang, X; An, N; Wei, LZ; Zhang, L; Huang, XX; Zhu, HH; Fang, YX; Gao, WQ				Zhou, Pei-Jie; Wang, Xiao; An, Na; Wei, Lianzi; Zhang, Long; Huang, Xingxu; Zhu, Helen He; Fang, Yu-Xiang; Gao, Wei-Qiang			Loss of Par3 promotes prostatic tumorigenesis by enhancing cell growth and changing cell division modes	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; HIPPO PATHWAY; STEM-CELL; POLARITY PROTEIN; CANCER; CYCLE; COMPLEX; MURINE; BASAL; LINK	Although cell polarity plays an important role in epithelial tumorigenesis, the consequence of polarity protein loss in prostatic tumorigenesis and the underlying mechanisms remain unclear. Using conditional knockout mouse models, we found in the current study that loss of polarity protein Par3 increases prostatic epithelial cell growth, elevates symmetrical cell divisions in basal cells, and randomizes spindle orientation in luminal cells, causing the development of high-grade prostatic intraepithelial neoplasia (PIN). Mechanistically, loss of Par3 dissociates the Par3/merlin/Lats1 complex, consequently inhibiting phosphorylation of Lats1 to attenuate the Hippo pathway. Furthermore, attenuated Hippo pathway enhances nuclear translocation of Yes-associated protein (YAP), which promotes cell proliferation and symmetrical cell divisions through transcriptional activation of Ki-67 and Sox2. In addition, Lats1 dephosphorylation impairs its interaction with G protein signaling modulator 2 (GPSM2, which is also known as LGN) that causes randomization of spindle orientation in luminal cells. Interestingly, co-deletion of Par3 and Lats1 for complete blockade of the Hippo pathway in mice results in prostate tumor initiation, whereas co-deletion of Par3 and YAP for disrupting YAP nuclear translocation reverses the phenotypes to a relatively normal state. Therefore, our findings highlight combination of Par3 loss and blockade of the Hippo pathway as a novel mechanism for prostatic tumorigenesis.	[Zhou, Pei-Jie; Wang, Xiao; An, Na; Wei, Lianzi; Zhu, Helen He; Fang, Yu-Xiang; Gao, Wei-Qiang] Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Renji Med X Clin Stern Cell Res Ctr, Ren Ji Hosp,Sch Med, Shanghai 200127, Peoples R China; [Zhang, Long] Zhejiang Univ, Life Sci Inst, Hangzhou 310058, Zhejiang, Peoples R China; [Zhang, Long] Zhejiang Univ, Innovat Ctr Cell Signalling Network, Hangzhou 310058, Zhejiang, Peoples R China; [Huang, Xingxu] ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China; [Gao, Wei-Qiang] Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai 200030, Peoples R China; [Gao, Wei-Qiang] Shanghai Jiao Tong Univ, Med X Res Inst, Shanghai 200030, Peoples R China	Shanghai Jiao Tong University; Zhejiang University; Zhejiang University; ShanghaiTech University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Fang, YX; Gao, WQ (corresponding author), Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Renji Med X Clin Stern Cell Res Ctr, Ren Ji Hosp,Sch Med, Shanghai 200127, Peoples R China.; Gao, WQ (corresponding author), Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai 200030, Peoples R China.; Gao, WQ (corresponding author), Shanghai Jiao Tong Univ, Med X Res Inst, Shanghai 200030, Peoples R China.	fyx2003108@sina.com; gao.weiqiang@sjtu.edu.cn	Zhang, Long/AAT-6571-2021; Gao, Wei/GXH-0380-2022	Zhang, Long/0000-0001-8139-0474; huang, xingxu/0000-0001-8934-1247	Ministry of Science and Technology of the People's Republic of China [2017YFA0102900, 2016YFA0502500]; National Natural Science Foundation of China [81672543, 81630073, 81372189]; Science and Technology Commission of Shanghai Municipality [16JC1405700]; High Peak IV subject on stem cells and translational medicine from Education Commission of Shanghai Municipality; KC Wong foundation	Ministry of Science and Technology of the People's Republic of China(Ministry of Science and Technology, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); High Peak IV subject on stem cells and translational medicine from Education Commission of Shanghai Municipality; KC Wong foundation	This study was supported by funds from the Ministry of Science and Technology of the People's Republic of China (2017YFA0102900 to W-QG, 2016YFA0502500 to LZ), National Natural Science Foundation of China (81672543 to Y-XF, 81630073 and 81372189 to W-QG), Science and Technology Commission of Shanghai Municipality (16JC1405700 to W-QG), High Peak IV subject on stem cells and translational medicine from Education Commission of Shanghai Municipality, and KC Wong foundation (to W-QG).	Abate-Shen C, 2003, CANCER RES, V63, P3886; Basu-Roy U, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7411; Boumahdi S, 2014, NATURE, V511, P246, DOI 10.1038/nature13305; Bultje RS, 2009, NEURON, V63, P189, DOI 10.1016/j.neuron.2009.07.004; Carminati M, 2016, NAT STRUCT MOL BIOL, V23, P155, DOI 10.1038/nsmb.3152; Chang YL, 2015, ONCOTARGET, V6, P24017, DOI 10.18632/oncotarget.4447; Choi N, 2012, CANCER CELL, V21, P253, DOI 10.1016/j.ccr.2012.01.005; Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048; Dikovskaya D, 2004, MOL BIOL CELL, V15, P2978, DOI 10.1091/mbc.E03-08-0613; Gladden AB, 2010, DEV CELL, V19, P727, DOI 10.1016/j.devcel.2010.10.008; Goldstein AS, 2008, P NATL ACAD SCI USA, V105, P20882, DOI 10.1073/pnas.0811411106; Goulas S, 2012, CELL STEM CELL, V11, P529, DOI 10.1016/j.stem.2012.06.017; Iden S, 2012, CANCER CELL, V22, P389, DOI 10.1016/j.ccr.2012.08.004; Ittmann M, 2013, CANCER RES, V73, P2718, DOI 10.1158/0008-5472.CAN-12-4213; Keder A, 2015, CURR BIOL, V25, P2739, DOI 10.1016/j.cub.2015.08.064; Lee YJ, 2014, NATURE, V510, P547, DOI 10.1038/nature13267; Lv XB, 2015, EMBO REP, V16, P975, DOI 10.15252/embr.201439951; Lygerou Z, 2000, SCIENCE, V290, P2271; Martin-Belmonte F, 2012, NAT REV CANCER, V12, P23, DOI 10.1038/nrc3169; McCaffrey LM, 2012, CANCER CELL, V22, P601, DOI 10.1016/j.ccr.2012.10.003; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Surzenko N, 2013, DEVELOPMENT, V140, P1445, DOI 10.1242/dev.071878; Thoma CR, 2009, NAT CELL BIOL, V11, P994, DOI 10.1038/ncb1912; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; von Stein W, 2005, DEVELOPMENT, V132, P1675, DOI 10.1242/dev.01720; Wang JJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4415; Wang X, 2009, NATURE, V461, P495, DOI 10.1038/nature08361; Williams SE, 2014, NAT CELL BIOL, V16, P758, DOI 10.1038/ncb3001; Xie YT, 2002, ONCOGENE, V21, P5791, DOI 10.1038/sj.onc.1205700; Yin F, 2013, CELL, V154, P1342, DOI 10.1016/j.cell.2013.08.025; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhou PJ, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0609-y	35	16	16	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2019	38	12					2192	2205		10.1038/s41388-018-0580-x	http://dx.doi.org/10.1038/s41388-018-0580-x			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP6UR	30467379				2022-12-28	WOS:000461822600014
J	Di Leo, L; Vegliante, R; Ciccarone, F; Salvatori, I; Scimeca, M; Bonanno, E; Sagnotta, A; Grazi, GL; Aquilano, K; Ciriolo, MR				Di Leo, Luca; Vegliante, Rolando; Ciccarone, Fabio; Salvatori, Illari; Scimeca, Manuel; Bonanno, Elena; Sagnotta, Andrea; Grazi, Gian Luca; Aquilano, Katia; Ciriolo, Maria Rosa			Forcing ATGL expression in hepatocarcinoma cells imposes glycolytic rewiring through PPAR-alpha/p300-mediated acetylation of p53	ONCOGENE			English	Article							ADIPOSE TRIGLYCERIDE LIPASE; HEPATOCELLULAR-CARCINOMA; TRIACYLGLYCEROL HYDROLYSIS; ENERGY-METABOLISM; LIPID-METABOLISM; FATTY-ACIDS; CANCER; LIPOLYSIS; OMEGA-3-FATTY-ACIDS; PHOSPHORYLATION	Metabolic reprogramming is a typical feature of cancer cells aimed at sustaining high-energetic demand and proliferation rate. Here, we report clear-cut evidence for decreased expression of the adipose triglyceride lipase (ATGL), the first and rate-limiting enzyme of triglyceride hydrolysis, in both human and mouse-induced hepatocellular carcinoma (HCC). We identified metabolic rewiring as major outcome of ATGL overexpression in HCC-derived cell lines. Indeed, ATGL slackened both glucose uptake/utilization and cell proliferation in parallel with increased oxidative metabolism of fatty acids and enhanced mitochondria capacity. We ascribed these ATGL-downstream events to the activity of the tumor-suppressor p53, whose protein levels-but not transcript-were upregulated upon ATGL overexpression. The role of p53 was further assessed by abrogation of the ATGL-mediated effects upon p53 silencing or in p53-null hepatocarcinoma Hep3B cells. Furthermore, we provided insights on the molecular mechanisms governed by ATGL in HCC cells, identifying a new PPAR-alpha/p300 axis responsible for p53 acetylation/accumulation. Finally, we highlighted that ATGL levels confer different susceptibility of HCC cells to common therapeutic drugs, with ATGL overexpressing cells being more resistant to glycolysis inhibitors (e.g., 2-deoxyglucose and 3-bromopyruvate), compared to genotoxic compounds. Collectively, our data provide evidence for a previously uncovered tumor-suppressor function of ATGL in HCC, with the outlined molecular mechanisms shedding light on new potential targets for anticancer therapy.	[Di Leo, Luca; Vegliante, Rolando; Ciccarone, Fabio; Aquilano, Katia; Ciriolo, Maria Rosa] Univ Roma Tor Vergata, Dept Biol, Via Ric Sci 1, I-00133 Rome, Italy; [Salvatori, Illari] IRCCS Fdn Santa Lucia, Santa Lucia Fdn, I-00143 Rome, Italy; [Scimeca, Manuel; Bonanno, Elena] Univ Roma Tor Vergata, Dept Expt Med & Surg, Via Montpellier 1, I-00133 Rome, Italy; [Scimeca, Manuel; Ciriolo, Maria Rosa] IRCCS San Raffaele Pisana, Via Pisana 235, I-00163 Rome, Italy; [Sagnotta, Andrea] Santa Maria di Terni Hosp, Digest Surg & Liver Unit, I-05100 Terni, Italy; [Sagnotta, Andrea] Sapienza Univ Rome, Fac Med & Psychol, St Andrea Hosp, Surg & Med Dept Translat Med, Via Grottarossa 1035-39, I-00189 Rome, Italy; [Grazi, Gian Luca] IRCCS, Regina Elena Natl Canc Inst, Dept Clin & Expt Oncol, Hepatopancreatobiliary Surg Unit, Via Elio Chianesi 53, I-00144 Rome, Italy; [Vegliante, Rolando] Inst Hematol & Immunol 1, INSERM U1109HOP CIVIL, Microenvironm Niche Tumorigenesis & Targeted Ther, Pl Hop, F-67091 Strasbourg, France	University of Rome Tor Vergata; IRCCS Santa Lucia; University of Rome Tor Vergata; IRCCS San Raffaele Pisana; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea	Ciriolo, MR (corresponding author), Univ Roma Tor Vergata, Dept Biol, Via Ric Sci 1, I-00133 Rome, Italy.; Ciriolo, MR (corresponding author), IRCCS San Raffaele Pisana, Via Pisana 235, I-00163 Rome, Italy.	ciriolo@bio.uniroma2.it	AQUILANO, KATIA/K-8888-2016; CICCARONE, FABIO/K-4225-2016; Salvatori, Illari/AAB-6129-2022; Ciccarone, Fabio/AAR-9128-2021	AQUILANO, KATIA/0000-0002-5905-9870; Salvatori, Illari/0000-0001-9700-1269; Ciccarone, Fabio/0000-0002-2425-2240; Sagnotta, Andrea/0000-0002-0606-0317; Di Leo, Luca/0000-0002-2419-2196	Italian Association for Cancer Research (AIRC) [IG 15403]	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro)	This work was supported by the Italian Association for Cancer Research (AIRC, IG 15403). The authors would like to thank Dr. Serena Castelli for her valid help during the revision process. This manuscript is dedicated to Prof. Maria Teresa Carri.	Agustsson T, 2007, CANCER RES, V67, P5531, DOI 10.1158/0008-5472.CAN-06-4585; Al-Zoughbi W, 2016, ONCOTARGET, V7, P33832, DOI 10.18632/oncotarget.9418; Allen MA, 2014, ELIFE, V3, DOI 10.7554/eLife.02200; Aquilano K, 2016, ONCOTARGET, V7, P23019, DOI 10.18632/oncotarget.8552; Barascu A, 2006, INT J BIOCHEM CELL B, V38, P196, DOI 10.1016/j.biocel.2005.08.015; Barbato DL, 2014, BBA-REV CANCER, V1845, P317, DOI 10.1016/j.bbcan.2014.02.003; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Boidot R, 2012, CANCER RES, V72, P939, DOI 10.1158/0008-5472.CAN-11-2474; Bruix J, 2017, J HEPATOL; Burns DM, 2008, GENE DEV, V22, P3449, DOI 10.1101/gad.1697808; Cardaci S, 2012, CANCER RES, V72, P4526, DOI 10.1158/0008-5472.CAN-12-1741; Cardaci S, 2012, J BIOENERG BIOMEMBR, V44, P17, DOI 10.1007/s10863-012-9422-7; Ciccarone F, 2017, SEMIN CANCER BIOL, V47, P50, DOI 10.1016/j.semcancer.2017.06.008; Cui W, 2010, AM J TRANSL RES, V2, P95; Das SK, 2011, SCIENCE, V333, P233, DOI 10.1126/science.1198973; DeWaal D, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02733-4; Doherty JR, 2014, CANCER RES, V74, P908, DOI 10.1158/0008-5472.CAN-13-2034; Duncan RE, 2010, J LIPID RES, V51, P309, DOI 10.1194/jlr.M000729; Gerber M, 2012, BRIT J NUTR, V107, pS228, DOI 10.1017/S0007114512001614; Grace SA, 2017, ANTICANCER RES, V37, P699, DOI 10.21873/anticanres.11366; Haemmerle G, 2006, SCIENCE, V312, P734, DOI 10.1126/science.1123965; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Ito K, 2004, CANCER RES, V64, P1071, DOI 10.1158/0008-5472.CAN-03-1670; Jha P, 2014, HEPATOLOGY, V59, P858, DOI 10.1002/hep.26732; Khan SA, 2015, DIABETES, V64, P418, DOI 10.2337/db14-0325; Kitamura K, 2011, J HEPATOL, V55, P846, DOI 10.1016/j.jhep.2011.01.038; Kobet E, 2000, P NATL ACAD SCI USA, V97, P12547, DOI 10.1073/pnas.97.23.12547; Kurahara H, 2018, ANN SURG ONCOL, V25, P1432, DOI 10.1245/s10434-018-6357-1; Labuschagne CF, 2018, BIOCH BIOPHYS ACTA; Lee James T, 2013, Genes Cancer, V4, P112, DOI 10.1177/1947601913484496; Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001; Liu Y, 2012, J BIOL CHEM, V287, P41469, DOI 10.1074/jbc.M112.367847; Mashek DG, 2015, HEPATOLOGY, V62, P964, DOI 10.1002/hep.27839; McDonnell E, 2016, CELL REP, V17, P1463, DOI 10.1016/j.celrep.2016.10.012; Meex RCR, 2015, AM J PHYSIOL-ENDOC M, V308, pE960, DOI 10.1152/ajpendo.00598.2014; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Nomura DK, 2010, CELL, V140, P49, DOI 10.1016/j.cell.2009.11.027; Ong KT, 2011, HEPATOLOGY, V53, P116, DOI 10.1002/hep.24006; Ou JJ, 2014, CELL REP, V9, P1798, DOI 10.1016/j.celrep.2014.11.016; Park EJ, 2010, CELL, V140, P197, DOI 10.1016/j.cell.2009.12.052; Puzio-Kuter Anna M, 2011, Genes Cancer, V2, P385, DOI 10.1177/1947601911409738; Reed SM, 2015, CANCERS, V7, P30, DOI 10.3390/cancers7010030; Reid BN, 2008, J BIOL CHEM, V283, P13087, DOI 10.1074/jbc.M800533200; Roessler S, 2010, CANCER RES, V70, P10202, DOI 10.1158/0008-5472.CAN-10-2607; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sapiro JM, 2009, J LIPID RES, V50, P1621, DOI 10.1194/jlr.M800614-JLR200; Sathyanarayan A, 2017, CELL REP, V19, P1, DOI 10.1016/j.celrep.2017.03.026; Schwartzenberg-Bar-Yoseph F, 2004, CANCER RES, V64, P2627, DOI 10.1158/0008-5472.CAN-03-0846; Sharma Arishya, 2012, Methods Mol Biol, V920, P613, DOI 10.1007/978-1-61779-998-3_40; So WW, 2015, NUTRIENTS, V7, P6956, DOI 10.3390/nu7085319; Stein M, 2010, PROSTATE, V70, P1388, DOI 10.1002/pros.21172; Tomin T, 2018, J PROTEOME RES, V17, P1415, DOI 10.1021/acs.jproteome.7b00782; Vegliante R, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0345-z; Vegliante R, 2016, CARCINOGENESIS, V37, P233, DOI 10.1093/carcin/bgw003; Waller LP, 2015, WORLD J HEPATOL, V7, P2648, DOI 10.4254/wjh.v7.i26.2648; Won KY, 2012, HUM PATHOL, V43, P221, DOI 10.1016/j.humpath.2011.04.021; Wu JW, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006716; Wu JW, 2011, HEPATOLOGY, V54, P122, DOI 10.1002/hep.24338; Xu SB, 2013, CELL RES, V23, P423, DOI 10.1038/cr.2012.162; Zagani R, 2015, ONCOTARGET, V6, P28282, DOI 10.18632/oncotarget.5061; Zechner R, 2012, CELL METAB, V15, P279, DOI 10.1016/j.cmet.2011.12.018; Zhang X, 2017, ELIFE, V6; Zheng SS, 2017, CANCER RES, V77, P4342, DOI 10.1158/0008-5472.CAN-17-0424; Zimmermann R, 2004, SCIENCE, V306, P1383, DOI 10.1126/science.1100747	64	28	28	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2019	38	11					1860	1875		10.1038/s41388-018-0545-0	http://dx.doi.org/10.1038/s41388-018-0545-0			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HO7XX	30367149	Green Published, hybrid			2022-12-28	WOS:000461164400006
J	Hu, YB; Yan, C; Mu, L; Mil, YL; Zhao, H; Hu, H; Li, XL; Tao, DD; Wu, YQ; Gong, JP; Qin, JC				Hu, Y-B; Yan, C.; Mu, L.; Mil, Y-L; Zhao, H.; Hu, H.; Li, X-L; Tao, D-D; Wu, Y-Q; Gong, J-P; Qin, J-C			Exosomal Wnt-induced dedifferentiation of colorectal cancer cells contributes to chemotherapy resistance	ONCOGENE			English	Article							STEM-CELLS; SELF-RENEWAL; BETA-CATENIN; EXPRESSION; PROGRESSION; HETEROGENEITY; EQUILIBRIUM; ENVIRONMENT; FIBROBLASTS; POPULATION	Cancer stem cells (CSCs) are inherently resistant to chemotherapy, and CSCs in chemotherapy-failed recurrent tumors are enriched; however, the cellular origin of chemotherapy-induced CSC enrichment remains unclear. Communication with stromal fibroblasts may induce cancer cell dedifferentiation into CSCs through secreted factors. We recently demonstrated that fibroblast-derived exosomes promote chemoresistance in colorectal cancer (CRC). Here, we report that fibroblasts confer CRC chemoresistance via exosome-induced reprogramming (dedifferentiation) of bulk CRC cells to phenotypic and functional CSCs. At the molecular level, we provided evidence that the major reprogramming regulators in fibroblast-exosomes are Wnts. Exosomal Wnts were found to increase Wnt activity and drug resistance in differentiated CRC cells, and inhibiting Wnt release diminished this effect in vitro and in vivo. Together, our results indicate that exosomal Wnts derived from fibroblasts could induce the dedifferentiation of cancer cells to promote chemoresistance in CRC, and suggest that interfering with exosomal Wnt signaling may help to improve chemosensitivity and the therapeutic window.	[Hu, Y-B; Yan, C.; Mu, L.; Mil, Y-L; Zhao, H.; Hu, H.; Wu, Y-Q; Gong, J-P; Qin, J-C] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Surg, Wuhan 430030, Hubei, Peoples R China; [Hu, Y-B; Yan, C.; Mu, L.; Mil, Y-L; Zhao, H.; Hu, H.; Li, X-L; Tao, D-D; Gong, J-P; Qin, J-C] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Mol Med Ctr, Wuhan 430030, Hubei, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology	Gong, JP; Qin, JC (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Surg, Wuhan 430030, Hubei, Peoples R China.; Gong, JP; Qin, JC (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Mol Med Ctr, Wuhan 430030, Hubei, Peoples R China.	jpgong@tjh.tjmu.edu.cn; jcqin@tjh.tjmu.edu.cn		Qin, Jichao/0000-0002-2961-7624	National Nature Science Foundation of China [81272660, 81572894, 81702948]; China Postdoctoral Science Foundation [2016M602313]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	The authors thank animal facility of Tongji Medical College for animal experiments. We apologize to the colleagues whose work was not cited owing to space constraint. This work was supported by National Nature Science Foundation of China (81272660, 81572894, 81702948), China Postdoctoral Science Foundation funded project (2016M602313).	Aguirre-Gamboa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074250; Azmi AS, 2013, CANCER METAST REV, V32, P623, DOI 10.1007/s10555-013-9441-9; Bissell MJ, 2005, CANCER CELL, V7, P17, DOI 10.1016/j.ccr.2004.12.013; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Chalamalasetty RB, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1381; Chen Y, 2017, ONCOGENE, V36, P4692, DOI 10.1038/onc.2017.100; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Gregorieff A, 2005, GASTROENTEROLOGY, V129, P626, DOI 10.1053/j.gastro.2005.06.007; Gross JC, 2012, NAT CELL BIOL, V14, P1036, DOI 10.1038/ncb2574; Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026; Hawinkels LJAC, 2014, ONCOGENE, V33, P97, DOI 10.1038/onc.2012.536; HONIG MG, 1986, J CELL BIOL, V103, P171, DOI 10.1083/jcb.103.1.171; Hu YB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125625; Huang EH, 2009, CANCER RES, V69, P3382, DOI 10.1158/0008-5472.CAN-08-4418; Janda CY, 2017, NATURE, V545, P234, DOI 10.1038/nature22306; Jeter CR, 2009, STEM CELLS, V27, P993, DOI 10.1002/stem.29; Koch R, 2014, BLOOD, V123, P2189, DOI 10.1182/blood-2013-08-523886; Kowal J, 2014, CURR OPIN CELL BIOL, V29, P116, DOI 10.1016/j.ceb.2014.05.004; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Lin L, 2011, CANCER RES, V71, P7226, DOI 10.1158/0008-5472.CAN-10-4660; Liu J, 2013, P NATL ACAD SCI USA, V110, P20224, DOI 10.1073/pnas.1314239110; Lotti F, 2013, J EXP MED, V210, P2851, DOI 10.1084/jem.20131195; Luga V, 2012, CELL, V151, P1542, DOI 10.1016/j.cell.2012.11.024; Marjanovic ND, 2013, CLIN CHEM, V59, P168, DOI 10.1373/clinchem.2012.184655; McAllister SS, 2014, NAT CELL BIOL, V16, P717, DOI 10.1038/ncb3015; Meads MB, 2009, NAT REV CANCER, V9, P665, DOI 10.1038/nrc2714; Mincheva-Nilsson L, 2016, CURR PROTOC IMMUNOL, V115; Mittelbrunn M, 2012, NAT REV MOL CELL BIO, V13, P328, DOI 10.1038/nrm3335; Mu L, 2017, ONCOTARGET, V8, DOI DOI 10.18632/ONCOTARGET.22.392; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Qin JC, 2012, CELL STEM CELL, V10, P556, DOI 10.1016/j.stem.2012.03.009; Ratajczak J, 2006, LEUKEMIA, V20, P847, DOI 10.1038/sj.leu.2404132; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Saha S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13096; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Simons M, 2009, CURR OPIN CELL BIOL, V21, P575, DOI 10.1016/j.ceb.2009.03.007; Tammela T, 2017, NATURE, V545, P355, DOI 10.1038/nature22334; Tang DG, 2012, CELL RES, V22, P457, DOI 10.1038/cr.2012.13; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001; TRAINER DL, 1988, INT J CANCER, V41, P287, DOI 10.1002/ijc.2910410221; Trajkovic K, 2008, SCIENCE, V319, P1244, DOI 10.1126/science.1153124; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Webber J, 2010, CANCER RES, V70, P9621, DOI 10.1158/0008-5472.CAN-10-1722; Wicha MS, 2014, NAT MED, V20, P14, DOI 10.1038/nm.3434; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Wilson BJ, 2011, CANCER RES, V71, P5307, DOI 10.1158/0008-5472.CAN-11-0221; Yan C, 2016, ONCOTARGET, V7, P80700, DOI 10.18632/oncotarget.13029	53	104	111	1	40	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2019	38	11					1951	1965		10.1038/s41388-018-0557-9	http://dx.doi.org/10.1038/s41388-018-0557-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HO7XX	30390075	Green Published, hybrid			2022-12-28	WOS:000461164400012
J	Probert, C; Dottorini, T; Speakman, A; Hunt, S; Nafee, T; Fazeli, A; Wood, S; Brown, JE; James, V				Probert, C.; Dottorini, T.; Speakman, A.; Hunt, S.; Nafee, T.; Fazeli, A.; Wood, S.; Brown, J. E.; James, V.			Communication of prostate cancer cells with bone cells via extracellular vesicle RNA; a potential mechanism of metastasis	ONCOGENE			English	Article							STIMULATE ANGIOGENESIS; MEMBRANE-VESICLES; NICHE FORMATION; STEM-CELLS; EXOSOMES; EXPRESSION; GROWTH; MICROVESICLES; MICRORNAS; PROTEINS	The role of extracellular vesicles (EVs) as vehicles for cell-to-cell communication between a tumour and its environment is a relatively new concept. The hypothesis that EVs may be critical in co-opting tissues by tumours to generate distant metastatic niches is particularly pertinent to prostate cancer (PCa), where metastatic-tropism to bone predominates over other tissue types. The potential role of EVs as a means of communication between PCa cells and cells of the bone stroma such as osteoblasts, is yet to be fully explored. In this study, we demonstrate that PCa cell EVs both enhance osteoblast viability and produce a significantly more supportive growth environment for PCa cells when grown in co-culture with EV-treated osteoblasts (p < 0.005). Characterisation of the RNA cargo of EVs produced by the bone-metastatic PCa cell line PC3, highlights the EV-RNA cargo is significantly enriched in genes relating to cell surface signalling, cell-cell interaction, and protein translation (p < 0.01). Using novel techniques to track RNA, we demonstrate the delivery of a set of PCa-RNAs to osteoblast via PCa-EVs and show the effect on osteoblast endogenous transcript abundance. Taken together, by using proof-of-concept studies we demonstrate for the first time the contribution of the RNA element of the PCa EV cargo, providing evidence to support PCa EV communication via RNA molecules as a potential novel route to mediate bone metastasis. We propose targeting PCa EVs could offer a potentially important preventative therapy for men at risk of metastatic PCa.	[Probert, C.; Dottorini, T.; Speakman, A.; James, V.] Univ Nottingham, Sch Vet Med & Sci, Nottingham LE12 5RD, England; [Dottorini, T.] Univ Nottingham, Adv Data Anal Ctr, Nottingham LE12 5RD, England; [Hunt, S.] Univ Sheffield, Sch Clin Dent, Sheffield S10 2TA, S Yorkshire, England; [Nafee, T.; Fazeli, A.] Univ Sheffield, Acad Unit Reprod & Dev Med, Jessop Wing, Jessop Wing, Sheffield S10 2SF, S Yorkshire, England; [Fazeli, A.] Univ Tartu, Inst Biomed & Translat Med, Dept Pathophysiol, Tartu, Estonia; [Wood, S.; Brown, J. E.] Univ Sheffield, Western Pk Hosp, Dept Oncol & Metab, Whitham Rd, Sheffield S10 2SJ, S Yorkshire, England	University of Nottingham; University of Nottingham; University of Sheffield; University of Sheffield; University of Tartu; University of Sheffield; Weston Park Hospital	James, V (corresponding author), Univ Nottingham, Sch Vet Med & Sci, Nottingham LE12 5RD, England.	victoria.james@nottingham.ac.uk	Fazeli, Alireza/G-3679-2010	Fazeli, Alireza/0000-0003-0870-9914; Dottorini, Tania/0000-0001-7733-906X; James, Victoria/0000-0002-9926-2953	Prostate Cancer Research UK [PA14-007]	Prostate Cancer Research UK	We thank Dr Nigel Mongan, Professor Susan Anderson (University of Nottingham) and Dr Penny Ottewell (University of Sheffield) for supplying reagents. C.P was supported by funding from Prostate Cancer Research UK (PA14-007) awarded to VJ and JEB.	Anderson SI, 1998, J MATER SCI-MATER M, V9, P731, DOI 10.1023/A:1008955002955; Bryant RJ, 2012, BRIT J CANCER, V106, P768, DOI 10.1038/bjc.2011.595; Center MM, 2012, EUR UROL, V61, P1079, DOI 10.1016/j.eururo.2012.02.054; Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev-cellbio-101512-122326; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Crescitelli R, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.20677; Cunningham David, 2015, J Biol Methods, V2; Deckers MML, 2002, ENDOCRINOLOGY, V143, P1545, DOI 10.1210/en.143.4.1545; Di Silvo I., 1995, THESIS; Ekstrom K, 2012, J EXTRACELL VESICLES, V1, DOI 10.3402/jev.v1i0.18389; Foj L, 2017, PROSTATE, V77, P573, DOI 10.1002/pros.23295; Grange C, 2011, CANCER RES, V71, P5346, DOI 10.1158/0008-5472.CAN-11-0241; He M, 2015, CARCINOGENESIS, V36, P1008, DOI 10.1093/carcin/bgv081; Heijnen HFG, 1999, BLOOD, V94, P3791, DOI 10.1182/blood.V94.11.3791.423a22_3791_3799; Hessvik NP, 2012, BBA-GENE REGUL MECH, V1819, P1154, DOI 10.1016/j.bbagrm.2012.08.016; Hood JL, 2011, CANCER RES, V71, P3792, DOI 10.1158/0008-5472.CAN-10-4455; Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756; Huang W, 2015, GENET TEST MOL BIOMA, V19, P469, DOI 10.1089/gtmb.2015.0088; Huang XY, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-319; Jung T, 2009, NEOPLASIA, V11, P1093, DOI 10.1593/neo.09822; Kalra H, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001450; Kashyap V, 2013, MOL ONCOL, V7, P555, DOI 10.1016/j.molonc.2013.01.003; Lasser C, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-9; Li M, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0502; Li X, 2007, J BIOL CHEM, V282, P33098, DOI 10.1074/jbc.M611781200; Liu YF, 2016, CANCER CELL, V30, P243, DOI 10.1016/j.ccell.2016.06.021; Matsuo K, 2012, CELL ADHES MIGR, V6, P148, DOI 10.4161/cam.20888; Montero A, 2000, J CLIN INVEST, V105, P1085, DOI 10.1172/JCI8641; Morhayim Jess, 2016, Curr Mol Biol Rep, V2, P48; Nolte-'t Hoen ENM, 2012, NUCLEIC ACIDS RES, V40, P9272, DOI 10.1093/nar/gks658; Pathan M, 2017, J EXTRACELL VESICLES, V6, DOI 10.1080/20013078.2017.1321455; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Prince M, 2001, J CELL BIOCHEM, V80, P424, DOI 10.1002/1097-4644(20010301)80:3<424::AID-JCB160>3.0.CO;2-6; Rana S, 2013, NEOPLASIA, V15, P281, DOI 10.1593/neo.122010; Rodriguez M, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0726-4; Sanchez CA, 2016, ONCOTARGET, V7, P3993, DOI 10.18632/oncotarget.6540; Sharp TV, 2004, P NATL ACAD SCI USA, V101, P16531, DOI 10.1073/pnas.0407123101; Suetsugu A, 2013, ADV DRUG DELIVER REV, V65, P383, DOI 10.1016/j.addr.2012.08.007; Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Van Deun J, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.24858; Wang X, 2015, ONCOL REP, V33, P2445, DOI 10.3892/or.2015.3843; Yao GQ, 2002, CALCIFIED TISSUE INT, V70, P339, DOI 10.1007/s00223-001-1079-x; Yeung CLA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11150; Zomer A, 2015, CELL, V161, P1046, DOI 10.1016/j.cell.2015.04.042	45	42	44	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2019	38	10					1751	1763		10.1038/s41388-018-0540-5	http://dx.doi.org/10.1038/s41388-018-0540-5			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN8DD	30353168	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000460423800013
J	Song, ZY; Wang, F; Cui, SX; Gao, ZH; Qu, XJ				Song, Zhi-Yu; Wang, Feng; Cui, Shu-Xiang; Gao, Zu-Hua; Qu, Xian-Jun			CXCR7/CXCR4 heterodimer-induced histone demethylation: a new mechanism of colorectal tumorigenesis	ONCOGENE			English	Article							SUPPRESSOR-CELLS; CHEMOKINE RECEPTOR; BETA-ARRESTIN; CANCER; CXCR7; REGULATORS; IMMUNE; TRIMETHYLATION; ACTIVATION; METASTASES	Both chemokine receptors (CXCRs) 7 and 4 can facilitate immune cell migration and mediate a vast array of physiological and pathological events. Herein we report, in both human and animal studies, that these two CXCRs can form heterodimers in vivo and promote colorectal tumorigenesis through histone demethylation. Compared with adjacent non-neoplastic tissue, human colorectal cancer (CRC) tissue showed a significant higher expression of CXCR4 and CXCR7, which was colocalized in the cancer cell epithelium. The CXCR/CXCR4 heterodimerization was associated with increased histone demethylase JMJD2A. Villin-CXCR7-CXCR4 transgenic mice demonstrated a greater degree of exacerbated colitis and tumorigenesis than villin-CXCR7 and villin-CXCR4 mice. The CXCR7/CXCR4 heterodimerization also promoted APC mutation-driven colorectal tumorigenesis in APC(Min/+)/villin-CXCR7-CXCR4 mice. Further analysis showed that the CXCR7/CXCR4 heterodimer induced nuclear beta arr1 recruitment and histone demethylase JMJD2A, leading to histone demethylation and resulting in transcription of inflammatory factors and oncogenes. This study uncovered a novel mechanism of colorectal tumorigenesis through the CXCR7/CXCR4 heterodimer-induced histone demethylation. Inhibition of CXCR7/CXCR4 heterodimer-induced histone demethylation could be an effective strategy for the prevention and treatment of colorectal cancer.	[Song, Zhi-Yu; Qu, Xian-Jun] Capital Med Univ, Sch Basic Med Sci, Dept Pharmacol, Beijing, Peoples R China; [Wang, Feng; Cui, Shu-Xiang] McGill Univ, Dept Pathol, Montreal, PQ, Canada; [Gao, Zu-Hua] Capital Med Univ, Sch Publ Hlth, Toxicol & Sanit Chem, Beijing, Peoples R China; [Song, Zhi-Yu] Henan Prov Peoples Hosp, Dept Pharm, Zhengzhou, Henan, Peoples R China	Capital Medical University; McGill University; Capital Medical University; Zhengzhou University	Qu, XJ (corresponding author), Capital Med Univ, Sch Basic Med Sci, Dept Pharmacol, Beijing, Peoples R China.; Gao, ZH (corresponding author), Capital Med Univ, Sch Publ Hlth, Toxicol & Sanit Chem, Beijing, Peoples R China.	zu-hua.gao@mcgill.ca; quxj@ccmu.edu.cn			Natural Science Foundation of China [81673449, 91629303]; Beijing Natural Science Foundation Program and Scientific Research Program of Municipal Commission of Education [KZ201710025020, KZ201810025033]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation Program and Scientific Research Program of Municipal Commission of Education	This work was supported by Natural Science Foundation of China (81673449 and 91629303) and Beijing Natural Science Foundation Program and Scientific Research Program of Municipal Commission of Education (KZ201710025020 and KZ201810025033).	Atreya I, 2008, EXPERT REV ANTICANC, V8, P561, DOI 10.1586/14737140.8.4.561; Balabanian K, 2005, J BIOL CHEM, V280, P35760, DOI 10.1074/jbc.M508234200; Beaulieu JM, 2005, CELL, V123, P755, DOI 10.1016/j.cell.2005.11.010; Berry WL, 2013, CANCER RES, V73, P2936, DOI 10.1158/0008-5472.CAN-12-4300; Burns JM, 2006, J EXP MED, V203, P2201, DOI 10.1084/jem.20052144; COOPER HS, 1993, LAB INVEST, V69, P238; Decaillot FM, 2011, J BIOL CHEM, V286, P32188, DOI 10.1074/jbc.M111.277038; Dhayalan A, 2010, J BIOL CHEM, V285, P26114, DOI 10.1074/jbc.M109.089433; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Graham GJ, 2009, EUR J IMMUNOL, V39, P342, DOI 10.1002/eji.200838858; Guerra-Calderas L, 2015, CANCER GENET-NY, V208, P215, DOI 10.1016/j.cancergen.2014.11.001; Haile LA, 2008, GASTROENTEROLOGY, V135, P871, DOI 10.1053/j.gastro.2008.06.032; Kang JH, 2005, CELL, V123, P833, DOI 10.1016/j.cell.2005.09.011; Katoh H, 2013, CANCER CELL, V24, P631, DOI 10.1016/j.ccr.2013.10.009; Katritch V, 2012, TRENDS PHARMACOL SCI, V33, P17, DOI 10.1016/j.tips.2011.09.003; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Klose RJ, 2006, NATURE, V442, P312, DOI 10.1038/nature04853; Kooistra SM, 2012, NAT REV MOL CELL BIO, V13, P297, DOI 10.1038/nrm3327; Kumar V, 2016, TRENDS IMMUNOL, V37, P208, DOI 10.1016/j.it.2016.01.004; Lefkowitz RJ, 2006, MOL CELL, V24, P643, DOI 10.1016/j.molcel.2006.11.007; Levoye A, 2009, BLOOD, V113, P6085, DOI 10.1182/blood-2008-12-196618; Liu XQ, 2017, BIOMATERIALS, V127, P61, DOI 10.1016/j.biomaterials.2017.02.035; Luker KE, 2010, ONCOGENE, V29, P4599, DOI 10.1038/onc.2010.212; Meidenbauer JJ, 2014, NUTR METAB, V11, DOI 10.1186/1743-7075-11-23; Saleiro D, 2012, INT J CANCER, V131, P2553, DOI 10.1002/ijc.27578; Salifou K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10174; Sanchez-Martin L, 2013, TRENDS MOL MED, V19, P12, DOI 10.1016/j.molmed.2012.10.004; Shin S, 2007, BIOCHEM BIOPH RES CO, V359, P742, DOI 10.1016/j.bbrc.2007.05.179; Steele CW, 2016, CANCER CELL, V29, P832, DOI 10.1016/j.ccell.2016.04.014; Sun CC, 2014, PATHOL RES PRACT, V210, P668, DOI 10.1016/j.prp.2014.06.016; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; Werner L, 2013, THERANOSTICS, V3, P40, DOI 10.7150/thno.5135; Werner L, 2011, J LEUKOCYTE BIOL, V90, P583, DOI 10.1189/jlb.0111101; Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028; Wu T, 2016, ONCOTARGET, V7, P19548, DOI 10.18632/oncotarget.6969; Xu GL, 2015, J BIOL CHEM, V290, P5414, DOI 10.1074/jbc.M114.610345; Yang D, 2015, INT J CLIN EXP PATHO, V8, P13051; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Zhang L, 2016, ONCOGENE, V35, P5641, DOI 10.1038/onc.2016.100; Zhang SS, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-85; Zhou ZH, 2015, J PATHOL, V236, P467, DOI 10.1002/path.4541	42	26	26	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2019	38	9					1560	1575		10.1038/s41388-018-0519-2	http://dx.doi.org/10.1038/s41388-018-0519-2			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN1KL	30337690				2022-12-28	WOS:000459945800014
J	He, YW; Davies, CM; Harrington, BS; Hellmers, L; Sheng, YH; Broomfield, A; McGann, T; Bastick, K; Zhong, L; Wu, A; Maresh, G; McChesney, S; Wong, KY; Adams, MN; Sullivan, RC; Palmer, JS; Burke, LJ; Ewing, AD; Zhang, X; Margolin, D; Li, L; Lourie, R; Matsika, A; Srinivasan, B; McGuckin, MA; Lumley, JW; Hooper, JD				He, Yaowu; Davies, Claire M.; Harrington, Brittney S.; Hellmers, Linh; Sheng, Yonghua; Broomfield, Amy; McGann, Thomas; Bastick, Kate; Zhong, Laurie; Wu, Andy; Maresh, Grace; McChesney, Shannon; Wong, Kuan Yau; Adams, Mark N.; Sullivan, Ryan C.; Palmer, James S.; Burke, Lez J.; Ewing, Adam D.; Zhang, Xin; Margolin, David; Li, Li; Lourie, Rohan; Matsika, Admire; Srinivasan, Bhuvana; McGuckin, Michael A.; Lumley, John W.; Hooper, John D.			CDCP1 enhances Wnt signaling in colorectal cancer promoting nuclear localization of beta-catenin and E-cadherin	ONCOGENE			English	Article							DOMAIN-CONTAINING PROTEIN-1; TUMOR-INITIATING CELLS; HUMAN COLON; PHENOTYPIC CHARACTERIZATION; ELEVATED CDCP1; PKC-DELTA; CARCINOMA; SURVIVAL; TARGET; GENE	Elevated CUB-domain containing protein 1 (CDCP1) is predictive of colorectal cancer (CRC) recurrence and poor patient survival. While CDCP1 expression identifies stem cell populations that mediate lung metastasis, mechanisms underlying the role of this cell surface receptor in CRC have not been defined. We sought to identify CDCP1 regulated processes in CRC using stem cell populations, enriched from primary cells and cell lines, in extensive in vitro and in vivo assays. These experiments, demonstrating that CDCP1 is functionally important in CRC tumor initiation, growth and metastasis, identified CDCP1 as a positive regulator of Wnt signaling. Detailed cell fractionation, immunoprecipitation, microscopy, and immunohistochemical analyses demonstrated that CDCP1 promotes translocation of the key regulators of Wnt signaling, beta-catenin, and E-cadherin, to the nucleus. Of functional importance, disruption of CDCP1 reduces nuclear localized, chromatin-associated beta-catenin and nuclear localized E-cadherin, increases sequestration of these proteins in cell membranes, disrupts regulation of CRC promoting genes, and reduces CRC tumor burden. Thus, disruption of CDCP1 perturbs pro-cancerous Wnt signaling including nuclear localization of beta-catenin and E-cadherin.	[He, Yaowu; Davies, Claire M.; Harrington, Brittney S.; Sheng, Yonghua; McGann, Thomas; Bastick, Kate; Zhong, Laurie; Wu, Andy; Wong, Kuan Yau; Adams, Mark N.; Palmer, James S.; Burke, Lez J.; Ewing, Adam D.; Lourie, Rohan; Srinivasan, Bhuvana; McGuckin, Michael A.; Hooper, John D.] Univ Queensland, Mater Res Inst, Woolloongabba, Qld 4102, Australia; [Davies, Claire M.; Broomfield, Amy; Lourie, Rohan; Matsika, Admire; Srinivasan, Bhuvana] Mater Hlth Serv, South Brisbane, Qld 4101, Australia; [Hellmers, Linh; Maresh, Grace; McChesney, Shannon; Sullivan, Ryan C.; Zhang, Xin; Margolin, David; Li, Li] Ochsner Clin Fdn, New Orleans, LA USA; [Matsika, Admire] Univ Queensland, Sch Biomed Sci, St Lucia, Qld 4072, Australia; [Lumley, John W.] Wesley Hosp, Auchenflower, Qld 4066, Australia	Mater Research; University of Queensland; Mater Health Services; Ochsner Health System; University of Queensland; Wesley Hospital	Hooper, JD (corresponding author), Univ Queensland, Mater Res Inst, Woolloongabba, Qld 4102, Australia.	john.hooper@mater.uq.edu.au	Adams, Mark/AAE-1209-2021; sheng, yong H/C-5052-2013; Harrington, Brittney/P-1687-2016; Ewing, Adam/M-3164-2014; Hooper, John/C-1481-2016	Adams, Mark/0000-0003-1906-5018; sheng, yong H/0000-0002-4623-9098; Wu, Andy C/0000-0002-0864-4447; McGuckin, Michael/0000-0002-8375-2675; Burke, Lez/0000-0002-2932-6843; HE, Yaowu/0000-0002-7828-263X; McGann, Thomas/0000-0002-7699-1010; Harrington, Brittney/0000-0001-7083-069X; Davies, Claire/0000-0001-8651-0914; Ewing, Adam/0000-0002-4544-994X; Hooper, John/0000-0003-1054-8486	Wesley Research Institute [2010-09]; Cancer Council Queensland [APP1021827, APP1045801]; National Health and Medical Research Council [APP1121970]; Australian Research Council [FT120100917]; NHMRC Early Career Fellowship [1091589]	Wesley Research Institute; Cancer Council Queensland(Cancer Council Queensland); National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council(Australian Research Council); NHMRC Early Career Fellowship(National Health and Medical Research Council (NHMRC) of Australia)	This work was funded by grant 2010-09 from the Wesley Research Institute to JWL and JDH, grants APP1021827 and APP1045801 from the Cancer Council Queensland, grant APP1121970 from the National Health and Medical Research Council to JDH, and Future Fellowship FT120100917 from the Australian Research Council to JDH, and NHMRC Early Career Fellowship 1091589 to MNA.	Adams MN, 2015, ONCOGENE, V34, P1375, DOI 10.1038/onc.2014.88; Alajati A, 2015, CELL REP, V11, P564, DOI 10.1016/j.celrep.2015.03.044; Benes CH, 2005, CELL, V121, P271, DOI 10.1016/j.cell.2005.02.019; Brocardo M, 2008, J BIOL CHEM, V283, P5950, DOI 10.1074/jbc.M708775200; Brown TA, 2004, J BIOL CHEM, V279, P14772, DOI 10.1074/jbc.M309678200; Bruun J, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00118; Casar B, 2014, ONCOGENE, V33, P255, DOI 10.1038/onc.2012.547; Casar B, 2012, ONCOGENE, V31, P3924, DOI 10.1038/onc.2011.555; Chou CT, 2015, ANN SURG ONCOL, V22, P4335, DOI 10.1245/s10434-015-4505-4; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Deryugina EI, 2009, MOL CANCER RES, V7, P1197, DOI 10.1158/1541-7786.MCR-09-0100; Dieter SM, 2011, CELL STEM CELL, V9, P357, DOI 10.1016/j.stem.2011.08.010; Dong Y, 2012, J BIOL CHEM, V287, P9792, DOI 10.1074/jbc.M111.335448; Emerling BM, 2013, P NATL ACAD SCI USA, V110, P3483, DOI 10.1073/pnas.1222435110; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Ganesh S, 2018, MOL CANCER THER, V17, P544, DOI 10.1158/1535-7163.MCT-17-0605; Gao WC, 2013, GASTROENTEROLOGY, V145, P636, DOI 10.1053/j.gastro.2013.05.049; Harrington BS, 2016, BRIT J CANCER, V114, P417, DOI 10.1038/bjc.2015.471; He Y, 2016, ONCOGENE, V35, P468, DOI 10.1038/onc.2015.101; Heuberger J, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002915; Hooper JD, 2003, ONCOGENE, V22, P1783, DOI 10.1038/sj.onc.1206220; Huang WS, 2007, WORLD J GASTROENTERO, V13, P6581, DOI 10.3748/wjg.13.6581; Ikeda JI, 2009, CANCER SCI, V100, P429, DOI 10.1111/j.1349-7006.2008.01066.x; Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233; Krieghoff E, 2006, J CELL SCI, V119, P1453, DOI 10.1242/jcs.02864; Law ME, 2013, ONCOGENE, V32, P1316, DOI 10.1038/onc.2012.138; Lin CY, 2014, CANCER RES, V74, P5229, DOI 10.1158/0008-5472.CAN-13-2995; Margolin DA, 2015, FASEB J, V29, P3571, DOI 10.1096/fj.14-268938; Mazzoni SM, 2014, CANCER LETT, V355, P1, DOI 10.1016/j.canlet.2014.09.018; Miyazawa Y, 2010, CANCER RES, V70, P5136, DOI 10.1158/0008-5472.CAN-10-0220; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morgan RG, 2014, J CELL BIOCHEM, V115, P1351, DOI 10.1002/jcb.24803; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Novellasdemunt L, 2015, AM J PHYSIOL-CELL PH, V309, pC511, DOI 10.1152/ajpcell.00117.2015; Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Orsulic S, 1999, J CELL SCI, V112, P1237; Razorenova OV, 2011, P NATL ACAD SCI USA, V108, P1931, DOI 10.1073/pnas.1011777108; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Scherl-Mostageer M, 2001, ONCOGENE, V20, P4402, DOI 10.1038/sj.onc.1204566; Turdo F, 2016, ONCOTARGET, V7, P69649, DOI 10.18632/oncotarget.11935; Uekita T, 2007, MOL CELL BIOL, V27, P7649, DOI 10.1128/MCB.01246-07; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; Wong CH, 2009, CLIN CANCER RES, V15, P2311, DOI 10.1158/1078-0432.CCR-08-2533; Wortmann A, 2011, J BIOL CHEM, V286, P42303, DOI 10.1074/jbc.M111.227462; Wright HJ, 2017, P NATL ACAD SCI USA, V114, pE6556, DOI 10.1073/pnas.1703791114; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304	47	19	19	3	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	1					219	233		10.1038/s41388-019-0983-3	http://dx.doi.org/10.1038/s41388-019-0983-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG3NM	31471585				2022-12-28	WOS:000509849200015
J	Westrich, JA; Vermeer, DW; Silva, A; Bonney, S; Berger, JN; Cicchini, L; Greer, RO; Song, JI; Raben, D; Slansky, JE; Lee, JH; Spanos, WC; Pyeon, D				Westrich, Joseph A.; Vermeer, Daniel W.; Silva, Alexa; Bonney, Stephanie; Berger, Jennifer N.; Cicchini, Louis; Greer, Robert O.; Song, John I.; Raben, David; Slansky, Jill E.; Lee, John H.; Spanos, William C.; Pyeon, Dohun			CXCL14 suppresses human papillomavirus-associated head and neck cancer through antigen-specific CD8(+) T-cell responses by upregulating MHC-I expression	ONCOGENE			English	Article							COMPLEX CLASS-I; CERVICAL INTRAEPITHELIAL NEOPLASIA; IMMUNE; SURVIVAL; TISSUE; INFILTRATION; NEUTROPHILS; CARCINOMA; DEPLETION; PROTECTS	Evasion of the host immune responses is critical for both persistent human papillomavirus (HPV) infection and associated cancer progression. We have previously shown that expression of the homeostatic chemokine CXCL14 is significantly downregulated by the HPV oncoprotein E7 during cancer progression. Restoration of CXCL14 expression in HPV-positive head and neck cancer (HNC) cells dramatically suppresses tumor growth and increases survival through an immune-dependent mechanism in mice. Although CXCL14 recruits natural killer (NK) and T cells to the tumor microenvironment, the mechanism by which CXCL14 mediates tumor suppression through NK and/or T cells remained undefined. Here we report that CD8(+) T cells are required for CXCL14-mediated tumor suppression. Using a CD8(+) T-cell receptor transgenic model, we show that the CXCL14-mediated antitumor CD8 + T-cell responses require antigen specificity. Interestingly, CXCL14 expression restores major histocompatibility complex class I (MHC-I) expression on HPV-positive HNC cells downregulated by HPV, and knockdown of MHC-I expression in HNC cells results in loss of tumor suppression even with CXCL14 expression. These results suggest that CXCL14 enacts antitumor immunity through restoration of MHC-I expression on tumor cells and promoting antigen-specific CD8(+) T-cell responses to suppress HPV-positive HNC.	[Westrich, Joseph A.; Silva, Alexa; Berger, Jennifer N.; Cicchini, Louis; Slansky, Jill E.; Pyeon, Dohun] Univ Colorado, Sch Med, Dept Immunol & Microbiol, Aurora, CO 80045 USA; [Vermeer, Daniel W.; Spanos, William C.] Sanford Res, Canc Biol Res Ctr, Sioux Falls, SD 57104 USA; [Bonney, Stephanie] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO 80045 USA; [Greer, Robert O.] Univ Colorado, Sch Med, Dept Pathol, Aurora, CO 80045 USA; [Greer, Robert O.] Univ Colorado, Sch Med, Dept Dermatol, Aurora, CO 80045 USA; [Greer, Robert O.] Univ Colorado, Sch Dent Med, Div Oral & Maxillofacial Pathol, Aurora, CO 80045 USA; [Song, John I.] Univ Colorado, Sch Med, Dept Otolaryngol, Aurora, CO 80045 USA; [Raben, David] Univ Colorado, Sch Med, Dept Radiat Oncol, Aurora, CO 80045 USA; [Lee, John H.] Chan Soon Shiong Inst Med, El Segundo, CA 90245 USA; [Pyeon, Dohun] Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA; [Westrich, Joseph A.] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; Sanford Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; Michigan State University; Colorado State University	Pyeon, D (corresponding author), Univ Colorado, Sch Med, Dept Immunol & Microbiol, Aurora, CO 80045 USA.; Pyeon, D (corresponding author), Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA.	dpyeon@msu.edu		Slansky, Jill/0000-0003-3820-1724; Pyeon, Dohun/0000-0003-1970-844X; Vermeer, Daniel/0000-0002-1501-0418	NIH [R01 DE026125, T32 AI052066]; Immunology and Microbiology Pilot Award; University of Colorado Cancer Center; Colorado Clinical and Translational Sciences Institute; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI052066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE026125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008730] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Immunology and Microbiology Pilot Award; University of Colorado Cancer Center; Colorado Clinical and Translational Sciences Institute; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Ross Kedl, Linda van Dyk, Eric Clambey, Paul Ahlquist, Paul Lambert, Xiao-Jing Wang, and members of the Pyeon laboratory for useful comments and suggestions. This work was supported in part by NIH R01 DE026125 (DP and WCS), NIH T32 AI052066 (JAW), Immunology and Microbiology Pilot Award (DP and JES), grants from the University of Colorado Cancer Center (DP), Colorado Clinical and Translational Sciences Institute (DP, JIS, and ROG), and a generous gift from the Marsico Fund (DR).	Augsten M, 2009, P NATL ACAD SCI USA, V106, P3414, DOI 10.1073/pnas.0813144106; BAL V, 1990, EUR J IMMUNOL, V20, P1893, DOI 10.1002/eji.1830200904; Bosch FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/jcp.55.4.244; Cao XT, 2000, J IMMUNOL, V165, P2588, DOI 10.4049/jimmunol.165.5.2588; Chaturvedi AK, 2011, J CLIN ONCOL, V29, P4294, DOI 10.1200/JCO.2011.36.4596; Chen LM, 2010, J IMMUNOL, V184, P4455, DOI 10.4049/jimmunol.0900525; Cicchini L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03295-7; Cicchini L, 2016, MBIO, V7, DOI 10.1128/mBio.00270-16; Cogliano V, 2005, LANCET ONCOL, V6, P204, DOI 10.1016/S1470-2045(05)70086-3; Cuburu N, 2012, J CLIN INVEST, V122, P4606, DOI 10.1172/JCI63287; Da Silva DM, 2015, PAPILLOMAVIRUS RES, V1, P12, DOI 10.1016/j.pvr.2015.05.001; de Martel C, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70137-7; de Oliveira LC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118225; DiMaio D, 2013, VIROLOGY, V445, P99, DOI 10.1016/j.virol.2013.05.006; Farkona S, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0623-5; FELTKAMP MCW, 1993, EUR J IMMUNOL, V23, P2242, DOI 10.1002/eji.1830230929; Ferris RL, 2016, NEW ENGL J MED, V375, P1856, DOI 10.1056/NEJMoa1602252; Garcia-Lora A, 2003, J CELL PHYSIOL, V195, P346, DOI 10.1002/jcp.10290; Glasner A, 2017, J VIROL, V91, P22; Handisurya A, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004314; Hata RI, 2015, SCI REP-UK, V5, DOI 10.1038/srep09083; Herzer K, 2003, J VIROL, V77, P8299, DOI 10.1128/JVI.77.15.8299-8309.2003; Hibma Merilyn H, 2012, Open Virol J, V6, P241, DOI 10.2174/1874357901206010241; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Hu CY, 2013, INT J ONCOL, V43, P1487, DOI 10.3892/ijo.2013.2078; Johnston RJ, 2014, CANCER CELL, V26, P923, DOI 10.1016/j.ccell.2014.10.018; Kansy BA, 2017, CANCER RES, V77, P6353, DOI 10.1158/0008-5472.CAN-16-3167; Kim DH, 2011, BIOCHEM BIOPH RES CO, V409, P792, DOI 10.1016/j.bbrc.2011.05.090; Klebanoff CA, 2006, IMMUNOL REV, V211, P214, DOI 10.1111/j.0105-2896.2006.00391.x; Kurth I, 2001, J EXP MED, V194, P855, DOI 10.1084/jem.194.6.855; Kuss-Duerkop SK, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10020082; Lee HT, 2017, THERANOSTICS, V7, P855, DOI 10.7150/thno.17558; Liu CQ, 2017, MOL MED REP, V15, P1063, DOI 10.3892/mmr.2017.6102; Lu JC, 2015, J CLIN INVEST, V125, P1839, DOI 10.1172/JCI78437; Lu J, 2016, J INFLAMM-LOND, V13, DOI 10.1186/s12950-015-0109-9; Lyu XJ, 2015, ONCOTARGET, V6, P6656, DOI 10.18632/oncotarget.3169; Maldonado L, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007323; Miyamoto C, 2014, BIOMED RES-TOKYO, V35, P381, DOI 10.2220/biomedres.35.381; Moses K, 2016, J LEUKOCYTE BIOL, V99, P811, DOI 10.1189/jlb.1HI0715-289R; Nasman A, 2013, INT J CANCER, V132, P72, DOI 10.1002/ijc.27635; Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731; Pasero C, 2015, ONCOTARGET, V6, P14360, DOI 10.18632/oncotarget.3965; Podolin PL, 2013, AM J PHYSIOL-LUNG C, V304, pL312, DOI 10.1152/ajplung.00152.2012; Ran XW, 2017, DRUG DES DEV THER, V11, P2007, DOI 10.2147/DDDT.S140687; Ribas A, 2017, CELL, V170, P1109, DOI 10.1016/j.cell.2017.08.027; Shurin GV, 2005, J IMMUNOL, V174, P5490, DOI 10.4049/jimmunol.174.9.5490; Smola Sigrun, 2017, Ther Adv Vaccines, V5, P69, DOI 10.1177/2051013617717914; Su RC, 2001, J IMMUNOL, V167, P4869, DOI 10.4049/jimmunol.167.9.4869; Tardif KD, 2003, J VIROL, V77, P11644, DOI 10.1128/JVI.77.21.11644-11650.2003; Tarek N, 2014, ADV EXP MED BIOL, V804, P341, DOI 10.1007/978-3-319-04843-7_19; Tindle RW, 2002, NAT REV CANCER, V2, P59, DOI 10.1038/nrc700; Trimble CL, 2010, J IMMUNOL, V185, P7107, DOI 10.4049/jimmunol.1002756; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Van Audenaerde JRM, 2018, PHARMACOL THERAPEUT, V189, P31, DOI 10.1016/j.pharmthera.2018.04.003; van der Burg SH, 2002, VIRUS RES, V89, P275, DOI 10.1016/S0168-1702(02)00196-X; Welters MJP, 2018, CLIN CANCER RES, V24, P634, DOI 10.1158/1078-0432.CCR-17-2140; Wente MN, 2008, CANCER LETT, V259, P209, DOI 10.1016/j.canlet.2007.10.021; Westrich JA, 2017, VIRUS RES, V231, P21, DOI 10.1016/j.virusres.2016.11.023; Woo YL, 2008, BJOG-INT J OBSTET GY, V115, P1616, DOI 10.1111/j.1471-0528.2008.01936.x; Woo Y. L., 2008, BJOG, V115, P1621	60	21	24	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2019	38	46					7166	7180		10.1038/s41388-019-0911-6	http://dx.doi.org/10.1038/s41388-019-0911-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JN5HX	31417179	Green Accepted, hybrid			2022-12-28	WOS:000496930500004
J	Ghosh, JC; Seo, JH; Agarwal, E; Wang, Y; Kossenkov, AV; Tang, HY; Speicher, DW; Altieri, DC				Ghosh, Jagadish C.; Seo, Jae Ho; Agarwal, Ekta; Wang, Yuan; Kossenkov, Andrew V.; Tang, Hsin-Yao; Speicher, David W.; Altieri, Dario C.			Akt phosphorylation of mitochondrial Lonp1 protease enables oxidative metabolism and advanced tumor traits	ONCOGENE			English	Article							STRESS; PROTEOSTASIS; CANCER; CLPP; DEGRADATION; DYNAMICS; DISEASE; ROS	Tumor mitochondria have heightened protein folding quality control, but the regulators of this process and how they impact cancer traits are not completely understood. Here we show that the ATP-directed mitochondrial protease, LonP1 is upregulated by stress conditions, including hypoxia, in tumor, but not normal cells. In mitochondria, LonP1 is phosphorylated by Akt on Ser173 and Ser181, enhancing its protease activity. Interference with this pathway induces accumulation of misfolded subunits of electron transport chain complex II and complex V, resulting in impaired oxidative bioenergetics and heightened ROS production. Functionally, this suppresses mitochondrial trafficking to the cortical cytoskeleton, shuts off tumor cell migration and invasion, and inhibits primary and metastatic tumor growth, in vivo. These data identify LonP1 as a key effector of mitochondrial reprogramming in cancer and potential therapeutic target.	[Ghosh, Jagadish C.; Seo, Jae Ho; Agarwal, Ekta; Wang, Yuan; Speicher, David W.; Altieri, Dario C.] Prostate Canc Discovery & Dev Program, Philadelphia, PA 19107 USA; [Ghosh, Jagadish C.; Seo, Jae Ho; Agarwal, Ekta; Wang, Yuan; Altieri, Dario C.] Wistar Inst Anat & Biol, Immunol Microenvironm & Metastasis Program, 3601 Spruce St, Philadelphia, PA 19104 USA; [Kossenkov, Andrew V.; Tang, Hsin-Yao; Speicher, David W.] Wistar Inst Anat & Biol, Ctr Syst & Computat Biol, 3601 Spruce St, Philadelphia, PA 19104 USA; [Speicher, David W.] Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, 3601 Spruce St, Philadelphia, PA 19104 USA	The Wistar Institute; The Wistar Institute; The Wistar Institute	Altieri, DC (corresponding author), Prostate Canc Discovery & Dev Program, Philadelphia, PA 19107 USA.; Altieri, DC (corresponding author), Wistar Inst Anat & Biol, Immunol Microenvironm & Metastasis Program, 3601 Spruce St, Philadelphia, PA 19104 USA.	daltieri@wistar.org		Agarwal, Ekta/0000-0002-5992-3358; Tang, Hsin-Yao/0000-0003-1838-018X	National Institutes of Health (NIH) [P01 CA140043, R35 CA220446, R50 CA221838, R50 CA211199]; Cancer Center Support Grant (CCSG) [CA010815]; NATIONAL CANCER INSTITUTE [P30CA010815, P01CA140043, R35CA220446] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Center Support Grant (CCSG); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank James Hayden and Frederick Keeney for assistance with time-lapse videomicroscopy and Sandra Harper for performing the HPLC gel filtration experiments. This work was supported by the National Institutes of Health (NIH) grants P01 CA140043 (DCA and DWS), R35 CA220446 (D.C.A.) R50 CA221838 (H-YT), and R50 CA211199 (AVK). and Support for Core Facilities utilized in this study was provided by Cancer Center Support Grant (CCSG) CA010815 to The Wistar Institute.	Altieri DC, 2013, CELL MOL LIFE SCI, V70, P2463, DOI 10.1007/s00018-012-1177-0; Anderson RG, 2018, BBA-REV CANCER, V1870, P96, DOI 10.1016/j.bbcan.2018.05.005; Balch WE, 2008, SCIENCE, V319, P916, DOI 10.1126/science.1141448; Bezawork-Geleta A, 2015, SCI REP-UK, V5, DOI 10.1038/srep17397; Bota DA, 2016, FREE RADICAL BIO MED, V100, P188, DOI 10.1016/j.freeradbiomed.2016.06.031; Caino MC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13730; Caino MC, 2015, P NATL ACAD SCI USA, V112, P8638, DOI 10.1073/pnas.1500722112; Calvo SE, 2016, NUCLEIC ACIDS RES, V44, pD1251, DOI 10.1093/nar/gkv1003; Cha SS, 2010, EMBO J, V29, P3520, DOI 10.1038/emboj.2010.226; Chae YC, 2016, CANCER CELL, V30, P257, DOI 10.1016/j.ccell.2016.07.004; Chae YC, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3139; Chevet E, 2015, CANCER DISCOV, V5, P586, DOI 10.1158/2159-8290.CD-14-1490; Ciechanover A, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2014.117; Cole A, 2015, CANCER CELL, V27, P864, DOI 10.1016/j.ccell.2015.05.004; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Desai SP, 2013, BIOPHYS J, V104, P2077, DOI 10.1016/j.bpj.2013.03.025; Fukuda R, 2007, CELL, V129, P111, DOI 10.1016/j.cell.2007.01.047; Ghosh JC, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju502; Gibellini L, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00254; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Granot Z, 2007, MOL ENDOCRINOL, V21, P2164, DOI 10.1210/me.2005-0458; Hartl FU, 2011, NATURE, V475, P324, DOI 10.1038/nature10317; Haynes CM, 2010, J CELL SCI, V123, P3849, DOI 10.1242/jcs.075119; Hetz C, 2015, NAT CELL BIOL, V17, P829, DOI 10.1038/ncb3184; Janku F, 2018, NAT REV CLIN ONCOL, V15, P273, DOI 10.1038/nrclinonc.2018.28; Kang BH, 2007, CELL, V131, P257, DOI 10.1016/j.cell.2007.08.028; Kao TY, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.9; Liu KY, 2014, CRIT REV BIOCHEM MOL, V49, P400, DOI 10.3109/10409238.2014.925421; Lu B, 2017, ADV EXP MED BIOL, V1038, P173, DOI 10.1007/978-981-10-6674-0_12; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Marchi S, 2019, EMBO J, V38, DOI 10.15252/embj.201899435; Pinti M, 2016, BBA-BIOENERGETICS, V1857, P1300, DOI 10.1016/j.bbabio.2016.03.025; Pinti M, 2015, CELL MOL LIFE SCI, V72, P4807, DOI 10.1007/s00018-015-2039-3; Piskounova E, 2015, NATURE, V527, P186, DOI 10.1038/nature15726; Potter M, 2016, BIOCHEM SOC T, V44, P1499, DOI 10.1042/BST20160094; Pryde KR, 2016, CELL REP, V17, P2522, DOI 10.1016/j.celrep.2016.11.027; Quiros PM, 2014, CELL REP, V8, P541, DOI 10.1016/j.celrep.2014.06.018; Rotanova TV, 2006, PROTEIN SCI, V15, P1815, DOI 10.1110/ps.052069306; Sabharwal SS, 2014, NAT REV CANCER, V14, P709, DOI 10.1038/nrc3803; Sanchez-Alvarez M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16662-1; Santi SA, 2010, AM J PHYSIOL-CELL PH, V298, pC580, DOI 10.1152/ajpcell.00375.2009; Senft D, 2016, CURR OPIN CELL BIOL, V39, P43, DOI 10.1016/j.ceb.2016.02.001; Seo JH, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002507; Tabas I, 2011, NAT CELL BIOL, V13, P184, DOI 10.1038/ncb0311-184; van Oosten-Hawle P, 2014, GENE DEV, V28, P1533, DOI 10.1101/gad.241125.114; Vieux EF, 2013, P NATL ACAD SCI USA, V110, pE2002, DOI 10.1073/pnas.1307066110; Vyas S, 2016, CELL, V166, P555, DOI 10.1016/j.cell.2016.07.002; Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365; Zhao J, 2013, ONCOGENE, V32, P4814, DOI 10.1038/onc.2012.494	49	23	23	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2019	38	43					6926	6939		10.1038/s41388-019-0939-7	http://dx.doi.org/10.1038/s41388-019-0939-7			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JH4GX	31406245	Green Accepted			2022-12-28	WOS:000492728000004
J	Wang, J; Li, N; Huang, ZB; Fu, S; Yu, SM; Fu, YM; Zhou, PC; Chen, RC; Zhou, RR; Huang, Y; Hu, XW; Fan, XG				Wang, Juan; Li, Ning; Huang, Ze-Bing; Fu, Sha; Yu, Song-Man; Fu, Yong-Ming; Zhou, Peng-Cheng; Chen, Ruo-Chan; Zhou, Rong-Rong; Huang, Yan; Hu, Xing-Wang; Fan, Xue-Gong			HBx regulates transcription factor PAX8 stabilization to promote the progression of hepatocellular carcinoma	ONCOGENE			English	Article							VIRUS X PROTEIN; AURORA KINASE; UBIQUITIN; DEGRADATION; SKP2; MYC; PHOSPHORYLATION; INHIBITION; EXPRESSION; STABILITY	Transcription factor PAX8 expression is upregulated in several types of cancers. However, little is known about the function of PAX8 in the progression of hepatoma and its regulatory mechanisms. Here, we show that PAX8 silencing inhibits the proliferation and clonogenicity of hepatoma cells and its growth in vivo. The HBV X protein (HBx) does not directly interacts, but stabilizes PAX8 by inhibiting proteasome-dependent ubiquitination and degradation. Furthermore, the E3 ubiquitin ligase complex component Skp2 through its LRR domain directly interacts with the Prd domain of PAX8 and targets PAX8 by recognizing its lysine 275 for ubiquitination and degradation in hepatoma cells. In addition, HBx directly interacts and is colocalized with Skp2 to inhibit its recognition and subsequent ubiquitination and degradation of PAX8 in hepatoma cells. Moreover, HBx upregulates the expression and phosphorylation of Aurora A, a serine-threonine kinase, which interacts with and phosphorylates PAX8 at S209 and T277, compromising the Skp2-recognized PAX8 ubiquitination and destabilization. Thus, HBx stabilizes PAX8 protein by inhibiting the Skp2 targeted PAX8 ubiquitination and enhancing the Aurora A-mediated its phosphorylation, contributing to the progression of hepatoma. Our findings suggest that PAX8 may a new target for design of therapies and uncover new insights into the pathogenesis of hepatoma.	[Wang, Juan; Huang, Ze-Bing; Fu, Sha; Yu, Song-Man; Fu, Yong-Ming; Zhou, Peng-Cheng; Chen, Ruo-Chan; Zhou, Rong-Rong; Huang, Yan; Hu, Xing-Wang; Fan, Xue-Gong] Cent S Univ, Xiangya Hosp, Dept Infect Dis, Changsha, Hunan, Peoples R China; [Wang, Juan; Huang, Ze-Bing; Fu, Sha; Yu, Song-Man; Fu, Yong-Ming; Zhou, Peng-Cheng; Chen, Ruo-Chan; Zhou, Rong-Rong; Huang, Yan; Hu, Xing-Wang; Fan, Xue-Gong] Key Lab Viral Hepatitis, Changsha, Hunan, Peoples R China; [Li, Ning] Cent S Univ, Xiangya Hosp, Dept Blood Transfus, Changsha, Hunan, Peoples R China	Central South University; Central South University	Hu, XW; Fan, XG (corresponding author), Cent S Univ, Xiangya Hosp, Dept Infect Dis, Changsha, Hunan, Peoples R China.; Hu, XW; Fan, XG (corresponding author), Key Lab Viral Hepatitis, Changsha, Hunan, Peoples R China.	lebithu@csu.edu.cn; xgfan@hotmail.com	Hu, Xingwang/ABG-6400-2021	Fu, Sha/0000-0001-7465-4929	International Scientific and Technology Cooperation Program of China [2015DFA31490]; National Natural Sciences Foundation of China [81700561, 81873574, 81402623]; National Science and Technology Major Project of China [2017YFC0908104, 2018ZX10732202]; Independent Exploration and Innovation Project of Graduate Student of Central South University [2016zzts519]	International Scientific and Technology Cooperation Program of China; National Natural Sciences Foundation of China(National Natural Science Foundation of China (NSFC)); National Science and Technology Major Project of China; Independent Exploration and Innovation Project of Graduate Student of Central South University	This work was supported by grant from International Scientific and Technology Cooperation Program of China (2015DFA31490), grant from National Natural Sciences Foundation of China (No. 81700561, No. 81873574, No. 81402623), the National Science and Technology Major Project of China (2017YFC0908104, 2018ZX10732202) and Independent Exploration and Innovation Project of Graduate Student of Central South University (No. 2016zzts519).	Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brockmann M, 2016, CANCER CELL, V30, P357, DOI 10.1016/j.ccell.2016.07.002; Campagnolo M, 2007, J BIOMOL STRUCT DYN, V24, P429, DOI 10.1080/07391102.2007.10507131; Chai HJ, 2017, ONCOL LETT, V14, P5871, DOI 10.3892/ol.2017.6949; Chen L, 2014, KAOHSIUNG J MED SCI, V30, P181, DOI 10.1016/j.kjms.2013.07.002; Chen RC, 2017, WORLD J GASTROENTERO, V23, P1787, DOI 10.3748/wjg.v23.i10.1787; de Cristofaro T, 2009, J MOL ENDOCRINOL, V42, P35, DOI 10.1677/JME-08-0100; Decorsiere A, 2016, NATURE, V531, P386, DOI 10.1038/nature17170; Delogu S, 2015, ONCOTARGET, V6, P2222, DOI 10.18632/oncotarget.2945; Di Palma T, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.262; Ding FB, 2014, FRONT BIOSCI-LANDMRK, V19, P886, DOI 10.2741/4254; Gao Y, 2017, HEPATOLOGY, V66, P1413, DOI 10.1002/hep.29316; Ghannam-Shahbari D, 2018, ONCOGENE, V37, P2213, DOI 10.1038/s41388-017-0040-z; Gong J, 2018, ONCOL LETT, V15, P8891, DOI 10.3892/ol.2018.8500; Hoeck JD, 2010, NAT NEUROSCI, V13, P1365, DOI 10.1038/nn.2644; Hou DS, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0823-3; Hung N, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-159; Hunter T, 2007, MOL CELL, V28, P730, DOI 10.1016/j.molcel.2007.11.019; Jacobsen A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24982-z; Jamal A, 2015, CELL CYCLE, V14, P2688, DOI 10.1080/15384101.2015.1056946; Kalra N, 2006, FEBS LETT, V580, P431, DOI 10.1016/j.febslet.2005.12.034; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Kivinummi K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18210-3; Lee S, 2016, ONCOGENE, V35, P1857, DOI 10.1038/onc.2015.251; Levrero M, 2016, J HEPATOL, V64, pS84, DOI 10.1016/j.jhep.2016.02.021; Li CG, 2011, ONCOGENE, V30, P4824, DOI 10.1038/onc.2011.190; Li J, 2017, ONCOTARGET, V8, P96027, DOI 10.18632/oncotarget.21630; Lin GY, 1998, VIROLOGY, V249, P189, DOI 10.1006/viro.1998.9317; Liu XJ, 2015, BIOCHEM BIOPH RES CO, V459, P214, DOI 10.1016/j.bbrc.2015.02.060; Liu ZG, 2017, EUR J CELL BIOL, V96, P695, DOI 10.1016/j.ejcb.2017.07.004; Llovet JM, 2018, NAT REV CLIN ONCOL, V15, P599, DOI 10.1038/s41571-018-0073-4; Lu LF, 2015, MOL CARCINOGEN, V54, P1467, DOI 10.1002/mc.22223; Ma SJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173700; Mattiroli F, 2014, NAT STRUCT MOL BIOL, V21, P308, DOI 10.1038/nsmb.2792; Minor MM, 2014, VIRUSES-BASEL, V6, P4683, DOI 10.3390/v6114683; Murphy CM, 2016, CELL REP, V16, P2846, DOI 10.1016/j.celrep.2016.08.026; Nandi D, 2006, J BIOSCIENCES, V31, P137, DOI 10.1007/BF02705243; Otto T, 2009, CANCER CELL, V15, P67, DOI 10.1016/j.ccr.2008.12.005; POLEEV A, 1992, DEVELOPMENT, V116, P611; Suzuki A, 2015, ENDOCR J, V62, P991, DOI 10.1507/endocrj.EJ15-0226; Varshavsky A, 2017, ANNU REV BIOCHEM, V86, P123, DOI 10.1146/annurev-biochem-061516-044859; VerPlank JJS, 2017, BIOCHEM J, V474, P3355, DOI 10.1042/BCJ20160809; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wang J, 2016, GASTROENT RES PRACT, V2016, DOI 10.1155/2016/8780695; Wang LY, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0830-3; Wang ZW, 2012, BBA-REV CANCER, V1825, P11, DOI 10.1016/j.bbcan.2011.09.002; Xu QD, 2019, ONCOL RES, V27, P509, DOI 10.3727/096504018X15278771272963; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	49	10	11	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2019	38	40					6696	6710		10.1038/s41388-019-0907-2	http://dx.doi.org/10.1038/s41388-019-0907-2			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JC0EY	31391550	hybrid			2022-12-28	WOS:000488953500004
J	Silva-Evangelista, C; Barret, E; Menez, V; Merlevede, J; Kergrohen, T; Saccasyn, A; Oberlin, E; Puget, S; Beccaria, K; Grill, J; Castel, D; Debily, MA				Silva-Evangelista, Claudia; Barret, Emilie; Menez, Virginie; Merlevede, Jane; Kergrohen, Thomas; Saccasyn, Ambre; Oberlin, Estelle; Puget, Stephanie; Beccaria, Kevin; Grill, Jacques; Castel, David; Debily, Marie-Anne			A kinome-wide shRNA screen uncovers vaccinia-related kinase 3 (VRK3) as an essential gene for diffuse intrinsic pontine glioma survival	ONCOGENE			English	Article							VIVO RNAI SCREEN; THERAPEUTIC TARGETS; BRAIN; INHIBITION; REGULATOR; PATHWAYS; CANCER; MUTATIONS; GROWTH	Diffuse intrinsic pontine glioma (or DIPG) are pediatric high-grade gliomas associated with a dismal prognosis. They harbor specific substitution in histone H3 at position K27 that induces major epigenetic dysregulations. Most clinical trials failed so far to increase survival, and radiotherapy remains the most efficient treatment, despite only transient tumor control. We conducted the first lentiviral shRNA dropout screen in newly diagnosed DIPG to generate a cancer-lethal signature as a basis for the development of specific treatments with increased efficacy and reduced side effects compared to existing anticancer therapies. The analysis uncovered 41 DIPG essential genes among the 672 genes of human kinases tested, for which several distinct interfering RNAs impaired cell expansion of three different DIPG stem-cell cultures without deleterious effect on two control neural stem cells. Among them, PLK1, AURKB, CHEK1, EGFR, and GSK3A were previously identified by similar approach in adult GBM indicating common dependencies of these cancer cells and pediatric gliomas. As expected, we observed an enrichment of genes involved in proliferation and cell death processes with a significant number of candidates belonging to PTEN/PI3K/AKT and EGFR pathways already under scrutiny in clinical trials in this disease. We highlighted VRK3, a gene involved especially in cell cycle regulation, DNA repair, and neuronal differentiation, as a non-oncogenic addiction in DIPG. Its repression totally blocked DIPG cell growth in the four cellular models evaluated, and induced cell death in H3.3-1(27M cells specifically but not in H3.1-K27M cells, supporting VRK3 as an interesting and promising target in DIPG.	[Silva-Evangelista, Claudia; Barret, Emilie; Menez, Virginie; Merlevede, Jane; Kergrohen, Thomas; Saccasyn, Ambre; Beccaria, Kevin; Grill, Jacques; Castel, David; Debily, Marie-Anne] Univ Paris Saclay, Univ Paris Sud, Gustave Roussy, Vectorol & Therapeut Anticanc,CNRS,UMR8203, Villejuif, France; [Oberlin, Estelle] Univ Paris Saclay, Univ Paris Sud, Inserm UMRS MD 1197, Villejuif, France; [Puget, Stephanie; Beccaria, Kevin] Univ Paris V Descartes, Dept Pediat Neurosurg, Sorbonne Paris Cite, Hop Necker Enfants Malad, Paris, France; [Grill, Jacques; Castel, David] Univ Paris Sud, Univ Paris Saclay, Gustave Roussy, Dept Cancerol Enfant & Adolescent, Villejuif, France; [Debily, Marie-Anne] Univ Evry Val dEssonne, Blvd Francois Mitterrand, Evry, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay	Debily, MA (corresponding author), Univ Paris Saclay, Univ Paris Sud, Gustave Roussy, Vectorol & Therapeut Anticanc,CNRS,UMR8203, Villejuif, France.; Debily, MA (corresponding author), Univ Evry Val dEssonne, Blvd Francois Mitterrand, Evry, France.	marie-anne.debily@gustaveroussy.fr	BECCARIA, Kévin/AAL-5122-2021; Castel, David/D-5353-2018; Debily, Marie-Anne/X-7697-2018; Oberlin, Estelle/M-4915-2018	Castel, David/0000-0003-0247-080X; Debily, Marie-Anne/0000-0002-8509-6165; Oberlin, Estelle/0000-0002-8200-9548; MENEZ, Virginie/0000-0002-3748-7428	Canceropole Ile de France; INCa; La Ligue Contre le Cancer [DILESS-DM/CB/003-17]; charity l'Etoile de Martin; National Council for Scientific and Technological Development (CNPq)/Program "Science without borders" in Brasil	Canceropole Ile de France(Region Ile-de-France); INCa(Institut National du Cancer (INCA) France); La Ligue Contre le Cancer(Ligue nationale contre le cancer); charity l'Etoile de Martin; National Council for Scientific and Technological Development (CNPq)/Program "Science without borders" in Brasil(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	DC, JG, and MAD acknowledge financial support from Canceropole Ile de France, INCa, La Ligue Contre le Cancer (projet DILESS-DM/CB/003-17) and the charity l'Etoile de Martin. The authors are grateful to the Necker hospital tumor and DNA banks and the Necker operating room nurses/assistants for their technical assistance. CSE acknowledges financial support from National Council for Scientific and Technological Development (CNPq)/Program "Science without borders" in Brasil. We thank N. Droin and the genomic core facility of Gustave Roussy.	Barde I, 2010, CURR PROTOC NEUROSCI; Chang JT, 2006, BIOINFORMATICS, V22, P2926, DOI 10.1093/bioinformatics/btl483; Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287; Cheng P, 2015, STEM CELL REP, V4, P899, DOI 10.1016/j.stemcr.2015.03.005; Cohen KJ, 2017, NEURO-ONCOLOGY, V19, P1025, DOI 10.1093/neuonc/nox021; Di Stefano AL, 2015, CLIN CANCER RES, V21, P3307, DOI 10.1158/1078-0432.CCR-14-2199; Ding Y, 2013, CANCER DISCOV, V3, P198, DOI 10.1158/2159-8290.CD-12-0353; Du ZH, 2018, INT J ONCOL, V52, P1415, DOI 10.3892/ijo.2018.4324; Farhan M, 2017, INT J BIOL SCI, V13, P815, DOI 10.7150/ijbs.20052; Fedorov O, 2007, P NATL ACAD SCI USA, V104, P20523, DOI 10.1073/pnas.0708800104; Filbin MG, 2018, SCIENCE, V360, P331, DOI 10.1126/science.aao4750; Gargiulo G, 2013, CANCER CELL, V23, P660, DOI 10.1016/j.ccr.2013.03.030; Goidts V, 2012, ONCOGENE, V31, P3235, DOI 10.1038/onc.2011.490; Grasso CS, 2015, NAT MED, V21, P555, DOI 10.1038/nm.3855; Grill J, 2012, PEDIATR BLOOD CANCER, V58, P489, DOI 10.1002/pbc.24060; Hargrove D, 2006, LANCET ONCOL, V7, P241, DOI 10.1016/S1470-2045(06)70615-5; Hart T, 2017, G3-GENES GENOM GENET, V7, P2719, DOI 10.1534/g3.117.041277; Hart T, 2014, MOL SYST BIOL, V10, DOI 10.15252/msb.20145216; Kang MS, 2017, J EXP MED, V214, P2947, DOI 10.1084/jem.20160974; Korur S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007443; Kotliarova S, 2008, CANCER RES, V68, P6643, DOI 10.1158/0008-5472.CAN-08-0850; Kulkarni S, 2018, MOL CANCER RES, V16, P103, DOI 10.1158/1541-7786.MCR-17-0146; Lee N, 2017, MOL CELLS, V40, P621, DOI 10.14348/molcells.2017.0108; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Misuraca KL, 2016, NEOPLASIA, V18, P60, DOI 10.1016/j.neo.2015.12.002; ORAHILLY R, 1987, AM J ANAT, V180, P69, DOI 10.1002/aja.1001800106; Plessier A, 2017, ONCOTARGET, V8, P52543, DOI 10.18632/oncotarget.15002; Sa JK, 2015, ONCOTARGET, V6, P20145, DOI 10.18632/oncotarget.3980; Shriver M, 2016, ONCOTARGET, V7, P45414, DOI 10.18632/oncotarget.9985; Song H, 2016, SCI REP-UK, V6, DOI 10.1038/srep38452; Tandle AT, 2013, EUR J CANCER, V49, P3020, DOI 10.1016/j.ejca.2013.05.013; Tang YY, 2013, J MOL NEUROSCI, V50, P324, DOI 10.1007/s12031-013-9981-z; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Taylor KR, 2014, NAT GENET, V46, P457, DOI 10.1038/ng.2925; Truffaux N, 2015, NEURO-ONCOLOGY, V17, P953, DOI 10.1093/neuonc/nou330; Varlet P, 2018, NEURO-ONCOLOGY, V20, P52; Warren KE, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00205; Wu G, 2012, NAT GENET, V44, P251, DOI 10.1038/ng.1102; Wurdak H, 2010, CELL STEM CELL, V6, P37, DOI 10.1016/j.stem.2009.11.002; Yang J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061915; Zarghooni M, 2010, J CLIN ONCOL, V28, P1337, DOI 10.1200/JCO.2009.25.5463	41	9	9	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2019	38	38					6479	6490		10.1038/s41388-019-0884-5	http://dx.doi.org/10.1038/s41388-019-0884-5			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IY7XR	31324890				2022-12-28	WOS:000486609000001
J	Noeparast, A; Giron, P; Noor, A; Shahi, RB; De Brakeleer, S; Eggermont, C; Vandenplas, H; Boeckx, B; Lambrechts, D; De Greve, J; Teugels, E				Noeparast, Amir; Giron, Philippe; Noor, Alfiah; Shahi, Rajendra Bahadur; De Brakeleer, Sylvia; Eggermont, Carolien; Vandenplas, Hugo; Boeckx, Bram; Lambrechts, Diether; De Greve, Jacques; Teugels, Erik			CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition	ONCOGENE			English	Article							DABRAFENIB PLUS TRAMETINIB; C-RAF; COMBINED BRAF; MAPK PATHWAY; B-RAF; KINASE; ACTIVATION; SORAFENIB; KRAS; PHOSPHORYLATION	Two out of 41 non-small cell lung cancer patients enrolled in a clinical study were found with a somatic CRAF mutation in their tumor, namely CRAF(P261A) and CRAF(P207S). To our knowledge, both mutations are novel in lung cancer and CRAF(P261A) has not been previously reported in cancer. Expression of CRAF(P261A) in HEK293T cells and BEAS-2B lung epithelial cells led to increased ERK pathway activation in a dimer-dependent manner, accompanied with loss of CRAF phosphorylation at the negative regulatory S259 residue. Moreover, stable expression of CRAF(P261A) in mouse embryonic fibroblasts and BEAS-2B cells led to anchorage-independent growth. Consistent with a previous report, we could not observe a gain-of-function with CRAF(P207S). Type II but not type I RAF inhibitors suppressed the CRAF(P261A)-induced ERK pathway activity in BEAS-2B cells, and combinatorial treatment with type II RAF inhibitors and a MEK inhibitor led to a stronger ERK pathway inhibition and growth arrest. Our findings suggest that the acquisition of a CRAF(P261A) mutation can provide oncogenic properties to cells, and that such cells are sensitive to combined MEK and type II RAF inhibitors. CRAF mutations should be diagnostically and therapeutically explored in lung and perhaps other cancers.	[Noeparast, Amir; Giron, Philippe; Noor, Alfiah; Shahi, Rajendra Bahadur; De Brakeleer, Sylvia; Eggermont, Carolien; Vandenplas, Hugo; De Greve, Jacques; Teugels, Erik] Vrije Univ Brussel, UZ Brussel, Oncol Ctr, Lab Mol Oncol, Brussels, Belgium; [Noeparast, Amir; Giron, Philippe; Noor, Alfiah; Shahi, Rajendra Bahadur; De Brakeleer, Sylvia; Eggermont, Carolien; Vandenplas, Hugo; De Greve, Jacques; Teugels, Erik] Vrije Univ Brussel, UZ Brussel, Oncol Ctr, Dept Med Oncol, Brussels, Belgium; [Boeckx, Bram; Lambrechts, Diether] VIB, Vesalius Res Ctr, B-3000 Leuven, Belgium; [Boeckx, Bram; Lambrechts, Diether] Katholieke Univ Leuven, Dept Oncol, Lab Translat Genet, B-3000 Louvain, Belgium	University Hospital Brussels; Vrije Universiteit Brussel; University Hospital Brussels; Vrije Universiteit Brussel; Flanders Institute for Biotechnology (VIB); KU Leuven	Noeparast, A; De Greve, J; Teugels, E (corresponding author), Vrije Univ Brussel, UZ Brussel, Oncol Ctr, Lab Mol Oncol, Brussels, Belgium.; Noeparast, A; De Greve, J; Teugels, E (corresponding author), Vrije Univ Brussel, UZ Brussel, Oncol Ctr, Dept Med Oncol, Brussels, Belgium.	amir.noeparast@vub.be; jacques.degreve@uzbrussel.be; eteugels@uzbrussel.be	, Noeparast/AAV-7252-2020; Lambrechts, Diether/AAJ-3167-2020; De Greve, Jacques/J-4939-2012	, Noeparast/0000-0002-3216-5630; Lambrechts, Diether/0000-0002-3429-302X; Giron, Philippe/0000-0002-1331-1890; Shahi, Rajendra Bahadur/0000-0002-7751-6852; De Greve, Jacques/0000-0002-2389-0742; Teugels, Erik/0000-0002-7828-4555; Eggermont, Carolien/0000-0001-6411-6422	Cancer Plan 29-39 Belgium; Wetenschappelijk Fonds Willy Gepts of the UZ Brussel; Interdisciplinary Research Program (IRP) Vrije Universiteit Brussel; Vrije Universiteit Brussel; Armand Everaert; Research Foundation-Flanders (FWO); Emmanuel van der Schueren research scholarship by Kom op Tegen Kanker	Cancer Plan 29-39 Belgium; Wetenschappelijk Fonds Willy Gepts of the UZ Brussel; Interdisciplinary Research Program (IRP) Vrije Universiteit Brussel; Vrije Universiteit Brussel; Armand Everaert; Research Foundation-Flanders (FWO)(FWO); Emmanuel van der Schueren research scholarship by Kom op Tegen Kanker	Grant Support The work was funded by the Cancer Plan 29-39 Belgium and by the Wetenschappelijk Fonds Willy Gepts of the UZ Brussel; Noeparast A. was funded by an Interdisciplinary Research Program (IRP) Vrije Universiteit Brussel. Noor A. is the beneficiary of Ph.D. Fellowship from Vrije Universiteit Brussel and was funded by Armand Everaert. Giron P. and Eggermont C. are the beneficiaries of a Ph.D. Fellowship from the Research Foundation-Flanders (FWO) and Emmanuel van der Schueren research scholarship by Kom op Tegen Kanker.	Antony R, 2013, CANCER RES, V73, P4840, DOI 10.1158/0008-5472.CAN-12-4089; Arnault JP, 2012, CLIN CANCER RES, V18, P263, DOI 10.1158/1078-0432.CCR-11-1344; Atefi M, 2016, SCI REP-UK, V6, DOI 10.1038/srep27454; Baik CS, 2017, ONCOLOGIST, V22, P786, DOI 10.1634/theoncologist.2016-0458; Chen YC, 2017, SCI REP-UK, V7, DOI 10.1038/srep44123; Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471; Dankner M, 2018, ONCOGENE, V37, P3183, DOI 10.1038/s41388-018-0171-x; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Dierks C, 2013, BLOOD, V122, P4121; Dumaz N, 2006, CANCER RES, V66, P9483, DOI 10.1158/0008-5472.CAN-05-4227; Emuss V, 2005, CANCER RES, V65, P9719, DOI 10.1158/0008-5472.CAN-05-1683; Fouladi F, 2015, LEUKEMIA LYMPHOMA, V56, P2690, DOI 10.3109/10428194.2014.1003055; Geissmann Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054072; Gilmartin AG, 2011, CLIN CANCER RES, V17, P989, DOI 10.1158/1078-0432.CCR-10-2200; Greger JG, 2012, MOL CANCER THER, V11, P909, DOI 10.1158/1535-7163.MCT-11-0989; Hatzivassiliou G, 2013, NATURE, V501, P232, DOI 10.1038/nature12441; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Holderfield M, 2014, BRIT J CANCER, V111, P640, DOI 10.1038/bjc.2014.139; Hu JC, 2013, CELL, V154, P1036, DOI 10.1016/j.cell.2013.07.046; Imielinski M, 2014, J CLIN INVEST, V124, P1582, DOI 10.1172/JCI72763; Johnson DB, 2014, J CLIN ONCOL, V32, P3697, DOI 10.1200/JCO.2014.57.3535; Karoulia Z, 2017, NAT REV CANCER, V17, P676, DOI 10.1038/nrc.2017.79; King AC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062613; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Krauthammer M, 2015, NAT GENET, V47, P996, DOI 10.1038/ng.3361; Kubicek M, 2002, J BIOL CHEM, V277, P7913, DOI 10.1074/jbc.M108733200; Lamba S, 2014, CELL REP, V8, P1475, DOI 10.1016/j.celrep.2014.07.033; Lavoie H, 2015, NAT REV MOL CELL BIO, V16, P281, DOI 10.1038/nrm3979; Li L, 2010, J CHROMATOGR B, V878, P3033, DOI 10.1016/j.jchromb.2010.08.049; Lito P, 2014, CANCER CELL, V25, P697, DOI 10.1016/j.ccr.2014.03.011; Long GV, 2017, ANN ONCOL, V28, P1631, DOI 10.1093/annonc/mdx176; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; MOLNAR E, 2018, ONCOGENE, V18, DOI DOI 10.1186/S12885-018-4455-X; Molzan M, 2012, J MOL BIOL, V423, P486, DOI 10.1016/j.jmb.2012.08.009; Molzan M, 2010, MOL CELL BIOL, V30, P4698, DOI 10.1128/MCB.01636-09; Noeparast Amir, 2018, Oncotarget, V9, P16110, DOI 10.18632/oncotarget.24576; Noeparast A, 2017, ONCOTARGET, V8, P60094, DOI 10.18632/oncotarget.11635; Nussinov Ruth, 2018, Biophys Rev, V10, P1263, DOI 10.1007/s12551-018-0461-0; Peng SB, 2015, CANCER CELL, V28, P384, DOI 10.1016/j.ccell.2015.08.002; Planchard D, 2016, LANCET ONCOL, V17, P984, DOI 10.1016/S1470-2045(16)30146-2; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Rajakulendran T, 2009, NATURE, V461, P542, DOI 10.1038/nature08314; Roring M, 2012, EMBO J, V31, P2629, DOI 10.1038/emboj.2012.100; Rosell R, 2017, LANCET ONCOL, V18, P1286, DOI 10.1016/S1470-2045(17)30678-2; Shapira S, 2007, CELL DEATH DIFFER, V14, P895, DOI 10.1038/sj.cdd.4402057; Takezawa K, 2009, CANCER RES, V69, P6515, DOI 10.1158/0008-5472.CAN-09-1076; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Tidyman WE, 2009, CURR OPIN GENET DEV, V19, P230, DOI 10.1016/j.gde.2009.04.001; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Vakana E, 2017, ONCOTARGET, V8, P9251, DOI 10.18632/oncotarget.14002; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Whittaker SR, 2015, MOL CANCER THER, V14, P2700, DOI 10.1158/1535-7163.MCT-15-0136-T; Yao Z, 2015, CANCER CELL, V28, P370, DOI 10.1016/j.ccell.2015.08.001; Zang MW, 2008, J BIOL CHEM, V283, P31429, DOI 10.1074/jbc.M802855200; Zhang C, 2015, NATURE, V526, P583, DOI 10.1038/nature14982	55	6	6	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2019	38	31					5933	5941		10.1038/s41388-019-0866-7	http://dx.doi.org/10.1038/s41388-019-0866-7			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IT3GE	31285551	Green Published, hybrid			2022-12-28	WOS:000482740000002
J	Saigi, M; Alburquerque-Bejar, JJ; Sanchez-Cespedes, M				Saigi, Maria; Alburquerque-Bejar, Juan J.; Sanchez-Cespedes, Montse			Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front	ONCOGENE			English	Review							TUMOR MUTATIONAL BURDEN; PD-1 BLOCKADE; IFN-GAMMA; CHECKPOINT INHIBITORS; ACQUIRED-RESISTANCE; OPEN-LABEL; NIVOLUMAB; PEMBROLIZUMAB; MECHANISM; IMMUNITY	The incorporation into clinical practice of immune-checkpoint inhibitors (ICIs), such as those targeting the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death 1 (PD-1) and its ligand (PD-L1), has represented a major breakthrough in non-small cell lung cancer (NSCLC) treatment, especially in cases where the cancer has no druggable genetic alterations. Despite becoming the standard of care in certain clinical settings, either alone or in combination with chemotherapy, a proportion of patients do not respond while others actually progress during treatment. Therefore, there is a clinical need to identify accurate predictive biomarkers and to develop novel therapeutic strategies based on ICIs. Although they have limitations, the current markers evaluated to select which patients will undergo ICI treatment are the levels of PD-Ll and the tumor mutational burden. In this paper we describe what is currently known about the dynamic interaction between the cancer cell and the immune system during carcinogenesis, with a particular focus on the description of the functions and gene alterations that preclude the host immunoresponse in NSCLC. We emphasize the deleterious gene alterations in components of the major histocompatibility complex (HLA-I or B2M) and of the response to IFN gamma (such as JAK2) which are mutually exclusive and can affect up to one fifth of the NSCLCs. The participation of other gene alterations, such as those of common oncogenes and tumor suppressors, and of the epigenetic alterations will also be discussed, in detail. Finally, we discuss the potential use of the tumor's genetic profile to predict sensitivity to ICIs.	[Saigi, Maria; Alburquerque-Bejar, Juan J.; Sanchez-Cespedes, Montse] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Genes & Canc Grp, Barcelona, Spain; [Saigi, Maria] Catalan Inst Oncol ICO, Dept Med Oncol, Avda Gran Via 199-203, Barcelona 08908, Spain; [Sanchez-Cespedes, Montse] Josep Carreras Leukemia Res Inst, Canc Genom Grp, IJC Bldg, Barcelona 08916, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Catalan Institute of Oncology; Institut de Recerca Contra la Leucemia Josep Carreras (IJC)	Sanchez-Cespedes, M (corresponding author), Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Genes & Canc Grp, Barcelona, Spain.; Sanchez-Cespedes, M (corresponding author), Josep Carreras Leukemia Res Inst, Canc Genom Grp, IJC Bldg, Barcelona 08916, Spain.	mscespedes@carrerasresearch.org	Sanchez-Cespedes, Montse/H-8485-2012; Alburquerque-Bejar, Juan/AAA-7666-2020	Sanchez-Cespedes, Montse/0000-0002-6045-5627; 	MINECO [SAF2014-54571-R]; Fundacion Cientifica Asociacion Espanola Contra el Cancer [GCB14142170MONT]; CERCA program;  [CM17/00180]	MINECO(Spanish Government); Fundacion Cientifica Asociacion Espanola Contra el Cancer; CERCA program; 	This work was supported by Spanish grant SAF2014-54571-R (to MSC) from the MINECO and a grant from the Fundacion Cientifica Asociacion Espanola Contra el CancerGCB14142170MONT. Saigi is supported by a Rio Hortega (CM17/00180) contract. We also thank the CERCA program for support.	Adeegbe DO, 2017, CANCER DISCOV, V7, P852, DOI 10.1158/2159-8290.CD-16-1020; Antonia SJ, 2018, NEW ENGL J MED, V379, P2342, DOI 10.1056/NEJMoa1809697; Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Best SA, 2018, CELL METAB, V27, P935, DOI 10.1016/j.cmet.2018.02.006; Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Brambilla E, 2016, J CLIN ONCOL, V34, P1223, DOI 10.1200/JCO.2015.63.0970; BURNET M, 1957, BMJ-BRIT MED J, V1, P841, DOI 10.1136/bmj.1.5023.841; Canadas I, 2018, NAT MED, V24, P1143, DOI 10.1038/s41591-018-0116-5; Carbone DP, 2017, NEW ENGL J MED, V376, P2415, DOI 10.1056/NEJMoa1613493; Champiat S, 2017, CLIN CANCER RES, V23, P1920, DOI 10.1158/1078-0432.CCR-16-1741; Cristescu R, 2018, SCIENCE, V362, P197, DOI 10.1126/science.aar3593; Donnem T, 2015, CLIN CANCER RES, V21, P2635, DOI 10.1158/1078-0432.CCR-14-1905; Dunn GP, 2006, NAT REV IMMUNOL, V6, P836, DOI 10.1038/nri1961; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; Duruisseaux M, 2018, LANCET RESP MED, V6, P771, DOI 10.1016/S2213-2600(18)30284-4; Fabrizio DA, 2018, ANN ONCOL, V29, P16; Frampton GM, 2015, CANCER DISCOV, V5, P850, DOI 10.1158/2159-8290.CD-15-0285; Gainor JF, 2016, CLIN CANCER RES, V22, P4585, DOI 10.1158/1078-0432.CCR-15-3101; Galon J, 2019, NAT REV DRUG DISCOV, V18, P197, DOI 10.1038/s41573-018-0007-y; Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005; Gao JJ, 2016, CELL, V167, P397, DOI 10.1016/j.cell.2016.08.069; Gettinger S, 2017, CANCER DISCOV, V7, P1420, DOI 10.1158/2159-8290.CD-17-0593; Goodman AM, 2018, JAMA ONCOL, V4, P1237, DOI 10.1001/jamaoncol.2018.1701; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; He YY, 2018, ONCOTARGETS THER, V11, P7005, DOI 10.2147/OTT.S170385; Hellmann MD, 2018, NEW ENGL J MED, V378, P2093, DOI 10.1056/NEJMoa1801946; Hellmann MD, 2018, CANCER CELL, V33, P843, DOI 10.1016/j.ccell.2018.03.018; Hellmann MD, 2017, LANCET ONCOL, V18, P31, DOI [10.1016/S1470-2045(16)30624-6, 10.1016/s1470-2045(16)30624-6]; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; IASLC, 2017, J THORAC ONCOL; Ihara S, 2012, CANCER RES, V72, P2990, DOI 10.1158/0008-5472.CAN-11-4062; Ikeda H, 2002, CYTOKINE GROWTH F R, V13, P95, DOI 10.1016/S1359-6101(01)00038-7; Ikeda S, 2016, J THORAC ONCOL, V11, P62, DOI 10.1016/j.jtho.2015.09.010; Johnston CJC, 2016, CELL IMMUNOL, V299, P14, DOI 10.1016/j.cellimm.2015.10.006; Jordan EJ, 2017, CANCER DISCOV, V7, P596, DOI 10.1158/2159-8290.CD-16-1337; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kataoka K, 2016, NATURE, V534, P402, DOI 10.1038/nature18294; Kato S, 2017, CLIN CANCER RES, V23, P4242, DOI 10.1158/1078-0432.CCR-16-3133; Kerdidani D, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09370-z; Kitapma S, 2019, CANCER DISCOV, V9, P34, DOI 10.1158/2159-8290.CD-18-0689; Koyama S, 2016, CANCER RES, V76, P999, DOI 10.1158/0008-5472.CAN-15-1439; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Lee CK, 2017, J THORAC ONCOL, V12, P403, DOI 10.1016/j.jtho.2016.10.007; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; O'Donnell JS, 2019, NAT REV CLIN ONCOL, V16, P151, DOI 10.1038/s41571-018-0142-8; Palomero T, 2014, NAT GENET, V46, P166, DOI 10.1038/ng.2873; Pan D, 2018, SCIENCE, V359, P770, DOI 10.1126/science.aao1710; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Paz-Ares L, 2018, NEW ENGL J MED, V379, P2040, DOI 10.1056/NEJMoa1810865; Peng WY, 2016, CANCER DISCOV, V6, P202, DOI 10.1158/2159-8290.CD-15-0283; Pereira C, 2017, CLIN CANCER RES, V23, P3203, DOI 10.1158/1078-0432.CCR-16-1946; Planchard D, 2018, ANN ONCOL, V29, P192, DOI 10.1093/annonc/mdy275; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Ribas A, 2015, NEW ENGL J MED, V373, P1490, DOI 10.1056/NEJMp1510079; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Rizvi H, 2018, J CLIN ONCOL, V36, P633, DOI 10.1200/JCO.2017.75.3384; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Roach C, 2016, APPL IMMUNOHISTO M M, V24, P392, DOI 10.1097/PAI.0000000000000408; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Romero OA, 2014, ONCOGENE, V33, P2681, DOI 10.1038/onc.2013.227; Sabari JK, 2018, ANN ONCOL, V29, P2085, DOI 10.1093/annonc/mdy334; Saigi M, 2018, CLIN CANCER RES, V24, P4579, DOI 10.1158/1078-0432.CCR-18-0267; Samstein RM, 2019, NAT GENET, V51, P202, DOI 10.1038/s41588-018-0312-8; Sanchez-Cespedes M, 2007, ONCOGENE, V26, P7825, DOI 10.1038/sj.onc.1210594; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Shin DS, 2017, CANCER DISCOV, V7, P188, DOI 10.1158/2159-8290.CD-16-1223; Shukla SA, 2015, NAT BIOTECHNOL, V33, P1152, DOI 10.1038/nbt.3344; Skoulidis F, 2018, CANCER DISCOV, V8, P822, DOI 10.1158/2159-8290.CD-18-0099; Skoulidis F, 2015, CANCER DISCOV, V5, P860, DOI 10.1158/2159-8290.CD-14-1236; Socinski MA, 2018, NEW ENGL J MED, V378, P2288, DOI 10.1056/NEJMoa1716948; Springer S, 2015, CURR OPIN IMMUNOL, V34, P83, DOI 10.1016/j.coi.2015.02.009; Swanton C, 2015, CANCER DISCOV, V5, P704, DOI 10.1158/2159-8290.CD-15-0344; Topalian SL, 2016, NAT REV CANCER, V16, P275, DOI 10.1038/nrc.2016.36; Vendetti FP, 2015, ONCOTARGET, V6, P56, DOI 10.18632/oncotarget.2695; Voron T, 2015, J EXP MED, V212, P139, DOI 10.1084/jem.20140559; Wang SX, 2018, ONCOGENE, V37, P3924, DOI 10.1038/s41388-018-0245-9; Wei SC, 2018, CANCER DISCOV, V8, P1069, DOI 10.1158/2159-8290.CD-18-0367; Yarchoan M, 2017, NEW ENGL J MED, V377, P2500, DOI 10.1056/NEJMc1713444; Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958; Zingg D, 2017, CELL REP, V20, P854, DOI 10.1016/j.celrep.2017.07.007	81	16	16	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2019	38	31					5921	5932		10.1038/s41388-019-0855-x	http://dx.doi.org/10.1038/s41388-019-0855-x			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IT3GE	31253869				2022-12-28	WOS:000482740000001
J	Yang, RM; Nanayakkara, D; Kalimutho, M; Mitra, P; Khanna, KK; Dray, E; Gonda, TJ				Yang, Ren-Ming; Nanayakkara, Devathri; Kalimutho, Murugan; Mitra, Partha; Khanna, Kum Kum; Dray, Eloise; Gonda, Thomas J.			MYB regulates the DNA damage response and components of the homology-directed repair pathway in human estrogen receptor-positive breast cancer cells	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; C-MYB; NUCLEAR FOCI; HISTONE H2AX; TARGET GENES; EXPRESSION; RAD51; RECOMBINATION; PHOSPHORYLATION; TRANSCRIPTION	Over 70% of human breast cancers are estrogen receptor-positive (ER+), most of which express MYB. In these and other cell types, the MYB transcription factor regulates the expression of many genes involved in cell proliferation, differentiation, tumorigenesis, and apoptosis. So far, no clear link has been established between MYB and the DNA damage response in breast cancer. Here, we found that silencing MYB in the ER+ breast cancer cell line MCF-7 led to increased DNA damage accumulation, as marked by increased gamma-H2AX foci following induction of double-stranded breaks. We further found that this was likely mediated by decreased homologous recombination-mediated repair (HRR), since silencing MYB impaired the formation of RAD51 foci in response to DNA damage. Moreover, cells depleted for MYB exhibited reduced expression of several key genes involved in HRR including BRCA1, PALB2, and TOPBP1. Taken together, these data imply that MYB and its targets play an important role in the response of ER+ breast cancer cells to DNA damage, and suggest that induction of DNA damage along with inhibition of MYB activity could offer therapeutic benefits for ER+ breast cancer and possibly other cancer types.	[Yang, Ren-Ming; Mitra, Partha; Gonda, Thomas J.] Univ Queensland, Sch Pharm, Brisbane, Qld 4102, Australia; [Nanayakkara, Devathri; Kalimutho, Murugan; Khanna, Kum Kum] QIMR Berghofer Med Res Inst, Signal Transduct Lab, Herston, Qld 4006, Australia; [Dray, Eloise] QUT, Translat Res Inst, Inst Hlth & Biomed Innovat, Brisbane, Qld 4102, Australia; [Dray, Eloise] Mater Res UQ, Translat Res Inst, Brisbane, Qld 4102, Australia; [Gonda, Thomas J.] Univ South Australia, Canc Res Inst, Adelaide, SA 5000, Australia; [Yang, Ren-Ming] Univ Southern Calif, Childrens Hosp Los Angeles Campus, Keck Sch Med, Los Angeles, CA 90027 USA; [Mitra, Partha] Queensland Univ Technol, Inst Hlth & Biomed Innovat, TRI, 37 Kent St, Woolloongabba, Qld 4102, Australia; [Dray, Eloise] Univ Texas Hlth, Dept Biochem & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA	University of Queensland; QIMR Berghofer Medical Research Institute; Queensland University of Technology (QUT); Mater Research; University of Queensland; University of South Australia; University of Southern California; Queensland University of Technology (QUT); University of Texas System; University of Texas Health San Antonio	Gonda, TJ (corresponding author), Univ Queensland, Sch Pharm, Brisbane, Qld 4102, Australia.; Dray, E (corresponding author), QUT, Translat Res Inst, Inst Hlth & Biomed Innovat, Brisbane, Qld 4102, Australia.; Dray, E (corresponding author), Mater Res UQ, Translat Res Inst, Brisbane, Qld 4102, Australia.; Gonda, TJ (corresponding author), Univ South Australia, Canc Res Inst, Adelaide, SA 5000, Australia.; Dray, E (corresponding author), Univ Texas Hlth, Dept Biochem & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	dray@uthscsa.edu; thomas.gonda@unisa.edu.au	Kalimutho, Murugan/AAD-1441-2019; Dray, Eloise/AAD-5147-2021; Dray, Eloise/E-3938-2012	Dray, Eloise/0000-0001-6793-9838; Kalimutho, Murugan/0000-0002-0772-8673; Gonda, Thomas/0000-0002-8792-3021; Khanna, Kum Kum/0000-0001-8650-5381	International Postgraduate Research Scholarship (Australia); University of Queensland Centennial Scholarship; National Breast Cancer Foundation; Australian government	International Postgraduate Research Scholarship (Australia)(Australian Government); University of Queensland Centennial Scholarship; National Breast Cancer Foundation; Australian government(Australian GovernmentCGIAR)	We would like to thank members of the Gonda laboratory for helpful discussions. RMY was the recipient of an International Postgraduate Research Scholarship (Australia) and a University of Queensland Centennial Scholarship. ED was supported by a National Breast Cancer Foundation Early Career Fellowship. KKK is a Senior Principal Research Fellow of the National Health and Medical Research Council (Australia). The Translational Research Institute is supported by an Australian government grant.	Abmayr Susan M, 2006, Curr Protoc Pharmacol, VChapter 12, DOI [10.1002/0471142727.mb1201s75, 10.1002/0471141755.ph1203s35]; Banath JP, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-4; Bell D, 2011, CANCER BIOL THER, V12, P569, DOI 10.4161/cbt.12.7.17008; Buisson R, 2010, NAT STRUCT MOL BIOL, V17, P1247, DOI 10.1038/nsmb.1915; Cheung-Ong K, 2013, CHEM BIOL, V20, P648, DOI 10.1016/j.chembiol.2013.04.007; Cousineau I, 2005, CANCER RES, V65, P11384, DOI 10.1158/0008-5472.CAN-05-2156; Cross RS, 2015, CLIN TRANSL IMMUNOL, V4, DOI 10.1038/cti.2014.29; Drabsch Y, 2007, P NATL ACAD SCI USA, V104, P13762, DOI 10.1073/pnas.0700104104; Drabsch Y, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2614; Dray E, 2010, NAT STRUCT MOL BIOL, V17, P1255, DOI 10.1038/nsmb.1916; Drier Y, 2016, NAT GENET, V48, P265, DOI 10.1038/ng.3502; Foulkes WD, 2004, CLIN CANCER RES, V10, P2029, DOI 10.1158/1078-0432.CCR-03-1061; Ganter B, 1999, ADV CANCER RES, V76, P21, DOI 10.1016/S0065-230X(08)60773-3; Gildemeister OS, 2009, J BIOL CHEM, V284, P31945, DOI 10.1074/jbc.M109.024646; Gonda TJ, 2015, NAT REV CANCER, V15, P686, DOI 10.1038/nrc4018; GUERIN M, 1990, ONCOGENE, V5, P131; GUERIN M, 1988, CR ACAD SCI III-VIE, V307, P855; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Harte MT, 2014, ONCOGENE, V33, P713, DOI 10.1038/onc.2013.10; Helleday T, 2007, DNA REPAIR, V6, P923, DOI 10.1016/j.dnarep.2007.02.006; Jin W, 2011, BREAST CANCER RES TR, V125, P699, DOI 10.1007/s10549-010-0876-1; Krejci L, 2012, NUCLEIC ACIDS RES, V40, P5795, DOI 10.1093/nar/gks270; Li LK, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005070; Liu SQ, 2012, NUCLEIC ACIDS RES, V40, P10780, DOI 10.1093/nar/gks849; Lord CJ, 2007, NAT STRUCT MOL BIOL, V14, P461, DOI 10.1038/nsmb0607-461; Miao RY, 2011, CANCER RES, V71, P7029, DOI 10.1158/0008-5472.CAN-11-1015; Mitchell AS, 2015, APOPTOSIS, V20, P310, DOI 10.1007/s10495-014-1078-9; Mitra P, 2016, ONCOTARGET, V7, P9069, DOI 10.18632/oncotarget.6997; Mitra P, 2012, NUCLEIC ACIDS RES, V40, P5988, DOI 10.1093/nar/gks286; Moudry P, 2016, J CELL BIOL, V212, P281, DOI 10.1083/jcb.201507042; Nitiss JL, 2009, NAT REV CANCER, V9, P338, DOI 10.1038/nrc2607; Pattabiraman DR, 2013, LEUKEMIA, V27, P269, DOI 10.1038/leu.2012.225; Pattabiraman DR, 2014, BLOOD, V123, P2682, DOI 10.1182/blood-2012-02-413187; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Persson M, 2009, P NATL ACAD SCI USA, V106, P18740, DOI 10.1073/pnas.0909114106; Quintana AM, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-30; Raderschall E, 1999, P NATL ACAD SCI USA, V96, P1921, DOI 10.1073/pnas.96.5.1921; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; RAMSAY RG, 1992, CELL GROWTH DIFFER, V3, P723; Ramsay RG, 2008, NAT REV CANCER, V8, P523, DOI 10.1038/nrc2439; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rossi DJ, 2007, NATURE, V447, P725, DOI 10.1038/nature05862; Rugo Hope S, 2016, Am Soc Clin Oncol Educ Book, V35, pe40, DOI 10.14694/EDBK_159198; Sanford RA, 2015, CANCER-AM CANCER SOC, V121, P3422, DOI 10.1002/cncr.29572; Shin SY, 2013, BMB REP, V46, P92, DOI 10.5483/BMBRep.2013.46.2.202; Sy SMH, 2009, P NATL ACAD SCI USA, V106, P7155, DOI 10.1073/pnas.0811159106; Tarsounas M, 2003, ONCOGENE, V22, P1115, DOI 10.1038/sj.onc.1206263; TORELLI G, 1987, CANCER RES, V47, P5266; Tsuchiya M, 2015, ONCOGENE, V34, P4656, DOI 10.1038/onc.2014.387; Uttarkar S, 2017, EXP HEMATOL, V47, P31, DOI 10.1016/j.exphem.2016.12.003; Uttarkar S, 2016, BLOOD, V127, P1173, DOI 10.1182/blood-2015-09-668632; Vinayak S, 2010, CURR BREAST CANCER R, V2, P190, DOI 10.1007/s12609-010-0026-0; Wang WJ, 2015, FEBS LETT, V589, P555, DOI 10.1016/j.febslet.2015.01.012; Ward A, 2015, CANCER TREAT REV, V41, P35, DOI 10.1016/j.ctrv.2014.10.006; Zeidler M, 2005, NEOPLASIA, V7, P1011, DOI 10.1593/neo.05472	56	12	12	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2019	38	26					5239	5249		10.1038/s41388-019-0789-3	http://dx.doi.org/10.1038/s41388-019-0789-3			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IF4AX	30971760	Green Accepted			2022-12-28	WOS:000473025300009
J	Contreras-Zarate, MJ; Day, NL; Ormond, DR; Borges, VF; Tobet, S; Gril, B; Steeg, PS; Cittelly, DM				Contreras-Zarate, Maria J.; Day, Nicole L.; Ormond, D. Ryan; Borges, Virginia F.; Tobet, Stuart; Gril, Brunilde; Steeg, Patricia S.; Cittelly, Diana M.			Estradiol induces BDNF/TrkB signaling in triple-negative breast cancer to promote brain metastases	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; NEUROTROPHIC FACTOR; TUMOR-GROWTH; ASTROCYTES; CELLS; BDNF; SURVIVAL; TRKB; MICROENVIRONMENT; IDENTIFICATION	Breast cancer brain metastases (BM) affect younger women disproportionally, including those lacking estrogen receptor (ER), progesterone receptor, and HER2 (known as triple-negative breast cancer; TNBC). Previous studies in preclinical models showed that pre-menopausal levels of estradiol (E2) promote TNBC-BM through incompletely understood mechanisms involving reactive astrocytes. Herein, a novel mechanism involving E2-dependent upregulation of brain-derived neurotrophic factor (BDNF) in astrocytes, and subsequent activation of tumor cell tropomyosin kinase receptor B (TrkB), is identified. E2 increased experimental BM of TNBC 4T1BR5 and E0771 cells by 21 and 3.6 fold, respectively, compared to E2-depleted mice. ER alpha(+) reactive astrocytes were found at early and late stages of BM, and E2 upregulated BDNF in ER+ reactive astrocytes in vitro and in vivo. TrkB was expressed in TNBC brain-trophic cell lines, BM-patient-derived xenografts, and breast cancer BM. Conditioned media from E2-treated astrocytes (CM-E2) activated TrkB and downstream AKT, ERK, and PLC-gamma signaling in TNBC cells, increasing their invasiveness and tumor-initiating capability in vitro. The promotion of BM by E2-activated astrocytes was found to be more complex, involving feedback loops and other receptor tyrosine kinases. In 4T1BR5 cells, there was a positive feedback loop whereby astrocytic BDNF induced cancer cell BDNF translation. Upregulation of cancer cell BDNF was required to promote full invasiveness of 4T1BR5 in response to CM-E2, and was observed in brain metastatic cells in E2-treated mice in vivo. Moreover, the non-competitive BDNF/TrkB inhibitor ANA-12 reduced E2-induced 4T1BR5 BM to levels similar to OVX mice. BDNF also activated EGFR in TrkB(+)EGFR(+) TNBC cells, suggesting that E2 action through astrocytes activates redundant pathways promoting BM. These findings have important therapeutic implications, as they provide a rationale to use E2-depletion therapies or TrkB inhibitors to prevent or delay development of BM in younger women.	[Contreras-Zarate, Maria J.; Day, Nicole L.; Cittelly, Diana M.] Univ Colorado Denver, Dept Pathol, Anschutz Med Campus, Aurora, CO 80045 USA; [Ormond, D. Ryan] Univ Colorado Denver, Dept Neurosurg, Anschutz Med Campus, Aurora, CO USA; [Borges, Virginia F.] Univ Colorado Denver, Div Med Oncol, Dept Med, Anschutz Med Campus, Aurora, CO USA; [Tobet, Stuart] Colorado State Univ, Dept Biomed Sci, Ft Collins, CO 80523 USA; [Gril, Brunilde; Steeg, Patricia S.] NCI, Womens Malignancies Branch, Bethesda, MD 20892 USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Colorado State University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Cittelly, DM (corresponding author), Univ Colorado Denver, Dept Pathol, Anschutz Med Campus, Aurora, CO 80045 USA.	Diana.Cittelly@ucdenver.edu	; Ormond, David Ryan/R-4847-2017	Cittelly, Diana/0000-0002-8392-0800; Day, Nicole/0000-0003-3490-4908; Ormond, David Ryan/0000-0001-7027-2915; CONTRERAS-ZARATE, MARIA J/0000-0002-0045-549X	ACS IRG [57-001-53, K22CA181250, R37 CA227984]; Drink for Pink and Cancer League of Colorado; Metavivor Research Foundation; NCI [P30CA046934]; CTSA [UL1TR001082]; NATIONAL CANCER INSTITUTE [ZIABC010538, R37CA227984, P30CA046934] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001082] Funding Source: NIH RePORTER	ACS IRG(American Cancer Society); Drink for Pink and Cancer League of Colorado; Metavivor Research Foundation; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CTSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This work was supported by ACS IRG #57-001-53, K22CA181250, R37 CA227984, Drink for Pink and Cancer League of Colorado, and the Metavivor Research Foundation (DMC). University of Colorado Cancer Center Shared Resources were supported by NCI P30CA046934 and CTSA UL1TR001082 Center grants.	Anders C, 2008, ONCOLOGY-NY, V22, P1233; Anders CK, 2008, J CLIN ONCOL, V26, P3324, DOI 10.1200/JCO.2007.14.2471; Anders CK, 2009, SEMIN ONCOL, V36, P237, DOI 10.1053/j.seminoncol.2009.03.001; Azcoitia I, 2011, NEUROSCIENCE, V191, P139, DOI 10.1016/j.neuroscience.2011.02.012; Azcoitia I, 2006, ANN NY ACAD SCI, V1007, P298; Azcoitia I, 2010, EUR J NEUROSCI, V32, P1995, DOI 10.1111/j.1460-9568.2010.07516.x; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; Biegon A, 2015, J NUCL MED, V56, P580, DOI 10.2967/jnumed.114.150383; Blurton-Jones M, 2001, J COMP NEUROL, V433, P115, DOI 10.1002/cne.1129; Boyle P, 2012, ANN ONCOL, V23, P7, DOI 10.1093/annonc/mds187; Chen Q, 2016, NATURE, V533, P493, DOI 10.1038/nature18268; Cheng PL, 2011, P NATL ACAD SCI USA, V108, P18430, DOI 10.1073/pnas.1115907108; Choy C, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0844-3; Contreras-Zarate MJ, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00252; Cunha C, 2010, FRONT MOL NEUROSCI, V3, DOI 10.3389/neuro.02.001.2010; de Vellis J, 2012, METHODS MOL BIOL, V814, P49, DOI 10.1007/978-1-61779-452-0_4; Dittrich F, 1999, P NATL ACAD SCI USA, V96, P8241, DOI 10.1073/pnas.96.14.8241; Dougherty KD, 2000, NEUROBIOL DIS, V7, P574, DOI 10.1006/nbdi.2000.0318; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Evans AJ, 2004, CLIN ONCOL-UK, V16, P345, DOI 10.1016/j.clon.2004.03.012; Ferreira TA, 2014, NAT METHODS, V11, P982, DOI 10.1038/nmeth.3125; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Fulmer CG, 2014, J NEUROSCI, V34, P8186, DOI 10.1523/JNEUROSCI.4267-13.2014; Gotz R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100944; Gravanis I, 2005, GLIA, V49, P177, DOI 10.1002/glia.20115; Hicks DG, 2006, AM J SURG PATHOL, V30, P1097; Howe EN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049987; Hung MH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089389; Iyer V, 2012, CANCER RES, V72, P2705, DOI 10.1158/0008-5472.CAN-11-3287; Ji YY, 2010, NAT NEUROSCI, V13, P302, DOI 10.1038/nn.2505; Kim MS, 2015, ONCOTARGET, V6, P40158, DOI 10.18632/oncotarget.5522; Kim SJ, 2011, NEOPLASIA, V13, P286, DOI 10.1593/neo.11112; Kodack DP, 2015, CANCER CELL, V27, P163, DOI 10.1016/j.ccell.2015.01.001; Kuo J, 2010, J NEUROSCI, V30, P12950, DOI 10.1523/JNEUROSCI.1158-10.2010; Lockman PR, 2010, CLIN CANCER RES, V16, P5664, DOI 10.1158/1078-0432.CCR-10-1564; Lorger M, 2010, AM J PATHOL, V176, P2958, DOI 10.2353/ajpath.2010.090838; Matsumoto T, 2008, NAT NEUROSCI, V11, P131, DOI 10.1038/nn2038; Mccarthy MM, 2008, PHYSIOL REV, V88, P91, DOI 10.1152/physrev.00010.2007; Micevych P, 2009, J NEUROENDOCRINOL, V21, P249, DOI 10.1111/j.1365-2826.2009.01833.x; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; Miyamoto N, 2015, J NEUROSCI, V35, P14002, DOI 10.1523/JNEUROSCI.1592-15.2015; Morris PG, 2012, BREAST J, V18, P345, DOI 10.1111/j.1524-4741.2012.01246.x; Murer MG, 2001, PROG NEUROBIOL, V63, P71, DOI 10.1016/S0301-0082(00)00014-9; Palmieri D, 2007, CANCER RES, V67, P4190, DOI 10.1158/0008-5472.CAN-06-3316; Pang PT, 2004, SCIENCE, V306, P487, DOI 10.1126/science.1100135; Pequeux C, 2012, CANCER RES, V72, P3010, DOI 10.1158/0008-5472.CAN-11-3768; Priego N, 2018, NAT MED, V24, P1024, DOI 10.1038/s41591-018-0044-4; Rose CR, 2003, NATURE, V426, P74, DOI 10.1038/nature01983; Sartori CR, 2011, NEUROSCIENCE, V180, P9, DOI 10.1016/j.neuroscience.2011.02.055; Sartorius CA, 2016, ONCOGENE, V35, P2881, DOI 10.1038/onc.2015.353; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Shao MM, 2011, MED MOL MORPHOL, V44, P15, DOI 10.1007/s00795-010-0495-2; Sinkevicius KW, 2014, P NATL ACAD SCI USA, V111, P10299, DOI 10.1073/pnas.1404399111; SOHRABJI F, 1995, P NATL ACAD SCI USA, V92, P11110, DOI 10.1073/pnas.92.24.11110; Spence RD, 2011, P NATL ACAD SCI USA, V108, P8867, DOI 10.1073/pnas.1103833108; Svoronos N, 2017, CANCER DISCOV, V7, P72, DOI 10.1158/2159-8290.CD-16-0502; Tham YL, 2006, CANCER, V107, P696, DOI 10.1002/cncr.22041; Tseng LM, 2013, NEOPLASMA, V60, P290, DOI 10.4149/neo_2013_038; Valiente M, 2014, CELL, V156, P1002, DOI 10.1016/j.cell.2014.01.040; Wang L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080933; Yin B, 2015, ONCOGENE, V34, P761, DOI 10.1038/onc.2014.8; Yoneda T, 2001, J BONE MINER RES, V16, P1486, DOI 10.1359/jbmr.2001.16.8.1486; Zagar TM, 2016, ONCOLOGY-NY, V30, P923; Zhang L, 2015, NATURE, V527, P100, DOI 10.1038/nature15376; Zhou L, 2010, ENDOCRINOLOGY, V151, P1153, DOI 10.1210/en.2009-0254	65	43	44	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2019	38	24					4685	4699		10.1038/s41388-019-0756-z	http://dx.doi.org/10.1038/s41388-019-0756-z			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IC7ND	30796353	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000471160500003
J	Permata, TBM; Hagiwara, Y; Sato, H; Yasuhara, T; Oike, T; Gondhowiardjo, S; Held, KD; Nakano, T; Shibata, A				Permata, Tiara Bunga Mayang; Hagiwara, Yoshihiko; Sato, Hiro; Yasuhara, Takaaki; Oike, Takahiro; Gondhowiardjo, Soehartati; Held, Kathryn D.; Nakano, Takashi; Shibata, Atsushi			Base excision repair regulates PD-L1 expression in cancer cells	ONCOGENE			English	Article							TUMOR-INFILTRATING LYMPHOCYTES; STRAND BREAK REPAIR; MISMATCH-REPAIR; OXIDATIVE STRESS; NEOANTIGEN LOAD; PATHWAY CHOICE; DNA-DAMAGE; ASSOCIATION; DOCETAXEL; NIVOLUMAB	Programmed death-ligand 1 (PD-L1) is a key factor influencing cancer immunotherapy; however, the regulation of PD-L1 expression in cancer cells remains unclear, particularly regarding DNA damage, repair and its signalling. Herein, we demonstrate that oxidative DNA damage induced by exogenously applied hydrogen peroxide (H2O2) upregulates PD-L1 expression in cancer cells. Further, depletion of the base excision repair (BER) enzyme DNA glycosylase augments PD-L1 upregulation in response to H2O2. PD-L1 upregulation in BER-depleted cells requires ATR/Chkl kinase activities, demonstrating that PD-L1 upregulation is mediated by DNA damage signalling. Further analysis of The Cancer Genome Atlas revealed that the expression of PD-L1 is negatively correlated with that of the BER/single-strand break repair (SSBR) and tumours with low BER/SSBR gene expression show high microsatellite instability and neoantigen production. Hence, these results suggest that PD-L1 expression is regulated in cancer cells via the DNA damage signalling and neoantigen- interferon-gamma pathway under oxidative stress.	[Permata, Tiara Bunga Mayang; Hagiwara, Yoshihiko; Sato, Hiro; Oike, Takahiro; Nakano, Takashi] Gunma Univ, Grad Sch Med, Dept Radiat Oncol, Maebashi, Gunma 3718511, Japan; [Permata, Tiara Bunga Mayang; Gondhowiardjo, Soehartati] Dr Cipto Mangunkusumo Natl Gen Hosp, Dept Radiotherapy, Jakarta, Indonesia; [Yasuhara, Takaaki] Univ Tokyo, Grad Sch Med, Ctr Dis Biol & Integrat Med, Lab Mol Radiol,Bunkyo Ku, Tokyo 1138655, Japan; [Held, Kathryn D.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA; [Held, Kathryn D.] Gunma Univ, Int Open Lab, Initiat Adv Res GIAR, Maebashi, Gunma 3718511, Japan; [Shibata, Atsushi] Gunma Univ, Grad Sch Med, Educ & Res Support Ctr, Maebashi, Gunma 3718511, Japan	Gunma University; University of Tokyo; Harvard University; Harvard Medical School; Massachusetts General Hospital; Gunma University; Gunma University	Shibata, A (corresponding author), Gunma Univ, Grad Sch Med, Educ & Res Support Ctr, Maebashi, Gunma 3718511, Japan.	shibata.at@gunma-u.ac.jp	Sato, Hiro/GWU-7659-2022; Shibata, Atsushi/AAX-1283-2021; Takaaki, Yasuhara/U-3345-2019	Shibata, Atsushi/0000-0001-8912-6977; Permata, Tiara Bunga Mayang/0000-0002-5890-5545; Yasuhara, Takaaki/0000-0002-6719-5709	Program of the network-type Joint Usage/Research Center for Radiation Disaster Medical Science of Hiroshima University; Nagasaki University; Fukushima Medical University; Ministry of Education, Culture, Sports, Science and Technology of Japan	Program of the network-type Joint Usage/Research Center for Radiation Disaster Medical Science of Hiroshima University; Nagasaki University; Fukushima Medical University; Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported by the Program of the network-type Joint Usage/Research Center for Radiation Disaster Medical Science of Hiroshima University, Nagasaki University and Fukushima Medical University. This work was also supported by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan for programs for Leading Graduate Schools, Cultivating Global Leaders in Heavy Ion Therapeutics and Engineering.	Antonia SJ, 2017, NEW ENGL J MED, V377, P1919, DOI 10.1056/NEJMoa1709937; AQUILINA G, 1994, P NATL ACAD SCI USA, V91, P8905, DOI 10.1073/pnas.91.19.8905; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Caldecott KW, 2008, NAT REV GENET, V9, P619, DOI 10.1038/nrg2380; Chen BPC, 2012, CANCER LETT, V327, P103, DOI 10.1016/j.canlet.2011.12.004; Chen MF, 2016, ONCOTARGET, V7, P7913, DOI 10.18632/oncotarget.6861; Cortes-Ciriano I, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15180; Eggermont AMM, 2018, NEW ENGL J MED, V378, P1789, DOI 10.1056/NEJMoa1802357; Ensminger M, 2014, J CELL BIOL, V206, P29, DOI 10.1083/jcb.201312078; Feng WR, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00634-0; Fiaschi Tania, 2012, Int J Cell Biol, V2012, P762825, DOI 10.1155/2012/762825; FISHEL R, 1994, SCIENCE, V266, P1403, DOI 10.1126/science.7973733; Garcia-Diaz A, 2017, CELL REP, V19, P1189, DOI 10.1016/j.celrep.2017.04.031; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hargadon KM, 2018, INT IMMUNOPHARMACOL, V62, P29, DOI 10.1016/j.intimp.2018.06.001; Howitt BE, 2015, JAMA ONCOL, V1, P1319, DOI 10.1001/jamaoncol.2015.2151; Hutter C, 2018, CELL, V173, P283, DOI 10.1016/j.cell.2018.03.042; Iwai Y, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0329-9; Karahalil B, 2012, HUM EXP TOXICOL, V31, P981, DOI 10.1177/0960327112444476; Kim ST, 2018, NAT MED, V24, P1449, DOI 10.1038/s41591-018-0101-z; Klein HL, 2002, MOL CELL, V9, P471, DOI 10.1016/S1097-2765(02)00493-8; Kumar B, 2008, CANCER RES, V68, P1777, DOI 10.1158/0008-5472.CAN-07-5259; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Li TW, 2017, CANCER RES, V77, pE108, DOI 10.1158/0008-5472.CAN-17-0307; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Liou GY, 2010, FREE RADICAL RES, V44, P479, DOI 10.3109/10715761003667554; Llosa NJ, 2015, CANCER DISCOV, V5, P43, DOI 10.1158/2159-8290.CD-14-0863; Maynard S, 2009, CARCINOGENESIS, V30, P2, DOI 10.1093/carcin/bgn250; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; Mouw KW, 2018, BRIT J CANCER, V118, P933, DOI 10.1038/s41416-018-0017-x; O'Connor MJ, 2015, MOL CELL, V60, P547, DOI 10.1016/j.molcel.2015.10.040; Qin Q, 2018, RADIAT RES, V190, P322, DOI 10.1667/RR15048.1; Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Roger A, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1442166; Sato H, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01883-9; Schumacker PT, 2006, CANCER CELL, V10, P175, DOI 10.1016/j.ccr.2006.08.015; Shen JF, 2018, NAT MED, V24, P556, DOI 10.1038/s41591-018-0012-z; Shibata A, 2017, MUTAT RES-FUND MOL M, V803, P51, DOI 10.1016/j.mrfmmm.2017.07.011; Shibata A, 2014, MOL CELL, V53, P7, DOI 10.1016/j.molcel.2013.11.003; Shin DS, 2017, CANCER DISCOV, V7, P188, DOI 10.1158/2159-8290.CD-16-1223; Strickland KC, 2016, ONCOTARGET, V7, P13587, DOI 10.18632/oncotarget.7277; Sunshine J, 2015, CURR OPIN PHARMACOL, V23, P32, DOI 10.1016/j.coph.2015.05.011; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Tubbs A, 2017, CELL, V168, DOI 10.1016/j.cell.2017.01.002; UMAR A, 1994, J BIOL CHEM, V269, P14367; Vendetti FP, 2018, J CLIN INVEST, V128, P3926, DOI 10.1172/JCI96519; Wallace SS, 2012, CANCER LETT, V327, P73, DOI 10.1016/j.canlet.2011.12.038; Weren RDA, 2015, NAT GENET, V47, P668, DOI 10.1038/ng.3287	53	45	46	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2019	38	23					4452	4466		10.1038/s41388-019-0733-6	http://dx.doi.org/10.1038/s41388-019-0733-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IB4KM	30755733				2022-12-28	WOS:000470240300002
J	Fischer, M				Fischer, Martin			Conservation and divergence of the p53 gene regulatory network between mice and humans	ONCOGENE			English	Article							CELL-CYCLE CHECKPOINT; DNA-POLYMERASE-ETA; TRANSCRIPTIONAL REPRESSION; BINDING-SITES; CHIP-SEQ; TARGET; MOUSE; DREAM; PATHWAY; IDENTIFICATION	Understanding the p53 tumor suppressor pathway remains crucial for the design of anticancer strategies. Studies in human tumors and mouse models help to unravel the molecular mechanisms that underlie the p53 signaling pathway. Yet, the p53 gene regulatory network (GRN) is not the same in mice and humans. The comparison of the regulatory networks of p53 in mice and humans reveals that gene up-and down-regulation by p53 are distinctly affected during evolution. Importantly, gene up-regulation by p53 underwent more rapid evolution and gene down-regulation has been evolutionarily constrained. This difference stems from the two major mechanisms employed by p53 to regulate gene expression: up-regulation through direct p53 target gene binding and indirect down-regulation through the p53-p21-DREAM pathway. More than 1000 genes have been identified to differ in their p53-dependent expression between mice and humans. Analysis of p53 gene expression profiles and p53 binding data reveal that turnover of p53 binding sites is the major mechanism underlying extensive variation in p53-dependent gene up-regulation. Only a core set of high-confidence genes appears to be directly regulated by p53 in both species. In contrast to up-regulation, p53-induced down-regulation is well conserved between mice and humans and controls cell cycle genes. Here a curated data set is provided that extends the previously established web-atlas at www.targetgenereg.org to assess the p53 response of any human gene of interest and its mouse ortholog. Taken together, the analysis reveals a limited translation potential from mouse models to humans for the p53 GRN.	[Fischer, Martin] Fritz Lipmann Inst, Leibniz Inst Aging, Computat Biol Grp, D-07745 Jena, Germany; [Fischer, Martin] Univ Leipzig, Sch Med, Mol Oncol Grp, D-04103 Leipzig, Germany	Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI); Leipzig University	Fischer, M (corresponding author), Fritz Lipmann Inst, Leibniz Inst Aging, Computat Biol Grp, D-07745 Jena, Germany.; Fischer, M (corresponding author), Univ Leipzig, Sch Med, Mol Oncol Grp, D-04103 Leipzig, Germany.	Martin.Fischer@leibniz-fli.de	Fischer, Martin/I-4825-2014	Fischer, Martin/0000-0002-3429-1876	German Research Foundation (DFG) [FI 1993/2-1]; University of Leipzig Medical School; Federal Government of Germany; State or Thuringia; AddOn Fellowship for Interdisciplinary Science in Systems Biology from the Joachim Herz Stiftung	German Research Foundation (DFG)(German Research Foundation (DFG)); University of Leipzig Medical School; Federal Government of Germany; State or Thuringia; AddOn Fellowship for Interdisciplinary Science in Systems Biology from the Joachim Herz Stiftung	This work was supported through research grant FI 1993/2-1 from the German Research Foundation (DFG), a junior research grant from the University of Leipzig Medical School and through an AddOn Fellowship for Interdisciplinary Science in Systems Biology from the Joachim Herz Stiftung. The FLI is a member of the Leibniz Association and is financially supported by the Federal Government of Germany and the State or Thuringia.	Agarwala R, 2018, NUCLEIC ACIDS RES, V46, pD8, DOI [10.1093/nar/gkx1095, 10.1093/nar/gkv1290]; Andrysik Z, 2017, GENOME RES, V27, P1645, DOI 10.1101/gr.220533.117; Assaily W, 2011, MOL CELL, V44, P491, DOI 10.1016/j.molcel.2011.08.038; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Bohlig L, 2011, NUCLEIC ACIDS RES, V39, P440, DOI 10.1093/nar/gkq796; Brady CA, 2011, CELL, V145, P571, DOI 10.1016/j.cell.2011.03.035; Broz DK, 2013, GENE DEV, V27, P1016, DOI 10.1101/gad.212282.112; Carvajal LA, 2012, GENE DEV, V26, P1533, DOI 10.1101/gad.184911.111; Chen YW, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-2-r11; Cheng Y, 2014, NATURE, V515, P371, DOI 10.1038/nature13985; Collavin L, 2000, FEBS LETT, V481, P57, DOI 10.1016/S0014-5793(00)01969-4; Conboy CM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001061; Dimitrova N, 2014, MOL CELL, V54, P777, DOI 10.1016/j.molcel.2014.04.025; Engeland K, 2018, CELL DEATH DIFFER, V25, P114, DOI 10.1038/cdd.2017.172; Fischer M, 2017, ONCOGENE, V36, P3943, DOI 10.1038/onc.2016.502; Fischer M, 2017, CRIT REV BIOCHEM MOL, V52, P638, DOI 10.1080/10409238.2017.1360836; Fischer M, 2016, NUCLEIC ACIDS RES, V44, P6070, DOI 10.1093/nar/gkw523; Fischer M, 2016, NUCLEIC ACIDS RES, V44, P164, DOI 10.1093/nar/gkv927; Fischer M, 2015, ONCOTARGET, V6, P41402, DOI 10.18632/oncotarget.6356; Fischer M, 2014, CELL CYCLE, V13, P3037, DOI 10.4161/15384101.2014.949083; Fischer M, 2014, NUCLEIC ACIDS RES, V42, P163, DOI 10.1093/nar/gkt849; Fischer M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063187; Gambino V, 2013, AGING CELL, V12, P435, DOI 10.1111/acel.12060; Horvath MM, 2007, PLOS GENET, V3, P1284, DOI 10.1371/journal.pgen.0030127; Hsieh WJ, 2008, BIOCHEM BIOPH RES CO, V369, P567, DOI 10.1016/j.bbrc.2008.02.047; Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040; Jegga AG, 2008, P NATL ACAD SCI USA, V105, P944, DOI 10.1073/pnas.0704694105; Kaiser AM, 2018, CELL DEATH DIFFER, V25, P93, DOI 10.1038/cdd.2017.171; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Lange SS, 2011, NAT REV CANCER, V11, P96, DOI 10.1038/nrc2998; Lee KH, 2010, P NATL ACAD SCI USA, V107, P69, DOI 10.1073/pnas.0909734107; Lerner LK, 2017, NUCLEIC ACIDS RES, V45, P1270, DOI 10.1093/nar/gkw1196; Lion M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116177; Liu G, 2006, MOL CELL BIOL, V26, P1398, DOI 10.1128/MCB.26.4.1398-1413.2006; Lo PK, 1999, ONCOGENE, V18, P7765, DOI 10.1038/sj.onc.1203167; Lozano G, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001115; Marin-Bejar O, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-9-r104; Mei SL, 2017, NUCLEIC ACIDS RES, V45, pD658, DOI 10.1093/nar/gkw983; Muller GA, 2017, ONCOTARGET, V8, P97736, DOI 10.18632/oncotarget.10888; Muller GA, 2014, NUCLEIC ACIDS RES, V42, P10331, DOI 10.1093/nar/gku696; Muller GA, 2012, NUCLEIC ACIDS RES, V40, P1561, DOI 10.1093/nar/gkr793; Nakaya N, 2007, MOL CELL BIOL, V27, P5430, DOI 10.1128/MCB.00551-06; Nitta KR, 2015, ELIFE, V4, DOI 10.7554/eLife.04837; Quaas M, 2012, CELL CYCLE, V11, P4661, DOI 10.4161/cc.22917; Rutkowski R, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001131; Sanchez-Macedo N, 2013, CELL DEATH DIFFER, V20, P659, DOI 10.1038/cdd.2012.168; Sethi I, 2017, NUCLEIC ACIDS RES, V45, P8208, DOI 10.1093/nar/gkx416; Stergachis AB, 2014, NATURE, V515, P365, DOI 10.1038/nature13972; Stewart AJ, 2012, GENETICS, V192, P973, DOI 10.1534/genetics.112.143370; Stewart-Ornstein J, 2017, CELL SYST, V5, P410, DOI 10.1016/j.cels.2017.09.012; Sullivan KD, 2018, CELL DEATH DIFFER, V25, P133, DOI 10.1038/cdd.2017.174; Tan T, 2002, MOL CELL BIOL, V22, P3247, DOI 10.1128/MCB.22.10.3247-3254.2002; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Timofeev O, 2013, CELL REP, V3, P1512, DOI 10.1016/j.celrep.2013.04.008; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Tonelli C, 2015, ONCOTARGET, V6, P24611, DOI 10.18632/oncotarget.5232; Tugrul M, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005639; Velasco-Miguel S, 2003, DNA REPAIR, V2, P91, DOI 10.1016/S1568-7864(02)00189-1; Vierstra J, 2014, SCIENCE, V346, P1007, DOI 10.1126/science.1246426; Wang S, 2013, NAT PROTOC, V8, P2502, DOI 10.1038/nprot.2013.150; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441; Younger ST, 2015, NUCLEIC ACIDS RES, V43, P4447, DOI 10.1093/nar/gkv284; Yue F, 2014, NATURE, V515, P355, DOI 10.1038/nature13992; Zhang XY, 2013, CELL CYCLE, V12, P1279, DOI 10.4161/cc.24364	64	24	26	3	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2019	38	21					4095	4109		10.1038/s41388-019-0706-9	http://dx.doi.org/10.1038/s41388-019-0706-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ3HX	30710145	hybrid, Green Published			2022-12-28	WOS:000468740200009
J	Mann, J; Githaka, JM; Buckland, TW; Yang, N; Montpetit, R; Patel, N; Li, L; Baksh, S; Godbout, R; Lemieux, H; Goping, IS				Mann, Jasdeep; Githaka, John Maringa; Buckland, Timothy W.; Yang, Ning; Montpetit, Rachel; Patel, Namrata; Li, Lei; Baksh, Shairaz; Godbout, Roseline; Lemieux, Helene; Goping, Ing Swie			Non-canonical BAD activity regulates breast cancer cell and tumor growth via 14-3-3 binding and mitochondrial metabolism	ONCOGENE			English	Article							DEATH AGONIST BAD; PROAPOPTOTIC BAD; BH3 DOMAIN; PHOSPHORYLATION; SURVIVAL; PROTEIN; EXPRESSION; RESPIRATION; INACTIVATE; GLYCOLYSIS	The Bcl-2-associated death promoter BAD is a prognostic indicator for good clinical outcome of breast cancer patients; however, whether BAD affects breast cancer biology is unknown. Here we showed that BAD increased cell growth in breast cancer cells through two distinct mechanisms. Phosphorylation of BAD at S118 increased S99 phosphorylation, 14-3-3 binding and AKT activation to promote growth and survival. Through a second, more prominent pathway, BAD stimulated mitochondrial oxygen consumption in a novel manner that was downstream of substrate entry into the mitochondria. BAD stimulated complex I activity that facilitated enhanced cell growth and sensitized cells to apoptosis in response to complex I blockade. We propose that this dependence on oxidative metabolism generated large but nonaggressive cancers. This model identifies a non-canonical role for BAD and reconciles BAD-mediated tumor growth with favorable outcomes in BAD-high breast cancer patients.	[Mann, Jasdeep; Githaka, John Maringa; Buckland, Timothy W.; Yang, Ning; Montpetit, Rachel; Patel, Namrata; Baksh, Shairaz; Goping, Ing Swie] Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; [Li, Lei; Baksh, Shairaz; Godbout, Roseline; Goping, Ing Swie] Univ Alberta, Dept Oncol, Edmonton, AB T6G 2H7, Canada; [Baksh, Shairaz] Univ Alberta, Dept Pediat, Edmonton, AB T6G 2H7, Canada; [Lemieux, Helene] Univ Alberta, Dept Med, Edmonton, AB T6G 2H7, Canada; [Lemieux, Helene] Univ Alberta, Fac St Jean, Edmonton, AB T6G 2H7, Canada	University of Alberta; University of Alberta; University of Alberta; University of Alberta; University of Alberta	Goping, IS (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada.; Goping, IS (corresponding author), Univ Alberta, Dept Oncol, Edmonton, AB T6G 2H7, Canada.	igoping@ualberta.ca	Baksh, Shairaz/GRX-2106-2022; Buckland, Timothy/AAV-9022-2021; Godbout, Roseline/I-4639-2016	Godbout, Roseline/0000-0002-4779-9265; lemieux, Helene/0000-0002-8864-6062	Women and Children's Health Research Institute; Canadian Breast Cancer Foundation; Alberta Cancer Foundation	Women and Children's Health Research Institute; Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); Alberta Cancer Foundation	We thank Dr. Bernard Lemire (University of Alberta), Dr. Thomas Simmen (University of Alberta), and Dr. Manijeh Pasdar (University of Alberta) for their generous gift of reagents. Additionally, we acknowledge all Goping lab members for the meaningful discussions and contributions to this work. This work was supported by operating grants from the Women and Children's Health Research Institute, Canadian Breast Cancer Foundation and Alberta Cancer Foundation to ISG.	Adachi M, 2002, CELL DEATH DIFFER, V9, P1240, DOI 10.1038/sj.cdd.4401097; Adams LD, 2004, CURR PROTOC MOL BIOL; Al-Bazz YO, 2009, EUR J CANCER, V45, P694, DOI 10.1016/j.ejca.2008.11.044; Cairns RA, 2011, COLD SH Q B, V76, P299, DOI 10.1101/sqb.2011.76.012856; Cannings E, 2007, BREAST CANCER RES TR, V102, P173, DOI 10.1007/s10549-006-9323-8; Chattopadhyay A, 2001, ONCOGENE, V20, P4507, DOI 10.1038/sj.onc.1204584; Craik AC, 2010, ONCOGENE, V29, P5381, DOI 10.1038/onc.2010.272; Czernick M, 2009, BIOCHEM BIOPH RES CO, V379, P145, DOI 10.1016/j.bbrc.2008.12.025; Danial NN, 2008, NAT MED, V14, P144, DOI 10.1038/nm1717; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DeBerardinis RJ, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600200; Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7; FALOONA GR, 1969, BIOCHEMISTRY-US, V8, P4497, DOI 10.1021/bi00839a041; Fouque A, 2016, CELL DEATH DIFFER, V23, P1702, DOI 10.1038/cdd.2016.61; Gimenez-Cassina A, 2014, CELL METAB, V19, P272, DOI 10.1016/j.cmet.2013.12.001; Gimenez-Cassina A, 2012, NEURON, V74, P719, DOI 10.1016/j.neuron.2012.03.032; Gnaiger E, 2000, P NATL ACAD SCI USA, V97, P11080, DOI 10.1073/pnas.97.20.11080; Gnaiger E, 1995, J BIOENERG BIOMEMBR, V27, P583, DOI 10.1007/BF02111656; GOPING IS, 1995, FEBS LETT, V373, P45; Grun D, 2016, ONCOGENE, V35, P4379, DOI 10.1038/onc.2015.507; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Janumyan YM, 2003, EMBO J, V22, P5459, DOI 10.1093/emboj/cdg533; John S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017674; Joshi S, 2015, CELL REP, V13, P1895, DOI 10.1016/j.celrep.2015.10.059; Lee KH, 2008, ONCOL RES, V17, P23, DOI 10.3727/096504008784046072; Lee KH, 2010, ONCOL RES, V19, P67, DOI 10.3727/096504010X12864748215043; Lu JR, 2015, CANCER LETT, V356, P156, DOI 10.1016/j.canlet.2014.04.001; Marchion DC, 2011, CLIN CANCER RES, V17, P6356, DOI 10.1158/1078-0432.CCR-11-0735; Martinez-Reyes I, 2016, MOL CELL, V61, P199, DOI 10.1016/j.molcel.2015.12.002; Maslyar DJ, 2001, ONCOGENE, V20, P5087, DOI 10.1038/sj.onc.1204662; Mathupala SP, 2006, ONCOGENE, V25, P4777, DOI 10.1038/sj.onc.1209603; Osundiji MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028016; Pandya V, 2016, ONCOTARGET, V7, P33272, DOI 10.18632/oncotarget.8924; Ranger AM, 2003, P NATL ACAD SCI USA, V100, P9324, DOI 10.1073/pnas.1533446100; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Sinicrope FA, 2008, CLIN CANCER RES, V14, P4128, DOI 10.1158/1078-0432.CCR-07-5160; Smith AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006224; Smith TAD, 2000, BRIT J BIOMED SCI, V57, P170; Spinazzi M, 2012, NAT PROTOC, V7, P1235, DOI 10.1038/nprot.2012.058; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Tuominen VJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2615; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Weinberg SE, 2015, NAT CHEM BIOL, V11, P9, DOI 10.1038/nchembio.1712; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Yang J, 2010, J THEOR BIOL, V266, P231, DOI 10.1016/j.jtbi.2010.06.009; YANG N, 2017, CELL DEATH DIS, V8; Yu YY, 2015, INT J CLIN EXP PATHO, V8, P13075; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200; 1999, J BIOL CHEM, V274, P3485; 2001, MOL PHARM, V60, P1325	56	13	13	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2019	38	18					3325	3339		10.1038/s41388-018-0673-6	http://dx.doi.org/10.1038/s41388-018-0673-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HW3RI	30635657	Green Published, hybrid			2022-12-28	WOS:000466610000001
J	Gold, A; Eini, L; Nissim-Rafinia, M; Viner, R; Ezer, S; Erez, K; Aqaqe, N; Hanania, R; Milyavsky, M; Meshorer, E; Goldberg, M				Gold, Ayala; Eini, Lital; Nissim-Rafinia, Malka; Viner, Ruth; Ezer, Shlomit; Erez, Keren; Aqaqe, Nasma; Hanania, Rotem; Milyavsky, Michael; Meshorer, Eran; Goldberg, Michal			Spironolactone inhibits the growth of cancer stem cells by impairing DNA damage response	ONCOGENE			English	Article							TRICHOSTATIN-A; APOPTOSIS; THERAPY; INDUCTION; SURVIVAL; SCREEN; AGENTS	The cancer stem cell (CSC) model suggests that a subpopulation of cells within the tumor, the CSCs, is responsible for cancer relapse and metastasis formation. CSCs hold unique characteristics, such as self-renewal, differentiation abilities, and resistance to chemotherapy, raising the need for discovering drugs that target CSCs. Previously we have found that the antihypertensive drug spironolactone impairs DNA damage response in cancer cells. Here we show that spironolactone, apart from inhibiting cancerous cell growth, is also highly toxic to CSCs. Notably, we demonstrate that CSCs have high basal levels of DNA double-strand breaks (DSBs). Mechanistically, we reveal that spironolactone does not damage the DNA but impairs DSB repair and induces apoptosis in cancer cells and CSCs while sparing healthy cells. In vivo, spironolactone treatment reduced the size and CSC content of tumors. Overall, we suggest spironolactone as an anticancer reagent, toxic to both cancer cells and, particularly to, CSCs.	[Gold, Ayala; Eini, Lital; Nissim-Rafinia, Malka; Viner, Ruth; Ezer, Shlomit; Erez, Keren; Hanania, Rotem; Meshorer, Eran; Goldberg, Michal] Hebrew Univ Jerusalem, Dept Genet, Inst Life Sci, Edmond J Safra Campus, IL-9190401 Jerusalem, Israel; [Nissim-Rafinia, Malka; Meshorer, Eran] Hebrew Univ Jerusalem, Edmond & Lily Safra Ctr Brain Sci ELSC, Edmond J Safra Campus, IL-9190401 Jerusalem, Israel; [Aqaqe, Nasma; Milyavsky, Michael] Tel Aviv Univ, Sackler Fac Med, Dept Pathol, IL-69978 Tel Aviv, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Tel Aviv University; Sackler Faculty of Medicine	Meshorer, E; Goldberg, M (corresponding author), Hebrew Univ Jerusalem, Dept Genet, Inst Life Sci, Edmond J Safra Campus, IL-9190401 Jerusalem, Israel.; Meshorer, E (corresponding author), Hebrew Univ Jerusalem, Edmond & Lily Safra Ctr Brain Sci ELSC, Edmond J Safra Campus, IL-9190401 Jerusalem, Israel.	eran.meshorer@mail.huji.ac.il; goldbergm@mail.huji.ac.il		Meshorer, Eran/0000-0003-4777-986X; Goldberg, Michal/0000-0001-9397-2383	Israel Science Foundation [1353/12, 1140/17]; Israel Cancer Association [20171152]; DKFZ-MOST Collaboration [CA180]	Israel Science Foundation(Israel Science Foundation); Israel Cancer Association; DKFZ-MOST Collaboration	This work was supported by grant 1353/12 from the Israel Science Foundation and grant 20171152 from the Israel Cancer Association, with the generous assistance of Nancy and Peter Brown through the ICA USA to MG, and by grant 1140/17 from the Israel Science Foundation and CA180 from the DKFZ-MOST Collaboration to EM.	Alekseev S, 2014, CHEM BIOL, V21, P398, DOI 10.1016/j.chembiol.2013.12.014; Bake M., 2008, NAT REP STEM CELLS, DOI [10.1038/stemcells.2008.153, DOI 10.1038/STEMCELLS.2008.153]; Bandhavkar S, 2016, CANCER MED-US, V5, P649, DOI 10.1002/cam4.629; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Belmokhtar CA, 2001, ONCOGENE, V20, P3354, DOI 10.1038/sj.onc.1204436; Biechonski S, 2017, CARCINOGENESIS, V38, P367, DOI 10.1093/carcin/bgx002; Campos B, 2010, CLIN CANCER RES, V16, P2715, DOI 10.1158/1078-0432.CCR-09-1800; Chadwick JA, 2015, FASEB J, V29, P4544, DOI 10.1096/fj.15-276782; Chang CH, 2015, STEM CELL REP, V5, P378, DOI 10.1016/j.stemcr.2015.07.009; Chen YL, 2012, J CELL BIOCHEM, V113, P3643, DOI 10.1002/jcb.24228; Cheung-Ong K, 2013, CHEM BIOL, V20, P648, DOI 10.1016/j.chembiol.2013.04.007; Choi YH, 2005, INT J ONCOL, V27, P473; Chuang YW, 2017, J HYPERTENS, V35, P170, DOI 10.1097/HJH.0000000000001130; Clarke MF, 2005, BIOL BLOOD MARROW TR, V11, P14, DOI 10.1016/j.bbmt.2004.11.011; Dictus C, 2007, J NEUROSCI METH, V161, P250, DOI 10.1016/j.jneumeth.2006.11.012; Ferguson LR, 2015, SEMIN CANCER BIOL, V35, pS5, DOI 10.1016/j.semcancer.2015.03.005; Funder JW, 2013, INTEGR BLOOD PRESS C, V6, P129, DOI 10.2147/IBPC.S13783; GARDINER P, 1989, J CLIN PHARMACOL, V29, P342, DOI 10.1002/j.1552-4604.1989.tb03339.x; Gavande NS, 2016, PHARMACOL THERAPEUT, V160, P65, DOI 10.1016/j.pharmthera.2016.02.003; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015; Helleday T, 2008, NAT REV CANCER, V8, P193, DOI 10.1038/nrc2342; Kotsantis P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13087; Lamb J, 2007, NAT REV CANCER, V7, P54, DOI 10.1038/nrc2044; Leung WH, 2013, J EXP MED, V210, P2675, DOI 10.1084/jem.20122292; Louka M, 2015, ADVANCES IN DNA REPAIR, P415, DOI 10.5772/61355; LUMB G, 1978, J ENVIRON PATHOL TOX, V1, P641; Ferreira JRO, 2013, TOXICOL IN VITRO, V27, P1458, DOI 10.1016/j.tiv.2013.03.010; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; Peitzsch C, 2017, SEMIN CANCER BIOL, V44, P10, DOI 10.1016/j.semcancer.2017.02.011; Rajanna A, 2016, MED HYPOTHESES, V88, P83, DOI 10.1016/j.mehy.2015.11.009; Scaffidi P, 2011, NAT CELL BIOL, V13, P1051, DOI 10.1038/ncb2308; Shahar OD, 2014, NUCLEIC ACIDS RES, V42, P5689, DOI 10.1093/nar/gku217; Shaked Y, 2016, NAT REV CLIN ONCOL, V13, P611, DOI 10.1038/nrclinonc.2016.57; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Struthers A, 2008, CLIN CARDIOL, V31, P153, DOI 10.1002/clc.20324; Taghiyev AF, 2005, CANCER BIOL THER, V4, P382; Torres CM, 2016, SCIENCE, V353, DOI 10.1126/science.aaf1644; Yao X, 2007, AM J MED SCI, V334, P115, DOI 10.1097/MAJ.0b013e31812dfe1e	39	17	20	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2019	38	17					3103	3118		10.1038/s41388-018-0654-9	http://dx.doi.org/10.1038/s41388-018-0654-9			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU8RI	30622338				2022-12-28	WOS:000465557200001
J	Ma, AH; Tang, M; Zhang, L; Wang, BS; Yang, ZJ; Liu, Y; Xu, GQ; Wu, L; Jing, TT; Xu, XL; Yang, SL; Liu, YZ				Ma, Aihui; Tang, Ming; Zhang, Li; Wang, Boshi; Yang, Zhaojuan; Liu, Yun; Xu, Guiqin; Wu, Lin; Jing, Tiantian; Xu, Xiaoli; Yang, Shengli; Liu, Yongzhong			USP1 inhibition destabilizes KPNA2 and suppresses breast cancer metastasis	ONCOGENE			English	Article							MULTIPLE-MYELOMA; STEM-CELLS; EXPRESSION; DEUBIQUITINATION; CARCINOMAS; SURVIVAL; RNA	Metastatic progression is the main cause of mortality in breast cancer, necessitating the determination of the molecular events driving this process for the development of new therapeutic approaches. Here, we demonstrate that hyperactivation of the deubiquitinase USP1 contributes to breast cancer metastasis. Upregulated USP1 expression in primary breast cancer specimens correlates with metastatic progression and poor prognosis in breast cancer patients. USP1 enhances the expression of a number of pro-metastatic genes in breast cancer cells, promotes cell migration and invasion in vitro, and facilitates lung metastasis of breast cancer cells. Moreover, USP1-mediated deubiquitination and stabilization of KPNA2 are revealed as the downstream events crucial for USP1-pro-metastatic function. Most importantly, pharmacological intervention of USP1 function by pimozide or ML323 significantly represses breast cancer metastasis in mice, suggesting a rationale for using USP1 inhibitors for treatment of patients with breast cancer. Taken together, our results establish USP1 as a promoter of breast cancer metastasis and provide evidence for the potential practice of USP1 targeting in the treatment of breast cancer.	[Ma, Aihui; Tang, Ming; Zhang, Li; Wang, Boshi; Yang, Zhaojuan; Liu, Yun; Xu, Guiqin; Wu, Lin; Jing, Tiantian; Xu, Xiaoli; Yang, Shengli; Liu, Yongzhong] Shanghai Jiao Tong Univ, Renji Hosp, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes,Sch Med, Shanghai 200032, Peoples R China	Shanghai Jiao Tong University	Liu, YZ (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes,Sch Med, Shanghai 200032, Peoples R China.	liuyzg@shsci.org		Liu, Yongzhong/0000-0002-1477-116X	National Natural Science Foundation of China [81572293, 31770976, 81672359]; Natural Science Foundation of Shanghai [18ZR1436800]; State Key Laboratory of Oncogenes and Related Genes [91-1705, 91-17-11]; Shanghai Cancer Institute [SB18-07]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai); State Key Laboratory of Oncogenes and Related Genes; Shanghai Cancer Institute	This work was supported by the National Natural Science Foundation of China (81572293, 31770976, and 81672359), Natural Science Foundation of Shanghai (18ZR1436800), the State Key Laboratory of Oncogenes and Related Genes (91-1705, 91-17-11), and Shanghai Cancer Institute (SB18-07).	Altan B, 2013, CARCINOGENESIS, V34, P2314, DOI 10.1093/carcin/bgt214; Auslander D, 2018, NAT METHODS, V15, P57, DOI [10.1038/NMETH.4505, 10.1038/nmeth.4505]; Brastianos PK, 2015, CANCER DISCOV, V5, P1164, DOI 10.1158/2159-8290.CD-15-0369; Brown D, 2017, NAT COMMUN, V8, DOI [10.1038/ncomms15759, 10.1038/ncomms14944]; Chen JJ, 2011, CHEM BIOL, V18, P1390, DOI 10.1016/j.chembiol.2011.08.014; Christiansen A, 2013, CANCER LETT, V331, P18, DOI 10.1016/j.canlet.2012.12.013; Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033; Dankof A, 2007, VIRCHOWS ARCH, V451, P877, DOI 10.1007/s00428-007-0513-5; Das DS, 2017, CLIN CANCER RES, V23, P4280, DOI 10.1158/1078-0432.CCR-16-2692; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Fujiwara T, 1998, GENOMICS, V54, P155, DOI 10.1006/geno.1998.5554; Gluz O, 2008, INT J CANCER, V123, P1433, DOI 10.1002/ijc.23628; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang TT, 2006, NAT CELL BIOL, V8, P339, DOI 10.1038/ncb1378; Jensen JB, 2011, EUR UROL, V59, P841, DOI 10.1016/j.eururo.2011.01.048; Kane RC, 2006, CLIN CANCER RES, V12, P2955, DOI 10.1158/1078-0432.CCR-06-0170; Lee JK, 2016, NEURO-ONCOLOGY, V18, P37, DOI 10.1093/neuonc/nov091; Liang Q, 2014, NAT CHEM BIOL, V10, P298, DOI [10.1038/nchembio.1455, 10.1038/NCHEMBIO.1455]; Mistry H, 2013, MOL CANCER THER, V12, P2651, DOI 10.1158/1535-7163.MCT-13-0103-T; Moreno-Bueno G, 2011, EMBO MOL MED, V3, P528, DOI 10.1002/emmm.201100156; Mothi M, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001949.pub3; Ni IBP, 2010, PATHOL RES PRACT, V206, P223, DOI 10.1016/j.prp.2009.11.006; Nicholson Benjamin, 2007, Future Oncol, V3, P191, DOI 10.2217/14796694.3.2.191; Nijman SMB, 2005, MOL CELL, V17, P331, DOI 10.1016/j.molcel.2005.01.008; Noetzel E, 2012, ONCOGENE, V31, P2101, DOI 10.1038/onc.2011.403; Oestergaard VH, 2007, MOL CELL, V28, P798, DOI 10.1016/j.molcel.2007.09.020; Ogrunc M, 2016, CELL REP, V15, P1401, DOI 10.1016/j.celrep.2016.04.033; Rahme GJ, 2016, CANCER RES, V76, P2964, DOI 10.1158/0008-5472.CAN-15-2157; Raimondi M, 2016, CELL CYCLE, V15, P106, DOI 10.1080/15384101.2015.1121325; Ree AH, 1997, CLIN CANCER RES, V3, P1623; Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rudland PS, 2000, CANCER RES, V60, P1595; Sampieri K, 2012, SEMIN CANCER BIOL, V22, P187, DOI 10.1016/j.semcancer.2012.03.002; Schmidt M, 2008, CANCER RES, V68, P5405, DOI 10.1158/0008-5472.CAN-07-5206; Siegel MB, 2018, J CLIN INVEST, V128, P1371, DOI 10.1172/JCI96153; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; TUETH MJ, 1993, SOUTH MED J, V86, P344, DOI 10.1097/00007611-199303000-00019; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; Williams SA, 2011, CELL, V146, P917, DOI 10.1016/j.cell.2011.07.040; Winnepenninckx VR, 2006, JNCI-J NATL CANCER I, V98, P472, DOI 10.1093/jnci/djj103; Wu YD, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14228; Xiao ZN, 2016, CANCER METAST REV, V35, P589, DOI 10.1007/s10555-016-9640-2; Yu ZX, 2017, J EXP MED, V214, P3553, DOI 10.1084/jem.20170180; Zhang JS, 2013, NAT CELL BIOL, V15, P1486, DOI 10.1038/ncb2874; Zhang L, 2012, NAT CELL BIOL, V14, P717, DOI 10.1038/ncb2522	50	49	53	5	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2019	38	13					2405	2419		10.1038/s41388-018-0590-8	http://dx.doi.org/10.1038/s41388-018-0590-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ7GN	30531833				2022-12-28	WOS:000462588000013
J	Traxel, S; Schadt, L; Eyer, T; Mordasini, V; Gysin, C; Munthe, LA; Niggli, F; Nadal, D; Burgler, S				Traxel, Sabrina; Schadt, Linda; Eyer, Tatjana; Mordasini, Vanessa; Gysin, Claudine; Munthe, Ludvig A.; Niggli, Felix; Nadal, David; Burgler, Simone			Bone marrow T helper cells with a Th1 phenotype induce activation and proliferation of leukemic cells in precursor B acute lymphoblastic leukemia patients	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; CHILDHOOD LEUKEMIA; MULTIPLE-MYELOMA; GENE-EXPRESSION; IFN-GAMMA; TRANSCRIPTION FACTOR; CYTOKINE PRODUCTION; LYMPHOMA-CELLS; IN-VITRO; PRE-B	Precursor B cell acute lymphoblastic leukemia (BCP-ALL) constitutes the leading cause of cancer-related death in children. While chromosomal alterations contribute to BCP-ALL pathogenesis, they are insufficient for leukemia development. Epidemiological data and evidence from a mouse model suggest that immune responses to infections may trigger the emergence of leukemia, but the mechanisms remain unclear. Here, we show that T helper (Th) cells from bone marrow of pediatric BCP-ALL patients can be attracted and activated by autologous BCP-ALL cells. Bone-marrow Th cells supportively interacted with BCP-ALL cells, inducing upregulation of important surface molecules and BCP-ALL cell proliferation. These Th cells displayed a Th1-like phenotype and produced high levels of IFN-gamma. IFN-gamma was responsible for the upregulation of CD38 in BCP-ALL cells, a molecule which we found to be associated with early relapse, and accountable for the production of IP-10, a chemokine involved in BCP-ALL migration and drug resistance. Thus, our data provide mechanistic support for an involvement of Th cell immune responses in the propagation of BCP-ALL and suggest that BCP-ALL cell-supportive Th cells may serve as therapeutic target.	[Traxel, Sabrina; Schadt, Linda; Eyer, Tatjana; Mordasini, Vanessa; Niggli, Felix; Nadal, David; Burgler, Simone] Univ Childrens Hosp Zurich, Expt Infect Dis & Canc Res, Childrens Res Ctr, Zurich, Switzerland; [Gysin, Claudine] Univ Childrens Hosp Zurich, Div Otolaryngol, Childrens Res Ctr, Zurich, Switzerland; [Munthe, Ludvig A.] Univ Oslo, KG Jebsen Ctr B Cell Malignancies, Inst Clin Med, Oslo, Norway	University Children's Hospital Zurich; University Children's Hospital Zurich; University of Oslo	Burgler, S (corresponding author), Univ Childrens Hosp Zurich, Expt Infect Dis & Canc Res, Childrens Res Ctr, Zurich, Switzerland.	simone.buergler@kispi.uzh.ch	Munthe, Ludvig/GRJ-3355-2022	Traxel, Sabrina/0000-0002-9193-5586; Munthe, Ludvig A/0000-0002-0344-3654	Forschungskredit of the University of Zurich; Children's Research Center (CRC) of the Children's Hospital Zurich; Stiftung fur Krebsbekampfung; Krebsliga Schweiz/Swiss Cancer League [KLS 3189-02-2013]; Charles Meyer Cancer Research Initiative	Forschungskredit of the University of Zurich; Children's Research Center (CRC) of the Children's Hospital Zurich; Stiftung fur Krebsbekampfung; Krebsliga Schweiz/Swiss Cancer League; Charles Meyer Cancer Research Initiative	We thank the pediatric patients and donors who provided the clinical samples. This work was supported by the Forschungskredit of the University of Zurich, The Children's Research Center (CRC) of the Children's Hospital Zurich, the Stiftung fur Krebsbekampfung and the Krebsliga Schweiz/Swiss Cancer League (grant number KLS 3189-02-2013), the Krebsliga Schweiz/Swiss Cancer League (grant number KLS 3189-02-2013) and the Charles Meyer Cancer Research Initiative.	Baldridge MT, 2010, NATURE, V465, P793, DOI 10.1038/nature09135; Boyerinas B, 2013, BLOOD, V121, P4821, DOI 10.1182/blood-2012-12-475483; Burgler S, 2015, CRIT REV IMMUNOL, V35, P417, DOI 10.1615/CritRevImmunol.v35.i5.50; Burgler S, 2015, J IMMUNOL, V194, P827, DOI 10.4049/jimmunol.1401350; BUSCHLE M, 1993, J EXP MED, V177, P213, DOI 10.1084/jem.177.1.213; Buske C, 1997, EXP HEMATOL, V25, P329; Cardoso AA, 1996, BLOOD, V88, P41; Chen JJY, 2002, J LEUKOCYTE BIOL, V72, P271; Chillemi A, 2014, FRONT BIOSCI-LANDMRK, V19, P152, DOI 10.2741/4201; Deckert J, 2014, CLIN CANCER RES, V20, P4574, DOI 10.1158/1078-0432.CCR-14-0695; Dhodapkar MV, 2003, J EXP MED, V198, P1753, DOI 10.1084/jem.20031030; Duan CW, 2014, CANCER CELL, V25, P778, DOI 10.1016/j.ccr.2014.04.015; Einav U, 2005, ONCOGENE, V24, P6367, DOI 10.1038/sj.onc.1208797; Fei F, 2015, ONCOTARGET, V6, P11378, DOI 10.18632/oncotarget.3409; Feuerer M, 2001, NAT MED, V7, P452, DOI 10.1038/86523; FLUCKIGER AC, 1992, BLOOD, V80, P3173; Ford AM, 1998, P NATL ACAD SCI USA, V95, P4584, DOI 10.1073/pnas.95.8.4584; Fortney JE, 2001, LEUKEMIA RES, V25, P901, DOI 10.1016/S0145-2126(01)00051-0; Ghia P, 2001, BLOOD, V98, P533, DOI 10.1182/blood.V98.3.533; Gomez AM, 2015, BLOOD CELL MOL DIS, V55, P220, DOI 10.1016/j.bcmd.2015.07.001; Greaves M, 2006, NAT REV CANCER, V6, P193, DOI 10.1038/nrc1816; Greaves M, 2018, NAT REV CANCER, V18, P471, DOI 10.1038/s41568-018-0015-6; Herndler-Brandstetter D, 2011, J IMMUNOL, V186, P6965, DOI 10.4049/jimmunol.1100243; Hersher R, 2012, NAT MED, V18, P1446, DOI 10.1038/nm1012-1446a; Hogan LE, 2011, BLOOD, V118, P5218, DOI 10.1182/blood-2011-04-345595; Iwamoto S, 2007, J CLIN INVEST, V117, P1049, DOI 10.1172/JCI30235; JOHNSON PWM, 1993, BLOOD, V82, P1848, DOI 10.1182/blood.V82.6.1848.bloodjournal8261848; KINLEN L, 1988, LANCET, V2, P1323; Ko RH, 2010, J CLIN ONCOL, V28, P648, DOI 10.1200/JCO.2009.22.2950; Kreis C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170020; Lee Y, 2012, BLOOD, V119, P227, DOI 10.1182/blood-2011-06-357442; Liston A, 2014, NAT REV IMMUNOL, V14, P154, DOI 10.1038/nri3605; Liu ML, 2011, CYTOKINE GROWTH F R, V22, P121, DOI 10.1016/j.cytogfr.2011.06.001; Lokhorst HM, 2015, NEW ENGL J MED, V373, P1207, DOI 10.1056/NEJMoa1506348; MacKenzie J, 2006, HAEMATOL-HEMATOL J, V91, P240; Martin-Lorenzo A, 2015, CANCER DISCOV, V5, P1328, DOI 10.1158/2159-8290.CD-15-0892; McHeyzer-Williams LJ, 2006, CURR TOP MICROBIOL, V311, P59; Mori H, 2002, P NATL ACAD SCI USA, V99, P8242, DOI 10.1073/pnas.112218799; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Mudry RE, 2000, BLOOD, V96, P1926, DOI 10.1182/blood.V96.5.1926.h8001926_1926_1932; Nakase K, 2007, LEUKEMIA, V21, P326, DOI 10.1038/sj.leu.2404497; Nijhof IS, 2015, CLIN CANCER RES, V21, P2802, DOI 10.1158/1078-0432.CCR-14-1813; Oeffinger KC, 2006, NEW ENGL J MED, V355, P1572, DOI 10.1056/NEJMsa060185; Okhrimenko A, 2014, P NATL ACAD SCI USA, V111, P9229, DOI 10.1073/pnas.1318731111; Os A, 2013, CELL REP, V4, P566, DOI 10.1016/j.celrep.2013.07.011; Pai SY, 2004, P NATL ACAD SCI USA, V101, P1993, DOI 10.1073/pnas.0308697100; Pangault C, 2010, LEUKEMIA, V24, P2080, DOI 10.1038/leu.2010.223; Pui CH, 2008, LANCET, V371, P1030, DOI 10.1016/S0140-6736(08)60457-2; Purizaca J, 2012, ARCH MED RES, V43, P89, DOI 10.1016/j.arcmed.2012.03.005; Raetz EA, 2012, HEMATOL-AM SOC HEMAT, P129, DOI 10.1182/asheducation-2012.1.129; Rakoff-Nahoum Seth, 2006, Yale J Biol Med, V79, P123; Reid GSD, 2003, LEUKEMIA RES, V27, P1135, DOI 10.1016/S0145-2126(03)00106-1; Renard N, 1996, BLOOD, V87, P5162, DOI 10.1182/blood.V87.12.5162.bloodjournal87125162; Richardson RB, 2011, LEUKEMIA RES, V35, P1425, DOI 10.1016/j.leukres.2011.07.023; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Taylor GM, 2009, LEUKEMIA, V23, P863, DOI 10.1038/leu.2008.374; Thompson P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100480; Tokoyoda K, 2009, IMMUNITY, V30, P721, DOI 10.1016/j.immuni.2009.03.015; UMETSU DT, 1990, J IMMUNOL, V144, P2550; Vaisitti T, 2015, LEUKEMIA, V29, P356, DOI 10.1038/leu.2014.207; van der Veer MS, 2011, BLOOD CANCER J, V1, DOI 10.1038/bcj.2011.42; Wang D, 2017, LEUKEMIA, V31, P2114, DOI 10.1038/leu.2017.69; Wu SL, 2005, CANCER-AM CANCER SOC, V103, P1054, DOI 10.1002/cncr.20869; Yamashita M, 2004, J BIOL CHEM, V279, P26983, DOI 10.1074/jbc.M403688200; Zaki M, 2000, LEUKEMIA RES, V24, P611, DOI 10.1016/S0145-2126(00)00022-9; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	66	4	5	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2019	38	13					2420	2431		10.1038/s41388-018-0594-4	http://dx.doi.org/10.1038/s41388-018-0594-4			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ7GN	30532071				2022-12-28	WOS:000462588000014
J	Weng, CC; Ding, PY; Liu, YH; Hawse, JR; Subramaniam, M; Wu, CC; Lin, YC; Chen, CY; Hung, WC; Cheng, KH				Weng, Ching-Chieh; Ding, Pei-Ya; Liu, Yu-Hsuan; Hawse, John R.; Subramaniam, Malayannan; Wu, Chia-Chen; Lin, Yu-Chun; Chen, Chiao-Yun; Hung, Wen-Chun; Cheng, Kuang-Hung			Mutant Kras-induced upregulation of CD24 enhances prostate cancer stemness and bone metastasis	ONCOGENE			English	Article							P-SELECTIN; POOR-PROGNOSIS; ADVANCED-STAGE; EXPRESSION; GROWTH; ACTIVATION; ANTIGEN; CELLS; RAF; ADENOCARCINOMA	Prostate cancer (PCA), one of the most common malignant tumors in men, is the second leading cause of cancer deaths in males worldwide. We report here that PCA models harboring conditional LSL/Kras(G12D) or BRAF(F-V600E) allele with prostate-specific abrogated p53 function recapitulate human PCA precursor lesions, histopathology, and clinical behaviors. We found that the development of reprogrammed EMT-like phenotypes and skeleton metastatic behavior requires concurrent activated Kras and p53 depletion in PCA. Microarray analyses of primary PCA cells derived from these models identified several cancer stemness genes including CD24, EpCAM, and CD133 upregulated by KRAS(G12D). Among these stemness markers, we identified CD24 as a key driver of tumorigenesis and metastasis in vivo. These data demonstrate that specific factors involved in cancer stemness are critical for metastatic conversion of PCA and may be ideal targets for therapeutic intervention.	[Weng, Ching-Chieh; Ding, Pei-Ya; Liu, Yu-Hsuan; Wu, Chia-Chen; Lin, Yu-Chun; Cheng, Kuang-Hung] Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung 804, Taiwan; [Hawse, John R.; Subramaniam, Malayannan] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; [Chen, Chiao-Yun] Kaohsiung Med Univ Hosp, Dept Med Imaging, Kaohsiung, Taiwan; [Hung, Wen-Chun; Cheng, Kuang-Hung] Natl Hlth Res Inst, Natl Inst Canc Res, Tainan, Taiwan; [Cheng, Kuang-Hung] Kaohsiung Med Univ, Dept Med Lab Sci & Biotechnol, Kaohsiung, Taiwan	National Sun Yat Sen University; Mayo Clinic; Kaohsiung Medical University; Kaohsiung Medical University Hospital; National Health Research Institutes - Taiwan; Kaohsiung Medical University	Cheng, KH (corresponding author), Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung 804, Taiwan.; Cheng, KH (corresponding author), Natl Hlth Res Inst, Natl Inst Canc Res, Tainan, Taiwan.; Cheng, KH (corresponding author), Kaohsiung Med Univ, Dept Med Lab Sci & Biotechnol, Kaohsiung, Taiwan.	khcheng@faculty.nsysu.edu.tw			MOST from the Ministry of Science and Technology, Taiwan, ROC [105-2320-B-110-004, 105-2321-B-400-010]; Kaohsiung Medical University, Kaohsiung, Taiwan [KMU-TP105G00]	MOST from the Ministry of Science and Technology, Taiwan, ROC; Kaohsiung Medical University, Kaohsiung, Taiwan	Supported by MOST grants 105-2320-B-110-004 and 105-2321-B-400-010 (to K.H. Cheng) from the Ministry of Science and Technology, Taiwan, ROC, and grant KMU-TP105G00 (to K.H. Cheng) from Kaohsiung Medical University, Kaohsiung, Taiwan.	Aigner S, 1997, BLOOD, V89, P3385, DOI 10.1182/blood.V89.9.3385; ARGUELLO F, 1988, CANCER RES, V48, P6876; Bedard PW, 2008, J PHARMACOL EXP THER, V324, P497, DOI 10.1124/jpet.107.128124; Beltran H, 2013, EUR UROL, V63, P920, DOI 10.1016/j.eururo.2012.08.053; BOOKSTEIN R, 1993, CANCER RES, V53, P3369; D'Amico AV, 2002, INT J RADIAT ONCOL, V53, P581, DOI 10.1016/S0360-3016(02)02797-9; Dai JL, 2008, CANCER RES, V68, P5785, DOI 10.1158/0008-5472.CAN-07-6541; Dong JT, 2006, J CELL BIOCHEM, V97, P433, DOI 10.1002/jcb.20696; Dosch JS, 2015, CANCER RES, V75, P4582, DOI 10.1158/0008-5472.CAN-14-2793; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Gangarosa LM, 1997, J BIOL CHEM, V272, P18926, DOI 10.1074/jbc.272.30.18926; Gao JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102590; Gao MQ, 2010, ONCOGENE, V29, P2672, DOI 10.1038/onc.2010.35; Gires O, 2009, NAT REV CANCER, V9, P143, DOI 10.1038/nrc2499-c1; Grammer TC, 1997, ONCOGENE, V14, P1635, DOI 10.1038/sj.onc.1201000; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Gu Z, 2000, ONCOGENE, V19, P1288, DOI 10.1038/sj.onc.1203426; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; ISAACS WB, 1994, COLD SPRING HARB SYM, V59, P653, DOI 10.1101/SQB.1994.059.01.075; ISAACS WB, 1991, CANCER RES, V51, P4716; Jeong JH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003949; Jin CL, 2003, PROSTATE, V57, P160, DOI 10.1002/pros.10283; KANO J, 1994, J CELL PHYSIOL, V161, P358, DOI 10.1002/jcp.1041610221; Kim YJ, 1998, P NATL ACAD SCI USA, V95, P9325, DOI 10.1073/pnas.95.16.9325; Kristiansen G, 2004, PROSTATE, V58, P183, DOI 10.1002/pros.10324; Lee JW, 2012, J NAT MED-TOKYO, V66, P8, DOI 10.1007/s11418-011-0537-7; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lin C, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0056499, 10.1371/journal.pone.0080883, 10.1371/journal.pone.0065734, 10.1371/journal.pone.0070187]; LITVINOV SV, 1994, J CELL BIOL, V125, P437, DOI 10.1083/jcb.125.2.437; Maetzel D, 2009, NAT CELL BIOL, V11, P162, DOI 10.1038/ncb1824; Miki J, 2007, CANCER RES, V67, P3153, DOI 10.1158/0008-5472.CAN-06-4429; Mirza AM, 2004, MOL CELL BIOL, V24, P10868, DOI 10.1128/MCB.24.24.10868-10881.2004; Nubel T, 2009, MOL CANCER RES, V7, P285, DOI 10.1158/1541-7786.MCR-08-0200; Overdevest JB, 2012, P NATL ACAD SCI USA, V109, pE3588, DOI 10.1073/pnas.1113960109; Rivlin Noa, 2011, Genes Cancer, V2, P466, DOI 10.1177/1947601911408889; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Sagiv E, 2008, CANCER RES, V68, P2803, DOI 10.1158/0008-5472.CAN-07-6463; Salmaninejad A, 2015, CLIN LAB, V61, P749, DOI 10.7754/Clin.Lab.2014.141210; Silan F, 2012, MOL BIOL REP, V39, P1595, DOI 10.1007/s11033-011-0898-8; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Sturge J, 2011, NAT REV CLIN ONCOL, V8, P357, DOI 10.1038/nrclinonc.2011.67; Thudi NK, 2011, PROSTATE, V71, P615, DOI 10.1002/pros.21277; Wang SY, 2006, P NATL ACAD SCI USA, V103, P1480, DOI 10.1073/pnas.0510652103; Wee S, 2009, CANCER RES, V69, P4286, DOI 10.1158/0008-5472.CAN-08-4765; Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055; Weng CC, 2017, ONCOGENE, V36, P5532, DOI 10.1038/onc.2017.155; Weng CC, 2016, PANCREAS, V45, P443, DOI 10.1097/MPA.0000000000000460; Yang CH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099412; Yang XR, 2009, CLIN CANCER RES, V15, P5518, DOI 10.1158/1078-0432.CCR-09-0151	50	26	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2019	38	12					2005	2019		10.1038/s41388-018-0575-7	http://dx.doi.org/10.1038/s41388-018-0575-7			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP6UR	30467381	Green Published, hybrid			2022-12-28	WOS:000461822600002
J	Kiavue, N; Cabel, L; Melaabi, S; Bataillon, G; Callens, C; Lerebours, F; Pierga, JY; Bidard, FC				Kiavue, Nicolas; Cabel, Luc; Melaabi, Samia; Bataillon, Guillaume; Callens, Celine; Lerebours, Florence; Pierga, Jean-Yves; Bidard, Francois-Clement			ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics	ONCOGENE			English	Review							GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITOR; CELL LUNG-CANCER; GENOMIC CHARACTERIZATION; BREAST; ACTIVATION; DOMAIN; TUMOR; HER3; LANDSCAPE	HER3, a member of the EGFR family of receptor tyrosine kinases coded by the ERBB3 gene, plays an important role in cancer, despite its lack of intrinsic kinase activity. As with genes coding for potential heterodimeric partners of HER3, EGFR, and HER2, oncogenic mutations of ERBB3 have been explored by several studies. In this review, we discuss the evidence presenting ERBB3 somatic mutations as potential tumoral drivers. We then show that ERBB3 mutations are not uncommon in many cancer types. Finally, we present the recent results of several studies evaluating different therapeutic approaches for treating patients with oncogenic ERBB3 mutations.	[Kiavue, Nicolas; Cabel, Luc; Melaabi, Samia; Bataillon, Guillaume; Callens, Celine; Lerebours, Florence; Pierga, Jean-Yves; Bidard, Francois-Clement] PSL Res Univ, Inst Curie, Dept Med Oncol, Paris, France; [Cabel, Luc; Bidard, Francois-Clement] Versailles St Quentin en Yvelines Univ, Paris Saclay Univ, Paris, France; [Pierga, Jean-Yves] Paris Descartes Univ, Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite	Bidard, FC (corresponding author), PSL Res Univ, Inst Curie, Dept Med Oncol, Paris, France.; Bidard, FC (corresponding author), Versailles St Quentin en Yvelines Univ, Paris Saclay Univ, Paris, France.	francois-clement.bidard@curie.fr						Agus DB, 2002, CANCER CELL, V2, P127, DOI 10.1016/S1535-6108(02)00097-1; Andre F, 2017, CANCER DISCOV, V7, P818, DOI 10.1158/2159-8290.CD-17-0151; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Bidard FC, 2015, ANN ONCOL, V26, P1704, DOI 10.1093/annonc/mdv217; Bose R, 2009, EXP CELL RES, V315, P649, DOI 10.1016/j.yexcr.2008.07.031; Brand TM, 2018, CANCER RES, V78, P2383, DOI 10.1158/0008-5472.CAN-17-1672; Braunstein EM, 2016, LEUKEMIA, V30, P2242, DOI 10.1038/leu.2016.173; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; Burk RD, 2017, NATURE, V543, P378, DOI 10.1038/nature21386; Burstein HJ, 2010, J CLIN ONCOL, V28, P1301, DOI 10.1200/JCO.2009.25.8707; Cabel L, 2018, JCO PRECIS ONCOL, V2, P1, DOI 10.1200/PO.17.00243; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chae J, 2018, BMB REP, V51, P584, DOI 10.5483/BMBRep.2018.51.11.091; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Chang MT, 2018, CANCER DISCOV, V8, P174, DOI 10.1158/2159-8290.CD-17-0321; Chang MT, 2016, NAT BIOTECHNOL, V34, P155, DOI 10.1038/nbt.3391; Chiou VL, 2015, J CLIN ONCOL, V33, P3541, DOI 10.1200/JCO.2015.61.6870; Cho HS, 2002, SCIENCE, V297, P1330, DOI 10.1126/science.1074611; Choudhury NJ, 2016, J CLIN ONCOL, V34, P2165, DOI 10.1200/JCO.2015.66.3047; Collier TS, 2013, J BIOL CHEM, V288, P25254, DOI 10.1074/jbc.M113.474882; Connell CM, 2017, ESMO OPEN, V2, DOI 10.1136/esmoopen-2017-000279; DeMatteo RP, 2009, LANCET, V373, P1097, DOI 10.1016/S0140-6736(09)60500-6; Deniziaut G, 2016, ONCOTARGET, V7, P73337, DOI 10.18632/oncotarget.11819; Desmedt C, 2016, J CLIN ONCOL, V34, P1872, DOI 10.1200/JCO.2015.64.0334; Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121; Frazier NM, 2019, ONCOGENE, V38, P1936, DOI 10.1038/s41388-018-0537-0; Gaborit N, 2016, HUM VACC IMMUNOTHER, V12, P576, DOI 10.1080/21645515.2015.1102809; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Garrett JT, 2011, P NATL ACAD SCI USA, V108, P5021, DOI 10.1073/pnas.1016140108; Gazdar AF, 2009, ONCOGENE, V28, pS24, DOI 10.1038/onc.2009.198; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Hanninen UA, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007200; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Hoadley KA, 2018, CELL, V173, P291, DOI 10.1016/j.cell.2018.03.022; Hutcheson IR, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2848; Hyman DM, 2018, NATURE, V554, P189, DOI 10.1038/nature25475; Iwai Y, 2002, P NATL ACAD SCI USA, V99, P12293, DOI 10.1073/pnas.192461099; Jaiswal BS, 2013, CANCER CELL, V23, P603, DOI 10.1016/j.ccr.2013.04.012; Jeong EG, 2006, INT J CANCER, V119, P2986, DOI 10.1002/ijc.22257; Junttila TT, 2009, CANCER CELL, V15, P429, DOI 10.1016/j.ccr.2009.03.020; Kennedy SP, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00088; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Kumar A, 2008, J CLIN ONCOL, V26, P1742, DOI 10.1200/JCO.2007.12.1178; Li M, 2018, GUT; Li ML, 2014, NAT GENET, V46, P872, DOI 10.1038/ng.3030; Littlefield P, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005786; Loree JM, 2018, JNCI-J NATL CANCER I, V110, P1409, DOI 10.1093/jnci/djy067; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Migden MR, 2018, NEW ENGL J MED, V379, P341, DOI 10.1056/NEJMoa1805131; Milewska M, 2018, THER ADV MED ONCOL, V10, DOI 10.1177/1758834017746040; Mishra R, 2018, ONCOTARGET, V9; Mishra R, 2018, ONCOL REV, V12, P45, DOI 10.4081/oncol.2018.355; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Narayan M, 2009, CANCER RES, V69, P2191, DOI 10.1158/0008-5472.CAN-08-1056; Narkis G, 2007, AM J HUM GENET, V81, P589, DOI 10.1086/520770; Petrelli F, 2017, BREAST CANCER RES TR, V166, P339, DOI 10.1007/s10549-017-4419-x; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Ross JS, 2018, CANCER-AM CANCER SOC, V124, P1358, DOI 10.1002/cncr.31125; Schrock AB, 2017, JAMA ONCOL, V3, P1546, DOI 10.1001/jamaoncol.2017.1051; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Shi FM, 2010, P NATL ACAD SCI USA, V107, P7692, DOI 10.1073/pnas.1002753107; Shigematsu H, 2006, INT J CANCER, V118, P257, DOI 10.1002/ijc.21496; Sithanandam G, 2008, CANCER GENE THER, V15, P413, DOI 10.1038/cgt.2008.15; Skoulidis F, 2015, CANCER DISCOV, V5, P860, DOI 10.1158/2159-8290.CD-14-1236; Steinkamp MP, 2014, MOL CELL BIOL, V34, P965, DOI 10.1128/MCB.01605-13; Strickley JD, 2018, EXP HEMATOL ONCOL, V7, DOI 10.1186/s40164-018-0111-z; Tamura S, 2018, BLADDER CANCER, V4, P77, DOI 10.3233/BLC-170144; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Umelo I, 2016, ONCOTARGET, V7, P3068, DOI 10.18632/oncotarget.6585; Verlingue L, 2018, EUR J CANCER, V92, P1, DOI 10.1016/j.ejca.2017.12.020; Wang SZE, 2006, CANCER CELL, V10, P25, DOI 10.1016/j.ccr.2006.05.023; Wang ZX, 2017, METHODS MOL BIOL, V1652, P3, DOI 10.1007/978-1-4939-7219-7_1; Watson P, 2005, FAM CANCER, V4, P245, DOI 10.1007/s10689-004-7994-z; Yin MX, 2015, ACTA BIOCH BIOPH SIN, V47, P39, DOI 10.1093/abbs/gmu111; Yun CH, 2007, CANCER CELL, V11, P217, DOI 10.1016/j.ccr.2006.12.017; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013	81	47	50	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					487	502		10.1038/s41388-019-1001-5	http://dx.doi.org/10.1038/s41388-019-1001-5			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31519989				2022-12-28	WOS:000509718300001
J	Liu, X; Huang, QL; Chen, LH; Zhang, HL; Schonbrunn, E; Chen, JD				Liu, Xia; Huang, Qingling; Chen, Lihong; Zhang, Huilai; Schonbrunn, Ernst; Chen, Jiandong			Tumor-derived CK1 alpha mutations enhance MDMX inhibition of p53	ONCOGENE			English	Article							CASEIN KINASE 1-ALPHA; MYELODYSPLASTIC SYNDROME; BETA-CATENIN; DEGRADATION; UBIQUITINATION; IDENTIFICATION; DESTRUCTION; DELETION; COMPLEX; SWITCH	Somatic missense mutations of the CSNK1A1 gene encoding casein kinase 1 alpha (CK1 alpha) occur in a subset of myelodysplastic syndrome (MDS) with del(5q) karyotype. The chromosomal deletion causes CSNK1A1 haplo-insufficiency. CK1 alpha mutations have also been observed in a variety of solid and hematopoietic tumors at low frequency. The functional consequence of CK1 alpha mutation remains unknown. Here we show that tumor-associated CK1 alpha mutations exclusively localize to the substrate-binding cleft. Functional analysis of recurrent mutants E98K and D140A revealed enhanced binding to the p53 inhibitor MDMX, increased ability to stimulate MDMX-p53 binding, and increased suppression of p21 expression. Furthermore, E98K and D140A mutants have reduced ability to promote phosphorylation of beta-catenin, resulting in enhanced Wnt signaling. The results suggest that the CK1 alpha mutations observed in tumors cause gain-of-function in cooperating with MDMX and inhibiting p53, and partial loss-of-function in suppressing Wnt signaling. These functional changes may promote expansion of abnormal myeloid progenitors in del(5q) MDS, and in rare cases drive the progression of other tumors.	[Liu, Xia; Huang, Qingling; Chen, Lihong; Chen, Jiandong] H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Dept, 12902 Magnolia Dr, Tampa, FL 33612 USA; [Liu, Xia; Zhang, Huilai] Tianjin Med Univ Canc Inst & Hosp, Tianjin Clin Res Ctr Canc, Sino US Ctr Lymphoma & Leukemia Res,Dept Lymphoma, Natl Clin Res Ctr Canc,Key Lab Canc Prevent & The, Tianjin 300060, Peoples R China; [Schonbrunn, Ernst] H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Dept, 12902 Magnolia Dr, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; Tianjin Medical University; H Lee Moffitt Cancer Center & Research Institute	Chen, JD (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Dept, 12902 Magnolia Dr, Tampa, FL 33612 USA.	Jiandong.chen@moffitt.org	Huang, Qingling/AAO-1728-2021	Zhang, Huilai/0000-0002-8558-3131; Schonbrunn, Ernst/0000-0002-3589-3510; Huang, Qingling/0000-0002-0538-8249	National Institutes of Health [CA141244, CA186917]; NCI Cancer Center Support Grant [P30-CA076292]; Tianjin Medical University Cancer Institute and Hospital	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Tianjin Medical University Cancer Institute and Hospital	We would like to thank the Moffitt Flow Cytometry Core. This work was supported in part by grants from the National Institutes of Health (CA141244, CA186917) (JC), and by the NCI Cancer Center Support Grant P30-CA076292. XL was partly supported by Tianjin Medical University Cancer Institute and Hospital.	Bello E, 2015, BRIT J HAEMATOL, V171, P210, DOI 10.1111/bjh.13563; Chen LH, 2005, MOL CELL BIOL, V25, P6509, DOI 10.1128/MCB.25.15.6509-6520.2005; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Drexler HG, 2009, LEUKEMIA RES, V33, P1011, DOI 10.1016/j.leukres.2009.03.005; Ebert BL, 2008, NATURE, V451, P335, DOI 10.1038/nature06494; Elyada E, 2011, NATURE, V470, P409, DOI 10.1038/nature09673; Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121; Heuser M, 2015, LEUKEMIA, V29, P1942, DOI 10.1038/leu.2015.49; Huart AS, 2009, J BIOL CHEM, V284, P32384, DOI 10.1074/jbc.M109.052647; Jaras M, 2014, J EXP MED, V211, P605, DOI 10.1084/jem.20131033; Knippschild U, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00096; Komrokji RS, 2013, BEST PRACT RES CL HA, V26, P365, DOI 10.1016/j.beha.2013.10.013; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kronke J, 2015, NATURE, V523, P183, DOI 10.1038/nature14610; Kronke J, 2014, SCIENCE, V343, P301, DOI 10.1126/science.1244851; Kulasekararaj AG, 2013, BRIT J HAEMATOL, V160, P660, DOI 10.1111/bjh.12203; Lu G, 2014, SCIENCE, V343, P305, DOI 10.1126/science.1244917; Petzold G, 2016, NATURE, V532, P127, DOI 10.1038/nature16979; Pribluda A, 2013, CANCER CELL, V24, P242, DOI 10.1016/j.ccr.2013.06.005; Schneider RK, 2016, NAT MED, V22, P288, DOI 10.1038/nm.4047; Schneider RK, 2014, CANCER CELL, V26, P509, DOI 10.1016/j.ccr.2014.08.001; Sinnberg T, 2010, CANCER RES, V70, P6999, DOI 10.1158/0008-5472.CAN-10-0645; Smith AE, 2015, LANCET HAEMATOL, V2, pE212, DOI 10.1016/S2352-3026(15)00050-2; Sobrado P, 2005, J CELL BIOCHEM, V94, P217, DOI 10.1002/jcb.20350; Starczynowski DT, 2010, NAT MED, V16, P49, DOI 10.1038/nm.2054; Tsujioka T, 2013, EXP HEMATOL, V41, P189, DOI 10.1016/j.exphem.2012.10.006; Wang L, 2008, HAEMATOL-HEMATOL J, V93, P994, DOI 10.3324/haematol.12603; Wei X, 2016, P NATL ACAD SCI USA, V113, pE2558, DOI 10.1073/pnas.1603838113; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wu SF, 2012, MOL CELL BIOL, V32, P4821, DOI 10.1128/MCB.00851-12	30	3	4	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	1					176	186		10.1038/s41388-019-0979-z	http://dx.doi.org/10.1038/s41388-019-0979-z			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG3NM	31462704	Green Accepted			2022-12-28	WOS:000509849200012
J	Wei, LY; Zhang, XM; Wang, J; Ye, QR; Zheng, X; Peng, Q; Zheng, Y; Liu, PS; Zhang, XY; Li, ZS; Liu, C; Yan, Q; Li, GY; Ma, J				Wei, Lingyu; Zhang, Xuemei; Wang, Jia; Ye, Qiurong; Zheng, Xiang; Peng, Qiu; Zheng, Ying; Liu, Peishan; Zhang, Xiaoyue; Li, Zhengshuo; Liu, Can; Yan, Qun; Li, Guiyuan; Ma, Jian			Lactoferrin deficiency induces a pro-metastatic tumor microenvironment through recruiting myeloid-derived suppressor cells in mice	ONCOGENE			English	Article							TOLL-LIKE RECEPTOR; IMMUNOSUPPRESSIVE ACTIVITY; NASOPHARYNGEAL CARCINOMA; PANCREATIC-CANCER; IMMUNE; LACTOTRANSFERRIN; DIFFERENTIATION; EXPRESSION; PROMOTES; MONOCYTES	Lactoferrin, an innate immunity molecule, is involved in anti-inflammatory, anti-microbial, and anti-tumor activities. We previously reported that lactoferrin is downregulated in specimens of nasopharyngeal carcinoma and negatively associated with tumor progression and metastasis of patients with nasopharyngeal carcinoma. However, the relationship between lactoferrin and the pro-metastatic microenvironment has not been reported yet. Here, by using the lactoferrin knockout mouse, we found that lactoferrin deficiency facilitated melanoma cells metastasizing to lungs, through recruiting myeloid-derived suppressor cells (MDSCs) in the lungs. Mechanistic studies showed that in the lung microenvironment of the lactoferrin knockout mice, the TLR9 signaling was the most repressed signaling. Lactoferrin can induce MDSCs differentiation and apoptosis, as well as upregulate TLR9 expression. TLR9 agonist or lactoferrin treatment can rescue this phenotype in the tumor metastasis mouse model. Our results suggest a protective role of lactoferrin in cancer metastasis, along with a deficiency in certain components of the innate immune system, may lead to a pro-metastatic tumor microenvironment.	[Wei, Lingyu; Zhang, Xuemei; Li, Guiyuan; Ma, Jian] Cent S Univ, Hunan Key Lab Nonresolving Inflammat & Canc, Xiangya Hosp 3, Changsha, Peoples R China; [Wei, Lingyu; Zhang, Xuemei; Wang, Jia; Ye, Qiurong; Zheng, Xiang; Peng, Qiu; Liu, Peishan; Zhang, Xiaoyue; Li, Zhengshuo; Liu, Can; Li, Guiyuan; Ma, Jian] Cent S Univ, Sch Basic Med, Canc Res Inst, Changsha, Peoples R China; [Wei, Lingyu; Li, Guiyuan; Ma, Jian] Minist Hlth, Key Lab Carcinogenesis, Changsha, Peoples R China; [Wei, Lingyu; Li, Guiyuan; Ma, Jian] Minist Hlth, Key Lab Carcinogenesis & Canc Invas, Changsha, Peoples R China; [Wei, Lingyu; Zhang, Xuemei; Ma, Jian] Cent S Univ, Hunan Key Lab Translat Radiat Oncol, Hunan Canc Hosp, Changsha, Peoples R China; [Wei, Lingyu; Zhang, Xuemei; Ma, Jian] Cent S Univ, Xiangya Sch Med, Affiliated Canc Hosp, Changsha, Peoples R China; [Zheng, Ying] Cent S Univ, Xiangya Hosp 2, Ctr Med Res, Changsha, Peoples R China; [Yan, Qun] Cent S Univ, Xiangya Hosp, Dept Clin Lab, Changsha, Peoples R China	Central South University; Central South University; Central South University; Central South University; Central South University; Central South University	Ma, J (corresponding author), Cent S Univ, Hunan Key Lab Nonresolving Inflammat & Canc, Xiangya Hosp 3, Changsha, Peoples R China.; Ma, J (corresponding author), Cent S Univ, Sch Basic Med, Canc Res Inst, Changsha, Peoples R China.; Ma, J (corresponding author), Minist Hlth, Key Lab Carcinogenesis, Changsha, Peoples R China.; Ma, J (corresponding author), Minist Hlth, Key Lab Carcinogenesis & Canc Invas, Changsha, Peoples R China.; Ma, J (corresponding author), Cent S Univ, Hunan Key Lab Translat Radiat Oncol, Hunan Canc Hosp, Changsha, Peoples R China.; Ma, J (corresponding author), Cent S Univ, Xiangya Sch Med, Affiliated Canc Hosp, Changsha, Peoples R China.	majian@csu.edu.cn		Ma, Jian/0000-0001-9395-0416	National Natural Science Foundation of China [81672889, 81874170, 81472694]; China 111 Project [111-2-12]; Hunan Province Science and Technology Project [2016JC2035]; Open Research Fund Program of Key Laboratory of Translational Radiation Oncology, Hunan Province [2015TP1009]; Independent Exploration and Innovation Project of Central South University [178301003]; National College Students' Innovation and Entrepreneurship Training Program of China [201810533376, GS201910533237]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China 111 Project(Ministry of Education, China - 111 Project); Hunan Province Science and Technology Project; Open Research Fund Program of Key Laboratory of Translational Radiation Oncology, Hunan Province; Independent Exploration and Innovation Project of Central South University; National College Students' Innovation and Entrepreneurship Training Program of China	This work was funded by National Natural Science Foundation of China (81672889, 81874170, and 81472694), China 111 Project (111-2-12), Hunan Province Science and Technology Project (2016JC2035), Open Research Fund Program of Key Laboratory of Translational Radiation Oncology, Hunan Province (2015TP1009), Independent Exploration and Innovation Project of Central South University (178301003), and National College Students' Innovation and Entrepreneurship Training Program of China (201810533376, GS201910533237). We thank Professors Wen Zhou and Ya Cao for providing reagents; Professor Penghui Zhou providing key suggestions.	Acharya KR, 2014, J BIOL CHEM, V289, P17406, DOI 10.1074/jbc.R113.546218; Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Aghaeepour N, 2017, J IMMUNOL, V199, P2171, DOI 10.4049/jimmunol.1700421; Aguirre-Gamboa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074250; Amit I, 2009, SCIENCE, V326, P257, DOI 10.1126/science.1179050; Balkwill FR, 2012, J CELL SCI, V125, P5591, DOI 10.1242/jcs.116392; Ballas ZK, 2001, J IMMUNOL, V167, P4878, DOI 10.4049/jimmunol.167.9.4878; Binnewies M, 2018, NAT MED, V24, P541, DOI 10.1038/s41591-018-0014-x; Blais A, 2014, BIOMETALS, V27, P857, DOI 10.1007/s10534-014-9779-7; Casey T, 2009, BREAST CANCER RES TR, V114, P47, DOI 10.1007/s10549-008-9982-8; Castano Z, 2018, NAT CELL BIOL, V20, P1084, DOI 10.1038/s41556-018-0173-5; Cen XH, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00878; Chen HM, 2018, J CLIN INVEST, V128, P5647, DOI 10.1172/JCI97570; Clark CE, 2007, CANCER RES, V67, P9518, DOI 10.1158/0008-5472.CAN-07-0175; Clavijo PE, 2019, CANCER IMMUNOL RES, V7, P282, DOI 10.1158/2326-6066.CIR-18-0156; Condamine T, 2015, J LEUKOCYTE BIOL, V98, P913, DOI 10.1189/jlb.4RI0515-204R; Deng M, 2013, ONCOGENE, V32, P4273, DOI 10.1038/onc.2012.434; Fang LS, 2019, ONCOGENE, V38, P896, DOI 10.1038/s41388-018-0484-9; Fehri E, 2016, CURR RES TRANSL MED, V64, P155, DOI 10.1016/j.retram.2016.01.010; Gabrilovich DI, 2017, CANCER IMMUNOL RES, V5, P3, DOI 10.1158/2326-6066.CIR-16-0297; Gallina G, 2006, J CLIN INVEST, V116, P2777, DOI 10.1172/JCI28828; Gonzalez-Chavez SA, 2009, INT J ANTIMICROB AG, V33, DOI 10.1016/j.ijantimicag.2008.07.020; He YM, 2018, NAT MED, V24, P224, DOI 10.1038/nm.4467; Hiratsuka S, 2008, NAT CELL BIOL, V10, P1349, DOI 10.1038/ncb1794; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Hossain DMS, 2015, CLIN CANCER RES, V21, P3771, DOI 10.1158/1078-0432.CCR-14-3145; Huh SJ, 2010, CANCER RES, V70, P6071, DOI 10.1158/0008-5472.CAN-09-4442; Ichikawa M, 2011, MOL CANCER RES, V9, P133, DOI 10.1158/1541-7786.MCR-10-0394; Jiang J, 2018, EXP CELL RES, V367, P81, DOI 10.1016/j.yexcr.2018.03.025; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kerkar SP, 2012, CANCER RES, V72, P3125, DOI 10.1158/0008-5472.CAN-11-4094; Kitakaze T, 2018, MOL MED REP, V17, P5912, DOI 10.3892/mmr.2018.8603; Kolonin MG, 2017, CANCER RES, V77, P3144, DOI 10.1158/0008-5472.CAN-16-0708; Kumar V, 2016, TRENDS IMMUNOL, V37, P208, DOI 10.1016/j.it.2016.01.004; Kusmartsev S, 2008, CLIN CANCER RES, V14, P8270, DOI 10.1158/1078-0432.CCR-08-0165; Lee Jae-Hye, 2016, Oncotarget, V7, P79774, DOI 10.18632/oncotarget.12967; Legrand D, 2012, BIOCHEM CELL BIOL, V90, P252, DOI [10.1139/O11-056, 10.1139/o11-056]; Li HY, 2017, J AGR FOOD CHEM, V65, P10464, DOI 10.1021/acs.jafc.7b03390; Lim KH, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a011247; Maglione PJ, 2015, ANN NY ACAD SCI, V1356, P1, DOI 10.1111/nyas.12763; Mantovani A, 2018, IMMUNOL REV, V281, P57, DOI 10.1111/imr.12614; Marigo I, 2008, IMMUNOL REV, V222, P162, DOI 10.1111/j.1600-065X.2008.00602.x; Martinez-Campos C, 2017, VIRAL IMMUNOL, V30, P98, DOI 10.1089/vim.2016.0103; Mei SY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135867; Moreno-Exposito L, 2018, LIFE SCI, V195, P61, DOI 10.1016/j.lfs.2018.01.002; Oh K, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3473; Ortiz ML, 2014, CANCER IMMUNOL RES, V2, P50, DOI 10.1158/2326-6066.CIR-13-0129; Perdijk O, 2018, NUTRIENTS, V10, DOI 10.3390/nu10070848; Raber P, 2012, IMMUNOL INVEST, V41, P614, DOI 10.3109/08820139.2012.680634; Ribechini E, 2017, BLOOD ADV, V1, P947, DOI 10.1182/bloodadvances.2017006858; Rodrigues L, 2009, CRIT REV FOOD SCI, V49, P203, DOI 10.1080/10408390701856157; Ruffell B, 2013, GENE DEV, V27, P2086, DOI 10.1101/gad.224899.113; Sathyanesan A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05656-w; Silvestrini MT, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90521; Simpson KD, 2012, J IMMUNOL, V189, P5533, DOI 10.4049/jimmunol.1201161; Siqueiros-Cendon T, 2014, ACTA PHARMACOL SIN, V35, P557, DOI 10.1038/aps.2013.200; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takahashi K, 2018, ONCOGENE, V37, P2757, DOI 10.1038/s41388-018-0144-0; Tasli PN, 2014, APPL BIOCHEM BIOTECH, V174, P2257, DOI 10.1007/s12010-014-1204-8; Telang S, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091228; Teng CT, 2010, BIOMETALS, V23, P359, DOI 10.1007/s10534-010-9310-8; Totiger TM, 2019, MOL CANCER THER, V18, P301, DOI 10.1158/1535-7163.MCT-18-0464; Uchida R, 2017, BIOCHEM CELL BIOL, V95, P64, DOI 10.1139/bcb-2016-0147; Valenti P, 2014, BIOMETALS, V27, P803, DOI 10.1007/s10534-014-9787-7; Vandrovcova M, 2015, J BIOMED MATER RES A, V103, P525, DOI 10.1002/jbm.a.35199; Velusamy SK, 2014, ANTIMICROB AGENTS CH, V58, P397, DOI 10.1128/AAC.00020-13; Velusamy SK, 2013, J PERIODONTOL, V84, P1690, DOI 10.1902/jop.2013.120587; Wakabayashi H, 2014, J INFECT CHEMOTHER, V20, P666, DOI 10.1016/j.jiac.2014.08.003; Wang B, 2019, CRIT REV FOOD SCI, V59, P580, DOI 10.1080/10408398.2017.1381583; Wang C, 2014, ASIAN PAC J CANCER P, V15, P4187, DOI 10.7314/APJCP.2014.15.10.4187; Won H, 2017, J LEUKOCYTE BIOL, V102, P423, DOI 10.1189/jlb.3MA1016-451RR; Xie F, 2018, ACTA BIOCH BIOPH SIN, V50, P121, DOI 10.1093/abbs/gmx123; Yang L, 2008, CANCER CELL, V13, P23, DOI 10.1016/j.ccr.2007.12.004; Yang Q, 2017, ONCOGENE, V36, P2969, DOI 10.1038/onc.2016.448; Ye QR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103298; Zambirinis CP, 2015, J EXP MED, V212, P2077, DOI 10.1084/jem.20142162; Zhang CX, 2019, CELL DEATH DIFFER, V26, P2314, DOI 10.1038/s41418-019-0302-0; Zhang H, 2017, ONCOGENE, V36, P2095, DOI 10.1038/onc.2016.367; Zhang WL, 2015, TUMOR BIOL, V36, P675, DOI 10.1007/s13277-014-2650-1; Zhou YH, 2008, INT J CANCER, V123, P2065, DOI 10.1002/ijc.23727; Zoglmeier C, 2011, CLIN CANCER RES, V17, P1765, DOI 10.1158/1078-0432.CCR-10-2672	81	12	18	6	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	1					122	135		10.1038/s41388-019-0970-8	http://dx.doi.org/10.1038/s41388-019-0970-8			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG3NM	31462711				2022-12-28	WOS:000509849200008
J	Yu, XF; Wang, RK; Zhang, YN; Zhou, L; Wang, W; Liu, HD; Li, W				Yu, Xinfang; Wang, Ruike; Zhang, Yangnan; Zhou, Li; Wang, Wei; Liu, Haidan; Li, Wei			Skp2-mediated ubiquitination and mitochondrial localization of Akt drive tumor growth and chemoresistance to cisplatin	ONCOGENE			English	Article							SENSITIZES NASOPHARYNGEAL CARCINOMA; POOR-PROGNOSIS; CANCER CELLS; SKP2; ACTIVATION; GLYCOLYSIS; LUNG; DEGRADATION; CONTRIBUTES; RESISTANCE	The E3 ligase S-phase kinase-associated protein 2(Skp2) is overexpressed in human cancers and correlated with poor prognosis, but its contributions to tumorigenesis and chemoresistance in nasopharyngeal carcinoma (NPC) are not evident. Herein we show that Skp2 is highly expressed in NPC tumor tissues and cell lines. Knockdown of Skp2 suppresses tumor cell growth, colony formation, glycolysis, and in vivo tumor growth. Skp2 promotes Akt K63-mediated ubiquitination and activation, which is required for EGF-induced Akt mitochondrial localization. Importantly, K63-linked ubiquitination enhances the interaction between Akt and HK2 and eventually increases HK2 phosphorylation on Thr473 and mitochondrial localization. Overexpression of Skp2 impaired the intrinsic apoptotic pathway and confers cisplatin resistance. Moreover, ectopic expression of Myr-Akt1 or phosphomimetic HK2-T473D rescued cisplatin-induced tumor suppression in Skp2 knockdown stable cells. Also, depletion of Akt ubiquitination enhances the antitumor efficacy of cisplatin in vitro and in vivo. Finally, we demonstrated that Skp2 is positively correlated with p-Akt and HK2 in NPC tumor tissues. This study highlights the clinical value of Skp2 targeting in NPC treatment.	[Yu, Xinfang; Liu, Haidan] Cent S Univ, Dept Cardiovasc Surg, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China; [Yu, Xinfang; Liu, Haidan] Cent S Univ, Clin Ctr Gene Diag & Therapy, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China; [Yu, Xinfang] Cleveland Clin, Dept Canc Biol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA; [Wang, Ruike; Zhang, Yangnan] Cent S Univ, Xiangya Sch Med, Changsha 410000, Hunan, Peoples R China; [Zhou, Li] Cent S Univ, Dept Pathol, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China; [Wang, Wei; Li, Wei] Cent S Univ, Dept Radiol, Xiangya Hosp 3, Changsha 410000, Hunan, Peoples R China	Central South University; Central South University; Cleveland Clinic Foundation; Central South University; Central South University; Central South University	Liu, HD (corresponding author), Cent S Univ, Dept Cardiovasc Surg, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.; Liu, HD (corresponding author), Cent S Univ, Clin Ctr Gene Diag & Therapy, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.; Wang, W; Li, W (corresponding author), Cent S Univ, Dept Radiol, Xiangya Hosp 3, Changsha 410000, Hunan, Peoples R China.	cjr.wangwei@vip.163.com; haidanliu@csu.edu.cn; weililx@csu.edu.cn			National Natural Science Foundation of China [81572280, 81502121, 81401548]; Natural Science Foundation of Hunan Province [2018JJ3787, 2019JJ40420]; New Xiangya Talent Project of the Third Xiangya Hospital of Central South University [JY2015011]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Hunan Province(Natural Science Foundation of Hunan Province); New Xiangya Talent Project of the Third Xiangya Hospital of Central South University	This work was supported by the National Natural Science Foundation of China (Nos. 81572280, 81502121, and 81401548), the Natural Science Foundation of Hunan Province (2018JJ3787 and 2019JJ40420), and the New Xiangya Talent Project of the Third Xiangya Hospital of Central South University (No. JY2015011).	Bhattacharyya T, 2018, J ONCOL, V2018, DOI 10.1155/2018/3725837; Bijur GN, 2003, J NEUROCHEM, V87, P1427, DOI 10.1046/j.1471-4159.2003.02113.x; Bissey PA, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0050-x; Byun WS, 2018, BIOCHEM PHARMACOL, V158, P84, DOI 10.1016/j.bcp.2018.10.002; Chae YC, 2016, CANCER CELL, V30, P257, DOI 10.1016/j.ccell.2016.07.004; Chan CH, 2013, CELL, V154, P556, DOI 10.1016/j.cell.2013.06.048; Chan CH, 2012, CELL, V149, P1098, DOI 10.1016/j.cell.2012.02.065; Chen D, 2011, CURR CANCER DRUG TAR, V11, P239, DOI 10.2174/156800911794519752; Cheng CY, 2018, BIOMED PHARMACOTHER, V108, P194, DOI 10.1016/j.biopha.2018.09.031; Fan L, 2018, INT J MOL MED, V42, P2247, DOI 10.3892/ijmm.2018.3778; Feng SY, 2017, CELL CYCLE, V16, P869, DOI 10.1080/15384101.2017.1308617; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Fu HC, 2016, ONCOTARGET, V7, P44047, DOI 10.18632/oncotarget.10057; Gallo LH, 2017, CELL CYCLE, V16, P634, DOI 10.1080/15384101.2017.1288326; Gao W, 2017, CANCER MED-US, V6, P439, DOI 10.1002/cam4.982; Ghosh JC, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju502; Katano A, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010502; Kuang CM, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.271; Lam W K Jacky, 2018, F1000Res, V7, DOI 10.12688/f1000research.15066.1; Lee AWM, 2015, J CLIN ONCOL, V33, P3356, DOI 10.1200/JCO.2015.60.9347; Lee AWM, 2005, J CLIN ONCOL, V23, P6966, DOI 10.1200/JCO.2004.00.7542; Lee SW, 2015, MOL CELL, V57, P1022, DOI 10.1016/j.molcel.2015.01.015; Lee VH, 2018, J ONCOL PRACT, V14, P594, DOI 10.1200/JOP.18.00219; Li SN, 2017, BRIT J CANCER, V117, P1518, DOI 10.1038/bjc.2017.323; Li S, 2017, CELL CYCLE, V16, P1601, DOI 10.1080/15384101.2017.1356508; Li W, 2018, J CELL MOL MED, V22, P6213, DOI 10.1111/jcmm.13908; Li W, 2018, CELL SIGNAL, V50, P131, DOI 10.1016/j.cellsig.2018.07.001; Li W, 2017, ONCOTARGET, V8, P32586, DOI 10.18632/oncotarget.15937; Li W, 2013, CANCER RES, V73, P6938, DOI 10.1158/0008-5472.CAN-13-0913; Liu F, 2018, CANCER BIOL THER, V19, P534, DOI 10.1080/15384047.2018.1450119; Liu HD, 2016, ONCOTARGET, V7, P56338, DOI 10.18632/oncotarget.10841; Mair R, 2018, CANCER RES, V78, P5408, DOI 10.1158/0008-5472.CAN-18-0759; Majewski N, 2004, MOL CELL, V16, P819, DOI 10.1016/j.molcel.2004.11.014; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; Roberts DJ, 2013, J BIOL CHEM, V288, P23798, DOI 10.1074/jbc.M113.482026; Ruan D, 2017, ONCOGENE, V36, P4299, DOI 10.1038/onc.2017.64; Shi C, 2018, ONCOGENE, V37, P3260, DOI 10.1038/s41388-018-0217-0; Shuang H, 2019, CLIN TRANSL ONCOL, V21, P213, DOI 10.1007/s12094-018-1911-7; Su CC, 2012, AM J PHYSIOL-HEART C, V302, pH716, DOI 10.1152/ajpheart.00455.2011; Swatek KN, 2016, CELL RES, V26, P399, DOI 10.1038/cr.2016.39; Tian YF, 2013, TUMOR BIOL, V34, P1107, DOI 10.1007/s13277-013-0652-z; Timmerbeul I, 2006, P NATL ACAD SCI USA, V103, P14009, DOI 10.1073/pnas.0606316103; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Wang J, 2014, ONCOTARGET, V5, P5591, DOI 10.18632/oncotarget.2149; Wang ZW, 2012, FRONT ONCOL, V1, DOI [10.3389/fonc.2011.00057, 10.3389/fonc.2012.00201]; Wu J, 2012, MOL CELL, V46, P351, DOI 10.1016/j.molcel.2012.02.018; Xiao L, 2014, ONCOGENE, V33, P4568, DOI 10.1038/onc.2014.32; Xie P, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.195; Yang TT, 2018, ONCOGENE, V37, P5997, DOI 10.1038/s41388-018-0386-x; Yang WL, 2009, SCIENCE, V325, P1134, DOI 10.1126/science.1175065; Yao F, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04620-y; Yu XF, 2017, MOL CARCINOGEN, V56, P1414, DOI 10.1002/mc.22602; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; Zhang XY, 2018, INT J BIOCHEM CELL B, V95, P9, DOI 10.1016/j.biocel.2017.12.010; Zhao HL, 2013, CANCER CELL, V24, P645, DOI 10.1016/j.ccr.2013.09.021; Zhen Y, 2017, ONCOGENE, V36, P275, DOI 10.1038/onc.2016.201	57	36	39	4	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2019	38	50					7457	7472		10.1038/s41388-019-0955-7	http://dx.doi.org/10.1038/s41388-019-0955-7			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JV7GY	31435020				2022-12-28	WOS:000502530500002
J	Berggren, KL; Cruz, SR; Hixon, MD; Cowan, AT; Keysar, SB; Craig, S; James, J; Barry, M; Ozbun, MA; Jimeno, A; McCance, DJ; Beswick, EJ; Gan, GN				Berggren, Kiersten L.; Cruz, Sebastian Restrepo; Hixon, Michael D.; Cowan, Andrew T.; Keysar, Stephen B.; Craig, Stephanie; James, Jacqueline; Barry, Marc; Ozbun, Michelle A.; Jimeno, Antonio; McCance, Dennis J.; Beswick, Ellen J.; Gan, Gregory N.			MAPKAPK2 (MK2) inhibition mediates radiation-induced inflammatory cytokine production and tumor growth in head and neck squamous cell carcinoma	ONCOGENE			English	Article							HUMAN-PAPILLOMAVIRUS; ENDOTHELIAL-CELLS; NECROSIS-FACTOR; KINASE 2; CANCER; SMOKING; FIBROBLASTS; EXPRESSION; HSP27; IL-6	Radiation therapy (RT) is a cornerstone of treatment in the management of head and neck squamous cell carcinomas (HNSCC), yet treatment failure and disease recurrence are common. The p38/MK2 pathway is activated in response to cellular stressors, including radiation, and promotes tumor inflammation in a variety of cancers. We investigated MK2 pathway activation in HNSCC and the interaction of MK2 and RT in vitro and in vivo. We used a combination of an oropharyngeal SCC tissue microarray, HNSCC cell lines, and patient-derived xenograft (PDX) tumor models to study the effect of RT on MK2 pathway activation and to determine how inhibition of MK2 by pharmacologic (PF-3644022) and genetic (siRNA) methods impacts tumor growth. We show that high phosphorylated MK2 (p-MK2) levels are associated with worsened disease-specific survival in p16-negative HNSCC patients. RT increased p-MK2 in both p16-positive, HPV-positive and p16-negative, HPV-negative HNSCC cell lines. Pharmacologic inhibition or gene silencing of MK2 in vitro abrogated RT-induced increases in p-MK2; inflammatory cytokine expression and expression of the downstream MK2 target, heat shock protein 27 (HSP27); and markers of epithelial-to-mesenchymal transition. Mouse PDX models treated with a combination of RT and MK2 inhibitor experienced decreased tumor growth and increased survival. Our results suggest that MK2 is a potential prognostic biomarker for head and neck cancer and that MK2 pathway activation can mediate radiation resistance in HNSCC.	[Berggren, Kiersten L.; Cruz, Sebastian Restrepo; Hixon, Michael D.] Univ New Mexico, Dept Internal Med, Sect Radiat Oncol, Albuquerque, NM 87131 USA; [Berggren, Kiersten L.; Cruz, Sebastian Restrepo; Hixon, Michael D.] Univ New Mexico, Ctr Comprehens Canc, Canc Therapeut Program, Albuquerque, NM 87131 USA; [Cowan, Andrew T.] Univ New Mexico, Dept Surg, Div Otolaryngol, Albuquerque, NM 87131 USA; [Cowan, Andrew T.; Ozbun, Michelle A.] Univ New Mexico, Ctr Comprehens Canc, Canc Biol & Signaling Program, Albuquerque, NM 87131 USA; [Keysar, Stephen B.; Jimeno, Antonio] Univ Colorado Denver, Dept Med, Div Med Oncol, Aurora, CO USA; [Craig, Stephanie; James, Jacqueline] Queens Univ, Ctr Canc Res & Cell Biol, Belfast BT9 7BL, Antrim, North Ireland; [Barry, Marc; McCance, Dennis J.] Univ New Mexico, Dept Pathol, Albuquerque, NM 87131 USA; [Ozbun, Michelle A.] Univ New Mexico, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA; [Beswick, Ellen J.] Univ Utah, Dept Internal Med, Div Gastroenterol Hepataol & Nutr, Salt Lake City, UT 84112 USA; [Gan, Gregory N.] Univ Kansas, Med Ctr, Dept Radiat Oncol, Kansas City, KS 66103 USA	University of New Mexico; University of New Mexico; University of New Mexico; University of New Mexico; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Queens University Belfast; University of New Mexico; University of New Mexico; Utah System of Higher Education; University of Utah; University of Kansas; University of Kansas Medical Center	Gan, GN (corresponding author), Univ Kansas, Med Ctr, Dept Radiat Oncol, Kansas City, KS 66103 USA.	greg.gan@gmail.com	Ozbun, Michelle/AAN-2922-2021; Craig, Stephanie/AAX-2060-2020	Ozbun, Michelle/0000-0001-8551-4606; Craig, Stephanie/0000-0002-5476-751X; Gan, Gregory/0000-0001-5090-0064	RSNA Foundation Research Scholar Grant; ACS-IRG [IRG-14-187-19]; University of New Mexico School of Medicine; STI CRC [U19 AI 113187]; NIH P30 Grant NCI [P30CA118100]; Department of Pathology; University of New Mexico Comprehensive Cancer Center [NCI P30CA118100]; NCI [2P30 CA118100]; University of New Mexico Cancer Center Animal Shared Resource - NCI [2P30 CA118100]; NATIONAL CANCER INSTITUTE [R01CA207051, P30CA118100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI113187] Funding Source: NIH RePORTER	RSNA Foundation Research Scholar Grant; ACS-IRG(American Cancer Society); University of New Mexico School of Medicine; STI CRC; NIH P30 Grant NCI; Department of Pathology; University of New Mexico Comprehensive Cancer Center; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); University of New Mexico Cancer Center Animal Shared Resource - NCI; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Work supported in part by RSNA Foundation Research Scholar Grant, ACS-IRG (IRG-14-187-19), Dedicated Health Research Fund from the University of New Mexico School of Medicine (UNM RAC 2018), STI CRC (U19 AI 113187), and the NIH P30 Grant NCI P30CA118100. The research in this paper was supported by the Human Tissue Repository and Tissue Analysis Shared Resource, funded by the Department of Pathology and The University of New Mexico Comprehensive Cancer Center and NCI P30CA118100. Many of the images in this paper were generated in the University of New Mexico Cancer Center Fluorescence Microscopy Shared Resource with current funding from NCI 2P30 CA118100. Initial support with PDX generation was performed with the assistance from the University of New Mexico Cancer Center Animal Shared Resource funded by NCI 2P30 CA118100. We also wish to acknowledge UNM Cancer Center Biostatistics Core Facility for their statistical assistance.	An SS, 2005, AM J PHYSIOL-CELL PH, V289, pC521, DOI 10.1152/ajpcell.00429.2004; Argiris A, 2008, LANCET, V371, P1695, DOI 10.1016/S0140-6736(08)60728-X; Argiris A, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00072; Bae JY, 2014, NEOPLASIA, V16, P928, DOI 10.1016/j.neo.2014.09.003; Cheng JCH, 2014, ANN SURG ONCOL, V21, P2361, DOI 10.1245/s10434-014-3611-z; Duffy SA, 2008, CANCER-AM CANCER SOC, V113, P750, DOI 10.1002/cncr.23615; Gan GN, 2014, CANCER RES, V74, P7024, DOI 10.1158/0008-5472.CAN-14-1346; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Gorska MM, 2007, J EXP MED, V204, P1637, DOI 10.1084/jem.20062621; Gurgis FMS, 2015, ONCOGENE, V34, P2934, DOI 10.1038/onc.2014.225; Guttmann DM, 2013, INT J RADIAT ONCOL, V87, P168, DOI 10.1016/j.ijrobp.2013.05.028; Haigentz M, 2018, ADV THER, V35, P255, DOI 10.1007/s12325-018-0682-4; Jank BJ, 2019, EUR ARCH OTO-RHINO-L, V276, P1487, DOI 10.1007/s00405-019-05381-0; Jomrich G, 2018, J CANCER, V9, P460, DOI 10.7150/jca.22310; Keysar SB, 2013, MOL ONCOL, V7, P776, DOI 10.1016/j.molonc.2013.03.004; Keysar SB, 2013, CANCER RES, V73, P3381, DOI 10.1158/0008-5472.CAN-12-4047; Kim JY, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22635-9; Klussmann JP, 2003, AM J PATHOL, V162, P747, DOI 10.1016/S0002-9440(10)63871-0; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Kumar B, 2017, ONCOTARGET, V8, P14847, DOI 10.18632/oncotarget.14682; Leon X, 2015, ONCOTARGET, V6, P37407, DOI 10.18632/oncotarget.6054; Liskamp CP, 2016, HEAD NECK-J SCI SPEC, V38, P1780, DOI 10.1002/hed.24516; Liu TG, 2007, AM J RESP CELL MOL, V37, P507, DOI 10.1165/rcmb.2007-0077OC; Mirghani H, 2018, ORAL ONCOL, V82, P131, DOI 10.1016/j.oraloncology.2018.05.007; Morandell S, 2013, CELL REP, V5, P868, DOI 10.1016/j.celrep.2013.10.025; Munshi Anupama, 2013, Genes Cancer, V4, P401, DOI 10.1177/1947601913485414; Muschter D, 2018, CLIN ORAL INVEST, V22, P2251, DOI 10.1007/s00784-017-2323-8; Neininger A, 2002, J BIOL CHEM, V277, P3065, DOI 10.1074/jbc.C100685200; Park KJ, 2003, J BIOL CHEM, V278, P35272, DOI 10.1074/jbc.M305095200; Pavan S, 2014, INT J CANCER, V134, P1289, DOI 10.1002/ijc.28464; Powrozek T, 2018, J CANCER RES CLIN, V144, P1423, DOI 10.1007/s00432-018-2679-4; Qin X, 2018, THERANOSTICS, V8, P921, DOI 10.7150/thno.22182; Ray AL, 2018, INT J CANCER, V142, P1702, DOI 10.1002/ijc.31191; Ray AL, 2016, INT J CANCER, V138, P770, DOI 10.1002/ijc.29716; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Schernberg A, 2019, HEAD NECK-J SCI SPEC, V41, P1441, DOI 10.1002/hed.25598; Seiwert TY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102112; Sharma RA, 2016, NAT REV CLIN ONCOL, V13, P627, DOI 10.1038/nrclinonc.2016.79; Shen BR, 2017, SCI REP-UK, V7, DOI 10.1038/srep46231; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Singh MK, 2017, J THERM BIOL, V69, P149, DOI 10.1016/j.jtherbio.2017.06.004; Singh RK, 2017, PHARMACOL REP, V69, P746, DOI 10.1016/j.pharep.2017.03.023; Stein AP, 2015, CANCER MED-US, V4, P699, DOI 10.1002/cam4.387; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; Sumner WA, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1268-7; Thuraisingam T, 2010, J INVEST DERMATOL, V130, P278, DOI 10.1038/jid.2009.209; Tribius S, 2012, ORAL ONCOL, V48, P1178, DOI 10.1016/j.oraloncology.2012.05.022; Xu L, 2014, J MOL CELL CARDIOL, V77, P86, DOI 10.1016/j.yjmcc.2014.09.011; Yadav A, 2017, ONCOTARGET, V8, P66912, DOI 10.18632/oncotarget.11464; Yeung YT, 2012, J NEURO-ONCOL, V109, P35, DOI 10.1007/s11060-012-0875-7; Zheng GP, 2018, CLIN CANCER RES, V24, P1163, DOI 10.1158/1078-0432.CCR-17-2619	51	7	7	0	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2019	38	48					7329	7341		10.1038/s41388-019-0945-9	http://dx.doi.org/10.1038/s41388-019-0945-9			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JR4XX	31417185	Green Accepted			2022-12-28	WOS:000499631000004
J	Xu, CL; Wang, XR; Zhou, Y; Chen, FX; Wang, HW; Li, KN; Fan, HY; Tang, XM; Jiang, GJ; Zhang, J				Xu, Congling; Wang, Xinrui; Zhou, Yu; Chen, Fei Xavier; Wang, Haiwei; Li, Kening; Fan, Huiyong; Tang, Xiaomei; Jiang, Guojuan; Zhang, Ji			Synergy between arsenic trioxide and JQ1 on autophagy in pancreatic cancer	ONCOGENE			English	Article							CELL-DEATH; MEDIATED APOPTOSIS; UP-REGULATION; TUMOR-GROWTH; NRF2; P53; INHIBITION; ACTIVATION; SURVIVAL; BIOLOGY	Pancreatic cancer is a deadliest type of malignancy and lacks effective intervention. We here report a potential strategy for treatment of this malignancy by the combination of arsenic trioxide (ATO) and BET bromodomain inhibitor JQ1. These two agents synergistically modulate multistages of autophagy and thus induce apoptosis effectively in pancreatic cancer cells. Our genomic and biochemical data have demonstrated that crosstalks between ER stress and autophagy play crucial roles during ATO-induced apoptosis, in which NRF2 may stand at the crossroad between cell death and survival. This has been further strengthened by our finding that NRF2 depletion renders insensitive cells into sensitive ones in regard to ATO treatment-caused cell death. The knockdown of NRF2 and the addition of JQ1 result in similar molecular/cellular effects in promoting effective ATO-induced apoptosis in cells that are insensitive to ATO treatment alone. Thus, the combination of ATO and JQ1 may represent a new treatment strategy for pancreatic cancer.	[Xu, Congling; Wang, Xinrui; Li, Kening; Fan, Huiyong; Tang, Xiaomei; Jiang, Guojuan; Zhang, Ji] Shanghai Jiao Tong Univ, Rui Jin Hosp, Shanghai Inst Hematol, State Key Lab Med Genom,Sch Med, Shanghai, Peoples R China; [Xu, Congling; Chen, Fei Xavier] Fudan Univ, Sch Basic Med Sci, Dept Syst Biol Med, Key Lab Mol Med,Shanghai Med Coll,Minist Educ, Shanghai 200032, Peoples R China; [Zhou, Yu] Civil Aviat Hosp Shanghai, Dept Orthoped, Shanghai, Peoples R China; [Wang, Haiwei] Fujian Med Univ, Fujian Prov Matern & Childrens Hosp, Fujian Key Lab Prenatal Diag & Birth Defect, Affiliated Hosp, Fuzhou 350001, Fujian, Peoples R China	Chinese Academy of Sciences; Shanghai Jiao Tong University; Fudan University; Fujian Medical University	Zhang, J (corresponding author), Shanghai Jiao Tong Univ, Rui Jin Hosp, Shanghai Inst Hematol, State Key Lab Med Genom,Sch Med, Shanghai, Peoples R China.	Zj11222@rjh.com.cn	Wang, Xinrui/AAW-5405-2021	Wang, Xinrui/0000-0002-7383-9128; CHEN, FEI/0000-0002-7827-7988	National Natural Science Foundation [81370655]; Shanghai Jiao Tong University School of Medicine, Shanghai Jiao Tong University	National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Shanghai Jiao Tong University School of Medicine, Shanghai Jiao Tong University	This study is supported in part by the National Natural Science Foundation (no. 81370655), and by Distinguished Professorship (JZ) from Shanghai Jiao Tong University School of Medicine, Shanghai Jiao Tong University.	Allemani C, 2018, LANCET, V391, P1023, DOI 10.1016/S0140-6736(17)33326-3; Antonucci L, 2015, P NATL ACAD SCI USA, V112, pE6166, DOI 10.1073/pnas.1519384112; Axe EL, 2008, J CELL BIOL, V182, P685, DOI 10.1083/jcb.200803137; Chen WM, 2009, MOL CELL, V34, P663, DOI 10.1016/j.molcel.2009.04.029; Cho HY, 2006, ANTIOXID REDOX SIGN, V8, P76, DOI 10.1089/ars.2006.8.76; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Du YZ, 2006, BLOOD, V107, P1582, DOI 10.1182/blood-2005-06-2318; Dunne RF, 2015, HEMATOL ONCOL CLIN N, V29, P595, DOI 10.1016/j.hoc.2015.04.003; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Garcia PL, 2016, ONCOGENE, V35, P833, DOI 10.1038/onc.2015.126; Gewirtz DA, 2014, CANCER RES, V74, P647, DOI 10.1158/0008-5472.CAN-13-2966; Ghaneh P, 2007, GUT, V56, P1134, DOI 10.1136/gut.2006.103333; Hayashi-Nishino M, 2009, NAT CELL BIOL, V11, P1433, DOI 10.1038/ncb1991; Hussong M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.157; Iacobuzio-Donahue CA, 2014, NEW ENGL J MED, V370, P1352, DOI 10.1056/NEJMcibr1400189; Kanzawa T, 2005, ONCOGENE, V24, P980, DOI 10.1038/sj.onc.1208095; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Kim J, 2013, CANCER CELL, V23, P23, DOI 10.1016/j.ccr.2012.11.017; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Ktistakis NT, 2016, TRENDS CELL BIOL, V26, P624, DOI 10.1016/j.tcb.2016.03.006; Kundu M, 2008, ANNU REV PATHOL-MECH, V3, P427, DOI 10.1146/annurev.pathmechdis.2.010506.091842; Langdon CG, 2017, MOL CANCER THER, V16, P1041, DOI 10.1158/1535-7163.MCT-16-0794; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Martina JA, 2016, EMBO J, V35, P479, DOI 10.15252/embj.201593428; Martina JA, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004754; Mazur PK, 2015, NAT MED, V21, P1163, DOI 10.1038/nm.3952; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Newman RA, 2007, INTEGR CANCER THER, V6, P354, DOI 10.1177/1534735407309623; Pietrocola F, 2013, SEMIN CANCER BIOL, V23, P310, DOI 10.1016/j.semcancer.2013.05.008; Piya S, 2017, AUTOPHAGY, V13, P214, DOI 10.1080/15548627.2016.1245263; Qian WB, 2007, LEUKEMIA RES, V31, P329, DOI 10.1016/j.leukres.2006.06.021; Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865; Rubinsztein DC, 2007, NAT REV DRUG DISCOV, V6, P304, DOI 10.1038/nrd2272; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Sakamaki JI, 2017, MOL CELL, V66, P517, DOI 10.1016/j.molcel.2017.04.027; Shah P, 2017, MOLECULES, V22, DOI 10.3390/molecules22020194; Sun H. D., 1992, CHIN J INTEGRAT CHIN, V12, P170; Sun XF, 2016, HEPATOLOGY, V63, P173, DOI 10.1002/hep.28251; Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299; Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611; Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0; Wakabayashi N, 2010, ANTIOXID REDOX SIGN, V13, P1649, DOI 10.1089/ars.2010.3216; Wang KK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007538; Wen X, 2017, AUTOPHAGY, V13, P1801, DOI 10.1080/15548627.2017.1364334; Xia Y, 2013, EXP BIOL MED, V238, P932, DOI 10.1177/1535370213492689; Yang A, 2014, CANCER DISCOV, V4, P905, DOI 10.1158/2159-8290.CD-14-0362; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Zhang T. D., 1973, HEILONGJIANG MED J, P66; Zhang YX, 2011, ANTIOXID REDOX SIGN, V15, P2867, DOI 10.1089/ars.2010.3685	53	14	15	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2019	38	47					7249	7265		10.1038/s41388-019-0930-3	http://dx.doi.org/10.1038/s41388-019-0930-3			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP0UL	31420604				2022-12-28	WOS:000497989400005
J	Nakagawa, M; Nakatani, F; Matsunaga, H; Seki, T; Endo, M; Ogawara, Y; Machida, Y; Katsumoto, T; Yamagata, K; Hattori, A; Fujita, S; Aikawa, Y; Ishikawa, T; Soga, T; Kawai, A; Chuman, H; Yokoyama, N; Fukushima, S; Yahiro, K; Kimura, A; Shimada, E; Hirose, T; Fujiwara, T; Setsu, N; Matsumoto, Y; Iwamoto, Y; Nakashima, Y; Kitabayashi, I				Nakagawa, Makoto; Nakatani, Fumihiko; Matsunaga, Hironori; Seki, Takahiko; Endo, Makoto; Ogawara, Yoko; Machida, Yukino; Katsumoto, Takuo; Yamagata, Kazutsune; Hattori, Ayuna; Fujita, Shuhei; Aikawa, Yukiko; Ishikawa, Takamasa; Soga, Tomoyoshi; Kawai, Akira; Chuman, Hirokazu; Yokoyama, Nobuhiko; Fukushima, Suguru; Yahiro, Kenichiro; Kimura, Atsushi; Shimada, Eijiro; Hirose, Takeshi; Fujiwara, Toshifumi; Setsu, Nokitaka; Matsumoto, Yoshihiro; Iwamoto, Yukihide; Nakashima, Yasuharu; Kitabayashi, Issay			Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma	ONCOGENE			English	Article							SOFT-TISSUE SARCOMA; OPEN-LABEL; ONCOMETABOLITE 2-HYDROXYGLUTARATE; OLLIER DISEASE; MUTATIONS; DIFFERENTIATION; CHEMOTHERAPY; SUFFICIENT; EXPRESSION; ENASIDENIB	Chondrosarcoma is the second most common malignant bone tumor. It is characterized by low vascularity and an abundant extracellular matrix, which confer these tumors resistance to chemotherapy and radiotherapy. There are currently no effective treatment options for relapsed or dedifferentiated chondrosarcoma, and new targeted therapies need to be identified. Isocitrate dehydrogenase (IDH) mutations, which are detected in similar to 50% of chondrosarcoma patients, contribute to malignant transformation by catalyzing the production of 2-hydroxyglutarate (2-HG), a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Mutant IDH inhibitors are therefore potential novel anticancer drugs in IDH mutant tumors. Here, we examined the efficacy of the inhibition of mutant IDH1 as an antitumor approach in chondrosarcoma cells in vitro and in vivo, and investigated the association between the IDH mutation and chondrosarcoma cells. DS-1001b, a novel, orally bioavailable, selective mutant IDH1 inhibitor, impaired the proliferation of chondrosarcoma cells with IDH1 mutations in vitro and in vivo, and decreased 2-HG levels. RNA-seq analysis showed that inhibition of mutant IDH1 promoted chondrocyte differentiation in the conventional chondrosarcoma L835 cell line and caused cell cycle arrest in the dedifferentiated JJ012 cell line. Mutant IDH1-mediated modulation of SOX9 and CDKN1C expression regulated chondrosarcoma tumor progression, and DS-1001b upregulated the expression of these genes via a common mechanism involving the demethylation of H3K9me3. DS-1001b treatment reversed the epigenetic changes caused by aberrant histone modifications. The present data strongly suggest that inhibition of mutant IDH1 is a promising therapeutic approach in chondrosarcoma, particularly for the treatment of relapsed or dedifferentiated chondrosarcoma.	[Nakagawa, Makoto; Ogawara, Yoko; Machida, Yukino; Katsumoto, Takuo; Yamagata, Kazutsune; Hattori, Ayuna; Fujita, Shuhei; Aikawa, Yukiko; Kitabayashi, Issay] Natl Canc Ctr, Div Hematol Malignancy, Tokyo, Japan; [Nakagawa, Makoto; Endo, Makoto; Yokoyama, Nobuhiko; Fukushima, Suguru; Yahiro, Kenichiro; Kimura, Atsushi; Shimada, Eijiro; Hirose, Takeshi; Fujiwara, Toshifumi; Setsu, Nokitaka; Matsumoto, Yoshihiro; Nakashima, Yasuharu] Kyushu Univ, Grad Sch Med Sci, Dept Orthopaed Surg, Fukuoka, Fukuoka, Japan; [Nakagawa, Makoto; Nakatani, Fumihiko; Kawai, Akira] Natl Canc Ctr, Div Musculoskeletal Oncol, Tokyo, Japan; [Matsunaga, Hironori; Seki, Takahiko] Daiichi Sankyo Co Ltd, Oncol Labs, Tokyo, Japan; [Ishikawa, Takamasa; Soga, Tomoyoshi] Keio Univ, Inst Adv Biosci, Yamagata, Japan; [Chuman, Hirokazu] Katai Orthopaed Internal Med Hosp, Div Orthopaed Surg, Fukuoka, Fukuoka, Japan; [Iwamoto, Yukihide] Kyushu Rosai Hosp, Div Orthopaed Surg, Fukuoka, Fukuoka, Japan	National Cancer Center - Japan; Kyushu University; National Cancer Center - Japan; Daiichi Sankyo Company Limited; Keio University	Kitabayashi, I (corresponding author), Natl Canc Ctr, Div Hematol Malignancy, Tokyo, Japan.	ikitabay@ncc.go.jp	Endo, Makoto/K-2896-2012	Endo, Makoto/0000-0002-7956-2190; Nakagawa, Makoto/0000-0001-8243-7705; Hirose, Takeshi/0000-0003-1588-9757; Kitabayashi, Issay/0000-0002-8409-0407	Foundation for Promotion of Cancer Research (FPCR); Acceleration Transformative Research for Medical Innovation from the Japan Agency for Medical Research and Development; National Cancer Center Research and Development Fund	Foundation for Promotion of Cancer Research (FPCR); Acceleration Transformative Research for Medical Innovation from the Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED)); National Cancer Center Research and Development Fund(National Cancer Center - Japan)	We wish to thank Dr Joel A. Block, Dr Judith V.M. G. Bovee, and Dr A. Ogose for providing important cell lines. We thank Yutaka Shima, Yuki Kagiyama, and Emi Takamatsu-Ichihara for expert advice and technical support. This work was supported by a Grant from Foundation for Promotion of Cancer Research (FPCR) (F.N.). IK was funded by Acceleration Transformative Research for Medical Innovation from the Japan Agency for Medical Research and Development and by the National Cancer Center Research and Development Fund.	Amary MF, 2011, NAT GENET, V43, P1262, DOI 10.1038/ng.994; Amary MF, 2011, J PATHOL, V224, P334, DOI 10.1002/path.2913; Amatangelo MD, 2017, BLOOD, V130, P732, DOI 10.1182/blood-2017-04-779447; Andreou D, 2011, ACTA ORTHOP, V82, P749, DOI 10.3109/17453674.2011.636668; Borger DR, 2012, ONCOLOGIST, V17, P72, DOI 10.1634/theoncologist.2011-0386; Cairns RA, 2012, BLOOD, V119, P1901, DOI 10.1182/blood-2011-11-391748; Chowdhury R, 2011, EMBO REP, V12, P463, DOI 10.1038/embor.2011.43; Clark JCM, 2010, CANCER CELL INT, V10, DOI 10.1186/1475-2867-10-20; Endo M, 2015, MODERN PATHOL, V28, P587, DOI 10.1038/modpathol.2014.155; Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015; Ghert MA, 2001, ONCOLOGY-BASEL, V61, P306, DOI 10.1159/000055338; Giuffrida AY, 2009, J BONE JOINT SURG AM, V91A, P1063, DOI 10.2106/JBJS.H.00416; Hirata M, 2015, P NATL ACAD SCI USA, V112, P2829, DOI 10.1073/pnas.1424400112; Hogendoorn P, 2013, WHO CLASSIFICATION T, V4, P264; Italiano A, 2013, ANN ONCOL, V24, P2916, DOI 10.1093/annonc/mdt374; Jin Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126956; Kawai A, 2015, LANCET ONCOL, V16, P406, DOI 10.1016/S1470-2045(15)70098-7; Koivunen P, 2012, NATURE, V483, P485, DOI 10.1038/nature10898; Kudo N, 2007, VIRCHOWS ARCH, V451, P691, DOI 10.1007/s00428-007-0426-3; Li L., 2015, J OCEAN WIND ENERGY, V2, P1, DOI DOI 10.1371/J0URNAL.P0NE.0133813; Losman JA, 2013, SCIENCE, V339, P1621, DOI 10.1126/science.1231677; Lu C, 2013, GENE DEV, V27, P1986, DOI 10.1101/gad.226753.113; Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Mitchell AD, 2000, J BONE JOINT SURG BR, V82B, P55, DOI 10.1302/0301-620X.82B1.9020; Ogawara Y, 2015, CANCER RES, V75, P2005, DOI 10.1158/0008-5472.CAN-14-2200; Pansuriya TC, 2011, NAT GENET, V43, P1256, DOI 10.1038/ng.1004; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Perut F, 2018, J ORTHOP RES, V36, P2305, DOI 10.1002/jor.23880; Pollack SM, 2018, J CLIN ONCOL, V36, P125, DOI 10.1200/JCO.2017.75.1610; Pollack SM, 2017, J IMMUNOTHER, V40, P302, DOI 10.1097/CJI.0000000000000183; Polychronidou G, 2017, FUTURE ONCOL, V13, P637, DOI 10.2217/fon-2016-0226; Pusch S, 2017, ACTA NEUROPATHOL, V133, P629, DOI 10.1007/s00401-017-1677-y; Rohle D, 2013, SCIENCE, V340, P626, DOI 10.1126/science.1236062; Sasaki M, 2012, GENE DEV, V26, P2038, DOI 10.1101/gad.198200.112; Schoffski P, 2016, LANCET, V387, P1629, DOI 10.1016/S0140-6736(15)01283-0; Stein EM, 2017, BLOOD, V130, P722, DOI 10.1182/blood-2017-04-779405; Streitbuerger A, 2012, J BONE JOINT SURG BR, V94B, P122, DOI 10.1302/0301-620X.94B1.26876; Suijker J, 2015, ONCOTARGET, V6, P12505, DOI 10.18632/oncotarget.3723; Tap WD, 2016, LANCET, V388, P488, DOI 10.1016/S0140-6736(16)30587-6; Tawbi HA, 2017, LANCET ONCOL, V18, P1493, DOI 10.1016/S1470-2045(17)30624-1; van der Graaf WTA, 2012, LANCET, V379, P1879, DOI 10.1016/S0140-6736(12)60651-5; van Oosterwijk JG, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-375; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yen K, 2017, CANCER DISCOV, V7, P478, DOI 10.1158/2159-8290.CD-16-1034; Zhao SM, 2009, SCIENCE, V324, P261, DOI 10.1126/science.1170944	47	31	32	1	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2019	38	42					6835	6849		10.1038/s41388-019-0929-9	http://dx.doi.org/10.1038/s41388-019-0929-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE5UU	31406254	hybrid			2022-12-28	WOS:000490758200003
J	Han, X; Ren, CN; Yang, TT; Qiao, PY; Wang, L; Jiang, AF; Meng, YH; Liu, ZJ; Du, Y; Yu, ZH				Han, Xue; Ren, Chune; Yang, Tingting; Qiao, Pengyun; Wang, Li; Jiang, Aifang; Meng, Yuhan; Liu, Zhijun; Du, Yu; Yu, Zhenhai			Negative regulation of AMPK alpha 1 by PIM2 promotes aerobic glycolysis and tumorigenesis in endometrial cancer	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; TUMOR-GROWTH; AMPK; PHOSPHORYLATION; INHIBITION; METABOLISM; PATHWAY; FAMILY; PKM2; AKT	Endometrial cancer (EC) is one of the most common gynecologic malignancies. However, the molecular mechanisms underlying the development and progression of EC remain unclear. Here, we demonstrated that the protein proviral insertion in murine lymphomas 2 (PIM2) was necessary for maintaining EC tumorigenesis in vivo and in vitro, and could inhibit AMPK alpha 1 kinase activity in EC cells. Specifically, we found that PIM2 bound to AMPK alpha 1, and directly phosphorylated it on Thr467. Phosphorylation of AMPK alpha 1 by PIM2 led to decreasing AMPK alpha 1 kinase activity, which in turn promoted aerobic glycolysis and tumor growth. In addition, PIM2 expression positively correlated with AMPK alpha 1 Thr467 phosphorylation in EC tissues. Further, treatment with a combination of the PIM2 inhibitor SMI-4a and the AMPK alpha 1 activator AICAR could effectively inhibit tumor growth. Thus, our findings provide insight into the role of PIM2 and AMPK alpha 1 in EC and suggest that combination targeting of these proteins may represent a new strategy for EC treatment.	[Han, Xue; Ren, Chune; Yang, Tingting; Qiao, Pengyun; Wang, Li; Jiang, Aifang; Meng, Yuhan; Yu, Zhenhai] Weifang Med Univ, Dept Reprod Med, Affiliated Hosp, Weifang, Shandong, Peoples R China; [Liu, Zhijun; Du, Yu] Weifang Med Univ, Dept Med Microbiol, Weifang, Shandong, Peoples R China	Weifang Medical University; Weifang Medical University	Yu, ZH (corresponding author), Weifang Med Univ, Dept Reprod Med, Affiliated Hosp, Weifang, Shandong, Peoples R China.	tomsyu@163.com			Innovation fund of National Natural Science Foundation of China [81602440, 81602301, 81501275, 81471048]; Shandong Province College Science and Technology Plan Project [J16LL08, J17KA254]; Projects of medical and health technology development program in Shandong province [2016WS0688, 2017WS398]	Innovation fund of National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shandong Province College Science and Technology Plan Project; Projects of medical and health technology development program in Shandong province	The study was supported by research grants from Innovation fund of National Natural Science Foundation of China (Grant no. 81602440, 81602301, 81501275 and 81471048), Shandong Province College Science and Technology Plan Project (Grant no. J16LL08 and J17KA254), Projects of medical and health technology development program in Shandong province (Grant no. 2016WS0688 and 2017WS398).	Beharry Z, 2011, P NATL ACAD SCI USA, V108, P528, DOI 10.1073/pnas.1013214108; Bungard D, 2010, SCIENCE, V329, P1201, DOI 10.1126/science.1191241; Daenthanasanmak A, 2018, J CLIN INVEST, V128, P2787, DOI 10.1172/JCI95407; Dagon Y, 2012, CELL METAB, V16, P104, DOI 10.1016/j.cmet.2012.05.010; Faubert B, 2013, CELL METAB, V17, P113, DOI 10.1016/j.cmet.2012.12.001; Garcia D, 2017, MOL CELL, V66, P789, DOI 10.1016/j.molcel.2017.05.032; Hall DT, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708307; Hardie DG, 2016, TRENDS CELL BIOL, V26, P190, DOI 10.1016/j.tcb.2015.10.013; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Hawley SA, 2014, BIOCHEM J, V459, P275, DOI 10.1042/BJ20131344; Herzig S, 2018, NAT REV MOL CELL BIO, V19, P121, DOI 10.1038/nrm.2017.95; Hospital MA, 2018, LEUKEMIA, V32, P597, DOI 10.1038/leu.2017.284; Jansen M, 2009, PHYSIOL REV, V89, P777, DOI 10.1152/physrev.00026.2008; Kreuz S, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0477-z; Lin SC, 2018, CELL METAB, V27, P299, DOI 10.1016/j.cmet.2017.10.009; Lu J, 2013, BLOOD, V122, P1610, DOI 10.1182/blood-2013-01-481457; Morishita D, 2008, CANCER RES, V68, P5076, DOI 10.1158/0008-5472.CAN-08-0634; Nair JR, 2017, LEUKEMIA, V31, P1715, DOI 10.1038/leu.2016.379; Narlik-Grassow M, 2014, MED RES REV, V34, P136, DOI 10.1002/med.21284; Onstad MA, 2016, J CLIN ONCOL, V34, P4225, DOI 10.1200/JCO.2016.69.4638; Ren CN, 2018, MOL ONCOL, V12, P690, DOI 10.1002/1878-0261.12192; Shukla K, 2017, CANCER LETT, V411, P57, DOI 10.1016/j.canlet.2017.09.031; Suzuki T, 2013, MOL CELL, V50, P407, DOI 10.1016/j.molcel.2013.03.022; Wang ZP, 2010, INT J BIOCHEM CELL B, V42, P1030, DOI 10.1016/j.biocel.2010.03.012; Warfel NA, 2015, PHARMACOL THERAPEUT, V151, P41, DOI 10.1016/j.pharmthera.2015.03.001; Yang TT, 2018, ONCOGENE, V37, P5997, DOI 10.1038/s41388-018-0386-x; Ye S, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2230-4; Yu ZH, 2016, BIOCHEM BIOPH RES CO, V473, P953, DOI 10.1016/j.bbrc.2016.03.160; Yu ZH, 2014, CELL SIGNAL, V26, P1560, DOI 10.1016/j.cellsig.2014.03.016; Yu ZH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088301; Yu ZH, 2013, J BIOL CHEM, V288, P35406, DOI 10.1074/jbc.M113.508226; Yuan JM, 2018, J BIOL CHEM, V293, P14276, DOI 10.1074/jbc.RA118.004597; Zhao YQ, 2016, ACTA PHARMACOL SIN, V37, P1237, DOI 10.1038/aps.2016.60; Zhou XK, 2017, CANCER LETT, V411, P1, DOI 10.1016/j.canlet.2017.09.027	34	16	16	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2019	38	38					6537	6549		10.1038/s41388-019-0898-z	http://dx.doi.org/10.1038/s41388-019-0898-z			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IY7XR	31358902				2022-12-28	WOS:000486609000005
J	Totsch, SK; Schlappi, C; Kang, KD; Ishizuka, AS; Lynn, GM; Fox, B; Beierle, EA; Whitley, RJ; Markert, JM; Gillespie, GY; Bernstock, JD; Friedman, GK				Totsch, Stacie K.; Schlappi, Charles; Kang, Kyung-Don; Ishizuka, Andrew S.; Lynn, Geoffrey M.; Fox, Brandon; Beierle, Elizabeth A.; Whitley, Richard J.; Markert, James M.; Gillespie, G. Yancey; Bernstock, Joshua D.; Friedman, Gregory K.			Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistance	ONCOGENE			English	Review							INTRATUMORAL INJECTION; VIRAL REPLICATION; MALIGNANT GLIOMA; EXPRESSING IL-12; CANCER VACCINES; CLINICAL-TRIAL; ENTER CELLS; GLIOBLASTOMA; HSV-1; G207	Malignant tumors of the central nervous system (CNS) continue to be a leading cause of cancer-related mortality in both children and adults. Traditional therapies for malignant brain tumors consist of surgical resection and adjuvant chemoradiation; such approaches are often associated with extreme morbidity. Accordingly, novel, targeted therapeutics for neoplasms of the CNS, such as immunotherapy with oncolytic engineered herpes simplex virus (HSV) therapy, are urgently warranted. Herein, we discuss treatment challenges related to HSV virotherapy delivery, entry, replication, and spread, and in so doing focus on host anti-viral immune responses and the immune microenvironment. Strategies to overcome such challenges including viral re-engineering, modulation of the immunoregulatory microenvironment and combinatorial therapies with virotherapy, such as checkpoint inhibitors, radiation, and vaccination, are also examined in detail.	[Totsch, Stacie K.; Schlappi, Charles; Kang, Kyung-Don; Friedman, Gregory K.] Univ Alabama Birmingham, Dept Pediat, Div Pediat Hematol & Oncol, Birmingham, AL 35294 USA; [Ishizuka, Andrew S.; Lynn, Geoffrey M.; Bernstock, Joshua D.] Avidea Technol Inc, Baltimore, MD 21205 USA; [Fox, Brandon; Bernstock, Joshua D.] Univ Alabama Birmingham, Med Scientist Training Program, Birmingham, AL 35294 USA; [Beierle, Elizabeth A.; Friedman, Gregory K.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA; [Whitley, Richard J.] Univ Alabama Birmingham, Div Pediat Infect Dis, Dept Pediat, Birmingham, AL USA; [Markert, James M.; Gillespie, G. Yancey; Friedman, Gregory K.] Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL 35294 USA; [Bernstock, Joshua D.] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Friedman, GK (corresponding author), Univ Alabama Birmingham, Dept Pediat, Div Pediat Hematol & Oncol, Birmingham, AL 35294 USA.; Bernstock, JD (corresponding author), Avidea Technol Inc, Baltimore, MD 21205 USA.; Bernstock, JD (corresponding author), Univ Alabama Birmingham, Med Scientist Training Program, Birmingham, AL 35294 USA.; Friedman, GK (corresponding author), Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA.; Friedman, GK (corresponding author), Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL 35294 USA.; Bernstock, JD (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA.	jdb82@uab.edu; gfriedman@peds.uab.edu		Friedman, Gregory/0000-0002-6653-7420; Ishizuka, Andrew/0000-0002-3024-7536; Bernstock, Joshua/0000-0002-7814-3867; Gillespie, George/0000-0001-6436-9542; Fox, Brandon/0000-0003-2242-2477	Food and Drug Administration Office of Orphan Products Development [R01FD005379]; Department of Defense [W81XWH-15-1-0108]; Rally Foundation for Childhood Cancer Research; Hyundai Hope on Wheels; Kaul Pediatric Research Institute; UAB Medical Scientist Training Program (MSTP); American Brain Tumor Association; National Cancer Institute of the National Institutes of Health [T32CA183926];  [R01CA217179]; FOOD AND DRUG ADMINISTRATION [R01FD005379] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA183926, R01CA217179] Funding Source: NIH RePORTER	Food and Drug Administration Office of Orphan Products Development; Department of Defense(United States Department of Defense); Rally Foundation for Childhood Cancer Research; Hyundai Hope on Wheels; Kaul Pediatric Research Institute; UAB Medical Scientist Training Program (MSTP); American Brain Tumor Association; National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ; FOOD AND DRUG ADMINISTRATION(United States Department of Health & Human Services); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported in part by grants from the Food and Drug Administration Office of Orphan Products Development (R01FD005379), the Department of Defense (W81XWH-15-1-0108) Rally Foundation for Childhood Cancer Research, Hyundai Hope on Wheels, and the Kaul Pediatric Research Institute to GKF and R01CA217179 to JMM and GYG. JDB was supported by the UAB Medical Scientist Training Program (MSTP) and an American Brain Tumor Association summer fellowship. SKT was supported by the National Cancer Institute of the National Institutes of Health under Award Number T32CA183926. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the U.S. FDA or the Department of Defense. The authors apologize to colleagues we couldn't cite given limitations on the number of references.	Aghi MK, 2009, MOL THER, V17, P51, DOI 10.1038/mt.2008.232; Aldape K, 2019, NAT REV CLIN ONCOL, V16, P509, DOI 10.1038/s41571-019-0177-5; Alvarez-Breckenridge CA, 2012, NAT MED, V18, P1827, DOI 10.1038/nm.3013; Alvarez-Breckenridge CA, 2012, J VIROL, V86, P4566, DOI 10.1128/JVI.05545-11; Andtbacka RHI, 2015, J CLIN ONCOL, V33, P2780, DOI 10.1200/JCO.2014.58.3377; Banchereau J, 2018, NAT REV CLIN ONCOL, V15, P9, DOI 10.1038/nrclinonc.2017.149; Bernstock JD, 2019, WORLD NEUROSURG, V122, pE1592, DOI 10.1016/j.wneu.2018.11.122; Bookstaver ML, 2018, TRENDS IMMUNOL, V39, P135, DOI 10.1016/j.it.2017.10.002; Bradley JD, 1999, CLIN CANCER RES, V5, P1517; Brencicova E, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00037; Cassady KA, 2005, J VIROL, V79, P8707, DOI 10.1128/JVI.79.14.8707-8715.2005; Cheema TA, 2013, P NATL ACAD SCI USA, V110, P12006, DOI 10.1073/pnas.1307935110; Chesney J, 2018, J CLIN ONCOL, V36, P1658, DOI 10.1200/JCO.2017.73.7379; Currier MA, 2013, MOL THER, V21, P1014, DOI 10.1038/mt.2013.39; Davis BK, 2011, ANNU REV IMMUNOL, V29, P707, DOI 10.1146/annurev-immunol-031210-101405; Dmitrieva N, 2011, CLIN CANCER RES, V17, P1362, DOI 10.1158/1078-0432.CCR-10-2213; Draper SJ, 2010, NAT REV MICROBIOL, V8, P62, DOI 10.1038/nrmicro2240; Evans SM, 2004, CLIN CANCER RES, V10, P8177, DOI 10.1158/1078-0432.CCR-04-1081; Facciabene A, 2012, CANCER RES, V72, P2162, DOI 10.1158/0008-5472.CAN-11-3687; Filley AC, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00106; Flingai S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00354; Foreman PM, 2017, NEUROTHERAPEUTICS, V14, P333, DOI 10.1007/s13311-017-0516-0; Friedman GK, 2015, GENE THER, V22, P348, DOI 10.1038/gt.2014.107; Friedman GK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32353-x; Friedman GK, 2012, TRANSL ONCOL, V5, P200, DOI 10.1593/tlo.12115; Friedman GK, 2009, MOL THER, V17, P1125, DOI 10.1038/mt.2009.73; Fukuhara H, 2016, CANCER SCI, V107, P1373, DOI 10.1111/cas.13027; Fulci G, 2007, CANCER RES, V67, P9398, DOI 10.1158/0008-5472.CAN-07-1063; Fulci G, 2006, P NATL ACAD SCI USA, V103, P12873, DOI 10.1073/pnas.0605496103; Ghonime MG, 2018, TRANSL ONCOL, V11, P86, DOI 10.1016/j.tranon.2017.10.005; Guo CQ, 2013, ADV CANCER RES, V119, P421, DOI 10.1016/B978-0-12-407190-2.00007-1; Han JF, 2015, CANCER RES, V75, P5273, DOI 10.1158/0008-5472.CAN-15-0894; Hardcastle J, 2010, MOL THER, V18, P285, DOI 10.1038/mt.2009.232; Harrow S, 2004, GENE THER, V11, P1648, DOI 10.1038/sj.gt.3302289; Herrera FG, 2017, CA-CANCER J CLIN, V67, P65, DOI 10.3322/caac.21358; Jackson JD, 2014, GENE THER, V21, P984, DOI 10.1038/gt.2014.72; Kambara H, 2005, CANCER RES, V65, P2832, DOI 10.1158/0008-5472.CAN-04-3227; Kamiyama H, 2006, GENE THER, V13, P621, DOI 10.1038/sj.gt.3302685; Kanai R, 2006, GENE THER, V13, P106, DOI 10.1038/sj.gt.3302636; Kaur B, 2009, CURR GENE THER, V9, P341, DOI 10.2174/156652309789753329; Kesari S, 1998, J GEN VIROL, V79, P525, DOI 10.1099/0022-1317-79-3-525; Kranz LM, 2016, NATURE, V534, P396, DOI 10.1038/nature18300; Krull KR, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2017.76.4696; Laquerre S, 1998, J VIROL, V72, P9683, DOI 10.1128/JVI.72.12.9683-9697.1998; Leddon JL, 2015, MOL THER-ONCOLYTICS, V2, DOI 10.1038/mto.2014.10; Leoni V, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007209; Liu R, 2005, GENE THER, V12, P647, DOI 10.1038/sj.gt.3302445; Liu ZQ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14754; Longo SL, 2011, CANCER GENE THER, V18, P123, DOI 10.1038/cgt.2010.62; Lynn GM, 2015, NAT BIOTECHNOL, V33, P1201, DOI 10.1038/nbt.3371; Markert JM, 2014, MOL THER, V22, P1048, DOI 10.1038/mt.2014.22; Markert JM, 2012, J VIROL, V86, P5304, DOI 10.1128/JVI.06998-11; Markert JM, 2009, MOL THER, V17, P199, DOI 10.1038/mt.2008.228; Markert JM, 2000, GENE THER, V7, P867, DOI 10.1038/sj.gt.3301205; Maroun J, 2017, FUTURE VIROL, V12, P193, DOI 10.2217/fvl-2016-0129; MARTUZA RL, 1991, SCIENCE, V252, P854, DOI 10.1126/science.1851332; Menotti L, 2008, J VIROL, V82, P10153, DOI 10.1128/JVI.01133-08; Miest TS, 2014, NAT REV MICROBIOL, V12, P23, DOI 10.1038/nrmicro3140; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; Mitchell BM, 1996, J IMMUNOL, V156, P246; MITTNACHT S, 1988, VIROLOGY, V164, P201, DOI 10.1016/0042-6822(88)90637-X; Nakashima H, 2018, CLIN CANCER RES, V24, P2574, DOI 10.1158/1078-0432.CCR-17-2954; Nakashima H, 2015, J CLIN INVEST, V125, P4269, DOI 10.1172/JCI80713; Okemoto K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071932; Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P1, DOI 10.1093/neuonc/nou223; Papanastassiou V, 2002, GENE THER, V9, P398, DOI 10.1038/sj.gt.3301664; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Parker JN, 2000, P NATL ACAD SCI USA, V97, P2208, DOI 10.1073/pnas.040557897; Passaro C, 2019, CLIN CANCER RES, V25, P290, DOI 10.1158/1078-0432.CCR-18-2311; Patel DM, 2016, HUM GENE THER CL DEV, V27, P69, DOI 10.1089/humc.2016.031; POND SM, 1984, CLIN PHARMACOKINET, V9, P1, DOI 10.2165/00003088-198409010-00001; Pulluri B, 2017, PHARMACOL RES, V123, P95, DOI 10.1016/j.phrs.2017.07.006; Rampling R, 2000, GENE THER, V7, P859, DOI 10.1038/sj.gt.3301184; Rasmussen SB, 2007, J VIROL, V81, P13315, DOI 10.1128/JVI.01167-07; Ricklefs FL, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aar2766; Ring EK, 2017, MOL THER-ONCOLYTICS, V7, P27, DOI 10.1016/j.omto.2017.09.003; Ring EK, 2017, CLIN CANCER RES, V23, P342, DOI 10.1158/1078-0432.CCR-16-1829; Roizman B, 1996, P NATL ACAD SCI USA, V93, P11307, DOI 10.1073/pnas.93.21.11307; Saha D, 2018, CLIN CANCER RES, V24, P3409, DOI 10.1158/1078-0432.CCR-17-1717; Saha D, 2017, CANCER CELL, V32, P253, DOI 10.1016/j.ccell.2017.07.006; Sarkaria JN, 2018, NEURO-ONCOLOGY, V20, P184, DOI 10.1093/neuonc/nox175; Shah AC, 2003, J NEURO-ONCOL, V65, P203, DOI 10.1023/B:NEON.0000003651.97832.6c; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Spear PG, 2004, CELL MICROBIOL, V6, P401, DOI 10.1111/j.1462-5822.2004.00389.x; Streby KA, 2017, CLIN CANCER RES, V23, P3566, DOI 10.1158/1078-0432.CCR-16-2900; Stronen E, 2016, SCIENCE, V352, P1337, DOI 10.1126/science.aaf2288; Sundaresan P, 2000, J VIROL, V74, P3832, DOI 10.1128/JVI.74.8.3832-3841.2000; Suschak JJ, 2017, HUM VACC IMMUNOTHER, V13, P2837, DOI 10.1080/21645515.2017.1330236; Tanaka T, 1997, NAT MED, V3, P437, DOI 10.1038/nm0497-437; Thorne AH, 2014, MOL THER, V22, P1678, DOI 10.1038/mt.2014.101; Trybala E, 2000, J VIROL, V74, P9106, DOI 10.1128/JVI.74.19.9106-9114.2000; Uchida H, 2013, MOL THER, V21, P561, DOI 10.1038/mt.2012.211; Wakimoto H, 2009, CANCER RES, V69, P3472, DOI 10.1158/0008-5472.CAN-08-3886; Wang PY, 2016, GENE THER, V23, P135, DOI 10.1038/gt.2015.105; Waters AM, 2017, HUM GENE THER CL DEV, V28, P7, DOI 10.1089/humc.2017.002; Yarchoan M, 2017, NAT REV CANCER, V17, DOI 10.1038/nrc.2017.74; Zhai LJ, 2018, CELL MOL IMMUNOL, V15, P447, DOI 10.1038/cmi.2017.143; Zhou GY, 2006, P NATL ACAD SCI USA, V103, P5508, DOI 10.1073/pnas.0601258103; Zhou GY, 2003, J VIROL, V77, P3759, DOI 10.1128/JVI.77.6.3759-3767.2003; Zhu H, 2007, CANCER BIOL THER, V6, P724, DOI 10.4161/cbt.6.5.3953	100	33	35	0	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2019	38	34					6159	6171		10.1038/s41388-019-0870-y	http://dx.doi.org/10.1038/s41388-019-0870-y			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IS5RM	31289361	Green Accepted			2022-12-28	WOS:000482210100001
J	Tassone, E; Bradaschia-Correa, V; Xiong, XZ; Sastre-Perona, A; Josephson, AM; Khodadadi-Jamayran, A; Melamed, J; Bu, L; Kahler, DJ; Ossowski, L; Leucht, P; Schober, M; Wilson, EL				Tassone, Evelyne; Bradaschia-Correa, Vivian; Xiong, Xiaozhong; Sastre-Perona, Ana; Josephson, Anne Marie; Khodadadi-Jamayran, Alireza; Melamed, Jonathan; Bu, Lei; Kahler, David J.; Ossowski, Liliana; Leucht, Philipp; Schober, Markus; Wilson, Elaine L.			KLF4 as a rheostat of osteolysis and osteogenesis in prostate tumors in the bone	ONCOGENE			English	Article							MARROW MICROENVIRONMENT; TNF-ALPHA; CANCER; GENE; EXPRESSION; GROWTH; CELLS; DIFFERENTIATION; METASTASIS; SUPPRESSOR	We previously showed that KLF4, a gene highly expressed in murine prostate stem cells, blocks the progression of indolent intraepithelial prostatic lesions into aggressive and rapidly growing tumors. Here, we show that the anti-tumorigenic effect of KLF4 extends to PC3 human prostate cancer cells growing in the bone. We compared KLF4 null cells with cells transduced with a DOX-inducible KLF4 expression system, and find KLF4 function inhibits PC3 growth in monolayer and soft agar cultures. Furthermore, KLF4 null cells proliferate rapidly, forming large, invasive, and osteolytic tumors when injected into mouse femurs, whereas KLF4 re-expression immediately after their intra-femoral inoculation blocks tumor development and preserves a normal bone architecture. KLF4 re-expression in established KLF4 null bone tumors inhibits their osteolytic effects, preventing bone fractures and inducing an osteogenic response with new bone formation. In addition to these profound biological changes, KLF4 also induces a transcriptional shift from an osteolytic program in KLF4 null cells to an osteogenic program. Importantly, bioinformatic analysis shows that genes regulated by KLF4 overlap significantly with those expressed in metastatic prostate cancer patients and in three individual cohorts with bone metastases, strengthening the clinical relevance of the findings in our xenograft model.	[Tassone, Evelyne; Bradaschia-Correa, Vivian; Xiong, Xiaozhong; Josephson, Anne Marie; Leucht, Philipp; Schober, Markus; Wilson, Elaine L.] NYU, Dept Cell Biol, Sch Med, New York, NY 10016 USA; [Bradaschia-Correa, Vivian; Josephson, Anne Marie; Leucht, Philipp] NYU, Dept Orthoped Surg, Sch Med, New York, NY 10016 USA; [Sastre-Perona, Ana; Schober, Markus] NYU, Ronald O Perelman Dept Dermatol, Sch Med, New York, NY 10016 USA; [Khodadadi-Jamayran, Alireza; Melamed, Jonathan] NYU, Dept Pathol, Sch Med, New York, NY 10016 USA; [Khodadadi-Jamayran, Alireza] NYU, Appl Bioinformat Labs, Sch Med, New York, NY 10016 USA; [Bu, Lei] NYU, Dept Med, Sch Med, New York, NY 10016 USA; [Kahler, David J.] NYU, High Throughput Biol Lab, Sch Med, New York, NY 10016 USA; [Ossowski, Liliana] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; [Wilson, Elaine L.] NYU, Dept Urol, Sch Med, New York, NY 10016 USA	New York University; New York University; New York University; New York University; New York University; New York University; New York University; Icahn School of Medicine at Mount Sinai; New York University	Schober, M; Wilson, EL (corresponding author), NYU, Dept Cell Biol, Sch Med, New York, NY 10016 USA.; Schober, M (corresponding author), NYU, Ronald O Perelman Dept Dermatol, Sch Med, New York, NY 10016 USA.; Wilson, EL (corresponding author), NYU, Dept Urol, Sch Med, New York, NY 10016 USA.	markus.schober@nyumc.org; elaine.wilson@nyumc.org	Melamed, Jonathan/AAV-3769-2020; Sastre-Perona, Ana/AAC-1202-2021	Melamed, Jonathan/0000-0003-2844-7990; Khodadadi-Jamayran, Alireza/0000-0003-2495-7504; Kahler, David/0000-0002-7144-2215; Tassone, Evelyne/0000-0003-0631-007X; Leucht, Philipp/0000-0002-8409-8513; BU, LEI/0000-0003-4476-2157	NIH [S10 OD010751, R01CA132641, R01AG056169, K08AR069099, R01CA181111, T32CA009161, T32AR064184]; American Cancer Society [RSG-16-033-01-DDC]; Department of Urology; Kimmel Center for Stem Cell Biology; Perlmutter Cancer Center [P30CA016087]; NYSTEM [C026719]; NATIONAL CANCER INSTITUTE [R01CA181111, P30CA016087, T32CA009161, R01CA132641] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR069099, T32AR064184] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG056169] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Department of Urology; Kimmel Center for Stem Cell Biology; Perlmutter Cancer Center; NYSTEM; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Dr. E. Hernando-Monge (NYU School of Medicine) for the GFP-luciferase plasmid (BLIV513PA-1) and Drs. S. Logan and M. Garabedian (NYU School of Medicine) for helpful discussions. This study was supported by the NIH (R01CA132641 to E.L.W., R01AG056169 and K08AR069099 to P.L., R01CA181111 to M.S., T32CA009161 and T32AR064184 to A.S-P.), the American Cancer Society (RSG-16-033-01-DDC to M. S.), the Department of Urology and the Kimmel Center for Stem Cell Biology. Core funding (Applied Bioinformatics Laboratories, Genome Technology Center, High Throughput Biology Laboratory, Experimental Pathology Research Laboratory, Micro-CT) is partially supported by the Perlmutter Cancer Center (P30CA016087), NYSTEM (contract C026719), and NIH (S10 OD010751).	Anders Simon, 2010, Genome Biol, V11, pR106, DOI 10.1186/gb-2010-11-10-r106; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Armstrong AP, 2008, PROSTATE, V68, P92, DOI 10.1002/pros.20678; Barba M, 2012, J BIOMED BIOTECHNOL, V2012, P1; Body JJ, 2015, NAT REV UROL, V12, P340, DOI 10.1038/nrurol.2015.90; Borowicz S, 2014, JOVE-J VIS EXP, DOI 10.3791/51998; Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chandran UR, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-64; Chen XM, 2003, J MOL BIOL, V326, P665, DOI 10.1016/S0022-2836(02)01449-3; Crockett JC, 2011, J CELL SCI, V124, P991, DOI 10.1242/jcs.063032; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Fradet A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075092; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200; Ghaleb AM, 2017, GENE, V611, P27, DOI 10.1016/j.gene.2017.02.025; Gooding S, 2016, CURR OPIN PHARMACOL, V28, P43, DOI 10.1016/j.coph.2016.02.013; Hockemeyer D, 2008, CELL STEM CELL, V3, P346, DOI 10.1016/j.stem.2008.08.014; Hopkins DR, 2007, MATRIX BIOL, V26, P508, DOI 10.1016/j.matbio.2007.05.004; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; KAIGHN ME, 1979, INVEST UROL, V17, P16; Kudo O, 2002, J PATHOL, V198, P220, DOI 10.1002/path.1190; Kumar A, 2016, NAT MED, V22, P369, DOI 10.1038/nm.4053; Lee HL, 2010, EXP MOL MED, V42, P437, DOI 10.3858/emm.2010.42.6.045; LeRoy BE, 2006, PROSTATE, V66, P1213, DOI 10.1002/pros.20408; Leucht P, 2007, BONE, V40, P919, DOI 10.1016/j.bone.2006.10.027; Li ZG, 2008, J CLIN INVEST, V118, P2697, DOI 10.1172/JCI33093; Liu YN, 2012, MOL CELL BIOL, V32, P941, DOI 10.1128/MCB.06306-11; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Morcos MW, 2018, BONE JOINT RES, V7, P397, DOI 10.1302/2046-3758.76.BJR-2017-0140.R2; Nandana S, 2017, CANCER RES, V77, P1331, DOI 10.1158/0008-5472.CAN-16-0497; Osta B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00048; Park SH, 2018, CALCIFIED TISSUE INT, V102, P152, DOI 10.1007/s00223-017-0350-8; Quigley DA, 2018, CELL, V174, P758, DOI 10.1016/j.cell.2018.06.039; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Rowland BD, 2006, NAT REV CANCER, V6, P11, DOI 10.1038/nrc1780; Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314; Rucci N, 2009, J CELL BIOL, V187, P669, DOI 10.1083/jcb.200906014; Sanchez-Sweatman Otto H., 1998, Invasion and Metastasis, V18, P297, DOI 10.1159/000024522; Sastre-Perona A, 2019, CELL STEM CELL, V24, P390, DOI 10.1016/j.stem.2019.01.003; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Sims NA, 2016, INT J BIOCHEM CELL B, V79, P14, DOI 10.1016/j.biocel.2016.08.003; Siu MK, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.79; Sottnik JL, 2013, CURR MOL MED, V13, P626; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tetreault MP, 2013, NAT REV CANCER, V13, P701, DOI 10.1038/nrc3582; Tsuji T, 2008, BIOCHEM BIOPH RES CO, V376, P186, DOI 10.1016/j.bbrc.2008.08.139; Uchimura T, 2017, DEVELOPMENT, V144, P3533, DOI 10.1242/dev.155598; Vela I, 2007, BJU INT, V99, P735, DOI 10.1111/j.1464-410X.2006.06670.x; Wang J, 2010, CANCER RES, V70, P10182, DOI 10.1158/0008-5472.CAN-10-2414; Wei DY, 2005, CANCER RES, V65, P2746, DOI 10.1158/0008-5472.CAN-04-3619; Wu JB, 2017, CANCER CELL, V31, P368, DOI 10.1016/j.ccell.2017.02.003; Xiong XZ, 2018, CELL REP, V25, P3006, DOI 10.1016/j.celrep.2018.11.065; Yoshida T, 2012, J BIOL CHEM, V287, P25706, DOI 10.1074/jbc.M112.361360; Zhao WD, 2004, ONCOGENE, V23, P395, DOI 10.1038/sj.onc.1207067	61	5	6	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	2019	38	29					5766	5777		10.1038/s41388-019-0841-3	http://dx.doi.org/10.1038/s41388-019-0841-3			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IQ4WS	31239516	Green Published, Green Accepted			2022-12-28	WOS:000480752800002
J	Zhou, LS; Jiang, YY; Liu, XJ; Li, LH; Yang, XG; Dong, CS; Liu, XL; Lin, YL; Li, Y; Yu, JH; He, R; Huang, SL; Liu, GW; Zhang, YM; Jeong, LS; Hoffman, RM; Jia, LJ				Zhou, Lisha; Jiang, Yanyu; Liu, Xiaojun; Li, Lihui; Yang, Xuguang; Dong, Changsheng; Liu, Xiaoli; Lin, Yuli; Li, Yan; Yu, Jinha; He, Rui; Huang, Shenglin; Liu, Guangwei; Zhang, Yanmei; Jeong, Lak Shin; Hoffman, Robert M.; Jia, Lijun			Promotion of tumor-associated macrophages infiltration by elevated neddylation pathway via NF-kappa B-CCL2 signaling in lung cancer	ONCOGENE			English	Article							NEDD8-ACTIVATING ENZYME-INHIBITOR; MONOCYTE CHEMOATTRACTANT PROTEIN-1; PEVONEDISTAT TAK-924/MLN4924; BREAST-CANCER; PHASE-I; EXPRESSION; MLN4924; PROGRESSION; SURVIVAL; GROWTH	Tumor-associated macrophages (TAMs) are the most abundant cancer stromal cells and play an essential role in tumor immunosuppression, providing a suitable microenvironment for cancer development and progression. However, mechanisms of regulating TAMs infiltration in tumor sites are not fully understood. Here, we show that inactivation of neddylation pathway significantly inhibits infiltration of TAMs, leading to the suppression of lung cancer metastasis. RNA-sequencing analysis revealed that neddylation inactivation suppresses the transactivation of chemotactic cytokine ligand 2 (CCL2). Mechanistically, neddylation inactivation inhibits the activity of Cullin-RING ligases (CRLs) and induces the accumulation of its substrate I kappa B alpha to block NF-kappa B transcriptional activity and CCL2 transactivation. As a result, neddylation inactivation exhibits lower chemotaxis of monocytes, thereby decreasing TAMs infiltration, which can be alleviated by CCL2 addition. Moreover, the expression level of NEDD8 is positively correlated with high CCL2 expression in lung adenocarcinoma, conferring a worse overall patient survival. Together, neddylation pathway promotes CCL2 transactivation and TAMs infiltration in lung cancer to provide a tumor-promoting microenvironment, which validates neddylation pathway as a promising target for anti-TAMs therapeutic strategies.	[Zhou, Lisha; Li, Lihui; Yang, Xuguang; Dong, Changsheng; Jia, Lijun] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Canc Inst, Shanghai, Peoples R China; [Jiang, Yanyu; Liu, Xiaojun; Liu, Xiaoli; Huang, Shenglin] Fudan Univ, Shanghai Canc Ctr, Canc Inst, Shanghai, Peoples R China; [Lin, Yuli; He, Rui] Fudan Univ, Sch Basic Med Sci, Dept Immunol, Shanghai, Peoples R China; [Li, Yan; Liu, Guangwei] Beijing Normal Univ, Coll Life Sci, Beijing, Peoples R China; [Yu, Jinha; Jeong, Lak Shin] Seoul Natl Univ, Coll Pharm, Seoul, South Korea; [Zhang, Yanmei] Fudan Univ, Huaong Hosp, Dept Lab Med, Shanghai, Peoples R China; [Hoffman, Robert M.] Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA	Shanghai University of Traditional Chinese Medicine; Fudan University; Fudan University; Beijing Normal University; Seoul National University (SNU); Fudan University; University of California System; University of California San Diego	Jia, LJ (corresponding author), Shanghai Univ Tradit Chinese Med, Longhua Hosp, Canc Inst, Shanghai, Peoples R China.	ljjia@shutcm.edu.cn	Liu, Xiaoli/HGE-7614-2022; Yang, Xuguang/GNP-2847-2022; He, Rui/P-7302-2019; Yu, Jinha/AAS-6463-2021; Dong, Changsheng/AAX-2495-2020; Dong, Changsheng/HCH-9181-2022; Huang, Shenglin/N-9472-2018	Yang, Xuguang/0000-0002-6198-6008; He, Rui/0000-0001-5288-9786; Dong, Changsheng/0000-0001-8385-7904; Huang, Shenglin/0000-0003-1279-0794; Liu, Guangwei/0000-0002-6008-2891; YU, JINHA/0000-0002-0495-5686	Chinese Minister of Science and Technology grant [2016YFA0501800]; National Natural Science Foundation of China [81820108022, 81625018, 81572340, 81772470, 81602072, 81401893, 81702244, 81871870]; Innovation Program of Shanghai Municipal Education Commission [2019-01-07-00-10-E00056]; National Thirteenth Five-Year Science and Technology Major Special Project for New Drug and Development [2017ZX09304001]; Program of Shanghai Academic/Technology Research Leader [18XD1403800]	Chinese Minister of Science and Technology grant; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Innovation Program of Shanghai Municipal Education Commission(Innovation Program of Shanghai Municipal Education Commission); National Thirteenth Five-Year Science and Technology Major Special Project for New Drug and Development; Program of Shanghai Academic/Technology Research Leader	The Chinese Minister of Science and Technology grant (2016YFA0501800), National Natural Science Foundation of China (Grant Nos. 81820108022, 81625018, 81572340, 81772470, 81602072, 81401893, 81702244 and 81871870), Innovation Program of Shanghai Municipal Education Commission (2019-01-07-00-10-E00056), National Thirteenth Five-Year Science and Technology Major Special Project for New Drug and Development (2017ZX09304001), and Program of Shanghai Academic/Technology Research Leader (18XD1403800), supported this work.	Bhatia S, 2016, INVEST NEW DRUG, V34, P439, DOI 10.1007/s10637-016-0348-5; Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027; Brownell JE, 2010, MOL CELL, V37, P102, DOI 10.1016/j.molcel.2009.12.024; Chanmee T, 2014, CANCERS, V6, P1670, DOI 10.3390/cancers6031670; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; De Palma M, 2013, CANCER CELL, V23, P277, DOI 10.1016/j.ccr.2013.02.013; Enchev RI, 2015, NAT REV MOL CELL BIO, V16, P30, DOI 10.1038/nrm3919; EZEKOWITZ RAB, 1984, CONTEMP TOP IMMUNOBI, V13, P33; Fridlender ZG, 2011, AM J RESP CELL MOL, V44, P230, DOI 10.1165/rcmb.2010-0080OC; Gao Q, 2014, ONCOTARGET, V5, P7820, DOI 10.18632/oncotarget.2309; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Hao JQ, 2018, CANCER RES, V78, P2343, DOI 10.1158/0008-5472.CAN-17-2465; Heagerty PJ, 2000, BIOMETRICS, V56, P337, DOI 10.1111/j.0006-341X.2000.00337.x; Heusinkveld M, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-216; Hildebrand DG, 2013, J IMMUNOL, V190, P4812, DOI 10.4049/jimmunol.1300089; Hua W, 2015, NEURO-ONCOLOGY, V17, P1333, DOI 10.1093/neuonc/nov066; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; Lee HW, 2011, J ORG CHEM, V76, P3557, DOI 10.1021/jo2001897; Li LH, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju083; Li XG, 2017, GUT, V66, P157, DOI 10.1136/gutjnl-2015-310514; Li XJ, 2016, NAT CELL BIOL, V18, P561, DOI 10.1038/ncb3338; Lu Y, 2006, PROSTATE, V66, P1311, DOI 10.1002/pros.20464; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Pachynski RK, 2012, J EXP MED, V209, P1427, DOI 10.1084/jem.20112124; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Sarantopoulos J, 2016, CLIN CANCER RES, V22, P847, DOI 10.1158/1078-0432.CCR-15-1338; Shah JJ, 2016, CLIN CANCER RES, V22, P34, DOI 10.1158/1078-0432.CCR-15-1237; Soria G, 2008, CYTOKINE, V44, P191, DOI 10.1016/j.cyto.2008.08.002; Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884; Swords RT, 2018, BLOOD, V131, P1415, DOI 10.1182/blood-2017-09-805895; Swords RT, 2015, BRIT J HAEMATOL, V169, P534, DOI 10.1111/bjh.13323; Tan M, 2014, ONCOGENE, V33, P5211, DOI 10.1038/onc.2013.473; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Wang YC, 2015, CANCER BIOL THER, V16, P420, DOI 10.1080/15384047.2014.1003003; Williams CB, 2016, NPJ BREAST CANCER, V2, DOI 10.1038/npjbcancer.2015.25; Xie P, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.195; Xirodimas DP, 2008, BIOCHEM SOC T, V36, P802, DOI 10.1042/BST0360802; Yao WT, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.21; Yoshidome H, 2009, INT J ONCOL, V34, P923, DOI 10.3892/ijo_00000218; Yu GZ, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0462-6; Zhang JX, 2013, LANCET ONCOL, V14, P1295, DOI 10.1016/S1470-2045(13)70491-1; Zhou LS, 2018, CELL SIGNAL, V44, P92, DOI 10.1016/j.cellsig.2018.01.009	47	38	39	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	2019	38	29					5792	5804		10.1038/s41388-019-0840-4	http://dx.doi.org/10.1038/s41388-019-0840-4			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IQ4WS	31243299				2022-12-28	WOS:000480752800004
J	Ramirez-Moya, J; Wert-Lamas, L; Riesco-Eizaguirre, G; Santisteban, P				Ramirez-Moya, Julia; Wert-Lamas, Leon; Riesco-Eizaguirre, Garcilaso; Santisteban, Pilar			Impaired microRNA processing by DICER1 downregulation endows thyroid cancer with increased aggressiveness	ONCOGENE			English	Article							MOLECULAR PATHOGENESIS; EXPRESSION; BIOGENESIS; MUTATIONS; METASTASIS; ONCOGENES; CELLS; RNAS	The global downregulation of microRNAs (miRNAs) is emerging as a common hallmark of cancer. However, the mechanisms underlying this phenomenon are not well known. We identified that the oncogenic miR-146b-5p attenuates miRNA biosynthesis by targeting DICER1 and reducing its expression. DICER1 overexpression inhibited all the miR-146b-induced aggressive phenotypes in thyroid cells. Systemic injection of an anti-miR-146b in mice with orthotopic thyroid tumors suppressed tumor growth and recovered DICER1 levels. Notably, DICER1 downregulation promoted proliferation, migration, invasion, and epithelial-mesenchymal transition through miRNA downregulation. Our analysis of The Cancer Genome Atlas revealed a general decrease in DICER1 expression in thyroid cancer that was associated with a worse clinical outcome. Administration of the small-molecule enoxacin to promote DICER1 complex activity reduced tumor aggressiveness both in vitro and in vivo. Overall, our data confirm DICER1 as a tumor suppressor and show that oncogenic miR-146b contributes to its downregulation. Moreover, our results highlight a potential therapeutic application of RNA-based therapies including miRNA inhibitors and restoration of the biogenesis machinery, which may provide treatments for thyroid and other cancers.	[Ramirez-Moya, Julia; Wert-Lamas, Leon; Riesco-Eizaguirre, Garcilaso; Santisteban, Pilar] UAM, CSIC, Inst Invest Biomed Alberto Sols, Madrid, Spain; [Ramirez-Moya, Julia; Riesco-Eizaguirre, Garcilaso; Santisteban, Pilar] Inst Salud Carlos III, Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain; [Wert-Lamas, Leon; Riesco-Eizaguirre, Garcilaso] Hosp Univ Mostoles, Dept Endocrinol & Nutr, Madrid, Spain; [Riesco-Eizaguirre, Garcilaso] Univ Francisco de Vitoria, Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Instituto de Salud Carlos III; Universidad Francisco de Vitoria	Santisteban, P (corresponding author), UAM, CSIC, Inst Invest Biomed Alberto Sols, Madrid, Spain.; Santisteban, P (corresponding author), Inst Salud Carlos III, Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain.	psantisteban@iib.uam.es	Ramírez-Moya, Julia/B-9104-2018; Wert-Lamas, Leon/ABD-2880-2020; Riesco-Eizaguirre, Garcilaso/O-8750-2015	Ramírez-Moya, Julia/0000-0002-2458-2186; Riesco-Eizaguirre, Garcilaso/0000-0002-2608-6397	MINECO, Spain [SAF2016-75531-R]; ISCIII, Spain (FEDER) [PI14/01980]; CAM [B2017/BMD-3724]; F-AECC [GCB14142311CRES]; MECD (Spain)	MINECO, Spain; ISCIII, Spain (FEDER); CAM; F-AECC; MECD (Spain)	This work was supported by grants SAF2016-75531-R from MINECO, Spain and PI14/01980 from ISCIII, Spain (FEDER)); B2017/BMD-3724 from CAM and GCB14142311CRES from F-AECC. JR-M holds a FPU fellowship from MECD (Spain).	Adams BD, 2017, J CLIN INVEST, V127, P761, DOI 10.1172/JCI84424; Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Bernstein E, 2003, NAT GENET, V35, P215, DOI 10.1038/ng1253; Boufraqech M, 2015, CANCER RES, V75, P367, DOI 10.1158/0008-5472.CAN-14-2304; Braun J, 2010, ONCOGENE, V29, P4237, DOI 10.1038/onc.2010.169; Penha RCC, 2017, CELL CYCLE, V16, P2282, DOI 10.1080/15384101.2017.1380127; Chendrimada TP, 2005, NATURE, V436, P740, DOI 10.1038/nature03868; Chou CK, 2013, J CLIN ENDOCR METAB, V98, pE196, DOI 10.1210/jc.2012-2666; de Kock L, 2014, J CLIN ENDOCR METAB, V99, pE1072, DOI 10.1210/jc.2013-4206; Emde A, 2015, EMBO J, V34, P2633, DOI 10.15252/embj.201490493; Erler P, 2014, SURGERY, V156, P1342, DOI 10.1016/j.surg.2014.08.007; Frezzetti D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027648; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Fuziwara CS, 2017, MOL CELL ENDOCRINOL, V456, P44, DOI 10.1016/j.mce.2016.12.017; Geraldo MV, 2012, ONCOGENE, V31, P1910, DOI 10.1038/onc.2011.381; Gregory RI, 2005, CANCER RES, V65, P3509, DOI 10.1158/0008-5472.CAN-05-0298; Hammond SM, 2006, CURR OPIN GENET DEV, V16, P4, DOI 10.1016/j.gde.2005.12.005; Haugen BR, 2013, ENDOCR REV, V34, P439, DOI 10.1210/er.2012-1038; Hebrant A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103871; Khan NE, 2017, J CLIN ENDOCR METAB, V102, P1614, DOI 10.1210/jc.2016-2954; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Lim H, 2017, JAMA-J AM MED ASSOC, V317, p[1974, 1338]; Lima CR, 2017, MOL CELL ENDOCRINOL, V456, P62, DOI 10.1016/j.mce.2017.03.015; Lin SB, 2015, NAT REV CANCER, V15, P321, DOI 10.1038/nrc3932; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017; Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016; Melo S, 2011, P NATL ACAD SCI USA, V108, P4394, DOI 10.1073/pnas.1014720108; Oue T, 2008, PEDIATR BLOOD CANCER, V50, P901, DOI 10.1002/pbc.21265; Ozen M, 2008, ONCOGENE, V27, P1788, DOI 10.1038/sj.onc.1210809; Pacifico F, 2010, MOL CELL ENDOCRINOL, V321, P29, DOI 10.1016/j.mce.2009.10.010; Pallante P, 2014, NAT REV ENDOCRINOL, V10, P88, DOI 10.1038/nrendo.2013.223; Ramirez-Moya J, 2018, ONCOGENE, V37, P3369, DOI 10.1038/s41388-017-0088-9; Riesco-Eizaguirre G, 2016, EUR J ENDOCRINOL, V175, pR203, DOI 10.1530/EJE-16-0202; Riesco-Eizaguirre G, 2015, CANCER RES, V75, P4119, DOI 10.1158/0008-5472.CAN-14-3547; Rodriguez W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029929; Rome A, 2008, PEDIATR BLOOD CANCER, V50, P1081, DOI 10.1002/pbc.21431; Rutter MM, 2016, J CLIN ENDOCR METAB, V101, P1, DOI 10.1210/jc.2015-2169; Saiselet M, 2016, ONCOTARGET, V7, P52475, DOI 10.18632/oncotarget.9655; Sastre-Perona A, 2016, ONCOTARGET, V7, P49435, DOI 10.18632/oncotarget.10356; Shan G, 2008, NAT BIOTECHNOL, V26, P933, DOI 10.1038/nbt.1481; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; Thomson JM, 2006, GENE DEV, V20, P2202, DOI 10.1101/gad.1444406; Xing MZ, 2013, NAT REV CANCER, V13, P184, DOI 10.1038/nrc3431; Yan M, 2012, PATHOL ONCOL RES, V18, P343, DOI 10.1007/s12253-011-9450-3; Zeng Y, 2002, MOL CELL, V9, P1327, DOI 10.1016/S1097-2765(02)00541-5	46	32	33	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2019	38	27					5486	5499		10.1038/s41388-019-0804-8	http://dx.doi.org/10.1038/s41388-019-0804-8			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IG5KR	30967628	Green Published, hybrid, Green Submitted			2022-12-28	WOS:000473842500011
J	Park, JE; Dutta, B; Tse, SW; Gupta, N; Tan, CF; Low, JK; Yeoh, KW; Kon, OL; Tam, JP; Sze, SK				Park, Jung Eun; Dutta, Bamaprasad; Tse, Shun Wilford; Gupta, Nikhil; Tan, Chee Fan; Low, Jee Keem; Yeoh, Kheng Wei; Kon, Oi Lian; Tam, James P.; Sze, Siu Kwan			Hypoxia-induced tumor exosomes promote M2-like macrophage polarization of infiltrating myeloid cells and microRNA-mediated metabolic shift	ONCOGENE			English	Article							HEAVY-CHAIN FERRITIN; CANCER-CELLS; SUPPRESSOR-CELLS; IMMUNE-RESPONSES; DENDRITIC CELL; M2 MACROPHAGE; PROGRESSION; SECRETION; MIGRATION; RECEPTOR	Developing tumors rapidly outgrow their oxygen supply and are subject to hypoxia, which stimulates hypersecretion of tumor-derived exosomes that promote angiogenesis, metastasis, and immunosuppression, but the molecular mediators of these pathological effects remain poorly defined. Using quantitative proteomics, we identified that exosomes produced by hypoxic tumor cells are highly enriched in immunomodulatory proteins and chemokines including CSF-1, CCL2, FTH, FTL, and TGF beta. Modeling exosome effects on tumor-infiltrating immune cells, we observed a potent ability of these hypoxia-induced vesicles to influence macrophage recruitment and promote M2-like polarization both in vitro and in vivo. In addition, hypoxic, but not normoxic, tumor exosomes enhanced oxidative phosphorylation in bone marrow-derived macrophages via transfer of let-7a miRNA, resulting in suppression of the insulin-Akt-mTOR signaling pathway. Together, these data demonstrate that hypoxia promotes tumor secretion of biomolecule-loaded exosomes that can modify the immunometabolic profile of infiltrating monocyte-macrophages to better evade host immunity and enhance tumor progression.	[Park, Jung Eun; Dutta, Bamaprasad; Tse, Shun Wilford; Gupta, Nikhil; Tan, Chee Fan; Tam, James P.; Sze, Siu Kwan] Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore; [Low, Jee Keem] Tan Tock Seng Hosp, Dept Surg, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore; [Yeoh, Kheng Wei] Natl Canc Ctr Singapore, Dept Radiat Oncol, 11 Hosp Dr, Singapore 169610, Singapore; [Kon, Oi Lian] Natl Canc Ctr Singapore, Div Med Sci, 11 Hosp Dr, Singapore 169610, Singapore	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Tan Tock Seng Hospital; National Cancer Centre Singapore (NCCS); National Cancer Centre Singapore (NCCS)	Park, JE; Sze, SK (corresponding author), Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore.	jepark@ntu.edu.sg; sksze@ntu.edu.sg	Tam, James P/A-2176-2011; Sze, Siu Kwan/AAO-3342-2020; Dutta, Bamaprasad/AAH-4006-2020	Tam, James P/0000-0003-4433-198X; Sze, Siu Kwan/0000-0002-5652-1687; Dutta, Bamaprasad/0000-0002-2309-8771; Tan, Chee Fan/0000-0002-4109-8724	Singapore Ministry of Education [MOE2014-T2-2-043, MOE2016-T2-2-018, MOE2016-T3-1-003]; National Medical Research Council of Singapore [NMRC-OF-IRG-0003-2016]	Singapore Ministry of Education(Ministry of Education, Singapore); National Medical Research Council of Singapore(National Medical Research Council, Singapore)	This work is in part supported by grants from the Singapore Ministry of Education (MOE2014-T2-2-043, MOE2016-T2-2-018, and MOE2016-T3-1-003) and the National Medical Research Council of Singapore (NMRC-OF-IRG-0003-2016).	Alkhateeb AA, 2013, BBA-REV CANCER, V1836, P245, DOI 10.1016/j.bbcan.2013.07.002; Alkhateeb AA, 2013, BREAST CANCER RES TR, V137, P733, DOI 10.1007/s10549-012-2405-x; Balogh KN, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197702; Bellomo C, 2016, BRIT J CANCER, V115, P761, DOI 10.1038/bjc.2016.255; Biswas SK, 2015, IMMUNITY, V43, P435, DOI 10.1016/j.immuni.2015.09.001; Boelens MC, 2014, CELL, V159, P499, DOI 10.1016/j.cell.2014.09.051; Bretz NP, 2013, J BIOL CHEM, V288, P36691, DOI 10.1074/jbc.M113.512806; Chen SC, 2012, J PATHOL, V228, P158, DOI 10.1002/path.3988; Chen X, 2004, CURR CANCER DRUG TAR, V4, P267, DOI 10.2174/1568009043333041; Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev-cellbio-101512-122326; Damuzzo V, 2015, CYTOM PART B-CLIN CY, V88, P77, DOI [10.1002/cyto.b.21206, 10.1002/cytob.21206]; De Toro J, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00203; Dueck A, 2012, NUCLEIC ACIDS RES, V40, P9850, DOI 10.1093/nar/gks705; Elliott LA, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00086; Espinoza JL, 2012, HAEMATOL-HEMATOL J, V97, P1295, DOI 10.3324/haematol.2011.058529; Finger EC, 2010, CANCER METAST REV, V29, P285, DOI 10.1007/s10555-010-9224-5; Galvan-Pena S, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00420; Geeraerts X, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00289; Genin M, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1546-9; Gialeli C, 2011, FEBS J, V278, P16, DOI 10.1111/j.1742-4658.2010.07919.x; Gilkes DM, 2013, MOL CANCER RES, V11, P456, DOI 10.1158/1541-7786.MCR-12-0629; Gray CP, 2003, CLIN CANCER RES, V9, P2551; Gray CP, 2002, BLOOD, V99, P3326, DOI 10.1182/blood.V99.9.3326; Green CE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006713; Hoffman RM, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3426; Hu JM, 2017, ONCOTARGET, V8, P21526, DOI 10.18632/oncotarget.15630; Hume DA, 2012, BLOOD, V119, P1810, DOI 10.1182/blood-2011-09-379214; Jezequel P, 2012, INT J CANCER, V131, P426, DOI 10.1002/ijc.26397; Jia WZ, 2013, AM J PATHOL, V182, P1821, DOI 10.1016/j.ajpath.2013.01.017; KAO J, 1994, J BIOL CHEM, V269, P25106; Kikushige Y, 2008, J IMMUNOL, V180, P7358, DOI 10.4049/jimmunol.180.11.7358; Kindt N, 2016, ONCOL LETT, V12, P2247, DOI 10.3892/ol.2016.4929; Kore RA, 2018, BIOCHEM BIOPHYS REP, V14, P104, DOI 10.1016/j.bbrep.2018.03.008; Kucharzewska P, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.20304; Kumar V, 2016, TRENDS IMMUNOL, V37, P208, DOI 10.1016/j.it.2016.01.004; LEBRUN JJ, 2012, ISRN MOL BIOL, V2012, P28; Leca J, 2016, J CLIN INVEST, V126, P4140, DOI 10.1172/JCI87734; Lee DD, 2016, AM J RESP CELL MOL, V55, P602, DOI 10.1165/rcmb.2016-0091OC; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li M, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.25474; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Liu YF, 2016, CANCER CELL, V30, P243, DOI 10.1016/j.ccell.2016.06.021; Lobb RJ, 2017, SEMIN CELL DEV BIOL, V67, P3, DOI 10.1016/j.semcdb.2017.01.004; Marie JC, 2005, J EXP MED, V201, P1061, DOI 10.1084/jem.20042276; Mogami T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080359; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Murdoch C, 2004, BLOOD, V104, P2224, DOI 10.1182/blood-2004-03-1109; Nielsen SR, 2017, MEDIAT INFLAMM, V2017, P11; O'Neill LAJ, 2016, J EXP MED, V213, P15, DOI 10.1084/jem.20151570; Otero-Albiol D, 2016, CANC TRANSL MED, V2, P175, DOI DOI 10.3892/OL.2016.4316; Park JE, 2017, SCI REP-UK, V7, DOI 10.1038/srep40569; Park JE, 2010, MOL CELL PROTEOMICS, V9, P1085, DOI 10.1074/mcp.M900381-MCP200; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Qi HB, 2015, ONCOL LETT, V10, P1947, DOI 10.3892/ol.2015.3498; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Robbins PD, 2014, NAT REV IMMUNOL, V14, P195, DOI 10.1038/nri3622; Roszer T, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/816460; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Simons M, 2009, CURR OPIN CELL BIOL, V21, P575, DOI 10.1016/j.ceb.2009.03.007; Storm MP, 2016, JOVE-J VIS EXP, DOI 10.3791/53431; Sudan B, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00253; Vo TTL, 2018, ANN NY ACAD SCI, V1431, P3, DOI 10.1111/nyas.13929; Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492; Torrisani J, 2007, CURR GENOMICS, V8, P229; Ugel S, 2015, J CLIN INVEST, V125, P3365, DOI 10.1172/JCI80006; Viaud S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004942; Villarroya-Beltri C, 2014, SEMIN CANCER BIOL, V28, P3, DOI 10.1016/j.semcancer.2014.04.009; Wang DZ, 2018, GENET TEST MOL BIOMA, V22, P366, DOI 10.1089/gtmb.2018.0009; Wargo JA, 2016, CURR OPIN IMMUNOL, V41, P23, DOI 10.1016/j.coi.2016.05.006; Wenes M, 2016, CELL METAB, V24, P701, DOI 10.1016/j.cmet.2016.09.008; Whiteside TL, 2016, J CLIN INVEST, V126, P1216, DOI 10.1172/JCI81136; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064; Winter J, 2011, RNA BIOL, V8, P1149, DOI 10.4161/rna.8.6.17665; Wu LJ, 2016, TUMOR BIOL, V37, P12169, DOI 10.1007/s13277-016-5071-5; Wu TF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149361; Young L, 2010, NAT PROTOC, V5, P929, DOI 10.1038/nprot.2010.43; Zhou JB, 2016, ONCOTARGET, V7, P50698, DOI 10.18632/oncotarget.9333; Zhu H, 2011, CELL, V147, P81, DOI 10.1016/j.cell.2011.08.033; Zhu Q, 2015, NAT METHODS, V12, P211, DOI [10.1038/NMETH.3249, 10.1038/nmeth.3249]	80	140	146	3	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2019	38	26					5158	5173		10.1038/s41388-019-0782-x	http://dx.doi.org/10.1038/s41388-019-0782-x			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IF4AX	30872795				2022-12-28	WOS:000473025300004
J	Villafanez, F; Garcia, IA; Carbajosa, S; Pansa, MF; Mansilla, S; Llorens, MC; Angiolini, V; Guantay, L; Jacobs, H; Madauss, KP; Gloger, I; Gottifredi, V; Bocco, JL; Soria, G				Villafanez, Florencia; Alejandra Garcia, Iris; Carbajosa, Sofia; Florencia Pansa, Maria; Mansilla, Sabrina; Candelaria Llorens, Maria; Angiolini, Virginia; Guantay, Laura; Jacobs, Heinz; Madauss, Kevin P.; Gloger, Israel; Gottifredi, Vanesa; Luis Bocco, Jose; Soria, Gaston			AKT inhibition impairs PCNA ubiquitylation and triggers synthetic lethality in homologous recombination-deficient cells submitted to replication stress	ONCOGENE			English	Article							PROTEIN-KINASE B; NUCLEAR ANTIGEN UBIQUITINATION; DNA-DAMAGE RESPONSE; SIGNALING PATHWAY; P21 DEGRADATION; REPAIR; ETA; POLYMERASES; AKT/PKB; CANCER	Translesion DNA synthesis (TLS) and homologous recombination (HR) cooperate during S-phase to safeguard replication forks integrity. Thus, the inhibition of TLS becomes a promising point of therapeutic intervention in HR-deficient cancers, where TLS impairment might trigger synthetic lethality (SL). The main limitation to test this hypothesis is the current lack of selective pharmacological inhibitors of TLS. Herein, we developed a miniaturized screening assay to identify inhibitors of PCNA ubiquitylation, a key post-translational modification required for efficient TLS activation. After screening a library of 627 kinase inhibitors, we found that targeting the pro-survival kinase AKT leads to strong impairment of PCNA ubiquitylation. Mechanistically, we found that AKT-mediated modulation of Proliferating Cell Nuclear Antigen (PCNA) ubiquitylation after UV requires the upstream activity of DNA PKcs, without affecting PCNA ubiquitylation levels in unperturbed cells. Moreover, we confirmed that persistent AKT inhibition blocks the recruitment of TLS polymerases to sites of DNA damage and impairs DNA replication forks processivity after UV irradiation, leading to increased DNA replication stress and cell death. Remarkably, when we compared the differential survival of HR-proficient vs HR-deficient cells, we found that the combination of UV irradiation and AKT inhibition leads to robust SL induction in HR-deficient cells. We link this phenotype to AKT ability to inhibit PCNA ubiquitylation, since the targeted knockdown of PCNA E3-ligase (RAD18) and a non-ubiquitylable (PCNA K164R) knock-in model recapitulate the observed SL induction. Collectively, this work identifies AKT as a novel regulator of PCNA ubiquitylation and provides the proof-of-concept of inhibiting TLS as a therapeutic approach to selectively kill HR-deficient cells submitted to replication stress.	[Villafanez, Florencia; Alejandra Garcia, Iris; Carbajosa, Sofia; Florencia Pansa, Maria; Candelaria Llorens, Maria; Angiolini, Virginia; Guantay, Laura; Luis Bocco, Jose; Soria, Gaston] Consejo Nacl Invest Cient & Tecn, CIBICI, Ctr Invest Bioquim Clin & Inmunol, Cordoba, Argentina; [Villafanez, Florencia; Alejandra Garcia, Iris; Carbajosa, Sofia; Florencia Pansa, Maria; Candelaria Llorens, Maria; Angiolini, Virginia; Guantay, Laura; Luis Bocco, Jose; Soria, Gaston] Univ Nacl Cordoba, Fac Ciencias Quim, Dept Bioquim Clin, Cordoba, Argentina; [Mansilla, Sabrina; Gottifredi, Vanesa] Fdn Inst Leloir, Buenos Aires, DF, Argentina; [Jacobs, Heinz] Netherlands Canc Inst, Tumor Biol & Immunol, Amsterdam, Netherlands; [Madauss, Kevin P.] GlaxoSmithKline Trust Sci, Global Hlth R&D, Upper Providence, PA USA; [Gloger, Israel] GlaxoSmithKline Trust Sci, Global Hlth R&D, Stevenage, Herts, England	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Cordoba; Leloir Institute; Netherlands Cancer Institute	Soria, G (corresponding author), Consejo Nacl Invest Cient & Tecn, CIBICI, Ctr Invest Bioquim Clin & Inmunol, Cordoba, Argentina.; Soria, G (corresponding author), Univ Nacl Cordoba, Fac Ciencias Quim, Dept Bioquim Clin, Cordoba, Argentina.	gsoria29@gmail.com	Carbajosa, Sofía/AAB-1554-2020; Gottifredi, Vanesa/AAI-1788-2019	Mansilla, Sabrina Florencia/0000-0001-7752-3377; Villafanez, Florencia/0000-0001-9835-2343; Gottifredi, Vanesa/0000-0001-9656-5951; Carbajosa Gonzalez, Sofia/0000-0002-0133-8287	Start-up grant from the Fondo para la Investigacion Cientifica y Tecnologica (FONCyT PICT start-up) [2013-1553]; KWF [10796/2016-2, 10032/2016-1]; FONCyT; Trust in Science (Global Health R& D) from GlaxoSmithKline [PAE-GLAXO 2014-0005]; National Institute of Cancer; CONICET	Start-up grant from the Fondo para la Investigacion Cientifica y Tecnologica (FONCyT PICT start-up); KWF; FONCyT(FONCyT); Trust in Science (Global Health R& D) from GlaxoSmithKline; National Institute of Cancer; CONICET(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET))	We thank the flow cytometry, microscopy and cell culture facilities of CIBICI-CONICET for technical support. We thank Nicolas Nieto Moreno for careful reading of the manuscript and helpful suggestions. We would like to thank Gerard Drewes of CellZome (a GSK company) for his scientific advice. This work was supported by a Start-up grant from the Fondo para la Investigacion Cientifica y Tecnologica (FONCyT PICT start-up 2013-1553), by KWF projects 10796/2016-2 and 10032/2016-1 to HJ and by a consortium grant of FONCyT and the Trust in Science (Global Health R& D) from GlaxoSmithKline (PAE-GLAXO 2014-0005). S.M, V.G., J.L.B. and G.S. are researchers from CONICET. FV, IAG, SC, and MCL were supported by fellowships from FONCyT, MFP and LG were supported by fellowships from the National Institute of Cancer and CONICET.	Joray MB, 2017, FOOD CHEM TOXICOL, V109, P888, DOI 10.1016/j.fct.2017.04.039; Bertolin AP, 2015, DNA REPAIR, V32, P158, DOI 10.1016/j.dnarep.2015.04.027; Bienko M, 2005, SCIENCE, V310, P1821, DOI 10.1126/science.1120615; Boehme KA, 2008, P NATL ACAD SCI USA, V105, P7785, DOI 10.1073/pnas.0703423105; Branzei D, 2016, DNA REPAIR, V44, P68, DOI 10.1016/j.dnarep.2016.05.008; Brown JS, 2017, PHARMACOL THERAPEUT, V172, P101, DOI 10.1016/j.pharmthera.2016.12.001; Brun Jan, 2010, BMC Res Notes, V3, P85, DOI 10.1186/1756-0500-3-85; Ceppi P, 2009, CLIN CANCER RES, V15, P1039, DOI 10.1158/1078-0432.CCR-08-1227; Cipolla L, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00105; Davies H, 2017, NAT MED, V23, P517, DOI 10.1038/nm.4292; Despras E, 2012, ENVIRON MOL MUTAGEN, V53, P752, DOI 10.1002/em.21741; Despras E, 2010, HUM MOL GENET, V19, P1690, DOI 10.1093/hmg/ddq046; Han EKH, 2007, ONCOGENE, V26, P5655, DOI 10.1038/sj.onc.1210343; Hendel A, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002262; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Huang TT, 2006, NAT CELL BIOL, V8, P339, DOI 10.1038/ncb1378; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Jia JH, 2013, CELL SIGNAL, V25, P1498, DOI 10.1016/j.cellsig.2013.02.021; Langerak P, 2007, J EXP MED, V204, P1989, DOI 10.1084/jem.20070902; Leonhardt H, 2000, J CELL BIOL, V149, P271, DOI 10.1083/jcb.149.2.271; Liu Q, 2014, NEURO-ONCOLOGY, V16, P1313, DOI 10.1093/neuonc/nou058; Lord CJ, 2016, NAT REV CANCER, V16, P110, DOI 10.1038/nrc.2015.21; Madia F, 2009, J CELL BIOL, V186, P509, DOI 10.1083/jcb.200906011; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Mansilla SF, 2013, NUCLEIC ACIDS RES, V41, P6942, DOI 10.1093/nar/gkt475; Martini M, 2014, ANN MED, V46, P372, DOI 10.3109/07853890.2014.912836; McIntyre J, 2015, DNA REPAIR, V29, P166, DOI 10.1016/j.dnarep.2015.02.011; Moldovan GL, 2007, CELL, V129, P665, DOI 10.1016/j.cell.2007.05.003; Niimi A, 2008, P NATL ACAD SCI USA, V105, P16125, DOI 10.1073/pnas.0802727105; Nitulescu GM, 2016, INT J ONCOL, V48, P869, DOI 10.3892/ijo.2015.3306; Park J, 2009, J BIOL CHEM, V284, P6169, DOI 10.1074/jbc.C800210200; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; Sabbioneda S, 2008, MOL BIOL CELL, V19, P5193, DOI 10.1091/mbc.E08-07-0724; Sale JE, 2012, J CELL SCI, V125, P1633, DOI 10.1242/jcs.094748; Sale JE, 2012, NAT REV MOL CELL BIO, V13, P141, DOI 10.1038/nrm3289; Sharma S, 2012, MOL PHARMACOL, V81, P778, DOI 10.1124/mol.111.076828; Sokol AM, 2013, SCI REP-UK, V3, DOI 10.1038/srep03277; Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x; Soria G, 2006, ONCOGENE, V25, P2829, DOI 10.1038/sj.onc.1209315; Soria G, 2008, J CELL SCI, V121, P3271, DOI 10.1242/jcs.027730; Soria G, 2013, CELL CYCLE, V12, P422, DOI 10.4161/cc.23215; Soria G, 2010, DNA REPAIR, V9, P358, DOI 10.1016/j.dnarep.2009.12.003; Soria G, 2009, CELL CYCLE, V8, P3340, DOI 10.4161/cc.8.20.9836; Srivastava AK, 2015, P NATL ACAD SCI USA, V112, P4411, DOI 10.1073/pnas.1421365112; Surucu B, 2008, J BIOL CHEM, V283, P30025, DOI 10.1074/jbc.M803053200; Tu Y, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-172; Vaisman A, 2017, CRIT REV BIOCHEM MOL, V52, P274, DOI 10.1080/10409238.2017.1291576; Wang SC, 2014, TRENDS PHARMACOL SCI, V35, P178, DOI 10.1016/j.tips.2014.02.004; Wang ZF, 2016, J CELL SCI, V129, P1223, DOI 10.1242/jcs.179408; Wit N, 2015, NUCLEIC ACIDS RES, V43, P282, DOI 10.1093/nar/gku1301; Wu YT, 2011, J BIOL CHEM, V286, P14190, DOI 10.1074/jbc.M111.219923; Yamanaka K, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006842; Zhang WW, 2011, FEBS LETT, V585, P2786, DOI 10.1016/j.febslet.2011.04.044	54	22	22	8	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2019	38	22					4310	4324		10.1038/s41388-019-0724-7	http://dx.doi.org/10.1038/s41388-019-0724-7			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IA1RB	30705406	Green Published, hybrid			2022-12-28	WOS:000469339100008
J	Yamazaki, D; Hasegawa, A; Funato, Y; Tran, HN; Mori, MX; Mori, Y; Sato, T; Miki, H				Yamazaki, Daisuke; Hasegawa, Ayaka; Funato, Yosuke; Ha Nam Tran; Mori, Masayuki X.; Mori, Yasuo; Sato, Toshiro; Miki, Hiroaki			Cnnm4 deficiency suppresses Ca2+ signaling and promotes cell proliferation in the colon epithelia	ONCOGENE			English	Article							CONE-ROD DYSTROPHY; ION-CHANNEL; SMALL-INTESTINE; STEM-CELLS; MG2+; MUTATIONS; ORGANOIDS	CNNM4 is a Mg2+ transporter highly expressed in the colon epithelia. Its importance in regulating intracellular Mg2+ levels and cancer development has been documented, but how CNNM4 function affects the dynamic homeostasis of the epithelial tissue remains unclear. Here, we show that Cnnm4 deficiency promotes cell proliferation and partly suppresses cell differentiation in the colon epithelia, making them vulnerable to cancer development. Such phenotypic characteristics are highly similar to those of mice lacking Trpv1, which encodes the cation channel involved in capsaicin-stimulated Ca2+ influx. Indeed, Ca2+-imaging analyses using the organoid culture reveal that Ca2+ influx stimulated by capsaicin is greatly impaired by Cnnm4 deficiency. Moreover, EGF receptor signaling is constitutively activated in the colon epithelia of Cnnm4-deficient mice, as is the case with Trpv1-deficient mice. The administration of gefitinib, a clinically available inhibitor of EGF receptor, cancels the augmented proliferation of cells observed in Cnnm4-deficient mice. Collectively, these results establish the functional interplay between Mg2+ and Ca2+ in the colon epithelia, which is crucial for maintaining the dynamic homeostasis of the epithelial tissue.	[Yamazaki, Daisuke; Hasegawa, Ayaka; Funato, Yosuke; Miki, Hiroaki] Osaka Univ, Microbial Dis Res Inst, Dept Cellular Regulat, Suita, Osaka 5650871, Japan; [Ha Nam Tran; Mori, Masayuki X.; Mori, Yasuo] Kyoto Univ, Grad Sch Engn, Dept Synthet Chem & Biol Chem, Kyoto 6158510, Japan; [Ha Nam Tran] Kyoto Univ, Grad Sch Global Environm Studies, Dept Technol & Ecol, Kyoto 6158510, Japan; [Sato, Toshiro] Keio Univ, Sch Med, Dept Gastroenterol, Shinjuku Ku, Tokyo 1608582, Japan	Osaka University; Kyoto University; Kyoto University; Keio University	Miki, H (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Cellular Regulat, Suita, Osaka 5650871, Japan.	hmiki@biken.osaka-u.ac.jp	Mori, Masayuki/AAI-6992-2020; Sato, Toshiro/J-3522-2014	TRAN, Ha Nam/0000-0002-4802-4541; Sato, Toshiro/0000-0001-8353-8137				Arteaga CL, 2001, CURR OPIN ONCOL, V13, P491, DOI 10.1097/00001622-200111000-00012; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Basak O, 2017, CELL STEM CELL, V20, P177, DOI 10.1016/j.stem.2016.11.001; Bessette DC, 2008, CANCER METAST REV, V27, P231, DOI 10.1007/s10555-008-9121-3; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; de Jong PR, 2014, J CLIN INVEST, V124, P3793, DOI 10.1172/JCI72340; Funato Y, 2018, J PHYSIOL-LONDON, V596, P743, DOI 10.1113/JP275248; Funato Y, 2014, J CLIN INVEST, V124, P5398, DOI 10.1172/JCI76614; Gimenez-Mascarell P, 2017, J BIOL CHEM, V292, P786, DOI 10.1074/jbc.M116.759944; Gunther T, 2006, MAGNESIUM RES, V19, P225; Gulerez I, 2016, EMBO REP, V17, P1890, DOI 10.15252/embr.201643393; Hardy S, 2015, ONCOGENE, V34, P986, DOI 10.1038/onc.2014.33; Hirata Y, 2014, J BIOL CHEM, V289, P14731, DOI 10.1074/jbc.M114.551176; ITO S, 1965, J CELL BIOL, V27, P475, DOI 10.1083/jcb.27.3.475; Luo JL, 2012, J INVEST DERMATOL, V132, P2158, DOI 10.1038/jid.2012.144; Miyoshi H, 2012, SCIENCE, V338, P108, DOI 10.1126/science.1223821; OCONNOR DT, 1983, LIFE SCI, V33, P1657, DOI 10.1016/0024-3205(83)90721-X; Parry DA, 2009, AM J HUM GENET, V84, P266, DOI 10.1016/j.ajhg.2009.01.009; Perse M, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/718617; Polok B, 2009, AM J HUM GENET, V84, P259, DOI 10.1016/j.ajhg.2009.01.006; Ren DJ, 2001, NATURE, V413, P603, DOI 10.1038/35098027; Romani AMP, 2011, ARCH BIOCHEM BIOPHYS, V512, P1, DOI 10.1016/j.abb.2011.05.010; Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Tian H, 2011, NATURE, V478, P255, DOI 10.1038/nature10408; Vinuesa AG, 2012, CANCER RES, V72, P1705, DOI 10.1158/0008-5472.CAN-11-3693; Yamazaki D, 2016, J CELL SCI, V129, P1940, DOI 10.1242/jcs.182220; Yamazaki D, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003983; Yang F, 2014, J GEN PHYSIOL, V143, P91, DOI 10.1085/jgp.201311024	30	10	10	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2019	38	20					3962	3969		10.1038/s41388-019-0682-0	http://dx.doi.org/10.1038/s41388-019-0682-0			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HY3OI	30670776				2022-12-28	WOS:000468035600014
J	Bagati, A; Moparthy, S; Fink, EE; Bianchi-Smiraglia, A; Yun, DH; Kolesnikova, M; Udartseva, OO; Wolff, DW; Roll, MV; Lipchick, BC; Han, ZN; Kozlova, NI; Jowdy, P; Berman, AE; Box, NF; Rodriguez, C; Bshara, W; Kandel, ES; Soengas, MS; Paragh, G; Nikiforov, MA				Bagati, Archis; Moparthy, Sudha; Fink, Emily E.; Bianchi-Smiraglia, Anna; Yun, Dong Hyun; Kolesnikova, Masha; Udartseva, Olga O.; Wolff, David W.; Roll, Matthew V.; Lipchick, Brittany C.; Han, Zhannan; Kozlova, Nadezhda I.; Jowdy, Peter; Berman, Albert E.; Box, Neil F.; Rodriguez, Cesar; Bshara, Wiam; Kandel, Eugene S.; Soengas, Maria S.; Paragh, Gyorgy; Nikiforov, Mikhail A.			KLF9-dependent ROS regulate melanoma progression in stage-specific manner	ONCOGENE			English	Article							KRUPPEL-LIKE FACTORS; OXIDATIVE STRESS; MITOCHONDRIAL THIOREDOXIN; KEAP1-NRF2 PATHWAY; KINASE; SENESCENCE; BRAF; PHOTOPROTECTION; DYSREGULATION; ACTIVATION	Although antioxidants promote melanoma metastasis, the role of reactive oxygen species (ROS) in other stages of melanoma progression is controversial. Moreover, genes regulating ROS have not been functionally characterized throughout the entire tumor progression in mouse models of cancer. To address this question, we crossed mice-bearing knock-out of Klf9, an ubiquitous transcriptional regulator of oxidative stress, with two conditional melanocytic mouse models: Braf(CA) mice, where Braf(V600E) causes premalignant melanocytic hyperplasia, and Braf(CA)/Pten(-/-) mice, where Braf(V600E) and loss of Pten induce primary melanomas and metastases. Klf9 deficiency inhibited premalignant melanocytic hyperplasia in Braf(CA) mice but did not affect formation and growth of Braf(CA)/Pten(-/-) primary melanomas. It also, as expected, promoted Braf(CA)/Pten(-/-) metastasis. Treatment with antioxidant N-acetyl cysteine phenocopied loss of Klf9 including suppression of melanocytic hyperplasia. We were interested in a different role of Klf9 in regulation of cell proliferation in Braf(CA) and Braf(CA)/Pten(-/-) melanocytic cells. Mechanistically, we demonstrated that BRAF(V600E) signaling transcriptionally upregulated KLF9 and that KLF9-dependent ROS were required for full-scale activation of ERK1/2 and induction of cell proliferation by BRAF(V600E). PTEN depletion in BRAF(V600E)-melanocytes did not further activate ERK1/2 and cell proliferation, but rendered these phenotypes insensitive to KLF9 and ROS. Our data identified an essential role of KLF9-dependent ROS in BRAF(V600E) signaling in premalignant melanocytes, offered an explanation to variable role of ROS in premalignant and transformed melanocytic cells and suggested a novel mechanism for suppression of premalignant growth by topical antioxidants.	[Bagati, Archis; Moparthy, Sudha; Fink, Emily E.; Bianchi-Smiraglia, Anna; Yun, Dong Hyun; Kolesnikova, Masha; Udartseva, Olga O.; Wolff, David W.; Roll, Matthew V.; Lipchick, Brittany C.; Han, Zhannan; Jowdy, Peter; Kandel, Eugene S.; Nikiforov, Mikhail A.] Roswell Pk Canc Inst, Dept Cell Stress Biol, Buffalo, NY 14263 USA; [Wolff, David W.; Roll, Matthew V.; Lipchick, Brittany C.; Han, Zhannan; Rodriguez, Cesar; Nikiforov, Mikhail A.] Wake Forest Univ, Dept Canc Biol, Comprehens Canc Ctr, Winston Salem, NC 27109 USA; [Lipchick, Brittany C.] Wake Forest Univ, Dept Hematol & Oncol, Comprehens Canc Ctr, Winston Salem, NC 27109 USA; [Kozlova, Nadezhda I.; Berman, Albert E.] Orekhovich Inst Biomed Chem, Moscow 119121, Russia; [Box, Neil F.] Univ Colorado, Dept Dermatol, Anschutz Med Campus, Aurora, CO USA; [Bshara, Wiam] Roswell Pk Canc Inst, Dept Pathol Resource Network, Buffalo, NY 14263 USA; [Soengas, Maria S.] Spanish Natl Canc Res Ctr CNIO, Mol Oncol Programme, Melanoma Lab, Madrid 28029, Spain; [Paragh, Gyorgy] Roswell Pk Canc Inst, Dept Dermatol, Buffalo, NY 14263 USA; [Bagati, Archis] Dana Farber Canc Inst, Dept Canc Immunol & Virol, Smith Bldg,SM-0728,450 Brookline Ave, Boston, MA 02215 USA	Roswell Park Cancer Institute; Wake Forest University; Wake Forest University; Russian Academy of Medical Sciences; Institute of Biomedical Chemistry; University of Colorado System; University of Colorado Anschutz Medical Campus; Roswell Park Cancer Institute; Centro Nacional de Investigaciones Oncologicas (CNIO); Roswell Park Cancer Institute; Harvard University; Dana-Farber Cancer Institute	Nikiforov, MA (corresponding author), Roswell Pk Canc Inst, Dept Cell Stress Biol, Buffalo, NY 14263 USA.; Nikiforov, MA (corresponding author), Wake Forest Univ, Dept Canc Biol, Comprehens Canc Ctr, Winston Salem, NC 27109 USA.	mnikifor@wakehealth.edu	Udartseva, Olga/AAB-6216-2020; Soengas, Maria S/H-6455-2015; EBerman, Albert/F-5042-2017; Kozlova, Nadezda/ABD-7878-2020	Udartseva, Olga/0000-0003-2896-2300; Soengas, Maria S/0000-0003-0612-6299; Kolesnikova, Masha/0000-0001-7803-9632; Fink, Emily/0000-0003-2738-5732; Wolff, David/0000-0003-4201-3857	NCI [CA190533, CA193981, CA220096, CA224434, P30CA16056]; Program for Basic Research of Russian State Academies of Sciences; Russian Foundation for Basic Research [17-04-00716]; NATIONAL CANCER INSTITUTE [R01CA190533, P30CA016056, R01CA193981, R01CA224434, R21CA220096] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Program for Basic Research of Russian State Academies of Sciences; Russian Foundation for Basic Research(Russian Foundation for Basic Research (RFBR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work has been supported by the following NCI grants to MAN: CA190533, CA193981, CA220096, CA224434, by NCI P30CA16056 to Roswell Park Cancer Institute and partially supported by the Program for Basic Research of Russian State Academies of Sciences for 2013-2020, and by the Russian Foundation for Basic Research (grant No. 17-04-00716).	Arner ESJ, 2009, BBA-GEN SUBJECTS, V1790, P495, DOI 10.1016/j.bbagen.2009.01.014; Bonett RM, 2009, ENDOCRINOLOGY, V150, P1757, DOI 10.1210/en.2008-1441; Bonham CA, 2009, J BIOL CHEM, V284, P22853, DOI 10.1074/jbc.M109.038612; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Chen Y, 2006, FEBS LETT, V580, P6596, DOI 10.1016/j.febslet.2006.11.007; Chu JLY, 2016, CELL REP, V17, P374, DOI 10.1016/j.celrep.2016.09.006; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Cymerman RM, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw121; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Day CP, 2017, LAB INVEST, V97, P698, DOI 10.1038/labinvest.2016.155; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Denat L, 2014, J INVEST DERMATOL, V134, P1512, DOI 10.1038/jid.2014.65; Denoyelle C, 2006, NAT CELL BIOL, V8, P1053, DOI 10.1038/ncb1471; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; Ekwueme DU, 2011, J AM ACAD DERMATOL, V65, pS133, DOI 10.1016/j.jaad.2011.04.036; GAYNOR R, 1980, NATURE, V286, P400, DOI 10.1038/286400a0; Good KL, 2007, P NATL ACAD SCI USA, V104, P13420, DOI 10.1073/pnas.0703872104; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Jenkins NC, 2011, ONCOGENE, V30, P265, DOI 10.1038/onc.2010.419; Jiang K, 2000, NAT IMMUNOL, V1, P419, DOI 10.1038/80859; Kaneko T, 1996, MUTAT RES-DNAGING G, V316, P277, DOI 10.1016/S0921-8734(96)90010-7; Kansanen E, 2013, REDOX BIOL, V1, P45, DOI 10.1016/j.redox.2012.10.001; Kidger AM, 2016, SEMIN CELL DEV BIOL, V50, P125, DOI 10.1016/j.semcdb.2016.01.009; Kirsch J, 2016, ARTERIOSCL THROM VAS, V36, P1891, DOI 10.1161/ATVBAHA.116.307843; Le Gal K, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad3740; Leinonen HM, 2014, ADV CANCER RES, V122, P281, DOI 10.1016/B978-0-12-420117-0.00008-6; Lin JY, 2003, J AM ACAD DERMATOL, V48, P866, DOI 10.1067/mjd.2003.425; Linos E, 2009, J INVEST DERMATOL, V129, P1666, DOI 10.1038/jid.2008.423; Matsui MS, 2009, J INVEST DERM SYMP P, V14, P56, DOI 10.1038/jidsymp.2009.14; McCubrey JA, 2006, ANTIOXID REDOX SIGN, V8, P1775, DOI 10.1089/ars.2006.8.1775; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Morita M, 2003, MOL CELL BIOL, V23, P2489, DOI 10.1128/MCB.23.7.2489-2500.2003; Piskounova E, 2015, NATURE, V527, P186, DOI 10.1038/nature15726; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Qiao F, 2016, MOL CARCINOGEN, V55, P280, DOI 10.1002/mc.22277; Sander CS, 2003, BRIT J DERMATOL, V148, P913, DOI 10.1046/j.1365-2133.2003.05303.x; Schieber M, 2014, CURR BIOL, V24, pR453, DOI 10.1016/j.cub.2014.03.034; Simmen FA, 2007, AM J PHYSIOL-GASTR L, V292, pG1757, DOI 10.1152/ajpgi.00013.2007; Simon JD, 2009, PIGM CELL MELANOMA R, V22, P563, DOI 10.1111/j.1755-148X.2009.00610.x; Son Yong, 2011, J Signal Transduct, V2011, P792639, DOI 10.1155/2011/792639; Tetreault MP, 2013, NAT REV CANCER, V13, P701, DOI 10.1038/nrc3582; Tucker MA, 1997, JAMA-J AM MED ASSOC, V277, P1439, DOI 10.1001/jama.277.18.1439; Ying MY, 2011, STEM CELLS, V29, P20, DOI 10.1002/stem.561; Zhuang D, 2008, ONCOGENE, V27, P6623, DOI 10.1038/onc.2008.258; Zucker SN, 2014, MOL CELL, V53, P916, DOI 10.1016/j.molcel.2014.01.033; Zuo L, 2015, ACTA PHYSIOL, V214, P329, DOI 10.1111/apha.12515	46	32	33	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2019	38	19					3585	3597		10.1038/s41388-019-0689-6	http://dx.doi.org/10.1038/s41388-019-0689-6			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HX4OU	30664687	Green Accepted			2022-12-28	WOS:000467379600003
J	Das, S; Bar-Sagi, D				Das, Shipra; Bar-Sagi, Dafna			BTK signaling drives CD1d(hi)CD5(+) regulatory B-cell differentiation to promote pancreatic carcinogenesis	ONCOGENE			English	Article							BRUTONS TYROSINE KINASE; T-CELLS; AUTOIMMUNITY; INHIBITION; CANCER; TUMOR; ACTIVATION; EXPRESSION	The immune microenvironment of pancreatic ductal adenocarcinoma (PDA) is comprised of a heterogeneous population of cells that are critical for disease evolution. Prominent among these are the specialized CD1d(hi)CD5(+) regulatory B (B-reg) cells that exert a pro-tumorigenic role by promoting tumor cell proliferation. Dissecting the molecular pathways regulating this immune sub-population can thus be valuable for uncovering potential therapeutic targets. Here, we investigate Bruton's tyrosine kinase (BTK), a key B-cell kinase, as a potential regulator of CD1d(hi)CD5(+) B-reg differentiation in the pancreatic tumor microenvironment. Treatment of cytokine-induced B cells in vitro with the high specificity BTK inhibitor Tirabrutinib inhibited CD1d(hi)CD5(+) B-reg differentiation and production of IL-10 and IL-35, essential mediators of B-reg immunosuppressive functions. The BTK signaling pathway was also found to be active in vivo in PanIN-associated regulatory B cells. Tirabrutinib treatment of mice bearing orthotopic Kras(G12D)-pancreatic lesions severely compromised stromal accumulation of the CD1d(hi)CD5(+) B-reg population. This was accompanied by an increase in stromal CD8(+)IFN gamma(+) cytotoxic T cells and significant attenuation of tumor cell proliferation and PanIN growth. Our results uncover a novel role for BTK in regulating CD1d(hi)CD5(+) B-reg differentiation and emphasize its potential as a therapeutic target for pancreatic cancer.	[Das, Shipra; Bar-Sagi, Dafna] NYU, Sch Med, Dept Biochem & Mol Pharmacol, New York, NY 10016 USA	New York University	Bar-Sagi, D (corresponding author), NYU, Sch Med, Dept Biochem & Mol Pharmacol, New York, NY 10016 USA.	dafna.bar-sagi@nyulangone.org		Bar-Sagi, Dafna/0000-0003-2597-8948	National Institutes of Health/National Cancer Institute [P30CA016087]; Gilead Sciences, Inc., Foster City, CA, USA; NIH/NCI [CA210263]; Lustgarten Foundation Pancreatic Cancer Convergence Dream Team grant [SU2C-AACR-DT14-14]; NATIONAL CANCER INSTITUTE [R35CA210263, P30CA016087] Funding Source: NIH RePORTER	National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Gilead Sciences, Inc., Foster City, CA, USA(Gilead Sciences); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Lustgarten Foundation Pancreatic Cancer Convergence Dream Team grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank L.J. Taylor for help with article preparation and members of the Bar-Sagi lab for valuable discussions and comments. The authors also thank NYU Langone's Cytometry and Cell Sorting Laboratory, which is supported in part by grant P30CA016087 from the National Institutes of Health/National Cancer Institute, for providing cell sorting/flow cytometry technologies. This work was supported in part by Gilead Sciences, Inc., Foster City, CA, USA, by NIH/NCI grant CA210263 (D.B.-S.) and by the Lustgarten Foundation Pancreatic Cancer Convergence Dream Team grant SU2C-AACR-DT14-14 (to D.B.-S.). Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research.	Brunner C, 2002, IMMUNOBIOLOGY, V206, P432, DOI 10.1078/0171-2985-00192; Burger JA, 2018, NAT REV CANCER, V18, P148, DOI 10.1038/nrc.2017.121; Corneth OBJ, 2016, J IMMUNOL, V197, P58, DOI 10.4049/jimmunol.1600208; De Monte L, 2011, J EXP MED, V208, P469, DOI 10.1084/jem.20101876; Delitto D, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1820-x; DiLillo DJ, 2010, ANN NY ACAD SCI, V1183, P38, DOI 10.1111/j.1749-6632.2009.05137.x; Doyle SL, 2007, J BIOL CHEM, V282, P36953, DOI 10.1074/jbc.M707682200; Egwuagu CE, 2015, CRIT REV IMMUNOL, V35, P49, DOI 10.1615/CritRevImmunol.2015012558; Granville CA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005061; Gunderson AJ, 2016, CANCER DISCOV, V6, P270, DOI 10.1158/2159-8290.CD-15-0827; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hiraoka N, 2006, CLIN CANCER RES, V12, P5423, DOI 10.1158/1078-0432.CCR-06-0369; Isaza-Correa JM, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0057-5; Jefferies CA, 2003, J BIOL CHEM, V278, P26258, DOI 10.1074/jbc.M301484200; Kurahara H, 2011, J SURG RES, V167, pE211, DOI 10.1016/j.jss.2009.05.026; Lee KE, 2016, CANCER DISCOV, V6, P256, DOI 10.1158/2159-8290.CD-15-0822; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; McAllister F, 2014, CANCER CELL, V25, P621, DOI 10.1016/j.ccr.2014.03.014; Mielgo A, 2013, BMB REP, V46, P131, DOI 10.5483/BMBRep.2013.46.3.036; Mohamed AJ, 2009, IMMUNOL REV, V228, P58, DOI 10.1111/j.1600-065X.2008.00741.x; Ochi A, 2012, J EXP MED, V209, P1671, DOI 10.1084/jem.20111706; Petro JB, 2001, J BIOL CHEM, V276, P1715, DOI 10.1074/jbc.M009137200; Ponader S, 2014, J CLIN ONCOL, V32, P1830, DOI 10.1200/JCO.2013.53.1046; Pylayeva-Gupta Y, 2016, CLIN CANCER RES, V22, P4973, DOI 10.1158/1078-0432.CCR-16-0743; Pylayeva-Gupta Y, 2016, CANCER DISCOV, V6, P247, DOI 10.1158/2159-8290.CD-15-0843; Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024; Rahib L, 2016, JAMA ONCOL, V2, P1209, DOI 10.1001/jamaoncol.2016.0585; Rishi A, 2015, SEMIN ONCOL, V42, P28, DOI 10.1053/j.seminoncol.2014.12.004; Rosser EC, 2014, NAT MED, V20, P1334, DOI 10.1038/nm.3680; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Schmidt NW, 2006, J IMMUNOL, V177, P7203, DOI 10.4049/jimmunol.177.10.7203; Schwartz M, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0145-x; Stromnes IM, 2014, CARCINOGENESIS, V35, P1451, DOI 10.1093/carcin/bgu115; Tai YT, 2012, BLOOD, V120, P1877, DOI 10.1182/blood-2011-12-396853; Unek T, 2013, HEPATO-GASTROENTEROL, V60, P2085, DOI 10.5754/hge.13421; Vonderheide RH, 2013, CURR OPIN IMMUNOL, V25, P200, DOI 10.1016/j.coi.2013.01.006; Zdanov S, 2016, CANCER IMMUNOL RES, V4, P354, DOI 10.1158/2326-6066.CIR-15-0241; Zhang JJ, 2018, CANCERS, V10, DOI 10.3390/cancers10020039; Zhang YQ, 2014, CANCER IMMUNOL RES, V2, P423, DOI 10.1158/2326-6066.CIR-14-0016-T; Zhu ZH, 2014, CANCER DISCOV, V4, P452, DOI 10.1158/2159-8290.CD-13-0646	40	37	40	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2019	38	17					3316	3324		10.1038/s41388-018-0668-3	http://dx.doi.org/10.1038/s41388-018-0668-3			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU8RI	30635655	Green Accepted			2022-12-28	WOS:000465557200015
J	Lan, Q; Peyvandi, S; Duffey, N; Huang, YT; Barras, D; Held, W; Richard, F; Delorenzi, M; Sotiriou, C; Desmedt, C; Lorusso, G; Ruegg, C				Lan, Qiang; Peyvandi, Sanam; Duffey, Nathalie; Huang, Yu-Ting; Barras, David; Held, Werner; Richard, Francois; Delorenzi, Mauro; Sotiriou, Christos; Desmedt, Christine; Lorusso, Girieca; Ruegg, Curzio			Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer	ONCOGENE			English	Article							TUMOR-INFILTRATING LYMPHOCYTES; IMMUNE-MEDIATED DORMANCY; CELLS; METASTASIS; MECHANISMS; EXPRESSION; RESISTANCE; PATHWAY; SITE	Neoadjuvant and adjuvant chemotherapies provide survival benefits to breast cancer patients, in particular in estrogen receptor negative (ER-) cancers, by reducing rates of recurrences. It is assumed that the benefits of (neo)adjuvant chemotherapy are due to the killing of disseminated, residual cancer cells, however, there is no formal evidence for it. Here, we provide experimental evidence that ER- breast cancer cells that survived high-dose Doxorubicin and Methotrexate based chemotherapies elicit a state of immunological dormancy. Hallmark of this dormant phenotype is the sustained activation of the IRF7/IFN-beta/IFNAR axis subsisting beyond chemotherapy treatment. Upregulation of IRF7 in treated cancer cells promoted resistance to chemotherapy, reduced cell growth and induced switching of the response from a myeloid derived suppressor cell-dominated immune response to a CD4(+)/CD8(+) T cell-dependent anti-tumor response. IRF7 silencing in tumor cells or systemic blocking of IFNAR reversed the state of dormancy, while spontaneous escape from dormancy was associated with loss of IFN-beta production. Presence of IFN-beta in the circulation of ER- breast cancer patients treated with neoadjuvant Epirubicin chemotherapy correlated with a significantly longer distant metastasis-free survival. These findings establish chemotherapy-induced immunological dormancy in ER- breast cancer as a novel concept for (neo)adjuvant chemotherapy activity, and implicate sustained activation of the IRF7/IFN-beta/IFNAR pathway in this effect. Further, IFN-beta emerges as a potential predictive biomarker and therapeutic molecule to improve outcome of ER- breast cancer patients treated with (neo)adjuvant chemotherapy.	[Lan, Qiang; Peyvandi, Sanam; Duffey, Nathalie; Huang, Yu-Ting; Lorusso, Girieca; Ruegg, Curzio] Univ Fribourg, Pathol Unit, Dept Oncol Microbiol & Immunol OMI, Fac Sci & Med, CH-1700 Fribourg, Switzerland; [Lan, Qiang; Huang, Yu-Ting; Lorusso, Girieca; Ruegg, Curzio] Ecole Polytech Fed Lausanne, NCCR, Swiss Inst Expt Canc Res ISREC, Mol Oncol, CH-1015 Lausanne, Switzerland; [Barras, David; Delorenzi, Mauro] SIB, CH-1015 Lausanne, Switzerland; [Held, Werner; Delorenzi, Mauro] Ludwig Inst Canc Res, CH-1066 Epalinges, Switzerland; [Held, Werner; Delorenzi, Mauro] Univ Lausanne, Dept Fundamental Oncol, CH-1011 Lausanne, Switzerland; [Richard, Francois; Sotiriou, Christos; Desmedt, Christine] Univ Libre Bruxelles, Breast Canc Translat Res Lab, Inst Jules Bordet, B-1000 Brussels, Belgium; [Ruegg, Curzio] Swiss Integrat Ctr Human Hlth, Fribourg, Switzerland; [Lan, Qiang] Univ Helsinki, Dev Biol Program, Inst Biotechnol, Helsinki, Finland	University of Fribourg; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Institute Experimental Cancer Research; Swiss Institute of Bioinformatics; Ludwig Institute for Cancer Research; University of Lausanne; Institut Jules Bordet; Universite Libre de Bruxelles; University of Helsinki	Ruegg, C (corresponding author), Univ Fribourg, Pathol Unit, Dept Oncol Microbiol & Immunol OMI, Fac Sci & Med, CH-1700 Fribourg, Switzerland.; Ruegg, C (corresponding author), Ecole Polytech Fed Lausanne, NCCR, Swiss Inst Expt Canc Res ISREC, Mol Oncol, CH-1015 Lausanne, Switzerland.; Ruegg, C (corresponding author), Swiss Integrat Ctr Human Hlth, Fribourg, Switzerland.	curzio.ruegg@unifr.ch	RICHARD, François/AAA-4193-2021; Desmedt, Christine/P-7438-2017	RICHARD, François/0000-0003-4353-3619; Lan, Qiang/0000-0002-7765-6767; Lorusso, Girieca/0000-0002-2807-3207; Desmedt, Christine/0000-0002-5223-5579	Swiss National Science Foundation [31003A_159824]; Swiss Cancer League [KFS-2814-08-2011]; Medic Foundation; Molecular Oncology Program of the National Center of Competence in Research (NCCR)	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss Cancer League; Medic Foundation; Molecular Oncology Program of the National Center of Competence in Research (NCCR)	We thank Dr. J. Sleeman (Medical Faculty at Heidelberg University, Mannheim, Germany) for providing D2A1/D2.0R cells, Dr. Fred R. Miller (Michigan Cancer Foundation, Detroit, MI, USA) for providing 4T1 cells, Dr. Khalil Zaman (Department of Oncology), University Hospital, University of Lausanne, Lausanne, Switzerland) for providing chemotherapeutic drugs. This work was supported by grants from Swiss National Science Foundation (31003A_159824), The Swiss Cancer League (KFS-2814-08-2011); the Medic Foundation, the Molecular Oncology Program of the National Center of Competence in Research (NCCR), a research instrument of the Swiss National Science Foundation.	Adams S, 2014, J CLIN ONCOL, V32, P2959, DOI 10.1200/JCO.2013.55.0491; Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Anampa J, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0439-8; Barkan D, 2011, JOVE-J VIS EXP, DOI 10.3791/2914; Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bidwell BN, 2012, NAT MED, V18, P1224, DOI 10.1038/nm.2830; Castiello L, 2018, CANCER IMMUNOL RES, V6, P658, DOI 10.1158/2326-6066.CIR-17-0675; DEMICHELI R, 1994, J NATL CANCER I, V86, P45; Demicheli R, 2001, SEMIN CANCER BIOL, V11, P297, DOI 10.1006/scbi.2001.0385; Demicheli R, 2007, NAT CLIN PRACT ONCOL, V4, P699, DOI 10.1038/ncponc0999; Desmedt C, 2008, CLIN CANCER RES, V14, P5158, DOI 10.1158/1078-0432.CCR-07-4756; Desmedt C, 2011, J CLIN ONCOL, V29, P1578, DOI 10.1200/JCO.2010.31.2231; Dunn GP, 2006, NAT REV IMMUNOL, V6, P836, DOI 10.1038/nri1961; Dunn GP, 2005, NAT IMMUNOL, V6, P722, DOI 10.1038/ni1213; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; Dushyanthen S, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0431-3; Ejlertsen B, 2016, DAN MED J, V63; Erdal E, 2017, GENE DEV, V31, P353, DOI 10.1101/gad.289769.116; Forero A, 2016, CANCER IMMUNOL RES, V4, P390, DOI 10.1158/2326-6066.CIR-15-0243; Galluzzi L, 2015, CANCER CELL, V28, P690, DOI 10.1016/j.ccell.2015.10.012; Goodison S, 2003, CLIN CANCER RES, V9, P3808; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Ignatiadis M, 2012, J CLIN ONCOL, V30, P1996, DOI 10.1200/JCO.2011.39.5624; Joensuu H, 2012, ANN ONCOL, V23, P40, DOI 10.1093/annonc/mds194; Kim ST, 2013, AM J CLIN ONCOL-CANC, V36, P224, DOI 10.1097/COC.0b013e3182467d90; Kim TK, 2000, CANCER RES, V60, P1153; Kim YA, 2016, BREAST CANCER RES TR, V156, P597, DOI 10.1007/s10549-016-3786-z; Klauber-DeMore N, 2001, CLIN CANCER RES, V7, P2434; Kroemer G, 2015, NAT MED, V21, P1128, DOI 10.1038/nm.3944; Lee HJ, 2016, J CLIN PATHOL, V69, P422, DOI 10.1136/jclinpath-2015-203089; Legrier M-E, 2015, BRIT J CANCER, V114, P177; Liu L, 2018, CLIN CANCER RES, V24, P2370, DOI 10.1158/1078-0432.CCR-17-2545; Liu YY, 2018, J CLIN INVEST, V128, P1057, DOI 10.1172/JCI96329; Ma Y, 2013, IMMUNITY, V38, P729, DOI 10.1016/j.immuni.2013.03.003; Monnier Y, 2008, CANCER RES, V68, P7323, DOI 10.1158/0008-5472.CAN-08-0841; MORRIS VL, 1993, CLIN EXP METASTAS, V11, P103, DOI 10.1007/BF00880071; Munzone E, 2012, ANN ONCOL, V23, P305, DOI 10.1093/annonc/mdr309; Naumov GN, 2002, CANCER RES, V62, P2162; Paez D, 2012, CLIN CANCER RES, V18, P645, DOI 10.1158/1078-0432.CCR-11-2186; Perez EA, 2015, J CLIN ONCOL, V33, P701, DOI 10.1200/JCO.2014.57.6298; Romero I, 2014, CANCER RES, V74, P6750, DOI 10.1158/0008-5472.CAN-14-2406; Rubovszky G, 2017, J BREAST CANCER, V20, P119, DOI 10.4048/jbc.2017.20.2.119; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; Shultz LD, 2007, NAT REV IMMUNOL, V7, P118, DOI 10.1038/nri2017; Sisirak V, 2012, CANCER RES, V72, P5188, DOI 10.1158/0008-5472.CAN-11-3468; Sistigu A, 2014, NAT MED, V20, P1301, DOI 10.1038/nm.3708; Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793; Stanton SE, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0165-6; Teng MWL, 2008, J LEUKOCYTE BIOL, V84, P988, DOI 10.1189/jlb.1107774; Teschendorff AE, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-8-r157; Wang K, 2016, ONCOTARGET, V7, P44288, DOI 10.18632/oncotarget.9988; Weichselbaum RR, 2008, P NATL ACAD SCI USA, V105, P18490, DOI 10.1073/pnas.0809242105	53	47	49	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2019	38	15					2814	2829		10.1038/s41388-018-0624-2	http://dx.doi.org/10.1038/s41388-018-0624-2			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HS8LQ	30546090	Green Published, hybrid			2022-12-28	WOS:000464121600011
J	Pan, WW; Moroishi, T; Koo, JH; Guan, KL				Pan, Wei-Wei; Moroishi, Toshiro; Koo, Ja Hyun; Guan, Kun-Liang			Cell type-dependent function of LATS1/2 in cancer cell growth	ONCOGENE			English	Article							TUMOR-SUPPRESSOR PATHWAY; ORGAN SIZE CONTROL; HIPPO PATHWAY; TEAD/TEF FAMILY; YAP; GENE; INACTIVATION; INHIBITION; YAP/TAZ; ROLES	The Hippo pathway controls organ size and tissue homeostasis, and its dysregulation often contributes to tumorigenesis. Extensive studies have shown that the Hippo pathway inhibits cell proliferation, and survival in a cell-autonomous manner. We examined the function of the Hippo pathway kinases LATS1/2 (large tumor suppressor 1 and 2) in cancer cells. As expected, loss of LATS1/2 promotes cancer cell growth in most cell lines. Surprisingly, however, LATS1/2 deletion inhibits the growth of murine MC38 colon cancer cells, especially under detachment conditions. This growth inhibitory effect caused by LATS1/2 deletion is due to uncontrolled activation of Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ), the key downstream transcriptional coactivators inhibited by LATS1/2. We identified Wnt inducible signaling pathway protein 2 (Wisp2) and coiled-coil domain containing 80 (Ccdc80) as direct targets of YAP/TAZ. Their expression is selectively induced by LATS1/2 deletion in MC38 cells. Furthermore, deletion of WISP2 and CCDC80 prevents the growth inhibitory effect of LATS1/2 loss in MC38 cells. Our study demonstrates that the function of LATS1/2 in cell growth is cell context dependent, suggesting that LATS1/2 inhibition can be a therapeutic approach for some cancer types.	[Pan, Wei-Wei; Moroishi, Toshiro; Koo, Ja Hyun; Guan, Kun-Liang] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; [Pan, Wei-Wei; Moroishi, Toshiro; Koo, Ja Hyun; Guan, Kun-Liang] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA; [Pan, Wei-Wei] Jiaxing Univ, Sch Med, Jiaxing 314001, Peoples R China; [Moroishi, Toshiro] Kumamoto Univ, Fac Life Sci, Dept Mol Enzymol, Kumamoto 8608556, Japan; [Moroishi, Toshiro] Kumamoto Univ, Fac Life Sci, Ctr Metab Regulat Hlth Aging, Kumamoto 8608556, Japan	University of California System; University of California San Diego; University of California System; University of California San Diego; Jiaxing University; Kumamoto University; Kumamoto University	Pan, WW; Guan, KL (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.; Pan, WW; Guan, KL (corresponding author), Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.; Pan, WW (corresponding author), Jiaxing Univ, Sch Med, Jiaxing 314001, Peoples R China.	aidspan@163.com; kuguan@ucsd.edu	Koo, Ja Hyun/GQP-5440-2022; Guan, Kun-Liang/ADK-7088-2022	Koo, Ja Hyun/0000-0001-5738-1105; Moroishi, Toshiro/0000-0001-6419-3882	National Institutes of Health [CA196878, CA217642, GM51586]; National Natural Science Foundation of China [31871402, 81402162]; Natural Science Foundation of Zhejiang Province [LY17H160060]; NATIONAL CANCER INSTITUTE [R01CA217642, R35CA196878] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051586] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Zhejiang Province(Natural Science Foundation of Zhejiang Province); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Zhipeng Meng, Rui Chen, Shenghong Ma, Zhengming Wu, Kimberly C, Lin and Min Luo for technical assistance; JiaYu Chen and Xiangdong Fu for help in bioinformatics analysis. This work was supported by grants from the National Institutes of Health (CA196878, CA217642, and GM51586) to K.L.G. This study was supported by grants from National Natural Science Foundation of China (31871402, 81402162), and the Natural Science Foundation of Zhejiang Province (LY17H160060) to W.W.P.	Baia GS, 2012, MOL CANCER RES, V10, P904, DOI 10.1158/1541-7786.MCR-12-0116; Barreto SC, 2016, J BUON, V21, P1359; Barry ER, 2013, CURR OPIN CELL BIOL, V25, P247, DOI 10.1016/j.ceb.2012.12.006; Barry ER, 2013, NATURE, V493, P106, DOI 10.1038/nature11693; Bommer GT, 2005, J BIOL CHEM, V280, P7962, DOI 10.1074/jbc.M412593200; Bueno R, 2016, NAT GENET, V48, P407, DOI 10.1038/ng.3520; Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; Cottini F, 2014, NAT MED, V20, P599, DOI 10.1038/nm.3562; Dhar G, 2008, CANCER RES, V68, P4580, DOI 10.1158/0008-5472.CAN-08-0316; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Ferraro A, 2013, J CLIN ENDOCR METAB, V98, P2834, DOI 10.1210/jc.2012-2926; Goulev Y, 2008, CURR BIOL, V18, P435, DOI 10.1016/j.cub.2008.02.034; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Herbst A, 2011, ONCOL LETT, V2, P981, DOI 10.3892/ol.2011.356; Huang HY, 2017, CANCER RES, V77, P5769, DOI 10.1158/0008-5472.CAN-17-0449; Ji JF, 2015, BRIT J CANCER, V113, P921, DOI 10.1038/bjc.2015.285; Jiao S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14058; Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161; Lu L, 2010, P NATL ACAD SCI USA, V107, P1437, DOI 10.1073/pnas.0911427107; Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115; Moroishi T, 2016, CELL, V167, P1525, DOI 10.1016/j.cell.2016.11.005; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; Murakami H, 2011, CANCER RES, V71, P873, DOI 10.1158/0008-5472.CAN-10-2164; Oh JE, 2015, J NEUROPATH EXP NEUR, V74, P952, DOI 10.1097/NEN.0000000000000238; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Sharpless NE, 2015, NAT REV CANCER, V15, P397, DOI 10.1038/nrc3960; Song H, 2010, P NATL ACAD SCI USA, V107, P1431, DOI 10.1073/pnas.0911409107; Wang Z, 2017, CANCER RES, V77, P2413, DOI 10.1158/0008-5472.CAN-16-3229; Wu S, 2008, DEV CELL, V14, P388, DOI 10.1016/j.devcel.2008.01.007; Yimlamai D, 2015, J HEPATOL, V63, P1491, DOI 10.1016/j.jhep.2015.07.008; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Yuan M, 2008, CELL DEATH DIFFER, V15, P1752, DOI 10.1038/cdd.2008.108; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zhang L, 2008, DEV CELL, V14, P377, DOI 10.1016/j.devcel.2008.01.006; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhou DW, 2009, CANCER CELL, V16, P425, DOI 10.1016/j.ccr.2009.09.026	39	20	22	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2019	38	14					2595	2610		10.1038/s41388-018-0610-8	http://dx.doi.org/10.1038/s41388-018-0610-8			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HR7LI	30531839	Green Accepted, Green Submitted			2022-12-28	WOS:000463335200011
J	Matsushita, A; Sato, T; Mukai, S; Fujishita, T; Mishiro-Sato, E; Okuda, M; Aoki, M; Hasegawa, Y; Sekido, Y				Matsushita, Akihiro; Sato, Tatsuhiro; Mukai, Satomi; Fujishita, Teruaki; Mishiro-Sato, Emi; Okuda, Maho; Aoki, Masahiro; Hasegawa, Yoshinori; Sekido, Yoshitaka			TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation	ONCOGENE			English	Article							MALIGNANT PLEURAL MESOTHELIOMA; YAP; MUTATIONS; NF2; INTERLEUKIN-1-BETA; PROLIFERATION; DEGRADATION; PROTEIN; INJURY	Malignant mesothelioma (MM) constitutes a very aggressive tumor that is caused by asbestos exposure after long latency. The NF2 tumor suppressor gene is mutated in 40-50% of MM; moreover, one of its downstream signaling cascades, the Hippo signaling pathway, is also frequently inactivated in MM cells. Although the YAP transcriptional coactivator, which is regulated by the Hippo pathway, can function as a pro-oncogenic protein, the role of TAZ, a paralog of YAP, in MM cells has not yet been clarified. Here, we show that TAZ is expressed and underphosphorylated (activated) in the majority of MM cells compared to immortalized mesothelial cells. ShRNA-mediated TAZ knockdown highly suppressed cell proliferation, anchorage-independent growth, cell motility, and invasion in MM cells harboring activated TAZ. Conversely, transduction of an activated form of TAZ in immortalized mesothelial cells enhanced these in vitro phenotypes and conferred tumorigenicity in vivo. Microarray analysis determined that activated TAZ most significantly enhanced the transcription of genes related to "cytokine-cytokine receptor interaction." Among selected cytokines, we found that IL-1 signaling activation plays a major role in proliferation in TAZ-activated MM cells. Both IL1B knockdown and an IL-1 receptor antagonist significantly suppressed malignant phenotypes of immortalized mesothelial cells and MM cells with activated TAZ. Overall, these results indicate an oncogenic role for TAZ in MMs via transcriptional induction of distinct pro-oncogenic genes including cytokines. Among these, IL-1 signaling appears as one of the most important cascades, thus potentially serving as a target pathway in MM cells harboring Hippo pathway inactivation.	[Matsushita, Akihiro; Sato, Tatsuhiro; Mukai, Satomi; Okuda, Maho; Sekido, Yoshitaka] Aichi Canc Ctr Res Inst, Div Canc Biol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi, Japan; [Matsushita, Akihiro; Hasegawa, Yoshinori] Nagoya Univ, Dept Resp Med, Grad Sch Med, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi, Japan; [Fujishita, Teruaki; Mishiro-Sato, Emi; Aoki, Masahiro] Aichi Canc Ctr Res Inst, Div Pathophysiol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi, Japan; [Aoki, Masahiro; Sekido, Yoshitaka] Nagoya Univ, Field Canc Pathobiol & Informat, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi, Japan	Aichi Cancer Center; Nagoya University; Aichi Cancer Center; Nagoya University	Sekido, Y (corresponding author), Aichi Canc Ctr Res Inst, Div Canc Biol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi, Japan.; Sekido, Y (corresponding author), Nagoya Univ, Field Canc Pathobiol & Informat, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi, Japan.	ysekido@aichi-cc.jp	Aoki, Masahiro/A-5149-2016	Aoki, Masahiro/0000-0003-4316-9490; Mishiro-Sato, Emi/0000-0001-5528-4440; Fujishita, Teruaki/0000-0002-4397-2438; Sekido, Yoshitaka/0000-0002-2428-3848	JSPS KAKENHI [25090053, 16H04706, 17K19628]; AMED P-PRIME; AMED P-CREATE; Aichi Cancer Research Foundation; Takeda Science Foundation	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); AMED P-PRIME; AMED P-CREATE; Aichi Cancer Research Foundation(Aichi Cancer Research Foundation); Takeda Science Foundation(Takeda Science Foundation (TSF))	We thank Ms. Ikue Hasegawa, Miwako Nishizawa, and Haruna Ikeda for technical assistance. We thank Dr. Hata for TAZ expression lentiviruses and Dr. Gazdar for MM cell lines. This work was supported by JSPS KAKENHI 25090053 (YS), 16H04706 (YS), and 17K19628 (YS); AMED P-PRIME and P-CREATE (YS); Aichi Cancer Research Foundation (TS); and Takeda Science Foundation (TS).	Adachi Y, 2006, INT J CANCER, V119, P1303, DOI 10.1002/ijc.22006; Bhat KPL, 2011, GENE DEV, V25, P2594, DOI 10.1101/gad.176800.111; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; Bibby AC, 2016, EUR RESPIR REV, V25, P472, DOI 10.1183/16000617.0063-2016; Bueno R, 2016, NAT GENET, V48, P407, DOI 10.1038/ng.3520; Chan SW, 2008, CANCER RES, V68, P2592, DOI 10.1158/0008-5472.CAN-07-2696; Chan SW, 2009, J BIOL CHEM, V284, P14347, DOI 10.1074/jbc.M901568200; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; Disselhorst MMJ, 2017, CURR TREAT OPTION ON, V18, DOI 10.1007/s11864-017-0488-7; Felley-Bosco E, 2014, TRANSL LUNG CANCER R, V3, P75, DOI 10.3978/j.issn.2218-6751.2014.02.03; Frank AL, 2014, ANN GLOB HEALTH, V80, P257, DOI 10.1016/j.aogh.2014.09.016; Fujii M, 2012, J EXP MED, V209, P479, DOI 10.1084/jem.20111653; Hansen CG, 2015, TRENDS CELL BIOL, V25, P499, DOI 10.1016/j.tcb.2015.05.002; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955; Huang W, 2012, J BIOL CHEM, V287, P26245, DOI 10.1074/jbc.M112.382036; Kadariya Y, 2016, CANCER PREV RES, V9, P406, DOI 10.1158/1940-6207.CAPR-15-0347; Kakiuchi T, 2016, CARCINOGENESIS, V37, P1098, DOI 10.1093/carcin/bgw084; Kanehisa M, 2006, NUCLEIC ACIDS RES, V34, pD354, DOI 10.1093/nar/gkj102; Mahoney WM, 2005, BIOCHEM J, V388, P217, DOI 10.1042/BJ20041434; Menezes ME, 2014, ADV EXP MED BIOL, V818, P127, DOI 10.1007/978-1-4471-6458-6_6; Mizuno T, 2012, ONCOGENE, V31, P5117, DOI 10.1038/onc.2012.5; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; Murakami H, 2011, CANCER RES, V71, P873, DOI 10.1158/0008-5472.CAN-10-2164; Nelson DB, 2017, J CLIN ONCOL, V35, P3354, DOI 10.1200/JCO.2017.73.8401; Robinson BWS, 2005, NEW ENGL J MED, V353, P1591, DOI 10.1056/NEJMra050152; SEKIDO Y, 1995, CANCER RES, V55, P1227; Sekido Y, 2013, CARCINOGENESIS, V34, P1413, DOI 10.1093/carcin/bgt166; Stadlmann S, 2006, WOUND REPAIR REGEN, V14, P187, DOI 10.1111/j.1743-6109.2006.00109.x; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tanaka I, 2015, ONCOGENE, V34, P73, DOI 10.1038/onc.2013.528; Tian Y, 2007, MOL CELL BIOL, V27, P6383, DOI 10.1128/MCB.00254-07; Tranchant R, 2017, CLIN CANCER RES, V23, P3191, DOI 10.1158/1078-0432.CCR-16-1971; Varelas X, 2008, NAT CELL BIOL, V10, P837, DOI 10.1038/ncb1748; Wang YH, 2004, INT J ONCOL, V25, P173; Whitaker EL, 2012, CYTOKINE GROWTH F R, V23, P323, DOI 10.1016/j.cytogfr.2012.08.004; Yang ZY, 2014, MOL CELL BIOL, V34, P1607, DOI 10.1128/MCB.01346-13; Yap TA, 2017, NAT REV CANCER, V17, P475, DOI 10.1038/nrc.2017.42; Yokoyama T, 2008, CARCINOGENESIS, V29, P2139, DOI 10.1093/carcin/bgn200; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005	41	12	12	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2019	38	11					1966	1978		10.1038/s41388-018-0417-7	http://dx.doi.org/10.1038/s41388-018-0417-7			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HO7XX	30401981				2022-12-28	WOS:000461164400013
J	Bakhshinyan, D; Venugopal, C; Adile, AA; Garg, N; Manoranjan, B; Hallett, R; Wang, X; Mahendram, S; Vora, P; Vijayakumar, T; Subapanditha, M; Singh, M; Kameda-Smith, MM; Qazi, M; McFarlane, N; Mann, A; Ajani, OA; Yarascavitch, B; Ramaswamy, V; Farooq, H; Morrissy, S; Cao, LX; Sydorenko, N; Baiazitov, R; Du, W; Sheedy, J; Weetall, M; Moon, YC; Lee, CS; Kwiecien, JM; Delaney, KH; Doble, B; Cho, YJ; Mitra, S; Kaplan, D; Taylor, MD; Davis, TW; Singh, SK				Bakhshinyan, David; Venugopal, Chitra; Adile, Ashley A.; Garg, Neha; Manoranjan, Branavan; Hallett, Robin; Wang, Xin; Mahendram, Sujeivan; Vora, Parvez; Vijayakumar, Thusyanth; Subapanditha, Minomi; Singh, Mohini; Kameda-Smith, Michelle Masayo; Qazi, Maleeha; McFarlane, Nicole; Mann, Aneet; Ajani, Olufemi A.; Yarascavitch, Blake; Ramaswamy, Vijay; Farooq, Hamza; Morrissy, Sorana; Cao, Liangxian; Sydorenko, Nadiya; Baiazitov, Ramil; Du, Wu; Sheedy, Josephine; Weetall, Marla; Moon, Young-Choon; Lee, Chang-Sun; Kwiecien, Jacek M.; Delaney, Kathleen H.; Doble, Brad; Cho, Yoon-Jae; Mitra, Siddhartha; Kaplan, David; Taylor, Michael D.; Davis, Thomas W.; Singh, Sheila K.			BMI1 is a therapeutic target in recurrent medulloblastoma	ONCOGENE			English	Article							NEURAL STEM-CELLS; CHILDHOOD MEDULLOBLASTOMA; MOLECULAR SUBGROUPS; MALIGNANT GLIOMA; CANCER; CLASSIFICATION; PREDICTION; REGULATORS; MODEL	Medulloblastoma (MB) is the most frequent malignant pediatric brain tumor, representing 20% of newly diagnosed childhood central nervous system malignancies. Although advances in multimodal therapy yielded a 5-year survivorship of 80%, MB still accounts for the leading cause of childhood cancer mortality. In this work, we describe the epigenetic regulator BMI1 as a novel therapeutic target for the treatment of recurrent human Group 3 MB, a childhood brain tumor for which there is virtually no treatment option beyond palliation. Current clinical trials for recurrent MB patients based on genomic profiles of primary, treatment-naive tumors will provide limited clinical benefit since recurrent metastatic MBs are highly genetically divergent from their primary tumor. Using a small molecule inhibitor against BMI1, PTC-028, we were able to demonstrate complete ablation of self-renewal of MB stem cells in vitro. When administered to mice xenografted with patient tumors, we observed significant reduction in tumor burden in both local and metastatic compartments and subsequent increased survival, without neurotoxicity. Strikingly, serial in vivo re-transplantation assays demonstrated a marked reduction in tumor initiation ability of recurrent MB cells upon re-transplantation of PTC-028-treated cells into secondary recipient mouse brains. As Group 3 MB is often metastatic and uniformly fatal at recurrence, with no current or planned trials of targeted therapy, an efficacious targeted agent would be rapidly transitioned to clinical trials.	[Bakhshinyan, David; Venugopal, Chitra; Adile, Ashley A.; Garg, Neha; Manoranjan, Branavan; Mahendram, Sujeivan; Vora, Parvez; Vijayakumar, Thusyanth; Subapanditha, Minomi; Singh, Mohini; Kameda-Smith, Michelle Masayo; Qazi, Maleeha; McFarlane, Nicole; Mann, Aneet; Doble, Brad; Singh, Sheila K.] McMaster Univ, McMaster Stem Cell & Canc Res Inst, Hamilton, ON L8S 4L8, Canada; [Bakhshinyan, David; Adile, Ashley A.; Manoranjan, Branavan; Vijayakumar, Thusyanth; Singh, Mohini; Kameda-Smith, Michelle Masayo; Qazi, Maleeha; Doble, Brad; Singh, Sheila K.] McMaster Univ, Dept Biochem, Hamilton, ON L8S 4L8, Canada; [Bakhshinyan, David; Adile, Ashley A.; Manoranjan, Branavan; Vijayakumar, Thusyanth; Singh, Mohini; Kameda-Smith, Michelle Masayo; Qazi, Maleeha; Doble, Brad; Singh, Sheila K.] McMaster Univ, Dept Biomed Sci, Hamilton, ON L8S 4L8, Canada; [Venugopal, Chitra; Garg, Neha; Mahendram, Sujeivan; Vora, Parvez; Subapanditha, Minomi; Kameda-Smith, Michelle Masayo; McFarlane, Nicole; Ajani, Olufemi A.; Yarascavitch, Blake; Singh, Sheila K.] McMaster Univ, Surg, Fac Hlth Sci, Hamilton, ON L8S 4L8, Canada; [Manoranjan, Branavan; Singh, Sheila K.] McMaster Univ, Michael G DeGroote Sch Med, Hamilton, ON L8S 4L8, Canada; [Hallett, Robin] Univ Toronto, Hosp Sick Children, Cell Biol Program, Toronto, ON M5S 1A1, Canada; [Wang, Xin; Ramaswamy, Vijay; Farooq, Hamza] Univ Toronto, Hosp Sick Children, Dev Stem Cell Biol Program, Toronto, ON M5S 1A1, Canada; [Wang, Xin; Farooq, Hamza; Taylor, Michael D.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A1, Canada; [Ramaswamy, Vijay; Morrissy, Sorana] Hosp Sick Children, Div Haematol Oncol, Toronto, ON M5G 1X8, Canada; [Cao, Liangxian; Sydorenko, Nadiya; Baiazitov, Ramil; Du, Wu; Sheedy, Josephine; Weetall, Marla; Moon, Young-Choon; Lee, Chang-Sun; Davis, Thomas W.] PTC Therapeut, 100 Corp Court, South Plainfield, NJ 07080 USA; [Kwiecien, Jacek M.; Delaney, Kathleen H.] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8S 4L8, Canada; [Kwiecien, Jacek M.] Med Univ Lublin, Dept Clin Pathomorphol, Lublin, Poland; [Cho, Yoon-Jae; Mitra, Siddhartha] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; [Cho, Yoon-Jae; Mitra, Siddhartha] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA; [Kaplan, David] Univ Toronto, Dept Mol Genet, Toronto, ON M5G 1X8, Canada; [Taylor, Michael D.] Hosp Sick Children, Div Neurosurg, Toronto, ON M5G 1X8, Canada	McMaster University; McMaster University; McMaster University; McMaster University; McMaster University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McMaster University; Medical University of Lublin; Stanford University; Stanford University; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Singh, SK (corresponding author), McMaster Univ, McMaster Stem Cell & Canc Res Inst, Hamilton, ON L8S 4L8, Canada.; Singh, SK (corresponding author), McMaster Univ, Dept Biochem, Hamilton, ON L8S 4L8, Canada.; Singh, SK (corresponding author), McMaster Univ, Dept Biomed Sci, Hamilton, ON L8S 4L8, Canada.; Singh, SK (corresponding author), McMaster Univ, Surg, Fac Hlth Sci, Hamilton, ON L8S 4L8, Canada.; Singh, SK (corresponding author), McMaster Univ, Michael G DeGroote Sch Med, Hamilton, ON L8S 4L8, Canada.	ssingh@mcmaster.ca	Doble, Bradley/V-7848-2019; Garg, Neha/AAG-5180-2020; Yarascavitch, Blake/AAR-8800-2021; Singh, Sheila K/W-2799-2018; Wang, Xin/O-8779-2019	Doble, Bradley/0000-0002-0260-2983; Garg, Neha/0000-0003-2227-8292; Yarascavitch, Blake/0000-0003-1810-1267; Singh, Sheila K/0000-0003-1272-5300; Wang, Xin/0000-0001-6292-3087; Ramaswamy, Vijay/0000-0002-6557-895X; Morrissy, Sorana/0000-0001-8526-562X; Adile, Ashley/0000-0002-3700-7527; Taylor, Michael/0000-0001-7009-3466	Canada Research Chair award; Canadian Institutes of Health Research (CIHR); Stem Cell Network; Ontario Institute for Cancer Research Cancer Stem Cell Program; Canadian Cancer Society Research Institute; Cancer Research Society; Brain Tumor Foundation of Canada	Canada Research Chair award(Natural Resources CanadaCanadian Forest ServiceCanada Research Chairs); Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Stem Cell Network; Ontario Institute for Cancer Research Cancer Stem Cell Program; Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Cancer Research Society; Brain Tumor Foundation of Canada	SKS is supported by Canada Research Chair award, and operating grants from Canadian Institutes of Health Research (CIHR), Stem Cell Network, the Ontario Institute for Cancer Research Cancer Stem Cell Program, the Canadian Cancer Society Research Institute, the Cancer Research Society, the Brain Tumor Foundation of Canada, and generous donations from the Box Run Foundation, Team Kelsey, and patients and their families.	ALKEMA MJ, 1993, HUM MOL GENET, V2, P1597, DOI 10.1093/hmg/2.10.1597; Bandopadhayay P, 2014, CLIN CANCER RES, V20, P912, DOI 10.1158/1078-0432.CCR-13-2281; Bruggeman SWM, 2007, CANCER CELL, V12, P328, DOI 10.1016/j.ccr.2007.08.032; Cavalli FMG, 2017, CANCER CELL, V31, P737, DOI 10.1016/j.ccell.2017.05.005; Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287; Cho JH, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-117; Cho YJ, 2011, J CLIN ONCOL, V29, P1424, DOI 10.1200/JCO.2010.28.5148; Ellison DW, 2010, ACTA NEUROPATHOL, V120, P305, DOI 10.1007/s00401-010-0726-6; Facchino S, 2010, J NEUROSCI, V30, P10096, DOI 10.1523/JNEUROSCI.1634-10.2010; Gargiulo G, 2013, CANCER CELL, V23, P660, DOI 10.1016/j.ccr.2013.03.030; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Hallett RM, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-16; Hallett RM, 2012, SCI REP-UK, V2, DOI 10.1038/srep00227; HE XM, 1991, LAB INVEST, V64, P833; Huse JT, 2010, NAT REV CANCER, V10, P319, DOI 10.1038/nrc2818; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Ismail IH, 2010, J CELL BIOL, V191, P45, DOI 10.1083/jcb.201003034; Kool M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003088; Kreso A, 2014, NAT MED, V20, P29, DOI 10.1038/nm.3418; Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385; Northcott PA, 2011, J CLIN ONCOL, V29, P1408, DOI 10.1200/JCO.2009.27.4324; Pei YX, 2012, CANCER CELL, V21, P155, DOI 10.1016/j.ccr.2011.12.021; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Ramaswamy V, 2013, LANCET ONCOL, V14, P1200, DOI 10.1016/S1470-2045(13)70449-2; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002; Schwalbe EC, 2017, LANCET ONCOL, V18, P958, DOI 10.1016/S1470-2045(17)30243-7; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taylor MD, 2012, ACTA NEUROPATHOL, V123, P465, DOI 10.1007/s00401-011-0922-z; Thompson MC, 2006, J CLIN ONCOL, V24, P1924, DOI 10.1200/JCO.2005.04.4974; Tropepe V, 1999, DEV BIOL, V208, P166, DOI 10.1006/dbio.1998.9192; Venugopal C, 2015, CLIN CANCER RES, V21, P5324, DOI 10.1158/1078-0432.CCR-14-3147; Venugopal C, 2012, J NEURO-ONCOL, V109, P457, DOI 10.1007/s11060-012-0917-1; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Wang X, 2012, ONCOGENE, V31, P187, DOI 10.1038/onc.2011.232; Wang X, 2015, ACTA NEUROPATHOL, V129, P449, DOI 10.1007/s00401-015-1389-0; Wu X, 2012, NATURE, V482, P529, DOI 10.1038/nature10825; Yong KJ, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad6066	40	17	18	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2019	38	10					1702	1716		10.1038/s41388-018-0549-9	http://dx.doi.org/10.1038/s41388-018-0549-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN8DD	30348991				2022-12-28	WOS:000460423800010
J	Wang, C; Gu, YY; Zhang, EB; Zhang, K; Qin, N; Dai, JC; Zhu, M; Liu, J; Xie, KP; Jiang, Y; Guo, XJ; Liu, MX; Jin, GF; Ma, HX; Jiang, T; Yin, R; Xia, YK; Liu, L; Wang, SY; Shen, B; Huo, R; Xu, L; Sha, JH; Qu, B; Shen, HB; Hu, ZB				Wang, Cheng; Gu, Yayun; Zhang, Erbao; Zhang, Kai; Qin, Na; Dai, Juncheng; Zhu, Meng; Liu, Jia; Xie, Kaipeng; Jiang, Yue; Guo, Xuejiang; Liu, Mingxi; Jin, Guangfu; Ma, Hongxia; Jiang, Tao; Yin, Rong; Xia, Yankai; Liu, Li; Wang, Shouyu; Shen, Bin; Huo, Ran; Xu, Lin; Sha, Jiahao; Qu, Bin; Shen, Hongbing; Hu, Zhibin			A cancer-testis non-coding RNA LIN28B-AS1 activates driver gene LIN28B by interacting with IGF2BP1 in lung adenocarcinoma	ONCOGENE			English	Article							DIFFERENTIAL EXPRESSION ANALYSIS; COPY NUMBER ANALYSIS; INHIBITOR; REGULATOR; HALLMARKS; PACKAGE; PROTEIN; GROWTH	Our previous work found cancer-testis (CT) genes as a new source of epi-driver candidates of cancer. LIN28B was a CT gene, but the "driver" ability and the activation mechanism in lung adenocarcinoma (LUAD) remain unclear. We observed that LIN28B expression was restricted in testis. It was re-activated in LUAD patients without known genomic alterations in oncogenes and was related to poorer survival. In vitro and In vivo experiments confirmed that the activation of LIN28B could promote the proliferation and metastasis of LUAD cells and can influence cell cycle, DNA damage repair, and genome instability. In addition to the known let-7-LIN28B regulation loop, our results further revealed a let-7-independent Cis-regulator of LIN28B: LIN28B-ASI. LIN28B-ASI is a CT long non-coding RNA (CT-lncRNA). It altered the messenger RNA stability of LIN28B by directly interacting with another CT protein IGF2BP1 but not with LIN28B and constituted a novel regulation network. In sum, we identify that LIN28B is an "epi-driver" of LUAD and clarify a new lncRNA-activated mechanism of LIN28B, which provide new candidate targets for precise anticancer therapy in the future.	[Wang, Cheng; Gu, Yayun; Zhang, Erbao; Zhang, Kai; Qin, Na; Dai, Juncheng; Zhu, Meng; Liu, Jia; Xie, Kaipeng; Jiang, Yue; Guo, Xuejiang; Liu, Mingxi; Jin, Guangfu; Ma, Hongxia; Jiang, Tao; Shen, Bin; Huo, Ran; Sha, Jiahao; Shen, Hongbing; Hu, Zhibin] Nanjing Med Univ, State Key Lab Reprod Med, Nanjing 211166, Jiangsu, Peoples R China; [Wang, Cheng; Gu, Yayun; Zhang, Erbao; Zhang, Kai; Qin, Na; Dai, Juncheng; Zhu, Meng; Liu, Jia; Xie, Kaipeng; Jiang, Yue; Jin, Guangfu; Ma, Hongxia; Jiang, Tao; Shen, Hongbing; Hu, Zhibin] Nanjing Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Ctr Global Hlth, Nanjing 211166, Jiangsu, Peoples R China; [Wang, Cheng; Gu, Yayun; Zhang, Erbao; Zhang, Kai; Qin, Na; Dai, Juncheng; Zhu, Meng; Liu, Jia; Xie, Kaipeng; Jiang, Yue; Jin, Guangfu; Ma, Hongxia; Jiang, Tao; Shen, Hongbing; Hu, Zhibin] Nanjing Med Univ, Jiangsu Collaborat Innovat Ctr Canc Personalized, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing 211166, Jiangsu, Peoples R China; [Wang, Cheng] Nanjing Med Univ, Sch Biomed Engn & Informat, Dept Bioinformat, Nanjing 211166, Jiangsu, Peoples R China; [Yin, Rong; Xu, Lin] Nanjing Med Univ, Affiliated Canc Hosp, Jiangsu Collaborat Innovat Ctr Canc Personalized, Jiangsu Key Lab Mol & Translat Canc Res, Nanjing 210009, Jiangsu, Peoples R China; [Xia, Yankai; Wang, Shouyu] Nanjing Med Univ, Jiangsu Collaborat Innovat Ctr Canc Personalized, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Dept Mol Cell Biol & Toxicol,Sch Publ Hlth, Nanjing 211166, Jiangsu, Peoples R China; [Liu, Li] Nanjing Med Univ, Digest Endoscopy Ctr, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China; [Qu, Bin] Saarland Univ, Sch Med, CIPMM, Dept Biophys, Saarbrucken, Germany	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Saarland University	Shen, HB; Hu, ZB (corresponding author), Nanjing Med Univ, State Key Lab Reprod Med, Nanjing 211166, Jiangsu, Peoples R China.; Shen, HB; Hu, ZB (corresponding author), Nanjing Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Ctr Global Hlth, Nanjing 211166, Jiangsu, Peoples R China.; Shen, HB; Hu, ZB (corresponding author), Nanjing Med Univ, Jiangsu Collaborat Innovat Ctr Canc Personalized, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing 211166, Jiangsu, Peoples R China.	hbshen@njmu.edu.cn; zhibin_hu@njmu.edu.cn	Shen, Bin/ABD-5084-2021; Guo, Xuejiang/J-9600-2014	Shen, Bin/0000-0002-8946-8448; Ma, Hongxia/0000-0002-9821-6955; zhang, erbao/0000-0002-5752-7976; Guo, Xuejiang/0000-0002-0475-5705; Qin, Na/0000-0001-6878-9464; Xu, Lin/0000-0002-2153-4840; Shen, Hongbing/0000-0002-2581-5906; Liu, Mingxi/0000-0001-6499-7899	Science Fund for Creative Research Groups of the National Natural Science Foundation of China [81521004]; State Key Program of National Natural Science of China [31530047]; National Key Research and Development Program of China [2017YFC0907905]; Young Scientists Fund of the National Natural Science Foundation of China [81703295, 81702266]; National Key Basic Research Program Grant [2015CB943003]; Ten Thousand Talent Program; Natural Science Foundation of Jiangsu Province [BK20160046]; Priority Academic Program for the Development of Jiangsu Higher Education Institutions (Public Health and Preventive Medicine); Top-notch Academic Programs Project of Jiangsu Higher Education Institutions [PPZY2015A067]; Jiangsu Specially-Appointed Professor project	Science Fund for Creative Research Groups of the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); State Key Program of National Natural Science of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program of China; Young Scientists Fund of the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Basic Research Program Grant(National Basic Research Program of China); Ten Thousand Talent Program; Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Priority Academic Program for the Development of Jiangsu Higher Education Institutions (Public Health and Preventive Medicine); Top-notch Academic Programs Project of Jiangsu Higher Education Institutions; Jiangsu Specially-Appointed Professor project	We thank the TCGA project for use of the multiomics data of LUAD samples, and the Genotype-Tissue Expression (GTEx) project for use of the expression abundance of multiple normal tissues. This work was supported by Science Fund for Creative Research Groups of the National Natural Science Foundation of China (81521004), the State Key Program of National Natural Science of China (31530047), National Key Research and Development Program of China (2017YFC0907905), the Young Scientists Fund of the National Natural Science Foundation of China (81703295, 81702266), the National Key Basic Research Program Grant (2015CB943003), the Ten Thousand Talent Program, Jiangsu Specially-Appointed Professor project, Natural Science Foundation of Jiangsu Province (BK20160046), the Priority Academic Program for the Development of Jiangsu Higher Education Institutions (Public Health and Preventive Medicine), and Top-notch Academic Programs Project of Jiangsu Higher Education Institutions (PPZY2015A067).	Alajez NM, 2012, ONCOTARGET, V3, P1641; Ali PSS, 2012, FEBS LETT, V586, P3986, DOI 10.1016/j.febslet.2012.09.034; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Anders S, 2013, NAT PROTOC, V8, P1765, DOI 10.1038/nprot.2013.099; Araujo AN, 2014, J CLIN ENDOCR METAB, V99, pE1104, DOI 10.1210/jc.2013-2993; Battistelli C, 2017, ONCOGENE, V36, P942, DOI 10.1038/onc.2016.260; Beachy SH, 2012, BLOOD, V120, P1048, DOI 10.1182/blood-2012-01-401760; Bergethon K, 2012, J CLIN ONCOL, V30, P863, DOI 10.1200/JCO.2011.35.6345; Busch B, 2016, NUCLEIC ACIDS RES, V44, P3845, DOI 10.1093/nar/gkw099; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Cuddihy AR, 2003, INT REV CYTOL, V222, P99; Darbre PD, 2014, J APPL TOXICOL, V34, P925, DOI 10.1002/jat.3027; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Drilon A, 2013, CANCER DISCOV, V3, P630, DOI 10.1158/2159-8290.CD-13-0035; Enright AJ, 2004, GENOME BIOL, V5; Fuentes-Mattei E, 2014, JNCI-J NATL CANCER I, P106; Gong XQ, 2017, CANCER CELL, V32, P761, DOI 10.1016/j.ccell.2017.11.006; Hu XW, 2014, CANCER CELL, V26, P344, DOI 10.1016/j.ccr.2014.07.009; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Kalb R, 2006, GENOME DYN, V1, P218, DOI 10.1159/000092510; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kertesz M, 2007, NAT GENET, V39, P1278, DOI 10.1038/ng2135; Khanam Tasneem, 2006, RNA Biol, V3, P170; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Leung ELH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014062; Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248; Molenaar JJ, 2012, NAT GENET, V44, P1199, DOI 10.1038/ng.2436; Morris KV, 2014, NAT REV GENET, V15, P423, DOI 10.1038/nrg3722; Nguyen LH, 2014, CANCER CELL, V26, P248, DOI 10.1016/j.ccr.2014.06.018; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pineda CT, 2015, CELL, V160, P715, DOI 10.1016/j.cell.2015.01.034; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Roos M, 2016, ACS CHEM BIOL, V11, P2773, DOI 10.1021/acschembio.6b00232; Shyh-Chang N, 2013, CELL STEM CELL, V12, P395, DOI 10.1016/j.stem.2013.03.005; Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669; Thornton JE, 2012, TRENDS CELL BIOL, V22, P474, DOI 10.1016/j.tcb.2012.06.001; Van Loo P, 2010, P NATL ACAD SCI USA, V107, P16910, DOI 10.1073/pnas.1009843107; Viswanathan SR, 2008, SCIENCE, V320, P97, DOI 10.1126/science.1154040; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wang C, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10499; Watkins J, 2015, CANCER DISCOV, V5, P488, DOI 10.1158/2159-8290.CD-14-1092; Yamada K, 2013, MOL CELL, V49, P922, DOI 10.1016/j.molcel.2012.12.023; Yeap BB, 2002, J BIOL CHEM, V277, P27183, DOI 10.1074/jbc.M202883200; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhang M, 2013, J PROTEOME RES, V12, P5260, DOI 10.1021/pr400476a	45	46	46	0	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2019	38	10					1611	1624		10.1038/s41388-018-0548-x	http://dx.doi.org/10.1038/s41388-018-0548-x			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN8DD	30353165				2022-12-28	WOS:000460423800003
J	Wang, YN; Lu, YX; Liu, J; Jin, Y; Bi, HC; Zhao, Q; Liu, ZX; Li, YQ; Hu, JJ; Sheng, H; Jiang, YM; Zhang, C; Tian, F; Chen, Y; Pan, ZZ; Chen, G; Zeng, ZL; Liu, KY; Ogasawara, M; Yun, JP; Ju, HQ; Feng, JX; Xie, D; Gao, S; Jia, WH; Kopetz, S; Xu, RH; Wang, F				Wang, Ying-Nan; Lu, Yun-Xin; Liu, Jie; Jin, Ying; Bi, Hui-Chang; Zhao, Qi; Liu, Ze-Xian; Li, Ying-Qin; Hu, Jia-Jia; Sheng, Hui; Jiang, Yi-Ming; Zhang, Chao; Tian, Feng; Chen, Yang; Pan, Zhi-Zhong; Chen, Gong; Zeng, Zhao-Lei; Liu, Kai-Yan; Ogasawara, Marcia; Yun, Jin-Ping; Ju, Huai-Qiang; Feng, Jian-Xiong; Xie, Dan; Gao, Song; Jia, Wei-Hua; Kopetz, Scott; Xu, Rui-Hua; Wang, Feng			AMPK alpha 1 confers survival advantage of colorectal cancer cells under metabolic stress by promoting redox balance through the regulation of glutathione reductase phosphorylation	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; NEGATIVE REGULATOR; COLON-CANCER; AMPK; GROWTH; EXPRESSION; NUTRIENT; RECEPTOR; GENE	Patients with stage II or III colorectal cancer (CRC) exhibit various clinical outcomes after radical treatments. The 5-year survival rate was between 50 and 87%. However, the underlying mechanisms of the variation remain unclear. Here we show that AMPK alpha 1 is overexpressed in CRC patient specimens and the high expression is correlated with poor patient survival. We further reveal a previously unrecognized function of AMPK alpha 1, which maintains high level of reduced glutathione to keep reduction-oxidation reaction (redox) homeostasis under stress conditions, thus promoting CRC cell survival under metabolic stress in vitro and enhancing tumorigenesis in vivo. Mechanistically, AMPK alpha 1 regulate the glutathione reductase (GSR) phosphorylation possibly through residue Thr507 which enhances its activity. Suppression of AMPK alpha 1 by using nano-sized polymeric vector induces a favorable therapeutic effect, especially when in combination with oxaliplatin. Our study uncovers a novel function of AMPK alpha 1 in redox regulation and identifies a promising therapeutic strategy for treatment of CRC.	[Wang, Ying-Nan; Lu, Yun-Xin; Jin, Ying; Zhao, Qi; Liu, Ze-Xian; Hu, Jia-Jia; Sheng, Hui; Zhang, Chao; Chen, Yang; Zeng, Zhao-Lei; Liu, Kai-Yan; Yun, Jin-Ping; Ju, Huai-Qiang; Feng, Jian-Xiong; Xie, Dan; Gao, Song; Jia, Wei-Hua; Xu, Rui-Hua; Wang, Feng] Sun Yat Sen Univ, Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China; [Wang, Ying-Nan; Lu, Yun-Xin; Jin, Ying; Zhao, Qi; Liu, Ze-Xian; Hu, Jia-Jia; Sheng, Hui; Zhang, Chao; Chen, Yang; Pan, Zhi-Zhong; Chen, Gong; Zeng, Zhao-Lei; Liu, Kai-Yan; Yun, Jin-Ping; Ju, Huai-Qiang; Feng, Jian-Xiong; Xie, Dan; Gao, Song; Jia, Wei-Hua; Xu, Rui-Hua; Wang, Feng] Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China; [Liu, Jie; Li, Ying-Qin] Sun Yat Sen Univ, Sch Engn, Dept Biomed Engn, Guangzhou 510006, Guangdong, Peoples R China; [Jin, Ying; Xu, Rui-Hua; Wang, Feng] Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China; [Bi, Hui-Chang; Jiang, Yi-Ming] Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou 510006, Guangdong, Peoples R China; [Tian, Feng; Kopetz, Scott] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA; [Pan, Zhi-Zhong; Chen, Gong] Sun Yat Sen Univ, Canc Ctr, Dept Colorectal Surg, Guangzhou 510060, Guangdong, Peoples R China; [Ogasawara, Marcia] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; University of Texas System; UTMD Anderson Cancer Center; Sun Yat Sen University; University of Texas System; UTMD Anderson Cancer Center	Xu, RH; Wang, F (corresponding author), Sun Yat Sen Univ, Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China.; Xu, RH; Wang, F (corresponding author), Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China.; Xu, RH; Wang, F (corresponding author), Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China.; Kopetz, S (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA.	skopetz@mdanderson.org; xurh@sysucc.org.cn; wangfeng@sysucc.org.cn	Kopetz, Scott/AAC-1387-2019; Chen, Yang/L-7304-2018; xu, rui/GRX-5734-2022; Liu, Zexian/D-1153-2011; Chen, Yang/AFL-4729-2022; Xu, Rui-Hua/AAW-4766-2021	Kopetz, Scott/0000-0001-9647-3416; Chen, Yang/0000-0001-7661-5923; Liu, Zexian/0000-0001-9698-0610; Xu, Rui-Hua/0000-0001-9771-8534; Gao, Song/0000-0001-7427-6681	National Key Research and Development Program of China [2017YFC1308900, 2018YFC1313300]; Natural Science Foundation of Guangdong Province [2014A030312015, 2017A030313485]; National Natural Science Foundation of China [81872011, 81572392]; Science and Technology Program of Guangdong [2019B020227002]; Science and Technology Program of Guangzhou [201904020046, 201803040019, 201704020228]; Guangzhou Health and Medical Collaborative Innovation Project [201704020220]; Sun Yat-sen University Clinical Research 5010 Program [2018014]	National Key Research and Development Program of China; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Program of Guangdong; Science and Technology Program of Guangzhou; Guangzhou Health and Medical Collaborative Innovation Project; Sun Yat-sen University Clinical Research 5010 Program	This study was supported, in part, by the National Key Research and Development Program of China (2017YFC1308900, 2018YFC1313300), Natural Science Foundation of Guangdong Province (2014A030312015, 2017A030313485); National Natural Science Foundation of China (81872011, 81572392); Science and Technology Program of Guangdong (2019B020227002), Science and Technology Program of Guangzhou (201904020046, 201803040019, 201704020228), Guangzhou Health and Medical Collaborative Innovation Project (201704020220), and the Sun Yat-sen University Clinical Research 5010 Program (2018014). FW is the Young Physician Scientist Program of Sun Yat-sen University Cancer Center.	[Anonymous], 2013, Cancer Discov, V3, pOF15, DOI 10.1158/2159-8290.CD-RW2013-018; Bhandaru M, 2014, J INVEST DERMATOL, V134, P1763, DOI 10.1038/jid.2014.26; Bi HC, 2014, CARCINOGENESIS, V35, P2264, DOI 10.1093/carcin/bgu174; Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9; Chen DL, 2014, HEPATOLOGY, V60, P598, DOI 10.1002/hep.27118; Chen WQ, 2015, CHIN J CANCER, V34, DOI 10.1186/s40880-015-0042-6; Chiu YC, 2009, CARCINOGENESIS, V30, P1651, DOI 10.1093/carcin/bgp156; Faubert B, 2015, CANCER LETT, V356, P165, DOI 10.1016/j.canlet.2014.01.018; Faubert B, 2013, CELL METAB, V17, P113, DOI 10.1016/j.cmet.2012.12.001; Fu X, 2013, MOL CELL BIOL, V33, P4517, DOI 10.1128/MCB.01078-13; Goh V, 2012, J NUCL MED, V53, P687, DOI 10.2967/jnumed.111.098525; Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311; Hari DM, 2013, J AM COLL SURGEONS, V217, P181, DOI 10.1016/j.jamcollsurg.2013.04.018; Hoffman NJ, 2015, CELL METAB, V22, P922, DOI 10.1016/j.cmet.2015.09.001; Huang FY, 2006, GYNECOL ONCOL, V103, P219, DOI 10.1016/j.ygyno.2006.02.028; Jeon SM, 2015, ARCH PHARM RES, V38, P346, DOI 10.1007/s12272-015-0549-z; Jeon Sang-Min, 2012, Cell Logist, V2, P197; Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066; Ju HQ, 2016, J PINEAL RES, V60, P27, DOI 10.1111/jpi.12285; Kato K, 2002, ONCOGENE, V21, P6082, DOI 10.1038/sj.onc.1205737; Lee YC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078709; Li M, 2005, WORLD J GASTROENTERO, V11, P4685, DOI 10.3748/wjg.v11.i30.4685; Liu SY, 2009, CANCER CELL, V15, P539, DOI 10.1016/j.ccr.2009.03.027; Lu SC, 2009, MOL ASPECTS MED, V30, P42, DOI 10.1016/j.mam.2008.05.005; Ma MZ, 2015, CANCER LETT, V368, P88, DOI 10.1016/j.canlet.2015.07.031; Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329; O'Connell JB, 2004, JNCI-J NATL CANCER I, V96, P1420, DOI 10.1093/jnci/djh275; Phoenix Kathryn N, 2012, Genes Cancer, V3, P51, DOI 10.1177/1947601912452883; Saito Y, 2015, CELL STEM CELL, V17, P585, DOI 10.1016/j.stem.2015.08.019; Santoro V, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv394; Schreuders EH, 2015, GUT, V64, P1637, DOI 10.1136/gutjnl-2014-309086; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Shaw RJ, 2015, CELL STEM CELL, V17, P503, DOI 10.1016/j.stem.2015.10.007; Sung JJY, 2015, GUT, V64, P121, DOI 10.1136/gutjnl-2013-306503; Svensson RU, 2012, NATURE, V485, P590, DOI 10.1038/485590a; Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Yu K, 2019, NUCLEIC ACIDS RES, V47, pD451, DOI 10.1093/nar/gky1052; Yuan SQ, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0174-2; Yun J, 2015, SCIENCE, V350, P1391, DOI 10.1126/science.aaa5004; Zeng ZL, 2014, CLIN CANCER RES, V20, P1042, DOI 10.1158/1078-0432.CCR-13-0171; Zhao G, 2013, MOL CANCER THER, V12, P83, DOI 10.1158/1535-7163.MCT-12-0534-T; Zhou Q, 2015, CHIN J CANCER, V34, P1, DOI 10.1186/s40880-015-0026-6	43	10	10	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					637	650		10.1038/s41388-019-1004-2	http://dx.doi.org/10.1038/s41388-019-1004-2			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31530934	hybrid, Green Published			2022-12-28	WOS:000509718300011
J	Leon, LM; Gautier, M; Allan, R; Ilie, M; Nottet, N; Pons, N; Paquet, A; Lebrigand, K; Truchi, M; Fassy, J; Magnone, V; Kinnebrew, G; Radovich, M; Cheok, MHC; Barbry, P; Vassaux, G; Marquette, CH; Ponzio, G; Ivan, M; Pottier, N; Hofman, P; Mari, B; Rezzonico, R				Leon, Laura Moreno; Gautier, Marine; Allan, Richard; Ilie, Marius; Nottet, Nicolas; Pons, Nicolas; Paquet, Agnes; Lebrigand, Kevin; Truchi, Marin; Fassy, Julien; Magnone, Virginie; Kinnebrew, Garrett; Radovich, Milan; Cheok, Meyling Hua-Chen; Barbry, Pascal; Vassaux, Georges; Marquette, Charles-Hugo; Ponzio, Gilles; Ivan, Mircea; Pottier, Nicolas; Hofman, Paul; Mari, Bernard; Rezzonico, Roger			The nuclear hypoxia-regulated NLUCAT1 long non-coding RNA contributes to an aggressive phenotype in lung adenocarcinoma through regulation of oxidative stress	ONCOGENE			English	Article							NF-KAPPA-B; CIGARETTE-SMOKE; GENE-EXPRESSION; CELL-PROLIFERATION; EPITHELIAL-CELLS; DRUG-RESISTANCE; POOR-PROGNOSIS; CANCER; TRANSCRIPTION; ANNOTATION	Lung cancer is the leading cause of cancer death worldwide, with poor prognosis and a high rate of recurrence despite early surgical removal. Hypoxic regions within tumors represent sources of aggressiveness and resistance to therapy. Although long non-coding RNAs (lncRNAs) are increasingly recognized as major gene expression regulators, their regulation and function following hypoxic stress are still largely unexplored. Combining profiling studies on early-stage lung adenocarcinoma (LUAD) biopsies and on A549 LUAD cell lines cultured in normoxic or hypoxic conditions, we identified a subset of lncRNAs that are both correlated with the hypoxic status of tumors and regulated by hypoxia in vitro. We focused on a new transcript, NLUCAT1, which is strongly upregulated by hypoxia in vitro and correlated with hypoxic markers and poor prognosis in LUADs. Full molecular characterization showed that NLUCAT1 is a large nuclear transcript composed of six exons and mainly regulated by NF-kappa B and NRF2 transcription factors. CRISPR-Cas9-mediated invalidation of NLUCAT1 revealed a decrease in proliferative and invasive properties, an increase in oxidative stress and a higher sensitivity to cisplatin-induced apoptosis. Transcriptome analysis of NLUCAT1-deficient cells showed repressed genes within the antioxidant and/or cisplatin-response networks. We demonstrated that the concomitant knockdown of four of these genes products, GPX2, GLRX, ALDH3A1, and PDK4, significantly increased ROS-dependent caspase activation, thus partially mimicking the consequences of NLUCAT1 inactivation in LUAD cells. Overall, we demonstrate that NLUCAT1 contributes to an aggressive phenotype in early-stage hypoxic tumors, suggesting it may represent a new potential therapeutic target in LUADs.	[Leon, Laura Moreno; Gautier, Marine; Allan, Richard; Nottet, Nicolas; Pons, Nicolas; Paquet, Agnes; Lebrigand, Kevin; Truchi, Marin; Fassy, Julien; Magnone, Virginie; Barbry, Pascal; Ponzio, Gilles; Mari, Bernard] Univ Cote Azur, CNRS, UMR7275, IPMC, Valbonne, France; [Leon, Laura Moreno; Gautier, Marine; Allan, Richard; Ilie, Marius; Nottet, Nicolas; Pons, Nicolas; Paquet, Agnes; Lebrigand, Kevin; Truchi, Marin; Fassy, Julien; Magnone, Virginie; Barbry, Pascal; Vassaux, Georges; Marquette, Charles-Hugo; Ponzio, Gilles; Hofman, Paul; Mari, Bernard; Rezzonico, Roger] FHU OncoAge, Nice, France; [Ilie, Marius; Marquette, Charles-Hugo; Hofman, Paul] Univ Cote Azur, CNRS, INSERM, IRCAN, Nice, France; [Ilie, Marius; Hofman, Paul] Pasteur Hosp, Hosp Related Biobank BB 0033 00025, Nice, France; [Kinnebrew, Garrett; Radovich, Milan] Indiana Univ Sch Med, Dept Surg Med & Mol Genet, Indianapolis, IN 46202 USA; [Cheok, Meyling Hua-Chen] Inst Canc Res Lille, Factors Leukemia Cell Persistence, INSERM, UMR S1172, Lille, France; [Vassaux, Georges; Rezzonico, Roger] Univ Cote Azur, INSERM, CNRS, UMR7275,IPMC, Valbonne, France; [Marquette, Charles-Hugo] CHU Nice, Dept Pneumol, Nice, France; [Ivan, Mircea] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA; [Ivan, Mircea] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; [Pottier, Nicolas] Fac Med Lille, Pole Rech, EA4483, Lille, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; Indiana University System; Indiana University Bloomington; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Universite de Lille - ISITE; Universite de Lille	Mari, B (corresponding author), Univ Cote Azur, CNRS, UMR7275, IPMC, Valbonne, France.; Mari, B; Rezzonico, R (corresponding author), FHU OncoAge, Nice, France.; Rezzonico, R (corresponding author), Univ Cote Azur, INSERM, CNRS, UMR7275,IPMC, Valbonne, France.	mari@unice.fr; rezzonico@ipmc.cnrs.fr	Moreno Leon, Laura/AGP-7137-2022; Mari, Bernard/Q-5832-2019; Cheok, Meyling h/C-3822-2014; Cheok, Meyling/AFS-4025-2022; Hofman, Paul/P-7654-2018; Vassaux, Georges/N-9724-2016; REZZONICO, Roger/N-9626-2016; Mari, Bernard P/GVS-3100-2022; Barbry, Pascal/O-5021-2016	Moreno Leon, Laura/0000-0002-5560-1765; Mari, Bernard/0000-0002-0422-9182; Cheok, Meyling h/0000-0002-7820-8026; Cheok, Meyling/0000-0002-7820-8026; Hofman, Paul/0000-0003-0431-9353; Vassaux, Georges/0000-0002-1149-7716; REZZONICO, Roger/0000-0002-8460-1641; Mari, Bernard P/0000-0002-0422-9182; GAUTIER-ISOLA, Marine/0000-0003-3768-8809; Kinnebrew, Garrett/0000-0001-7384-6582; Nottet, Nicolas/0000-0002-8699-6747; Barbry, Pascal/0000-0001-9632-6483	Plan Cancer 2018 "ARN non-codants en cancerologie: du fondamental au translationnel" [18CN045]; Canceropole PACA; Fondation ARC pour la Recherche sur le Cancer; Fondation Unice (AIR project); Ligue contre le cancer (comite departemental du Nord); French Government (Agence Nationale de Recherche, ANR) through the Investments for the Future LABEX SIGNALIFE [ANR-11-LABX-0028-01]; French Government (Agence Nationale de Recherche, ANR) through the FRANCE GENOMIQUE [ANR-10-INBS-09-03, ANR-10-INBS-09-02]; Fondation pour la Recherche Medicale	Plan Cancer 2018 "ARN non-codants en cancerologie: du fondamental au translationnel"; Canceropole PACA(Region Grand-Est); Fondation ARC pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le Cancer); Fondation Unice (AIR project); Ligue contre le cancer (comite departemental du Nord); French Government (Agence Nationale de Recherche, ANR) through the Investments for the Future LABEX SIGNALIFE(French National Research Agency (ANR)); French Government (Agence Nationale de Recherche, ANR) through the FRANCE GENOMIQUE(French National Research Agency (ANR)); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale)	We gratefully acknowledge the outstanding technical support of the UCA GenomiX platform and MICA imaging facility of the University Cote d'Azur, and the staff from the CHU Nice Biobank. This work was supported by Plan Cancer 2018 "ARN non-codants en cancerologie: du fondamental au translationnel" (number 18CN045), Canceropole PACA, Fondation ARC pour la Recherche sur le Cancer, Fondation Unice (AIR project), Ligue contre le cancer (comite departemental du Nord), and the French Government (Agence Nationale de Recherche, ANR) through the Investments for the Future LABEX SIGNALIFE (ANR-11-LABX-0028-01) and FRANCE GENOMIQUE (ANR-10-INBS-09-03 and ANR-10-INBS-09-02). LML was a recipient of the Fondation pour la Recherche Medicale.	Akagi I, 2013, CANCER RES, V73, P3821, DOI 10.1158/0008-5472.CAN-13-0031; Ashouri A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13197; Bertero T, 2013, CELL DEATH DIFFER, V20, P800, DOI 10.1038/cdd.2013.5; Bertero T, 2017, INT REV CEL MOL BIO, V333, P91, DOI 10.1016/bs.ircmb.2017.03.006; Blanco MR, 2017, EMBO J, V36, P964, DOI 10.15252/embj.201796796; Buelna-Chontal M, 2013, CELL SIGNAL, V25, P2548, DOI 10.1016/j.cellsig.2013.08.007; Buffa FM, 2010, BRIT J CANCER, V102, P428, DOI 10.1038/sj.bjc.6605450; Burke JR, 2003, J BIOL CHEM, V278, P1450, DOI 10.1074/jbc.M209677200; Cabili MN, 2011, GENE DEV, V25, P1915, DOI 10.1101/gad.17446611; Chang MY, 2007, J THORAC CARDIOV SUR, V134, P850, DOI 10.1016/j.jtcvs.2007.03.044; Chang YN, 2016, GENE, V575, P1, DOI 10.1016/j.gene.2015.08.049; Choi YM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135083; Clark MB, 2012, GENOME RES, V22, P885, DOI 10.1101/gr.131037.111; Davidovich C, 2013, NAT STRUCT MOL BIOL, V20, P1250, DOI 10.1038/nsmb.2679; Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111; Dong J, 2016, TUMOR BIOL, V37, P1379, DOI 10.1007/s13277-015-4457-0; Du Z, 2013, NAT STRUCT MOL BIOL, V20, P908, DOI 10.1038/nsmb.2591; Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283; Engreitz JM, 2016, NATURE, V539, P452, DOI 10.1038/nature20149; Fang JH, 2014, FREE RADICAL BIO MED, V68, P80, DOI 10.1016/j.freeradbiomed.2013.11.028; Fang SS, 2018, NUCLEIC ACIDS RES, V46, pD308, DOI 10.1093/nar/gkx1107; Ferdin J, 2013, CELL DEATH DIFFER, V20, P1675, DOI 10.1038/cdd.2013.119; Fitzpatrick SF, 2011, J IMMUNOL, V186, P1091, DOI 10.4049/jimmunol.1002256; Galluzzi L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.428; Gastaldi C, 2014, CARCINOGENESIS, V35, P1110, DOI 10.1093/carcin/bgt490; Gee HE, 2014, ANTIOXID REDOX SIGN, V21, P1220, DOI 10.1089/ars.2013.5639; Gorlach Agnes, 2008, Biochem J, V412, pe17, DOI 10.1042/BJ20080920; Grosso S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.71; Guttman M, 2012, NATURE, V482, P339, DOI 10.1038/nature10887; Hangauer MJ, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003569; Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111; Heery R, 2017, CANCERS, V9, DOI 10.3390/cancers9040038; Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599; Duong HQ, 2017, ANTIOXIDANTS-BASEL, V6, DOI 10.3390/antiox6030052; Hu Y, 2018, ONCOTARGETS THER, V11, P3185, DOI 10.2147/OTT.S158104; Ilie M, 2010, BRIT J CANCER, V102, P1627, DOI 10.1038/sj.bjc.6605690; Iyer MK, 2015, NAT GENET, V47, P199, DOI 10.1038/ng.3192; Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106; Lassen N, 2006, FREE RADICAL BIO MED, V41, P1459, DOI 10.1016/j.freeradbiomed.2006.08.009; Leclerc D, 2017, BRIT J CANCER, V116, P930, DOI 10.1038/bjc.2017.38; Li WB, 2016, NAT REV GENET, V17, P207, DOI 10.1038/nrg.2016.4; Lin AF, 2016, NAT CELL BIOL, V18, P213, DOI 10.1038/ncb3295; Lin CX, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003231; Liu XB, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111835; Liu XB, 2015, INVEST OPHTH VIS SCI, V56, P2821, DOI 10.1167/iovs.14-15876; Loewen G, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0090-4; Lugthart S, 2005, CANCER CELL, V7, P375, DOI 10.1016/j.ccr.2005.03.002; Marullo R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081162; Muzio G, 2012, FREE RADICAL BIO MED, V52, P735, DOI 10.1016/j.freeradbiomed.2011.11.033; Naiki T, 2014, CARCINOGENESIS, V35, P1962, DOI 10.1093/carcin/bgu048; Nakajima S, 2013, FREE RADICAL BIO MED, V65, P162, DOI 10.1016/j.freeradbiomed.2013.06.020; Oliver KM, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2575; Ou SHI, 2007, CANCER-AM CANCER SOC, V110, P1532, DOI 10.1002/cncr.22938; Patten DA, 2010, MOL BIOL CELL, V21, P3247, DOI 10.1091/mbc.E10-01-0025; Portoso M, 2017, EMBO J, V36, P981, DOI 10.15252/embj.201695335; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Puissegur MP, 2011, CELL DEATH DIFFER, V18, P465, DOI 10.1038/cdd.2010.119; Quinn JJ, 2016, NAT REV GENET, V17, P47, DOI 10.1038/nrg.2015.10; Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006; Rius J, 2008, NATURE, V453, P807, DOI 10.1038/nature06905; Schmidt LH, 2011, J THORAC ONCOL, V6, P1984, DOI 10.1097/JTO.0b013e3182307eac; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Shelton P, 2013, FASEB J, V27, P414, DOI 10.1096/fj.12-217257; Singh A, 2006, AM J RESP CELL MOL, V35, P639, DOI 10.1165/rcmb.2005-0325OC; Sun Y, 2017, ONCOTARGET, V8, P28297, DOI 10.18632/oncotarget.16044; Tafani M, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3907147; Tani H, 2012, GENOME RES, V22, P947, DOI 10.1101/gr.130559.111; Thai P, 2013, AM J RESP CELL MOL, V49, P204, DOI 10.1165/rcmb.2013-0159RC; Toth RK, 2017, ANTIOXIDANTS-BASEL, V6, DOI 10.3390/antiox6020027; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; Volders PJ, 2015, NUCLEIC ACIDS RES, V43, P4363, DOI 10.1093/nar/gkv295; Volders PJ, 2013, NUCLEIC ACIDS RES, V41, pD246, DOI 10.1093/nar/gks915; Wang YM, 2006, METHODS, V39, P356, DOI 10.1016/j.ymeth.2006.06.010; White NM, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0429-8; Woolbright BL, 2018, MOL CANCER THER, V17, P2004, DOI 10.1158/1535-7163.MCT-18-0063; Wu X, 2018, ANTIOXID REDOX SIGN, V29, P922, DOI 10.1089/ars.2017.7293; Yan WS, 2006, J BIOL CHEM, V281, P7856, DOI 10.1074/jbc.M512655200; Yang F, 2014, MOL CELL, V53, P88, DOI 10.1016/j.molcel.2013.11.004; Yang F, 2013, MOL CELL, V49, P1083, DOI 10.1016/j.molcel.2013.01.010; Zhang Y, 2016, J BIOL CHEM, V291, P17405, DOI 10.1074/jbc.M116.713735; Zheng ZG, 2016, SCI REP-UK, V6, DOI 10.1038/srep26093	81	42	42	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2019	38	46					7146	7165		10.1038/s41388-019-0935-y	http://dx.doi.org/10.1038/s41388-019-0935-y			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JN5HX	31417181				2022-12-28	WOS:000496930500003
J	Yang, CX; Cao, ML; Liu, YW; He, YQ; Du, Y; Zhang, GL; Gao, F				Yang, Cuixia; Cao, Manlin; Liu, Yiwen; He, Yiqing; Du, Yan; Zhang, Guoliang; Gao, Feng			Inducible formation of leader cells driven by CD44 switching gives rise to collective invasion and metastases in luminal breast carcinomas	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CANCER STEM-CELLS; DYNAMIC EQUILIBRIUM; TUMOR-CELLS; MIGRATION; HETEROGENEITY; DISSEMINATION; PLASTICITY; IDENTIFICATION; CONTRIBUTES	Collective invasion into adjacent tissue is a hallmark of luminal breast cancer, and similar to 20% of these cases eventually undergo metastasis. How less aggressive luminal-like breast cancer transitions to invasive cancer remains unclear. Our study revealed that CD44(hi) cancer cells are the leading subpopulation in collectively invading luminal cancer cells and efficiently promote the collective invasion of CD44(lo)/follower cells. The CD44(hi)/leader subpopulation showed a specific gene signature of various hybrid epithelial/mesenchymal genes and key functional coregulators of collective invasion, which was distinct from that of CD44(lo)/follower cells. However, the CD44(hi)/leader cells, which showed a partial epithelial-mesenchymal transition (EMT) phenotype, readily switched to the CD44(lo) phenotype along with collective migration and vice versa; this phenomenon was spontaneous and sensitive to the tumor microenvironment. The CD44(lo)-to-CD44(hi) conversion was accompanied by a shift in CD44s to CD44v but not a conversion of non-cancer stem cells to cancer stem cells (CSCs). Therefore, the CD44(hi) leader cells, as currently identified, are not a stable subpopulation in breast tumors. This plasticity and ability to generate CD44(hi) carcinoma cells with enhanced migratory and invasive behavior might be responsible for the transition from in situ to invasive behavior of luminal-type breast cancer.	[Yang, Cuixia; Liu, Yiwen; He, Yiqing; Du, Yan; Zhang, Guoliang; Gao, Feng] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Mol Biol Lab, Shanghai, Peoples R China; [Yang, Cuixia; Gao, Feng] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Clin Lab, Shanghai, Peoples R China; [Cao, Manlin] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Rehabil Med, Shanghai 200233, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Gao, F (corresponding author), Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Mol Biol Lab, Shanghai, Peoples R China.; Gao, F (corresponding author), Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Clin Lab, Shanghai, Peoples R China.	gao3507@126.com	liu, yi/GXE-9662-2022		National Natural Science Foundation of China [81672843, 81572821, 81502490, 81502491, 81402419, 81702852, 81872357]; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support [20171924]; Shanghai Training and Support Program for Medical Technologist; Natural Science Foundation of Shanghai Municipality [14YF1412200]; Shanghai Shen-Kang Hospital Development Center [SHDC22014004]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support; Shanghai Training and Support Program for Medical Technologist; Natural Science Foundation of Shanghai Municipality(Natural Science Foundation of Shanghai); Shanghai Shen-Kang Hospital Development Center	This work was supported by the National Natural Science Foundation of China (81672843, 81572821, 81502490, 81502491, 81402419, 81702852, 81872357), the Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (20171924), the Shanghai Training and Support Program for Medical Technologist (2017), the Natural Science Foundation of Shanghai Municipality (14YF1412200), and the Shanghai Shen-Kang Hospital Development Center (SHDC22014004).	Aceto N, 2014, CELL, V158, P1110, DOI 10.1016/j.cell.2014.07.013; Ahmed M, 2016, CANCER CELL, V30, P432, DOI 10.1016/j.ccell.2016.08.002; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Almendro V, 2013, ANNU REV PATHOL-MECH, V8, P277, DOI 10.1146/annurev-pathol-020712-163923; Banky B, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-83; Brown RL, 2011, J CLIN INVEST, V121, P1064, DOI 10.1172/JCI44540; Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005; Chapnick DA, 2014, MOL BIOL CELL, V25, P1586, DOI 10.1091/mbc.E14-01-0697; Cheung KJ, 2016, P NATL ACAD SCI USA, V113, pE854, DOI 10.1073/pnas.1508541113; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Chiasson-MacKenzie C, 2015, J CELL BIOL, V211, P391, DOI 10.1083/jcb.201503081; Corsa CAS, 2016, CELL REP, V15, P2510, DOI 10.1016/j.celrep.2016.05.033; Dang TT, 2011, CANCER RES, V71, P6857, DOI 10.1158/0008-5472.CAN-11-1818; Das T, 2015, NAT CELL BIOL, V17, P276, DOI 10.1038/ncb3115; Donatello S, 2012, AM J PATHOL, V181, P2172, DOI 10.1016/j.ajpath.2012.08.025; Drees F, 2005, CELL, V123, P903, DOI 10.1016/j.cell.2005.09.021; Fehon RG, 2010, NAT REV MOL CELL BIO, V11, P276, DOI 10.1038/nrm2866; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Fortier AM, 2013, J BIOL CHEM, V288, P11555, DOI 10.1074/jbc.M112.428920; Freeman SA, 2018, CELL, V172, P305, DOI 10.1016/j.cell.2017.12.023; Friedl P, 2012, NAT CELL BIOL, V14, P777, DOI 10.1038/ncb2548; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; Godar S, 2008, CELL, V134, P62, DOI 10.1016/j.cell.2008.06.006; Gregory PA, 2011, MOL BIOL CELL, V22, P1686, DOI 10.1091/mbc.E11-02-0103; Guo W, 2014, ONCOGENE, V33, P537, DOI 10.1038/onc.2013.260; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108; Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038; Ito T, 2015, CLIN BREAST CANCER, V15, pE93, DOI 10.1016/j.clbc.2014.11.002; Kennecke H, 2010, J CLIN ONCOL, V28, P3271, DOI 10.1200/JCO.2009.25.9820; Nguyen-Ngoc KV, 2012, P NATL ACAD SCI USA, V109, pE2595, DOI 10.1073/pnas.1212834109; Klymkowsky MW, 2009, AM J PATHOL, V174, P1588, DOI 10.2353/ajpath.2009.080545; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Liu LY, 2013, P NATL ACAD SCI USA, V110, P1686, DOI 10.1073/pnas.1221147110; Matak A, 2018, HEPATOLOGY, V68, P933, DOI 10.1002/hep.29679; McGranahan N, 2015, CANCER CELL, V27, P15, DOI 10.1016/j.ccell.2014.12.001; Morath I, 2018, ONCOGENE, V37, P1472, DOI 10.1038/s41388-017-0030-1; Park SY, 2010, J CLIN INVEST, V120, P636, DOI 10.1172/JCI40724; Pinto Mauricio P, 2011, Front Endocrinol (Lausanne), V2, P15, DOI 10.3389/fendo.2011.00015; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Preca BT, 2015, INT J CANCER, V137, P2566, DOI 10.1002/ijc.29642; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Reffay M, 2014, NAT CELL BIOL, V16, P217, DOI 10.1038/ncb2917; Ribeiro AS, 2015, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00371; Roswall P, 2018, NAT MED, V24, P463, DOI 10.1038/nm.4494; Shamir ER, 2014, J CELL BIOL, V204, P839, DOI 10.1083/jcb.201306088; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Yadav A, 2011, MOL CANCER RES, V9, P1658, DOI 10.1158/1541-7786.MCR-11-0271; Yae T, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1892; Yang CX, 2015, ONCOTARGET, V6, P15283, DOI 10.18632/oncotarget.3681; Yang CX, 2012, J BIOL CHEM, V287, P43094, DOI 10.1074/jbc.M112.349209; Yang G, 2012, BRIT J CANCER, V106, P1512, DOI 10.1038/bjc.2012.126; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522; Zajac O, 2018, NAT CELL BIOL, V20, P296, DOI 10.1038/s41556-017-0027-6; Zhang GL, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1172154; Zhao S, 2016, CLIN CANCER RES, V22, P5592, DOI 10.1158/1078-0432.CCR-15-3115; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	62	35	35	2	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2019	38	46					7113	7132		10.1038/s41388-019-0899-y	http://dx.doi.org/10.1038/s41388-019-0899-y			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JN5HX	31417182				2022-12-28	WOS:000496930500001
J	Tang, K; Yu, YD; Zhu, LY; Xu, PW; Chen, J; Ma, JW; Zhang, HF; Fang, HQ; Sun, WW; Zhou, L; Wei, KK; Li, F; Lv, JD; Xie, J; Liu, YY; Huang, B				Tang, Ke; Yu, Yuandong; Zhu, Liyan; Xu, Pingwei; Chen, Jie; Ma, Jingwei; Zhang, Huafeng; Fang, Haiqing; Sun, Weiwei; Zhou, Li; Wei, Keke; Li, Fei; Lv, Jiadi; Xie, Jing; Liu, Yuying; Huang, Bo			Hypoxia-reprogrammed tricarboxylic acid cycle promotes the growth of human breast tumorigenic cells	ONCOGENE			English	Article							CANCER STEM-CELLS; TUMOR-REPOPULATING CELLS; MITOCHONDRIAL ROS; PHOSPHOENOLPYRUVATE CARBOXYKINASE; METASTASIS; HETEROGENEITY; ANGIOGENESIS; MAINTENANCE; METABOLISM; ADAPTATION	Clinical applications of antiangiogenic agents profoundly affect tumor cell behaviors via the resultant hypoxia. To date, how the hypoxia regulates tumor cells remains unclear. Here, we show that hypoxia promotes the growth of human breast tumorigenic cells that repopulate tumors [tumor-repopulating cells (TRCs)] in vitro and in vivo. This stimulating effect is ascribed to hypoxia-induced reactive oxygen species (ROS) that activates Akt and NF-kappa B, dependent on the attenuated tricarboxylic acid (TCA) cycle. We find that fumarate is accumulated in the TCA cycle of hypoxic TRCs, leading to glutathione succination, NADPH/NADP(+) decrease, and an increase in ROS levels. Mechanistically, hypoxia-increased HIF-1 alpha transcriptionally downregulates the expression of mitochondrial phosphoenolpyruvate carboxykinase (PCK2), leading to TCA cycle attenuation and fumarate accumulation. These findings reveal that hypoxia-reprogrammed TCA cycle promotes human breast TRCs growth via a HIF-1 alpha-downregulated PCK2 pathway, implying a need for a combination of an antiangiogenic therapy with an antioxidant modulator.	[Tang, Ke; Yu, Yuandong; Zhu, Liyan; Xu, Pingwei; Chen, Jie; Ma, Jingwei; Zhang, Huafeng; Fang, Haiqing; Sun, Weiwei; Zhou, Li; Wei, Keke; Li, Fei; Huang, Bo] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Biochem & Mol Biol, Wuhan 430030, Hubei, Peoples R China; [Lv, Jiadi; Xie, Jing; Liu, Yuying; Huang, Bo] Chinese Acad Med Sci & Peking Union Med Coll, Dept Immunol, Inst Basic Med Sci, Beijing 100005, Peoples R China; [Lv, Jiadi; Xie, Jing; Liu, Yuying; Huang, Bo] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Med Mol Biol, Beijing 100005, Peoples R China; [Liu, Yuying; Huang, Bo] Chinese Acad Med Sci, Clin Immunol Ctr, Beijing 100005, Peoples R China	Huazhong University of Science & Technology; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College	Huang, B (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Biochem & Mol Biol, Wuhan 430030, Hubei, Peoples R China.; Huang, B (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Dept Immunol, Inst Basic Med Sci, Beijing 100005, Peoples R China.; Huang, B (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Med Mol Biol, Beijing 100005, Peoples R China.; Huang, B (corresponding author), Chinese Acad Med Sci, Clin Immunol Ctr, Beijing 100005, Peoples R China.	tjhuangbo@hotmail.com	Liu, Yuying/ABD-9637-2021	Liu, Yuying/0000-0003-2182-7210	National Natural Science Foundation of China [81788101, 81530080, 81601366]; CAMS Initiative for Innovative Medicine [2016-I2M-1-007]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); CAMS Initiative for Innovative Medicine	This work was supported by National Natural Science Foundation of China (81788101, 81530080, and 81601366), CAMS Initiative for Innovative Medicine (2016-I2M-1-007).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Alderson NL, 2006, ARCH BIOCHEM BIOPHYS, V450, P1, DOI 10.1016/j.abb.2006.03.005; Bell EL, 2011, ONCOGENE, V30, P2986, DOI 10.1038/onc.2011.37; Bertout JA, 2008, NAT REV CANCER, V8, P967, DOI 10.1038/nrc2540; Brooks MD, 2015, CELL STEM CELL, V17, P260, DOI 10.1016/j.stem.2015.08.014; Bruna A, 2016, CELL, V167, P260, DOI 10.1016/j.cell.2016.08.041; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Chua YL, 2010, J BIOL CHEM, V285, P31277, DOI 10.1074/jbc.M110.158485; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Conley SJ, 2012, P NATL ACAD SCI USA, V109, P2784, DOI 10.1073/pnas.1018866109; Dieter SM, 2011, CELL STEM CELL, V9, P357, DOI 10.1016/j.stem.2011.08.010; Garcia-Perez C, 2012, P NATL ACAD SCI USA, V109, P4497, DOI 10.1073/pnas.1118244109; Ghajar CM, 2015, NAT REV CANCER, V15, P238, DOI 10.1038/nrc3910; Gilkes DM, 2014, NAT REV CANCER, V14, P430, DOI 10.1038/nrc3726; Hitosugi T, 2011, MOL CELL, V44, P864, DOI 10.1016/j.molcel.2011.10.015; Hou HG, 2016, MED GAS RES, V6, P138, DOI 10.4103/2045-9912.191359; Koren S, 2015, MOL CELL, V60, P537, DOI 10.1016/j.molcel.2015.10.031; Lee CU, 2015, ANGEW CHEM INT EDIT, V54, P13796, DOI 10.1002/anie.201506338; Li Y, 2015, CANCER RES, V75, P1191, DOI 10.1158/0008-5472.CAN-14-2615; Liou GY, 2010, FREE RADICAL RES, V44, P479, DOI 10.3109/10715761003667554; Liu J, 2012, NAT MATER, V11, P734, DOI [10.1038/NMAT3361, 10.1038/nmat3361]; Liu YY, 2018, CANCER CELL, V33, P480, DOI 10.1016/j.ccell.2018.02.005; Liu YY, 2018, J CLIN INVEST, V128, P1057, DOI 10.1172/JCI96329; Lou YM, 2011, CANCER RES, V71, P3364, DOI 10.1158/0008-5472.CAN-10-4261; Luo S, 2017, ONCOGENE, V36, P3609, DOI 10.1038/onc.2016.520; Ma RH, 2018, NAT CELL BIOL, V20, P21, DOI 10.1038/s41556-017-0002-2; Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003; Man JH, 2018, CELL STEM CELL, V22, P104, DOI 10.1016/j.stem.2017.10.005; McIntyre A, 2012, CLIN CANCER RES, V18, P3100, DOI 10.1158/1078-0432.CCR-11-1877; Medema JP, 2013, NAT CELL BIOL, V15, P338, DOI 10.1038/ncb2717; Montagner M, 2012, NATURE, V487, P380, DOI 10.1038/nature11207; Muz B, 2015, HYPOXIA, V3, P83, DOI 10.2147/HP.S93413; Olcina MM, 2016, ONCOGENE, V35, P793, DOI 10.1038/onc.2015.134; Ostergaard L, 2013, CANCER RES, V73, P5618, DOI 10.1158/0008-5472.CAN-13-0964; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Sabharwal SS, 2014, NAT REV CANCER, V14, P709, DOI 10.1038/nrc3803; Samanta D, 2016, CANCER RES, V76, P4430, DOI 10.1158/0008-5472.CAN-16-0530; Semenza GL, 2017, EMBO J, V36, P252, DOI 10.15252/embj.201695204; Shadel GS, 2015, CELL, V163, P560, DOI 10.1016/j.cell.2015.10.001; Sullivan LB, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-17; Sullivan LB, 2013, MOL CELL, V51, P236, DOI 10.1016/j.molcel.2013.05.003; Vincent EE, 2015, MOL CELL, V60, P195, DOI 10.1016/j.molcel.2015.08.013; Weyemi U, 2012, ONCOGENE, V31, P1117, DOI 10.1038/onc.2011.327; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064; Wong CCL, 2011, P NATL ACAD SCI USA, V108, P16369, DOI 10.1073/pnas.1113483108; Xing F, 2011, ONCOGENE, V30, P4075, DOI 10.1038/onc.2011.122; Yang CD, 2014, MOL CELL, V56, P414, DOI 10.1016/j.molcel.2014.09.025; Zheng L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7001	48	32	34	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2019	38	44					6970	6984		10.1038/s41388-019-0932-1	http://dx.doi.org/10.1038/s41388-019-0932-1			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ1AO	31409901	hybrid			2022-12-28	WOS:000493892900002
J	Gobbi, G; Donati, B; Do Valle, IF; Reggiani, F; Torricelli, F; Remondini, D; Castellani, G; Ambrosetti, DC; Ciarrocchi, A; Sancisi, V				Gobbi, Giulia; Donati, Benedetta; Do Valle, Italo Faria; Reggiani, Francesca; Torricelli, Federica; Remondini, Daniel; Castellani, Gastone; Ambrosetti, Davide Carlo; Ciarrocchi, Alessia; Sancisi, Valentina			The Hippo pathway modulates resistance to BET proteins inhibitors in lung cancer cells	ONCOGENE			English	Article							DOSE-ESCALATION; TAZ; BRD4; YAP; SENSITIVITY; EXPRESSION; OVEREXPRESSION; TUMORIGENESIS; PROGRESSION; SUPPRESSES	Inhibitors of BET proteins (BETi) are anti-cancer drugs that have shown efficacy in pre-clinical settings and are currently in clinical trials for different types of cancer, including non-small cell lung cancer (NSCLC). Currently, no predictive biomarker is available to identify patients that may benefit from this treatment. To uncover the mechanisms of resistance to BETi, we performed a genome-scale CRISPR/Cas9 screening in lung cancer cells. We identified three Hippo pathway genes, LATS2, TAOK1, and NF2, as key determinants for sensitivity to BETi. The knockout of these genes induces resistance to BETi, by promoting TAZ nuclear localization and transcriptional activity. Conversely, TAZ expression promotes resistance to these drugs. We also showed that TAZ, YAP, and their partner TEAD are direct targets of BRD4 and that treatment with BETi downregulates their expression. Noticeably, molecular alterations in one or more of these genes are present in a large fraction of NSCLC patients and TAZ amplification or overexpression correlates with a worse outcome in lung adenocarcinoma. Our data define the central role of Hippo pathway in mediating resistance to BETi and provide a rationale for using BETi to counter-act YAP/TAZ-mediated pro-oncogenic activity.	[Gobbi, Giulia; Donati, Benedetta; Reggiani, Francesca; Torricelli, Federica; Ciarrocchi, Alessia; Sancisi, Valentina] Azienda USL Reggio Emilia IRCCS, Lab Translat Res, Reggio Emilia, Italy; [Do Valle, Italo Faria] Northeastern Univ, Dept Phys, Ctr Complex Network Res, Boston, MA 02115 USA; [Remondini, Daniel; Castellani, Gastone] Univ Bologna, Dept Phys & Astron, Bologna, Italy; [Ambrosetti, Davide Carlo] Univ Bologna, Dept Pharm & Biotechnol FaBit, Bologna, Italy	Northeastern University; University of Bologna; University of Bologna	Sancisi, V (corresponding author), Azienda USL Reggio Emilia IRCCS, Lab Translat Res, Reggio Emilia, Italy.	valentina.sancisi@ausl.re.it	dovalle, italo/AAH-2621-2020; Sancisi, Valentina/H-6701-2018; Donati, Benedetta/H-7741-2018; torricelli, federica/H-7734-2018; REGGIANI, FRANCESCA/K-1082-2018; Gobbi, Giulia/AAB-6104-2019; Donati, Benedetta/AAA-7779-2022; Ciarrocchi, Alessia/AAA-1130-2019; Remondini, Daniel/ABA-9971-2020	Sancisi, Valentina/0000-0003-4357-1228; Donati, Benedetta/0000-0002-9163-8194; torricelli, federica/0000-0003-1954-5695; REGGIANI, FRANCESCA/0000-0002-4090-8908; Gobbi, Giulia/0000-0002-4746-967X; Donati, Benedetta/0000-0002-9163-8194; Ciarrocchi, Alessia/0000-0002-5541-2075; 				Amorim S, 2016, LANCET HAEMATOL, V3, pE196, DOI 10.1016/S2352-3026(16)00021-1; Bartucci M, 2015, ONCOGENE, V34, P681, DOI 10.1038/onc.2014.5; Basu-Roy U, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7411; Berthon C, 2016, LANCET HAEMATOL, V3, pE186, DOI 10.1016/S2352-3026(15)00247-1; Boggiano JC, 2011, DEV CELL, V21, P888, DOI 10.1016/j.devcel.2011.08.028; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chan SW, 2008, CANCER RES, V68, P2592, DOI 10.1158/0008-5472.CAN-07-2696; Chan SW, 2009, J BIOL CHEM, V284, P14347, DOI 10.1074/jbc.M901568200; Cheng HY, 2016, ONCOTARGET, V7, P28976, DOI 10.18632/oncotarget.6721; Dai XP, 2017, NAT MED, V23, DOI 10.1038/nm.4378; Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509; Donati B, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0915-9; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Gao ZY, 2018, CANCER BIOL THER, V19, P407, DOI 10.1080/15384047.2018.1423923; Ghiso E, 2017, NEOPLASIA, V19, P1012, DOI 10.1016/j.neo.2017.10.003; Gugnoni M, 2017, ONCOGENE, V36, P667, DOI 10.1038/onc.2016.237; Gujral TS, 2017, P NATL ACAD SCI USA, V114, pE3729, DOI 10.1073/pnas.1703096114; Janouskova H, 2017, MOL CELL PROTEOMICS, V16, pS68; Kanno T, 2014, NAT STRUCT MOL BIOL, V21, P1047, DOI 10.1038/nsmb.2912; Kawano S, 2015, J BIOCHEM, V158, P413, DOI 10.1093/jb/mvv051; Klingbeil O, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.271; Lau AN, 2014, EMBO J, V33, P468, DOI 10.1002/embj.201386082; Li W, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0843-6; Lin LP, 2015, NAT GENET, V47, P250, DOI 10.1038/ng.3218; Lockwood WW, 2012, P NATL ACAD SCI USA, V109, P19408, DOI 10.1073/pnas.1216363109; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; Manzotti G, 2019, CANCERS, V11, DOI 10.3390/cancers11030304; Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115; Mohseni M, 2014, NAT CELL BIOL, V16, P108, DOI 10.1038/ncb2884; Sancisi V, 2017, NUCLEIC ACIDS RES, V45, P11249, DOI 10.1093/nar/gkx802; Sancisi V, 2015, CANCER RES, V75, P1868, DOI 10.1158/0008-5472.CAN-14-2087; Sancisi V, 2012, J CLIN ENDOCR METAB, V97, pE2006, DOI 10.1210/jc.2012-1903; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Shalem O, 2015, NAT REV GENET, V16, P299, DOI 10.1038/nrg3899; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Shi J, 2014, CANCER CELL, V25, P210, DOI 10.1016/j.ccr.2014.01.028; Shimamura T, 2013, CLIN CANCER RES, V19, P6183, DOI 10.1158/1078-0432.CCR-12-3904; Stein C, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005465; Varelas X, 2014, DEVELOPMENT, V141, P1614, DOI 10.1242/dev.102376; Wang Y, 2010, CANCER SCI, V101, P1279, DOI 10.1111/j.1349-7006.2010.01511.x; Xie M, 2012, J THORAC ONCOL, V7, P799, DOI 10.1097/JTO.0b013e318248240b; Xu MZ, 2011, ONCOGENE, V30, P1229, DOI 10.1038/onc.2010.504; Yin F, 2013, CELL, V154, P1342, DOI 10.1016/j.cell.2013.08.025; Zaman A, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.05.02; Zanconato F, 2018, NAT MED, V24, P1599, DOI 10.1038/s41591-018-0158-8; Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216; Zhang PZ, 2017, NAT MED, V23, P1055, DOI 10.1038/nm.4379; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao Y, 2016, CELL REP, V16, P2003, DOI 10.1016/j.celrep.2016.07.032	50	36	36	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2019	38	42					6801	6817		10.1038/s41388-019-0924-1	http://dx.doi.org/10.1038/s41388-019-0924-1			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE5UU	31406246				2022-12-28	WOS:000490758200001
J	Liao, SY; Kuo, IY; Chen, YT; Liao, PC; Liu, YF; Wu, HY; Lai, WW; Wang, YC				Liao, Sheng-You; Kuo, I-Ying; Chen, Yu-Ting; Liao, Pao-Chi; Liu, Ya-Fen; Wu, Hsin-Yi; Lai, Wu-Wei; Wang, Yi-Ching			AKT-mediated phosphorylation enhances protein stability and transcription activity of ZNF322A to promote lung cancer progression	ONCOGENE			English	Article							ZINC-FINGER PROTEIN; INHIBITOR; GROWTH; RECOGNITION; DEGRADATION; ACTIVATION; EXPRESSION; EFFICACY; PATHWAY; MK-2206	ZNF322A is an oncogenic zinc-finger transcription factor. Our published results show that ZNF322A positively regulates transcription of alpha-adducin (ADD1) and cyclin D1 (CCND1) to promote tumorgenicity of lung cancer. However, the upstream regulatory mechanisms of ZNF322A protein function remain elusive. Here, we demonstrate that AKT could phosphorylate ZNF322A by in vitro kinase assay and cell-based mass spectrometry analysis. Overexpression of AKT promoted ZNF322A protein stability and transcriptional activity, whereas these effects were inhibited by knockdown of AKT or treating with AKT inhibitor. We studied AKT-mediated phosphorylation sites, viz. Thr-150, Ser-224, Thr-234, and Thr-262. ZNF322A phosphorylation at Thr-262 by AKT promoted ZNF322A protein stability thus increased ADD1 promoter activity. Interestingly, phosphorylation at Thr-150, Ser-224, and Thr-234 enhanced transcription activity without affecting protein stability of ZNF322A. Chromatin immunoprecipitation and DNA affinity precipitation assays showed that ZNF322A phosphorylation defective mutants Thr-150A, Ser-224A, and Thr-234A attenuated chromatin binding and DNA binding affinity to ADD1 and CCNDI promoters compared with wild-type ZNF322A. Furthermore, AKT-mediated Thr-150, Ser-224, Thr-234, and Thr-262 phosphorylation promoted lung cancer cell growth and metastasis in vitro and in vivo. Clinically, expression of phosphorylated ZNF322A (p-ZNF) correlated with actively phosphorylated AKT (p-AKT) in tumor specimens from 150 lung cancer patients. Multivariate Cox regression analysis indicated that combined p-AKT and p-ZNF expression profile was an independent factor to predict the clinical outcome in lung cancer patients. Our results reveal a new mechanism of AKT signaling in promoting ZNF322A protein stability and transcriptional activity in lung cancer cell, xenograft, and clinical models.	[Liao, Sheng-You; Wang, Yi-Ching] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 70101, Taiwan; [Kuo, I-Ying; Chen, Yu-Ting; Liu, Ya-Fen; Wang, Yi-Ching] Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan; [Liao, Pao-Chi] Natl Cheng Kung Univ, Coll Med, Dept Environm & Occupat Hlth, Tainan 704, Taiwan; [Wu, Hsin-Yi] Natl Taiwan Univ, Instrumentat Ctr, Tainan 10617, Taiwan; [Lai, Wu-Wei] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Surg, Tainan 70101, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Taiwan University; National Cheng Kung University; National Cheng Kung University Hospital	Wang, YC (corresponding author), Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 70101, Taiwan.; Wang, YC (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan.	ycw5798@mail.ncku.edu.tw	Wang, Yi-Ching/J-8702-2019; , 賴吾為/T-8615-2019; Kuo, I-Ying/AAE-4741-2020	Wang, Yi-Ching/0000-0002-7694-2067; , 賴吾為/0000-0001-9174-8310; 	Human Biobank, Research Center of Clinical Medicine, National Cheng Kung University Hospital; Taiwan Ministry of Science and Technology [MOST106-2320-B-006-071-MY3]	Human Biobank, Research Center of Clinical Medicine, National Cheng Kung University Hospital; Taiwan Ministry of Science and Technology	We are grateful for the support from the Human Biobank, Research Center of Clinical Medicine, National Cheng Kung University Hospital. We thank Mass Spectrometry Facilities of National Cheng Kung University for MS analysis. This work is supported by the Taiwan Ministry of Science and Technology Grant MOST106-2320-B-006-071-MY3.	Agarwal NK, 2016, BLOOD, V127, P605, DOI 10.1182/blood-2015-07-658781; Carpenter RL, 2015, ONCOGENE, V34, P546, DOI 10.1038/onc.2013.582; Chuang CW, 2013, J CELL PHYSIOL, V228, P341, DOI 10.1002/jcp.24136; Faber AC, 2009, P NATL ACAD SCI USA, V106, P19503, DOI 10.1073/pnas.0905056106; Fang L, 2014, MOL CELL, V55, P537, DOI 10.1016/j.molcel.2014.06.018; Filtz TM, 2014, TRENDS PHARMACOL SCI, V35, P76, DOI 10.1016/j.tips.2013.11.005; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138; Gamsjaeger R, 2007, TRENDS BIOCHEM SCI, V32, P63, DOI 10.1016/j.tibs.2006.12.007; Harper J, 2007, CANCER RES, V67, P8736, DOI 10.1158/0008-5472.CAN-07-1617; Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012; Hong J, 2011, CANCER RES, V71, P3980, DOI 10.1158/0008-5472.CAN-10-2914; Ichihara E, 2017, CANCER RES, V77, P2990, DOI 10.1158/0008-5472.CAN-16-2300; Jacobsen K, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00450-6; Jen J, 2016, ONCOGENE, V35, P2357, DOI 10.1038/onc.2015.296; Jen JY, 2019, CELL DEATH DIFFER, V26, P1283, DOI 10.1038/s41418-018-0204-6; Laity JH, 2001, CURR OPIN STRUC BIOL, V11, P39, DOI 10.1016/S0959-440X(00)00167-6; Lehmann W, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10498; Li YQ, 2004, BIOCHEM BIOPH RES CO, V325, P1383, DOI 10.1016/j.bbrc.2004.10.183; Liao SY, 2017, ONCOGENE, V36, P5722, DOI 10.1038/onc.2017.168; Lo FY, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-235; McCarty AS, 2003, MOL CELL, V11, P459, DOI 10.1016/S1097-2765(03)00043-1; Ono M, 2004, MOL CANCER THER, V3, P465; Persikov AV, 2015, NUCLEIC ACIDS RES, V43, P1965, DOI 10.1093/nar/gku1395; Phuchareon J, 2015, P NATL ACAD SCI USA, V112, pE3855, DOI 10.1073/pnas.1510733112; Po A, 2017, ONCOGENE, V36, P4641, DOI 10.1038/onc.2017.91; Ramos A, 2018, FASEB J, V32, P6982, DOI 10.1096/fj.201801167RR; Razin SV, 2012, BIOCHEMISTRY-MOSCOW+, V77, P217, DOI 10.1134/S0006297912030017; Riverso M, 2017, ONCOGENE, V36, P3322, DOI 10.1038/onc.2016.481; Singh AR, 2016, MOL CANCER THER, V15, P2553, DOI 10.1158/1535-7163.MCT-15-0976; Tasian SK, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00108; Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183; Wolin EM, 2013, CANCER LETT, V335, P1, DOI 10.1016/j.canlet.2013.02.016; Yap TA, 2011, J CLIN ONCOL, V29, P4688, DOI 10.1200/JCO.2011.35.5263; Zheng HQ, 2014, CANCER CELL, V26, P358, DOI 10.1016/j.ccr.2014.07.022	35	14	14	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2019	38	41					6723	6736		10.1038/s41388-019-0928-x	http://dx.doi.org/10.1038/s41388-019-0928-x			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JC8UZ	31399647				2022-12-28	WOS:000489552900001
J	Deng, L; Qian, GQ; Zhang, S; Zheng, HM; Fan, SQ; Lesinski, GB; Owonikoko, TK; Ramalingam, SS; Sun, SY				Deng, Liang; Qian, Guoqing; Zhang, Shuo; Zheng, Hongmei; Fan, Sonqing; Lesinski, Gregory B.; Owonikoko, Taofeek K.; Ramalingam, Suresh S.; Sun, Shi-Yong			Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced beta-TrCP degradation	ONCOGENE			English	Article							MAMMALIAN TARGET; PREDICTIVE BIOMARKERS; ACTIVATION; EXPRESSION; EVEROLIMUS; EFFICACY; BLOCKADE; PATHWAY; AKT; AMPLIFICATION	The involvement of mammalian target of rapamycin (mTOR) in the positive regulation of oncogenesis has been well documented and thus mTOR has emerged as an attractive cancer therapeutic target. Although rapamycin and its analogues (rapalogs) are FDA-approved for the treatment of certain cancers, major success in targeting mTOR, particularly with new generation mTOR kinase inhibitors, for the effective treatment of cancers has not been achieved. Hence, a thorough understanding of the biology of the mTOR axis in cancer is still needed. It is now recognized that programmed death-ligand 1 (PD-L1) expression on cancer cells is a critical mechanism contributing to immunosuppression and immune escape via interacting with program death-1 (PD-1) on immune cells. This study has revealed a previously undiscovered role of the mTOR complex 1 (mTORC1)/p70 S6 kinase (p70S6K) in the negative regulation of PD-L1 on cancer cells and tissues. We demonstrate that disruption of this signaling pathway with mTOR inhibitors, raptor knockdown or p70S6K inhibitors elevated PD-L1 levels in some lung and other cancer cell lines. Elevation of PD-L1 by inhibition of mTORC1/p70S6K signaling is likely due to suppression of 13-TrCP-mediated proteasomal degradation of PD-L1, because inhibition of either mTORC1 or p70S6K facilitated beta-TrCP degradation accompanied with enhanced PD-L1 protein stabilization. Our current findings indicate the complexity of the mTOR axis in cancer, which should be considered when targeting this axis for effective cancer treatment. Our findings also suggest a strong scientific rationale for enhancing PD-1/PD-L1-targeted cancer immunotherapy through co-targeting mTORC1/p70S6K signaling.	[Deng, Liang] Cent S Univ, Xiangya Hosp, Dept Oncol, Changsha, Hunan, Peoples R China; [Deng, Liang; Qian, Guoqing; Zhang, Shuo; Lesinski, Gregory B.; Owonikoko, Taofeek K.; Ramalingam, Suresh S.; Sun, Shi-Yong] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA; [Deng, Liang; Qian, Guoqing; Zhang, Shuo; Lesinski, Gregory B.; Owonikoko, Taofeek K.; Ramalingam, Suresh S.; Sun, Shi-Yong] Winship Canc Inst, Atlanta, GA 30322 USA; [Zhang, Shuo] Xi An Jiao Tong Univ, Coll Med, Affiliated Hosp 1, Xian, Shaanxi, Peoples R China; [Zheng, Hongmei; Fan, Sonqing] Cent S Univ, Dept Pathol, Xiangya Hosp 2, Changsha, Hunan, Peoples R China	Central South University; Emory University; Xi'an Jiaotong University; Central South University	Sun, SY (corresponding author), Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA.; Sun, SY (corresponding author), Winship Canc Inst, Atlanta, GA 30322 USA.	ssun@emory.edu	Ramalingam, Suresh/AAV-7478-2020; Qian, Guoqing/ABH-1307-2021	Qian, Guoqing/0000-0003-1804-7993	Winship Cancer Institute lung cancer pilot award of Emory University	Winship Cancer Institute lung cancer pilot award of Emory University	We are grateful to Dr. Wenyi Wei for providing beta-TrCP shRNAs and expression plasmids. We also thank Dr. Anthea Hammond in our department for editing the paper. This work was supported by Winship Cancer Institute lung cancer pilot award of Emory University (S-YS). S-YS, TKO and SSR are Georgia Research Alliance Distinguished Cancer Scientists. S-YS is a Halpern Research Scholar. LD was a visiting medical student participating in the Xiangya-Emory Visiting Medical Student Program.	Abraham RT, 2007, CLIN CANCER RES, V13, P3109, DOI 10.1158/1078-0432.CCR-06-2798; Amato RJ, 2009, CANCER-AM CANCER SOC, V115, P2438, DOI 10.1002/cncr.24280; Amiel E, 2012, J IMMUNOL, V189, P2151, DOI 10.4049/jimmunol.1103741; Araki K, 2010, IMMUNOL REV, V235, P234, DOI 10.1111/j.0105-2896.2010.00898.x; Araki K, 2009, NATURE, V460, P108, DOI 10.1038/nature08155; Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653; Ben-Sahra I, 2017, CURR OPIN CELL BIOL, V45, P72, DOI 10.1016/j.ceb.2017.02.012; Benson DM, 2010, BLOOD, V116, P2286, DOI 10.1182/blood-2010-02-271874; Beziaud L, 2016, CANCER RES, V76, P4100, DOI 10.1158/0008-5472.CAN-15-2452; Chapman NM, 2014, IMMUNOTHERAPY-UK, V6, P1295, DOI 10.2217/imt.14.84; Chi H, 2012, NAT REV IMMUNOL, V12, P325, DOI 10.1038/nri3198; Diken M, 2013, CANCER IMMUNOL RES, V1, P386, DOI 10.1158/2326-6066.CIR-13-0046; Duan SS, 2011, MOL CELL, V44, P317, DOI 10.1016/j.molcel.2011.09.005; Fan SQ, 2006, HUM PATHOL, V37, P593, DOI 10.1016/j.humpath.2006.01.010; Fantus D, 2015, AM J TRANSPLANT, V15, P891, DOI 10.1111/ajt.13151; Fu L, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-315; Gao DM, 2011, MOL CELL, V44, P290, DOI 10.1016/j.molcel.2011.08.030; Gordon SR, 2017, NATURE, V545, P495, DOI 10.1038/nature22396; Guan J, 2017, ARCH PATHOL LAB MED, V141, P851, DOI 10.5858/arpa.2016-0361-RA; Hirayama Y, 2016, CANCER SCI, V107, P1736, DOI 10.1111/cas.13099; Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838; Ilagan E, 2016, TRENDS CANCER, V2, P241, DOI 10.1016/j.trecan.2016.03.008; Iwai Y, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0329-9; Koo JH, 2015, MOL CELL BIOL, V35, P2344, DOI 10.1128/MCB.01525-14; Koo J, 2015, ONCOTARGET, V6, P8974, DOI 10.18632/oncotarget.3291; Koo J, 2014, CANCER RES, V74, P2555, DOI 10.1158/0008-5472.CAN-13-2946; Lastwika KJ, 2016, CANCER RES, V76, P227, DOI 10.1158/0008-5472.CAN-14-3362; Li CW, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12632; Lim SO, 2016, CANCER CELL, V30, P925, DOI 10.1016/j.ccell.2016.10.010; Mannick JB, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009892; Mineharu Y, 2014, MOL CANCER THER, V13, P3024, DOI 10.1158/1535-7163.MCT-14-0400; Moore EC, 2016, CANCER IMMUNOL RES, V4, P611, DOI 10.1158/2326-6066.CIR-15-0252; Motzer RJ, 2008, LANCET, V372, P449, DOI 10.1016/S0140-6736(08)61039-9; Ott PA, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0218-5; Ou JN, 2012, SCI REP-UK, V2, DOI 10.1038/srep00295; Remon J, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0819-3; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.03.035, 10.1016/j.cell.2017.02.004]; Shi PY, 2016, CANCER LETT, V380, P494, DOI 10.1016/j.canlet.2016.07.021; Shien K, 2016, LUNG CANCER, V99, P79, DOI 10.1016/j.lungcan.2016.06.016; Shimizu K, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aah4117; Somasundaram A, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0456-5; Song Y, 2019, IMMUNOTHERAPY-UK, V11, P515, DOI 10.2217/imt-2018-0173; Sparks CA, 2010, ONCOGENE, V29, P3733, DOI 10.1038/onc.2010.139; Stambrook PJ, 2017, MOL CANCER RES, V15, P635, DOI 10.1158/1541-7786.MCR-16-0427; Sun SY, 2013, CANCER LETT, V340, P1, DOI 10.1016/j.canlet.2013.06.017; Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917; Thomas DL, 2011, CANCER IMMUNOL IMMUN, V60, P1461, DOI 10.1007/s00262-011-1045-z; Wander SA, 2011, J CLIN INVEST, V121, P1231, DOI 10.1172/JCI44145; Wang XR, 2008, CANCER RES, V68, P7409, DOI 10.1158/0008-5472.CAN-08-1522; Wen QY, 2016, ONCOTARGET, V7, P27787, DOI 10.18632/oncotarget.8497; Yao JC, 2011, NEW ENGL J MED, V364, P514, DOI 10.1056/NEJMoa1009290; Yao WL, 2015, CANCER LETT, V364, P70, DOI 10.1016/j.canlet.2015.04.028; Zhang YJ, 2011, DRUG DISCOV TODAY, V16, P325, DOI 10.1016/j.drudis.2011.02.008; Zhao YC, 2011, MOL CELL, V44, P304, DOI 10.1016/j.molcel.2011.08.029	56	29	32	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2019	38	35					6270	6282		10.1038/s41388-019-0877-4	http://dx.doi.org/10.1038/s41388-019-0877-4			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IU9RZ	31316145				2022-12-28	WOS:000483919400003
J	Sun, QY; Ding, LW; Johnson, K; Zhou, SQ; Tyner, JW; Yang, H; Doan, NB; Said, JW; Xiao, JF; Loh, XY; Ran, XB; Venkatachalam, N; Lao, ZT; Chen, Y; Xu, L; Fan, LF; Chien, WW; Lin, DC; Koeffler, HP				Sun, Qiao-Yang; Ding, Ling-Wen; Johnson, Kara; Zhou, Siqin; Tyner, Jeffrey W.; Yang, Henry; Doan, Ngan B.; Said, Jonathan W.; Xiao, Jin-Fen; Loh, Xin-Yi; Ran, Xue-Bin; Venkatachalam, Nachiyappan; Lao, Zhentang; Chen, Ye; Xu, Liang; Fan, Li-Fei; Chien, Wenwen; Lin, De-Chen; Koeffler, H. Phillip			SOX7 regulates MAPK/ERK-BIM mediated apoptosis in cancer cells	ONCOGENE			English	Article							HISTONE DEACETYLASE INHIBITOR; LUNG-CANCER; GLUCOCORTICOID RESISTANCE; DRUG-RESISTANCE; EXPRESSION; ACTIVATION; PROMOTES; SURVIVAL; PATHWAY; GENES	Apoptosis of cancer cells occurs by a complex gene regulatory network. Here we showed that SOX7 was significantly downregulated in different cancer types, especially in lung and breast cancers. Low expression of SOX7 was associated with advantage stage of cancer with shorter overall survival. Cancer cells with loss of SOX7 promoted cell survival and colony formation, suppressed cellular apoptosis and produced a drug resistant phenotype against a variety of chemo/targeting therapeutic agents. Mechanistically, SOX7 induced cellular apoptosis through upregulation of genes associated with both P38 and apoptotic signaling pathway, as well as preventing the proteasome mediated degradation of pro-apoptotic protein BIM. Treatment of either a proteasome inhibitor MG132 or bortezomib, or with a p-ERK/MEK inhibitor U0126 attenuate the SOX7 promoted BIM degradation. We identified Panobinostat, an FDA approved pan-HDAC inhibitor, could elevate and restore SOX7 expression in SOX7 silenced lung cancer cells. Taken together, these data revealed an unappreciated role of SOX7 in regulation of cellular apoptosis through control of MAPK/ERK-BIM signaling.	[Sun, Qiao-Yang; Ding, Ling-Wen; Zhou, Siqin; Yang, Henry; Xiao, Jin-Fen; Loh, Xin-Yi; Ran, Xue-Bin; Venkatachalam, Nachiyappan; Lao, Zhentang; Chen, Ye; Xu, Liang; Fan, Li-Fei; Koeffler, H. Phillip] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore; [Johnson, Kara; Tyner, Jeffrey W.] Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97239 USA; [Doan, Ngan B.; Said, Jonathan W.] Ronald Reagan UCLA Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; [Fan, Li-Fei] Inner Mongolia Univ, Sch Life Sci, Hohhot 010021, Inner Mongolia, Peoples R China; [Chien, Wenwen; Lin, De-Chen; Koeffler, H. Phillip] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA	National University of Singapore; Oregon Health & Science University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Ronald Reagan UCLA Medical Center; Inner Mongolia University; Cedars Sinai Medical Center	Ding, LW (corresponding author), Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore.	lingwen.dlw@gmail.com	Sun, Qiao-Yang/ABA-6813-2020; Xu, Liang/I-9877-2014; Ding, Ling-Wen/H-6916-2019	Xu, Liang/0000-0002-2700-4840; Ding, Ling-Wen/0000-0003-0022-1551; Nachi, Nachiyappan/0000-0003-4293-8278; Sun, Qiao-Yang/0000-0002-9855-5586; Johnson, Kara/0000-0002-0993-4470; Said, Jonathan/0000-0001-9474-2563	National Research Foundation Singapore under the Singapore Translational Research (STaR) Investigator Award [NMRC/STaR/0021/2014]; NMRC Centre Grant; RNA Biology Center at the Cancer Science Institute of Singapore (NUS, as part of Singapore Ministry of Education) [MOE2014-T3-1-006]; Tower Cancer Research Foundation; Department of Defense USAMRMC [W81XWH-17-1-0093, BM160010]	National Research Foundation Singapore under the Singapore Translational Research (STaR) Investigator Award(National Research Foundation, Singapore); NMRC Centre Grant(National Medical Research Council, Singapore); RNA Biology Center at the Cancer Science Institute of Singapore (NUS, as part of Singapore Ministry of Education)(Ministry of Education, SingaporeNational University of Singapore); Tower Cancer Research Foundation; Department of Defense USAMRMC(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC))	Research was supported by the National Research Foundation Singapore under the Singapore Translational Research (STaR) Investigator Award (NMRC/STaR/0021/2014) and administered by the Singapore Ministry of Health's National Medical Research Council (NMRC), the NMRC Centre Grant awarded to National University Cancer Institute of Singapore, the National Research Foundation Singapore, the Singapore Ministry of Education under its Research Centers of Excellence initiatives and RNA Biology Center at the Cancer Science Institute of Singapore (NUS, as part of funding under the Singapore Ministry of Education's Tier 3 grants, grant number MOE2014-T3-1-006). This research was also supported by the Tower Cancer Research Foundation Michele and Ted Kaplan Family Senior Investigator Grant and Department of Defense USAMRMC (Proposal Number BM160010, Award Number W81XWH-17-1-0093).	Afouda BA, 2018, DATA BRIEF, V17, P559, DOI 10.1016/j.dib.2018.01.005; Barton K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12731; Brown JA, 2018, CANCER CELL, V34, P869, DOI 10.1016/j.ccell.2018.11.011; Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031-10; Chakraborty AR, 2013, BLOOD, V121, P4115, DOI 10.1182/blood-2012-08-449140; Cragg MS, 2007, PLOS MED, V4, P1681, DOI 10.1371/journal.pmed.0040316; Ding LW, 2015, ONCOGENE, V34, P1463, DOI 10.1038/onc.2014.34; Dong C, 2004, CYTOGENET GENOME RES, V105, P442, DOI 10.1159/000078217; Einolf HJ, 2017, DRUG METAB DISPOS, V45, P1304, DOI 10.1124/dmd.117.076851; Ewings KE, 2007, CELL CYCLE, V6, P2236, DOI 10.4161/cc.6.18.4728; Faber AC, 2011, CANCER DISCOV, V1, P352, DOI 10.1158/2159-8290.CD-11-0106; Fan R, 2018, DNA CELL BIOL, V37, P126, DOI 10.1089/dna.2017.3866; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Gettinger S, 2016, J CLIN ONCOL, V34, P2980, DOI 10.1200/JCO.2016.66.9929; Guo LH, 2008, MOL CANCER RES, V6, P1421, DOI 10.1158/1541-7786.MCR-07-2175; Gurtner A, 2010, J BIOL CHEM, V285, P14160, DOI 10.1074/jbc.M109.094813; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Han LC, 2017, J CELL MOL MED, V21, P2000, DOI 10.1111/jcmm.13120; Hayano T, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-17; Hishida T, 2012, STEM CELLS, V30, P1634, DOI 10.1002/stem.1147; Housman G, 2014, CANCERS, V6, P1769, DOI 10.3390/cancers6031769; Jiang Q, 2013, FEBS LETT, V587, P2420, DOI 10.1016/j.febslet.2013.06.011; Jing DH, 2018, CANCER CELL, V34, P906, DOI 10.1016/j.ccell.2018.11.002; Kanki Y, 2017, NUCLEIC ACIDS RES, V45, P4344, DOI 10.1093/nar/gkx159; Kidger AM, 2016, SEMIN CELL DEV BIOL, V50, P125, DOI 10.1016/j.semcdb.2016.01.009; Kim IK, 2018, J EXP MED, V215, P963, DOI 10.1084/jem.20170123; Kohno T, 2015, TRANSL LUNG CANCER R, V4, P156, DOI 10.3978/j.issn.2218-6751.2014.11.11; Lenassi M, 2006, RADIOL ONCOL, V40, P51; Lilly AJ, 2017, MECH DEVELOP, V146, P31, DOI 10.1016/j.mod.2017.05.004; Liu HD, 2016, SCI REP-UK, V6, DOI 10.1038/srep26136; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Mah V, 2011, LUNG CANCER, V74, P318, DOI 10.1016/j.lungcan.2011.03.009; Man CH, 2015, BLOOD, V125, P3928, DOI 10.1182/blood-2014-06-580993; Maytin EV, 2001, EXP CELL RES, V267, P193, DOI 10.1006/excr.2001.5248; Meunier I, 2016, HUM MOL GENET, V25, P916, DOI 10.1093/hmg/ddv624; Montero J, 2015, CELL, V160, P977, DOI 10.1016/j.cell.2015.01.042; Ng KP, 2012, NAT MED, V18, P521, DOI 10.1038/nm.2713; Oh KY, 2017, J ORAL PATHOL MED, V46, P752, DOI 10.1111/jop.12566; Paoli P, 2013, BBA-MOL CELL RES, V1833, P3481, DOI 10.1016/j.bbamcr.2013.06.026; Rajgara RF, 2017, STEM CELL REP, V9, P1139, DOI 10.1016/j.stemcr.2017.08.014; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Ropero S, 2007, MOL ONCOL, V1, P19, DOI 10.1016/j.molonc.2007.01.001; Rueff J, 2016, METHODS MOL BIOL, V1395, P1, DOI 10.1007/978-1-4939-3347-1_1; Sahay B, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000687; Scuto A, 2008, BLOOD, V111, P5093, DOI 10.1182/blood-2007-10-117762; Shojaee Samira, 2017, F1000Res, V6, P2110, DOI 10.12688/f1000research.11471.1; Stovall DB, 2014, HISTOL HISTOPATHOL, V29, P439, DOI 10.14670/HH-29.10.439; Stovall DB, 2013, AM J PATHOL, V183, P1645, DOI 10.1016/j.ajpath.2013.07.025; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun QY, 2015, J PATHOL, V235, P559, DOI 10.1002/path.4482; Takeuchi K, 2012, NAT MED, V18, P378, DOI 10.1038/nm.2658; Wang DP, 2017, ONCOL REP, V38, P2078, DOI 10.3892/or.2017.5854; Yan L, 2018, J CELL BIOCHEM, V119, P3989, DOI 10.1002/jcb.26553; Yoon NK, 2010, HUM PATHOL, V41, P1794, DOI 10.1016/j.humpath.2010.06.010; Zhang Y, 2009, CANCER LETT, V277, P29, DOI 10.1016/j.canlet.2008.11.014; Zhang ZF, 2010, CARCINOGENESIS, V31, P577, DOI 10.1093/carcin/bgq020; Zhou YS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116095	58	28	34	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2019	38	34					6196	6210		10.1038/s41388-019-0865-8	http://dx.doi.org/10.1038/s41388-019-0865-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IS5RM	31332289				2022-12-28	WOS:000482210100004
J	Chen, ZL; Ren, R; Wan, DW; Wang, YL; Xue, XF; Jiang, M; Shen, JQ; Han, Y; Liu, F; Shi, JM; Kuang, YT; Li, W; Zhi, QM				Chen, Zhenlong; Ren, Rui; Wan, Daiwei; Wang, Yilin; Xue, Xiaofeng; Jiang, Min; Shen, Jiaqing; Han, Ye; Liu, Fei; Shi, Jianming; Kuang, Yuting; Li, Wei; Zhi, Qiaoming			Hsa_circ_101555 functions as a competing endogenous RNA of miR-597-5p to promote colorectal cancer progression	ONCOGENE			English	Article							REPLICATION PROTEIN-A; CIRCULAR RNA; CELL-PROLIFERATION; EXPRESSION; INVASION; SIGNATURE; APOPTOSIS; MIGRATION; ROLES; GENE	CircRNAs have been reported to exert momentous roles in regulating pathophysiological process and guiding clinical diagnosis and treatment in colorectal cancer (CRC). However, there are still a lot of circRNAs that need to be unearthed. In this study, we evaluated the expression profile of circRNAs in 10 CRC tissues and their corresponding normal-appearing tissues (NATs) by microarray, and identified that hsa_circ_101555 (circ101555) was significantly up-regulated in tumor tissues and closely related to the prognosis of CRC patients. A specific close loop structure of circ101555 was described, which was generated by back-splicing of the host gene CSNK1G1 and showed greater stability than the linear RNA. The results in vitro and in vivo showed that silencing circ101555 expression significantly suppressed cell proliferation, induced apoptosis and impaired the DNA repair capacity of CRC cells, while rescue experiments suggested that down-expression of miR-597-5p could significantly attenuate the biological effects of circ101555 knockdown on CRC cells. Subsequent experiments in vitro, including double fluorescence in situ hybridization (D-FISH) analysis, RIP analysis and biotin-coupled probe pull down assay, confirmed that miR-597-5p was effectively enriched by circ101555, and circ101555 might serve as a sponge of miR-597-5p. Moreover, two putative oncogenes (CDK6 and RPA3) were identified as the miR-597-5p potential targets. Taken together, our results proved that circ101555 might function as a competing endogenous RNA of miR-597-5p to up-regulate CDK6 and RPA3 expression in CRC. Circ101555 could be a useful prognostic indicator in patients with CRC, and silence of circ101555 provided a new attractive therapeutic measure for CRC.	[Chen, Zhenlong; Wan, Daiwei; Xue, Xiaofeng; Han, Ye; Kuang, Yuting; Zhi, Qiaoming] Soochow Univ, Dept Gen Surg, Affiliated Hosp 1, Suzhou 215006, Peoples R China; [Ren, Rui] Soochow Univ, Dept Gen Surg, Affiliated Hosp 2, Suzhou 215000, Peoples R China; [Wang, Yilin] Fudan Univ, Dept Hepat Surg, Shanghai Canc Ctr, Shanghai 200032, Peoples R China; [Wang, Yilin] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China; [Jiang, Min; Li, Wei] Soochow Univ, Dept Oncol, Affiliated Hosp 1, Suzhou 215006, Peoples R China; [Shen, Jiaqing; Liu, Fei] Soochow Univ, Dept Gastroenterol, Affiliated Hosp 1, Suzhou 215006, Peoples R China; [Shi, Jianming] Nanjing Med Univ, Affiliated Suzhou Hosp, Dept Oncol, Suzhou Municipal Hosp, Suzhou 215002, Peoples R China	Soochow University - China; Soochow University - China; Fudan University; Fudan University; Soochow University - China; Soochow University - China; Nanjing Medical University	Zhi, QM (corresponding author), Soochow Univ, Dept Gen Surg, Affiliated Hosp 1, Suzhou 215006, Peoples R China.; Wang, YL (corresponding author), Fudan Univ, Dept Hepat Surg, Shanghai Canc Ctr, Shanghai 200032, Peoples R China.; Wang, YL (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China.; Li, W (corresponding author), Soochow Univ, Dept Oncol, Affiliated Hosp 1, Suzhou 215006, Peoples R China.	linglingwangyi@126.com; liwei10@suda.edu.cn; strexboy@163.com		, Daiwei/0000-0001-8838-6144	Special Subject of Diagnosis Treatment of Key Clinical Diseases of Suzhou City Sci-tech Bureau [LCZX201401]; Jiangsu Provincial Medical Youth Talent [QNRC2016723]; Suzhou Gusu Medical Youth Talent [GSWS2019032]; Project of Invigorating Health Care through Science, Technology and Education	Special Subject of Diagnosis Treatment of Key Clinical Diseases of Suzhou City Sci-tech Bureau; Jiangsu Provincial Medical Youth Talent; Suzhou Gusu Medical Youth Talent; Project of Invigorating Health Care through Science, Technology and Education	This study was supported by grants from the Special Subject of Diagnosis Treatment of Key Clinical Diseases of Suzhou City Sci-tech Bureau (LCZX201401), the Project of Invigorating Health Care through Science, Technology and Education, Jiangsu Provincial Medical Youth Talent (QNRC2016723) and Suzhou Gusu Medical Youth Talent (GSWS2019032).	Chen CC, 2017, CARCINOGENESIS, V38, P196, DOI 10.1093/carcin/bgw123; Chen GW, 2017, ONCOTARGETS THER, V10, P5783, DOI 10.2147/OTT.S150678; Chen L, 2017, ONCOGENE, V36, P4551, DOI 10.1038/onc.2017.89; Chen LL, 2016, NAT REV MOL CELL BIO, V17, P205, DOI 10.1038/nrm.2015.32; Chen LL, 2015, RNA BIOL, V12, P381, DOI 10.1080/15476286.2015.1020271; Chen S, 2018, ONCOL REP, V39, P2499, DOI 10.3892/or.2018.6372; COCQUERELLE C, 1993, FASEB J, V7, P155, DOI 10.1096/fasebj.7.1.7678559; Dragomir M, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00179; Du WW, 2017, EUR HEART J, V38, P1402, DOI 10.1093/eurheartj/ehw001; Du WW, 2016, NUCLEIC ACIDS RES, V44, P2846, DOI 10.1093/nar/gkw027; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Givalos N, 2007, MODERN PATHOL, V20, P159, DOI 10.1038/modpathol.3800719; Guo JN, 2016, ONCOTARGETS THER, V9, P7451, DOI 10.2147/OTT.S123220; Haddad FGH, 2018, FUTURE ONCOL, V14, P2097, DOI 10.2217/fon-2017-0708; Hansen TB, 2013, CANCER RES, V73, P5609, DOI 10.1158/0008-5472.CAN-13-1568; Hawk ET, 2005, J CLIN ONCOL, V23, P378, DOI 10.1200/JCO.2005.08.097; Holdt LM, 2018, CELL MOL LIFE SCI, V75, P1071, DOI 10.1007/s00018-017-2688-5; Hsiao KY, 2017, CANCER RES, V77, P2339, DOI 10.1158/0008-5472.CAN-16-1883; Jiang WQ, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00034; Kanakis D, 2011, HUM PATHOL, V42, P1545, DOI 10.1016/j.humpath.2010.12.018; Li TW, 2018, J MOL MED, V96, P85, DOI 10.1007/s00109-017-1600-y; Pattison AM, 2016, WORLD J GASTROENTERO, V22, P8070, DOI 10.3748/wjg.v22.i36.8070; Pek M, 2017, ONCOGENE, V36, P4975, DOI 10.1038/onc.2017.120; Qu SB, 2015, CANCER LETT, V365, P141, DOI 10.1016/j.canlet.2015.06.003; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sobecki M, 2017, CANCER RES, V77, P2722, DOI 10.1158/0008-5472.CAN-16-0707; Sun S, 2018, DIS MARKERS, V2018, DOI 10.1155/2018/6514795; Wang XN, 2015, INT J CLIN EXP PATHO, V8, P16020; Wilkins T, 2018, AM FAM PHYSICIAN, V97, P658; Wu J, 2018, CANCER LETT, V430, P179, DOI 10.1016/j.canlet.2018.05.033; Xiao WB, 2017, DIGEST DIS, V36, P26, DOI 10.1159/000478977; Xiong DD, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1593-5; Xu N, 2018, CELL PHYSIOL BIOCHEM, V48, P2046, DOI 10.1159/000492543; Yang Q, 2017, CELL DEATH DIFFER, V24, P1609, DOI 10.1038/cdd.2017.86; Yang X, 2017, J CANCER, V8, P3456, DOI 10.7150/jca.19345; Yao ZC, 2017, MOL ONCOL, V11, P422, DOI 10.1002/1878-0261.12045; Yu DH, 2013, CELL BIOCHEM BIOPHYS, V67, P175, DOI 10.1007/s12013-013-9530-y; Yuan Y, 2018, BIOCHEM BIOPH RES CO, V503, P870, DOI 10.1016/j.bbrc.2018.06.089; Zeng KX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0454-8; Zeng YJ, 2017, INT J MOL MED, V40, P1818, DOI 10.3892/ijmm.2017.3189; Zhang R, 2018, EUR REV MED PHARMACO, V22, P118, DOI 10.26355/eurrev_201801_14108; Zhang XW, 2018, ONCOTARGETS THER, V11, P2853, DOI 10.2147/OTT.S158008; Zhang XL, 2017, CELL BIOL INT, V41, P1056, DOI 10.1002/cbin.10826; Zhong YX, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0827-8; Zhou RY, 2018, CANCER LETT, V425, P134, DOI 10.1016/j.canlet.2018.03.035; Zhu MC, 2017, BIOMED PHARMACOTHER, V88, P138, DOI 10.1016/j.biopha.2016.12.097	46	56	57	1	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2019	38	32					6017	6034		10.1038/s41388-019-0857-8	http://dx.doi.org/10.1038/s41388-019-0857-8			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IP8XH	31300733				2022-12-28	WOS:000480329900002
J	Zhu, YF; Xie, MX; Meng, ZY; Leung, LK; Chan, FL; Hu, X; Chi, KW; Liu, CL; Yao, XQ				Zhu, Yifei; Xie, Mingxu; Meng, Zhaoyue; Leung, Lai-Kwok; Chan, Franky Leung; Hu, Xin; Chi, Kaiwen; Liu, Cuiling; Yao, Xiaoqiang			Knockdown of TM9SF4 boosts ER stress to trigger cell death of chemoresistant breast cancer cells	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM STRESS; MULTIDRUG-RESISTANCE; PROTEIN; ADHESION; PROLIFERATION	Drug resistance is one of the major obstacles to breast cancer therapy. However, the mechanisms of how cancer cells develop chemoresistance are still not fully understood. In the present study, we found that expression of TM9SF4 proteins was much higher in adriamycin (ADM)-resistant breast cancer cells MCF-7/ADM than in its parental line wild-type breast cancer cells MCF-7/WT. shRNA-mediated knockdown of TM9SF4 preferentially reduced cell growth and triggered cell death in chemoresistant MCF-7/ADM cells compared with MCF-7/WT cells. Knockdown of TM9SF4 also reduced cell growth and triggered cell death in chemoresistant MDA-MB-231/GEM cells. Mechanistic studies showed that TM9SF4 knockdown increased protein misfolding and elevated endoplasmic reticulum (ER) stress level in MCF-7/ADM cells, as indicated by aggresome formation and upregulated expression of ER stress markers, the effect of which was reversed by a small molecule chaperone 4-phenybutyric acid. In an athymic nude mouse model of ADM-resistant human breast xenograft tumor, knockdown of TM9SF4 decreased the growth of tumor xenografts. In chemoresistant breast cancer patients, chemotherapy increased the expression of TM9SF4 proteins in breast tumor samples. Taken together, these results uncovered a novel role of TM9SF4 proteins in alleviating ER stress and protecting chemoresistant breast cancer cells from apoptotic/necrotic cell death. These results highlight a possible strategy of targeting TM9SF4 to overcome breast cancer chemoresistance.	[Zhu, Yifei; Xie, Mingxu; Meng, Zhaoyue; Chan, Franky Leung; Yao, Xiaoqiang] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Peoples R China; [Zhu, Yifei; Xie, Mingxu; Meng, Zhaoyue; Chan, Franky Leung; Yao, Xiaoqiang] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Peoples R China; [Zhu, Yifei] Jiangnan Univ, Wuxi Sch Med, Wuxi, Jiangsu, Peoples R China; [Leung, Lai-Kwok] Chinese Univ Hong Kong, Sch Life Sci, Hong Kong, Peoples R China; [Hu, Xin] Fudan Univ, Dept Breast Surg, Key Lab Breast Canc Shanghai, Shanghai Canc Ctr, Shanghai, Peoples R China; [Chi, Kaiwen; Liu, Cuiling] Peking Univ, Dept Pathol, Hlth Sci Ctr, Beijing, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Jiangnan University; Chinese University of Hong Kong; Fudan University; Peking University	Yao, XQ (corresponding author), Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Peoples R China.; Yao, XQ (corresponding author), Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Peoples R China.	yao2068@cuhk.edu.hk	Leung, Lai K/E-6314-2011; Yao, Xiaoqiang/I-5413-2016	Leung, Lai K/0000-0002-7781-3099; Yao, Xiaoqiang/0000-0002-0687-8186	Hong Kong Research Grant Committee [AoE/M-05/12, GRF/14118516, RIF/R4005-18F]; Hong Kong Innovation and Technology Fund [ITF/096/18, PiH/230/18, PiH/049/19]	Hong Kong Research Grant Committee(Hong Kong Research Grants Council); Hong Kong Innovation and Technology Fund	This work was supported by grants from Hong Kong Research Grant Committee [AoE/M-05/12, GRF/14118516, RIF/R4005-18F] and Hong Kong Innovation and Technology Fund [ITF/096/18, PiH/230/18 and PiH/049/19].	Benghezal M, 2003, MOL BIOL CELL, V14, P2890, DOI 10.1091/mbc.E02-11-0724; Bergeret E, 2008, J CELL SCI, V121, P3325, DOI 10.1242/jcs.030163; Borst P, 2012, OPEN BIOL, V2, DOI 10.1098/rsob.120066; Chang HY, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.504; Chen JA, 2011, CANCER LETT, V300, P48, DOI 10.1016/j.canlet.2010.09.005; Corboy Michael J., 2005, V301, P305; Cornillon S, 2000, J BIOL CHEM, V275, P34287, DOI 10.1074/jbc.M006725200; Daniel C, 2013, BBA-MOL BASIS DIS, V1832, P606, DOI 10.1016/j.bbadis.2013.01.020; Fais S, 2012, TRENDS MOL MED, V18, P4, DOI 10.1016/j.molmed.2011.09.001; Goda K, 2009, CURR CANCER DRUG TAR, V9, P281, DOI 10.2174/156800909788166493; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Harbeck N, 2017, LANCET, V389, P1134, DOI [10.1016/s0140-6736(16)31891-8, 10.1016/S0140-6736(16)31891-8]; Iannitti T, 2011, DRUGS R&D, V11, P227, DOI 10.2165/11591280-000000000-00000; Iliopoulos D, 2007, CLIN CANCER RES, V13, P268, DOI 10.1158/1078-0432.CCR-06-2038; Jones LJ, 2001, J IMMUNOL METHODS, V254, P85, DOI 10.1016/S0022-1759(01)00404-5; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Lebeau P, 2017, J BIOL CHEM, V292, P1510, DOI 10.1074/jbc.M116.744235; Lozupone F, 2015, ONCOGENE, V34, P5163, DOI 10.1038/onc.2014.437; Lozupone F, 2009, EMBO REP, V10, P1348, DOI 10.1038/embor.2009.236; Ma X, 2012, P NATL ACAD SCI USA, V109, P16282, DOI 10.1073/pnas.1202989109; Mekahli D, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004317; Nishitoh H, 2012, J BIOCHEM, V151, P217, DOI 10.1093/jb/mvr143; Ogston KN, 2003, BREAST, V12, P320, DOI 10.1016/S0960-9776(03)00106-1; Paolillo R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126968; Park J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15730; Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003; Ralevic V, 1998, PHARMACOL REV, V50, P413; Ranganathan AC, 2006, CANCER RES, V66, P1702, DOI 10.1158/0008-5472.CAN-05-3092; Salaroglio IC, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0657-0; Salic A, 2008, P NATL ACAD SCI USA, V105, P2415, DOI 10.1073/pnas.0712168105; Sun L, 2018, CELL DEATH DIFFER, V25, P368, DOI 10.1038/cdd.2017.166; Tavera-Mendoza LE, 2017, LAB ANIM-UK, V51, P85, DOI 10.1177/0023677216640706; Wang M, 2014, NAT REV CANCER, V14, P581, DOI 10.1038/nrc3800; Welch WJ, 1996, CELL STRESS CHAPERON, V1, P109, DOI 10.1379/1466-1268(1996)001<0109:IOMACC>2.3.CO;2; Ye FG, 2015, CANCER RES, V75, P1504, DOI 10.1158/0008-5472.CAN-14-2341	35	14	16	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	2019	38	29					5778	5791		10.1038/s41388-019-0846-y	http://dx.doi.org/10.1038/s41388-019-0846-y			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IQ4WS	31249383				2022-12-28	WOS:000480752800003
J	Nicolae, CM; O'Connor, MJ; Schleicher, EM; Song, CH; Gowda, R; Robertson, G; Dovat, S; Moldovan, GL				Nicolae, Claudia M.; O'Connor, Michael J.; Schleicher, Emily M.; Song, Chunhua; Gowda, Raghavendra; Robertson, Gavin; Dovat, Sinisa; Moldovan, George-Lucian			PARI (PARPBP) suppresses replication stress-induced myeloid differentiation in leukemia cells	ONCOGENE			English	Article							NF-KAPPA-B; DNA-DAMAGE; HOMOLOGOUS RECOMBINATION; GENOMIC INSTABILITY; FORK REVERSAL; ACTIVATION; PROTEIN; EXPRESSION; PCNA; TUMORIGENESIS	Hyperproliferative cancer cells face increased replication stress, which can result in accumulation of DNA damage. As DNA damage can arrest proliferation, and, in the case of myeloid leukemia, induce differentiation of cancer cells, understanding the mechanisms that regulate the replication stress response is paramount. Here, we show that PARI, a replisome protein involved in regulating DNA repair and replication stress, suppresses differentiation of myeloid leukemia cells. We show that PARI is overexpressed in myeloid leukemia cells, and its knockdown reduces leukemia cell proliferation in vitro and in vivo in xenograft mouse models. PARI depletion enhances replication stress and DNA-damage accumulation, coupled with increased myeloid differentiation. Mechanistically, we show that PARI inhibits activation of the NF-kappa B pathway, which can initiate p21-mediated differentiation and proliferation arrest. Finally, we show that PARI expression negatively correlates with expression of differentiation markers in clinical myeloid leukemia samples, suggesting that targeting PARI may restore differentiation ability of leukemia cells and antagonize their proliferation.	[Nicolae, Claudia M.; O'Connor, Michael J.; Schleicher, Emily M.; Moldovan, George-Lucian] Penn State Univ, Dept Biochem & Mol Biol, Coll Med, 500 Univ Dr, Hershey, PA 17033 USA; [Song, Chunhua; Dovat, Sinisa] Penn State Univ, Dept Pediat, Coll Med, 500 Univ Dr, Hershey, PA 17033 USA; [Gowda, Raghavendra; Robertson, Gavin] Penn State Univ, Dept Pharmacol, Coll Med, 500 Univ Dr, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Moldovan, GL (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, Coll Med, 500 Univ Dr, Hershey, PA 17033 USA.	glm29@psu.edu	song, chunhua/K-7882-2016	song, chunhua/0000-0002-4081-2543; Schleicher, Emily/0000-0002-2315-346X; George-Lucian, Moldovan/0000-0003-3825-149X; Dovat, Sinisa/0000-0003-3906-6165	Department of Defense [CA140303]; St. Baldrick Foundation; Alex's Lemonade Stand; Hyundai Hope on Wheels Scholar Grant; Bear Necessities Pediatric Cancer Foundation; NIH [R01CA209829, R01CA213912]; NATIONAL CANCER INSTITUTE [R01CA213912, R01CA209829] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); St. Baldrick Foundation; Alex's Lemonade Stand; Hyundai Hope on Wheels Scholar Grant; Bear Necessities Pediatric Cancer Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Dr. Alan D'Andrea for EUFA130 cells, Dr. Chandrika Gowda for experimental advice, Daniel Constantin for technical support, and the Penn State College of Medicine Flow Cytometry and Genome Sciences cores. This work was supported by: the Department of Defense (award CA140303) and the St. Baldrick Foundation (to GLM); NIH R01CA209829, R01CA213912, Alex's Lemonade Stand, Hyundai Hope on Wheels Scholar Grant, and Bear Necessities Pediatric Cancer Foundation (to SD).	Allen C, 2011, J MOL CELL BIOL, V3, P4, DOI 10.1093/jmcb/mjq049; Ammon C, 2000, IMMUNOLOGY, V100, P364, DOI 10.1046/j.1365-2567.2000.00056.x; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Vallerga MB, 2015, P NATL ACAD SCI USA, V112, pE6624, DOI 10.1073/pnas.1508543112; Bhat KP, 2018, NAT STRUCT MOL BIOL, V25, P446, DOI 10.1038/s41594-018-0075-z; Bruserud O, 2000, Oncologist, V5, P454, DOI 10.1634/theoncologist.5-6-454; Burkovics P, 2016, NUCLEIC ACIDS RES, V44, P3176, DOI 10.1093/nar/gkw024; Cheung KJJ, 2009, BRIT J HAEMATOL, V146, P257, DOI 10.1111/j.1365-2141.2009.07739.x; Choe KN, 2016, EMBO REP, V17, P874, DOI 10.15252/embr.201541685; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; de The H, 2018, NAT REV CANCER, V18, P117, DOI 10.1038/nrc.2017.103; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fey MF, 2007, ANN ONCOL, V18, pI9, DOI 10.1093/annonc/mdl444; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Georgakilas AG, 2017, TRENDS MOL MED, V23, P310, DOI 10.1016/j.molmed.2017.02.001; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hayden MS, 2012, GENE DEV, V26, P203, DOI 10.1101/gad.183434.111; Hou HA, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.59; Huang TT, 2000, J BIOL CHEM, V275, P9501, DOI 10.1074/jbc.275.13.9501; Huang TT, 2002, MOL CELL BIOL, V22, P5813, DOI 10.1128/MCB.22.16.5813-5825.2002; Huang TT, 2001, MOL CELL BIOL, V21, P4737, DOI 10.1128/MCB.21.14.4737-4747.2001; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Macheret M, 2015, ANNU REV PATHOL-MECH, V10, P425, DOI 10.1146/annurev-pathol-012414-040424; Mao ZY, 2008, DNA REPAIR, V7, P1765, DOI 10.1016/j.dnarep.2008.06.018; Melo Monica B, 2002, Hematology, V7, P13, DOI 10.1080/10245330290020090; Mochizuki AL, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00117-17; Moldovan GL, 2012, MOL CELL, V45, P75, DOI 10.1016/j.molcel.2011.11.010; Nicolae CM, 2018, ONCOGENE, V37, P3647, DOI 10.1038/s41388-018-0219-y; O'Connor KW, 2013, CANCER RES, V73, P2529, DOI 10.1158/0008-5472.CAN-12-3313; Piao L, 2011, GENE CHROMOSOME CANC, V50, P13, DOI 10.1002/gcc.20828; Pitroda SP, 2017, CLIN CANCER RES, V23, P4493, DOI 10.1158/1078-0432.CCR-16-2845; Pitroda SP, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008291; Quinet A, 2017, MOL CELL, V68, P830, DOI 10.1016/j.molcel.2017.11.022; Santos MA, 2014, NATURE, V514, P107, DOI 10.1038/nature13483; Schleicher EM, 2018, NUCLEIC ACIDS RES, V46, P8908, DOI 10.1093/nar/gky658; Song CH, 2015, BLOOD, V126, P1813, DOI 10.1182/blood-2015-06-651505; Talati C, 2018, LEUKEMIA RES, V73, P58, DOI 10.1016/j.leukres.2018.09.001; Tilstra JS, 2011, AGING DIS, V2, P449; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; Vassen L, 2012, AM J BLOOD RES, V2, P228; Wang J, 2011, J CELL BIOCHEM, V112, P2443, DOI 10.1002/jcb.23165; Wang XN, 2014, J CELL PHYSIOL, V229, P856, DOI 10.1002/jcp.24513; Watts JM, 2014, BLOOD REV, V28, P205, DOI 10.1016/j.blre.2014.07.001; Wu ZH, 2006, SCIENCE, V311, P1141, DOI 10.1126/science.1121513; Xie CZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079106; Yoon SW, 2014, STEM CELLS DEV, V23, P2700, DOI 10.1089/scd.2014.0129; Zafar MK, 2017, CHEM RES TOXICOL, V30, P1942, DOI 10.1021/acs.chemrestox.7b00157; Zellweger R, 2015, J CELL BIOL, V208, P563, DOI 10.1083/jcb.201406099; Zeman MK, 2014, NAT CELL BIOL, V16, P2, DOI 10.1038/ncb2897; Zhao KW, 2004, BLOOD, V104, P3731, DOI 10.1182/blood-2004-04-1630	52	9	9	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2019	38	27					5530	5540		10.1038/s41388-019-0810-x	http://dx.doi.org/10.1038/s41388-019-0810-x			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IG5KR	30967629				2022-12-28	WOS:000473842500014
J	Chen, C; Bai, LP; Cao, FQ; Wang, SN; He, HW; Song, MC; Chen, HL; Liu, Y; Guo, J; Si, Q; Pan, YD; Zhu, RZ; Chuang, TH; Xiang, R; Luo, YP				Chen, Chong; Bai, Lipeng; Cao, Fengqi; Wang, Shengnan; He, Huiwen; Song, Mingcheng; Chen, Huilin; Liu, Yan; Guo, Jian; Si, Qin; Pan, Yundi; Zhu, Ruizhe; Chuang, Tsung-Hsien; Xiang, Rong; Luo, Yunping			Targeting LIN28B reprograms tumor glucose metabolism and acidic microenvironment to suppress cancer stemness and metastasis	ONCOGENE			English	Article							EXTRACELLULAR PH; MELANOMA-CELLS; MYC; HETEROGENEITY; MITOCHONDRIAL; EXPRESSION; GROWTH; REPRESSION	The altered metabolism and acidic microenvironment plays an important role in promoting tumor malignant characteristics. A small population of cancer stem cells (CSCs) were considered as a therapy target to reserve tumor relapse, resistance, and metastasis. However, the molecular mechanism that regulates CSCs metabolism remains poorly understood. In this study, we demonstrate a fundamental role of stemness gene LIN28B in maintaining CSCs glycolysis metabolism. Using LIN28B-expressing cancer cell lines, we found that the rate of extracellular acidification, glucose uptake, and lactate secretion are all suppressed by LIN28B knockdown in vitro and in vivo. Importantly, metabolic analyses reveal that CSCs have enhanced aerobic glycolysis metabolic characteristics and the glycolytic product lactate further promotes cancer associated stemness properties. LIN28B silencing suppresses MYC expression that further increases miR-34a-5p level. Furthermore, the glycolysis metabolism of human breast cancer cell line MDA-MB-231 is suppressed by either MYC siRNA or miR-34a-5p mimic Clinically, high MYC and low miR-34a-5p level are correlated with high LIN28B expression and poor prognosis in human breast cancer patients. Notably, blocking LIN28B/MYC/miR-34a-5p signaling pathway by LIN28B-specific inhibitor causes dramatic inhibition of tumor growth and metastasis in immunodeficient orthotopic mouse models of human breast cancer cell MDA-MB-231. Taken together, our findings offer a preclinical investigation of targeting LIN28B to suppress CSCs glycolysis metabolism and tumor progression that may improve the therapeutic benefit for cancer patients.	[Chen, Chong; Bai, Lipeng; Cao, Fengqi; Wang, Shengnan; He, Huiwen; Song, Mingcheng; Chen, Huilin; Liu, Yan; Guo, Jian; Si, Qin; Pan, Yundi; Zhu, Ruizhe; Luo, Yunping] Chinese Acad Med Sci, Inst Basic Med Sci, Dept Immunol, Beijing 100005, Peoples R China; [Chen, Chong; Bai, Lipeng; Cao, Fengqi; Wang, Shengnan; He, Huiwen; Song, Mingcheng; Chen, Huilin; Liu, Yan; Guo, Jian; Si, Qin; Pan, Yundi; Zhu, Ruizhe; Luo, Yunping] Peking Union Med Coll, Sch Basic Med, Beijing 100005, Peoples R China; [Chen, Chong; Bai, Lipeng; Cao, Fengqi; Wang, Shengnan; He, Huiwen; Song, Mingcheng; Chen, Huilin; Liu, Yan; Guo, Jian; Si, Qin; Pan, Yundi; Zhu, Ruizhe; Luo, Yunping] Chinese Acad Med Sci, Inst Basic Med Sci, Collaborat Innovat Ctr Biotherapy, Beijing 100005, Peoples R China; [Bai, Lipeng] Jiangxi Canc Hosp, Dept Clin Lab, Nanchang 330029, Jiangxi, Peoples R China; [Chuang, Tsung-Hsien] Natl Hlth Res Inst, Immunol Res Ctr, Miaoli, Taiwan; [Xiang, Rong] Nankai Univ, Dept Immunol, Tianjin 300071, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; National Health Research Institutes - Taiwan; Nankai University	Luo, YP (corresponding author), Chinese Acad Med Sci, Inst Basic Med Sci, Dept Immunol, Beijing 100005, Peoples R China.; Luo, YP (corresponding author), Peking Union Med Coll, Sch Basic Med, Beijing 100005, Peoples R China.; Luo, YP (corresponding author), Chinese Acad Med Sci, Inst Basic Med Sci, Collaborat Innovat Ctr Biotherapy, Beijing 100005, Peoples R China.	ypluo@ibms.pumc.edu.cn	Zhu, Ruizhe/HGF-1928-2022; Chuang, Tsung-Hsien/F-9679-2010		973 Program of China [2013CB967202]; Fundamental Research Funds for the Central Universities [33320140173]; National Natural Science Foundation of China [91029734, 81071711, 81502562]	973 Program of China(National Basic Research Program of China); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This project was supported by grants from the 973 Program of China (2013CB967202, Yunping Luo); the National Natural Science Foundation of China (91029734 and 81071711, Yunping Luo), the National Natural Science Foundation of China (81502562, Chong Chen); and the Fundamental Research Funds for the Central Universities (33320140173, Chong Chen). We thank Zhigang Wang (Department of Bioengineering, Chinese Academy of Medical Sciences) for the bioinformatics analysis in this study and Cameron R. Mckay (Department of Immunology, Nankai University) for critically reading and polishing this manuscript.	ALBRIGHT JD, 1981, J MED CHEM, V24, P592, DOI 10.1021/jm00137a020; American Type Culture Collection, 2007, ATCC TECHN B, V8; Bu PC, 2013, CELL STEM CELL, V12, P602, DOI 10.1016/j.stem.2013.03.002; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chen C, 2015, CANCER RES, V75, P1725, DOI 10.1158/0008-5472.CAN-14-2111; Ciavardelli D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.285; Corbet C, 2016, CELL METAB, V24, P311, DOI 10.1016/j.cmet.2016.07.003; Davidson SM, 2016, CELL METAB, V23, P517, DOI 10.1016/j.cmet.2016.01.007; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Faubert B, 2017, CELL, V171, P358, DOI 10.1016/j.cell.2017.09.019; Feng C, 2012, CELL CYCLE, V11, P2486, DOI 10.4161/cc.20893; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hensley CT, 2016, CELL, V164, P681, DOI 10.1016/j.cell.2015.12.034; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Huang L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088893; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Ito K, 2012, NAT MED, V18, P1350, DOI 10.1038/nm.2882; Janiszewska M, 2012, GENE DEV, V26, P1926, DOI 10.1101/gad.188292.112; King CE, 2011, CANCER RES, V71, P4260, DOI 10.1158/0008-5472.CAN-10-4637; Kleppe M, 2014, NAT MED, V20, P342, DOI 10.1038/nm.3522; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Lee KM, 2017, CELL METAB, V26, P633, DOI 10.1016/j.cmet.2017.09.009; Levi BP, 2009, BLOOD, V113, P1670, DOI 10.1182/blood-2008-05-156752; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Ma XY, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6212; Mayr F, 2013, INT J MOL SCI, V14, P16532, DOI 10.3390/ijms140816532; Moellering RE, 2008, CLIN EXP METASTAS, V25, P411, DOI 10.1007/s10585-008-9145-7; Nguyen LH, 2014, CANCER CELL, V26, P248, DOI 10.1016/j.ccr.2014.06.018; Park EY, 2014, CANCER RES, V74, P7573, DOI 10.1158/0008-5472.CAN-14-1140; Piskounova E, 2011, CELL, V147, P1066, DOI 10.1016/j.cell.2011.10.039; Qiu CH, 2010, NUCLEIC ACIDS RES, V38, P1240, DOI 10.1093/nar/gkp1071; Rofstad EK, 2006, CANCER RES, V66, P6699, DOI 10.1158/0008-5472.CAN-06-0983; Roos M, 2016, ACS CHEM BIOL, V11, P2773, DOI 10.1021/acschembio.6b00232; Sancho P, 2015, CELL METAB, V22, P590, DOI 10.1016/j.cmet.2015.08.015; Shyh-Chang N, 2013, CELL STEM CELL, V12, P395, DOI 10.1016/j.stem.2013.03.005; Silva AS, 2009, CANCER RES, V69, P2677, DOI 10.1158/0008-5472.CAN-08-2394; Spinelli JB, 2017, SCIENCE, V358, P941, DOI 10.1126/science.aam9305; Stine ZE, 2015, CANCER DISCOV, V5, P1024, DOI 10.1158/2159-8290.CD-15-0507; Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334; Valton J, 2014, METHODS, V69, P151, DOI 10.1016/j.ymeth.2014.06.013; Vazquez F, 2013, CANCER CELL, V23, P287, DOI 10.1016/j.ccr.2012.11.020; Viswanathan SR, 2008, SCIENCE, V320, P97, DOI 10.1126/science.1154040; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; Walz S, 2014, NATURE, V511, P483, DOI 10.1038/nature13473; Wang Y, 2011, ONCOGENE, V30, P1470, DOI 10.1038/onc.2010.531; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wu LW, 2015, ELIFE, V4, DOI 10.7554/eLife.09431; Xiao ZG, 2014, CANCER RES, V74, P6236, DOI 10.1158/0008-5472.CAN-14-0855; Ye XQ, 2011, INT J CANCER, V129, P820, DOI 10.1002/ijc.25944; Zhang J, 2016, CELL STEM CELL, V19, P66, DOI 10.1016/j.stem.2016.05.009; Zhang SY, 2014, CANCER RES, V74, P5311, DOI 10.1158/0008-5472.CAN-14-0529; Zhu H, 2010, NAT GENET, V42, P626, DOI 10.1038/ng.593	53	41	43	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2019	38	23					4527	4539		10.1038/s41388-019-0735-4	http://dx.doi.org/10.1038/s41388-019-0735-4			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IB4KM	30742065				2022-12-28	WOS:000470240300007
J	Choucair, A; Pham, TH; Omarjee, S; Jacquemetton, J; Kassem, L; Tredan, O; Rambaud, J; Marangoni, E; Corbo, L; Treilleux, I; Le Romancer, M				Choucair, Ali; Thuy Ha Pham; Omarjee, Soleilmane; Jacquemetton, Julien; Kassem, Loay; Tredan, Olivier; Rambaud, Juliette; Marangoni, Elisabetta; Corbo, Laura; Treilleux, Isabelle; Le Romancer, Muriel			The arginine methyltransferase PRMT1 regulates IGF-1 signaling in breast cancer	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; FACTOR-I RECEPTOR; METHYLATION; RESISTANCE; EXPRESSION; PROMOTES; CHAIN	Aside from its well-known nuclear routes of signaling, estrogen also mediates its effects through cytoplasmic signaling. Estrogen signaling involves numerous posttranslational modifications of its receptor ER alpha, the best known being phosphorylation. Our research group previously showed that upon estrogen stimulation, ER alpha is methylated on residue R260 and forms the mER alpha/Src/PI3K complex, central to the rapid transduction of nongenomic estrogen signals. Regulation of ER alpha signaling via its phosphorylation by growth factors is well recognized, and we wondered whether they could also trigger ER alpha methylation (mER alpha). Here, we found that IGF-1 treatment of MCF-7 cells induced rapid ER alpha methylation by the arginine methyltransferase PRMT1 and triggered the binding of mER alpha to IGF-1R. Mechanistically, we showed that PRMT1 bound constitutively to IGF-1R and that PRMT1 became activated upon IGF-1 stimulation. Moreover, we found that expression or pharmacological inhibition of PRMT1 impaired mER alpha and IGF-1 signaling. Our findings were substantiated in a cohort of breast tumors in which IGF-1R expression was positively correlated with ER alpha/Src and ER alpha/PI3K expression, hallmarks of nongenomic estrogen signaling, reinforcing the link between IGF-1R and mER alpha. Altogether, these results provide a new insight into ER alpha and IGF-1R interference, and open novel perspectives for combining endocrine therapies with PRMT1 inhibitors in ER alpha-positive tumors.	[Choucair, Ali; Thuy Ha Pham; Omarjee, Soleilmane; Jacquemetton, Julien; Rambaud, Juliette; Corbo, Laura; Treilleux, Isabelle; Le Romancer, Muriel] Ctr Rech Cancerol Lyon, INSERM, U1052, Lyon, France; [Choucair, Ali; Thuy Ha Pham; Omarjee, Soleilmane; Jacquemetton, Julien; Rambaud, Juliette; Corbo, Laura; Treilleux, Isabelle; Le Romancer, Muriel] Ctr Rech Cancerol Lyon, CNRS, UMR5286, Lyon, France; [Choucair, Ali; Thuy Ha Pham; Omarjee, Soleilmane; Jacquemetton, Julien; Rambaud, Juliette; Corbo, Laura; Treilleux, Isabelle; Le Romancer, Muriel] Univ Lyon 1, Lyon, France; [Omarjee, Soleilmane] Univ Cambridge, Cambridge Inst, Canc Res UK, Cambridge CB2 0RE, England; [Kassem, Loay] Cairo Univ, Fac Med, Dept Clin Oncol, Cairo, Egypt; [Tredan, Olivier] Ctr Leon Berard, Dept Oncol, Lyon, France; [Marangoni, Elisabetta] Inst Curie, Translat Res Dept, F-75005 Paris, France; [Treilleux, Isabelle] Ctr Leon Berard, Dept Pathol, Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UNICANCER; Centre Leon Berard; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; Egyptian Knowledge Bank (EKB); Cairo University; UNICANCER; Centre Leon Berard; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UNICANCER; Centre Leon Berard	Le Romancer, M (corresponding author), Ctr Rech Cancerol Lyon, INSERM, U1052, Lyon, France.; Le Romancer, M (corresponding author), Ctr Rech Cancerol Lyon, CNRS, UMR5286, Lyon, France.; Le Romancer, M (corresponding author), Univ Lyon 1, Lyon, France.	muriel.leromancer@lyon.unicancer.fr	Marangoni, Elisabetta/GSO-3945-2022; Tredan, Olivier/N-9794-2017	Marangoni, Elisabetta/0000-0002-3337-6448; Le Romancer, Muriel/0000-0002-8491-4015; Omarjee, Soleilmane/0000-0001-8686-7286; Jacquemetton, Julien/0000-0003-0513-6604; Tredan, Olivier/0000-0001-5881-9383	Fondation ARC Cancer; DGOS; "la ligue contre le cancer", comity of the Saone-et-Loire; INCA; Ministry of Research; ligue nationale contre le cancer	Fondation ARC Cancer; DGOS; "la ligue contre le cancer", comity of the Saone-et-Loire; INCA(Institut National du Cancer (INCA) France); Ministry of Research(Ministry of Research and Technology of the Republic of Indonesia (RISTEK)); ligue nationale contre le cancer(Ligue nationale contre le cancer)	We thank the Fondation ARC Cancer, the INCA and DGOS and "la ligue contre le cancer", comity of the Saone-et-Loire, the Fondation ARC Cancer and DGOS for JJ, and the Ministry of Research and the ligue nationale contre le cancer for financial support to AC.	Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; Baserga R, 1997, BBA-REV CANCER, V1332, pF105, DOI 10.1016/S0304-419X(97)00007-3; Becker MA, 2011, MOL ENDOCRINOL, V25, P516, DOI 10.1210/me.2010-0373; Bedford MT, 2009, MOL CELL, V33, P1, DOI 10.1016/j.molcel.2008.12.013; Bianchini L, 1997, J BIOL CHEM, V272, P271; Bouchekioua-Bouzaghou K, 2014, INT J CANCER, V135, P1307, DOI 10.1002/ijc.28781; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Chakraborty AK, 2010, BREAST CANCER RES TR, V120, P327, DOI 10.1007/s10549-009-0382-5; Christopoulos PF, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0291-7; Cottu P, 2014, CLIN CANCER RES, V20, P4314, DOI 10.1158/1078-0432.CCR-13-3230; Dupont J, 2003, CELL CYCLE, V2, P270, DOI 10.4161/cc.2.4.408; Eram MS, 2016, ACS CHEM BIOL, V11, P772, DOI 10.1021/acschembio.5b00839; Goulet I, 2007, J BIOL CHEM, V282, P33009, DOI 10.1074/jbc.M704349200; Happerfield LC, 1997, J PATHOL, V183, P412; He X, 2010, ONCOGENE, V29, P2238, DOI 10.1038/onc.2009.513; Herrmann F, 2005, J BIOL CHEM, V280, P38005, DOI 10.1074/jbc.M502458200; Herrmann F, 2009, GENES CELLS, V14, P309, DOI 10.1111/j.1365-2443.2008.01266.x; Heskamp S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117745; Infantino S, 2010, J EXP MED, V207, P711, DOI 10.1084/jem.20091303; Ishihara H, 1998, BIOCHEM BIOPH RES CO, V252, P139, DOI 10.1006/bbrc.1998.9621; Jackson JG, 1999, GROWTH HORM IGF RES, V9, P280, DOI 10.1054/ghir.1999.0113; Johnston SRD, 2010, CLIN CANCER RES, V16, P1979, DOI 10.1158/1078-0432.CCR-09-1823; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; La Rosa P, 2012, MOL ENDOCRINOL, V26, P762, DOI 10.1210/me.2011-1208; Lannigan DA, 2003, STEROIDS, V68, P1, DOI 10.1016/S0039-128X(02)00110-1; Le Romancer M, 2008, MOL CELL, V31, P212, DOI 10.1016/j.molcel.2008.05.025; Levin ER, 2005, MOL ENDOCRINOL, V19, P1951, DOI 10.1210/me.2004-0390; Liao HW, 2015, J CLIN INVEST, V125, P4529, DOI 10.1172/JCI82826; Lisztwan J, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2113; Marangoni E, 2007, CLIN CANCER RES, V13, P3989, DOI 10.1158/1078-0432.CCR-07-0078; Massarweh S, 2008, CANCER RES, V68, P826, DOI 10.1158/0008-5472.CAN-07-2707; Morelli C, 2003, ONCOGENE, V22, P4007, DOI 10.1038/sj.onc.1206436; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Pollak MN, 2004, NAT REV CANCER, V4, P505, DOI 10.1038/nrc1387; Poulard C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087982; Poulard C, 2012, EMBO MOL MED, V4, P1200, DOI 10.1002/emmm.201201615; Simpson A, 2017, TARGET ONCOL, V12, P571, DOI 10.1007/s11523-017-0514-5; Soderberg Ola, 2007, Genet Eng (N Y), V28, P85, DOI 10.1007/978-0-387-34504-8_5; Song RXD, 2007, ENDOCRINOLOGY, V148, P4091, DOI 10.1210/en.2007-0240; STEWART AJ, 1992, BRIT J CANCER, V66, P640, DOI 10.1038/bjc.1992.330; Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9; Thordarson G, 2004, BREAST CANCER RES TR, V87, P277, DOI 10.1007/s10549-004-9504-2; Tian J, 2012, J CLIN INVEST, V122, P192, DOI 10.1172/JCI42204; Totta P, 2015, MOL ENDOCRINOL, V29, P739, DOI 10.1210/me.2014-1385; Xu J, 2013, MOL CELL, V51, P5, DOI 10.1016/j.molcel.2013.05.004; Yan SC, 2015, ONCOTARGETS THER, V8, P279, DOI 10.2147/OTT.S74774; Yee D, 2000, J MAMMARY GLAND BIOL, V5, P107, DOI 10.1023/A:1009575518338; Yu ZB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061627; Zhang YH, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2883	49	21	21	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2019	38	21					4015	4027		10.1038/s41388-019-0694-9	http://dx.doi.org/10.1038/s41388-019-0694-9			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ3HX	30692633	Green Published, hybrid			2022-12-28	WOS:000468740200004
J	Yang, CY; Chang, PW; Hsu, WH; Chang, HC; Chen, CL; Lai, CC; Chiu, WT; Chen, HC				Yang, Cheng-Yi; Chang, Po-Wei; Hsu, Wen-Hsin; Chang, Hsuan-Chia; Chen, Chien-Lin; Lai, Chien-Chen; Chiu, Wen-Tai; Chen, Hong-Chen			Src and SHP2 coordinately regulate the dynamics and organization of vimentin filaments during cell migration	ONCOGENE			English	Article							MICROTUBULE-DEPENDENT TRANSPORT; INTERMEDIATE-FILAMENTS; PHOSPHORYLATION; KINASE; ADHESION; ACTIN; RHO; REORGANIZATION; SITE; CYTOSKELETON	Vimentin intermediate filaments (VIFs), expressed in most mesenchymal and cancer cells, undergo dramatic reorganization during cell migration; however, the mechanism remains obscure. This study demonstrates that upon growth-factor stimulation, Src directly phosphorylates vimentin at Tyr117, leading to VIF disassembly into squiggles and particles at the cell edge during lamellipodia formation. The protein tyrosine phosphatase SHP2 counteracted the Src effects on VIF tyrosine phosphorylation and organization. VIFs formed by vimentin Y117D mutant were more soluble and dynamic than those formed by the wild-type and Y117F mutant. Increased expression of vimentin promoted growth-factor induced lamellipodia formation and cell migration, whereas the mutants suppressed both. The vimentin-induced increase in lamellipodia formation correlated with the activation of Rac and Vav2, with the latter associated with VIFs and recruited to the plasma membrane upon growth-factor stimulation. These results reveal a novel mechanism for regulating VIF dynamics through Src and SHP2 and demonstrate that proper VIF dynamics are important for Rac activation and cell migration.	[Yang, Cheng-Yi; Chang, Po-Wei; Chen, Chien-Lin] Natl Chung Hsing Univ, Dept Life Sci, Taichung, Taiwan; [Hsu, Wen-Hsin; Chen, Hong-Chen] Natl Yang Ming Univ, Canc Progress Res Ctr, Taipei, Taiwan; [Chang, Hsuan-Chia; Chen, Hong-Chen] Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei, Taiwan; [Lai, Chien-Chen] Natl Chung Hsing Univ, Inst Mol Biol, Taichung, Taiwan; [Chiu, Wen-Tai] Natl Cheng Kung Univ, Dept Biomed Engn, Tainan, Taiwan	National Chung Hsing University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Chung Hsing University; National Cheng Kung University	Chen, HC (corresponding author), Natl Yang Ming Univ, Canc Progress Res Ctr, Taipei, Taiwan.; Chen, HC (corresponding author), Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei, Taiwan.; Lai, CC (corresponding author), Natl Chung Hsing Univ, Inst Mol Biol, Taichung, Taiwan.; Chiu, WT (corresponding author), Natl Cheng Kung Univ, Dept Biomed Engn, Tainan, Taiwan.	lailai@dragon.nchu.edu.tw; wtchiu@mail.ncku.edu.tw; hcchen1029@ym.edu.tw	/AGZ-4617-2022	/0000-0002-7133-8266; Hsu, Wen-Hsin/0000-0001-6050-6255; Chiu, Wen-Tai/0000-0003-0310-0675	Ministry of Science and Technology, Taiwan [105-2320-B-005-005-MY3, 106-2320-B-005-011-MY3, 107-2923-B-005-002-MY3]; Cancer Progression Research Center, National Yang-Ming University from the Featured Areas Research Center Program	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan); Cancer Progression Research Center, National Yang-Ming University from the Featured Areas Research Center Program	We thank the Bio-image Core Facility Program for Biotechnology, the Ministry of Science and Technology, Taiwan, for the support of advanced microscopy and the International Institute of Macromolecular Analysis and Nanomedicine Innovation (i-MANI), National Cheng Kung University, Taiwan, for cryo-EM. We are grateful to Dr. Shang-Rung Wu for her technical support. This work was supported by the Ministry of Science and Technology, Taiwan (grant number 105-2320-B-005-005-MY3, 106-2320-B-005-011-MY3, and 107-2923-B-005-002-MY3) and the Cancer Progression Research Center, National Yang-Ming University from the Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan.	Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; ANDO S, 1989, BIOCHEMISTRY-US, V28, P2974, DOI 10.1021/bi00433a035; ANDO S, 1991, BIOCHEM BIOPH RES CO, V175, P955, DOI 10.1016/0006-291X(91)91658-Y; Chan PC, 2003, J BIOL CHEM, V278, P44075, DOI 10.1074/jbc.M305745200; Chan PC, 2014, J CELL BIOL, V204, P19, DOI 10.1083/jcb.201306083; Chan PC, 2012, CANCER RES, V72, P2405, DOI 10.1158/0008-5472.CAN-11-3078; Chang L, 2004, NAT REV MOL CELL BIO, V5, P601, DOI 10.1038/nrm1438; Cheng TJ, 2003, J CELL BIOCHEM, V89, P589, DOI 10.1002/jcb.10511; CHOU YH, 1991, J BIOL CHEM, V266, P7325; Chung BM, 2013, CURR OPIN CELL BIOL, V25, P600, DOI 10.1016/j.ceb.2013.06.008; DELLAGI K, 1985, BLOOD, V65, P1444, DOI 10.1182/blood.V65.6.1444.bloodjournal6561444; Eriksson JE, 2004, J CELL SCI, V117, P919, DOI 10.1242/jcs.00906; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Goto H, 1998, J BIOL CHEM, V273, P11728, DOI 10.1074/jbc.273.19.11728; Goto H, 2002, GENES CELLS, V7, P91, DOI 10.1046/j.1356-9597.2001.00504.x; Goto H, 2003, J BIOL CHEM, V278, P8526, DOI 10.1074/jbc.M210892200; Gregor M, 2014, FASEB J, V28, P715, DOI 10.1096/fj.13-231829; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANSSON GK, 1984, P NATL ACAD SCI-BIOL, V81, P3103, DOI 10.1073/pnas.81.10.3103; Havel LS, 2015, ONCOGENE, V34, P1979, DOI 10.1038/onc.2014.123; Helfand BT, 2011, MOL BIOL CELL, V22, P1274, DOI 10.1091/mbc.E10-08-0699; Herrmann H, 2004, ANNU REV BIOCHEM, V73, P749, DOI 10.1146/annurev.biochem.73.011303.073823; Herrmann H, 2009, J CLIN INVEST, V119, P1772, DOI 10.1172/JCI38214; Hesse M, 2001, J CELL SCI, V114, P2569; Hookway C, 2015, MOL BIOL CELL, V26, P1675, DOI 10.1091/mbc.E14-09-1398; HUANG TJ, 1994, J PROTEIN CHEM, V13, P517, DOI 10.1007/BF01901533; INAGAKI M, 1987, NATURE, V328, P649, DOI 10.1038/328649a0; Ivaska J, 2005, EMBO J, V24, P3834, DOI 10.1038/sj.emboj.7600847; Jiu Y, 2017, J CELL SCI, V130, P892, DOI 10.1242/jcs.196881; Kirmse R, 2007, J BIOL CHEM, V282, P18563, DOI 10.1074/jbc.M701063200; Leduc C, 2017, J CELL BIOL, V216, P1689, DOI 10.1083/jcb.201607045; Lombardo LJ, 2004, J MED CHEM, V47, P6658, DOI 10.1021/jm049486a; Lowery J, 2015, J BIOL CHEM, V290, P17145, DOI 10.1074/jbc.R115.640359; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; Margiotta A, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5020020; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Meier M, 2009, J MOL BIOL, V390, P245, DOI 10.1016/j.jmb.2009.04.067; Mendez MG, 2010, FASEB J, V24, P1838, DOI 10.1096/fj.09-151639; Meriane M, 2000, J BIOL CHEM, V275, P33046, DOI 10.1074/jbc.M001566200; Mucke N, 2004, J MOL BIOL, V340, P97, DOI 10.1016/j.jmb.2004.04.039; Nakamura Y, 2000, GENES CELLS, V5, P823, DOI 10.1046/j.1365-2443.2000.00372.x; Nieminen M, 2006, NAT CELL BIOL, V8, P156, DOI 10.1038/ncb1355; Niki T, 1999, HEPATOLOGY, V29, P520, DOI 10.1002/hep.510290232; Pan YR, 2013, J CELL SCI, V126, P657, DOI 10.1242/jcs.116624; Pan YR, 2011, J CELL BIOL, V195, P113, DOI 10.1083/jcb.201103016; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Robert A, 2016, BIOESSAYS, V38, P232, DOI 10.1002/bies.201500142; Robert A, 2015, P NATL ACAD SCI USA, V112, pE3505, DOI 10.1073/pnas.1505303112; Robert A, 2014, FASEB J, V28, P2879, DOI 10.1096/fj.14-250019; Rogel MR, 2011, FASEB J, V25, P3873, DOI 10.1096/fj.10-170795; Rotty JD, 2012, J CELL BIOL, V197, P381, DOI 10.1083/jcb.201107078; Rush J, 2005, NAT BIOTECHNOL, V23, P94, DOI 10.1038/nbt1046; Satelli A, 2011, CELL MOL LIFE SCI, V68, P3033, DOI 10.1007/s00018-011-0735-1; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Schoumacher M, 2010, J CELL BIOL, V189, P541, DOI 10.1083/jcb.200909113; Schweizer J, 2006, J CELL BIOL, V174, P169, DOI 10.1083/jcb.200603161; Snider NT, 2013, J BIOL CHEM, V288, P31329, DOI 10.1074/jbc.M113.502724; Tamas P, 2003, J BIOL CHEM, V278, P5163, DOI 10.1074/jbc.M207555200; Tang DD, 2005, BIOCHEM J, V388, P773, DOI 10.1042/BJ20050065; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Toivola DM, 2010, TRENDS CELL BIOL, V20, P79, DOI 10.1016/j.tcb.2009.11.004; Tsai WC, 2015, ONCOTARGET, V6, P23845, DOI 10.18632/oncotarget.4313; TSUJIMURA K, 1994, J BIOL CHEM, V269, P31097; Tsuruta D, 2003, J CELL SCI, V116, P4977, DOI 10.1242/jcs.00823; Valgeirsdottir S, 1998, J CELL SCI, V111, P1973; Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29; Yamaguchi T, 2005, J CELL BIOL, V171, P431, DOI 10.1083/jcb.200504091; Zhang X, 2010, J MED CHEM, V53, P2482, DOI 10.1021/jm901645u; Zhou Q, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013538; Zhu QS, 2011, ONCOGENE, V30, P457, DOI 10.1038/onc.2010.421	71	20	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2019	38	21					4075	4094		10.1038/s41388-019-0705-x	http://dx.doi.org/10.1038/s41388-019-0705-x			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ3HX	30696956	Green Published, hybrid			2022-12-28	WOS:000468740200008
J	Cannataro, VL; Gaffney, SG; Sasaki, T; Issaeva, N; Grewal, NKS; Grandis, JR; Yarbrough, WG; Burtness, B; Anderson, KS; Townsend, JP				Cannataro, Vincent L.; Gaffney, Stephen G.; Sasaki, Tomoaki; Issaeva, Natalia; Grewal, Nicholas K. S.; Grandis, Jennifer R.; Yarbrough, Wendell G.; Burtness, Barbara; Anderson, Karen S.; Townsend, Jeffrey P.			APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma	ONCOGENE			English	Article							PAPILLOMAVIRUS-ASSOCIATED HEAD; FBW7 UBIQUITIN LIGASE; CYTOSINE DEAMINATION; OROPHARYNGEAL CANCER; SOMATIC MUTATIONS; GERMLINE VARIANTS; GENETIC LANDSCAPE; GENOMIC ANALYSIS; STRUCTURAL BASIS; DNA CYTOSINE	Recent studies have revealed the mutational signatures underlying the somatic evolution of cancer, and the prevalences of associated somatic genetic variants. Here we estimate the intensity of positive selection that drives mutations to high frequency in tumors, yielding higher prevalences than expected on the basis of mutation and neutral drift alone. We apply this approach to a sample of 525 head and neck squamous cell carcinoma exomes, producing a rank-ordered list of gene variants by selection intensity. Our results illustrate the complementarity of calculating the intensity of selection on mutations along with tallying the prevalence of individual substitutions in cancer: while many of the most prevalently-altered genes were heavily selected, their relative importance to the cancer phenotype differs from their prevalence and from their P value, with some infrequent variants exhibiting evidence of strong positive selection. Furthermore, we extend our analysis of effect size by quantifying the degree to which mutational processes (such as APOBEC mutagenesis) contributes mutations that are highly selected, driving head and neck squamous cell carcinoma. We calculate the substitutions caused by APOBEC mutagenesis that make the greatest contribution to cancer phenotype among patients. Lastly, we demonstrate via in vitro biochemical experiments that the APOBEC3B protein can deaminate the cytosine bases at two sites whose mutant states are subject to high net realized selection intensities-PIK3CA E545K and E542K. By quantifying the effects of mutations, we deepen the molecular understanding of carcinogenesis in head and neck squamous cell carcinoma.	[Cannataro, Vincent L.; Gaffney, Stephen G.; Townsend, Jeffrey P.] Yale Sch Publ Hlth, Dept Biostat, New Haven, CT 06510 USA; [Sasaki, Tomoaki; Anderson, Karen S.] Yale Univ, Dept Pharmacol, New Haven, CT USA; [Issaeva, Natalia; Yarbrough, Wendell G.; Burtness, Barbara; Anderson, Karen S.] Yale Univ, Yale Canc Ctr, New Haven, CT USA; [Issaeva, Natalia; Yarbrough, Wendell G.] Yale Sch Med, Dept Surg, Div Otolaryngol, New Haven, CT USA; [Grewal, Nicholas K. S.; Townsend, Jeffrey P.] Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT 06520 USA; [Grandis, Jennifer R.] Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA USA; [Yarbrough, Wendell G.] Yale Univ, Yale Sch Med, Dept Pathol, New Haven, CT USA; [Burtness, Barbara] Yale Univ, Yale Sch Med, Dept Med, New Haven, CT USA; [Anderson, Karen S.] Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT USA; [Townsend, Jeffrey P.] Yale Univ, Program Computat Biol & Bioinformat, New Haven, CT 06520 USA	Yale University; Yale University; Yale University; Yale University; Yale University; University of California System; University of California San Francisco; Yale University; Yale University; Yale University; Yale University	Townsend, JP (corresponding author), Yale Sch Publ Hlth, Dept Biostat, New Haven, CT 06510 USA.; Townsend, JP (corresponding author), Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT 06520 USA.; Townsend, JP (corresponding author), Yale Univ, Program Computat Biol & Bioinformat, New Haven, CT 06520 USA.	Jeffrey.Townsend@Yale.edu	; Townsend, Jeffrey/D-6457-2017	Issaeva, Natalia/0000-0001-5483-6610; Grewal, Nicholas/0000-0001-5118-7774; Cannataro, Vincent/0000-0002-6364-7747; Gaffney, Stephen/0000-0002-5490-2945; Townsend, Jeffrey/0000-0002-9890-3907	Yale Cancer Center TTARE pilot award; American Cancer Society; NIH [R01DE023685, P50CA097190]; Department of Defence [W81XWH-15-1-0290]; Notsew Orm Sands Foundation; Gilead Sciences, Inc; NATIONAL CANCER INSTITUTE [R35CA231998, T32CA193200, P50CA097190] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE023685] Funding Source: NIH RePORTER	Yale Cancer Center TTARE pilot award; American Cancer Society(American Cancer Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defence; Notsew Orm Sands Foundation; Gilead Sciences, Inc(Gilead Sciences); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This research was funded by a Yale Cancer Center TTARE pilot award to WGY and BB, by grants from The American Cancer Society and NIH grants R01DE023685 and P50CA097190 to JRG, by award W81XWH-15-1-0290 from the Department of Defence to KA, and by support from the Notsew Orm Sands Foundation to JPT. Whole-exome sequencing of tumor tissue was supported by funding from Gilead Sciences, Inc to JRG and JPT. Funders had no role in the study design, collection, analysis or interpretation of the data, writing the manuscript, or the decision to submit the paper for publication.	Adolph MB, 2017, NUCLEIC ACIDS RES, V45, P11925, DOI 10.1093/nar/gkx832; Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923; Alexandrov LB, 2015, NAT GENET, V47, P1402, DOI 10.1038/ng.3441; Alexandrov LB, 2014, CURR OPIN GENET DEV, V24, P52, DOI 10.1016/j.gde.2013.11.014; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Applebaum KM, 2007, JNCI-J NATL CANCER I, V99, P1801, DOI 10.1093/jnci/djm233; Bhatia A, 2015, J CLIN ONCOL, V33, P3243, DOI 10.1200/JCO.2015.61.2358; Burns MB, 2013, NAT GENET, V45, P977, DOI 10.1038/ng.2701; Burns MB, 2013, NATURE, V494, P366, DOI 10.1038/nature11881; Cannataro VL, 2018, ONCOGENE, V37, P2444, DOI 10.1038/s41388-017-0105-z; Cao S, 2016, SCI REP-UK, V6, DOI 10.1038/srep28294; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chaussade C, 2009, BIOCHEM BIOPH RES CO, V381, P577, DOI 10.1016/j.bbrc.2009.02.081; Chelico L, 2006, NAT STRUCT MOL BIOL, V13, P392, DOI 10.1038/nsmb1086; Davis RJ, 2014, CANCER CELL, V26, P455, DOI 10.1016/j.ccell.2014.09.013; de Bruin EC, 2014, SCIENCE, V346, P251, DOI 10.1126/science.1253462; Faden DL, 2017, ORAL ONCOL, V74, P8, DOI 10.1016/j.oraloncology.2017.09.002; Fakhry C, 2008, JNCI-J NATL CANCER I, V100, P261, DOI 10.1093/jnci/djn011; Flores-Obando RE, 2010, BIOMARKERS, V15, P379, DOI 10.3109/13547501003797664; Fousteri M, 2008, CELL RES, V18, P73, DOI 10.1038/cr.2008.6; Fu Y, 2015, BIOCHEM J, V471, P25, DOI 10.1042/BJ20150382; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Glaser AP, 2018, ONCOTARGET, V9, P4537, DOI 10.18632/oncotarget.23344; Grossman RL, 2016, NEW ENGL J MED, V375, P1109, DOI 10.1056/NEJMp1607591; Hajek M, 2017, CANCER-AM CANCER SOC, V123, P1778, DOI 10.1002/cncr.30570; Hammerman PS, 2015, CANCER DISCOV, V5, P239, DOI 10.1158/2159-8290.CD-14-1205; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; Hayes DN, 2015, J CLIN ONCOL, V33, P3227, DOI 10.1200/JCO.2015.62.1086; Hayes DN, 2015, J CLIN INVEST, V125, P462, DOI 10.1172/JCI68339; Hedberg ML, 2016, J CLIN INVEST, V126, P169, DOI 10.1172/JCI82066; Henderson S, 2014, CELL REP, V7, P1833, DOI 10.1016/j.celrep.2014.05.012; Hoopes JI, 2016, CELL REP, V14, P1273, DOI 10.1016/j.celrep.2016.01.021; Huang KL, 2018, CELL, V173, P355, DOI 10.1016/j.cell.2018.03.039; Jiron J, 2014, AM J OTOLARYNG, V35, P147, DOI 10.1016/j.amjoto.2013.09.004; Kazanov MD, 2015, CELL REP, V13, P1103, DOI 10.1016/j.celrep.2015.09.077; Kox C, 2010, LEUKEMIA, V24, P2005, DOI 10.1038/leu.2010.203; Krupar R, 2014, EUR ARCH OTO-RHINO-L, V271, P1737, DOI 10.1007/s00405-013-2693-8; Kwon YW, 2012, MOL CANCER RES, V10, P834, DOI 10.1158/1541-7786.MCR-12-0025; Lawrence M, 2009, BIOINFORMATICS, V25, P1841, DOI 10.1093/bioinformatics/btp328; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; LECHNER M, 2013, GENOME MED, V5; Lewis JS, 2018, ARCH PATHOL LAB MED, V142, P559, DOI 10.5858/arpa.2017-0286-CP; Lui VWY, 2013, CANCER DISCOV, V3, P761, DOI 10.1158/2159-8290.CD-13-0103; Martin D, 2014, ONCOTARGET, V5, P8906, DOI 10.18632/oncotarget.2417; Martincorena I, 2017, CELL, V171, P1029, DOI 10.1016/j.cell.2017.09.042; McGranahan N., 2015, SCI TRANSL MED, V7; Mirghani H, 2018, CLIN TRANSL RAD ONCO, V8, P4, DOI 10.1016/j.ctro.2017.10.005; Montgomery ND, 2018, J MOL DIAGN, V20, P123, DOI 10.1016/j.jmoldx.2017.09.008; Mori S, 2017, J VIROL, V91, DOI 10.1128/JVI.02413-16; Mori S, 2015, BIOCHEM BIOPH RES CO, V460, P555, DOI 10.1016/j.bbrc.2015.03.068; Mroz EA, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001786; Nik-Zainal S, 2014, NAT GENET, V46, P487, DOI 10.1038/ng.2955; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731; Ramakodi MP, 2017, CANCER-AM CANCER SOC, V123, P849, DOI 10.1002/cncr.30457; Ramakodi MP, 2016, GENOMICS, V107, P76, DOI 10.1016/j.ygeno.2015.12.004; Roberts SA, 2013, NAT GENET, V45, P970, DOI 10.1038/ng.2702; Roberts SA, 2012, MOL CELL, V46, P424, DOI 10.1016/j.molcel.2012.03.030; Rosenthal R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0893-4; Rous P, 1911, J EXP MED, V13, P397, DOI 10.1084/jem.13.4.397; Seiwert TY, 2015, CLIN CANCER RES, V21, P632, DOI 10.1158/1078-0432.CCR-13-3310; Shi K, 2017, NAT STRUCT MOL BIOL, V24, P131, DOI 10.1038/nsmb.3344; Stamatoyannopoulos JA, 2009, NAT GENET, V41, P393, DOI 10.1038/ng.363; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Sun W, 2018, NUCLEIC ACIDS RES, V46, P3009, DOI 10.1093/nar/gky131; Teng CL, 2012, CELL CYCLE, V11, P4059, DOI 10.4161/cc.22381; Theurer JA, 2016, PATHOL ONCOL RES, V22, P35, DOI 10.1007/s12253-015-9970-3; Venkatesan S, 2018, ANN ONCOL, V29, P563, DOI 10.1093/annonc/mdy003; Vieira VC, 2014, MBIO, V5, DOI 10.1128/mBio.02234-14; VIEIRA VC, 2013, BIOMED RES INT, V2013, P1; Wang XJ, 2011, J VIROL, V85, P3142, DOI 10.1128/JVI.02049-10; Weinberger PM, 2006, J CLIN ONCOL, V24, P736, DOI 10.1200/JCO.2004.00.3335; Weiss RA, 2011, J EXP MED, V208, P2351, DOI 10.1084/jem.20112160; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Wu ES, 2016, HEAD NECK-J SCI SPEC, V38, P1234, DOI 10.1002/hed.24420	78	53	53	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2019	38	18					3475	3487		10.1038/s41388-018-0657-6	http://dx.doi.org/10.1038/s41388-018-0657-6			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HW3RI	30647454	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000466610000011
J	Ahodantin, J; Bou-Nader, M; Cordier, C; Megret, J; Soussan, P; Desdouets, C; Kremsdorf, D				Ahodantin, James; Bou-Nader, Myriam; Cordier, Corinne; Megret, Jerome; Soussan, Patrick; Desdouets, Chantal; Kremsdorf, Dina			Hepatitis B virus X protein promotes DNA damage propagation through disruption of liver polyploidization and enhances hepatocellular carcinoma initiation	ONCOGENE			English	Article							HBX PROTEIN; CELL-DEATH; KINASE; REPLICATION; P38; EXPRESSION; INCREASES; REPAIR; HEPATOCYTES; INHIBITION	Hepatitis B virus X protein (HBx) contributes to Hepatitis B virus (HBV)-related liver cancer. However, its impact on hepatocyte proliferation and genomic stability remains elusive. We studied the role of HBx expression on the progression of cell cycle and liver polyploidization during proliferation and liver carcinogenesis. Full-length HBx transgenic mice (FL-HBx) were developed to investigate liver ploidy as well as hepatocyte proliferation, along normal liver maturation and during cancer initiation (chemical carcinogen treatment). Investigation of postnatal liver development in FL-HBx showed an aberrant G1/S and G2/M transitions, triggered (1) a delay of the formation of hepatocytes binucleation, (2) the early synthesis of polyploidy nuclei (>= 4n) and (3) DNA damage appearance. Moreover, HBV infection during hepatocytes proliferation in a humanized liver mouse model led, to modifications in polyploidy of hepatocytes. In initiation of hepatocellular carcinoma, FL-HBx protein decreased ChK1 phosphorylation, Mre11 and Rad51 expression, upregulated IL-6 expression and impaired apoptosis. This was related to DNA damage accumulation in FL-HBx mice. At day 75 after initiation of hepatocellular carcinoma, FL-HBx mice revealed significant cell cycle changes related to the increased amount of 4n nuclei and of markers of cancer progenitor cells. Finally, PLK1 upregulation and p38/ERK activation in FL-HBx mice were implicated in aberrant polyploidization favoring DNA damage propagation and hepatocyte transformation. In conclusion, our data indicate that FL-HBx protein increases DNA damage through the hijack of hepatocyte polyploidization. That leads to enhancement of hepatocellular carcinoma initiation in an inflammatory context.	[Ahodantin, James; Soussan, Patrick; Kremsdorf, Dina] Inserm U1135 CIMI Paris, Team Persistent Viral Infect, Paris, France; [Ahodantin, James; Soussan, Patrick; Kremsdorf, Dina] Univ Paris 06, Paris, France; [Ahodantin, James; Soussan, Patrick; Kremsdorf, Dina] CNRS, ERL 8255, Paris, France; [Bou-Nader, Myriam; Desdouets, Chantal] INSERM, Inst Cochin, U1016, Paris, France; [Bou-Nader, Myriam; Desdouets, Chantal] CNRS, UMR8104, Paris, France; [Bou-Nader, Myriam; Desdouets, Chantal] Univ Paris 05, Sorbonne Paris Cite, Paris, France; [Cordier, Corinne; Megret, Jerome] Inserm US24, CNRS UMS 3633, SFR Necker, Cytometry Core Facil, Paris, France; [Cordier, Corinne; Megret, Jerome] Paris Descartes, Fac Med, Paris, France	UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Kremsdorf, D (corresponding author), Inserm U1135 CIMI Paris, Team Persistent Viral Infect, Paris, France.; Kremsdorf, D (corresponding author), Univ Paris 06, Paris, France.; Kremsdorf, D (corresponding author), CNRS, ERL 8255, Paris, France.	dina.kremsdorf@inserm.fr	soussan, patrick/O-9801-2017; Cordier, Corinne/F-9966-2018; Ahodantin, James/AAB-7216-2022; Ahodantin, James/AAK-3326-2020	soussan, patrick/0000-0003-2706-7371; Cordier, Corinne/0000-0003-4799-6143; Ahodantin, James/0000-0003-4405-2593; Ahodantin, James/0000-0003-4405-2593	Agence Nationale de Recherches sur le Sida et les Hepatites Virales (ANRS) [AO 2014-1 16032]; Ligue Contre le Cancer [RS16/75-7, 2017 RS17/75-23]; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Pierre et Marie Curie (UPMC); ANRS doctoral grant	Agence Nationale de Recherches sur le Sida et les Hepatites Virales (ANRS)(ANRSFrench National Research Agency (ANR)); Ligue Contre le Cancer(Ligue nationale contre le cancer); Institut National de la Sante et de la Recherche Medicale (Inserm)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Universite Pierre et Marie Curie (UPMC); ANRS doctoral grant	This work was supported by grants from the Agence Nationale de Recherches sur le Sida et les Hepatites Virales (ANRS) (AO 2014-1 16032), Ligue Contre le Cancer (2016, RS16/75-7 and 2017 RS17/75-23), Institut National de la Sante et de la Recherche Medicale (Inserm) and Universite Pierre et Marie Curie (UPMC). J.A. was supported by an ANRS doctoral grant.	Awad MM, 2000, J BIOL CHEM, V275, P38716, DOI 10.1074/jbc.M008040200; Bandopadhyay M, 2016, INFECT AGENTS CANCER, V11, DOI 10.1186/s13027-016-0085-6; Bontron S, 2002, J BIOL CHEM, V277, P38847, DOI 10.1074/jbc.M205722200; Brezillon N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025096; Celton-Morizur S, 2009, J CLIN INVEST, V119, P1880, DOI 10.1172/JCI38677; Chaisaingmongkol J, 2017, CANCER CELL, V32, P57, DOI 10.1016/j.ccell.2017.05.009; Cheng B, 2010, LIVER INT, V30, P319, DOI 10.1111/j.1478-3231.2009.02167.x; Dan Yue, 2016, Sci Rep, V6, P24430, DOI 10.1038/srep24430; Desdouets C, 2015, ONCOTARGET, V6, P8430, DOI 10.18632/oncotarget.3809; Duncan AW, 2012, GASTROENTEROLOGY, V142, P25, DOI 10.1053/j.gastro.2011.10.029; Duncan AW, 2010, NATURE, V467, P707, DOI 10.1038/nature09414; Forgues M, 2003, MOL CELL BIOL, V23, P5282, DOI 10.1128/MCB.23.15.5282-5292.2003; Gentric G, 2015, J CLIN INVEST, V125, P981, DOI 10.1172/JCI73957; Gentric G, 2014, AM J PATHOL, V184, P322, DOI 10.1016/j.ajpath.2013.06.035; Guidotti JE, 2003, J BIOL CHEM, V278, P19095, DOI 10.1074/jbc.M300982200; He GB, 2013, CELL, V155, P384, DOI 10.1016/j.cell.2013.09.031; He ZL, 2009, WORLD J GASTROENTERO, V15, P4177, DOI 10.3748/wjg.15.4177; Kawai H, 2000, HEPATOLOGY, V31, P1246, DOI 10.1053/jhep.2000.7298; Kew MC, 2011, J GASTROEN HEPATOL, V26, P144, DOI 10.1111/j.1440-1746.2010.06546.x; Kim S, 2015, J GEN VIROL, V96, P2242, DOI 10.1099/vir.0.000150; KUDRYAVTSEV BN, 1993, VIRCHOWS ARCH B, V64, P387, DOI 10.1007/BF02915139; Kurata S, 2000, J BIOL CHEM, V275, P23413, DOI 10.1074/jbc.C000308200; Levrero M, 2016, J HEPATOL, V64, pS84, DOI 10.1016/j.jhep.2016.02.021; Margall-Ducos G, 2007, J CELL SCI, V120, P3633, DOI 10.1242/jcs.016907; Na TY, 2016, ONCOGENE, V35, P5435, DOI 10.1038/onc.2016.82; Pandey V, 2012, J BIOL CHEM, V287, P20545, DOI 10.1074/jbc.M112.359760; Pandit SK, 2013, TRENDS CELL BIOL, V23, P556, DOI 10.1016/j.tcb.2013.06.002; Parrilla A, 2016, CELL CYCLE, V15, P3177, DOI 10.1080/15384101.2016.1249544; Qadri I, 2011, BMC MICROBIOL, V11, DOI 10.1186/1471-2180-11-48; Qiao L, 2001, HEPATOLOGY, V34, P906, DOI 10.1053/jhep.2001.28886; Quetier I, 2015, J GEN VIROL, V96, P614, DOI 10.1099/vir.0.070680-0; Quetier I, 2013, J HEPATOL, V59, P285, DOI 10.1016/j.jhep.2013.03.021; Rakotomalala L, 2008, J BIOL CHEM, V283, P28729, DOI 10.1074/jbc.M802751200; Schmit TL, 2007, MOL CANCER THER, V6, P1920, DOI 10.1158/1535-7163.MCT-06-0781; Studach L, 2010, J BIOL CHEM, V285, P30282, DOI 10.1074/jbc.M109.093963; Studach LL, 2009, HEPATOLOGY, V50, P414, DOI 10.1002/hep.22996; Tarn C, 2002, J VIROL, V76, P9763, DOI 10.1128/JVI.76.19.9763-9772.2002; Tormos AM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171738; Toyoda H, 2005, GUT, V54, P297, DOI 10.1136/gut.2004.043893; Wang C, 2012, HEPATOLOGY, V55, P108, DOI 10.1002/hep.24675; Wang SN, 2012, EUR J CLIN INVEST, V42, P1295, DOI 10.1111/eci.12003; Wang YL, 2016, ONCOTARGET, V7, P11284, DOI 10.18632/oncotarget.7022; Wong VWS, 2009, INT J CANCER, V124, P2766, DOI 10.1002/ijc.24281; Wu BK, 2006, BIOCHEM BIOPH RES CO, V340, P916, DOI 10.1016/j.bbrc.2005.12.089; Yun C, 2004, MOL CANCER RES, V2, P159	45	21	25	0	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2019	38	14					2645	2657		10.1038/s41388-018-0607-3	http://dx.doi.org/10.1038/s41388-018-0607-3			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HR7LI	30538294				2022-12-28	WOS:000463335200014
J	Nishimura, T; Nakata, A; Chen, XX; Nishi, K; Meguro-Horike, M; Sasaki, S; Kita, K; Horike, S; Saitoh, K; Kato, K; Igarashi, K; Murayama, T; Kohno, S; Takahashi, C; Mukaida, N; Yano, SJ; Soga, T; Tojo, A; Gotoh, N				Nishimura, Tatsunori; Nakata, Asuka; Chen, Xiaoxi; Nishi, Kurumi; Meguro-Horike, Makiko; Sasaki, Soichiro; Kita, Kenji; Horike, Shin-ichi; Saitoh, Kaori; Kato, Keiko; Igarashi, Kaori; Murayama, Takahiko; Kohno, Susumu; Takahashi, Chiaki; Mukaida, Naofumi; Yano, Seiji; Soga, Tomoyoshi; Tojo, Arinobu; Gotoh, Noriko			Cancer stem-like properties and gefitinib resistance are dependent on purine synthetic metabolism mediated by the mitochondrial enzyme MTHFD2	ONCOGENE			English	Article							CELL LUNG-CANCER; TUMOR-INITIATING CELLS; METHYLENETETRAHYDROFOLATE DEHYDROGENASE; ACQUIRED-RESISTANCE; GLYCINE; AMPK; GROWTH; SERINE; MAINTENANCE; MECHANISMS	Tumor recurrence is attributable to cancer stem-like cells (CSCs), the metabolic mechanisms of which currently remain obscure. Here, we uncovered the critical role of folate-mediated one-carbon (1C) metabolism involving mitochondrial methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) and its downstream purine synthesis pathway. MTHFD2 knockdown greatly reduced tumorigenesis and stem-like properties, which were associated with purine nucleotide deficiency, and caused marked accumulation of 5-aminoimidazole carboxamide ribonucleotide (AICAR)-the final intermediate of the purine synthesis pathway. Lung cancer cells with acquired resistance to the targeted drug gefitinib, caused by elevated expression of components of the beta-catenin pathway, exhibited increased stem-like properties and enhanced expression of MTHFD2. MTHFD2 knockdown or treatment with AICAR reduced the stem-like properties and restored gefitinib sensitivity in these gefitinib-resistant cancer cells. Moreover, overexpression of MTHFD2 in gefitinib-sensitive lung cancer cells conferred resistance to gefitinib. Thus, MTHFD2-mediated mitochondrial 1C metabolism appears critical for cancer stem-like properties and resistance to drugs including gefitinib through consumption of AICAR, leading to depletion of the intracellular pool of AICAR. Because CSCs are dependent on MTHFD2, therapies targeting MTHFD2 may eradicate tumors and prevent recurrence.	[Nishimura, Tatsunori; Nakata, Asuka; Chen, Xiaoxi; Nishi, Kurumi; Gotoh, Noriko] Kanazawa Univ, Canc Res Inst, Div Canc Cell Biol, Kanazawa, Ishikawa 9201192, Japan; [Meguro-Horike, Makiko; Horike, Shin-ichi] Kanazawa Univ, Adv Sci Res Ctr, Div Funct Genom, Kanazawa, Ishikawa 9201192, Japan; [Sasaki, Soichiro; Mukaida, Naofumi] Kanazawa Univ, Canc Res Inst, Div Mol Bioregulat, Kanazawa, Ishikawa 9201192, Japan; [Kita, Kenji; Yano, Seiji] Kanazawa Univ, Canc Res Inst, Div Med Oncol, 13-1 Takaramachi, Kanazawa, Ishikawa 9200934, Japan; [Saitoh, Kaori; Kato, Keiko; Igarashi, Kaori; Soga, Tomoyoshi] Keio Univ, Inst Adv Biosci, 246-2 Minakami, Tsuruoka, Yamagata 9970052, Japan; [Murayama, Takahiko; Tojo, Arinobu; Gotoh, Noriko] Univ Tokyo, Inst Med Sci, Div Mol Therapy, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan; [Kohno, Susumu; Takahashi, Chiaki] Kanazawa Univ, Canc Res Inst, Div Oncol & Mol Biol, Kanazawa, Ishikawa 9201192, Japan	Kanazawa University; Kanazawa University; Kanazawa University; Kanazawa University; Keio University; University of Tokyo; Kanazawa University	Gotoh, N (corresponding author), Kanazawa Univ, Canc Res Inst, Div Canc Cell Biol, Kanazawa, Ishikawa 9201192, Japan.; Gotoh, N (corresponding author), Univ Tokyo, Inst Med Sci, Div Mol Therapy, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	ngotoh@staff.kanazawa-u.ac.jp	GOTOH, Noriko/D-8430-2015; KITA, Kenji/D-8437-2015; Mukaida, Naofumi/D-7623-2011	KITA, Kenji/0000-0002-4622-6633; Murayama, Takahiko/0000-0003-0764-8646; Mukaida, Naofumi/0000-0002-4193-1851	Extramural Collaborative Research Grant from the Cancer Research Institute, Kanazawa University; MEXT [22130009]; JSPS [15H04294, 17K19587, 17K15021]; AMED Project for Development of Innovative Research on Cancer Therapeutics	Extramural Collaborative Research Grant from the Cancer Research Institute, Kanazawa University; MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); AMED Project for Development of Innovative Research on Cancer Therapeutics	We thank H. Miyoshi for his kind gift of pCMV-VSV-G-RSV-Rev and pCAG-HIVgp and J. Yokota and T. Kohno for their kind gift of lung cancer cell lines. We are grateful to K. Kitamura and Y. Tanabe for their technical assistance. This work was supported in part by an Extramural Collaborative Research Grant from the Cancer Research Institute, Kanazawa University, Hokkoku Gan-Kikin, a Grant-in-Aid for Scientific Research on Innovative Areas from MEXT (22130009), a Grant-in-Aid for Scientific Research (B) from JSPS (15H04294, 17K19587), and a research grant from AMED Project for Development of Innovative Research on Cancer Therapeutics to NG. This work was supported in part by a Grant-in-Aid for Scientific Research for Young Scientists (B) from JSPS (17K15021) to TN.	Ablett MP, 2012, EUR J CANCER, V48, P2104, DOI 10.1016/j.ejca.2012.03.019; Amelio I, 2014, TRENDS BIOCHEM SCI, V39, P191, DOI 10.1016/j.tibs.2014.02.004; Arnold K, 2006, BIOINFORMATICS, V22, P195, DOI 10.1093/bioinformatics/bti770; Biasini M, 2014, NUCLEIC ACIDS RES, V42, pW252, DOI 10.1093/nar/gku340; Bordoli L, 2009, NAT PROTOC, V4, P1, DOI 10.1038/nprot.2008.197; Camidge DR, 2014, NAT REV CLIN ONCOL, V11, P473, DOI 10.1038/nrclinonc.2014.104; Carling D, 2017, CURR OPIN CELL BIOL, V45, P31, DOI 10.1016/j.ceb.2017.01.005; Chae HD, 2012, STEM CELLS, V30, P140, DOI 10.1002/stem.778; Christensen KE, 2005, J BIOL CHEM, V280, P34316, DOI 10.1074/jbc.M505210200; Di Pietro E, 2002, MOL CELL BIOL, V22, P4158, DOI 10.1128/MCB.22.12.4158-4166.2002; Ducker GS, 2016, CELL METAB, V23, P1140, DOI 10.1016/j.cmet.2016.04.016; Engelman JA, 2008, CLIN CANCER RES, V14, P2895, DOI 10.1158/1078-0432.CCR-07-2248; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; Gotoh N, 2011, CANC STEM CELLS THEO, P261; Guo DL, 2009, P NATL ACAD SCI USA, V106, P12932, DOI 10.1073/pnas.0906606106; Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311; Hinohara K, 2012, P NATL ACAD SCI USA, V109, P6584, DOI 10.1073/pnas.1113271109; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Hussein HA, 2015, NUCLEIC ACIDS RES, V43, pW436, DOI 10.1093/nar/gkv462; Jain M, 2012, SCIENCE, V336, P1040, DOI 10.1126/science.1218595; Jin L, 2016, ONCOGENE, V35, P3619, DOI 10.1038/onc.2015.447; Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233; Kim D, 2015, NATURE, V520, P363, DOI 10.1038/nature14363; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Korkaya H, 2011, J CLIN INVEST, V121, P3804, DOI 10.1172/JCI57099; Koufaris C, 2016, J PROTEOME RES, V15, P2618, DOI 10.1021/acs.jproteome.6b00188; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Labuschagne CF, 2014, CELL REP, V7, P1248, DOI 10.1016/j.celrep.2014.04.045; Lehtinen L, 2013, ONCOTARGET, V4, P48, DOI 10.18632/oncotarget.756; Liu XN, 2014, P NATL ACAD SCI USA, V111, pE435, DOI 10.1073/pnas.1311121111; Locasale JW, 2013, NAT REV CANCER, V13, P572, DOI 10.1038/nrc3557; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Ma I, 2011, STEM CELL REV REP, V7, P292, DOI 10.1007/s12015-010-9208-4; MEJIA NR, 1985, J BIOL CHEM, V260, P4616; Moran DM, 2014, MOL CANCER THER, V13, P1611, DOI 10.1158/1535-7163.MCT-13-0649; Murayama T, 2016, CANCER RES, V76, P974, DOI 10.1158/0008-5472.CAN-15-2135; Murohashi M, 2010, BRIT J CANCER, V102, P206, DOI 10.1038/sj.bjc.6605468; Nakata A, 2015, SCI REP-UK, V5, DOI 10.1038/srep13076; Nakayama S, 2014, CANCER RES, V74, P5891, DOI 10.1158/0008-5472.CAN-14-0184; Nilsson R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4128; Okayama H, 2012, CANCER RES, V72, P100, DOI 10.1158/0008-5472.CAN-11-1403; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pikman Y, 2016, J EXP MED, V213, P1285, DOI 10.1084/jem.20151574; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Russo A, 2015, ONCOTARGET, V6, P26814, DOI 10.18632/oncotarget.4254; Sebastian C, 2012, CELL, V151, P1185, DOI 10.1016/j.cell.2012.10.047; Shedden K, 2008, NAT MED, V14, P822, DOI 10.1038/nm.1790; Shen BW, 1999, PROTEIN SCI, V8, P1342, DOI 10.1110/ps.8.6.1342; Sheppard NG, 2015, SCI REP-UK, V5, DOI 10.1038/srep15029; SMITH GK, 1990, ARCH BIOCHEM BIOPHYS, V283, P367, DOI 10.1016/0003-9861(90)90656-J; Soga T, 2002, ANAL CHEM, V74, P2233, DOI 10.1021/ac020064n; Soga T, 2003, J PROTEOME RES, V2, P488, DOI 10.1021/pr034020m; Soga T, 2000, ANAL CHEM, V72, P1236, DOI 10.1021/ac990976y; Soga T, 2006, J BIOL CHEM, V281, P16768, DOI 10.1074/jbc.M601876200; Soga T, 2009, ANAL CHEM, V81, P6165, DOI 10.1021/ac900675k; Stewart B., 2014, WORLD CANC REPORT, P630; Suski M, 2017, EUR J PHARM SCI, V104, P406, DOI 10.1016/j.ejps.2017.04.021; Tibbetts AS, 2010, ANNU REV NUTR, V30, P57, DOI 10.1146/annurev.nutr.012809.104810; Tominaga K, 2017, ONCOGENE, V36, P1276, DOI 10.1038/onc.2016.293; Valent P, 2012, NAT REV CANCER, V12, P767, DOI 10.1038/nrc3368; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Wang XX, 2017, NAT NEUROSCI, V20, P661, DOI 10.1038/nn.4537; Yamauchi M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043923; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang WC, 2012, CELL, V148, P259, DOI 10.1016/j.cell.2011.11.050	65	41	44	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2019	38	14					2464	2481		10.1038/s41388-018-0589-1	http://dx.doi.org/10.1038/s41388-018-0589-1			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HR7LI	30532069	Green Published, hybrid			2022-12-28	WOS:000463335200003
J	Chong, YC; Lim, TE; Fu, YY; Shin, EM; Tergaonkar, V; Han, WP				Chong, Yong Chun; Lim, Tau En; Fu, Yanyun; Shin, Eun Myoung; Tergaonkar, Vinay; Han, Weiping			Indian Hedgehog links obesity to development of hepatocellular carcinoma	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; HEPATIC STELLATE CELLS; PATHWAY ACTIVATION; WNT/BETA-CATENIN; C-MYC; LIVER; CANCER; FIBROSIS; ROLES; SHH	Obesity increases the risk of hepatocellular carcinoma (HCC), but precise identification and characterization of druggable oncogenic pathways that contribute to the progression of NAFLD to HCC, and hence to the increased incidence and aggressiveness of HCC in obese individuals is lacking. In this regard, we demonstrate that the Indian Hedgehog (Ihh) signaling pathway is upregulated in the fatty livers of mice consuming a high fat diet, and furthermore sustained in HCC tumors specifically within the context of a NAFLD microenvironment. Using a diet-induced mouse model of HCC wherein only obese mice develop HCC, targeted ablation of hepatocyte-secreted Ihh results in a decreased tumor burden and lower grade tumors. Ihh activation regulates the transdifferentiation of ciliated stellate cells and proliferation of Epcam(+) ductal cells to promote fibrosis. Mechanistically, increased expression of hitherto uncharacterized effectors of Hh pathway, namely Myc and Tgf-beta 2 is critical to the observed physiology. This pro-tumorigenic response is driven by increased expression of Wnt5a to effect a poorly-differentiated and invasive tumor phenotype. Wnt5a secreted from activated stellate cells act on Ror2-expressing hepatocytes. We further demonstrate that Wnt5a expression is also elevated in poorly-differentiated HCC cells, suggesting that these ligands are also able to function in an autocrine positive feedback manner to sustain poorly-differentiated tumors. Taken together, our study provides a mechanistic understanding for how Ihh signaling promotes HCC tumorigenesis specifically in obese mice. We propose that therapeutic targeting of the Hh pathway offers benefit for patients with dietary / NAFLD-driven steatotic HCC.	[Chong, Yong Chun; Lim, Tau En; Fu, Yanyun; Han, Weiping] ASTAR, Singapore Bioimaging Consortium, Lab Metab Med, Singapore, Singapore; [Shin, Eun Myoung] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore; [Shin, Eun Myoung; Tergaonkar, Vinay; Han, Weiping] ASTAR, Inst Mol & Cell Biol, Singapore, Singapore; [Tergaonkar, Vinay; Han, Weiping] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore, Singapore; [Tergaonkar, Vinay] Univ South Australia, Ctr Canc Biol, Adelaide, SA, Australia; [Tergaonkar, Vinay] SA Pathol, Adelaide, SA, Australia	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Bioengineering & Bioimaging (IBB); A*STAR - Singapore Bioimaging Consortium (SBIC); National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Centre for Cancer Biology; University of South Australia; SA Pathology	Han, WP (corresponding author), ASTAR, Singapore Bioimaging Consortium, Lab Metab Med, Singapore, Singapore.; Han, WP (corresponding author), ASTAR, Inst Mol & Cell Biol, Singapore, Singapore.; Han, WP (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore, Singapore.	Weiping_Han@sbic.a-star.edu.sg		Chong, Yong Chun/0000-0001-9664-1715	A*STAR Biomedical Research Council [OFYIRG17may044]; National Medical Research Council, Singapore	A*STAR Biomedical Research Council(Agency for Science Technology & Research (A*STAR)); National Medical Research Council, Singapore(National Medical Research Council, SingaporeUK Research & Innovation (UKRI)Medical Research Council UK (MRC))	WH is supported by intramural funding from the A*STAR Biomedical Research Council. YCC is supported by a Young Individual Research Grant (OFYIRG17may044) from the National Medical Research Council, Singapore.	Ahn S, 2004, CELL, V118, P505, DOI 10.1016/j.cell.2004.07.023; Akinyemiju T, 2017, JAMA ONCOL, V3, P1683, DOI 10.1001/jamaoncol.2017.3055; Axelson M, 2013, CLIN CANCER RES, V19, P2289, DOI 10.1158/1078-0432.CCR-12-1956; Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Bai CB, 2002, DEVELOPMENT, V129, P4753; Bajenaru ML, 2002, MOL CELL BIOL, V22, P5100, DOI 10.1128/MCB.22.14.5100-5113.2002; Bijlsma MF, 2008, EXP BIOL MED, V233, P989, DOI 10.3181/0711-RM-307; Bitgood MJ, 1996, CURR BIOL, V6, P298, DOI 10.1016/S0960-9822(02)00480-3; Blaner WS, 2009, BBA-MOL CELL BIOL L, V1791, P467, DOI 10.1016/j.bbalip.2008.11.001; Cairo S, 2008, CANCER CELL, V14, P471, DOI 10.1016/j.ccr.2008.11.002; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Calle EE, 2004, NAT REV CANCER, V4, P579, DOI 10.1038/nrc1408; Casey D, 2017, CLIN CANCER RES, V23, P2377, DOI 10.1158/1078-0432.CCR-16-2051; Choi SS, 2011, INT J BIOCHEM CELL B, V43, P238, DOI 10.1016/j.biocel.2010.10.015; Choi SS, 2009, AM J PHYSIOL-GASTR L, V297, pG1093, DOI 10.1152/ajpgi.00292.2009; Corbit KC, 2005, NATURE, V437, P1018, DOI 10.1038/nature04117; Czech MP, 2017, NAT MED, V23, P804, DOI 10.1038/nm.4350; Debebe A, 2017, ONCOGENE, V36, P6020, DOI 10.1038/onc.2017.207; Dohi T, 2012, J LEUKOCYTE BIOL, V92, P265, DOI 10.1189/jlb.0112042; Fabian SL, 2012, AM J PATHOL, V180, P1441, DOI 10.1016/j.ajpath.2011.12.039; Fabregat I, 2016, FEBS J, V283, P2219, DOI 10.1111/febs.13665; Fendrich V, 2008, GASTROENTEROLOGY, V135, P621, DOI 10.1053/j.gastro.2008.04.011; Feng L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038400; Font-Burgada J, 2016, CELL METAB, V23, P48, DOI 10.1016/j.cmet.2015.12.015; Friedman SL, 2008, PHYSIOL REV, V88, P125, DOI 10.1152/physrev.00013.2007; Gujral TS, 2014, CELL, V159, P844, DOI 10.1016/j.cell.2014.10.032; Hassan MM, 2015, GASTROENTEROLOGY, V149, P119, DOI 10.1053/j.gastro.2015.03.044; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jung IH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027941; Kaposi-Novak P, 2009, CANCER RES, V69, P2775, DOI 10.1158/0008-5472.CAN-08-3357; Kim J, 2009, P NATL ACAD SCI USA, V106, P21666, DOI 10.1073/pnas.0912180106; Lodato F, 2006, WORLD J GASTROENTERO, V12, P7239, DOI 10.3748/wjg.v12.i45.7239; Long FX, 2001, DEVELOPMENT, V128, P5099; Loo TM, 2017, CANCER DISCOV, V7, P522, DOI 10.1158/2159-8290.CD-16-0932; Luga V, 2012, CELL, V151, P1542, DOI 10.1016/j.cell.2012.11.024; Mehlem A, 2013, NAT PROTOC, V8, P1149, DOI 10.1038/nprot.2013.055; Monga SP, 2015, GASTROENTEROLOGY, V148, P1294, DOI 10.1053/j.gastro.2015.02.056; Novoyatleva T, 2013, BASIC RES CARDIOL, V108, DOI 10.1007/s00395-012-0325-x; Omenetti A, 2008, J CLIN INVEST, V118, P3331, DOI 10.1172/JCI35875; Park EJ, 2010, CELL, V140, P197, DOI 10.1016/j.cell.2009.12.052; Peng T, 2015, NATURE, V526, P578, DOI 10.1038/nature14984; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Potter JJ, 1999, LIVER, V19, P135, DOI 10.1111/j.1478-3231.1999.tb00023.x; Razzaque MS, 2005, J PATHOL, V207, P453, DOI 10.1002/path.1870; Rohatgi R, 2007, SCIENCE, V317, P372, DOI 10.1126/science.1139740; Schlange T, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1769; Schuppan D, 2008, LANCET, V371, P838, DOI 10.1016/S0140-6736(08)60383-9; Shin K, 2011, NATURE, V472, P110, DOI 10.1038/nature09851; Stewart GA, 2003, J PATHOL, V199, P488, DOI 10.1002/path.1295; Swiderska-Syn M, 2014, GUT, V63, P1333, DOI 10.1136/gutjnl-2013-305962; Szczepny A, 2017, ONCOGENE, V36, P5544, DOI 10.1038/onc.2017.173; Teglund S, 2010, BBA-REV CANCER, V1805, P181, DOI 10.1016/j.bbcan.2010.01.003; Tirnitz-Parker JEE, 2007, INT J BIOCHEM CELL B, V39, P2226, DOI 10.1016/j.biocel.2007.06.008; Velazquez RF, 2003, HEPATOLOGY, V37, P520, DOI 10.1053/jhep.2003.50093; VESSELINOVITCH SD, 1983, CANCER RES, V43, P4253; Wang XB, 2016, CELL METAB, V24, P848, DOI 10.1016/j.cmet.2016.09.016; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Williams MJ, 2014, GASTROENTEROLOGY, V146, P349, DOI 10.1053/j.gastro.2013.11.034; Yuzugullu H, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-90; Zhang XM, 2001, CELL, V105, P781, DOI 10.1016/S0092-8674(01)00385-3	60	17	17	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2019	38	12					2206	2222		10.1038/s41388-018-0585-5	http://dx.doi.org/10.1038/s41388-018-0585-5			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP6UR	30470823				2022-12-28	WOS:000461822600015
J	Zhang, CY; Wang, HM; Liu, XM; Hu, YP; Ding, L; Zhang, X; Sun, QL; Li, YL				Zhang, Caiyan; Wang, Huimin; Liu, Xiaomin; Hu, Yanping; Ding, Lei; Zhang, Xing; Sun, Qiangling; Li, Yanli			Oncogenic microRNA-411 promotes lung carcinogenesis by directly targeting suppressor genes SPRY4 and TXNIP	ONCOGENE			English	Article							PROSTATE-CANCER CELLS; DOWN-REGULATION; STEM-CELLS; SPROUTY4; PROLIFERATION; MIGRATION; INVASION; PATHWAY; CONTRIBUTES; METHYLATION	Lung cancer is one of the most common malignant diseases globally, composed of non-small cell lung cancer (NSCLC, 85%) and small cell lung cancer (SCLC, 15%). MicroRNAs (miRNAs) are single-stranded noncoding RNAs having important roles in lung cancer development. miR-411-5p/3p were reported to be increased significantly in human NSCLC tissues and cell lines. Moreover, miR-411-5p/3p overexpression could accelerate cell proliferation and migration, and impede cell apoptosis in NSCLC cell lines. Mechanically, SPRY4 is confirmed a direct target of miR-411-5p/3p. Furthermore, our findings showed that miR-411-5p/3p promoted lung tumor growth in vivo, decreased SPRY4 expression dramatically, and induced EGFR, AKT signaling activation, as well as epithelial-mesenchymal transition (EMT) simultaneously in tumor tissues. In addition, we showed that miR-411-5p also targeted tumor suppressor TXNIP, involved in regulating positively cell cycle progress in SPC-A1 cells rather than in H1299. Whether cell specificity of low TXNIP mRNA level in H1299 is responsible for the different response to cell cycle between H1299 and SPC-A1 would need further explorations. Collectively, these results suggest that miR-411-5p/3p are required for NSCLC development by suppressing SPRY4 and TXNIP; thus, the miR-411-SPRY4-AKT axis might act as a promising target for lung cancer therapy clinically.	[Zhang, Caiyan; Wang, Huimin; Hu, Yanping; Ding, Lei; Li, Yanli] Shanghai Univ, Sch Life Sci, Lab Noncoding RNA & Canc, Shanghai 200444, Peoples R China; [Liu, Xiaomin; Zhang, Xing] Shanghai Univ, Sch Environm Sci & Engn, Shanghai 200444, Peoples R China; [Hu, Yanping] China Pharmaceut Univ, Sch Life Sci & Technol, Nanjing 210009, Jiangsu, Peoples R China; [Sun, Qiangling] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Cent Lab, Shanghai 200030, Peoples R China	Shanghai University; Shanghai University; China Pharmaceutical University; Shanghai Jiao Tong University	Li, YL (corresponding author), Shanghai Univ, Sch Life Sci, Lab Noncoding RNA & Canc, Shanghai 200444, Peoples R China.	liyanli@shu.edu.cn	li, yanli/AAT-2012-2021; wang, hui/GRS-4730-2022; wang, huimin/HDM-8421-2022	li, yanli/0000-0002-2936-0339; DING, LEI/0000-0001-9556-9635; Zhang, Xing/0000-0003-4680-5085	NNSFC (National Natural Science Foundation of China) [91543123]	NNSFC (National Natural Science Foundation of China)(National Natural Science Foundation of China (NSFC))	This work is supported by NNSFC (National Natural Science Foundation of China, Training Program of the Major Research Plan) No. 91543123	Baranwal S, 2010, INT J CANCER, V126, P1283, DOI 10.1002/ijc.25014; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bisson I, 2009, CELL RES, V19, P683, DOI 10.1038/cr.2009.43; Carter CA, 2016, CASE REP ONCOL, V9, P62, DOI 10.1159/000443725; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Chen MW, 2017, CANCER RES, V77, P1955, DOI 10.1158/0008-5472.CAN-16-1115; Cherni I, 2011, FUTURE ONCOL, V7, P1045, DOI [10.2217/fon.11.74, 10.2217/FON.11.74]; Djuranovic S, 2011, SCIENCE, V331, P550, DOI 10.1126/science.1191138; Guo LF, 2016, MOL MED REP, V14, P2975, DOI 10.3892/mmr.2016.5645; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Heinrich EM, 2012, CIRC RES, V110, P1014, DOI 10.1161/CIRCRESAHA.111.243394; Hwang HW, 2006, BRIT J CANCER, V94, P776, DOI 10.1038/sj.bjc.6603023; Jiang L, 2016, INFLAMM RES, V65, P905, DOI 10.1007/s00011-016-0973-7; Jing HY, 2016, CANCER CELL INT, V16, DOI 10.1186/s12935-016-0292-7; Jovanovic M, 2006, ONCOGENE, V25, P6176, DOI 10.1038/sj.onc.1209912; Leeksma OC, 2002, EUR J BIOCHEM, V269, P2546, DOI 10.1046/j.1432-1033.2002.02921.x; Li YL, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.50; Li Yan, 2015, Asian Pac J Cancer Prev, V16, P2953; Mason JM, 2006, TRENDS CELL BIOL, V16, P45, DOI 10.1016/j.tcb.2005.11.004; Mazieres J, 2005, CANCER LETT, V222, P1, DOI 10.1016/j.canlet.2004.08.040; Nadal E, 2014, CLIN CANCER RES, V20, P3107, DOI 10.1158/1078-0432.CCR-13-3348; Nie WW, 2015, ONCOTARGET, V6, P3003, DOI 10.18632/oncotarget.3096; Peter ME, 2010, CELL STEM CELL, V6, P4, DOI 10.1016/j.stem.2009.12.006; Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704; Sasaki A, 2003, NAT CELL BIOL, V5, P427, DOI 10.1038/ncb978; Scrima M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030427; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; So WK, 2016, TUMOR BIOL, V37, P9197, DOI 10.1007/s13277-016-4790-y; Spangle JM, 2016, CELL REP, V15, P2692, DOI 10.1016/j.celrep.2016.05.046; Sun M, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.225; Tennis MA, 2010, MOL CANCER RES, V8, P833, DOI 10.1158/1541-7786.MCR-09-0400; van Schooneveld E, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3127; Vanas V, 2014, TUMOR BIOL, V35, P4447, DOI 10.1007/s13277-013-1587-0; Wang GD, 2015, AM J TRANSL RES, V7, P2000; Wang JH, 2006, PROSTATE, V66, P613, DOI 10.1002/pros.20353; Wang P, 2017, ONCOTARGET, V8, P57012, DOI 10.18632/oncotarget.18505; Wei M, 2017, ONCOTARGET, V8, P5323, DOI 10.18632/oncotarget.14142; Wu JY, 2017, CANCER LETT, V400, P18, DOI 10.1016/j.canlet.2017.04.021; Xia KK, 2015, BIOMED PHARMACOTHER, V70, P158, DOI 10.1016/j.biopha.2015.01.001; Yamamoto K, 2014, ONCOL REP, V32, P2365, DOI 10.3892/or.2014.3481; Zhang YD, 2016, BIOCHEM BIOPH RES CO, V476, P607, DOI 10.1016/j.bbrc.2016.06.006; Zhao ZJ, 2016, TUMOR BIOL, V37, P5551, DOI 10.1007/s13277-015-4425-8	44	51	51	1	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2019	38	11					1892	1904		10.1038/s41388-018-0534-3	http://dx.doi.org/10.1038/s41388-018-0534-3			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HO7XX	30390072	Green Published, hybrid			2022-12-28	WOS:000461164400008
J	Leong, TL; Gayevskiy, V; Steinfort, DP; De Massy, MR; Gonzalez-Rajal, A; Marini, KD; Stone, E; Chin, V; Havryk, A; Plit, M; Irving, LB; Jennings, BR; McCloy, RA; Jayasekara, WSN; Alamgeer, M; Boolell, V; Field, A; Russell, PA; Kumar, B; Gough, DJ; Szczepny, A; Ganju, V; Rossello, FJ; Cain, JE; Papenfuss, AT; Asselin-Labat, ML; Cowley, MJ; Watkins, DN				Leong, Tracy L.; Gayevskiy, Velimir; Steinfort, Daniel P.; De Massy, Marc R.; Gonzalez-Rajal, Alvaro; Marini, Kieren D.; Stone, Emily; Chin, Venessa; Havryk, Adrian; Plit, Marshall; Irving, Louis B.; Jennings, Barton R.; McCloy, Rachael A.; Jayasekara, W. Samantha N.; Alamgeer, Muhammad; Boolell, Vishal; Field, Andrew; Russell, Prudence A.; Kumar, Beena; Gough, Daniel J.; Szczepny, Anette; Ganju, Vinod; Rossello, Fernando J.; Cain, Jason E.; Papenfuss, Anthony T.; Asselin-Labat, Marie-Liesse; Cowley, Mark J.; Watkins, D. Neil			Deep multi-region whole-genome sequencing reveals heterogeneity and gene-by-environment interactions in treatment-naive, metastatic lung cancer	ONCOGENE			English	Article							INTRATUMOR HETEROGENEITY; MUTATIONAL SIGNATURES; FRAMEWORK; CANCERIZATION; HYPERMUTATION; EPIDEMIOLOGY; EVOLUTIONARY; LANDSCAPE; PROFILES; SMOKING	Our understanding of genomic heterogeneity in lung cancer is largely based on the analysis of early-stage surgical specimens. Here we used endoscopic sampling of paired primary and intrathoracic metastatic tumors from 11 lung cancer patients to map genomic heterogeneity inoperable lung cancer with deep whole-genome sequencing. Intra-patient heterogeneity in driver or targetable mutations was predominantly in the form of copy number gain. Private mutation signatures, including patterns consistent with defects in homologous recombination, were highly variable both within and between patients. Irrespective of histotype, we observed a smaller than expected number of private mutations, suggesting that ancestral clones accumulated large mutation burdens immediately prior to metastasis. Single-region whole-genome sequencing of from 20 patients showed that tumors in ever-smokers with the strongest tobacco signatures were associated with germline variants in genes implicated in the repair of cigarette-induced DNA damage. Our results suggest that lung cancer precursors in ever-smokers accumulate large numbers of mutations prior to the formation of frank malignancy followed by rapid metastatic spread. In advanced lung cancer, germline variants in DNA repair genes may interact with the airway environment to influence the pattern of founder mutations, whereas similar interactions with the tumor microenvironment may play a role in the acquisition of mutations following metastasis.	[Leong, Tracy L.; Asselin-Labat, Marie-Liesse] Walter & Eliza Hall Inst Med Res, ACRF Stem Cells & Canc Div, Parkville, Vic 3050, Australia; [Leong, Tracy L.; Steinfort, Daniel P.; Irving, Louis B.; Asselin-Labat, Marie-Liesse] Univ Melbourne, Dept Med Biol, Parkville, Vic 3050, Australia; [Gayevskiy, Velimir; De Massy, Marc R.; Cowley, Mark J.] Garvan Inst Med Res, Kinghorn Ctr Clin Genom, Darlinghurst, NSW 2010, Australia; [Steinfort, Daniel P.; Irving, Louis B.] Royal Melbourne Hosp, Dept Resp Med, Parkville, Vic 3050, Australia; [Gonzalez-Rajal, Alvaro; Chin, Venessa; McCloy, Rachael A.; Watkins, D. Neil] Garvan Inst Med Res, Kinghorn Canc Ctr, Darlinghurst, NSW 2010, Australia; [Marini, Kieren D.; Stone, Emily; Jayasekara, W. Samantha N.; Alamgeer, Muhammad; Boolell, Vishal; Gough, Daniel J.; Szczepny, Anette; Ganju, Vinod; Cain, Jason E.] Hudson Inst Med Res, Clayton, Vic 3168, Australia; [Stone, Emily; Havryk, Adrian; Plit, Marshall; Watkins, D. Neil] St Vincents Hosp, Dept Thorac Med, Darlinghurst, NSW 2010, Australia; [Chin, Venessa; Havryk, Adrian; Plit, Marshall; Field, Andrew; Cowley, Mark J.; Watkins, D. Neil] UNSW Sydney, St Vincents Clin Sch, Darlinghurst, NSW 2010, Australia; [Chin, Venessa; Watkins, D. Neil] St Vincents Hosp, Dept Med Oncol, Darlinghurst, NSW 2010, Australia; [Jennings, Barton R.] Monash Hlth, Dept Resp & Sleep Med, Clayton, Vic 3168, Australia; [Field, Andrew] St Vincents Hosp, Dept Pathol, Sydney, NSW 2010, Australia; [Russell, Prudence A.] St Vincents Hosp Melbourne, Dept Pathol, Fitzroy, Vic 3000, Australia; [Kumar, Beena] Monash Hlth, Dept Pathol, Clayton, Vic 3168, Australia; [Gough, Daniel J.; Ganju, Vinod; Cain, Jason E.] Monash Univ, Dept Mol & Translat Sci, Fac Med Nursing & Hlth Sci, Clayton, Vic, Australia; [Rossello, Fernando J.] Monash Univ, Dept Anat & Dev Biol, Fac Med Nursing & Hlth Sci, Clayton, Vic 3168, Australia; [Rossello, Fernando J.] Monash Univ, Australian Regenerat Med Inst, Clayton, Vic 3168, Australia; [Papenfuss, Anthony T.] Peter MacCallum Canc Ctr, Computat Canc Biol Program, Melbourne, Vic 3000, Australia; [Papenfuss, Anthony T.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic 3052, Australia; [Papenfuss, Anthony T.] Walter & Eliza Hall Inst Med Res, Bioinformat Div, Parkville, Vic 3052, Australia; [Cowley, Mark J.] Childrens Canc Inst, Kensington, NSW 2750, Australia	Walter & Eliza Hall Institute; University of Melbourne; Garvan Institute of Medical Research; Royal Melbourne Hospital; Garvan Institute of Medical Research; Hudson Institute of Medical Research; St Vincents Hospital Sydney; University of New South Wales Sydney; St Vincents Hospital Sydney; St Vincents Hospital Sydney; St Vincent's Hospital Melbourne; Monash University; Monash University; Australian Regenerative Medicine Institute; Monash University; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne; Walter & Eliza Hall Institute; Children's Cancer Institute	Asselin-Labat, ML (corresponding author), Walter & Eliza Hall Inst Med Res, ACRF Stem Cells & Canc Div, Parkville, Vic 3050, Australia.; Asselin-Labat, ML (corresponding author), Univ Melbourne, Dept Med Biol, Parkville, Vic 3050, Australia.; Cowley, MJ (corresponding author), Garvan Inst Med Res, Kinghorn Ctr Clin Genom, Darlinghurst, NSW 2010, Australia.; Watkins, DN (corresponding author), Garvan Inst Med Res, Kinghorn Canc Ctr, Darlinghurst, NSW 2010, Australia.; Watkins, DN (corresponding author), St Vincents Hosp, Dept Thorac Med, Darlinghurst, NSW 2010, Australia.; Cowley, MJ; Watkins, DN (corresponding author), UNSW Sydney, St Vincents Clin Sch, Darlinghurst, NSW 2010, Australia.; Watkins, DN (corresponding author), St Vincents Hosp, Dept Med Oncol, Darlinghurst, NSW 2010, Australia.; Cowley, MJ (corresponding author), Childrens Canc Inst, Kensington, NSW 2750, Australia.	labat@wehi.edu.au; m.cowley@garvan.org.au; dr.neil.watkins@gmail.com	Rossello, Fernando/B-1208-2015; Papenfuss, Anthony T/C-6297-2008; Stone, Emily/AAP-1249-2021; Steinfort, Daniel/AAO-6898-2020; Gonzalez-Rajal, Alvaro/ABA-6874-2020; Alamgeer, Muhammad/AAM-4784-2021; Stone, Emily/GZL-2451-2022	Rossello, Fernando/0000-0003-3885-8777; Papenfuss, Anthony T/0000-0002-1102-8506; Stone, Emily/0000-0001-9021-8449; Steinfort, Daniel/0000-0002-8998-2949; Gonzalez-Rajal, Alvaro/0000-0002-9230-0339; McCloy, Rachael/0000-0001-7791-4044; Cowley, Mark/0000-0002-9519-5714; Robert de Massy, Marc/0000-0002-3048-1680; Gough, Daniel/0000-0001-5725-8668; Watkins, Neil/0000-0001-8218-4920; Chin, Venessa/0000-0002-4630-4451; Gough, Daniel/0000-0001-6479-1735	Victorian Cancer Agency [TS10-01]; Petre Foundation; Victorian Government's Operational Infrastructure Support Program; Baxter Charitable Foundation; St Vincent's Clinic Foundation; Tour de Cure; Australian Government NHMRC IRIISS; Victorian State Government Operational Infrastructure Support; Australian Cancer Therapeutics CRC; Australian Cancer Research Foundation; NHMRC Career Development Fellowship [GNT1063914]; Victoria Cancer Agency Mid-Career Fellowship [MCRF17014]; Viertel Foundation Senior Medical Researcher Fellowship; Cancer Institute NSW Early Career Fellowship [13ECF/1-46]; NSW Health Early-Mid-Career Fellowship; Kinghorn Foundation; NHMRC Senior Research Fellowship [GNT546107]	Victorian Cancer Agency; Petre Foundation; Victorian Government's Operational Infrastructure Support Program; Baxter Charitable Foundation; St Vincent's Clinic Foundation; Tour de Cure; Australian Government NHMRC IRIISS(National Health and Medical Research Council (NHMRC) of Australia); Victorian State Government Operational Infrastructure Support; Australian Cancer Therapeutics CRC; Australian Cancer Research Foundation; NHMRC Career Development Fellowship(National Health and Medical Research Council (NHMRC) of Australia); Victoria Cancer Agency Mid-Career Fellowship; Viertel Foundation Senior Medical Researcher Fellowship; Cancer Institute NSW Early Career Fellowship; NSW Health Early-Mid-Career Fellowship; Kinghorn Foundation; NHMRC Senior Research Fellowship(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by the Victorian Cancer Agency, (TS10-01), the Petre Foundation, the Victorian Government's Operational Infrastructure Support Program, the Baxter Charitable Foundation, the St Vincent's Clinic Foundation, Tour de Cure, the Australian Government NHMRC IRIISS, the Victorian State Government Operational Infrastructure Support, the Australian Cancer Therapeutics CRC (TLL), the Australian Cancer Research Foundation, an NHMRC Career Development Fellowship (GNT1063914, DJG), a Victoria Cancer Agency Mid-Career Fellowship (MCRF17014, JEC), a Viertel Foundation Senior Medical Researcher Fellowship (M-LA-L), a Cancer Institute NSW Early Career Fellowship (13ECF/1-46) and NSW Health Early-Mid-Career Fellowship (MJC), the Kinghorn Foundation (MJC, VG), and an NHMRC Senior Research Fellowship (GNT546107, DNW). We thank the Victorian Cancer Biobank for technical support.	Adamo P, 2016, ONCOGENE, V35, P403, DOI 10.1038/onc.2015.109; Alexandrov LB, 2016, SCIENCE, V354, P618, DOI 10.1126/science.aag0299; Alioto TS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10001; Amirouchene-Angelozzi N, 2017, CANCER DISCOV, V7, P805, DOI 10.1158/2159-8290.CD-17-0343; Bakhoum SF, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a029611; Campbell BB, 2017, CELL, V171, P1042, DOI 10.1016/j.cell.2017.09.048; Cancer Genome Atlas Research Network, 2014, Nature, V511, P543, DOI [10.1038/s41586-018-0228-6, 10.1038/nature13385]; Cardarella S, 2013, AM J RESP CRIT CARE, V188, P770, DOI 10.1164/rccm.201305-0843PP; Chansky K, 2017, J THORAC ONCOL, V12, P1109, DOI 10.1016/j.jtho.2017.04.011; Chaudhuri J, 2004, NATURE, V430, P992, DOI 10.1038/nature02821; Chen X, 2014, CELL REP, V7, P104, DOI 10.1016/j.celrep.2014.03.003; Chen XY, 2016, BIOINFORMATICS, V32, P1220, DOI 10.1093/bioinformatics/btv710; Detterbeck FC, 2009, CHEST, V136, P260, DOI 10.1378/chest.08-0978; Favero F, 2015, ANN ONCOL, V26, P64, DOI 10.1093/annonc/mdu479; Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gayevskiy V, 2019, BIOINFORMATICS, V35, P122, DOI 10.1093/bioinformatics/bty540; Gehring JS, 2015, BIOINFORMATICS, V31, P3673, DOI 10.1093/bioinformatics/btv408; George J, 2015, NATURE, V524, P47, DOI 10.1038/nature14664; Gonzalez-Perez A, 2013, NAT METHODS, V10, P1081, DOI [10.1038/NMETH.2642, 10.1038/nmeth.2642]; Grainge CL, 2013, CHEST, V144, P1906, DOI 10.1378/chest.12-1944; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Houghton AM, 2013, NAT REV CANCER, V13, P233, DOI 10.1038/nrc3477; Jakubek Y, 2016, CANCER RES, V76, P3676, DOI 10.1158/0008-5472.CAN-15-3064; Jamal-Hanjani M, 2017, NEW ENGL J MED, V376, P2109, DOI 10.1056/NEJMoa1616288; Jin XR, 2017, ONCOTARGET, V8, P23130, DOI 10.18632/oncotarget.15506; Kadara H, 2016, CANCER PREV RES, V9, P518, DOI 10.1158/1940-6207.CAPR-15-0400; Kadara Humam, 2012, Proc Am Thorac Soc, V9, P38, DOI 10.1513/pats.201201-004MS; Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; Leong TL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106862; Makohon-Moore AP, 2017, NAT GENET, V49, P358, DOI 10.1038/ng.3764; Maley CC, 2017, NAT REV CANCER, V17, P605, DOI 10.1038/nrc.2017.69; McGranahan N, 2015, CANCER CELL, V27, P15, DOI 10.1016/j.ccell.2014.12.001; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; McLaren W, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0974-4; Meienberg J, 2016, HUM GENET, V135, P359, DOI 10.1007/s00439-015-1631-9; Nahar R, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02584-z; Reiter JG, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14114; Samet JM, 2009, CLIN CANCER RES, V15, P5626, DOI 10.1158/1078-0432.CCR-09-0376; Saunders CT, 2012, BIOINFORMATICS, V28, P1811, DOI 10.1093/bioinformatics/bts271; Shields PG, 2002, ONCOGENE, V21, P6870, DOI 10.1038/sj.onc.1205832; Shugay M, 2013, BIOINFORMATICS, V29, P2539, DOI 10.1093/bioinformatics/btt445; TheGeneOntologyConsortium, 2017, Nucleic Acids Res, V45, pD331, DOI 10.1093/nar/gkw1108; Turajlic S, 2016, SCIENCE, V352, P169, DOI 10.1126/science.aaf2784; Um SW, 2016, CANCER RES, V76, P6568, DOI 10.1158/0008-5472.CAN-16-0873; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Wiencke JK, 2002, ONCOGENE, V21, P7376, DOI 10.1038/sj.onc.1205799; Wu XF, 2004, ONCOGENE, V23, P6500, DOI 10.1038/sj.onc.1207811; Yu AM, 2016, ONCOTARGET, V7, P28624, DOI 10.18632/oncotarget.8721; Zappasodi R, 2018, CANCER CELL, V33, P581, DOI 10.1016/j.ccell.2018.03.005; Zhang JJ, 2014, SCIENCE, V346, P256, DOI 10.1126/science.1256930	52	13	13	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2019	38	10					1661	1675		10.1038/s41388-018-0536-1	http://dx.doi.org/10.1038/s41388-018-0536-1			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN8DD	30348992	Green Published, hybrid			2022-12-28	WOS:000460423800007
J	Joseph, J; Radulovich, N; Wang, T; Raghavan, V; Zhu, CQ; Tsao, MS				Joseph, Joella; Radulovich, Nikolina; Wang, Tao; Raghavan, Vibha; Zhu, Chang-Qi; Tsao, Ming-Sound			Rho guanine nucleotide exchange factor ARHGEF10 is a putative tumor suppressor in pancreatic ductal adenocarcinoma	ONCOGENE			English	Article							UP-REGULATION; LUNG-CANCER; EXPRESSION; KINASE; CELLS; SRC; INHIBITION; GENE; VAV1; OVEREXPRESSION	Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal human cancers, with 5-year patient survival rates of KRAS are the predominant oncogenic drivers of PDAC but are accompanied by additional lower frequency genetic alterations. Our group previously identified the guanine nucleotide exchange factor ARHGEF10 in a genomic screen for genes with copy number alterations that may synergize with oncogenic KRAS to promote PDAC carcinogenesis. In the present study we show that ARHGEF10 possesses putative tumor suppressor function in PDAC. ARHGEF10 expression is reduced in over 70% of PDAC cell lines, and copy number loss is documented in more than 30% of PDAC patient-derived xenografts. Loss of ARHGEF10 expression enhanced subcutaneous tumor growth in mouse models, while its exogenous expression greatly impaired tumorigenesis. Loss of ARHGEF10 expression also increased in vitro proliferation, invasion, and motility of PDAC cell lines, and enhanced their metastatic spread in orthotopic mouse models. Treatment of ARHGEF10-depleted cells with the inhibitor dasatinib reduced levels of phospho Src kinase and attenuated motility and invasion in vitro. Together, our data indicate that ARHGEF10 may function as a tumor suppressor in PDAC.	[Joseph, Joella; Radulovich, Nikolina; Wang, Tao; Raghavan, Vibha; Zhu, Chang-Qi; Tsao, Ming-Sound] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada; [Joseph, Joella; Tsao, Ming-Sound] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Wang, Tao; Tsao, Ming-Sound] Univ Hlth Network, Dept Pathol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Tsao, MS (corresponding author), Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada.; Tsao, MS (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.; Tsao, MS (corresponding author), Univ Hlth Network, Dept Pathol, Toronto, ON, Canada.	ming.tsao@uhn.ca	Tsao, Ming-Sound/M-3503-2017; Tsao, Ming Sound/AFQ-7332-2022	Tsao, Ming Sound/0000-0002-9160-5405	Canadian Cancer Society [700809]; Canadian Institutes of Health Research Foundation Scheme grant [FDN-148395]; Ontario Ministry of Health and Long Term Care; Terry Fox Foundation Training Program in Molecular Pathology of Cancer at CIHR [STP 53912]	Canadian Cancer Society(Canadian Cancer Society (CCS)); Canadian Institutes of Health Research Foundation Scheme grant(Canadian Institutes of Health Research (CIHR)); Ontario Ministry of Health and Long Term Care(Ministry of Health and Long-Term Care, Ontario); Terry Fox Foundation Training Program in Molecular Pathology of Cancer at CIHR(Canadian Institutes of Health Research (CIHR))	We thank Ming Li for his assistance with orthotopic implantation, Jing Xu for her assistance with immunohistochemistry, and Quan Li for his assistance with the analysis of gene expression data. This work was supported by the Canadian Cancer Society grant #700809, the Canadian Institutes of Health Research Foundation Scheme grant FDN-148395, and the Ontario Ministry of Health and Long Term Care. TW was supported by the Terry Fox Foundation Training Program in Molecular Pathology of Cancer at CIHR (STP 53912). Dr Tsao is the M. Qasim Choksi Chair in Lung Cancer Translational Research. The microarray data reported in this paper have been deposited into the Gene Expression Omnibus (GEO) database (accession number GSE131859).	Abr?moff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Adnane J, 2002, CLIN CANCER RES, V8, P2225; Aoki T, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-56; Barrio-Real L, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003543; Bashyam MD, 2005, NEOPLASIA, V7, P556, DOI 10.1593/neo.04586; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Cai YY, 2016, CANCER CELL, V29, P751, DOI 10.1016/j.ccell.2016.04.003; Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu, 2017, Cancer Cell, V32, P185, DOI 10.1016/j.ccell.2017.07.007; Cooke SL, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-288; Furukawa T, 1996, AM J PATHOL, V148, P1763; Harada T, 2008, ONCOGENE, V27, P1951, DOI 10.1038/sj.onc.1210832; Harada T, 2009, PANCREATOLOGY, V9, P13, DOI 10.1159/000178871; Horiuchi A, 2003, LAB INVEST, V83, P861, DOI 10.1097/01.LAB.0000073128.16098.31; Hudson TJ, 2010, NATURE, V464, P993, DOI 10.1038/nature08987; Jin H, 2011, HUM PATHOL, V42, P541, DOI 10.1016/j.humpath.2010.08.013; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kazerounian S, 2013, CANCER RES, V73, P50, DOI 10.1158/0008-5472.CAN-11-3055; Konstantinidou G, 2013, CANCER DISCOV, V3, P444, DOI 10.1158/2159-8290.CD-12-0388; Lazer G, 2009, J PATHOL, V219, P25, DOI 10.1002/path.2579; Liu AX, 2001, P NATL ACAD SCI USA, V98, P6192, DOI 10.1073/pnas.111137198; Lohse I, 2014, CANCERS, V6, P459, DOI 10.3390/cancers6010459; Lopez J, 2012, CELL DEATH DIFFER, V19, P1459, DOI 10.1038/cdd.2012.21; Lutz MP, 1998, BIOCHEM BIOPH RES CO, V243, P503, DOI 10.1006/bbrc.1997.8043; Mak AB, 2010, MOL CELL PROTEOMICS, V9, P811, DOI 10.1074/mcp.M000002-MCP201; Marlow LA, 2009, CANCER RES, V69, P1536, DOI 10.1158/0008-5472.CAN-08-3718; Mazieres J, 2004, CLIN CANCER RES, V10, P2742, DOI 10.1158/1078-0432.CCR-03-0149; Mohl M, 2006, N-S ARCH PHARMACOL, V373, P333, DOI 10.1007/s00210-006-0083-0; Morton JP, 2010, GASTROENTEROLOGY, V139, P292, DOI 10.1053/j.gastro.2010.03.034; Nagaraj NS, 2010, MOL CANCER THER, V9, P2322, DOI 10.1158/1535-7163.MCT-09-1212; Qian JY, 2005, CANCER RES, V65, P5045, DOI 10.1158/0008-5472.CAN-04-3208; Qin J, 2009, ONCOGENE, V28, P1853, DOI 10.1038/onc.2009.30; Radulovich N, 2015, ONCOGENE, V34, P4238, DOI 10.1038/onc.2014.357; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Razidlo GL, 2015, CANCER RES, V75, P2907, DOI 10.1158/0008-5472.CAN-14-3103; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Robles-Valero J, 2017, CANCER CELL, V32, P608, DOI 10.1016/j.ccell.2017.10.004; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Shi HB, 2012, J AM CHEM SOC, V134, P3001, DOI 10.1021/ja208518u; Shields DJ, 2011, ONCOGENE, V30, P2123, DOI 10.1038/onc.2010.589; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Summy JM, 2005, PANCREAS, V31, P263, DOI 10.1097/01.mpa.0000178280.50534.0c; Tan YG, 2015, ONCOTARGET, V6, P17391, DOI 10.18632/oncotarget.3975; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Wang N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105570; Williams SV, 2010, GENE CHROMOSOME CANC, V49, P642, DOI 10.1002/gcc.20775; Witkiewicz AK, 2016, CELL REP, V16, P2017, DOI 10.1016/j.celrep.2016.07.023; Xue W, 2012, P NATL ACAD SCI USA, V109, P8212, DOI 10.1073/pnas.1206062109; Zandvakili I, 2017, ONCOGENE, V36, P3213, DOI 10.1038/onc.2016.473; Zhou JT, 2011, INT J CANCER, V128, P1057, DOI 10.1002/ijc.25445	50	8	8	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	2					308	321		10.1038/s41388-019-0985-1	http://dx.doi.org/10.1038/s41388-019-0985-1			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KD3JY	31477830				2022-12-28	WOS:000507766400005
J	Prokhorova, EA; Egorshina, AY; Zhivotovsky, B; Kopeina, GS				Prokhorova, Evgeniia A.; Egorshina, Aleksandra Yu.; Zhivotovsky, Boris; Kopeina, Gelina S.			The DNA-damage response and nuclear events as regulators of nonapoptotic forms of cell death	ONCOGENE			English	Review							POLY(ADP-RIBOSE) PAR POLYMER; PREMATURE SENESCENCE SIPS; DOMAIN-LIKE PROTEIN; 2 DISTINCT MODES; MITOTIC CATASTROPHE; TUMOR-SUPPRESSOR; MOLECULAR-MECHANISMS; GENOTOXIC STRESS; ONCOGENIC RAS; AUTOPHAGY	The maintenance of genome stability is essential for the cell as the integrity of genomic information guaranties reproduction of a whole organism. DNA damage occurring in response to different natural and nonnatural stimuli (errors in DNA replication, UV radiation, chemical agents, etc.) is normally detected by special cellular machinery that induces DNA repair. However, further accumulation of genetic lesions drives the activation of cell death to eliminate cells with defective genome. This particular feature is used for targeting fast-proliferating tumor cells during chemo-, radio-, and immunotherapy. Among different cell death modalities induced by DNA damage, apoptosis is the best studied. Nevertheless, nonapoptotic cell death and adaptive stress responses are also activated following genotoxic stress and play a crucial role in the outcome of anticancer therapy. Here, we provide an overview of nonapoptotic cell death pathways induced by DNA damage and discuss their interplay with cellular senescence, mitotic catastrophe, and autophagy.	[Prokhorova, Evgeniia A.; Egorshina, Aleksandra Yu.; Zhivotovsky, Boris; Kopeina, Gelina S.] Moscow MV Lomonosov State Univ, Fac Fundamental Med, Moscow 119991, Russia; [Zhivotovsky, Boris] Karolinska Inst, Inst Environm Med, Div Toxicol, Box 210, S-17177 Stockholm, Sweden; [Prokhorova, Evgeniia A.] Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	Lomonosov Moscow State University; Karolinska Institutet; University of Oxford	Zhivotovsky, B; Kopeina, GS (corresponding author), Moscow MV Lomonosov State Univ, Fac Fundamental Med, Moscow 119991, Russia.; Zhivotovsky, B (corresponding author), Karolinska Inst, Inst Environm Med, Div Toxicol, Box 210, S-17177 Stockholm, Sweden.	Boris.Zhivotovsky@ki.se; lirroster@gmail.com	Kopeina, Gelina/AAD-5713-2022; Egorshina, Aleksandra/AAM-7411-2020; Zhivotovsky, Boris/A-4346-2014	Egorshina, Aleksandra/0000-0001-7818-1161; Prokhorova, Evgeniia/0000-0002-5467-5586; Gelina, Kopeina/0000-0002-7143-6923; Zhivotovsky, Boris/0000-0002-2238-3482	Russian Science Foundation [19-15-00125]; Russian Foundation for Basic Research [18-29-09005, 18-015-00211]; Swedish Cancer Society; Swedish Childhood Cancer Foundation; Stockholm Cancer Society	Russian Science Foundation(Russian Science Foundation (RSF)); Russian Foundation for Basic Research(Russian Foundation for Basic Research (RFBR)); Swedish Cancer Society(Swedish Cancer Society); Swedish Childhood Cancer Foundation(European Commission); Stockholm Cancer Society	This work was supported by the Grant from the Russian Science Foundation (19-15-00125). The work in the authors' laboratories is also supported by the Grants from the Russian Foundation for Basic Research (18-29-09005, 18-015-00211), the Swedish and Stockholm Cancer Societies and the Swedish Childhood Cancer Foundation. We apologize to those authors whose primary works could not be cited owing to space limitations.	Acosta JC, 2012, TRENDS CELL BIOL, V22, P211, DOI 10.1016/j.tcb.2011.11.006; Alano CC, 2010, J NEUROSCI, V30, P2967, DOI 10.1523/JNEUROSCI.5552-09.2010; Allocati N, 2012, EXP CELL RES, V318, P1285, DOI 10.1016/j.yexcr.2012.01.023; Allsopp RC, 1996, EXP GERONTOL, V31, P235, DOI 10.1016/0531-5565(95)02008-X; Andersen JL, 2009, EMBO J, V28, P3216, DOI 10.1038/emboj.2009.253; Andrabi SA, 2006, P NATL ACAD SCI USA, V103, P18308, DOI 10.1073/pnas.0606526103; Andrabi SA, 2014, P NATL ACAD SCI USA, V111, P10209, DOI 10.1073/pnas.1405158111; Andrabi SA, 2011, NAT MED, V17, P692, DOI 10.1038/nm.2387; Bae H, 2011, MOL CANCER RES, V9, P1232, DOI 10.1158/1541-7786.MCR-11-0098; Baek SH, 2013, MOL CELLS, V36, P258, DOI 10.1007/s10059-013-0172-0; Batchelor E, 2008, MOL CELL, V30, P277, DOI 10.1016/j.molcel.2008.03.016; Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070; Bianchi-Smiraglia A, 2012, CELL CYCLE, V11, P4147, DOI 10.4161/cc.22589; Biton S, 2011, CELL, V145, P92, DOI 10.1016/j.cell.2011.02.023; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brown JM, 1999, CANCER RES, V59, P1391; Brunyanszki A, 2016, FREE RADICAL BIO MED, V100, P257, DOI 10.1016/j.freeradbiomed.2016.02.024; Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653; Castedo M, 2004, ONCOGENE, V23, P4362, DOI 10.1038/sj.onc.1207572; Castedo M, 2006, EMBO J, V25, P2584, DOI 10.1038/sj.emboj.7601127; Chen JH, 2015, AUTOPHAGY, V11, P239, DOI 10.1080/15548627.2015.1009767; Chen NC, 2016, SCI REP-UK, V6, DOI 10.1038/srep20417; Chen X, 2014, CELL RES, V24, P105, DOI 10.1038/cr.2013.171; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Chen Z, 2009, BBA-BIOENERGETICS, V1787, P553, DOI 10.1016/j.bbabio.2009.03.003; Chiu LY, 2011, BIOCHEM PHARMACOL, V81, P459, DOI 10.1016/j.bcp.2010.10.016; Christmann M, 2013, NUCLEIC ACIDS RES, V41, P8403, DOI 10.1093/nar/gkt635; Christofferson DE, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.64; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Colicchia V, 2017, ONCOGENE, V36, P4682, DOI 10.1038/onc.2017.40; Dantzer F, 2004, MOL CELL BIOL, V24, P1595, DOI 10.1128/MCB.24.4.1595-1607.2004; Dashzeveg N, 2015, CANCER LETT, V367, P108, DOI 10.1016/j.canlet.2015.07.019; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Delgado-Camprubi M, 2016, CELL DEATH DIFFER, V1, P1; Denchi EL, 2007, NATURE, V448, P1068, DOI 10.1038/nature06065; Denisenko TV, 2016, DRUG RESIST UPDATE, V24, P1, DOI 10.1016/j.drup.2015.11.002; di Fagagna FD, 2008, NAT REV CANCER, V8, P512, DOI 10.1038/nrc2440; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Dolle C, 2013, FEBS J, V280, P3530, DOI 10.1111/febs.12304; Dolle C, 2010, CELL MOL LIFE SCI, V67, P433, DOI 10.1007/s00018-009-0190-4; Douglas DL, 2014, J CELL SCI, V127, P4134, DOI 10.1242/jcs.128009; Duursma AM, 2013, MOL CELL, V50, P116, DOI 10.1016/j.molcel.2013.03.006; Eapen VV, 2017, P NATL ACAD SCI USA, V114, pE1158, DOI 10.1073/pnas.1614364114; Eom YW, 2005, ONCOGENE, V24, P4765, DOI 10.1038/sj.onc.1208627; Erdelyi K, 2009, FASEB J, V23, P3553, DOI 10.1096/fj.09-133264; Fatokun AA, 2014, BRIT J PHARMACOL, V171, P2000, DOI 10.1111/bph.12416; Feoktistova M, 2011, MOL CELL, V43, P449, DOI 10.1016/j.molcel.2011.06.011; Ferbeyre G, 2000, GENE DEV, V14, P2015; Fouquerel E, 2014, CELL REP, V8, P1819, DOI 10.1016/j.celrep.2014.08.036; Gagne JP, 2008, NUCLEIC ACIDS RES, V36, P6959, DOI 10.1093/nar/gkn771; Galluzzi L, 2015, CELL DEATH DIFFER, V22, P1237, DOI 10.1038/cdd.2015.54; Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96; Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4; Gao RJ, 2007, BIOMED ENVIRON SCI, V20, P189; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Guo WJ, 2011, CANCER LETT, V312, P55, DOI 10.1016/j.canlet.2011.07.024; Haldar S, 2015, J BIOL CHEM, V290, P6574, DOI 10.1074/jbc.M114.617886; Hanson B, 2016, CANCER BIOL THER, V17, P899, DOI 10.1080/15384047.2016.1210732; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; He Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071562; He Y, 2019, MOL CANCER RES, V17, P1129, DOI 10.1158/1541-7786.MCR-18-1306; Hildebrand JM, 2014, P NATL ACAD SCI USA, V111, P15072, DOI 10.1073/pnas.1408987111; Huang Y, 2005, CANCER RES, V65, P7446, DOI 10.1158/0008-5472.CAN-04-4267; Jakhar R, 2018, MOL CANCER RES, V16, P1625, DOI 10.1158/1541-7786.MCR-18-0024; Jang KH, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.437; Janssen A, 2009, P NATL ACAD SCI USA, V106, P19108, DOI 10.1073/pnas.0904343106; Jeong NY, 2012, INT J ONCOL, V40, P1949, DOI 10.3892/ijo.2012.1401; Jiang L, 2015, NATURE, V520, P57, DOI 10.1038/nature14344; Jing L, 2018, CANCER LETT, V414, P136, DOI 10.1016/j.canlet.2017.10.047; Kang C, 2016, AUTOPHAGY, V12, P898, DOI 10.1080/15548627.2015.1121361; Kang C, 2015, SCIENCE, V349, DOI 10.1126/science.aaa5612; Karakashev S, 2017, CELL REP, V21, P3398, DOI 10.1016/j.celrep.2017.11.095; Karlseder J, 2004, PLOS BIOL, V2, P1150, DOI 10.1371/journal.pbio.0020240; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356; Knizhnik AV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055665; Koh DW, 2004, P NATL ACAD SCI USA, V101, P17699, DOI 10.1073/pnas.0406182101; KUNZ C, 1995, NUCLEIC ACIDS RES, V23, P3710, DOI 10.1093/nar/23.18.3710; Kwok M, 2016, BLOOD, V127, P582, DOI 10.1182/blood-2015-05-644872; LASTER SM, 1988, J IMMUNOL, V141, P2629; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105; Lee SY, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.266; Lescarbeau RS, 2016, MOL CANCER THER, V15, P1332, DOI [10.1158/1535-7163.MCT-15-0692-T, 10.1158/1535-7163.MCT-15-0692]; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; Lin SY, 2018, AUTOPHAGY, V14, P778, DOI 10.1080/15548627.2017.1386359; Linkermann A, 2013, P NATL ACAD SCI USA, V110, P12024, DOI 10.1073/pnas.1305538110; Liu MD, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06556-9; Liu XX, 2011, FEBS LETT, V585, P1363, DOI 10.1016/j.febslet.2011.04.018; Lu JV, 2012, IMMUNOL REV, V249, P205, DOI 10.1111/j.1600-065X.2012.01147.x; Ma K, 2017, AUTOPHAGY, V13, P579, DOI 10.1080/15548627.2016.1272742; Mannava S, 2013, AM J PATHOL, V182, P142, DOI 10.1016/j.ajpath.2012.09.011; Rodriguez-Vargas JM, 2012, CELL RES, V22, P1181, DOI 10.1038/cr.2012.70; Manzl C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.470; Maskey D, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3130; Matt S, 2016, CELL MOL LIFE SCI, V73, P2829, DOI 10.1007/s00018-016-2130-4; Menon MB, 2018, TRENDS BIOCHEM SCI, V43, P170, DOI 10.1016/j.tibs.2017.12.002; Mohammad RM, 2015, SEMIN CANCER BIOL, V35, pS78, DOI 10.1016/j.semcancer.2015.03.001; Morselli E, 2011, CELL CYCLE, V10, P2763, DOI 10.4161/cc.10.16.16868; Munoz-Gomez JA, 2009, AUTOPHAGY, V5, P61, DOI 10.4161/auto.5.1.7272; Nardella C, 2011, NAT REV CANCER, V11, P503, DOI 10.1038/nrc3057; Niere M, 2008, MOL CELL BIOL, V28, P814, DOI 10.1128/MCB.01766-07; Oberst A, 2011, NATURE, V471, P363, DOI 10.1038/nature09852; Okamura H, 2008, J CELL BIOCHEM, V103, P1488, DOI 10.1002/jcb.21537; Orlotti NI, 2012, AUTOPHAGY, V8, P1185, DOI 10.4161/auto.20519; Pietkiewicz S, 2015, J IMMUNOL METHODS, V423, P99, DOI 10.1016/j.jim.2015.04.025; Pietrobono S, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0142-0; Pietrocola F, 2013, SEMIN CANCER BIOL, V23, P310, DOI 10.1016/j.semcancer.2013.05.008; Polo SE, 2011, GENE DEV, V25, P409, DOI 10.1101/gad.2021311; Prokhorova EA, 2015, CELL MOL LIFE SCI, V72, P4593, DOI 10.1007/s00018-015-2031-y; Qian YJ, 2008, J BIOL CHEM, V283, P2896, DOI 10.1074/jbc.M708624200; Qian Yingjuan, 2013, Methods Mol Biol, V965, P37, DOI 10.1007/978-1-62703-239-1_3; Qin SH, 2018, WORLD J CLIN ONCOL, V9, P180, DOI 10.5306/wjco.v9.i8.180; Rao SG, 2016, TRENDS CANCER, V2, P676, DOI 10.1016/j.trecan.2016.10.001; Reinhardt HC, 2009, CURR OPIN CELL BIOL, V21, P245, DOI 10.1016/j.ceb.2009.01.018; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Salama R, 2014, GENE DEV, V28, P99, DOI 10.1101/gad.235184.113; Samali Afshin, 2010, Int J Cell Biol, V2010, P245803, DOI 10.1155/2010/245803; Sapkota GP, 2002, BIOCHEM J, V368, P507, DOI 10.1042/BJ20021284; Sedic M, 2008, MOL CANCER THER, V7, P2121, DOI 10.1158/1535-7163.MCT-07-2261; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sidi S, 2008, CELL, V133, P864, DOI 10.1016/j.cell.2008.03.037; Singh K, 2012, AUTOPHAGY, V8, P236, DOI 10.4161/auto.8.2.18600; SKALKA M, 1976, FEBS LETT, V72, P271, DOI 10.1016/0014-5793(76)80984-2; Sorokina IV, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14901-z; Spriggs KA, 2010, MOL CELL, V40, P228, DOI 10.1016/j.molcel.2010.09.028; Suzuki K, 2003, ONCOGENE, V22, P6988, DOI 10.1038/sj.onc.1206881; Suzuki M, 2008, J RADIAT RES, V49, P105, DOI 10.1269/jrr.07081; Tait SWG, 2014, J CELL SCI, V127, P2135, DOI 10.1242/jcs.093575; Tenev T, 2011, MOL CELL, V43, P432, DOI 10.1016/j.molcel.2011.06.006; Tomasini R, 2008, GENE DEV, V22, P2677, DOI 10.1101/gad.1695308; Tomasini R, 2009, P NATL ACAD SCI USA, V106, P797, DOI 10.1073/pnas.0812096106; Toussaint O, 2000, EXP GERONTOL, V35, P927, DOI 10.1016/S0531-5565(00)00180-7; Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P555, DOI 10.1038/sj.cdd.4402286; Vanden Berghe T, 2014, NAT REV MOL CELL BIO, V15, P134, DOI 10.1038/nrm3737; Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970; Vanpouille-Box C, 2018, CANCER CELL, V34, P361, DOI 10.1016/j.ccell.2018.05.013; Vaseva AV, 2012, CELL, V149, P1536, DOI 10.1016/j.cell.2012.05.014; Velarde MC, 2013, INTERD TOP GERONTOL, V38, P17, DOI 10.1159/000343572; Vernier M, 2011, GENE DEV, V25, P41, DOI 10.1101/gad.1975111; Vitale I, 2011, NAT REV MOL CELL BIO, V12, P384, DOI 10.1038/nrm3115; von Moltke J, 2012, NATURE, V490, P107, DOI 10.1038/nature11351; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wang HY, 2014, MOL CELL, V54, P133, DOI 10.1016/j.molcel.2014.03.003; Wang L, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007541; Wang YN, 2016, MOL CELL, V63, P34, DOI 10.1016/j.molcel.2016.05.027; Wang YF, 2016, SCIENCE, V354, DOI 10.1126/science.aad6872; Wang YF, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2000902; Wang YF, 2009, J NEUROCHEM, V110, P687, DOI 10.1111/j.1471-4159.2009.06167.x; Wei YJ, 2008, AUTOPHAGY, V4, P949, DOI 10.4161/auto.6788; Xu YF, 2017, CELL SIGNAL, V31, P112, DOI 10.1016/j.cellsig.2017.01.004; Ying WH, 2003, BIOCHEM BIOPH RES CO, V308, P809, DOI 10.1016/S0006-291X(03)01483-9; Ying WH, 2002, J CEREBR BLOOD F MET, V22, P774, DOI 10.1097/00004647-200207000-00002; Yoon S, 2016, CELL DEATH DIFFER, V23, P253, DOI 10.1038/cdd.2015.92; Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709; Yu SW, 2006, P NATL ACAD SCI USA, V103, P18314, DOI 10.1073/pnas.0606528103; Yun M, 2009, MOL CANCER RES, V7, P371, DOI 10.1158/1541-7786.MCR-08-0056; Zamaraev AV, 2018, INT J BIOCHEM CELL B, V102, P101, DOI 10.1016/j.biocel.2018.07.006; Zhang FJ, 2014, TOXICOL SCI, V140, P118, DOI 10.1093/toxsci/kfu073; Zhang T, 2016, NAT MED, V22, P175, DOI 10.1038/nm.4017; Zhang XD, 2010, ACTA PHARMACOL SIN, V31, P1208, DOI 10.1038/aps.2010.151	167	32	32	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	1					1	16		10.1038/s41388-019-0980-6	http://dx.doi.org/10.1038/s41388-019-0980-6			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG3NM	31462710				2022-12-28	WOS:000509849200001
J	Wang, JY; Nagy, N; Masucci, MG				Wang, Jiayu; Nagy, Noemi; Masucci, Maria G.			The Epstein-Barr virus nuclear antigen-1 upregulates the cellular antioxidant defense to enable B-cell growth transformation and immortalization	ONCOGENE			English	Article							PROMOTES GENOMIC INSTABILITY; BASE-EXCISION-REPAIR; DNA-DAMAGE; OXIDATIVE STRESS; CANCER; MTH1; PATHWAY; ESTABLISHMENT; TRANSCRIPTION; INHIBITION	Epstein-Barr virus (EBV) immortalizes human B-lymphocytes and is implicated in the pathogenesis of lymphoid and epithelial cell malignancies. The EBV nuclear antigen (EBNA)-1 induces the accumulation of reactive oxygen species (ROS), which enables B-cell immortalization but causes oxidative DNA damage and triggers antiproliferative DNA damage responses. By comparing pairs of EBV-negative and -positive tumor cell lines we found that, while associated with the accumulation of oxidized nucleotides, EBV carriage promotes the concomitant activation of oxo-dNTP sanitization and purging pathways, including upregulation of the nucleoside triphosphatase mut-T homolog 1 (MTH1) and the DNA glycosylases 8-oxoguanine-glycosylase-1 (OGG1) and mut-Y homolog (MUTYH). Expression of EBNA1 was reversibly associated with transcriptional activation of this cellular response. DNA damage and apoptosis were preferentially induced in EBNA1-positive cell lines by treatment with MTH1 inhibitors, suggesting that virus carriage is linked to enhanced vulnerability to oxidative stress. MTH1, OGG1, and MUTYH were upregulated upon EBV infection in primary B-cells and treatment with MTH1 inhibitors prevented B-cell immortalization. These findings highlight an important role of the cellular antioxidant response in sustaining EBV infection, and suggests that targeting this cellular defense may offer a novel approach to antiviral therapy and could reduce the burden of EBV associated cancer.	[Wang, Jiayu; Nagy, Noemi; Masucci, Maria G.] Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden	Karolinska Institutet	Masucci, MG (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden.	maria.masucci@ki.se	Wang, jiayu/ABB-6772-2020	Masucci, Maria/0000-0002-5541-2809; Nagy, Noemi/0000-0002-7800-3493	Swedish Cancer Society; Swedish Medical Research Council; Karolinska Institutet, Stockholm, Sweden	Swedish Cancer Society(Swedish Cancer Society); Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Karolinska Institutet, Stockholm, Sweden	This study was supported by grants awarded by the Swedish Cancer Society, the Swedish Medical Research Council and the Karolinska Institutet, Stockholm, Sweden. We are grateful to Drs Martin Row, Alan Chang, and Georg Klein for the generous gift of cell lines and reagents and to Dr Teresa Frisan and members of the Masucci group for helpful discussion and careful revision of the manuscript.	BARRANCO SC, 1983, CANCER RES, V43, P1703; Borrego S, 2013, INT J MOL SCI, V14, P3467, DOI 10.3390/ijms14023467; Bottero V, 2013, J VIROL, V87, P1733, DOI 10.1128/JVI.02958-12; Brautigam L, 2016, CANCER RES, V76, P2366, DOI 10.1158/0008-5472.CAN-15-2380; Carter RJ, 2016, MOL CELL BIOL, V36, P1426, DOI 10.1128/MCB.00030-16; Cerimele F, 2005, P NATL ACAD SCI USA, V102, P175, DOI 10.1073/pnas.0408381102; Chen X, 2016, ONCOGENE, V35, P3807, DOI 10.1038/onc.2015.450; Chen XS, 2014, SEMIN CANCER BIOL, V26, P43, DOI 10.1016/j.semcancer.2014.01.006; Chlichlia K, 2010, CHEM-BIOL INTERACT, V188, P359, DOI 10.1016/j.cbi.2010.06.005; Chodosh J, 1998, J INFECT DIS, V177, P1194, DOI 10.1086/515290; Coppotelli G, 2013, NUCLEIC ACIDS RES, V41, P2950, DOI 10.1093/nar/gkt032; Delia D, 2017, INT J HEMATOL, V106, P328, DOI 10.1007/s12185-017-2300-7; Frappier L, 2015, CURR TOP MICROBIOL, V391, P3, DOI 10.1007/978-3-319-22834-1_1; Gad H, 2014, NATURE, V508, P215, DOI 10.1038/nature13181; Grande BM, 2019, BLOOD, V133, P1313, DOI 10.1182/blood-2018-09-871418; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; Gruhne B, 2009, ONCOGENE, V28, P3997, DOI 10.1038/onc.2009.258; Gruhne B, 2009, SEMIN CANCER BIOL, V19, P394, DOI 10.1016/j.semcancer.2009.07.005; Gruhne B, 2009, P NATL ACAD SCI USA, V106, P2313, DOI 10.1073/pnas.0810619106; Guerreiro-Cacais AO, 2007, J VIROL, V81, P1390, DOI 10.1128/JVI.01999-06; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Harris IS, 2015, CANCER CELL, V27, P211, DOI 10.1016/j.ccell.2014.11.019; Huber KVM, 2014, NATURE, V508, P222, DOI 10.1038/nature13194; Ivanov AV, 2013, VIRUSES-BASEL, V5, P439, DOI 10.3390/v5020439; Kamranvar SA, 2007, ONCOGENE, V26, P5115, DOI 10.1038/sj.onc.1210324; Kamranvar SA, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9080217; Kang MS, 2001, P NATL ACAD SCI USA, V98, P15233, DOI 10.1073/pnas.211556598; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; Kawamura T, 2016, SCI REP-UK, V6, DOI 10.1038/srep26521; Kettle JG, 2016, J MED CHEM, V59, P2346, DOI 10.1021/acs.jmedchem.5b01760; Klaunig JE, 2004, ANNU REV PHARMACOL, V44, P239, DOI 10.1146/annurev.pharmtox.44.101802.121851; Lenoir G M, 1985, IARC Sci Publ, P309; Li Q, 2013, ASIAN PAC J CANCER P, V14, P5145, DOI 10.7314/APJCP.2013.14.9.5145; Lin CT, 1997, AM J PATHOL, V150, P1745; LIN CT, 1993, LAB INVEST, V68, P716; Lunn RM, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0266; Markkanen E, 2017, DNA REPAIR, V59, P82, DOI 10.1016/j.dnarep.2017.09.007; MENEZES J, 1975, BIOMEDICINE, V22, P276; MILLER G, 1972, P NATL ACAD SCI USA, V69, P383, DOI 10.1073/pnas.69.2.383; Molesworth SJ, 2000, J VIROL, V74, P6324, DOI 10.1128/JVI.74.14.6324-6332.2000; Moloney JN, 2018, SEMIN CELL DEV BIOL, V80, P50, DOI 10.1016/j.semcdb.2017.05.023; Nakabeppu Y, 2014, INT J MOL SCI, V15, P12543, DOI 10.3390/ijms150712543; Nikitin PA, 2010, CELL HOST MICROBE, V8, P510, DOI 10.1016/j.chom.2010.11.004; Ogrunc M, 2014, CELL DEATH DIFFER, V21, P998, DOI 10.1038/cdd.2014.16; Samaranayake GJ, 2017, CANCERS, V9, DOI 10.3390/cancers9050047; SHIMIZU N, 1994, J VIROL, V68, P6069, DOI 10.1128/JVI.68.9.6069-6073.1994; Sompallae R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012052; Taddei F, 1997, SCIENCE, V278, P128, DOI 10.1126/science.278.5335.128; Wang JY, 2016, J INVEST DERMATOL, V136, P2277, DOI 10.1016/j.jid.2016.06.625; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452	50	11	11	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					603	616		10.1038/s41388-019-1003-3	http://dx.doi.org/10.1038/s41388-019-1003-3			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31511648	Green Published, hybrid			2022-12-28	WOS:000509718300009
J	Zeng, FR; Wang, QY; Wang, SY; Liang, SM; Huang, WM; Guo, Y; Peng, J; Li, M; Zhu, WL; Guo, LL				Zeng, Fanrui; Wang, Qiongyao; Wang, Shuyu; Liang, Shumei; Huang, Weimei; Guo, Ying; Peng, Juan; Li, Man; Zhu, Weiliang; Guo, Linlang			Linc00173 promotes chemoresistance and progression of small cell lung cancer by sponging miR-218 to regulate Etk expression	ONCOGENE			English	Article							NONCODING RNA; DOWN-REGULATION; MICRORNA; CATENIN; GENE; INCREASE	The functional effects of long noncoding RNAs (lncRNAs) in cancer have been widely recognized. However, there is little research on SCLC-related lncRNAs. Here, long intergenic nonprotein coding RNA 173 (Linc00173) was first shown to be involved in chemoresistance and progression of small-cell lung cancer (SCLC). We found that Linc00173 was highly expressed in SCLC chemoresistant cell lines, and promoted SCLC cells chemoresistance, proliferation, and migration-invasion. Animal studies validated that Linc00173 induced tumor chemoresistance and growth of SCLC in vivo. Moreover, Linc00173 upregulated Etk through functioning as a competitive endogenous RNA (ceRNA) by "sponging" miRNA-218 and led to the upregulation of GSKIP and NDRG1, resulting in the translocation of beta-catenin. Importantly, expression analysis revealed that both Linc00173 and Etk were upregulated in SCLC patient samples and exhibiting positive Linc00173/Etk correlation. High expression of Linc00173 closely correlated with chemoresistance, extensive stage, and shorter survival in SCLC patients. Collectively, our study illustrated a Linc00173-mediated process that facilitated chemoresistance and progression in SCLC, which might provide treatment strategy against SCLC.	[Zeng, Fanrui; Wang, Shuyu; Liang, Shumei; Huang, Weimei; Li, Man; Guo, Linlang] Southern Med Univ, Zhujiang Hosp, Dept Pathol, 253 Gongye Rd, Guangzhou 510282, Peoples R China; [Zeng, Fanrui] Guangzhou Med Univ, Affiliated Hosp 1, Dept Radiat Oncol, Guangzhou 510080, Peoples R China; [Wang, Qiongyao; Zhu, Weiliang] Southern Med Univ, Zhujiang Hosp, Dept Oncol, 253 Gongye Rd, Guangzhou 510282, Peoples R China; [Guo, Ying] Southern Med Univ, Zhujiang Hosp, Dept Organ Transplantat, Guangzhou 510282, Guangdong, Peoples R China; [Peng, Juan] Guangzhou Med Univ, Affiliated Hosp 3, Dept Pathol, Guangzhou 510150, Peoples R China	Southern Medical University - China; Guangzhou Medical University; Southern Medical University - China; Southern Medical University - China; Guangzhou Medical University	Guo, LL (corresponding author), Southern Med Univ, Zhujiang Hosp, Dept Pathol, 253 Gongye Rd, Guangzhou 510282, Peoples R China.; Zhu, WL (corresponding author), Southern Med Univ, Zhujiang Hosp, Dept Oncol, 253 Gongye Rd, Guangzhou 510282, Peoples R China.	zhuwl2017@163.com; linlangg@yahoo.com	Wang, shuyu/GZM-3462-2022	Guo, Linlang/0000-0002-1859-7592	National Natural Science Foundation of China [81572244, 81602631, 81772458]; Natural Science Foundation of Guangdong Province [2015A030311028]; Clinical Research Initiative Project of Southern Medical University [LC2016ZD029]; Major Basic Research Projects and Major Applied Research Projects of Educational Commission of Guangdong Province [2017KZDXM015]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Clinical Research Initiative Project of Southern Medical University; Major Basic Research Projects and Major Applied Research Projects of Educational Commission of Guangdong Province	This work was supported by grants from the National Natural Science Foundation of China (Nos. 81572244, 81602631, and 81772458); Natural Science Foundation of Guangdong Province (key) (2015A030311028); The Clinical Research Initiative Project of Southern Medical University (LC2016ZD029); Major Basic Research Projects and Major Applied Research Projects of Educational Commission of Guangdong Province (2017KZDXM015).	Bartonicek N, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0530-6; Bian ZH, 2018, CLIN CANCER RES, V24, P4808, DOI 10.1158/1078-0432.CCR-17-2967; Cao CH, 2015, GASTROENTEROLOGY, V148, P415, DOI 10.1053/j.gastro.2014.10.012; Cazalla D, 2010, SCIENCE, V328, P1563, DOI 10.1126/science.1187197; Chen X, 2012, TRENDS BIOCHEM SCI, V37, P457, DOI 10.1016/j.tibs.2012.08.005; Dema A, 2016, J BIOL CHEM, V291, P19618, DOI 10.1074/jbc.M116.738047; Guo LL, 2010, EUR J CANCER, V46, P1692, DOI 10.1016/j.ejca.2010.02.043; Guo LL, 2010, EXP MOL PATHOL, V88, P401, DOI 10.1016/j.yexmp.2010.02.003; Guo LL, 2010, EUR J CANCER, V46, P636, DOI 10.1016/j.ejca.2009.11.009; Hansen TB, 2011, EMBO J, V30, P4414, DOI 10.1038/emboj.2011.359; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Kim SS, 2018, NUCLEIC ACIDS RES, V46, P1424, DOI 10.1093/nar/gkx1221; Kopp F, 2018, CELL, V172, P393, DOI 10.1016/j.cell.2018.01.011; Leung AKL, 2015, TRENDS CELL BIOL, V25, P601, DOI 10.1016/j.tcb.2015.07.005; Lin CC, 2009, J CELL BIOCHEM, V108, P1325, DOI 10.1002/jcb.22362; Lu WJ, 2015, ONCOTARGET, V6, P29847, DOI 10.18632/oncotarget.4913; Ma YL, 2016, GUT, V65, P1494, DOI 10.1136/gutjnl-2014-308392; Makarova JA, 2016, PROG HISTOCHEM CYTO, V51, P33, DOI 10.1016/j.proghi.2016.06.001; Mao Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27307-2; Niu YC, 2017, MOL CANCER, V16, DOI 10.1186/s12943-016-0575-6; Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016; Sabari JK, 2017, NAT REV CLIN ONCOL, V14, P549, DOI 10.1038/nrclinonc.2017.71; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Schwarzer A, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00212-4; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sun YQ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0113-5; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20; Wang F, 2014, HEPATOLOGY, V60, P1278, DOI 10.1002/hep.27239; Wang K, 2016, EUR HEART J, V37, P2602, DOI 10.1093/eurheartj/ehv713; Wang Q, 2017, CLIN CANCER RES, V24, P1475; Wang YF, 2017, CANCER LETT, V401, P53, DOI 10.1016/j.canlet.2017.04.031; Wei T, 2011, CANCER LETT, V309, P151, DOI 10.1016/j.canlet.2011.05.029; Xiao J, 2017, CELL PHYSIOL BIOCHEM, V43, P1926, DOI 10.1159/000484116; Xiao L, 2018, GASTROENTEROLOGY, V154, P599, DOI 10.1053/j.gastro.2017.10.009	36	63	66	2	30	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	2					293	307		10.1038/s41388-019-0984-2	http://dx.doi.org/10.1038/s41388-019-0984-2			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KD3JY	31477834				2022-12-28	WOS:000507766400004
J	Zhang, MH; Zhang, HH; Du, XH; Gao, J; Li, C; Shi, HR; Li, SZ				Zhang, Ming-Hui; Zhang, Hui-Hui; Du, Xue-Hua; Gao, Jie; Li, Chao; Shi, Hui-Rong; Li, Shang-Ze			UCHL3 promotes ovarian cancer progression by stabilizing TRAF2 to activate the NF-kappa B pathway	ONCOGENE			English	Article							C-TERMINAL HYDROLASES; TARGETS TRAF2; UBIQUITIN; INFLAMMATION; METASTASIS; EXPRESSION; PROGNOSIS; NEDD8; GAIN; MICE	The inflammatory response plays an important role in carcinogenesis. However, the functional role and mechanism of the UCHL3-associated inflammatory response in ovarian cancer remain to be characterized. Here, we report that increased expression of UCHL3 facilitates tumourigenesis by targeting TRAF2 protein, thereby enhancing the inflammatory response. The expression of UCHL3 is elevated in ovarian cancer patients and is associated with an unfavourable prognosis. Genetic ablation of UCHL3 was found to markedly block ovarian cancer cell proliferation, viability and migration both in vitro and in vivo. Mechanistically, luciferase pathway screening results show that NF-kappa B signalling is clearly activated compared with other pathways. UCHL3 was found to activate NF-kappa B signalling by deubiquitinating and stabilizing TRAF2, leading to tumourigenesis. Our results indicate that highly expressed UCHL3 enhances inflammation by stabilizing TRAF2, which in turn facilitates tumourigenesis in ovarian cancer, and that UCHL3 is a potential target for ovarian cancer patients with increased inflammation.	[Zhang, Ming-Hui; Shi, Hui-Rong; Li, Shang-Ze] Zhengzhou Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Zhengzhou 450052, Henan, Peoples R China; [Zhang, Hui-Hui] Hunan Normal Univ, Coll Med, Changsha 410013, Hunan, Peoples R China; [Du, Xue-Hua; Gao, Jie; Li, Chao] Wuhan Univ, Coll Life Sci, Hubei Key Lab Cell Homeostasis, Wuhan 430072, Hubei, Peoples R China; [Li, Shang-Ze] Wuhan Univ, Zhongnan Hosp, Med Sci Res Ctr, Wuhan 430071, Hubei, Peoples R China	Zhengzhou University; Hunan Normal University; Wuhan University; Wuhan University	Li, SZ (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Zhengzhou 450052, Henan, Peoples R China.; Li, SZ (corresponding author), Wuhan Univ, Zhongnan Hosp, Med Sci Res Ctr, Wuhan 430071, Hubei, Peoples R China.	shangze.li@whu.edu.cn	li, shangze/AAW-6317-2021	li, shangze/0000-0003-3134-532X	National Natural Science Foundation of China [81602450]; Fundamental Research Funds for the Central Universities [413000099]; Zhongnan Hospital of Wuhan University Science, Technology and Innovation Seed Fund Project [cxpy2017005]; Foundation of Hunan Educational Committee [16B161]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Zhongnan Hospital of Wuhan University Science, Technology and Innovation Seed Fund Project; Foundation of Hunan Educational Committee	This work was supported by grants from the National Natural Science Foundation of China [81602450] and the Fundamental Research Funds for the Central Universities [413000099] and Zhongnan Hospital of Wuhan University Science, Technology and Innovation Seed Fund Project [cxpy2017005] and Foundation of Hunan Educational Committee (16B161).	Artavanis-Tsakonas K, 2010, J BIOL CHEM, V285, P6857, DOI 10.1074/jbc.M109.072405; Borghi A, 2016, BIOCHEM PHARMACOL, V116, P1, DOI 10.1016/j.bcp.2016.03.009; Browning L, 2018, CANCER MANAG RES, V10, P6685, DOI 10.2147/CMAR.S179189; Cheong KM, 2011, LANCET ONCOL, V12, P1183, DOI 10.1016/S1470-2045(11)70351-5; Etemadi N, 2015, ELIFE, V4, DOI 10.7554/eLife.10592; Fang Y, 2010, BBA-REV CANCER, V1806, P1, DOI 10.1016/j.bbcan.2010.03.001; Frickel EM, 2007, CELL MICROBIOL, V9, P1601, DOI 10.1111/j.1462-5822.2007.00896.x; Gupta KK, 2019, INT J GYNECOL CANCER, V29, P195, DOI 10.1136/ijgc-2018-000016; Gupta M, 2016, HUM PATHOL, V54, P82, DOI 10.1016/j.humpath.2016.03.006; Habelhah H, 2002, EMBO J, V21, P5756, DOI 10.1093/emboj/cdf576; Kim JY, 2011, FEBS LETT, V585, P1121, DOI 10.1016/j.febslet.2011.03.053; Kisielewski R, 2013, GINEKOL POL, V84, P293; Li LY, 2009, BBA-MOL CELL RES, V1793, P346, DOI 10.1016/j.bbamcr.2008.09.013; Li S, 2018, FASEB J, V32, P230, DOI 10.1096/fj.201700415RR; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Lin TB, 2015, J NEUROSCI, V35, P16545, DOI 10.1523/JNEUROSCI.2301-15.2015; Maccio A, 2012, CYTOKINE, V58, P133, DOI 10.1016/j.cyto.2012.01.015; Menon U, 2014, GYNECOL ONCOL, V132, P490, DOI 10.1016/j.ygyno.2013.11.030; Moufarrij S, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-018-0602-0; Mtango NR, 2012, J CELL PHYSIOL, V227, P2022, DOI 10.1002/jcp.22931; Mtango NR, 2012, J CELL PHYSIOL, V227, P1592, DOI 10.1002/jcp.22876; Nishi R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-36235-0; Omori E, 2006, J BIOL CHEM, V281, P19610, DOI 10.1074/jbc.M603384200; Peramuhendige P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18327-5; Popp MW, 2009, J BIOL CHEM, V284, P3593, DOI 10.1074/jbc.M807172200; Reyes-Turcu FE, 2009, ANNU REV BIOCHEM, V78, P363, DOI 10.1146/annurev.biochem.78.082307.091526; Riedlinger T, 2017, BBA-MOL CELL RES, V1864, P1785, DOI 10.1016/j.bbamcr.2017.07.005; Sano Y, 2006, AM J PATHOL, V169, P132, DOI 10.2353/ajpath.2006.060085; Setsuie R, 2010, NEUROCHEM INT, V56, P911, DOI 10.1016/j.neuint.2010.03.021; Song HM, 2014, BIOCHEM BIOPH RES CO, V452, P722, DOI 10.1016/j.bbrc.2014.08.144; Suzuki M, 2009, ENDOCRINOLOGY, V150, P5230, DOI 10.1210/en.2009-0332; Tesio M, 2015, J EXP MED, V212, P525, DOI 10.1084/jem.20141438; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Wada H, 1998, BIOCHEM BIOPH RES CO, V251, P688, DOI 10.1006/bbrc.1998.9532; Wei BB, 2017, MED SCI MONITOR, V23, DOI 10.12659/MSM.903500; Wei BB, 2017, BIOMED PHARMACOTHER, V93, P462, DOI 10.1016/j.biopha.2017.05.145; White KL, 2012, CANCER RES, V72, P1064, DOI 10.1158/0008-5472.CAN-11-3512; Wood MA, 2005, HIPPOCAMPUS, V15, P610, DOI 10.1002/hipo.20082; Wu CJ, 2005, EMBO J, V24, P1886, DOI 10.1038/sj.emboj.7600649; Xiao N, 2012, BIOCHEM J, V441, P979, DOI 10.1042/BJ20111358; Zhang J, 2015, INT J CLIN EXP PATHO, V8, P14228; Zhang YN, 2013, NAT CHEM BIOL, V9, P51, DOI [10.1038/NCHEMBIO.1134, 10.1038/nchembio.1134]; Zhao JJ, 2018, J GASTROEN HEPATOL, V33, P431, DOI 10.1111/jgh.13818; Zhao P, 2017, ANTIVIR RES, V144, P120, DOI 10.1016/j.antiviral.2017.06.002; Zhong HJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080976	45	20	22	2	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	2					322	333		10.1038/s41388-019-0987-z	http://dx.doi.org/10.1038/s41388-019-0987-z			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KD3JY	31477831				2022-12-28	WOS:000507766400006
J	Alptekin, A; Ye, BW; Yu, YJ; Poole, CJ; van Riggelen, J; Zha, YH; Ding, HF				Alptekin, Ahmet; Ye, Bingwei; Yu, Yajie; Poole, Candace J.; van Riggelen, Jan; Zha, Yunhong; Ding, Han-Fei			Glycine decarboxylase is a transcriptional target of MYCN required for neuroblastoma cell proliferation and tumorigenicity	ONCOGENE			English	Article							ONE-CARBON METABOLISM; N-MYC; GLUTAMINE-METABOLISM; PROGNOSTIC MARKER; SYNTHESIS PATHWAY; C-MYC; SERINE; CANCER; FOLATE; FLUX	Genomic amplification of the oncogene MYCN is a major driver in the development of high-risk neuroblastoma, a pediatric cancer with poor prognosis. Given the challenge in targeting MYCN directly for therapy, we sought to identify MYCN-dependent metabolic vulnerabilities that can be targeted therapeutically. Here, we report that the gene encoding glycine decarboxylase (GLDC), which catalyzes the first and rate-limiting step in glycine breakdown with the production of the one-carbon unit 5,10-methylene-tetrahydrofolate, is a direct transcriptional target of MYCN. As a result, GLDC expression is markedly elevated in MYCN-amplified neuroblastoma tumors and cell lines. This transcriptional upregulation of GLDC expression is of functional significance, as GLDC depletion by RNA interference inhibits the proliferation and tumorigenicity of MYCN-amplified neuroblastoma cell lines by inducing G1 arrest. Metabolomic profiling reveals that GLDC knockdown disrupts purine and central carbon metabolism and reduces citrate production, leading to a decrease in the steady-state levels of cholesterol and fatty acids. Moreover, blocking purine or cholesterol synthesis recapitulates the growth-inhibitory effect of GLDC knockdown. These findings reveal a critical role of GLDC in sustaining the proliferation of neuroblastoma cells with high-level GLDC expression and suggest that MYCN amplification is a biomarker for GLDC-based therapeutic strategies against high-risk neuroblastoma.	[Alptekin, Ahmet; Poole, Candace J.; van Riggelen, Jan; Ding, Han-Fei] Augusta Univ, Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; [Alptekin, Ahmet; Ye, Bingwei; Poole, Candace J.; van Riggelen, Jan; Ding, Han-Fei] Augusta Univ, Med Coll Georgia, Georgia Canc Ctr, Augusta, GA 30912 USA; [Yu, Yajie; Zha, Yunhong] Three Gorges Univ, Hosp Yichang 1, Inst Neural Regenerat & Repair, Coll Med, Yichang 443000, Peoples R China; [Yu, Yajie; Zha, Yunhong] Three Gorges Univ, Hosp Yichang 1, Dept Neurol, Coll Med, Yichang 443000, Peoples R China; [Ding, Han-Fei] Augusta Univ, Med Coll Georgia, Dept Pathol, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; China Three Gorges University; China Three Gorges University; University System of Georgia; Augusta University	Ding, HF (corresponding author), Augusta Univ, Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA.; Ding, HF (corresponding author), Augusta Univ, Med Coll Georgia, Georgia Canc Ctr, Augusta, GA 30912 USA.; Ding, HF (corresponding author), Augusta Univ, Med Coll Georgia, Dept Pathol, Augusta, GA 30912 USA.	hding@augusta.edu	Ye, Bingwei/AAH-1139-2021	Alptekin, Ahmet/0000-0002-7039-1911; Ding, Han-Fei/0000-0001-5702-3439; Langan, Candace Jean/0000-0003-1811-587X; yu, yajie/0000-0002-8645-9976	NIH [R01 CA190429]; NATIONAL CANCER INSTITUTE [R01CA190429] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by an NIH grant (R01 CA190429) to HFD.	Alam G, 2009, AM J PATHOL, V175, P856, DOI 10.2353/ajpath.2009.090019; Altman BJ, 2016, NAT REV CANCER, V16, P619, DOI 10.1038/nrc.2016.71; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Brooks EE, 1997, J BIOL CHEM, V272, P29207, DOI 10.1074/jbc.272.46.29207; Campbell K, 2017, CANCER-AM CANCER SOC, V123, P4224, DOI 10.1002/cncr.30873; Cheung NKV, 2013, NAT REV CANCER, V13, P397, DOI 10.1038/nrc3526; Cohn SL, 2009, J CLIN ONCOL, V27, P289, DOI 10.1200/JCO.2008.16.6785; Comte B, 2002, AM J PHYSIOL-HEART C, V283, pH1505, DOI 10.1152/ajpheart.00287.2002; Conter C, 2006, J INHERIT METAB DIS, V29, P135, DOI 10.1007/s10545-006-0202-6; Cui HJ, 2005, J BIOL CHEM, V280, P9474, DOI 10.1074/jbc.M410450200; DADAMO AF, 1965, J BIOL CHEM, V240, P613; Dang CV, 2017, NAT REV CANCER, V17, P502, DOI 10.1038/nrc.2017.36; Dang CV, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014217; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Dejure FR, 2017, EMBO J, V36, P3409, DOI 10.15252/embj.201796438; Ding J, 2013, CELL METAB, V18, P896, DOI 10.1016/j.cmet.2013.11.004; Ducker GS, 2017, CELL METAB, V25, P27, DOI 10.1016/j.cmet.2016.08.009; Ducker GS, 2016, CELL METAB, V23, P1140, DOI 10.1016/j.cmet.2016.04.016; Fiehn O, 2008, PLANT J, V53, P691, DOI 10.1111/j.1365-313X.2007.03387.x; Herbig K, 2002, J BIOL CHEM, V277, P38381, DOI 10.1074/jbc.M205000200; Holleran AL, 1995, MOL CELL BIOCHEM, V152, P95, DOI 10.1007/BF01076071; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang M, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014415; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kim D, 2015, NATURE, V520, P363, DOI 10.1038/nature14363; Kocak H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.84; Labuschagne CF, 2014, CELL REP, V7, P1248, DOI 10.1016/j.celrep.2014.04.045; Lamers Y, 2009, J NUTR, V139, P666, DOI 10.3945/jn.108.103580; Leung KY, 2017, CELL REP, V21, P1795, DOI 10.1016/j.celrep.2017.10.072; Liu ML, 2016, CELL REP, V17, P609, DOI 10.1016/j.celrep.2016.09.021; Locasale JW, 2013, NAT REV CANCER, V13, P572, DOI 10.1038/nrc3557; Locasale JW, 2011, NAT GENET, V43, P869, DOI 10.1038/ng.890; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; MANFREDI JP, 1985, ANNU REV PHYSIOL, V47, P691, DOI 10.1146/annurev.ph.47.030185.003355; Mao L, 2012, ONCOGENE, V31, P3785, DOI 10.1038/onc.2011.536; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Marshall GM, 2014, NAT REV CANCER, V14, P277, DOI 10.1038/nrc3679; Metallo CM, 2012, NATURE, V481, P380, DOI 10.1038/nature10602; Molenaar JJ, 2012, NATURE, V483, P589, DOI 10.1038/nature10910; Narisawa A, 2012, HUM MOL GENET, V21, P1496, DOI 10.1093/hmg/ddr585; Narkewicz MR, 1996, BIOCHEM J, V313, P991, DOI 10.1042/bj3130991; NEWSHOLME EA, 1985, BIOSCIENCE REP, V5, P393, DOI 10.1007/BF01116556; Nilsson R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4128; Pai YJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7388; Pajic A, 2000, INT J CANCER, V87, P787, DOI 10.1002/1097-0215(20000915)87:6<787::AID-IJC4>3.0.CO;2-6; Park JR, 2013, PEDIATR BLOOD CANCER, V60, P985, DOI 10.1002/pbc.24433; PFENDNER W, 1980, ARCH BIOCHEM BIOPHYS, V200, P503, DOI 10.1016/0003-9861(80)90382-3; Pinto NR, 2015, J CLIN ONCOL, V33, P3008, DOI 10.1200/JCO.2014.59.4648; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159-8290.CD-12-0418; Reid MA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07868-6; ROSIERS CD, 1995, J BIOL CHEM, V270, P10027, DOI 10.1074/jbc.270.17.10027; Schuhmacher M, 1999, CURR BIOL, V9, P1255, DOI 10.1016/S0960-9822(99)80507-7; SCHWAB M, 1993, SEMIN CANCER BIOL, V4, P13; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Stewart E, 2017, NATURE, V549, P96, DOI 10.1038/nature23647; Stover PJ, 1997, J BIOL CHEM, V272, P1842, DOI 10.1074/jbc.272.3.1842; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tadesse S, 2019, J MED CHEM, V62, P4233, DOI 10.1021/acs.jmedchem.8b01469; Teitz T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019133; Tibbetts AS, 2010, ANNU REV NUTR, V30, P57, DOI 10.1146/annurev.nutr.012809.104810; Valentijn LJ, 2012, P NATL ACAD SCI USA, V109, P19190, DOI 10.1073/pnas.1208215109; Wang WW, 2013, AMINO ACIDS, V45, P463, DOI 10.1007/s00726-013-1493-1; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Wiederschain D, 2009, CELL CYCLE, V8, P498, DOI 10.4161/cc.8.3.7701; Xia JG, 2011, NAT PROTOC, V6, P743, DOI 10.1038/nprot.2011.319; Xia YF, 2019, CANCER RES, V79, P3837, DOI 10.1158/0008-5472.CAN-18-3541; Yang M, 2016, NAT REV CANCER, V16, P650, DOI 10.1038/nrc.2016.81; Yoo H, 2008, J BIOL CHEM, V283, P20621, DOI 10.1074/jbc.M706494200; YOSHIDA T, 1970, ARCH BIOCHEM BIOPHYS, V139, P380, DOI 10.1016/0003-9861(70)90490-X; Zhang J, 2017, EMBO J, V36, P1302, DOI 10.15252/embj.201696151; Zhang WC, 2012, CELL, V148, P259, DOI 10.1016/j.cell.2011.11.050; Zhang WQ, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0694-1; Zhao EH, 2016, CELL REP, V14, P506, DOI 10.1016/j.celrep.2015.12.053	76	12	12	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2019	38	50					7504	7520		10.1038/s41388-019-0967-3	http://dx.doi.org/10.1038/s41388-019-0967-3			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JV7GY	31444411	Green Accepted			2022-12-28	WOS:000502530500005
J	Beyes, S; Andrieux, G; Schrempp, M; Aicher, D; Wenzel, J; Anton-Garcia, P; Boerries, M; Hecht, A				Beyes, Sven; Andrieux, Geoffroy; Schrempp, Monika; Aicher, David; Wenzel, Janna; Anton-Garcia, Pablo; Boerries, Melanie; Hecht, Andreas			Genome-wide mapping of DNA-binding sites identifies stemness-related genes as directly repressed targets of SNAIL1 in colorectal cancer cells	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; EPHB3 TUMOR-SUPPRESSOR; COMPETITIVE DISPLACEMENT; SMALL-INTESTINE; EXPRESSION; MYB; TRANSCRIPTION; ASCL2; RNA; EMT	At the molecular level, epithelial-to-mesenchymal transition (EMT) necessitates extensive transcriptional reprogramming which is orchestrated by a small group of gene-regulatory factors that include the zinc-finger DNA-binding protein SNAIL1. Although SNAIL1 is a well-known master regulator of EMT, knowledge of its immediate target genes is incomplete. Here, we used ChIP-seq to identify genes directly regulated by SNAIL1 in colorectal adenocarcinoma cells. When comparing the genomic distribution of SNAIL1 to that of the intestinal stem cell (ISC) transcription factors ASCL2 and TCF7L2, we observed a significant overlap. Furthermore, SNAIL1 ChIP-seq peaks are associated with a substantial fraction of ISC signature genes. In two colorectal cancer cell lines, we verified that SNAIL1 decreases ISC marker expression. Likewise, SNAIL1 directly represses the proto-oncogene MYB, and the long noncoding RNA (lncRNA) WiNTRLINC1, a recently described regulator of ASCL2. SNAIL1 targets multiple regulatory elements at the MYB and WiNTRLINC1 loci, and displaces ASCL2 and TCF7L2 from their binding regions at a MYB downstream regulatory element. Correlation analyses and expression profiling showed antiparallel expression of SNAIL1 and MYB in colorectal and breast cancer cell lines and tumor transcriptomes, suggesting that SNAIL1 controls MYB expression in different tissues. MYB loss-of-function attenuated proliferation and impaired clonogenicity in two- and three-dimensional cell cultures. Therefore, SNAIL1-mediated downregulation of MYB and ISC markers like WiNTRLINC1 likely contributes to the decrease in proliferation known to be associated with EMT, while simultaneously abrogating stemness features of colorectal cancer cells. Apparently, the relationship between EMT and stemness varies in different tumor entities.	[Beyes, Sven; Andrieux, Geoffroy; Schrempp, Monika; Aicher, David; Wenzel, Janna; Anton-Garcia, Pablo; Boerries, Melanie; Hecht, Andreas] Univ Freiburg, Fac Med, Inst Mol Med & Cell Res, Freiburg, Germany; [Beyes, Sven; Wenzel, Janna; Anton-Garcia, Pablo; Hecht, Andreas] Univ Freiburg, Fac Biol, Freiburg, Germany; [Andrieux, Geoffroy; Boerries, Melanie] Univ Freiburg, Univ Med Ctr Freiburg, Fac Med, Inst Med Bioinformat & Syst Med, Freiburg, Germany; [Andrieux, Geoffroy; Boerries, Melanie] German Canc Consortium DKTK, Partner Site Freiburg, Freiburg, Germany; [Andrieux, Geoffroy; Boerries, Melanie] German Canc Res Ctr, Heidelberg, Germany; [Boerries, Melanie] Univ Freiburg, Univ Med Ctr, Fac Med, CCCF, Freiburg, Germany; [Hecht, Andreas] Univ Freiburg, BIOSS Ctr Biol Signalling Studies, Freiburg, Germany	University of Freiburg; University of Freiburg; University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of Freiburg; University of Freiburg	Hecht, A (corresponding author), Univ Freiburg, Fac Med, Inst Mol Med & Cell Res, Freiburg, Germany.; Hecht, A (corresponding author), Univ Freiburg, Fac Biol, Freiburg, Germany.; Hecht, A (corresponding author), Univ Freiburg, BIOSS Ctr Biol Signalling Studies, Freiburg, Germany.	andreas.hecht@mol-med.uni-freiburg.de	Boerries, Melanie/AAM-2602-2021	ANDRIEUX, GEOFFROY/0000-0002-5389-9481	Deutsche Forschungsgemeinschaft [DFG HE2004/11-1, CRC-850, GRK2344]; German Federal Ministry of Education and Research (BMBF) [FKZ 01ZX1708F]; Deutsche Forschungsgemeinschaft Research Training Group [GRK2344]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); Deutsche Forschungsgemeinschaft Research Training Group(German Research Foundation (DFG))	The authors are grateful to K. Geiger and D. Herchenbach for excellent technical assistance, and to the team of the Genomics and Proteomics Core Facility, German Cancer Research Center/DKFZ, Heidelberg, Germany, for their sequencing service. This work was financially supported by the Deutsche Forschungsgemeinschaft (DFG HE2004/11-1 to AH; CRC-850 subprojects B5 to AH and Z1 to MB; GRK2344 subprojects B02 to MB and B03 to AH), and by the German Federal Ministry of Education and Research (BMBF) within the framework of the e:Med research and funding concept CoNfirm (FKZ 01ZX1708F to MB). JW and PAG were funded by the Deutsche Forschungsgemeinschaft Research Training Group GRK2344 "MeInBio-BioInMe".	Afgan E, 2016, NUCLEIC ACIDS RES, V44, pW3, DOI 10.1093/nar/gkw343; Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Beck B, 2015, CELL STEM CELL, V16, P67, DOI 10.1016/j.stem.2014.12.002; Blick T, 2008, CLIN EXP METASTAS, V25, P629, DOI 10.1007/s10585-008-9170-6; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Caja L, 2018, ONCOGENE, V37, P2515, DOI 10.1038/s41388-018-0136-0; Celia-Terrassa T, 2012, J CLIN INVEST, V122, P1849, DOI 10.1172/JCI59218; Cheasley D, 2011, STEM CELLS, V29, P2042, DOI 10.1002/stem.761; Ciznadija D, 2009, CELL DEATH DIFFER, V16, P1530, DOI 10.1038/cdd.2009.94; Fabregat I, 2016, J CLIN MED, V5, DOI 10.3390/jcm5030037; Fellmann C, 2013, CELL REP, V5, P1704, DOI 10.1016/j.celrep.2013.11.020; Giakountis A, 2016, CELL REP, V15, P2588, DOI 10.1016/j.celrep.2016.05.038; Giresi PG, 2007, GENOME RES, V17, P877, DOI 10.1101/gr.5533506; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Haraguchi M, 2008, J BIOL CHEM, V283, P23514, DOI 10.1074/jbc.M801125200; Hsu DSS, 2014, CANCER CELL, V26, P534, DOI 10.1016/j.ccell.2014.09.002; Hsu PD, 2013, NAT BIOTECHNOL, V31, P827, DOI 10.1038/nbt.2647; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Hugo HJ, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3580; Hwang WL, 2014, NAT CELL BIOL, V16, P268, DOI 10.1038/ncb2910; Hwang WL, 2011, GASTROENTEROLOGY, V141, P279, DOI 10.1053/j.gastro.2011.04.008; Ikenouchi J, 2003, J CELL SCI, V116, P1959, DOI 10.1242/jcs.00389; Jagle S, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1007109; Jagle S, 2014, P NATL ACAD SCI USA, V111, P4886, DOI 10.1073/pnas.1314523111; Javaid S, 2013, CELL REP, V5, P1679, DOI 10.1016/j.celrep.2013.11.034; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Koo BK, 2012, NATURE, V488, P665, DOI 10.1038/nature11308; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lambert SA, 2018, CELL, V172, P650, DOI 10.1016/j.cell.2018.01.029; Lawrence M, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003118; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; Lin YW, 2010, EMBO J, V29, P1803, DOI 10.1038/emboj.2010.63; Malaterre J, 2016, ONCOGENE, V35, P2475, DOI 10.1038/onc.2015.305; Malaterre J, 2007, P NATL ACAD SCI USA, V104, P3829, DOI 10.1073/pnas.0610055104; Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Maturi V, 2018, MOL ONCOL, V12, P1153, DOI 10.1002/1878-0261.12317; Meyer-Schaller N, 2019, DEV CELL, V48, P539, DOI 10.1016/j.devcel.2018.12.023; Miao RY, 2011, CANCER RES, V71, P7029, DOI 10.1158/0008-5472.CAN-11-1015; Millanes-Romero A, 2013, MOL CELL, V52, P746, DOI 10.1016/j.molcel.2013.10.015; Mokry M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015092; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Munoz J, 2012, EMBO J, V31, P3079, DOI 10.1038/emboj.2012.166; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Preca BT, 2015, INT J CANCER, V137, P2566, DOI 10.1002/ijc.29642; Ramsay RG, 2008, NAT REV CANCER, V8, P523, DOI 10.1038/nrc2439; Rembold M, 2014, GENE DEV, V28, P167, DOI 10.1101/gad.230953.113; Ronsch K, 2015, MOL ONCOL, V9, P335, DOI 10.1016/j.molonc.2014.08.016; Rosmaninho P, 2018, EMBO J, V37, DOI 10.15252/embj.201797115; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Schnappauf O, 2016, BBA-GENE REGUL MECH, V1859, P1353, DOI 10.1016/j.bbagrm.2016.08.002; Schuijers J, 2015, CELL STEM CELL, V16, P158, DOI 10.1016/j.stem.2014.12.006; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Soleimani VD, 2012, MOL CELL, V47, P457, DOI 10.1016/j.molcel.2012.05.046; Srivastava SK, 2015, BRIT J CANCER, V113, P1694, DOI 10.1038/bjc.2015.400; Stanisavljevic J, 2011, J CELL SCI, V124, P4159, DOI 10.1242/jcs.078824; Stemmer V, 2008, ONCOGENE, V27, P5075, DOI 10.1038/onc.2008.140; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tran DD, 2011, MOL CANCER RES, V9, P1644, DOI 10.1158/1541-7786.MCR-11-0371; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Van der Auwera, 2013, CURR PROTOC BIOINFOR, V43; van der Flier LG, 2009, CELL, V136, P903, DOI 10.1016/j.cell.2009.01.031; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Weise A, 2010, NUCLEIC ACIDS RES, V38, P1964, DOI 10.1093/nar/gkp1197; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897; Yu GC, 2015, BIOINFORMATICS, V31, P2382, DOI 10.1093/bioinformatics/btv145; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhu P, 2018, NAT CELL BIOL, V1134	75	20	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2019	38	40					6647	6661		10.1038/s41388-019-0905-4	http://dx.doi.org/10.1038/s41388-019-0905-4			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JC0EY	31391555	hybrid			2022-12-28	WOS:000488953500001
J	Sun, B; Zhao, XD; Ming, JG; Liu, X; Liu, DM; Jiang, CL				Sun, Bo; Zhao, Xudong; Ming, Jianguang; Liu, Xing; Liu, Daming; Jiang, Chuanlu			Stepwise detection and evaluation reveal miR-10b and miR-222 as a remarkable prognostic pair for glioblastoma	ONCOGENE			English	Article							GLIOMA-CELLS; PTEN; APOPTOSIS; P53; EXPRESSION; PATHWAY; MDM2; TEMOZOLOMIDE; SUPPRESSION; P27(KIP1)	Despite the existence of many clinical and molecular factors reported that contribute to survival in glioblastoma, prevailing studies fell into partial or local feature selection for survival analysis. We proposed a feature selection strategy including not only joint covariate detection but also its evaluations, and performed it on miRNA expression profiles with glioblastoma. MiR-10b and miR-222 were selected as the most significant two-dimensional feature. Crucially, we integrated in vitro experiments on GBM cells and in vivo studies on a mouse model of human glioma to elucidate the synergistic effects between miR-10b and miR-222. Inhibition of miR-10b and miR-222 strongly suppress GBM cells growth, invasion, and induce apoptosis by co-targeting PTEN and leading to activation of p53 ultimately. We also demonstrated that miR-10b and miR-222 co-target BIM to induce apoptosis independent of p53 status. The results define mir-10b and mir-222 important roles in gliomagenesis and provided a reliable survival analysis strategy.	[Sun, Bo; Ming, Jianguang; Liu, Daming; Jiang, Chuanlu] Harbin Med Univ, Affiliated Hosp 2, Dept Neurosurg, Harbin 150086, Heilongjiang, Peoples R China; [Zhao, Xudong] Northeast Forestry Univ, Coll Informat & Comp Engn, Harbin 150040, Heilongjiang, Peoples R China; [Liu, Xing] Beijing Neurosurg Inst, Beijing 100050, Peoples R China	Harbin Medical University; Northeast Forestry University - China; Beijing Neurosurgical Institute	Jiang, CL (corresponding author), Harbin Med Univ, Affiliated Hosp 2, Dept Neurosurg, Harbin 150086, Heilongjiang, Peoples R China.; Zhao, XD (corresponding author), Northeast Forestry Univ, Coll Informat & Comp Engn, Harbin 150040, Heilongjiang, Peoples R China.	zhaoxudong@nefu.edu.cn; jcl6688@163.com			National Key Research and Development Plan [2016YFC0902500]; National Natural Science Foundation of China [81702972, 81572701, 81772666]; Special Fund Project of Translational Medicine in the Chinese-Russian Medical Research Center [CR201417]; Fundamental Research Funds for the Central Universities [2572018BH01]; Specialized Personnel Start-up Grant [41113237]	National Key Research and Development Plan; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Special Fund Project of Translational Medicine in the Chinese-Russian Medical Research Center; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Specialized Personnel Start-up Grant	This work is supported by the National Key Research and Development Plan (No. 2016YFC0902500); the National Natural Science Foundation of China (No. 81702972, No. 81572701, and No. 81772666); the Special Fund Project of Translational Medicine in the Chinese-Russian Medical Research Center (No. CR201417). Besides, Xudong Zhao would like to thank the financial support of Fundamental Research Funds for the Central Universities (No. 2572018BH01) and Specialized Personnel Start-up Grant (No. 41113237).	Bahena-Ocampo I, 2016, EMBO REP, V17, P648, DOI 10.15252/embr.201540678; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chang CJ, 2004, J BIOL CHEM, V279, P29841, DOI 10.1074/jbc.M401488200; Chen HY, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0435-y; Chen LC, 2012, ONCOL REP, V27, P854, DOI 10.3892/or.2011.1535; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Cheng W, 2015, ONCOTARGET, V6, P29285, DOI 10.18632/oncotarget.4978; Chow LML, 2006, CANCER LETT, V241, P184, DOI 10.1016/j.canlet.2005.11.042; Chow LML, 2011, CANCER CELL, V19, P305, DOI 10.1016/j.ccr.2011.01.039; COX DR, 1972, J R STAT SOC B, V34, P187; Duda R. O., 2001, PATTERN CLASSIFICATI; Dweep H, 2015, NAT METHODS, V12, P697, DOI 10.1038/nmeth.3485; Fan QW, 2007, CANCER RES, V67, P7960, DOI 10.1158/0008-5472.CAN-07-2154; Gabriely G, 2011, CANCER RES, V71, P3563, DOI 10.1158/0008-5472.CAN-10-3568; Garofalo M, 2009, CANCER CELL, V16, P498, DOI 10.1016/j.ccr.2009.10.014; Gilbert MR, 2014, NEW ENGL J MED, V370, P699, DOI 10.1056/NEJMoa1308573; Han B, 2017, AGING-US, V9, P1885, DOI 10.18632/aging.101271; Hombach-Klonisch S, 2018, PHARMACOL THERAPEUT, V184, P13, DOI 10.1016/j.pharmthera.2017.10.017; Ishwaran H, 2008, ANN APPL STAT, V2, P841, DOI 10.1214/08-AOAS169; Ji YC, 2015, TUMOR BIOL, V36, P4461, DOI 10.1007/s13277-015-3086-y; Kim J, 2014, CANCER RES, V74, P1541, DOI 10.1158/0008-5472.CAN-13-1449; Klein JP, 2014, CH CRC HANDB MOD STA, P1; le Sage C, 2007, EMBO J, V26, P3699, DOI 10.1038/sj.emboj.7601790; Liu X, 2014, ONCOTARGET, V5, P11681, DOI 10.18632/oncotarget.2585; Martin A, 2005, CANCER CELL, V7, P591, DOI 10.1016/j.ccr.2005.05.006; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Ming JG, 2017, AGING-US, V9, P1233, DOI 10.18632/aging.101224; Mure H, 2010, NEURO-ONCOLOGY, V12, P221, DOI 10.1093/neuonc/nop026; Niyazi M, 2016, ONCOTARGET, V7, P45764, DOI 10.18632/oncotarget.9945; Niyazi M, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-153; Omuro A, 2013, JAMA-J AM MED ASSOC, V310, P1842, DOI 10.1001/jama.2013.280319; Srinivasan S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017438; Suh SS, 2012, P NATL ACAD SCI USA, V109, P5316, DOI 10.1073/pnas.1202465109; Sun CQ, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/3017948; Terasawa K, 2009, FEBS J, V276, P3269, DOI 10.1111/j.1742-4658.2009.07041.x; Vazquez A, 2008, NAT REV DRUG DISCOV, V7, P979, DOI 10.1038/nrd2656; Vlachos IS, 2015, NUCLEIC ACIDS RES, V43, pW460, DOI 10.1093/nar/gkv403; Wu YW, 2018, BMC GENOMICS, V19, DOI 10.1186/s12864-017-4327-9; Zhang CZ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-367; Zhang CZ, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-119; Zhang W, 2012, NEURO-ONCOLOGY, V14, P712, DOI 10.1093/neuonc/nos089; Zheng HW, 2008, NATURE, V455, P1129, DOI 10.1038/nature07443; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	45	18	19	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2019	38	33					6142	6157		10.1038/s41388-019-0867-6	http://dx.doi.org/10.1038/s41388-019-0867-6			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IR6TP	31289362	Green Published, hybrid			2022-12-28	WOS:000481572400005
J	Naito, Y; Yamamoto, Y; Sakamoto, N; Shimomura, I; Kogure, A; Kumazaki, M; Yokoi, A; Yashiro, M; Kiyono, T; Yanagihara, K; Takahashi, RU; Hirakawa, K; Yasui, W; Ochiya, T				Naito, Yutaka; Yamamoto, Yusuke; Sakamoto, Naoya; Shimomura, Iwao; Kogure, Akiko; Kumazaki, Minami; Yokoi, Akira; Yashiro, Masakazu; Kiyono, Tohru; Yanagihara, Kazuyoshi; Takahashi, Ryou-u; Hirakawa, Kosei; Yasui, Wataru; Ochiya, Takahiro			Cancer extracellular vesicles contribute to stromal heterogeneity by inducing chemokines in cancer-associated fibroblasts	ONCOGENE			English	Article							TGF-BETA; CELLS; RECRUITMENT; EXPRESSION; CARCINOMA; GROWTH; CXCL1; CHEMORESISTANCE; INTERLEUKIN-8; LOCALIZATION	Cancer-associated fibroblasts (CAFs), one of the major components of a tumour microenvironment, comprise heterogeneous populations involved in tumour progression. However, it remains obscure how CAF heterogeneity is governed by cancer cells. Here, we show that cancer extracellular vesicles (EVs) induce a series of chemokines in activated fibroblasts and contribute to the formation of the heterogeneity. In a xenograft model of diffuse-type gastric cancer, we showed two distinct fibroblast subpopulations with alpha-smooth muscle actin (alpha-SMA) expression or chemokine expression. MicroRNAs (miRNAs) profiling of the EVs and the transfection experiment suggested that several miRNAs played a role in the induction of chemokines such as CXCL1 and CXCL8 in fibroblasts, but not for the myofibroblastic differentiation. Clinically, aberrant activation of CXCL1 and CXCL8 in CAFs correlated with poorer survival in gastric cancer patients. Thus, this link between chemokine expression in CAFs and tumour progression may provide novel targets for anticancer therapy.	[Naito, Yutaka; Yamamoto, Yusuke; Shimomura, Iwao; Kogure, Akiko; Kumazaki, Minami; Yokoi, Akira; Takahashi, Ryou-u; Ochiya, Takahiro] Natl Canc Ctr, Div Mol & Cellular Med, Tokyo, Japan; [Sakamoto, Naoya; Yasui, Wataru] Hiroshima Univ, Dept Mol Pathol, Grad Sch Biomed & Hlth Sci, Hiroshima, Japan; [Yashiro, Masakazu; Hirakawa, Kosei] Osaka City Univ, Mol Oncol & Therapeut, Grad Sch Med, Osaka, Japan; [Kiyono, Tohru] Natl Canc Ctr, Div Carcinogenesis & Canc Prevent, Tokyo, Japan; [Yanagihara, Kazuyoshi] Natl Canc Ctr, Div Biomarker Discovery, Exploratory Oncol & Clin Trial Ctr, Chiba, Japan; [Takahashi, Ryou-u] Hiroshima Univ, Dept Cellular & Mol Biol, Div Integrated Med Sci, Grad Sch Biomed Sci, Hiroshima, Japan; [Ochiya, Takahiro] Tokyo Med Univ, Dept Mol & Cellular Med, Inst Med Sci, Tokyo, Japan	National Cancer Center - Japan; Hiroshima University; Osaka Metropolitan University; National Cancer Center - Japan; National Cancer Center - Japan; Hiroshima University; Tokyo Medical University	Ochiya, T (corresponding author), Natl Canc Ctr, Div Mol & Cellular Med, Tokyo, Japan.; Ochiya, T (corresponding author), Tokyo Med Univ, Dept Mol & Cellular Med, Inst Med Sci, Tokyo, Japan.	tochiya@ncc.go.jp	Ochiya, Takahiro/AAH-7585-2019; Asada, Akiko/ABF-7324-2020		JSPS KAKENHI Grant [15K21646, 17H04991, 17K19625]; JSPS [15J10473]; Center of Open Innovation Network for Smart Health (COINS); Council for Science; Japan Agency for Medical Research and development, AMED; Naito foundation	JSPS KAKENHI Grant(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Center of Open Innovation Network for Smart Health (COINS); Council for Science; Japan Agency for Medical Research and development, AMED(Japan Agency for Medical Research and Development (AMED)); Naito foundation(Naito Memorial Foundation)	We thank Mr. Shinichi Norimura in Hiroshima University for his excellent technical assistance. This work was supported by JSPS KAKENHI Grant Number 15K21646, 17H04991 and 17K19625, and JSPS Fellows 15J10473 and in part by a Grant-in-Aid for the Japan Science and Technology Agency (JST) through the Center of Open Innovation Network for Smart Health (COINS) initiated by the Council for Science, a Grant-in-Aid for the Project for Cancer Research And Therapeutic Evolution (P-CREATE) from the Japan Agency for Medical Research and development, AMED; and the research grant from Naito foundation.	Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Al-Alwan LA, 2013, J IMMUNOL, V191, P2731, DOI 10.4049/jimmunol.1203421; Anderberg C, 2009, CANCER RES, V69, P369, DOI 10.1158/0008-5472.CAN-08-2724; Asfaha S, 2013, GASTROENTEROLOGY, V144, P155, DOI 10.1053/j.gastro.2012.09.057; Baroni S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.224; Belli C, 2018, CANCER TREAT REV, V65, P22, DOI 10.1016/j.ctrv.2018.02.004; Bhattacharyya S, 2011, J BIOL CHEM, V286, P11604, DOI 10.1074/jbc.M110.198390; Cheng WL, 2011, ANN ONCOL, V22, P2267, DOI 10.1093/annonc/mdq739; Costa A, 2018, CANCER CELL, V33, P463, DOI 10.1016/j.ccell.2018.01.011; De Filippo K, 2013, BLOOD, V121, P4930, DOI 10.1182/blood-2013-02-486217; Eck M, 2003, CLIN EXP IMMUNOL, V134, P508, DOI 10.1111/j.1365-2249.2003.02305.x; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Fang T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02583-0; Givel AM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03348-z; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Jackson DG, 2001, TRENDS IMMUNOL, V22, P317, DOI 10.1016/S1471-4906(01)01936-6; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Kasashima H, 2016, AM J PATHOL, V186, P3028, DOI 10.1016/j.ajpath.2016.07.024; Kawajiri H, 2008, CLIN CANCER RES, V14, P2850, DOI 10.1158/1078-0432.CCR-07-1634; Kitadai Y, 1998, AM J PATHOL, V152, P93; Kojima Y, 2010, P NATL ACAD SCI USA, V107, P20009, DOI 10.1073/pnas.1013805107; Kosaka N, 2013, J BIOL CHEM, V288, P10849, DOI 10.1074/jbc.M112.446831; Kosaka N, 2010, J BIOL CHEM, V285, P17442, DOI 10.1074/jbc.M110.107821; Lazennec G, 2010, TRENDS MOL MED, V16, P133, DOI 10.1016/j.molmed.2010.01.003; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; MIZOI T, 1993, CANCER RES, V53, P183; Ohlund D, 2014, J EXP MED, V211, P1503, DOI 10.1084/jem.20140692; Ohlund D, 2017, J EXP MED, V214, P579, DOI 10.1084/jem.20162024; Paggetti J, 2015, BLOOD, V126, P1106, DOI 10.1182/blood-2014-12-618025; Powell DR, 2016, TRENDS IMMUNOL, V37, P41, DOI 10.1016/j.it.2015.11.008; Raja UM, 2017, CYTOKINE, V89, P82, DOI 10.1016/j.cyto.2016.08.032; Roswall P, 2018, NAT MED, V24, P463, DOI 10.1038/nm.4494; Shinto O, 2010, BRIT J CANCER, V102, P844, DOI 10.1038/sj.bjc.6605561; Su SC, 2018, CELL, V172, P841, DOI 10.1016/j.cell.2018.01.009; Sugimoto H, 2014, CANCER BIOL THER, V5, P1640; Tominaga N, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7716; Verbeke H, 2011, CANCER LETT, V302, P54, DOI 10.1016/j.canlet.2010.12.013; Webber JP, 2015, ONCOGENE, V34, P319, DOI 10.1038/onc.2013.560; Webber J, 2010, CANCER RES, V70, P9621, DOI 10.1158/0008-5472.CAN-10-1722; Wu RF, 2018, J CLIN INVEST, V128, P2551, DOI 10.1172/JCI97426; Yamaguchi H, 2015, CANCERS, V7, P2054, DOI 10.3390/cancers7040876; Yanagihara K, 2004, CANCER SCI, V95, P575, DOI 10.1111/j.1349-7006.2004.tb02489.x; Yanagihara K, 2006, CANCER RES, V66, P7532, DOI 10.1158/0008-5472.CAN-05-3259; Yanez-Mo M, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27066; Zhou WY, 2014, CANCER CELL, V25, P501, DOI 10.1016/j.ccr.2014.03.007; Zomer A, 2015, CELL, V161, P1046, DOI 10.1016/j.cell.2015.04.042	48	53	54	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2019	38	28					5566	5579		10.1038/s41388-019-0832-4	http://dx.doi.org/10.1038/s41388-019-0832-4			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IH9RW	31147602	Green Published, hybrid			2022-12-28	WOS:000474845100002
J	Fadhlullah, SFB; Halim, NBA; Yeo, JYT; Ho, RLY; Um, P; Ang, BT; Tang, C; Ng, WH; Virshup, DM; Ho, IAW				Fadhlullah, Siti Farah Bte; Halim, Nurashikin Bte Abdul; Yeo, Jacqueline Y. T.; Ho, Rachel L. Y.; Um, Phoebe; Ang, Beng Ti; Tang, Carol; Ng, Wai H.; Virshup, David M.; Ho, Ivy A. W.			Pathogenic mutations in neurofibromin identifies a leucine-rich domain regulating glioma cell invasiveness	ONCOGENE			English	Article							NF1 TUMOR-SUPPRESSOR; EPITHELIAL-MESENCHYMAL TRANSITION; INTEGRATED GENOMIC ANALYSIS; PATIENT SURVIVAL; PROTEIN-KINASE; UP-REGULATION; GLIOBLASTOMA; CANCER; EXPRESSION; SUBTYPES	Glioblastoma (GBM) is the most aggressive tumor of the brain. NF1, a tumor suppressor gene and RAS-GTPase, is one of the highly mutated genes in GBM. Dysregulated NF1 expression promotes cell invasion, proliferation, and tumorigenesis. Loss of NF1 expression in glioblastoma is associated with increased aggressiveness of the tumor. Here, we show that NF1-loss in patient-derived glioma cells using shRNA increases self-renewal, heightens cell invasion, and promotes mesenchymal subtype and epithelial mesenchymal transition-specific gene expression that enhances tumorigenesis. The neurofibromin protein contains at least four major domains, with the GAP-related domain being the most well-studied. In this study, we report that the leucine-rich domain (LRD) of neurofibromin inhibits invasion of human glioblastoma cells without affecting their proliferation. Moreover, under conditions tested, the NF1-LRD fails to hydrolyze Ras-GTP to Ras-GDP, suggesting that its suppressive function is independent of Ras signaling. We further demonstrate that rare variants within the NF1-LRD domain found in a subset of the patients are pathogenic and reduce NF1-LRD's invasion suppressive function. Taken together, our results show, for the first time, that NF1-LRD inhibits glioma invasion, and provides evidence of a previously unrecognized function of NF1-LRD in glioma biology.	[Fadhlullah, Siti Farah Bte; Halim, Nurashikin Bte Abdul; Yeo, Jacqueline Y. T.; Ho, Rachel L. Y.; Um, Phoebe; Ho, Ivy A. W.] Natl Neurosci Inst, Mol Neurotherapeut Lab, Singapore 308433, Singapore; [Um, Phoebe] Univ Penn, Philadelphia, PA 19104 USA; [Ang, Beng Ti; Ng, Wai H.] Natl Neurosci Inst, Dept Neurosurg, Singapore 308433, Singapore; [Ang, Beng Ti; Ho, Ivy A. W.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore 119228, Singapore; [Ang, Beng Ti] ASTAR, Singapore Inst Clin Sci, Singapore 117609, Singapore; [Ang, Beng Ti; Ho, Ivy A. W.] Duke NUS Med Sch, Singapore 169857, Singapore; [Tang, Carol] Natl Neurosci Inst, Dept Res, Singapore 308433, Singapore; [Tang, Carol; Virshup, David M.] Duke NUS Med Sch, Program Canc & Stem Cell Biol, Singapore 169857, Singapore; [Tang, Carol] Natl Canc Ctr, Div Cellular & Mol Res, Singapore 169610, Singapore; [Virshup, David M.] Duke Univ, Dept Pediat, Sch Med, Durham, NC 27703 USA; [Fadhlullah, Siti Farah Bte] Lucence Diagnost Pte Ltd, Singapore, Singapore	National Neuroscience Institute (NNI); University of Pennsylvania; National Neuroscience Institute (NNI); National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Singapore Institute for Clinical Sciences (SICS); National University of Singapore; National Neuroscience Institute (NNI); National University of Singapore; National Cancer Centre Singapore (NCCS); Duke University	Ho, IAW (corresponding author), Natl Neurosci Inst, Mol Neurotherapeut Lab, Singapore 308433, Singapore.; Ho, IAW (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore 119228, Singapore.; Ho, IAW (corresponding author), Duke NUS Med Sch, Singapore 169857, Singapore.	ivy_aw_ho@nni.com.sg	Virshup, David M/C-1449-2009	Virshup, David M/0000-0001-6976-850X; Ho, Ivy/0000-0002-2948-3726; Tang, Carol/0000-0002-1835-5083	NCC Research Fund and Oncology Academic Program [NCCRF-OACPCCS-YR2014-AUG-3]; National Medical Research Council [NMRC/OFIRG/0039/2017]; Singapore Ministry of Health's National Medical Research Council under its Translational and Clinical Research (TCR) Flagship Program-Tier 1 [NMRC/TCR/016-NNI/2016]	NCC Research Fund and Oncology Academic Program; National Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Singapore Ministry of Health's National Medical Research Council under its Translational and Clinical Research (TCR) Flagship Program-Tier 1	This project is funded by grants from NCC Research Fund and Oncology Academic Program (NCCRF-OACPCCS-YR2014-AUG-3), National Medical Research Council (NMRC/OFIRG/0039/2017), and institutional center grant to IAWH. This work is also partially supported by the Singapore Ministry of Health's National Medical Research Council under its Translational and Clinical Research (TCR) Flagship Program-Tier 1 (Project No. NMRC/TCR/016-NNI/2016) awarded to BTA and CT.	Ambrosini G, 2008, MOL CANCER THER, V7, P890, DOI 10.1158/1535-7163.MCT-07-0518; Arima Y, 2010, EXP DERMATOL, V19, pE136, DOI 10.1111/j.1600-0625.2009.01017.x; Bayo P, 2015, MOL ONCOL, V9, P1704, DOI 10.1016/j.molonc.2015.05.006; Berezovsky AD, 2014, NEOPLASIA, V16, DOI 10.1016/j.neo.2014.03.006; Boissan M, 2010, CANCER RES, V70, P7710, DOI 10.1158/0008-5472.CAN-10-1887; Bonneau F, 2009, PROTEIN EXPRES PURIF, V65, P30, DOI 10.1016/j.pep.2008.12.001; Brennan C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007752; Brown DV, 2015, ONCOTARGET, V6, P6267, DOI 10.18632/oncotarget.3365; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cheng GZ, 2008, CANCER RES, V68, P957, DOI 10.1158/0008-5472.CAN-07-5067; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Chong YK, 2009, STEM CELLS, V27, P29, DOI 10.1634/stemcells.2008-0009; Chow RD, 2017, NAT NEUROSCI, V20, P1329, DOI 10.1038/nn.4620; Cichowski K, 2001, CELL, V104, P593, DOI 10.1016/S0092-8674(01)00245-8; Cui Y, 2019, HUM MUTAT, V40, P187, DOI 10.1002/humu.23681; D'Angelo I, 2006, EMBO REP, V7, P174, DOI 10.1038/sj.embor.7400602; de Bruin EC, 2014, CANCER DISCOV, V4, P606, DOI 10.1158/2159-8290.CD-13-0741; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Dodd RD, 2013, MOL CANCER THER, V12, P1906, DOI 10.1158/1535-7163.MCT-13-0189; Dombi E, 2016, NEW ENGL J MED, V375, P2550, DOI 10.1056/NEJMoa1605943; Elston MS, 2009, J CLIN ENDOCR METAB, V94, P1436, DOI 10.1210/jc.2008-2075; Feng LP, 2004, FEBS LETT, V557, P275, DOI 10.1016/S0014-5793(03)01507-2; Foong Charlene Shu Fen, 2011, Front Biosci (Schol Ed), V3, P698, DOI 10.2741/s181; Fortier AM, 2013, J BIOL CHEM, V288, P11555, DOI 10.1074/jbc.M112.428920; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Guo JM, 2017, AM J CANCER RES, V7, P923; Herting CJ, 2017, GLIA, V65, P1914, DOI 10.1002/glia.23203; Ho IAW, 2009, STEM CELLS, V27, P1366, DOI 10.1002/stem.50; Holen I, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3201; Holzel M, 2010, CELL, V142, P218, DOI 10.1016/j.cell.2010.06.004; Hsueh YP, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-33; Johnson DR, 2012, J NEURO-ONCOL, V107, P359, DOI 10.1007/s11060-011-0749-4; Joseph NM, 2008, CANCER CELL, V13, P129, DOI 10.1016/j.ccr.2008.01.003; Kahen Elliot John, 2018, Oncotarget, V9, P22571, DOI 10.18632/oncotarget.25181; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; Koh LWH, 2013, ANTIOXID REDOX SIGN, V19, P2261, DOI 10.1089/ars.2012.4999; Kweh F, 2009, MOL CARCINOGEN, V48, P1005, DOI 10.1002/mc.20552; Kwiatkowska A, 2011, BBA-MOL CELL RES, V1813, P655, DOI 10.1016/j.bbamcr.2011.01.020; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Lee JK, 2014, ONCOTARGETS THER, V7, P1933, DOI 10.2147/OTT.S36582; Lin YL, 2007, J CELL BIOL, V177, P829, DOI 10.1083/jcb.200608121; Llaguno SA, 2009, CANCER CELL, V15, P45, DOI 10.1016/j.ccr.2008.12.006; Llaguno SRA, 2015, CANCER CELL, V28, P429, DOI 10.1016/j.ccell.2015.09.007; Maertens O, 2013, CANCER DISCOV, V3, P338, DOI 10.1158/2159-8290.CD-12-0313; Maki RG, 2009, J CLIN ONCOL, V27, P3133, DOI 10.1200/JCO.2008.20.4495; McGillicuddy LT, 2009, CANCER CELL, V16, P44, DOI 10.1016/j.ccr.2009.05.009; Mendes-Pereira AM, 2012, P NATL ACAD SCI USA, V109, P2730, DOI 10.1073/pnas.1018872108; Miller SJ, 2006, CANCER RES, V66, P2584, DOI 10.1158/0008-5472.CAN-05-3330; Ng FSL, 2012, CLIN CANCER RES, V18, P4122, DOI 10.1158/1078-0432.CCR-11-3064; Nissan MH, 2014, CANCER RES, V74, P2340, DOI 10.1158/0008-5472.CAN-13-2625; Ozawa T, 2014, CANCER CELL, V26, P288, DOI 10.1016/j.ccr.2014.06.005; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Patrakitkomjorn S, 2008, J BIOL CHEM, V283, P9399, DOI 10.1074/jbc.M708206200; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Pu PY, 2006, J NEURO-ONCOL, V76, P1, DOI 10.1007/s11060-005-3029-3; Qian Y, 2004, AM J PHYSIOL-CELL PH, V286, pC153, DOI 10.1152/ajpcell.00142.2003; Ratner N, 2015, NAT REV CANCER, V15, P290, DOI 10.1038/nrc3911; Scheffzek K, 2012, FEBS LETT, V586, P2662, DOI 10.1016/j.febslet.2012.06.006; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308; Sintupisut N, 2013, NUCLEIC ACIDS RES, V41, P8803, DOI 10.1093/nar/gkt656; Stowe IB, 2012, GENE DEV, V26, P1421, DOI 10.1101/gad.190876.112; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; THE I, 1993, NAT GENET, V3, P62, DOI 10.1038/ng0193-62; Tokuo H, 2001, FEBS LETT, V494, P48, DOI 10.1016/S0014-5793(01)02309-2; Tuominen VJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2615; Vallee B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047283; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang HF, 2011, J CLIN INVEST, V121, P4820, DOI 10.1172/JCI45677; Wang KZQ, 2006, J CELL SCI, V119, P1579, DOI 10.1242/jcs.02889; Welti S, 2007, J MOL BIOL, V366, P551, DOI 10.1016/j.jmb.2006.11.055; Whittaker SR, 2013, CANCER DISCOV, V3, P350, DOI 10.1158/2159-8290.CD-12-0470; Yamaguchi N, 2015, SCI REP-UK, V5, DOI 10.1038/srep07656; Yulyana Y, 2013, STEM CELLS DEV, V22, P1870, DOI 10.1089/scd.2012.0529; Zhu Y, 2001, EXP CELL RES, V264, P19, DOI 10.1006/excr.2000.5138	75	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2019	38	27					5367	5380		10.1038/s41388-019-0809-3	http://dx.doi.org/10.1038/s41388-019-0809-3			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IG5KR	30967630	hybrid, Green Published			2022-12-28	WOS:000473842500003
J	Cao, ZY; Xue, JH; Cheng, YN; Wang, JY; Liu, YJ; Li, H; Jiang, W; Li, G; Gui, YT; Zhang, XW				Cao, Zhengyi .; Xue, Junhui; Cheng, Yuning; Wang, Jiyin; Liu, Yujuan; Li, Hui; Jiang, Wei; Li, Gang; Gui, Yaoting; Zhang, Xiaowei			MDM2 promotes genome instability by ubiquitinating the transcription factor HBP1	ONCOGENE			English	Article							TUMOR-SUPPRESSOR PROTEIN; DNA-DAMAGE; CELL-CYCLE; EXPRESSION; DEGRADATION; GENE; OVEREXPRESSION; CANCER; APOPTOSIS; PATHWAY	Genome instability is a common feature of tumor cells, and the persistent presence of genome instability is a potential mechanism of tumorigenesis. The E3 ubiquitin ligase MDM2 is intimately involved in genome instability, but its mechanisms are unclear. Our data demonstrated that the transcription factor HBP1 is a target of MDM2. MDM2 facilitates HBP1 proteasomal degradation by ubiquitinating HBP1, regardless of p53 status, thus attenuating the transcriptional inhibition of HBP1 in the expression of its target genes, such as the DNA methyltransferase DNMT1 and histone methyltransferase EZH2, which results in global DNA hypermethylation and histone hypermethylation and ultimately genome instability. The repression of HBP1 by MDM2 finally promotes cell growth and tumorigenesis. Next, we thoroughly explored the regulatory mechanism of the MDM2/HBP1 axis in DNA damage repair following ionizing radiation. Our data indicated that MDM2 overexpression-mediated repression of HBP1 delays DNA damage repair and causes cell death in a p53-independent manner. This investigation elucidated the mechanism of how MDM2 promotes genome instability and enhances tumorigenesis in the absence of p53, thus providing a theoretical and experimental basis for targeting MDM2 as a cancer therapy.	[Cao, Zhengyi .; Xue, Junhui; Cheng, Yuning; Wang, Jiyin; Liu, Yujuan; Li, Hui; Jiang, Wei; Li, Gang; Zhang, Xiaowei] Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol,Sch Basic Med Sci, Beijing Key Lab Prot Posttranslat Modificat & Cel, Beijing 100191, Peoples R China; [Gui, Yaoting] Hong Kong Univ Sci & Technol, Shenzhen Peking Univ, Peking Univ Shenzhen Hosp,Inst Urol,Med Ctr, Guangdong & Shenzhen Key Lab Male Reprod Med & Ge, Shenzhen 518000, Peoples R China	Peking University; Hong Kong University of Science & Technology; Peking University	Zhang, XW (corresponding author), Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol,Sch Basic Med Sci, Beijing Key Lab Prot Posttranslat Modificat & Cel, Beijing 100191, Peoples R China.	xiaoweizhang@bjmu.edu.cn	gui, yaoting/GLT-3684-2022; Cheng, Yuning/GSE-2360-2022	Cheng, Yuning/0000-0002-8171-8748	National Natural Science Foundation of China [81672717, 31471292, 81874141, 81572705]; Beijing Natural Science Foundation [5162013]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation(Beijing Natural Science Foundation)	This work was supported by grants of the National Natural Science Foundation of China (No. 81672717, 31471292, 81874141, and 81572705) and Beijing Natural Science Foundation Grant (No. 5162013).	Alt JR, 2005, J BIOL CHEM, V280, P18771, DOI 10.1074/jbc.M413387200; Bartel F, 2002, CANCER CELL, V2, P9, DOI 10.1016/S1535-6108(02)00091-0; Berasi SP, 2004, MOL CELL BIOL, V24, P3011, DOI 10.1128/MCB.24.7.3011-3024.2004; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Chen YF, 2016, J BIOL CHEM, V291, P12688, DOI 10.1074/jbc.M116.714147; Chene P, 2004, MOL CANCER RES, V2, P20; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; CORDONCARDO C, 1994, CANCER RES, V54, P794; Deb Swati Palit, 2014, Subcell Biochem, V85, P215, DOI 10.1007/978-94-017-9211-0_12; Eischen CM, 2017, J MOL CELL BIOL, V9, P69, DOI 10.1093/jmcb/mjw052; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Escamilla-Powers JR, 2010, J BIOL CHEM, V285, P4847, DOI 10.1074/jbc.M109.074856; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Ganguli G, 2003, MOL CANCER RES, V1, P1027; Gartel AL, 1998, ONCOGENE, V17, P3463, DOI 10.1038/sj.onc.1202240; Iwasa H, 2013, J BIOL CHEM, V288, P30320, DOI 10.1074/jbc.M113.507384; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Legube G, 2002, EMBO J, V21, P1704, DOI 10.1093/emboj/21.7.1704; Lehmann C, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0280-3; Lemercier C, 2000, MOL CELL BIOL, V20, P6627, DOI 10.1128/MCB.20.18.6627-6637.2000; Li H, 2010, ONCOGENE, V29, P5083, DOI 10.1038/onc.2010.252; Li Q, 2013, CLIN CANCER RES, V19, P34, DOI 10.1158/1078-0432.CCR-12-0053; Li YL, 2014, CANCER CELL, V26, P262, DOI 10.1016/j.ccr.2014.06.014; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Mendrysa SM, 2006, GENE DEV, V20, P16, DOI 10.1101/gad.1378506; Meulmeester E, 2005, MOL CELL, V18, P565, DOI 10.1016/j.molcel.2005.04.024; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Pan KW, 2013, MOL CELL BIOL, V33, P887, DOI 10.1128/MCB.00637-12; Pan Y, 2003, MOL CELL BIOL, V23, P5113, DOI 10.1128/MCB.23.15.5113-5121.2003; Rayburn E, 2005, CURR CANCER DRUG TAR, V5, P27, DOI 10.2174/1568009053332636; Riley MF, 2016, ONCOGENE, V35, P358, DOI 10.1038/onc.2015.88; Saadatzadeh MR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102216; Slack A, 2005, P NATL ACAD SCI USA, V102, P731, DOI 10.1073/pnas.0405495102; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Wang P, 2008, ONCOGENE, V27, P1590, DOI 10.1038/sj.onc.1210788; Wang P, 2006, ONCOGENE, V25, P3708, DOI 10.1038/sj.onc.1209411; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; Wang SY, 2017, J BIOL CHEM, V292, P8207, DOI 10.1074/jbc.M116.768101; Watanabe T, 1996, LEUKEMIA LYMPHOMA, V21, P391, DOI 10.3109/10428199609093436; Wen W, 2014, ONCOGENE, V33, P421, DOI 10.1038/onc.2012.605; Wienken M, 2016, MOL CELL, V61, P68, DOI 10.1016/j.molcel.2015.12.008; Xiu M, 2003, MOL CELL BIOL, V23, P8890, DOI 10.1128/MCB.23.23.8890-8901.2003; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Yang JY, 2006, MOL CELL BIOL, V26, P7269, DOI 10.1128/MCB.00172-06; Yao CJ, 2005, LEUKEMIA, V19, P1958, DOI 10.1038/sj.leu.2403918; Yu JW, 2016, CELL PROLIFERAT, V49, P79, DOI 10.1111/cpr.12238; Zhang XW, 2006, MOL CELL BIOL, V26, P8252, DOI 10.1128/MCB.00604-06; Zhao YJ, 2015, J MED CHEM, V58, P1038, DOI 10.1021/jm501092z; Zhou YL, 2018, CANCER BIOL THER, V19, P465, DOI 10.1080/15384047.2018.1433500	53	16	21	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2019	38	24					4835	4855		10.1038/s41388-019-0761-2	http://dx.doi.org/10.1038/s41388-019-0761-2			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IC7ND	30816344	Green Published, hybrid			2022-12-28	WOS:000471160500013
J	Dang, SW; Zhou, JS; Chen, YJ; Chen, P; Ji, MJ; Shi, BY; Yang, Q; Hou, P				Dang, Siwen; Zhou, Jingshi; Chen, Yijun; Chen, Pu; Ji, Meiju; Shi, Bingyin; Yang, Qi; Hou, Peng			Dynamic expression of ZNF382 and its tumor-suppressor role in hepatitis B virus-related hepatocellular carcinogenesis	ONCOGENE			English	Article							MAJOR SIGNALING PATHWAYS; X-PROTEIN; PROGNOSTIC-SIGNIFICANCE; CANCER STATISTICS; THYROID-CANCER; C-JUN; METHYLATION; GENE; ACTIVATION; GENOME	Hepatitis B virus (HBV) infection is the primary cause of hepatocellular carcinoma (HCC). Zinc-finger protein 382 (ZNF382), which belongs to zinc-finger protein family, has been documented to be downregulated in certain types of cancer. However, its role in HCC remains largely unknown. In this study, we demonstrated that ZNF382 expression was significantly elevated in HBV-infected liver cirrhosis tissues relative to HBV-negative normal liver tissues at protein levels, but not at mRNA levels, and was positively correlated with the levels of HBV DNA and hepatitis B virus X protein (HBx). Further studies revealed that ZNF382 was a target of miR-6867, and HBx promoted the translation of ZNF382 during HBV chronic infection through Erk-mediated miR-6867 inhibition. In addition, our data showed that ZNF382 was frequently downregulated by promoter methylation in HBV-related HCCs relative to HBV-infected liver cirrhosis tissues, and decreased expression of ZNF382 was strongly correlated with poor survival in early-stage HCC patients. Functional studies demonstrated that ZNF382 was a potent tumor suppressor in HCC cells through inhibiting cell proliferation, colony formation, migration, invasion, and tumorigenic potential in nude mice, and inducing cell apoptosis. Mechanistically, ZNF382 exerted its tumor-suppressor functions in HCC through transcriptionally repressing its downstream targets such as Fos proto-oncogene (FOS), Jun proto-oncogene (JUN), disheveled segment polarity protein 2 (DVL2), and frizzled class receptor 1 (FZD1), thereby impairing the activities of activating protein 1 (AP-1) and Wnt/beta-catenin pathways and activating p53 signaling. Altogether, our data show that ZNF382 acts as a tumor suppressor, and is co-regulated by HBx and epigenetic mechanism in HBV-related hepatocellular carcinogenesis.	[Dang, Siwen; Chen, Yijun; Chen, Pu; Shi, Bingyin; Yang, Qi; Hou, Peng] Xi An Jiao Tong Univ, Affiliated Hosp 1, Key Lab Tumor Precis Med Shaanxi Prov, Xian 710061, Shaanxi, Peoples R China; [Dang, Siwen; Chen, Yijun; Chen, Pu; Shi, Bingyin; Yang, Qi; Hou, Peng] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Endocrinol, Xian 710061, Shaanxi, Peoples R China; [Zhou, Jingshi] Fourth Mil Med Univ, Xijing Hosp, Dept Hepatobiliary Surg, Xian 710032, Shaanxi, Peoples R China; [Ji, Meiju] Xi An Jiao Tong Univ, Affiliated Hosp 1, Ctr Translat Med, Xian 710061, Shaanxi, Peoples R China	Xi'an Jiaotong University; Xi'an Jiaotong University; Air Force Military Medical University; Xi'an Jiaotong University	Yang, Q; Hou, P (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Key Lab Tumor Precis Med Shaanxi Prov, Xian 710061, Shaanxi, Peoples R China.; Yang, Q; Hou, P (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Endocrinol, Xian 710061, Shaanxi, Peoples R China.	docqiyang@163.com; phou@xjtu.edu.cn			National Nature Science Foundation of China [81402340, 81572627, 81672645]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Nature Science Foundation of China (no. 81402340, 81572627, and 81672645).	ANTUNOVIC J, 1993, CELL MOL BIOL RES, V39, P463; Arzumanyan A, 2013, NAT REV CANCER, V13, P123, DOI 10.1038/nrc3449; Arzumanyan A, 2012, CANCER RES, V72, P5912, DOI 10.1158/0008-5472.CAN-12-2329; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Berindan-Neagoe I, 2014, CA-CANCER J CLIN, V64, P311, DOI 10.3322/caac.21244; Bui-Nguyen TM, 2010, ONCOGENE, V29, P1179, DOI 10.1038/onc.2009.404; Calvisi DF, 2007, J CLIN INVEST, V117, P2713, DOI 10.1172/JCI31457; Chan SL, 2016, J CLIN ONCOL, V34, P83, DOI 10.1200/JCO.2015.61.5724; Chen JL, 2014, MOL THER, V22, P303, DOI 10.1038/mt.2013.212; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Cheng YD, 2010, CANCER RES, V70, P6516, DOI 10.1158/0008-5472.CAN-09-4566; Chiu CM, 2007, P NATL ACAD SCI USA, V104, P2571, DOI 10.1073/pnas.0609498104; Diao JY, 2001, CYTOKINE GROWTH F R, V12, P189, DOI 10.1016/S1359-6101(00)00034-4; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; Kim DJ, 2014, J CLIN ONCOL, V32, P745, DOI 10.1200/JCO.2013.49.9525; Li YJ, 2018, CANCER RES, V78, P5216, DOI 10.1158/0008-5472.CAN-18-0003; Lim SO, 2008, GASTROENTEROLOGY, V135, P2128, DOI 10.1053/j.gastro.2008.07.027; Liu ZJ, 2014, CLIN CANCER RES, V20, P4598, DOI 10.1158/1078-0432.CCR-13-3380; Luo KM, 2002, BIOCHEM BIOPH RES CO, V299, P606, DOI 10.1016/S0006-291X(02)02700-6; Murata M, 2009, HEPATOLOGY, V49, P1203, DOI 10.1002/hep.22765; Muthukrishnan D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10027; Neuveut C, 2010, J HEPATOL, V52, P594, DOI 10.1016/j.jhep.2009.10.033; Nishida N, 2012, HEPATOLOGY, V56, P994, DOI 10.1002/hep.25706; Niu YD, 2017, HEPATOLOGY, V65, P893, DOI 10.1002/hep.28924; Qiang W, 2014, J CLIN ENDOCR METAB, V99, pE1163, DOI 10.1210/jc.2013-3729; Qiu X, 2013, ONCOGENE, V32, P3296, DOI 10.1038/onc.2013.150; Revill K, 2013, GASTROENTEROLOGY, V145, P1424, DOI 10.1053/j.gastro.2013.08.055; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Schwabe RF, 2003, HEPATOLOGY, V37, P824, DOI 10.1053/jhep.2003.50135; Shan CL, 2010, CELL RES, V20, P563, DOI 10.1038/cr.2010.49; Shi J, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.346; Shi J, 2015, ONCOTARGET, V6, P14344, DOI 10.18632/oncotarget.3852; Shi J, 2012, INT J MOL SCI, V13, P4714, DOI 10.3390/ijms13044714; Shi J, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-50; Shi J, 2012, AM J CANCER RES, V2, P116; Shin YJ, 2013, CANCER BIOL THER, V14, P213, DOI 10.4161/cbt.23292; Song K, 2013, HEPATOLOGY, V58, P1681, DOI 10.1002/hep.26514; Sun HL, 2016, CANCER CELL, V30, P723, DOI 10.1016/j.ccell.2016.10.001; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Urrutia R, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-231; Wang C, 2012, HEPATOLOGY, V55, P108, DOI 10.1002/hep.24675; Wang D, 2014, AM J CANCER RES, V4, P725; Xu XJ, 2013, J CLIN INVEST, V123, P630, DOI 10.1172/JCI64265; Ye H, 2014, ONCOGENE, V33, P5133, DOI 10.1038/onc.2013.468; Zhang C, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0604-z; Zhang T, 2012, HEPATOLOGY, V56, P2051, DOI 10.1002/hep.25899; Zhou SJ, 2017, CELL DEATH DIFFER, V24, P1577, DOI 10.1038/cdd.2017.87	48	24	24	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2019	38	24					4804	4819		10.1038/s41388-019-0759-9	http://dx.doi.org/10.1038/s41388-019-0759-9			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IC7ND	30804458				2022-12-28	WOS:000471160500011
J	Yang, J; Guo, YQ; Lu, CJ; Zhang, RH; Wang, YY; Luo, L; Zhang, YL; Chu, CH; Wang, KJ; Obbad, S; Yan, WB; Li, X				Yang, Jian; Guo, Yuqi; Lu, Cuijie; Zhang, Ruohan; Wang, Yaoyu; Luo, Liang; Zhang, Yanli; Chu, Catherine H.; Wang, Katherine J.; Obbad, Sabrine; Yan, Wenbo; Li, Xin			Inhibition of Karyopherin beta 1 suppresses prostate cancer growth	ONCOGENE			English	Article							NF-KAPPA-B; TUMOR-CELL SURVIVAL; IMPORTIN BETA-1; NUCLEAR IMPORT; C-MYC; MESENCHYMAL TRANSITION; TRANSPORT RECEPTOR; METFORMIN TARGETS; POOR-PROGNOSIS; PROTEIN	Prostate cancer (PCa) initiation and progression requires activation of numerous oncogenic signaling pathways. Nuclear-cytoplasmic transport of oncogenic factors is mediated by Karyopherin proteins during cell transformation. However, the role of nuclear transporter proteins in PCa progression has not been well defined. Here, we report that the KPNB1, a key member of Karyopherin beta subunits, is highly expressed in advanced prostate cancers. Further study showed that targeting KPNB1 suppressed the proliferation of prostate cancer cells. The knockdown of KPNB1 reduced nuclear translocation of c-Myc, the expression of downstream cell cycle modulators, and phosphorylation of regulator of chromatin condensation 1 (RCC1), a key protein for spindle assembly during mitosis. Meanwhile, CHIP assay demonstrated the binding of c-Myc to KPNB1 promoter region, which indicated a positive feedback regulation of KPNB1 expression mediated by the c-Myc. In addition, NF-kappa B subunit p50 translocation to nuclei was blocked by KPNB1 inhibition, which led to an increase in apoptosis and a decrease in tumor sphere formation of PCa cells. Furthermore, subcutaneous xenograft tumor models with a stable knockdown of KPNB1 in C42B PCa cells validated that the inhibition of KPNB1 could suppress the growth of prostate tumor in vivo. Moreover, the intravenously administration of importazole, a specific inhibitor for KPNB1, effectively reduced PCa tumor size and weight in mice inoculated with PC3 PCa cells. In summary, our data established the functional link between KPNB1 and PCa prone c-Myc, NF-kB, and cell cycle modulators. More importantly, inhibition of KPNB1 could be a new therapeutic target for PCa treatment.	[Yang, Jian; Guo, Yuqi; Lu, Cuijie; Zhang, Ruohan; Wang, Yaoyu; Luo, Liang; Zhang, Yanli; Chu, Catherine H.; Wang, Katherine J.; Obbad, Sabrine; Yan, Wenbo; Li, Xin] NYU, Coll Dent, Dept Basic Sci & Craniofacial Biol, New York, NY 10010 USA; [Li, Xin] NYU, Langone Med Ctr, Dept Urol, New York, NY 10016 USA; [Li, Xin] NYU, Langone Med Ctr, Perlmutter Canc Inst, New York, NY 10016 USA	New York University; New York University; NYU Langone Medical Center; New York University; NYU Langone Medical Center	Li, X (corresponding author), NYU, Coll Dent, Dept Basic Sci & Craniofacial Biol, New York, NY 10010 USA.; Li, X (corresponding author), NYU, Langone Med Ctr, Dept Urol, New York, NY 10016 USA.; Li, X (corresponding author), NYU, Langone Med Ctr, Perlmutter Canc Inst, New York, NY 10016 USA.	xl15@nyu.edu	yan, wenbo/GXV-2795-2022	Li, Xin/0000-0002-7414-5734	NYU CSCB Pilot Study Award; National Institutes of Health [R01CA180277, R01DE025992, R01DE027074]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE025992, R01DE027074] Funding Source: NIH RePORTER	NYU CSCB Pilot Study Award; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This study was partly supported by NYU CSCB Pilot Study Award to JY, National Institutes of Health grants R01CA180277, R01DE025992 and R01DE027074 to XL. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aggarwal A, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/476357; Akinyeke T, 2013, CARCINOGENESIS, V34, P2823, DOI 10.1093/carcin/bgt307; Alshareeda AT, 2015, BRIT J CANCER, V112, P1929, DOI 10.1038/bjc.2015.165; Altan B, 2013, CARCINOGENESIS, V34, P2314, DOI 10.1093/carcin/bgt214; Angus L, 2014, CARCINOGENESIS, V35, P1121, DOI 10.1093/carcin/bgt491; Bretones G, 2015, BBA-GENE REGUL MECH, V1849, P506, DOI 10.1016/j.bbagrm.2014.03.013; Cai YX, 2016, DIGEST DIS SCI, V61, P747, DOI 10.1007/s10620-015-3948-6; Chen T, 2007, NAT CELL BIOL, V9, P596, DOI 10.1038/ncb1572; Elgogary A, 2016, P NATL ACAD SCI USA, V113, pE5328, DOI 10.1073/pnas.1611406113; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Fagerlund R, 2005, J BIOL CHEM, V280, P15942, DOI 10.1074/jbc.M500814200; Gagne B, 2017, TRAFFIC, V18, P362, DOI 10.1111/tra.12480; Ghildyal R, 2005, BIOCHEMISTRY-US, V44, P12887, DOI 10.1021/bi050701e; Gurel B, 2008, MODERN PATHOL, V21, P1156, DOI 10.1038/modpathol.2008.111; Ha S, 2018, CHEMBIOCHEM, V19, P131, DOI 10.1002/cbic.201700489; Hadjebi O, 2008, BBA-MOL CELL RES, V1783, P1467, DOI 10.1016/j.bbamcr.2008.03.015; He XL, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0422-1; Hood FE, 2007, J CELL SCI, V120, P3436, DOI 10.1242/jcs.009092; Huang L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.256; Huang L, 2018, J CANCER, V9, P157, DOI 10.7150/jca.20879; Hutchins JRA, 2004, CURR BIOL, V14, P1099, DOI 10.1016/j.cub.2004.05.021; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Koch HB, 2007, CELL CYCLE, V6, P205, DOI 10.4161/cc.6.2.3742; Kodama M, 2017, P NATL ACAD SCI USA, V114, pE7301, DOI 10.1073/pnas.1705441114; Koh Cheryl M, 2010, Genes Cancer, V1, P617, DOI 10.1177/1947601910379132; Kuusisto HV, 2015, BBA-MOL CELL RES, V1853, P1870, DOI 10.1016/j.bbamcr.2015.05.002; Laurila E, 2014, EXP CELL RES, V322, P159, DOI 10.1016/j.yexcr.2013.11.014; Liang PZ, 2013, TRAFFIC, V14, P1132, DOI 10.1111/tra.12097; Lo HW, 2006, J CELL BIOCHEM, V98, P1570, DOI 10.1002/jcb.20876; Lu T, 2016, BIOCHEM BIOPH RES CO, V478, P1189, DOI 10.1016/j.bbrc.2016.08.093; Lundberg L, 2013, ANTIVIR RES, V100, P662, DOI 10.1016/j.antiviral.2013.10.004; Mahipal A, 2016, PHARMACOL THERAPEUT, V164, P135, DOI 10.1016/j.pharmthera.2016.03.020; Martens-de Kemp SR, 2013, CLIN CANCER RES, V19, P1994, DOI 10.1158/1078-0432.CCR-12-2539; Moore WJ, 2002, CURR BIOL, V12, P1442, DOI 10.1016/S0960-9822(02)01076-X; Nakanishi C, 2005, NAT REV CANCER, V5, P297, DOI 10.1038/nrc1588; Qin ZH, 1999, J NEUROSCI, V19, P4023; Schmitz MHA, 2010, NAT CELL BIOL, V12, P886, DOI 10.1038/ncb2092; Shen SH, 2017, ONCOTARGET, V8, P41432, DOI 10.18632/oncotarget.18186; Soderholm JF, 2011, ACS CHEM BIOL, V6, P700, DOI 10.1021/cb2000296; Stelma T, 2016, IUBMB LIFE, V68, P268, DOI 10.1002/iub.1484; THALMANN GN, 1994, CANCER RES, V54, P2577; van der Watt PJ, 2016, MOL CANCER THER, V15, P560, DOI 10.1158/1535-7163.MCT-15-0052; van der Watt PJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027723; Vuorinen EM, 2017, BBA-MOL BASIS DIS, V1863, P211, DOI 10.1016/j.bbadis.2016.09.015; Wang HJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep13072; Wang J, 2016, ONCOL REP, V36, P441, DOI 10.3892/or.2016.4830; Wang SX, 2015, J PHYSIOL BIOCHEM, V71, P763, DOI 10.1007/s13105-015-0440-x; Watson PA, 2005, CANCER RES, V65, P11565, DOI 10.1158/0008-5472.CAN-05-3441; Winkler J, 2014, HEPATOLOGY, V60, P884, DOI 10.1002/hep.27207; WU HC, 1994, INT J CANCER, V57, P406, DOI 10.1002/ijc.2910570319; Yan WQ, 2015, CELL SIGNAL, V27, P851, DOI 10.1016/j.cellsig.2015.01.013; Yang J, 2017, ONCOGENE, V36, P2868, DOI 10.1038/onc.2016.440; Yang L, 2015, ASIA PAC J OPER RES, V32, DOI 10.1142/S0217595915400084; Zhang PY, 2014, J PATHOL, V232, P308, DOI 10.1002/path.4294	54	24	26	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2019	38	24					4700	4714		10.1038/s41388-019-0745-2	http://dx.doi.org/10.1038/s41388-019-0745-2			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IC7ND	30742095	Green Accepted			2022-12-28	WOS:000471160500004
J	Block, I; Muller, C; Sdogati, D; Pedersen, H; List, M; Jaskot, AM; Syse, SD; Hansen, PL; Schmidt, S; Christiansen, H; Casella, C; Olsen, SB; Blomstrom, MM; Riedel, A; Thomassen, M; Kruse, TA; Hansen, SWK; Kioschis, P; Mollenhauer, J				Block, Ines; Mueller, Carolin; Sdogati, Daniel; Pedersen, Henriette; List, Markus; Jaskot, Aleksandra M.; Syse, Silje Damkjaer; Hansen, Pernille Lund; Schmidt, Steffen; Christiansen, Helle; Casella, Cinzia; Olsen, Sidsel Bering; Blomstrom, Monica M.; Riedel, Angela; Thomassen, Mads; Kruse, Torben A.; Hansen, Soren W. Karlskov; Kioschis, Petra; Mollenhauer, Jan			CFP suppresses breast cancer cell growth by TES-mediated upregulation of the transcription factor DDIT3	ONCOGENE			English	Article							UNFOLDED PROTEIN RESPONSE; SOMATIC MUTATIONS; PROPERDIN BINDS; LARGE-SCALE; INHIBITION; EXPRESSION; PROLIFERATION; DEFICIENCY; LANDSCAPE; MORTALITY	Breast cancer is a heterogeneous genetic disease driven by the accumulation of individual mutations per tumor. Whole-genome sequencing approaches have identified numerous genes with recurrent mutations in primary tumors. Although mutations in well characterized tumor suppressors and oncogenes are overrepresented in these sets, the majority of the genetically altered genes have so far unknown roles in breast cancer progression. To improve the basic understanding of the complex disease breast cancer and to potentially identify novel drug targets or regulators of known cancer-driving pathways, we analyzed 86 wild-type genes and 94 mutated variants for their effect on cell growth using a serially constructed panel of MCF7 cell lines. We demonstrate in subsequent experiments that the metal cation transporter CNNM4 regulates growth by induction of apoptosis and identified a tumor suppressive role of complement factor properdin (CFP) in vitro and in vivo. CFP appears to induce the intracellular upregulation of the pro-apoptotic transcription factor DDIT3 which is associated with endoplasmic reticulum-stress response.	[Block, Ines; Mueller, Carolin; Sdogati, Daniel; Pedersen, Henriette; List, Markus; Jaskot, Aleksandra M.; Syse, Silje Damkjaer; Hansen, Pernille Lund; Schmidt, Steffen; Christiansen, Helle; Casella, Cinzia; Olsen, Sidsel Bering; Blomstrom, Monica M.; Riedel, Angela; Mollenhauer, Jan] Univ Southern Denmark, Inst Mol Med, Lundbeckfonden Ctr Excellence NanoCAN, Odense, Denmark; [Block, Ines; Mueller, Carolin; Sdogati, Daniel; Pedersen, Henriette; List, Markus; Jaskot, Aleksandra M.; Syse, Silje Damkjaer; Hansen, Pernille Lund; Schmidt, Steffen; Christiansen, Helle; Casella, Cinzia; Olsen, Sidsel Bering; Blomstrom, Monica M.; Riedel, Angela; Mollenhauer, Jan] Univ Southern Denmark, Inst Mol Med, Mol Oncol, Odense, Denmark; [Block, Ines; Thomassen, Mads; Kruse, Torben A.] Odense Univ Hosp, Dept Clin Genet, Odense, Denmark; [Hansen, Pernille Lund; Olsen, Sidsel Bering; Hansen, Soren W. Karlskov] Univ Southern Denmark, Dept Canc & Inflammat Res, Odense, Denmark; [Thomassen, Mads; Kruse, Torben A.] Univ Southern Denmark, Dept Human Genet, Odense, Denmark; [Kioschis, Petra] Mannheim Univ Appl Sci, Dept Biotechnol, Mannheim, Germany; [Block, Ines] Martin Luther Univ Halle Wittenberg, Inst Physiol Chem, Halle, Saale, Germany; [Mueller, Carolin] Univ Southern Denmark, Dept Biochem & Mol Biol, Odense, Denmark; [Pedersen, Henriette; Blomstrom, Monica M.] Danish Canc Soc Res Ctr, Brain Tumor Biol Grp, Copenhagen, Denmark; [List, Markus] Tech Univ Munich, TUM Sch Life Sci, Chair Expt Bioinformat, Big Data BioMed Grp, D-85354 Freising Weihenstephan, Germany; [Riedel, Angela] HI STEM gGmbH, Heidelberg Inst Stem Cell Technol & Expt Med, Heidelberg, Germany; [Riedel, Angela] German Canc Res Ctr, Cell Biol & Tumor Biol Program, Heidelberg, Germany	Lundbeckfonden; University of Southern Denmark; University of Southern Denmark; University of Southern Denmark; Odense University Hospital; University of Southern Denmark; University of Southern Denmark; Martin Luther University Halle Wittenberg; University of Southern Denmark; Danish Cancer Society; Technical University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ)	Block, I (corresponding author), Univ Southern Denmark, Inst Mol Med, Lundbeckfonden Ctr Excellence NanoCAN, Odense, Denmark.; Block, I (corresponding author), Univ Southern Denmark, Inst Mol Med, Mol Oncol, Odense, Denmark.; Block, I (corresponding author), Odense Univ Hosp, Dept Clin Genet, Odense, Denmark.; Block, I (corresponding author), Martin Luther Univ Halle Wittenberg, Inst Physiol Chem, Halle, Saale, Germany.	Ines.Block@uk-halle.de	Block, Ines/Q-5507-2016; Riedel, Angela/ABC-7207-2020; Hansen, Pernille Lund/F-3919-2016; Pedersen, Henriette/S-6231-2017	Block, Ines/0000-0003-1964-6031; Hansen, Soren/0000-0002-8186-4630; Bering Olsen, Sidsel/0000-0001-8465-6629; Hansen, Pernille Lund/0000-0001-8284-4917; Pedersen, Henriette/0000-0002-6872-0405; List, Markus/0000-0002-0941-4168	Lundbeck Foundation (Grant NanoCAN); Rektorspuljen SDU2020 Program [DAWN-2020]; Region Syddanmarks Ph.D.- and Forskningspulje; Fonden Til Laegevidenskabens Fremme; MIO project of the OUH Frontlinjepuljen; Aase og Ejnar Danielsens Fond; Torben og Alice Frimodts Fond; Kong Christian den Tiendes Fond; Brodrene Hartmanns Fond; Fru Astrid Thaysens Legat for Laegevidenskabelig Grundforskning; Grosserer A. V. Lykfeldt og Hustrus Legat; Familien Hede Nielsens Fond; Oda og Hans Svenningsens Fond; Lippmann Fonden; Gangsted Fonden; Kraeftens Bekaempelse; INTERREG 4A-program Syddanmark-Schleswig-K.E.R.N.; European Regional Development Fund	Lundbeck Foundation (Grant NanoCAN); Rektorspuljen SDU2020 Program; Region Syddanmarks Ph.D.- and Forskningspulje; Fonden Til Laegevidenskabens Fremme; MIO project of the OUH Frontlinjepuljen; Aase og Ejnar Danielsens Fond; Torben og Alice Frimodts Fond; Kong Christian den Tiendes Fond; Brodrene Hartmanns Fond; Fru Astrid Thaysens Legat for Laegevidenskabelig Grundforskning; Grosserer A. V. Lykfeldt og Hustrus Legat; Familien Hede Nielsens Fond; Oda og Hans Svenningsens Fond; Lippmann Fonden; Gangsted Fonden; Kraeftens Bekaempelse; INTERREG 4A-program Syddanmark-Schleswig-K.E.R.N.; European Regional Development Fund(European Commission)	The work was supported by the Lundbeck Foundation (Grant NanoCAN), and the Rektorspuljen SDU2020 Program (Grant: DAWN-2020); Region Syddanmarks Ph.D.- and Forskningspulje; Fonden Til Laegevidenskabens Fremme; MIO project of the OUH Frontlinjepuljen; Aase og Ejnar Danielsens Fond; Torben og Alice Frimodts Fond, Kong Christian den Tiendes Fond, Brodrene Hartmanns Fond, Fru Astrid Thaysens Legat for Laegevidenskabelig Grundforskning, Grosserer A. V. Lykfeldt og Hustrus Legat, Familien Hede Nielsens Fond, Oda og Hans Svenningsens Fond, Lippmann Fonden and Gangsted Fonden. The work was further support by scholarships granted by Kraeftens Bekaempelse and was co-financed by the INTERREG 4A-program Syddanmark-Schleswig-K.E.R.N. with funds from The European Regional Development Fund. The funding sources had no role in study design, collection of data and analysis, nor in the decision to publish, or preparation of the article.	Al-Rayahi IAM, 2017, IMMUN INFLAMM DIS, V5, P68, DOI 10.1002/iid3.142; Appenzeller-Herzog C, 2012, TRENDS CELL BIOL, V22, P274, DOI 10.1016/j.tcb.2012.02.006; Bathum L, 2006, MOL IMMUNOL, V43, P473, DOI 10.1016/j.molimm.2005.02.017; Biunno I, 2006, J CELL PHYSIOL, V208, P23, DOI 10.1002/jcp.20574; Chittenden TW, 2008, GENOMICS, V91, P508, DOI 10.1016/j.ygeno.2008.03.002; End C, 2009, EUR J IMMUNOL, V39, P833, DOI 10.1002/eji.200838689; Felsher DW, 2000, P NATL ACAD SCI USA, V97, P10544, DOI 10.1073/pnas.190327097; Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fijen CAP, 1999, MOL IMMUNOL, V36, P863, DOI 10.1016/S0161-5890(99)00107-8; Flamant L, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-391; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Funato Y, 2014, J CLIN INVEST, V124, P5398, DOI 10.1172/JCI76614; Gulerez I, 2016, EMBO REP, V17, P1890, DOI 10.15252/embr.201643393; Guo DH, 2005, MOL PAIN, V1, DOI 10.1186/1744-8069-1-15; Guo J, 2015, ONCOL REP, V33, P3124, DOI 10.3892/or.2015.3902; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Jiao X, 2012, GENE CHROMOSOME CANC, V51, P480, DOI 10.1002/gcc.21935; Kemper C, 2008, P NATL ACAD SCI USA, V105, P9023, DOI 10.1073/pnas.0801015105; Kemper C, 2010, ANNU REV IMMUNOL, V28, P131, DOI 10.1146/annurev-immunol-030409-101250; Kostantin E, 2016, J BIOL CHEM, V291, P10716, DOI 10.1074/jbc.M115.705863; Kretowski R, 2016, MOL CELL BIOCHEM, V417, P35, DOI 10.1007/s11010-016-2711-4; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Laurberg T, 2017, ACTA ONCOL, V56, P59, DOI 10.1080/0284186X.2016.1246803; List M, 2014, SCI REP-UK, V4, DOI 10.1038/srep04278; Luo B, 2013, ONCOGENE, V32, P805, DOI 10.1038/onc.2012.130; Marcotte R, 2016, CELL, V164, P293, DOI 10.1016/j.cell.2015.11.062; McDonald ER, 2017, CELL, V170, P577, DOI 10.1016/j.cell.2017.07.005; Mi HY, 2013, NAT PROTOC, V8, P1551, DOI 10.1038/nprot.2013.092; Mollenhauer J, 2000, CANCER RES, V60, P1704; Muller H, 2008, CLIN EXP IMMUNOL, V151, P123, DOI 10.1111/j.1365-2249.2007.03528.x; Nik-Zainal S, 2016, NATURE, V534, P47, DOI 10.1038/nature17676; Orlandi R, 2002, CANCER RES, V62, P567; Park SH, 2012, J BIOL CHEM, V287, P19841, DOI 10.1074/jbc.M111.330639; Parry DA, 2009, AM J HUM GENET, V84, P266, DOI 10.1016/j.ajhg.2009.01.009; PILLEMER L, 1954, SCIENCE, V120, P279, DOI 10.1126/science.120.3112.279; Pio R, 2013, SEMIN IMMUNOL, V25, P54, DOI 10.1016/j.smim.2013.04.001; Pluquet O, 2015, AM J PHYSIOL-CELL PH, V308, pC415, DOI 10.1152/ajpcell.00334.2014; Schlesinger M, 1996, LEUKEMIA, V10, P1509; Schroder M, 2008, CELL MOL LIFE SCI, V65, P862, DOI 10.1007/s00018-007-7383-5; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Vivian J, 2017, NAT BIOTECHNOL, V35, P314, DOI 10.1038/nbt.3772; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wittig-Blaich S, 2017, ONCOTARGET, V8, P23760, DOI 10.18632/oncotarget.15863; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Wouters BG, 2008, NAT REV CANCER, V8, P851, DOI 10.1038/nrc2501; Xu W, 2008, J IMMUNOL, V180, P7613, DOI 10.4049/jimmunol.180.11.7613; Yamazaki D, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003983; Zhu J, 2012, CANCER SCI, V103, P2092, DOI 10.1111/cas.12020	52	8	8	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2019	38	23					4560	4573		10.1038/s41388-019-0739-0	http://dx.doi.org/10.1038/s41388-019-0739-0			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IB4KM	30755730				2022-12-28	WOS:000470240300009
J	Zhou, F; Gao, S; Han, D; Han, WT; Chen, SJ; Patalano, S; Macoska, JA; He, HSHS; Cai, CM				Zhou, Feng; Gao, Shuai; Han, Dong; Han, Wanting; Chen, Sujun; Patalano, Susan; Macoska, Jill A.; He, Housheng Hansen; Cai, Changmeng			TMPRSS2-ERG activates NO-cGMP signaling in prostate cancer cells	ONCOGENE			English	Article							SOLUBLE GUANYLATE-CYCLASE; ANDROGEN RECEPTOR; NITRIC-OXIDE; GENE FUSIONS; 5 INHIBITORS; PATHWAY; MIGRATION; EXPRESSION; ANGIOGENESIS; PERMEABILITY	The aberrant activation of the ERG oncogenic pathway due to the TMPRSS2-ERG gene fusion is the major event that contributes to prostate cancer (PCa) development. However, the critical downstream effectors that can be therapeutically targeted remain to be identified. In this study, we have found that the expression of the alpha 1 and beta 1 subunits of soluble guanylyl cyclase (sGC) was directly and specifically regulated by ERG in vitro and in vivo and was significantly associated with TMPRSS2-ERG fusion in clinical PCa cohorts. sGC is the major mediator of nitric oxide (NO)-cGMP signaling in cells that, upon NO binding, catalyzes the synthesis of cGMP and subsequently activates protein kinase G (PKG). We showed that cGMP synthesis was significantly elevated by ERG in PCa cells, leading to increased PKG activity and cell proliferation. Importantly, we also demonstrated that sGC inhibitor treatment repressed tumor growth in TMPRSS2-ERG-positive PCa xenograft models and can act in synergy with a potent AR antagonist, enzalutamide. This study strongly suggests that targeting NO-cGMP signaling pathways may be a novel therapeutic strategy to treat PCa with TMPRSS2-ERG gene fusion.	[Zhou, Feng] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Urol, Hangzhou 310003, Zhejiang, Peoples R China; [Zhou, Feng; Gao, Shuai; Han, Dong; Han, Wanting; Patalano, Susan; Macoska, Jill A.; Cai, Changmeng] Univ Massachusetts, Ctr Personalized Canc Therapy, Boston, MA 02125 USA; [Zhou, Feng; Gao, Shuai; Han, Dong; Han, Wanting; Patalano, Susan; Macoska, Jill A.; Cai, Changmeng] Dana Farber Harvard Canc Ctr, Boston, MA 02215 USA; [Chen, Sujun; He, Housheng Hansen] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON M5G 1L7, Canada	Zhejiang University; University of Massachusetts System; University of Massachusetts Boston; Harvard University; Dana-Farber Cancer Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Cai, CM (corresponding author), Dana Farber Harvard Canc Ctr, Boston, MA 02215 USA.	changmeng.cai@umb.edu	Cai, Changmeng/AAE-6835-2020; Han, Wanting/AEX-5349-2022; Han, Dong/AAG-9502-2021; He, Hansen/ABD-8439-2020; Han, Wanting/GQA-5728-2022	Han, Wanting/0000-0002-2173-3647; Han, Dong/0000-0002-6224-855X; He, Hansen/0000-0003-2898-3363; Macoska, Jill/0000-0001-8471-2221; Gao, Shuai/0000-0002-7304-8801	NIH [R00 CA166507, R01 CA211350, U54 CA156734-06A1]; DOD [W81XWH-15-1-0554, W81XWH-16-1-0445]; Zhejiang Provincial Natural Science Foundation of China [LH19H05001]; NATIONAL CANCER INSTITUTE [U54CA156734, R01CA211350, R00CA166507] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD(United States Department of Defense); Zhejiang Provincial Natural Science Foundation of China(Natural Science Foundation of Zhejiang Province); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported by grants from NIH (R00 CA166507 and R01 CA211350 to CC, and U54 CA156734-06A1 to JAM), DOD (W81XWH-15-1-0554 to SG, and W81XWH-16-1-0445 to CC), and the research grant from Zhejiang Provincial Natural Science Foundation of China (LH19H05001 to FZ). We thank Drs. Sen Chen, Steven P. Balk (Beth Israel Deaconess Medical Center), and Eva Corey (Fred Hutchinson Cancer Center) for the support of animal study and Dr. Lirim Shemshedini (University of Toledo) for the advice on manuscript writing.	Birdsey GM, 2008, BLOOD, V111, P3498, DOI 10.1182/blood-2007-08-105346; Birdsey GM, 2012, BLOOD, V119, P894, DOI 10.1182/blood-2011-04-350025; Brenner JC, 2011, CANCER CELL, V19, P664, DOI 10.1016/j.ccr.2011.04.010; Cai C, 2007, ONCOGENE, V26, P1606, DOI 10.1038/sj.onc.1209956; Cai CM, 2007, MOL ENDOCRINOL, V21, P1835, DOI 10.1210/me.2006-0480; Cai CM, 2013, J CLIN INVEST, V123, P1109, DOI 10.1172/JCI66666; Cai CM, 2012, MOL ENDOCRINOL, V26, P292, DOI 10.1210/me.2010-0394; Cai CM, 2009, CANCER RES, V69, P6027, DOI 10.1158/0008-5472.CAN-09-0395; Carvajal JA, 2000, J CELL PHYSIOL, V184, P409, DOI 10.1002/1097-4652(200009)184:3<409::AID-JCP16>3.3.CO;2-B; Carver BS, 2009, NAT GENET, V41, P619, DOI 10.1038/ng.370; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chavez AH, 2013, ASIAN J ANDROL, V15, P246, DOI 10.1038/aja.2012.162; Chen Y, 2013, NAT MED, V19, P1023, DOI 10.1038/nm.3216; Chinnaiyan AM, 2008, NEOPLASIA, V10, P177, DOI 10.1593/neo.07822; Ciani E, 2002, J NEUROCHEM, V81, P218, DOI 10.1046/j.1471-4159.2002.00857.x; Corey E, 2003, PROSTATE, V55, P239, DOI 10.1002/pros.10198; Dhayade S, 2016, CELL REP, V14, P2599, DOI 10.1016/j.celrep.2016.02.028; DRAIJER R, 1995, CIRC RES, V76, P199, DOI 10.1161/01.RES.76.2.199; Fajardo AM, 2014, CANCERS, V6, P436, DOI 10.3390/cancers6010436; Fraser M, 2017, NATURE, V541, P359, DOI 10.1038/nature20788; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gao S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064189; Hollenhorst PC, 2011, GENE DEV, V25, P2147, DOI 10.1101/gad.17546311; Kawasaki K, 2003, MOL CELL BIOL, V23, P5726, DOI 10.1128/MCB.23.16.5726-5737.2003; King JC, 2009, NAT GENET, V41, P524, DOI 10.1038/ng.371; Klinger James R, 2017, Am J Cardiol, V120, pS71, DOI 10.1016/j.amjcard.2017.06.012; Kron KJ, 2017, NAT GENET, V49, P1336, DOI 10.1038/ng.3930; Li WQ, 2014, JAMA INTERN MED, V174, P964, DOI 10.1001/jamainternmed.2014.594; Loberg RD, 2006, NEOPLASIA, V8, P578, DOI 10.1593/neo.06280; Michl U, 2015, J UROLOGY, V193, P479, DOI 10.1016/j.juro.2014.08.111; Mittendorf J, 2009, CHEMMEDCHEM, V4, P853, DOI 10.1002/cmdc.200900014; Monica FZ, 2018, NAT REV UROL, V15, P42, DOI 10.1038/nrurol.2017.181; Morbidelli L, 2010, AM J PHYSIOL-REG I, V298, pR824, DOI 10.1152/ajpregu.00222.2009; Mosquera JM, 2008, CLIN CANCER RES, V14, P3380, DOI 10.1158/1078-0432.CCR-07-5194; Nguyen HM, 2017, PROSTATE, V77, P654, DOI 10.1002/pros.23313; Nikolova-Krstevski V, 2009, BMC DEV BIOL, V9, DOI 10.1186/1471-213X-9-72; Olesen SP, 1998, BRIT J PHARMACOL, V123, P299, DOI 10.1038/sj.bjp.0701603; Pyriochou A, 2006, J PHARMACOL EXP THER, V319, P663, DOI 10.1124/jpet.106.108878; Reffelmann T, 2006, CURR PHARM DESIGN, V12, P3485, DOI 10.2174/138161206778343073; Schwappacher R, 2013, J CELL SCI, V126, P1626, DOI 10.1242/jcs.118190; Stojanovic A, 2006, J BIOL CHEM, V281, P16333, DOI 10.1074/jbc.M512378200; Sun C, 2008, ONCOGENE, V27, P5348, DOI 10.1038/onc.2008.183; Surapisitchat J, 2007, CIRC RES, V101, P811, DOI 10.1161/CIRCRESAHA.107.154229; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tomlins SA, 2006, CANCER RES, V66, P3396, DOI 10.1158/0008-5472.CAN-06-0168; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tomlins SA, 2007, NATURE, V448, P595, DOI 10.1038/nature06024; Wang L, 2005, J CEREBR BLOOD F MET, V25, P1150, DOI 10.1038/sj.jcbfm.9600112; Wang XJ, 2017, CANCER CELL, V31, P532, DOI 10.1016/j.ccell.2017.02.017; Wu LT, 2013, CANCER RES, V73, P6068, DOI 10.1158/0008-5472.CAN-13-0882; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Yuan X, 2014, ONCOGENE, V33, P2815, DOI 10.1038/onc.2013.235; Zhou J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184088	53	16	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2019	38	22					4397	4411		10.1038/s41388-019-0730-9	http://dx.doi.org/10.1038/s41388-019-0730-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IA1RB	30718921	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000469339100014
J	Ge, XL; Li, GY; Jiang, L; Jia, LQ; Zhang, ZZ; Li, XL; Wang, RR; Zhou, M; Zhou, YH; Zeng, ZY; Xiang, JJ; Li, Z				Ge, Xiaolu; Li, Gui-yuan; Jiang, Lin; Jia, Liqing; Zhang, Zhezhe; Li, Xiaoling; Wang, Ranran; Zhou, Ming; Zhou, Yanhong; Zeng, Zhaoyang; Xiang, Juanjuan; Li, Zheng			Long noncoding RNA CAR10 promotes lung adenocarcinoma metastasis via miR-203/30/SNAI axis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CANCER STATISTICS; DOWN-REGULATION; IDENTIFICATION; MALAT1; ANRIL; GENE	Long noncoding RNAs (lncRNAs) play an important role in lung adenocarcinoma (LUAD) metastasis. Here, we found that lncRNA chromatin-associated RNA 10 (CAR10) was upregulated in the tumor tissue of patients with LUAD and enhanced tumor metastasis in vitro and in vivo. Mechanistically, CAR10 induced epithelial-to-mesenchymal transition (EMT) by directly binding with miR-30 and miR-203 and then regulating the expression of SNAH and SNAI2. CAR10 overexpression was positively correlated with a poor prognosis in LUAD patients, whereas overexpression of both CAR10 and SNAI was correlated with even worse clinical outcomes. In conclusion, the CAR10/miR-30/203/SNAI axis is a novel and potential therapeutic target for LUAD.	[Ge, Xiaolu; Li, Gui-yuan; Jiang, Lin; Jia, Liqing; Zhang, Zhezhe; Li, Xiaoling; Zhou, Ming; Zhou, Yanhong; Zeng, Zhaoyang; Xiang, Juanjuan; Li, Zheng] Cent South Univ, Hunan Canc Hosp, Key Lab Carcinogenesis, Chinese Minist Hlth, Changsha, Hunan, Peoples R China; [Ge, Xiaolu; Li, Gui-yuan; Jiang, Lin; Jia, Liqing; Zhang, Zhezhe; Li, Xiaoling; Zhou, Ming; Zhou, Yanhong; Zeng, Zhaoyang; Xiang, Juanjuan; Li, Zheng] Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Hunan, Peoples R China; [Ge, Xiaolu; Li, Gui-yuan; Jiang, Lin; Jia, Liqing; Zhang, Zhezhe; Li, Xiaoling; Zhou, Ming; Zhou, Yanhong; Zeng, Zhaoyang; Xiang, Juanjuan; Li, Zheng] Cent South Univ, Sch Basic Med Sci, Canc Res Inst, Changsha, Hunan, Peoples R China; [Ge, Xiaolu; Li, Zheng] Cent South Univ, Canc Res Inst, Key Lab Carcinogenesis & Canc Invas, Chinese Minist Educ, Changsha, Hunan, Peoples R China; [Wang, Ranran] Cent South Univ, Xiangya Hosp 2, Dept Thorac & Cardiovasc Surg, Changsha 410011, Hunan, Peoples R China; [Li, Zheng] Cent South Univ, High Resolut Mass Spectrometry Lab, Adv Res Ctr, Changsha, Hunan, Peoples R China	Central South University; Central South University; Central South University; Central South University; Central South University; Central South University	Li, Z (corresponding author), Cent South Univ, Hunan Canc Hosp, Key Lab Carcinogenesis, Chinese Minist Hlth, Changsha, Hunan, Peoples R China.; Li, Z (corresponding author), Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Hunan, Peoples R China.; Li, Z (corresponding author), Cent South Univ, Sch Basic Med Sci, Canc Res Inst, Changsha, Hunan, Peoples R China.; Li, Z (corresponding author), Cent South Univ, Canc Res Inst, Key Lab Carcinogenesis & Canc Invas, Chinese Minist Educ, Changsha, Hunan, Peoples R China.; Li, Z (corresponding author), Cent South Univ, High Resolut Mass Spectrometry Lab, Adv Res Ctr, Changsha, Hunan, Peoples R China.	lizheng@csu.edu.cn	li, xiaofeng/GXF-9442-2022; li, xiao/GSN-6181-2022	LI, ZHENG/0000-0002-3758-8165; Jia, Liqing/0000-0003-1734-6043; Xiaolu, Ge/0000-0002-5533-7749	Overseas Expertise Introduction Project for Discipline Innovation (111 Project) [111-2-12]; National Natural Science Foundation of China [81602030]; National Undergraduate Free Exploration Program of Central South University [201810533372]; Open-End Fund for the Valuable and Precision Instruments of Central South University [CSUZC2014044]	Overseas Expertise Introduction Project for Discipline Innovation (111 Project); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Undergraduate Free Exploration Program of Central South University; Open-End Fund for the Valuable and Precision Instruments of Central South University	This study was supported by grants from the Overseas Expertise Introduction Project for Discipline Innovation (111 Project, No. 111-2-12), the National Natural Science Foundation of China (81602030), the National Undergraduate Free Exploration Program of Central South University (201810533372), and the Open-End Fund for the Valuable and Precision Instruments of Central South University (No. CSUZC2014044).	Alves CP, 2013, STEM CELLS, V31, P2827, DOI 10.1002/stem.1547; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Guo HY, 2014, ONCOTARGET, V5, P8625, DOI 10.18632/oncotarget.2349; Ho TT, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gku1198; Hou J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010312; Huang JW, 2013, CANCER SCI, V104, P1609, DOI 10.1111/cas.12291; Jen JY, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0674-z; Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928; Jiang SM, 2016, MOL MED REP, V13, P4101, DOI 10.3892/mmr.2016.5010; Kao CJ, 2014, ONCOGENE, V33, P2495, DOI 10.1038/onc.2013.200; Klingenberg M, 2018, HEPATOLOGY, V68, P1817, DOI 10.1002/hep.30102; Li CH, 2013, INT J BIOCHEM CELL B, V45, P1895, DOI 10.1016/j.biocel.2013.05.030; Lin L, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0247-7; Liu H, 2017, ONCOTARGET, V8, P101899, DOI 10.18632/oncotarget.22058; Liu MJ, 2016, ONCOL REP, V36, P1679, DOI 10.3892/or.2016.4909; Mondal T, 2010, GENOME RES, V20, P899, DOI 10.1101/gr.103473.109; Nie FQ, 2015, MOL CANCER THER, V14, P268, DOI 10.1158/1535-7163.MCT-14-0492; Otsuki Y, 2018, DEV DYNAM, V247, P462, DOI 10.1002/dvdy.24596; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pasmant E, 2007, CANCER RES, V67, P3963, DOI 10.1158/0008-5472.CAN-06-2004; Pillai R, 2011, J MOL DIAGN, V13, P48, DOI 10.1016/j.jmoldx.2010.11.001; Roberts L, 2009, GENOMICS, V94, P341, DOI 10.1016/j.ygeno.2009.07.007; Rodriguez Luis G, 2005, Methods Mol Biol, V294, P23; Rousseaux S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005723; Savagner P, 2010, ANN ONCOL, V21, P89, DOI 10.1093/annonc/mdq292; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Shen LQ, 2015, J NEURO-ONCOL, V121, P101, DOI 10.1007/s11060-014-1613-0; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Travis WD, 2014, PATHOLOGE, V35, P188, DOI 10.1007/s00292-014-1974-3; Van Grembergen O, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600220; Wang D, 2017, EUR REV MED PHARMACO, V21, P4584; Wang Q, 2017, ONCOTARGET, V8, P2558, DOI 10.18632/oncotarget.13708; Wei MM, 2016, ONCOTARGET, V7, P59556, DOI 10.18632/oncotarget.10006; Wei YZ, 2017, ONCOTARGET, V8, P71430, DOI 10.18632/oncotarget.19864; Wen X, 2018, J CELL BIOCHEM, V119, P1827, DOI 10.1002/jcb.26344; Xiang Y, 2017, CELL PHYSIOL BIOCHEM, V42, P357, DOI 10.1159/000477479; Xu S, 2018, ONCOL REP, V39, P2376, DOI 10.3892/or.2018.6316; Yuan S, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0472-6; Zhang Zhiqian, 2011, Genes Cancer, V2, P782, DOI 10.1177/1947601911429743; Zhou M, 2016, ONCOTARGET, V7, P29720, DOI 10.18632/oncotarget.8825	41	54	56	2	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2019	38	16					3061	3076		10.1038/s41388-018-0645-x	http://dx.doi.org/10.1038/s41388-018-0645-x			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU3IV	30617305	Green Published, hybrid			2022-12-28	WOS:000465167600014
J	Chen, J; Zhang, WM; Wang, Y; Zhao, D; Wu, MJ; Fan, JW; Li, JT; Gong, Y; Dan, NN; Yang, D; Liu, R; Zhan, QM				Chen, Jie; Zhang, Weimin; Wang, Yan; Zhao, Di; Wu, Mengjiao; Fan, Jiawen; Li, Jinting; Gong, Ying; Dan, Nana; Yang, Di; Liu, Rui; Zhan, Qimin			The diacylglycerol kinase alpha (DGK alpha)/Akt/NF-kappa B feedforward loop promotes esophageal squamous cell carcinoma (ESCC) progression via FAK-dependent and FAK-independent manner	ONCOGENE			English	Article							FOCAL ADHESION KINASE; NF-KAPPA-B; EPIDERMAL-GROWTH-FACTOR; ACTIVATION; INFLAMMATION; AKT; PROLIFERATION; INHIBITION; MIGRATION; SUBUNIT	Many reports have described DGK alpha as an oncogene, hence, we investigated its function and the underlying mechanisms in esophageal squamous cell carcinoma (ESCC) progression. This study demonstrated that DGK alpha was upregulated by inflammatory stimulants and formed feedforward loop with Akt/NF-kappa B signaling in ESCC cells. Mechanistically, DGK alpha-activated Akt/NF-kappa B signaling via stimulating PA production to reduce cAMP level and PTEN activity, and specifically, independently of its kinase function, through direct interaction with the FERM domain of FAK to relieve the auto-inhibitory effect of FERM domain on FAK. Overexpression of DGK alpha promoted cancer malignant progression both in vitro and in vivo, whereas depletion of DGK alpha suppressed these effects. Importantly, DGK alpha expression was tightly correlated with the malignancy of various inflammation-related squamous carcinomas and the oncogenic Akt/NF-kappa B activity. Therefore, DGK alpha is critically involved in inflammation-mediated ESCC progression, supporting DGK alpha as a potential target for ESCC therapy.	[Chen, Jie; Zhang, Weimin; Wang, Yan; Zhao, Di; Wu, Mengjiao; Fan, Jiawen; Li, Jinting; Gong, Ying; Dan, Nana; Yang, Di; Liu, Rui; Zhan, Qimin] Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing,Lab Mol Oncol, Beijing 100142, Peoples R China; [Zhan, Qimin] Chinese Acad Med Sci, State Key Lab Mol Oncol, Canc Inst, Beijing 100021, Peoples R China; [Zhan, Qimin] Chinese Acad Med Sci, Canc Hosp, Beijing 100021, Peoples R China; [Zhan, Qimin] Peking Union Med Coll, Beijing 100021, Peoples R China	Peking University; Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Zhan, QM (corresponding author), Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing,Lab Mol Oncol, Beijing 100142, Peoples R China.; Zhan, QM (corresponding author), Chinese Acad Med Sci, State Key Lab Mol Oncol, Canc Inst, Beijing 100021, Peoples R China.; Zhan, QM (corresponding author), Chinese Acad Med Sci, Canc Hosp, Beijing 100021, Peoples R China.; Zhan, QM (corresponding author), Peking Union Med Coll, Beijing 100021, Peoples R China.	zhanqimin@bjmu.edu.en			National 973 Program [2015CB553904]; National Natural Fund of China [81830086, 81490753, 81502110, 81772504]; Beijing Municipal Administration of Hospitals's Youth Program [QML20171105]	National 973 Program(National Basic Research Program of China); National Natural Fund of China; Beijing Municipal Administration of Hospitals's Youth Program	This work is supported by the National 973 Program (2015CB553904) and National Natural Fund of China (81830086, 81490753, 81502110, and 81772504). Beijing Municipal Administration of Hospitals's Youth Program, code: QML20171105.	Andl CD, 2003, J BIOL CHEM, V278, P1824, DOI 10.1074/jbc.M209148200; Balkwill F, 2006, CANCER METAST REV, V25, P409, DOI 10.1007/s10555-006-9005-3; Castellano E, 2013, CANCER CELL, V24, P617, DOI 10.1016/j.ccr.2013.09.012; Chechlinska M, 2010, NAT REV CANCER, V10, P2, DOI 10.1038/nrc2782; Chen J, 2015, ONCOGENE, V34, P5114, DOI 10.1038/onc.2014.434; Chen J, 2015, CANCER RES, V75, P4198, DOI 10.1158/0008-5472.CAN-15-1062; Chen MF, 2012, J MOL MED, V90, P89, DOI 10.1007/s00109-011-0809-4; Dan HC, 2008, GENE DEV, V22, P1490, DOI 10.1101/gad.1662308; Dominguez CL, 2013, CANCER DISCOV, V3, P782, DOI 10.1158/2159-8290.CD-12-0215; Elinav E, 2013, NAT REV CANCER, V13, P759, DOI 10.1038/nrc3611; Guo ST, 2016, ONCOGENE, V35, P3049, DOI 10.1038/onc.2015.361; Guo W, 2005, CHINESE MED J-PEKING, V118, P1870; Hellyer NJ, 1998, BIOCHEM J, V333, P757, DOI 10.1042/bj3330757; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; Ito T, 2008, CANCER RES, V68, P3214, DOI 10.1158/0008-5472.CAN-07-3043; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Li Y, 2018, CANCER LETT, V430, P57, DOI 10.1016/j.canlet.2018.05.013; Lin CY, 2013, CANCER RES, V73, P3638, DOI 10.1158/0008-5472.CAN-12-4028; Lou LG, 2002, J BIOL CHEM, V277, P32799, DOI 10.1074/jbc.M201491200; Luzzatto L, 2015, NEW ENGL J MED, V373, P84, DOI 10.1056/NEJMsb1502456; Martinez K, 2013, J LIPID RES, V54, P662, DOI 10.1194/jlr.M031211; Merida I, 2008, BIOCHEM J, V409, P1, DOI 10.1042/BJ20071040; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Nemoz G, 1997, MOL PHARMACOL, V51, P242, DOI 10.1124/mol.51.2.242; Okada M, 2012, BIOCHEM BIOPH RES CO, V420, P479, DOI 10.1016/j.bbrc.2012.03.057; Poullet P, 2001, J BIOL CHEM, V276, P37686, DOI 10.1074/jbc.M106175200; Rainero E, 2012, J CELL BIOL, V196, P277, DOI 10.1083/jcb.201109112; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Song LB, 2012, GASTROENTEROLOGY, V143, P995, DOI 10.1053/j.gastro.2012.06.033; Streblow DN, 2003, J BIOL CHEM, V278, P50456, DOI 10.1074/jbc.M307936200; Sugimoto N, 2011, NEUROSCI LETT, V497, P55, DOI 10.1016/j.neulet.2011.04.028; Takeishi K, 2012, J HEPATOL, V57, P77, DOI 10.1016/j.jhep.2012.02.026; Torres-Ayuso P, 2014, ONCOTARGET, V5, P9710, DOI 10.18632/oncotarget.2344; van Blitterswijk WJ, 2000, CELL SIGNAL, V12, P595, DOI 10.1016/S0898-6568(00)00113-3; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100; Wang F, 2009, CURR OPIN PHARMACOL, V9, P389, DOI 10.1016/j.coph.2009.06.005; Wu DW, 2015, ONCOGENE, V34, P3882, DOI 10.1038/onc.2015.203; Xia H, 2004, J BIOL CHEM, V279, P33024, DOI 10.1074/jbc.M313265200; Zhang B, 2017, DNA CELL BIOL, V36, P237, DOI 10.1089/dna.2016.3535; Zhou H, 2010, CANCER CELL, V17, P560, DOI 10.1016/j.ccr.2010.04.023	41	17	19	1	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2019	38	14					2533	2550		10.1038/s41388-018-0604-6	http://dx.doi.org/10.1038/s41388-018-0604-6			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HR7LI	30532074				2022-12-28	WOS:000463335200007
J	Grabosch, S; Bulatovic, M; Zeng, FTZ; Ma, TZ; Zhang, LX; Ross, M; Brozickl, J; Fang, YS; Tseng, G; Kim, E; Gambotto, A; Elishaev, E; Edwards, RP; Vlad, AM				Grabosch, Shannon; Bulatovic, Mirna; Zeng, Feitianzhi; Ma, Tianzhou; Zhang, Lixin; Ross, Malcolm; Brozickl, Joan; Fang, YuSi; Tseng, George; Kim, Eun; Gambotto, Andrea; Elishaev, Esther; Edwards, Robert P.; Vlad, Anda M.			Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles	ONCOGENE			English	Article							LONG-TERM SAFETY; CELLS; CHEMOTHERAPY; SURVIVAL; EXPRESSION; APOPTOSIS; ANTIBODY; THERAPY; TUMORS; PD-L1	The backbone of ovarian cancer treatment is platinum-based chemotherapy and aggressive surgical debulking. New therapeutic approaches using immunotherapy via immune checkpoint blockade, which have demonstrated clinical efficacy in other tumor types, have been less promising in ovarian cancer. To increase their clinical efficacy, checkpoint inhibitors are now being tested in clinical trials in combination with chemotherapy. Here, we evaluated the impact of cisplatin on tumor immunogenicity and its in vivo roles when used alone or in combination with anti-PD-L1, in two novel murine ovarian cancer cell models. The 2F8 and its platinum-resistant derivative 2F8cis model, display distinct inflammatory profiles and chemotherapy sensitivities, and mirror the primary and recurrent human disease, respectively. Acute and chronic exposure to cisplatin enhances tumor immunogenicity by increasing calreticulin, MHC class I, antigen presentation and T-cell infiltration. Cisplatin also upregulates PD-L1 expression in vitro and in vivo, demonstrating a dual, paradoxical immune modulatory effect and supporting the rationale for combination with immune checkpoint blockade. One of the pathways activated by cisplatin treatment is the cGAS/STING pathway. Chronic cisplatin treatment led to upregulation of cGAS and STING proteins in 2F8cis compared to parental 2F8 cells, while acute exposure to cisplatin further increases cGAS and STING levels in both 2F8 and 2F8cis cells. Overexpression of cGAS/STING modifies tumor immunogenicity by upregulating PD-L1, MHC I and calreticulin in tumor cells. Anti-PD-L1 alone in a platinum-sensitive model or with cisplatin in a platinum-resistant model increases survival. These studies have high translational potential in ovarian cancer.	[Grabosch, Shannon; Bulatovic, Mirna; Zeng, Feitianzhi; Zhang, Lixin; Ross, Malcolm; Brozickl, Joan; Edwards, Robert P.; Vlad, Anda M.] Magee Womens Res Inst, Pittsburgh, PA 15213 USA; [Grabosch, Shannon; Bulatovic, Mirna; Zeng, Feitianzhi; Zhang, Lixin; Ross, Malcolm; Edwards, Robert P.; Vlad, Anda M.] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15213 USA; [Grabosch, Shannon; Ross, Malcolm; Edwards, Robert P.] Univ Pittsburgh, Magee Womens Hosp, Med Ctr, Pittsburgh, PA 15213 USA; [Zeng, Feitianzhi] Cent South Univ, Xiangya Sch Med, Changsha, Hunan, Peoples R China; [Ma, Tianzhou; Fang, YuSi; Tseng, George] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA; [Kim, Eun; Gambotto, Andrea] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA; [Elishaev, Esther] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA; [Ma, Tianzhou] Univ Maryland, Dept Epidemiol & Biostat, Sch Publ Hlth, Pittsburgh, MD 20742 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Central South University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Vlad, AM (corresponding author), Magee Womens Res Inst, Pittsburgh, PA 15213 USA.; Vlad, AM (corresponding author), Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15213 USA.	vladam@upmc.edu	Ma, Tianzhou/AAC-8221-2021; Bulatovic, Mirna/L-6826-2015	Ma, Tianzhou/0000-0003-3605-0811; Bulatovic, Mirna/0000-0002-5472-6144	NIH/NCI [R01 CA163462]; Pennsylvania Department of Health; NATIONAL CANCER INSTITUTE [R01CA163462] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Pennsylvania Department of Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was partly supported by the NIH/NCI R01 CA163462, Pennsylvania Department of Health and a philanthropic donation from Mr. Matthew Fletcher Deitch.	Bakhoum SF, 2018, NATURE, V553, P467, DOI 10.1038/nature25432; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; Bilbao R, 2003, GENE THER, V10, P1821, DOI 10.1038/sj.gt.3302084; Budiu RA, 2013, ONCOGENE, V32, P3664, DOI 10.1038/onc.2012.397; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Cortez MA, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv303; Dasari S, 2014, EUR J PHARMACOL, V740, P364, DOI 10.1016/j.ejphar.2014.07.025; Demaria O, 2015, P NATL ACAD SCI USA, V112, P15408, DOI 10.1073/pnas.1512832112; Di Blasio S, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1192739; Dieu-Nosjean MC, 2014, TRENDS IMMUNOL, V35, P571, DOI 10.1016/j.it.2014.09.006; Ding L, 2015, BBA-MOL BASIS DIS, V1852, P2494, DOI 10.1016/j.bbadis.2015.08.011; Feili-Hariri M, 2003, HUM GENE THER, V14, P13, DOI 10.1089/10430340360464679; Feng MY, 2015, P NATL ACAD SCI USA, V112, P2145, DOI 10.1073/pnas.1424907112; Gaillard Stephanie L, 2016, Gynecol Oncol Res Pract, V3, P11; Gao WT, 2004, BIOTECHNOL PROGR, V20, P443, DOI 10.1021/bp0300467; Garcia-Diaz A, 2017, CELL REP, V19, P1189, DOI 10.1016/j.celrep.2017.04.031; Grabosch S, 2017, GYNECOL ONCOL, V146, P137, DOI 10.1016/j.ygyno.2017.04.008; Hamanishi J, 2007, P NATL ACAD SCI USA, V104, P3360, DOI 10.1073/pnas.0611533104; Hamanishi J, 2016, INT IMMUNOL, V28, P339, DOI 10.1093/intimm/dxw020; Hamanishi J, 2015, J CLIN ONCOL, V33, P4015, DOI 10.1200/JCO.2015.62.3397; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; HAVRILESKY LJ, 1995, OBSTET GYNECOL, V85, P1007, DOI 10.1016/0029-7844(95)00058-Y; Hughes PE, 2016, TRENDS IMMUNOL, V37, P462, DOI 10.1016/j.it.2016.04.010; Jiang Run-De, 2003, Ai Zheng, V22, P337; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Lemos H, 2016, CANCER RES, V76, P2076, DOI 10.1158/0008-5472.CAN-15-1456; Markman M, 2000, Oncologist, V5, P26, DOI 10.1634/theoncologist.5-1-26; McDermott DF, 2015, J CLIN ONCOL, V33, P2013, DOI 10.1200/JCO.2014.58.1041; Merritt RE, 2003, J THORAC CARDIOV SUR, V126, P1609, DOI 10.1016/S0022-5223(03)00707-4; Mesnage SJL, 2017, ANN ONCOL, V28, P651, DOI 10.1093/annonc/mdw625; Mony JT, 2015, CANCER IMMUNOL IMMUN, V64, P1095, DOI 10.1007/s00262-015-1712-6; Nejad EB, 2016, CANCER RES, V76, P6017, DOI 10.1158/0008-5472.CAN-16-0881; Oliveros J., 2007, VENNY INTERACTIVE TO; Parker BS, 2016, NAT REV CANCER, V16, P131, DOI 10.1038/nrc.2016.14; Pujade-Lourraine E, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.TPS5600; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Tang CHA, 2016, CANCER RES, V76, P2137, DOI 10.1158/0008-5472.CAN-15-1885; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001; Topalian SL, 2014, J CLIN ONCOL, V32, P1020, DOI 10.1200/JCO.2013.53.0105; Varga A, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.5513; Webb JR, 2016, GYNECOL ONCOL, V141, P293, DOI 10.1016/j.ygyno.2016.03.008; Yang H, 2017, P NATL ACAD SCI USA, V114, pE4612, DOI 10.1073/pnas.1705499114	48	108	116	1	40	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2019	38	13					2380	2393		10.1038/s41388-018-0581-9	http://dx.doi.org/10.1038/s41388-018-0581-9			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ7GN	30518877	Green Accepted			2022-12-28	WOS:000462588000011
J	Aydin, E; Hallner, A; Wiktorin, HG; Staffas, A; Hellstrand, K; Martner, A				Aydin, Ebru; Hallner, Alexander; Wiktorin, Hanna Grauers; Staffas, Anna; Hellstrand, Kristoffer; Martner, Anna			NOX2 inhibition reduces oxidative stress and prolongs survival in murine KRAS-induced myeloproliferative disease	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; DNA-DAMAGE; GENOMIC INSTABILITY; HYDROGEN-PEROXIDE; NADPH OXIDASES; NK CELLS; ROS; HISTAMINE; MELANOMA; METASTASIS	Mutations leading to constitutive RAS activation contribute in myeloid leukemogenesis. RAS mutations in myeloid cells are accompanied by excessive formation of reactive oxygen species (ROS), but the source of ROS and their role for the initiation and progression of leukemia have not been clearly defined. To determine the role of NOX2-derived ROS in RAS-driven leukemia, double transgenic LSL-Kras(G12D) x Mx1-Cre mice expressing oncogenic KRAS in hematopoietic cells (M-Kras(G12D)) were treated with N-alpha-methyl-histamine (NMH) that targeted the production of NOX2-derived ROS in leukemic cells by agonist activity at histamine H-2 receptors. M-Kras(G12D) mice developed myeloid leukemia comprising mature CD11b(+)Gr1(+) myeloid cells that produced NOX2-derived ROS. Treatment of M-Kras(G12D) mice with NMH delayed the development of myeloproliferative disease and prolonged survival. In addition, NMH-treated M-Kras(G12D) mice showed reduction of intracellular ROS along with reduced DNA oxidation and reduced occurence of double-stranded DNA breaks in myeloid cells. The in vivo expansion of leukemia was markedly reduced in triple transgenic mice where KRAS was expressed in hematopoietic cells of animals with genetic NOX2 deficiency (Nox2(-/-) x LSL-Kras(G12D) x Mx1-Cre). Treatment with NMH did not alter in vivo expansion of leukemia in these NOX2-deficient transgenic mice. We propose that NOX2-derived ROS may contribute to the progression of KRAS-induced leukemia and that strategies to target NOX2 merit further evaluation in RAS-mutated hematopoietic cancer.	[Aydin, Ebru; Hallner, Alexander; Wiktorin, Hanna Grauers; Staffas, Anna; Hellstrand, Kristoffer; Martner, Anna] Univ Gothenburg, Sahlgrenska Canc Ctr, TIMM Lab, S-41390 Gothenburg, Sweden; [Staffas, Anna] Univ Gothenburg, Sahlgrenska Acad, Dept Clin Chem & Transfus Med, S-41345 Gothenburg, Sweden	University of Gothenburg; University of Gothenburg	Martner, A (corresponding author), Univ Gothenburg, Sahlgrenska Canc Ctr, TIMM Lab, S-41390 Gothenburg, Sweden.	anna.martner@gu.se		Aydin, Ebru/0000-0003-2395-7529; Martner, Anna/0000-0002-6598-5221; Hallner, Alexander/0000-0002-4973-5097; Hellstrand, Kristoffer/0000-0002-6617-5976				Aurelius J, 2017, J LEUKOCYTE BIOL, V102, P459, DOI 10.1189/jlb.5VMA1116-454R; Aurelius J, 2012, HAEMATOL-HEMATOL J, V97, P1904, DOI 10.3324/haematol.2012.066399; Aurelius J, 2012, BLOOD, V119, P5832, DOI 10.1182/blood-2011-11-391722; Aydin E, 2017, CANCER IMMUNOL RES, V5, P804, DOI 10.1158/2326-6066.CIR-16-0382; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Betten A, 2003, SCAND J IMMUNOL, V58, P321, DOI 10.1046/j.1365-3083.2003.01301.x; Bowen DT, 2005, BLOOD, V106, P2113, DOI 10.1182/blood-2005-03-0867; Braun BS, 2004, P NATL ACAD SCI USA, V101, P597, DOI 10.1073/pnas.0307203101; BRITTAIN RT, 1981, SCAND J GASTROENTERO, V16, P1; Dahlgren C, 1999, J IMMUNOL METHODS, V232, P3, DOI 10.1016/S0022-1759(99)00146-5; DeFlora S, 1996, INT J CANCER, V67, P842, DOI 10.1002/(SICI)1097-0215(19960917)67:6<842::AID-IJC14>3.0.CO;2-3; Dikalov S, 2011, FREE RADICAL BIO MED, V51, P1289, DOI 10.1016/j.freeradbiomed.2011.06.033; Galadari S, 2017, FREE RADICAL BIO MED, V104, P144, DOI 10.1016/j.freeradbiomed.2017.01.004; Govindarajan B, 2007, J CLIN INVEST, V117, P719, DOI 10.1172/JCI30102; Gritsman K, 2014, J CLIN INVEST, V124, P1794, DOI 10.1172/JCI69927; Gysin Stephan, 2011, Genes Cancer, V2, P359, DOI 10.1177/1947601911412376; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Hansson M, 1996, J IMMUNOL, V156, P42; HELLSTRAND K, 1994, J IMMUNOL, V153, P4940; Hordijk PL, 2006, CIRC RES, V98, P453, DOI 10.1161/01.RES.0000204727.46710.5e; Hoyal CR, 2003, P NATL ACAD SCI USA, V100, P5130, DOI 10.1073/pnas.1031526100; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Kelkka T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084148; Kiffin R, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00218; Kuo LJ, 2008, IN VIVO, V22, P305; Le Gal K, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad3740; Ligtenberg MA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129786; Loh ML, 2011, BRIT J HAEMATOL, V152, P677, DOI 10.1111/j.1365-2141.2010.08525.x; Lyubynska N, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001069; Marlein CR, 2017, BLOOD, V130, P1649, DOI 10.1182/blood-2017-03-772939; Martner A, 2015, J IMMUNOL, V194, P5014, DOI 10.4049/jimmunol.1402991; Mitsushita J, 2004, CANCER RES, V64, P3580, DOI 10.1158/0008-5472.CAN-03-3909; Moiseeva O, 2009, MOL CELL BIOL, V29, P4495, DOI 10.1128/MCB.01868-08; Panieri E, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.105; Piskounova E, 2015, NATURE, V527, P186, DOI 10.1038/nature15726; Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612; Quinlan MP, 2009, FUTURE ONCOL, V5, P105, DOI 10.2217/14796694.5.1.105; Rada Balazs, 2008, V15, P164, DOI 10.1159/000136357; Rassool FV, 2007, CANCER RES, V67, P8762, DOI 10.1158/0008-5472.CAN-06-4807; Saitoh T, 2002, GUT, V50, P786, DOI 10.1136/gut.50.6.786; Sallmyr A, 2008, CANCER LETT, V270, P1, DOI 10.1016/j.canlet.2008.03.036; Sallmyr A, 2008, BLOOD, V111, P3173, DOI 10.1182/blood-2007-05-092510; Sattler M, 2000, J BIOL CHEM, V275, P24273, DOI 10.1074/jbc.M002094200; Sayin VI, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007653; Scott AJ, 2016, CANCER J, V22, P165, DOI 10.1097/PPO.0000000000000187; Stanicka J, 2015, J BIOL CHEM, V290, P9348, DOI 10.1074/jbc.M113.510495; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Vachhani P, 2014, PHYSIOL GENOMICS, V46, P448, DOI 10.1152/physiolgenomics.00173.2013; Valavanidis A, 2009, J ENVIRON SCI HEAL C, V27, P120, DOI 10.1080/10590500902885684; Van Etten RA, 2004, CANCER CELL, V6, P547, DOI 10.1016/j.ccr.2004.12.004; Ward AF, 2012, BLOOD, V120, P3397, DOI 10.1182/blood-2012-05-378596; Weyemi U, 2012, ONCOGENE, V31, P1117, DOI 10.1038/onc.2011.327; Wiktorin HG, 2018, BRIT J HAEMATOL, V182, P290, DOI 10.1111/bjh.14772; Will M, 2014, CANCER DISCOV, V4, P334, DOI 10.1158/2159-8290.CD-13-0611; Wu RF, 2009, FREE RADICAL BIO MED, V47, P1276, DOI 10.1016/j.freeradbiomed.2009.05.037; Zeng M, 2017, CELL CHEM BIOL, V24, P1005, DOI 10.1016/j.chembiol.2017.06.017	56	14	15	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2019	38	9					1534	1543		10.1038/s41388-018-0528-1	http://dx.doi.org/10.1038/s41388-018-0528-1			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN1KL	30323311	hybrid, Green Published			2022-12-28	WOS:000459945800012
J	Fotouhi, O; Kjellin, H; Juhlin, CC; Pan, YB; Vesterlund, M; Ghaderi, M; Yousef, A; Andersson-Sand, H; Kharaziha, P; Caramuta, S; Kjellman, M; Zedenius, J; Larsson, C; Orre, LM				Fotouhi, Omid; Kjellin, Hanna; Juhlin, C. Christofer; Pan, Yanbo; Vesterlund, Mattias; Ghaderi, Mehran; Yousef, Abdelhamid; Andersson-Sand, Hillevi; Kharaziha, Pedram; Caramuta, Stefano; Kjellman, Magnus; Zedenius, Jan; Larsson, Catharina; Orre, Lukas M.			Proteomics identifies neddylation as a potential therapy target in small intestinal neuroendocrine tumors	ONCOGENE			English	Article							NEDD8-ACTIVATING ENZYME-INHIBITOR; PEVONEDISTAT TAK-924/MLN4924; RBX1 EXPRESSION; HUMAN CANCER; PHASE-I; NEDD8; P27(KIP1); CULLIN; DEGRADATION; SUPPRESSOR	Patients with small intestinal neuroendocrine tumors (SI-NETs) frequently develop spread disease; however, the underlying molecular mechanisms of disease progression are not known and effective preventive treatment strategies are lacking. Here, protein expression profiling was performed by HiRIEF-LC-MS in 14 primary SI-NETs from patients with and without liver metastases detected at the time of surgery and initial treatment. Among differentially expressed proteins, overexpression of the ubiquitin-like protein NEDD8 was identified in samples from patients with liver metastasis. Further, NEDD8 correlation analysis indicated co-expression with RBX1, a key component in cullin-RING ubiquitin ligases (CRLs). In vitro inhibition of neddylation with the therapeutic agent pevonedistat (MLN4924) resulted in a dramatic decrease of proliferation in SI-NET cell lines. Subsequent mass spectrometry-based proteomics analysis of pevonedistat effects and effects of the proteasome inhibitor bortezomib revealed stabilization of multiple targets of CRLs including p27, an established tumor suppressor in SI-NET. Silencing of NEDD8 and RBX1 using siRNA resulted in a stabilization of p27, suggesting that the cellular levels of NEDD8 and RBX1 affect CRL activity. Inhibition of CRL activity, by either NEDD8/RBX1 silencing or pevonedistat treatment of cells resulted in induction of apoptosis that could be partially rescued by siRNA-based silencing of p27. Differential expression of both p27 and NEDD8 was confirmed in a second cohort of SI-NET using immunohistochemistry. Collectively, these findings suggest a role for CRLs and the ubiquitin proteasome system in suppression of p27 in SI-NET, and inhibition of neddylation as a putative therapeutic strategy in SI-NET.	[Fotouhi, Omid; Juhlin, C. Christofer; Pan, Yanbo; Vesterlund, Mattias; Ghaderi, Mehran; Larsson, Catharina; Orre, Lukas M.] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden; [Kjellin, Hanna; Kjellman, Magnus; Zedenius, Jan] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden; [Juhlin, C. Christofer] Karolinska Univ Hosp Solna, Dept Pathol & Cytol, Stockholm, Sweden; [Pan, Yanbo; Vesterlund, Mattias; Andersson-Sand, Hillevi; Orre, Lukas M.] SciLifeLab, Stockholm, Sweden; [Yousef, Abdelhamid] Univ Cambridge, Dept Pharmacol, Cambridge, England; [Kharaziha, Pedram] Linkoping Univ Hosp, Dept Clin Genet, Linkoping, Sweden; [Caramuta, Stefano] Uppsala Univ, Uppsala Clin Res Ctr, Uppsala, Sweden; [Kjellman, Magnus; Zedenius, Jan] Karolinska Univ Hosp Solna, Dept Breast Endocrine Tumours & Sarcoma, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; SciLifeLab; University of Cambridge; Linkoping University; Uppsala University; Karolinska Institutet; Karolinska University Hospital	Larsson, C; Orre, LM (corresponding author), Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden.; Orre, LM (corresponding author), SciLifeLab, Stockholm, Sweden.	catharina.larsson@ki.se; lukas.orre@ki.se	Vesterlund, Mattias/AAX-8014-2021; Juhlin, Carl Christofer/C-1125-2016; Pan, Yanbo/G-9371-2016; Ghaderi, Mehran/AAB-7416-2021	Juhlin, Carl Christofer/0000-0002-5945-9081; Pan, Yanbo/0000-0001-9442-7782; Vesterlund, Mattias/0000-0001-9471-6592; Orre, Lukas/0000-0002-0384-1003	Novartis; Swedish Research Council; Swedish Cancer Society; Cancer Society in Stockholm; Gustav V Jubilee Foundation; Stockholm County Council; Karolinska Institutet	Novartis(Novartis); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); Cancer Society in Stockholm; Gustav V Jubilee Foundation; Stockholm County Council(Stockholm County Council); Karolinska Institutet(Karolinska Institutet)	The study was supported by grants from Novartis, the Swedish Research Council, the Swedish Cancer Society, the Cancer Society in Stockholm, the Gustav V Jubilee Foundation, Stockholm County Council, and Karolinska Institutet. Mass spectrometry-based proteomics analysis was performed at the Clinical Proteomics Mass Spectrometry facility located at SciLifeLab in Solna, Sweden.	Bhatia S, 2016, INVEST NEW DRUG, V34, P439, DOI 10.1007/s10637-016-0348-5; Branca RMM, 2014, NAT METHODS, V11, P59, DOI [10.1038/NMETH.2732, 10.1038/nmeth.2732]; Brownell JE, 2010, MOL CELL, V37, P102, DOI 10.1016/j.molcel.2009.12.024; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Cunningham JL, 2011, EUR J CLIN INVEST, V41, P1353, DOI 10.1111/j.1365-2362.2011.02537.x; Duda DM, 2008, CELL, V134, P995, DOI 10.1016/j.cell.2008.07.022; Edfeldt K, 2017, NEUROENDOCRINOLOGY, V105, P170, DOI 10.1159/000452891; Emanuele MJ, 2011, CELL, V147, P459, DOI 10.1016/j.cell.2011.09.019; Enchev RI, 2015, NAT REV MOL CELL BIO, V16, P30, DOI 10.1038/nrm3919; Fotouhi O, 2016, J CLIN ENDOCR METAB, V101, P3616, DOI 10.1210/jc.2016-2028; Francis JM, 2013, NAT GENET, V45, P1483, DOI 10.1038/ng.2821; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Galvan JA, 2013, AM J CLIN PATHOL, V140, P61, DOI 10.1309/AJCPIV40ISTBXRAX; Gao H, 2004, P NATL ACAD SCI USA, V101, P17204, DOI 10.1073/pnas.0407693101; Gao J, 2009, GLIA, V57, P989, DOI 10.1002/glia.20823; Hashemi J, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-505; Karpathakis A, 2016, CLIN CANCER RES, V22, P250, DOI 10.1158/1078-0432.CCR-15-0373; Klimstra, 2010, WHO CLASSIFICATION T, P102; Kytola S, 2001, AM J PATHOL, V158, P1803, DOI 10.1016/S0002-9440(10)64136-3; Lee J, 2009, EXP MOL MED, V41, P765, DOI 10.3858/emm.2009.41.11.102; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Migita K, 2014, GASTRIC CANCER, V17, P601, DOI 10.1007/s10120-013-0318-y; Muraoka RS, 2002, MOL CELL BIOL, V22, P2204, DOI 10.1128/MCB.22.7.2204-2219.2002; Nieser M, 2017, NEUROENDOCRINOLOGY, V104, P302, DOI 10.1159/000446917; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pan ZQ, 2004, ONCOGENE, V23, P1985, DOI 10.1038/sj.onc.1207414; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; Ritz C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0146021; Salon C, 2007, J PATHOL, V213, P303, DOI 10.1002/path.2223; Sarantopoulos J, 2016, CLIN CANCER RES, V22, P847, DOI 10.1158/1078-0432.CCR-15-1338; Shah JJ, 2016, CLIN CANCER RES, V22, P34, DOI 10.1158/1078-0432.CCR-15-1237; Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884; Stalberg P, 2016, J INTERN MED, V280, P584, DOI 10.1111/joim.12526; Swords RT, 2018, BLOOD, V131, P1415, DOI 10.1182/blood-2017-09-805895; Tian DW, 2019, CANCER SCI, V110, P458, DOI 10.1111/cas.13865; Wang W, 2013, J SURG ONCOL, V107, P758, DOI 10.1002/jso.23317; Watson IR, 2011, CANCER CELL, V19, P168, DOI 10.1016/j.ccr.2011.01.002; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Xie P, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.195; Xing R, 2016, SURG ONCOL, V25, P147, DOI 10.1016/j.suronc.2016.05.006; Yang WJ, 2013, NUCLEIC ACIDS RES, V41, pD955, DOI 10.1093/nar/gks1111; Yu J, 2018, CANC MED; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zhou LS, 2018, CELL SIGNAL, V44, P92, DOI 10.1016/j.cellsig.2018.01.009; Zhou Y, 2017, ONCOGENE, V36, P731, DOI 10.1038/onc.2016.242	47	5	6	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2019	38	43					6881	6897		10.1038/s41388-019-0938-8	http://dx.doi.org/10.1038/s41388-019-0938-8			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JH4GX	31406256	Green Published, hybrid			2022-12-28	WOS:000492728000001
J	Nitta, RT; Bolin, S; Luo, E; Solow-Codero, DE; Samghabadi, P; Purzner, T; Aujla, PS; Nwagbo, G; Cho, YJ; Li, G				Nitta, Ryan T.; Bolin, Sara; Luo, Emily; Solow-Codero, David E.; Samghabadi, Peyman; Purzner, Teresa; Aujla, Parvir S.; Nwagbo, Ginikachi; Cho, Yoon-Jae; Li, Gordon			Casein kinase 2 inhibition sensitizes medulloblastoma to temozolomide	ONCOGENE			English	Article							UNFAVORABLE PROGNOSTIC MARKER; BRAIN-TUMORS; CK2-ALPHA; CHEMOTHERAPY; EXPRESSION; SUBGROUPS; CARCINOMA; PATHWAYS; CHILDREN; TARGET	Medulloblastoma (MB) is the most common malignant pediatric brain tumor. Since surviving patients experience severe neurocognitive disabilities, better and more effective treatments are needed to enhance their quality of life. Casein kinase 2 (CK2) is known to regulate cell growth and survival in multiple cancers; however, the role of CK2 in MB is currently being studied. In this study, we verified the importance of CK2 in MB tumorigenesis and discovered that inhibition of CK2 using the small molecule inhibitor, CX-4945, can sensitize MB cells to a well-known and tolerated chemotherapeutic, temozolomide (TMZ). To study the role of CK2 in MB we modulated CK2 expression in multiple MB cells. Exogenous expression of CK2 enhanced cell growth and tumor growth in mice, while depletion or inhibition of CK2 expression decreased MB tumorigenesis. Treatment with CX-4945 reduced MB growth and increased apoptosis. We conducted a high-throughput screen where 4000 small molecule compounds were analyzed to identify compounds that increased the anti-tumorigenic properties of CX-4945. TMZ was found to work synergistically with CX-4945 to decrease cell survival and increase apoptosis in MB cells. O-6-methylguanine-DNA methyltransferase (MGMT) activity is directly correlated to TMZ sensitivity. We found that loss of CK2 activity reduced beta-catenin expression, a known MGMT regulator, which in turn led to a decrease in MGMT expression and an increased sensitivity to TMZ. Our findings show that CK2 is important for MB maintenance and that treatment with CX-4945 can sensitize MB cells to TMZ treatment.	[Nitta, Ryan T.; Bolin, Sara; Luo, Emily; Aujla, Parvir S.; Nwagbo, Ginikachi; Li, Gordon] Stanford Univ, Dept Neurosurg, Stanford, CA 94305 USA; [Solow-Codero, David E.] Stanford Univ, Dept Chem & Syst Biol, High Throughput Biosci Ctr, Stanford, CA 94305 USA; [Samghabadi, Peyman] Stanford Univ, Dept Neuropathol, Stanford, CA 94305 USA; [Purzner, Teresa] Stanford Univ, Dept Dev Biol, Stanford, CA 94305 USA; [Purzner, Teresa] Univ Toronto, Div Neurosurg, Toronto, ON, Canada; [Cho, Yoon-Jae] Oregon Hlth & Sci Univ, Dept Pediat, Pape Family Pediat Res Inst, Knight Canc Inst, 3181 Sw Sam Jackson Pk Rd, Portland, OR 97201 USA	Stanford University; Stanford University; Stanford University; Stanford University; University of Toronto; Oregon Health & Science University	Nitta, RT (corresponding author), Stanford Univ, Dept Neurosurg, Stanford, CA 94305 USA.	rnitta@stanford.edu		Li, Gordon/0000-0001-8372-0676; Solow-Cordero, David/0000-0002-9886-5058; Bolin, Sara/0000-0003-2835-1518	Stanford Cancer Institute Bioscience Screening Award; Swedish Childhood Cancer Foundation;  [NIH-KNS085333A]; NATIONAL CANCER INSTITUTE [P30CA124435] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS085333] Funding Source: NIH RePORTER	Stanford Cancer Institute Bioscience Screening Award; Swedish Childhood Cancer Foundation(European Commission); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We would like to thank Albert Wong and the Cell Sciences Imaging Facility (CSIF) at Stanford University for use of their equipment. This work was funded by generous donations of the Anatoly Machulskiy family, Keith Tsu and Carmelita Ko, Steven Sommer, and the Yatindra Singh family. This research was also funded by Stanford Cancer Institute Bioscience Screening Award and NIH-KNS085333A and SB was supported by the Swedish Childhood Cancer Foundation.	Aguilera D, 2013, CHILD NERV SYST, V29, P589, DOI 10.1007/s00381-012-2013-4; Akyuz C, 2012, CHILD NERV SYST, V28, P111, DOI 10.1007/s00381-011-1561-3; Bae JS, 2015, INT J CANCER, V136, P797, DOI 10.1002/ijc.29043; Berchtold NC, 2008, P NATL ACAD SCI USA, V105, P15605, DOI 10.1073/pnas.0806883105; BORAD MJ, 2017, J CLIN ONCOL S, V35; Cavalli FMG, 2017, CANCER CELL, V31, P737, DOI 10.1016/j.ccell.2017.05.005; Chua MMJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188854; Chua MMJ, 2017, PHARMACEUTICALS-BASE, V10, DOI 10.3390/ph10010018; Dhall G, 2009, J CHILD NEUROL, V24, P1418, DOI 10.1177/0883073809341668; Faoro D, 2011, J NEURO-ONCOL, V103, P59, DOI 10.1007/s11060-010-0366-7; Gajjar A, 2006, LANCET ONCOL, V7, P813, DOI 10.1016/S1470-2045(06)70867-1; Guo B, 2000, CLIN CANCER RES, V6, P718; Kim HS, 2014, FEBS J, V281, P851, DOI 10.1111/febs.12652; Kim JS, 2007, CLIN CANCER RES, V13, P1019, DOI 10.1158/1078-0432.CCR-06-1602; Kool M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003088; Lin K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018608; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Marschke RF, 2011, ASCO M ABSTRACTS S, V29, P3087, DOI DOI 10.1200/jco.2011.29.15_suppl.3087; Michaelis M, 2015, SCI REP-UK, V5, DOI 10.1038/srep08202; Nitta RT, 2015, ONCOGENE, V34, P3688, DOI 10.1038/onc.2014.299; Nitta RT, 2011, ONCOGENE, V30, P234, DOI 10.1038/onc.2010.414; Nitta RT, 2013, J MOL GENET MED, V8, P1; Ortega CE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115609; Othman RT, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-57; Packer RJ, 2006, J CLIN ONCOL, V24, P4202, DOI 10.1200/JCO.2006.06.4980; Purzner J, 2007, J NEUROSCI, V27, P6029, DOI 10.1523/JNEUROSCI.5441-06.2007; Purzner T, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aau5147; Rabjerg M, 2017, ONCOTARGET, V8, P1613, DOI 10.18632/oncotarget.13693; Robinson G, 2012, NATURE, V488, P43, DOI 10.1038/nature11213; Swartling FJ, 2012, CANCER CELL, V21, P601, DOI 10.1016/j.ccr.2012.04.012; Taylor MD, 2012, ACTA NEUROPATHOL, V123, P465, DOI 10.1007/s00401-011-0922-z; von Bueren AO, 2012, BRIT J CANCER, V107, P1399, DOI 10.1038/bjc.2012.403; Wickstrom M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9904; Zhang HX, 2015, ONCOTARGET, V6, P34800, DOI 10.18632/oncotarget.5470; Zheng Y, 2013, CLIN CANCER RES, V19, P6484, DOI 10.1158/1078-0432.CCR-13-0265	35	13	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2019	38	42					6867	6879		10.1038/s41388-019-0927-y	http://dx.doi.org/10.1038/s41388-019-0927-y			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE5UU	31406250	hybrid, Green Accepted			2022-12-28	WOS:000490758200005
J	Ki, DH; Oppel, F; Durbin, AD; Look, AT				Ki, Dong Hyuk; Oppel, Felix; Durbin, Adam D.; Look, A. Thomas			Mechanisms underlying synergy between DNA topoisomerase I-targeted drugs and mTOR kinase inhibitors in NF1-associated malignant peripheral nerve sheath tumors	ONCOGENE			English	Article							PHASE-II; NUCLEAR EXPORT; SOFT-TISSUE; CAMPTOTHECIN; INITIATION; ZEBRAFISH; PATHWAYS; MODELS; TRANSLATION; REPRESSION	Malignant peripheral nerve sheath tumors (MPNSTs) are soft-tissue sarcomas that frequently arise in patients with neurofibromatosis type 1 (NF1). Most of these tumors are unresectable at diagnosis and minimally responsive to conventional treatment, lending urgency to the identification of new pathway dependencies and drugs with potent antitumor activities. We therefore examined a series of candidate agents for their ability to induce apoptosis in MPNST cells arising in nf1/tp53-deficient zebrafish. In this study, we found that DNA topoisomerase I-targeted drugs and mTOR kinase inhibitors were the most effective single agents in eliminating MPNST cells without prohibitive toxicity. In addition, three members of these classes of drugs, either AZD2014 or INK128 in combination with irinotecan, acted synergistically to induce apoptosis both in vitro and in vivo. In mechanistic studies, irinotecan not only induces apoptosis by eliciting a DNA damage response, but also acts synergistically with AZD2014 to potentiate the hypophosphorylation of 4E-BP1, a downstream target of mTORC1. Profound hypophosphorylation of 4E-BP1 induced by this drug combination causes an arrest of protein synthesis, which potently induces tumor cell apoptosis. Our findings provide a compelling rationale for further in vivo evaluation of the combination of DNA topoisomerase I-targeted drugs and mTOR kinase inhibitors against these aggressive nerve sheath tumors.	[Ki, Dong Hyuk; Oppel, Felix; Durbin, Adam D.; Look, A. Thomas] Harvard Med Sch, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; [Ki, Dong Hyuk; Oppel, Felix; Durbin, Adam D.; Look, A. Thomas] Boston Childrens Hosp, Div Pediat Hematol Oncol, Boston, MA 02115 USA; [Durbin, Adam D.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute	Look, AT (corresponding author), Harvard Med Sch, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.	Thomas_Look@dfci.harvard.edu		Ki, Dong Hyuk/0000-0002-1571-7077; Look, A. Thomas/0000-0001-7851-8617; Durbin, Adam/0000-0002-5472-9847	Boston Children's Hospital Neurofibromatosis program; Department of Defense [W81XWH-12-1-0125]; Drug Discovery Initiative Award; NF1 Research Consortium Fund; Children's Tumor Foundation; NF Research Initiative at Boston Children's Hospital; German Cancer Aid; Mildred-Scheel-Postdoctoral program of the Mildred-Scheel Foundation; Alex's Lemonade Stand Young Investigator Award; American Society of Clinical Oncology Young Investigator Award; Rally Foundation for Childhood Cancer Research Young Investigator Award;  [DRSG-24-18]	Boston Children's Hospital Neurofibromatosis program; Department of Defense(United States Department of Defense); Drug Discovery Initiative Award; NF1 Research Consortium Fund; Children's Tumor Foundation; NF Research Initiative at Boston Children's Hospital; German Cancer Aid(Deutsche Krebshilfe); Mildred-Scheel-Postdoctoral program of the Mildred-Scheel Foundation; Alex's Lemonade Stand Young Investigator Award; American Society of Clinical Oncology Young Investigator Award; Rally Foundation for Childhood Cancer Research Young Investigator Award; 	We thank Dr. Donna Neuberg for biostatistical advice regarding the sample size, statistical power, and most appropriate statistical tests. We are grateful to Hillary Layden and Grace Thurston for their expert assistance with zebrafish husbandry and to Drs. Karen Cichowski and Nancy Ratner for providing human MPNST cell lines. This work was supported by the Latsis family fellowship from the Boston Children's Hospital Neurofibromatosis program, a grant from the Department of Defense (grant number W81XWH-12-1-0125), a Drug Discovery Initiative Award, the NF1 Research Consortium Fund, and Children's Tumor Foundation Young Investigator Award to DHK supported by the NF Research Initiative at Boston Children's Hospital made possible by an anonymous gift. FO acknowledges the German Cancer Aid for their generous funding within the Mildred-Scheel-Postdoctoral program of the Mildred-Scheel Foundation. ADD is a Damon-Runyon Sohn Pediatric Fellow (grant number DRSG-24-18), and acknowledges grant support from the Alex's Lemonade Stand Young Investigator Award, the American Society of Clinical Oncology Young Investigator Award and the Rally Foundation for Childhood Cancer Research Young Investigator Award.	Barbazuk WB, 2000, GENOME RES, V10, P1351, DOI 10.1101/gr.144700; Beauchamp RL, 2015, ONCOTARGET, V6, P16981, DOI 10.18632/oncotarget.4858; BLAIR SC, 1994, AM J CLIN ONCOL-CANC, V17, P480, DOI 10.1097/00000421-199412000-00005; Brohl AS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15183-1; Cam H, 2010, MOL CELL, V40, P509, DOI 10.1016/j.molcel.2010.10.030; Cam M, 2014, J BIOL CHEM, V289, P4083, DOI 10.1074/jbc.M113.530303; Charest Mathieu, 2017, J Nucl Med Technol, DOI 10.2967/jnmt.117.199927; Choo AY, 2008, P NATL ACAD SCI USA, V105, P17414, DOI 10.1073/pnas.0809136105; Chugh R, 2009, J CLIN ONCOL, V27, P3148, DOI 10.1200/JCO.2008.20.5054; Cichowski K, 2001, CELL, V104, P593, DOI 10.1016/S0092-8674(01)00245-8; Cubitt Christopher L., 2013, Sarcoma, V2013, P365723, DOI 10.1155/2013/365723; De Raedt T, 2014, NATURE, V514, P247, DOI 10.1038/nature13561; Dickson MA, 2016, ANN ONCOL, V27, P1855, DOI 10.1093/annonc/mdw281; Durbin AD, 2016, ADV EXP MED BIOL, V916, P495, DOI 10.1007/978-3-319-30654-4_22; Endo M, 2013, CLIN CANCER RES, V19, P450, DOI 10.1158/1078-0432.CCR-12-1067; EricksonMiller CL, 1997, CANCER CHEMOTH PHARM, V39, P467, DOI 10.1007/s002800050600; Etchin J, 2013, BRIT J HAEMATOL, V161, P117, DOI 10.1111/bjh.12231; Evans DGR, 2011, EUR J HUM GENET, V19, P1187, DOI 10.1038/ejhg.2011.113; Ferner RE, 2007, LANCET NEUROL, V6, P340, DOI 10.1016/S1474-4422(07)70075-3; Ferrari Andrea, 2007, Paediatr Drugs, V9, P239, DOI 10.2165/00148581-200709040-00005; Gilbert DC, 2012, BRIT J CANCER, V106, P18, DOI 10.1038/bjc.2011.498; Goodsell DS, 1999, STEM CELLS, V17, P235, DOI 10.1002/stem.170235; Gupta G, 2008, NEUROSURG CLIN N AM, V19, P533, DOI 10.1016/j.nec.2008.07.004; Hagel C, 2007, J NEURO-ONCOL, V82, P187, DOI 10.1007/s11060-006-9266-2; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Jessen WJ, 2013, J CLIN INVEST, V123, P340, DOI 10.1172/JCI60578; Kebudi R, 2013, PEDIATR HEMAT ONCOL, V30, P170, DOI 10.3109/08880018.2013.767868; Ki DH, 2017, ONCOGENE, V36, P1058, DOI 10.1038/onc.2016.269; Kim AeRang, 2017, Sarcoma, V2017, P7429697, DOI 10.1155/2017/7429697; Kim J, 2016, NATURE, V538, P114, DOI 10.1038/nature19771; Kroep JR, 2011, ANN ONCOL, V22, P207, DOI 10.1093/annonc/mdq338; Lansiaux A, 2007, MOL PHARMACOL, V72, P311, DOI 10.1124/mol.107.034637; Lee W, 2014, NAT GENET, V46, P1227, DOI 10.1038/ng.3095; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; MADER S, 1995, MOL CELL BIOL, V15, P4990; Maki RG, 2009, J CLIN ONCOL, V27, P3133, DOI 10.1200/JCO.2008.20.4495; Malone CF, 2014, CANCER DISCOV, V4, P1062, DOI 10.1158/2159-8290.CD-14-0159; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; Nair JS, 2017, CLIN CANCER RES, V23, P4301, DOI 10.1158/1078-0432.CCR-16-2632; Nkere UU, 1997, EUR J CARDIO-THORAC, V12, P144, DOI 10.1016/S1010-7940(97)00085-7; Schuetze SM, 2016, CANCER-AM CANCER SOC, V122, P868, DOI 10.1002/cncr.29858; Shin J, 2012, DIS MODEL MECH, V5, P881, DOI 10.1242/dmm.009779; Staker BL, 2002, P NATL ACAD SCI USA, V99, P15387, DOI 10.1073/pnas.242259599; Stucky CCH, 2012, ANN SURG ONCOL, V19, P878, DOI 10.1245/s10434-011-1978-7; Tee AR, 2000, ONCOGENE, V19, P3021, DOI 10.1038/sj.onc.1203622; Thompson J, 1998, BBA-GENE STRUCT EXPR, V1400, P301, DOI 10.1016/S0167-4781(98)00143-2; Duong TA, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-18; Valentin T, 2016, EUR J CANCER, V56, P77, DOI 10.1016/j.ejca.2015.12.015; Varin J, 2016, ONCOTARGET, V7, P35753, DOI 10.18632/oncotarget.7099; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang Jun, 2014, Cancer Cell Microenviron, V1; Watson AL, 2014, ONCOTARGET, V5, P1502, DOI 10.18632/oncotarget.1609; Westerfield M., 1993, ZEBRAFISH BOOK GUIDE; White RM, 2008, CELL STEM CELL, V2, P183, DOI 10.1016/j.stem.2007.11.002; Zhao CJ, 2011, CARCINOGENESIS, V32, P1143, DOI 10.1093/carcin/bgr076	56	11	11	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2019	38	39					6585	6598		10.1038/s41388-019-0965-5	http://dx.doi.org/10.1038/s41388-019-0965-5			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JA5AQ	31444410	hybrid			2022-12-28	WOS:000487856000002
J	Kleinschmidt, EG; Miller, NLG; Ozmadenci, D; Tancioni, I; Osterman, CD; Barrie, AM; Taylor, KN; Ye, A; Jiang, SL; Connolly, DC; Stupack, DG; Schlaepfer, DD				Kleinschmidt, Elizabeth G.; Miller, Nichol L. G.; Ozmadenci, Duygu; Tancioni, Isabelle; Osterman, Carlos Diaz; Barrie, Allison M.; Taylor, Kristin N.; Ye, Aaron; Jiang, Shulin; Connolly, Denise C.; Stupack, Dwayne G.; Schlaepfer, David D.			Rgnef promotes ovarian tumor progression and confers protection from oxidative stress	ONCOGENE			English	Article							NUCLEOTIDE EXCHANGE FACTOR; SET ENRICHMENT ANALYSIS; NF-KAPPA-B; ADHESION; CELL; EXPRESSION; P190RHOGEF; GENE; ANTIOXIDANT	Ovarian cancer is the fifth-leading cause of cancer death among women. The dissemination of ovarian tumors and growth as spheroids accompanies late-stage disease. In cell culture, ovarian tumor cell spheroids can exhibit elevated resistance to environmental stressors, such as reactive oxygen species. Homeostatic balance of the antioxidant response is a protective mechanism that prevents anoikis, a form of programmed cell death. Signaling pathways activated by integrin receptors suppress anoikis. Rgnef (ARHGEF28/p190RhoGEF) is a guanine nucleotide exchange factor that is activated downstream of integrins. We find that Rgnef protein levels are elevated in late-stage serous ovarian cancer, high Rgnef mRNA levels are associated with decreased progression-free and overall survival, and genomic ARHGEF28 loss is associated with increased patient survival. Using transgenic and transplantable Rgnef knockout mouse models, we find that Rgnef is essential for supporting three-dimensional ovarian spheroid formation in vitro and tumor growth in mice. Using RNA-sequencing and bioinformatic analyses, we identify a conserved Rgnef-supported anti-oxidant gene signature including Gpx4, Nqo1, and Gsta4; common targets of the NF-kB transcription factor. Antioxidant treatment enhanced growth of Rgnef-knockout spheroids and Rgnef re-expression facilitated NF-kappa B-dependent tumorsphere survival. These studies reveal a new role for Rgnef in ovarian cancer to facilitate NF-kappa B-mediated gene expression protecting cells from oxidative stress.	[Kleinschmidt, Elizabeth G.; Miller, Nichol L. G.; Ozmadenci, Duygu; Tancioni, Isabelle; Osterman, Carlos Diaz; Barrie, Allison M.; Taylor, Kristin N.; Ye, Aaron; Jiang, Shulin; Stupack, Dwayne G.; Schlaepfer, David D.] UC San Diego Hlth, Dept Obstet Gynecol & Reprod Sci, Moores Canc Ctr, La Jolla, CA 92093 USA; [Kleinschmidt, Elizabeth G.] UC San Diego Hlth, Biomed Sci Grad Program, La Jolla, CA 92093 USA; [Connolly, Denise C.] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Miller, Nichol L. G.] Pfizer Inc, La Jolla, CA 92121 USA	Fox Chase Cancer Center; Pfizer	Schlaepfer, DD (corresponding author), UC San Diego Hlth, Dept Obstet Gynecol & Reprod Sci, Moores Canc Ctr, La Jolla, CA 92093 USA.	dschlaepfer@ucsd.edu		Diaz Osterman, Carlos/0000-0002-7003-1115	NIH [RO1CA107263, T32-CA121938]; Gaines Family fellowship; NCI [P30 CA006927, CA195723]; DOD [W81XWH-16-1-0142]; UCSD Cancer Center Support grant [P30CA023100]; UCSD Altman Clinical and Translational Research grant [NIH UL1TR001442];  [RO1CA180769];  [RO1CA102310]; NATIONAL CANCER INSTITUTE [R01CA180769, P30CA023100, R01CA102310, P30CA006927, T32CA121938] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001442] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Gaines Family fellowship; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DOD(United States Department of Defense); UCSD Cancer Center Support grant; UCSD Altman Clinical and Translational Research grant; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	Supported by grants RO1CA180769, RO1CA102310, and UCSD Cancer Center Support grant P30CA023100, from UCSD Altman Clinical and Translational Research grant NIH UL1TR001442, and from charitable donations from Nine Girls Ask. DGS was supported by NIH RO1CA107263. KNT and AMB are fellows of the UCSD Reproductive Medicine Gynecologic Oncology Program and were supported by the Gaines Family fellowship. CDO was supported by NIH training grant (T32-CA121938). DCC was supported by NCI P30 CA006927, NCI CA195723, DOD W81XWH-16-1-0142 and charitable donations from The Roberta Dubrow Fund.	Al Habyan S, 2018, ONCOGENE, V37, P5127, DOI 10.1038/s41388-018-0317-x; Anders Simon, 2010, Genome Biol, V11, pR106, DOI 10.1186/gb-2010-11-10-r106; Baccam M, 2003, J IMMUNOL, V170, P3099, DOI 10.4049/jimmunol.170.6.3099; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cheung K, 2017, MOL CELL NEUROSCI, V82, P88, DOI 10.1016/j.mcn.2017.05.003; Connolly DC, 2003, CANCER RES, V63, P1389; de la Vega MR, 2018, CANCER CELL, V34, P21, DOI 10.1016/j.ccell.2018.03.022; Diviani D, 2016, CELL CHEM BIOL, V23, P1135, DOI 10.1016/j.chembiol.2016.07.015; Gabbasov R, 2018, ONCOGENE, V37, P4854, DOI 10.1038/s41388-018-0296-y; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Harris IS, 2015, CANCER CELL, V27, P211, DOI 10.1016/j.ccell.2014.11.019; Hellner K, 2016, EBIOMEDICINE, V10, P137, DOI 10.1016/j.ebiom.2016.06.048; Kenny HA, 2009, CANCER TREAT RES, V149, P335, DOI 10.1007/978-0-387-98094-2_16; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Konstantinopoulos PA, 2009, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-59; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Lachmann A, 2010, BIOINFORMATICS, V26, P2438, DOI 10.1093/bioinformatics/btq466; Lanczky A, 2016, BREAST CANCER RES TR, V160, P439, DOI 10.1007/s10549-016-4013-7; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Lee JR, 2003, J IMMUNOL, V170, P19, DOI 10.4049/jimmunol.170.1.19; Lim Y, 2008, J CELL BIOL, V180, P187, DOI 10.1083/jcb.200708194; Masia-Balague M, 2015, J BIOL CHEM, V290, P15197, DOI 10.1074/jbc.M114.628164; Michael J Morgan, 2011, Cell Research, V21, P103; Miller NLG, 2014, CURR MOL MED, V14, P221, DOI 10.2174/1566524014666140128110339; Miller NLG, 2013, J CELL SCI, V126, P5074, DOI 10.1242/jcs.135509; Miller NLG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037830; Quinn BA, 2010, J OVARIAN RES, V3, DOI 10.1186/1757-2215-3-24; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Reddig PJ, 2005, CANCER METAST REV, V24, P425, DOI 10.1007/s10555-005-5134-3; Roy L, 2018, CANCERS, V10, DOI 10.3390/cancers10080241; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Schieber M, 2014, CURR BIOL, V24, pR453, DOI 10.1016/j.cub.2014.03.034; Seguin L, 2015, TRENDS CELL BIOL, V25, P234, DOI 10.1016/j.tcb.2014.12.006; Shield K, 2009, GYNECOL ONCOL, V113, P143, DOI 10.1016/j.ygyno.2008.11.032; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tancioni I, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0551-x; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; van der Wijst MGP, 2014, BBA-REV CANCER, V1846, P494, DOI 10.1016/j.bbcan.2014.09.004; Ward KK, 2013, CLIN EXP METASTAS, V30, P579, DOI 10.1007/s10585-012-9562-5; Wu JH, 2003, MOL BRAIN RES, V117, P27, DOI 10.1016/S0169-328X(03)00263-8; Yu HG, 2011, CANCER RES, V71, P360, DOI 10.1158/0008-5472.CAN-10-2894; Zhang H, 2016, CELL, V166, P755, DOI 10.1016/j.cell.2016.05.069	47	15	15	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2019	38	36					6323	6337		10.1038/s41388-019-0881-8	http://dx.doi.org/10.1038/s41388-019-0881-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IX6EX	31308489	Green Submitted, Green Accepted			2022-12-28	WOS:000485776800001
J	Nguyen, T; Duchesne, L; Narayana, GHNS; Boggetto, N; Fernig, DD; Murade, CU; Ladoux, B; Mege, RM				Thao Nguyen; Duchesne, Laurence; Narayana, Gautham Hari Narayana Sankara; Boggetto, Nicole; Fernig, David D.; Murade, Chandrashekhar Uttamrao; Ladoux, Benoit; Mege, Rene-Marc			Enhanced cell-cell contact stability and decreased N-cadherin-mediated migration upon fibroblast growth factor receptor-N-cadherin cross talk	ONCOGENE			English	Article							P120 CATENIN; NEURITE OUTGROWTH; ADHESION MOLECULE; LIGAND-BINDING; TYROSINE PHOSPHORYLATION; MORPHOGENETIC MOVEMENT; NEURONAL MIGRATION; BREAST-CANCER; FGF RECEPTOR; EXPRESSION	N-cadherin adhesion has been reported to enhance cancer and neuronal cell migration either by mediating actomyosin-based force transduction or initiating fibroblast growth factor receptor (FGFR)-dependent biochemical signalling. Here we show that FGFR1 reduces N-cadherin-mediated cell migration. Both proteins are co-stabilised at cell-cell contacts through direct interaction. As a consequence, cell adhesion is strengthened, limiting the migration of cells on N-cadherin. Both the inhibition of migration and the stabilisation of cell adhesions require the FGFR activity stimulated by N-cadherin engagement. FGFR1 stabilises N-cadherin at the cell membrane through a pathway involving Src and p120. Moreover, FGFR1 stimulates the anchoring of N-cadherin to actin. We found that the migratory behaviour of cells depends on an optimum balance between FGFR-regulated N-cadherin adhesion and actin dynamics Based on these findings we propose a positive feed-back loop between N-cadherin and FGFR at adhesion sites limiting N-cadherin-based single-cell migration.	[Thao Nguyen; Narayana, Gautham Hari Narayana Sankara; Boggetto, Nicole; Murade, Chandrashekhar Uttamrao; Ladoux, Benoit; Mege, Rene-Marc] Univ Paris Diderot, Inst Jacques Monod, CNRS, 15 Rue Helene Brion, F-75205 Paris 13, France; [Duchesne, Laurence] Univ Rennes, CNRS, UMR 6290, IGDR, F-35000 Rennes, France; [Fernig, David D.] Univ Liverpool, Dept Biochem, Inst Integrated Biol, Liverpool L69 7ZB, Merseyside, England	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Rennes; University of Liverpool	Mege, RM (corresponding author), Univ Paris Diderot, Inst Jacques Monod, CNRS, 15 Rue Helene Brion, F-75205 Paris 13, France.	rene-marc.mege@ijm.fr	Fernig, David G/A-3590-2008	Fernig, David G/0000-0003-4875-4293; Duchesne, Laurence/0000-0003-1985-6266; Ladoux, Benoit/0000-0003-2086-1556; Sankara Narayana, Gautham Hari Narayana/0000-0002-2534-5836; Mege, Rene-Marc/0000-0001-8128-5543	CNRS; ARC foundation [PJA 20151203185]; Human Frontier Science Program (HFSP) [RPG0040/2012]; European Research Council under the European Union's Seventh Framework Program (FP7/2007-2013)/ERC grant [617233]; Agence Nationale de la Recherche [ANR 2010 Blan1515]; NUS-USPC exchange program; HFSP [RPG0040/2012]; Fondation pour la Recherche Medicale and Labex WhoAmI; Region Ile de France [E539]; Ligue contre le Cancer [R03/75-79]; Fondation pour la Recherche Medicale [FDT20150532600]; Association pour la Recherche contre le Cancer (Fondation ARC) [P2009 CDD POST-DOC]; DDF by North West Cancer; Cancer and Polio Research Fund; ImagoSeine core facility of the Institut Jacques Monod, member of IBiSA and France-BioImaging [ANR-10-INBS-04]	CNRS(Centre National de la Recherche Scientifique (CNRS)); ARC foundation(Australian Research Council); Human Frontier Science Program (HFSP)(Human Frontier Science Program); European Research Council under the European Union's Seventh Framework Program (FP7/2007-2013)/ERC grant; Agence Nationale de la Recherche(French National Research Agency (ANR)); NUS-USPC exchange program; HFSP(Human Frontier Science Program); Fondation pour la Recherche Medicale and Labex WhoAmI; Region Ile de France(Region Ile-de-France); Ligue contre le Cancer(Ligue nationale contre le cancer); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Association pour la Recherche contre le Cancer (Fondation ARC); DDF by North West Cancer; Cancer and Polio Research Fund; ImagoSeine core facility of the Institut Jacques Monod, member of IBiSA and France-BioImaging	This work was supported by grants from the CNRS, ARC foundation (contract number: PJA 20151203185), Human Frontier Science Program (HFSP grant RPG0040/2012), European Research Council under the European Union's Seventh Framework Program (FP7/2007-2013)/ERC grant agreements no 617233 (BL), Agence Nationale de la Recherche (ANR 2010 Blan1515) and NUS-USPC exchange program. TN was supported by a HFSP grant RPG0040/2012, then by Fondation pour la Recherche Medicale and Labex WhoAmI. We would like also to thank all present and past members of the Cell Adhesion & Mechanics lab at the Institute Jacques Monod for constant support and exchange. We thank Region Ile de France (E539) and Ligue contre le Cancer (R03/75-79) for the acquisition of the equipment. We thank CUM and M. Yao for held with magnetic tweezer experiment. CUM was supported by Fondation pour la Recherche Medicale (FDT20150532600), LD by the Association pour la Recherche contre le Cancer (Fondation ARC, P2009 CDD POST-DOC) and DDF by North West Cancer and the Cancer and Polio Research Fund. We thank O. Thoumine and R. Horwitz for their kind gift of NcadAAA and FGFR1 encoding plasmids, respectively. We acknowledge the ImagoSeine core facility of the Institut Jacques Monod, member of IBiSA and France-BioImaging (ANR-10-INBS-04) infrastructures.	Anastasiadis PZ, 2001, CURR OPIN CELL BIOL, V13, P604, DOI 10.1016/S0955-0674(00)00258-1; Bard L, 2008, J NEUROSCI, V28, P5879, DOI 10.1523/JNEUROSCI.5331-07.2008; BIXBY JL, 1990, J CELL BIOL, V110, P1253, DOI 10.1083/jcb.110.4.1253; Boscher C, 2008, CELL SIGNAL, V20, P1061, DOI 10.1016/j.cellsig.2008.01.008; Brittis PA, 1996, MOL CELL NEUROSCI, V8, P120, DOI 10.1006/mcne.1996.0051; Carmeliet P, 2000, ANN NY ACAD SCI, V902, P249; Carmeliet P., 2000, ANN NY ACAD SCI, V902, P62; Chen XY, 2003, J CELL BIOL, V163, P547, DOI 10.1083/jcb.200305137; Chu WC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073878; Chu YS, 2006, J BIOL CHEM, V281, P2901, DOI 10.1074/jbc.M506185200; Ciruna B, 2001, DEV CELL, V1, P37, DOI 10.1016/S1534-5807(01)00017-X; Ciruna BG, 1997, DEVELOPMENT, V124, P2829; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; Debiais F, 2001, J CELL BIOCHEM, V81, P68, DOI 10.1002/1097-4644(20010401)81:1<68::AID-JCB1024>3.0.CO;2-S; del Valle-Perez B, 2011, J CELL SCI, V124, P2298, DOI 10.1242/jcs.082693; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; Derycke LDM, 2004, INT J DEV BIOL, V48, P463, DOI 10.1387/ijdb.041793ld; Franco SJ, 2011, NEURON, V69, P482, DOI 10.1016/j.neuron.2011.01.003; Gavard J, 2004, J BIOL CHEM, V279, P36795, DOI 10.1074/jbc.M401705200; Giannone G, 2009, TRENDS CELL BIOL, V19, P475, DOI 10.1016/j.tcb.2009.07.001; Giannotta M, 2013, DEV CELL, V26, P441, DOI 10.1016/j.devcel.2013.08.020; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Huttenlocher A, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005074; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Jossin Y, 2011, NAT NEUROSCI, V14, P697, DOI 10.1038/nn.2816; Kadowaki M, 2007, DEV BIOL, V304, P22, DOI 10.1016/j.ydbio.2006.12.014; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; Kashima T, 2003, INT J CANCER, V104, P147, DOI 10.1002/ijc.10931; Kawauchi T, 2010, NEURON, V67, P588, DOI 10.1016/j.neuron.2010.07.007; KE YQ, 1992, BIOCHIM BIOPHYS ACTA, V1131, P307, DOI 10.1016/0167-4781(92)90029-Y; Kolijn K, 2015, ONCOTARGET, V6, P24488, DOI 10.18632/oncotarget.4177; Kontaridis MI, 2002, MOL CELL BIOL, V22, P3875, DOI 10.1128/MCB.22.11.3875-3891.2002; Kourtidis A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129964; Kourtidis A, 2013, PROG MOL BIOL TRANSL, V116, P409, DOI 10.1016/B978-0-12-394311-8.00018-2; Lebreton G, 2016, DEV DYNAM, V245, P372, DOI 10.1002/dvdy.24345; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; LETOURNEAU PC, 1990, DEV BIOL, V138, P430, DOI 10.1016/0012-1606(90)90209-2; Li G, 2001, CANCER RES, V61, P3819; Luccardini C, 2013, J NEUROSCI, V33, P18149, DOI 10.1523/JNEUROSCI.0593-13.2013; Mariner DJ, 2004, J CELL SCI, V117, P1339, DOI 10.1242/jcs.01001; Mariner DJ, 2001, J BIOL CHEM, V276, P28006, DOI 10.1074/jbc.M102443200; MATSUNAGA M, 1988, NATURE, V334, P62, DOI 10.1038/334062a0; Mayor R, 2016, NAT REV MOL CELL BIO, V17, P97, DOI 10.1038/nrm.2015.14; McCrea PD, 2015, CURR TOP DEV BIOL, V112, P129, DOI 10.1016/bs.ctdb.2014.11.018; McIntosh I, 2000, CELL STRUCT FUNCT, V25, P85, DOI 10.1247/csf.25.85; Mege RM, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a028738; Meng WX, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a002899; Nagi C, 2005, BREAST CANCER RES TR, V94, P225, DOI 10.1007/s10549-005-7727-5; Nakashima T, 2003, BRIT J CANCER, V88, P1727, DOI 10.1038/sj.bjc.6600955; Nanes BA, 2012, J CELL BIOL, V199, P365, DOI 10.1083/jcb.201205029; Oas RG, 2013, MOL BIOL CELL, V24, P704, DOI 10.1091/mbc.E12-06-0471; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Peterson SJ, 2015, CELL, V160, P313, DOI 10.1016/j.cell.2014.11.043; Peyton SR, 2005, J CELL PHYSIOL, V204, P198, DOI 10.1002/jcp.20274; Plestant C, 2014, J CELL SCI, V127, P1660, DOI 10.1242/jcs.131284; Porta R, 2017, CRIT REV ONCOL HEMAT, V113, P256, DOI 10.1016/j.critrevonc.2017.02.018; Prasad M, 2011, METHODS MOL BIOL, V769, P277, DOI 10.1007/978-1-61779-207-6_19; Redies C, 1996, DEV BIOL, V180, P413, DOI 10.1006/dbio.1996.0315; Ren MQ, 2011, CANCER RES, V71, P7312, DOI 10.1158/0008-5472.CAN-11-1109; Rieger-Christ KM, 2004, ONCOGENE, V23, P4745, DOI 10.1038/sj.onc.1207629; Scarpa E, 2015, DEV CELL, V34, P421, DOI 10.1016/j.devcel.2015.06.012; Strale PO, 2015, J CELL BIOL, V210, P333, DOI 10.1083/jcb.201410111; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Suzuki SC, 2008, DEV GROWTH DIFFER, V50, pS119, DOI 10.1111/j.1440-169X.2008.01002.x; Taeger J, 2011, MOL CANCER THER, V10, P2157, DOI 10.1158/1535-7163.MCT-11-0312; Takehara T, 2015, SCI REP-UK, V5, DOI 10.1038/srep14722; Nguyen T, 2016, EUR J CELL BIOL, V95, P415, DOI 10.1016/j.ejcb.2016.05.002; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Thoumine O, 2006, MOL BIOL CELL, V17, P862, DOI 10.1091/mbc.E05-04-0335; Treubert-Zimmermann U, 2002, J NEUROSCI, V22, P7617; Trolice MP, 1997, ENDOCRINOLOGY, V138, P107, DOI 10.1210/en.138.1.107; Utton MA, 2001, J NEUROCHEM, V76, P1421, DOI 10.1046/j.1471-4159.2001.00140.x; van Roy F, 2008, CELL MOL LIFE SCI, V65, P3756, DOI 10.1007/s00018-008-8281-1; van Roy F, 2014, NAT REV CANCER, V14, P121, DOI 10.1038/nrc3647; Wesche J, 2011, BIOCHEM J, V437, P199, DOI 10.1042/BJ20101603; Wheelock MJ, 2001, J MAMMARY GLAND BIOL, V6, P275, DOI 10.1023/A:1011319507155; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; Xiao KY, 2003, J CELL BIOL, V163, P535, DOI 10.1083/jcb.200306001; YAMAGUCHI TP, 1994, GENE DEV, V8, P3032, DOI 10.1101/gad.8.24.3032; ZHAN X, 1994, J BIOL CHEM, V269, P20221	81	11	11	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2019	38	35					6283	6300		10.1038/s41388-019-0875-6	http://dx.doi.org/10.1038/s41388-019-0875-6			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IU9RZ	31312021	Green Submitted			2022-12-28	WOS:000483919400004
J	Murugan, AK; Liu, RY; Xing, MZ				Murugan, Avaniyapuram Kannan; Liu, Rengyun; Xing, Mingzhao			Identification and characterization of two novel oncogenic mTOR mutations	ONCOGENE			English	Article							SOMATIC MUTATIONS; MAMMALIAN TARGET; GENETIC ALTERATIONS; POINT MUTATIONS; THYROID-CANCER; PATHWAY; ACTIVATION; KINASE; RAPAMYCIN; CONFER	Mammalian target of rapamycin (mTOR) signaling is often aberrantly activated, particularly when genetically altered, in human cancers. mTOR inhibitors targeting the activated mTOR signaling are highly promising anti-cancer drugs. Knowing the activating genetic change in mTOR can help guide the use of mTOR inhibitors for cancer treatment. This study was conducted to identify and characterize novel oncogenic mTOR mutations that can potentially be therapeutic targets in human cancer. We sequenced 30 exons of the mTOR gene in 12 thyroid cancer cell lines, 3 melanoma cell lines, 20 anaplastic thyroid cancer (ATC) tumors, and 23 melanoma tumors and functionally characterized the identified novel mTOR mutations in vitro and in vivo. We identified a novel point mutation A1256G in ATC cell line and G7076A in melanoma tumor in exon 9 and exon 51 of the mTOR gene, respectively. Over-expression of the corresponding mTOR mutants H419R and G2359E created through induced mutagenesis showed markedly elevated protein kinase activities associated with the activation of mTOR/p70S6K signaling in HEK293T cells. Stable expression of the two mTOR mutants in NIH3T3 cells strongly activated the mTOR/p70S6K signaling pathway and induced morphologic transformation, cell focus formation, anchorage-independent cell growth, and invasion. Inoculation of these mutant-expressing cells in athymic nude mice induced rapid tumor development, showing their driving oncogenicity. We also demonstrated that transfection with the novel mutants conferred cells high sensitivities to the mTOR inhibitor temsirolimus. We speculate that human cancers harboring these mTOR mutations, such as ATC and melanoma, may be effectively treated with inhibitors targeting mTOR.	[Murugan, Avaniyapuram Kannan; Liu, Rengyun; Xing, Mingzhao] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Lab Cellular & Mol Thyroid Res, Sch Med,Dept Med,Div Endocrinol Diabet & Metab, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine	Xing, MZ (corresponding author), Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Lab Cellular & Mol Thyroid Res, Sch Med,Dept Med,Div Endocrinol Diabet & Metab, Baltimore, MD 21287 USA.	mxing1@jhmi.edu	Liu, Rengyun/O-4039-2018; Murugan, Avaniyapuram Kannan/AAI-8222-2020	Liu, Rengyun/0000-0002-1408-2372; Murugan, Avaniyapuram Kannan/0000-0002-3096-6100	U.S.A. National Institutes of Health (NIH) [R01CA215142, R01CA189224]; NATIONAL CANCER INSTITUTE [R01CA215142, R01CA189224] Funding Source: NIH RePORTER	U.S.A. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by U.S.A. National Institutes of Health (NIH) grants R01CA215142 and R01CA189224 to M. Xing.	Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Berven LA, 2000, IMMUNOL CELL BIOL, V78, P447, DOI 10.1046/j.1440-1711.2000.00928.x; Davies H, 2005, CANCER RES, V65, P7591, DOI 10.1158/0008-5472.CAN-05-1855; Edinger AL, 2004, ONCOGENE, V23, P5654, DOI 10.1038/sj.onc.1207738; Fukui Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014180; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Ghosh AP, 2015, ONCOTARGET, V6, P17895, DOI 10.18632/oncotarget.4963; Grabiner BC, 2014, CANCER DISCOV, V4, P554, DOI 10.1158/2159-8290.CD-13-0929; Hardt M, 2011, GENES CELLS, V16, P141, DOI 10.1111/j.1365-2443.2010.01482.x; Janku F, 2018, NAT REV CLIN ONCOL, V15, P273, DOI 10.1038/nrclinonc.2018.28; Jiao QL, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0801-5; Kang SY, 2005, P NATL ACAD SCI USA, V102, P802, DOI 10.1073/pnas.0408864102; Karbowniczek M, 2008, J INVEST DERMATOL, V128, P980, DOI 10.1038/sj.jid.5701074; Kong Y, 2016, CLIN CANCER RES, V22, P1018, DOI 10.1158/1078-0432.CCR-15-1110; Kunstman JW, 2015, HUM MOL GENET, V24, P2318, DOI 10.1093/hmg/ddu749; Lancia I, 2016, J CLIN INVEST, V126, P1052, DOI 10.1172/JCI85271; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Li YY, 2015, CLIN CANCER RES, V21, P1447, DOI 10.1158/1078-0432.CCR-14-1773; de Souza ECL, 2011, EXPERT OPIN THER TAR, V15, P1099, DOI 10.1517/14728222.2011.594044; Liu DX, 2009, CANCER RES, V69, P7311, DOI 10.1158/0008-5472.CAN-09-1077; Liu J, 2010, ANN CLIN LAB SCI, V40, P211; Liu Z, 2008, J CLIN ENDOCR METAB, V93, P3106, DOI 10.1210/jc.2008-0273; Lochhead PA, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.254pe4; Murugan AK, 2015, META GENE, V6, P69, DOI 10.1016/j.mgene.2015.08.005; Murugan AK, 2013, J BIOL CHEM, V288, P6511, DOI 10.1074/jbc.M112.399485; Murugan AK, 2011, CANCER RES, V71, P4403, DOI 10.1158/0008-5472.CAN-10-4041; Murugan AK, 2009, CELL CYCLE, V8, P2122, DOI 10.4161/cc.8.13.8710; Neff RL, 2008, ENDOCRIN METAB CLIN, V37, P525, DOI 10.1016/j.ecl.2008.02.003; Ohne Y, 2008, J BIOL CHEM, V283, P31861, DOI 10.1074/jbc.M801546200; Paquette M, 2018, CANCERS, V10, DOI 10.3390/cancers10010018; Prete A, 2018, CLIN CANCER RES, V24, P6078, DOI 10.1158/1078-0432.CCR-18-0693; Sadow PM, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju182; Saji M, 2010, MOL CELL ENDOCRINOL, V321, P20, DOI 10.1016/j.mce.2009.10.016; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sato T, 2010, ONCOGENE, V29, P2746, DOI 10.1038/onc.2010.28; Schweppe RE, 2008, J CLIN ENDOCR METAB, V93, P4331, DOI 10.1210/jc.2008-1102; Sekulic A, 2000, CANCER RES, V60, P3504; Sturgill TW, 2009, ACS CHEM BIOL, V4, P999, DOI 10.1021/cb900193e; Urano J, 2007, P NATL ACAD SCI USA, V104, P3514, DOI 10.1073/pnas.0608510104; Volkers M, 2013, P NATL ACAD SCI USA, V110, P12661, DOI 10.1073/pnas.1301455110; Wagle N, 2014, NEW ENGL J MED, V371, P1426, DOI 10.1056/NEJMoa1403352; Xing MZ, 2010, THYROID, V20, P697, DOI 10.1089/thy.2010.1646; Xu JN, 2016, J CLIN INVEST, V126, P3526, DOI 10.1172/JCI86120; Yamaguchi H, 2015, CANCER SCI, V106, P1687, DOI 10.1111/cas.12828	45	16	17	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2019	38	26					5211	5226		10.1038/s41388-019-0787-5	http://dx.doi.org/10.1038/s41388-019-0787-5			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IF4AX	30918329	Green Accepted			2022-12-28	WOS:000473025300007
J	Zhu, SM; Tian, H; Niu, XD; Wang, J; Li, X; Jiang, N; Wen, SM; Chen, XR; Ren, SC; Xu, CL; Chang, CS; Flores-Morales, A; Shang, ZQ; Sun, YH; Niu, YJ				Zhu, Shimiao; Tian, Hao; Niu, Xiaodan; Wang, Jiang; Li, Xing; Jiang, Ning; Wen, Simeng; Chen, Xuanrong; Ren, Shancheng; Xu, Chuanliang; Chang, Chawnshang; Flores-Morales, Amilcar; Shang, Zhiqun; Sun, Yinghao; Niu, Yuanjie			Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer	ONCOGENE			English	Article							ANDROGEN-DEPRIVATION THERAPY; TUMOR-CELLS; INCREASED SURVIVAL; DIFFERENTIATION; ADENOCARCINOMA; PHENOTYPE; RESISTANCE; MECHANISM; BIOLOGY	Castration-resistant prostate cancer (CRPC) with neuroendocrine differentiation (NED) is a lethal disease for which effective therapies are urgently needed. The mechanism underlying development of CRPC with NED, however, remains largely uncharacterized. In this study, we explored and characterized the functional role of neurotensin (NTS) in cell line and animal models of CRPC with NED. NTS was acutely induced by androgen deprivation in animal models of prostate cancer (PCa) and activated downstream signaling leading to NED through activation of neurotensin receptor 1 (NTSR1) and neurotensin receptor 3 (NTSR3), but not neurotensin receptor 2 (NTSR2). Our findings also revealed the existence of a CK8(+)/CK14(+) subpopulation in the LNCaP cell line that expresses high levels of both NTSR1 and NTSR3, and displays an enhanced susceptibility to develop neuroendocrine-like phenotypes upon treatment with NTS. More importantly, NTSR1 pathway inhibition prevented the development of NED and castration resistance in vivo. We propose a novel role of NTS in the development of CRPC with NED, and a possible strategy to prevent the onset of NED by targeting the NTS signaling pathway.	[Zhu, Shimiao; Tian, Hao; Wang, Jiang; Li, Xing; Jiang, Ning; Wen, Simeng; Chen, Xuanrong; Shang, Zhiqun; Niu, Yuanjie] Tianjin Med Univ, Hosp 2, Tianjin Inst Urol, Dept Urol, Tianjin 300211, Peoples R China; [Niu, Xiaodan] Univ Minnesota, Minneapolis, MN 55455 USA; [Ren, Shancheng; Xu, Chuanliang; Sun, Yinghao] Second Mil Med Univ, Changhai Hosp, Dept Urol, Shanghai 200433, Peoples R China; [Chang, Chawnshang] Univ Rochester, Dept Pathol, Rochester, NY 14620 USA; [Flores-Morales, Amilcar] Univ Copenhagen, Dept Hlth Sci, Fac Hlth & Med Sci, DK-2200 Copenhagen, Denmark	Tianjin Medical University; University of Minnesota System; University of Minnesota Twin Cities; Naval Medical University; University of Rochester; University of Copenhagen	Shang, ZQ; Niu, YJ (corresponding author), Tianjin Med Univ, Hosp 2, Tianjin Inst Urol, Dept Urol, Tianjin 300211, Peoples R China.; Sun, YH (corresponding author), Second Mil Med Univ, Changhai Hosp, Dept Urol, Shanghai 200433, Peoples R China.	zhiqun_shang@tmu.edu.cn; sunyh@medmail.com.cn; niuyuanjie9317@163.com		Wen, Simeng/0000-0001-7989-7700	National Basic Research Program of China [2012CB518304]; National Natural Science Foundation of China [81802573, 81472682, 81772756]; Natural Science Foundation of Tianjin [17JCZDJC35300, 15JCZDJC35400, 15JCYBJC27200]	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Tianjin(Natural Science Foundation of Tianjin)	This work was supported by National Basic Research Program of China (2012CB518304), National Natural Science Foundation of China (81802573, 81472682, and 81772756), and Natural Science Foundation of Tianjin (17JCZDJC35300, 15JCZDJC35400, and 15JCYBJC27200).	Arora VK, 2013, CELL, V155, P1309, DOI 10.1016/j.cell.2013.11.012; Azzouni F, 2012, UROL CLIN N AM, V39, P435, DOI 10.1016/j.ucl.2012.07.002; Beltran H, 2012, J CLIN ONCOL, V30, pE386, DOI 10.1200/JCO.2011.41.5166; Cindolo L, 2007, UROL INT, V79, P287, DOI 10.1159/000109711; Davies AH, 2018, NAT REV UROL, V15, P271, DOI 10.1038/nrurol.2018.22; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Delk NA, 2012, AUTOPHAGY, V8, P650, DOI 10.4161/auto.19226; Fiaschi T, 2012, CANCER RES, V72, P5130, DOI 10.1158/0008-5472.CAN-12-1949; Friedlander TW, 2012, UROL CLIN N AM, V39, P453, DOI 10.1016/j.ucl.2012.07.003; Gingrich JR, 1997, CANCER RES, V57, P4687; Hashimoto K, 2015, LAB INVEST, V95, P283, DOI 10.1038/labinvest.2014.165; Huang JT, 2006, PROSTATE, V66, P1399, DOI 10.1002/pros.20434; Ito T, 2001, ONCOL REP, V8, P1221; Jiang N, 2015, ONCOGENE, V34, P2764, DOI 10.1038/onc.2014.206; Kaplan-Lefko PJ, 2003, PROSTATE, V55, P219, DOI 10.1002/pros.10215; Lapuk AV, 2012, J PATHOL, V227, P286, DOI 10.1002/path.4047; Li P, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-55; Li YA, 2017, EUR UROL, V71, P68, DOI 10.1016/j.eururo.2016.04.028; Lorente D, 2015, NAT REV UROL, V12, P37, DOI 10.1038/nrurol.2014.345; Martin S, 2002, GASTROENTEROLOGY, V123, P1135, DOI 10.1053/gast.2002.36000; Niu Y, 2010, ONCOGENE, V29, P3593, DOI 10.1038/onc.2010.121; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12182, DOI 10.1073/pnas.0804700105; Palapattu GS, 2009, PROSTATE, V69, P787, DOI 10.1002/pros.20928; Qi JF, 2010, CANCER CELL, V18, P23, DOI 10.1016/j.ccr.2010.05.024; Sauer CG, 2006, PROSTATE, V66, P227, DOI 10.1002/pros.20338; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; SEHGAL I, 1994, P NATL ACAD SCI USA, V91, P4673, DOI 10.1073/pnas.91.11.4673; Sella A, 2000, EUR UROL, V38, P250, DOI 10.1159/000020289; Tyler-McMahon BM, 2000, REGUL PEPTIDES, V93, P125, DOI 10.1016/S0167-0115(00)00183-X; Valerie NCK, 2011, CANCER RES, V71, P6817, DOI 10.1158/0008-5472.CAN-11-1646; Vashchenko N, 2005, EUR UROL, V47, P147, DOI 10.1016/j.eururo.2004.09.007; Vincent JP, 1999, TRENDS PHARMACOL SCI, V20, P302, DOI 10.1016/S0165-6147(99)01357-7; Wu Zherui, 2012, Front Endocrinol (Lausanne), V3, P184, DOI 10.3389/fendo.2012.00184; Yuan TC, 2007, ENDOCR-RELAT CANCER, V14, P531, DOI 10.1677/ERC-07-0061; Yuan TC, 2006, ENDOCR-RELAT CANCER, V13, P151, DOI 10.1677/erc.1.01043; Zou M, 2017, CANCER DISCOV, V7, P736, DOI 10.1158/2159-8290.CD-16-1174	37	23	23	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2019	38	24					4875	4884		10.1038/s41388-019-0750-5	http://dx.doi.org/10.1038/s41388-019-0750-5			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IC7ND	30770901	hybrid, Green Published			2022-12-28	WOS:000471160500015
J	Nishikawa, Y; Kodama, Y; Shiokawa, M; Matsumori, T; Marui, S; Kuriyama, K; Kuwada, T; Sogabe, Y; Kakiuchi, N; Tomono, T; Mima, A; Morita, T; Ueda, T; Tsuda, M; Yamauchi, Y; Sakuma, Y; Ota, Y; Maruno, T; Uza, N; Uesugi, M; Kageyama, R; Chiba, T; Seno, H				Nishikawa, Yoshihiro; Kodama, Yuzo; Shiokawa, Masahiro; Matsumori, Tomoaki; Marui, Saiko; Kuriyama, Katsutoshi; Kuwada, Takeshi; Sogabe, Yuko; Kakiuchi, Nobuyuki; Tomono, Teruko; Mima, Atsushi; Morita, Toshihiro; Ueda, Tatsuki; Tsuda, Motoyuki; Yamauchi, Yuki; Sakuma, Yojiro; Ota, Yuji; Maruno, Takahisa; Uza, Norimitsu; Uesugi, Motonari; Kageyama, Ryoichiro; Chiba, Tsutomu; Seno, Hiroshi			Hes1 plays an essential role in Kras-driven pancreatic tumorigenesis	ONCOGENE			English	Article							DUCTAL ADENOCARCINOMA; CELL PLASTICITY; BETA-CELL; CANCER; ENDOCRINE; INDUCTION; LINEAGE	Most pancreatic ductal adenocarcinoma (PDAC) develops from pancreatic epithelial cells bearing activating mutant KRAS genes through precancerous lesions, i.e. acinar-to-ductal metaplasia (ADM) and pancreatic intraepithelial neoplasia (PanIN). During pancreatic tumorigenesis, Hes1 expression starts with the transition from acinar cells to ADM, and continues during PanIN and PDAC formation, but the role of Hes1 in pancreatic tumorigenesis is not fully elucidated. Here we show that Hes1 plays an essential role in the initiation and progression of KRAS-driven pancreatic tumorigenesis. In vitro, activation of MAPK signaling due to EGF or mutant KRAS activation induced sustained Hes1 expression in pancreatic acinar cells. In vivo, acinar cell-specific activation of mutant KRAS by Elastase1-CreERT2;Kras(G12D) induced ADM/PanIN formation with Hes1 expression in mice, and genetic ablation of Hes1 in these mice dramatically suppressed PanIN formation. Gene expression analysis and lineage tracing revealed that Hes1 regulates acinar-to-ductal reprogramming-related genes and, in a Hes1-deficient state, mutant Kras-induced ADM could not progress into PanIN, but re-differentiated into acinar cells. In the Elastase1-CreERT2; Kras(G12D); Trp53(R172H) mouse PDAC model, genetic ablation of Hes1 completely blocked PDAC formation by keeping PanIN lesions in low-grade conditions, in addition to reducing the occurrence of PanIN. Together, these findings indicate that mutant KRAS-induced Hes1 plays an essential role in PDAC initiation and progression by regulating acinar-to-ductal reprogramming-related genes.	[Nishikawa, Yoshihiro; Kodama, Yuzo; Shiokawa, Masahiro; Matsumori, Tomoaki; Marui, Saiko; Kuriyama, Katsutoshi; Kuwada, Takeshi; Sogabe, Yuko; Kakiuchi, Nobuyuki; Tomono, Teruko; Mima, Atsushi; Morita, Toshihiro; Ueda, Tatsuki; Tsuda, Motoyuki; Yamauchi, Yuki; Sakuma, Yojiro; Ota, Yuji; Maruno, Takahisa; Uza, Norimitsu; Chiba, Tsutomu; Seno, Hiroshi] Kyoto Univ, Dept Gastroenterol & Hepatol, Grad Sch Med, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan; [Kodama, Yuzo] Kobe Univ, Dept Gastroenterol, Grad Sch Med, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan; [Uesugi, Motonari] Kyoto Univ, Inst Chem Res, Uji, Kyoto 6110011, Japan; [Uesugi, Motonari; Kageyama, Ryoichiro] Kyoto Univ, Inst Integrated Cell Mat Sci iCeMS, Uji, Kyoto 6110011, Japan; [Kageyama, Ryoichiro] Kyoto Univ, Inst Frontier Life & Med Sci, Sakyo Ku, Kyoto 6068507, Japan; [Chiba, Tsutomu] Kansai Elect Power Hosp, Fukushima Ku, 2-1-7 Fukushima, Osaka 5530003, Japan	Kyoto University; Kobe University; Kyoto University; Kyoto University; Kyoto University	Kodama, Y (corresponding author), Kyoto Univ, Dept Gastroenterol & Hepatol, Grad Sch Med, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.; Kodama, Y (corresponding author), Kobe Univ, Dept Gastroenterol, Grad Sch Med, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	kodamayu@kuhp.kyoto-u.ac.jp	Uesugi, Motonari/AAM-9777-2020	Uza, Norimitsu/0000-0002-1334-5740; Nishikawa, Yoshihiro/0000-0002-1113-6937; Morita, Toshihiro/0000-0002-4114-9894	JSPS; MEXT KAKENHI [15J05143, 16K09395, 17H06803]; AMED P-DIRECT Grant [15cm0106120h0002]	JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); MEXT KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); AMED P-DIRECT Grant	This work was supported by the JSPS and MEXT KAKENHI Grant Numbers 15J05143, 16K09395, and 17H06803; AMED P-DIRECT Grant Number 15cm0106120h0002.	Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Desai BM, 2007, J CLIN INVEST, V117, P971, DOI 10.1172/JCI29988; Eser S, 2013, CANCER CELL, V23, P406, DOI 10.1016/j.ccr.2013.01.023; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gu GQ, 2002, DEVELOPMENT, V129, P2447; Guerra C, 2007, CANCER CELL, V11, P291, DOI 10.1016/j.ccr.2007.01.012; Guerra C, 2011, CANCER CELL, V19, P728, DOI 10.1016/j.ccr.2011.05.011; Hidalgo-Sastre A, 2016, AM J PATHOL, V186, P2934, DOI 10.1016/j.ajpath.2016.07.025; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Horn S, 2012, P NATL ACAD SCI USA, V109, P7356, DOI 10.1073/pnas.1203605109; Hruban RH, 2001, AM J SURG PATHOL, V25, P579, DOI 10.1097/00000478-200105000-00003; Imayoshi I, 2008, DEVELOPMENT, V135, P2531, DOI 10.1242/dev.021535; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jensen J, 2000, NAT GENET, V24, P36, DOI 10.1038/71657; Kageyama R, 2007, DEVELOPMENT, V134, P1243, DOI 10.1242/dev.000786; Kawaguchi Y, 2013, J CLIN INVEST, V123, P1881, DOI 10.1172/JCI66022; Kong B, 2018, GUT, V67, P146, DOI 10.1136/gutjnl-2015-310913; Kopinke D, 2011, DEVELOPMENT, V138, P431, DOI 10.1242/dev.053843; Kopp JL, 2012, CANCER CELL, V22, P737, DOI 10.1016/j.ccr.2012.10.025; Krah NM, 2015, ELIFE, V4, DOI 10.7554/eLife.07125; Liu ZH, 2015, CANCER BIOL THER, V16, P353, DOI 10.1080/15384047.2015.1016662; Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467; Miyamoto Y, 2003, CANCER CELL, V3, P565, DOI 10.1016/S1535-6108(03)00140-5; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Perron A, 2018, J BIOL CHEM, V293, P8285, DOI 10.1074/jbc.RA118.002316; Rani A, 2016, CYTOKINE GROWTH FACT; Shi GL, 2009, GASTROENTEROLOGY, V136, P1368, DOI 10.1053/j.gastro.2008.12.066; Shih HP, 2012, DEVELOPMENT, V139, P2488, DOI 10.1242/dev.078634; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Singh A, 2012, CELL, V148, P639, DOI 10.1016/j.cell.2011.12.033; Stockhausen MT, 2005, EXP CELL RES, V310, P218, DOI 10.1016/j.yexcr.2005.07.011; Wei DY, 2016, CANCER CELL, V29, P324, DOI 10.1016/j.ccell.2016.02.005; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754	35	19	19	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2019	38	22					4283	4296		10.1038/s41388-019-0718-5	http://dx.doi.org/10.1038/s41388-019-0718-5			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IA1RB	30705405	Green Submitted			2022-12-28	WOS:000469339100006
J	Velez, MVL; Verhaegh, GW; Smit, F; Sedelaar, JPM; Schalken, JA				Velez, Maria V. Luna; Verhaegh, Gerald W.; Smit, Frank; Sedelaar, J. P. Michiel; Schalken, Jack A.			Suppression of prostate tumor cell survival by antisense oligonucleotide-mediated inhibition of AR-V7 mRNA synthesis	ONCOGENE			English	Article							ANDROGEN-RECEPTOR; SPLICE VARIANTS; POLY(ADP-RIBOSE) POLYMERASE; RESISTANT; CANCER; ENZALUTAMIDE; PREDICTION; THERAPY; FUSION; IDENTIFICATION	One of the mechanisms by which advanced prostate cancer develops resistance to androgen deprivation therapy is the elevated expression of C-terminally truncated androgen receptor (AR) variants. These variants, such as AR-V7, originate from aberrant splicing of the AR pre-mRNA and the inclusion of a cryptic exon containing a premature stop codon in the mRNA. The resulting loss of the ligand-binding domain allows AR-V7 to act as a constitutively active transcription factor. Here, we designed two antisense oligonucleotides (AONs) directed against cryptic splicing signals within the AR pre-mRNA. These two AONs, AON-ISE and AON-ESE, demonstrated high efficiency in silencing AR-V7 splicing without affecting full-length AR expression. The subsequent downregulation of AR-V7-target gene UBE2C was accompanied by inhibition of androgen-independent cell proliferation and induction of apoptosis in castration-resistant prostate cancer (CRPC)-derived cell line models 22Rv1, DuCaP, and VCaP. Our results show that splicing-directed AONs can efficiently prevent expression of AR-V7, providing an attractive new therapeutic option for the treatment of CRPC.	[Velez, Maria V. Luna; Verhaegh, Gerald W.; Sedelaar, J. P. Michiel; Schalken, Jack A.] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Mol Life Sci, Dept Urol, Nijmegen, Netherlands; [Smit, Frank] MDxHealth, Nijmegen, Netherlands	Radboud University Nijmegen	Schalken, JA (corresponding author), Radboud Univ Nijmegen, Med Ctr, Radboud Inst Mol Life Sci, Dept Urol, Nijmegen, Netherlands.	Jack.Schalken@radboudumc.nl	Schalken, Jack A/B-1277-2014; Sedelaar, Michiel/L-4643-2015	Schalken, Jack A/0000-0001-8274-7797; Sedelaar, Michiel/0000-0002-3768-7374; Verhaegh, Gerald/0000-0003-0227-2280	NWO [022.003.007]	NWO(Netherlands Organization for Scientific Research (NWO))	The authors would like to thank Sophie Cools, Cornelius Jansen, and Mirjam de Weijert for their excellent technical assistance. We also would like to thank Dr. Kenneth J. Pienta M.D. from Johns Hopkins for kindly providing us with the DuCaP and VCaP cell lines. This work was sponsored by an NWO grant (Project number: 022.003.007).	Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Armstrong AJ, 2010, CLIN CANCER RES, V16, P203, DOI 10.1158/1078-0432.CCR-09-2514; Beer TM, 2017, LANCET ONCOL, V18, P1532, DOI 10.1016/S1470-2045(17)30605-8; Bianchini D, 2013, BRIT J CANCER, V109, P2579, DOI 10.1038/bjc.2013.619; Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001; Cao B, 2014, ONCOTARGET, V5, P1646, DOI 10.18632/oncotarget.1802; Cartegni L, 2003, NUCLEIC ACIDS RES, V31, P3568, DOI 10.1093/nar/gkg616; Chiriboga CA, 2016, NEUROLOGY, V86, P890, DOI 10.1212/WNL.0000000000002445; Chou CP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093934; Cornford P, 2017, EUR UROL, V71, P630, DOI 10.1016/j.eururo.2016.08.002; D'Amours D, 1998, RADIAT RES, V150, P3, DOI 10.2307/3579638; De Clercq E, 1969, Antimicrob Agents Chemother (Bethesda), V9, P187; Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594; Ding Y, 2004, NUCLEIC ACIDS RES, V32, pW135, DOI 10.1093/nar/gkh449; Geary RS, 2015, ADV DRUG DELIVER REV, V87, P46, DOI 10.1016/j.addr.2015.01.008; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; Hache M, 2016, J CHILD NEUROL, V31, P899, DOI 10.1177/0883073815627882; Havens MA, 2016, NUCLEIC ACIDS RES, V44, P6549, DOI 10.1093/nar/gkw533; Hebsgaard SM, 1996, NUCLEIC ACIDS RES, V24, P3439, DOI 10.1093/nar/24.17.3439; Hessels D, 2007, CLIN CANCER RES, V13, P5103, DOI 10.1158/1078-0432.CCR-07-0700; Hornberg E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019059; Hu R, 2012, CANCER RES, V72, P3457, DOI 10.1158/0008-5472.CAN-11-3892; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; KRONGRAD A, 1991, MOL CELL ENDOCRINOL, V76, P79, DOI 10.1016/0303-7207(91)90262-Q; Leyten GHJM, 2015, CLIN CANCER RES, V21, P3061, DOI 10.1158/1078-0432.CCR-14-3334; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Liu LL, 2014, ONCOGENE, V33, P3140, DOI 10.1038/onc.2013.284; Manoharan M, 1999, BBA-GENE STRUCT EXPR, V1489, P117, DOI 10.1016/S0167-4781(99)00138-4; Mendell JR, 2016, ANN NEUROL, V79, P257, DOI 10.1002/ana.24555; Mostaghel EA, 2011, CLIN CANCER RES, V17, P5913, DOI 10.1158/1078-0432.CCR-11-0728; Moulder SL, 2008, CLIN CANCER RES, V14, P7909, DOI 10.1158/1078-0432.CCR-08-1104; Mounir Z, 2015, ONCOGENE, V34, P3815, DOI 10.1038/onc.2014.308; Nadiminty N, 2013, MOL CANCER THER, V12, P1629, DOI 10.1158/1535-7163.MCT-13-0027; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Sazani P, 2003, J CLIN INVEST, V112, P481, DOI 10.1172/JCI200319547; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Scoles DR, 2017, NATURE, V544, P362, DOI 10.1038/nature22044; Sedelaar JPM, 2009, PROSTATE, V69, P1724, DOI 10.1002/pros.21028; Smith PJ, 2006, HUM MOL GENET, V15, P2490, DOI 10.1093/hmg/ddl171; SPROAT BS, 1989, NUCLEIC ACIDS RES, V17, P3373, DOI 10.1093/nar/17.9.3373; Swayampakula AK, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.11550; Tasfaout H, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15661; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Verhaart IEC, 2013, NUCLEIC ACID THER, V23, P228, DOI 10.1089/nat.2012.0398; Voit T, 2014, LANCET NEUROL, V13, P987, DOI 10.1016/S1474-4422(14)70195-4; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; Wang JH, 2008, CANCER RES, V68, P8516, DOI 10.1158/0008-5472.CAN-08-1147; Wheeler TM, 2012, NATURE, V488, P111, DOI 10.1038/nature11362; Wraight CJ, 2000, NAT BIOTECHNOL, V18, P521, DOI 10.1038/75382; Yamamoto Y, 2015, CLIN CANCER RES, V21, P1675, DOI 10.1158/1078-0432.CCR-14-1108; Yeo GW, 2005, P NATL ACAD SCI USA, V102, P2850, DOI 10.1073/pnas.0409742102; Zhang XT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027970	53	17	17	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2019	38	19					3696	3709		10.1038/s41388-019-0696-7	http://dx.doi.org/10.1038/s41388-019-0696-7			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HX4OU	30664691	Green Published, hybrid			2022-12-28	WOS:000467379600010
J	Panagopoulou, M; Karaglani, M; Balgkouranidou, I; Biziota, E; Koukaki, T; Karamitrousis, E; Nena, E; Tsamardinos, I; Kolios, G; Lianidou, E; Kakolyris, S; Chatzaki, E				Panagopoulou, Maria; Karaglani, Makrina; Balgkouranidou, Ioanna; Biziota, Eirini; Koukaki, Triantafillia; Karamitrousis, Evaggelos; Nena, Evangelia; Tsamardinos, Ioannis; Kolios, George; Lianidou, Evi; Kakolyris, Stylianos; Chatzaki, Ekaterini			Circulating cell-free DNA in breast cancer: size profiling, levels, and methylation patterns lead to prognostic and predictive classifiers	ONCOGENE			English	Article							SOX17 PROMOTER METHYLATION; TUMOR DNA; DIAGNOSTIC MARKER; LIQUID BIOPSY; NUCLEIC-ACIDS; PLASMA DNA; EXPRESSION; BLOOD; INTEGRITY; BIOMARKER	Blood circulating cell-free DNA (ccfDNA) is a suggested biosource of valuable clinical information for cancer, meeting the need for a minimally-invasive advancement in the route of precision medicine. In this paper, we evaluated the prognostic and predictive potential of ccfDNA parameters in early and advanced breast cancer. Groups consisted of 150 and 16 breast cancer patients under adjuvant and neoadjuvant therapy respectively, 34 patients with metastatic disease and 35 healthy volunteers. Direct quantification of ccfDNA in plasma revealed elevated concentrations correlated to the incidence of death, shorter PFS, and non-response to pharmacotherapy in the metastatic but not in the other groups. The methylation status of a panel of cancer-related genes chosen based on previous expression and epigenetic data (KLK10, SOX17, WNT5A, MSH2, GATA3) was assessed by quantitative methylation-specific PCR. All but the GATA3 gene was more frequently methylated in all the patient groups than in healthy individuals (all p < 0.05). The methylation of WNT5A was statistically significantly correlated to greater tumor size and poor prognosis characteristics and in advanced stage disease with shorter OS. In the metastatic group, also SOX17 methylation was significantly correlated to the incidence of death, shorter PFS, and OS. KLK10 methylation was significantly correlated to unfavorable clinicopathological characteristics and relapse, whereas in the adjuvant group to shorter DFI. Methylation of at least 3 or 4 genes was significantly correlated to shorter OS and no pharmacotherapy response, respectively. Classification analysis by a fully automated, machine learning software produced a single-parametric linear model using ccfDNA plasma concentration values, with great discriminating power to predict response to chemotherapy (AUC 0.803, 95% CI [0.606, 1.000]) in the metastatic group. Two more multi-parametric signatures were produced for the metastatic group, predicting survival and disease outcome. Finally, a multiple logistic regression model was constructed, discriminating between patient groups and healthy individuals. Overall, ccfDNA emerged as a highly potent predictive classifier in metastatic breast cancer. Upon prospective clinical evaluation, all the signatures produced could aid accurate prognosis.	[Panagopoulou, Maria; Karaglani, Makrina; Balgkouranidou, Ioanna; Kolios, George; Chatzaki, Ekaterini] Democritus Univ Thrace, Med Sch, Lab Pharmacol, Alexandroupolis 68100, Greece; [Balgkouranidou, Ioanna; Biziota, Eirini; Koukaki, Triantafillia; Karamitrousis, Evaggelos; Kakolyris, Stylianos] Democritus Univ Thrace, Med Sch, Dept Oncol, Alexandroupolis 68100, Greece; [Nena, Evangelia] Democritus Univ Thrace, Lab Hyg & Environm Protect, Med Sch, Alexandroupolis 68100, Greece; [Tsamardinos, Ioannis] Univ Crete, Dept Comp Sci, Voutes, Greece; [Tsamardinos, Ioannis] Gnosis Data Anal, Voutes 70013, Crete, Greece; [Lianidou, Evi] Univ Athens, Dept Chem, Lab Analyt Chem, Anal Circulating Tumor Cells, Athens, Greece; [Chatzaki, Ekaterini] Fdn Res & Technol Hellas, Voutes 70013, Crete, Greece	Democritus University of Thrace; Democritus University of Thrace; Democritus University of Thrace; University of Crete; National & Kapodistrian University of Athens; Foundation for Research & Technology - Hellas (FORTH)	Chatzaki, E (corresponding author), Democritus Univ Thrace, Med Sch, Lab Pharmacol, Alexandroupolis 68100, Greece.; Chatzaki, E (corresponding author), Fdn Res & Technol Hellas, Voutes 70013, Crete, Greece.	achatzak@med.duth.gr	Chatzaki, Ekaterini/AAW-9507-2020; Chatzaki, Ekaterini/CAF-7645-2022; Nena, Evangelia/AAD-9385-2019; Kolios, George/N-6641-2013	Chatzaki, Ekaterini/0000-0002-5832-4257; Nena, Evangelia/0000-0003-0381-4715; Kolios, George/0000-0002-2066-4782; Karaglani, Makrina/0000-0002-9853-3571; Lianidou, Evi/0000-0002-7796-5914	Act: "PROGRAM FOR THE GRANTING OF SCHOLARSHIPS FOR POSTGRADUATE STUDIES OF SECOND CYCLE STUDIES"; State Scholarship Foundation in Greece (IKY) (Operational Program "Human Resources Development-Education and Lifelong Learning", Partnership Agreement PA 2014-2020)	Act: "PROGRAM FOR THE GRANTING OF SCHOLARSHIPS FOR POSTGRADUATE STUDIES OF SECOND CYCLE STUDIES"; State Scholarship Foundation in Greece (IKY) (Operational Program "Human Resources Development-Education and Lifelong Learning", Partnership Agreement PA 2014-2020)	Ms Maria Panagopoulou received a scholarship for the implementation of her PhD Thesis, co-funded through the Act: "PROGRAM FOR THE GRANTING OF SCHOLARSHIPS FOR POSTGRADUATE STUDIES OF SECOND CYCLE STUDIES". State Scholarship Foundation in Greece (IKY) (Operational Program "Human Resources Development-Education and Lifelong Learning", Partnership Agreement PA 2014-2020).	Agassi R, 2015, AM J CLIN PATHOL, V143, P18, DOI 10.1309/AJCPI5YHG0OGFAHM; Alix-Panabieres C, 2016, CANCER DISCOV, V6, P479, DOI 10.1158/2159-8290.CD-15-1483; ANKER P, 1975, CANCER RES, V35, P2375; Balgkouranidou I, 2016, CLIN CHEM LAB MED, V54, P1385, DOI 10.1515/cclm-2015-0776; Boser B. E., 1992, Proceedings of the Fifth Annual ACM Workshop on Computational Learning Theory, P144, DOI 10.1145/130385.130401; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; Breiman L., 1984, CLASSIFICATION REGRE; Catarino R, 2008, DNA CELL BIOL, V27, P415, DOI 10.1089/dna.2008.0744; Chimonidou M, 2013, CLIN CHEM, V59, P270, DOI 10.1373/clinchem.2012.191551; Cooper SJ, 2010, ONCOGENE, V29, P2905, DOI 10.1038/onc.2010.64; Dawson SJ, 2013, NEW ENGL J MED, V368, P1199, DOI 10.1056/NEJMoa1213261; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Elshimali YI, 2013, INT J MOL SCI, V14, P18925, DOI 10.3390/ijms140918925; Fu DY, 2010, BREAST CANCER RES TR, V119, P601, DOI 10.1007/s10549-009-0339-8; Fu DY, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000637; Hattermann K, 2008, ANAL BIOCHEM, V377, P62, DOI 10.1016/j.ab.2008.03.014; HOERL AE, 1970, TECHNOMETRICS, V12, P55, DOI 10.1080/00401706.1970.10488634; Jiang PY, 2015, P NATL ACAD SCI USA, V112, pE1317, DOI 10.1073/pnas.1500076112; Jonsson M, 2002, CANCER RES, V62, P409; Kappil MA, 2016, ANTICANCER RES, V36, P4039; Kioulafa M, 2009, ANN ONCOL, V20, P1020, DOI 10.1093/annonc/mdn733; Laktionov PP, 2004, NUCLEOS NUCLEOT NUCL, V23, P879, DOI 10.1081/NCN-200026035; Lamb YN, 2017, MOL DIAGN THER, V21, P225, DOI 10.1007/s40291-017-0259-y; LEON SA, 1977, CANCER RES, V37, P646; Leris ACA, 2005, ANTICANCER RES, V25, P731; Li B, 2001, CANCER RES, V61, P8014; LI Y, 2015, BMC CANCER, V15; List M, 2014, J INTEGR BIOINFORMAT, V11, pCP4, DOI 10.2390/biecoll-jib-2014-236; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu Jun-Liang, 2016, Chronic Dis Transl Med, V2, P223, DOI 10.1016/j.cdtm.2016.12.001; Madhavan D, 2014, BREAST CANCER RES TR, V146, P163, DOI 10.1007/s10549-014-2946-2; Markaki M, 2018, EBIOMEDICINE, V31, P36, DOI 10.1016/j.ebiom.2018.03.027; Mastoraki S, 2018, CLIN CANCER RES, V24, P1500, DOI 10.1158/1078-0432.CCR-17-1181; Matthaios D, 2016, ONCOL LETT, V12, P748, DOI 10.3892/ol.2016.4649; McCleskey BC, 2015, AM J CLIN PATHOL, V144, P756, DOI 10.1309/AJCP5MMR1FJVVTPK; Miao F, 2014, DIABETES, V63, P1748, DOI 10.2337/db13-1251; Mouliere F, 2015, P NATL ACAD SCI USA, V112, P3178, DOI 10.1073/pnas.1501321112; Olsson E, 2015, EMBO MOL MED, V7, P1034, DOI 10.15252/emmm.201404913; Orfanoudaki G, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03557-4; Pantel K, 2013, CANCER RES, V73, P6384, DOI 10.1158/0008-5472.CAN-13-2030; Salvi S, 2016, ONCOTARGETS THER, V9, P6549, DOI 10.2147/OTT.S100901; Schwarzenbach H, 2011, NAT REV CANCER, V11, P426, DOI 10.1038/nrc3066; Stroun M, 2001, CLIN CHIM ACTA, V313, P139, DOI 10.1016/S0009-8981(01)00665-9; Tan GQ, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010197; Tangvarasittichai O, 2015, INDIAN J CLIN BIOCHE, V30, P55, DOI 10.1007/s12291-013-0407-z; Trifa F, 2013, TUMOR BIOL, V34, P1625, DOI 10.1007/s13277-013-0694-2; Tsamardinos I, 2018, MACH LEARN, V107, P1895, DOI 10.1007/s10994-018-5714-4; Umetani N, 2006, J CLIN ONCOL, V24, P4270, DOI 10.1200/JCO.2006.05.9493; Underhill HR, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006162; van der Meide WF, 2011, GYNECOL ONCOL, V123, P116, DOI 10.1016/j.ygyno.2011.06.015; Yousef GM, 2004, BRIT J CANCER, V90, P167, DOI 10.1038/sj.bjc.6601451; 2008, BIOCELL, V32, P237	53	84	90	2	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2019	38	18					3387	3401		10.1038/s41388-018-0660-y	http://dx.doi.org/10.1038/s41388-018-0660-y			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HW3RI	30643192				2022-12-28	WOS:000466610000005
J	Pidugu, VK; Wu, MM; Yen, AH; Pidugu, HB; Chang, KW; Liu, CJ; Lee, TC				Pidugu, Vijaya Kumar; Wu, Meei-Maan; Yen, Ai-Hsin; Pidugu, Hima Bindu; Chang, Kuo-Wei; Liu, Chung-Ji; Lee, Te-Chang			IFIT1 and IFIT3 promote oral squamous cell carcinoma metastasis and contribute to the anti-tumor effect of gefitinib via enhancing p-EGFR recycling	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; LYMPH-NODE METASTASIS; INTERFERON-INDUCED PROTEIN; IFN-INDUCED PROTEIN; REPEATS 3 IFIT3; NECK-CANCER; PROGNOSTIC MARKER; ANNEXIN A2; HEAD; INVASION	IFIT1 and IFIT3 are abundant products of interferon-stimulating genes. While the importance of IFIT1 and IFIT3 in the prognosis of cancer has been reported, the molecular basis of IFIT1 and IFIT3 in cancer progression remains unexplored. In the present study, we investigated the modes of action and the clinical significance of IFIT1 and IFIT3 in oral squamous cell carcinoma (OSCC). Ectopic expression of IFIT1 or IFIT3 induced OSCC cell invasion by promoting the epithelial-mesenchymal transition, whereas IFIT1 or IFIT3 knockdown exhibited opposite effects. Overexpression of IFIT1 or IFIT3 promoted tumor growth, regional and distant metastasis in xenograft and orthotopic nude mice models. Most importantly, IFIT1 or IFIT3 overexpression increased the levels of p-EGFR(Y1068) and p-AKT(S473) in OSCC cells and also enhanced tumor inhibitory effect of gefitinib. By immunoprecipitation and LC-MS/MS analysis, we found that IFIT1 and IFIT3 interacted with ANXA2 that enhanced p-EGFR(Y1068) endosomal recycling. Depletion of ANXA2 using siRNA therefore abolished p-EGFR(Y1068) and p-AKT(S473) expression in IFIT1- or IFIT3-overexpressed cells. Furthermore, a significant positive association of increased IFIT1 and IFIT3 expression with advanced T-stage, lymph node metastasis, perineural invasion, lymphovascular invasion, extranodal extension, and poor overall survival rate was confirmed in OSCC patients. We also found a statistically positive correlation of p-EGFR(Y1068) expression with IFIT1 and IFIT3 in OSCC tumors and poor clinical outcome in patients. Collectively, we demonstrated a novel role of IFIT1 and IFIT3 in driving OSCC progression and metastasis by interacting with ANXA2 and hence enhancing p-EGFR recycling and its downstream signaling.	[Pidugu, Vijaya Kumar; Lee, Te-Chang] Natl Yang Ming Univ, Taiwan Int Grad Program Mol Med, Taipei, Taiwan; [Pidugu, Vijaya Kumar; Lee, Te-Chang] Acad Sinica, Taipei, Taiwan; [Pidugu, Vijaya Kumar; Yen, Ai-Hsin; Pidugu, Hima Bindu; Lee, Te-Chang] Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; [Wu, Meei-Maan] Taipei Med Univ, Sch Med, Dept Publ Hlth, Coll Med, Taipei 11031, Taiwan; [Chang, Kuo-Wei] Natl Yang Ming Univ, Sch Dent, Dept Dent, Taipei 11221, Taiwan; [Liu, Chung-Ji] Mackay Mem Hosp, Dept Oral & Maxillofacial Surg, Taipei 10449, Taiwan; [Lee, Te-Chang] Natl Yang Ming Univ, Sch Med, Inst Pharmacol, Taipei 11221, Taiwan	National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; Academia Sinica - Taiwan; Taipei Medical University; National Yang Ming Chiao Tung University; Mackay Memorial Hospital; National Yang Ming Chiao Tung University	Lee, TC (corresponding author), Natl Yang Ming Univ, Taiwan Int Grad Program Mol Med, Taipei, Taiwan.; Lee, TC (corresponding author), Acad Sinica, Taipei, Taiwan.; Lee, TC (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan.; Liu, CJ (corresponding author), Mackay Mem Hosp, Dept Oral & Maxillofacial Surg, Taipei 10449, Taiwan.; Lee, TC (corresponding author), Natl Yang Ming Univ, Sch Med, Inst Pharmacol, Taipei 11221, Taiwan.	cjliu@ms2.mmh.org.tw; bmtcl@ibms.sinica.edu.tw	Lee, TC/B-3245-2011; Yen, Ai-Hsin/AAS-8409-2021; Pidugu, Vijaya Kumar/B-2798-2012	Lee, TC/0000-0003-4448-1507; Pidugu, Vijaya Kumar/0000-0001-5435-0100; Yen, Ai-Hsin/0000-0001-9469-360X	Ministry of Science and Technology [NSC 101-2321-B-001-044, NSC 102-2321-B-001-032, MOST 103-2321-B-001-019, MOST 104-2320-B-001-008]	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea)	This work was supported by grants from the Ministry of Science and Technology (NSC 101-2321-B-001-044, NSC 102-2321-B-001-032, MOST 103-2321-B-001-019, and MOST 104-2320-B-001-008), Taiwan (T.C. Lee).	Bagan J, 2010, ORAL ONCOL, V46, P414, DOI 10.1016/j.oraloncology.2010.03.009; Bharadwaj A, 2013, INT J MOL SCI, V14, P6259, DOI 10.3390/ijms14036259; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Borden EC, 2007, NAT REV DRUG DISCOV, V6, P975, DOI 10.1038/nrd2422; Bossi P, 2016, ONCOTARGET, V7, P74362, DOI 10.18632/oncotarget.11413; Bruzzese F, 2006, CLIN CANCER RES, V12, P617, DOI 10.1158/1078-0432.CCR-05-1671; Chen IH, 2003, BRIT J CANCER, V89, P681, DOI 10.1038/sj.bjc.6601171; Cheon H, 2014, SEMIN ONCOL, V41, P156, DOI 10.1053/j.seminoncol.2014.02.002; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; D'Andrea LD, 2003, TRENDS BIOCHEM SCI, V28, P655, DOI 10.1016/j.tibs.2003.10.007; Danish HH, 2013, BREAST J, V19, P231, DOI 10.1111/tbj.12097; de Graauw M, 2014, ONCOGENE, V33, P2610, DOI 10.1038/onc.2013.219; Diamond MS, 2014, CYTOKINE GROWTH F R, V25, P543, DOI 10.1016/j.cytogfr.2014.05.002; Fang YT, 2012, J CELL PHYSIOL, V227, P2775, DOI 10.1002/jcp.23026; Fensterl V, 2015, J VIROL, V89, P2462, DOI 10.1128/JVI.02744-14; Fensterl V, 2011, J INTERF CYTOK RES, V31, P71, DOI 10.1089/jir.2010.0101; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Futter CE, 2007, TRAFFIC, V8, P951, DOI 10.1111/j.1600-0854.2007.00590.x; Gerke V, 2005, NAT REV MOL CELL BIO, V6, P449, DOI 10.1038/nrm1661; Grandal MV, 2008, J CELL MOL MED, V12, P1527, DOI 10.1111/j.1582-4934.2008.00298.x; Grewal T, 2009, CELL SIGNAL, V21, P847, DOI 10.1016/j.cellsig.2009.01.031; Hayes MJ, 2006, EMBO J, V25, P1816, DOI 10.1038/sj.emboj.7601078; Hong KO, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-28; Huang SF, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3586-9; Jimenez L, 2015, ARCH PATHOL LAB MED, V139, P1334, DOI 10.5858/arpa.2014-0498-RA; Kapoor C, 2015, INDIAN J CANCER, V52, P417, DOI 10.4103/0019-509X.176750; Kirby AM, 2006, BRIT J CANCER, V94, P631, DOI 10.1038/sj.bjc.6602999; Krisanaprakornkit Suttichai, 2012, ISRN Oncol, V2012, P681469, DOI 10.5402/2012/681469; Lai KC, 2013, ONCOGENE, V32, P3686, DOI 10.1038/onc.2012.384; Lai KC, 2008, MOL CANCER RES, V6, P1431, DOI 10.1158/1541-7786.MCR-08-0141; Lang JY, 2014, FUTURE ONCOL, V10, P1635, DOI [10.2217/fon.14.44, 10.2217/FON.14.44]; Lorusso A, 2006, EMBO J, V25, P5443, DOI 10.1038/sj.emboj.7601419; Matsushita Y, 2015, INT J ORAL MAX SURG, V44, P543, DOI 10.1016/j.ijom.2015.01.018; Mehra R, 2011, DRUG RESIST UPDATE, V14, P260, DOI 10.1016/j.drup.2011.08.002; Moon C, 2010, EXP BIOL MED, V235, P907, DOI 10.1258/ebm.2009.009181; Moreira J, 2017, DRUGS, V77, P843, DOI 10.1007/s40265-017-0734-0; Morel E, 2009, J BIOL CHEM, V284, P1604, DOI 10.1074/jbc.M806499200; Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521; Murphy JE, 2009, P NATL ACAD SCI USA, V106, P17615, DOI 10.1073/pnas.0906541106; Niess H, 2015, ONCOTARGET, V6, P3306, DOI 10.18632/oncotarget.2494; Ono M, 2006, CLIN CANCER RES, V12, P7242, DOI 10.1158/1078-0432.CCR-06-0646; Parker BS, 2016, NAT REV CANCER, V16, P131, DOI 10.1038/nrc.2016.14; Perea S, 2004, J CLIN ONCOL, V22, p196S; Ribeiro FAP, 2014, ANTICANCER RES, V34, P1547; Rao SVK, 2013, ASIAN PAC J CANCER P, V14, P5567, DOI 10.7314/APJCP.2013.14.10.5567; Rivera C, 2014, ONCOL LETT, V8, P7, DOI 10.3892/ol.2014.2103; Schmid SL, 2017, J CELL BIOL, V216, P2623, DOI 10.1083/jcb.201705017; Shetty PK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044299; Shield KD, 2017, CA-CANCER J CLIN, V67, P51, DOI 10.3322/caac.21384; Shingaki S, 2003, AM J SURG, V185, P278, DOI 10.1016/S0002-9610(02)01378-8; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Staquicini DI, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03470-w; Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937; Vermorken JB, 2007, J CLIN ONCOL, V25, P2171, DOI 10.1200/JCO.2006.06.7447; Yang JL, 2007, BJU INT, V99, P1539, DOI 10.1111/j.1464-410X.2007.06778.x; Yang JL, 2005, CANCER LETT, V225, P61, DOI 10.1016/j.canlet.2004.11.041; Yang YY, 2017, HEPATOLOGY, V66, P152, DOI 10.1002/hep.29156; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Yoon H, 2015, J HISTOCHEM CYTOCHEM, V63, P114, DOI 10.1369/0022155414561498; Zhang JF, 2016, HUM PATHOL, V52, P136, DOI 10.1016/j.humpath.2016.01.013; Zhao Y, 2017, J CANCER RES CLIN, V143, P1061, DOI 10.1007/s00432-017-2351-4; Zhou XF, 2006, NEOPLASIA, V8, P925, DOI 10.1593/neo.06430; Zuo JH, 2011, J CELL BIOCHEM, V112, P2508, DOI 10.1002/jcb.23175; [No title captured], DOI DOI 10.1016/J.JFMA.2015.10.011	64	34	35	4	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2019	38	17					3232	3247		10.1038/s41388-018-0662-9	http://dx.doi.org/10.1038/s41388-018-0662-9			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU8RI	30626937				2022-12-28	WOS:000465557200009
J	Gomes, AM; Carron, EC; Mills, KL; Dow, AM; Gray, Z; Fecca, CR; Lakey, MA; Carmeliet, P; Kittrell, F; Medina, D; Machado, HL				Gomes, Angelica M.; Carron, Emily C.; Mills, Kylie L.; Dow, Alexa M.; Gray, Zane; Fecca, Christopher R.; Lakey, Meredith A.; Carmeliet, Peter; Kittrell, Frances; Medina, Daniel; Machado, Heather L.			Stromal Gas6 promotes the progression of premalignant mammary cells	ONCOGENE			English	Article							TUMOR-ASSOCIATED MACROPHAGES; TO-MESENCHYMAL TRANSITION; RECEPTOR TYROSINE KINASE; AXL KINASE; CANCER; GROWTH; ACTIVATION; EXPRESSION; SURVIVAL; MODEL	Tumor progression is regulated by a complex interplay between neoplastic cells and the tumor microenvironment. Tumor-associated macrophages have been shown to promote breast cancer progression in advanced disease and more recently, in early stage cancers. However, little is known about the macrophage-derived factors that promote tumor progression in early stage lesions. Using a p53-null model of early stage mammary tumor progression, we found that Gas6 is highly expressed in pre-invasive lesions associated with increased infiltrating macrophages, as compared with those with few recruited macrophages. We show that F4/80(+)CD11b(+ )macrophages produce Gas6 in premalignant lesions in vivo, and that macrophage-derived Gas6 induces a tumor-like phenotype ex vivo. Using a 3-D co-culture system, we show that macrophage-derived Gas6 activates its receptor Axl and downstream survival signals including Akt and STAT3, which was accompanied by altered E-cadherin expression to induce a malignant morphology. In vivo studies demonstrated that deletion of stromal Gas6 delays early stage progression and decreases tumor formation, while tumor growth in established tumors remains unaffected. These studies suggest that macrophage-derived Gas6 is a critical regulator of the transition from premalignant to invasive cancer, and may lead to the development of unique biomarkers of neoplastic progression for patients with early stage breast cancer, including ductal carcinoma in situ.	[Gomes, Angelica M.; Mills, Kylie L.; Dow, Alexa M.; Gray, Zane; Fecca, Christopher R.; Machado, Heather L.] Tulane Sch Med, Tulane Canc Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; [Carron, Emily C.] La Jolla Inst Allergy & Immunol, Div Cellular Biol, La Jolla, CA USA; [Lakey, Meredith A.] Ochsner Clin Fdn, Ochsner Biorepository, Dept Res, New Orleans, LA USA; [Carmeliet, Peter] VIB, Vesalius Res Ctr, Lab Angiogenesis & Vasc Metab, Ctr Canc Biol, B-3000 Leuven, Belgium; [Carmeliet, Peter] Sun Yat Sen Univ, State Key Lab Ophthalmol, Zhongsan Ophthalm Ctr, Guangzhou, Guangdong, Peoples R China; [Carmeliet, Peter] Katholieke Univ Leuven, Lab Angiogenesis & Vasc Metab, Dept Oncol, B-3000 Leuven, Belgium; [Carmeliet, Peter] Katholieke Univ Leuven, Leuven Canc Inst LKI, B-3000 Leuven, Belgium; [Kittrell, Frances; Medina, Daniel] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Tulane University; La Jolla Institute for Immunology; Ochsner Health System; Flanders Institute for Biotechnology (VIB); Sun Yat Sen University; KU Leuven; KU Leuven; Baylor College of Medicine	Machado, HL (corresponding author), Tulane Sch Med, Tulane Canc Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA.	hmachado@tulane.edu	Carmeliet, Peter/AAQ-5140-2020	Carmeliet, Peter/0000-0001-7961-1821	Susan G. Komen [CCR16377665]; NIH [R01 CA212518]; Tulane Cancer Center through the Cancer Crusaders of New Orleans; NATIONAL CANCER INSTITUTE [R01CA212518] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM114732] Funding Source: NIH RePORTER	Susan G. Komen(Susan G. Komen Breast Cancer Foundation); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Tulane Cancer Center through the Cancer Crusaders of New Orleans; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by Susan G. Komen CCR16377665 (HLM), NIH R01 CA212518 (HLM), and the Tulane Cancer Center through the Cancer Crusaders of New Orleans. We would like to thank Dr. Dorota Wyczechowska from the LCRC Cell Immunology and Metabolism Core (NIH/NIGMS 1P30GM114732-01) for assistance with FACS and Dr. Leann Myers for help with statistical analysis. We would like to acknowledge Alexandra Giardina at the LCRC Biospecimen Core and Dr. Lyndsey Buckner Baiamonte, Jeannine Ascani, and Dr. Michelle Ponder at the Oschner Biorepository Unit for human DCIS tissues.	Angelillo-Scherrer A, 2001, NAT MED, V7, P215, DOI 10.1038/84667; Asiedu MK, 2014, ONCOGENE, V33, P1316, DOI 10.1038/onc.2013.57; Behbod F, 2018, J MAMMARY GLAND BIOL, V23, P269, DOI 10.1007/s10911-018-9408-0; Ben-Batalla I, 2013, BLOOD, V122, P2443, DOI 10.1182/blood-2013-03-491431; Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027; Bohrer LR, 2014, CANCER RES, V74, P374, DOI 10.1158/0008-5472.CAN-13-2469; Bohrer LR, 2012, MOL CANCER RES, V10, P1294, DOI 10.1158/1541-7786.MCR-12-0275; Bottai G, 2016, NPJ BREAST CANCER, V2, P1, DOI 10.1038/npjbcancer.2016.33; Braunger J, 1997, ONCOGENE, V14, P2619, DOI 10.1038/sj.onc.1201123; Buehler M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/238284; Carron EC, 2017, ONCOTARGET, V8, P50731, DOI 10.18632/oncotarget.14913; Geng K, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01521; Gjerdrum C, 2010, P NATL ACAD SCI USA, V107, P1124, DOI 10.1073/pnas.0909333107; Gocheva V, 2010, GENE DEV, V24, P241, DOI 10.1101/gad.1874010; Goruppi S, 1996, ONCOGENE, V12, P471; Goruppi S, 2001, MOL CELL BIOL, V21, P902, DOI 10.1128/MCB.21.3.902-915.2001; Goyette MA, 2018, CELL REP, V23, P1476, DOI 10.1016/j.celrep.2018.04.019; Holland SJ, 2010, CANCER RES, V70, P1544, DOI 10.1158/0008-5472.CAN-09-2997; Ishimoto Y, 2000, J BIOCHEM-TOKYO, V127, P411, DOI 10.1093/oxfordjournals.jbchem.a022622; Jerry DJ, 2000, ONCOGENE, V19, P1052, DOI 10.1038/sj.onc.1203270; Jerry DJ, 1998, ONCOGENE, V17, P2305, DOI 10.1038/sj.onc.1202157; Kariolis MS, 2017, J CLIN INVEST, V127, P183, DOI 10.1172/JCI85610; Kirane A, 2015, CANCER RES, V75, P3699, DOI 10.1158/0008-5472.CAN-14-2887-T; LaMarca HL, 2010, STEM CELLS, V28, P535, DOI 10.1002/stem.297; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Lew ED, 2014, ELIFE, V3, DOI 10.7554/eLife.03385; Lin Elaine Y, 2004, Novartis Found Symp, V256, P158; Lin EY, 2006, CANCER RES, V66, P11238, DOI 10.1158/0008-5472.CAN-06-1278; Loges S, 2010, BLOOD, V115, P2264, DOI 10.1182/blood-2009-06-228684; Lyons TR, 2011, NAT MED, V17, P1109, DOI 10.1038/nm.2416; Mc Cormack O, 2008, BRIT J CANCER, V98, P1141, DOI 10.1038/sj.bjc.6604260; Medina D, 2005, CANCER RES, V65, P3493, DOI 10.1158/0008.5472.CAN-04-3869; Medina D, 2002, FASEB J, V16, P881, DOI 10.1096/fj.01-0885fje; Medrek C, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-306; Meyer AS, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004155; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Paccez JD, 2013, ONCOGENE, V32, P689, DOI 10.1038/onc.2012.89; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Shieh YS, 2005, NEOPLASIA, V7, P1058, DOI 10.1593/neo.05640; Shiozawa Y, 2010, NEOPLASIA, V12, P116, DOI 10.1593/neo.91384; Tjwa M, 2008, BLOOD, V111, P4096, DOI 10.1182/blood-2007-05-089565; Tsou WI, 2014, J BIOL CHEM, V289, P25750, DOI 10.1074/jbc.M114.569020; Vouri M, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.66; Wang W, 2015, MOL MED REP, V11, P2397, DOI 10.3892/mmr.2014.3018; Weischenfeldt Joachim, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot5080; Wu GL, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.113; Wu XL, 2017, J CANCER RES CLIN, V143, P1947, DOI 10.1007/s00432-017-2408-4; Wu XL, 2014, ONCOTARGET, V5, P9546, DOI 10.18632/oncotarget.2542; Xue J, 2014, IMMUNITY, V40, P274, DOI 10.1016/j.immuni.2014.01.006; Yanagita M, 2001, J BIOL CHEM, V276, P42364, DOI 10.1074/jbc.M107488200; Zhang X., 2008, CURR PROTOC IMMUNOL; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330; Zucca LE, 2018, UROL ONCOL-SEMIN ORI, V36, DOI 10.1016/j.urolonc.2017.09.003	55	21	23	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2019	38	14					2437	2450		10.1038/s41388-018-0593-5	http://dx.doi.org/10.1038/s41388-018-0593-5			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HR7LI	30531835	Green Accepted			2022-12-28	WOS:000463335200001
J	An, JN; Du, Y; Fan, XJ; Wang, YH; Ivan, C; Zhang, XG; Sood, AK; An, ZQ; Zhang, NY				An, Jingnan; Du, Yi; Fan, Xuejun; Wang, Yanhong; Ivan, Cristina; Zhang, Xue-Guang; Sood, Anil K.; An, Zhiqiang; Zhang, Ningyan			EGFL6 promotes breast cancer by simultaneously enhancing cancer cell metastasis and stimulating tumor angiogenesis	ONCOGENE			English	Article							GROWTH; EMT	EGFL6, a member of the EGF-like superfamily, plays an important role during embryonic development and has been implicated in promotion of tumor angiogenesis without affecting wound healing. There is very little known about the function of EGFL6 in cancer cells. Here, we investigated whether EGFL6 plays a direct role in cancer cells in addition to the promotion of tumor angiogenesis. Our study showed that EGFL6 promoted epithelial-mesenchymal transition (EMT) and stemness of breast cancer cells and increased cell migration and invasion in cell culture studies. We also found that EGFL6 reduced apoptotic signaling in cancer cells and promoted tumor growth in vivo. Importantly, expression of EGFL6 in cancer cells and tumor endothelial cells not only increased tumor angiogenesis but also promoted migration of cancer cells. Such dual engagement of cancer and stromal cells suggests crosstalk mediated by EGFL6 in the tumor microenvironment. Blockade of EGFL6 using our novel anti-EGFL6 monoclonal antibody significantly reduced cancer cell migration, tumor angiogenesis, and tumor growth in mouse xenograft tumor models. Silencing EGFL6 mRNA by shRNA transfection of cancer cells also significantly reduced cancer cell migration, tumor angiogenesis, and tumor growth in mouse xenograft tumor models. Taken together, the results of this study indicate that targeting EGFL6 is a unique strategy for inhibiting both cancer cell metastasis and tumor angiogenesis.	[An, Jingnan; Zhang, Xue-Guang] Soochow Univ, Jiangsu Inst Clin Immunol, Affiliated Hosp 1, 708 Renmin Rd, Suzhou, Peoples R China; [An, Jingnan; Du, Yi; Fan, Xuejun; Wang, Yanhong; An, Zhiqiang; Zhang, Ningyan] Univ Texas Hlth Sci Ctr Houston, Brown Fdn Inst Mol Med, Texas Therapeut Inst, 1825 Pressler St, Houston, TX 77030 USA; [Wang, Yanhong] Shanxi Med Univ, Dept Microbiol & Immunol, Taiyuan, Shanxi, Peoples R China; [Ivan, Cristina] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Non Coding RNA, Dept Expt Therapeut, Houston, TX 77030 USA; [Sood, Anil K.] Univ Texas MD Anderson Canc Ctr, Gynecol Oncol & Reprod Med, Houston, TX 77030 USA	Soochow University - China; University of Texas System; University of Texas Health Science Center Houston; Shanxi Medical University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	An, ZQ; Zhang, NY (corresponding author), Univ Texas Hlth Sci Ctr Houston, Brown Fdn Inst Mol Med, Texas Therapeut Inst, 1825 Pressler St, Houston, TX 77030 USA.	Zhiqiang.An@uth.tmc.edu; Ningyan.zhang@uth.tmc.edu	Sood, Anoop Kumar/A-7344-2013	Sood, Anoop Kumar/0000-0001-5702-4108; An, Zhiqiang/0000-0001-9309-2335; Zhang, Ningyan/0000-0002-4348-2180; Du, Yi/0000-0002-3969-2652; Ivan, Cristina/0000-0002-4848-0168	Welch Foundation [AU-0042-20030616]; Cancer Prevention and Research Institute of Texas (CPRIT) [RP150230, RP150551]; NIH [P50 CA217685]; Frank McGraw Memorial Chair in Cancer Research; ACS Research Professor Award; NATIONAL CANCER INSTITUTE [P30CA016672, P50CA217685] Funding Source: NIH RePORTER	Welch Foundation(The Welch Foundation); Cancer Prevention and Research Institute of Texas (CPRIT); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Frank McGraw Memorial Chair in Cancer Research; ACS Research Professor Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr. Wei Xiong and Ms. Hui Deng for their technical assistance in cell culture and antibody preparation. We also want to thank Dr. Yunfei Wen and Dr. Prahlad Ram for their suggestions and discussion on data analysis during the manuscript preparation. We thank Dr. Georgina Salazar for her critical editing of the manuscript. This study was supported in part by Welch Foundation grant (AU-0042-20030616) to ZA, and Cancer Prevention and Research Institute of Texas (CPRIT) Grants (RP150230 and RP150551) to ZA and NZ. This research was also supported by NIH support (P50 CA217685) to AKS, the Frank McGraw Memorial Chair in Cancer Research, and the ACS Research Professor Award.	Bai SM, 2016, CANCER RES, V76, P6396, DOI 10.1158/0008-5472.CAN-16-0225; Biddle A, 2012, CANCER METAST REV, V31, P285, DOI 10.1007/s10555-012-9345-0; Brabletz T, 2012, CANCER CELL, V22, P699, DOI 10.1016/j.ccr.2012.11.009; Buckanovich RJ, 2007, J CLIN ONCOL, V25, P852, DOI 10.1200/JCO.2006.08.8583; Chim SM, 2011, J BIOL CHEM, V286, P22035, DOI 10.1074/jbc.M110.187633; Dhupkar Pooja, 2016, Biochem Biophys Rep, V8, P382, DOI 10.1016/j.bbrep.2016.10.009; DONG LJ, 1995, J BIOL CHEM, V270, P15838, DOI 10.1074/jbc.270.26.15838; Fan XJ, 2015, MOL CANCER THER, V14, P681, DOI 10.1158/1535-7163.MCT-14-0715; Fujiwara H, 2011, CELL, V144, P577, DOI 10.1016/j.cell.2011.01.014; Garcia-Carbonero R, 2017, ONCOLOGIST, V22, P1281, DOI 10.1634/theoncologist.2016-0133erratum; Gong C, 2017, ONCOTARGET, V8, P52527, DOI 10.18632/oncotarget.17283; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Larimer BM, 2014, J MOL BIOMARK DIAGN, V5, P178; Lu CH, 2007, CANCER RES, V67, P1757, DOI 10.1158/0008-5472.CAN-06-3700; Mas VR, 2007, TRANSPLANTATION, V84, P1262, DOI 10.1097/01.tp.0000287596.91520.1a; Nichol D, 2012, BLOOD, V119, P1345, DOI 10.1182/blood-2011-10-322446; Nichol D, 2010, BLOOD, V116, P6133, DOI 10.1182/blood-2010-03-274860; Noh K, 2017, CELL REP, V21, P2785, DOI 10.1016/j.celrep.2017.11.020; Papaioannou D, 2017, P NATL ACAD SCI USA, V114, pE4641, DOI 10.1073/pnas.1703142114; Parker LH, 2004, NATURE, V428, P754, DOI 10.1038/nature02416; Salameh A, 2017, ONCOTARGET, V8, P6526, DOI 10.18632/oncotarget.14313; Shi Y, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3637; Stankovic ND, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708420; von Pawel J, 2018, ONCOLOGIST, V23, P654, DOI 10.1634/theoncologist.2017-0690; Wang FYF, 2017, CANCER LETT, V384, P9, DOI 10.1016/j.canlet.2016.10.009; Wang XJ, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0040084, 10.1371/journal.pone.0040711, 10.1371/journal.pone.0038932, 10.1371/journal.pone.0052707, 10.1371/journal.pone.0036663, 10.1371/journal.pone.0045380, 10.1371/journal.pone.0052082, 10.1371/journal.pone.0040857, 10.1371/journal.pone.0047429, 10.1371/journal.pone.0045939, 10.1371/journal.pone.0045036]; Wang YF, 2013, CURR CANCER DRUG TAR, V13, P963, DOI 10.2174/15680096113136660102; Yeung G, 1999, GENOMICS, V62, P304, DOI 10.1006/geno.1999.6011; Zhang S, 2016, ONCOTARGET, V7, P65758, DOI 10.18632/oncotarget.11613	29	19	23	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2019	38	12					2123	2134		10.1038/s41388-018-0565-9	http://dx.doi.org/10.1038/s41388-018-0565-9			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP6UR	30455428	Green Accepted			2022-12-28	WOS:000461822600009
J	Jia, YF; Gu, DS; Wan, J; Yu, BQ; Zhang, XL; Chiorean, EG; Wang, YS; Xie, JW				Jia, Yanfei; Gu, Dongsheng; Wan, Jun; Yu, Beiqin; Zhang, Xiaoli; Chiorean, E. Gabriela; Wang, Yunshan; Xie, Jingwu			The role of GLI-SOX2 signaling axis for gemcitabine resistance in pancreatic cancer	ONCOGENE			English	Article							STEM-CELLS; HEDGEHOG PATHWAY; PROMOTES; INHIBITION; IDENTIFICATION; CHEMOTHERAPY; ACTIVATION; GROWTH; EXPRESSION; TRIAL	Pancreatic cancer, mostly pancreatic ductal adenocarcinomas (PDAC), is one of the most lethal cancers, with a dismal median survival around 8 months. PDAC is notoriously resistant to chemotherapy. Thus far, numerous attempts using novel targeted therapies and immunotherapies yielded limited clinical benefits for pancreatic cancer patients. It is hoped that delineating the molecular mechanisms underlying drug resistance in pancreatic cancer may provide novel therapeutic options. Using acquired gemcitabine resistant pancreatic cell lines, we revealed an important role of the GLI-SOX2 signaling axis for regulation of gemcitabine sensitivity in vitro and in animal models. Down-regulation of GLI transcriptional factors (GLI1 or GLI2), but not SMO signaling inhibition, reduces tumor sphere formation, a characteristics of tumor initiating cell (TIC). Down-regulation of GLI transcription factors also decreased expression of TIC marker CD24. Similarly, high SOX2 expression is associated with gemcitabine resistance whereas down-regulation of SOX2 sensitizes pancreatic cancer cells to gemcitabine treatment. We further revealed that elevated SOX2 expression is associated with an increase in GLI1 or GLI2 expression. Our ChIP assay revealed that GLI proteins are associated with a putative Gli binding site within the SOX2 promoter, suggesting a more direct regulation of SOX2 by GLI transcription factors. The relevance of our findings to human disease was revealed in human cancer specimens. We found that high SOX2 protein expression is associated with frequent tumor relapse and poor survival in stage II PDAC patients (all of them underwent gemcitabine treatment), indicating that reduced SOX2 expression or down-regulation of GLI transcription factors may be effective in sensitizing pancreatic cancer cells to gemcitabine treatment.	[Jia, Yanfei; Wang, Yunshan] Shandong Univ, Cent Lab, Jinan Cent Hosp, Jinan, Shandong, Peoples R China; [Jia, Yanfei; Gu, Dongsheng; Yu, Beiqin; Zhang, Xiaoli; Xie, Jingwu] Indiana Univ Sch Med, Dept Pediat, Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; [Wan, Jun] Indiana Univ, Simon Canc Ctr, Dept Mol & Med Genet, Indianapolis, IN 46202 USA; [Yu, Beiqin] Shanghai Jiao Tong Univ, Shanghai Key Lab Gastr Neoplasms, Shanghai Inst Digest Surg, Ruijin Hosp,Sch Med, Shanghai 200025, Peoples R China; [Chiorean, E. Gabriela] Univ Washington, Div Med Oncol, 825 Eastlake Ave E,G4-833, Seattle, WA 98109 USA; [Chiorean, E. Gabriela] Fred Hutchinson Canc Res Ctr, 825 Eastlake Ave E,G4-833, Seattle, WA 98109 USA	Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University-Purdue University Indianapolis; Shanghai Jiao Tong University; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Wang, YS (corresponding author), Shandong Univ, Cent Lab, Jinan Cent Hosp, Jinan, Shandong, Peoples R China.; Xie, JW (corresponding author), Indiana Univ Sch Med, Dept Pediat, Wells Ctr Pediat Res, Indianapolis, IN 46202 USA.	w_yunshan@126.com; jinxie@iu.edu	Liu, Bingya/GMW-5655-2022; Xie, J/AAR-7259-2020; Wan, Jun/AAN-1337-2020; Xin, Xiaofei/N-4518-2018	Wan, Jun/0000-0001-9286-6562; Xin, Xiaofei/0000-0002-7618-0808; xie, jingwu/0000-0002-3674-332X	Department of Pediatrics; Well Center for Pediatric Research; Jeff Gordon Research Laboratory; AGA; Healthcare Initiatives, Inc.; CTSI Indiana; Walther Cancer Foundation; Riley Foundation for Children; National Natural Science Foundation of China [31671468, 81602593]; Shandong Provincial Natural Science Foundation of China [ZR2015HM018];  [NIH-R01-155086]; NATIONAL CANCER INSTITUTE [R01CA155086] Funding Source: NIH RePORTER	Department of Pediatrics; Well Center for Pediatric Research; Jeff Gordon Research Laboratory; AGA; Healthcare Initiatives, Inc.; CTSI Indiana; Walther Cancer Foundation; Riley Foundation for Children; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shandong Provincial Natural Science Foundation of China(Natural Science Foundation of Shandong Province); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank you Professor Keping Xie and Dr. Zizheng Dong for help with cell line generation, and generous support from the Department of Pediatrics, The Well Center for Pediatric Research, Jeff Gordon Research Laboratory, AGA, Healthcare Initiatives, Inc., and CTSI Indiana. The bioinformatics data analysis was performed in collaboration with the Collaborative Core for Cancer Bioinformatics (C3B) shared by Indiana University Simon Cancer Center and Purdue University Center for Cancer Research with support from the Walther Cancer Foundation. This work was supported by the following grants and foundations: NIH-R01-155086; Riley Foundation for Children; National Natural Science Foundation of China (No. 31671468 and 81602593), Shandong Provincial Natural Science Foundation of China (ZR2015HM018).	Abel EV, 2013, GASTROENTEROLOGY, V144, P1241, DOI 10.1053/j.gastro.2013.01.072; Athar M, 2004, CANCER RES, V64, P7545, DOI 10.1158/0008-5472.CAN-04-1393; Boehme KA, 2016, INT J ONCOL, V48, P801, DOI 10.3892/ijo.2015.3293; Bruns Christiane J., 1999, Neoplasia (New York), V1, P50, DOI 10.1038/sj.neo.7900005; Cao X, 2012, ONCOGENE, V31, P104, DOI 10.1038/onc.2011.219; Catenacci DVT, 2015, J CLIN ONCOL, V33, P4284, DOI 10.1200/JCO.2015.62.8719; Chen T, 2012, CELL RES, V22, P248, DOI 10.1038/cr.2011.109; Chen WJ, 2013, HEPATO-GASTROENTEROL, V60, P949, DOI 10.5754/hge12881; Cheung HOL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000405; Fan QP, 2014, CANCER RES, V74, P471, DOI 10.1158/0008-5472.CAN-13-2134-T; Frenzel A, 2009, APOPTOSIS, V14, P584, DOI 10.1007/s10495-008-0300-z; Fukamachi H, 2011, CANCER SCI, V102, P1313, DOI 10.1111/j.1349-7006.2011.01947.x; Goldman J, 2015, CLIN CANCER RES, V21, P1002, DOI 10.1158/1078-0432.CCR-14-1234; Gu DS, 2013, MOL CANCER THER, V12, P1038, DOI 10.1158/1535-7163.MCT-12-1030; GUDJONSSON B, 1987, CANCER, V60, P2284, DOI 10.1002/1097-0142(19871101)60:9<2284::AID-CNCR2820600930>3.0.CO;2-V; He J, 2006, J BIOL CHEM, V281, P35598, DOI 10.1074/jbc.C600200200; Hong SP, 2009, INT J CANCER, V125, P2323, DOI 10.1002/ijc.24573; Huang SH, 2006, CARCINOGENESIS, V27, P1334, DOI 10.1093/carcin/bgi378; Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038; Jeon HM, 2011, CANCER RES, V71, P3410, DOI 10.1158/0008-5472.CAN-10-3340; Jiang J, 2012, ONCOGENE, V31, P671, DOI 10.1038/onc.2011.282; Julian LM, 2017, CURR OPIN GENET DEV, V46, P24, DOI 10.1016/j.gde.2017.06.005; Justilien V, 2015, CLIN CANCER RES, V21, P505, DOI 10.1158/1078-0432.CCR-14-0507; Kim EJ, 2014, CLIN CANCER RES, V20, P5937, DOI 10.1158/1078-0432.CCR-14-1269; Kim J, 2013, CANCER CELL, V23, P23, DOI 10.1016/j.ccr.2012.11.017; Lauressergues E, 2016, PHARMACOL RES PERSPE, V4, DOI 10.1002/prp2.214; Lauth M, 2007, P NATL ACAD SCI USA, V104, P8455, DOI 10.1073/pnas.0609699104; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Liu Hailan, 2011, Chin J Cancer, V30, P13; LoRusso PM, 2011, CLIN CANCER RES, V17, P2502, DOI 10.1158/1078-0432.CCR-10-2745; Ma XL, 2006, INT J CANCER, V118, P139, DOI 10.1002/ijc.21295; Mondesire WH, 2004, CLIN CANCER RES, V10, P7031, DOI 10.1158/1078-0432.CCR-04-0361; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; O'Neil BH, 2015, ANN ONCOL, V26, P2505, DOI 10.1093/annonc/mdv477; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Peter Marcus E, 2004, Biochem J, V382, pe1; Piva M, 2014, EMBO MOL MED, V6, P66, DOI 10.1002/emmm.201303411; Platzbecker U, 2017, J CLIN ONCOL, V35, P605, DOI 10.1200/JCO.2016.67.1982; Rahib L, 2016, JAMA ONCOL, V2, P1209, DOI 10.1001/jamaoncol.2016.0585; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Rassouli FB, 2016, TUMOR BIOL, V37, P7, DOI 10.1007/s13277-015-4155-y; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Schniewind B, 2004, INT J CANCER, V109, P182, DOI 10.1002/ijc.11679; Shimokawa T, 2008, J BIOL CHEM, V283, P14345, DOI 10.1074/jbc.M800299200; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Stacy AE, 2013, MOL PHARMACOL, V84, P655, DOI 10.1124/mol.113.088609; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Takebe N, 2015, NAT REV CLIN ONCOL, V12, P445, DOI 10.1038/nrclinonc.2015.61; Tesei A, 2002, CLIN CANCER RES, V8, P233; Vogelzang NJ, 2012, J CLIN ONCOL, V30, P88, DOI 10.1200/JCO.2011.40.1919; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Wang T, 2011, BRIT J CANCER, V105, P658, DOI 10.1038/bjc.2011.287; Weiswald LB, 2015, NEOPLASIA, V17, P1, DOI 10.1016/j.neo.2014.12.004; Yang DG, 2013, ACTA HAEMATOL-BASEL, V130, P260, DOI 10.1159/000351603; Yang L, 2010, ONCOGENE, V29, P469, DOI 10.1038/onc.2009.392; Yu BQ, 2017, ONCOTARGET, V8, P27412, DOI 10.18632/oncotarget.16174; Zhang LN, 2017, CELL BIOSCI, V7, DOI 10.1186/s13578-017-0145-7; Zhang ZL, 2016, CANCER LETT, V382, P53, DOI 10.1016/j.canlet.2016.08.023; Zhao D, 2013, CANCER CELL, V23, P464, DOI 10.1016/j.ccr.2013.02.005; Zhao HQ, 2017, J CELL MOL MED, V21, P2055, DOI 10.1111/jcmm.13126	60	31	33	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2019	38	10					1764	1777		10.1038/s41388-018-0553-0	http://dx.doi.org/10.1038/s41388-018-0553-0			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN8DD	30382189	hybrid, Green Accepted, Green Submitted, Green Published			2022-12-28	WOS:000460423800014
J	Lee, SY; Park, JH; Jeong, S; Kim, BY; Kang, YK; Xu, Y; Chung, SK				Lee, Seo-Young; Park, Jung-Hyun; Jeong, Sangkyun; Kim, Bu-Yeo; Kang, Yong-Kook; Xu, Yang; Chung, Sun-Ku			K120R mutation inactivates p53 by creating an aberrant splice site leading to nonsense-mediated mRNA decay	ONCOGENE			English	Article							CELL-CYCLE ARREST; ACETYLATION; APOPTOSIS; ACTIVATION; SURVIVAL; CANCERS; PREDICT; TP53; GENE	The point mutation that substitutes lysine with arginine at position 120 of human p53 has been characterized as a missense mutation. The K120R mutation renders the p53 protein disabled for acetylation and, as a result, defective for apoptotic function, which provides a mechanistic link between the missense mutation and tumorigenesis. However, we noticed the failures of tumorigenesis in mice with the mutation, and of the related studies to notice that it has arbitrarily reflected in amino acid change through a sequence modification (AGA) of the original tumor mutation (AGG) by codon degeneracy. Unlike this modified version, we also discovered a novel splicing site the original mutation, TP53 c.359A>G, may induce. Using a human induced pluripotent stem cell line that was engineered to be homozygous for the original mutation, we here identified that the accidental splicing site generates a defective transcript variant with a frame-shifted premature termination codon which is subjected to nonsense-mediated mRNA decay. The authentic splicing still occurs but in extremely low amounts. Taken together, this mutation causes depletion of cellular p53 via defective mRNA, suggesting a new link to tumorigenesis.	[Lee, Seo-Young; Park, Jung-Hyun; Jeong, Sangkyun; Kim, Bu-Yeo; Chung, Sun-Ku] Korea Inst Oriental Med, Div Clin Med, 1672 Yuseong Daero, Daejeon 34054, South Korea; [Kang, Yong-Kook] Korea Res Inst Biosci & Biotechnol, Dev & Differentiat Res Ctr, 125 Gwahak Ro, Daejeon 34141, South Korea; [Kang, Yong-Kook] Korea Univ Sci & Technol, Dept Funct Genom, Daejeon, South Korea; [Xu, Yang] Univ Calif San Diego, Div Biol Sci, 9500 Gilman Dr, La Jolla, CA 92093 USA	Korea Institute of Oriental Medicine (KIOM); Korea Research Institute of Bioscience & Biotechnology (KRIBB); University of Science & Technology (UST); University of California System; University of California San Diego	Chung, SK (corresponding author), Korea Inst Oriental Med, Div Clin Med, 1672 Yuseong Daero, Daejeon 34054, South Korea.	skchung@kiom.re.kr		Xu, Yang/0000-0001-5574-921X	National Research Foundation of Korea [NRF-2013M3A9B4076487]; Korea Institute of Oriental Medicine Grants [K18131]	National Research Foundation of Korea(National Research Foundation of Korea); Korea Institute of Oriental Medicine Grants	We thank B-J. Park, K-S. Chae, and I. Horikawa for comments on the manuscript and Y-D. Kim for technical assistance. This research was supported in part by the National Research Foundation of Korea Grants (NRF-2013M3A9B4076487) and Korea Institute of Oriental Medicine Grants (K18131).	Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Chung SK, 2007, GASTROENTEROLOGY, V132, P2459, DOI 10.1053/j.gastro.2007.04.024; Deissler H, 2004, ONCOL REP, V11, P1281; Franks TM, 2010, CELL, V143, P938, DOI 10.1016/j.cell.2010.11.043; Gong L, 2018, ONCOGENE, V37, P2150, DOI 10.1038/s41388-017-0117-8; Hashimoto T, 1999, CANCER RES, V59, P5572; Hayes VM, 1999, BRAIN PATHOL, V9, P463, DOI 10.1111/j.1750-3639.1999.tb00535.x; Jayasinghe RG, 2018, CELL REP, V23, P270, DOI 10.1016/j.celrep.2018.03.052; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kim BY, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.43; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Lee SY, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/2725670; Leitao MM, 2004, GYNECOL ONCOL, V93, P301, DOI 10.1016/j.ygyno.2004.01.043; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; Liebermann DA, 2007, CELL CYCLE, V6, P166, DOI 10.4161/cc.6.2.3789; Liu NS, 2013, CANCER RES, V73, P3749, DOI 10.1158/0008-5472.CAN-12-3684; Liu XF, 2016, EMBO REP, V17, P349, DOI 10.15252/embr.201540505; Maquat LE, 2004, NAT REV MOL CELL BIO, V5, P89, DOI 10.1038/nrm1310; MEYERS FJ, 1993, J NATL CANCER I, V85, P1856, DOI 10.1093/jnci/85.22.1856; Monteith JA, 2016, MOL ONCOL, V10, P1207, DOI 10.1016/j.molonc.2016.05.007; Shinmen N, 2009, FEBS LETT, V583, P1916, DOI 10.1016/j.febslet.2009.04.041; Song H, 2010, CELL STEM CELL, V6, P80, DOI 10.1016/j.stem.2009.11.016; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Tang J, 2000, J MICROBIOL METH, V39, P121, DOI 10.1016/S0167-7012(99)00107-4; Tang Y, 2008, CELL, V133, P612, DOI 10.1016/j.cell.2008.03.025; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Yu H, 2009, GENOMICS, V94, P355, DOI 10.1016/j.ygeno.2009.08.004; Yun T, 2016, J BIOL CHEM, V291, P7386, DOI 10.1074/jbc.M115.706341	28	13	14	3	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2019	38	10					1597	1610		10.1038/s41388-018-0542-3	http://dx.doi.org/10.1038/s41388-018-0542-3			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN8DD	30348990				2022-12-28	WOS:000460423800002
J	Jiang, SH; Hu, LP; Wang, X; Li, J; Zhang, ZG				Jiang, Shu-Heng; Hu, Li-Peng; Wang, Xu; Li, Jun; Zhang, Zhi-Gang			Neurotransmitters: emerging targets in cancer	ONCOGENE			English	Review							GAMMA-AMINOBUTYRIC-ACID; BETA-BLOCKER USE; PROMOTES TUMOR-GROWTH; NEUROPEPTIDE-Y; GASTROINTESTINAL CANCER; ACETYLCHOLINE-RECEPTOR; CELL PROLIFERATION; GASTRIC-CANCER; NK-1 RECEPTOR; MOUSE MODEL	Neurotransmitters are conventionally viewed as nerve-secreted substances that mediate the stimulatory or inhibitory neuronal functions through binding to their respective receptors. In the past decades, many novel discoveries come to light elucidating the regulatory roles of neurotransmitters in the physiological and pathological functions of tissues and organs. Notably, emerging data suggest that cancer cells take advantage of the neurotransmitters-initiated signaling pathway to activate uncontrolled proliferation and dissemination. In addition, neurotransmitters can affect immune cells and endothelial cells in the tumor microenvironment to promote tumor progression. Therefore, a better understanding of the mechanisms underlying neurotransmitter function in tumorigenesis, angiogenesis, and inflammation is expected to enable the development of the next generation of antitumor therapies. Here, we summarize the recent important studies on the different neurotransmitters, their respective receptors, target cells, as well as pro/antitumor activity of specific neurotransmitter/receptor axis in cancers and provide perspectives and insights regarding the rationales and strategies of targeting neurotransmitter system to cancer treatment.	[Jiang, Shu-Heng; Hu, Li-Peng; Wang, Xu; Li, Jun; Zhang, Zhi-Gang] Shanghai Jiao Tong Univ, Ren Ji Hosp, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes,Sch Med, Shanghai 200240, Peoples R China	Shanghai Jiao Tong University	Zhang, ZG (corresponding author), Shanghai Jiao Tong Univ, Ren Ji Hosp, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes,Sch Med, Shanghai 200240, Peoples R China.	zzhang@shsci.org		Wang, Xu/0000-0002-3768-777X; Hu, Lipeng/0000-0002-5941-3825; Zhang, Zhi-gang/0000-0001-8965-223X	National Natural Science Foundation of China [81701945, 81672358, 81871923, 81802890, 81872242]; Natural Science Foundation of Shanghai [18ZR1436900]; Shanghai Sailing Program [19YF1445700]; China Postdoctoral Science Foundation [2018M640403]; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support [20181708]; Program of Shanghai Academic/Technology Research Leader [19XD1403400]; Science and Technology Commission of Shanghai Municipality [18410721000]; Shanghai Municipal Health Bureau [2018BR32]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai); Shanghai Sailing Program; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support; Program of Shanghai Academic/Technology Research Leader; Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); Shanghai Municipal Health Bureau	This work was supported by grants from the National Natural Science Foundation of China (81701945, 81672358, 81871923, 81802890, and 81872242), the Natural Science Foundation of Shanghai (18ZR1436900), Shanghai Sailing Program (19YF1445700), China Postdoctoral Science Foundation (2018M640403), Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (20181708), Program of Shanghai Academic/Technology Research Leader (19XD1403400), Science and Technology Commission of Shanghai Municipality (18410721000), and Shanghai Municipal Health Bureau (2018BR32).	Abdul M, 2008, ACTA ONCOL, V47, P1546, DOI 10.1080/02841860801961265; Anastas JN, 2019, MOL CELL, V74, P418, DOI 10.1016/j.molcel.2019.04.017; Arreola R, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/354957; Asada M, 2009, NEOPLASIA, V11, P408, DOI 10.1593/neo.81630; Barron TI, 2011, J CLIN ONCOL, V29, P2635, DOI 10.1200/JCO.2010.33.5422; Berger M, 2009, ANNU REV MED, V60, P355, DOI 10.1146/annurev.med.60.042307.110802; Bergeret M, 1998, BIOMED PHARMACOTHER, V52, P214, DOI 10.1016/S0753-3322(98)80019-X; Blanchart A, 2017, ONCOGENE, V36, P777, DOI 10.1038/onc.2016.245; Boilly B, 2017, CANCER CELL, V31, P342, DOI 10.1016/j.ccell.2017.02.005; Briggs KJ, 2016, CELL, V166, P126, DOI 10.1016/j.cell.2016.05.042; Chabbi-Achengli Y, 2012, P NATL ACAD SCI USA, V109, P2567, DOI 10.1073/pnas.1117792109; Chakroborty D, 2004, CLIN CANCER RES, V10, P4349, DOI 10.1158/1078-0432.CCR-04-0059; Chakroborty D, 2008, J CLIN INVEST, V118, P1380, DOI 10.1172/JCI33125; Coelho M, 2017, J CANCER RES CLIN, V143, P275, DOI 10.1007/s00432-016-2278-1; Cosentino M, 2007, BLOOD, V109, P632, DOI 10.1182/blood-2006-01-028423; Covenas R, 2014, HISTOL HISTOPATHOL, V29, P881, DOI 10.14670/HH-29.881; Czarnecka M, 2015, ONCOGENE, V34, P3131, DOI 10.1038/onc.2014.253; De Giorgi V, 2018, JAMA ONCOL, V4, DOI 10.1001/jamaoncol.2017.2908; Del Bello F, 2019, EUR J MED CHEM, V168, P461, DOI 10.1016/j.ejmech.2019.02.056; Dimitrov S, 2019, J EXP MED, V216, P517, DOI 10.1084/jem.20181169; Dolma S, 2016, CANCER CELL, V29, P859, DOI 10.1016/j.ccell.2016.05.002; Elisia I, 2019, CARCINOGENESIS, V40, P448, DOI 10.1093/carcin/bgz060; Entschladen F, 2004, LANCET ONCOL, V5, P254, DOI 10.1016/S1470-2045(04)01431-7; Entschladen F, 2008, SEMIN CANCER BIOL, V18, P171, DOI 10.1016/j.semcancer.2007.12.004; Farrelly LA, 2019, NATURE, V567, P535, DOI 10.1038/s41586-019-1024-7; Fujii T, 2017, J PHARMACOL SCI, V134, P1, DOI 10.1016/j.jphs.2017.05.002; Fujii T, 2014, J NEUROIMMUNOL, V267, P43, DOI 10.1016/j.jneuroim.2013.12.003; Galli S, 2016, AM J PATHOL, V186, P3040, DOI 10.1016/j.ajpath.2016.07.019; Gautam J, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0559-6; Gelb T, 2015, ONCOGENE, V34, P2711, DOI 10.1038/onc.2014.231; Grando SA, 2014, NAT REV CANCER, V14, P419, DOI 10.1038/nrc3725; Griffin N, 2018, PHARMACOL RES, V135, P12, DOI 10.1016/j.phrs.2018.07.019; Grygier B, 2013, PHARMACOL REP, V65, P672, DOI 10.1016/S1734-1140(13)71045-4; Grytli HH, 2014, EUR UROL, V65, P635, DOI 10.1016/j.eururo.2013.01.007; Gumireddy K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10715; Hanoun M, 2015, NEURON, V86, P360, DOI 10.1016/j.neuron.2015.01.026; Hayakawa Y, 2017, CANCER CELL, V31, P21, DOI 10.1016/j.ccell.2016.11.005; Hondermarck H, 2018, TRENDS CANCER, V4, P93, DOI 10.1016/j.trecan.2017.11.008; Hsieh HY, 2016, CANCER LETT, V370, P56, DOI 10.1016/j.canlet.2015.09.018; Hujber Z, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0946-5; Inbar S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019246; Jandaghi P, 2016, GASTROENTEROLOGY, V151, P1218, DOI 10.1053/j.gastro.2016.08.040; Jansen L, 2012, CANCER-AM CANCER SOC, V118, P3911, DOI 10.1002/cncr.26727; Jiang SH, 2019, GUT, V68, P1994, DOI 10.1136/gutjnl-2018-317479; Jiang SH, 2017, GASTROENTEROLOGY, V153, P277, DOI 10.1053/j.gastro.2017.03.008; Kaczynska K, 2018, PULM PHARMACOL THER, V48, P217, DOI 10.1016/j.pupt.2017.12.001; Kanbara K, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4149-4; Kast RE, 2010, BRIT J PHARMACOL, V161, P481, DOI 10.1111/j.1476-5381.2010.00923.x; Kim H, 2010, NAT MED, V16, P804, DOI 10.1038/nm.2173; Kim HB, 2017, INT J CANCER, V140, P513, DOI 10.1002/ijc.30443; Kim TH, 2019, FASEB J, V33, P3997, DOI 10.1096/fj.201801429RR; Krizanova O, 2016, STRESS, V19, P419, DOI 10.1080/10253890.2016.1203415; Lang K, 2003, IMMUNOL LETT, V90, P165, DOI 10.1016/j.imlet.2003.09.004; Lang K, 2007, PROG EXP TUMOR RES, V39, P99, DOI 10.1159/000100070; Le CP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10634; Levite M, 2017, J NEURAL TRANSM, V124, P775, DOI 10.1007/s00702-016-1661-z; Li JA, 2015, REGEN BIOMATER, V2, P215, DOI 10.1093/rb/rbv013; Li J, 2014, J HEPATOL, V60, P1225, DOI 10.1016/j.jhep.2014.02.025; Li ZJ, 2011, EUR J PHARMACOL, V667, P17, DOI 10.1016/j.ejphar.2011.05.077; Liu X, 2008, J CELL BIOCHEM, V105, P53, DOI 10.1002/jcb.21802; Liu Y, 2019, EUR J CANCER, V114, P8, DOI 10.1016/j.ejca.2019.03.017; Maemura K, 2009, J GASTROEN HEPATOL, V24, P688, DOI 10.1111/j.1440-1746.2008.05687.x; Magnon C, 2013, SCIENCE, V341, P143, DOI 10.1126/science.1236361; Mammadova-Bach E, 2018, PLATELETS, V29, P541, DOI 10.1080/09537104.2018.1478072; Melhem-Bertrandt A, 2011, J CLIN ONCOL, V29, P2645, DOI 10.1200/JCO.2010.33.4441; Minami K, 2017, SCI REP-UK, V7, DOI 10.1038/srep45686; Moody TW, 2016, CURR OPIN ENDOCRINOL, V23, P38, DOI 10.1097/MED.0000000000000218; Moody TW, 2015, PEPTIDES, V72, P106, DOI 10.1016/j.peptides.2015.03.018; Muma NA, 2015, ACS CHEM NEUROSCI, V6, P961, DOI 10.1021/cn500329r; Munoz M, 2017, PHARMACOL REP, V69, P696, DOI 10.1016/j.pharep.2017.02.002; Munoz M, 2016, SAUDI J GASTROENTERO, V22, P260, DOI 10.4103/1319-3767.187601; Munoz M, 2011, CURR DRUG TARGETS, V12, P909, DOI 10.2174/138945011795528796; Na ZJ, 2018, ONCOTARGETS THER, V11, P4913, DOI 10.2147/OTT.S167422; Nasi G, 2019, J NEUROIMMUNOL, V332, P233, DOI 10.1016/j.jneuroim.2019.02.007; Nilsson MB, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aao4307; Nimmakayala RK, 2018, GASTROENTEROLOGY, V155, P892, DOI 10.1053/j.gastro.2018.05.041; Nocito A, 2008, CANCER RES, V68, P5152, DOI 10.1158/0008-5472.CAN-08-0202; Ondrovics M, 2017, ONCOTARGET, V8, P25783, DOI 10.18632/oncotarget.15419; Ouyang Q, 2017, CLIN EXP PHARMACOL P, V44, P841, DOI 10.1111/1440-1681.12787; Palamiuc L, 2018, J EXP MED, V215, P17, DOI 10.1084/jem.20172050; Patane S, 2014, INT J CARDIOL, V177, P646, DOI 10.1016/j.ijcard.2014.09.178; Pinoli M, 2017, J NEUROIMMUNE PHARM, V12, P602, DOI 10.1007/s11481-017-9749-2; Powe DG, 2011, NAT REV CLIN ONCOL, V8, P511, DOI 10.1038/nrclinonc.2011.123; Reijmen E, 2018, IMMUNOL LETT, V202, P38, DOI 10.1016/j.imlet.2018.07.006; Renz BW, 2018, CANCER DISCOV, V8, P1458, DOI 10.1158/2159-8290.CD-18-0046; Renz BW, 2018, CANCER CELL, V33, P75, DOI 10.1016/j.ccell.2017.11.007; Ribeiro MPC, 2017, CANCER CHEMOTH PHARM, V79, P219, DOI 10.1007/s00280-016-3129-0; Rolland B, 2015, EUR NEUROPSYCHOPHARM, V25, P1631, DOI 10.1016/j.euroneuro.2015.05.008; Roney MSI, 2018, ARCH PHARM RES, V41, P384, DOI 10.1007/s12272-018-1017-3; Russo P, 2014, CURR MOL MED, V14, P1126, DOI 10.2174/1566524014666141015152601; Santala EEE, 2019, INT J CANCER, V144, P440, DOI 10.1002/ijc.31802; Sarkar C, 2008, CLIN CANCER RES, V14, P2502, DOI 10.1158/1078-0432.CCR-07-1778; Sarkar C, 2013, J NEUROIMMUNE PHARM, V8, P7, DOI 10.1007/s11481-012-9395-7; Sarrouilhe D, 2015, CURR MOL MED, V15, P62, DOI 10.2174/1566524015666150114113411; Sarrouilhe D, 2019, BIOCHIMIE, V161, P46, DOI 10.1016/j.biochi.2018.06.016; Schaal CM, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0901-2; Schuller HM, 2008, ANTI-CANCER DRUG, V19, P655, DOI 10.1097/CAD.0b013e3283025b58; Schuller HM, 2018, CURR MED CHEM, V25, P2566, DOI 10.2174/0929867324666170303121708; Shahzad MMK, 2010, J BIOL CHEM, V285, P35462, DOI 10.1074/jbc.M110.109579; Shapovalov Y, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-598; Shimizu R, 2019, INT J ONCOL, V54, P283, DOI 10.3892/ijo.2018.4631; Sloan EK, 2010, CANCER RES, V70, P7042, DOI 10.1158/0008-5472.CAN-10-0522; Soll C, 2010, HEPATOLOGY, V51, P1244, DOI 10.1002/hep.23441; Song YF, 2017, CANCER RES, V77, P1611, DOI 10.1158/0008-5472.CAN-16-2143; Sood AK, 2010, J CLIN INVEST, V120, P1515, DOI 10.1172/JCI40802; Sorensen GV, 2013, J CLIN ONCOL, V31, P2265, DOI 10.1200/JCO.2012.43.9190; Spera G, 2017, ANN ONCOL, V28, P1836, DOI 10.1093/annonc/mdx264; Sung HY, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.62; Takehara A, 2007, CANCER RES, V67, P9704, DOI 10.1158/0008-5472.CAN-07-2099; Thaker PH, 2006, NAT MED, V12, P939, DOI 10.1038/nm1447; Tilan J, 2016, NEUROPEPTIDES, V55, P55, DOI 10.1016/j.npep.2015.10.005; Wang QH, 2019, J CELL PHYSIOL, V234, P14432, DOI 10.1002/jcp.28214; Wang T, 2008, LIFE SCI, V82, P536, DOI 10.1016/j.lfs.2007.12.014; Wessler IK, 2017, J NEUROCHEM, V142, P144, DOI 10.1111/jnc.13953; Wu J, 2015, J LEUKOCYTE BIOL, V97, P191, DOI 10.1189/jlb.5A1113-626RR; Wu XY, 2018, CELL PHYSIOL BIOCHEM, V48, P2258, DOI 10.1159/000492644; Xia S, 2017, MOL PHARMACOL, V92, P265, DOI 10.1124/mol.116.107854; Yu HF, 2017, SCI REP-UK, V7, DOI 10.1038/srep40802; Yu LMJ, 2017, NEUROPHARMACOLOGY, V115, P193, DOI 10.1016/j.neuropharm.2016.02.011; Zahalka AH, 2017, SCIENCE, V358, P321, DOI 10.1126/science.aah5072; Zhang DP, 2014, CANCER LETT, V348, P100, DOI 10.1016/j.canlet.2014.03.006; Zhang XX, 2014, J RECEPT SIG TRANSD, V34, P431, DOI 10.3109/10799893.2013.856918; Zhao CM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009569; Zila I, 2017, PHYSIOL RES, V66, pS139, DOI 10.33549/physiolres.933671	124	74	76	9	40	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					503	515		10.1038/s41388-019-1006-0	http://dx.doi.org/10.1038/s41388-019-1006-0			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31527667				2022-12-28	WOS:000509718300002
J	Chu, TH; Huang, ST; Yang, SF; Li, CJ; Lin, HW; Weng, BC; Yang, SM; Huang, SC; Wu, JC; Chang, YC; Wen, ZH; Chen, YMA; Wu, WJ; Kung, ML; Tai, PH; Wu, DC; Tai, MH				Chu, Tian-Huei; Huang, Shih-Tsung; Yang, Sheau-Fang; Li, Chia-Jung; Lin, Hung-Wei; Weng, Bi-Chuang; Yang, Shih-Ming; Huang, Shih-Chung; Wu, Jian-Ching; Chang, Yi-Chen; Wen, Zhi-Hong; Chen, Yi-Ming Arthur; Wu, Wen-Jeng; Kung, Mei-Lang; Tai, Po-Han; Wu, Deng-Chyang; Tai, Ming-Hong			Hepatoma-derived growth factor participates in Helicobacter Pylori-induced neutrophils recruitment, gastritis and gastric carcinogenesis	ONCOGENE			English	Article							INTESTINAL METAPLASIA; KAPPA-B; HEPATOCELLULAR-CARCINOMA; SUPPRESSOR-CELLS; FACTOR HDGF; RECEPTOR 2; CANCER; TNF; EXPRESSION; INFECTION	Helicobacter pylori (Hp) infection and overexpression of hepatoma-derived growth factor (HDGF) are involved in gastric carcinogenesis. However, the relationship between Hp-induced gastric diseases and HDGF upregulation is not yet completely clear. This study aimed to elucidate the role of HDGF in Hp-induced gastric inflammation and carcinogenesis. HDGF expression in gastric biopsy and serum from patients was analyzed by immunohistochemical and ELISA analysis, respectively. Hp and gastric cells coculture system was employed to delineate the mechanism underlying HDGF overexpression during Hp infection. The gastric pathologies of wild type and HDGF knockout mice after Hp infection were investigated by immunohistochemical, immunoblot, and immunofluorescence analyses. HDGF level was significantly elevated in patients with Hp infection or intestinal metaplasia (IM, a precancerous lesion), and HDGF overexpression was positively correlated with Hp load, IM, and neutrophil infiltration in gastric biopsy. Consistently, patients with Hp infection or IM had significantly higher serum HDGF level. By using coculture assay, Hp infection led to HDGF upregulation and secretion in gastric cells. In mice model, HDGF ablation significantly suppressed the Hp-induced neutrophil infiltration and inflammatory TNF-alpha/COX-2 signaling, thereby relieving the tissue damage in stomach. This was further supported by that recombinant HDGF (rHDGF) stimulated the differentiation/chemotaxis of cultured neutrophils and oncogenic behaviors of gastric cells. Time series studies showed that Hp infection elicited an inflammatory TNF-alpha/HDGF/COX-2 cascade in stomach. HDGF secretion by Hp infection promotes the neutrophils infiltration and relays Hp-induced inflammatory signaling. Thus, HDGF may constitute a novel diagnostic marker and therapeutic target for Hp-induced gastritis and carcinogenesis.	[Chu, Tian-Huei; Tai, Po-Han; Tai, Ming-Hong] Natl Sun Yat Sen Univ, Ctr Neurosci, Kaohsiung, Taiwan; [Chu, Tian-Huei; Lin, Hung-Wei; Yang, Shih-Ming; Huang, Shih-Chung; Chen, Yi-Ming Arthur; Tai, Po-Han; Wu, Deng-Chyang; Tai, Ming-Hong] Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung, Taiwan; [Huang, Shih-Tsung; Wu, Jian-Ching; Chang, Yi-Chen; Tai, Ming-Hong] Natl Sun Yat Sen Univ, Doctoral Degree Program Marine Biotechnol, Kaohsiung, Taiwan; [Huang, Shih-Tsung; Wu, Jian-Ching; Chang, Yi-Chen; Tai, Ming-Hong] Acad Sinica, Kaohsiung, Taiwan; [Yang, Sheau-Fang] Kaohsiung Med Univ, Coll Med, Sch Med, Dept Pathol, Kaohsiung, Taiwan; [Yang, Sheau-Fang; Wu, Wen-Jeng] Kaohsiung Med Univ, Coll Med, Grad Inst Med, Kaohsiung, Taiwan; [Li, Chia-Jung; Weng, Bi-Chuang; Wu, Deng-Chyang] Kaohsiung Med Univ Hosp, Dept Internal Med, Div Gastroenterol, Kaohsiung, Taiwan; [Huang, Shih-Chung] Kaohsiung Aimed Forces Gen Hosp, Dept Internal Med, Kaohsiung, Taiwan; [Wen, Zhi-Hong] Natl Sun Yat Sen Univ, Asia Pacific Ocean Res Ctr, Dept Marine Biotechnol & Resources, Kaohsiung, Taiwan; [Chen, Yi-Ming Arthur] Kaohsiung Med Univ, Ctr Infect Dis & Canc Res, Kaohsiung, Taiwan; [Chen, Yi-Ming Arthur] Kaohsiung Med Univ, Dept Microbiol & Immunol, Inst Med Res, Coll Med, Kaohsiung, Taiwan; [Chen, Yi-Ming Arthur] Kaohsiung Med Univ, Coll Med, Inst Clin Med, Kaohsiung, Taiwan; [Wu, Wen-Jeng] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Urol, Kaohsiung, Taiwan; [Wu, Wen-Jeng] Kaohsiung Med Univ, Coll Med, Sch Med, Dept Urol, Kaohsiung, Taiwan; [Wu, Wen-Jeng] Kaohsiung Med Univ, Kaohsiung Municipal Ta Tung Hosp, Dept Urol, Kaohsiung, Taiwan; [Wu, Wen-Jeng; Wu, Deng-Chyang; Tai, Ming-Hong] Kaohsiung Med Univ, Regenerat Med & Cell Therapy Res Ctr, Kaohsiung, Taiwan; [Kung, Mei-Lang] Natl Sun Yat Sen Univ, Dept Chem, Kaohsiung, Taiwan; [Wu, Deng-Chyang] Kaohsiung Med Univ, Dept Med, Fac Med, Coll Med, Kaohsiung, Taiwan	National Sun Yat Sen University; National Sun Yat Sen University; National Sun Yat Sen University; Academia Sinica - Taiwan; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; National Sun Yat Sen University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Municipal Ta-Tung Hospital; Kaohsiung Medical University; National Sun Yat Sen University; Kaohsiung Medical University	Tai, MH (corresponding author), Natl Sun Yat Sen Univ, Ctr Neurosci, Kaohsiung, Taiwan.; Wu, DC; Tai, MH (corresponding author), Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung, Taiwan.; Tai, MH (corresponding author), Natl Sun Yat Sen Univ, Doctoral Degree Program Marine Biotechnol, Kaohsiung, Taiwan.; Tai, MH (corresponding author), Acad Sinica, Kaohsiung, Taiwan.; Wu, DC (corresponding author), Kaohsiung Med Univ Hosp, Dept Internal Med, Div Gastroenterol, Kaohsiung, Taiwan.; Wu, DC; Tai, MH (corresponding author), Kaohsiung Med Univ, Regenerat Med & Cell Therapy Res Ctr, Kaohsiung, Taiwan.; Wu, DC (corresponding author), Kaohsiung Med Univ, Dept Med, Fac Med, Coll Med, Kaohsiung, Taiwan.	dechwu@yahoo.com; minghongtai@gmail.com	Wen, Zhi-Hong/AAG-8034-2019	Chu, Tian-Huei/0000-0003-1197-5754; Wu, Deng-Chyang/0000-0003-3742-0634	National Research Program for Biopharmaceuticals [103NPP1002-3, MOST103-2325-B-110-002]; Ministry of Science and Technology [107-2320-B-110-003]; Kaohsiung Medical University Research Center Grant [KMU-TC108A02]; Center for Infectious Disease and Cancer Research, Kaohsiung Medical University [KMUTP105E20]; Kaohsiung Medical University Research Foundation [KMUOR105]; Kaohsiung Medical University Center for Stem Cell Research [KMUTP105G01]; NSYSU-KMU Joint Research Project [NSYSUKMU103-I010, NSYSUKMU-105-P023, NSYSUKMU-106-P020]; Kaohsiung Armed Forces General Hospital [103-6]	National Research Program for Biopharmaceuticals; Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Kaohsiung Medical University Research Center Grant; Center for Infectious Disease and Cancer Research, Kaohsiung Medical University; Kaohsiung Medical University Research Foundation; Kaohsiung Medical University Center for Stem Cell Research; NSYSU-KMU Joint Research Project; Kaohsiung Armed Forces General Hospital	This work was supported by the grants from National Research Program for Biopharmaceuticals (103NPP1002-3, MOST103-2325-B-110-002), from Ministry of Science and Technology (107-2320-B-110-003), from Kaohsiung Medical University Research Center Grant (KMU-TC108A02), from the Center for Infectious Disease and Cancer Research, Kaohsiung Medical University (KMUTP105E20), from Kaohsiung Medical University Research Foundation (KMUOR105), from Kaohsiung Medical University Center for Stem Cell Research (KMUTP105G01), from the NSYSU-KMU Joint Research Project (NSYSUKMU103-I010, NSYSUKMU-105-P023, NSYSUKMU-106-P020) and Kaohsiung Armed Forces General Hospital (103-6). In addition, the authors thank Dr. Sebastian Franken (Institute of Physiological Chemistry, University of Bonn, Bonn, Germany) for sharing HDGF-KO mice.	Albrengues J, 2018, SCIENCE, V361, P1353, DOI 10.1126/science.aao4227; Asaka M, 2010, HELICOBACTER, V15, P1, DOI 10.1111/j.1523-5378.2009.00738.x; Byrd JC, 2000, GASTROENTEROLOGY, V118, P1072, DOI 10.1016/S0016-5085(00)70360-X; Cao MW, 2017, J IMMUNOL, V198, P1887, DOI 10.4049/jimmunol.1600622; Chen SC, 2015, ONCOTARGET, V6, P16253, DOI 10.18632/oncotarget.3608; Chen SC, 2012, J PATHOL, V228, P158, DOI 10.1002/path.3988; Chu TH, 2018, CANCER MED-US, V7, P2567, DOI 10.1002/cam4.1487; Chu TH, 2014, ONCOTARGET, V5, P1475, DOI 10.18632/oncotarget.1745; Ding L, 2016, J CLIN INVEST, V126, P2867, DOI 10.1172/JCI82529; Dixon MF, 1996, AM J SURG PATHOL, V20, P1161, DOI 10.1097/00000478-199610000-00001; Finsterbusch M, 2014, J EXP MED, V211, P1306, DOI 10.1084/jem.20132413; Gallitzendoerfer R, 2008, DEV DYNAM, V237, P1875, DOI 10.1002/dvdy.21589; Goldblum JR, 1998, GASTROENTEROLOGY, V114, P633, DOI 10.1016/S0016-5085(98)70576-1; Gomez-Mejiba SE, 2010, J BIOL CHEM, V285, P20062, DOI 10.1074/jbc.M109.086579; Gong YF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149629; Hayden MS, 2014, SEMIN IMMUNOL, V26, P253, DOI 10.1016/j.smim.2014.05.004; Hsu SS, 2012, J NEURO-ONCOL, V107, P101, DOI 10.1007/s11060-011-0733-z; Hu TH, 2003, CANCER-AM CANCER SOC, V98, P1444, DOI 10.1002/cncr.11653; Jeong M, 2015, ONCOTARGET, V6, P29513, DOI 10.18632/oncotarget.4897; Kwon HJ, 2012, GUT, V61, P53, DOI 10.1136/gutjnl-2011-300361; Lemos HP, 2009, P NATL ACAD SCI USA, V106, P5954, DOI 10.1073/pnas.0812782106; Li S, 2016, MICROB PATHOGENESIS, V98, P63, DOI 10.1016/j.micpath.2016.06.028; Liu CJ, 2018, CANCERS, V10, DOI 10.3390/cancers10120479; Lo J, 2015, HEPATOLOGY, V62, P534, DOI 10.1002/hep.27859; NAKAMURA H, 1989, CLIN CHIM ACTA, V183, P273, DOI 10.1016/0009-8981(89)90361-6; Nakamura H, 2002, J GASTROENTEROL, V37, P8, DOI 10.1007/BF03326407; Narayana JL, 2015, BIOMATERIALS, V61, P41, DOI 10.1016/j.biomaterials.2015.05.014; Nemati M, 2017, LIFE SCI, V178, P17, DOI 10.1016/j.lfs.2017.04.006; Ng GZ, 2016, GUT, V65, P1087, DOI 10.1136/gutjnl-2014-307175; Nupponen I, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.1.e12; Park JS, 2014, P NATL ACAD SCI USA, V111, P5896, DOI 10.1073/pnas.1402087111; Patel SK, 2014, WORLD J GASTROENTERO, V20, P12847, DOI 10.3748/wjg.v20.i36.12847; Ray A, 2015, J IMMUNOL, V195, P3071, DOI 10.4049/jimmunol.1500153; Rogers AB, 2005, CANCER RES, V65, P10709, DOI 10.1158/0008-5472.CAN-05-1846; ROKKAS T, 1991, GUT, V32, P1110, DOI 10.1136/gut.32.10.1110; SCHMEKEL B, 1990, INFLAMMATION, V14, P447, DOI 10.1007/BF00914095; Shetty A, 2016, UROL ONCOL-SEMIN ORI, V34, DOI 10.1016/j.urolonc.2016.05.027; Shibata J, 1999, GUT, V45, P24, DOI 10.1136/gut.45.1.24; Sierra JC, 2018, GUT, V67, P1247, DOI 10.1136/gutjnl-2016-312888; Sozzi M, 1998, AM J GASTROENTEROL, V93, P375, DOI 10.1111/j.1572-0241.1998.00375.x; Suganuma M, 2012, CANCER LETT, V322, P133, DOI 10.1016/j.canlet.2012.03.027; Sun AM, 2015, CYTOKINE, V72, P31, DOI 10.1016/j.cyto.2014.12.001; Suzuki M, 2009, CELL HOST MICROBE, V5, P23, DOI 10.1016/j.chom.2008.11.010; Tao F, 2014, WORLD J GASTROENTERO, V20, P9564, DOI 10.3748/wjg.v20.i28.9564; Toller IM, 2010, GASTROENTEROLOGY, V138, P1455, DOI 10.1053/j.gastro.2009.12.006; Verghese MW, 1996, J BIOL CHEM, V271, P15597, DOI 10.1074/jbc.271.26.15597; Wang TT, 2017, GUT, V66, P1900, DOI 10.1136/gutjnl-2016-313075; Watanabe T, 2014, INT J CANCER, V134, P2373, DOI 10.1002/ijc.28582; Watanabe T, 2010, J CANCER RES CLIN, V136, P911, DOI 10.1007/s00432-009-0733-y; Wong BCY, 2004, JAMA-J AM MED ASSOC, V291, P187, DOI 10.1001/jama.291.2.187; Wong BCY, 2012, GUT, V61, P812, DOI 10.1136/gutjnl-2011-300154; Wroblewski LE, 2010, CLIN MICROBIOL REV, V23, P713, DOI 10.1128/CMR.00011-10; Yamamoto S, 2006, CLIN CANCER RES, V12, P117, DOI 10.1158/1078-0432.CCR-05-1347; Yang J, 2016, AM J RESP CRIT CARE, V194, P1264, DOI 10.1164/rccm.201512-2498OC; Yeh JJ, 2010, BLOOD, V115, P4247, DOI 10.1182/blood-2009-09-241166; Yoon JH, 2011, J PROTEOME RES, V10, P5315, DOI 10.1021/pr200573b; Youn JI, 2012, J LEUKOCYTE BIOL, V91, P167, DOI 10.1189/jlb.0311177; Zhao L, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01181-4	58	19	22	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2019	38	37					6461	6477		10.1038/s41388-019-0886-3	http://dx.doi.org/10.1038/s41388-019-0886-3			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IX6FR	31332288				2022-12-28	WOS:000485778800005
J	Ding, KK; Ji, JX; Zhang, X; Huang, B; Chen, AJ; Zhang, D; Li, XG; Wang, XY; Wang, J				Ding, Kaikai; Ji, Jianxiong; Zhang, Xin; Huang, Bin; Chen, Anjing; Zhang, Di; Li, Xingang; Wang, Xinyu; Wang, Jian			RNA splicing factor USP39 promotes glioma progression by inducing TAZ mRNA maturation	ONCOGENE			English	Article							TRANSCRIPTIONAL COACTIVATOR TAZ; LENTIVIRUS-MEDIATED INHIBITION; CELL-PROLIFERATION; HEPATOCELLULAR-CARCINOMA; DESTRUCTION COMPLEX; CANCER GROWTH; HIPPO; SUPPRESSES; KNOCKDOWN; PATHWAY	Increasing evidence demonstrates that ubiquitin specific protease 39 (USP39) plays an oncogenic role in various human tumors. Here, using expression analysis of the publicly available Oncomine database, clinical glioma patient samples, and glioma cells, we found that USP39 was overexpressed in human gliomas. Knockdown of USP39 in glioma cells demonstrated that the protein promoted cell growth, invasion and migration in vitro and in a tumor model in nude mice. To identify mediators of USP39 growth-promoting properties, we used luciferase reporter constructs under transcriptional control of various promoters specific to seven canonical cancer-associated pathways. Luciferase activity from a synthetic TEAD-dependent YAP/TAZ-responsive reporter, as a direct readout of the Hippo signaling pathway, was decreased by 92% in cells with USP39 knockdown, whereas the luciferase activities from the other six cancer pathways, including MAPK/ERK, MAPK/JNK, NF kappa B, Notch, TGF beta, and Wnt, remained unchanged. TAZ protein expression however was decreased independent of canonical Hippo signaling. Immunohistochemistry revealed a positive correlation between USP39 and TAZ proteins in orthotopic xenografts derived from modified glioma cells expressing USP39 shRNAs and primary human glioma samples (p < 0.05). Finally, loss of USP39 decreased TAZ pre-mRNA splicing efficiency in glioma cells in vitro, which led to reduced levels of TAZ protein. In summary, USP39 has oncogenic properties that increase TAZ protein levels by inducing maturation of its mRNA. USP39 therefore provides a novel therapeutic target for the treatment of human glioma.	[Ding, Kaikai; Ji, Jianxiong; Zhang, Xin; Huang, Bin; Chen, Anjing; Zhang, Di; Li, Xingang; Wang, Xinyu; Wang, Jian] Shandong Univ, Dept Neurosurg, Qilu Hosp, Jinan 250012, Shandong, Peoples R China; [Ding, Kaikai; Ji, Jianxiong; Zhang, Xin; Huang, Bin; Chen, Anjing; Zhang, Di; Li, Xingang; Wang, Xinyu; Wang, Jian] Shandong Univ, Inst Brain & Brain Inspired Sci, Jinan 250012, Shandong, Peoples R China; [Ding, Kaikai; Ji, Jianxiong; Zhang, Xin; Huang, Bin; Chen, Anjing; Zhang, Di; Li, Xingang; Wang, Xinyu; Wang, Jian] Shandong Key Lab Brain Funct Remodeling, Jinan 250012, Shandong, Peoples R China; [Wang, Jian] Univ Bergen, Dept Biomed, N-5009 Bergen, Norway	Shandong University; Shandong University; University of Bergen	Wang, XY; Wang, J (corresponding author), Shandong Univ, Dept Neurosurg, Qilu Hosp, Jinan 250012, Shandong, Peoples R China.; Wang, XY; Wang, J (corresponding author), Shandong Univ, Inst Brain & Brain Inspired Sci, Jinan 250012, Shandong, Peoples R China.; Wang, XY; Wang, J (corresponding author), Shandong Key Lab Brain Funct Remodeling, Jinan 250012, Shandong, Peoples R China.; Wang, J (corresponding author), Univ Bergen, Dept Biomed, N-5009 Bergen, Norway.	wangxinyu@sdu.edu.cn; jian.wang@sdu.edu.cn	Wang, Xin/GYU-1129-2022; Huang, Bin/AAT-4514-2021; Chen, Anjing/GYE-2355-2022		National Natural Science Foundation of China [81701329, 81702474]; Department of Science & Technology of Shandong Province [2016GSF201060, 2017CXGC1502, 2018GSF118082]; Special Foundation for Taishan Scholars [ts20110814, tshw201502056, tsqn20161067]; Shandong Provincial Natural Science Foundation [ZR2017MH116, ZR2017MH015]; China Postdoctoral Science Foundation [2018M642666]; Jinan Science and Technology Bureau of Shandong Province [201704096]; University of Bergen; K.G. Jebsen Brain Tumor Research Centre	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Department of Science & Technology of Shandong Province; Special Foundation for Taishan Scholars; Shandong Provincial Natural Science Foundation(Natural Science Foundation of Shandong Province); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Jinan Science and Technology Bureau of Shandong Province; University of Bergen; K.G. Jebsen Brain Tumor Research Centre	We appreciate the assistance from other members of the lab. This work was supported by the National Natural Science Foundation of China (81701329 and 81702474), the Department of Science & Technology of Shandong Province (2016GSF201060, 2017CXGC1502, and 2018GSF118082), the Special Foundation for Taishan Scholars (ts20110814, tshw201502056, and tsqn20161067), the Shandong Provincial Natural Science Foundation (ZR2017MH116 and ZR2017MH015), the China Postdoctoral Science Foundation (2018M642666), the Jinan Science and Technology Bureau of Shandong Province (201704096), the University of Bergen, and the K.G. Jebsen Brain Tumor Research Centre.	An Y, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0669-4; Azzolin L, 2014, CELL, V158, P157, DOI 10.1016/j.cell.2014.06.013; Azzolin L, 2012, CELL, V151, P1443, DOI 10.1016/j.cell.2012.11.027; Behin A, 2003, LANCET, V361, P323, DOI 10.1016/S0140-6736(03)12328-8; Bhat KPL, 2011, GENE DEV, V25, P2594, DOI 10.1101/gad.176800.111; Cai J, 2017, BIOCHEM BIOPH RES CO, V486, P184, DOI 10.1016/j.bbrc.2017.03.025; Chan SW, 2009, J BIOL CHEM, V284, P14347, DOI 10.1074/jbc.M901568200; Chen J, 2017, CANCER DISCOV, V7, P766, DOI 10.1158/2159-8290.CD-16-0908; Choi W, 2018, CANCER RES, V78, P3306, DOI 10.1158/0008-5472.CAN-17-3487; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; Deel MD, 2018, CLIN CANCER RES, V24, P2616, DOI 10.1158/1078-0432.CCR-17-1207; Diamantopoulou Z, 2017, CANCER CELL, V31, P621, DOI 10.1016/j.ccell.2017.03.007; Ehmer U, 2016, MOL CANCER RES, V14, P127, DOI 10.1158/1541-7786.MCR-15-0305; Fraile JM, 2017, J BIOL CHEM, V292, P4164, DOI 10.1074/jbc.M116.762757; Gan ZH, 2017, BIOL RES, V50, DOI 10.1186/s40659-017-0121-z; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; Huang Y, 2016, ONCOTARGET, V7, P22016, DOI 10.18632/oncotarget.7882; Ji JX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0548-3; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Lapointe S, 2018, LANCET, V392, P432, DOI 10.1016/S0140-6736(18)30990-5; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Li KY, 2016, CANCER BIOMARK, V16, P137, DOI 10.3233/CBM-150549; Li WJ, 2016, ONCOTARGET, V7, P82686, DOI 10.18632/oncotarget.12625; Lin ZF, 2016, MOL CELL BIOCHEM, V422, P97, DOI 10.1007/s11010-016-2809-8; Lu L, 2010, P NATL ACAD SCI USA, V107, P1437, DOI 10.1073/pnas.0911427107; Lygerou Z, 1999, MOL CELL BIOL, V19, P2008; Makarova OV, 2001, EMBO J, V20, P2553, DOI 10.1093/emboj/20.10.2553; Miranda MZ, 2017, J BIOL CHEM, V292, P14902, DOI 10.1074/jbc.M117.780502; Nallet-Staub F, 2014, J INVEST DERMATOL, V134, P123, DOI 10.1038/jid.2013.319; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014; Rios Y, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001271; Schwartzbaum JA, 2006, NAT CLIN PRACT NEURO, V2, P494, DOI 10.1038/ncpneuro0289; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; van Leuken RJ, 2008, CELL CYCLE, V7, P2710, DOI 10.4161/cc.7.17.6553; Wang HB, 2013, ONCOL REP, V30, P2871, DOI 10.3892/or.2013.2798; Wang LJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065539; Wang XB, 2016, MOL MED REP, V14, P301, DOI 10.3892/mmr.2016.5252; Wen PY, 2016, NAT REV NEUROL, V12, P69, DOI 10.1038/nrneurol.2015.242; Xing ZY, 2018, ONCOL LETT, V15, P5443, DOI [10.3892/ol.2018.808061, 10.3892/ol.2018.8061]; Xu Y, 2018, MOL MED REP, V17, P4729, DOI 10.3892/mmr.2018.8421; Yuan XW, 2017, ONCOL REP, V37, P2398, DOI 10.3892/or.2017.5454; Yuan XW, 2015, ONCOL REP, V34, P823, DOI 10.3892/or.2015.4065; Zhang H, 2016, TUMOR BIOL, V37, P11321, DOI 10.1007/s13277-016-4995-0; Zhang H, 2009, J BIOL CHEM, V284, P13355, DOI 10.1074/jbc.M900843200; Zhao Y, 2016, TUMOR BIOL, V37, P13167, DOI 10.1007/s13277-016-5212-x	46	27	28	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2019	38	37					6414	6428		10.1038/s41388-019-0888-1	http://dx.doi.org/10.1038/s41388-019-0888-1			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IX6FR	31332287	Green Published, hybrid			2022-12-28	WOS:000485778800002
J	Alasiri, G; Jiramongkol, Y; Zona, S; Fan, LYN; Mahmud, Z; Gong, G; Lee, HJ; Lam, EWF				Alasiri, Glowi; Jiramongkol, Yannasittha; Zona, Stefania; Fan, Lavender Y. N.; Mahmud, Zimam; Gong, Gyungyub; Lee, Hee Jin; Lam, Eric W-F			Regulation of PERK expression by FOXO3: a vulnerability of drug-resistant cancer cells	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM STRESS; DNA-DAMAGE RESPONSE; ER STRESS; BREAST-CANCER; TRANSCRIPTION FACTOR; FOXM1 EXPRESSION; GEFITINIB IRESSA; KINASE; INHIBITOR; AUTOPHAGY	The major impediment to effective cancer therapy has been the development of drug resistance. The tumour suppressive transcription factor FOXO3 promotes cell cycle arrest, senescence and cell death, and mediates the cytotoxic and cytostatic functions of cancer therapeutics. In consequence, FOXO3 is often downregulated as an adaptive response in cancer and particularly in chemotherapeutic drug-resistant cells. Consistently, we find that FOXO3 expression is attenuated in the drug-resistant MCF-7-Epi(R) and MCF-7-Tax(R) compared to the parental MCF-7 breast cancer cells. Using ChIP, short-interfering RNA (siRNA) knockdown, and overexpression assays as well as Foxo(1/3/4-/-) MEFs, we establish the endoplasmic reticulum (ER)-stress defence modulator PERK (eIF2AK3) as a direct downstream transcriptional target of FOXO3. In agreement, there is also a positive correlation between FOXO3 and PERK expression at the protein and RNA levels in breast cancer patient samples. We uncover that PERK expression is downregulated but its activity constitutively elevated in the drug-resistant cells. With this in mind, we exploit this adaptive response of low FOXO3 and PERK expression, and high PERK activity in drug-resistant breast cancer cells and show that these drug-resistant cells are specifically sensitive to PERK inhibition. In support of this finding, we show that ectopic overexpression of FOXO3 can reduce the sensitivity of the resistant cells to the PERK inhibitor GSK2606414, while the Foxo(1/3/4-/-) MEFs expressing lower levels of PERK are more sensitive to PERK inhibition compared to wild-type MEFs. PERK inhibitor-titration and -time course experiments showed that the drug-resistant cells, which express lower expression and higher activity levels of PERK, are more sensitive to the increasing concentrations of PERK inhibitor compared to parental MCF-7 cells. Our present work thus reveals a chemotherapeutic drug-resistant cancer cell vulnerability in PERK and suggests PERK as a potential target for cancer therapy, specifically in the context of drug-resistant cancers.	[Alasiri, Glowi; Jiramongkol, Yannasittha; Zona, Stefania; Fan, Lavender Y. N.; Mahmud, Zimam; Lam, Eric W-F] Imperial Coll London, Dept Surg & Canc, Hammersmith Hosp Campus, London W12 0NN, England; [Gong, Gyungyub; Lee, Hee Jin] Univ Ulsan, Asan Med Ctr, Dept Pathol, Coll Med, Seoul, South Korea	Imperial College London; University of Ulsan; Asan Medical Center	Lam, EWF (corresponding author), Imperial Coll London, Dept Surg & Canc, Hammersmith Hosp Campus, London W12 0NN, England.	eric.lam@imperial.ac.uk	Lam, Eric W-F/AAW-8566-2020	Lam, Eric W-F/0000-0003-1274-3576; Jiramongkol, Yannasittha/0000-0003-1824-4313; Lee, Hee Jin/0000-0002-4963-6603	MRC [MR/N012097/1]; CRUK [C37/A12011]; Breast Cancer Now [2012MayPR070, 2012NovPhD016, 2014NovPhD326]; Cancer Research UK Imperial Centre; NIHR Imperial BRC; Saudi Arabian Cultural Bureau in London [MSU434]; Medical Research Council (MRC) of UK [MR/N012097/1]; Commonwealth Scholarship Commission [BDCS-2015-63]; Korean Health Technology R&D Project, Ministry of Health Welfare [HI15C0708, HI17C0337]; Basic Science Research Programs through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT & Future Planning, Republic of Korea [NRF-2017R1D1A1B03027977]; Imperial ECMC	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); CRUK(Cancer Research UK); Breast Cancer Now; Cancer Research UK Imperial Centre; NIHR Imperial BRC; Saudi Arabian Cultural Bureau in London; Medical Research Council (MRC) of UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Commonwealth Scholarship Commission; Korean Health Technology R&D Project, Ministry of Health Welfare; Basic Science Research Programs through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT & Future Planning, Republic of Korea; Imperial ECMC	Eric W.-F. Lam's work is supported by MRC (MR/N012097/1), CRUK (C37/A12011), Breast Cancer Now (2012MayPR070; 2012NovPhD016; 2014NovPhD326), the Cancer Research UK Imperial Centre, Imperial ECMC and NIHR Imperial BRC. Glowi Alasiri is a recipient of a scholarship from the Saudi Arabian Cultural Bureau in London (MSU434). Stefania Zona was a post-doctoral research associate supported by the Medical Research Council (MRC) of UK (MR/N012097/1) and Breast Cancer Now (2012MayPR070). Zimam Mahmud was supported by a fellowship from the Commonwealth Scholarship Commission (BDCS-2015-63). Gyungyub Gong and Hee Jin Lee are supported by The Korean Health Technology R&D Project, Ministry of Health & Welfare (HI15C0708 and HI17C0337) and Basic Science Research Programs through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning, Republic of Korea (NRF-2017R1D1A1B03027977).	Alasiri G, 2018, MOL CELL ENDOCRINOL, V462, P67, DOI 10.1016/j.mce.2017.05.027; Axten JM, 2012, J MED CHEM, V55, P7193, DOI 10.1021/jm300713s; Bella L, 2014, SEMIN CANCER BIOL, V29, P32, DOI 10.1016/j.semcancer.2014.07.008; Bhattacharyya S, 2014, NAT REV MOL CELL BIO, V15, P122, DOI 10.1038/nrm3741; Bines J, 2014, ANN ONCOL, V25, P1079, DOI 10.1093/annonc/mdu007; Bobrovnikova-Marjon E, 2012, MOL CELL BIOL, V32, P2268, DOI 10.1128/MCB.00063-12; Bu YW, 2016, J CELL PHYSIOL, V231, P2088, DOI 10.1002/jcp.25336; Chen JR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013704; Clarke HJ, 2014, CANCER CELL, V25, P563, DOI 10.1016/j.ccr.2014.03.015; de Moraes GN, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2015.26; de Moraes GN, 2016, CURR DRUG TARGETS, V17, P164, DOI 10.2174/1389450115666141122211549; de Olano N, 2012, MOL CANCER RES, V10, P1189, DOI 10.1158/1541-7786.MCR-11-0559; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Eijkelenboom A, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2012.74; Essafi A, 2005, ONCOGENE, V24, P2317, DOI 10.1038/sj.onc.1208421; Essaghir A, 2009, J BIOL CHEM, V284, P10334, DOI 10.1074/jbc.M808848200; Francis RE, 2009, INT J ONCOL, V35, P57, DOI 10.3892/ijo_00000313; Garg Abhishek D, 2015, Mol Cell Oncol, V2, pe975089, DOI 10.4161/23723556.2014.975089; Guertin DA, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.267pe24; Ho KK, 2008, ONCOGENE, V27, P2300, DOI 10.1038/onc.2008.23; Ho KK, 2012, J BIOL CHEM, V287, P1545, DOI 10.1074/jbc.M111.284224; Hui RCY, 2008, MOL CANCER THER, V7, P670, DOI 10.1158/1535-7163.MCT-07-0397; Im J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0652-4; Intuyod K, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1235-0; Ji GR, 2015, INT J BIOL SCI, V11, P803, DOI 10.7150/ijbs.11100; Jiang YQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065756; Kajihara T, 2006, MOL ENDOCRINOL, V20, P2444, DOI 10.1210/me.2006-0118; Karadedou CT, 2012, ONCOGENE, V31, P1845, DOI 10.1038/onc.2011.368; Khongkow M, 2013, CARCINOGENESIS, V34, P1476, DOI 10.1093/carcin/bgt098; Khongkow P, 2016, ONCOGENE, V35, P990, DOI 10.1038/onc.2015.152; Khongkow P, 2014, ONCOGENE, V33, P4144, DOI 10.1038/onc.2013.457; Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755; Koo CY, 2012, BBA-GENE REGUL MECH, V1819, P28, DOI 10.1016/j.bbagrm.2011.09.004; Krol J, 2007, MOL CANCER THER, V6, P3169, DOI 10.1158/1535-7163.MCT-07-0507; Kwok JMM, 2008, MOL CANCER THER, V7, P2022, DOI 10.1158/1535-7163.MCT-08-0188; Lam EWF, 2006, BIOCHEM SOC T, V34, P722, DOI 10.1042/BST0340722; Lam EWF, 2013, NAT REV CANCER, V13, P482, DOI 10.1038/nrc3539; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Lee HJ, 2015, VIRCHOWS ARCH, V467, P701, DOI 10.1007/s00428-015-1861-1; Lee JJ, 2016, INT J EXP PATHOL, V97, P170, DOI 10.1111/iep.12187; Ma XH, 2014, J CLIN INVEST, V124, P1406, DOI 10.1172/JCI70454; Mahoney E, 2013, AUTOPHAGY, V9, P434, DOI 10.4161/auto.23027; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; McGovern UB, 2009, MOL CANCER THER, V8, P582, DOI 10.1158/1535-7163.MCT-08-0805; Mujtaba T, 2011, DISCOV MED, V12, P471; Myatt S.S., 2008, CANCER, V8, P242, DOI DOI 10.1038/NRC2223-C2; Nabholtz JM, 2001, ONCOLOGIST, V6, P5, DOI 10.1634/theoncologist.6-suppl_3-5; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Pytel D, 2016, ONCOGENE, V35, P1207, DOI 10.1038/onc.2015.178; Salaroglio IC, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0657-0; Sunters A, 2006, CANCER RES, V66, P212, DOI 10.1158/0008-5472.CAN-05-1997; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Urra H, 2016, TRENDS CANCER, V2, P252, DOI 10.1016/j.trecan.2016.03.007; van der Vos KE, 2012, NAT CELL BIOL, V14, P829, DOI 10.1038/ncb2536; Varghese V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38017-0; Xie J, 2010, ONCOGENE, V29, P2499, DOI 10.1038/onc.2010.18; Yecies JL, 2011, CANCER RES, V71, P2815, DOI 10.1158/0008-5472.CAN-10-4158; Zhang W, 2015, CELL SIGNAL, V27, P436, DOI 10.1016/j.cellsig.2014.12.010; Zhang W, 2013, GENE DEV, V27, P441, DOI 10.1101/gad.201731.112; Zona S, 2014, BBA-GENE REGUL MECH, V1839, P1316, DOI 10.1016/j.bbagrm.2014.09.016	60	20	20	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2019	38	36					6382	6398		10.1038/s41388-019-0890-7	http://dx.doi.org/10.1038/s41388-019-0890-7			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IX6EX	31312024	Green Published, hybrid			2022-12-28	WOS:000485776800005
J	Chen, XH; Mangala, LS; Mooberry, L; Bayraktar, E; Dasari, SK; Ma, SL; Ivan, C; Court, KA; Rodriguez-Aguayo, C; Bayraktar, R; Raut, S; Sabnis, N; Kong, XC; Yang, XB; Lopez-Berestein, G; Lacko, AG; Sood, AK				Chen, Xiuhui; Mangala, Lingegowda S.; Mooberry, Linda; Bayraktar, Emine; Dasari, Santosh K.; Ma, Shaolin; Ivan, Cristina; Court, Karem A.; Rodriguez-Aguayo, Cristian; Bayraktar, Recep; Raut, Sangram; Sabnis, Nirupama; Kong, Xianchao; Yang, Xianbin; Lopez-Berestein, Gabriel; Lacko, Andras G.; Sood, Anil K.			Identifying and targeting angiogenesis-related microRNAs in ovarian cancer	ONCOGENE			English	Article							HIGH-DENSITY-LIPOPROTEIN; ENDOTHELIAL GROWTH-FACTOR; TUMOR-GROWTH; MIR-204; DELIVERY; EXPRESSION; PACLITAXEL; THERAPY; THROMBOSPONDIN-1; IDENTIFICATION	Current anti-angiogenic therapy for cancer is based mainly on inhibition of the vascular endothelial growth factor pathway. However, due to the transient and only modest benefit from such therapy, additional approaches are needed. Deregulation of microRNAs (miRNAs) has been demonstrated to be involved in tumor angiogenesis and offers opportunities for a new therapeutic approach. However, effective miRNA-delivery systems are needed for such approaches to be successful. In this study, miRNA profiling of patient data sets, along with in vitro and in vivo experiments, revealed that miR-204-5p could promote angiogenesis in ovarian tumors through THBS1. By binding with scavenger receptor class B type 1 (SCARB1), reconstituted high-density lipoprotein-nanoparticles (rHDL-NPs) were effective in delivering miR-204-5p inhibitor (miR-204-5p-inh) to tumor sites to suppress tumor growth. These results offer a new understanding of miR-204-5p in regulating tumor angiogenesis.	[Chen, Xiuhui; Mangala, Lingegowda S.; Bayraktar, Emine; Dasari, Santosh K.; Ma, Shaolin; Court, Karem A.; Sood, Anil K.] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA; [Chen, Xiuhui; Kong, Xianchao] Harbin Med Univ, Affiliated Hosp 2, Dept Obstet & Gynecol, Harbin, Heilongjiang, Peoples R China; [Mangala, Lingegowda S.; Bayraktar, Emine; Ivan, Cristina; Rodriguez-Aguayo, Cristian; Lopez-Berestein, Gabriel; Sood, Anil K.] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNAs, Houston, TX 77030 USA; [Mooberry, Linda; Raut, Sangram; Sabnis, Nirupama; Lacko, Andras G.] Univ North Texas, Hlth Sci Ctr, Dept Physiol & Anat, Ft Worth, TX USA; [Ivan, Cristina; Rodriguez-Aguayo, Cristian; Bayraktar, Recep; Lopez-Berestein, Gabriel] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Yang, Xianbin] AM Biotechnol, Houston, TX USA; [Lacko, Andras G.] Univ North Texas, Hlth Sci Ctr, Dept Pediat, Ft Worth, TX USA; [Sood, Anil K.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Harbin Medical University; University of Texas System; UTMD Anderson Cancer Center; University of North Texas System; University of North Texas Denton; University of Texas System; UTMD Anderson Cancer Center; University of North Texas System; University of North Texas Denton; University of Texas System; UTMD Anderson Cancer Center	Mangala, LS; Sood, AK (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA.; Mangala, LS; Sood, AK (corresponding author), Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNAs, Houston, TX 77030 USA.; Sood, AK (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA.	lsmangala@mdanderson.org; asood@mdanderson.org	Sood, Anoop Kumar/A-7344-2013; dasari, santosh kumar/V-3867-2019; Chen, Xiuhui/CAE-9641-2022; Court, Karem A./C-2328-2014	Sood, Anoop Kumar/0000-0001-5702-4108; dasari, santosh kumar/0000-0003-3078-3424; Court, Karem A./0000-0002-6334-6960; Bayraktar, Recep/0000-0002-8227-2055; RODRIGUEZ-AGUAYO, CRISTIAN/0000-0002-7880-7723; Chen, Xiuhui/0000-0002-7184-9568; Bayraktar, Emine/0000-0002-5189-1507; Ivan, Cristina/0000-0002-4848-0168	National Institutes of Health [CA016672, UH3TR000943, P50 CA217685, P50 CA098258, R35 CA209904]; Ovarian Cancer Research Fund, Inc.; Blanton-Davis Ovarian Cancer Research Program; American Cancer Society Research Professor Award; Frank McGraw Memorial Chair in Cancer Research; CPRIT [DP150091]; Foundation for Women's Cancer Grant; SPORE in Ovarian Cancer at MD Anderson [P50 CA217685]; NATIONAL CANCER INSTITUTE [R35CA209904, P50CA217685, P50CA098258] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ovarian Cancer Research Fund, Inc.; Blanton-Davis Ovarian Cancer Research Program; American Cancer Society Research Professor Award(American Cancer Society); Frank McGraw Memorial Chair in Cancer Research; CPRIT; Foundation for Women's Cancer Grant; SPORE in Ovarian Cancer at MD Anderson; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported, in part, by the National Institutes of Health (CA016672, UH3TR000943, P50 CA217685, P50 CA098258, R35 CA209904), Ovarian Cancer Research Fund, Inc. (Program Project Development Grant), Mr. and Mrs. Daniel P. Gordon, The Blanton-Davis Ovarian Cancer Research Program, the American Cancer Society Research Professor Award, and the Frank McGraw Memorial Chair in Cancer Research (AKS) and CPRIT (DP150091; LSM). SKD was supported by Foundation for Women's Cancer Grant, CRA was supported by the P50 CA217685 from the SPORE in Ovarian Cancer at MD Anderson.	Al-Abd AM, 2017, J ADV RES, V8, P591, DOI 10.1016/j.jare.2017.06.006; Armstrong DK, 2006, NEW ENGL J MED, V354, P34, DOI 10.1056/NEJMoa052985; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Cao YH, 2016, CHIN J CANCER, V35, DOI 10.1186/s40880-016-0084-4; Courboulin A, 2011, J EXP MED, V208, P535, DOI 10.1084/jem.20101812; Dey N, 2015, AM J TRANSL RES, V7, P1675; Dunn LL, 2014, DIABETES, V63, P675, DOI 10.2337/db13-0417; Flores-Perez A, 2016, SCI REP-UK, V6, DOI 10.1038/srep34504; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Hausser J, 2014, NAT REV GENET, V15, P599, DOI 10.1038/nrg3765; Huang J, 2010, STEM CELLS, V28, P357, DOI 10.1002/stem.288; Imam JS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052397; Inforzato A, 2010, J BIOL CHEM, V285, P17681, DOI 10.1074/jbc.M109.085639; Jayson GC, 2016, LANCET, V388, P518, DOI 10.1016/S0140-6736(15)01088-0; Johnson R, 2017, BREAST CANCER-TARGET, V9, P383, DOI 10.2147/BCTT.S131038; Kaalund SS, 2014, EPILEPSIA, V55, P2017, DOI 10.1111/epi.12839; Kang Y, 2013, JNCI-J NATL CANCER I, V105, P1485, DOI 10.1093/jnci/djt210; Kuai R, 2017, INT J NANOMED, V12, P6581, DOI 10.2147/IJN.S140591; Kuai R, 2016, ACS NANO, V10, P3015, DOI 10.1021/acsnano.5b07522; Lacko AG, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00247; Lawler J, 2002, J CELL MOL MED, V6, P1, DOI 10.1111/j.1582-4934.2002.tb00307.x; Lawler PR, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006627; Lee H, 2016, SCI REP-UK, V6, DOI 10.1038/srep25287; Li Y, 2017, CANCER LETT, V397, P111, DOI 10.1016/j.canlet.2017.03.032; Lu CH, 2010, CANCER CELL, V18, P185, DOI 10.1016/j.ccr.2010.06.016; MacFarlane LA, 2010, CURR GENOMICS, V11, P537, DOI 10.2174/138920210793175895; Mooberry LK, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00466; Mutharasan RK, 2016, J MATER CHEM B, V4, P188, DOI 10.1039/c5tb01332a; Niu G, 2010, CURR DRUG TARGETS, V11, P1000, DOI 10.2174/138945010791591395; Ohana R, 2015, DEVELOPMENT, V142, P2487, DOI 10.1242/dev.121533; Pecot CV, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3427; Qiu YH, 2013, CELL PHYSIOL BIOCHEM, V32, P1331, DOI 10.1159/000354531; Rajora MA, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00326; Resovi A, 2014, MATRIX BIOL, V37, P83, DOI 10.1016/j.matbio.2014.01.012; Rodrigueza WV, 1999, J BIOL CHEM, V274, P20344, DOI 10.1074/jbc.274.29.20344; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shahzad MMK, 2011, NEOPLASIA, V13, P309, DOI 10.1593/neo.101372; Simonsen JB, 2016, NANOMED-NANOTECHNOL, V12, P2161, DOI 10.1016/j.nano.2016.05.009; Son JC, 2017, CANCER INFORM, V16, DOI 10.1177/1176935117702878; Tatiparti K, 2017, NANOMATERIALS-BASEL, V7, DOI 10.3390/nano7040077; Todorova K, 2017, HORM CANCER-US, V8, P28, DOI 10.1007/s12672-016-0279-9; Vickers KC, 2014, J LIPID RES, V55, P4, DOI 10.1194/jlr.R035964; Vickers KC, 2011, NAT CELL BIOL, V13, P423, DOI 10.1038/ncb2210; Wang W, 2014, ONCOL REP, V32, P2127, DOI 10.3892/or.2014.3439; Wang XJ, 2016, BIOMED PHARMACOTHER, V82, P202, DOI 10.1016/j.biopha.2016.04.060; Wu SY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11169; Xu GL, 2016, MOL ENDOCRINOL, V30, P917, DOI 10.1210/me.2016-1056; Yan HL, 2015, INT J GYNECOL CANCER, V25, P944, DOI 10.1097/IGC.0000000000000456; Yu B, 2013, BLOOD, V121, P136, DOI 10.1182/blood-2012-01-407742; Zhang FR, 2016, EUR J PHARM SCI, V92, P11, DOI 10.1016/j.ejps.2016.06.017; Zhang J, 2012, MODERN PATHOL, V25, P456, DOI 10.1038/modpathol.2011.170; Zhang WC, 2014, TUMOR BIOL, V35, P6235, DOI 10.1007/s13277-014-2202-8; Zhao Y, 2014, BIOCHEM BIOPH RES CO, V454, P183, DOI 10.1016/j.bbrc.2014.10.068	53	30	33	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2019	38	33					6095	6108		10.1038/s41388-019-0862-y	http://dx.doi.org/10.1038/s41388-019-0862-y			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IR6TP	31289363	Green Accepted			2022-12-28	WOS:000481572400002
J	Crawford, NT; McIntyre, AJ; McCormick, A; D'Costa, ZC; Buckley, NE; Mullan, PB				Crawford, N. T.; McIntyre, A. J.; McCormick, A.; D'Costa, Z. C.; Buckley, N. E.; Mullan, P. B.			TBX2 interacts with heterochromatin protein 1 to recruit a novel repression complex to EGR1-targeted promoters to drive the proliferation of breast cancer cells	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; HISTONE H3; EXPRESSION; METHYLATION; MECHANISM; GROWTH; G9A; PROGRESSION; SENESCENCE; BYPASS	Early Growth Response 1 (EGR1) is a stress response transcription factor with multiple tumour suppressor roles in breast tissue, whose expression is often lost in breast cancers. We have previously shown that the breast cancer oncogene TBX2 (T-BOX2) interacts with EGR1 to co-repress EGR1-target genes including the breast tumour suppressor NDRG1. Here, we show the mechanistic basis of this TBX2 repression complex. We show that siRNA knockdown of TBX2, EGR1, Heterochromatin Protein 1 (HP1) isoforms and the generic HP1-associated corepressor protein KAP1 all resulted in growth inhibition of TBX2-expressing breast cancer cells. We show that TBX2 interacts with HP1 through a conserved HP1-binding motif in its N-terminus, which in turn leads to the recruitment of KAP1 and other associated proteins. Mutation of the TBX2 HP1 binding domain abrogates the TBX2-HP1 interaction and loss of repression of target genes such as NDRG1. Chromatin-immunoprecipitation (ChIP) assays showed that TBX2 establishes a repressive chromatin mark, specifically H3K9me3, around the NDRG1 proximal promoter coincident with the recruitment of the DNA methyltransferase DNMT3B and histone methyltransferase (HMT) complex components (G9A, Enhancer of Zeste 2 (EZH2) and Suppressor of Zeste 12 (SUZ12)). Knockdown of G9A, EZH2 or SUZ12 resulted in upregulation of TBX2/EGR1 co-regulated targets accompanied by a dramatic inhibition of cell proliferation. We show that a generic inhibitor of HMT activity, DzNep, phenocopies expression of an inducible dominant negative TBX2. Knockdown of TBX2, KAP1 or HP1 inhibited NDRG1 promoter decoration specifically with the H3K9me3 repression mark. Correspondingly, treatment with a G9A inhibitor effectively reversed TBX2 repression of NDRG1 and synergistically downregulated cell proliferation following TBX2 functional inhibition. These data demonstrate that TBX2 promotes suppression of normal growth control mechanisms through recruitment of a large repression complex to EGR1-responsive promoters leading to the uncontrolled proliferation of breast cancer cells.	[Crawford, N. T.; McIntyre, A. J.; McCormick, A.; D'Costa, Z. C.; Buckley, N. E.; Mullan, P. B.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast BT9 7BL, Antrim, North Ireland	Queens University Belfast	Mullan, PB (corresponding author), Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast BT9 7BL, Antrim, North Ireland.	p.mullan@qub.ac.uk		Crawford, Nyree/0000-0003-2258-4687; Buckley, Niamh/0000-0001-9326-8513; McIntyre, Alexander/0000-0002-8411-2581	Breast Cancer Campaign; NEC; AMCI; AMCC; ZCD'C; NEB; PBM	Breast Cancer Campaign; NEC; AMCI; AMCC; ZCD'C; NEB; PBM	Special thanks to Dr James Murray (Trinity College Dublin) for the kind gift of sheep anti-human NDRG1 antibody and Professor Max Costa (University of New York) for NDRG1 promoter luciferase constructs. This work was supported by grants from the Breast Cancer Campaign and Breast Cancer Now (NEC, AMCI, AMCC, ZCD'C, NEB, PBM).	Abrahams A, 2010, IUBMB LIFE, V62, P92, DOI 10.1002/iub.275; Adem C, 2004, GENE CHROMOSOME CANC, V41, P1, DOI 10.1002/gcc.20057; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Barlund M, 2000, CANCER RES, V60, P5340; Buckley NE, 2007, MOL CANCER RES, V5, P261, DOI 10.1158/1541-7786.MCR-06-0250; Chapman DL, 1996, DEV DYNAM, V206, P379, DOI 10.1002/(SICI)1097-0177(199608)206:4<379::AID-AJA4>3.0.CO;2-F; Cowieson NP, 2000, CURR BIOL, V10, P517, DOI 10.1016/S0960-9822(00)00467-X; de Belle I, 1999, ONCOGENE, V18, P3633, DOI 10.1038/sj.onc.1202696; de la Cruz CC, 2007, CHROMOSOME RES, V15, P2007, DOI 10.1007/s10577-007-1126-1; Della Ragione F, 2003, J BIOL CHEM, V278, P23360, DOI 10.1074/jbc.M300771200; Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Frietze S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015082; Granit RZ, 2013, ONCOGENE, V32, P3886, DOI 10.1038/onc.2012.390; Hartman ZC, 2013, CANCER RES, V73, P3470, DOI 10.1158/0008-5472.CAN-12-4524-T; Hosey AM, 2007, J NATL CANCER I, V99, P1683, DOI 10.1093/jnci/djm207; Ismail A, 2009, CANCER LETT, V278, P230, DOI 10.1016/j.canlet.2009.01.006; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Krones-Herzig A, 2003, P NATL ACAD SCI USA, V100, P3233, DOI 10.1073/pnas.2628034100; Kwon SH, 2010, GENE DEV, V24, P2133, DOI 10.1101/gad.1959110; Li YH, 2002, P NATL ACAD SCI USA, V99, P16462, DOI 10.1073/pnas.162371699; Martin N, 2012, EMBO J, V31, P95, DOI 10.1038/emboj.2011.370; Moore HM, 2013, BREAST CANCER RES TR, V138, P741, DOI 10.1007/s10549-013-2498-x; Prince S, 2004, CANCER RES, V64, P1669, DOI 10.1158/0008-5472.CAN-03-3286; Purcell DJ, 2012, J CELL BIOCHEM, V113, P2406, DOI 10.1002/jcb.24114; Redmond KL, 2010, ONCOGENE, V29, P3252, DOI 10.1038/onc.2010.84; Roll JD, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-15; Roylance R, 1999, CANCER RES, V59, P1433; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; Sinclair CS, 2002, CANCER RES, V62, P3587; Tirkkonen M, 1997, CANCER RES, V57, P1222; Vance KW, 2010, MOL BIOL CELL, V21, P2770, DOI 10.1091/mbc.E09-12-1029; Vance KW, 2005, CANCER RES, V65, P2260, DOI 10.1158/0008-5472.CAN-04-3045; Vormer TL, 2008, MOL CELL BIOL, V28, P7263, DOI 10.1128/MCB.00313-08; Wang B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041355; Wozniak RJ, 2007, ONCOGENE, V26, P77, DOI 10.1038/sj.onc.1209763; Wu H, 2010, PLOS ONE, V5, DOI [10.1371/journal.pone.0008570, 10.1371/journal.pone.0013316]; Yu HX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051239	38	24	25	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2019	38	31					5971	5986		10.1038/s41388-019-0853-z	http://dx.doi.org/10.1038/s41388-019-0853-z			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IT3GE	31253870	Green Accepted			2022-12-28	WOS:000482740000005
J	Babicky, ML; Harper, MM; Chakedis, J; Cazes, A; Mose, ES; Jaquish, DV; French, RP; Childers, B; Alakus, H; Schmid, MC; Foubert, P; Miyamoto, J; Holman, PJ; Walterscheid, ZJ; Tang, CM; Varki, N; Sicklick, JK; Messer, K; Varner, JA; Waltz, SE; Lowy, AM				Babicky, Michele L.; Harper, Megan M.; Chakedis, Jeffery; Cazes, Alex; Mose, Evangeline S.; Jaquish, Dawn, V; French, Randall P.; Childers, Betzaira; Alakus, Hakan; Schmid, Michael C.; Foubert, Phillippe; Miyamoto, Jaclyn; Holman, Patrick J.; Walterscheid, Zakkary J.; Tang, Chih-Min; Varki, Nissi; Sicklick, Jason K.; Messer, Karen; Varner, Judith A.; Waltz, Susan E.; Lowy, Andrew M.			MST1R kinase accelerates pancreatic cancer progression via effects on both epithelial cells and macrophages	ONCOGENE			English	Article							DUCTAL ADENOCARCINOMA; TUMOR-GROWTH; EXPRESSION; PROMOTES; POLARIZATION; ACTIVATION; COOPERATE; SURVIVAL; KRAS	The MST1R (RON) kinase is overexpressed in >80% of human pancreatic cancers, but its role in pancreatic carcinogenesis is unknown. In this study, we examined the relevance of Mst1r kinase to Kras driven pancreatic carcinogenesis using genetically engineered mouse models. In the setting of mutant Kras, Mst1r overexpression increased acinar-ductal metaplasia (ADM), accelerated the progression of pancreatic intraepithelial neoplasia (PanIN), and resulted in the accumulation of (mannose receptor C type 1) MRC1+, (arginase 1) Arg+ macrophages in the tumor microenvironment. Conversely, absence of a functional Mst1r kinase slowed PanIN initiation, resulted in smaller tumors, prolonged survival and a reduced tumor-associated macrophage content. Mst1r expression was associated with increased production of its ligand Mst1, and in orthotopic models, suppression of Mst1 expression resulted in reduced tumor size, changes in macrophage polarization and enhanced T cell infiltration. This study demonstrates the functional significance of Mst1r during pancreatic cancer initiation and progression. Further, it provides proof of concept that targeting Mst1r can modulate pancreatic cancer growth and the microenvironment. This study provides further rationale for targeting Mst1r as a therapeutic strategy.	[Babicky, Michele L.; Harper, Megan M.; Chakedis, Jeffery; Cazes, Alex; Mose, Evangeline S.; Jaquish, Dawn, V; French, Randall P.; Childers, Betzaira; Alakus, Hakan; Miyamoto, Jaclyn; Holman, Patrick J.; Walterscheid, Zakkary J.; Tang, Chih-Min; Sicklick, Jason K.; Lowy, Andrew M.] Univ Calif San Diego, Div Surg Oncol, Dept Surg, La Jolla, CA 92093 USA; [Schmid, Michael C.; Foubert, Phillippe; Varner, Judith A.] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; [Varki, Nissi; Messer, Karen] Univ Calif San Diego, Dept Family Med & Epidemiol, La Jolla, CA 92093 USA; [Waltz, Susan E.] Univ Cincinnati, Dept Canc Biol, Coll Med, Cincinnati, OH 45267 USA; [Waltz, Susan E.] Cincinnati Vet Adm Med Ctr, Res Serv, Cincinnati, OH 45267 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center	Lowy, AM (corresponding author), Univ Calif San Diego, Div Surg Oncol, Dept Surg, La Jolla, CA 92093 USA.	alowy@ucsd.edu	Cazes, Alex/K-9899-2019	Childers, Betzaira/0000-0002-0173-4132; Harper, Megan/0000-0002-2935-6292; Schmid, Michael/0000-0002-3445-0013; Waltz, Susan/0000-0003-3572-4642	NIH [CA155620, T32CA121938]; Ride the Point; Cure Pancreatic Cancer Fund; NATIONAL CANCER INSTITUTE [R01CA167426, T32CA121938, R01CA155620] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ride the Point; Cure Pancreatic Cancer Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH CA155620 (AML), NIH T32CA121938 (MLB), Ride the Point (AML) and generous gifts to the Sally Ride Fund for Pancreatic Cancer Research (AML) and the Cure Pancreatic Cancer Fund (AML).	Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; Baumgarth N, 2000, J IMMUNOL METHODS, V243, P77, DOI 10.1016/S0022-1759(00)00229-5; Bayne LJ, 2012, CANCER CELL, V21, P822, DOI 10.1016/j.ccr.2012.04.025; Benight NM, 2015, ONCOTARGET, V6, P17445, DOI 10.18632/oncotarget.3641; Bronte V, 2005, NAT REV IMMUNOL, V5, P641, DOI 10.1038/nri1668; Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490; Correll PH, 2004, J LEUKOCYTE BIOL, V75, P731, DOI 10.1189/jlb.0703347; Eyob H, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.25670; Gardner CR, 2012, TOXICOL APPL PHARM, V262, P139, DOI 10.1016/j.taap.2012.04.027; Gurusamy D, 2013, CANCER RES, V73, P1752, DOI 10.1158/0008-5472.CAN-12-2474; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Ko AH, 2015, J CLIN ONCOL, V33, P1779, DOI 10.1200/JCO.2014.59.7625; Liu QP, 1999, J IMMUNOL, V163, P6606; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Logan-Collins J, 2010, CANCER RES, V70, P1130, DOI 10.1158/0008-5472.CAN-09-0761; Martinez FO, 2006, J IMMUNOL, V177, P7303, DOI 10.4049/jimmunol.177.10.7303; Mazur PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013578; Monti P, 2003, CANCER RES, V63, P7451; Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325; Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024; Sanford DE, 2013, CLIN CANCER RES, V19, P3404, DOI 10.1158/1078-0432.CCR-13-0525; Schmid MC, 2010, J ONCOL, V2010, DOI 10.1155/2010/201026; Sharda DR, 2011, J IMMUNOL, V187, P2181, DOI 10.4049/jimmunol.1003460; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Tactacan CM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-395; Thobe MN, 2010, ONCOGENE, V29, P214, DOI 10.1038/onc.2009.331; Thomas RM, 2007, CANCER RES, V67, P6075, DOI 10.1158/0008-5472.CAN-06-4128; Tseng WW, 2010, CLIN CANCER RES, V16, P3684, DOI 10.1158/1078-0432.CCR-09-2384; Vasiliauskas J, 2014, ONCOTARGET, V5, P5547, DOI 10.18632/oncotarget.2139; Waltz SE, 2001, J CLIN INVEST, V108, P567, DOI 10.1172/JCI11881; Zhu Y, 2017, IMMUNITY, V47, P323, DOI 10.1016/j.immuni.2017.07.014; Zinser GM, 2006, CANCER RES, V66, P11967, DOI 10.1158/0008-5472.CAN-06-2473	33	25	28	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2019	38	28					5599	5611		10.1038/s41388-019-0811-9	http://dx.doi.org/10.1038/s41388-019-0811-9			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IH9RW	30967626	Green Accepted, Green Submitted			2022-12-28	WOS:000474845100004
J	Cui, YM; Wu, XQ; Lin, CY; Zhang, X; Ye, LP; Ren, LL; Chen, M; Yang, MSZ; Li, Y; Li, MF; Li, J; Guan, J; Song, LB				Cui, Yanmei; Wu, Xianqiu; Lin, Chuyong; Zhang, Xin; Ye, Liping; Ren, Liangliang; Chen, Min; Yang, Meisongzhu; Li, Yue; Li, Mengfeng; Li, Jun; Guan, Jian; Song, Libing			AKIP1 promotes early recurrence of hepatocellular carcinoma through activating the Wnt/beta-catenin/CBP signaling pathway	ONCOGENE			English	Article							APC TUMOR-SUPPRESSOR; PROTEIN-KINASE-A; BETA-CATENIN; CELL-LINE; CANCER; PHOSPHORYLATION; MUTATIONS; ASSOCIATION; CLONES; GENES	The early recurrence of hepatocellular carcinoma (HCC) is the main obstacle for long-term survival of patients. Wnt/beta-catenin signaling has been involved in the development and progression of HCC. However, the molecular changes that link Wnt/beta-catenin activation and HCC early recurrence remain poorly understood. Here we identified AKIP1 as a binding partner of beta-catenin. AKIP1 interacted with and sustained beta-catenin in the nuclear by blocking its interaction with adenomatous polyposis coli protein (APC). Moreover, AKIP1 enhanced the protein kinase A catalytic subunit (PKAc)-mediated phosphorylation of beta-catenin, leading to recruitment of cyclic AMP response element-binding protein (CBP) and activation of beta-catenin downstream transcription. Increased AKIP1 expression was observed in HCC clinical samples and correlated with early recurrence and poor prognosis of HCC. AKIP1 promoted invasion and colony outgrowth in vitro and increased intrahepatic and lung metastasis in vivo. Treatment with a CBP inhibitor ICG-001 effectively inhibited the metastatic progression of HCC tumors that had elevated AKIP1 in both cell line and patient-derived xenograft mouse models. Our findings not only establish AKIP1 as a novel regulator of Wnt/beta-catenin signaling as well as HCC early recurrence but also highlight targeting the AKIP1/beta-catenin/CBP axis as attractive therapies for combating HCC metastatic relapse.	[Cui, Yanmei; Wu, Xianqiu; Lin, Chuyong; Zhang, Xin; Ye, Liping; Ren, Liangliang; Li, Yue; Song, Libing] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Expt Res, State Key Lab Oncol Southern China,Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China; [Cui, Yanmei] Sun Yat Sen Univ, Affiliated Hosp 6, Guangdong Inst Gastroenterol, Guangdong Prov Key Lab Colorectal & Pelv Floor Di, Guangzhou 510655, Guangdong, Peoples R China; [Chen, Min; Guan, Jian] Sourthern Med Univ, Nanfang Hosp, Dept Radiat Oncol, Guangzhou 510515, Guangdong, Peoples R China; [Yang, Meisongzhu; Li, Jun] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, Guangzhou 510080, Guangdong, Peoples R China; [Li, Mengfeng] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Microbiol, Guangzhou 510080, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Southern Medical University - China; Sun Yat Sen University; Sun Yat Sen University	Song, LB (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Expt Res, State Key Lab Oncol Southern China,Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China.; Guan, J (corresponding author), Sourthern Med Univ, Nanfang Hosp, Dept Radiat Oncol, Guangzhou 510515, Guangdong, Peoples R China.; Li, J (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, Guangzhou 510080, Guangdong, Peoples R China.	lijun37@mail.sysu.edu.cn; guanjian5461@163.com; songlb@sysucc.org.cn	Ren, Liangliang/AAR-6436-2020; Zhang, Xin/C-2464-2017; Song, LB/AAL-1968-2020; Lin, Chuyong/AAA-9931-2020	Zhang, Xin/0000-0001-6036-2685; Lin, Chuyong/0000-0003-4887-5386	Natural Science Foundation of China [81572688, 81872386, 81530082, 81773106, 91740118, 81830082, 91740119, 91529301, 81621004, 81472546]; Natural Science Foundation of Guangdong Province [2016A030308002, 2018B030311060, 2018B030311009]; Science and Technology Program of Guangzhou [201504010015]; Guangzhou Science and Technology Plan Projects [201803010098]; Fundamental Research Funds for the Central Universities [17ykjc02]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Science and Technology Program of Guangzhou; Guangzhou Science and Technology Plan Projects; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This work was supported by The Natural Science Foundation of China (Nos. 81572688, 81872386, 81530082, 81773106, 91740118, 81830082, 91740119, 91529301, 81621004, 81472546); The Natural Science Foundation of Guangdong Province (Nos. 2016A030308002, 2018B030311060, 2018B030311009); The Science and Technology Program of Guangzhou (201504010015); Guangzhou Science and Technology Plan Projects (201803010098); and The Fundamental Research Funds for the Central Universities [No. 17ykjc02].	Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Anson M, 2012, J CLIN INVEST, V122, P586, DOI 10.1172/JCI43937; Arce L, 2006, ONCOGENE, V25, P7492, DOI 10.1038/sj.onc.1210056; Chen JX, 2016, GUT, V65, P1522, DOI 10.1136/gutjnl-2015-310625; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Cui YM, 2015, ONCOGENE, V34, P4379, DOI 10.1038/onc.2014.368; Dema A, 2016, J BIOL CHEM, V291, P19618, DOI 10.1074/jbc.M116.738047; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Gang EJ, 2014, ONCOGENE, V33, P2169, DOI 10.1038/onc.2013.169; Gao N, 2008, J BIOL CHEM, V283, P7834, DOI 10.1074/jbc.M710285200; Guichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Hoshida Y, 2009, CANCER RES, V69, P7385, DOI 10.1158/0008-5472.CAN-09-1089; Huang H, 1999, AM J PATHOL, V155, P1795, DOI 10.1016/S0002-9440(10)65496-X; Imamura H, 2003, J HEPATOL, V38, P200, DOI 10.1016/S0168-8278(02)00360-4; Kitching R, 2003, BBA-GENE STRUCT EXPR, V1625, P116, DOI 10.1016/S0167-4781(02)00562-6; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Li CC, 2016, P NATL ACAD SCI USA, V113, P5946, DOI 10.1073/pnas.1601918113; Li Y, 2001, WORLD J GASTROENTERO, V7, P630; Lin C, 2015, ONCOGENE, V34, P332, DOI 10.1038/onc.2013.559; Ma D, 2018, EXP CELL RES, V362, P142, DOI 10.1016/j.yexcr.2017.11.011; Marquardt JU, 2014, CANCER CELL, V25, P550, DOI 10.1016/j.ccr.2014.04.002; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nagaraj AB, 2015, ONCOTARGET, V6, P23720, DOI 10.18632/oncotarget.4690; Nguyen DX, 2009, CELL, V138, P51, DOI 10.1016/j.cell.2009.04.030; Pez F, 2013, J HEPATOL, V59, P1107, DOI 10.1016/j.jhep.2013.07.001; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Sasaki Y, 2006, ANN SURG, V244, P771, DOI 10.1097/01.sla.0000225126.56483.b3; Sastri M, 2005, P NATL ACAD SCI USA, V102, P349, DOI 10.1073/pnas.0408608102; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Taurin S, 2006, J BIOL CHEM, V281, P9971, DOI 10.1074/jbc.M508778200; Tian J, 1999, BRIT J CANCER, V81, P814, DOI 10.1038/sj.bjc.6690769; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; Wang WH, 2016, NEOPLASIA, V18, P711, DOI 10.1016/j.neo.2016.10.004; Wend P, 2013, EMBO J, V32, P1977, DOI 10.1038/emboj.2013.127; Xing Y, 2004, MOL CELL, V15, P523, DOI 10.1016/j.molcel.2004.08.001	42	31	33	3	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2019	38	27					5516	5529		10.1038/s41388-019-0807-5	http://dx.doi.org/10.1038/s41388-019-0807-5			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IG5KR	30936461				2022-12-28	WOS:000473842500013
J	Gowrikumar, S; Ahmad, R; Uppada, SB; Washington, MK; Shi, CJ; Singh, AB; Dhawan, P				Gowrikumar, Saiprasad; Ahmad, Rizwan; Uppada, Srijayaprakash Babu; Washington, Mary K.; Shi, Chanjuan; Singh, Amar B.; Dhawan, Punita			Upregulated claudin-1 expression promotes colitis-associated cancer by promoting beta-catenin phosphorylation and activation in Notch/p-AKT-dependent manner	ONCOGENE			English	Article							INFLAMMATORY-BOWEL-DISEASE; INTESTINAL STEM-CELLS; COLON-CANCER; COLORECTAL-CANCER; WNT/BETA-CATENIN; MODULATION; MODEL	In IBD patients, integration between a hyper-activated immune system and epithelial cell plasticity underlies colon cancer development. However, molecular regulation of such a circuity remains undefined. Claudin-1 (Cld-1), a tight-junction integral protein deregulation alters colonic epithelial cell (CEC) differentiation, and promotes colitis severity while impairing colitis-associated injury/repair. Tumorigenesis is a product of an unregulated wound-healing process and therefore we postulated that upregulated Cld-1 levels render IBD patients susceptible to the colitis-associated cancer (CAC). Villin Cld-1 mice are used to carryout overexpressed studies in mice. The role of deregulated Cld-1 expression in CAC and the underlying mechanism was determined using a well-constructed study scheme and mouse models of DSS colitis/recovery and CAC. Using an inclusive investigative scheme, we here report that upregulated Cld-1 expression promotes susceptibility to the CAC and its malignancy. Increased mucosal inflammation and defective epithelial homeostasis accompanied the increased CAC in Villin-Cld-1-Tg mice. We further found significantly increased levels of protumorigenic M2 macrophages and beta-cateninSer552 (beta-CatSer552) expression in the CAC in Cld-1 Tg vs. WT mice. Mechanistic studies identified the role of PI3K/Akt signaling in Cld-1 -dependent activation of the beta-CatSer552, which, in turn, was dependent on proinflammatory signals. Our studies identify a critical role of Cld-1 in promoting susceptibility to CAC. Importantly, these effects of deregulated Cld-1 were not associated with altered tight junction integrity, but on its noncanonical role in regulating Notch/PI3K/Wnt/beta-CatSer552 signaling. Overall, outcome from our current studies identifies Cld-1 as potential prognostic biomarker for IBD severity and CAC, and a novel therapeutic target.	[Gowrikumar, Saiprasad; Ahmad, Rizwan; Uppada, Srijayaprakash Babu; Singh, Amar B.; Dhawan, Punita] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Washington, Mary K.; Shi, Chanjuan] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; [Singh, Amar B.; Dhawan, Punita] VA Nebraska Western Iowa Hlth Care Syst, Omaha, NE 68198 USA; [Singh, Amar B.; Dhawan, Punita] Univ Nebraska Med Ctr, Buffet Canc Ctr, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Nebraska-Western Iowa Health Care System; University of Nebraska System; University of Nebraska Medical Center	Dhawan, P (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.; Dhawan, P (corresponding author), VA Nebraska Western Iowa Hlth Care Syst, Omaha, NE 68198 USA.; Dhawan, P (corresponding author), Univ Nebraska Med Ctr, Buffet Canc Ctr, Omaha, NE 68198 USA.	punita.dhawan@unmc.edu	Gowrikumar, Saiprasad/AAG-9611-2019; Uppada, Srijayaprakash/AAD-7728-2021		VA merit [BX002086, BX002761]; NIH/NCI [CA216746]; Fred and Pamela Buffet Cancer Center; National Cancer Institute Cancer Center Support Grant [P30 CA036727]; NIH/NIDDK [DK088902]; NATIONAL CANCER INSTITUTE [R21CA216746, P30CA036727] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002761, I01BX002086] Funding Source: NIH RePORTER	VA merit(US Department of Veterans Affairs); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Fred and Pamela Buffet Cancer Center; National Cancer Institute Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs(US Department of Veterans Affairs)	This study was supported by BX002086 (VA merit), CA216746 (NIH/NCI) and a pilot project award from Fred and Pamela Buffet Cancer Center, which is funded by a National Cancer Institute Cancer Center Support Grant under award number P30 CA036727 to P.D. and DK088902 (NIH/NIDDK) and BX002761 (VA merit) to A.B.S.	Ahmad R, 2017, ONCOGENE, V36, P6592, DOI 10.1038/onc.2017.259; Balint K, 2005, J CLIN INVEST, V115, P3166, DOI 10.1172/JCI25001; Breynaert C, 2008, ACTA GASTRO-ENT BELG, V71, P367; Brown JB, 2011, INFECT IMMUN, V79, P1863, DOI 10.1128/IAI.01025-10; Chassaing B., 2014, CURR PROTOC IMMUNOL, V104; Clapper ML, 2007, ACTA PHARMACOL SIN, V28, P1450, DOI 10.1111/j.1745-7254.2007.00695.x; Dave Maneesh, 2012, Gastroenterol Hepatol (N Y), V8, P29; Gonzalez ACD, 2016, AN BRAS DERMATOL, V91, P614, DOI 10.1590/abd1806-4841.20164741; Deitrick J, 2016, PROG MOL BIOL TRANSL, V144, P49, DOI 10.1016/bs.pmbts.2016.09.010; Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543; Erben U, 2014, INT J CLIN EXP PATHO, V7, P4557; Goretsky T, 2016, J BIOL CHEM, V291, P4166, DOI 10.1074/jbc.M115.669416; Gunzel D, 2013, PHYSIOL REV, V93, P525, DOI 10.1152/physrev.00019.2012; He XC, 2007, NAT GENET, V39, P189, DOI 10.1038/ng1928; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; Landy J, 2016, WORLD J GASTROENTERO, V22, P3117, DOI 10.3748/wjg.v22.i11.3117; Lee G, 2010, GASTROENTEROLOGY, V139, P869, DOI 10.1053/j.gastro.2010.05.037; Leong KG, 2007, J EXP MED, V204, P2935, DOI 10.1084/jem.20071082; Liu L, 2012, AM J PHYSIOL-CELL PH, V302, pC277, DOI 10.1152/ajpcell.00341.2011; Liu Y, 2014, CELL MOL IMMUNOL, V11, P49, DOI [10.1038/cmi.2013.40, 10.1038/cmi.2014.83]; Low D, 2014, INFLAMM BOWEL DIS, V20, P2115, DOI 10.1097/MIB.0000000000000094; Mendes RD, 2016, HAEMATOLOGICA, V101, P1010, DOI 10.3324/haematol.2016.146381; Miwa N, 2001, ONCOL RES, V12, P469, DOI 10.3727/096504001108747477; Villegas SN, 2018, CELL REP, V22, P2541, DOI 10.1016/j.celrep.2018.02.049; Neal MD, 2011, J SURG RES, V167, P1, DOI 10.1016/j.jss.2010.04.037; Ormanns S, 2014, ONCOTARGET, V5, P2999, DOI 10.18632/oncotarget.1626; Ouban A, 2018, HISTOL HISTOPATHOL, V33, P1013, DOI 10.14670/HH-11-980; Parang B, 2017, GUT, V66, P852, DOI 10.1136/gutjnl-2015-310255; Pope JL, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-167; Pope JL, 2014, GUT, V63, P622, DOI 10.1136/gutjnl-2012-304241; Sabatino L, 2014, WORLD J GASTROENTERO, V20, P7137, DOI 10.3748/wjg.v20.i23.7137; Sebio A, 2014, EXPERT OPIN THER TAR, V18, P611, DOI 10.1517/14728222.2014.906580; Sengupta N, 2016, DIGEST DIS SCI, V61, P980, DOI 10.1007/s10620-015-3979-z; Shiou SR, 2007, CANCER RES, V67, P1571, DOI 10.1158/0008-5472.CAN-06-1680; Singh AB, 2011, GASTROENTEROLOGY, V141, P2140, DOI 10.1053/j.gastro.2011.08.038; Snider AJ, 2016, METHODS MOL BIOL, V1438, P245, DOI 10.1007/978-1-4939-3661-8_14; Stidham RW, 2018, CLIN COLON RECT SURG, V31, P168, DOI 10.1055/s-0037-1602237; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; Ullman TA, 2011, GASTROENTEROLOGY, V140, P1807, DOI 10.1053/j.gastro.2011.01.057; Waniczek D, 2017, ARCH IMMUNOL THER EX, V65, P445, DOI 10.1007/s00005-017-0463-9; Wong GW, 2012, BLOOD, V120, P1439, DOI 10.1182/blood-2011-12-395319	41	19	20	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2019	38	26					5321	5337		10.1038/s41388-019-0795-5	http://dx.doi.org/10.1038/s41388-019-0795-5			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IF4AX	30971761	Green Accepted			2022-12-28	WOS:000473025300015
J	Li, BB; Hong, JX; Hong, M; Wang, YJ; Yu, TT; Zang, SB; Wu, QL				Li, Beibei; Hong, Jiaxin; Hong, Mei; Wang, Yajun; Yu, Tingting; Zang, Sibin; Wu, Qiuling			piRNA-823 delivered by multiple myeloma-derived extracellular vesicles promoted tumorigenesis through re-educating endothelial cells in the tumor environment	ONCOGENE			English	Article							NOVO DNA METHYLATION; BONE-MARROW MICROENVIRONMENT; LEUKEMIA-CELLS; SMALL RNA; EXOSOMES; MICROVESICLES; ANGIOGENESIS; CONTRIBUTES; PROTEINS; MIRNAS	Extracellular vesicles (EVs) can carry a wide array of RNAs in the tumor microenvironment, and are crucial for communication between tumor and surrounding stromal cells, including endothelial cells. Piwi-interacting RNAs (piRNAs) are important regulators implicated in the pathogenesis of multiple myeloma (MM). However, little is understood about the role of piRNA-823 in intercellular communication between MM and endothelial cells. In this study, we found that piRNA-823 mainly accumulated in EVs from peripheral blood of MM patients and EVs derived from MM cells (MM-derived-EVs). Increased piRNA-823 expression was associated with late stages and poor prognosis of MM. The MM-derived-EVs effectively transferred piRNA-823 to EA.hy926 endothelial cells. The piRNA-823 mimic and inhibitor were designed to upregulate or to suppress the endogenous function of piRNA-823. Transfection with piRNA-823 mimic or treatment with MM-derived-EVs significantly promoted the proliferation, tube formation, and invasion of EA.hy926 cells by enhancing the expression of VEGF, IL-6, and ICAM-1 and attenuating apoptosis. EA.hy926 cells transfected with piRNA-823 mimic or pre-treated with MM-derived-EVs promoted the growth of xenograft MM in mice. In contrast, the transfection with piRNA-823 inhibitor or treatment with EVs from piRNA-823 inhibitor-transfected-MM cells had diametrically opposite effects. Our findings demonstrated that piRNA-823 carried by MM-derived-EVs is essential for the re-education of ECs toward a unique environment amenable to the growth of MM cells by altering its biological characteristics. Our findings may pave the way for the development of new piRNA-mediated prognostic stratification and therapeutic strategies for MM.	[Li, Beibei; Hong, Jiaxin; Hong, Mei; Wang, Yajun; Yu, Tingting; Zang, Sibin; Wu, Qiuling] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Inst Hematol, Wuhan, Hubei, Peoples R China; [Hong, Jiaxin] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan, Hubei, Peoples R China; [Hong, Mei] Soochow Univ, Collaborat Innovat Ctr Hematol, Suzhou, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Soochow University - China	Wu, QL (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Inst Hematol, Wuhan, Hubei, Peoples R China.	wuqiuling927@qq.com	yu, tingting/HGA-4783-2022	Wu, Qiuling/0000-0001-6488-5731	National Natural Science Foundation of P.R China [30500686, 81770219]	National Natural Science Foundation of P.R China(National Natural Science Foundation of China (NSFC))	The authors would like to thank all the participants for their kind cooperation. The research was supported by the National Natural Science Foundation of P.R China (no. 30500686, for Q-LW) and (no. 81770219, for Q-LW).	Abdi J, 2014, BIOMARK RES, V2, DOI 10.1186/2050-7771-2-10; Aravin A, 2006, NATURE, V442, P203, DOI 10.1038/nature04916; Aravin AA, 2008, MOL CELL, V31, P785, DOI 10.1016/j.molcel.2008.09.003; Aravin AA, 2008, GENE DEV, V22, P970, DOI 10.1101/gad.1669408; Becker A, 2016, CANCER CELL, V30, P836, DOI 10.1016/j.ccell.2016.10.009; Canella A, 2016, EXPERT REV MOL DIAGN, V16, P277, DOI 10.1586/14737159.2016.1132627; Chantrain CF, 2008, CANCER MICROENVIRON, V1, P23, DOI 10.1007/s12307-008-0010-7; Cheng J, 2012, CANCER LETT, V315, P12, DOI 10.1016/j.canlet.2011.10.004; Cheng J, 2011, CLIN CHIM ACTA, V412, P1621, DOI 10.1016/j.cca.2011.05.015; Cui L, 2011, CLIN BIOCHEM, V44, P1050, DOI 10.1016/j.clinbiochem.2011.06.004; Girard A, 2006, NATURE, V442, P199, DOI 10.1038/nature04917; Grange C, 2006, ONCOL REP, V15, P381; Hida K, 2004, CANCER RES, V64, P8249, DOI 10.1158/0008-5472.CAN-04-1567; Jinek M, 2009, NATURE, V457, P405, DOI 10.1038/nature07755; Korn C, 2017, BLOOD, V129, P811, DOI 10.1182/blood-2016-09-670224; Ku HY, 2014, NATL SCI REV, V1, P205, DOI 10.1093/nsr/nwu014; Kuramochi-Miyagawa S, 2008, GENE DEV, V22, P908, DOI 10.1101/gad.1640708; Kyle RA, 2004, NEW ENGL J MED, V351, P1860, DOI 10.1056/NEJMra041875; Laffont B, 2013, BLOOD, V122, P253, DOI 10.1182/blood-2013-03-492801; Li J, 2013, J BIOL CHEM, V288, P23586, DOI 10.1074/jbc.M113.489302; Li LM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046957; Manier S, 2017, BLOOD, V129, P2429, DOI 10.1182/blood-2016-09-742296; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Mineo M, 2012, ANGIOGENESIS, V15, P33, DOI 10.1007/s10456-011-9241-1; Morgan GJ, 2012, NAT REV CANCER, V12, P335, DOI 10.1038/nrc3257; Nazarenko I, 2010, CANCER RES, V70, P1668, DOI 10.1158/0008-5472.CAN-09-2470; Ogata-Kawata H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092921; Paggetti J, 2015, BLOOD, V126, P1106, DOI 10.1182/blood-2014-12-618025; Pezzolo A, 2007, J CLIN ONCOL, V25, P376, DOI 10.1200/JCO.2006.09.0696; Raaijmakers MHGP, 2010, NATURE, V464, P852, DOI 10.1038/nature08851; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557; Rigolin GM, 2006, BLOOD, V107, P2531, DOI 10.1182/blood-2005-04-1768; Sarkar A, 2017, FASEB J, V31, P436, DOI 10.1096/fj.201600637RR; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; St Croix B, 2000, SCIENCE, V289, P1197; Streubel B, 2004, NEW ENGL J MED, V351, P250, DOI 10.1056/NEJMoa033153; Svensson KJ, 2013, BIOCHEM SOC T, V41, P273, DOI 10.1042/BST20120248; Tadokoro H, 2013, J BIOL CHEM, V288, P34343, DOI 10.1074/jbc.M113.480822; Taverna S, 2012, INT J CANCER, V130, P2033, DOI 10.1002/ijc.26217; Umezu T, 2013, ONCOGENE, V32, P2747, DOI 10.1038/onc.2012.295; Umezu T, 2014, BLOOD, V124, P3748, DOI 10.1182/blood-2014-05-576116; Wang JH, 2016, ONCOTARGET, V7, P38927, DOI 10.18632/oncotarget.7792; Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624; Wu QL, 2010, BIOCHEM BIOPH RES CO, V396, P915, DOI 10.1016/j.bbrc.2010.05.022; Yan H, 2015, LEUKEMIA, V29, P196, DOI 10.1038/leu.2014.135	46	69	69	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2019	38	26					5227	5238		10.1038/s41388-019-0788-4	http://dx.doi.org/10.1038/s41388-019-0788-4			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IF4AX	30890754				2022-12-28	WOS:000473025300008
J	Bai, SS; Cao, SB; Jin, LJ; Kobelski, M; Schouest, B; Wang, XJ; Ungerleider, N; Baddoo, M; Zhang, WS; Corey, E; Vessella, RL; Dong, XS; Zhang, K; Yu, XH; Flemington, EK; Dong, Y				Bai, Shanshan; Cao, Subing; Jin, Lianjin; Kobelski, Margaret; Schouest, Blake; Wang, Xiaojie; Ungerleider, Nathan; Baddoo, Melody; Zhang, Wensheng; Corey, Eva; Vessella, Robert L.; Dong, Xuesen; Zhang, Kun; Yu, Xianghui; Flemington, Erik K.; Dong, Yan			A positive role of c-Myc in regulating androgen receptor and its splice variants in prostate cancer	ONCOGENE			English	Article							FULL-LENGTH; CELL-LINE; RADICAL PROSTATECTOMY; GENOMIC CLASSIFIER; INCREASED SURVIVAL; EXPRESSION; RESISTANCE; ENZALUTAMIDE; PROGRESSION; ABIRATERONE	Increased expression of the full-length androgen receptor (AR-FL) and AR splice variants (AR-Vs) drives the progression of castration-resistant prostate cancer (CRPC). The levels of AR-FL and AR-V transcripts are often tightly correlated in individual CRPC samples, yet our understanding of how their expression is co-regulated is limited. Here, we report a role of c-Myc in accounting for coordinated AR-FL and AR-V expression. Analysis of gene-expression data from 159 metastatic CRPC samples and 2142 primary prostate tumors showed that the level of c-Myc is positively correlated with that of individual AR isoforms. A striking positive correlation also exists between the activity of the c-Myc pathway and the level of individual AR isoforms, between the level of c-Myc and the activity of the AR pathway, and between the activities of the two pathways. Moreover, the c-Myc signature is highly enriched in tumors expressing high levels of AR, as is the AR signature in c-Myc-high-expressing tumors. Using shRNA knockdown, we confirmed c-Myc regulation of expression and activity of AR-FL and AR-Vs in cell models and a patient-derived xenograft model. Mechanistically, c-Myc promotes the transcription of the AR gene and enhances the stability of the AR-FL and AR-V proteins without altering AR RNA splicing. Importantly, inhibiting c-Myc sensitizes enzalutamide-resistant cells to growth inhibition by enzalutamide. Overall, this study highlights a critical role of c-Myc in regulating the coordinated expression of AR-FL and AR-Vs that is commonly observed in CRPC and suggests the utility of targeting c-Myc as an adjuvant to AR-directed therapy.	[Bai, Shanshan; Wang, Xiaojie; Yu, Xianghui] Jilin Univ, Sch Life Sci, Changchun, Jilin, Peoples R China; [Bai, Shanshan; Cao, Subing; Jin, Lianjin; Kobelski, Margaret; Wang, Xiaojie; Dong, Yan] Tulane Univ, Dept Struct & Cellular Biol, Sch Med, Tulane Canc Ctr, New Orleans, LA 70118 USA; [Schouest, Blake; Ungerleider, Nathan; Baddoo, Melody; Flemington, Erik K.] Tulane Univ, Sch Med, Dept Pathol, Tulane Canc Ctr, New Orleans, LA 70118 USA; [Zhang, Wensheng; Zhang, Kun] Xavier Univ Louisiana, Bioinformat Facil, Dept Comp Sci, Xavier RCMI Ctr Canc Res, New Orleans, LA USA; [Corey, Eva; Vessella, Robert L.] Univ Washington, Dept Urol, Seattle, WA 98195 USA; [Dong, Xuesen] Univ British Columbia, Vancouver Prostate Ctr, Dept Urol Sci, Vancouver, BC, Canada	Jilin University; Tulane University; Tulane University; Xavier University of Louisiana; University of Washington; University of Washington Seattle; University of British Columbia	Dong, Y (corresponding author), Tulane Univ, Dept Struct & Cellular Biol, Sch Med, Tulane Canc Ctr, New Orleans, LA 70118 USA.; Flemington, EK (corresponding author), Tulane Univ, Sch Med, Dept Pathol, Tulane Canc Ctr, New Orleans, LA 70118 USA.	erik@tulane.edu; ydong@tulane.edu	Dong, Xuesen/AGF-9228-2022	Dong, Yan/0000-0003-1622-5354; Kobelski, Margaret/0000-0002-8829-4562	National Institutes of Health [R01CA188609, R01AI101046, R01AI106676, P01CA214091, RCMI 2G12MD007595, P20GM103518]; Department of Defense [W81XWH-15-1-0439, W81XWH-16-1-0317, W81XWH-16-1-0318, W81XWH-14-1-0485]; National Natural Science Foundation of China [81430087]; Richard M. Lucas Foundation; NATIONAL CANCER INSTITUTE [R01CA188609, P01CA214091, R21CA236549, R01CA243793] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI106676] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [G12MD007595, U54MD007595] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Richard M. Lucas Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	This work was supported by the following grants: the National Institutes of Health grants R01CA188609, R01AI101046, R01AI106676, P01CA214091, RCMI 2G12MD007595, and P20GM103518; Department of Defense grants W81XWH-15-1-0439, W81XWH-16-1-0317, W81XWH-16-1-0318, and W81XWH-14-1-0485; National Natural Science Foundation of China Project 81430087. The Richard M. Lucas Foundation supported the development of the LuCaP 35CR model. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.	Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; ASKEW DS, 1991, ONCOGENE, V6, P1915; Barfeld SJ, 2017, EBIOMEDICINE, V18, P83, DOI 10.1016/j.ebiom.2017.04.006; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Bluemn EG, 2017, CANCER CELL, V32, P474, DOI 10.1016/j.ccell.2017.09.003; Burnstein KL, 2005, J CELL BIOCHEM, V95, P657, DOI 10.1002/jcb.20460; Cao B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111201; Cao B, 2014, ONCOTARGET, V5, P1646, DOI 10.18632/oncotarget.1802; Cao B, 2013, INT J CANCER, V132, P1277, DOI 10.1002/ijc.27754; Cao SB, 2016, ENDOCR-RELAT CANCER, V23, pT199, DOI 10.1530/ERC-16-0298; Carabet LA, 2018, EUR J MED CHEM, V160, P108, DOI 10.1016/j.ejmech.2018.09.023; Chan SC, 2012, J BIOL CHEM, V287, P19736, DOI 10.1074/jbc.M112.352930; CHEN CH, 1994, RADIAT RES, V139, P307, DOI 10.2307/3578828; Chen Z, 2018, P NATL ACAD SCI USA, V115, P6810, DOI 10.1073/pnas.1718811115; Corey E, 2003, PROSTATE, V55, P239, DOI 10.1002/pros.10198; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594; Den RB, 2014, INT J RADIAT ONCOL, V89, P1038, DOI 10.1016/j.ijrobp.2014.04.052; Dong Y, 2004, CANCER RES, V64, P19, DOI 10.1158/0008-5472.CAN-03-2789; Dong Y, 2003, CANCER RES, V63, P52; Dong Y, 2005, MOL CANCER THER, V4, P1047, DOI 10.1158/1535-7163.MCT-05-0124; Erho N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066855; Fan LL, 2018, P NATL ACAD SCI USA, V115, pE4584, DOI 10.1073/pnas.1802415115; Ferraldeschi R, 2016, CANCER RES, V76, P2731, DOI 10.1158/0008-5472.CAN-15-2186; Freedland SJ, 2016, EUR UROL, V70, P588, DOI 10.1016/j.eururo.2016.01.008; Gao LN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063563; Grad JM, 1999, MOL ENDOCRINOL, V13, P1896, DOI 10.1210/me.13.11.1896; Guo JX, 2009, CANCER CHEMOTH PHARM, V63, P615, DOI 10.1007/s00280-008-0774-y; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; Hornberg E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019059; Hu R, 2012, CANCER RES, V72, P3457, DOI 10.1158/0008-5472.CAN-11-3892; Hu R, 2011, PROSTATE, V71, P1656, DOI 10.1002/pros.21382; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Jung M, 2017, CANCER RES, V77, P971, DOI 10.1158/0008-5472.CAN-15-2906; Karnes RJ, 2013, J UROLOGY, V190, P2047, DOI 10.1016/j.juro.2013.06.017; Klein EA, 2015, EUR UROL, V67, P778, DOI 10.1016/j.eururo.2014.10.036; Knudsen KE, 2009, CLIN CANCER RES, V15, P4792, DOI 10.1158/1078-0432.CCR-08-2660; Koh Cheryl M, 2010, Genes Cancer, V1, P617, DOI 10.1177/1947601910379132; Kregel S, 2016, ONCOTARGET, V7, P26259, DOI 10.18632/oncotarget.8456; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Li YM, 2011, CANCER RES, V71, P2108, DOI 10.1158/0008-5472.CAN-10-1998; Liu LL, 2014, ONCOGENE, V33, P3140, DOI 10.1038/onc.2013.284; Miyamoto DT, 2015, SCIENCE, V349, P1351, DOI 10.1126/science.aab0917; Mostaghel EA, 2011, CLIN CANCER RES, V17, P5913, DOI 10.1158/1078-0432.CCR-11-0728; Nadiminty N, 2015, MOL CANCER THER, V14, P1884, DOI 10.1158/1535-7163.MCT-14-1057; Nadiminty N, 2013, MOL CANCER THER, V12, P1629, DOI 10.1158/1535-7163.MCT-13-0027; Nadiminty N, 2012, J BIOL CHEM, V287, P1527, DOI 10.1074/jbc.M111.278705; NAG A, 1989, PROSTATE, V15, P115, DOI 10.1002/pros.2990150205; Nakagawa T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002318; Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299; Nuhn P, 2019, EUR UROL, V75, P88, DOI 10.1016/j.eururo.2018.03.028; Nyquist MD, 2013, P NATL ACAD SCI USA, V110, P17492, DOI 10.1073/pnas.1308587110; Pang S, 1997, CANCER RES, V57, P495; Piccolo SR, 2012, GENOMICS, V100, P337, DOI 10.1016/j.ygeno.2012.08.003; Prensner JR, 2014, LANCET ONCOL, V15, P1469, DOI 10.1016/S1470-2045(14)71113-1; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Ross AE, 2016, EUR UROL, V69, P157, DOI 10.1016/j.eururo.2015.05.042; Scher HI, 2016, JAMA ONCOL, V2, P1441, DOI 10.1001/jamaoncol.2016.1828; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; Sharp A, 2019, J CLIN INVEST, V129, P192, DOI 10.1172/JCI122819; Shiota M, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw005; Smith MR, 2018, NEW ENGL J MED, V378, P1408, DOI 10.1056/NEJMoa1715546; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Stockley J, 2015, SCI REP-UK, V5, DOI 10.1038/srep13426; Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824; Todenhofer T, 2017, J UROLOGY, V197, P135, DOI 10.1016/j.juro.2016.06.094; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; Tummala R, 2016, PROSTATE, V76, P445, DOI 10.1002/pros.23134; Ungerleider N, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007206; Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179; Wang L, 2018, ANN ONCOL, V29, P352, DOI 10.1093/annonc/mdx689; Watson PA, 2010, P NATL ACAD SCI USA, V107, P16759, DOI 10.1073/pnas.1012443107; Welti J, 2016, EUR UROL, V70, P599, DOI 10.1016/j.eururo.2016.03.049; Whitfield JR, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00010; Xu D, 2015, CANCER RES, V75, P3663, DOI 10.1158/0008-5472.CAN-15-0381; Yin XY, 2003, ONCOGENE, V22, P6151, DOI 10.1038/sj.onc.1206641; Younis I, 2010, MOL CELL BIOL, V30, P1718, DOI 10.1128/MCB.01301-09; Yu ZY, 2014, CLIN CANCER RES, V20, P1590, DOI 10.1158/1078-0432.CCR-13-1863; Zhang ZQ, 2016, ONCOTARGET, V7, P15481, DOI 10.18632/oncotarget.7139; Zhao SG, 2017, JAMA ONCOL, V3, P1663, DOI 10.1001/jamaoncol.2017.0751	83	60	61	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2019	38	25					4977	4989		10.1038/s41388-019-0768-8	http://dx.doi.org/10.1038/s41388-019-0768-8			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IE1KY	30820039	Green Accepted			2022-12-28	WOS:000472145900007
J	Wang, WC; Yang, X; Dai, JL; Lu, Y; Zhang, J; Keller, ET				Wang, Wenchu; Yang, Xin; Dai, Jinlu; Lu, Yi; Zhang, Jian; Keller, Evan T.			Prostate cancer promotes a vicious cycle of bone metastasis progression through inducing osteocytes to secrete GDF15 that stimulates prostate cancer growth and invasion	ONCOGENE			English	Article							TRANSCRIPTION FACTOR; CELL-PROLIFERATION; FACTOR EGR-1; IN-VITRO; TUMOR; MICROENVIRONMENT; EXPRESSION; RECEPTOR; PROTEIN; DIFFERENTIATION	Bone is the most frequent site of prostate cancer (PCa) metastasis; however, little is known about the role of the most common cell in bone, the osteocyte (OCy), in cancer biology. In this study we explored the crosstalk between PCa cells and OCys to determine if it contributes to PCa progression. PCa cells induced OCys to promote PCa proliferation, migration and invasion. A chemokine screen revealed that PCa cell induced OCys to produce growth-derived factor 15 (GDF15). Knockdown of GDF15 in OCys demonstrated that PCa cells conferred the ability on OCys to promote PCa proliferation, migration and invasion through GDF15. Consistent with this finding was the observation that the GDF15 receptor, GFRAL, was expressed on multiple PCa cell lines. Transcription factor array screening of PCa cells exposed to OCys with or without knockdown of GDF15 revealed that GDF15 in OCys promoted early growth response 1 (EGR1) expression in the PCa cells. Knockdown of EGR1 expression in PCa cells revealed it was required for the OCy-derived GDF15-mediated induction of in vitro PCa cell proliferation, migration and invasion. Subcutaneous co-injection of PCa cells and OCys into mice revealed that OCys promoted tumor growth in vivo, which was diminished by knockdown of GDF15 in the OCys. Knockdown of GDF15 in the tibiae diminished growth of PCa cancer cells injected into the tibiae, which was accompanied by decreased tumor cell proliferation and EGR1 expression. These results shed light on a novel mechanism through which PCa cells educate OCys to promote progression of PCa bone metastasis. They also suggest that targeting of GDF15-based and EGR1-based signaling pathways should be further explored for their potential to diminish progression of PCa bone metastasis.	[Wang, Wenchu; Yang, Xin; Zhang, Jian] Guangxi Med Univ, Ctr Translat Med, Guangxi 530021, Peoples R China; [Wang, Wenchu; Yang, Xin; Dai, Jinlu; Keller, Evan T.] Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA; [Wang, Wenchu; Yang, Xin; Zhang, Jian] Guangxi Med Univ, Sch Preclin Med, Guangxi, Peoples R China; [Wang, Wenchu; Yang, Xin; Zhang, Jian] Minist Educ, Key Lab Longev & Ageing Related Dis, Nanning, Peoples R China; [Lu, Yi; Zhang, Jian] Southern Univ Sci & Technol, Sch Med, Shenzhen, Guangdong, Peoples R China; [Keller, Evan T.] Univ Michigan, Biointerfaces Inst, Ann Arbor, MI 48109 USA	Guangxi Medical University; University of Michigan System; University of Michigan; Guangxi Medical University; Southern University of Science & Technology; University of Michigan System; University of Michigan	Keller, ET (corresponding author), Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA.; Keller, ET (corresponding author), Univ Michigan, Biointerfaces Inst, Ann Arbor, MI 48109 USA.	etkeller@umich.edu	ZHANG, JIAN/Q-6334-2018; Lu, Yi/J-6746-2018; Keller, Evan T/M-1446-2016; Dai, Jin/GVT-2414-2022	Lu, Yi/0000-0002-1060-6925; Keller, Evan T/0000-0002-7592-7535; Dai, Jin/0000-0003-3063-746X	NIH [R01-CA190554, P01-CA093900]; NSFC [81130046, 81773146, JCYJ20170412154619484]; NATIONAL CANCER INSTITUTE [P01CA093900, R01CA190554] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSFC(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH R01-CA190554, NIH P01-CA093900, NSFC Key Project 81130046, NSFC 81773146 and JCYJ20170412154619484.	Adamson E, 2003, CANCER BIOL THER, V2, P617; Adamson ED, 2002, TUMOR BIOL, V23, P93, DOI 10.1159/000059711; Arora S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-11-r166; Baron V, 2006, CANCER GENE THER, V13, P115, DOI 10.1038/sj.cgt.7700896; Baron V, 2003, ONCOGENE, V22, P4194, DOI 10.1038/sj.onc.1206560; Bonewald LF, 2008, BONE, V42, P606, DOI 10.1016/j.bone.2007.12.224; Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320; Brown DA, 2006, CLIN CANCER RES, V12, P89, DOI 10.1158/1078-0432.CCR-05-1331; Bruzzese F, 2014, CANCER RES, V74, P3408, DOI 10.1158/0008-5472.CAN-13-2259; Bultynck G, 2016, BBA-REV CANCER, V1866, P121, DOI 10.1016/j.bbcan.2016.07.003; Compton JT, 2014, J BONE JOINT SURG AM, V96A, P1659, DOI 10.2106/JBJS.M.01096; Cui YX, 2016, ANTICANCER RES, V36, P1193; Dai JL, 2014, CLIN CANCER RES, V20, P617, DOI 10.1158/1078-0432.CCR-13-0839; Dai JL, 2010, CANCER RES, V70, P5014, DOI 10.1158/0008-5472.CAN-10-0100; Dallas SL, 2013, ENDOCR REV, V34, P658, DOI 10.1210/er.2012-1026; Delgado-Calle J, 2016, CANCER RES, V76, P1089, DOI 10.1158/0008-5472.CAN-15-1703; Deng XY, 2014, CANCER TREAT REV, V40, P730, DOI 10.1016/j.ctrv.2014.04.003; Emmerson PJ, 2017, NAT MED, V23, P1215, DOI 10.1038/nm.4393; Florkowska M, 2012, BMC MOL BIOL, V13, DOI 10.1186/1471-2199-13-8; Gartrell BA, 2015, EUR UROL, V68, P850, DOI 10.1016/j.eururo.2015.06.039; Gitenay D, 2009, FUTURE ONCOL, V5, P993, DOI 10.2217/FON.09.67; Hall CL, 2006, CANCER METAST REV, V25, P551, DOI 10.1007/s10555-006-9022-2; Han MH, 2013, TOXICOL LETT, V220, P157, DOI 10.1016/j.toxlet.2013.04.020; Hayes VM, 2006, CANCER EPIDEM BIOMAR, V15, P1223, DOI 10.1158/1055-9965.EPI-06-0063; Hensel J, 2016, UROLOGY, V92, P6, DOI 10.1016/j.urology.2015.12.039; Hinoi E, 2012, J BONE MINER RES, V27, P938, DOI 10.1002/jbmr.1538; Hsu JY, 2017, NATURE, V550, P255, DOI 10.1038/nature24042; Husaini Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043833; Kalajzic I, 2013, BONE, V54, P296, DOI 10.1016/j.bone.2012.09.040; Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014; Keller ET, 2001, CANCER METAST REV, V20, P333, DOI 10.1023/A:1015599831232; Korenchuk S, 2001, IN VIVO, V15, P163; KOUTSILIERIS M, 1993, ANTICANCER RES, V13, P443; Krishn SR, 2019, MATRIX BIOL, V77, P41, DOI 10.1016/j.matbio.2018.08.004; Languino LR, 2016, AM J TRANSL RES, V8, P2432; Li J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122249; Liu CT, 1996, CRIT REV ONCOGENESIS, V7, P101, DOI 10.1615/CritRevOncog.v7.i1-2.70; Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528; Ma JJ, 2009, J BIOL CHEM, V284, P34600, DOI 10.1074/jbc.M109.016246; Ma Y, 2016, ONCOL REP, V35, P3068, DOI 10.3892/or.2016.4641; Miftakhova R, 2016, CANCER RES, V76, P2453, DOI 10.1158/0008-5472.CAN-15-2340; Mullican SE, 2017, NAT MED, V23, P1150, DOI 10.1038/nm.4392; Ortiz A, 2012, RECENT RESULTS CANC, V192, P225, DOI 10.1007/978-3-642-21892-7_11; Ozen E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042717; Paralkar VM, 1998, J BIOL CHEM, V273, P13760, DOI 10.1074/jbc.273.22.13760; Parra E, 2013, ONCOL REP, V30, P911, DOI 10.3892/or.2013.2503; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Salah Z, 2007, CANCER RES, V67, P9835, DOI 10.1158/0008-5472.CAN-07-1886; Selander KS, 2007, CANCER EPIDEM BIOMAR, V16, P532, DOI 10.1158/1055-9965.EPI-06-0841; Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008-5472.CAN-04-2442; Shin SY, 2010, MOL CANCER RES, V8, P507, DOI 10.1158/1541-7786.MCR-09-0454; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sottnik JL, 2015, CANCER RES, V75, P2151, DOI 10.1158/0008-5472.CAN-14-2493; Stern AR, 2012, BIOTECHNIQUES, V52, P361, DOI 10.2144/0000113876; Sun T, 2013, DIGEST DIS SCI, V58, P423, DOI 10.1007/s10620-012-2356-4; Tsai VWW, 2018, CELL METAB, V28, P353, DOI 10.1016/j.cmet.2018.07.018; Turner CJ, 2016, CURR OSTEOPOROS REP, V14, P170, DOI 10.1007/s11914-016-0323-2; Vanhara P, 2012, PROSTATE CANCER P D, V15, P320, DOI 10.1038/pcan.2012.6; Welsh JB, 2003, P NATL ACAD SCI USA, V100, P3410, DOI 10.1073/pnas.0530278100; Wu TT, 1998, INT J CANCER, V77, P887, DOI 10.1002/(SICI)1097-0215(19980911)77:6<887::AID-IJC15>3.0.CO;2-Z; Yang LD, 2017, NAT MED, V23, P1158, DOI 10.1038/nm.4394; Yi JH, 2007, NEUROCHEM INT, V50, P1014, DOI 10.1016/j.neuint.2007.04.019; Zhang M, 2017, MOL CANCER RES, V15, P457, DOI 10.1158/1541-7786.MCR-16-0392; Zhang W, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167222; Zhou JZ, 2016, ONCOGENE, V35, P5597, DOI 10.1038/onc.2016.101	66	47	51	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2019	38	23					4540	4559		10.1038/s41388-019-0736-3	http://dx.doi.org/10.1038/s41388-019-0736-3			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IB4KM	30755731	Green Accepted			2022-12-28	WOS:000470240300008
J	Zhang, L; Li, WL; Cao, L; Xu, JY; Qian, Y; Chen, HR; Zhang, YQ; Kang, W; Gou, HY; Wong, CC; Yu, J				Zhang, Li; Li, Weilin; Cao, Lei; Xu, Jiaying; Qian, Yun; Chen, Huarong; Zhang, Yanquan; Kang, Wei; Gou, Hongyan; Wong, Chi Chun; Yu, Jun			PKNOX2 suppresses gastric cancer through the transcriptional activation of IGFBP5 and p53	ONCOGENE			English	Article							FACTOR-BINDING PROTEIN-5; EPITHELIAL-MESENCHYMAL TRANSITION; GROWTH; DIFFERENTIATION; TUMORIGENESIS; PROGRESSION; EXPRESSION; PBX1	Promoter methylation plays a vital role in tumorigenesis through transcriptional silencing of tumor suppressive genes. Using genome-wide methylation array, we first identified PBX/Knotted Homeobox 2 (PKNOX2) as a candidate tumor suppressor in gastric cancer. PKNOX2 mRNA expression is largely silenced in gastric cancer cell lines and primary gastric cancer via promoter methylation. Promoter methylation of PKNOX2 was associated with poor survival in gastric cancer patients. A series of in vitro and in vivo functional studies revealed that PKNOX2 functions as a tumor suppressor. Ectopic PKNOX2 expression inhibited cell proliferation in GC cell lines and suppressed growth of tumor xenografts in mice via induction of apoptosis and cell cycle arrest; and suppressed cell migration and invasion by blocking epithelial-to-mesenchymal transition. On the other hand, knockdown PKNOX2 in normal gastric epithelial cells triggered diverse malignant phenotypes. Mechanistically, PKNOX2 exerts its tumor suppressive effect by promoting the up-regulation of Insulin like Growth Factor Binding Protein 5 (IGFBP5) and TP53. PKNOX2 binds to the promoter regions of IGFBP5 and TP53 and transcriptionally activated their expression by chromatin immunoprecipitation (ChIP)-PCR assay. IGFBP5 knockdown partly abrogated tumor suppressive effect of PKNOX2, indicating that the function(s) of PKNOX2 are dependent on IGFBP5. IGFBP5 promoted PKNOX2-mediated up-regulation of p53. As a consequence, p53 transcription target genes were coordinately upregulated in PKNOX2-expressing GC cells, leading to tumor suppression. In summary, our results identified PKNOX2 as a tumor suppressor in gastric cancer by activation of IGFBP5 and p53 signaling pathways. PKNOX2 promoter hypermethylation might be a biomarker for the poor survival of gastric cancer patients.	[Zhang, Li; Li, Weilin; Cao, Lei; Xu, Jiaying; Chen, Huarong; Zhang, Yanquan; Gou, Hongyan; Wong, Chi Chun; Yu, Jun] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Peoples R China; [Zhang, Li; Li, Weilin; Cao, Lei; Xu, Jiaying; Chen, Huarong; Zhang, Yanquan; Gou, Hongyan; Wong, Chi Chun; Yu, Jun] Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, State Key Lab Digest Dis,Dept Med & Therapeut, Hong Kong, Peoples R China; [Li, Weilin] Chinese Univ Hong Kong, Dept Surg, Hong Kong, Peoples R China; [Qian, Yun] Shenzhen Univ Hosp, Dept Gastroenterol, Shenzhen, Peoples R China; [Kang, Wei] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Shenzhen University; Chinese University of Hong Kong	Wong, CC; Yu, J (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Peoples R China.; Wong, CC; Yu, J (corresponding author), Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, State Key Lab Digest Dis,Dept Med & Therapeut, Hong Kong, Peoples R China.	chichun.wong@cuhk.edu.hk; junyu@cuhk.edu.hk	Wong, Chi Chun/C-4636-2016; Chen, Huarong/ABZ-5810-2022; Zhang, Yanquan/D-5615-2017; Yu, Jun/D-8569-2015; chen, huarong/ABH-8561-2020; KANG, Wei/C-5451-2016; xu, jia/GSD-6347-2022; Li, Weilin/ABG-9032-2021	Zhang, Yanquan/0000-0003-3527-9972; Yu, Jun/0000-0001-5008-2153; chen, huarong/0000-0003-2192-1864; KANG, Wei/0000-0002-4651-677X; 	National Key R&D Program of China [2018YFC135000/2018YFC1315004]; RGC/GRF Hong Kong [14114615, 14101917, 14111216, 14106145, 14108718]; National Natural Science Foundation of China (NSFC) [81772501, 81502064]; HMRF Hong Kong [03140856]; Vice-Chancellor's Discretionary Fund CUHK; Shenzhen Virtual University Park Support Scheme; CUHK direct grant	National Key R&D Program of China; RGC/GRF Hong Kong(Hong Kong Research Grants Council); National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); HMRF Hong Kong; Vice-Chancellor's Discretionary Fund CUHK; Shenzhen Virtual University Park Support Scheme; CUHK direct grant(Chinese University of Hong Kong)	This project was supported by research funds from National Key R&D Program of China (No. 2018YFC135000/2018YFC1315004), RGC/GRF Hong Kong (14114615, 14101917, 14111216, 14106145, and 14108718); National Natural Science Foundation of China (NSFC) (81772501 and 81502064); HMRF Hong Kong (03140856); Vice-Chancellor's Discretionary Fund CUHK; Shenzhen Virtual University Park Support Scheme to CUHK Shenzhen Research Institute; CUHK direct grant.	Adrien D, 2010, LANGENBECK ARCH SURG, V395, P261, DOI 10.1007/s00423-009-0465-0; Ahn BY, 2010, CANCER RES, V70, P3013, DOI 10.1158/0008-5472.CAN-09-3108; Albrecht JH, 1998, ONCOGENE, V16, P2141, DOI 10.1038/sj.onc.1201728; Banno K, 2012, INT J ONCOL, V41, P793, DOI 10.3892/ijo.2012.1528; Brendolan A, 2005, DEVELOPMENT, V132, P3113, DOI 10.1242/dev.01884; Butt AJ, 2003, J BIOL CHEM, V278, P29676, DOI 10.1074/jbc.M301965200; Capellini TD, 2006, DEVELOPMENT, V133, P2263, DOI 10.1242/dev.02395; Castro AC, 2007, J PATHOL, V211, P507, DOI DOI 10.1002/PATH.2138; Choi YJ, 2015, CARCINOGENESIS, V36, P553, DOI 10.1093/carcin/bgv022; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fernandez LC, 2008, CANCER LETT, V266, P144, DOI 10.1016/j.canlet.2008.02.042; Gullu G, 2012, CHIN J CANCER, V31, P266, DOI 10.5732/cjc.011.10405; Haller K, 2002, DEV DYNAM, V225, P358, DOI 10.1002/dvdy.10167; Hung PS, 2008, J PATHOL, V214, P368, DOI 10.1002/path.2280; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Kim KS, 2007, MOL BIOL CELL, V18, P4543, DOI 10.1091/mbc.E07-03-0280; Lee TI, 2006, NAT PROTOC, V1, P729, DOI 10.1038/nprot.2006.98; Li WL, 2018, ONCOGENE, V37, P6383, DOI 10.1038/s41388-018-0402-1; Mao BJ, 2015, INT J ONCOL, V46, P459, DOI 10.3892/ijo.2014.2765; Natalwala A, 2008, WORLD J GASTROENTERO, V14, P3792, DOI 10.3748/wjg.14.3792; Pirini F, 2017, ONCOTARGET, V8, P38501, DOI 10.18632/oncotarget.16258; Qian Y, 2017, CANCER RES, V77, P1968, DOI 10.1158/0008-5472.CAN-16-1595; Qin P, 2004, J BIOL CHEM, V279, P16263, DOI 10.1074/jbc.M313938200; Saavedra K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125834; Shah N, 2014, CLIN CANCER RES, V20, P4400, DOI 10.1158/1078-0432.CCR-13-1486; Shersher DD, 2011, ANN THORAC SURG, V92, P1805, DOI 10.1016/j.athoracsur.2011.06.058; Sureshbabu A, 2012, J CELL SCI, V125, P1693, DOI 10.1242/jcs.092882; Yamashita H, 2009, CANCER SCI, V100, P2028, DOI 10.1111/j.1349-7006.2009.01274.x; Zhang L, 2010, MOL BIOL REP, V37, P2579, DOI 10.1007/s11033-009-9777-y	30	22	22	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2019	38	23					4590	4604		10.1038/s41388-019-0743-4	http://dx.doi.org/10.1038/s41388-019-0743-4			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IB4KM	30745575	Green Published, hybrid			2022-12-28	WOS:000470240300011
J	Kreis, NN; Steinhauser, K; Ritter, A; Kloble, P; Hoock, SC; Roth, S; Louwen, F; Oswald, F; Yuan, JP				Kreis, Nina-Naomi; Steinhaeuser, Kerstin; Ritter, Andreas; Kloeble, Patricia; Hoock, Samira Catharina; Roth, Susanne; Louwen, Frank; Oswald, Franz; Yuan, Juping			Potential involvement of RITA in the activation of Aurora A at spindle poles during mitosis	ONCOGENE			English	Article							HUMAN HEPATOCELLULAR-CARCINOMA; MICROTUBULE-ASSOCIATED PROTEIN; CELL LYMPHOMA 6; A KINASE; CENTROSOME AMPLIFICATION; MITOTIC DEFECTS; TPX2; NUCLEATION; TUBULIN; HURP	The mitotic kinase Aurora A is crucial for various mitotic events. Its activation has been intensively investigated and is not yet completely understood. RITA, the RBP-J interacting and tubulin-associated protein, has been shown to modulate microtubule dynamics in mitosis. We asked if RITA could be related to the activation of Aurora A. We show here that RITA is colocalized with Aurora A and its activator TPX2 at spindle poles during mitosis. FLAG-RITA is precipitated with the complex of Aurora A, TPX2 and tubulin. Depletion of RITA increases exclusively active Aurora A and TPX2 at spindle poles in diverse cancer cell lines and in RITA knockout mouse embryonic fibroblasts. The enhanced active Aurora A, its substrate p-TACC3 and TPX2 are restored by adding back of RITA but not its Delta tub mutant with an impaired tubulin-binding capability, indicating that RITA' s role as Aurora A's modulator is mediated through its interaction with tubulin. Also, the mitotic failures in cells depleted of RITA are rescued by the inhibition of Aurora A. RITA itself does not directly interfere with the catalytic activity of Aurora A, instead, affects the microtubule binding of its activator TPX2. Moreover, Aurora A's activation correlates with microtubule stabilization induced by the microtubule stabilizer paclitaxel, implicating that stabilized microtubules caused by RITA depletion could also account for increased active Aurora A. Our data suggest a potential role for RITA in the activation of Aurora A at spindle poles by modulating the microtubule binding of TPX2 and the microtubule stability during mitosis.	[Kreis, Nina-Naomi; Steinhaeuser, Kerstin; Ritter, Andreas; Hoock, Samira Catharina; Roth, Susanne; Louwen, Frank; Yuan, Juping] Goethe Univ Frankfurt, Sch Med, Dept Gynecol & Obstet, Theodor Stern Kai 7, D-60590 Frankfurt, Germany; [Kloeble, Patricia; Oswald, Franz] Univ Med Ctr Ulm, Ctr Internal Med, Dept Internal Med 1, Albert Einstein Allee 23, D-89081 Ulm, Germany; [Steinhaeuser, Kerstin] Solvadis Distribut GmbH, Hafen 4, D-64579 Gernsheim, Germany	Goethe University Frankfurt; Ulm University	Yuan, JP (corresponding author), Goethe Univ Frankfurt, Sch Med, Dept Gynecol & Obstet, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	yuan@em.uni-frankfurt.de	Ritter, Andreas/AAX-3938-2020; Ritter, Andreas/ABB-6348-2020; Kreis, Nina-Naomi/AAF-5407-2019; Oswald, Franz/AAO-9584-2020	Ritter, Andreas/0000-0002-5955-859X; Kreis, Nina-Naomi/0000-0003-4304-0160; Yuan, Juping/0000-0003-0694-0565	Deutsche Forschungsgemeinschaft [SFB1074/A3, Yu 156/7-1]; BMBF (research nucleus SyStAR); International Graduate School in Molecular Medicine, Ulm [GSC270]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); BMBF (research nucleus SyStAR)(Federal Ministry of Education & Research (BMBF)); International Graduate School in Molecular Medicine, Ulm	We gratefully thank Ms. Friemel (Frankfurt) and Ms. Schirmer (Ulm) for their technical assistance. The work was partially supported by the Deutsche Forschungsgemeinschaft (SFB1074/A3 to FO, Yu 156/7-1 to JY) and the BMBF (research nucleus SyStAR to FO). PK was supported by the International Graduate School in Molecular Medicine, Ulm (GSC270).	Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Asteriti IA, 2010, BBA-REV CANCER, V1806, P230, DOI 10.1016/j.bbcan.2010.08.001; Barr AR, 2007, J CELL SCI, V120, P2987, DOI 10.1242/jcs.013136; Bayliss R, 2003, MOL CELL, V12, P851, DOI 10.1016/S1097-2765(03)00392-7; Brunet S, 2004, MOL BIOL CELL, V15, P5318, DOI 10.1091/mbc.E04-05-0385; Burgess SG, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005345; Carmena M, 2009, CURR OPIN CELL BIOL, V21, P796, DOI 10.1016/j.ceb.2009.09.008; D'Assoro AB, 2016, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00295; Dodson CA, 2012, J BIOL CHEM, V287, P1150, DOI 10.1074/jbc.M111.312090; Ertych N, 2014, NAT CELL BIOL, V16, P779, DOI 10.1038/ncb2994; Eyers PA, 2004, J BIOL CHEM, V279, P9008, DOI 10.1074/jbc.M312424200; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Garrett S, 2002, CURR BIOL, V12, P2055, DOI 10.1016/S0960-9822(02)01277-0; Giet R, 1999, J BIOL CHEM, V274, P15005, DOI 10.1074/jbc.274.21.15005; Goepfert TM, 2002, CANCER RES, V62, P4115; Gruss OJ, 2004, J CELL BIOL, V166, P949, DOI 10.1083/jcb.200312112; Gruss OJ, 2002, NAT CELL BIOL, V4, P871, DOI 10.1038/ncb870; Hochegger H, 2013, OPEN BIOL, V3, DOI 10.1098/rsob.120185; Jasmer B, 2017, ONCOTARGET, V8, P108643, DOI 10.18632/oncotarget.20586; Karthigeyan D, 2011, MED RES REV, V31, P757, DOI 10.1002/med.20203; Kinoshita K, 2005, J CELL BIOL, V170, P1047, DOI 10.1083/jcb.200503023; Koffa MD, 2006, CURR BIOL, V16, P743, DOI 10.1016/j.cub.2006.03.056; Kreis NN, 2014, ONCOGENE, V33, P5716, DOI 10.1038/onc.2013.518; Kreis NN, 2016, ONCOTARGET, V7, P50215, DOI 10.18632/oncotarget.10330; Kreis NN, 2015, ONCOTARGET, V6, P6611, DOI 10.18632/oncotarget.2844; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Magiera MM, 2013, METHOD CELL BIOL, V115, P247, DOI 10.1016/B978-0-12-407757-7.00016-5; Manfredi MG, 2007, P NATL ACAD SCI USA, V104, P4106, DOI 10.1073/pnas.0608798104; Marumoto T, 2005, NAT REV CANCER, V5, P42, DOI 10.1038/nrc1526; Marumoto T, 2003, J BIOL CHEM, V278, P51786, DOI 10.1074/jbc.M306275200; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Muschol-Steinmetz C, 2016, CELL CYCLE, V15, P827, DOI 10.1080/15384101.2016.1149273; Nguyen HL, 1999, J CELL SCI, V112, P1813; Noujaim M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086786; Ritter A, 2018, STEM CELL REP, V10, P583, DOI 10.1016/j.stemcr.2017.12.022; Ritter A, 2016, CRIT REV BIOCHEM MOL, V51, P228, DOI 10.1080/10409238.2016.1178705; Ritter A, 2015, CELL CYCLE, V14, P3755, DOI 10.1080/15384101.2015.1068481; Rodel F, 2018, RADIOTHER ONCOL, V126, P214, DOI 10.1016/j.radonc.2017.10.028; Rohena CC, 2013, BIOCHEM PHARMACOL, V85, P1104, DOI 10.1016/j.bcp.2013.01.030; Rosasco-Nitcher SE, 2008, SCIENCE, V319, P469, DOI 10.1126/science.1148980; Sanhaji M, 2010, MOL CELL BIOL, V30, P2594, DOI 10.1128/MCB.00098-10; Sardon T, 2008, EMBO J, V27, P2567, DOI 10.1038/emboj.2008.173; Sardon T, 2010, EMBO REP, V11, P977, DOI 10.1038/embor.2010.171; Schatz CA, 2003, EMBO J, V22, P2060, DOI 10.1093/emboj/cdg195; Silva VC, 2013, MOL BIOL CELL, V24, P3819, DOI 10.1091/mbc.E13-02-0108; Steinhauser K, 2017, ONCOGENE, V36, P2146, DOI 10.1038/onc.2016.372; Tang AQ, 2017, ONCOTARGET, V8, P23937, DOI 10.18632/oncotarget.14893; Thakur HC, 2013, BIOL CHEM, V394, P1411, DOI 10.1515/hsz-2013-0184; Tsai MY, 2005, CURR BIOL, V15, P2156, DOI 10.1016/j.cub.2005.10.054; Wacker SA, 2011, EMBO J, V30, P43, DOI 10.1038/emboj.2010.289; Wang HH, 2014, BIOCHEM BIOPH RES CO, V454, P71, DOI 10.1016/j.bbrc.2014.10.023; Wang HH, 2012, ONCOL RES, V20, P437, DOI 10.3727/096504013X13685487925059; Wittmann T, 1998, J CELL BIOL, V143, P673, DOI 10.1083/jcb.143.3.673; Wong J, 2008, MOL BIOL CELL, V19, P2083, DOI 10.1091/mbc.E07-10-1088; Wu JM, 2013, P NATL ACAD SCI USA, V110, pE1779, DOI 10.1073/pnas.1220523110; Zhang R, 2017, ELIFE, V6, DOI 10.7554/eLife.30959; Zhang X, 2008, MOL BIOL CELL, V19, P2752, DOI 10.1091/mbc.E08-02-0198	57	3	3	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2019	38	22					4199	4214		10.1038/s41388-019-0716-7	http://dx.doi.org/10.1038/s41388-019-0716-7			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IA1RB	30705408				2022-12-28	WOS:000469339100001
J	Perotti, V; Baldassari, P; Molla, A; Nicolini, G; Bersani, I; Grazia, G; Benigni, F; Maurichi, A; Santinami, M; Anichini, A; Mortarini, R				Perotti, Valentina; Baldassari, Paola; Molla, Alessandra; Nicolini, Gabriella; Bersani, Ilaria; Grazia, Giulia; Benigni, Fabio; Maurichi, Andrea; Santinami, Mario; Anichini, Andrea; Mortarini, Roberta			An actionable axis linking NFATc2 to EZH2 controls the EMT-like program of melanoma cells	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; E-CADHERIN; MALIGNANT-MELANOMA; CANCER CELLS; PROGRESSION; METASTASIS; EXPRESSION; BREAST; GROWTH; DIFFERENTIATION	Discovery of new actionable targets and functional networks in melanoma is an urgent need as only a fraction of metastatic patients achieves durable clinical benefit by targeted therapy or immunotherapy approaches. Here we show that NFATc2 expression is associated with an EMT-like transcriptional program and with an invasive melanoma phenotype, as shown by analysis of melanoma cell lines at the mRNA and protein levels, interrogation of the TCGA melanoma dataset and characterization of melanoma lesions by immunohistochemistry. Gene silencing or pharmacological inhibition of NFATc2 downregulated EMT-related genes and AXL, and suppressed c-Myc, FOXM1, and EZH2. Targeting of c-Myc suppressed FOXM1 and EZH2, while targeting of FOXM1 suppressed EZH2. Inhibition of c-Myc, or FOXM1, or EZH2 downregulated EMT-related gene expression, upregulated MITF and suppressed migratory and invasive activity of neoplastic cells. Stable silencing of NFATc2 impaired melanoma cell proliferation in vitro and tumor growth in vivo in SCID mice. In NFATc2(+) EZH2(+) melanoma cell lines pharmacological co-targeting of NFATc2 and EZH2 exerted strong anti-proliferative and proapoptotic activity, irrespective of BRAF or NRAS mutations and of BRAF inhibitor resistance. These results provide preclinical evidence for a role of NFATc2 in shaping the EMT-like melanoma phenotype and reveal a targetable vulnerability associated with NFATc2 and EZH2 expression in melanoma cells belonging to different mutational subsets.	[Perotti, Valentina; Baldassari, Paola; Molla, Alessandra; Nicolini, Gabriella; Bersani, Ilaria; Grazia, Giulia; Anichini, Andrea; Mortarini, Roberta] Dept Res, Human Tumors Immunobiol Unit, Milan, Italy; [Benigni, Fabio] HuMabs Biomed, Subsidiary Vir Biotechnol, Bellinzona, Switzerland; [Maurichi, Andrea; Santinami, Mario] Fdn IRCCS, Dept Surg, Melanoma & Sarcoma Unit, Ist Nazl Tumori, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan	Mortarini, R (corresponding author), Dept Res, Human Tumors Immunobiol Unit, Milan, Italy.	roberta.mortarini@istitutotumori.mi.it	Maurichi, Andrea/E-7030-2017; Maurichi, Andrea/AAX-5020-2020; Santinami, Mario/I-3795-2017; Anichini, Andrea/K-1434-2016; Perotti, Valentina/C-1049-2017	Maurichi, Andrea/0000-0002-6503-5373; Maurichi, Andrea/0000-0002-6503-5373; Santinami, Mario/0000-0001-8436-4757; Anichini, Andrea/0000-0001-5096-5538; Perotti, Valentina/0000-0003-4506-2363	Associazione Italiana per la Ricerca sul Cancro (A.I.R.C.) [IG15860]	Associazione Italiana per la Ricerca sul Cancro (A.I.R.C.)(Fondazione AIRC per la ricerca sul cancro)	This work was supported by the Associazione Italiana per la Ricerca sul Cancro (A.I.R.C.), grant IG15860 to RM.	Anichini A, 2006, CANCER RES, V66, P6405, DOI 10.1158/0008-5472.CAN-06-0854; Bankhead P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17204-5; Baumgart S, 2016, MOL CANCER THER, V15, P491, DOI 10.1158/1535-7163.MCT-15-0309; Braig S, 2011, BRIT J CANCER, V105, P231, DOI 10.1038/bjc.2011.226; Caballero FJ, 2007, BIOCHEM PHARMACOL, V73, P1013, DOI 10.1016/j.bcp.2006.12.001; Caramel J, 2013, CANCER CELL, V24, P466, DOI 10.1016/j.ccr.2013.08.018; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Ciuffreda L, 2009, NEOPLASIA, V11, P720, DOI 10.1593/neo.09398; Courboulin A, 2011, J EXP MED, V208, P535, DOI 10.1084/jem.20101812; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eriksson J, 2016, ONCOTARGET, V7, P15065, DOI 10.18632/oncotarget.7604; Garay T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117021; Geback T, 2009, BIOTECHNIQUES, V46, P265, DOI 10.2144/000113083; Izumi H, 2015, SURG TODAY, V45, P487, DOI 10.1007/s00595-015-1126-2; Kim SH, 2015, STEM CELL REP, V4, P226, DOI 10.1016/j.stemcr.2014.12.006; Konieczkowski DJ, 2014, CANCER DISCOV, V4, P816, DOI 10.1158/2159-8290.CD-13-0424; Kreiseder B, 2013, INT J CANCER, V132, P521, DOI 10.1002/ijc.27698; Kudo-Saito C, 2013, CANCER RES, V73, P6185, DOI 10.1158/0008-5472.CAN-13-1364; Liu L, 2016, BJU INT, V117, P351, DOI 10.1111/bju.12702; Lu J, 2015, MOL MED REP, V12, P2668, DOI 10.3892/mmr.2015.3752; Mahmoud F, 2016, CANCER BIOL THER, V17, P579, DOI 10.1080/15384047.2016.1167291; Mann KM, 2004, J CELL BIOL, V165, P483, DOI 10.1083/jcb.200402105; Paluncic J, 2016, BBA-MOL CELL RES, V1863, P770, DOI 10.1016/j.bbamcr.2016.01.025; Parvani JG, 2015, CANCER RES, V75, P2316, DOI 10.1158/0008-5472.CAN-14-3485; Pearlman RL, 2017, CANCER LETT, V391, P125, DOI 10.1016/j.canlet.2017.01.029; Penna I, 2016, ONCOTARGET, V7, P3947, DOI 10.18632/oncotarget.6600; Peres J, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-117; Perotti V, 2016, ONCOGENE, V35, P2862, DOI 10.1038/onc.2015.355; Perotti V, 2012, J INVEST DERMATOL, V132, P2652, DOI 10.1038/jid.2012.179; Rai K, 2015, CANCER DISCOV, V5, P1314, DOI 10.1158/2159-8290.CD-15-0493; Ramsdale R, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aab1111; Rastelli L, 2011, INT J ONCOL, V39, P401, DOI 10.3892/ijo.2011.1040; Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349; Schech AJ, 2013, MOL CANCER THER, V12, P1356, DOI 10.1158/1535-7163.MCT-12-0304; Sensi M, 2011, J INVEST DERMATOL, V131, P2448, DOI 10.1038/jid.2011.218; Shankar J, 2010, CANCER RES, V70, P3780, DOI 10.1158/0008-5472.CAN-09-4439; Singh SK, 2011, J BIOL CHEM, V286, P28761, DOI 10.1074/jbc.M110.197533; Tian L, 2016, INT J ONCOL, V48, P783, DOI 10.3892/ijo.2015.3282; Tiffen JC, 2015, ONCOTARGET, V6, P27023, DOI 10.18632/oncotarget.4809; Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020; Tsoi J, 2018, CANCER CELL, V33, P890, DOI 10.1016/j.ccell.2018.03.017; Verfaillie A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7683; Wang B, 2012, BIOCHEM BIOPH RES CO, V417, P601, DOI 10.1016/j.bbrc.2011.12.014; Wells A, 2008, CLIN EXP METASTAS, V25, P621, DOI 10.1007/s10585-008-9167-1; Xu N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059412; Yamamoto K, 2014, MOL CELL, V53, P904, DOI 10.1016/j.molcel.2014.02.028; Yang KK, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0158-1; Yin LL, 2015, J INVEST DERMATOL, V135, P2455, DOI 10.1038/jid.2015.179; Zhang K, 2013, NAT CELL BIOL, V15, P677, DOI 10.1038/ncb2743; Zingg D, 2017, CELL REP, V20, P854, DOI 10.1016/j.celrep.2017.07.007	50	21	22	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2019	38	22					4384	4396		10.1038/s41388-019-0729-2	http://dx.doi.org/10.1038/s41388-019-0729-2			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IA1RB	30710146	Green Published, hybrid			2022-12-28	WOS:000469339100013
J	Jiang, Y; Su, SY; Zhang, YQ; Qian, JY; Liu, PD				Jiang, Yao; Su, Siyuan; Zhang, Yanqiong; Qian, Jiayi; Liu, Pengda			Control of mTOR signaling by ubiquitin	ONCOGENE			English	Review							REGULATES AKT UBIQUITINATION; PROTEIN PHOSPHATASE 2A; E3 LIGASE; TUMOR-SUPPRESSOR; BETA-TRCP; PROTEASOMAL DEGRADATION; MEDIATED DEGRADATION; PTEN; PROMOTES; COMPLEX	The evolutionarily conserved mTOR signaling pathway plays essential roles in cell growth, proliferation, metabolism and responses to cellular stresses. Hyperactivation of the mTOR signaling is observed in virtually all solid tumors and has been an attractive drug target. In addition to changes at genetic levels, aberrant activation of the mTOR signaling is also a result from dysregulated posttranslational modifications on key pathway members, such as phosphorylation that has been extensively studied. Emerging evidence also supports a critical role for ubiquitin-mediated modifications in dynamically regulating the mTOR signaling pathway, while a comprehensive review for relevant studies is missing. In this review, we will summarize characterized ubiquitination events on major mTOR signaling components, their modifying E3 ubiquitin ligases, deubiquitinases and corresponding pathophysiological functions. We will also reveal methodologies that have been used to identify E3 ligases or DUBs to facilitate the search for yet-to-be discovered ubiquitin-mediated regulatory mechanisms in mTOR signaling. We hope that our review and perspectives provide rationales and strategies to target ubiquitination for inhibiting mTOR signaling to treat human diseases.	[Jiang, Yao] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Ctr Canc, Wuhan 430022, Hubei, Peoples R China; [Jiang, Yao; Su, Siyuan; Zhang, Yanqiong; Qian, Jiayi; Liu, Pengda] Univ N Carolina, Dept Biochem & Biophys, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	Huazhong University of Science & Technology; University of North Carolina; University of North Carolina Chapel Hill	Liu, PD (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	pengda_liu@med.unc.edu		Su, Siyuan/0000-0002-8816-9577	NIH [R00CA181342]; V Foundation Research Scholar Grant [V2018-009]; UNC IBM Junior Faculty Development Award; UNC University Cancer Research Fund; NATIONAL CANCER INSTITUTE [R00CA181342] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); V Foundation Research Scholar Grant; UNC IBM Junior Faculty Development Award(International Business Machines (IBM)); UNC University Cancer Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors sincerely apologize to all those colleagues whose important work were not cited in this review owing to space limitations, especially many prominent and pioneer work in the mTOR field. We thank other Liu members for critical reading of the manuscript and helpful discussions. This work was supported by the NIH grants (R00CA181342 to PL), a V Foundation Research Scholar Grant (V2018-009 to PL), a UNC IBM Junior Faculty Development Award (PL) and the UNC University Cancer Research Fund (PL).	Agrawal P, 2012, J BIOL CHEM, V287, P21164, DOI 10.1074/jbc.M111.328021; Bachelder RE, 2001, J BIOL CHEM, V276, P34702, DOI 10.1074/jbc.M102806200; Bae SH, 2012, CELL RES, V22, P873, DOI 10.1038/cr.2012.38; Bar-Peled L, 2013, SCIENCE, V340, P1100, DOI 10.1126/science.1232044; Belova L, 2006, BIOCHEM J, V400, P235, DOI 10.1042/BJ20060905; Bisson JA, 2015, DEV BIOL, V398, P80, DOI 10.1016/j.ydbio.2014.11.015; Brand C, 2010, BBA-MOL CELL RES, V1803, P1265, DOI 10.1016/j.bbamcr.2010.07.006; Bridges CR, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00149-0; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Chan CH, 2012, CELL, V149, P1098, DOI 10.1016/j.cell.2012.02.065; Chano T, 2006, INT J MOL MED, V18, P425; Chen J, 2018, NATURE, V557, P585, DOI 10.1038/s41586-018-0128-9; Chen Z, 2018, MOL THER-NUCL ACIDS, V10, P254, DOI 10.1016/j.omtn.2017.12.010; Cheng L, 2018, INT J ONCOL, V53, P203, DOI 10.3892/ijo.2018.4377; Chu J, 2017, MOL PSYCHIATR, V22, P1002, DOI 10.1038/mp.2016.214; Davis RJ, 2014, CANCER CELL, V26, P455, DOI 10.1016/j.ccell.2014.09.013; de Araujo MEG, 2013, J BIOL CHEM, V288, P18228, DOI 10.1074/jbc.M112.349480; Dehan E, 2009, MOL CELL, V33, P109, DOI 10.1016/j.molcel.2008.12.020; Deng L, 2015, MOL CELL, V58, P804, DOI 10.1016/j.molcel.2015.03.033; Dickey CA, 2008, P NATL ACAD SCI USA, V105, P3622, DOI 10.1073/pnas.0709180105; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; Duan SS, 2011, MOL CELL, V44, P317, DOI 10.1016/j.molcel.2011.09.005; Emanuele MJ, 2011, CELL, V147, P459, DOI 10.1016/j.cell.2011.09.019; Fan CD, 2013, J BIOL CHEM, V288, P1674, DOI 10.1074/jbc.M112.416339; Gao DM, 2010, MOL CELL, V39, P797, DOI 10.1016/j.molcel.2010.08.016; Ghosh P, 2008, CELL CYCLE, V7, P373, DOI 10.4161/cc.7.3.5267; Guan F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146553; Guo P, 2018, ONCOGENE, V37, P478, DOI 10.1038/onc.2017.349; Hamidi A, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aal4186; Han S, 2008, CELL SIGNAL, V20, P1084, DOI 10.1016/j.cellsig.2008.01.020; Harraz MM, 2016, MOL PSYCHIATR, V21, P313, DOI [10.1038/mp.2015211, 10.1038/mp.2015.211]; Hoffmeister M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116150; Hu J, 2008, GENE DEV, V22, P866, DOI 10.1101/gad.1624008; Hussain S, 2013, MOL CELL BIOL, V33, P1188, DOI 10.1128/MCB.01389-12; Iturrioz X, 2007, FEBS LETT, V581, P1397, DOI 10.1016/j.febslet.2007.02.059; Jiang H, 2018, CELL METAB, V28, P7, DOI 10.1016/j.cmet.2018.06.018; Jin GX, 2015, MOL CELL, V58, P989, DOI 10.1016/j.molcel.2015.05.010; Jin JP, 2004, GENE DEV, V18, P2573, DOI 10.1101/gad.1255304; Joo HM, 2011, EUR J CELL BIOL, V90, P420, DOI 10.1016/j.ejcb.2010.12.001; Kim JH, 2018, EMBO REP, V19, DOI 10.15252/embr.201744378; Kim SY, 2015, ONCOTARGET, V6, P33382, DOI 10.18632/oncotarget.5407; Ko HR, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.79; Koo J, 2015, J BIOL CHEM, V290, P14120, DOI 10.1074/jbc.M114.633057; Kuchay S, 2018, CELL REP, V25, P833, DOI 10.1016/j.celrep.2018.09.088; Kuchay S, 2017, NATURE, V546, P554, DOI 10.1038/nature22965; Kuchay S, 2013, NAT CELL BIOL, V15, P472, DOI 10.1038/ncb2731; Leng SH, 2010, J ENDOCRINOL, V206, P171, DOI 10.1677/JOE-09-0456; Li T, 2017, J NEUROSCI, V37, P12123, DOI 10.1523/JNEUROSCI.1751-17.2017; Li W, 2013, CANCER RES, V73, P6938, DOI 10.1158/0008-5472.CAN-13-0913; Li X, 2009, MOL CELL BIOL, V29, P6192, DOI 10.1128/MCB.00681-09; Lim JH, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1776; Linares JF, 2013, MOL CELL, V51, P283, DOI 10.1016/j.molcel.2013.06.020; Liu PD, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aar8133; Liu PD, 2014, NATURE, V508, P541, DOI 10.1038/nature13079; Lu C, 2018, CANCER LETT, V436, P139, DOI 10.1016/j.canlet.2018.07.032; Maddika S, 2011, NAT CELL BIOL, V13, P728, DOI 10.1038/ncb2240; Mao JH, 2008, SCIENCE, V321, P1499, DOI 10.1126/science.1162981; Meszaros B, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aak9982; Nagashima K, 2017, ONCOTARGET, V8, P9947, DOI 10.18632/oncotarget.14221; Oberg EA, 2012, J BIOL CHEM, V287, P43378, DOI 10.1074/jbc.M112.420281; Park D, 2014, CELL SIGNAL, V26, P2122, DOI 10.1016/j.cellsig.2014.06.010; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Rui LY, 2002, J BIOL CHEM, V277, P42394, DOI 10.1074/jbc.C200444200; Ruschmann J, 2010, EXP HEMATOL, V38, P392, DOI 10.1016/j.exphem.2010.03.010; Sacco JJ, 2014, ONCOGENE, V33, P4265, DOI 10.1038/onc.2013.512; Sattler M, 1997, ONCOGENE, V15, P2379, DOI 10.1038/sj.onc.1201422; Schoenebeck B, 2005, MOL CELL NEUROSCI, V30, P249, DOI 10.1016/j.mcn.2005.07.017; Seo G, 2011, FREE RADICAL RES, V45, P389, DOI 10.3109/10715762.2010.535530; Shi J, 2011, DEV CELL, V21, P835, DOI 10.1016/j.devcel.2011.09.011; Shimizu K, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aah4117; Skaar JR, 2013, NAT REV MOL CELL BIO, V14, P369, DOI 10.1038/nrm3582; Su CH, 2011, CELL SIGNAL, V23, P1824, DOI 10.1016/j.cellsig.2011.06.018; Suizu F, 2009, DEV CELL, V17, P800, DOI 10.1016/j.devcel.2009.09.007; Sun J, 2018, MOL CELL BIOCHEM, V441, P1, DOI 10.1007/s11010-017-3170-2; Tan MJ, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0567-6; Tatebe H, 2017, BIOMOLECULES, V7, DOI 10.3390/biom7040077; Trockenbacher A, 2001, NAT GENET, V29, P287, DOI 10.1038/ng762; Tsun ZY, 2013, MOL CELL, V52, P495, DOI 10.1016/j.molcel.2013.09.016; Uras IZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031003; Van Themsche C, 2009, J BIOL CHEM, V284, P20462, DOI 10.1074/jbc.C109.009522; Wakatsuki S, 2011, NAT CELL BIOL, V13, P1415, DOI 10.1038/ncb2373; Wang B, 2017, NATURE, V545, P365, DOI 10.1038/nature22344; Wang FF, 2017, CANCER LETT, V388, P85, DOI 10.1016/j.canlet.2016.11.031; Wang M, 2017, ONCOTARGET, V8, P89692, DOI 10.18632/oncotarget.21058; Wang ZX, 2016, J BIOL CHEM, V291, P17467, DOI 10.1074/jbc.M116.726083; Wong JJL, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001657; Wu Y, 2014, ANTIOXID REDOX SIGN, V20, P1382, DOI 10.1089/ars.2013.5498; Xiang T, 2008, CANCER RES, V68, P10040, DOI 10.1158/0008-5472.CAN-08-3009; Xu XS, 2008, MOL CELL, V30, P403, DOI 10.1016/j.molcel.2008.03.009; Yang MJ, 2011, J EXP MED, V208, P2099, DOI 10.1084/jem.20102667; Yang WL, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003197; Yang WL, 2009, SCIENCE, V325, P1134, DOI 10.1126/science.1175065; Yoshihara H, 2012, BIOCHEM BIOPH RES CO, V423, P122, DOI 10.1016/j.bbrc.2012.05.093; Yu C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9017; Yuan L, 2015, NAT CELL BIOL, V17, P1169, DOI 10.1038/ncb3218; Zhang JD, 2017, FEBS LETT, V591, P145, DOI 10.1002/1873-3468.12521; Zhang JS, 2013, NAT CELL BIOL, V15, P1486, DOI 10.1038/ncb2874; Zhao LL, 2018, J BIOL CHEM, V293, P4883, DOI 10.1074/jbc.M117.809533; Zhou RF, 2005, J BIOL CHEM, V280, P4518, DOI 10.1074/jbc.M411053200	100	24	24	2	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2019	38	21					3989	4001		10.1038/s41388-019-0713-x	http://dx.doi.org/10.1038/s41388-019-0713-x			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ3HX	30705402	Green Accepted			2022-12-28	WOS:000468740200002
J	Rosenfeld, YBZ; Krumbein, M; Yeffet, A; Schiffmann, N; Mishalian, I; Pikarsky, E; Oberman, F; Fridlender, Z; Yisraeli, JK				Rosenfeld, Yifat Bar-Zakay; Krumbein, Miriam; Yeffet, Avner; Schiffmann, Nathan; Mishalian, Inbal; Pikarsky, Eli; Oberman, Froma; Fridlender, Zvi; Yisraeli, Joel K.			VICKZ1 enhances tumor progression and metastasis in lung adenocarcinomas in mice	ONCOGENE			English	Article							BREAST-CANCER CELLS; MESSENGER-RNA; BINDING-PROTEIN; PANCREATIC-CANCER; STEM-CELLS; CRD-BP; EXPRESSION; PROMOTE; GROWTH; IGF2BP1	The VICKZ (Igf2bp) family of RNA binding proteins regulate RNA function at many levels, including intracellular RNA localization, RNA stability, and translational control. One or more of the three VICKZ paralogs are upregulated in many different types of cancers. Here, we show how VICKZ1 enhances, and dominant negative VICKZ1 inhibits, cell migration, growth in soft agar, and wound healing in a mouse lung adenocarcinoma cell line containing a constitutively active, mutant Kras. Similarly, modulation of VICKZ1 activity promotes or inhibits metastases upon implantation of these cells into syngeneic mice. To test these effects in a genetic model system, we generated a mouse with an inducible VICKZ1 transgene and found that isolated overexpression of VICKZ1 in the lungs had no noticeable effect on morphology. Although directed overexpression of mutant Kras in the lungs led to the formation of small adenomas, concurrent overexpression of VICKZ1 remarkably accelerated tumor growth and formation of pulmonary adenocarcinomas. VICKZ1-containing ribonucleoprotein complexes are highly enriched in Kras mRNA in lung adenocarcinoma cells, and Kras signaling is enhanced in these cells by overexpression of VICKZ1. Analysis of lung carcinoma patients reveals that elevated VICKZ1 expression correlates with lower overall survival; this reduction is dramatically enhanced in those patients bearing a mutant Kras gene. Our study reveals that RNA binding proteins of the VICKZ family can synergize with Kras to influence signaling and oncogenic activity.	[Rosenfeld, Yifat Bar-Zakay; Krumbein, Miriam; Yeffet, Avner; Schiffmann, Nathan; Oberman, Froma; Yisraeli, Joel K.] Hebrew Univ Hadassah Med Sch, Inst Med Res Israel Canada, Dept Dev Biol & Canc Res, IL-91120 Jerusalem, Israel; [Mishalian, Inbal; Fridlender, Zvi] Hadassah Hebrew Univ Med Ctr, Inst Pulm Med, POB 12000, IL-91120 Jerusalem, Israel; [Pikarsky, Eli] Hebrew Univ Hadassah Med Sch, Inst Med Res Israel Canada, Lautenberg Ctr Immunol & Canc Res, Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Yisraeli, JK (corresponding author), Hebrew Univ Hadassah Med Sch, Inst Med Res Israel Canada, Dept Dev Biol & Canc Res, IL-91120 Jerusalem, Israel.	joely@ekmd.huji.ac.il	Yisraeli, Joel/S-2031-2019; pikarsky, eli/GXV-7099-2022	Yisraeli, Joel/0000-0001-6538-6686; pikarsky, eli/0000-0003-4186-7105	Israel Science Foundation; Israel Cancer Research Fund; Eliahu Penn Foundation (JKY)	Israel Science Foundation(Israel Science Foundation); Israel Cancer Research Fund; Eliahu Penn Foundation (JKY)	This research was supported by the Israel Science Foundation, the Israel Cancer Research Fund, and the Eliahu Penn Foundation (JKY).	Barghash A, 2016, ONCOTARGET, V7, P49743, DOI 10.18632/oncotarget.10439; Bell JL, 2013, CELL MOL LIFE SCI, V70, P2657, DOI 10.1007/s00018-012-1186-z; Boyerinas B, 2012, INT J CANCER, V130, P1787, DOI 10.1002/ijc.26190; Busch B, 2016, NUCLEIC ACIDS RES, V44, P3845, DOI 10.1093/nar/gkw099; Carmel MS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136408; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; Chen CL, 2013, J CLIN INVEST, V123, P2832, DOI 10.1172/JCI65859; Conway AE, 2016, CELL REP, V15, P666, DOI 10.1016/j.celrep.2016.03.052; Dai N, 2015, CELL METAB, V21, P609, DOI 10.1016/j.cmet.2015.03.006; Dai N, 2013, GENE DEV, V27, P301, DOI 10.1101/gad.209130.112; Dai N, 2011, GENE DEV, V25, P1159, DOI 10.1101/gad.2042311; Davidson B, 2014, HUM PATHOL, V45, P1520, DOI 10.1016/j.humpath.2014.03.005; Degrauwe N, 2016, GENE DEV, V30, P2459, DOI 10.1101/gad.287540.116; Degrauwe N, 2016, CELL REP, V15, P1634, DOI 10.1016/j.celrep.2016.04.086; Doyle GAR, 1998, NUCLEIC ACIDS RES, V26, P5036, DOI 10.1093/nar/26.22.5036; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Fridlender ZG, 2011, AM J RESP CELL MOL, V44, P230, DOI 10.1165/rcmb.2010-0080OC; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gong Y, 2014, ADV ANAT PATHOL, V21, P191, DOI 10.1097/PAP.0000000000000021; Goswami S, 2010, J BIOL CHEM, V285, P20532, DOI 10.1074/jbc.M110.109298; Gu W, 2012, J CELL SCI, V125, P81, DOI 10.1242/jcs.086132; Gu W, 2009, J CELL SCI, V122, P1895, DOI 10.1242/jcs.045278; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Hamilton KE, 2013, CARCINOGENESIS, V34, P2647, DOI 10.1093/carcin/bgt217; Ioannidis P, 2004, CANCER LETT, V209, P245, DOI 10.1016/j.canlet.2003.12.015; Janiszewska M, 2012, GENE DEV, V26, P1926, DOI 10.1101/gad.188292.112; JnBaptiste CK, 2017, GENE DEV, V31, P674, DOI 10.1101/gad.296301.117; Kalous A, 2014, DEV NEUROBIOL, V74, P303, DOI 10.1002/dneu.22110; Kato T, 2007, CLIN CANCER RES, V13, P434, DOI 10.1158/1078-0432.CCR-06-1297; Khan P, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2078-7; Kim HY, 2018, CANCER LETT, V415, P30, DOI 10.1016/j.canlet.2017.11.039; Kugel S, 2016, CELL, V165, P1401, DOI 10.1016/j.cell.2016.04.033; Laggai S, 2014, J LIPID RES, V55, P1087, DOI 10.1194/jlr.M045500; LEADER M, 1986, HISTOPATHOLOGY, V10, P1315, DOI 10.1111/j.1365-2559.1986.tb02574.x; Maizels Y, 2015, J CELL SCI, V128, P1922, DOI 10.1242/jcs.163972; Mongroo PS, 2011, CANCER RES, V71, P2172, DOI 10.1158/0008-5472.CAN-10-3295; Mueller S, 2018, NATURE, V554, P62, DOI 10.1038/nature25459; Muller S, 2018, NUCLEIC ACIDS RES, V46, P6285, DOI 10.1093/nar/gky229; Noubissi FK, 2006, NATURE, V441, P898, DOI 10.1038/nature04839; Noubissi Felicite K, 2010, Genes Cancer, V1, P1074, DOI 10.1177/1947601910395581; Noubissi FK, 2009, CANCER RES, V69, P8572, DOI 10.1158/0008-5472.CAN-09-1500; Nwokafor CU, 2016, ONCOTARGET, V7, P72662, DOI 10.18632/oncotarget.12083; Oberman F, 2007, RNA, V13, P1558, DOI 10.1261/rna.559507; Samanta S, 2013, J BIOL CHEM, V288, P12569, DOI 10.1074/jbc.C112.442319; Stohr N, 2012, GENE DEV, V26, P176, DOI 10.1101/gad.177642.111; Stoskus M, 2016, BLOOD CELL MOL DIS, V57, P30, DOI 10.1016/j.bcmd.2015.11.006; Tessier CR, 2004, CANCER RES, V64, P209, DOI 10.1158/0008-5472.CAN-03-2927; Timar J, 2014, CURR OPIN ONCOL, V26, P138, DOI 10.1097/CCO.0000000000000051; Uekita T, 2014, MOL CANCER RES, V12, P1449, DOI 10.1158/1541-7786.MCR-13-0587; Vainer G, 2008, J PATHOL, V215, P445, DOI 10.1002/path.2376; Vikesaa J, 2006, EMBO J, V25, P1456, DOI 10.1038/sj.emboj.7601039; Wang GL, 2016, ONCOTARGET, V7, P15690, DOI 10.18632/oncotarget.7464; Yisraeli JK, 2005, BIOL CELL, V97, P87; Zhang JH, 2015, ONCOL LETT, V9, P1927, DOI 10.3892/ol.2015.2910	55	16	16	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2019	38	21					4169	4181		10.1038/s41388-019-0715-8	http://dx.doi.org/10.1038/s41388-019-0715-8			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ3HX	30700831				2022-12-28	WOS:000468740200014
J	Zhou, XL; Zhu, CY; Wu, ZG; Guo, X; Zou, W				Zhou, Xiao-Lei; Zhu, Chong-Yue; Wu, Zhi-Gang; Guo, Xin; Zou, Wei			The oncoprotein HBXIP competitively binds KEAP1 to activate NRF2 and enhance breast cancer cell growth and metastasis	ONCOGENE			English	Article							TRANSCRIPTION FACTOR NRF2; PROMOTE PROLIFERATION; FACTOR SP1; MIGRATION; PROTEIN; PATHWAY; DYSREGULATION; DEGRADATION; MECHANISMS; MUTATIONS	The nuclear factor E2-related factor 2 (NRF2)-Kelch-like ECH-associated protein 1 (KEAP1) signaling cascades is a key transcriptional pathway governing cellular oxidative stress and tumor development. Mammalian hepatitis B X-interacting protein (HBXIP) has critical roles in modulating cancer malignance and tumor progression. However, whether HBXIP interacts with KEAP1 and NRF2 is unclear. Here, we found that HBXIP can effectually compete with NRF2 for binding with KEAP1 protein via its highly conserved GLNLG motif. The HBXIP-mediated reduction in NRF2-KEAP1 complexes promotes NRF2 accumulation and nuclear entry, which facilities the activation of antioxidant response element (ARE)dependent signaling cascades, thereby reducing the accumulation of endogenous cellular reactive oxygen species (ROS). We also found a strong positive correlation between HBXIP expression and NRF2 expression in breast cancer cells, tissue microarrays and clinical breast cancer tissues. Furthermore, this positive correlation was further confirmed via analysis of 1905 clinical cases of breast carcinoma provided by the cancer genomics database cBioPortal. Strikingly, disrupting the HBXIP-KEAP1 axis via mutating the GLNLG motif of HBXIP leads to potent inhibition of the malignancy of breast carcinoma both in vivo and in vitro. Our findings broaden our understanding of HBXIP as a modulation factor of cellular oxidative stress and address a novel regulatory mechanism governing redox homeostasis and the progression of breast carcinoma.	[Zhou, Xiao-Lei; Zhu, Chong-Yue; Wu, Zhi-Gang; Zou, Wei] Hebei Univ Sci & Technol, Publ R&D Ctr Biomanufacture, Shijiazhuang 050018, Hebei, Peoples R China; [Guo, Xin] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Mol & Cellular Pathol, 8-35-1 Sakuragaoka, Kagoshima 8908544, Japan	Hebei University of Science & Technology; Kagoshima University	Zhou, XL (corresponding author), Hebei Univ Sci & Technol, Publ R&D Ctr Biomanufacture, Shijiazhuang 050018, Hebei, Peoples R China.	foxlei@live.cn			National Natural Scientific Foundation [81602428]; Colleges and Universities in Hebei Province Science and Technology Research Project [QN2016020]; Science and Technology Research and Developmental Guidance Program of Shijiazhuang City [171201073 A]	National Natural Scientific Foundation(National Natural Science Foundation of China (NSFC)); Colleges and Universities in Hebei Province Science and Technology Research Project; Science and Technology Research and Developmental Guidance Program of Shijiazhuang City	This project was supported by grants from the National Natural Scientific Foundation (No. 81602428), the Colleges and Universities in Hebei Province Science and Technology Research Project (No. QN2016020), and the Science and Technology Research and Developmental Guidance Program of Shijiazhuang City (No. 171201073 A)	Bar-Peled L, 2012, CELL, V150, P1196, DOI 10.1016/j.cell.2012.07.032; Bauer AK, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/746432; Camp ND, 2012, J BIOL CHEM, V287, P6539, DOI 10.1074/jbc.M111.316471; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen WM, 2009, MOL CELL, V34, P663, DOI 10.1016/j.molcel.2009.04.029; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Giudice A, 2006, BIOESSAYS, V28, P169, DOI 10.1002/bies.20359; Hast BE, 2014, CANCER RES, V74, P808, DOI 10.1158/0008-5472.CAN-13-1655; Hu N, 2011, J BIOL CHEM, V286, P13714, DOI 10.1074/jbc.M110.204131; Kansanen E, 2013, REDOX BIOL, V1, P45, DOI 10.1016/j.redox.2012.10.001; Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046; Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021; Leinonen HM, 2015, BIOCHEM SOC T, V43, P645, DOI 10.1042/BST20150048; Li H, 2018, J BIOL CHEM, V293, P2053, DOI 10.1074/jbc.M117.809582; Li H, 2015, J BIOL CHEM, V290, P22649, DOI 10.1074/jbc.M115.658468; Li LL, 2015, BIOCHEM BIOPH RES CO, V458, P720, DOI 10.1016/j.bbrc.2015.02.036; Li YH, 2014, CANCER LETT, V355, P288, DOI 10.1016/j.canlet.2014.09.047; Liu BW, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0577-5; Liu Q, 2013, INT J CANCER, V133, P1310, DOI 10.1002/ijc.28154; Liu SP, 2012, J BIOL CHEM, V287, P30228, DOI 10.1074/jbc.M112.343947; Ma JL, 2012, MOL CELL BIOL, V32, P1506, DOI 10.1128/MCB.06271-11; Marusawa H, 2003, EMBO J, V22, P2729, DOI 10.1093/emboj/cdg263; Melegari M, 1998, J VIROL, V72, P1737, DOI 10.1128/JVI.72.3.1737-1743.1998; Nagy A, 2000, GENESIS, V26, P99, DOI 10.1002/(SICI)1526-968X(200002)26:2<99::AID-GENE1>3.0.CO;2-B; Onodera Y, 2014, ENDOCR-RELAT CANCER, V21, P241, DOI 10.1530/ERC-13-0234; Padmanabhan B, 2006, MOL CELL, V21, P689, DOI 10.1016/j.molcel.2006.01.013; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Shi H, 2016, BIOCHEM BIOPH RES CO, V471, P89, DOI 10.1016/j.bbrc.2016.01.174; Shibata T, 2008, GASTROENTEROLOGY, V135, P1358, DOI 10.1053/j.gastro.2008.06.082; Stacy DR, 2006, HEAD NECK-J SCI SPEC, V28, P813, DOI 10.1002/hed.20430; Taguchi K, 2011, GENES CELLS, V16, P123, DOI 10.1111/j.1365-2443.2010.01473.x; Tong KI, 2007, MOL CELL BIOL, V27, P7511, DOI 10.1128/MCB.00753-07; Torrente L, 2017, ONCOGENE, V36, P6204, DOI 10.1038/onc.2017.221; Virostko J, 2010, MOL IMAGING BIOL, V12, P42, DOI 10.1007/s11307-009-0240-1; Wang J, 2008, CANCER BIOL THER, V7, P1875, DOI 10.4161/cbt.7.12.7067; Xu FQ, 2013, CANCER LETT, V333, P124, DOI 10.1016/j.canlet.2013.01.029; Yamamoto T, 2008, MOL CELL BIOL, V28, P2758, DOI 10.1128/MCB.01704-07; Zhang YY, 2013, J BIOL CHEM, V288, P18961, DOI 10.1074/jbc.M113.458638; Zhang YY, 2013, BIOCHEM BIOPH RES CO, V434, P305, DOI 10.1016/j.bbrc.2013.02.123; Zhao Y, 2016, CANCER RES, V76, P4696, DOI 10.1158/0008-5472.CAN-15-1734; Zhou XL, 2018, ACTA PHARMACOL SIN, V39, P459, DOI 10.1038/aps.2017.157; Zipper LM, 2002, J BIOL CHEM, V277, P36544, DOI 10.1074/jbc.M206530200	45	23	25	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2019	38	21					4028	4046		10.1038/s41388-019-0698-5	http://dx.doi.org/10.1038/s41388-019-0698-5			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ3HX	30692632				2022-12-28	WOS:000468740200005
J	Tang, H; Jiang, LX; Zhu, CL; Liu, R; Wu, YF; Yan, Q; Liu, M; Jia, YX; Chen, J; Qin, YR; Lee, VHF; Luo, SX; Wang, QM; Guan, XY				Tang, Hong; Jiang, Lingxi; Zhu, Cailei; Liu, Raymond; Wu, Yufeng; Yan, Qian; Liu, Ming; Jia, Yongxu; Chen, Juan; Qin, Yanru; Lee, Victor Ho-Fun; Luo, Suxia; Wang, Qiming; Guan, Xin-Yuan			Loss of cell adhesion molecule L1 like promotes tumor growth and metastasis in esophageal squamous cell carcinomay	ONCOGENE			English	Article							CHROMOSOME 3P; GENETIC ALTERATIONS; HIGH-FREQUENCY; BETA-CATENIN; CANCER; SUPPRESSOR; LUNG; NEUROPILIN-1; METHYLATION; ABERRATIONS	Esophageal squamous cells carcinoma (ESCC) is a major common thoracic tumor characterized by distinctly high incidences and mortality rates. Despite advances in multimodality therapy, the mortality rate of ESCC remains high and understanding of molecular alterations leading to the development and progression of ESCC is still very limited. In this study, a new tumor suppressor candidate, cell adhesion molecule with homology to L1CAM (CHL1), located at 3p26 which was frequently deleted in ESCC was identified. Reduced expression of CHL1 correlated with poor differentiation, increased invasion, and lymph-node metastasis, advanced tumor stage, and decreased overall survival. Methylation-specific PCR and FISH assays revealed that down-regulation of CHL1 in both ESCC cell lines and clinical samples were associated with promoter hypermethylation and loss of heterozygosity. Functional studies using lentiviral-based overexpression and knockdown systems provided direct support of CHL1 to function as an important tumor suppressor with both anti-proliferation and anti-metastasis abilities, through Merlin and SEMA3B-Np1-mediated inhibition of AKT signaling pathway. Further characterization of CHL1 may provide a novel therapeutic target in ESCC treatment.	[Tang, Hong; Wu, Yufeng; Luo, Suxia; Wang, Qiming] Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, Dept Internal Med, Zhengzhou, Henan, Peoples R China; [Tang, Hong; Jiang, Lingxi; Zhu, Cailei; Liu, Raymond; Yan, Qian; Chen, Juan; Lee, Victor Ho-Fun; Guan, Xin-Yuan] Univ Hong Kong, Dept Clin Oncol, Li Ka Shing Fac Med, Hong Kong, Peoples R China; [Jiang, Lingxi] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Shanghai Key Lab Gastr Neoplasms, Shanghai, Peoples R China; [Liu, Ming] Guangzhou Med Univ, Sch Basic Med Sci, Key Lab Prot Modificat & Degradat, Guangzhou, Guangdong, Peoples R China; [Jia, Yongxu; Qin, Yanru] Zhengzhou Univ, Dept Clin Oncol, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China	Zhengzhou University; University of Hong Kong; Shanghai Jiao Tong University; Guangzhou Medical University; Zhengzhou University	Luo, SX; Wang, QM (corresponding author), Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, Dept Internal Med, Zhengzhou, Henan, Peoples R China.; Guan, XY (corresponding author), Univ Hong Kong, Dept Clin Oncol, Li Ka Shing Fac Med, Hong Kong, Peoples R China.	luosxrm@163.com; qimingwang1006@126.com; xyguan@hku.hk	; /A-3639-2009	Lee, Victor/0000-0002-6283-978X; /0000-0003-1874-9805; LIU, MING/0000-0003-3222-8715; Wu, Yufeng/0000-0003-0510-0388	National Key R&D Program of China [2017YFC1309000]; Shenzhen Peacock Team Project [KQTD2015033117210153]; National Natural Science Foundation of China [81472250, 81602061, 81772554]; Hong Kong Research Grant Council [HKU/7668/11 M, 767313, C7038-14G, C7027-14G]; Health and Medical Research Fund [04150826]; Natural Science Foundation of Henan Province [182300410376, 182300410297, 162300410300]	National Key R&D Program of China; Shenzhen Peacock Team Project; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Hong Kong Research Grant Council(Hong Kong Research Grants Council); Health and Medical Research Fund; Natural Science Foundation of Henan Province	This work was supported by grants from National Key R&D Program of China (2017YFC1309000), Shenzhen Peacock Team Project (KQTD2015033117210153), National Natural Science Foundation of China (81472250, 81602061, and 81772554), the Hong Kong Research Grant Council grants including GRF (HKU/7668/11 M and 767313), CRF (C7038-14G and C7027-14G), Health and Medical Research Fund (04150826), and Natural Science Foundation of Henan Province (182300410376, 182300410297, and 162300410300). Professor XY Guan is Sophie YM Chan Professor in cancer research.	Ackermann S, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-840; Castro-Rivera E, 2008, CANCER RES, V68, P8295, DOI 10.1158/0008-5472.CAN-07-6601; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chan ASC, 2000, CANCER RES, V60, P5365; Chen J, 2012, CHIN J CANCER, V31, P215, DOI 10.5732/cjc.011.10364; DALBAGNI G, 1993, LANCET, V342, P469, DOI 10.1016/0140-6736(93)91595-D; Fu L, 2007, CANCER RES, V67, P10720, DOI 10.1158/0008-5472.CAN-07-2411; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Guan XY, 2001, CANCER RES, V61, P3806; Knosel T, 2005, CLIN EXP METASTAS, V22, P533, DOI 10.1007/s10585-005-5239-7; Kou CH, 2015, BIOCHEM BIOPH RES CO, V464, P519, DOI 10.1016/j.bbrc.2015.06.173; Kwong D, 2004, HUM PATHOL, V35, P309, DOI 10.1016/j.humpath.2003.10.020; Li J Y, 1982, Natl Cancer Inst Monogr, V62, P113; Li K, 2002, INT J CANCER, V102, P271, DOI [10.1002/ijc.10706, 10.1002/jhc.10706]; Li Y, 2002, J BIOL CHEM, V277, P11352, DOI 10.1074/jbc.M109062200; Loginov VI, 2009, MOL BIOL+, V43, P1014, DOI 10.1134/S0026893309060156; Ming XY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13568; Miyoshi Y, 1998, CANCER RES, V58, P2524; OGASAWARA S, 1995, CANCER RES, V55, P891; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Ognibene Marzia, 2018, Oncotarget, V9, P25903, DOI 10.18632/oncotarget.25403; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Portale G, 2006, J AM COLL SURGEONS, V202, P588, DOI 10.1016/j.jamcollsurg.2005.12.022; PRESTI JC, 1991, CANCER RES, V51, P5405; Qian CN, 2006, CANCER RES, V66, P10365, DOI 10.1158/0008-5472.CAN-06-2977; Qin YR, 2008, INT J CANCER, V123, P826, DOI 10.1002/ijc.23577; Raju SC, 2015, ORAL ONCOL, V51, P470, DOI 10.1016/j.oraloncology.2015.01.014; Rong R, 2004, P NATL ACAD SCI USA, V101, P18200, DOI 10.1073/pnas.0405971102; Schlatter MC, 2008, J NEUROCHEM, V104, P731, DOI 10.1111/j.1471-4159.2007.05013.x; Senchenko VN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015612; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091; Uchida K, 2011, ONCOL REP, V26, P463, DOI 10.3892/or.2011.1327; Wright AG, 2007, J NEUROSCI, V27, P13667, DOI 10.1523/JNEUROSCI.2888-07.2007; Xie D, 2003, INT J CANCER, V107, P896, DOI 10.1002/ijc.11514; Yamaguchi H, 2007, BBA-MOL CELL RES, V1773, P642, DOI 10.1016/j.bbamcr.2006.07.001; Yen CC, 2007, LUNG CANCER, V57, P292, DOI 10.1016/j.lungcan.2007.04.007; Zhang YJ, 2002, MOL CARCINOGEN, V35, P85, DOI 10.1002/mc.10076; Zhu C, 2009, ONCOGENE, V28, P2821, DOI 10.1038/onc.2009.137; 2001, CANCER, V92, P2769; 2010, INT J CANCER, V127, P2893, DOI DOI 10.1002/IJC.25516	41	17	18	4	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2019	38	17					3119	3133		10.1038/s41388-018-0648-7	http://dx.doi.org/10.1038/s41388-018-0648-7			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU8RI	30622339				2022-12-28	WOS:000465557200002
J	Liu, BY; Yi, JJ; Yan, X; Liu, L; Lou, XL; Zhang, ZY; Qi, H; Wang, Z; Zou, JH; Zhu, WG; Gu, W; Luo, JY				Liu, Boya; Yi, Jingjie; Yan, Xin; Liu, Lu; Lou, Xinlin; Zhang, Zeyuan; Qi, Hao; Wang, Zhe; Zou, Junhua; Zhu, Wei-Guo; Gu, Wei; Luo, Jianyuan			MDM2-mediated degradation of WRN promotes cellular senescence in a p53-independent manner	ONCOGENE			English	Article							WERNER-SYNDROME PROTEIN; DNA-DAMAGE; TARGETS WRN; P53 PATHWAY; S-PHASE; MDM2; HELICASE; PHOSPHORYLATION; E3; PRODUCT	MDM2 (Murine double minute 2) acts as a key repressor for p53-mediated tumor-suppressor functions, which includes cellular senescence. We found that MDM2 can promote cellular senescence by modulating WRN stability. Werner syndrome (WS), caused by mutations of the WRN gene, is an autosomal recessive disease, which is characterized by premature aging. Loss of WRN function induces cellular senescence in human cancer cells. Here, we found that MDM2 acts as an E3 ligase for WRN protein. MDM2 interacts with WRN both in vivo and in vitro. MDM2 induces ubiquitination of WRN and dramatically downregulates the levels of WRN protein in human cells. During DNA damage response, WRN is translocated to the nucleoplasm to facilitate its DNA repair functions; however, it is degraded by the MDM2-mediated ubiquitination pathway. Moreover, the senescent phenotype induced by DNA damage reagents, such as Etoposide, is at least in part mediated by MDM2-dependent WRN degradation as it can be significantly attenuated by ectopic expression of WRN. These results show that MDM2 is critically involved in regulating WRN function via ubiquitin-dependent degradation and reveal an unexpected role of MDM2 in promoting cellular senescence through a p53-independent manner.	[Liu, Boya; Yan, Xin; Liu, Lu; Lou, Xinlin; Zhang, Zeyuan; Qi, Hao; Wang, Zhe; Zou, Junhua; Luo, Jianyuan] Peking Univ, Hlth Sci Ctr, Dept Med Genet, 38 Xueyuan Rd, Beijing 100191, Peoples R China; [Yi, Jingjie; Gu, Wei] Columbia Univ, Inst Canc Genet, New York, NY 10032 USA; [Zhu, Wei-Guo] Shenzhen Univ, Sch Med, Dept Biochem & Mol Biol, Shenzhen, Peoples R China	Peking University; Columbia University; Shenzhen University	Luo, JY (corresponding author), Peking Univ, Hlth Sci Ctr, Dept Med Genet, 38 Xueyuan Rd, Beijing 100191, Peoples R China.	luojianyuan@bjmu.edu.cn	Luo, Jianyuan/ABI-7585-2020	Luo, Jianyuan/0000-0001-6057-2914; Zhu, Wei-Guo/0000-0001-8385-6581; Yang, Xin/0000-0003-0222-5839	National Natural Science Foundation of China [81270427, 81471405, 81671389, 81720108027, 81321003]; National Research Program of National Natural Science Foundation of China China [2013CB530801]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Research Program of National Natural Science Foundation of China China(National Natural Science Foundation of China (NSFC))	This work was supported by National Natural Science Foundation of China (81270427, 81471405, 81671389, 81720108027 and 81321003) and from National Research Program of National Natural Science Foundation of China China (973 Program, 2013CB530801).	Ammazzalorso F, 2010, EMBO J, V29, P3156, DOI 10.1038/emboj.2010.205; Bernstein KA, 2010, ANNU REV GENET, V44, P393, DOI 10.1146/annurev-genet-102209-163602; Blander G, 2002, J BIOL CHEM, V277, P50934, DOI 10.1074/jbc.M210479200; Bohr VA, 2000, EXP GERONTOL, V35, P695, DOI 10.1016/S0531-5565(00)00145-5; Brenkman AB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002819; Cheng WH, 2003, MOL CELL BIOL, V23, P6385, DOI 10.1128/MCB.23.18.6385-6395.2003; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Crabbe L, 2004, SCIENCE, V306, P1951, DOI 10.1126/science.1103619; Croteau DL, 2014, ANNU REV BIOCHEM, V83, P519, DOI 10.1146/annurev-biochem-060713-035428; Ghosh A, 2009, J BIOL CHEM, V284, P31074, DOI 10.1074/jbc.M109.027532; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Itahana K, 2007, CANCER CELL, V12, P355, DOI 10.1016/j.ccr.2007.09.007; Kang C, 2015, SCIENCE, V349, DOI 10.1126/science.aaa5612; Kawabe Y, 2000, J BIOL CHEM, V275, P20963, DOI 10.1074/jbc.C000273200; Kusumoto R, 2007, MECH AGEING DEV, V128, P50, DOI 10.1016/j.mad.2006.11.010; Lebel M, 1998, P NATL ACAD SCI USA, V95, P13097, DOI 10.1073/pnas.95.22.13097; Li K, 2008, J BIOL CHEM, V283, P7590, DOI 10.1074/jbc.M709707200; Li K, 2010, PLOS ONE, V5, DOI [10.1371/journal.pone.0012286, 10.1371/journal.pone.0010341]; Mikawa T, 2014, J CELL BIOL, V204, P729, DOI 10.1083/jcb.201306149; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Muftuoglu M, 2008, HUM GENET, V124, P369, DOI 10.1007/s00439-008-0562-0; Muftuoglu M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001918; Palermo V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12880; Pichierri P, 2003, ONCOGENE, V22, P1491, DOI 10.1038/sj.onc.1206169; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; Rufini A, 2013, ONCOGENE, V32, P5129, DOI 10.1038/onc.2012.640; Shamanna RA, 2016, ONCOTARGET, V7, P13269, DOI 10.18632/oncotarget.7906; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Sidorova JM, 2008, CELL CYCLE, V7, P796, DOI 10.4161/cc.7.6.5566; Su FT, 2016, ONCOTARGET, V7, P46, DOI 10.18632/oncotarget.6659; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Tollini LA, 2014, CANCER CELL, V26, P235, DOI 10.1016/j.ccr.2014.06.006; Uchida CH, 2005, EMBO J, V24, P160, DOI 10.1038/sj.emboj.7600486; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Wu ZH, 2006, SCIENCE, V311, P1141, DOI 10.1126/science.1121513; Yannone SM, 2001, J BIOL CHEM, V276, P38242; Zuckerman V, 2009, J PATHOL, V219, P3, DOI 10.1002/path.2584	41	13	13	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2019	38	14					2501	2515		10.1038/s41388-018-0605-5	http://dx.doi.org/10.1038/s41388-018-0605-5			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HR7LI	30532073				2022-12-28	WOS:000463335200005
J	Chen, CW; Li, YM; Hu, SY; Zhou, W; Meng, YX; Li, ZZ; Zhang, Y; Sun, J; Bob, Z; DePamphilis, ML; Yen, Y; Han, ZY; Zhu, WG				Chen, Chi-Wei; Li, Yongming; Hu, Shuya; Zhou, Wei; Meng, Yunxiao; Li, Zongzhu; Zhang, Yi; Sun, Jing; Bob, Zhou; DePamphilis, Melvin L.; Yen, Yun; Han, Zhiyong; Zhu, Wenge			DHS (trans-4,4 '-dihydroxystilbene) suppresses DNA replication and tumor growth by inhibiting RRM2 (ribonucleotide reductase regulatory subunit M2)	ONCOGENE			English	Article							CHEMOPREVENTIVE AGENT RESVERATROL; CANCER CELL-LINES; TAMOXIFEN RESISTANCE; ENHANCED ANTIOXIDANT; DOWN-REGULATION; GEMCITABINE; ANALOG; DAMAGE; CYCLE; MOUSE	DNA replication machinery is responsible for accurate and efficient duplication of the chromosome. Since inhibition of DNA replication can lead to replication fork stalling, resulting in DNA damage and apoptotic death, inhibitors of DNA replication are commonly used in cancer chemotherapy. Ribonucleotide reductase (RNR) is the rate-limiting enzyme in the biosynthesis of deoxyribonucleoside triphosphates (dNTPs) that are essential for DNA replication and DNA damage repair. Gemcitabine, a nucleotide analog that inhibits RNR, has been used to treat various cancers. However, patients often develop resistance to this drug during treatment. Thus, new drugs that inhibit RNR are needed to be developed. In this study, we identified a synthetic analog of resveratrol (3,5,4'-trihydroxy-trans-stilbene), termed DHS (trans-4,4'-dihydroxystilbene), that acts as a potent inhibitor of DNA replication. Molecular docking analysis identified the RRM2 (ribonucleotide reductase regulatory subunit M2) of RNR as a direct target of DHS. At the molecular level, DHS induced cyclin F-mediated down-regulation of RRM2 by the proteasome. Thus, treatment of cells with DHS reduced RNR activity and consequently decreased synthesis of dNTPs with concomitant inhibition of DNA replication, arrest of cells at S-phase, DNA damage, and finally apoptosis. In mouse models of tumor xenografts, DHS was efficacious against pancreatic, ovarian, and colorectal cancer cells. Moreover, DHS overcame both gemcitabine resistance in pancreatic cancer and cisplatin resistance in ovarian cancer. Thus, DHS is a novel anti-cancer agent that targets RRM2 with therapeutic potential either alone or in combination with other agents to arrest cancer development.	[Chen, Chi-Wei; Li, Yongming; Zhou, Wei; Meng, Yunxiao; Li, Zongzhu; Zhang, Yi; Sun, Jing; Zhu, Wenge] George Washington Univ, Sch Med & Hlth Sci, Dept Biochem & Mol Med, Washington, DC 20052 USA; [Chen, Chi-Wei; Zhou, Wei; Meng, Yunxiao; Li, Zongzhu; Zhang, Yi; Sun, Jing; Zhu, Wenge] George Washington Univ, GW Canc Ctr, Washington, DC 20052 USA; [Li, Yongming] Dalian Med Univ, Coll Basic Med Sci, Dalian, Peoples R China; [Hu, Shuya; Yen, Yun] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA; [Zhou, Wei] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Colorectal Surg, Hangzhou, Zhejiang, Peoples R China; [Bob, Zhou] Lanzhou Univ, State Key Lab Appl Organ Chem, Lanzhou, Gansu, Peoples R China; [DePamphilis, Melvin L.] NICHHD, Bethesda, MD 20892 USA; [Han, Zhiyong] Seton Hall Univ, Dept Med Sci, Hackensack Meridian Sch Med, S Orange, NJ 07079 USA	George Washington University; George Washington University; Dalian Medical University; City of Hope; Zhejiang University; Lanzhou University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Seton Hall University	Zhu, WG (corresponding author), George Washington Univ, Sch Med & Hlth Sci, Dept Biochem & Mol Med, Washington, DC 20052 USA.; Zhu, WG (corresponding author), George Washington Univ, GW Canc Ctr, Washington, DC 20052 USA.; Han, ZY (corresponding author), Seton Hall Univ, Dept Med Sci, Hackensack Meridian Sch Med, S Orange, NJ 07079 USA.	zhiyong.han@shu.edu; wz6812@gwu.edu	Zhang, Bob/HIR-3656-2022; li, yong/HDN-3885-2022	Chen, Chi-Wei/0000-0001-8658-055X	National Institutes of Health [CA177898, CA184717, RSG-13-214-01-DMC]; American Cancer Society; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000506] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA177898, R01CA184717] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was partially supported by funding from the National Institutes of Health (CA177898 and CA184717 to WZ). WZ was supported by a Research Scholar Grant, RSG-13-214-01-DMC from the American Cancer Society.	Aye Y, 2015, ONCOGENE, V34, P2011, DOI 10.1038/onc.2014.155; Balan KV, 2006, BIOCHEM PHARMACOL, V72, P573, DOI 10.1016/j.bcp.2006.05.023; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bikadi Z, 2009, J CHEMINFORMATICS, V1, DOI 10.1186/1758-2946-1-15; Brown VA, 2010, CANCER RES, V70, P9003, DOI 10.1158/0008-5472.CAN-10-2364; Cai YJ, 2004, ANTICANCER RES, V24, P999; Chabes A, 2000, J BIOL CHEM, V275, P17747, DOI 10.1074/jbc.M000799200; Chen CW, 2016, NEOPLASIA, V18, P199, DOI 10.1016/j.neo.2016.02.005; Chen MC, 2015, MOL PHARMACOL, V87, P996, DOI 10.1124/mol.114.094987; Chen W, 2015, ANAL BIOANAL CHEM, V407, P5793, DOI 10.1007/s00216-015-8762-7; Chen ZH, 2004, CARCINOGENESIS, V25, P2005, DOI 10.1093/carcin/bgh183; Chen ZM, 2011, BIOCHEM BIOPH RES CO, V413, P383, DOI 10.1016/j.bbrc.2011.08.111; D'Angiolella V, 2012, CELL, V149, P1023, DOI 10.1016/j.cell.2012.03.043; Fabbrocini G, 2011, AM J CLIN DERMATOL, V12, P133, DOI 10.2165/11530630-000000000-00000; Fan GJ, 2009, BIOORGAN MED CHEM, V17, P2360, DOI 10.1016/j.bmc.2009.02.014; Fang JG, 2002, CHEM-EUR J, V8, P4191, DOI 10.1002/1521-3765(20020916)8:18<4191::AID-CHEM4191>3.0.CO;2-S; Fontecave M, 1998, FEBS LETT, V421, P277, DOI 10.1016/S0014-5793(97)01572-X; Gertz M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049761; Goan YG, 1999, CANCER RES, V59, P4204; Harikumar KB, 2010, INT J CANCER, V127, P257, DOI 10.1002/ijc.25041; Hehlmann R, 2003, LEUKEMIA, V17, P1010, DOI 10.1038/sj.leu.2402951; Hosseini A, 2015, AVICENNA J PHYTOMEDI, V5, P84; Hsieh YY, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.27; Hu S, 2016, ACTA BIOCH BIOPH SIN, V48, P528, DOI 10.1093/abbs/gmw026; Jafari R, 2014, NAT PROTOC, V9, P2100, DOI 10.1038/nprot.2014.138; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Jung CP, 2001, CLIN CANCER RES, V7, P2527; Kimura Y, 2008, CANCER SCI, V99, P2083, DOI 10.1111/j.1349-7006.2008.00948.x; Kitao H, 2018, CANCER SCI, V109, P264, DOI 10.1111/cas.13455; Kohnken R, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0446-6; Li GM, 2013, CANCER PREV RES, V6, P27, DOI 10.1158/1940-6207.CAPR-12-0349; Liu J, 2004, NEUROSCI LETT, V363, P257, DOI 10.1016/j.neulet.2004.03.075; Liu XY, 2013, CLIN SCI, V124, P567, DOI 10.1042/CS20120240; LOEWE S, 1953, ARZNEIMITTEL-FORSCH, V3, P285; Lopez-Contreras AJ, 2015, GENE DEV, V29, P690, DOI 10.1101/gad.256958.114; Lu AG, 2012, WORLD J GASTROENTERO, V18, P4704, DOI 10.3748/wjg.v18.i34.4704; Ma LJ, 2015, INT J ONCOL, V47, P1460, DOI 10.3892/ijo.2015.3124; Maccario C, 2012, CARCINOGENESIS, V33, P2172, DOI 10.1093/carcin/bgs244; Minami K, 2015, J PHARMACOL SCI, V127, P319, DOI 10.1016/j.jphs.2015.01.006; Mini E, 2006, ANN ONCOL, V17, pV7, DOI 10.1093/annonc/mdj941; Morikawa T, 2010, HISTOPATHOLOGY, V57, P885, DOI 10.1111/j.1365-2559.2010.03725.x; Morikawa T, 2010, HUM PATHOL, V41, P1742, DOI 10.1016/j.humpath.2010.06.001; Nakano Y, 2007, BRIT J CANCER, V96, P457, DOI 10.1038/sj.bjc.6603559; Nessa MU, 2012, ANTICANCER RES, V32, P53; Nordlund N, 2006, ANNU REV BIOCHEM, V75, P681, DOI 10.1146/annurev.biochem.75.103004.142443; O'Connor MJ, 2015, MOL CELL, V60, P547, DOI 10.1016/j.molcel.2015.10.040; Piotrowska H, 2013, TOXICOL IN VITRO, V27, P2127, DOI 10.1016/j.tiv.2013.09.012; Piotrowska H, 2012, TOXICOL APPL PHARM, V263, P53, DOI 10.1016/j.taap.2012.05.023; Plunkett W, 1995, ANTI-CANCER DRUG, V6, P7, DOI 10.1097/00001813-199512006-00002; PLUNKETT W, 1995, SEMIN ONCOL, V22, P3; Puigvert JC, 2016, FEBS J, V283, P232, DOI 10.1111/febs.13574; Saha B, 2017, ONCOTARGET, V8, P73905, DOI 10.18632/oncotarget.17879; Saiki Y, 2012, BIOCHEM BIOPH RES CO, V421, P98, DOI 10.1016/j.bbrc.2012.03.122; Sale S, 2005, INT J CANCER, V115, P194, DOI 10.1002/ijc.20884; Savio M, 2016, SCI REP-UK, V6, DOI 10.1038/srep19973; Scharadin TM, 2016, CHEM RES TOXICOL, V29, P1843, DOI 10.1021/acs.chemrestox.6b00247; Shah KN, 2015, MOL CANCER THER, V14, P2411, DOI 10.1158/1535-7163.MCT-14-0689; Shah KN, 2014, MOL CANCER RES, V12, P394, DOI 10.1158/1541-7786.MCR-13-0219; SHERMAN PA, 1989, ANAL BIOCHEM, V180, P222, DOI 10.1016/0003-2697(89)90420-X; Shewach DS, 2007, J CLIN ONCOL, V25, P4043, DOI 10.1200/JCO.2007.11.5287; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; THELANDER M, 1985, J BIOL CHEM, V260, P2737; Varoni EM, 2016, FRONT NUTR, V3, DOI 10.3389/fnut.2016.00008; Wang LM, 2012, CHINESE MED J-PEKING, V125, P2151, DOI 10.3760/cma.j.issn.0366-6999.2012.12.013; Yamaguchi T, 2001, CANCER RES, V61, P8256; Zhang J, 2016, GENES-BASEL, V7, DOI 10.3390/genes7080051; Zhou BS, 2013, CANCER RES, V73, P6484, DOI 10.1158/0008-5472.CAN-13-1094; Zhou BS, 1998, BIOCHEM PHARMACOL, V55, P1657, DOI 10.1016/S0006-2952(98)00042-2; Zhou W, 2018, ONCOGENE, V37, P3981, DOI 10.1038/s41388-018-0238-8; Zhu WG, 2007, GENE DEV, V21, P2288, DOI 10.1101/gad.1585607	70	30	30	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2019	38	13					2364	2379		10.1038/s41388-018-0584-6	http://dx.doi.org/10.1038/s41388-018-0584-6			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ7GN	30518875	Green Accepted			2022-12-28	WOS:000462588000010
J	Gooding, AJ; Zhang, B; Gunawardane, L; Beard, A; Valadkhan, S; Schiemann, WP				Gooding, Alex J.; Zhang, Bing; Gunawardane, Lalith; Beard, Abigail; Valadkhan, Saba; Schiemann, William P.			The lncRNA BORG facilitates the survival and chemoresistance of triple-negative breast cancers	ONCOGENE			English	Article							NF-KAPPA-B; LONG NONCODING RNAS; CELL-CYCLE; OXIDATIVE STRESS; PROTEIN; TUMOR; GENE; DOXORUBICIN; ACTIVATION; PATTERNS	Disseminated breast cancer cells employ adaptive molecular responses following cytotoxic therapeutic insult which promotes their survival and subsequent outgrowth. Here we demonstrate that expression of the pro-metastatic lncRNA BORG (BMP/OP-Responsive Gene) is greatly induced within triple-negative breast cancer (TNBC) cells subjected to environmental and chemotherapeutic stresses commonly faced by TNBC cells throughout the metastatic cascade. This stress-mediated induction of BORG expression fosters the survival of TNBC cells and renders them resistant to the cytotoxic effects of doxorubicin both in vitro and in vivo. The chemoresistant traits of BORG depend upon its robust activation of the NF-kappa B signaling axis via a novel BORG-mediated feed-forward signaling loop, and via its ability to bind and activate RPA1. Indeed, genetic and pharmacologic inhibition of NF-kappa B signaling or the DNA-binding activity of RPA1 abrogates the pro-survival features of BORG and renders BORG-expressing TNBCs sensitive to doxorubicin-induced cytotoxicity. These findings suggest that therapeutic targeting of BORG or its downstream molecular effectors may provide a novel means to alleviate TNBC recurrence.	[Gooding, Alex J.; Beard, Abigail; Schiemann, William P.] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA; [Zhang, Bing; Gunawardane, Lalith; Valadkhan, Saba] Case Western Reserve Univ, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Schiemann, WP (corresponding author), Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA.; Valadkhan, S (corresponding author), Case Western Reserve Univ, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA.	saba.valadkhan@case.edu; william.schiemann@case.edu	Valadkhan, Saba/G-7271-2012	Valadkhan, Saba/0000-0002-6859-4883	National Institutes of Health [CA129359, CA177069, CA194518, T32GM007250, F30CA203233]; METAvivor Foundation; Case Comprehensive Cancer Center's Research Innovation Fund - Case Council; Friends of the Case Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE [F30CA203233] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [TL1TR002549] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007250] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); METAvivor Foundation; Case Comprehensive Cancer Center's Research Innovation Fund - Case Council; Friends of the Case Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Members of the Schiemann Laboratory are thanked for critical comments and reading of the manuscript. We thank Dr. Ricky Chan for assistance in our analyses of RNA-seq data. We also acknowledge the expertise provided by members of the Case Comprehensive Cancer Center's Core Facilities, including the Gene Expression & Genotyping Core, the Imaging Research Core, Tissue Resources Core, and the Genomics Core. Research support was provided in part by the National Institutes of Health to W.P.S. (CA129359, CA177069, and CA194518) and A.J.G (T32GM007250 and F30CA203233). Additional support was graciously provided by the METAvivor Foundation (W.P.S.), and by pilot funding from the Case Comprehensive Cancer Center's Research Innovation Fund, which is supported by the Case Council and Friends of the Case Comprehensive Cancer Center (W.P.S. and S.V.).	Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Ahmed KM, 2006, ANTICANCER RES, V26, P4235; Alluri P, 2014, SURG ONCOL CLIN N AM, V23, P567, DOI 10.1016/j.soc.2014.03.003; BARAL E, 1990, INT J RADIAT ONCOL, V19, P963, DOI 10.1016/0360-3016(90)90019-G; Boehm JS, 2007, CELL, V129, P1065, DOI 10.1016/j.cell.2007.03.052; Boutet-Robinet E, 2013, BIO PROTOC, V3, P12; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Catalano V, 2013, SEMIN CANCER BIOL, V23, P522, DOI 10.1016/j.semcancer.2013.08.007; Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239; Courilleau C, 2012, J CELL BIOL, V199, P1067, DOI 10.1083/jcb.201205059; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Di Gesualdo F, 2014, ONCOTARGET, V5, P10976, DOI 10.18632/oncotarget.2770; DiPaola RS, 2002, CLIN CANCER RES, V8, P3311; Farre D, 2003, NUCLEIC ACIDS RES, V31, P3651, DOI 10.1093/nar/gkg605; Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149; Furlow PW, 2015, NAT CELL BIOL, V17, P943, DOI 10.1038/ncb3194; Godwin P, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00120; Gomis RR, 2006, CANCER CELL, V10, P203, DOI 10.1016/j.ccr.2006.07.019; Gooding AJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12716-6; Gupta SC, 2010, BBA-GENE REGUL MECH, V1799, P775, DOI 10.1016/j.bbagrm.2010.05.004; Guzman C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092444; Haring SJ, 2008, J BIOL CHEM, V283, P19095, DOI 10.1074/jbc.M800881200; Hayden MS, 2012, GENE DEV, V26, P203, DOI 10.1101/gad.183434.111; Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86; Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599; Huang B, 2009, MOL CELL BIOL, V29, P1375, DOI 10.1128/MCB.01365-08; Huang Z, 2016, INT J CANCER, V139, P23, DOI 10.1002/ijc.29990; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Israel A, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000158; Jezierska-Drutel A, 2013, ADV CANCER RES, V119, P107, DOI 10.1016/B978-0-12-407190-2.00003-4; Khan S, 2013, CANCER LETT, V337, P90, DOI 10.1016/j.canlet.2013.05.020; Klein CA, 2011, CURR OPIN GENET DEV, V21, P42, DOI 10.1016/j.gde.2010.10.011; Kouroukis TC, 2014, CURR ONCOL, V21, pE573, DOI 10.3747/co.21.1798; Labun K, 2016, NUCLEIC ACIDS RES, V44, pW272, DOI 10.1093/nar/gkw398; Lakhotia SC, 2012, WIRES RNA, V3, P779, DOI 10.1002/wrna.1135; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Li CH, 2013, INT J BIOCHEM CELL B, V45, P1895, DOI 10.1016/j.biocel.2013.05.030; Li SD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098021; Ling YH, 1996, MOL PHARMACOL, V49, P832; Lopez JS, 2017, NAT REV CLIN ONCOL, V14, P57, DOI 10.1038/nrclinonc.2016.96; Lu SQ, 2013, BIOMARK RES, V1, DOI 10.1186/2050-7771-1-13; Lupertz R, 2010, TOXICOLOGY, V271, P115, DOI 10.1016/j.tox.2010.03.012; Luzzi KJ, 1998, AM J PATHOL, V153, P865, DOI 10.1016/S0002-9440(10)65628-3; Mahadevan NR, 2011, J IMMUNOL, V187, P4403, DOI 10.4049/jimmunol.1101531; Malhotra A, 2017, ONCOTARGET, V8, P110671, DOI 10.18632/oncotarget.22577; Mao XH, 2017, IMMUNOLOGY, V150, P379, DOI 10.1111/imm.12698; Mary Goldman B. C., 2019, BIORXIV, DOI [DOI 10.1101/326470, 10.1101/326470]; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Montagut C, 2006, ENDOCR-RELAT CANCER, V13, P607, DOI 10.1677/erc.1.01171; Neil JR, 2008, CANCER RES, V68, P1462, DOI 10.1158/0008-5472.CAN-07-3094; Neil JR, 2009, J BIOL CHEM, V284, P21209, DOI 10.1074/jbc.M109.018374; Paramore A, 2003, NAT REV DRUG DISCOV, V2, P611, DOI 10.1038/nrd1159; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Piva R, 2006, ANTIOXID REDOX SIGN, V8, P478, DOI 10.1089/ars.2006.8.478; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Senft D, 2016, TRENDS CANCER, V2, P429, DOI 10.1016/j.trecan.2016.06.004; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Shuck SC, 2010, CANCER RES, V70, P3189, DOI 10.1158/0008-5472.CAN-09-3422; Somaiah C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145068; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takeda K, 1998, J BIOL CHEM, V273, P17079, DOI 10.1074/jbc.273.27.17079; Tiligada E, 2006, ENDOCR-RELAT CANCER, V13, pS115, DOI 10.1677/erc.1.01272; Tong AJ, 2016, CELL, V165, P165, DOI 10.1016/j.cell.2016.01.020; Tornatore L, 2014, CANCER CELL, V26, P495, DOI 10.1016/j.ccr.2014.07.027; Torre LA, 2017, CANCER EPIDEM BIOMAR, V26, P444, DOI 10.1158/1055-9965.EPI-16-0858; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Tyagi AK, 2002, CLIN CANCER RES, V8, P3512; Valadkhan S, 2016, CURR TOP MICROBIOL, V394, P203, DOI 10.1007/82_2015_489; Vanharanta S, 2013, CANCER CELL, V24, P410, DOI 10.1016/j.ccr.2013.09.007; Victorino VJ, 2014, CURR MED CHEM, V21, P3211, DOI 10.2174/0929867321666140601164647; Wan FY, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000067; Wendt MK, 2011, MOL BIOL CELL, V22, P2423, DOI 10.1091/mbc.E11-04-0306; White E, 2015, CLIN CANCER RES, V21, P5037, DOI 10.1158/1078-0432.CCR-15-0490; Wullaert A, 2011, CELL RES, V21, P146, DOI 10.1038/cr.2010.175; Yap WT, 2013, TISSUE ENG PT A, V19, P2361, DOI [10.1089/ten.tea.2013.0033, 10.1089/ten.TEA.2013.0033]; Yuan Y, 2003, J BIOL CHEM, V278, P15911, DOI 10.1074/jbc.M300463200; Zanotto A, 2016, MOL CANCER THER, V15, P3000, DOI 10.1158/1535-7163.MCT-16-0271; Zhang B, 2014, MOL CELL BIOL, V34, P2318, DOI 10.1128/MCB.01673-13; Zhao MM, 2017, CELL REP, V20, P1997, DOI 10.1016/j.celrep.2017.08.015; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	83	55	56	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2019	38	12					2020	2041		10.1038/s41388-018-0586-4	http://dx.doi.org/10.1038/s41388-018-0586-4			22	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP6UR	30467380	Green Accepted			2022-12-28	WOS:000461822600003
J	Kumari, S; Srivastav, RK; Wilkesi, DW; Ross, T; Kim, S; Kowalski, J; Chatlal, S; Zhang, Q; Nayak, A; Guha, M; Fuchs, SY; Thomas, C; Chakrabarti, R				Kumari, Sushi; Srivastav, Ratnesh Kumar; Wilkesi, David W.; Ross, Taylor; Kim, Sabrina; Kowalski, Jules; Chatlal, Srinivas; Zhang, Qing; Nayak, Anupma; Guha, Manti; Fuchs, Serge Y.; Thomas, Christoforos; Chakrabarti, Rumela			Estrogen-dependent DLL1-mediated Notch signaling promotes luminal breast cancer	ONCOGENE			English	Article							STEM-CELLS; TARGETING NOTCH; RECEPTOR; HETEROGENEITY; ANGIOGENESIS; METASTASIS; SUBTYPES; MEDIATOR; PATHWAY; FATE	Aberrant Notch signaling is implicated in several cancers, including breast cancer. However, the mechanistic details of the specific receptors and function of ligand-mediated Notch signaling that promote breast cancer remains elusive. In our studies we show that DLL1, a Notch signaling ligand, is significantly overexpressed in ER alpha(+) luminal breast cancer. Intriguingly, DLL1 overexpression correlates with poor prognosis in ER alpha(+) luminal breast cancer, but not in other subtypes of breast cancer. In addition, this effect is specific to DLL1, as other Notch ligands (DLL3, JAGGED1, and JAGGED2) do not influence the clinical outcome of ER alpha(+) patients. Genetic studies show that DLL1-mediated Notch signaling in breast cancer is important for tumor cell proliferation, angiogenesis, and cancer stem cell function. Consistent with prognostic clinical data, we found the tumor-promoting function of DLL1 is exclusive to ER alpha(+) luminal breast cancer, as loss of DLL1 inhibits both tumor growth and lung metastasis of luminal breast cancer. Importantly, we find that estrogen signaling stabilizes DLL1 protein by preventing its proteasomal and lysososmal degradations. Moreover, estrogen inhibits ubiquitination of DLL1. Together, our results highlight an unexpected and novel subtype-specific function of DLL1 in promoting luminal breast cancer that is regulated by estrogen signaling. Our studies also emphasize the critical role of assessing subtype-specific mechanisms driving tumor growth and metastasis to generate effective subtype-specific therapeutics.	[Kumari, Sushi; Srivastav, Ratnesh Kumar; Wilkesi, David W.; Ross, Taylor; Kim, Sabrina; Kowalski, Jules; Chatlal, Srinivas; Guha, Manti; Fuchs, Serge Y.; Chakrabarti, Rumela] Univ Penn, Dept Biomed Sci, Sch Vet Med, Philadelphia, PA 19104 USA; [Zhang, Qing] Univ N Carolina, Dept Pathol & Lab Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Nayak, Anupma] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Hosp Univ Penn, Philadelphia, PA 19104 USA; [Thomas, Christoforos] Univ Penn, Perelman Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of North Carolina; University of North Carolina Chapel Hill; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine	Chakrabarti, R (corresponding author), Univ Penn, Dept Biomed Sci, Sch Vet Med, Philadelphia, PA 19104 USA.	rumela@vet.upenn.edu	Kumar, Sushil/AAF-1312-2019; Srivastav, Ratnesh/CAI-4994-2022; ZHANG, QING/AGY-7972-2022; Chatla, Srinivas/AAA-9299-2020	Kumar, Sushil/0000-0003-0547-745X; ZHANG, QING/0000-0002-6595-8995; Chatla, Srinivas/0000-0002-8509-8494	NATIONAL CANCER INSTITUTE [R01CA092900] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA092900] Funding Source: Medline; NIH HHS [T35 OD010919] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Allenspach EJ, 2002, CANCER BIOL THER, V1, P466, DOI 10.4161/cbt.1.5.159; Andersson ER, 2014, NAT REV DRUG DISCOV, V13, P359, DOI 10.1038/nrd4252; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Bertucci Francois, 2008, J Biol, V7, P6, DOI 10.1186/jbiol67; Bray SJ, 2016, NAT REV MOL CELL BIO, V17, P722, DOI 10.1038/nrm.2016.94; Capaccione KM, 2013, CARCINOGENESIS, V34, P1420, DOI 10.1093/carcin/bgt127; Carroll JS, 2016, EUR J ENDOCRINOL, V175, pR41, DOI 10.1530/EJE-16-0124; Chakrabarti R, 2014, NAT CELL BIOL, V16; Chakrabarti R, 2018, SCIENCE, V360, P1421, DOI 10.1126/science.aan4153; Chakrabarti Rumela, 2015, Methods Mol Biol, V1267, P367, DOI 10.1007/978-1-4939-2297-0_18; Chakrabarti R, 2012, NAT CELL BIOL, V14, P1212, DOI 10.1038/ncb2607; Chakrabarti R, 2012, STEM CELLS, V30, P1496, DOI 10.1002/stem.1112; Chen L, 2012, BIOMATERIALS, V33, P1437, DOI 10.1016/j.biomaterials.2011.10.056; Cho RW, 2008, STEM CELLS, V26, P364, DOI 10.1634/stemcells.2007-0440; Choi YS, 2009, DEV BIOL, V329, P227, DOI 10.1016/j.ydbio.2009.02.032; Clarke R, 2015, MOL CELL ENDOCRINOL, V418, P220, DOI 10.1016/j.mce.2015.09.035; Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854; Dickson BC, 2007, MODERN PATHOL, V20, P685, DOI 10.1038/modpathol.3800785; Dikic I, 2017, ANNU REV BIOCHEM, V86, P193, DOI 10.1146/annurev-biochem-061516-044908; Doody RS, 2013, NEW ENGL J MED, V369, P341, DOI 10.1056/NEJMoa1210951; Dufraine J, 2008, ONCOGENE, V27, P5132, DOI 10.1038/onc.2008.227; Fessler E, 2013, CANCER LETT, V341, P97, DOI 10.1016/j.canlet.2012.10.015; Fisher R, 2013, BRIT J CANCER, V108, P479, DOI 10.1038/bjc.2012.581; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Holliday DL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2889; Huang YH, 2011, CANCER RES, V71, P6122, DOI 10.1158/0008-5472.CAN-10-4366; Kofler Natalie M, 2011, Genes Cancer, V2, P1106, DOI 10.1177/1947601911423030; Kwon YT, 2017, TRENDS BIOCHEM SCI, V42, P873, DOI 10.1016/j.tibs.2017.09.002; Li PP, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0479-5; Liu J, 2016, CRIT REV ONCOL HEMAT, V104, P21, DOI 10.1016/j.critrevonc.2016.05.010; Miele L, 1999, J CELL PHYSIOL, V181, P393, DOI 10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6; Miele L, 2006, CURR MOL MED, V6, P905, DOI 10.2174/156652406779010830; Milner LA, 1999, BLOOD, V93, P2431, DOI 10.1182/blood.V93.8.2431.408k33_2431_2448; Moretti J, 2013, INT J MOL SCI, V14, P6359, DOI 10.3390/ijms14036359; Nandagopal N, 2018, CELL, V172, P869, DOI 10.1016/j.cell.2018.01.002; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Onitilo AA, 2009, CLIN MED RES, V7, P4, DOI 10.3121/cmr.2009.825; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; Reedijk M, 2012, ADV EXP MED BIOL, V727, P241, DOI 10.1007/978-1-4614-0899-4_18; Rizzo P, 2008, CANCER RES, V68, P5226, DOI 10.1158/0008-5472.CAN-07-5744; Sethi N, 2011, CANCER CELL, V19, P192, DOI 10.1016/j.ccr.2010.12.022; Slemmons KK, 2017, MOL CANCER RES, V15, P1777, DOI 10.1158/1541-7786.MCR-17-0004; So JY, 2015, J STEROID BIOCHEM, V148, P111, DOI 10.1016/j.jsbmb.2014.12.013; Soares R, 2004, MOL ENDOCRINOL, V18, P2333, DOI 10.1210/me.2003-0362; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Takebe N, 2015, NAT REV CLIN ONCOL, V12, P445, DOI 10.1038/nrclinonc.2015.61; Thomas C, 2015, TRENDS ENDOCRIN MET, V26, P467, DOI 10.1016/j.tem.2015.06.007; Thomas C, 2011, NAT REV CANCER, V11, P597, DOI 10.1038/nrc3093; van Es JH, 2012, NAT CELL BIOL, V14, P1099, DOI 10.1038/ncb2581; Volk-Draper LD, 2012, NEOPLASIA, V14, P926, DOI 10.1593/neo.12956; Wan LL, 2014, CANCER CELL, V26, P92, DOI 10.1016/j.ccr.2014.04.027; Wei YA, 2012, ONCOL REP, V27, P504, DOI 10.3892/or.2011.1536; Wong GT, 2004, J BIOL CHEM, V279, P12876, DOI 10.1074/jbc.M311652200; Xiao W, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0507-3; Yang F, 2016, INT J BIOL SCI, V12, P1568, DOI 10.7150/ijbs.16874; Yuan X, 2015, CANCER LETT, V369, P20, DOI 10.1016/j.canlet.2015.07.048; Zhang C, 2017, ONCOTARGET, V8, P33353, DOI 10.18632/oncotarget.16495	61	45	45	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2019	38	12					2092	2107		10.1038/s41388-018-0562-z	http://dx.doi.org/10.1038/s41388-018-0562-z			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP6UR	30442981	hybrid, Green Published			2022-12-28	WOS:000461822600007
J	Wang, LH; Zhang, ZY; Yu, XD; Huang, X; Liu, Z; Chai, YH; Yang, L; Wang, Q; Li, M; Zhao, J; Hou, J; Li, F				Wang, Lianghai; Zhang, Zhiyu; Yu, Xiaodan; Huang, Xuan; Liu, Zheng; Chai, Yuhang; Yang, Lei; Wang, Qian; Li, Man; Zhao, Jin; Hou, Jun; Li, Feng			Unbalanced YAP-SOX9 circuit drives stemness and malignant progression in esophageal squamous cell carcinoma	ONCOGENE			English	Article							YAP; SOX9; TAZ; EXPRESSION; PATHWAY; SUPPRESSES; PROLIFERATION; ACTIVATION; LANDSCAPE; ONCOGENE	Yes-associated protein (YAP) has been identified as a key regulator of tissue homeostasis. However, the precise role and regulatory mechanism of YAP in esophageal squamous cell carcinoma (ESCC) remains unclear. Here we report that the genetic or pharmacological inhibition of YAP repressed cancer stem cell (CSC)-like properties, including tumorsphere-forming potential, cell motility, and chemoresistance in vitro, and was sufficient to attenuate tumor growth and CSC marker expression in ESCC xenografts. Mechanistically, YAP transcriptionally activated its downstream target SOX9 via TEAD1-mediated binding. We also observed a positive correlation between YAP signaling and SOX9 expression in two independent clinical cohorts. Intriguingly, YAP-targeting microRNAs, including miR-506-3p, which were induced by SOX9, post-transcriptionally repressed YAP expression, contributing to a negative feedback mechanism. Dual inhibition of YAP and SOX9 robustly suppressed malignant phenotypes. Notably, ESCC samples from The Cancer Genome Atlas (TCGA) dataset had frequent (44%) instances of YAP gene amplification and genetic inactivation of Hippo pathway regulators. Nuclear YAP expression was elevated in 197 ESCC tissues from a Chinese cohort. Together, our findings provide evidence that genetic hyperactivation of YAP unbalances the YAP-SOX9 feedback loop and confers CSC-like features in ESCC, suggesting that this YAP-SOX9 circuit represents a potential therapeutic target.	[Wang, Lianghai; Zhang, Zhiyu; Yu, Xiaodan; Chai, Yuhang; Wang, Qian; Li, Man; Zhao, Jin; Hou, Jun; Li, Feng] Shihezi Univ, Sch Med, Dept Pathol Immunol, Shihezi, Xinjiang, Peoples R China; [Wang, Lianghai; Zhang, Zhiyu; Yu, Xiaodan; Chai, Yuhang; Wang, Qian; Li, Man; Zhao, Jin; Hou, Jun; Li, Feng] Shihezi Univ, Sch Med, Key Lab Xinjiang Endem & Ethn Dis, Shihezi, Xinjiang, Peoples R China; [Zhang, Zhiyu; Huang, Xuan; Liu, Zheng; Yang, Lei; Li, Feng] Capital Med Univ, Beijing Chaoyang Hosp, Dept Pathol, Beijing, Peoples R China; [Zhang, Zhiyu; Huang, Xuan; Liu, Zheng; Yang, Lei; Li, Feng] Capital Med Univ, Beijing Chaoyang Hosp, Med Res Ctr, Beijing, Peoples R China; [Wang, Lianghai] Cornell Univ, Dept Biomed Sci, Ithaca, NY USA; [Yu, Xiaodan] Shihezi Univ, Affiliated Hosp 1, Dept Stomatol, Sch Med, Shihezi, Peoples R China	Shihezi University; Shihezi University; Capital Medical University; Capital Medical University; Cornell University; Shihezi University	Hou, J; Li, F (corresponding author), Shihezi Univ, Sch Med, Dept Pathol Immunol, Shihezi, Xinjiang, Peoples R China.; Hou, J; Li, F (corresponding author), Shihezi Univ, Sch Med, Key Lab Xinjiang Endem & Ethn Dis, Shihezi, Xinjiang, Peoples R China.; Li, F (corresponding author), Capital Med Univ, Beijing Chaoyang Hosp, Dept Pathol, Beijing, Peoples R China.; Li, F (corresponding author), Capital Med Univ, Beijing Chaoyang Hosp, Med Res Ctr, Beijing, Peoples R China.	houjun229@163.com; lifeng7855@126.com	YANG, LEI/GQH-4271-2022	Wang, Lianghai/0000-0003-3128-7780	National Natural Science Foundation of China [81460416, 81560399, 81602810]; Ministry of Science and Technology of China [2012AA02A503]; State Scholarship Foundation of China [201608650002]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China); State Scholarship Foundation of China	This work was supported by the National Natural Science Foundation of China (No. 81460416, 81560399, 81602810), the Ministry of Science and Technology of China (2012AA02A503), and the State Scholarship Foundation of China (201608650002).	Ciamporcero E, 2016, ONCOGENE, V35, P1541, DOI 10.1038/onc.2015.219; Deng J, 2015, TUMOR BIOL, V36, P6823, DOI 10.1007/s13277-015-3364-8; Feng XD, 2014, CANCER CELL, V25, P831, DOI 10.1016/j.ccr.2014.04.016; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Galuppini F, 2017, VIRCHOWS ARCH, V471, P651, DOI 10.1007/s00428-017-2227-7; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gao YB, 2014, NAT GENET, V46, P1097, DOI 10.1038/ng.3076; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Hansen CG, 2015, TRENDS CELL BIOL, V25, P499, DOI 10.1016/j.tcb.2015.05.002; Hayashi H, 2015, CANCER RES, V75, P4985, DOI 10.1158/0008-5472.CAN-15-0291; He C, 2015, ONCOGENE, V34, P6040, DOI 10.1038/onc.2015.52; Hu N, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1919-0; Jiang SS, 2010, CLIN CANCER RES, V16, P4363, DOI 10.1158/1078-0432.CCR-10-0138; Jiang YQ, 2010, ANN THORAC SURG, V90, P908, DOI 10.1016/j.athoracsur.2010.05.060; Kang W, 2011, CLIN CANCER RES, V17, P2130, DOI 10.1158/1078-0432.CCR-10-2467; Leung CY, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3251; Liu CG, 2016, HEPATOLOGY, V64, P117, DOI 10.1002/hep.28509; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Ma F, 2016, J CLIN INVEST, V126, P1745, DOI 10.1172/JCI78815; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mathelier A, 2016, NUCLEIC ACIDS RES, V44, pD110, DOI 10.1093/nar/gkv1176; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; Muramatsu T, 2011, CARCINOGENESIS, V32, P389, DOI 10.1093/carcin/bgq254; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Sawada G, 2016, GASTROENTEROLOGY, V150, P1171, DOI 10.1053/j.gastro.2016.01.035; Schlegelmilch K, 2011, CELL, V144, P782, DOI 10.1016/j.cell.2011.02.031; Shi ZC, 2015, NUCLEIC ACIDS RES, V43, P6257, DOI 10.1093/nar/gkv568; Slemmons KK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140781; Song SM, 2014, CANCER RES, V74, P4170, DOI 10.1158/0008-5472.CAN-13-3569; Song YM, 2014, NATURE, V509, P91, DOI 10.1038/nature13176; Sorrentino G, 2014, NAT CELL BIOL, V16, P357, DOI 10.1038/ncb2936; Stein C, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005465; Tanaka K, 2017, CANCER LETT, V385, P215, DOI 10.1016/j.canlet.2016.10.020; Varelas X, 2014, DEVELOPMENT, V141, P1614, DOI 10.1242/dev.102376; Vermeulen L, 2012, LANCET ONCOL, V13, pE83, DOI 10.1016/S1470-2045(11)70257-1; Wang LH, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0658-2; Wang LH, 2016, INFECT AGENTS CANCER, V11, DOI 10.1186/s13027-016-0065-x; Xu J, 2018, J CELL BIOCHEM, V119, P2492, DOI 10.1002/jcb.26343; Yeo MK, 2012, ANTICANCER RES, V32, P3835; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zhang SK, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1096-1	41	57	57	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2019	38	12					2042	2055		10.1038/s41388-018-0476-9	http://dx.doi.org/10.1038/s41388-018-0476-9			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP6UR	30401982	Green Published, hybrid			2022-12-28	WOS:000461822600004
J	Wei, CY; Zhu, MX; Lu, NH; Peng, R; Yang, X; Zhang, PF; Wang, L; Gu, JY				Wei, Chuan-Yuan; Zhu, Meng-Xuan; Lu, Nan-Hang; Peng, Rui; Yang, Xuan; Zhang, Peng-Fei; Wang, Lu; Gu, Jian-Ying			Bioinformatics-based analysis reveals elevated MFSD12 as a key promoter of cell proliferation and a potential therapeutic target in melanoma	ONCOGENE			English	Article							INTEGRATIVE ANALYSIS; AKT; IDENTIFICATION; FACILITATORS; SUPERFAMILY; PROGRESSION; PATHWAYS; PROTEINS; CANCER	Although recent therapeutic advances based on our understanding of molecular phenomena have prolonged the survival of melanoma patients, the prognosis of melanoma remains dismal and further understanding of the underlying mechanism of melanoma progression is needed. In this study, differential expression analyses revealed that many genes, including AKT1 and CDK2, play important roles in melanoma. Functional analyses of differentially expressed genes (DEGs), obtained from the GEO (Gene Expression Omnibus) database, indicated that high proliferative and metastatic abilities are the main characteristics of melanoma and that the PI3K and MAPK pathways play essential roles in melanoma progression. Among these DEGs, major facilitator superfamily domain-containing 12 (MFSD12) was found to have significantly and specifically upregulated expression in melanoma, and elevated MFSD12 level promoted cell proliferation by promoting cell cycle progression. Mechanistically, MFSD12 upregulation was found to activate PI3K signaling, and a PI3K inhibitor reversed the increase in cell proliferation endowed by MFSD12 upregulation. Clinically, high MFSD12 expression was positively associated with shorter overall survival (OS) and disease-free survival (DFS) in melanoma patients, and MFSD12 was an independent prognostic factor for OS and DFS in melanoma patients. Therapeutically, in vivo assays further confirmed that MFSD12 interference inhibited tumor growth and lung metastasis in melanoma. In conclusion, elevated MFSD12 expression promotes melanoma cell proliferation, and MFSD12 is a valuable prognostic biomarker and promising therapeutic target in melanoma.	[Wei, Chuan-Yuan; Lu, Nan-Hang; Wang, Lu; Gu, Jian-Ying] Fudan Univ, Zhongshan Hosp, Dept Plast Surg, Shanghai 200032, Peoples R China; [Wei, Chuan-Yuan; Zhu, Meng-Xuan; Peng, Rui; Yang, Xuan; Zhang, Peng-Fei] Fudan Univ, Minist Educ, Key Lab Carcinogenesis & Canc Invas, Liver Canc Inst,Zhongshan Hosp, Shanghai 200032, Peoples R China	Fudan University; Fudan University	Gu, JY (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Plast Surg, Shanghai 200032, Peoples R China.	zhongshanhospital@163.com			Scientific Research Fund of Zhongshan Hospital, Fudan University [2016ZSFZ62]; National Natural Science Foundation of China [G2016-023]; Science and Technology Committee of Shanghai [14DZ1940304]	Scientific Research Fund of Zhongshan Hospital, Fudan University; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Committee of Shanghai(Shanghai Science & Technology Committee)	This study was funded by the Scientific Research Fund of Zhongshan Hospital, Fudan University (2016ZSFZ62), the National Natural Science Foundation of China (G2016-023), and the Science and Technology Committee of Shanghai (14DZ1940304).	Ascierto PA, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-85; Augustin R, 2010, IUBMB LIFE, V62, P315, DOI 10.1002/iub.315; Berger M, 2018, GIORN ITAL DERMAT V, V153, P349, DOI 10.23736/S0392-0488.18.05970-9; Bi DB, 2015, COMPUT BIOL CHEM, V56, P71, DOI 10.1016/j.compbiolchem.2015.04.001; Cai JB, 2015, HEPATOLOGY, V61, P1603, DOI 10.1002/hep.27682; Chen YL, 2017, INT J ONCOL, V51, P1280, DOI 10.3892/ijo.2017.4092; Crawford NG, 2017, SCIENCE, V358, P1; Cura AJ, 2012, COMPR PHYSIOL, V2, P863, DOI 10.1002/cphy.c110024; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Halestrap AP, 2012, IUBMB LIFE, V64, P109, DOI 10.1002/iub.572; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang XY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096860; Kanda M, 2016, ONCOTARGET, V7, P13667, DOI 10.18632/oncotarget.7269; Kang Q, 2017, J CLIN PATHOL, V70, P677, DOI 10.1136/jclinpath-2016-204251; Ke AW, 2009, HEPATOLOGY, V49, P491, DOI 10.1002/hep.22639; Khunlertgit N, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-1224-1; Kuo YC, 2008, J BIOL CHEM, V283, P1882, DOI 10.1074/jbc.M709585200; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; Namiki T, 2015, CANCER RES, V75, P2708, DOI 10.1158/0008-5472.CAN-13-3209; Park J, 2017, CANCER IMMUNOL RES, V5, P618, DOI 10.1158/2326-6066.CIR-17-0051; Peng JH, 2017, SCI REP-UK, V7, DOI 10.1038/srep46577; Peng R, 2018, CANCER MED-US, V7, P796, DOI 10.1002/cam4.1313; Rajabi Parvin, 2017, Adv Biomed Res, V6, P14, DOI 10.4103/2277-9175.200789; Rebelo TM, 2018, EXP CELL RES, V368, P1, DOI 10.1016/j.yexcr.2018.04.003; Reddy VS, 2012, FEBS J, V279, P2022, DOI 10.1111/j.1742-4658.2012.08588.x; Robertson AG, 2017, CANCER CELL, V32, P204, DOI 10.1016/j.ccell.2017.07.003; Sean D, 2007, BIOINFORMATICS, V23, P1846, DOI 10.1093/bioinformatics/btm254; Shi GM, 2008, J CANCER RES CLIN, V134, P1155, DOI 10.1007/s00432-008-0407-1; Sinnberg T, 2009, J INVEST DERMATOL, V129, P1500, DOI 10.1038/jid.2008.379; Spinola M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-62; Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tazzari PL, 2004, BRIT J HAEMATOL, V126, P675, DOI 10.1111/j.1365-2141.2004.05121.x; Wang L, 2016, ONCOTARGET, V7, P3791, DOI 10.18632/oncotarget.6302; Wang SC, 2014, TRENDS PHARMACOL SCI, V35, P178, DOI 10.1016/j.tips.2014.02.004; Wei CY, 2018, ONCOL REP, V39, P2553, DOI 10.3892/or.2018.6356; Xing ZH, 2016, BBA-GEN SUBJECTS, V1860, P2725, DOI 10.1016/j.bbagen.2016.01.012; Xu ZZ, 2016, MED ONCOL, V33, DOI 10.1007/s12032-016-0840-y	38	29	30	4	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2019	38	11					1876	1891		10.1038/s41388-018-0531-6	http://dx.doi.org/10.1038/s41388-018-0531-6			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HO7XX	30385854	Green Published, hybrid			2022-12-28	WOS:000461164400007
J	Arnold, JM; Gu, F; Ambati, CR; Rasaily, U; Ramirez-Pena, E; Joseph, R; Manikkam, M; San Martin, R; Charles, C; Pan, YH; Chatterjee, SS; Den Hollander, P; Zhang, WJ; Nagi, C; Sikora, AG; Rowley, D; Putluri, N; Zhang, XHF; Karanam, B; Mani, SA; Sreekumar, A				Arnold, James M.; Gu, Franklin; Ambati, Chandrashekar R.; Rasaily, Uttam; Ramirez-Pena, Esmeralda; Joseph, Robiya; Manikkam, Mohan; San Martin, Rebeca; Charles, Christy; Pan, Yinghong; Chatterjee, Sujash S.; Den Hollander, Petra; Zhang, Weijie; Nagi, Chandandeep; Sikora, Andrew G.; Rowley, David; Putluri, Nagireddy; Zhang, Xiang H-F; Karanam, Balasubramanyam; Mani, Sendurai A.; Sreekumar, Arun			UDP-glucose 6-dehydrogenase regulates hyaluronic acid production and promotes breast cancer progression	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; SURVIVAL; CELLS; METASTASIS; REVEALS; FOXC2	An improved understanding of the biochemical alterations that accompany tumor progression and metastasis is necessary to inform the next generation of diagnostic tools and targeted therapies. Metabolic reprogramming is known to occur during the epithelial-mesenchymal transition (EMT), a process that promotes metastasis. Here, we identify metabolic enzymes involved in extracellular matrix remodeling that are upregulated during EMT and are highly expressed in patients with aggressive mesenchymal-like breast cancer. Activation of EMT significantly increases production of hyaluronic acid, which is enabled by the reprogramming of glucose metabolism. Using genetic and pharmacological approaches, we show that depletion of the hyaluronic acid precursor UDP-glucuronic acid is sufficient to inhibit several mesenchymal-like properties including cellular invasion and colony formation in vitro, as well as tumor growth and metastasis in vivo. We found that depletion of UDP-glucuronic acid altered the expression of PPAR-gamma target genes and increased PPAR-gamma DNA-binding activity. Taken together, our findings indicate that the disruption of EMT-induced metabolic reprogramming affects hyaluronic acid production, as well as associated extracellular matrix remodeling and represents pharmacologically actionable target for the inhibition of aggressive mesenchymal-like breast cancer progression.	[Arnold, James M.; Gu, Franklin; Charles, Christy; Sreekumar, Arun] Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Arnold, James M.; Gu, Franklin; Rasaily, Uttam; Manikkam, Mohan; San Martin, Rebeca; Charles, Christy; Zhang, Weijie; Rowley, David; Putluri, Nagireddy; Zhang, Xiang H-F; Sreekumar, Arun] Baylor Coll Med, Dept Mol & Cellular Biol, One Baylor Plaza, Houston, TX 77030 USA; [Arnold, James M.; Gu, Franklin; Ambati, Chandrashekar R.; Rasaily, Uttam; Charles, Christy; Putluri, Nagireddy; Sreekumar, Arun] Baylor Coll Med, Alkek Ctr Mol Discovery, Houston, TX 77030 USA; [Ramirez-Pena, Esmeralda; Joseph, Robiya; Den Hollander, Petra; Mani, Sendurai A.] MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Ramirez-Pena, Esmeralda] NCI, Div Canc Prevent, Rockville, MD 20850 USA; [Pan, Yinghong; Chatterjee, Sujash S.] Univ Houston, Dept Biol & Biochem, Seq N Edit Core, Houston, TX 77004 USA; [Pan, Yinghong] UPMC, Genome Ctr, Pittsburgh, PA 15232 USA; [Zhang, Weijie; Zhang, Xiang H-F] Baylor Coll Med, Lester & Sue Smith Breast Ctr, One Baylor Plaza, Houston, TX 77030 USA; [Zhang, Weijie] Baylor Coll Med, Duncan L Canc Ctr, One Baylor Plaza, Houston, TX 77030 USA; [Nagi, Chandandeep] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA; [Sikora, Andrew G.] Baylor Coll Med, Dept Otolaryngol Head & Neck Surg, Houston, TX 77030 USA; [Karanam, Balasubramanyam] Tuskegee Univ, Dept Biol & Canc Res, Tuskegee, AL 36088 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Houston System; University of Houston; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Tuskegee University	Sreekumar, A (corresponding author), Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA.; Sreekumar, A (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, One Baylor Plaza, Houston, TX 77030 USA.; Sreekumar, A (corresponding author), Baylor Coll Med, Alkek Ctr Mol Discovery, Houston, TX 77030 USA.	sreekuma@bcm.edu	Mani, Sendurai A./A-7244-2009	Mani, Sendurai A./0000-0002-5918-4276; Joseph, Robiya/0000-0003-3214-890X; Putluri, Nagireddy/0000-0003-4488-7400; Zhang, Weijie/0000-0002-6462-6067; San Martin, Rebeca/0000-0001-7249-3922; Pan, Yinghong/0000-0001-7334-1787				Battula VL, 2010, STEM CELLS, V28, P1435, DOI 10.1002/stem.467; Bhowmik SK, 2015, ONCOTARGET, V6, P42651, DOI 10.18632/oncotarget.4765; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dasgupta S, 2015, J CLIN INVEST, V125, P1174, DOI 10.1172/JCI76029; Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hollier BG, 2013, CANCER RES, V73, P1981, DOI 10.1158/0008-5472.CAN-12-2962; Jacobetz MA, 2013, GUT, V62, P112, DOI 10.1136/gutjnl-2012-302529; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Kultti A, 2009, EXP CELL RES, V315, P1914, DOI 10.1016/j.yexcr.2009.03.002; Li M, 2015, JOVE-J VIS EXP, V104, P52411; Lucena MC, 2016, J BIOL CHEM, V291, P12917, DOI 10.1074/jbc.M116.729236; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marshall J, 2011, METHODS MOL BIOL, V769, P97, DOI 10.1007/978-1-61779-207-6_8; Misra S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00201; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Oyinlade O, 2018, ONCOGENE, V37, P2615, DOI 10.1038/s41388-018-0138-y; Putluri N, 2014, NEOPLASIA, V16, P390, DOI 10.1016/j.neo.2014.05.007; Putluri N, 2011, CANCER RES, V71, P7376, DOI 10.1158/0008-5472.CAN-11-1154; Ricciardelli C, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-476; Saito T, 2013, ONCOL LETT, V5, P1068, DOI 10.3892/ol.2013.1124; Sato N, 2016, CANCER SCI, V107, P569, DOI 10.1111/cas.12913; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Toole BP, 2009, CLIN CANCER RES, V15, P7462, DOI 10.1158/1078-0432.CCR-09-0479; van der Horst EH, 2004, BIOTECHNIQUES, V37, P940, DOI 10.2144/04376ST02; Vigetti D, 2014, MATRIX BIOL, V35, P8, DOI 10.1016/j.matbio.2013.10.002; Werden SJ, 2016, ONCOGENE, V35, P5977, DOI 10.1038/onc.2016.203; Yates TJ, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv085	29	21	21	2	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	15					3089	3101		10.1038/s41388-019-0885-4	http://dx.doi.org/10.1038/s41388-019-0885-4			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LB8NS	31308490	Green Accepted			2022-12-28	WOS:000524887800004
J	Bruno, G; Cencetti, F; Pini, A; Tondo, A; Cuzzubbo, D; Fontani, F; Strinna, V; Buccoliero, AM; Casazza, G; Donati, C; Filippi, L; Bruni, P; Favre, C; Calvani, M				Bruno, Gennaro; Cencetti, Francesca; Pini, Alessandro; Tondo, Annalisa; Cuzzubbo, Daniela; Fontani, Filippo; Strinna, Vanessa; Buccoliero, Anna Maria; Casazza, Gabriella; Donati, Chiara; Filippi, Luca; Bruni, Paola; Favre, Claudio; Calvani, Maura			beta 3-adrenoreceptor blockade reduces tumor growth and increases neuronal differentiation in neuroblastoma via SK2/S1P(2) modulation	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; HUMAN-MELANOMA; MESSENGER-RNA; BETA-BLOCKERS; COLON-CANCER; BONE-MARROW; CELL LINES; EXPRESSION; CLASSIFICATION; ADRENOCEPTORS	Neuroblastoma (NB) is the most frequently observed among extracranial pediatric solid tumors. It displays an extreme clinical heterogeneity, in particular for the presentation at diagnosis and response to treatment, often depending on cancer cell differentiation/stemness. The frequent presence of elevated hematic and urinary levels of catecholamines in patients affected by NB suggests that the dissection of adrenergic system is crucial for a better understanding of this cancer. beta 3-adrenoreceptor (beta 3-AR) is the last identified member of adrenergic receptors, involved in different tumor conditions, such as melanoma. Multiple studies have shown that the dysregulation of the bioactive lipid sphingosine 1-phosphate (S1P) metabolism and signaling is involved in many pathological diseases including cancer. However, whether S1P is crucial for NB progression and aggressiveness is still under investigation. Here we provide experimental evidence that beta 3-AR is expressed in NB, both human specimens and cell lines, where it is critically involved in the activation of proliferation and the regulation between stemness/differentiation, via its functional cross-talk with sphingosine kinase 2 (SK2)/S1P receptor 2 (S1P(2)) axis. The specific antagonism of beta 3-AR by SR59230A inhibits NB growth and tumor progression, by switching from stemness to cell differentiation both in vivo and in vitro through the specific blockade of SK2/S1P(2) signaling.	[Bruno, Gennaro; Fontani, Filippo] Univ Florence, Dept Hlth Sci, Florence, Italy; [Bruno, Gennaro; Tondo, Annalisa; Cuzzubbo, Daniela; Fontani, Filippo; Strinna, Vanessa; Favre, Claudio; Calvani, Maura] A Meyer Univ, Dept Paediat Haematol Oncol, Childrens Hosp, Florence, Italy; [Cencetti, Francesca; Donati, Chiara; Bruni, Paola] Univ Florence, Dept Expt & Clin Biomed Sci Mario Serio, Florence, Italy; [Pini, Alessandro] Univ Florence, Dept Expt & Clin Med, Florence, Italy; [Buccoliero, Anna Maria] A Meyer Univ, Pathol Unit, Childrens Hosp, Florence, Italy; [Casazza, Gabriella] Santa Chiara Hosp, Pediat Hematol Oncol & Bone Marrow Transplant Uni, Pisa, Italy; [Filippi, Luca] A Meyer Univ, Med Surg Feto Neonatal Dept, Neonatal Intens Care Unit, Childrens Hosp, Florence, Italy	University of Florence; University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER; University of Florence; University of Florence; University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER; Santa Chiara Hospital; University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER	Calvani, M (corresponding author), A Meyer Univ, Dept Paediat Haematol Oncol, Childrens Hosp, Florence, Italy.; Cencetti, F (corresponding author), Univ Florence, Dept Expt & Clin Biomed Sci Mario Serio, Florence, Italy.	francesca.cencetti@unifi.it; maura.calvani@meyer.it	Bruni, Paola/A-1151-2008; Filippi, Luca/AAD-5019-2021; Bruno, Gennaro/AAL-6465-2020; donati, chiara/AAN-2682-2021	Bruno, Gennaro/0000-0001-6252-3825; donati, chiara/0000-0003-2224-4199; Bruni, Paola/0000-0002-1151-3413	Fondazione Ospedale Pediatrico Meyer; FFARB2017 - Fondi Finanziamento Ateneo Ricerca di Base anno 2017; Fondi Ateneo (RICATEN, ex-60%)	Fondazione Ospedale Pediatrico Meyer; FFARB2017 - Fondi Finanziamento Ateneo Ricerca di Base anno 2017; Fondi Ateneo (RICATEN, ex-60%)	This work was supported by funds from Fondazione Ospedale Pediatrico Meyer to CF, FFARB2017 - Fondi Finanziamento Ateneo Ricerca di Base anno 2017 to FC, Fondi Ateneo (RICATEN, ex-60%) to PB, CD, FC.	Bossard F, 2011, AM J RESP CELL MOL, V44, P91, DOI 10.1165/rcmb.2009-0372OC; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Bruno G, 2018, CELL SIGNAL, V45, P110, DOI 10.1016/j.cellsig.2018.02.001; Buhagiar Alfred, 2015, ANAL CELL PATHOL, V2015, P1; Calvani M, 2015, ONCOTARGET, V6, P4615, DOI 10.18632/oncotarget.2652; Cannavo A, 2017, J AM COLL CARDIOL, V70, P182, DOI 10.1016/j.jacc.2017.05.020; Cencetti F, 2010, MOL BIOL CELL, V21, P1111, DOI 10.1091/mbc.E09-09-0812; Chisholm KM, 2012, MODERN PATHOL, V25, P1446, DOI 10.1038/modpathol.2012.108; Choi HS, 2005, PEDIATR BLOOD CANCER, V45, P68, DOI 10.1002/pbc.20315; Chumanevich AA, 2010, CARCINOGENESIS, V31, P1787, DOI 10.1093/carcin/bgq158; Cohn SL, 2009, J CLIN ONCOL, V27, P289, DOI 10.1200/JCO.2008.16.6785; Daguze Justine, 2016, JAAD Case Rep, V2, P497, DOI 10.1016/j.jdcr.2016.10.005; Dal Monte M, 2013, J MOL MED, V91, P1407, DOI 10.1007/s00109-013-1073-6; Garaventa A, 2009, EUR J CANCER, V45, P2835, DOI 10.1016/j.ejca.2009.06.010; Hafer R, 1999, J NEUROIMMUNOL, V96, P201, DOI 10.1016/S0165-5728(99)00030-2; Hansford LM, 2007, CANCER RES, V67, P11234, DOI 10.1158/0008-5472.CAN-07-0718; Huang P, 2011, CANCER RES, V71, P2938, DOI 10.1158/0008-5472.CAN-10-3524; Lamkin DM, 2012, BRAIN BEHAV IMMUN, V26, P635, DOI 10.1016/j.bbi.2012.01.013; Leaute-Labreze C, 2008, NEW ENGL J MED, V358, P2649, DOI 10.1056/NEJMc0708819; Li MH, 2013, PEDIATR BLOOD CANCER, V60, P1418, DOI 10.1002/pbc.24564; Li MH, 2011, CANCER PREV RES, V4, P1325, DOI 10.1158/1940-6207.CAPR-11-0017; London WB, 2017, CANCER-AM CANCER SOC, V123, P4914, DOI 10.1002/cncr.30934; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Matthay KK, 2009, J CLIN ONCOL, V27, P1007, DOI 10.1200/JCO.2007.13.8925; Montoya A, 2017, ONCOTARGET, V8, P6446, DOI 10.18632/oncotarget.14119; Mora J, 2001, CANCER RES, V61, P6892; Moretti S, 2013, LAB INVEST, V93, P279, DOI 10.1038/labinvest.2012.175; Pasquier E, 2013, BRIT J CANCER, V108, P2485, DOI 10.1038/bjc.2013.205; Perez-Sayans M, 2010, ONCOL RES, V19, P45, DOI 10.3727/096504010X12828372551867; Perrone MG, 2008, ONCOLOGY-BASEL, V75, P224, DOI 10.1159/000163851; Pinto NR, 2015, J CLIN ONCOL, V33, P3008, DOI 10.1200/JCO.2014.59.4648; Pyne NJ, 2010, NAT REV CANCER, V10, P489, DOI 10.1038/nrc2875; Rains Steven L, 2017, Oncoscience, V4, P95, DOI 10.18632/oncoscience.357; Reynolds CP, 2003, CANCER LETT, V197, P185, DOI 10.1016/S0304-3835(03)00108-3; ROSS RA, 1995, CELL GROWTH DIFFER, V6, P449; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shimada H, 1999, CANCER, V86, P364, DOI 10.1002/(SICI)1097-0142(19990715)86:2<364::AID-CNCR21>3.3.CO;2-Z; Stiles J, 2012, EXP THER MED, V4, P594, DOI 10.3892/etm.2012.654; Strub GM, 2010, ADV EXP MED BIOL, V688, P141; Takenobu H, 2011, ONCOGENE, V30, P97, DOI 10.1038/onc.2010.383; Takuwa N, 2010, CANCER RES, V0008-5472.CAN-09-2722; Tong QS, 2008, WORLD J PEDIATR, V4, P58, DOI 10.1007/s12519-008-0012-z; Voigt A, 1997, J NEUROIMMUNOL, V78, P117, DOI 10.1016/S0165-5728(97)00088-X; Wallington-Beddoe CT, 2014, CANCER RES, V74, P2803, DOI 10.1158/0008-5472.CAN-13-2732; Walton JD, 2004, NEOPLASIA, V6, P838, DOI 10.1593/neo.04310; Watkins JL, 2015, CANCER-AM CANCER SOC, V121, P3444, DOI 10.1002/cncr.29392; Weigert A, 2009, INT J CANCER, V125, P2114, DOI 10.1002/ijc.24594; Wolter JK, 2014, ONCOTARGET, V5, P161, DOI 10.18632/oncotarget.1083; Yang EV, 2009, BRAIN BEHAV IMMUN, V23, P267, DOI 10.1016/j.bbi.2008.10.005; Zhang WL, 2014, J BIOL CHEM, V289, P32178, DOI 10.1074/jbc.M114.601096	50	22	22	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	2					368	384		10.1038/s41388-019-0993-1	http://dx.doi.org/10.1038/s41388-019-0993-1			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KD3JY	31477835	Green Published, hybrid			2022-12-28	WOS:000507766400009
J	Li, Y; Li, WG; Zeng, XM; Tang, XM; Zhang, S; Zhong, FY; Peng, XN; Zhong, Y; Rosol, TJ; Deng, XY; Liu, ZH; Peng, SH; Peng, XN				Li, Yue; Li, Weiguo; Zeng, Xiaomin; Tang, Xuemei; Zhang, Shan; Zhong, Feiya; Peng, Xiangni; Zhong, Yang; Rosol, Thomas J.; Deng, Xiyun; Liu, Zhonghua; Peng, Sihua; Peng, Xiaoning			The role of microRNA-148a and downstream DLGAP1 on the molecular regulation and tumor progression on human glioblastoma	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CELL INVASION; PROTEIN; MIR-148A; POLARITY; MIGRATION; SURVIVAL; GROWTH; PROLIFERATION; TUMORIGENESIS	Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Currently, the prognosis of the patients with GBM is very poor and new molecular targets and treatment strategies are urgently needed to combat it. MicroRNA-148a (miR-148a) has been shown to be dysregulated in certain tumor types. However, the role of miR-148a in the pathogenesis of GBM is not fully understood. Here we comprehensively analyzed the roles of miR-148a, downstream DLGAP1, and their molecular pathways in GBM. We showed that miR-148a promote the proliferation and growth of GBM cells both in vitro and in vivo, and also induced the migration, invasion, and EMT (epithelial-mesenchymal transition) program of GBM cells by directly targeting DLGAP1. Furthermore, we identified 31 new miR-148a targets and found that miR-148a function was mainly involved in the cell adhesion signaling pathway and was associated with nervous system diseases. Our findings provide a new mechanism for miR-148a-mediated GBM cell invasion and reveal previously unreported targets of miR-148a as well as novel miR-148 a-mediated regulatory networks in GBM. These results increase the understanding of the role of miR-148a in GBM and may lead to novel therapeutic strategies for GBM.	[Li, Yue; Tang, Xuemei; Zhang, Shan; Deng, Xiyun; Peng, Xiaoning] Hunan Normal Univ, Dept Pathol & Pathophysiol, Sch Med, Changsha 410013, Hunan, Peoples R China; [Li, Yue] Xiangtan Cent Hosp, Dept Pathol, Xiangtan 411100, Peoples R China; [Li, Weiguo] Hunan Normal Univ, Coll Math & Comp Sci, Dept Stat, Changsha 410081, Hunan, Peoples R China; [Zeng, Xiaomin] Cent S Univ, Publ Hlth Sch, Dept Epidemiol & Hlth Stat, Changsha 410078, Hunan, Peoples R China; [Zhong, Feiya] Wuhan Univ, Coll Life Sci, Dept Genet, Wuhan 430072, Hubei, Peoples R China; [Peng, Xiangni; Zhong, Yang] Xiangtan Univ, Sch Math & Computat Sci, Dept Informat & Comp Sci, Xiangtan 411105, Peoples R China; [Rosol, Thomas J.] Ohio Univ, Heritage Coll Osteopath Med, Dept Biomed Sci, Athens, OH 45701 USA; [Liu, Zhonghua] Hunan Normal Univ, Coll Life Sci, Dept Biochem & Mol Biol, Changsha 410081, Hunan, Peoples R China; [Peng, Sihua] Shanghai Ocean Univ, Minist Educ, Key Lab Explorat & Utilizat Aquat Genet Resources, Shanghai 201306, Peoples R China; [Peng, Sihua] Minist Agr, Natl Pathogen Collect Ctr Aquat Anim, Shanghai 201306, Peoples R China; [Peng, Sihua] Shanghai Ocean Univ, Minist Sci & Technol, Int Res Ctr Marine Biosci, Shanghai 201306, Peoples R China; [Peng, Xiaoning] Jishou Univ, Dept Pathophysiol, Sch Med, Jishou 416000, Peoples R China	Hunan Normal University; Hunan Normal University; Central South University; Wuhan University; Xiangtan University; University System of Ohio; Ohio University; Hunan Normal University; Shanghai Ocean University; Ministry of Agriculture & Rural Affairs; Shanghai Ocean University; Jishou University	Peng, XN (corresponding author), Hunan Normal Univ, Dept Pathol & Pathophysiol, Sch Med, Changsha 410013, Hunan, Peoples R China.; Liu, ZH (corresponding author), Hunan Normal Univ, Coll Life Sci, Dept Biochem & Mol Biol, Changsha 410081, Hunan, Peoples R China.; Peng, SH (corresponding author), Shanghai Ocean Univ, Minist Educ, Key Lab Explorat & Utilizat Aquat Genet Resources, Shanghai 201306, Peoples R China.; Peng, SH (corresponding author), Minist Agr, Natl Pathogen Collect Ctr Aquat Anim, Shanghai 201306, Peoples R China.; Peng, SH (corresponding author), Shanghai Ocean Univ, Minist Sci & Technol, Int Res Ctr Marine Biosci, Shanghai 201306, Peoples R China.; Peng, XN (corresponding author), Jishou Univ, Dept Pathophysiol, Sch Med, Jishou 416000, Peoples R China.	liuzh@hunnu.edu.cn; shpeng@shou.edu.cn; pxiaoning@hunnu.edu.cn		weiguo, li/0000-0002-9345-580X; Rosol, Thomas/0000-0003-3737-1190	National Natural Science Foundation of China [81472860]; Construct Program of the Key Discipline of Basic Medicine in Hunan Normal University; Hunan Province	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Construct Program of the Key Discipline of Basic Medicine in Hunan Normal University; Hunan Province	This study was jointly supported by the National Natural Science Foundation of China (Grant Number 81472860) and the Construct Program of the Key Discipline of Basic Medicine in Hunan Normal University and Hunan Province.	Bethke L, 2008, CANCER EPIDEM BIOMAR, V17, P987, DOI 10.1158/1055-9965.EPI-07-2807; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Chen YL, 2017, ANTICANCER RES, V37, P781, DOI 10.21873/anticanres.11377; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Cui DM, 2017, ONCOTARGET, V8, P25345, DOI 10.18632/oncotarget.15867; Elias MC, 2005, NEOPLASIA, V7, P824, DOI 10.1593/neo.04352; Freed E, 1999, GENE DEV, V13, P2242, DOI 10.1101/gad.13.17.2242; Han CL, 2008, MOL CELL PROTEOMICS, V7, P1983, DOI 10.1074/mcp.M800068-MCP200; Hatanpaa KJ, 2010, NEOPLASIA, V12, P675, DOI 10.1593/neo.10688; Hsu CW, 2008, PROTEOMICS, V8, P1975, DOI 10.1002/pmic.200701004; Hu CW, 2013, J PROTEOME RES, V12, P3993, DOI 10.1021/pr400302w; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang JR, 2017, ONCOL LETT, V14, P5386, DOI 10.3892/ol.2017.6844; Jin SG, 2016, AM J TRANSL RES, V8, P1826; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Karagkouni D, 2018, NUCLEIC ACIDS RES, V46, pD239, DOI 10.1093/nar/gkx1141; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim J, 2014, CANCER RES, V74, P1541, DOI 10.1158/0008-5472.CAN-13-1449; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; Lee HK, 2008, NEURO-ONCOLOGY, V10, P236, DOI 10.1215/15228517-2008-006; Lee JK, 2014, ONCOTARGETS THER, V7, P1933, DOI 10.2147/OTT.S36582; Li Y, 2016, J CANCER, V7, P1233, DOI 10.7150/jca.14616; Liffers ST, 2011, LAB INVEST, V91, P1472, DOI 10.1038/labinvest.2011.99; Manneville JB, 2010, J CELL BIOL, V191, P585, DOI 10.1083/jcb.201002151; McCaffrey LM, 2012, CANCER CELL, V22, P601, DOI 10.1016/j.ccr.2012.10.003; Mittal V, 2018, ANNU REV PATHOL-MECH, V13, P395, DOI 10.1146/annurev-pathol-020117-043854; Ohgaki H, 2005, J NEUROPATH EXP NEUR, V64, P479, DOI 10.1093/jnen/64.6.479; Ohgaki Hiroko, 2009, V472, P323, DOI 10.1007/978-1-60327-492-0_14; Pearson HB, 2011, J CLIN INVEST, V121, P4257, DOI 10.1172/JCI58509; Piva R, 2002, MOL CELL BIOL, V22, P8375, DOI 10.1128/MCB.22.23.8375-8387.2002; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Prasad TSK, 2009, NUCLEIC ACIDS RES, V37, pD767, DOI 10.1093/nar/gkn892; Qin Y, 2005, J CELL BIOL, V171, P1061, DOI 10.1083/jcb.200506094; Rennie W, 2016, RNA BIOL, V13, P554, DOI 10.1080/15476286.2016.1182279; Roth P, 2011, J NEUROCHEM, V118, P449, DOI 10.1111/j.1471-4159.2011.07307.x; Sanchez-Valle J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04400-6; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; Sims JN, 2014, INT J ENV RES PUB HE, V11, P5006, DOI 10.3390/ijerph110505006; Skiriute D, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-218; Smoot ME, 2011, BIOINFORMATICS, V27, P431, DOI 10.1093/bioinformatics/btq675; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Tso CL, 2006, MOL CANCER RES, V4, P607, DOI 10.1158/1541-7786.MCR-06-0005; Wang H, 2015, MOL CANCER, V14, DOI 10.1186/1476-4598-14-2; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Xiong JQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107272; Yu J, 2011, J BIOMED RES, V25, P170, DOI 10.1016/S1674-8301(11)60022-5; Zhan LX, 2008, CELL, V135, P865, DOI 10.1016/j.cell.2008.09.045; Zhang JP, 2014, ONCOGENE, V33, P4069, DOI 10.1038/onc.2013.369; Zheng BQ, 2011, CLIN CANCER RES, V17, P7574, DOI 10.1158/1078-0432.CCR-11-1714	51	14	14	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2019	38	47					7234	7248		10.1038/s41388-019-0922-3	http://dx.doi.org/10.1038/s41388-019-0922-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP0UL	31477833	hybrid			2022-12-28	WOS:000497989400004
J	Duan, L; Perez, RE; Chastain, PD; Mathew, MT; Bijukumar, DR; Maki, CG				Duan, Lei; Perez, Ricardo E.; Chastain, Paul D., II; Mathew, Mathew T.; Bijukumar, Divya Rani; Maki, Carl G.			JMJD2 promotes acquired cisplatin resistance in non-small cell lung carcinoma cells	ONCOGENE			English	Article							MOLECULAR-MECHANISMS; ERCC1 EXPRESSION; CANCER CELLS; DNA-REPAIR; S-PHASE; REPLICATION; ATR; DEMETHYLASES; CHROMATIN; CHK1	Platinum-based drugs such as cisplatin (CP) are the first-line chemotherapy for non-small-cell lung carcinoma (NSCLC). Unfortunately, NSCLC has a low response rate to CP and acquired resistance always occurs. Histone methylation regulates chromatin structure and is implicated in DNA repair. We hypothesize histone methylation regulators are involved in CP resistance. We therefore screened gene expression of known histone methyltransferases and demethylases in three NSCLC cell lines with or without acquired resistance to CP. JMJD2s are a family of histone demethylases that remove tri-methyl groups from H3K9 and H3K36. We found expression of several JMJD2 family genes upregulated in CP-resistant cells, with JMJD2B expression being upregulated in all three CP-resistant NSCLC cell lines. Further analysis showed increased JMJD2 protein expression coincided with decreased H3K9me3 and H3K36me3. Chemical inhibitors of JMJD2-family proteins increased H3K9me3 and H3K36me3 levels and sensitized resistant cells to CP. Mechanistic studies showed that JMJD2 inhibition decreased chromatin association of ATR and Chk1 and inhibited the ATR-Chk1 replication checkpoint. Our results reveal that JMJD2 demethylases are potential therapeutic targets to overcome CP resistance in NSCLC.	[Duan, Lei; Perez, Ricardo E.; Maki, Carl G.] Rush Univ, Dept Cell & Mol Med, Med Ctr, Chicago, IL 60612 USA; [Chastain, Paul D., II] Univ Illinois, Dept Hlth Sci Educ, Coll Med Rockford, Rockford, IL 61107 USA; [Mathew, Mathew T.; Bijukumar, Divya Rani] Univ Illinois, Dept Biomed Sci, Coll Med Rockford, Rockford, IL 61107 USA	Rush University; University of Illinois System; University of Illinois Chicago; University of Illinois Rockford; University of Illinois System; University of Illinois Chicago; University of Illinois Rockford	Maki, CG (corresponding author), Rush Univ, Dept Cell & Mol Med, Med Ctr, Chicago, IL 60612 USA.	Carl_Maki@rush.edu	Chastain, Paul/AAN-2692-2020	Chastain, Paul/0000-0001-6782-6788	Swim Across America	Swim Across America	This work was supported in part by a grant from Swim Across America (to CGM). We would like to thank the flow cytometry core at the University of Illinois at Chicago for their assistance in helping us run the replication start assay.	Aggarwal C, 2017, ONCOLOGIST, V22, P700, DOI 10.1634/theoncologist.2016-0345; Agger K, 2007, NATURE, V449, P731, DOI 10.1038/nature06145; Agger K, 2016, GENE DEV, V30, P1278, DOI 10.1101/gad.280495.116; Andrade-Lima LC, 2015, J CELL SCI, V128, P150, DOI 10.1242/jcs.161596; Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22; Basu A, 2010, J NUCLEIC ACIDS, V2010, DOI 10.4061/2010/201367; Berry WL, 2013, CANCER RES, V73, P2936, DOI 10.1158/0008-5472.CAN-12-4300; Bhagwat N, 2009, MOL CELL BIOL, V29, P6427, DOI 10.1128/MCB.00086-09; Britten RA, 2000, INT J CANCER, V89, P453, DOI 10.1002/1097-0215(20000920)89:5<453::AID-IJC9>3.3.CO;2-5; Chang A, 2011, LUNG CANCER, V71, P3, DOI 10.1016/j.lungcan.2010.08.022; Chastain PD, 2015, PHOTOCHEM PHOTOBIOL, V91, P109, DOI 10.1111/php.12361; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; D'Oto A, 2016, J MED ONCOL THER, V1, P34; Dasari S, 2014, EUR J PHARMACOL, V740, P364, DOI 10.1016/j.ejphar.2014.07.025; Dinant C, 2008, EPIGENET CHROMATIN, V1, DOI 10.1186/1756-8935-1-9; EASTMAN A, 1988, BIOCHEMISTRY-US, V27, P4730, DOI 10.1021/bi00413a022; Enoiu M, 2012, NUCLEIC ACIDS RES, V40, P8953, DOI 10.1093/nar/gks670; Ezponda T, 2017, CELL REP, V21, P628, DOI 10.1016/j.celrep.2017.09.078; Ferry KV, 2000, BIOCHEM PHARMACOL, V60, P1305, DOI 10.1016/S0006-2952(00)00441-X; Gadhikar MA, 2013, MOL CANCER THER, V12, P1860, DOI 10.1158/1535-7163.MCT-13-0157; Gagou ME, 2010, MOL BIOL CELL, V21, P739, DOI 10.1091/mbc.E09-07-0618; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Gong F, 2017, J CELL BIOL, V216, P1959, DOI 10.1083/jcb.201611135; Gursoy-Yuzugullu O, 2016, J MOL BIOL, V428, P1846, DOI 10.1016/j.jmb.2015.11.021; Hartlerode AJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049211; Hromas R, 2012, ONCOGENE, V31, P4245, DOI 10.1038/onc.2011.586; Hsiao KY, 2013, J MOL CELL BIOL, V5, P157, DOI 10.1093/jmcb/mjs066; Hyun K, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.11; Johnson DH, 2014, J CLIN ONCOL, V32, P973, DOI 10.1200/JCO.2013.53.1228; KELLAND LR, 1995, J MED CHEM, V38, P3016, DOI 10.1021/jm00016a004; Kooistra SM, 2012, NAT REV MOL CELL BIO, V13, P297, DOI 10.1038/nrm3327; Kumagai A, 2006, CELL CYCLE, V5, P1265, DOI 10.4161/cc.5.12.2834; Kuo LJ, 2008, IN VIVO, V22, P305; Li CC, 2016, ONCOTARGET, V7, P1947, DOI 10.18632/oncotarget.6482; Lord RVN, 2002, CLIN CANCER RES, V8, P2286; Mallette FA, 2012, EMBO J, V31, P1865, DOI 10.1038/emboj.2012.47; Mendoza J, 2013, BRIT J CANCER, V109, P68, DOI 10.1038/bjc.2013.303; Mutreja K, 2018, CELL REP, V24, P2629, DOI 10.1016/j.celrep.2018.08.019; Nam EA, 2011, BIOCHEM J, V436, P527, DOI 10.1042/BJ20102162; Northcott PA, 2009, NAT GENET, V41, P465, DOI 10.1038/ng.336; Petermann E, 2010, P NATL ACAD SCI USA, V107, P16090, DOI 10.1073/pnas.1005031107; Price BD, 2013, CELL, V152, P1344, DOI 10.1016/j.cell.2013.02.011; Saksouk N, 2015, EPIGENET CHROMATIN, V8, DOI 10.1186/1756-8935-8-3; Sangster-Guity N, 2011, ONCOGENE, V30, P2526, DOI 10.1038/onc.2010.624; Sanjiv K, 2016, CELL REP, V14, P298, DOI 10.1016/j.celrep.2015.12.032; Seiler JA, 2007, MOL CELL BIOL, V27, P5806, DOI 10.1128/MCB.02278-06; Steuer CE, 2017, JAMA ONCOL, V3, P1120, DOI 10.1001/jamaoncol.2016.4280; Steward O, 2012, EXP NEUROL, V233, P597, DOI 10.1016/j.expneurol.2011.06.017; Sun YL, 2009, NAT CELL BIOL, V11, P1376, DOI 10.1038/ncb1982; Toledo LI, 2013, CELL, V155, P1088, DOI 10.1016/j.cell.2013.10.043; Toyokawa G, 2016, ANTICANCER RES, V36, P4841, DOI 10.21873/anticanres.11046; Turinetto V, 2015, NUCLEIC ACIDS RES, V43, P2489, DOI 10.1093/nar/gkv061; Usanova S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-248; Vendetti FP, 2015, ONCOTARGET, V6, P44289, DOI 10.18632/oncotarget.6247; Wakeman TP, 2012, EMBO J, V31, P2169, DOI 10.1038/emboj.2012.50; Zhang YW, 2005, MOL CELL, V19, P607, DOI 10.1016/j.molcel.2005.07.019; Zheng H, 2014, ONCOGENE, V33, P734, DOI 10.1038/onc.2013.6; Zhou WD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083978	58	14	17	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2019	38	28					5643	5657		10.1038/s41388-019-0814-6	http://dx.doi.org/10.1038/s41388-019-0814-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IH9RW	30967636				2022-12-28	WOS:000474845100007
J	Stetka, J; Vyhlidalova, P; Lanikova, L; Koralkova, P; Gursky, J; Hlusi, A; Flodr, P; Hubackova, S; Bartek, J; Hodny, Z; Divoky, V				Stetka, J.; Vyhlidalova, P.; Lanikova, L.; Koralkova, P.; Gursky, J.; Hlusi, A.; Flodr, P.; Hubackova, S.; Bartek, J.; Hodny, Z.; Divoky, V			Addiction to DUSP1 protects JAK2V617F-driven polycythemia vera progenitors against inflammatory stress and DNA damage, allowing chronic proliferation	ONCOGENE			English	Article							STEM-CELL FUNCTION; REACTIVE OXYGEN; REPLICATION STRESS; OXIDATIVE STRESS; HEMATOPOIETIC PROGENITORS; IFN-GAMMA; EXPRESSION; DISEASE; ACTIVATION; PROGRESSION	Inflammatory and oncogenic signaling converge in disease evolution of BCR-ABL-negative myeloproliferative neoplasms, clonal hematopoietic stem cell disorders characterized by gain-of-function mutation in JAK2 kinase (JAK2V617F), with highest prevalence in patients with polycythemia vera (PV). Despite the high risk, DNA-damaging inflammatory microenvironment, PV progenitors tend to preserve their genomic stability over decades until their progression to post-PV myelofibrosis/acute myeloid leukemia. Using induced pluripotent stem cells-derived CD34(+) progenitor-enriched cultures from JAK2V617F(+) PV patient and from JAK2 wild-type healthy control, CRISPR-modified HEL cells and patients' bone marrow sections from different disease stages, we demonstrate that JAK2V617F induces an intrinsic IFN gamma- and NF-kappa B associated inflammatory program, while suppressing inflammation-evoked DNA damage both in vitro and in vivo. We show that cells with JAK2V617F tightly regulate levels of inflammatory cytokines-induced reactive oxygen species, do not fully activate the ATM/p53/p21waf1 checkpoint and p38/JNK MAPK stress pathway signaling when exposed to inflammatory cytokines, suppress DNA single-strand break repair genes' expression yet overexpress the dual-specificity phosphatase (DUSP) 1. RNAi-mediated knock-down and pharmacological inhibition of DUSP1, involved in p38/JNK deactivation, in HEL cells reveals growth addiction to DUSP1, consistent with enhanced DNA damage response and apoptosis in DUSP1inhibited parental JAK2V617F(+) cells, but not in CRISPR-modified JAK2 wild-type cells. Our results indicate that the JAK2V617F+ PV progenitors utilize DUSP1 activity as a protection mechanism against DNA damage accumulation, promoting their proliferation and survival in the inflammatory microenvironment, identifying DUSP1 as a potential therapeutic target in PV.	[Stetka, J.; Vyhlidalova, P.; Lanikova, L.; Koralkova, P.; Divoky, V] Palacky Univ, Dept Biol, Fac Med & Dent, Olomouc, Czech Republic; [Vyhlidalova, P.] Palacky Univ, Dept Histol & Embryol, Fac Med & Dent, Olomouc, Czech Republic; [Lanikova, L.] Inst Mol Genet ASCR Vvi, Lab Cell & Dev Biol, Prague, Czech Republic; [Gursky, J.; Bartek, J.] Palacky Univ, Inst Mol & Translat Med, Fac Med & Dent, Olomouc, Czech Republic; [Hlusi, A.; Divoky, V] Palacky Univ, Dept Hematooncol, Univ Hosp, Olomouc, Czech Republic; [Hlusi, A.; Flodr, P.; Divoky, V] Palacky Univ, Fac Med & Dent, Olomouc, Czech Republic; [Flodr, P.] Palacky Univ, Dept Clin & Mol Pathol, Univ Hosp, Olomouc, Czech Republic; [Hubackova, S.] Czech Acad Sci, Lab Mol Therapy, Inst Biotechnol, BIOCEV, Prague 25250, Czech Republic; [Bartek, J.] Danish Canc Soc Res Ctr, DK-2100 Copenhagen, Denmark; [Bartek, J.; Hodny, Z.] Inst Mol Genet ASCR Vvi, Lab Genome Integr, Prague, Czech Republic; [Bartek, J.] Karolinska Inst, Div Genome Biol, Dept Biochem & Biophys, Sci Life Lab, Stockholm, Sweden	Palacky University Olomouc; Palacky University Olomouc; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Palacky University Olomouc; Palacky University Olomouc; University Hospital Olomouc; University Hospital Plzen; Palacky University Olomouc; Palacky University Olomouc; University Hospital Olomouc; Czech Academy of Sciences; Institute of Biotechnology of the Czech Academy of Sciences; Danish Cancer Society; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Karolinska Institutet	Divoky, V (corresponding author), Palacky Univ, Dept Biol, Fac Med & Dent, Olomouc, Czech Republic.; Bartek, J (corresponding author), Palacky Univ, Inst Mol & Translat Med, Fac Med & Dent, Olomouc, Czech Republic.; Divoky, V (corresponding author), Palacky Univ, Dept Hematooncol, Univ Hosp, Olomouc, Czech Republic.; Divoky, V (corresponding author), Palacky Univ, Fac Med & Dent, Olomouc, Czech Republic.; Bartek, J (corresponding author), Danish Canc Soc Res Ctr, DK-2100 Copenhagen, Denmark.; Bartek, J; Hodny, Z (corresponding author), Inst Mol Genet ASCR Vvi, Lab Genome Integr, Prague, Czech Republic.; Bartek, J (corresponding author), Karolinska Inst, Div Genome Biol, Dept Biochem & Biophys, Sci Life Lab, Stockholm, Sweden.	jb@cancer.dk; zdenek.hodny@img.cas.cz; vladimir.divoky@upol.cz	Flodr, Patrik/GLS-0074-2022; Koralkova, Pavla/AAL-2965-2020; Vyhlidalova, Pavla/O-8178-2019	Vyhlidalova, Pavla/0000-0002-2522-6749; Stetka, Jan/0000-0003-4301-2856; Lanikova, Lucie/0000-0002-2845-8692; Stemberkova Hubackova, Sona/0000-0002-3454-6840	Czech Science Foundation [14-10687P]; Internal Grant Agency of Palacky University [IGA_LF_2018_010]; Danish Council for Independent Research; Swedish Research Council; European Regional Development Fund [ENOCH/CZ.02.1.01/0.0/0.0/16_019/0000868];  [LTAUSA17142]	Czech Science Foundation(Grant Agency of the Czech Republic); Internal Grant Agency of Palacky University; Danish Council for Independent Research(Det Frie Forskningsrad (DFF)); Swedish Research Council(Swedish Research CouncilEuropean Commission); European Regional Development Fund(European Commission); 	Czech Science Foundation Project 14-10687P (PV), LTAUSA17142 project (JS, LL, and VD), Internal Grant Agency of Palacky University, Project IGA_LF_2018_010 (JS and PK), Danish Council for Independent Research (JB), Swedish Research Council (JB), and European Regional Development Fund-Project ENOCH/CZ.02.1.01/0.0/0.0/16_019/0000868 (ZH and JB).	Algood HMS, 2004, J IMMUNOL, V172, P6846, DOI 10.4049/jimmunol.172.11.6846; Andersson AC, 2006, J HISTOCHEM CYTOCHEM, V54, P1413, DOI 10.1369/jhc.6A7001.2006; Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Arthur JSC, 2013, NAT REV IMMUNOL, V13, P679, DOI 10.1038/nri3495; Baba T, 2016, BLOOD, V127, P2607, DOI 10.1182/blood-2015-10-673087; Babicki S, 2016, NUCLEIC ACIDS RES, V44, pW147, DOI 10.1093/nar/gkw419; Bagnyukova TV, 2013, BRIT J CANCER, V109, P1063, DOI 10.1038/bjc.2013.353; Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartkova J, 2010, ONCOGENE, V29, P5095, DOI 10.1038/onc.2010.249; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bennett BT, 2009, METHODS, V48, P63, DOI 10.1016/j.ymeth.2009.02.009; Berglund UW, 2016, ANN ONCOL, V27, P2275, DOI 10.1093/annonc/mdw429; Besancenot R, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000476; BEUTLER E, 1977, BRIT J HAEMATOL, V35, P331, DOI 10.1111/j.1365-2141.1977.tb00589.x; Bock O, 2005, J PATHOL, V205, P548, DOI 10.1002/path.1744; Campbell PJ, 2006, NEW ENGL J MED, V355, P2452, DOI 10.1056/NEJMra063728; Carvalho BS, 2010, BIOINFORMATICS, V26, P2363, DOI 10.1093/bioinformatics/btq431; Cerquozzi S, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.95; Chagraoui H, 2002, BLOOD, V100, P3495, DOI 10.1182/blood-2002-04-1133; Chen E, 2015, CELL REP, V13, P2345, DOI 10.1016/j.celrep.2015.11.037; Chen E, 2014, P NATL ACAD SCI USA, V111, P15190, DOI 10.1073/pnas.1401873111; Chen E, 2010, CANCER CELL, V18, P524, DOI 10.1016/j.ccr.2010.10.013; Desterke C, 2011, CANCER RES, V71, P2901, DOI 10.1158/0008-5472.CAN-10-1731; FARBER JM, 1990, P NATL ACAD SCI USA, V87, P5238, DOI 10.1073/pnas.87.14.5238; Fleischman AG, 2011, BLOOD, V118, P6392, DOI 10.1182/blood-2011-04-348144; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Harris IS, 2015, CANCER CELL, V27, P211, DOI 10.1016/j.ccell.2014.11.019; Hasselbalch HC, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/102476; Heaton WL, 2018, LEUKEMIA, V32, P2399, DOI 10.1038/s41375-018-0131-z; Herwig R, 2016, NAT PROTOC, V11, P1889, DOI 10.1038/nprot.2016.117; Horvathova M, 2012, HAEMATOL-HEMATOL J, V97, P1480, DOI 10.3324/haematol.2011.059550; Hu P, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05955-2; Hubackova S, 2016, ONCOGENE, V35, P1236, DOI 10.1038/onc.2015.162; Hubackova S, 2012, AGING-US, V4, P932, DOI 10.18632/aging.100520; Iwasa H, 2003, GENES CELLS, V8, P131, DOI 10.1046/j.1365-2443.2003.00620.x; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Karigane D, 2016, CELL STEM CELL, V19, P192, DOI 10.1016/j.stem.2016.05.013; Kennedy M, 2012, CELL REP, V2, P1722, DOI 10.1016/j.celrep.2012.11.003; Kesarwani M, 2017, NAT MED, V23, P472, DOI 10.1038/nm.4310; Kidger AM, 2016, SEMIN CELL DEV BIOL, V50, P125, DOI 10.1016/j.semcdb.2016.01.009; Kleppe M, 2017, CELL STEM CELL, V21, P489, DOI 10.1016/j.stem.2017.08.011; Koledova Z, 2010, STEM CELLS DEV, V19, P181, DOI 10.1089/scd.2009.0065; Kozlov SV, 2016, MOL CELL PROTEOMICS, V15, P1032, DOI 10.1074/mcp.M115.055723; Lee J, 2019, CURR GENET, V65, P417, DOI 10.1007/s00294-018-0898-5; Li JA, 2010, BLOOD, V116, P1528, DOI 10.1182/blood-2009-12-259747; Lu M, 2010, EXP HEMATOL, V38, P472, DOI 10.1016/j.exphem.2010.03.005; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; Majumder S, 1998, J IMMUNOL, V161, P4736; Manshouri T, 2011, CANCER RES, V71, P3831, DOI 10.1158/0008-5472.CAN-10-4002; Marty C, 2013, LEUKEMIA, V27, P2187, DOI 10.1038/leu.2013.102; Mills RJ, 2017, P NATL ACAD SCI USA, V114, pE8372, DOI 10.1073/pnas.1707316114; Molina G, 2009, NAT CHEM BIOL, V5, P680, DOI 10.1038/nchembio.190; Pearl LH, 2015, NAT REV CANCER, V15, P166, DOI 10.1038/nrc3891; Pietras EM, 2017, BLOOD, V130, P1693, DOI 10.1182/blood-2017-06-780882; Plo I, 2008, BLOOD, V112, P1402, DOI 10.1182/blood-2008-01-134114; Rasmussen RD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13398; Schepers K, 2013, CELL STEM CELL, V13, P285, DOI 10.1016/j.stem.2013.06.009; Schnoder TM, 2017, J CANCER RES CLIN, V143, P807, DOI 10.1007/s00432-017-2354-1; Smith C, 2015, MOL THER, V23, P570, DOI 10.1038/mt.2014.226; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takacova S, 2012, CANCER CELL, V21, P517, DOI 10.1016/j.ccr.2012.01.021; Tefferi A, 2014, BLOOD, V124, P2507, DOI 10.1182/blood-2014-05-579136; Turpie AGG, 2017, BLOOD, V130; Vaidya R, 2012, AM J HEMATOL, V87, P1003, DOI 10.1002/ajh.23295; Vainchenker W, 2017, BLOOD, V129, P667, DOI 10.1182/blood-2016-10-695940; van Dekken H, 2008, AM J CLIN PATHOL, V130, P745, DOI 10.1309/AJCPO31THGVEUIDH; Vener C, 2010, EXP HEMATOL, V38, P1058, DOI 10.1016/j.exphem.2010.07.005; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Walter D, 2015, NATURE, V520, P549, DOI 10.1038/nature14131; Wernig G, 2017, P NATL ACAD SCI USA, V114, P4757, DOI 10.1073/pnas.1621375114; Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017; Wu XF, 2018, CELL, V172, P423, DOI 10.1016/j.cell.2017.11.018; Ye ZH, 2014, STEM CELLS, V32, P269, DOI 10.1002/stem.1545; Zambetti NA, 2016, CELL STEM CELL, V19, P613, DOI 10.1016/j.stem.2016.08.021; Zhou A, 2003, ONCOGENE, V22, P2054, DOI 10.1038/sj.onc.1206262; Zidova Z, 2014, CELL PHYSIOL BIOCHEM, V34, P2221, DOI 10.1159/000369665; Ziv Y, 2006, NAT CELL BIOL, V8, P870, DOI 10.1038/ncb1446	82	22	22	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2019	38	28					5627	5642		10.1038/s41388-019-0813-7	http://dx.doi.org/10.1038/s41388-019-0813-7			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IH9RW	30967632	Green Published, hybrid			2022-12-28	WOS:000474845100006
J	Barry, S; Carlsen, E; Marques, P; Stiles, CE; Gadaleta, E; Berney, DM; Roncaroli, F; Chelala, C; Solomou, A; Herincs, M; Caimari, F; Grossman, AB; Crnogorac-Jurcevic, T; Haworth, O; Gaston-Massuet, C; Korbonits, M				Barry, Sayka; Carlsen, Eivind; Marques, Pedro; Stiles, Craig E.; Gadaleta, Emanuela; Berney, Dan M.; Roncaroli, Federico; Chelala, Claude; Solomou, Antonia; Herincs, Maria; Caimari, Francisca; Grossman, Ashley B.; Crnogorac-Jurcevic, Tatjana; Haworth, Oliver; Gaston-Massuet, Carles; Korbonits, Marta			Tumor microenvironment defines the invasive phenotype of AIP-mutation-positive pituitary tumors	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL-TRANSITION; DIFFERENTIAL GENE-EXPRESSION; INTERACTING PROTEIN; GROWTH-HORMONE; T-CELLS; SOMATOTROPH ADENOMAS; COLON-CANCER; MACROPHAGES; FLI-1; PROGRESSION	The molecular mechanisms leading to aryl hydrocarbon receptor interacting protein (AIP) mutation-induced aggressive, young-onset growth hormone-secreting pituitary tumors are not fully understood. In this study, we have identified that AIP-mutation-positive tumors are infiltrated by a large number of macrophages compared to sporadic tumors. Tissue from pituitary-specific Aip-knockout (Aip(Flox/Flox) ; Hesx1(cre/+)) mice recapitulated this phenotype. Our human pituitary tumor transcriptome data revealed the "epithelial-to-mesenchymal transition (EMT) pathway" as one of the most significantly altered pathways in AIP(pos) tumors. Our in vitro data suggest that bone marrow-derived macrophage-conditioned media induces more prominent EMT-like phenotype and enhanced migratory and invasive properties in Aip-knockdown somatomammotroph cells compared to non-targeting controls. We identified that tumor-derived cytokine CCL5 is upregulated in AIP-mutation-positive human adenomas. Aip-knockdown GH3 cell-conditioned media increases macrophage migration, which is inhibited by the CCL5/CCR5 antagonist maraviroc. Our results suggest that a crosstalk between the tumor and its microenvironment plays a key role in the invasive nature of AIP-mutation-positive tumors and the CCL5/CCR5 pathway is a novel potential therapeutic target.	[Barry, Sayka; Marques, Pedro; Stiles, Craig E.; Solomou, Antonia; Herincs, Maria; Caimari, Francisca; Grossman, Ashley B.; Haworth, Oliver; Gaston-Massuet, Carles; Korbonits, Marta] Queen Mary Univ London, William Harvey Res Inst, Barts & London Sch Med, Ctr Endocrinol, London EC1M 6BQ, England; [Carlsen, Eivind] STHF, Dept Pathol, N-3710 Skien, Norway; [Gadaleta, Emanuela; Berney, Dan M.; Chelala, Claude; Crnogorac-Jurcevic, Tatjana] Queen Mary Univ London, Barts Canc Inst, Barts & London Sch Med, Mol Oncol, London EC1M 6BQ, England; [Roncaroli, Federico] Univ Manchester, Div Neurosci & Expt Psychol, Manchester M13 9PL, Lancs, England	University of London; Queen Mary University London; University of London; Queen Mary University London; University of Manchester	Korbonits, M (corresponding author), Queen Mary Univ London, William Harvey Res Inst, Barts & London Sch Med, Ctr Endocrinol, London EC1M 6BQ, England.	m.korbonits@qmul.ac.uk		Marques, Pedro/0000-0002-4959-5725; Korbonits, Marta/0000-0002-4101-9432; Roncaroli, Federico/0000-0003-3650-5572; Caimari, Francisca/0000-0003-3327-9098; Gadaleta, Emanuela/0000-0002-5740-6293	Medical Research Council [MR/M018539/1]; Wellcome Trust [097970/Z/11/Z]; Fundacion Alfonso Martin Escudero Fellowship; Rosetrees Trust [M505]; Barts and the London Charity; Pfizer UK [WS 733753]; MRC [MR/M018539/1] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); Fundacion Alfonso Martin Escudero Fellowship; Rosetrees Trust(Rosetrees Trust); Barts and the London Charity; Pfizer UK(Pfizer); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by the Medical Research Council (MR/M018539/1 to MK), Wellcome Trust (Clinical Training fellowship 097970/Z/11/Z to CES), Fundacion Alfonso Martin Escudero Fellowship (to FC), Rosetrees Trust (M505 to MK and CG-M), Barts and the London Charity (to PM and MK) and Pfizer UK (WS 733753 to MK).	Aldinucci D, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/292376; Azorin E, 2012, ARCH BIOCHEM BIOPHYS, V528, P148, DOI 10.1016/j.abb.2012.08.011; Balkwill FR, 2012, J CELL SCI, V125, P5591, DOI 10.1242/jcs.116392; Barry S, 2012, END ABSTR, pP1349; Basu R, 2017, ONCOTARGET, V8, P21579, DOI 10.18632/oncotarget.15375; Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Bonde AK, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-35; Brittain AL, 2017, J CLIN ENDOCR METAB, V102, P3662, DOI 10.1210/jc.2017-01000; Brown JM, 2017, CLIN CANCER RES, V23, P3241, DOI 10.1158/1078-0432.CCR-16-3122; Chahal HS, 2012, J CLIN ENDOCR METAB, V97, pE1411, DOI 10.1210/jc.2012-1111; Chahal HS, 2011, NEW ENGL J MED, V364, P43, DOI 10.1056/NEJMoa1008020; Chang LY, 2012, CANCER RES, V72, P1092, DOI 10.1158/0008-5472.CAN-11-2493; Chesnokova V, 2016, P NATL ACAD SCI USA, V113, pE3250, DOI 10.1073/pnas.1600561113; Condeelis J, 2003, NAT REV CANCER, V3, P921, DOI 10.1038/nrc1231; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Daly AF, 2010, J CLIN ENDOCR METAB, V95, pE373, DOI 10.1210/jc.2009-2556; Evans CO, 2008, PITUITARY, V11, P231, DOI 10.1007/s11102-007-0082-2; Evans CO, 2001, J CLIN ENDOCR METAB, V86, P3097, DOI 10.1210/jc.86.7.3097; Fan QM, 2014, CANCER LETT, V352, P160, DOI 10.1016/j.canlet.2014.05.008; Fidler IJ, 2002, SEMIN CANCER BIOL, V12, P89, DOI 10.1006/scbi.2001.0416; Fukunishi T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158555; Galland F, 2010, ENDOCR-RELAT CANCER, V17, P361, DOI 10.1677/ERC-10-0018; Grigore AD, 2016, J CLIN MED, V5, P51, DOI 10.3390/jcm5050051; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Heliovaara E, 2009, AM J PATHOL, V175, P2501, DOI 10.2353/ajpath.2009.081131; Heshmati HM, 1998, ENDOCR J, V45, P357, DOI 10.1507/endocrj.45.357; Igreja S, 2010, HUM MUTAT, V31, P950, DOI 10.1002/humu.21292; Jaffrain-Rea ML, 2009, ENDOCR-RELAT CANCER, V16, P1029, DOI 10.1677/ERC-09-0094; Jiang ZQ, 2010, EXP THER MED, V1, P905, DOI 10.3892/etm.2010.137; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Keophiphath M, 2010, ARTERIOSCL THROM VAS, V30, P39, DOI 10.1161/ATVBAHA.109.197442; Kimura A, 2014, INT IMMUNOL, V26, P209, DOI 10.1093/intimm/dxt067; Lekva T, 2013, ENDOCRINOLOGY, V154, P3331, DOI 10.1210/en.2013-1051; Lekva T, 2012, J CLIN ENDOCR METAB, V97, pE1506, DOI 10.1210/jc.2012-1760; Leontiou CA, 2008, J CLIN ENDOCR METAB, V93, P2390, DOI 10.1210/jc.2007-2611; Li Y, 2015, ONCOGENE, V34, P2022, DOI 10.1038/onc.2014.162; Liu WP, 2005, J MED INVESTIG, V52, P151, DOI 10.2152/jmi.52.151; Lu JQ, 2015, ENDOCR PATHOL, V26, P263, DOI 10.1007/s12022-015-9383-6; Lupi I, 2010, J CLIN ENDOCR METAB, V95, P289, DOI 10.1210/jc.2009-1583; Moreno CS, 2005, CANCER RES, V65, P10214, DOI 10.1158/0008-5472.CAN-05-0884; Moreno-Bueno G, 2009, NAT PROTOC, V4, P1591, DOI 10.1038/nprot.2009.152; Morris DG, 2005, EUR J ENDOCRINOL, V153, P143, DOI 10.1530/eje.1.01937; Ojalvo LS, 2010, J IMMUNOL, V184, P702, DOI 10.4049/jimmunol.0902360; Oriola J, 2013, EUR J ENDOCRINOL, V168, P9, DOI 10.1530/EJE-12-0457; Osorio Joana, 2012, Nat Rev Endocrinol, V8, P444, DOI 10.1038/nrendo.2012.94; Pasqualato A, 2013, CELL ADHES MIGR, V7, P450, DOI 10.4161/cam.26765; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Richard MLL, 2014, J IMMUNOL, V193, P2661, DOI 10.4049/jimmunol.1302779; ROSSI ML, 1990, TUMORI, V76, P543, DOI 10.1177/030089169007600605; Rossi R, 2011, CLIN EXP IMMUNOL, V166, P184, DOI 10.1111/j.1365-2249.2011.04409.x; Ruebel KH, 2006, ENDOCRINE, V29, P435, DOI 10.1385/ENDO:29:3:435; Sato S, 2014, CLIN EXP IMMUNOL, V177, P102, DOI 10.1111/cei.12310; Stockinger B, 2014, ANNU REV IMMUNOL, V32, P403, DOI 10.1146/annurev-immunol-032713-120245; Subramani R, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2014.61; Tan MCB, 2009, J IMMUNOL, V182, P1746, DOI 10.4049/jimmunol.182.3.1746; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Torlakovic EE, 2008, HISTOL HISTOPATHOL, V23, P1309, DOI 10.14670/HH-23.1309; Tsai CH, 2017, SCI REP-UK, V7, DOI 10.1038/srep41927; Tsai HP, 2017, ONCOTARGET, V8, P29174, DOI 10.18632/oncotarget.16303; Tuominen I, 2015, ONCOGENE, V34, P1174, DOI 10.1038/onc.2014.50; Wang JJ, 2017, ONCOTARGET, V8; Wartenberg M, 2015, ONCOTARGET, V6, P4190, DOI 10.18632/oncotarget.2775; Wierinckx A, 2007, ENDOCR-RELAT CANCER, V14, P887, DOI 10.1677/ERC-07-0062; Wolf D, 2005, CLIN CANCER RES, V11, P8326, DOI 10.1158/1078-0432.CCR-05-1244; Xu WW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046609; Zhan XQ, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-13; Zhan XQ, 2005, MASS SPECTROM REV, V24, P783, DOI 10.1002/mas.20039	68	41	42	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2019	38	27					5381	5395		10.1038/s41388-019-0779-5	http://dx.doi.org/10.1038/s41388-019-0779-5			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IG5KR	30867568	Green Accepted, Green Submitted, Green Published, hybrid			2022-12-28	WOS:000473842500004
J	Wang, HR; Zhou, YJ; Oyang, LD; Han, YQ; Xia, LZ; Lin, JG; Tang, YY; Su, M; Tan, SM; Tian, YT; Chen, XY; Luo, X; Liang, JX; Rao, S; Wang, Y; Xiong, W; Zeng, ZY; Wang, H; Li, GY; Liao, QJ				Wang, Heran; Zhou, Yujuan; Oyang, Linda; Han, Yaqian; Xia, Longzheng; Lin, Jingguan; Tang, Yanyan; Su, Min; Tan, Shiming; Tian, Yutong; Chen, Xiaoyan; Luo, Xia; Liang, Jiaxin; Rao, Shan; Wang, Ying; Xiong, Wei; Zeng, Zhaoyang; Wang, Hui; Li, Guiyuan; Liao, Qianjin			LPLUNC1 stabilises PHB1 by counteracting TRIM21-mediated ubiquitination to inhibit NF-kappa B activity in nasopharyngeal carcinoma	ONCOGENE			English	Article							PROTEIN-DEGRADATION; CANCER-CELLS; PROHIBITIN; BPIFB1; TRIM21; MICE; IDENTIFICATION; TUMORIGENESIS	Long-palate, lung and nasal epithelium clone 1 (LPLUNC1) is a tumour suppressor gene in nasopharyngeal carcinoma (NPC), and low expression of LPLUNC1 is associated with poor prognosis. Our previous study showed that LPLUNC1 upregulates Prohibitin 1 (PHB1), a pleiotropic protein that functions as a tumour suppressor gene in various cancers. Low expression of PHB1 was also found to be associated with the poor prognosis of NPC patients. However, the mechanisms by which LPLUNC1 upregulates PHB1 and the potential role of PHB1 in NPC are unclear. Here, we found that LPLUNC1 stabilised PHB1 by inhibiting PHB1 ubiquitination, which is mediated by E3 ligase TRIM21. LPLUNC1 competitively impaired the binding of PHB1 to TRIM21 due to its stronger binding affinity to PHB1, suppressing the ubiquitination of PHB1. Therefore, our study indicates that PHB1 acted as a tumour suppressor gene by inhibiting NF-kB activity. Depletion of PHB1 significantly attenuated the anti-tumour effects of LPLUNC1 in NPC cells, and the inhibitory effect of LPLUNC1 on NF-kappa B activity was thus reversed. Together, our findings revealed a novel mechanism underlying the anticancer effect of LPLUNC1 and clarified that PHB1 may represent a novel, promising candidate tumour suppressor gene in NPC, with potential therapeutic target value.	[Wang, Heran; Zhou, Yujuan; Oyang, Linda; Han, Yaqian; Xia, Longzheng; Lin, Jingguan; Tang, Yanyan; Su, Min; Tan, Shiming; Tian, Yutong; Chen, Xiaoyan; Luo, Xia; Liang, Jiaxin; Rao, Shan; Wang, Ying; Wang, Hui; Liao, Qianjin] Cent S Univ, Hunan Canc Hosp, Hunan Key Lab Translat Radiat Oncol, 283 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China; [Wang, Heran; Zhou, Yujuan; Oyang, Linda; Han, Yaqian; Xia, Longzheng; Lin, Jingguan; Tang, Yanyan; Su, Min; Tan, Shiming; Tian, Yutong; Chen, Xiaoyan; Luo, Xia; Liang, Jiaxin; Rao, Shan; Wang, Ying; Wang, Hui; Liao, Qianjin] Cent S Univ, Affiliated Canc Hosp, Hunan Key Lab Translat Radiat Oncol, Xiangya Sch Med, 283 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China; [Xiong, Wei; Zeng, Zhaoyang; Li, Guiyuan] Cent S Univ, Canc Res Inst, Key Lab Carcinogenesis & Canc Invas, Minist Educ, Changsha 410078, Hunan, Peoples R China	Central South University; Central South University; Central South University	Liao, QJ (corresponding author), Cent S Univ, Hunan Canc Hosp, Hunan Key Lab Translat Radiat Oncol, 283 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China.; Liao, QJ (corresponding author), Cent S Univ, Affiliated Canc Hosp, Hunan Key Lab Translat Radiat Oncol, Xiangya Sch Med, 283 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China.	march-on@126.com	chen, xi/GXH-3653-2022; chen, xia/GYR-3948-2022; chen, xia/GXM-5435-2022	Zhou, Yujuan/0000-0002-5195-8724; Liao, Qianjin/0000-0001-9320-3090	National Natural Science Foundation of China [81472595, 81701510, 81872281]; Natural Science Foundation of Hunan Province [2018JJ1013, 2016JJ4059]; Research Project of the Health and Family Planning Commission of Hunan Province [B20180400, B20180582]; Changsha Science and Technology Board [kq1706045, kq1706043]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Hunan Province(Natural Science Foundation of Hunan Province); Research Project of the Health and Family Planning Commission of Hunan Province; Changsha Science and Technology Board	This work was supported by grants from the National Natural Science Foundation of China (81472595, 81701510 and 81872281), the Natural Science Foundation of Hunan Province (2018JJ1013, 2016JJ4059), the Research Project of the Health and Family Planning Commission of Hunan Province (B20180400, B20180582), and the Changsha Science and Technology Board (kq1706045, kq1706043).	Amin H, 2015, ACS MED CHEM LETT, V6, P1071, DOI 10.1021/acsmedchemlett.5b00257; Bingle CD, 2010, HISTOCHEM CELL BIOL, V133, P505, DOI 10.1007/s00418-010-0683-0; Das A, 2015, VIROLOGY, V485, P383, DOI 10.1016/j.virol.2015.08.013; De Smet EG, 2018, INT J CHRONIC OBSTR, V13, P11, DOI 10.2147/COPD.S144136; Donoghue LJ, 2017, GENETICS, V207, P801, DOI 10.1534/genetics.117.300211; El-Etreby NM, 2017, J OVARIAN RES, V10, DOI 10.1186/s13048-017-0325-4; Fan W, 2017, HEPATOLOGY, V65, P1249, DOI 10.1002/hep.28964; Fletcher CE, 2012, HUM MOL GENET, V21, P3112, DOI 10.1093/hmg/dds139; Gao J, 2015, AM J PHYSIOL-LUNG C, V309, pL17, DOI 10.1152/ajplung.00082.2015; Han J, 2014, CELL SIGNAL, V26, P2086, DOI 10.1016/j.cellsig.2014.06.006; Hildesheim A, 2012, SEMIN CANCER BIOL, V22, P107, DOI 10.1016/j.semcancer.2012.01.007; Inobe T, 2014, CURR OPIN STRUC BIOL, V24, P156, DOI 10.1016/j.sbi.2014.02.002; Jin JM, 2016, CELL TISSUE RES, V363, P805, DOI 10.1007/s00441-015-2280-y; Kang DC, 2017, ULTRASON SONOCHEM, V38, P317, DOI 10.1016/j.ultsonch.2017.03.026; Kathiria AS, 2012, CANCER RES, V72, P5778, DOI 10.1158/0008-5472.CAN-12-0603; Koushyar S, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.32; Kumar C, 2017, MEDCHEMCOMM, V8, P2115, DOI 10.1039/c7md00267j; Liao Q, 2014, ONCOGENE, V33, P2098, DOI 10.1038/onc.2013.161; Liao QJ, 2013, EUR J CANCER PREV, V22, P68, DOI 10.1097/CEJ.0b013e328354d351; Mantovani A, 2010, CURR MOL MED, V10, P369, DOI 10.2174/156652410791316968; Mishra S, 2006, J CELL MOL MED, V10, P353, DOI 10.1111/j.1582-4934.2006.tb00404.x; Mishra S, 2010, FEBS J, V277, P3937, DOI 10.1111/j.1742-4658.2010.07809.x; Nguyen JQ, 2017, CANCER BIOL THER, V18, P16, DOI 10.1080/15384047.2016.1252880; Nih LR, 2017, ADV MATER, V29, DOI 10.1002/adma.201606471; Pan JA, 2016, MOL CELL, V61, P720, DOI 10.1016/j.molcel.2016.02.007; Patel N, 2010, P NATL ACAD SCI USA, V107, P2503, DOI 10.1073/pnas.0910649107; Qureshi R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141826; Shin OS, 2011, J INFECT DIS, V204, P1349, DOI 10.1093/infdis/jir544; Shum AK, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006998; Sievers C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012735; Theiss AL, 2011, BBA-MOL CELL RES, V1813, P1137, DOI 10.1016/j.bbamcr.2011.01.033; Theiss AL, 2009, MOL BIOL CELL, V20, P4412, DOI 10.1091/mbc.E09-05-0361; Vargas PA, 2008, ORAL DIS, V14, P613, DOI 10.1111/j.1601-0825.2007.01429.x; Wang HY, 2016, CHIN J CANCER, V35, DOI 10.1186/s40880-016-0103-5; Wang SM, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/9343460; Wang T, 2012, J CELL MOL MED, V16, P1134, DOI 10.1111/j.1582-4934.2011.01388.x; Wang XY, 2017, MACROMOL BIOSCI, V17, DOI 10.1002/mabi.201700186; Wei F, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0409-0; Wei F, 2018, BRIT J CANCER, V118, P233, DOI 10.1038/bjc.2017.385; Wu CC, 2018, CANCERS, V10, DOI 10.3390/cancers10040120; Yang LT, 2018, J INVEST DERMATOL, V138, P2568, DOI 10.1016/j.jid.2018.05.016; Yang YX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062869; Ye X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109152; Yuan GJ, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0695-5; Zeng ZY, 2011, SCI CHINA LIFE SCI, V54, P966, DOI 10.1007/s11427-011-4223-5; Zhang BC, 2003, GENE CHROMOSOME CANC, V38, P80, DOI 10.1002/gcc.10247; Zhang L, 2012, ASIAN PAC J CANCER P, V13, P3803, DOI 10.7314/APJCP.2012.13.8.3803; Zhou WQ, 2017, OPEN MED-WARSAW, V12, P299, DOI 10.1515/med-2017-0044; Zhou YJ, 2016, J CANCER, V7, P367, DOI 10.7150/jca.13695	49	24	28	3	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2019	38	25					5062	5075		10.1038/s41388-019-0778-6	http://dx.doi.org/10.1038/s41388-019-0778-6			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IE1KY	30886235	Green Published, hybrid			2022-12-28	WOS:000472145900013
J	Hsu, FF; Chou, YT; Chiang, MT; Li, FA; Yeh, CT; Lee, WH; Chau, LY				Hsu, Fu-Fei; Chou, Yi-Tai; Chiang, Ming-Tsai; Li, Fu-An; Yeh, Chi-Tai; Lee, Wei-Hwa; Chau, Lee-Young			Signal peptide peptidase promotes tumor progression via facilitating FKBP8 degradation	ONCOGENE			English	Article							INTRAMEMBRANE PROTEOLYSIS; HEME OXYGENASE-1; CLEAVAGE; PROTEIN; IDENTIFICATION; INHIBITOR; MECHANISM; BCL-2	Signal peptide peptidase (SPP) is an endoplasmic reticulum (ER)-resident aspartyl protease mediating intramembrane cleavage of type II transmembrane proteins. Increasing evidence has supported the role of SPP in ER-associated protein degradation. In the present study, we show that SPP expression is highly induced in human lung and breast cancers and correlated with disease outcome. Stable depletion of SPP expression in lung and breast cancer cell lines significantly reduced cell growth and migration/invasion abilities. Quantitative analysis of the proteomic changes of microsomal proteins in lung cancer cells by the stable isotope labeling with amino acids in cell culture (SILAC) approach revealed that the level of FKBP8, an endogenous inhibitor of mTOR, was significantly increased following SPP depletion. Co-immunoprecipitation assay and confocal immunofluorescence demonstrated that SPP interacted and colocalized with FKBP8 in ER, supporting that FKBP8 is a protein substrate of SPP. Cycloheximide chase and proteasome inhibition experiments revealed that SPP-mediated proteolysis facilitated FKBP8 protein degradation in cytosol. Further experiment demonstrated that the levels of phosphorylation in mTOR and its downstream effectors, S6K and 4E-BP1, were significantly lower in SPP-depleted cells. The reduced mTOR signaling and decreases of growth and migration/invasion abilities induced by SPP depletion in cancer cells could be reversed by FKBP8 downregulation. The implication of FKBP8 in SPP-mediated tumorigenicity was also observed in the xenograft model. Together, these findings disclose that SPP promotes tumor progression, at least in part, via facilitating the degradation of FKBP8 to enhance mTOR signaling.	[Hsu, Fu-Fei; Chou, Yi-Tai; Chiang, Ming-Tsai; Li, Fu-An; Chau, Lee-Young] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan; [Yeh, Chi-Tai; Lee, Wei-Hwa] Taipei Med Univ, Shuang Ho Hosp, Canc Ctr, Taipei, Taiwan	Academia Sinica - Taiwan; Taipei Medical University; Shuang Ho Hospital	Chau, LY (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei, Taiwan.	lyc@ibms.sinica.edu.tw	Chau, Lee-Young/N-7659-2018; Li, Fu-An/M-8506-2019	Chau, Lee-Young/0000-0002-6316-2328; Li, Fu-An/0000-0002-0580-7765	Ministry of Science and Technology Taiwan [MOST 103-2320-B-001-013-MY3]; Institute of Biomedical Sciences, Academia Sinica	Ministry of Science and Technology Taiwan(Ministry of Science and Technology, Taiwan); Institute of Biomedical Sciences, Academia Sinica(Academia Sinica - Taiwan)	This work was supported by the Ministry of Science and Technology Taiwan (MOST 103-2320-B-001-013-MY3) and Institute of Biomedical Sciences, Academia Sinica.	Avci D, 2015, TRENDS CELL BIOL, V25, P611, DOI 10.1016/j.tcb.2015.07.003; Avci D, 2014, MOL CELL, V56, P630, DOI 10.1016/j.molcel.2014.10.012; Bai XC, 2007, SCIENCE, V318, P977, DOI 10.1126/science.1147379; Barth S, 2009, J BIOL CHEM, V284, P23046, DOI 10.1074/jbc.M109.032631; Boname JM, 2014, J CELL BIOL, V205, P847, DOI 10.1083/jcb.201312009; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Chen CY, 2014, EMBO J, V33, P2492, DOI 10.15252/embj.201488208; Chen XL, 2015, PROTEOMICS, V15, P3175, DOI 10.1002/pmic.201500108; Choi MS, 2011, BIOCHEM BIOPH RES CO, V406, P305, DOI 10.1016/j.bbrc.2011.02.037; Das I, 2004, J BIOL CHEM, V279, P30771, DOI 10.1074/jbc.M309252200; Edlich F, 2005, EMBO J, V24, P2688, DOI 10.1038/sj.emboj.7600739; Fong S, 2003, P NATL ACAD SCI USA, V100, P14253, DOI 10.1073/pnas.2332307100; Guan M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09698; Hsu FF, 2015, ONCOGENE, V34, P2360, DOI 10.1038/onc.2014.166; Hwang HW, 2009, J BIOL CHEM, V284, P22672, DOI 10.1074/jbc.M109.028001; LAM E, 1995, GENE, V160, P297, DOI 10.1016/0378-1119(95)00216-S; Lemberg MK, 2002, MOL CELL, V10, P735, DOI 10.1016/S1097-2765(02)00655-X; Loureiro J, 2006, NATURE, V441, P894, DOI 10.1038/nature04830; Mentrup T, 2017, EUR J CELL BIOL, V96, P372, DOI 10.1016/j.ejcb.2017.03.002; Murakami D, 2003, ONCOGENE, V22, P1511, DOI 10.1038/sj.onc.1206298; Okamoto K, 2004, J VIROL, V78, P6370, DOI 10.1128/JVI.78.12.6370-6380.2004; Shi XH, 2016, P NATL ACAD SCI USA, V113, P8825, DOI 10.1073/pnas.1603364113; Shirane M, 2003, NAT CELL BIOL, V5, P28, DOI 10.1038/ncb894; Song W, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9022; Targett-Adams P, 2006, J BIOL CHEM, V281, P29221, DOI 10.1074/jbc.M605373200; Urban S, 2002, CURR OPIN GENET DEV, V12, P512, DOI 10.1016/S0959-437X(02)00334-9; Cespedes MV, 2010, AM J PATHOL, V177, P2067, DOI 10.2353/ajpath.2010.100079; Voss M, 2013, BBA-BIOMEMBRANES, V1828, P2828, DOI 10.1016/j.bbamem.2013.03.033; Wahlstrom AM, 2007, BLOOD, V109, P763, DOI 10.1182/blood-2006-05-024752; Wei JW, 2017, CNS NEUROSCI THER, V23, P257, DOI 10.1111/cns.12672; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Wolfe MS, 2009, J BIOL CHEM, V284, P13969, DOI 10.1074/jbc.R800039200	32	17	18	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2019	38	10					1688	1701		10.1038/s41388-018-0539-y	http://dx.doi.org/10.1038/s41388-018-0539-y			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN8DD	30348988				2022-12-28	WOS:000460423800009
J	Simhadri, S; Vincelli, G; Huo, YY; Misenko, S; Foo, TK; Ahlskog, J; Sorensen, CS; Oakley, GG; Ganesan, S; Bunting, SF; Xia, B				Simhadri, Srilatha; Vincelli, Gabriele; Huo, Yanying; Misenko, Sarah; Foo, Tzeh Keong; Ahlskog, Johanna; Sorensen, Claus S.; Oakley, Gregory G.; Ganesan, Shridar; Bunting, Samuel F.; Xia, Bing			PALB2 connects BRCA1 and BRCA2 in the G2/M checkpoint response	ONCOGENE			English	Article							DNA-DAMAGE RESPONSE; HOMOLOGOUS RECOMBINATION; BRCA1-PALB2 INTERACTION; CANCER; PHOSPHORYLATION; PROTEIN; PARTNER; SUPPRESSION; INSTABILITY; EXPRESSION	The G2/M checkpoint inhibits mitotic entry upon DNA damage, thereby preventing segregation of broken chromosomes and preserving genome stability. The tumor suppressor proteins BRCA1, PALB2 and BRCA2 constitute a BRCA1-PALB2-BRCA2 axis that is essential for homologous recombination (HR)-based DNA doublestrand break repair. Besides HR, BRCA1 has been implicated in both the initial activation and the maintenance of the G2/M checkpoint, while BRCA2 and PALB2 have been shown to be critical for its maintenance. Here we show that all three proteins can play a significant role in both checkpoint activation and checkpoint maintenance, depending on cell type and context, and that PALB2 links BRCA1 and BRCA2 in the checkpoint response. The BRCA1-PALB2 interaction can be important for checkpoint activation, whereas the PALB2-BRCA2 complex formation appears to be more critical for checkpoint maintenance. Interestingly, the function of PALB2 in checkpoint response appears to be independent of CHK1 and CHK2 phosphorylation. Following ionizing radiation, cells with disengaged BRCA1-PALB2 interaction show greatly increased chromosomal abnormalities due apparently to combined defects in HR and checkpoint control. These findings provide new insights into DNA damage checkpoint control and further underscore the critical importance of the proper cooperation of the BRCA and PALB2 proteins in genome maintenance.	[Simhadri, Srilatha; Vincelli, Gabriele; Huo, Yanying; Foo, Tzeh Keong; Ganesan, Shridar; Xia, Bing] Rutgers Canc Inst New Jersey, New Brunswick, NJ 08901 USA; [Simhadri, Srilatha; Vincelli, Gabriele; Huo, Yanying; Foo, Tzeh Keong; Xia, Bing] Rutgers Robert Wood Johnson Med Sch, Dept Radiat Oncol, New Brunswick, NJ 08903 USA; [Simhadri, Srilatha; Ganesan, Shridar] Rutgers Robert Wood Johnson Med Sch, Dept Med, New Brunswick, NJ 08903 USA; [Misenko, Sarah; Bunting, Samuel F.] Rutgers State Univ, Sch Arts & Sci, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; [Ahlskog, Johanna; Sorensen, Claus S.] Univ Copenhagen, BRIC, Copenhagen, Denmark; [Oakley, Gregory G.] Univ Nebraska, Med Ctr, Coll Dent, Dept Oral Biol, Lincoln, NE 68583 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; University of Copenhagen; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska Medical Center	Xia, B (corresponding author), Rutgers Canc Inst New Jersey, New Brunswick, NJ 08901 USA.; Xia, B (corresponding author), Rutgers Robert Wood Johnson Med Sch, Dept Radiat Oncol, New Brunswick, NJ 08903 USA.	xiabi@cinj.rutgers.edu	Foo, Tzeh Keong/AAE-5830-2021	Foo, Tzeh Keong/0000-0003-0168-7054; Sorensen, Claus/0000-0001-6022-9710; HUO, YANYING/0000-0003-4747-4951	National Institutes of Health [R01CA138804, R01CA188096, R01CA190858, R01CA169182]; New Jersey Commission for Cancer Research (NJCCR); NATIONAL CANCER INSTITUTE [R01CA188096, R01CA138804, R01CA169182, R01CA190858] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); New Jersey Commission for Cancer Research (NJCCR); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs. J. Jonkers (Netherlands Cancer Institute) and D. Boothman (UT Southwestern Medical Center) for provision of the KB2 mouse mammary tumor cells and isogenic HCT116 cells, respectively. This work was supported by the National Institutes of Health (R01CA138804 and R01CA188096 to BX, R01CA190858 to SFB and R01CA169182 to SG). GV was supported by a postdoctoral fellowship and SM by a predoctoral fellowship from the New Jersey Commission for Cancer Research (NJCCR).	Apostolou P, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/747318; Barlow JH, 2013, CELL, V152, P620, DOI 10.1016/j.cell.2013.01.006; Bartek J, 2007, CURR OPIN CELL BIOL, V19, P238, DOI 10.1016/j.ceb.2007.02.009; Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cavanagh H, 2015, HERED CANCER CLIN PR, V13, DOI 10.1186/s13053-015-0038-x; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Cotta-Ramusino C, 2011, SCIENCE, V332, P1313, DOI 10.1126/science.1203430; Couch FJ, 2014, SCIENCE, V343, P1466, DOI 10.1126/science.1251827; Cruz-Garcia A, 2014, CELL REP, V9, P451, DOI 10.1016/j.celrep.2014.08.076; Davis TW, 1998, CANCER RES, V58, P767; Evers B, 2010, CLIN CANCER RES, V16, P99, DOI 10.1158/1078-0432.CCR-09-2434; Foo TK, 2017, ONCOGENE, V36, P4161, DOI 10.1038/onc.2017.46; Huo YY, 2013, CANCER DISCOV, V3, P894, DOI 10.1158/2159-8290.CD-13-0011; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Juan G, 1998, CYTOMETRY, V32, P71, DOI 10.1002/(SICI)1097-0320(19980601)32:2<71::AID-CYTO1>3.0.CO;2-H; Lee M, 2004, ONCOGENE, V23, P865, DOI 10.1038/sj.onc.1207223; Lin HR, 2003, J BIOL CHEM, V278, P35979, DOI 10.1074/jbc.M210659200; Lobrich M, 2007, NAT REV CANCER, V7, P861, DOI 10.1038/nrc2248; Lu C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10086; Ma JL, 2012, MOL CELL BIOL, V32, P1506, DOI 10.1128/MCB.06271-11; Menzel T, 2011, EMBO REP, V12, P705, DOI 10.1038/embor.2011.99; Moynahan ME, 2010, NAT REV MOL CELL BIO, V11, P196, DOI 10.1038/nrm2851; Murphy AK, 2014, J CELL BIOL, V206, P493, DOI 10.1083/jcb.201404111; Oliver AW, 2009, EMBO REP, V10, P990, DOI 10.1038/embor.2009.126; Orthwein A, 2015, NATURE, V528, P422, DOI 10.1038/nature16142; Polo SE, 2011, GENE DEV, V25, P409, DOI 10.1101/gad.2021311; Roy R, 2012, NAT REV CANCER, V12, P68, DOI 10.1038/nrc3181; Shabbeer S, 2013, ONCOGENE, V32, P5005, DOI 10.1038/onc.2012.522; Simhadri S, 2014, J BIOL CHEM, V289, P24617, DOI 10.1074/jbc.M114.566141; Sy SMH, 2009, P NATL ACAD SCI USA, V106, P7155, DOI 10.1073/pnas.0811159106; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tischkowitz M, 2010, CANCER RES, V70, P7353, DOI 10.1158/0008-5472.CAN-10-1012; Venkitaraman AR, 2014, SCIENCE, V343, P1470, DOI 10.1126/science.1252230; Walsh T, 2011, P NATL ACAD SCI USA, V108, P18032, DOI 10.1073/pnas.1115052108; Xia B, 2007, NAT GENET, V39, P159, DOI 10.1038/ng1942; Xia B, 2006, MOL CELL, V22, P719, DOI 10.1016/j.molcel.2006.05.022; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Yu XC, 2004, MOL CELL BIOL, V24, P9478, DOI 10.1128/MCB.24.21.9478-9486.2004; Zhang F, 2009, MOL CANCER RES, V7, P1110, DOI 10.1158/1541-7786.MCR-09-0123; Zhang F, 2009, CURR BIOL, V19, P524, DOI 10.1016/j.cub.2009.02.018	45	27	27	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2019	38	10					1585	1596		10.1038/s41388-018-0535-2	http://dx.doi.org/10.1038/s41388-018-0535-2			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN8DD	30337689	Green Accepted, Green Submitted			2022-12-28	WOS:000460423800001
J	Lin, SC; Lin, CH; Shih, NC; Liu, HL; Wang, WC; Lin, KY; Liu, ZY; Tseng, YJ; Chang, HK; Lin, YC; Yeh, YC; Minato, H; Fujii, T; Wu, YC; Chen, MY; Chou, TY				Lin, Shin-Chih; Lin, Chia-Hung; Shih, Nien-Chu; Liu, Hsin-Ling; Wang, Wen-Chao; Lin, Kun-Yang; Liu, Zih-Yu; Tseng, Yu-Jhen; Chang, Hsueh-Kai; Lin, Yi-Cheng; Yeh, Yi-Chen; Minato, Hiroshi; Fujii, Takeshi; Wu, Yu-Chung; Chen, Mei-Yu; Chou, Teh-Ying			Cellular prion protein transcriptionally regulated by NFIL3 enhances lung cancer cell lamellipodium formation and migration through JNK signaling	ONCOGENE			English	Article							GENE-EXPRESSION; MAP KINASES; RESISTANCE; SURVIVAL; INVASION; COLON; METASTASIS; STATISTICS; APOPTOSIS; FAMILY	Tumor invasion and metastasis are the major causes of treatment failure and mortality in lung cancer patients. In this study, we identified a group of genes with differential expression in in situ and invasive lung adenocarcinoma tissues by expression profiling; among these genes we further characterized the association of the upregulation of PRNP, the gene encoding cellular Prion protein (PrPc), with lung adenocarcinoma invasiveness. Immunohistochemistry on clinical specimens showed an association of PrPc expression with invasive but not in situ lung adenocarcinoma. Consistently, the expression of PrPc was higher in the highly invasive than in the lowly invasive lung adenocarcinoma cell lines. Knockdown of PrPc expression in cultured lung adenocarcinoma cells decreased their lamellipodium formation, in vitro migration and invasion, and in vivo experimental lung metastasis. Phosphorylation of JNKs was found to correlate with PrPc expression and the inhibition of JNKs suppressed the PrPc-induced up-regulation of lamellipodium formation, cell migration, and invasion. Moreover, we identified the nuclear factor, interleukin 3 regulated (NFIL3) protein as a transcriptional activator of the PRNP promoter. Accordingly, NFIL3 promoted lung cancer cell migration and invasion in a PrPc-dependent manner. High NFIL3 expression in clinical specimens of lung adenocarcinoma was also associated with tumor invasiveness. Overall, our observations suggest that the NFIL3/PrPc axis, through regulating lamellipodium formation and cell mobility via JNK signaling, plays a critical role in lung cancer invasiveness and metastasis.	[Lin, Shin-Chih; Chen, Mei-Yu; Chou, Teh-Ying] Natl Yang Ming Univ, Program Mol Med, Taipei 11221, Taiwan; [Lin, Shin-Chih; Chen, Mei-Yu; Chou, Teh-Ying] Acad Sinica, Taipei 11221, Taiwan; [Lin, Shin-Chih; Liu, Hsin-Ling; Lin, Kun-Yang; Chen, Mei-Yu; Chou, Teh-Ying] Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 11221, Taiwan; [Lin, Chia-Hung; Lin, Yi-Cheng; Yeh, Yi-Chen; Chou, Teh-Ying] Taipei Vet Gen Hosp, Dept Pathol & Lab Med, Div Mol Pathol, Taipei 11221, Taiwan; [Shih, Nien-Chu; Wang, Wen-Chao; Liu, Zih-Yu; Tseng, Yu-Jhen; Chang, Hsueh-Kai; Chou, Teh-Ying] Natl Yang Ming Univ, Inst Clin Med, Taipei 11221, Taiwan; [Minato, Hiroshi] Kanazawa Med Univ, Dept Pathol & Lab Med, 1-1 Daigaku, Kahoku, Ishikawa 9200293, Japan; [Fujii, Takeshi] Toranomon Gen Hosp, Dept Pathol, Minato Ku, 2-2-2 Toranomon, Tokyo 1058470, Japan; [Wu, Yu-Chung] Taipei Vet Gen Hosp, Dept Surg, Div Thorac Surg, Taipei 11221, Taiwan	National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; Kanazawa Medical University; Toranomon Hospital; Taipei Veterans General Hospital	Chen, MY; Chou, TY (corresponding author), Natl Yang Ming Univ, Program Mol Med, Taipei 11221, Taiwan.; Chen, MY; Chou, TY (corresponding author), Acad Sinica, Taipei 11221, Taiwan.; Chen, MY; Chou, TY (corresponding author), Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 11221, Taiwan.; Chou, TY (corresponding author), Taipei Vet Gen Hosp, Dept Pathol & Lab Med, Div Mol Pathol, Taipei 11221, Taiwan.; Chou, TY (corresponding author), Natl Yang Ming Univ, Inst Clin Med, Taipei 11221, Taiwan.	meychen@ym.edu.tw; tychou@vghtpe.gov.tw	Fujii, Takeshi/D-5877-2014	Fujii, Takeshi/0000-0001-7237-1183; Lin, Kun-Yang/0000-0002-6197-3995; Lin, Chia-Hung/0000-0002-1819-7310; CHEN, MEI-YU/0000-0002-5765-9178	Ministry of Science and Technology [102-2320-B-010-005-MY3]; Taipei Veterans General Hospital, Taiwan [VGH94-286, V98C1-102, V99C1-187, V100C-082, V101C-009]	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Taipei Veterans General Hospital, Taiwan(Taipei Veterans General Hospital)	This work was supported by grant 102-2320-B-010-005-MY3 from the Ministry of Science and Technology and grants VGH94-286, V98C1-102, V99C1-187, V100C-082 and V101C-009 from Taipei Veterans General Hospital, Taiwan.	Bellingham SA, 2009, J BIOL CHEM, V284, P1291, DOI 10.1074/jbc.M804755200; Bos JL, 2007, CELL, V129, P865, DOI 10.1016/j.cell.2007.05.018; Bounhar Y, 2001, J BIOL CHEM, V276, P39145, DOI 10.1074/jbc.C100443200; Burgess STG, 2009, J BIOL CHEM, V284, P6716, DOI 10.1074/jbc.M807065200; Carulla P, 2011, MOL BIOL CELL, V22, P3041, DOI 10.1091/mbc.E11-04-0321; Chen JJW, 2001, CANCER RES, V61, P5223; Cheng YY, 2014, MOL CARCINOGEN, V53, P686, DOI 10.1002/mc.22021; Chieng CKL, 2015, TUMOR BIOL, V36, P8107, DOI 10.1007/s13277-015-3530-z; Chou TY, 2009, CELL SIGNAL, V21, P704, DOI 10.1016/j.cellsig.2009.01.008; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Cichon AC, 2014, MOL CELL NEUROSCI, V63, P31, DOI 10.1016/j.mcn.2014.09.001; COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070; Danson CM, 2007, J CELL SCI, V120, P4144, DOI 10.1242/jcs.013714; Dery MA, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3398; Dovas A, 2005, BIOCHEM J, V390, P1, DOI 10.1042/BJ20050104; Du L, 2013, CANCER RES, V73, P2682, DOI 10.1158/0008-5472.CAN-12-3759; Ehrlich JS, 2002, DEV CELL, V3, P259, DOI 10.1016/S1534-5807(02)00216-2; Gil M, 2016, BIOCHEM BIOPH RES CO, V470, P213, DOI 10.1016/j.bbrc.2016.01.038; Goswami CP, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-970; Herms J, 1999, J NEUROSCI, V19, P8866, DOI 10.1523/JNEUROSCI.19-20-08866.1999; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Ikushima S, 1997, P NATL ACAD SCI USA, V94, P2609, DOI 10.1073/pnas.94.6.2609; Kamizono S, 2009, J EXP MED, V206, P2977, DOI 10.1084/jem.20092176; Keniry M, 2013, GENE DEV, V27, P916, DOI 10.1101/gad.214049.113; Kim HJ, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.37; Kuribara R, 1999, MOL CELL BIOL, V19, P2754; Li QQ, 2011, CANCER SCI, V102, P400, DOI 10.1111/j.1349-7006.2010.01811.x; Lin JZ, 2011, PROTEIN SCI, V20, P216, DOI 10.1002/pro.548; Liu T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071896; Lopes MH, 2005, J NEUROSCI, V25, P11330, DOI 10.1523/JNEUROSCI.2313-05.2005; Martins VR, 2002, FEBS LETT, V512, P25, DOI 10.1016/S0014-5793(02)02291-3; Mattei V, 2004, FEBS LETT, V560, P14, DOI 10.1016/S0014-5793(04)00029-8; Mehrpour M, 2010, CANCER LETT, V290, P1, DOI 10.1016/j.canlet.2009.07.009; Misiewicz M, 2013, J BIOL CHEM, V288, P20378, DOI 10.1074/jbc.M113.457242; Morel E, 2004, J BIOL CHEM, V279, P1499, DOI 10.1074/jbc.M308578200; Ohno T, 2007, NUCLEIC ACIDS RES, V35, P648, DOI 10.1093/nar/gkl868; Pan YL, 2006, FASEB J, V20, P1886, DOI 10.1096/fj.06-6138fje; Qi JJ, 2016, GUT, V65, P1690, DOI 10.1136/gutjnl-2014-307900; Santuccione A, 2005, J CELL BIOL, V169, P341, DOI 10.1083/jcb.200409127; Satoh J, 2009, NEUROPATH APPL NEURO, V35, P16, DOI 10.1111/j.1365-2990.2008.00947.x; Seillet C, 2014, J IMMUNOL, V192, P2667, DOI 10.4049/jimmunol.1302605; Shaul YD, 2016, NUCLEIC ACIDS RES, V44, pD560, DOI 10.1093/nar/gkv1337; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Solis GP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070327; Takabayashi T, 2010, J BIOL CHEM, V285, P16155, DOI 10.1074/jbc.M109.081901; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Wang JH, 2011, WORLD J GASTROENTERO, V17, P3986, DOI 10.3748/wjg.v17.i35.3986; Yap YHY, 2012, CELL BIOL INT, V36, P273, DOI 10.1042/CBI20110088; Yap YHY, 2011, CANCER LETT, V306, P111, DOI 10.1016/j.canlet.2011.02.040; ZHANG W, 1995, MOL CELL BIOL, V15, P6055	51	15	16	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	2					385	398		10.1038/s41388-019-0994-0	http://dx.doi.org/10.1038/s41388-019-0994-0			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KD3JY	31477838				2022-12-28	WOS:000507766400010
J	Qian, MY; Wang, SB; Guo, XF; Wang, J; Zhang, ZP; Qiu, W; Gao, X; Chen, ZH; Xu, JY; Zhao, RR; Xue, H; Li, G				Qian, Mingyu; Wang, Shaobo; Guo, Xiaofan; Wang, Jian; Zhang, Zongpu; Qiu, Wei; Gao, Xiao; Chen, Zihang; Xu, Jianye; Zhao, Rongrong; Xue, Hao; Li, Gang			Hypoxic glioma-derived exosomes deliver microRNA-1246 to induce M2 macrophage polarization by targeting TERF2IP via the STAT3 and NF-kappa B pathways	ONCOGENE			English	Article							EXTRACELLULAR VESICLES; GENE-EXPRESSION; TUMOR-GROWTH; CANCER; CELLS; GLIOBLASTOMA; MICROVESICLES; MEDIATE	Exosomes are emerging as important elements that participate in intercellular communication and tumor microenvironment modulation, but the exact mechanisms by which tumor exosomes facilitate the generation of the immunosuppressive microenvironment remain unclear. Here we investigated the effects of glioma-derived exosomes (GDEs) on macrophage polarization and glioma progression. We also performed microRNA sequencing analysis of GDEs to identify the microRNA that mediated macrophage polarization. The microRNA-associated intracellular signaling pathway in macrophages was further investigated. Compared with normoxic glioma-derived exosomes (N-GDEs), hypoxic glioma-derived exosomes (H-GDEs) markedly induced M2 macrophage polarization, which subsequently promoted glioma proliferation, migration and invasion in vitro and in vivo. MicroRNA sequencing analysis identified miR-1246 as the most enriched microRNA in H-GDEs. Moreover, miR-1246 was enriched in the CSF of GBM patients and decreased after tumor resection. Further investigation determined that miR-1246 mediated H-GDE-induced M2 macrophage polarization by targeting TERF2IP to activate the STAT3 signaling pathway and inhibit the NF-kappa B signaling pathway. Our study elucidated a mechanism by which hypoxia and glioma influence M2 macrophage polarization via exosomes, which could facilitate the formation of the immunosuppressive microenvironment. Moreover, our results suggested that miR-1246 in the CSF of GBM patients may be a novel biomarker for GBM diagnosis and that treatment targeting microRNA-1246 may contribute to antitumor immunotherapy.	[Qian, Mingyu; Wang, Shaobo; Guo, Xiaofan; Wang, Jian; Zhang, Zongpu; Qiu, Wei; Gao, Xiao; Chen, Zihang; Xu, Jianye; Zhao, Rongrong; Xue, Hao; Li, Gang] Shandong Univ, Qilu Hosp, Dept Neurosurg, Jinan, Shandong, Peoples R China; [Qian, Mingyu; Wang, Shaobo; Guo, Xiaofan; Wang, Jian; Zhang, Zongpu; Qiu, Wei; Gao, Xiao; Chen, Zihang; Xu, Jianye; Zhao, Rongrong; Xue, Hao; Li, Gang] Shandong Univ, Inst Brain & Brain Inspired Sci, Jinan, Shandong, Peoples R China; [Qian, Mingyu; Wang, Shaobo; Guo, Xiaofan; Wang, Jian; Zhang, Zongpu; Qiu, Wei; Gao, Xiao; Chen, Zihang; Xu, Jianye; Zhao, Rongrong; Xue, Hao; Li, Gang] Shandong Key Lab Brain Funct Remodeling, Jinan, Shandong, Peoples R China; [Wang, Jian] Univ Bergen, Dept Biomed, Brain Tumor Res Ctr, Bergen, Norway	Shandong University; Shandong University; University of Bergen	Xue, H; Li, G (corresponding author), Shandong Univ, Qilu Hosp, Dept Neurosurg, Jinan, Shandong, Peoples R China.; Xue, H; Li, G (corresponding author), Shandong Univ, Inst Brain & Brain Inspired Sci, Jinan, Shandong, Peoples R China.; Xue, H; Li, G (corresponding author), Shandong Key Lab Brain Funct Remodeling, Jinan, Shandong, Peoples R China.	xuehao@sdu.edu.cn; ligangqiluhospital@163.com	Xu, Jianye/AAO-5514-2020; Wang, Shaobo/AAI-4190-2020; Xue, Hao/GXV-4717-2022	Xu, Jianye/0000-0001-7241-6994; Wang, Shaobo/0000-0001-7759-1687; Wang, Jian/0000-0002-9482-5227; Li, Gang/0000-0003-3184-1032	National Natural Science Foundation of China [30872645, 81372719, 81172403, 81571284, 91542115, 81874083, 81702468]; Natural Science Foundation of Shandong Province of China [2017CXGC1203, 2013GGE27006, 2017G006012]; Taishan Scholars of Shandong Province of China [ts201511093]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shandong Province of China(Natural Science Foundation of Shandong Province); Taishan Scholars of Shandong Province of China	This work was supported by grants from the National Natural Science Foundation of China (grant No.30872645, 81372719, 81172403, 81571284, 91542115, 81874083, 81702468), Natural Science Foundation of Shandong Province of China (grant No.2017CXGC1203, 2013GGE27006, 2017G006012) and the Taishan Scholars of Shandong Province of China (grant No. ts201511093).	Bang C, 2014, J CLIN INVEST, V124, P2136, DOI 10.1172/JCI70577; Bott A, 2017, ONCOTARGET, V8, P43897, DOI 10.18632/oncotarget.14915; Brat DJ, 2003, ANN INTERN MED, V138, P659, DOI 10.7326/0003-4819-138-8-200304150-00014; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cai Y, 2015, CELL CYCLE, V14, P3580, DOI 10.1080/15384101.2015.1100771; Charles NA, 2012, GLIA, V60, P502, DOI 10.1002/glia.21264; Colwell N, 2017, NEURO-ONCOLOGY, V19, P887, DOI 10.1093/neuonc/now258; Cooks T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03224-w; De Beule N, 2017, J PATHOL, V241, P534, DOI 10.1002/path.4860; Fang T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02583-0; Gabrusiewicz K, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1412909; Giurisato E, 2018, P NATL ACAD SCI USA, V115, pE2801, DOI 10.1073/pnas.1707929115; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Guo XF, 2019, INT J CANCER, V144, P3111, DOI 10.1002/ijc.32052; Guo XF, 2018, ONCOGENE, V37, P4239, DOI 10.1038/s41388-018-0261-9; Guo XF, 2016, ONCOTARGET, V7, P80521, DOI 10.18632/oncotarget.11825; Iero M, 2008, CELL DEATH DIFFER, V15, P80, DOI 10.1038/sj.cdd.4402237; King HW, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-421; Lapointe S, 2018, LANCET, V392, P432, DOI 10.1016/S0140-6736(18)30990-5; Lee JH, 2018, NATURE, V560, P243, DOI 10.1038/s41586-018-0389-3; Li H, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01175; Li L, 2016, CANCER RES, V76, P1770, DOI 10.1158/0008-5472.CAN-15-1625; Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018; Liu T, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0981-7; Lu X, 2010, CLIN CANCER RES, V16, P5928, DOI 10.1158/1078-0432.CCR-10-1360; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Murdoch C, 2005, INT J CANCER, V117, P701, DOI 10.1002/ijc.21422; Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P896, DOI 10.1093/neuonc/nou087; Qi L, 2016, ONCOTARGET, V7, P71673, DOI 10.18632/oncotarget.12317; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Sakha S, 2016, SCI REP-UK, V6, DOI 10.1038/srep38750; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Steinbichler TB, 2017, SEMIN CANCER BIOL, V44, P170, DOI 10.1016/j.semcancer.2017.02.006; Tadokoro H, 2013, J BIOL CHEM, V288, P34343, DOI 10.1074/jbc.M113.480822; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Tkach M, 2016, CELL, V164, P1226, DOI 10.1016/j.cell.2016.01.043; Vaupel P, 2007, CANCER METAST REV, V26, P225, DOI 10.1007/s10555-007-9055-1; Wang QH, 2017, CANCER CELL, V32, P42, DOI 10.1016/j.ccell.2017.06.003; Whiteside TL, 2013, BIOCHEM SOC T, V41, P245, DOI 10.1042/BST20120265; Xue H, 2016, AUTOPHAGY, V12, P1129, DOI 10.1080/15548627.2016.1178446; Zhang HG, 2011, CLIN CANCER RES, V17, P959, DOI 10.1158/1078-0432.CCR-10-1489	42	138	147	17	119	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	2					428	442		10.1038/s41388-019-0996-y	http://dx.doi.org/10.1038/s41388-019-0996-y			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KD3JY	31485019				2022-12-28	WOS:000507766400013
J	Singh, JP; Qian, K; Lee, JS; Zhou, JF; Han, XM; Zhang, BC; Ong, QX; Ni, WM; Jiang, MZ; Ruan, HB; Li, MD; Zhang, KS; Ding, ZB; Lee, P; Singh, K; Wu, J; Herzog, RI; Kaech, S; Wendel, HG; Yates, III; Han, WP; Sherwin, RS; Nie, YZ; Yang, XY				Singh, Jay Prakash; Qian, Kevin; Lee, Jeong-Sang; Zhou, Jinfeng; Han, Xuemei; Zhang, Bichen; Ong, Qunxiang; Ni, Weiming; Jiang, Mingzuo; Ruan, Hai-Bin; Li, Min-Dian; Zhang, Kaisi; Ding, Zhaobing; Lee, Philip; Singh, Kamini; Wu, Jing; Herzog, Raimund, I; Kaech, Susan; Wendel, Hans-Guido; Yates, John R., III; Han, Weiping; Sherwin, Robert S.; Nie, Yongzhan; Yang, Xiaoyong			O-GlcNAcase targets pyruvate kinase M2 to regulate tumor growth	ONCOGENE			English	Article							CANCER METABOLISM; TRANSFERASE; PROMOTES; PROTEIN; ACETYLTRANSFERASE; GENERATION; ISOFORM; NEURONS; DOMAIN; CELLS	Cancer cells are known to adopt aerobic glycolysis in order to fuel tumor growth, but the molecular basis of this metabolic shift remains largely undefined. O-GlcNAcase (OGA) is an enzyme harboring O-linked beta-N-acetylglucosamine (O-GlcNAc) hydrolase and cryptic lysine acetyltransferase activities. Here, we report that OGA is upregulated in a wide range of human cancers and drives aerobic glycolysis and tumor growth by inhibiting pyruvate kinase M2 (PKM2). PKM2 is dynamically O-GlcNAcylated in response to changes in glucose availability. Under high glucose conditions, PKM2 is a target of OGA-associated acetyltransferase activity, which facilitates O-GlcNAcylation of PKM2 by O-GlcNAc transferase (OGT). O-GlcNAcylation inhibits PKM2 catalytic activity and thereby promotes aerobic glycolysis and tumor growth. These studies define a causative role for OGA in tumor progression and reveal PKM2 O-GlcNAcylation as a metabolic rheostat that mediates exquisite control of aerobic glycolysis.	[Singh, Jay Prakash; Qian, Kevin; Lee, Jeong-Sang; Zhang, Bichen; Ong, Qunxiang; Ni, Weiming; Ruan, Hai-Bin; Li, Min-Dian; Zhang, Kaisi; Wu, Jing; Yang, Xiaoyong] Yale Univ, Sch Med, Program Integrat Cell Signaling & Neurobiol Metab, 333 Cedar St, New Haven, CT 06519 USA; [Singh, Jay Prakash; Qian, Kevin; Lee, Jeong-Sang; Zhang, Bichen; Ong, Qunxiang; Ni, Weiming; Ruan, Hai-Bin; Li, Min-Dian; Zhang, Kaisi; Wu, Jing; Yang, Xiaoyong] Yale Univ, Dept Comparat Med, Sch Med, 333 Cedar St, New Haven, CT 06519 USA; [Qian, Kevin; Li, Min-Dian; Zhang, Kaisi; Yang, Xiaoyong] Yale Univ, Dept Cellular & Mol Physiol, Sch Med, 333 Cedar St, New Haven, CT 06519 USA; [Zhou, Jinfeng; Jiang, Mingzuo; Nie, Yongzhan] Fourth Mil Med Univ, Xijing Hosp Digest Dis, State Key Lab Canc Biol, 127 West Changle Rd, Xian 710032, Shaanxi, Peoples R China; [Han, Xuemei; Yates, John R., III] Scripps Res Inst, Dept Chem Physiol, 10550 North Torrey Pines Rd, La Jolla, CA 92037 USA; [Ong, Qunxiang; Ding, Zhaobing; Lee, Philip; Han, Weiping] Singapore Bioimaging Consortium, Singapore, Singapore; [Singh, Kamini; Wendel, Hans-Guido] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10065 USA; [Wu, Jing] Xi An Jiao Tong Univ, Sch Life Sci & Technol, Xian 710049, Shaanxi, Peoples R China; [Herzog, Raimund, I; Sherwin, Robert S.] Yale Univ, Dept Med, Sch Med, 333 Cedar St, New Haven, CT 06519 USA; [Kaech, Susan] Yale Univ, Dept Immunobiol, Sch Med, 333 Cedar St, New Haven, CT 06519 USA	Yale University; Yale University; Yale University; Air Force Military Medical University; Scripps Research Institute; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Bioengineering & Bioimaging (IBB); A*STAR - Singapore Bioimaging Consortium (SBIC); Memorial Sloan Kettering Cancer Center; Xi'an Jiaotong University; Yale University; Yale University	Yang, XY (corresponding author), Yale Univ, Sch Med, Program Integrat Cell Signaling & Neurobiol Metab, 333 Cedar St, New Haven, CT 06519 USA.; Yang, XY (corresponding author), Yale Univ, Dept Comparat Med, Sch Med, 333 Cedar St, New Haven, CT 06519 USA.; Yang, XY (corresponding author), Yale Univ, Dept Cellular & Mol Physiol, Sch Med, 333 Cedar St, New Haven, CT 06519 USA.	xiaoyong.yang@yale.edu	Li, Min-Dian/F-1721-2015; Ruan, Hai-Bin/AAN-7777-2021; Zhang, Bichen/ABH-3118-2020	Li, Min-Dian/0000-0002-3650-1507; Ruan, Hai-Bin/0000-0002-3858-1272; Zhang, Bichen/0000-0002-0150-1267; Ding, Zhaobing/0000-0002-8812-298X	NIH [R01 DK089098, P01 DK057751]; Yale Comprehensive Cancer Center Pilot Grant; American Cancer Society Research Scholar Grant	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Yale Comprehensive Cancer Center Pilot Grant; American Cancer Society Research Scholar Grant(American Cancer Society)	We thank Dr. Jinbo Yang for providing the Flag-PKM2 plasmid and shPKM2 lentivirus. We thank Dr. Julie T. Feldstein for helping with immunohistochemical analysis of human cancer tissues. We thank Dr. Neeraj Tiwari for helping with sucrose density gradient ultracentrifugation. This work was supported by NIH R01 DK089098, P01 DK057751, Yale Comprehensive Cancer Center Pilot Grant, and American Cancer Society Research Scholar Grant to XY.	Anastasiou D, 2012, NAT CHEM BIOL, V8, P839, DOI 10.1038/NCHEMBIO.1060; ASHIZAWA K, 1991, J BIOL CHEM, V266, P16842; Bond MR, 2013, ANNU REV NUTR, V33, P205, DOI 10.1146/annurev-nutr-071812-161240; Bowe DB, 2006, MOL CELL BIOL, V26, P8539, DOI 10.1128/MCB.01053-06; Caldwell SA, 2010, ONCOGENE, V29, P2831, DOI 10.1038/onc.2010.41; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667; Ferrer CM, 2014, MOL CELL, V54, P820, DOI 10.1016/j.molcel.2014.04.026; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hart GW, 2007, NATURE, V446, P1017, DOI 10.1038/nature05815; Hayakawa K, 2013, J BIOL CHEM, V288, P17099, DOI 10.1074/jbc.M113.455899; He Y, 2014, ACTA CRYSTALLOGR D, V70, P186, DOI 10.1107/S1399004713029155; Heiden MGV, 2010, SCIENCE, V329, P1492, DOI 10.1126/science.1188015; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431; Krzeslak A, 2012, CLIN EXP MED, V12, P61, DOI 10.1007/s10238-011-0138-5; Li MD, 2013, CELL METAB, V17, P303, DOI 10.1016/j.cmet.2012.12.015; Luo J, 2007, NAT PROTOC, V2, P1236, DOI 10.1038/nprot.2007.135; Lv L, 2013, MOL CELL, V52, P340, DOI 10.1016/j.molcel.2013.09.004; Lv L, 2011, MOL CELL, V42, P719, DOI 10.1016/j.molcel.2011.04.025; Ong QX, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00599; Patel AB, 2005, P NATL ACAD SCI USA, V102, P5588, DOI 10.1073/pnas.0501703102; Qian KV, 2018, J BIOL CHEM, V293, P13989, DOI 10.1074/jbc.RA118.004709; Rao FV, 2013, OPEN BIOL, V3, DOI 10.1098/rsob.130021; Ruan HB, 2014, CELL, V159, P306, DOI 10.1016/j.cell.2014.09.010; Ruan HB, 2013, TRENDS ENDOCRIN MET, V24, P301, DOI 10.1016/j.tem.2013.02.002; Ruan HB, 2012, CELL METAB, V16, P226, DOI 10.1016/j.cmet.2012.07.006; Singh JP, 2015, CANCER LETT, V356, P244, DOI 10.1016/j.canlet.2014.04.014; Slawson C, 2011, NAT REV CANCER, V11, P678, DOI 10.1038/nrc3114; Sonveaux P, 2008, J CLIN INVEST, V118, P3930, DOI 10.1172/JCI36843; Toleman C, 2004, J BIOL CHEM, V279, P53665, DOI 10.1074/jbc.M410406200; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Whisenhunt TR, 2006, GLYCOBIOLOGY, V16, P551, DOI 10.1093/glycob/cwj096; Yang WW, 2013, CANCER LETT, V339, P153, DOI 10.1016/j.canlet.2013.06.008; Yang WW, 2012, NAT CELL BIOL, V14, P1295, DOI 10.1038/ncb2629; Yang XY, 2008, NATURE, V451, P964, DOI 10.1038/nature06668; Yang XY, 2017, NAT REV MOL CELL BIO, V18, P452, DOI 10.1038/nrm.2017.22; Yang YR, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.24; Yi W, 2012, SCIENCE, V337, P975, DOI 10.1126/science.1222278; Zhang KS, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00221	41	27	27	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					560	573		10.1038/s41388-019-0975-3	http://dx.doi.org/10.1038/s41388-019-0975-3			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31501520	Green Accepted			2022-12-28	WOS:000509718300006
J	Liu, HJ; Lam, HC; Baglini, CV; Nijmeh, J; Cottrill, AA; Chan, SY; Henske, EP				Liu, Heng-Jia; Lam, Hilaire C.; Baglini, Christian, V; Nijmeh, Julie; Cottrill, Alischer A.; Chan, Stephen Y.; Henske, Elizabeth P.			Rapamycin-upregulated miR-29b promotes mTORC1-hyperactive cell growth in TSC2-deficient cells by downregulating tumor suppressor retinoic acid receptor beta (RAR beta)	ONCOGENE			English	Article							TUBEROUS SCLEROSIS COMPLEX; MICRORNA-29 FAMILY; HUMAN-MELANOMA; CANCER; MIGRATION; INVASION; MULTICENTER; EXPRESSION; EVEROLIMUS; INHIBITOR	miR-29b has been identified as a rapamycin-induced microRNA (miRNA) in Tsc2-deficient, mTORC1-hyperactive cells. The biological significance of this induction of miR-29b is unknown. We have found that miR-29b acts as an oncogenic miRNA in Tsc2-deficient cells: inhibition of miR-29b suppressed cell proliferation, anchorage-independent cell growth, cell migration, invasion, and the growth of Tsc2-deficient tumors in vivo. Importantly, the combination of miR-29b inhibition with rapamycin treatment further inhibited these tumor-associated cellular processes. To gain insight into the molecular mechanisms by which miR-29b promotes tumorigenesis, we used RNA sequencing to identify the tumor suppressor retinoid receptor beta (RAR beta) as a target gene of miR-29b. We found that miR-29b directly targeted the 3'UTR of RAR beta. Forced expression of RAR beta reversed the effects of miR-29b overexpression in proliferation, migration, and invasion, indicating that it is a critical target. miR-29b expression correlated with low RAR beta expression in renal clear cell carcinomas and bladder urothelial carcinomas, tumors associated with TSC gene mutations. We further identified growth family member 4 (ING4) as a novel interacting partner of RAR beta. Overexpression of ING4 inhibited the migration and invasion of Tsc2-deficient cells while silencing of ING4 reversed the RAR beta-mediated suppression of cell migration and invasion. Taken together, our findings reveal a novel miR-29b/RAR beta/ING4 pathway that regulates tumorigenic properties of Tsc2-deficient cells, and that may serve as a potential therapeutic target for TSC, lymphangioleiomyomatosis (LAM), and other mTORC1-hyperactive tumors.	[Liu, Heng-Jia; Lam, Hilaire C.; Baglini, Christian, V; Nijmeh, Julie; Henske, Elizabeth P.] Brigham & Womens Hosp, Dept Med, Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA; [Liu, Heng-Jia; Lam, Hilaire C.; Baglini, Christian, V; Nijmeh, Julie; Henske, Elizabeth P.] Harvard Med Sch, Boston, MA 02115 USA; [Cottrill, Alischer A.; Chan, Stephen Y.] Univ Pittsburgh, Sch Med, Dept Med, Div Cardiol,Ctr Pulm Vasc Biol & Med,Pittsburgh H, Pittsburgh, PA 15213 USA; [Cottrill, Alischer A.; Chan, Stephen Y.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Henske, EP (corresponding author), Brigham & Womens Hosp, Dept Med, Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA.; Henske, EP (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	EHENSKE@BWH.HARVARD.EDU			Engles Program in TSC and LAM research, Department of Defense [W81XWH-15-1-0263 TS14003]; Tuberous Sclerosis Alliance; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL138437, R01HL122596, R01HL124021] Funding Source: NIH RePORTER	Engles Program in TSC and LAM research, Department of Defense; Tuberous Sclerosis Alliance; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Lorena Pantano of the Harvard Chan Bioinformatics Core for assistance with RNAseq analysis. This work was supported by the Engles Program in TSC and LAM research, Department of Defense grant W81XWH-15-1-0263 TS14003 (EPH) and a postdoctoral Fellowship from Tuberous Sclerosis Alliance (HJL).	Ben-Sahra I, 2017, CURR OPIN CELL BIOL, V45, P72, DOI 10.1016/j.ceb.2017.02.012; Bertolini F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199371; Bissler JJ, 2008, NEW ENGL J MED, V358, P140, DOI 10.1056/NEJMoa063564; Bissler JJ, 2013, LANCET, V381, P817, DOI 10.1016/S0140-6736(12)61767-X; Byron SA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046823; Carsillo T, 2000, P NATL ACAD SCI USA, V97, P6085, DOI 10.1073/pnas.97.11.6085; Cheadle JP, 2000, HUM GENET, V107, P97, DOI 10.1007/s004390000348; Chen CZ, 2005, NEW ENGL J MED, V353, P1768, DOI 10.1056/NEJMp058190; Cheng JJ, 2013, CELL REP, V5, P471, DOI 10.1016/j.celrep.2013.08.050; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Cui SY, 2015, CELL PHYSIOL BIOCHEM, V36, P409, DOI 10.1159/000430108; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Franz DN, 2013, LANCET, V381, P125, DOI 10.1016/S0140-6736(12)61134-9; Garzon R, 2009, BLOOD, V113, P6411, DOI 10.1182/blood-2008-07-170589; Gong JN, 2014, CELL DEATH DIFFER, V21, P100, DOI 10.1038/cdd.2013.133; Henske EP, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.35; Henske EP, 2003, GENE CHROMOSOME CANC, V38, P376, DOI 10.1002/gcc.10252; Hou Y, 2014, ONCOGENE, V33, P1997, DOI 10.1038/onc.2013.135; Jiang HS, 2014, ONCOL REP, V31, P1509, DOI 10.3892/or.2014.3036; Kinoshita T, 2013, BRIT J CANCER, V109, P2636, DOI 10.1038/bjc.2013.607; Krueger DA, 2010, NEW ENGL J MED, V363, P1801, DOI 10.1056/NEJMoa1001671; Lam HC, 2017, ONCOTARGET, V8, P64714, DOI 10.18632/oncotarget.19947; Li J, 2008, CARCINOGENESIS, V29, P1373, DOI 10.1093/carcin/bgn086; McCormack FX, 2012, AM J RESP CRIT CARE, V186, P1210, DOI 10.1164/rccm.201205-0848OE; Mott JL, 2007, ONCOGENE, V26, P6133, DOI 10.1038/sj.onc.1210436; Mott JL, 2010, J CELL BIOCHEM, V110, P1155, DOI 10.1002/jcb.22630; Ogorek B, 2018, HUM MOL GENET, V27, P1654, DOI 10.1093/hmg/ddy073; Palacios A, 2008, J BIOL CHEM, V283, P15956, DOI 10.1074/jbc.M710020200; Park SY, 2009, NAT STRUCT MOL BIOL, V16, P23, DOI 10.1038/nsmb.1533; Poudyal D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075034; Ravasi T, 2010, CELL, V140, P744, DOI 10.1016/j.cell.2010.01.044; Ren MQ, 2005, MOL CELL BIOL, V25, P10591, DOI 10.1128/MCB.25.23.10591-10603.2005; Rosset C, 2017, GENET MOL BIOL, V40, P69, DOI [10.1590/1678-4685-GMB-2015-0321, 10.1590/1678-4685-gmb-2015-0321]; Rossi M, 2013, J CELL PHYSIOL, V228, P1506, DOI 10.1002/jcp.24306; Ru P, 2012, MOL CANCER THER, V11, P1166, DOI 10.1158/1535-7163.MCT-12-0100; Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246; Shen JC, 2007, CANCER RES, V67, P2552, DOI 10.1158/0008-5472.CAN-06-3870; Song SM, 2005, ONCOGENE, V24, P8268, DOI 10.1038/sj.onc.1208992; Sun SY, 2000, J BIOL CHEM, V275, P17149, DOI 10.1074/jbc.M000527200; Tang Y, 2014, CARCINOGENESIS, V35, P86, DOI 10.1093/carcin/bgt346; Trindade AJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060014; Wang C, 2012, J CANCER RES CLIN, V138, P2127, DOI 10.1007/s00432-012-1288-x; Wang C, 2011, MOL CELL BIOCHEM, V352, P197, DOI 10.1007/s11010-011-0755-z; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Xu F, 2013, J INT MED RES, V41, P1803, DOI 10.1177/0300060513505266; Yan B, 2015, ONCOTARGETS THER, V8, P539, DOI 10.2147/OTT.S75899; Ye PY, 2015, MOL CELL, V57, P708, DOI 10.1016/j.molcel.2014.12.034; Young LR, 2013, LANCET RESP MED, V1, P445, DOI 10.1016/S2213-2600(13)70090-0; ZIMMER A, 1992, DEVELOPMENT, V116, P977	51	8	8	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2019	38	49					7367	7383		10.1038/s41388-019-0957-5	http://dx.doi.org/10.1038/s41388-019-0957-5			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JT4BN	31420607	Green Accepted			2022-12-28	WOS:000500936600001
J	Yuan, YM; Ma, N; Zhang, EB; Chen, TW; Jiang, H; Yin, FF; Wang, JJ; Zhang, FK; Ni, QZ; Wang, X; Bao, Y; Wang, K; Cheng, SQ; Zhang, XL; Wang, XF; Li, JJ; Xie, D				Yuan, Yan-Mei; Ma, Ning; Zhang, Er-Bin; Chen, Tian-Wei; Jiang, Hao; Yin, Fen-Fen; Wang, Jing-Jing; Zhang, Feng-Kun; Ni, Qian-Zhi; Wang, Xiang; Bao, Ying; Wang, Kang; Cheng, Shu-Qun; Zhang, Xue-Li; Wang, Xiao-Fan; Li, Jing-Jing; Xie, Dong			BMP10 suppresses hepatocellular carcinoma progression via PTPRS-STAT3 axis	ONCOGENE			English	Article							GROWTH-FACTOR; TUMOR-SUPPRESSOR; CANCER; EXPRESSION; RECEPTOR; STAT3; CELLS; AGGRESSIVENESS; IDENTIFICATION; PROLIFERATION	Bone morphogenetic protein 10 (BMP10), one member of the BMP family, is involved in various development events. Dysregulation of BMP10 has been observed in several diseases, including hypertensive cardiac hypertrophy, Hirschsprung disease and blood vessel formation. However, its role in liver cancer remains largely unknown. In this study, we reported that BMP10 was significantly downregulated in HCC at both mRNA and protein level. Decreased BMP10 was associated with bigger tumor size, worse TNM stage, earlier recurrence and poorer survival. BMP10 negatively regulated HCC cell proliferation in vitro and in vivo. Mechanism study revealed that BMP10 suppressed tumor cell growth by inhibiting STAT3 signaling. Interestingly, we found that cytoplasmic BMP10 interacted with both receptor protein tyrosine phosphatase sigma (PTPRS) and STAT3, which facilitated dephosphorylation of STAT3 by PTPRS. Altogether, our study has revealed the clinical significance of BMP10 in HCC, and suppression of HCC cell growth by BMP10 via PTPRS-STAT3 axis, providing a potential therapeutic strategy for targeting STAT3 signaling in HCC.	[Yuan, Yan-Mei; Ma, Ning; Zhang, Er-Bin; Chen, Tian-Wei; Jiang, Hao; Yin, Fen-Fen; Wang, Jing-Jing; Zhang, Feng-Kun; Ni, Qian-Zhi; Li, Jing-Jing; Xie, Dong] Chinese Acad Sci, Univ Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Inst Nutr & Hlth,CAS Key Lab Nutr Metab, Shanghai 200031, Peoples R China; [Wang, Xiang] Huzhou Univ, First Peoples Hosp Affiliated, Key Lab Translat Med, Huzhou 313000, Peoples R China; [Bao, Ying] Huzhou Univ, First Peoples Hosp Affiliated, Dept Surg, Huzhou 313000, Peoples R China; [Wang, Kang; Cheng, Shu-Qun] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 6, Shanghai 200438, Peoples R China; [Zhang, Xue-Li] Southern Med Univ, Fengxian Hosp, Dept Gen Surg, 6600 Nanfeng Rd, Shanghai 201499, Peoples R China; [Wang, Xiao-Fan] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; [Xie, Dong] ShanghaiTech Univ, Sch Life Sci & Technol, 393 Middle Huaxia Rd, Shanghai 201210, Peoples R China; [Xie, Dong] China Natl Ctr Food Safety Risk Assessment, NHC Key Lab Food Safety Risk Assessment, Beijing 100022, Peoples R China	Chinese Academy of Sciences; Shanghai Institute of Nutrition & Health, CAS; Shanghai Institutes for Biological Sciences, CAS; University of Chinese Academy of Sciences, CAS; Huzhou University; Huzhou University; Naval Medical University; Southern Medical University - China; Duke University; ShanghaiTech University	Li, JJ; Xie, D (corresponding author), Chinese Acad Sci, Univ Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Inst Nutr & Hlth,CAS Key Lab Nutr Metab, Shanghai 200031, Peoples R China.; Xie, D (corresponding author), ShanghaiTech Univ, Sch Life Sci & Technol, 393 Middle Huaxia Rd, Shanghai 201210, Peoples R China.; Xie, D (corresponding author), China Natl Ctr Food Safety Risk Assessment, NHC Key Lab Food Safety Risk Assessment, Beijing 100022, Peoples R China.	tide7@163.com; dxie@sibs.ac.cn	cheng, sq/GPT-4112-2022	Xie, Dong/0000-0002-1150-8657; Wang, Xiang/0000-0002-0913-0501	National Key R&D Program of China [2018YFC1603002, 2018YFC1604404]; "Personalized Medicines-Molecular Signature-based Drug Discovery and Development", Strategic Priority Research Program of the Chinese Academy of Sciences [XDA12010316]; National Natural Science Foundation of China [31520103907, 81730083, 31771538]; Youth Innovation Promotion Association of Chinese Academy of Sciences; Sanofi-SIBS 2018 Young Faculty Award	National Key R&D Program of China; "Personalized Medicines-Molecular Signature-based Drug Discovery and Development", Strategic Priority Research Program of the Chinese Academy of Sciences; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Youth Innovation Promotion Association of Chinese Academy of Sciences; Sanofi-SIBS 2018 Young Faculty Award	This work was supported by the National Key R&D Program of China (2018YFC1603002, 2018YFC1604404), the "Personalized Medicines-Molecular Signature-based Drug Discovery and Development", Strategic Priority Research Program of the Chinese Academy of Sciences (Grant no. XDA12010316), and National Natural Science Foundation of China (31520103907, 81730083) to Dong Xie; and National Natural Science Foundation of China (31771538), Youth Innovation Promotion Association of Chinese Academy of Sciences fund and Sanofi-SIBS 2018 Young Faculty Award to Jing-Jing Li.	Cai Z, 2018, CANCER RES, V78, P2536, DOI 10.1158/0008-5472.CAN-17-0028; Castonguay R, 2011, J BIOL CHEM, V286, P30034, DOI 10.1074/jbc.M111.260133; Chen YW, 2015, BLOOD, V125, P1589, DOI 10.1182/blood-2014-07-588970; David L, 2007, BLOOD, V109, P1953, DOI 10.1182/blood-2006-07-034124; Deng YZ, 2007, J BIOL CHEM, V282, P36571, DOI 10.1074/jbc.M704141200; Felin JE, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-20; Geiger JL, 2016, ORAL ONCOL, V56, P84, DOI 10.1016/j.oraloncology.2015.11.022; Hjertner O, 2001, BLOOD, V97, P516, DOI 10.1182/blood.V97.2.516; Hou JJ, 2013, HEPATOLOGY, V57, P678, DOI 10.1002/hep.25980; Hover LD, 2016, NEURO-ONCOLOGY, V18, P928, DOI 10.1093/neuonc/nov310; Kawamura C, 2000, BLOOD, V96, P2005, DOI 10.1182/blood.V96.6.2005.h8002005a_2005_2011; Kim BR, 2015, TUMOR BIOL, V36, P9475, DOI 10.1007/s13277-015-3681-y; Langenfeld EM, 2006, ONCOGENE, V25, P685, DOI 10.1038/sj.onc.1209110; Lei HM, 2016, TUMOR BIOL, V37, P3025, DOI 10.1007/s13277-015-4116-5; Levet S, 2015, P NATL ACAD SCI USA, V112, pE3207, DOI 10.1073/pnas.1508386112; Li JJ, 2009, ONCOGENE, V28, P1759, DOI 10.1038/onc.2009.15; Min KW, 2016, ONCOGENE, V35, P377, DOI 10.1038/onc.2015.95; Mitrofan CG, 2017, J BIOL CHEM, V292, P13714, DOI 10.1074/jbc.M117.778506; Nakano N, 2007, AM J PHYSIOL-HEART C, V293, pH3396, DOI 10.1152/ajpheart.00311.2007; Neuhaus H, 1999, MECH DEVELOP, V80, P181, DOI 10.1016/S0925-4773(98)00221-4; Pestana ES, 1999, ONCOGENE, V18, P4069, DOI 10.1038/sj.onc.1202794; Shin DS, 2009, CANCER RES, V69, P193, DOI 10.1158/0008-5472.CAN-08-2575; Su FQ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3134; Sun LJ, 2014, J CELL BIOCHEM, V115, P1868, DOI 10.1002/jcb.24856; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Veeriah S, 2009, P NATL ACAD SCI USA, V106, P9435, DOI 10.1073/pnas.0900571106; Wu M, 2014, INT J CLIN EXP PATHO, V7, P529; Ye L, 2010, CANCER SCI, V101, P2137, DOI 10.1111/j.1349-7006.2010.01648.x; Ye L, 2009, J UROLOGY, V181, P2749, DOI 10.1016/j.juro.2009.01.098; Zhang N, 2013, ANTICANCER RES, V33, P1917; Zhang XD, 2007, P NATL ACAD SCI USA, V104, P4060, DOI 10.1073/pnas.0611665104	31	7	8	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2019	38	48					7281	7293		10.1038/s41388-019-0943-y	http://dx.doi.org/10.1038/s41388-019-0943-y			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JR4XX	31417183				2022-12-28	WOS:000499631000001
J	Jallow, F; O'Leary, KA; Rugowski, DE; Guerrero, JF; Ponik, SM; Schuler, LA				Jallow, Fatou; O'Leary, Kathleen A.; Rugowski, Debra E.; Guerrero, Jorge F.; Ponik, Suzanne M.; Schuler, Linda A.			Dynamic interactions between the extracellular matrix and estrogen activity in progression of ER plus breast cancer	ONCOGENE			English	Article							ENDOCRINE THERAPY; TAMOXIFEN RESISTANCE; DNA-BINDING; IN-VIVO; COLLAGEN; AP-1; GROWTH; CELLS; ASSOCIATION; TUMORS	Metastatic, antiestrogen resistant estrogen receptor a positive (ER+) breast cancer is the leading cause of breast cancer deaths in USA women. While studies have demonstrated the importance of the stomal tumor microenvironment in cancer progression and therapeutic responses, effects on the responses of ER+ cancers to estrogen and antiestrogens are poorly understood, particularly in the complex in vivo environment. In this study, we used an estrogen responsive syngeneic mouse model to interrogate how a COL1A1-enriched fibrotic ECM modulates integrated hormonal responses in cancer progression. We orthotopically transplanted the ER+ TC11 cell line into wild-type (WT) or collagen-dense (Col1a1(t)(m1Jae/+),mCol1a1 syngeneic FVB/N female mice. Once tumors were established, recipients were supplemented with 17 beta-estradiol (E2), tamoxifen, or left untreated. Although the dense/stiff environment in mCol1a1 recipients did not alter the rate of E2-induced proliferation of the primary tumor, it fostered the agonist activity of tamoxifen to increase proliferation and AP-1 activity. Manipulation of estrogen activity did not alter the incidence of lung lesions in either WT or mCol1a1 hosts. However, the mCol1a1 environment enabled tamoxifen-stimulated growth of pulmonary metastases and further fueled estrogen-driven growth. Moreover, E2 remodeled peritumoral ECM architecture in WT animals, modifying alignment of collagen fibers and altering synthesis of ECM components associated with increased alignment and stiffness, and increasing FN1 and POSTN expression in the pulmonary metastatic niche. These studies demonstrate dynamic interactions between ECM properties and estrogen activity in progression of ER+ breast cancer, and support the need for therapeutics that target both ER and the tumor microenvironment.	[Jallow, Fatou; O'Leary, Kathleen A.; Rugowski, Debra E.; Schuler, Linda A.] Univ Wisconsin, Dept Comparat Biosci, 2015 Linden Dr W, Madison, WI 53706 USA; [Jallow, Fatou] Univ Wisconsin, Endocrinol Reprod Physiol Program, Madison, WI USA; [Guerrero, Jorge F.; Ponik, Suzanne M.] Univ Wisconsin, Dept Cell & Regenerat Biol, Madison, WI USA; [Ponik, Suzanne M.; Schuler, Linda A.] Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Schuler, LA (corresponding author), Univ Wisconsin, Dept Comparat Biosci, 2015 Linden Dr W, Madison, WI 53706 USA.; Schuler, LA (corresponding author), Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53706 USA.	linda.schuler@wisc.edu	Ponik, Suzanne/AAF-5572-2020	Ponik, Suzanne/0000-0003-1367-4349	National Institutes of Health [R01 CA157675, R01 CA179556, T32 HD041921, R25 GM083252, P30CA014520]; UWCCC Breast Disease Oriented Team; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD041921] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA179556, R01CA206458, P30CA014520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM083252] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UWCCC Breast Disease Oriented Team; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the National Institutes of Health [R01 CA157675 (LAS) and R01 CA179556 (LAS, SMP), T32 HD041921 and R25 GM083252 (FJ), and P30CA014520 (University of Wisconsin Carbone Cancer Center)], and funds from the UWCCC Breast Disease Oriented Team.	ALADNANI MS, 1975, BRIT J CANCER, V31, P653, DOI 10.1038/bjc.1975.112; Anderson WF, 2011, J NATL CANCER I, V103, P1397, DOI 10.1093/jnci/djr257; Barcus CE, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0801-1; Barcus CE, 2016, ONCOTARGET, V7, P48093, DOI 10.18632/oncotarget.10137; Barcus CE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116891; Barcus CE, 2013, J BIOL CHEM, V288, P12722, DOI 10.1074/jbc.M112.447631; Bertrand KA, 2018, HORM CANCER-US, V9, P117, DOI 10.1007/s12672-017-0321-6; Burstein HJ, 2014, J CLIN ONCOL, V32, P2255, DOI 10.1200/JCO.2013.54.2258; Byrne C, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx001; Calvo E, 2012, BREAST CANCER RES TR, V134, P625, DOI 10.1007/s10549-012-2104-7; Campbell KM, 2019, CELL REP, V28, P1526, DOI 10.1016/j.celrep.2019.06.098; Cheung E, 2005, P NATL ACAD SCI USA, V102, P559, DOI 10.1073/pnas.0407113102; Clark IA, 2008, INT J BIOCHEM CELL B, V40, P1362, DOI 10.1016/j.biocel.2007.12.006; Conklin MW, 2011, AM J PATHOL, V178, P1221, DOI 10.1016/j.ajpath.2010.11.076; Cox TR, 2014, CLIN CANCER RES, V20, P3637, DOI 10.1158/1078-0432.CCR-13-1059; Dabrosin C, 2003, INT J CANCER, V107, P535, DOI 10.1002/ijc.11398; Dumont JA, 1996, CELL GROWTH DIFFER, V7, P351; Dupont S, 2016, EXP CELL RES, V343, P42, DOI 10.1016/j.yexcr.2015.10.034; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Esbona K, 2018, AM J PATHOL, V188, P559, DOI 10.1016/j.ajpath.2017.10.025; Evans A, 2018, BREAST CANCER RES TR, V171, P383, DOI 10.1007/s10549-018-4836-5; Gerard C, 2017, J MAMMARY GLAND BIOL, V22, P1, DOI 10.1007/s10911-016-9368-1; Goddard ET, 2017, CANCER DISCOV, V7, P177, DOI 10.1158/2159-8290.CD-16-0822; Gyorfi AH, 2018, MATRIX BIOL, V68-69, P8, DOI 10.1016/j.matbio.2017.12.016; Haslam SZ, 2001, BREAST CANCER RES, V3, P365, DOI 10.1186/bcr324; Hattar R, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2220; He H, 2018, ONCOGENE, V37, P2586, DOI 10.1038/s41388-018-0165-8; Helleman J, 2008, CLIN CANCER RES, V14, P5555, DOI 10.1158/1078-0432.CCR-08-0555; Holm C, 2006, JNCI-J NATL CANCER I, V98, P671, DOI 10.1093/jnci/djj185; Houthuijzen JM, 2018, CANCER METAST REV, V37, P577, DOI 10.1007/s10555-018-9768-3; Insua-Rodriguez J, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201809003; Jakacka M, 2001, J BIOL CHEM, V276, P13615, DOI 10.1074/jbc.M008384200; Jallow F, 2018, J ENDOCR SOC, V2, P293, DOI 10.1210/js.2017-00399; Johnston SRD, 1999, CLIN CANCER RES, V5, P251; Kang JS, 2009, BIOL PHARM BULL, V32, P150, DOI 10.1248/bpb.32.150; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Kaushik S, 2016, CANCER METAST REV, V35, P655, DOI 10.1007/s10555-016-9650-0; Keely PJ, 2011, J MAMMARY GLAND BIOL, V16, P205, DOI 10.1007/s10911-011-9226-0; Kennecke H, 2010, J CLIN ONCOL, V28, P3271, DOI 10.1200/JCO.2009.25.9820; Kim KK, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a022293; Klein CA, 2009, NAT REV CANCER, V9, P302, DOI 10.1038/nrc2627; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; LIU X, 1995, J CELL BIOL, V130, P227, DOI 10.1083/jcb.130.1.227; Liu YM, 2017, METHODS MOL BIOL, V1627, P429, DOI 10.1007/978-1-4939-7113-8_28; Lupien M, 2010, GENE DEV, V24, P2219, DOI 10.1101/gad.1944810; Malorni L, 2016, MOL CANCER RES, V14, P470, DOI 10.1158/1541-7786.MCR-15-0423; Massarweh S, 2008, CANCER RES, V68, P826, DOI 10.1158/0008-5472.CAN-07-2707; Molnar IA, 2017, VIRCHOWS ARCH, V470, P275, DOI 10.1007/s00428-017-2065-7; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; Nagaraj G, 2015, BREAST CANCER RES TR, V150, P231, DOI 10.1007/s10549-015-3316-4; Nardone A, 2015, BREAST, V24, pS60, DOI 10.1016/j.breast.2015.07.015; Nelson ER, 2013, SCIENCE, V342, P1094, DOI 10.1126/science.1241908; O'Leary KA, 2015, ADV EXP MED BIOL, V846, P201, DOI 10.1007/978-3-319-12114-7_9; Ong CC, 2011, P NATL ACAD SCI USA, V108, P7177, DOI 10.1073/pnas.1103350108; Oskarsson T, 2011, NAT MED, V17, P867, DOI 10.1038/nm.2379; Pan HC, 2017, NEW ENGL J MED, V377, P1836, DOI 10.1056/NEJMoa1701830; Pontiggia O, 2012, BREAST CANCER RES TR, V133, P459, DOI 10.1007/s10549-011-1766-x; Provenzano PP, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-11; Provenzano PP, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-38; Robertson C, 2016, EXP CELL RES, V343, P73, DOI 10.1016/j.yexcr.2015.11.009; Sampayo RG, 2018, J CELL BIOL, V217, P2777, DOI 10.1083/jcb.201703037; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shea MP, 2018, CANCER LETT, V433, P1, DOI 10.1016/j.canlet.2018.06.025; Shen Q, 2008, ONCOGENE, V27, P366, DOI 10.1038/sj.onc.1210643; Smid M, 2008, CANCER RES, V68, P3108, DOI 10.1158/0008-5472.CAN-07-5644; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; Socovich AM, 2019, SEMIN CELL DEV BIOL, V89, P157, DOI 10.1016/j.semcdb.2018.06.005; Svoronos N, 2017, CANCER DISCOV, V7, P72, DOI 10.1158/2159-8290.CD-16-0502; Tomko LA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31126-w; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Walker RA, 2001, BREAST CANCER RES, V3, P143, DOI 10.1186/bcr287; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; Wegner KA, 2017, J HISTOCHEM CYTOCHEM, V65, P479, DOI 10.1369/0022155417718541; Wernig G, 2017, P NATL ACAD SCI USA, V114, P4757, DOI 10.1073/pnas.1621375114; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216; Zhou YM, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-59	78	20	20	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2019	38	43					6913	6925		10.1038/s41388-019-0941-0	http://dx.doi.org/10.1038/s41388-019-0941-0			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JH4GX	31406251	Green Accepted			2022-12-28	WOS:000492728000003
J	Huang, W; Hu, H; Zhang, Q; Wu, X; Wei, FX; Yang, F; Gan, L; Wang, N; Yang, XL; Guo, AY				Huang, Wei; Hu, Hui; Zhang, Qiong; Wu, Xian; Wei, Fuxiang; Yang, Fang; Gan, Lu; Wang, Ning; Yang, Xiangliang; Guo, An-Yuan			Regulatory networks in mechanotransduction reveal key genes in promoting cancer cell stemness and proliferation	ONCOGENE			English	Article							EXPRESSION; FIBRIN; GROWTH; ACTIVATION; POPULATION; INHIBITION; CARCINOMA; PATHWAYS; NANOG; COLON	Tumor-repopulating cells (TRCs) are cancer stem cell (CSC)-like cells with highly tumorigenic and self-renewing abilities, which were selected from tumor cells in soft three-dimensional (3D) fibrin gels with unidentified mechanisms. Here we evaluated the transcriptome alteration during TRCs generation in 3D culture and revealed that a variety of molecules related with integrin/membrane and stemness were continuously altered by mechanical environment. Some key regulators such as MYC/STAT3/hsa-miR-199a-5p, were changed in the TRCs generation. They regulated membrane genes and the downstream mechanotransduction pathways such as Hippo/WNT/TGF-beta/PI3K-AKT pathways, thus further affecting the expression of downstream cancer-related genes. By integrating networks for membrane proteins, the WNT pathway and cancer-related genes, we identified key molecules in the selection of TRCs, such as ATF4, SLC3A2, CCT3, and hsa-miR-199a-5p. Silencing ATF4 or CCT3 inhibited the selection and growth of TRCs whereas reduction of SLC3A2 or hsa-miR-199a-5p promoted TRCs growth. Further studies showed that CCT3 promoted cell proliferation and stemness in vitro, while its suppression inhibited TRCs-induced tumor formation. We also contemplated CCT3 as a stemness-related gene. Our findings provide insights in the mechanism of TRCs selection through transcriptome analysis.	[Huang, Wei; Wu, Xian; Gan, Lu; Yang, Xiangliang] Huazhong Univ Sci & Technol, Coll Life Sci & Technol, Natl Engn Res Ctr Nanomed, Wuhan 430074, Hubei, Peoples R China; [Hu, Hui; Zhang, Qiong; Guo, An-Yuan] Huazhong Univ Sci & Technol, Coll Life Sci & Technol, Hubei Bioinformat & Mol Imaging Key Lab, Key Lab Mol Biophys,Minist Educ, Wuhan 430074, Hubei, Peoples R China; [Wei, Fuxiang; Yang, Fang; Wang, Ning] Huazhong Univ Sci & Technol, Coll Life Sci & Technol, Dept Biomed Engn, Wuhan 430074, Hubei, Peoples R China; [Wang, Ning] Univ Illinois, Coll Engn, Dept Mech Sci & Engn, Urbana, IL 61801 USA	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology; University of Illinois System; University of Illinois Urbana-Champaign	Yang, XL (corresponding author), Huazhong Univ Sci & Technol, Coll Life Sci & Technol, Natl Engn Res Ctr Nanomed, Wuhan 430074, Hubei, Peoples R China.; Guo, AY (corresponding author), Huazhong Univ Sci & Technol, Coll Life Sci & Technol, Hubei Bioinformat & Mol Imaging Key Lab, Key Lab Mol Biophys,Minist Educ, Wuhan 430074, Hubei, Peoples R China.	yangxl@hust.edu.cn; guoay@hust.edu.cn	Zhang, Qiong/AIC-0940-2022; Zhang, Qiong/GYE-1270-2022	Zhang, Qiong/0000-0001-5001-8434; Hu, Hui/0000-0002-9208-1041; Guo, An-Yuan/0000-0002-5099-7465; Wei, Fuxiang/0000-0002-6200-6219	National Basic Research Program of China [2015CB931802]; National Natural Science Foundation of China (NSFC) [81627901, 81773653, 31822030, 31771458]; Program for Changjiang Scholars and Innovative Research Team in University (PCSIRT) [IRT 13016]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM072744] Funding Source: NIH RePORTER	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Program for Changjiang Scholars and Innovative Research Team in University (PCSIRT)(Program for Changjiang Scholars & Innovative Research Team in University (PCSIRT)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We acknowledge the research funding from National Basic Research Program of China (2015CB931802), National Natural Science Foundation of China (NSFC) [81627901, 81773653, 31822030, and 31771458], and Program for Changjiang Scholars and Innovative Research Team in University (PCSIRT) [No. IRT 13016].	Addla SK, 2008, AM J PHYSIOL-RENAL, V295, pF680, DOI 10.1152/ajprenal.90286.2008; Amini S, 2014, ANAT CELL BIOL, V47, P1, DOI 10.5115/acb.2014.47.1.1; Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101; Bu PC, 2016, CELL STEM CELL, V18, P189, DOI 10.1016/j.stem.2016.01.006; Chen JW, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03877-7; Chen KD, 1999, J BIOL CHEM, V274, P18393, DOI 10.1074/jbc.274.26.18393; COSTANTINI V, 1992, CANCER METAST REV, V11, P283, DOI 10.1007/BF01307183; Cui X, 2015, WORLD J GASTROENTERO, V21, P8588, DOI 10.3748/wjg.v21.i28.8588; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Estrach S, 2014, CANCER RES, V74, P6878, DOI 10.1158/0008-5472.CAN-14-0579; Gong J, 2014, RNA BIOL, V11, P1375, DOI 10.1080/15476286.2014.996465; Guo CL, 2016, CELL BIOL INT, V40, P847, DOI 10.1002/cbin.10539; Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6; Hamzeh MT, 2015, AM J PHYSIOL-RENAL, V308, pF425, DOI 10.1152/ajprenal.00589.2014; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Jung K, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-328; Koshizuka K, 2017, CANCER SCI, V108, P1681, DOI 10.1111/cas.13298; Lam WA, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-35; Li Y, 2015, CANCER RES, V75, P1191, DOI 10.1158/0008-5472.CAN-14-2615; Lin Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep09653; Liu J, 2012, NAT MATER, V11, P734, DOI [10.1038/NMAT3361, 10.1038/nmat3361]; Lopez-Saavedra A, 2016, CELL CYCLE, V15, P2066, DOI 10.1080/15384101.2016.1198863; Luo YM, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/3598542; Malik G, 2010, CANCER RES, V70, P4327, DOI 10.1158/0008-5472.CAN-09-3312; Matsumoto T, 2017, ONCOGENESIS, V6, DOI 10.1038/s41389-017-0009-3; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Mobus S, 2015, J HEPATOL, V62, P101, DOI 10.1016/j.jhep.2014.08.016; Morgan JT, 2013, EXP EYE RES, V115, P1, DOI 10.1016/j.exer.2013.06.012; Najafi M, 2019, J CELL PHYSIOL, V234, P8381, DOI 10.1002/jcp.27740; Nimmakayala RK, 2019, BBA-REV CANCER, V1871, P50, DOI 10.1016/j.bbcan.2018.10.006; Ning W, 2017, J PHYS D, V50; Palumbo JS, 2001, HAEMOSTASIS, V31, P11; Pertea M, 2016, NAT PROTOC, V11, P1650, DOI 10.1038/nprot.2016.095; Rivera B, 2011, ANN ONCOL, V22, P903, DOI 10.1093/annonc/mdq465; Rysa J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23042-w; SCHERER WF, 1953, J EXP MED, V97, P695, DOI 10.1084/jem.97.5.695; Shafer B, 2011, DEV CELL, V20, P177, DOI 10.1016/j.devcel.2011.01.002; Shi L, 2010, ONCOTARGET, V1, P22, DOI 10.18632/oncotarget.105; Sironen RK, 2002, BIORHEOLOGY, V39, P111; Sun HF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036808; Susswein LR, 2016, GENET MED, V18, P823, DOI 10.1038/gim.2015.166; Takebe N, 2011, NAT REV CLIN ONCOL, V8, P97, DOI 10.1038/nrclinonc.2010.196; Tan YH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5619; Tarazona S, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv711; van Sluis GL, 2011, CANCER LETT, V306, P106, DOI 10.1016/j.canlet.2011.02.038; VILADIU P, 1975, SURG GYNECOL OBSTET, V140, P544; Vining KH, 2017, NAT REV MOL CELL BIO, V18, P728, DOI 10.1038/nrm.2017.108; Wang J, 2013, MOL NEUROBIOL, V47, P228, DOI 10.1007/s12035-012-8335-0; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Wang T, 2015, ONCOTARGET, V6, P30975, DOI 10.18632/oncotarget.5199; Wozniak MA, 2009, NAT REV MOL CELL BIO, V10, P34, DOI 10.1038/nrm2592; Xia HF, 2017, J HISTOCHEM CYTOCHEM, V65, P285, DOI 10.1369/0022155417694872; Zhang HM, 2015, BRIEF BIOINFORM, V16, P45, DOI 10.1093/bib/bbt085; Zhang T, 2003, BIOCHEM J, V376, P457, DOI 10.1042/BJ20030668; Zhang YY, 2016, CANCER LETT, V372, P101, DOI 10.1016/j.canlet.2015.12.029; Zhao YZ, 2015, BLOOD, V126, P2383, DOI 10.1182/blood-2015-03-633354; Zheng J, 2015, ONCOTARGET, V6, P25339, DOI 10.18632/oncotarget.4509	58	21	21	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2019	38	42					6818	6834		10.1038/s41388-019-0925-0	http://dx.doi.org/10.1038/s41388-019-0925-0			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE5UU	31406247	Green Accepted, hybrid			2022-12-28	WOS:000490758200002
J	Yao, S; Huang, HY; Han, XK; Ye, Y; Qin, Z; Zhao, GX; Li, FM; Hu, GH; Hu, L; Ji, HB				Yao, Shun; Huang, Hsin-Yi; Han, Xiangkun; Ye, Yi; Qin, Zhen; Zhao, Gaoxiang; Li, Fuming; Hu, Guohong; Hu, Liang; Ji, Hongbin			Keratin 14-high subpopulation mediates lung cancer metastasis potentially through Gkn1 upregulation	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMAS; 1 INDUCES SENESCENCE; K-RAS ONCOGENE; SIGNALING PATHWAY; MESENCHYMAL TRANSITION; MOLECULAR SWITCH; GENE-EXPRESSION; GASTRIC-MUCOSA; PROTEIN; DIFFERENTIATION	Metastasis is the leading cause of lung cancer-related death. Elucidating the metastasis process can provide new avenues to inhibit this malignant behavior of cancer cells. Here we found that human lung cancers with high Keratin 14 (K14) expression were associated with nodal metastasis and poor survival. Using the Kras(G12D)/Trp53(L/L) lung cancer mouse model, we confirmed that K14-high cancer cells harbored increased metastatic potential. Mechanistic investigation revealed that Gastrokine 1 (Gknl) expression positively correlated with K14 level, cancer metastasis, and poor patient survival. Importantly, ectopic expression of Gknl enhanced the metastatic capability of K14-low cells in vitro and in vivo, whereas knockdown of Gknl did the opposite, indicating the importance of Gknl in mediating the metastasis of K14-high cells. Further study demonstrated that Gknl expression conferred K14-high cells resistance to anoikis, which is critical for cancer metastasis. Collectively, our findings demonstrate that K14-high cells contribute to lung cancer metastasis potentially through inhibition of anoikis via upregulation of Gknl.	[Yao, Shun; Huang, Hsin-Yi; Han, Xiangkun; Ye, Yi; Qin, Zhen; Zhao, Gaoxiang; Li, Fuming; Hu, Liang; Ji, Hongbin] Chinese Acad Sci, Shanghai Inst Biochem & Cell Biol, State Key Lab Cell Biol, Shanghai 200031, Peoples R China; [Yao, Shun; Huang, Hsin-Yi; Han, Xiangkun; Ye, Yi; Qin, Zhen; Zhao, Gaoxiang; Li, Fuming; Hu, Liang; Ji, Hongbin] Chinese Acad Sci, Shanghai Inst Biochem & Cell Biol, Innovat Ctr Cell Signaling Network, Shanghai 200031, Peoples R China; [Yao, Shun; Huang, Hsin-Yi; Han, Xiangkun; Ye, Yi; Qin, Zhen; Zhao, Gaoxiang; Li, Fuming; Hu, Liang; Ji, Hongbin] Chinese Acad Sci, Shanghai Inst Biochem & Cell Biol, CAS Ctr Excellence Mol Cell Sci, Shanghai 200031, Peoples R China; [Yao, Shun; Qin, Zhen; Ji, Hongbin] Univ Chinese Acad Sci, Beijing 100049, Peoples R China; [Ye, Yi; Ji, Hongbin] Shanghai Tech Univ, Sch Life Sci & Technol, Shanghai 200120, Peoples R China; [Hu, Guohong] Chinese Acad Sci, Inst Hlth Sci, Shanghai Inst Biol Sci, Key Lab Stem Cell Biol, Shanghai 200031, Peoples R China; [Hu, Guohong] Shanghai Jiao Tong Univ, Sch Med, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; ShanghaiTech University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University	Hu, L; Ji, HB (corresponding author), Chinese Acad Sci, Shanghai Inst Biochem & Cell Biol, State Key Lab Cell Biol, Shanghai 200031, Peoples R China.; Hu, L; Ji, HB (corresponding author), Chinese Acad Sci, Shanghai Inst Biochem & Cell Biol, Innovat Ctr Cell Signaling Network, Shanghai 200031, Peoples R China.; Hu, L; Ji, HB (corresponding author), Chinese Acad Sci, Shanghai Inst Biochem & Cell Biol, CAS Ctr Excellence Mol Cell Sci, Shanghai 200031, Peoples R China.; Ji, HB (corresponding author), Univ Chinese Acad Sci, Beijing 100049, Peoples R China.; Ji, HB (corresponding author), Shanghai Tech Univ, Sch Life Sci & Technol, Shanghai 200120, Peoples R China.	liang.hu@sibcb.ac.cn; hbji@sibcb.ac.cn	; ji, hong bin/I-5625-2017	Hu, Guohong/0000-0002-2980-5166; Huang, Hsinyi/0000-0003-1217-4131; ji, hong bin/0000-0003-0891-6390	National Basic Research Program of China [2017YFA0505501]; Strategic Priority Research Program of the Chinese Academy of Sciences [XDB19020201]; National Natural Science Foundation of China [81430066, 91731314, 31621003, 81872312, 81871875, 81802279]; China Postdoctoral Science Foundation [2016M601667]	National Basic Research Program of China(National Basic Research Program of China); Strategic Priority Research Program of the Chinese Academy of Sciences(Chinese Academy of Sciences); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	The authors thank Dr. Tyler Jacks and Dr. KwokKin Wong for kindly providing the Kras<SUP>G12D</SUP>/Trp53<SUP>L/L</SUP> mice. We are grateful to Dr. Luonan Chen, Ying Tang, and Zaoyuan Fang for providing bioinformatic supports. We thank Dr. Lin He for critical review of the manuscript. This work was supported by the National Basic Research Program of China (Grant 2017YFA0505501), Strategic Priority Research Program of the Chinese Academy of Sciences (Grant XDB19020201), the National Natural Science Foundation of China (Grants 81430066, 91731314, 31621003, 81872312, 81871875 and 81802279), and the China Postdoctoral Science Foundation (2016M601667).	Aceto N, 2014, CELL, V158, P1110, DOI 10.1016/j.cell.2014.07.013; Almendro V, 2013, ANNU REV PATHOL-MECH, V8, P277, DOI 10.1146/annurev-pathol-020712-163923; Banyard J, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-387; Bao LM, 2016, CELL BIOL TOXICOL, V32, P419, DOI 10.1007/s10565-016-9343-z; Barcelos ACN, 2009, J CUTAN PATHOL, V36, P647, DOI 10.1111/j.1600-0560.2008.01127.x; Boone J, 2008, VIRCHOWS ARCH, V452, P507, DOI 10.1007/s00428-008-0602-0; Brady JJ, 2016, CANCER CELL, V29, P697, DOI 10.1016/j.ccell.2016.03.003; Camolotto SA, 2018, ELIFE, V7, DOI 10.7554/eLife.38579; Carrington EM, 2017, CELL DEATH DIFFER, V24, P878, DOI 10.1038/cdd.2017.30; Chen PL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125490; Chen Y, 2011, ONCOLOGY-BASEL, V80, P333, DOI 10.1159/000329098; Cheung KJ, 2016, P NATL ACAD SCI USA, V113, pE854, DOI 10.1073/pnas.1508541113; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Choi KH, 2010, CANCER RES TREAT, V42, P107, DOI 10.4143/crt.2010.42.2.107; Chu PG, 2002, HISTOPATHOLOGY, V40, P403, DOI 10.1046/j.1365-2559.2002.01387.x; Chu PG, 2001, HISTOPATHOLOGY, V39, P9, DOI 10.1046/j.1365-2559.2001.01105.x; Chuang CH, 2017, NAT MED, V23, P291, DOI 10.1038/nm.4285; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Dhanda J, 2014, BRIT J CANCER, V111, P2114, DOI 10.1038/bjc.2014.500; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Doerks T, 2002, GENOME RES, V12, P47, DOI 10.1101/gr.203201; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Gu Y, 2012, ONCOGENE, V31, P469, DOI 10.1038/onc.2011.247; Guo XY, 2014, WORLD J GASTROENTERO, V20, P16702, DOI 10.3748/wjg.v20.i44.16702; Han CP, 2009, MODERN PATHOL, V22, P797, DOI 10.1038/modpathol.2009.31; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kim BG, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3203; Kim YN, 2012, INT J CELL BIOL, V2012, DOI DOI 10.1155/2012/306879; Kong HK, 2012, J BIOL CHEM, V287, P38889, DOI 10.1074/jbc.M112.394270; Koster MI, 2004, GENE DEV, V18, P126, DOI 10.1101/gad.1165104; Kouwenhoven EN, 2015, EMBO REP, V16, P863, DOI 10.15252/embr.201439941; LACY ER, 1993, J CLIN GASTROENTEROL, V17, pS125, DOI 10.1097/00004836-199312001-00023; Lyda MH, 2000, HUM PATHOL, V31, P980, DOI 10.1053/hupa.2000.9076; Martin TE, 2003, AM J PHYSIOL-GASTR L, V285, pG332, DOI 10.1152/ajpgi.00453.2002; Martini M, 2014, ANN MED, V46, P372, DOI 10.3109/07853890.2014.912836; Massague J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038; Mazzoccoli G, 2012, J CANCER RES CLIN, V138, P501, DOI 10.1007/s00432-011-1126-6; Moquet-Torcy G, 2014, NUCLEIC ACIDS RES, V42, P11011, DOI 10.1093/nar/gku814; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; O'Gorman DM, 2001, LEUKEMIA, V15, P21, DOI 10.1038/sj.leu.2401998; Offield MF, 1996, DEVELOPMENT, V122, P983; Oien KA, 2004, J PATHOL, V203, P789, DOI 10.1002/path.1583; Ooi AT, 2010, CANCER RES, V70, P6639, DOI 10.1158/0008-5472.CAN-10-0455; Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd; Paoli P, 2013, BBA-MOL CELL RES, V1833, P3481, DOI 10.1016/j.bbamcr.2013.06.026; Portt L, 2011, BBA-MOL CELL RES, V1813, P238, DOI 10.1016/j.bbamcr.2010.10.010; Quemener C, 2007, CANCER RES, V67, P9, DOI 10.1158/0008-5472.CAN-06-2448; Rippa E, 2011, J CELL PHYSIOL, V226, P2571, DOI 10.1002/jcp.22601; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; RODENHUIS S, 1988, CANCER RES, V48, P5738; Russo C, 2018, P NATL ACAD SCI USA, V115, pE906, DOI 10.1073/pnas.1713773115; Sakai Y, 2013, INT J SURG PATHOL, V21, P476, DOI 10.1177/1066896913489345; Schmidt M, 2002, BRIT J CANCER, V87, P924, DOI 10.1038/sj.bjc.6600566; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Simone TM, 2014, ADV WOUND CARE, V3, P281, DOI 10.1089/wound.2013.0512; Snyder EL, 2013, MOL CELL, V50, P185, DOI 10.1016/j.molcel.2013.02.018; Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; Tang L, 2013, CLIN CANCER RES, V19, P2014, DOI 10.1158/1078-0432.CCR-12-0349; Toback FG, 2003, AM J PHYSIOL-GASTR L, V285, pG344, DOI 10.1152/ajpgi.00455.2002; Tuveson DA, 1999, ONCOGENE, V18, P5318, DOI 10.1038/sj.onc.1203107; van Dorst EBL, 1998, J CLIN PATHOL, V51, P679, DOI 10.1136/jcp.51.9.679; Walia V, 2012, ONCOGENE, V31, P2237, DOI 10.1038/onc.2011.392; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Winslow MM, 2011, NATURE, V473, P101, DOI 10.1038/nature09881; Woolf PJ, 2009, LUNG CANCER METASTASIS: NOVEL BIOLOGICAL MECHANISMS AND IMPACT ON CLINICAL PRACTICE, P383, DOI 10.1007/978-1-4419-0772-1_17; Xing R, 2012, GUT, V61, P43, DOI 10.1136/gut.2010.230623; Yoon JH, 2014, J GASTRIC CANCER, V14, P147, DOI 10.5230/jgc.2014.14.3.147; Yoon JH, 2014, ONCOTARGET, V5, P11695, DOI 10.18632/oncotarget.2586; Yoon JH, 2013, J CELL BIOCHEM, V114, P1800, DOI 10.1002/jcb.24524; Yoon JH, 2011, J CANCER RES CLIN, V137, P1697, DOI 10.1007/s00432-011-1051-8; Yoon JH, 2011, J PATHOL, V223, P618, DOI 10.1002/path.2838; Yu XM, 2016, CLIN CANCER RES, V22, P3582, DOI 10.1158/1078-0432.CCR-15-1749; Zhang S, 2015, DIS MARKERS, V2015, DOI 10.1155/2015/824304; Zheng YB, 2016, ONCOTARGET, V7, P62159, DOI 10.18632/oncotarget.11398	80	5	5	2	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2019	38	36					6354	6369		10.1038/s41388-019-0889-0	http://dx.doi.org/10.1038/s41388-019-0889-0			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IX6EX	31320708				2022-12-28	WOS:000485776800003
J	Zong, L; Hattori, N; Yasukawa, Y; Kimura, K; Mori, A; Seto, Y; Ushijima, T				Zong, Liang; Hattori, Naoko; Yasukawa, Yoshimi; Kimura, Kana; Mori, Akiko; Seto, Yasuyuki; Ushijima, Toshikazu			LINC00162 confers sensitivity to 5-Aza-2 '-deoxycytidine via modulation of an RNA splicing protein, HNRNPH1	ONCOGENE			English	Article							RISK MYELODYSPLASTIC SYNDROMES; HELICOBACTER-PYLORI INFECTION; ACUTE MYELOID-LEUKEMIA; DNA METHYLATION; HYPOMETHYLATING AGENT; DEMETHYLATING AGENTS; TUMOR-SUPPRESSOR; PHASE-II; CANCER; AZACITIDINE	DNA demethylation therapy is now expanding from hematological tumors to solid tumors. To exploit its maximum efficacy, long-term treatment is needed, and stratification of sensitive patients is critically important. Here, we identified a long non-coding RNA, LINC00162, as highly and frequently expressed in gastric cancer cell lines sensitive to 5-aza-2'-deoxycytidine (5-aza-dC). Knockdown of LINC00162 decreased the sensitivity while its overexpression increased the sensitivity. In vivo experiments also showed that LINC00162 overexpression increased the sensitivity. LINC00162 enhanced cell cycle arrest and apoptosis induced by 5-aza-dC, but did not affect its DNA demethylation effect. Mechanistically, LINC00162 interacted with an RNA splicing protein, HNRNPH1, and decreased splicing of an anti-apoptotic splicing variant, BCL-XL. LINC00162 may have translational value to predict patients who will respond to 5-aza-dC.	[Zong, Liang; Hattori, Naoko; Yasukawa, Yoshimi; Kimura, Kana; Mori, Akiko; Ushijima, Toshikazu] Natl Canc Ctr, Res Inst, Div Epigen, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan; [Zong, Liang; Yasukawa, Yoshimi; Seto, Yasuyuki] Univ Tokyo, Grad Sch Med, Dept Gastrointestinal Surg, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan	National Cancer Center - Japan; University of Tokyo	Ushijima, T (corresponding author), Natl Canc Ctr, Res Inst, Div Epigen, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	tushijim@ncc.go.jp	Ushijima, Toshikazu/AAP-5742-2021	Ushijima, Toshikazu/0000-0003-3405-7817; Hattori, Naoko/0000-0002-0901-4869	AMED [JP18ck0106421]; JSPS KAKENHI [JP18H02704]	AMED(Japan Agency for Medical Research and Development (AMED)); JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study was supported by AMED under Grant Number JP18ck0106421 to Toshikazu Ushijima and JSPS KAKENHI under Grant Number JP18H02704 to Toshikazu Ushijima.	Ajani JA, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.36; Asada K, 2013, ONCOGENE, V32, P2140, DOI 10.1038/onc.2012.228; Belinsky SA, 2003, CANCER RES, V63, P7089; Cascinu S, 1997, J CLIN ONCOL, V15, P3313, DOI 10.1200/JCO.1997.15.11.3313; Chandler DS, 2006, CANCER RES, V66, P9502, DOI 10.1158/0008-5472.CAN-05-4271; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; Chuang JC, 2010, MOL CANCER THER, V9, P1443, DOI 10.1158/1535-7163.MCT-09-1048; Cowan LA, 2010, EPIGENOMICS-UK, V2, P71, DOI 10.2217/EPI.09.44; Cui Y, 2014, CANCER RES, V74, P3834, DOI 10.1158/0008-5472.CAN-13-2287; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Fang F, 2014, CLIN CANCER RES, V20, P6504, DOI 10.1158/1078-0432.CCR-14-1553; Fenaux P, 2009, LANCET ONCOL, V10, P223, DOI 10.1016/S1470-2045(09)70003-8; Gao XD, 2014, ACTA BIOCH BIOPH SIN, V46, P72, DOI 10.1093/abbs/gmt118; Garneau D, 2005, J BIOL CHEM, V280, P22641, DOI 10.1074/jbc.M501070200; Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080; Greenberg PL, 2011, J NATL COMPR CANC NE, V9, P30, DOI 10.6004/jnccn.2011.0005; He DX, 2014, MOL PHARMACOL, V86, P536, DOI 10.1124/mol.114.092759; Hironaka S, 2016, LANCET ONCOL, V17, P99, DOI 10.1016/S1470-2045(15)00410-6; Issa JPJ, 2004, BLOOD, V103, P1635, DOI 10.1182/blood-2003-03-0687; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Juergens RA, 2011, CANCER DISCOV, V1, P598, DOI 10.1158/2159-8290.CD-11-0214; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Kantarjian H, 2006, CANCER-AM CANCER SOC, V106, P1794, DOI 10.1002/cncr.21792; Kantarjian H, 2007, BLOOD, V109, P52, DOI 10.1182/blood-2006-05-021162; Katsushima K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13616; Kim JG, 2013, CANCER LETT, V330, P33, DOI 10.1016/j.canlet.2012.11.022; Liu BD, 2015, CANCER CELL, V27, P370, DOI 10.1016/j.ccell.2015.02.004; Lu MR, 2015, SCI REP-UK, V5, DOI 10.1038/srep08735; Lue M, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.267; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Magklara A, 2001, CLIN CANCER RES, V7, P806; Man CH, 2014, BLOOD, V123, P2530, DOI 10.1182/blood-2013-07-512194; Mills JD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078480; Navada SC, 2014, J CLIN INVEST, V124, P40, DOI 10.1172/JCI69739; Niwa T, 2013, CANCER PREV RES, V6, P263, DOI 10.1158/1940-6207.CAPR-12-0369; Niwa T, 2010, CANCER RES, V70, P1430, DOI 10.1158/0008-5472.CAN-09-2755; Okochi-Takada E, 2014, ONCOGENE, V33, P2273, DOI 10.1038/onc.2013.174; Piipponen M, 2016, J INVEST DERMATOL, V136, P1701, DOI 10.1016/j.jid.2016.03.028; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Schneider BJ, 2017, CLIN CANCER RES, V23, P2673, DOI 10.1158/1078-0432.CCR-16-1896; Sekeres MA, 2017, J CLIN ONCOL, V35, P2745, DOI 10.1200/JCO.2015.66.2510; SORM F, 1968, NEOPLASMA, V15, P339; Stewart ML, 2015, CANCER RES, V75, P2897, DOI 10.1158/0008-5472.CAN-14-2860; Tsai HC, 2012, CANCER CELL, V21, P430, DOI 10.1016/j.ccr.2011.12.029; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571; Welch JS, 2016, NEW ENGL J MED, V375, P2023, DOI 10.1056/NEJMoa1605949; Wijermans P, 2000, J CLIN ONCOL, V18, P956, DOI 10.1200/JCO.2000.18.5.956; Yun S, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0233-2; Zong L, 2016, GASTRIC CANCER, V19, P361, DOI 10.1007/s10120-015-0475-2; Zouridis H, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004504	52	12	13	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2019	38	26					5281	5293		10.1038/s41388-019-0792-8	http://dx.doi.org/10.1038/s41388-019-0792-8			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IF4AX	30914798				2022-12-28	WOS:000473025300012
J	Schade, AE; Oser, MG; Nicholson, HE; DeCaprio, JA				Schade, Amy E.; Oser, Matthew G.; Nicholson, Hilary E.; DeCaprio, James A.			Cyclin D-CDK4 relieves cooperative repression of proliferation and cell cycle gene expression by DREAM and RB	ONCOGENE			English	Article							DEPENDENT KINASE 4/6; FAMILY-MEMBERS; B-MYB; COMPLEX; P130; E2F; PHOSPHORYLATION; MECHANISMS; PROMOTER; DISTINCT	The retinoblastoma protein (RB) restricts cell cycle gene expression and entry into the cell cycle. The RB-related protein p130 forms the DREAM (DP, RB-like, E2F, and MuvB) complex and contributes to repression of cell cycle-dependent genes during quiescence. Although both RB and DREAM bind and repress an overlapping set of E2F-dependent gene promoters, it remains unclear whether they cooperate to restrict cell cycle entry. To test the specific contributions of RB and DREAM, we generated RB and p130 knockout cells in primary human fibroblasts. Knockout of both p130 and RB yielded higher levels of cell cycle gene expression in GO and G1 cells compared to cells with knockout of RB alone, indicating a role for DREAM and RB in repression of cell cycle genes. We observed that RB had a dominant role in E2F-dependent gene repression during mid to late G1 while DREAM activity was more prominent during GO and early G1. Cyclin D-Cyclin-Dependent Kinase 4 (CDK4)-dependent phosphorylation of p130 occurred during early G1, and led to the release of p130 and MuvB from E2F4 and decreased p130 and MuvB binding to cell cycle promoters. Specific inhibition of CDK4 activity by palbociclib blocked DREAM complex disassembly during cell cycle entry. In addition, sensitivity to CDK4 inhibition was dependent on RB and an intact DREAM complex in both normal cells as well as in palbociclib-sensitive cancer cell lines. Although RB knockout cells were partially resistant to CDK4 inhibition, RB and p130 double knockout cells were significantly more resistant to palbociclib treatment. These results indicate that DREAM cooperates with RB in repressing E2F-dependent gene expression and cell cycle entry and supports a role for DREAM as a therapeutic target in cancer.	[Schade, Amy E.; DeCaprio, James A.] Harvard Univ, Grad Sch Arts & Sci, Div Med Sci, Program Virol, Boston, MA 02115 USA; [Schade, Amy E.; Oser, Matthew G.; Nicholson, Hilary E.; DeCaprio, James A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Oser, Matthew G.; DeCaprio, James A.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA; [Oser, Matthew G.; DeCaprio, James A.] Harvard Med Sch, Boston, MA 02115 USA	Harvard University; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	DeCaprio, JA (corresponding author), Harvard Univ, Grad Sch Arts & Sci, Div Med Sci, Program Virol, Boston, MA 02115 USA.; DeCaprio, JA (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.; DeCaprio, JA (corresponding author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.; DeCaprio, JA (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	james_decaprio@dfci.harvard.edu		Nicholson, Hilary/0000-0002-3393-3013; Schade, Amy/0000-0002-0342-8251	US Public Health Service [R01CA63113, R01CA173023, P01CA050661, F31CA220800, K08CA222657]; Harvard Landry Biology Consortium Fellowship; NATIONAL CANCER INSTITUTE [P01CA203655, K08CA222657, F31CA220800, R01CA063113, F32CA220849, R01CA173023] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR069625] Funding Source: NIH RePORTER	US Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); Harvard Landry Biology Consortium Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by US Public Health Service grants R01CA63113, R01CA173023, and P01CA050661 to JAD; F31CA220800 to AES; K08CA222657 to MGO; and a Harvard Landry Biology Consortium Fellowship to AES.	Aka JA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031532; Araki K, 2003, ONCOGENE, V22, P7632, DOI 10.1038/sj.onc.1206840; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bhattacharya S, 2003, ONCOGENE, V22, P2443, DOI 10.1038/sj.onc.1206339; Boichuk S, 2013, CANCER RES, V73, P5120, DOI 10.1158/0008-5472.CAN-13-0579; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; Burke JR, 2014, J MOL BIOL, V426, P245, DOI 10.1016/j.jmb.2013.09.031; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Canhoto AJ, 2000, ONCOGENE, V19, P5116, DOI 10.1038/sj.onc.1203893; Chicas A, 2010, CANCER CELL, V17, P376, DOI 10.1016/j.ccr.2010.01.023; Corona SP, 2018, DRUG DES DEV THER, V12, P321, DOI 10.2147/DDDT.S137783; Davis PK, 2001, BIOTECHNIQUES, V30, P1322, DOI 10.2144/01306rv01; Dick FA, 2013, NAT REV MOL CELL BIO, V14, P297, DOI 10.1038/nrm3567; Farkas T, 2002, J BIOL CHEM, V277, P26741, DOI 10.1074/jbc.M200381200; Finn RS, 2015, LANCET ONCOL, V16, P25, DOI 10.1016/S1470-2045(14)71159-3; Fischer M, 2017, CRIT REV BIOCHEM MOL, V52, P638, DOI 10.1080/10409238.2017.1360836; Fischer M, 2016, NUCLEIC ACIDS RES, V44, P6070, DOI 10.1093/nar/gkw523; Fry DW, 2004, MOL CANCER THER, V3, P1427; Gaubatz S, 2001, MOL CELL BIOL, V21, P1384, DOI 10.1128/MCB.21.4.1384-1392.2001; George J, 2015, NATURE, V524, P47, DOI 10.1038/nature14664; Guiley KZ, 2015, GENE DEV, V29, P961, DOI 10.1101/gad.257568.114; Hansen K, 2001, EMBO J, V20, P422, DOI 10.1093/emboj/20.3.422; Hesbacher S, 2016, ONCOTARGET, V7, P32956, DOI 10.18632/oncotarget.8793; Hitomi M, 1999, CURR BIOL, V9, P1075, DOI 10.1016/S0960-9822(99)80476-X; Ho VM, 2009, ONCOGENE, V28, P1393, DOI 10.1038/onc.2008.491; Jorda R, 2018, J MED CHEM, V61, P9105, DOI 10.1021/acs.jmedchem.8b00049; Lara MF, 2008, MOL CARCINOGEN, V47, P209, DOI 10.1002/mc.20376; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; Liban TJ, 2016, J MOL BIOL, V428, P3960, DOI 10.1016/j.jmb.2016.08.017; Litovchick L, 2007, MOL CELL, V26, P539, DOI 10.1016/j.molcel.2007.04.015; MacDonald J, 2017, MOL CANCER RES, V15, P371, DOI 10.1158/1541-7786.MCR-16-0323-T; Mages CFS, 2017, ELIFE, V6, DOI 10.7554/eLife.26876; Marceau AH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12301; Mayhew CN, 2005, CANCER RES, V65, P4568, DOI 10.1158/0008-5472.CAN-04-4221; Muller GA, 2014, NUCLEIC ACIDS RES, V42, P10331, DOI 10.1093/nar/gku696; Muller GA, 2012, NUCLEIC ACIDS RES, V40, P1561, DOI 10.1093/nar/gkr793; Narasimha AM, 2014, ELIFE, V3, DOI 10.7554/eLife.02872; Odajima J, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006429; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; Ortiz AB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188068; Osterloh L, 2007, EMBO J, V26, P144, DOI 10.1038/sj.emboj.7601478; Pilkinton M, 2007, ONCOGENE, V26, P7535, DOI 10.1038/sj.onc.1210562; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Rashid NN, 2016, VIROL J, V13, DOI 10.1186/s12985-015-0460-8; Ruiz S, 2004, DEVELOPMENT, V131, P2737, DOI 10.1242/dev.01148; Sadasivam S, 2012, GENE DEV, V26, P474, DOI 10.1101/gad.181933.111; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Schaffer BE, 2010, CANCER RES, V70, P3877, DOI 10.1158/0008-5472.CAN-09-4228; Schmit F, 2007, CELL CYCLE, V6, P1903, DOI 10.4161/cc.6.15.4512; Schmit F, 2009, FEBS J, V276, P5703, DOI 10.1111/j.1742-4658.2009.07261.x; Sherr CJ, 2016, CANCER DISCOV, V6, P353, DOI 10.1158/2159-8290.CD-15-0894; Takahashi Y, 2000, GENE DEV, V14, P804; Tang B, 2015, SCI REP-UK, V5, DOI 10.1038/srep13563; TOBEY RA, 1988, EXP CELL RES, V179, P400, DOI 10.1016/0014-4827(88)90279-0; Toogood PL, 2005, J MED CHEM, V48, P2388, DOI 10.1021/jm049354h; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714	56	27	28	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2019	38	25					4962	4976		10.1038/s41388-019-0767-9	http://dx.doi.org/10.1038/s41388-019-0767-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IE1KY	30833638	Green Accepted			2022-12-28	WOS:000472145900006
J	Sun, Y; Ding, YY; Guo, C; Liu, CM; Ma, P; Ma, S; Wang, Z; Liu, J; Qian, T; Ma, LY; Deng, Y; Wu, CY				Sun, Ying; Ding, Yanyan; Guo, Chen; Liu, Chengmin; Ma, Ping; Ma, Shuang; Wang, Zhe; Liu, Jie; Qian, Tao; Ma, Luyao; Deng, Yi; Wu, Chuanyue			alpha-Parvin promotes breast cancer progression and metastasis through interaction with G3BP2 and regulation of TWIST1 signaling	ONCOGENE			English	Article							INTEGRIN-LINKED KINASE; FOCAL ADHESION PROTEIN; EPITHELIAL-MESENCHYMAL TRANSITION; CH-ILKBP; TUMOR-METASTASIS; CELL-SURVIVAL; MATRIX; PHOSPHORYLATION; ACTOPAXIN; INVASION	Identification of molecular alterations driving breast cancer progression is critical for the development of effective therapy. In this study, we show that the level of alpha-parvin is elevated in triple-negative breast cancer cells. The depletion of alpha-parvin from triple-negative breast cancer cells effectively inhibits breast cancer cell growth, migration, and invasion in vitro, and tumor progression and metastasis in vivo. At the molecular level, we identify Ras-GTPase-activing protein SH3-domain-binding protein 2 (G3BP2) as an alpha-parvin-binding protein. Knockdown of alpha-parvin promotes G3BP2 interaction with TWIST1, increases ubiquitination and proteasome-dependent degradation of TWIST1, and consequently reduces the cellular level of TWIST1 and its downstream signaling. Importantly, the depletion of G3BP2 reverses the reduction in the level and signaling of TWIST1 and the suppression of breast cancer progression induced by the loss of alpha-parvin. Furthermore, the reexpression of an alpha-parvin mutant in which the G3BP2-binding site is ablated, unlike that of wild-type alpha-parvin, in alpha-parvin-deficient breast cancer cells, is unable to restore the level and signaling of TWIST1 and promote breast cancer progression. Finally, we show that protein level of alpha-parvin is highly positively correlated with that of TWIST1 in human triple-negative breast cancer patients. Our studies reveal a novel signaling pathway consisting of alpha-parvin, G3BP2, and TWIST1 that regulates breast cancer progression and metastasis, and suggest that the activation of this signaling pathway is a key factor for driving the progression and poor clinical outcome of human ER-negative breast cancer.	[Sun, Ying; Ding, Yanyan; Guo, Chen; Liu, Chengmin; Ma, Ping; Ma, Shuang; Wang, Zhe; Liu, Jie; Qian, Tao; Ma, Luyao; Deng, Yi] Southern Univ Sci & Technol, Dept Biol, Guangdong Prov Key Lab Cell Microenvironm & Dis R, Shenzhen 518055, Peoples R China; [Sun, Ying; Ding, Yanyan; Guo, Chen; Liu, Chengmin; Ma, Ping; Ma, Shuang; Wang, Zhe; Liu, Jie; Qian, Tao; Ma, Luyao; Deng, Yi] Southern Univ Sci & Technol, Shenzhen Key Lab Cell Microenvironm, Shenzhen 518055, Peoples R China; [Wu, Chuanyue] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15260 USA; [Wu, Chuanyue] Univ Pittsburgh, Canc Inst, Pittsburgh, PA 15260 USA	Southern University of Science & Technology; Southern University of Science & Technology; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Sun, Y (corresponding author), Southern Univ Sci & Technol, Dept Biol, Guangdong Prov Key Lab Cell Microenvironm & Dis R, Shenzhen 518055, Peoples R China.; Sun, Y (corresponding author), Southern Univ Sci & Technol, Shenzhen Key Lab Cell Microenvironm, Shenzhen 518055, Peoples R China.; Wu, CY (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15260 USA.; Wu, CY (corresponding author), Univ Pittsburgh, Canc Inst, Pittsburgh, PA 15260 USA.	suny@sustc.edu.cn; carywu@pitt.edu	ding, yy/HHS-9589-2022; Sun, Ying/F-9124-2019; Liu, Chengmin/GRO-0365-2022; MA, ShuangYue/GWV-0339-2022	Deng, Yi/0000-0003-1378-015X; Liu, Chengmin/0000-0002-0882-582X	Chinese Ministry of Science and Technology [2016YFC1302100]; National Natural Science Foundation of China [81772983, 81430068, 31471311]; Natural Science Foundation of Guangdong Province [2017B030301018]; Shenzhen Innovation Committee of Science and Technology, China [JCYJ20170817104854302, ZDSYS20140509142721429, JCYJ20150831142427959]	Chinese Ministry of Science and Technology(Ministry of Science and Technology, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Shenzhen Innovation Committee of Science and Technology, China	We thank Dr. Ruijun Tian of the Department of Chemistry, Southern University of Science and Technology, for help with nano LC-MS/MS analyses, Dr. Z-M Yuan (Harvard School of Public Health) for the Flag-G3BP2a construct, and Drs. Jason D. Weber (Washington University) and Yandong Zhang (Southern University of Science and Technology) for pLVX-AcGFP1-N1 and pLVX-IRES-Hyg vectors. This work was supported by the Chinese Ministry of Science and Technology (2016YFC1302100), the National Natural Science Foundation of China (81772983, 81430068, and 31471311), the Natural Science Foundation of Guangdong Province (2017B030301018), and the Shenzhen Innovation Committee of Science and Technology, China (JCYJ20170817104854302, ZDSYS20140509142721429, and JCYJ20150831142427959).	Ashikari D, 2017, ONCOGENE, V36, P6272, DOI 10.1038/onc.2017.225; Attwell S, 2003, MOL BIOL CELL, V14, P4813, DOI 10.1091/mbc.E03-05-0308; Bikkavilli RK, 2012, J CELL SCI, V125, P2446, DOI 10.1242/jcs.100933; Chen WD, 2016, ANAL CHEM, V88, P4864, DOI 10.1021/acs.analchem.6b00631; Cheng GZ, 2008, J BIOL CHEM, V283, P14665, DOI 10.1074/jbc.M707429200; Cheng GZ, 2008, CANCER RES, V68, P957, DOI 10.1158/0008-5472.CAN-07-5067; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239; Clarke DM, 2004, J CELL BIOL, V166, P901, DOI 10.1083/jcb.200404024; Ellsworth RE, 2017, SEMIN CELL DEV BIOL, V64, P65, DOI 10.1016/j.semcdb.2016.08.025; Fu JJ, 2011, CELL RES, V21, P275, DOI 10.1038/cr.2010.118; Fukuda T, 2003, J BIOL CHEM, V278, P51324, DOI 10.1074/jbc.M309122200; Fukuda T, 2003, J CELL BIOL, V160, P1001, DOI 10.1083/jcb.200212113; Guo L, 2002, FASEB J, V16, P1298, DOI 10.1096/fj.02-0089fje; Gupta N, 2017, P NATL ACAD SCI USA, V114, P1033, DOI 10.1073/pnas.1525387114; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hu W, 2017, ELIFE, V6, DOI 10.7554/eLife.26057; Huang AH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118530; Irvine K, 2004, INT J DEV BIOL, V48, P1065, DOI 10.1387/ijdb.041893ki; Ito M, 2014, BREAST CANCER RES TR, V144, P59, DOI 10.1007/s10549-014-2859-0; Jin X, 2015, BREAST CANCER-BASIC, V9, P23, DOI 10.4137/BCBCR.S25460; Kim MM, 2007, ONCOGENE, V26, P4209, DOI 10.1038/sj.onc.1210212; Koren S, 2015, MOL CELL, V60, P537, DOI 10.1016/j.molcel.2015.10.031; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; LaLonde DP, 2005, J BIOL CHEM, V280, P21680, DOI 10.1074/jbc.m500752200; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Legate KR, 2006, NAT REV MOL CELL BIO, V7, P20, DOI 10.1038/nrm1789; Li CW, 2016, CANCER RES, V76, P1451, DOI 10.1158/0008-5472.CAN-15-1941; Li QQ, 2009, CLIN CANCER RES, V15, P2657, DOI 10.1158/1078-0432.CCR-08-2372; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Martin TA, 2005, ANN SURG ONCOL, V12, P488, DOI 10.1245/ASO.2005.04.010; Matsuki H, 2013, GENES CELLS, V18, P135, DOI 10.1111/gtc.12023; Mironchik Y, 2005, CANCER RES, V65, P10801, DOI 10.1158/0008-5472.CAN-05-0712; Moon S, 2014, SCI REP-UK, V4, DOI 10.1038/srep04376; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Nikolopoulos SN, 2000, J CELL BIOL, V151, P1435, DOI 10.1083/jcb.151.7.1435; Olski TM, 2001, J CELL SCI, V114, P525; Pignatelli J, 2012, J BIOL CHEM, V287, P37309, DOI 10.1074/jbc.M112.385229; Prigent M, 2000, J BIOL CHEM, V275, P36441, DOI 10.1074/jbc.M004751200; Qin L, 2009, CANCER RES, V69, P3819, DOI 10.1158/0008-5472.CAN-08-4389; Qin Q, 2012, CELL RES, V22, P90, DOI 10.1038/cr.2011.144; Rivenbark AG, 2013, AM J PATHOL, V183, P1113, DOI 10.1016/j.ajpath.2013.08.002; Sepulveda JL, 2006, CELL MOL LIFE SCI, V63, P25, DOI 10.1007/s00018-005-5355-1; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Sun Y, 2017, J AM SOC NEPHROL, V28, P3545, DOI 10.1681/ASN.2016091021; Sun Y, 2012, J CELL SCI, V125, P4507, DOI 10.1242/jcs.105023; Tu YZ, 2001, J CELL BIOL, V153, P585, DOI 10.1083/jcb.153.3.585; Turashvili G, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00227; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Watson MA, 2007, CLIN CANCER RES, V13, P5001, DOI 10.1158/1078-0432.CCR-07-0024; Wei SC, 2015, NAT CELL BIOL, V17, P678, DOI 10.1038/ncb3157; Wu CY, 2004, BBA-MOL CELL RES, V1692, P55, DOI 10.1016/j.bbamcr.2004.01.006; Xu Y, 2013, AM J PATHOL, V183, P1281, DOI 10.1016/j.ajpath.2013.06.021; Xu YX, 2017, P NATL ACAD SCI USA, V114, P11494, DOI 10.1073/pnas.1618091114; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Zhang YJ, 2004, J BIOL CHEM, V279, P41695, DOI 10.1074/jbc.M401563200; Zhang YJ, 2002, J CELL SCI, V115, P4777, DOI 10.1242/jcs.00166	57	7	7	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2019	38	24					4856	4874		10.1038/s41388-019-0762-1	http://dx.doi.org/10.1038/s41388-019-0762-1			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IC7ND	30804457				2022-12-28	WOS:000471160500014
J	Lin, T; Lin, TC; McGrail, DJ; Bhupal, PK; Ku, YH; Zhang, W; Meng, LJ; Lin, SY; Peng, G; Tsai, RYL				Lin, Tao; Lin, Tsung-Chin; McGrail, Daniel J.; Bhupal, Parnit K.; Ku, Yi-Hsuan; Zhang, Wen; Meng, Lingjun; Lin, Shiaw-Yih; Peng, Guang; Tsai, Robert Y. L.			Nucleostemin reveals a dichotomous nature of genome maintenance in mammary tumor progression	ONCOGENE			English	Article							STEM-CELLS; SOMATIC MUTATIONS; SELF-RENEWAL; REPAIR; DAMAGE; REPLICATION; INHIBITION; EXPRESSION; LANDSCAPE; MAINTAINS	A defective homologous recombination (HR) repair program increases tumor incidence as well as providing a survival advantage in patients with breast and ovarian cancers. Here we hypothesize that the tumor-promoting side of genome maintenance programs may be contributed by a self-renewal protein, nucleostemin (NS). To address this issue, we established its functional importance in mammary tumor progression in mice and showed that mammary tumor cells become highly susceptible to replicative DNA damage following NS depletion and are protected from hydroxyurea-induced damage by NS overexpression. Breast cancer cells with basal-like characters display more reliance on NS for genome maintenance than those with luminal characters. Mechanistically, NS-deficient cells demonstrate a significantly reduced HR repair activity. TCGA analyses of human breast cancers revealed that NS is co-enriched positively with HR repair proteins and that high NS expression correlates with low HR defects and predicts poor progression-free survival and resistance to knockdown of cell-cycle checkpoint genes in triple-negative/basal-like breast cancers. This work indicates that NS constitutes a tumor-promoting genome maintenance program required for mammary tumor progression.	[Lin, Tao; Lin, Tsung-Chin; Bhupal, Parnit K.; Ku, Yi-Hsuan; Zhang, Wen; Meng, Lingjun; Tsai, Robert Y. L.] Texas A&M Univ, Inst Biosci & Technol, Houston, TX 77030 USA; [McGrail, Daniel J.; Lin, Shiaw-Yih] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Peng, Guang] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA; [Tsai, Robert Y. L.] Texas A&M Univ, Dept Mol & Cellular Med, College Stn, TX 77843 USA	Texas A&M University System; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Texas A&M University System; Texas A&M University College Station	Tsai, RYL (corresponding author), Texas A&M Univ, Inst Biosci & Technol, Houston, TX 77030 USA.; Tsai, RYL (corresponding author), Texas A&M Univ, Dept Mol & Cellular Med, College Stn, TX 77843 USA.	rtsai@ibt.tamhsc.edu	McGrail, Daniel/F-3967-2014	McGrail, Daniel/0000-0002-6669-6069; Tsai, Robert/0000-0002-8357-0812	NCI-PHS grants [R01 CA113750, R03 CA201988, R21AG052006]; National Science Council Postdoctoral Fellowship (ROC); G. Komen [PDF17483544]; CPRIT [RP140456]; NATIONAL CANCER INSTITUTE [R03CA201988] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R21AG052006] Funding Source: NIH RePORTER	NCI-PHS grants; National Science Council Postdoctoral Fellowship (ROC); G. Komen; CPRIT; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Margie Moczygemba at the IBT Flow Cytometry Core for her help in cell cycle analysis. This work was supported by NCI-PHS grants (R01 CA113750, R03 CA201988, R21AG052006) to RYT, National Science Council Postdoctoral Fellowship (ROC) to TCL, G. Komen PDF17483544 to DJM, and CPRIT RP140456 to GP.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Baddoo M, 2003, J CELL BIOCHEM, V89, P1235, DOI 10.1002/jcb.10594; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bennardo N, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000683; Bennardo N, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000110; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Dai MS, 2008, MOL CELL BIOL, V28, P4365, DOI 10.1128/MCB.01662-07; ETIENNE MC, 1989, BRIT J CANCER, V60, P30, DOI 10.1038/bjc.1989.214; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Graeser M, 2010, CLIN CANCER RES, V16, P6159, DOI 10.1158/1078-0432.CCR-10-1027; Gunn Amanda, 2012, Methods Mol Biol, V920, P379, DOI 10.1007/978-1-61779-998-3_27; Gunn A, 2011, J BIOL CHEM, V286, P42470, DOI 10.1074/jbc.M111.309252; Hsu JK, 2012, J CELL BIOL, V197, P613, DOI 10.1083/jcb.201109038; Huang G, 2015, CELL DEATH DISCOV, V1, DOI 10.1038/cddiscovery.2015.60; Knijnenburg TA, 2018, CELL REP, V23, P239, DOI 10.1016/j.celrep.2018.03.076; Kobayashi T, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-215; Konstantinopoulos PA, 2015, CANCER DISCOV, V5, P1137, DOI 10.1158/2159-8290.CD-15-0714; Lin T, 2014, J CELL SCI, V127, P2302, DOI 10.1242/jcs.143842; Lin T, 2013, HEPATOLOGY, V58, P2176, DOI 10.1002/hep.26600; Lin T, 2010, CANCER RES, V70, P9444, DOI 10.1158/0008-5472.CAN-10-2159; Lindahl T, 2000, COLD SPRING HARB SYM, V65, P127, DOI 10.1101/sqb.2000.65.127; LOEB LA, 1974, CANCER RES, V34, P2311; Meng LJ, 2013, P NATL ACAD SCI USA, V110, P11415, DOI 10.1073/pnas.1301672110; Meng LJ, 2008, J CELL SCI, V121, P4037, DOI 10.1242/jcs.037952; Mertins P, 2016, NATURE, V534, P55, DOI 10.1038/nature18003; Michel B, 2004, P NATL ACAD SCI USA, V101, P12783, DOI 10.1073/pnas.0401586101; Nik-Zainal S, 2016, NATURE, V534, P47, DOI 10.1038/nature17676; O'Connell BC, 2003, J BIOL CHEM, V278, P12563, DOI 10.1074/jbc.M210462200; Peng G, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4361; Phillips TM, 2006, JNCI-J NATL CANCER I, V98, P1777, DOI 10.1093/jnci/djj495; Pritchard CC, 2016, NEW ENGL J MED, V375, P443, DOI 10.1056/NEJMoa1603144; Qu J, 2012, J CELL BIOL, V197, P731, DOI 10.1083/jcb.201103071; Seashore-Ludlow B, 2015, CANCER DISCOV, V5, P1210, DOI 10.1158/2159-8290.CD-15-0235; Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610; Tsai RYL, 2016, CELL MOL LIFE SCI, V73, P1803, DOI 10.1007/s00018-016-2152-y; Tsai RYL, 2014, J CELL SCI, V127, P3885, DOI 10.1242/jcs.154054; Tsai RYL, 2011, PROTEIN REV, V15, P301, DOI 10.1007/978-1-4614-0514-6_13; Tsai RYL, 2009, INT J BIOCHEM CELL B, V41, P2122, DOI 10.1016/j.biocel.2009.05.020; Tsai RYL, 2002, GENE DEV, V16, P2991, DOI 10.1101/gad.55671; Tubbs A, 2017, CELL, V168, DOI 10.1016/j.cell.2017.01.002; Watkins JA, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3670; Wiedemeyer WR, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00034; Zhu QB, 2006, MOL CELL BIOL, V26, P9279, DOI 10.1128/MCB.00724-06; Zwolinska AK, 2012, ONCOGENE, V31, P3311, DOI 10.1038/onc.2011.507; 2010, CELL CYCLE, V9, P3227, DOI DOI 10.4161/CC.9.16.12605	47	8	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2019	38	20					3919	3931		10.1038/s41388-019-0710-0	http://dx.doi.org/10.1038/s41388-019-0710-0			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HY3OI	30692636	Green Accepted			2022-12-28	WOS:000468035600011
J	Fletcher, JS; Springer, MG; Choi, K; Jousma, E; Rizvi, TA; Dombi, E; Kim, MO; Wu, JQ; Ratner, N				Fletcher, Jonathan S.; Springer, Mitchell G.; Choi, Kwangmin; Jousma, Edwin; Rizvi, Tilat A.; Dombi, Eva; Kim, Mi-Ok; Wu, Jianqiang; Ratner, Nancy			STAT3 inhibition reduces macrophage number and tumor growth in neurofibroma	ONCOGENE			English	Article							SCHWANN-CELLS; TARGETING STAT3; BONE-MARROW; NF1 LOSS; PLEXIFORM; ROLES; CCR2; ANGIOGENESIS; RECRUITMENT; DIAGNOSIS	Plexiform neurofibroma, a benign peripheral nerve tumor, is associated with the biallelic loss of function of the NF1 tumor suppressor in Schwann cells. Here, we show that FLLL32, a small molecule inhibitor of JAK2/STAT3 signaling, reduces neurofibroma growth in mice with conditional, biallelic deletion of Nf1 in the Schwann cell lineage. FLLL32 treatment or Stat3 deletion in tumor cells reduced inflammatory cytokine expression and tumor macrophage numbers in neurofibroma. Although STAT3 inhibition downregulated the chemokines CCL2 and CCL12, which can signal through CCR2 to recruit macrophages to peripheral nerves, deletion of Ccr2 did not improve survival or reduce macrophage numbers in neurofibroma-bearing mice. Interestingly, Iba1+; F4/80+;CD11b+ macrophages accounted for similar to 20-40% of proliferating cells in untreated tumors. FLLL32 suppressed macrophage proliferation, implicating STAT3-dependent, local proliferation in neurofibroma macrophage accumulation, and decreased Schwann cell proliferation and increased Schwann cell death. The functions of STAT3 signaling in neurofibroma Schwann cells and macrophages, and its relevance as a therapeutic target in neurofibroma, merit further investigation.	[Fletcher, Jonathan S.; Springer, Mitchell G.; Choi, Kwangmin; Jousma, Edwin; Rizvi, Tilat A.; Wu, Jianqiang; Ratner, Nancy] Univ Cincinnati, Div Expt Hematol & Canc Biol, Cincinnati Childrens Hosp, Dept Pediat,Coll Med, 3333 Burnet Ave, Cincinnati, OH 45229 USA; [Fletcher, Jonathan S.] Univ Cincinnati, Coll Med, Grad Program Immunol, Cincinnati, OH 45229 USA; [Dombi, Eva] NCI, Ctr Canc Res, Bldg 10,Room 1-5750, Bethesda, MD 20892 USA; [Kim, Mi-Ok] UCSF Helen Diller Family Comprehens Canc Ctr, Dept Epidemiol & Biostat, UCS F Box 0128, San Francisco, CA 94143 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Wu, JQ; Ratner, N (corresponding author), Univ Cincinnati, Div Expt Hematol & Canc Biol, Cincinnati Childrens Hosp, Dept Pediat,Coll Med, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Jianqiang.Wu@cchmc.org; Nancy.Ratner@cchmc.org		RATNER, NANCY/0000-0001-5030-9354; Kim, Mi-Ok/0000-0002-7712-3653	DOD [W81XWH-11-1-0057, W81XWH-11-1-0259]; Neurofibromatosis Therapeutic Acceleration Program (NTAP) at Johns Hopkins University;  [R01 NS28840];  [5 F30 NS096796]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F30NS096796, R01NS028840] Funding Source: NIH RePORTER	DOD(United States Department of Defense); Neurofibromatosis Therapeutic Acceleration Program (NTAP) at Johns Hopkins University; ; ; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank James Fuchs and Jiayuh Lin (The Ohio State University) for providing FLLL32, and the Imaging Resource Center at Cincinnati Children's Hospital Medical Center (R. Scott Dunn) for MRI Imaging. This work was supported by R01 NS28840 (to NR and JW), and DOD W81XWH-11-1-0057 (to NR), DOD W81XWH-11-1-0259 (to JW), and RNA-Seq by an Agreement with the Neurofibromatosis Therapeutic Acceleration Program (NTAP) at Johns Hopkins University (to NR). JSF was the recipient of 5 F30 NS096796.	Beert E, 2012, GENE CHROMOSOME CANC, V51, P852, DOI 10.1002/gcc.21969; Bournazou Eirini, 2013, JAKSTAT, V2, pe23828, DOI 10.4161/jkst.23828; Campana L, 2018, J IMMUNOL, V200, P1169, DOI 10.4049/jimmunol.1701247; Choi K, 2017, SCI REP-UK, V7, DOI 10.1038/srep43315; Cortez-Retamozo V, 2012, P NATL ACAD SCI USA, V109, P2491, DOI 10.1073/pnas.1113744109; Ferner RE, 2007, J MED GENET, V44, P81, DOI 10.1136/jmg.2006.045906; Ferner RE, 2013, HAND CLINIC, V115, P939, DOI 10.1016/B978-0-444-52902-2.00053-9; Furtek SL, 2016, ACS CHEM BIOL, V11, P308, DOI 10.1021/acschembio.5b00945; Gauri P, 2016, HISTOPATHOLOGY, V70, P946; Gazzaniga S, 2007, J INVEST DERMATOL, V127, P2031, DOI 10.1038/sj.jid.5700827; Herrmann A, 2010, CANCER RES, V70, P7455, DOI 10.1158/0008-5472.CAN-10-0736; Hiatt KK, 2001, J BIOL CHEM, V276, P7240, DOI 10.1074/jbc.M009202200; KIM HA, 1995, ONCOGENE, V11, P325; Kujawski M, 2008, J CLIN INVEST, V118, P3367, DOI 10.1172/JCI35213; Lederle W, 2011, INT J CANCER, V128, P2803, DOI 10.1002/ijc.25621; Li XG, 2017, GUT, V66, P157, DOI 10.1136/gutjnl-2015-310514; Lin L, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-217; Miller SJ, 2009, EMBO MOL MED, V1, P236, DOI 10.1002/emmm.200900027; Muller M, 2008, GLIA, V56, P1005, DOI 10.1002/glia.20674; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Oberlander M, 2010, MOL CELL NEUROSCI, V45, P59, DOI 10.1016/j.mcn.2010.05.009; Pemov A, 2017, ONCOGENE, V36, P3168, DOI 10.1038/onc.2016.464; Prada CE, 2013, ACTA NEUROPATHOL, V125, P159, DOI 10.1007/s00401-012-1056-7; Prada CE, 2012, J PEDIATR-US, V160, P461, DOI 10.1016/j.jpeds.2011.08.051; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Roca H, 2009, J BIOL CHEM, V284, P34342, DOI 10.1074/jbc.M109.042671; Saederup N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013693; Serbina NV, 2006, NAT IMMUNOL, V7, P311, DOI 10.1038/ni1309; Sherman LS, 2000, J BIOL CHEM, V275, P30740, DOI 10.1074/jbc.M001702200; Siebert H, 2000, J NEUROIMMUNOL, V110, P177, DOI 10.1016/S0165-5728(00)00343-X; Staser K, 2010, BLOOD, V116, P157, DOI 10.1182/blood-2009-09-242875; Tacke F, 2007, J CLIN INVEST, V117, P185, DOI 10.1172/JCI28549; Tsou CL, 2007, J CLIN INVEST, V117, P902, DOI 10.1172/JCI29919; Wu J, 2017, ONCOGENE, V36, P1669, DOI 10.1038/onc.2016.386; Wu JQ, 2008, CANCER CELL, V13, P105, DOI 10.1016/j.ccr.2007.12.027; Wu JQ, 2016, CELL REP, V14, P1979, DOI 10.1016/j.celrep.2016.01.074; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zhang J, 2010, JNCI-J NATL CANCER I, V102, P522, DOI 10.1093/jnci/djq044; Zhu Y, 2002, SCIENCE, V296, P920, DOI 10.1126/science.1068452	39	26	27	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2019	38	15					2876	2884		10.1038/s41388-018-0600-x	http://dx.doi.org/10.1038/s41388-018-0600-x			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HS8LQ	30542122	Green Accepted			2022-12-28	WOS:000464121600015
J	Zhang, JX; Tan, P; Guo, L; Gong, J; Ma, JJ; Li, J; Lee, M; Fang, SH; Jing, J; Johnson, G; Sun, DQ; Cao, WM; Dashwood, R; Han, L; Zhou, YB; Dong, WG; Huang, Y				Zhang, Jixiang; Tan, Peng; Guo, Lei; Gong, Jing; Ma, Jingjing; Li, Jia; Lee, Minjung; Fang, Shaohai; Jing, Ji; Johnson, Gavin; Sun, Deqiang; Cao, Wen-ming; Dashwood, Roderick; Han, Leng; Zhou, Yubin; Dong, Wei-Guo; Huang, Yun			p53-dependent autophagic degradation of TET2 modulates cancer therapeutic resistance	ONCOGENE			English	Article							DNA-DAMAGE; STEM-CELLS; P53; 5-HYDROXYMETHYLCYTOSINE; 5-METHYLCYTOSINE; ANTICANCER; MUTATIONS; MOUSE; REPLICATION; METHYLATION	Tumor cells with p53 inactivation frequently exhibit chemotherapy resistance, which poses a long-standing challenge to cancer treatment. Here we unveiled a previously unrecognized role of TET2 in mediating p53-loss induced chemotherapy resistance in colon cancer. Deletion of TET2 in p53-null colon cancer cells enhanced DNA damage and restored chemotherapy sensitivity. By taking a two-pronged approach that combined pharmacological inhibition with genetic depletion, we discovered that p53 destabilized TET2 at the protein level by promoting its autophagic degradation. At the molecular level, we further revealed a physical association between TET2 and p53 that facilitated the nucleoplasmic shuttling of TET2, as well as its recruitment to the autophagosome for degradation. Our study has unveiled a functional interplay between TET2 and p53 during anti-cancer therapy. Our findings establish the rationale for targeting TET2 to overcome chemotherapy resistance associated with mutant p53 tumors.	[Zhang, Jixiang; Guo, Lei; Li, Jia; Lee, Minjung; Fang, Shaohai; Johnson, Gavin; Sun, Deqiang; Dashwood, Roderick; Huang, Yun] Texas A&M Univ, Ctr Epigenet & Dis Prevent, Inst Biosci & Technol, Houston, TX 77030 USA; [Zhang, Jixiang; Ma, Jingjing; Dong, Wei-Guo] Wuhan Univ, Dept Gastroenterol, Renmin Hosp, Wuhan 430060, Hubei, Peoples R China; [Tan, Peng; Guo, Lei; Jing, Ji; Zhou, Yubin] Texas A&M Univ, Inst Biosci & Technol, Ctr Translat Canc Res, Houston, TX 77030 USA; [Gong, Jing; Han, Leng] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Cao, Wen-ming] Zhejiang Canc Hosp, Dept Breast Med Oncol, Hangzhou 310022, Zhejiang, Peoples R China; [Dashwood, Roderick; Huang, Yun] Texas A&M Univ, Coll Med, Dept Mol & Cellular Med, College Stn, TX 77843 USA; [Zhou, Yubin] Texas A&M Univ, Coll Med, Dept Med Physiol, Temple, TX 76504 USA	Texas A&M University System; Wuhan University; Texas A&M University System; University of Texas System; University of Texas Health Science Center Houston; Zhejiang Cancer Hospital; Texas A&M University System; Texas A&M University College Station; Texas A&M University System	Huang, Y (corresponding author), Texas A&M Univ, Ctr Epigenet & Dis Prevent, Inst Biosci & Technol, Houston, TX 77030 USA.; Dong, WG (corresponding author), Wuhan Univ, Dept Gastroenterol, Renmin Hosp, Wuhan 430060, Hubei, Peoples R China.; Zhou, YB (corresponding author), Texas A&M Univ, Inst Biosci & Technol, Ctr Translat Canc Res, Houston, TX 77030 USA.; Huang, Y (corresponding author), Texas A&M Univ, Coll Med, Dept Mol & Cellular Med, College Stn, TX 77843 USA.; Zhou, YB (corresponding author), Texas A&M Univ, Coll Med, Dept Med Physiol, Temple, TX 76504 USA.	yzhou@ibt.tamhsc.edu; dwg@whu.edu.cn; yun.huang@ibt.tamhsc.edu	Tan, Peng/HGD-6812-2022; Dashwood, Roderick/AAF-2025-2020; Han, Leng/HCH-3491-2022; Zhou, Yubin/D-4748-2011; Tan, Peng/ABD-8190-2020	Han, Leng/0000-0002-7380-2640; Zhou, Yubin/0000-0001-7962-0517; sun, deqiang/0000-0002-5806-7289; Fang, Shaohai/0000-0003-3940-9586; Tan, Peng/0000-0001-6992-9000; Cao, Wen-Ming/0000-0002-5644-3156	Cancer Prevention and Research Institute of Texas [RR140053, RP170660, RR150085]; American Heart Association [16IRG27250155]; John S. Dunn Foundation; Center for Translational Environmental Health Research (CTEHR); National Institute of Health [R01HL134780, R01GM112003]; Welch Foundation [BE-1913]; American Cancer Society [RSG-18-043-01-LIB, RSG-16-215-01-TBE]; Texas AM University; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL134780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM112003] Funding Source: NIH RePORTER	Cancer Prevention and Research Institute of Texas; American Heart Association(American Heart Association); John S. Dunn Foundation; Center for Translational Environmental Health Research (CTEHR); National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Welch Foundation(The Welch Foundation); American Cancer Society(American Cancer Society); Texas AM University; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by grants from Cancer Prevention and Research Institute of Texas (RR140053 to YH, to RP170660 to YZ, RR150085 to LH), the Innovation Award from American Heart Association (16IRG27250155 to YH), the John S. Dunn Foundation Collaborative Research Award (to YH), the Center for Translational Environmental Health Research (CTEHR) Seed Grant to YH, the National Institute of Health grants (R01HL134780 to YH, R01GM112003 to YZ), the Welch Foundation (BE-1913 to YZ), the American Cancer Society (RSG-18-043-01-LIB to YH, RSG-16-215-01-TBE to YZ), and by an allocation from the Texas A&M University start-up funds (YH).	Abdel-Wahab O, 2009, BLOOD, V114, P144, DOI 10.1182/blood-2009-03-210039; An J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10071; Bejar R, 2012, J CLIN ONCOL, V30, P3376, DOI 10.1200/JCO.2011.40.7379; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Bieging KT, 2014, NAT REV CANCER, V14, P359, DOI 10.1038/nrc3711; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Boyer J, 2004, CLIN CANCER RES, V10, P2158, DOI 10.1158/1078-0432.CCR-03-0362; Delhommeau F, 2009, NEW ENGL J MED, V360, P2289, DOI 10.1056/NEJMoa0810069; Dou ZX, 2015, NATURE, V527, P105, DOI 10.1038/nature15548; Dunkern TR, 2003, DNA REPAIR, V2, P49, DOI 10.1016/S1568-7864(02)00185-4; Guo JY, 2013, CELL, V155, P1216, DOI 10.1016/j.cell.2013.11.019; Hashimoto H, 2012, NUCLEIC ACIDS RES, V40, P4841, DOI 10.1093/nar/gks155; He YF, 2011, SCIENCE, V333, P1303, DOI 10.1126/science.1210944; Hientz K, 2017, ONCOTARGET, V8, P8921, DOI 10.18632/oncotarget.13475; Huang Y, 2014, TRENDS GENET, V30, P464, DOI 10.1016/j.tig.2014.07.005; Inoue A, 2011, SCIENCE, V334, P194, DOI 10.1126/science.1212483; Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597; Jiang DW, 2017, EMBO REP, V18, P781, DOI 10.15252/embr.201643179; Kafer GR, 2016, CELL REP, V14, P1283, DOI 10.1016/j.celrep.2016.01.035; Ko M, 2013, NATURE, V497, P122, DOI 10.1038/nature12052; Ko M, 2010, NATURE, V468, P839, DOI 10.1038/nature09586; Koh KP, 2011, CELL STEM CELL, V8, P200, DOI 10.1016/j.stem.2011.01.008; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lemonnier F, 2012, BLOOD, V120, P1466, DOI 10.1182/blood-2012-02-408542; Lian CG, 2012, CELL, V150, P1135, DOI 10.1016/j.cell.2012.07.033; Liang SH, 2001, EUR J BIOCHEM, V268, P2779, DOI 10.1046/j.1432-1327.2001.02227.x; Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Nakagawa T, 2015, MOL CELL, V57, P247, DOI 10.1016/j.molcel.2014.12.002; Papaemmanuil E, 2011, NEW ENGL J MED, V365, P1384, DOI 10.1056/NEJMoa1103283; Pommier Y, 2010, CHEM BIOL, V17, P421, DOI 10.1016/j.chembiol.2010.04.012; Quivoron C, 2011, CANCER CELL, V20, P25, DOI 10.1016/j.ccr.2011.06.003; Shetzer Y, 2014, CARCINOGENESIS, V35, P1196, DOI 10.1093/carcin/bgu073; Tacar O, 2013, J PHARM PHARMACOL, V65, P157, DOI 10.1111/j.2042-7158.2012.01567.x; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Tefferi A, 2009, LEUKEMIA, V23, P1343, DOI 10.1038/leu.2009.59; Thienpont B, 2016, NATURE, V537, P63, DOI 10.1038/nature19081; Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691; Wang Y, 2014, CELL REP, V6, P278, DOI 10.1016/j.celrep.2013.12.031; White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262; Yang H, 2013, ONCOGENE, V32, P663, DOI 10.1038/onc.2012.67; Yeung TM, 2010, P NATL ACAD SCI USA, V107, P3722, DOI 10.1073/pnas.0915135107; Zhang YW, 2017, MOL CELL, V65, P323, DOI 10.1016/j.molcel.2016.12.013	44	13	14	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2019	38	11					1905	1919		10.1038/s41388-018-0524-5	http://dx.doi.org/10.1038/s41388-018-0524-5			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HO7XX	30390073	Green Accepted			2022-12-28	WOS:000461164400009
J	Chen, D; Ning, Z; Chen, H; Lu, C; Liu, XL; Xia, T; Qi, H; Wang, W; Ling, T; Guo, X; Tekcham, DS; Liu, XM; Liu, J; Wang, AM; Yan, Q; Liu, JW; Tan, G; Piao, HL				Chen, Di; Ning, Zhen; Chen, Huan; Lu, Chang; Liu, Xiaolong; Xia, Tian; Qi, Huan; Wang, Wen; Ling, Ting; Guo, Xin; Tekcham, Dinesh Singh; Liu, Xiumei; Liu, Jing; Wang, Aman; Yan, Qiu; Liu, Ji-Wei; Tan, Guang; Piao, Hai-long			An integrative pan-cancer analysis of biological and clinical impacts underlying ubiquitin-specific-processing proteases	ONCOGENE			English	Article							DEUBIQUITINATING ENZYME; SIGNALING PATHWAY; INHIBITION; KINASE; DEGRADATION; ACTIVATION; HAUSP; TOOL; P53	Ubiquitin-specific-processing proteases (USPs), the largest deubiquitinating enzyme (DUB) subfamily, play critical roles in cancer. However, clinical utility of USPs is hindered by limited knowledge about their varied and substrate-dependent actions. Here, we performed a comprehensive investigation on pan-cancer impacts of USPs by integrating multi-omics data and annotated data resources, especially a deubiquitination network. Meaningful insights into the roles of 54 USPs in 29 types of cancers were generated. Although rare mutations were observed, a majority of USPs exhibited significant expressional alterations, prognostic impacts and strong correlations with cancer hallmark pathways. Notably, from our DUB-substrate interaction prediction model, additional USP-substrate interactions (USIs) were recognized to complement knowledge gap about cancer-relevant USIs. Intriguingly, expression signatures of the USIs revealed clinically meaningful cancer subtypes, where key USPs and substrates cooperatively contributed to significant prognosis differences among subtypes. Overall, this investigation provides a valuable resource to assist mechanism research and clinical utility about USPs.	[Chen, Di; Ning, Zhen; Chen, Huan; Lu, Chang; Liu, Xiaolong; Xia, Tian; Qi, Huan; Wang, Wen; Ling, Ting; Guo, Xin; Tekcham, Dinesh Singh; Liu, Xiumei; Liu, Jing; Piao, Hai-long] Chinese Acad Sci, Dalian Inst Chem Phys, Sci Res Ctr Translat Med, CAS Key Lab Separat Sci Analyt Chem, Dalian 116023, Peoples R China; [Ning, Zhen; Lu, Chang; Guo, Xin; Wang, Aman; Yan, Qiu; Liu, Ji-Wei; Tan, Guang] Dalian Med Univ, Affiliated Hosp 2, Dalian 116000, Peoples R China	Chinese Academy of Sciences; Dalian Institute of Chemical Physics, CAS; Dalian Medical University	Piao, HL (corresponding author), Chinese Acad Sci, Dalian Inst Chem Phys, Sci Res Ctr Translat Med, CAS Key Lab Separat Sci Analyt Chem, Dalian 116023, Peoples R China.; Liu, JW; Tan, G (corresponding author), Dalian Med Univ, Affiliated Hosp 2, Dalian 116000, Peoples R China.	jiweiliudl@126.com; tanguangdl@126.com; hpiao@dicp.ac.cn		Liu, Xiaolong/0000-0003-4384-0360; Chen, Di/0000-0002-2181-4703	National Natural Science Foundation of China [81672440, 31701156, 81502024, 81572881]; China Postdoctoral Science Foundation [2017M611281]; Innovation program of science and research from the DICP, CAS [DICP TMSR201601, DICP ZZBS201803]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Innovation program of science and research from the DICP, CAS	Dedicated to the 70th anniversary of Dalian Institute of Chemical Physics, CAS. We thank Guowang Xu, Tongming Li, and all members of the Dr. Piao laboratory for helpful discussions and suggestions. This study is supported by the National Natural Science Foundation of China (Grant Nos. 81672440, 31701156, 81502024, and 81572881), Project funded by China Postdoctoral Science Foundation (No. 2017M611281), Innovation program of science and research from the DICP, CAS (DICP TMSR201601, DICP ZZBS201803).	Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bailey MH, 2018, CELL, V173, P371, DOI [10.1016/j.cell.2018.02.060, 10.1016/j.cell.2018.07.034]; Barabasi AL, 2009, SCIENCE, V325, P412, DOI 10.1126/science.1173299; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; Brown NR, 2007, CELL CYCLE, V6, P1350, DOI 10.4161/cc.6.11.4278; Cancer Genome Atlas Research Network, 2013, Nat Genet, V45, P1113, DOI 10.1038/ng.2764; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Chauhan D, 2012, CANCER CELL, V22, P345, DOI 10.1016/j.ccr.2012.08.007; Chawla NV, 2002, J ARTIF INTELL RES, V16, P321, DOI 10.1613/jair.953; Chen D, 2019, ISCIENCE, V16, P177, DOI 10.1016/j.isci.2019.05.033; Chen MF, 2011, P NATL ACAD SCI USA, V108, P9119, DOI 10.1073/pnas.1100028108; Colaprico A, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv1507; Cotto-Rios XM, 2011, CELL CYCLE, V10, P4009, DOI 10.4161/cc.10.23.18501; Cummins JM, 2004, NATURE, V428, DOI 10.1038/nature02501; D'Arcy P, 2011, NAT MED, V17, P1636, DOI 10.1038/nm.2536; Davis MI, 2016, J BIOL CHEM, V291, P24628, DOI 10.1074/jbc.M116.738567; Edwards NJ, 2015, J PROTEOME RES, V14, P2707, DOI 10.1021/pr501254j; Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121; Ge ZQ, 2018, CELL REP, V23, P213, DOI 10.1016/j.celrep.2018.03.047; Hanpude P, 2015, IUBMB LIFE, V67, P544, DOI 10.1002/iub.1402; Huang XD, 2016, CELL RES, V26, P484, DOI 10.1038/cr.2016.31; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Kapoor A, 2014, CELL, V158, P185, DOI 10.1016/j.cell.2014.06.003; Kim MS, 2014, NATURE, V509, P575, DOI 10.1038/nature13302; Landi S, 2003, CANCER RES, V63, P3560; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Li J, 2017, CANCER CELL, V31, P225, DOI 10.1016/j.ccell.2017.01.005; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Li Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00299-9; Lu C, 2018, CANCER LETT, V436, P139, DOI 10.1016/j.canlet.2018.07.032; Luise C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015891; Matsumoto M, 1998, ACM T MODEL COMPUT S, V8, P28; Meuwissen MEC, 2016, J EXP MED, V213, P1163, DOI 10.1084/jem.20151529; Nijman SMB, 2005, MOL CELL, V17, P331, DOI 10.1016/j.molcel.2005.01.008; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Rani J, 2015, J BIOSCIENCES, V40, P671, DOI 10.1007/s12038-015-9552-2; Ronnstrand L, 2004, CELL MOL LIFE SCI, V61, P2535, DOI 10.1007/s00018-004-4189-6; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Sorrentino A, 2008, NAT CELL BIOL, V10, P1199, DOI 10.1038/ncb1780; Srinivas NR, 2017, XENOBIOTICA, V47, P354, DOI 10.1080/00498254.2016.1184356; Sun J, 2018, MOL CELL BIOCHEM, V441, P1, DOI 10.1007/s11010-017-3170-2; Tarca AL, 2009, BIOINFORMATICS, V25, P75, DOI 10.1093/bioinformatics/btn577; Toloczko A, 2017, CANCER RES, V77, P4921, DOI 10.1158/0008-5472.CAN-16-3413; Torgo L., 2010, DATA MINING R LEARNI; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Turnbull AP, 2017, NATURE, V550, P481, DOI 10.1038/nature24451; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; Wang YM, 2018, CELL REP, V25, P1304, DOI 10.1016/j.celrep.2018.10.001; Weisberg EL, 2017, NAT CHEM BIOL, V13, P1207, DOI [10.1038/NCHEMBIO.2486, 10.1038/nchembio.2486]; Wilkerson MD, 2010, BIOINFORMATICS, V26, P1572, DOI 10.1093/bioinformatics/btq170; Yang B, 2016, ONCOTARGET, V7, P79501, DOI 10.18632/oncotarget.12819; Yu DH, 2000, ONCOGENE, V19, P6115, DOI 10.1038/sj.onc.1203972; Yuan T, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01080; Zhang JD, 2009, BIOINFORMATICS, V25, P1470, DOI 10.1093/bioinformatics/btp167; Zhu C, 2018, J BIOL CHEM, V293, P1178, DOI 10.1074/jbc.RA117.000392	57	7	7	1	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					587	602		10.1038/s41388-019-1002-4	http://dx.doi.org/10.1038/s41388-019-1002-4			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31511647				2022-12-28	WOS:000509718300008
J	Hu, JM; Xia, XQ; Gorlick, R; Li, SL				Hu, Jiemiao; Xia, Xueqing; Gorlick, Richard; Li, Shulin			Induction of NKG2D ligand expression on tumor cells by CD8(+) T-cell engagement-mediated activation of nuclear factor-kappa B and p300/CBP-associated factor	ONCOGENE			English	Article							IFN-GAMMA; CARCINOMA CELLS; 4-1BB CD137; RECEPTOR; TRANSCRIPTION; MODULATION; CHEMOATTRACTANT; COSTIMULATION; CHEMOKINES; MECHANISM	The ligands for the natural killer group 2 (NKG2D) protein render tumor cells susceptible to NKG2D-dependent immune cell attack. However, cancer cells escape from immune surveillance by downregulating NKG2D ligands. We previously discovered that engagement of activated CD8(+) T cells and tumor cells induces NKG2D ligands on tumor cells, but the underlying mechanism remains to be defined. Both in vivo mouse tumor models and in vitro cell assays were performed to study the downstream signaling. Our results supported the notion that, upon engagement with the cognate receptors, CD137 ligand and CD40 initiates activation of nuclear factor-kappa B (NF-kappa B) signaling in tumor cells even in the absence of CD8(+) T cells. Like tumor and CD8(+) T cell contact-dependent NKG2D ligand induction, this CD137L/CD40-mediated signaling activation was associated with elevated levels of acetyltransferase P300/CBP-associated factor (PCAF), whereas inhibition of phosphorylated NF-kappa B abrogated PCAF induction. Although stimulation of CD137L/CD40-mediated signaling is vital, inflammatory cytokines, including interferon gamma (IFN gamma) and TNF alpha, also facilitate NKG2D ligand-induced immune surveillance via both facilitating T-cell chemotaxis and CD137L/CD40 induced NF-kappa B/PCAF activation. Collectively, our results unveil a novel mechanism of NKG2D ligand upregulation involving reverse signaling of CD40 and CD137L on tumor cells which, along with inflammatory cytokines IFN gamma and TNF alpha, stimulate downstream NF-kappa B and PCAF activation. Understanding this mechanism may help in development of induced NKG2D ligand-dependent T-cell therapy against cancers.	[Hu, Jiemiao; Xia, Xueqing; Gorlick, Richard; Li, Shulin] Univ Texas MD Anderson Canc Ctr, Div Pediat, Dept Pediat Res, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Li, SL (corresponding author), Univ Texas MD Anderson Canc Ctr, Div Pediat, Dept Pediat Res, Houston, TX 77030 USA.	Sli4@mdanderson.org	Li, Shulin/D-6478-2011		Cancer Center Support Grant [P30 CA016672]; NATIONAL CANCER INSTITUTE [R01CA120895, P30CA016672, R01CA200574] Funding Source: NIH RePORTER	Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The following Cancer Center Support Grant core resources were used: Genetically Engineered Mouse Facility and Monoclonal Antibody Core Facility with Cancer Center Support Grant P30 CA016672. The authors would like to thank Ms. Kathryn L Hale from the Department of Scientific Publications for editing the manuscript.	Altenburg A, 1999, J IMMUNOL, V162, P4140; Antonelli A, 2009, J CLIN ENDOCR METAB, V94, P1803, DOI 10.1210/jc.2008-2450; Arch RH, 1998, MOL CELL BIOL, V18, P558, DOI 10.1128/MCB.18.1.558; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Bartkowiak T, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00117; Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Bui JD, 2006, J IMMUNOL, V176, P905, DOI 10.4049/jimmunol.176.2.905; Cannons JL, 2000, J IMMUNOL, V165, P6193, DOI 10.4049/jimmunol.165.11.6193; Carayannopoulos LN, 2002, J IMMUNOL, V169, P4079, DOI 10.4049/jimmunol.169.8.4079; Cerwenka A, 2000, IMMUNITY, V12, P721, DOI 10.1016/S1074-7613(00)80222-8; Cooke PW, 1999, J PATHOL, V188, P38; Elgueta R, 2009, IMMUNOL REV, V229, P152, DOI 10.1111/j.1600-065X.2009.00782.x; Gallagher NJ, 2002, J CLIN PATHOL-MOL PA, V55, P110, DOI 10.1136/mp.55.2.110; Gasser S, 2005, NATURE, V436, P1186, DOI 10.1038/nature03884; Gasser S, 2006, SEMIN CANCER BIOL, V16, P344, DOI 10.1016/j.semcancer.2006.07.004; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Han S, 2014, BRIT J CANCER, V110, P2560, DOI 10.1038/bjc.2014.162; Hauer J, 2005, P NATL ACAD SCI USA, V102, P2874, DOI 10.1073/pnas.0500187102; Held-Feindt J, 2002, INT J CANCER, V98, P352, DOI 10.1002/ijc.10207; Hu J, 2017, ENVIRON SCI POLLUT R, V24, P17090, DOI 10.1007/s11356-017-9057-7; Hu JM, 2017, CANCER IMMUNOL RES, V5, P300, DOI 10.1158/2326-6066.CIR-16-0234; Hu JB, 2017, DRUG DELIV, V24, P1856, DOI 10.1080/10717544.2017.1410258; Jung H, 2012, J EXP MED, V209, P2409, DOI 10.1084/jem.20120565; Kelly JM, 2002, NAT IMMUNOL, V3, P83, DOI 10.1038/ni746; Kim HH, 2000, MOL CELLS, V10, P247; Lanier LL, 2015, CANCER IMMUNOL RES, V3, P575, DOI 10.1158/2326-6066.CIR-15-0098; Lee DS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058748; Lin D, 2012, J BIOL CHEM, V287, P4299, DOI 10.1074/jbc.M111.282152; Martinez-Forero I, 2013, J IMMUNOL, V190, P6694, DOI 10.4049/jimmunol.1203010; Mohan K, 2002, J IMMUNOL, V168, P6420, DOI 10.4049/jimmunol.168.12.6420; Molinero LL, 2004, J IMMUNOL, V173, P5583, DOI 10.4049/jimmunol.173.9.5583; Moser B, 1998, Int Rev Immunol, V16, P323, DOI 10.3109/08830189809043000; Murdoch C, 2000, BLOOD, V95, P3032; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Sabbagh L, 2008, J IMMUNOL, V180, P8093, DOI 10.4049/jimmunol.180.12.8093; Salih HR, 2000, J IMMUNOL, V165, P2903, DOI 10.4049/jimmunol.165.5.2903; Saoulli K, 1998, J EXP MED, V187, P1849, DOI 10.1084/jem.187.11.1849; Sauer M, 2017, ONCOGENE, V36, P933, DOI 10.1038/onc.2016.259; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Tirapu I, 2006, CANCER RES, V66, P2442, DOI 10.1158/0008-5472.CAN-05-1681; Trebing J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.555; Werbajh S, 2000, FEBS LETT, V485, P195, DOI 10.1016/S0014-5793(00)02223-7; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhu S, 2007, CLIN CANCER RES, V13, P4252, DOI 10.1158/1078-0432.CCR-06-2894	47	3	3	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2019	38	49					7433	7446		10.1038/s41388-019-0960-x	http://dx.doi.org/10.1038/s41388-019-0960-x			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JT4BN	31427736	Green Accepted			2022-12-28	WOS:000500936600005
J	Majem, B; Parrilla, A; Jimenez, C; Suarez-Cabrera, L; Barber, M; Marin, A; Castellvi, J; Tamayo, G; Moreno-Bueno, G; Ponce, J; Matias-Guiu, X; Alameda, F; Romero, I; Sanchez, JL; Perez-Benavente, A; Moran, S; Esteller, M; Reventos, J; Rigau, M; Gil-Moreno, A; Segura, MF; Santamaria, A				Majem, Blanca; Parrilla, Alfonso; Jimenez, Carlos; Suarez-Cabrera, Leticia; Barber, Marta; Marin, Andrea; Castellvi, Josep; Tamayo, Gabriel; Moreno-Bueno, Gema; Ponce, Jordi; Matias-Guiu, Xavier; Alameda, Francesc; Romero, Ignacio; Luis Sanchez, Jose; Perez-Benavente, Asuncion; Moran, Sebastian; Esteller, Manel; Reventos, Jaume; Rigau, Marina; Gil-Moreno, Antonio; Segura, Miguel F.; Santamaria, Anna			MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC, WNT and AKT pathways	ONCOGENE			English	Article							SPHEROID FORMATION; DNA METHYLATION; ELEVATED CDCP1; EXPRESSION; PLAGL2; CELLS; PROGRESSION; CARCINOMA; SURVIVAL; LEUKEMIA	Ovarian cancer is the most lethal gynecological malignancy due to the silent nature on its early onset and the rapid acquisition of drug resistance. Histologically heterogeneous, it includes several subtypes with different mutational landscapes, hampering the development of effective targeted therapies. Non-coding RNAs are emerging as potential new therapeutic targets in cancer. To search for a microRNA signature related to ovarian carcinomas and study its potential as effective targeted therapy, we examined the expression of 768 miRNA in a large collection of tumor samples and found miR-654-5p to be infraexpressed in ovarian serous carcinomas, the most common and aggressive type. Restoration of miR654-5p levels reduced tumor cell viability in vitro and in vivo and impaired sphere formation capacity and viability of ovarian cancer patient-derived ascitic cells ex vivo. CDCP1 and PLAGL2 oncogenes were found to be the most relevant direct miR-654-5p targets and both genes convey in a molecular signature associated with key cancer pathways relevant to ovarian tumorigenesis, such as MYC, WNT and AKT pathways. Together, we unveiled the tumor suppressor function of miR-654-5p, suggesting that its restoration or co-targeting of CDCP1 and PLAGL2 may be an effective therapeutic approach for ovarian cancer.	[Majem, Blanca; Parrilla, Alfonso; Suarez-Cabrera, Leticia; Barber, Marta; Marin, Andrea; Tamayo, Gabriel; Santamaria, Anna] UAB, Cell Cycle & Canc Lab, Grp Biomed Res Urol, Vall Hebron Res Inst VHIR, Barcelona 08035, Spain; [Jimenez, Carlos; Segura, Miguel F.] UAB, Grp Translat Res Child & Adolescent Canc, Vall Hebron Res Inst VHIR, Barcelona 08035, Spain; [Castellvi, Josep] Vall Hebron Univ Hosp, Dept Pathol, Barcelona 08035, Spain; [Moreno-Bueno, Gema] UAM, Dept Biochem, Inst Invest Biomed Alberto Sols, CIBERONC,IdiPaz,CSIC, Madrid 28029, Spain; [Moreno-Bueno, Gema] Fdn MD Anderson Int, Madrid 28033, Spain; [Ponce, Jordi] Univ Barcelona, Univ Hosp Bellvitge IDIBELL, Dept Gynaecol, Barcelona 08908, Spain; [Matias-Guiu, Xavier] Univ Lleida, Dept Pathol, Hosp Univ Arnau de Vilanova, IRB Lleida, Lleida 25198, Spain; [Matias-Guiu, Xavier; Reventos, Jaume] Hosp Univ Bellvitge, CIBERONC, IDIBELL, Dept Pathol, Barcelona 08908, Spain; [Alameda, Francesc] Hosp del Mar, Pathol Dept, Barcelona 08003, Spain; [Romero, Ignacio] IVO, Dept Med Oncol, Valencia 46009, Spain; [Luis Sanchez, Jose; Perez-Benavente, Asuncion; Gil-Moreno, Antonio] UAB, Dept Gynecol Oncol, Vall Hebron Univ Hosp, Barcelona 08035, Spain; [Luis Sanchez, Jose; Perez-Benavente, Asuncion; Gil-Moreno, Antonio] UAB, CIBERONC, Grp Biomed Res Gynecol, Vall Hebron Res Inst VHIR, Barcelona 08035, Spain; [Moran, Sebastian; Esteller, Manel] Bellvitge Biomed Res Inst IDIBELL, CIBERONC, Canc Epigenet & Biol Program PEBC, Barcelona 08908, Spain; [Esteller, Manel] UB, Physiol Sci Dept, Sch Med & Hlth Sci, Barcelona 08036, Spain; [Esteller, Manel] ICREA, Barcelona 08010, Spain; [Reventos, Jaume] Univ Int Catalunya, Dept Basic Sci, Barcelona 08017, Spain; [Rigau, Marina] Bellvitge Biomed Res Inst IDIBELL, Barcelona 08908, Spain; [Majem, Blanca] Bellvitge Biomed Res Inst IDIBELL, Cell Death Regulat Grp, Oncobell Program, Barcelona 08908, Spain	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Hospital Universitari Vall d'Hebron; Autonomous University of Madrid; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Texas System; UTMD Anderson Cancer Center; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; Universitat de Lleida; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Instituto Valenciano De Oncologia; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; ICREA; Universitat Internacional de Catalunya (UIC); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL)	Santamaria, A (corresponding author), UAB, Cell Cycle & Canc Lab, Grp Biomed Res Urol, Vall Hebron Res Inst VHIR, Barcelona 08035, Spain.	anna.santamaria@vhir.org	matias-guiu, xavier/C-3039-2009; /AAD-2326-2020; Castellvi, Josep/C-5092-2014; Segura, Miguel F/J-4749-2013; Majem, Blanca/AAN-6687-2021; Esteller, Manel/L-5956-2014; Moreno-Bueno, Gema/K-9354-2016; PEREZ BENAVENTE, ASUNCION/J-8272-2016	matias-guiu, xavier/0000-0002-7201-6605; /0000-0001-9219-3492; Castellvi, Josep/0000-0001-5745-9996; Segura, Miguel F/0000-0003-0916-3618; Esteller, Manel/0000-0003-4490-6093; Moreno-Bueno, Gema/0000-0002-5030-6687; PEREZ BENAVENTE, ASUNCION/0000-0003-1872-9003	Instituto de la Mujer Dexeus [DEXEUSB29/012]; CIBER [CB16/12/00328]; SGR [2017 SGR 1661]; Fondos FEDER [RTC-2015-3821-1]; Instituto Carlos III [PI15/00238, PI17/00564]; Miguel Servet Program [CP13/00158, CPII18/00027, CPII16/00006]; predoctoral VHIR fellowships [VHIR: PRED-VHIR-2014-11, PRED-VHIR-2017]; AGAUR predoctoral fellowship [AGAUR: 2017FI_ B_ 00095]; Ministerio de Economia y Competitividad	Instituto de la Mujer Dexeus; CIBER; SGR; Fondos FEDER(European Commission); Instituto Carlos III(Instituto de Salud Carlos III); Miguel Servet Program; predoctoral VHIR fellowships; AGAUR predoctoral fellowship; Ministerio de Economia y Competitividad(Spanish Government)	We are thankful to Drs. Diego Arango and Agueda Martinez, Dr. Sung Goo Park and Dr. Rosanna Paciucci for 9E10 c-Myc, anti-HAX1 and anti-RB and anti-p-RB antibodies, respectively. We thank Dr. Francesc Vinals, Dr. Barbara Vanderhyden, Dr. Antonio Rosato, Dr. Erich A. Nigg and the Ovarian Cancer Research Team for cell lines. We are grateful to Drs. Aroa Soriano and Luz Jubierre for experimental help. We acknowledge technical support from the Flow Cytometry Facility at Center of Genomic Regulation (CRG) and the Unitat d'Estadistica i Bioinformatica (UEB) and the Unitat d'Alta Tecnologia (UAT) at VHIR. We thank all our lab members for support and helpful discussions. This work was supported in part by grants from Instituto de la Mujer Dexeus (DEXEUSB29/012), CIBER (CB16/12/00328), SGR (2017 SGR 1661), the Ministerio de Economia y Competitividad and Fondos FEDER (RTC-2015-3821-1), Instituto Carlos III (PI15/00238 to A. S. and PI17/00564 to M. F. S) and the Miguel Servet Program (CP13/00158 and CPII18/00027 to AS. and CPII16/00006 to MFS). AP and LS were supported by predoctoral VHIR fellowships and CJ by an AGAUR predoctoral fellowship (VHIR: PRED-VHIR-2014-11 and PRED-VHIR-2017; AGAUR: 2017FI_ B_ 00095, respectively).	Adair SJ, 2009, CANCER IMMUNOL IMMUN, V58, P589, DOI 10.1007/s00262-008-0582-6; Banerjee S, 2013, CLIN CANCER RES, V19, P961, DOI 10.1158/1078-0432.CCR-12-2243; Beg MS, 2017, INVEST NEW DRUG, V35, P180, DOI 10.1007/s10637-016-0407-y; Bi LL, 2016, ONCOL REP, V36, P2563, DOI 10.3892/or.2016.5055; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Chen MW, 2017, CANCER RES, V77, P1955, DOI 10.1158/0008-5472.CAN-16-1115; Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103; Dweep H, 2015, NAT METHODS, V12, P697, DOI 10.1038/nmeth.3485; George A, 2017, NAT REV CLIN ONCOL, V14, P284, DOI 10.1038/nrclinonc.2016.191; Harrington BS, 2016, BRIT J CANCER, V114, P417, DOI 10.1038/bjc.2015.471; He Y, 2016, ONCOGENE, V35, P468, DOI 10.1038/onc.2015.101; Hensen K, 2002, CANCER RES, V62, P1510; Honkoop AH, 1997, AM J CLIN PATHOL, V107, P211, DOI 10.1093/ajcp/107.2.211; Iorio F, 2016, CELL, V166, P740, DOI 10.1016/j.cell.2016.06.017; Jaco F, 2014, BMC MOL BIOL, V15, DOI 10.1186/1471-2199-15-24; Ji WD, 2017, GENES-BASEL, V8, DOI 10.3390/genes8010021; Jubierre L, 2016, ONCOGENE, V35, P5179, DOI 10.1038/onc.2016.50; Karnezis AN, 2017, NAT REV CANCER, V17, P65, DOI 10.1038/nrc.2016.113; Kipps E, 2013, NAT REV CANCER, V13, P273, DOI 10.1038/nrc3432; Kircher M, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-346; Klinkebiel D, 2016, MOL CANCER RES, V14, P787, DOI 10.1158/1541-7786.MCR-16-0097; Landrette SF, 2011, LEUKEMIA, V25, P655, DOI 10.1038/leu.2010.301; Landrette SF, 2005, BLOOD, V105, P2900, DOI 10.1182/blood-2004-09-3630; Li Jianqi, 2015, Zhonghua Zhong Liu Za Zhi, V37, P324; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maire G, 2011, CANCER GENET-NY, V204, P138, DOI 10.1016/j.cancergen.2010.12.012; Mateescu B, 2011, NAT MED, V17, P1627, DOI 10.1038/nm.2512; Matulonis UA, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.61; Moran S, 2014, EPIGENETICS-US, V9, P829, DOI 10.4161/epi.28790; Ostling P, 2011, CANCER RES, V71, P1956, DOI 10.1158/0008-5472.CAN-10-2421; Paydas S, 2016, MED ONCOL, V33, DOI 10.1007/s12032-016-0749-5; Poole CJ, 2017, GENES-BASEL, V8, DOI 10.3390/genes8050142; Prahm KP, 2016, APMIS, V124, P337, DOI 10.1111/apm.12514; Reyes-Gonzalez JM, 2015, MOL CANCER THER, V14, P2260, DOI 10.1158/1535-7163.MCT-14-0801; Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246; Sato E, 2005, P NATL ACAD SCI USA, V102, P18538, DOI 10.1073/pnas.0509182102; Sehouli J, 2016, GEBURTSH FRAUENHEILK, V76, P164, DOI 10.1055/s-0035-1558185; Shepherd TG, 2006, NAT PROTOC, V1, P2643, DOI 10.1038/nprot.2006.328; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Soriano A, 2016, ONCOTARGET, V7, P9271, DOI 10.18632/oncotarget.7005; Takahashi M, 2016, CANCER SCI, V107, P417, DOI 10.1111/cas.12892; Tan YY, 2016, AM J CANCER RES, V6, P522; Ueland FR, 2017, DIAGNOSTICS, V7, DOI 10.3390/diagnostics7010014; Vaughan S, 2011, NAT REV CANCER, V11, P719, DOI 10.1038/nrc3144; Wang YP, 2017, ONCOL REP, V37, P1961, DOI 10.3892/or.2017.5485; Yang D, 2013, CANCER CELL, V23, P186, DOI 10.1016/j.ccr.2012.12.020; Zehavi L, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-44; Zhang L, 2008, P NATL ACAD SCI USA, V105, P7004, DOI 10.1073/pnas.0801615105; Zheng HW, 2010, CANCER CELL, V17, P497, DOI 10.1016/j.ccr.2010.03.020	49	44	47	1	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2019	38	32					6035	6050		10.1038/s41388-019-0860-0	http://dx.doi.org/10.1038/s41388-019-0860-0			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IP8XH	31278368	Green Published			2022-12-28	WOS:000480329900003
J	Zhu, YX; He, D; Bo, H; Liu, ZX; Xiao, MQ; Xiang, L; Zhou, JD; Liu, Y; Liu, XM; Gong, L; Ma, YN; Zhou, YH; Zhou, M; Xiong, W; Yang, F; Xing, XW; Li, RH; Li, W; Cao, K				Zhu, Yuxing; He, Dong; Bo, Hao; Liu, Zexian; Xiao, Mengqing; Xiang, Liang; Zhou, Jianda; Liu, Yan; Liu, Xiaoming; Gong, Lian; Ma, Yanni; Zhou, Yanhong; Zhou, Ming; Xiong, Wei; Yang, Fei; Xing, Xiaowei; Li, Ruhong; Li, Wei; Cao, Ke			The MRVI1-AS1/ATF3 signaling loop sensitizes nasopharyngeal cancer cells to paclitaxel by regulating the Hippo-TAZ pathway	ONCOGENE			English	Article							NONCODING RNAS; BREAST-CANCER; CARCINOMA; RADIOTHERAPY; CHEMORADIOTHERAPY; TUMORIGENICITY; PROGRESSION; MIR-27B; GROWTH; NPC	Long non-coding RNA (lncRNA) plays an important role in malignant tumor occurrence, development, and chemoresistance, but the mechanism of how they affect nasopharyngeal cancer (NPC) paclitaxel chemosensitivity is unclear. In this study, lncRNA array of CNE-1 and HNE-2 paclitaxel-resistant cells and their parental strains revealed that the paclitaxel-resistant strains had significantly lower MRVI1-AS1 (murine retrovirus integration site 1 homolog antisense RNA 1) expression than the parental strains, and that MRVI1-AS1 overexpression in vitro and in vivo increased paclitaxel chemosensitivity. Further, MRVI1-AS1 upregulated ATF3 (activating transcription factor 3) by simultaneously inhibiting miR-513a-5p (microRNA-513a-5p) and miR-27b-3p expression levels to increase NPC paclitaxel chemosensitivity. Chromatin immunoprecipitation and quantitative real-time PCR showed that ATF3 could feed-back MRVI1-AS1 regulation positively. Furthermore, MRVI1-AS1 and ATF3 could form a positive feedback loop, which promoted the expression of RASSF1 (Ras association domain family member 1), a Hippo-TAZ (tafazzin) signaling pathway regulatory factor, thereby inhibiting TAZ expression. The MTT (3-[4,5- dimethylthiazol- 2- yl]- 2,5 diphenyltetrazolium bromide) assay and flow cytometry showed that the decreased TAZ increased NPC cell paclitaxel chemosensitivity. Overall, the results indicate that the MRVI1-AS1/ATF3 signaling pathway can increase NPC paclitaxel chemosensitivity by modulating the Hippo-TAZ signaling pathway. Therefore, targeting the loop may be a new NPC treatment strategy.	[Zhu, Yuxing; Xiao, Mengqing; Xiang, Liang; Gong, Lian; Ma, Yanni; Cao, Ke] Cent S Univ, Dept Oncol, Xiangya Hosp 3, Changsha 410013, Hunan, Peoples R China; [He, Dong] Hunan Univ Chinese Med, Dept Respirat, Peoples Hosp Hunan Prov 2, Changsha 410000, Hunan, Peoples R China; [Bo, Hao] Cent S Univ, Inst Reprod & Stem Cell Engn, Changsha 410083, Hunan, Peoples R China; [Liu, Zexian] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China; [Zhou, Jianda; Liu, Yan] Cent S Univ, Xiangya Hosp 3, Dept Plast Surg, Changsha 410013, Hunan, Peoples R China; [Liu, Xiaoming] Cent S Univ, Dept Gastroenterol, Xiangya Hosp 3, Changsha 410013, Hunan, Peoples R China; [Zhou, Yanhong; Zhou, Ming; Xiong, Wei] Cent S Univ, Canc Res Inst, Minist Hlth, Changsha 410078, Hunan, Peoples R China; [Zhou, Yanhong; Zhou, Ming; Xiong, Wei] Cent S Univ, Key Lab Carcinogenesis, Minist Hlth, Changsha 410078, Hunan, Peoples R China; [Yang, Fei] Cent S Univ, Sch Publ Hlth, Changsha 410078, Hunan, Peoples R China; [Xing, Xiaowei] Cent S Univ, Xiangya Hosp 3, Ctr Med Expt, Changsha 410013, Hunan, Peoples R China; [Li, Ruhong] Kunming Med Univ, Yanan Affiliated Hosp, Kunming 650051, Yunnan, Peoples R China; [Li, Wei] Cent S Univ, Xiangya Hosp 3, Dept Otolaryngol Head Neck Surg, Changsha 410013, Hunan, Peoples R China	Central South University; Hunan University of Chinese Medicine; Central South University; State Key Lab Oncology South China; Sun Yat Sen University; Central South University; Central South University; Central South University; Central South University; Central South University; Central South University; Kunming Medical University; Central South University	Cao, K (corresponding author), Cent S Univ, Dept Oncol, Xiangya Hosp 3, Changsha 410013, Hunan, Peoples R China.	csucaoke@163.com	wu, Xianrui/AAM-6540-2021; Liu, Zexian/D-1153-2011	wu, Xianrui/0000-0003-4803-5934; Liu, Zexian/0000-0001-9698-0610; Cao, Ke/0000-0001-5392-2306	National Natural Science Foundation of China [81874137]; Outstanding Youth Foundation of Hunan Province [2018JJ1047]; Huxiang Young Talent Project [2016RS3022]; Innovation-Driven Project of Central South University [2017CX012]; Fundamental Research Funds for the Central Universities of Central South University [2018zzts955]; New Xiangya Talent Projects of the Third Xiangya Hospital of Central South University [20150201, JY201710]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Outstanding Youth Foundation of Hunan Province; Huxiang Young Talent Project; Innovation-Driven Project of Central South University; Fundamental Research Funds for the Central Universities of Central South University; New Xiangya Talent Projects of the Third Xiangya Hospital of Central South University	This work was supported by the National Natural Science Foundation of China (81874137), the Outstanding Youth Foundation of Hunan Province (2018JJ1047), the Huxiang Young Talent Project (2016RS3022), the Innovation-Driven Project of Central South University (2017CX012), the Fundamental Research Funds for the Central Universities of Central South University, Grant/Award Number: 2018zzts955, and the New Xiangya Talent Projects of the Third Xiangya Hospital of Central South University (20150201, JY201710).	Blanchard P, 2015, LANCET ONCOL, V16, P645, DOI 10.1016/S1470-2045(15)70126-9; Chan SW, 2011, J CELL PHYSIOL, V226, P928, DOI 10.1002/jcp.22435; Chang YS, 2017, P NATL ACAD SCI USA, V114, pE7159, DOI 10.1073/pnas.1700455114; Chueh AC, 2017, CLIN CANCER RES, V23, P5573, DOI 10.1158/1078-0432.CCR-17-0466; Giovinazzi S, 2012, ONCOGENE, V31, P13, DOI 10.1038/onc.2011.211; Guo Z, 2017, ONCOTARGET, V8, P62286, DOI 10.18632/oncotarget.19725; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Kassler Susannah, 2012, Mol Biol Int, V2012, P263267, DOI 10.1155/2012/263267; Lai D, 2011, CANCER RES, V71, P2728, DOI 10.1158/0008-5472.CAN-10-2711; Lee JJ, 2012, ONCOGENE, V31, P3818, DOI 10.1038/onc.2011.543; Lin CR, 2018, TRENDS CELL BIOL, V28, P287, DOI 10.1016/j.tcb.2017.11.008; Lin JC, 2003, J CLIN ONCOL, V21, P631, DOI 10.1200/JCO.2003.06.158; Liu J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0246-6; Lo KW, 2012, SEMIN CANCER BIOL, V22, P79, DOI 10.1016/j.semcancer.2011.12.011; Matsui M, 2017, NAT REV DRUG DISCOV, V16, P167, DOI 10.1038/nrd.2016.117; Maugeri-Sacca M, 2018, PHARMACOL THERAPEUT, V186, P60, DOI 10.1016/j.pharmthera.2017.12.011; Mo JS, 2014, EMBO REP, V15, P642, DOI 10.15252/embr.201438638; Muti P, 2018, CARCINOGENESIS, V39, P98, DOI 10.1093/carcin/bgx126; Oh YK, 2008, MOL CANCER RES, V6, P1232, DOI 10.1158/1541-7786.MCR-07-0297; Panciera T, 2017, NAT REV MOL CELL BIO, V18, P758, DOI 10.1038/nrm.2017.87; Quinn JJ, 2016, NAT REV GENET, V17, P47, DOI 10.1038/nrg.2015.10; Ren SL, 2016, ONCOL REP, V36, P1861, DOI 10.3892/or.2016.4981; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Shen SJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100664; Sun YQ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0113-5; Suzuki M, 2016, J CLIN INVEST, V126, P254, DOI 10.1172/JCI79775; Taniue K, 2016, P NATL ACAD SCI USA, V113, P12739, DOI 10.1073/pnas.1605938113; Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20; Totaro A, 2018, NAT CELL BIOL, V20, P888, DOI 10.1038/s41556-018-0142-z; van Heesch S, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-1-r6; Wang QS, 2017, CELL CYCLE, V16, P795, DOI 10.1080/15384101.2017.1301334; Wang SY, 2017, J CLIN INVEST, V127, P4498, DOI 10.1172/JCI91553; Wang YF, 2009, J BIOL CHEM, V284, P23094, DOI 10.1074/jbc.M109.012617; Xiong H, 2017, ONCOGENE, V36, P3528, DOI 10.1038/onc.2016.521; Yang YQ, 2018, J INVEST DERMATOL, V138, P2205, DOI 10.1016/j.jid.2018.03.1510; You R, 2017, THERANOSTICS, V7, P4825, DOI 10.7150/thno.21815; Zeng PY, 2006, BIOTECHNIQUES, V41, P694, DOI 10.2144/000112297; Zeng QH, 2018, CLIN CANCER RES, V24, P445, DOI 10.1158/1078-0432.CCR-17-0419; Zhao B, 2011, NAT CELL BIOL, V13, P877, DOI 10.1038/ncb2303; Zhu J, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.361	40	30	30	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2019	38	32					6065	6081		10.1038/s41388-019-0858-7	http://dx.doi.org/10.1038/s41388-019-0858-7			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IP8XH	31273338				2022-12-28	WOS:000480329900005
J	Bernat-Peguera, A; Simon-Extremera, P; da Silva-Diz, V; de Munain, ML; Diaz-Gil, L; Penin, RM; Gonzalez-Suarez, E; Sidelnikova, DP; Bermejo, O; Vinals, JM; Vinals, F; Munoz, P				Bernat-Peguera, Adria; Simon-Extremera, Pilar; da Silva-Diz, Victoria; Lopez de Munain, Mikel; Diaz-Gil, Laura; Penin, Rosa M.; Gonzalez-Suarez, Eva; Sidelnikova, Diana Perez; Bermejo, Oriol; Vinals, Joan Maria; Vinals, Francesc; Munoz, Purificacion			PDGFR-induced autocrine SDF-1 signaling in cancer cells promotes metastasis in advanced skin carcinoma	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER; TUMOR-GROWTH; CHEMOKINE RECEPTOR; FACTOR-I; SDF-1/CXCR4 AXIS; CXCR4; EXPRESSION; PROGRESSION; SURVIVAL	Advanced and undifferentiated skin squamous cell carcinomas (SCCs) exhibit aggressive growth and enhanced metastasis capability, which is associated in mice with an expansion of the cancer stem-like cell (CSC) population and with changes in the regulatory mechanisms that control the proliferation and invasion of these cells. Indeed, autocrine activation of PDGFR alpha induces CSC invasion and promotes distant metastasis in advanced SCCs. However, the mechanisms involved in this process were unclear. Here, we show that CSCs of mouse advanced SCCs (L-CSCs) express CXCR4 and CXCR7, both receptors of SDF-1. PDGFR alpha signaling induces SDF-1 expression and secretion, and the autocrine activation of this pathway in L-CSCs. Autocrine SDF-1/CXCR4 signaling induces L-CSC proliferation and survival, and mediates PDGFR alpha-induced invasion, promoting in vivo lung metastasis. Validation of these findings in patient samples of skin SCCs shows a strong correlation between the expression of SDF1, PDGFRA, and PDGFRB, which is upregulated, along CXCR4 in tumor cells of advanced SCCs. Furthermore, PDGFR regulates SDF-1 expression and inhibition of SDF-1/CXCR4 and PDGFR pathways blocks distant metastasis of human PD/S-SCCs. Our results indicate that functional crosstalk between PDGFR/ SDF-1 signaling regulates tumor cell invasion and metastasis in human and mouse advanced SCCs, and suggest that CXCR4 and/or PDGFR inhibitors could be used to block metastasis of these aggressive tumors.	[Bernat-Peguera, Adria; Simon-Extremera, Pilar; da Silva-Diz, Victoria; Lopez de Munain, Mikel; Diaz-Gil, Laura; Gonzalez-Suarez, Eva; Munoz, Purificacion] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona, Spain; [Penin, Rosa M.] Hosp Univ Bellvitge, Pathol Serv, IDIBELL, Barcelona, Spain; [Sidelnikova, Diana Perez; Bermejo, Oriol; Vinals, Joan Maria] Hosp Univ Bellvitge, Plast Surg Unit, IDIBELL, Barcelona, Spain; [Vinals, Francesc] Catalan Inst Oncol ICO, Lab Translat Res, IDIBELL, Barcelona, Spain; [Vinals, Francesc] Univ Barcelona, Dept Ciencies Fisiol, Unitat Bioquim & Biol Mol, IDIBELL, Barcelona, Spain; [da Silva-Diz, Victoria] Rutgers State Univ, Rutgers Canc Inst New Jersey, New Brunswick, NJ USA	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Munoz, P (corresponding author), Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona, Spain.	p.munoz@idibell.cat	Gonzalez-Suarez, Eva/L-6298-2014; Viñals, Francesc/F-5928-2016	Gonzalez-Suarez, Eva/0000-0003-0858-8171; Viñals, Francesc/0000-0002-9918-6751; Simon, Pilar/0000-0002-0702-2443; Bernat Peguera, Adria/0000-0002-3108-0571	IDIBELL Fellowship; Spanish Ministry of Science and Innovation Fellowships; Spanish Ministry of Economy and Competitiveness MINECO [SAF2014-55944R, SAF2017-84976R]; FEDER funds/European Regional Development Fund (ERDF); Catalan Department of Health (Generalitat de Catalunya) [2017SGR595]	IDIBELL Fellowship; Spanish Ministry of Science and Innovation Fellowships; Spanish Ministry of Economy and Competitiveness MINECO(Spanish Government); FEDER funds/European Regional Development Fund (ERDF); Catalan Department of Health (Generalitat de Catalunya)	AB-P received an IDIBELL Fellowship, VdS-D and PS-E are funded by Spanish Ministry of Science and Innovation Fellowships; the research of PM's group is supported by the Spanish Ministry of Economy and Competitiveness MINECO (SAF2014-55944R; SAF2017-84976R, co-funded by FEDER funds/European Regional Development Fund (ERDF)-a way to build Europa) and by the Catalan Department of Health (Generalitat de Catalunya; 2017SGR595). We thank J. Comas (Universitat de Barcelona-SCT) for technical support with flow cytometry; the patients enrolled in this study for their participation; the Hospital Universitario Ramon y Cajal, Hospital Virgen de la Salud, Biobanco del Principado de Asturias and Fundacion Instituto Valenciano de Oncologia, which are members of the Spanish Hospital Platform Biobanks Network; Y. Perez (Tumor Bank, Hospital de Bellvitge) for help with human tumor sample collection; and the IDIBELL animal facility service for mouse care.	ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; Balabanian K, 2005, J BIOL CHEM, V280, P35760, DOI 10.1074/jbc.M508234200; Basile J, 2008, J CUTAN PATHOL, V35, P623, DOI 10.1111/j.1600-0560.2007.00879.x; Bertolini G, 2009, P NATL ACAD SCI USA, V106, P16281, DOI 10.1073/pnas.0905653106; Boumahdi S, 2014, NATURE, V511, P246, DOI 10.1038/nature13305; Burns JM, 2006, J EXP MED, V203, P2201, DOI 10.1084/jem.20052144; Chen SJ, 2009, BRIT J DERMATOL, V160, P710, DOI 10.1111/j.1365-2133.2008.08996.x; Cherpelis BS, 2002, DERMATOL SURG, V28, P268, DOI 10.1046/j.1524-4725.2002.01169.x; Coussens LM, 1996, AM J PATHOL, V149, P1899; da Silva-Diz V, 2018, SEMIN CANCER BIOL, V53, P48, DOI 10.1016/j.semcancer.2018.08.009; da Silva-Diz V, 2016, CANCER RES, V76, P1245, DOI 10.1158/0008-5472.CAN-15-1631; Darash-Yahana M, 2004, FASEB J, V18, P1240, DOI 10.1096/fj.03-0935fje; Ehtesham M, 2009, CANCER LETT, V274, P305, DOI 10.1016/j.canlet.2008.09.034; Folkins C, 2009, CANCER RES, V69, P7243, DOI 10.1158/0008-5472.CAN-09-0167; Franco R, 2013, EXPERT OPIN BIOL TH, V13, P51, DOI 10.1517/14712598.2012.725720; Gatti M, 2013, TOXICOLOGY, V314, P209, DOI 10.1016/j.tox.2013.10.003; Gellmini S, 2008, J ENDOCRINOL INVEST, V31, P809, DOI 10.1007/BF03349262; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hu SCS, 2014, EXP DERMATOL, V23, P902, DOI 10.1111/exd.12557; Hu TH, 2014, CANCER LETT, V354, P417, DOI 10.1016/j.canlet.2014.08.012; Kang H, 2005, BREAST CANCER RES, V7, pR402, DOI 10.1186/bcr1022; Kong LX, 2016, INT J ONCOL, V48, P1085, DOI 10.3892/ijo.2016.3343; Kryczek I, 2007, AM J PHYSIOL-CELL PH, V292, pC987, DOI 10.1152/ajpcell.00406.2006; Lapouge G, 2012, EMBO J, V31, P4563, DOI 10.1038/emboj.2012.312; Li XQ, 2014, MOL CELL BIOCHEM, V392, P77, DOI 10.1007/s11010-014-2020-8; Liang ZX, 2004, CANCER RES, V64, P4302, DOI 10.1158/0008-5472.CAN-03-3958; Matthys P, 2001, J IMMUNOL, V167, P4686, DOI 10.4049/jimmunol.167.8.4686; Miao Z, 2007, P NATL ACAD SCI USA, V104, P15735, DOI 10.1073/pnas.0610444104; Miki J, 2007, CANCER RES, V67, P3153, DOI 10.1158/0008-5472.CAN-06-4429; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nassar D, 2016, ANNU REV PATHOL-MECH, V11, P47, DOI 10.1146/annurev-pathol-012615-044438; Naumann U, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009175; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Pablos JL, 1999, AM J PATHOL, V155, P1577, DOI 10.1016/S0002-9440(10)65474-0; PONTEN F, 1994, J INVEST DERMATOL, V102, P304, DOI 10.1111/1523-1747.ep12371787; Quan CJ, 2015, PROTEIN CELL, V6, P890, DOI 10.1007/s13238-015-0198-5; Rogers HW, 2010, ARCH DERMATOL, V146, P283, DOI 10.1001/archdermatol.2010.19; Sciaccaluga M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073426; Stratigos A, 2015, EUR J CANCER, V51, P1989, DOI 10.1016/j.ejca.2015.06.110; Sun XQ, 2010, CANCER METAST REV, V29, P709, DOI 10.1007/s10555-010-9256-x; Tang X, 2016, TUMOR BIOL, V37, P13425, DOI 10.1007/s13277-016-5180-1; Uchida D, 2007, MOL CANCER RES, V5, P685, DOI 10.1158/1541-7786.MCR-06-0368; Uchida DE, 2004, LAB INVEST, V84, P1538, DOI 10.1038/labinvest.3700190; Uemae Y, 2014, J NEURO-ONCOL, V117, P43, DOI 10.1007/s11060-014-1364-y; Wang JF, 2004, BBA-MOL CELL RES, V1691, P129, DOI 10.1016/j.bbamcr.2004.01.002; Wang X, 2016, ONCOTARGET, V8, P36149; White RA, 2013, J CLIN INVEST, V123, P4390, DOI 10.1172/JCI65856; Wong CE, 2013, GENE DEV, V27, P670, DOI 10.1101/gad.210427.112; Wu YC, 2016, ONCOGENE, V35, P2123, DOI 10.1038/onc.2015.274; Yang P, 2014, CURR MOL MED, V14, P174, DOI 10.2174/1566524013666131121115656; Yuan LP, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-18	52	17	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2019	38	25					5021	5037		10.1038/s41388-019-0773-y	http://dx.doi.org/10.1038/s41388-019-0773-y			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IE1KY	30874597	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000472145900010
J	Wang, TY; Song, P; Zhong, TT; Wang, XJ; Xiang, XP; Liu, Q; Chen, HY; Xia, T; Liu, H; Niu, YM; Hu, YS; Xu, L; Shao, YK; Zhu, LJ; Qi, HY; Shen, J; Hou, TJ; Fodde, RCRO; Shao, JM				Wang, Tingyang; Song, Ping; Zhong, Tingting; Wang, Xianjun; Xiang, Xueping; Liu, Qian; Chen, Haiyi; Xia, Tian; Liu, Hong; Niu, Yumiao; Hu, Yanshi; Xu, Lei; Shao, Yingkuan; Zhu, Lijun; Qi, Hongyan; Shen, Jing; Hou, Tingjun; Fodde, Riccardo; Shao, Jimin			The inflammatory cytokine IL-6 induces FRA1 deacetylation promoting colorectal cancer stem-like properties	ONCOGENE			English	Article							HISTONE DEACETYLASE; SELF-RENEWAL; C-JUN; CELLS; PROTEIN; NANOG; INTERLEUKIN-6; P53; ACCUMULATION; MACROPHAGES	Colorectal cancer (CRC) has long been known for its tight association with chronic inflammation, thought to play a key role in tumor onset and malignant progression through the modulation of cancer stemness. However, the underlying molecular and cellular mechanisms are still largely elusive. Here we show that the IL-6/STAT3 inflammatory signaling axis induces the deacetylation of FRA1 at the Lys-116 residue located within its DNA-binding domain. The HDAC6 deacetylase underlies this key modification leading to the increase of FRA1 transcriptional activity, the subsequent transactivation of NANOG expression, and the acquisition of stem-like cellular features. As validated in a large (n = 123) CRC cohort, IL-6 secretion was invariably accompanied by increased FRA1 deacetylation at K116 and an overall increase in its protein levels, coincident with malignant progression and poor prognosis. Of note, combined treatment with the conventional cytotoxic drug 5-FU together with Tubastatin A, a HDAC6-specific inhibitor, resulted in a significant in vivo synergistic inhibitory effect on tumor growth through suppression of CRC stemness. Our results reveal a novel transcriptional and posttranslational regulatory cross-talk between inflammation and stemness signaling pathways that underlie self-renewal and maintenance of CRC stem cells and promote their malignant behavior. Combinatorial treatment aimed at the core regulatory mechanisms downstream of IL-6 may offer a novel promising approach for CRC treatment.	[Wang, Tingyang; Song, Ping; Zhong, Tingting; Wang, Xianjun; Xiang, Xueping; Liu, Qian; Xia, Tian; Liu, Hong; Niu, Yumiao; Shao, Yingkuan; Qi, Hongyan; Shen, Jing; Shao, Jimin] Zhejiang Univ, Affiliated Hosp 2, Dept Pathol & Pathophysiol, Sch Med, Hangzhou, Zhejiang, Peoples R China; [Wang, Tingyang; Song, Ping; Zhong, Tingting; Wang, Xianjun; Xiang, Xueping; Liu, Qian; Xia, Tian; Liu, Hong; Niu, Yumiao; Shao, Yingkuan; Qi, Hongyan; Shen, Jing; Shao, Jimin] Zhejiang Univ, Affiliated Hosp 2, Canc Inst, Sch Med, Hangzhou, Zhejiang, Peoples R China; [Wang, Tingyang; Song, Ping; Xiang, Xueping; Shao, Yingkuan; Shao, Jimin] Zhejiang Univ, Sch Med, Key Lab Dis Prote Zhejiang Prov, Key Lab Canc Prevent & Intervent,China Natl Minis, Hangzhou, Zhejiang, Peoples R China; [Wang, Tingyang; Song, Ping; Xiang, Xueping; Shao, Yingkuan; Shao, Jimin] Zhejiang Univ, Sch Med, Res Ctr Air Pollut & Hlth, Hangzhou, Zhejiang, Peoples R China; [Chen, Haiyi; Hou, Tingjun] Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou, Zhejiang, Peoples R China; [Hu, Yanshi] Zhejiang Univ, Coll Life Sci, Dept Bioinformat, Hangzhou, Zhejiang, Peoples R China; [Xu, Lei; Hou, Tingjun] Jiangsu Univ Technol, Sch Elect & Informat Engn, Inst Bioinformat & Med Engn, Changzhou, Peoples R China; [Zhu, Lijun] Zhejiang Univ, Affiliated Hosp 1, Key Lab Precis Diag & Treatment Hepatobiliary & P, Sch Med, Hangzhou, Zhejiang, Peoples R China; [Fodde, Riccardo] Erasmus MC, Erasmus MC Canc Inst, Dept Pathol, Rotterdam, Netherlands; [Zhong, Tingting] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Pathol, Sch Med, Hangzhou, Zhejiang, Peoples R China; [Liu, Hong] Zhejiang Normal Univ Jinhua Peoples Hosp Joint Ct, Jinhua, Zhejiang, Peoples R China	Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang University; Jiangsu University of Technology; Zhejiang University; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Zhejiang University	Shao, JM (corresponding author), Zhejiang Univ, Affiliated Hosp 2, Dept Pathol & Pathophysiol, Sch Med, Hangzhou, Zhejiang, Peoples R China.; Shao, JM (corresponding author), Zhejiang Univ, Affiliated Hosp 2, Canc Inst, Sch Med, Hangzhou, Zhejiang, Peoples R China.; Shao, JM (corresponding author), Zhejiang Univ, Sch Med, Key Lab Dis Prote Zhejiang Prov, Key Lab Canc Prevent & Intervent,China Natl Minis, Hangzhou, Zhejiang, Peoples R China.; Shao, JM (corresponding author), Zhejiang Univ, Sch Med, Res Ctr Air Pollut & Hlth, Hangzhou, Zhejiang, Peoples R China.; Fodde, RCRO (corresponding author), Erasmus MC, Erasmus MC Canc Inst, Dept Pathol, Rotterdam, Netherlands.	r.fodde@erasmusmc.nl; shaojimin@zju.edu.cn	Shao, Yingkuan/AAO-9244-2020; Fodde, Riccardo/AAW-9394-2021; Hou, Tingjun/C-7492-2011; Hu, Yanshi/G-1650-2017	Shao, Yingkuan/0000-0001-9683-5691; Fodde, Riccardo/0000-0001-9839-4324; Hou, Tingjun/0000-0001-7227-2580; Hu, Yanshi/0000-0003-3219-3778	National Natural Science Foundation of China [81572384, 81372138, 81702401, 81771518]; National Key R&D Program of China [2016YFC1303401]; National Science and Technology Major Project of China [2018ZX10302206-006-007]; ZJU funds; Dutch Digestive Foundation [FP 15-09]; Dutch Cancer Society; Erasmus MC [EMCR 2015-8090]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key R&D Program of China; National Science and Technology Major Project of China; ZJU funds; Dutch Digestive Foundation; Dutch Cancer Society(KWF Kankerbestrijding); Erasmus MC	The authors are grateful to the contribution of the specimen donors. We thank Professor Xin-Hua Feng from Life Sciences Institute and Innovation Center for Cell Signaling Network, Zhejiang University for providing HDAC6 overexpressing plasmids; Professor Qun-Ying Lei from Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Fudan University for providing HDAC1-6 overexpressing plasmids; Professor Cheng Qian from the Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University for providing Lv-NANOG, Lv-shNANOG, and Lv-scrambled plasmids; and Professor Chong Liu from the Department of Pathology & Pathophysiology, Zhejiang University School of Medicine for help with immunofluorescence technology. This work was supported by National Natural Science Foundation of China (81572384, 81372138, 81702401 and 81771518), National Key R&D Program of China (2016YFC1303401), and National Science and Technology Major Project of China (2018ZX10302206-006-007). RF is supported by ZJU funds and by the Dutch Digestive Foundation (FP 15-09), Dutch Cancer Society, and the Erasmus MC (EMCR 2015-8090).	Ali I, 2018, CHEM REV, V118, P340, DOI 10.1021/acs.chemrev.7b00181; Belguise K, 2012, ONCOGENE, V31, P4889, DOI 10.1038/onc.2011.659; Butler KV, 2010, J AM CHEM SOC, V132, P10842, DOI 10.1021/ja102758v; Canettieri G, 2010, NAT CELL BIOL, V12, P132, DOI 10.1038/ncb2013; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Du L, 2008, CLIN CANCER RES, V14, P6751, DOI 10.1158/1078-0432.CCR-08-1034; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; Grivennikov SI, 2011, ANN RHEUM DIS, V70, pI104, DOI 10.1136/ard.2010.140145; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He WZ, 2018, CANCER RES, V78, P3293, DOI 10.1158/0008-5472.CAN-17-3131; Hong A, 2018, CANCER DISCOV, V8, P74, DOI 10.1158/2159-8290.CD-17-0682; Hou T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089575; Hou TJ, 2012, J PROTEOME RES, V11, P2982, DOI 10.1021/pr3000688; Hou TJ, 2011, J CHEM INF MODEL, V51, P69, DOI 10.1021/ci100275a; Ibrahim EE, 2012, STEM CELLS, V30, P2076, DOI 10.1002/stem.1182; Jacobson MP, 2004, PROTEINS, V55, P351, DOI 10.1002/prot.10613; Kakumoto K, 2006, P NATL ACAD SCI USA, V103, P5490, DOI 10.1073/pnas.0601222103; Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j; Kryczek I, 2014, IMMUNITY, V40, P772, DOI 10.1016/j.immuni.2014.03.010; Lasry A, 2016, NAT IMMUNOL, V17, P230, DOI 10.1038/ni.3384; Lau EYT, 2016, CELL REP, V15, P1175, DOI 10.1016/j.celrep.2016.04.019; Lee TKW, 2011, CELL STEM CELL, V9, P50, DOI 10.1016/j.stem.2011.06.005; Liu H, 2015, CARCINOGENESIS, V36, P459, DOI 10.1093/carcin/bgv017; Liu YJ, 2012, J BIOL CHEM, V287, P29168, DOI 10.1074/jbc.M112.371120; Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255; Pakay JL, 2012, ONCOGENE, V31, P1817, DOI 10.1038/onc.2011.375; Qi J, 2015, CELL STEM CELL, V17, P597, DOI 10.1016/j.stem.2015.08.004; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Ryu HW, 2017, CANCER LETT, V391, P162, DOI 10.1016/j.canlet.2017.01.033; Salomon-Ferrer R, 2013, WIRES COMPUT MOL SCI, V3, P198, DOI 10.1002/wcms.1121; Sayan AE, 2012, ONCOGENE, V31, P1493, DOI 10.1038/onc.2011.336; Sun HY, 2014, PHYS CHEM CHEM PHYS, V16, P22035, DOI 10.1039/c4cp03179b; Sveen A, 2011, GENOME MED, V3, DOI 10.1186/gm248; Tam WL, 2013, CANCER CELL, V24, P347, DOI 10.1016/j.ccr.2013.08.005; van der Zee M, 2015, CANCER RES, V75, P3608, DOI 10.1158/0008-5472.CAN-14-2498; Vries RGJ, 2001, EMBO J, V20, P6095, DOI 10.1093/emboj/20.21.6095; Wan SS, 2014, GASTROENTEROLOGY, V147, P1393, DOI 10.1053/j.gastro.2014.08.039; Wang DZ, 2015, GASTROENTEROLOGY, V149, P1884, DOI 10.1053/j.gastro.2015.07.064; Wang DL, 2016, NATURE, V538, P118, DOI 10.1038/nature19759; Wang QS, 2010, CELL RES, V20, P701, DOI 10.1038/cr.2010.52; Xu L, 2013, J PHYS CHEM B, V117, P8408, DOI 10.1021/jp404160y; Xu RH, 2008, CELL STEM CELL, V3, P196, DOI 10.1016/j.stem.2008.07.001; Yang W, 2018, CANCER LETT, V415, P164, DOI 10.1016/j.canlet.2017.12.005; Yang XJ, 2005, MOL CELL BIOL, V25, P2873, DOI 10.1128/MCB.25.8.2873-2884.2005; Yao C, 2016, STEM CELLS, V34, P820, DOI 10.1002/stem.2320; Yoon DS, 2014, STEM CELLS, V32, P3219, DOI 10.1002/stem.1811; Zerbini LF, 2003, CANCER RES, V63, P2206; Zhang J, 2013, ONCOGENE, V32, P4397, DOI 10.1038/onc.2012.461	49	32	35	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2019	38	25					4932	4947		10.1038/s41388-019-0763-0	http://dx.doi.org/10.1038/s41388-019-0763-0			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IE1KY	30804456	hybrid, Green Published			2022-12-28	WOS:000472145900004
J	Cao, J; Zhu, Z; Wang, H; Nichols, TC; Lui, GYL; Deng, SB; Rejto, PA; VanArsdale, T; Hardwick, JS; Weinrich, SL; Wei, P				Cao, Joan; Zhu, Zhou; Wang, Hui; Nichols, Timothy C.; Lui, Goldie Y. L.; Deng, Shibing; Rejto, Paul A.; VanArsdale, Todd; Hardwick, James S.; Weinrich, Scott L.; Wei, Ping			Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer	ONCOGENE			English	Article							DEPENDENT KINASE 4/6; BREAST-CANCER; EXPRESSION; ANGIOGENESIS; PHOSPHORYLATION; TRANSCRIPTION; REPLICATION; SENSITIVITY; DISRUPTION; RECEPTOR	The CDK4/6 inhibitor palbociclib reduces tumor growth by decreasing retinoblastoma (RB) protein phosphorylation and inducing cell cycle arrest at the G1/S phase transition. Palbociclib in combination with anti-hormonal therapy brings significant benefit to breast cancer patients. In this study, novel combination approaches and underlying molecular/cellular mechanisms for palbociclib were explored in squamous cell lung cancer (SqCLC), the second most common subtype of non-small cell lung cancer. While approximate 20% lung patients benefit from immunotherapy, most SqCLC patients who receive platinum-doublet chemotherapy as first-line treatment, which often includes a taxane, are still in need of more effective combination therapies. Our results demonstrated enhanced cytotoxicity and anti-tumor effect with palbociclib plus taxanes at clinically achievable doses in multiple SqCLC models with diverse cancer genetic backgrounds. Comprehensive gene expression analysis revealed a sustained disruption of pRB-E2F signaling by combination that was accompanied with enhanced regulation of pleiotropic biological effects. These included several novel mechanisms such as abrogation of G2/M and mitotic spindle assembly checkpoints, as well as impaired induction of hypoxia-inducible factor 1 alpha (HIF-1 alpha). The decrease in HIF-1 alpha modulated a couple key angiogenic and anti-angiogenic factors, resulting in an enhanced anti-angiogenic effect. This preclinical work suggests a new therapeutic opportunity for palbociclib in lung and other cancers currently treated with taxane based chemotherapy as standard of care.	[Cao, Joan; Zhu, Zhou; Rejto, Paul A.; Hardwick, James S.; Weinrich, Scott L.; Wei, Ping] Pfizer Inc, Oncol Translat Res, San Diego, CA 92121 USA; [Wang, Hui] Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA; [Nichols, Timothy C.] Pfizer Inc, Drug Safety Res & Dev, San Diego, CA 92121 USA; [Lui, Goldie Y. L.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; [Deng, Shibing] Pfizer Inc, La Jolla Labs, Biostat, San Diego, CA 92121 USA; [VanArsdale, Todd] Pfizer Inc, Tumor Cell Biol Oncol Res & Dev, San Diego, CA 92121 USA	Pfizer; Novartis; Pfizer; Fred Hutchinson Cancer Center; Pfizer; Pfizer	Wei, P (corresponding author), Pfizer Inc, Oncol Translat Res, San Diego, CA 92121 USA.	ping.wei@pfizer.com	Lui, Goldie/J-7874-2019	Lui, Goldie/0000-0003-2741-6025				Anders L, 2011, CANCER CELL, V20, P620, DOI 10.1016/j.ccr.2011.10.001; Bakker WJ, 2013, TRANSCR-AUSTIN, V4, P62, DOI 10.4161/trns.23680; Bertoli C, 2016, CELL REP, V15, P1412, DOI 10.1016/j.celrep.2016.04.036; Bocci G, 2013, ANGIOGENESIS, V16, P481, DOI 10.1007/s10456-013-9334-0; Bosco EE, 2007, J CLIN INVEST, V117, P218, DOI 10.1172/JCI28803; Bretz F, 2011, MULTIPLE COMP USING, DOI DOI 10.1201/9781420010909; Buck E, 2006, MOL CANCER THER, V5, P2676, DOI 10.1158/1535-7163.MCT-06-0166; Budde A, 2005, ONCOGENE, V24, P1802, DOI 10.1038/sj.onc.1208369; Dean JL, 2012, J BIOL CHEM, V287, P29075, DOI 10.1074/jbc.M112.365494; Deville JL, 2010, EXPERT OPIN THER TAR, V14, P1059, DOI 10.1517/14728222.2010.522328; Dhillon S, 2015, DRUGS, V75, P543, DOI 10.1007/s40265-015-0379-9; Dominguez-Brauer C, 2015, MOL CELL, V60, P524, DOI 10.1016/j.molcel.2015.11.006; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Ertel A, 2010, CELL CYCLE, V9, P4153, DOI 10.4161/cc.9.20.13454; Escuin D, 2005, CANCER RES, V65, P9021, DOI 10.1158/0008-5472.CAN-04-4095; Ferrara R, 2016, EXPERT OPIN PHARMACO, V17, P1113, DOI 10.1517/14656566.2016.1157581; Flaherty KT, 2012, CLIN CANCER RES, V18, P568, DOI 10.1158/1078-0432.CCR-11-0509; Fry DW, 2004, MOL CANCER THER, V3, P1427; Gabellini C, 2006, ONCOGENE, V25, P5326, DOI 10.1038/sj.onc.1209631; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Gong XQ, 2017, CANCER CELL, V32, P761, DOI 10.1016/j.ccell.2017.11.006; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Johnson J, 2016, ONCOGENE, V35, P4829, DOI 10.1038/onc.2016.32; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Krock Bryan L, 2011, Genes Cancer, V2, P1117, DOI 10.1177/1947601911423654; Kwong LN, 2012, NAT MED, V18, P1503, DOI 10.1038/nm.2941; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Mabjeesh NJ, 2003, CANCER CELL, V3, P363, DOI 10.1016/S1535-6108(03)00077-1; Manchado E, 2012, CELL DEATH DIFFER, V19, P369, DOI 10.1038/cdd.2011.197; Manning AL, 2012, NAT REV CANCER, V12, P220, DOI 10.1038/nrc3216; Newcomb EW, 2005, NEURO-ONCOLOGY, V7, P225, DOI 10.1215/S1152851704000997; O'Leary B, 2016, NAT REV CLIN ONCOL, V13, P417, DOI 10.1038/nrclinonc.2016.26; Oh E, 2016, SCI REP, V6, P1; Raspe E, 2017, EMBO MOL MED, V9, P1052, DOI 10.15252/emmm.201607084; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Schaal C, 2014, ADV CANCER RES, V121, P147, DOI 10.1016/B978-0-12-800249-0.00004-4; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Socinski MA, 2014, CURR ONCOL, V21, pE691, DOI 10.3747/co.21.1997; Spilker ME, 2017, CLIN CANCER RES, V23, P1080, DOI 10.1158/1078-0432.CCR-16-1164; Stetler-Stevenson WG, 2005, TRENDS MOL MED, V11, P97, DOI 10.1016/j.molmed.2005.01.007; Subramaniam D, 2012, MOL CANCER THER, V11, P1598, DOI 10.1158/1535-7163.MCT-12-0102; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Syed YY, 2017, DRUGS, V77, P799, DOI 10.1007/s40265-017-0742-0; Tse AN, 2007, CLIN CANCER RES, V13, P1955, DOI 10.1158/1078-0432.CCR-06-2793; VanArsdale T, 2015, CLIN CANCER RES, V21, P2905, DOI 10.1158/1078-0432.CCR-14-0816; Vernell R, 2003, J BIOL CHEM, V278, P46124, DOI 10.1074/jbc.M304930200; Vora SR, 2014, CANCER CELL, V26, P136, DOI 10.1016/j.ccr.2014.05.020; Weijts BGMW, 2012, EMBO J, V31, P3871, DOI 10.1038/emboj.2012.231; Witkiewicz AK, 2012, CLIN CANCER RES, V18, P5110, DOI 10.1158/1078-0432.CCR-12-0903; Zhang XH, 2013, CANCER BIOL THER, V14, P597, DOI 10.4161/cbt.24592	53	19	19	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2019	38	21					4125	4141		10.1038/s41388-019-0708-7	http://dx.doi.org/10.1038/s41388-019-0708-7			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ3HX	30700828				2022-12-28	WOS:000468740200011
J	Kim, BR; Park, SH; Jeong, YA; Na, YJ; Kim, JL; Jo, MJ; Jeong, S; Yun, HK; Oh, SC; Lee, DH				Kim, Bo Ram; Park, Seong Hye; Jeong, Yoon A.; Na, Yoo Jin; Kim, Jung Lim; Jo, Min Jee; Jeong, Soyeon; Yun, Hye Kyeong; Oh, Sang Cheul; Lee, Dae-Hee			RUNX3 enhances TRAIL-induced apoptosis by upregulating DR5 in colorectal cancer	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM STRESS; DEATH RECEPTOR 5; LIGAND (TRAIL)-INDUCED APOPTOSIS; TRANSCRIPTION FACTOR RUNX3; NF-KAPPA-B; ER STRESS; MEDIATED APOPTOSIS; TUMOR-SUPPRESSOR; GENE-EXPRESSION; GASTRIC-CANCER	RUNX3 is frequently inactivated by DNA hypermethylation in numerous cancers. Here, we show that RUNX3 has an important role in modulating apoptosis in immediate response to tumor necrosis factor-related apoptosis-including ligand (TRAIL). Importantly, no combined effect of TRAIL and RUNX3 was observed in non-cancerous cells. We investigated the expression of the death receptors (DRs) DR4 and DR5, which are related to TRAIL resistance. Overexpression of RUNX3 increased DR5 expression via induction of the reactive oxygen species (ROS)-endoplasmic reticulum (ER) stress-effector CHOP. Reduction of DR5 markedly decreased apoptosis enhanced by the combined therapy of TRAIL and RUNX3. Interestingly, RUNX3 induced reactive oxygen species production by inhibiting SOD3 transcription via binding to the Superoxide dismutase 3 (SOD3) promoter. Additionally, the combined effect of TRAIL and RUNX3 decreased tumor growth in xenograft models. Our results demonstrate a direct role for RUNX3 in TRAIL-induced apoptosis via activation of DR5 and provide further support for RUNX3 as an anti-tumor.	[Kim, Bo Ram; Kim, Jung Lim; Jeong, Soyeon; Oh, Sang Cheul; Lee, Dae-Hee] Korea Univ, Coll Med, Guro Hosp, Dept Oncol, Seoul, South Korea; [Park, Seong Hye; Jeong, Yoon A.; Na, Yoo Jin; Jo, Min Jee; Yun, Hye Kyeong] Korea Univ, Grad Sch Med, Coll Med, Seoul, South Korea	Korea University; Korea University Medicine (KU Medicine); Korea University; Korea University Medicine (KU Medicine)	Oh, SC; Lee, DH (corresponding author), Korea Univ, Coll Med, Guro Hosp, Dept Oncol, Seoul, South Korea.	sachoh@korea.ac.kr; neogene@korea.ac.kr			National Research Foundation (NRF) of Korea [NRF-2017R1A6A3A11030765]; Korea University Grant; project for cooperative R&D between Industry, Academy, and Research Institute [Co558375]	National Research Foundation (NRF) of Korea(National Research Foundation of Korea); Korea University Grant; project for cooperative R&D between Industry, Academy, and Research Institute	This work was supported by a National Research Foundation (NRF) of Korea grant funded the Korean government (MSIP) [NRF-2017R1A6A3A11030765] and was supported by Korea University Grant and was supported by project for cooperative R&D between Industry, Academy, and Research Institute funded Korea ministry of SMES and Startups in 2018 [Grants No. Co558375].	Boyce M, 2006, CELL DEATH DIFFER, V13, P363, DOI 10.1038/sj.cdd.4401817; Chawla-Sarkar M, 2004, CELL DEATH DIFFER, V11, P915, DOI 10.1038/sj.cdd.4401416; Chi XZ, 2005, MOL CELL BIOL, V25, P8097, DOI 10.1128/MCB.25.18.8097-8107.2005; Daga A, 1996, GENE DEV, V10, P1194, DOI 10.1101/gad.10.10.1194; Dufour F, 2017, ONCOTARGET, V8, P9974, DOI 10.18632/oncotarget.14285; Franco AV, 2001, J IMMUNOL, V166, P5337, DOI 10.4049/jimmunol.166.9.5337; Fritsche H, 2015, ONCOTARGET, V6, P9502, DOI 10.18632/oncotarget.3321; Fukai T, 2011, ANTIOXID REDOX SIGN, V15, P1583, DOI 10.1089/ars.2011.3999; Gan HC, 2016, AM J PHYSIOL-LUNG C, V311, pL1101, DOI 10.1152/ajplung.00278.2016; Gan HC, 2015, SCI REP-UK, V5, DOI 10.1038/srep17916; Giambra V, 2012, NAT MED, V18, P1693, DOI 10.1038/nm.2960; Glab JA, 2017, CELL DEATH DIFFER, V24, P944, DOI 10.1038/cdd.2017.53; Guha P, 2017, ONCOTARGET, V8, P68191, DOI 10.18632/oncotarget.19277; Harashima N, 2017, ONCOTARGET, V8, P42887, DOI 10.18632/oncotarget.17157; Hartwig T, 2017, MOL CELL, V65, P730, DOI 10.1016/j.molcel.2017.01.021; He K, 2016, ONCOGENE, V35, P148, DOI 10.1038/onc.2015.79; He L, 2013, MOL CARCINOGEN, V52, P85, DOI 10.1002/mc.21831; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Ito K, 2005, CANCER RES, V65, P7743, DOI 10.1158/0008-5472.CAN-05-0743; Ito Y, 1999, GENES CELLS, V4, P685, DOI 10.1046/j.1365-2443.1999.00298.x; Iurlaro R, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00479-16; Jiang YN, 2017, MOL IMMUNOL, V82, P123, DOI 10.1016/j.molimm.2016.12.023; Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465; Jung EM, 2005, CARCINOGENESIS, V26, P1905, DOI 10.1093/carcin/bgi167; Kadara H, 2007, CANCER BIOL THER, V6, P705, DOI 10.4161/cbt.6.5.3963; Kandasamy K, 2002, CANCER RES, V62, P4929; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; Kapur A, 2016, SCI REP-UK, V6, DOI 10.1038/srep27530; Kim BR, 2016, ONCOL REP, V36, P2601, DOI 10.3892/or.2016.5086; Kim BR, 2017, ONCOTARGET, V8; Kodach LL, 2010, CARCINOGENESIS, V31, P1567, DOI 10.1093/carcin/bgq147; Ku JL, 2004, ONCOGENE, V23, P6736, DOI 10.1038/sj.onc.1207731; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lee DH, 2016, J CELL BIOCHEM, V117, P1078, DOI 10.1002/jcb.25289; Lee DH, 2014, TOXICOL APPL PHARM, V279, P253, DOI 10.1016/j.taap.2014.06.030; Lee DH, 2009, BRIT J PHARMACOL, V157, P1189, DOI 10.1111/j.1476-5381.2009.00245.x; Lee JH, 2011, CLIN EXP DERMATOL, V36, P769, DOI 10.1111/j.1365-2230.2011.04069.x; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Li TL, 2015, J BIOL CHEM, V290, P11108, DOI 10.1074/jbc.M115.645333; Lim JH, 2009, CARCINOGENESIS, V30, P729, DOI 10.1093/carcin/bgn265; Liu ZX, 2016, CHEM RES TOXICOL, V29, P1510, DOI 10.1021/acs.chemrestox.6b00181; Lotem J, 2015, BBA-REV CANCER, V1855, P131, DOI 10.1016/j.bbcan.2015.01.004; Lu M, 2014, SCIENCE, V345, P98, DOI 10.1126/science.1254312; Ma ZQ, 2016, SCI REP-UK, V6, DOI 10.1038/srep35196; Na YJ, 2017, INT J BIOCHEM CELL B, V89, P147, DOI 10.1016/j.biocel.2017.06.010; Pal S, 2016, CANCER MICROENVIRON, V9, P77, DOI 10.1007/s12307-016-0184-3; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Park HS, 2011, BIOCHEM PHARMACOL, V82, P1110, DOI 10.1016/j.bcp.2011.07.085; Park SH, 2016, ONCOTARGET, V7, P59503, DOI 10.18632/oncotarget.11147; Prasad S, 2014, TRENDS PHARMACOL SCI, V35, P520, DOI 10.1016/j.tips.2014.07.004; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Shi K, 2017, THERANOSTICS, V7, P4480, DOI 10.7150/thno.21707; Tian XB, 2011, J BIOL CHEM, V286, P29408, DOI 10.1074/jbc.M110.197665; Toscano F, 2008, ONCOGENE, V27, P4161, DOI 10.1038/onc.2008.52; von Karstedt S, 2015, CANCER CELL, V27, P561, DOI 10.1016/j.ccell.2015.02.014; Wagner KW, 2007, NAT MED, V13, P1070, DOI 10.1038/nm1627; Waki T, 2003, CANCER SCI, V94, P360, DOI 10.1111/j.1349-7006.2003.tb01447.x; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Yang F, 2010, CELL DEATH DIFFER, V17, P1354, DOI 10.1038/cdd.2010.29; Zhang KZ, 2010, INT J CLIN EXP MED, V3, P33; ZLOTORYNSKI E, 2014, NAT REV MOL CELL BIO, V15, P498	61	18	20	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2019	38	20					3903	3918		10.1038/s41388-019-0693-x	http://dx.doi.org/10.1038/s41388-019-0693-x			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HY3OI	30692634				2022-12-28	WOS:000468035600010
J	Somers, K; Wen, VW; Middlemiss, SMC; Osborne, B; Forgham, H; Jung, M; Karsa, M; Clifton, M; Bongers, A; Gao, JX; Mayoh, C; Raoufi-Rad, N; Kusnadi, EP; Hannan, KM; Scott, DA; Kwek, A; Liu, B; Flemming, C; Chudakova, DA; Pandher, R; Failes, TW; Lim, J; Angeli, A; Osterman, AL; Imamura, T; Kees, UR; Supuran, CT; Pearson, RB; Hannan, RD; Davis, TP; McCarroll, J; Kavallaris, M; Turner, N; Gudkov, AV; Haber, M; Norris, MD; Henderson, MJ				Somers, Klaartje; Wen, Victoria W.; Middlemiss, Shiloh M. C.; Osborne, Brenna; Forgham, Helen; Jung, MoonSun; Karsa, Mawar; Clifton, Molly; Bongers, Angelika; Gao, Jixuan; Mayoh, Chelsea; Raoufi-Rad, Newsha; Kusnadi, Eric P.; Hannan, Kate M.; Scott, David A.; Kwek, Alan; Liu, Bing; Flemming, Claudia; Chudakova, Daria A.; Pandher, Ruby; Failes, Tim W.; Lim, James; Angeli, Andrea; Osterman, Andrei L.; Imamura, Toshihiko; Kees, Ursula R.; Supuran, Claudiu T.; Pearson, Richard B.; Hannan, Ross D.; Davis, Thomas P.; McCarroll, Joshua; Kavallaris, Maria; Turner, Nigel; Gudkov, Andrei V.; Haber, Michelle; Norris, Murray D.; Henderson, Michelle J.			A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction	ONCOGENE			English	Article							TARGETING MITOCHONDRIA; THERAPEUTIC STRATEGY; CARBONIC-ANHYDRASES; OXIDATIVE STRESS; MEIS1; CANCER; INHIBITION; EXPRESSION; METABOLISM; TRANSLOCATIONS	Survival rates for pediatric patients suffering from mixed lineage leukemia (MLL)-rearranged leukemia remain below 50% and more targeted, less toxic therapies are urgently needed. A screening method optimized to discover cytotoxic compounds selective for MLL-rearranged leukemia identified CCI-006 as a novel inhibitor of MLL-rearranged and CALM-AF10 translocated leukemias that share common leukemogenic pathways. CCI-006 inhibited mitochondrial respiration and induced mitochondrial membrane depolarization and apoptosis in a subset (7/11, 64%) of MLL-rearranged leukemia cell lines within a few hours of treatment. The unresponsive MLL-rearranged leukemia cells did not undergo mitochondrial membrane depolarization or apoptosis despite a similar attenuation of mitochondrial respiration by the compound. In comparison to the sensitive cells, the unresponsive MLL-rearranged leukemia cells were characterized by a more glycolytic metabolic phenotype, exemplified by a more pronounced sensitivity to glycolysis inhibitors and elevated HIF1 alpha expression. Silencing of HIF1 alpha expression sensitized an intrinsically unresponsive MLL-rearranged leukemia cell to CCI-006, indicating that this pathway plays a role in determining sensitivity to the compound. In addition, unresponsive MLL-rearranged leukemia cells expressed increased levels of MEIS1, an important leukemogenic MLL target gene that plays a role in regulating metabolic phenotype through HIF1 alpha. MEIS1 expression was also variable in a pediatric MLL-rearranged ALL patient dataset, highlighting the existence of a previously undescribed metabolic variability in MLL-rearranged leukemia that may contribute to the heterogeneity of the disease. This study thus identified a novel small molecule that rapidly kills MLL-rearranged leukemia cells by targeting a metabolic vulnerability in a subset of low HIF1 alpha/low MEIS1-expressing MLL-rearranged leukemia cells.	[Somers, Klaartje; Wen, Victoria W.; Middlemiss, Shiloh M. C.; Forgham, Helen; Jung, MoonSun; Karsa, Mawar; Clifton, Molly; Bongers, Angelika; Gao, Jixuan; Mayoh, Chelsea; Raoufi-Rad, Newsha; Kwek, Alan; Liu, Bing; Flemming, Claudia; Chudakova, Daria A.; Pandher, Ruby; Failes, Tim W.; Lim, James; McCarroll, Joshua; Kavallaris, Maria; Haber, Michelle; Norris, Murray D.; Henderson, Michelle J.] UNSW, Childrens Canc Inst, Lowy Canc Res Ctr, Randwick, NSW, Australia; [Osborne, Brenna; Turner, Nigel] UNSW, Sch Med Sci, Mitochondrial Bioenerget Lab, Randwick, NSW, Australia; [Forgham, Helen; McCarroll, Joshua; Kavallaris, Maria] UNSW Australia, Australian Ctr NanoMed, ARC Ctr Excellence Convergent Bionano Sci & Techn, Sydney, NSW, Australia; [Kusnadi, Eric P.; Pearson, Richard B.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [Hannan, Kate M.; Hannan, Ross D.] Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT, Australia; [Scott, David A.; Osterman, Andrei L.] Sanford Burnham Prebys Med Discovery Inst, La Jolla, CA 92037 USA; [Failes, Tim W.] UNSW, ACRF Drug Discovery Ctr, Childrens Canc Inst, Lowy Canc Res Ctr, Sydney, NSW, Australia; [Angeli, Andrea; Supuran, Claudiu T.] Univ Florence, Neurofarba Dept, Florence, Italy; [Imamura, Toshihiko] Kyoto Prefectural Univ Med, Dept Pediat, Kyoto, Japan; [Kees, Ursula R.] Univ Western Australia, Telethon Kids Inst, Perth, WA, Australia; [Davis, Thomas P.] Monash Univ, ARC Ctr Excellence Convergent Bionano Sci & Techn, Monash Inst Pharmaceut Sci, Clayton, Vic, Australia; [Davis, Thomas P.] Univ Warrick, Dept Chem, Coventry, W Midlands, England; [Gudkov, Andrei V.] Roswell Pk Canc Inst, Dept Cell Stress Biol, Buffalo, NY 14263 USA; [Gudkov, Andrei V.] Oncotartis Inc, Buffalo, NY USA; [Norris, Murray D.] UNSW Ctr Childhood Canc Res, Sydney, NSW, Australia	Children's Cancer Institute; University of New South Wales Sydney; University of New South Wales Sydney; University of New South Wales Sydney; Peter Maccallum Cancer Center; Australian National University; John Curtin School of Medical Research; Sanford Burnham Prebys Medical Discovery Institute; Children's Cancer Institute; University of New South Wales Sydney; University of Florence; Kyoto Prefectural University of Medicine; Telethon Kids Institute; University of Western Australia; Monash University; University of Warwick; Roswell Park Cancer Institute	Henderson, MJ (corresponding author), UNSW, Childrens Canc Inst, Lowy Canc Res Ctr, Randwick, NSW, Australia.	mhenderson@ccia.unsw.edu.au	Davis, Thomas/B-6395-2008; Chudakova, Daria/ABB-3032-2020; Mayoh, Chelsea/AAE-7349-2021; Turner, Nigel/H-7176-2013; Osborne, Brenna/F-5950-2018; McCarroll, Joshua/E-8481-2010	Davis, Thomas/0000-0003-2581-4986; Mayoh, Chelsea/0000-0002-6398-3046; Turner, Nigel/0000-0002-0119-9328; Osborne, Brenna/0000-0002-0197-3010; McCarroll, Joshua/0000-0001-8807-3623; Supuran, Claudiu/0000-0003-4262-0323; Karsa, Mawar/0000-0001-9682-1118; Scott, David/0000-0002-8668-2449; Forgham, Helen/0000-0002-6871-3213; Haber, Michelle/0000-0003-2036-8817; Gao, Jixuan/0000-0002-2209-3143; Hannan, Katherine/0000-0003-4186-8167; angeli, andrea/0000-0002-1470-7192; Kavallaris, Maria/0000-0003-2309-898X	NHMRC; Leukemia Foundation; NSW Cancer Council; Cancer Institute NSW; Tenix Foundation; ISG Foundation; Children's Leukemia & Cancer Research Foundation, Perth; NCI Cancer Center Support Grant [P30 CA30199]; Anthony Rothe Memorial Trust; NATIONAL CANCER INSTITUTE [P30CA030199] Funding Source: NIH RePORTER	NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Leukemia Foundation; NSW Cancer Council(Cancer Council New South Wales); Cancer Institute NSW; Tenix Foundation; ISG Foundation; Children's Leukemia & Cancer Research Foundation, Perth; NCI Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Anthony Rothe Memorial Trust; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by NHMRC, Leukemia Foundation, Anthony Rothe Memorial Trust, NSW Cancer Council, Cancer Institute NSW, Tenix Foundation, ISG Foundation and the Children's Leukemia & Cancer Research Foundation, Perth. Metabolic analysis was performed at the Cancer Metabolism Core, SBP Medical Discovery Institute, with assistance from Olga Zagnitko and support of NCI Cancer Center Support Grant P30 CA30199.	Appleby RD, 1999, EUR J BIOCHEM, V262, P108, DOI 10.1046/j.1432-1327.1999.00350.x; Arechederra RL, 2013, BIOORGAN MED CHEM, V21, P1544, DOI 10.1016/j.bmc.2012.06.053; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Bao XR, 2016, ELIFE, V5, DOI 10.7554/eLife.10575; BLISS CI, 1956, BACTERIOL REV, V20, P243, DOI 10.1128/MMBR.20.4.243-258.1956; Cardaci S, 2012, J BIOENERG BIOMEMBR, V44, P17, DOI 10.1007/s10863-012-9422-7; Caudell D, 2007, CANCER RES, V67, P8022, DOI 10.1158/0008-5472.CAN-06-3749; Chen L, 2013, LEUKEMIA, V27, P813, DOI 10.1038/leu.2012.327; Chen LL, 2016, ONCOTARGET, V7, P25208, DOI 10.18632/oncotarget.8199; Cole A, 2015, CANCER CELL, V27, P864, DOI 10.1016/j.ccell.2015.05.004; Daigle SR, 2013, BLOOD, V122, P1017, DOI 10.1182/blood-2013-04-497644; Driessen EMC, 2016, LEUKEMIA, V30, P1184, DOI 10.1038/leu.2015.246; Faber J, 2009, BLOOD, V113, P2375, DOI 10.1182/blood-2007-09-113597; Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hulbert AJ, 2006, J COMP PHYSIOL B, V176, P93, DOI 10.1007/s00360-005-0025-z; Hulleman E, 2009, BLOOD, V113, P2014, DOI 10.1182/blood-2008-05-157842; Jhas B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058367; Kees UR, 2003, MOL CANCER THER, V2, P671; Klaus CR, 2014, J PHARMACOL EXP THER, V350, P646, DOI 10.1124/jpet.114.214577; Kocabas F, 2012, BLOOD, V120, P4963, DOI 10.1182/blood-2012-05-432260; Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253; Kuhn A, 2016, ONCOTARGET, V7, P35341, DOI 10.18632/oncotarget.9241; Kumar AR, 2009, BLOOD, V113, P1756, DOI 10.1182/blood-2008-06-163287; Lagadinou ED, 2013, CELL STEM CELL, V12, P329, DOI 10.1016/j.stem.2012.12.013; Lee EA, 2015, CANCER RES, V75, P2478, DOI 10.1158/0008-5472.CAN-14-2676; MacArthur DG, 2008, HUM MOL GENET, V17, P1076, DOI 10.1093/hmg/ddm380; Marin-Hernandez A, 2009, MINI-REV MED CHEM, V9, P1084, DOI 10.2174/138955709788922610; Marschalek R, 2016, ANN LAB MED, V36, P85, DOI 10.3343/alm.2016.36.2.85; Orlovsky K, 2011, P NATL ACAD SCI USA, V108, P7956, DOI 10.1073/pnas.1103154108; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Pieters R, 2007, LANCET, V370, P240, DOI 10.1016/S0140-6736(07)61126-X; Quiros PM, 2017, J CELL BIOL, V216, P2027, DOI 10.1083/jcb.201702058; Ratnikov B, 2015, ONCOTARGET, V6, P7379, DOI 10.18632/oncotarget.3132; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Roychoudhury J, 2015, BLOOD, V125, P2544, DOI 10.1182/blood-2014-09-599258; Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028; Shah GN, 2013, J PHARMACOL EXP THER, V344, P637, DOI 10.1124/jpet.112.201400; Skrtic M, 2011, CANCER CELL, V20, P674, DOI 10.1016/j.ccr.2011.10.015; Somers K, 2016, ONCOTARGET, V7, P46067, DOI 10.18632/oncotarget.10022; Sriskanthadevan S, 2015, BLOOD, V125, P2120, DOI 10.1182/blood-2014-08-594408; Stam RW, 2010, BLOOD, V115, P2835, DOI 10.1182/blood-2009-07-233049; Stein EM, 2018, BLOOD, V131, P2661, DOI 10.1182/blood-2017-12-818948; Supuran CT, 2008, NAT REV DRUG DISCOV, V7, P168, DOI 10.1038/nrd2467; Teo J, 2016, BIOMACROMOLECULES, V17, P2337, DOI 10.1021/acs.biomac.6b00185; Thorsteinsdottir U, 2001, MOL CELL BIOL, V21, P224, DOI 10.1128/MCB.21.1.224-234.2001; Trentin L, 2009, EUR J HAEMATOL, V83, P406, DOI 10.1111/j.1600-0609.2009.01305.x; Turner N, 2007, DIABETES, V56, P2085, DOI 10.2337/db07-0093; Unnisa Z, 2012, BLOOD, V120, P4973, DOI 10.1182/blood-2012-06-435800; van der Linden MH, 2009, BLOOD, V114, P3764, DOI 10.1182/blood-2009-02-204214; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Weinberg SE, 2015, NAT CHEM BIOL, V11, P9, DOI 10.1038/nchembio.1712; Wong P, 2007, GENE DEV, V21, P2762, DOI 10.1101/gad.1602107; Zhao W, 2014, J BIOMOL SCREEN, V19, P817, DOI 10.1177/1087057114521867	55	13	13	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2019	38	20					3824	3842		10.1038/s41388-018-0666-5	http://dx.doi.org/10.1038/s41388-018-0666-5			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HY3OI	30670779	Green Published, hybrid			2022-12-28	WOS:000468035600005
J	Karvonen, H; Perttila, R; Niininen, W; Hautanen, V; Barker, H; Murumagi, A; Heckman, CA; Ungureanu, D				Karvonen, Hanna; Perttila, Robert; Niininen, Wilhelmiina; Hautanen, Veera; Barker, Harlan; Murumagi, Astrid; Heckman, Caroline A.; Ungureanu, Daniela			Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; STEM-CELLS; DISEASE; IDENTIFICATION; HEMATOPOIESIS; CHEMOTAXIS; MECHANISMS; INHIBITORS; CROSSTALK; PATHWAYS	B-cell precursor acute lymphoblastic leukemia (BCP-ALL) with TCF3-PBX1 fusion gene expression has constitutively elevated levels of Wnt16b and ROR1 (receptor tyrosine kinase-like orphan receptor), a ligand and a receptor from the Wnt signaling pathway, respectively. Although survival rate is usually high after the initial chemotherapy, many TCF3-PBX1 BCP-ALL patients relapse and subsequently develop treatment resistance, resulting in poor prognosis. Here, we aimed to investigate the molecular signaling associated with Wnt16b and ROR1 overexpression in TCF3-PBX1 cell lines and primary samples, and to identify effective treatment options via ROR1 targeting. We detected higher ROR1 expression on TCF3-PBX1 leukemic cells even at a later stage of patient relapse, providing a strong rationale for the use of ROR1-targeted therapy. We found that Wnt5a-ROR1 signaling enhances proliferation of TCF3-PBX1 cells via RhoA/Rac1 GTPases activation and STAT3 upregulation. Wnt16b also activated the RhoA/Rac1 signaling cascade suggesting the activation of a non-canonical Wnt pathway in TCF3-PBX1 cells. Wnt16 could interact with ROR1 but not in TCF3-PBX1 cells, suggesting that Wnt5a is the ligand signaling via ROR1 in TCF3-PBX1 cells. By high throughput drug-sensitivity testing of TCF3-PBX1 cells before and after ROR1 knockdown we found that targeting ROR1 significantly improves the therapeutic efficacy of Bcl-2 family inhibitors venetoclax and navitoclax, and this synergism was confirmed ex vivo using a drug-resistant primary sample from a relapsed TCF3-PBX1 patient. Our work underlines a new type of targeted combination therapy that could be clinically advantageous for patients with TCF3-PBX1 BCP-ALL.	[Karvonen, Hanna; Perttila, Robert; Niininen, Wilhelmiina; Hautanen, Veera; Barker, Harlan; Ungureanu, Daniela] Tampere Univ, BioMediTech Inst, Tampere, Finland; [Karvonen, Hanna; Perttila, Robert; Niininen, Wilhelmiina; Hautanen, Veera; Barker, Harlan; Ungureanu, Daniela] Tampere Univ, Fac Med & Hlth Technol, Tampere, Finland; [Murumagi, Astrid; Heckman, Caroline A.] Univ Helsinki, Helsinki Inst Life Sci, Inst Mol Med Finland FIMM, Helsinki, Finland	Tampere University; Tampere University; University of Helsinki	Ungureanu, D (corresponding author), Tampere Univ, BioMediTech Inst, Tampere, Finland.; Ungureanu, D (corresponding author), Tampere Univ, Fac Med & Hlth Technol, Tampere, Finland.	daniela.ungureanu@tuni.fi	Perttilä, Robert/S-8006-2019	Perttilä, Robert/0000-0001-8030-7077; Karvonen, Hanna/0000-0002-7815-0709; Hautanen, Veera/0000-0002-6278-4109; Murumagi, Astrid/0000-0002-7797-188X; Ungureanu, Daniela/0000-0002-9314-4972; Heckman, Caroline/0000-0002-4324-8706; Barker, Harlan/0000-0003-4125-2522	Doctoral Program in Medicine and Life Sciences at University of Tampere; Academy of Finland; Center of Excellence for Translational Cancer Biology; Sigrid Juselius Foundation	Doctoral Program in Medicine and Life Sciences at University of Tampere; Academy of Finland(Academy of Finland); Center of Excellence for Translational Cancer Biology; Sigrid Juselius Foundation(Sigrid Juselius Foundation)	This work was supported by the Doctoral Program in Medicine and Life Sciences at University of Tampere, Academy of Finland, Center of Excellence for Translational Cancer Biology, and the Sigrid Juselius Foundation.	Asem MS, 2016, CANCERS, V8, DOI 10.3390/cancers8090079; Balakrishnan A, 2016, CLIN CANC RES; Bengoa-Vergniory N, 2017, MOL NEUROBIOL, V54, P6213, DOI 10.1007/s12035-016-0151-5; Berger C, 2015, CANCER IMMUNOL RES, V3, P206, DOI 10.1158/2326-6066.CIR-14-0163; Bicocca VT, 2012, CANCER CELL, V22, P656, DOI 10.1016/j.ccr.2012.08.027; Borcherding N, 2014, PROTEIN CELL, V5, P496, DOI 10.1007/s13238-014-0059-7; Burmeister T, 2010, HAEMATOL-HEMATOL J, V95, P241, DOI 10.3324/haematol.2009.011346; Casagrande G, 2006, HAEMATOLOGICA, V91, P765; CHEN Y, 2017, BLOOD S1, V130; Choi MY, 2018, CELL STEM CELL, V22, P951, DOI 10.1016/j.stem.2018.05.018; Daneshmanesh AH, 2012, LEUKEMIA, V26, P1348, DOI 10.1038/leu.2011.362; Dave H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052655; DeBruine ZJ, 2017, BRIT J PHARMACOL, V174, P4564, DOI 10.1111/bph.14048; Eldfors S, 2017, LEUKEMIA, V31, P51, DOI 10.1038/leu.2016.202; Geng HM, 2015, CANCER CELL, V27, P409, DOI 10.1016/j.ccell.2015.02.003; Grumolato L, 2010, GENE DEV, V24, P2517, DOI 10.1101/gad.1957710; Harvey RC, 2010, BLOOD, V116, P4874, DOI 10.1182/blood-2009-08-239681; Hojjat-Farsangi M, 2018, LEUKEMIA, V32, P2291, DOI 10.1038/s41375-018-0113-1; Hunter JD, 2007, COMPUT SCI ENG, V9, P90, DOI 10.1109/MCSE.2007.55; Janovska P, 2017, BRIT J PHARMACOL, V174, P4701, DOI 10.1111/bph.13949; Janovska P, 2016, CLIN CANCER RES, V22, P459, DOI 10.1158/1078-0432.CCR-15-0154; Kang HN, 2010, BLOOD, V115, P1394, DOI 10.1182/blood-2009-05-218560; Karjalainen R, 2017, BLOOD, V130, P789, DOI 10.1182/blood-2016-02-699363; Karvonen H, 2017, BLOOD ADV, V1, P2257, DOI 10.1182/bloodadvances.2017010215; Karvonen H, 2017, BIOCHEM SOC T, V45, P457, DOI 10.1042/BST20160272; Katoh M, 2007, INT J MOL MED, V19, P273; Li P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011859; Lu DS, 2004, P NATL ACAD SCI USA, V101, P3118, DOI 10.1073/pnas.0308648100; Mazieres J, 2005, ONCOGENE, V24, P5396, DOI 10.1038/sj.onc.1208568; Mendrola JM, 2013, BIOCHEM SOC T, V41, P1029, DOI 10.1042/BST20130104; Mihalyova J, 2018, EXP HEMATOL, V61, P10, DOI 10.1016/j.exphem.2018.02.002; Muschen M, 2015, BLOOD, V125, P3688, DOI 10.1182/blood-2015-01-567842; Murphy JM, 2014, BIOCHEM J, V457, P323, DOI 10.1042/BJ20131174; Nemeth MJ, 2007, P NATL ACAD SCI USA, V104, P15436, DOI 10.1073/pnas.0704747104; Nygren MK, 2009, EXP HEMATOL, V37, P225, DOI 10.1016/j.exphem.2008.10.007; Oliphant TE, 2007, COMPUT SCI ENG, V9, P10, DOI 10.1109/MCSE.2007.58; Pemovska T, 2013, CANCER DISCOV, V3, P1416, DOI 10.1158/2159-8290.CD-13-0350; Pui C, 2004, NEW ENGL J MED, V350, P1535, DOI 10.1056/NEJMra023001; Rassenti LZ, 2017, P NATL ACAD SCI USA, V114, P10731, DOI 10.1073/pnas.1708264114; Roberts AW, 2016, NEW ENGL J MED, V374, P311, DOI 10.1056/NEJMoa1513257; Schreck C, 2014, ANN NY ACAD SCI, V1310, P32, DOI 10.1111/nyas.12384; Staal FJT, 2005, NAT REV IMMUNOL, V5, P21, DOI 10.1038/nri1529; Sun Y, 2016, ONCOGENE, V35, P4321, DOI 10.1038/onc.2015.494; Teh MT, 2007, J CELL SCI, V120, P330, DOI 10.1242/jcs.03329; Wee S, 2008, P NATL ACAD SCI USA, V105, P13057, DOI 10.1073/pnas.0802655105; Wiederschain D, 2009, CELL CYCLE, V8, P498, DOI 10.4161/cc.8.3.7701; Wilson WH, 2010, LANCET ONCOL, V11, P1149, DOI 10.1016/S1470-2045(10)70261-8; Yadav B, 2014, SCI REP-UK, V4, DOI 10.1038/srep05193; Yu J, 2017, LEUKEMIA, V31, P1333, DOI 10.1038/leu.2016.368; Yu J, 2016, J CLIN INVEST, V126, P585, DOI 10.1172/JCI83535	50	24	24	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2019	38	17					3288	3300		10.1038/s41388-018-0670-9	http://dx.doi.org/10.1038/s41388-018-0670-9			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU8RI	30631148				2022-12-28	WOS:000465557200013
J	Abdelwahab, EMM; Pal, S; Kvell, K; Sarosi, V; Bai, P; Rue, R; Krymskaya, V; McPhail, D; Porter, A; Pongracz, JE				Abdelwahab, E. M. M.; Pal, S.; Kvell, K.; Sarosi, V; Bai, P.; Rue, R.; Krymskaya, V; McPhail, D.; Porter, A.; Pongracz, J. E.			Mitochondrial dysfunction is a key determinant of the rare disease lymphangioleiomyomatosis and provides a novel therapeutic target	ONCOGENE			English	Article							CYTOCHROME-C; CELL; BIOGENESIS; TSC2; PHOSPHORYLATION; ESTROGEN; FEATURES; CHAIN; GENE	Lymphangioleiomyomatosis (LAM) is a rare and progressive systemic disease affecting mainly young women of childbearing age. A deterioration in lung function is driven by neoplastic growth of atypical smooth muscle-like LAM cells in the pulmonary interstitial space that leads to cystic lung destruction and spontaneous pneumothoraces. Therapeutic options for preventing disease progression are limited and often end with lung transplantation temporarily delaying an inevitable decline. To identify new therapeutic strategies for this crippling orphan disease, we have performed array based and metabolic molecular analysis on patient-derived cell lines. Our results point to the conclusion that mitochondrial biogenesis and mitochondrial dysfunction in LAM cells provide a novel target for treatment.	[Abdelwahab, E. M. M.; Kvell, K.; Pongracz, J. E.] Univ Pecs, Sch Pharm, Dept Pharmaceut Biotechnol, Pecs, Hungary; [Abdelwahab, E. M. M.; Kvell, K.; Pongracz, J. E.] Univ Pecs, Janos Szentagothai Res Ctr, Pecs, Hungary; [Pal, S.] Univ Pecs, Sch Pharm, Dept Pharmaceut Technol, Pecs, Hungary; [Sarosi, V] Univ Pecs, Sch Med, Dept Internal Med, Pecs, Hungary; [Sarosi, V] Univ Pecs, Clin Ctr, Pecs, Hungary; [Bai, P.] Univ Debrecen, Dept Med Chem, MTA DE Lendulet Lab Cellular Metab, Debrecen, Hungary; [Bai, P.] Univ Debrecen, Fac Med, Res Ctr Mol Med, Debrecen, Hungary; [Rue, R.; Krymskaya, V] Univ Penn, Dept Med, Pulm Allergy & Crit Care Div, Perelman Sch Med, Philadelphia, PA 19104 USA; [McPhail, D.; Porter, A.] Antoxis Ltd, Aberdeen, Scotland; [Porter, A.] Univ Aberdeen, Sch Med & Med Sci, Aberdeen, Scotland	University of Pecs; University of Pecs; University of Pecs; University of Pecs; University of Pecs; University of Debrecen; University of Debrecen; University of Pennsylvania; Pennsylvania Medicine; University of Aberdeen	Pongracz, JE (corresponding author), Univ Pecs, Sch Pharm, Dept Pharmaceut Biotechnol, Pecs, Hungary.; Pongracz, JE (corresponding author), Univ Pecs, Janos Szentagothai Res Ctr, Pecs, Hungary.	judit.e.pongracz@gmail.com	Pongracz, Judit E/N-7927-2018; Pongracz, Judit E/J-7517-2019	Pongracz, Judit E/0000-0002-0278-5556; Pongracz, Judit E/0000-0002-0278-5556; ELHUSSEINY, MOHAMED MAHMOUD ABDELWAHAB/0000-0003-4102-2233	European Union; State of Hungary - European Social Fund [TAMOP-4.2.4, A/2-11/1-2012-0001]	European Union(European Commission); State of Hungary - European Social Fund	JEP was supported by the European Union and the State of Hungary, co-financed by the European Social Fund in the framework of TAMOP-4.2.4.A/2-11/1-2012-0001 "National Excellence Program".	Astrinidis A, 2000, J MED GENET, V37, P55, DOI 10.1136/jmg.37.1.55; Barros RPA, 2011, CELL METAB, V14, P289, DOI 10.1016/j.cmet.2011.08.005; Bennett CJ, 2004, BIOORGAN MED CHEM, V12, P2079, DOI 10.1016/j.bmc.2004.02.031; Chang WYC, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-34; Drummond NJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12072-5; Fernandez-Vizarra E, 2009, BBA-MOL CELL RES, V1793, P200, DOI 10.1016/j.bbamcr.2008.05.028; Finck BN, 2007, CIRCULATION, V115, P2540, DOI 10.1161/CIRCULATIONAHA.107.670588; Goncharova EA, 2006, AM J RESP CELL MOL, V34, P473, DOI 10.1165/rcmb.2005-0374OC; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Gozuacik D, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00065; Gyftopoulos K, 2000, EUR UROL, V38, P323, DOI 10.1159/000020301; Hald SM, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1446-z; Harknett EC, 2011, QJM-INT J MED, V104, P971, DOI 10.1093/qjmed/hcr116; Hayashi K, 2001, JPN J CANCER RES, V92, P42, DOI 10.1111/j.1349-7006.2001.tb01046.x; Hayashida M, 2007, RESPIROLOGY, V12, P523, DOI 10.1111/j.1440-1843.2007.01101.x; Huttemann M, 2011, MITOCHONDRION, V11, P369, DOI 10.1016/j.mito.2011.01.010; Julian LM, 2017, CANCER RES, V77, P5491, DOI 10.1158/0008-5472.CAN-17-0925; Kovacs T, 2014, AGING CELL, V13, P838, DOI 10.1111/acel.12240; Krymskaya VP, 2017, ANNU REV MED, V68, P69, DOI 10.1146/annurev-med-050715-104245; Lawler PR, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006627; Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Lu C, 2017, ANN AM THORAC SOC, V14, P919, DOI 10.1513/AnnalsATS.201610-824OC; MacKeigan JP, 2015, NEURO-ONCOLOGY, V17, P1550, DOI 10.1093/neuonc/nov152; Marin-Hernandez A, 2009, MINI-REV MED CHEM, V9, P1084, DOI 10.2174/138955709788922610; Mei LL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185636; Miglio G, 2009, NEUROCHEM INT, V55, P496, DOI 10.1016/j.neuint.2009.05.001; Moini H, 1999, REDOX REP, V4, P35, DOI 10.1179/135100099101534729; Motalleb G, 2014, CELL J, V15, P324; Rigobello MP, 2002, BRIT J PHARMACOL, V136, P1162, DOI 10.1038/sj.bjp.0704823; Shao D, 2010, MITOCHONDRION, V10, P516, DOI 10.1016/j.mito.2010.05.012; Simiantonaki N, 2008, INT J ONCOL, V32, P585; Uldry M, 2006, CELL METAB, V3, P333, DOI 10.1016/j.cmet.2006.04.002	33	4	4	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2019	38	16					3093	3101		10.1038/s41388-018-0625-1	http://dx.doi.org/10.1038/s41388-018-0625-1			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU3IV	30573768	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000465167600015
J	White, SM; Murakami, S; Yi, CL				White, Shannon M.; Murakami, Shigekazu; Yi, Chunling			The complex entanglement of Hippo-Yap/Taz signaling in tumor immunity	ONCOGENE			English	Review							CANCER-ASSOCIATED FIBROBLASTS; INNATE IMMUNITY; YAP; MST1; PATHWAY; CELLS; PROLIFERATION; COMBINATION; ACTIVATION; EXPRESSION	The Hippo-Yap/Taz pathway, originally identified as a central developmental regulator of organ size, has been found perturbed in many types of human tumors, and linked to tumor growth, survival, evasion, metastasis, stemness, and drug resistance. Beside these tumor-cell-intrinsic functions, Hippo signaling also plays important immune-regulatory roles. In this review, we will summarize and discuss recent breakthroughs in our understanding of how various components of the HippoYap/Taz pathway influence the tumor immune microenvironment, including their effects on the tumor secretome and immune infiltrates, their roles in regulating crosstalk between tumor cells and T cells, and finally their intrinsic functions in various types of innate and adaptive immune cells. While further research is needed to integrate and reconcile existing findings and to discern the overall effects of Hippo signaling on tumor immunity, it is clear that Hippo signaling functions as a key bridge connecting tumor cells with both the adaptive and innate immune systems. Thus, all future therapeutic development against the Hippo-Yap/Taz pathway should take into account their multi-faceted roles in regulating tumor immunity in addition to their growth-regulatory functions. Given that immune therapies have become the mainstay of cancer treatment, it is also important to pursue how to manipulate Hippo signaling to boost response or overcome resistance to existing immune therapies.	[White, Shannon M.; Murakami, Shigekazu; Yi, Chunling] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA	Georgetown University	Yi, CL (corresponding author), Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA.	cy232@georgetown.edu		Morgan, Shannon/0000-0002-1351-943X	NIH [R01CA187090]; Toulmin Pilot Award; Cancer Center Support Grant [CA051008]; National Science Foundation Graduate Research Fellowship (NSFGRF) [2018265935]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Toulmin Pilot Award; Cancer Center Support Grant; National Science Foundation Graduate Research Fellowship (NSFGRF)(National Science Foundation (NSF))	Research in Yi lab is currently supported by NIH (R01CA187090), Toulmin Pilot Award, Sher Grant and Cancer Center Support Grant (CA051008). Shannon White is a current recipient of National Science Foundation Graduate Research Fellowship (NSFGRF#2018265935).	Abdollahpour H, 2012, BLOOD, V119, P3450, DOI 10.1182/blood-2011-09-378158; Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784; Aragona M, 2013, CELL, V154, P1047, DOI 10.1016/j.cell.2013.07.042; Bai XM, 2016, BLOOD ADV, V1, P219, DOI 10.1182/bloodadvances.2016000588; Boro M, 2016, SCI REP-UK, V6, DOI 10.1038/srep37695; Calvo F, 2013, NAT CELL BIOL, V15, P637, DOI 10.1038/ncb2756; Cen XH, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00878; Choi J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008011; Cisowski J, 2016, ONCOGENE, V35, P1328, DOI 10.1038/onc.2015.186; Dong YL, 2009, J IMMUNOL, V183, P3865, DOI 10.4049/jimmunol.0900678; Du XR, 2018, NATURE, V558, P141, DOI 10.1038/s41586-018-0177-0; Du XR, 2014, J IMMUNOL, V192, P1525, DOI 10.4049/jimmunol.1301060; Dubey SK, 2018, MOL NEUROBIOL, V55, P1193, DOI 10.1007/s12035-017-0388-7; Ehmer U, 2014, CELL REP, V8, P370, DOI 10.1016/j.celrep.2014.06.025; Elosegui-Artola A, 2016, NAT CELL BIOL, V18, P540, DOI 10.1038/ncb3336; Foster CT, 2017, GENE DEV, V31, P2361, DOI 10.1101/gad.304501.117; Fu V, 2017, CURR OPIN CELL BIOL, V49, P99, DOI 10.1016/j.ceb.2017.12.012; Furth N, 2017, CELL DEATH DIFFER, V24, P1488, DOI 10.1038/cdd.2017.99; Furukawa KT, 2017, CELL REP, V20, P1435, DOI 10.1016/j.celrep.2017.07.032; Galan JA, 2016, BIOCHEMISTRY-US, V55, P5507, DOI 10.1021/acs.biochem.6b00763; Gascard P, 2016, GENE DEV, V30, P1002, DOI 10.1101/gad.279737.116; Geng J, 2017, NAT IMMUNOL, V18, P800, DOI 10.1038/ni.3748; Geng J, 2015, NAT IMMUNOL, V16, P1142, DOI 10.1038/ni.3268; Guo XC, 2017, GENE DEV, V31, P247, DOI 10.1101/gad.294348.116; Iurescia S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00711; Jiang H, 2016, NAT MED, V22, P851, DOI 10.1038/nm.4123; Jiao S, 2018, J EXP MED, V215, P699, DOI 10.1084/jem.20171116; Kang TW, 2011, NATURE, V479, P547, DOI 10.1038/nature10599; Katagiri K, 2006, NAT IMMUNOL, V7, P919, DOI 10.1038/ni1374; Katagiri K, 2009, EMBO J, V28, P1319, DOI 10.1038/emboj.2009.82; Kim J, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/8605471; Kim TW, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9769; Kim W, 2018, GUT, V67, P1692, DOI 10.1136/gutjnl-2017-314061; Knochelmann HM, 2018, CELL MOL IMMUNOL, V15, P458, DOI 10.1038/s41423-018-0004-4; Laklai H, 2016, NAT MED, V22, P497, DOI 10.1038/nm.4082; Lee BS, 2017, BIOCHEM BIOPH RES CO, V491, P493, DOI 10.1016/j.bbrc.2017.07.007; Lee DH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11961; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Li CX, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14275; Li J, 2015, J BIOL CHEM, V290, P30762, DOI 10.1074/jbc.M115.668442; Li WY, 2015, J CLIN INVEST, V125, P4239, DOI 10.1172/JCI81203; Liu B, 2016, CELL, V164, P406, DOI 10.1016/j.cell.2015.12.029; Liu CY, 2010, J BIOL CHEM, V285, P37159, DOI 10.1074/jbc.M110.152942; Liu F, 2015, AM J PHYSIOL-LUNG C, V308, pL344, DOI 10.1152/ajplung.00300.2014; Liu ZQ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14754; Lo B, 2017, CURR OPIN IMMUNOL, V49, P14, DOI 10.1016/j.coi.2017.07.014; Luecke S, 2017, CYTOKINE, V98, P4, DOI 10.1016/j.cyto.2016.10.003; Meng FS, 2016, GENE DEV, V30, P1086, DOI 10.1101/gad.277533.116; Meng ZP, 2018, NATURE, V560, P655, DOI 10.1038/s41586-018-0444-0; Miao J, 2017, ONCOTARGET, V8, P89802, DOI 10.18632/oncotarget.21155; Miyamura N, 2017, NAT COMMUN, V8, P1, DOI 10.1038/ncomms16017; Moon S, 2018, CELL MOL LIFE SCI, V75, P2303, DOI 10.1007/s00018-018-2804-1; Moroishi T, 2016, CELL, V167, P1525, DOI 10.1016/j.cell.2016.11.005; Mou F, 2012, J EXP MED, V209, P741, DOI 10.1084/jem.20111692; Moynihan KD, 2017, CANCER RES, V77, P5215, DOI 10.1158/0008-5472.CAN-17-1340; Murakami S, 2017, ONCOGENE, V36, P1232, DOI 10.1038/onc.2016.288; Murphy TL, 2016, ANNU REV IMMUNOL, V34, P93, DOI 10.1146/annurev-immunol-032713-120204; Nardone G, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15321; Nehme NT, 2012, BLOOD, V119, P3458, DOI 10.1182/blood-2011-09-378364; Ni X., 2018, CANC DISCOV; Nishikimi A, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005199; Ramjee V, 2017, J CLIN INVEST, V127, P899, DOI 10.1172/JCI88759; Ribas A, 2017, CELL, V170, P1109, DOI 10.1016/j.cell.2017.08.027; Samson A, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aam7577; Sansores-Garcia L, 2011, EMBO J, V30, P2325, DOI 10.1038/emboj.2011.157; Sarkisian CJ, 2007, NAT CELL BIOL, V9, P493, DOI 10.1038/ncb1567; Schupp J, 2019, CELL IMMUNOL, V343, DOI 10.1016/j.cellimm.2017.10.013; Sharma Padmanee, 2017, CELL REV, V168; Sica A, 2017, J AUTOIMMUN, V85, P117, DOI 10.1016/j.jaut.2017.07.010; Thaventhiran JED, 2012, P NATL ACAD SCI USA, V109, pE2223, DOI 10.1073/pnas.1209115109; Ueda Y, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2105; van Rensburg HJJ, 2018, CANCER RES, V78, P1457, DOI 10.1158/0008-5472.CAN-17-3139; von Ahrens D, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0448-5; Wang GC, 2016, CANCER DISCOV, V6, P80, DOI 10.1158/2159-8290.CD-15-0224; Wang S, 2017, NAT IMMUNOL, V18, P733, DOI 10.1038/ni.3744; Xu XL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105561; Yuan L, 2017, PALMITIC ACID DYSREG, DOI [10.1074/jbc.M117.804005, DOI 10.1074/JBC.M117.804005]; Zamarin D, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008095; Zappasodi R, 2018, CANCER CELL, V33, P581, DOI 10.1016/j.ccell.2018.03.005; Zhang Q, 2017, NAT CELL BIOL, V19, P362, DOI 10.1038/ncb3496; Zhang WY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005049; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zhou DW, 2008, P NATL ACAD SCI USA, V105, P20321, DOI 10.1073/pnas.0810773105	84	33	37	2	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2019	38	16					2899	2909		10.1038/s41388-018-0649-6	http://dx.doi.org/10.1038/s41388-018-0649-6			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU3IV	30617303	Green Accepted			2022-12-28	WOS:000465167600002
J	Torres-Adorno, AM; Vitrac, H; Qi, Y; Tans, L; Levental, KR; Fan, YY; Yang, PY; Chapkin, RS; Eckhardt, BL; Ueno, NT				Torres-Adorno, Angie M.; Vitrac, Heidi; Qi, Yuan; Tans, Lin; Levental, Kandice R.; Fan, Yang-Yi; Yang, Peiying; Chapkin, Robert S.; Eckhardt, Bedrich L.; Ueno, Naoto T.			Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux	ONCOGENE			English	Article							HISTONE DEACETYLASE INHIBITOR; RECEPTOR TYROSINE KINASE; POOR-PROGNOSIS; FISH-OIL; EXPRESSION; OMEGA-3-FATTY-ACIDS; PROGRESSION; CELLS; OVEREXPRESSION; TUMORIGENESIS	Triple-negative breast cancer (TNBC), the most aggressive breast cancer subtype, currently lacks effective targeted therapy options. Eicosapentaenoic acid (EPA), an omega-3 fatty acid and constituent of fish oil, is a common supplement with anti-inflammatory properties. Although it is not a mainstream treatment, several preclinical studies have demonstrated that EPA exerts anti-tumor activity in breast cancer. However, against solid tumors, EPA as a monotherapy is clinically ineffective; thus, we sought to develop a novel targeted drug combination to bolster its therapeutic action against TNBC. Using a high-throughput functional siRNA screen, we identified Ephrin type-A receptor 2 (EPHA2), an oncogenic cell-surface receptor tyrosine kinase, as a therapeutic target that sensitizes TNBC cells to EPA. EPHA2 expression was uniquely elevated in TNBC cell lines and patient tumors. In independent functional expression studies in TNBC models, EPHA2 gene-silencing combined with EPA significantly reduced cell growth and enhanced apoptosis compared with monotherapies, both in vitro and in vivo. EPHA2-specific inhibitors similarly enhanced the therapeutic action of EPA. Finally, we identified that therapy-mediated apoptosis was attributed to a lethal increase in cancer cell membrane polarity due to ABCA1 inhibition and subsequent dysregulation of cholesterol homeostasis. This study provides new molecular and preclinical evidence to support a clinical evaluation of EPA combined with EPHA2 inhibition in patients with TNBC.	[Torres-Adorno, Angie M.] Univ Texas MD Anderson Canc Ctr, UThlth Grad Sch Biomed Sci, Houston, TX 77030 USA; [Torres-Adorno, Angie M.; Eckhardt, Bedrich L.; Ueno, Naoto T.] Univ Texas MD Anderson Canc Ctr, Sect Translat Breast Canc Res, Houston, TX 77030 USA; [Torres-Adorno, Angie M.; Eckhardt, Bedrich L.; Ueno, Naoto T.] Univ Texas MD Anderson Canc Ctr, Morgan Welch Inflammatory Breast Canc Res Program, Dept Breast Med Oncol, Houston, TX 77030 USA; [Vitrac, Heidi] McGovern Med Sch, UThlth, Dept Biochem & Mol Biol, Houston, TX USA; [Qi, Yuan] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Tans, Lin; Yang, Peiying] Univ Texas MD Anderson Canc Ctr, Dept Palliat Rehabil & Integrat Med, Houston, TX 77030 USA; [Levental, Kandice R.] McGovern Med Sch, UThlth, Dept Integrat Biol & Pharmacol, Houston, TX USA; [Fan, Yang-Yi; Chapkin, Robert S.] Texas A&M Univ, Dept Nutr & Food Sci, Program Integrat Nutr & Complex Dis, College Stn, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; Texas A&M University System; Texas A&M University College Station	Eckhardt, BL; Ueno, NT (corresponding author), Univ Texas MD Anderson Canc Ctr, Sect Translat Breast Canc Res, Houston, TX 77030 USA.; Eckhardt, BL; Ueno, NT (corresponding author), Univ Texas MD Anderson Canc Ctr, Morgan Welch Inflammatory Breast Canc Res Program, Dept Breast Med Oncol, Houston, TX 77030 USA.	beckhardt@mdanderson.org; nueno@mdanderson.org	; Vitrac, Heidi/R-7117-2018	Chapkin, Robert/0000-0002-6515-3898; Vitrac, Heidi/0000-0002-8858-4914; Eckhardt, Bedrich/0000-0002-3402-3900	Morgan Welch Inflammatory Breast Cancer Research Program; State of Texas Rare and Aggressive Breast Cancer Research Program; National Institutes of Health/National Cancer Institute [R01CA123318, P30CA016672]; Cancer Prevention and Research Institute of Texas [RP110532-P3]; John Dunn Research Foundation Endowment; NATIONAL CANCER INSTITUTE [P30CA016672, R35CA197707] Funding Source: NIH RePORTER	Morgan Welch Inflammatory Breast Cancer Research Program; State of Texas Rare and Aggressive Breast Cancer Research Program; National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Prevention and Research Institute of Texas; John Dunn Research Foundation Endowment; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the Morgan Welch Inflammatory Breast Cancer Research Program, the State of Texas Rare and Aggressive Breast Cancer Research Program, the National Institutes of Health/National Cancer Institute through grants R01CA123318 and P30CA016672 (used the Characterized Cell Line Core, the Flow Cytometry and Cellular Imaging Facility, and the Bioinformatics Shared Resource at MD Anderson Cancer Center), the Cancer Prevention and Research Institute of Texas through grant RP110532-P3 (used MD Anderson's siRNA Screening Service), and the John Dunn Research Foundation Endowment awarded to William Dowhan.	Arnato KR, 2014, J CLIN INVEST, V124, P2037, DOI 10.1172/JCI72522; Bae SY, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1121-4; Brantley-Sieders DM, 2008, J CLIN INVEST, V118, P64, DOI 10.1172/JCI33154; Brinton EA, 2017, LIPIDS HEALTH DIS, V16, DOI 10.1186/s12944-017-0415-8; Chou JL, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-014-0036-2; Ciftci O, 2014, ANDROLOGIA, V46, P1161, DOI 10.1111/and.12209; Corsetto PA, 2012, CELL BIOCHEM BIOPHYS, V64, P45, DOI 10.1007/s12013-012-9365-y; Corsetto PA, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-73; Cortese F, 2016, PHARMACOL RES, V107, P1, DOI 10.1016/j.phrs.2016.02.012; Dunne PD, 2016, CLIN CANCER RES, V22, P230, DOI 10.1158/1078-0432.CCR-15-0603; Fabian CJ, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0571-6; Fan C, 2006, NEW ENGL J MED, V355, P560, DOI 10.1056/NEJMoa052933; Ford NA, 2015, CANCER PREV RES, V8, P796, DOI 10.1158/1940-6207.CAPR-15-0018; Fournier N, 2016, BBA-MOL CELL BIOL L, V1861, P331, DOI 10.1016/j.bbalip.2016.01.002; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Hou H, 2017, NEOPLASMA, V64, P81, DOI 10.4149/neo_2017_110; Hoy SM, 2017, AM J CARDIOVASC DRUG, V17, P157, DOI 10.1007/s40256-017-0213-8; Hu Yan-Wei, 2009, Atherosclerosis, V204, pe35, DOI 10.1016/j.atherosclerosis.2008.11.003; Huang J, 2014, ONCOGENE, V33, P2737, DOI 10.1038/onc.2013.238; Jaureguiberry MS, 2014, ACTA BIOCH BIOPH SIN, V46, P273, DOI 10.1093/abbs/gmt155; Kamat AA, 2009, CANCER-AM CANCER SOC, V115, P2684, DOI 10.1002/cncr.24335; Kinch MS, 2003, CLIN CANCER RES, V9, P613; Laviano A, 2013, CURR OPIN CLIN NUTR, V16, P156, DOI 10.1097/MCO.0b013e32835d2d99; Le Du F, 2015, ONCOTARGET, V6, P12890, DOI 10.18632/oncotarget.3849; Lee AHS, 1996, BRIT J CANCER, V74, P796, DOI 10.1038/bjc.1996.438; Lee J, 2014, BREAST CANCER RES TR, V146, P259, DOI 10.1007/s10549-014-3014-7; Madden SF, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3444; Makarewicz-Wujec M, 2017, KARDIOL POL, V75, P673, DOI 10.5603/KP.a2017.0072; Mandal CC, 2010, BIOCHEM BIOPH RES CO, V402, P602, DOI 10.1016/j.bbrc.2010.10.063; McAuliffe PF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136851; Miao H, 2009, CANCER CELL, V16, P9, DOI 10.1016/j.ccr.2009.04.009; Miserez AR, 2002, ATHEROSCLEROSIS, V164, P15, DOI 10.1016/S0021-9150(01)00762-6; Mudali SV, 2006, CLIN EXP METASTAS, V23, P357, DOI 10.1007/s10585-006-9045-7; Nandi S, 2009, J LIPID RES, V50, P456, DOI 10.1194/jlr.M800345-JLR200; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Park JE, 2013, GENES-BASEL, V4, P334, DOI 10.3390/genes4030334; Pencina MJ, 2014, NEW ENGL J MED, V370, P1422, DOI 10.1056/NEJMoa1315665; Pounds S, 2003, BIOINFORMATICS, V19, P1236, DOI 10.1093/bioinformatics/btg148; Ramos EJB, 2004, J AM COLL SURGEONS, V199, P716, DOI 10.1016/j.jamcollsurg.2004.07.014; Rose DP, 1996, CLIN CANCER RES, V2, P1751; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Song W, 2017, ONCOGENE, V36, P5620, DOI 10.1038/onc.2017.170; Sugiyama N, 2013, CELL CYCLE, V12, P2927, DOI 10.4161/cc.26180; Tandon M, 2011, EXPERT OPIN THER TAR, V15, P31, DOI 10.1517/14728222.2011.538682; Thaker PH, 2004, CLIN CANCER RES, V10, P5145, DOI 10.1158/1078-0432.CCR-03-0589; Torres-Adorno AM, 2017, CLIN CANCER RES, V23, P4780, DOI 10.1158/1078-0432.CCR-16-2622; Wang XP, 2017, ONCOTARGET, V8, P67904, DOI 10.18632/oncotarget.18958; Zelinski DP, 2001, CANCER RES, V61, P2301; Zhao WN, 2016, CANCER RES, V76, P2037, DOI 10.1158/0008-5472.CAN-15-1970	51	16	18	3	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2019	38	12					2135	2150		10.1038/s41388-018-0569-5	http://dx.doi.org/10.1038/s41388-018-0569-5			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP6UR	30459358	Green Accepted			2022-12-28	WOS:000461822600010
J	Witten, LW; Cheng, CJ; Slac, FJ				Witten, Lisa W.; Cheng, Christopher J.; Slac, Frank J.			miR-155 drives oncogenesis by promoting and cooperating with mutations in the c-Kit oncogene	ONCOGENE			English	Article							KINASE-ACTIVITY; MICRORNA-155; EXPRESSION; INHIBITION; ACTIVATION; CANCER; CELLS; MODEL; OVEREXPRESSION; PROLIFERATION	MicroRNAs (miRNAs) have emerged as crucial players in the development and maintenance of disease. miR-155 is an inflammation-associated, oncogenic miRNA, frequently overexpressed in hematological malignancies and solid tumors. However, the mechanism of oncogenesis by miR-155 is not well characterized, and research has focused primarily on individual, direct targets, which does not recapitulate the complexities of cancer. Using a powerful, inducible transgenic mouse model that overexpresses miR-155 and develops miR-155-addicted hematological malignancy, we describe here a multi-step process of oncogenesis by miR-155, which involves cooperation between miR-155, its direct targets, and other oncogenes. miR-155 is known to target DNA-repair proteins, leading to a mutator phenotype, and we find that over 93% of tumors in our miR-155 overexpressing mice contain activating mutations in a single oncogene, c-Kit. Treating mice with dasatinib or imatinib, which target c-Kit, resulted in complete tumor regression, indicating that c-Kit activity is crucial in the oncogenic process. Interestingly, c-Kit expression is high when miR-155 is overexpressed, indicating further cooperation between miR-155 and c-Kit. Our findings support a multi-step model of oncogenesis by miR-155 in which miR-155 promotes both a mutator phenotype and a cellular environment particularly susceptible to mutations in a given oncogene.	[Witten, Lisa W.; Slac, Frank J.] Beth Israel Deaconess Med Ctr, Dept Pathol, HMS Initiat RNA Med, 330 Brookline Ave, Boston, MA 02115 USA; [Cheng, Christopher J.] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06511 USA; [Cheng, Christopher J.] Casebia Therapeut, 610 Main St, Cambridge, MA 02139 USA	Harvard University; Beth Israel Deaconess Medical Center; Yale University	Slac, FJ (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, HMS Initiat RNA Med, 330 Brookline Ave, Boston, MA 02115 USA.	fslack@bidmc.harvard.edu		Slack, Frank/0000-0001-8263-0409	Ludwig Center at Harvard	Ludwig Center at Harvard	We wish to thank Bohyung Yoon and Eleni Anastasiadou for assistance with animal care and Jacob Witten for critical reading of the manuscript. The work was supported by the Ludwig Center at Harvard.	Babar IA, 2012, P NATL ACAD SCI USA, V109, pE1695, DOI 10.1073/pnas.1201516109; Cheng CJ, 2015, NATURE, V518, P107, DOI 10.1038/nature13905; Costinean S, 2006, P NATL ACAD SCI USA, V103, P7024, DOI 10.1073/pnas.0602266103; Costinean S, 2009, BLOOD, V114, P1374, DOI 10.1182/blood-2009-05-220814; Czochor JR, 2016, MOL CANCER RES, V14, P363, DOI 10.1158/1541-7786.MCR-15-0399; Dorsett Y, 2008, IMMUNITY, V28, P630, DOI 10.1016/j.immuni.2008.04.002; Eis PS, 2005, P NATL ACAD SCI USA, V102, P3627, DOI 10.1073/pnas.0500613102; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Faraoni I, 2009, BBA-MOL BASIS DIS, V1792, P497, DOI 10.1016/j.bbadis.2009.02.013; Fulci V, 2007, BLOOD, V109, P4944, DOI 10.1182/blood-2006-12-062398; Gironella M, 2007, P NATL ACAD SCI USA, V104, P16170, DOI 10.1073/pnas.0703942104; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Kastner P, 2008, INT J BIOCHEM CELL B, V40, P22, DOI 10.1016/j.biocel.2007.01.026; Klimenko OV, 2013, CANCER GENE THER, V20, P237, DOI 10.1038/cgt.2013.11; Kosmider O, 2005, CANCER CELL, V8, P467, DOI 10.1016/j.ccr.2005.11.009; Kosmider O, 2006, CELL CYCLE, V5, P569, DOI 10.4161/cc.5.6.2577; Larizza L, 2005, LEUKEMIA LYMPHOMA, V46, P247, DOI 10.1080/10428190400007565; Lennartsson J, 2012, PHYSIOL REV, V92, P1619, DOI 10.1152/physrev.00046.2011; Mol CD, 2004, J BIOL CHEM, V279, P31655, DOI 10.1074/jbc.M403319200; Ning ZQ, 2001, BLOOD, V97, P3559, DOI 10.1182/blood.V97.11.3559; O'Connell RM, 2008, J EXP MED, V205, P585, DOI 10.1084/jem.20072108; O'Connell RM, 2009, P NATL ACAD SCI USA, V106, P7113, DOI 10.1073/pnas.0902636106; Pedersen IM, 2009, EMBO MOL MED, V1, P288, DOI 10.1002/emmm.200900028; Ratajczak MZ, 1998, BLOOD, V91, P1934, DOI 10.1182/blood.V91.6.1934.1934_1934_1946; Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246; Schittenhelm MM, 2006, CANCER RES, V66, P473, DOI 10.1158/0008-5472.CAN-05-2050; Thai TH, 2007, SCIENCE, V316, P604, DOI 10.1126/science.1141229; Tili E, 2011, P NATL ACAD SCI USA, V108, P4908, DOI 10.1073/pnas.1101795108; Valeri N, 2010, P NATL ACAD SCI USA, V107, P21098, DOI 10.1073/pnas.1015541107; Valeri N, 2010, P NATL ACAD SCI USA, V107, P6982, DOI 10.1073/pnas.1002472107; Vandenbark GR, 1996, CELL GROWTH DIFFER, V7, P1383; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wallace JA, 2017, BLOOD, V129, P3074, DOI 10.1182/blood-2016-09-740209	36	16	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2019	38	12					2151	2161		10.1038/s41388-018-0571-y	http://dx.doi.org/10.1038/s41388-018-0571-y			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP6UR	30459357				2022-12-28	WOS:000461822600011
J	Feng, TT; Zhao, R; Sun, FF; Lu, QQ; Wang, XL; Hu, J; Wang, SG; Gao, L; Zhou, QQ; Xiong, XT; Dong, XS; Wang, L; Han, B				Feng, Tingting; Zhao, Ru; Sun, Feifei; Lu, Qiqi; Wang, Xueli; Hu, Jing; Wang, Shiguan; Gao, Lin; Zhou, Qianqian; Xiong, Xueting; Dong, Xuesen; Wang, Lin; Han, Bo			TXNDC9 regulates oxidative stress-induced androgen receptor signaling to promote prostate cancer progression	ONCOGENE			English	Article							CASTRATION; AR; PEROXIREDOXIN; THIOREDOXIN; DEGRADATION; ANTIOXIDANT; INVOLVEMENT; CARCINOMA; ESTROGEN; COMPLEX	Reactive oxygen species (ROS) and ROS-induced oxidative stress are associated with prostate cancer (PCa) development and castrate-resistant tumor progression. This is in part through the activation of the androgen receptor (AR) signaling. However, the molecular underpinning of ROS to activate AR remains poorly understood. Here, we report that the thioredoxin domain-containing 9 (TXNDC9) is an important regulator of ROS to trigger AR signaling. TXNDC9 expression is upregulated by ROS inducer, and increased TXNDC9 expression in patient tumors is associated with advanced clinical stages. TXNDC9 promotes PCa cell survival and proliferation. It is required for AR protein expression and AR transcriptional activity under oxidative stress conditions. Mechanistically, ROS inducers promote TXNDC9 to dissociate from PRDX1, but enhance a protein association with MDM2. Concurrently, PRDX1 enhances its association with AR. These protein interaction exchanges result in not only MDM2 protein degradation, but also PRDX1 mediated AR protein stabilization, and subsequent elevation of AR signaling. Blocking PRDX1 by its inhibitor, Conoidin A (CoA), suppresses AR signaling, PCa cell proliferation, and xenograft tumor growth even under androgen-deprived conditions. These tumor-suppressive effects of CoA were further strengthened when in combination with enzalutamide treatment. Together, these studies demonstrate that the TXNDC9-PRDX1 axis plays an important role for ROS to activate AR functions. It provides a proof-of-principle that co-targeting AR and PRDX1 may be more effective to control PCa growth.	[Feng, Tingting; Zhao, Ru; Sun, Feifei; Wang, Xueli; Hu, Jing; Gao, Lin; Zhou, Qianqian; Han, Bo] Shandong Univ, Sch Basic Med Sci, Minist Educ, Key Lab Expt Teratol, Jinan 250012, Peoples R China; [Feng, Tingting; Zhao, Ru; Sun, Feifei; Wang, Xueli; Hu, Jing; Gao, Lin; Zhou, Qianqian; Han, Bo] Shandong Univ, Sch Basic Med Sci, Dept Pathol, Jinan 250012, Peoples R China; [Lu, Qiqi; Wang, Shiguan; Wang, Lin] Shandong First Med Univ & Shandong Acad Med Sci, Res Ctr Med Biotechnol, Key Lab Rare & Uncommon Dis Shandong Prov, Jinan 250012, Peoples R China; [Wang, Xueli] Binzhou Cent Hosp, Dept Pathol, Binzhou 256610, Peoples R China; [Xiong, Xueting] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada; [Dong, Xuesen] Univ British Columbia, Vancouver Prostate Ctr, Dept Urol Sci, Vancouver, BC, Canada; [Han, Bo] Shandong Univ, Dept Pathol, Qilu Hosp, Jinan 250012, Peoples R China	Shandong University; Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences; University of Toronto; University of British Columbia; Shandong University	Han, B (corresponding author), Shandong Univ, Sch Basic Med Sci, Minist Educ, Key Lab Expt Teratol, Jinan 250012, Peoples R China.; Han, B (corresponding author), Shandong Univ, Sch Basic Med Sci, Dept Pathol, Jinan 250012, Peoples R China.; Wang, L (corresponding author), Shandong First Med Univ & Shandong Acad Med Sci, Res Ctr Med Biotechnol, Key Lab Rare & Uncommon Dis Shandong Prov, Jinan 250012, Peoples R China.; Han, B (corresponding author), Shandong Univ, Dept Pathol, Qilu Hosp, Jinan 250012, Peoples R China.	wanglin.83@163.com; boh@sdu.edu.cn	Zhou, Qianqian/GXG-4345-2022; Dong, Xuesen/AGF-9228-2022	Wang, Lin/0000-0002-0503-9727	National Key Research And Development Program of China [2018YFC0114703]; National Natural Science Foundation of China [81572544, 81772760, 81472417, 81672554]; Key Research and Development Project of Shandong [2016GSF201166]; Shandong Taishan Scholarship [tsqn20161076]	National Key Research And Development Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Research and Development Project of Shandong; Shandong Taishan Scholarship	This work was supported by the National Key Research And Development Program of China (No. 2018YFC0114703), the National Natural Science Foundation of China (grant nos. 81572544, 81772760, 81472417, 81672554), The Key Research and Development Project of Shandong (grant no. 2016GSF201166), The Shandong Taishan Scholarship (grant no. tsqn20161076).	Best CJM, 2005, CLIN CANCER RES, V11, P6823, DOI 10.1158/1078-0432.CCR-05-0585; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Chen DW, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1150-4; Feng TT, 2016, ONCOTARGET, V7, P58381, DOI 10.18632/oncotarget.11126; Fizazi K, 2018, CLIN GENITOURIN CANC, V16, P332, DOI 10.1016/j.clgc.2018.07.017; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; Gloire G, 2006, BIOCHEM PHARMACOL, V72, P1493, DOI 10.1016/j.bcp.2006.04.011; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Grad JM, 1999, MOL ENDOCRINOL, V13, P1896, DOI 10.1210/me.13.11.1896; Grogan TM, 2000, HUM PATHOL, V31, P475, DOI 10.1053/hp.2000.6546; Groner AC, 2017, J CLIN INVEST, V127, P1126, DOI 10.1172/JCI88885; Guha P, 2017, ONCOTARGET, V8, P68191, DOI 10.18632/oncotarget.19277; Haraldsen JD, 2009, ORG BIOMOL CHEM, V7, P3040, DOI 10.1039/b901735f; Harashima K, 2005, INT J RADIAT BIOL, V81, P63, DOI 10.1080/09553000400029460; Huggins C, 2002, J UROLOGY, V168, P9, DOI 10.1016/S0022-5347(05)64820-3; Jacquot JP, 2002, BIOCHEM PHARMACOL, V64, P1065, DOI 10.1016/S0006-2952(02)01177-2; Jang HH, 2004, CELL, V117, P625, DOI 10.1016/j.cell.2004.05.002; Kakolyris S, 2001, CLIN CANCER RES, V7, P3087; Kumsta C, 2009, BIOCHEMISTRY-US, V48, P4666, DOI 10.1021/bi9003556; Leslie NR, 2003, EMBO J, V22, P5501, DOI 10.1093/emboj/cdg513; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Liu F, 2016, SCI REP-UK, V6, DOI 10.1038/srep21260; Liu G, 2010, CHEMMEDCHEM, V5, P41, DOI 10.1002/cmdc.200900391; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Nakka M, 2013, INT J BIOCHEM CELL B, V45, P763, DOI 10.1016/j.biocel.2012.12.012; Park SY, 2007, CANCER RES, V67, P9294, DOI 10.1158/0008-5472.CAN-07-0651; Parolia A, 2019, NATURE, V571, P413, DOI 10.1038/s41586-019-1347-4; Rhee SG, 2001, IUBMB LIFE, V52, P35, DOI 10.1080/15216540252774748; Sabharwal SS, 2014, NAT REV CANCER, V14, P709, DOI 10.1038/nrc3803; Samaranayake GJ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01269-x; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Sharifi N, 2013, ENDOCRINOLOGY, V154, P4010, DOI 10.1210/en.2013-1466; Shiota M, 2010, ONCOGENE, V29, P237, DOI 10.1038/onc.2009.322; Shiota M, 2011, FREE RADICAL BIO MED, V51, P1320, DOI 10.1016/j.freeradbiomed.2011.07.011; Tam NNC, 2003, AM J PATHOL, V163, P2513, DOI 10.1016/S0002-9440(10)63606-1; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Wang L, 2015, ONCOGENE, V34, P4735, DOI 10.1038/onc.2014.401; Wang L, 2017, CANCER RES, V77, P5755, DOI 10.1158/0008-5472.CAN-17-0150; Xu BH, 2019, CELL RES, V29, P773, DOI 10.1038/s41422-019-0204-1; Yamamoto T, 2000, FEBS LETT, V486, P143, DOI 10.1016/S0014-5793(00)02296-1; Zoubeidi A, 2007, CANCER RES, V67, P10455, DOI 10.1158/0008-5472.CAN-07-2057	42	13	15	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	2					356	367		10.1038/s41388-019-0991-3	http://dx.doi.org/10.1038/s41388-019-0991-3			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KD3JY	31477836				2022-12-28	WOS:000507766400008
J	Peng, WX; He, RZ; Zhang, ZQ; Yang, L; Mo, YY				Peng, Wan-Xin; He, Rong-Zhang; Zhang, Ziqiang; Yang, Liu; Mo, Yin-Yuan			LINC00346 promotes pancreatic cancer progression through the CTCF-mediated Myc transcription	ONCOGENE			English	Article							LONG NONCODING RNA; C-MYC; INSIGHTS; GENE; ACTIVATION; EXPRESSION; GENOMICS; PROTEIN; ROLES; CELLS	Although multiple factors are known to contribute to pancreatic ductal adenocarcinoma (PDAC) progression, the role of long non-coding RNAs (lncRNAs) in PDAC remains largely unknown. In this study, we present data that long intergenic noncoding RNA 346 (LINC00346) functions as a promoting factor for PDAC development. We first show that LINC00346 is highly expressed in pancreatic tumor specimens as compared to normal pancreatic tissue based on interrogation of The Cancer Genome Atlas (TCGA) pancreatic adenocarcinoma dataset. Of significance, this upregulation of LINC00346 is associated with overall survival (OS) and disease-free survival (DFS), respectively. We further show that knockout (KO) of LINC00346 impairs pancreatic cancer cell proliferation, tumorigenesis, migration, and invasion ability. Importantly, these phenotypes can be restored by LINC00346 re-expression in KO cells (i.e., rescue experiment). RNA precipitation assays combined with mass spectrometry analysis indicate that LINC00346 interacts with CCCTC-binding factor (CTCF), a known transcriptional repressor of c-Myc. This interaction between LINC00346 and CTCF prevents the binding of CTCF to c-Myc promoter, relieving the CTCF-mediated repression of c-Myc. Thus, LINC00346 functions as a positive transcriptional regulator of c-Myc. Together, these results suggest that LINC00346 contributes to PDAC pathogenesis by activating c-Myc, and as such, LINC00346 may serve as a potential biomarker and therapeutic target for PDAC.	[Peng, Wan-Xin; Yang, Liu] Hangzhou Med Coll, Peoples Hosp, Key Lab Tumor Mol Diag & Individualized Med Zheji, Zhejiang Prov Peoples Hosp, Hangzhou 310014, Zhejiang, Peoples R China; [Peng, Wan-Xin; He, Rong-Zhang; Mo, Yin-Yuan] Univ Mississippi, Med Ctr, Canc Inst, Jackson, MS 39216 USA; [He, Rong-Zhang] First Peoples Hosp Chenzhou, Translat Med Inst, Natl & Local Joint Engn Lab High Through Mol Diag, Chenzhou 423000, Hunan, Peoples R China; [Zhang, Ziqiang] Tongji Univ, Tongji Hosp, Dept Pulm Med, Shanghai 200065, Peoples R China; [Mo, Yin-Yuan] Univ Mississippi, Med Ctr, Dept Pharmacol Toxicol, Jackson, MS 39216 USA	Hangzhou Medical College; Zhejiang Provincial People's Hospital; University of Mississippi; University of Mississippi Medical Center; Tongji University; University of Mississippi; University of Mississippi Medical Center	Yang, L (corresponding author), Hangzhou Med Coll, Peoples Hosp, Key Lab Tumor Mol Diag & Individualized Med Zheji, Zhejiang Prov Peoples Hosp, Hangzhou 310014, Zhejiang, Peoples R China.; Mo, YY (corresponding author), Univ Mississippi, Med Ctr, Canc Inst, Jackson, MS 39216 USA.; Mo, YY (corresponding author), Univ Mississippi, Med Ctr, Dept Pharmacol Toxicol, Jackson, MS 39216 USA.	yangliuqq2003@163.com; ymo@umc.edu	彭, 琬昕/HDN-9075-2022; Peng, Wan-Xin/AAU-1368-2020	彭, 琬昕/0000-0002-2551-8899; 	National Natural Science Foundation of China [81772575]; key project of Health Bureau of Zhejiang Province [2018274734]; NIH [R01 CA154989]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); key project of Health Bureau of Zhejiang Province; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This research was supported by grants from National Natural Science Foundation of China, No. 81772575 (LY) and the key project of Health Bureau of Zhejiang Province, No. 2018274734 (LY), and NIH grant R01 CA154989 (YM).	Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen H, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0008-7; Conacci-Sorrell Maralice, 2014, Cold Spring Harb Perspect Med, V4, pa014357, DOI 10.1101/cshperspect.a014357; Dang CV, 2015, CANCER CELL, V27, P160, DOI 10.1016/j.ccell.2015.01.004; Dunn KL, 2003, BIOCHEM CELL BIOL, V81, P161, DOI 10.1139/o03-052; Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; Fitzmaurice C, 2017, JAMA ONCOL, V3, P524, DOI 10.1001/jamaoncol.2016.5688; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Gupta SC, 2014, ONCOTARGET, V5, P12070, DOI 10.18632/oncotarget.2514; Guttman M, 2011, NATURE, V477, P295, DOI 10.1038/nature10398; Herold M, 2012, DEVELOPMENT, V139, P1045, DOI 10.1242/dev.065268; Hessmann E, 2016, ONCOGENE, V35, P1609, DOI 10.1038/onc.2015.216; Hu WQ, 2012, EMBO REP, V13, P971, DOI 10.1038/embor.2012.145; Huang JG, 2016, NUCLEIC ACIDS RES, V44, P3059, DOI 10.1093/nar/gkv1353; Hung CL, 2014, P NATL ACAD SCI USA, V111, P18697, DOI 10.1073/pnas.1415669112; Hung T, 2011, NAT GENET, V43, P621, DOI 10.1038/ng.848; Iaccarino I, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071497; Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106; Khan MA, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040779; Kim J, 2018, NAT GENET, V50, P1705, DOI 10.1038/s41588-018-0252-3; KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612; Kung JTY, 2013, GENETICS, V193, P651, DOI 10.1534/genetics.112.146704; Li M, 2015, NAT STRUCT MOL BIOL, V22, P2, DOI 10.1038/nsmb.2946; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; LOBANENKOV VV, 1990, ONCOGENE, V5, P1743; Lu YQ, 2018, CANCER RES, V78, P64, DOI 10.1158/0008-5472.CAN-17-0815; Maldotti M, 2016, BBA-GENE REGUL MECH, V1859, P1322, DOI 10.1016/j.bbagrm.2016.06.010; McMahon SB, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014407; Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521; Peng WX, 2017, ONCOGENE, V36, P5661, DOI 10.1038/onc.2017.184; Peng WX, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0727-3; Sachdeva M, 2011, ONCOGENE, V30, P822, DOI 10.1038/onc.2010.463; Schmitt AM, 2016, NAT GENET, V48, P1370, DOI 10.1038/ng.3673; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; Singh R, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.168; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Wu FT, 2007, MOL CANCER THER, V6, P1823, DOI 10.1158/1535-7163.MCT-06-0771; Xiang JF, 2014, CELL RES, V24, P513, DOI 10.1038/cr.2014.35; Xiao ZD, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00902-z; Zetsche B, 2015, CELL, V163, P759, DOI 10.1016/j.cell.2015.09.038; Zhang PF, 2016, EMBO REP, V17, P1204, DOI 10.15252/embr.201642067	48	34	35	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2019	38	41					6770	6780		10.1038/s41388-019-0918-z	http://dx.doi.org/10.1038/s41388-019-0918-z			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JC8UZ	31391552				2022-12-28	WOS:000489552900005
J	Liang, LY; Patel, O; Janes, PW; Murphy, JM; Lucet, IS				Liang, Lung-Yu; Patel, Onisha; Janes, Peter W.; Murphy, James M.; Lucet, Isabelle S.			Eph receptor signalling: from catalytic to non-catalytic functions	ONCOGENE			English	Review							TYROSINE PHOSPHORYLATION SITES; SAM DOMAIN; LIGAND ACTIVATION; CRYSTAL-STRUCTURE; TUMOR-SUPPRESSOR; CELL-ADHESION; KINASE; EXPRESSION; PROMOTES; JUXTAMEMBRANE	Eph receptors, the largest subfamily of receptor tyrosine kinases, are linked with proliferative disease, such as cancer, as a result of their deregulated expression or mutation. Unlike other tyrosine kinases that have been clinically targeted, the development of therapeutics against Eph receptors remains at a relatively early stage. The major reason is the limited understanding on the Eph receptor regulatory mechanisms at a molecular level. The complexity in understanding Eph signalling in cells arises due to following reasons: (1) Eph receptors comprise 14 members, two of which are pseudokinases, EphA10 and EphB6, with relatively uncharacterised function; (2) activation of Eph receptors results in dimerisation, oligomerisation and formation of clustered signalling centres at the plasma membrane, which can comprise different combinations of Eph receptors, leading to diverse downstream signalling outputs; (3) the non-catalytic functions of Eph receptors have been overlooked. This review provides a structural perspective of the intricate molecular mechanisms that drive Eph receptor signalling, and investigates the contribution of intra-and inter-molecular interactions between Eph receptors intracellular domains and their major binding partners. We focus on the non-catalytic functions of Eph receptors with relevance to cancer, which are further substantiated by exploring the role of the two pseudokinase Eph receptors, EphA10 and EphB6. Throughout this review, we carefully analyse and reconcile the existing/conflicting data in the field, to allow researchers to further the current understanding of Eph receptor signalling.	[Liang, Lung-Yu; Patel, Onisha; Murphy, James M.; Lucet, Isabelle S.] Walter & Eliza Hall Inst Med Res, Parkville, Vic 3052, Australia; [Liang, Lung-Yu; Patel, Onisha; Murphy, James M.; Lucet, Isabelle S.] Univ Melbourne, Dept Med Biol, Parkville, Vic 3052, Australia; [Janes, Peter W.] Olivia Newton John Canc Res Inst, 145 Studley Rd, Heidelberg, Vic 3084, Australia	Walter & Eliza Hall Institute; University of Melbourne; La Trobe University; Olivia Newton-John Cancer Research Institute	Murphy, JM; Lucet, IS (corresponding author), Walter & Eliza Hall Inst Med Res, Parkville, Vic 3052, Australia.; Murphy, JM; Lucet, IS (corresponding author), Univ Melbourne, Dept Med Biol, Parkville, Vic 3052, Australia.	jamesm@wehi.edu.au; lucet.i@wehi.edu.au	Liang, Lung-Yu/AAC-6505-2019; Murphy, James/B-4863-2017	Patel, Onisha/0000-0001-6701-7139; Murphy, James/0000-0003-0195-3949; lucet, isabelle/0000-0002-8563-8753	Australian Cancer Research Foundation; Cancer Council of Victoria; Walter and Eliza Hall Institute; Melbourne Research Scholarship; NHMRC [1105754]	Australian Cancer Research Foundation; Cancer Council of Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); Walter and Eliza Hall Institute; Melbourne Research Scholarship; NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	This work is supported by the Australian Cancer Research Foundation (to LYL, OP and IL), and the Cancer Council of Victoria (to PWJ). IL acknowledges support from the Walter and Eliza Hall Institute. LYL is supported by Melbourne Research Scholarship. JMM is grateful to the NHMRC for fellowship support (1105754). We acknowledge the NHMRC IRIISS and the Victorian State Government Operational Infrastructure Support Scheme.	Aasheim HC, 2005, BBA-GEN SUBJECTS, V1723, P1, DOI 10.1016/j.bbagen.2005.01.011; Akada M, 2014, CELL SIGNAL, V26, P2879, DOI 10.1016/j.cellsig.2014.08.031; Arnato KR, 2014, J CLIN INVEST, V124, P2037, DOI 10.1172/JCI72522; Astin JW, 2010, NAT CELL BIOL, V12, P1194, DOI 10.1038/ncb2122; Atapattu L, 2014, CELL ADHES MIGR, V8, P294, DOI 10.4161/19336918.2014.970026; Bhushan L, 2014, CANCER GENOM PROTEOM, V11, P239; Bin Fang W, 2005, ONCOGENE, V24, P7859, DOI 10.1038/sj.onc.1208937; Bin Fang W, 2008, J BIOL CHEM, V283, P16017, DOI 10.1074/jbc.M709934200; Borthakur S, 2014, J BIOL CHEM, V289, P19694, DOI 10.1074/jbc.M114.567602; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; Carvalho RF, 2006, NAT NEUROSCI, V9, P322, DOI 10.1038/nn1655; Cho WCS, 2012, PLOS ONE, V7; Dai DD, 2014, BBA-PROTEINS PROTEOM, V1844, P1729, DOI 10.1016/j.bbapap.2014.07.002; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Davis TL, 2008, STRUCTURE, V16, P873, DOI 10.1016/j.str.2008.03.008; Day BW, 2013, CANCER CELL, V23, P238, DOI 10.1016/j.ccr.2013.01.007; Dionne U, 2018, MOL CELL, V70, P995, DOI 10.1016/j.molcel.2018.05.013; Dong MM, 2018, BIOPHYS J, V115, P865, DOI 10.1016/j.bpj.2018.06.031; Fox BP, 2006, BIOCHEM BIOPH RES CO, V340, P268, DOI 10.1016/j.bbrc.2005.11.174; Freywald A, 2002, J BIOL CHEM, V277, P3823, DOI 10.1074/jbc.M108011200; Fu DY, 2010, HUM PATHOL, V41, P48, DOI 10.1016/j.humpath.2009.06.007; Han DC, 2002, J BIOL CHEM, V277, P45655, DOI 10.1074/jbc.M203165200; Himanen JP, 2001, NATURE, V414, P933, DOI 10.1038/414933a; Himanen JP, 2010, P NATL ACAD SCI USA, V107, P10860, DOI 10.1073/pnas.1004148107; Holmberg J, 2000, NATURE, V408, P203, DOI 10.1038/35041577; Jacobsen AV, 2017, BIOCHEM SOC T, V45, P665, DOI 10.1042/BST20160331; Janes PW, 2011, J CELL BIOL, V195, P1033, DOI 10.1083/jcb.201104037; Janes PW, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000215; Jiang J, 2015, SCI REP-UK, V5, DOI 10.1038/srep11765; Jorgensen C, 2009, SCIENCE, V326, P1502, DOI 10.1126/science.1176615; Kalo MS, 1999, BIOCHEMISTRY-US, V38, P14396, DOI 10.1021/bi991628t; Kalo MS, 2001, J BIOL CHEM, V276, P38940, DOI 10.1074/jbc.M105815200; Kao TJ, 2011, NEURON, V71, P76, DOI 10.1016/j.neuron.2011.05.031; Koshikawa N, 2015, CANCER RES, V75, P3327, DOI 10.1158/0008-5472.CAN-14-2798; Kullander K, 2001, NEURON, V29, P73, DOI 10.1016/S0896-6273(01)00181-7; Kwon A, 2018, J BIOL CHEM, V293, P5102, DOI 10.1074/jbc.RA117.001296; Lawrenson ID, 2002, J CELL SCI, V115, P1059; Lee J, 2015, STEM CELL REP, V5, P480, DOI 10.1016/j.stemcr.2015.09.001; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Li G, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1675; Li SB, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.507; Li SB, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1025-3; Li Y, 2017, ONCOTARGET, V8, P30344, DOI 10.18632/oncotarget.15910; Lim BK, 2008, NAT NEUROSCI, V11, P160, DOI 10.1038/nn2033; Lisabeth EM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a009159; Littlefield P, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005786; Locard-Paulet M, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aac5820; Luo HY, 2012, J BIOL CHEM, V287, P6819, DOI 10.1074/jbc.M111.293365; Mateo-Lozano S, 2017, SCI REP-UK, V7, DOI 10.1038/srep43702; Matsuoka H, 2005, J BIOL CHEM, V280, P29355, DOI 10.1074/jbc.M500010200; McDonell LM, 2015, HUM MOL GENET, V24, pR60, DOI 10.1093/hmg/ddv254; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Miao H, 2009, CANCER CELL, V16, P9, DOI 10.1016/j.ccr.2009.04.009; Muller-Tidow C, 2005, CANCER RES, V65, P1778, DOI 10.1158/0008-5472.CAN-04-3388; Murphy JM, 2017, CURR OPIN STRUC BIOL, V47, P95, DOI 10.1016/j.sbi.2017.07.004; Murphy JM, 2014, BIOCHEM J, V457, P323, DOI 10.1042/BJ20131174; Murphy JM, 2018, KINASE DRUG DISCOVER, P359; Nagano K, 2014, J CONTROL RELEASE, V189, P72, DOI 10.1016/j.jconrel.2014.06.010; Nagano K, 2014, BIOCHEM BIOPH RES CO, V450, P545, DOI 10.1016/j.bbrc.2014.06.007; Nagano K, 2013, CANCER MED-US, V2, P972, DOI 10.1002/cam4.156; Nievergall E, 2012, CELL MOL LIFE SCI, V69, P1813, DOI 10.1007/s00018-011-0900-6; Noberini R, 2012, CELL ADHES MIGR, V6, P102, DOI 10.4161/cam.19620; Ojosnegros S, 2017, P NATL ACAD SCI USA, V114, P13188, DOI 10.1073/pnas.1713564114; Oricchio E, 2011, CELL, V147, P554, DOI 10.1016/j.cell.2011.09.035; Palmer A, 2002, MOL CELL, V9, P725, DOI 10.1016/S1097-2765(02)00488-4; Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806; Peng LB, 2014, J MOL HISTOL, V45, P555, DOI 10.1007/s10735-014-9577-0; Pesti S, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-36; Reiterer V, 2014, TRENDS CELL BIOL, V24, P489, DOI 10.1016/j.tcb.2014.03.008; Rohani N, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001955; Sahin M, 2005, NEURON, V46, P191, DOI 10.1016/j.neuron.2005.01.030; Schaupp A, 2014, J CELL BIOL, V204, P409, DOI 10.1083/jcb.201305037; Seiradake E, 2013, NAT STRUCT MOL BIOL, V20, P958, DOI 10.1038/nsmb.2617; Seiradake E, 2010, NAT STRUCT MOL BIOL, V17, P398, DOI 10.1038/nsmb.1782; Shi W, 2019, J BIOL CHEM, V294, P6871, DOI 10.1074/jbc.RA118.005767; Shi X, 2017, TRANSLATIONAL MED CO, V2, P7; Shi XJ, 2017, SCI REP-UK, V7, DOI 10.1038/srep45084; Shintani T, 2006, NAT NEUROSCI, V9, P761, DOI 10.1038/nn1697; Singh DR, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-018-0017-7; Singh DR, 2017, BBA-MOL CELL RES, V1864, P31, DOI 10.1016/j.bbamcr.2016.10.011; Singh DR, 2015, BIOCHEM J, V471, P101, DOI 10.1042/BJ20150433; Singla N, 2011, CHEM BIOL, V18, P361, DOI 10.1016/j.chembiol.2011.01.011; Song W, 2017, ONCOGENE, V36, P5620, DOI 10.1038/onc.2017.170; Song WQ, 2014, CANCER RES, V74, P2444, DOI 10.1158/0008-5472.CAN-13-2136; Stallaert W, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aat0114; Stapleton D, 1999, NAT STRUCT BIOL, V6, P44; Staquicini FI, 2015, J BIOL CHEM, V290, P7345, DOI 10.1074/jbc.M114.630525; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Sugiyama N, 2013, J CELL BIOL, V201, P467, DOI 10.1083/jcb.201205176; Thanos CD, 1999, SCIENCE, V283, P833, DOI 10.1126/science.283.5403.833; Toosi BM, 2018, ONCOGENE, V37, P4073, DOI 10.1038/s41388-018-0228-x; Truitt L, 2010, CANCER RES, V70, P1141, DOI 10.1158/0008-5472.CAN-09-1710; Vail ME, 2014, CANCER RES, V74, P4470, DOI 10.1158/0008-5472.CAN-14-0218; Wang X, 2019, HEPATOLOGY, V69, P573, DOI 10.1002/hep.29792; Wang Y, 2018, ELIFE, V7, DOI 10.7554/eLife.35677; Wang YJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19215-2; Wiesner S, 2006, EMBO J, V25, P4686, DOI 10.1038/sj.emboj.7601315; Wilkinson DG, 2014, CELL ADHES MIGR, V8, P339, DOI 10.4161/19336918.2014.970007; Wimmer-Kleikamp SH, 2008, BLOOD, V112, P721, DOI 10.1182/blood-2007-11-121681; Wimmer-Kleikamp SH, 2004, J CELL BIOL, V164, P661, DOI 10.1083/jcb.200312001; Wybenga-Groot LE, 2001, CELL, V106, P745, DOI 10.1016/S0092-8674(01)00496-2; Xu K, 2013, P NATL ACAD SCI USA, V110, P14634, DOI 10.1073/pnas.1311000110; Yang NY, 2011, CELL SIGNAL, V23, P201, DOI 10.1016/j.cellsig.2010.09.004; Yeddula N, 2015, P NATL ACAD SCI USA, V112, pE6476, DOI 10.1073/pnas.1520110112; Yin Y, 2004, NEUROSCI RES, V48, P285, DOI 10.1016/j.neures.2003.11.009; Yu J, 2010, CLIN CANCER RES, V16, P2275, DOI 10.1158/1078-0432.CCR-09-2000; Zelinski DP, 2001, CANCER RES, V61, P2301; Zhao J, 2017, NEUROSCIENCE, V347, P11, DOI 10.1016/j.neuroscience.2017.01.038; Zisch AH, 1998, ONCOGENE, V16, P2657, DOI 10.1038/sj.onc.1201823	111	49	51	7	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2019	38	39					6567	6584		10.1038/s41388-019-0931-2	http://dx.doi.org/10.1038/s41388-019-0931-2			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JA5AQ	31406248	hybrid			2022-12-28	WOS:000487856000001
J	Wang, Z; Kang, L; Zhang, HF; Huang, YY; Fang, L; Li, MH; Brown, PJ; Arrowsmith, CH; Li, JW; Wong, JM				Wang, Zhen; Kang, Li; Zhang, Huifang; Huang, Yuanyong; Fang, Lan; Li, Menghan; Brown, Peter J.; Arrowsmith, Cheryl H.; Li, Jiwen; Wong, Jiemin			AKT drives SOX2 overexpression and cancer cell stemness in esophageal cancer by protecting SOX2 from UBR5-mediated degradation	ONCOGENE			English	Article							TUMOR-INITIATING CELLS; UBIQUITIN LIGASE UBR5; SELF-RENEWAL; IN-VITRO; PROMOTES; TARGET; GROWTH; GENE; LUNG; PHOSPHORYLATION	As a transcription factor critical for embryonic and adult stem cell self-renewal and function, SOX2 gene amplification has been recognized as a driving factor for various cancers including esophageal cancer. SOX2 overexpression occurs more broadly in cancer than gene amplification, but the mechanism is poorly understood. Here we showed that in esophageal cancer cell lines the levels of SOX2 proteins are not directly correlated to the copy numbers of SOX2 genes and are strongly influenced by proteostasis. We showed that AKT is a major determinant for SOX2 overexpression and does so by protecting SOX2 from ubiquitin-dependent protein degradation. We identified UBR5 as a major ubiquitin E3 ligase that induces SOX2 degradation through ubiquitinating SOX2 at lysine 115. Phosphorylation of SOX2 at threonine 116 by AKT inhibits the interaction of UBR5 with SOX2 and thus stabilizes SOX2. We provided evidence that AKT inhibitor can effectively downregulate SOX2 and suppress esopheageal cancer cell proliferation and stemness. Taken together, our study provides new insight into the mechanism of SOX2 overexpression in cancer and evidence for targeting AKT as a potential therapeutic strategy for SOX2-positive cancers.	[Wang, Zhen; Kang, Li; Zhang, Huifang; Huang, Yuanyong; Fang, Lan; Li, Menghan; Li, Jiwen; Wong, Jiemin] East China Normal Univ, Fengxian Dist Cent Hosp ECNU Joint Ctr Translat M, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, Shanghai 200241, Peoples R China; [Wang, Zhen; Kang, Li; Zhang, Huifang; Huang, Yuanyong; Fang, Lan; Li, Menghan; Li, Jiwen; Wong, Jiemin] East China Normal Univ, Sch Life Sci, Shanghai 200241, Peoples R China; [Brown, Peter J.; Arrowsmith, Cheryl H.] Univ Toronto, Struct Genom Consortium, Toronto, ON M5G 1L7, Canada; [Wong, Jiemin] State Key Lab Oncogene & Related Genes, Shanghai, Peoples R China; [Fang, Lan] Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Shanghai 200072, Peoples R China; [Fang, Lan] Tongji Univ, Sch Life Sci & Technol, Shanghai 200072, Peoples R China	East China Normal University; East China Normal University; University of Toronto; Structural Genomics Consortium; Tongji University; Tongji University	Li, JW; Wong, JM (corresponding author), East China Normal Univ, Fengxian Dist Cent Hosp ECNU Joint Ctr Translat M, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, Shanghai 200241, Peoples R China.; Li, JW; Wong, JM (corresponding author), East China Normal Univ, Sch Life Sci, Shanghai 200241, Peoples R China.; Wong, JM (corresponding author), State Key Lab Oncogene & Related Genes, Shanghai, Peoples R China.	jwli@bio.ecnu.edu.cn; jmweng@bio.ecnu.edu.cn	Wang, Zhen/GYI-9962-2022	Wang, Zhen/0000-0002-1215-1661; Brown, Peter/0000-0002-8454-0367; Arrowsmith, Cheryl/0000-0002-4971-3250; Wong, Jiemin/0000-0002-5311-842X	National Natural Science Foundation of China [81530078]; Ministry of Science and Technology of China [2017YFA0504201, 2015CB910402]; State Key Laboratory of Oncogenes and Related Genes [90-17-05]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China); State Key Laboratory of Oncogenes and Related Genes	We thank Dr. Shimin Zhao from Fudan University for providing expression plasmids for UBR5C, Dr. Tianbang Kang from SUN YAT-SEN University (Guangzhou, China) for providing K30, K140, K410 and K520 cells and Dr. Zhihua Liu at Cancer Hospital Chinese Academy of Medical Sciences (Beijing, China) for providing K70, K150, K450 and K510 cells. We also thank members of Wong's lab for valuable discussion. This study is supported by grants from the National Natural Science Foundation of China (81530078), the Ministry of Science and Technology of China (2017YFA0504201 and 2015CB910402 to J.W.) and the Grants from the State Key Laboratory of Oncogenes and Related Genes (No. 90-17-05).	Alonso MM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026740; Arnold K, 2011, CELL STEM CELL, V9, P317, DOI 10.1016/j.stem.2011.09.001; Barsyte-Lovejoy D, 2014, P NATL ACAD SCI USA, V111, P12853, DOI 10.1073/pnas.1407358111; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Basu-Roy U, 2012, ONCOGENE, V31, P2270, DOI 10.1038/onc.2011.405; Boumahdi S, 2014, NATURE, V511, P246, DOI 10.1038/nature13305; Callaghan MJ, 1998, ONCOGENE, V17, P3479, DOI 10.1038/sj.onc.1202249; Cox JL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062857; Fang L, 2014, MOL CELL, V55, P537, DOI 10.1016/j.molcel.2014.06.018; Fang XF, 2011, PROTEOMICS, V11, P921, DOI 10.1002/pmic.201000419; Gangemi RMR, 2009, STEM CELLS, V27, P40, DOI 10.1634/stemcells.2008-0493; Gen Y, 2013, CANCER SCI, V104, P810, DOI 10.1111/cas.12155; Gen Y, 2010, CANCER GENET CYTOGEN, V202, P82, DOI 10.1016/j.cancergencyto.2010.01.023; Gupta N, 2018, CANCERS, V10, DOI 10.3390/cancers10020041; Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012; Hussenet T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008960; Ikushima H, 2011, J BIOL CHEM, V286, P41434, DOI 10.1074/jbc.M111.300863; Jeong CH, 2010, STEM CELLS, V28, P2141, DOI 10.1002/stem.540; Kim J, 2017, NATURE, V541, P169, DOI 10.1038/nature20805; Lefebvre V, 2007, INT J BIOCHEM CELL B, V39, P2195, DOI 10.1016/j.biocel.2007.05.019; Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338; Liu KC, 2013, CELL STEM CELL, V12, P304, DOI 10.1016/j.stem.2013.01.007; Lu YX, 2014, CLIN CANCER RES, V20, P2631, DOI 10.1158/1078-0432.CCR-13-2348; Maier S, 2011, HUM PATHOL, V42, P1078, DOI 10.1016/j.humpath.2010.11.010; Masui S, 2007, NAT CELL BIOL, V9, P625, DOI 10.1038/ncb1589; Mayer IA, 2016, ANNU REV MED, V67, P11, DOI 10.1146/annurev-med-062913-051343; Meissner B, 2013, BLOOD, V121, P3161, DOI 10.1182/blood-2013-01-478834; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Ozen M, 2015, CANCER INVEST, V33, P251, DOI 10.3109/07357907.2015.1025407; Peltier J, 2011, STEM CELLS DEV, V20, P1153, DOI 10.1089/scd.2010.0130; Riggi N, 2010, GENE DEV, V24, P916, DOI 10.1101/gad.1899710; Sarkar A, 2013, CELL STEM CELL, V12, P15, DOI 10.1016/j.stem.2012.12.007; Saunders DN, 2004, MOL CELL BIOL, V24, P7225, DOI 10.1128/MCB.24.16.7225-7234.2004; Shearer RF, 2015, MOL CANCER RES, V13, P1523, DOI 10.1158/1541-7786.MCR-15-0383; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Singh S, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-73; Tam WL, 2014, CANCER CELL, V26, P3, DOI 10.1016/j.ccr.2014.06.024; Vanner RJ, 2014, CANCER CELL, V26, P33, DOI 10.1016/j.ccr.2014.05.005; Wang H, 2018, METHODS MOL BIOL, V1692, P77, DOI 10.1007/978-1-4939-7401-6_7; Weina K, 2014, CLIN TRANSL MED, V3, DOI 10.1186/2001-1326-3-19; Wuebben EL, 2017, ONCOTARGET, V8, P44917, DOI 10.18632/oncotarget.16570; Xu N, 2009, CELL, V137, P647, DOI 10.1016/j.cell.2009.02.038; Zhang HF, 2016, STEM CELLS, V34, P2040, DOI 10.1002/stem.2395; Zhang JQ, 2011, CELL RES, V21, P1723, DOI 10.1038/cr.2011.176	44	45	50	3	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2019	38	26					5250	5264		10.1038/s41388-019-0790-x	http://dx.doi.org/10.1038/s41388-019-0790-x			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IF4AX	30894683				2022-12-28	WOS:000473025300010
J	Yang, H; Zhu, RX; Zhao, XP; Liu, L; Zhou, ZL; Zhao, L; Liang, BB; Ma, WJ; Zhao, J; Liu, JJ; Huang, G				Yang, Hao; Zhu, Rongxuan; Zhao, Xiaoping; Liu, Liu; Zhou, Zhaoli; Zhao, Li; Liang, Beibei; Ma, Wenjing; Zhao, Jian; Liu, Jianjun; Huang, Gang			Sirtuin-mediated deacetylation of hnRNP A1 suppresses glycolysis and growth in hepatocellular carcinoma	ONCOGENE			English	Article							PYRUVATE-KINASE; PKM2 PROMOTES; M2 ISOFORM; CANCER; EXPRESSION; PROTEINS; PHOSPHORYLATION; ACETYLATION; REGULATOR; DISCOVERY	Tumor cells undergo a metabolic shift in order to adapt to the altered microenvironment, although the underlying mechanisms have not been fully explored. HnRNP A1 is involved in the alternative splicing of the pyruvate kinase (PK) mRNA, allowing tumor cells to specifically produce the PKM2 isoform. We found that the acetylation status of hnRNP A1 in hepatocellular carcinoma (HCC) cells was dependent on glucose availability, which affected the PKM2-dependent glycolytic pathway. In the glucose-starved HCC cells, SIRT1 and SIRT6, members of deacetylase sirtuin family, were highly expressed and deacetylated hnRNP A1 after direct binding. We identified four lysine residues in hnRNP A1 that were deacetylated by SIRT1 and SIRT6, resulting in significant inhibition of glycolysis in HCC cells. Deacetylated hnRNP A1 reduced PKM2 and increased PKM1 alternative splicing in HCC cells under normal glucose conditions, thereby reducing the metabolic activity of PK and the non-metabolic PKM2-beta-catenin signaling pathway. However, under glucose starvation, the low levels of acetylated hnRNP A1 reduced HCC cell metabolism to adapt to the nutrient deficiency. Taken together, sirtuin-mediated hnRNP A1 deacetylation inhibits HCC cell proliferation and tumorigenesis in a PKM2-dependent manner. These findings point to the metabolic reprogramming induced by hnRNP A1 acetylation in order to adapt to the nutritional status of the tumor microenvironment.	[Yang, Hao; Zhou, Zhaoli; Liang, Beibei; Ma, Wenjing; Huang, Gang] Shanghai Univ Med & Hlth Sci, Shanghai Key Lab Mol Imaging, Shanghai 201318, Peoples R China; [Yang, Hao; Zhao, Xiaoping; Zhao, Li; Liu, Jianjun; Huang, Gang] Shanghai Jiao Tong Univ, Ren Ji Hosp, Dept Nucl Med, Sch Med, Shanghai 200127, Peoples R China; [Zhu, Rongxuan] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Oncol, Sch Med, Shanghai 200080, Peoples R China; [Liu, Liu] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Nucl Med, Shanghai 200030, Peoples R China; [Zhao, Jian] Second Mil Med Univ, Int Joint Canc Inst, Shanghai 200433, Peoples R China	Shanghai University of Medicine & Health Sciences; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Naval Medical University	Huang, G (corresponding author), Shanghai Univ Med & Hlth Sci, Shanghai Key Lab Mol Imaging, Shanghai 201318, Peoples R China.; Liu, JJ; Huang, G (corresponding author), Shanghai Jiao Tong Univ, Ren Ji Hosp, Dept Nucl Med, Sch Med, Shanghai 200127, Peoples R China.	nuclearj@163.com; huanggang@sumhs.edu.cn		Yang, Hao/0000-0002-3781-7271	National Natural Science Foundation of China [81530053, 81830052, 81771858, 81602415, 81670573, 81572719, 81874202, 81803581]; Shanghai Municipal Education Commission (Class II Plateau Disciplinary Construction Program for Medical Technology of SUMHS)	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Municipal Education Commission (Class II Plateau Disciplinary Construction Program for Medical Technology of SUMHS)	This work was supported by research grants from the National Natural Science Foundation of China (Nos. 81530053, 81830052, 81771858, 81602415, 81670573, 81572719, 81874202, and 81803581) and Shanghai Municipal Education Commission (Class II Plateau Disciplinary Construction Program for Medical Technology of SUMHS, 2018-2020).	Agerholm M, 2018, AM J PHYSIOL-ENDOC M, V314, pE377, DOI 10.1152/ajpendo.00213.2017; Ampferl R, 2018, RADIOTHER ONCOL, V126, P465, DOI 10.1016/j.radonc.2017.10.020; Bhardwaj A, 2016, P NATL ACAD SCI USA, V113, pE538, DOI 10.1073/pnas.1520045113; Chang CM, 2015, MOL CELL, V60, P930, DOI 10.1016/j.molcel.2015.10.037; Chen H, 2003, P NATL ACAD SCI USA, V100, P6109, DOI 10.1073/pnas.1031395100; Chen J, 2013, HEPATOLOGY, V57, P2287, DOI 10.1002/hep.26278; Chen M, 2010, CANCER RES, V70, P8977, DOI 10.1158/0008-5472.CAN-10-2513; Chen YH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04815-3; Chettouh H, 2013, CANCER RES, V73, P3974, DOI 10.1158/0008-5472.CAN-12-3824; Clower CV, 2010, P NATL ACAD SCI USA, V107, P1894, DOI 10.1073/pnas.0914845107; David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697; Dayton TL, 2018, CANCER METAB, V6, DOI 10.1186/s40170-018-0179-2; Fang X, 2018, EXP CELL RES, V362, P279, DOI 10.1016/j.yexcr.2017.11.028; Gu ZM, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0392-4; Huang JZ, 2017, MOL CELL, V68, P171, DOI 10.1016/j.molcel.2017.09.015; Iansante V, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8882; Kashima T, 2007, HUM MOL GENET, V16, P3149, DOI 10.1093/hmg/ddm276; Kim YJ, 2017, INT J GYNECOL CANCER, V27, P326, DOI 10.1097/IGC.0000000000000868; Lee JY, 2014, J CELL SCI, V127, P4954, DOI 10.1242/jcs.157321; Li HL, 2012, AM J PHYSIOL-ENDOC M, V303, pE1234, DOI 10.1152/ajpendo.00198.2012; Li LY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122024; Luan WK, 2015, ONCOTARGET, V6, P13006, DOI 10.18632/oncotarget.3514; Lv L, 2011, MOL CELL, V42, P719, DOI 10.1016/j.molcel.2011.04.025; Mazurek S, 2011, INT J BIOCHEM CELL B, V43, P969, DOI 10.1016/j.biocel.2010.02.005; Mohagheghi F, 2016, HUM MOL GENET, V25, P534, DOI 10.1093/hmg/ddv491; Ning XL, 2017, EUR J MED CHEM, V138, P343, DOI 10.1016/j.ejmech.2017.06.064; Ong ALC, 2018, AGEING RES REV, V43, P64, DOI 10.1016/j.arr.2018.02.004; Parenti MD, 2014, J MED CHEM, V57, P4796, DOI 10.1021/jm500487d; Park SH, 2016, CANCER RES, V76, P3802, DOI 10.1158/0008-5472.CAN-15-2498; Park WC, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2387-x; Pina JM, 2018, BIOCHEMISTRY-US, V57, P3873, DOI 10.1021/acs.biochem.8b00256; PUN KK, 1988, J CLIN ENDOCR METAB, V67, P546, DOI 10.1210/jcem-67-3-546; Roda D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130543; Roy R, 2017, WIRES RNA, V8, DOI 10.1002/wrna.1431; Sun Y, 2017, ONCOL LETT, V14, P7323, DOI 10.3892/ol.2017.7085; Williams AL, 2018, PHYSIOL GENOMICS, V50, P479, DOI 10.1152/physiolgenomics.00130.2017; Xiong Y, 2011, COLD SH Q B, V76, P285, DOI 10.1101/sqb.2011.76.010942; Xu Q, 2015, ONCOGENE, V34, P5482, DOI 10.1038/onc.2015.6; Xuan Y, 2016, MOL ONCOL, V10, P610, DOI 10.1016/j.molonc.2015.11.010; Yang WW, 2012, NAT CELL BIOL, V14, P1295, DOI 10.1038/ncb2629; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Zhang LF, 2015, EMBO J, V34, P2671, DOI 10.15252/embj.201591803; Zhang ZY, 2015, J HEPATOL, V62, P121, DOI 10.1016/j.jhep.2014.08.007; Zhu YM, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-15	44	29	32	2	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2019	38	25					4915	4931		10.1038/s41388-019-0764-z	http://dx.doi.org/10.1038/s41388-019-0764-z			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IE1KY	30858544				2022-12-28	WOS:000472145900003
J	Blijlevens, M; van der Meulen-Muileman, IH; de Menezes, RX; Smit, EF; van Beusechem, VW				Blijlevens, Maxime; van der Meulen-Muileman, Ida H.; de Menezes, Renee X.; Smit, Egbert F.; van Beusechem, Victor W.			High-throughput RNAi screening reveals cancer-selective lethal targets in the RNA spliceosome	ONCOGENE			English	Article							FALSE DISCOVERY RATE; PHASE-I; ORGANIZATION; MACHINERY; E7107; CORE	Novel therapeutic strategies for non-small-cell lung cancer (NSCLC) are urgently needed. RNA splicing, orchestrated by the spliceosome, is deregulated in many forms of cancer, including NSCLC. Here, we performed high-throughput screening with a small interfering RNA library targeting all annotated human spliceosome proteins to identify cancer-selective lethal targets in the RNA splicing machinery. Silencing of several spliceosome proteins reduced cell viability in a panel of NSCLC cell lines, but not in non-malignant lung fibroblasts and epithelial cells. Interestingly, the cancer-selective lethal target set comprised all seven Sm proteins that, together with small nuclear RNA, form the core structure of most spliceosome subunits. Interfering with Sm protein expression induced apoptosis in NSCLC cells, but not in non-malignant cells. In silico analysis revealed that Sm proteins are frequently upregulated in NSCLC. For several Sm proteins, increased expression showed a positive correlation with disease severity. Together, our results suggest that the Sm proteins represent particularly useful novel targets for selective treatment of NSCLC.	[Blijlevens, Maxime; van der Meulen-Muileman, Ida H.; van Beusechem, Victor W.] Vrije Univ Amsterdam, Amsterdam UMC, Canc Ctr Amsterdam, Med Oncol, Boelelaan 1118, Amsterdam, Netherlands; [de Menezes, Renee X.] Vrije Univ Amsterdam, Amsterdam UMC, Netherlands Bioinformat Ctr, Epidemiol & Biostat, Boelelaan 1118, Amsterdam, Netherlands; [Smit, Egbert F.] Netherlands Canc Inst, Dept Thorac Oncol, Amsterdam, Netherlands	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Netherlands Cancer Institute	van Beusechem, VW (corresponding author), Vrije Univ Amsterdam, Amsterdam UMC, Canc Ctr Amsterdam, Med Oncol, Boelelaan 1118, Amsterdam, Netherlands.	vw.vanbeusechem@vumc.nl	Menezes, Renee/L-2182-2019	Smit, Egbert/0000-0002-7329-6995	Walter Bruckerhoff Stiftung; Stichting VUmc-CCA	Walter Bruckerhoff Stiftung; Stichting VUmc-CCA	This work was supported by Walter Bruckerhoff Stiftung and Stichting VUmc-CCA.	[Anonymous], 2014, R LANG ENV STAT COMP; Bachas C, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859-018-2306-z; Benjamini Y, 2001, ANN STAT, V29, P1165; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bonnal S, 2012, NAT REV DRUG DISCOV, V11, P847, DOI 10.1038/nrd3823; Campbell JD, 2016, NAT GENET, V48, P607, DOI 10.1038/ng.3564; Carbon S, 2009, BIOINFORMATICS, V25, P288, DOI 10.1093/bioinformatics/btn615; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Citterio L, 1999, BIOCHEM BIOPH RES CO, V266, P110, DOI 10.1006/bbrc.1999.1769; Croft D, 2011, NUCLEIC ACIDS RES, V39, pD691, DOI 10.1093/nar/gkq1018; David CJ, 2010, GENE DEV, V24, P2343, DOI 10.1101/gad.1973010; Dutertre M, 2010, CANCER RES, V70, P896, DOI 10.1158/0008-5472.CAN-09-2703; Effenberger KA., 2017, WILEY INTERDISCIP RE, V8, P1; Eskens FALM, 2013, CLIN CANCER RES, V19, P6296, DOI 10.1158/1078-0432.CCR-13-0485; Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gao Y, 2013, ACS CHEM BIOL, V8, P895, DOI 10.1021/cb300602j; Hong DS, 2014, INVEST NEW DRUG, V32, P436, DOI 10.1007/s10637-013-0046-5; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Kambach C, 1999, CELL, V96, P375, DOI 10.1016/S0092-8674(00)80550-4; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Langer W, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-676; Matera AG, 2014, NAT REV MOL CELL BIO, V15, P108, DOI 10.1038/nrm3742; Oltean S, 2014, ONCOGENE, V33, P5311, DOI 10.1038/onc.2013.533; Pao W, 2011, LANCET ONCOL, V12, P175, DOI 10.1016/S1470-2045(10)70087-5; Pomeranz Krummel Daniel A, 2009, Nature, V458, P475, DOI 10.1038/nature07851; Quidville V, 2013, CANCER RES, V73, P2247, DOI 10.1158/0008-5472.CAN-12-2501; Reck M, 2013, LANCET, V382, P709, DOI 10.1016/S0140-6736(13)61502-0; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Siebring-van Olst E, 2017, MOL ONCOL, V11, P534, DOI 10.1002/1878-0261.12052; Wahl MC, 2009, CELL, V136, P701, DOI 10.1016/j.cell.2009.02.009; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Webb TR, 2013, DRUG DISCOV TODAY, V18, P43, DOI 10.1016/j.drudis.2012.07.013; Weber G, 2010, EMBO J, V29, P4172, DOI 10.1038/emboj.2010.295	34	12	12	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2019	38	21					4142	4153		10.1038/s41388-019-0711-z	http://dx.doi.org/10.1038/s41388-019-0711-z			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ3HX	30705407				2022-12-28	WOS:000468740200012
J	Zhang, SP; Guo, XW; Wu, HG; Sun, Y; Ma, XJ; Li, JK; Xu, Q; Wu, CX; Li, QW; Jiang, CZ; Li, WZ; Ho, MS; Lv, ZW; Xue, L				Zhang, Shiping; Guo, Xiaowei; Wu, Honggui; Sun, Ying; Ma, Xianjue; Li, Jikai; Xu, Qian; Wu, Chenxi; Li, Qiwen; Jiang, Cizhong; Li, Wenzhe; Ho, Margaret S.; Lv, Zhongwei; Xue, Lei			Wingless modulates activator protein-1-mediated tumor invasion	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; LONG-RANGE ACTION; BETA-CATENIN; ONCOGENIC RAS; CELL-DEATH; DROSOPHILA; MIGRATION; GROWTH; CANCER; PROLIFERATION	Metastasis begins with a subset of local tumor cells acquiring the potential to invade into surrounding tissues, and remains to be a major obstacle for cancer treatments. More than 90% of cancer patients died from tumor metastasis, instead of primary tumor growth. The canonical Wnt/beta-catenin pathway plays essential roles in promoting tumor formation, yet its function in regulating tumor metastasis and the underlying mechanisms remain controversial. Here we employed well-established Drosophila tumor models to investigate the regulating mechanism of Wingless (Wg) pathway in tumor invasion. Our results showed that Wg signaling is necessary and sufficient for cell polarity disruption-induced cell migration and molecular changes reminiscent of epithelial-mesenchymal transition (EMT). Moreover, reducing Wg signaling suppressed lgl(-/-)/Ras(V12)-induced tumor invasion, and cooperation between Arm and Ras(V12) is sufficient to induce tumor invasion. Mechanistically, we found that cell polarity disruption activates JNK signaling, which in turn upregulate wg expression through transcription factor activator protein-1 (AP-1). We identified a consensus AP-1 binding site located in the 2nd intron of wg, and confirmed that it is essential for AP-1 induced wg transcription both in vitro and in vivo. Lastly, we confirmed that the transcriptional activation of WNT by AP-1 is conserved in human cancer cells. These evidences reveal a positive role of Wnt/beta-catenin pathway in tumor invasion, and provide a conserved mechanism that connects JNK and Wnt signaling in regulating tumor progression.	[Zhang, Shiping; Guo, Xiaowei; Wu, Honggui; Sun, Ying; Ma, Xianjue; Li, Jikai; Wu, Chenxi; Li, Qiwen; Jiang, Cizhong; Li, Wenzhe; Lv, Zhongwei; Xue, Lei] Tongji Univ, Shanghai Peoples Hosp 10, Shanghai Key Lab Signaling & Dis Res, Inst Intervent Vessel,Sch Life Sci & Technol, 1239 Siping Rd, Shanghai 200092, Peoples R China; [Zhang, Shiping; Ho, Margaret S.] ShanghaiTech Univ, Sch Life Sci & Technol, 393 Middle Huaxia Rd, Shanghai 201210, Peoples R China; [Ma, Xianjue] Yale Univ, Sch Med, Dept Genet, Howard Hughes Med Inst, 295 Congress Ave, New Haven, CT 06519 USA; [Xu, Qian] Fujian Univ Tradit Chinese Med, Inst Integrated Chinese & Western Med, 1 Qiu Yang Rd, Fuzhou 350122, Fujian, Peoples R China; [Wu, Chenxi] North China Univ Sci & Technol, Coll Tradit Chinese Med, 21 Bohai Rd, Tangshan 063210, Peoples R China; [Xue, Lei] Zhuhai Peoples Hosp, Ctr Intervent Radiol, Zhuhai 519000, Peoples R China	Tongji University; ShanghaiTech University; Howard Hughes Medical Institute; Yale University; Fujian University of Traditional Chinese Medicine; North China University of Science & Technology	Xue, L (corresponding author), Tongji Univ, Shanghai Peoples Hosp 10, Shanghai Key Lab Signaling & Dis Res, Inst Intervent Vessel,Sch Life Sci & Technol, 1239 Siping Rd, Shanghai 200092, Peoples R China.; Xue, L (corresponding author), Zhuhai Peoples Hosp, Ctr Intervent Radiol, Zhuhai 519000, Peoples R China.	lei.xue@tongji.edu.cn	Ho, Margaret/K-6310-2017	Ho, Margaret/0000-0002-2387-7564; Ma, Xianjue/0000-0003-4360-3947	National Natural Science Foundation of China [31571516, 31701278, 31771595]; Shanghai Committee of Science and Technology [18430711600, 18140900400, 09DZ2260100]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Committee of Science and Technology(Shanghai Science & Technology Committee)	We thank Bloomington Drosophila Stock Center, Vienna Drosophila RNAi Center, Fly Stocks of National Institute of Genetics, the Core Facility of Drosophila Resource and Technology at SIBCB of CAS, Developmental Studies Hybridoma Bank, Dr. Jose ' Carlos Pastor-Pareja and Dr. Haiyun Song for fly stocks and antibodies. We thank Drs. Zhihua Liu, Ru Zhang, Fan Zhang and Jian Fei for cell lines and plasmids. We thank Dr. Mark Peifer and other lab members for discussion and critical comments. This work is founded by National Natural Science Foundation of China (31571516, 31701278 and 31771595), and Shanghai Committee of Science and Technology (18430711600, 18140900400, 09DZ2260100).	Agnes F, 1999, DEVELOPMENT, V126, P5453; Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Arozarena I, 2011, ONCOGENE, V30, P4531, DOI 10.1038/onc.2011.162; Bachmann IM, 2005, CLIN CANCER RES, V11, P8606, DOI 10.1158/1078-0432.CCR-05-0011; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chien AJ, 2009, P NATL ACAD SCI USA, V106, P1193, DOI 10.1073/pnas.0811902106; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Cordero JB, 2010, DEV CELL, V18, P999, DOI 10.1016/j.devcel.2010.05.014; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Fu L, 2011, GUT, V60, P1635, DOI 10.1136/gut.2011.241638; Gerlitz O, 2002, GENE DEV, V16, P1055, DOI 10.1101/gad.991802; Gonzalez C, 2013, NAT REV CANCER, V13, P172, DOI 10.1038/nrc3461; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hunter Kent W, 2008, Breast Cancer Res, V10 Suppl 1, pS2, DOI 10.1186/bcr1988; Igaki T, 2006, CURR BIOL, V16, P1139, DOI 10.1016/j.cub.2006.04.042; Jung A, 2001, AM J PATHOL, V159, P1613, DOI 10.1016/S0002-9440(10)63007-6; Jung HY, 2015, CLIN CANCER RES, V21, P962, DOI 10.1158/1078-0432.CCR-13-3173; Liu LA, 2010, CLIN CANCER RES, V16, P2740, DOI 10.1158/1078-0432.CCR-09-2610; Ma X, 2016, ONCOGENE, V35, P846, DOI 10.1038/onc.2015.137; Ma X, 2014, CELL DEATH DIFFER, V21, P407, DOI 10.1038/cdd.2013.154; Ma X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.392; Ma XJ, 2017, P NATL ACAD SCI USA, V114, P1934, DOI 10.1073/pnas.1621359114; Ma XJ, 2013, DEV BIOL, V380, P211, DOI 10.1016/j.ydbio.2013.05.013; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Millar JBA, 2002, GENOME BIOL, V3; Morin X, 2001, P NATL ACAD SCI USA, V98, P15050, DOI 10.1073/pnas.261408198; Neumann CJ, 1997, DEVELOPMENT, V124, P871; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Pastor-Pareja JC, 2011, DEV CELL, V21, P245, DOI 10.1016/j.devcel.2011.06.026; Qiang YW, 2005, BLOOD, V106, P1786, DOI 10.1182/blood-2005-01-0049; Rallis A, 2010, DEV BIOL, V339, P65, DOI 10.1016/j.ydbio.2009.12.016; Rubin GM, 2000, SCIENCE, V287, P2216, DOI 10.1126/science.287.5461.2216; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Swarup S, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007930; Uhlirova M, 2006, EMBO J, V25, P5294, DOI 10.1038/sj.emboj.7601401; Ulivieri A, 2008, J PATHOL, V215, P87, DOI 10.1002/path.2331; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; van Amerongen R, 2009, DEVELOPMENT, V136, P3205, DOI 10.1242/dev.033910; Vidal M, 2006, DEV CELL, V10, P33, DOI 10.1016/j.devcel.2005.11.007; Wang AL, 2014, MOL CELL BIOCHEM, V395, P211, DOI 10.1007/s11010-014-2127-y; Wang X, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.196; Weston CR, 2007, CURR OPIN CELL BIOL, V19, P142, DOI 10.1016/j.ceb.2007.02.001; Yamben IF, 2013, DEV BIOL, V384, P41, DOI 10.1016/j.ydbio.2013.09.027; Yang JB, 2015, INT J CLIN EXP PATHO, V8, P11837; Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zhang S, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.85; Zhang SP, 2016, SCI REP-UK, V6, DOI 10.1038/srep22348; Zhao M, 2008, GENETICS, V178, P1947, DOI 10.1534/genetics.108.086983; Zi XL, 2005, CANCER RES, V65, P9762, DOI 10.1158/0008-5472.CAN-05-0103; Zulehner G, 2010, AM J PATHOL, V176, P472, DOI 10.2353/ajpath.2010.090300	56	15	15	2	29	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2019	38	20					3871	3885		10.1038/s41388-018-0629-x	http://dx.doi.org/10.1038/s41388-018-0629-x			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HY3OI	30683884				2022-12-28	WOS:000468035600008
J	Brix, DM; Tvingsholm, SA; Hansen, MB; Clemmensen, KB; Ohman, T; Siino, V; Lambrughi, M; Hansen, K; Puustinen, P; Gromova, I; James, P; Papaleo, E; Varjosalo, M; Moreira, J; Jaattela, M; Kallunki, T				Brix, Ditte Marie; Tvingsholm, Siri Amanda; Hansen, Malene Bredahl; Clemmensen, Knut Bundgaard; Ohman, Tiina; Siino, Valentina; Lambrughi, Matteo; Hansen, Klaus; Puustinen, Pietri; Gromova, Irina; James, Peter; Papaleo, Elena; Varjosalo, Markku; Moreira, Jose; Jaattela, Marja; Kallunki, Tuula			Release of transcriptional repression via ErbB2-induced, SUMO-directed phosphorylation of myeloid zinc finger-1 serine 27 activates lysosome redistribution and invasion	ONCOGENE			English	Article							CANCER CELL INVASION; HUMAN-BREAST-CANCER; PROTEIN; EXPRESSION; RECEPTOR; ERBB2; HER2; IDENTIFICATION; PROGRESSION; INHIBITORS	HER2/ErbB2 activation turns on transcriptional processes that induce local invasion and lead to systemic metastasis. The early transcriptional changes needed for ErbB2-induced invasion are poorly understood. Here, we link ErbB2 activation to invasion via ErbB2-induced, SUMO-directed phosphorylation of a single serine residue, S27, of the transcription factor myeloid zinc finger-1 (MZF1). Utilizing an antibody against MZF1-pS27, we show that the phosphorylation of S27 correlates significantly (p < 0.0001) with high-level expression of ErbB2 in primary invasive breast tumors. Phosphorylation of MZF1-S27 is an early response to ErbB2 activation and results in increased transcriptional activity of MZF1. It is needed for the ErbB2-induced expression of MZF1 target genes CTSB and PRKCA, and invasion of single-cells from ErbB2-expressing breast cancer spheroids. The phosphorylation of MZF1-S27 is preceded by poly-SUMOylation of K23, which can make S27 accessible to efficient phosphorylation by PAK4. Based on our results, we suggest for an activation mechanism where phosphorylation of MZF1-S27 triggers MZF1 dissociation from its transcriptional repressors such as the CCCTC-binding factor (CTCF). Our findings increase understanding of the regulation of invasive signaling in breast cancer by uncovering a detailed biological mechanism of how ErbB2 activation can rapidly lead to its invasion-promoting target gene expression and invasion.	[Brix, Ditte Marie; Tvingsholm, Siri Amanda; Hansen, Malene Bredahl; Clemmensen, Knut Bundgaard; Puustinen, Pietri; Jaattela, Marja; Kallunki, Tuula] Danish Canc Soc, Res Ctr, Cell Death & Metab, Ctr Autophagy Recycling & Dis, Strandboulevarden 49, DK-2100 Copenhagen, Denmark; [Ohman, Tiina; Varjosalo, Markku] Univ Helsinki, Inst Biotechnol, Helsinki Inst Life Sci, Helsinki 00014, Finland; [Siino, Valentina] Lund Univ, Inst Immunotechnol, S-22381 Lund, Sweden; [Lambrughi, Matteo; Papaleo, Elena] Danish Canc Soc, Res Ctr, Computat Biol Lab, Ctr Autophagy Recycling & Dis, DK-2100 Copenhagen, Denmark; [Hansen, Klaus] Univ Copenhagen, Biotech Res & Innovat Ctr, DK-2200 Copenhagen, Denmark; [Gromova, Irina] Danish Canc Soc, Res Ctr, Unit Genome Integr, Ctr Autophagy Recycling & Dis,Breast Canc Biol, DK-2100 Copenhagen, Denmark; [James, Peter] Abo Akad Univ, Turku Ctr Biotechnol, Turku 20014, Finland; [James, Peter] Univ Turku, Turku 20014, Finland; [Moreira, Jose; Kallunki, Tuula] Univ Copenhagen, Fac Hlth & Med Sci, Dept Drug Design & Pharmacol, DK-2200 Copenhagen, Denmark	Danish Cancer Society; University of Helsinki; Lund University; Danish Cancer Society; University of Copenhagen; Danish Cancer Society; Abo Akademi University; University of Turku; University of Turku; University of Copenhagen	Jaattela, M; Kallunki, T (corresponding author), Danish Canc Soc, Res Ctr, Cell Death & Metab, Ctr Autophagy Recycling & Dis, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.; Kallunki, T (corresponding author), Univ Copenhagen, Fac Hlth & Med Sci, Dept Drug Design & Pharmacol, DK-2200 Copenhagen, Denmark.	mj@cancer.dk; tk@cancer.dk	Jäättelä, Marja/AAT-7932-2021; Lambrughi, Matteo/AAF-1749-2020; Papaleo, Elena/M-6629-2014; Varjosalo, Markku/K-6424-2015	Jäättelä, Marja/0000-0001-5950-7111; Kallunki, Tuula/0000-0002-8571-383X; Moreira, Jose/0000-0002-9944-1214; , Elena/0000-0003-2296-898X; Papaleo, Elena/0000-0002-7376-5894; Bredahl Hansen, Malene/0000-0003-2006-3503; Varjosalo, Markku/0000-0002-1340-9732; Hansen, Klaus/0000-0001-9657-8816; Ohman, Tiina/0000-0001-6647-8873; Lambrughi, Matteo/0000-0002-0894-8627; Siino, Valentina/0000-0002-0489-6380	Novo Nordisk Foundation [NNF15OC0017324]; Danish Medical Research Council [0602-02386B]; Danish Cancer Society Scientific Committee (KBVU) [R124-A7854-15-S2, R56-A3108-12-S2]; Danish National Research Foundation [DNRF125]; European Research Council [AdG 340751]; EU-PRACE DECI13th grant; DeiC Pilot Grant 2015-2016 for the Danish Supercomputing Center Computerome	Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Danish Cancer Society Scientific Committee (KBVU); Danish National Research Foundation(Danmarks Grundforskningsfond); European Research Council(European Research Council (ERC)European Commission); EU-PRACE DECI13th grant; DeiC Pilot Grant 2015-2016 for the Danish Supercomputing Center Computerome	Funding was provided by the Novo Nordisk Foundation (NNF15OC0017324) (TK), the Danish Medical Research Council (0602-02386B) (TK), the Danish Cancer Society Scientific Committee (KBVU) (R124-A7854-15-S2 and R56-A3108-12-S2) (TK), the Danish National Research Foundation (DNRF125) (MJ), the European Research Council (AdG 340751) (MJ), EU-PRACE DECI13th grant for computational resources (EP), and the DeiC Pilot Grant 2015-2016 for the Danish Supercomputing Center Computerome (EP).	Abdel-Magid AF, 2015, ACS MED CHEM LETT, V6, P17, DOI 10.1021/ml500445c; Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; Bailey TA, 2014, J BIOL CHEM, V289, P30443, DOI 10.1074/jbc.M114.608992; Baker AF, 2005, CLIN CANCER RES, V11, P4338, DOI 10.1158/1078-0432.CCR-05-0422; Bawa-Khalfe Tasneem, 2010, Genes Cancer, V1, P748; Brix DM, 2014, MOL ONCOL, V8, P1703, DOI 10.1016/j.molonc.2014.07.004; Deng Y, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/868131; Dittmer J, 2017, SEMIN CANCER BIOL, V44, P72, DOI 10.1016/j.semcancer.2017.03.006; Duchnowska R, 2015, NEURO-ONCOLOGY, V17, P1241, DOI 10.1093/neuonc/nov012; Egeblad M, 2001, INT J CANCER, V94, P185, DOI 10.1002/ijc.1459; Eguchi T, 2015, J CELL BIOCHEM, V116, P2146, DOI 10.1002/jcb.25203; Fonovic M, 2014, BBA-GEN SUBJECTS, V1840, P2560, DOI 10.1016/j.bbagen.2014.03.017; Ha BH, 2015, J BIOL CHEM, V290, P12975, DOI 10.1074/jbc.R115.650416; Hamalisto S, 2016, CURR OPIN CELL BIOL, V39, P69, DOI 10.1016/j.ceb.2016.02.009; Hendriks IA, 2017, NAT STRUCT MOL BIOL, V24, P325, DOI 10.1038/nsmb.3366; Hietakangas V, 2006, P NATL ACAD SCI USA, V103, P45, DOI 10.1073/pnas.0503698102; Ivascu A, 2006, J BIOMOL SCREEN, V11, P922, DOI 10.1177/1087057106292763; Kallunki T, 2013, ONCOGENE, V32, P1995, DOI 10.1038/onc.2012.292; Kim KI, 2006, MOL CELLS, V22, P247; Kim S, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2015.33; Ko H, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0035-9; Marshall AD, 2014, CURR OPIN GENET DEV, V24, P8, DOI 10.1016/j.gde.2013.10.011; Mason SD, 2011, TRENDS CELL BIOL, V21, P228, DOI 10.1016/j.tcb.2010.12.002; Mathelier A, 2014, NUCLEIC ACIDS RES, V42, pD142, DOI 10.1093/nar/gkt997; Mertins P, 2016, NATURE, V534, P55, DOI 10.1038/nature18003; Minden Audrey, 2012, ISRN Oncol, V2012, P694201, DOI 10.5402/2012/694201; Mudduluru G, 2010, MOL CANCER RES, V8, P159, DOI 10.1158/1541-7786.MCR-09-0326; Nagashima T, 2007, J BIOL CHEM, V282, P4045, DOI 10.1074/jbc.M608653200; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Noll L, 2008, LEUKEMIA RES, V32, P1582, DOI 10.1016/j.leukres.2008.03.024; Ogawa H, 2003, J BIOL CHEM, V278, P2921, DOI 10.1074/jbc.M207615200; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rafn B, 2012, MOL CELL, V45, P764, DOI 10.1016/j.molcel.2012.01.029; Saez R, 2006, CLIN CANCER RES, V12, P424, DOI 10.1158/1078-0432.CCR-05-1807; Sander TL, 2000, J BIOL CHEM, V275, P12857, DOI 10.1074/jbc.275.17.12857; Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134; Seeler JS, 2017, NAT REV CANCER, V17, P184, DOI 10.1038/nrc.2016.143; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; Sevenich L, 2014, GENE DEV, V28, P2331, DOI 10.1101/gad.250647.114; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Subramonian D, 2014, J PROTEOME RES, V13, P3905, DOI 10.1021/pr500119a; Tan M, 2006, ONCOGENE, V25, P3286, DOI 10.1038/sj.onc.1209361; Tsai LH, 2015, ONCOGENE, V34, P1641, DOI 10.1038/onc.2014.118; Tural D, 2014, EXPERT REV ANTICANC, V14, P1089, DOI 10.1586/14737140.2014.929946; Tvingsholm SA, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-017-0014-6; Varjosalo M, 2013, NAT METHODS, V10, P307, DOI [10.1038/NMETH.2400, 10.1038/nmeth.2400]; Venur VA, 2016, INT J MOL SCI, P17; Weber CE, 2015, ONCOGENE, V34, P4821, DOI 10.1038/onc.2014.410; Xiao YX, 2015, ANAL BIOCHEM, V477, P95, DOI 10.1016/j.ab.2014.11.006; Yue CH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127420; Yue CH, 2012, CHINESE J PHYSIOL, V55, P31, DOI 10.4077/CJP.2012.AMM109	52	12	13	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2019	38	17					3170	3184		10.1038/s41388-018-0653-x	http://dx.doi.org/10.1038/s41388-018-0653-x			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU8RI	30622337	Green Submitted, Green Accepted			2022-12-28	WOS:000465557200005
J	Causse, SZ; Marcion, G; Chanteloup, G; Uyanik, B; Boudesco, C; Grigorash, BB; Douhard, R; Dias, AMM; Dumetier, B; Dondaine, L; Gozzi, GJ; Moussay, E; Paggetti, J; Mirjolet, C; de Thonel, A; Dubrez, L; Demidov, ON; Gobbo, J; Garrido, C				Causse, Sebastien Z.; Marcion, Guillaume; Chanteloup, Gaetan; Uyanik, Burhan; Boudesco, Christophe; Grigorash, Bogdan B.; Douhard, Romain; Dias, Alexandre M. M.; Dumetier, Baptiste; Dondaine, Lucile; Gozzi, Gustavo J.; Moussay, Etienne; Paggetti, Jerome; Mirjolet, Celine; de Thonel, Aurelie; Dubrez, Laurence; Demidov, Oleg N.; Gobbo, Jessica; Garrido, Carmen			HSP110 translocates to the nucleus upon genotoxic chemotherapy and promotes DNA repair in colorectal cancer cells	ONCOGENE			English	Article							HEAT-SHOCK PROTEINS; EXPRESSION; HSP70	A multicenter clinical study demonstrated the presence of a loss-of-function HSP110 mutation in about 15% of colorectal cancers, which resulted from an alternative splicing and was produced at the detriment of wild-type HSP110. Patients expressing low levels of wild-type HSP110 had excellent outcomes (i.e. response to an oxaliplatin-based chemotherapy). Here, we show in vitro, in vivo, and in patients' biopsies that HSP110 co-localizes with DNA damage (gamma-H2AX). In colorectal cancer cells, HSP110 translocates into the nucleus upon treatment with genotoxic chemotherapy such as oxaliplatin. Furthermore, we show that HSP110 interacts with the Ku70/Ku80 heterodimer, an essential element of the nonhomologous end joining (NHEJ) repair machinery. We also demonstrate by evaluating the resolved 53BP1 foci that depletion in HSP110 impairs repair steps of the NHEJ pathway, which is associated with an increase in DNA double-strand breaks and in the cells' sensitivity to oxaliplatin. HSP110-depleted cells sensitization to oxaliplatin-induced DNA damage is abolished upon re-expression of HSP110. Confirming a role for HSP110 in DNA non-homologous repair, SCR7 and NU7026, two inhibitors of the NHEJ pathway, circumvents HSP110-induced resistance to chemotherapy. In conclusion, HSP110 through its interaction with the Ku70/80 heterodimer may participate in DNA repair, thereby inducing a protection against genotoxic therapy.	[Causse, Sebastien Z.; Marcion, Guillaume; Chanteloup, Gaetan; Uyanik, Burhan; Boudesco, Christophe; Grigorash, Bogdan B.; Douhard, Romain; Dias, Alexandre M. M.; Dumetier, Baptiste; Dondaine, Lucile; Gozzi, Gustavo J.; Dubrez, Laurence; Demidov, Oleg N.; Gobbo, Jessica; Garrido, Carmen] INSERM, Equipe Labellisee Ligue Natl Canc, UMR 1231, Dijon, France; [Causse, Sebastien Z.; Marcion, Guillaume; Chanteloup, Gaetan; Uyanik, Burhan; Boudesco, Christophe; Grigorash, Bogdan B.; Douhard, Romain; Dias, Alexandre M. M.; Dumetier, Baptiste; Dondaine, Lucile; Gozzi, Gustavo J.; Dubrez, Laurence; Demidov, Oleg N.; Gobbo, Jessica; Garrido, Carmen] Lab Excellence LipSTIC, Dijon, France; [Causse, Sebastien Z.; Marcion, Guillaume; Chanteloup, Gaetan; Uyanik, Burhan; Boudesco, Christophe; Grigorash, Bogdan B.; Douhard, Romain; Dias, Alexandre M. M.; Dumetier, Baptiste; Dondaine, Lucile; Gozzi, Gustavo J.; Dubrez, Laurence; Demidov, Oleg N.; Gobbo, Jessica; Garrido, Carmen] Univ Bourgogne Franche Comte, Dijon, France; [Moussay, Etienne; Paggetti, Jerome] Luxembourg Inst Hlth, 84 Val Fleuri, L-1526 Luxembourg, Luxembourg; [Mirjolet, Celine; Gobbo, Jessica; Garrido, Carmen] Anticanc Ctr Georges Francois Leclerc Unicanc, Dijon, France; [de Thonel, Aurelie] Univ Paris Diderot, Unite Epigenet & Destin Cellulaire, Paris, France	Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Luxembourg Institute of Health; UDICE-French Research Universities; Universite Paris Cite	Garrido, C (corresponding author), INSERM, Equipe Labellisee Ligue Natl Canc, UMR 1231, Dijon, France.; Garrido, C (corresponding author), Lab Excellence LipSTIC, Dijon, France.; Garrido, C (corresponding author), Univ Bourgogne Franche Comte, Dijon, France.; Garrido, C (corresponding author), Anticanc Ctr Georges Francois Leclerc Unicanc, Dijon, France.	cgarrido@u-bourgogne.fr	Laurence, Dubrez/P-9472-2019; Causse, Sebastien Zwe/AAZ-7365-2021; Garrido, Carolina/GWM-5557-2022; Garrido, carmen/G-1633-2018; Moussay, Etienne/I-3729-2019; Demidov, Oleg/AAC-4462-2021; Paggetti, Jerome/I-2786-2019	Laurence, Dubrez/0000-0002-7030-2181; Garrido, carmen/0000-0003-1368-1493; Moussay, Etienne/0000-0002-0879-8067; Demidov, Oleg/0000-0003-4323-7174; Paggetti, Jerome/0000-0001-9460-5876; de Thonel, Aurelie/0000-0003-0405-0745; Causse, Sebastien/0000-0003-3246-3491; DUMETIER, Baptiste/0000-0001-9087-2344; Mirjolet Didelot, Celine/0000-0003-0047-9421; Marcion, Guillaume/0000-0002-3634-6316	Institut National du Cancer; Ligue Nationale Contre le Cancer; Conseil Regional de Bourgogne; French Government [ANR-11-LABX-0021]; European Union programme FEDER; La Ligue Nationale contre le Cancer; Association pour la Recherche sur le Cancer; "Fondation de France"; "Fondation pour la Recherche Medicale [ECO20160736090]	Institut National du Cancer(Institut National du Cancer (INCA) France); Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Conseil Regional de Bourgogne(Region Bourgogne-Franche-Comte); French Government; European Union programme FEDER(European Commission); La Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); "Fondation de France"(Fondation de France); "Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale)	We are grateful professor Gorbunova for allowing us using her NHEJ DNA repair system and to Alex Duval and Ada Collura for helpful discussions. We also thank the Platforms of cytometry Cellimap. This work was supported by grants from the Institut National du Cancer, Ligue Nationale Contre le Cancer, and the Conseil Regional de Bourgogne. The work was also supported by a French Government grant managed by the French National Research Agency under the program "Investissements d'Avenir" with reference ANR-11-LABX-0021 (LabEX LipSTIC). We thank the European Union programme FEDER for their financial support. SC had a fellowship from La Ligue Nationale contre le Cancer, GM from the Association pour la Recherche sur le Cancer, GG from the "Fondation de France", and GC from the "Fondation pour la Recherche Medicale (ECO20160736090)".	Berthenet K, 2017, ONCOGENE, V36, P2328, DOI 10.1038/onc.2016.403; Calderwood SK, 2006, TRENDS BIOCHEM SCI, V31, P164, DOI 10.1016/j.tibs.2006.01.006; Collura A, 2014, GASTROENTEROLOGY, V146, P401, DOI 10.1053/j.gastro.2013.10.054; Dorard C, 2011, NAT MED, V17, P1283, DOI 10.1038/nm.2457; Dufour A, 2011, IEEE T IMAGE PROCESS, V20, P1925, DOI 10.1109/TIP.2010.2099125; Garrido C, 2006, CELL CYCLE, V5, P2592, DOI 10.4161/cc.5.22.3448; Gravina GL, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0085-1; Guttmann DM, 2011, CANCER BIOL THER, V12, P1023, DOI 10.4161/cbt.12.12.18374; Kai M, 2003, ONCOL REP, V10, P1777; Kimura A, 2016, ONCOTARGET, V7, P18415, DOI 10.18632/oncotarget.7821; Mao ZY, 2008, CELL CYCLE, V7, P2902, DOI 10.4161/cc.7.18.6679; Mattoo RUH, 2013, J BIOL CHEM, V288, P21399, DOI 10.1074/jbc.M113.479253; Olivo-Marin JC, 2002, PATTERN RECOGN, V35, P1989, DOI 10.1016/S0031-3203(01)00127-3; Panier S, 2014, NAT REV MOL CELL BIO, V15, P7, DOI 10.1038/nrm3719; Rampelt H, 2012, EMBO J, V31, P4221, DOI 10.1038/emboj.2012.264; Saito Y, 2007, EXP CELL RES, V313, P3707, DOI 10.1016/j.yexcr.2007.06.009; Thomas X, 2005, LEUKEMIA RES, V29, P1049, DOI 10.1016/j.leukres.2005.02.010; Willmore E, 2004, BLOOD, V103, P4659, DOI 10.1182/blood-2003-07-2527; Yang ZG, 2015, INT J MED SCI, V12, P256, DOI 10.7150/ijms.10735; Yu N, 2015, MOL CELL BIOL, V35, P1390, DOI 10.1128/MCB.01307-14	20	20	21	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2019	38	15					2767	2777		10.1038/s41388-018-0616-2	http://dx.doi.org/10.1038/s41388-018-0616-2			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HS8LQ	30542121				2022-12-28	WOS:000464121600007
J	Zhang, HY; Deng, T; Ge, SH; Liu, Y; Bai, M; Zhu, KG; Fan, Q; Li, JL; Ning, T; Tian, F; Li, HL; Sun, W; Ying, GG; Ba, Y				Zhang, Haiyang; Deng, Ting; Ge, Shaohua; Liu, Ying; Bai, Ming; Zhu, Kegan; Fan, Qian; Li, Jialu; Ning, Tao; Tian, Fei; Li, Hongli; Sun, Wu; Ying, Guoguang; Ba, Yi			Exosome circRNA secreted from adipocytes promotes the growth of hepatocellular carcinoma by targeting deubiquitination-related USP7	ONCOGENE			English	Article							CELL-PROLIFERATION; CIRCULAR RNAS; BETA-CATENIN; CANCER; STABILIZATION; BIOGENESIS; DELIVERY; PROTEIN	Hepatocellular carcinoma (HCC), the major form of liver cancer, has shown increasing incidence and poor prognosis. Adipose tissue is known to function in energy storage and metabolism regulation by the secretion of adipokines. Circular RNAs (circRNAs), a novel type of noncoding RNA, have recently been recognized as key factors in tumor development, but the role of exosome circRNAs derived from adipose tissues has not been defined yet. Here, adipose-secreted circRNAs were found to regulate deubiquitination in HCC, thus facilitating cell growth. It was observed that exosome circ-deubiquitination (circ-DB) is upregulated in HCC patients with higher body fat ratios. Moreover, in vitro and in vivo studies showed that exocirc-DB promotes HCC growth and reduces DNA damage via the suppression of miR-34a and the activation of deubiquitination-related USP7. Finally, the results showed that the effects of adipose exosomes on HCC cells can be reversed by knockdown of circ-DB. These results indicate that exosome circRNAs secreted from adipocytes promote tumor growth and reduce DNA damage by suppressing miR-34a and activating the USP7/Cyclin A2 signaling pathway.	[Zhang, Haiyang; Deng, Ting; Ge, Shaohua; Liu, Ying; Bai, Ming; Zhu, Kegan; Fan, Qian; Ning, Tao; Tian, Fei; Li, Hongli; Sun, Wu; Ying, Guoguang; Ba, Yi] Tianjin Med Univ, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Canc Inst & Hosp,Tianjins Clin Res Ctr Canc, Tianjin 300060, Peoples R China; [Li, Jialu] Shanghai Jiao Tong Univ, Div Gastroenterol & Hepatol, Shanghai Inst Digest Dis, Sch Med,Renji Hosp, Shanghai 200001, Peoples R China; [Li, Jialu] Shanghai Jiao Tong Univ, Key Lab Gastroenterol & Hepatol, Minist Hlth, Sch Med,Renji Hosp, Shanghai 200001, Peoples R China	Tianjin Medical University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Ying, GG; Ba, Y (corresponding author), Tianjin Med Univ, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Canc Inst & Hosp,Tianjins Clin Res Ctr Canc, Tianjin 300060, Peoples R China.	yingguoguang163@163.com; bayi@tjmuch.com	li, jia/GVT-7587-2022	ying, guoguang/0000-0002-9563-991X	National Natural Science Foundation of China [81772629, 81772843, 81702431, 81702275, 81702437, 81602158, 81602156]; Individualized Medical Platform of National Clinical Research Center for Cancer [13ZCZCSY20300]; Demonstrative research platform of clinical evaluation technology for new anticancer drugs [2018ZX09206004]; CAMS Innovation Fund for Medical Sciences (CIFMS) [2016-I2M-1-017, 2017-I2M-BR-13]; Nature Science Foundation of Tianjin City [16PTSYJC00170]; Science& Technology Development fund of Tianjin Education Commission for Higher Education [2018KJ046]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Individualized Medical Platform of National Clinical Research Center for Cancer; Demonstrative research platform of clinical evaluation technology for new anticancer drugs; CAMS Innovation Fund for Medical Sciences (CIFMS); Nature Science Foundation of Tianjin City; Science& Technology Development fund of Tianjin Education Commission for Higher Education	This work was supported by National Natural Science Foundation of China (Nos. 81772629, 81772843, 81702431, 81702275, 81702437, 81602158, and 81602156), Individualized Medical Platform of National Clinical Research Center for Cancer (13ZCZCSY20300) and Demonstrative research platform of clinical evaluation technology for new anticancer drugs (No. 2018ZX09206004). This study was also supported by CAMS Innovation Fund for Medical Sciences (CIFMS, 2016-I2M-1-017 and 2017-I2M-B&R-13), Nature Science Foundation of Tianjin City (16PTSYJC00170) and the Science& Technology Development fund of Tianjin Education Commission for Higher Education (2018KJ046). The funders had no role in study design, collection, analysis, or interpretation of the data, in the writing of the report, or in the decision to submit this article for publication.	Aspichueta P, 2018, GUT, V67, P1376, DOI 10.1136/gutjnl-2018-316047; Axley P, 2018, J CLIN TRANSL HEPATO, V6, P79, DOI 10.14218/JCTH.2017.00067; Cao CH, 2015, GASTROENTEROLOGY, V148, P415, DOI 10.1053/j.gastro.2014.10.012; Carra G, 2017, ONCOTARGET, V8, P35508, DOI 10.18632/oncotarget.16348; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Colleran A, 2013, P NATL ACAD SCI USA, V110, P618, DOI 10.1073/pnas.1208446110; Cooks T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03224-w; Coombs N, 2011, INT J MED MICROBIOL, V301, P213, DOI 10.1016/j.ijmm.2010.09.004; Deng XJ, 2018, EXP THER MED, V15, P3705, DOI 10.3892/etm.2018.5920; Dong L, 2018, ONCOGENE, V37, P2702, DOI 10.1038/s41388-018-0137-z; Farooqi AA, 2018, BIOTECHNOL ADV, V36, P328, DOI 10.1016/j.biotechadv.2017.12.010; Felicetti F, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0811-2; Gan L, 2018, BBA-REV CANCER, V1869, P97, DOI 10.1016/j.bbcan.2017.12.006; Gopinathan L, 2014, CANCER RES, V74, P3870, DOI 10.1158/0008-5472.CAN-13-3440; Hagstrom H, 2018, GUT, V67, P1536, DOI 10.1136/gutjnl-2016-313622; Hannafon BN, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0400-7; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112; Ji Q, 2018, ONCOL LETT, V15, P23, DOI 10.3892/ol.2017.7348; Li SS, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0579-3; Lv T, 2018, BIOCHEM CELL BIOL, V96, P663, DOI 10.1139/bcb-2018-0031; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Morra F, 2017, ONCOTARGET, V8, P31815, DOI 10.18632/oncotarget.16463; Novellasdemunt L, 2017, CELL REP, V21, P612, DOI 10.1016/j.celrep.2017.09.072; Palmer C, 2010, GUT, V59, P397, DOI 10.1136/gut.2008.165316; Petruzziello Arnolfo, 2018, Open Virol J, V12, P26, DOI 10.2174/1874357901812010026; Salzman J, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003777; Schmittgen TD, 2008, METHODS, V44, P31, DOI 10.1016/j.ymeth.2007.09.006; Sun L, 2016, CYTOTHERAPY, V18, P413, DOI 10.1016/j.jcyt.2015.11.018; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Wang Q, 2016, J CLIN INVEST, V126, P2205, DOI 10.1172/JCI85747; Wei Y, 2016, MOLECULES, V21, DOI 10.3390/molecules21060777; Wilusz JE, 2013, SCIENCE, V340, P440, DOI 10.1126/science.1238522; Yin Y, 2014, CELL RES, V24, P1164, DOI 10.1038/cr.2014.121; Yu B, 2016, SCI REP-UK, V6, DOI 10.1038/srep34562; Zhang C, 2016, INT J BIOCHEM CELL B, V79, P209, DOI 10.1016/j.biocel.2016.08.025; Zhang HY, 2016, CANCER LETT, V375, P331, DOI 10.1016/j.canlet.2016.03.026; Ziogas IA, 2017, WORLD J GASTRO SURG, V9, P233, DOI 10.4240/wjgs.v9.i12.233	39	207	220	11	70	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2019	38	15					2844	2859		10.1038/s41388-018-0619-z	http://dx.doi.org/10.1038/s41388-018-0619-z			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HS8LQ	30546088	hybrid, Green Published			2022-12-28	WOS:000464121600013
J	Zhang, R; Hong, JJ; Yang, QY; Ong, CT; Li, BA; Liou, YC				Zhang, Rui; Hong, Jing-Jing; Yang, Qiaoyun; Ong, Chin-Tong; Li, Bo-An; Liou, Yih-Cherng			Poly(ADP-ribosyl)ation of OVOL2 regulates aneuploidy and cell death in cancer cells	ONCOGENE			English	Article							DROSOPHILA-OVO; CYCLIN-E; CHROMOSOMAL INSTABILITY; CENTROSOME; PHOSPHORYLATION; UBIQUITINATION; IDENTIFICATION; POLYMERASE; EXPRESSION; MECHANISM	Poly(ADP-ribosyl)ation (PARylation) is a post-translational modification by which poly ADP-ribose (PAR) polymers are covalently added to proteins through a PAR polymerase (PARP). Here, using proteomic approach, we identify the transcriptional regulator, OVOL2, is a novel substrate of PARP1 and can be PARylated at residues Lysine 145, Lysine 176, and Lysine 212 within its C2H2 zinc finger domains. Overexpression of PARylated OVOL2 alters cell morphology and induces lagging chromosomes and aneuploidy. To define the underlying molecular mechanism by which OVOL2 induces abnormal cell cycle and centrosome amplification, we uncover that the OVOL2 elevates the protein levels of Cyclin E by enhancing its stability. Furthermore, we identify Skp2, the E3 ubiquitin ligase of Cyclin E, as a direct target of PARylated OVOL2. Using ChIP assay, the OVOL2 binding site on the promoter region of Skp2 is mapped. To further explore the physiological effect, we show that PARylated OVOL2 can induce cell death. Furthermore, to investigate PARylated OVOL2 function in vivo, we further develop a null-mice xenograft model and generate MMTV-PyVT transgenic mice and monitor the effect of wild-type OVOL2 and non-PARylated OVOL2-3IQA mutants on tumor progression. Consistently, overexpression of wild-type OVOL2 in both null-mice xenograft and MMTV-PyVT transgenic mice displays significantly reduction of tumor progression, respectively, further indicating that the function of OVOL2 as a tumor suppressor in vivo is highly regulated by PARylation. Taken together, our study sheds new light on PARP1-induced PARylation as a critical event in the OVOL2-mediated regulation of chromosomal integrity and suppression of cancer cells growth.	[Zhang, Rui; Yang, Qiaoyun; Ong, Chin-Tong; Liou, Yih-Cherng] Natl Univ Singapore, Dept Biol Sci, Fac Sci, Singapore 117543, Singapore; [Hong, Jing-Jing; Li, Bo-An] Xiamen Univ, State Key Lab Cellular Stress Biol, Sch Life Sci, Xiamen 361005, Fujian, Peoples R China; [Ong, Chin-Tong] Natl Univ Singapore, Temasek Life Sci Lab, Singapore 117604, Singapore; [Liou, Yih-Cherng] Natl Univ Singapore, NUS Grad Sch Integrat Sci & Engn, Singapore 117573, Singapore	National University of Singapore; Xiamen University; National University of Singapore; National University of Singapore	Liou, YC (corresponding author), Natl Univ Singapore, Dept Biol Sci, Fac Sci, Singapore 117543, Singapore.; Li, BA (corresponding author), Xiamen Univ, State Key Lab Cellular Stress Biol, Sch Life Sci, Xiamen 361005, Fujian, Peoples R China.; Liou, YC (corresponding author), Natl Univ Singapore, NUS Grad Sch Integrat Sci & Engn, Singapore 117573, Singapore.	bali@xmu.edu.cn; dbslyc@nus.edu.sg		ZHANG, RUI/0000-0003-2250-8617	Ministry of Education, Singapore [R-154-000-A61-112, A15-114]; National Natural Science Foundation of China [U1705284, 81772958]	Ministry of Education, Singapore(Ministry of Education, Singapore); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank all members in the Y-C Liou laboratory for their support and valuable discussion. We would also like to thank the Center of BioImaging Sciences (CBIS) for their technical support on confocal microscopy, and Flow Cytometry Laboratory in Yong Loo Lin School of Medicine at the National University of Singapore for FACS assay. In addition, the authors thank Protein Proteomic Center (PPC) for the technical support on protein identification. We particularly thank Dr. Boon Chuan Low for kindly providing several reagents and helpful discussions and suggestions. In addition, we thank Dr. Kyunghee Lee for helping imaging and cell cycle assay. This work was supported in part by MOE grants Tier 2, R-154-000-A61-112 and Tier 1, A15-114 from the Ministry of Education, Singapore to Y.-C.L; grants from the National Natural Science Foundation of China (Grant Numbers U1705284, 81772958) to B.-A.L.	Ahel I, 2008, NATURE, V451, P81, DOI 10.1038/nature06420; Altmeyer M, 2009, NUCLEIC ACIDS RES, V37, P3723, DOI 10.1093/nar/gkp229; ALVAREZGONZALEZ R, 1987, BIOCHEMISTRY-US, V26, P3218, DOI 10.1021/bi00385a042; Amiri KI, 2006, ONCOGENE, V25, P7714, DOI 10.1038/sj.onc.1209751; Bakhoum SF, 2014, CURR BIOL, V24, pR148, DOI 10.1016/j.cub.2014.01.019; Caiafa P, 2009, FASEB J, V23, P672, DOI 10.1096/fj.08-123265; CHAMBON P, 1963, BIOCHEM BIOPH RES CO, V11, P39, DOI 10.1016/0006-291X(63)90024-X; Coldwell MJ, 2013, CELL CYCLE, V12, P3615, DOI 10.4161/cc.26588; Conde C, 2001, EMBO J, V20, P3535, DOI 10.1093/emboj/20.13.3535; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Giam M, 2015, CELL DIV, V10, DOI 10.1186/s13008-015-0009-7; Gibson BA, 2012, NAT REV MOL CELL BIO, V13, P411, DOI 10.1038/nrm3376; Godinho SA, 2014, NATURE, V510, P167, DOI 10.1038/nature13277; Gonzalez-Sanchez M, 2004, GENETICS, V166, P999, DOI 10.1534/genetics.166.2.999; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hottiger MO, 2010, TRENDS BIOCHEM SCI, V35, P208, DOI 10.1016/j.tibs.2009.12.003; JUAREZSALINAS H, 1982, J BIOL CHEM, V257, P607; Kanai M, 2007, BIOCHEM BIOPH RES CO, V359, P426, DOI 10.1016/j.bbrc.2007.05.108; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Lee B, 2014, DEV CELL, V29, P47, DOI 10.1016/j.devcel.2014.03.005; Lee S, 2000, NUCLEIC ACIDS RES, V28, P826, DOI 10.1093/nar/28.3.826; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Leung AKL, 2014, J CELL BIOL, V205, P613, DOI 10.1083/jcb.201402114; Li B, 2002, GENOMICS, V80, P319, DOI 10.1006/geno.2002.6831; Liu DW, 2015, ONCOTARGET, V6, P38552, DOI 10.18632/oncotarget.6035; Luo X, 2012, GENE DEV, V26, P417, DOI 10.1101/gad.183509.111; Mackay DR, 2006, DEV BIOL, V291, P38, DOI 10.1016/j.ydbio.2005.12.003; Masutani M, 2003, GENE CHROMOSOME CANC, V38, P339, DOI 10.1002/gcc.10250; MIWA M, 1981, J BIOL CHEM, V256, P2916; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Oei SL, 1998, BIOCHEMISTRY-US, V37, P1465, DOI 10.1021/bi9727390; Ogden A, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.164; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Ong CT, 2013, CELL, V155, P148, DOI 10.1016/j.cell.2013.08.052; Salisbury JL, 2004, J MAMMARY GLAND BIOL, V9, P275, DOI 10.1023/B:JOMG.0000048774.27697.30; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Silkworth WT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006564; Simbulan-Rosenthal CM, 2003, ONCOGENE, V22, P8460, DOI 10.1038/sj.onc.1206897; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; Teng A, 2007, BBA-MOL BASIS DIS, V1772, P89, DOI 10.1016/j.bbadis.2006.08.012; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; Unezaki S, 2007, GENES CELLS, V12, P773, DOI 10.1111/j.1365-2443.2007.01084.x; van Drogen F, 2006, MOL CELL, V23, P37, DOI 10.1016/j.molcel.2006.05.020; Vitale I, 2011, NAT REV MOL CELL BIO, V12, P384, DOI 10.1038/nrm3115; Watanabe K, 2014, DEV CELL, V29, P59, DOI 10.1016/j.devcel.2014.03.006; Wells J, 2009, J BIOL CHEM, V284, P29125, DOI 10.1074/jbc.M109.008847; Ye GD, 2016, GASTROENTEROLOGY, V150, P659, DOI 10.1053/j.gastro.2015.11.041	49	6	7	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2019	38	15					2750	2766		10.1038/s41388-018-0615-3	http://dx.doi.org/10.1038/s41388-018-0615-3			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HS8LQ	30542118				2022-12-28	WOS:000464121600006
J	Gianni, M; Terao, M; Kurosaki, M; Paroni, G; Brunelli, L; Pastorelli, R; Zanetti, A; Lupi, M; Acquavita, A; Bolis, M; Fratelli, M; Rochette-Egly, C; Garattini, E				Gianni, Maurizio; Terao, Mineko; Kurosaki, Mami; Paroni, Gabriela; Brunelli, Laura; Pastorelli, Roberta; Zanetti, Adriana; Lupi, Monica; Acquavita, Andrea; Bolis, Marco; Fratelli, Maddalena; Rochette-Egly, Cecile; Garattini, Enrico			S100A3 a partner protein regulating the stability/activity of RAR alpha and PML-RAR alpha in cellular models of breast/lung cancer and acute myeloid leukemia	ONCOGENE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; UNION-OF-PHARMACOLOGY; GROWTH-FACTOR; NUCLEAR; RECEPTOR; CELLS; DEGRADATION; PHOSPHORYLATION; EXPRESSION	All trans-retinoic acid (ATRA) is used in the treatment of acute promyelocytic leukemia (APL) and it is a promising agent also in solid tumors. The pharmacological activity of ATRA is mediated by the ligand-activated RAR and RXR transcription factors. In the present study, we define the basal and ATRA dependent RAR alpha interactome in a RAR alpha-overexpressing breast cancer cellular model, identifying 28 nuclear proteins. We focus our attention on the S100A3 calcium-binding protein, which interacts with RAR alpha constitutively. In ATRA-sensitive breast cancer cells, S100A3 binds to RAR alpha in basal conditions and binding is reduced by the retinoid. The interaction of S100A3 with RAR alpha is direct and in lung cancer, APL and acute-myeloid-leukemia (AML) cells. In APL, S100A3 interacts not only with RAR alpha, but also with PML-RAR alpha. The interaction surface maps to the RAR alpha ligand-binding domain, where the I396 residue plays a crucial role. Binding of S100A3 to RARWPML-RAR alpha controls the constitutive and ATRA-dependent degradation of these receptors. S100A3 knockdown decreases the amounts of RAR alpha in breast- and lung cancer cells, inducing resistance to ATRA-dependent antiproliferative/differentiating effects. Conversely, S100A3 knockdown in PML-RAR alpha(+) APL and PML-RAR alpha(-) AML cells reduces the amounts of RAR alpha/PML-RAR alpha and increases basal and ATRA-induced differentiation. In this cellular context, opposite effects on RAR alpha/PML-RAR alpha levels and ATRA-induced differentiation are observed upon S100A3 overexpression. Our results provide new insights into the molecular mechanisms controlling RARa activity and have practical implications, as S100A3 represents a novel target for rational drug combinations aimed at potentiating the activity of ATRA.	[Gianni, Maurizio; Terao, Mineko; Kurosaki, Mami; Paroni, Gabriela; Zanetti, Adriana; Acquavita, Andrea; Bolis, Marco; Fratelli, Maddalena; Garattini, Enrico] IRCCS, Ist Ric Farmacol Mario Negri, Lab Mol Biol, Via La Masa 19, I-20156 Milan, Italy; [Brunelli, Laura; Pastorelli, Roberta] IRCCS, Ist Ric Farmacol Mario Negri, Lab Mass Spectrometry, Via La Masa 19, I-20156 Milan, Italy; [Lupi, Monica] IRCCS, Ist Ric Farmacol Mario Negri, Lab Canc Pharmacol, Via La Masa 19, I-20156 Milan, Italy; [Rochette-Egly, Cecile] Univ Strasbourg, CNRS, Dept Funct Genom & Canc, IGBMC,INSERM,U964,UMR7104, 1 Rue Laurent Fries,BP 10142, F-67404 Illkirch Graffenstaden, France	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Garattini, E (corresponding author), IRCCS, Ist Ric Farmacol Mario Negri, Lab Mol Biol, Via La Masa 19, I-20156 Milan, Italy.	enrico.garattini@marionegri.it	adriana, zanetti/ABA-1189-2020; terao, mineko/AAU-8089-2020; Paroni, Gabriela/J-4848-2018; Pastorelli, Roberta/AAA-6736-2020; Bolis, Marco/AAC-2379-2019; Terao, Mineko/AAA-6415-2020; Brunelli, Laura/J-8664-2018; Gianni, Maurizio/ABG-6322-2020; Garattini, Enrico/AAI-1998-2019; KUROSAKI, Mami/ABG-2224-2020; Fratelli, Maddalena/AAA-6446-2020; Lupi, Monica/AAH-5704-2019	adriana, zanetti/0000-0002-5825-9707; Paroni, Gabriela/0000-0003-0132-0869; Pastorelli, Roberta/0000-0001-5097-600X; Bolis, Marco/0000-0003-4377-5079; Terao, Mineko/0000-0002-9976-9869; Brunelli, Laura/0000-0002-5465-9586; Gianni, Maurizio/0000-0002-6945-708X; KUROSAKI, Mami/0000-0001-8231-713X; Fratelli, Maddalena/0000-0002-1769-3427; Lupi, Monica/0000-0002-9835-7870; Garattini, Enrico/0000-0001-8983-886X	Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) [to Enrico Garattini] Funding Source: Medline	Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)(Fondazione AIRC per la ricerca sul cancro)		Benbrook DM, 2014, SUBCELL BIOCHEM, V70, P1, DOI 10.1007/978-94-017-9050-5_1; Berry DC, 2007, PPAR RES, V2007, DOI 10.1155/2007/73256; Bolis M, 2017, ANN ONCOL, V28, P611, DOI 10.1093/annonc/mdw660; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; Caccamo D, 2013, AMINO ACIDS, V44, P151, DOI 10.1007/s00726-011-1083-z; Carrier M, 2018, FEBS LETT, V592, P1426, DOI 10.1002/1873-3468.13033; Centritto F, 2015, EMBO MOL MED, V7, P950, DOI 10.15252/emmm.201404670; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; DANIELPOUR D, 1991, J CELL PHYSIOL, V148, P235, DOI 10.1002/jcp.1041480208; de The H, 2018, NAT REV CANCER, V18, P117, DOI 10.1038/nrc.2017.103; de The H, 2017, CANCER CELL, V32, P552, DOI 10.1016/j.ccell.2017.10.002; Eckert RL, 2004, J INVEST DERMATOL, V123, P23, DOI 10.1111/j.0022-202X.2004.22719.x; Gaillard E, 2006, P NATL ACAD SCI USA, V103, P9548, DOI 10.1073/pnas.0509717103; Garattini E, 2007, VITAM HORM, V75, P301, DOI 10.1016/S0083-6729(06)75012-9; Germain P, 2006, PHARMACOL REV, V58, P712, DOI 10.1124/pr.58.4.4; Germain P, 2006, PHARMACOL REV, V58, P760, DOI 10.1124/pr.58.4.7; Gianni M, 2006, EMBO J, V25, P739, DOI 10.1038/sj.emboj.7600981; Gianni M, 2012, LEUKEMIA, V26, P1850, DOI 10.1038/leu.2012.50; Gianni M, 1996, BLOOD, V87, P1520, DOI 10.1182/blood.V87.4.1520.bloodjournal8741520; Gianni' M, 2001, BLOOD, V97, P3234, DOI 10.1182/blood.V97.10.3234; Gianni M, 2017, ONCOTARGET, V8, P37041, DOI 10.18632/oncotarget.10556; Gianni M, 2009, CANCER RES, V69, P1016, DOI 10.1158/0008-5472.CAN-08-2603; Hatakeyama D, 2002, BBA-MOL CELL RES, V1589, P15, DOI 10.1016/S0167-4889(01)00183-5; Heizmann C. W., 2007, V45, P93; Hoedt E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104563; Hu LZ, 2014, J STEROID BIOCHEM, V144, P237, DOI 10.1016/j.jsbmb.2013.11.002; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Huang D, 2017, FRONT MED-PRC, V11, P410, DOI 10.1007/s11684-017-0527-6; Joo K, 2013, P NATL ACAD SCI USA, V110, P5987, DOI 10.1073/pnas.1220927110; Kani K, 2017, METHODS MOL BIOL, V1550, P171, DOI 10.1007/978-1-4939-6747-6_13; Kizawa K, 2013, BBA-MOL CELL RES, V1833, P1712, DOI 10.1016/j.bbamcr.2012.07.009; Kizawa K, 2011, BIOCHIMIE, V93, P2038, DOI 10.1016/j.biochi.2011.05.028; Lalevee S, 2010, METHODS MOL BIOL, V647, P251, DOI 10.1007/978-1-60761-738-9_15; le Maire A, 2010, NAT STRUCT MOL BIOL, V17, P801, DOI 10.1038/nsmb.1855; Levi L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9794; Li XP, 2016, ONCOL LETT, V11, P2839, DOI 10.3892/ol.2016.4294; Luscinskas FW, 2012, EUR J IMMUNOL, V42, P296, DOI 10.1002/eji.201142342; Mark M, 2006, ANNU REV PHARMACOL, V46, P451, DOI 10.1146/annurev.pharmtox.46.120604.141156; O'Connell PA, 2011, BLOOD, V117, P4095, DOI 10.1182/blood-2010-07-298851; Ovcharenko A, 2013, LEUKEMIA RES, V37, P956, DOI 10.1016/j.leukres.2013.03.010; Paroni G, 2012, ONCOGENE, V31, P3431, DOI 10.1038/onc.2011.506; Parrella E, 2004, J BIOL CHEM, V279, P42026, DOI 10.1074/jbc.M406530200; Piskunov A, 2014, SUBCELL BIOCHEM, V70, P103, DOI 10.1007/978-94-017-9050-5_6; Sahin U, 2014, J PATHOL, V234, P289, DOI 10.1002/path.4426; Schug TT, 2007, CELL, V129, P723, DOI 10.1016/j.cell.2007.02.050; Soderstrom M, 1997, MOL ENDOCRINOL, V11, P682, DOI 10.1210/me.11.6.682; Steinbach D, 2007, CANCER GENET CYTOGEN, V177, P51, DOI 10.1016/j.cancergencyto.2007.05.011; TAHAYATO A, 1993, MOL ENDOCRINOL, V7, P1642, DOI 10.1210/me.7.12.1642; Wu YZ, 2004, LEUKEMIA RES, V28, P203, DOI 10.1016/S0145-2126(03)00211-X; Yoshida H, 1996, CANCER RES, V56, P2945; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807; Zhu YL, 2017, FRONT MED-PRC, V11, P87, DOI 10.1007/s11684-016-0469-4	52	15	16	5	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2019	38	14					2482	2500		10.1038/s41388-018-0599-z	http://dx.doi.org/10.1038/s41388-018-0599-z			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HR7LI	30532072	hybrid, Green Published			2022-12-28	WOS:000463335200004
J	Naik, R; Galande, S				Naik, Rutika; Galande, Sanjeev			SATB family chromatin organizers as master regulators of tumor progression	ONCOGENE			English	Review							SEQUENCE-BINDING PROTEIN-1; CANCER STEM-CELLS; INDEPENDENT PROGNOSTIC-FACTOR; GENE-EXPRESSION; T-CELLS; DENDRITIC CELLS; CHROMOSOME TERRITORIES; MESENCHYMAL TRANSITION; NUCLEAR ARCHITECTURE; SPATIAL-ORGANIZATION	SATB (Special AT-rich binding protein) family proteins have emerged as key regulators that integrate higher-order chromatin organization with the regulation of gene expression. Studies over the past decade have elucidated the specific roles of SATB1 and SATB2, two closely related members of this family, in cancer progression. SATB family chromatin organizers play diverse and important roles in regulating the dynamic equilibrium of apoptosis, cell invasion, metastasis, proliferation, angiogenesis, and immune modulation. This review highlights cellular and molecular events governed by SATB1 influencing the structural organization of chromatin and interacting with several co-activators and co-repressors of transcription towards tumor progression. SATB1 expression across tumor cell types generates cellular and molecular heterogeneity culminating in tumor relapse and metastasis. SATB1 exhibits dynamic expression within intratumoral cell types regulated by the tumor microenvironment, which culminates towards tumor progression. Recent studies suggested that cell-specific expression of SATB1 across tumor recruited dendritic cells (DC), cytotoxic T lymphocytes (CTL), T regulatory cells (Tregs) and tumor epithelial cells along with tumor microenvironment act as primary determinants of tumor progression and tumor inflammation. In contrast, SATB2 is differentially expressed in an array of cancer types and is involved in tumorigenesis. Survival analysis for patients across an array of cancer types correlated with expression of SATB family chromatin organizers suggested tissue-specific expression of SATB1 and SATB2 contributing to disease prognosis. In this context, it is pertinent to understand molecular players, cellular pathways, genetic and epigenetic mechanisms governed by cell types within tumors regulated by SATB proteins. We propose that patient survival analysis based on the expression profile of SATB chromatin organizers would facilitate their unequivocal establishment as prognostic markers and therapeutic targets for cancer therapy.	[Naik, Rutika; Galande, Sanjeev] Indian Inst Sci Educ & Res, Dept Biol, Ctr Excellence Epigenet, Pune 411008, Maharashtra, India	Indian Institute of Science Education & Research (IISER) Pune	Galande, S (corresponding author), Indian Inst Sci Educ & Res, Dept Biol, Ctr Excellence Epigenet, Pune 411008, Maharashtra, India.	sanjeev@iiserpune.ac.in			IISER Pune; Department of Biotechnology, Government of India; Department of Science and Technology, Science and Engineering Research Board, Government of India	IISER Pune; Department of Biotechnology, Government of India(Department of Biotechnology (DBT) India); Department of Science and Technology, Science and Engineering Research Board, Government of India	Work was supported by intramural funding from IISER Pune to SG. RN is supported by a postdoctoral fellowship from the Department of Biotechnology, Government of India, and the national postdoctoral fellowship of the Department of Science and Technology, Science and Engineering Research Board, Government of India. Authors wish to thank Drs. Prachi Patil for discussion and Chandan Kumar Sinha for insightful comments on the manuscript.	Agrelo R, 2013, ONCOGENE, V32, P5492, DOI 10.1038/onc.2013.158; Agrelo R, 2009, DEV CELL, V16, P507, DOI 10.1016/j.devcel.2009.03.006; Ahlfors H, 2010, BLOOD, V116, P1443, DOI 10.1182/blood-2009-11-252205; Akimova T, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.94075; Al-Sohaily S, 2014, HISTOPATHOLOGY, V65, P155, DOI 10.1111/his.12295; Alcamo EA, 2008, NEURON, V57, P364, DOI 10.1016/j.neuron.2007.12.012; Allis CD, 2007, CELL, V131, P633, DOI 10.1016/j.cell.2007.10.039; Alvarez JD, 2000, GENE DEV, V14, P521; Anaya J, 2016, PEERJ COMPUT SCI, DOI 10.7717/peerj-cs.67; Aprelikova O, 2010, CELL CYCLE, V9, P4387, DOI 10.4161/cc.9.21.13674; Arnaud O, 2018, CANCER LETT, V419, P266, DOI 10.1016/j.canlet.2018.01.046; Asanoma K, 2012, J BIOL CHEM, V287, P2257, DOI 10.1074/jbc.M111.287128; Balamotis MA, 2012, MOL CELL BIOL, V32, P333, DOI 10.1128/MCB.05917-11; Banyard J, 2015, CONNECT TISSUE RES, V56, P403, DOI 10.3109/03008207.2015.1060970; Beyer M, 2011, NAT IMMUNOL, V12, P898, DOI 10.1038/ni.2084; Bian TT, 2017, ONCOTARGET, V8, P63442, DOI 10.18632/oncotarget.18828; Borghesi L, 2014, J IMMUNOL, V193, P2053, DOI 10.4049/jimmunol.1400936; Britanova O, 2005, EUR J NEUROSCI, V21, P658, DOI 10.1111/j.1460-9568.2005.03897.x; Britanova O, 2008, NEURON, V57, P378, DOI 10.1016/j.neuron.2007.12.028; Britanova O, 2006, AM J HUM GENET, V79, P668, DOI 10.1086/508214; Brocato J, 2015, CARCINOGENESIS, V36, P186, DOI 10.1093/carcin/bgu322; Brown KE, 2003, CHROMOSOME RES, V11, P423, DOI 10.1023/A:1024966424909; Cai ST, 2006, NAT GENET, V38, P1278, DOI 10.1038/ng1913; Cai ST, 2003, NAT GENET, V34, P42, DOI 10.1038/ng1146; Chai JJ, 2005, CANCER RES, V65, P10192, DOI 10.1158/0008-5472.CAN-05-1896; Chatterjee A, 2018, SEMIN CANCER BIOL, V51, P149, DOI 10.1016/j.semcancer.2017.08.004; Chen B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064877; Cheng C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097406; Choi S, 2011, BIOCHEM BIOPH RES CO, V412, P207, DOI 10.1016/j.bbrc.2011.07.060; Choudhary D, 2018, UROL ONCOL-SEMIN ORI, V36, DOI 10.1016/j.urolonc.2017.10.004; Chu SH, 2014, MOL BIOL REP, V41, P977, DOI 10.1007/s11033-013-2942-3; Chu SH, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-149; Clapier CR, 2017, NAT REV MOL CELL BIO, V18, P407, DOI 10.1038/nrm.2017.26; Conejo-Garcia JR, 2016, PHARMACOL THERAPEUT, V164, P97, DOI 10.1016/j.pharmthera.2016.04.003; Cremer T, 2001, NAT REV GENET, V2, P292, DOI 10.1038/35066075; Cremer T, 2006, CURR OPIN CELL BIOL, V18, P307, DOI 10.1016/j.ceb.2006.04.007; Dalotto-Moreno T, 2013, CANCER RES, V73, P1107, DOI 10.1158/0008-5472.CAN-12-2418; de Belle I, 1998, J CELL BIOL, V141, P335, DOI 10.1083/jcb.141.2.335; de Laat W, 2003, CHROMOSOME RES, V11, P447, DOI 10.1023/A:1024922626726; Deng BW, 2013, SEMIN CANCER BIOL, V23, P65, DOI 10.1016/j.semcancer.2012.01.003; Deng YF, 2014, INT J CLIN EXP PATHO, V7, P2454; Ding M, 2018, CANCER INVEST, V36, P28, DOI 10.1080/07357907.2018.1423688; Dobreva G, 2003, GENE DEV, V17, P3048, DOI 10.1101/gad.1153003; Dobreva G, 2006, CELL, V125, P971, DOI 10.1016/j.cell.2006.05.012; Doi Y, 2018, CELL REP, V23, P3223, DOI 10.1016/j.celrep.2018.05.042; Dragomir A, 2014, AM J CLIN PATHOL, V141, P630, DOI 10.1309/AJCPWW2URZ9JKQJU; Eberhard J, 2012, BRIT J CANCER, V106, P931, DOI 10.1038/bjc.2012.34; Elebro J, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0289-8; ElShamy WM, 2013, CANCER LETT, V341, P2, DOI 10.1016/j.canlet.2013.06.020; Feng YL, 2018, EXP THER MED, V15, P4339, DOI 10.3892/etm.2018.5954; Fessing MY, 2011, J CELL BIOL, V194, P825, DOI 10.1083/jcb.201101148; FitzPatrick DR, 2003, HUM MOL GENET, V12, P2491, DOI 10.1093/hmg/ddg248; Fredholm S, 2018, J INVEST DERMATOL, V138, P1805, DOI 10.1016/j.jid.2018.03.1526; Freiman RN, 2003, CELL, V112, P11, DOI 10.1016/S0092-8674(02)01278-3; Fry CJ, 2001, CURR BIOL, V11, pR185, DOI 10.1016/S0960-9822(01)00090-2; Fu WX, 2012, NAT IMMUNOL, V13, P972, DOI 10.1038/ni.2420; Galande S, 2007, CURR OPIN GENET DEV, V17, P408, DOI 10.1016/j.gde.2007.08.003; Ganesan AP, 2013, J IMMUNOL, V191, P2009, DOI 10.4049/jimmunol.1301317; Gao XY, 2015, EXP THER MED, V9, P1665, DOI 10.3892/etm.2015.2329; Gibcus JH, 2018, SCIENCE, V359, P652, DOI 10.1126/science.aao6135; Gondor A, 2013, SEMIN CANCER BIOL, V23, P90, DOI 10.1016/j.semcancer.2013.01.002; Gong FR, 2011, NUCLEIC ACIDS RES, V39, P4640, DOI 10.1093/nar/gkr023; Gottimukkala KP, 2016, MOL IMMUNOL, V77, P34, DOI 10.1016/j.molimm.2016.07.005; Groth A, 2007, CELL, V128, P721, DOI 10.1016/j.cell.2007.01.030; Grzanka J, 2013, INT IMMUNOPHARMACOL, V16, P343, DOI 10.1016/j.intimp.2013.02.004; Gu JF, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12455; Guo CC, 2015, INT J CLIN EXP PATHO, V8, P3710; Han B, 2013, TUMOR BIOL, V34, P2943, DOI 10.1007/s13277-013-0857-1; Han HJ, 2008, NATURE, V452, P187, DOI 10.1038/nature06781; Hanker LC, 2011, BREAST, V20, P309, DOI 10.1016/j.breast.2010.10.002; Hao B, 2015, J EXP MED, V212, P809, DOI 10.1084/jem.20142207; Hedner C, 2014, VIRCHOWS ARCH, V465, P649, DOI 10.1007/s00428-014-1667-6; Helming KC, 2014, CANCER CELL, V26, P309, DOI 10.1016/j.ccr.2014.07.018; Hwang SS, 2017, BBA-GENE REGUL MECH, V1860, P383, DOI 10.1016/j.bbagrm.2017.01.008; Ilarregui JM, 2009, NAT IMMUNOL, V10, P981, DOI 10.1038/ni.1772; Iorns E, 2010, JNCI-J NATL CANCER I, V102, P1284, DOI 10.1093/jnci/djq243; Ishibashi T, 2018, BIOCHEM BIOPH RES CO, V495, P2338, DOI 10.1016/j.bbrc.2017.12.117; Jolly MK, 2017, MOL ONCOL, V11, P755, DOI 10.1002/1878-0261.12083; Kakugawa K, 2017, CELL REP, V19, P1176, DOI 10.1016/j.celrep.2017.04.038; Kitagawa Y, 2017, NAT IMMUNOL, V18, P173, DOI 10.1038/ni.3646; Kohwi-Shigematsu T, 2013, SEMIN CANCER BIOL, V23, P72, DOI 10.1016/j.semcancer.2012.06.009; Kohwi-Shigematsu T, 2012, METHODS, V58, P243, DOI 10.1016/j.ymeth.2012.06.019; Kolla V, 2015, BIOCHEM J, V468, P345, DOI 10.1042/BJ20150030; Kondo M, 2016, J IMMUNOL, V196, P563, DOI 10.4049/jimmunol.1501429; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kowalczyk AE, 2016, CANCER GENOM PROTEOM, V13, P209; Krangel MS, 2007, NAT IMMUNOL, V8, P686, DOI 10.1038/ni1484; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Kucuksayan H, 2017, TUMOUR BIOL, V39; Kucuksayan H, 2016, LUNG CANCER, V98, P122, DOI 10.1016/j.lungcan.2016.05.032; Kumar P, 2007, NAT CELL BIOL, V9, P45, DOI 10.1038/ncb1516; Kurkewich JL, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006887; Lai AY, 2011, NAT REV CANCER, V11, P588, DOI 10.1038/nrc3091; Laurinavicius A, 2015, ONCOTARGET, V6, P41134, DOI 10.18632/oncotarget.5838; Lee JJ, 2016, BMB REP, V49, P578, DOI 10.5483/BMBRep.2016.49.10.156; Leone DP, 2015, CEREB CORTEX, V25, P3406, DOI 10.1093/cercor/bhu156; Li QQ, 2011, CELL DEATH DIFFER, V18, P16, DOI 10.1038/cdd.2010.103; Li Y, 2016, WORLD J GASTROENTERO, V22, P8528, DOI 10.3748/wjg.v22.i38.8528; Liu SH, 2017, MOL CELL BIOCHEM, V430, P47, DOI 10.1007/s11010-017-2953-9; Liu TS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031001; Lo PK, 2017, J BIOL CHEM, V292, P11466, DOI 10.1074/jbc.M117.775080; Ma J, 2017, TUMOUR BIOL, V39; Ma XC, 2016, DRUG DES DEV THER, V10, P1419, DOI 10.2147/DDDT.S102541; Ma Y, 2012, SEMIN CANCER BIOL, V22, P298, DOI 10.1016/j.semcancer.2012.02.010; Mansour MA, 2016, ONCOTARGET, V7, P4993, DOI 10.18632/oncotarget.6651; Mansouri L, 2018, SEMIN CANCER BIOL, V51, P1, DOI 10.1016/j.semcancer.2018.02.001; Mao LJ, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-111; Mardaryev AN, 2014, DEVELOPMENT, V141, P101, DOI 10.1242/dev.103200; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005; Meaburn KJ, 2008, J CELL BIOL, V180, P39, DOI 10.1083/jcb.200708204; Millard CJ, 2014, CANCER METAST REV, V33, P857, DOI 10.1007/s10555-014-9513-5; Mir R, 2016, ONCOGENE, V35, P1679, DOI 10.1038/onc.2015.232; Mir R, 2012, CURR DRUG TARGETS, V13, P1603, DOI 10.2174/138945012803530008; Misteli T, 2007, CELL, V128, P787, DOI 10.1016/j.cell.2007.01.028; Monteiro J, 2010, EUR J CANCER, V46, P1198, DOI 10.1016/j.ejca.2010.02.030; Nagpal N, 2013, CARCINOGENESIS, V34, P1889, DOI 10.1093/carcin/bgt107; Nixon BG, 2017, IMMUNITY, V46, P3, DOI 10.1016/j.immuni.2017.01.002; Nodin B, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-115; Notani D, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000296; Pavan KP, 2006, MOL CELL, V22, P231, DOI 10.1016/j.molcel.2006.03.010; Peng YR, 2017, NEURON, V95, P869, DOI 10.1016/j.neuron.2017.07.019; Qi HG, 2017, ONCOL LETT, V13, P2577, DOI 10.3892/ol.2017.5765; Raker VK, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00569; Rao HY, 2018, BIOL REPROD, V98, P810, DOI 10.1093/biolre/ioy033; Recillas-Targa F, 2001, CRIT REV EUKAR GENE, V11, P227; Reddy CNL, 2010, MOL MED REP, V3, P857, DOI 10.3892/mmr.2010.338; Reisman D, 2009, ONCOGENE, V28, P1653, DOI 10.1038/onc.2009.4; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Satoh Y, 2013, IMMUNITY, V38, P1105, DOI 10.1016/j.immuni.2013.05.014; Savarese F, 2009, GENE DEV, V23, P2625, DOI 10.1101/gad.1815709; Scheuermann RH, 1999, CRIT REV EUKAR GENE, V9, P295, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.140; Schubeler D, 2000, GENE DEV, V14, P940; Selinger CI, 2011, J THORAC ONCOL, V6, P1179, DOI 10.1097/JTO.0b013e31821b4ce0; Seong BKA, 2015, ONCOGENE, V34, P3582, DOI 10.1038/onc.2014.289; Shannon MF, 2003, NAT GENET, V34, P4, DOI 10.1038/ng0503-4; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; Song GQ, 2017, ONCOTARGET, V8, P17771, DOI 10.18632/oncotarget.14849; Spector DL, 2003, ANNU REV BIOCHEM, V72, P573, DOI 10.1146/annurev.biochem.72.121801.161724; Stephen TL, 2017, IMMUNITY, V46, P51, DOI 10.1016/j.immuni.2016.12.015; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sun JR, 2018, J INVEST DERMATOL, V138, P1795, DOI 10.1016/j.jid.2018.02.028; Sun ZK, 2015, MOL MED REP, V11, P3235, DOI 10.3892/mmr.2015.3192; Tan JAT, 2008, J BIOL CHEM, V283, P18124, DOI 10.1074/jbc.M800512200; Tan JAT, 2010, MOL CELL BIOL, V30, P2823, DOI 10.1128/MCB.01603-09; Tanaka Y, 2017, J IMMUNOL, V199, P4016, DOI 10.4049/jimmunol.1700550; Tesone AJ, 2016, CELL REP, V14, P1774, DOI 10.1016/j.celrep.2016.01.056; Torres-Aguilar H, 2010, J CLIN IMMUNOL, V30, P659, DOI 10.1007/s10875-010-9430-5; Toscano MA, 2007, NAT IMMUNOL, V8, P825, DOI 10.1038/ni1482; Tsuji T, 2009, CANCER RES, V69, P7135, DOI 10.1158/0008-5472.CAN-09-1618; Tu W, 2012, LIVER INT, V32, P1064, DOI 10.1111/j.1478-3231.2012.02815.x; Wan F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117518; Wang FF, 2015, P NATL ACAD SCI USA, V112, pE4995, DOI 10.1073/pnas.1513780112; Wang GB, 2015, TUMOR BIOL, V36, P4715, DOI 10.1007/s13277-015-3120-0; Wang JF, 2009, J IMMUNOL, V182, P4036, DOI 10.4049/jimmunol.0802981; Wang MJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056730; Wang Q, 2018, EXP THER MED, V15, P3028, DOI 10.3892/etm.2018.5792; Wang S, 2009, J PATHOL, V219, P114, DOI 10.1002/path.2575; Wang SX, 2015, JPN J CLIN ONCOL, V45, P812, DOI 10.1093/jjco/hyv093; Watanabe R, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0473; Wei JW, 2012, J CELL BIOL, V197, P509, DOI 10.1083/jcb.201201057; Wen J, 2005, BLOOD, V105, P3330, DOI 10.1182/blood-2004-08-2988; Will B, 2013, NAT IMMUNOL, V14, P437, DOI 10.1038/ni.2572; Wu DM, 2016, ONCOL LETT, V12, P4377, DOI 10.3892/ol.2016.5281; Xiang JD, 2012, ONCOL LETT, V3, P865, DOI 10.3892/ol.2012.571; Yamashita T, 2013, J CLIN INVEST, V123, P1911, DOI 10.1172/JCI66024; Yang MH, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-109; Yang MH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0085353; Yasui D, 2002, NATURE, V419, P641, DOI 10.1038/nature01084; Yu W, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05458-y; Yu W, 2017, STEM CELL RES, V19, P139, DOI 10.1016/j.scr.2017.01.011; Yuqian Yang, 2015, 2015 Asia-Pacific Microwave Conference (APMC). Proceedings, P1, DOI 10.1109/APMC.2015.7413222; Zhang HY, 2013, MOL CELL BIOCHEM, V378, P39, DOI 10.1007/s11010-013-1591-0; Zhang S, 2017, ONCOTARGET, V8, P48410, DOI 10.18632/oncotarget.16867; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zheng J, 2008, WOMENS HEALTH, V4, P329, DOI 10.2217/17455057.4.4.329; Zhou LQ, 2012, J BIOL CHEM, V287, P30641, DOI 10.1074/jbc.M112.355271	176	25	25	4	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2019	38	12					1989	2004		10.1038/s41388-018-0541-4	http://dx.doi.org/10.1038/s41388-018-0541-4			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP6UR	30413763	Bronze			2022-12-28	WOS:000461822600001
J	Karsch-Bluman, A; Feiglin, A; Arbib, E; Stern, T; Shoval, H; Schwob, O; Berger, M; Benny, O				Karsch-Bluman, Adi; Feiglin, Ariel; Arbib, Eliran; Stern, Tal; Shoval, Hila; Schwob, Ouri; Berger, Michael; Benny, Ofra			Tissue necrosis and its role in cancer progression	ONCOGENE			English	Article							CELL SURVIVAL; TUMOR-CELLS; MOLECULAR-PATTERNS; METABOLIC STRESS; HYPOXIA; ADHESION; EXPRESSION; MEDIATORS; INVASION; PROLIFERATION	Great efforts have been made in revealing the mechanisms governing cancer resistance and recurrence. The in-situ effects of cell death, caused by hypoxia and metabolic stress, were largely studied in association with inflammation. However, in this work, we focused on the direct effects of necrosis on cancer promotion and on the tumor microenvironment. The conditions leading to cell necrosis, upon nutrient and oxygen deprivation, were recapitulated in-vitro and were used to generate samples for computational proteomic analysis. Under these conditions, we identified clusters of enriched pathways that may be involved in tumor resistance, leading to cancer recurrence. We show that the content of necrotic cells enhances angiogenesis and proliferation of endothelial cells, induces vasculature, as well as increases migration, invasion, and cell-cell interactions. In-vivo studies, where MDA-MB-231 xenografts were exposed to necrotic lysates, resulted in an increase in both proliferation and angiogenesis. Histological analysis of tumor tissues revealed high expression levels of key mediators that were identified by proteomic analysis. Moreover, when cells were injected systemically, coupled with necrotic lysates, a higher number of large lesions was detected in the lung. Finally, using xenografts, we demonstrated that combining an antagonist of a necrotic signal with an anticancer treatment potentiates the prolonged therapeutic effect. This approach suggests a paradigm shift in which targeting late necrotic-secreted factors may increase survival and enhance the efficacy of anticancer therapy.	[Karsch-Bluman, Adi; Stern, Tal; Shoval, Hila; Schwob, Ouri; Benny, Ofra] Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Inst Drug Res, Jerusalem, Israel; [Feiglin, Ariel] Harvard Med Sch, Dept Biomed Informat, Boston, MA 02115 USA; [Arbib, Eliran; Berger, Michael] Hebrew Univ Jerusalem, Fac Med, Lautenberg Ctr Immunol & Canc Res, IMRIC,Concern Fdn Labs, Jerusalem, Israel	Hebrew University of Jerusalem; Harvard University; Harvard Medical School; Hebrew University of Jerusalem	Benny, O (corresponding author), Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Inst Drug Res, Jerusalem, Israel.	ofrab@ekmd.huji.ac.il	Benny, Ofra/AAB-3294-2021		Marie Curie Career Integration Grants (CIG) [0305116]; Israel Cancer Association (ICA) [0394691]; Israel Foundation of Science (ISF) [0394883]; David R. Blum Center for Pharmacy at The Hebrew University; Shukor Gladi fund; Frances Brody fund; Eliyahu Pen Fund	Marie Curie Career Integration Grants (CIG); Israel Cancer Association (ICA); Israel Foundation of Science (ISF); David R. Blum Center for Pharmacy at The Hebrew University; Shukor Gladi fund; Frances Brody fund; Eliyahu Pen Fund	This study was kindly supported by grants from the Marie Curie Career Integration Grants (CIG) (No. 0305116), Israel Cancer Association (ICA) (No. 0394691), Israel Foundation of Science (ISF) (No. 0394883), David R. Blum Center for Pharmacy at The Hebrew University, The Shukor Gladi fund, The Frances Brody fund, and Eliyahu Pen Fund. We thank Dr. Gil Hornung and The De Botton Protein Profiling Institute of the Nancy and Stephen Grand Israel National Center for Personalized Medicine, Weizmann Institute of Science, for their support of the proteomic data generating process.	Aalinkeel R, 2004, CANCER RES, V64, P5311, DOI 10.1158/0008-5472.CAN-2506-2; Ahn SH, 2016, SCI REP-UK, V6, DOI 10.1038/srep24552; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Boroughs LK, 2015, NAT CELL BIOL, V17, P351, DOI 10.1038/ncb3124; Bredholt G, 2015, ONCOTARGET, V6, P39676, DOI 10.18632/oncotarget.5344; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Caino MC, 2013, J CLIN INVEST, V123, P2907, DOI 10.1172/JCI67841; Chen MJ, 2008, J EXP MED, V205, P2791, DOI 10.1084/jem.20080767; Chung TW, 2017, J ETHNOPHARMACOL, V195, P309, DOI 10.1016/j.jep.2016.11.036; Comito G, 2014, ONCOGENE, V33, P2423, DOI 10.1038/onc.2013.191; Crowley LC, 2016, COLD SPRING HARB PRO, V2016; Cuvier C, 1997, CLIN EXP METASTAS, V15, P19; Eales KL, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.50; Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283; Esmatabadi MJD, 2016, J BIOSCIENCES, V41, P497, DOI 10.1007/s12038-016-9624-y; Eustace A, 2013, RADIOTHER ONCOL, V108, P40, DOI 10.1016/j.radonc.2013.05.017; Festjens N, 2006, BBA-BIOENERGETICS, V1757, P1371, DOI 10.1016/j.bbabio.2006.06.014; Forte D, 2017, ONCOTARGET, V8, P2261, DOI 10.18632/oncotarget.13664; Franco M, 2011, BLOOD, V118, P2906, DOI 10.1182/blood-2011-01-331694; Gho YS, 2001, CANCER RES, V61, P4253; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hernandez C, 2016, ONCOGENE, V35, P5931, DOI 10.1038/onc.2016.104; Herszenyi L, 2012, DIGEST DIS, V30, P249, DOI 10.1159/000336914; Housman G, 2014, CANCERS, V6, P1769, DOI 10.3390/cancers6031769; Howard K, 2014, J SURG RES, V187, P19, DOI 10.1016/j.jss.2013.11.001; Indovina P, 2008, ANTICANCER RES, V28, P1013; Janakiram NB, 2009, CURR MOL MED, V9, P565, DOI 10.2174/156652409788488748; Kaczmarek A, 2013, IMMUNITY, V38, P209, DOI 10.1016/j.immuni.2013.02.003; Karsch-Bluman A, 2017, ONCOTARGET, V8, P32706, DOI 10.18632/oncotarget.16188; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kevil CG, 2004, J BIOL CHEM, V279, P19230, DOI 10.1074/jbc.M312025200; Krock Bryan L, 2011, Genes Cancer, V2, P1117, DOI 10.1177/1947601911423654; Land Walter G, 2015, Sultan Qaboos Univ Med J, V15, pe157; Li W, 2013, MOL MED, V19, P203, DOI 10.2119/molmed.2013.00064; Liu H, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-583; Liu R, 2009, MOL CELL PROTEOMICS, V8, P70, DOI 10.1074/mcp.M800195-MCP200; Liu WD, 2012, ONCOL LETT, V4, P1315, DOI 10.3892/ol.2012.940; Martinive P, 2006, CANCER RES, V66, P11736, DOI 10.1158/0008-5472.CAN-06-2056; Maurer AJ, 2015, INFLAMM RES, V64, P185, DOI 10.1007/s00011-015-0796-y; McIntosh A, 2007, AM J CLIN ONCOL-CANC, V30, P146, DOI 10.1097/01.coc.0000251357.45879.7f; Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984; Nagelkerke A, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3373; Pang C, 2008, AM J PHYSIOL-ENDOC M, V295, pE313, DOI 10.1152/ajpendo.90296.2008; Polychronidis Alexandros C, 2003, Folia Med (Plovdiv), V45, P20; Rahman M, 2015, METABOLITES, V5, P571, DOI 10.3390/metabo5040571; Riffle S, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3319-0; Rosette C, 2005, CARCINOGENESIS, V26, P943, DOI 10.1093/carcin/bgi070; Rundqvist H, 2013, J INTERN MED, V274, P105, DOI 10.1111/joim.12091; Schroder C, 2011, J CANCER RES CLIN, V137, P1193, DOI 10.1007/s00432-011-0984-2; Shoval H, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10699-y; Simard S, 2013, J CANCER SURVIV, V7, P300, DOI 10.1007/s11764-013-0272-z; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sulciner ML, 2018, J EXP MED, V215, P115, DOI 10.1084/jem.20170681; Sun Y, 2016, CANCER LETT, V380, P205, DOI 10.1016/j.canlet.2015.07.044; Sunami E, 2000, Oncologist, V5, P108, DOI 10.1634/theoncologist.5-2-108; Tomes L, 2003, BREAST CANCER RES TR, V81, P61, DOI 10.1023/A:1025476722493; Wellen KE, 2010, MOL CELL, V40, P323, DOI 10.1016/j.molcel.2010.10.004; Yang DG, 2016, SCI REP-UK, V6, DOI 10.1038/srep35316; Yang M, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.144; Ye JB, 2010, EMBO J, V29, P2082, DOI 10.1038/emboj.2010.81; Yodkeeree S, 2010, EUR J PHARMACOL, V627, P8, DOI 10.1016/j.ejphar.2009.09.052; Zhang Q, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00071	62	53	53	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2019	38	11					1920	1935		10.1038/s41388-018-0555-y	http://dx.doi.org/10.1038/s41388-018-0555-y			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HO7XX	30390074				2022-12-28	WOS:000461164400010
J	Sirkisoon, SR; Carpenter, RL; Rimkus, T; Doheny, D; Zhu, DQ; Aguayo, NR; Xing, F; Chan, M; Ruiz, J; Metheny-Barlow, LJ; Strowd, R; Lin, J; Regua, AT; Arrigo, A; Anguelov, M; Pasche, B; Debinski, W; Watabe, K; Lo, HW				Sirkisoon, Sherona R.; Carpenter, Richard L.; Rimkus, Tadas; Doheny, Daniel; Zhu, Dongqin; Aguayo, Noah R.; Xing, Fei; Chan, Michael; Ruiz, Jimmy; Metheny-Barlow, Linda J.; Strowd, Roy; Lin, Jiayuh; Regua, Angelina T.; Arrigo, Austin; Anguelov, Marlyn; Pasche, Boris; Debinski, Waldemar; Watabe, Kounosuke; Lo, Hui-Wen			TGLI1 transcription factor mediates breast cancer brain metastasis via activating metastasis-initiating cancer stem cells and astrocytes in the tumor microenvironment	ONCOGENE			English	Article							PROGNOSTIC-FACTORS; PREFERENTIAL SITE; SPLICE VARIANT; EXPRESSION; GLIOBLASTOMA; OCT4; GLI1; ANGIOGENESIS; RESISTANCE; SUBTYPES	Mechanisms for breast cancer metastasis remain unclear. Whether truncated glioma-associated oncogene homolog 1 (TGLI1), a transcription factor known to promote angiogenesis, migration and invasion, plays any role in metastasis of any tumor type has never been investigated. In this study, results of two mouse models of breast cancer metastasis showed that ectopic expression of TGLI1, but not GLI1, promoted preferential metastasis to the brain. Conversely, selective TGLI1 knockdown using antisense oligonucleotides led to decreased breast cancer brain metastasis (BCBM) in vivo. Immunohistochemical staining showed that TGLI1, but not GLI1, was increased in lymph node metastases compared to matched primary tumors, and that TGLI1 was expressed at higher levels in BCBM specimens compared to primary tumors. TGLI1 activation is associated with a shortened time to develop BCBM and enriched in HER2-enriched and triple-negative breast cancers. Radioresistant BCBM cell lines and specimens expressed higher levels of TGLI1, but not GLI1, than radiosensitive counterparts. Since cancer stem cells (CSCs) are radioresistant and metastasis-initiating cells, we examined TGLI1 for its involvement in breast CSCs and found TGLI1 to transcriptionally activate stemness genes CD44, Nanog, Sox2, and OCT4 leading to CSC renewal, and TGLI1 outcompetes with GLI1 for binding to target promoters. We next examined whether astrocyte-priming underlies TGLI1-mediated brain tropism and found that TGLI1-positive CSCs strongly activated and interacted with astrocytes in vitro and in vivo. These findings demonstrate, for the first time, that TGLI1 mediates breast cancer metastasis to the brain, in part, through promoting metastasis-initiating CSCs and activating astrocytes in BCBM microenvironment.	[Sirkisoon, Sherona R.; Carpenter, Richard L.; Rimkus, Tadas; Doheny, Daniel; Zhu, Dongqin; Aguayo, Noah R.; Regua, Angelina T.; Arrigo, Austin; Anguelov, Marlyn; Pasche, Boris; Debinski, Waldemar; Watabe, Kounosuke; Lo, Hui-Wen] Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, 300 S Hawthorne Rd, Winston Salem, NC 27103 USA; [Xing, Fei; Chan, Michael; Ruiz, Jimmy; Metheny-Barlow, Linda J.; Strowd, Roy; Pasche, Boris; Debinski, Waldemar; Watabe, Kounosuke; Lo, Hui-Wen] Wake Forest Univ, Bowman Gray Sch Med, Comprehens Canc Ctr, 300 S Hawthorne Rd, Winston Salem, NC 27103 USA; [Chan, Michael; Metheny-Barlow, Linda J.] Wake Forest Univ, Bowman Gray Sch Med, Dept Radiat Oncol, 300 S Hawthorne Rd, Winston Salem, NC 27103 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Hematol & Oncol, 300 S Hawthorne Rd, Winston Salem, NC 27103 USA; [Ruiz, Jimmy] Wake Forest Univ, Bowman Gray Sch Med, Dept Neurol, 300 S Hawthorne Rd, Winston Salem, NC 27103 USA; [Strowd, Roy] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; [Lin, Jiayuh] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Bloomington, IN USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; University System of Maryland; University of Maryland Baltimore; Indiana University System; Indiana University Bloomington	Lo, HW (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, 300 S Hawthorne Rd, Winston Salem, NC 27103 USA.; Lo, HW (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Comprehens Canc Ctr, 300 S Hawthorne Rd, Winston Salem, NC 27103 USA.	hlo@wakehealth.edu		Doheny, Daniel/0000-0002-1455-3090; Carpenter, Richard/0000-0001-9986-6493; Regua, Angelina/0000-0003-2595-8242; Strowd, Roy/0000-0001-6651-5267	NIH [R01NS087169, F31CA224805-01A1, T32CA079448, R01NS087169-3S1, P30CA012197]; DoD [W81XWH-17-1-0044, W81XWH-19-1-0072, BC181274]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DoD(United States Department of Defense)	We thank Dr. Shadi Qasem for providing pathology support. We acknowledge the funding support from NIH grants R01NS087169 (to H-WL), F31CA224805-01A1 (to SRS, HWL), T32CA079448 (to SK, RLC), R01NS087169-3S1 (to H-WL, SRS), P30CA012197 (to BP; core facility), and DoD grants W81XWH-17-1-0044 (to H-WL), W81XWH-19-1-0072 (to H-WL), and BC181274 (to H-WL).	Abraham BK, 2005, CLIN CANCER RES, V11, P1154; Ahmed MAH, 2012, BREAST CANCER RES TR, V133, P979, DOI 10.1007/s10549-011-1865-8; Akrap N, 2016, STEM CELL REP, V6, P121, DOI 10.1016/j.stemcr.2015.12.006; Almeida MI, 2011, MUTAT RES-FUND MOL M, V717, P1, DOI 10.1016/j.mrfmmm.2011.03.009; Bora-Singhal N, 2015, NEOPLASIA, V17, P538, DOI 10.1016/j.neo.2015.07.001; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Cao X, 2012, ONCOGENE, V31, P104, DOI 10.1038/onc.2011.219; Carpenter RL, 2015, ONCOTARGET, V6, P22653, DOI 10.18632/oncotarget.4248; Dahmane N, 2001, DEVELOPMENT, V128, P5201; Deleidi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019926; Di Mauro C, 2017, BRIT J CANCER, V116, P1425, DOI 10.1038/bjc.2017.116; Duex JE, 2017, CANCER RES, V77, P4858, DOI 10.1158/0008-5472.CAN-17-0367; Ekici K, 2016, J BUON, V21, P958; Fan YH, 2016, ONCOGENE, V35, P116, DOI 10.1038/onc.2015.67; Gril B, 2013, AM J PATHOL, V182, P2368, DOI 10.1016/j.ajpath.2013.02.043; Gwak JM, 2017, ONCOTARGET, V8, P36305, DOI 10.18632/oncotarget.16750; Han W, 2013, CANC HALLMARKS, V1, P28, DOI DOI 10.1166/CH.2013.1006; He DX, 2015, J PHARMACEUT BIOMED, V102, P500, DOI 10.1016/j.jpba.2014.10.018; Huang DL, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0917-x; Komada M, 2008, BIOCHEM BIOPH RES CO, V369, P350, DOI 10.1016/j.bbrc.2008.02.015; Li Q, 2016, J BIOL CHEM, V291, P7171, DOI 10.1074/jbc.M116.714857; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Lo HW, 2009, CANCER RES, V69, P6790, DOI 10.1158/0008-5472.CAN-09-0886; Lorger M, 2010, AM J PATHOL, V176, P2958, DOI 10.2353/ajpath.2010.090838; Miyake A, 2005, DEV BIOL, V288, P259, DOI 10.1016/j.ydbio.2005.09.042; Niikura N, 2014, BREAST CANCER RES TR, V147, P103, DOI 10.1007/s10549-014-3090-8; Rimkus TK, 2018, CANCER RES, V78, P2589, DOI 10.1158/0008-5472.CAN-17-2933; Shen L, 2014, BBA-MOL BASIS DIS, V1842, P2087, DOI 10.1016/j.bbadis.2014.07.015; Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sirkisoon SR, 2018, ONCOGENE, V37, P2502, DOI 10.1038/s41388-018-0132-4; Smid M, 2008, CANCER RES, V68, P3108, DOI 10.1158/0008-5472.CAN-07-5644; Wang JX, 2017, EUR REV MED PHARMACO, V21, P3857; Wang L, 2018, METHODS MOL BIOL, V1692, P31, DOI 10.1007/978-1-4939-7401-6_3; Wang T, 2015, ONCOTARGET, V6, P44191, DOI 10.18632/oncotarget.6176; Wang Z, 2012, CELL STEM CELL, V10, P440, DOI 10.1016/j.stem.2012.02.016; Wang Z, 2017, INT J BIOL MARKER, V32, pE75, DOI 10.5301/jbm.5000224; Wu Q, 2017, ONCOTARGET, V8, P27990, DOI 10.18632/oncotarget.15856; Zhang XM, 2013, CANCER RES, V73, P4885, DOI 10.1158/0008-5472.CAN-12-4081; Zhao XD, 2018, MOL CARCINOGEN, V57, P1616, DOI 10.1002/mc.22884; Zhu H, 2014, CANCER LETT, V343, P51, DOI 10.1016/j.canlet.2013.09.014; Zucchi I, 2004, P NATL ACAD SCI USA, V101, P18147, DOI 10.1073/pnas.0408260101	42	38	40	2	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	1					64	78		10.1038/s41388-019-0959-3	http://dx.doi.org/10.1038/s41388-019-0959-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG3NM	31462709	Green Submitted, Green Accepted			2022-12-28	WOS:000509849200006
J	Sheng, YH; Wong, KY; Seim, I; Wang, R; He, YW; Wu, A; Patrick, M; Lourie, R; Schreiber, V; Giri, R; Ng, CP; Popat, A; Hooper, J; Kijanka, G; Florin, TH; Begun, J; Radford, KJ; Hasnain, S; McGuckin, MA				Sheng, Yong Hua; Wong, Kuan Yau; Seim, Inge; Wang, Ran; He, Yaowu; Wu, Andy; Patrick, Maya; Lourie, Rohan; Schreiber, Veronika; Giri, Rabina; Ng, Choa Ping; Popat, Amirali; Hooper, John; Kijanka, Gregor; Florin, Timothy H.; Begun, Jakob; Radford, Kristen J.; Hasnain, Sumaira; McGuckin, Michael A.			MUC13 promotes the development of colitis-associated colorectal tumors via beta-catenin activity	ONCOGENE			English	Article							CELL-SURFACE MUCIN; SUPPRESSOR-CELLS; DENDRITIC CELLS; MUCOSAL BARRIER; STEM-CELLS; COLON; INFLAMMATION; RESPONSES; PATHWAY; OVEREXPRESSION	Many adenocarcinomas, including colorectal cancer (CRC), overexpress the MUC13 cell surface mucin, but the functional significance and mechanisms are unknown. Here, we report the roles of MUC13 in colonic tumorigenesis and tumor progression. High-MUC13 expression is associated with poor survival in two independent patient cohorts. In a comprehensive series of in vivo experiments, we identified a critical role for MUC13 in the development of this malignancy, by promoting survival and proliferation of tumor-initiating cells and driving an immunosuppressive environment that protects tumors from checkpoint inhibitor immunotherapy. In Muc13-deficient mice, fewer tumors are generated after exposure to carcinogens and inflammation, they have markedly reduced beta-catenin signaling, have more tumor-infiltrating CD103(+) dendritic cells and CD8(+) T lymphocytes, fewer myeloid-derived suppressor cells, and are rendered sensitive to checkpoint inhibitor immunotherapy (anti-PD-L1). Mechanistically, we show that MUC13 protects beta-catenin from degradation, by interacting with GSK-3 beta, which increases beta-catenin nuclear translocation and promotes its signaling, thereby driving cancer initiation, progression, invasion, and immune suppression. Therefore, MUC13 is a potential marker of poor prognosis in colorectal cancer, and inhibiting MUC13 may be useful in the treatment of colitis-associated cancer and sensitizing tumors to immunotherapy.	[Sheng, Yong Hua; Wong, Kuan Yau; Seim, Inge; Wang, Ran; Patrick, Maya; Lourie, Rohan; Ng, Choa Ping; Popat, Amirali; Hasnain, Sumaira; McGuckin, Michael A.] Univ Queensland, Translat Res Inst, Mater Res Inst, Inflammatory Dis Biol & Therapeut Grp, Brisbane, Qld 4102, Australia; [Seim, Inge] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Translat Res Inst, Comparat & Endocrine Biol Lab, Brisbane, Qld 4012, Australia; [Seim, Inge] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Translat Res Inst, Ghrelin Res Grp, Brisbane, Qld 4102, Australia; [Seim, Inge] Nanjing Normal Univ, Coll Life Sci, Integrat Biol Lab, Nanjing 210023, Jiangsu, Peoples R China; [He, Yaowu; Hooper, John] Univ Queensland, Mater Res Inst, Canc Biol Grp, Brisbane, Qld 4101, Australia; [Wu, Andy] Univ Queensland, Translat Res Inst, Mater Res Inst, Bones & Immunol Grp, Brisbane, Qld 4102, Australia; [Lourie, Rohan; Schreiber, Veronika; Giri, Rabina; Florin, Timothy H.; Begun, Jakob] Univ Queensland, Translat Res Inst, Mater Res Inst, Inflammatory Bowel Dis Grp, Brisbane, Qld 4102, Australia; [Popat, Amirali] Univ Queensland, Sch Pharm, Brisbane, Qld 4072, Australia; [Kijanka, Gregor] Univ Queensland, Translat Res Inst, Mater Res Inst, Immune Profiling & Canc Grp, Brisbane, Qld 4102, Australia; [Radford, Kristen J.] Univ Queensland, Translat Res Inst, Mater Res Inst, Canc Immunotherapies Grp, Brisbane, Qld 4101, Australia; [McGuckin, Michael A.] Univ Melbourne, Fac Med Dent & Hlth Sci, Melbourne, Vic 3010, Australia	Mater Research; University of Queensland; Queensland University of Technology (QUT); Queensland University of Technology (QUT); Nanjing Normal University; Mater Research; University of Queensland; Mater Research; University of Queensland; Mater Research; University of Queensland; University of Queensland; Mater Research; University of Queensland; Mater Research; University of Queensland; University of Melbourne	Hasnain, S; McGuckin, MA (corresponding author), Univ Queensland, Translat Res Inst, Mater Res Inst, Inflammatory Dis Biol & Therapeut Grp, Brisbane, Qld 4102, Australia.; McGuckin, MA (corresponding author), Univ Melbourne, Fac Med Dent & Hlth Sci, Melbourne, Vic 3010, Australia.	sumaira.hasnain@mater.uq.edu.au; michael.mcguckin@unimelb.edu.au	Begun, Jakob/J-6793-2014; sheng, yong H/C-5052-2013; Radford, Kristen J/B-5550-2011; Wang, Ran/AAP-1920-2020; Hooper, John/C-1481-2016; Hasnain, Sumaira/N-3412-2014	Begun, Jakob/0000-0001-5256-7672; sheng, yong H/0000-0002-4623-9098; Radford, Kristen J/0000-0001-6512-6323; Wang, Ran/0000-0002-1741-6446; HE, Yaowu/0000-0002-7828-263X; Giri, Rabina/0000-0002-6712-6076; Hooper, John/0000-0003-1054-8486; Hasnain, Sumaira/0000-0001-8577-8628; Schreiber, Veronika/0000-0001-6088-7828; McGuckin, Michael/0000-0002-8375-2675; Wu, Andy C/0000-0002-0864-4447	NHMRC [1060698]; Mater Foundation; NHMRC; Betty McGrath/Mater Practitioner Research Fellowship; QUT Vice-Chancellor's Senior Research Fellowship; Australian Government	NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Mater Foundation; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Betty McGrath/Mater Practitioner Research Fellowship; QUT Vice-Chancellor's Senior Research Fellowship; Australian Government(Australian GovernmentCGIAR)	Supported by NHMRC project grant 1060698 and funding by the Mater Foundation, MAM was supported by an NHMRC Principal Research Fellowship. RL was partly supported by a Betty McGrath/Mater Practitioner Research Fellowship. IS is supported by a QUT Vice-Chancellor's Senior Research Fellowship. The Translational Research Institute (TRI) is supported by a grant from the Australian Government.	Augustin I, 2016, STEM CELL RES, V17, P607, DOI 10.1016/j.scr.2016.10.010; Bedoui S, 2009, NAT IMMUNOL, V10, P488, DOI 10.1038/ni.1724; Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002; Brabletz S, 2009, J PATHOL, V217, P307, DOI 10.1002/path.2475; Chauhan SC, 2012, MOL CANCER THER, V11, P24, DOI 10.1158/1535-7163.MCT-11-0598; Chauhan SC, 2009, CANCER RES, V69, P765, DOI 10.1158/0008-5472.CAN-08-0587; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Day FL, 2013, CLIN CANCER RES, V19, P3285, DOI 10.1158/1078-0432.CCR-12-3614; De Robertis Mariangela, 2011, J Carcinog, V10, P9, DOI 10.4103/1477-3163.78279; Fuertes MB, 2011, J EXP MED, V208, P2005, DOI 10.1084/jem.20101159; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Gavert N, 2007, J CELL BIOCHEM, V102, P820, DOI 10.1002/jcb.21505; Goldman M, 2015, NUCLEIC ACIDS RES, V43, pD812, DOI 10.1093/nar/gku1073; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Gupta BK, 2014, J GASTROENTEROL, V49, P1378, DOI 10.1007/s00535-013-0885-z; Gupta BK, 2012, J HISTOCHEM CYTOCHEM, V60, P822, DOI 10.1369/0022155412460678; Hildner K, 2008, SCIENCE, V322, P1097, DOI 10.1126/science.1164206; Hong Y, 2015, CANCER RES, V75, P656, DOI 10.1158/0008-5472.CAN-14-2377; Jensen MA, 2017, BLOOD, V130, P453, DOI 10.1182/blood-2017-03-735654; Jonckheere N, 2014, BBA-REV CANCER, V1846, P142, DOI 10.1016/j.bbcan.2014.04.008; Katoh H, 2013, CANCER CELL, V24, P631, DOI 10.1016/j.ccr.2013.10.009; Khan S, 2017, ONCOGENE, V36, P491, DOI 10.1038/onc.2016.218; Khan S, 2014, ONCOTARGET, V5, P7599, DOI 10.18632/oncotarget.2281; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Linden SK, 2008, MUCOSAL IMMUNOL, V1, P183, DOI 10.1038/mi.2008.5; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; McAuley JL, 2007, J CLIN INVEST, V117, P2313, DOI 10.1172/JCI26705; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Najdi Rani, 2011, J Carcinog, V10, P5, DOI 10.4103/1477-3163.78111; Nath S, 2014, TRENDS MOL MED, V20, P332, DOI 10.1016/j.molmed.2014.02.007; Pai P, 2016, CARCINOGENESIS, V37, P223, DOI 10.1093/carcin/bgw005; Said AH, 2014, CANCERS, V6, P366, DOI 10.3390/cancers6010366; Salmon H, 2016, IMMUNITY, V44, P924, DOI 10.1016/j.immuni.2016.03.012; Schmierer B, 2007, NAT REV MOL CELL BIO, V8, P970, DOI 10.1038/nrm2297; Schneikert J, 2007, GUT, V56, P417, DOI 10.1136/gut.2006.093310; Sheng YH, 2017, ONCOGENE, V36, P700, DOI 10.1038/onc.2016.241; Sheng YH, 2013, MUCOSAL IMMUNOL, V6, P557, DOI 10.1038/mi.2012.98; Sheng YH, 2012, J GASTROEN HEPATOL, V27, P28, DOI 10.1111/j.1440-1746.2011.06909.x; Sheng YH, 2011, GUT, V60, P1661, DOI 10.1136/gut.2011.239194; Sheng YH, 2017, INT J CANCER, V140, P2351, DOI 10.1002/ijc.30651; Shimamura T, 2005, CANCER SCI, V96, P265, DOI 10.1111/j.1349-7006.2005.00043.x; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Spranger S, 2017, CANCER CELL, V31, P711, DOI 10.1016/j.ccell.2017.04.003; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Vilar E, 2010, NAT REV CLIN ONCOL, V7, P153, DOI 10.1038/nrclinonc.2009.237; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Walsh MD, 2007, HUM PATHOL, V38, P883, DOI 10.1016/j.humpath.2006.11.020; Williams SJ, 2001, J BIOL CHEM, V276, P18327, DOI 10.1074/jbc.M008850200; WITTY JP, 1994, CANCER RES, V54, P4805; Youn JI, 2008, J IMMUNOL, V181, P5791, DOI 10.4049/jimmunol.181.8.5791; Zauber AG, 2012, NEW ENGL J MED, V366, P687, DOI 10.1056/NEJMoa1100370; Zhi XF, 2014, CANCER LETT, V346, P104, DOI 10.1016/j.canlet.2013.12.021	54	14	14	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2019	38	48					7294	7310		10.1038/s41388-019-0951-y	http://dx.doi.org/10.1038/s41388-019-0951-y			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JR4XX	31427737	Green Submitted			2022-12-28	WOS:000499631000002
J	Yao, N; Fu, Y; Chen, L; Liu, Z; He, J; Zhu, YC; Xia, TS; Wang, S				Yao, Na; Fu, Yue; Chen, Lie; Liu, Zhao; He, Jing; Zhu, Yichao; Xia, Tiansong; Wang, Shui			Long non-coding RNA NONHSAT101069 promotes epirubicin resistance, migration, and invasion of breast cancer cells through NONHSAT101069/miR-129-5p/Twist1 axis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; HEPATOCELLULAR-CARCINOMA; POOR-PROGNOSIS; CHEMORESISTANCE; METASTASIS; ACTIVATION; MIR-129-5P; CERNA; TWIST; PROLIFERATION	Drug resistance, including epirubicin-based therapeutic resistance, is one of the major reasons responsible for the unfavorable prognosis of patients diagnosed with breast cancer (BC). Acquired chemoresistance and metastatic properties have been identified to be closely associated with the process of epithelial-mesenchymal transition (EMT). Recently, dysregulation of long non-coding RNAs (lncRNAs) have been increasingly reported to perform promotive or suppressive functions in chemoresistance and EMT process in multiple cancers. However, relevant novel lncRNA participating in epirubicin resistance and EMT and its underlying molecular mechanisms remain unknown in BC. Herein, we established the epirubicin-resistant breast cancer cell subline (MCF-7/ADR), which presented mesenchymal phenotype and increased metastatic potential. A panel of differentially expressed lncRNAs, including 268 upregulated and 49 downregulated lncRNAs, were identified by high-flux microarray investigation in MCF-7 and MCF-7/ADR cells. The novel lncRNA NONHSAT101069 was significantly overexpressed in BC specimens, BC cell lines, and epirubicin-resistant cell sublines. The knockdown of NONHSAT101069 significantly repressed, whereas overexpression of NONHSAT101069 promoted the epirubicin resistance, migration, invasion and EMT process of BC cells both in vitro and in vivo. Further mechanism-related researches uncovered that NONHSAT101069 functioned as a ceRNA (competing endogenous RNA) via sponging miR-1295p. Twist1 was a direct downstream protein of NONHSAT101069/miR-129-5p axis in BC cells. To conclude, NONHSAT101069 was upregulated in BC tissues and promoted epirubicin resistance, migration and invasion of BC cells via regulation of NONHSAT101069/miR-129-5p/Twist1 axis, highlighting its potential as an oncogene and a therapeutic biomarker for BC.	[Yao, Na; Chen, Lie; Xia, Tiansong; Wang, Shui] Nanjing Med Univ, Breast Dis Ctr, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China; [Yao, Na] Nanjing Univ TCM, Wuxi City Hosp TCM, Dept Thyroid & Breast Surg, Affiliated Hosp, Wuxi 214000, Jiangsu, Peoples R China; [Fu, Yue] Nanjing Med Univ, Dept Gen Surg, Affiliated Changzhou Peoples Hosp 2, Changzhou 213000, Jiangsu, Peoples R China; [Liu, Zhao] Xuzhou Med Univ, Dept Thyroid & Breast Surg, Affiliated Hosp, Xuzhou 222100, Jiangsu, Peoples R China; [He, Jing] Jiangnan Univ, Dept Surg Oncol, Affiliated Hosp, Wuxi 214000, Jiangsu, Peoples R China; [Zhu, Yichao] Nanjing Med Univ, Dept Physiol, Nanjing 211166, Jiangsu, Peoples R China; [Zhu, Yichao] Nanjing Med Univ, State Key Lab Reprod Med, Nanjing 211166, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing University of Chinese Medicine; Nanjing Medical University; Xuzhou Medical University; Jiangnan University; Nanjing Medical University; Nanjing Medical University	Xia, TS; Wang, S (corresponding author), Nanjing Med Univ, Breast Dis Ctr, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China.; Zhu, YC (corresponding author), Nanjing Med Univ, Dept Physiol, Nanjing 211166, Jiangsu, Peoples R China.; Zhu, YC (corresponding author), Nanjing Med Univ, State Key Lab Reprod Med, Nanjing 211166, Jiangsu, Peoples R China.	zhuyichao@njmu.edu.cn; xiats@njmu.edu.cn; ws0801@hotmail.com	yao, na/HDL-8772-2022		National Natural Science Foundation of China [81572607, 81472703]; Natural Science Foundation of Jiangsu Province [BK20181367]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province)	This work was supported by grants from the National Natural Science Foundation of China (81572607, 81472703) and the Natural Science Foundation of Jiangsu Province (BK20181367). The results shown here were partially based upon data obtained from public TCGA datasets. We thank Prof. Donglei Yang (Nanjing Agricultural University, Nanjing, China) and Dr. Macara (University of Virginia, VA) for providing the technical guidance to Northern blotting and the constructs of MS2-tagged RNA affinity purification assay, respectively.	Cheng GZ, 2008, CANCER RES, V68, P957, DOI 10.1158/0008-5472.CAN-07-5067; DeSantis C, 2014, CA-CANCER J CLIN, V64, P52, DOI 10.3322/caac.21203; Fang L, 2017, AM J PHYSIOL-GASTR L, V313, pG150, DOI 10.1152/ajpgi.00426.2016; Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Fu Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0807-2; Gao YR, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.311; Gonzalez-Angulo AM, 2007, ADV EXP MED BIOL, V608, P1; Hiscox S, 2006, INT J CANCER, V118, P290, DOI 10.1002/ijc.21355; Hu GH, 2009, CANCER CELL, V15, P9, DOI 10.1016/j.ccr.2008.11.013; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Karunarathna U, 2016, ONCOGENE, V35, P1433, DOI 10.1038/onc.2015.208; Khasraw M, 2012, BREAST, V21, P142, DOI 10.1016/j.breast.2011.12.012; Lee HJ, 2016, MOL CELL, V63, P1021, DOI 10.1016/j.molcel.2016.08.009; Lee JW, 2018, CANCER SCI, V109, P1404, DOI 10.1111/cas.13588; Li PL, 2017, MOL CANCER THER, V16, P739, DOI 10.1158/1535-7163.MCT-16-0591; Liang  Y., 2018, ADV MATER INTERFACES, V5, P1, DOI DOI 10.1017/S0266466617000317; Liang YR, 2018, CANCER BIOL THER, V19, P120, DOI 10.1080/15384047.2017.1394543; Liu K, 2017, CELL CYCLE, V16, P578, DOI 10.1080/15384101.2017.1288324; Lu W, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0685-9; Luan QX, 2016, EUR REV MED PHARMACO, V20, P4257; Ma N, 2015, BIOCHEM BIOPH RES CO, V461, P618, DOI 10.1016/j.bbrc.2015.04.075; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Meng QC, 2018, ONCOGENE, V37, P5843, DOI 10.1038/s41388-018-0392-z; Qi XL, 2015, J MED GENET, V52, P710, DOI 10.1136/jmedgenet-2015-103334; Rho JK, 2009, LUNG CANCER, V63, P219, DOI 10.1016/j.lungcan.2008.05.017; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Santisteban M, 2009, CANCER RES, V69, P2887, DOI 10.1158/0008-5472.CAN-08-3343; Shen CJ, 2017, J DRUG TARGET, V25, P637, DOI 10.1080/1061186X.2017.1307379; Shi SJ, 2015, ONCOTARGET, V6, P11652, DOI 10.18632/oncotarget.3457; Shi Y, 2015, INT J INF TECH DECIS, V14, P1, DOI 10.1142/S0219622015020022; Tang J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.518; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20; Tuck AC, 2013, CELL, V154, P996, DOI 10.1016/j.cell.2013.07.047; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; van Staalduinen J, 2018, ONCOGENE, V37, P6195, DOI 10.1038/s41388-018-0378-x; Vesuna F, 2012, ONCOGENE, V31, P3223, DOI 10.1038/onc.2011.483; Wang YF, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0702-z; Wang ZW, 2009, CANCER RES, V69, P2400, DOI 10.1158/0008-5472.CAN-08-4312; Wu YH, 2017, INT J CANCER, V141, P2305, DOI 10.1002/ijc.30932; Xu T, 2016, CANCER LETT, V377, P140, DOI 10.1016/j.canlet.2016.04.026; Xu Y, 2017, ONCOGENE, V36, P1157, DOI 10.1038/onc.2016.286; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yao N, 2019, MOL CARCINOGEN, V58, P1291, DOI 10.1002/mc.23011; Yu Y, 2015, ONCOTARGET, V6, P34423, DOI 10.18632/oncotarget.5406; Zhang DY, 2017, BIOMED PHARMACOTHER, V95, P1187, DOI 10.1016/j.biopha.2017.09.045; Zhang P, 2017, CELL PHYSIOL BIOCHEM, V42, P242, DOI 10.1159/000477323; Zhang YZ, 2016, ONCOL LETT, V12, P5163, DOI 10.3892/ol.2016.5372; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	50	61	63	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2019	38	47					7216	7233		10.1038/s41388-019-0904-5	http://dx.doi.org/10.1038/s41388-019-0904-5			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP0UL	31444414				2022-12-28	WOS:000497989400003
J	Shankaraiah, RC; Callegari, E; Guerriero, P; Rimessi, A; Pinton, P; Gramantieri, L; Silini, EM; Sabbioni, S; Negrini, M				Shankaraiah, Ram C.; Callegari, Elisa; Guerriero, Paola; Rimessi, Alessandro; Pinton, Paolo; Gramantieri, Laura; Silini, Enrico M.; Sabbioni, Silvia; Negrini, Massimo			Metformin prevents liver tumourigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma	ONCOGENE			English	Article							RISK; CANCER; PHOSPHORYLATION; EPIDEMIOLOGY; CIRRHOSIS; DISEASE; OBESITY	Metformin is a hypoglycaemic agent used to treat type 2 diabetes mellitus (DM2) patients, with a broad safety profile. Since previous epidemiological studies had shown that the incidence of hepatocellular carcinoma (HCC) decreased significantly in metformin treated DM2 patients, we hypothesised that intervention with metformin could reduce the risk of neoplastic transformation of hepatocytes. HCC is the most common primary liver malignancy and it generally originates in a background of liver fibrosis and cirrhosis. In the present study, we took advantage of a transgenic mouse (TG221) characterized by microRNA-221 overexpression, with cirrhotic liver background induced by chronic administration of carbon tetrachloride (CC14). This mouse model develops fibrosis, cirrhosis and liver tumours that become visible in 100% of mice at 5-6 months of age. Our results demonstrated that metformin intervention improves liver function, inhibits hepatic stellate cell (HSC) activation, reduces liver fibrosis, depletes lipid accumulation in hepatocytes, halts progression to decompensated cirrhosis and abrogates development HCC in CC14 challenged transgenic mouse model. The study establishes the rationale for investigating metformin in cirrhotic patients regardless of concomitant DM2 status.	[Shankaraiah, Ram C.; Callegari, Elisa; Guerriero, Paola; Rimessi, Alessandro; Pinton, Paolo; Negrini, Massimo] Univ Ferrara, Dept Morphol Surg & Expt Med, Ferrara, Italy; [Gramantieri, Laura] St Orsola Malpighi Univ Hosp, Ctr Appl Biomed Res, I-40138 Bologna, Italy; [Silini, Enrico M.] Univ Hosp Parma, Sect Anat & Pathol, Parma, Italy; [Sabbioni, Silvia] Univ Ferrara, Dept Life Sci & Biotechnol, Ferrara, Italy	University of Ferrara; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Parma; University Hospital of Parma; University of Ferrara	Negrini, M (corresponding author), Univ Ferrara, Dept Morphol Surg & Expt Med, Ferrara, Italy.	ngm@unife.it	Pinton, Paolo/J-8025-2012; SILINI, ENRICO MARIA/AAB-8747-2019; rimessi, alessandro/O-3335-2019; Gramantieri, Laura/K-8603-2016; NEGRINI, Massimo/J-2377-2016; Callegari, Elisa/J-5763-2016	Pinton, Paolo/0000-0001-7108-6508; SILINI, ENRICO MARIA/0000-0003-2578-3059; rimessi, alessandro/0000-0001-7091-5765; GUERRIERO, Paola/0000-0003-3724-7472; Gramantieri, Laura/0000-0002-5187-9559; NEGRINI, Massimo/0000-0002-0007-1920; Callegari, Elisa/0000-0002-4969-5400	Italian Association for Cancer Research [AIRG IG-15615, AIRC IG-20055]	Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro)	This work was supported by the Italian Association for Cancer Research (AIRG IG-15615, AIRC IG-20055) to Massimo Negrini, PhD.	Akinyemiju T, 2017, JAMA ONCOL, V3, P1683, DOI 10.1001/jamaoncol.2017.3055; Blachier M, 2013, J HEPATOL, V58, P593, DOI 10.1016/j.jhep.2012.12.005; Bo S, 2012, DIABETES OBES METAB, V14, P23, DOI 10.1111/j.1463-1326.2011.01480.x; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Callegari E, 2012, HEPATOLOGY, V56, P1025, DOI 10.1002/hep.25747; Chaube B, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.404; Chen HP, 2013, GUT, V62, P606, DOI 10.1136/gutjnl-2011-301708; Dasgupta B, 2016, TRENDS PHARMACOL SCI, V37, P192, DOI 10.1016/j.tips.2015.11.007; DePeralta DK, 2016, CANCER-AM CANCER SOC, V122, P1216, DOI 10.1002/cncr.29912; Deutsch MJ, 2014, ANAL BIOCHEM, V445, P87, DOI 10.1016/j.ab.2013.10.001; Donadon V, 2009, WORLD J GASTROENTERO, V15, P2506, DOI 10.3748/wjg.15.2506; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; European Assoc Study Liver, 2012, EUR J CANCER, V48, P599, DOI 10.1016/j.ejca.2011.12.021; Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149; Fukumura D, 2016, MICROCIRCULATION, V23, P191, DOI 10.1111/micc.12270; Fullerton MD, 2013, NAT MED, V19, P1649, DOI 10.1038/nm.3372; Gardini AC, 2017, EUR J CANCER, V86, P106, DOI 10.1016/j.ejca.2017.09.003; Gardini AC, 2015, EXPERT OPIN PHARMACO, V16, P2719, DOI 10.1517/14656566.2015.1102887; Gluchowski NL, 2017, NAT REV GASTRO HEPAT, V14, P343, DOI 10.1038/nrgastro.2017.32; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hardie DG, 2011, GENE DEV, V25, P1895, DOI 10.1101/gad.17420111; Hassan MM, 2010, CANCER-AM CANCER SOC, V116, P1938, DOI 10.1002/cncr.24982; Hollander MC, 2011, ONCOGENE, V30, P1812, DOI 10.1038/onc.2010.556; Incio J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141392; Ioannou GN, 2018, J HEPATOL, V68, P25, DOI 10.1016/j.jhep.2017.08.030; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kao JH, 2002, LANCET INFECT DIS, V2, P395, DOI 10.1016/S1473-3099(02)00315-8; Kasmari AJ, 2017, AM J MED, V130, DOI 10.1016/j.amjmed.2016.12.029; Kim JH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18762-4; Kim JH, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2015.115; Kluwe J, 2011, GUT, V60, P1260, DOI 10.1136/gut.2010.209551; Kodack DP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal4682; Lee JH, 2012, INT J CANCER, V131, P752, DOI 10.1002/ijc.26421; Lee MS, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-20; Linnerth-Petrik NM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094595; Liu WJ, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1629-z; Llovet JM, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.18, 10.1038/nrdp.2016.19]; Memmott RM, 2010, CANCER PREV RES, V3, P1066, DOI 10.1158/1940-6207.CAPR-10-0055; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Muir AJ, 2015, CLIN THER, V37, P1822, DOI 10.1016/j.clinthera.2015.05.507; Murff HJ, 2018, CANCER CAUSE CONTROL, V29, P823, DOI 10.1007/s10552-018-1058-4; Nkontchou G, 2011, J CLIN ENDOCR METAB, V96, P2601, DOI 10.1210/jc.2010-2415; Nordenstedt H, 2010, DIGEST LIVER DIS, V42, pS206, DOI 10.1016/S1590-8658(10)60507-5; Qian WK, 2018, LIFE SCI, V208, P253, DOI 10.1016/j.lfs.2018.07.046; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Scaglione S, 2015, J CLIN GASTROENTEROL, V49, P690, DOI 10.1097/MCG.0000000000000208; Schulte L, 2019, LIVER INT, V39, P714, DOI 10.1111/liv.14048; Singh S, 2013, AM J GASTROENTEROL, V108, P881, DOI 10.1038/ajg.2013.5; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tandra S, 2011, J HEPATOL, V55, P654, DOI 10.1016/j.jhep.2010.11.021; Tennant DA, 2009, CARCINOGENESIS, V30, P1269, DOI 10.1093/carcin/bgp070; Tsuchida T, 2017, NAT REV GASTRO HEPAT, V14, P397, DOI 10.1038/nrgastro.2017.38; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wong FWY, 1998, TOXICOL APPL PHARM, V153, P109, DOI 10.1006/taap.1998.8547; Yang XL, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0308-4; Yoon KH, 2006, LANCET, V368, P1681, DOI 10.1016/S0140-6736(06)69703-1	56	33	35	1	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2019	38	45					7035	7045		10.1038/s41388-019-0942-z	http://dx.doi.org/10.1038/s41388-019-0942-z			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JL9XI	31409896	Green Submitted			2022-12-28	WOS:000495878400001
J	Cao, TF; Jiang, Y; Wang, ZS; Zhang, N; Al-Hendy, A; Mamillapalli, R; Kallen, AN; Kodaman, P; Taylor, HS; Li, D; Huang, YQ				Cao, Tiefeng; Jiang, Ying; Wang, Zhangsheng; Zhang, Na; Al-Hendy, Ayman; Mamillapalli, Ramanaiah; Kallen, Amanda N.; Kodaman, Pinar; Taylor, Hugh S.; Li, Da; Huang, Yingqun			H19 lncRNA identified as a master regulator of genes that drive uterine leiomyomas	ONCOGENE			English	Article							EXTRACELLULAR-MATRIX; PULMONARY-FIBROSIS; GENOME-WIDE; TGF-BETA; GROWTH; LET-7; MED12; PROLIFERATION; EXPRESSION; PATHWAYS	Uterine leiomyomas or fibroids (UFs) are benign tumors characterized by hyperplastic smooth muscle cells and excessive deposition of extracellular matrix (ECM). Afflicting similar to 80% of women, and symptomatic in 25%, UFs bring tremendous suffering and are an economic burden worldwide; they cause severe pain and bleeding, and are the leading cause of hysterectomy. Yet, UFs are severely understudied with few effective treatment options available; those that are available frequently have significant side effects such as menopausal symptoms. Recently, integrated genome-scale studies have revealed mutations and fibroid subtype-specific expression changes in key driver genes, with MED12 and HMGA2 together contributing to nearly 90% of all UFs, but their regulation of expression is poorly characterized. Here we report that the expression of H19 long noncoding RNA (lncRNA) is aberrantly increased in UFs. Using cell culture and genome-wide transcriptome and methylation profiling analyses, we demonstrate that H19 promotes expression of MED12, HMGA2, and key ECM-remodeling genes via multiple mechanisms including a new class of epigenetic modification by TET3. Our results mark the first example of an evolutionarily conserved lncRNA in pathogenesis of UFs and regulation of TET expression. Given the link between a H19 single-nucleotide polymorphism (SNP) and increased risk and tumor size of UFs, and the existence of multiple fibroid subtypes driven by key pathway genes regulated by H19, we propose a unifying mechanism for pathogenesis of uterine fibroids mediated by H19 and identify a pathway for future exploration of novel target therapies for uterine leiomyomas.	[Cao, Tiefeng; Jiang, Ying; Wang, Zhangsheng; Mamillapalli, Ramanaiah; Kallen, Amanda N.; Kodaman, Pinar; Taylor, Hugh S.; Huang, Yingqun] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, 333 Cedar St, New Haven, CT 06510 USA; [Cao, Tiefeng] Sun Yat Sen Univ, Dept Gynecol & Obstet, Affiliated Hosp 1, Guangzhou 510070, Guangdong, Peoples R China; [Jiang, Ying] Zhejiang Univ, Dept Obstet, Womens Hosp, Sch Med, Hangzhou 310006, Zhejiang, Peoples R China; [Wang, Zhangsheng] Fudan Univ, Peoples Hosp Shanghai 5, Dept Cardiol, Shanghai 200240, Peoples R China; [Zhang, Na] Univ Connecticut, Dept Genet & Genome Sci, Hlth Ctr, Farmington, CT 06030 USA; [Al-Hendy, Ayman] Univ Illinois, Coll Med, Dept Obstet & Gynecol, Chicago, IL 60612 USA; [Li, Da] China Med Univ, Shengjing Hosp, Dept Obstet & Gynecol, Ctr Reprod Med, Shenyang 110004, Liaoning, Peoples R China	Yale University; Sun Yat Sen University; Zhejiang University; Fudan University; University of Connecticut; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; China Medical University	Huang, YQ (corresponding author), Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, 333 Cedar St, New Haven, CT 06510 USA.; Li, D (corresponding author), China Med Univ, Shengjing Hosp, Dept Obstet & Gynecol, Ctr Reprod Med, Shenyang 110004, Liaoning, Peoples R China.	leeda@ymail.com; Yingqun.huang@yale.edu			Albert Mckern Scholar Award; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD000849] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001863] Funding Source: NIH RePORTER	Albert Mckern Scholar Award; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This work was supported by an Albert Mckern Scholar Award to YH.	Aissani B, 2015, INT J MOL EPIDEMIOL, V6, P9; Aissani B, 2015, FERTIL STERIL, V103, P528, DOI 10.1016/j.fertnstert.2014.10.025; Al-Hendy A, 2017, ENDOCRINOLOGY, V158, P592, DOI 10.1210/en.2016-1097; An J, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.5; Bogusiewicz M, 2012, HISTOL HISTOPATHOL, V27, P1495, DOI 10.14670/HH-27.1495; Borahay MA, 2015, MOL MED, V21, P242, DOI 10.2119/molmed.2014.00053; Carney SA, 2002, LAB INVEST, V82, P719, DOI 10.1097/01.LAB.0000017499.51216.3E; Chegini N, 2010, SEMIN REPROD MED, V28, P179, DOI 10.1055/s-0030-1251476; Fabian MR, 2012, NAT STRUCT MOL BIOL, V19, P586, DOI 10.1038/nsmb.2296; Gabory A, 2010, BIOESSAYS, V32, P473, DOI 10.1002/bies.200900170; Ghazal S, 2015, EMBO MOL MED, V7, P996, DOI 10.15252/emmm.201505245; Ishikawa H, 2010, ENDOCRINOLOGY, V151, P2433, DOI 10.1210/en.2009-1225; Islam MS, 2018, HUM REPROD UPDATE, V24, P59, DOI 10.1093/humupd/dmx032; Kallen AN, 2013, MOL CELL, V52, P101, DOI 10.1016/j.molcel.2013.08.027; Koh KP, 2011, CELL STEM CELL, V8, P200, DOI 10.1016/j.stem.2011.01.008; Laughlin SK, 2010, SEMIN REPROD MED, V28, P203, DOI 10.1055/s-0030-1251477; Lee YS, 2007, GENE DEV, V21, P1025, DOI 10.1101/gad.1540407; Liu RJ, 2013, CIRCULATION, V128, P2047, DOI 10.1161/CIRCULATIONAHA.113.002887; Lu QC, 2018, INFLAMMATION, V41, P896, DOI 10.1007/s10753-018-0744-4; Makinen N, 2011, SCIENCE, V334, P252, DOI 10.1126/science.1208930; Mayr C, 2007, SCIENCE, V315, P1576, DOI 10.1126/science.1137999; Mehine M, 2016, P NATL ACAD SCI USA, V113, P1315, DOI 10.1073/pnas.1518752113; Mehine M, 2014, FERTIL STERIL, V102, P621, DOI 10.1016/j.fertnstert.2014.06.050; Meng XM, 2016, NAT REV NEPHROL, V12, P325, DOI 10.1038/nrneph.2016.48; Mittal P, 2015, J CLIN INVEST, V125, P3280, DOI 10.1172/JCI81534; Murphy-Ullrich JE, 2018, MATRIX BIOL, V68-69, P28, DOI 10.1016/j.matbio.2017.12.009; Navarro A, 2014, J CLIN ENDOCR METAB, V99, pE2437, DOI 10.1210/jc.2014-2264; Philibert RA, 1999, HUM GENET, V105, P174, DOI 10.1007/s004390051084; Song YF, 2017, HEPATOLOGY, V66, P1183, DOI 10.1002/hep.29209; Stenina-Adognravi O, 2014, MATRIX BIOL, V37, P69, DOI 10.1016/j.matbio.2014.02.001; Stewart EA, 2015, NEW ENGL J MED, V372, P1646, DOI [10.1056/NEJMcp1411029, 10.1038/nrdp.2016.43]; Styer AK, 2016, BEST PRACT RES CL OB, V34, P3, DOI 10.1016/j.bpobgyn.2015.11.018; Wong SLI, 2017, BRIT J PHARMACOL, V174, P3, DOI 10.1111/bph.13653; Xie H, 2016, ONCOTARGET, V7, P51473, DOI 10.18632/oncotarget.10444; Yamashita S, 2008, CANCER RES, V68, P2112, DOI 10.1158/0008-5472.CAN-07-5282; Yan L, 2015, ONCOGENE, V34, P3076, DOI 10.1038/onc.2014.236; Zhong T, 2017, ONCOGENE, V36, P2345, DOI 10.1038/onc.2016.391; Zhou JC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10221; Zuckerwise L, 2016, ONCOTARGET, V7, P38398, DOI 10.18632/oncotarget.9534	39	33	37	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2019	38	27					5356	5366		10.1038/s41388-019-0808-4	http://dx.doi.org/10.1038/s41388-019-0808-4			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IG5KR	31089260	hybrid, Green Published			2022-12-28	WOS:000473842500002
J	Bu, L; Baba, H; Yoshida, N; Miyake, K; Yasuda, T; Uchihara, T; Tan, P; Ishimoto, T				Bu, Luke; Baba, Hideo; Yoshida, Naoya; Miyake, Keisuke; Yasuda, Tadahito; Uchihara, Tomoyuki; Tan, Patrick; Ishimoto, Takatsugu			Biological heterogeneity and versatility of cancer-associated fibroblasts in the tumor microenvironment	ONCOGENE			English	Review							CARCINOMA-ASSOCIATED FIBROBLASTS; EPITHELIAL-MESENCHYMAL TRANSITION; PANCREATIC STELLATE CELL; BREAST-CANCER; STROMAL FIBROBLASTS; GENE-EXPRESSION; ACTIVATION PROTEIN; COLON-CANCER; SERINE-PROTEASE; STEM-CELLS	Increasing lines of evidence show that the malignant behavior of cancer is not exclusively attributable to cancer cells but also radically influenced by cancerous stroma activity and controlled through various mechanisms by the microenvironment. In addition to structural components, such as the extracellular matrix, stromal cells, such as macrophages, endothelial cells, and specifically cancer-associated fibroblasts (CAFs), have attracted substantial attention over recent decades. CAFs provide routes for aggressive carcinomas and contribute to invasion and metastasis through the biochemical alteration and regulation of cancer-related pathways. However, another facet of CAFs that has been neglected by numerous studies is that CAFs might serve as a negative regulator of cancer progression under certain circumstances. The various origins of CAFs, the diverse tissues in which they reside and their interactions with different cancer cells appear to be responsible for this inconsistency. This review summarizes the latest knowledge regarding CAF heterogeneity and offers a novel perspective and a beneficial approach for obtaining an improved understanding of CAFs.	[Bu, Luke; Baba, Hideo; Yoshida, Naoya; Miyake, Keisuke; Yasuda, Tadahito; Uchihara, Tomoyuki; Ishimoto, Takatsugu] Kumamoto Univ, Grad Sch Life Sci, Dept Gastroenterol Surg, Kumamoto, Japan; [Bu, Luke; Miyake, Keisuke; Yasuda, Tadahito; Uchihara, Tomoyuki; Ishimoto, Takatsugu] Kumamoto Univ, Int Res Ctr Med Sci, Gastrointestinal Canc Biol, Kumamoto, Japan; [Tan, Patrick] Duke NUS Med Sch, Canc & Stem Cell Biol, Singapore, Singapore	Kumamoto University; Kumamoto University; National University of Singapore	Ishimoto, T (corresponding author), Kumamoto Univ, Grad Sch Life Sci, Dept Gastroenterol Surg, Kumamoto, Japan.; Ishimoto, T (corresponding author), Kumamoto Univ, Int Res Ctr Med Sci, Gastrointestinal Canc Biol, Kumamoto, Japan.	taka1516@kumamoto-u.ac.jp	Ishimoto, Takatsugu/AAP-1356-2020	Ishimoto, Takatsugu/0000-0003-1852-1835	Japan Society for the Promotion of Science KAKENHI [16H06257, 17K10639, 18K08543]	Japan Society for the Promotion of Science KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported, in part, by the Japan Society for the Promotion of Science KAKENHI (grant numbers 16H06257, 17K10639, and 18K08543).	Albrengues J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10204; Anderberg C, 2009, CANCER RES, V69, P369, DOI 10.1158/0008-5472.CAN-08-2724; Armulik A, 2011, DEV CELL, V21, P193, DOI 10.1016/j.devcel.2011.07.001; Augsten M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00062; Bauer M, 2010, ONCOGENE, V29, P1732, DOI 10.1038/onc.2009.463; Berdiel-Acer M, 2014, MOL ONCOL, V8, P1290, DOI 10.1016/j.molonc.2014.04.006; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Biffi G, 2019, CANCER DISCOV, V9, P282, DOI 10.1158/2159-8290.CD-18-0710; Bochet L, 2013, CANCER RES, V73, P5657, DOI 10.1158/0008-5472.CAN-13-0530; Boire A, 2005, CELL, V120, P303, DOI 10.1016/j.cell.2004.12.018; Brechbuhl HM, 2017, CLIN CANCER RES, V23, P1710, DOI 10.1158/1078-0432.CCR-15-2851; Calvo F, 2013, NAT CELL BIOL, V15, P637, DOI 10.1038/ncb2756; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; Chang HY, 2002, P NATL ACAD SCI USA, V99, P12877, DOI 10.1073/pnas.162488599; Chen WJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4472; Chen Y, 2017, ONCOGENE, V36, P4692, DOI 10.1038/onc.2017.100; Cheng F, 2016, P NATL ACAD SCI USA, V113, pE4320, DOI 10.1073/pnas.1519197113; Chronopoulos A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12630; Cirri P, 2011, AM J CANCER RES, V1, P482; Comito G, 2014, ONCOGENE, V33, P2423, DOI 10.1038/onc.2013.191; Costa A, 2018, CANCER CELL, V33, P463, DOI 10.1016/j.ccell.2018.01.011; Costea DE, 2013, CANCER RES, V73, P3888, DOI 10.1158/0008-5472.CAN-12-4150; De Wever O, 2004, FASEB J, V18, P1016, DOI 10.1096/fj.03-1110fje; De Wever O, 2008, INT J CANCER, V123, P2229, DOI 10.1002/ijc.23925; Driskell RR, 2013, NATURE, V504, P277, DOI 10.1038/nature12783; Enkelmann A, 2011, J CANCER RES CLIN, V137, P751, DOI 10.1007/s00432-010-0932-6; Erdogan B, 2017, J CELL BIOL, V216, P3799, DOI 10.1083/jcb.201704053; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Feig C, 2013, P NATL ACAD SCI USA, V110, P20212, DOI 10.1073/pnas.1320318110; Fiaschi T, 2012, CANCER RES, V72, P5130, DOI 10.1158/0008-5472.CAN-12-1949; Froeling FEM, 2011, GASTROENTEROLOGY, V141, P1486, DOI 10.1053/j.gastro.2011.06.047; Fuchigami T, 2014, BIOCHEM BIOPH RES CO, V451, P491, DOI 10.1016/j.bbrc.2014.07.137; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; GABBIANI G, 1971, EXPERIENTIA, V27, P549, DOI 10.1007/BF02147594; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Gardner H, 1996, DEV BIOL, V175, P301, DOI 10.1006/dbio.1996.0116; Gascard P, 2016, GENE DEV, V30, P1002, DOI 10.1101/gad.279737.116; Giulianelli S, 2008, INT J CANCER, V123, P2518, DOI 10.1002/ijc.23802; Goetz JG, 2011, CELL, V146, P148, DOI 10.1016/j.cell.2011.05.040; Guido C, 2012, CELL CYCLE, V11, P3019, DOI 10.4161/cc.21384; Ha SY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099955; Harper J, 2014, SEMIN CANCER BIOL, V25, P69, DOI 10.1016/j.semcancer.2013.12.005; Hasegawa T, 2014, INT J CANCER, V134, P1785, DOI 10.1002/ijc.28520; Hayashi Y, 2016, CARCINOGENESIS, V37, P972, DOI 10.1093/carcin/bgw085; Hinz B, 2001, MOL BIOL CELL, V12, P2730, DOI 10.1091/mbc.12.9.2730; Hosein AN, 2010, CANCER RES, V70, P5770, DOI 10.1158/0008-5472.CAN-10-0673; Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596; Hu YB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125625; Huber MA, 2003, J INVEST DERMATOL, V120, P182, DOI 10.1046/j.1523-1747.2003.12035.x; Ishii G, 2016, ADV DRUG DELIVER REV, V99, P186, DOI 10.1016/j.addr.2015.07.007; Ishimoto T, 2017, GASTROENTEROLOGY, V153, P191, DOI 10.1053/j.gastro.2017.03.046; Ishimoto T, 2016, INT J CANCER, V138, P1337, DOI 10.1002/ijc.29627; Izumi D, 2016, INT J CANCER, V138, P1207, DOI 10.1002/ijc.29864; Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8; Jung EJ, 2007, INT J CANCER, V120, P2331, DOI 10.1002/ijc.22434; Jung YH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2766; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Kawase A, 2008, INT J CANCER, V123, P1053, DOI 10.1002/ijc.23611; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kisselbach L, 2009, CYTOTECHNOLOGY, V59, P31, DOI 10.1007/s10616-009-9190-3; Kisseleva T, 2012, P NATL ACAD SCI USA, V109, P9448, DOI 10.1073/pnas.1201840109; Kraman M, 2010, SCIENCE, V330, P827, DOI 10.1126/science.1195300; Kuen J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182039; Labernadie A, 2017, NAT CELL BIOL, V19, P224, DOI 10.1038/ncb3478; Lawrenson K, 2015, INT J CANCER, V136, P1390, DOI 10.1002/ijc.29092; Li L, 2009, INT J CANCER, V125, P1796, DOI 10.1002/ijc.24463; Li P, 2015, CELL RES, V25, P588, DOI 10.1038/cr.2015.51; Li YY, 2018, EBIOMEDICINE, V36, P209, DOI 10.1016/j.ebiom.2018.09.006; Liao D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007965; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Lynch MD, 2018, J CLIN INVEST, V128, P26, DOI 10.1172/JCI93555; Marlow R, 2008, CANCER RES, V68, P7819, DOI 10.1158/0008-5472.CAN-08-1357; Matsumoto T, 2008, J CELL PHYSIOL, V215, P210, DOI 10.1002/jcp.21304; Murata T, 2011, CANCER RES, V71, P6633, DOI 10.1158/0008-5472.CAN-11-0034; Nakagawa H, 2004, ONCOGENE, V23, P7366, DOI 10.1038/sj.onc.1208013; Nardi F, 2018, J CELL SCI, V131, DOI 10.1242/jcs.213579; Neri S, 2015, INT J CANCER, V137, P784, DOI 10.1002/ijc.29464; Ohlund D, 2014, J EXP MED, V211, P1503, DOI 10.1084/jem.20140692; Osterreicher CH, 2011, P NATL ACAD SCI USA, V108, P308, DOI 10.1073/pnas.1017547108; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Olumi AF, 1999, CANCER RES, V59, P5002; Omary MB, 2007, J CLIN INVEST, V117, P50, DOI 10.1172/JCI30082; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Orimo A, 2006, CELL CYCLE, V5, P1597, DOI 10.4161/cc.5.15.3112; Ostermann E, 2008, CLIN CANCER RES, V14, P4584, DOI 10.1158/1078-0432.CCR-07-5211; Patel AK, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0087-x; Paulsson J, 2014, SEMIN CANCER BIOL, V25, P61, DOI 10.1016/j.semcancer.2014.02.006; Petersen OW, 2003, AM J PATHOL, V162, P391, DOI 10.1016/S0002-9440(10)63834-5; Pietras K, 2008, PLOS MED, V5, P123, DOI 10.1371/journal.pmed.0050019; Pietras K, 2010, EXP CELL RES, V316, P1324, DOI 10.1016/j.yexcr.2010.02.045; Prasad A, 2004, J BIOL CHEM, V279, P9115, DOI 10.1074/jbc.M308083200; Qin X, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-018-1604-0; Qiu W, 2008, NAT GENET, V40, P650, DOI 10.1038/ng.117; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Ramirez-Montagut T, 2004, ONCOGENE, V23, P5435, DOI 10.1038/sj.onc.1207730; Ranogajec I, 2012, MED ONCOL, V29, P561, DOI 10.1007/s12032-011-9984-y; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Richards KE, 2017, ONCOGENE, V36, P1770, DOI 10.1038/onc.2016.353; Rupp C, 2015, ONCOGENE, V34, P815, DOI 10.1038/onc.2014.18; Saito RA, 2010, CANCER RES, V70, P2644, DOI 10.1158/0008-5472.CAN-09-3644; Salem AF, 2012, CELL CYCLE, V11, P4167, DOI 10.4161/cc.22316; Sanz-Moreno V, 2011, CANCER CELL, V20, P229, DOI 10.1016/j.ccr.2011.06.018; SCHOR SL, 1986, INT J CANCER, V37, P831, DOI 10.1002/ijc.2910370606; Sherman MH, 2014, CELL, V159, P80, DOI 10.1016/j.cell.2014.08.007; Shyer AE, 2015, CELL, V161, P569, DOI 10.1016/j.cell.2015.03.041; STRUTZ F, 1995, NEPHROL DIAL TRANSPL, V10, P1504; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; Su SC, 2018, CELL, V172, P841, DOI 10.1016/j.cell.2018.01.009; TARIN D, 1969, J ANAT, V105, P189; Taylor DD, 2011, SEMIN IMMUNOPATHOL, V33, P441, DOI 10.1007/s00281-010-0234-8; Tran E, 2013, J EXP MED, V210, P1125, DOI 10.1084/jem.20130110; Trimboli AJ, 2009, NATURE, V461, P1084, DOI 10.1038/nature08486; True LD, 2010, MODERN PATHOL, V23, P1346, DOI 10.1038/modpathol.2010.122; Vered M, 2010, INT J CANCER, V127, P1356, DOI 10.1002/ijc.25358; Verghese ET, 2013, J PATHOL, V231, P388, DOI 10.1002/path.4248; VIRCHOW R, 1989, NUTR REV, V47, P23; Vizoso M, 2015, CARCINOGENESIS, V36, P1453, DOI 10.1093/carcin/bgv146; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Weber CE, 2015, ONCOGENE, V34, P4821, DOI 10.1038/onc.2014.410; Weigel MT, 2013, ANN ONCOL, V24, P126, DOI 10.1093/annonc/mds240; Witkiewicz AK, 2009, AM J PATHOL, V174, P2023, DOI 10.2353/ajpath.2009.080873; Yan W, 2018, NAT CELL BIOL, V20, P597, DOI 10.1038/s41556-018-0083-6; Ye F, 2008, CANCER INVEST, V26, P569, DOI 10.1080/07357900701837044; Yeung CLA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11150; Yin CY, 2013, J CLIN INVEST, V123, P1902, DOI 10.1172/JCI66369; Yu T, 2017, ONCOGENE, V36, P2131, DOI 10.1038/onc.2016.370; Yu Y, 2014, BRIT J CANCER, V110, P724, DOI 10.1038/bjc.2013.768; Zeisberg EM, 2007, CANCER RES, V67, P10123, DOI 10.1158/0008-5472.CAN-07-3127; Zhang AB, 2017, CANCER MED-US, V6, P463, DOI 10.1002/cam4.993; Zhao LY, 2012, INT J BIOCHEM CELL B, V44, P2051, DOI 10.1016/j.biocel.2012.08.005; Zhao XL, 2017, J PATHOL, V243, P376, DOI 10.1002/path.4958	132	128	135	5	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2019	38	25					4887	4901		10.1038/s41388-019-0765-y	http://dx.doi.org/10.1038/s41388-019-0765-y			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IE1KY	30816343				2022-12-28	WOS:000472145900001
J	Kim, AR; Choi, KW				Kim, Ah-Ram; Choi, Kwang-Wook			TRiC/CCT chaperonins are essential for organ growth by interacting with insulin/TOR signaling in Drosophila	ONCOGENE			English	Article							EUKARYOTIC CHAPERONIN; CELLULAR GROWTH; CCT CHAPERONIN; IN-VIVO; COMPLEX; PROTEINS; BIOGENESIS; ACTIVATION; EXPRESSION; AUTOPHAGY	Organ size is regulated by intercellular signaling for cell growth and proliferation. The TOR pathway mediates a key signaling mechanism for controlling cell size and number in organ growth. Chaperonin containing TCP-1 (CCT) is a complex that assists protein folding and function, but its role in animal development is largely unknown. Here we show that the CCT complex is required for organ growth by interacting with the TOR pathway in Drosophila. Reduction of CCT4 results in growth defects by affecting both cell size and proliferation. Loss of CCT4 causes preferential cell death anterior to the morphogenetic furrow in the eye disc and within wing pouch in the wing disc. Depletion of any CCT subunit in the eye disc results in headless phenotype. Overgrowth by active TOR signaling is suppressed by CCT RNAi. The CCT complex physically interacts with TOR signaling components including TOR, Rheb, and S6K. Loss of CCT leads to decreased phosphorylation of S6K and S6 while increasing phosphorylation of Akt. Insulin/TOR signaling is also necessary and sufficient for promoting CCT complex transcription. Our data provide evidence that the CCT complex regulates organ growth by directly interacting with the TOR signaling pathway.	[Kim, Ah-Ram; Choi, Kwang-Wook] Korea Adv Inst Sci & Technol, Dept Biol Sci, Daejeon 305701, South Korea; [Kim, Ah-Ram] Harvard Med Sch, Dept Genet, Boston, MA 02115 USA	Korea Advanced Institute of Science & Technology (KAIST); Harvard University; Harvard Medical School	Choi, KW (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Daejeon 305701, South Korea.	kchoi100@kaist.ac.kr	Choi, Kwang-Wook/C-1707-2011	Choi, Kwang-Wook/0000-0002-8997-3065; Kim, Ah-Ram/0000-0001-9597-6759	National Research Foundation of Korea - Ministry of Education, Science & Technology, Republic of Korea [NRF-2014K1A1A2042982, NRF-2017R1A2B3007516]	National Research Foundation of Korea - Ministry of Education, Science & Technology, Republic of Korea	We are grateful to Kyungok Cho, Jongkyeong Chung, Aurelio Teleman, Gabor Juhasz, Norbert Perrimon, the Bloomington Drosophila Stock Center, the National Institute of Genetics, the the Vienna Drosophila Resource Center, the Kyoto Stock Center, the Drosophila Genomics Resource Center, and the Developmental Studies Hybridoma Bank for reagents and fly stocks. We also thank Jean Jung for commenting on the manuscript. This research was supported by grants (NRF-2014K1A1A2042982 and NRF-2017R1A2B3007516) of the National Research Foundation of Korea funded by the Ministry of Education, Science & Technology, Republic of Korea.	Abe Y, 2009, J BIOL CHEM, V284, P14939, DOI 10.1074/jbc.M900097200; Antonova SV, 2018, NAT STRUCT MOL BIOL, V25, P1119, DOI 10.1038/s41594-018-0156-z; Bassiouni R, 2016, CLIN CANCER RES, V22, P4366, DOI 10.1158/1078-0432.CCR-15-2502; Bateman JR, 2006, GENETICS, V173, P769, DOI 10.1534/genetics.106.056945; Berger J, 2018, CELL REP, V22, P313, DOI 10.1016/j.celrep.2017.12.069; Boudiaf-Benmammar C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060895; Edgar BA, 2006, CELL, V124, P267, DOI 10.1016/j.cell.2006.01.005; Feldman DE, 1999, MOL CELL, V4, P1051, DOI 10.1016/S1097-2765(00)80233-6; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hodeify R, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aau1935; Housden BE, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aab3729; Hsu YC, 2007, NATURE, V445, P785, DOI 10.1038/nature05528; Hu YH, 2013, G3-GENES GENOM GENET, V3, P1607, DOI 10.1534/g3.113.007021; Jaeger K, 2019, APOPTOSIS, V24, P62, DOI 10.1007/s10495-018-1505-4; Jeong JY, 2012, APPL ENVIRON MICROB, V78, P5440, DOI 10.1128/AEM.00844-12; Kaisari S, 2017, P NATL ACAD SCI USA, V114, P956, DOI 10.1073/pnas.1620451114; Karim FD, 1998, DEVELOPMENT, V125, P1; Kim W, 2017, DEV CELL, V42, P363, DOI 10.1016/j.devcel.2017.07.020; Kockel L, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000990; Le TP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11501; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; Liu XQ, 2005, MOL CELL BIOL, V25, P4993, DOI 10.1128/MCB.25.12.4993-5010.2005; Liu YG, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.460; Lundin VF, 2008, DEV BIOL, V313, P320, DOI 10.1016/j.ydbio.2007.10.022; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Nagy P, 2014, AUTOPHAGY, V10, P453, DOI 10.4161/auto.27442; Noormohammadi A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13649; Pavel M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13821; Prober DA, 2000, CELL, V100, P435, DOI 10.1016/S0092-8674(00)80679-0; Raineri E, 2010, BIOINFORMATICS, V26, P1685, DOI 10.1093/bioinformatics/btq287; Ramadan N, 2007, NAT PROTOC, V2, P2245, DOI 10.1038/nprot.2007.250; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; Reiling JH, 2006, ONCOGENE, V25, P6373, DOI 10.1038/sj.onc.1209889; Roh SH, 2015, INT J MOL SCI, V16, P26706, DOI 10.3390/ijms161125975; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.03.035, 10.1016/j.cell.2017.02.004]; Seo S, 2010, P NATL ACAD SCI USA, V107, P1488, DOI 10.1073/pnas.0910268107; Spiess C, 2004, TRENDS CELL BIOL, V14, P598, DOI 10.1016/j.tcb.2004.09.015; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Stoldt V, 1996, YEAST, V12, P523, DOI 10.1002/(SICI)1097-0061(199605)12:6<523::AID-YEA962>3.3.CO;2-3; Stowers RS, 1999, GENETICS, V152, P1631; Svanstrom A, 2016, CELL STRESS CHAPERON, V21, P55, DOI 10.1007/s12192-015-0637-5; Tang HW, 2018, CELL METAB, V27, P1040, DOI 10.1016/j.cmet.2018.02.023; Trinidad AG, 2013, MOL CELL, V50, P805, DOI 10.1016/j.molcel.2013.05.002; Tsokanos FF, 2016, EMBO J, V35, P1058, DOI 10.15252/embj.201593118; Vinayagam A, 2016, CELL REP, V16, P3062, DOI 10.1016/j.celrep.2016.08.029; Wells CA, 2006, J BIOL CHEM, V281, P20221, DOI 10.1074/jbc.M602409200; White MF, 2003, SCIENCE, V302, P1710, DOI 10.1126/science.1092952; Won KA, 1998, MOL CELL BIOL, V18, P7584, DOI 10.1128/MCB.18.12.7584; Yam AY, 2008, NAT STRUCT MOL BIOL, V15, P1255, DOI 10.1038/nsmb.1515; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000	51	13	13	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2019	38	24					4739	4754		10.1038/s41388-019-0754-1	http://dx.doi.org/10.1038/s41388-019-0754-1			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IC7ND	30792539	Green Published, hybrid			2022-12-28	WOS:000471160500007
J	Zhao, YF; Qiao, SP; Hou, XL; Tian, H; Deng, S; Ye, KR; Nie, YZ; Chen, XB; Yan, HJ; Tian, WM				Zhao, Yufang; Qiao, Shupei; Hou, Xiaolu; Tian, Hui; Deng, Shuai; Ye, Kangruo; Nie, Yongzhan; Chen, Xiongbiao; Yan, Hongji; Tian, Weiming			Bioengineered tumor microenvironments with naked mole rats high-molecular-weight hyaluronan induces apoptosis in breast cancer cells	ONCOGENE			English	Article							CD44; RESISTANCE; HAS2; P53; INVASION; GROWTH	The naked mole rat (nmr) is cancer resistant due to the abundant production of extremely high-molecular-weight hyaluronan (EHMW-HA). However, whether EHMW-HA has similar anti-cancer effects in mice and humans remains to be determined. The present study used breast cancer cells to clarify the effect of EHMW-HA on breast cancer. First, the overexpression of nmrHas2 in 4T1 and BT549 cell lines in both two-dimensional (2D) and three-dimensional (3D) models to mimic tumor microenvironment was established. The 4T1/BT549-nmrHas2 cells could secrete EHMW-HA (with a molecular weight of up to 6 MDa), which was similar to that found in the naked mole rat. Second, EHMW-HA altering tumor microenvironment in both 2D monolayers and 3D spheroids significantly enhanced apoptosis, inhibiting the proliferation of 4T1 and BT549 cells. The prominent anticancer effects of EHMW-HA on the cancer-cell apoptosis phenotype were further confirmed by inhibiting tumor formation in nude mice. Finally, EHMW-HA significantly induced higher p53 protein expression, which enhanced pro-apoptotic proteins p21 and Bax in breast cancer cells; this is in contrast with the triggering of hypersensitivity of the naked mole rat cells to early contact inhibition (ECI). These results have important implications for the design of therapeutic approaches based on the application of EHMW-HA.	[Zhao, Yufang; Qiao, Shupei; Hou, Xiaolu; Tian, Hui; Deng, Shuai; Ye, Kangruo; Tian, Weiming] Harbin Inst Technol, Sch Life Sci & Technol, Harbin 150080, Heilongjiang, Peoples R China; [Zhao, Yufang] Harbin Inst Technol, Res Ctr Basic Space Sci, Space Environm Stimulat & Res Interface, Harbin 150080, Heilongjiang, Peoples R China; [Nie, Yongzhan] Fourth Mil Med Univ, State Key Lab Canc Biol, Harbin 150080, Heilongjiang, Peoples R China; [Nie, Yongzhan] Fourth Mil Med Univ, Xijing Hosp Digest Dis, Harbin 150080, Heilongjiang, Peoples R China; [Chen, Xiongbiao] Univ Saskatchewan, Dept Mech Engn, Saskatoon, SK S7N 5A2, Canada; [Yan, Hongji] AlbaNova Univ Ctr, Sch Engn Sci Chem Biotechnol & Hlth, KTHRoyal Inst Technol, Dept Chem,Div Glycosci, S-10691 Stockholm, Sweden	Harbin Institute of Technology; Harbin Institute of Technology; Air Force Military Medical University; Air Force Military Medical University; University of Saskatchewan; Royal Institute of Technology	Tian, WM (corresponding author), Harbin Inst Technol, Sch Life Sci & Technol, Harbin 150080, Heilongjiang, Peoples R China.	tianweiming@hit.edu.cn	Yan, Hongji/AAL-7040-2021	Tian, Weiming/0000-0003-4958-4118; DENG, Shuai/0000-0001-7622-2097; Chen, Xiongbiao (Daniel)/0000-0002-4716-549X; /0000-0001-7257-5522	National Natural Science Foundation of China [51773050, 81770923]; Opening Foundation of the State Key Laboratory of Cancer Biology [CBSKL201106]; Heilongjiang Postdoctoral Fund [LBH-Z18068]; China Postdoctoral Science Foundation [2018M641837]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Opening Foundation of the State Key Laboratory of Cancer Biology; Heilongjiang Postdoctoral Fund; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This research was supported by the National Natural Science Foundation of China (Grant No.: 51773050 and 81770923), the Opening Foundation of the State Key Laboratory of Cancer Biology (CBSKL201106), and the author was supported by the Heilongjiang Postdoctoral Fund (No. LBH-Z18068) and a general financial grant from the China Postdoctoral Science Foundation (No. 2018M641837).	Beasley KL, 2009, FACIAL PLAST SURG, V25, P86, DOI 10.1055/s-0029-1220647; Bernert B, 2011, J BIOL CHEM, V286, P42349, DOI 10.1074/jbc.M111.278598; Brown TJ, 2008, CURR PHARM BIOTECHNO, V9, P253, DOI 10.2174/138920108785161514; Carvalho MP, 2016, CARBOHYD POLYM, V150, P139, DOI 10.1016/j.carbpol.2016.05.005; COOPER EH, 1988, BRIT J CANCER, V58, P668, DOI 10.1038/bjc.1988.283; Fuchs K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.364; Gao F, 2008, CLIN INVEST MED, V31, pE106, DOI 10.25011/cim.v31i3.3467; Gao F, 2010, MATRIX BIOL, V29, P107, DOI 10.1016/j.matbio.2009.11.002; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GILLI R, 1994, CARBOHYD RES, V263, P315, DOI 10.1016/0008-6215(94)00147-2; Giorgio M, 2005, CELL, V122, P221, DOI 10.1016/j.cell.2005.05.011; Godar S, 2008, CELL, V134, P62, DOI 10.1016/j.cell.2008.06.006; Goldsworthy TL, 1996, MUTAT RES-REV GENET, V365, P71, DOI 10.1016/S0165-1110(96)90013-5; Heldin P, 2013, J BIOCHEM, V154, P395, DOI 10.1093/jb/mvt085; Huang Z, 2014, INFLAMM CELL SIGNAL, V1; Karbownik MS, 2013, PHARMACOL REP, V65, P1056, DOI 10.1016/S1734-1140(13)71465-8; Kultti Anne, 2012, Cancers (Basel), V4, P873, DOI 10.3390/cancers4030873; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LAURENT TC, 1995, ANN RHEUM DIS, V54, P429, DOI 10.1136/ard.54.5.429; Lee YJ, 2016, ACTA PHARMACOL SIN, V37, P664, DOI 10.1038/aps.2015.151; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Louderbough JMV, 2011, MOL CANCER RES, V9, P1573, DOI 10.1158/1541-7786.MCR-11-0156; Masters KS, 2005, BIOMATERIALS, V26, P2517, DOI 10.1016/j.biomaterials.2004.07.018; Mirzayans R, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/170325; Miyawaki S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11471; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Nikitovic D, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/929531; Okuda H, 2012, CANCER RES, V72, P537, DOI 10.1158/0008-5472.CAN-11-1678; Pampaloni F, 2007, NAT REV MOL CELL BIO, V8, P839, DOI 10.1038/nrm2236; Park TJ, 2017, SCIENCE, V356, P305, DOI 10.1126/science.aab3896; Rayahin JE, 2015, ACS BIOMATER SCI ENG, V1, P481, DOI 10.1021/acsbiomaterials.5b00181; Rowley JA, 1999, BIOMATERIALS, V20, P45, DOI 10.1016/S0142-9612(98)00107-0; Seluanov A, 2018, NAT REV CANCER, V18, P433, DOI 10.1038/s41568-018-0004-9; Seluanov A, 2009, P NATL ACAD SCI USA, V106, P19352, DOI 10.1073/pnas.0905252106; Song YK, 2002, AM J PATHOL, V160, P1069, DOI 10.1016/S0002-9440(10)64927-9; Thanos CD, 2016, NOVEL IMMUNOTHERAPEU, P249; Tian X, 2015, P NATL ACAD SCI USA, V112, P1053, DOI 10.1073/pnas.1418203112; Tian X, 2013, NATURE, V499, P346, DOI 10.1038/nature12234; Udabage L, 2005, EXP CELL RES, V310, P205, DOI 10.1016/j.yexcr.2005.07.026; Wu M, 2015, FASEB J, V29, P1290, DOI 10.1096/fj.14-259978; Yang CX, 2012, J BIOL CHEM, V287, P43094, DOI 10.1074/jbc.M112.349209; Zhao Y, 2018, P NATL ACAD SCI USA, V115, P1801, DOI 10.1073/pnas.1721160115; Zhao YF, 2017, ACS APPL MATER INTER, V9, P9327, DOI 10.1021/acsami.6b15187	43	13	14	1	72	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2019	38	22					4297	4309		10.1038/s41388-019-0719-4	http://dx.doi.org/10.1038/s41388-019-0719-4			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IA1RB	30700830				2022-12-28	WOS:000469339100007
J	Wang, DW; Xu, QQ; Yuan, Q; Jia, MQ; Niu, HM; Liu, XF; Zhang, JS; Young, CY; Yuan, HQ				Wang, Dawei; Xu, Qingqing; Yuan, Quan; Jia, Mengqi; Niu, Huanmin; Liu, Xiaofei; Zhang, Jinsan; Young, Charles Yf; Yuan, Huiqing			Proteasome inhibition boosts autophagic degradation of ubiquitinated-AGR2 and enhances the antitumor efficiency of bevacizumab	ONCOGENE			English	Article							PRO-METASTATIC PROTEIN; ANTERIOR GRADIENT 2; SELECTIVE AUTOPHAGY; CANCER; AGR2; EXPRESSION; BORTEZOMIB; RECEPTOR; GENES; COMBINATION	Anterior gradient 2 (AGR2), a protein belonging to the protein disulfide isomerase (PDI) family, is overexpressed in multiple cancers and promotes angiogenesis to drive cancer progression. The mechanisms controlling AGR2 abundance in cancer remain largely unknown. Here, we observed that AGR2 expression is significantly suppressed by proteasome inhibitor MG132/bortezomib at mRNA and protein levels in lung cancer cells. MG132-mediated repression of AGR2 transcription was independent of ROS generation and ER stress induction, but partially resulted from the downregulated E2F1. Further investigation revealed that MG132 facilitated polyubiquitinated AGR2 degradation through activation of autophagy, as evidenced by predominant restoration of AGR2 level in cells genetic depletion of Atg5 and Atg7, or by autophagy inhibitors. Activation of autophagy by rapamycin noticeably reduced the AGR2 protein in cells and in the mouse tissue samples administrated with bortezomib. We also provided evidence identifying the K48-linked polyubiquitin chains conjugating onto K89 of AGR2 by an E3 ligase UBR5. In addition, an autophagy receptor NBR1 was demonstrated to be important in polyubiquitinated AGR2 clearance in response to MG132 or bortezomib. Importantly, downregulation of AGR2 by proteasome inhibition significantly enhanced antitumor activity of bevacizumab, highlighting the importance of AGR2 as a predictive marker for selection of subgroup patients in chemotherapy.	[Wang, Dawei; Xu, Qingqing; Yuan, Quan; Jia, Mengqi; Niu, Huanmin; Liu, Xiaofei; Yuan, Huiqing] Shandong Univ, Hosp 2, Inst Med Sci, Key Lab Expt Teratol,Minist Educ, Jinan, Shandong, Peoples R China; [Zhang, Jinsan; Young, Charles Yf] Mayo Clin, Coll Med, Dept Urol, Rochester, MN USA	Shandong University; Mayo Clinic	Yuan, HQ (corresponding author), Shandong Univ, Hosp 2, Inst Med Sci, Key Lab Expt Teratol,Minist Educ, Jinan, Shandong, Peoples R China.	lyuanhq@sdu.edu.cn		Xu, Qingqing/0000-0002-7703-5872	973 Program [2013CB910900]; National Natural Science Foundation of China [81473238, 81872896]; Shandong key innovative research program [2018CXGC1216]	973 Program(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shandong key innovative research program	We would like to thank Professor Srikumar P. Chellappan for kindly providing the plasmid of E2F1, Professor Xuejun Jiang for the gift of GFP-LC3B construct, and Professor Chengjiang Gao for the gift of HA-K48, HA-63, HA-K48R, and HA-63R plasmids (Department of Immunology, School of Medicine of Shandong University, China). This work was supported by 973 Program (2013CB910900), the National Natural Science Foundation of China (81473238, 81872896), and Shandong key innovative research program (2018CXGC1216).	Bu H, 2013, FEBS J, V280, P1249, DOI 10.1111/febs.12118; Chevet E, 2013, ONCOGENE, V32, P2499, DOI 10.1038/onc.2012.346; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Chung Kyukwang, 2012, Osaka City Med J, V58, P13; Dasgupta P, 2011, JNCI-J NATL CANCER I, V103, P317, DOI 10.1093/jnci/djq541; Fritzsche FR, 2007, HISTOL HISTOPATHOL, V22, P703, DOI 10.14670/HH-22.703; Gao ZH, 2010, AUTOPHAGY, V6, P126, DOI 10.4161/auto.6.1.10928; Ge PF, 2009, ACTA PHARMACOL SIN, V30, P1046, DOI 10.1038/aps.2009.71; Grice GL, 2016, CELL MOL LIFE SCI, V73, P3497, DOI 10.1007/s00018-016-2255-5; Guo H, 2017, ONCOGENE, V36, P5098, DOI 10.1038/onc.2017.132; Guo YY, 2017, J NEUROSCI, V37, P5978, DOI 10.1523/JNEUROSCI.3148-16.2017; Hengel SM, 2011, J PROTEOME RES, V10, P4567, DOI 10.1021/pr2004117; Hideshima T, 2005, P NATL ACAD SCI USA, V102, P8567, DOI 10.1073/pnas.0503221102; Higa A, 2011, J BIOL CHEM, V286, P44855, DOI 10.1074/jbc.M111.275529; Hrstka R, 2010, ONCOGENE, V29, P4838, DOI 10.1038/onc.2010.228; Hu ZY, 2012, CARCINOGENESIS, V33, P1178, DOI 10.1093/carcin/bgs141; Ichimura Y, 2008, J BIOL CHEM, V283, P22847, DOI 10.1074/jbc.M802182200; Jia MQ, 2018, BBA-MOL BASIS DIS, V1864, P1622, DOI 10.1016/j.bbadis.2018.01.021; Kawaguchi T, 2011, INT J ONCOL, V38, P643, DOI 10.3892/ijo.2010.882; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Khaminets A, 2016, TRENDS CELL BIOL, V26, P6, DOI 10.1016/j.tcb.2015.08.010; Kraft C, 2010, NAT CELL BIOL, V12, P836, DOI 10.1038/ncb0910-836; Krig SR, 2007, J BIOL CHEM, V282, P9703, DOI 10.1074/jbc.M611752200; Li SR, 2012, DEVELOPMENT, V139, P2500, DOI 10.1242/dev.079699; Lim JH, 2004, BIOCHEM BIOPH RES CO, V318, P868, DOI 10.1016/j.bbrc.2004.04.103; Lin HK, 2002, J BIOL CHEM, V277, P36570, DOI 10.1074/jbc.M204751200; Liu ZZ, 2014, CANCER CELL, V26, P106, DOI 10.1016/j.ccr.2014.05.015; Mancias JD, 2016, J MOL BIOL, V428, P1659, DOI 10.1016/j.jmb.2016.02.027; Nakajima S, 2011, FEBS LETT, V585, P2249, DOI 10.1016/j.febslet.2011.05.047; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Piperdi B, 2012, J THORAC ONCOL, V7, P1032, DOI 10.1097/JTO.0b013e31824de2fa; Pohler E, 2004, MOL CELL PROTEOMICS, V3, P534, DOI 10.1074/mcp.M300089-MCP200; Tang CH, 2014, BBA-GENE REGUL MECH, V1839, P425, DOI 10.1016/j.bbagrm.2014.04.017; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Thompson DA, 1998, BIOCHEM BIOPH RES CO, V251, P111, DOI 10.1006/bbrc.1998.9440; Vanderlaag KE, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2586; Wang XJ, 2013, AUTOPHAGY, V9, P1500, DOI 10.4161/auto.25573; Waters S, 2009, FEBS LETT, V583, P1846, DOI 10.1016/j.febslet.2009.04.049; White D, 2013, CANCER-AM CANCER SOC, V119, P339, DOI 10.1002/cncr.27745; Wu WKK, 2008, BIOCHEM BIOPH RES CO, V374, P258, DOI 10.1016/j.bbrc.2008.07.031; Yu HX, 2012, MOL BIOSYST, V8, P2710, DOI 10.1039/c2mb25160d; Yuan C, 2012, J BIOL CHEM, V287, P17006, DOI 10.1074/jbc.M112.341198; Zhao LL, 2009, CANCER RES, V69, P7696, DOI 10.1158/0008-5472.CAN-08-4901; 2014, J BIOL CHEM, V289, P1389, DOI DOI 10.1074/JBC.M114.555441; 2011, J BIOL CHEM, V286, P1830, DOI DOI 10.1074/JBC.M110.215707; 2011, CANCER RES, V71, P7091, DOI DOI 10.1158/0008-5472.CAN-11-1367	46	35	35	3	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2019	38	18					3458	3474		10.1038/s41388-019-0675-z	http://dx.doi.org/10.1038/s41388-019-0675-z			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HW3RI	30647455	hybrid, Green Published			2022-12-28	WOS:000466610000010
J	Zhao, XY; Reebye, V; Hitchen, P; Fan, J; Jiang, HC; Saetrom, P; Rossi, J; Habib, NA; Huang, KW				Zhao, Xiaoyang; Reebye, Vikash; Hitchen, Paul; Fan, Jia; Jiang, Hongchi; Saetrom, Pal; Rossi, John; Habib, Nagy. A.; Huang, Kai-Wen			Mechanisms involved in the activation of C/EBP alpha by small activating RNA in hepatocellular carcinoma	ONCOGENE			English	Article							CELL-CYCLE; BINDING; PROTEIN; BETA; EXPRESSION; CEBPA; REPRESSION; P21; LIP	Hepatocellular carcinoma (HCC) is generally accompanied by high mortality and low cure rate. CCAAT enhancer-binding proteins (CEBPs) are transcriptional regulators that play a key role in maintaining liver function. Altered expression of C/EBP alpha and C/EBP beta occurs in many tumours including HCC. saRNAs are small double-stranded RNAs that enhance target gene expression at the transcriptional level. In this report, we activate CEPBA with saRNAs and suppress CEBPB with siRNAs in cells that represent three different degrees of HCC. We performed functional assays to investigate the effects of enhancing C/EBP alpha and its downstream targets, p21 and albumin across these lines. We also used Mass-spectrometry (MS) subsequent to a ChIP pull-down assay to characterise the components of the protein complex involved in regulating saRNA function. Putative saRNA interacting protein candidates that were identified by MS were knocked-down with siRNAs to investigate its impact on saRNA activity. We confirmed CEBPA-saRNA decreased proliferation and migration in the differentiated lines (HepG3/Hep3B). The undifferentiated line (PLCPRF5) showed saRNA-induced increase in CEBPA but with no loss in proliferation. This effect was reversed when CEBPB was suppressed with CEBPB-siRNA. When interrogating saRNA mode of action; three saRNA interacting proteins, CTR9, HnRNPA2/B1 and DDX5 were identified by MS. Targeted knock-down of these two proteins (by siRNA) abrogated saRNA activity. This study provides insight into how different HCC lines are affected by CEBPA-saRNAs and that endogenous abundance of CEBPB and saRNA accessory proteins may dictate efficacy of CEBPA-saRNA when used in a therapeutic context.	[Zhao, Xiaoyang; Reebye, Vikash; Habib, Nagy. A.] Imperial Coll London, Dept Surg & Canc, Hammersmith Hosp, HPB Surg Unit, London W12 0HS, England; [Zhao, Xiaoyang; Fan, Jia] Fudan Univ, Zhongshan Hosp, Dept Surg, Shanghai 200032, Peoples R China; [Zhao, Xiaoyang; Jiang, Hongchi] Harbin Med Univ, Affiliated Hosp 1, Dept Gen Surg, Harbin 150001, Heilongjiang, Peoples R China; [Hitchen, Paul] Imperial Coll London, Dept Life Sci, London SW7 2AZ, England; [Saetrom, Pal] Norwegian Univ Sci & Technol, Dept Canc Res & Mol Med, NO-7489 Trondheim, Norway; [Saetrom, Pal] Norwegian Univ Sci & Technol, Dept Comp Sci, NO-7489 Trondheim, Norway; [Rossi, John] City Hope Natl Med Ctr, Beckman Res Inst, Div Mol Biol, Duarte, CA 91010 USA; [Huang, Kai-Wen] Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan; [Huang, Kai-Wen] Natl Taiwan Univ Hosp, Hepatitis Res Ctr, Taipei, Taiwan; [Huang, Kai-Wen] Natl Taiwan Univ, Grad Inst Clin Med, Taipei, Taiwan	Imperial College London; Fudan University; Harbin Medical University; Imperial College London; Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); City of Hope; Beckman Research Institute of City of Hope; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Huang, KW (corresponding author), Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan.; Huang, KW (corresponding author), Natl Taiwan Univ Hosp, Hepatitis Res Ctr, Taipei, Taiwan.; Huang, KW (corresponding author), Natl Taiwan Univ, Grad Inst Clin Med, Taipei, Taiwan.	skywing@ntuh.gov.tw	Sætrom, Pål/AAH-1216-2019	Sætrom, Pål/0000-0001-8142-7441; HUANG, KAI-WEN/0000-0001-6375-8714	National Taiwan University Hospital and Imperial College London	National Taiwan University Hospital and Imperial College London	This work was funded by National Taiwan University Hospital and Imperial College London.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Begay V, 2015, J MOL MED, V93, P39, DOI 10.1007/s00109-014-1215-5; Bertran E, 2013, HEPATOLOGY, V58, P2032, DOI 10.1002/hep.26597; Burgess-Beusse BL, 1999, HEPATOLOGY, V29, P597, DOI 10.1002/hep.510290245; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Huan HB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153117; Jakobsen JS, 2013, GENOME RES, V23, P592, DOI 10.1101/gr.146399.112; Kuttippurathu L, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2492-x; LOPEZCABRERA M, 1991, VIROLOGY, V183, P825, DOI 10.1016/0042-6822(91)91019-D; Lourenco AR, 2017, ONCOGENE, V14, P1; Luedde T, 2004, HEPATOLOGY, V40, P356, DOI 10.1002/hep.20333; Ohkoshi S, 2015, WORLD J GASTROENTERO, V21, P12150, DOI 10.3748/wjg.v21.i42.12150; Pabst T, 2009, CLIN CANCER RES, V15, P5303, DOI 10.1158/1078-0432.CCR-08-2941; Portnoy V, 2016, CELL RES, V26, P320, DOI 10.1038/cr.2016.22; Reebye V, 2018, ONCOGENE, V37, P3216, DOI 10.1038/s41388-018-0126-2; Reebye V, 2014, HEPATOLOGY, V59, P216, DOI 10.1002/hep.26669; Tomizawa M, 2002, INT J MOL MED, V9, P597; van der Krieken SE, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/324815; Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179; Voutila J, 2017, MOL THER, V25, P2705, DOI 10.1016/j.ymthe.2017.07.018; Welm AL, 2000, J BIOL CHEM, V275, P27406; Xu L, 2001, CANCER RES, V61, P3176; ZHOU DX, 1991, J BIOL CHEM, V266, P23416; Zuo Y, 2006, J BIOL CHEM, V281, P7960, DOI 10.1074/jbc.M510682200	25	21	21	3	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2019	38	18					3446	3457		10.1038/s41388-018-0665-6	http://dx.doi.org/10.1038/s41388-018-0665-6			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HW3RI	30643190				2022-12-28	WOS:000466610000009
J	Zhou, HY; Yu, CL; Kong, LM; Xu, XL; Yan, JM; Li, YC; An, T; Gong, L; Gong, YX; Zhu, HF; Zhang, HB; Yang, XD; Li, Y				Zhou, Hongyu; Yu, Chunlei; Kong, Lingmei; Xu, Xiaoliang; Yan, Juming; Li, Yingchao; An, Tao; Gong, Liang; Gong, Yaxiao; Zhu, Huifang; Zhang, Hongbin; Yang, Xiaodong; Li, Yan			B591, a novel specific pan-PI3K inhibitor, preferentially targets cancer stem cells	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; IN-VITRO PROPAGATION; MTOR; ACTIVATION; PATHWAY; IDENTIFICATION; EXPRESSION; VIABILITY; RECEPTOR; GROWTH	Cancer stem cells (CSCs) have been implicated in metastasis, relapse, and therapeutic resistance of cancer, so successful cancer therapy may therefore require the development of drugs against CSCs or combining anti-CSCs drugs with conventional therapies. The phosphoinositide 3-kinase (PI3K) signaling pathway is one of the most frequently activated signaling pathways in human cancer, playing a central role in tumorigenesis as well as the maintenance of CSCs. Here, we designed and identified B591, a dihydrobenzofuran-imidazolium salt, as a novel specific pan-PI3K inhibitor with potent inhibitory activity against class I PI3K isoforms, which showed effective inhibition of cellular PI3K/mTOR signaling pathway and robust antitumor activity in a set of cancer cell lines. Notably, compared with bulk tumor cell populations, B591 exhibited more potency in suppressing CSCs survival and inducing CSCs apoptosis, and presence of B591 effectively eliminated paclitaxel-enriched CSCs. B591 diminished self-renewal capacity and decreased the expression of epithelial-mesenchymal transition (EMT) markers of CSCs. In vivo, B591 preferentially decreased CSCs levels in mouse xenograft model of human breast cancer as evidenced especially by remarkable reduction of tumor-initiating ability. Consistent with the preferential targeting of CSCs, B591 effectively inhibited breast tumor metastasis and delayed tumor regrowth following paclitaxel treatment. Taken together, our findings establish B591, a novel PI3K inhibitor, as a strong candidate for clinical evaluation as a CSCs targeting agent.	[Zhou, Hongyu; Yu, Chunlei; Kong, Lingmei; Yan, Juming; An, Tao; Gong, Liang; Gong, Yaxiao; Zhu, Huifang; Li, Yan] Chinese Acad Sci, Kunming Inst Bot, State Key Lab Phytochem & Plant Resources West Ch, Kunming, Yunnan, Peoples R China; [Yu, Chunlei] North Sichuan Med Coll, Sch Pharm, Inst Mat Med, Nanchong, Peoples R China; [Xu, Xiaoliang; Li, Yingchao; Zhang, Hongbin; Yang, Xiaodong] Yunnan Univ, Sch Chem Sci & Technol, Minist Educ & Yunnan Prov, Key Lab Med Chem Nat Resource, Kunming, Yunnan, Peoples R China; [Yan, Juming; Gong, Liang; Gong, Yaxiao; Zhu, Huifang] Univ Chinese Acad Sci, Beijing, Peoples R China; [An, Tao; Li, Yan] Chinese Acad Sci, Kunming Inst Bot, Yunnan Key Lab Nat Med Chem, Kunming, Yunnan, Peoples R China	Chinese Academy of Sciences; Kunming Institute of Botany, CAS; North Sichuan Medical University; Yunnan University; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Chinese Academy of Sciences; Kunming Institute of Botany, CAS	Li, Y (corresponding author), Chinese Acad Sci, Kunming Inst Bot, State Key Lab Phytochem & Plant Resources West Ch, Kunming, Yunnan, Peoples R China.; Zhang, HB; Yang, XD (corresponding author), Yunnan Univ, Sch Chem Sci & Technol, Minist Educ & Yunnan Prov, Key Lab Med Chem Nat Resource, Kunming, Yunnan, Peoples R China.; Li, Y (corresponding author), Chinese Acad Sci, Kunming Inst Bot, Yunnan Key Lab Nat Med Chem, Kunming, Yunnan, Peoples R China.	zhanghb@ynu.edu.cn; xdyang@ynu.edu.cn; liyanb@mail.kib.ac.cn	Yu, Chunlei/I-9383-2016	Yu, Chunlei/0000-0002-2934-2122; Yan, Juming/0000-0003-0857-8870; Yang, Xiaodong/0000-0002-8466-5418; Zhou, Hongyu/0000-0001-5852-3953	National Natural Science Foundation of China [U1402227, 21662043, 81302807]; Yunnan Province [U1402227]; Program for Changjiang Scholars and Innovative Research Team in University [IRT17R94]; Exploitation and Utilization of Abundant Natural Products from Plants from Kunming Institute of Botany [KIB2017009]; West Light Foundation of The Chinese Academy of Sciences	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Yunnan Province; Program for Changjiang Scholars and Innovative Research Team in University(Program for Changjiang Scholars & Innovative Research Team in University (PCSIRT)); Exploitation and Utilization of Abundant Natural Products from Plants from Kunming Institute of Botany; West Light Foundation of The Chinese Academy of Sciences(Chinese Academy of Sciences)	This work was supported by the Joint Funds of the National Natural Science Foundation of China and Yunnan Province (U1402227), the Program for Changjiang Scholars and Innovative Research Team in University (IRT17R94), the Exploitation and Utilization of Abundant Natural Products from Plants from Kunming Institute of Botany (KIB2017009), the National Natural Science Foundation of China (No. 21662043, 81302807), and the West Light Foundation of The Chinese Academy of Sciences (H.Z.).	Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35; Akbari-Birgani S, 2016, DRUG DISCOV TODAY, V21, P836, DOI 10.1016/j.drudis.2016.03.004; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]; Chang L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.407; Chen K, 2013, ACTA PHARMACOL SIN, V34, P732, DOI 10.1038/aps.2013.27; Chen XS, 2013, MOL CANCER RES, V11, P1269, DOI 10.1158/1541-7786.MCR-13-0212; Culjkovic B, 2008, J CELL BIOL, V181, P51, DOI 10.1083/jcb.200707018; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Djuzenova CS, 2016, ONCOTARGET, V7, P38191, DOI 10.18632/oncotarget.9501; Dolgikh N, 2018, CANCER RES, V78, P2000, DOI 10.1158/0008-5472.CAN-17-1737; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Dubrovska A, 2009, P NATL ACAD SCI USA, V106, P268, DOI 10.1073/pnas.0810956106; Efeyan A, 2010, CURR OPIN CELL BIOL, V22, P169, DOI 10.1016/j.ceb.2009.10.007; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; Gedaly R, 2010, ANTICANCER RES, V30, P4951; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Hu YP, 2012, AM J CANCER RES, V2, P340; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Ilagan E, 2016, TRENDS CANCER, V2, P241, DOI 10.1016/j.trecan.2016.03.008; Korkaya H, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000121; Kwitkowski VE, 2010, ONCOLOGIST, V15, P428, DOI 10.1634/theoncologist.2009-0178; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Leung ELH, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0065-9; Liu PD, 2015, CANCER DISCOV, V5, P1194, DOI 10.1158/2159-8290.CD-15-0460; Liu SL, 2010, J CLIN ONCOL, V28, P4006, DOI 10.1200/JCO.2009.27.5388; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Markham A, 2017, DRUGS, V77, P1247, DOI 10.1007/s40265-017-0771-8; Marone R, 2008, BBA-PROTEINS PROTEOM, V1784, P159, DOI 10.1016/j.bbapap.2007.10.003; Medema JP, 2013, NAT CELL BIOL, V15, P338, DOI 10.1038/ncb2717; Miller BW, 2015, CLIN CANCER RES, V21, P1525, DOI 10.1158/1078-0432.CCR-14-2522; Morales GA, 2013, J MED CHEM, V56, P1922, DOI 10.1021/jm301522m; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253; Peitzsch C, 2017, SEMIN CANCER BIOL, V44, P10, DOI 10.1016/j.semcancer.2017.02.011; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Pulaski BA, 2000, CANCER RES, V60, P2710; Rahman M, 2011, NEUROSURGERY, V68, P531, DOI 10.1227/NEU.0b013e3181ff9eb5; Riaz N, 2018, TRANSL ONCOL, V11, P920, DOI 10.1016/j.tranon.2018.05.002; Ricardo S, 2011, J CLIN PATHOL, V64, P937, DOI 10.1136/jcp.2011.090456; Rong L, 2008, RNA, V14, P1318, DOI 10.1261/rna.950608; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Smith AL, 2012, J MED CHEM, V55, P5188, DOI 10.1021/jm300184s; Steeg PS, 2016, NAT REV CANCER, V16, P201, DOI 10.1038/nrc.2016.25; Thorpe LM, 2015, NAT REV CANCER, V15, P7, DOI 10.1038/nrc3860; Wan X, 2007, ONCOGENE, V26, P1932, DOI 10.1038/sj.onc.1209990; Weng LP, 2001, HUM MOL GENET, V10, P599, DOI 10.1093/hmg/10.6.599; WEXLER H, 1966, JNCI-J NATL CANCER I, V36, P641, DOI 10.1093/jnci/36.4.641; Xia P, 2015, AM J CANCER RES, V5, P1602; Zhou JB, 2007, P NATL ACAD SCI USA, V104, P16158, DOI 10.1073/pnas.0702596104; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	55	16	17	2	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2019	38	18					3371	3386		10.1038/s41388-018-0674-5	http://dx.doi.org/10.1038/s41388-018-0674-5			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HW3RI	30635656	hybrid, Green Published			2022-12-28	WOS:000466610000004
J	Cortes, E; Lachowski, D; Rice, A; Thorpe, SD; Robinson, B; Yeldag, G; Lee, DA; Ghemtio, L; Rombouts, K; Hernandez, AED				Cortes, Ernesto; Lachowski, Dariusz; Rice, Alistair; Thorpe, Stephen D.; Robinson, Benjamin; Yeldag, Gulcen; Lee, David A.; Ghemtio, Leo; Rombouts, Krista; Hernandez, Armando E. del Rio			Tamoxifen mechanically deactivates hepatic stellate cells via the G protein-coupled estrogen receptor	ONCOGENE			English	Article							HYPOXIA-INDUCIBLE FACTORS; HEPATOCELLULAR-CARCINOMA; EXTRACELLULAR-MATRIX; ACTIVATION; STIFFNESS; MECHANOTRANSDUCTION; EXPRESSION; PRESTRESS; RISK; GPER	Tamoxifen has been used for many years to target estrogen receptor signalling in breast cancer cells. Tamoxifen is also an agonist of the G protein-coupled estrogen receptor (GPER), a GPCR ubiquitously expressed in tissues that mediates the acute response to estrogens. Here we report that tamoxifen promotes mechanical quiescence in hepatic stellate cells (HSCs), stromal fibroblast-like cells whose activation triggers and perpetuates liver fibrosis in hepatocellular carcinomas. This mechanical deactivation is mediated by the GPER/RhoA/myosin axis and induces YAP deactivation. We report that tamoxifen decreases the levels of hypoxia-inducible factor-1 alpha (HIF-1 alpha) and the synthesis of extracellular matrix proteins through a mechanical mechanism that involves actomyosin-dependent contractility and mechanosensing of tissue stiffness. Our results implicate GPER-mediated estrogen signalling in the mechanosensory-driven activation of HSCs and put forward estrogenic signalling as an option for mechanical reprogramming of myofibroblast-like cells in the tumour microenvironment. Tamoxifen, with half a century of safe clinical use, might lead this strategy of drug repositioning.	[Cortes, Ernesto; Lachowski, Dariusz; Rice, Alistair; Robinson, Benjamin; Yeldag, Gulcen; Hernandez, Armando E. del Rio] Imperial Coll London, Dept Bioengn, Cellular & Mol Biomech Lab, London SW7 2AZ, England; [Thorpe, Stephen D.; Lee, David A.] Queen Mary Univ London, Sch Engn & Mat Sci, Inst Bioengn, London E1 4NS, England; [Ghemtio, Leo] Univ Helsinki, Fac Pharm, Div Pharmaceut Biosci, Drug Res Program, FI-00014 Helsinki, Finland; [Rombouts, Krista] UCL, Royal Free Hosp, Inst Liver & Digest Hlth, Regenerat Med & Fibrosis Grp, London, England	Imperial College London; University of London; Queen Mary University London; University of Helsinki; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Hernandez, AED (corresponding author), Imperial Coll London, Dept Bioengn, Cellular & Mol Biomech Lab, London SW7 2AZ, England.	a.del-rio-hernandez@imperial.ac.uk	Cortes Lopez, Ernesto/ABE-5343-2021; del rio hernandez, armando e/N-4262-2013; Rombouts, Krista/ABB-2602-2020; Thorpe, Stephen/C-1656-2018; del Río Hernández, Armando E/D-3555-2012; Rombouts, Krista/AAE-8179-2020	Cortes Lopez, Ernesto/0000-0001-6106-1323; del rio hernandez, armando e/0000-0001-5062-8910; Thorpe, Stephen/0000-0002-4707-7756; del Río Hernández, Armando E/0000-0001-5062-8910; Rombouts, Krista/0000-0001-9440-0571; ghemtio, leo/0000-0003-3591-5676; Lee, David/0000-0001-7646-4643; Lachowski, Dariusz/0000-0003-1194-8019	European Research Council (ERC) [282051]; Drug Discovery and Chemical Biology - Biocenter Finland; BBSRC [BB/N018532/1] Funding Source: UKRI	European Research Council (ERC)(European Research Council (ERC)); Drug Discovery and Chemical Biology - Biocenter Finland; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This work was supported by the European Research Council (ERC grant 282051). LG gratefully acknowledges the support of The Drug Discovery and Chemical Biology - Biocenter Finland.	Balogh J, 2016, J HEPATOCELL CARCINO, V3, P41, DOI 10.2147/JHC.S61146; Bologa CG, 2006, NAT CHEM BIOL, V2, P207, DOI 10.1038/nchembio775; Calvo F, 2013, NAT CELL BIOL, V15, P637, DOI 10.1038/ncb2756; Cano A, 2012, FUTURE ONCOL, V8, P1095, DOI [10.2217/FON.12.105, 10.2217/fon.12.105]; Carloni V, 2014, LIVER INT, V34, P834, DOI 10.1111/liv.12465; Chakrabarti S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052357; Chen C, 2017, ONCOTARGET, V8, P46691, DOI 10.18632/oncotarget.17358; Chen SY, 2016, J CELL BIOCHEM, V117, P267, DOI 10.1002/jcb.25283; Chronopoulos A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12630; Copple BL, 2011, LIVER INT, V31, P230, DOI 10.1111/j.1478-3231.2010.02347.x; Cortes E, 2019, HEPATOLOGY, V69, P785, DOI 10.1002/hep.30193; Coulouarn C, 2012, CANCER RES, V72, P2533, DOI 10.1158/0008-5472.CAN-11-3317; Cui XD, 2014, MOL MED REP, V9, P1641, DOI 10.3892/mmr.2014.2036; Cuzick J, 2004, JNCI-J NATL CANCER I, V96, P621, DOI 10.1093/jnci/djh106; Cuzick J, 2015, LANCET ONCOL, V16, P67, DOI 10.1016/S1470-2045(14)71171-4; Dennis MK, 2009, NAT CHEM BIOL, V5, P421, DOI 10.1038/nchembio.168; Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Fattovich G, 2004, GASTROENTEROLOGY, V127, pS35, DOI 10.1053/j.gastro.2004.09.014; Feng S, 2017, ARTERIOSCL THROM VAS, V37, P2087, DOI 10.1161/ATVBAHA.117.309249; Guilluy C, 2011, NAT CELL BIOL, V13, P722, DOI 10.1038/ncb2254; Haining AWM, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2005599; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Howell A, 2000, CANCER-AM CANCER SOC, V89, P817, DOI 10.1002/1097-0142(20000815)89:4<817::AID-CNCR14>3.0.CO;2-6; Humphrey JD, 2014, NAT REV MOL CELL BIO, V15, P802, DOI 10.1038/nrm3896; Ju C, 2016, J MOL MED, V94, P613, DOI 10.1007/s00109-016-1408-1; Kelloff G J, 1994, J Cell Biochem Suppl, V20, P252; Kim CH, 2002, CIRC RES, V90, pE25, DOI 10.1161/hh0202.104923; Krishnamachary B, 2003, CANCER RES, V63, P1138; Kuznetsova TG, 2007, MICRON, V38, P824, DOI 10.1016/j.micron.2007.06.011; Lachowski D, 2018, FASEB J, V32, P1099, DOI 10.1096/fj.201700721R; Lachowski D, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02689-x; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Mandlekar S, 2000, CANCER RES, V60, P6601; Moreira RK, 2007, ARCH PATHOL LAB MED, V131, P1728; Mueller S, 2010, HEPATIC MED-EVID RES, V2, P49; Nathan L, 2001, P NATL ACAD SCI USA, V98, P3589, DOI 10.1073/pnas.051003698; Prossnitz ER, 2011, NAT REV ENDOCRINOL, V7, P715, DOI 10.1038/nrendo.2011.122; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Rice AJ, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.54; Robinson BK, 2016, BIOL OPEN, V5, P875, DOI 10.1242/bio.017632; Rodriguez-Hernandez Irene, 2016, F1000Res, V5, DOI 10.12688/f1000research.7909.1; Sakurai T, 2013, LIVER CANCER, V2, P365, DOI 10.1159/000343851; Sarper M, 2016, SCI REP-UK, V6, DOI 10.1038/srep27639; Shi L, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-93; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; Soon RK, 2008, CLIN LIVER DIS, V12, P791, DOI 10.1016/j.cld.2008.07.004; Stamenovic D, 2005, ACTA BIOMATER, V1, P255, DOI 10.1016/j.actbio.2005.01.004; Wang N, 2002, AM J PHYSIOL-CELL PH, V282, pC606, DOI 10.1152/ajpcell.00269.2001; Wells RG, 2005, J CLIN GASTROENTEROL, V39, pS158, DOI 10.1097/01.mcg.0000155516.02468.0f; Wilson GK, 2014, J HEPATOL, V61, P1397, DOI 10.1016/j.jhep.2014.08.025; Yin CY, 2013, J CLIN INVEST, V123, P1902, DOI 10.1172/JCI66369; Zimmerman MA, 2016, CLIN SCI, V130, P1005, DOI 10.1042/CS20160114	54	33	34	3	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2019	38	16					2910	2922		10.1038/s41388-018-0631-3	http://dx.doi.org/10.1038/s41388-018-0631-3			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU3IV	30575816	Green Published, Green Submitted, hybrid			2022-12-28	WOS:000465167600003
J	Iida, M; Brand, TM; Campbell, DA; Li, C; Wheeler, DL				Iida, M.; Brand, T. M.; Campbell, D. A.; Li, C.; Wheeler, D. L.			Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor (vol 32, pg 759, 2013)	ONCOGENE			English	Correction									[Iida, M.; Brand, T. M.; Campbell, D. A.; Li, C.; Wheeler, D. L.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Human Oncol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Wheeler, DL (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Human Oncol, Madison, WI 53706 USA.	dlwheeler@wisc.edu						Iida M, 2013, ONCOGENE, V32, P759, DOI 10.1038/onc.2012.90	1	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2019	38	13					2435	2435		10.1038/s41388-018-0572-x	http://dx.doi.org/10.1038/s41388-018-0572-x			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ7GN	30518873	Bronze			2022-12-28	WOS:000462588000016
J	Papa, S; Choy, PM; Bubici, C				Papa, Salvatore; Choy, Pui Man; Bubici, Concetta			The ERK and JNK pathways in the regulation of metabolic reprogramming	ONCOGENE			English	Review							PYRUVATE-KINASE M2; AEROBIC GLYCOLYSIS; CELL-METABOLISM; GLUCOSE-METABOLISM; BRAF INHIBITION; DENDRITIC CELL; PROTEIN-KINASE; TUMOR-GROWTH; STEM-CELLS; CANCER	Most tumor cells reprogram their glucose metabolism as a result of mutations in oncogenes and tumor suppressors, leading to the constitutive activation of signaling pathways involved in cell growth. This metabolic reprogramming, known as aerobic glycolysis or the Warburg effect, allows tumor cells to sustain their fast proliferation and evade apoptosis. Interfering with oncogenic signaling pathways that regulate the Warburg effect in cancer cells has therefore become an attractive anticancer strategy. However, evidence for the occurrence of the Warburg effect in physiological processes has also been documented. As such, close consideration of which signaling pathways are beneficial targets and the effect of their inhibition on physiological processes are essential. The MAPK/ERK and MAPK/JNK pathways, crucial for normal cellular responses to extracellular stimuli, have recently emerged as key regulators of the Warburg effect during tumorigenesis and normal cellular functions. In this review, we summarize our current understanding of the roles of the ERK and JNK pathways in controlling the Warburg effect in cancer and discuss their implication in controlling this metabolic reprogramming in physiological processes and opportunities for targeting their downstream effectors for therapeutic purposes.	[Papa, Salvatore; Choy, Pui Man] Univ Leeds, St James Univ Hosp, Fac Med & Hlth, Cell Signaling & Canc Lab,Leeds Inst Canc & Patho, Leeds, W Yorkshire, England; [Choy, Pui Man] hVIVO PLC, Dept Res & Dev, Biopk,Broadwater Rd, Welwyn Garden City, Herts, England; [Bubici, Concetta] Brunel Univ London, Div Biosci, Inst Environm Hlth & Soc, Coll Hlth & Life Sci,Dept Life Sci, Uxbridge, Middx, England; [Bubici, Concetta] Imperial Coll London, Fac Med, Dept Med, London, England	Saint James's University Hospital; University of Leeds; Brunel University; Imperial College London	Papa, S (corresponding author), Univ Leeds, St James Univ Hosp, Fac Med & Hlth, Cell Signaling & Canc Lab,Leeds Inst Canc & Patho, Leeds, W Yorkshire, England.; Bubici, C (corresponding author), Brunel Univ London, Div Biosci, Inst Environm Hlth & Soc, Coll Hlth & Life Sci,Dept Life Sci, Uxbridge, Middx, England.; Bubici, C (corresponding author), Imperial Coll London, Fac Med, Dept Med, London, England.	s.papa@leeds.ac.uk; concetta.bubici@brunel.ac.uk	Papa, Salvatore/J-9413-2012	Papa, Salvatore/0000-0002-8369-6538; Bubici, Concetta/0000-0002-8074-4661	Brunel Research Initiative & Enterprise Fund, Brunel University of London; Kay Kendall Leukemia Fund [KKL443]; 250 Great Minds Fellowship, University of Leeds; AMMF Cholangiocarcinoma Charity; Bloodwise [17014]	Brunel Research Initiative & Enterprise Fund, Brunel University of London; Kay Kendall Leukemia Fund; 250 Great Minds Fellowship, University of Leeds; AMMF Cholangiocarcinoma Charity; Bloodwise	The authors acknowledge the research funding from Brunel Research Initiative & Enterprise Fund, Brunel University of London (to CB), Kay Kendall Leukemia Fund (KKL443) (to CB), 250 Great Minds Fellowship, University of Leeds (to SP), AMMF Cholangiocarcinoma Charity (to SP and PMC), and Bloodwise (17014) (to SP and CB).	Agathocleous M, 2012, NAT CELL BIOL, V14, P859, DOI 10.1038/ncb2531; Anastasiou D, 2012, NAT CHEM BIOL, V8, P839, DOI 10.1038/NCHEMBIO.1060; Anbalagan M, 2012, INT J CANCER, V130, P1967, DOI 10.1002/ijc.26207; Aras S, 2017, BRIT J CANCER, V117, P1583, DOI 10.1038/bjc.2017.356; Barbarulo A, 2013, ONCOGENE, V32, P4231, DOI 10.1038/onc.2012.448; Barthel A, 1999, J BIOL CHEM, V274, P20281, DOI 10.1074/jbc.274.29.20281; Birsoy K, 2015, CELL, V162, P540, DOI 10.1016/j.cell.2015.07.016; Biswas SK, 2012, IMMUNOL RES, V53, P11, DOI 10.1007/s12026-012-8291-9; Biswas SK, 2012, CELL METAB, V15, P432, DOI 10.1016/j.cmet.2011.11.013; Blaxter K, 1989, ENERGY METABOLISM AN; Board RE, 2009, BRIT J CANCER, V101, P1724, DOI 10.1038/sj.bjc.6605371; Bubici C, 2014, BRIT J PHARMACOL, V171, P24, DOI 10.1111/bph.12432; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Canto C, 2015, CELL METAB, V22, P31, DOI 10.1016/j.cmet.2015.05.023; Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031-10; Caunt CJ, 2015, NAT REV CANCER, V15, P577, DOI 10.1038/nrc4000; Cellurale C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012469; Chang CH, 2016, NAT IMMUNOL, V17, P364, DOI 10.1038/ni.3415; Chang CH, 2013, CELL, V153, P1239, DOI 10.1016/j.cell.2013.05.016; Chen NY, 2001, CANCER RES, V61, P3908; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667; Chung S, 2010, J MOL CELL CARDIOL, V48, P725, DOI 10.1016/j.yjmcc.2009.12.014; Cortes-Cros M, 2013, P NATL ACAD SCI USA, V110, P489, DOI 10.1073/pnas.1212780110; Cui J, 2006, CANCER RES, V66, P10024, DOI 10.1158/0008-5472.CAN-06-0136; Dang CV, 2008, NAT REV CANCER, V8, P51, DOI 10.1038/nrc2274; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; Dang EV, 2011, CELL, V146, P772, DOI 10.1016/j.cell.2011.07.033; Dankner M, 2018, ONCOGENE, V37, P3183, DOI 10.1038/s41388-018-0171-x; David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697; Dayton TL, 2018, CANCER METAB, V6, DOI 10.1186/s40170-018-0179-2; Dayton TL, 2016, GENE DEV, V30, P1020, DOI 10.1101/gad.278549.116; Deng HB, 2008, J BIOL CHEM, V283, P20754, DOI 10.1074/jbc.M800024200; Dixit D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.179; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Edmunds LR, 2014, J BIOL CHEM, V289, P25382, DOI 10.1074/jbc.M114.580662; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Everts B, 2012, BLOOD, V120, P1422, DOI 10.1182/blood-2012-03-419747; Faubert B, 2013, CELL METAB, V17, P113, DOI 10.1016/j.cmet.2012.12.001; Ferreira LMR, 2012, ONCOGENE, V31, P3999, DOI 10.1038/onc.2011.576; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Folmes CDL, 2013, J CARDIOVASC TRANSL, V6, P10, DOI 10.1007/s12265-012-9431-2; Folmes CDL, 2011, CELL METAB, V14, P264, DOI 10.1016/j.cmet.2011.06.011; Fritz HL, 1999, HISTOCHEM CELL BIOL, V112, P359, DOI 10.1007/s004180050417; Galluzzi L, 2013, NAT REV DRUG DISCOV, V12, P829, DOI 10.1038/nrd4145; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Ghesquiere B, 2014, NATURE, V511, P167, DOI 10.1038/nature13312; Goetzman ES, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00129; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Goyal MS, 2014, CELL METAB, V19, P49, DOI 10.1016/j.cmet.2013.11.020; Grassian AR, 2011, GENE DEV, V25, P1716, DOI 10.1101/gad.16771811; Graves JA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037699; Gururajan M, 2005, BLOOD, V106, P1382, DOI 10.1182/blood-2004-10-3819; Hall A, 2013, ONCOTARGET, V4, P584, DOI 10.18632/oncotarget.965; Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003; Hardeman KN, 2017, SCI REP-UK, V7, DOI 10.1038/srep42604; Hardie DG, 2016, TRENDS CELL BIOL, V26, P190, DOI 10.1016/j.tcb.2015.10.013; Hardie DG, 2015, CLIN CANCER RES, V21, P3836, DOI 10.1158/1078-0432.CCR-14-3300; Hay N, 2016, NAT REV CANCER, V16, P635, DOI 10.1038/nrc.2016.77; HEDESKOV CJ, 1968, BIOCHEM J, V110, P373, DOI 10.1042/bj1100373; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431; Ho PC, 2015, CELL, V162, P1217, DOI 10.1016/j.cell.2015.08.012; Hom JR, 2011, DEV CELL, V21, P469, DOI 10.1016/j.devcel.2011.08.008; Hosios AM, 2018, J BIOL CHEM, V293, P7490, DOI 10.1074/jbc.TM117.000239; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Hui LJ, 2008, J CLIN INVEST, V118, P3943, DOI 10.1172/JCI37156; Iansante V, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8882; Israelsen WJ, 2015, SEMIN CELL DEV BIOL, V43, P43, DOI 10.1016/j.semcdb.2015.08.004; Israelsen WJ, 2013, CELL, V155, P397, DOI 10.1016/j.cell.2013.09.025; John S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017674; Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509; Kawashima I, 2015, EXP HEMATOL, V43, P524, DOI 10.1016/j.exphem.2015.03.005; Ke HN, 2010, CANCER RES, V70, P3080, DOI 10.1158/0008-5472.CAN-09-2923; Khamari R, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0340-4; Kishore M, 2017, IMMUNITY, V47, P875, DOI 10.1016/j.immuni.2017.10.017; Kondoh H, 2007, ANTIOXID REDOX SIGN, V9, P293, DOI 10.1089/ars.2006.1467; Kosteli A, 2010, J CLIN INVEST, V120, P3466, DOI 10.1172/JCI42845; Krawczyk CM, 2010, BLOOD, V115, P4742, DOI 10.1182/blood-2009-10-249540; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Lee KM, 2017, CELL METAB, V26, P633, DOI 10.1016/j.cmet.2017.09.009; Lee MH, 2011, J CLIN ENDOCR METAB, V96, pE19, DOI 10.1210/jc.2010-1071; Lee SH, 2010, NAT MED, V16, P665, DOI 10.1038/nm.2143; Lehninger A., 1993, PRINCIPLES BIOCH; Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494; Li F, 2005, MOL CELL BIOL, V25, P6225, DOI 10.1128/MCB.25.14.6225-6234.2005; Li WL, 2018, ONCOGENE, V37, P6383, DOI 10.1038/s41388-018-0402-1; Li XJ, 2016, MOL CELL, V61, P705, DOI 10.1016/j.molcel.2016.02.009; Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001; Lim SO, 2016, CANCER RES, V76, P1284, DOI 10.1158/0008-5472.CAN-15-2478; Locasale JW, 2011, CELL METAB, V14, P443, DOI 10.1016/j.cmet.2011.07.014; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; Lum JJ, 2007, GENE DEV, V21, P1037, DOI 10.1101/gad.1529107; Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881; Lunt SY, 2015, MOL CELL, V57, P95, DOI 10.1016/j.molcel.2014.10.027; Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237; Lusk G, 1909, ELEMENTS SCI NUTR; Marko AJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015425; Martin OJ, 2014, CIRC RES, V114, P626, DOI 10.1161/CIRCRESAHA.114.302562; Martinez-Outschoorn UE, 2017, NAT REV CLIN ONCOL, V14, P11, DOI 10.1038/nrclinonc.2016.60; Michalek RD, 2011, J IMMUNOL, V186, P3299, DOI 10.4049/jimmunol.1003613; Michelakis ED, 2008, BRIT J CANCER, V99, P989, DOI 10.1038/sj.bjc.6604554; Mingo-Sion AM, 2004, ONCOGENE, V23, P596, DOI 10.1038/sj.onc.1207147; Miniotis MF, 2013, CANCER RES, V73, P4039, DOI 10.1158/0008-5472.CAN-12-1969; Miyamoto S, 2008, CELL DEATH DIFFER, V15, P521, DOI 10.1038/sj.cdd.4402285; MUNYON WH, 1959, EXP CELL RES, V17, P490, DOI 10.1016/0014-4827(59)90069-2; Nemoto S, 2000, MOL CELL BIOL, V20, P7311, DOI 10.1128/MCB.20.19.7311-7318.2000; O'Neill LAJ, 2016, J EXP MED, V213, P15, DOI 10.1084/jem.20151570; O'Neill LAJ, 2013, NATURE, V493, P346, DOI 10.1038/nature11862; Palsson-McDermott EM, 2015, CELL METAB, V21, P65, DOI [10.1016/j.cmet.2014.12.005, 10.1016/j.cmet.2015.01.017]; Panopoulos AD, 2012, CELL RES, V22, P168, DOI 10.1038/cr.2011.177; Papa S, 2006, CELL DEATH DIFFER, V13, P712, DOI 10.1038/sj.cdd.4401865; Papa S, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2015.1103398; Parmenter TJ, 2014, CANCER DISCOV, V4, P423, DOI 10.1158/2159-8290.CD-13-0440; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; POUYSSEGUR J, 1980, NATURE, V287, P445, DOI 10.1038/287445a0; Raman M, 2007, ONCOGENE, V26, P3100, DOI 10.1038/sj.onc.1210392; Semba H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11635; Senyilmaz Deniz, 2015, F1000Prime Rep, V7, P41, DOI 10.12703/P7-41; Shanware NP, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5900; Shapouri-Moghaddam A, 2018, J CELL PHYSIOL, V233, P6425, DOI 10.1002/jcp.26429; Shi LZ, 2011, J EXP MED, V208, P1367, DOI 10.1084/jem.20110278; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Solinas G, 2017, MOL METAB, V6, DOI 10.1016/j.molmet.2016.12.001; Stine ZE, 2015, CANCER DISCOV, V5, P1024, DOI 10.1158/2159-8290.CD-15-0507; Sullivan LB, 2015, CELL, V162, P552, DOI 10.1016/j.cell.2015.07.017; Taha C, 1999, J BIOL CHEM, V274, P33085, DOI 10.1074/jbc.274.46.33085; Tannahill GM, 2013, NATURE, V496, P238, DOI 10.1038/nature11986; Tech K, 2017, CANCER RES, V77, P3217, DOI 10.1158/0008-5472.CAN-16-3304; Traves PG, 2012, J IMMUNOL, V188, P1402, DOI 10.4049/jimmunol.1101781; Van den Bossche J, 2016, CELL REP, V17, P684, DOI 10.1016/j.celrep.2016.09.008; Vander Heiden MG, 2017, CELL, V168, DOI 10.1016/j.cell.2016.12.039; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Varum S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020914; Vernia S, 2014, CELL METAB, V20, P512, DOI 10.1016/j.cmet.2014.06.010; Wang RN, 2012, NAT IMMUNOL, V13, P907, DOI 10.1038/ni.2386; Wang YH, 2014, CELL, V158, P1309, DOI 10.1016/j.cell.2014.07.048; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Ward PS, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a006783; West AP, 2011, NATURE, V472, P476, DOI 10.1038/nature09973; Wiernan HL, 2007, MOL BIOL CELL, V18, P1437, DOI 10.1091/mbc.E06-07-0593; Wiese EK, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00079; Wu N, 2013, MOL CELL, V49, P1167, DOI 10.1016/j.molcel.2013.01.035; Yang R, 2007, J BIOL CHEM, V282, P22765, DOI 10.1074/jbc.M700790200; Yang WW, 2012, NAT CELL BIOL, V14, P1295, DOI 10.1038/ncb2629; Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058; Yun JY, 2009, SCIENCE, V325, P1555, DOI 10.1126/science.1174229; Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001; Zhao YJ, 2014, NAT REV CLIN ONCOL, V11, P385, DOI 10.1038/nrclinonc.2014.83; Zheng B, 2009, MOL CELL, V33, P237, DOI 10.1016/j.molcel.2008.12.026; Zheng X, 2016, ELIFE, V5, DOI [10.7554/eLife.18638, 10.7554/eLife.13374]; Zhou Q, 2008, J NEUROCHEM, V104, P325, DOI 10.1111/j.1471-4159.2007.04957.x; Zhou WY, 2012, EMBO J, V31, P2103, DOI 10.1038/emboj.2012.71	153	146	150	4	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2019	38	13					2223	2240		10.1038/s41388-018-0582-8	http://dx.doi.org/10.1038/s41388-018-0582-8			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ7GN	30487597	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000462588000001
J	Salama, MF; Liu, ML; Clarke, CJ; Espaillat, MP; Haley, JD; Jin, T; Wang, DF; Obeid, LM; Hannun, YA				Salama, Mohamed F.; Liu, Mengling; Clarke, Christopher J.; Espaillat, Mel Pilar; Haley, John D.; Jin, Ting; Wang, Daifeng; Obeid, Lina M.; Hannun, Yusuf A.			PKC alpha is required for Akt-mTORC1 activation in non-small cell lung carcinoma (NSCLC) with EGFR mutation	ONCOGENE			English	Article							PROTEIN-KINASE-C; AKT PHOSPHORYLATION; TUMOR-FORMATION; CANCER; SUPPRESSES; RESISTANCE; EXPRESSION; SEQUESTRATION; ENZASTAURIN; MIGRATION	Mutational activation of the epidermal growth factor receptor (EGFR) is a major player in the pathogenesis of non-small cell lung cancer (NSCLC). NSCLC patients with constitutively active EGFR mutations eventually develop drug resistance against EGFR tyrosine-kinase inhibitors; therefore, better understandings of key components of mutant EGFR (mtEGFR) signaling are required. Here, we initially observed aberrantly high expression of protein kinase C alpha (PKC alpha) in lung adenocarcinomas, especially those with EGFR mutations, and proceeded to examine the role of PKC alpha in the regulation of the signaling pathways downstream of mtEGFR. The results showed that NSCLC cell lines with constitutively active EGFR mutations tend to have very or moderately high PKC alpha levels. Furthermore, PKC alpha was constitutively activated in HCC827 and H4006 cells which have an EGFR deletion mutation in exon 19. Interestingly, mtEGFR was not required for the induction of PKC alpha at protein and message levels suggesting that the increased levels of PKC alpha are due to independent selection. On the other hand, mtEGFR activity was required for robust activation of PKC alpha. Loss of functions studies revealed that the NSCLC cells rely heavily on PKC alpha for the activation of the mTORC1 signaling pathway. Unexpectedly, the results demonstrated that PKC alpha was required for activation of Akt upstream of mTOR but only in cells with the mtEGFR and with the increased expression of PKC alpha. Functionally, inhibition of PKC alpha in HCC827 led to caspase-3-dependent apoptosis and a significant decrease in cell survival in response to cellular stress induced by serum starvation. In summary, the results identified important roles of PKC alpha in regulating mTORC1 activity in lung cancer cells, whereby a primary switching occurs from PKC alpha-independent to PKC alpha-dependent signaling in the presence of EGFR mutations. The results present PKC alpha as a potential synergistic target of personalized treatment for NSCLC with constitutively active mutant forms of EGFR and constitutively active PKC alpha.	[Salama, Mohamed F.; Liu, Mengling; Clarke, Christopher J.; Espaillat, Mel Pilar; Obeid, Lina M.; Hannun, Yusuf A.] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA; [Salama, Mohamed F.; Liu, Mengling; Clarke, Christopher J.; Espaillat, Mel Pilar; Obeid, Lina M.; Hannun, Yusuf A.] Stony Brook Univ Hosp, Stony Brook Canc Ctr, Stony Brook, NY 11794 USA; [Salama, Mohamed F.] Mansoura Univ, Dept Biochem, Fac Vet Med, Mansoura, Egypt; [Liu, Mengling] HD Biosci Inc, Dept Immunooncol, San Diego, CA 92121 USA; [Haley, John D.; Hannun, Yusuf A.] SUNY Stony Brook, Dept Biochem, Stony Brook, NY 11794 USA; [Haley, John D.; Hannun, Yusuf A.] SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA; [Jin, Ting; Wang, Daifeng] SUNY Stony Brook, Dept Biomed Informat, Stony Brook, NY 11794 USA; [Wang, Daifeng] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53792 USA; [Wang, Daifeng] Univ Wisconsin, Waisman Ctr, Madison, WI 53792 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital; Egyptian Knowledge Bank (EKB); Mansoura University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Hannun, YA (corresponding author), SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA.; Hannun, YA (corresponding author), Stony Brook Univ Hosp, Stony Brook Canc Ctr, Stony Brook, NY 11794 USA.; Hannun, YA (corresponding author), SUNY Stony Brook, Dept Biochem, Stony Brook, NY 11794 USA.; Hannun, YA (corresponding author), SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA.	yusuf.hannun@stonybrookmedicine.edu	Salama, Mohamed F/C-9010-2017; Salama, Mohamed/S-3493-2019	Salama, Mohamed F/0000-0002-0002-9108; Salama, Mohamed/0000-0002-0002-9108; obeid, lina/0000-0002-0734-0847	NCI [CA97132]; NATIONAL CANCER INSTITUTE [P01CA097132] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NCI grant CA97132.	Abera MB, 2015, MOL PHARMACOL, V87, P832, DOI 10.1124/mol.115.097725; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Antal CE, 2015, CELL, V160, P489, DOI 10.1016/j.cell.2015.01.001; Antonicelli A, 2013, INT J MED SCI, V10, P320, DOI 10.7150/ijms.4609; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Caino MC, 2012, ONCOGENE, V31, P2593, DOI 10.1038/onc.2011.428; Cheng CY, 2009, J CELL PHYSIOL, V219, P183, DOI 10.1002/jcp.21669; Cooper WA, 2013, J THORAC DIS, V5, pS479, DOI 10.3978/j.issn.2072-1439.2013.08.03; El Osta M, 2014, FASEB J, V28, P495, DOI 10.1096/fj.13-230557; Fan Q. W., 2009, SCI SIGNAL, V2, pra4, DOI DOI 10.1126/SCISIGNAL.2000014; Feng X, 1998, J BIOL CHEM, V273, P26870, DOI 10.1074/jbc.273.41.26870; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Gallay N, 2009, LEUKEMIA, V23, P1029, DOI 10.1038/leu.2008.395; Gazdar AF, 2009, ONCOGENE, V28, pS24, DOI 10.1038/onc.2009.198; Griner EM, 2007, NAT REV CANCER, V7, P281, DOI 10.1038/nrc2110; Gupta AK, 1996, CELL PROLIFERAT, V29, P655, DOI 10.1111/j.1365-2184.1996.tb00979.x; Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009; Hill KS, 2014, ONCOGENE, V33, P2134, DOI 10.1038/onc.2013.147; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hsieh YH, 2007, CANCER RES, V67, P4320, DOI 10.1158/0008-5472.CAN-06-2486; Idkowiak-Baldys J, 2006, J BIOL CHEM, V281, P22321, DOI 10.1074/jbc.M512540200; Idkowiak-Baldys J, 2009, J BIOL CHEM, V284, P22322, DOI 10.1074/jbc.M109.026765; Jiang XH, 2004, CANCER RES, V64, P5787, DOI 10.1158/0008-5472.CAN-03-1172; Jin G, 2010, LUNG CANCER, V69, P279, DOI 10.1016/j.lungcan.2009.11.012; Kanne JP, 2014, AM J ROENTGENOL, V202, P530, DOI 10.2214/AJR.13.11540; Kim S, 2012, J SURG RES, V176, pE21, DOI 10.1016/j.jss.2011.11.1041; Kong CZ, 2005, UROLOGY, V65, P1228, DOI 10.1016/j.urology.2005.01.007; Lahn Michael, 2004, Clin Lung Cancer, V6, P184, DOI 10.3816/CLC.2004.n.032; LaPorta CAM, 1997, CARCINOGENESIS, V18, P715, DOI 10.1093/carcin/18.4.715; Liu ML, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080721; Mattoon DR, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-24; Molina JR, 2008, MAYO CLIN PROC, V83, P584, DOI 10.4065/83.5.584; O'Neill AK, 2011, J BIOL CHEM, V286, P43559, DOI 10.1074/jbc.M111.294603; Oster H, 2006, CANCER RES, V66, P6955, DOI 10.1158/0008-5472.CAN-06-0268; Pulkoski-Gross MJ, 2018, J LIPID RES, V59, P462, DOI 10.1194/jlr.M081307; REISSMANN PT, 1993, ONCOGENE, V8, P1913; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Shames DS, 2014, J PATHOL, V232, P121, DOI 10.1002/path.4275; Singhal SS, 2005, FEBS LETT, V579, P4635, DOI 10.1016/j.febslet.2005.07.032; Smith SD, 2012, J BIOL CHEM, V287, P29336, DOI 10.1074/jbc.M112.341917; Song XL, 2015, CANCER RES, V75, P1035, DOI 10.1158/0008-5472.CAN-13-1625; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Steinberg SF, 2008, PHYSIOL REV, V88, P1341, DOI 10.1152/physrev.00034.2007; Steins M, 2014, RECENT RESULTS CANC, V201, P109, DOI 10.1007/978-3-642-54490-3_6; Tsurutani J, 2006, J CLIN ONCOL, V24, P306, DOI 10.1200/JCO.2005.02.4133; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vansteenkiste J, 2012, ONCOLOGY-BASEL, V82, P25, DOI 10.1159/000335268; Vincent EE, 2011, BRIT J CANCER, V104, P1755, DOI 10.1038/bjc.2011.132; Wang C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073985; Willey CD, 2010, INT J RADIAT ONCOL, V77, P1518, DOI 10.1016/j.ijrobp.2009.06.044	52	6	6	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2019	38	48					7311	7328		10.1038/s41388-019-0950-z	http://dx.doi.org/10.1038/s41388-019-0950-z			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JR4XX	31420605	Green Accepted			2022-12-28	WOS:000499631000003
J	Wang, S; Zhang, X; Li, Z; Wang, WZ; Li, BW; Huang, XX; Sun, GL; Xu, JH; Li, Q; Xu, ZP; Xia, YW; Wang, L; Zhang, Q; Li, Q; Zhang, L; Chen, J; Wu, YJ; Cao, JC; Xu, PH; Zhang, DC; Xu, H; Xu, ZK				Wang, Sen; Zhang, Xing; Li, Zheng; Wang, Weizhi; Li, Bowen; Huang, Xiaoxu; Sun, Guangli; Xu, Jianghao; Li, Qing; Xu, Zhipeng; Xia, Yiwen; Wang, Lu; Zhang, Qiang; Li, Qiang; Zhang, Lu; Chen, Jie; Wu, Yangjun; Cao, Jiacheng; Xu, Penghui; Zhang, Diancai; Xu, Hao; Xu, Zekuan			Circular RNA profile identifies circOSBPL10 as an oncogenic factor and prognostic marker in gastric cancer	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; CELL-GROWTH; CROSS-TALK; WNT2; CHINA; PROGRESSION; STATISTICS; EXPRESSION; CIRCHIPK3; MIGRATION	The prognosis after curative resection of gastric cancer (GC) remains unsatisfactory, and thus, the development of treatments involving alternative molecular and genetic targets is critical. Circular RNAs (circRNAs), which are newly discovered molecules with key roles in the non-coding RNA network, have been identified as critical regulators in various cancers. Here, we aimed to determine the circRNA expression profile and to investigate the functional and prognostic significance of circRNA in GC. Using next-generation sequencing profiling, we first characterized an abundant circRNA in GC, hsa_circ_0008549, derived from the OSBPL10 gene and named it circOSBPL10. The expression of circOSBPL10 was found to be upregulated in GC tissues by quantitative RT-PCR, and silencing of circOSBPL10 significantly inhibited GC cell growth, migration, and invasion in multiple experiments. We further confirmed that miR-136-5p is a downstream target of circOSBPL10 using RNA pull-down and luciferase reporter assays. Rescue experiments confirmed that circOSBPL10 regulates biological functions in GC cells via a circOSBPL10-miR-136-5p-WNT2 axis. In vivo experiments showed that circOSBPL10 promotes tumor growth and metastasis in mice. Furthermore, the level of circOSBPL10 was observed to be a prognostic marker of the overall survival and disease-free survival of patients with GC. Taken together, our findings reveal that circOSBPL10 may serve as a new proliferation factor and prognostic marker in GC.	[Wang, Sen; Zhang, Xing; Li, Zheng; Wang, Weizhi; Li, Bowen; Huang, Xiaoxu; Sun, Guangli; Xu, Jianghao; Li, Qing; Xu, Zhipeng; Xia, Yiwen; Wang, Lu; Zhang, Qiang; Li, Qiang; Zhang, Lu; Cao, Jiacheng; Xu, Penghui; Zhang, Diancai; Xu, Hao; Xu, Zekuan] Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Nanjing 210029, Jiangsu, Peoples R China; [Chen, Jie; Wu, Yangjun] Fudan Univ, Shanghai Med Coll, Shanghai Canc Ctr, Shanghai 200032, Peoples R China; [Xu, Zekuan] Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Nanjing 210029, Jiangsu, Peoples R China	Nanjing Medical University; Fudan University; Nanjing Medical University	Xu, ZK (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Nanjing 210029, Jiangsu, Peoples R China.; Xu, ZK (corresponding author), Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Nanjing 210029, Jiangsu, Peoples R China.	xuzekuan@njmu.edu.cn		Wang, Sen/0000-0001-7179-626X; xu, zekuan/0000-0001-5179-4128	National Natural Science Foundation of China [81572362]; National Natural Science Foundation Project of International Cooperation (NSFC-NIH) [81361120398]; Primary Research & Development Plan of Jiangsu Province [BE2016786]; Program for Development of Innovative Research Team in the First Affiliated Hospital of NJMU; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD) [JX10231801]; 333 Project of Jiangsu Province [BRA2015474]; Jiangsu Key Medical Discipline (General Surgery) [ZDXKA2016005]; Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation Project of International Cooperation (NSFC-NIH); Primary Research & Development Plan of Jiangsu Province; Program for Development of Innovative Research Team in the First Affiliated Hospital of NJMU; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); 333 Project of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Jiangsu Key Medical Discipline (General Surgery); Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University	This work was partially supported by the National Natural Science Foundation of China (81572362); the National Natural Science Foundation Project of International Cooperation (NSFC-NIH, 81361120398); the Primary Research & Development Plan of Jiangsu Province (BE2016786); the Program for Development of Innovative Research Team in the First Affiliated Hospital of NJMU; the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD, JX10231801); 333 Project of Jiangsu Province (BRA2015474); Jiangsu Key Medical Discipline (General Surgery) (ZDXKA2016005); and Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University.	Abu N, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00355; Allemani C, 2015, LANCET, V385, P977, DOI 10.1016/S0140-6736(14)62038-9; Ashwal-Fluss R, 2014, MOL CELL, V56, P55, DOI 10.1016/j.molcel.2014.08.019; Burd CE, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001233; Chen J, 2017, CANCER LETT, V388, P208, DOI 10.1016/j.canlet.2016.12.006; Chen L, 2017, ONCOGENE, V36, P4551, DOI 10.1038/onc.2017.89; Chen PJ, 2018, ONCOL LETT, V15, P5995, DOI 10.3892/ol.2018.8081; Chen WQ, 2017, CANCER LETT, V401, P63, DOI 10.1016/j.canlet.2017.04.024; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Cheng XX, 2005, CLIN EXP METASTAS, V22, P85, DOI 10.1007/s10585-005-4578-8; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Cui JA, 2011, NUCLEIC ACIDS RES, V39, P1197, DOI 10.1093/nar/gkq960; Ding H, 2017, MOL MED REP, V16, P5393, DOI 10.3892/mmr.2017.7275; Dmitriev AA, 2015, DIS MARKERS, V2015, DOI 10.1155/2015/241301; Dong YP, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-016-0370-2; Du WW, 2017, EUR HEART J, V38, P1402, DOI 10.1093/eurheartj/ehw001; Ferreira Humberto J, 2018, Oncotarget, V9, P29208, DOI 10.18632/oncotarget.25673; Fu L, 2011, GUT, V60, P1635, DOI 10.1136/gut.2011.241638; Geng HH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151753; Han D, 2017, HEPATOLOGY, V66, P1151, DOI 10.1002/hep.29270; Hang D, 2018, CANCER MED-US, V7, P2783, DOI 10.1002/cam4.1514; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Hentze MW, 2013, EMBO J, V32, P923, DOI 10.1038/emboj.2013.53; Huang L, 2006, HUM PATHOL, V37, P1557, DOI 10.1016/j.humpath.2006.05.015; Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112; Jung YS, 2015, ONCOTARGET, V6, P37257, DOI 10.18632/oncotarget.6133; Karreth FA, 2013, CANCER DISCOV, V3, P1113, DOI 10.1158/2159-8290.CD-13-0202; Katoh M, 2003, INT J MOL MED, V12, P811; Kramer N, 2017, ONCOGENE, V36, P5460, DOI 10.1038/onc.2017.144; Kristensen H, 2016, ONCOTARGET, V7, P30760, DOI [10.18632/oncotarget.8953, 10.16632/oncotarget.8953]; Li DX, 2017, ONCOTARGET, V8, P88163, DOI 10.18632/oncotarget.21513; Li X, 2017, MOL CELL, V67, P214, DOI 10.1016/j.molcel.2017.05.023; Li YW, 2017, EMBO REP, V18, P1646, DOI 10.15252/embr.201643581; Liu J, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0630-y; Lu C, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0833-x; Meleshina AV, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0003-7; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Meng SJ, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0663-2; NIGRO JM, 1991, CELL, V64, P607, DOI 10.1016/0092-8674(91)90244-S; Oh SC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04179-8; Park JK, 2009, NEOPLASMA, V56, P119, DOI 10.4149/neo_2009_02_119; Pongor L, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0228-1; Qi JJ, 2016, GUT, V65, P1690, DOI 10.1136/gutjnl-2014-307900; Salzman J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030733; Sarkar TR, 2015, ONCOGENE, V34, P2958, DOI 10.1038/onc.2014.245; Sierra B, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006220; Singh A, 2016, ONCOTARGET, V7, P17945, DOI 10.18632/oncotarget.7595; Sun GL, 2018, J GASTROENTEROL, V53, P725, DOI 10.1007/s00535-017-1408-0; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Vater I, 2015, LEUKEMIA, V29, P677, DOI 10.1038/leu.2014.264; Wang N, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0240-8; Weng WH, 2017, CLIN CANCER RES, V23, P3918, DOI 10.1158/1078-0432.CCR-16-2541; Yang YB, 2018, JNCI-J NATL CANCER I, V110, DOI 10.1093/jnci/djx166; Yao ZC, 2017, MOL ONCOL, V11, P422, DOI 10.1002/1878-0261.12045; Yuan HJ, 2017, J CELL MOL MED, V21, P3254, DOI 10.1111/jcmm.13229; Zhang F, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201703326; Zhang J, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.006642; Zheng QP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11215; Zheng RS, 2016, CANCER LETT, V370, P33, DOI 10.1016/j.canlet.2015.10.003; Zhong ZY, 2017, CANCER LETT, V403, P305, DOI 10.1016/j.canlet.2017.06.027; Zhou Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160414	61	63	64	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2019	38	44					6985	7001		10.1038/s41388-019-0933-0	http://dx.doi.org/10.1038/s41388-019-0933-0			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ1AO	31409903				2022-12-28	WOS:000493892900003
J	Raoof, S; Mulford, IJ; Frisco-Cabanos, H; Nangia, V; Timonina, D; Labrot, E; Hafeez, N; Bilton, SJ; Drier, Y; Ji, F; Greenberg, M; Williams, A; Kattermann, K; Damon, L; Sovath, S; Rakiec, DP; Korn, JM; Ruddy, DA; Benes, CH; Hammerman, PS; Piotrowska, Z; Sequist, LV; Niederst, MJ; Barretina, J; Engelman, JA; Hata, AN				Raoof, Sana; Mulford, Iain J.; Frisco-Cabanos, Heidie; Nangia, Varuna; Timonina, Daria; Labrot, Emma; Hafeez, Nafeeza; Bilton, Samantha J.; Drier, Yotam; Ji, Fei; Greenberg, Max; Williams, August; Kattermann, Krystina; Damon, Leah; Sovath, Sosathya; Rakiec, Daniel P.; Korn, Joshua M.; Ruddy, David A.; Benes, Cyril H.; Hammerman, Peter S.; Piotrowska, Zofia; Sequist, Lecia, V; Niederst, Matthew J.; Barretina, Jordi; Engelman, Jeffrey A.; Hata, Aaron N.			Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer	ONCOGENE			English	Article							TO-MESENCHYMAL TRANSITION; GROWTH-FACTOR RECEPTOR-3; ACTIVATING MUTATIONS; ACQUIRED-RESISTANCE; MET AMPLIFICATION; MULTIPLE-MYELOMA; GEFITINIB; INHIBITOR; PATHWAY; METASTASIS	Evolved resistance to tyrosine kinase inhibitor (TKI)-targeted therapies remains a major clinical challenge. In epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer (NSCLC), failure of EGFR TKIs can result from both genetic and epigenetic mechanisms of acquired drug resistance. Widespread reports of histologic and gene expression changes consistent with an epithelial-to-mesenchymal transition (EMT) have been associated with initially surviving drug-tolerant persister cells, which can seed bona fide genetic mechanisms of resistance to EGFR TKIs. While therapeutic approaches targeting fully resistant cells, such as those harboring an EGFR(T79M) mutation, have been developed, a clinical strategy for preventing the emergence of persister cells remains elusive. Using mesenchymal cell lines derived from biopsies of patients who progressed on EGFR TKI as surrogates for persister populations, we performed whole-genome CRISPR screening and identified fibroblast growth factor receptor 1 (FGFR1) as the top target promoting survival of mesenchymal EGFR mutant cancers. Although numerous previous reports of FGFR signaling contributing to EGFR TKI resistance in vitro exist, the data have not yet been sufficiently compelling to instigate a clinical trial testing this hypothesis, nor has the role of FGFR in promoting the survival of persister cells been elucidated. In this study, we find that combining EGFR and FGFR inhibitors inhibited the survival and expansion of EGFR mutant drug-tolerant cells over long time periods, preventing the development of fully resistant cancers in multiple vitro models and in vivo. These results suggest that dual EGFR and FGFR blockade may be a promising clinical strategy for both preventing and overcoming EMT-associated acquired drug resistance and provide motivation for the clinical study of combined EGFR and FGFR inhibition in EGFR-mutated NSCLCs.	[Raoof, Sana; Frisco-Cabanos, Heidie; Nangia, Varuna; Timonina, Daria; Bilton, Samantha J.; Drier, Yotam; Ji, Fei; Greenberg, Max; Williams, August; Kattermann, Krystina; Damon, Leah; Benes, Cyril H.; Piotrowska, Zofia; Sequist, Lecia, V; Hata, Aaron N.] Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; [Mulford, Iain J.; Labrot, Emma; Hafeez, Nafeeza; Sovath, Sosathya; Rakiec, Daniel P.; Korn, Joshua M.; Ruddy, David A.; Hammerman, Peter S.; Niederst, Matthew J.; Barretina, Jordi; Engelman, Jeffrey A.] Novartis Inst Biomed Res, Oncol Dis Area, Cambridge, MA USA; [Benes, Cyril H.; Piotrowska, Zofia; Sequist, Lecia, V; Hata, Aaron N.] Harvard Med Sch, Dept Med, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Novartis; Harvard University; Harvard Medical School	Hata, AN (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA.; Hata, AN (corresponding author), Harvard Med Sch, Dept Med, Boston, MA 02115 USA.	ahata@mgh.harvard.edu	Drier, Yotam/K-5208-2012	Drier, Yotam/0000-0003-1725-2995; Cabanos, Heidie/0000-0003-2643-8273; Nangia, Varuna/0000-0001-5142-4653; Damon, Leah/0000-0002-0863-0328; Williams, August/0000-0003-1994-2033	NIH [F30 CA213726-01A1, K08CA197389, R01CA137008]; Doris Duke Charitable Foundation; Stand Up To Cancer; National Science Foundation; V Foundation; Ludwig Cancer Research; LungStrong; Be a Piece of the Solution; NATIONAL CANCER INSTITUTE [K08CA197389, F30CA213726, R01CA137008] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); Stand Up To Cancer; National Science Foundation(National Science Foundation (NSF)); V Foundation; Ludwig Cancer Research; LungStrong; Be a Piece of the Solution; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr. Rafael Irizarry and Irineo Cabreros for guidance in statistical analyses related to shRNA dropout screening. We also thank Drs. Cyril Benes, Daniel Haber, Joan Brugge, Kornelia Polyak, and Robert Weinberg for helpful discussions throughout the development of this work. This study was funded by support from the NIH F30 CA213726-01A1 (SR), K08CA197389 (ANH), R01CA137008 (LVS), Doris Duke Charitable Foundation (ANH), Stand Up To Cancer (ANH and LVS), National Science Foundation (JAE), V Foundation (JAE), Ludwig Cancer Research (ANH), LungStrong, and Be a Piece of the Solution.	Azuma K, 2014, ONCOTARGET, V5, P5908, DOI 10.18632/oncotarget.1866; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bhang HEC, 2015, NAT MED, V21, P440, DOI 10.1038/nm.3841; Cardnell RJ, 2013, CLIN CANCER RES, V19, P6322, DOI 10.1158/1078-0432.CCR-13-1975; Cheng T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057284; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Crystal AS, 2014, SCIENCE, V346, P1480, DOI 10.1126/science.1254721; Dailey L, 2003, J CELL BIOL, V161, P1053, DOI 10.1083/jcb.200302075; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Floyd SR, 2013, NATURE, V498, P246, DOI 10.1038/nature12147; Gainor JF, 2016, CANCER DISCOV, V6, P1118, DOI 10.1158/2159-8290.CD-16-0596; Goyal L, 2017, CANCER DISCOV, V7, P252, DOI 10.1158/2159-8290.CD-16-1000; Guagnano V, 2011, J MED CHEM, V54, P7066, DOI 10.1021/jm2006222; Hata AN, 2016, NAT MED, V22, P262, DOI 10.1038/nm.4040; Haugsten EM, 2010, MOL CANCER RES, V8, P1439, DOI 10.1158/1541-7786.MCR-10-0168; Isozaki H, 2016, CANCER RES, V76, P1506, DOI 10.1158/0008-5472.CAN-15-1010; Janne PA, 2015, NEW ENGL J MED, V372, P1689, DOI 10.1056/NEJMoa1411817; Javle M, 2018, J CLIN ONCOL, V36, P276, DOI 10.1200/JCO.2017.75.5009; Jia Y, 2016, CANCER RES, V76, P1591, DOI 10.1158/0008-5472.CAN-15-2581; Kanai M, 1997, J BIOL CHEM, V272, P6621, DOI 10.1074/jbc.272.10.6621; Katayama R, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003316; Kitai H, 2016, CANCER DISCOV, V6, P754, DOI 10.1158/2159-8290.CD-15-1377; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Loboda A, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-9; LOEWE S, 1953, ARZNEIMITTEL-FORSCH, V3, P285; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Manchado E, 2016, NATURE, V534, P647, DOI 10.1038/nature18600; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Moon AM, 2006, DEV CELL, V10, P71, DOI 10.1016/j.devcel.2005.12.003; Moosa S, 2016, SEMIN CELL DEV BIOL, V53, P115, DOI 10.1016/j.semcdb.2015.12.005; Ornitz DM, 2015, WIRES DEV BIOL, V4, P215, DOI 10.1002/wdev.176; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Quintanal-Villalonga A, 2019, J THORAC ONCOL, V14, P641, DOI 10.1016/j.jtho.2018.12.021; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; Sarabipour S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10262; Seo JH, 2009, MOL CELL BIOL, V29, P3076, DOI 10.1128/MCB.01686-08; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Song KA, 2018, CLIN CANCER RES, V24, P197, DOI 10.1158/1078-0432.CCR-17-1577; Terai H, 2013, MOL CANCER RES, V11, P759, DOI 10.1158/1541-7786.MCR-12-0652; Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022; Uramoto H, 2010, ANTICANCER RES, V30, P2513; Viswanathan VS, 2017, NATURE, V547, P453, DOI 10.1038/nature23007; Ware KE, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.4; Ware Kathryn E, 2010, PLoS One, V5, pe14117, DOI 10.1371/journal.pone.0014117; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064; Zhou WY, 2016, CANCER BIOL MED, V13, P260, DOI 10.20892/j.issn.2095-3941.2015.0102	51	85	89	2	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2019	38	37					6399	6413		10.1038/s41388-019-0887-2	http://dx.doi.org/10.1038/s41388-019-0887-2			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IX6FR	31324888	Green Accepted			2022-12-28	WOS:000485778800001
J	Guo, Y; Zhang, XJ; Xu, QB; Gong, FX; Shi, XQ; Li, CK; Huang, R; Nie, FY; Zhu, W; Li, JJ; Tang, JB; Li, RT; Zhang, LM; Chen, LX; Ma, RLZ				Guo, Yu; Zhang, Xiaojuan; Xu, Quanbin; Gong, Fuxing; Shi, Xiaoqian; Li, Chaokun; Huang, Rui; Nie, Fangyuan; Zhu, Wen; Li, Jiujie; Tang, Junbo; Li, Runting; Zhang, Limeng; Chen, Longxin; Ma, Runlin Z.			Human Papillomavirus 16 oncoprotein E7 retards mitotic progression by blocking Mps1-MAP4 signaling cascade	ONCOGENE			English	Article							MICROTUBULES; MAP4; MPS1; NEOPLASIA; TUBULIN; EXPRESSION; STABILITY; INFECTION; CELLS	Human epithelial cells can be infected by more than 200 types of human papilloma viruses (HPVs), and persistent HPV infections lead to cervical cancer or other deadly cancers. It has been established that mitotic progression is critical for HPV16 infection, but the underlying mechanism remains unknown. Here, we report that oncoprotein E7 of HPV16 but not HPV18 retards mitotic progression in host cell by direct binding to the C terminus of Microtubule-Associated Protein 4 (MAP4). MAP4 is a novel bona fide target of HPV16E7 protein which binds and recruits the latter to spindle microtubule in mitosis. HPV16E7 protein promotes MAP4 stability by inhibiting MAP4 phosphorylation- mediated degradation to increase the stability of microtubule polymerization and cause an extend mitotic progression. We further uncovered that Mps1 is a kinase of MAP4, and E7MAP4 binding blocks Mps1 phosphorylation of MAP4, thereby interrupting phosphorylation-dependent MAP4 degradation. Mutations of MAP4 at T927ES928E partially abolished E7-binding capacity and rescued mitotic progression in host cells. In conclusion, our study reveals a molecular mechanism by which HPV16E7 perturbs host mitotic progression by interfering Mps1MAP4 signaling cascade, which results in an extended infection window and may facilitate the persistent HPV16 infection.	[Guo, Yu; Gong, Fuxing; Shi, Xiaoqian; Li, Chaokun; Huang, Rui; Nie, Fangyuan; Zhu, Wen; Li, Jiujie; Ma, Runlin Z.] Univ Chinese Acad Sci, Sch Life Sci, Beijing 100049, Peoples R China; [Guo, Yu; Zhang, Xiaojuan; Gong, Fuxing; Shi, Xiaoqian; Li, Chaokun; Huang, Rui; Nie, Fangyuan; Ma, Runlin Z.] Chinese Acad Sci, Inst Genet & Dev Biol, State Key Lab Mol Dev Biol, Beijing 100101, Peoples R China; [Xu, Quanbin] Univ Colorado, Dept Biochem, Boulder, CO 80309 USA; [Tang, Junbo] China Agr Univ, Coll Food Sci & Nutr Engn, Beijing 100083, Peoples R China; [Li, Runting; Zhang, Limeng; Chen, Longxin; Ma, Runlin Z.] Zhengzhou Normal Univ, Zhengzhou City Key Lab Mol Biol, Zhengzhou 450044, Henan, Peoples R China	Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Chinese Academy of Sciences; Institute of Genetics & Developmental Biology, CAS; University of Colorado System; University of Colorado Boulder; China Agricultural University; Zhengzhou Normal University	Ma, RLZ (corresponding author), Univ Chinese Acad Sci, Sch Life Sci, Beijing 100049, Peoples R China.; Ma, RLZ (corresponding author), Chinese Acad Sci, Inst Genet & Dev Biol, State Key Lab Mol Dev Biol, Beijing 100101, Peoples R China.; Ma, RLZ (corresponding author), Zhengzhou Normal Univ, Zhengzhou City Key Lab Mol Biol, Zhengzhou 450044, Henan, Peoples R China.	rlma@genetics.ac.cn	gong, fuxing/GXF-5949-2022; Chen, Longxin/HGD-3900-2022	Xu, Quanbin/0000-0002-2833-9773; Li, Chaokun/0000-0001-9037-488X	National Basic Research Program of China [2014CB138505]; National Natural Science Foundation of China [81871130]	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported in part by grants from National Basic Research Program of China (2014CB138505) and National Natural Science Foundation of China (81871130).	Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; Andersen SSL, 2000, TRENDS CELL BIOL, V10, P261, DOI 10.1016/S0962-8924(00)01786-4; Bosch FX, 2002, VIRUS RES, V89, P183, DOI 10.1016/S0168-1702(02)00187-9; Burger MPM, 1997, INT J GYNECOL PATHOL, V16, P10, DOI 10.1097/00004347-199701000-00002; DiGiuseppe S, 2016, P NATL ACAD SCI USA, V113, P6289, DOI 10.1073/pnas.1600638113; Dou Z, 2003, CELL RES, V13, P443, DOI 10.1038/sj.cr.7290186; Frisch M, 1999, LANCET, V354, P1442, DOI 10.1016/S0140-6736(99)92824-6; Gallo DE, 2012, VIROLOGY, V422, P13, DOI 10.1016/j.virol.2011.09.015; Hiruma Y, 2015, SCIENCE, V348, P1264, DOI 10.1126/science.aaa4055; Holmfeldt P, 2003, J CELL SCI, V116, P3701, DOI 10.1242/jcs.00685; Holmfeldt P, 2002, CURR BIOL, V12, P1034, DOI 10.1016/S0960-9822(02)00897-7; Jiang YY, 2016, ONCOGENE, V35, P4846, DOI 10.1038/onc.2016.17; Koshiol J, 2008, AM J EPIDEMIOL, V168, P123, DOI 10.1093/aje/kwn036; Kremer BE, 2005, MOL BIOL CELL, V16, P4648, DOI 10.1091/mbc.E05-03-0267; LAUZE E, 1995, EMBO J, V14, P1655, DOI 10.1002/j.1460-2075.1995.tb07154.x; Maciejowski J, 2017, DEV CELL, V41, P143, DOI 10.1016/j.devcel.2017.03.025; MANDELKOW E, 1995, CURR OPIN CELL BIOL, V7, P72, DOI 10.1016/0955-0674(95)80047-6; Espinosa AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055975; Marur S, 2010, LANCET ONCOL, V11, P781, DOI 10.1016/S1470-2045(10)70017-6; Mirabello L, 2017, CELL, V170, P1164, DOI 10.1016/j.cell.2017.08.001; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; Ou Y, 2014, UROL ONCOL, V32, P21; PIPERNO G, 1987, J CELL BIOL, V104, P289, DOI 10.1083/jcb.104.2.289; Pyeon D, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000318; Shaw R, 2011, BRIT J ORAL MAX SURG, V49, P423, DOI 10.1016/j.bjoms.2010.06.023; STEINMANN KE, 1994, ONCOGENE, V9, P387; Takahashi M, 2003, AM J PHYSIOL-HEART C, V285, pH2072, DOI 10.1152/ajpheart.00396.2003; Thomas LK, 2014, EUR J CANCER, V50, P85, DOI 10.1016/j.ejca.2013.08.022; WEST RR, 1991, J BIOL CHEM, V266, P21886; Bosch FX, 2008, VACCINE, V26, pK1, DOI 10.1016/j.vaccine.2008.05.064; Xu QB, 2009, MOL BIOL CELL, V20, P10, DOI 10.1091/mbc.E08-03-0324; Zahnleiter D, 2015, HUM MUTAT, V36, P87, DOI 10.1002/humu.22711	32	3	5	3	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2019	38	31					5959	5970		10.1038/s41388-019-0851-1	http://dx.doi.org/10.1038/s41388-019-0851-1			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IT3GE	31253867				2022-12-28	WOS:000482740000004
J	Zhang, C; Stockwell, SR; Elbanna, M; Ketteler, R; Freeman, J; Al-Lazikani, B; Eccles, S; Brandon, AS; Raynaud, F; Hayes, A; Clarke, PA; Workman, P; Mittnacht, S				Zhang, Chi; Stockwell, Simon R.; Elbanna, May; Ketteler, Robin; Freeman, Jamie; Al-Lazikani, Bissan; Eccles, Suzanne; Brandon, Alexis De Haven; Raynaud, Florence; Hayes, Angela; Clarke, Paul A.; Workman, Paul; Mittnacht, Sibylle			Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases	ONCOGENE			English	Article							ACQUIRED-RESISTANCE; DEPENDENT KINASES; CANCER; COMBINATION; INHIBITION; PROTEIN; ARREST; PHOSPHORYLATION; MECHANISMS; RECEPTOR	Deregulation of cyclin-dependent kinases 4 and 6 (CDK4/6) is highly prevalent in cancer; yet, inhibitors against these kinases are currently used only in restricted tumour contexts. The extent to which cancers depend on CDK4/6 and the mechanisms that may undermine such dependency are poorly understood. Here, we report that signalling engaging the MET proto-oncogene receptor tyrosine kinase/focal adhesion kinase (FAK) axis leads to CDK4/6-independent CDK2 activation, involving as critical mechanistic events loss of the CDKI p21(CIP1) and gain of its regulator, the ubiquitin ligase subunit SKP2. Combined inhibition of MET/FAK and CDK4/6 eliminates the proliferation capacity of cancer cells in culture, and enhances tumour growth inhibition in vivo. Activation of the MET/FAK axis is known to arise through cancer extrinsic and intrinsic cues. Our work predicts that such cues support cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases and identifies MET/FAK as a tractable route to broaden the utility of CDK4/6 inhibitor-based therapies in the clinic.	[Zhang, Chi; Stockwell, Simon R.; Elbanna, May; Mittnacht, Sibylle] UCL, UCL Canc Inst, London WC1E 6DD, England; [Zhang, Chi; Al-Lazikani, Bissan; Eccles, Suzanne; Brandon, Alexis De Haven; Raynaud, Florence; Hayes, Angela; Clarke, Paul A.; Workman, Paul] Inst Canc Res, Canc Res UK Canc Therapeut Unit, London SM2 5NG, England; [Ketteler, Robin; Freeman, Jamie] UCL, MRC Lab Mol Cell Biol, London WC1E 6BT, England	University of London; University College London; Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; MRC Laboratory Molecular Biology; University of London; University College London	Mittnacht, S (corresponding author), UCL, UCL Canc Inst, London WC1E 6DD, England.; Workman, P (corresponding author), Inst Canc Res, Canc Res UK Canc Therapeut Unit, London SM2 5NG, England.	paul.workman@icr.ac.uk; s.mittnacht@cancer.ucl.ac.uk	Al-Lazikani, Bissan/AAG-4723-2022; Elbanna, May/ABC-3736-2021; Al-Lazikani, Bissan/AFK-6457-2022	Elbanna, May/0000-0002-9745-9066; Al-Lazikani, Bissan/0000-0003-3367-2519; Raynaud, Florence/0000-0003-0957-6279; Stockwell, Simon/0000-0002-3345-8945; Clarke, Paul/0000-0001-9342-1290; Zhang, Chi/0000-0002-9188-6307	Cancer Research UK [C309/A11566, C309/A8274, C309/A8992, C423/A1421, C423/A15043]; World Cancer Research Fund (WCRF) [12-1280]; Wellcome Trust [094885/Z/10/Z]	Cancer Research UK(Cancer Research UK); World Cancer Research Fund (WCRF)(World Cancer Research Fund International (WCRF)); Wellcome Trust(Wellcome TrustEuropean Commission)	The authors thank Nicky Evans for editorial help with writing this paper, and Albert Hallsworth, Melanie Valenti and Gary Box for assisting with the mouse work. We thank the Vogelstein laboratory for providing isogenic TP53<SUP>-/-</SUP> and TP53<SUP>WT</SUP> HCT116 human colorectal cancer cells. Financial support: The work was supported by grants from Cancer Research UK (ref. C309/A11566, ref. C309/A8274 and ref. C309/A8992 (PW), ref. C423/A1421 and ref. C423/A15043 (SM)) and the World Cancer Research Fund (WCRF) (ref. 12-1280). CZ was supported by a Wellcome Trust studentship (ref. 094885/Z/10/Z). PW is a Cancer Research UK Life Fellow. The funders had no role in the design of the study, the collection, analysis and interpretation of the data, the writing of the paper or the decision to submit the paper for publication.	Asghar U, 2015, NAT REV DRUG DISCOV, V14, P130, DOI 10.1038/nrd4504; Bilgin B, 2017, CURR MED RES OPIN, V33, P1559, DOI 10.1080/03007995.2017.1348344; Binne UK, 2007, NAT CELL BIOL, V9, P225, DOI 10.1038/ncb1532; Blagg J, 2017, CANCER CELL, V32, P9, DOI 10.1016/j.ccell.2017.06.005; Bond M, 2004, J BIOL CHEM, V279, P37304, DOI 10.1074/jbc.M404307200; Bryant P, 2006, MOL CELL BIOL, V26, P4201, DOI 10.1128/MCB.01612-05; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cabodi S, 2010, ADV EXP MED BIOL, V674, P43; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; Choi YJ, 2014, ONCOGENE, V33, P1890, DOI 10.1038/onc.2013.137; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Dean JL, 2010, ONCOGENE, V29, P4018, DOI 10.1038/onc.2010.154; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Engels B, 2012, SEMIN CANCER BIOL, V22, P41, DOI 10.1016/j.semcancer.2011.12.008; Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419; Franco J, 2014, ONCOTARGET, V5, P6512, DOI 10.18632/oncotarget.2270; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Gentile A, 2008, CANCER METAST REV, V27, P85, DOI 10.1007/s10555-007-9107-6; Goel S, 2016, CANCER CELL, V29, P255, DOI 10.1016/j.ccell.2016.02.006; Golubovskaya VM, 2014, FRONT BIOSCI-LANDMRK, V19, P687, DOI 10.2741/4236; Gu JM, 2004, MOL BIOL CELL, V15, P3320, DOI 10.1091/mbc.E04-03-0227; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Hamilton E, 2016, CANCER TREAT REV, V45, P129, DOI 10.1016/j.ctrv.2016.03.002; Herrera-Abreu MT, 2016, CANCER RES, V76, P2301, DOI 10.1158/0008-5472.CAN-15-0728; Huang G, 2014, ANTI-CANCER AGENT ME, V14, P9, DOI 10.2174/18715206113139990141; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Knudsen ES, 2017, TRENDS CANCER, V3, P39, DOI 10.1016/j.trecan.2016.11.006; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; Leontieva OV, 2013, CELL CYCLE, V12, P3063, DOI 10.4161/cc.26130; Lv PC, 2018, EXPERT OPIN THER PAT, V28, P139, DOI 10.1080/13543776.2018.1414183; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Matsumoto K, 2006, INT J CANCER, V119, P477, DOI 10.1002/ijc.21808; O'Leary B, 2016, NAT REV CLIN ONCOL, V13, P417, DOI 10.1038/nrclinonc.2016.26; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Richardson E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031627; Rocca A, 2017, THER ADV MED ONCOL, V9, P83, DOI 10.1177/1758834016677961; Roy-Luzarraga M, 2016, CLIN CANCER RES, V22, P3718, DOI 10.1158/1078-0432.CCR-14-2021; Satyanarayana A, 2009, ONCOGENE, V28, P2925, DOI 10.1038/onc.2009.170; Schettini F, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00608; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Sherr CJ, 2016, CANCER DISCOV, V6, P353, DOI 10.1158/2159-8290.CD-15-0894; Sherr CJ, 2000, CANCER RES, V60, P3689; Shibue T, 2013, CANCER CELL, V24, P481, DOI 10.1016/j.ccr.2013.08.012; Swanton C, 2007, CANCER CELL, V11, P498, DOI 10.1016/j.ccr.2007.04.011; Verschuren EW, 2007, DEV CELL, V12, P169, DOI 10.1016/j.devcel.2007.01.015; Wang L, 2007, BLOOD, V110, P2075, DOI 10.1182/blood-2007-02-071266; Whittaker SR, 2017, PHARMACOL THERAPEUT, V173, P83, DOI 10.1016/j.pharmthera.2017.02.008; Ye F, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-S8-S3; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997; 1988, LAB ANIM UK, V22, P195	52	13	14	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 25	2019	38	30					5905	5920		10.1038/s41388-019-0850-2	http://dx.doi.org/10.1038/s41388-019-0850-2			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IT3FY	31296956	hybrid, Green Published, Green Submitted			2022-12-28	WOS:000482739300005
J	Tsai, FJ; Lai, MT; Cheng, J; Chao, SCC; Korla, PK; Chen, HJ; Lin, CM; Tsai, MH; Hua, CH; Jan, CI; Jinawath, N; Wu, CC; Chen, CM; Kuo, BYT; Chen, LW; Yang, J; Hwang, T; Sheu, JJC				Tsai, Fuu-Jen; Lai, Ming-Tsung; Cheng, Jack; Chao, Stev Chun-Chin; Korla, Praveen Kumar; Chen, Hui-Jye; Lin, Chung-Ming; Tsai, Ming-Hsui; Hua, Chun-Hung; Jan, Chia-Ing; Jinawath, Natini; Wu, Chia-Chen; Chen, Chih-Mei; Kuo, Brian Yu-Ting; Chen, Li-Wen; Yang, Jacky; Hwang, Tritium; Sheu, Jim Jinn-Chyuan			Novel K6-K14 keratin fusion enhances cancer sternness and aggressiveness in oral squamous cell carcinoma	ONCOGENE			English	Article							GENOMIC CHARACTERIZATION; RHABDOID FEATURES; STEM-CELLS; HEAD; ORGANIZATION; EXPRESSION; INVASION; METASTASIS; RESISTANCE; MIGRATION	Keratin intermediate filament (IF) is one component of cellular architectures, which provides necessary mechanical support to conquer environmental stresses. Recent findings reveal its involvement in mechano-transduction and the associated stem cell reprogramming, suggesting the possible roles in cancer development. Here, we report t(12;17)(q13.13;q21.2) chromosomal rearrangement as the most common fusion event in OSCC, resulting in a variety of inter-keratin fusions. Junction site mapping verified 9 in-frame K6-K14 variants, three of which were correlated with lymph node invasion, late tumor stages (T3/T4) and shorter disease-free survival times. When expressed in OSCC cells, those fusion variants disturbed wild-type K14 organization through direct interaction or aggregate formation, leading to perinuclear structure loss and nuclear deformation. Protein array analyses showed the ability of K6-K14 variant 7 (K6-K14/V7) to upregulate TGF-beta and G-CSF signaling, which contributed to cell stemness, drug tolerance, and cell aggressiveness. Notably, K6-K14/V7-expressing cells easily adapted to a soft 3-D culture condition in vitro and formed larger, less differentiated tumors in vivo. In addition to the anti-mechanical-stress activity, our data uncover oncogenic functionality of novel keratin filaments caused by gene fusions during OSCC development.	[Tsai, Fuu-Jen; Cheng, Jack; Chao, Stev Chun-Chin; Chen, Chih-Mei; Sheu, Jim Jinn-Chyuan] China Med Univ Hosp, Human Genet Ctr, Taichung 40447, Taiwan; [Tsai, Fuu-Jen; Sheu, Jim Jinn-Chyuan] China Med Univ, Sch Chinese Med, Taichung 40402, Taiwan; [Lai, Ming-Tsung] Taichung Hosp, Minist Hlth & Welf, Dept Pathol, Taichung 40343, Taiwan; [Korla, Praveen Kumar; Wu, Chia-Chen; Kuo, Brian Yu-Ting; Chen, Li-Wen; Yang, Jacky; Hwang, Tritium; Sheu, Jim Jinn-Chyuan] Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung 80424, Taiwan; [Chen, Hui-Jye] China Med Univ, Sch Med, Taichung 40402, Taiwan; [Lin, Chung-Ming] Ming Chuan Univ, Dept Biotechnol, Taoyuan 33348, Taiwan; [Tsai, Ming-Hsui; Hua, Chun-Hung] China Med Univ Hosp, Dept Otolaryngol, Taichung 40447, Taiwan; [Jan, Chia-Ing] China Med Univ Hosp, Dept Pathol, Taichung 40447, Taiwan; [Jinawath, Natini] Mahidol Univ, Ramathibodi Hosp, Fac Med, Program Translat Med, Bangkok 10400, Thailand; [Sheu, Jim Jinn-Chyuan] Asia Univ, Dept Hlth & Nutr Biotechnol, Taichung 41354, Taiwan	China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; National Sun Yat Sen University; China Medical University Taiwan; Ming Chuan University; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; Mahidol University; Asia University Taiwan	Sheu, JJC (corresponding author), China Med Univ Hosp, Human Genet Ctr, Taichung 40447, Taiwan.; Sheu, JJC (corresponding author), China Med Univ, Sch Chinese Med, Taichung 40402, Taiwan.; Sheu, JJC (corresponding author), Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung 80424, Taiwan.; Sheu, JJC (corresponding author), Asia Univ, Dept Hlth & Nutr Biotechnol, Taichung 41354, Taiwan.	jimsheu@mail.nsysu.edu.tw	Korla, Praveen Kumar/AAZ-4949-2020	Korla, Praveen Kumar/0000-0003-1655-625X	Ministry of Science and Technology (MOST), Taiwan [NSC-102-2628-B-039-001-MY3, MOST 103-2314-B-039-009-MY3, MOST 106-2314-B-110-001-MY3]; NSYSU-KMU joint research projects [107-P012, 105-P021]	Ministry of Science and Technology (MOST), Taiwan; NSYSU-KMU joint research projects	The authors thank technical assistance from Ms. Lesley Lin at China Medical University Hospital and Mr. Ming-Der Pong at National Sun Yatsen University. The authors also thank critical comments from Prof. Mien-Chie Hung at MD Anderson Cancer Center/U.S., Prof. Chung Chang at National Sun Yatsen University/Taiwan, Prof. Ming-Jer Tang at National Cheng Kung University/Taiwan, and Prof. Ka-Lok Ng at Asia University/Taiwan. This study was supported by grants from Ministry of Science and Technology (MOST), Taiwan with numbers: NSC-102-2628-B-039-001-MY3, MOST 103-2314-B-039-009-MY3, and MOST 106-2314-B-110-001-MY3, and the NSYSU-KMU joint research projects: 107-P012 and 105-P021.	Agarwal S, 2015, CANCER RES, V75, P2566, DOI 10.1158/0008-5472.CAN-14-2946; Baillie R, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00112; Beil M, 2003, NAT CELL BIOL, V5, P803, DOI 10.1038/ncb1037; Bu W, 2011, ONCOGENE, V30, P4399, DOI 10.1038/onc.2011.147; Chen JL, 2006, J CELL SCI, V119, P5067, DOI 10.1242/jcs.03298; Cheung KJ, 2016, P NATL ACAD SCI USA, V113, pE854, DOI 10.1073/pnas.1508541113; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Chu PG, 2002, HISTOPATHOLOGY, V40, P403, DOI 10.1046/j.1365-2559.2002.01387.x; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Feng X, 2015, J BIOL CHEM, V290, P22507, DOI 10.1074/jbc.M115.654749; Feng X, 2015, J CELL BIOL, V209, P59, DOI 10.1083/jcb.201408079; Fortier AM, 2013, J BIOL CHEM, V288, P11555, DOI 10.1074/jbc.M112.428920; Foty R, 2011, JOVE-J VIS EXP, DOI 10.3791/2720; Fuxe J, 2010, CELL CYCLE, V9, P2363, DOI 10.4161/cc.9.12.12050; Gemenetzidis E, 2015, ONCOTARGET, V6, P43964, DOI 10.18632/oncotarget.6268; Guo T, 2016, INT J CANCER, V139, P373, DOI 10.1002/ijc.30081; Hsu DM, 2013, CANCER RES, V73, P4134, DOI 10.1158/0008-5472.CAN-12-4056; Iwaya K, 2005, SEMIN CANCER BIOL, V15, P309, DOI 10.1016/j.semcancer.2005.04.006; Joosse SA, 2012, CLIN CANCER RES, V18, P993, DOI 10.1158/1078-0432.CCR-11-2100; Kang NY, 2011, NAT PROTOC, V6, P1044, DOI 10.1038/nprot.2011.350; Karantza V, 2011, ONCOGENE, V30, P127, DOI 10.1038/onc.2010.456; Kawai T, 2015, CLIN CANCER RES, V21, P3081, DOI 10.1158/1078-0432.CCR-14-1936; Kim S, 2006, NATURE, V441, P362, DOI 10.1038/nature04659; Kuroiwa K, 2002, HISTOPATHOLOGY, V41, P538, DOI 10.1046/j.1365-2559.2002.01427.x; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Li R, 2015, HEAD NECK-J SCI SPEC, V37, P1642, DOI 10.1002/hed.23807; Loschke F, 2015, CURR OPIN CELL BIOL, V32, P56, DOI 10.1016/j.ceb.2014.12.006; McGregor AL, 2016, CURR OPIN CELL BIOL, V40, P32, DOI 10.1016/j.ceb.2016.01.011; Moll R, 2008, HISTOCHEM CELL BIOL, V129, P705, DOI 10.1007/s00418-008-0435-6; Ohmoto T, 2015, PATHOL INT, V65, P264, DOI 10.1111/pin.12283; Pickering CR, 2013, CANCER DISCOV, V3, P770, DOI 10.1158/2159-8290.CD-12-0537; Przybycin CG, 2014, AM J SURG PATHOL, V38, P1260, DOI 10.1097/PAS.0000000000000251; Reinholz MM, 2011, CLIN CANCER RES, V17, P7183, DOI 10.1158/1078-0432.CCR-11-0981; Rudland SD, 2011, AM J PATHOL, V179, P1061, DOI 10.1016/j.ajpath.2011.04.022; Sawant MS, 2017, INT REV CEL MOL BIO, V330, P171, DOI 10.1016/bs.ircmb.2016.09.005; Seiwert TY, 2015, CLIN CANCER RES, V21, P632, DOI 10.1158/1078-0432.CCR-13-3310; Seltmann K, 2013, P NATL ACAD SCI USA, V110, P18507, DOI 10.1073/pnas.1310493110; Sewell A, 2014, CLIN CANCER RES, V20, P2300, DOI 10.1158/1078-0432.CCR-13-2585; Sheu JJC, 2014, ONCOGENE, V33, P1375, DOI 10.1038/onc.2013.98; Sheu JJC, 2009, CANCER RES, V69, P2568, DOI 10.1158/0008-5472.CAN-08-3199; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Snider NT, 2014, NAT REV MOL CELL BIO, V15, P163, DOI 10.1038/nrm3753; Souto GR, 2010, J ORAL PATHOL MED, V39, P605, DOI 10.1111/j.1600-0714.2010.00907.x; Sugimoto K, 2016, BRAIN TUMOR PATHOL, V33, P137, DOI 10.1007/s10014-015-0243-3; Swift J, 2013, SCIENCE, V341, DOI 10.1126/science.1240104; van Helvert S, 2018, NAT CELL BIOL, V20, P8, DOI 10.1038/s41556-017-0012-0; Wang GY, 2011, CANCER CELL, V19, P114, DOI 10.1016/j.ccr.2010.11.007; Willipinski-Stapelfeldt B, 2005, CLIN CANCER RES, V11, P8006, DOI 10.1158/1078-0432.CCR-05-0632; Yoshihara K, 2015, ONCOGENE, V34, P4845, DOI 10.1038/onc.2014.406; Zaphiropoulos Peter G., 2011, Frontiers in Genetics, V2, P92, DOI 10.3389/fgene.2011.00092	50	8	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2019	38	26					5113	5126		10.1038/s41388-019-0781-y	http://dx.doi.org/10.1038/s41388-019-0781-y			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IF4AX	30867567				2022-12-28	WOS:000473025300001
J	Sinha, KM; Bagheri-Yarmand, R; Lahiri, S; Lu, Y; Zhang, M; Amra, S; Rizvi, Y; Wan, XH; Navone, N; Ozpolat, B; Logothetis, C; Gagel, RF; Huard, J				Sinha, Krishna M.; Bagheri-Yarmand, Rozita; Lahiri, Sharmistha; Lu, Yue; Zhang, Miao; Amra, Sarah; Rizvi, Yasmeen; Wan, Xinhai; Navone, Nora; Ozpolat, Bulent; Logothetis, Christopher; Gagel, Robert F.; Huard, Johnny			Oncogenic and osteolytic functions of histone demethylase NO66 in castration-resistant prostate cancer	ONCOGENE			English	Article							TRANSCRIPTION FACTOR OSTERIX; PROTEIN SIGNALING 2; GENE-EXPRESSION; BETA-CATENIN; EPIGENETIC REGULATION; BONE METASTASES; CELLS; PROMOTES; GROWTH; REGULATOR	Epigenetic changes that cause dysregulated gene expression during progression of androgen-independent prostate cancer (PCa) and metastatic skeletal lesions remain elusive. Here, we explored the role of histone demethylase NO66 in the pathogenesis of PCa and bone metastasis-related skeletal lesions. Tissue and cDNA microarrays of PCa were analyzed for NO66 mRNA and protein levels. We examined the effects of gain and loss of NO66 function on cell viability, colony formation, migration, invasion, and tumor-induced skeletal lesions in femoral bone. RNAseq and ChIPseq were performed to elucidate NO66-target genes in PCa. We report that NO66 levels were upregulated in advanced primary prostate tumors compared to normal tissue or tumors with low Gleason scores. Forced expression of N066 promoted cell survival and invasion of PCa cells; whereas, knockdown of NO66 resulted in decreased cell survival and increased sensitivity to docetaxel. NO66-overexpressing PC3 cells implanted into the femoral bone of male SCID mice caused massive bone loss and stimulation of mouse osteoclast-promoting genes, including Dickkopf1, Cathepsin K, Nf-k beta,; and Cater, suggesting a role for NO66 in tumor growth in bone and osteoclast activity. Combined RNAseq and ChIP-seq revealed that NO66 activates the survival gene MCL1, the invasion-associated genes IGFBP5 and MMP3, the pro-oncogenic genes CTNNB1 and CCND1, and the epigenetic modifier gene KMT2A in androgen-independent PCa. Our findings uncover the role of NO66 as a key oncogenic driver in PCa, causing osteolytic lesions through upstream epigenetic regulation of key genes for survival, invasion and metastasis, and pro-osteoclastic factors.	[Sinha, Krishna M.; Bagheri-Yarmand, Rozita; Lahiri, Sharmistha; Rizvi, Yasmeen; Gagel, Robert F.] Univ Texas MD Anderson Canc Ctr, Endocrine Neoplasia & Hormonal Disorders, Houston, TX 77030 USA; [Sinha, Krishna M.; Amra, Sarah; Huard, Johnny] Univ Texas MD Anderson Canc Ctr, Dept Orthopaed Surg, McGovern Med Sch, Houston, TX 77030 USA; [Lu, Yue] Univ Texas MD Anderson Canc Ctr, Epigenet & Mol Carcinogenesis, Houston, TX 77030 USA; [Zhang, Miao; Wan, Xinhai; Navone, Nora; Logothetis, Christopher] Univ Texas MD Anderson Canc Ctr, Genitourinary Med Oncol, Houston, TX 77030 USA; [Ozpolat, Bulent] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Huard, Johnny] Steadman Philippon Res Inst, Vail, CO 81657 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Steadman Philippon Research Institute	Sinha, KM (corresponding author), Univ Texas MD Anderson Canc Ctr, Endocrine Neoplasia & Hormonal Disorders, Houston, TX 77030 USA.; Sinha, KM; Huard, J (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Orthopaed Surg, McGovern Med Sch, Houston, TX 77030 USA.; Huard, J (corresponding author), Steadman Philippon Res Inst, Vail, CO 81657 USA.	Krishna.M.Sinha@uth.tmc.edu; Johnny.Huard@uth.tmc.edu		Lahiri, Sharmistha/0000-0001-9215-3634; Lu, Yue/0000-0002-5479-9095; Zhang, Miao/0000-0003-4912-2570; Ozpolat, Bulent/0000-0001-8602-7463; Bagheri-Yarmand, Rozita/0000-0001-5139-6381	National Institutes of Health [P50 CA140388]; Bone Diseases Program of Texas; UTHealth startup fund; Center for Epigenetics at MDACC allowance for Next-Gen sequencing; NATIONAL CANCER INSTITUTE [P50CA140388] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bone Diseases Program of Texas; UTHealth startup fund; Center for Epigenetics at MDACC allowance for Next-Gen sequencing; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by National Institutes of Health Grant P50 CA140388 (NCI-SPORE-Developmental Research Program) to CL and KMS, Center for Epigenetics at MDACC allowance for Next-Gen sequencing to KMS, the Bone Diseases Program of Texas to RFG, and by UTHealth startup funding to JH.	Adeniji AO, 2013, J STEROID BIOCHEM, V137, P136, DOI 10.1016/j.jsbmb.2013.05.012; Akech J, 2010, ONCOGENE, V29, P811, DOI 10.1038/onc.2009.389; Bagheri-Yarmand R, 2001, J BIOL CHEM, V276, P29403, DOI 10.1074/jbc.M103129200; Begley LA, 2008, NEOPLASIA, V10, P244, DOI 10.1593/neo.07976; Bettin A, 2016, INT J BIOL MARKER, V31, pE153, DOI 10.5301/jbm.5000184; Bragina O, 2010, ONCOL LETT, V1, P319, DOI 10.3892/ol_00000057; Brien GL, 2012, NAT STRUCT MOL BIOL, V19, P1273, DOI 10.1038/nsmb.2449; Cacan E, 2017, J CHEMOTHERAPY, V29, P173, DOI 10.1080/1120009X.2016.1277007; Cai SW, 2015, ONCOTARGET, V6, P3904, DOI 10.18632/oncotarget.2880; Chen GP, 2004, CANCER-AM CANCER SOC, V101, P1345, DOI 10.1002/cncr.20518; Chen XG, 2015, MOL CARCINOGEN, V54, P1086, DOI 10.1002/mc.22177; Chowdhury R, 2014, NATURE, V510, P422, DOI 10.1038/nature13263; Chowdry RP, 2016, CAN J UROL, V23, P8483; Crea F, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-52; D'Souza S, 2012, BLOOD, V119, P1888, DOI 10.1182/blood-2011-11-393348; Ellinger J, 2010, PROSTATE, V70, P61, DOI 10.1002/pros.21038; Feeley BT, 2006, BONE, V38, P154, DOI 10.1016/j.bone.2005.07.015; Feeley BT, 2005, J BONE MINER RES, V20, P2189, DOI 10.1359/JBMR.050802; Ge C, 2016, ONCOGENE, V35, P366, DOI 10.1038/onc.2015.91; Ge W, 2012, NAT CHEM BIOL, V8, P960, DOI [10.1038/NCHEMBIO.1093, 10.1038/nchembio.1093]; Guo X, 2015, TUMOR BIOL, V36, P9303, DOI 10.1007/s13277-015-3676-8; Ji K, 2013, INT J MOL MED, V32, P747, DOI 10.3892/ijmm.2013.1472; Jin HJ, 2013, CANCER RES, V73, P3725, DOI 10.1158/0008-5472.CAN-12-3468; Joly MM, 2016, CANCER RES, V76, P4752, DOI 10.1158/0008-5472.CAN-15-3393; Kim TD, 2016, J CLIN INVEST, V126, P706, DOI 10.1172/JCI78132; Lee YC, 2011, CANCER RES, V71, P5194, DOI 10.1158/0008-5472.CAN-10-4374; Li ZG, 2008, J CLIN INVEST, V118, P2697, DOI 10.1172/JCI33093; Liang GD, 2018, BIOCHEM CELL BIOL, V96, P332, DOI 10.1139/bcb-2017-0151; Liang GD, 2018, ACTA HISTOCHEM, V120, P56, DOI 10.1016/j.acthis.2017.11.002; Liu XH, 2007, CANCER RES, V67, P5747, DOI 10.1158/0008-5472.CAN-07-0478; Logothetis CJ, 2008, CLIN CANCER RES, V14, P1599, DOI 10.1158/1078-0432.CCR-07-4603; Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528; Malik R, 2015, NAT MED, V21, P344, DOI 10.1038/nm.3830; Nandana S, 2017, CANCER RES, V77, P1331, DOI 10.1158/0008-5472.CAN-16-0497; Nishizawa Y, 2017, ANN SURG ONCOL, V24, P841, DOI 10.1245/s10434-016-5395-9; Ortiz A, 2012, RECENT RESULTS CANC, V192, P225, DOI 10.1007/978-3-642-21892-7_11; Park MH, 2012, IMMUNOLOGY, V135, P63, DOI 10.1111/j.1365-2567.2011.03513.x; Pires-Luis AS, 2015, EPIGENETICS-US, V10, P1033, DOI 10.1080/15592294.2015.1103578; Rebollo Juan, 2017, Int J Biomed Sci, V13, P35; Saha B, 2008, PROSTATE, V68, P1681, DOI 10.1002/pros.20836; Shang CL, 2016, ONCOL REP, V35, P3185, DOI 10.3892/or.2016.4715; Sheth S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051655; Sinha KM, 2014, J BONE MINER RES, V29, P855, DOI 10.1002/jbmr.2103; Sinha KM, 2013, J CELL BIOCHEM, V114, P975, DOI 10.1002/jcb.24439; Sinha KM, 2010, EMBO J, V29, P68, DOI 10.1038/emboj.2009.332; Sottnik Joseph L, 2012, Bonekey Rep, V1, P101, DOI 10.1038/bonekey.2012.101; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; Suzuki C, 2007, MOL CANCER THER, V6, P542, DOI 10.1158/1535-7163.MCT-06-0659; Tamada H, 2001, J BONE MINER RES, V16, P487, DOI 10.1359/jbmr.2001.16.3.487; Tao Y, 2013, J BIOL CHEM, V288, P16430, DOI 10.1074/jbc.M112.446849; Theurillat JPP, 2014, SCIENCE, V346, P85, DOI 10.1126/science.1250255; Verras M, 2006, CANCER LETT, V237, P22, DOI 10.1016/j.canlet.2005.06.004; Vieira FQ, 2014, ENDOCR-RELAT CANCER, V21, P51, DOI 10.1530/ERC-13-0375; Wan XH, 2012, CLIN CANCER RES, V18, P726, DOI 10.1158/1078-0432.CCR-11-2521; Wang HH, 2012, AM J PATHOL, V180, P1170, DOI 10.1016/j.ajpath.2011.11.020; Wang SW, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0869-2; Wang ZW, 2012, CANCER DISCOV, V2, P489, DOI 10.1158/2159-8290.CD-12-0177; Wolff DW, 2012, INT J CANCER, V130, P1521, DOI 10.1002/ijc.26138; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Yang B, 2016, CANCER BIOMARK, V17, P223, DOI 10.3233/CBM-160634; Yang YA, 2013, PROTEIN CELL, V4, P331, DOI 10.1007/s13238-013-2093-2; Yepuru M, 2013, CLIN CANCER RES, V19, P5613, DOI 10.1158/1078-0432.CCR-13-1151; Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498; Zeng CM, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00119; Zhou HJ, 2005, CANCER RES, V65, P7976, DOI 10.1158/0008-5472.CAN-04-4076	65	10	11	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2019	38	25					5038	5049		10.1038/s41388-019-0774-x	http://dx.doi.org/10.1038/s41388-019-0774-x			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IE1KY	30858546				2022-12-28	WOS:000472145900011
J	Wang, Y; Xie, BH; Lin, WH; Huang, YH; Ni, JY; Hu, J; Cui, W; Zhou, J; Shen, L; Xu, LF; Lian, F; Li, HP				Wang, Yu; Xie, Bin-hui; Lin, Wei-hao; Huang, Yong-hui; Ni, Jia-yan; Hu, Jie; Cui, Wei; Zhou, Jun; Shen, Long; Xu, Lin-feng; Lian, Fan; Li, He-ping			Amplification of SMYD3 promotes tumorigenicity and intrahepatic metastasis of hepatocellular carcinoma via upregulation of CDK2 and MMP2	ONCOGENE			English	Article							DOMAIN-CONTAINING PROTEIN-3; MATRIX METALLOPROTEINASES; CELL-PROLIFERATION; LYSINE METHYLATION; EARLY-DIAGNOSIS; POOR-PROGNOSIS; RISK-FACTORS; CANCER; OVEREXPRESSION; EXPRESSION	SMYD3, a member that belongs to the SET and MYND-domain (SMYD) family, has also been proven to largely participate in gene transcription regulation and progression of several human cancers as a histone lysine methyltransferase. However, the role and significance of SMYD3 in both the clinic and progression of hepatocellular carcinoma (HCC) remain unclear. Herein, we find that SMYD3 is increased in cirrhotic livers, and strikingly upregulated in hepatocellular carcinoma (HCC) tissues and cell lines. Subsequent analyses suggest that high expression level of SMYD3 significantly correlates with the malignant characteristics of HCC, and predicts poor prognosis in patients. Our results show that overexpression of SMYD3 increases, while silencing of SMYD3 inhibits, cell proliferation, invasiveness and tumorigenicity both in vitro and in vivo. SMYD3 also promotes intrahepatic metastasis of HCC cells. For the mechanisms, we identify that SMYD3 bound to CDK2 and MMP2 promoter and increased H3K4me3 modification at the corresponding promoters to promote gene transcription. Importantly, pharmacological targeting of SMYD3 with BCI-121 inhibitor effectively repressed the tumorigenicity of HCC cells. Finally, our results show that gene locus amplification is a cause for SMYD3 overexpression in HCC. These findings not only uncover that SMYD3 overexpression promotes the tumorigenicity and intrahepatic metastasis of HCC cell via upregulation of CDK2 and MMP2, but also suggest SMYD3 could be a practical prognosis marker or therapeutic target against the disease.	[Wang, Yu; Cui, Wei; Shen, Long] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Intervent Oncol, Guangzhou 510080, Guangdong, Peoples R China; [Xie, Bin-hui] Gannan Med Univ, Dept Hepatobiliary Surg, Affiliated Hosp 1, Ganzhou 341000, Peoples R China; [Lin, Wei-hao] Sun Yat Sen Univ, Dept Thyroid & Breast Surg, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China; [Huang, Yong-hui] Sun Yat Sen Univ, Dept Intervent Radiol, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China; [Ni, Jia-yan; Xu, Lin-feng] Sun Yat Sen Univ, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Dept Intervent Radiol, Sun Yat Sen Mem Hosp, Guangzhou 510120, Guangdong, Peoples R China; [Hu, Jie; Li, He-ping] Sun Yat Sen Univ, Dept Med Oncol, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China; [Zhou, Jun; Lian, Fan] Sun Yat Sen Univ, Dept Rheumatol & Clin Immunol, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China	Sun Yat Sen University; Gannan Medical University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Xu, LF (corresponding author), Sun Yat Sen Univ, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Dept Intervent Radiol, Sun Yat Sen Mem Hosp, Guangzhou 510120, Guangdong, Peoples R China.; Li, HP (corresponding author), Sun Yat Sen Univ, Dept Med Oncol, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China.; Lian, F (corresponding author), Sun Yat Sen Univ, Dept Rheumatol & Clin Immunol, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China.	xulf1@21cn.com; lianfan_1@hotmail.com; drliheping@163.com		Huang, Yonghui/0000-0001-5921-583X	Natural Science Foundation of China [30600156, 30970837, 81101135, 81102270, 81602701, 81760496]; Natural Science Foundation of Guangdong Province [2014A030313053, 2016A030313278, 2016A030313365, 2017A030313547]; Science and Technology Projects Foundation of Guangdong Province [2015A070710006, 2016A020215053]; Science and Technology Projects Foundation of Guangzhou City [201507020037, 201607010260]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Science and Technology Projects Foundation of Guangdong Province; Science and Technology Projects Foundation of Guangzhou City	This study was supported by the grants including Natural Science Foundation of China (No. 30600156; 30970837; 81101135; 81102270; 81602701, 81760496), Natural Science Foundation of Guangdong Province (No. 2014A030313053; 2016A030313278; 2016A030313365; 2017A030313547), Science and Technology Projects Foundation of Guangdong Province (No. 2015A070710006; 2016A020215053), and Science and Technology Projects Foundation of Guangzhou City (No. 201507020037; 201607010260).	Chen LB, 2007, WORLD J GASTROENTERO, V13, P5718, DOI 10.3748/wjg.v13.i43.5718; Cock-Rada AM, 2012, CANCER RES, V72, P810, DOI 10.1158/0008-5472.CAN-11-1052; Dai B, 2015, ONCOL REP, V34, P2722, DOI 10.3892/or.2015.4239; Della Corte C, 2016, LIVER INT, V36, P166, DOI 10.1111/liv.12965; Dong SW, 2014, ONCOL REP, V32, P1064, DOI 10.3892/or.2014.3307; Duarte S, 2015, MATRIX BIOL, V44-46, P147, DOI 10.1016/j.matbio.2015.01.004; Farinati F, 2006, AM J GASTROENTEROL, V101, P524, DOI 10.1111/j.1572-0241.2006.00443.x; Foreman KW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022290; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Furuta M, 2017, J HEPATOL, V66, P363, DOI 10.1016/j.jhep.2016.09.021; Giannandrea M, 2014, DIS MODEL MECH, V7, P193, DOI 10.1242/dmm.012062; Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173; Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151; Hamamoto R, 2006, CANCER SCI, V97, P113, DOI 10.1111/j.1349-7006.2006.00146.x; Hao SH, 2017, J GASTROINTEST SURG, V21, P312, DOI 10.1007/s11605-016-3311-z; He CC, 2012, HUM PATHOL, V43, P1425, DOI 10.1016/j.humpath.2011.11.003; Hu LP, 2009, CANCER RES, V69, P4067, DOI 10.1158/0008-5472.CAN-08-4097; Huang L, 2017, AM J TRANSL RES, V9, P1; Imamura H, 2003, J HEPATOL, V38, P200, DOI 10.1016/S0168-8278(02)00360-4; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kim H, 2009, J BIOL CHEM, V284, P19867, DOI 10.1074/jbc.M109.021485; Komatsu S, 2015, BRIT J CANCER, V112, P357, DOI 10.1038/bjc.2014.543; Kunizaki M, 2007, CANCER RES, V67, P10759, DOI 10.1158/0008-5472.CAN-07-1132; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Liu C, 2007, CANCER RES, V67, P2626, DOI 10.1158/0008-5472.CAN-06-4126; Liu C, 2013, JNCI-J NATL CANCER I, V105, P1719, DOI 10.1093/jnci/djt304; Liu C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052703; Liu Y, 2015, TUMOR BIOL, V36, P4377, DOI 10.1007/s13277-015-3077-z; Liu Y, 2015, TUMOR BIOL, V36, P2685, DOI 10.1007/s13277-014-2891-z; Ma WJ, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-212; Mazur PK, 2014, NATURE, V510, P283, DOI 10.1038/nature13320; Notarpaolo A, 2017, J HEPATOL, V66, P552, DOI 10.1016/j.jhep.2016.10.038; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Peserico A, 2015, J CELL PHYSIOL, V230, P2447, DOI 10.1002/jcp.24975; Raje N, 2005, BLOOD, V106, P1042, DOI 10.1182/blood-2005-01-0320; Ren TN, 2011, MED ONCOL, V28, pS91, DOI 10.1007/s12032-010-9718-6; Sarris ME, 2016, CANCER CELL, V29, P354, DOI 10.1016/j.ccell.2016.01.013; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; Stender JD, 2012, MOL CELL, V48, P28, DOI 10.1016/j.molcel.2012.07.020; Tan XG, 2006, P NATL ACAD SCI USA, V103, P7935, DOI 10.1073/pnas.0602555103; Thomenius MJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197372; Tracy CM, 2018, CURR OPIN PHYSIOL, V1, P140, DOI 10.1016/j.cophys.2017.10.001; Tsuchiya N, 2015, WORLD J GASTROENTERO, V21, P10573, DOI 10.3748/wjg.v21.i37.10573; Van Aller GS, 2012, EPIGENETICS-US, V7, P340, DOI 10.4161/epi.19506; Venkatesh HS, 2017, NATURE, V549, P533, DOI 10.1038/nature24014; Wang L, 2017, J GASTRIC CANCER, V17, P295, DOI 10.5230/jgc.2017.17.e33; Xu ST, 2011, J MOL CELL BIOL, V3, P293, DOI 10.1093/jmcb/mjr015; Zhang XD, 2018, NUCLEIC ACIDS RES, V46, P1793, DOI 10.1093/nar/gkx1259; Zou JN, 2009, CANCER LETT, V280, P78, DOI 10.1016/j.canlet.2009.02.015	49	36	38	4	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2019	38	25					4948	4961		10.1038/s41388-019-0766-x	http://dx.doi.org/10.1038/s41388-019-0766-x			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IE1KY	30842588				2022-12-28	WOS:000472145900005
J	Kresinsky, A; Schnoder, TM; Jacobsen, ID; Rauner, M; Hofbauer, LC; Ast, V; Konig, R; Hoffmann, B; Svensson, CM; Figge, MT; Hilger, I; Heidel, FH; Bohmer, FD; Muller, JP				Kresinsky, Anne; Schnoeder, Tina M.; Jacobsen, Ilse D.; Rauner, Martina; Hofbauer, Lorenz C.; Ast, Volker; Koenig, Rainer; Hoffmann, Bianca; Svensson, Carl-Magnus; Figge, Marc Thilo; Hilger, Ingrid; Heidel, Florian H.; Boehmer, Frank-D.; Mueller, Joerg P.			Lack of CD45 in FLT3-ITD mice results in a myeloproliferative phenotype, cortical porosity, and ectopic bone formation	ONCOGENE			English	Article							INTERNAL TANDEM DUPLICATION; ACUTE MYELOID-LEUKEMIA; PROTEIN-TYROSINE PHOSPHATASES; CELL-TRANSFORMATION; STEM-CELLS; B-CELL; MUTATIONS; DISEASE; LIGAND; PROGENITORS	The receptor tyrosine kinase FLT3 is expressed in myeloid and lymphoid progenitor cells. Activating mutations in FLT3 occur in 25-30% of acute myeloid leukaemia (AML) patients. Most common are internal tandem duplications of sequence (ITD) leading to constitutive FLT3-ITD kinase activity with an altered signalling quality promoting leukaemic cell transformation. Here, we observed the attenuating role of the receptor-like protein tyrosine phosphatase (RPTP) CD45/Ptprc in FLT3 signalling in vivo. Low level expression of this abundant RPTP correlates with a poor prognosis of FLT3-ITD-positive AML patients. To get a further insight into the regulatory role of Ptprc in FLT3-ITD activity in vivo, Ptprc knockout mice were bred with FLT3-ITD knock-in mice. Inactivation of the Ptprc gene in FLT3-ITD mice resulted in a drastically shortened life span and development of severe monocytosis, a block in B-cell development and anaemia. The myeloproliferative phenotype was associated with extramedullary haematopoiesis, splenohepatomegaly and severe alterations of organ structures. The phenotypic alterations were associated with increased transforming signalling of FLT3-ITD, including activation of its downstream target STAT5. These data reveal the capacity of Ptprc for the regulation of FLT3-ITD signalling activity in vivo. In addition, histopathology and computed tomography (CT) revealed an unexpected bone phenotype; the FLT3-ITD Ptprc(-/-) mice, but none of the controls, showed pronounced alterations in bone morphology and, in part, apparent features of osteoporosis. In the spleen, ectopic bone formation was observed. The observed bone phenotypes suggest a previously unappreciated capacity of FLT3-ITD (and presumably FLT3) to regulate bone development/remodelling, which is under negative control of CD45/Ptprc.	[Kresinsky, Anne; Boehmer, Frank-D.; Mueller, Joerg P.] Jena Univ Hosp, CMB, Inst Mol Cell Biol, Jena, Germany; [Schnoeder, Tina M.; Heidel, Florian H.] Jena Univ Hosp, Dept Haematol & Oncol, Internal Med 2, Jena, Germany; [Jacobsen, Ilse D.] Hans Knoell Inst, Leibniz Inst Nat Prod Res & Infect Biol, Res Grp Microbial Immunol, Jena, Germany; [Rauner, Martina; Hofbauer, Lorenz C.] Tech Univ Dresden, Dept Med 3, Dresden, Germany; [Rauner, Martina; Hofbauer, Lorenz C.] Tech Univ Dresden, Ctr Hlth Aging, Dresden, Germany; [Ast, Volker; Koenig, Rainer] Hans Knoell Inst, Leibniz Inst Nat Prod Res & Infect Biol, Network Modelling, Jena, Germany; [Ast, Volker; Koenig, Rainer] Jena Univ Hosp, CSCC, Integrated Res & Treatment Ctr, Klinikum 1, D-07747 Jena, Germany; [Hoffmann, Bianca; Svensson, Carl-Magnus; Figge, Marc Thilo] Hans Knoell Inst, Leibniz Inst Nat Prod Res & Infect Biol, Appl Syst Biol, Jena, Germany; [Figge, Marc Thilo] Friedrich Schiller Univ Jena, Fac Biol Sci, Jena, Germany; [Hilger, Ingrid] Jena Univ Hosp, Inst Diagnost & Intervent Radiol, Jena, Germany	Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Hans Knoll Institute (HKI); Technische Universitat Dresden; Technische Universitat Dresden; Hans Knoll Institute (HKI); Friedrich Schiller University of Jena; Hans Knoll Institute (HKI); Friedrich Schiller University of Jena; Friedrich Schiller University of Jena	Muller, JP (corresponding author), Jena Univ Hosp, CMB, Inst Mol Cell Biol, Jena, Germany.	joerg.mueller2@med.uni-jena.de		Heidel, Florian/0000-0003-2438-1955	Deutsche Forschungsgemeinschaft [Mu955/11-1]; Federal Ministry of Education and Research (BMBF), Germany, CancerTelSys [FKZ 01ZX1302B, 01ZX1602B]; IFB/CSCC [01EO1002, 01EO1502]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Federal Ministry of Education and Research (BMBF), Germany, CancerTelSys; IFB/CSCC	We are thankful to Jorg Cammenga (Lund University, Sweden) for kindly providing FLT3-ITD mice and Klaus Metzeler for providing array data. The work was supported by Deutsche Forschungsgemeinschaft (grant Mu955/11-1), the Federal Ministry of Education and Research (BMBF), Germany, CancerTelSys (FKZ 01ZX1302B, 01ZX1602B) and IFB/CSCC (01EO1002, 01EO1502).	Alexander DR, 2000, SEMIN IMMUNOL, V12, P349, DOI 10.1006/smim.2000.0218; Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Arora D, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-19; Arora D, 2011, J BIOL CHEM, V286, P10918, DOI 10.1074/jbc.M110.205021; Bohmer F, 2013, FEBS J, V280, P413, DOI 10.1111/j.1742-4658.2012.08655.x; Choudhary C, 2009, MOL CELL, V36, P326, DOI 10.1016/j.molcel.2009.09.019; DeFranco AL, 1998, SEMIN IMMUNOL, V10, P299, DOI 10.1006/smim.1998.0122; Ebeling PR, 1999, J BONE MINER RES, V14, P342, DOI 10.1359/jbmr.1999.14.3.342; Pinheiro RF, 2007, LEUKEMIA RES, V31, P1015, DOI 10.1016/j.leukres.2006.09.018; Frohling S, 2007, CANCER CELL, V12, P501, DOI 10.1016/j.ccr.2007.11.005; GABBIANELLI M, 1995, BLOOD, V86, P1661, DOI 10.1182/blood.V86.5.1661.bloodjournal8651661; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Godfrey R, 2012, BLOOD, V119, P4499, DOI 10.1182/blood-2011-02-336446; Hayakawa F, 2000, ONCOGENE, V19, P624, DOI 10.1038/sj.onc.1203354; Hendriks WJAJ, 2013, BBA-MOL BASIS DIS, V1832, P1673, DOI 10.1016/j.bbadis.2013.05.022; Jayavelu AK, 2016, LEUKEMIA, V30, P473, DOI 10.1038/leu.2015.234; Kelly LM, 2002, BLOOD, V99, P310, DOI 10.1182/blood.V99.1.310; Lacombe F, 1997, LEUKEMIA, V11, P1878, DOI 10.1038/sj.leu.2400847; Lee BH, 2007, CANCER CELL, V12, P367, DOI 10.1016/j.ccr.2007.08.031; Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047; Li L, 2008, BLOOD, V111, P3849, DOI 10.1182/blood-2007-08-109942; Li L, 2011, BLOOD, V118, P4935, DOI 10.1182/blood-2011-01-328096; Mizuki M, 2000, BLOOD, V96, P3907, DOI 10.1182/blood.V96.12.3907; Ostman A, 2006, NAT REV CANCER, V6, P307, DOI 10.1038/nrc1837; Papaemmanuil E, 2016, NEW ENGL J MED, V374, P2209, DOI 10.1056/NEJMoa1516192; Pyzer AR, 2017, BLOOD, V129, P1791, DOI 10.1182/blood-2016-07-730614; Rasko JEJ, 1995, LEUKEMIA, V9, P2058; Rusten LS, 1996, BLOOD, V87, P1317, DOI 10.1182/blood.V87.4.1317.bloodjournal8741317; Sallmyr A, 2008, BLOOD, V111, P3173, DOI 10.1182/blood-2007-05-092510; Schmidt-Arras DE, 2005, MOL CELL BIOL, V25, P3690, DOI 10.1128/MCB.25.9.3690-3703.2005; Schulte C, 2000, OSTEOPOROSIS INT, V11, P344, DOI 10.1007/s001980070124; Shivtiel S, 2008, J EXP MED, V205, P2381, DOI 10.1084/jem.20080072; Stirewalt DL, 2003, NAT REV CANCER, V3, P650, DOI 10.1038/nrc1169; Verhaak RGW, 2009, HAEMATOL-HEMATOL J, V94, P131, DOI 10.3324/haematol.13299; Voronov I, 2016, J LEUKOCYTE BIOL, V99, P401, DOI 10.1189/jlb.3CE0915-445RR; Zhu JW, 2008, IMMUNITY, V28, P183, DOI 10.1016/j.immuni.2007.11.024	36	5	5	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2019	38	24					4773	4787		10.1038/s41388-019-0757-y	http://dx.doi.org/10.1038/s41388-019-0757-y			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IC7ND	30820040				2022-12-28	WOS:000471160500009
J	Aguilera-Montilla, N; Bailon, E; Uceda-Castro, R; Ugarte-Berzal, E; Santos, A; Gutierrez-Gonzalez, A; Perez-Sanchez, C; Van den Steen, PE; Opdenakker, G; Garcia-Marco, JA; Garcia-Pardo, A				Aguilera-Montilla, Noemi; Bailon, Elvira; Uceda-Castro, Rebeca; Ugarte-Berzal, Estefania; Santos, Andrea; Gutierrez-Gonzalez, Alejandra; Perez-Sanchez, Cristina; Van den Steen, Philippe E.; Opdenakker, Ghislain; Garcia-Marco, Jose A.; Garcia-Pardo, Angeles			MMP-9 affects gene expression in chronic lymphocytic leukemia revealing CD99 as an MMP-9 target and a novel partner in malignant cell migration/arrest	ONCOGENE			English	Article							ALPHA-4-BETA-1 INTEGRIN; GELATINASE-B; MATRIX-METALLOPROTEINASE-9; SP1; PATHOGENESIS; INHIBITION; HEMOPEXIN; INVASION; PATHWAYS; SURVIVAL	We previously showed that MMP-9 contributes to CLL pathology by regulating cell survival and migration and that, when present at high levels, MMP-9 induces cell arrest. To further explore the latter function, we studied whether MMP-9 influences the gene-expression profile in CLL. Microarray analyses rendered 131 differentially expressed genes in MEC-1 cells stably transfected with MMP-9 (MMP-9-cells) versus cells transfected with empty vector (Mock-cells). Ten out of twelve selected genes were also differentially expressed in MEC-1 cells expressing the catalytically inactive MMP-9MutE mutant (MMP-9MutE-cells). Incubation of primary CLL cells with MMP-9 or MMP-9MutE also regulated gene and protein expression, including CD99, CD226, CD52, and CD274. Because CD99 is involved in leukocyte transendothelial migration, we selected CD99 for functional and mechanistic studies. The link between MMP-9 and CD99 was reinforced with MMP-9 gene silencing studies, which resulted in CD99 upregulation. CD99 gene silencing significantly reduced CLL cell adhesion, chemotaxis and transendothelial migration, while CD99 overexpression increased cell migration. Mechanistic analyses indicated that MMP-9 downregulated CD99 via binding to alpha 4 beta 1 integrin and subsequent inactivation of the Sp1 transcription factor. This MMP-9-induced mechanism is active in CLL lymphoid tissues, since CD99 expression and Sp1 phosphorylation was lower in bone marrow-derived CLL cells than in their peripheral blood counterparts. Our study establishes a new gene regulatory function for MMP-9 in CLL. It also identifies CD99 as an MMP-9 target and a novel contributor to CLL cell adhesion, migration and arrest. CD99 thus constitutes a new therapeutic target in CLL, complementary to MMP-9.	[Aguilera-Montilla, Noemi; Bailon, Elvira; Uceda-Castro, Rebeca; Santos, Andrea; Gutierrez-Gonzalez, Alejandra; Perez-Sanchez, Cristina; Garcia-Pardo, Angeles] CSIC, Ctr Invest Biol, Dept Mol Biomed, Madrid, Spain; [Ugarte-Berzal, Estefania; Van den Steen, Philippe E.; Opdenakker, Ghislain] Univ Leuven, KU Leuven, Rega Inst Med Res, Dept Microbiol & Immunol, Leuven, Belgium; [Garcia-Marco, Jose A.] Hosp Univ Puerta Hierro, Dept Hematol, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); KU Leuven; Hospital Puerta de Hierro-Majadahonda	Garcia-Pardo, A (corresponding author), CSIC, Ctr Invest Biol, Dept Mol Biomed, Madrid, Spain.	agarciapardo@cib.csic.es	Gutiérrez, Alejandra/ABH-7404-2020; Opdenakker, Ghislain/Q-3130-2017; Opdenakker, Ghislain/V-8562-2019; Van den Steen, Philippe E/K-5132-2012	Gutiérrez, Alejandra/0000-0002-2858-2730; Opdenakker, Ghislain/0000-0003-1714-2294; Opdenakker, Ghislain/0000-0003-1714-2294; Van den Steen, Philippe E/0000-0002-7334-9145	Red Tematica de Investigacion Cooperativa en Cancer Grant from the Ministry of Economy and Competitivity (Spain) [RD12/0036/0061]; Comunidad de Madrid/European Union [S2010/BMD-2314]; Concerted Research Actions (KU Leuven C1 Grant) [C16/17/010]; Research Foundation of Flanders (FWO-Vlaanderen); Ministry of Economy and Competitivity (Spain) [SAF2015-69180R]	Red Tematica de Investigacion Cooperativa en Cancer Grant from the Ministry of Economy and Competitivity (Spain); Comunidad de Madrid/European Union; Concerted Research Actions (KU Leuven C1 Grant); Research Foundation of Flanders (FWO-Vlaanderen)(FWO); Ministry of Economy and Competitivity (Spain)	This work was supported by Grant SAF2015-69180R and Red Tematica de Investigacion Cooperativa en Cancer Grant RD12/0036/0061 from the Ministry of Economy and Competitivity (Spain) (to AGP); S2010/BMD-2314 (to AGP) from the Comunidad de Madrid/European Union; and by the Concerted Research Actions (KU Leuven C1 Grant C16/17/010) and the Research Foundation of Flanders (FWO-Vlaanderen, to EUB, PEVdS, and GO).	Alberti I, 2002, FASEB J, V16, P1946, DOI 10.1096/fj.02-0049fje; Amigo-Jimenez I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099993; Bailon E, 2018, BIOCHEM BIOPH RES CO, V495, P124, DOI 10.1016/j.bbrc.2017.10.129; Bailon E, 2014, J LEUKOCYTE BIOL, V96, P185, DOI 10.1189/jlb.3HI0913-521R; Bauvois B, 2002, LEUKEMIA, V16, P791, DOI 10.1038/sj.leu.2402472; Beishline K, 2015, FEBS J, V282, P224, DOI 10.1111/febs.13148; Bernard G, 2000, EUR J IMMUNOL, V30, P3061, DOI 10.1002/1521-4141(200010)30:10<3061::AID-IMMU3061>3.0.CO;2-M; Brachtl G, 2014, ANN HEMATOL, V93, P361, DOI 10.1007/s00277-013-1967-y; Coustan-Smith E, 2011, BLOOD, V117, P6267, DOI 10.1182/blood-2010-12-324004; Creighton Chad, 2003, In Silico Biology, V3, P301; Dal Bo M, 2016, LEUKEMIA, V30, P2011, DOI 10.1038/leu.2016.88; Davids MS, 2012, OPEN J HEMATOL, V3, pi, DOI DOI 10.13055/OJHMT_3_S1_03; Forconi F, 2015, BLOOD, V126, P573, DOI 10.1182/blood-2015-03-567388; Ganghammer S, 2016, HAEMATOLOGICA, V101, pE99, DOI 10.3324/haematol.2015.133470; Garc~ia-Pardo A, 2015, METALLOPROTEINASES M, V2015, P19, DOI DOI 10.2147/MNM.S63629; Gonzalo P, 2010, DEV CELL, V18, P77, DOI 10.1016/j.devcel.2009.11.012; Goswami D, 2017, BLOOD, V129, P1811, DOI 10.1182/blood-2016-08-733394; Hahn JH, 1997, J IMMUNOL, V159, P2250; Hallek M, 2017, AM J HEMATOL, V92, P946, DOI 10.1002/ajh.24826; Herishanu Y, 2011, BLOOD, V117, P563, DOI 10.1182/blood-2010-05-284984; Imbert AM, 2006, BLOOD, V108, P2578, DOI 10.1182/blood-2005-12-010827; Kamiguti AS, 2004, BRIT J HAEMATOL, V125, P128, DOI 10.1111/j.1365-2141.2004.04877.x; Lee IS, 2001, BLOOD, V97, P3596, DOI 10.1182/blood.V97.11.3596; Lee JH, 2007, CLIN CANCER RES, V13, P2584, DOI 10.1158/1078-0432.CCR-06-1785; Manara MC, 2018, GENES-BASEL, V9, DOI 10.3390/genes9030159; Marchant DJ, 2014, NAT MED, V20, P497, DOI 10.1038/nm.3508; McClanahan F, 2015, BLOOD, V126, P203, DOI 10.1182/blood-2015-01-622936; Mittal AK, 2014, MOL MED, V20, P290, DOI 10.2119/molmed.2012.00303; Muller WA, 2016, IMMUNOL REV, V273, P61, DOI 10.1111/imr.12443; Opdenakker G, 2001, TRENDS IMMUNOL, V22, P571, DOI 10.1016/S1471-4906(01)02023-3; Parry HM, 2016, ONCOTARGET, V7, P68513, DOI 10.18632/oncotarget.12097; Pasello M, 2018, J CELL COMMUN SIGNAL, V12, P55, DOI 10.1007/s12079-017-0445-z; Pettitt AR, 2012, J CLIN ONCOL, V30, P1647, DOI 10.1200/JCO.2011.35.9695; Prudova A, 2010, MOL CELL PROTEOMICS, V9, P894, DOI 10.1074/mcp.M000050-MCP201; Redondo-Munoz J, 2008, BLOOD, V112, P169, DOI 10.1182/blood-2007-08-109249; Redondo-Munoz J, 2008, BLOOD, V111, P383, DOI 10.1182/blood-2007-08-107300; Redondo-Munoz J, 2006, BLOOD, V108, P3143, DOI 10.1182/blood-2006-03-007294; Redondo-Munoz J, 2010, CANCER CELL, V17, P160, DOI 10.1016/j.ccr.2009.12.044; Sakamoto T, 2009, GENES CELLS, V14, P617, DOI 10.1111/j.1365-2443.2009.01293.x; Schenkel AR, 2002, NAT IMMUNOL, V3, P143, DOI 10.1038/ni749; Scotlandi K, 2007, ONCOGENE, V26, P6604, DOI 10.1038/sj.onc.1210481; Seol Ho Jun, 2012, Genes Cancer, V3, P535, DOI 10.1177/1947601912473603; Tan NY, 2009, MOL CELL BIOL, V29, P2483, DOI 10.1128/MCB.01828-08; ten Hacken E, 2016, BBA-MOL CELL RES, V1863, P401, DOI 10.1016/j.bbamcr.2015.07.009; Van den Steen PE, 2006, J BIOL CHEM, V281, P18626, DOI 10.1074/jbc.M512308200; Vandooren J, 2013, CRIT REV BIOCHEM MOL, V48, P222, DOI 10.3109/10409238.2013.770819; Vestweber D, 2015, NAT REV IMMUNOL, V15, P692, DOI 10.1038/nri3908; Zenz T, 2010, NAT REV CANCER, V10, P37, DOI 10.1038/nrc2764; Zucchini C, 2014, ONCOGENE, V33, P1912, DOI 10.1038/onc.2013.152	49	6	6	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2019	38	23					4605	4619		10.1038/s41388-019-0744-3	http://dx.doi.org/10.1038/s41388-019-0744-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IB4KM	30760844	Green Submitted			2022-12-28	WOS:000470240300012
J	Rossa, C; D'Silva, NJ				Rossa, Carlos, Jr.; D'Silva, Nisha J.			Immune-relevant aspects of murine models of head and neck cancer'	ONCOGENE			English	Review							SQUAMOUS-CELL CARCINOMA; ATHYMIC NUDE-MICE; NF-KAPPA-B; SEVERE COMBINED IMMUNODEFICIENCY; ANIMAL-MODELS; ORAL-CANCER; TONGUE CARCINOGENESIS; COLORECTAL-CANCER; FC-RECEPTORS; MOUSE MODELS	Head and neck cancers (HNCs) cause significant mortality and morbidity. There have been few advances in therapeutic management of HNC in the past 4 to 5 decades, which support the need for studies focusing on HNC biology. In recent years, increased recognition of the relevance of the host response in cancer progression has led to novel therapeutic strategies and putative biomarkers of tumor aggressiveness. However, tumor-immune interactions are highly complex and vary with cancer type. Pre-clinical, in vivo models represent an important and necessary step in understanding biological processes involved in development, progression and treatment of HNC. Rodents (mice, rats, hamsters) are the most frequently used animal models in HNC research. The relevance and utility of information generated by studies in murine models is unquestionable, but it is also limited in application to tumor-immune interactions. In this review, we present information regarding the immune-specific characteristics of the murine models most commonly used in HNC research, including immunocompromised and immunocompetent animals. The particular characteristics of xenograft, chemically induced, syngeneic, transgenic, and humanized models are discussed in order to provide context and insight for researchers interested in the in vivo study of tumor-immune interactions in HNC.	[Rossa, Carlos, Jr.] UNESP State Univ Sao Paulo, Sch Dent Araraquara, Dept Diag & Surg, Araraquara, SP, Brazil; [Rossa, Carlos, Jr.; D'Silva, Nisha J.] Sch Dent, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA; [D'Silva, Nisha J.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	Universidade Estadual Paulista; University of Michigan System; University of Michigan	Rossa, C (corresponding author), UNESP State Univ Sao Paulo, Sch Dent Araraquara, Dept Diag & Surg, Araraquara, SP, Brazil.; Rossa, C; D'Silva, NJ (corresponding author), Sch Dent, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA.	c.rossa@unesp.br; njdsilva@umich.edu	Rossa, Carlos/D-8328-2012	Rossa, Carlos/0000-0003-1705-5481; D'Silva, Nisha/0000-0001-7030-3187	FAPESP [2017/14283-5]; NIH/NIDCR [DE027551, DE022567]; UM-FAPESP [2014/50312-1]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R35DE027551, R01DE022567] Funding Source: NIH RePORTER	FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); NIH/NIDCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); UM-FAPESP; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work was supported by grants from FAPESP 2017/14283-5 (CRJ) and NIH/NIDCR DE027551 and DE022567 (NJD), and UM-FAPESP 2014/50312-1 (NJD and CRJ).	Ahn HJ, 2015, WORLD J GASTRO ONCOL, V7, P455, DOI 10.4251/wjgo.v7.i12.455; Albanesi M, 2013, BLOOD, V122, P3160, DOI 10.1182/blood-2013-04-497446; Andratschke M, 2003, ANTICANCER RES, V23, P1467; Annamalai G, 2018, BIOMED PHARMACOTHER, V98, P484, DOI 10.1016/j.biopha.2017.12.009; Aromando RF, 2008, ORAL ONCOL, V44, P1080, DOI 10.1016/j.oraloncology.2008.01.016; BAKER SR, 1985, LARYNGOSCOPE, V95, P43; Bao A, 2006, OTOLARYNG HEAD NECK, V135, P853, DOI 10.1016/j.otohns.2006.06.1257; Baskaran N, 2018, MOL CELL BIOCHEM, V440, P11, DOI 10.1007/s11010-017-3151-5; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; Bozinovski S, 2016, BRIT J PHARMACOL, V173, P635, DOI 10.1111/bph.13198; BUDZYNSKI W, 1994, IMMUNOPHARM IMMUNOT, V16, P319, DOI 10.3109/08923979409007097; CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; CARDINALI G, 1964, NATURE, V203, P90, DOI 10.1038/203090b0; Chen B, 2017, STEM CELL REP, V9, P1034, DOI 10.1016/j.stemcr.2017.08.018; Chicha L, 2005, ANN NY ACAD SCI, V1044, P236, DOI 10.1196/annals.1349.029; Clynes R, 2006, HEMATOL ONCOL CLIN N, V20, P585, DOI 10.1016/j.hoc.2006.02.010; CRANE IJ, 1988, BRIT J EXP PATHOL, V69, P749; de Araujo WS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115606; Dogan V, 2018, CLIN OTOLARYNGOL, V43, P13, DOI 10.1111/coa.12895; Economopoulos V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027508; EVESON JW, 1981, J ORAL PATHOL MED, V10, P322, DOI 10.1111/j.1600-0714.1981.tb01284.x; Fan S, 2011, INT J ORAL SCI, V3, P180, DOI 10.4248/IJOS11068; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; FISKER AV, 1990, DAN MED BULL, V37, P433; FLANAGAN SP, 1966, GENET RES, V8, P295, DOI 10.1017/S0016672300010168; FU KK, 1984, INT J RADIAT ONCOL, V10, P1473, DOI 10.1016/0360-3016(84)90371-7; Gao XP, 2011, INFLAMM RES, V60, P195, DOI 10.1007/s00011-010-0254-9; GHIABI M, 1992, CANCER RES, V52, P389; GHOSHAL NG, 1990, LAB ANIM, V24, P228, DOI 10.1258/002367790780866083; GIUNTA JL, 1985, J ORAL PATHOL MED, V14, P263, DOI 10.1111/j.1600-0714.1985.tb00490.x; Grandis JR, 2000, CLIN CANCER RES, V6, P2794; Greenberg JS, 2003, CANCER, V97, P1464, DOI 10.1002/cncr.11202; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HIER MP, 1995, LARYNGOSCOPE, V105, P1077, DOI 10.1288/00005537-199510000-00013; HIRST DG, 1982, BRIT J CANCER, V46, P109, DOI 10.1038/bjc.1982.172; Ho AS, 2017, J CLIN ONCOL, V35, P3601, DOI 10.1200/JCO.2016.71.1176; HOLUB M, 1984, J LEUKOCYTE BIOL, V35, P605; HOUGEN HP, 1991, APMIS, V99, P1; Hu Z, 2011, BLOOD, V118, P5938, DOI 10.1182/blood-2010-11-321414; Ishida K, 2017, ORAL ONCOL, V73, P16, DOI 10.1016/j.oraloncology.2017.07.028; Jacobson MC, 2018, CURR OPIN SUPPORT PA, V12, P65, DOI 10.1097/SPC.0000000000000322; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; KOTLOFF DB, 1993, J EXP MED, V178, P1981, DOI 10.1084/jem.178.6.1981; Kundu JK, 2008, MUTAT RES-REV MUTAT, V659, P15, DOI 10.1016/j.mrrev.2008.03.002; Lea J, 2010, HEAD NECK-J SCI SPEC, V32, P184, DOI 10.1002/hed.21163; Lerman I, 2017, MOL CANCER RES, V15, P1138, DOI 10.1158/1541-7786.MCR-17-0003; Li J, 2013, ORAL ONCOL, V49, P299, DOI 10.1016/j.oraloncology.2012.10.013; Lieber MR, 2010, ANNU REV BIOCHEM, V79, P181, DOI 10.1146/annurev.biochem.052308.093131; Lin W, 2005, LARYNGOSCOPE, V115, P1154, DOI 10.1097/01.MLG.0000165368.81032.E2; Lin Y, 2005, J REPROD IMMUNOL, V68, P39, DOI 10.1016/j.jri.2005.05.002; Liu B, 2017, EXP CELL RES, V360, P105, DOI 10.1016/j.yexcr.2017.08.031; Liu YC, 2012, TOXICOL APPL PHARM, V262, P107, DOI 10.1016/j.taap.2012.04.023; Lu SL, 2006, HEAD NECK-J SCI SPEC, V28, P945, DOI 10.1002/hed.20397; Mashimo T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008870; MATTHEWS JB, 1986, CARCINOGENESIS, V7, P783, DOI 10.1093/carcin/7.5.783; Mery B, 2017, ORAL ONCOL, V65, P51, DOI 10.1016/j.oraloncology.2016.12.010; Mognetti B, 2006, ORAL ONCOL, V42, P448, DOI 10.1016/j.oraloncology.2005.07.014; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NAUTA M, 1995, INT J ORAL MAX SURG, V24, P53, DOI 10.1016/S0901-5027(05)80857-4; Nishimura A, 1999, J DENT RES, V78, P1264, DOI 10.1177/00220345990780061101; Niu ZY, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00523-6; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; Noguti J, 2012, CANCER GENOM PROTEOM, V9, P329; NONOYAMA S, 1993, J IMMUNOL, V150, P3817; Ohbo K, 1996, BLOOD, V87, P956, DOI 10.1182/blood.V87.3.956.bloodjournal873956; OMalley BW, 1997, ARCH OTOLARYNGOL, V123, P20; Osugi Y, 1996, J Osaka Dent Univ, V30, P29; PANTELOURIS EM, 1968, NATURE, V217, P370, DOI 10.1038/217370a0; Pelleitier M, 1975, Methods Achiev Exp Pathol, V7, P149; Peng SH, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-198; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Ramu A, 2018, BIOMED PHARMACOTHER, V98, P523, DOI 10.1016/j.biopha.2017.12.049; Rodriguez GV, 2017, CANCER IMMUNOL RES, V5, P234, DOI 10.1158/2326-6066.CIR-16-0150; Sakaki T, 2003, J ORAL PATHOL MED, V32, P530, DOI 10.1034/j.1600-0714.2003.00174.x; SALLEY JJ, 1954, J DENT RES, V33, P253, DOI 10.1177/00220345540330021201; Sano D, 2009, HEAD NECK ONCOL, V1, DOI 10.1186/1758-3284-1-32; Schmitd LB, 2018, J DENT RES, V97, P742, DOI 10.1177/0022034518756297; Selvasundaram R, 2018, MOL CELL BIOCHEM, V448, P145, DOI 10.1007/s11010-018-3321-0; Seymour R, 2006, VET PATHOL, V43, P401, DOI 10.1354/vp.43-4-401; Shinohara H, 2017, J IMMUNOL, V199, P1505, DOI 10.4049/jimmunol.1700167; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Simpson-Abelson MR, 2008, J IMMUNOL, V180, P7009, DOI 10.4049/jimmunol.180.10.7009; Smith LP, 2006, INT J CANCER, V118, P2111, DOI 10.1002/ijc.21694; Strasner A, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00128; Supsavhad W, 2016, VET J, V210, P7, DOI 10.1016/j.tvjl.2015.11.006; Szadvari I, 2016, PHYSIOL RES, V65, pS441, DOI 10.33549/physiolres.933526; Tang XH, 2004, CLIN CANCER RES, V10, P301, DOI 10.1158/1078-0432.CCR-0999-3; THOMAS DW, 1995, J ORAL PATHOL MED, V24, P23, DOI 10.1111/j.1600-0714.1995.tb01125.x; Timar J, 2005, CANCER METAST REV, V24, P107, DOI 10.1007/s10555-005-5051-5; Vahle AK, 2012, CANCER LETT, V317, P199, DOI 10.1016/j.canlet.2011.11.027; Veliz LP, 2008, AM J PHYSIOL-HEART C, V295, pH1056, DOI 10.1152/ajpheart.00266.2008; VETVICKA V, 1984, EUR J CELL BIOL, V35, P35; Watts CJ, 2009, J INFECT DIS, V199, P673, DOI 10.1086/596631; WILLIAMS DE, 1971, BRIT J CANCER, V25, P533, DOI 10.1038/bjc.1971.68; WONG PNC, 1983, J ORAL PATHOL MED, V12, P375, DOI 10.1111/j.1600-0714.1983.tb00350.x; Yamamoto T, 2017, CLIN CANCER RES, V23, P833, DOI 10.1158/1078-0432.CCR-16-0520; Yashiro M, 2015, DIGEST DIS SCI, V60, P2251, DOI 10.1007/s10620-015-3646-4; YUAN B, 1994, CANCER RES, V54, P5310	100	12	12	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2019	38	21					3973	3988		10.1038/s41388-019-0686-9	http://dx.doi.org/10.1038/s41388-019-0686-9			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ3HX	30696955	Green Accepted			2022-12-28	WOS:000468740200001
J	Kim, I; Shin, SH; Lee, JE; Park, JW				Kim, Iljin; Shin, Seung-Hyun; Lee, Jae Eun; Park, Jong-Wan			Oxygen sensor FIH inhibits HACE1-dependent ubiquitination of Rac1 to enhance metastatic potential in breast cancer cells	ONCOGENE			English	Article							ANKYRIN REPEAT DOMAIN; INDUCIBLE FACTOR FIH; ASPARAGINYL HYDROXYLATION; LIGASE HACE1; TRANSCRIPTIONAL ACTIVITY; PROTEIN INTERACTIONS; DUCTAL CARCINOMA; HYPOXIA; TUMOR; UBIQUITYLATION	Oxygen is an indispensable element for cell survival and maintenance. Eukaryotic cells are equipped with a series of signaling pathways that cope with hypoxia. The dioxygenase factor inhibiting HIF (FIH) is an oxygen sensor that regulates the transcriptional activity of hypoxia-inducible factor (HIF) through asparaginyl hydroxylation. Given that HACE1 was detected as an FIH-interacting protein in a previous proteomics study, we tested whether the E3 ubiquitin ligase HACE1 is a substrate for FIH. FIH interacted with HACE1, in cells and in vitro, and was determined to hydroxylate HACE1 at the N191 residue within the ankyrin repeat domain. Hydroxylation disrupted the physical association between HACE1 and its representative target, Rac1. Under hypoxic conditions, HACE1 is less hydroxylated due to the inactivation of FIH, and subsequently functions to ubiquitinate the active form of Rac1, leading to the proteasomal degradation of Rac1. Since Rac1 stimulates cell movement, HACE1 inhibits cell migration and invasion in breast cancer by removing active Rac1. Such an effect of HACE1 is reinforced under hypoxia because HACE1 escapes from FIH-mediated hydroxylation. In clinical datasets, HACE1 downregulation is associated with poor outcomes in patients with breast cancer. Taken together, FIH is likely to act as an oxygen sensor that determines oxygen-dependent cancer progression.	[Kim, Iljin; Shin, Seung-Hyun; Lee, Jae Eun; Park, Jong-Wan] Seoul Natl Univ, Coll Med, Dept Biomed Sci, 103 Daehak Ro, Seoul, South Korea; [Kim, Iljin; Shin, Seung-Hyun; Lee, Jae Eun; Park, Jong-Wan] Seoul Natl Univ, Coll Med, Hypox Dis Inst, Canc Res Inst & Ischem, 103 Daehak Ro, Seoul, South Korea; [Shin, Seung-Hyun; Park, Jong-Wan] Seoul Natl Univ, Coll Med, Dept Pharmacol, 103 Daehak Ro, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU)	Park, JW (corresponding author), Seoul Natl Univ, Coll Med, Dept Biomed Sci, 103 Daehak Ro, Seoul, South Korea.; Park, JW (corresponding author), Seoul Natl Univ, Coll Med, Hypox Dis Inst, Canc Res Inst & Ischem, 103 Daehak Ro, Seoul, South Korea.; Park, JW (corresponding author), Seoul Natl Univ, Coll Med, Dept Pharmacol, 103 Daehak Ro, Seoul, South Korea.	parkjw@snu.ac.kr		Park, Jong-Wan/0000-0003-4676-5191; Lee, Judy/0000-0001-9862-3502	National Research Foundation of Korea [2017R1A4A1015015]	National Research Foundation of Korea(National Research Foundation of Korea)	This study was supported by a grant from the National Research Foundation of Korea (2017R1A4A1015015; to J.W.P).	Andrio E, 2017, SCI REP-UK, V7, DOI 10.1038/srep44779; Anglesio MS, 2004, HUM MOL GENET, V13, P2061, DOI 10.1093/hmg/ddh215; Berndsen CE, 2014, NAT STRUCT MOL BIOL, V21, P301, DOI 10.1038/nsmb.2780; Bosco EE, 2009, CELL MOL LIFE SCI, V66, P370, DOI 10.1007/s00018-008-8552-x; Brunner AL, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-5-r71; Castillo-Lluva S, 2013, ONCOGENE, V32, P1735, DOI 10.1038/onc.2012.189; Chun YS, 2000, BIOCHEM BIOPH RES CO, V268, P652, DOI 10.1006/bbrc.2000.2180; Cockman ME, 2006, P NATL ACAD SCI USA, V103, P14767, DOI 10.1073/pnas.0606877103; Cockman ME, 2009, ANN NY ACAD SCI, V1177, P9, DOI 10.1111/j.1749-6632.2009.05042.x; Cockman ME, 2009, MOL CELL PROTEOMICS, V8, P535, DOI 10.1074/mcp.M800340-MCP200; Coleman ML, 2007, J BIOL CHEM, V282, P24027, DOI 10.1074/jbc.M704102200; Daugaard M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3180; Ferguson JE, 2007, MOL CELL BIOL, V27, P6407, DOI 10.1128/MCB.00511-07; Giaccia A, 2003, NAT REV DRUG DISCOV, V2, P803, DOI 10.1038/nrd1199; Goka ET, 2015, ONCOGENE, V34, P5395, DOI 10.1038/onc.2014.468; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hewitson KS, 2008, J BIOL CHEM, V283, P25971, DOI 10.1074/jbc.M804999200; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hordijk PL, 2006, CIRC RES, V98, P453, DOI 10.1161/01.RES.0000204727.46710.5e; Hyseni A, 2011, CELL ONCOL, V34, P565, DOI 10.1007/s13402-011-0053-5; Janke K, 2013, J CELL SCI, V126, P2629, DOI 10.1242/jcs.117564; Kallberg M, 2012, NAT PROTOC, V7, P1511, DOI 10.1038/nprot.2012.085; Karttunen S, 2015, J CELL SCI, V128, P225, DOI 10.1242/jcs.158451; Kretschmer C, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-15; Lachance V, 2014, J CELL SCI, V127, P111, DOI 10.1242/jcs.132944; Lancaster DE, 2004, BIOCHEM SOC T, V32, P943, DOI 10.1042/BST0320943; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lee GY, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0089-y; Lee SD, 2016, CANCER LETT, V373, P138, DOI 10.1016/j.canlet.2016.01.031; Lesurf R, 2016, CELL REP, V16, P1166, DOI 10.1016/j.celrep.2016.06.051; Linke S, 2004, J BIOL CHEM, V279, P14391, DOI 10.1074/jbc.M313614200; Liu ZZ, 2014, CANCER CELL, V26, P106, DOI 10.1016/j.ccr.2014.05.015; Loi S, 2007, J CLIN ONCOL, V25, P1239, DOI 10.1200/JCO.2006.07.1522; Masson N, 2012, EMBO REP, V13, P251, DOI 10.1038/embor.2012.9; Palicharla VR, 2015, CELL SIGNAL, V27, P2355, DOI 10.1016/j.cellsig.2015.09.001; PETTERSEN EO, 1986, CANCER RES, V46, P4346; Rankin EB, 2016, SCIENCE, V352, P175, DOI 10.1126/science.aaf4405; Rodriguez J, 2016, CELL REP, V14, P2745, DOI 10.1016/j.celrep.2016.02.043; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Scholz CC, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002347; Semenza GL, 2007, J MOL MED-JMM, V85, P1293, DOI 10.1007/s00109-007-0285-z; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 2016, BBA-MOL CELL RES, V1863, P382, DOI 10.1016/j.bbamcr.2015.05.036; So JH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109517; Tan EY, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1838; Torrino S, 2011, DEV CELL, V21, P959, DOI 10.1016/j.devcel.2011.08.015; Tortola L, 2016, CELL REP, V16, P3414, DOI 10.1016/j.celrep.2016.08.072; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wilkins SE, 2016, CHEMMEDCHEM, V11, P773, DOI 10.1002/cmdc.201600012; Yan M, 2009, BRIT J CANCER, V101, P1168, DOI 10.1038/sj.bjc.6605287; Yang M, 2011, FEBS J, V278, P1086, DOI 10.1111/j.1742-4658.2011.08022.x; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Zhang L, 2007, NAT MED, V13, P1060, DOI 10.1038/nm1621; Zhang LY, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4430; Zucchi I, 2004, P NATL ACAD SCI USA, V101, P18147, DOI 10.1073/pnas.0408260101; 2003, J BIOL CHEM, V278, P1802, DOI DOI 10.1074/JBC.C200644200; 2001, GENE DEV, V15, P2675	57	13	13	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2019	38	19					3651	3666		10.1038/s41388-019-0676-y	http://dx.doi.org/10.1038/s41388-019-0676-y			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HX4OU	30659265				2022-12-28	WOS:000467379600007
J	Sepult, C; Bellefroid, M; Rocks, N; Donati, K; Gerard, C; Gilles, C; Ludwig, A; Duysinx, B; Noel, A; Cataldo, D				Sepult, Christelle; Bellefroid, Marine; Rocks, Natacha; Donati, Kim; Gerard, Catherine; Gilles, Christine; Ludwig, Andreas; Duysinx, Bernard; Noel, Agnes; Cataldo, Didier			ADAM10 mediates malignant pleural mesothelioma invasiveness	ONCOGENE			English	Article							ALPHA-SECRETASE ADAM10; N-CADHERIN; CLEAVAGE; GROWTH; MIGRATION; METALLOPROTEINASES; DISINTEGRIN; INVASION	Malignant pleural mesothelioma (MPM) is an aggressive cancer with limited therapeutic options and treatment efficiency. Even if the latency period between asbestos exposure, the main risk factor, and mesothelioma development is very long, the local invasion of mesothelioma is very rapid leading to a mean survival of one year after diagnosis. ADAM10 (A Disintegrin And Metalloprotease) sheddase targets membrane-bound substrates and its overexpression is associated with progression in several cancers. However, nothing is known about ADAM10 implication in MPM. In this study, we demonstrated higher ADAM10 expression levels in human MPM as compared to control pleural samples and in human MPM cell line. This ADAM10 overexpression was also observed in murine MPM samples. Two mouse mesothelioma cell lines were used in this study including one primary cell line obtained by repeated asbestos fibre injections. We show, in vitro, that ADAM10 targeting through shRNA and pharmacological (GI254023X) approaches reduced drastically mesothelioma cell migration and invasion, as well as for human mesothelioma cells treated with siRNA targeting ADAM10. Moreover, ADAM10 downregulation in murine mesothelioma cells significantly impairs MPM progression in vivo after intrapleural cell injection. We also demonstrate that ADAM10 sheddase downregulation decreases the production of a soluble N-cadherin fragment through membrane N-cadherin, which stimulated mesothelioma cell migration. Taken together, we demonstrate that ADAM10 is overexpressed in MPM and takes part to MPM progression through the generation of N-cadherin fragment that stimulates mesothelioma cell migration. ADAM10 inhibition is worth considering as a therapeutic perspective in mesothelioma context.	[Sepult, Christelle; Bellefroid, Marine; Rocks, Natacha; Donati, Kim; Gerard, Catherine; Gilles, Christine; Noel, Agnes; Cataldo, Didier] Univ Liege, Lab Tumour & Dev Biol, GIGA Canc, Ave Hippocrate 13, B-4000 Liege, Belgium; [Ludwig, Andreas] Rhein Westfal TH Aachen, Inst Pharmacol & Toxicol, Aachen, Germany; [Duysinx, Bernard; Cataldo, Didier] CHU Liege, Dept Resp Dis, Ave Hippocrate 13, B-4000 Liege, Belgium; [Duysinx, Bernard; Cataldo, Didier] Univ Liege, Ave Hippocrate 13, B-4000 Liege, Belgium	University of Liege; RWTH Aachen University; University of Liege; University of Liege	Cataldo, D (corresponding author), Univ Liege, Lab Tumour & Dev Biol, GIGA Canc, Ave Hippocrate 13, B-4000 Liege, Belgium.; Cataldo, D (corresponding author), CHU Liege, Dept Resp Dis, Ave Hippocrate 13, B-4000 Liege, Belgium.; Cataldo, D (corresponding author), Univ Liege, Ave Hippocrate 13, B-4000 Liege, Belgium.	didier.cataldo@uliege.be	Ludwig, Andreas/I-5685-2012; Cataldo, Didier/GPG-3453-2022	Ludwig, Andreas/0000-0001-8536-4986; Noel, Agnes/0000-0002-7670-6179	Fonds National pour la Recherche Scientifique (FRS-FNRS Televie) [7463213 F, 7457116 F]; Centre AntiCancereux (University of Liege); foundation Leon Fredericq (University of Liege); Foundation against Cancer, Belgium [FA/2014/314]; Interuniversity Attraction Poles Program-Belgian State-Belgian Science Policy [P7/30]	Fonds National pour la Recherche Scientifique (FRS-FNRS Televie)(Fonds de la Recherche Scientifique - FNRS); Centre AntiCancereux (University of Liege)(University of Liege); foundation Leon Fredericq (University of Liege); Foundation against Cancer, Belgium; Interuniversity Attraction Poles Program-Belgian State-Belgian Science Policy(Belgian Federal Science Policy Office)	The authors acknowledge the contribution of the GIGA Viral Vectors Platform, of Silvia Blacher for the statistical analysis, and Vincent Heinen for his contribution to human sample collection. The authors thank Pascale Heneaux, Fabienne Perin and especially Christine Fink and Celine Vanwinge for technical support. This study was financially supported by grants from the Fonds National pour la Recherche Scientifique (FRS-FNRS Televie, Grants no 7463213 F and no 7457116 F), the Centre AntiCancereux (University of Liege), The foundation Leon Fredericq (University of Liege), the Foundation against Cancer (FA/2014/314), Belgium, Interuniversity Attraction Poles Program-Belgian State-Belgian Science Policyproject P7/30.	Altomare DA, 2005, ONCOGENE, V24, P6080, DOI 10.1038/sj.onc.1208744; Altomare DA, 2005, CANCER RES, V65, P8090, DOI 10.1158/0008-5472.CAN-05-2312; Andreini C, 2005, J PROTEOME RES, V4, P881, DOI 10.1021/pr0500096; Bononi A, 2015, EXPERT REV RESP MED, V9, P633, DOI 10.1586/17476348.2015.1081066; Bot J, 2003, PATHOL RES PRACT, V199, P341, DOI 10.1078/0344-0338-00427; Brooks AN, 2012, CLIN CANCER RES, V18, P1855, DOI 10.1158/1078-0432.CCR-11-0699; Carnet O, 2015, NEOPLASIA, V17, P552, DOI 10.1016/j.neo.2015.07.002; Chae YK, 2017, ONCOTARGET, V8, P16052, DOI 10.18632/oncotarget.14109; Derycke L, 2006, CLIN EXP METASTAS, V23, P187, DOI 10.1007/s10585-006-9029-7; Donaldson K, 2013, ADV DRUG DELIVER REV, V65, P2078, DOI 10.1016/j.addr.2013.07.014; Donati K, 2017, CANCER GROWTH METAST, V10, DOI 10.1177/1179064417738513; Dreymueller D, 2017, PLATELETS, V28, P354, DOI 10.1080/09537104.2016.1203396; Dreymueller D, 2015, AM J PHYSIOL-LUNG C, V308, pL325, DOI 10.1152/ajplung.00294.2014; Fu L, 2014, TUMOR BIOL, V35, P9263, DOI 10.1007/s13277-014-2201-9; Guo JL, 2012, ONCOL REP, V28, P1709, DOI 10.3892/or.2012.2003; Huang YH, 2017, J ADOLESCENT HEALTH, V61, P527, DOI 10.1016/j.jadohealth.2017.05.003; Hundhausen C, 2003, BLOOD, V102, P1186, DOI 10.1182/blood-2002-12-3775; Kern A, 2006, J BIOL CHEM, V281, P2405, DOI 10.1074/jbc.M505625200; Kim JB, 2000, J CELL BIOL, V151, P1193, DOI 10.1083/jcb.151.6.1193; Kohutek ZA, 2009, J NEUROSCI, V29, P4605, DOI 10.1523/JNEUROSCI.5126-08.2009; Liu SY, 2015, MOL MED REP, V11, P597, DOI 10.3892/mmr.2014.2652; Madoux F, 2016, SCI REP-UK, V6, DOI 10.1038/s41598-016-0013-4; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Mezzapelle R, 2016, SCI REP, V6, P1; Moss ML, 2008, CURR PHARM BIOTECHNO, V9, P2, DOI 10.2174/138920108783497613; Moss ML, 2007, J BIOL CHEM, V282, P35712, DOI 10.1074/jbc.M703231200; Mullooly M, 2015, BRIT J CANCER, V113, P945, DOI 10.1038/bjc.2015.288; Otjacques E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062818; PARADIES NE, 1993, J NEUROSCI RES, V36, P33, DOI 10.1002/jnr.490360105; Paulissen G, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-127; Pruessmeyer J, 2014, BLOOD, V123, P4077, DOI 10.1182/blood-2013-09-511543; Quispel-Janssen JM, 2018, CLIN CANCER RES, V24, P84, DOI 10.1158/1078-0432.CCR-17-1172; Ray M, 2009, CHEST, V136, P888, DOI 10.1378/chest.08-2665; Reiss K, 2005, EMBO J, V24, P742, DOI 10.1038/sj.emboj.7600548; Rocks N, 2008, BIOCHIMIE, V90, P369, DOI 10.1016/j.biochi.2007.08.008; Rocks N, 2006, BRIT J CANCER, V94, P724, DOI 10.1038/sj.bjc.6602990; Schnell J, 2017, DTSCH ARZTEBL INT, V114, P739, DOI 10.3238/arztebl.2017.0739; Schuck F, 2016, J ALZHEIMERS DIS, V50, P817, DOI 10.3233/JAD-150737; Shackleton B, 2016, FLUIDS BARRIERS CNS, V13, DOI 10.1186/s12987-016-0038-x; Sun YZ, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317712592; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Nguyen T, 2016, EUR J CELL BIOL, V95, P415, DOI 10.1016/j.ejcb.2016.05.002; Utton MA, 2001, J NEUROCHEM, V76, P1421, DOI 10.1046/j.1471-4159.2001.00140.x; Vincent B, 2016, BRAIN RES BULL, V126, P154, DOI 10.1016/j.brainresbull.2016.03.020; Yap TA, 2017, NAT REV CANCER, V17, P475, DOI 10.1038/nrc.2017.42; Yaziji H, 2006, MODERN PATHOL, V19, P514, DOI 10.1038/modpathol.3800534; Yilmaz M, 2010, MOL CANCER RES, V8, P629, DOI 10.1158/1541-7786.MCR-10-0139; You B, 2015, CANCER SCI, V106, P1506, DOI 10.1111/cas.12800; Zhang WQ, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.07.03	49	17	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2019	38	18					3521	3534		10.1038/s41388-018-0669-2	http://dx.doi.org/10.1038/s41388-018-0669-2			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HW3RI	30651596	Green Published, hybrid			2022-12-28	WOS:000466610000014
J	Han, QR; Xu, LJ; Lin, WH; Yao, XQ; Jiang, MH; Zhou, R; Sun, XG; Zhao, L				Han, Qinrui; Xu, Lijun; Lin, Weihao; Yao, Xueqing; Jiang, Muhong; Zhou, Rui; Sun, Xuegang; Zhao, Liang			Long noncoding RNA CRCMSL suppresses tumor invasive and metastasis in colorectal carcinoma through nucleocytoplasmic shuttling of HMGB2	ONCOGENE			English	Article							MESENCHYMAL TRANSITION; CANCER; PROGRESSION; CHROMATIN; COLON; PROTEINS; PROMOTES; BINDING; CELLS; LIM	Long noncoding RNAs (lncRNAs) are pervasive transcripts that play pivotal roles in regulating chromatin dynamics, gene and protein expression. Aberrant expression and mutations of lncRNAs represent a driving force behind tumor invasion and metastasis, making them attractive cancer targets. However, most of the lncRNAs are still being discovered and conclusive experimental evidence for their functional relevance is still lacking for most malignancies. In this study, a differentially expressed 1ncRNA, designated as lnc-CRCMSL, is identified by microarray-based screenings on non-metastatic and metastatic CRC specimens. Lnc-CRCMSL is verified as an anti-metastatic gene and negatively correlated with the poor prognosis of CRC patients. Lnc-CRCMSL overexpression restricts tumor growth and metastasis in vivo and in vitro. Instead, lnc-CRCMSL silencing accelerates CRC cell proliferation and migration. RNA-pulldown assay identifies high mobility group box 2 (HMGB2) as a downstream protein of lnc-CRCMSL. Mechanically, lnc-CRCMSL physically binds to HMGB2 and stabilizes the localization of HMGB2 in the cytoplasm. Notably, lnc-CRCMSL knockdown lead to the shift of HMGB2 into nuclear, in which it triggers epithelial to mesenchymal transition (EMT) programming. Importantly, lnc-CRCMSL controls the cytoplasmic retention of HMGB2 and attenuates the interaction between HMGB2 and OCT4 to suppress EMT. Treatment of leptomycin B (LMB), a potent and specific nuclear export inhibitor, counteracts lnc-CRCMSL-mediated suppression of aggressive phenotypes and EMT process by accumulating the nuclear HMGB2. Conclusion Our data highlight the anti-metastatic role of lnc-CRCMSL in stabilizing HMGB2 through lncRNA-protein interactions in the cytoplasm, and suggest that targeting lnc-CRCMSL may represent a therapeutic opportunity for managing metastatic CRC.	[Han, Qinrui; Sun, Xuegang] Southern Med Univ, Sch Tradit Chinese Med, Guangzhou 510515, Guangdong, Peoples R China; [Xu, Lijun; Zhao, Liang] Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China; [Xu, Lijun; Lin, Weihao; Jiang, Muhong; Zhou, Rui; Zhao, Liang] Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China; [Lin, Weihao] Southern Med Univ, Sch Clin Med 2, Guangzhou 510515, Guangdong, Peoples R China; [Yao, Xueqing] Guangdong Gen Hosp, Dept Gastrointestinal Surg, Guangzhou 510120, Guangdong, Peoples R China; [Jiang, Muhong; Zhou, Rui; Zhao, Liang] Southern Med Univ, Guangdong Prov Key Lab Mol Tumor Pathol, Guangzhou 510515, Guangdong, Peoples R China	Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; Guangdong Academy of Medical Sciences & Guangdong General Hospital; Southern Medical University - China	Sun, XG (corresponding author), Southern Med Univ, Sch Tradit Chinese Med, Guangzhou 510515, Guangdong, Peoples R China.; Zhao, L (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China.; Zhao, L (corresponding author), Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China.; Zhao, L (corresponding author), Southern Med Univ, Guangdong Prov Key Lab Mol Tumor Pathol, Guangzhou 510515, Guangdong, Peoples R China.	sxg_smu@126.com; liangsmu@foxmail.com	Zhao, Liang/T-9147-2019		National Natural Science Foundation of China [81572813, 81773082, 81573848, 81774172]; Guangdong Natural Science Foundation [2015A030313274]; Science and Technology Program of Guangzhou [1563000235]; Special Funds for the Cultivation of Guangdong College Students' Scientific and Technological Innovation [pdjhb0105]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Natural Science Foundation(National Natural Science Foundation of Guangdong Province); Science and Technology Program of Guangzhou; Special Funds for the Cultivation of Guangdong College Students' Scientific and Technological Innovation	This work was supported by the National Natural Science Foundation of China (Nos. 81572813, 81773082, 81573848, 81774172), Guangdong Natural Science Foundation (2015A030313274), Science and Technology Program of Guangzhou (1563000235) and Special Funds for the Cultivation of Guangdong College Students' Scientific and Technological Innovation (pdjhb0105).	Aird KM, 2016, J CELL BIOL, V215, P325, DOI 10.1083/jcb.201608026; Barsyte-Lovejoy D, 2006, CANCER RES, V66, P5330, DOI 10.1158/0008-5472.CAN-06-0037; Bhan A, 2017, CANCER RES, V77, P3965, DOI 10.1158/0008-5472.CAN-16-2634; Campbell PA, 2013, STEM CELLS, V31, P1107, DOI 10.1002/stem.1365; Cao CH, 2015, GASTROENTEROLOGY, V148, P415, DOI 10.1053/j.gastro.2014.10.012; Castillo-Quan JI, 2016, CELL, V167, P1670, DOI 10.1016/j.cell.2016.11.058; Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606; Fu DY, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0219-0; Huang QH, 2018, CANCER METAST REV, V37, P75, DOI 10.1007/s10555-017-9713-x; Islam SS, 2016, MOL CARCINOGEN, V55, P537, DOI 10.1002/mc.22300; Kopp F, 2018, CELL, V172, P393, DOI 10.1016/j.cell.2018.01.011; Kwon JH, 2010, CLIN CANCER RES, V16, P5511, DOI 10.1158/1078-0432.CCR-10-0825; Lagarde J, 2017, NAT GENET, V49, P1731, DOI 10.1038/ng.3988; Ling H, 2013, GENOME RES, V23, P1446, DOI 10.1101/gr.152942.112; Mandal G, 2018, BBA-MOL BASIS DIS, V1864, P2053, DOI 10.1016/j.bbadis.2018.03.010; Pennisi E, 2013, SCIENCE, V340, P910; Reeves R, 2015, DNA REPAIR, V36, P122, DOI 10.1016/j.dnarep.2015.09.015; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Schmoll HJ, 2012, ANN ONCOL, V23, P2479, DOI 10.1093/annonc/mds236; Takeuchi T, 2013, UROL J, V10, P960; Ueda T, 2010, BBA-GENE REGUL MECH, V1799, P114, DOI 10.1016/j.bbagrm.2009.11.005; Ugrinova I, 2009, BIOCHEMISTRY-US, V48, P6502, DOI 10.1021/bi9004304; Ulitsky I, 2016, NAT REV GENET, V17, P601, DOI 10.1038/nrg.2016.85; Wang H, 2014, CLIN CANCER RES, V20, P5835, DOI 10.1158/1078-0432.CCR-14-0485; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Wang KC, 2011, NATURE, V472, P120, DOI 10.1038/nature09819; Wang P, 2016, ONCOL LETT, V12, P4605, DOI 10.3892/ol.2016.5288; Weidle UH, 2017, CANCER GENOM PROTEOM, V14, P143, DOI 10.21873/cgp.20027; Yue B, 2016, J GASTROEN HEPATOL, V31, P595, DOI 10.1111/jgh.13206; Zhang FF, 2016, CANCER LETT, V373, P203, DOI 10.1016/j.canlet.2016.01.037; Zhang Yan-Fei, 2007, Nan Fang Yi Ke Da Xue Xue Bao, V27, P126; Zhang YF, 2016, SCI REP-UK, V6, DOI 10.1038/srep37821; Zhao LA, 2010, GUT, V59, P1226, DOI 10.1136/gut.2009.202739; Zhao YL, 2017, HEPATOL COMMUN, V1, P816, DOI 10.1002/hep4.1086; Zhi XL, 2015, HEPATOLOGY, V61, P598, DOI 10.1002/hep.27558	35	35	38	4	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2019	38	16					3019	3032		10.1038/s41388-018-0614-4	http://dx.doi.org/10.1038/s41388-018-0614-4			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU3IV	30575817				2022-12-28	WOS:000465167600011
J	De Oliveira, T; Ramakrishnan, M; Diamanti, MA; Ziegler, PK; Brombacher, F; Greten, FR				De Oliveira, Tiago; Ramakrishnan, Mallika; Diamanti, Michaela A.; Ziegler, Paul K.; Brombacher, Frank; Greten, Florian R.			Loss of Stat6 affects chromatin condensation in intestinal epithelial cells causing diverse outcome in murine models of inflammation-associated and sporadic colon carcinogenesis	ONCOGENE			English	Article							MACROPHAGE ACTIVATION; LINKS INFLAMMATION; INDUCED COLITIS; MOUSE MODEL; ER STRESS; CANCER; INHIBITION; RESPONSES; DNA; INTERLEUKIN-4	While great advances have been achieved regarding the genetic basis of colorectal cancer, the complex role of cell-cell communication and cytokine-induced signaling during its pathogenesis remains less understood. Signal transducer and activator of transcription 6 (Stat6) is the main transcription factor of interleukin-4 (IL-4) signaling and its participation in the development of various tumor types has been already reported. Here we aimed to examine the contribution of Stat6 in intestinal epithelial cells (IEC) in mouse models of intestinal carcinogenesis. Wild-type (WT), Stat6 knockout (Stat6(-/-)), and intestinal epithelial cell-specific IL-4R alpha knockout (Il-4r alpha P-Delta(IEC) ) mice were subjected to colitis-associated (AOM/DSS) and colitis-independent (sporadic) carcinogenesis. IEC proliferation, apoptosis and RNA expression were evaluated by immunohistochemical, immunoblot, and RT-PCR analysis. We found that Stat6( -/- )mice developed more tumors in the colitis-associated carcinogenesis model. This was accompanied by a more pronounced inflammatory response during colitis and an elevated Stat3-dependent proliferation of IEC. Increased sensitivity to DSS-induced colitis was caused by elevated cell death in response to the initial carcinogen exposure as Stat6 deficiency led to increased chromatin compaction affecting DNA damage response in IEC upon treatment with alkylating agents independently of IL-4R alpha engagement. Thus, loss of Stat6 caused more severe colitis and increased tumor load, however loss-of-initiated Stat6(-/-) IEC prevented tumor formation in the absence of overt inflammation. Our data unravel unexpected IL-4- independent functions of Stat6 in chromatin compaction in intestinal epithelial cells ultimately providing both tumor suppressive as well as tumor promoting effects in different models of intestinal tumorigenesis.	[De Oliveira, Tiago; Ramakrishnan, Mallika; Diamanti, Michaela A.; Ziegler, Paul K.; Greten, Florian R.] Georg Speyer Haus, Inst Tumor Biol & Expt Therapy, D-60596 Frankfurt, Germany; [Brombacher, Frank] Int Ctr Genet Engn & Biotechnol, Anzio Rd, ZA-7925 Cape Town, South Africa; [Brombacher, Frank] Univ Cape Town, Anzio Rd, ZA-7925 Cape Town, South Africa; [Brombacher, Frank] South African Med Res Ctr, External Unit, Anzio Rd, ZA-7925 Cape Town, South Africa; [Greten, Florian R.] German Canc Consortium DKTK, D-69120 Heidelberg, Germany; [Greten, Florian R.] German Canc Res Ctr, D-69120 Heidelberg, Germany	Octapharma; International Center for Genetic Engineering & Biotechnology (ICGEB); ICGEB Cape Town; University of Cape Town; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Greten, FR (corresponding author), Georg Speyer Haus, Inst Tumor Biol & Expt Therapy, D-60596 Frankfurt, Germany.; Greten, FR (corresponding author), German Canc Consortium DKTK, D-69120 Heidelberg, Germany.; Greten, FR (corresponding author), German Canc Res Ctr, D-69120 Heidelberg, Germany.	greten@gsh.uni-frankfurt.de	Greten, Florian R/AAF-5196-2020; Ziegler, Paul/AAO-4379-2021	Greten, Florian R/0000-0002-3928-6080; Ziegler, Paul/0000-0002-7703-7747; De Oliveira, Tiago/0000-0002-2502-7897	LOEWE Center for Cell and Gene Therapy Frankfurt (CGT) [III L 4-518/17.004]; Georg-Speyer-Haus; Deutsche Forschungsgemeinschaft [Gr1916/5-1, FOR2438: Gr1916/11-1, SFB 815, 1177, 1292]	LOEWE Center for Cell and Gene Therapy Frankfurt (CGT); Georg-Speyer-Haus; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We thank Christin Danneil, Hana Kunkel, Preeti Gupta, Kathleen Mohs, and Eva Rudolf for technical assistance as well as Petra Dinse at the Histology Core Facility at the Georg-Speyer-Haus for excellent technical support and all members of the Greten lab for insightful discussion. We also thank Birgitta Michels for help with karyotype analysis. This work was supported in part by the LOEWE Center for Cell and Gene Therapy Frankfurt (CGT, III L 4-518/17.004) and institutional funds from the Georg-Speyer-Haus, as well as grants from the Deutsche Forschungsgemeinschaft (Gr1916/5-1 and FOR2438: Gr1916/11-1; SFB 815, 1177 and 1292) to F.R.G..	Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Blackford AN, 2017, MOL CELL, V66, P801, DOI 10.1016/j.molcel.2017.05.015; Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002; Cao H, 2016, ONCOTARGET, V7, P61183, DOI 10.18632/oncotarget.11282; Clapper ML, 2007, ACTA PHARMACOL SIN, V28, P1450, DOI 10.1111/j.1745-7254.2007.00695.x; Cosin-Roger J, 2016, MUCOSAL IMMUNOL, V9, P986, DOI 10.1038/mi.2015.123; Das S, 2010, BIOCHEMISTRY-US, V49, P2216, DOI 10.1021/bi9013038; Dawson MR, 2009, NATURE, V461, pE4, DOI 10.1038/nature08254; De Robertis Mariangela, 2011, J Carcinog, V10, P9, DOI 10.4103/1477-3163.78279; Diamanti MA, 2017, J EXP MED, V214, P423, DOI 10.1084/jem.20161867; Dinant C, 2009, MOL CELL BIOL, V29, P6335, DOI 10.1128/MCB.01048-09; Elinav E, 2013, NAT REV CANCER, V13, P759, DOI 10.1038/nrc3611; Elrod JW, 2005, INFLAMM BOWEL DIS, V11, P883, DOI 10.1097/01.MIB.0000182871.76434.57; Falk M, 2008, BBA-MOL CELL RES, V1783, P2398, DOI 10.1016/j.bbamcr.2008.07.010; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fichtner-Feigl S, 2006, NAT MED, V12, P99, DOI 10.1038/nm1332; Gandhi NA, 2016, NAT REV DRUG DISCOV, V15, P35, DOI 10.1038/nrd4624; Goenka S, 2011, IMMUNOL RES, V50, P87, DOI 10.1007/s12026-011-8205-2; Gooch JL, 2002, NEOPLASIA, V4, P324, DOI 10.1038/sj.neo.7900248; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Grivennikov SI, 2012, NATURE, V491, P254, DOI 10.1038/nature11465; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Gurvich N, 2004, CANCER RES, V64, P1079, DOI 10.1158/0008-5472.CAN-03-0799; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heller NM, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1164795; Herbert DR, 2004, IMMUNITY, V20, P623, DOI 10.1016/S1074-7613(04)00107-4; Jayakumar A, 2017, NEOPLASIA, V19, P595, DOI 10.1016/j.neo.2017.04.006; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Khan O, 2012, IMMUNOL CELL BIOL, V90, P85, DOI 10.1038/icb.2011.100; LaPorte SL, 2008, CELL, V132, P259, DOI 10.1016/j.cell.2007.12.030; Leon-Cabrera SA, 2017, CANCER IMMUNOL RES, V5, P385, DOI 10.1158/2326-6066.CIR-16-0168; Li WX, 2008, TRENDS CELL BIOL, V18, P545, DOI 10.1016/j.tcb.2008.08.008; Liu L, 2017, GASTROENTEROLOGY, V153, P1517, DOI 10.1053/j.gastro.2017.08.045; Luzina IG, 2012, J LEUKOCYTE BIOL, V92, P753, DOI 10.1189/jlb.0412214; Madigan JP, 2002, NUCLEIC ACIDS RES, V30, P3698, DOI 10.1093/nar/gkf496; Madison BB, 2002, J BIOL CHEM, V277, P33275, DOI 10.1074/jbc.M204935200; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Nishitoh H, 2012, J BIOCHEM, V151, P217, DOI 10.1093/jb/mvr143; Pallangyo CK, 2015, J EXP MED, V212, P2253, DOI 10.1084/jem.20150576; Pegoraro G, 2009, NAT CELL BIOL, V11, P1261, DOI 10.1038/ncb1971; Peng JC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000435; Schwitalla S, 2013, CANCER CELL, V23, P93, DOI 10.1016/j.ccr.2012.11.014; Shi S, 2008, NAT CELL BIOL, V10, P491, DOI 10.1038/ncb1713; Shi S, 2006, NAT GENET, V38, P1071, DOI 10.1038/ng1860; Sica A, 2008, SEMIN CANCER BIOL, V18, P349, DOI 10.1016/j.semcancer.2008.03.004; Takeda K, 1996, J IMMUNOL, V157, P3220; Takeda K, 1998, J IMMUNOL, V161, P4652; Taniguchi K, 2015, NATURE, V519, P57, DOI 10.1038/nature14228; Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492; Varga J, 2017, NAT CELL BIOL, V19, P1133, DOI 10.1038/ncb3611; Wali RK, 1999, CARCINOGENESIS, V20, P2355, DOI 10.1093/carcin/20.12.2355; Whetstone RD, 2016, MOL CARCINOGEN, V55, P1187, DOI 10.1002/mc.22361; Yan DY, 2016, CELL REP, V16, P2914, DOI 10.1016/j.celrep.2016.08.035; Yan SJ, 2011, FASEB J, V25, P232, DOI 10.1096/fj.10-169367; Zhang HS, 2015, J BIOL CHEM, V290, P15327, DOI 10.1074/jbc.M114.633560	56	10	10	3	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2019	38	11					1787	1801		10.1038/s41388-018-0551-2	http://dx.doi.org/10.1038/s41388-018-0551-2			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HO7XX	30353167	Green Published, hybrid			2022-12-28	WOS:000461164400001
J	Guo, H; Zeng, DF; Zhang, H; Bell, T; Yao, J; Liu, Y; Huang, SJ; Li, CJ; Lorence, E; Zhou, SH; Gong, TJ; Jiang, CY; Ahmed, M; Yao, YX; Nomie, KJ; Zhang, L; Wang, M				Guo, Hui; Zeng, Dongfeng; Zhang, Hui; Bell, Taylor; Yao, Jun; Liu, Yang; Huang, Shengjian; Li, Carrie J.; Lorence, Elizabeth; Zhou, Shouhao; Gong, Tiejun; Jiang, Changying; Ahmed, Makhdum; Yao, Yixin; Nomie, Krystle J.; Zhang, Liang; Wang, Michael			( Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma )	ONCOGENE			English	Article							IBRUTINIB RESISTANCE; FOLLICULAR LYMPHOMA; DNA-DAMAGE; OPEN-LABEL; PHASE-I; IDELALISIB; CUDC-907; HDAC; APOPTOSIS; PATHWAY	The dysregulation of PI3K signaling has been implicated as an underlying mechanism associated with resistance to Bruton's tyrosine kinase inhibition by ibrutinib in both chronic lymphocytic leukemia and mantle cell lymphoma (MCL). Ibrutinib resistance has become a major unmet clinical need, and the development of therapeutics to overcome ibrutinib resistance will greatly improve the poor outcomes of ibrutinib-exposed MCL patients. CUDC-907 inhibits both PI3K and HDAC functionality to exert synergistic or additive effects. Therefore, the activity of CUDC-907 was examined in MCL cell lines and patient primary cells, including ibrutinib-resistant MCL cells. The efficacy of CUDC-907 was further examined in an ibrutinib-resistant MCL patient-derived xenograft (PDX) mouse model. The molecular mechanisms by which CUDC-907 dually inhibits PI3K and histone deacetylation were assessed using reverse protein array, immunoblotting, and chromatin immunoprecipitation (ChIP) coupled with sequencing. We showed evidence that CUDC-907 treatment increased histone acetylation in MCL cells. We found that CUDC-907 caused decreased proliferation and increased apoptosis in MCL in vitro and in vivo MCL models. In addition, CUDC-907 was effective in inducing lethality in ibrutinib-resistant MCL cells. Lastly, CUDC-907 treatment increased histone acetylation in MCL cells. Overall, these studies suggest that CUDC-907 may be a promising therapeutic option for relapsed or resistant MCL.	[Guo, Hui; Zeng, Dongfeng; Zhang, Hui; Bell, Taylor; Liu, Yang; Huang, Shengjian; Li, Carrie J.; Lorence, Elizabeth; Jiang, Changying; Ahmed, Makhdum; Yao, Yixin; Nomie, Krystle J.; Zhang, Liang; Wang, Michael] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA; [Zeng, Dongfeng] Third Mil Med Univ, Xinqiao Hosp, Dept Hematol, Chongqing 430000, Peoples R China; [Yao, Jun] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Zhou, Shouhao] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; [Gong, Tiejun] First Hosp Harbin, Inst Hematol & Oncol, Harbin 150010, Heilongjiang, Peoples R China; [Wang, Michael] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Army Medical University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Wang, M (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA.; Wang, M (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA.	miwang@mdanderson.org	Jiang, Changying/AAL-3711-2020	Guo, Hui/0000-0003-3901-6336; Jiang, Changying/0000-0003-3778-4438; Yao, Yixin/0000-0002-8439-6043; dongfeng, zeng/0000-0002-0460-7593	NIH [P30 CA016672, R21 CA202104]; Gary Rogers Foundation; Kinder Foundation; Pharmacyclics, an AbbVie Company; NCI [CA016672]; NATIONAL CANCER INSTITUTE [R21CA202104, P30CA016672] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Gary Rogers Foundation; Kinder Foundation; Pharmacyclics, an AbbVie Company; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the NIH-funded Cancer Center Support Grant (CCSG) P30 CA016672 and the R21 CA202104 (Michael Wang, PI). This study was also partially supported by the generous philanthropic support to the MD Anderson B Cell Lymphoma Moon Shot Project and philanthropy funds from The Gary Rogers Foundation and the Kinder Foundation. Pharmacyclics, an AbbVie Company, also provided funds for this laboratory work. The reagent CUDC-907 was provided by Curis, Inc. The laboratory research was not supported by Curis, Inc. Ibrutinib was provided by Pharmacyclics, an AbbVie Company. Cell line authentication was performed by the MD Anderson Cancer Center Characterized Cell Line Core Facility, funded by grant NCI # CA016672.	Ahn IE, 2017, BLOOD, V129, P1469, DOI 10.1182/blood-2016-06-719294; Ali D, 2017, STEM CELLS DEV, V26, P353, DOI 10.1089/scd.2016.0183; Bolden JE, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.9; Cheah CY, 2016, J CLIN ONCOL, V34, P1256, DOI 10.1200/JCO.2015.63.5904; Cheah CY, 2015, BLOOD, V125, P3357, DOI 10.1182/blood-2015-03-633156; Cheng S, 2015, LEUKEMIA, V29, P895, DOI 10.1038/leu.2014.263; Chiron D, 2014, CANCER DISCOV, V4, P1022, DOI 10.1158/2159-8290.CD-14-0098; Dreyling M, 2016, LANCET, V387, P770, DOI 10.1016/S0140-6736(15)00667-4; Dudakovic A, 2013, J BIOL CHEM, V288, P28783, DOI 10.1074/jbc.M113.489732; Ghosh K, 2018, J DERMATOL SCI, V89, P226, DOI 10.1016/j.jdermsci.2017.12.006; Giles F, 2006, CLIN CANCER RES, V12, P4628, DOI 10.1158/1078-0432.CCR-06-0511; Gopal AK, 2017, BLOOD, V129, P3037, DOI 10.1182/blood-2016-12-757740; Gopal AK, 2014, NEW ENGL J MED, V370, P1008, DOI 10.1056/NEJMoa1314583; Goy A, 2016, HEMATOL ONCOL CLIN N, V30, P1345, DOI 10.1016/j.hoc.2016.07.014; Graf SA, 2016, EXPERT OPIN PHARMACO, V17, P265, DOI 10.1517/14656566.2016.1135130; Khan O, 2012, IMMUNOL CELL BIOL, V90, P85, DOI 10.1038/icb.2011.100; Lee EJ, 2011, BIOCHEM BIOPH RES CO, V414, P384, DOI 10.1016/j.bbrc.2011.09.083; Lee JH, 2010, P NATL ACAD SCI USA, V107, P14639, DOI 10.1073/pnas.1008522107; Lemoine M, 2010, DISCOV MED, V10, P462; Lim HJ, 2016, ANTICANCER RES, V36, P5765, DOI 10.21873/anticanres.11160; Martin P, 2016, LANCET, V388, P535, DOI 10.1016/S0140-6736(16)30451-2; Martin P, 2016, LANCET, V387, P728, DOI 10.1016/S0140-6736(15)01040-5; Medina DJ, 2012, HAEMATOL-HEMATOL J, V97, P1255, DOI 10.3324/haematol.2011.040659; Oki Y, 2017, HAEMATOLOGICA, V102, P1923, DOI 10.3324/haematol.2017.172882; Ozes ON, 2001, P NATL ACAD SCI USA, V98, P4640, DOI 10.1073/pnas.051042298; Qian DZ, 2006, CLIN CANCER RES, V12, P634, DOI 10.1158/1078-0432.CCR-05-1132; Rahal R, 2014, NAT MED, V20, P87, DOI 10.1038/nm.3435; Rahmani M, 2009, BLOOD, V114, P4507, DOI 10.1182/blood-2008-09-177881; Salles G, 2017, HAEMATOLOGICA, V102, pE156, DOI 10.3324/haematol.2016.151738; Scuto A, 2008, BLOOD, V111, P5093, DOI 10.1182/blood-2007-10-117762; Sun KM, 2017, MOL CANCER THER, V16, P285, DOI 10.1158/1535-7163.MCT-16-0390; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang CH, 2014, FEBS LETT, V588, P4654, DOI 10.1016/j.febslet.2014.10.037; Woyach JA, 2017, J CLIN ONCOL, V35, P1437, DOI 10.1200/JCO.2016.70.2282; Yoshioka T, 2013, GYNECOL ONCOL, V129, P425, DOI 10.1016/j.ygyno.2013.02.008; Younes A, 2016, LANCET ONCOL, V17, P622, DOI 10.1016/S1470-2045(15)00584-7; Zhang L, 2017, CLIN CANCER RES, V23, P4212, DOI 10.1158/1078-0432.CCR-16-2703; Zhang XC, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-168; Zhao XH, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14920	39	11	11	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2019	38	11					1802	1814		10.1038/s41388-018-0550-3	http://dx.doi.org/10.1038/s41388-018-0550-3			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HO7XX	30361685				2022-12-28	WOS:000461164400002
J	Kheimar, A; Trimpert, J; Groenke, N; Kaufer, BB				Kheimar, Ahmed; Trimpert, Jakob; Groenke, Nicole; Kaufer, Benedikt B.			Overexpression of cellular telomerase RNA enhances virus-induced cancer formation	ONCOGENE			English	Article							MAREKS-DISEASE VIRUS; CELLS; MYC; IDENTIFICATION; RECOMBINATION; EXPRESSION; PROTEINS; SUBUNIT; GENES	The telomerase RNA subunit (TR) is overexpressed in many tumors; however, the contribution of TR in cancer formation remains elusive. The most frequent clinically diagnosed cancer in the animal kingdom is caused by the highly oncogenic herpesvirus Marek's disease virus (MDV). MDV encodes a TR (vTR) that plays an important role in virus-induced tumorigenesis and shares 88% sequence identity with its cellular homologue. To determine if the cellular TR possesses pro-oncogenic activity, we replaced vTR with the cellular homologue in the virus genome. Insertion of cellular TR resulted in a strong overexpression in virus infected cells, while virus replication was not affected. Strikingly, cellular TR promoted tumor formation as efficient as vTR, while tumorigenesis was severely impaired in the absence of vTR. Our data provide the first evidence that overexpression of cellular TR can contribute to tumor formation in vivo using this natural virus-host model for herpesvirus-induced oncogenesis.	[Kheimar, Ahmed; Trimpert, Jakob; Groenke, Nicole; Kaufer, Benedikt B.] Free Univ Berlin, Inst Virol, Robert von Ostertag Str 7-13, D-14163 Berlin, Germany; [Kheimar, Ahmed] Sohag Univ, Fac Vet Med, Dept Poultry Dis, Sohag 82424, Egypt	Free University of Berlin; Egyptian Knowledge Bank (EKB); Sohag University	Kaufer, BB (corresponding author), Free Univ Berlin, Inst Virol, Robert von Ostertag Str 7-13, D-14163 Berlin, Germany.	b.kaufer@fu-berlin.de	Kaufer, Benedikt B./AAZ-8216-2020; Kheimar, Ahmed/AAM-7694-2021; Kheimar, Ahmed M./AAB-4022-2021	Kaufer, Benedikt B./0000-0003-1328-2695; Kheimar, Ahmed/0000-0001-8121-8981; Groenke, Nicole/0000-0002-6927-3774; Trimpert, Jakob/0000-0003-1616-0810	DFG [KA 3492/3-1]; Ministry of High Education Egypt (MOHE); Studienstiftung des deutschen Volkes	DFG(German Research Foundation (DFG)); Ministry of High Education Egypt (MOHE); Studienstiftung des deutschen Volkes	DFG grant (KA 3492/3-1), Ministry of High Education Egypt (MOHE), and Studienstiftung des deutschen Volkes.	Akincilar SC, 2015, FEBS LETT, V589, P974, DOI 10.1016/j.febslet.2015.02.035; Anderson SJ, 2007, IMMUNITY, V26, P759, DOI 10.1016/j.immuni.2007.04.012; Autexier C, 2006, ANNU REV BIOCHEM, V75, P493, DOI 10.1146/annurev.biochem.75.103004.142412; Baena-Del Valle JA, 2018, J PATHOL, V244, P11, DOI 10.1002/path.4980; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Cao Y, 2008, CANCER SCI, V99, P1092, DOI 10.1111/j.1349-7006.2008.00815.x; Chbab N, 2010, VET RES, V41, DOI 10.1051/vetres/2010026; Chen JL, 2000, CELL, V100, P503, DOI 10.1016/S0092-8674(00)80687-X; Collins K, 2008, MECH AGEING DEV, V129, P91, DOI 10.1016/j.mad.2007.10.008; Engel AT, 2012, J VIROL, V86, P8536, DOI 10.1128/JVI.00556-12; Fragnet L, 2005, J BIOL CHEM, V280, P23502, DOI 10.1074/jbc.M501163200; Fragnet L, 2003, J VIROL, V77, P5985, DOI 10.1128/JVI.77.10.5985-5996.2003; Gazzaniga FS, 2014, BLOOD, V124, P3675, DOI 10.1182/blood-2014-06-582254; Ghosh A, 2012, NAT CELL BIOL, V14, P1270, DOI 10.1038/ncb2621; Jarosinski K, 2007, P NATL ACAD SCI USA, V104, P20025, DOI 10.1073/pnas.0706295104; Jarosinski KW, 2007, J VIROL, V81, P10575, DOI 10.1128/JVI.01065-07; Jarosinski KW, 2005, J VIROL, V79, P11647, DOI 10.1128/JVI.79.18.11647-11659.2005; Kaufer BB, 2011, J EXP MED, V208, P605, DOI 10.1084/jem.20101402; Kaufer BB, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001073; Khattar E, 2016, J CLIN INVEST, V126, P4045, DOI 10.1172/JCI86042; Kheimar A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18638-7; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Koh CM, 2015, J CLIN INVEST, V125, P2109, DOI 10.1172/JCI79134; Le SY, 2000, MOL BIOL CELL, V11, P999, DOI 10.1091/mbc.11.3.999; Li L, 2014, EUR J GYNAECOL ONCOL, V35, P289; Martin-Rivera L, 2001, J BIOL CHEM, V276, P5856, DOI 10.1074/jbc.M008419200; Mason M, 2011, CURR OPIN STRUC BIOL, V21, P92, DOI 10.1016/j.sbi.2010.11.005; Murre C, 2007, IMMUNITY, V26, P751, DOI 10.1016/j.immuni.2007.06.001; Nowak T, 2006, ONCOL REP, V16, P301; Osterrieder N, 2006, NAT REV MICROBIOL, V4, P283, DOI 10.1038/nrmicro1382; Penzo M, 2015, ONCOTARGET, V6, P21755, DOI 10.18632/oncotarget.4580; Rao SY, 2016, CANCER RES, V76, P3387, DOI 10.1158/0008-5472.CAN-15-2698; Rao SY, 2012, BLOOD, V120, P3764, DOI 10.1182/blood-2012-03-415349; Rumin Wen JL, 2006, CHINESE J CLIN ONCOL, V3, P326; Schumacher D, 2005, J VIROL, V79, P3987, DOI 10.1128/JVI.79.7.3987-3997.2005; Shkreli M, 2007, J VIROL, V81, P4848, DOI 10.1128/JVI.02530-06; Tischer BK, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/472537; Tischer BK, 2010, METHODS MOL BIOL, V634, P421, DOI 10.1007/978-1-60761-652-8_30; Tischer BK, 2006, BIOTECHNIQUES, V40, P191, DOI 10.2144/000112096; Trapp S, 2006, J EXP MED, V203, P1307, DOI 10.1084/jem.20052240; Wyatt HDM, 2010, NUCLEIC ACIDS RES, V38, P5609, DOI 10.1093/nar/gkq370	41	14	14	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2019	38	10					1778	1786		10.1038/s41388-018-0544-1	http://dx.doi.org/10.1038/s41388-018-0544-1			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN8DD	30846849				2022-12-28	WOS:000460423800015
J	Wang, MD; Nagle, RB; Knudsen, BS; Cress, AE; Rogers, GC				Wang, Mengdie; Nagle, Raymond B.; Knudsen, Beatrice S.; Cress, Anne E.; Rogers, Gregory C.			Centrosome loss results in an unstable genome and malignant prostate tumors	ONCOGENE			English	Article							CHROMOSOMAL INSTABILITY; CENTRIOLE DUPLICATION; C-MYC; CANCER; AMPLIFICATION; EXPRESSION; CELLS; DIFFERENTIATION; TUMORIGENESIS; PROGRESSION	Localized, nonindolent prostate cancer (PCa) is characterized by large-scale genomic rearrangements, aneuploidy, chromothripsis, and other forms of chromosomal instability (CIN), yet how this occurs remains unclear. A well-established mechanism of CIN is the overproduction of centrosomes, which promotes tumorigenesis in various mouse models. Therefore, we developed a single-cell assay for quantifying centrosomes in human prostate tissue. Surprisingly, centrosome loss-which has not been described in human cancer-was associated with PCa progression. By chemically or genetically inducing centrosome loss in nontumorigenic prostate epithelial cells, mitotic errors ensued, producing aneuploid, and multinucleated cells. Strikingly, transient or chronic centrosome loss transformed prostate epithelial cells, which produced highly proliferative and poorly differentiated malignant tumors in mice. Our findings suggest that centrosome loss could create a cellular crisis with oncogenic potential in prostate epithelial cells.	[Wang, Mengdie; Cress, Anne E.; Rogers, Gregory C.] Univ Arizona, Canc Ctr, Dept Cellular & Mol Med, Tucson, AZ 85724 USA; [Nagle, Raymond B.] Univ Arizona, Canc Ctr, Dept Pathol, Tucson, AZ 85724 USA; [Knudsen, Beatrice S.] Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USA	University of Arizona; University of Arizona; Cedars Sinai Medical Center	Cress, AE; Rogers, GC (corresponding author), Univ Arizona, Canc Ctr, Dept Cellular & Mol Med, Tucson, AZ 85724 USA.	cress@email.arizona.edu; gcrogers@email.arizona.edu		Cress, Anne/0000-0001-6194-0061	DoD PCa Research Program [W81XWH-14-2-0182, W81XWH-14-2-0183, W81XWH-14-2-0185, W81XWH-14-2-0186, W81XWH-15-2-0062]; NIH [NCI P30 CA23074, R01GM110166, R01GM126035, R01CA159406]; Tim and Diane Bowden Cancer Biology Research Fellowship	DoD PCa Research Program(United States Department of Defense); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Tim and Diane Bowden Cancer Biology Research Fellowship	We thank K. Oegema for providing centrinone and CRISPR constructs, D. Pellman for histone-H2B construct, V. Bautch for centrin1 construct, W. Hahn for PrEC cells, C. Miranti for iPEC37 cells, and N. Ellis and J. DeLuca for technical advice. Tissue samples were obtained from the PCa Biorepository Network (PCBN) (DoD PCa Research Program Award No W81XWH-14-2-0182, W81XWH-14-2-0183, W81XWH-14-2-0185, W81XWH-14-2-0186, and W81XWH-15-2-0062). This work was supported by NIH grants NCI P30 CA23074, R01GM110166, and R01GM126035 to GCR, R01CA159406 to AEC and Tim and Diane Bowden Cancer Biology Research Fellowship to MW.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Armenia J, 2018, NAT GENET, V50, P645, DOI 10.1038/s41588-018-0078-z; Baca SC, 2013, CELL, V153, P666, DOI 10.1016/j.cell.2013.03.021; Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279; Bazzi H, 2014, P NATL ACAD SCI USA, V111, pE1491, DOI 10.1073/pnas.1400568111; Beheshti B, 2001, NEOPLASIA, V3, P62, DOI 10.1038/sj.neo.7900125; Bello D, 1997, CARCINOGENESIS, V18, P1215, DOI 10.1093/carcin/18.6.1215; Berger R, 2004, CANCER RES, V64, P8867, DOI 10.1158/0008-5472.CAN-04-2938; Bettencourt-Dias M, 2005, CURR BIOL, V15, P2199, DOI 10.1016/j.cub.2005.11.042; Bettencourt-Dias M, 2007, NAT REV MOL CELL BIO, V8, P451, DOI 10.1038/nrm2180; Boutros PC, 2015, NAT GENET, V47, P736, DOI 10.1038/ng.3315; Cangemi R, 2008, ONCOGENE, V27, P2877, DOI 10.1038/sj.onc.1210953; Chan JY, 2011, INT J BIOL SCI, V7, P1122, DOI 10.7150/ijbs.7.1122; Chatterjee SJ, 2014, BREAST CANCER-TARGET, V6, P15, DOI 10.2147/BCTT.S43764; Coelho PA, 2015, OPEN BIOL, V5, DOI 10.1098/rsob.150209; Conduit PT, 2015, NAT REV MOL CELL BIO, V16, P611, DOI 10.1038/nrm4062; Cosenza MR, 2017, CELL REP, V20, P1906, DOI 10.1016/j.celrep.2017.08.005; Crasta K, 2012, NATURE, V482, P53, DOI 10.1038/nature10802; Denu RA, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2083-x; Edick MJ, 2007, MOL BIOL CELL, V18, P2481, DOI 10.1091/mbc.E06-04-0261; Espiritu SMG, 2018, CELL, V173, P1003, DOI 10.1016/j.cell.2018.03.029; Fraser M, 2017, NATURE, V541, P359, DOI 10.1038/nature20788; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Gmyrek GA, 2001, AM J PATHOL, V159, P579, DOI 10.1016/S0002-9440(10)61729-4; Godinho SA, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0467; Godinho SA, 2014, NATURE, V510, P167, DOI 10.1038/nature13277; Gregan J, 2011, TRENDS CELL BIOL, V21, P374, DOI 10.1016/j.tcb.2011.01.003; Habedanck R, 2005, NAT CELL BIOL, V7, P1140, DOI 10.1038/ncb1320; Khodjakov A, 2001, J CELL BIOL, V153, P237, DOI 10.1083/jcb.153.1.237; Kushner EJ, 2014, J CELL BIOL, V206, P257, DOI 10.1083/jcb.201311013; Lambrus BG, 2015, J CELL BIOL, V210, P63, DOI 10.1083/jcb.201502089; Lawo S, 2012, NAT CELL BIOL, V14, P1148, DOI 10.1038/ncb2591; Levine MS, 2017, DEV CELL, V40, P313, DOI 10.1016/j.devcel.2016.12.022; Lipponen P, 2001, EUR J CANCER, V37, P849, DOI 10.1016/S0959-8049(00)00448-2; Malhas AN, 2014, ADV EXP MED BIOL, V773, P523, DOI 10.1007/978-1-4899-8032-8_24; Meunier S, 2016, TRENDS CELL BIOL, V26, P80, DOI 10.1016/j.tcb.2015.09.001; Nigg EA, 2018, NAT REV MOL CELL BIO, V19, P297, DOI 10.1038/nrm.2017.127; Ouyang XS, 2001, BBA-MOL CELL RES, V1541, P212, DOI 10.1016/S0167-4889(01)00157-4; PETEIN M, 1991, AM J CLIN PATHOL, V96, P628, DOI 10.1093/ajcp/96.5.628; Pihan GA, 2001, CANCER RES, V61, P2212; Pimenta-Marques A, 2016, SCIENCE, V353, DOI 10.1126/science.aaf4866; Rickman DS, 2012, P NATL ACAD SCI USA, V109, P9083, DOI 10.1073/pnas.1112570109; Robinson DR, 2017, NATURE, V548, P297, DOI 10.1038/nature23306; Rubin MA, 2001, HUM PATHOL, V32, P690, DOI 10.1053/hupa.2001.25902; Sercin O, 2016, NAT CELL BIOL, V18, P100, DOI 10.1038/ncb3270; Shi QH, 2005, NATURE, V437, P1038, DOI 10.1038/nature03958; Silkworth WT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006564; Sir JH, 2013, J CELL BIOL, V203, P747, DOI 10.1083/jcb.201309038; Sun C, 2008, ONCOGENE, V27, P5348, DOI 10.1038/onc.2008.183; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; van Bokhoven A, 2001, PROSTATE, V47, P36; Vitre B, 2015, P NATL ACAD SCI USA, V112, pE6321, DOI 10.1073/pnas.1519388112; Wang M, 2019, MOL BIOL CELL, DOI [10.1091/mcb.E18-10-0651, DOI 10.1091/MCB.E18-10-0651]; Wang MD, 2017, J CELL SCI, V130, P104, DOI 10.1242/jcs.188177; Werner S, 2017, J CELL SCI, V130, P3789, DOI 10.1242/jcs.203505; Wong YL, 2015, SCIENCE, V348, P1155, DOI 10.1126/science.aaa5111; Wu YM, 2018, CELL, V173, P1770, DOI 10.1016/j.cell.2018.04.034; Xue JZ, 2013, DEV CELL, V27, P47, DOI 10.1016/j.devcel.2013.08.002; Zeng W, 2015, INT J CLIN EXP PATHO, V8, P1878	59	11	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	2					399	413		10.1038/s41388-019-0995-z	http://dx.doi.org/10.1038/s41388-019-0995-z			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KD3JY	31477840	Green Accepted			2022-12-28	WOS:000507766400011
J	Polonen, P; Deen, AJ; Leinonen, HM; Jyrkkanen, HK; Kuosmanen, S; Mononen, M; Jain, A; Tuomainen, T; Pasonen-Seppanen, S; Hartikainen, JM; Mannermaa, A; Nykter, M; Tavi, P; Johansen, T; Heinaniemi, M; Levonen, AL				Polonen, Petri; Deen, Ashik Jawahar; Leinonen, Hanna M.; Jyrkkanen, Henna-Kaisa; Kuosmanen, Suvi; Mononen, Mimmi; Jain, Ashish; Tuomainen, Tomi; Pasonen-Seppanen, Sanna; Hartikainen, Jaana M.; Mannermaa, Arto; Nykter, Matti; Tavi, Pasi; Johansen, Terje; Heinaniemi, Merja; Levonen, Anna-Liisa			Nrf2 and SQSTM1/p62 jointly contribute to mesenchymal transition and invasion in glioblastoma	ONCOGENE			English	Article							TRANSCRIPTION FACTOR NRF2; KEAP1-NRF2 PATHWAY; SIGNALING PATHWAYS; CELL LINE; ACTIVATION; MUTATIONS; GENE; EXPRESSION; P62; ABNORMALITIES	Accumulating evidence suggests that constitutively active Nrf2 has a pivotal role in cancer as it induces pro-survival genes that promote cancer cell proliferation and chemoresistance. The mechanisms of Nrf2 dysregulation and functions in cancer have not been fully characterized. Here, we jointly analyzed the Broad-Novartis Cancer Cell Line Encyclopedia (CCLE) and the Cancer Genome Atlas (TCGA) multi-omics data in order to identify cancer types where Nrf2 activation is present. We found that Nrf2 is hyperactivated in a subset of glioblastoma (GBM) patients, whose tumors display a mesenchymal subtype, and uncover several different mechanisms contributing to increased Nrf2 activity. Importantly, we identified a positive feedback loop between SQSTM1/p62 and Nrf2 as a mechanism for activation of the Nrf2 pathway. We also show that autophagy and serine/threonine signaling regulates p62 mediated Keap1 degradation. Our results in glioma cell lines indicate that both Nrf2 and p62 promote proliferation, invasion and mesenchymal transition. Finally, Nrf2 activity was associated with decreased progression free survival in TCGA GBM patient samples, suggesting that treatments have limited efficacy if this transcription factor is overactivated. Overall, our findings place Nrf2 and p62 as the key components of the mesenchymal subtype network, with implications to tumorigenesis and treatment resistance. Thus, Nrf2 activation could be used as a surrogate prognostic marker in mesenchymal subtype GBMs. Furthermore, strategies aiming at either inhibiting Nrf2 or exploiting Nrf2 hyperactivity for targeted gene therapy may provide novel treatment options for this subset of GBM.	[Polonen, Petri; Pasonen-Seppanen, Sanna; Tavi, Pasi; Heinaniemi, Merja] Univ Eastern Finland, Sch Med, Inst Biomed, POB 1627, FIN-70211 Kuopio, Finland; [Deen, Ashik Jawahar; Leinonen, Hanna M.; Jyrkkanen, Henna-Kaisa; Kuosmanen, Suvi; Mononen, Mimmi; Tuomainen, Tomi; Levonen, Anna-Liisa] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Biotechnol & Mol Med, POB 1627, FIN-70211 Kuopio, Finland; [Jain, Ashish; Johansen, Terje] Univ Tromso, Inst Med Biol, N-9037 Tromso, Norway; [Jain, Ashish] Oslo Univ Hosp, Inst Canc Res, Dept Mol Cell Biol, N-0379 Oslo, Norway; [Jain, Ashish] Univ Oslo, Fac Med, Ctr Canc Biomed, POB 1627, N-0379 Oslo, Norway; [Hartikainen, Jaana M.; Mannermaa, Arto] Univ Eastern Finland, Inst Clin Med, POB 1627, FIN-70211 Kuopio, Finland; [Nykter, Matti] Univ Tampere, Fac Med & Life Sci, POB 100, FIN-33014 Tampere, Finland; [Nykter, Matti] Univ Tampere, BioMediTech Inst, POB 100, FIN-33014 Tampere, Finland	University of Eastern Finland; University of Eastern Finland; UiT The Arctic University of Tromso; University of Oslo; University of Oslo; University of Eastern Finland; Tampere University; Tampere University	Levonen, AL (corresponding author), Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Biotechnol & Mol Med, POB 1627, FIN-70211 Kuopio, Finland.	anna-liisa.levonen@uef.fi	Johansen, Terje/N-2971-2015; Jain, Ashish/H-7356-2017; Hartikainen, Jaana M/E-6256-2015; Heinaniemi, Merja/AAS-4530-2020; Linna-Kuosmanen, Suvi/P-4574-2018	Johansen, Terje/0000-0003-1451-9578; Jain, Ashish/0000-0001-6549-2788; Hartikainen, Jaana M/0000-0001-8267-1905; Heinaniemi, Merja/0000-0001-6190-3439; Linna-Kuosmanen, Suvi/0000-0002-3278-2727; Levonen, Anna-Liisa/0000-0002-6575-2137; Nykter, Matti/0000-0001-6956-2843; Tuomainen, Tomi/0000-0002-2387-6369	Finnish Cancer Organizations; Jane and Aatos Erkko Foundation; Sigrid Juselius Foundation; Academy of Finland; Finnish Cultural Foundation; Cancer Society of Finland; North-Savo Regional Cancer Society; Fund of Matti and Vappu Maukonen	Finnish Cancer Organizations; Jane and Aatos Erkko Foundation; Sigrid Juselius Foundation(Sigrid Juselius Foundation); Academy of Finland(Academy of Finland); Finnish Cultural Foundation(Finnish Cultural FoundationFinnish IT center for science); Cancer Society of Finland; North-Savo Regional Cancer Society; Fund of Matti and Vappu Maukonen	This study was supported by the Finnish Cancer Organizations, The Jane and Aatos Erkko Foundation, Sigrid Juselius Foundation, Academy of Finland, Finnish Cultural Foundation, Cancer Society of Finland, North-Savo Regional Cancer Society and Fund of Matti and Vappu Maukonen. Mrs. Arja Korhonen is thanked for her technical assistance. We thank SIBLabs for performing TEM and Dr. Eeva-Liisa Eskelinen, University of Helsinki, for helping with the analysis of TEM pictures.	Agnihotri S, 2016, NEURO-ONCOLOGY, V18, P160, DOI 10.1093/neuonc/nov125; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bouvy-Liivrand M, 2017, NUCLEIC ACIDS RES, V45, P9837, DOI 10.1093/nar/gkx680; Bowman RL, 2017, NEURO-ONCOLOGY, V19, P139, DOI 10.1093/neuonc/now247; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Chang JT, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-443; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Galavotti S, 2013, ONCOGENE, V32, P699, DOI 10.1038/onc.2012.111; Goldstein LD, 2016, CELL REP, V16, P2605, DOI 10.1016/j.celrep.2016.08.010; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Hayes JD, 2014, TRENDS BIOCHEM SCI, V39, P199, DOI 10.1016/j.tibs.2014.02.002; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Ichimura Y, 2013, MOL CELL, V51, P618, DOI 10.1016/j.molcel.2013.08.003; Inami Y, 2011, J CELL BIOL, V193, P275, DOI 10.1083/jcb.201102031; Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976; Jin LT, 2015, CANCER CELL, V27, P257, DOI 10.1016/j.ccell.2014.12.006; Johansen T, 2011, AUTOPHAGY, V7, P279, DOI 10.4161/auto.7.3.14487; Johnson DR, 2012, J NEURO-ONCOL, V107, P359, DOI 10.1007/s11060-011-0749-4; Jyrkkanen HK, 2011, BIOCHEM J, V440, P167, DOI 10.1042/BJ20110526; Kanamori M, 2014, NEURO-ONCOLOGY, V1, P1; Kansanen E, 2012, FREE RADICAL BIO MED, V52, P973, DOI 10.1016/j.freeradbiomed.2011.11.038; Kansanen E, 2011, J BIOL CHEM, V286, P14019, DOI 10.1074/jbc.M110.190710; Kansanen E, 2009, J BIOL CHEM, V284, P33233, DOI 10.1074/jbc.M109.064873; Kim YR, 2010, J PATHOL, V220, P446, DOI 10.1002/path.2653; Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021; Koponen JK, 2007, MOL THER, V15, P2172, DOI 10.1038/sj.mt.6300302; Lau A, 2010, MOL CELL BIOL, V30, P3275, DOI 10.1128/MCB.00248-10; Leinonen HM, 2014, ADV CANCER RES, V122, P281, DOI 10.1016/B978-0-12-420117-0.00008-6; Leinonen HM, 2012, CANCER RES, V72, P6227, DOI 10.1158/0008-5472.CAN-12-1166; Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Lister A, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-37; Mitsuishi Y, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00200; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Omuro A, 2013, JAMA-J AM MED ASSOC, V310, P1842, DOI 10.1001/jama.2013.280319; Ooi A, 2013, CANCER RES, V73, P2044, DOI 10.1158/0008-5472.CAN-12-3227; Padmanabhan B, 2006, MOL CELL, V21, P689, DOI 10.1016/j.molcel.2006.01.013; Pajares M, 2016, AUTOPHAGY, V12, P1902, DOI 10.1080/15548627.2016.1208889; Rinaldi M, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060984; Rokavec M, 2017, SCI REP, V7, P1; Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035; Shibata T, 2008, P NATL ACAD SCI USA, V105, P13568, DOI 10.1073/pnas.0806268105; Shibata T, 2010, CANCER RES, V70, P9095, DOI 10.1158/0008-5472.CAN-10-0384; Singer E, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.566; Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420; Solis LM, 2010, CLIN CANCER RES, V16, P3743, DOI 10.1158/1078-0432.CCR-09-3352; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Xie Y, 2015, EBIOMEDICINE, V2, P1351, DOI 10.1016/j.ebiom.2015.08.026; Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33; Yoo NJ, 2012, HISTOPATHOLOGY, V60, P943, DOI 10.1111/j.1365-2559.2012.04178.x	53	34	35	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2019	38	50					7473	7490		10.1038/s41388-019-0956-6	http://dx.doi.org/10.1038/s41388-019-0956-6			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JV7GY	31444413	Green Accepted			2022-12-28	WOS:000502530500003
J	Hsueh, YS; Chang, HH; Shan, YS; Sun, HS; Fletcher, JA; Li, CF; Chen, LT				Hsueh, Yuan-Shuo; Chang, Hui Hua; Shan, Yan-Shen; Sun, H. Sunny; Fletcher, Jonathan Alfred; Li, Chien-Feng; Chen, Li-Tzong			Nuclear KIT induces a NFKBIB-RELA-KIT autoregulatory loop in imatinib-resistant gastrointestinal stromal tumors	ONCOGENE			English	Article							NF-KAPPA-B; SIGNAL-TRANSDUCTION; MOLECULAR-BASIS; CELLS; PROLIFERATION; DEGRADATION; EXPRESSION; RECEPTOR; GROWTH; MECHANISMS	Gastrointestinal stromal tumors (GISTs) are frequently driven by auto-activated, mutant KIT and have durable response to KIT tyrosine kinase inhibitor. However, acquired resistance is an increasing clinical issue in GIST patients receiving frontline imatinib therapy. Our previous studies showed the colocalization of KIT with DAPI-stained nuclei in GIST cells without knowing the role of nuclear KIT in GIST tumorigenesis. In this article, we first identified the binding of nuclear KIT to the promoter of NFKB inhibitor beta (NFKBIB) by chromatin immunoprecipitation (ChIP) sequencing and ChIP assays, which was accompanied with enhanced NFKBIB protein expression in GIST cells. Clinically, high NCCN risk GISTs had significantly higher mean expression levels of nuclear phospho-KIT and NFKBIB as compared with those of intermediate or low/very low-risk GISTs. Conversely, downregulation of NFKBIB by siRNA led to RELA nuclear translocation that could bind to the KIT promoter region and subsequently reduced KIT transcription/expression and the viability of GIST cells. These findings were further confirmed by either RELA overexpression or NFKB/RELA inducer, valproic acid, treatment to result in reduced KIT expression and relative cell viability of imatinib-resistant GIST cells. Combining valproic acid with imatinib showed significantly better growth inhibitory effects on imatinib-resistant GIST48 and GIST430 cells in vitro, and in the GIST430 animal xenograft model. Taken together, these results demonstrate the existence of a nuclear KIT-driven NFKBIB-RELA-KIT autoregulatory loop in GIST tumorigenesis, which are potential targets for developing combination therapy to overcome imatinib-resistant of KIT-expressing GISTs.	[Hsueh, Yuan-Shuo; Li, Chien-Feng; Chen, Li-Tzong] Natl Hlth Res Inst, Natl Inst Canc Res, Tainan, Taiwan; [Hsueh, Yuan-Shuo] Natl Cheng Kung Univ, Int Ctr Wound Repair & Regenerat, Tainan, Taiwan; [Chang, Hui Hua; Chen, Li-Tzong] Natl Cheng Kung Univ, Coll Med, Inst Clin Pharm & Pharmaceut Sci, Tainan, Taiwan; [Chang, Hui Hua] Natl Cheng Kung Univ, Coll Med, Sch Pharm, Tainan, Taiwan; [Chang, Hui Hua] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Pharm, Tainan, Taiwan; [Chang, Hui Hua] Natl Cheng Kung Univ Hosp, Dept Pharm, Dou Liou Branch, Touliu, Yunlin, Taiwan; [Shan, Yan-Shen] Natl Cheng Kung Univ, Coll Med, Inst Clin Med, Tainan, Taiwan; [Shan, Yan-Shen] Natl Cheng Kung Univ Hosp, Dept Surg, Tainan, Taiwan; [Sun, H. Sunny] Natl Cheng Kung Univ, Coll Med, Inst Mol Med, Tainan, Taiwan; [Sun, H. Sunny] Natl Cheng Kung Univ, Bioinformat Ctr, Tainan, Taiwan; [Fletcher, Jonathan Alfred] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Fletcher, Jonathan Alfred] Harvard Med Sch, Boston, MA 02115 USA; [Li, Chien-Feng] Chi Mei Fdn Med Ctr, Dept Pathol, Tainan, Taiwan; [Li, Chien-Feng] Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan; [Chen, Li-Tzong] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan, Taiwan; [Chen, Li-Tzong] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Kaohsiung, Taiwan	National Health Research Institutes - Taiwan; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Chi Mei Hospital; Southern Taiwan University of Science & Technology; National Cheng Kung University; National Cheng Kung University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital	Li, CF; Chen, LT (corresponding author), Natl Hlth Res Inst, Natl Inst Canc Res, Tainan, Taiwan.; Chen, LT (corresponding author), Natl Cheng Kung Univ, Coll Med, Inst Clin Pharm & Pharmaceut Sci, Tainan, Taiwan.; Li, CF (corresponding author), Chi Mei Fdn Med Ctr, Dept Pathol, Tainan, Taiwan.; Li, CF (corresponding author), Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan.; Chen, LT (corresponding author), Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan, Taiwan.; Chen, LT (corresponding author), Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Kaohsiung, Taiwan.	angelo.p@yahoo.com.tw; leochen@nhri.org.tw		Li, Chien-Feng/0000-0002-9527-7576; Sun, Sunny/0000-0002-3661-4448; Hsueh, Yuan-Shuo/0000-0002-2584-9380	NHRI [05A1-CAPP19-014, 06A1-CAPP19-014]; Ministry of Science and Technology in Executive Yuan, Taiwan [MOST 104-2321-B-400-019-MY3]	NHRI(National Health Research Institutes - Taiwan); Ministry of Science and Technology in Executive Yuan, Taiwan	We appreciate the funding support provided by NHRI (05A1-CAPP19-014, 06A1-CAPP19-014) and the Ministry of Science and Technology (MOST 104-2321-B-400-019-MY3) in Executive Yuan, Taiwan.	Pavon MA, 2016, HEAD NECK-J SCI SPEC, V38, pE1392, DOI 10.1002/hed.24232; Blanke CD, 2008, J CLIN ONCOL, V26, P620, DOI 10.1200/JCO.2007.13.4403; Casteran N, 2003, ONCOGENE, V22, P4710, DOI 10.1038/sj.onc.1206587; Chen FE, 1999, ONCOGENE, V18, P6845, DOI 10.1038/sj.onc.1203224; Chen F, 2007, CANCER RES, V67, P11093, DOI 10.1158/0008-5472.CAN-07-1576; Chen F, 2006, J BIOL CHEM, V281, P37142, DOI 10.1074/jbc.M603631200; Chen PS, 2017, PHARMACOGENOMICS J, V17, P155, DOI 10.1038/tpj.2015.96; Chen YW, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00219; Demetri GD, 2013, LANCET, V381, P295, DOI 10.1016/S0140-6736(12)61857-1; Dong Y, 2015, CANCER LETT, V361, P137, DOI 10.1016/j.canlet.2015.02.044; Du YP, 2016, TUMOR BIOL, V37, P1261, DOI 10.1007/s13277-015-3921-1; Duensing A, 2004, ONCOGENE, V23, P3999, DOI 10.1038/sj.onc.1207525; Floris G, 2011, MOL CANCER THER, V10, P1897, DOI 10.1158/1535-7163.MCT-11-0148; Foster R, 2004, J MOL GRAPH MODEL, V23, P139, DOI 10.1016/j.jmgm.2004.04.003; Hayashi Y, 2015, GASTROENTEROLOGY, V149, P420, DOI 10.1053/j.gastro.2015.04.006; Hsueh YS, 2014, ONCOTARGET, V5, P11723, DOI 10.18632/oncotarget.2607; Hsueh YS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065762; Hsueh YS, 2013, AUTOPHAGY, V9, P220, DOI 10.4161/auto.22802; Isaksson HS, 2014, ONCOTARGET, V5, P4040, DOI 10.18632/oncotarget.1938; Jones J, 2009, J CELL MOL MED, V13, P2342, DOI 10.1111/j.1582-4934.2008.00603.x; Kim J, 2012, P NATL ACAD SCI USA, V109, P6124, DOI 10.1073/pnas.1203203109; Le Gall M, 2015, MOL CANCER THER, V14, P2595, DOI 10.1158/1535-7163.MCT-15-0321; Lee CC, 2010, ONCOGENE, V29, P3110, DOI 10.1038/onc.2010.55; Lerebours F, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-41; Liberati S, 2014, CELLS-BASEL, V3, P660, DOI 10.3390/cells3020660; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Liu SJ, 2010, CANCER CELL, V17, P333, DOI 10.1016/j.ccr.2010.03.008; Luedde T, 2007, CANCER CELL, V11, P119, DOI 10.1016/j.ccr.2006.12.016; Ma LJ, 2014, TUMOR BIOL, V35, P1703, DOI 10.1007/s13277-013-1235-8; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Mol CD, 2004, CURR OPIN DRUG DISC, V7, P639; Napetschnig J, 2013, ANNU REV BIOPHYS, V42, P443, DOI 10.1146/annurev-biophys-083012-130338; Natoli G, 2008, SCI SIGNAL, V1, DOI 10.1126/stke.11pe1; Nishida T, 2000, HISTOL HISTOPATHOL, V15, P1293, DOI 10.14670/HH-15.1293; Rezaeian AH, 2017, NAT CELL BIOL, V19, P38, DOI 10.1038/ncb3445; Rubin BP, 2007, LANCET, V369, P1731, DOI 10.1016/S0140-6736(07)60780-6; Rusakiewicz S, 2013, CANCER RES, V73, P3499, DOI 10.1158/0008-5472.CAN-13-0371; Sarfstein Rive, 2010, Cancers (Basel), V2, P233, DOI 10.3390/cancers2020233; Sehat B, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000628; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Sleijfer S, 2007, ONCOLOGIST, V12, P719, DOI 10.1634/theoncologist.12-6-719; Sugito K, 2013, PEDIATR BLOOD CANCER, V60, P383, DOI 10.1002/pbc.24282; Taguchi T, 2002, LAB INVEST, V82, P663, DOI 10.1038/labinvest.3780461; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Wang CY, 2016, MOL NEUROBIOL, V53, P6774, DOI 10.1007/s12035-015-9600-9; Warsito D, 2012, EMBO REP, V13, P244, DOI 10.1038/embor.2011.251	46	7	8	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2019	38	38					6550	6565		10.1038/s41388-019-0900-9	http://dx.doi.org/10.1038/s41388-019-0900-9			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IY7XR	31363162	Green Published, hybrid			2022-12-28	WOS:000486609000006
J	Cordero, A; Kanojia, D; Miska, J; Panek, WK; Xiao, AN; Han, Y; Bonamici, N; Zhou, WD; Xiaol, T; Wu, MJ; Ahmed, AU; Lesniak, MS				Cordero, Alex; Kanojia, Deepak; Miska, Jason; Panek, Wojciech K.; Xiao, Annie; Han, Yu; Bonamici, Nicolas; Zhou, Weidong; Xiaol, Ting; Wu, Meijing; Ahmed, Atique U.; Lesniak, Maciej S.			FABP7 is a key metabolic regulator in HER2+breast cancer brain metastasis	ONCOGENE			English	Article							ACID-BINDING PROTEIN; HUMAN-BREAST-CANCER; POOR-PROGNOSIS; SURVIVAL; EXPRESSION; TUMOR; HYPOXIA; CELLS; GENE; OXIDATION	Overexpression of human epidermal growth factor receptor 2 (HER2) in breast cancer patients is associated with increased incidence of breast cancer brain metastases (BCBM), but the mechanisms underlying this phenomenon remain unclear. Here, to identify brain-predominant genes critical for the establishment of BCBM, we conducted an in silico screening analysis and identified that increased levels of fatty acid-binding protein 7 (FABP7) correlate with a lower survival and higher incidence of brain metastases in breast cancer patients. We validated these findings using HER2+ BCBM cells compared with parental breast cancer cells. Importantly, through knockdown and overexpression assays, we characterized the role of FABP7 in the BCBM process in vitro and in vivo. Our results uncover a key role of FABP7 in metabolic reprogramming of HER2 + breast cancer cells, supporting a glycolytic phenotype and storage of lipid droplets that enable their adaptation and survival in the brain microenvironment. In addition, FABP7 is shown to be required for upregulation of key metastatic genes and pathways, such as integrins-Src and VEGFA, and for the growth of HER2+ breast cancer cells in the brain microenvironment in vivo. Together, our results support FABP7 as a potential target for the treatment of HER2+ BCBM.	[Cordero, Alex; Kanojia, Deepak; Miska, Jason; Panek, Wojciech K.; Xiao, Annie; Han, Yu; Bonamici, Nicolas; Xiaol, Ting; Wu, Meijing; Ahmed, Atique U.; Lesniak, Maciej S.] Northwestern Univ, Dept Neurol Surg, Feinberg Sch Med, Chicago, IL 60611 USA; [Zhou, Weidong] George Mason Univ, Ctr Appl Prot & Mol Med, Manassas, VA 20110 USA	Northwestern University; Feinberg School of Medicine; George Mason University	Lesniak, MS (corresponding author), Northwestern Univ, Dept Neurol Surg, Feinberg Sch Med, Chicago, IL 60611 USA.	maciej.lesniak@northwestern.edu	Casanovas, Alex Cordero/AAA-8157-2020; Kanojia, Deepak/G-5120-2014	Kanojia, Deepak/0000-0003-4295-4972; Panek, Wojciech Krzysztof/0000-0002-5667-5715; Cordero Casanovas, Alejandro/0000-0002-2224-7122	NIH [R35CA197725, R01NS87990, R01NS093903, 1R01NS096376-01A1]; NATIONAL CANCER INSTITUTE [R35CA197725, P50CA221747] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS096376, R01NS087990, R01NS093903] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We would like to thank Dr Katarzyna C. Pituch and Dr Diana Saleiro for helpful discussions during the preparation of this paper; Paul Joseph Mehl, Aurora Lopez-Rosas, and Northwestern University animal facility for their technical assistance. This work was supported by NIH grants R35CA197725, R01NS87990, R01NS093903 (MSL), and 1R01NS096376-01A1 (AUA).	Anthony TE, 2005, GENE DEV, V19, P1028, DOI 10.1101/gad.1302105; Beloribi-Djefaflia S, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.49; Bennett V, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a003012; Bensaad K, 2014, CELL REP, V9, P349, DOI 10.1016/j.celrep.2014.08.056; Blackwell KL, 2012, J CLIN ONCOL, V30, P2585, DOI 10.1200/JCO.2011.35.6725; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Camarda R, 2016, NAT MED, V22, P427, DOI 10.1038/nm.4055; Cheng C, 2012, CELL ONCOL, V35, P217, DOI 10.1007/s13402-012-0081-9; Chlenski A, 2000, BBA-GENE STRUCT EXPR, V1493, P319, DOI 10.1016/S0167-4781(00)00185-8; Chua J, 2009, P NATL ACAD SCI USA, V106, P20770, DOI 10.1073/pnas.0909812106; Ciminera AK, 2017, CLIN EXP METASTAS, V34, P401, DOI 10.1007/s10585-017-9864-8; DeBerardinis RJ, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600200; Desai S, 2014, ONCOTARGET, V5, P8202, DOI 10.18632/oncotarget.1159; Dong GC, 2016, ONCOL LETT, V11, P1980, DOI 10.3892/ol.2016.4168; Emi Y, 2002, SURGERY, V131, pS217, DOI 10.1067/msy.2002.119580; Enerly E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016915; FENG L, 1994, NEURON, V12, P895, DOI 10.1016/0896-6273(94)90341-7; Feng YX, 2018, GENES DIS, V5, P77, DOI 10.1016/j.gendis.2018.05.001; Gajria D, 2011, EXPERT REV ANTICANC, V11, P263, DOI 10.1586/ERA.10.226; Gatenby RA, 2006, CANCER RES, V66, P5216, DOI 10.1158/0008-5472.CAN-05-4193; Gilkes DM, 2013, J BIOL CHEM, V288, P10819, DOI 10.1074/jbc.M112.442939; Guaita-Esteruelas S, 2018, MOL CELL ENDOCRINOL, V462, P107, DOI 10.1016/j.mce.2017.02.002; Han TY, 2013, CELL ADHES MIGR, V7, P395, DOI 10.4161/cam.26345; Hao JQ, 2018, CELL METAB, V28, P689, DOI 10.1016/j.cmet.2018.07.006; Hao JQ, 2018, CANCER RES, V78, P2343, DOI 10.1158/0008-5472.CAN-17-2465; Haunerland NH, 2004, PROG LIPID RES, V43, P328, DOI 10.1016/j.plipres.2004.05.001; Kaloshi G, 2007, J NEURO-ONCOL, V84, P245, DOI 10.1007/s11060-007-9377-4; Kanojia D, 2015, STEM CELLS, V33, P2985, DOI 10.1002/stem.2109; Kanojia D, 2015, MOL CANCER THER, V14, P1152, DOI 10.1158/1535-7163.MCT-14-0950; Kim HM, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0354-3; Kodack DP, 2015, CANCER CELL, V27, P163, DOI 10.1016/j.ccell.2015.01.001; Koizume S, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091430; Krakhmal NV, 2015, ACTA NATURAE, V7, P17, DOI 10.32607/20758251-2015-7-2-17-28; LaGory EL, 2016, NAT CELL BIOL, V18, P356, DOI 10.1038/ncb3330; Lamborn KR, 2004, NEURO-ONCOLOGY, V6, P227, DOI 10.1215/S1152851703000620; Leyland-Jones B, 2009, J CLIN ONCOL, V27, P5278, DOI 10.1200/JCO.2008.19.8481; Liang Y, 2005, P NATL ACAD SCI USA, V102, P5814, DOI 10.1073/pnas.0402870102; Listenberger Laura L, 2016, Curr Protoc Cell Biol, V71, DOI 10.1002/cpcb.7; Liu Katy C, 2012, Bioarchitecture, V2, P158, DOI 10.4161/bioa.21791; Liu RZ, 2012, J PATHOL, V228, P310, DOI 10.1002/path.4001; Martin TA, 2004, EUR J CANCER, V40, P2717, DOI 10.1016/j.ejca.2004.08.008; Martin TA, 2009, BBA-BIOMEMBRANES, V1788, P872, DOI 10.1016/j.bbamem.2008.11.005; Miska J, 2019, CELL REP, V27, P226, DOI 10.1016/j.celrep.2019.03.029; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Muz B, 2015, HYPOXIA, V3, P83, DOI 10.2147/HP.S93413; Marie SKN, 2011, CLINICS, V66, P33, DOI 10.1590/S1807-59322011001300005; Neman J, 2014, P NATL ACAD SCI USA, V111, P984, DOI 10.1073/pnas.1322098111; Nguyen A, 2016, J CLIN INVEST, V126, P681, DOI 10.1172/JCI83587; Park JH, 2016, CELL REP, V14, P2154, DOI 10.1016/j.celrep.2016.02.004; Pascual G, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.032920; Pascual G, 2017, NATURE, V541, P41, DOI 10.1038/nature20791; Pelletier M, 2014, METHOD ENZYMOL, V542, P125, DOI 10.1016/B978-0-12-416618-9.00007-8; Reily C, 2013, REDOX BIOL, V1, P86, DOI 10.1016/j.redox.2012.11.009; Seliger B, 2005, PROTEOMICS, V5, P2631, DOI 10.1002/pmic.200401264; Seyfried TN, 2011, BBA-BIOENERGETICS, V1807, P577, DOI 10.1016/j.bbabio.2010.08.009; Sihto H, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2944; Sjobakk TE, 2013, INT J MOL SCI, V14, P2104, DOI 10.3390/ijms14012104; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Slipicevic A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-276; Stivarou T, 2015, CANCERS, V7, P238, DOI 10.3390/cancers7010238; Storch J, 2008, ANNU REV NUTR, V28, P73, DOI 10.1146/annurev.nutr.27.061406.093710; Talasila KM, 2017, NEURO-ONCOLOGY, V19, P383, DOI 10.1093/neuonc/now175; Tang ZY, 2016, ONCOTARGET, V7, P46253, DOI 10.18632/oncotarget.10086; Thakur R, 2015, SCI REP-UK, V5, DOI 10.1038/srep10194; Thupari JN, 2001, BIOCHEM BIOPH RES CO, V285, P217, DOI 10.1006/bbrc.2001.5146; Valiente M, 2014, CELL, V156, P1002, DOI 10.1016/j.cell.2014.01.040; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Wang TY, 2018, CELL METAB, V27, P1357, DOI 10.1016/j.cmet.2018.04.018; Zhang SY, 2013, CANCER RES, V73, P5764, DOI 10.1158/0008-5472.CAN-12-1803; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017; Zhang YW, 2014, CANCER RES, V74, P2986, DOI 10.1158/0008-5472.CAN-13-2689; Zhou YQ, 2017, ONCOTARGET, V8, P35877, DOI 10.18632/oncotarget.16270	72	36	36	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2019	38	37					6445	6460		10.1038/s41388-019-0893-4	http://dx.doi.org/10.1038/s41388-019-0893-4			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IX6FR	31324889	Green Accepted			2022-12-28	WOS:000485778800004
J	Pallmann, N; Livgard, M; Tesikova, M; Nenseth, HZ; Akkus, E; Sikkeland, J; Jin, YX; Koc, D; Kuzu, OF; Pradhan, M; Danielsen, HE; Kahraman, N; Mokhlis, HM; Ozpolat, B; Banerjee, PP; Uren, A; Fazli, L; Rennie, PS; Jin, Y; Saatcioglu, F				Pallmann, Nora; Livgard, Marte; Tesikova, Martina; Nenseth, Hatice Zeynep; Akkus, Erman; Sikkeland, Jorgen; Jin, Yixin; Koc, Dogukan; Kuzu, Omer Faruk; Pradhan, Manohar; Danielsen, Havard E.; Kahraman, Nermin; Mokhlis, Hamada M.; Ozpolat, Bulent; Banerjee, Partha P.; Uren, Aykut; Fazli, Ladan; Rennie, Paul S.; Jin, Yang; Saatcioglu, Fahri			Regulation of the unfolded protein response through ATF4 and FAM129A in prostate cancer Nora	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM STRESS; GENE-EXPRESSION; ANDROGEN; NIBAN; PROLIFERATION; METABOLISM; REVEALS; BETA; RNA	Cancer cells exploit many of the cellular adaptive responses to support their survival needs. One such critical pathway in eukaryotic cells is the unfolded protein response (UPR) that is important in normal physiology as well as disease states, including cancer. Since UPR can serve as a lever between survival and death, regulated control of its activity is critical for tumor formation and growth although the underlying mechanisms are poorly understood. Here we show that one of the main transcriptional effectors of UPR, activating transcription factor 4 (ATF4), is essential for prostate cancer (PCa) growth and survival. Using systemic unbiased gene expression and proteomic analyses, we identified a novel direct ATF4 target gene, family with sequence similarity 129 member A (FAM129A), which is critical in mediating ATF4 effects on prostate tumorigenesis. Interestingly, FAM129A regulated both PERK and eIF2a in a feedback loop that differentially channeled the UPR output. ATF4 and FAM129A protein expression is increased in patient PCa samples compared with benign prostate. Importantly, in vivo therapeutic silencing of ATF4-FAM129A axis profoundly inhibited tumor growth in a preclinical PCa model. These data support that one of the canonical UPR branches, through ATF4 and its target gene FAM129A, is required for PCa growth and thus may serve as a novel therapeutic target.	[Pallmann, Nora; Livgard, Marte; Tesikova, Martina; Nenseth, Hatice Zeynep; Akkus, Erman; Sikkeland, Jorgen; Jin, Yixin; Koc, Dogukan; Kuzu, Omer Faruk; Jin, Yang; Saatcioglu, Fahri] Univ Oslo, Dept Biosci, Oslo, Norway; [Livgard, Marte; Sikkeland, Jorgen; Pradhan, Manohar; Danielsen, Havard E.; Jin, Yang; Saatcioglu, Fahri] Oslo Univ Hosp, Inst Canc Genet & Informat, Oslo, Norway; [Danielsen, Havard E.] Univ Oslo, Dept Informat, Oslo, Norway; [Danielsen, Havard E.] Univ Oxford, Nuffield Div Clin Lab Sci, Oxford, England; [Kahraman, Nermin; Mokhlis, Hamada M.; Ozpolat, Bulent] MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX USA; [Banerjee, Partha P.; Uren, Aykut] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA; [Fazli, Ladan; Rennie, Paul S.] Vancouver Prostate Ctr, Vancouver, BC, Canada; [Jin, Yixin] Oslo Univ Hosp, Dept Canc Immunol, Inst Canc Res, Oslo, Norway; [Koc, Dogukan] Dokuz Eylul Univ, Fac Med, Dept Child & Adolescent Psychiat, Izmir, Turkey	University of Oslo; University of Oslo; University of Oslo; University of Oxford; University of Texas System; UTMD Anderson Cancer Center; Georgetown University; University of Oslo; Dokuz Eylul University	Saatcioglu, F (corresponding author), Univ Oslo, Dept Biosci, Oslo, Norway.; Saatcioglu, F (corresponding author), Oslo Univ Hosp, Inst Canc Genet & Informat, Oslo, Norway.	fahris@ibv.uio.no	Jin, Yang/GXF-7896-2022; Koc, Dogukan/AAD-8357-2020; Danielsen, Havard/AAK-8489-2020; MOKHLIS, HAMADA/ABB-6198-2021	Jin, Yang/0000-0002-7996-048X; Koc, Dogukan/0000-0002-2309-1051; MOKHLIS, HAMADA/0000-0003-3360-6319; Ozpolat, Bulent/0000-0001-8602-7463	Norwegian Research Council grant [193337]; Norwegian Cancer Society [419204]; Health South East Norway [36024]; Faculty of Medicine at NTNU; Central Norway Regional Health Authority	Norwegian Research Council grant(Research Council of Norway); Norwegian Cancer Society(Norwegian Cancer Society); Health South East Norway; Faculty of Medicine at NTNU; Central Norway Regional Health Authority	We would like to thank Veronica F. Blihovde, Xia Sheng and Deane Stryker for experimental help and members of the FS laboratory for helpful discussions. We would like to thank Jeffrey Petro for excellent technical support and Drs Eva Corey and Colm Morrissey of University of Washington for providing LuCaP PDX lines. This work was supported by Norwegian Research Council grant 193337, Norwegian Cancer Society grant 419204, and Health South East Norway grant 36024. The microarray gene expression service was provided by the Genomics Core Facility (GCF), Norwegian University of Science and Technology (NTNU). GCF is funded by the Faculty of Medicine at NTNU and Central Norway Regional Health Authority. The LC-MS analyses were performed by the proteomics core facility at the Department of Biosciences, University of Oslo.	Adachi H, 2004, ONCOGENE, V23, P3495, DOI 10.1038/sj.onc.1207468; Ameri K, 2008, INT J BIOCHEM CELL B, V40, P14, DOI 10.1016/j.biocel.2007.01.020; Attard G, 2016, LANCET, V387, P70, DOI 10.1016/S0140-6736(14)61947-4; Brijwani N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01566-x; Chevet E, 2015, CANCER DISCOV, V5, P586, DOI 10.1158/2159-8290.CD-14-1490; Clarke HJ, 2014, CANCER CELL, V25, P563, DOI 10.1016/j.ccr.2014.03.015; Cohen DM, 2015, ELIFE, V4, DOI 10.7554/eLife.06821; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Evstafieva AG, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191107; Halterman MW, 2008, MOL CELL NEUROSCI, V38, P125, DOI 10.1016/j.mcn.2008.01.014; Han J, 2013, NAT CELL BIOL, V15, P481, DOI 10.1038/ncb2738; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Ito S, 2010, HEAD NECK-J SCI SPEC, V32, P96, DOI 10.1002/hed.21153; Ji HT, 2012, EMBO REP, V13, P554, DOI 10.1038/embor.2012.53; Jin Y, 2015, EMBO MOL MED, V7, P315, DOI 10.15252/emmm.201404181; Jin Y, 2013, P NATL ACAD SCI USA, V110, pE2572, DOI 10.1073/pnas.1304318110; Kannangai R, 2005, HUM PATHOL, V36, P341, DOI 10.1016/j.humpath.2005.01.002; Kilberg MS, 2012, ADV NUTR, V3, P295, DOI 10.3945/an.112.001891; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Massie CE, 2011, EMBO J, V30, P2719, DOI 10.1038/emboj.2011.158; Mills IG, 2014, NAT REV CANCER, V14, P187, DOI 10.1038/nrc3678; Nevedomskaya E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051359; Pakos-Zebrucka K, 2016, EMBO REP, V17, P1374, DOI 10.15252/embr.201642195; Quiros PM, 2017, J CELL BIOL, V216, P2027, DOI 10.1083/jcb.201702058; Shan JX, 2016, NUCLEIC ACIDS RES, V44, P9719, DOI 10.1093/nar/gkw667; Shaw GL, 2016, EUR UROL, V70, P214, DOI 10.1016/j.eururo.2015.10.042; Sheng X, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08152-3; Sheng X, 2015, EMBO MOL MED, V7, P788, DOI 10.15252/emmm.201404509; Storm M, 2016, ONCOTARGET, V7, P54051, DOI 10.18632/oncotarget.9912; Sun GD, 2007, BIOCHEM BIOPH RES CO, V360, P181, DOI 10.1016/j.bbrc.2007.06.021; Thomas BC, 2016, ENDOCR-RELAT CANCER, V23, P797, DOI 10.1530/ERC-16-0287; Vizcaino JA, 2013, NUCLEIC ACIDS RES, V41, pD1063, DOI 10.1093/nar/gks1262; Wang M, 2014, NAT REV CANCER, V14, P581, DOI 10.1038/nrc3800; Wortel IMN, 2017, TRENDS ENDOCRIN MET, V28, P794, DOI 10.1016/j.tem.2017.07.003; Ye JB, 2010, EMBO J, V29, P2082, DOI 10.1038/emboj.2010.81; Yu KF, 2014, FEBS J, V281, P2399, DOI 10.1111/febs.12792; Yuki R, 2015, J CELL BIOCHEM, V116, P954, DOI 10.1002/jcb.25046	37	30	31	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2019	38	35					6301	6318		10.1038/s41388-019-0879-2	http://dx.doi.org/10.1038/s41388-019-0879-2			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IU9RZ	31312022	Green Accepted			2022-12-28	WOS:000483919400005
J	Ohsug, T; Yamaguchi, K; Zhu, C; Ikenoue, T; Takane, K; Shinozaki, M; Tsurita, G; Yano, H; Furukawa, Y				Ohsug, Tomoyuki; Yamaguchi, Kiyoshi; Zhu, Chi; Ikenoue, Tsuneo; Takane, Kiyoko; Shinozaki, Masaru; Tsurita, Giichiro; Yano, Hideaki; Furukawa, Yoichi			Anti-apoptotic effect by the suppression of IRF1 as a downstream of Wnt/beta-catenin signaling in colorectal cancer cells	ONCOGENE			English	Article							REGULATORY FACTOR-I; TRANSCRIPTION FACTOR; TUMOR-SUPPRESSOR; INTERFERON-GAMMA; GROWTH-FACTOR; STEM-CELLS; GENE; UBIQUITINATION; EXPRESSION; COLON	Impaired Wnt signaling pathway plays a crucial role in the development of colorectal cancer through activation of the beta-catenin/TCF7L2 complex. Although genes upregulated by Wnt/beta-catenin signaling have been intensively studied, the roles of downregulated genes are poorly understood. Previously, we reported that interferon-induced proteins with tetratricopeptide repeats 2 (IFIT2) was downregulated by the Wnt/beta-catenin signaling, and that the suppressed expression of IFIT2 conferred antiapoptotic property to colorectal cancer (CRC) cells. However, the mechanisms underlying how Wnt/beta-catenin signaling regulates IFIT2 remain to be elucidated. In this study, we have uncovered that the expression of IFIT2 is induced by IRF1, which is negatively regulated by the Wnt/beta-catenin signaling. In addition, we found that downregulation of IRF1 is mediated by its degradation through the ubiquitination-proteasome pathway, and that decreased activity of a deubiquitinase complex containing USP1 and UAF1 is involved in the degradation of IRF1 by Wnt/beta-catenin signaling. These data should provide better understanding of the Wnt signaling pathway and human carcinogenesis.	[Ohsug, Tomoyuki; Yamaguchi, Kiyoshi; Zhu, Chi; Ikenoue, Tsuneo; Takane, Kiyoko; Furukawa, Yoichi] Univ Tokyo, Adv Clin Res Ctr, Inst Med Sci, Div Clin Genome Res, Tokyo 1088639, Japan; [Shinozaki, Masaru; Tsurita, Giichiro] Univ Tokyo, IMSUT Hosp, Inst Med Sci, Dept Surg, Tokyo 1088639, Japan; [Yano, Hideaki] Natl Ctr Global Hlth & Med, Dept Surg, Ctr Hosp, Tokyo 1628655, Japan	University of Tokyo; University of Tokyo; National Center for Global Health & Medicine - Japan	Furukawa, Y (corresponding author), Univ Tokyo, Adv Clin Res Ctr, Inst Med Sci, Div Clin Genome Res, Tokyo 1088639, Japan.	furukawa@ims.u-tokyo.ac.jp		ZHU, CHI/0000-0001-9529-7000	JSPS KAKENHI [JP17H03575]; Sasakawa Scientific Research Grant from the Japan Science Society [29-435]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Sasakawa Scientific Research Grant from the Japan Science Society	This work was supported in part by JSPS KAKENHI Grant numbers JP17H03575 (Y. F.) and the Sasakawa Scientific Research Grant (Grant numbers 29-435, T. O.) from the Japan Science Society.	[Anonymous], 2017, J EXP MED, V214, P3553; Au J Sancea, 2000, ONCOGENE, V19, P3372; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; BENECH P, 1987, MOL CELL BIOL, V7, P4498, DOI 10.1128/MCB.7.12.4498; Breuhahn K, 2006, ONCOGENE, V25, P3787, DOI 10.1038/sj.onc.1209556; Chen JJ, 2011, CHEM BIOL, V18, P1390, DOI 10.1016/j.chembiol.2011.08.014; Clarke N, 2004, EMBO J, V23, P3051, DOI 10.1038/sj.emboj.7600302; Cohn MA, 2007, MOL CELL, V28, P786, DOI 10.1016/j.molcel.2007.09.031; Cohn MA, 2009, J BIOL CHEM, V284, P5343, DOI 10.1074/jbc.M808430200; Connett JM, 2005, J INTERF CYTOK RES, V25, P587, DOI 10.1089/jir.2005.25.587; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Gao J, 2010, CELL DEATH DIFFER, V17, P699, DOI 10.1038/cdd.2009.156; Giatromanolaki A, 2004, CYTOKINE, V26, P164, DOI 10.1016/j.cyto.2004.03.001; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; HARADA H, 1994, ONCOGENE, V9, P3313; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; Hoeller D, 2009, NATURE, V458, P438, DOI 10.1038/nature07960; Huang TT, 2006, NAT CELL BIOL, V8, P339, DOI 10.1038/ncb1378; Kano A, 1999, BIOCHEM BIOPH RES CO, V257, P672, DOI 10.1006/bbrc.1999.0276; Kim EJ, 2002, J CELL BIOCHEM, V85, P369, DOI 10.1002/jcb.10142; Kim JH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081604; Kim PKM, 2004, ONCOGENE, V23, P1125, DOI 10.1038/sj.onc.1207023; Kroger A, 2003, ONCOGENE, V22, P1045, DOI 10.1038/sj.onc.1206260; Landre V, 2013, BIOCHEM J, V449, P707, DOI 10.1042/BJ20121076; Lebwohl D, 1998, EUR J CANCER, V34, P1522, DOI 10.1016/S0959-8049(98)00224-X; Lecona E, 2016, NAT STRUCT MOL BIOL, V23, P270, DOI 10.1038/nsmb.3185; Lee KY, 2010, J BIOL CHEM, V285, P10362, DOI 10.1074/jbc.M109.092544; Li X, 2013, ONCOGENE, V32, P471, DOI 10.1038/onc.2012.66; Liang FS, 2016, CELL REP, V15, P2118, DOI 10.1016/j.celrep.2016.05.007; Lien WH, 2014, GENE DEV, V28, P1517, DOI 10.1101/gad.244772.114; Lowney JK, 1999, ANN SURG ONCOL, V6, P604, DOI 10.1007/s10434-999-0604-4; Mannick EE, 2005, J GASTROEN HEPATOL, V20, P371, DOI 10.1111/j.1440-1746.2005.03573.x; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; Mistry H, 2013, MOL CANCER THER, V12, P2651, DOI 10.1158/1535-7163.MCT-13-0103-T; Moretti J, 2012, J BIOL CHEM, V287, P29429, DOI 10.1074/jbc.M112.366807; Moriyama Y, 2001, CLIN CANCER RES, V7, P1293; Murai J, 2011, MOL CELL BIOL, V31, P2462, DOI 10.1128/MCB.05058-11; Murtas D, 2013, BRIT J CANCER, V109, P76, DOI 10.1038/bjc.2013.335; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Narayan V, 2011, J BIOL CHEM, V286, P607, DOI 10.1074/jbc.M110.153122; Nozawa H, 1998, INT J CANCER, V77, P522, DOI 10.1002/(SICI)1097-0215(19980812)77:4<522::AID-IJC8>3.0.CO;2-W; Nozawa H, 1999, GENE DEV, V13, P1240, DOI 10.1101/gad.13.10.1240; Oestergaard VH, 2007, MOL CELL, V28, P798, DOI 10.1016/j.molcel.2007.09.020; Ohsugi T, 2017, ONCOTARGET, V8, P100176, DOI 10.18632/oncotarget.22122; Palacios J, 1998, CANCER RES, V58, P1344; Pamment J, 2002, ONCOGENE, V21, P7776, DOI 10.1038/sj.onc.1205981; Penninger JM, 1997, IMMUNITY, V7, P243, DOI 10.1016/S1074-7613(00)80527-0; Pettersson S, 2009, BIOCHEM J, V418, P575, DOI 10.1042/BJ20082087; Ritorto MS, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5763; Ruiz-Ruiz C, 2004, J BIOL CHEM, V279, P19712, DOI 10.1074/jbc.M313023200; Sakai T, 2014, PANCREAS, V43, P909, DOI 10.1097/MPA.0000000000000116; Salahshor S, 2005, J CLIN PATHOL, V58, P225, DOI 10.1136/jcp.2003.009506; Sansom OJ, 2007, NATURE, V446, P676, DOI 10.1038/nature05674; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Schwartz JL, 2011, INT J BREAST CANCER, V2011, DOI 10.4061/2011/912102; Tada S, 1998, INT J ONCOL, V13, P1207; Tamura G, 1996, CANCER RES, V56, P612; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tan RSP, 1996, CANCER RES, V56, P2417; TANAKA N, 1994, CANCER LETT, V83, P191, DOI 10.1016/0304-3835(94)90318-2; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tomita Y, 2003, INT J CANCER, V104, P400, DOI 10.1002/ijc.10956; van Twest S, 2017, MOL CELL, V65, P247, DOI 10.1016/j.molcel.2016.11.005; Wang Y, 2007, CANCER RES, V67, P2535, DOI 10.1158/0008-5472.CAN-06-3530; Xie D, 2001, CANCER RES, V61, P8917; Yanai H, 2012, ONCOIMMUNOLOGY, V1, P1376, DOI 10.4161/onci.22475; Yin JP, 2015, STRUCTURE, V23, P2043, DOI 10.1016/j.str.2015.08.010; Yuan L, 2015, CANCER LETT, V359, P136, DOI 10.1016/j.canlet.2015.01.003; Zeng G, 2007, NEOPLASIA, V9, P951, DOI 10.1593/neo.07469; Zurawel RH, 1998, CANCER RES, V58, P896	70	15	16	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2019	38	32					6051	6064		10.1038/s41388-019-0856-9	http://dx.doi.org/10.1038/s41388-019-0856-9			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IP8XH	31292489				2022-12-28	WOS:000480329900004
J	Marcus, J; Bejerano-Sagie, M; Patterson, N; Bagchi, S; Verkhusha, VV; Connolly, D; Goldberg, GL; Golden, A; Sharma, VP; Condeelis, J; Montagna, C				Marcus, Jenna; Bejerano-Sagie, Michal; Patterson, Nicole; Bagchi, Susmita; Verkhusha, Vladislav V.; Connolly, Diana; Goldberg, Gary L.; Golden, Aaron; Sharma, Ved P.; Condeelis, John; Montagna, Cristina			Septin 9 isoforms promote tumorigenesis in mammary epithelial cells by increasing migration and ECM degradation through metalloproteinase secretion at focal adhesions	ONCOGENE			English	Article							BREAST-CANCER CELLS; COMPREHENSIVE MOLECULAR PORTRAITS; ALTERNATE READING FRAME; MATRIX-METALLOPROTEINASE; INVADOPODIA FORMATION; NEURALGIC AMYOTROPHY; MAMMALIAN SEPTIN; EXPRESSION; GENE; INVASION	The cytoskeletal interacting protein Septin 9 (SEPT9), a member of the septin gene family, has been proposed to have oncogenic functions. It is a known hot spot of retroviral tagging insertion and a fusion partner of both de novo and therapy-induced mixed lineage leukemia (MLL). Of all septins, SEPT9 holds the strongest link to cancer, especially breast cancer. Murine models of breast cancer frequently exhibit SEPT9 amplification in the form of double minute chromosomes, and about 20% of human breast cancer display genomic amplification and protein over expression at the SEPT9 locus. Yet, a clear mechanism by which SEPT9 elicits tumor-promoting functions is lacking. To obtain unbiased insights on molecular signatures of SEPT9 upregulation in breast tumors, we overexpressed several of its isoforms in breast cancer cell lines. Global transcriptomic profiling supports a role of SEPT9 in invasion. Functional studies reveal that SEPT9 upregulation is sufficient to increase degradation of the extracellular matrix, while SEPT9 downregulation inhibits this process. The degradation pattern is peripheral and associated with focal adhesions (FAs), where it is coupled with increased expression of matrix metalloproteinases (MMPs). SEPT9 overexpression induces MMP upregulation in human tumors and in culture models and promotes MMP3 secretion to the media at FAs. Downregulation of SEPT9 or chemical inhibition of septin filament assembly impairs recruitment of MMP3 to FAs. Our results indicate that SEPT9 promotes upregulation and both trafficking and secretion of MMPs near FAs, thus enhancing migration and invasion of breast cancer cells.	[Marcus, Jenna; Goldberg, Gary L.] Yeshiva Univ, Albert Einstein Coll Med, Dept Obstet & Gynecol, Bronx, NY USA; [Marcus, Jenna; Goldberg, Gary L.] Yeshiva Univ, Albert Einstein Coll Med, Dept Womens Hlth, Bronx, NY USA; [Bejerano-Sagie, Michal; Patterson, Nicole; Bagchi, Susmita; Connolly, Diana; Golden, Aaron; Montagna, Cristina] Yeshiva Univ, Albert Einstein Coll Med, Genet, Bronx, NY 10461 USA; [Verkhusha, Vladislav V.; Golden, Aaron] Natl Univ Ireland Galway, Sch Math Stat & Appl Math, Galway, Ireland; [Sharma, Ved P.; Condeelis, John] Yeshiva Univ, Anat & Struct Biol, Albert Einstein Coll Med, Bronx, NY USA; [Sharma, Ved P.; Condeelis, John] Yeshiva Univ, Albert Einstein Coll Med, Gruss Lipper Biophoton Ctr, Bronx, NY USA; [Montagna, Cristina] Yeshiva Univ, Albert Einstein Coll Med, Pathol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Ollscoil na Gaillimhe-University of Galway; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Montagna, C (corresponding author), Yeshiva Univ, Albert Einstein Coll Med, Genet, Bronx, NY 10461 USA.; Montagna, C (corresponding author), Yeshiva Univ, Albert Einstein Coll Med, Pathol, Bronx, NY 10461 USA.	cristina.montagna@einstein.yu.edu	Verkhusha, Vladislav/AAU-7784-2020; Marcus, Jenna/AAK-7334-2021; Marcus, Jenna/GQP-7232-2022	Verkhusha, Vladislav/0000-0002-2083-8121; 	Albert Einstein Cancer Center support grant of the National Institutes of Health [P30CA013330, CA150344]; NATIONAL CANCER INSTITUTE [P30CA013330, R01CA150344] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R35GM122567] Funding Source: NIH RePORTER	Albert Einstein Cancer Center support grant of the National Institutes of Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We would like to thank the following shared resources at the Albert Einstein College of Medicine: Molecular Cytogenetic Core, in particular Dr. Jidong Shan; and the Analytical Imaging Facility in particular Dr. Vera DesMarais. Research reported in this publication was supported by the Albert Einstein Cancer Center support grant of the National Institutes of Health under award number P30CA013330 as well as CA150344 to JC.	Akil A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12203; Alvarez ML, 2012, KIDNEY INT, V82, P1024, DOI 10.1038/ki.2012.256; Amir S, 2010, MOL CANCER RES, V8, P643, DOI 10.1158/1541-7786.MCR-09-0497; Amir S, 2009, J BIOL CHEM, V284, P11142, DOI 10.1074/jbc.M808348200; Angelis D, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00122; Artym VV, 2006, CANCER RES, V66, P3034, DOI 10.1158/0008-5472.CAN-05-2177; Bai XB, 2016, MOL BIOL CELL, V27, P897, DOI 10.1091/mbc.E15-07-0493; Bai XB, 2013, J CELL BIOL, V203, P895, DOI 10.1083/jcb.201308068; Barral Y, 2008, CURR OPIN CELL BIOL, V20, P12, DOI 10.1016/j.ceb.2007.12.001; Beaty BT, 2013, MOL BIOL CELL, V24, P1661, DOI 10.1091/mbc.E12-12-0908; Bourguignon LYW, 1998, J CELL PHYSIOL, V176, P206, DOI 10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3; BYERS JR, 1971, CAN J ZOOLOG, V49, P1185, DOI 10.1139/z71-179; Cazorla M, 1998, J PATHOL, V186, P144, DOI 10.1002/(SICI)1096-9896(1998100)186:2<144::AID-PATH147>3.0.CO;2-#; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cerveira N, 2011, BIOL CHEM, V392, P713, DOI 10.1515/BC.2011.072; Chacko AD, 2005, J PATHOL, V206, P458, DOI 10.1002/path.1794; Chacko AD, 2012, CELL ONCOL, V35, P85, DOI 10.1007/s13402-011-0066-0; Chan KT, 2009, J CELL BIOL, V185, P357, DOI 10.1083/jcb.200809110; Chen QK, 2013, DIFFERENTIATION, V86, P126, DOI 10.1016/j.diff.2013.03.003; Cichon MA, 2015, CANCER INFORM, V14, P1, DOI 10.4137/CIN.S18965; Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033; Clark ES, 2008, EUR J CELL BIOL, V87, P581, DOI 10.1016/j.ejcb.2008.01.008; Clay L, 2014, ELIFE, V3, DOI 10.7554/eLife.01883; Connolly D, 2014, BIOL CHEM, V395, P157, DOI 10.1515/hsz-2013-0247; Connolly D, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2924; DICKSON SR, 1992, J HISTOCHEM CYTOCHEM, V40, P697, DOI 10.1177/40.5.1315355; Dolat L, 2014, J CELL BIOL, V207, P225, DOI 10.1083/jcb.201405050; Eddy RJ, 2017, TRENDS CELL BIOL, V27, P595, DOI 10.1016/j.tcb.2017.03.003; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Fabregat A, 2016, NUCLEIC ACIDS RES, V44, pD481, DOI 10.1093/nar/gkv1351; Fata JE, 2004, BREAST CANCER RES, V6, P1, DOI 10.1186/bcr634; Filipe V, 2010, PHARM RES-DORDR, V27, P796, DOI 10.1007/s11095-010-0073-2; Flores-Pliego A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145366; Genna A, 2018, J CELL BIOL, V217, P375, DOI 10.1083/jcb.201702184; Golan M, 2013, CELL CYCLE, V12, P2297, DOI 10.4161/cc.25379; Gonzalez ME, 2007, CANCER RES, V67, P8554, DOI 10.1158/0008-5472.CAN-07-1474; Gonzalez ME, 2009, CELL SIGNAL, V21, P477, DOI 10.1016/j.cellsig.2008.11.007; Hall PA, 2005, J PATHOL, V206, P269, DOI 10.1002/path.1789; Heasley LR, 2014, EUKARYOT CELL, V13, P1411, DOI 10.1128/EC.00191-14; Hecht M, 2019, G3-GENES GENOM GENET, V9, P1869, DOI 10.1534/g3.119.400197; Helwa I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170628; Hoshino D, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002964; Hu JL, 2012, CURR BIOL, V22, P1109, DOI 10.1016/j.cub.2012.04.019; Jacob A, 2013, J CELL SCI, V126, P4647, DOI 10.1242/jcs.126573; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Khokha R, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004333; Knauper V, 2002, FEBS LETT, V532, P127, DOI 10.1016/S0014-5793(02)03654-2; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kotepui M, 2016, WSPOLCZESNA ONKOL, V20, P225, DOI 10.5114/wo.2016.61565; Lee Gilho, 2011, Int Neurourol J, V15, P4, DOI 10.5213/inj.2011.15.1.4; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; MAEDA K, 1987, P NATL ACAD SCI USA, V84, P6536, DOI 10.1073/pnas.84.18.6536; Magalhaes MAO, 2011, J CELL BIOL, V195, P903, DOI 10.1083/jcb.201103045; McDade SS, 2007, HUM MOL GENET, V16, P742, DOI 10.1093/hmg/ddm003; McGowan PM, 2008, ANN ONCOL, V19, P1566, DOI 10.1093/annonc/mdn180; Mehdiani A, 2015, JOVE-J VIS EXP, DOI 10.3791/50974; MONSKY WL, 1993, CANCER RES, V53, P3159; Montagna C, 2003, CANCER RES, V63, P2179; Montagna C, 2015, RES REP BIOCHEM, V5, P59, DOI 10.2147/RRBC.S59060; Mostowy S, 2012, NAT REV MOL CELL BIO, V13, P183, DOI 10.1038/nrm3284; Nabeshima K, 2002, PATHOL INT, V52, P255, DOI 10.1046/j.1440-1827.2002.01343.x; Nagano T, 2006, DEVELOPMENT, V133, P4643, DOI 10.1242/dev.02657; Nagata K, 2003, J BIOL CHEM, V278, P18538, DOI 10.1074/jbc.M205246200; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Neubauer K, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00003; Nile AH, 2014, NAT CHEM BIOL, V10, P76, DOI [10.1038/NCHEMBIO.1389, 10.1038/nchembio.1389]; Nistico P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011908; Noordstra Ivar, 2017, F1000Res, V6, P469, DOI 10.12688/f1000research.10729.1; Osaka M, 1999, P NATL ACAD SCI USA, V96, P6428, DOI 10.1073/pnas.96.11.6428; Poincloux R, 2009, J CELL SCI, V122, P3015, DOI 10.1242/jcs.034561; Ramos-DeSimone N, 1999, J BIOL CHEM, V274, P13066, DOI 10.1074/jbc.274.19.13066; Rozen S, 2000, Methods Mol Biol, V132, P365; Russell SEH, 2000, CANCER RES, V60, P4729; Schmidt K, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-43; Scott M, 2005, ONCOGENE, V24, P4688, DOI 10.1038/sj.onc.1208574; Sellin ME, 2012, MOL BIOL CELL, V23, P4242, DOI 10.1091/mbc.E12-06-0486; Sharma VP, 2013, CURR BIOL, V23, P2079, DOI 10.1016/j.cub.2013.08.044; Sharma VP, 2013, METHODS MOL BIOL, V1046, P343, DOI 10.1007/978-1-62703-538-5_21; Shimoda M, 2017, BBA-MOL CELL RES, V1864, P1989, DOI 10.1016/j.bbamcr.2017.05.027; Simian M, 2001, DEVELOPMENT, V128, P3117; Smith C, 2015, J MOL BIOL, V427, P3273, DOI 10.1016/j.jmb.2015.07.026; Sorensen AB, 2002, GENE, V285, P79, DOI 10.1016/S0378-1119(02)00406-7; Spiliotis ET, 2008, J CELL BIOL, V180, P295, DOI 10.1083/jcb.200710039; Spiliotis ET, 2006, J CELL SCI, V119, P4, DOI 10.1242/jcs.02746; Stehbens SJ, 2014, NAT CELL BIOL, V16, P558, DOI 10.1038/ncb2975; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Sudo K, 2007, HUM MUTAT, V28, P1005, DOI 10.1002/humu.20554; Tai KY, 2008, ONCOGENE, V27, P4044, DOI 10.1038/onc.2008.57; Team RC, 2016, R LANG ENV STAT COMP; Tkach M, 2016, CELL, V164, P1226, DOI 10.1016/j.cell.2016.01.043; Tokhtaeva E, 2015, J BIOL CHEM, V290, P5280, DOI 10.1074/jbc.M114.616201; Valenzuela-Iglesias A, 2015, EUR J CELL BIOL, V94, P78, DOI 10.1016/j.ejcb.2014.12.002; Vardi-Oknin D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073179; Verdier-Pinard P, 2017, SCI REP-UK, V7, DOI 10.1038/srep44976; Walter W, 2015, BIOINFORMATICS, V31, P2912, DOI 10.1093/bioinformatics/btv300; Wang LG, 2012, BIOINFORMATICS, V28, P2184, DOI 10.1093/bioinformatics/bts356; Wang Y, 2016, INTRAVITAL, V5; Wang Y, 2012, J CELL BIOL, V196, P375, DOI 10.1083/jcb.201105153; Weidmann MD, 2016, SCI REP-UK, V6, DOI 10.1038/srep36142; Winer A, 2018, MOL CANCER THER, V17, P1147, DOI 10.1158/1535-7163.MCT-17-0646; Winer A, 2016, MOL CANCER THER, V15, P2370, DOI 10.1158/1535-7163.MCT-16-0194; Wiseman BS, 2003, J CELL BIOL, V162, P1123, DOI 10.1083/jcb.200302090; Wolfgang CD, 2000, P NATL ACAD SCI USA, V97, P9437, DOI 10.1073/pnas.160270597; Wolfgang CD, 2001, CANCER RES, V61, P8122; Wu XR, 2009, KIDNEY INT, V75, P1153, DOI 10.1038/ki.2009.73; Zhang JS, 1999, CURR BIOL, V9, P1458, DOI 10.1016/S0960-9822(00)80115-3; Zhao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017845; Zhou ZN, 2014, ONCOGENE, V33, P3784, DOI 10.1038/onc.2013.363	108	13	13	3	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 25	2019	38	30					5839	5859		10.1038/s41388-019-0844-0	http://dx.doi.org/10.1038/s41388-019-0844-0			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IT3FY	31285548	Green Accepted			2022-12-28	WOS:000482739300001
J	Luo, AP; Zhou, XT; Shi, X; Zhao, YH; Men, Y; Chang, X; Chen, HY; Ding, F; Li, Y; Su, D; Xiao, ZF; Hui, ZG; Liu, ZH				Luo, Aiping; Zhou, Xuantong; Shi, Xing; Zhao, Yahui; Men, Yu; Chang, Xiao; Chen, Hongyan; Ding, Fang; Li, Yi; Su, Dan; Xiao, Zefen; Hui, Zhouguang; Liu, Zhihua			Exosome-derived miR-339-5p mediates radiosensitivity by targeting Cdc25A in locally advanced esophageal squamous cell carcinoma	ONCOGENE			English	Article							NEOADJUVANT CHEMORADIOTHERAPY; P53-INDUCIBLE MICRORNAS; PROGNOSTIC-SIGNIFICANCE; H2AX PHOSPHORYLATION; TUMOR-SUPPRESSOR; DOWN-REGULATION; DNA-DAMAGE; CANCER; STAGE; EXPRESSION	Cancer cells associated with radioresistance are likely to give rise to local recurrence and distant metastatic relapse. However, it remains unclear whether specific miRNAs have direct roles in radioresistance and/or prognosis. In this study, we find that miR-339-5p promotes radiosensitivity, and is downregulated in radioresistant subpopulations of esophageal cancer cells. Notably, miR-339-5p was selectively secreted into blood via exosomes, and that higher serum miR-339-5p levels were positively associated with radiotherapy sensitivity and good survival. Moreover, miR-339-5p expression was downregulated in the T3/T4 stage compared with T1/T2 stage in esophageal squamous cell carcinoma (ESCC) patients (P = 0.04), and low miR-339-5p expression in tissue was significantly associated with poor overall survival (P = 0.036) and disease-free survival (P = 0.037). Overexpression of miR-339-5p enhanced radiosensitivity in vitro and in vivo. Mechanistically, miR-339-5p enhances radiosensitivity by targeting Cdc25A, and is transcriptionally regulated by Runx3. Correlations were observed between miR-339-5p levels and Cdc25A/Runx3 levels in tissue samples. Intriguingly, combined analysis of miR-339-5p expression with Runx3 increased the separation of the survival curves obtained for either gene alone in the TCGA datasets (P = 0.009). Overall, exosome-derived miR-339-5p mediates radiosensitivity through downregulation of Cdc25A, and predicts pathological response to preoperative radiotherapy in locally advanced ESCC, suggesting it could be a promising non-invasive biomarker for facilitating personalized treatments.	[Luo, Aiping; Zhou, Xuantong; Zhao, Yahui; Chen, Hongyan; Ding, Fang; Li, Yi; Liu, Zhihua] Chinese Acad Med Sci, State Key Lab Mol Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing 100021, Peoples R China; [Luo, Aiping; Zhou, Xuantong; Zhao, Yahui; Men, Yu; Chang, Xiao; Chen, Hongyan; Ding, Fang; Li, Yi; Xiao, Zefen; Hui, Zhouguang; Liu, Zhihua] Peking Union Med Coll, Beijing 100021, Peoples R China; [Shi, Xing] Chinese Acad Sci, Beijing Inst Genom, Key Lab Genome Sci & Informat, Beijing 100101, Peoples R China; [Men, Yu; Chang, Xiao; Xiao, Zefen; Hui, Zhouguang] Chinese Acad Med Sci, Dept Radiotherapy, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing 100021, Peoples R China; [Su, Dan] Zhejiang Canc Hosp, Dept Pathol, Hangzhou 310022, Zhejiang, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Sciences; Beijing Institute of Genomics, CAS; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Zhejiang Cancer Hospital	Liu, ZH (corresponding author), Chinese Acad Med Sci, State Key Lab Mol Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing 100021, Peoples R China.; Xiao, ZF; Hui, ZG; Liu, ZH (corresponding author), Peking Union Med Coll, Beijing 100021, Peoples R China.; Xiao, ZF; Hui, ZG (corresponding author), Chinese Acad Med Sci, Dept Radiotherapy, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing 100021, Peoples R China.	xiaozefen@sina.com; huizg@cicams.ac.cn; liuzh@cicams.ac.cn	su, dan/GYJ-1940-2022; dong, wang/T-9093-2019	Zhao, Yahui/0000-0002-9613-1384; Xiao, Zefen/0000-0003-0503-6814; Chang, Xiao/0000-0003-0560-2441	National Key R&D program of China [2016YFC1302100]; National Natural Science Foundation of China [81472791, 81372418]; CAMS Initiative for Innovative Medicine [2016-I2M-1-001]	National Key R&D program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); CAMS Initiative for Innovative Medicine	We thank Dr. Yutaka Shimada for the generous gifts of ESCC cell lines (KYSE series). This research was supported by National Key R&D program of China (2016YFC1302100), National Natural Science Foundation of China (81472791, 81372418), and CAMS Initiative for Innovative Medicine (2016-I2M-1-001).	Banath JP, 2004, CANCER RES, V64, P7144, DOI 10.1158/0008-5472.CAN-04-1433; Challagundla KB, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv135; Chowdhury D, 2013, NAT REV MOL CELL BIO, V14, P181, DOI 10.1038/nrm3523; Davies L, 2010, CLIN ONCOL-UK, V22, P578, DOI 10.1016/j.clon.2010.05.023; Eriksson D, 2010, TUMOR BIOL, V31, P363, DOI 10.1007/s13277-010-0042-8; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Georges SA, 2008, CANCER RES, V68, P10105, DOI 10.1158/0008-5472.CAN-08-1846; Gupta S, 2014, NATURE, V512, P101, DOI 10.1038/nature13382; Hamai Y, 2017, ANTICANCER RES, V37, P5639, DOI 10.21873/anticanres.11999; Jansson MD, 2015, ONCOGENE, V34, P1908, DOI 10.1038/onc.2014.130; Jorgensen S, 2010, METHODS, V52, P375, DOI 10.1016/j.ymeth.2010.07.002; Kawai T, 2017, ANTICANCER RES, V37, P3301, DOI 10.21873/anticanres.11697; Kim S, 2008, J BIOL CHEM, V283, P18158, DOI 10.1074/jbc.M800186200; Kosaka N, 2010, J BIOL CHEM, V285, P17442, DOI 10.1074/jbc.M110.107821; Krishnan V, 2017, ADV EXP MED BIOL, V962, P491, DOI 10.1007/978-981-10-3233-2_29; Long JM, 2014, J BIOL CHEM, V289, P5184, DOI 10.1074/jbc.M113.518241; Maier P, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010102; Majidinia M, 2016, DNA REPAIR, V47, P1, DOI 10.1016/j.dnarep.2016.09.003; Melo SA, 2014, CANCER CELL, V26, P707, DOI 10.1016/j.ccell.2014.09.005; Morgan MA, 2015, CLIN CANCER RES, V21, P2898, DOI 10.1158/1078-0432.CCR-13-3229; Nedaeinia R, 2017, CANCER GENE THER, V24, P48, DOI 10.1038/cgt.2016.77; Odenthal M, 2013, INT J CANCER, V133, P2454, DOI 10.1002/ijc.28253; Pasquinelli AE, 2012, NAT REV GENET, V13, P271, DOI 10.1038/nrg3162; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Phinney DG, 2017, STEM CELLS, V35, P851, DOI 10.1002/stem.2575; Pichiorri F, 2010, CANCER CELL, V18, P367, DOI 10.1016/j.ccr.2010.09.005; Prathipati P, 2017, STEM CELL REV REP, V13, P79, DOI 10.1007/s12015-016-9696-y; Sakakura C, 2007, ONCOGENE, V26, P5927, DOI 10.1038/sj.onc.1210403; Schwarzenbach H, 2014, NAT REV CLIN ONCOL, V11, P145, DOI 10.1038/nrclinonc.2014.5; Shapiro J, 2015, LANCET ONCOL, V16, P1090, DOI 10.1016/S1470-2045(15)00040-6; Shen B, 2015, FEBS LETT, V589, P3205, DOI 10.1016/j.febslet.2015.09.009; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sjoquist KM, 2011, LANCET ONCOL, V12, P681, DOI 10.1016/S1470-2045(11)70142-5; Takeshita N, 2013, BRIT J CANCER, V108, P644, DOI 10.1038/bjc.2013.8; Tanaka Y, 2013, CANCER-AM CANCER SOC, V119, P1159, DOI 10.1002/cncr.27895; Taneja N, 2004, J BIOL CHEM, V279, P2273, DOI 10.1074/jbc.M310030200; Tellez CS, 2016, CANCER RES, V76, P4741, DOI 10.1158/0008-5472.CAN-15-3367; Ueda R, 2009, P NATL ACAD SCI USA, V106, P10746, DOI 10.1073/pnas.0811817106; Villarroya-Beltri C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3980; Weber CEM, 2016, CANCER RES, V76, P3562, DOI 10.1158/0008-5472.CAN-15-2932; Wu ZS, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-542; Yamada C, 2010, J BIOL CHEM, V285, P16693, DOI 10.1074/jbc.M109.055525; Zhang PJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6671	44	48	50	3	34	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2019	38	25					4990	5006		10.1038/s41388-019-0771-0	http://dx.doi.org/10.1038/s41388-019-0771-0			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IE1KY	30858545				2022-12-28	WOS:000472145900008
J	Torres-Hernandez, A; Wang, W; Nikiforov, Y; Tejada, K; Torres, L; Kalabin, A; Wu, Y; Ul Haq, MI; Khan, MY; Zhao, Z; Su, WY; Camargo, J; Hundeyin, M; Diskin, B; Adam, S; Rossi, JAK; Kurz, E; Aykut, B; Shadaloey, SAA; Leinwand, J; Miller, G				Torres-Hernandez, Alejandro; Wang, Wei; Nikiforov, Yuri; Tejada, Karla; Torres, Luisana; Kalabin, Aleksandr; Wu, Yue; Ul Haq, Muhammad Israr; Khan, Mohammed Y.; Zhao, Zhen; Su, Wenyu; Camargo, Jimmy; Hundeyin, Mautin; Diskin, Brian; Adam, Salma; Rossi, Juan A. Kochen; Kurz, Emma; Aykut, Berk; Shadaloey, Sorin A. A.; Leinwand, Joshua; Miller, George			Targeting SYK signaling in myeloid cells protects against liver fibrosis and hepatocarcinogenesis	ONCOGENE			English	Article							HEPATIC STELLATE CELLS; TYROSINE KINASE; RECEPTOR 4; INFLAMMATION; INHIBITION; INJURY; NK	Liver fibrosis and fibrosis-associated hepatocarcinogenesis are driven by chronic inflammation and are leading causes of morbidity and death worldwide. SYK signaling regulates critical processes in innate and adaptive immunity, as well as parenchymal cells. We discovered high SYK expression in the parenchymal hepatocyte, hepatic stellate cell (HSC), and the inflammatory compartments in the fibrotic liver. We postulated that targeting SYK would mitigate hepatic fibrosis and oncogenic progression. We found that inhibition of SYK with the selective small molecule inhibitors Piceatannol and PRT062607 markedly protected against toxin-induced hepatic fibrosis, associated hepatocellular injury and intra-hepatic inflammation, and hepatocarcinogenesis. SYK inhibition resulted in increased intra-tumoral expression of the p16 and p53 but decreased expression of Bcl-xL and SMAD4. Further, hepatic expression of genes regulating angiogenesis, apoptosis, cell cycle regulation, and cellular senescence were affected by targeting SYK. We found that SYK inhibition mitigated both HSC trans-differentiation and acquisition of an inflammatory phenotype in T cells, B cells, and myeloid cells. However, in vivo experiments employing selective targeted deletion of SYK indicated that only SYK deletion in the myeloid compartment was sufficient to confer protection against fibrogenic progression. Targeting SYK promoted myeloid cell differentiation into hepato-protective TNF alpha(low) CD206(hi) phenotype downregulating mTOR, IL-8 signaling and oxidative phosphorylation. Collectively, these data suggest that SYK is an attractive target for experimental therapeutics in treating hepatic fibrosis and oncogenesis.	[Torres-Hernandez, Alejandro; Wang, Wei; Nikiforov, Yuri; Tejada, Karla; Torres, Luisana; Kalabin, Aleksandr; Wu, Yue; Ul Haq, Muhammad Israr; Khan, Mohammed Y.; Zhao, Zhen; Su, Wenyu; Camargo, Jimmy; Hundeyin, Mautin; Diskin, Brian; Adam, Salma; Rossi, Juan A. Kochen; Kurz, Emma; Aykut, Berk; Shadaloey, Sorin A. A.; Leinwand, Joshua; Miller, George] NYU, Sch Med, Dept Surg, SA Localio Lab, 450 East 29th St, New York, NY 10016 USA; [Miller, George] NYU, Sch Med, Dept Cell Biol, 450 East 29th St, New York, NY 10016 USA	New York University; New York University	Miller, G (corresponding author), NYU, Sch Med, Dept Surg, SA Localio Lab, 450 East 29th St, New York, NY 10016 USA.; Miller, G (corresponding author), NYU, Sch Med, Dept Cell Biol, 450 East 29th St, New York, NY 10016 USA.	george.miller@nyumc.org	Hundeyin, Mautin/AAU-6792-2020	Kalabin, Aleksandr/0000-0003-4133-6267	Cancer Center Support Grant at the Laura and Isaac Perlmutter Cancer Center [P30CA016087]; NYU Cancer Institute Center Support Grant [NIH/NCI 5 P30CA16087]; NCI [CA168611, CA155649, CA193111]; Society of University Surgeons-Ethicon Resident Research Award; American Liver Foundation-Thomas F. Nealon, III Postdoctoral Research Fellowship Honoring Zachery Rue; American Liver Foundation Postdoctoral Research Fellowship; NYU Physician-Scientist Training Program; NATIONAL CANCER INSTITUTE [P30CA016087] Funding Source: NIH RePORTER	Cancer Center Support Grant at the Laura and Isaac Perlmutter Cancer Center; NYU Cancer Institute Center Support Grant; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Society of University Surgeons-Ethicon Resident Research Award; American Liver Foundation-Thomas F. Nealon, III Postdoctoral Research Fellowship Honoring Zachery Rue; American Liver Foundation Postdoctoral Research Fellowship; NYU Physician-Scientist Training Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the NYU Langone Health Genome Technology Center (GTC) for expert library preparation and sequencing; the GTC is partially supported by the Cancer Center Support Grant P30CA016087 at the Laura and Isaac Perlmutter Cancer Center. We thank the NYU Langone Health Experimental Pathology Research Laboratory, which is partially funded by NYU Cancer Institute Center Support Grant NIH/NCI 5 P30CA16087, for expert tissue processing and equipment support. This work was supported by NCI CA168611 (GM), CA155649 (GM), CA193111 (ATH, BD), Society of University Surgeons-Ethicon Resident Research Award (ATH), American Liver Foundation-Thomas F. Nealon, III Postdoctoral Research Fellowship Honoring Zachery Rue (ATH), American Liver Foundation Postdoctoral Research Fellowship (WW), NYU Physician-Scientist Training Program (ATH).	Anderson Robert N, 2005, Natl Vital Stat Rep, V53, P1; Coffey G, 2017, J CLIN PHARMACOL, V57, P194, DOI 10.1002/jcph.794; Cornall RJ, 2000, P NATL ACAD SCI USA, V97, P1713, DOI 10.1073/pnas.97.4.1713; Daley D, 2017, J EXP MED, V214, P1711, DOI 10.1084/jem.20161707; Dapito DH, 2012, CANCER CELL, V21, P504, DOI 10.1016/j.ccr.2012.02.007; de Rosamel L, 2017, EXPERT OPIN EMERG DR, V22, P175, DOI 10.1080/14728214.2017.1336538; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Guo JS, 2010, FIBROGENESIS TISSUE, V3, DOI 10.1186/1755-1536-3-21; Hellerbrand C, 1999, J HEPATOL, V30, P77, DOI 10.1016/S0168-8278(99)80010-5; Inarrairaegui M, 2018, CLIN CANCER RES, V24, P1518, DOI 10.1158/1078-0432.CCR-17-0289; Kant R, 2014, J MED MICROBIOL, V63, P293, DOI 10.1099/jmm.0.064220-0; Koyama Y, 2017, J CLIN INVEST, V127, P55, DOI 10.1172/JCI88881; Kurniawan DW, 2018, J CONTROL RELEASE, V288, P227, DOI 10.1016/j.jconrel.2018.09.004; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Marcus A, 2014, ADV IMMUNOL, V122, P91, DOI 10.1016/B978-0-12-800267-4.00003-1; Melhem A, 2006, J HEPATOL, V45, P60, DOI 10.1016/j.jhep.2005.12.025; Miller YI, 2012, BRIT J PHARMACOL, V167, P990, DOI 10.1111/j.1476-5381.2012.02097.x; Mocsai A, 2010, NAT REV IMMUNOL, V10, P387, DOI 10.1038/nri2765; Moreira RK, 2007, ARCH PATHOL LAB MED, V131, P1728; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; Notas G, 2009, CLIN IMMUNOL, V130, P16, DOI 10.1016/j.clim.2008.08.008; Novobrantseva TI, 2005, J CLIN INVEST, V115, P3072, DOI 10.1172/JCI24798; O'Neill LAJ, 2016, CELL REP, V17, P625, DOI 10.1016/j.celrep.2016.09.085; Ochi A, 2012, J EXP MED, V209, P1671, DOI 10.1084/jem.20111706; Poynard T, 2003, J HEPATOL, V38, P257, DOI 10.1016/S0168-8278(02)00413-0; Pradere JP, 2013, HEPATOLOGY, V58, P1461, DOI 10.1002/hep.26429; Pradere JP, 2010, SEMIN LIVER DIS, V30, P232, DOI 10.1055/s-0030-1255353; Qu C, 2018, HEPATOLOGY, V68, P1125, DOI 10.1002/hep.29881; Seifert L, 2015, CELL REP, V13, P1909, DOI 10.1016/j.celrep.2015.10.058; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Thapa M, 2015, HEPATOLOGY, V61, P2067, DOI 10.1002/hep.27761; Uehara T., 2014, CURR PROTOC PHARM, V66, P11; Wang W, 2017, HEPATOLOGY, V66, P108, DOI 10.1002/hep.29129; Weiskirchen Ralf, 2014, Hepatobiliary Surg Nutr, V3, P344, DOI 10.3978/j.issn.2304-3881.2014.11.03; Wick G, 2010, TRENDS IMMUNOL, V31, P110, DOI 10.1016/j.it.2009.12.001; Yang J, 2015, J HEPATOCELL CARCINO, V2, P11, DOI 10.2147/JHC.S44515; Yang L, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00138; Zambirinis CP, 2015, J EXP MED, V212, P2077, DOI 10.1084/jem.20142162; Zhou Z, 2018, CELL MOL GASTROENTER, V5, P399, DOI 10.1016/j.jcmgh.2018.01.003	41	15	16	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2019	38	23					4512	4526		10.1038/s41388-019-0734-5	http://dx.doi.org/10.1038/s41388-019-0734-5			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IB4KM	30742098				2022-12-28	WOS:000470240300006
J	Sloot, YJE; Rabold, K; Netea, MG; Smit, JWA; Hoogerbrugge, N; Netea-Maier, RT				Sloot, Yvette J. E.; Rabold, Katrin; Netea, Mihai G.; Smit, Johannes W. A.; Hoogerbrugge, Nicoline; Netea-Maier, Romana T.			Effect of PTEN inactivating germline mutations on innate immune cell function and thyroid cancer-induced macrophages in patients with PTEN hamartoma tumor syndrome	ONCOGENE			English	Article							HEMATOPOIETIC STEM-CELLS; COWDEN SYNDROME; METFORMIN; MTOR; MYELOPOIESIS; REINFECTION; EXPRESSION; PROTECTION; MONOCYTES; KINASE	PTEN hamartoma tumor syndrome (PHTS) is caused by inactivating germline PTEN mutations with subsequent activation of Akt-mTOR signaling, leading to an increased risk of developing thyroid carcinoma (TC). Activation of Akt-mTOR signaling is essential for innate immune cell activation and reprogramming of TC-induced macrophages. Here, we aim to assess the effect of PTEN mutations on innate immune cell function in PHTS patients, especially in the context of TC, using a unique ex vivo model. Monocyte-derived cytokine responses were assessed in 29 PHTS patients and 29 controls. To assess the functional profile of TC-induced-macrophages, a co-culture model with two TC cell lines was performed. Rapamycin, a lactate transport blocker and metformin were used as modulators of the Akt-mTOR pathway and cell metabolism. Monocytes from PHTS patients showed increased production of IL-6, TNF-alpha, IL-8 and MCP-1, and higher lactate production. After co-culture with TC cell lines, TC-induced macrophages showed significantly increased production of cytokines in both patients and controls, especially after co-culture with a PTEN-deficient TC cell line; these effects were abolished after use of rapamycin or a lactate transport blocker. Metformin blocked the production of anti-inflammatory cytokines. In conclusion, innate immune cells from PHTS patients have increased lactate production and a more proinflammatory phenotype, especially after co-culture with PTEN-deficient TC. Metformin promotes a proinflammatory phenotype by blocking anti-inflammatory cytokine response, whereas rapamycin reduces production of proinflammatory cytokines. This indicates that PHTS patients may benefit from treatment with mTOR blocking agents to limit the inflammatory response in the tumor microenvironment.	[Sloot, Yvette J. E.; Rabold, Katrin; Smit, Johannes W. A.; Netea-Maier, Romana T.] Radboud Univ Nijmegen, Med Ctr, Div Endocrinol, Dept Internal Med, Nijmegen, Netherlands; [Rabold, Katrin] Radboud Univ Nijmegen, Med Ctr, Dept Radiat Oncol, Radiotherapy & OncoImmunol Lab, Nijmegen, Netherlands; [Netea, Mihai G.] Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, Nijmegen, Netherlands; [Netea, Mihai G.] Radboud Univ Nijmegen, Med Ctr, Radboud Ctr Infect Dis RCI, Nijmegen, Netherlands; [Hoogerbrugge, Nicoline] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen	Netea-Maier, RT (corresponding author), Radboud Univ Nijmegen, Med Ctr, Div Endocrinol, Dept Internal Med, Nijmegen, Netherlands.	romana.netea-maier@radboudumc.nl	Netea, Mihai/N-5155-2014; Rabold, Katrin/R-9495-2017	Netea, Mihai/0000-0003-2421-6052	Netherlands Cancer Foundation (KWF) [10559]; Spinoza grant of the Netherlands Organization for Scientific Research	Netherlands Cancer Foundation (KWF); Spinoza grant of the Netherlands Organization for Scientific Research	This work was supported by a grant from the Netherlands Cancer Foundation (KWF) [grant number #10559, 2017]. MGN was supported by a Spinoza grant of the Netherlands Organization for Scientific Research.	Aguirre-Gamboa R, 2016, CELL REP, V17, P2474, DOI 10.1016/j.celrep.2016.10.053; Amer M, 2011, INT J DERMATOL, V50, P516, DOI 10.1111/j.1365-4632.2010.04669.x; Arts RJW, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1229725; Arts RJW, 2016, CELL REP, V17, P2562, DOI 10.1016/j.celrep.2016.11.011; Bekkering S, 2016, CLIN VACCINE IMMUNOL, V23, P926, DOI 10.1128/CVI.00349-16; Bridges HR, 2014, BIOCHEM J, V462, P475, DOI 10.1042/BJ20140620; Caillou B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022567; Chen HH, 2017, J ALLERGY CLIN IMMUN, V139, P607, DOI 10.1016/j.jaci.2016.03.059; Cheng SC, 2014, SCIENCE, V345, P1579, DOI 10.1126/science.1250684; Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490; Delgoffe GM, 2009, IMMUNITY, V30, P832, DOI 10.1016/j.immuni.2009.04.014; Dinarello CA, 2011, BLOOD, V117, P3720, DOI 10.1182/blood-2010-07-273417; Fu YC, 2004, BLOOD CELL MOL DIS, V32, P182, DOI 10.1016/j.bcmd.2003.09.002; Han BY, 2015, TUMOR BIOL, V36, P6295, DOI 10.1007/s13277-015-3315-4; Heindl M, 2012, GASTROENTEROLOGY, V142, P1093, DOI 10.1053/j.gastro.2012.01.011; Hou P, 2007, CLIN CANCER RES, V13, P1161, DOI 10.1158/1078-0432.CCR-06-1125; Jang EK, 2015, EUR THYROID J, V4, P181, DOI 10.1159/000437365; Kleinnijenhuis J, 2012, P NATL ACAD SCI USA, V109, P17537, DOI 10.1073/pnas.1202870109; Klubo-Gwiezdzinska J, 2013, J CLIN ENDOCR METAB, V98, P3269, DOI 10.1210/jc.2012-3799; Kozicky LK, 2015, SEMIN IMMUNOL, V27, P276, DOI 10.1016/j.smim.2015.07.001; Landsberg J, 2012, NATURE, V490, P412, DOI 10.1038/nature11538; Mehta A, 2018, CANCER DISCOV, V8, P935, DOI 10.1158/2159-8290.CD-17-1178; Mitroulis I, 2018, CELL, V172, P147, DOI 10.1016/j.cell.2017.11.034; Molnarfi N, 2007, J IMMUNOL, V178, P446, DOI 10.4049/jimmunol.178.1.446; Morani F, 2014, J MOL ENDOCRINOL, V53, P247, DOI 10.1530/JME-14-0118; Murdoch C, 2008, NAT REV CANCER, V8, P618, DOI 10.1038/nrc2444; Netea MG, 2017, J LEUKOCYTE BIOL, V102, P1323, DOI 10.1189/jlb.5RI0217-064RR; Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098; Newton RH, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00151; Nieuwenhuis MH, 2014, FAM CANCER, V13, P57, DOI 10.1007/s10689-013-9674-3; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Peng WY, 2016, CANCER DISCOV, V6, P202, DOI 10.1158/2159-8290.CD-15-0283; Phadngam S, 2016, ONCOTARGET, V7, P84999, DOI 10.18632/oncotarget.13113; Pilarski R, 2013, JNCI-J NATL CANCER I, V105, P1607, DOI 10.1093/jnci/djt277; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Quintin J, 2012, CELL HOST MICROBE, V12, P223, DOI 10.1016/j.chom.2012.06.006; Ryder M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054302; Saccardi A, 1994, Minerva Stomatol, V43, P417; Sarrazy V, 2016, CIRC RES, V118, P1062, DOI 10.1161/CIRCRESAHA.115.307599; Schweppe RE, 2008, J CLIN ENDOCR METAB, V93, P4331, DOI 10.1210/jc.2008-1102; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; STARINK TM, 1986, CLIN GENET, V29, P222; Xie SB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094496; Xu J, 2012, CRIT REV FOOD SCI, V52, P373, DOI 10.1080/10408398.2010.500245; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505; 1989, OBSTET GYNECOL 2, V73, P890	47	16	17	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2019	38	19					3743	3755		10.1038/s41388-019-0685-x	http://dx.doi.org/10.1038/s41388-019-0685-x			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HX4OU	30670777				2022-12-28	WOS:000467379600013
J	Yang, Z; Qu, CB; Zhang, Y; Zhang, WF; Wang, DD; Gao, CC; Ma, L; Chen, JS; Liu, KL; Zheng, B; Zhang, XH; Zhang, ML; Wang, XL; Wen, JK; Li, W				Yang, Zhan; Qu, Chang-Bao; Zhang, Yong; Zhang, Wen-Feng; Wang, Dan-Dan; Gao, Chun-Cheng; Ma, Long; Chen, Jin-Suo; Liu, Kai-Long; Zheng, Bin; Zhang, Xin-Hua; Zhang, Man-Li; Wang, Xiao-Lu; Wen, Jin-Kun; Li, Wei			Dysregulation of p53-RBM25-mediated circAMOTL1L biogenesis contributes to prostate cancer progression through the circAMOTL1L-miR-193a-5p-Pcdha pathway	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CIRCULAR RNA; REVEALS; THERAPY; P53; PROTOCADHERINS; METHYLATION; EXPRESSION; ANGIOMOTIN; MIGRATION	p53, circRNAs and miRNAs are important components of the regulatory network that activates the EMT program in cancer metastasis. In prostate cancer (PCa), however, it has not been investigated whether and how p53 regulates EMT by circRNAs and miRNAs. Here we show that a Amotll-derived circRNA, termed circAMOTL1L, is downregulated in human PCa, and that decreased circAMOTL1L facilitates PCa cell migration and invasion through downregulating E-cadherin and upregulating vimentin, thus leading to EMT and PCa progression. Mechanistically, we demonstrate that circAMOTL1L serves as a sponge for binding miR-193a-5p in PCa cells, relieving miR-193a-5p repression of Pcdha gene cluster (a subset of the cadherin superfamily members). Accordingly, dysregulation of the circAMOTL1L-miR-193a-5p-Pcdha8 regulatory pathway mediated by circAMOTL1L downregulation contributes to PCa growth in vivo. Further, we show that RBM25 binds directly to circAMOTL1L and induces its biogenesis, whereas p53 regulates EMT via direct activation of RBM25 gene. These findings have linked p53/RBM25-mediated circAMOTL1L-miR-193a-5p-Pcdha regulatory axis to EMT in metastatic progression of PCa. Targeting this newly identified regulatory axis provides a potential therapeutic strategy for aggressive PCa.	[Yang, Zhan; Qu, Chang-Bao; Zhang, Yong; Zhang, Wen-Feng; Wang, Dan-Dan; Gao, Chun-Cheng; Ma, Long; Chen, Jin-Suo; Liu, Kai-Long; Wang, Xiao-Lu; Li, Wei] Hebei Med Univ, Dept Urol, Hosp 2, 215 Heping W Rd, Shijiazhuang 050000, Hebei, Peoples R China; [Yang, Zhan; Zheng, Bin; Zhang, Xin-Hua; Zhang, Man-Li; Wen, Jin-Kun] Hebei Med Univ, Dept Biochem & Mol Biol, Minist Educ China, 361 Zhongshan E Rd, Shijiazhuang 050017, Hebei, Peoples R China; [Yang, Zhan] Hebei Med Univ, Dept Sci & Technol, Hosp 2, 215 Heping W Rd, Shijiazhuang 050000, Hebei, Peoples R China; [Zhang, Man-Li] Hebei Med Univ, Dept Emergency Med, Hosp 2, Shijiazhuang 050000, Hebei, Peoples R China	Hebei Medical University; Hebei Medical University; Ministry of Education, China; Hebei Medical University; Hebei Medical University	Wang, XL; Li, W (corresponding author), Hebei Med Univ, Dept Urol, Hosp 2, 215 Heping W Rd, Shijiazhuang 050000, Hebei, Peoples R China.; Wen, JK (corresponding author), Hebei Med Univ, Dept Biochem & Mol Biol, Minist Educ China, 361 Zhongshan E Rd, Shijiazhuang 050017, Hebei, Peoples R China.	wx12106@126.com; wjk@hebmu.edu.cn; Weill_hb2h@163.com	Yang, Zhan/GQG-9995-2022	Wen, Jinkun/0000-0002-8453-4549; Yang, Zhan/0000-0001-7191-2910	National Natural Science Foundation of China [81672555, 81600237]; Hebei Province Natural Science Foundation [H2017206032]; Higher Education Science and Technology Research Project of Hebei Province [BJ2018001]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Hebei Province Natural Science Foundation(Natural Science Foundation of Hebei Province); Higher Education Science and Technology Research Project of Hebei Province	We thank Dr. Yu-mei Ma (Department of Pathology, The Second Hospital of Hebei Medical University) for scoring PCa histology and pathological analysis. We are grateful to Hao Huang (Leica, China) and Qian Du (Biocaring Biotechnology Co., Ltd, Shijiazhuang) for technical support. This study was partially supported by The National Natural Science Foundation of China (No. 81672555 and 81600237), Hebei Province Natural Science Foundation (H2017206032), and Higher Education Science and Technology Research Project of Hebei Province (No. BJ2018001).	Amini-Nik S, 2014, J CLIN INVEST, V124, P2599, DOI 10.1172/JCI62059; Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850; Banelli B, 2012, LAB INVEST, V92, P458, DOI 10.1038/labinvest.2011.169; Biferi MG, 2017, MOL THER, V25, P2038, DOI 10.1016/j.ymthe.2017.05.017; Carlson SM, 2017, J BIOL CHEM, V292, P13381, DOI 10.1074/jbc.M117.784371; Castellanos JA, 2013, ONCOTARGETS THER, V6, P1261, DOI 10.2147/OTT.S34670; Chen YH, 2016, J MED GENET, V53, P359, DOI 10.1136/jmedgenet-2016-103758; Cho HJ, 2014, CANCER DISCOV, V4, P318, DOI 10.1158/2159-8290.CD-13-0346; Conn SJ, 2015, CELL, V160, P1125, DOI 10.1016/j.cell.2015.02.014; Dallosso AR, 2012, ONCOGENE, V31, P4409, DOI 10.1038/onc.2011.609; Dallosso AR, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000745; Dehm SM, 2006, J CELL BIOCHEM, V99, P333, DOI 10.1002/jcb.20794; Ebbesen KK, 2016, BBA-GENE REGUL MECH, V1859, P163, DOI 10.1016/j.bbagrm.2015.07.007; Gerstberger S, 2014, NAT REV GENET, V15, P829, DOI 10.1038/nrg3813; Guo F, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/1756-8722-7-19; Hall MP, 2013, RNA, V19, P627, DOI 10.1261/rna.038422.113; Han MH, 2010, MOL CELL PROTEOMICS, V9, P71, DOI 10.1074/mcp.M900343-MCP200; Han ZW, 2018, CANCER RES, V78, P2550, DOI 10.1158/0008-5472.CAN-17-1575; Ivanov A, 2015, CELL REP, V10, P170, DOI 10.1016/j.celrep.2014.12.019; Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Katori S, 2009, J NEUROSCI, V29, P9137, DOI 10.1523/JNEUROSCI.5478-08.2009; Keeler AB, 2015, CELL ADHES MIGR, V9, P214, DOI 10.1080/19336918.2014.1000069; Khan MAF, 2016, CIRC RES, V119, P996, DOI 10.1161/CIRCRESAHA.116.309568; Kong Z, 2017, BIOCHEM BIOPH RES CO, V493, P1217, DOI 10.1016/j.bbrc.2017.07.162; Lee HM, 2017, MOL CELL ENDOCRINOL, V457, P103, DOI 10.1016/j.mce.2016.12.026; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li X, 2017, MOL CELL, V67, P214, DOI 10.1016/j.molcel.2017.05.023; Li ZY, 2015, NAT STRUCT MOL BIOL, V22, P256, DOI 10.1038/nsmb.2959; Matsumoto A, 2009, INT J UROL, V16, P687, DOI 10.1111/j.1442-2042.2009.02341.x; Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031; Muller PAJ, 2011, J CELL BIOL, V192, P209, DOI 10.1083/jcb.201009059; Ortiz A, 2015, FASEB J, V29, P1080, DOI 10.1096/fj.14-261594; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pencik J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8736; Rehmsmeier M, 2004, RNA, V10, P1507, DOI 10.1261/rna.5248604; Ren D, 2013, INT J ONCOL, V42, P1473, DOI 10.3892/ijo.2013.1825; Sun Y, 2017, CIRC RES, V121, P628, DOI 10.1161/CIRCRESAHA.117.311441; Waha A, 2005, NEOPLASIA, V7, P193, DOI 10.1593/neo.04490; Wang LZ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6909; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; Wetherill YB, 2006, MOL CANCER THER, V5, P3181, DOI 10.1158/1535-7163.MCT-06-0272; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yang W, 2016, ONCOGENE, V35, P3919, DOI 10.1038/onc.2015.460; Yang Z, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0649-3; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Yu J, 2009, GASTROENTEROLOGY, V136, P640, DOI 10.1053/j.gastro.2008.10.050; Zeng Y, 2017, THERANOSTICS, V7, P3842, DOI 10.7150/thno.19764; Zhang GW, 2018, BIOMED PHARMACOTHER, V97, P736, DOI 10.1016/j.biopha.2017.10.163; Zhang L, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-108; Zheng QP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11215; Zheng YJ, 2009, CIRC RES, V105, P260, DOI 10.1161/CIRCRESAHA.109.195156; Zhou A, 2008, MOL CELL BIOL, V28, P5924, DOI 10.1128/MCB.00560-08; Zou C, 2007, NEUROSCIENCE, V144, P579, DOI 10.1016/j.neuroscience.2006.10.011	54	90	94	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2019	38	14					2516	2532		10.1038/s41388-018-0602-8	http://dx.doi.org/10.1038/s41388-018-0602-8			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HR7LI	30531834	Green Published, hybrid			2022-12-28	WOS:000463335200006
J	Sun, BW; Mason, S; Wilson, RC; Hazard, SE; Wang, YB; Fang, R; Wang, QW; Yeh, ES; Yang, MX; Roberts, TM; Zhao, JJ; Wang, Q				Sun, Bowen; Mason, Seth; Wilson, Robert C.; Hazard, Starr E.; Wang, Yubao; Fang, Rong; Wang, Qiwei; Yeh, Elizabeth S.; Yang, Meixiang; Roberts, Thomas M.; Zhao, Jean J.; Wang, Qi			Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers	ONCOGENE			English	Article							TRASTUZUMAB RESISTANCE; MEDIATES RESISTANCE; TERMINAL DOMAIN; RECEPTOR; ACTIVATION; LAPATINIB; TUMORS; EXPRESSION; MUTATIONS; PATHWAY	Resistance of breast cancer to human epidermal growth factor receptor 2 (HER2) inhibitors involves reprogramming of the kinome through HER2/HER3 signaling via the activation of multiple tyrosine kinases and transcriptional upregulation. The heterogeneity of induced kinases prevents kinase targeting by a single kinase inhibitor and presents a major challenge to the treatment of therapeutically recalcitrant HER2-positive breast cancers (HER2+ BCs). As a result, there is a critical need for effective treatment that attacks the aberrant kinome activation associated with resistance to HER2-targeted therapy. Here, we describe a novel treatment strategy that targets cyclin-dependent kinase 7 (CDK7) in HER2 inhibitor-resistant (HER2iR) breast cancer. We show that both HER2 inhibitor-sensitive (HER2iS) and HER2iR breast cancer cell lines exhibit high sensitivity to THZ1, a newly identified covalent inhibitor of the transcription regulatory kinase CDK7. CDK7 promotes cell cycle progression through inhibition of transcription, rather than via direct phosphorylation of classical CDK targets. The transcriptional kinase activity of CDK7 is regulated by HER2, and by the receptor tyrosine kinases activated in response to HER2 inhibition, as well as by the downstream SHP2 and PI3K/AKT pathways. A low dose of THZ1 displayed potent synergy with the HER2 inhibitor lapatinib in HER2iR BC cells in vitro. Dual HER2 and CDK7 inhibition induced tumor regression in two HER2iR BC xenograft models in vivo. Our data support the utilization of CDK7 inhibition as an additional therapeutic avenue that blocks the activation of genes engaged by multiple HER2iR kinases.	[Sun, Bowen; Yeh, Elizabeth S.; Yang, Meixiang] Jinan Univ, Biomed Translat Res Inst, Affiliated Hosp 1, Guangzhou 510632, Peoples R China; [Sun, Bowen; Yeh, Elizabeth S.; Yang, Meixiang] Jinan Univ, Sch Pharm, Guangzhou 510632, Peoples R China; [Sun, Bowen; Mason, Seth; Wilson, Robert C.; Wang, Qi] Med Univ South Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; [Hazard, Starr E.] Med Univ South Carolina, Computat Biol Resource Ctr, Charleston, SC 29425 USA; [Wang, Yubao; Fang, Rong; Wang, Qiwei; Roberts, Thomas M.; Zhao, Jean J.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; [Wang, Yubao; Fang, Rong; Wang, Qiwei; Roberts, Thomas M.; Zhao, Jean J.] Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; [Fang, Rong] Ningbo Univ, Sch Med, Zhejiang Prov Key Lab Pathophysiol, Dept Pathol, Ningbo 315211, Peoples R China; [Yeh, Elizabeth S.] Med Univ South Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, Charleston, SC 29425 USA	Jinan University; Jinan University; Medical University of South Carolina; Medical University of South Carolina; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Ningbo University; Medical University of South Carolina	Wang, Q (corresponding author), Med Univ South Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA.	wangq@musc.edu	mason, seth/GYU-3141-2022	Hazard, E. Starr/0000-0002-4645-7642; Wang, Qiwei/0000-0003-3897-2529	American Cancer Society [ACS_IRG IRG-97-219-14]; Genomic Shared Resource, Hollings Cancer Center, Medical University of South Carolina [P30 CA138313]; NIH [R01 CA187305, R35 CA210057 CA187918, 1P50CA168504]; Breast Cancer Research Foundation; Rosanna's Rush for Research	American Cancer Society(American Cancer Society); Genomic Shared Resource, Hollings Cancer Center, Medical University of South Carolina; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Breast Cancer Research Foundation; Rosanna's Rush for Research	This work was supported by pilot research funding form an American Cancer Society Institutional Research Grant awarded to the Hollings Cancer Center, Medical University of South Carolina (ACS_IRG IRG-97-219-14, QW); Supported in part by the Genomic Shared Resource, Hollings Cancer Center, Medical University of South Carolina (P30 CA138313); NIH grants R01 CA187305 (ESY), R35 CA210057 CA187918 (TMR and JJZ), 1P50CA168504 (TMR and JJZ); the Breast Cancer Research Foundation (JJZ); Rosanna's Rush for Research (JJZ). We also like to thank Dr Stephen Ethier (Medical University of South Carolina, SC, USA) for providing cell line Sum149.	Akhtar MS, 2009, MOL CELL, V34, P387, DOI 10.1016/j.molcel.2009.04.016; Alexander PB, 2017, J BIOL CHEM, V292, P748, DOI 10.1074/jbc.M116.754960; Bentires-Alj M, 2006, NAT MED, V12, P114, DOI 10.1038/nm1341; Bentires-Alj M, 2004, CANCER RES, V64, P8816, DOI 10.1158/0008-5472.CAN-04-1923; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Blackwell KL, 2010, J CLIN ONCOL, V28, P1124, DOI 10.1200/JCO.2008.21.4437; Chen DS, 2002, ONCOGENE, V21, P4921, DOI 10.1038/sj.onc.1205420; Chen YNP, 2016, NATURE, V535, P148, DOI 10.1038/nature18621; Chipumuro E, 2014, CELL, V159, P1126, DOI 10.1016/j.cell.2014.10.024; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Christensen CL, 2014, CANCER CELL, V26, P909, DOI 10.1016/j.ccell.2014.10.019; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dueck AC, 2013, CLIN CANCER RES, V19, P5798, DOI 10.1158/1078-0432.CCR-13-0558; Eichhorn PJA, 2008, CANCER RES, V68, P9221, DOI 10.1158/0008-5472.CAN-08-1740; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Ercan D, 2010, ONCOGENE, V29, P2346, DOI 10.1038/onc.2009.526; Glover-Cutter K, 2009, MOL CELL BIOL, V29, P5455, DOI 10.1128/MCB.00637-09; Goel S, 2016, CANCER CELL, V29, P255, DOI 10.1016/j.ccell.2016.02.006; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Hanker AB, 2017, CLIN CANCER RES, V23, P4323, DOI 10.1158/1078-0432.CCR-16-2287; Hanker AB, 2013, P NATL ACAD SCI USA, V110, P14372, DOI 10.1073/pnas.1303204110; Harrod A, 2017, ONCOGENE, V36, P2286, DOI 10.1038/onc.2016.382; Hellmuth K, 2008, P NATL ACAD SCI USA, V105, P7275, DOI 10.1073/pnas.0710468105; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Jeselsohn R, 2018, CANCER CELL, V33, P173, DOI 10.1016/j.ccell.2018.01.004; Julovi SM, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00120; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kwiatkowski N, 2014, NATURE, V511, P616, DOI 10.1038/nature13393; Larochelle S, 2007, MOL CELL, V25, P839, DOI 10.1016/j.molcel.2007.02.003; Larochelle S, 2012, NAT STRUCT MOL BIOL, V19, P1108, DOI 10.1038/nsmb.2399; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Loi S, 2014, ANN ONCOL, V25, P1544, DOI 10.1093/annonc/mdu112; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; Mayer IA, 2014, CLIN CANCER RES, V20, P782, DOI 10.1158/1078-0432.CCR-13-0583; Moasser MM, 2015, JAMA ONCOL, V1, P1154, DOI 10.1001/jamaoncol.2015.2286; Musolino A, 2008, J CLIN ONCOL, V26, P1789, DOI 10.1200/JCO.2007.14.8957; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Oliveras-Ferraros C, 2012, CELL CYCLE, V11, P4020, DOI 10.4161/cc.22225; Palancade B, 2003, EUR J BIOCHEM, V270, P3859, DOI 10.1046/j.1432-1033.2003.03794.x; Prahallad A, 2015, CELL REP, V12, P1978, DOI 10.1016/j.celrep.2015.08.037; Rusan M, 2018, CANCER DISCOV, V8, P59, DOI 10.1158/2159-8290.CD-17-0461; Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134; Scaltriti M, 2011, P NATL ACAD SCI USA, V108, P3761, DOI 10.1073/pnas.1014835108; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Stoeck A, 2014, CANCER DISCOV, V4, P1154, DOI 10.1158/2159-8290.CD-13-0830; Stuhlmiller TJ, 2014, CLIN PHARMACOL THER, V95, P413, DOI 10.1038/clpt.2014.8; Stuhlmiller TJ, 2015, CELL REP, V11, P390, DOI 10.1016/j.celrep.2015.03.037; Wang Q, 2016, ONCOGENE, V35, P3607, DOI 10.1038/onc.2015.406; Wang YB, 2015, CELL, V163, P174, DOI 10.1016/j.cell.2015.08.063; Zhang SQ, 2002, MOL CELL BIOL, V22, P4062, DOI 10.1128/MCB.22.12.4062-4072.2002; Zhuang GL, 2010, CANCER RES, V70, P299, DOI 10.1158/0008-5472.CAN-09-1845	52	30	31	3	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	1					50	63		10.1038/s41388-019-0953-9	http://dx.doi.org/10.1038/s41388-019-0953-9			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG3NM	31462705	hybrid, Green Published			2022-12-28	WOS:000509849200005
J	Ko, YS; Bae, JA; Kim, KY; Kim, SJ; Sun, EG; Lee, KH; Kim, N; Kang, H; Seo, YW; Kim, H; Chung, IJ; Kim, KK				Ko, Yoo-Seung; Bae, Jeong A.; Kim, Keon Young; Kim, Sung Jin; Sun, Eun Gene; Lee, Kyung Hwa; Kim, Nacksung; Kang, Hyuno; Seo, Young-Woo; Kim, Hangun; Chung, Ik Joo; Kim, Kyung Keun			MYO1D binds with kinase domain of the EGFR family to anchor them to plasma membrane before their activation and contributes carcinogenesis	ONCOGENE			English	Article							NONMUSCLE MYOSIN-II; UNCONVENTIONAL MYOSINS; NEGATIVE REGULATION; CARGO RECOGNITION; RECEPTOR; MOTOR; RESISTANCE; KITENIN; SIGNAL; INVASIVENESS	The cell surface receptor tyrosine kinase (RTK) exists in a dynamic state, however, it remains unknown how single membrane-spanning RTK proteins are retained in the plasma membrane before their activation. This study was undertaken to investigate how RTK proteins are anchored in the plasma membrane before they bind with their respective extracellular ligands for activation through protein-protein interaction, co-localization, and functional phenotype studies. Here we show that unconventional myosin-I MYO1D functions to hold members of the EGFR family (except ErbB3) at the plasma membrane. MYO1D binds only with unphosphorylated EGFRs and anchors them to underlying actin cytoskeleton at the plasma membrane. The C-terminal end region of the MYO1D tail domain containing a beta-meander motif is critical for direct binding with kinase domain of the EGFR family, and expression of the tail domain alone suppresses the oncogenic action of full-length MYO1D. Overexpressed MYO1D increases colorectal and breast cancer cell motility and viability through upregulating EGFR level, and thereby promotes colorectal tumor progression in a syngeneic mouse model. MYO1D is upregulated in human colorectal cancer tissues from advanced stages. Collectively, molecular motor MYO1D plays a distinct role in the dynamic regulation of EGFR family levels by holding them at the plasma membrane before their activation. Overexpressed MYO1D contributes to colorectal carcinogenesis possibly as a novel oncogene and thus may serve as an additional target for suppression of RTK signaling in cancer treatment.	[Ko, Yoo-Seung; Bae, Jeong A.; Kim, Keon Young; Kim, Sung Jin; Kim, Nacksung; Kim, Kyung Keun] Chonnam Natl Univ, Dept Pharmacol, Med Sch, Gwangju 61469, South Korea; [Sun, Eun Gene; Chung, Ik Joo] Chonnam Natl Univ, Dept Hematol Oncol, Med Sch, Gwangju 61469, South Korea; [Lee, Kyung Hwa] Chonnam Natl Univ, Dept Pathol, Med Sch, Gwangju 61469, South Korea; [Kang, Hyuno; Seo, Young-Woo] Korea Basic Sci Inst, Gwangju Ctr, Gwangju 61186, South Korea; [Kim, Hangun] Sunchon Natl Univ, Coll Pharm, Sunchon 57922, North Korea	Chonnam National University; Chonnam National University; Chonnam National University; Korea Basic Science Institute (KBSI)	Kim, KK (corresponding author), Chonnam Natl Univ, Dept Pharmacol, Med Sch, Gwangju 61469, South Korea.	kimkk@chonnam.ac.kr		, Eun-Gene Sun/0000-0002-3396-6966; Kim, Keon Young/0000-0001-9703-9195	National Research Foundation of Korea - Korea government (MSIP) [NRF-2018R1A5A2024181, NRF-2017R1A2B2002040]; National Research Foundation of Korea [NRF-2017R1A6A3A11031332, NRF-2015R1C1A2A01052689]	National Research Foundation of Korea - Korea government (MSIP); National Research Foundation of Korea(National Research Foundation of Korea)	This work was supported by the National Research Foundation of Korea grant (NRF-2018R1A5A2024181, NRF-2017R1A2B2002040) funded by the Korea government (MSIP). KYS (NRF-2017R1A6A3A11031332) and JAB (NRF-2015R1C1A2A01052689) were partly supported by the by the National Research Foundation of Korea grant.	ADAMS RJ, 1989, NATURE, V340, P565, DOI 10.1038/340565a0; Almeida CG, 2011, NAT CELL BIOL, V13, P779, DOI 10.1038/ncb2262; Arif E, 2011, MOL CELL BIOL, V31, P2134, DOI 10.1128/MCB.05051-11; Bae JA, 2014, CLIN CANCER RES, V20, P4115, DOI 10.1158/1078-0432.CCR-13-2863; BAHLER M, 1994, J CELL BIOL, V126, P375, DOI 10.1083/jcb.126.2.375; Barylko B, 2005, ACTA BIOCHIM POL, V52, P373; Barylko B, 2000, BBA-MOL CELL RES, V1496, P23, DOI 10.1016/S0167-4889(00)00006-9; Bergeron JJM, 2016, ANNU REV BIOCHEM, V85, P573, DOI 10.1146/annurev-biochem-060815-014659; Bose A, 2002, NATURE, V420, P821, DOI 10.1038/nature01246; Casaletto JB, 2012, NAT REV CANCER, V12, P386, DOI 10.1038/nrc3277; Chandrasekar I, 2014, TRAFFIC, V15, P418, DOI 10.1111/tra.12152; Dutta Dipannita, 2012, Cell Logist, V2, P203; Fang Y, 2015, BIOSENSORS-BASEL, V5, P223, DOI 10.3390/bios5020223; Fry WHD, 2009, EXP CELL RES, V315, P697, DOI 10.1016/j.yexcr.2008.07.022; Gillespie PG, 2001, J CELL BIOL, V155, P703, DOI 10.1083/jcb.200110032; Goh LK, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a017459; Hegan PS, 2015, CYTOSKELETON, V72, P503, DOI 10.1002/cm.21259; Hokanson DE, 2006, MOL BIOL CELL, V17, P4856, DOI 10.1091/mbc.e06-05-0449; Huber LA, 2000, TRAFFIC, V1, P494, DOI 10.1034/j.1600-0854.2000.010607.x; Kho DH, 2009, GUT, V58, P509, DOI 10.1136/gut.2008.150938; Kim JH, 2012, J BIOL CHEM, V287, P27345, DOI 10.1074/jbc.M111.304824; Komaba S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138012; Krendel M, 2005, PHYSIOLOGY, V20, P239, DOI 10.1152/physiol.00014.2005; Lee JH, 2005, CANCER RES, V65, P8993, DOI 10.1158/0008-5472.CAN-05-0590; Lee JH, 2004, CANCER RES, V64, P4235, DOI 10.1158/0008-5472.CAN-04-0275; Li JC, 2016, TRAFFIC, V17, P822, DOI 10.1111/tra.12383; Lu Q, 2014, ACCOUNTS CHEM RES, V47, P3061, DOI 10.1021/ar500216z; Macia E, 2006, DEV CELL, V10, P839, DOI 10.1016/j.devcel.2006.04.002; Maina F, 2014, CURR MED CHEM, V21, P1607, DOI 10.2174/09298673113209990222; Mazerik JN, 2014, BIOPHYS J, V106, P649, DOI 10.1016/j.bpj.2013.12.038; McConnell RE, 2010, TRENDS CELL BIOL, V20, P418, DOI 10.1016/j.tcb.2010.04.004; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; Ouderkirk JL, 2014, CYTOSKELETON, V71, P447, DOI 10.1002/cm.21187; Ouyang XM, 1999, J CELL PHYSIOL, V179, P52, DOI 10.1002/(SICI)1097-4652(199904)179:1<52::AID-JCP7>3.0.CO;2-M; Patino-Lopez G, 2010, J BIOL CHEM, V285, P8675, DOI 10.1074/jbc.M109.086959; Rosenzweig SA, 2012, BIOCHEM PHARMACOL, V83, P1041, DOI 10.1016/j.bcp.2011.12.025; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Sweeney C, 2004, BRIT J CANCER, V90, P289, DOI 10.1038/sj.bjc.6601500; Tiwari A, 2013, AM J PHYSIOL-HEART C, V304, pH687, DOI 10.1152/ajpheart.00744.2012; Valley CC, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a020735; Visuttijai K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164063; Vouri M, 2017, CANCER RES, V77, P2775, DOI 10.1158/0008-5472.CAN-16-2675; Wheeler DL, 2010, NAT REV CLIN ONCOL, V7, P493, DOI 10.1038/nrclinonc.2010.97; Xu AM, 2010, CANCER RES, V70, P3857, DOI 10.1158/0008-5472.CAN-10-0163; Yamazaki R, 2016, ASN NEURO, V8, DOI 10.1177/1759091416669609; Zeng FH, 2009, FASEB J, V23, P1935, DOI 10.1096/fj.08-121947; Zinchuk V, 2013, SCI REP-UK, V3, DOI 10.1038/srep01365	47	8	8	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2019	38	49					7416	7432		10.1038/s41388-019-0954-8	http://dx.doi.org/10.1038/s41388-019-0954-8			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JT4BN	31420606				2022-12-28	WOS:000500936600004
J	Caslini, C; Hong, S; Ban, YJ; Chen, XS; Ince, TA				Caslini, Corrado; Hong, Sunhwa; Ban, Yuguang J.; Chen, Xi S.; Ince, Tan A.			HDAC7 regulates histone 3 lysine 27 acetylation and transcriptional activity at super-enhancer-associated genes in breast cancer stem cells	ONCOGENE			English	Article							DEACETYLASE INHIBITORS; EXPRESSION; MATURATION; REPRESSION; PROMOTER; IDENTITY; ROLES; TIP60	Chromatin regulation through histone modifications plays an essential role in coordinated expression of multiple genes. Alterations in chromatin induced by histone modifiers and readers regulate critical transcriptional programs involved in both normal development and tumor differentiation. Recently, we identified that histone deacetylases HDAC1 and HDAC7 are necessary to maintain cancer stem cells (CSCs) in both breast and ovarian tumors. Here, we sought to investigate the CSC-specific function of HDAC1 and HDAC7 mechanistically by using a stem-like breast cancer (BrCa) cell model BPLER and matched nonstem tumor cell (nsTC)-like HMLER, along with conventional BrCa cell lines with different CSC enrichment levels. We found that HDAC1 and HDAC3 inhibition or knockdown results in HDAC7 downregulation, which is associated with a decrease in histone 3 lysine 27 acetylation (H3K27ac) at transcription start sites (TSS) and super-enhancers (SEs) prominently in stem-like BrCa cells. Importantly, these changes in chromatin landscape also correlate with the repression of many SE-associated oncogenes, including c-MYC, CD44, CDKN1B, SLUG, VDR, SMAD3, VEGFA, and XBP1. In stem-like BrCa cells, HDAC7 binds near TSS and to SEs of these oncogenes where it appears to contribute to both H3K27ac and transcriptional regulation. These results suggest that HDAC7 inactivation, directly or through inhibition of HDAC1 and HDAC3, can result in the inhibition of the CSC phenotype by downregulating multiple SE-associated oncogenes. The CSC selective nature of this mechanism and the prospect of inhibiting multiple oncogenes simultaneously makes development of HDAC7 specific inhibitors a compelling objective.	[Caslini, Corrado; Hong, Sunhwa; Ban, Yuguang J.; Chen, Xi S.; Ince, Tan A.] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Biomed Res Bldg, Miami, FL 33136 USA; [Ban, Yuguang J.; Chen, Xi S.] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA; [Ince, Tan A.] Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA; [Ince, Tan A.] Univ Miami, Miller Sch Med, Interdisciplinary Stem Cell Inst, Miami, FL 33136 USA	University of Miami; University of Miami; University of Miami; University of Miami	Caslini, C; Ince, TA (corresponding author), Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Biomed Res Bldg, Miami, FL 33136 USA.; Ince, TA (corresponding author), Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA.; Ince, TA (corresponding author), Univ Miami, Miller Sch Med, Interdisciplinary Stem Cell Inst, Miami, FL 33136 USA.	ccaslini@med.miami.edu; TInce@med.miami.edu	Caslini, Corrado/W-6123-2019	Caslini, Corrado/0000-0001-8326-8368; Ban, Yuguang/0000-0002-2874-0647; Ince, Tan/0000-0003-0315-6425	Breast Cancer Research Foundation (NY); Florida Breast Cancer Foundation (FL); Sylvester Comprehensive Cancer Center	Breast Cancer Research Foundation (NY); Florida Breast Cancer Foundation (FL); Sylvester Comprehensive Cancer Center	We gratefully acknowledge the Sylvester Comprehensive Cancer Center, Onco-Genomics Shared Resource for ChIP, and RNA sequencing services. This work was funded by grants to TAI from Breast Cancer Research Foundation (NY), Florida Breast Cancer Foundation (FL), and Sylvester Comprehensive Cancer Center.	Afgan E, 2018, NUCLEIC ACIDS RES, V46, pW537, DOI 10.1093/nar/gky379; Ahn MY, 2017, J ORAL PATHOL MED, V46, P276, DOI 10.1111/jop.12560; Ai W, 2007, NUCLEIC ACIDS RES, V35, P6137, DOI 10.1093/nar/gkm656; Aude-Garcia C, 2010, BIOCHEM J, V430, P237, DOI 10.1042/BJ20100131; Barneda-Zahonero B, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.594; Caslini C, 2006, ONCOGENE, V25, P5446, DOI 10.1038/sj.onc.1209533; Dokmanovic M, 2007, MOL CANCER THER, V6, P2525, DOI 10.1158/1535-7163.MCT-07-0251; Dressel U, 2001, J BIOL CHEM, V276, P17007, DOI 10.1074/jbc.M101508200; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; Fischle W, 2001, J BIOL CHEM, V276, P35826, DOI 10.1074/jbc.M104935200; Gao S, 2018, CLIN TRANSL ONCOL, V20, P703, DOI 10.1007/s12094-017-1770-7; Glaser KB, 2003, MOL CANCER THER, V2, P151; Greer CB, 2015, CELL REP, V13, P1444, DOI 10.1016/j.celrep.2015.10.013; Halkidou K, 2004, PROSTATE, V59, P177, DOI 10.1002/pros.20022; Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053; Hull EE, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/8797206; Ince TA, 2007, CANCER CELL, V12, P160, DOI 10.1016/j.ccr.2007.06.013; Jensen ED, 2008, J BONE MINER RES, V23, P361, DOI 10.1359/JBMR.071104; Kaletsch A, 2018, CLIN EPIGENETICS, V10, DOI 10.1186/s13148-018-0531-y; Kao HY, 2001, J BIOL CHEM, V276, P47496, DOI 10.1074/jbc.M107631200; Kato H, 2004, J BIOL CHEM, V279, P41966, DOI 10.1074/jbc.M406320200; Kim YJ, 2013, ONCOGENE, V32, P2828, DOI 10.1038/onc.2013.32; Laugesen A, 2014, CELL STEM CELL, V14, P735, DOI 10.1016/j.stem.2014.05.006; Lei YB, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0736-2; Li B, 2007, P NATL ACAD SCI USA, V104, P4571, DOI 10.1073/pnas.0700298104; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; Ma C, 2011, J BIOL CHEM, V286, P4819, DOI 10.1074/jbc.M110.146860; Malik S, 2010, MOL CELL BIOL, V30, P399, DOI 10.1128/MCB.00907-09; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Morrison BE, 2006, MOL CELL BIOL, V26, P3550, DOI 10.1128/MCB.26.9.3550-3564.2006; Pasini D, 2010, NUCLEIC ACIDS RES, V38, P4958, DOI 10.1093/nar/gkq244; Rickels R, 2018, TRENDS CELL BIOL, V28, P608, DOI 10.1016/j.tcb.2018.04.003; Sanchez GJ, 2018, NUCLEIC ACIDS RES, V46, P1756, DOI 10.1093/nar/gkx1225; Seto E, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a018713; Singh J, 2002, ONCOGENE, V21, P1812, DOI 10.1038/sj.onc.1205252; Toh Y, 2003, ONCOL REP, V10, P333; Whyte WA, 2013, CELL, V153, P307, DOI 10.1016/j.cell.2013.03.035; Whyte WA, 2012, NATURE, V482, P221, DOI 10.1038/nature10805; Wilson AJ, 2006, J BIOL CHEM, V281, P13548, DOI 10.1074/jbc.M510023200; Witt AE, 2017, ONCOGENE, V36, P1707, DOI 10.1038/onc.2016.337; Xiao H, 2003, J BIOL CHEM, V278, P11197, DOI 10.1074/jbc.M210816200; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245; Yano M, 2018, ONCOL LETT, V15, P3524, DOI 10.3892/ol.2018.7726; Yu Y, 2017, CLIN TRANSL ONCOL, V19, P1045, DOI 10.1007/s12094-017-1639-9; Zhu CH, 2011, J MOL MED, V89, P279, DOI 10.1007/s00109-010-0701-7	45	46	46	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2019	38	39					6599	6614		10.1038/s41388-019-0897-0	http://dx.doi.org/10.1038/s41388-019-0897-0			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JA5AQ	31375747	hybrid			2022-12-28	WOS:000487856000003
J	Short, SP; Barrett, CW; Stengel, KR; Revetta, FL; Choksi, YA; Coburn, LA; Lintel, MK; McDonough, EM; Washington, MK; Wilson, KT; Prokhortchouk, E; Chen, X; Hiebert, SW; Reynolds, AB; Williams, CS				Short, Sarah P.; Barrett, Caitlyn W.; Stengel, Kristy R.; Revetta, Frank L.; Choksi, Yash A.; Coburn, Lori A.; Lintel, Mary K.; McDonough, Elizabeth M.; Washington, M. Kay; Wilson, Keith T.; Prokhortchouk, Egor; Chen, Xi; Hiebert, Scott W.; Reynolds, Albert B.; Williams, Christopher S.			Kaiso is required for MTG16-dependent effects on colitis-associated carcinoma	ONCOGENE			English	Article							HUMAN BREAST; STEM-CELLS; IN-VITRO; GENE; DNA; CANCER; EXPRESSION; COLON; MTG16; BETA	The myeloid translocation gene family member MTG16 is a transcriptional corepressor that relies on the DNA-binding ability of other proteins to determine specificity. One such protein is the ZBTB family member Kaiso, and the MTG16:Kaiso interaction is necessary for repression of Kaiso target genes, such as matrix metalloproteinase-7. Using the azoxymethane and dextran sodium sulfate (AOM/DSS) murine model of colitis-associated carcinoma, we previously determined that MTG16 loss accelerates tumorigenesis and inflammation. However, it was unknown whether this effect was modified by Kaiso-dependent transcriptional repression. To test for a genetic interaction between MTG16 and Kaiso in inflammatory carcinogenesis, we subjected single and double knockout (DKO) mice to the AOM/DSS protocol. Mtg16(-/-) mice demonstrated increased colitis and tumor burden; in contrast, disease severity in Kaiso(-/-) mice was equivalent to wild-type controls. Surprisingly, Kaiso deficiency in the context of MTG16 loss reversed injury and pro-tumorigenic responses in the intestinal epithelium following AOM/DSS treatment, and tumor numbers were returned to near to wild-type levels. Transcriptomic analysis of non-tumor colon tissue demonstrated that changes induced by MTG16 loss were widely mitigated by concurrent Kaiso loss, and DKO mice demonstrated downregulation of metabolism and cytokine-associated gene sets with concurrent activation of DNA damage checkpoint pathways as compared with Mtg16(-/-). Further, Kaiso knockdown in intestinal enteroids reduced stem- and WNT-associated phenotypes, thus abrogating the induction of these pathways observed in Mtg16(-/-) samples. Together, these data suggest that Kaiso modifies MTG16-driven inflammation and tumorigenesis and suggests that Kaiso deregulation contributes to MTG16-dependent colitis and CAC phenotypes.	[Short, Sarah P.; Barrett, Caitlyn W.; Choksi, Yash A.; Coburn, Lori A.; Lintel, Mary K.; McDonough, Elizabeth M.; Wilson, Keith T.; Williams, Christopher S.] Vanderbilt Univ, Med Ctr, Dept Med, Div Gastroenterol, Nashville, TN 37232 USA; [Short, Sarah P.; Barrett, Caitlyn W.; Choksi, Yash A.; Wilson, Keith T.; Reynolds, Albert B.; Williams, Christopher S.] Vanderbilt Univ, Program Canc Biol, Nashville, TN 37232 USA; [Stengel, Kristy R.; Hiebert, Scott W.] Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA; [Revetta, Frank L.; Washington, M. Kay; Wilson, Keith T.] Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Med Ctr, Nashville, TN 37232 USA; [Choksi, Yash A.; Coburn, Lori A.; Wilson, Keith T.; Williams, Christopher S.] Vet Affairs Tennessee Valley Hlth Care Syst, Nashville, TN 37232 USA; [Coburn, Lori A.; Wilson, Keith T.; Williams, Christopher S.] Vanderbilt Univ, Ctr Mucosal Inflammat & Canc, Med Ctr, Nashville, TN 37232 USA; [McDonough, Elizabeth M.] Our Lady Lake Childrens Hosp, Dept Pediat, Div Gastroenterol, Baton Rouge, TN 70808 USA; [Wilson, Keith T.; Hiebert, Scott W.; Reynolds, Albert B.; Williams, Christopher S.] Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; [Prokhortchouk, Egor] Russian Acad Sci, Inst Bioengn, Res Ctr Biotechnol, Moscow, Russia; [Chen, Xi] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA; [Chen, Xi] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; Vanderbilt University; Research Center of Biotechnology RAS; Russian Academy of Sciences; University of Miami; University of Miami	Williams, CS (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Div Gastroenterol, Nashville, TN 37232 USA.; Williams, CS (corresponding author), Vanderbilt Univ, Program Canc Biol, Nashville, TN 37232 USA.; Williams, CS (corresponding author), Vet Affairs Tennessee Valley Hlth Care Syst, Nashville, TN 37232 USA.; Williams, CS (corresponding author), Vanderbilt Univ, Ctr Mucosal Inflammat & Canc, Med Ctr, Nashville, TN 37232 USA.; Williams, CS (corresponding author), Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA.	Christopher.williams@vanderbilt.edu	Prokhortchouk, Egor/I-9108-2014; Williams, Christopher/W-3524-2019	Williams, Christopher/0000-0002-1541-579X; Short, Sarah/0000-0001-9606-7370; Coburn, Lori/0000-0003-3249-9806; Wilson, Keith/0000-0003-4421-1830; Stengel, Kristy/0000-0002-8330-5744	National Institutes of Health [R01DK099204, R01AT004821, R01CA178030, 1F31CA167920, F32DK108492]; Federal Research Center "Fundamentals of Biotechnology" budget [01201371085]; Office of Medical Research, Department of Veterans Affairs [1I01BX001426, 1I01BX001453, 1IK2BX002126]; NIH [P30DK058404]; NATIONAL CANCER INSTITUTE [R01CA178030, R01CA164605] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [R01AT004821] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK099204, P30DK058404, F32DK108492] Funding Source: NIH RePORTER; Veterans Affairs [IK2BX002126, I01BX001426, I01BX001453] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Federal Research Center "Fundamentals of Biotechnology" budget; Office of Medical Research, Department of Veterans Affairs(US Department of Veterans Affairs); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Veterans Affairs(US Department of Veterans Affairs)	National Institutes of Health (R01DK099204 to CSW; R01AT004821 to KTW; R01CA178030 to SWH; 1F31CA167920 to CWB; F32DK108492 to SPS); the Federal Research Center "Fundamentals of Biotechnology" budget (No. 01201371085 to EP); Office of Medical Research, Department of Veterans Affairs (1I01BX001426 to CSW; 1I01BX001453 to KTW; 1IK2BX002126 to LAC). Additional support was provided by the NIH grant P30DK058404 (Vanderbilt Digestive Disease Research Center).	Barrett CW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051205; Barrett CW, 2011, CANCER RES, V71, P1302, DOI 10.1158/0008-5472.CAN-10-3317; Becker C, 2006, NAT PROTOC, V1, P2900, DOI 10.1038/nprot.2006.446; Becker C, 2005, GUT, V54, P950, DOI 10.1136/gut.2004.061283; Bergstrom KSB, 2008, INFECT IMMUN, V76, P796, DOI 10.1128/IAI.00093-07; Blattler A, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756-8935-6-13; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Brown JJ, 2018, J VIROL, V92, DOI 10.1128/JVI.02062-17; Buchert M, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000816; Buck-Koehntop BA, 2012, FEBS LETT, V586, P734, DOI 10.1016/j.febslet.2012.01.045; Chaudhary R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074160; Christie M, 2013, ONCOGENE, V32, P4675, DOI 10.1038/onc.2012.486; Daniel JM, 1999, MOL CELL BIOL, V19, P3614; Davis JN, 2003, GENE, V303, P1, DOI 10.1016/S0378-1119(02)01172-1; Donaldson IJ, 2012, NUCLEIC ACIDS RES, V40, P3990, DOI 10.1093/nar/gkr1240; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Filion GJP, 2006, MOL CELL BIOL, V26, P169, DOI 10.1128/MCB.26.1.169-181.2006; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Heijmans J, 2013, CELL REP, V3, P1128, DOI 10.1016/j.celrep.2013.02.031; Kim SW, 2004, NAT CELL BIOL, V6, P1212, DOI 10.1038/ncb1191; Koch S, 2011, GASTROENTEROLOGY, V141, P259, DOI 10.1053/j.gastro.2011.03.043; Kochetkova M, 2002, CANCER RES, V62, P4599; Li Q, 2005, CANCER RES, V65, P8622, DOI 10.1158/0008-5472.CAN-05-2145; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Lopes EC, 2008, CANCER RES, V68, P7258, DOI 10.1158/0008-5472.CAN-08-0344; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Martinez JA, 2006, GASTROENTEROLOGY, V131, P579, DOI 10.1053/j.gastro.2006.06.009; MCCORMICK DA, 1990, J CLIN PATHOL, V43, P143, DOI 10.1136/jcp.43.2.143; McDonough EM, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.78210; Miyoshi H, 2013, NAT PROTOC, V8, P2471, DOI 10.1038/nprot.2013.153; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nowarski R, 2015, CELL, V163, P1444, DOI 10.1016/j.cell.2015.10.072; Park JI, 2005, DEV CELL, V8, P843, DOI 10.1016/j.devcel.2005.04.010; Pierre CC, 2015, BBA-MOL BASIS DIS, V1852, P1846, DOI 10.1016/j.bbadis.2015.06.011; Poindexter SV, 2015, AM J PHYSIOL-GASTR L, V308, pG562, DOI 10.1152/ajpgi.00253.2014; Pozner A, 2016, J BIOL CHEM, V291, P24538, DOI 10.1074/jbc.M116.746370; Prokhortchouk A, 2006, MOL CELL BIOL, V26, P199, DOI 10.1128/MCB.26.1.199-208.2006; Raghav SK, 2012, MOL CELL, V46, P335, DOI 10.1016/j.molcel.2012.03.017; Reddy VK, 2016, STEM CELLS, V34, P1626, DOI 10.1002/stem.2307; Rudolph KL, 2009, GASTROENTEROLOGY, V137, P754, DOI 10.1053/j.gastro.2009.07.037; Ruzov A, 2009, DEVELOPMENT, V136, P729, DOI 10.1242/dev.025569; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Spring CM, 2005, EXP CELL RES, V305, P253, DOI 10.1016/j.yexcr.2005.01.007; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Syljuasen RG, 1999, CANCER RES, V59, P1008; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Williams CS, 2013, GUT, V62, P1446, DOI 10.1136/gutjnl-2011-301439; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441	51	8	8	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2019	38	25					5091	5106		10.1038/s41388-019-0777-7	http://dx.doi.org/10.1038/s41388-019-0777-7			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IE1KY	30858547	Green Accepted			2022-12-28	WOS:000472145900015
J	Venkadakrishnan, VB; DePriest, AD; Kumari, S; Senapati, D; Ben-Salem, S; Su, YX; Mudduluru, G; Hu, Q; Cortes, E; Pop, E; Mohler, JL; Azabdaftari, G; Attwood, K; Shah, RB; Jamieson, C; Dehm, SM; Magi-Galluzzi, C; Klein, E; Sharifi, N; Liu, S; Heemers, HV				Venkadakrishnan, Varadha Balaji; DePriest, Adam D.; Kumari, Sangeeta; Senapati, Dhirodatta; Ben-Salem, Salma; Su, Yixue; Mudduluru, Giridhar; Hu, Qiang; Cortes, Eduardo; Pop, Elena; Mohler, James L.; Azabdaftari, Gissou; Attwood, Kristopher; Shah, Rajal B.; Jamieson, Christina; Dehm, Scott M.; Magi-Galluzzi, Cristina; Klein, Eric; Sharifi, Nima; Liu, Song; Heemers, Hannelore V.			Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy	ONCOGENE			English	Article							LESTAURTINIB CEP701; RECEPTOR; INHIBITOR; PHOSPHORYLATION; INDUCTION; RESISTANT; CEP-701; TRIAL; IDENTIFICATION; PROLIFERATION	Sustained reliance on androgen receptor (AR) after failure of AR-targeting androgen deprivation therapy (ADT) prevents effective treatment of castration-recurrent (CR) prostate cancer (CaP). Interfering with the molecular machinery by which AR drives CaP progression may be an alternative therapeutic strategy but its feasibility remains to be tested. Here, we explore targeting the mechanism by which AR, via RhoA, conveys androgen-responsiveness to serum response factor (SRF), which controls aggressive CaP behavior and is maintained in CR-CaP. Following a siRNA screen and candidate gene approach, RNA-Seq studies confirmed that the RhoA effector Protein Kinase N1 (PKN1) transduces androgen-responsiveness to SRF. Androgen treatment induced SRF-PKN1 interaction, and PKN1 knockdown or overexpression severely impaired or stimulated, respectively, androgen regulation of SRF target genes. PKN1 overexpression occurred during clinical CR-CaP progression, and hastened CaP growth and shortened CR-CaP survival in orthotopic CaP xenografts. PKN1's effects on SRF relied on its kinase domain. The multikinase inhibitor lestaurtinib inhibited PKN1 action and preferentially affected androgen regulation of SRF over direct AR target genes. In a CR-CaP patient-derived xenograft, expression of SRF target genes was maintained while AR target gene expression declined and proliferative gene expression increased. PKN1 inhibition decreased viability of CaP cells before and after ADT. In patient-derived CaP explants, lestaurtinib increased AR target gene expression but did not significantly alter SRF target gene or proliferative gene expression. These results provide proof-of-principle for selective forms of ADT that preferentially target different fractions of AR's transcriptional output to inhibit CaP growth.	[Venkadakrishnan, Varadha Balaji; Kumari, Sangeeta; Senapati, Dhirodatta; Ben-Salem, Salma; Su, Yixue; Mudduluru, Giridhar; Sharifi, Nima; Heemers, Hannelore V.] Cleveland Clin, Dept Canc Biol, Cleveland, OH 44106 USA; [Venkadakrishnan, Varadha Balaji] Cleveland State Univ, Dept Biol Geol & Environm Sci, Cleveland, OH 44115 USA; [DePriest, Adam D.] Roswell Pk Comprehens Canc Ctr, Dept Canc Genet, Buffalo, NY USA; [Hu, Qiang; Cortes, Eduardo; Attwood, Kristopher; Liu, Song] Roswell Pk Comprehens Canc Ctr, Dept Biostat & Bioinformat, Buffalo, NY USA; [Pop, Elena; Mohler, James L.; Azabdaftari, Gissou] Roswell Pk Comprehens Canc Ctr, Dept Urol, Buffalo, NY USA; [Azabdaftari, Gissou] Roswell Pk Comprehens Canc Ctr, Dept Pathol & Lab Med, Buffalo, NY USA; [Shah, Rajal B.; Magi-Galluzzi, Cristina] Cleveland Clin, Dept Anat Pathol, Cleveland, OH 44106 USA; [Jamieson, Christina] Univ Calif San Diego, Dept Urol, La Jolla, CA 92093 USA; [Dehm, Scott M.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA; [Dehm, Scott M.] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; [Dehm, Scott M.] Univ Minnesota, Dept Urol, Minneapolis, MN USA; [Klein, Eric; Sharifi, Nima; Heemers, Hannelore V.] Cleveland Clin, Dept Urol, Cleveland, OH 44106 USA; [Sharifi, Nima; Heemers, Hannelore V.] Cleveland Clin, Dept Hematol Med Oncol, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; University System of Ohio; Cleveland State University; Cleveland Clinic Foundation; University of California System; University of California San Diego; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Heemers, HV (corresponding author), Cleveland Clin, Dept Canc Biol, Cleveland, OH 44106 USA.; Heemers, HV (corresponding author), Cleveland Clin, Dept Urol, Cleveland, OH 44106 USA.; Heemers, HV (corresponding author), Cleveland Clin, Dept Hematol Med Oncol, Cleveland, OH 44106 USA.	heemerh@ccf.org	Magi-Galluzzi, Cristina/AAW-6484-2020; Ben-Salem, Salma/E-1702-2016; Kumari, Sangeeta/AAB-7154-2022; Cortes, Eduardo/AAW-8005-2021	Ben-Salem, Salma/0000-0001-5023-6781; Kumari, Sangeeta/0000-0002-0692-0452; Klein, Eric A/0000-0002-1783-0698	DOD PCRP award [W81XWH-16-1-0404]; NIH NCI [CA166440, CA174777, CA077739, CA232979, CA016056]; NATIONAL CANCER INSTITUTE [P30CA016056, R01CA174777, R01CA166440, U24CA232979] Funding Source: NIH RePORTER	DOD PCRP award; NIH NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	These studies were supported by DOD PCRP award W81XWH-16-1-0404 (HVH), NIH NCI grants CA166440 (HVH), CA174777 (SMD), CA077739 (JLM), CA232979 (SL) and CA016056 (JLM and SL).	Attard G, 2018, J CLIN ONCOL, V36, P2639, DOI 10.1200/JCO.2018.77.9827; Centenera MM, 2013, NAT REV UROL, V10, P483, DOI 10.1038/nrurol.2013.126; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Collins C, 2007, CANCER BIOL THER, V6, P1360; Dai C, 2017, COLD SPRING HARB PER, V7; Esnault C, 2014, GENE DEV, V28, P943, DOI 10.1101/gad.239327.114; George DJ, 1999, CANCER RES, V59, P2395; Godebu E, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0275-1; Gualdrini F, 2016, MOL CELL, V64, P1048, DOI 10.1016/j.molcel.2016.10.016; He AB, 2011, P NATL ACAD SCI USA, V108, P5632, DOI 10.1073/pnas.1016959108; Heemers HV, 2007, ENDOCR REV, V28, P778, DOI 10.1210/er.2007-0019; Heemers HV, 2007, CANCER RES, V67, P10592, DOI 10.1158/0008-5472.CAN-07-1917; Heemers HV, 2013, CURR DRUG TARGETS, V14, P481; Heemers HV, 2011, CANCER RES, V71, P1978, DOI 10.1158/0008-5472.CAN-10-2512; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Hexner EO, 2008, BLOOD, V111, P5663, DOI 10.1182/blood-2007-04-083402; Itkonen HM, 2017, ONCOTARGET, V8, P38264, DOI 10.18632/oncotarget.16123; Iyer R, 2010, CLIN CANCER RES, V16, P1478, DOI 10.1158/1078-0432.CCR-09-1531; Jilg CA, 2014, ONCOTARGET, V5, P12646, DOI 10.18632/oncotarget.2653; Kajimoto K, 2011, AM J PHYSIOL-HEART C, V300, pH191, DOI 10.1152/ajpheart.00232.2010; Karantanos T, 2015, EUR UROL, V67, P470, DOI 10.1016/j.eururo.2014.09.049; Kim JY, 2014, MOL CELL, V54, P613, DOI 10.1016/j.molcel.2014.03.043; Klaeger S, 2017, SCIENCE, V358, DOI 10.1126/science.aan4368; Knapper S, 2006, BLOOD, V108, P3262, DOI 10.1182/blood-2006-04-015560; Kohler J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034973; Kumari S, 2017, ENDOCR-RELAT CANCER, V24, pR275, DOI 10.1530/ERC-17-0121; Labbe DP, 2017, CLIN CANCER RES, V23, P7072, DOI 10.1158/1078-0432.CCR-17-0413; Li JN, 2017, ELIFE, V6, DOI 10.7554/eLife.20183; Li ZF, 2016, NATURE, V533, P547, DOI 10.1038/nature17954; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Liu S, 2017, ELIFE, V6, DOI 10.7554/eLife.28482.001; Luo J, 2018, EUR UROL, V73, P715, DOI 10.1016/j.eururo.2017.11.038; Magee JA, 2006, ENDOCRINOLOGY, V147, P590, DOI 10.1210/en.2005-1001; Marshall JL, 2005, INVEST NEW DRUG, V23, P31, DOI 10.1023/B:DRUG.0000047103.64335.b0; Metzger E, 2003, EMBO J, V22, P270, DOI 10.1093/emboj/cdg023; Metzger E, 2008, NAT CELL BIOL, V10, P53, DOI 10.1038/ncb1668; Mills IG, 2014, NAT REV CANCER, V14, P187, DOI 10.1038/nrc3678; Mitchell SH, 2000, MOL CELL ENDOCRINOL, V168, P89, DOI 10.1016/S0303-7207(00)00319-1; Miyamoto DT, 2018, CANCER DISCOV, V8, P288, DOI 10.1158/2159-8290.CD-16-1406; Miyamoto DT, 2015, SCIENCE, V349, P1351, DOI 10.1126/science.aab0917; Nakagawa T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002318; Nyquist MD, 2013, P NATL ACAD SCI USA, V110, P17492, DOI 10.1073/pnas.1308587110; O'Hurley G, 2014, PROSTATE, V74, P306, DOI 10.1002/pros.22752; O'Sullivan AG, 2017, BBA-MOL BASIS DIS, V1863, P838, DOI 10.1016/j.bbadis.2017.01.011; Olmos D, 2012, LANCET ONCOL, V13, P1114, DOI 10.1016/S1470-2045(12)70372-8; Prencipe M, 2015, PROSTATE, V75, P1704, DOI 10.1002/pros.23051; Prencipe M, 2013, PROSTATE, V73, P743, DOI 10.1002/pros.22618; Ravindranathan P, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2912; Scher HI, 2016, J CLIN ONCOL, V34, P1402, DOI 10.1200/JCO.2015.64.2702; Schlesinger J, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001313; Schmidt LJ, 2012, MOL ENDOCRINOL, V26, P716, DOI 10.1210/me.2011-1130; Shabbir M, 2010, EXPERT OPIN INV DRUG, V19, P427, DOI 10.1517/13543781003598862; Shibata H, 1999, MOL BRAIN RES, V74, P126, DOI 10.1016/S0169-328X(99)00273-9; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Sun Q, 2006, GENOME RES, V16, P197, DOI 10.1101/gr.4108706; Takanaga H, 1998, EXP CELL RES, V241, P363, DOI 10.1006/excr.1998.4060; Taniguchi T, 2001, J BIOL CHEM, V276, P10025, DOI 10.1074/jbc.M007427200; Treisman R, 1998, COLD SPRING HARB SYM, V63, P643, DOI 10.1101/sqb.1998.63.643; Viswanathan SR, 2018, CELL, V174, P433, DOI 10.1016/j.cell.2018.05.036; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; Weeraratna AT, 2001, CLIN CANCER RES, V7, P2237; Yamoah K, 2015, J CLIN ONCOL, V33, P2789, DOI 10.1200/JCO.2014.59.8912; Yu WD, 2011, CLIN CANCER RES, V17, P4355, DOI 10.1158/1078-0432.CCR-10-2858	63	6	6	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2019	38	23					4496	4511		10.1038/s41388-019-0732-7	http://dx.doi.org/10.1038/s41388-019-0732-7			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IB4KM	30742064	Green Accepted			2022-12-28	WOS:000470240300005
J	Avraham, S; Korin, B; Aviram, S; Shechter, D; Shaked, Y; Aronheim, A				Avraham, Shimrit; Korin, Ben; Aviram, Sharon; Shechter, Dvir; Shaked, Yuval; Aronheim, Ami			ATF3 and JDP2 deficiency in cancer associated fibroblasts promotes tumor growth via SDF-1 transcription	ONCOGENE			English	Article							JUN DIMERIZATION PROTEIN-2; ADAPTIVE-RESPONSE; AP-1 REPRESSOR; CELLS; MICROENVIRONMENT; ANGIOGENESIS; SDF-1/CXCL12; FACTOR-3; GENE; BETA	The activating transcription factor 3 (ATF3) and the c-Jun dimerization protein 2 (JDP2) are members of the basic leucine zipper (bZIP) family of transcription factors. These proteins share a high degree of homology and both can activate or repress transcription. Deficiency of either one of them in the non-cancer host cells was shown to reduce metastases. As ATF3 and JDP2 compensate each other's function, we studied the double deficiency of ATF3 and JDP2 in the stromal tumor microenvironment. Here, we show that mice with ATF3 and JDP2 double deficiency (designated thereafter dKO) developed larger tumors with high vascular perfusion and increased cell proliferation rate compared to wild type (WT) mice. We further identify that the underlying mechanism involves tumor associated fibroblasts which secrete high levels of stromal cell-derived factor 1 (SDF-1) in dKO fibroblasts. SDF-1 depletion in dKO fibroblasts dampened tumor growth and blood vessel perfusion. Furthermore, ATF3 and JDP2 were found to regulate SDF-1 transcription and secretion in fibroblasts, a phenomenon that is potentiated in the presence of cancer cells. Collectively, our results suggest that ATF3 and JDP2 regulate the expression of essential tumor promoting factors expressed by fibroblasts within the tumor microenvironment, and thus restrain tumor growth.	[Avraham, Shimrit; Aviram, Sharon; Shechter, Dvir; Shaked, Yuval; Aronheim, Ami] Technion Israel Inst Technol, Dept Cell Biol & Canc Sci, Rappaport Fac Med B, Haifa, Israel; [Korin, Ben] Technion Israel Inst Technol, Dept Immunol, Rappaport Fac Med B, Dept Neurosci, Haifa, Israel	Technion Israel Institute of Technology; Technion Israel Institute of Technology	Shaked, Y; Aronheim, A (corresponding author), Technion Israel Inst Technol, Dept Cell Biol & Canc Sci, Rappaport Fac Med B, Haifa, Israel.	yshaked@technion.ac.il; aronheim@technion.ac.il			Israel Science Foundation [731/17]; European Research Council H2020 [771112]; United States-Israel Binational grant [2015139]	Israel Science Foundation(Israel Science Foundation); European Research Council H2020; United States-Israel Binational grant	This research work was partially supported by the Israel Science Foundation grant #731/17 to A.A, the United States-Israel Binational grant #2015139 to A.A and the European Research Council H2020 (No. 771112) given to YS.	Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Barbarov Y, 2015, ONCOTARGET, V6, P37737, DOI 10.18632/oncotarget.5648; Bastian Seubert, 2015, HEPATOLOG, V61, P238; Bitton-Worms K, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-54; Buganim Y, 2011, CARCINOGENESIS, V32, P1749, DOI 10.1093/carcin/bgr203; Chang YS, 2017, P NATL ACAD SCI USA, V114, pE7159, DOI 10.1073/pnas.1700455114; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; Christopher W, 2003, NAT MED, V9, P8; Darlyuk-Saadon I, 2013, BIOCHIM BIOPHYS ACTA, V10, P54; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; FOLKMAN J, 1986, CANCER RES, V46, P467; Franco M, 2006, CANCER RES, V66, P3639, DOI 10.1158/0008-5472.CAN-05-3295; Franco OE, 2010, SEMIN CELL DEV BIOL, V21, P33, DOI 10.1016/j.semcdb.2009.10.010; Garcia-Moruja C, 2005, J MOL BIOL, V348, P43, DOI 10.1016/j.jmb.2005.02.016; Goel HL, 2013, NAT REV CANCER, V13, P871, DOI 10.1038/nrc3627; Hai T, 2010, GENE EXPRESSION, V15, P1, DOI 10.3727/105221610X12819686555015; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hartman MG, 2004, MOL CELL BIOL, V24, P5721, DOI 10.1128/MCB.24.13.5721-5732.2004; Heinrich R, 2004, J BIOL CHEM, V279, P5708, DOI 10.1074/jbc.M307608200; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Jin CY, 2001, FEBS LETT, V489, P34, DOI 10.1016/S0014-5793(00)02387-5; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kalfon R, 2017, INT J CARDIOL, V249, P357, DOI 10.1016/j.ijcard.2017.08.074; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Katz S, 2001, FEBS LETT, V506, P196, DOI 10.1016/S0014-5793(01)02907-6; Kojima Y, 2010, P NATL ACAD SCI USA, V107, P20009, DOI 10.1073/pnas.1013805107; Kryczek I, 2007, AM J PHYSIOL-CELL PH, V292, pC987, DOI 10.1152/ajpcell.00406.2006; Lu D, 2006, J BIOL CHEM, V281, P10473, DOI 10.1074/jbc.M509278200; Ma S, 2014, CELL DEATH DIFFER, V21, P216, DOI 10.1038/cdd.2013.158; Madlambayan GJ, 2009, BLOOD, V114, P4310, DOI 10.1182/blood-2009-03-211342; Mao Y, 2013, CANCER METAST REV, V32, P303, DOI 10.1007/s10555-012-9415-3; Mashima T, 2001, J CELL PHYSIOL, V188, P352, DOI 10.1002/jcp.1130; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Pan J, 2010, ONCOGENE, V29, P6245, DOI 10.1038/onc.2010.355; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Shaked Y, 2008, CANCER CELL, V14, P263, DOI 10.1016/j.ccr.2008.08.001; Sharon Y, 2013, JOVE-J VIS EXP, DOI 10.3791/4425; Spaeth EL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004992; Timaner M, 2016, CURR PROTOC CELL BIO, V2016; Tsai MH, 2016, GENE, V590, P193, DOI 10.1016/j.gene.2016.03.048; Urruticoechea A, 2005, J CLIN ONCOL, V23, P7212, DOI 10.1200/JCO.2005.07.501; Wardell SE, 2002, MOL CELL BIOL, V22, P5451, DOI 10.1128/MCB.22.15.5451-5466.2002; Weidenfeld-Baranboim K, 2008, NUCLEIC ACIDS RES, V36, P3608, DOI 10.1093/nar/gkn268; Wolford CC, 2013, J CLIN INVEST, V123, P2893, DOI 10.1172/JCI64410; Yin X, 2008, ONCOGENE, V27, P2118, DOI 10.1038/sj.onc.1210861	49	15	15	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2019	38	20					3812	3823		10.1038/s41388-019-0692-y	http://dx.doi.org/10.1038/s41388-019-0692-y			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HY3OI	30670778	hybrid, Green Published			2022-12-28	WOS:000468035600004
J	Ubby, I; Krueger, C; Rosato, R; Qian, W; Chang, J; Sabapathy, K				Ubby, Ifeoma; Krueger, Christian; Rosato, Roberto; Qian, Wei; Chang, Jenny; Sabapathy, Kanaga			Cancer therapeutic targeting using mutant-p53-specific siRNAs	ONCOGENE			English	Article							MUTANT P53; RNA INTERFERENCE; WILD-TYPE; GENE; MUTATIONS; TP53; GAIN; EXPRESSION; ABROGATION; GEFITINIB	Mutations in Tp53 compromise therapeutic response, due either to the dominant-negative effect over the functional wild-type allele; or as a result of the survival advantage conferred by mutant p53 to which cancer cells become addicted. Thus, targeting mutant p53 represents an effective therapeutic strategy to treat over half of all cancers. We have therefore generated a series of small-interfering-RNAs, capable of targeting four p53 hot-spot mutants which represent similar to 20% of all p53 mutations. These mutant-p53-specific siRNAs (MupSi) are highly specific in silencing the expression of the intended mutants without affecting wild-type p53. Functionally, these MupSis induce cell death by abrogating both the addiction to mutant p53 and the dominant-negative effect; and retard tumor growth in xenografts when administered in a therapeutic setting. These data together demonstrate the possibility of targeting mutant p53 specifically to improve clinical outcome.	[Ubby, Ifeoma; Krueger, Christian; Sabapathy, Kanaga] Natl Canc Ctr Singapore, Humphrey Oei Inst Canc Res, Div Cellular & Mol Res, Singapore 169610, Singapore; [Rosato, Roberto; Qian, Wei; Chang, Jenny] Houston Methodist Canc Ctr, 6445 Main St, Houston, TX 77030 USA; [Sabapathy, Kanaga] Duke NUS Med Sch, Canc & Stem Cell Biol Program, Singapore 169857, Singapore; [Sabapathy, Kanaga] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 119228, Singapore; [Sabapathy, Kanaga] Inst Mol & Cellular Biol, Singapore 138673, Singapore	National Cancer Centre Singapore (NCCS); The Methodist Hospital System; The Methodist Hospital - Houston; National University of Singapore; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Sabapathy, K (corresponding author), Natl Canc Ctr Singapore, Humphrey Oei Inst Canc Res, Div Cellular & Mol Res, Singapore 169610, Singapore.; Sabapathy, K (corresponding author), Duke NUS Med Sch, Canc & Stem Cell Biol Program, Singapore 169857, Singapore.; Sabapathy, K (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 119228, Singapore.; Sabapathy, K (corresponding author), Inst Mol & Cellular Biol, Singapore 138673, Singapore.	cmrksb@nccs.com.sg			National Medical Research Council of Singapore	National Medical Research Council of Singapore(National Medical Research Council, Singapore)	We thank the National Medical Research Council of Singapore for funding support to KS.	Alexandrova EM, 2015, NATURE, V523, P352, DOI 10.1038/nature14430; Allen EHA, 2013, INVEST OPHTH VIS SCI, V54, P494, DOI 10.1167/iovs.12-10528; Barata P, 2016, CANCER TREAT REV, V50, P35, DOI 10.1016/j.ctrv.2016.08.004; Berghmans S, 2005, P NATL ACAD SCI USA, V102, P407, DOI 10.1073/pnas.0406252102; Bieging KT, 2014, NAT REV CANCER, V14, P359, DOI 10.1038/nrc3711; Blagosklonny MV, 2005, CANCER RES, V65, P7386, DOI 10.1158/0008-5472.CAN-04-3433; Bossi G, 2006, ONCOGENE, V25, P304, DOI 10.1038/sj.onc.1209026; Bouaoun L, 2016, HUM MUTAT, V37, P865, DOI 10.1002/humu.23035; Capdeville R, 2002, NAT REV DRUG DISCOV, V1, P493, DOI 10.1038/nrd839; Dave B, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw292; Dave B, 2014, P NATL ACAD SCI USA, V111, P8838, DOI 10.1073/pnas.1320769111; Dearth LR, 2007, CARCINOGENESIS, V28, P289, DOI 10.1093/carcin/bgl132; Donehower LA, 2014, HUM MUTAT, V35, P715, DOI 10.1002/humu.22507; Eiden AM, 2016, CLIN CANCER RES, V22, P277, DOI 10.1158/1078-0432.CCR-14-3239; Evans EK, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aao1690; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017; Giles FJ, 2009, LEUKEMIA, V23, P1698, DOI 10.1038/leu.2009.111; Hanel W, 2013, CELL DEATH DIFFER, V20, P898, DOI 10.1038/cdd.2013.17; Hansen SA, 2016, DIS MODEL MECH, V9, P1139, DOI 10.1242/dmm.025767; Herbst RS, 2004, NAT REV CANCER, V4, P956, DOI 10.1038/nrc1506; Hickerson RP, 2008, J INVEST DERMATOL, V128, P594, DOI 10.1038/sj.jid.5701060; Hwang LA, 2018, CELL REP, V22, P299, DOI 10.1016/j.celrep.2017.11.112; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kim A, 2016, EXPERT OPIN DRUG DIS, V11, P907, DOI 10.1080/17460441.2016.1201057; Klaeger S, 2017, SCIENCE, V358, DOI 10.1126/science.aan4368; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Leachman SA, 2010, MOL THER, V18, P442, DOI 10.1038/mt.2009.273; Lee MK, 2008, J CELL SCI, V121, P1899, DOI 10.1242/jcs.022822; Lee MK, 2012, CANCER CELL, V22, P751, DOI 10.1016/j.ccr.2012.10.022; Liu Y, 2016, J INVEST DERMATOL, V136, P45, DOI 10.1038/JID.2015.375; Martinez LA, 2002, P NATL ACAD SCI USA, V99, P14849, DOI 10.1073/pnas.222406899; Merino Diana, 2014, Subcell Biochem, V85, P1, DOI 10.1007/978-94-017-9211-0_1; Montgomery Mary K, 2004, Methods Mol Biol, V265, P3; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Novelli F, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.118; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Phang BH, 2015, P NATL ACAD SCI USA, V112, pE6349, DOI 10.1073/pnas.1510043112; Rasheed SAK, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0337-x; Sabapathy K, 2018, NAT REV CLIN ONCOL, V15, P13, DOI 10.1038/nrclinonc.2017.151; Sabapathy K, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00276; Schrama D, 2006, NAT REV DRUG DISCOV, V5, P147, DOI 10.1038/nrd1957; Semczuk A, 2010, ONCOLOGY-BASEL, V78, P220, DOI 10.1159/000314353; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Shrivastava Neeta, 2008, Biotechnol J, V3, P339, DOI 10.1002/biot.200700215; Solomon BJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144559; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; Sur S, 2009, P NATL ACAD SCI USA, V106, P3964, DOI 10.1073/pnas.0813333106; Trochet D, 2018, EMBO MOL MED, V10, P239, DOI 10.15252/emmm.201707988; Trochet D, 2015, CURR GENE THER, V15, P503, DOI 10.2174/1566523215666150812115730; Vikhanskaya F, 2007, NUCLEIC ACIDS RES, V35, P2093, DOI 10.1093/nar/gkm099; Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X; Wang YX, 2011, J CLIN INVEST, V121, P893, DOI 10.1172/JCI44504; Zilfou JT, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001883	54	17	18	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2019	38	18					3415	3427		10.1038/s41388-018-0652-y	http://dx.doi.org/10.1038/s41388-018-0652-y			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HW3RI	30643191	Green Published, hybrid			2022-12-28	WOS:000466610000007
J	Wiesweg, M; Kasper, S; Worm, K; Herold, T; Reis, H; Sara, L; Metzenmacher, M; Abendroth, A; Darwiche, K; Aigner, C; Wedemeyer, HH; Helfritz, FA; Stuschke, M; Schumacher, B; Markus, P; Paul, A; Rahmann, S; Schmid, KW; Schuler, M				Wiesweg, Marcel; Kasper, Stefan; Worm, Karl; Herold, Thomas; Reis, Henning; Sara, Linda; Metzenmacher, Martin; Abendroth, Annalena; Darwiche, Kaid; Aigner, Clemens; Wedemeyer, Heiner H.; Helfritz, Fabian A.; Stuschke, Martin; Schumacher, Brigitte; Markus, Peter; Paul, Andreas; Rahmann, Sven; Schmid, Kurt W.; Schuler, Martin			Impact of RAS mutation subtype on clinical outcome-a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer	ONCOGENE			English	Article							SIDED COLON-CANCER; DNA-DAMAGE; KRAS MUTATIONS; BRAF MUTANTS; ADENOCARCINOMA; SENSITIVITY; EGFR; CHEMOTHERAPY; MECHANISMS; INHIBITION	Mutated RAS onco-proteins are key drivers across many cancers. The distribution of somatic RAS mutations varies between cancer entities. Retrospective analyses have associated some RAS mutations with distinct clinical outcomes. However, the clinical impact of the full spectrum of RAS mutations in their disease contextuality remains to be defined. To improve upon this situation, we studied genomically and clinically annotated, prospectively recruited cohorts of patients with RAS-mutated metastatic lung cancer and colorectal cancer. Mutational spectra were compared with predictions derived from analyzing the mutagenic impact at the genome level for each entity. Interestingly, we found concordance of predicted signatures with those actually observed in our patients. Thus, composition of the functionally active RAS mutational subtypes is primarily determined by the mutagenic context. Most RAS mutations seemed dominant oncogenic drivers with entity-dependent clinical outcomes. RAS comutations were enriched in tumors harboring class 2/3 BRAF mutations, highlighting the functional dependency of some mutated BRAF isoforms on RAS. With our dataset, we established a probabilistic model for cross-entity comparison of the prognostic impact of specific RAS mutational subtypes. The resulting prognostic clusters showed largely consistent clinical categorizations in both entities. This suggests mutant subtype-specific functional properties leading to similar clinical effects. A notable exception is KRAS G12C, which imparted an adverse prognosis only in colorectal cancer. Our findings provide a framework for risk stratification of specific RAS mutations across several cancer entities, which is required to guide the analysis of clinical findings in patients treated with direct RAS inhibitors or agents targeting downstream pathways.	[Wiesweg, Marcel; Kasper, Stefan; Sara, Linda; Metzenmacher, Martin; Abendroth, Annalena; Schuler, Martin] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Dept Med Oncol, Hufelandstr 55, D-45122 Essen, Germany; [Wiesweg, Marcel; Rahmann, Sven] Univ Duisburg Essen, Univ Hosp Essen, Inst Human Genet, Genome Informat, Hufelandstr 55, D-45122 Essen, Germany; [Kasper, Stefan; Stuschke, Martin; Schmid, Kurt W.; Schuler, Martin] Partner Site Univ Hosp Essen, German Canc Consortium DKTK, Hufelandstr 55, D-45122 Essen, Germany; [Worm, Karl; Herold, Thomas; Reis, Henning; Schmid, Kurt W.] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Inst Pathol, Hufelandstr 55, D-45122 Essen, Germany; [Darwiche, Kaid] Univ Duisburg Essen, Ruhrlandklin Univ Hosp Essen, Sect Intervent Pneumol, Dept Pulm Med, Tuschener Weg 40, D-45239 Essen, Germany; [Aigner, Clemens] Univ Duisburg Essen, Ruhrlandklin Univ Hosp Essen, Dept Thorac Surg & Endoscopy, Tuschener Weg 40, D-45239 Essen, Germany; [Wedemeyer, Heiner H.] Univ Duisburg Essen, Dept Gastroenterol & Hepatol, West German Canc Ctr, Univ Hosp Essen, Hufelandstr 55, D-45122 Essen, Germany; [Helfritz, Fabian A.; Paul, Andreas] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Dept Gen Visceral & Transplantat Surg, Hufelandstr 55, D-45122 Essen, Germany; [Stuschke, Martin] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Dept Radiotherapy, Hufelandstr 55, D-45122 Essen, Germany; [Schumacher, Brigitte] Elisabeth Hosp Essen, Dept Gastroenterol, Klara Kopp Weg 1, D-45138 Essen, Germany; [Markus, Peter] Elisabeth Hosp Essen, Dept Gen Visceral & Trauma Surg, Klara Kopp Weg 1, D-45138 Essen, Germany; [Schuler, Martin] Univ Duisburg Essen, Ruhrlandklin Univ Hosp Essen, Div Thorac Oncol, Tuschener Weg 40, D-45239 Essen, Germany	University of Duisburg Essen; University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ); University of Duisburg Essen; University of Duisburg Essen; University of Duisburg Essen; University of Duisburg Essen; University of Duisburg Essen; University of Duisburg Essen; University of Duisburg Essen	Schuler, M (corresponding author), Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Dept Med Oncol, Hufelandstr 55, D-45122 Essen, Germany.; Schuler, M (corresponding author), Partner Site Univ Hosp Essen, German Canc Consortium DKTK, Hufelandstr 55, D-45122 Essen, Germany.; Schuler, M (corresponding author), Univ Duisburg Essen, Ruhrlandklin Univ Hosp Essen, Div Thorac Oncol, Tuschener Weg 40, D-45239 Essen, Germany.	martin.schuler@uk-essen.de	Reis, Henning/AAX-9545-2020; Aigner, Clemens/A-7284-2019; Kasper, Stefan/I-4521-2015	Reis, Henning/0000-0003-1373-5295; Aigner, Clemens/0000-0002-7787-991X; Kasper, Stefan/0000-0002-5947-8733; Wiesweg, Marcel/0000-0002-9698-9559	Oncology Center of Excellence Program of the Deutsche Krebshilfe [110534]; German Federal government via the German Cancer Consortium (DKTK); Novartis Pharma AG; Medical Faculty of the University Duisburg-Essen (IFORES fellowship); North Rhine-Westphalian State government via the German Cancer Consortium (DKTK)	Oncology Center of Excellence Program of the Deutsche Krebshilfe; German Federal government via the German Cancer Consortium (DKTK); Novartis Pharma AG; Medical Faculty of the University Duisburg-Essen (IFORES fellowship); North Rhine-Westphalian State government via the German Cancer Consortium (DKTK)	This work was supported by the Oncology Center of Excellence Program of the Deutsche Krebshilfe (grant number 110534); the German Federal and North Rhine-Westphalian State governments via the German Cancer Consortium (DKTK); Novartis Pharma AG (research grant); the Medical Faculty of the University Duisburg-Essen (IFORES fellowship to M.W.). The funding sources had no influence on the analysis and interpretation of data, and contents of the manuscript.	Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Ambrogio C, 2018, CELL, V172, P857, DOI 10.1016/j.cell.2017.12.020; Arnold D, 2017, ANN ONCOL, V28, P1713, DOI 10.1093/annonc/mdx175; Blanpain C, 2011, CELL STEM CELL, V8, P16, DOI 10.1016/j.stem.2010.12.012; Blons H, 2014, ANN ONCOL, V25, P2378, DOI 10.1093/annonc/mdu464; Bose R, 2013, CANCER DISCOV, V3, P224, DOI 10.1158/2159-8290.CD-12-0349; Brannon AR, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0454-7; Castellucci E, 2017, ONCOLOGIST, V22, P497, DOI 10.1634/theoncologist.2017-0034; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Cserepes M, 2014, EUR J CANCER, V50, P1819, DOI 10.1016/j.ejca.2014.04.001; Deihimi S, 2017, ONCOTARGET, V8, P39945, DOI 10.18632/oncotarget.18098; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Dion V, 2014, TRENDS GENET, V30, P220, DOI 10.1016/j.tig.2014.04.005; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Garassino MC, 2011, ANN ONCOL, V22, P235, DOI 10.1093/annonc/mdq680; Giannakis M, 2016, CELL REP, V15, P857, DOI 10.1016/j.celrep.2016.03.075; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Guerrero S, 2000, CANCER RES, V60, P6750; Haigis KM, 2017, TRENDS CANCER, V3, P686, DOI 10.1016/j.trecan.2017.08.006; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hunter JC, 2015, MOL CANCER RES, V13, P1325, DOI 10.1158/1541-7786.MCR-15-0203; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Iyama T, 2013, DNA REPAIR, V12, P620, DOI 10.1016/j.dnarep.2013.04.015; Jamal-Hanjani M, 2017, NEW ENGL J MED, V376, P2109, DOI 10.1056/NEJMoa1616288; Jones JC, 2017, J CLIN ONCOL, V35, P2624, DOI 10.1200/JCO.2016.71.4394; Jones RP, 2017, BRIT J CANCER, V116, P923, DOI 10.1038/bjc.2017.37; Jordan EJ, 2017, CANCER DISCOV, V7, P596, DOI 10.1158/2159-8290.CD-16-1337; Karahalil B, 2002, FASEB J, V16, P1895, DOI 10.1096/fj.02-0463com; Kerner GSMA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070346; Kuong KJ, 2013, NAT GENET, V45, P964, DOI 10.1038/ng.2736; Kwak MS, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007882; Lans H, 2015, DNA REPAIR, V32, P141, DOI 10.1016/j.dnarep.2015.04.025; Larki P, 2017, CELL J, V19, P113, DOI 10.22074/cellj.2017.5123; Lee GH, 2015, EJSO-EUR J SURG ONC, V41, P300, DOI 10.1016/j.ejso.2014.11.001; Lito P, 2016, SCIENCE, V351, P604, DOI 10.1126/science.aad6204; McGranahan N, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa1408; Messner I, 2013, J CANCER RES CLIN, V139, P201, DOI 10.1007/s00432-012-1319-7; Metro G, 2012, LUNG CANCER, V78, P81, DOI 10.1016/j.lungcan.2012.06.005; Nan XL, 2015, P NATL ACAD SCI USA, V112, P7996, DOI 10.1073/pnas.1509123112; Oh Bo-Young, 2011, J Korean Soc Coloproctol, V27, P127, DOI 10.3393/jksc.2011.27.3.127; Ostrem JM, 2013, NATURE, V503, P548, DOI 10.1038/nature12796; Ostrow SL, 2016, SCI REP-UK, V6, DOI 10.1038/srep21927; Patricelli MP, 2016, CANCER DISCOV, V6, P316, DOI 10.1158/2159-8290.CD-15-1105; Petrelli F, 2017, JAMA ONCOL, V3, P211, DOI 10.1001/jamaoncol.2016.4227; Pfeifer GP, 2002, ONCOGENE, V21, P7435, DOI 10.1038/sj.onc.1205803; Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612; Sahin IH, 2013, J CANCER, V4, P320, DOI 10.7150/jca.3619; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; Shepherd FA, 2013, J CLIN ONCOL, V31, P2173, DOI 10.1200/JCO.2012.48.1390; Simanshu DK, 2017, CELL, V170, P17, DOI 10.1016/j.cell.2017.06.009; Takamochi K, 2013, ONCOL LETT, V6, P1207, DOI 10.3892/ol.2013.1551; Tejpar S, 2017, JAMA ONCOL, V3, P194, DOI 10.1001/jamaoncol.2016.3797; Tejpar S, 2012, J CLIN ONCOL, V30, P3570, DOI 10.1200/JCO.2012.42.2592; Toyooka S, 2007, CLIN CANCER RES, V13, P3431, DOI 10.1158/1078-0432.CCR-07-0070; Vitale I, 2017, MOL CELL, V66, P306, DOI 10.1016/j.molcel.2017.04.006; Vittal A, 2017, CASE REP ONCOL MED, V2017, DOI 10.1155/2017/2321052; Wiesweg M, 2018, CLIN COLORECTAL CANC, V17, pE331, DOI 10.1016/j.clcc.2018.02.003; Wiesweg M, 2017, J THORAC ONCOL, V12, P54, DOI 10.1016/j.jtho.2016.08.137; Wiesweg M, 2013, EUR J CANCER, V49, P3076, DOI 10.1016/j.ejca.2013.06.014; Xing KL, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0036-2; Yao Z, 2017, NATURE, V548, P234, DOI 10.1038/nature23291; Yao Z, 2015, CANCER CELL, V28, P370, DOI 10.1016/j.ccell.2015.08.001; Yu HA, 2015, J THORAC ONCOL, V10, P431, DOI 10.1097/JTO.0000000000000432; Zhao H, 2014, ELIFE, V3, DOI 10.7554/eLife.02725; Zheng G, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1811-y	66	27	27	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2019	38	16					2953	2966		10.1038/s41388-018-0634-0	http://dx.doi.org/10.1038/s41388-018-0634-0			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU3IV	30568222				2022-12-28	WOS:000465167600006
J	Zepecki, JP; Snyder, KM; Moreno, MM; Fajardo, E; Fiser, A; Ness, J; Sarkar, A; Toms, SA; Tapinos, N				Zepecki, J. P.; Snyder, K. M.; Moreno, M. M.; Fajardo, E.; Fiser, A.; Ness, J.; Sarkar, A.; Toms, S. A.; Tapinos, N.			Regulation of human glioma cell migration, tumor growth, and stemness gene expression using a Lck targeted inhibitor	ONCOGENE			English	Article							SCHWANN-CELLS; KINASE LCK; INVASION; NEURONS; HETEROGENEITY; MYELINATION; ACTIVATION; PHENOTYPE	Migration of human glioma cells (hGCs) within the brain parenchyma makes glioblastoma one of the most aggressive and lethal tumors. Studies of the cellular and molecular mechanisms underlying hGC migration are hindered by the limitations of existing glioma models. Here we developed a dorsal root ganglion axon-oligodendrocyte-hGC co-culture to study in real time the migration and interaction of hGCs with their microenvironment. hGCs interact with myelinated and non-myelinated axons through the formation of pseudopodia. Isolation of pseudopodia-localized polysome-bound RNA reveals transcripts of Lck, Paxillin, Crk-II, and Rac I that undergo local translation. Inhibition of Lck phosphorylation using a small-molecule inhibitor (Lck-I), blocks the phosphorylation of Paxillin and Crk-II, the formation of pseudopodia and the migration of hGCs. In vivo intraventricular administration of the Lck-I using an orthotopic xenograft glioma model, results in statistically significant inhibition of tumor size and significant down-regulation of Nanog-targeted genes, which are associated with glioblastoma patient survival. Moreover, treatment of human glioma stem cells (hGSCs) with Lck-I, results in significant inhibition of self-renewal and tumor-sphere formation. The involvement of Lck in different levels of glioma malignant progression, such as migration, tumor growth, and regulation of cancer stemness, makes Lck a potentially important therapeutic target for human glioblastomas.	[Zepecki, J. P.; Moreno, M. M.; Toms, S. A.; Tapinos, N.] Brown Univ, Mol Neurosci & Neurooncol Lab, Providence, RI 02912 USA; [Snyder, K. M.] Univ Minnesota, Coll Vet Med, St Paul, MN 55108 USA; [Fajardo, E.; Fiser, A.] Albert Einstein Coll Med, Dept Syst & Computat Biol, Bronx, NY 10467 USA; [Ness, J.] Messiah Coll, Dept Biol Sci, Mechanicsburg, PA USA; [Sarkar, A.] Geisinger Med Clin, Dept Neurosurg, Danville, PA USA; [Toms, S. A.; Tapinos, N.] Brown Univ, Rhode Isl Hosp, Dept Neurosurg, Providence, RI 02903 USA	Brown University; University of Minnesota System; University of Minnesota Twin Cities; Yeshiva University; Albert Einstein College of Medicine; Geisinger Medical Center; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital	Tapinos, N (corresponding author), Brown Univ, Mol Neurosci & Neurooncol Lab, Providence, RI 02912 USA.; Tapinos, N (corresponding author), Brown Univ, Rhode Isl Hosp, Dept Neurosurg, Providence, RI 02903 USA.	nikos_tapinos@brown.edu		Zepecki, John P/0000-0003-4127-4668; Toms, Steven/0000-0001-8732-0522; Snyder, Kristin M./0000-0002-6598-1837	Molecular Pathology Core of the COBRE Center for Cancer Research Development - National Institute of General Medical Sciences of the National Institutes of Health [P30GM110759]; Geisinger Clinic; Department of Neurosurgery of Brown University; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI141816] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM110759] Funding Source: NIH RePORTER	Molecular Pathology Core of the COBRE Center for Cancer Research Development - National Institute of General Medical Sciences of the National Institutes of Health; Geisinger Clinic; Department of Neurosurgery of Brown University; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank members of the Tapinos lab for critically reviewing the manuscript. We would like to thank Kara Lombardo and Ashlee Sturtevant at the Pathology Core of Rhode Island Hospital for the assistance with glioblastoma tissue sections and stainings. We also thank Oliver Tang for analysis of the TCGA dataset. All animal work was performed according to institutional guidelines and approved by the IACUC committee of Rhode Island Hospital and Geisinger Clinic. Work included in this publication was supported by the Molecular Pathology Core of the COBRE Center for Cancer Research Development, funded by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number P30GM110759. This research project was also supported by institutional funds of the Geisinger Clinic to N.T., S.A.T., and A.S. and by institutional funds of the Department of Neurosurgery of Brown University to N.T. and S.A.T.	Adilakshmi T, 2011, J NEUROSCI, V31, P5106, DOI 10.1523/JNEUROSCI.5635-10.2011; Aubert M, 2008, J R SOC INTERFACE, V5, P75, DOI 10.1098/rsif.2007.1070; Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Bedard PL, 2013, NATURE, V501, P355, DOI 10.1038/nature12627; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; CAMPENOT RB, 1982, DEV BIOL, V93, P1, DOI 10.1016/0012-1606(82)90232-9; Chambers I, 2007, NATURE, V450, P1230, DOI 10.1038/nature06403; Chan JR, 2004, NEURON, V43, P183, DOI 10.1016/j.neuron.2004.06.024; de la Iglesia N, 2009, CURR MOL MED, V9, P580; de la Roche M, 2013, SCIENCE, V342, P1247, DOI 10.1126/science.1244689; Deakin NO, 2008, J CELL SCI, V121, P2435, DOI 10.1242/jcs.018044; Demuth T, 2004, J NEURO-ONCOL, V70, P217, DOI 10.1007/s11060-004-2751-6; Diemert S, 2012, J NEUROSCI METH, V203, P69, DOI 10.1016/j.jneumeth.2011.09.012; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Gandin V, 2014, JOVE-J VIS EXP, DOI 10.3791/51455; Giese A, 1996, NEUROSURGERY, V38, P755, DOI 10.1227/00006123-199604000-00026; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Joy AM, 2003, J CELL SCI, V116, P4409, DOI 10.1242/jcs.00712; Jung H, 2014, CELL, V157, P26, DOI 10.1016/j.cell.2014.03.005; Kaur H, 2012, MOL CANCER RES, V10, P293, DOI 10.1158/1541-7786.MCR-11-0457; Kim RK, 2010, BIOCHEM BIOPH RES CO, V402, P631, DOI 10.1016/j.bbrc.2010.10.072; Koul D, 2005, MOL CANCER THER, V4, P1681, DOI 10.1158/1535-7163.MCT-05-0258; Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Merzak A, 1997, CANCER METAST REV, V16, P155, DOI 10.1023/A:1005760726850; Mili S, 2008, NATURE, V453, P115, DOI 10.1038/nature06888; Ness JK, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2928; Park JB, 2014, ONCOTARGET, V5, P9382, DOI 10.18632/oncotarget.2412; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Pinto JP, 2015, NUCLEIC ACIDS RES, V43, pW72, DOI 10.1093/nar/gkv529; Rao SS, 2013, BIOMATERIALS, V34, P5181, DOI 10.1016/j.biomaterials.2013.03.069; Reyes SB, 2013, MOL BIOL CELL, V24, P474, DOI 10.1091/mbc.E12-07-0521; REYNOLDS PJ, 1992, ONCOGENE, V7, P1949; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Ruffini F, 2004, AM J PATHOL, V165, P2167, DOI 10.1016/S0002-9440(10)63266-X; Singh SK, 2003, CANCER RES, V63, P5821; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Soni Priyanka, 2017, Asian Pac J Cancer Prev, V18, P2215; Stachlewitz RF, 2005, J PHARMACOL EXP THER, V315, P36, DOI 10.1124/jpet.105.089169; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Stupp R, 2015, JAMA-J AM MED ASSOC, V314, P2535, DOI 10.1001/jama.2015.16669; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang Y., 2007, SCI STKE, V2007, P14; Wick W, 2001, J NEUROSCI, V21, P3360, DOI 10.1523/JNEUROSCI.21-10-03360.2001; WINDEBANK AJ, 1985, J NEUROSCI, V5, P1563; WOOD PM, 1976, BRAIN RES, V115, P361, DOI 10.1016/0006-8993(76)90355-3; Wu KY, 2005, NATURE, V436, P1020, DOI 10.1038/nature03885; Wu TD, 2010, BIOINFORMATICS, V26, P873, DOI 10.1093/bioinformatics/btq057; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; Zbinden M, 2010, EMBO J, V29, P2659, DOI 10.1038/emboj.2010.137	56	34	35	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2019	38	10					1734	1750		10.1038/s41388-018-0546-z	http://dx.doi.org/10.1038/s41388-018-0546-z			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN8DD	30353164	Green Published, hybrid			2022-12-28	WOS:000460423800012
J	Lujambio, A; Portela, A; Liz, J; Melo, SA; Rossi, S; Spizzo, R; Croce, CM; Calin, GA; Esteller, M				Lujambio, A.; Portela, A.; Liz, J.; Melo, S. A.; Rossi, S.; Spizzo, R.; Croce, C. M.; Calin, G. A.; Esteller, M.			CpG island hypermethylation-associated silencing of non-coding RNAs transcribed from ultraconserved regions in human cancer (vol 29, pg 6390, 2010)	ONCOGENE			English	Correction									[Lujambio, A.; Portela, A.; Liz, J.; Melo, S. A.; Esteller, M.] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona 08907, Spain; [Rossi, S.; Spizzo, R.; Calin, G. A.] Texas State Univ, Univ Texas MD Anderson Canc Ctr, Expt Therapeut & Canc Genet, Houston, TX USA; [Croce, C. M.] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; [Esteller, M.] ICREA, Barcelona, Catalonia, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Texas State University System; Texas State University San Marcos; University of Texas System; UTMD Anderson Cancer Center; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; ICREA	Esteller, M (corresponding author), Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona 08907, Spain.; Esteller, M (corresponding author), ICREA, Barcelona, Catalonia, Spain.	mesteller@iconcologia.net	Esteller, Manel/L-5956-2014	Esteller, Manel/0000-0003-4490-6093; Calin, George/0000-0002-7427-0578; Calin, George/0000-0001-6704-5615				Lujambio A, 2010, ONCOGENE, V29, P6390, DOI 10.1038/onc.2010.361	1	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2019	38	5					765	766		10.1038/s41388-018-0560-1	http://dx.doi.org/10.1038/s41388-018-0560-1			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HJ6LI	30397238	Green Published, hybrid			2022-12-28	WOS:000457300300011
J	Kweon, J; Jang, AH; Shin, HR; See, JE; Lee, W; Lee, JW; Chang, S; Kim, K; Kim, Y				Kweon, Jiyeon; Jang, An-Hee; Shin, Ha Rim; See, Ji-Eun; Lee, Woochang; Lee, Jong Won; Chang, Suhwan; Kim, Kyunggon; Kim, Yongsub			A CRISPR-based base-editing screen for the functional assessment of BRCA1 variants	ONCOGENE			English	Article							GENOMIC DNA; SITES	Genetic mutations in BRCA1, which is crucial for the process of DNA repair and maintenance of genomic integrity, are known to increase markedly the risk of breast and ovarian cancers. Clinical genetic testing has been used to identify new BRCA1 variants; however, functional assessment and determination of their pathogenicity still poses challenges for clinical management. Here, we describe that CRISPR-mediated cytosine base editor, known as BE3, can be used for the functional analysis of BRCA1 variants. We performed CRISPR-mediated base-editing screening using 745 gRNAs targeting all exons in BRCA1 to identify loss-of-function variants and identified variants whose function has heretofore remained unknown, such as c.-97C>T, c.154C>T, c.3847C>T, c.5056C>T, and c.4986+5G>A. Our results show that CRISPR-mediated base editor is a powerful tool for the reclassification of variants of uncertain significance (VUSs) in BRCA1.	[Kweon, Jiyeon; Jang, An-Hee; Shin, Ha Rim; See, Ji-Eun; Chang, Suhwan; Kim, Yongsub] Univ Ulsan, Coll Med, Asan Med Inst Convergence Sci & Technol, Dept Biomed Sci,Asan Med Ctr, Seoul, South Korea; [Kweon, Jiyeon; Jang, An-Hee; Shin, Ha Rim; See, Ji-Eun; Kim, Yongsub] Univ Ulsan, Coll Med, Stem Cell Immunomodulat Res Ctr, Seoul, South Korea; [Lee, Woochang] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Lab Med, Seoul, South Korea; [Lee, Jong Won] Univ Ulsan, Coll Med, Asan Med Ctr, Div Breast Surg,Dept Surg, Seoul, South Korea; [Kim, Kyunggon] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Convergence Med, Seoul, South Korea; [Kim, Kyunggon] Asan Inst Life Sci, Clin Prote Core Lab, Seoul, South Korea	University of Ulsan; University of Ulsan; University of Ulsan; Asan Medical Center; University of Ulsan; Asan Medical Center; University of Ulsan; Asan Medical Center	Kim, Y (corresponding author), Univ Ulsan, Coll Med, Asan Med Inst Convergence Sci & Technol, Dept Biomed Sci,Asan Med Ctr, Seoul, South Korea.; Kim, Y (corresponding author), Univ Ulsan, Coll Med, Stem Cell Immunomodulat Res Ctr, Seoul, South Korea.	yongsub1.kim@gmail.com		Kim, Yongsub/0000-0002-9334-4333; Chang, Suhwan/0000-0002-0282-0120	National Research Foundation of Korea [2017M3A9B4062419, 2019R1F1A1057637, 2018R1A5A2020732]; Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea [HI17C0337]; Asan institute for Life Sciences, Republic of Korea [2018-784, 2018-725]	National Research Foundation of Korea(National Research Foundation of Korea); Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea; Asan institute for Life Sciences, Republic of Korea	This work was supported by the National Research Foundation of Korea (grants 2017M3A9B4062419, 2019R1F1A1057637, and 2018R1A5A2020732 to Y.K.), the Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (grant HI17C0337 to Y.K.), and Asan institute for Life Sciences, Republic of Korea (grants 2018-784, and 2018-725 to Y.K.).	Bae S, 2014, BIOINFORMATICS, V30, P1473, DOI 10.1093/bioinformatics/btu048; Blomen VA, 2015, SCIENCE, V350, P1092, DOI 10.1126/science.aac7557; BRUNAK S, 1991, J MOL BIOL, V220, P49, DOI 10.1016/0022-2836(91)90380-O; Desmet FO, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp215; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Findlay GM, 2018, NATURE, V562, P217, DOI 10.1038/s41586-018-0461-z; Findlay GM, 2014, NATURE, V513, P120, DOI 10.1038/nature13695; Gaudelli NM, 2017, NATURE, V551, P464, DOI 10.1038/nature24644; Gibson TJ, 2013, NAT METHODS, V10, P715, DOI 10.1038/nmeth.2534; Hess GT, 2016, NAT METHODS, V13, P1036, DOI [10.1038/NMETH.4038, 10.1038/nmeth.4038]; Hu JH, 2018, NATURE, V556, P57, DOI 10.1038/nature26155; Joung J, 2017, NAT PROTOC, V12, P828, DOI 10.1038/nprot.2017.016; Kim K, 2017, NAT BIOTECHNOL, V35, P435, DOI 10.1038/nbt.3816; Kim Y, 2013, NAT BIOTECHNOL, V31, P251, DOI 10.1038/nbt.2517; Knott GJ, 2018, SCIENCE, V361, P866, DOI 10.1126/science.aat5011; Komor AC, 2016, NATURE, V533, P420, DOI 10.1038/nature17946; Kuchenbaecker KB, 2017, JAMA-J AM MED ASSOC, V317, P2402, DOI 10.1001/jama.2017.7112; Kweon J, 2018, ARCH PHARM RES, V41, P875, DOI 10.1007/s12272-018-1029-z; Kweon J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199473; Landrum MJ, 2016, NUCLEIC ACIDS RES, V44, pD862, DOI 10.1093/nar/gkv1222; Millot GA, 2012, HUM MUTAT, V33, P1526, DOI 10.1002/humu.22150; Nishimasu H, 2018, SCIENCE, V361, P1259, DOI 10.1126/science.aas9129; Park DS, 2017, MOL CELLS, V40, P823, DOI 10.14348/molcells.2017.0262; Roy R, 2012, NAT REV CANCER, V12, P68, DOI 10.1038/nrc3181; Sayers EW, 2019, NUCLEIC ACIDS RES, V47, pD94, DOI 10.1093/nar/gky989; Wang T, 2015, SCIENCE, V350, P1096, DOI 10.1126/science.aac7041	26	35	35	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	1					30	35		10.1038/s41388-019-0968-2	http://dx.doi.org/10.1038/s41388-019-0968-2			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG3NM	31467430	hybrid, Green Published			2022-12-28	WOS:000509849200003
J	Shi, HC; Sun, Y; He, M; Yang, X; Hamada, M; Fukunaga, T; Zhang, XP; Chang, CS				Shi, Hangchuan; Sun, Yin; He, Miao; Yang, Xiong; Hamada, Michiaki; Fukunaga, Tsukasa; Zhang, Xiaoping; Chang, Chawnshang			Targeting the TR4 nuclear receptor-mediated lncTASR/AXL signaling with tretinoin increases the sunitinib sensitivity to better suppress the RCC progression	ONCOGENE			English	Article							RENAL-CELL CARCINOMA; TRANS-RETINOIC ACID; ACUTE PROMYELOCYTIC LEUKEMIA; IN-VITRO; GENE-EXPRESSION; TUMOR-CELLS; CANCER; METFORMIN; THERAPY; RESISTANCE	Renal cell carcinoma (RCC) is one of the most lethal urological tumors. Using sunitinib to improve the survival has become the first-line therapy for metastatic RCC patients. However, the occurrence of sunitinib resistance in the clinical application has curtailed its efficacy. Here we found TR4 nuclear receptor might alter the sunitinib resistance to RCC via altering the TR4/lncTASR/AXL signaling. Mechanism dissection revealed that TR4 could modulate lncTASR (ENST00000600671.1) expression via transcriptional regulation, which might then increase AXL protein expression via enhancing the stability of AXL mRNA to increase the sunitinib resistance in RCC. Human clinical surveys also linked the expression of TR4, lncTASR, and AXL to the RCC survival, and results from multiple RCC cell lines revealed that targeting this newly identified TR4-mediated signaling with small molecules, including tretinoin, metformin, or TR4-shRNAs, all led to increase the sunitinib sensitivity to better suppress the RCC progression, and our preclinical study using the in vivo mouse model further proved tretinoin had a better synergistic effect to increase sunitinib sensitivity to suppress RCC progression. Future successful clinical trials may help in the development of a novel therapy to better suppress the RCC progression.	[Shi, Hangchuan; Yang, Xiong; Zhang, Xiaoping] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Urol, Wuhan 430022, Peoples R China; [Shi, Hangchuan; Sun, Yin; He, Miao; Yang, Xiong; Chang, Chawnshang] Univ Rochester, Wilmot Canc Inst, Radiat Oncol, Med Ctr, Rochester, NY 14642 USA; [Hamada, Michiaki; Fukunaga, Tsukasa] Waseda Univ, Fac Sci & Engn, Tokyo 1698555, Japan; [Chang, Chawnshang] China Med Univ Hosp, Sex Hormone Res Ctr, Taichung 404, Taiwan; [Chang, Chawnshang] China Med Univ Hosp, Dept Urol, Taichung 404, Taiwan; [Hamada, Michiaki] Natl Inst Adv Ind Sci & Technol, Computat Bio Big Data Open Innovat Lab CBBD OIL, Tokyo 1698555, Japan	Huazhong University of Science & Technology; University of Rochester; Waseda University; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; National Institute of Advanced Industrial Science & Technology (AIST)	Zhang, XP (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Urol, Wuhan 430022, Peoples R China.; Chang, CS (corresponding author), Univ Rochester, Wilmot Canc Inst, Radiat Oncol, Med Ctr, Rochester, NY 14642 USA.; Chang, CS (corresponding author), China Med Univ Hosp, Sex Hormone Res Ctr, Taichung 404, Taiwan.; Chang, CS (corresponding author), China Med Univ Hosp, Dept Urol, Taichung 404, Taiwan.	xzhang@hust.edu.cn; chang@urmc.rochester.edu	Shi, Hangchuan/GWV-5076-2022; Shi, Hangchuan/J-2637-2014; Hamada, Michiaki/L-9371-2018	Chang, Chawnshang/0000-0001-8510-3516; Shi, Hangchuan/0000-0001-6269-742X; Hamada, Michiaki/0000-0001-9466-1034	NIH [CA156700]; George Whipple Professorship Endowment; Taiwan Department of Health Clinical Trial and Research Center of Excellence [MOHW104-TDU-B-212-113002]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); George Whipple Professorship Endowment; Taiwan Department of Health Clinical Trial and Research Center of Excellence	We thank Karen Wolf for help with manuscript preparation. This work was supported by NIH grant (CA156700), George Whipple Professorship Endowment and Taiwan Department of Health Clinical Trial and Research Center of Excellence (MOHW104-TDU-B-212-113002) to China Medical University, Taichung, Taiwan). Computations were partially performed on the NIG supercomputer at ROIS National Institute of Genetics.	Adelaiye-Ogala R, 2018, CANCER RES, V78, P2886, DOI 10.1158/0008-5472.CAN-17-3386; Bai J, 2018, ONCOGENE, V37, P5901, DOI 10.1038/s41388-018-0269-1; Baldewijns MML, 2008, BBA-REV CANCER, V1785, P133, DOI 10.1016/j.bbcan.2007.12.002; Benson MJ, 2007, J EXP MED, V204, P1765, DOI 10.1084/jem.20070719; Busch J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-295; Chae YK, 2016, ONCOTARGET, V7, P40767, DOI 10.18632/oncotarget.8194; Chandel NS, 2016, CELL METAB, V23, P569, DOI 10.1016/j.cmet.2016.03.010; Chen WF, 2016, NATURE, V539, P112, DOI 10.1038/nature19796; Chen XY, 2014, CLIN CANCER RES, V20, P2617, DOI 10.1158/1078-0432.CCR-13-3224; Choueiri TK, 2018, EUR J CANCER, V94, P115, DOI 10.1016/j.ejca.2018.02.012; Coppin C, 2011, BJU INT, V108, P1556, DOI 10.1111/j.1464-410X.2011.10629.x; Ding XF, 2015, MOL CANCER, V14, DOI 10.1186/s12943-014-0281-1; Ellis L, 2012, MOL CANCER THER, V11, P383, DOI 10.1158/1535-7163.MCT-11-0748; Faivre S, 2007, NAT REV DRUG DISCOV, V6, P734, DOI 10.1038/nrd2380; Froushani SMA, 2014, IRAN J BASIC MED SCI, V17, P632; Fukunaga T, 2017, BIOINFORMATICS, V33, P2666, DOI 10.1093/bioinformatics/btx287; Gilkes DM, 2014, NAT REV CANCER, V14, P430, DOI 10.1038/nrc3726; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Huang D, 2010, CANCER RES, V70, P1053, DOI 10.1158/0008-5472.CAN-09-3722; Jin RA, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0287-5; Jing YK, 2001, BLOOD, V97, P264, DOI 10.1182/blood.V97.1.264; Joosten SC, 2015, BBA-REV CANCER, V1855, P1, DOI 10.1016/j.bbcan.2014.11.002; Kasznicki J, 2014, ANN TRANSL MED, V2, DOI 10.3978/j.issn.2305-5839.2014.06.01; Kim E, 2011, DIABETES, V60, P1493, DOI 10.2337/db10-0393; Kordes S, 2015, LANCET ONCOL, V16, P839, DOI 10.1016/S1470-2045(15)00027-3; Li B, 2015, EUR J PHARMACOL, V749, P107, DOI 10.1016/j.ejphar.2015.01.009; Liu J, 2013, UROL ONCOL-SEMIN ORI, V31, P264, DOI 10.1016/j.urolonc.2011.01.003; Liu L, 2009, CANCER RES, V69, P6871, DOI 10.1158/0008-5472.CAN-08-4490; Liu QL, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.417; Liu S, 2014, ENDOCR-RELAT CANCER, V21, pR279, DOI 10.1530/ERC-13-0529; Liu XZ, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.197; Lorenzen JM, 2016, NAT REV NEPHROL, V12, P360, DOI 10.1038/nrneph.2016.51; Lou N, 2017, UROL ONCOL-SEMIN ORI, V35, DOI 10.1016/j.urolonc.2016.07.012; Mahadevan D, 2007, ONCOGENE, V26, P3909, DOI 10.1038/sj.onc.1210173; Mei D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182835; Motzer RJ, 2009, J CLIN ONCOL, V27, P3584, DOI 10.1200/JCO.2008.20.1293; Pawlyk AC, 2014, DIABETES, V63, P2590, DOI 10.2337/db13-1367; Qu L, 2016, CANCER CELL, V29, P653, DOI 10.1016/j.ccell.2016.03.004; Rho JK, 2014, CANCER RES, V74, P253, DOI 10.1158/0008-5472.CAN-13-1103; Rini BI, 2009, LANCET ONCOL, V10, P992, DOI 10.1016/S1470-2045(09)70240-2; Schodel J, 2016, EUR UROL, V69, P646, DOI 10.1016/j.eururo.2015.08.007; Seo GY, 2017, CELL IMMUNOL, V322, P49, DOI 10.1016/j.cellimm.2017.10.001; Shalita A, 1996, J AM ACAD DERMATOL, V34, P482, DOI 10.1016/S0190-9622(96)90443-0; Shen JL, 2016, ONCOTARGET, V7, P32088, DOI 10.18632/oncotarget.8525; Shojaei F, 2010, CANCER RES, V70, P10090, DOI 10.1158/0008-5472.CAN-10-0489; Staehler M, 2005, CURR DRUG TARGETS, V6, P835, DOI 10.2174/138945005774574498; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tannir NM, 2017, CURR ONCOL REP, V19, DOI 10.1007/s11912-017-0566-9; Terai G, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-015-2307-5; van der Mijn JC, 2016, INT J CANCER, V138, P3002, DOI 10.1002/ijc.30022; Wang MC, 2018, INT J CANCER, V143, P100, DOI 10.1002/ijc.31289; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; Weiss RH, 2018, SEMIN NEPHROL, V38, P175, DOI 10.1016/j.semnephrol.2018.01.006; Wheaton WW, 2014, ELIFE, V3, DOI 10.7554/eLife.02242; Yoon JH, 2012, MOL CELL, V47, P648, DOI 10.1016/j.molcel.2012.06.027; Yu SC, 2015, PROSTATE, V75, P1632, DOI 10.1002/pros.23044; Zhai W, 2017, CELL DEATH DIFFER, V24, P1502, DOI 10.1038/cdd.2017.74; Zhou L, 2016, ONCOGENE, V35, P2687, DOI 10.1038/onc.2015.343; Zhou XE, 2011, J BIOL CHEM, V286, P2877, DOI 10.1074/jbc.M110.168740	59	13	14	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					530	545		10.1038/s41388-019-0962-8	http://dx.doi.org/10.1038/s41388-019-0962-8			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31501521	Green Published, hybrid			2022-12-28	WOS:000509718300004
J	He, H; Song, DD; Sinha, I; Hessling, B; Li, XD; Haldosen, LA; Zhao, CY				He, Huan; Song, Dandan; Sinha, Indranil; Hessling, Bernd; Li, Xidan; Haldosen, Lars-Arne; Zhao, Chunyan			Endogenous interaction profiling identifies DDX5 as an oncogenic coactivator of transcription factor Fra-1	ONCOGENE			English	Article							RNA HELICASES P68; ESTROGEN-RECEPTOR; MASS-SPECTROMETRY; BINDING-PROTEIN; REVEALS; PROLIFERATION; ALPHA; AP-1; INVASIVENESS; EXPRESSION	Fra-1, a member of the activator protein 1 (AP-1) family, is overexpressed in triple-negative breast cancer (TNBC) and plays crucial roles in tumor growth. Here we report the identification of 118 proteins interacting with endogenous chromatinbound Fra-1 in TNBC cells, highlighting DDX5 as the most enriched Fra-1-interacting protein. DDX5, a previously unrecognized protein in the Fra-1 transcriptional network, shows extensive overlap with Fra-1 cistrome and transcriptome that are highly associated with the TNBC cell growth. We provide evidence that DDX5 expression enhances Fra-1 transcriptional activity and potentiates Fra-1-driven cell proliferation. Furthermore, we show that the DDX5 target gene signature predicts poor clinical outcome in breast cancer patients. DDX5 protein level was higher in triple-negative basallike tumors than in non-basal-like tumors, including luminal A, luminal B, and HER2-enriched subtypes. Collectively, by combining proteomic and genomic approaches we reveal a role for DDX5 as a regulatory protein of Fra-1 signaling and suggest DDX5 as a potential therapeutic target for TNBC.	[He, Huan; Song, Dandan; Sinha, Indranil; Haldosen, Lars-Arne; Zhao, Chunyan] Karolinska Inst, Dept Biosci & Nutr, S-14183 Huddinge, Sweden; [Hessling, Bernd] Heidelberg Univ, Ctr Mol Biol ZMBH, D-69120 Heidelberg, Germany; [Hessling, Bernd] German Canc Res Ctr, D-69120 Heidelberg, Germany; [Li, Xidan] Karolinska Inst, Integrated Cardio Metab Ctr, Dept Med, S-14183 Huddinge, Sweden	Karolinska Institutet; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Karolinska Institutet	Zhao, CY (corresponding author), Karolinska Inst, Dept Biosci & Nutr, S-14183 Huddinge, Sweden.	chunyan.zhao@ki.se	He, Huan/AAF-9644-2019	He, Huan/0000-0001-8123-5765; Sinha, Indranil/0000-0002-2513-5927	China Scholarship Council; Karolinska Institutet; Swedish Cancer Society (Cancerfonden); Swedish Research Council	China Scholarship Council(China Scholarship Council); Karolinska Institutet(Karolinska Institutet); Swedish Cancer Society (Cancerfonden)(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission)	This work was supported by scholarship from the China Scholarship Council, a Ph.D. student grant (KID) from the Karolinska Institutet and grants from the Swedish Cancer Society (Cancerfonden) and the Swedish Research Council. We thank SciLifeLab, Stockholm, for their RNA-seq technical support and the Karolinska Institute/Astra Zeneca Integrated Cardio Metabolic Center (ICMC) for their consultative support. We are grateful to Karin Dahlman-Wright for critically reading the first version of the manuscript.	Andersson R, 2014, NATURE, V507, P455, DOI 10.1038/nature12787; Bates GJ, 2005, EMBO J, V24, P543, DOI 10.1038/sj.emboj.7600550; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; Browne AL, 2018, ONCOGENE, V37, P2008, DOI 10.1038/s41388-017-0042-x; Caretti G, 2006, DEV CELL, V11, P547, DOI 10.1016/j.devcel.2006.08.003; Chiappetta G, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-17; Christmann M, 2013, NUCLEIC ACIDS RES, V41, P8403, DOI 10.1093/nar/gkt635; Clark ES, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057832; Clark EL, 2008, CANCER RES, V68, P7938, DOI 10.1158/0008-5472.CAN-08-0932; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Dahlman-Wright K, 2012, CARCINOGENESIS, V33, P1684, DOI 10.1093/carcin/bgs223; Dardenne E, 2014, CELL REP, V7, P1900, DOI 10.1016/j.celrep.2014.05.010; Das M, 2018, RNA BIOL, V15, P214, DOI 10.1080/15476286.2017.1397261; Desmet CJ, 2013, P NATL ACAD SCI USA, V110, P5139, DOI 10.1073/pnas.1222085110; Dhillon AS, 2015, ONCOGENE, V34, P4421, DOI 10.1038/onc.2014.374; Diefenbacher ME, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097549; Diesch J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088950; Engstrom K, 2017, ARCH TOXICOL, V91, P2067, DOI 10.1007/s00204-016-1879-4; Fuller-Pace FV, 2013, BBA-GENE REGUL MECH, V1829, P756, DOI 10.1016/j.bbagrm.2013.03.004; Fuller-Pace FV, 2013, RNA BIOL, V10, P121, DOI 10.4161/rna.23312; Fuller-Pace FV, 2011, FUTURE ONCOL, V7, P239, DOI 10.2217/FON.11.1; Guturi KKN, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0496-5; He H, 2018, ONCOGENE, V37, P2586, DOI 10.1038/s41388-018-0165-8; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hendrickson DG, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0878-3; Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730; Iskit S, 2015, ONCOTARGET, V6, P43146, DOI 10.18632/oncotarget.6454; Ji X, 2015, P NATL ACAD SCI USA, V112, P3841, DOI 10.1073/pnas.1502971112; Kim TY, 2012, MOL CELL PROTEOMICS, V11, P1586, DOI 10.1074/mcp.M112.021162; Mazurek A, 2012, CANCER DISCOV, V2, P812, DOI 10.1158/2159-8290.CD-12-0116; Mohammed H, 2016, NAT PROTOC, V11, P316, DOI 10.1038/nprot.2016.020; Ogilvie VC, 2003, NUCLEIC ACIDS RES, V31, P1470, DOI 10.1093/nar/gkg236; Peng YW, 2002, BLOOD, V99, P2408, DOI 10.1182/blood.V99.7.2408; Qiao YC, 2015, ONCOTARGET, V6, P7804, DOI 10.18632/oncotarget.3158; Ross-Innes CS, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-593; Sayan AE, 2012, ONCOGENE, V31, P1493, DOI 10.1038/onc.2011.336; Schreiber M, 2000, DEVELOPMENT, V127, P4937; Searle BC, 2010, PROTEOMICS, V10, P1265, DOI 10.1002/pmic.200900437; Shao AW, 2016, CELL DEATH DIFFER, V23, P865, DOI 10.1038/cdd.2015.150; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2010, CELL SIGNAL, V22, P894, DOI 10.1016/j.cellsig.2009.12.008; Shevchenko A, 2006, NAT PROTOC, V1, P2856, DOI 10.1038/nprot.2006.468; Shin S, 2007, CANCER RES, V67, P7572, DOI 10.1158/0008-5472.CAN-06-4652; Stelloo S, 2018, ONCOGENE, V37, P313, DOI 10.1038/onc.2017.330; Tyanova S, 2016, NAT PROTOC, V11, P2301, DOI 10.1038/nprot.2016.136; Villanueva CJ, 2011, CELL METAB, V13, P413, DOI 10.1016/j.cmet.2011.02.014; Warner DR, 2004, BIOCHEM BIOPH RES CO, V324, P70, DOI 10.1016/j.bbrc.2004.09.017; Yao HJ, 2010, GENE DEV, V24, P2543, DOI 10.1101/gad.1967810; Zhao CY, 2007, CANCER RES, V67, P3955, DOI 10.1158/0008-5472.CAN-06-3505; Zhao CY, 2014, CANCER RES, V74, P3983, DOI 10.1158/0008-5472.CAN-13-3396	50	14	14	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2019	38	28					5725	5738		10.1038/s41388-019-0824-4	http://dx.doi.org/10.1038/s41388-019-0824-4			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IH9RW	31015574				2022-12-28	WOS:000474845100012
J	Lee, CF; Dang, A; Hernandez, E; Pong, RC; Chen, B; Sonavane, R; Raj, G; Kapur, P; Lin, HY; Wu, SR; Ko, CJ; Lo, UG; Lee, HY; Hsieh, JT; Lee, MS				Lee, Cheng-Fan; Dang, Andrew; Hernandez, Elizabeth; Pong, Rey-Chen; Chen, Benjamin; Sonavane, Rajni; Raj, Ganesh; Kapur, Payal; Lin, Hsin-Ying; Wu, Shang-Ru; Ko, Chun-Jung; Lo, U-Ging; Lee, Hsin-yu; Hsieh, Jer-Tsong; Lee, Ming-Shyue			Activation of sphingosine kinase by lipopolysaccharide promotes prostate cancer cell invasion and metastasis via SphK1/S1PR4/matriptase	ONCOGENE			English	Article							C-REACTIVE PROTEIN; NF-KAPPA-B; HUMAN OVARIAN-CANCER; GROWTH-FACTOR; MATRIPTASE ACTIVATION; SIGNALING PATHWAY; PLASMA-MEMBRANE; SPHINGOSINE-1-PHOSPHATE; 1-PHOSPHATE; MIGRATION	Gram-negative bacteria have been found to be a major population in prostatitis and prostate cancer (PCa) tissues. Lipopolysaccharide (LPS), a major compound of Gram-negative bacteria, with stimulatory activities in some cancer types, but has not been fully studied in PCa. In this study, we examined the effect of LPS on the invasion of PCa cells. Interestingly, LPS can enhance the invasiveness of PCa, but had no significant effect on PCa cell viability. Using protease inhibitor screening and biochemical analyses, matriptase, a member of the membrane-anchored serine protease family, is found to play a key role in LPS-induced PCa cell invasion. Mechanistically, Toll-like receptor 4 (TLR4, LPS receptor)sphingosine kinase 1 (SphK1) signaling underlies LPS-induced matriptase activation and PCa cell invasion. Specifically, LPS induced the S225 phosphorylation of SphK1 and the translocation of SphK1 to plasma membrane, leading to the production of sphingosine 1-phosphate (S1P), ERK1/2 and matriptase activation via S1P receptor 4 (S1PR4). This phenomenon is further validated using the patient-derived explant (PDE) model. Indeed, there is a significant correlation among the elevated SphK1 levels, the Gleason grades of PCa specimens, and the poor survival of PCa patients. Taken together, this study demonstrates a potential impact of LPS on PCa progression. Our results provide not only a new finding of the role of bacterial infection in PCa progression but also potential therapeutic target(s) associated with PCa metastasis.	[Lee, Cheng-Fan; Lin, Hsin-Ying; Wu, Shang-Ru; Ko, Chun-Jung; Lee, Ming-Shyue] Natl Taiwan Univ, Dept Biochem & Mol Biol, Coll Med, Taipei, Taiwan; [Lee, Cheng-Fan; Dang, Andrew; Hernandez, Elizabeth; Pong, Rey-Chen; Sonavane, Rajni; Raj, Ganesh; Lo, U-Ging; Hsieh, Jer-Tsong] Univ Texas Southwestern Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA; [Chen, Benjamin] Univ Texas Southwestern Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75390 USA; [Kapur, Payal] Univ Texas Southwestern Med Ctr Dallas, Urol & Pathol, Dallas, TX 75390 USA; [Ko, Chun-Jung] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; [Lee, Hsin-yu] Natl Taiwan Univ, Dept Life Sci, Taipei, Taiwan	National Taiwan University; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; UTMD Anderson Cancer Center; National Taiwan University	Lee, MS (corresponding author), Natl Taiwan Univ, Dept Biochem & Mol Biol, Coll Med, Taipei, Taiwan.; Hsieh, JT (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA.	jt.hsieh@utsouthwestern.edu; mslee2006@ntu.edu.tw	Ko, Chun-Jung/AAA-6187-2022	Ko, Chun-Jung/0000-0001-6565-7060	United States Army [W81XWH-11-1-0491, W81XWH-16-1-0474]; Taiwan National Science Council [NSC 100-2628-B-002-004-MY4]; National Health Research Institutes Grant [NHRI-EX102-9909BC, NHRI-EX106-10401BI]; National Taiwan University [NTU-CESRP-104R7602C4, 107L890504]; Ministry of Science and Technology [MOST 103-2321-B-002-096, MOST 104-2320B-002-044- MY3, MOST 104-2911-I-002-578, MOST 105-2911-I-002-521, MOST 106-2320-B-002-046-MY3]	United States Army(United States Department of DefenseUnited States Army); Taiwan National Science Council(Ministry of Science and Technology, Taiwan); National Health Research Institutes Grant; National Taiwan University(National Taiwan University); Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea)	This work was supported in part by grants from the United States Army (W81XWH-11-1-0491 and W81XWH-16-1-0474) to Jer-Tsong Hsieh, and by Taiwan National Science Council Grant NSC 100-2628-B-002-004-MY4, Ministry of Science and Technology Grants (MOST 103-2321-B-002-096, MOST 104-2320B-002-044- MY3, MOST 104-2911-I-002-578, MOST 105-2911-I-002-521 and MOST 106-2320-B-002-046-MY3), National Health Research Institutes Grant (NHRI-EX102-9909BC and NHRI-EX106-10401BI), and National Taiwan University Grant NTU-CESRP-104R7602C4 and 107L890504 to Ming-Shyue Lee. We thank Dr. Bink W. Wattenberg at James Graham Brown Cancer Center for SphK1 plasmid, Dr. Ming-Fong Lin at the University of Nebraska Medical Center for human prostate cancer cell lines, Dr. Chen-Yong Lin at the Georgetown University for his gifts of antibodies and I-Wen Huang and Kuan-Jin Yu for their technical supports.	Adams DR, 2016, TRENDS BIOCHEM SCI, V41, P395, DOI 10.1016/j.tibs.2016.02.007; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Asghar MY, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196992; Balthasar S, 2006, BIOCHEM J, V398, P547, DOI 10.1042/BJ20060299; Beach JA, 2016, ONCOTARGET, V7, P4167, DOI 10.18632/oncotarget.6703; Benaud C, 2002, J BIOL CHEM, V277, P10539, DOI 10.1074/jbc.M109064200; Bi Y, 2014, AM J PATHOL, V184, P2791, DOI 10.1016/j.ajpath.2014.06.023; Cheng JC, 2013, J CLIN INVEST, V123, P4344, DOI 10.1172/JCI64791; Datta A, 2014, ONCOTARGET, V5, P5920, DOI 10.18632/oncotarget.1874; Delon C, 2004, J BIOL CHEM, V279, P44763, DOI 10.1074/jbc.M405771200; Devine KM, 2008, GYNECOL ONCOL, V110, P237, DOI 10.1016/j.ygyno.2008.04.013; Fleming JK, 2016, J LIPID RES, V57, P1737, DOI 10.1194/jlr.D068866; Gebhardt C, 2009, J VET EMERG CRIT CAR, V19, P450, DOI 10.1111/j.1476-4431.2009.00462.x; Gonzalez-Reyes S, 2011, CANCER IMMUNOL IMMUN, V60, P217, DOI 10.1007/s00262-010-0931-0; Guo YX, 2015, INT J CLIN EXP MED, V8, P20349; Illuzzi G, 2010, J BIOL CHEM, V285, P18594, DOI 10.1074/jbc.M109.072801; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Kalhori V, 2015, MOL CELL ENDOCRINOL, V404, P113, DOI 10.1016/j.mce.2015.01.037; Kim ES, 2011, J CELL SCI, V124, P2220, DOI 10.1242/jcs.076794; Kiyomiya KI, 2006, AM J PHYSIOL-CELL PH, V291, pC40, DOI 10.1152/ajpcell.00351.2005; Ko CJ, 2017, ONCOGENE, V36, P4597, DOI 10.1038/onc.2017.82; Ko CJ, 2015, CANCER RES, V75, P2949, DOI 10.1158/0008-5472.CAN-14-3297; Koh E, 2007, CELL SIGNAL, V19, P1328, DOI 10.1016/j.cellsig.2007.01.005; Lanoix JP, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-183; Lee MS, 2006, J CANC MOL, V2, P183; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Lehrer S, 2005, BJU INT, V95, P961, DOI 10.1111/j.1464-410X.2005.05447.x; Li J, 2017, ANAT REC, V300, P1219, DOI 10.1002/ar.23590; Li MH, 2009, CANCER LETT, V276, P171, DOI 10.1016/j.canlet.2008.11.025; Liang J, 2013, CANCER CELL, V23, P107, DOI 10.1016/j.ccr.2012.11.013; Lin CY, 2008, FRONT BIOSCI-LANDMRK, V13, P621, DOI 10.2741/2707; Lipsky BA, 2010, CLIN INFECT DIS, V50, P1641, DOI 10.1086/652861; Liu XX, 2017, BIOMED PHARMACOTHER, V92, P429, DOI 10.1016/j.biopha.2017.05.102; Ma D, 2017, BIOCHEM BIOPH RES CO, V482, P366, DOI 10.1016/j.bbrc.2016.11.069; Maceyka M, 2014, NATURE, V510, P58, DOI 10.1038/nature13475; Malavaud B, 2010, EUR J CANCER, V46, P3417, DOI 10.1016/j.ejca.2010.07.053; Miller AV, 2008, MOL CELL BIOL, V28, P4142, DOI 10.1128/MCB.01465-07; Mukhopadhyay P, 2015, BREAST CANCER MANAG, V4, P241, DOI 10.2217/bmt.15.20; Nagahashi M., 2014, BIOMED RES INT, V2014, P1; Nakajima M, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317699133; Newman JV, 2001, J INFECT DIS, V184, P227, DOI 10.1086/321998; Nunes J, 2012, BRIT J CANCER, V106, P909, DOI 10.1038/bjc.2012.14; Ohotski J, 2012, BRIT J CANCER, V106, P1453, DOI 10.1038/bjc.2012.98; Park KS, 2007, BIOCHEM BIOPH RES CO, V356, P239, DOI 10.1016/j.bbrc.2007.02.112; Pchejetski D, 2011, NAT REV UROL, V8, P569, DOI 10.1038/nrurol.2011.117; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; Pitson SM, 2005, J EXP MED, V201, P49, DOI 10.1084/jem.20040559; Proia RL, 2015, J CLIN INVEST, V125, P1379, DOI 10.1172/JCI76369; Pyne Nigel J., 2015, Advances in Biological Regulation, V60, P151, DOI 10.1016/j.jbior.2015.09.001; Pyne NJ, 2012, BIOCHEM SOC T, V40, P94, DOI 10.1042/BST20110602; Rosenberg AJ, 2015, APPL RADIAT ISOTOPES, V102, P5, DOI 10.1016/j.apradiso.2015.04.010; Salama MF, 2015, FASEB J, V29, P2803, DOI 10.1096/fj.15-270413; Sevenich L, 2014, GENE DEV, V28, P2331, DOI 10.1101/gad.250647.114; Shida D, 2008, CANCER RES, V68, P6569, DOI 10.1158/0008-5472.CAN-08-0411; Shu XD, 2002, MOL CELL BIOL, V22, P7758, DOI 10.1128/MCB.22.22.7758-7768.2002; Simons BW, 2015, J PATHOL, V235, P478, DOI 10.1002/path.4472; Sordillo LA, 2016, ANTICANCER RES, V36, P2085; St Hill CA, 2015, FRONT CHEM, V3, DOI 10.3389/fchem.2015.00055; Syed SN, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/7510496; Szajnik M, 2009, ONCOGENE, V28, P4353, DOI 10.1038/onc.2009.289; Taitt HE, 2018, AM J MENS HEALTH, V12, P1807, DOI 10.1177/1557988318798279; Tan YH, 2014, MOL CELL, V54, P212, DOI 10.1016/j.molcel.2014.03.012; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Thamilselvan V, 2002, IN VITRO CELL DEV-AN, V38, P246; Tsai CH, 2014, ONCOGENE, V33, P4643, DOI 10.1038/onc.2013.412; Vaarala MH, 2016, ONCOL LETT, V12, P1149, DOI 10.3892/ol.2016.4702; Visentin B, 2006, CANCER CELL, V9, P225, DOI 10.1016/j.ccr.2006.02.023; Wang D, 2008, MOL CANCER THER, V7, P1993, DOI 10.1158/1535-7163.MCT-08-0088; Watson C, 2010, AM J PATHOL, V177, P2205, DOI 10.2353/ajpath.2010.100220; Weichand B, 2017, J EXP MED, V214, P2695, DOI 10.1084/jem.20160392; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Wu SR, 2010, AM J PATHOL, V177, P3145, DOI 10.2353/ajpath.2010.100228; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yatomi Y, 2008, BBA-GEN SUBJECTS, V1780, P606, DOI 10.1016/j.bbagen.2007.10.006; Young N, 2009, MOL CANCER RES, V7, P23, DOI 10.1158/1541-7786.MCR-08-0061; Zeng Y, 2016, ONCOL LETT, V12, P379, DOI 10.3892/ol.2016.4661; Zhan ZZ, 2014, AUTOPHAGY, V10, P257, DOI 10.4161/auto.27162; Zhu GW, 2016, CELL PHYSIOL BIOCHEM, V39, P1665, DOI 10.1159/000447868; Ziaee S, 2015, TRANSL ANDROL UROL, V4, P438, DOI 10.3978/j.issn.2223-4683.2015.04.10	80	26	27	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2019	38	28					5580	5598		10.1038/s41388-019-0833-3	http://dx.doi.org/10.1038/s41388-019-0833-3			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IH9RW	31152147				2022-12-28	WOS:000474845100003
J	D'Errico, G; Alonso-Nocelo, M; Vallespinos, M; Hermann, PC; Alcala, S; Garcia, CP; Martin-Hijano, L; Valle, S; Earl, J; Cassiano, C; Lombardia, L; Feliu, J; Monti, MC; Seufferlein, T; Garcia-Bermejo, L; Martinelli, P; Carrato, A; Sainz, B				D'Errico, Gabriele; Alonso-Nocelo, Marta; Vallespinos, Mireia; Hermann, Patrick C.; Alcala, Sonia; Pedrero Garcia, Coral; Martin-Hijano, Laura; Valle, Sandra; Earl, Julie; Cassiano, Chiara; Lombardia, Luis; Feliu, Jaime; Monti, Maria Chiara; Seufferlein, Thomas; Garcia-Bermejo, Laura; Martinelli, Paola; Carrato, Alfredo; Sainz, Bruno, Jr.			Tumor-associated macrophage-secreted 14-3-3 zeta signals via AXL to promote pancreatic cancer chemoresistance	ONCOGENE			English	Article							DUCTAL ADENOCARCINOMA; CELL-DEATH; GROWTH; CHEMOTHERAPY; METASTASIS; INHIBITION; LIVER; IDENTIFICATION; INFLAMMATION; EXPRESSION	Pancreatic ductal adenocarcinoma (PDAC) is an inherently chemoresistant tumor. Chemotherapy leads to apoptosis of cancer cells, and in previous studies we have shown that tumor-associated macrophage (TAM) infiltration increases following chemotherapy in PDAC. Since one of the main functions of macrophages is to eliminate apoptotic cells, we hypothesized that TAMs phagocytose chemotherapy-induced apoptotic cells and secrete factors, which favor PDAC chemoresistance. To test this hypothesis, primary human PDAC cultures were treated with conditioned media (CM) from monocyte-derived macrophage cultures incubated with apoptotic PDAC cells (Mempty set(Apop)CM). Mempty set(Apop)CM pretreatment rendered naive PDAC cells resistant to Gemcitabine- or Abraxane-induced apoptosis. Proteomic analysis of Mempty set(Apop)CM identified YWHAZ/14-3-3 protein zeta/delta (14-3-3 zeta), a major regulator of apoptotic cellular pathways, as a potential mediator of chemoresistance, which was subsequently validated in patient transcriptional datasets, serum samples from PDAC patients and using recombinant 14-3-3 zeta and inhibitors thereof Moreover, in mice bearing orthotopic PDAC tumors, the antitumor potential of Gemcitabine was significantly enhanced by elimination of TAMs using clodronate liposomes or by pharmacological inhibition of the Axl receptor tyrosine kinase, a 14-3-3 zeta interacting partner. These data highlight a unique regulatory mechanism by which chemotherapy-induced apoptosis acts as a switch to initiate a protumor/antiapoptotic mechanism in PDAC via 14-3-3 zeta/Axl signaling, leading to phosphorylation of Akt and activation of cellular prosurvival mechanisms The data presented therefore challenge the idea that apoptosis of tumor cells is therapeutically beneficial, at least when immune sensor cells, such as macrophages, are present.	[D'Errico, Gabriele; Alonso-Nocelo, Marta; Vallespinos, Mireia; Alcala, Sonia; Pedrero Garcia, Coral; Martin-Hijano, Laura; Valle, Sandra; Sainz, Bruno, Jr.] UAM, Dept Biochem, Madrid, Spain; [D'Errico, Gabriele; Feliu, Jaime] La Paz Univ Hosp, Dept Med Oncol, Madrid, Spain; [Alonso-Nocelo, Marta; Vallespinos, Mireia; Alcala, Sonia; Pedrero Garcia, Coral; Martin-Hijano, Laura; Valle, Sandra; Sainz, Bruno, Jr.] CSIC UAM, Inst Invest Biomed Alberto Sols IIBM, Dept Canc Biol, Madrid, Spain; [Alonso-Nocelo, Marta; Vallespinos, Mireia; Alcala, Sonia; Pedrero Garcia, Coral; Martin-Hijano, Laura; Valle, Sandra; Earl, Julie; Carrato, Alfredo; Sainz, Bruno, Jr.] IRYCIS, Chron Dis & Canc Area 3, Madrid, Spain; [Hermann, Patrick C.; Seufferlein, Thomas] Ulm Univ, Dept Internal Med 1, Ulm, Germany; [Earl, Julie; Feliu, Jaime; Carrato, Alfredo] Biomed Res Network Canc CIBERONC, CB16 12 00446, Madrid, Spain; [Earl, Julie; Feliu, Jaime; Carrato, Alfredo] Biomed Res Network Canc CIBERONC, CB16 12 00398, Madrid, Spain; [Earl, Julie; Carrato, Alfredo] Alcala Univ, Ramon y Cajal Univ Hosp, Med Oncol Dept, Madrid, Spain; [Cassiano, Chiara; Monti, Maria Chiara] Univ Salerno, Dept Pharm, Salerno, Italy; [Lombardia, Luis] Spanish Natl Canc Res Ctr CNIO, Mol Diagnost Unit, Clin Res Programme, Madrid, Spain; [Garcia-Bermejo, Laura] Biomarkers & Therapeut Targets Grp IRYCIS, Madrid, Spain; [Martinelli, Paola] Med Univ Wien, Inst Canc Res, Comprehens Canc Ctr, Vienna, Austria	Autonomous University of Madrid; Hospital Universitario La Paz; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Ulm University; Hospital Universitario Ramon y Cajal; Universidad de Alcala; University of Salerno; Centro Nacional de Investigaciones Oncologicas (CNIO); Medical University of Vienna	Sainz, B (corresponding author), UAM, Dept Biochem, Madrid, Spain.; Sainz, B (corresponding author), CSIC UAM, Inst Invest Biomed Alberto Sols IIBM, Dept Canc Biol, Madrid, Spain.; Sainz, B (corresponding author), IRYCIS, Chron Dis & Canc Area 3, Madrid, Spain.	bruno.sainz@uam.es	Hermann, Patrick/Y-6254-2019; Seufferlein, Thomas TW/P-7147-2018; Anding, Bruno Sainz/ABH-5365-2020; Vallespinós, Mireia/AAL-1708-2021; Vallespinós, Mireia/AAC-9628-2022	Hermann, Patrick/0000-0003-0418-0478; Anding, Bruno Sainz/0000-0003-4829-7651; Alcala, Sonia/0000-0002-7644-4973; CARRATO, ALFREDO/0000-0001-7749-8140; Earl, Julie/0000-0001-9360-4716; Alonso-Nocelo, Marta/0000-0001-8838-363X	Ministerio de Economia y Competitividad, Spain [RYC-2012-12104]; Clinic and Laboratory Integration Program (CLIP) grant from the Cancer Research Institute (CRI), NY; Fundacion Asociacion Espanola Contra el Cancer (AECC) [GC16173694BARB]; Fondo de Investigaciones Sanitarias (FIS) from the Instituto de Salud Carlos III (ISCIII), Spain [PI15/01507, PI15/01715, PI15/02101]; Fondo Europeo de Desarrollo Regional (FEDER); Biomedical Research Network in Cancer [CIBER-ONC:CB16/12/00446]; Austrian Science Fund [FWF-B27361]; Ingrid Shaker-Nessmann Foundation; Max Eder Fellowship of the German Cancer Aid [111746]; German Research Foundation (DFG) [CRC 1279]	Ministerio de Economia y Competitividad, Spain; Clinic and Laboratory Integration Program (CLIP) grant from the Cancer Research Institute (CRI), NY; Fundacion Asociacion Espanola Contra el Cancer (AECC); Fondo de Investigaciones Sanitarias (FIS) from the Instituto de Salud Carlos III (ISCIII), Spain; Fondo Europeo de Desarrollo Regional (FEDER)(European Commission); Biomedical Research Network in Cancer; Austrian Science Fund(Austrian Science Fund (FWF)); Ingrid Shaker-Nessmann Foundation; Max Eder Fellowship of the German Cancer Aid; German Research Foundation (DFG)(German Research Foundation (DFG))	We are indebted to Jose German Casas for CD14-enriched monocyte preparations, Carmen Sanchez Palomo and Esperanza Macarena Rodriguez Serrano for IHC and histological assistance, and Maria Gonzalez Dionis for in vitro technical assistance. The research was supported by a Ramon y Cajal Merit Award (RYC-2012-12104) from the Ministerio de Economia y Competitividad, Spain (BS, Jr.), a Clinic and Laboratory Integration Program (CLIP) grant from the Cancer Research Institute (CRI), NY (BS, Jr.), a Coordinated grant (GC16173694BARB) from the Fundacion Asociacion Espanola Contra el Cancer (AECC) (AC and BS, Jr.), Fondo de Investigaciones Sanitarias (FIS) grants PI15/01507 (BS, Jr.), PI15/01715 (LGB) and PI15/02101 (AC) (co-financed through Fondo Europeo de Desarrollo Regional (FEDER) "Una manera de hacer Europa") from the Instituto de Salud Carlos III (ISCIII), Spain, funding from the Biomedical Research Network in Cancer (CIBER-ONC:CB16/12/00446) for clinical sample and data collection (AC), funding from the Austrian Science Fund (FWF-B27361) and Ingrid Shaker-Nessmann Foundation for Cancer Research (PM), a Max Eder Fellowship of the German Cancer Aid (111746) (PCH), and by the German Research Foundation (DFG, CRC 1279 "Exploiting the human peptidome for Novel Antimicrobial and Anticancer Agents") (PCH).	Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; D'Costa Z, 2017, CANCER RES, V77, P5952, DOI 10.1158/0008-5472.CAN-16-2833; Dengler M, 2017, ONCOTARGET, V8, P46234, DOI 10.18632/oncotarget.17598; DUVALL E, 1985, IMMUNOLOGY, V56, P351; Eng EW, 2007, MOL BIOL CELL, V18, P2389, DOI 10.1091/mbc.e06-12-1128; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Gjerdrum C, 2010, P NATL ACAD SCI USA, V107, P1124, DOI 10.1073/pnas.0909333107; Hidalgo M, 2015, PANCREATOLOGY, V15, P8, DOI 10.1016/j.pan.2014.10.001; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hu H, 2016, TUMOR BIOL, V37, P8657, DOI 10.1007/s13277-015-4741-z; Ireland L, 2016, CANCER RES, V76, P6851, DOI 10.1158/0008-5472.CAN-16-1201; Jandaghi P, 2016, GASTROENTEROLOGY, V151, P1218, DOI 10.1053/j.gastro.2016.08.040; Janky R, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2540-6; Kariolis MS, 2017, J CLIN INVEST, V127, P183, DOI 10.1172/JCI85610; Khorrami A, 2017, HORM MOL BIOL CLIN I, V32, DOI 10.1515/hmbci-2017-0032; Kirane A, 2015, CANCER RES, V75, P3699, DOI 10.1158/0008-5472.CAN-14-2887-T; Kitamura T, 2015, NAT REV IMMUNOL, V15, P73, DOI 10.1038/nri3789; Klemm C, 2014, PATHOL RES PRACT, V210, P335, DOI 10.1016/j.prp.2014.01.001; Ko AH, 2015, J CLIN ONCOL, V33, P1779, DOI 10.1200/JCO.2014.59.7625; Kobayashi R, 2009, CANCER IMMUNOL IMMUN, V58, P247, DOI 10.1007/s00262-008-0549-7; Korshunov VA, 2012, CLIN SCI, V122, P361, DOI 10.1042/CS20110411; Ludwig KF, 2018, CANCER RES, V78, P246, DOI 10.1158/0008-5472.CAN-17-1973; Martinelli P, 2017, GUT, V66, P1665, DOI 10.1136/gutjnl-2015-311256; Masters SC, 2001, J BIOL CHEM, V276, P45193, DOI 10.1074/jbc.M105971200; Matta A, 2016, PROTEOMICS, V16, P1079, DOI 10.1002/pmic.201500489; Matta A, 2012, EXPERT OPIN THER TAR, V16, P515, DOI 10.1517/14728222.2012.668185; Mueller MT, 2009, GASTROENTEROLOGY, V137, P1102, DOI 10.1053/j.gastro.2009.05.053; Nielsen SR, 2016, NAT CELL BIOL, V18, P549, DOI 10.1038/ncb3340; Nywening TM, 2016, LANCET ONCOL, V17, P651, DOI 10.1016/S1470-2045(16)00078-4; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Olson OC, 2017, CELL REP, V19, P101, DOI 10.1016/j.celrep.2017.03.038; Powell DW, 2002, J BIOL CHEM, V277, P21639, DOI 10.1074/jbc.M203167200; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Reichl P, 2015, HEPATOLOGY, V61, P930, DOI 10.1002/hep.27492; Sainz B, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/9012369; Sainz B, 2015, GUT, V64, P1921, DOI 10.1136/gutjnl-2014-308935; Sainz B, 2014, CANCER RES, V74, P7309, DOI 10.1158/0008-5472.CAN-14-1354; Seifert L, 2016, GASTROENTEROLOGY, V150, P1659, DOI 10.1053/j.gastro.2016.02.070; Sica A, 2008, CANCER LETT, V267, P204, DOI 10.1016/j.canlet.2008.03.028; Vakkila J, 2004, NAT REV IMMUNOL, V4, P641, DOI 10.1038/nri1415; Wang WQ, 2016, BRIT J SURG, V103, P1189, DOI 10.1002/bjs.10187; Wang XC, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0180-7; Weizman N, 2014, ONCOGENE, V33, P3812, DOI 10.1038/onc.2013.357; Werba G, 2016, CELL CYCLE, V15, P2095, DOI 10.1080/15384101.2016.1191251; Wu GL, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.113; Zhang X, 2016, CANCER LETT, V381, P305, DOI 10.1016/j.canlet.2016.08.004; Zhou N, 2015, INT J MOL SCI, V16, P11966, DOI 10.3390/ijms160611966	48	35	35	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2019	38	27					5469	5485		10.1038/s41388-019-0803-9	http://dx.doi.org/10.1038/s41388-019-0803-9			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IG5KR	30936462				2022-12-28	WOS:000473842500010
J	Haney, SL; Varney, ML; Chhonker, YS; Shin, S; Mehla, K; Crawford, AJ; Smith, HJ; Smith, LM; Murry, DJ; Hollingsworth, MA; Holstein, SA				Haney, Staci L.; Varney, Michelle L.; Chhonker, Yashpal S.; Shin, Simon; Mehla, Kamiya; Crawford, Ayrianne J.; Smith, Heather Jensen; Smith, Lynette M.; Murry, Daryl J.; Hollingsworth, Michael A.; Holstein, Sarah A.			Inhibition of geranylgeranyl diphosphate synthase is a novel therapeutic strategy for pancreatic ductal adenocarcinoma	ONCOGENE			English	Article							CANCER; MUC1; MUCINS; TRAFFICKING; BORTEZOMIB; ANTIBODY; CELLS	Rab proteins play an essential role in regulating intracellular membrane trafficking processes. Rab activity is dependent upon geranylgeranylation, a post-translational modification that involves the addition of 20-carbon isoprenoid chains via the enzyme geranylgeranyl transferase (GGTase) II. We have focused on the development of inhibitors against geranylgeranyl diphosphate synthase (GGDPS), which generates the isoprenoid donor (GGPP), as anti-Rab agents. Pancreatic ductal adenocarcinoma (PDAC) is characterized by abnormal mucin production and these mucins play important roles in tumor development, metastasis and chemo-resistance. We hypothesized that GGDPS inhibitor (GGDPSi) treatment would induce PDAC cell death by disrupting mucin trafficking, thereby inducing the unfolded protein response pathway (UPR) and apoptosis. To this end, we evaluated the effects of RAM2061, a potent GGDPSi, against PDAC. Our studies revealed that GGDPSi treatment activates the UPR and triggers apoptosis in a variety of human and mouse PDAC cell lines. Furthermore, GGDPSi treatment was found to disrupt the intracellular trafficking of key mucins such as MUC1. These effects could be recapitulated by incubation with a specific GGTase II inhibitor, but not a GGTase I inhibitor, consistent with the effect being dependent on disruption of Rab-mediated activities. In addition, siRNA-mediated knockdown of GGDPS induces upregulation of UPR markers and disrupts MUC1 trafficking in PDAC cells. Experiments in two mouse models of PDAC demonstrated that GGDPSi treatment significantly slows tumor growth. Collectively, these data support further development of GGDPSi therapy as a novel strategy for the treatment of PDAC.	[Haney, Staci L.; Varney, Michelle L.; Holstein, Sarah A.] Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE 68198 USA; [Haney, Staci L.; Varney, Michelle L.; Shin, Simon; Mehla, Kamiya; Crawford, Ayrianne J.; Smith, Heather Jensen; Murry, Daryl J.; Hollingsworth, Michael A.; Holstein, Sarah A.] Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA; [Chhonker, Yashpal S.; Murry, Daryl J.] Univ Nebraska Med Ctr, Dept Pharm Practice, Omaha, NE USA; [Shin, Simon; Mehla, Kamiya; Crawford, Ayrianne J.; Smith, Heather Jensen; Hollingsworth, Michael A.] Univ Nebraska Med Ctr, Eppley Inst Res Canc, Omaha, NE USA; [Smith, Lynette M.] Univ Nebraska Med Ctr, Coll Publ Hlth, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Holstein, SA (corresponding author), Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE 68198 USA.; Holstein, SA (corresponding author), Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA.	sarah.holstein@unmc.edu		Varney, Michelle/0000-0001-5339-2077	Fred & Pamela Buffett Cancer Center Support Grant from the National Cancer Institute [P30 CA036727]; National Institutes of Health [P50CA127297]; Fred & Pamela Buffett Cancer Center Advanced Microscopy Core Facility; Flow Cytometry Research Facility; National Cancer Institute [P30 CA036727]; NATIONAL CANCER INSTITUTE [P30CA036727, P50CA127297] Funding Source: NIH RePORTER	Fred & Pamela Buffett Cancer Center Support Grant from the National Cancer Institute; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Fred & Pamela Buffett Cancer Center Advanced Microscopy Core Facility; Flow Cytometry Research Facility; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the Fred & Pamela Buffett Cancer Center Support Grant from the National Cancer Institute under award P30 CA036727 and the National Institutes of Health P50CA127297. The authors wish to acknowledge the support of the Fred & Pamela Buffett Cancer Center Advanced Microscopy Core Facility and the Flow Cytometry Research Facility, supported by the National Cancer Institute under award P30 CA036727. We thank Janice A. Taylor and James R. Talaska of the Advanced Microscopy Core Facility for providing assistance with confocal microscopy.	Besmer DM, 2011, CANCER RES, V71, P4432, DOI 10.1158/0008-5472.CAN-10-4439; Born EJ, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.64; Chhonker YS, 2018, MOLECULES, V23, DOI 10.3390/molecules23123275; Coxon FP, 2014, EUR J MED CHEM, V84, P77, DOI 10.1016/j.ejmech.2014.06.062; Deer EL, 2010, PANCREAS, V39, P425, DOI 10.1097/MPA.0b013e3181c15963; Haney SL, 2018, INVEST NEW DRUG, V36, P810, DOI 10.1007/s10637-018-0571-3; Haney SL, 2017, MOLECULES, V22, DOI 10.3390/molecules22060886; Hanson RL, 2016, BIOMOLECULES, V6, DOI 10.3390/biom6030034; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Holstein SA, 2001, LEUKEMIA RES, V25, P651, DOI 10.1016/S0145-2126(00)00162-4; Holstein SA, 2011, LEUKEMIA RES, V35, P551, DOI 10.1016/j.leukres.2010.08.008; Igarashi T, 2017, ONCOTARGET, V8, P12290, DOI 10.18632/oncotarget.14703; IWAMURA T, 1992, J GASTROEN HEPATOL, V7, P512, DOI 10.1111/j.1440-1746.1992.tb01030.x; Jin CN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039432; Jonckheere N, 2014, BBA-REV CANCER, V1846, P142, DOI 10.1016/j.bbcan.2014.04.008; Kaur S, 2013, NAT REV GASTRO HEPAT, V10, P607, DOI 10.1038/nrgastro.2013.120; Kinlough CL, 2006, J BIOL CHEM, V281, P12112, DOI 10.1074/jbc.M512996200; Liu XL, 2008, BIOCHEM BIOPH RES CO, V376, P688, DOI 10.1016/j.bbrc.2008.09.065; Luberice K, 2017, AM J SURG, V214, P341, DOI 10.1016/j.amjsurg.2017.05.007; Marten A, 2008, MOL CANCER THER, V7, P3624, DOI 10.1158/1535-7163.MCT-08-0393; Matthiesen RA, 2018, BIOORGAN MED CHEM, V26, P376, DOI 10.1016/j.bmc.2017.10.023; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Nath S, 2014, TRENDS MOL MED, V20, P332, DOI 10.1016/j.molmed.2014.02.007; Qi WM, 2001, HYBRIDOMA HYBRIDOM, V20, P313, DOI 10.1089/15368590152740716; Sorensen AL, 2006, GLYCOBIOLOGY, V16, P96, DOI 10.1093/glycob/cwj044; Suh H, 2017, AM J CANCER RES, V7, P1372; Taylor-Papadimitriou J, 2018, BIOCHEM SOC T, V46, P659, DOI 10.1042/BST20170400; TAYLORPAPADIMITRIOU J, 1981, INT J CANCER, V28, P17, DOI 10.1002/ijc.2910280104; Wang HB, 2012, ANTICANCER RES, V32, P1027; Wills VS, 2015, ACS MED CHEM LETT, V6, P1195, DOI 10.1021/acsmedchemlett.5b00334; Wssniowski TT, 2012, INT J ONCOL, V40, P1581, DOI 10.3892/ijo.2012.1337; Yan Y, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-445; Yu DC, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-248	34	12	12	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2019	38	26					5308	5320		10.1038/s41388-019-0794-6	http://dx.doi.org/10.1038/s41388-019-0794-6			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IF4AX	30918331	Green Accepted			2022-12-28	WOS:000473025300014
J	Castagnoli, L; Cancila, V; Cordoba-Romero, SL; Faraci, S; Talarico, G; Belmonte, B; Iorio, MV; Milani, M; Volpari, T; Chiodoni, C; Hidalgo-Miranda, A; Tagliabue, E; Tripodo, C; Sangaletti, S; Di Nicola, M; Pupa, SM				Castagnoli, Lorenzo; Cancila, Valeria; Cordoba-Romero, Sandra L.; Faraci, Simona; Talarico, Giovanna; Belmonte, Beatrice; Iorio, Marilena V.; Milani, Matteo; Volpari, Tatiana; Chiodoni, Claudia; Hidalgo-Miranda, Alfredo; Tagliabue, Elda; Tripodo, Claudio; Sangaletti, Sabina; Di Nicola, Massimo; Pupa, Serenella M.			WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer	ONCOGENE			English	Article							TUMOR-INFILTRATING LYMPHOCYTES; PROGNOSTIC VALUE; PATHWAY; STABILIZATION; ONTOLOGY	Triple-negative breast cancers (TNBCs) are characterized by a poor prognosis and lack of targeted treatments, and thus, new therapeutic strategies are urgently needed. Inhibitors against programmed death-1 (PD-1)/PD-1 ligand (PD-L1) have shown significant efficacy in various solid cancers, but their activity against TNBCs remains limited. Here, we report that human TNBCs molecularly stratified for high levels of PD-L1 (PD-L1(High)) showed significantly enriched expression of immune and cancer stemness pathways compared with those with low PD-L1 expression (PD-L1(Low)). In addition, the PD-L1(High) cases were significantly associated with a high stemness score (SSHigh) signature. TNBC cell lines gated for aldehyde dehydrogenase (ALDH) and CD44 stemness markers exhibited increased levels of PD-L1 versus their ALDH-negative and CD44(Low) counterparts, and PD-L1(High) cells generated significantly more mammospheres than PD-L1(Low) cells. Murine mammary SCA-1-positive tumor cells with PD-L1(High) expression generated tumors in vivo with higher efficacy than PD-L1(Low) cells. Furthermore, treatment of TNBC cells with selective WNT inhibitors or activators downregulated or upregulated PD-L1 expression, respectively, implying a functional cross-talk between WNT activity and PD-L1 expression. Remarkably, human TNBC samples contained tumor elements co-expressing PD-L1 with ALDH1A1 and/or CD44v6. Additionally, both PD-L1-/SCA1-positive and ALDH1A1-positive tumor elements were found in close contact with CD3-, and PD-1-positive T cells in murine and human tumor samples. Overall, our study suggests that PD-L1-positive tumor elements with a stemness phenotype may participate in the complex dynamics of TNBC-related immune evasion, which might be targeted through WNT signaling inhibition.	[Castagnoli, Lorenzo; Cordoba-Romero, Sandra L.; Faraci, Simona; Iorio, Marilena V.; Tagliabue, Elda; Pupa, Serenella M.] Fdn IRCCS Ist Nazl Tumori Milano, Dept Res, Mol Targeting Unit, Milan, Italy; [Cancila, Valeria; Belmonte, Beatrice; Tripodo, Claudio] Univ Palermo, Sch Med, Dept Hlth Sci, Tumor Immunol Unit,Human Pathol Sect, Palermo, Italy; [Talarico, Giovanna; Milani, Matteo; Chiodoni, Claudia; Sangaletti, Sabina] Fdn IRCCS Ist Nazl Tumori Milano, Dept Res, Mol Immunol Unit, Milan, Italy; [Volpari, Tatiana; Di Nicola, Massimo] Fdn IRCCS Ist Nazl Tumori Milano, Dept Med Oncol & Hematol, Unit Immunotherapy & Anticanc Innovat Therapeut, Milan, Italy; [Hidalgo-Miranda, Alfredo] Natl Inst Genom Med, Canc Genom Lab, Mexico City, DF, Mexico	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Palermo; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Instituto Nacional de Medicina Genomica	Pupa, SM (corresponding author), Fdn IRCCS Ist Nazl Tumori Milano, Dept Res, Mol Targeting Unit, Milan, Italy.; Di Nicola, M (corresponding author), Fdn IRCCS Ist Nazl Tumori Milano, Dept Med Oncol & Hematol, Unit Immunotherapy & Anticanc Innovat Therapeut, Milan, Italy.	massimo.dinicola@istitutotumori.mi.it; serenella.pupa@istitutotumori.mi.it	Talarico, Giovanna/AAB-2251-2019; Romero, Sandra/A-2246-2014; Cancila, Valeria/AAJ-3041-2021; Tripodo, Claudio/AAB-6004-2022; Pupa, Serenella/K-6388-2016; Hidalgo-Miranda, Alfredo/B-2123-2010; Sangaletti, Sabina/AAB-5873-2019; Cancila, Valeria/AIE-4354-2022; Castagnoli, Lorenzo/J-1893-2014; Milani, Matteo/AAC-1988-2020; Iorio, Marilena V/K-5446-2016; Tagliabue, Elda/B-9377-2017; Chiodoni, Claudia/C-2172-2017	Talarico, Giovanna/0000-0001-5051-6468; Romero, Sandra/0000-0002-5591-696X; Tripodo, Claudio/0000-0002-0821-6231; Pupa, Serenella/0000-0002-4592-6830; Hidalgo-Miranda, Alfredo/0000-0003-2315-3977; Sangaletti, Sabina/0000-0001-7047-287X; Cancila, Valeria/0000-0002-9502-1191; Castagnoli, Lorenzo/0000-0002-0220-6497; Milani, Matteo/0000-0002-9127-9523; Iorio, Marilena V/0000-0002-6058-1527; Tagliabue, Elda/0000-0001-9877-2903; Belmonte, Beatrice/0000-0001-9668-0925; Chiodoni, Claudia/0000-0002-7644-9969	Associazione Italiana Ricerca Cancro (AIRC) [16918]; Mexican National Council of Science and Technology [CVU 363453]	Associazione Italiana Ricerca Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Mexican National Council of Science and Technology(Consejo Nacional de Ciencia y Tecnologia (CONACyT))	This work was funded by grants from Ricerca Strategica Istituzionale call 2016 to M. Di Nicola and the Associazione Italiana Ricerca Cancro (AIRC) 16918 to S.M. Pupa. S.L. Cordoba-Romero received the Postdoctoral fellowship "Estancias Posdoctorales en el Extranjero Vinculadas a la Consolidacion de Grupos de Investigatiocion y Fortalecimiento del Posgrado Nacional" from the Mexican National Council of Science and Technology (CVU 363453).	Abramson VG, 2015, CANCER-AM CANCER SOC, V121, P8, DOI 10.1002/cncr.28914; Adams S, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.SABCS15-P2-11-06; Adams S, 2014, J CLIN ONCOL, V32, P2959, DOI 10.1200/JCO.2013.55.0491; Almozyan S, 2017, INT J CANCER, V141, P1402, DOI 10.1002/ijc.30834; Alsuliman A, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0421-2; Annett S, 2018, PHARMACOL THERAPEUT, V187, P13, DOI 10.1016/j.pharmthera.2018.02.001; Ascierto PA, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1309-2; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bruttel VS, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00360; Carbon S, 2009, BIOINFORMATICS, V25, P288, DOI 10.1093/bioinformatics/btn615; Charoentong P, 2017, CELL REP, V18, P248, DOI 10.1016/j.celrep.2016.12.019; Dey N, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-537; Emens LA, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.AM2015-2859; Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205; Guastella D, 2016, J VIS COMMUN IMAGE R, V36, P149, DOI 10.1016/j.jvcir.2016.01.012; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hsu JM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04313-6; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Jang GB, 2015, SCI REP-UK, V5, DOI 10.1038/srep12465; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Juneja VR, 2017, J EXP MED, V214, P895, DOI 10.1084/jem.20160801; Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lee Y, 2016, CLIN CANCER RES, V22, P3571, DOI 10.1158/1078-0432.CCR-15-2665; Li CL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12574; Li CW, 2018, CANCER CELL, V33, P187, DOI 10.1016/j.ccell.2018.01.009; Lim SO, 2016, CANCER CELL, V30, P925, DOI 10.1016/j.ccell.2016.10.010; Liu SZ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3148; Loi S, 2013, J CLIN ONCOL, V31, P860, DOI 10.1200/JCO.2011.41.0902; McCloskey CW, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00053; Mittendorf EA, 2014, CANCER IMMUNOL RES, V2, P361, DOI 10.1158/2326-6066.CIR-13-0127; Mohammed MK, 2016, GENES DIS, V3, P11, DOI 10.1016/j.gendis.2015.12.004; Muenst S, 2015, EXPERT OPIN THER TAR, V19, P201, DOI 10.1517/14728222.2014.980235; Nanda R, 2016, J CLIN ONCOL, V34, P2460, DOI 10.1200/JCO.2015.64.8931; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Pohl SG, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.14; Polonia A, 2017, J CLIN PATHOL, V70, P860, DOI 10.1136/jclinpath-2016-203990; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Sangaletti S, 2016, CELL REP, V17, P233, DOI 10.1016/j.celrep.2016.08.075; Sciortino G, 2016, IMAGE ANAL STEREOL, V35, P105, DOI 10.5566/ias.1352; Shats I, 2011, CANCER RES, V71, P1772, DOI 10.1158/0008-5472.CAN-10-1735; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tai D, 2015, ONCOLOGIST, V20, P1189, DOI 10.1634/theoncologist.2015-0057; Vareki SM, 2017, CRIT REV ONCOL HEMAT, V116, P116, DOI 10.1016/j.critrevonc.2017.06.001; Xu JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117097; Yam C, 2017, ONCOLOGIST, V22, P1086, DOI 10.1634/theoncologist.2017-0095; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Zou WP, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7118	49	102	105	5	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2019	38	21					4047	4060		10.1038/s41388-019-0700-2	http://dx.doi.org/10.1038/s41388-019-0700-2			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ3HX	30705400	Green Published, hybrid			2022-12-28	WOS:000468740200006
J	Llanos, S; Megias, D; Blanco-Aparicio, C; Hernandez-Encinas, E; Rovira, M; Pietrocola, F; Serrano, M				Llanos, Susana; Megias, Diego; Blanco-Aparicio, Carmen; Hernandez-Encinas, Elena; Rovira, Miguel; Pietrocola, Federico; Serrano, Manuel			Lysosomal trapping of palbociclib and its functional implications	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMA; INDUCED SENESCENCE; DRUGS; RESISTANCE; RADIATION; HEAD; PROLIFERATION; SENSITIVITY; INHIBITION; MECHANISMS	Palbociclib is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) approved for the treatment of some cancers. The main mechanism of action of palbociclib is to induce cell cycle arrest and senescence on responsive cells. Here, we report that palbociclib concentrates in intracellular acidic vesicles, where it can be readily observed due to its intrinsic fluorescence, and it is released from these vesicles upon dilution or washing out of the extracellular medium. This reversible storage of drugs into acidic vesicles is generally known as lysosomal trapping and, based on this, we uncover novel properties of palbociclib. In particular, a short exposure of cells to palbociclib is sufficient to produce a stable cell-cycle arrest and long-term senescence. Moreover, after washing out the drug, palbociclib-treated cells release the drug to the medium and this conditioned medium is active on susceptible cells. Interestingly, cancer cells resistant to palbociclib also accumulate and release the drug producing paracrine senescence on susceptible cells. Finally, other lysosomotropic drugs, such as chloroquine, interfere with the accumulation of palbociclib into lysosomes, thereby reducing the minimal dose of palbociclib required for cell-cycle arrest and senescence. In summary, lysosomal trapping explains the prolonged temporal activity of palbociclib, the paracrine activity of exposed cells, and the cooperation with lysosomotropic drugs. These are important features that may help to improve the therapeutic dosing and efficacy of palbociclib. Finally, two other clinically approved CDK4/6 inhibitors, ribociclib and abemaciclib, present a similar behavior as palbociclib, suggesting that lysosomal trapping is a property common to all three clinically-approved CDK4/6 inhibitors.	[Llanos, Susana; Megias, Diego; Blanco-Aparicio, Carmen; Hernandez-Encinas, Elena; Serrano, Manuel] Spanish Natl Canc Res Ctr CNIO, Madrid, Spain; [Rovira, Miguel; Pietrocola, Federico; Serrano, Manuel] BIST, Inst Res Biomed IRB Barcelona, Barcelona, Spain; [Serrano, Manuel] Catalan Inst Res & Adv Studies ICREA, Barcelona, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; ICREA	Llanos, S; Serrano, M (corresponding author), Spanish Natl Canc Res Ctr CNIO, Madrid, Spain.; Serrano, M (corresponding author), BIST, Inst Res Biomed IRB Barcelona, Barcelona, Spain.; Serrano, M (corresponding author), Catalan Inst Res & Adv Studies ICREA, Barcelona, Spain.	sllanos@cnio.es; manuel.serrano@irbbarcelona.org	Megías, Diego/L-6008-2014; Pietrocola, Federico/AAW-9621-2020; , Susana/AAA-9282-2019; Serrano, Manuel/H-2634-2015; Blanco-Aparicio, Carmen/I-3162-2015	Pietrocola, Federico/0000-0002-2930-234X; Serrano, Manuel/0000-0001-7177-9312; Blanco-Aparicio, Carmen/0000-0002-3249-6595; Megias, Diego/0000-0003-0755-0518; Rovira, Miguel/0000-0002-1391-8465; Llanos, Susana/0000-0002-8555-9326	"la Caixa"-Severo Ochoa PhD scholarship; EMBO Long-Term Postdoctoral Fellowship [ALTF 358-2017]; CNIO; IRB; Spanish Ministry of Economy (MINECO, SAF); European Research Council (ERC); Botin Foundation; Banco Santander (Santander Universities Global Division); "la Caixa" Foundation; MINECO	"la Caixa"-Severo Ochoa PhD scholarship; EMBO Long-Term Postdoctoral Fellowship(European Molecular Biology Organization (EMBO)); CNIO; IRB; Spanish Ministry of Economy (MINECO, SAF); European Research Council (ERC)(European Research Council (ERC)European Commission); Botin Foundation; Banco Santander (Santander Universities Global Division); "la Caixa" Foundation(La Caixa Foundation); MINECO(Spanish Government)	M.R. was holder of a "la Caixa"-Severo Ochoa PhD scholarship. F.P. is supported by EMBO Long-Term Postdoctoral Fellowship (ALTF 358-2017). Work in the laboratory of M.S. was funded by the CNIO and the IRB, and by grants from the Spanish Ministry of Economy (MINECO, SAF), the European Research Council (ERC Advanced Grant), the Botin Foundation and Banco Santander (Santander Universities Global Division), and by "la Caixa" Foundation. CNIO and IRB Barcelona are recipients of a Severo Ochoa Award of Excellence from the MINECO. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acosta JC, 2012, TRENDS CELL BIOL, V22, P211, DOI 10.1016/j.tcb.2011.11.006; Anders L, 2011, CANCER CELL, V20, P620, DOI 10.1016/j.ccr.2011.10.001; Beaver JA, 2015, CLIN CANCER RES, V21, P4760, DOI 10.1158/1078-0432.CCR-15-1185; Chen F, 2017, ANTI-CANCER AGENT ME, V17, P1; Chen L, 2017, BRIT J PHARMACOL, V174, P2427, DOI 10.1111/bph.13836; Daniel WA, 2003, PROG NEURO-PSYCHOPH, V27, P65, DOI 10.1016/S0278-5846(02)00317-2; Daniel WA, 1997, PHARMACOL TOXICOL, V80, P62, DOI 10.1111/j.1600-0773.1997.tb00285.x; Daniel WA, 1999, EUR NEUROPSYCHOPHARM, V9, P483, DOI 10.1016/S0924-977X(99)00034-6; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Ewald JA, 2010, JNCI-J NATL CANCER I, V102, P1536, DOI 10.1093/jnci/djq364; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419; Freund A, 2010, TRENDS MOL MED, V16, P238, DOI 10.1016/j.molmed.2010.03.003; Goel S, 2017, NATURE, V548, P471, DOI 10.1038/nature23465; Goldman SDB, 2009, BIOANALYSIS, V1, P1445, DOI 10.4155/BIO.09.128; GRENMAN R, 1991, CANCER, V67, P2741, DOI 10.1002/1097-0142(19910601)67:11<2741::AID-CNCR2820671105>3.0.CO;2-S; Hay T, 2009, DRUG METAB DISPOS, V37, P1864, DOI 10.1124/dmd.109.027888; Hernandez-Segura A, 2018, TRENDS CELL BIOL, V28, P436, DOI 10.1016/j.tcb.2018.02.001; Herranz N, 2015, NAT CELL BIOL, V17, P1205, DOI 10.1038/ncb3225; Kazmi F, 2013, DRUG METAB DISPOS, V41, P897, DOI 10.1124/dmd.112.050054; Knas M, 2012, FOLIA HISTOCHEM CYTO, V50, P220, DOI 10.5603/FHC.2012.0031; Kurz DJ, 2000, J CELL SCI, V113, P3613; Laberge RM, 2015, NAT CELL BIOL, V17, P1049, DOI 10.1038/ncb3195; Leontieva OV, 2015, ONCOTARGET, V6, P23238, DOI 10.18632/oncotarget.4836; Leontieva OV, 2013, CELL CYCLE, V12, P3063, DOI 10.4161/cc.26130; LI WW, 1995, P NATL ACAD SCI USA, V92, P10436, DOI 10.1073/pnas.92.22.10436; MACINTYRE AC, 1988, BIOPHARM DRUG DISPOS, V9, P513, DOI 10.1002/bod.2510090602; Massaro RR, 2017, PHARMACOL RES, V119, P242, DOI 10.1016/j.phrs.2017.02.013; Miettinen TP, 2018, EMBO J, V37, DOI 10.15252/embj.201798359; Mok CC, 2017, EXPERT REV CLIN IMMU, V13, P35, DOI 10.1080/1744666X.2016.1212659; Munoz-Espin D, 2014, NAT REV MOL CELL BIO, V15, P482, DOI 10.1038/nrm3823; Murayama N, 2006, J PHARM SCI-US, V95, P1763, DOI 10.1002/jps.20530; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Ndolo RA, 2010, J PHARMACOL EXP THER, V333, P120, DOI 10.1124/jpet.109.160226; Palmgren JJ, 2006, EUR J PHARM BIOPHARM, V64, P369, DOI 10.1016/j.ejpb.2006.06.005; PEKKOLAHEINO K, 1994, ARCH OTOLARYNGOL, V120, P750; PEKKOLAHEINO K, 1995, J CANCER RES CLIN, V121, P452, DOI 10.1007/BF01218360; Pierzynska-Mach A, 2014, CYTOM PART A, V85A, P729, DOI 10.1002/cyto.a.22495; Purvis JE, 2012, SCIENCE, V336, P1440, DOI 10.1126/science.1218351; Robinson TJW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078641; Servomaa K, 1996, CELL PROLIFERAT, V29, P219, DOI 10.1046/j.1365-2184.1996.01009.x; Valenzuela CA, 2017, EXP CELL RES, V360, P390, DOI 10.1016/j.yexcr.2017.09.031; VanArsdale T, 2015, CLIN CANCER RES, V21, P2905, DOI 10.1158/1078-0432.CCR-14-0816; Verhaegen M, 2012, ONCOGENE, V31, P828, DOI 10.1038/onc.2011.277; Vijayaraghavan S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15916; Wang HZ, 2017, NATURE, V546, P426, DOI 10.1038/nature22797; Zhitomirsky B, 2016, DRUG RESIST UPDATE, V24, P23, DOI 10.1016/j.drup.2015.11.004; 2009, METHOD ENZYMOL, V452, P181, DOI DOI 10.1016/S0076-6879(08)03612-4; 2012, EXPERT OPIN DRUG MET, V8, P943, DOI DOI 10.1517/17425255.2012.691165	49	37	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2019	38	20					3886	3902		10.1038/s41388-019-0695-8	http://dx.doi.org/10.1038/s41388-019-0695-8			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HY3OI	30692638	Green Published, hybrid			2022-12-28	WOS:000468035600009
J	De Marchi, E; Orioli, E; Pegoraro, A; Sangaletti, S; Portararo, P; Curti, A; Colombo, MP; Di Virgilio, F; Adinolfi, E				De Marchi, Elena; Orioli, Elisa; Pegoraro, Anna; Sangaletti, Sabina; Portararo, Paola; Curti, Antonio; Colombo, Mario Paolo; Di Virgilio, Francesco; Adinolfi, Elena			The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment	ONCOGENE			English	Article							P2X(7) RECEPTOR; INCREASES; CANCER; OX40; MICROVESICLES; INFLAMMATION; STIMULATION; MACROPHAGES; INVOLVEMENT; PANNEXIN-1	In the tumor microenvironment (TME) ATP and its receptor P2X7 exert a pivotal influence on cancer growth and tumor-host interactions. Here we analyzed the different effect of P2X7 genetic deficiency versus its antagonism on response against P2X7-expressing implanted tumors. We focused on immune cell expression of ATP degrading enzymes CD39 and CD73 and in vivo measured TME's ATP. The immune infiltrate of tumors growing in P2X7 null mice shows a decrease in CD8(+) cells and an increased number of Tregs, overexpressing the fitness markers OX40, PD-1, and CD73. A similar Treg phenotype is also present in the spleen of tumor-bearing P2X7 null mice and it is paralleled by a decrease in proinflammatory cytokines and an increase in TGF-beta. Differently, systemic administration of the P2X7 blocker A740003 in wild-type mice left unaltered the number of tumor-infiltrating CD8(+) and Treg lymphocytes but increased CD4(+) effector cells and decreased their expression of CD39 and CD73. P2X7 blockade did not affect spleen immune cell composition or ectonucleotidase expression but increased circulating INF-gamma. Augmented CD73 in P2X7 null mice was mirrored by a decrease in TME ATP concentration and nucleotide reduced secretion from immune cells. On the contrary, TME ATP levels remained unaltered upon P2X7 antagonism, owing to release of ATP from cancerous cells and diminished ectonucleotidase expression by CD4(+) and dendritic cells. These data point at P2X7 receptor as a key determinant of TME composition due to its combined action on immune cell infiltrate, ectonucleotidases, and ATP release.	[De Marchi, Elena; Orioli, Elisa; Pegoraro, Anna; Di Virgilio, Francesco; Adinolfi, Elena] Univ Ferrara, Sect Pathol Oncol & Expt Biol, Dept Morphol Surg & Expt Med, Via Luigi Borsari 46, I-44121 Ferrara, Italy; [Sangaletti, Sabina; Portararo, Paola; Colombo, Mario Paolo] Ist Nazl Tumori IRCCS, Mol Immunol Unit, Dept Expt Oncol, Via Amadeo 42, I-20133 Milan, Italy; [Curti, Antonio] Univ Bologna, S Orsola Malpighi Hosp, Inst Hematol L & A Seragnoli, Dept Expt Diagnost & Specialty Med, Via Massarenti 9, I-40138 Bologna, Italy	University of Ferrara; Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna	Adinolfi, E (corresponding author), Univ Ferrara, Sect Pathol Oncol & Expt Biol, Dept Morphol Surg & Expt Med, Via Luigi Borsari 46, I-44121 Ferrara, Italy.	elena.adinolfi@unife.it	DI VIRGILIO, Francesco/O-4634-2019; Di Virgilio, Francesco/J-3754-2018; Sangaletti, Sabina/AAB-5873-2019; Adinolfi, Elena/F-9169-2010; Colombo, Mario P./V-7166-2017; Portararo, Paola/P-8231-2019; Curti, Antonio/AAB-9461-2019; Pegoraro, Anna/AAC-4573-2022; Pegoraro, Anna/AAV-7894-2021	DI VIRGILIO, Francesco/0000-0003-3566-1362; Di Virgilio, Francesco/0000-0003-3566-1362; Sangaletti, Sabina/0000-0001-7047-287X; Adinolfi, Elena/0000-0001-8129-9929; Colombo, Mario P./0000-0003-0042-7955; Portararo, Paola/0000-0003-0085-6901; Curti, Antonio/0000-0002-7752-6049; De Marchi, Elena/0000-0003-0064-4335; Pegoraro, Anna/0000-0002-7045-5161	Italian Association for Cancer Research Investigator Grant (AIRC) [IG 16812, IG 13025, IG 18581]	Italian Association for Cancer Research Investigator Grant (AIRC)(Fondazione AIRC per la ricerca sul cancro)	The authors thank Marzia Scarletti, Federica Poletti, and Asia Milani for technical assistance. This study was funded by an Italian Association for Cancer Research Investigator Grant to EA (AIRC, IG 16812) and to FDV (AIRC, IG 13025 and IG 18581).	Adinolfi E, 2005, MOL BIOL CELL, V16, P3260, DOI 10.1091/mbc.E04-11-1025; Adinolfi E, 2018, BIOCHEM PHARMACOL, V151, P234, DOI 10.1016/j.bcp.2017.12.021; Adinolfi E, 2015, CANCER RES, V75, P635, DOI 10.1158/0008-5472.CAN-14-1259; Adinolfi E, 2012, CANCER RES, V72, P2957, DOI 10.1158/0008-5472.CAN-11-1947; Adinolfi E, 2010, FASEB J, V24, P3393, DOI 10.1096/fj.09-153601; Adinolfi E, 2009, J BIOL CHEM, V284, P10120, DOI 10.1074/jbc.M805805200; Allard B, 2017, IMMUNOL REV, V276, P121, DOI 10.1111/imr.12528; Allard D., 2018, IMMUNOL LETT; Amores-Iniesta J, 2017, CELL REP, V21, P3414, DOI 10.1016/j.celrep.2017.11.079; Amoroso F, 2015, ONCOGENE, V34, P5240, DOI 10.1038/onc.2014.444; Amoroso F, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.105; Amoroso F, 2016, ONCOTARGET, V7, P49664, DOI 10.18632/oncotarget.10430; Anderson KG, 2017, CANCER CELL, V31, P311, DOI 10.1016/j.ccell.2017.02.008; Savio LEB, 2017, MOL NEUROBIOL, V54, P6459, DOI 10.1007/s12035-016-0168-9; Baroni M, 2007, FASEB J, V21, P1926, DOI 10.1096/fj.06-7238com; Buchan SL, 2018, BLOOD, V131, P39, DOI 10.1182/blood-2017-07-741025; Castro F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00847; Colombo MP, 2017, CLIN CANCER RES, V23, P5999, DOI 10.1158/1078-0432.CCR-17-2332; De Marchi E, 2016, ADV PROTEIN CHEM STR, V104, P39, DOI 10.1016/bs.apcsb.2015.11.004; Di Virgilio F, 2017, ONCOGENE, V36, P293, DOI 10.1038/onc.2016.206; Di Virgilio F, 2018, NAT REV CANCER, V18, P601, DOI 10.1038/s41568-018-0037-0; Di Virgilio F, 2017, IMMUNITY, V47, P15, DOI 10.1016/j.immuni.2017.06.020; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Furler RL, 2018, CANCERS, V10, DOI 10.3390/cancers10060199; Giannuzzo A, 2016, INT J CANCER, V139, P2540, DOI 10.1002/ijc.30380; Giuliani AL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107224; Gulinelli S, 2012, EUR J IMMUNOL, V42, P3334, DOI 10.1002/eji.201142268; Hattori F, 2012, EUR J PHARMACOL, V695, P20, DOI 10.1016/j.ejphar.2012.09.001; Hofman P, 2015, CANCER RES, V75, P835, DOI 10.1158/0008-5472.CAN-14-1778; Honore P, 2006, J PHARMACOL EXP THER, V319, P1376, DOI 10.1124/jpet.106.111559; Hyman MC, 2009, J CLIN INVEST, V119, P1136, DOI 10.1172/JCI36433; Janssen B, 2014, J LABELLED COMPD RAD, V57, P509, DOI 10.1002/jlcr.3206; Kepp O, 2017, IMMUNOL REV, V280, P83, DOI 10.1111/imr.12571; Kuhny M, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/s12964-014-0040-3; Lecciso M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01918; Lemaire I, 2006, J IMMUNOL, V177, P7257, DOI 10.4049/jimmunol.177.10.7257; Lemaire I, 2011, J IMMUNOL, V187, P3878, DOI 10.4049/jimmunol.1002780; Levesque SA, 2010, EUR J IMMUNOL, V40, P1473, DOI 10.1002/eji.200939741; Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347; Orioli E, 2017, CURR MED CHEM, V24, P2261, DOI 10.2174/0929867324666170303161659; Pellegatti P, 2005, MOL BIOL CELL, V16, P3659, DOI 10.1091/mbc.E05-03-0222; Pellegatti P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002599; Piconese S, 2010, EUR J IMMUNOL, V40, P2902, DOI 10.1002/eji.201040505; Pietrocola F, 2016, CANCER CELL, V30, P147, DOI 10.1016/j.ccell.2016.05.016; Pizzirani C, 2007, BLOOD, V109, P3856, DOI 10.1182/blood-2005-06-031377; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Salaro E, 2016, SCI REP-UK, V6, DOI 10.1038/srep26280; Shitara K, 2018, ANN NY ACAD SCI, V1417, P104, DOI 10.1111/nyas.13625; Syberg S, 2012, J OSTEOPOROS, V2012, DOI 10.1155/2012/391097; Vandenabeele P, 2016, ADV EXP MED BIOL, V930, P133, DOI 10.1007/978-3-319-39406-0_6; Vijayan D, 2017, NAT REV CANCER, V17, P765, DOI 10.1038/nrc.2017.110; Wilhelm K, 2010, NAT MED, V16, P1434, DOI 10.1038/nm.2242; Yang DH, 2015, IMMUNITY, V43, P923, DOI 10.1016/j.immuni.2015.10.009; Younas M, 2013, J IMMUNOL, V191, P3161, DOI 10.4049/jimmunol.1203547; 2018, NATURE, V559, P264, DOI DOI 10.1038/S41586-018-0282-0	55	100	100	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2019	38	19					3636	3650		10.1038/s41388-019-0684-y	http://dx.doi.org/10.1038/s41388-019-0684-y			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HX4OU	30655604	Green Published, hybrid			2022-12-28	WOS:000467379600006
J	Mancuso, P; Tricarico, R; Bhattacharjee, V; Cosentino, L; Kadariya, Y; Jelinek, J; Nicolas, E; Einarson, M; Beeharry, N; Devarajan, K; Katz, RA; Dorjsuren, DG; Sun, H; Simeonov, A; Giordano, A; Testa, JR; Davidson, G; Davidson, I; Larue, L; Sobol, RW; Yen, TJ; Bellacosa, A				Mancuso, Pietro; Tricarico, Rossella; Bhattacharjee, Vikram; Cosentino, Laura; Kadariya, Yuwaraj; Jelinek, Jaroslav; Nicolas, Emmanuelle; Einarson, Margret; Beeharry, Neil; Devarajan, Karthik; Katz, Richard A.; Dorjsuren, Dorjbal G.; Sun, Hongmao; Simeonov, Anton; Giordano, Antonio; Testa, Joseph R.; Davidson, Guillaume; Davidson, Irwin; Larue, Lionel; Sobol, Robert W.; Yen, Timothy J.; Bellacosa, Alfonso			Thymine DNA glycosylase as a novel target for melanoma	ONCOGENE			English	Article							BASE EXCISION-REPAIR; TRANSCRIPTION FACTOR; READ ALIGNMENT; SENESCENCE; DEMETHYLATION; MUTATIONS; GENES; 5-HYDROXYMETHYLCYTOSINE; 5-CARBOXYLCYTOSINE; DISCOVERY	Melanoma is an aggressive neoplasm with increasing incidence that is classified by the NCI as a recalcitrant cancer, i.e., a cancer with poor prognosis, lacking progress in diagnosis and treatment. In addition to conventional therapy, melanoma treatment is currently based on targeting the BRAF/MEK/ERK signaling pathway and immune checkpoints. As drug resistance remains a major obstacle to treatment success, advanced therapeutic approaches based on novel targets are still urgently needed. We reasoned that the base excision repair enzyme thymine DNA glycosylase (TDG) could be such a target for its dual role in safeguarding the genome and the epigenome, by performing the last of the multiple steps in DNA demethylation. Here we show that TDG knockdown in melanoma cell lines causes cell cycle arrest, senescence, and death by mitotic alterations; alters the transcriptome and methylome; and impairs xenograft tumor formation. Importantly, untransformed melanocytes are minimally affected by TDG knockdown, and adult mice with conditional knockout of Tdg are viable. Candidate TDG inhibitors, identified through a high-throughput fluorescence-based screen, reduced viability and clonogenic capacity of melanoma cell lines and increased cellular levels of 5-carboxylcytosine, the last intermediate in DNA demethylation, indicating successful on-target activity. These findings suggest that TDG may provide critical functions specific to cancer cells that make it a highly suitable anti-melanoma drug target. By potentially disrupting both DNA repair and the epigenetic state, targeting TDG may represent a completely new approach to melanoma therapy.	[Mancuso, Pietro; Tricarico, Rossella; Cosentino, Laura; Nicolas, Emmanuelle; Einarson, Margret; Katz, Richard A.; Bellacosa, Alfonso] Fox Chase Canc Ctr, Canc Epigenet Program, 333 Cottman Ave, Philadelphia, PA 19111 USA; [Mancuso, Pietro; Giordano, Antonio] Univ Siena, Dept Med Biotechnol, Siena, Italy; [Mancuso, Pietro] PSL Res Univ, Inst Curie, INSERM, U1021 Normal & Pathol Dev Melanocytes, F-91405 Orsay, France; [Bhattacharjee, Vikram; Kadariya, Yuwaraj; Beeharry, Neil; Testa, Joseph R.; Yen, Timothy J.] Fox Chase Canc Ctr, Canc Biol Program, 333 Cottman Ave, Philadelphia, PA 19111 USA; [Jelinek, Jaroslav] Temple Univ, Sch Med, Fels Inst Canc & Mol Biol, Philadelphia, PA 19140 USA; [Devarajan, Karthik] Fox Chase Canc Ctr, Dept Biostat, 333 Cottman Ave, Philadelphia, PA 19111 USA; [Dorjsuren, Dorjbal G.; Sun, Hongmao; Simeonov, Anton] NIH, Div Preclin Innovat, Natl Ctr Adv Translat Sci, Rockville, MD 20850 USA; [Giordano, Antonio] Temple Univ, Coll Sci & Technol, Dept Biol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; [Davidson, Guillaume; Davidson, Irwin] ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; [Davidson, Irwin; Larue, Lionel] Equipe Labellisee Ligue Canc, Orsay, France; [Larue, Lionel] Univ Paris Saclay, Univ Paris Sud, CNRS, UMR3347, Orsay, France; [Sobol, Robert W.] Univ S Alabama, Mitchell Canc Inst, Dept Oncol Sci, Mobile, AL 36604 USA	Fox Chase Cancer Center; University of Siena; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Fox Chase Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Fox Chase Cancer Center; National Institutes of Health (NIH) - USA; NIH National Center for Advancing Translational Sciences (NCATS); Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Saclay; University of South Alabama	Bellacosa, A (corresponding author), Fox Chase Canc Ctr, Canc Epigenet Program, 333 Cottman Ave, Philadelphia, PA 19111 USA.	Alfonso.Bellacosa@fccc.edu	Mancuso, Pietro/J-1636-2019; Sobol, Robert/E-4125-2013; Giordano, Antonio/F-1927-2010	Sobol, Robert/0000-0001-7385-3563; TRICARICO, ROSSELLA/0000-0001-7055-7208; Davidson, Guillaume/0000-0001-9272-3924; Davidson, Irwin/0000-0001-5533-1171; Giordano, Antonio/0000-0002-5959-016X	Edwards Family; David A. Hungerford Endowed Fund in Basic Chromosome Research; NIH [CA78412, CA191956, CA06927]; National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH); PA Department of Health C.U.R.E.; Commonwealth of Pennsylvania; INCa Project [PLBIO11-027]; William J. Avery Endowed Postdoctoral Fellowship; National Institutes of Health [CA148629, ES025138]; Ligue Nationale Contre le Cancer; INCa; ITMO cancer; program "Investissements d'Avenir" [ANR-11-LBX-0038, ANR-10-IDEX-0001-02 PSL]; Ligue National contre le cancer; Labex INRT [ANR-10-IDEX-0001-02]; IGBMC high-throughput sequencing facility, a member of "France Genomique" consortium [ANR10-INBS-09-08]; NATIONAL CANCER INSTITUTE [R01CA175691, P30CA006927, R21CA191956, R50CA211479, R01CA148629] Funding Source: NIH RePORTER	Edwards Family; David A. Hungerford Endowed Fund in Basic Chromosome Research; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); PA Department of Health C.U.R.E.; Commonwealth of Pennsylvania; INCa Project; William J. Avery Endowed Postdoctoral Fellowship; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); INCa(Institut National du Cancer (INCA) France); ITMO cancer; program "Investissements d'Avenir"(French National Research Agency (ANR)); Ligue National contre le cancer(Ligue nationale contre le cancer); Labex INRT; IGBMC high-throughput sequencing facility, a member of "France Genomique" consortium; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr. P. Abbosh and Dr. I. Astsaturov for critical reading of the manuscript; Dr. R. Zaidi for comments and advice; L. Cathay for secretarial assistance; and John and Robin Spurlino and the Edwards Family for their generous support of this research. We would like to thank Alice M. Hungerford for her philanthropic funding through the David A. Hungerford Endowed Fund in Basic Chromosome Research, honoring her late husband's legacy as a renowned scientist and the co-discoverer of the Philadelphia Chromosome. We thank the following core services at Fox Chase Cancer Center: Genomics, Cell Culture, Cell Sorting, Biological Imaging, High-Throughput Screening, Biostatistics and Bioinformatics, and Laboratory Animal Facilities. This study was supported by NIH grants CA78412 (to A. Bellacosa), CA191956 (to A. Bellacosa and T. Yen), and CA06927; the intramural research program of the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), PA Department of Health C.U.R.E. and an appropriation from the Commonwealth of Pennsylvania to the Fox Chase Cancer Center. PM was supported in part by INCa Project PLBIO11-027. RT was supported in part by a William J. Avery Endowed Postdoctoral Fellowship. RWS was supported by grants from the National Institutes of Health (CA148629 and ES025138) and is an Abraham A. Mitchell Distinguished Investigator. LL was supported by a grant from Ligue Nationale Contre le Cancer, INCa, ITMO cancer, and is under the program "Investissements d'Avenir" launched by the French Government and implemented by ANR Labex CelTisPhyBio (ANR-11-LBX-0038 and ANR-10-IDEX-0001-02 PSL). Work in the laboratory of ID was supported by grants from the INCa, the Ligue National contre le cancer, and the Labex INRT (ANR-10-IDEX-0001-02). RNA-seq was performed at the IGBMC high-throughput sequencing facility, a member of "France Genomique" consortium (ANR10-INBS-09-08). LL and ID are "equipes labelisees of the Ligue National Contre le cancer." AB would like to dedicate this article to the memory of his mother Maria, who showed that strength and tenderness, elegance and simplicity, resilience and joyfulness can coexist, and who will be missed tremendously.	Arantes-Rodrigues R, 2012, LAB ANIMAL, V41, P129, DOI 10.1038/laban0512-129; Bandyopadhyay D, 2002, CANCER RES, V62, P6231; Beeharry N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040342; Bellacosa A, 2015, DNA REPAIR, V32, P33, DOI 10.1016/j.dnarep.2015.04.011; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berger MF, 2012, NATURE, V485, P502, DOI 10.1038/nature11071; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chong CR, 2006, NAT CHEM BIOL, V2, P415, DOI 10.1038/nchembio806; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Cortazar D, 2007, DNA REPAIR, V6, P489, DOI 10.1016/j.dnarep.2006.10.013; Cortazar D, 2011, NATURE, V470, P419, DOI 10.1038/nature09672; Cortellino S, 2011, CELL, V146, P67, DOI 10.1016/j.cell.2011.06.020; Dalton SR, 2012, EPIGENOMICS-UK, V4, P459, DOI [10.2217/EPI.12.36, 10.2217/epi.12.36]; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; Eichenbaum G, 2011, J APPL TOXICOL, V31, P342, DOI 10.1002/jat.1592; Fitzgerald ME, 2008, J BIOL CHEM, V283, P32680, DOI 10.1074/jbc.M805504200; Gambichler T, 2013, MELANOMA RES, V23, P218, DOI 10.1097/CMR.0b013e32835f9bd4; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Giuliano S, 2011, PIGM CELL MELANOMA R, V24, P295, DOI 10.1111/j.1755-148X.2010.00820.x; Giuliano S, 2010, CANCER RES, V70, P3813, DOI 10.1158/0008-5472.CAN-09-2913; Goding CR, 2016, CANCER CELL, V29, P619, DOI 10.1016/j.ccell.2016.04.010; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Ha GH, 2009, CELL DEATH DIFFER, V16, P483, DOI 10.1038/cdd.2008.182; Hayward NK, 2017, NATURE, V545, P175, DOI 10.1038/nature22071; He YF, 2011, SCIENCE, V333, P1303, DOI 10.1126/science.1210944; Henry RA, 2016, BIOCHEMISTRY-US, V55, P6766, DOI 10.1021/acs.biochem.6b00841; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Huang JM, 2017, DERMATOL CLIN, V35, P85, DOI 10.1016/j.det.2016.08.001; Itahana Koji, 2007, Methods Mol Biol, V371, P21; Jelinek J, 2012, EPIGENETICS-US, V7, P1368, DOI 10.4161/epi.22552; Joshi S, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006600; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Krauthammer M, 2015, NAT GENET, V47, P996, DOI 10.1038/ng.3361; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Leucci E, 2016, NATURE, V531, P518, DOI 10.1038/nature17161; Levy C, 2006, TRENDS MOL MED, V12, P406, DOI 10.1016/j.molmed.2006.07.008; Li H, 2011, BIOINFORMATICS, V27, P2987, DOI 10.1093/bioinformatics/btr509; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Lian CG, 2012, CELL, V150, P1135, DOI 10.1016/j.cell.2012.07.033; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Maiti A, 2011, J BIOL CHEM, V286, P35334, DOI 10.1074/jbc.C111.284620; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Ohanna M, 2011, GENE DEV, V25, P1245, DOI 10.1101/gad.625811; Petronzelli F, 2000, J BIOL CHEM, V275, P32422, DOI 10.1074/jbc.M004535200; Prieur A, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1473; Rambow F, 2015, CELL REP, V13, P840, DOI 10.1016/j.celrep.2015.09.037; Ruzankina Y, 2007, CELL STEM CELL, V1, P113, DOI 10.1016/j.stem.2007.03.002; Sato S, 1997, ONCOGENE, V14, P3083, DOI 10.1038/sj.onc.1201298; Sato T, 2017, CANCER RES, V77, P470, DOI 10.1158/0008-5472.CAN-16-0834; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Song FJ, 2014, CARCINOGENESIS, V35, P2097, DOI 10.1093/carcin/bgu140; Strub T, 2011, ONCOGENE, V30, P2319, DOI 10.1038/onc.2010.612; Svilar D, 2012, JOVE-J VIS EXP, DOI 10.3791/4168; Takahashi A, 2006, NAT CELL BIOL, V8, P1291, DOI 10.1038/ncb1491; TOMAYKO MM, 1989, CANCER CHEMOTH PHARM, V24, P148, DOI 10.1007/BF00300234; Turner DP, 2006, CANCER RES, V66, P7686, DOI 10.1158/0008-5472.CAN-05-4488; Xu JF, 2017, ONCOTARGET, V8, P89988, DOI 10.18632/oncotarget.21219; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206; 2003, AM J PATHOL, V163, P333	61	22	22	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2019	38	19					3710	3728		10.1038/s41388-018-0640-2	http://dx.doi.org/10.1038/s41388-018-0640-2			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HX4OU	30674989	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000467379600011
J	Domenici, G; Aurrekoetxea-Rodriguez, I; Simoes, BM; Rabano, M; Lee, SY; San Millan, J; Comaills, V; Oliemuller, E; Lopez-Ruiz, JA; Zabalza, I; Howard, BA; Kypta, RM; Vivanco, MD				Domenici, Giacomo; Aurrekoetxea-Rodriguez, Iskander; Simoes, Bruno M.; Rabano, Miriam; Lee, So Young; San Millan, Julia; Comaills, Valentine; Oliemuller, Erik; Lopez-Ruiz, Jose A.; Zabalza, Ignacio; Howard, Beatrice A.; Kypta, Robert M.; Vivanco, Maria d M.			A Sox2-Sox9 signalling axis maintains human breast luminal progenitor and breast cancer stem cells	ONCOGENE			English	Article							MAMMARY STEM; ALDEHYDE DEHYDROGENASE; TRANSCRIPTION FACTOR; WNT PATHWAY; SOX9; RESISTANCE; DIFFERENTIATION; IDENTIFICATION; EXPRESSION; ACTIVATION	Increased cancer stem cell content during development of resistance to tamoxifen in breast cancer is driven by multiple signals, including Sox2-dependent activation of Wnt signalling. Here, we show that Sox2 increases and estrogen reduces the expression of the transcription factor Sox9. Gain and loss of function assays indicate that Sox9 is implicated in the maintenance of human breast luminal progenitor cells. CRISPR/Cas knockout of Sox9 reduces growth of tamoxifen-resistant breast tumours in vivo. Mechanistically, Sox9 acts downstream of Sox2 to control luminal progenitor cell content and is required for expression of the cancer stem cell marker ALDH1A3 and Wnt signalling activity. Sox9 is elevated in breast cancer patients after endocrine therapy failure. This new regulatory axis highlights the relevance of SOX family transcription factors as potential therapeutic targets in breast cancer.	[Domenici, Giacomo; Aurrekoetxea-Rodriguez, Iskander; Simoes, Bruno M.; Rabano, Miriam; Lee, So Young; San Millan, Julia; Comaills, Valentine; Kypta, Robert M.; Vivanco, Maria d M.] CIC BioGUNE, Technol Pk Bizkaia, Derio 48160, Spain; [Oliemuller, Erik; Howard, Beatrice A.] Inst Canc Res, Breast Canc Now Toby Robins Res Ctr, London, England; [Lopez-Ruiz, Jose A.] Radiodiagnost Serv PreteImagen, Bilbao, Spain; [Zabalza, Ignacio] Galdakao Usansolo Hosp, Dept Pathol, Galdakao, Spain; [Kypta, Robert M.] Imperial Coll London, Dept Surg & Canc, London, England	CIC bioGUNE; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Galdakao Hospital; Imperial College London	Vivanco, MD (corresponding author), CIC BioGUNE, Technol Pk Bizkaia, Derio 48160, Spain.	mdmvivanco@cicbiogune.es	Domenici, Giacomo/AAG-6224-2019; COMAILLS, VALENTINE/AAX-1697-2021; Simoes, Bruno/AAB-2582-2019; Vivanco, Maria/G-2393-2011; Kypta, Robert/F-7699-2011	COMAILLS, VALENTINE/0000-0001-8857-6976; Simoes, Bruno/0000-0003-1253-6657; Vivanco, Maria/0000-0002-9540-247X; Kypta, Robert/0000-0002-2389-310X; Oliemuller Garcia, Erik/0000-0002-4506-0504; Aurrekoetxea-Rodriguez, Iskander/0000-0001-5294-7798; Lee, So Young/0000-0003-3130-785X; Domenici, Giacomo/0000-0002-3947-5930	Spanish Ministry of Education and Science; Institute of Health Carlos III [PI14/01328]; Department of Education of the Government of the Autonomous Community of the Basque Country [PRE_2013_1_991]; Department of Health of the Government of the Autonomous Community of the Basque Country [2014111145]; Department of Industry, Tourism and Trade (Etortek) of the Government of the Autonomous Community of the Basque Country; Department of Innovation Technology of the Government of the Autonomous Community of the Basque Country; RED Nurcamein; Breast Cancer Now;  [SAF2017-84934-R];  [SAF2017-84092-R]	Spanish Ministry of Education and Science(Spanish Government); Institute of Health Carlos III(Instituto de Salud Carlos III); Department of Education of the Government of the Autonomous Community of the Basque Country; Department of Health of the Government of the Autonomous Community of the Basque Country; Department of Industry, Tourism and Trade (Etortek) of the Government of the Autonomous Community of the Basque Country; Department of Innovation Technology of the Government of the Autonomous Community of the Basque Country; RED Nurcamein; Breast Cancer Now; ; 	We are grateful for the generosity of many women and patients that collaborated in this project. We thank the members of the laboratory for helpful discussions and Jessica Cellot for technical help. This work was supported by grants from the Spanish Ministry of Education and Science, the Institute of Health Carlos III (PI14/01328 to M.V.), the Departments of Education (PRE_2013_1_991 to G.D.) and Health (2014111145 to M.V.) of the Government of the Autonomous Community of the Basque Country, the Department of Industry, Tourism and Trade (Etortek) and Department of Innovation Technology of the Government of the Autonomous Community of the Basque Country (to R.K. and M.V.), the RED Nurcamein and SAF2017-84934-R (to M.V.) and SAF2017-84092-R (to R.K.). We thank Breast Cancer Now for funding this work as part of Programme Funding to the Breast Cancer Now Toby Robins Research Centre (to B.H.). We are particularly grateful for the generosity of ACAMBI and all its supporters (to M.V.).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Aleman A, 2008, BRIT J CANCER, V98, P466, DOI 10.1038/sj.bjc.6604143; Arendt LM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111442; Ashkenazi S, 2016, ONCOTARGET, V7, P30166, DOI 10.18632/oncotarget.7379; Blache P, 2004, J CELL BIOL, V166, P37, DOI 10.1083/jcb.200311021; Boras-Granic Kata, 2008, Organogenesis, V4, P116; Bourdeau V, 2004, MOL ENDOCRINOL, V18, P1411, DOI 10.1210/me.2003-0441; Burdelski C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128525; Cai CM, 2013, J CLIN INVEST, V123, P1109, DOI 10.1172/JCI66666; Canino C, 2015, ONCOTARGET, V6, P12637, DOI 10.18632/oncotarget.3703; Chakravarty G, 2011, EXP BIOL MED, V236, P145, DOI 10.1258/ebm.2010.010086; Chang DR, 2013, P NATL ACAD SCI USA, V110, P18042, DOI 10.1073/pnas.1311760110; Chen MH, 2016, CLIN CANCER RES, V22, P4225, DOI 10.1158/1078-0432.CCR-15-1800; Cheng PF, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0594-4; Clayton H, 2004, EXP CELL RES, V297, P444, DOI 10.1016/j.yexcr.2004.03.029; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dey N, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-537; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Eirew P, 2008, NAT MED, V14, P1384, DOI 10.1038/nm.1791; Elizalde C, 2011, STEM CELLS, V29, P141, DOI 10.1002/stem.562; Forget MA, 2007, BRIT J CANCER, V96, P646, DOI 10.1038/sj.bjc.6603579; Furuyama K, 2011, NAT GENET, V43, P34, DOI 10.1038/ng.722; Gascoyne DM, 2003, CELL CYCLE, V2, P238, DOI 10.4161/cc.2.3.355; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Gonzalez E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083955; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Hayashida T, 2010, P NATL ACAD SCI USA, V107, P1100, DOI 10.1073/pnas.0912710107; Huang YH, 2015, SCI REP-UK, V5, DOI 10.1038/srep10398; Iriondo O, 2015, ONCOTARGET, V6, P31721, DOI 10.18632/oncotarget.5564; Iriondo O, 2015, METHODS MOL BIOL, V1293, P63, DOI 10.1007/978-1-4939-2519-3_3; Jeselsohn R, 2017, P NATL ACAD SCI USA, V114, pE4482, DOI 10.1073/pnas.1620993114; Kang HM, 2016, CELL REP, V14, P861, DOI 10.1016/j.celrep.2015.12.071; KASTAN MB, 1990, BLOOD, V75, P1947; Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125; Kim MP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020636; Kong SL, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.59; Kopp JL, 2012, CANCER CELL, V22, P737, DOI 10.1016/j.ccr.2012.10.025; Larsimont JC, 2015, CELL STEM CELL, V17, P60, DOI 10.1016/j.stem.2015.05.008; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Ling SZ, 2011, CANCER RES, V71, P3812, DOI 10.1158/0008-5472.CAN-10-3072; Ma F, 2016, J CLIN INVEST, V126, P1745, DOI 10.1172/JCI78815; Malhotra GK, 2014, BMC DEV BIOL, V14, DOI 10.1186/s12861-014-0047-4; Malladi S, 2016, CELL, V165, P45, DOI 10.1016/j.cell.2016.02.025; Marcato P, 2011, CELL CYCLE, V10, P1378, DOI 10.4161/cc.10.9.15486; Martin-Martin N, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12595; Matheu A, 2012, CANCER RES, V72, P1301, DOI 10.1158/0008-5472.CAN-11-3660; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Piva M, 2014, EMBO MOL MED, V6, P66, DOI 10.1002/emmm.201303411; Poche RA, 2008, J COMP NEUROL, V510, P237, DOI 10.1002/cne.21746; Prevostel C, 2016, ONCOTARGET, V7, P82228, DOI 10.18632/oncotarget.10573; Scott CE, 2010, NAT NEUROSCI, V13, P1181, DOI 10.1038/nn.2646; Seymour PA, 2007, P NATL ACAD SCI USA, V104, P1865, DOI 10.1073/pnas.0609217104; Simoes BM, 2011, FUTURE ONCOL, V7, P995, DOI [10.2217/FON.11.80, 10.2217/fon.11.80]; Simoes BM, 2011, BREAST CANCER RES TR, V129, P23, DOI 10.1007/s10549-010-1169-4; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Swartling FJ, 2012, CANCER CELL, V21, P601, DOI 10.1016/j.ccr.2012.04.012; Thomsen MK, 2008, DEV BIOL, V316, P302, DOI 10.1016/j.ydbio.2008.01.030; Vidal VPI, 2005, CURR BIOL, V15, P1340, DOI 10.1016/j.cub.2005.06.064; Villadsen R, 2007, J CELL BIOL, V177, P87, DOI 10.1083/jcb.200611114; Visvader JE, 2014, GENE DEV, V28, P1143, DOI 10.1101/gad.242511.114; Vivanco MD, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001215; Wang HY, 2015, ONCOTARGET, V6, P20711, DOI 10.18632/oncotarget.4133; Wang HY, 2013, J BIOL CHEM, V288, P6478, DOI 10.1074/jbc.M112.419184; Woodward WA, 2007, P NATL ACAD SCI USA, V104, P618, DOI 10.1073/pnas.0606599104; Wu F, 2012, CELL SIGNAL, V24, P1989, DOI 10.1016/j.cellsig.2012.07.008; Zhou CH, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-18	68	80	83	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2019	38	17					3151	3169		10.1038/s41388-018-0656-7	http://dx.doi.org/10.1038/s41388-018-0656-7			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU8RI	30622340	Green Published, hybrid			2022-12-28	WOS:000465557200004
J	Sun, ZQ; Ou, CL; Liu, JB; Chen, C; Zhou, QB; Yang, SX; Li, GY; Wang, GX; Song, JM; Li, Z; Zhang, ZY; Yuan, WT; Li, XY				Sun, Zhenqiang; Ou, Chunlin; Liu, Jinbo; Chen, Chen; Zhou, Quanbo; Yang, Shuaixi; Li, Guiyuan; Wang, Guixian; Song, Junmin; Li, Zhen; Zhang, Zhiyong; Yuan, Weitang; Li, Xiayu			YAP1-induced MALAT1 promotes epithelial-mesenchymal transition and angiogenesis by sponging miR-126-5p in colorectal cancer	ONCOGENE			English	Article							LONG NONCODING RNA; OSTEOSARCOMA DEVELOPMENT; EXPRESSION PROFILES; CELL-PROLIFERATION; POOR-PROGNOSIS; TUMOR-GROWTH; YAP1; METASTASIS; ONCOGENE; PROGRESSION	Yes-associated protein 1 (YAP1) exerts significant effects in various malignancies. However, the oncogenic role of YAP1 remains controversial, and the mechanism by which YAP1 regulates non-coding RNAs is still largely unknown. The present study aimed to assess the effect of YAP1 on the malignant behaviors of colorectal carcinoma (CRC) and explore the underlying regulatory mechanism of the YAP1-MALAT1-miR-126-5p axis. YAP1 was highly expressed in CRC tissues as assessed by GSE20916 and its expression was negatively correlated with overall survival in 83 CRC cases. Meanwhile, YAP1 promoted proliferation, invasion, and migration in colon cancer cells, in vitro and in vivo. MALAT1 was obviously expressed, with differential expression of 11 lncRNAs in HCT116 cells after transfection with siYAP1 or si-Ctl. Based on bioinformatics prediction, immunoprecipitation (IP), and chromatin immunoprecipitation (ChIP), the interaction of YAP1 with TCF4/beta-catenin was regulated by MALAT1. Bioinformatics prediction, dual luciferase assay, RNA-IP, and RNA pulldown assay demonstrated that YAP1-induced MALAT1 promoted the expression of metastasis-associated molecules such as VEGFA, SLUG, and TWIST, by sponging miR-126-5p in CRC. These findings indicated that the YAP1-MALAT1-miR126-5p axis could control angiogenesis and epithelial-mesenchymal transition in CRC, providing potential biomarkers and therapeutic targets for CRC.	[Sun, Zhenqiang; Liu, Jinbo; Chen, Chen; Zhou, Quanbo; Yang, Shuaixi; Wang, Guixian; Song, Junmin; Li, Zhen; Zhang, Zhiyong; Yuan, Weitang] Zhengzhou Univ, Dept Anorectal Surg, Affiliated Hosp 1, Zhengzhou 450052, Henan, Peoples R China; [Sun, Zhenqiang; Ou, Chunlin; Li, Guiyuan] Cent S Univ, Dept Pathol, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China; [Sun, Zhenqiang; Ou, Chunlin; Li, Guiyuan] Cent S Univ, Key Lab Carcinogenesis & Canc Invas, Chinese Minist Educ, Canc Res Inst, Changsha 410078, Hunan, Peoples R China; [Ou, Chunlin; Li, Xiayu] Cent S Univ, Xiangya Hosp 3, Hunan Key Lab Nonresolving Inflammat & Canc, Changsha 410013, Hunan, Peoples R China; [Li, Xiayu] Cent S Univ, Dept Gastroenterol, Xiangya Hosp 3, Changsha 410013, Hunan, Peoples R China	Zhengzhou University; Central South University; Central South University; Central South University; Central South University	Sun, ZQ; Yuan, WT (corresponding author), Zhengzhou Univ, Dept Anorectal Surg, Affiliated Hosp 1, Zhengzhou 450052, Henan, Peoples R China.; Sun, ZQ (corresponding author), Cent S Univ, Dept Pathol, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China.; Sun, ZQ (corresponding author), Cent S Univ, Key Lab Carcinogenesis & Canc Invas, Chinese Minist Educ, Canc Res Inst, Changsha 410078, Hunan, Peoples R China.; Li, XY (corresponding author), Cent S Univ, Xiangya Hosp 3, Hunan Key Lab Nonresolving Inflammat & Canc, Changsha 410013, Hunan, Peoples R China.; Li, XY (corresponding author), Cent S Univ, Dept Gastroenterol, Xiangya Hosp 3, Changsha 410013, Hunan, Peoples R China.	zqsun82@csu.edu.cn; yuanweitang@zzu.edu.cn; lixiayu002@sina.com	li, xia/HHZ-7468-2022	Ou, Chunlin/0000-0003-2313-4186	National Natural Science Foundation of China [81560385]; Natural Science Foundation of Xinjiang Uygur Autonomous Region [2015211C136]; Medical Scientific and Technological Research Project of Henan Province [201702027]; China Postdoctoral Science Foundation [2017M610462]; Youth Innovation Fund Project of The First Affiliated Hospital of Zhengzhou University [YNQN2017035]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Xinjiang Uygur Autonomous Region; Medical Scientific and Technological Research Project of Henan Province; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Youth Innovation Fund Project of The First Affiliated Hospital of Zhengzhou University	This work was supported by the National Natural Science Foundation of China (81560385), the Natural Science Foundation of Xinjiang Uygur Autonomous Region (2015211C136), the Medical Scientific and Technological Research Project of Henan Province (201702027), China Postdoctoral Science Foundation (2017M610462), and the Youth Innovation Fund Project of The First Affiliated Hospital of Zhengzhou University (YNQN2017035).	Ai FY, 2015, ONCOTARGET, V6, P5412, DOI 10.18632/oncotarget.3027; Arun G, 2016, GENE DEV, V30, P34, DOI 10.1101/gad.270959.115; Bottomley A, 2002, LANCET, V359, P1537, DOI 10.1016/S0140-6736(02)08526-4; Chan LH, 2014, ONCOGENE, V33, P4857, DOI 10.1038/onc.2013.433; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Di Cecilia S, 2016, CANCER RES, V76, P5615, DOI 10.1158/0008-5472.CAN-15-1824; Ebrahimi F, 2015, EXP CELL RES, V339, P333, DOI 10.1016/j.yexcr.2015.10.004; Fiala O, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317709283; Ghosh A, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.123; Gibb EA, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-38; Hong Y, 2010, CLIN EXP METASTAS, V27, P83, DOI 10.1007/s10585-010-9305-4; Hu Y, 2015, CLIN GASTROENTEROL H, V75, P6890; Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040; Ji Q, 2014, BRIT J CANCER, V111, P736, DOI 10.1038/bjc.2014.383; Kapranov P, 2007, SCIENCE, V316, P1484, DOI 10.1126/science.1138341; Kogo R, 2011, CANCER RES, V71, P6320, DOI 10.1158/0008-5472.CAN-11-1021; Lee KW, 2015, CLIN CANCER RES, V21, P357, DOI 10.1158/1078-0432.CCR-14-1374; Lee NK, 2017, BMC CANCER, V17, DOI 10.1186/s12885-016-2988-4; Li C, 2017, ONCOTARGET, V8, P28683, DOI 10.18632/oncotarget.15640; Li HL, 2018, BIOCHEM BIOPH RES CO, V495, P2350, DOI 10.1016/j.bbrc.2017.12.114; Li PL, 2017, MOL CANCER THER, V16, P739, DOI 10.1158/1535-7163.MCT-16-0591; Li QL, 2016, CANCER LETT, V383, P28, DOI 10.1016/j.canlet.2016.09.019; Li S, 2015, UROL ONCOL-SEMIN ORI, V33, DOI 10.1016/j.urolonc.2015.06.003; Li W, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0612-3; Li Y, 2017, CANCER LETT, V395, P31, DOI 10.1016/j.canlet.2017.02.035; Ling H, 2013, GENOME RES, V23, P1446, DOI 10.1101/gr.152942.112; Liu K, 2017, CELL CYCLE, V16, P578, DOI 10.1080/15384101.2017.1288324; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu TT, 2018, CANCER LETT, V423, P36, DOI 10.1016/j.canlet.2018.02.015; Ma XY, 2017, J BIOL CHEM, V292, P17046, DOI 10.1074/jbc.M117.805655; Ma YL, 2016, GUT, V65, P1494, DOI 10.1136/gutjnl-2014-308392; Matsumura K, 2017, ONCOGENE, V36, P1191, DOI 10.1038/onc.2016.282; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; Nagy ZB, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-016-0305-3; de Almeida ALNR, 2016, ACTA CIR BRAS, V31, P13, DOI 10.1590/S0102-86502016001300004; Okazaki S, 2012, INT J ONCOL, V40, P209, DOI [10.3892/ijo.2011.1201, 10.3892/ijo.2011.120]; Ou CL, 2017, CANCER LETT, V399, P53, DOI 10.1016/j.canlet.2017.04.011; Ou CL, 2015, ONCOL REP, V33, P2779, DOI 10.3892/or.2015.3913; Park J, 2015, ONCOTARGET, V6, P34658, DOI 10.18632/oncotarget.5778; Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209; Ren WG, 2016, ARCH MED RES, V47, P214, DOI 10.1016/j.arcmed.2016.07.001; Ross J, 2009, NUCLEIC ACIDS RES, V37, P5295, DOI 10.1093/nar/gkp545; Sarver AL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-401; Schetter AJ, 2008, JAMA-J AM MED ASSOC, V299, P425, DOI 10.1001/jama.299.4.425; Seton-Rogers S, 2014, NAT REV CANCER, V14, DOI 10.1038/nrc3791; Shao DD, 2014, CELL, V158, P171, DOI 10.1016/j.cell.2014.06.004; Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395; Skrzypczak M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013091; Sun D, 2016, ONCOTARGET, V7, P81062, DOI 10.18632/oncotarget.13188; Sun M, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0445-8; Sun ZQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135119; Tan DSW, 2017, NAT MED, V23, P1167, DOI 10.1038/nm.4401; Tan XY, 2017, J CELL BIOCHEM, V118, P3643, DOI 10.1002/jcb.25862; Tsai KW, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0821-1; Wang K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4596; Wang Z, 2017, CANCER RES, V77, P2413, DOI 10.1158/0008-5472.CAN-16-3229; Watanabe T, 2011, CLIN TRANSL ONCOL, V13, P419, DOI 10.1007/s12094-011-0676-z; Xiong W, 2008, BLOOD, V112, P4235, DOI 10.1182/blood-2007-10-119123; Yamada N, 2017, HUM PATHOL, V60, P151, DOI 10.1016/j.humpath.2016.10.007; Yang F, 2011, HEPATOLOGY, V54, P1679, DOI 10.1002/hep.24563; Yuan JS, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-85; Zeng ZY, 2007, HUM PATHOL, V38, P120, DOI 10.1016/j.humpath.2006.06.023; Zeng ZY, 2016, TUMOR BIOL, V37, P729, DOI 10.1007/s13277-015-3860-x; Zhang XM, 2015, INT J CANCER, V137, P2803, DOI 10.1002/ijc.29671; Zheng HT, 2014, INT J CLIN EXP PATHO, V7, P3174; Zhou Y., 2017, J CELLULAR PHYSL, V233, P5805, DOI 10. 1002/jcp. 26357; Zhou Y, 2013, INT J SYST DYN APPL, V2, P1, DOI 10.4018/ijsda.2013040101	67	146	149	5	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2019	38	14					2627	2644		10.1038/s41388-018-0628-y	http://dx.doi.org/10.1038/s41388-018-0628-y			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HR7LI	30531836	Green Published, hybrid			2022-12-28	WOS:000463335200013
J	Liu, Y; Li, F; Yang, YT; Xu, XD; Chen, JS; Chen, TL; Chen, HJ; Zhu, YB; Lin, JY; Li, Y; Xie, XM; Sun, XL; Ke, YQ				Liu, Y.; Li, F.; Yang, Y. T.; Xu, X. D.; Chen, J. S.; Chen, T. L.; Chen, H. J.; Zhu, Y. B.; Lin, J. Y.; Li, Y.; Xie, X. M.; Sun, X. L.; Ke, Y. Q.			IGFBP2 promotes vasculogenic mimicry formation via regulating CD144 and MMP2 expression in glioma	ONCOGENE			English	Article							FACTOR-BINDING PROTEIN-2; STEM-LIKE CELLS; HUMAN-MELANOMA CELLS; VASCULAR MIMICRY; GENE-EXPRESSION; GROWTH; CHEMORESISTANCE; IDENTIFICATION; MIGRATION; THERAPY	Vasculogenic mimicry (VM) refers to the fluid-conducting channels formed by aggressive tumor cells rather than endothelial cells (EC) with elevated expression of genes associated with vascularization. VM has been considered as one of the reasons that glioblastoma becomes resistant to anti-VEGF therapy. However, the molecular basis underlying VM formation remains unclear. Here we report that the insulin-like growth factor-binding protein 2 (IGFBP2) acts as a potent factor to enhance VM formation in glioma. Evidence showed that elevated IGFBP2 expression was positively related with VM formation in patients with glioma. Enforced expression of IGFBP2 increased network formation of glioma cells in vitro by activating CD144 and MMP2 (Matrix Metalloproteinase 2). U251 cells with stable knockdown of IGFBP2 led to decreased VM formation and tumor progression in orthotopic mouse model. Mechanistically, IGFBP2 interacts with integrin alpha 5 and beta 1 subunits and augments CD144 expression in a FAK/ERK pathway-dependent manner. Luciferase reporter and ChIP assay suggested that IGFBP2 activated the transcription factor SP1, which could bind to CD144 promoter. Thus, IGFBP2 acts as a stimulator of VM formation in glioma cells via enhancing CD144 and MMP2 expression.	[Liu, Y.; Li, F.; Yang, Y. T.; Xu, X. D.; Chen, J. S.; Chen, T. L.; Chen, H. J.; Zhu, Y. B.; Lin, J. Y.; Li, Y.; Xie, X. M.; Sun, X. L.; Ke, Y. Q.] Southern Med Univ, Zhujiang Hosp, Dept Neurosurg, Guangzhou, Guangdong, Peoples R China; [Liu, Y.; Li, F.; Yang, Y. T.; Xu, X. D.; Chen, J. S.; Chen, T. L.; Chen, H. J.; Zhu, Y. B.; Lin, J. Y.; Li, Y.; Xie, X. M.; Sun, X. L.; Ke, Y. Q.] Educ Minist China, Engn Technol Res Ctr, Natl Key Clin Specialty, Guangzhou, Guangdong, Peoples R China; [Liu, Y.; Li, F.; Yang, Y. T.; Xu, X. D.; Chen, J. S.; Chen, T. L.; Chen, H. J.; Zhu, Y. B.; Lin, J. Y.; Li, Y.; Xie, X. M.; Sun, X. L.; Ke, Y. Q.] Guangdong Prov Key Lab Brain Funct Repair & Regen, Guangzhou, Guangdong, Peoples R China	Southern Medical University - China	Sun, XL; Ke, YQ (corresponding author), Southern Med Univ, Zhujiang Hosp, Dept Neurosurg, Guangzhou, Guangdong, Peoples R China.; Sun, XL; Ke, YQ (corresponding author), Educ Minist China, Engn Technol Res Ctr, Natl Key Clin Specialty, Guangzhou, Guangdong, Peoples R China.; Sun, XL; Ke, YQ (corresponding author), Guangdong Prov Key Lab Brain Funct Repair & Regen, Guangzhou, Guangdong, Peoples R China.	zjsunxinlin@163.com; kyquan@smu.edu.cn			National Natural Science Foundation of China [81772651, 81772652]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (No. 81772651 and No. 81772652)	Biernacka KM, 2013, ENDOCR-RELAT CANCER, V20, P741, DOI 10.1530/ERC-13-0077; Braghiroli MI, 2017, EXPERT REV ANTICANC, V12, P567; Chen XL, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-72; Chiao MT, 2011, CURR NEUROVASC RES, V8, P210, DOI 10.2174/156720211796558023; Dunlap SM, 2007, P NATL ACAD SCI USA, V104, P11736, DOI 10.1073/pnas.0703145104; Dvorak HF, 2015, CANCER J, V21, P237, DOI 10.1097/PPO.0000000000000124; El Hallani S, 2010, BRAIN, V133, P973, DOI 10.1093/brain/awq044; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Francescone R, 2012, J BIOL CHEM, V287, P24821, DOI 10.1074/jbc.M111.334540; Frommer KW, 2006, J MOL ENDOCRINOL, V37, P13, DOI 10.1677/jme.1.01955; Fuller GN, 1999, CANCER RES, V59, P4228; Gao S, 2016, CANCER RES, V76, P6543, DOI 10.1158/0008-5472.CAN-16-0438; Godard S, 2003, CANCER RES, V63, P6613; Guo P, 2005, AM J PATHOL, V166, P877, DOI 10.1016/S0002-9440(10)62308-5; Hendrix MJC, 2003, NAT REV CANCER, V3, P411, DOI 10.1038/nrc1092; Hendrix MJC, 2001, P NATL ACAD SCI USA, V98, P8018, DOI 10.1073/pnas.131209798; Hsieh D, 2010, BIOCHEM BIOPH RES CO, V397, P367, DOI 10.1016/j.bbrc.2010.05.145; Huang YF, 2014, ENDOCR-RELAT CANCER, V21, P217, DOI 10.1530/ERC-13-0274; Kirschmann DA, 2012, CLIN CANCER RES, V18, P2726, DOI 10.1158/1078-0432.CCR-11-3237; Koch S, 2011, BIOCHEM J, V437, P169, DOI 10.1042/BJ20110301; Kuhnl A, 2011, LEUKEMIA RES, V35, P1585, DOI 10.1016/j.leukres.2011.08.006; Lai A, 2011, J CLIN ONCOL, V29, P142, DOI 10.1200/JCO.2010.30.2729; Lai CY, 2012, CANCER RES, V72, P5111, DOI 10.1158/0008-5472.CAN-12-0624; Liu TJ, 2013, ONCOGENE, V32, P544, DOI 10.1038/onc.2012.85; Liu X, 2015, CANCER SCI, V106, P857, DOI 10.1111/cas.12684; Liu XM, 2011, J NEURO-ONCOL, V105, P173, DOI 10.1007/s11060-011-0578-5; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Mei X, 2017, NEURO-ONCOLOGY, V42, P1; Mendes KN, 2010, INT J ONCOL, V37, P143, DOI 10.3892/ijo_00000662; Moore MG, 2003, INT J CANCER, V105, P14, DOI 10.1002/ijc.11015; Norden AD, 2009, J NEURO-ONCOL, V92, P149, DOI 10.1007/s11060-008-9745-8; Ohgaki H, 2005, ACTA NEUROPATHOL, V109, P93, DOI 10.1007/s00401-005-0991-y; Pereira JJ, 2004, CANCER RES, V64, P977, DOI 10.1158/0008-5472.CAN-03-3056; Ping YF, 2011, CURR MOL MED, V11, P69, DOI 10.2174/156652411794474383; Renehan AG, 2000, BRIT J CANCER, V83, P1344, DOI 10.1054/bjoc.2000.1462; Russo VC, 2015, CYTOKINE GROWTH F R, V26, P329, DOI 10.1016/j.cytogfr.2014.12.001; Russo VC, 2005, ENDOCRINOLOGY, V146, P4445, DOI 10.1210/en.2005-0467; Sallinen SL, 2000, CANCER RES, V60, P6617; Schutt BS, 2004, J MOL ENDOCRINOL, V32, P859, DOI 10.1677/jme.0.0320859; Scully S, 2012, J NEUROSCI, V32, P12950, DOI 10.1523/JNEUROSCI.2017-12.2012; Seftor REB, 2001, CANCER RES, V61, P6322; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; So AI, 2008, CLIN CANCER RES, V14, P6944, DOI 10.1158/1078-0432.CCR-08-0408; Uzoh CC, 2011, BRIT J CANCER, V104, P1587, DOI 10.1038/bjc.2011.127; Velez DO, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01556-7; Wagenblast E, 2015, NATURE, V520, P358, DOI 10.1038/nature14403; Wang H, 2003, CANCER RES, V63, P4315; Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624; Yue WY, 2005, J HISTOCHEM CYTOCHEM, V53, P997, DOI 10.1369/jhc.4A6521.2005; Zhu SM, 2017, GUT, V66, P802, DOI 10.1136/gutjnl-2016-312141	51	49	52	3	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2019	38	11					1815	1831		10.1038/s41388-018-0525-4	http://dx.doi.org/10.1038/s41388-018-0525-4			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HO7XX	30368528				2022-12-28	WOS:000461164400003
J	Liu, XJ; Bao, YH; Meng, W; Yang, P; An, Y; Ma, J; Tang, YJ; Liu, ZG; Lu, Y; Zhou, JF; Zhang, Y; Feng, JF; Gao, XF; Su, ZD; Pu, YY; He, C				Liu, Xiujie; Bao, Yinghui; Meng, Wei; Yang, Ping; An, Yi; Ma, Jie; Tang, Yujie; Liu, Zhigang; Lu, Yan; Zhou, Jianfeng; Zhang, Yong; Feng, Jifeng; Gao, Xiaofei; Su, Zhida; Pu, Yingyan; He, Cheng			TROY interacts with RKIP to promote glioma development	ONCOGENE			English	Article							NF-KAPPA-B; KINASE INHIBITOR PROTEIN; RECEPTOR FAMILY-MEMBER; GENOME-WIDE ASSOCIATION; THERAPEUTIC TARGET; TYROSINE KINASES; EXPRESSION; GLIOBLASTOMA; CANCER; TNF	TROY is a component of the Nogo receptor complex and plays the key role in neuronal survival, migration, and differentiation. Here, we show the up-regulation of TROY in human glioma tissues and cells. Inhibition of TROY expression slowed glioma development in vivo and in vitro. Raf kinase inhibitor (RKIP) was found to interact with TROY. The physical interaction of TROY/RKIP was confirmed via co-immunoprecipitation (co-IP) assays. Furthermore, we found that the TROY/RKIP interaction was enhanced by fetal bovine serum (FBS) exposure, and TROY knockdown also led to down-regulation of NF-kappa B. Finally, disruption of the TROY/RKIP interaction using the TAT-TROY (234-371 aa) protein reduced the glioma development in xenografted mice. This suggests the TROY/RKIP interaction is a potential target for therapy of gliomas.	[Liu, Xiujie; Lu, Yan; Zhou, Jianfeng; Zhang, Yong; Feng, Jifeng; Gao, Xiaofei; Su, Zhida; Pu, Yingyan; He, Cheng] Second Mil Med Univ, Minist Educ, Key Lab Mol Neurobiol, Inst Neurosci, Shanghai 200433, Peoples R China; [Liu, Xiujie; Lu, Yan; Zhou, Jianfeng; Zhang, Yong; Feng, Jifeng; Gao, Xiaofei; Su, Zhida; Pu, Yingyan; He, Cheng] Second Mil Med Univ, Collaborat Innovat Ctr Brain Sci, Shanghai 200433, Peoples R China; [Bao, Yinghui] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Neurosurg, Shanghai 200127, Peoples R China; [Meng, Wei; Ma, Jie] Shanghai Jiao Tong Univ, Sch Med, Xin Hua Hosp, Dept Pediat Neurosurg, Shanghai 200092, Peoples R China; [Yang, Ping] Fudan Univ, Sch Pharm, Instrumental Anal Ctr, Shanghai 201203, Peoples R China; [An, Yi] Yale Univ, Sch Med, Dept Therapeut Oncol, New Haven, CT USA; [Tang, Yujie] Shanghai Jiao Tong Univ, Sch Med, Key Lab Cell Differentiat & Apoptosis, Natl Minist Educ,Dept Pathophysiol, 280 South Chongqing Rd, Shanghai 200025, Peoples R China; [Liu, Zhigang] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Radiat Oncol, Zhuhai 519001, Guangdong, Peoples R China; [Liu, Zhigang] Sun Yat Sen Univ, Affiliated Hosp 5, Phase Clin Trial Ward 1, Zhuhai 519001, Guangdong, Peoples R China	Naval Medical University; Naval Medical University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Fudan University; Yale University; Shanghai Jiao Tong University; Sun Yat Sen University; Sun Yat Sen University	Liu, XJ; He, C (corresponding author), Second Mil Med Univ, Minist Educ, Key Lab Mol Neurobiol, Inst Neurosci, Shanghai 200433, Peoples R China.; Liu, XJ; He, C (corresponding author), Second Mil Med Univ, Collaborat Innovat Ctr Brain Sci, Shanghai 200433, Peoples R China.	LXJ186517@126.com; chenghe@smmu.edu.cn	Su, Zhida/G-6094-2015		National Key Basic Research Program [2011CB504401]; National Natural Science Foundation of China [81572500]; Natural Science Foundation of Shanghai City [13ZR1448500]; Hunan Young Talents [2016RS3036]	National Key Basic Research Program(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shanghai City(Natural Science Foundation of Shanghai); Hunan Young Talents	This work was supported by the National Key Basic Research Program (2011CB504401), the National Natural Science Foundation of China (31070922; 31130024; 81471224) and the Natural Science Foundation of Shanghai City (13ZR1448500). This work was partially supported by National Natural Science Foundation of China (NO. 81572500); Hunan Young Talents (NO. 2016RS3036).	Al-Mulla F, 2006, J CLIN ONCOL, V24, P5672, DOI 10.1200/JCO.2006.07.5499; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Behin A, 2003, LANCET, V361, P323, DOI 10.1016/S0140-6736(03)12328-8; Bei JX, 2010, NAT GENET, V42, P599, DOI 10.1038/ng.601; Bossen C, 2006, J BIOL CHEM, V281, P13964, DOI 10.1074/jbc.M601553200; Carrasco-Garcia E, 2014, CELLS-BASEL, V3, P199, DOI 10.3390/cells3020199; Chumbalkar VC, 2005, PROTEOMICS, V5, P1167, DOI 10.1002/pmic.200401202; Corbit KC, 2003, J BIOL CHEM, V278, P13061, DOI 10.1074/jbc.M210015200; DeAngelis LM, 2001, NEW ENGL J MED, V344, P114, DOI 10.1056/NEJM200101113440207; Ding X, 2010, JNCI-J NATL CANCER I, V102, P1052, DOI 10.1093/jnci/djq217; Eby MT, 2000, J BIOL CHEM, V275, P15336, DOI 10.1074/jbc.275.20.15336; Fafilek B, 2013, GASTROENTEROLOGY, V144, P381, DOI 10.1053/j.gastro.2012.10.048; Fu Z, 2003, J NATL CANCER I, V95, P878, DOI 10.1093/jnci/95.12.878; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Granovsky AE, 2008, CELL RES, V18, P452, DOI 10.1038/cr.2008.43; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hashimoto T, 2008, CELL CYCLE, V7, P106, DOI 10.4161/cc.7.1.5135; He SQ, 2011, NEURON, V69, P120, DOI 10.1016/j.neuron.2010.12.001; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hisaoka T, 2006, BRAIN RES, V1110, P81, DOI 10.1016/j.brainres.2006.06.068; Hu ZB, 2011, NAT GENET, V43, P792, DOI 10.1038/ng.875; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Kojima T, 2000, J BIOL CHEM, V275, P20742, DOI 10.1074/jbc.M002691200; Lee HC, 2006, GASTROENTEROLOGY, V131, P1208, DOI 10.1053/j.gastro.2006.07.012; Loftus JC, 2013, MOL CANCER RES, V11, P865, DOI 10.1158/1541-7786.MCR-13-0008; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Lu Y, 2013, J BIOL CHEM, V288, P34276, DOI 10.1074/jbc.M113.519744; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Maresch J, 2011, CANCER-AM CANCER SOC, V117, P2499, DOI 10.1002/cncr.25799; Mi S, 2008, CYTOKINE GROWTH F R, V19, P245, DOI 10.1016/j.cytogfr.2008.04.007; Nogueira L, 2011, ONCOTARGET, V2, P646, DOI 10.18632/oncotarget.322; Ohazama A, 2004, DEV DYNAM, V229, P131, DOI 10.1002/dvdy.10400; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Park JB, 2005, NEURON, V45, P345, DOI 10.1016/j.neuron.2004.12.040; Paulino VM, 2010, MOL CANCER RES, V8, P1558, DOI 10.1158/1541-7786.MCR-10-0334; Pispa J, 2008, HUM MOL GENET, V17, P3380, DOI 10.1093/hmg/ddn232; Purow B, 2009, NAT REV NEUROL, V5, P419, DOI 10.1038/nrneurol.2009.96; Reyes SB, 2013, MOL BIOL CELL, V24, P474, DOI 10.1091/mbc.E12-07-0521; Satoh J, 2007, NEUROPATH APPL NEURO, V33, P99, DOI 10.1111/j.1365-2990.2006.00787.x; Schuierer MM, 2004, CANCER RES, V64, P5186, DOI 10.1158/0008-5472.CAN-03-3861; Shao ZH, 2005, NEURON, V45, P353, DOI 10.1016/j.neuron.2004.12.050; Shin SY, 2009, J CELL SCI, V122, P425, DOI 10.1242/jcs.036319; Spanjaard RA, 2007, INT J CANCER, V120, P1304, DOI 10.1002/ijc.22367; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Tam SJ, 2012, DEV CELL, V22, P403, DOI 10.1016/j.devcel.2011.11.018; Trakul N, 2005, CELL RES, V15, P19, DOI 10.1038/sj.cr.7290258; Trakul N, 2005, J BIOL CHEM, V280, P24931, DOI 10.1074/jbc.M413929200; Wan JH, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0556-3; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Yeung KC, 2001, MOL CELL BIOL, V21, P7207, DOI 10.1128/MCB.21.21.7207-7217.2001; Yu ZW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009956; Ziegler DS, 2008, J CLIN INVEST, V118, P3109, DOI 10.1172/JCI34120; Zwick E, 2002, TRENDS MOL MED, V8, P17, DOI 10.1016/S1471-4914(01)02217-1	54	2	3	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2019	38	9					1544	1559		10.1038/s41388-018-0503-x	http://dx.doi.org/10.1038/s41388-018-0503-x			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN1KL	30337686	Green Published, hybrid			2022-12-28	WOS:000459945800013
J	Sava, GP; Fan, HL; Fisher, RA; Lusvarghi, S; Pancholi, S; Ambudkar, SV; Martin, LA; Coombes, RC; Buluwela, L; Ali, S				Sava, Georgina P.; Fan, Hailing; Fisher, Rosemary A.; Lusvarghi, Sabrina; Pancholi, Sunil; Ambudkar, Suresh, V; Martin, Lesley-Ann; Coombes, R. Charles; Buluwela, Lakjaya; Ali, Simak			ABC-transporter upregulation mediates resistance to the CDK7 inhibitors THZ1 and ICEC0942	ONCOGENE			English	Article							DEPENDENT KINASE INHIBITOR; MESSENGER-RNA EXPRESSION; BREAST-CANCER; MULTIDRUG-RESISTANCE; DRUG-RESISTANCE; IN-VITRO; TRANSCRIPTIONAL ADDICTION; LUNG-CANCER; PROTEIN; GLYCOPROTEIN	The CDK7 inhibitors (CDK7i) ICEC0942 and THZ1, are promising new cancer therapeutics. Resistance to targeted drugs frequently compromises cancer treatment. We sought to identify mechanisms by which cancer cells may become resistant to CDK7i. Resistant lines were established through continuous drug selection. ABC-transporter copy number, expression and activity were examined using real-time PCR, immunoblotting and flow cytometry. Drug responses were measured using growth assays. ABCB1 was upregulated in ICEC0942-resistant cells and there was cross-resistance to THZ1. THZ1-resistant cells upregulated ABCG2 but remained sensitive to ICEC0942. Drug resistance in both cell lines was reversible upon inhibition of ABC-transporters. CDK7i response was altered in adriamycin- and mitoxantrone-resistant cell lines demonstrating ABC-transporter upregulation. ABCB1 expression correlated with ICEC0942 and THZ1 response, and ABCG2 expression with THZ2 response, in a panel of cancer cell lines. We have identified ABCB1 upregulation as a common mechanism of resistance to ICEC0942 and THZ1, and confirmed that ABCG2 upregulation is a mechanism of resistance to THZ1. The identification of potential mechanisms of CDK7i resistance and differences in susceptibility of ICEC0942 and THZ1 to ABC-transporters, may help guide their future clinical use.	[Sava, Georgina P.; Fan, Hailing; Fisher, Rosemary A.; Coombes, R. Charles; Buluwela, Lakjaya; Ali, Simak] Imperial Coll London, Dept Surg & Canc, Div Canc, Hammersmith Hosp Campus, London, England; [Lusvarghi, Sabrina; Ambudkar, Suresh, V] NCI, Lab Cell Biol, Ctr Canc Res, Bethesda, MD 20892 USA; [Pancholi, Sunil; Martin, Lesley-Ann] Breast Canc Now Toby Robins Res Ctr, Inst Canc Res, London, England	Imperial College London; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Ali, S (corresponding author), Imperial Coll London, Dept Surg & Canc, Div Canc, Hammersmith Hosp Campus, London, England.	simak.ali@imperial.ac.uk	Ali, Simak/M-6912-2018	Ali, Simak/0000-0002-1320-0816; Pancholi, Sunil/0000-0002-0880-1588; Ambudkar, Suresh/0000-0002-2639-4955; Coombes, Raoul Charles/0000-0002-4811-1100; Fisher, Rosemary/0000-0002-2721-8726; Lusvarghi, Sabrina/0000-0003-1793-0450; Sava, Georgina/0000-0001-5904-3978	Cancer Research UK [C37/A18784]; Breast Cancer Now's Catalyst Programme - Pfizer	Cancer Research UK(Cancer Research UK); Breast Cancer Now's Catalyst Programme - Pfizer	This study was supported by Cancer Research UK grant C37/A18784. HF is funded by Breast Cancer Now's Catalyst Programme, which is supported by funding from Pfizer.	Ali S, 2009, CANCER RES, V69, P6208, DOI 10.1158/0008-5472.CAN-09-0301; Allen JD, 2002, MOL CANCER THER, V1, P417; Amiri-Kordestani L, 2012, DRUG RESIST UPDATE, V15, P50, DOI 10.1016/j.drup.2012.02.002; Bondke A, 2016, US patent, Patent No. [0362410 A1, 0362410]; Bradner JE, 2017, CELL, V168, P629, DOI 10.1016/j.cell.2016.12.013; Bugde P, 2017, EXPERT OPIN THER TAR, V21, P511, DOI 10.1080/14728222.2017.1310841; Chen DS, 2000, MOL CELL, V6, P127, DOI 10.1016/S1097-2765(00)00014-9; Christensen CL, 2014, CANCER CELL, V26, P909, DOI 10.1016/j.ccell.2014.10.019; Christie EL, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09312-9; Chymkowitch P, 2011, EMBO J, V30, P468, DOI 10.1038/emboj.2010.337; Clarke R, 2005, SEMIN ONCOL, V32, pS9, DOI 10.1053/j.seminoncol.2005.09.009; CORNWELL MM, 1987, J BIOL CHEM, V262, P2166; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Durbin AD, 2018, NAT GENET, V50, P1240, DOI 10.1038/s41588-018-0191-z; Eliades P, 2018, J INVEST DERMATOL, V138, P1582, DOI 10.1016/j.jid.2017.09.056; Fisher RP, 2005, J CELL SCI, V118, P5171, DOI 10.1242/jcs.02718; Gao Y, 2018, CELL CHEM BIOL, V25, P135, DOI 10.1016/j.chembiol.2017.11.007; Harrod A, 2017, ONCOGENE, V36, P2286, DOI 10.1038/onc.2016.382; Hu SH, 2019, CANCER RES, V79, P3479, DOI 10.1158/0008-5472.CAN-19-0119; Huff LM, 2005, CANCER RES, V65, P11694; Iniguez AB, 2018, CANCER CELL, V33, P202, DOI 10.1016/j.ccell.2017.12.009; Iorio F, 2016, CELL, V166, P740, DOI 10.1016/j.cell.2016.06.017; Jeselsohn R, 2018, CANCER CELL, V33, P173, DOI 10.1016/j.ccell.2018.01.004; Jiang YY, 2017, GUT, V66, P1358, DOI 10.1136/gutjnl-2016-311818; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; Kaliszczak M, 2013, BRIT J CANCER, V109, P2356, DOI 10.1038/bjc.2013.584; Katayama R, 2016, EBIOMEDICINE, V3, P54, DOI 10.1016/j.ebiom.2015.12.009; Kim Yeo-Kyeoung, 2014, Chonnam Med J, V50, P102, DOI 10.4068/cmj.2014.50.3.102; Kim YH, 2009, LUNG CANCER, V65, P105, DOI 10.1016/j.lungcan.2008.10.008; Kwiatkowski N, 2014, NATURE, V511, P616, DOI 10.1038/nature13393; Larochelle S, 2012, NAT STRUCT MOL BIOL, V19, P1108, DOI 10.1038/nsmb.2399; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; Mansoori B, 2017, ADV PHARM BULL, V7, P339, DOI 10.15171/apb.2017.041; Martin C, 1999, BRIT J PHARMACOL, V128, P403, DOI 10.1038/sj.bjp.0702807; McDermott M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00040; Mistry P, 2001, CANCER RES, V61, P749; NAKAGAWA M, 1992, CANCER RES, V52, P6175; Patch AM, 2015, NATURE, V521, P489, DOI 10.1038/nature14410; Patel H, 2018, MOL CANCER THER, V17, P1156, DOI 10.1158/1535-7163.MCT-16-0847; Pick A, 2010, CHEMMEDCHEM, V5, P1498, DOI 10.1002/cmdc.201000216; Robey RW, 2018, NAT REV CANCER, V18, P452, DOI 10.1038/s41568-018-0005-8; Robinson AN, 2019, DRUG METAB DISPOS, V47, P715, DOI 10.1124/dmd.118.086181; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; Roschke AV, 2003, CANCER RES, V63, P8634; Ross DD, 1999, J NATL CANCER I, V91, P429, DOI 10.1093/jnci/91.5.429; Sadik H, 2016, CANCER RES, V76, P4443, DOI 10.1158/0008-5472.CAN-16-0774; Schachter MM, 2013, CELL CYCLE, V12, P3239, DOI 10.4161/cc.26355; Scharenberg CW, 2002, BLOOD, V99, P507, DOI 10.1182/blood.V99.2.507; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; Shiozawa K, 2004, INT J CANCER, V108, P146, DOI 10.1002/ijc.11528; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Skuta C, 2017, NAT METHODS, V14, P758, DOI 10.1038/nmeth.4365; Szafraniec MJ, 2014, DRUG METAB REV, V46, P459, DOI 10.3109/03602532.2014.942037; Turner NC, 2015, NEW ENGL J MED, V373, P209, DOI 10.1056/NEJMoa1505270; UEDA K, 1986, BIOCHEM BIOPH RES CO, V141, P956, DOI 10.1016/S0006-291X(86)80136-X; Uggla B, 2005, LEUKEMIA RES, V29, P141, DOI 10.1016/j.leukres.2004.06.004; Wang YB, 2015, CELL, V163, P174, DOI 10.1016/j.cell.2015.08.063	57	9	10	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					651	663		10.1038/s41388-019-1008-y	http://dx.doi.org/10.1038/s41388-019-1008-y			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31530935	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000509718300012
J	Yang, SS; Ren, XL; Liang, YS; Yan, YR; Zhou, YS; Hu, JL; Wang, ZZ; Song, FY; Wang, FF; Liao, WJ; Liao, WT; Ding, YQ; Liang, L				Yang, Shaoshan; Ren, Xiaoli; Liang, Yunshi; Yan, Yongrong; Zhou, Yangshu; Hu, Jinlong; Wang, Zhizhi; Song, Fuyao; Wang, Feifei; Liao, Wangjun; Liao, Wenting; Ding, Yanqing; Liang, Li			KNK437 restricts the growth and metastasis of colorectal cancer via targeting DNAJA1/CDC45 axis	ONCOGENE			English	Article							SHOCK-PROTEIN 27; CELL LUNG-CANCER; EMERGING ROLES; DNAJ HOMOLOG; HEAT; INHIBITOR; IDENTIFICATION; GANETESPIB; EXPRESSION; RESISTANCE	As an inhibitor of heat shock proteins (HSPs), KNK437 has been reported to play an anti-tumor role in several cancers. But its therapeutic effect and mechanisms in colorectal cancer (CRC) remain unclear. Here, KNK437 sharply inhibited the level of DnaJ heat shock protein family (Hsp40) member A1 (DNAJA1), followed by DNAJB1, but had little effect on the levels of HSP27, HSP105, HSP90, and HSP70 in CRC cells. DNAJA1 promoted CRC cell proliferation in vitro and tumor growth and metastasis in vivo. Mechanistically, DNAJA1 was activated by E2F transcription factor 1 (E2F1) and then promoted cell cycle by stabilizing cell division cycle protein 45 (CDC45), which could be reversed by KNK437. DNAJA1 was significantly upregulated in CRC tissues and positively correlated with serosa invasion, lymph node metastasis. High level of DNAJA1 predicted poor prognosis for CRC patients. Its expression was highly linked with E2F1 and CDC45 in CRC tissues. More importantly, KNK437 significantly suppressed the growth of DNAJA1 expressing tumor in vivo. The combined treatment of KNK437 with 5-FU/L-OHP chemotherapy reduced liver metastasis of CRC. These data reveal a novel mechanism of KNK437 in anti-tumor therapy of CRC and provides a newly therapeutic strategy with potential translation to the CRC patients.	[Yang, Shaoshan; Ren, Xiaoli; Liang, Yunshi; Yan, Yongrong; Zhou, Yangshu; Hu, Jinlong; Wang, Zhizhi; Song, Fuyao; Wang, Feifei; Liao, Wenting; Ding, Yanqing; Liang, Li] Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China; [Yang, Shaoshan; Ren, Xiaoli; Liang, Yunshi; Yan, Yongrong; Zhou, Yangshu; Hu, Jinlong; Wang, Zhizhi; Song, Fuyao; Wang, Feifei; Liao, Wenting; Ding, Yanqing; Liang, Li] Guangdong Prov Key Lab Mol Tumor Pathol, Guangzhou 510515, Guangdong, Peoples R China; [Yang, Shaoshan] Shantou Univ, Med Coll, Affiliated Hosp 2, Dept Pathol, Shantou 515041, Guangdong, Peoples R China; [Liao, Wangjun] Southern Med Univ, Nanfang Hosp, Dept Oncol, Guangzhou 510515, Guangdong, Peoples R China	Southern Medical University - China; Shantou University; Southern Medical University - China	Liang, L (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China.; Liang, L (corresponding author), Guangdong Prov Key Lab Mol Tumor Pathol, Guangzhou 510515, Guangdong, Peoples R China.	lli@fimmu.com	liang, li/AAB-9126-2022; Liao, Yulin/AAP-6315-2021		National key R&D program of China [2017YFC1309002]; National Basic Research Program of China (973 Program) [2015CB554002]; National Natural Science Foundation of China [81672821, 81472313, 81773101, 81272759, 81401927, 81302151, 81802306]; China Postdoctoral Science Foundation [2018M633081, 2018M633079]; Natural Science Foundation of Guangdong Province [2018A030310457]	National key R&D program of China; National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province)	This work was supported by the National key R&D program of China (2017YFC1309002), National Basic Research Program of China (973 Program, 2015CB554002), National Natural Science Foundation of China (81672821, 81472313, 81773101, 81272759, 81401927, 81302151, and 81802306), Project funded by China Postdoctoral Science Foundation (2018M633081 and 2018M633079), Natural Science Foundation of Guangdong Province (2018A030310457).	Ban HS, 2016, BIOCONJUGATE CHEM, V27, P1911, DOI 10.1021/acs.bioconjchem.6b00305; Banerji U, 2005, J CLIN ONCOL, V23, P4152, DOI 10.1200/JCO.2005.00.612; Barrio S, 2013, BRIT J HAEMATOL, V161, P667, DOI 10.1111/bjh.12308; Bauerschmidt C, 2007, GENES CELLS, V12, P745, DOI 10.1111/j.1365-2443.2007.01090.x; Bodoor Khaldon, 2016, Asian Pac J Cancer Prev, V17, P3929; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696; Gibbs SJ, 2008, NEUROBIOL DIS, V32, P196, DOI 10.1016/j.nbd.2008.07.016; Hadchity E, 2009, MOL THER, V17, P1387, DOI 10.1038/mt.2009.90; Haggerty TJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114506; Haider S, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0105-3; Hardy CFJ, 1997, GENE, V187, P239, DOI 10.1016/S0378-1119(96)00761-5; Jaattela M, 1999, ANN MED, V31, P261, DOI 10.3109/07853899908995889; Jagadish N, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0425-9; Jhaveri K, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0879-5; Kimura A, 2017, WORLD J GASTROENTERO, V23, P7541, DOI 10.3748/wjg.v23.i42.7541; Kotlarz A, 2013, CELL STRESS CHAPERON, V18, P653, DOI 10.1007/s12192-013-0407-1; Kudryavtsev VA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173640; Kuramitsu Y, 2012, ANTICANCER RES, V32, P2295; Lee HG, 2017, ONCOL LETT, V13, P2817, DOI 10.3892/ol.2017.5794; Li HY, 2017, NEOPLASMA, V64, P22, DOI 10.4149/neo_2017_103; Matijasevic Z, 1998, ONCOL RES, V10, P605; Meshalkina DA, 2016, ONCOTARGET, V7, P22050, DOI 10.18632/oncotarget.7872; Nasheuer HP, 2002, PROG NUCLEIC ACID RE, V72, P41, DOI 10.1016/S0079-6603(02)72067-9; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Oommen D, 2012, BIOCHEM BIOPH RES CO, V421, P538, DOI 10.1016/j.bbrc.2012.04.040; Parrales A, 2016, NAT CELL BIOL, V18, P1233, DOI 10.1038/ncb3427; Qiu XB, 2006, CELL MOL LIFE SCI, V63, P2560, DOI 10.1007/s00018-006-6192-6; Ramalingam S, 2015, ANN ONCOL, V26, P1741, DOI 10.1093/annonc/mdv220; Sahin E, 2011, INT J HYPERTHER, V27, P63, DOI 10.3109/02656736.2010.528139; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sonna LA, 2002, J APPL PHYSIOL, V92, P1725, DOI 10.1152/japplphysiol.01143.2001; Stark JL, 2014, BIOCHEMISTRY-US, V53, P1360, DOI 10.1021/bi401329a; Sun J, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317705342; Taba K, 2011, CHEMOTHERAPY, V57, P12, DOI 10.1159/000321019; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Tane S, 2015, CANCER SCI, V106, P1625, DOI 10.1111/cas.12770; Terada K, 2005, EMBO J, V24, P611, DOI 10.1038/sj.emboj.7600549; Thorsteinsdottir J, 2017, J NEURO-ONCOL, V135, P443, DOI 10.1007/s11060-017-2600-z; Walsh P, 2004, EMBO REP, V5, P567, DOI 10.1038/sj.embor.7400172; Wang CC, 2006, CANCER RES, V66, P6756, DOI 10.1158/0008-5472.CAN-06-0185; Wang YF, 2016, CLIN CANCER RES, V22, P5876, DOI 10.1158/1078-0432.CCR-15-2190; Yokota S, 2000, CANCER RES, V60, P2942	43	27	27	3	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	2					249	261		10.1038/s41388-019-0978-0	http://dx.doi.org/10.1038/s41388-019-0978-0			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KD3JY	31477839				2022-12-28	WOS:000507766400001
J	Li, DK; Tian, Y; Hu, Y; Qi, YJ; Tian, NY; Li, SS; Hu, PS; Wu, F; Wei, QF; Wei, ZZ; Wang, SS; Yin, B; Jiang, T; Yuan, JG; Qiang, BQ; Han, W; Peng, XZ				Li, Dengke; Tian, Yuan; Hu, Yan; Qi, Yingjiao; Tian, Ningyu; Li, Shanshan; Hu, Peishan; Wu, Fan; Wei, Qunfang; Wei, Zhizhong; Wang, Shanshan; Yin, Bin; Jiang, Tao; Yuan, Jiangang; Qiang, Boqin; Han, Wei; Peng, Xiaozhong			Glioma-associated human endothelial cell-derived extracellular vesicles specifically promote the tumourigenicity of glioma stem cells via CD9	ONCOGENE			English	Article							INITIATING CELLS; TETRASPANIN CD9; TUMOR-GROWTH; PROLIFERATION; EXOSOMES; ACTIVATION; CROSSTALK; BETA; INTERLEUKIN-8; EXPRESSION	The perivascular niche in glioma is critical for the maintenance of glioma stem cells (GSCs), and tumour-endothelial cell (EC) communication impacts tumourigenesis in ways that are incompletely understood. Here, we show that gliomaassociated human endothelial cells (GhECs), a main component of the perivascular niche, release extracellular vesicles (EVs) that increase GSC proliferation and tumour-sphere formation. GSCs treated with GhEC-EVs create a significantly greater tumour burden than do untreated GSCs in orthotopic xenografts. Mechanistic, analysis of EVs content identified CD9 as a mediator of the effects on GSCs. CD9 can activate the BMX/STAT3 signalling pathway in GSCs. Our results illuminate the tumour-supporting role of ECs by identifying that EC-derived EVs transfer of CD9 during intercellular communication, thereby enhancing the aggressiveness of glioblastoma by specifically maintaining GSCs.	[Li, Dengke; Tian, Yuan; Hu, Yan; Qi, Yingjiao; Tian, Ningyu; Li, Shanshan; Hu, Peishan; Wei, Qunfang; Wei, Zhizhong; Wang, Shanshan; Yin, Bin; Yuan, Jiangang; Qiang, Boqin; Han, Wei; Peng, Xiaozhong] Chinese Acad Med Sci, Peking Union Med Coll,Sch Basic Med, State Key Lab Med Mol Biol,Dept Mol Biol & Bioche, Inst Basic Med Sci,Med Primate Res Ctr,Neurosci C, Beijing, Peoples R China; [Wu, Fan; Jiang, Tao] Capital Med Univ, Beijing Neurosurg Inst, Dept Mol Neuropathol, Beijing, Peoples R China; [Wei, Zhizhong; Peng, Xiaozhong] Chinese Acad Med Sci, Inst Med Biol, Peking Union Med Coll, Kunming, Yunnan, Peoples R China; [Jiang, Tao] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Beijing Neurosurgical Institute; Capital Medical University; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Medical Biology - CAMS; Peking Union Medical College; Capital Medical University	Han, W; Peng, XZ (corresponding author), Chinese Acad Med Sci, Peking Union Med Coll,Sch Basic Med, State Key Lab Med Mol Biol,Dept Mol Biol & Bioche, Inst Basic Med Sci,Med Primate Res Ctr,Neurosci C, Beijing, Peoples R China.; Peng, XZ (corresponding author), Chinese Acad Med Sci, Inst Med Biol, Peking Union Med Coll, Kunming, Yunnan, Peoples R China.	hanwei2012@ibms.pumc.edu.cn; pengxiaozhong@pumc.edu.cn	jiang, tao/GWC-7108-2022	wei, zhizhong/0000-0002-9840-1878	National Key Research and Development Program of China [2016YFC0902500, 2016YFC0902502, 2016YFA0100702]; National Sciences Foundation of China [31671316, 31670789]; CAMS Innovation Fund for Medical Sciences (CIFMS) [2016-I2M-1-001, 2016-I2M-2-001, 2016-I2M-1-004, 2017-I2M-2-004, 2017-I2M-3-010, 2017-I2M-1-004]	National Key Research and Development Program of China; National Sciences Foundation of China(National Natural Science Foundation of China (NSFC)); CAMS Innovation Fund for Medical Sciences (CIFMS)	The National Key Research and Development Program of China (2016YFC0902500, 2016YFC0902502 and 2016YFA0100702), and National Sciences Foundation of China (31671316, 31670789), CAMS Innovation Fund for Medical Sciences (CIFMS, 2016-I2M-1-001, 2016-I2M-2-001, 2016-I2M-1-004, 2017-I2M-2-004, 2017-I2M-3-010 and 2017-I2M-1-004).	Atay S, 2014, P NATL ACAD SCI USA, V111, P711, DOI 10.1073/pnas.1310501111; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bassett EA, 2016, ELIFE, V5, DOI 10.7554/eLife.16764; Bhuvanalakshmi G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127517; Boelens MC, 2014, CELL, V159, P499, DOI 10.1016/j.cell.2014.09.051; Bovy N, 2015, ONCOTARGET, V6, P10253, DOI 10.18632/oncotarget.3520; Brat DJ, 2005, NEURO-ONCOLOGY, V7, P122, DOI 10.1215/S1152851704001061; Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020; Charles N, 2010, CELL STEM CELL, V6, P141, DOI 10.1016/j.stem.2010.01.001; Charles NA, 2011, GLIA, V59, P1169, DOI 10.1002/glia.21136; Chen C, 2015, CANCER RES, V75, P1725, DOI 10.1158/0008-5472.CAN-14-2111; Cheng L, 2010, BIOCHEM PHARMACOL, V80, P654, DOI 10.1016/j.bcp.2010.04.035; Cherepanov SA, 2016, B EXP BIOL MED+, V161, P674, DOI 10.1007/s10517-016-3483-2; Di Modica M, 2017, CANCER LETT, V384, P94, DOI 10.1016/j.canlet.2016.09.013; Eyler CE, 2011, CELL, V146, P53, DOI 10.1016/j.cell.2011.06.006; Figueroa J, 2017, CANCER RES, V77, P5808, DOI 10.1158/0008-5472.CAN-16-2524; Filatova A, 2013, BBA-GEN SUBJECTS, V1830, P2496, DOI 10.1016/j.bbagen.2012.10.008; Galan-Moya EM, 2011, EMBO REP, V12, P470, DOI 10.1038/embor.2011.39; Hu PS, 2017, ONCOGENE, V36, P4706, DOI 10.1038/onc.2017.34; Huang CI, 1998, AM J PATHOL, V153, P973, DOI 10.1016/S0002-9440(10)65639-8; Infanger DW, 2013, CANCER RES, V73, P7079, DOI 10.1158/0008-5472.CAN-13-1355; Jeon HM, 2014, CANCER RES, V74, P4482, DOI 10.1158/0008-5472.CAN-13-1597; Kowal J, 2016, P NATL ACAD SCI USA, V113, pE968, DOI 10.1073/pnas.1521230113; Kucharzewska P, 2013, P NATL ACAD SCI USA, V110, P7312, DOI 10.1073/pnas.1220998110; Kurachi M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159158; Leca J, 2016, J CLIN INVEST, V126, P4140, DOI 10.1172/JCI87734; Liu SH, 2014, INT J CLIN EXP PATHO, V7, P4857; Lombardo G, 2016, SCI REP-UK, V6, DOI 10.1038/srep25689; Longo N, 2001, BLOOD, V98, P3717, DOI 10.1182/blood.V98.13.3717; Mahmoud AM, 2017, FASEB J, V31, P4636, DOI 10.1096/fj.201601244RR; Mathivanan S, 2010, J PROTEOMICS, V73, P1907, DOI 10.1016/j.jprot.2010.06.006; Miyake M, 1996, CANCER RES, V56, P1244; Mori M, 1998, CLIN CANCER RES, V4, P1507; Muller L, 2016, SCI REP-UK, V6, DOI 10.1038/srep20254; Murayama Y, 2008, J CELL PHYSIOL, V216, P135, DOI 10.1002/jcp.21384; Osterberg N, 2016, NEURO-ONCOLOGY, V18, P939, DOI 10.1093/neuonc/now005; Pan YZ, 2017, INT J ONCOL, V50, P1965, DOI 10.3892/ijo.2017.3965; She XW, 2004, INT J CANCER, V108, P251, DOI 10.1002/ijc.11551; Shi Y, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aah6816; Shi Y, 2017, CELL DEATH DIFFER, V24, P167, DOI 10.1038/cdd.2016.110; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Solly F, 2008, CANCER GENE THER, V15, P685, DOI 10.1038/cgt.2008.36; Treps L, 2016, ONCOGENE, V35, P2615, DOI 10.1038/onc.2015.317; Treps L, 2017, J EXTRACELL VESICLES, V6, DOI 10.1080/20013078.2017.1359479; Valentijn KM, 2008, J STRUCT BIOL, V161, P447, DOI 10.1016/j.jsb.2007.08.001; Wang GP, 2015, MOL MED REP, V12, P1381, DOI 10.3892/mmr.2015.3466; Weyerbrock A, 2012, NEUROSURGERY, V70, P497, DOI 10.1227/NEU.0b013e31823209cf; Wirsching HG, 2014, BRAIN, V137, P433, DOI 10.1093/brain/awt333; Xu R, 2016, J CLIN INVEST, V126, P1152, DOI 10.1172/JCI81129; Yamashita D, 2015, CANCER RES, V75, P1123, DOI 10.1158/0008-5472.CAN-14-0938; Yan GN, 2014, J PATHOL, V234, P11, DOI 10.1002/path.4349; Yan K, 2013, CURR OPIN NEUROL, V26, P701, DOI 10.1097/WCO.0000000000000032; Yanez-Mo M, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27066; Yue SJ, 2015, ONCOTARGET, V6, P2366, DOI 10.18632/oncotarget.2958; Zomer A, 2015, CELL, V161, P1046, DOI 10.1016/j.cell.2015.04.042	57	12	13	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2019	38	43					6898	6912		10.1038/s41388-019-0903-6	http://dx.doi.org/10.1038/s41388-019-0903-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JH4GX	31399645				2022-12-28	WOS:000492728000002
J	Feng, DF; Qin, B; Pal, K; Sun, L; Dutta, S; Dong, HD; Liu, X; Mukhopadhyay, D; Huang, SB; Sinicrope, FA				Feng, Daofu; Qin, Bo; Pal, Krishnendu; Sun, Lei; Dutta, Shamit; Dong, Haidong; Liu, Xin; Mukhopadhyay, Debabrata; Huang, Shengbing; Sinicrope, Frank A.			BRAF(V600E)-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts	ONCOGENE			English	Article							B7-H1 PD-L1; EXPRESSION; MEK; ACTIVATION; BLOCKADE; PROTEIN; RESISTANCE; RECEPTOR; MUTATION; CASCADE	Programmed death ligand 1 (PD-L1) is an immune checkpoint protein; however, emerging data suggest that tumor cell PD-L1 may regulate immune-independent and intrinsic cellular functions. We demonstrate regulation of PD-L1 by oncogenic BRAF(V600E) and investigated its ability to influence apoptotic susceptibility in colorectal cancer (CRC) cells. Endogenous or exogenous mutant vs. wild-type BRAF were shown to increase PD-L1 messenger RNA (mRNA) and protein expression that was attenuated by MEK (mitogen-activated protein kinase/extracellular signal-regulated kinase) inhibition or c-JUN and YAP knockdown. Deletion of PD-L1 reduced tumor cell growth in vitro and in vivo. Loss of PD-L1 was also shown to attenuate DNA damage and apoptosis induced by diverse anti-cancer drugs that could be reversed by restoration of wild-type PD-L1, but not mutants with deletion of its extra- or intracellular domain. The effect of PD-L1 on chemosensitivity was confirmed in MC38 murine tumor xenografts generated from PD-L1-knockout vs. parental cells. Deletion of PD-L1 suppressed BH3-only BIM and BIK proteins that could be restored by re-expression of PD-L1; re-introduction of BIM enhanced apoptosis. PD-L1 expression was significantly increased in BRAF(V600E) human colon cancers, and patients whose tumors had high vs. low PD-L1 had significantly better survival. In summary, BRAF(V600E) can transcriptionally upregulate PD-L1 expression that was shown to induce BIM and BIK to enhance chemotherapy-induced apoptosis. These data indicate an intrinsic, non-immune function of PD-L1, and suggest the potential for tumor cell PD-L1 as a predictive biomarker.	[Feng, Daofu; Qin, Bo; Sun, Lei; Huang, Shengbing; Sinicrope, Frank A.] Gastrointestinal Res Unit, Rochester, MN 55905 USA; [Pal, Krishnendu; Dutta, Shamit; Mukhopadhyay, Debabrata] Mayo Clin, Dept Biochem & Mol Biol, Jacksonville, FL 32224 USA; [Dong, Haidong; Liu, Xin] Mayo Clin, Dept Immunol, Rochester, MN 55905 USA; [Sinicrope, Frank A.] Dept Med, Rochester, MN 55905 USA; [Sinicrope, Frank A.] Dept Oncol, Rochester, MN 55905 USA; [Sinicrope, Frank A.] Mayo Clin, Rochester, MN 55905 USA; [Sinicrope, Frank A.] Mayo Comprehens Canc Ctr, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Sinicrope, FA (corresponding author), Gastrointestinal Res Unit, Rochester, MN 55905 USA.; Sinicrope, FA (corresponding author), Dept Med, Rochester, MN 55905 USA.; Sinicrope, FA (corresponding author), Dept Oncol, Rochester, MN 55905 USA.; Sinicrope, FA (corresponding author), Mayo Clin, Rochester, MN 55905 USA.; Sinicrope, FA (corresponding author), Mayo Comprehens Canc Ctr, Rochester, MN 55905 USA.	sinicrope.frank@mayo.edu		Pal, Krishnendu/0000-0002-4006-213X	NCI R01 [CA210509-01A1]; Scientific Research Training Program for Young Talents of Tianjin Medical University General Hospital, PRC; Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; NATIONAL CANCER INSTITUTE [R01CA210509] Funding Source: NIH RePORTER	NCI R01(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Scientific Research Training Program for Young Talents of Tianjin Medical University General Hospital, PRC; Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported, in part, by NCI R01 (CA210509-01A1) to F.A.S. D.F. was supported by the Scientific Research Training Program for Young Talents of Tianjin Medical University General Hospital, PRC; current address is Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, China. L.S. is supported by the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. The authors' express their gratitude to Mr. Matthew A. Bockol for downloading TCGA data.	Adams JM, 2018, CELL DEATH DIFFER, V25, P27, DOI 10.1038/cdd.2017.161; Atefi M, 2014, CLIN CANCER RES, V20, P3446, DOI 10.1158/1078-0432.CCR-13-2797; Audrito V, 2017, ONCOTARGET, V8, P15894, DOI 10.18632/oncotarget.15213; Azuma T, 2008, BLOOD, V111, P3635, DOI 10.1182/blood-2007-11-123141; Bae SU, 2018, ONCOL LETT, V16, P5214, DOI 10.3892/ol.2018.9264; Baeten JM, 2016, NEW ENGL J MED, V375, P2121, DOI 10.1056/NEJMoa1506110; Bhalla S, 2011, BLOOD, V118, P1052, DOI 10.1182/blood-2011-03-340109; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Chen N, 2015, J THORAC ONCOL, V10, P910, DOI 10.1097/JTO.0000000000000500; Clark CA, 2016, CANCER RES, V76, P6964, DOI 10.1158/0008-5472.CAN-16-0258; Corcoran RB, 2018, CANCER DISCOV, V8, P428, DOI 10.1158/2159-8290.CD-17-1226; Dong HD, 1999, NAT MED, V5, P1365; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Droeser RA, 2013, EUR J CANCER, V49, P2233, DOI 10.1016/j.ejca.2013.02.015; Ghebeh H, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2605; Guzman C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092444; Hamanishi J, 2016, INT J CLIN ONCOL, V21, P462, DOI 10.1007/s10147-016-0959-z; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hersey P, 2013, CLIN CANCER RES, V19, P514, DOI 10.1158/1078-0432.CCR-12-3312; Kawakami H, 2016, MOL CANCER THER, V15, P3015, DOI 10.1158/1535-7163.MCT-16-0017; Kim MH, 2018, CANCER IMMUNOL RES, V6, P255, DOI 10.1158/2326-6066.CIR-17-0320; King AC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062613; Kleffel S, 2015, CELL, V162, P1242, DOI 10.1016/j.cell.2015.08.052; Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497; Le DT, 2017, CANCER IMMUNOL RES, V5, P942, DOI 10.1158/2326-6066.CIR-17-0375; Lee BS, 2017, BIOCHEM BIOPH RES CO, V491, P493, DOI 10.1016/j.bbrc.2017.07.007; Li YQ, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0539-x; Liu JZ, 2007, BLOOD, V110, P296, DOI 10.1182/blood-2006-10-051482; Liu J, 2018, ONCOL LETT, V15, P3321, DOI 10.3892/ol.2017.7682; Loi S, 2016, CLIN CANCER RES, V22, P1499, DOI 10.1158/1078-0432.CCR-15-1125; Luo H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.3; Merino D, 2009, J CELL BIOL, V186, P355, DOI 10.1083/jcb.200905153; Missiaglia E, 2014, ANN ONCOL, V25, P1995, DOI 10.1093/annonc/mdu275; Monje P, 2005, J BIOL CHEM, V280, P35081, DOI 10.1074/jbc.C500353200; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Orzechowski A, 2014, CANCER RES, V74, DOI 10.1158/1538-7445.AM2014-5026; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Phipps AI, 2015, CANCER EPIDEM BIOMAR, V24, P1046, DOI 10.1158/1055-9965.EPI-15-0204; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Shaul YD, 2007, BBA-MOL CELL RES, V1773, P1213, DOI 10.1016/j.bbamcr.2006.10.005; Song MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055761; Sznol M, 2013, CLIN CANCER RES, V19, P5542, DOI 10.1158/1078-0432.CCR-13-2234; Taieb J, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw272; Tang HD, 2018, J CLIN INVEST, V128, P580, DOI 10.1172/JCI96061; Taube JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003689; Topalian SL, 2012, CURR OPIN IMMUNOL, V24, P207, DOI 10.1016/j.coi.2011.12.009; Tu XY, 2019, MOL CELL, V74, P1215, DOI 10.1016/j.molcel.2019.04.005; Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834; YAN F, 2016, PLOS ONE, V11, DOI DOI 10.1371/JOURNAL.PONE.0156889; Yang SM, 2018, INT J MOL MED, V42, P3477, DOI 10.3892/ijmm.2018.3890; Zaanan A, 2015, J BIOL CHEM, V290, P23838, DOI 10.1074/jbc.M115.657833; Zhang P, 2018, MOL CANCER RES, V16, P378, DOI 10.1158/1541-7786.MCR-17-0404; Zhang XH, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.37	54	36	41	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2019	38	41					6752	6766		10.1038/s41388-019-0919-y	http://dx.doi.org/10.1038/s41388-019-0919-y			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JC8UZ	31406255	Green Accepted			2022-12-28	WOS:000489552900003
J	Wang, JC; Jiang, J; Chen, H; Wang, LY; Guo, H; Yang, LK; Xiao, DB; Qing, GL; Liu, HD				Wang, Jingchao; Jiang, Jue; Chen, Hui; Wang, Liyuan; Guo, Hao; Yang, Likun; Xiao, Daibiao; Qing, Guoliang; Liu, Hudan			FDA-approved drug screen identifies proteasome as a synthetic lethal target in MYC-driven neuroblastoma	ONCOGENE			English	Article							AMINO-ACID-METABOLISM; CELL-DEATH; N-MYC; STRESS; STABILIZATION; ATF4; BAX; TRANSFORMATION; AMPLIFICATION; ACETYLATION	MYCN amplification in neuroblastoma predicts poor prognosis and resistance to therapy. Yet pharmacological strategies of direct MYC inhibition remain unsuccessful due to its "undruggable" protein structure. We herein developed a synthetic lethal screen against MYCN-amplified neuroblastomas using clinically approved therapeutic reagents. We performed a high-throughput screen, from a library of 938 FDA-approved drugs, for candidates that elicit synthetic lethal effects in MYC-driven neuroblastoma cells. The proteasome inhibitors, which are FDA approved for the first-line treatment of multiple myeloma, emerge as top hits to elicit MYC-mediated synthetic lethality. Proteasome inhibition activates the PERK-eIF2 alpha-ATF4 axis in MYC-transformed cells and induces BAX-mediated apoptosis through ATF4-dependent NOXA and TRIB3 induction. A combination screen reveals the proteasome inhibitor bortezomib (BTZ) and the histone deacetylase (HDAC) inhibitor vorinostat (SAHA) concertedly induce dramatic cell death in part through synergistic activation of BAX. This combination causes marked tumor suppression in vivo, supporting dual proteasome/HDAC inhibition as a potential therapeutic approach for MYC-driven cancers. This FDA-approved drug screen with in vivo validation thus provides a rationale for clinical evaluation of bortezomib, alone or in combination with vorinostat, in MYC-driven neuroblastoma patients.	[Wang, Jingchao; Qing, Guoliang; Liu, Hudan] Wuhan Univ, Hubei Canc Clin Study Ctr, Dept Radiat & Med Oncol, Hubei Key Lab Tumor Biol Behav,Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China; [Wang, Jingchao; Jiang, Jue; Chen, Hui; Wang, Liyuan; Guo, Hao; Xiao, Daibiao; Qing, Guoliang; Liu, Hudan] Wuhan Univ, Med Res Inst, Wuhan 430071, Hubei, Peoples R China; [Yang, Likun] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Urol, Wuhan 430022, Hubei, Peoples R China	Wuhan University; Wuhan University; Huazhong University of Science & Technology	Qing, GL; Liu, HD (corresponding author), Wuhan Univ, Hubei Canc Clin Study Ctr, Dept Radiat & Med Oncol, Hubei Key Lab Tumor Biol Behav,Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China.; Qing, GL; Liu, HD (corresponding author), Wuhan Univ, Med Res Inst, Wuhan 430071, Hubei, Peoples R China.	qingguoliang@whu.edu.cn; hudanliu@whu.edu.cn			National Key R&D Program of China [2017YFA0505600]; National Natural Science Foundation of China [81830084, 81572736, 81770177]; National Science Fund for Distinguished Young Scholars [81725013]; Hubei Provincial Natural Science Fund for Distinguished Young Scholars [2017CFA072]; Hubei Provincial Natural Science Fund for Creative Research Groups [2018CFA018]; Innovative Research Grant from Wuhan University [2042017kf0282]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science Fund for Distinguished Young Scholars(National Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars); Hubei Provincial Natural Science Fund for Distinguished Young Scholars; Hubei Provincial Natural Science Fund for Creative Research Groups; Innovative Research Grant from Wuhan University	We are grateful to HL and GQ lab members for technical support and critical reading of the paper. We would like to thank the Core Facility of Medical Research Institute at Wuhan University for confocal microscopy and histological analysis. This study was supported by grants from the National Key R&D Program of China (2017YFA0505600 to GQ), the National Natural Science Foundation of China (81830084 and 81572736 to GQ, 81770177 to HL), National Science Fund for Distinguished Young Scholars (81725013 to GQ), Hubei Provincial Natural Science Fund for Distinguished Young Scholars (2017CFA072 to HL), Hubei Provincial Natural Science Fund for Creative Research Groups (2018CFA018 to GQ), and Innovative Research Grant from Wuhan University (2042017kf0282 to GQ).	Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Ameri K, 2008, INT J BIOCHEM CELL B, V40, P14, DOI 10.1016/j.biocel.2007.01.020; Bhatt S, 2013, J CLIN INVEST, V123, P2616, DOI 10.1172/JCI64503; Braso-Maristany F, 2016, NAT MED, V22, P1303, DOI 10.1038/nm.4198; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Carracedo A, 2006, CANCER CELL, V9, P301, DOI 10.1016/j.ccr.2006.03.005; Carroll PA, 2015, CANCER CELL, V27, P271, DOI 10.1016/j.ccell.2014.11.024; Chen H, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0008-7; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2; Cohn SL, 2009, J CLIN ONCOL, V27, P289, DOI 10.1200/JCO.2008.16.6785; Cole KA, 2011, P NATL ACAD SCI USA, V108, P3336, DOI 10.1073/pnas.1012351108; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Gan L, 2016, ONCOGENE, V35, P3037, DOI 10.1038/onc.2015.360; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hart LS, 2012, J CLIN INVEST, V122, P4621, DOI 10.1172/JCI62973; Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270; Hui KF, 2013, MOL CANCER THER, V12, P747, DOI 10.1158/1535-7163.MCT-12-0811; Kessler JD, 2012, SCIENCE, V335, P348, DOI 10.1126/science.1212728; Kilberg MS, 2009, TRENDS ENDOCRIN MET, V20, P436, DOI 10.1016/j.tem.2009.05.008; Lange PS, 2008, J EXP MED, V205, P1227, DOI 10.1084/jem.20071460; Liu X, 2008, ONCOGENE, V27, P1478, DOI 10.1038/sj.onc.1210769; Maris JM, 2010, NEW ENGL J MED, V362, P2202, DOI 10.1056/NEJMra0804577; O'Neil NJ, 2017, NAT REV GENET, V18, P613, DOI 10.1038/nrg.2017.47; Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596; Otto T, 2009, CANCER CELL, V15, P67, DOI 10.1016/j.ccr.2008.12.005; Porro A, 2010, J BIOL CHEM, V285, P19532, DOI 10.1074/jbc.M109.078584; Qing GL, 2012, CANCER CELL, V22, P631, DOI 10.1016/j.ccr.2012.09.021; Raedler Lisa, 2015, Am Health Drug Benefits, V8, P135; Ren P, 2015, J PATHOL, V235, P90, DOI 10.1002/path.4429; Sato A, 2012, BJU INT, V109, P1258, DOI 10.1111/j.1464-410X.2011.10533.x; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Suraweera A, 2012, MOL CELL, V48, P242, DOI 10.1016/j.molcel.2012.08.003; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Toyoshima M, 2012, P NATL ACAD SCI USA, V109, P9545, DOI 10.1073/pnas.1121119109; Voorhees PM, 2006, ANNU REV PHARMACOL, V46, P189, DOI 10.1146/annurev.pharmtox.46.120604.141300; Wang ZJ, 2017, CLIN CANCER RES, V23, P3834, DOI 10.1158/1078-0432.CCR-16-2880; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Wek RC, 2006, BIOCHEM SOC T, V34, P7, DOI 10.1042/BST0340007; Xiao DB, 2016, MOL CELL, V64, P493, DOI 10.1016/j.molcel.2016.09.016; Xie H, 2018, J CLIN INVEST, V128, P1300, DOI 10.1172/JCI95864; Yue M, 2017, CELL REP, V21, P3819, DOI 10.1016/j.celrep.2017.12.002	43	22	22	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2019	38	41					6737	6751		10.1038/s41388-019-0912-5	http://dx.doi.org/10.1038/s41388-019-0912-5			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JC8UZ	31406244				2022-12-28	WOS:000489552900002
J	Zhong, Z; Sepramaniam, S; Chew, XH; Wood, K; Lee, MA; Madan, B; Virshup, DM				Zhong, Zheng; Sepramaniam, Sugunavathi; Chew, Xin Hui; Wood, Kris; Lee, May Ann; Madan, Babita; Virshup, David M.			PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers	ONCOGENE			English	Article							ADVANCED PANCREATIC-CANCER; IN-VIVO; C-MYC; GEMCITABINE; PHOSPHORYLATION; REVEALS; PATHWAY; PROTEIN; TRIAL; DEPENDENCIES	Pancreatic cancer (pancreatic ductal adenocarcinoma, PDAC) is aggressive and lethal. Although there is an urgent need for effective therapeutics in treating pancreatic cancer, none of the targeted therapies tested in clinical trials to date significantly improve its outcome. PORCN inhibitors show efficacy in preclinical models of Wnt-addicted cancers, including RNF43-mutant pancreatic cancers and have advanced to clinical trials. In this study, we aimed to develop drug combination strategies to further enhance the therapeutic efficacy of the PORCN inhibitor ETC-159. To identify additional druggable vulnerabilities in Wnt-driven pancreatic cancers, we performed an in vivo CRISPR loss-of-function screen. CTNNB1, KRAS, and MYC were reidentified as key oncogenic drivers. Notably, glucose metabolism pathway genes were important in vivo but less so in vitro. Knockout of multiple genes regulating PI3K/mTOR signaling impacted the growth of Wnt-driven pancreatic cancer cells in vivo. Importantly, multiple PI3K/mTOR pathway inhibitors in combination with ETC-159 synergistically suppressed the growth of multiple Wnt-addicted cancer cell lines in soft agar. Furthermore, the combination of the PORCN inhibitor ETC-159 and the pan-PI3K inhibitor GDC-0941 potently suppressed the in vivo growth of RNF43-mutant pancreatic cancer xenografts. This was largely due to enhanced suppressive effects on both cell proliferation and glucose metabolism. These findings demonstrate that dual PORCN and PI3K/mTOR inhibition is a potential strategy for treating Wnt-driven pancreatic cancers.	[Zhong, Zheng; Madan, Babita; Virshup, David M.] Duke NUS Med Sch, Program Canc & Stem Cell Biol, Singapore, Singapore; [Zhong, Zheng] Natl Univ Singapore, Dept Physiol, Singapore, Singapore; [Sepramaniam, Sugunavathi; Chew, Xin Hui; Lee, May Ann] ASTAR, Biopolis, Expt Therapeut Ctr, Singapore, Singapore; [Wood, Kris] Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC USA; [Virshup, David M.] Duke Univ, Dept Pediat, Durham, NC 27706 USA	National University of Singapore; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Experimental Drug Development Centre (EDDC); Experimental Therapeutics Centre; Duke University; Duke University	Madan, B; Virshup, DM (corresponding author), Duke NUS Med Sch, Program Canc & Stem Cell Biol, Singapore, Singapore.; Virshup, DM (corresponding author), Duke Univ, Dept Pediat, Durham, NC 27706 USA.	babita.madan@duke-nus.edu.sg; david.virshup@duke-nus.edu.sg	Virshup, David M/C-1449-2009	Virshup, David M/0000-0001-6976-850X; Zhong, Zheng/0000-0003-1614-7798; Wood, Kris/0000-0002-5887-2253	National Research Foundation Singapore; Singapore Ministry of Health's National Medical Research Council Open Fund-Independent Research Grant	National Research Foundation Singapore(National Research Foundation, Singapore); Singapore Ministry of Health's National Medical Research Council Open Fund-Independent Research Grant(Ministry of Health-SingaporeNational Medical Research Council, Singapore)	This study is supported in part by the National Research Foundation Singapore and administered by the Singapore Ministry of Health's National Medical Research Council under the STAR Award Program to DMV. BM acknowledges the support of the Singapore Ministry of Health's National Medical Research Council Open Fund-Independent Research Grant. We gratefully acknowledge the assistance from Yun Ka Wong and other members of both the Virshup lab and the Experimental Therapeutics Centre. We thank Prof. Stuart Cook and Edmund Pua for help with the MiSeq; Muhammad Idris Bin Kachi Mydin for help with bioinformatic analysis; Duke-NUS Metabolomics Facility, Dr. Jianhong Ching, and Dr. Zing Tan for help with the glucose metabolite quantification, and Profs. Shazib Pervaiz and Patrick Tan for useful suggestions on this study. Figure 1a was adapted from Servier Medical Art, licensed under a Creative Commons Attribution 3.0 Unported License (https://smart.servier.com).	Anderson GR, 2017, CELL REP, V20, P999, DOI 10.1016/j.celrep.2017.07.006; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu, 2017, Cancer Cell, V32, P185, DOI 10.1016/j.ccell.2017.07.007; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Chung V, 2017, JAMA ONCOL, V3, P516, DOI 10.1001/jamaoncol.2016.5383; Coombs GS, 2010, J CELL SCI, V123, P3357, DOI 10.1242/jcs.072132; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; Hammel P, 2016, JAMA-J AM MED ASSOC, V315, P1844, DOI 10.1001/jama.2016.4324; Hao HX, 2012, NATURE, V485, P195, DOI 10.1038/nature11019; Hart T, 2015, CELL, V163, DOI 10.1016/j.cell.2015.11.015; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Infante JR, 2014, EUR J CANCER, V50, P2072, DOI 10.1016/j.ejca.2014.04.024; Janda CY, 2012, SCIENCE, V337, P59, DOI 10.1126/science.1222879; Janku F, 2015, MOL CANCER THER, V14, pC45, DOI DOI 10.1158/1535-7163.TARG-15-C45; Javle MM, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-368; Jiang XM, 2013, P NATL ACAD SCI USA, V110, P12649, DOI 10.1073/pnas.1307218110; Ko AH, 2016, CLIN CANCER RES, V22, P61, DOI 10.1158/1078-0432.CCR-15-0979; Koo BK, 2012, NATURE, V488, P665, DOI 10.1038/nature11308; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Li W, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0554-4; Lin RT, 2015, NAT CELL BIOL, V17, P1484, DOI 10.1038/ncb3255; Madan B, 2016, ONCOGENE, V35, P2197, DOI 10.1038/onc.2015.280; Madan B, 2018, J CLIN INVEST, V128, P5620, DOI 10.1172/JCI122383; Madan B, 2018, BONE RES, V6, DOI 10.1038/s41413-018-0017-8; Madan B, 2016, ONCOTARGET, V7, P12386, DOI 10.18632/oncotarget.7157; McDonald ER, 2017, CELL, V170, P577, DOI 10.1016/j.cell.2017.07.005; Miller TE, 2017, NATURE, V547, P355, DOI 10.1038/nature23000; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; Muir A, 2018, SCIENCE, V360, P962, DOI 10.1126/science.aar5986; Najdi R, 2012, DIFFERENTIATION, V84, P203, DOI 10.1016/j.diff.2012.06.004; Ng M, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.2584; Papke B, 2017, SCIENCE, V355, P1158, DOI 10.1126/science.aam7622; Pate KT, 2014, EMBO J, V33, P1454, DOI 10.15252/embj.201488598; Picco G, 2017, EMBO MOL MED, V9, P293, DOI 10.15252/emmm.201606773; Possik PA, 2014, CELL REP, V9, P1375, DOI 10.1016/j.celrep.2014.10.024; Proffitt KD, 2012, J BIOL CHEM, V287, P34167, DOI 10.1074/jbc.M112.381970; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Schmid P, 2016, J CLIN ONCOL, V34, P1987, DOI 10.1200/JCO.2015.63.9179; Schulze A, 2012, NATURE, V491, P364, DOI 10.1038/nature11706; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Takada R, 2006, DEV CELL, V11, P791, DOI 10.1016/j.devcel.2006.10.003; Van Cutsem E, 2017, J CLIN ONCOL, V33, P344; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Wall M, 2008, BLOOD, V112, P2305, DOI 10.1182/blood-2007-09-111856; Wang T, 2014, SCIENCE, V343, P80, DOI 10.1126/science.1246981; Ward PS, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a006783; Whittaker SR, 2004, CANCER RES, V64, P262, DOI 10.1158/0008-5472.CAN-03-0110; Wolpin BM, 2009, J CLIN ONCOL, V27, P193, DOI 10.1200/JCO.2008.18.9514; Wu J, 2011, P NATL ACAD SCI USA, V108, P21188, DOI 10.1073/pnas.1118046108; Zhang L, 2014, J BIOL CHEM, V289, P24863, DOI 10.1074/jbc.M114.586818	53	36	36	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2019	38	40					6662	6677		10.1038/s41388-019-0908-1	http://dx.doi.org/10.1038/s41388-019-0908-1			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JC0EY	31391551	hybrid			2022-12-28	WOS:000488953500002
J	Wang, MX; Ferreira, RB; Law, ME; Davis, BJ; Yaaghubi, E; Ghilardi, AF; Sharma, A; Avery, BA; Rodriguez, E; Chiang, CW; Narayan, S; Heldermon, CD; Castellano, RK; Law, BK				Wang, Mengxiong; Ferreira, Renan B.; Law, Mary E.; Davis, Bradley J.; Yaaghubi, Elham; Ghilardi, Amanda F.; Sharma, Abhisheak; Avery, Bonnie A.; Rodriguez, Edgardo; Chiang, Chi-Wu; Narayan, Satya; Heldermon, Coy D.; Castellano, Ronald K.; Law, Brian K.			A novel proteotoxic combination therapy for EGFR+ and HER2+cancers	ONCOGENE			English	Article							UNFOLDED PROTEIN RESPONSE; CYCLOSPORINE-A; EXTRACELLULAR REGION; ORGANIC DISULFIDES; CRYSTAL-STRUCTURE; ER STRESS; CANCER; GROWTH; CELLS; SUBSTANCES	While HER2 and EGFR are overexpressed in breast cancers and multiple other types of tumors, the use of EGFR and/or HER2 inhibitors have failed to cure many cancer patients, largely because cancers acquire resistance to HER2/EGFR-specific drugs. Cancers that overexpress the HER-family proteins EGFR, HER2, and HER3 are uniquely sensitive to agents that disrupt HER2 and EGFR protein folding. We previously showed that disruption of disulfide bond formation by Disulfide Disrupting Agents (DDAs) kills HER2/EGFR overexpressing cells through multiple mechanisms. Herein, we show that interference with proline isomerization in HER2/EGFR overexpressing cells also induces cancer cell death. The peptidyl-prolyl isomerase inhibitor Cyclosporine A (CsA) selectively kills EGFR+ or HER2+ breast cancer cells in vitro by activating caspase-dependent apoptotic pathways. Further, CsA synergizes with the DDA tcyDTDO to kill HER2/EGFR overexpressing cells in vitro and the two agents cooperate to kill HER2+ tumors in vivo. There is a critical need for novel strategies to target HER2+ and EGFR+ cancers that are resistant to currently available mechanism-based agents. Drugs that target HER2/EGFR protein folding, including DDAs and CsA, have the potential to kill cancers that overexpress EGFR or HER2 through the induction of proteostatic synthetic lethality.	[Wang, Mengxiong; Law, Mary E.; Davis, Bradley J.; Rodriguez, Edgardo; Law, Brian K.] Univ Florida, Dept Pharmacol, Gainesville, FL 32610 USA; [Ferreira, Renan B.; Yaaghubi, Elham; Ghilardi, Amanda F.; Castellano, Ronald K.] Univ Florida, Dept Chem, Gainesville, FL 32611 USA; [Sharma, Abhisheak; Avery, Bonnie A.] Univ Florida, Dept Pharmaceut, Gainesville, FL 32610 USA; [Chiang, Chi-Wu] Natl Cheng Kung Univ, Coll Med, Inst Mol Med, Tainan, Taiwan; [Chiang, Chi-Wu] Natl Cheng Kung Univ, Ctr Infect Dis & Signaling Res, Tainan, Taiwan; [Narayan, Satya] Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; [Narayan, Satya; Heldermon, Coy D.; Castellano, Ronald K.; Law, Brian K.] Univ Florida, UF Hlth Canc Ctr, Gainesville, FL 32610 USA; [Heldermon, Coy D.] Univ Florida, Dept Med, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; National Cheng Kung University; National Cheng Kung University; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Law, BK (corresponding author), Univ Florida, Dept Pharmacol, Gainesville, FL 32610 USA.; Castellano, RK (corresponding author), Univ Florida, Dept Chem, Gainesville, FL 32611 USA.; Castellano, RK; Law, BK (corresponding author), Univ Florida, UF Hlth Canc Ctr, Gainesville, FL 32610 USA.	castellano@chem.ufl.edu; bklaw@ufl.edu	Ferreira, Renan/O-4919-2019; Sharma, Abhisheak/H-9327-2019; Sharma, Abhisheak/V-8401-2017; Castellano, Ronald/AAY-3252-2020	Ferreira, Renan/0000-0001-5205-659X; Sharma, Abhisheak/0000-0003-0553-4039; Castellano, Ronald/0000-0003-4322-9932; Wang, Mengxiong/0000-0002-8290-151X; Yaaghubi, Elham/0000-0003-1821-1052; Heldermon, Coy/0000-0002-2148-2868	Office of the Assistant Secretary of Defense for Health Affairs through the Breast Cancer Research Program [W81XWH-15-1-0199, W81XWH-15-1-0200]; Florida Breast Cancer Foundation; Ocala Royal Dames for Cancer Research; Florida Department of Health Bankhead-Coley Program [4BF03]; UF-Health Cancer Center pilot project award; University of Florida; Collaboration of Scientists for Critical Research in Biomedicine (CSCRB, Inc.)	Office of the Assistant Secretary of Defense for Health Affairs through the Breast Cancer Research Program; Florida Breast Cancer Foundation; Ocala Royal Dames for Cancer Research; Florida Department of Health Bankhead-Coley Program; UF-Health Cancer Center pilot project award; University of Florida(University of Florida); Collaboration of Scientists for Critical Research in Biomedicine (CSCRB, Inc.)	This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Breast Cancer Research Program under Award Nos. W81XWH-15-1-0199 (BL) and W81XWH-15-1-0200 (RC). These studies were supported in part by grants from the Florida Breast Cancer Foundation (BL and RC), The Ocala Royal Dames for Cancer Research (BL), the Florida Department of Health Bankhead-Coley Program (4BF03, BL), the Collaboration of Scientists for Critical Research in Biomedicine (CSCRB, Inc., BL), and a UF-Health Cancer Center pilot project award (BL, RC, and CH). RF is grateful to the University of Florida for a Graduate School Fellowship.	Ahmed-Belkacem A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12777; Anderson DJ, 2015, CANCER CELL, V28, P653, DOI 10.1016/j.ccell.2015.10.002; BASS SW, 1980, J ORG CHEM, V45, P710, DOI 10.1021/jo01292a032; Chlebowski RT, 2013, JNCI-J NATL CANCER I, V105, P526, DOI 10.1093/jnci/djt043; Cho HS, 2002, SCIENCE, V297, P1330, DOI 10.1126/science.1074611; Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Ciechomska IA, 2013, ONCOGENE, V32, P1518, DOI 10.1038/onc.2012.174; DeRose Yoko S, 2013, Curr Protoc Pharmacol, VChapter 14, DOI 10.1002/0471141755.ph1423s60; Dunyak BM, 2016, J MED CHEM, V59, P9622, DOI 10.1021/acs.jmedchem.6b00411; Erdogan E, 2006, J BIOL CHEM, V281, P28450, DOI 10.1074/jbc.M606054200; Feng XL, 2014, EXP HEMATOL, V42, P172, DOI 10.1016/j.exphem.2013.11.010; Ferreira RB, 2017, ONCOTARGET, V8, P28971, DOI 10.18632/oncotarget.15952; Ferreira RB, 2015, ONCOTARGET, V6, P10445, DOI 10.18632/oncotarget.3398; FIELD L, 1972, J MED CHEM, V15, P312, DOI 10.1021/jm00273a024; Garg AD, 2014, PHOTOCH PHOTOBIO SCI, V13, P474, DOI 10.1039/c3pp50333j; Garrett TPJ, 2003, MOL CELL, V11, P495, DOI 10.1016/S1097-2765(03)00048-0; GOETHALS EJ, 1969, B SOC CHIM BELG, V78, P191; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hartman DA, 2003, CURR PROTOC PHARM, V7, P6; Hysing Jan, 2011, Tidsskr Nor Laegeforen, V131, P2239, DOI 10.4045/tidsskr.10.0862; IYER RP, 1990, J AM CHEM SOC, V112, P1253, DOI 10.1021/ja00159a059; KALLIONIEMI OP, 1992, P NATL ACAD SCI USA, V89, P5321, DOI 10.1073/pnas.89.12.5321; Kopper L, 2008, PATHOL ONCOL RES, V14, P1, DOI 10.1007/s12253-008-9018-z; Law BK, 2000, J BIOL CHEM, V275, P38261, DOI 10.1074/jbc.M005545200; Law ME, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0741-1; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Liu XF, 2012, AM J PATHOL, V180, P599, DOI 10.1016/j.ajpath.2011.10.036; Neckers L, 2000, Breast Dis, V11, P49; Ni SS, 2009, J MED CHEM, V52, P5295, DOI 10.1021/jm9008295; Obeng EA, 2006, BLOOD, V107, P4907, DOI 10.1182/blood-2005-08-3531; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Robinson PJ, 2017, J BIOL CHEM, V292, P6978, DOI 10.1074/jbc.M117.780742; SHIMIZU T, 1989, IMMUNOBIOLOGY, V178, P401, DOI 10.1016/S0171-2985(89)80062-2; Singh N, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa6922; SRIVASTAVA PK, 1972, J ORG CHEM, V37, P4196, DOI 10.1021/jo00798a055; Stocki P, 2014, J BIOL CHEM, V289, P23086, DOI 10.1074/jbc.M114.570911; Takenokuchi M, 2015, ANTICANCER RES, V35, P3307; Theuerkorn M, 2011, CURR OPIN PHARMACOL, V11, P281, DOI 10.1016/j.coph.2011.03.007; Vekaria PH, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00181; Wang MX, 2018, CRIT REV ONCOL HEMAT, V127, P66, DOI 10.1016/j.critrevonc.2018.05.003; Werneck MBF, 2012, CELL CYCLE, V11, P3997, DOI 10.4161/cc.22222	43	5	5	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2019	38	22					4264	4282		10.1038/s41388-019-0717-6	http://dx.doi.org/10.1038/s41388-019-0717-6			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IA1RB	30718919				2022-12-28	WOS:000469339100005
J	Chang, HW; Kim, MR; Lee, HJ; Lee, HM; Kim, GC; Lee, YS; Nam, HY; Lee, M; Jang, HJ; Lee, KE; Lee, JC; Byun, Y; Kim, SW; Kim, SY				Chang, Hyo Won; Kim, Mi Ra; Lee, Hyang Ju; Lee, Hye Min; Kim, Gui Chul; Lee, Yoon Sun; Nam, Hae Yun; Lee, Myungjin; Jang, Hye Jin; Lee, Kyung Eun; Lee, Jong Cheol; Byun, Youngro; Kim, Seong Who; Kim, Sang Yoon			p53/BNIP3-dependent mitophagy limits glycolytic shift in radioresistant cancer	ONCOGENE			English	Article							MITOCHONDRIAL FISSION; RADIATION-RESISTANCE; P53; PARKIN; HEAD; AUTOPHAGY; BNIP3; METABOLISM; INHIBITION; MECHANISMS	The role of p53 in genotoxic therapy-induced metabolic shift in cancers is not yet known. In this study, we investigated the role of p53 in the glycolytic shift in head and neck squamous cell carcinoma cell lines following irradiation. Isogenic p53-null radioresistant cancer cells established through cumulative irradiation showed decreased oxygen consumption and increased glycolysis with compromised mitochondria, corresponding with their enhanced sensitivity to drugs that target glycolysis. In contrast, radioresistant cancer cells with wild-type p53 preserved their primary metabolic profile with intact mitophagic processes and maintained their mitochondrial integrity. Moreover, we identified a previously unappreciated link between p53 and mitophagy, which limited the glycolytic shift through the BNIP3-dependent clearance of abnormal mitochondria. Thus, drugs targeting glycolysis could be used as an alternative strategy for overcoming radioresistant cancers, and the p53 status could be used as a biomarker for selecting participants for clinical trials.	[Chang, Hyo Won; Lee, Hye Min; Kim, Gui Chul; Lee, Yoon Sun; Lee, Myungjin; Jang, Hye Jin; Kim, Sang Yoon] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Otolaryngol, Seoul, South Korea; [Kim, Mi Ra] Inje Univ, Coll Med, Haeundae Paik Hosp, Dept Otorhinolaryngol Head & Neck Surg, Busan, South Korea; [Lee, Hyang Ju; Nam, Hae Yun; Kim, Seong Who] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Biochem & Mol Biol, Seoul, South Korea; [Lee, Kyung Eun; Kim, Sang Yoon] Korea Inst Sci & Technol, Biomed Res Inst, Seoul, South Korea; [Lee, Jong Cheol] Ulsan Univ Hosp, Dept Otolaryngol, Ulsan, South Korea; [Byun, Youngro] Seoul Natl Univ, Coll Pharm, Pharmaceut Res Inst, Seoul, South Korea	University of Ulsan; Asan Medical Center; Inje University; University of Ulsan; Asan Medical Center; Korea Institute of Science & Technology (KIST); University of Ulsan; Ulsan University Hospital; Seoul National University (SNU)	Kim, SY (corresponding author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Otolaryngol, Seoul, South Korea.; Kim, SW (corresponding author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Biochem & Mol Biol, Seoul, South Korea.; Kim, SY (corresponding author), Korea Inst Sci & Technol, Biomed Res Inst, Seoul, South Korea.	swhokim@gmail.com; sykim3715@gmail.com			Basic Science Research Program through the National Research Foundation of Korea (NRF) - the Ministry of Science, ICT and Future planning [2018R1A2A1A05020064, 2014R1A1A1003484, 2015R1A2A2A01003235]; Ministry of Education [2018R1D1A1B07042783]; MRC grant - Korean government (MSIT) [2018R1A5A2020732]; Global High-tech Biomedicine Technology Development Program of the NRF; Korea Health Industry Development Institute (KHIDI) (MSIPMOHW) [2015M3D6A1065364]; Asan Institute for Life Science [2017-073]	Basic Science Research Program through the National Research Foundation of Korea (NRF) - the Ministry of Science, ICT and Future planning; Ministry of Education; MRC grant - Korean government (MSIT); Global High-tech Biomedicine Technology Development Program of the NRF; Korea Health Industry Development Institute (KHIDI) (MSIPMOHW); Asan Institute for Life Science	This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future planning (2018R1A2A1A05020064, 2014R1A1A1003484, 2015R1A2A2A01003235), the Ministry of Education (2018R1D1A1B07042783), MRC grant funded by the Korean government (MSIT) (2018R1A5A2020732), the Global High-tech Biomedicine Technology Development Program of the NRF & Korea Health Industry Development Institute (KHIDI) (MSIP&MOHW) (2015M3D6A1065364), and the Asan Institute for Life Science (2017-073).	Bansal N, 2014, ANTIOXID REDOX SIGN, V21, P221, DOI 10.1089/ars.2013.5690; Bernardini JP, 2017, ONCOGENE, V36, P1315, DOI 10.1038/onc.2016.302; Chang HW, 2016, HEAD NECK-J SCI SPEC, V38, pE1909, DOI 10.1002/hed.24347; Chourasia AH, 2015, EMBO REP, V16, P1145, DOI 10.15252/embr.201540759; Feng X, 2011, EMBO J, V30, P3397, DOI 10.1038/emboj.2011.248; Galluzzi L, 2013, NAT REV DRUG DISCOV, V12, P829, DOI 10.1038/nrd4145; Guo K, 2001, CELL DEATH DIFFER, V8, P367, DOI 10.1038/sj.cdd.4400810; Gustafsson AB, 2011, PEDIATR CARDIOL, V32, P267, DOI 10.1007/s00246-010-9876-5; Hamacher-Brady A, 2016, CELL MOL LIFE SCI, V73, P775, DOI 10.1007/s00018-015-2087-8; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hensley CT, 2013, J CLIN INVEST, V123, P3678, DOI 10.1172/JCI69600; Hollville E, 2014, MOL CELL, V55, P451, DOI 10.1016/j.molcel.2014.06.001; Hoshino A, 2014, P NATL ACAD SCI USA, V111, P3116, DOI 10.1073/pnas.1318951111; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Kruiswijk F, 2015, NAT REV MOL CELL BIO, V16, P393, DOI 10.1038/nrm4007; Lall R, 2014, CELL DEATH DIFFER, V21, P836, DOI 10.1038/cdd.2014.24; Lambrecht M, 2009, RADIOTHER ONCOL, V93, P498, DOI 10.1016/j.radonc.2009.08.038; Lee Y, 2011, AM J PHYSIOL-HEART C, V301, pH1924, DOI 10.1152/ajpheart.00368.2011; Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494; Li GB, 2018, ONCOGENE, V37, P1485, DOI 10.1038/s41388-017-0064-4; Liu K, 2016, J BIOL CHEM, V291, P10307, DOI 10.1074/jbc.M115.703066; Lu HQ, 2013, AUTOPHAGY, V9, P1720, DOI 10.4161/auto.26550; Maes H, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.94; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; Mauro-Lizcano M, 2015, AUTOPHAGY, V11, P833, DOI 10.1080/15548627.2015.1034403; Mims J, 2015, RADIAT RES, V183, P291, DOI 10.1667/RR13828.1; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; Palikaras K, 2018, NAT CELL BIOL, V20, P1013, DOI 10.1038/s41556-018-0176-2; Rajeshkumar NV, 2015, CANCER RES, V75, P3355, DOI 10.1158/0008-5472.CAN-15-0108; Sancho P, 2015, CELL METAB, V22, P590, DOI 10.1016/j.cmet.2015.08.015; Skinner HD, 2012, CLIN CANCER RES, V18, P290, DOI 10.1158/1078-0432.CCR-11-2260; Tang L, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0758-7; Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730; Toyama EQ, 2016, SCIENCE, V351, P275, DOI 10.1126/science.aab4138; Tracy K, 2007, AUTOPHAGY, V3, P616, DOI 10.4161/auto.4892; Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504; Villa E, 2017, CELL REP, V20, P2846, DOI 10.1016/j.celrep.2017.08.087; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715; Vyas S, 2016, CELL, V166, P555, DOI 10.1016/j.cell.2016.07.002; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Wauer T, 2015, NATURE, V524, P370, DOI 10.1038/nature14879; Wu HM, 2015, SCI REP-UK, V5, DOI 10.1038/srep12291; Yan C, 2017, CANCER LETT, V388, P34, DOI 10.1016/j.canlet.2016.11.018; Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028; Zhang C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3935; Zhang C, 2011, P NATL ACAD SCI USA, V108, P16259, DOI 10.1073/pnas.1113884108; Zhang J, 2015, CANCER LETT, V363, P108, DOI 10.1016/j.canlet.2015.04.015; Zhang TM, 2016, J BIOL CHEM, V291, P21616, DOI 10.1074/jbc.M116.733410	49	19	19	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2019	38	19					3729	3742		10.1038/s41388-019-0697-6	http://dx.doi.org/10.1038/s41388-019-0697-6			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HX4OU	30664690				2022-12-28	WOS:000467379600012
J	Cheng, MS; Sheng, L; Gao, Q; Xiong, QC; Zhang, HJ; Wu, MQ; Liang, Y; Zhu, FY; Zhang, YY; Zhang, XH; Yuan, Q; Li, Y				Cheng, Maosheng; Sheng, Lu; Gao, Qian; Xiong, Qiuchan; Zhang, Haojie; Wu, Mingqing; Liang, Yu; Zhu, Fengyu; Zhang, Yingyin; Zhang, Xiuhong; Yuan, Quan; Li, Yang			The m(6)A methyltransferase METTL3 promotes bladder cancer progression via AFF4/NF-kappa B/MYC signaling network	ONCOGENE			English	Article							MYC INHIBITOR KSI-3716; MESSENGER-RNA; C-MYC; ELONGATION COMPLEX; ANTITUMOR-ACTIVITY; NUCLEAR-RNA; N-6-METHYLADENOSINE; METHYLATION; TRANSLATION; N6-METHYLADENOSINE	N-6-methyladenosine (m6A) is the most abundant modification in eukaryotic messenger RNAs (mRNAs), and plays important roles in many bioprocesses. However, its functions in bladder cancer (BCa) remain elusive. Here, we discovered that methyltransferase-like 3 (METTL3), a major RNA N-6-adenosine methyltransferase, was significantly up-regulated in human BCa. Knockdown of METTL3 drastically reduced BCa cell proliferation, invasion, and survival in vitro and tumorigenicity in vivo. On the other hand, overexpression of METTL3 significantly promoted BCa cell growth and invasion. Through transcriptome sequencing, m(6)A sequencing and m(6)A methylated RNA immuno-precipitation quantitative reverse-transcription polymerase chain reaction, we revealed the profile of METTL3-mediated m(6)A modification in BCa cells for the first time. AF4/FMR2 family member 4 (AFF4), two key regulators of NF-kappa B pathway (IKBKB and RELA) and MYC were further identified as direct targets of METTL3-mediated m(6)A modification. In addition, we showed that besides NF-kappa B, AFF4 binds to the promoter of MYC and promotes its expression, implying a novel multilevel regulatory network downstream of METTL3. Our results uncovered an AFF4/NF-kappa B/MYC signaling network operated by METTL3-mediated m6A modification and provided insight into the mechanisms of BCa progression.	[Cheng, Maosheng; Gao, Qian; Wu, Mingqing; Liang, Yu; Zhu, Fengyu; Zhang, Yingyin; Zhang, Xiuhong; Li, Yang] Anhui Med Univ, Sch Life Sci, Dept Genet, Hefei 230031, Anhui, Peoples R China; [Sheng, Lu; Zhang, Haojie] Fudan Univ, Huadong Hosp, Dept Urol, Shanghai 200040, Peoples R China; [Xiong, Qiuchan; Yuan, Quan] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu, Sichuan, Peoples R China; [Xiong, Qiuchan; Yuan, Quan] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Chengdu, Sichuan, Peoples R China	Anhui Medical University; Fudan University; Sichuan University; Sichuan University	Li, Y (corresponding author), Anhui Med Univ, Sch Life Sci, Dept Genet, Hefei 230031, Anhui, Peoples R China.	liyang@ahmu.edu.cn	yuan, quan/GZM-5597-2022	Yuan, Quan/0000-0002-2836-1081	National Natural Science Foundation of China [81872313, 81672776, 81802391, 31501838]; Anhui Provincial Natural Science Foundation [1808085QH266]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Anhui Provincial Natural Science Foundation(Natural Science Foundation of Anhui Province)	This work was supported by the National Natural Science Foundation of China (81872313 and 81672776 to YL, 81802391 to QG, 31501838 to XH Z), and Anhui Provincial Natural Science Foundation (1808085QH266 to QG)	Alarcon CR, 2015, NATURE, V519, P482, DOI 10.1038/nature14281; Barbieri I, 2017, NATURE, V552, P126, DOI 10.1038/nature24678; Batista PJ, 2014, CELL STEM CELL, V15, P707, DOI 10.1016/j.stem.2014.09.019; BOKAR JA, 1994, J BIOL CHEM, V269, P17697; Cai XL, 2018, CANCER LETT, V415, P11, DOI 10.1016/j.canlet.2017.11.018; Cao GC, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.160003; Chen MN, 2018, HEPATOLOGY, V67, P2254, DOI 10.1002/hep.29683; Choe J, 2018, NATURE, V561, P556, DOI 10.1038/s41586-018-0538-8; Cui Q, 2017, CELL REP, V18, P2622, DOI 10.1016/j.celrep.2017.02.059; Deng P, 2018, CARCINOGENESIS, V39, P937, DOI 10.1093/carcin/bgy046; Deng XL, 2018, CELL RES, V28, P507, DOI 10.1038/s41422-018-0034-6; DESROSIERS R, 1974, P NATL ACAD SCI USA, V71, P3971, DOI 10.1073/pnas.71.10.3971; Dominissini D, 2013, NAT PROTOC, V8, P176, DOI 10.1038/nprot.2012.148; Dominissini D, 2012, NATURE, V485, P201, DOI 10.1038/nature11112; Doyle GAR, 1998, NUCLEIC ACIDS RES, V26, P5036, DOI 10.1093/nar/26.22.5036; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; El-Sheikh A, 2010, PEDIATR BLOOD CANCER, V55, P35, DOI 10.1002/pbc.22465; Felsenstein KM, 2018, NAT REV UROL, V15, P92, DOI 10.1038/nrurol.2017.179; Gabay M, 2014, COLD SPRING HARBOR P, V4; Huang HL, 2018, NAT CELL BIOL, V20, P285, DOI 10.1038/s41556-018-0045-z; Jeong KC, 2014, J UROLOGY, V191, P510, DOI 10.1016/j.juro.2013.07.019; Jia GF, 2011, NAT CHEM BIOL, V7, P885, DOI [10.1038/NCHEMBIO.687, 10.1038/nchembio.687]; Kamat AM, 2009, CANCER RES, V69, P8958, DOI 10.1158/0008-5472.CAN-09-2045; Li Y, 2015, ONCOTARGET, V6, P10195, DOI 10.18632/oncotarget.3555; Li Y, 2013, BIOMED REP, V1, P918, DOI 10.3892/br.2013.157; Li YF, 2013, CELL TISSUE RES, V354, P533, DOI 10.1007/s00441-013-1715-6; Liang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep29479; Lin CQ, 2010, MOL CELL, V37, P429, DOI 10.1016/j.molcel.2010.01.026; Lin SB, 2016, MOL CELL, V62, P335, DOI 10.1016/j.molcel.2016.03.021; Liu JZ, 2014, NAT CHEM BIOL, V10, P93, DOI 10.1038/nchembio.1432; Luo ZJ, 2012, MOL CELL BIOL, V32, P2608, DOI 10.1128/MCB.00182-12; Ma JZ, 2017, HEPATOLOGY, V65, P529, DOI 10.1002/hep.28885; Mahe M, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708163; Merkurjev D, 2018, NAT NEUROSCI, V21, P1004, DOI 10.1038/s41593-018-0173-6; Meyer KD, 2015, CELL, V163, P999, DOI 10.1016/j.cell.2015.10.012; Meyer KD, 2014, NAT REV MOL CELL BIO, V15, P313, DOI 10.1038/nrm3785; Mukherjee N, 2015, CARCINOGENESIS, V36, P299, DOI 10.1093/carcin/bgu321; Niu Yamei, 2013, Genomics Proteomics & Bioinformatics, V11, P8, DOI 10.1016/j.gpb.2012.12.002; Oing C, 2016, J UROLOGY, V195, P254, DOI 10.1016/j.juro.2015.06.115; Ping XL, 2014, CELL RES, V24, P177, DOI 10.1038/cr.2014.3; Ribas A, 2014, CLIN CANCER RES, V20, P4982, DOI 10.1158/1078-0432.CCR-14-0933; Seo HK, 2014, ONCOTARGET, V5, P326, DOI 10.18632/oncotarget.1545; Shi HL, 2018, NATURE, V563, P249, DOI 10.1038/s41586-018-0666-1; Shiina H, 2002, J UROLOGY, V168, P2220, DOI 10.1016/S0022-5347(05)64359-5; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Stine ZE, 2015, CANCER DISCOV, V5, P1024, DOI 10.1158/2159-8290.CD-15-0507; Su R, 2018, CELL, V172, P90, DOI 10.1016/j.cell.2017.11.031; Tabach Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014632; Taketo K, 2018, INT J ONCOL, V52, P621, DOI 10.3892/ijo.2017.4219; Tong JY, 2018, CELL RES, V28, P253, DOI 10.1038/cr.2018.7; van Kessel KEM, 2015, NAT REV UROL, V12, P681, DOI 10.1038/nrurol.2015.231; Visvanathan A, 2018, ONCOGENE, V37, P522, DOI 10.1038/onc.2017.351; Vu LP, 2017, NAT MED, V23, P1369, DOI 10.1038/nm.4416; Wang X, 2015, CELL, V161, P1388, DOI 10.1016/j.cell.2015.05.014; Wang Y, 2014, NAT CELL BIOL, V16, P191, DOI 10.1038/ncb2902; Watters AD, 2002, BRIT J CANCER, V87, P654, DOI 10.1038/sj.bjc.6600531; Weng HY, 2018, CELL STEM CELL, V22, P191, DOI 10.1016/j.stem.2017.11.016; Weng YL, 2018, NEURON, V97, P313, DOI 10.1016/j.neuron.2017.12.036; Wu YS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06898-4; Wu YS, 2018, CURR STEM CELL RES T, V13, P31, DOI 10.2174/1574888X12666170621125457; Zhang CZ, 2016, P NATL ACAD SCI USA, V113, pE2047, DOI 10.1073/pnas.1602883113; Zheng GQ, 2013, MOL CELL, V49, P18, DOI 10.1016/j.molcel.2012.10.015; Zheng J, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3401-7; Zheng QL, 2017, NAT IMMUNOL, V18, P1094, DOI 10.1038/ni.3830; Zhu FY, 2017, STEM CELL REP, V9, P429, DOI 10.1016/j.stemcr.2017.07.004; Zhu JL, 2017, NEOPLASIA, V19, P672, DOI 10.1016/j.neo.2017.06.002	66	214	221	6	84	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2019	38	19					3667	3680		10.1038/s41388-019-0683-z	http://dx.doi.org/10.1038/s41388-019-0683-z			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HX4OU	30659266				2022-12-28	WOS:000467379600008
J	Vitiello, M; Evangelista, M; Di Lascio, N; Kusmic, C; Massa, A; Orso, F; Sarti, S; Marranci, A; Rodzik, K; Germelli, L; Chandra, D; Salvetti, A; Pucci, A; Taverna, D; Faita, F; Gravekamp, C; Poliseno, L				Vitiello, Marianna; Evangelista, Monica; Di Lascio, Nicole; Kusmic, Claudia; Massa, Annamaria; Orso, Francesca; Sarti, Samanta; Marranci, Andrea; Rodzik, Katarzyna; Germelli, Lorenzo; Chandra, Dinesh; Salvetti, Alessandra; Pucci, Angela; Taverna, Daniela; Faita, Francesco; Gravekamp, Claudia; Poliseno, Laura			Antitumoral effects of attenuated Listeria monocytogenes in a genetically engineered mouse model of melanoma	ONCOGENE			English	Article							VACCINE; IMMUNOTHERAPY	Attenuated Listeria monocytogenes (Lm(at)-LLO) represents a valuable anticancer vaccine and drug delivery platform. Here we show that in vitro Lm(at)-LLO causes ROS production and, in turn, apoptotic killing of a wide variety of melanoma cells, irrespectively of their stage, mutational status, sensitivity to BRAF inhibitors or degree of stemness. We also show that, when administered in the therapeutic setting to Braf/Pten genetically engineered mice, Lm(at)-LLO causes a strong decrease in the size and volume of primary melanoma tumors, as well as a reduction of the metastatic burden. At the molecular level, we confirm that the anti-melanoma activity exerted in vivo by Lm(at)-LLO depends also on its ability to potentiate the immune response of the organism against the infected tumor. Our data pave the way to the preclinical testing of listeria-based immunotherapeutic strategies against metastatic melanoma, using a genetically engineered mouse rather than xenograft models.	[Vitiello, Marianna; Evangelista, Monica; Di Lascio, Nicole; Kusmic, Claudia; Sarti, Samanta; Marranci, Andrea; Germelli, Lorenzo; Faita, Francesco; Poliseno, Laura] CNR, Inst Clin Physiol, Pisa, Italy; [Vitiello, Marianna; Sarti, Samanta; Marranci, Andrea; Germelli, Lorenzo; Poliseno, Laura] ISPRO, Core Res Lab, Oncogen Unit, Pisa, Italy; [Massa, Annamaria; Orso, Francesca; Taverna, Daniela] Univ Torino, MBC, Turin, Italy; [Massa, Annamaria; Orso, Francesca; Taverna, Daniela] Univ Torino, Dept Mol Biotechnol & Hlth Sci, Turin, Italy; [Orso, Francesca; Taverna, Daniela] Univ Torino, Ctr Complex Syst Mol Biol & Med, Turin, Italy; [Rodzik, Katarzyna] Ctr Postgrad Med Educ, Dept Biochem & Mol Biol, Warsaw, Poland; [Chandra, Dinesh; Gravekamp, Claudia] Albert Einstein Coll Med, Dept Microbiol & Immunol, New York, NY USA; [Salvetti, Alessandra] Univ Pisa, Dept Clin & Expt Med, Unit Expt Biol & Genet, Pisa, Italy; [Pucci, Angela] Pisa Univ Hosp, Dept Histopathol, Pisa, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); University of Turin; University of Turin; University of Turin; Centre of Postgraduate Medical Education - Poland; Yeshiva University; University of Pisa; University of Pisa; Azienda Ospedaliero Universitaria Pisana	Vitiello, M; Poliseno, L (corresponding author), CNR, Inst Clin Physiol, Pisa, Italy.; Vitiello, M; Poliseno, L (corresponding author), ISPRO, Core Res Lab, Oncogen Unit, Pisa, Italy.	mariannavitiello@live.it; laura.poliseno@cnr.it	Poliseno, Laura/B-5711-2012; Orso, Francesca/B-1985-2014; Massa, Annamaria/AAB-9872-2019; Chandra, Dinesh/P-4377-2014; Marranci, Andrea/AAA-7874-2019; Rodzik, Katarzyna/V-1038-2019; Kusmic, Claudia/AGY-5715-2022; Vitiello, Marianna/AAC-3659-2022; Pucci, Angela/A-6509-2013; Faita, Francesco/K-6681-2016	Massa, Annamaria/0000-0002-8156-3037; Chandra, Dinesh/0000-0001-5763-1645; Marranci, Andrea/0000-0002-8334-8795; Vitiello, Marianna/0000-0001-7443-2728; Pucci, Angela/0000-0001-8110-4458; Faita, Francesco/0000-0002-6201-1843; GERMELLI, LORENZO/0000-0002-7318-7545; Orso, Francesca/0000-0003-4706-6464	MFAG grant - Associazione Italiana per la Ricerca sul Cancro (AIRC) [17095]; ITT-Istituto Toscano Tumori; ISPRO-Istituto per lo Studio, la Prevenzione e la Rete Oncologica; Italian Ministry of Health [GR-2011-02348535]; EMBO short-term fellowship; AIRC fellowship	MFAG grant - Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); ITT-Istituto Toscano Tumori; ISPRO-Istituto per lo Studio, la Prevenzione e la Rete Oncologica; Italian Ministry of Health(Ministry of Health, Italy); EMBO short-term fellowship(European Molecular Biology Organization (EMBO)); AIRC fellowship(Fondazione AIRC per la ricerca sul cancro)	The authors would like to thank all the Poliseno lab members for their insightful discussions; S. Burchielli (FTGM, Pisa) for her assistance with animal procedures; D. Colecchia (IFC-CNR, ISPRO, Siena) for his assistance in preparing the figures; M. La Ferla (Fondazione Pisana per la Scienza, Pisa) for his assistance with the detection of listeria by FACS; G. Pelosi (IFC-CNR, Pisa) for his assistance with light microscopy; A. Ripoli (IFC-CNR, Pisa) for his support with statistical analyses; B. Stecca (ISPRO, Firenze) for providing us with the Aldefluor (TM). This work was supported by MFAG #17095 grant awarded by Associazione Italiana per la Ricerca sul Cancro (AIRC) to LP; start up funding awarded by ITT-Istituto Toscano Tumori and ISPRO-Istituto per lo Studio, la Prevenzione e la Rete Oncologica to LP. It was also supported by GR-2011-02348535 grant awarded by Italian Ministry of Health to LP. MV was supported by an EMBO short-term fellowship and an AIRC fellowship.	Boiko AD, 2010, NATURE, V466, P133, DOI 10.1038/nature09161; Buonaguro L, 2011, CLIN VACCINE IMMUNOL, V18, P23, DOI 10.1128/CVI.00286-10; Chandra D, 2017, ONCOTARGET, V8, P20729, DOI 10.18632/oncotarget.15117; Damsky WE, 2011, CANCER CELL, V20, P741, DOI 10.1016/j.ccr.2011.10.030; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Deng WW, 2018, P NATL ACAD SCI USA, V115, P8179, DOI 10.1073/pnas.1801910115; Flickinger JC, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030048; Grzywa TM, 2017, TRANSL ONCOL, V10, P956, DOI 10.1016/j.tranon.2017.09.007; Hellmann MD, 2017, IMMUNITY, V47, P221, DOI 10.1016/j.immuni.2017.08.001; Jahangir A, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1342025; Karachaliou N, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.06.47; Kee D, 2017, EJSO-EUR J SURG ONC, V43, P594, DOI 10.1016/j.ejso.2016.07.014; Kim SH, 2008, BRIT J CANCER, V99, P741, DOI 10.1038/sj.bjc.6604526; Kim SH, 2009, CANCER RES, V69, P5860, DOI 10.1158/0008-5472.CAN-08-4855; Klein WM, 2007, MODERN PATHOL, V20, P102, DOI 10.1038/modpathol.3800720; Liao W, 2011, CURR OPIN IMMUNOL, V23, P598, DOI 10.1016/j.coi.2011.08.003; Menzies AM, 2016, JAMA ONCOL, V2, P1259, DOI 10.1001/jamaoncol.2016.3418; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Pan ZK, 1999, CANCER RES, V59, P5264; Quispe-Tintaya W, 2013, P NATL ACAD SCI USA, V110, P8668, DOI 10.1073/pnas.1211287110; Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Vitiello M, 2017, ONCOTARGET, V8, P25395, DOI 10.18632/oncotarget.15915; Wood LM, 2014, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00051; Xin G, 2017, P NATL ACAD SCI USA, V114, P740, DOI 10.1073/pnas.1614315114; Yuan P, 2013, P NATL ACAD SCI USA, V110, P18226, DOI 10.1073/pnas.1317577110	26	15	16	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2019	38	19					3756	3762		10.1038/s41388-019-0681-1	http://dx.doi.org/10.1038/s41388-019-0681-1			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HX4OU	30664692	hybrid, Green Published			2022-12-28	WOS:000467379600014
J	Wang, LN; Yu, T; Li, W; Li, MM; Zuo, QF; Zou, QM; Xiao, B				Wang, Lina; Yu, Ting; Li, Wei; Li, Mengmeng; Zuo, Qianfei; Zou, Quanming; Xiao, Bin			The miR-29c-KIAA1199 axis regulates gastric cancer migration by binding with WBP11 and PTP4A3	ONCOGENE			English	Article							PRL-3 PROMOTES; MESENCHYMAL TRANSITION; SIGNALING PATHWAY; SPLICING FACTOR; UP-REGULATION; METASTASIS; KIAA1199; PROTEIN; EXPRESSION; INVASION	Gastric cancer (GC) is the second leading cause of death among patients with cancer in China. The primary reason of GC treatment failure is metastasis. Therefore, identifying metastatic biomarkers and clarifying the regulatory mechanisms involved in the GC metastatic process are important. Here, we found that KIAA1199, a cell migration-inducing protein, was significantly overexpressed in GC and correlated with lymph node metastasis and poorer patient survival. Additionally, the introduction of KIAA1199 dramatically promoted GC cell proliferation and migration in vitro and in vivo, and the inhibition of KIAA1199 suppressed GC cell growth and migration and induced GC cell apoptosis. Cell migration is a functional consequence of the epithelial-mesenchymal transition (EMT). In this study, we found that KIAA1199 inhibition or overexpression regulated the expression of E-cadherin and N-cadherin through KIAA1199 binding to WW domain binding protein 11 (WBP11) and protein tyrosine phosphatase type IVA, member 3 (PTP4A3) and through the subsequent activation of the FGFR4/Wnt/beta-catenin and EGFR signaling pathways. More importantly, ectopic expression of WBP11 or PTP4A3 blocked the stimulatory effects of KIAA1199 on GC cell proliferation and migration. Meanwhile, we illustrated that KIAA1199 was a target gene of miR-29c-3p and that miR-29c-3p overexpression led to decreased migration of GC cells in vitro and in vivo by suppressing the expression of KIAA1199 and several key proteins in the Wnt/beta-catenin and EGFR signaling pathways (e.g., WBP11, FGFR4, and PTP4A3). Taken together, these data demonstrate that KIAA1199 promotes GC metastasis by activating EMT-related signaling pathways and that miR-29c-3p regulates GC cell migration in vitro and in vivo by regulating KIAA1199 expression and activating the FGFR4/Wnt/beta-catenin and EGFR signaling pathways. These findings provide a new understanding of GC development and progression and may provide novel therapeutic strategies for GC.	[Wang, Lina; Yu, Ting; Li, Mengmeng; Zuo, Qianfei; Zou, Quanming; Xiao, Bin] Third Mil Med Univ, Natl Engn Res Ctr Immunol Prod, Dept Microbiol & Biochem Pharm, Coll Pharm, Chongqing 400038, Peoples R China; [Li, Wei] Third Mil Med Univ, Southwest Hosp, Dept Pharm, Chongqing 400038, Peoples R China	Army Medical University; Army Medical University	Zuo, QF; Zou, QM; Xiao, B (corresponding author), Third Mil Med Univ, Natl Engn Res Ctr Immunol Prod, Dept Microbiol & Biochem Pharm, Coll Pharm, Chongqing 400038, Peoples R China.	zqfzqma@163.com; qmzoutmmu@yeah.net; binxiaotmmu@163.com			Chongqing Youth Science and Technology Talent Training Project [cstc2014kjrc-qnrc10008]; National Science Foundation of China (NSFC) [81872392]	Chongqing Youth Science and Technology Talent Training Project; National Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC))	This work was supported by the Chongqing Youth Science and Technology Talent Training Project (cstc2014kjrc-qnrc10008) and National Science Foundation of China (NSFC) (81872392).	Abe S, 2003, J HUM GENET, V48, P564, DOI 10.1007/s10038-003-0079-2; Al-aidaroos AQO, 2013, J CLIN INVEST, V123, P3459, DOI 10.1172/JCI66824; Allemani C, 2015, LANCET, V385, P977, DOI 10.1016/S0140-6736(14)62038-9; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bessette DC, 2008, CANCER METAST REV, V27, P231, DOI 10.1007/s10555-008-9121-3; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Cheng XB, 2016, ONCOTARGET, V7, P4829, DOI 10.18632/oncotarget.6617; Da N, 2009, WORLD J GASTROENTERO, V15, P1499, DOI 10.3748/wjg.15.1499; Diepenbruck M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01197-w; Dong Q, 2016, J ORAL PATHOL MED, V45, P111, DOI 10.1111/jop.12331; Evensen NA, 2015, ONCOTARGET, V6, P20723, DOI 10.18632/oncotarget.3978; Evensen NA, 2013, JNCI-J NATL CANCER I, V105, P1402, DOI 10.1093/jnci/djt224; Guo K, 2004, CANCER BIOL THER, V3, P945, DOI 10.4161/cbt.3.10.1111; Han TS, 2015, GUT, V64, P203, DOI 10.1136/gutjnl-2013-306640; He X, 2005, CELL, V120, P156, DOI 10.1016/j.cell.2005.01.006; Iwasaki Y, 2014, DEVELOPMENT, V141, P3740, DOI 10.1242/dev.106658; Jia SQ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175058; Ju JY, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00988-5; Kato H, 2004, CLIN CANCER RES, V10, P7318, DOI 10.1158/1078-0432.CCR-04-0485; Kohi S, 2017, ONCOTARGET, V8, P17156, DOI 10.18632/oncotarget.15052; Li BS, 2015, ONCOGENE, V34, P2556, DOI 10.1038/onc.2014.214; Li L, 2017, J CANCER, V8, P2238, DOI 10.7150/jca.19295; Liu R, 2013, CANCER RES, V73, P5926, DOI 10.1158/0008-5472.CAN-12-4718; Llorian M, 2004, BIOCHEM J, V378, P229, DOI 10.1042/BJ20030950; Matsuo M, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-15; Matsuzaki S, 2009, ANN SURG ONCOL, V16, P2042, DOI 10.1245/s10434-009-0469-6; Mendell JT, 2005, CELL CYCLE, V4, P1179, DOI 10.4161/cc.4.9.2032; Michishita E, 2006, CANCER LETT, V239, P71, DOI 10.1016/j.canlet.2005.07.028; Mitra R, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01781-0; Nagase T, 1999, DNA Res, V6, P337, DOI 10.1093/dnares/6.5.337; Natsuizaka M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01500-9; Pencheva N, 2013, NAT CELL BIOL, V15, P546, DOI 10.1038/ncb2769; Rizzolio S, 2018, CANCER RES, V78, P1058, DOI 10.1158/0008-5472.CAN-17-2020; Ruedel A, 2015, INT J CLIN EXP PATHO, V8, P4953; Shostak K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6232; Thrumurthy SG, 2015, NAT REV CLIN ONCOL, V12, P676, DOI 10.1038/nrclinonc.2015.132; Tiwari A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069473; Wang YX, 2015, CANCER RES, V75, P1332, DOI 10.1158/0008-5472.CAN-14-0787; Wrighton KH, 2015, NAT REV MOL CELL BIO, V16, P518, DOI 10.1038/nrm4045; Xiong JB, 2016, ONCOL REP, V36, P1819, DOI 10.3892/or.2016.5030; Yanaka Y, 2015, CARCINOGENESIS, V36, P1363, DOI 10.1093/carcin/bgv106; Ye GD, 2016, GASTROENTEROLOGY, V150, P659, DOI 10.1053/j.gastro.2015.11.041; Ye YW, 2011, CANCER-AM CANCER SOC, V117, P5304, DOI 10.1002/cncr.26207; Yoshida H, 2013, P NATL ACAD SCI USA, V110, P5612, DOI 10.1073/pnas.1215432110; Yu BQ, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3096-9; Yu T, 2018, CANCER SCI, V109, P1393, DOI 10.1111/cas.13583; Zaravinos A., 2015, J ONCOL, V2015, DOI DOI 10.1155/2015/865816; Zhang DJ, 2017, INT J CANCER, V140, P2298, DOI 10.1002/ijc.30656; Zhang YS, 2014, ONCOL REP, V31, P1503, DOI 10.3892/or.2014.3038; Zuo QF, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.297; Zuo QF, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.573	52	45	46	5	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2019	38	17					3134	3150		10.1038/s41388-018-0642-0	http://dx.doi.org/10.1038/s41388-018-0642-0			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU8RI	30626935				2022-12-28	WOS:000465557200003
J	Jing, Y; Zhang, Y; Zhu, H; Zhang, K; Cai, MC; Ma, PF; Shen, PY; Zhang, ZF; Shao, MH; Wang, J; Yu, MH; Yin, X; Zhang, MY; Hu, Y; Chen, DN; Di, W; Wang, XJ; Zhuang, GL				Jing, Ying; Zhang, Yi; Zhu, Hui; Zhang, Ke; Cai, Mei-Chun; Ma, Pengfei; Shen, Peiye; Zhang, Zhenfeng; Shao, Minghui; Wang, Jing; Yu, Minhua; Yin, Xia; Zhang, Meiying; Hu, Yuan; Chen, Danni; Di, Wen; Wang, Xiaojie; Zhuang, Guanglei			Hybrid sequencing-based personal full-length transcriptomic analysis implicates proteostatic stress in metastatic ovarian cancer	ONCOGENE			English	Article							UPDATED RESOURCE; ALIGNMENT; QUANTIFICATION; HETEROGENEITY; CARBOPLATIN; MECHANISMS; BORTEZOMIB; LANDSCAPE; CARCINOMA; ONCOLOGY	Comprehensive molecular characterization of myriad somatic alterations and aberrant gene expressions at personal level is key to precision cancer therapy, yet limited by current short-read sequencing technology, individualized catalog of complete genomic and transcriptomic features is thus far elusive. Here, we integrated second- and third-generation sequencing platforms to generate a multidimensional dataset on a patient affected by metastatic epithelial ovarian cancer. Whole-genome and hybrid transcriptome dissection captured global genetic and transcriptional variants at previously unparalleled resolution. Particularly, single-molecule mRNA sequencing identified a vast array of unannotated transcripts, novel long noncoding RNAs and gene chimeras, permitting accurate determination of transcription start, splice, polyadenylation and fusion sites. Phylogenetic and enrichment inference of isoform-level measurements implicated early functional divergence and cytosolic proteostatic stress in shaping ovarian tumorigenesis. A complementary imaging-based high-throughput drug screen was performed and subsequently validated, which consistently pinpointed proteasome inhibitors as an effective therapeutic regime by inducing protein aggregates in ovarian cancer cells. Therefore, our study suggests that clinical application of the emerging long-read full-length analysis for improving molecular diagnostics is feasible and informative. An in-depth understanding of the tumor transcriptome complexity allowed by leveraging the hybrid sequencing approach lays the basis to reveal novel and valid therapeutic vulnerabilities in advanced ovarian malignancies.	[Jing, Ying; Zhang, Yi; Ma, Pengfei; Shen, Peiye; Yu, Minhua; Yin, Xia; Zhang, Meiying; Hu, Yuan; Di, Wen; Zhuang, Guanglei] Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Dept Obstet & Gynecol, Ren Ji Hosp,Sch Med, Shanghai, Peoples R China; [Jing, Ying; Zhang, Yi; Yu, Minhua; Yin, Xia; Zhang, Meiying; Hu, Yuan; Di, Wen; Zhuang, Guanglei] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Shanghai Key Lab Gynecol Oncol, Shanghai, Peoples R China; [Zhu, Hui] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Anesthesiol, Shanghai, Peoples R China; [Zhang, Ke] Rizhao Peoples Hosp, Dept Oncol, Rizhao, Shandong, Peoples R China; [Cai, Mei-Chun; Zhang, Zhenfeng] Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst, Ren Ji Hosp,Sch Med, Shanghai, Peoples R China; [Shao, Minghui; Wang, Jing] Novogene Bioinformat Technol Co Ltd, Beijing, Peoples R China; [Chen, Danni; Wang, Xiaojie] Shanghai Jiao Tong Univ, Tongren Hosp, Dept Obstet & Gynecol, Sch Med, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Zhuang, GL (corresponding author), Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Dept Obstet & Gynecol, Ren Ji Hosp,Sch Med, Shanghai, Peoples R China.; Zhuang, GL (corresponding author), Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Shanghai Key Lab Gynecol Oncol, Shanghai, Peoples R China.; Wang, XJ (corresponding author), Shanghai Jiao Tong Univ, Tongren Hosp, Dept Obstet & Gynecol, Sch Med, Shanghai, Peoples R China.	wangxiaojie2008@hotmail.com; zhuangguanglei@gmail.com	Zhang, Yi/ABE-2574-2020	Zhuang, Guanglei/0000-0001-8141-5096	National Natural Science Foundation of China [81472537, 81672714, 81502597, 81472426]; State Key Laboratory of Oncogenes and Related Genes [SB17-06]; Shanghai Jiao Tong University School of Medicine [DLY201505, YG2016MS51]; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support [20161313]; Shanghai Institutions of Higher Learning (Eastern Scholar); Shanghai Rising-Star Program [16QA1403600]; Shanghai Municipal Commission of Health and Family Planning [2013ZYJB0202, 15GWZK0701, 20174Y0189, 20174Y0043]; Shanghai Key Laboratory of Gynecologic Oncology [FKZL-2017-01]; Science and Technology Commission of Shanghai Municipality [16140904401]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); State Key Laboratory of Oncogenes and Related Genes; Shanghai Jiao Tong University School of Medicine; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support; Shanghai Institutions of Higher Learning (Eastern Scholar); Shanghai Rising-Star Program; Shanghai Municipal Commission of Health and Family Planning; Shanghai Key Laboratory of Gynecologic Oncology; Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM))	This work was supported by the National Natural Science Foundation of China (81472537 and 81672714 to GZ; 81502597 to YJ; 81472426 to WD), the Grants from the State Key Laboratory of Oncogenes and Related Genes (SB17-06 to M-CC), the grants from Shanghai Jiao Tong University School of Medicine (DLY201505 to WD; YG2016MS51 to XY), Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (20161313 to GZ), the Shanghai Institutions of Higher Learning (Eastern Scholar to GZ), Shanghai Rising-Star Program (16QA1403600 to GZ), Shanghai Municipal Commission of Health and Family Planning (2013ZYJB0202 and 15GWZK0701 to WD; 20174Y0189 to YJ; 20174Y0043 to M-CC), the grant from Shanghai Key Laboratory of Gynecologic Oncology (FKZL-2017-01 to YJ), and the grant from Science and Technology Commission of Shanghai Municipality (16140904401 to XY).	Abdel-Ghany SE, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11706; Adzhubei Ivan, 2013, Curr Protoc Hum Genet, VChapter 7, DOI 10.1002/0471142905.hg0720s76; Alkan C, 2011, NAT METHODS, V8, P61, DOI 10.1038/NMETH.1527; Au KF, 2013, P NATL ACAD SCI USA, V110, pE4821, DOI 10.1073/pnas.1320101110; Bashashati A, 2013, J PATHOL, V231, P21, DOI 10.1002/path.4230; Bazzaro M, 2006, CANCER RES, V66, P3754, DOI 10.1158/0008-5472.CAN-05-2321; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Boeva V, 2012, BIOINFORMATICS, V28, P423, DOI 10.1093/bioinformatics/btr670; Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203; Chatterjee S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091978; Chen K, 2009, NAT METHODS, V6, P677, DOI [10.1038/NMETH.1363, 10.1038/nmeth.1363]; Choi YJ, 2017, J PATHOL, V241, P57, DOI 10.1002/path.4819; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Cieslik M, 2018, NAT REV GENET, V19, P93, DOI 10.1038/nrg.2017.96; Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762; Cui TY, 2018, NUCLEIC ACIDS RES, V46, pD371, DOI 10.1093/nar/gkx1025; de Klerk E, 2015, TRENDS GENET, V31, P128, DOI 10.1016/j.tig.2015.01.001; Eid J, 2009, SCIENCE, V323, P133, DOI 10.1126/science.1162986; Engstrom PG, 2013, NAT METHODS, V10, P1185, DOI [10.1038/NMETH.2722, 10.1038/nmeth.2722]; Faoro R, 2018, P NATL ACAD SCI USA, V115, P1204, DOI 10.1073/pnas.1717282115; Finn RD, 2016, NUCLEIC ACIDS RES, V44, pD279, DOI 10.1093/nar/gkv1344; Forrest ARR, 2014, NATURE, V507, P462, DOI 10.1038/nature13182; Fulda S, 2012, EMBO MOL MED, V4, P545, DOI 10.1002/emmm.201100707; Hackl T, 2014, BIOINFORMATICS, V30, P3004, DOI 10.1093/bioinformatics/btu392; Hoogstraat M, 2014, GENOME RES, V24, P200, DOI 10.1101/gr.161026.113; Jandial DA, 2017, GYNECOL ONCOL, V145, P236, DOI 10.1016/j.ygyno.2017.03.013; Jia WL, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-2-r12; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Kong L, 2007, NUCLEIC ACIDS RES, V35, pW345, DOI 10.1093/nar/gkm391; Koren S, 2012, NAT BIOTECHNOL, V30, P692, DOI 10.1038/nbt.2280; Kornblihtt AR, 2013, NAT REV MOL CELL BIO, V14, P153, DOI 10.1038/nrm3525; Kuang Z, 2017, GENOME RES, V27, P145, DOI 10.1101/gr.208041.116; Kumar SK, 2017, J NATL COMPR CANC NE, V15, P709, DOI 10.6004/jnccn.2017.0080; Kumar-Sinha C, 2018, NAT BIOTECHNOL, V36, P46, DOI 10.1038/nbt.4017; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Li AM, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-311; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li S, 2016, DEV CELL, V39, P508, DOI 10.1016/j.devcel.2016.10.012; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Manasanch EE, 2017, NAT REV CLIN ONCOL, V14, P417, DOI [10.1038/nrclinonc.2016.206, 10.1007/s12079-011-0121-7]; Matulonis UA, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.61; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; McPherson A, 2016, NAT GENET, V48, P758, DOI 10.1038/ng.3573; Mertens F, 2015, NAT REV CANCER, V15, P371, DOI 10.1038/nrc3947; Miller CA, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003665; Mills Kathryn, 2017, F1000Res, V6, P84, DOI 10.12688/f1000research.9977.1; Nandi D, 2006, J BIOSCIENCES, V31, P137, DOI 10.1007/BF02705243; Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509; Niu BF, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-187; Ozsolak F, 2011, NAT REV GENET, V12, P87, DOI 10.1038/nrg2934; Patch AM, 2015, NATURE, V521, P489, DOI 10.1038/nature14410; Ramirez PT, 2008, GYNECOL ONCOL, V108, P68, DOI 10.1016/j.ygyno.2007.08.071; Rhoads A, 2015, GENOM PROTEOM BIOINF, V13, P278, DOI 10.1016/j.gpb.2015.08.002; Roberts RJ, 2013, GENOME BIOL, V14, DOI [10.1186/gb-2013-14-7-405, 10.1186/gb-2013-14-6-405]; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rosenthal R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0893-4; Roth A, 2014, NAT METHODS, V11, P396, DOI [10.1038/nmeth.2883, 10.1038/NMETH.2883]; Rubio-Perez C, 2015, CANCER CELL, V27, P382, DOI 10.1016/j.ccell.2015.02.007; Schram AM, 2017, NAT REV CLIN ONCOL, V14, P735, DOI 10.1038/nrclinonc.2017.127; Sharon D, 2013, NAT BIOTECHNOL, V31, P1009, DOI 10.1038/nbt.2705; Steijger T, 2013, NAT METHODS, V10, P1177, DOI [10.1038/nmeth.2714, 10.1038/NMETH.2714]; Sun L, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt646; Tang ZJ, 2015, CELL, V160, P729, DOI 10.1016/j.cell.2015.01.028; Tian B, 2017, NAT REV MOL CELL BIO, V18, P18, DOI 10.1038/nrm.2016.116; Tilgner H, 2014, P NATL ACAD SCI USA, V111, P9869, DOI 10.1073/pnas.1400447111; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Travers KJ, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq543; Trincado JL, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1417-1; Turajlic S, 2016, SCIENCE, V352, P169, DOI 10.1126/science.aaf2784; Vilasi S, 2018, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00099; Wang B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11708; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Wang YK, 2017, NAT GENET, V49, P856, DOI 10.1038/ng.3849; Weirather JL, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv562; Wu TD, 2016, METHODS MOL BIOL, V1418, P283, DOI 10.1007/978-1-4939-3578-9_15; Xia Z, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6274; Yi Y, 2017, NUCLEIC ACIDS RES, V45, pD115, DOI 10.1093/nar/gkw1052; Yin X, 2017, CANCER RES, V77, P6551, DOI 10.1158/0008-5472.CAN-17-1461; Zhang T, 2017, NUCLEIC ACIDS RES, V45, pD135, DOI 10.1093/nar/gkw728; Zhang ZF, 2017, MOL CANCER THER, V16, P1739, DOI 10.1158/1535-7163.MCT-17-0078; Zhang ZF, 2016, THERANOSTICS, V6, P219, DOI 10.7150/thno.13178	83	2	3	5	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2019	38	16					3047	3060		10.1038/s41388-018-0644-y	http://dx.doi.org/10.1038/s41388-018-0644-y			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU3IV	30617306				2022-12-28	WOS:000465167600013
J	Tiemann, K; Garri, C; Lee, SB; Malihi, PD; Park, M; Alvarez, RM; Yap, LP; Ma, P; Katz, JE; Gross, ME; Kani, K				Tiemann, Katrin; Garri, Carolina; Lee, Sang Bok; Malihi, Paymaneh D.; Park, Mincheol; Alvarez, Ruth M.; Yap, Li Peng; Ma, Parag; Katz, Jonathan E.; Gross, Mitchell E.; Kani, Kian			Loss of ER retention motif of AGR2 can impact mTORC signaling and promote cancer metastasis	ONCOGENE			English	Article							ANTERIOR GRADIENT 2; PROSTATE-CANCER; ISOMERASE AGR2; HIPPO PATHWAY; SERUM AGR2; PROTEIN; EXPRESSION; GROWTH; BIOMARKER; GENE	Anterior gradient 2 (AGR2) is a member of the protein disulfide isomerase (PDI) family, which plays a role in the regulation of protein homeostasis and the unfolded protein response pathway (UPR). AGR2 has also been characterized as a protooncogene and a potential cancer biomarker. Cellular localization of AGR2 is emerging as a key component for understanding the role of AGR2 as a proto-oncogene. Here, we provide evidence that extracellular AGR2 (eAGR2) promotes tumor metastasis in various in vivo models. To further characterize the role of the intracellular-resident versus extracellular protein, we performed a comprehensive protein-protein interaction screen. Based on these results, we identify AGR2 as an interacting partner of the mTORC2 pathway. Importantly, our data indicates that eAGR2 promotes increased phosphorylation of RICTOR (T1135), while intracellular AGR2 (iAGR2) antagonizes its levels and phosphorylation. Localization of AGR2 also has opposing effects on the Hippo pathway, spheroid formation, and response to chemotherapy in vitro. Collectively, our results identify disparate phenotypes predicated on AGR2 localization. Our findings also provide credence for screening of eAGR2 to guide therapeutic decisions.	[Tiemann, Katrin; Garri, Carolina; Lee, Sang Bok; Malihi, Paymaneh D.; Park, Mincheol; Alvarez, Ruth M.; Katz, Jonathan E.; Gross, Mitchell E.; Kani, Kian] Univ Southern Calif, Keck Sch Med, Lawrence J Ellison Inst Transformat Med, Los Angeles, CA 90007 USA; [Yap, Li Peng] Keck Sch Med, Dept Radiol, Los Angeles, CA USA; [Ma, Parag] Stanford Univ, Dept Radiol, Los Angeles, CA USA	University of Southern California; Stanford University	Kani, K (corresponding author), Univ Southern Calif, Keck Sch Med, Lawrence J Ellison Inst Transformat Med, Los Angeles, CA 90007 USA.	Kani@usc.edu		Kani, Kian/0000-0001-7774-265X	Lawrence J. Ellison Medical Foundation	Lawrence J. Ellison Medical Foundation	Drs. Philip Roux and Dos Sarbossov provided valuable insight and reagents (Roux) on the mTOR pathway. We are grateful for the guidance of Dr. David Agus and the generous financial support of the Lawrence J. Ellison Medical Foundation. We appreciate the support of Autumn Beemer, Lisa Flashner, Laura Ng, and Jeffrey Wang.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Aceto N, 2014, CELL, V158, P1110, DOI 10.1016/j.cell.2014.07.013; Arumugam T, 2015, MOL CANCER THER, V14, P941, DOI 10.1158/1535-7163.MCT-14-0470; Boulbes D, 2010, MOL CANCER RES, V8, P896, DOI 10.1158/1541-7786.MCR-09-0409; Brychtova V, 2015, SEMIN CANCER BIOL, V33, P16, DOI 10.1016/j.semcancer.2015.04.005; Chan SW, 2008, CANCER RES, V68, P2592, DOI 10.1158/0008-5472.CAN-07-2696; Chen R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-149; Chung K, 2011, CANCER BIOMARK, V10, P101, DOI 10.3233/CBM-2012-0234; Clarke C, 2015, MOL CELL BIOCHEM, V408, P245, DOI 10.1007/s11010-015-2502-3; Darb-Esfahani S, 2012, VIRCHOWS ARCH, V461, P109, DOI 10.1007/s00428-012-1273-4; Dong AW, 2011, J BIOL CHEM, V286, P18301, DOI 10.1074/jbc.M110.215707; Fan R, 2013, P NATL ACAD SCI USA, V110, P2569, DOI 10.1073/pnas.1216462110; Fessart D, 2016, ELIFE, V5, DOI 10.7554/eLife.13887; Fletcher GC, 2003, BRIT J CANCER, V88, P579, DOI 10.1038/sj.bjc.6600740; Fritzsche FR, 2007, HISTOL HISTOPATHOL, V22, P703, DOI 10.14670/HH-22.703; Fritzsche FR, 2006, CLIN CANCER RES, V12, P1728, DOI 10.1158/1078-0432.CCR-05-2057; Garri Carolina, 2018, Oncotarget, V9, P27363, DOI 10.18632/oncotarget.25221; Gray TA, 2013, PROTEIN SCI, V22, P1266, DOI 10.1002/pro.2299; Guo H, 2017, ONCOGENE, V36, P5098, DOI 10.1038/onc.2017.132; Hengel SM, 2011, J PROTEOME RES, V10, P4567, DOI 10.1021/pr2004117; Higa A, 2011, J BIOL CHEM, V286, P44855, DOI 10.1074/jbc.M111.275529; Jia MQ, 2018, BBA-MOL BASIS DIS, V1864, P1622, DOI 10.1016/j.bbadis.2018.01.021; Jiang YQ, 2010, CLIN CHEM, V56, P1492, DOI 10.1373/clinchem.2010.143297; Julien LA, 2010, MOL CELL BIOL, V30, P908, DOI 10.1128/MCB.00601-09; Kani K, 2017, MOL CANCER THER, V16, P1645, DOI 10.1158/1535-7163.MCT-16-0564; Kani K, 2013, PROSTATE, V73, P306, DOI 10.1002/pros.22569; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Lee S, 2006, ONCOL REP, V16, P747; Liu D, 2005, CANCER RES, V65, P3796, DOI 10.1158/0008-5472.CAN-04-3823; Lundberg E, 2010, PROTEOMICS, V10, P3984, DOI 10.1002/pmic.201000125; Maslon MM, 2010, J MOL BIOL, V404, P418, DOI 10.1016/j.jmb.2010.09.035; Matoulkova E, 2017, EXP CELL RES, V356, P40, DOI 10.1016/j.yexcr.2017.04.011; Mellacheruvu D, 2013, NAT METHODS, V10, P730, DOI 10.1038/nmeth.2557; Mohtar MA, 2018, MOL CELL PROTEOMICS, V17, P737, DOI 10.1074/mcp.RA118.000573; Muniz VP, 2011, MOL CANCER RES, V9, P867, DOI 10.1158/1541-7786.MCR-10-0475; Park K, 2011, EXP MOL MED, V43, P91, DOI 10.3858/emm.2011.43.2.011; Park SW, 2009, P NATL ACAD SCI USA, V106, P6950, DOI 10.1073/pnas.0808722106; Patel P, 2013, J MOL BIOL, V425, P929, DOI 10.1016/j.jmb.2012.12.009; Rice GE, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-62; Riener MO, 2009, HISTOL HISTOPATHOL, V24, P1121, DOI 10.14670/HH-24.1121; Roux Kyle J, 2013, Curr Protoc Protein Sci, V74, DOI 10.1002/0471140864.ps1923s74; Roux KJ, 2012, J CELL BIOL, V196, P801, DOI 10.1083/jcb.201112098; Ryu J, 2013, BIOCHEM BIOPH RES CO, V430, P610, DOI 10.1016/j.bbrc.2012.11.105; Salmans ML, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3408; Scher HI, 2008, J CLIN ONCOL, V26, P1148, DOI 10.1200/JCO.2007.12.4487; Skarra DV, 2011, PROTEOMICS, V11, P1508, DOI 10.1002/pmic.201000770; Smirnov DA, 2005, CANCER RES, V65, P4993, DOI 10.1158/0008-5472.CAN-04-4330; Tackett AJ, 2005, J PROTEOME RES, V4, P1752, DOI 10.1021/pr050225e; Tian SB, 2018, EXP CELL RES, V364, P198, DOI 10.1016/j.yexcr.2018.02.004; Tohti M, 2017, CLIN NEUROL NEUROSUR, V154, P19, DOI 10.1016/j.clineuro.2017.01.004; Wang Z, 2008, CANCER RES, V68, P492, DOI 10.1158/0008-5472.CAN-07-2930; Xu CH, 2016, TUMOR BIOL, V37, P6091, DOI 10.1007/s13277-015-4481-0; Zhang JS, 2005, GENE CHROMOSOME CANC, V43, P249, DOI 10.1002/gcc.20188; Zweitzig DR, 2007, MOL CELL BIOCHEM, V306, P255, DOI 10.1007/s11010-007-9562-y	55	20	21	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2019	38	16					3003	3018		10.1038/s41388-018-0638-9	http://dx.doi.org/10.1038/s41388-018-0638-9			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU3IV	30575818	Green Accepted			2022-12-28	WOS:000465167600010
J	Wen, Y; Zhou, XQ; Lu, MT; He, ML; Tian, Y; Liu, LX; Wang, MN; Tan, WC; Deng, YT; Yang, XS; Mayer, MP; Zou, F; Chen, XM				Wen, Ying; Zhou, Xueqiong; Lu, Meiting; He, Meiling; Tian, Ye; Liu, Lixia; Wang, Mengnan; Tan, Wenchong; Deng, Yaotang; Yang, Xushan; Mayer, Matthias P.; Zou, Fei; Chen, Xuemei			Bclaf1 promotes angiogenesis by regulating HIF-1 alpha transcription in hepatocellular carcinoma	ONCOGENE			English	Article							HYPOXIA; CANCER; APOPTOSIS; GROWTH; VEGF; BTF	The development of hepatocellular carcinomas (HCC) depends on their local microenvironment and the induction of neovascularization is a decisive step in tumor progression, since the growth of solid tumors is limited by nutrient and oxygen supply. Hypoxia is the critical factor that induces transcription of the hypoxia inducible factor-1 alpha (HIF-1 alpha) encoding gene HIF1A and HIF-1 alpha protein accumulation to promote angiogenesis. However, the basis for the transcriptional regulation of HIF1A expression in HCC is still unclear. Here, we show that Bcalf1 levels are highly correlated with HIF-1 alpha levels in HCC tissues, and that knockdown of Bcalf1 in HCC cell lines significantly reduces hypoxia-induced HIF1A expression. Furthermore, we found that Bcalf1 promotes HIF1A transcription via its bZIP domain, leading subsequently to increased transcription of the HIF-1 alpha downstream targets VEGFA, TGFB, and EPO that in turn promote HCC-associated angiogenesis and thus survival and thriving of HCC cells. Moreover, we demonstrate that HIF-alpha levels and microvessel density decrease after the shRNA-mediated Bcalf1 knockdown in xenograft tumors. Finally, we found that Bcalf1 levels increase in hypoxia in a HIF-1 alpha dependent manner. Therefore, our study identifies Bcalf1 as a novel positive regulator of HIF-1 alpha in the hypoxic microenvironment, providing new incentives for promoting Bcalf1 as a potential therapeutic target for an anti-HCC strategy.	[Wen, Ying; Zhou, Xueqiong; Lu, Meiting; He, Meiling; Tian, Ye; Liu, Lixia; Wang, Mengnan; Tan, Wenchong; Deng, Yaotang; Yang, Xushan; Zou, Fei; Chen, Xuemei] Southern Med Univ, Sch Publ Hlth, Dept Occupat Hlth & Med, Guangdong Prov Key Lab Trop Dis Res, 1838 Guangzhou Rd North, Guangzhou 510515, Guangdong, Peoples R China; [Mayer, Matthias P.] Heidelberg Univ ZMBH, Ctr Mol Biol, DKFZ ZMBH Alliance, Neuenheimer Feld 282, D-69120 Heidelberg, Germany	Southern Medical University - China; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	Zou, F; Chen, XM (corresponding author), Southern Med Univ, Sch Publ Hlth, Dept Occupat Hlth & Med, Guangdong Prov Key Lab Trop Dis Res, 1838 Guangzhou Rd North, Guangzhou 510515, Guangdong, Peoples R China.; Mayer, MP (corresponding author), Heidelberg Univ ZMBH, Ctr Mol Biol, DKFZ ZMBH Alliance, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	m.mayer@zmbh.uni-heidelberg.de; zfei@smu.edu.cn; cxmcsz@smu.edu.cn	Mayer, Matthias P./B-9340-2013	Mayer, Matthias P./0000-0002-7859-3112	National Natural Science Foundation of China (NSFC) [81673216, 81741131, 81671860]; Deutsche Forschungsgemeinschaft [SFB/TRR77 C5, SFB1036 TP09]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was supported by National Natural Science Foundation of China (NSFC): No. 81673216 to Xuemei Chen, Nos. 81741131 and 81671860 to Fei Zou; Deutsche Forschungsgemeinschaft (SFB/TRR77 C5, SFB1036 TP09) to Matthias P. Mayer. We like to thank the kind gifts of plasmid from Prof. J. Tang (China Agricultural University, China).	Azoitei N, 2014, CANCER RES, V74, P7125, DOI 10.1158/0008-5472.CAN-14-1017; Bao H, 2018, FASEB J, V32, P3912, DOI 10.1096/fj.201701073R; Bonello S, 2007, ARTERIOSCL THROM VAS, V27, P755, DOI 10.1161/01.ATV.0000258979.92828.bc; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen TT, 2010, J CELL BIOL, V188, P595, DOI 10.1083/jcb.200906044; Cuconati A, 2002, GENE DEV, V16, P2465, DOI 10.1101/gad.1012702; Dell'Aversana C, 2017, LEUKEMIA, V31, P2315, DOI 10.1038/leu.2017.64; Doe MR, 2012, CANCER RES, V72, P949, DOI 10.1158/0008-5472.CAN-11-2371; El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061; Finn RS, 2009, EXPERT REV ANTICANC, V9, P503, DOI 10.1586/ERA.09.6; Fontoura BMA, 2005, IUBMB LIFE, V57, P65, DOI 10.1080/15216540500078608; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gorlach A, 2009, CURR PHARM DESIGN, V15, P3844, DOI 10.2174/138161209789649420; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Ju UI, 2015, BIOCHEM BIOPH RES CO, V464, P1008, DOI 10.1016/j.bbrc.2015.07.037; Kang YB, 2013, CANCER CELL, V23, P573, DOI 10.1016/j.ccr.2013.04.017; Kasof GM, 1999, MOL CELL BIOL, V19, P4390; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Koukourakis MI, 2000, CANCER RES, V60, P3088; Lee YY, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.76; Li Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep12495; Li YS, 2015, CELL REP, V12, P388, DOI 10.1016/j.celrep.2015.06.033; Masoud GN, 2015, ACTA PHARM SIN B, V5, P378, DOI 10.1016/j.apsb.2015.05.007; McPherson JP, 2009, CELL DEATH DIFFER, V16, P331, DOI 10.1038/cdd.2008.167; McPherson JP, 2011, ATLAS GENET CYTOGENE, V15, P994; Page EL, 2002, J BIOL CHEM, V277, P48403, DOI 10.1074/jbc.M209114200; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Rankin EB, 2016, SCIENCE, V352, P175, DOI 10.1126/science.aaf4405; Sarras H, 2010, THESCIENTIFICWORLDJO, V10, P1450, DOI 10.1100/tsw.2010.132; Savage KI, 2014, MOL CELL, V54, P445, DOI 10.1016/j.molcel.2014.03.021; Shao AW, 2016, CELL DEATH DIFFER, V23, P865, DOI 10.1038/cdd.2015.150; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Thurnherr T, 2016, SCI REP-UK, V6, DOI 10.1038/srep20065; Varia S, 2013, NUCLEUS-AUSTIN, V4, P229, DOI 10.4161/nucl.25187; Vohhodina J, 2017, NUCLEIC ACIDS RES, V45, DOI 10.1093/nar/gkx1046; Wang D, 2016, IUBMB LIFE, V68, P748, DOI 10.1002/iub.1537; Wei H, 2014, MOL CARCINOGEN, V53, P1, DOI 10.1002/mc.21917; Wilson GK, 2014, J HEPATOL, V61, P1397, DOI 10.1016/j.jhep.2014.08.025; Yoshitomi T, 2011, ONCOL REP, V25, P1661, DOI 10.3892/or.2011.1253; Zhou XQ, 2019, HEPATOLOGY, V69, P1564, DOI 10.1002/hep.30172; Zhou XX, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5581; Zhu AX, 2011, NAT REV CLIN ONCOL, V8, P292, DOI 10.1038/nrclinonc.2011.30; Zundel W, 2000, GENE DEV, V14, P391	44	55	58	1	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2019	38	11					1845	1859		10.1038/s41388-018-0552-1	http://dx.doi.org/10.1038/s41388-018-0552-1			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HO7XX	30367150	Green Published, hybrid			2022-12-28	WOS:000461164400005
J	McAuley, JR; Bailey, KM; Ekambaram, P; Klei, LR; Kang, H; Hu, D; Freeman, TJ; Concel, VJ; Hubel, NE; Lee, JY; Klei, HB; Cheng, J; Sekar, P; Bridwell, RE; Covic, L; Lucas, PC; McAllister-Lucas, LM				McAuley, J. Randall; Bailey, Kelly M.; Ekambaram, Prasanna; Klei, Linda R.; Kang, Heejae; Hu, Dong; Freeman, Tanner J.; Concel, Vincent J.; Hubel, Nathaniel E.; Lee, Jia-Ying (Lloyd); Klei, Hanna B.; Cheng, Jing; Sekar, Preethiya; Bridwell, Rachel E.; Covic, Lidija; Lucas, Peter C.; McAllister-Lucas, Linda M.			MALT1 is a critical mediator of PAR1-driven NF-kappa B activation and metastasis in multiple tumor types	ONCOGENE			English	Article							BREAST-CANCER; PARACASPASE MALT1; IN-VITRO; THROMBIN; RECEPTOR; PROTEASE; PAR1; OSTEOSARCOMA; TUMORIGENESIS; INFLAMMATION	Protease-activated receptor 1 (PAR1), a thrombin-responsive G protein-coupled receptor (GPCR), is implicated in promoting metastasis in multiple tumor types, including both sarcomas and carcinomas, but the molecular mechanisms responsible remain largely unknown. We previously discovered that PAR1 stimulation in endothelial cells leads to activation of NF-kappa B, mediated by a protein complex comprised of CARMA3, Bc110, and the MALT1 effector protein (CBM complex). Given the strong association between NF-kappa B and metastasis, we hypothesized that this CBM complex could play a critical role in the PAR1-driven metastatic progression of specific solid tumors. In support of our hypothesis, we demonstrate that PAR1 stimulation results in NF-kappa B activation in both osteosarcoma and breast cancer, which is suppressed by siRNA-mediated MALT1 knockdown, suggesting that an intact CBM complex is required for the response in both tumor cell types. We identify several metastasis-associated genes that are upregulated in a MALT1-dependent manner after PAR1 stimulation in cancer cells, including those encoding the matrix remodeling protein, MMP9, and the cytokines, IL-1 beta and IL-8. Further, exogenous expression of PAR1 in MCF7 breast cancer cells confers highly invasive and metastatic behavior which can be blocked by CRISPR/Cas9-mediated MALT1 knockout. Importantly, we find that PAR1 stimulation induces MALT1 protease activity in both osteosarcoma and breast cancer cells, an activity that is mechanistically linked to NF-kappa B activation and potentially other responses associated with aggressive phenotype. Several small molecule MALT1 protease inhibitors have recently been described that could therefore represent promising new therapeutics for the prevention and/or treatment of PAR1-driven tumor metastasis.	[McAuley, J. Randall; Klei, Linda R.; Kang, Heejae; Hu, Dong; Freeman, Tanner J.; Hubel, Nathaniel E.; Lee, Jia-Ying (Lloyd); Lucas, Peter C.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA; [Bailey, Kelly M.; Ekambaram, Prasanna; Concel, Vincent J.; Hubel, Nathaniel E.; Klei, Hanna B.; Cheng, Jing; Sekar, Preethiya; Bridwell, Rachel E.; Lucas, Peter C.; McAllister-Lucas, Linda M.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA; [Covic, Lidija] Tufts Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Tufts Medical Center	McAllister-Lucas, LM (corresponding author), Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA.	linda.mcallister@chp.edu	Cheng, Jing/AGR-7527-2022; Nuñez, Gabriel/A-7160-2014	Bailey, Kelly/0000-0003-3925-3243; Lucas, Peter/0000-0003-4880-7172; Lee, Jia-Ying/0000-0001-9012-766X	NIH [5F30CA196095]; Hyundai Scholar's Hope Grant [91499PA]; University of Pittsburgh Medical Scientist Training Program (MSTP) [T32GM008208]; NIH career development award [K12HD052892]; Alex's Lemonade Stand Foundation Young Investigator Award; John G. Rangos Senior Research Scholar Fund; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD052892] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008208] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Hyundai Scholar's Hope Grant; University of Pittsburgh Medical Scientist Training Program (MSTP); NIH career development award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Alex's Lemonade Stand Foundation Young Investigator Award; John G. Rangos Senior Research Scholar Fund; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors wish to thank Celia Paris for her support and Katrina O'Halloran, Emily Elliott, Yijen Wu, Amir Borhani, and Nathan Salamacha for their technical assistance. In addition, we thank Dr Ed Prochownik for use of his laboratory equipment. This work was supported by NIH Grant 5F30CA196095 to JRM and a Hyundai Scholar's Hope Grant #91499PA to LMM-L. JRM also received support from The University of Pittsburgh Medical Scientist Training Program (MSTP) T32GM008208. KMB received support from an NIH career development award, K12HD052892, an Alex's Lemonade Stand Foundation Young Investigator Award, and the John G. Rangos Senior Research Scholar Fund.	Afonina IS, 2015, FEBS J, V282, P3286, DOI 10.1111/febs.13325; Bacci G, 2005, ACTA ONCOL, V44, P748, DOI 10.1080/02841860500327503; Bagati A, 2015, JOVE-J VIS EXP, DOI 10.3791/51480; Bardet M, 2018, IMMUNOL CELL BIOL, V96, P81, DOI 10.1111/imcb.1018; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Baud V, 2009, NAT REV DRUG DISCOV, V8, P33, DOI 10.1038/nrd2781; Biswas DK, 2004, P NATL ACAD SCI USA, V101, P10137, DOI 10.1073/pnas.0403621101; Bohers E, 2015, LEUKEMIA LYMPHOMA, V56, P1213, DOI 10.3109/10428194.2014.941836; Bohers E, 2014, GENE CHROMOSOME CANC, V53, P144, DOI 10.1002/gcc.22126; Boire A, 2005, CELL, V120, P303, DOI 10.1016/j.cell.2004.12.018; Borensztajn K, 2009, BRIT J HAEMATOL, V145, P548, DOI 10.1111/j.1365-2141.2009.07643.x; Chay CH, 2002, UROLOGY, V60, P760, DOI 10.1016/S0090-4295(02)01969-6; Chen HT, 2010, J CELL PHYSIOL, V223, P737, DOI 10.1002/jcp.22083; Cisowski J, 2011, AM J PATHOL, V179, P513, DOI 10.1016/j.ajpath.2011.03.025; Coornaert B, 2008, NAT IMMUNOL, V9, P263, DOI 10.1038/ni1561; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; Dai BY, 2017, BLOOD, V129, P333, DOI 10.1182/blood-2016-05-718775; Delekta PC, 2010, J BIOL CHEM, V285, P41432, DOI 10.1074/jbc.M110.158949; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Ekambaram P, 2018, CANCER RES, V78, P1225, DOI 10.1158/0008-5472.CAN-17-1089; Foley CJ, 2012, J BIOL CHEM, V287, P24330, DOI 10.1074/jbc.M112.356303; Fontan L, 2018, J CLIN INVEST, V128, P4397, DOI 10.1172/JCI99436; Fontan L, 2012, CANCER CELL, V22, P812, DOI 10.1016/j.ccr.2012.11.003; Hailfinger S, 2011, P NATL ACAD SCI USA, V108, P14596, DOI 10.1073/pnas.1105020108; Han N, 2011, ONCOL LETT, V2, P599, DOI 10.3892/ol.2011.291; Hernandez NA, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-47; Hernandez-Rodriguez NA, 2002, INT J BIOL MARKER, V17, P189, DOI 10.1177/172460080201700308; Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Ichikawa J, 2012, CANCER-AM CANCER SOC, V118, P2494, DOI 10.1002/cncr.26518; Jaworski M, 2016, CELL MOL LIFE SCI, V73, P459, DOI 10.1007/s00018-015-2059-z; Justus CR, 2014, JOVE-J VIS EXP, DOI 10.3791/51046; Kelly AD, 2013, GENOME MED, V5, DOI 10.1186/gm406; Lenz G, 2008, SCIENCE, V319, P1676, DOI 10.1126/science.1153629; Liao D, 2015, CLIN CANCER RES, V21, P5349, DOI 10.1158/1078-0432.CCR-15-0198; Lim SM, 2015, J MED CHEM, V58, P8491, DOI 10.1021/acs.jmedchem.5b01415; Lin C, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3081-3; Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23; Ludeman MJ, 2004, J BIOL CHEM, V279, P18592, DOI 10.1074/jbc.M310836200; Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322; Mahanivong C, 2008, ONCOGENE, V27, P1273, DOI 10.1038/sj.onc.1210746; Massague J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038; McAllister-Lucas LM, 2007, P NATL ACAD SCI USA, V104, P139, DOI 10.1073/pnas.0601947103; McAllister-Lucas LM, 2010, J BIOL CHEM, V285, P25880, DOI 10.1074/jbc.C110.109421; McAuley JR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01887; Meloni L, 2018, MOLECULES, V23, DOI 10.3390/molecules23123144; Nagel D, 2012, CANCER CELL, V22, P825, DOI 10.1016/j.ccr.2012.11.002; Pagani O, 2010, JNCI-J NATL CANCER I, V102, P456, DOI 10.1093/jnci/djq029; Pires BRB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169622; Queiroz KCS, 2014, INT J CANCER, V135, P2294, DOI 10.1002/ijc.28726; Radjabi AR, 2008, J BIOL CHEM, V283, P2822, DOI 10.1074/jbc.M704855200; Rebeaud F, 2008, NAT IMMUNOL, V9, P272, DOI 10.1038/ni1568; Rehman AO, 2009, INT J ORAL SCI, V1, P105, DOI 10.4248/IJOS.09059; Sano T, 1999, INT J ONCOL, V15, P1197; Shi XL, 2004, MOL CANCER RES, V2, P395; Smith SM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106966; Staal J, 2011, EMBO J, V30, P1742, DOI 10.1038/emboj.2011.85; Steeg PS, 2016, NAT REV CANCER, V16, P201, DOI 10.1038/nrc.2016.25; Sun XQ, 2010, CANCER METAST REV, V29, P709, DOI 10.1007/s10555-010-9256-x; Szasz AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337; Tang QL, 2012, JNCI-J NATL CANCER I, V104, P749, DOI 10.1093/jnci/djs210; Taniguchi K, 2018, NAT REV IMMUNOL, V18, P309, DOI 10.1038/nri.2017.142; Tantivejkul K, 2005, J CELL BIOCHEM, V96, P641, DOI 10.1002/jcb.20533; Toruner M, 2006, J BIOL CHEM, V281, P8686, DOI 10.1074/jbc.M512178200; Villares GJ, 2011, ONCOTARGET, V2, P8; Wu Y, 2009, CANCER CELL, V15, P416, DOI 10.1016/j.ccr.2009.03.016; Xia YF, 2014, CANCER IMMUNOL RES, V2, P823, DOI 10.1158/2326-6066.CIR-14-0112; Yang E, 2016, ONCOGENE, V35, P1529, DOI 10.1038/onc.2015.217; Yuan Ta-Chun, 2004, Clin Prostate Cancer, V3, P189, DOI 10.3816/CGC.2004.n.030; Zhang SL, 2017, PROTEIN CELL, V8, P856, DOI 10.1007/s13238-017-0441-3; Zigler M, 2011, CANCER RES, V71, P6561, DOI 10.1158/0008-5472.CAN-11-1432	71	15	15	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2019	38	49					7384	7398		10.1038/s41388-019-0958-4	http://dx.doi.org/10.1038/s41388-019-0958-4			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JT4BN	31420608				2022-12-28	WOS:000500936600002
J	Kim, SJ; Garcia-Recio, S; Creighton, CJ; Perou, CM; Rosen, JM				Kim, S. J.; Garcia-Recio, S.; Creighton, C. J.; Perou, C. M.; Rosen, J. M.			Alterations in Wnt- and/or STAT3 signaling pathways and the immune microenvironment during metastatic progression	ONCOGENE			English	Article							REGULATORY T-CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER CELLS; TUMOR-INITIATING CELLS; STEM-CELLS; WNT/BETA-CATENIN; PROMOTES; DIFFERENTIATION; IDENTIFICATION; PROLIFERATION	Metastatic breast cancer is an extremely complex disease with limited treatment options due to the lack of information about the major characteristics of metastatic disease. There is an urgent need, therefore, to understand the changes in cellular complexity and dynamics that occur during metastatic progression. In the current study, we analyzed the cellular and molecular differences between primary tumors and paired lung metastases using a syngeneic p53-null mammary tumor model of basal-like breast cancer. Distinct subpopulations driven by the Wnt- and/or STAT3 signaling pathways were detected in vivo using a lentiviral Wnt- and STAT3 signaling reporter system. A significant increase in the overlapping populations driven by both the Wnt- and STAT3 signaling pathways was observed in the lung metastases as compared to the primary tumors. Furthermore, the overlapping populations showed a higher metastatic potential relative to the other populations and pharmacological inhibition of both signaling pathways was shown to markedly reduce the metastatic lesions in established lung metastases. An analysis of the unique molecular features of the lung metastases revealed a significant association with immune response signatures. Specifically, Foxp3 gene expression was markedly increased and elevated levels of Foxp3 + Treg cells were detected in close proximity to lung metastases. Collectively, these studies illustrate the importance of analyzing intratumoral heterogeneity, changes in population dynamics, and the immune microenvironment during metastatic progression.	[Kim, S. J.; Rosen, J. M.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Garcia-Recio, S.; Perou, C. M.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27515 USA; [Garcia-Recio, S.; Perou, C. M.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA; [Creighton, C. J.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Creighton, C. J.] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA	Baylor College of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Baylor College of Medicine; Baylor College of Medicine	Rosen, JM (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.	jrosen@bcm.edu	Recio, Susana Garcia/M-4723-2019; Perou, Charles M/H-9934-2014	Recio, Susana Garcia/0000-0003-3820-1679; Perou, Charles M/0000-0001-9827-2247; Rosen, Jeffrey/0000-0002-6637-844X	NIH [RO1 CA148761]; Susan G. Komen [PDF17479425]; Cytometry and Cell Sorting Core [NIH CA125123, RR024574]; NATIONAL CANCER INSTITUTE [P30CA125123, R01CA148761, R01CA195754, R01CA016303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES010126] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Susan G. Komen(Susan G. Komen Breast Cancer Foundation); Cytometry and Cell Sorting Core; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	;This work was supported by NIH RO1 CA148761 (to JMR and CMP) and by the Susan G. Komen to SGR (PDF17479425). We would like to thank to Dr. Michael T. Lewis for generously providing us with the STAT3-GFP and EFS-GFP reporters. This project was conducted with technical support from the Cytometry and Cell Sorting Core (NIH CA125123 and RR024574) and the expert assistance of Joel M. Sederstrom, the Integrated Microscopy core (NCI CA125123, NIDDK56338, CPRIT RP150578 and John S. Dunn Gulf Coast Consortium for Chemical Genomics), the Lester and Sue Smith Breast Center Pathology Core, and Human Genome Sequencing Center at Baylor College of Medicine. We thank Yiqun Zhang for technical assistance with the gene expression analyses. We would also like to thank to the IHC laboratory at University of Texas MD Anderson Cancer Center for scanning of IHC images. We specially thank Drs. Michael T. Lewis and Kevin P. Roarty for critically reading and editing the manuscript.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Ansari AM, 2016, STEM CELL REV REP, V12, P553, DOI 10.1007/s12015-016-9670-8; Bates GJ, 2006, J CLIN ONCOL, V24, P5373, DOI 10.1200/JCO.2006.05.9584; Bockhorn J, 2014, CANCER RES, V74, P7406, DOI 10.1158/0008-5472.CAN-14-1188; Bos PD, 2013, J EXP MED, V210, P2435, DOI 10.1084/jem.20130762; Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Celia-Terrassa T, 2016, GENE DEV, V30, P892, DOI 10.1101/gad.277681.116; Chang CH, 2015, STEM CELL REP, V5, P378, DOI 10.1016/j.stemcr.2015.07.009; Chen MW, 2017, CANCER RES, V77, P1955, DOI 10.1158/0008-5472.CAN-16-1115; Chen Q, 2011, CANCER CELL, V20, P538, DOI 10.1016/j.ccr.2011.08.025; Chuang CH, 2017, NAT MED, V23, P291, DOI 10.1038/nm.4285; Dalotto-Moreno T, 2013, CANCER RES, V73, P1107, DOI 10.1158/0008-5472.CAN-12-2418; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Dent R, 2009, BREAST CANCER RES TR, V115, P423, DOI 10.1007/s10549-008-0086-2; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Dobin Alexander, 2015, Curr Protoc Bioinformatics, V51, DOI 10.1002/0471250953.bi1114s51; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; Fan C, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-3; Fantozzi A, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1530; Feuerer M, 2009, NAT IMMUNOL, V10, P689, DOI 10.1038/ni.1760; Follenzi A, 2004, BLOOD, V103, P3700, DOI 10.1182/blood-2003-09-3217; Garraway LA, 2013, CELL, V153, P17, DOI 10.1016/j.cell.2013.03.002; Gatza ML, 2014, NAT GENET, V46, P1051, DOI 10.1038/ng.3073; Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205; Gujral TS, 2014, CELL, V159, P844, DOI 10.1016/j.cell.2014.10.032; Halvorsen EC, 2014, CANCER METAST REV, V33, P1025, DOI 10.1007/s10555-014-9529-x; Herschkowitz JI, 2012, P NATL ACAD SCI USA, V109, P2778, DOI 10.1073/pnas.1018862108; Jacob LS, 2015, CANCER RES, V75, P3713, DOI 10.1158/0008-5472.CAN-15-0562; Jerry DJ, 2000, ONCOGENE, V19, P1052, DOI 10.1038/sj.onc.1203270; Jiang XM, 2013, P NATL ACAD SCI USA, V110, P12649, DOI 10.1073/pnas.1307218110; Jones LM, 2016, CANCER RES, V76, P1416, DOI 10.1158/0008-5472.CAN-15-2770; Jung KH, 2017, CLIN CANCER RES, V23, P5537, DOI 10.1158/1078-0432.CCR-16-2253; Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125; Kim E, 2013, CANCER CELL, V23, P839, DOI 10.1016/j.ccr.2013.04.008; Kim MJ, 2014, CANCER LETT, V354, P33, DOI 10.1016/j.canlet.2014.06.023; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lawson DA, 2015, NATURE, V526, P131, DOI 10.1038/nature15260; Lee-Chang C, 2013, J IMMUNOL, V191, P4141, DOI 10.4049/jimmunol.1300606; Linde N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02481-5; Liu HP, 2010, P NATL ACAD SCI USA, V107, P18115, DOI 10.1073/pnas.1006732107; Liu J, 2013, P NATL ACAD SCI USA, V110, P20224, DOI 10.1073/pnas.1314239110; Lopez-Knowles E, 2010, CANCER EPIDEM BIOMAR, V19, P301, DOI 10.1158/1055-9965.EPI-09-0741; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; McAllister SS, 2014, NAT CELL BIOL, V16, P717, DOI 10.1038/ncb3015; Medina D, 2002, FASEB J, V16, P881, DOI 10.1096/fj.01-0885fje; Moon SH, 2013, INT J ONCOL, V42, P921, DOI 10.3892/ijo.2013.1765; Mougiakakos D, 2010, ADV CANCER RES, V107, P57, DOI 10.1016/S0065-230X(10)07003-X; Myant KB, 2013, CELL STEM CELL, V12, P761, DOI 10.1016/j.stem.2013.04.006; Naxerova K, 2015, NAT REV CLIN ONCOL, V12, P258, DOI 10.1038/nrclinonc.2014.238; Oskarsson T, 2014, CELL STEM CELL, V14, P306, DOI 10.1016/j.stem.2014.02.002; Patro R, 2017, NAT METHODS, V14, P417, DOI 10.1038/nmeth.4197; Perry JM, 2011, GENE DEV, V25, P1928, DOI 10.1101/gad.17421911; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Ranger JJ, 2009, CANCER RES, V69, P6823, DOI 10.1158/0008-5472.CAN-09-1684; Redell MS, 2011, BLOOD, V117, P5701, DOI 10.1182/blood-2010-04-280123; Roarty K, 2017, ONCOGENE, V36, P5958, DOI 10.1038/onc.2017.206; Roarty K, 2015, J CELL BIOL, V208, P351, DOI 10.1083/jcb.201408058; Rokavec M, 2014, J CLIN INVEST, V124, P1853, DOI 10.1172/JCI73531; Schepers AG, 2012, SCIENCE, V337, P730, DOI 10.1126/science.1224676; Schroeder A, 2014, CANCER RES, V74, P1227, DOI 10.1158/0008-5472.CAN-13-0594; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Pereira LMS, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00605; Tan W, 2011, NATURE, V470, P548, DOI 10.1038/nature09707; ten Berge D, 2008, CELL STEM CELL, V3, P508, DOI 10.1016/j.stem.2008.09.013; Thakur R, 2015, SCI REP-UK, V5, DOI 10.1038/srep10194; Todaro M, 2014, CELL STEM CELL, V14, P342, DOI 10.1016/j.stem.2014.01.009; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vanharanta S, 2013, CANCER CELL, V24, P410, DOI 10.1016/j.ccr.2013.09.007; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wang RF, 2008, HUM IMMUNOL, V69, P811, DOI 10.1016/j.humimm.2008.08.276; Wei W, 2014, STEM CELLS, V32, P2571, DOI 10.1002/stem.1752; Williams CB, 2016, NPJ BREAST CANCER, V2, DOI 10.1038/npjbcancer.2015.25; Wu JQ, 2016, CELL REP, V14, P1979, DOI 10.1016/j.celrep.2016.01.074; Xu L, 2010, CLIN IMMUNOL, V135, P466, DOI 10.1016/j.clim.2010.01.014; Xu XJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004783; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yan M, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2869; Yates LR, 2015, NAT MED, V21, P751, DOI 10.1038/nm.3886; Zhang CH, 2015, ONCOL REP, V33, P1872, DOI 10.3892/or.2015.3783; Zhang M, 2010, P NATL ACAD SCI USA, V107, P3522, DOI 10.1073/pnas.0910179107; Zhu L, 2019, BIORXIV, DOI [10.1101/525071, DOI 10.1101/525071]	86	8	8	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2019	38	31					5942	5958		10.1038/s41388-019-0852-0	http://dx.doi.org/10.1038/s41388-019-0852-0			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IT3GE	31289359	Green Accepted			2022-12-28	WOS:000482740000003
J	Mishra, S; Bernal, C; Silvano, M; Anand, S; Altaba, ARI				Mishra, Sonakshi; Bernal, Carolina; Silvano, Marianna; Anand, Santosh; Altaba, Ariel Ruiz i			The protein secretion modulator TMED9 drives CNIH4/TGF alpha/GLI signaling opposing TMED3-WNT-TCF to promote colon cancer metastases	ONCOGENE			English	Article							GROWTH-FACTOR-ALPHA; TGF-ALPHA; FACTOR RECEPTOR; P24 FAMILY; BETA-CATENIN; COLORECTAL-CANCER; EXOCYTIC VESICLES; CARGO RECEPTORS; PROTGF-ALPHA; TUMOR-GROWTH	How cells in primary tumors initially become pro-metastatic is not understood. A previous genome-wide RNAi screen uncovered colon cancer metastatic suppressor and WNT promoting functions of TMED3, a member of the p24 ER-to-Golgi protein secretion family. Repression of canonical WNT signaling upon knockdown (kd) of TMED3 might thus be sufficient to drive metastases. However, searching for transcriptional influences on other family members here we find that TMED3 kd leads to enhanced TMED9, that TMED9 acts downstream of TMED3 and that TMED9 kd compromises metastasis. Importantly, TMED9 pro-metastatic function is linked to but distinct from the repression of TMED3-WNT-TCF signaling. Functional rescue of the migratory deficiency of TMED9 kd cells identifies TGF alpha as a mediator of TMED9 pro-metastatic activity. Moreover, TMED9 kd compromises the biogenesis, and thus function, of TGF alpha. Analyses in three colon cancer cell types highlight a TMED9-dependent gene set that includes CNIH4, a member of the CORNICHON family of TGF alpha exporters. Our data indicate that TGFA and CNIH4, which display predictive value for disease-free survival, promote colon cancer cell metastatic behavior, and suggest that TMED9 pro-metastatic function involves the modulation of the secretion of TGF alpha ligand. Finally, TMED9/TMED3 antagonism impacts WNT-TCF and GLI signaling, where TMED9 primacy over TMED3 leads to the establishment of a positive feedback loop together with CNIH4, TGF alpha, and GLI1 that enhances metastases. We propose that primary colon cancer cells can transition between two states characterized by secretion-transcription regulatory loops gated by TMED3 and TMED9 that modulate their metastatic proclivities.	[Mishra, Sonakshi; Bernal, Carolina; Silvano, Marianna; Anand, Santosh; Altaba, Ariel Ruiz i] Univ Geneva, Dept Genet Med & Dev, Fac Med, Med Sch, 1 Rue Michel Servet, CH-1211 Geneva, Switzerland	University of Geneva	Altaba, ARI (corresponding author), Univ Geneva, Dept Genet Med & Dev, Fac Med, Med Sch, 1 Rue Michel Servet, CH-1211 Geneva, Switzerland.	Ariel.RuizAltaba@unige.ch		Anand, Santosh/0000-0003-2287-0229	Swiss Government pre-doctoral grant; Swiss National Science Foundation; Swiss Cancer League; Departement d'Instruction Publique de Geneve	Swiss Government pre-doctoral grant; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss Cancer League; Departement d'Instruction Publique de Geneve	We are grateful to R. Coffey for the kind gift of HA/FLAG-tagged TGFa, to all Ruiz i Altaba lab members for discussion, to M. Kuciak and A. Conod for comments on the manuscript and to I. Borges Grazina for technical help. This work was supported by a Swiss Government pre-doctoral grant to SM and by grants from the Swiss National Science Foundation and the Swiss Cancer League, and by funds from the Departement d'Instruction Publique de Geneve to ARA.	Aberger F, 2014, SEMIN CELL DEV BIOL, V33, P93, DOI 10.1016/j.semcdb.2014.05.003; Adolf A, 2018, PROTEOMIC PROFILING; Ahn Y, 2010, DEVELOPMENT, V137, P3221, DOI 10.1242/dev.054668; ALISON MR, 1993, CELL PROLIFERAT, V26, P449, DOI 10.1111/j.1365-2184.1993.tb00132.x; Altaba ARI, 1999, DEVELOPMENT, V126, P3205; Azzolin L, 2014, CELL, V158, P157, DOI 10.1016/j.cell.2014.06.013; Azzolin L, 2012, CELL, V151, P1443, DOI 10.1016/j.cell.2012.11.027; Barr FA, 2001, J CELL BIOL, V155, P885, DOI 10.1083/jcb.200108102; Bokel C, 2006, DEVELOPMENT, V133, P459, DOI 10.1242/dev.02219; Briley GP, 1997, MOL BIOL CELL, V8, P1619, DOI 10.1091/mbc.8.8.1619; Buechling T, 2011, EMBO REP, V12, P1265, DOI 10.1038/embor.2011.212; Cao Z, 2008, MOL CELL PROTEOMICS, V7, P1651, DOI 10.1074/mcp.M700155-MCP200; Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; Connolly DJ, 2013, J BIOL CHEM, V288, P5616, DOI 10.1074/jbc.M112.403899; De Jong KP, 1998, HEPATOLOGY, V28, P971, DOI 10.1002/hep.510280411; Denzel A, 2000, CURR BIOL, V10, P55, DOI 10.1016/S0960-9822(99)00266-3; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; Desnoyers L, 2008, ONCOGENE, V27, P85, DOI 10.1038/sj.onc.1210623; Dhawan P, 2011, ONCOGENE, V30, P3234, DOI 10.1038/onc.2011.43; Doyle SL, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1706; Duquet A, 2014, EMBO MOL MED, V6, P882, DOI 10.15252/emmm.201303799; Eberl M, 2012, EMBO MOL MED, V4, P218, DOI 10.1002/emmm.201100201; El-Hariry I, 2001, INT J CANCER, V94, P652, DOI 10.1002/ijc.1515; Emery G, 2000, J CELL SCI, V113, P2507; Fraisier V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082223; Freeman TJ, 2012, GASTROENTEROLOGY, V142, P562, DOI 10.1053/j.gastro.2011.11.026; Fullekrug J, 1999, MOL BIOL CELL, V10, P1939, DOI 10.1091/mbc.10.6.1939; Giancotti FG, 2013, CELL, V155, P750, DOI 10.1016/j.cell.2013.10.029; Grant CE, 2011, BIOINFORMATICS, V27, P1017, DOI 10.1093/bioinformatics/btr064; Gregorieff A, 2015, NATURE, V526, P715, DOI 10.1038/nature15382; Gu XH, 2012, CLIN EXP MED, V12, P195, DOI 10.1007/s10238-011-0155-4; Gwak J, 2016, ONCOTARGET, V7, P48250, DOI 10.18632/oncotarget.10198; Hu TH, 2010, J BIOL CHEM, V285, P13561, DOI 10.1074/jbc.M109.075945; HUANG F, 1995, EXP CELL RES, V219, P8, DOI 10.1006/excr.1995.1198; Jenne N, 2002, J BIOL CHEM, V277, P46504, DOI 10.1074/jbc.M206989200; Jerome-Majewska LA, 2010, DEV BIOL, V341, P154, DOI 10.1016/j.ydbio.2010.02.019; Kho DH, 2009, GUT, V58, P509, DOI 10.1136/gut.2008.150938; Krausova M, 2014, CELL SIGNAL, V26, P570, DOI 10.1016/j.cellsig.2013.11.032; Kuo A, 2000, EMBO J, V19, P6427, DOI 10.1093/emboj/19.23.6427; Lai W, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0566-z; LaLonde DP, 2006, CURR BIOL, V16, P1375, DOI 10.1016/j.cub.2006.05.057; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lau TS, 2017, ONCOGENE, V36, P3576, DOI 10.1038/onc.2016.509; Lavoie C, 1999, J CELL BIOL, V146, P285, DOI 10.1083/jcb.146.2.285; Li CX, 2007, MOL BIOL CELL, V18, P3081, DOI 10.1091/mbc.E07-02-0172; Li CX, 2004, P NATL ACAD SCI USA, V101, P5571, DOI 10.1073/pnas.0401294101; Li X, 2015, BIOCHEM BIOPH RES CO, V463, P483, DOI 10.1016/j.bbrc.2015.04.151; Liao XY, 2015, INT J MOL SCI, V16, P17655, DOI 10.3390/ijms160817655; Liaunardy-Jopeace A, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005275; Liu Q, 2016, ONCOTARGET, V7, P36800, DOI 10.18632/oncotarget.9191; Luga V, 2012, CELL, V151, P1542, DOI 10.1016/j.cell.2012.11.024; Luo WB, 2007, J BIOL CHEM, V282, P30246, DOI 10.1074/jbc.M703205200; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; Maye P, 2004, J BIOL CHEM, V279, P24659, DOI 10.1074/jbc.M311724200; Mayor S, 2004, NAT REV MOL CELL BIO, V5, P110, DOI 10.1038/nrm1309; MILLER W, 1985, CLIN EXP METASTAS, V3, P189, DOI 10.1007/BF01786762; Mitrovic S, 2008, MOL BIOL CELL, V19, P1976, DOI 10.1091/mbc.E07-10-0989; Najdi R, 2012, DIFFERENTIATION, V84, P203, DOI 10.1016/j.diff.2012.06.004; Pagant S, 2015, CURR BIOL, V25, P403, DOI 10.1016/j.cub.2014.11.070; Park HW, 2015, CELL, V162, P780, DOI 10.1016/j.cell.2015.07.013; Perez Castro C, 2007, J CELL SCI, V120, P2454, DOI 10.1242/jcs.004200; Pobbati AV, 2013, CANCER BIOL THER, V14, P390, DOI 10.4161/cbt.23788; Port F, 2011, EMBO REP, V12, P1144, DOI 10.1038/embor.2011.165; Price MA, 2011, PIGM CELL MELANOMA R, V24, P1148, DOI 10.1111/j.1755-148X.2011.00929.x; Qin W, 2014, INT J ONCOL, V45, P1225, DOI 10.3892/ijo.2014.2506; Radaelli E, 2009, HISTOL HISTOPATHOL, V24, P879, DOI 10.14670/HH-24.879; REPESH LA, 1989, INVAS METAST, V9, P192; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Rieger ME, 2010, MOL CELL BIOL, V30, P4267, DOI 10.1128/MCB.01418-09; Riku M, 2016, ONCOTARGET, V7, P5690, DOI 10.18632/oncotarget.6788; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Romagnoli M, 2014, EMBO MOL MED, V6, P278, DOI 10.1002/emmm.201303373; Ruifrok ACC, 1997, RADIAT RES, V147, P1, DOI 10.2307/3579436; Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pD91, DOI 10.1093/nar/gkh012; Sasaki T, 2008, AM J PATHOL, V173, P205, DOI 10.2353/ajpath.2008.071147; Sauvageau E, 2014, TRAFFIC, V15, P383, DOI 10.1111/tra.12148; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; Seth C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150697; Singh Bhuminder, 2016, F1000Res, V5, DOI 10.12688/f1000research.9025.1; Singh B, 2014, ANNU REV PHYSIOL, V76, P275, DOI 10.1146/annurev-physiol-021113-170406; Singovski G, 2016, J MOL CELL BIOL, V8, P157, DOI 10.1093/jmcb/mjv034; Smith JJ, 2010, GASTROENTEROLOGY, V138, P958, DOI 10.1053/j.gastro.2009.11.005; Stecca B, 2007, P NATL ACAD SCI USA, V104, P5895, DOI 10.1073/pnas.0700776104; Stecca B, 2010, J MOL CELL BIOL, V2, P84, DOI 10.1093/jmcb/mjp052; Strating JRPM, 2009, BIOL CELL, V101, P495, DOI 10.1042/BC20080233; Sukhotnik I, 2008, PEDIATR SURG INT, V24, P1303, DOI 10.1007/s00383-008-2271-0; Tada M, 2000, DEVELOPMENT, V127, P2227; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; Takida S, 2008, BIOCHEM J, V409, P555, DOI 10.1042/BJ20070234; Uysal-Onganer P, 2012, ACTA PHYSIOL, V204, P52, DOI 10.1111/j.1748-1716.2011.02297.x; Varnat F, 2010, EMBO MOL MED, V2, P440, DOI 10.1002/emmm.201000098; Varnat F, 2009, EMBO MOL MED, V1, P338, DOI 10.1002/emmm.200900039; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Voloshanenko O, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3610; von Karstedt S, 2015, CANCER CELL, V27, P561, DOI 10.1016/j.ccell.2015.02.014; Wajapeyee N, 2009, MOL CANCER THER, V8, P3009, DOI 10.1158/1535-7163.MCT-09-0470; Wang P, 2015, BIOCHEM BIOPH RES CO, V460, P314, DOI 10.1016/j.bbrc.2015.03.032; Wang XC, 2012, PANCREAS, V41, P10, DOI 10.1097/MPA.0b013e318223c7e4; Wang YW, 2017, ONCOTARGET, V8, P34429, DOI 10.18632/oncotarget.16260; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Wong SF, 2005, CLIN THER, V27, P684, DOI 10.1016/j.clinthera.2005.06.003; Zeelenberg IS, 2003, CANCER RES, V63, P3833; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333; Zhang PC, 2016, MOL BIOL CELL, V27, P1938, DOI 10.1091/mbc.E16-02-0090; Zheng H, 2016, SCI REP-UK, V6, DOI 10.1038/srep37070	106	20	20	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	2019	38	29					5817	5837		10.1038/s41388-019-0845-z	http://dx.doi.org/10.1038/s41388-019-0845-z			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IQ4WS	31253868	Green Published, hybrid			2022-12-28	WOS:000480752800006
J	Jiao, D; Huan, Y; Zheng, J; Wei, M; Zheng, GX; Han, DH; Wu, JH; Xi, WJ; Wei, FL; Yang, AG; Qin, WJ; Wang, H; Wen, WH				Jiao, Dian; Huan, Yi; Zheng, Jia; Wei, Ming; Zheng, Guoxu; Han, Donghui; Wu, Jieheng; Xi, Wenjin; Wei, Feilong; Yang, An-Gang; Qin, Weijun; Wang, He; Wen, Weihong			UHRF1 promotes renal cell carcinoma progression through epigenetic regulation of TXNIP	ONCOGENE			English	Article							THIOREDOXIN-BINDING PROTEIN-2; BREAST-CANCER; GROWTH; DNA; APOPTOSIS; PROLIFERATION; METHYLATION; EXPRESSION; INHIBITOR	UHRF1 is an important epigenetic regulator that belongs to the UHRF family. Overexpression of UHRF1 has been found in many kinds of tumors and its overexpression is associated with poor prognosis and short survival in certain cancer types. However, its function in renal cell carcinoma (RCC) is not clear. Here we report that RCC tumor tissues had obviously higher UHRF1 expression than normal renal tissues. Downregulation of UHRF1 by siRNA or shRNA in RCC cell lines resulted in decreased cell viability, inhibited cell migration and invasion, and increased apoptosis. UHRF1 knockdown RCC xenografts also resulted in obviously inhibited tumor growth in vivo. After downregulation of UHRF1 in RCC cells, the expression of TXNIP was upregulated. In addition, after UHRF1 and TXNIP were simultaneously downregulated, cell viability and cell invasion increased, whereas cell apoptosis decreased compared with UHRF1 single downregulated cells. We also showed that UHRF1 could recruit HDAC1 to the TXNIP promoter and mediate the deacetylation of histone H3K9, resulting in the inhibition of TXNIP expression. Our results confirm that UHRF1 has oncogenic function in RCC and UHRF1 may promote tumor progression through epigenetic regulation of TXNIP. UHRF1 might be used as a therapeutic target for RCC treatment.	[Jiao, Dian; Wang, He] Fourth Mil Med Univ, Dept Urol, Tangdu Hosp, Xian 710038, Shaanxi, Peoples R China; [Huan, Yi] Fourth Mil Med Univ, Dept Radiol, Xijing Hosp, Xian 710032, Shaanxi, Peoples R China; [Zheng, Jia] Zhengzhou Univ, Dept Oncol, Affiliated Hosp 1, Zhengzhou 450052, Henan, Peoples R China; [Wei, Ming] 150th Cent Hosp PLA, Dept Urol, Luoyang 471000, Peoples R China; [Zheng, Guoxu] Fourth Mil Med Univ, Dept Physiol & Pathophysiol, Xian 710032, Shaanxi, Peoples R China; [Han, Donghui; Qin, Weijun] Fourth Mil Med Univ, Dept Urol, Xijing Hosp, Xian 710032, Shaanxi, Peoples R China; [Wu, Jieheng; Xi, Wenjin; Yang, An-Gang; Wen, Weihong] Fourth Mil Med Univ, State Key Lab Canc Biol, Dept Immunol, Xian 710032, Shaanxi, Peoples R China; [Wei, Feilong] Fourth Mil Med Univ, Dept Orthoped, Tangdu Hosp, Xian 710038, Shaanxi, Peoples R China	Air Force Military Medical University; Air Force Military Medical University; Zhengzhou University; Air Force Military Medical University; Air Force Military Medical University; Air Force Military Medical University; Air Force Military Medical University	Wang, H (corresponding author), Fourth Mil Med Univ, Dept Urol, Tangdu Hosp, Xian 710038, Shaanxi, Peoples R China.; Qin, WJ (corresponding author), Fourth Mil Med Univ, Dept Urol, Xijing Hosp, Xian 710032, Shaanxi, Peoples R China.; Wen, WH (corresponding author), Fourth Mil Med Univ, State Key Lab Canc Biol, Dept Immunol, Xian 710032, Shaanxi, Peoples R China.	qinweij@fmmu.edu.cn; dusxjhw@fmmu.edu.cn; wenweih@fmmu.edu.cn	Jiao, Dian/HDN-6625-2022; Wu, Jieheng/ABF-2371-2021; 温, 家琦/GYV-3177-2022; Wei, Fei-Long/GRS-0966-2022; Wei, Fei-Long/AAI-5371-2021	Wu, Jieheng/0000-0003-4927-3897; Wei, Fei-Long/0000-0002-9260-5386; Wei, Fei-Long/0000-0002-9260-5386	National Natural Science Foundation of China [81772734, 81220108011, 81372225, 81372771]; open project program of the State Key Laboratory of Cancer Biology (Fourth Military Medical University) [CBSKL201705]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); open project program of the State Key Laboratory of Cancer Biology (Fourth Military Medical University)	This work was supported by grants from the National Natural Science Foundation of China (No. 81772734, 81220108011, 81372225, and 81372771) and the open project program of the State Key Laboratory of Cancer Biology (Fourth Military Medical University) (CBSKL201705).	Arita K, 2008, NATURE, V455, P818, DOI 10.1038/nature07249; Babbio F, 2012, ONCOGENE, V31, P4878, DOI 10.1038/onc.2011.641; Bhatt JR, 2014, NAT REV UROL, V11, P517, DOI 10.1038/nrurol.2014.194; Bostick M, 2007, SCIENCE, V317, P1760, DOI 10.1126/science.1147939; Butler LM, 2002, P NATL ACAD SCI USA, V99, P11700, DOI 10.1073/pnas.182372299; Cartron PF, 2013, MOL ONCOL, V7, P452, DOI 10.1016/j.molonc.2012.11.004; Creel PA, 2014, CLIN J ONCOL NURS, V18, P694, DOI 10.1188/14.CJON.694-700; Daskalos A, 2011, CANCER-AM CANCER SOC, V117, P1027, DOI 10.1002/cncr.25531; Dutta KK, 2005, LAB INVEST, V85, P798, DOI 10.1038/labinvest.3700280; Ge TT, 2016, J OVARIAN RES, V9, DOI 10.1186/s13048-016-0253-8; Geng Y, 2013, CANCER SCI, V104, P194, DOI 10.1111/cas.12052; Han SH, 2003, ONCOGENE, V22, P4035, DOI 10.1038/sj.onc.1206610; Hashimoto H, 2008, NATURE, V455, P826, DOI 10.1038/nature07280; Hervouet Eric, 2010, Genes Cancer, V1, P434, DOI 10.1177/1947601910373794; Hervouet E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011333; Ikarashi M, 2002, ANTICANCER RES, V22, P4045; Jenkins Y, 2005, MOL BIOL CELL, V16, P5621, DOI 10.1091/mbc.E05-03-0194; Kim JK, 2009, NUCLEIC ACIDS RES, V37, P493, DOI 10.1093/nar/gkn961; Li J, 2017, ONCOL REP, V37, P3369, DOI 10.3892/or.2017.5577; Liu XC, 2017, ONCOTARGET, V8, P10510, DOI 10.18632/oncotarget.14446; Lopez-Beltran A, 2009, INT J UROL, V16, P432, DOI 10.1111/j.1442-2042.2009.02302.x; Morrison JA, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-62; Mudbhary R, 2014, CANCER CELL, V25, P196, DOI 10.1016/j.ccr.2014.01.003; Nakamura K, 2016, ONCOTARGET, V7, P57821, DOI 10.18632/oncotarget.11067; Qin J, 2013, NATURE, V493, P236, DOI 10.1038/nature11674; Qin YY, 2014, ONCOL REP, V31, P2635, DOI 10.3892/or.2014.3145; Rini BI, 2009, LANCET, V373, P1119, DOI 10.1016/S0140-6736(09)60229-4; Sabatino L, 2012, ONCOGENE, V31, P5061, DOI 10.1038/onc.2012.3; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sharif J, 2007, NATURE, V450, P908, DOI 10.1038/nature06397; Shen LL, 2015, P NATL ACAD SCI USA, V112, P5425, DOI 10.1073/pnas.1501555112; Sheng Y, 2016, GYNECOL ONCOL, V140, P145, DOI 10.1016/j.ygyno.2015.11.017; Sheth SS, 2006, ONCOGENE, V25, P3528, DOI 10.1038/sj.onc.1209394; Shi T, 2015, PLANT MOL BIOL, V89, P253, DOI 10.1007/s11103-015-0366-2; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Tauber M, 2015, NUCLEUS-PHILA, V6, P123, DOI 10.1080/19491034.2015.1026022; Unoki M, 2004, ONCOGENE, V23, P7601, DOI 10.1038/sj.onc.1208053; Wan XC, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0308-0; Wei M, 2017, ONCOTARGET, V8, P5323, DOI 10.18632/oncotarget.14142; Yan Feng, 2015, Asian Pac J Cancer Prev, V16, P1343; Zhang ZY, 2016, MED ONCOL, V33, DOI 10.1007/s12032-016-0799-8; Zhou JBA, 2011, INT J BIOCHEM CELL B, V43, P1668, DOI 10.1016/j.biocel.2011.09.005; Zhou JB, 2011, BLOOD, V118, P2830, DOI 10.1182/blood-2010-07-294827; Zhuo H, 2016, MOL CARCINOGEN, V55, P209, DOI 10.1002/mc.22270	44	25	27	0	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2019	38	28					5686	5699		10.1038/s41388-019-0822-6	http://dx.doi.org/10.1038/s41388-019-0822-6			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IH9RW	31043707				2022-12-28	WOS:000474845100010
J	Zhou, PT; Li, YY; Li, B; Zhang, MC; Liu, YH; Yao, Y; Li, D				Zhou, Pingting; Li, Yanyan; Li, Bo; Zhang, Meichao; Liu, Yuanhua; Yao, Yuan; Li, Dong			NMIIA promotes tumor growth and metastasis by activating the Wnt/beta-catenin signaling pathway and EMT in pancreatic cancer	ONCOGENE			English	Article							NONMUSCLE MYOSIN-II; EPITHELIAL-MESENCHYMAL TRANSITION; HEAVY-CHAIN; BETA-CATENIN; EXPRESSION; PHOSPHORYLATION; CDC42; MECHANISMS; INVASION; CLONING	Non-muscle myosin IIA (NMIIA) protein plays an important role in cell cytokinesis and cell migration. The role and underlying regulatory mechanisms of NMIIA in pancreatic cancer (PC) remain elusive. We found that NMIIA is highly expressed in PC tissues and contributes to PC poor progression by using open microarray datasets from the Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA), and PC tissue arrays. NMIIA regulates beta-catenin mediated EMT to promote the proliferation, migration, invasion, and sphere formation of PC cells in vitro and in vivo. NMIIA controls the beta-catenin transcriptional activity by interacting with beta-catenin. Moreover, MEK/ERK signaling is critical in MLC2 (Ser19) phosphorylation, which can mediate NMIIA activity and regulate Wnt/beta-catenin signaling. These findings highlight the significance of NMIIA in tumor regression and implicate NMIIA as a promising candidate for PC treatment.	[Zhou, Pingting; Li, Yanyan; Zhang, Meichao; Yao, Yuan; Li, Dong] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Radiat Oncol, Sch Med, Shanghai, Peoples R China; [Li, Bo] Second Mil Med Univ, Changzheng Hosp, Dept Orthoped Oncol, Shanghai, Peoples R China; [Liu, Yuanhua] Nanjing Med Univ, Dept Chemotherapy, Affiliated Canc Hosp, Canc Inst Jiangsu Prov, Nanjing, Jiangsu, Peoples R China	Shanghai Jiao Tong University; Naval Medical University; Nanjing Medical University	Yao, Y; Li, D (corresponding author), Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Radiat Oncol, Sch Med, Shanghai, Peoples R China.; Liu, YH (corresponding author), Nanjing Med Univ, Dept Chemotherapy, Affiliated Canc Hosp, Canc Inst Jiangsu Prov, Nanjing, Jiangsu, Peoples R China.	Yuanhualiu02@hotmail.com; yaoyuan@shsmu.edu.cn; lidong@shsmu.edu.cn			National Natural Science Foundation of China [81370600]; Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning [TP2015022]; Shanghai Pujiang Program [15PJ1404800]; Innovation Program of Shanghai Municipal Education Commission [15ZZ056]; Innovation Program for Ph.D. students in Shanghai Jiaotong University School of Medicine [BXJ201731]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning; Shanghai Pujiang Program(Shanghai Pujiang Program); Innovation Program of Shanghai Municipal Education Commission(Innovation Program of Shanghai Municipal Education Commission); Innovation Program for Ph.D. students in Shanghai Jiaotong University School of Medicine	This work was supported by National Natural Science Foundation of China (grant 81370600, DL); The Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning (TP2015022, DL); Shanghai Pujiang Program (15PJ1404800, DL); Innovation Program of Shanghai Municipal Education Commission (15ZZ056, DL); and Innovation Program for Ph.D. students in Shanghai Jiaotong University School of Medicine (BXJ201731).	Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Arozarena I, 2011, CANCER CELL, V19, P45, DOI 10.1016/j.ccr.2010.10.029; Beach JR, 2011, P NATL ACAD SCI USA, V108, P17991, DOI 10.1073/pnas.1106499108; Betapudi V, 2006, CANCER RES, V66, P4725, DOI 10.1158/0008-5472.CAN-05-4236; Brabletz T, 2012, NAT REV CANCER, V12, P425, DOI 10.1038/nrc3265; Brower V, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv195; Chew TL, 1998, J MUSCLE RES CELL M, V19, P839, DOI 10.1023/A:1005417926585; Choi OH, 1996, J MUSCLE RES CELL M, V17, P69, DOI 10.1007/BF00140325; Coaxum SD, 2017, ONCOTARGET, V8, P22991, DOI 10.18632/oncotarget.14967; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COTE GP, 1984, J BIOL CHEM, V259, P2781; Cowen D, 2002, CLIN CANCER RES, V8, P1148; D'Apolito M, 2002, GENE, V286, P215, DOI 10.1016/S0378-1119(02)00455-9; Derycke L, 2011, INT J DEV BIOL, V55, P835, DOI 10.1387/ijdb.113336ld; Diala I, 2013, EMBO REP, V14, P356, DOI 10.1038/embor.2013.16; Du M, 2012, J BIOL CHEM, V287, P15330, DOI 10.1074/jbc.M112.349787; Dulyaninova NG, 2007, MOL BIOL CELL, V18, P3144, DOI 10.1091/mbc.E06-11-1056; Fagotto F, 2013, EMBO REP, V14, P422, DOI 10.1038/embor.2013.45; Faruqi TR, 2001, P NATL ACAD SCI USA, V98, P9014, DOI 10.1073/pnas.161281298; Gjoerup O, 1998, J BIOL CHEM, V273, P18812, DOI 10.1074/jbc.273.30.18812; Golomb E, 2004, J BIOL CHEM, V279, P2800, DOI 10.1074/jbc.M309981200; Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189; Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476; Hoelzle MK, 2012, MOL BIOL CELL, V23, P310, DOI 10.1091/mbc.E11-08-0719; Hotz B, 2007, CLIN CANCER RES, V13, P4769, DOI 10.1158/1078-0432.CCR-06-2926; Iacobuzio-Donahue CA, 2009, J CLIN ONCOL, V27, P1806, DOI 10.1200/JCO.2008.17.7188; Ivanov AI, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-36; Jacobs K, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-255; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kim JH, 2011, J CELL PHYSIOL, V226, P2881, DOI 10.1002/jcp.22631; Li CX, 2014, J CLIN INVEST, V124, P2172, DOI 10.1172/JCI71103; Li D, 2010, J CELL BIOL, V191, P631, DOI 10.1083/jcb.201006094; Liao Q, 2017, BRIT J CANCER, V117, P563, DOI 10.1038/bjc.2017.193; Liu CC, 2017, ONCOGENE, V36, P1779, DOI 10.1038/onc.2016.339; Liu DN, 2012, INT J MOL SCI, V13, P15291, DOI 10.3390/ijms131115291; Liu T, 2016, MOL MED REP, V13, P1639, DOI 10.3892/mmr.2015.4742; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Nakashima M, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-79; Newell-Litwa KA, 2015, DIS MODEL MECH, V8, P1495, DOI 10.1242/dmm.022103; Ning BF, 2010, CANCER RES, V70, P7640, DOI 10.1158/0008-5472.CAN-10-0824; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y; Schramek D, 2014, SCIENCE, V343, P309, DOI 10.1126/science.1248627; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; SIMONS M, 1991, CIRC RES, V69, P530, DOI 10.1161/01.RES.69.2.530; Smith BN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104987; Stewart CJR, 2013, HISTOPATHOLOGY, V62, P31, DOI 10.1111/his.12057; Strohm C, 2000, J CARDIOVASC PHARM, V36, P218, DOI 10.1097/00005344-200008000-00012; Thaker PH, 2004, CLIN CANCER RES, V10, P5145, DOI 10.1158/1078-0432.CCR-03-0589; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; Vicente-Manzanares M, 2009, NAT REV MOL CELL BIO, V10, P778, DOI 10.1038/nrm2786; Wang C, 2017, MOL ONCOL, V11, P455, DOI 10.1002/1878-0261.12036; White BD, 2012, GASTROENTEROLOGY, V142, P219, DOI 10.1053/j.gastro.2011.12.001; WINKELMANN DA, 1984, NATURE, V307, P758, DOI 10.1038/307758a0; Xia HP, 2010, BIOCHEM BIOPH RES CO, V391, P535, DOI 10.1016/j.bbrc.2009.11.093; Zeng Q, 2000, J CELL SCI, V113, P471; Zhou PT, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0624-9	61	56	62	1	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2019	38	27					5500	5515		10.1038/s41388-019-0806-6	http://dx.doi.org/10.1038/s41388-019-0806-6			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IG5KR	30967633				2022-12-28	WOS:000473842500012
J	He, WM; Liang, BS; Wang, CL; Li, SW; Zhao, Y; Huang, Q; Liu, ZX; Yao, ZQ; Wu, QJ; Liao, WJ; Zhang, SY; Liu, YJ; Xiang, Y; Liu, J; Shi, M				He, Wanming; Liang, Bishan; Wang, Chunlin; Li, Shaowei; Zhao, Yang; Huang, Qiong; Liu, Zexian; Yao, Zhiqi; Wu, Qijing; Liao, Wangjun; Zhang, Shuyi; Liu, Yajing; Xiang, Yi; Liu, Jia; Shi, Min			MSC-regulated lncRNA MACC1-AS1 promotes stemness and chemoresistance through fatty acid oxidation in gastric cancer	ONCOGENE			English	Article							TGF-BETA; DRUG-RESISTANCE; CELLS; MECHANISMS; CHEMOTHERAPY; METASTASIS; METABOLISM; SURVIVAL	Chemotherapy is the preferred treatment for advanced stage gastric cancer (GC) patients and chemotherapy resistance is the major obstacle to effective cancer therapy. Increasing evidence suggests that mesenchymal stem cells (MSCs) make important contributions to development of drug resistance. However, the underlying mechanism remains elusive. In this study, we discovered that abundant MSCs in tumor tissues predicted a poor prognosis in GC patients. MSCs promoted stemness and chemoresistance in GC cells through fatty acid oxidation (FAO) in vitro and in vivo. Mechanically, transforming growth factor beta 1 (TGF-beta 1) secretion by MSCs activated SMAD2/3 through TGF-beta receptors and induced long non-coding RNA (lncRNA) MACC1-AS1 expression in GC cells, which promoted FAO-dependent stemness and chemoresistance through antagonizing miR-145-5p. Moreover, pharmacologic inhibition of FAO with etomoxir (ETX) attenuated MSC-induced FOLFOX regiment resistance in vivo. These results suggest that FAO plays an important role in MSC-mediated stemness and chemotherapy resistance in GC and FAO inhibitors in combination with chemotherapeutic drugs present as a promising strategy to overcome chemoresistance.	[He, Wanming; Liang, Bishan; Wang, Chunlin; Li, Shaowei; Zhao, Yang; Huang, Qiong; Yao, Zhiqi; Wu, Qijing; Liao, Wangjun; Zhang, Shuyi; Liu, Yajing; Xiang, Yi; Liu, Jia; Shi, Min] Southern Med Univ, Nanfang Hosp, Dept Oncol, Guangzhou, Guangdong, Peoples R China; [Liu, Zexian] Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China	Southern Medical University - China; State Key Lab Oncology South China; Sun Yat Sen University	Shi, M (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Oncol, Guangzhou, Guangdong, Peoples R China.	nfyyshimin@163.com	Liu, Zexian/D-1153-2011	Liu, Zexian/0000-0001-9698-0610	National Key R&D Program of China [2017YFC1105000]; National Natural Science Foundation of China [81702398]; Natural Science Foundation of Guangdong Province of China [2016A020215232]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province of China(National Natural Science Foundation of Guangdong Province)	This study was supported by National Key R&D Program of China (grant number 2017YFC1105000), National Natural Science Foundation of China (grant number 81702398), and Natural Science Foundation of Guangdong Province of China (grant number 2016A020215232).	Ajani JA, 2016, J NATL COMPR CANC NE, V14, P1286, DOI 10.6004/jnccn.2016.0137; Carracedo A, 2013, NAT REV CANCER, V13, P227, DOI 10.1038/nrc3483; Chen CT, 2010, BBA-GEN SUBJECTS, V1800, P257, DOI 10.1016/j.bbagen.2009.09.001; Davidson M, 2015, CLIN COLORECTAL CANC, V14, P239, DOI 10.1016/j.clcc.2015.05.013; Di Francesco AM, 2016, J CELL PHYSIOL, V231, P2081, DOI 10.1002/jcp.25318; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Digklia A, 2016, WORLD J GASTROENTERO, V22, P2403, DOI 10.3748/wjg.v22.i8.2403; Graversen M, 2017, CLIN EXP METASTAS, V34, P309, DOI 10.1007/s10585-017-9849-7; Groppe J, 2008, MOL CELL, V29, P157, DOI 10.1016/j.molcel.2007.11.039; Gurumurthy S, 2010, NATURE, V468, P659, DOI 10.1038/nature09572; Guttman M, 2012, NATURE, V482, P339, DOI 10.1038/nature10887; Hao SH, 2017, NEOPLASIA, V19, P1022, DOI 10.1016/j.neo.2017.10.005; Houthuijzen J, 2012, BRIT J CANCER, V106, P1901, DOI 10.1038/bjc.2012.201; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Hung SP, 2013, CELL TRANSPLANT, V22, P1869, DOI 10.3727/096368912X657954; Ito K, 2012, NAT MED, V18, P1350, DOI 10.1038/nm.2882; Kastaniotis AJ, 2017, BBA-MOL CELL BIOL L, V1862, P39, DOI 10.1016/j.bbalip.2016.08.011; Kim HM, 2012, ANN SURG ONCOL, V19, pS539, DOI 10.1245/s10434-011-2040-5; Li HJ, 2012, CANCER DISCOV, V2, P840, DOI 10.1158/2159-8290.CD-12-0101; Lin YY, 2014, MOL CELL BIOL, V34, P2339, DOI 10.1128/MCB.00042-14; Liu B, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0706-7; Liu RL, 2015, TUMOR BIOL, V36, P5011, DOI 10.1007/s13277-015-3152-5; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Meads MB, 2008, CLIN CANCER RES, V14, P2519, DOI 10.1158/1078-0432.CCR-07-2223; Naka K, 2010, NATURE, V463, P676, DOI 10.1038/nature08734; Nakada D, 2010, NATURE, V468, P653, DOI 10.1038/nature09571; Novikova IV, 2013, J MOL BIOL, V425, P3731, DOI 10.1016/j.jmb.2013.02.030; Penuelas S, 2009, CANCER CELL, V15, P315, DOI 10.1016/j.ccr.2009.02.011; Pickup M, 2013, NAT REV CANCER, V13, P788, DOI 10.1038/nrc3603; Pike LS, 2011, BBA-BIOENERGETICS, V1807, P726, DOI 10.1016/j.bbabio.2010.10.022; Ricci-Vitiani L, 2009, J MOL MED, V87, P1097, DOI 10.1007/s00109-009-0518-4; Roberto M, 2016, EXPERT REV ANTICANC, V16, P717, DOI 10.1080/14737140.2016.1184979; Roodhart JML, 2011, CANCER CELL, V20, P370, DOI 10.1016/j.ccr.2011.08.010; Samudio I, 2010, J CLIN INVEST, V120, P142, DOI 10.1172/JCI38942; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shitara K, 2017, GASTRIC CANCER, V20, pS102, DOI 10.1007/s10120-016-0648-7; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Simsek T, 2010, CELL STEM CELL, V7, P380, DOI 10.1016/j.stem.2010.07.011; Wang H, 2017, J CELL PHYSIOL, V232, P1030, DOI 10.1002/jcp.25499; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Wang TY, 2018, CELL METAB, V27, P136, DOI 10.1016/j.cmet.2017.11.001; Wang YY, 2015, CELL STEM CELL, V16, P413, DOI 10.1016/j.stem.2015.03.003; Washington K, 2010, ANN SURG ONCOL, V17, P3077, DOI 10.1245/s10434-010-1362-z; Xu Z, 2016, NEURO-ONCOLOGY, V18, P830, DOI 10.1093/neuonc/nov298; Ye HM, 2012, CANCER INVEST, V30, P513, DOI 10.3109/07357907.2012.692171; Yuan SX, 2016, HEPATOLOGY, V63, P499, DOI 10.1002/hep.27893; Zhan M, 2016, TUMOR BIOL, V37, P10553, DOI 10.1007/s13277-016-4957-6; Zhao Y, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0820-2; Zhao Y, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0648-1	49	147	153	4	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2019	38	23					4637	4654		10.1038/s41388-019-0747-0	http://dx.doi.org/10.1038/s41388-019-0747-0			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IB4KM	30742067	hybrid, Green Published			2022-12-28	WOS:000470240300014
J	Rossi, F; Legnini, I; Megiorni, F; Colantoni, A; Santini, T; Morlando, M; Di Timoteo, G; Dattilo, D; Dominici, C; Bozzoni, I				Rossi, Francesca; Legnini, Ivano; Megiorni, Francesca; Colantoni, Alessio; Santini, Tiziana; Morlando, Mariangela; Di Timoteo, Gaia; Dattilo, Dario; Dominici, Carlo; Bozzoni, Irene			Circ-ZNF609 regulates G1-S progression in rhabdomyosarcoma	ONCOGENE			English	Article							E2F TARGET GENES; CIRCULAR RNAS; CELL-PROLIFERATION; PROMOTES; PATHWAY; IDENTIFICATION; TRANSLATION; MECHANISMS; EXPRESSION; CIRCRNAS	Circular RNAs (circRNAs) represent a class of covalently closed RNAs, derived from non-canonical splicing events, which are expressed in all eukaryotes and often conserved among different species. We previously showed that the circRNA originating from the ZNF609 locus (circ-ZNF609) acts as a crucial regulator of human primary myoblast growth: indeed, the downregulation of the circRNA, and not of its linear counterpart, strongly reduced the proliferation rate of in vitro cultured myoblasts. To deepen our knowledge about circ-ZNF609 role in cell cycle regulation, we studied its expression and function in rhabdomyosarcoma (RMS), a pediatric skeletal muscle malignancy. We found that circ-ZNF609 is upregulated in biopsies from the two major RMS subtypes, embryonal (ERMS) and alveolar (ARMS). Moreover, we discovered that in an ERMS-derived cell line circ-ZNF609 knock-down induced a specific block at the G1-S transition, a strong decrease of p-Akt protein level and an alteration of the pRb/Rb ratio. Regarding p-Akt, we were able to show that circ-ZNF609 acts by counteracting p-Akt proteasome-dependent degradation, thus working as a new regulator of cell proliferation-related pathways. As opposed to ERMS-derived cells, the circRNA depletion had no cell cycle effects in ARMS-derived cells. Since in these cells the p53 gene resulted downregulated, with a concomitant upregulation of its cell cycle-related target genes, we suggest that this could account for the lack of circ-ZNF609 effect in ARMS.	[Rossi, Francesca; Legnini, Ivano; Colantoni, Alessio; Morlando, Mariangela; Di Timoteo, Gaia; Dattilo, Dario; Bozzoni, Irene] Sapienza Univ Rome, Dept Biol & Biotechnol Charles Darwin, Rome, Italy; [Megiorni, Francesca; Dominici, Carlo] Sapienza Univ Rome, Dept Pediat, Rome, Italy; [Santini, Tiziana; Bozzoni, Irene] Ist Italiano Tecnol, Ctr Life Nano Sci Sapienza, Rome, Italy	Sapienza University Rome; Sapienza University Rome; Istituto Italiano di Tecnologia - IIT	Bozzoni, I (corresponding author), Sapienza Univ Rome, Dept Biol & Biotechnol Charles Darwin, Rome, Italy.; Bozzoni, I (corresponding author), Ist Italiano Tecnol, Ctr Life Nano Sci Sapienza, Rome, Italy.	irene.bozzoni@uniroma1.it	di timoteo, gaia/AAD-1952-2021; Megiorni, Francesca/AAC-1597-2019	Megiorni, Francesca/0000-0003-3705-3248; Di TIMOTEO, Gaia/0000-0003-4516-9945; COLANTONI, ALESSIO/0000-0001-7402-0176; Morlando, Mariangela/0000-0002-8327-4423; Rossi, Francesca/0000-0001-7327-6364; bozzoni, irene/0000-0002-3485-8537; Legnini, Ivano/0000-0002-8984-5215; Dattilo, Dario/0000-0003-2774-3835	ERC-2013 [AdG 340172-MUNCODD]; Telethon [GGP16213]; Human Frontiers Science Program Award [RGP0009/2014]; Parent Project Italia; AFM-Telethon [17835]; Epigen-Epigenomics Flagship Project; EU-H2020 Marie Sklodowska-Curie Action (circRTrain) [721890]	ERC-2013; Telethon(Fondazione Telethon); Human Frontiers Science Program Award; Parent Project Italia; AFM-Telethon(Association Francaise contre les Myopathies); Epigen-Epigenomics Flagship Project; EU-H2020 Marie Sklodowska-Curie Action (circRTrain)	The authors acknowledge O. Sthandier and M. Marchioni for technical help, S. Camero and M. Guarnacci for experimental support, M. Caruso for anti-Rb and anti-phospho-Rb antibodies, B. Pizer and R. Shukla for biological samples. The Telethon Network Genetic Biobanks (GTB12001F) and EuroBioBank are acknowledged for biological samples. This work was partially supported by grants from: ERC-2013 (AdG 340172-MUNCODD), Telethon (GGP16213), Human Frontiers Science Program Award RGP0009/2014, Parent Project Italia, AFM-Telethon (17835), Epigen-Epigenomics Flagship Project and EU-H2020 Marie Sklodowska-Curie Action (721890, circRTrain).	Abdelmohsen K, 2017, RNA BIOL, V14, P361, DOI 10.1080/15476286.2017.1279788; Ahmed I, 2016, ONCOTARGET, V7, P36366, DOI 10.18632/oncotarget.8917; Alvarez MJ, 2016, NAT GENET, V48, P838, DOI 10.1038/ng.3593; Besson A, 2006, GENE DEV, V20, P47, DOI 10.1101/gad.1384406; Bonizzato A, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2016.81; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Chen TD, 2012, J BIOL CHEM, V287, P37540, DOI 10.1074/jbc.M111.260679; CLEMENS MJ, 1985, BIOCHEM J, V226, P345, DOI 10.1042/bj2260345; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Du WW, 2016, NUCLEIC ACIDS RES, V44, P2846, DOI 10.1093/nar/gkw027; Egas-Bejar D, 2014, ADOLESC HEALTH MED T, V5, P115, DOI 10.2147/AHMT.S44582; Endo H, 2012, J BIOCHEM, V151, P139, DOI 10.1093/jb/mvr128; Fabregat A, 2018, NUCLEIC ACIDS RES, V46, pD649, DOI [10.1093/nar/gkz1031, 10.1093/nar/gkx1132]; FELIX CA, 1992, CANCER RES, V52, P2243; Feng GG, 2017, FEBS LETT, V591, P760, DOI 10.1002/1873-3468.12587; Galea GL, 2017, GENE, V599, P36, DOI 10.1016/j.gene.2016.11.006; Geistlinger L, 2011, BIOINFORMATICS, V27, pI366, DOI 10.1093/bioinformatics/btr228; Guarnerio J, 2016, CELL, V165, P289, DOI 10.1016/j.cell.2016.03.020; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; HERTZOG PJ, 1994, MOL REPROD DEV, V39, P226; Hinson ARP, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00183; Iwanaga R, 2006, ONCOGENE, V25, P1786, DOI 10.1038/sj.onc.1209210; Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Krautkramer KA, 2013, AM J PHYSIOL-ENDOC M, V305, pE600, DOI 10.1152/ajpendo.00147.2013; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Legnini I, 2017, MOL CELL, V66, P22, DOI 10.1016/j.molcel.2017.02.017; Liu PJ, 2009, CELL CYCLE, V8, P125, DOI 10.4161/cc.8.1.7528; Megiorni F, 2016, ONCOTARGET, V7, P79328, DOI 10.18632/oncotarget.12688; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Mio C, 2016, ENDOCR-RELAT CANCER, V23, P335, DOI 10.1530/ERC-15-0322; Miyachi M, 2009, CLIN CANCER RES, V15, P4077, DOI 10.1158/1078-0432.CCR-08-2955; Mori K, 2016, CANCER SCI, V107, P963, DOI 10.1111/cas.12953; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Pamudurti NR, 2017, MOL CELL, V66, P9, DOI 10.1016/j.molcel.2017.02.021; Patop IL, 2018, CURR OPIN GENET DEV, V48, P121, DOI 10.1016/j.gde.2017.11.007; Peng L, 2017, ONCOTARGET, V8, P808, DOI 10.18632/oncotarget.13656; Piwecka M, 2017, SCIENCE, V357, DOI 10.1126/science.aam8526; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Qu K, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.352; Remoli ME, 2002, J IMMUNOL, V169, P366, DOI 10.4049/jimmunol.169.1.366; Salzman J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030733; Sangfelt O, 2000, FRONT BIOSCI-LANDMRK, V5, pD479, DOI 10.2741/Sangfelt; Schaaf GJ, 2005, FASEB J, V19, P404, DOI 10.1096/fj.04-2104fje; Sun Xin, 2015, Sarcoma, V2015, P232010, DOI 10.1155/2015/232010; Tang CM, 2017, SCI REP-UK, V7, DOI 10.1038/srep40342; Taylor AC, 2000, MED PEDIATR ONCOL, V35, P96, DOI 10.1002/1096-911X(200008)35:2<96::AID-MPO2>3.0.CO;2-Z; Wang S, 2017, ONCOL REP, V38, P735, DOI 10.3892/or.2017.5769; Xia WJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep35576; Ying HN, 2018, ONCOTARGETS THER, V11, P689, DOI 10.2147/OTT.S152138; Zhang ML, 2018, ONCOGENE, V37, P1805, DOI 10.1038/s41388-017-0019-9; Zheng QP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11215	52	62	65	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2019	38	20					3843	3854		10.1038/s41388-019-0699-4	http://dx.doi.org/10.1038/s41388-019-0699-4			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HY3OI	30670781	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000468035600006
J	Zhu, JL; Huang, G; Hua, XH; Li, Y; Yan, HY; Che, X; Tian, ZX; Liufu, HT; Huang, C; Li, JX; Xu, JH; Dai, W; Huang, HS; Huang, CS				Zhu, Junlan; Huang, Grace; Hua, Xiaohui; Li, Yang; Yan, Huiying; Che, Xun; Tian, Zhongxian; Liufu, Huating; Huang, Chao; Li, Jingxia; Xu, Jiheng; Dai, Wei; Huang, Haishan; Huang, Chuanshu			CD44s is a crucial ATG7 downstream regulator for stem-like property, invasion, and lung metastasis of human bladder cancer (BC) cells	ONCOGENE			English	Article							MALIGNANT-TRANSFORMATION; DOWN-REGULATION; AUTOPHAGY; PROTEINS; USP28; OVEREXPRESSION; MAINTENANCE; INHIBITOR; 5-HYDROXYMETHYLCYTOSINE; PROLIFERATION	Over half a million US residents are suffering with bladder cancer (BC), which costs a total $4 billion in treatment annually. Although recent studies report that autophagy-related gene 7 (ATG7) is overexpressed in BCs, the regulatory effects of ATG7 on cancer stem-like phenotypes and invasion have not been explored yet. Current studies demonstrated that the deficiency of ATG7 by its shRNA dramatically reduced sphere formation and invasion in vitro, as well as lung metastasis in vivo in human invasive BC cells. Further studies indicated that the knockdown of ATG7 attenuated the expression of CD44 standard (CD44s), while ectopic introduction of CD44s, was capable of completely restoring sphere formation, invasion, and lung metastasis in T24T(shATG7) cells. Mechanistic studies revealed that ATG7 overexpression stabilized CD44s proteins accompanied with upregulating USP28 proteins. Upregulated USP28 was able to bind to CD44s and remove the ubiquitin group from CD44s' protein, resulting in the stabilization of CD44s protein. Moreover, ATG7 inhibition stabilized AUF1 protein and thereby reduced tet1 mRNA stability and expression, which was able to demethylate usp28 promoter, reduced USP28 expression, finally promoting CD44s degradation. In addition, CD44s was defined to inhibit degradation of RhoGDI beta, which in turn promotes BC invasion. Our results demonstrate that CD44s is a key ATG7 downstream regulator of the sphere formation, invasion, and lung metastasis of BCs, providing significant insight into understanding the BC invasions, metastasis, and stem-like properties.	[Zhu, Junlan; Huang, Grace; Hua, Xiaohui; Li, Yang; Yan, Huiying; Che, Xun; Tian, Zhongxian; Liufu, Huating; Huang, Chao; Li, Jingxia; Xu, Jiheng; Dai, Wei; Huang, Haishan; Huang, Chuanshu] NYU, Sch Med, Nelson Inst Environm Med, New York, NY 10010 USA	New York University	Huang, HS; Huang, CS (corresponding author), NYU, Sch Med, Nelson Inst Environm Med, New York, NY 10010 USA.	haishan_333@163.com; Chuanshu.huang@nyulangone.org	Xu, Jiheng/AAV-5732-2020	Xu, Jiheng/0000-0002-3538-3174; Dai, Wei/0000-0003-0169-8327; Huang, Chuanshu/0000-0003-4133-5096	NIH/NCI [CA177665, CA165980, CA217923]; NIH/NIEHS [ES000260]; NATIONAL CANCER INSTITUTE [P01CA165980, R01CA217923, R01CA177665] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000260] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Dr. Martin Eilers from the Institute of Molecular Biology and Tumor Research, Marburg, Germany, and Dr. James M. Angelastro from the Department of Molecular Biosciences, University of California at Davis for their generous gifts of the Flagtagged USP28 plasmid, the pcDNA3.1/NT-GFP-CD133, and pcDNA3.1/NT-GFP plasmids. We also thank Ms. Nedda Tichi for her critical reading of the manuscript. This work was partially supported by grants from NIH/NCI CA177665, CA165980, CA217923, and NIH/NIEHS ES000260.	Bartakova A., 2017, J OBSTET GYNAECOL, P1; Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Belinsky SA, 2004, NAT REV CANCER, V4, P707, DOI 10.1038/nrc1432; Blaveri E, 2005, CLIN CANCER RES, V11, P4044, DOI 10.1158/1078-0432.CCR-04-2409; Boya P, 2013, NAT CELL BIOL, V15, P713, DOI 10.1038/ncb2788; Ceriani M, 2015, EXP CELL RES, V333, P49, DOI 10.1016/j.yexcr.2015.01.019; Chan KS, 2010, CURR OPIN UROL, V20, P393, DOI 10.1097/MOU.0b013e32833cc9df; Chandrasekar T, 2016, INVESTIG CLIN UROL, V57, pS89, DOI 10.4111/icu.2016.57.S1.S89; Chen Q, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.142; Chetty C, 2012, CELL SIGNAL, V24, P549, DOI 10.1016/j.cellsig.2011.10.008; Cho Y, 2015, ONCOTARGET, V6, P8709, DOI 10.18632/oncotarget.3325; Ciesielski P, 2015, POSTEP HIG MED DOSW, V69, P1371; Damrauer JS, 2014, P NATL ACAD SCI USA, V111, P3110, DOI 10.1073/pnas.1318376111; Dickstein RJ, 2012, CANCER BIOL THER, V13, P1325, DOI 10.4161/cbt.21793; Faesen AC, 2012, BIOCHEM SOC T, V40, P539, DOI 10.1042/BST20120004; Gewirtz DA, 2014, CANCER RES, V74, P647, DOI 10.1158/0008-5472.CAN-13-2966; Gomez-Puerto MC, 2016, STEM CELLS, V34, P1651, DOI 10.1002/stem.2347; Gong C, 2012, AUTOPHAGY, V8, P1853, DOI 10.4161/auto.21996; Good CR, 2017, NUCLEIC ACIDS RES, V45, P8269, DOI 10.1093/nar/gkx435; Guo GY, 2014, TUMOR BIOL, V35, P4017, DOI 10.1007/s13277-013-1525-1; Han X, 2017, CELL BIOL INT, V41, P405, DOI 10.1002/cbin.10734; Hofner T, 2014, UROL ONCOL-SEMIN ORI, V32, P678, DOI 10.1016/j.urolonc.2014.01.001; Hua XH, 2018, CANCER LETT, V436, P38, DOI 10.1016/j.canlet.2018.08.013; Huang HS, 2016, AUTOPHAGY, V12, P1687, DOI 10.1080/15548627.2016.1196313; Jin BL, 2013, ADV EXP MED BIOL, V754, P3, DOI 10.1007/978-1-4419-9967-2_1; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019; Kobayashi K, 2016, ONCOL REP, V36, P2852, DOI 10.3892/or.2016.5061; Komander D, 2009, NAT REV MOL CELL BIO, V10, P550, DOI 10.1038/nrm2731; Lee BH, 2010, NATURE, V467, P179, DOI 10.1038/nature09299; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Li XZ, 2012, ANN SURG ONCOL, V19, P145, DOI 10.1245/s10434-011-1944-4; Liang YG, 2016, AUTOPHAGY, V12, P1229, DOI 10.1080/15548627.2016.1179403; Lin CJ, 2013, INT J ONCOL, V42, P993, DOI 10.3892/ijo.2013.1791; Lin YC, 2016, J UROLOGY, V195, P1126, DOI 10.1016/j.juro.2015.10.128; Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003; Mandelbaum J., 2015, AUTOPHAGY; Mani J, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1239-4; Maycotte P, 2015, MOL CANCER RES, V13, P651, DOI 10.1158/1541-7786.MCR-14-0487; Mizuno E, 2005, MOL BIOL CELL, V16, P5163, DOI 10.1091/mbc.E05-06-0560; Murata A, 2015, ONCOTARGET, V6, P23372, DOI 10.18632/oncotarget.4281; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Nishino M, 2017, J CANCER, V8, P1774, DOI 10.7150/jca.19732; Pastrana E, 2011, CELL STEM CELL, V8, P486, DOI 10.1016/j.stem.2011.04.007; Pei YF, 2016, ONCOTARGET, V7, P31322, DOI 10.18632/oncotarget.8900; Peth A, 2009, MOL CELL, V36, P794, DOI 10.1016/j.molcel.2009.11.015; Popov N, 2007, NAT CELL BIOL, V9, P765, DOI 10.1038/ncb1601; Quail DF, 2012, CURR STEM CELL RES T, V7, P197; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Scudder SL, 2014, J NEUROSCI, V34, P16637, DOI 10.1523/JNEUROSCI.2452-14.2014; Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610; Sjodahl G, 2012, CLIN CANCER RES, V18, P3377, DOI 10.1158/1078-0432.CCR-12-0077-T; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Wang XF, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0208-z; Warrick JI, 2016, SCI REP-UK, V6, DOI 10.1038/srep38531; Whelan KA, 2017, ONCOGENE, V36, P4843, DOI 10.1038/onc.2017.102; Wu YD, 2013, CELL REP, V5, P224, DOI 10.1016/j.celrep.2013.08.030; Yang F, 2014, DNA CELL BIOL, V33, P781, DOI 10.1089/dna.2014.2545; Yi B, 2015, ONCOL REP, V33, P1201, DOI 10.3892/or.2015.3707; Yin XT, 2016, ADV EXP MED BIOL, V945, P275, DOI 10.1007/978-3-319-43624-1_12; Ying L, 2013, MOL BIOSYST, V9, P407, DOI 10.1039/c2mb25386k; Ying QL, 2008, NATURE, V453, P519, DOI 10.1038/nature06968; Yu G, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0115-4; Zavros Y, 2017, CELL MOL GASTROENTER, V4, P55, DOI 10.1016/j.jcmgh.2017.03.003; Zhang D, 2006, CELL, V126, P529, DOI 10.1016/j.cell.2006.06.039; Zhou C, 2017, ONCOGENE, V36, P3878, DOI 10.1038/onc.2017.14; Zhou FF, 2017, EMBO J, V36, P1623, DOI 10.15252/embj.201695372; Zhu JL, 2017, NEOPLASIA, V19, P672, DOI 10.1016/j.neo.2017.06.002; Zhu JL, 2017, MOL THER-NUCL ACIDS, V7, P299, DOI 10.1016/j.omtn.2017.04.012; Zhu JL, 2014, CANCER PREV RES, V7, P1270, DOI 10.1158/1940-6207.CAPR-14-0233	70	25	25	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2019	38	17					3301	3315		10.1038/s41388-018-0664-7	http://dx.doi.org/10.1038/s41388-018-0664-7			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU8RI	30635654	Green Accepted			2022-12-28	WOS:000465557200014
J	Zhang, L; Cheng, FL; Wei, YJ; Zhang, LJ; Guo, DS; Wang, BF; Li, W				Zhang, Lei; Cheng, Fangling; Wei, Yiju; Zhang, Lijun; Guo, Dongsheng; Wang, Baofeng; Li, Wei			Inhibition of TAZ contributes radiation-induced senescence and growth arrest in glioma cells	ONCOGENE			English	Article							IONIZING-RADIATION; GLIOBLASTOMA-MULTIFORME; HIPPO PATHWAY; GENE; EXPRESSION; PROGRESSION; SUBTYPES; THERAPY	Glioblastoma (GBM) is the most aggressive brain tumor and resistant to current available therapeutics, such as radiation. To improve the clinical efficacy, it is important to understand the cellular mechanisms underlying tumor responses to radiation. Here, we investigated long-term cellular responses of human GBM cells to ionizing radiation. Comparing to the initial response within 12 hours, gene expression modulation at 7 days after radiation is markedly different. While genes related to cell cycle arrest and DNA damage responses are mostly modulated at the initial stage; immune-related genes are specifically affected as the long-term effect. This later response is associated with increased cellular senescence and inhibition of transcriptional coactivator with PDZ-binding motif (TAZ). Mechanistically, TAZ inhibition does not depend on the canonical Hippo pathway, but relies on enhanced degradation mediated by the beta-catenin destruction complex in the Wnt pathway. We further showed that depletion of TAZ by RNAi promotes radiation-induced senescence and growth arrest. Pharmacological activation of the beta-catenin destruction complex is able to promote radiation-induced TAZ inhibition and growth arrest in these tumor cells. The correlation between senescence and reduced expression of TAZ as well as beta-catenin also occurs in human gliomas treated by radiation. Collectively, these findings suggested that inhibition of TAZ is involved in radiation-induced senescence and might benefit GBM radiotherapy.	[Zhang, Lei; Wei, Yiju; Li, Wei] Penn State Coll Med, Div Pediat Hematol Oncol, Dept Pediat, Penn State Hlth Hershey Med Ctr, Hershey, PA 17033 USA; [Zhang, Lei] Huazhong Univ Sci & Technol, Hepat Surg Ctr, Tongji Hosp, Tongji Med Coll, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China; [Cheng, Fangling; Guo, Dongsheng; Wang, Baofeng] Huazhong Univ Sci & Technol, Dept Neurosurg, Tongji Hosp, Tongji Med Coll, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China; [Zhang, Lijun] Penn State Coll Med, Inst Personalized Med, Penn State Hlth Hershey Med Ctr, Hershey, PA 17033 USA; [Zhang, Lijun; Li, Wei] Penn State Coll Med, Dept Biochem & Mol Biol, Penn State Hlth Hershey Med Ctr, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Li, W (corresponding author), Penn State Coll Med, Div Pediat Hematol Oncol, Dept Pediat, Penn State Hlth Hershey Med Ctr, Hershey, PA 17033 USA.; Li, W (corresponding author), Penn State Coll Med, Dept Biochem & Mol Biol, Penn State Hlth Hershey Med Ctr, Hershey, PA 17033 USA.	weili@pennstatehealth.psu.edu	Zhang, Lei/AAJ-2148-2020	Zhang, Lei/0000-0002-2227-0613; Li, Wei/0000-0001-5696-4309	National Natural Science Foundation of China [81472364]; National Institutes of Health [K22 5K22CA190440]; American Cancer Society-Institutional Research Grant [124171-IRG-13-043-01]; Four Diamonds Fund for Pediatric Cancer Research; NATIONAL CANCER INSTITUTE [K22CA190440] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society-Institutional Research Grant(American Cancer Society); Four Diamonds Fund for Pediatric Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Brian J. Lorah, Kim Powell, Bryan E. Achey and Steven P. Leibig in the Division of Health Physics, Yuka Imamura Kawasawa in the Institute for Personalized Medicine of Penn State College of Medicine for technical support. We thank Dong Kuang and Yan-Bing Chen in Department of Pathology of Tongji Hospital, Tongji Medical College, HUST for pathologic analysis. This work was supported by the National Natural Science Foundation of China 81472364 (to B.W.), the National Institutes of Health Grant K22 5K22CA190440 (to W.L.), the American Cancer Society-Institutional Research Grant 124171-IRG-13-043-01 (to W.L.), and the Four Diamonds Fund for Pediatric Cancer Research (to W.L.).	Azzolin L, 2012, CELL, V151, P1443, DOI 10.1016/j.cell.2012.11.027; Bassi CL, 2008, HUM EXP TOXICOL, V27, P919, DOI 10.1177/0960327108102045; BERNHARD EJ, 1995, RADIAT ENVIRON BIOPH, V34, P79, DOI 10.1007/BF01275210; Bhat KPL, 2011, GENE DEV, V25, P2594, DOI 10.1101/gad.176800.111; BURGER PC, 1983, J NEUROSURG, V58, P159, DOI 10.3171/jns.1983.58.2.0159; Camphausen KV, 2005, CANCER RES, V65, P10389, DOI 10.1158/0008-5472.CAN-05-1904; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137; Ewald JA, 2010, JNCI-J NATL CANCER I, V102, P1536, DOI 10.1093/jnci/djq364; Godoy PRDV, 2013, MUTAT RES-GEN TOX EN, V756, P46, DOI 10.1016/j.mrgentox.2013.06.010; Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356; Jin HH, 2017, EUR J PHARM SCI, V96, P323, DOI 10.1016/j.ejps.2016.10.002; Jin X, 2017, NAT MED, V23, P1352, DOI 10.1038/nm.4415; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Li W, 2014, CANCER CELL, V26, P48, DOI 10.1016/j.ccr.2014.05.001; Liu CY, 2010, J BIOL CHEM, V285, P37159, DOI 10.1074/jbc.M110.152942; Liu ZJ, 2019, ONCOGENE, V38, P120, DOI 10.1038/s41388-018-0425-7; Lv DG, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01731-w; Ma H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.412; Nardella C, 2011, NAT REV CANCER, V11, P503, DOI 10.1038/nrc3057; Otomo T, 2004, J RADIAT RES, V45, P53, DOI 10.1269/jrr.45.53; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Quick QA, 2006, J NEUROSURG, V105, P111, DOI 10.3171/jns.2006.105.1.111; Schosserer M, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00278; Tihan T, 2006, HUM PATHOL, V37, P272, DOI 10.1016/j.humpath.2005.11.010; Tsai MH, 2007, CANCER RES, V67, P3845, DOI 10.1158/0008-5472.CAN-06-4250; VAN MEIR EG, 1994, CANCER RES, V54, P649; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang J, 2017, J CLIN INVEST, V127, P3075, DOI 10.1172/JCI89092; Wang QH, 2017, CANCER CELL, V32, P42, DOI 10.1016/j.ccell.2017.06.003; Xie Q, 2013, CANCER RES, V73, P3615, DOI 10.1158/0008-5472.CAN-12-3793; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Zamorano L, 1989, Acta Neurochir Suppl (Wien), V46, P90; Zhang LH, 2015, ONCOGENE, V34, P600, DOI 10.1038/onc.2013.593	34	28	28	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2019	38	15					2788	2799		10.1038/s41388-018-0626-0	http://dx.doi.org/10.1038/s41388-018-0626-0			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HS8LQ	30542117	Green Accepted			2022-12-28	WOS:000464121600009
J	Shirai, YT; Mizutani, A; Nishijima, S; Horie, M; Kikuguchi, C; Elisseeva, O; Yamamoto, T				Shirai, Yo-Taro; Mizutani, Anna; Nishijima, Saori; Horie, Masafumi; Kikuguchi, Chisato; Elisseeva, Olga; Yamamoto, Tadashi			CNOT3 targets negative cell cycle regulators in non-small cell lung cancer development	ONCOGENE			English	Article							MESSENGER-RNA DEADENYLATION; KRUPPEL-LIKE FACTOR-2; GENE-EXPRESSION; CCR4-NOT COMPLEX; DNA METHYLATION; ROLES; ADENOCARCINOMA; SUBUNITS; LEVEL	Lung cancer is one of the major causes of cancer death and clarification of its molecular pathology is highly prioritized. The physiological importance of mRNA degradation through the CCR4-NOT deadenylase has recently been highlighted. For example, mutation in CNOT3, a gene coding for CNOT3 subunit of the CCR4-NOT complex, is found to be associated with T-cell acute lymphoblastic leukemia, T-ALL, though its contribution to other cancers has not been reported. Here, we provide evidence suggesting that CNOT3 is required for the growth of non-small cell lung cancer. Depletion of CNOT3 suppresses proliferation of A549 human non-small cell lung cancer cells with enhanced mRNA stability and subsequent elevated expression of p21. In addition, we identified the mRNA for Kruppel-like factor 2 transcription factor, an inducer of p21, as a novel mRNA degradation target of CNOT3 in non-small cell lung cancer cells. Aberrant up-regulation of Kruppel-like factor 2 by CNOT3 depletion leads to impairment in the proliferation of A549 cells. Consistent with these findings, elevated mRNA expression of CNOT3 in non-small cell lung cancer in comparison with the paired normal lung epithelium was confirmed through scrutinization of the RNA-sequencing datasets from The Cancer Genome Atlas. Moreover, we found an inverse correlation between CNOT3 and CDKN1A (encoding p21) mRNA expression using the combined datasets of normal lung epithelium and non-small cell lung cancer. Thus, we propose that the up-regulation of CNOT3 facilitates the development of non-small cell lung cancer through down-regulation of Kruppel-like factor 2 and p21, contrary to tumor suppressive functions of CNOT3 in T-ALL.	[Shirai, Yo-Taro; Nishijima, Saori; Kikuguchi, Chisato; Elisseeva, Olga; Yamamoto, Tadashi] Grad Univ, Okinawa Inst Sci & Technol, Cell Signal Unit, Onna Son, Okinawa, Japan; [Mizutani, Anna] Japanese Fdn Canc Res, Canc Chemotherapy Ctr, Div Mol Biotherapy, Koto Ku, Tokyo, Japan; [Horie, Masafumi] Univ Tokyo, Grad Sch Med, Dept Resp Med, Bunkyo Ku, Tokyo, Japan; [Horie, Masafumi] Univ Tokyo, Div Hlth Serv Promot, Bunkyo Ku, Tokyo, Japan; [Kikuguchi, Chisato; Elisseeva, Olga; Yamamoto, Tadashi] RIKEN Ctr Integrat Sci, Lab Immunogenet, Yokohama, Kanagawa, Japan; [Shirai, Yo-Taro] NCI, Lab Metab, NIH, Bethesda, MD 20892 USA	Okinawa Institute of Science & Technology Graduate University; Japanese Foundation for Cancer Research; University of Tokyo; University of Tokyo; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Shirai, YT; Yamamoto, T (corresponding author), Grad Univ, Okinawa Inst Sci & Technol, Cell Signal Unit, Onna Son, Okinawa, Japan.; Yamamoto, T (corresponding author), RIKEN Ctr Integrat Sci, Lab Immunogenet, Yokohama, Kanagawa, Japan.; Shirai, YT (corresponding author), NCI, Lab Metab, NIH, Bethesda, MD 20892 USA.	yo-taro.shirai@nih.gov; tadashi.yamamoto@oist.jp			OIST; KAKENHI from the Japan Society for the Promotion of Science (JSPS) [21229006, 25121734, 26830066, 16K18437, 24890289, 26893050]	OIST(Okinawa Institute of Science & Technology Graduate University); KAKENHI from the Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The authors would like to thank Dr. Hiroyuki Miyoshi (RIKEN) for lentivirus vector system. The authors also thank all the members of Cell Signal Unit at the Okinawa Institute of Science and Technology Graduate University (OIST) for discussion and advice. This research was supported by subsidiary of OIST and KAKENHI Grants-in-Aid for scientific research (S) (21229006 to TY), for Scientific Research on Innovative Areas (25121734 to TY), for Young Scientists (B) (26830066 to AM and 16K18437 to MH), and for Research Activity Start-up (24890289 to Y-TS and 26893050 to MH) from the Japan Society for the Promotion of Science (JSPS).	Anaya J, 2016, PEERJ COMPUT SCI, DOI 10.7717/peerj-cs.67; Andersson R, 2014, NATURE, V507, P455, DOI 10.1038/nature12787; Aslam A, 2009, MOL BIOL CELL, V20, P3840, DOI 10.1091/mbc.E09-02-0146; Bartlam M, 2010, PROTEIN CELL, V1, P443, DOI 10.1007/s13238-010-0060-8; Campbell JD, 2016, NAT GENET, V48, P607, DOI 10.1038/ng.3564; Castro D, 2017, ONCOTARGET, V8, P81679, DOI 10.18632/oncotarget.20955; Cejas P, 2017, CANCER RES, V77, P766, DOI 10.1158/0008-5472.CAN-16-1346; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; De Keersmaecker K, 2013, NAT GENET, V45, P186, DOI 10.1038/ng.2508; Dela Cruz CS, 2011, CLIN CHEST MED, V32, P605, DOI 10.1016/j.ccm.2011.09.001; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Faraji F, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005820; Faraji F, 2014, GENOME RES, V24, P227, DOI 10.1101/gr.166223.113; Forrest ARR, 2014, NATURE, V507, P462, DOI 10.1038/nature13182; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Goldstrohm AC, 2008, NAT REV MOL CELL BIO, V9, P337, DOI 10.1038/nrm2370; Harris T, 2011, CLIN CANCER RES, V17, P690, DOI 10.1158/1078-0432.CCR-10-1892; Horie M, 2017, MOL CANCER RES, V15, P1354, DOI 10.1158/1541-7786.MCR-17-0191; Horie M, 2016, SCI REP-UK, V6, DOI 10.1038/srep33666; Hoshina N, 2013, NEURON, V78, P839, DOI 10.1016/j.neuron.2013.03.031; Hoshino Y, 2011, J BIOCHEM, V149, P55, DOI 10.1093/jb/mvq114; Hou J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010312; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Inoue T, 2015, J EXP MED, V212, P1465, DOI 10.1084/jem.20150384; Ito K, 2011, PROTEIN CELL, V2, P755, DOI 10.1007/s13238-011-1092-4; Jiang WB, 2017, AM J TRANSL RES, V9, P2024; Kanamori-Katayama M, 2011, GENOME RES, V21, P1150, DOI 10.1101/gr.115469.110; Kawabe S, 2000, ONCOGENE, V19, P5359, DOI 10.1038/sj.onc.1203935; Landi MT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001651; Lau NC, 2009, BIOCHEM J, V422, P443, DOI 10.1042/BJ20090500; Li WG, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13770; Lin SB, 2015, NAT REV CANCER, V15, P321, DOI 10.1038/nrc3932; Mittal S, 2011, MOL BIOL CELL, V22, P748, DOI 10.1091/mbc.E10-11-0898; Morita M, 2007, MOL CELL BIOL, V27, P4980, DOI 10.1128/MCB.02304-06; Morita M, 2011, EMBO J, V30, P4678, DOI 10.1038/emboj.2011.320; Nabel EG, 2002, NAT REV DRUG DISCOV, V1, P587, DOI 10.1038/nrd869; Neely GG, 2010, CELL, V141, P142, DOI 10.1016/j.cell.2010.02.023; Okayama H, 2012, CANCER RES, V72, P100, DOI 10.1158/0008-5472.CAN-11-1403; Petersen I, 2016, J CANCER RES CLIN, V142, P895, DOI 10.1007/s00432-015-2004-4; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Schuster K, 2014, MOL CANCER RES, V12, P912, DOI 10.1158/1541-7786.MCR-13-0620-T; Selamat SA, 2012, GENOME RES, V22, P1197, DOI 10.1101/gr.132662.111; Shirai YT, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00286; Shirai Y, 2011, AM J PATHOL, V179, P2920, DOI 10.1016/j.ajpath.2011.08.022; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Su LJ, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-140; Suzuki T, 2015, SCI REP-UK, V5, DOI 10.1038/srep14779; Takahashi A, 2012, BIOCHEM BIOPH RES CO, V419, P268, DOI 10.1016/j.bbrc.2012.02.007; Tetreault MP, 2013, NAT REV CANCER, V13, P701, DOI 10.1038/nrc3582; Wani MA, 1999, J BIOL CHEM, V274, P21180, DOI 10.1074/jbc.274.30.21180; Watanabe C, 2014, P NATL ACAD SCI USA, V111, P2692, DOI 10.1073/pnas.1316932111; Wehrkamp CJ, 2018, RNA BIOL, V15, P391, DOI 10.1080/15476286.2017.1422471; Winkelmann R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097953; Wu JH, 2004, ONCOGENE, V23, P8088, DOI 10.1038/sj.onc.1207996; Yin L, 2015, TUMOR BIOL, V36, P3075, DOI 10.1007/s13277-014-2943-4; Zheng XF, 2016, STEM CELL REP, V7, P897, DOI 10.1016/j.stemcr.2016.09.007; Zheng XF, 2012, STEM CELLS, V30, P910, DOI 10.1002/stem.1070	59	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2019	38	14					2580	2594		10.1038/s41388-018-0603-7	http://dx.doi.org/10.1038/s41388-018-0603-7			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HR7LI	30531840	Green Submitted			2022-12-28	WOS:000463335200010
J	Gao, LX; Lang, LW; Zhao, XD; Shay, C; Shull, AY; Teng, Y				Gao, Lixia; Lang, Liwei; Zhao, Xiangdong; Shay, Chloe; Shull, Austin Y.; Teng, Yong			FGF19 amplification reveals an oncogenic dependency upon autocrine FGF19/FGFR4 signaling in head and neck squamous cell carcinoma	ONCOGENE			English	Article							GROWTH-FACTOR 19; SKELETAL-MUSCLE MASS; HEPATOCELLULAR-CARCINOMA; CANCER; GENE; EXPRESSION; FGFR4	The fibroblast growth factor 19 gene FGF19 has previously been reported to be amplified in several cancer types and encodes for a key autocrine signaler known to promote tumorigenic growth. Thus, it is imperative to understand which cancers are oncogenically addicted to FGF19 amplification as well as the role it serves in these cancer types. We report for the first time high FGF19 amplification in head and neck squamous cell carcinomas (HNSCC), which is associated with increased autocrine secretion of FGF19 and poor patient outcome in HNSCC. FGF19 amplification corresponded with constitutive activation of FGF receptor 4 (FGFR4)-dependent ERK/AKT-p70S6K-S6 signaling activation in HNSCC cells, and addition of human recombinant FGF19 could promote cell proliferation and soft agar colony formation in HNSCC cells with low FGF19 expression through activation of FGFR4 and downstream signaling cascades. In contrast, FGF19 knockout counteracts the observed effects in HNSCC cells carrying high endogenous FGF19, with knockout of FGF19 significantly suppressing tumor growth in an orthotopic mouse model of HNSCC. Collectively, this study demonstrates that FGF19 gene amplification corresponds with an increased dependency upon FGF19/FGFR4 autocrine signaling in HNSCC, revealing a therapeutic target for this cancer type.	[Gao, Lixia; Lang, Liwei; Zhao, Xiangdong; Teng, Yong] Augusta Univ, Dept Oral Biol & Diagnost Sci, Augusta, GA 30912 USA; [Shay, Chloe] Emory Univ, Emory Childrens Ctr, Atlanta, GA 30322 USA; [Shull, Austin Y.] Presbyterian Coll, Dept Biol, Clinton, SC USA; [Teng, Yong] Augusta Univ, Georgia Canc Ctr, Augusta, GA 30912 USA	University System of Georgia; Augusta University; Emory University; University System of Georgia; Augusta University	Teng, Y (corresponding author), Augusta Univ, Dept Oral Biol & Diagnost Sci, Augusta, GA 30912 USA.; Teng, Y (corresponding author), Augusta Univ, Georgia Canc Ctr, Augusta, GA 30912 USA.	yteng@augusta.edu	Lang, Liwei/I-7744-2019; Teng, Yong/AAK-4160-2020	Teng, Yong/0000-0002-1856-7289; Lang, Liwei/0000-0002-2374-645X	Dental College of Georgia Special Funding Initiative; Department of Defense [W81XWH-14-1-0412]	Dental College of Georgia Special Funding Initiative; Department of Defense(United States Department of Defense)	This work was supported in part by Dental College of Georgia Special Funding Initiative and a grant from the Department of Defense (W81XWH-14-1-0412) (to Y.T.). The authors sincerely thank Dr. Andrew W. Yeudall (Augusta University) for providing HNSCC cells for this study.	Ahn SM, 2014, HEPATOLOGY, V60, P1972, DOI 10.1002/hep.27198; Angelin B, 2012, CELL METAB, V16, P693, DOI 10.1016/j.cmet.2012.11.001; Benoit B, 2017, NAT MED, V23, P990, DOI 10.1038/nm.4363; CARDINALI M, 1995, INT J CANCER, V61, P98, DOI 10.1002/ijc.2910610117; Chi AC, 2015, CA-CANCER J CLIN, V65, P401, DOI 10.3322/caac.21293; de Mello RA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086697; Gao LX, 2018, CELL ONCOL, V41, P85, DOI 10.1007/s13402-017-0354-4; Gao LX, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-016-0478-9; Gibcus JH, 2007, CLIN CANCER RES, V13, P6257, DOI 10.1158/1078-0432.CCR-07-1247; Glass DJ, 2017, CELL METAB, V26, P287, DOI 10.1016/j.cmet.2017.07.017; Hagel M, 2015, CANCER DISCOV, V5, P424, DOI 10.1158/2159-8290.CD-14-1029; Katoh M, 2003, INT J MOL MED, V12, P45; Kir S, 2011, SCIENCE, V331, P1621, DOI 10.1126/science.1198363; Lang LW, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0623-3; Lang LW, 2019, CURR CANCER DRUG TAR, V19, P17, DOI 10.2174/1568009618666180319091731; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; Mandic A, 2003, J BIOL CHEM, V278, P9100, DOI 10.1074/jbc.M210284200; Marcelin G, 2014, MOL METAB, V3, P19, DOI 10.1016/j.molmet.2013.10.002; Morrison C, 2006, J CLIN ONCOL, V24, P2376, DOI 10.1200/JCO.2005.03.4827; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Sawey ET, 2011, CANCER CELL, V19, P347, DOI 10.1016/j.ccr.2011.01.040; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; Schwab M, 1999, ONCOGENE AMPLIFICATI, P319; Song KH, 2009, HEPATOLOGY, V49, P297, DOI 10.1002/hep.22627; Teng Y, 2010, BRIT J CANCER, V103, P1066, DOI 10.1038/sj.bjc.6605850; Teng Y, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0485-0; Tiong KH, 2016, ONCOTARGET, V7, P57633, DOI 10.18632/oncotarget.9328; Wan ZY, 2016, HEPATOLOGY, V64, P1289, DOI 10.1002/hep.28639; Xie XY, 2016, ONCOTARGET, V7, P58111, DOI 10.18632/oncotarget.11185; YEUDALL WA, 1994, CARCINOGENESIS, V15, P2683, DOI 10.1093/carcin/15.12.2683; Zhao HK, 2016, ONCOTARGET, V7, P13575, DOI 10.18632/oncotarget.6185; Zhao XD, 2018, MOL CARCINOGEN, V57, P1616, DOI 10.1002/mc.22884; Zhou M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15433	34	39	42	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2019	38	13					2394	2404		10.1038/s41388-018-0591-7	http://dx.doi.org/10.1038/s41388-018-0591-7			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ7GN	30518874				2022-12-28	WOS:000462588000012
J	Lu, X; Liu, R; Wang, MN; Kumar, AK; Pan, FY; He, LF; Hu, ZG; Guo, ZG				Lu, Xiao; Liu, Rui; Wang, Meina; Kumar, Alagamuthu Karthick; Pan, Feiyan; He, Lingfeng; Hu, Zhigang; Guo, Zhigang			MicroRNA-140 impedes DNA repair by targeting FEN1 and enhances chemotherapeutic response in breast cancer	ONCOGENE			English	Article							BASE EXCISION-REPAIR; YIN YANG 1; DAMAGE RESPONSE; FACTOR YY1; RESISTANCE; INVASION; MIR-140; EXPRESSION; MECHANISM; NUCLEASE	An increased DNA repair capacity is associated with drug resistance and limits the efficacy of chemotherapy in breast cancers. Flap endonuclease 1 (FEN1) participates in various DNA repair pathways and contributes to cancer progression and drug resistance in chemotherapy. Inhibition of FEN1 serves as a potent strategy for cancer therapy. Here, we demonstrate that microRNA-140 (miR-140) inhibits FEN1 expression via directly binding to its 3 ' untranslated region, leading to impaired DNA repair and repressed breast cancer progression. Overexpression of miR-140 sensitizes breast cancer cells to chemotherapeutic agents and overcomes drug resistance in breast cancer. Notably, ectopic expression of FEN1 abates the effects of miR-140 on DNA damage and the chemotherapy response in breast cancer cells. Furthermore, the transcription factor/repressor Ying Yang 1 (YY1) directly binds to the miR-140 promoter and activates miR-140 expression, which is attenuated in doxorubicin resistance. Our results demonstrate that miR-140 acts as a tumor suppressor in breast cancer by inhibiting FEN1 to repress DNA damage repair and reveal miR-140 to be a new anti-tumorigenesis factor for adjunctive breast cancer therapy. This novel mechanism will enhance the treatment effect of chemotherapy in breast cancer.	[Lu, Xiao; Liu, Rui; Wang, Meina; Kumar, Alagamuthu Karthick; Pan, Feiyan; He, Lingfeng; Hu, Zhigang; Guo, Zhigang] Nanjing Normal Univ, Jiangsu Key Lab Mol & Med Biotechnol, Coll Life Sci, 1 WenYuan Rd, Nanjing 210023, Jiangsu, Peoples R China	Nanjing Normal University	Hu, ZG; Guo, ZG (corresponding author), Nanjing Normal Univ, Jiangsu Key Lab Mol & Med Biotechnol, Coll Life Sci, 1 WenYuan Rd, Nanjing 210023, Jiangsu, Peoples R China.	huzg_2000@126.com; guo@njnu.edu.cn	kumar, Alagamuthu Karthick/X-4468-2019	He, Lingfeng/0000-0002-9668-419X	National Natural Science Foundation of China [81872284, 31400659, 31701179]; China Postdoctoral Science Foundation [2016M591877]; Priority Academic Program Development of Jiangsu Higher Education Institutions	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Priority Academic Program Development of Jiangsu Higher Education Institutions	This work was supported by the National Natural Science Foundation of China (81872284, 31400659, and 31701179), China Postdoctoral Science Foundation (2016M591877), and the Priority Academic Program Development of Jiangsu Higher Education Institutions.	Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005; Balakrishnan L, 2013, ANNU REV BIOCHEM, V82, P119, DOI 10.1146/annurev-biochem-072511-122603; Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Castellano G, 2009, CELL CYCLE, V8, P1367, DOI 10.4161/cc.8.9.8314; Deng Z, 2009, ONCOGENE, V28, P3746, DOI 10.1038/onc.2009.231; di Fagagna FD, 2014, TRENDS CELL BIOL, V24, P171, DOI 10.1016/j.tcb.2013.09.008; Farre D, 2003, NUCLEIC ACIDS RES, V31, P3651, DOI 10.1093/nar/gkg605; Frasor J, 2006, CANCER RES, V66, P7334, DOI 10.1158/0008-5472.CAN-05-4269; Gordon S, 2006, ONCOGENE, V25, P1125, DOI 10.1038/sj.onc.1209080; Guo ZG, 2012, MOL CELL, V47, P444, DOI 10.1016/j.molcel.2012.05.042; He LF, 2018, DNA REPAIR, V63, P1, DOI 10.1016/j.dnarep.2018.01.003; He LF, 2017, MOL ONCOL, V11, P640, DOI 10.1002/1878-0261.12058; He LF, 2016, EBIOMEDICINE, V14, P32, DOI 10.1016/j.ebiom.2016.11.012; Hu HL, 2011, J MOL CELL BIOL, V3, P151, DOI 10.1093/jmcb/mjq042; Hu ZG, 2017, J MOL ENDOCRINOL, V59, P269, DOI 10.1530/JME-17-0011; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Kai Y, 2014, BIOCHEM BIOPH RES CO, V448, P308, DOI 10.1016/j.bbrc.2014.02.032; Kato M, 2009, ONCOGENE, V28, P3008, DOI 10.1038/onc.2009.218; Krishnan K, 2013, RNA, V19, P230, DOI 10.1261/rna.034926.112; Lee JH, 2015, CANCER RES, V75, P1298, DOI 10.1158/0008-5472.CAN-14-2783; Li Q, 2014, ONCOGENE, V33, P2589, DOI 10.1038/onc.2013.226; Liu L, 2012, CARCINOGENESIS, V33, P119, DOI 10.1093/carcin/bgr250; Lu Y, 2017, CANCER GENE THER, V24, P386, DOI 10.1038/cgt.2017.30; O'Connor MJ, 2015, MOL CELL, V60, P547, DOI 10.1016/j.molcel.2015.10.040; Ramos P, 2015, ONCOGENE, V34, P3617, DOI 10.1038/onc.2014.314; Rebucci M, 2013, BIOCHEM PHARMACOL, V85, P1219, DOI 10.1016/j.bcp.2013.02.017; Senkevich TG, 2009, P NATL ACAD SCI USA, V106, P17921, DOI 10.1073/pnas.0909529106; Singh P, 2008, MOL CANCER RES, V6, P1710, DOI 10.1158/1541-7786.MCR-08-0269; Song B, 2009, ONCOGENE, V28, P4065, DOI 10.1038/onc.2009.274; Sun H, 2017, ONCOGENE, V36, P194, DOI 10.1038/onc.2016.188; Tubbs A, 2017, CELL, V168, DOI 10.1016/j.cell.2017.01.002; Valeri N, 2010, P NATL ACAD SCI USA, V107, P21098, DOI 10.1073/pnas.1015541107; Wang CC, 2005, ONCOGENE, V24, P4081, DOI 10.1038/sj.onc.1208573; Wang JW, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1043-1; Wang MN, 2018, GENE, V668, P196, DOI 10.1016/j.gene.2018.05.072; Wu XT, 1999, P NATL ACAD SCI USA, V96, P1303, DOI 10.1073/pnas.96.4.1303; Xie QH, 2011, BIOCHEM BIOPH RES CO, V410, P440, DOI 10.1016/j.bbrc.2011.05.153; Yang H, 2013, HEPATOLOGY, V58, P205, DOI 10.1002/hep.26315; Yang M, 2009, HUM MUTAT, V30, P1320, DOI 10.1002/humu.21060; Yoon JH, 1999, BIOCHEMISTRY-US, V38, P4809, DOI 10.1021/bi990105i; Yuan YF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073604; Zhang YS, 2012, J BIOL CHEM, V287, P41514, DOI 10.1074/jbc.M112.404871; Zheng L, 2011, NUCLEIC ACIDS RES, V39, P781, DOI 10.1093/nar/gkq884; Zhou T, 2016, ONCOTARGET, V7, P6902, DOI 10.18632/oncotarget.6849	45	43	43	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	1					234	247		10.1038/s41388-019-0986-0	http://dx.doi.org/10.1038/s41388-019-0986-0			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG3NM	31471584				2022-12-28	WOS:000509849200016
J	Verrico, A; Rovella, P; Di Francesco, L; Damizia, M; Staid, DS; Le Pera, L; Schinina, ME; Lavia, P				Verrico, Annalisa; Rovella, Paola; Di Francesco, Laura; Damizia, Michela; Staid, David Sasah; Le Pera, Loredana; Schinina, M. Eugenia; Lavia, Patrizia			Importin-beta/karyopherin-beta 1 modulates mitotic microtubule function and taxane sensitivity in cancer cells via its nucleoporin-binding region	ONCOGENE			English	Article							IMPORT RECEPTOR KPN-BETA-1; SPINDLE ASSEMBLY FACTORS; UP-REGULATION; AURORA-A; HURP; BETA; PROLIFERATION; INHIBITOR; TRANSPORT; PROTEIN	The nuclear transport receptor importin-beta/karyopherin-beta 1 is overexpressed in cancers that display genomic instability. It is regarded as a promising cancer target and inhibitors are being developed. In addition to its role in nucleo-cytoplasmic transport, importin-beta regulates mitosis, but the programmes and pathways in which it operates are defined only in part. To unravel importin-beta's mitotic functions we have developed cell lines expressing either wild-type or a mutant importin-beta form in characterised residues required for nucleoporin binding. Both forms similarly disrupted spindle pole organisation, while only wild-type importin-beta affected microtubule plus-end function and microtubule stability. A proteome-wide search for differential interactors identified a set of spindle regulators sensitive to mutations in the nucleoporin-binding region. Among those, HURP (hepatoma up-regulated protein) is an importin-beta interactor and a microtubule-stabilising factor. We found that induction of wild type, but not mutant importin-beta, under the same conditions that destabilise mitotic microtubules, delocalised HURP, indicating that the spatial distribution of HURP along the spindle requires importin-beta's nucleoporin-binding residues. Concomitantly, importin-beta overexpression sensitises cells to taxanes and synergistically increases mitotic cell death. Thus, the nucleoporin-binding domain is dispensable for importin-beta function in spindle pole organisation, but regulates microtubule stability, at least in part via HURP, and renders cells vulnerable to certain microtubule-targeting drugs.	[Verrico, Annalisa; Rovella, Paola; Damizia, Michela; Staid, David Sasah; Le Pera, Loredana; Lavia, Patrizia] CNR, Inst Mol Biol & Pathol IBPM, I-00185 Rome, Italy; [Di Francesco, Laura; Staid, David Sasah; Schinina, M. Eugenia] Sapienza Univ Rome, Dept Biochem Sci Alessandro Rossi Fanelli, I-00185 Rome, Italy; [Damizia, Michela; Lavia, Patrizia] Sapienza Univ Rome, Dept Biol & Biotechnol Charles Darwin, I-00185 Rome, Italy; [Le Pera, Loredana] CNR, Inst Biomembranes Bioenerget & Mol Biotechnol IBI, I-70126 Bari, Italy; [Verrico, Annalisa] Univ Paris Diderot, Sorbonne Paris Cite, CNRS, Inst Jacques Monod,UMR7592, F-75205 Paris, France	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite	Lavia, P (corresponding author), CNR, Inst Mol Biol & Pathol IBPM, I-00185 Rome, Italy.; Lavia, P (corresponding author), Sapienza Univ Rome, Dept Biol & Biotechnol Charles Darwin, I-00185 Rome, Italy.	patrizia.lavia@uniroma1.it	Le Pera, Loredana/ABD-3398-2020; Lavia, Patrizia/AAL-3982-2021	Le Pera, Loredana/0000-0002-0076-9878; Lavia, Patrizia/0000-0003-3310-6701; VERRICO, ANNALISA/0000-0002-1458-2545	AIRC (Associazione Italiana per la Ricerca sul Cancro) [IG14534]; CNR Flagship programme InterOmics (project SYNLETHER); MIUR	AIRC (Associazione Italiana per la Ricerca sul Cancro)(Fondazione AIRC per la ricerca sul cancro); CNR Flagship programme InterOmics (project SYNLETHER); MIUR(Ministry of Education, Universities and Research (MIUR))	This work was supported by grants from AIRC (Associazione Italiana per la Ricerca sul Cancro IG14534) and the CNR Flagship programme InterOmics (project SYNLETHER). MD was supported by a PhD fellowship from MIUR. We are grateful to our colleagues Alessandro Rosa (Department of Biology and Biotechnology, University La Sapienza, Rome) for the design and engineering of inducible expression vectors, to Enrico Cundari and Daniela Trisciuoglio (IBPM-CNR, Rome) for help with FACS experiments, to Maria Giubettini (Joint Lab CrestOptics/IIT CLNS@Sapienza, Rome) for contributing to early stages of this work, and to Veronica Morea and Andrea Ilari (IBPM-CNR and Biocrystal Facility, Rome) for insightful discussions and suggestions. We wish to dedicate this paper to our late Director and founder, Prof. Emilia Chiancone.	Bayliss R, 2000, CELL, V102, P99, DOI 10.1016/S0092-8674(00)00014-3; Bayliss R, 2002, J BIOL CHEM, V277, P50597, DOI 10.1074/jbc.M209037200; Cagatay T, 2018, CURR OPIN CELL BIOL, V52, P30, DOI 10.1016/j.ceb.2018.01.006; Christie M, 2016, J MOL BIOL, V428, P2060, DOI 10.1016/j.jmb.2015.10.023; Ciciarello M, 2004, J CELL SCI, V117, P6511, DOI 10.1242/jcs.01569; Di Cesare E, 2017, ONCOTARGET, V8, P19738, DOI 10.18632/oncotarget.14980; Di Francesco L, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19351-9; Eifler K, 2015, TRENDS BIOCHEM SCI, V40, P779, DOI 10.1016/j.tibs.2015.09.006; Forbes DJ, 2015, CURR OPIN CELL BIOL, V35, P78, DOI 10.1016/j.ceb.2015.04.012; Forwood JK, 2010, STRUCTURE, V18, P1171, DOI 10.1016/j.str.2010.06.015; Gilistro E, 2017, J CELL SCI, V130, P2564, DOI 10.1242/jcs.197905; Gorlich D, 2003, EMBO J, V22, P1088, DOI 10.1093/emboj/cdg113; Ha S, 2017, ANTICANCER RES, V37, P2373, DOI 10.21873/anticanres.11575; Haschka MD, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7891; He S, 2016, J CANCER RES CLIN, V142, P561, DOI 10.1007/s00432-015-2057-4; Hezwani M, 2017, SEMIN CELL DEV BIOL, V68, P2, DOI 10.1016/j.semcdb.2017.05.004; Jiang H, 2015, J CELL BIOL, V211, P7, DOI 10.1083/jcb.201503122; Joseph J, 2004, CURR BIOL, V14, P611, DOI 10.1016/j.cub.2004.03.031; Kimura M, 2017, ELIFE, V6, DOI 10.7554/eLife.21184; Kimura M, 2013, J BIOL CHEM, V288, P24540, DOI 10.1074/jbc.M113.489286; Koffa MD, 2006, CURR BIOL, V16, P743, DOI 10.1016/j.cub.2006.03.056; Kosyna FK, 2015, BIOL CHEM, V396, P1357, DOI 10.1515/hsz-2015-0171; Kuo TC, 2011, BIOCHEM PHARMACOL, V82, P184, DOI 10.1016/j.bcp.2011.04.008; Lavia P, 2016, CHROMOSOME RES, V24, P53, DOI 10.1007/s10577-015-9514-4; Lee MS, 2009, BBA-MOL CELL RES, V1793, P1571, DOI 10.1016/j.bbamcr.2009.07.005; Linder MI, 2017, DEV CELL, V43, P141, DOI 10.1016/j.devcel.2017.08.020; Lu T, 2016, BIOCHEM BIOPH RES CO, V478, P1189, DOI 10.1016/j.bbrc.2016.08.093; Martens-de Kemp SR, 2013, CLIN CANCER RES, V19, P1994, DOI 10.1158/1078-0432.CCR-12-2539; Ritterhoff T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11482; Rosa A, 2014, DEV BIOL, V391, P81, DOI 10.1016/j.ydbio.2014.03.020; Roscioli E, 2012, J CELL BIOL, V196, P435, DOI 10.1083/jcb.201109104; Santarella RA, 2007, J MOL BIOL, V365, P1587, DOI 10.1016/j.jmb.2006.10.064; Schmitz MHA, 2010, NAT CELL BIOL, V12, P886, DOI 10.1038/ncb2092; Sillje HHW, 2006, CURR BIOL, V16, P731, DOI 10.1016/j.cub.2006.02.070; Sloss O, 2016, ONCOTARGET, V7, P5176, DOI 10.18632/oncotarget.6894; Smith AE, 2002, SCIENCE, V295, P488, DOI 10.1126/science.1064732; Soderholm JF, 2011, ACS CHEM BIOL, V6, P700, DOI 10.1021/cb2000296; Song L, 2010, MOL CELL, V38, P369, DOI 10.1016/j.molcel.2010.02.038; Stelma T, 2016, IUBMB LIFE, V68, P268, DOI 10.1002/iub.1484; Tedeschi A, 2007, J CELL SCI, V120, P3748, DOI 10.1242/jcs.009308; Tsou AP, 2003, ONCOGENE, V22, P298, DOI 10.1038/sj.onc.1206129; van der Watt PJ, 2016, MOL CANCER THER, V15, P560, DOI 10.1158/1535-7163.MCT-15-0052; van der Watt PJ, 2013, CRIT REV EUKAR GENE, V23, P1; van der Watt PJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027723; Van der Watt PJ, 2009, INT J CANCER, V124, P1829, DOI 10.1002/ijc.24146; Wang CX, 2017, BIOCHEM BIOPH RES CO, V493, P1555, DOI 10.1016/j.bbrc.2017.10.016; Wong J, 2008, MOL BIOL CELL, V19, P2083, DOI 10.1091/mbc.E07-10-1088; Wong J, 2006, J CELL BIOL, V173, P879, DOI 10.1083/jcb.200511132; Wu JM, 2013, P NATL ACAD SCI USA, V110, pE1779, DOI 10.1073/pnas.1220523110; Yan WQ, 2015, CELL SIGNAL, V27, P851, DOI 10.1016/j.cellsig.2015.01.013; Yang J, 2019, ONCOGENE, V38, P4700, DOI 10.1038/s41388-019-0745-2; Yang LL, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0559-1; Yu CTR, 2005, MOL CELL BIOL, V25, P5789, DOI 10.1128/MCB.25.14.5789-5800.2005; Zhu J, 2016, TUMOR BIOL, V37, P661, DOI 10.1007/s13277-015-3839-7	54	3	4	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	2					454	468		10.1038/s41388-019-0989-x	http://dx.doi.org/10.1038/s41388-019-0989-x			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KD3JY	31492900				2022-12-28	WOS:000507766400015
J	Cook, LM; Frieling, JS; Nerlakanti, N; McGuire, JJ; Stewart, PA; Burger, KL; Cleveland, JL; Lynch, CC				Cook, Leah M.; Frieling, Jeremy S.; Nerlakanti, Niveditha; McGuire, Jeremy J.; Stewart, Paul A.; Burger, Karen L.; Cleveland, John L.; Lynch, Conor C.			Betaglycan drives the mesenchymal stromal cell osteogenic program and prostate cancer-induced osteogenesis	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; TGF-BETA; STEM-CELLS; BONE METASTASES; RECEPTOR; WNT5A; EXPRESSION; DIFFERENTIATION; INHIBITION; MIGRATION	Bone metastatic prostate cancer provokes extensive osteogenesis by driving the recruitment and osteoblastic differentiation of mesenchymal stromal cells (MSCs). The resulting lesions greatly contribute to patient morbidity and mortality, underscoring the need for defining how prostate metastases subvert the MSC-osteoblast differentiation program. To gain insights into this process we profiled the effects of co-culture of primary MSCs with validated bone metastatic prostate cancer cell line models. These analyses revealed a cast of shared differentially induced genes in MSC, including betaglycan, a co-receptor for TGF beta. Betaglycan has not been studied in the context of bone metastatic disease previously. Here we report that loss of betaglycan in MSC is sufficient to augment TGF beta signaling, proliferation and migration, and completely blocks the MSC-osteoblast differentiation program. Further, betaglycan was revealed as necessary for prostate cancer-induced osteogenesis in vivo. Mechanistically, gene expression analysis revealed betaglycan controls the expression of a large repertoire of genes in MSCs, and that betaglycan loss provokes >60-fold increase in the expression of Wnt5a that plays important roles in stemness. In accord with the increased Wnt5a levels, there was a marked induction of canonical Wnt signaling in betaglycan ablated MSCs, and the addition of recombinant Wnt5a to MSCs was sufficient to impair osteogenic differentiation. Finally, the addition of Wnt5a neutralizing antibody was sufficient to induce the expression of osteogenic genes in betaglycan-ablated MSCs. Collectively, these findings suggest a betaglycan-Wnt5a circuit represents an attractive vulnerability to ameliorate prostate cancer-induced osteogenesis.	[Cook, Leah M.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA; [Frieling, Jeremy S.; Nerlakanti, Niveditha; McGuire, Jeremy J.; Burger, Karen L.; Cleveland, John L.; Lynch, Conor C.] H Lee Moffitt Canc Ctr & Res Inst, Tumor Biol Dept, Tampa, FL 33612 USA; [Nerlakanti, Niveditha; McGuire, Jeremy J.] Univ S Florida, Canc Biol PhD Program, Tampa, FL USA; [Stewart, Paul A.] H Lee Moffitt Canc Ctr & Res Inst, Biostat & Bioinformat Shared Resource, Tampa, FL USA	University of Nebraska System; University of Nebraska Medical Center; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute	Lynch, CC (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Tumor Biol Dept, Tampa, FL 33612 USA.	conor.lynch@moffitt.org	Cook, Leah/AAV-9640-2021; Nerlakanti, Niveditha/X-5741-2019	Cook, Leah/0000-0002-9996-7419; Nerlakanti, Niveditha/0000-0001-8808-2220; Frieling, Jeremy/0000-0002-2181-1836; Stewart, Paul/0000-0003-0882-308X; Burger, Karen/0000-0002-3805-9580	American Cancer Society [PF-13-175-01-CSM]; Biostatistics and Bioinformatics Shared Resource at the H. Lee Moffitt Cancer Center & Research Institute, an NCI designated Comprehensive Cancer Center [P30-CA076292]; Miles for Moffitt; Department of Defense PCRP program [W81XWH1810523]; Cortner-Couch Endowed Chair for Cancer Research from the University of South Florida; Molecular Genomics Core; Analytic Microscopy Core; Small Animal Imaging Laboratory Core; NATIONAL CANCER INSTITUTE [P30CA076292, P50CA097186] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); Biostatistics and Bioinformatics Shared Resource at the H. Lee Moffitt Cancer Center & Research Institute, an NCI designated Comprehensive Cancer Center; Miles for Moffitt; Department of Defense PCRP program(United States Department of Defense); Cortner-Couch Endowed Chair for Cancer Research from the University of South Florida; Molecular Genomics Core; Analytic Microscopy Core; Small Animal Imaging Laboratory Core; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr. Colm Morrissey, University of Washington for providing human bone metastatic prostate cancer specimens (P50-CA097186 16A1). LMC was supported by a fellowship from the American Cancer Society (PF-13-175-01-CSM). This work has been supported in part by the Molecular Genomics Core, the Analytic Microscopy Core, the Small Animal Imaging Laboratory Core and the Biostatistics and Bioinformatics Shared Resource at the H. Lee Moffitt Cancer Center & Research Institute, an NCI designated Comprehensive Cancer Center (P30-CA076292). Funding also provided by Miles for Moffitt (CCL), the Department of Defense PCRP program (W81XWH1810523; CCL), and by the Cortner-Couch Endowed Chair for Cancer Research from the University of South Florida (JLC).	Araujo A, 2014, CANCER RES, V74, P2391, DOI 10.1158/0008-5472.CAN-13-2652; Balooch G, 2005, P NATL ACAD SCI USA, V102, P18813, DOI 10.1073/pnas.0507417102; Bauer M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080526; Belotti D, 2016, MATRIX BIOL, V55, P106, DOI 10.1016/j.matbio.2016.03.003; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Bilandzic M, 2011, MOL CELL ENDOCRINOL, V339, P180, DOI 10.1016/j.mce.2011.04.014; Biswas S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027090; Bragado P, 2013, NAT CELL BIOL, V15, P1351, DOI 10.1038/ncb2861; Canesin G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184418; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; Cook LM, 2016, SCI REP-UK, V6, DOI 10.1038/srep29384; Cook LM, 2014, CANCER METAST REV, V33, P511, DOI 10.1007/s10555-014-9494-4; Crane JL, 2014, J CLIN INVEST, V124, P466, DOI 10.1172/JCI70050; Dai JL, 2014, CLIN CANCER RES, V20, P617, DOI 10.1158/1078-0432.CCR-13-0839; Dong M, 2007, J CLIN INVEST, V117, P206, DOI 10.1172/JCI29293; Edwards JR, 2010, J BONE MINER RES, V25, P2419, DOI 10.1002/jbmr.139; Eickelberg O, 2002, J BIOL CHEM, V277, P823, DOI 10.1074/jbc.M105110200; Erlebacher A, 1996, J CELL BIOL, V132, P195, DOI 10.1083/jcb.132.1.195; Fournier PGJ, 2010, BONE, V47, pS268, DOI 10.1016/j.bone.2010.01.332; Fournier PGJ, 2015, CANCER CELL, V27, P809, DOI 10.1016/j.ccell.2015.04.009; Frieling JS, 2015, CANCER CONTROL, V22, P109, DOI 10.1177/107327481502200114; Gebken J, 1999, J ENDOCRINOL, V161, P503, DOI 10.1677/joe.0.1610503; Guise TA, 2003, CLIN ORTHOP RELAT R, pS32, DOI 10.1097/01.blo.0000093055.96273.69; Hasegawa D, 2018, J CELL PHYSIOL, V233, P1752, DOI 10.1002/jcp.26086; Hill CR, 2015, DEV DYNAM, V244, P122, DOI 10.1002/dvdy.24225; Hodgkinson CP, 2013, STEM CELLS, V31, P1669, DOI 10.1002/stem.1416; Huang S, 2015, J ORTHOP TRANSL, V3, P26, DOI 10.1016/j.jot.2014.07.005; Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004-0001; Jenkins LM, 2016, J BIOL CHEM, V291, P25716, DOI 10.1074/jbc.M116.748624; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Katoh M, 2017, INT J ONCOL, V51, P1357, DOI 10.3892/ijo.2017.4129; Korpal M, 2010, EUR J CANCER, V46, P1232, DOI 10.1016/j.ejca.2010.02.040; Korpal M, 2009, NAT MED, V15, P960, DOI 10.1038/nm.1943; Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551; Kumawat K, 2013, FASEB J, V27, P1631, DOI 10.1096/fj.12-217539; Lee GT, 2018, BRIT J CANCER, V118, P670, DOI 10.1038/bjc.2017.451; Logothetis C, 2018, CANCER METAST REV, V37, P189, DOI 10.1007/s10555-017-9719-4; Lopez-Casillas F, 2003, J BIOL CHEM, V278, P382, DOI 10.1074/jbc.M208520200; Luo K, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022137; Miyamoto DT, 2015, SCIENCE, V349, P1351, DOI 10.1126/science.aab0917; Mohammad KS, 2011, CANCER RES, V71, P175, DOI 10.1158/0008-5472.CAN-10-2651; Mythreye K, 2009, P NATL ACAD SCI USA, V106, P8221, DOI 10.1073/pnas.0812879106; Nishida J, 2018, ONCOGENE, V37, P2197, DOI 10.1038/s41388-017-0084-0; OHTSUKI M, 1992, MOL CELL BIOL, V12, P261, DOI 10.1128/MCB.12.1.261; Olivares-Navarrete R, 2011, ACTA BIOMATER, V7, P2740, DOI 10.1016/j.actbio.2011.02.030; Ren D, 2019, J EXP MED, V216, P428, DOI 10.1084/jem.20180661; Ren GW, 2015, J MOL MED, V93, P1203, DOI 10.1007/s00109-015-1329-4; Roarty K, 2007, DEVELOPMENT, V134, P3929, DOI 10.1242/dev.008250; Sakaki-Yumoto M, 2013, BBA-GEN SUBJECTS, V1830, P2280, DOI 10.1016/j.bbagen.2012.08.008; Sanford LP, 1997, DEVELOPMENT, V124, P2659; Serra R, 2011, J MAMMARY GLAND BIOL, V16, P157, DOI 10.1007/s10911-011-9205-5; Shinojima N, 2013, CANCER RES, V73, P2333, DOI 10.1158/0008-5472.CAN-12-3086; Stenvers KL, 2003, MOL CELL BIOL, V23, P4371, DOI 10.1128/MCB.23.12.4371-4385.2003; Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979; Thiele Stefanie, 2018, Oncotarget, V9, P27293, DOI 10.18632/oncotarget.25551; Thiele S, 2016, J BONE MINER RES, V31, P1488, DOI 10.1002/jbmr.2899; Thiele S, 2015, J BONE MINER RES, V30, P488, DOI 10.1002/jbmr.2362; Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403; Todorovic N, 2011, BIOMARK MED, V5, P855, DOI [10.2217/BMM.11.59, 10.2217/bmm.11.59]; Turley RS, 2007, CANCER RES, V67, P1090, DOI 10.1158/0008-5472.CAN-06-3117; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; Warrington JA, 2000, PHYSIOL GENOMICS, V2, P143, DOI 10.1152/physiolgenomics.2000.2.3.143; Watabe T, 2009, CELL RES, V19, P103, DOI 10.1038/cr.2008.323; WU HC, 1994, INT J CANCER, V57, P406, DOI 10.1002/ijc.2910570319; Zhang SJ, 2016, EUR REV MED PHARMACO, V20, P899	65	12	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2019	38	44					6959	6969		10.1038/s41388-019-0913-4	http://dx.doi.org/10.1038/s41388-019-0913-4			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ1AO	31409900	Green Accepted			2022-12-28	WOS:000493892900001
J	Li, MY; Peng, WH; Wu, CH; Chang, YM; Lin, YL; Chang, GD; Wu, HC; Chen, GC				Li, Meng-Yen; Peng, Wen-Hsin; Wu, Chien-Hsun; Chang, Ya-Min; Lin, Yu-Ling; Chang, Geen-Dong; Wu, Han-Chung; Chen, Guang-Chao			PTPN3 suppresses lung cancer cell invasiveness by counteracting Src-mediated DAAM1 activation and actin polymerization	ONCOGENE			English	Article							PROTEIN-TYROSINE PHOSPHATASES; FAMILY KINASES; MIGRATION; INVASION; ADHESION; METASTASIS; GROWTH; MORPHOGENESIS; PROLIFERATION; EXPRESSION	Cancer cell migration plays a crucial role during the metastatic process. Reversible tyrosine phosphorylation by protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs) have been implicated in the regulation of cancer cell migration and invasion. However, the underlying mechanisms have not been fully elucidated. Here, we show that depletion of the FERM and PDZ domain-containing protein tyrosine phosphatase PTPN3 enhances lung cancer cell migration/invasion and metastasis by promoting actin filament assembly and focal adhesion dynamics. We further identified Src and DAAM1 (dishevelled associated activator of morphogenesis 1) as interactors of PTPN3. DAAM1 is a formin-like protein involved in the regulation of actin cytoskeletal remodeling. PTPN3 inhibits Src activity and Src-mediated phosphorylation of Tyr652 on DAAM1. The tyrosine phosphorylation of DAAM1 is essential for DAAM1 homodimer formation and actin polymerization. Ectopic expression of a DAAM1 phosphodeficient mutant inhibited F-actin assembly and suppressed lung cancer cell migration and invasion. Our findings reveal a novel mechanism by which reversible tyrosine phosphorylation of DAAM1 by Src and PTPN3 regulates actin dynamics and lung cancer invasiveness.	[Li, Meng-Yen; Peng, Wen-Hsin; Lin, Yu-Ling; Chen, Guang-Chao] Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; [Chang, Ya-Min; Chang, Geen-Dong; Chen, Guang-Chao] Natl Taiwan Univ, Coll Life Sci, Inst Biochem Sci, Taipei 106, Taiwan; [Wu, Chien-Hsun; Wu, Han-Chung] Acad Sinica, Inst Cellular & Organism Biol, Taipei 115, Taiwan	Academia Sinica - Taiwan; National Taiwan University; Academia Sinica - Taiwan	Chen, GC (corresponding author), Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan.; Chen, GC (corresponding author), Natl Taiwan Univ, Coll Life Sci, Inst Biochem Sci, Taipei 106, Taiwan.	gcchen@gate.sinica.edu.tw	Wu, Han-Chung/B-1209-2011	Wu, Han-Chung/0000-0002-5185-1169; Chen, Guang-Chao/0000-0002-4980-4718	Ministry of Science and Technology of Taiwan [NSC102-2311-B-001-027-MY3]; Academia Sinica	Ministry of Science and Technology of Taiwan(Ministry of Science and Technology, Taiwan); Academia Sinica(Academia Sinica - Taiwan)	We thank Ruey-Hwa Chen, Raymond Habas, Jean-Cheng Kuo, Jai Prakash Singh, and Tzu-Ching Meng for helpful discussion and reagents. We thank Chin-Chun Hung for confocal and cell imaging assistance; Suh-Yuen Liang for the bioinformatic support; Min-Feng Hsu for structural assistance; the National RNAi Core Facility for shRNAs; Academia Sinica Common Mass Spectrometry Facilities for mass spectrometric assistance; IBC Histopathology Core Facility for tissue processing and histology. We are grateful to Cindy Lee for English editing. This work was supported by the Ministry of Science and Technology of Taiwan (NSC102-2311-B-001-027-MY3) and Academia Sinica.	Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Aspenstrom P, 2006, EXP CELL RES, V312, P2180, DOI 10.1016/j.yexcr.2006.03.013; Bollu LR, 2017, CLIN CANCER RES, V23, P2136, DOI 10.1158/1078-0432.CCR-16-0934; Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079; Campellone KG, 2010, NAT REV MOL CELL BIO, V11, P237, DOI 10.1038/nrm2867; Chen DY, 2012, J CELL SCI, V125, P4841, DOI 10.1242/jcs.108597; Devreotes P, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a005959; Disanza A, 2005, CELL MOL LIFE SCI, V62, P955, DOI 10.1007/s00018-004-4472-6; Dong L, 2018, MOL CELL BIOCHEM, V438, P183, DOI 10.1007/s11010-017-3125-7; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Friedl P, 2010, J CELL BIOL, V188, P11, DOI 10.1083/jcb.200909003; Gao Q, 2014, GASTROENTEROLOGY, V146, P1397, DOI 10.1053/j.gastro.2014.01.062; Gardberg M, 2016, J PATHOL CLIN RES, V2, P41, DOI 10.1002/cjp2.34; Gardel ML, 2010, ANNU REV CELL DEV BI, V26, P315, DOI 10.1146/annurev.cellbio.011209.122036; Glondu-Lassis M, 2010, CANCER RES, V70, P5116, DOI 10.1158/0008-5472.CAN-09-4368; Guarino M, 2010, J CELL PHYSIOL, V223, P14, DOI 10.1002/jcp.22011; Hou SW, 2010, CANCER RES, V70, P2901, DOI 10.1158/0008-5472.CAN-09-3229; Huveneers S, 2009, J CELL SCI, V122, P1059, DOI 10.1242/jcs.039446; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jung Y, 2012, GENE CHROMOSOME CANC, V51, P590, DOI 10.1002/gcc.21945; Kan-o M, 2012, BIOL OPEN, V1, P889, DOI 10.1242/bio.20121370; Kedrin D, 2007, J MAMMARY GLAND BIOL, V12, P143, DOI 10.1007/s10911-007-9046-4; Kim D, 2016, ONCOTARGET, V7, P17829, DOI 10.18632/oncotarget.7429; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Labbe DP, 2012, PROG MOL BIOL TRANSL, V106, P253, DOI 10.1016/B978-0-12-396456-4.00009-2; Li DQ, 2011, DEVELOPMENT, V138, P303, DOI 10.1242/dev.055566; Li MY, 2015, ONCOGENE, V34, P3791, DOI 10.1038/onc.2014.312; Li SQ, 2016, SCI REP-UK, V6, DOI 10.1038/srep36873; Lin G, 2011, GENE DEV, V25, P1412, DOI 10.1101/gad.2018911; Liu GY, 2018, ONCOL REP, V39, P465, DOI 10.3892/or.2017.6124; Lizarraga F, 2009, CANCER RES, V69, P2792, DOI 10.1158/0008-5472.CAN-08-3709; Lu CL, 2015, ONCOTARGET, V6, P24912, DOI 10.18632/oncotarget.4701; Lu J, 2007, J MOL BIOL, V369, P1258, DOI 10.1016/j.jmb.2007.04.002; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Mendoza MC, 2013, SEMIN CELL DEV BIOL, V24, P272, DOI 10.1016/j.semcdb.2013.01.007; Nelson KS, 2012, NAT CELL BIOL, V14, P518, DOI 10.1038/ncb2467; Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160; Patel A, 2016, LIFE SCI, V157, P52, DOI 10.1016/j.lfs.2016.05.036; Prokop Andreas, 2011, Commun Integr Biol, V4, P538, DOI 10.4161/cib.4.5.16511; Randall TS, 2014, EUR J CELL BIOL, V93, P205, DOI 10.1016/j.ejcb.2013.11.004; Reig G, 2014, DEVELOPMENT, V141, P1999, DOI 10.1242/dev.101451; Reynolds AB, 2014, ONCOGENE, V33, P4537, DOI 10.1038/onc.2013.416; Ridley AJ, 2015, CURR OPIN CELL BIOL, V36, P103, DOI 10.1016/j.ceb.2015.08.005; SEN B, 2011, J SIGNAL TRANSDUCT, DOI DOI 10.1063/1.3603036; Shojima K, 2015, SCI REP-UK, V5, DOI 10.1038/srep08042; Stehbens SJ, 2014, METHOD CELL BIOL, V123, P335, DOI 10.1016/B978-0-12-420138-5.00018-5; Svitkina Tatyana, 2018, Cold Spring Harb Perspect Biol, V10, DOI 10.1101/cshperspect.a018267; Tepass U, 2009, CURR OPIN GENET DEV, V19, P357, DOI 10.1016/j.gde.2009.05.006; van Vliet C, 2005, NAT IMMUNOL, V6, P253, DOI 10.1038/ni1169; Wang SE, 2005, MOL CELL BIOL, V25, P4703, DOI 10.1128/MCB.25.11.4703-4715.2005; Wang XW, 2018, CELL BIOL INT, V42, P598, DOI 10.1002/cbin.10936; Wang ZH, 2004, SCIENCE, V304, P1164, DOI 10.1126/science.1096096; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Xiong HP, 2018, CELL SIGNAL, V44, P33, DOI 10.1016/j.cellsig.2018.01.013; Yamashita M, 2007, GENES CELLS, V12, P1255, DOI 10.1111/j.1365-2443.2007.01132.x; Yan T, 2018, J BIOL CHEM, V293, P10172, DOI 10.1074/jbc.RA117.000327; Yin M, 2017, ONCOTARGET, V8, P88232, DOI 10.18632/oncotarget.21088; Young KG, 2010, BBA-MOL CELL RES, V1803, P183, DOI 10.1016/j.bbamcr.2008.09.017; Zeng YF, 2015, EXP MOL PATHOL, V98, P260, DOI 10.1016/j.yexmp.2015.03.008; Zheng YH, 2013, CHIN J CANCER, V32, P75, DOI [10.5732/cjc.012.10084, 10.5732/cjc.012.1008]; Zhou F, 2009, HUM MOL GENET, V18, P2472, DOI 10.1093/hmg/ddp185; Zhu XL, 2008, INT J COLORECTAL DIS, V23, P1041, DOI 10.1007/s00384-008-0520-2; Zhu YC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037823	63	17	17	2	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2019	38	44					7002	7016		10.1038/s41388-019-0948-6	http://dx.doi.org/10.1038/s41388-019-0948-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ1AO	31406243				2022-12-28	WOS:000493892900004
J	Bhoopathi, P; Pradhan, AK; Bacolod, MD; Emdad, L; Sarkar, D; Das, SK; Fisher, PB				Bhoopathi, Praveen; Pradhan, Anjan K.; Bacolod, Manny D.; Emdad, Luni; Sarkar, Devanand; Das, Swadesh K.; Fisher, Paul B.			Regulation of neuroblastoma migration, invasion, and in vivo metastasis by genetic and pharmacological manipulation of MDA-9/Syntenin	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; ALPHA-6-BETA-4 INTEGRIN; TUMOR INVASION; CANCER; EXPRESSION; PROLIFERATION; GLYCOPROTEIN; INHIBITION; GTPASES; TARGET	Despite multi-modality treatments, prognosis for advanced stage neuroblastoma (NB) remains challenging with residual long-term disabilities in survivors. Advanced stage NB is metastatic, which is a principal cause of cancer-related deaths. We presently document a primary role of MDA-9 in NB progression and define the molecular mechanisms by which MDA-9 promotes transformed phenotypes. NB cell lines and clinical samples display elevated MDA-9 expression and bioinformatic analysis supports an association between elevated MDA-9 and bone metastasis and poor prognosis. Genetic (shmda-9, mda9 siRNA) or pharmacological (small molecule inhibitor of protein-protein interactions; PDZ1i) blockade of MDA-9 decreases NB migration, invasion, and metastasis. Blocking mda-9 expression or disrupting MDA-9 partner protein interactions downregulates integrin alpha 6 and beta 4, diminishing Src activity and suppressing Rho-Rac-Cdc42 activity. These signaling changes inhibit cofilin and matrix metalloproteinases reducing in vitro and in vivo NB cell migration. Overexpression of integrin a6 and beta 4 rescues the invasion phenotype and increases Src activity, supporting integrins as essential regulators of MDA-9-mediated NB migration and invasion. We identify MDA-9 as a key contributor to NB pathogenesis and show that genetic or pharmacological inhibition suppresses NB pathogenesis by an integrin-mediated Src-disruption pathway.	[Bhoopathi, Praveen; Pradhan, Anjan K.; Emdad, Luni; Sarkar, Devanand; Das, Swadesh K.; Fisher, Paul B.] Virginia Commonwealth Univ, Dept Human & Mol Genet, Sch Med, Richmond, VA 23284 USA; [Bhoopathi, Praveen; Pradhan, Anjan K.; Emdad, Luni; Sarkar, Devanand; Das, Swadesh K.; Fisher, Paul B.] Virginia Commonwealth Univ, Sch Med, VCU Inst Mol Med, Richmond, VA 23284 USA; [Bacolod, Manny D.] Weill Cornell Med Coll, New York, NY USA; [Emdad, Luni; Sarkar, Devanand; Das, Swadesh K.; Fisher, Paul B.] Virginia Commonwealth Univ, VCU Massey Canc Ctr, Sch Med, Richmond, VA 23284 USA	Virginia Commonwealth University; Virginia Commonwealth University; Cornell University; Virginia Commonwealth University	Fisher, PB (corresponding author), Virginia Commonwealth Univ, Dept Human & Mol Genet, Sch Med, Richmond, VA 23284 USA.; Fisher, PB (corresponding author), Virginia Commonwealth Univ, Sch Med, VCU Inst Mol Med, Richmond, VA 23284 USA.; Fisher, PB (corresponding author), Virginia Commonwealth Univ, VCU Massey Canc Ctr, Sch Med, Richmond, VA 23284 USA.	paul.fisher@vcuhealth.org	Pradhan, Anjan K/O-2555-2014	Bacolod, Manny/0000-0002-2085-4877	National Foundation for Cancer Research (NFCR); NCI Cancer Center Support Grant [P30 CA016059]; VCU Institute of Molecular Medicine (VIMM); Genetics Enhancement Fund; InVaMet Therapeutics, Inc. (IVMT); NATIONAL CANCER INSTITUTE [P30CA016059] Funding Source: NIH RePORTER	National Foundation for Cancer Research (NFCR); NCI Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); VCU Institute of Molecular Medicine (VIMM); Genetics Enhancement Fund; InVaMet Therapeutics, Inc. (IVMT); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The present study was supported in part by the National Foundation for Cancer Research (NFCR) (to PBF), NCI Cancer Center Support Grant to VCU Massey Cancer Center (MCC) P30 CA016059 (to PBF and DS), the VCU Institute of Molecular Medicine (VIMM) (PBF) and the Genetics Enhancement Fund (PBF, SKD, and LE). Support was also provided by a Sponsored Research Agreement from InVaMet Therapeutics, Inc. (IVMT) (SKD). PBF holds the Thelma Newmeyer Corman Chair in Cancer Research at the MCC.	Bacolod MD, 2015, ADV CANCER RES, V127, P49, DOI 10.1016/bs.acr.2015.04.006; Bhoopathi P, 2016, CANCER RES, V76, P3572, DOI 10.1158/0008-5472.CAN-15-2959; Bhoopathi P, 2011, CELL SIGNAL, V23, P1978, DOI 10.1016/j.cellsig.2011.07.008; Bolos V, 2010, ONCOTARGETS THER, V3, P83; Boukerche H, 2005, CANCER RES, V65, P10901, DOI 10.1158/0008-5472.CAN-05-1614; Boukerche H, 2008, P NATL ACAD SCI USA, V105, P15914, DOI 10.1073/pnas.0808171105; Chaturvedi NK, 2016, ONCOTARGET, V7, P15215, DOI 10.18632/oncotarget.7714; Colburn ZT, 2018, J CELL SCI, V131, DOI 10.1242/jcs.214593; Das SK, 2019, MOL CANCER THER, V18, P1997, DOI 10.1158/1535-7163.MCT-18-1019; Das SK, 2019, ADV CANCER RES, V144, P137, DOI 10.1016/bs.acr.2019.03.011; Das SK, 2019, ACS CHEM NEUROSCI, V10, P1121, DOI 10.1021/acschemneuro.9b00016; Das SK, 2018, CANCER RES, V78, P2852, DOI 10.1158/0008-5472.CAN-17-2992; Das SK, 2016, ONCOTARGET, V7, P46848, DOI 10.18632/oncotarget.10040; Das SK, 2013, CANCER RES, V73, P844, DOI 10.1158/0008-5472.CAN-12-1681; Das SK, 2012, CANCER RES, V72, P6217, DOI 10.1158/0008-5472.CAN-12-0402; Das SK, 2012, FRONT BIOSCI-LANDMRK, V17, P1, DOI 10.2741/3911; Dasgupta S, 2013, CLIN CANCER RES, V19, P4621, DOI 10.1158/1078-0432.CCR-13-0585; Dominguez-Gimenez P, 2007, J CELL SCI, V120, P1061, DOI 10.1242/jcs.03404; Guan XM, 2015, ACTA PHARM SIN B, V5, P402, DOI 10.1016/j.apsb.2015.07.005; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Kaminska K, 2015, J CELL MOL MED, V19, P283, DOI 10.1111/jcmm.12408; Kegelman TP, 2017, P NATL ACAD SCI USA, V114, P370, DOI 10.1073/pnas.1616100114; Kegelman TP, 2015, EXPERT OPIN THER TAR, V19, P97, DOI 10.1517/14728222.2014.959495; Kegelman TP, 2014, NEURO-ONCOLOGY, V16, P50, DOI 10.1093/neuonc/not157; Kramer M, 2016, J NEUROSCI, V36, P10425, DOI 10.1523/JNEUROSCI.0183-16.2016; Lee SH, 2010, MOL CELLS, V29, P311, DOI 10.1007/s10059-010-0053-8; Lin JJ, 1996, MOL CELL DIFFER, V4, P317; Lin JJ, 1998, GENE, V207, P105, DOI 10.1016/S0378-1119(97)00562-3; Melzer C, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/8534371; Menezes ME, 2016, ONCOTARGET, V7, P80175, DOI 10.18632/oncotarget.13373; Mercurio AM, 2001, CURR OPIN CELL BIOL, V13, P541, DOI 10.1016/S0955-0674(00)00249-0; Meyer A, 2004, NEOPLASIA, V6, P332, DOI 10.1593/neo.03445; Miao H, 2002, J CELL SCI, V115, P2199; Morandi F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029922; Nakajima S, 2004, CLIN CANCER RES, V10, P4125, DOI 10.1158/1078-0432.CCR-0578-03; O'Connor KL, 2012, AM J PHYSIOL-CELL PH, V302, pC605, DOI 10.1152/ajpcell.00095.2011; Rastogi P, 2015, INDIAN J HEMATOL BLO, V31, P57, DOI 10.1007/s12288-014-0405-1; Russell AJ, 2003, J CELL SCI, V116, P3543, DOI 10.1242/jcs.00663; Sarkar D, 2008, CANCER RES, V68, P3087, DOI 10.1158/0008-5472.CAN-07-6210; Schwartz MA, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a005066; Seong BKA, 2017, CANCER RES, V77, P696, DOI 10.1158/0008-5472.CAN-16-1502; Shohet J, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1863; Son H, 2010, TOX RESEARCH, V26, P245, DOI 10.5487/TR.2010.26.4.245; Stivarou T, 2015, CANCERS, V7, P238, DOI 10.3390/cancers7010238; Su ZZ, 2002, ONCOGENE, V21, P3592, DOI 10.1038/sj.onc.1205445; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221; Talukdar S, 2018, AUTOPHAGY, V14, P1845, DOI 10.1080/15548627.2018.1502564; Talukdar S, 2018, P NATL ACAD SCI USA, V115, P5768, DOI 10.1073/pnas.1721650115; Talukdar S, 2016, ONCOTARGET, V7, P54102, DOI 10.18632/oncotarget.10851; Webb AH, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3418-y; Welch DR, 2016, ADV CANCER RES, V132, P1	51	17	17	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2019	38	41					6781	6793		10.1038/s41388-019-0920-5	http://dx.doi.org/10.1038/s41388-019-0920-5			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JC8UZ	31406249	Green Accepted			2022-12-28	WOS:000489552900006
J	Skrott, Z; Majera, D; Gursky, J; Buchtova, T; Hajduch, M; Mistrik, M; Bartek, J				Skrott, Zdenek; Majera, Dusana; Gursky, Jan; Buchtova, Tereza; Hajduch, Marian; Mistrik, Martin; Bartek, Jiri			Disulfiram's anti-cancer activity reflects targeting NPL4, not inhibition of aldehyde dehydrogenase	ONCOGENE			English	Article							CANCER STEM-CELLS; INITIATING CELLS; MITOCHONDRIAL; DRUG; ACETALDEHYDE; METASTASIS; METABOLISM; RESISTANCE; REVERSES; ADDUCTS	Aldehyde dehydrogenase (ALDH) is a proposed biomarker and possible target to eradicate cancer stem cells. ALDH inhibition as a treatment approach is supported by anti-cancer effects of the alcohol-abuse drug disulfiram (DSF, Antabuse). Given that metabolic products of DSF, rather than DSF itself inhibit ALDH in vivo, and that DSF's anti-cancer activity is potentiated by copper led us to investigate the relevance of ALDH as the suggested molecular cancer-relevant target of DSF. Here we show that DSF does not directly inhibit ALDH activity in diverse human cell types, while DSF's in vivo metabolite, S-methyl-N, N-diethylthiocarbamate-sulfoxide inhibits ALDH activity yet does not impair cancer cell viability. Our data indicate that the anti-cancer activity of DSF does not involve ALDH inhibition, and rather reflects the impact of DSF's copper-containing metabolite (CuET), that forms spontaneously in vivo and in cell culture media, and kills cells through aggregation of NPL4, a subunit of the p97/VCP segregase. We also show that the CuET-mediated, rather than any ALDH-inhibitory activity of DSF underlies the preferential cytotoxicity of DSF towards BRCA1-and BRCA2-deficient cells. These findings provide evidence clarifying the confusing literature about the anti-cancer mechanism of DSF, a drug currently tested in clinical trials for repositioning in oncology.	[Skrott, Zdenek; Majera, Dusana; Gursky, Jan; Buchtova, Tereza; Hajduch, Marian; Mistrik, Martin; Bartek, Jiri] Palacky Univ, Fac Med & Dent, Inst Mol & Translat Med, Olomouc, Czech Republic; [Bartek, Jiri] Danish Canc Soc Res Ctr, Copenhagen, Denmark; [Bartek, Jiri] Karolinska Inst, Dept Med Biochem & Biophys, Div Genome Biol, Sci Life Lab, Stockholm, Sweden	Palacky University Olomouc; Danish Cancer Society; Karolinska Institutet	Mistrik, M; Bartek, J (corresponding author), Palacky Univ, Fac Med & Dent, Inst Mol & Translat Med, Olomouc, Czech Republic.; Bartek, J (corresponding author), Danish Canc Soc Res Ctr, Copenhagen, Denmark.; Bartek, J (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Genome Biol, Sci Life Lab, Stockholm, Sweden.	martin.mistrik@upol.cz; jb@cancer.dk	MAJERA, Dusana/U-1079-2019; Buchtová, Tereza/GSI-5771-2022; Hajduch, Marian/J-4015-2014	Hajduch, Marian/0000-0002-4834-908X; Mistrik, Martin/0000-0002-2321-0348; Buchtova, Tereza/0000-0001-5233-1504; Skrott, Zdenek/0000-0001-6004-3609	Grant agency of Czech Rep. GACR [17-25976 S]; MEYS CR [LM2015062, DRO-61989592]; Internal grant of University of Palacky [IGA_LF_2019_026]; Cancer Research Czech Republic, Ministry of School, Education, Youth and Sports of the Czech Republic [LM2015064, CZ.02.1.01/0.0/0.0/16_019/0000868]; Novo Nordisk Foundation [16854]; Danish National Research Foundation [DNRF125]; Danish Cancer Society [R204-A12617]; Swedish Research Council [VR-MH 2014-46602-117891-30]; Swedish Cancer Society [170176]	Grant agency of Czech Rep. GACR; MEYS CR; Internal grant of University of Palacky; Cancer Research Czech Republic, Ministry of School, Education, Youth and Sports of the Czech Republic; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Danish National Research Foundation(Danmarks Grundforskningsfond); Danish Cancer Society(Danish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society)	We thank Dr. M. Tarsounas (Oxford, UK) for the human H1299 cell lines with regulatable expression of shBRCA1 and shBRCA2. The study was supported by grants from: Grant agency of Czech Rep. GACR 17-25976 S, MEYS CR (LM2015062 Czech-BioImaging and DRO-61989592), Internal grant of University of Palacky IGA_LF_2019_026, Cancer Research Czech Republic, Ministry of School, Education, Youth and Sports of the Czech Republic (EATRIS-CZ No. LM2015064 and ENOCH No. CZ.02.1.01/0.0/0.0/16_019/0000868), the Novo Nordisk Foundation (no. 16854), the Danish National Research Foundation (project CARD: no. DNRF125), the Danish Cancer Society (R204-A12617) the Swedish Research Council (VR-MH 2014-46602-117891-30), and the Swedish Cancer Society (no. 170176).	Allensworth JL, 2015, MOL ONCOL, V9, P1155, DOI 10.1016/j.molonc.2015.02.007; Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409; Bista R, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0493-5; Brooks PJ, 2005, ALCOHOL, V35, P187, DOI 10.1016/j.alcohol.2005.03.009; Bryan N, 2011, BIOSCIENCE REP, V31, P199, DOI 10.1042/BSR20100064; Chang JS, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0327-y; Charafe-Jauffret E, 2010, CLIN CANCER RES, V16, P45, DOI 10.1158/1078-0432.CCR-09-1630; Chen D, 2006, CANCER RES, V66, P10425, DOI 10.1158/0008-5472.CAN-06-2126; Chen W, 2018, ACS APPL MATER INTER, V10, P41118, DOI 10.1021/acsami.8b14940; Choi SA, 2015, NEURO-ONCOLOGY, V17, P810, DOI 10.1093/neuonc/nou305; Duan JJ, 2016, INT J CANCER, V139, P965, DOI 10.1002/ijc.30091; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; HART BW, 1993, BIOCHEM PHARMACOL, V46, P2285, DOI 10.1016/0006-2952(93)90619-8; Huddle BC, 2018, J MED CHEM, V61, P8754, DOI 10.1021/acs.jmedchem.8b00930; Jin N, 2018, J CELL BIOCHEM, V119, P6882, DOI 10.1002/jcb.26885; Koppaka V, 2012, PHARMACOL REV, V64, P520, DOI 10.1124/pr.111.005538; Lai CL, 2014, ALCOHOL CLIN EXP RES, V38, P44, DOI 10.1111/acer.12215; Lam JP, 1997, BIOCHEMISTRY-US, V36, P13748, DOI 10.1021/bi970948e; Lipsky JJ, 2001, CHEM-BIOL INTERACT, V130, P93, DOI 10.1016/S0009-2797(00)00225-8; Liu P, 2013, BRIT J CANCER, V109, P1876, DOI 10.1038/bjc.2013.534; Liu P, 2012, BRIT J CANCER, V107, P1488, DOI 10.1038/bjc.2012.442; Liu P, 2014, ONCOTARGET, V5, P7471, DOI 10.18632/oncotarget.2166; Liu XW, 2016, ONCOTARGET, V7, P58516, DOI 10.18632/oncotarget.11305; MacDonagh L, 2017, ONCOTARGET, V8, P72544, DOI 10.18632/oncotarget.19881; Majera D, 2019, PROSTATE, V79, P352, DOI 10.1002/pros.23741; Marchitti SA, 2008, EXPERT OPIN DRUG MET, V4, P697, DOI [10.1517/17425255.4.6.697, 10.1517/17425255.4.6.697 ]; Marques DS, 2010, LEUKEMIA RES, V34, P757, DOI 10.1016/j.leukres.2009.11.004; MAYS DC, 1995, BIOCHEM PHARMACOL, V49, P693, DOI 10.1016/0006-2952(94)00504-F; Peng XY, 2019, BIOMACROMOLECULES, V20, P2372, DOI 10.1021/acs.biomac.9b00367; Pors K, 2014, DRUG DISCOV TODAY, V19, P1953, DOI 10.1016/j.drudis.2014.09.009; Raha D, 2014, CANCER RES, V74, P3579, DOI 10.1158/0008-5472.CAN-13-3456; Shen ML, 2001, BIOCHEM PHARMACOL, V61, P537, DOI 10.1016/S0006-2952(00)00586-4; Skrott Z, 2017, NATURE, V552, P194, DOI 10.1038/nature25016; Suh JJ, 2006, J CLIN PSYCHOPHARM, V26, P290, DOI 10.1097/01.jcp.0000222512.25649.08; Tacconi EMC, 2017, EMBO MOL MED, V9, P1398, DOI 10.15252/emmm.201607446; Tirino V, 2013, FASEB J, V27, P13, DOI 10.1096/fj.12-218222; van den Hoogen C, 2010, CANCER RES, V70, P5163, DOI 10.1158/0008-5472.CAN-09-3806; Wang NN, 2018, EXP CELL RES, V362, P72, DOI 10.1016/j.yexcr.2017.11.004; Wu L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-35619-6; Yip NC, 2011, BRIT J CANCER, V104, P1564, DOI 10.1038/bjc.2011.126; YOURICK JJ, 1991, BIOCHEM PHARMACOL, V42, P1361, DOI 10.1016/0006-2952(91)90446-C; Zhou L, 2019, CELL BIOL TOXICOL, V35, P161, DOI 10.1007/s10565-018-9444-y	43	41	41	2	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2019	38	40					6711	6722		10.1038/s41388-019-0915-2	http://dx.doi.org/10.1038/s41388-019-0915-2			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JC0EY	31391554				2022-12-28	WOS:000488953500005
J	Li, LC; Ameri, AH; Wang, SM; Jansson, KH; Casey, OM; Yang, Q; Beshiri, ML; Fang, L; Lake, RG; Agarwal, S; Alilin, AN; Xu, WH; Yin, JJ; Kelly, K				Li, Lechen; Ameri, Amir H.; Wang, Simeng; Jansson, Keith H.; Casey, Orla M.; Yang, Qi; Beshiri, Michael L.; Fang, Lei; Lake, Ross G.; Agarwal, Supreet; Alilin, Aian N.; Xu, Wanhai; Yin, JuanJuan; Kelly, Kathleen			EGR1 regulates angiogenic and osteoclastogenic factors in prostate cancer and promotes metastasis	ONCOGENE			English	Article							TRANSCRIPTION FACTOR EGR1; MESENCHYMAL TRANSITION; TGF-BETA; IN-VITRO; CELLS; GROWTH; BONE; EXPRESSION; RECEPTOR; PTEN	Early growth response-1 (EGR1) is a transcription factor correlated with prostate cancer (PC) progression in a variety of contexts. For example, EGR1 levels increase in response to suppressed androgen receptor signaling or loss of the tumor suppressor, PTEN. EGR1 has been shown to regulate genes influencing proliferation, apoptosis, immune cell activation, and matrix degradation, among others. Despite this, the impact of EGR1 on PC metastatic colonization is unclear. We demonstrate using a PC model (DU145/RasB1) of bone and brain metastasis that EGR1 expression regulates angiogenic and osteoclastogenic properties of metastases. We have shown previously that FN14 (TNFRSF12A) and downstream NF-kappa B signaling is required for metastasis in this model. Here we demonstrate that FN14 ligation also leads to NF-kappa B-independent, MEK-dependent EGR1 expression. EGR/ -depletion in DU145/RasB1 cells reduced both the number and size of metastases but did not affect primary tumor growth. Decreased EGR1 expression led to reduced blood vessel density in brain and bone metastases as well as decreased osteolytic bone lesion area and reduced numbers of osteoclasts at the bone-tumor interface. TWEAK (TNFSF12) induced several EGR/ -dependent angiogenic and osteoclastogenic factors (e.g., PDGFA, TGFB1, SPP1, IL6, IL8, and TGFA, among others). Consistent with this, in clinical samples of PC, the level of several genes encoding angiogenic/osteoclastogenic pathway effectors correlated with EGR1 levels. Thus, we show here that EGR1 has a direct effect on prostate cancer metastases. EGR1 regulates angiogenic and osteoclastogenic factors, informing the underlying signaling networks that impact autonomous and microenvironmental mechanisms of cancer metastases.	[Li, Lechen; Xu, Wanhai] Harbin Med Univ, Dept Urol, Hosp 4, Harbin, Heilongjiang, Peoples R China; [Ameri, Amir H.; Wang, Simeng; Jansson, Keith H.; Casey, Orla M.; Yang, Qi; Beshiri, Michael L.; Fang, Lei; Lake, Ross G.; Agarwal, Supreet; Alilin, Aian N.; Yin, JuanJuan; Kelly, Kathleen] NCI, Lab Genitourinary Canc Pathogenesis, CCR, Bethesda, MD 20892 USA	Harbin Medical University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Xu, WH (corresponding author), Harbin Med Univ, Dept Urol, Hosp 4, Harbin, Heilongjiang, Peoples R China.; Kelly, K (corresponding author), NCI, Lab Genitourinary Canc Pathogenesis, CCR, Bethesda, MD 20892 USA.	xuwanhai@163.com; kellyka@mail.nih.gov	agarwal, supreet/AAI-7296-2021	Li, Lechen/0000-0003-3978-9582; Ameri, Amir H./0000-0003-0284-8286; Beshiri, Michael/0000-0003-3128-3851	Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research; National Natural Science Foundation of China [81270022, 81611130070, 81771898]; NATIONAL CANCER INSTITUTE [ZICBC010947] Funding Source: NIH RePORTER	Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research and National Natural Science Foundation of China (81270022, 81611130070, and 81771898; to WX).	Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231; Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Adamson E, 2003, CANCER BIOL THER, V2, P617; Adamson ED, 2002, TUMOR BIOL, V23, P93, DOI 10.1159/000059711; Aytes A, 2013, P NATL ACAD SCI USA, V110, pE3506, DOI 10.1073/pnas.1303558110; Baron V, 2006, CANCER GENE THER, V13, P115, DOI 10.1038/sj.cgt.7700896; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Caffo O, 2012, J NEURO-ONCOL, V107, P191, DOI 10.1007/s11060-011-0734-y; Cancro MP, 2009, NAT REV IMMUNOL, V9, P657, DOI 10.1038/nri2621; CHANG J, 1989, CANCER CELL-MON REV, V1, P17; Eid MA, 1998, CANCER RES, V58, P2461; Faltermeier CM, 2016, P NATL ACAD SCI USA, V113, pE172, DOI 10.1073/pnas.1521674112; Gitenay D, 2009, FUTURE ONCOL, V5, P993, DOI 10.2217/FON.09.67; Hardaway AL, 2015, CLIN EXP METASTAS, V32, P353, DOI 10.1007/s10585-015-9714-5; Hatzoglou V, 2014, J NEUROIMAGING, V24, P161, DOI 10.1111/j.1552-6569.2012.00767.x; Jansson KH, 2012, PROSTATE, V72, P1080, DOI 10.1002/pros.21512; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Juarez P, 2011, BONE, V48, P23, DOI 10.1016/j.bone.2010.08.004; Kinkade CW, 2008, J CLIN INVEST, V118, P3051, DOI 10.1172/JCI34764; Krones-Herzig A, 2005, CANCER RES, V65, P5133, DOI 10.1158/0008-5472.CAN-04-3742; Kundumani-Sridharan V, 2010, BLOOD, V115, P2105, DOI 10.1182/blood-2009-09-241802; Kuo PL, 2011, J CELL PHYSIOL, V226, P1224, DOI 10.1002/jcp.22445; Liao YJ, 2004, J BIOL CHEM, V279, P43107, DOI 10.1074/jbc.M407969200; Liu CT, 1996, P NATL ACAD SCI USA, V93, P11831, DOI 10.1073/pnas.93.21.11831; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; Mayer SI, 2009, J CELL SCI, V122, P3340, DOI 10.1242/jcs.048272; Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100; Muller I, 2012, ENDOCRINOLOGY, V153, P3040, DOI 10.1210/en.2012-1064; Mulholland DJ, 2012, CANCER RES, V72, P1878, DOI 10.1158/0008-5472.CAN-11-3132; Mulholland DJ, 2011, CANCER CELL, V19, P792, DOI 10.1016/j.ccr.2011.05.006; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; O'Donovan KJ, 1999, TRENDS NEUROSCI, V22, P167, DOI 10.1016/S0166-2236(98)01343-5; Rostovskaya M, 2018, STEM CELL REP, V11, P212, DOI 10.1016/j.stemcr.2018.05.014; Ruscetti M, 2015, CANCER RES, V75, P2749, DOI 10.1158/0008-5472.CAN-14-3476; Silverman ES, 1997, AM J PHYSIOL-HEART C, V273, pH1415, DOI 10.1152/ajpheart.1997.273.3.H1415; Singha B, 2014, J BIOL CHEM, V289, P2687, DOI 10.1074/jbc.M113.502641; Sperandio S, 2009, MOL CARCINOGEN, V48, P38, DOI 10.1002/mc.20454; Starmans MHW, 2012, RADIOTHER ONCOL, V102, P436, DOI 10.1016/j.radonc.2012.02.002; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tsai MH, 2007, CANCER RES, V67, P3845, DOI 10.1158/0008-5472.CAN-06-4250; Wang T, 2005, BLOOD, V105, P2836, DOI 10.1182/blood-2004-07-2878; Winkles JA, 2008, NAT REV DRUG DISCOV, V7, P411, DOI 10.1038/nrd2488; Wu JN, 2014, CANCER-AM CANCER SOC, V120, P818, DOI 10.1002/cncr.28485; Wu SY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11169; Yamamoto C, 2010, CANCER RES, V70, P8715, DOI 10.1158/0008-5472.CAN-10-0043; Yang SZ, 2006, J CELL BIOCHEM, V97, P1292, DOI 10.1002/jcb.20736; Yang SZ, 2003, J BIOL CHEM, V278, P39906, DOI 10.1074/jbc.M307250200; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523; Yin JJ, 2010, CANCER RES, V70, P8662, DOI 10.1158/0008-5472.CAN-10-1435; Yin JJ, 2007, MOL CELL BIOL, V27, P7538, DOI 10.1128/MCB.00955-07; Yin JJ, 2014, CANCER RES, V74, P4306, DOI 10.1158/0008-5472.CAN-13-3233; Zagurovskaya M, 2009, ONCOGENE, V28, P1121, DOI 10.1038/onc.2008.461; Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685	55	47	48	2	25	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2019	38	35					6241	6255		10.1038/s41388-019-0873-8	http://dx.doi.org/10.1038/s41388-019-0873-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IU9RZ	31312026	Green Accepted			2022-12-28	WOS:000483919400001
J	Dent, P; Booth, L; Roberts, JL; Liu, JC; Poklepovic, A; Lalani, AS; Tuveson, D; Martinez, J; Hancock, JF				Dent, Paul; Booth, Laurence; Roberts, Jane L.; Liu, Junchen; Poklepovic, Andrew; Lalani, Alshad S.; Tuveson, David; Martinez, Jennifer; Hancock, John F.			Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells	ONCOGENE			English	Article							PROTEIN-KINASE; PATHWAY; LIVER; RISK	Prior studies demonstrated that the irreversible ERBB1/2/4 inhibitor neratinib caused plasma membrane-associated mutant K-RAS to localize in intracellular vesicles, concomitant with its degradation. Herein, we discovered that neratinib interacted with the chemically distinct irreversible ERBB1/2/4 inhibitor afatinib to reduce expression of ERBB1, ERBB2, K-RAS and N-RAS; this was associated with greater-than-additive cell killing of pancreatic tumor cells. Knock down of Beclin1, ATG16L1, Rubicon or cathepsin B significantly lowered the ability of neratinib to reduce ERBB1 and K-RAS expression, and to cause tumor cell death. Knock down of ATM-AMPK suppressed vesicle formation and knock down of cathepsin B-AIF significantly reduced neratinib lethality. PKG phosphorylates K-RAS and HMG CoA reductase inhibitors reduce K-RAS farnesylation both of which remove K-RAS from the plasma membrane, abolishing its activity. Neratinib interacted with the PKG activator sildenafil and the HMG CoA reductase inhibitor atorvastatin to further reduce K-RAS expression, and to further enhance cell killing Neratinib is also a Ste20 kinase family inhibitor and in carcinoma cells, and hematopoietic cancer cells lacking ERBB1/2/4, it reduced K-RAS expression and the phosphorylation of MST1/3/4/Ezrin by similar to 30%. Neratinib increased LATS1 phosphorylation as well as that of YAP and TAZ also by similar to 30%, caused the majority of YAP to translocate into the cytosol and reduced YAP/TAZ protein levels. Neratinib lethality was enhanced by knock down of YAP. Neratinib, in a Rubicon-dependent fashion, reduced PAK1 phosphorylation and that of its substrate Merlin. Our data demonstrate that neratinib coordinately suppresses both mutant K-RAS and YAP function to kill pancreatic tumor cells.	[Dent, Paul; Booth, Laurence; Roberts, Jane L.] Virginia Commonwealth Univ, Dept Biochem, Med Coll Virginia Campus, Richmond, VA 23298 USA; [Dent, Paul; Booth, Laurence; Roberts, Jane L.] Virginia Commonwealth Univ, Dept Mol Biol, Med Coll Virginia Campus, Richmond, VA 23298 USA; [Liu, Junchen; Hancock, John F.] Univ Texas Hlth Sci Ctr Houston, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; [Poklepovic, Andrew] Virginia Commonwealth Univ, Dept Med, Med Coll Virginia Campus, Richmond, VA 23298 USA; [Lalani, Alshad S.] Puma Biotechnol Inc, 1880 Wilshire Blvd, Los Angeles, CA 90024 USA; [Tuveson, David] Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA; [Martinez, Jennifer] NIEHS, Inflammat & Autoimmun Grp, POB 12233, Res Triangle Pk, NC 27709 USA	Virginia Commonwealth University; Virginia Commonwealth University; University of Texas System; University of Texas Health Science Center Houston; Virginia Commonwealth University; Cold Spring Harbor Laboratory; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Dent, P (corresponding author), Virginia Commonwealth Univ, Dept Biochem, Med Coll Virginia Campus, Richmond, VA 23298 USA.; Dent, P (corresponding author), Virginia Commonwealth Univ, Dept Mol Biol, Med Coll Virginia Campus, Richmond, VA 23298 USA.	paul.dent@vcuhealth.org	Martinez, Jennifer/C-3740-2019	Martinez, Jennifer/0000-0002-3060-2518; Hancock, John/0000-0003-0542-4710; Liu, Junchen/0000-0003-2765-9780	Massey Cancer Center; Universal Inc.; Chair in Signal Transduction Research; NATIONAL CANCER INSTITUTE [R01CA192613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES103286] Funding Source: NIH RePORTER	Massey Cancer Center; Universal Inc.; Chair in Signal Transduction Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Support for the present study was funded from philanthropic funding from Massey Cancer Center and the Universal Inc. Chair in Signal Transduction Research.	Abdel-Rahman O, 2019, CLIN TRANSL ONCOL, V21, P810, DOI 10.1007/s12094-018-1992-3; Archibugi L, 2019, DIGEST LIVER DIS, V51, P28, DOI 10.1016/j.dld.2018.09.007; Avruch J, 2012, SEMIN CELL DEV BIOL, V23, P770, DOI 10.1016/j.semcdb.2012.07.002; Bae SJ, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20171469; Bitra A, 2017, SCI REP-UK, V7, DOI 10.1038/srep45020; Booth L, 2019, CANCER BIOL THER, V20, P700, DOI 10.1080/15384047.2018.1551747; Booth L, 2019, J CELL PHYSIOL, V234, P4874, DOI 10.1002/jcp.27276; Booth Laurence, 2018, Oncotarget, V9, P6062, DOI 10.18632/oncotarget.23681; Booth L, 2017, ONCOTARGET, V8, P90262, DOI 10.18632/oncotarget.21660; Booth L, 2017, ONCOTARGET, V8, P16367, DOI 10.18632/oncotarget.14829; Booth L, 2016, ONCOTARGET, V7, P19620, DOI 10.18632/oncotarget.7746; Burada F, 2016, PATHOL ONCOL RES, V22, P317, DOI 10.1007/s12253-015-0006-9; Chandra A, 2012, NAT CELL BIOL, V14, P148, DOI 10.1038/ncb2394; Chen M, 2018, J BIOL CHEM, V293, P14455, DOI 10.1074/jbc.RA118.003279; Chen S, 2018, AGING DIS, V9, P537, DOI 10.14336/AD.2017.0702; Cho KJ, 2016, MOL CELL BIOL, V36, P3086, DOI 10.1128/MCB.00365-16; Crawford JJ, 2018, EXPERT OPIN THER PAT, V28, P867, DOI 10.1080/13543776.2018.1549226; Davis MI, 2011, NAT BIOTECHNOL, V29, P1046, DOI 10.1038/nbt.1990; E JY, 2018, CURR MED CHEM, V25, P2595, DOI 10.2174/0929867324666170412145232; Hamada T, 2018, CLIN GASTROENTEROL H, V16, P1300, DOI 10.1016/j.cgh.2018.02.022; Hergovich A, 2016, GENES-BASEL, V7, DOI 10.3390/genes7050021; Hergovich A, 2013, CELL BIOSCI, V3, DOI 10.1186/2045-3701-3-32; Hsu CL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03340-7; Hsu PC, 2018, J CELL MOL MED, V22, P3073, DOI 10.1111/jcmm.13582; Kapoor A, 2014, CELL, V158, P185, DOI 10.1016/j.cell.2014.06.003; Kong DL, 2015, J DRUG TARGET, V23, P125, DOI 10.3109/1061186X.2014.983522; Kruspig B, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao2565; Lassen KG, 2014, P NATL ACAD SCI USA, V111, P7741, DOI 10.1073/pnas.1407001111; Lavoie S, 2019, ELIFE, V8, DOI 10.7554/eLife.39982; Li SX, 2015, CELL DISCOV, V1, DOI 10.1038/celldisc.2015.38; Liu YT, 2019, ONCOL REP, V41, P1455, DOI 10.3892/or.2019.6956; Martinez J, 2018, CURR OPIN IMMUNOL, V55, P54, DOI 10.1016/j.coi.2018.09.011; Meng ZP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9357; Mohamed AD, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33852-7; Moll HP, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao2301; Muniz-Feliciano L, 2017, AUTOPHAGY, V13, P2072, DOI 10.1080/15548627.2017.1380124; Nussinov R, 2016, SEMIN CELL DEV BIOL, V58, P79, DOI 10.1016/j.semcdb.2016.04.001; Park JY, 2018, MICROELECTRON ENG, V200, P1, DOI 10.1016/j.mee.2018.08.004; Patel SH, 2017, GASTROENTEROLOGY, V152, P533, DOI 10.1053/j.gastro.2016.10.047; Rawat SJ, 2015, TRENDS BIOCHEM SCI, V40, P149, DOI 10.1016/j.tibs.2015.01.001; Sadabad MS, 2015, GUT, V64, P1546, DOI 10.1136/gutjnl-2014-307289; Singh H, 2018, CLIN CANCER RES, V24, P3486, DOI 10.1158/1078-0432.CCR-17-3628; Stegert MR, 2005, MOL CELL BIOL, V25, P11019, DOI 10.1128/MCB.25.24.11019-11029.2005; Thompson BJ, 2015, J CELL BIOL, V210, P871, DOI 10.1083/jcb.201507005; Wang MH, 2012, INFLAMM BOWEL DIS, V18, P2277, DOI 10.1002/ibd.22931; Wang OH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152300; Waters AM, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aao3332; Zhang WY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005049; Zhang Y, 2019, PANCREAS, V48, P142, DOI 10.1097/MPA.0000000000001226; Zheng YG, 2015, DEV CELL, V34, P642, DOI 10.1016/j.devcel.2015.08.014	50	40	43	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 25	2019	38	30					5890	5904		10.1038/s41388-019-0849-8	http://dx.doi.org/10.1038/s41388-019-0849-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IT3FY	31253872	Green Accepted			2022-12-28	WOS:000482739300004
J	Hu, JW; Mirshahidi, S; Simental, A; Lee, SC; Filho, PAD; Peterson, NR; Duerksen-Hughes, P; Yuan, XP				Hu, Jinwei; Mirshahidi, Saied; Simental, Alfred; Lee, Steve C.; Filho, Pedro A. De Andrade; Peterson, Nathaniel R.; Duerksen-Hughes, Penelope; Yuan, Xiangpeng			Cancer stem cell self-renewal as a therapeutic target in human oral cancer	ONCOGENE			English	Article							TUMOR-GROWTH; BMI-1; HEAD; IDENTIFICATION; KINASE; METASTASES; MITOPHAGY; PROMOTES; SURVIVAL; SITES	Tumor recurrence following treatment remains a major clinical challenge in oral cavity cancer. Cancer stem cells (CSCs) have been isolated from human oral cancers and been considered as the driving force of tumor recurrence and metastasis. However, it still remains unclear whether targeting CSCs in oral cancer is a clinically relevant strategy to combat cancer recurrence and metastasis. Here, using clinical cancer specimens and patient-derived xenografts, we show that the self-renewal regulator BMI1 is highly expressed in CSCs of oral cavity squamous cell carcinoma. Inhibition of BMI1 decreases oral CSCs' self-renewal and tumor-initiating potential. Treatment of pre-established human oral cancer xenografts with a BMI1 inhibitor resulted in abrogation of tumor progression and reduced the frequency of CSCs in the xenografts. Remarkably, the BMI1 inhibitor has therapeutic effects in cisplatin-resistant tumors and can reduce metastases initiated by circulating CSCs. Mechanistically, BMI1-inhibition leads to oral CSC necroptotic cell death, which underlies the self-renewal impairment after inhibiting BMIl. Our data provide a pre-clinical proof-of-concept that targeting BMI1-related CSC self-renewal is a clinically relevant anti-cancer therapy in human oral cavity squamous cell carcinoma.	[Hu, Jinwei; Simental, Alfred; Lee, Steve C.; Filho, Pedro A. De Andrade; Peterson, Nathaniel R.; Yuan, Xiangpeng] Loma Linda Univ, Med Ctr, Dept Otolaryngol Head & Neck Surg, Loma Linda, CA 92354 USA; [Mirshahidi, Saied] Loma Linda Univ, Canc Ctr Biospecimen Lab, Med Ctr, Loma Linda, CA 92354 USA; [Mirshahidi, Saied; Duerksen-Hughes, Penelope; Yuan, Xiangpeng] Loma Linda Univ, Sch Med, Dept Basic Sci, Loma Linda, CA 92354 USA; [Hu, Jinwei] Kaiser Permanente, Fontana Med Ctr, Dept Head & Neck Surg, Fontana, CA 92335 USA	Loma Linda University; Loma Linda University; Loma Linda University; Kaiser Permanente	Yuan, XP (corresponding author), Loma Linda Univ, Med Ctr, Dept Otolaryngol Head & Neck Surg, Loma Linda, CA 92354 USA.; Yuan, XP (corresponding author), Loma Linda Univ, Sch Med, Dept Basic Sci, Loma Linda, CA 92354 USA.	xyuan@llu.edu		Lee, Steve/0000-0002-4460-4303; Duerksen-Hughes, Penelope/0000-0002-0998-2157	Department of Otolaryngology-Head & Neck Surgery and Cancer Center at Loma Linda University;  [GCAT 2140225];  [GRASP 2140307];  [GCAT 2150204]	Department of Otolaryngology-Head & Neck Surgery and Cancer Center at Loma Linda University; ; ; 	This work was supported in parts by the Department of Otolaryngology-Head & Neck Surgery and Cancer Center at Loma Linda University, and by institutional grants GCAT 2140225, GCAT 2150204, and GRASP 2140307.	Ablett MP, 2014, ONCOTARGET, V5, P599, DOI 10.18632/oncotarget.1169; Bansal N, 2016, CLIN CANCER RES, V22, P6176, DOI 10.1158/1078-0432.CCR-15-3107; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Brooks MD, 2015, CELL STEM CELL, V17, P260, DOI 10.1016/j.stem.2015.08.014; Bruggeman SWM, 2007, CANCER CELL, V12, P328, DOI 10.1016/j.ccr.2007.08.032; Cai ZY, 2014, NAT CELL BIOL, V16, P55, DOI 10.1038/ncb2883; Chen DM, 2017, CELL STEM CELL, V20, P621, DOI 10.1016/j.stem.2017.02.003; Clay MR, 2010, HEAD NECK-J SCI SPEC, V32, P1195, DOI 10.1002/hed.21315; Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83; Dey A, 2016, AUTOPHAGY, V12, P659, DOI 10.1080/15548627.2016.1147670; Dovey JS, 2008, P NATL ACAD SCI USA, V105, P11857, DOI 10.1073/pnas.0803574105; Du JJ, 2010, MED ONCOL, V27, P1273, DOI 10.1007/s12032-009-9373-y; Ferlito A, 2001, ORL-J OTO-RHIN-LARYN, V63, P202, DOI 10.1159/000055740; Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012; Greene AW, 2012, EMBO REP, V13, P378, DOI 10.1038/embor.2012.14; Hu JW, 2006, CANCER RES, V66, P8887, DOI 10.1158/0008-5472.CAN-05-3448; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Kim JH, 2004, CANCER LETT, V203, P217, DOI 10.1016/j.canlet.2003.07.009; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Kreso A, 2014, NAT MED, V20, P29, DOI 10.1038/nm.3418; Kreso A, 2013, SCIENCE, V339, P543, DOI 10.1126/science.1227670; Krishnamurthy S, 2010, CANCER RES, V70, P9969, DOI 10.1158/0008-5472.CAN-10-1712; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385; Li DW, 2010, J CANCER RES CLIN, V136, P997, DOI 10.1007/s00432-009-0745-7; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Lim YC, 2014, ORAL ONCOL, V50, P633, DOI 10.1016/j.oraloncology.2014.04.004; Lukacs RU, 2010, CELL STEM CELL, V7, P682, DOI 10.1016/j.stem.2010.11.013; Majeti R, 2009, CELL, V138, P286, DOI 10.1016/j.cell.2009.05.045; Mandal P, 2014, MOL CELL, V56, P481, DOI 10.1016/j.molcel.2014.10.021; Mirshahidi S, 2018, EXP CELL RES, V362, P515, DOI 10.1016/j.yexcr.2017.12.017; Mizumura K, 2014, J CLIN INVEST, V124, P3987, DOI 10.1172/JCI74985; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Nor C, 2014, NEOPLASIA, V16, P137, DOI 10.1593/neo.131744; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Pastrana E, 2011, CELL STEM CELL, V8, P486, DOI 10.1016/j.stem.2011.04.007; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Sangiorgi E, 2008, NAT GENET, V40, P915, DOI 10.1038/ng.165; Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002; Scott FL, 2005, EMBO J, V24, P645, DOI 10.1038/sj.emboj.7600544; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Song J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011456; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Sun LM, 2012, CELL, V148, P213, DOI 10.1016/j.cell.2011.11.031; Tehranchi R, 2010, NEW ENGL J MED, V363, P1025, DOI 10.1056/NEJMoa0912228; Tian H, 2011, NATURE, V478, P255, DOI 10.1038/nature10408; Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001; Trumpp A, 2008, NAT CLIN PRACT ONCOL, V5, P337, DOI 10.1038/ncponc1110; Wang JCY, 2007, CELL STEM CELL, V1, P497, DOI 10.1016/j.stem.2007.10.005; White RA, 2013, J CLIN INVEST, V123, P4390, DOI 10.1172/JCI65856; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645	52	27	28	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2019	38	27					5440	5456		10.1038/s41388-019-0800-z	http://dx.doi.org/10.1038/s41388-019-0800-z			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IG5KR	30936460				2022-12-28	WOS:000473842500008
J	Vazquez-Dominguez, I; Gonzalez-Sanchez, L; Lopez-Nieva, P; Fernandez-Navarro, P; Villa-Morales, M; Cobos-Fernandez, MA; Sastre, I; Fraga, MF; Fernandez, AF; Malumbres, M; Salazar-Roa, M; Grana-Castro, O; Santos, J; Llamas, P; Lopez-Lorenzo, JL; Fernandez-Piqueras, J				Vazquez-Dominguez, Irene; Gonzalez-Sanchez, Laura; Lopez-Nieva, Pilar; Fernandez-Navarro, Pablo; Villa-Morales, Maria; Cobos-Fernandez, Maria A.; Sastre, Isabel; Fraga, Mario F.; Fernandez, Agustin F.; Malumbres, Marcos; Salazar-Roa, Maria; Grana-Castro, Osvaldo; Santos, Javier; Llamas, Pilar; Lopez-Lorenzo, Jose L.; Fernandez-Piqueras, Jose			Downregulation of specific FBXW7 isoforms with differential effects in T-cell lymphoblastic lymphoma	ONCOGENE			English	Article							FBW7 UBIQUITIN LIGASE; TUMOR-SUPPRESSOR; STEM-CELLS; BETA-FORM; CYCLIN-E; LEUKEMIA; MUTATIONS; NOTCH1; EXPRESSION; CHILDHOOD	FBXW7 is a driver gene in T-cell lymphoblastic neoplasia acting through proteasome degradation of key proto-oncogenes. FBXW7 encodes three isoforms, alpha, beta and gamma, which differ only in the N-terminus. In this work, massive sequencing revealed significant downregulation of FBXW7 in a panel of primary T-cell lymphoblastic lymphomas characterised by the absence of mutations in its sequence. We observed that decreased expression mainly affected the FBXW7 beta isoform and to a lesser extent FBXW7 alpha and may be attributed to the combined effect of epigenetic changes, alteration of upstream factors and upregulation of miRNAs. Transient transfections with miRNA mimics in selected cell lines resulted in a significant decrease of total FBXW7 expression and its different isoforms separately, with the consequent increment of critical substrates and the stimulation of cell proliferation. Transient inhibition of endogenous miRNAs in a T-cell lymphoblastic-derived cell line (SUP-T1) was capable of reversing these proliferative effects. Finally, we show how FBXW7 isoforms display different roles within the cell. Simultaneous downregulation of the alpha and gamma isoforms modulates the amount of CCNE1, whilst the beta-isoform alone was found to have a prominent role in modulating the amount of c-MYC. Our data also revealed that downregulation of all isoforms is a sine qua non condition to induce a proliferative pattern in our cell model system. Taking these data into account, potential new treatments to reverse downregulation of all or a specific FBXW7 isoform may be an effective strategy to counteract the proliferative capacity of these tumour cells.	[Vazquez-Dominguez, Irene; Gonzalez-Sanchez, Laura; Lopez-Nieva, Pilar; Villa-Morales, Maria; Cobos-Fernandez, Maria A.; Sastre, Isabel; Santos, Javier; Fernandez-Piqueras, Jose] UAM, CSIC, CBMSO, Madrid, Spain; [Vazquez-Dominguez, Irene; Gonzalez-Sanchez, Laura; Lopez-Nieva, Pilar; Villa-Morales, Maria; Cobos-Fernandez, Maria A.; Santos, Javier; Llamas, Pilar; Lopez-Lorenzo, Jose L.; Fernandez-Piqueras, Jose] IIS Fdn Jimenez Diaz, Madrid, Spain; [Gonzalez-Sanchez, Laura; Lopez-Nieva, Pilar; Villa-Morales, Maria; Santos, Javier; Fernandez-Piqueras, Jose] Consorcio Invest Biomed Enfermedades Raras CIBERE, Madrid, Spain; [Fernandez-Navarro, Pablo] Inst Salud Carlos III, Ctr Nacl Epidemiol, Unidad Epidemiol Ambiental & Canc, Madrid, Spain; [Fernandez-Navarro, Pablo] Consorcio Invest Biomed Epidemiol & Salud Publ CI, Madrid, Spain; [Fraga, Mario F.] Univ Oviedo Principado Asturias, CSIC, CINN, Oviedo, Spain; [Fernandez, Agustin F.] Inst Invest Sanitaria Principado Asturias ISPA HU, Fdn Invest Biosanitaria Asturias FINBA, Unidad Epigenet Canc, IUOPA, Oviedo, Spain; [Malumbres, Marcos; Salazar-Roa, Maria] CNIO, Grp Div Celular & Canc, Madrid, Spain; [Grana-Castro, Osvaldo] CNIO, Unidad Bioinformat Biol Estruct & Biocomputac, Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Fundacion Jimenez Diaz; Instituto de Salud Carlos III; Centro Nacional de Epidemiologia (CNE); CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion en Nanomateriales y Nanotecnologia (CINN); University of Oviedo; Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO)	Fernandez-Piqueras, J (corresponding author), UAM, CSIC, CBMSO, Madrid, Spain.; Fernandez-Piqueras, J (corresponding author), IIS Fdn Jimenez Diaz, Madrid, Spain.; Fernandez-Piqueras, J (corresponding author), Consorcio Invest Biomed Enfermedades Raras CIBERE, Madrid, Spain.	jfpiqueras@cbm.csic.es	Domínguez, Irene Vázquez/R-4512-2018; Fraga, Mario F/H-7824-2017; Fernandez, Agustin F./N-7302-2014; Santos, Javier/ABF-5755-2021; VILLA-MORALES, MARIA C./H-8797-2015; Malumbres, Marcos/E-8834-2011	Domínguez, Irene Vázquez/0000-0001-9753-521X; Fraga, Mario F/0000-0001-8450-2603; Fernandez, Agustin F./0000-0002-3792-4085; Santos, Javier/0000-0002-4168-6251; VILLA-MORALES, MARIA C./0000-0001-7906-0169; Malumbres, Marcos/0000-0002-0829-6315; Grana-Castro, Osvaldo/0000-0003-1615-4242; Llamas Sillero, Pilar/0000-0002-8552-3219; Gonzalez-Sanchez, Laura/0000-0002-4749-2423	Spanish Ministry of Economy and Competitiveness [SAF2015-70561-R, BES-2013-065740]; Autonomous Community of Madrid, Spain [B2017/BMD-3778]; Spanish Association against Cancer (AECC, 2018) [PROYE18054PIRI]; Instituto de Salud Carlos III (ISCIII) [ACCI-CIBERER-17]; Fundacion Ramon Areces; Banco de Santander	Spanish Ministry of Economy and Competitiveness(Spanish Government); Autonomous Community of Madrid, Spain; Spanish Association against Cancer (AECC, 2018); Instituto de Salud Carlos III (ISCIII)(Instituto de Salud Carlos IIIEuropean Commission); Fundacion Ramon Areces; Banco de Santander	Spanish Ministry of Economy and Competitiveness (SAF2015-70561-R; MINECO/FEDER, EU; BES-2013-065740); the Autonomous Community of Madrid, Spain (B2017/BMD-3778; LINFOMAS-CM); the Spanish Association against Cancer (AECC, 2018; PROYE18054PIRI) and the Instituto de Salud Carlos III (ISCIII) (ACCI-CIBERER-17). Institutional grants from the Fundacion Ramon Areces and Banco de Santander to the CBMSO are also acknowledged.	Aifantis I, 2008, NAT REV IMMUNOL, V8, P380, DOI 10.1038/nri2304; Akhoondi S, 2007, CANCER RES, V67, P9006, DOI 10.1158/0008-5472.CAN-07-1320; Akhoondi S, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2788; Andres-Leon E, 2015, MIRGATE CURATED DATA, V2015; Atak ZK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038463; Balamurugan K, 2010, EMBO J, V29, P4106, DOI 10.1038/emboj.2010.280; Baldus CD, 2009, HAEMATOL-HEMATOL J, V94, P1383, DOI 10.3324/haematol.2008.005272; Bonn BR, 2013, BLOOD, V121, P3153, DOI 10.1182/blood-2012-12-474148; Burkhardt B, 2010, BRIT J HAEMATOL, V149, P653, DOI 10.1111/j.1365-2141.2009.08006.x; Callens C, 2012, J CLIN ONCOL, V30, P1966, DOI 10.1200/JCO.2011.39.7661; Cheng YB, 2013, J INVEST DERMATOL, V133, P1794, DOI 10.1038/jid.2013.58; Correia NC, 2013, LEUKEMIA, V27, P1603, DOI 10.1038/leu.2013.63; Crusio KM, 2010, ONCOGENE, V29, P4865, DOI 10.1038/onc.2010.222; Davis RJ, 2014, CANCER CELL, V26, P455, DOI 10.1016/j.ccell.2014.09.013; de Leval L, 2009, CRIT REV ONCOL HEMAT, V72, P125, DOI 10.1016/j.critrevonc.2009.01.002; Feng DD, 2011, J CELL MOL MED, V15, P2164, DOI 10.1111/j.1582-4934.2010.01213.x; Gedman AL, 2009, LEUKEMIA, V23, P1417, DOI 10.1038/leu.2009.64; Grinkevich VV, 2009, CANCER CELL, V15, P441, DOI 10.1016/j.ccr.2009.03.021; Gu Z, 2008, GENES GENET SYST, V83, P347, DOI 10.1266/ggs.83.347; Gu ZD, 2008, BIOCHEM BIOPH RES CO, V377, P685, DOI 10.1016/j.bbrc.2008.10.047; Guo DM, 2009, LEUKEMIA RES, V33, P678, DOI 10.1016/j.leukres.2008.10.026; Ho MS, 2006, J BIOMED SCI, V13, P181, DOI 10.1007/s11373-005-9058-2; Hu JP, 2017, ONCOTARGETS THER, V10, P3709, DOI 10.2147/OTT.S141652; Huang HS, 2014, ONCOTARGET, V5, P493, DOI 10.18632/oncotarget.1643; Jin HY, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00340; Katt ME, 2016, FRONT BIOENG BIOTECH, V4, DOI 10.3389/fbioe.2016.00012; Khoury MP, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000927; Kimura T, 2003, CANCER SCI, V94, P431, DOI 10.1111/j.1349-7006.2003.tb01460.x; King B, 2013, CELL, V153, P1552, DOI 10.1016/j.cell.2013.05.041; Knuutila S, 1999, AM J PATHOL, V155, P683, DOI 10.1016/S0002-9440(10)65166-8; Kourtis N, 2015, NAT CELL BIOL, V17, P322, DOI 10.1038/ncb3121; Kumar V, 2014, LEUKEMIA, V28, P2324, DOI 10.1038/leu.2014.133; Lai EC, 2015, RNA, V21, P675, DOI 10.1261/rna.051193.115; Malyukova A, 2007, CANCER RES, V67, P5611, DOI 10.1158/0008-5472.CAN-06-4381; Mansour MR, 2013, J EXP MED, V210, P1545, DOI 10.1084/jem.20122516; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Matsuoka S, 2008, GENE DEV, V22, P986, DOI 10.1101/gad.1621808; Mavrakis KJ, 2011, NAT GENET, V43, P673, DOI 10.1038/ng.858; Mullokandov G, 2012, NAT METHODS, V9, P840, DOI [10.1038/NMETH.2078, 10.1038/nmeth.2078]; Mussolin L, 2014, LEUKEMIA, V28, P1909, DOI 10.1038/leu.2014.134; Neumann M, 2015, ONCOTARGET, V6, P2754, DOI 10.18632/oncotarget.2218; O'Neil J, 2007, J EXP MED, V204, P1813, DOI 10.1084/jem.20070876; Onoyama I, 2007, J EXP MED, V204, P2875, DOI 10.1084/jem.20062299; Park MJ, 2009, BRIT J HAEMATOL, V145, P198, DOI 10.1111/j.1365-2141.2009.07607.x; Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; Rocher-Ros V, 2010, ONCOGENE, V29, P2950, DOI 10.1038/onc.2010.57; Sancho R, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001586; Sionov RV, 2013, CELL CYCLE, V12, P3547, DOI 10.4161/cc.26591; Spruck CH, 2002, CANCER RES, V62, P4535; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Thompson BJ, 2007, J EXP MED, V204, P1825, DOI 10.1084/jem.20070872; Trausch-Azar JS, 2015, J CELL PHYSIOL, V230, P842, DOI 10.1002/jcp.24812; Tremblay CS, 2014, CURR OPIN HEMATOL, V21, P320, DOI 10.1097/MOH.0000000000000058; van Drogen F, 2006, MOL CELL, V23, P37, DOI 10.1016/j.molcel.2006.05.020; Van Vlierberghe P, 2012, J CLIN INVEST, V122, P3398, DOI 10.1172/JCI61269; Wang LX, 2014, ONCOTARGET, V5, P2000, DOI 10.18632/oncotarget.1859; Wei XF, 2015, ONCOTARGET, V6, P18389, DOI 10.18632/oncotarget.4089; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Xu WS, 2016, SEMIN CANCER BIOL, V36, P62, DOI 10.1016/j.semcancer.2015.09.005; Yumimoto K, 2015, J CLIN INVEST, V125, P621, DOI 10.1172/JCI78782; Zhou ZY, 2015, ONCOL REP, V34, P2215, DOI 10.3892/or.2015.4227	63	5	5	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2019	38	23					4620	4636		10.1038/s41388-019-0746-1	http://dx.doi.org/10.1038/s41388-019-0746-1			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IB4KM	30742097				2022-12-28	WOS:000470240300013
J	Dai, W; Xu, XH; Wang, DY; Wu, J; Wang, JK				Dai, Wei; Xu, Xinhui; Wang, Danyang; Wu, Jian; Wang, Jinke			Cancer therapy with a CRISPR-assisted telomerase-activating gene expression system	ONCOGENE			English	Article							GENOME; RNA; MAINTENANCE; IMETELSTAT; INHIBITOR; SEQUENCE; TOOL	Cancer is caused by a series of alterations in genome and epigenome and exists in multiple complex forms, making it difficult to be prevented and/or treated. Telomerase, an enzyme responsible for the maintenance of telomere, is silent in most normal somatic cells but activated in 90% of cancer cells, making it an excellent target for cancer therapy. Therefore, various telomerase activity inhibitors have been developed to treat cancer but all failed due to side effects. Here we acted oppositely to develop a cancer gene therapy named telomerase-activating gene expression (Tage) system by utilizing the telomerase activity in cancer cells. The Tage system consisted of an effector gene expression vector that carried a 3' telomerase-recognizable stick end and an artificial transcription factor expression vector that could express dCas9-VP64 and an sgRNA targeting telomere repeat sequences. By using Cas9 as an effector gene, the Tage system effectively killed various cancer cells, including HepG2, HeLa, PANC-1, MDA-MB-453, A549, HT-29, SKOV-3, Hepa1-6, and RAW264.7, without affecting normal cells MRC-5, HL7702, and bone marrow mesenchymal stem cell (BMSC). More importantly, a four-base 3' stick end produced by the homothallic switching endonuclease in cells could be recognized by telomerase, allowing the Tage system to effectively kill cancer cells in vivo. The Tage system could effectively and safely realize its in vivo application by using adeno-associated virus (AAV) as gene vector. The virus-loaded Tage system could significantly and specifically kill cancer cells in mice by intravenous drug administration without side effects or toxicity.	[Dai, Wei; Xu, Xinhui; Wang, Danyang; Wu, Jian; Wang, Jinke] Southeast Univ, State Key Lab Bioelect, Nanjing 210096, Jiangsu, Peoples R China	Southeast University - China	Wang, JK (corresponding author), Southeast Univ, State Key Lab Bioelect, Nanjing 210096, Jiangsu, Peoples R China.	wangjinke@seu.edu.cn	Wang, Jinke/AAT-7832-2021	Wang, Jinke/0000-0002-3352-4690	National Natural Science Foundation of China [61571119]; National Key Research and Development Program of China [2017YFA0205502]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program of China	This work was supported by the National Natural Science Foundation of China (61571119) and the National Key Research and Development Program of China (2017YFA0205502).	Aschacher T, 2016, ONCOGENE, V35, P94, DOI 10.1038/onc.2015.65; Banerjee Budhaditya, 2017, Curr Opin Syst Biol, V1, P1, DOI 10.1016/j.coisb.2016.12.016; Bikard D, 2014, NAT BIOTECHNOL, V32, P1146, DOI 10.1038/nbt.3043; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BLACKBURN EH, 1984, CELL, V37, P7, DOI 10.1016/0092-8674(84)90295-2; Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47; Chavez A, 2016, NAT METHODS, V13, P563, DOI [10.1038/NMETH.3871, 10.1038/nmeth.3871]; Colgin LM, 1999, CURR OPIN GENET DEV, V9, P97, DOI 10.1016/S0959-437X(99)80014-8; Colgin LM, 2003, CURR BIOL, V13, P942, DOI 10.1016/S0960-9822(03)00339-7; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; Deltcheva E, 2011, NATURE, V471, P602, DOI 10.1038/nature09886; Deng YB, 2007, LAB INVEST, V87, P1071, DOI 10.1038/labinvest.3700673; Diede SJ, 1999, CELL, V99, P723, DOI 10.1016/S0092-8674(00)81670-0; Doudna JA, 2014, SCIENCE, V346, P1077, DOI 10.1126/science.1258096; Dunbar CE, 2018, SCIENCE, V359, P175, DOI 10.1126/science.aan4672; Gasiunas G, 2012, P NATL ACAD SCI USA, V109, pE2579, DOI 10.1073/pnas.1208507109; George LA, 2017, BLOOD ADV, V1, P2591, DOI 10.1182/bloodadvances.2017009878; Henson JD, 2002, ONCOGENE, V21, P598, DOI 10.1038/sj.onc.1205058; Horvath P, 2010, SCIENCE, V327, P167, DOI 10.1126/science.1179555; Huang FW, 2013, SCIENCE, V339, P957, DOI 10.1126/science.1229259; Jafri MA, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0324-x; Jinek M, 2013, ELIFE, V2, DOI 10.7554/eLife.00471; Khan FA, 2016, ONCOTARGET, V7, P52541, DOI 10.18632/oncotarget.9646; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Maciejowski J, 2017, NAT REV MOL CELL BIO, V18, P175, DOI 10.1038/nrm.2016.171; Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033; Martinez P, 2010, AGING CELL, V9, P653, DOI 10.1111/j.1474-9726.2010.00596.x; Mendell JR, 2017, NEW ENGL J MED, V377, P1713, DOI 10.1056/NEJMoa1706198; Mosoyan G, 2017, LEUKEMIA, V31, P2458, DOI 10.1038/leu.2017.78; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; Nissim L, 2017, CELL, V171, P1138, DOI 10.1016/j.cell.2017.09.049; Niu YY, 2014, CELL, V156, P836, DOI 10.1016/j.cell.2014.01.027; Platt RJ, 2014, CELL, V159, P440, DOI 10.1016/j.cell.2014.09.014; Sachdeva M, 2015, CANCER GENE THER, V22, P509, DOI 10.1038/cgt.2015.54; Samanta MK, 2016, TRANSGENIC RES, V25, P561, DOI 10.1007/s11248-016-9953-5; SHAMPAY J, 1984, NATURE, V310, P154, DOI 10.1038/310154a0; Shay JW, 2011, SEMIN CANCER BIOL, V21, P349, DOI 10.1016/j.semcancer.2011.10.001; Stewart SA, 2010, CANCER RES, V70, P7365, DOI 10.1158/0008-5472.CAN-10-1373; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Tefferi A, 2015, NEW ENGL J MED, V373, P908, DOI 10.1056/NEJMoa1310523; Valdmanis PN, 2017, HUM GENE THER, V28, P361, DOI 10.1089/hum.2016.171; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Williams TL, 2010, J BIOL CHEM, V285, P35814, DOI 10.1074/jbc.M110.170167; Wright WE, 1996, DEV GENET, V18, P173; Wright WE, 2002, NAT BIOTECHNOL, V20, P682, DOI 10.1038/nbt0702-682; Xue W, 2014, NATURE, V514, P380, DOI 10.1038/nature13589	46	15	15	2	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2019	38	21					4110	4124		10.1038/s41388-019-0707-8	http://dx.doi.org/10.1038/s41388-019-0707-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ3HX	30696954	Green Submitted			2022-12-28	WOS:000468740200010
J	Fang, S; Liu, M; Li, L; Zhang, FF; Li, Y; Yan, Q; Cui, YZ; Zhu, YH; Yuan, YF; Guan, XY				Fang, Shuo; Liu, Ming; Li, Lei; Zhang, Fei-Fei; Li, Yun; Yan, Qian; Cui, Yu-Zhu; Zhu, Ying-Hui; Yuan, Yun-Fei; Guan, Xin-Yuan			Lymphoid enhancer-binding factor-1 promotes stemness and poor differentiation of hepatocellular carcinoma by directly activating the NOTCH pathway	ONCOGENE			English	Article							SIGNALING PATHWAY; GENE-EXPRESSION; WNT; CELLS; SURVIVAL; LEF-1; TRANSLOCATION; LEUKEMIA; TARGET; SPLIT	The poorly differentiated hepatocellular carcinoma (HCC) cells are usually characterized by immature hepatic progenitor cell-like properties, such as enhanced self-renewal ability, resistance to chemotherapeutic drugs, and a loss of mature hepatocyte proteins. However, the molecular mechanisms governing this process still remain unclear. In this study, we found the lymphoid enhancer-binding factor-1 (LEF1), a transcriptional factor, was frequently overexpressed in HCCs, which was significantly associated with poor prognosis and tumor cell differentiation. Functional studies have found that LEF1 enhanced cell growth, foci formation, colony formation in soft agar, and tumor formation in nude mice. Different from its canonical roles in the WNT signaling pathway, we found that LEF1 could activate the critical members (e.g., NOTCH1 and NOTCH2) of the NOTCH signaling pathway through directly binding to their promoter regions. Further studies have found that LEF1 could enhance the self-renewal ability, drug resistance, dedifferentiation, and invasion of HCC cells. The oncogenic functions and the effects of LEF1 on cancer stemness could be effectively inhibited by NOTCH inhibitor. Further characterization of LEF1 may lead to the development of novel therapeutic strategies for HCC treatment.	[Fang, Shuo; Zhang, Fei-Fei; Li, Yun; Yan, Qian; Cui, Yu-Zhu; Guan, Xin-Yuan] Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China; [Fang, Shuo; Zhang, Fei-Fei; Li, Yun; Yan, Qian; Cui, Yu-Zhu; Guan, Xin-Yuan] Univ Hong Kong, State Key Lab Liver Res, Hong Kong, Peoples R China; [Fang, Shuo] Sun Yat Sen Univ, Affiliated Hosp 7, Shenzhen, Peoples R China; [Liu, Ming] Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Sch Basic Med Sci, Key Lab Prot Modificat & Degradat, Guangzhou, Guangdong, Peoples R China; [Li, Lei; Zhu, Ying-Hui; Yuan, Yun-Fei; Guan, Xin-Yuan] Sun Yat Sen Univ, State Key Lab Oncol Southern China, Guangzhou, Guangdong, Peoples R China	University of Hong Kong; University of Hong Kong; Sun Yat Sen University; Guangzhou Medical University; State Key Lab Oncology South China; Sun Yat Sen University	Guan, XY (corresponding author), Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China.; Guan, XY (corresponding author), Univ Hong Kong, State Key Lab Liver Res, Hong Kong, Peoples R China.; Guan, XY (corresponding author), Sun Yat Sen Univ, State Key Lab Oncol Southern China, Guangzhou, Guangdong, Peoples R China.	xyguan@hku.hk	SHUO, FANG/GQP-5192-2022; /A-3639-2009	SHUO, FANG/0000-0002-1724-404X; Yuan, Yunfei/0000-0003-2467-3683; LIU, MING/0000-0003-3222-8715; /0000-0003-1874-9805	Hong Kong Research Grant Council (RGC) [17143716, 767313, C7038-14G, C7027-14G, T12-704/16-R]; National Natural Science Foundation of China [81772554, 81272416, 81372583]; Shenzhen Peacock Team Project [KQTD 2015033117210153]	Hong Kong Research Grant Council (RGC)(Hong Kong Research Grants Council); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shenzhen Peacock Team Project	This work was supported by grants from the Hong Kong Research Grant Council (RGC), including GRF (17143716 and 767313), Collaborative Research Funds (C7038-14G and C7027-14G), Theme-based Research Scheme (T12-704/16-R), and National Natural Science Foundation of China (81772554, 81272416, and 81372583). This work was also supported by the Shenzhen Peacock Team Project (KQTD 2015033117210153). Professor XY Guan is a Sophie YM Chan Professor in Cancer Research.	Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Chen LL, 2011, GUT, V60, P534, DOI 10.1136/gut.2010.224071; Chen LL, 2010, J CLIN INVEST, V120, P1178, DOI 10.1172/JCI40665; Chen LL, 2009, HEPATOLOGY, V50, P122, DOI 10.1002/hep.22933; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Collu GM, 2014, CELL MOL LIFE SCI, V71, P3553, DOI 10.1007/s00018-014-1644-x; Cook JJ, 2010, J NEUROSCI, V30, P6743, DOI 10.1523/JNEUROSCI.1381-10.2010; Dhanasekaran R., 2016, F1000 RES, V5, P879; Fu L, 2007, CANCER RES, V67, P10720, DOI 10.1158/0008-5472.CAN-07-2411; Galceran J, 2004, GENE DEV, V18, P2718, DOI 10.1101/gad.1249504; Heitzler P, 1996, DEVELOPMENT, V122, P161; Ji JF, 2012, SEMIN ONCOL, V39, P461, DOI 10.1053/j.seminoncol.2012.05.011; Kabos P, 2002, J BIOL CHEM, V277, P8763, DOI 10.1074/jbc.C100758200; Kim K, 2002, CELL BIOL INT, V26, P463, DOI 10.1006/cbir.2002.0901; Kohn A, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.21; Kopan R, 2002, J CELL SCI, V115, P1095; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Lai EC, 2004, DEVELOPMENT, V131, P965, DOI 10.1242/dev.01074; Leimeister C, 1999, MECH DEVELOP, V85, P173, DOI 10.1016/S0925-4773(99)00080-5; Liu M, 2016, HEPATOLOGY, V63, P1544, DOI 10.1002/hep.28437; Ma NF, 2008, HEPATOLOGY, V47, P503, DOI 10.1002/hep.22072; Ma S, 2008, ONCOGENE, V27, P1749, DOI 10.1038/sj.onc.1210811; McGregor SM, 2009, THESIS; Mishra L, 2009, HEPATOLOGY, V49, P318, DOI 10.1002/hep.22704; Nakahara F, 2014, BLOOD, V123, P3932, DOI 10.1182/blood-2013-01-476747; Okamura RM, 1998, IMMUNITY, V8, P11, DOI 10.1016/S1074-7613(00)80454-9; Oswald F, 1998, MOL CELL BIOL, V18, P2077, DOI 10.1128/MCB.18.4.2077; Park HJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132992; Petropoulos K, 2008, J EXP MED, V205, P515, DOI 10.1084/jem.20071875; Ranganathan P, 2011, NAT REV CANCER, V11, P338, DOI 10.1038/nrc3035; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074-7613(00)00004-2; Sekiya S, 2012, J CLIN INVEST, V122, P3914, DOI 10.1172/JCI63065; Si-Tayeb K, 2010, DEV CELL, V18, P175, DOI 10.1016/j.devcel.2010.01.011; Staal FJT, 2008, NAT REV IMMUNOL, V8, P581, DOI 10.1038/nri2360; Tong MJ, 2010, J CLIN GASTROENTEROL, V44, pE63, DOI 10.1097/MCG.0b013e3181b4b68b; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Ungerback J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017957; Valenti L, 2013, DIABETES, V62, P4052, DOI 10.2337/db13-0769; Vasaikar SV, 2018, NUCLEIC ACIDS RES, V46, pD956, DOI 10.1093/nar/gkx1090; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Waterman ML, 2004, CANCER METAST REV, V23, P41, DOI 10.1023/A:1025858928620; Weng AP, 2006, GENE DEV, V20, P2096, DOI 10.1101/gad.1450406; Wu W, 2016, ONCOTARGET, V7, P21631, DOI 10.18632/oncotarget.7795; Zhang Y, 2013, INT J MED SCI, V10, P738, DOI 10.7150/ijms.5693	46	22	23	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2019	38	21					4061	4074		10.1038/s41388-019-0704-y	http://dx.doi.org/10.1038/s41388-019-0704-y			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ3HX	30696957				2022-12-28	WOS:000468740200007
J	Tang, B; Wu, J; Zhu, MX; Sun, XM; Liu, JJ; Xie, R; Dong, TX; Xiao, YF; Carethers, JM; Yang, SM; Dong, H				Tang, Bo; Wu, Jilin; Zhu, Michael X.; Sun, Xuemei; Liu, Jingjing; Xie, Rui; Dong, Tobias Xiao; Xiao, Yufeng; Carethers, John M.; Yang, Shiming; Dong, Hui			VPAC1 couples with TRPV4 channel to promote calcium-dependent gastric cancer progression via a novel autocrine mechanism	ONCOGENE			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; CELL-PROLIFERATION; CA2+; VIP; RECEPTOR; ACTIVATION; OVEREXPRESSION; EXPRESSION; SECRETION; CATENIN	Although VPAC1 and its ligand vasoactive intestinal peptide (VIP) are important in gastrointestinal physiology, their involvements in progression of gastrointestinal tumor have not been explored. Here, we found that higher expression of VIP/VPAC1 was observed in gastric cancer compared to the adjacent normal tissues. The increased expression of VIP/VPAC1 in gastric cancer correlated positively with invasion, tumor stage, lymph node, distant metastases, and poor survival. Moreover, high expression of VIP and VPAC1, advanced tumor stage and distant metastasis were independent prognostic factors. VPAC1 activation by VIP markedly induced TRPV4-mediated Ca2+ entry, and eventually promoted gastric cancer progression in a Ca2+ signaling-dependent manner. Inhibition of VPAC1 and its signaling pathway could block the progressive responses. VPAC1/TRPV4/Ca2+ signaling in turn enhanced the expression and secretion of VIP in gastric cancer cells, enforcing a positive feedback regulation mechanism. Taken together, our study demonstrate that VPAC1 is significantly overexpressed in gastric cancer and VPAC1/TRPV4/Ca2+ signaling axis could enforce a positive feedback regulation in gastric cancer progression. VIP/VPAC1 may serve as potential prognostic markers and therapeutic targets for gastric cancer.	[Tang, Bo; Sun, Xuemei; Liu, Jingjing; Xie, Rui; Xiao, Yufeng; Yang, Shiming; Dong, Hui] Third Mil Med Univ, Xinqiao Hosp, Dept Gastroenterol, Chongqing, Peoples R China; [Tang, Bo; Dong, Tobias Xiao; Dong, Hui] Univ Calif San Diego, Sch Med, Dept Med, San Diego, CA 92103 USA; [Wu, Jilin; Zhu, Michael X.] Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai, Peoples R China; [Wu, Jilin] Univ Chinese Acad Sci, Beijing, Peoples R China; [Zhu, Michael X.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; [Xie, Rui] Zunyi Med Coll, Affiliated Hosp, Dept Gastroenterol, Zunyi, Peoples R China; [Carethers, John M.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA	Army Medical University; University of California System; University of California San Diego; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; University of Texas System; University of Texas Health Science Center Houston; Zunyi Medical University; University of Michigan System; University of Michigan	Yang, SM; Dong, H (corresponding author), Third Mil Med Univ, Xinqiao Hosp, Dept Gastroenterol, Chongqing, Peoples R China.; Dong, H (corresponding author), Univ Calif San Diego, Sch Med, Dept Med, San Diego, CA 92103 USA.	shimingyang@yahoo.com; h2dong@ucsd.edu		Dong, Xiao/0000-0001-5500-7099	National Key Research and Development Program of China [2016YFC1302200]; National Natural Science Foundation of China [81602577]; Basic Science and Frontier Technology Research Project of Chongqing [cstc2017jcyjAX0149]; NATIONAL CANCER INSTITUTE [R01CA206010] Funding Source: NIH RePORTER	National Key Research and Development Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Basic Science and Frontier Technology Research Project of Chongqing; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Key Research and Development Program of China (No. 2016YFC1302200 to HD), National Natural Science Foundation of China (No. 81602577 to BT), and Basic Science and Frontier Technology Research Project of Chongqing (No. cstc2017jcyjAX0149 to BT).	Andrikopoulos P, 2015, J BIOL CHEM, V290, P18412, DOI 10.1074/jbc.M114.628156; Badgwell B, 2016, LANCET ONCOL, V17, P1628, DOI 10.1016/S1470-2045(16)30521-6; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Chen F, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0278-7; Chen YF, 2016, BBA-MOL CELL RES, V1863, P1427, DOI 10.1016/j.bbamcr.2015.11.030; Chen YF, 2013, J BIOMED SCI, V20, DOI 10.1186/1423-0127-20-23; D'Aldebert E, 2011, GASTROENTEROLOGY, V140, P275, DOI 10.1053/j.gastro.2010.09.045; Deliot N, 2015, BBA-BIOMEMBRANES, V1848, P2512, DOI 10.1016/j.bbamem.2015.06.009; Dickson L, 2009, PHARMACOL THERAPEUT, V121, P294, DOI 10.1016/j.pharmthera.2008.11.006; Evans AM, 2016, SCI CHINA LIFE SCI, V59, P749, DOI 10.1007/s11427-016-5071-0; Favia A, 2014, P NATL ACAD SCI USA, V111, pE4706, DOI 10.1073/pnas.1406029111; Fernandez-Martinez AB, 2012, HISTOL HISTOPATHOL, V27, P1093, DOI 10.14670/HH-27.1093; Galione A, 2002, CELL CALCIUM, V32, P343, DOI 10.1016/S0143416002001902; Hagen BM, 2006, AM J PHYSIOL-CELL PH, V291, pC375, DOI 10.1152/ajpcell.00495.2005; Hahm SH, 1998, ANN NY ACAD SCI, V865, P10, DOI 10.1111/j.1749-6632.1998.tb11158.x; Hejna M, 2001, ANTICANCER RES, V21, P1183; Herrera JL, 2009, J CELL MOL MED, V13, P3209, DOI 10.1111/j.1582-4934.2009.00662.x; Hofer AM, 2003, NAT REV MOL CELL BIO, V4, P530, DOI 10.1038/nrm1154; Hogan PG, 2017, CELL CALCIUM, V63, P66, DOI 10.1016/j.ceca.2017.01.014; Holzer P, 2011, CURR PHARM BIOTECHNO, V12, P24, DOI 10.2174/138920111793937862; Kodama D, 2013, BIOCHEM BIOPH RES CO, V437, P239, DOI 10.1016/j.bbrc.2013.06.047; Leuner K, 2010, MOL PHARMACOL, V77, P368, DOI 10.1124/mol.109.057513; Li D, 2013, INVEST OPHTH VIS SCI, V54, P2872, DOI 10.1167/iovs.12-11264; Liu F, 2015, ONCOTARGET, V6, P11585, DOI 10.18632/oncotarget.3412; Liu SH, 2014, TUMOR BIOL, V35, P6397, DOI 10.1007/s13277-014-1852-x; Ma YL, 2016, GUT, V65, P1494, DOI 10.1136/gutjnl-2014-308392; Monteith GR, 2012, J BIOL CHEM, V287, P31666, DOI 10.1074/jbc.R112.343061; Pla AF, 2012, ONCOGENE, V31, P200, DOI 10.1038/onc.2011.231; Reubi JC, 2000, CANCER RES, V60, P3105; Schwarz EC, 2013, BBA-MOL CELL RES, V1833, P1603, DOI 10.1016/j.bbamcr.2012.11.016; Seoane IV, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149141; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Song WQ, 2014, CANCER RES, V74, P2444, DOI 10.1158/0008-5472.CAN-13-2136; Storch U, 2017, P NATL ACAD SCI USA, V114, pE37, DOI 10.1073/pnas.1612263114; Tabuchi A, 2002, J BIOL CHEM, V277, P35920, DOI 10.1074/jbc.M204784200; Tan P, 2015, GASTROENTEROLOGY, V149, P1153, DOI 10.1053/j.gastro.2015.05.059; Thrasivoulou C, 2013, J BIOL CHEM, V288, P35651, DOI 10.1074/jbc.M112.437913; Tompkins JD, 2010, J MOL NEUROSCI, V42, P390, DOI 10.1007/s12031-010-9367-4; Vacas E, 2013, CANCER LETT, V336, P196, DOI 10.1016/j.canlet.2013.04.033; Vacas E, 2013, MOL CELL ENDOCRINOL, V365, P212, DOI 10.1016/j.mce.2012.10.021; Valdehita A, 2007, REGUL PEPTIDES, V144, P101, DOI 10.1016/j.regpep.2007.06.006; Valdehita A, 2009, MOL CELL ENDOCRINOL, V302, P41, DOI 10.1016/j.mce.2008.11.024; Wei CL, 2009, NATURE, V457, P901, DOI 10.1038/nature07577; White CM, 2010, CNS NEUROL DISORD-DR, V9, P661; Woo DH, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-42; Xiao G, 2015, ONCOTARGET, V6, P14165, DOI 10.18632/oncotarget.3690; Xie R, 2017, CANCER RES, V77, P6499, DOI 10.1158/0008-5472.CAN-17-0360; Yin YL, 2016, P NATL ACAD SCI USA, V113, pE3773, DOI 10.1073/pnas.1604519113; Zhang SA, 2010, J PHYSIOL SCI, V60, P389, DOI 10.1007/s12576-010-0107-x; Zhou ZC, 2014, GASTROENTEROLOGY, V147, P1043, DOI 10.1053/j.gastro.2014.07.021; Zhu MX, 2016, SCI CHINA LIFE SCI, V59, P743, DOI 10.1007/s11427-016-5098-2	51	24	24	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2019	38	20					3946	3961		10.1038/s41388-019-0709-6	http://dx.doi.org/10.1038/s41388-019-0709-6			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HY3OI	30692637	Green Submitted			2022-12-28	WOS:000468035600013
J	Carrero, I; Liu, HC; Sikora, AG; Milosavljevic, A				Carrero, Ivenise; Liu, Hsuan-Chen; Sikora, Andrew G.; Milosavljevic, Aleksandar			Histoepigenetic analysis of HPV- and tobacco-associated head and neck cancer identifies both subtype-specific and common therapeutic targets despite divergent microenvironments	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMA; DNA METHYLATION DATA; HUMAN-PAPILLOMAVIRUS; GENE-EXPRESSION; POSITIVE HEAD; SURVIVAL; GENOME; EPIDEMIOLOGY; SIGNATURE; MUTATION	Although head and neck squamous cell carcinoma (HNSCC) has in the past been largely associated with tobacco use, human papillomavirus (HPV+) oropharynx cancer has in recent years emerged as the fastest growing type of HNSCC. Patients with HPV+ HNSCC have a better prognosis; however, the 5-year survival for both HPV+ and HPV- subtypes with recurrent or metastatic disease is poor. To gain insights into the tumor microenvironments of both HNSCC subtypes and identify potential therapeutic targets, we performed epigenomic deconvolution on 580 HNSCC samples from the TCGA dataset. Deconvolution revealed distinct molecular and histoepigenetic profiles of the two tumor subtypes, including their cellular composition, epigenomic profiles and gene expression for constituent cell types, and potential cancer cell-specific targets. Our analyses show that high abundance of both CD8 T-cells and B-cells explains better prognosis in HPV+ HNSCC. Deconvolution of gene expression profiles revealed higher expression of the immunotherapy target PD-1 in HPV+ immune cells compared to HPV- cells, suggesting that HPV+ tumors may preferentially benefit from PD-1 targeted therapy. Further analyses identified HPV+ and HPV- cancer cell surface proteins that can also serve as potential targets for therapy. Specifically, Wnt pathway receptor ROR2 is preferentially overexpressed in HPV+ subtypes, suggesting opportunities for development of targeted therapy based on HPV status. In summary, the comprehensive molecular and histoepigenetic analysis of tumor microenvironments by epigenomic deconvolution reveals potential novel biomarkers and targets for precision therapy of HNSCC.	[Carrero, Ivenise; Milosavljevic, Aleksandar] Baylor Coll Med, Mol & Human Genet Dept, Houston, TX 77030 USA; [Carrero, Ivenise; Milosavljevic, Aleksandar] Baylor Coll Med, Epigenome Ctr, Houston, TX 77030 USA; [Liu, Hsuan-Chen] Baylor Coll Med, Translat Biol & Mol Med Program, Houston, TX 77030 USA; [Liu, Hsuan-Chen; Sikora, Andrew G.] Baylor Coll Med, Dept Otolaryngol Head & Neck Surg, Houston, TX 77030 USA; [Milosavljevic, Aleksandar] Baylor Coll Med, Program Quantitat & Computat Biosci, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Milosavljevic, A (corresponding author), Baylor Coll Med, Mol & Human Genet Dept, Houston, TX 77030 USA.; Milosavljevic, A (corresponding author), Baylor Coll Med, Epigenome Ctr, Houston, TX 77030 USA.; Sikora, AG (corresponding author), Baylor Coll Med, Dept Otolaryngol Head & Neck Surg, Houston, TX 77030 USA.; Milosavljevic, A (corresponding author), Baylor Coll Med, Program Quantitat & Computat Biosci, Houston, TX 77030 USA.	Andrew.Sikora@bcm.edu; amilosav@bcm.edu		Liu, Hsuan-Chen/0000-0001-7857-0204	Common Fund of the National Institutes of Health (NIH) [5U54 DA036134]; Carolyn Weiss Law Foundation for Academic Excellence; Baylor College of Medicine Dan L. Duncan Cancer Center Pilot Grant; NATIONAL INSTITUTE ON DRUG ABUSE [U54DA036134] Funding Source: NIH RePORTER	Common Fund of the National Institutes of Health (NIH); Carolyn Weiss Law Foundation for Academic Excellence; Baylor College of Medicine Dan L. Duncan Cancer Center Pilot Grant; NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by a grant from the Common Fund of the National Institutes of Health (NIH) (5U54 DA036134) (to A. M.), the Carolyn Weiss Law Foundation for Academic Excellence (to AS), and the Baylor College of Medicine Dan L. Duncan Cancer Center Pilot Grant (to AS).	Afghahi A, 2015, CANCER J, V21, P294, DOI 10.1097/PPO.0000000000000135; Ahmed S, 2015, BREAST CANCER-TOKYO, V22, P101, DOI 10.1007/s12282-015-0587-x; Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Aran D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9971; Argiris A, 2009, CANCER-AM CANCER SOC, V115, P4504, DOI 10.1002/cncr.24528; Assenov Y, 2014, NAT METHODS, V11, P1138, DOI [10.1038/NMETH.3115, 10.1038/nmeth.3115]; Bausch-Fluck D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121314; Becht E, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1070-5; Becht E, 2016, ADV IMMUNOL, V130, P95, DOI 10.1016/bs.ai.2015.12.002; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Castiglioni P, 2005, EUR J IMMUNOL, V35, P1360, DOI 10.1002/eji.200425530; Chaturvedi AK, 2011, J CLIN ONCOL, V29, P4294, DOI 10.1200/JCO.2011.36.4596; Chen AX, 2016, INT J CLIN EXP PATHO, V9, P10981; Clements WM, 2002, CANCER RES, V62, P3503; Dalen AGD, 2003, INT J CANCER, V103, P768, DOI 10.1002/ijc.10903; Debey S, 2004, PHARMACOGENOMICS J, V4, P193, DOI 10.1038/sj.tpj.6500240; Esposti DD, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0419-z; Fakhry C, 2008, JNCI-J NATL CANCER I, V100, P261, DOI 10.1093/jnci/djn011; Ford CE, 2013, INT J CANCER, V133, P779, DOI 10.1002/ijc.27984; Forster MD, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00310; Ganguly KK, 2013, CELL ADHES MIGR, V7, P251, DOI 10.4161/cam.23840; Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909; Gutman DA, 2013, J AM MED INFORM ASSN, V20, P1091, DOI 10.1136/amiajnl-2012-001469; Houseman EA, 2014, CANCER INFORM, V13, P53, DOI 10.4137/CIN.S13980; Houseman EA, 2014, BIOINFORMATICS, V30, P1431, DOI 10.1093/bioinformatics/btu029; Ishikawa N, 2007, CANCER RES, V67, P11601, DOI 10.1158/0008-5472.CAN-07-3243; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kamburov A, 2011, NUCLEIC ACIDS RES, V39, pD712, DOI 10.1093/nar/gkq1156; Knights Alexander J, 2012, Trends Cancer Res, V8, P61; Kong HK, 2012, J BIOL CHEM, V287, P38889, DOI 10.1074/jbc.M112.394270; Koshizuka K, 2018, ONCOTARGET, V9, P3663, DOI 10.18632/oncotarget.23194; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Li Y, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-S5-S11; Litwin TR, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9080206; Lleras RA, 2013, CLIN CANCER RES, V19, P5444, DOI 10.1158/1078-0432.CCR-12-3280; Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653; Mandal R, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.89829; McCormack PL, 2008, DRUGS, V68, P487, DOI 10.2165/00003495-200868040-00009; McKaig RG, 1998, HEAD NECK-J SCI SPEC, V20, P250, DOI 10.1002/(SICI)1097-0347(199805)20:3<250::AID-HED11>3.0.CO;2-O; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Mroz Edmund A, 2016, World J Otorhinolaryngol Head Neck Surg, V2, P60, DOI 10.1016/j.wjorl.2016.05.007; Nulton TJ, 2017, ONCOTARGET, V8, P17684, DOI 10.18632/oncotarget.15179; Onuchic V, 2016, CELL REP, V17, P2075, DOI 10.1016/j.celrep.2016.10.057; Orentas RJ, 2012, FRONT ONCOL, V2, DOI [10.3389/FONC.2012.00194/ABSTRACT, DOI 10.3389/FONC.2012.00194/ABSTRACT]; Organization WH, 2014, REV CANC MED WHO LIS, P1; Ragin CCR, 2007, J DENT RES, V86, P104, DOI 10.1177/154405910708600202; Riaz N, 2014, GENES DIS, V1, P75, DOI 10.1016/j.gendis.2014.07.002; Rieke DT, 2016, ONCOL RES TREAT, V39, P780, DOI 10.1159/000452432; Sakamoto T, 2017, ORAL ONCOL, V69, P15, DOI 10.1016/j.oraloncology.2017.03.019; Seguin L, 2015, TRENDS CELL BIOL, V25, P234, DOI 10.1016/j.tcb.2014.12.006; Seiwert TY, 2015, CLIN CANCER RES, V21, P632, DOI 10.1158/1078-0432.CCR-13-3310; Smith EM, 2008, ORAL ONCOL, V44, P133, DOI 10.1016/j.oraloncology.2007.01.010; Snell LM, 2017, TRENDS IMMUNOL, V38, P542, DOI 10.1016/j.it.2017.05.005; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tagliamonte M, 2014, HUM VACC IMMUNOTHER, V10, P3332, DOI 10.4161/21645515.2014.973317; Tong CCL, 2012, IMMUNOL RES, V54, P266, DOI 10.1007/s12026-012-8306-6; Voloshanenko O, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20641-5; Wang B, 2015, GENET MOL RES, V14, P17406, DOI 10.4238/2015.December.21.10; Wang JP, 2015, ONCOTARGET, V6, P18162, DOI 10.18632/oncotarget.4216; Yearley JH, 2017, CLIN CANCER RES, V23, P3158, DOI 10.1158/1078-0432.CCR-16-1761; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304; Zhang YX, 2016, CLIN CANCER RES, V22, P4735, DOI 10.1158/1078-0432.CCR-16-0323	62	17	17	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2019	38	19					3551	3568		10.1038/s41388-018-0659-4	http://dx.doi.org/10.1038/s41388-018-0659-4			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HX4OU	30655605	Green Published, hybrid			2022-12-28	WOS:000467379600001
J	Kumar, R; Njauw, CN; Reddy, BY; Ji, ZY; Rajadurai, A; Klebanov, N; Tsao, HS				Kumar, Raj; Njauw, Ching-Ni; Reddy, Bobby Y.; Ji, Zhenyu; Rajadurai, Anpuchchelvi; Klebanov, Nikolai; Tsao, Hensin			Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma	ONCOGENE			English	Article							GENE-EXPRESSION; SINGLE-CELL; B-RAF; SENESCENCE; BRAF; RESISTANCE; PATHWAYS; MITF; INHIBITOR; MUTATIONS	The underlying forces that shape mutational patterns within any type of cancer have been poorly characterized. One of the best preserved exclusionary relationships is that between BRAF(V600E) and NRAS(Q61) in melanomas. To explore possible mechanisms which could explain this phenomenon, we overexpressed NRAS(Q61) in a set of BRAF(V600E) melanoma lines and vice versa. Controlled expression of a second activating oncogene led to growth arrest ("synthetic suppression") in a subset of cells, which was accompanied by cell cycle arrest and senescence in several melanoma cell lines along with apoptosis. Through differential gene expression analysis, we identified SPRY4 as the potential mediator of this synthetic response to dual oncogene suppression. Ectopic introduction of SPRY4 recapitulated the growth arrest phenotype of dual BRAF(V600E)/NRAS(Q61) expression while SPRY4 depletion led to a partial rescue from oncogenic antagonism. This study thus defined SPRY4 as a potential mediator of synthetic suppression, which is likely to contribute to the observed exclusivity between BRAF(V600E) and NRAS(Q61R) mutations in melanoma. Further leverage of the SPRY4 pathway may also hold therapeutic promise for NRAS(Q61) melanomas.	[Kumar, Raj; Njauw, Ching-Ni; Reddy, Bobby Y.; Ji, Zhenyu; Rajadurai, Anpuchchelvi; Klebanov, Nikolai; Tsao, Hensin] Harvard Med Sch, Dept Dermatol, Massachusetts Gen Hosp, Edwards 211 50 Blossom St, Boston, MA 02115 USA; [Kumar, Raj; Njauw, Ching-Ni; Reddy, Bobby Y.; Ji, Zhenyu; Rajadurai, Anpuchchelvi; Klebanov, Nikolai] Harvard Med Sch, Wellman Ctr Photomed, Massachusetts Gen Hosp, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Tsao, HS (corresponding author), Harvard Med Sch, Dept Dermatol, Massachusetts Gen Hosp, Edwards 211 50 Blossom St, Boston, MA 02115 USA.	htsao@partners.org			Melanoma Research Alliance; NIH [K24 CA149202]; CDMRP grant: Department of Defense [CA160385]; Massachusetts General Hospital; NATIONAL CANCER INSTITUTE [K24CA149202] Funding Source: NIH RePORTER	Melanoma Research Alliance; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CDMRP grant: Department of Defense(United States Department of Defense); Massachusetts General Hospital(General Electric); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Dr. Jie Zhao, and technical assistants, Danian Cao, Jermaine Henderson and Neema Kumar for performing FACS, H&E and IHC staining (MGH). Technical Associate, Jennifer Love, for performing mRNA microarray (MIT). We thank the MGH-IACUC for animal care. This research was partially supported by grants from the Melanoma Research Alliance and NIH (K24 CA149202), CDMRP grant: Department of Defense CA160385 and by the generous donors at the Massachusetts General Hospital.	Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Beloribi-Djefaflia S, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.49; Bloethner S, 2005, CARCINOGENESIS, V26, P1224, DOI 10.1093/carcin/bgi066; Cabrita MA, 2008, ANGIOGENESIS, V11, P53, DOI 10.1007/s10456-008-9089-1; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Freeman AK, 2013, MOL CELL, V49, P751, DOI 10.1016/j.molcel.2012.12.018; Garnett MJ, 2004, CANCER CELL, V6, P313, DOI 10.1016/j.ccr.2004.09.022; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Hoek KS, 2008, PIGM CELL MELANOMA R, V21, P665, DOI 10.1111/j.1755-148X.2008.00505.x; Ji ZY, 2015, J INVEST DERMATOL, V135, P1863, DOI 10.1038/jid.2015.105; Kumar R, 2015, J INVEST DERMATOL, V135, P1089, DOI 10.1038/jid.2014.528; Lackner DH, 2014, AGING CELL, V13, P946, DOI 10.1111/acel.12234; Lu C, 2015, J INVEST DERMATOL, V135, P816, DOI 10.1038/jid.2014.425; Miao BC, 2015, CANCER DISCOV, V5, P274, DOI 10.1158/2159-8290.CD-14-0295; O'Neil NJ, 2017, NAT REV GENET, V18, P613, DOI 10.1038/nrg.2017.47; Opriessnig T, 2003, VET PATHOL, V40, P521, DOI 10.1354/vp.40-5-521; Pavey S, 2004, ONCOGENE, V23, P4060, DOI 10.1038/sj.onc.1207563; Petti C, 2006, CANCER RES, V66, P6503, DOI 10.1158/0008-5472.CAN-05-4671; Sasaki A, 2003, CELL CYCLE, V2, P281, DOI 10.4161/cc.2.4.418; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Sensi M, 2006, ONCOGENE, V25, P3357, DOI 10.1038/sj.onc.1209379; Seo H, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17591-9; Shi HB, 2014, CANCER DISCOV, V4, P80, DOI 10.1158/2159-8290.CD-13-0642; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Tennis MA, 2010, MOL CANCER RES, V8, P833, DOI 10.1158/1541-7786.MCR-09-0400; Tsavachidou D, 2004, CANCER RES, V64, P5556, DOI 10.1158/0008-5472.CAN-04-1669; van Tuyn J, 2017, J INVEST DERMATOL, V137, P2197, DOI 10.1016/j.jid.2017.05.030; Vizioli MG, 2014, ONCOTARGET, V5, P8270, DOI 10.18632/oncotarget.2013; Wagatsuma A, 2005, J EXP BIOL, V208, P2389, DOI 10.1242/jeb.01625; Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032; Xu YX, 2014, TRENDS BIOCHEM SCI, V39, P268, DOI 10.1016/j.tibs.2014.04.004; 2016, ONCOTARGET, V7, P7716, DOI DOI 10.18632/ONCOTARGET.12848	32	6	6	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2019	38	18					3504	3520		10.1038/s41388-018-0632-2	http://dx.doi.org/10.1038/s41388-018-0632-2			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HW3RI	30651601	Green Published, hybrid			2022-12-28	WOS:000466610000013
J	Urtishak, KA; Wang, LS; Culjkovic-Kraljacic, B; Davenport, JW; Porazzi, P; Vincent, TL; Teachey, DT; Tasian, SK; Moore, JS; Seif, AE; Jin, SH; Barrett, JS; Robinson, BW; Chen, IML; Harvey, RC; Carroll, MP; Carroll, AJ; Heerema, NA; Devidas, M; Dreyer, ZE; Hilden, JM; Hunger, SP; Willman, CL; Borden, KLB; Felix, CA				Urtishak, Karen A.; Wang, Li-San; Culjkovic-Kraljacic, Biljana; Davenport, James W.; Porazzi, Patrizia; Vincent, Tiffaney L.; Teachey, David T.; Tasian, Sarah K.; Moore, Jonni S.; Seif, Alix E.; Jin, Shenghao; Barrett, Jeffrey S.; Robinson, Blaine W.; Chen, I-Ming L.; Harvey, Richard C.; Carroll, Martin P.; Carroll, Andrew J.; Heerema, Nyla A.; Devidas, Meenakshi; Dreyer, ZoAnn E.; Hilden, Joanne M.; Hunger, Stephen P.; Willman, Cheryl L.; Borden, Katherine L. B.; Felix, Carolyn A.			Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; INITIATION-FACTOR EIF4E; GENE-EXPRESSION; PROGNOSTIC-FACTORS; IMPROVED SURVIVAL; DRUG-RESISTANCE; ANTIVIRAL DRUG; RNA REGULON; CELL-CYCLE; FACTOR 4E	The poor outcomes in infant acute lymphoblastic leukemia (ALL) necessitate new treatments. Here we discover that EIF4E protein is elevated in most cases of infant ALL and test EIF4E targeting by the repurposed antiviral agent ribavirin, which has anticancer properties through EIF4E inhibition, as a potential treatment. We find that ribavirin treatment of actively dividing infant ALL cells on bone marrow stromal cells (BMSCs) at clinically achievable concentrations causes robust proliferation inhibition in proportion with EIF4E expression. Further, we find that ribavirin treatment of KMT2A-rearranged (KMT2A-R) infant ALL cells and the KMT2A-AFF1 cell line RS4:11 inhibits EIF4E, leading to decreases in oncogenic EIF4E-regulated cell growth and survival proteins. In ribavirin-sensitive KMT2A-R infant ALL cells and RS4:11 cells, EIF4E-regulated proteins with reduced levels of expression following ribavirin treatment include MYC, MCL1, NBN, BCL2 and BIRC5. Ribavirin-treated RS4:11 cells exhibit impaired EIF4E-dependent nuclear to cytoplasmic export and/or translation of the corresponding mRNAs, as well as reduced phosphorylation of the p-AKT1, p-EIF4EBP1, p-RPS6 and p-EIF4E signaling proteins. This leads to an S-phase cell cycle arrest in RS4:11 cells corresponding to the decreased proliferation. Ribavirin causes nuclear EIF4E to re-localize to the cytoplasm in KMT2A-AFF1 infant ALL and RS4:11 cells, providing further evidence for EIF4E inhibition. Ribavirin slows increases in peripheral blasts in KMT2A-R infant ALL xenograft-bearing mice. Ribavirin cooperates with chemotherapy, particularly L-asparaginase, in reducing live KMT2A-AFF1 infant ALL cells in BMSC co-cultures. This work establishes that EIF4E is broadly elevated across infant ALL and that clinically relevant ribavirin exposures have preclinical activity and effectively inhibit EIF4E in KMT2A-R cases, suggesting promise in EIF4E targeting using ribavirin as a means of treatment.	[Urtishak, Karen A.; Davenport, James W.; Porazzi, Patrizia; Vincent, Tiffaney L.; Teachey, David T.; Tasian, Sarah K.; Seif, Alix E.; Robinson, Blaine W.; Hunger, Stephen P.; Felix, Carolyn A.] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; [Wang, Li-San; Moore, Jonni S.] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA USA; [Culjkovic-Kraljacic, Biljana; Borden, Katherine L. B.] Univ Montreal, IRIC, Dept Pathol & Cell Biol, Montreal, PQ, Canada; [Teachey, David T.; Tasian, Sarah K.; Seif, Alix E.; Barrett, Jeffrey S.; Hunger, Stephen P.; Felix, Carolyn A.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Jin, Shenghao; Carroll, Martin P.] Univ Penn, Div Hematol & Oncol, Perelman Sch Med, Philadelphia, PA USA; [Barrett, Jeffrey S.] Childrens Hosp Philadelphia, Div Clin Pharmacol & Therapeut, Philadelphia, PA 19104 USA; [Chen, I-Ming L.; Harvey, Richard C.; Willman, Cheryl L.] Univ New Mexico Hlth Serv, Dept Pathol, Albuquerque, NM USA; [Chen, I-Ming L.; Harvey, Richard C.; Willman, Cheryl L.] Univ New Mexico Hlth Serv, UNM Canc Ctr, Albuquerque, NM USA; [Carroll, Andrew J.] Univ Alabama Birmingham, Dept Genet, Birmingham, AL USA; [Heerema, Nyla A.] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; [Devidas, Meenakshi] Dept Biostat, Childrens Oncol Grp, Gainesville, FL USA; [Dreyer, ZoAnn E.] Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA; [Hilden, Joanne M.] Childrens Hosp Colorado, Aurora, CO USA; [Hilden, Joanne M.] Univ Colorado, Sch Med, Aurora, CO USA; [Urtishak, Karen A.] NewAgeSys Inc, Princeton Jct, NJ USA; [Porazzi, Patrizia] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Barrett, Jeffrey S.] Bill & Melinda Gates Med Res Inst, Cambridge, MA USA; [Robinson, Blaine W.] Leukemia & Lymphoma Soc, Therapy Accelerat Program, Rye Brook, NY USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Universite de Montreal; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of New Mexico; University of New Mexico; University of Alabama System; University of Alabama Birmingham; University System of Ohio; Ohio State University; Children's Oncology Group (COG); Baylor College of Medicine; Texas Children's Cancer Center; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Jefferson University	Felix, CA (corresponding author), Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA.; Felix, CA (corresponding author), Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA.	felix@email.chop.edu	Porazzi, Patrizia/AAA-3151-2020; Devidas, Meenakshi/H-1170-2019; Seif, Alix/B-9918-2013	Devidas, Meenakshi/0000-0002-1099-3478; Teachey, David/0000-0001-7373-8987; Porazzi, Patrizia/0000-0002-1372-7482; Tasian, Sarah/0000-0003-1327-1662; Seif, Alix/0000-0002-1799-2582	Leukemia & Lymphoma Society [SCOR 7372-07]; ASH Bridge Funding Program; CHOP Bridge Funding Program; Eagles Fly for Leukemia; CHOP Hematologic Malignancies Research Fund; SU2C St. Baldrick's Pediatric Dream Team Translational Research [SU2C-AACR-DT1113]; Cookies for Kids' Cancer Foundation; Rally Foundation [K08CA184418]; Hyundai Hope on Wheels Scholar Award [ACS MRSG-12-215-01-LIB]; Canada Research Chair [R01CA098571, R01CA080728]; COG Statistical Center [U10CA98413]; COG Specimen Banking [U24CA114766];  [R01CA198089]; NATIONAL CANCER INSTITUTE [U10CA098413, R01CA080728, R01CA098571, K08CA184418, U10CA180886, R01CA198089, P30CA016520, U10CA180899] Funding Source: NIH RePORTER	Leukemia & Lymphoma Society(Leukemia and Lymphoma Society); ASH Bridge Funding Program; CHOP Bridge Funding Program; Eagles Fly for Leukemia; CHOP Hematologic Malignancies Research Fund; SU2C St. Baldrick's Pediatric Dream Team Translational Research; Cookies for Kids' Cancer Foundation; Rally Foundation; Hyundai Hope on Wheels Scholar Award; Canada Research Chair(Natural Resources CanadaCanadian Forest ServiceCanada Research Chairs); COG Statistical Center; COG Specimen Banking; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	CAF, LSW, J.S.B., CLW, MD, and SPH supported by Leukemia & Lymphoma Society SCOR 7372-07. CAF supported by ASH Bridge Funding Program, CHOP Bridge Funding Program, Eagles Fly for Leukemia, and CHOP Hematologic Malignancies Research Fund. C.A.F. and S.K.T. supported by SU2C St. Baldrick's Pediatric Dream Team Translational Research Grant SU2C-AACR-DT1113 (SU2C is a program of Entertainment Industry Foundation administered by AACR). CAF and DTT supported by Cookies for Kids' Cancer Foundation. SKT supported by K08CA184418 and Rally Foundation for Childhood Cancer Research and was ALSF Scholar in Developmental Therapeutics. AES supported by ACS MRSG-12-215-01-LIB and Hyundai Hope on Wheels Scholar Award. MPC supported by R01CA198089. KLBB funded by R01CA098571 and R01CA080728 and holds a Canada Research Chair. Other support provided by U10CA98413 (COG Statistical Center), U24CA114766 (COG Specimen Banking).	Aebi C, 1997, J PEDIATR-US, V130, P612, DOI 10.1016/S0022-3476(97)70246-4; Asano K, 2001, COLD SPRING HARB SYM, V66, P403, DOI 10.1101/sqb.2001.66.403; ASSELIN BL, 1993, J CLIN ONCOL, V11, P1780, DOI 10.1200/JCO.1993.11.9.1780; Assouline S, 2015, HAEMATOLOGICA, V100, pE7, DOI 10.3324/haematol.2014.111245; Assouline S, 2009, BLOOD, V114, P257, DOI 10.1182/blood-2009-02-205153; Barrett D, 2012, PEDIATR DRUGS, V14, P299, DOI 10.2165/11594740-000000000-00000; Barrington-Trimis JL, 2017, INT J CANCER, V140, P1000, DOI 10.1002/ijc.30487; Biondi A, 2006, HAEMATOLOGICA, V91, P534; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Borden KLB, 2016, TRANSLATION, V4, DOI 10.1080/21690731.2016.1220899; Borden KLB, 2010, LEUKEMIA LYMPHOMA, V51, P1805, DOI 10.3109/10428194.2010.496506; Bunpo P, 2010, J NUTR, V140, P2020, DOI 10.3945/jn.110.129197; Bunpo P, 2009, J BIOL CHEM, V284, P32742, DOI 10.1074/jbc.M109.047910; Chapuis N, 2010, LEUKEMIA, V24, P1686, DOI 10.1038/leu.2010.170; Cheok MH, 2006, NAT REV CANCER, V6, P117, DOI 10.1038/nrc1800; Culjkovic B, 2008, J CELL BIOL, V181, P51, DOI 10.1083/jcb.200707018; Culjkovic B, 2006, J CELL BIOL, V175, P415, DOI 10.1083/jcb.200607020; Culjkovic B, 2007, CELL CYCLE, V6, P65, DOI 10.4161/cc.6.1.3688; Culjkovic B, 2009, J ONCOL, V2009, DOI 10.1155/2009/981679; Culjkovic-Kraljacic B, 2016, BLOOD, V127, P858, DOI 10.1182/blood-2015-05-645069; Dai DH, 2017, BIOCHEM BIOPH RES CO, V482, P1259, DOI 10.1016/j.bbrc.2016.12.025; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Dordelmann M, 1999, BLOOD, V94, P1209, DOI 10.1182/blood.V94.4.1209.416k05_1209_1217; Dreyer ZE, 2015, PEDIATR BLOOD CANCER, V62, P419, DOI 10.1002/pbc.25322; Dunn LA, 2018, HEAD NECK-J SCI SPEC, V40, P233, DOI 10.1002/hed.24938; Ekins S, 2011, DRUG DISCOV TODAY, V16, P298, DOI 10.1016/j.drudis.2011.02.016; Endres CJ, 2009, J PHARMACOL EXP THER, V331, P287, DOI 10.1124/jpet.109.153130; Faber J, 2009, BLOOD, V113, P2375, DOI 10.1182/blood-2007-09-113597; FERSTER A, 1994, BRIT J HAEMATOL, V86, P284, DOI 10.1111/j.1365-2141.1994.tb04727.x; Frost BM, 2002, MED PEDIATR ONCOL, V38, P329, DOI 10.1002/mpo.10052; Glue P, 1999, SEMIN LIVER DIS, V19, P17; Groninger E, 2004, CRIT REV ONCOL HEMAT, V52, P173, DOI 10.1016/j.critrevonc.2004.08.007; HALL CB, 1983, NEW ENGL J MED, V308, P1443, DOI 10.1056/NEJM198306163082403; Hijiya N, 2009, CANCER-AM CANCER SOC, V115, P23, DOI 10.1002/cncr.23988; Hilden JM, 2006, BLOOD, V108, P441, DOI 10.1182/blood-2005-07-3011; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Holleman A, 2004, NEW ENGL J MED, V351, P533, DOI 10.1056/NEJMoa033513; Hunger SP, 2012, J CLIN ONCOL, V30, P1663, DOI 10.1200/JCO.2011.37.8018; Imamura T, 2002, BRIT J HAEMATOL, V119, P119, DOI 10.1046/j.1365-2141.2002.03803.x; Isakovic AM, 2017, EXP CELL RES, V350, P32, DOI 10.1016/j.yexcr.2016.11.001; Jarvis SM, 1998, BRIT J PHARMACOL, V123, P1587, DOI 10.1038/sj.bjp.0701775; Jedema I, 2004, EXP HEMATOL, V32, P188, DOI 10.1016/j.exphem.2003.11.005; Jones RM, 1996, MOL CELL BIOL, V16, P4754; Kang HN, 2012, BLOOD, V119, P1872, DOI 10.1182/blood-2011-10-382861; Kentsis A, 2005, RNA, V11, P1762, DOI 10.1261/rna.2238705; Kentsis A, 2004, P NATL ACAD SCI USA, V101, P18105, DOI 10.1073/pnas.0406927102; KHARE GP, 1973, ANTIMICROB AGENTS CH, V3, P517, DOI 10.1128/AAC.3.4.517; Koren G, 2003, CAN MED ASSOC J, V168, P1289; Kosaka T, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.6_suppl.329; Kosaka T, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.e14010; Kraljacic BC, 2011, LEUKEMIA, V25, P1197, DOI 10.1038/leu.2011.57; Krilov LR, 2002, PEDIATR INFECT DIS J, V21, P479, DOI 10.1097/00006454-200205000-00037; KRISHAN A, 1976, CANCER RES, V36, P143; Landon AL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6413; LASKIN OL, 1987, CLIN PHARMACOL THER, V41, P546, DOI 10.1038/clpt.1987.70; Lin CJ, 2009, CANCER RES, V69, P7491, DOI 10.1158/0008-5472.CAN-09-0813; LOWIS SP, 1993, CANCER RES, V53, P4881; Mamane Y, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000242; Manara MC, 2013, CURR PHARM DESIGN, V19, P5344, DOI 10.2174/1381612811319300004; Matsuo Y, 1998, LEUKEMIA RES, V22, P567, DOI 10.1016/S0145-2126(98)00050-2; MCLEOD HL, 1992, BRIT J CANCER, V66, pS23; MCLEOD HL, 1993, CANCER SURV, V17, P253; Mihara K, 2003, BRIT J HAEMATOL, V120, P846, DOI 10.1046/j.1365-2141.2003.04217.x; Moore AS, 2011, J PAEDIATR CHILD H, V47, P875, DOI 10.1111/j.1440-1754.2011.02103.x; Munson ME, 2010, CYTOM PART A, V77A, P909, DOI 10.1002/cyto.a.20935; Ogino A, 2014, ONCOL LETT, V8, P2469, DOI 10.3892/ol.2014.2569; Pessetto ZY, 2013, MOL CANCER THER, V12, P1299, DOI 10.1158/1535-7163.MCT-12-0968; Pettersson F, 2015, CANCER RES, V75, P1102, DOI 10.1158/0008-5472.CAN-14-1996; Pettersson F, 2011, CLIN CANCER RES, V17, P2874, DOI 10.1158/1078-0432.CCR-10-2334; Pieters R, 2007, LANCET, V370, P240, DOI 10.1016/S0140-6736(07)61126-X; Pozarowski Piotr, 2004, Curr Protoc Cell Biol, VChapter 18, DOI [10.1002/0471142956.cy0719s25, 10.1002/0471143030.cb1808s21]; Ramakers-van Woerden NL, 2004, LEUKEMIA, V18, P521, DOI 10.1038/sj.leu.2403253; Reaman GH, 1999, J CLIN ONCOL, V17, P445, DOI 10.1200/JCO.1999.17.2.445; Riner A, 2009, POSTGRAD MED, V121, P139, DOI 10.3810/pgm.2009.05.2014; Rixe O, 2007, CLIN CANCER RES, V13, P7280, DOI 10.1158/1078-0432.CCR-07-2141; Robinson BW, 2008, BRIT J HAEMATOL, V141, P827, DOI 10.1111/j.1365-2141.2008.07100.x; Roederer M, 2011, CYTOM PART A, V79A, P95, DOI 10.1002/cyto.a.21010; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; SANDERSON RD, 1989, CELL REGUL, V1, P27, DOI 10.1091/mbc.1.1.27; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Schotte D, 2011, HAEMATOL-HEMATOL J, V96, P703, DOI 10.3324/haematol.2010.026138; Scully RE, 2007, CARDIOVASC TOXICOL, V7, P122, DOI 10.1007/s12012-007-0006-4; Shi FF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136746; Sidwell RW, 2005, ANTIVIR RES, V68, P10, DOI 10.1016/j.antiviral.2005.06.003; Smee Donald F., 2004, Antiviral Chemistry & Chemotherapy, V15, P261; Stam RW, 2010, BLOOD, V115, P2835, DOI 10.1182/blood-2009-07-233049; Tan J, 2018, J BIOCHEM MOL TOXIC, V32, DOI 10.1002/jbt.22007; Tan K, 2008, BIOCHEM BIOPH RES CO, V375, P341, DOI 10.1016/j.bbrc.2008.07.163; Teachey DT, 2006, BLOOD, V107, P1149, DOI 10.1182/blood-2005-05-1935; Teng LC, 2014, CANCER CELL INT, V14, DOI 10.1186/1475-2867-14-63; Topisirovic I, 2005, MOL CELL BIOL, V25, P1100, DOI 10.1128/MCB.25.3.1100-1112.2005; Topisirovic I, 2004, CANCER RES, V64, P8639, DOI 10.1158/0008-5472.CAN-04-2677; Topisirovic I, 2003, MOL CELL BIOL, V23, P8992, DOI 10.1128/MCB.23.24.8992-9002.2003; Topisirovic I, 2009, MOL CELL BIOL, V29, P1152, DOI 10.1128/MCB.01532-08; Trentin L, 2009, EUR J HAEMATOL, V83, P406, DOI 10.1111/j.1600-0609.2009.01305.x; Urtishak KA, 2013, BLOOD, V121, P2689, DOI 10.1182/blood-2012-04-425033; Vallee S, 2000, EUR J PHARMACOL, V404, P49, DOI 10.1016/S0014-2999(00)00596-3; van Leeuwen IMM, 2012, CELL CYCLE, V11, P1851, DOI 10.4161/cc.20254; Volpin F, 2017, ONCOGENE, V36, P3037, DOI 10.1038/onc.2016.457; Volpon L, 2016, P NATL ACAD SCI USA, V113, P5263, DOI 10.1073/pnas.1524291113; Volpon L, 2013, BIOCHEM BIOPH RES CO, V434, P614, DOI 10.1016/j.bbrc.2013.03.125; Wendel HG, 2007, GENE DEV, V21, P3232, DOI 10.1101/gad.1604407; WILLIS RC, 1978, P NATL ACAD SCI USA, V75, P3042, DOI 10.1073/pnas.75.7.3042; Xi CL, 2018, BIOCHEM BIOPH RES CO, V503, P2286, DOI 10.1016/j.bbrc.2018.06.150; Xu K, 2011, BRIEF BIOINFORM, V12, P341, DOI 10.1093/bib/bbr006; Yang CHT, 2017, J CLIN TRANSL HEPATO, V5, P59, DOI 10.14218/JCTH.2016.00053; Yang L, 2008, J CLIN ONCOL, V26, P1932, DOI 10.1200/JCO.2007.13.8404; Zahreddine HA, 2014, NATURE, V511, P90, DOI 10.1038/nature13283	108	21	21	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2019	38	13					2241	2262		10.1038/s41388-018-0567-7	http://dx.doi.org/10.1038/s41388-018-0567-7			22	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ7GN	30478448	Green Accepted			2022-12-28	WOS:000462588000002
J	Ganguly, SS; Hostetter, G; Tang, L; Frank, SB; Saboda, K; Mehra, R; Wang, LS; Li, XH; Keller, ET; Miranti, CK				Ganguly, Sourik S.; Hostetter, Galen; Tang, Lin; Frank, Sander B.; Saboda, Kathylynn; Mehra, Rohit; Wang, Lisha; Li, Xiaohong; Keller, Evan T.; Miranti, Cindy K.			Notch3 promotes prostate cancer-induced bone lesion development via MMP-3	ONCOGENE			English	Article							MATRIX METALLOPROTEINASES; CELLS; PROGRESSION; INHIBITION; ASSOCIATION; EXPRESSION; CASTRATION; METASTASES; OSTEOBLAST; INDUCTION	Prostate cancer metastases primarily localize in the bone where they induce a unique osteoblastic response. Elevated Notch activity is associated with high-grade disease and metastasis. To address how Notch affects prostate cancer bone lesions, we manipulated Notch expression in mouse tibia xenografts and monitored tumor growth, lesion phenotype, and the bone microenvironment. Prostate cancer cell lines that induce mixed osteoblastic lesions in bone expressed 5-6 times more Notch3, than tumor cells that produce osteolytic lesions. Expression of active Notch3 (NICD3) in osteolytic tumors reduced osteolytic lesion area and enhanced osteoblastogenesis, while loss of Notch3 in osteoblastic tumors enhanced osteolytic lesion area and decreased osteoblastogensis. This was accompanied by a respective decrease and increase in the number of active osteoclasts and osteoblasts at the tumor-bone interface, without any effect on tumor proliferation. Conditioned medium from NICD3-expressing cells enhanced osteoblast differentiation and proliferation in vitro, while simultaneously inhibiting osteoclastogenesis. MMP-3 was specifically elevated and secreted by NICD3-expressing tumors, and inhibition of MMP-3 rescued the NICD3-induced osteoblastic phenotypes. Clinical osteoblastic bone metastasis samples had higher levels of Notch3 and MMP-3 compared with patient matched visceral metastases or osteolytic metastasis samples. We identified a Notch3-MMP-3 axis in human prostate cancer bone metastases that contributes to osteoblastic lesion formation by blocking osteoclast differentiation, while also contributing to osteoblastogenesis. These studies define a new role for Notch3 in manipulating the tumor microenvironment in bone metastases.	[Ganguly, Sourik S.; Li, Xiaohong; Miranti, Cindy K.] Ctr Canc & Cell Biol, Program Skeletal Dis & Tumor Microenvironm, Grand Rapids, MI 49503 USA; [Ganguly, Sourik S.; Tang, Lin; Frank, Sander B.; Miranti, Cindy K.] Univ Arizona, Canc Ctr, Dept Cellular & Mol Med, Tucson, AZ 85719 USA; [Hostetter, Galen] Van Andel Res Inst, Tissue Repository & Pathol Core, Grand Rapids, MI USA; [Saboda, Kathylynn; Miranti, Cindy K.] Univ Arizona, Canc Ctr, Tucson, AZ 85719 USA; [Mehra, Rohit; Wang, Lisha; Keller, Evan T.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA	University of Arizona; Van Andel Institute; University of Arizona; University of Michigan System; University of Michigan	Miranti, CK (corresponding author), Ctr Canc & Cell Biol, Program Skeletal Dis & Tumor Microenvironm, Grand Rapids, MI 49503 USA.; Miranti, CK (corresponding author), Univ Arizona, Canc Ctr, Dept Cellular & Mol Med, Tucson, AZ 85719 USA.; Miranti, CK (corresponding author), Univ Arizona, Canc Ctr, Tucson, AZ 85719 USA.	cmiranti@email.arizona.edu	Miranti, Cindy/AAJ-3783-2020	Frank, Sander/0000-0001-7591-944X; , Xiaohong/0000-0001-5074-193X	DOD [W81XWH-14-1-0479, W81XWH-16-1-0136]; University of Arizona Cancer Center (UACC) [NIH/NCI P30CA023074]; Van Andel Research Institute (VARI); University of Arizona; DOD Prostate Cancer Research Program [W81XWH-14-2-0182, W81XWH-14-2-0183, W81XWH-14-2-0185, W81XWH-14-2-0186, W81XWH-15-2-0062]	DOD(United States Department of Defense); University of Arizona Cancer Center (UACC); Van Andel Research Institute (VARI); University of Arizona; DOD Prostate Cancer Research Program	Funding for this project was provided by a DOD Postdoctoral Fellowship W81XWH-16-1-0136 (SSG), DOD W81XWH-14-1-0479 (SBF, LT, CKM), University of Arizona Cancer Center (UACC) NIH/NCI P30CA023074 (KS, CKM), the Van Andel Research Institute (VARI) (GH, XL), and the University of Arizona (CKM). The TMA obtained from the Prostate Cancer Biorepository Network (PCBN) was supported by funds from the DOD Prostate Cancer Research Program: W81XWH-14-2-0182, W81XWH-14-2-0183, W81XWH-14-2-0185, W81XWH-14-2-0186, and W81XWH-15-2-0062. We wish to thank the following: Dr Denise Roe, Director of Biostatistics Shared Resource at UACC for biostatistics support; Dr Chunyan Liu at Ventana Medical Services, Oro Valley, AZ for her pathology services; Dr Colm Morrissey in the Department of Urology, University of Washington, Seattle WA, for his assistance with providing pathological assessment of bone metastasis lesions in the PCBN TMA. Alexandra VanderArk, Veronique Schulz, and Ghada Y.T Mohsen at Van Andel Research Institute for their technical expertise; Zachary Madaj for statistical analysis expertise; Lisa Turner, Kristin Feenstra, and Bree Berghuis of the VARI Pathology and Biorepository Core for their pathology and Aperio expertise; Su Yanli and Staff of the VARI Vivarium and Transgenics core for technical assistance with animal experiments; David Nadziejka for technical editing of the paper; Jeanie Wedberg and Michelle Minard at the Van Andel Institute and David Alvarado at University of Arizona for their administrative support.	Ally MMTM, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/183653; Bin Hafeez B, 2009, CLIN CANCER RES, V15, P452, DOI 10.1158/1078-0432.CCR-08-1631; Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165; Campeau E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006529; Cui D, 2015, CLIN CANCER RES, V21, P4619, DOI 10.1158/1078-0432.CCR-15-0242; Cui J, 2018, INT J CANCER, V143, P645, DOI 10.1002/ijc.31346; Dang L, 2006, DEV NEUROSCI-BASEL, V28, P58, DOI 10.1159/000090753; Danza G, 2013, INT J CANCER, V133, P2577, DOI 10.1002/ijc.28293; Edick MJ, 2007, MOL BIOL CELL, V18, P2481, DOI 10.1091/mbc.E06-04-0261; Evans KE, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-4; Frank SB, 2017, J CELL SCI, V130, P1952, DOI 10.1242/jcs.197152; Frank SB, 2017, BMC BIOTECHNOL, V17, DOI 10.1186/s12896-017-0341-x; Frank SB, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00273; Frieling JS, 2017, ONCOGENE, V36, P4498, DOI 10.1038/onc.2017.70; Furic L, 2010, P NATL ACAD SCI USA, V107, P14134, DOI 10.1073/pnas.1005320107; Ganguly SS, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00364; Garcia AJ, 2013, J BONE MINER RES, V28, P283, DOI 10.1002/jbmr.1747; Gilkes DM, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101669; Gong YX, 2014, CANCERS, V6, P1298, DOI 10.3390/cancers6031298; Hong MH, 2000, J BONE MINER RES, V15, P911, DOI 10.1359/jbmr.2000.15.5.911; Huang JF, 2016, J BUON, V21, P235; Hudson RS, 2012, NUCLEIC ACIDS RES, V40, P3689, DOI 10.1093/nar/gkr1222; Ibrahim T, 2010, CANCER-AM CANCER SOC, V116, P1406, DOI 10.1002/cncr.24896; Imamura Y, 2016, INT J UROL, V23, P654, DOI 10.1111/iju.13137; Jin JK, 2011, INT J CANCER, V128, P2545, DOI 10.1002/ijc.26024; Jung K, 1997, INT J CANCER, V74, P220, DOI 10.1002/(SICI)1097-0215(19970422)74:2<220::AID-IJC14>3.0.CO;2-H; Karayi MK, 2004, PROSTATE CANCER P D, V7, P6, DOI 10.1038/sj.pcan.4500697; Keller ET, 2004, J CELL BIOCHEM, V91, P718, DOI 10.1002/jcb.10662; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Kusano K, 1998, ENDOCRINOLOGY, V139, P1338, DOI 10.1210/en.139.3.1338; Kwon OJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5416; Li XH, 2012, MOL CANCER RES, V10, P494, DOI 10.1158/1541-7786.MCR-11-0506; Long Q, 2011, AM J PATHOL, V179, P46, DOI 10.1016/j.ajpath.2011.03.008; Lynch CC, 2005, CANCER CELL, V7, P485, DOI 10.1016/j.ccr.2005.04.013; Mehner Christine, 2015, Genes Cancer, V6, P480; Ross AE, 2011, PROSTATE, V71, P1568, DOI 10.1002/pros.21373; Roudier MP, 2008, J UROLOGY, V180, P1154, DOI 10.1016/j.juro.2008.04.140; Sasaki K, 2007, J BIOMED MATER RES B, V80B, P491, DOI 10.1002/jbm.b.30622; Sethi N, 2011, CANCER CELL, V19, P192, DOI 10.1016/j.ccr.2010.12.022; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Sottnik JL, 2013, CURR MOL MED, V13, P626; Srivastava P, 2013, GENE, V530, P273, DOI 10.1016/j.gene.2013.06.087; Su QT, 2016, HISTOL HISTOPATHOL, V31, P149, DOI 10.14670/HH-11-685; Thalmann GN, 2000, PROSTATE, V44, P91; Wang XD, 2004, J BIOL CHEM, V279, P24733, DOI 10.1074/jbc.M401602200; Ye QF, 2012, ONCOL LETT, V3, P879, DOI 10.3892/ol.2012.572; Yu XB, 2006, STEM CELLS, V24, P876, DOI 10.1634/stemcells.2005-0598; Zanotti S, 2010, MOL CELL BIOL, V30, P886, DOI 10.1128/MCB.01285-09; Zhang SB, 2014, NEOPLASIA, V16, P158, DOI 10.1593/neo.131870; Zhang ZY, 2010, AM J PATHOL, V177, P1459, DOI 10.2353/ajpath.2010.090476	50	19	22	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	1					204	218		10.1038/s41388-019-0977-1	http://dx.doi.org/10.1038/s41388-019-0977-1			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG3NM	31467432	Green Accepted			2022-12-28	WOS:000509849200014
J	Sun, J; Yan, J; Qiao, HY; Zhao, FY; Li, C; Jiang, JY; Liu, BQ; Meng, XN; Wang, HQ				Sun, Jia; Yan, Jing; Qiao, Huai-Yu; Zhao, Fu-Ying; Li, Chao; Jiang, Jing-Yi; Liu, Bao-Qin; Meng, Xiao-Na; Wang, Hua-Qin			Loss of TRIM29 suppresses cancer stem cell-like characteristics of PDACs via accelerating ISG15 degradation	ONCOGENE			English	Article							BREAST-CANCER; PROMOTES PROLIFERATION; ONCOGENIC FUNCTION; PANCREATIC-CANCER; TUMOR-SUPPRESSOR; INTERFERON; GROWTH; IDENTIFICATION; METASTASIS; AUTOPHAGY	TRIM family proteins are defined as E3 ubiquitin ligases because of their RING-finger domains. The ubiquitin-like protein interferon-stimulated gene 15 (ISG15) encodes a 15-kDa protein, that is implicated in the posttranslational modification of diverse proteins. Both TRIM29 and ISG15 play both pro-tumoral and anti-tumoral functions in cancer cells derived from different histology. In the current study, we demonstrated that correlation expression of TRIM29 and ISG15 in pancreatic ductal adenocarcinomas (PDACs). The current study demonstrated that TRIM29 knockdown destabilized ISG15 protein via promoting its processing by calpain 3 (CAPN3). Importantly, the current study found that TRIM29 knockdown suppressed cancer stem cell-like features of PDACs, which can be rescued by ISG15 independent of its conjugation function. In addition, the current study demonstrated that extracellular free ISG15 played an important role in maintenance of cancer stem cell-like features of PDACs. Thereby, the current study displayed a novel mechanism by which TRIM29 modulates ISG15 stability via CAPN3-mediated processing, and subsequently extracellular ISG15 maintains the cancer stem cell-like features of PDAC via autocrine mode of action.	[Sun, Jia; Yan, Jing; Qiao, Huai-Yu; Zhao, Fu-Ying; Li, Chao; Jiang, Jing-Yi; Liu, Bao-Qin; Meng, Xiao-Na; Wang, Hua-Qin] China Med Univ, Dept Biochem & Mol Biol, Shenyang 110122, Peoples R China; [Sun, Jia; Wang, Hua-Qin] China Med Univ, Minist Publ Hlth, Key Lab Cell Biol, Shenyang 110122, Peoples R China; [Sun, Jia; Wang, Hua-Qin] China Med Univ, Minist Educ, Key Lab Med Cell Biol, Shenyang 110122, Peoples R China	China Medical University; China Medical University; China Medical University	Wang, HQ (corresponding author), China Med Univ, Dept Biochem & Mol Biol, Shenyang 110122, Peoples R China.; Wang, HQ (corresponding author), China Med Univ, Minist Publ Hlth, Key Lab Cell Biol, Shenyang 110122, Peoples R China.; Wang, HQ (corresponding author), China Med Univ, Minist Educ, Key Lab Med Cell Biol, Shenyang 110122, Peoples R China.	hqwang@cmu.edu.cn			National Natural Science Foundation of China [81572828, 81602510, 81602439]; China Postdoctoral Science Foundation [2017M611286]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This work was partly supported by National Natural Science Foundation of China (81572828, 81602510, and 81602439) and China Postdoctoral Science Foundation (2017M611286).	Ai LB, 2014, CANCER RES, V74, P4875, DOI 10.1158/0008-5472.CAN-13-3579; Balic A, 2012, EXP CELL RES, V318, P691, DOI 10.1016/j.yexcr.2011.11.007; Burks J, 2014, ONCOGENE, V33, P794, DOI 10.1038/onc.2012.633; Burks J, 2015, ONCOTARGET, V6, P7221, DOI 10.18632/oncotarget.3372; Charton K, 2015, HUM MOL GENET, V24, P3718, DOI 10.1093/hmg/ddv116; Chen RH, 2016, ONCOTARGET, V7, P16910, DOI 10.18632/oncotarget.7626; Chronopoulos A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12630; Desai SD, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1052935; Desai SD, 2012, EXP BIOL MED, V237, P38, DOI 10.1258/ebm.2011.011236; Du ZY, 2017, BIOCHEM BIOPH RES CO, V491, P343, DOI 10.1016/j.bbrc.2017.07.098; Dukel M, 2016, J BIOL CHEM, V291, P21541, DOI 10.1074/jbc.M116.730960; Feng Q, 2008, MOL CANCER THER, V7, P3780, DOI 10.1158/1535-7163.MCT-08-0753; Giannakopoulos NV, 2009, J VIROL, V83, P1602, DOI 10.1128/JVI.01590-08; HAAS AL, 1987, J BIOL CHEM, V262, P11315; Hatakeyama S, 2017, TRENDS BIOCHEM SCI, V42, P297, DOI 10.1016/j.tibs.2017.01.002; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Jeon YJ, 2012, J CLIN INVEST, V122, P2622, DOI 10.1172/JCI61762; Jiang T, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0715-4; KAPP LN, 1992, AM J HUM GENET, V51, P45; Kosaka Y, 2007, ANN SURG ONCOL, V14, P2543, DOI 10.1245/s10434-007-9461-1; Lenschow DJ, 2005, J VIROL, V79, P13974, DOI 10.1128/JVI.79.22.13974-13983.2005; Liu J, 2012, AM J PATHOL, V180, P839, DOI 10.1016/j.ajpath.2011.10.020; LOEB KR, 1992, J BIOL CHEM, V267, P7806; Mao HW, 2016, ONCOTARGET, V7, P70143, DOI 10.18632/oncotarget.12160; Mizushima N, 2010, NAT CELL BIOL, V12, P823, DOI 10.1038/ncb0910-823; Mustachio LM, 2018, CANCER RES, V78, P587, DOI 10.1158/0008-5472.CAN-17-1752; Mutter GL, 2001, GYNECOL ONCOL, V83, P177, DOI 10.1006/gyno.2001.6352; Paget S, 1989, LANCET, V8, P98, DOI [DOI 10.1016/S0140-6736(00)49915-0, 10.1016/S0140-6736(00)49915-0]; Pattyn E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002427; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Sainz B, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/9012369; Sainz B, 2014, CANCER RES, V74, P7309, DOI 10.1158/0008-5472.CAN-14-1354; Sho T, 2011, BBA-MOL CELL RES, V1813, P1245, DOI 10.1016/j.bbamcr.2011.03.018; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Singh SK, 2003, CANCER RES, V63, P5821; Song XM, 2015, ONCOL LETT, V10, P2283, DOI 10.3892/ol.2015.3623; Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952; Tan ST, 2016, CANCER RES TREAT, V48, P1302, DOI 10.4143/crt.2015.381; Tanaka K, 2009, P JPN ACAD B-PHYS, V85, P12, DOI [10.2183/pjab.85.12, 10.2183/pjab/85.12]; Valle S, 2018, CANCERS, V10, DOI 10.3390/cancers10020033; Vlashi E, 2015, SEMIN CANCER BIOL, V31, P28, DOI 10.1016/j.semcancer.2014.07.001; Vries RGJ, 2010, MOL ONCOL, V4, P373, DOI 10.1016/j.molonc.2010.05.001; Wang LD, 2015, GENE DEV, V29, P171, DOI 10.1101/gad.253591.114; Wang LD, 2009, CANCER CELL, V15, P207, DOI 10.1016/j.ccr.2009.01.018; Wang T, 2015, ONCOTARGET, V6, P44191, DOI 10.18632/oncotarget.6176; Xu R, 2016, ONCOTARGET, V7, P28579, DOI 10.18632/oncotarget.8686; Yanagi T, 2018, CANCER RES, V78, P6795, DOI 10.1158/0008-5472.CAN-18-1495; Yoo L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0138-9; Yuan HY, 2018, EXP CELL RES, V367, P47, DOI 10.1016/j.yexcr.2018.03.017; Yuan ZG, 2010, MOL CELL BIOL, V30, P3004, DOI 10.1128/MCB.01023-09; Zhang QM, 2017, EXP THER MED, V14, P2329, DOI 10.3892/etm.2017.4720; Zhou MJ, 2017, INT J MOL MED, V39, P446, DOI 10.3892/ijmm.2016.2845; Zhou XM, 2016, ONCOTARGET, V7, P13634, DOI 10.18632/oncotarget.7215	53	16	16	1	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					546	559		10.1038/s41388-019-0992-2	http://dx.doi.org/10.1038/s41388-019-0992-2			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31501523				2022-12-28	WOS:000509718300005
J	Xu, BS; Chen, HY; Que, Y; Xiao, W; Zeng, MS; Zhang, X				Xu, Bu-Shu; Chen, Huo-Ying; Que, Yi; Xiao, Wei; Zeng, Mu-Sheng; Zhang, Xing			ALK(ATI) interacts with c-Myc and promotes cancer stem cell-like properties in sarcoma	ONCOGENE			English	Article							CASSETTE TRANSPORTER GENES; SOFT-TISSUE SARCOMAS; LUNG-CANCER; ALK; EXPRESSION; PHENOTYPE; MUTATIONS; RECEPTOR; PATHWAY; TUMORS	Soft tissue sarcoma (STS) is a highly malignant tumor with limited targeted therapies. A novel anaplastic lymphoma kinase (ALK) transcript, ALK(ATI), was identified recently and could be targeted by ALK inhibitors in melanoma. However, the clinical and functional role of aberrant ALK(ATI) expression in STS remains unknown. Here we demonstrate that as a new ALK transcript, ALK(ATI) is frequently found in STS. ALK(ATI) expression correlates with a lower probability of progression-free survival in STS patients. Compared with the other ALK isoforms, ALK(ATI) expresses not only in the cytoplasm, but also in the nucleus of sarcoma cells. Functionally, overexpression of ALK(ATI) promoted cancer stem cell (CSC)-like properties in sarcoma cells by promoting sphere formation and upregulating the expression of stem cell markers. Moreover, the ALK inhibitors not only suppressed the oncogenic functions of ALK(ATI) but also attenuated ALK(ATI)-induced CSC-like properties by reducing the expression of stem cell markers such as c-Myc, ABCG2, BMI1, and OCT4 both in vitro and in vivo. Furthermore, ALK(ATI) interacted with c-Myc and increased the binding of c-Myc to the ABCG2 promoter, resulting in the induction of stem cell-like properties. Together, these findings indicate that ALK(ATI) may be a potential prognostic marker and therapeutic target for STS patients harboring such ALK aberrations.	[Xu, Bu-Shu; Chen, Huo-Ying; Que, Yi; Xiao, Wei; Zhang, Xing] Sun Yat Sen Univ, Melanoma & Sarcoma Med Oncol Unit, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Canc Ctr, 651 Dongfeng Rd East, Guangzhou 510060, Peoples R China; [Chen, Huo-Ying] Guilin Med Univ, Affiliated Hosp 2, Dept Lab Med, Guilin 541100, Peoples R China; [Zeng, Mu-Sheng] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Canc Ctr, 651 Dongfeng Rd East, Guangzhou 510060, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Guilin Medical University; State Key Lab Oncology South China; Sun Yat Sen University	Zhang, X (corresponding author), Sun Yat Sen Univ, Melanoma & Sarcoma Med Oncol Unit, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Canc Ctr, 651 Dongfeng Rd East, Guangzhou 510060, Peoples R China.	zhangxing@sysucc.org.cn		zeng, musheng/0000-0003-3509-5591	National Key Research and Development Program [2017YFA0505600]; National Natural Science Foundation of China Programs [81772863, 81572403]	National Key Research and Development Program; National Natural Science Foundation of China Programs(National Natural Science Foundation of China (NSFC))	This work was supported by the National Key Research and Development Program (2017YFA0505600) and the National Natural Science Foundation of China Programs (Grant Nos 81772863 and 81572403). We thank Dr Deng Xianming (Principal Investigator for Chemical Biology and Medicinal Chemistry School of Life Sciences, Xiamen University, China) for generously providing the plasmids.	[Anonymous], 2013, FDA APPR PAZ HYDR; [Anonymous], 2016, FDA APPR 1 DRUG SHOW; Armstrong F, 2007, EUR J CANCER, V43, P640, DOI 10.1016/j.ejca.2006.12.005; Beck B, 2013, NAT REV CANCER, V13, P727, DOI 10.1038/nrc3597; Bonvini P, 2013, BRIT J CANCER, V109, P3084, DOI 10.1038/bjc.2013.653; Brown HK, 2017, CANCER LETT, V386, P189, DOI 10.1016/j.canlet.2016.11.019; Busam KJ, 2016, AM J SURG PATHOL, V40, P786, DOI 10.1097/PAS.0000000000000611; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Dandawate PR, 2016, SEMIN CANCER BIOL, V40-41, P192, DOI 10.1016/j.semcancer.2016.09.001; Deshmukh A, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0555-x; FDA, 2015, LAB CHANG REQ SOFT T; FDA, 2016, FDA GRANTS ACC APPR; Feng BH, 2013, ONCOL REP, V30, P815, DOI 10.3892/or.2013.2486; Fujiwara T, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/2603092; Grande E, 2011, MOL CANCER THER, V10, P569, DOI 10.1158/1535-7163.MCT-10-0615; Gravina GL, 2016, RADIAT RES, V185, P411, DOI 10.1667/RR14237.1; Haldar M, 2007, CANCER CELL, V11, P375, DOI 10.1016/j.ccr.2007.01.016; Huang FF, 2013, CANCER LETT, V336, P96, DOI 10.1016/j.canlet.2013.04.006; Ishibashi Y, 2015, ONCOL REP, V33, P1667, DOI 10.3892/or.2015.3806; Janoueix-Lerosey I, 2008, NATURE, V455, P967, DOI 10.1038/nature07398; Jiang Q, 2017, ORPHANET J RARE DIS, V12, DOI 10.1186/s13023-017-0647-8; Kim J, 2010, CELL, V143, P313, DOI 10.1016/j.cell.2010.09.010; Kimbara S, 2014, JPN J CLIN ONCOL, V44, P868, DOI 10.1093/jjco/hyu069; Kuo CY, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0317-9; Lee JC, 2017, J PATHOL, V241, P316, DOI 10.1002/path.4836; Lewis JJ, 1997, J CLIN ONCOL, V15, P646, DOI 10.1200/JCO.1997.15.2.646; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; Mansfield AS, 2016, ANN ONCOL, V27, P2111, DOI 10.1093/annonc/mdw405; Pisters PWT, 1996, J CLIN ONCOL, V14, P1679, DOI 10.1200/JCO.1996.14.5.1679; Porro A, 2011, MOL CANCER RES, V9, P1054, DOI 10.1158/1541-7786.MCR-10-0510; Porro A, 2010, J BIOL CHEM, V285, P19532, DOI 10.1074/jbc.M109.078584; Riggi N, 2005, CANCER RES, V65, P11459, DOI 10.1158/0008-5472.CAN-05-1696; Schulte JH, 2011, CLIN CANCER RES, V17, P5082, DOI 10.1158/1078-0432.CCR-10-2809; Shaw AT, 2009, J CLIN ONCOL, V27, P4247, DOI 10.1200/JCO.2009.22.6993; Sheng JY, 2016, SURG CLIN N AM, V96, P1141, DOI 10.1016/j.suc.2016.06.006; Subbiah V, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0160-2; Todaro M, 2010, GASTROENTEROLOGY, V138, P2151, DOI 10.1053/j.gastro.2009.12.063; Toro JR, 2006, INT J CANCER, V119, P2922, DOI 10.1002/ijc.22239; Van Roosbroeck K, 2010, HAEMATOL-HEMATOL J, V95, P509, DOI 10.3324/haematol.2009.014761; Wang YW, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0307-y; Wiesner T, 2015, NATURE, V526, P453, DOI 10.1038/nature15258; Xia P, 2015, AM J CANCER RES, V5, P1602; Xie XK, 2013, MOL MED REP, V8, P168, DOI 10.3892/mmr.2013.1484; Zhou JX, 2013, ANN ONCOL, V24, P1319, DOI 10.1093/annonc/mds626	44	9	9	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	1					151	163		10.1038/s41388-019-0973-5	http://dx.doi.org/10.1038/s41388-019-0973-5			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG3NM	31462708				2022-12-28	WOS:000509849200010
J	He, YF; Johnson, DT; Yang, JS; Wu, HQ; You, S; Yoon, J; Lee, DH; Kim, WK; Aldahl, J; Le, V; Hooker, E; Yu, EJ; Geradts, J; Cardiff, RD; Sun, ZJ				He, Yongfeng; Johnson, Daniel T.; Yang, Julie S.; Wu, Huiqing; You, Sungyong; Yoon, Junhee; Lee, Dong-Hoon; Kim, Won Kyung; Aldahl, Joseph; Le, Vien; Hooker, Erika; Yu, Eun-Jeong; Geradts, Joseph; Cardiff, Robert D.; Sun, Zijie			Loss of the tumor suppressor, Tp53, enhances the androgen receptor-mediated oncogenic transformation and tumor development in the mouse prostate	ONCOGENE			English	Article							TRANSCRIPTION FACTOR; RB DEFICIENCY; CHIP-SEQ; CANCER; P53; GENE; DATABASE; EXPRESSION; STEM; RESISTANCE	Recent genome analysis of human prostate cancers demonstrated that both AR gene amplification and TP53 mutation are among the most frequently observed alterations in advanced prostate cancer. However, the biological role of these dual genetic alterations in prostate tumorigenesis is largely unknown. In addition, there are no biologically relevant models that can be used to assess the molecular mechanisms for these genetic abnormalities. Here, we report a novel mouse model, in which elevated transgenic AR expression and Trp53 deletion occur simultaneously in mouse prostatic epithelium to mimic human prostate cancer cells. These compound mice developed an earlier onset of high-grade prostatic intraepithelial neoplasia and accelerated prostate tumors in comparison with mice harboring only the AR transgene. Histological analysis showed prostatic sarcomatoid and basaloid carcinomas with massive squamous differentiation in the above compound mice. RNA-sequencing analyses identified a robust enrichment of the signature genes for human prostatic basal cell carcinomas in the above prostate tumors. Master regulator analysis revealed SOX2 as a transcriptional regulator in prostatic basal cell tumors. Elevated expression of SOX2 and its downstream target genes were detected in prostatic tumors of the compound mice. Chromatin immunoprecipitation analyses implicate a coregulatory role of AR and SOX2 in the expression of prostatic basal cell signature genes. Our data demonstrate a critical role of SOX2 in prostate tumorigenesis and provide mechanistic insight into prostate tumor aggressiveness and progression mediated by aberrant AR and p53 signaling pathways.	[He, Yongfeng; Yang, Julie S.; Lee, Dong-Hoon; Kim, Won Kyung; Aldahl, Joseph; Le, Vien; Hooker, Erika; Yu, Eun-Jeong; Sun, Zijie] City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, Duarte, CA 91010 USA; [He, Yongfeng; Johnson, Daniel T.; Hooker, Erika; Yu, Eun-Jeong; Sun, Zijie] Stanford Univ, Sch Med, Dept Urol, Stanford, CA 94305 USA; [Wu, Huiqing] City Hope Natl Med Ctr, Beckman Res Inst, Dept Pathol, Duarte, CA 91010 USA; [You, Sungyong; Yoon, Junhee] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Dept Surg, Div Canc Biol & Therapeut, Los Angeles, CA 90048 USA; [Geradts, Joseph] City Hope Natl Med Ctr, Beckman Res Inst, Dept Populat Sci, Duarte, CA 91010 USA; [Cardiff, Robert D.] Univ Calif Davis, Ctr Comparat Med, 4115 Primate Res Dr, Davis, CA 95616 USA	City of Hope; Beckman Research Institute of City of Hope; Stanford University; City of Hope; Beckman Research Institute of City of Hope; Cedars Sinai Medical Center; City of Hope; Beckman Research Institute of City of Hope; University of California System; University of California Davis	Sun, ZJ (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, Duarte, CA 91010 USA.; Sun, ZJ (corresponding author), Stanford Univ, Sch Med, Dept Urol, Stanford, CA 94305 USA.	zjsun@coh.org	le, vien/GWV-7308-2022; You, Sungyong/AAJ-7372-2020; He, Yongfeng/AAR-8257-2020	You, Sungyong/0000-0003-3513-1783; Hooker, Erika/0000-0002-4515-4041; Johnson, Daniel/0000-0003-4669-037X	Public Health Service grants [R01CA070297, R01CA166894, R21CA190021, R01DK104941]; NATIONAL CANCER INSTITUTE [R01CA070297, R21CA190021, R01CA166894] Funding Source: NIH RePORTER	Public Health Service grants(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Public Health Service grants, R01CA070297, R01CA166894, R21CA190021, and R01DK104941.	Aggarwal R, 2018, J CLIN ONCOL, V36, P2492, DOI 10.1200/JCO.2017.77.6880; BOOKSTEIN R, 1993, CANCER RES, V53, P3369; Cahan P, 2014, CELL, V158, P903, DOI 10.1016/j.cell.2014.07.020; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chamarthy Murthy R., 2011, Yale Journal of Biology and Medicine, V84, P391; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen L, 2011, BIOINFORMATICS, V27, P1447, DOI 10.1093/bioinformatics/btr156; Chen Y, 2013, NAT MED, V19, P1023, DOI 10.1038/nm.3216; Esposito S, 2015, ONCOTARGET, V6, P17121, DOI 10.18632/oncotarget.2736; Ewels P, 2016, BIOINFORMATICS, V32, P3047, DOI 10.1093/bioinformatics/btw354; Frohwitter G, 2016, ONCOL LETT, V12, P107, DOI 10.3892/ol.2016.4588; Grieshammer U, 2008, GENESIS, V46, P69, DOI 10.1002/dvg.20366; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Huggins C, 2002, J UROLOGY, V168, P9, DOI 10.1016/S0022-5347(05)64820-3; Ittmann M, 2013, CANCER RES, V73, P2718, DOI 10.1158/0008-5472.CAN-12-4213; Johnson DT, 2013, J BIOL CHEM, V288, P3727, DOI 10.1074/jbc.M112.417568; Kleihues P, 1997, AM J PATHOL, V150, P1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Koivisto P, 1997, CANCER RES, V57, P314; Kwak MK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053476; KYPRIANOU N, 1988, ENDOCRINOLOGY, V122, P552, DOI 10.1210/endo-122-2-552; Lachmann A, 2010, BIOINFORMATICS, V26, P2438, DOI 10.1093/bioinformatics/btq466; Lee J, 2007, NUCLEIC ACIDS RES, V35, P4523, DOI 10.1093/nar/gkm476; Lee SH, 2016, ONCOGENE, V35, P702, DOI 10.1038/onc.2015.117; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Linhart C, 2008, GENOME RES, V18, P1180, DOI 10.1101/gr.076117.108; Matusik RJ, 2008, DIFFERENTIATION, V76, P682, DOI 10.1111/j.1432-0436.2008.00276.x; Mollaoglu G, 2018, IMMUNITY, V49, P764, DOI 10.1016/j.immuni.2018.09.020; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Quigley DA, 2018, CELL, V174, P758, DOI 10.1016/j.cell.2018.06.039; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25; Sarkar A, 2013, CELL STEM CELL, V12, P15, DOI 10.1016/j.stem.2012.12.007; Smith BA, 2015, P NATL ACAD SCI USA, V112, pE6544, DOI 10.1073/pnas.1518007112; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; Stoyanova T, 2013, P NATL ACAD SCI USA, V110, P20111, DOI 10.1073/pnas.1320565110; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takeda DY, 2018, CELL, V174, P422, DOI 10.1016/j.cell.2018.05.037; VOELLER HJ, 1994, J UROLOGY, V151, P492; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wyce A, 2010, MOL ENDOCRINOL, V24, P1665, DOI 10.1210/me.2010-0138; Yang JH, 2013, NUCLEIC ACIDS RES, V41, pD177, DOI 10.1093/nar/gks1060; You SY, 2016, CANCER RES, V76, P4948, DOI 10.1158/0008-5472.CAN-16-0902; You S, 2014, P NATL ACAD SCI USA, V111, P550, DOI 10.1073/pnas.1311239111; Zhao SG, 2017, JAMA ONCOL, V3, P1663, DOI 10.1001/jamaoncol.2017.0751; Zhou ZX, 2007, CANCER RES, V67, P5683, DOI 10.1158/0008-5472.CAN-07-0768; Zhou ZX, 2006, CANCER RES, V66, P7889, DOI 10.1158/0008-5472.CAN-06-0486; Zhu CF, 2011, J BIOL CHEM, V286, P33478, DOI 10.1074/jbc.M111.269894	49	6	6	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2019	38	38					6507	6520		10.1038/s41388-019-0901-8	http://dx.doi.org/10.1038/s41388-019-0901-8			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IY7XR	31358900	Green Accepted, Green Submitted			2022-12-28	WOS:000486609000003
J	Kim, YE; Won, M; Lee, SG; Park, C; Song, CH; Kim, KK				Kim, Yong-Eun; Won, Minho; Lee, Sung-Gwon; Park, Chungoo; Song, Chang-Hwa; Kim, Kee K.			RBM47-regulated alternative splicing of TJP1 promotes actin stress fiber assembly during epithelial-to-mesenchymal transition	ONCOGENE			English	Article							JUNCTION PROTEIN ZO-1; RNA-BINDING PROTEINS; TIGHT JUNCTIONS; CELLS; ISOFORMS; GROWTH; MOTIF	Morphological and functional changes in cells during the epithelial-mesenchymal transition (EMT) process are known to be regulated by alternative splicing. However, only a few splicing factors involved in EMT have been reported and their underlying mechanisms remain largely unknown. Here, we showed that an isoform of tight junction protein 1 (TJP1) lacking exon 20 (TJP1-alpha-) is predominantly expressed in tumor tissues and in A549 cells during transforming growth factor-beta (TGF-beta-induced EMT. RBM47 promoted the inclusion of exon 20 of TJP1, the alternative exon encoding the a-domain, by which RBM47 recognizes to (U)GCAUG in the downstream intronic region of exon 20. We also found that the first RNA recognition motif (RRM) domain of RBM47 is critical in the regulation of alternative splicing and its recognition to pre-mRNA of TJP1. Furthermore, we demonstrated that the TJP1-alpha- isoform enhances the assembly of actin stress fibers, thereby promoting cellular migration in a wound healing assay. Our results suggest the regulatory mechanism for the alternative splicing of TJP1 pre-mRNA by RBM47 during EMT, providing a basis for studies related to the modulation of EMT via alternative splicing.	[Kim, Yong-Eun; Kim, Kee K.] Chungnam Natl Univ, Dept Biochem, Daejeon 34134, South Korea; [Kim, Yong-Eun; Song, Chang-Hwa] Chungnam Natl Univ, Coll Med, Brain Korea Plus Project Med Sci 21, Dept Med Sci,Dept Microbiol, Daejeon 35015, South Korea; [Won, Minho] Chungnam Natl Univ, Sch Med, Dept Pharmacol, Daejeon 35015, South Korea; [Lee, Sung-Gwon; Park, Chungoo] Chonnam Natl Univ, Sch Biol Sci & Technol, Gwangju 61186, South Korea	Chungnam National University; Chungnam National University; Chungnam National University; Chonnam National University	Kim, KK (corresponding author), Chungnam Natl Univ, Dept Biochem, Daejeon 34134, South Korea.	songch@cnu.ac.kr; kimkk@cnu.ac.kr	Song, Chang-Hwa/AAD-7917-2022	Song, Chang-Hwa/0000-0002-9490-0573; Lee, Sung-Gwon/0000-0002-0928-9950; Won, Minho/0000-0002-5873-5216	National Research Foundation of Korea within the Basic Science Research Program through the Ministry of Education [NRF-2018R1A1A1A05018628]; National Research Foundation of Korea (NRF) - Korean government (MEST) [NRF-2016R1A2B2008178]	National Research Foundation of Korea within the Basic Science Research Program through the Ministry of Education(Ministry of Education (MOE), Republic of Korea); National Research Foundation of Korea (NRF) - Korean government (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaNational Research Foundation of KoreaKorean Government)	This work was supported by the National Research Foundation of Korea within the Basic Science Research Program through the Ministry of Education under Grant NRF-2018R1A1A1A05018628. This research was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MEST) (NRF-2016R1A2B2008178).	Aparicio LA, 2013, CELL MOL LIFE SCI, V70, P4463, DOI 10.1007/s00018-013-1379-0; Balda MS, 2003, J CELL BIOL, V160, P423, DOI 10.1083/jcb.200210020; BALDA MS, 1993, AM J PHYSIOL, V264, pC918, DOI 10.1152/ajpcell.1993.264.4.C918; BIEDLER JL, 1973, CANCER RES, V33, P2643; Braeutigam C, 2014, ONCOGENE, V33, P1082, DOI 10.1038/onc.2013.50; Buratti E, 2004, MOL CELL BIOL, V24, P10505, DOI 10.1128/MCB.24.24.10505-10514.2004; Chen M, 2009, NAT REV MOL CELL BIO, V10, P741, DOI 10.1038/nrm2777; Ciana A, 2010, CELL BIOL INT, V34, P669, DOI 10.1042/CBI20090067; Cooper TA, 2005, METHODS, V37, P331, DOI 10.1016/j.ymeth.2005.07.015; Cramer P, 1997, P NATL ACAD SCI USA, V94, P11456, DOI 10.1073/pnas.94.21.11456; Fan Q, 2015, ONCOL REP, V34, P1787, DOI 10.3892/or.2015.4143; Fanning AS, 2002, FASEB J, V16, P1835, DOI 10.1096/fj.02-0121fje; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Fong N, 2014, GENE DEV, V28, P2663, DOI 10.1101/gad.252106.114; Fossat N, 2014, EMBO REP, V15, P903, DOI 10.15252/embr.201438450; Gonzalez-Mariscal L, 2000, SEMIN CELL DEV BIOL, V11, P315, DOI 10.1006/scdb.2000.0178; Gonzalez-Mariscal L, 2008, BBA-BIOMEMBRANES, V1778, P729, DOI 10.1016/j.bbamem.2007.08.018; Haynes J, 2011, MOL BIOL CELL, V22, P4750, DOI 10.1091/mbc.E11-02-0119; Heiner M, 2010, RNA BIOL, V7, P56, DOI 10.4161/rna.7.1.10402; Ikenouchi J, 2003, J CELL SCI, V116, P1959, DOI 10.1242/jcs.00389; Inada M, 2016, INT J MOL MED, V37, P1521, DOI 10.3892/ijmm.2016.2568; Kadener S, 2002, P NATL ACAD SCI USA, V99, P8185, DOI 10.1073/pnas.122246099; Kasai H, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-56; Kim KK, 2009, J BIOL CHEM, V284, P31052, DOI 10.1074/jbc.M109.052969; Kim YE, 2016, MOL CELLS, V39, P625, DOI 10.14348/molcells.2016.0150; Lu X, 2004, NEOPLASIA, V6, P603, DOI 10.1593/neo.04241; Lunde BM, 2007, NAT REV MOL CELL BIO, V8, P479, DOI 10.1038/nrm2178; Maris C, 2005, FEBS J, V272, P2118, DOI 10.1111/j.1742-4658.2005.04653.x; Nakahata S, 2005, NUCLEIC ACIDS RES, V33, P2078, DOI 10.1093/nar/gki338; Pradella D, 2017, MOL CANCER, V16, DOI 10.1186/s12943-016-0579-2; Ray D, 2013, NATURE, V499, P172, DOI 10.1038/nature12311; Rokavec M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04234-2; Sakurai T, 2016, ONCOGENE, V35, P5000, DOI 10.1038/onc.2016.35; Shapiro IM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002218; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Vanharanta S, 2014, ELIFE, V3, DOI 10.7554/eLife.02734; Wan LD, 2019, GUT, V68, P118, DOI 10.1136/gutjnl-2017-314983; Warzecha CC, 2010, EMBO J, V29, P3286, DOI 10.1038/emboj.2010.195; Yang YQ, 2016, MOL CELL BIOL, V36, P1704, DOI 10.1128/MCB.00019-16; Zhang JY, 2016, J CLIN MED, V5, DOI 10.3390/jcm5040041; Zhang K, 2013, INT J MOL MED, V32, P464, DOI 10.3892/ijmm.2013.1396; Zhao Q, 2017, CELL MOL NEUROBIOL, V37, P643, DOI 10.1007/s10571-016-0401-0	42	20	20	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2019	38	38					6521	6536		10.1038/s41388-019-0892-5	http://dx.doi.org/10.1038/s41388-019-0892-5			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IY7XR	31358901				2022-12-28	WOS:000486609000004
J	Rathore, M; Girard, C; Ohanna, M; Tichet, M; Ben Jouira, R; Garcia, E; Larbret, F; Gesson, M; Audebert, S; Lacour, JP; Montaudie, H; Prod'Homme, V; Tartare-Deckert, S; Deckert, M				Rathore, M.; Girard, C.; Ohanna, M.; Tichet, M.; Ben Jouira, R.; Garcia, E.; Larbret, F.; Gesson, M.; Audebert, S.; Lacour, J. -P.; Montaudie, H.; Prod'Homme, V.; Tartare-Deckert, S.; Deckert, M.			Cancer cell-derived long pentraxin 3 (PTX3) promotes melanoma migration through a toll-like receptor 4 (TLR4)/NF-kappa B signaling pathway	ONCOGENE			English	Article							NF-KAPPA-B; EPITHELIAL-MESENCHYMAL TRANSITION; UP-REGULATION; INFLAMMATION; EXPRESSION; RESISTANCE; GROWTH; INHIBITION; PHENOTYPE; INVASION	Cutaneous melanoma is one of the most aggressive cancers characterized by a high plasticity, a propensity for metastasis, and drug resistance. Melanomas are composed of phenotypically diverse subpopulations of tumor cells with heterogeneous molecular profiles that reflect intrinsic invasive abilities. In an attempt to identify novel factors of the melanoma invasive cell state, we previously investigated the nature of the invasive secretome by using a comparative proteomic approach. Here, we have extended this analysis to show that PTX3, an acute phase inflammatory glycoprotein, is one such factor secreted by invasive melanoma to promote tumor cell invasiveness. Elevated PTX3 production was observed in the population of MITFlow invasive cells but not in the population of MITFhigh differentiated melanoma cells. Consistently, MITF knockdown increased PTX3 expression in MITFhigh proliferative and poorly invasive cells. High levels of PTX3 were found in tissues and blood of metastatic melanoma patients, and in BRAF inhibitor-resistant melanoma cells displaying a mesenchymal invasive MITFlow phenotype. Genetic silencing of PTX3 in invasive melanoma cells dramatically impaired migration and invasion in vitro and in experimental lung extravasation assay in xenografted mice. In contrast, addition of melanoma-derived or recombinant PTX3, or expression of PTX3 enhanced motility of low migratory cells. Mechanistically, autocrine production of PTX3 by melanoma cells triggered an IKIC/NF kappa B signaling pathway that promotes migration, invasion, and expression of the EMT factor TWIST1. Finally, we found that TLR4 and MYD88 knockdown inhibited PTX3-induced melanoma cell migration, suggesting that PTX3 functions through a TLR4-dependent pathway. Our work reveals that tumor-derived PTX3 contributes to melanoma cell invasion via targetable inflammation-related pathways. In addition to providing new insights into the biology of melanoma invasive behavior, this study underscores the notion that secreted PTX3 represents a potential biomarker and therapeutic target in a subpopulation of MITFlow invasive and/or refractory melanoma.	[Rathore, M.; Girard, C.; Ohanna, M.; Tichet, M.; Ben Jouira, R.; Garcia, E.; Larbret, F.; Gesson, M.; Prod'Homme, V.; Tartare-Deckert, S.; Deckert, M.] Univ Cote Azur, INSERM, C3M, Nice, France; [Rathore, M.; Girard, C.; Ohanna, M.; Larbret, F.; Prod'Homme, V.; Tartare-Deckert, S.; Deckert, M.] Equipe Labellisee Ligue Canc 2016, Nice, France; [Rathore, M.] Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA; [Audebert, S.] Aix Marseille Univ, Inst Paoli Calmettes, INSERM, CNRS,CRCM, Marseille, France; [Lacour, J. -P.; Montaudie, H.] Univ Cote Azur, CHU Nice, Nice, France; [Tichet, M.] Ecole Polytech Fed Lausanne, Lab Translat Oncol, ISREC, Lausanne, Switzerland	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; University of Minnesota System; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); CHU Nice; UDICE-French Research Universities; Universite Cote d'Azur; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Institute Experimental Cancer Research	Tartare-Deckert, S; Deckert, M (corresponding author), Univ Cote Azur, INSERM, C3M, Nice, France.; Tartare-Deckert, S; Deckert, M (corresponding author), Equipe Labellisee Ligue Canc 2016, Nice, France.	tartare@unice.fr; deckert@unice.fr	Ohanna, Mickael/O-5784-2016; TARTARE-DECKERT, Sophie/P-6057-2015; Prod'homme, Virginie/A-3948-2012; Deckert, Marcel/T-3566-2019; Girard, Christophe/O-8455-2016	Ohanna, Mickael/0000-0002-7751-9164; TARTARE-DECKERT, Sophie/0000-0001-8680-5720; Prod'homme, Virginie/0000-0002-9664-4710; Deckert, Marcel/0000-0003-2094-559X; Girard, Christophe/0000-0002-4560-4479; Audebert, Stephane/0000-0002-9409-2588; Ben Jouira, Rania/0000-0001-6999-4566	Ligue Contre le Cancer; Fondation ARC; Fondation de France; French Government (National Research Agency); (ANR) through the "Investments for the Future" LABEX SIGNALIFE [ANR-11-LABX-0028-01]; Conseil General des Alpes-Maritimes; Canceropole PACA; Region PACA; IBiSA (Infrastructures Biologie Sante et Agronomie); Institut Paoli-Calmettes	Ligue Contre le Cancer(Ligue nationale contre le cancer); Fondation ARC; Fondation de France(Fondation de France); French Government (National Research Agency); (ANR) through the "Investments for the Future" LABEX SIGNALIFE(French National Research Agency (ANR)); Conseil General des Alpes-Maritimes(Region Provence-Alpes-Cote d'Azur); Canceropole PACA(Region Grand-Est); Region PACA(Region Provence-Alpes-Cote d'Azur); IBiSA (Infrastructures Biologie Sante et Agronomie); Institut Paoli-Calmettes	We thank RS Lo and R Ballotti for melanoma cells. We acknowledge the C3M animal and imaging (Microscopy and Imaging platform Cote d'Azur, MICA) facilities. This work was supported by Ligue Contre le Cancer, Fondation ARC, Fondation de France and the French Government (National Research Agency, ANR) through the "Investments for the Future" LABEX SIGNALIFE: program reference #ANR-11-LABX-0028-01. We also thank financial supports by Conseil General des Alpes-Maritimes, Canceropole PACA and Region PACA. MR was a recipient of a post-doctoral fellowship from Fondation ARC. The Marseille Proteomic facility (MaP; http://map.univmed.fr/) is supported by IBiSA (Infrastructures Biologie Sante et Agronomie), Canceropole PACA, Region PACA, and Institut Paoli-Calmettes.	Ahn JH, 2008, EXP DERMATOL, V17, P412, DOI 10.1111/j.1600-0625.2008.00701.x; Bailet O, 2009, CANCER RES, V69, P2748, DOI 10.1158/0008-5472.CAN-08-2690; Bonavita E, 2015, CELL, V160, P700, DOI 10.1016/j.cell.2015.01.004; Bottazzi B, 2016, J HEPATOL, V64, P1416, DOI 10.1016/j.jhep.2016.02.029; Bozza S, 2014, J IMMUNOL, V193, P2340, DOI 10.4049/jimmunol.1400814; Caramel J, 2013, CANCER CELL, V24, P466, DOI 10.1016/j.ccr.2013.08.018; Carmo RF, 2016, J VIRAL HEPATITIS, V23, P116, DOI 10.1111/jvh.12472; Chan SH, 2017, ONCOTARGET, V8, P41364, DOI 10.18632/oncotarget.17326; Chang WC, 2015, ONCOTARGET, V6, P7741, DOI 10.18632/oncotarget.3482; Cheli Y, 2012, ONCOGENE, V31, P2461, DOI 10.1038/onc.2011.425; Choi B, 2015, ANTICANCER RES, V35, P2663; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Diamandis EP, 2011, CLIN CANCER RES, V17, P2395, DOI 10.1158/1078-0432.CCR-10-3024; Didier R, 2018, MOL CANCER THER, V17, P1416, DOI 10.1158/1535-7163.MCT-17-0919; Eiro N, 2013, ARCH DERMATOL RES, V305, P59, DOI 10.1007/s00403-012-1300-y; Fenouille N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040378; Fenouille N, 2011, PIGM CELL MELANOMA R, V24, P219, DOI 10.1111/j.1755-148X.2010.00790.x; Flaherty KT, 2012, NAT REV CANCER, V12, P349, DOI 10.1038/nrc3218; Garlanda C, 2016, CURR OPIN IMMUNOL, V38, P39, DOI 10.1016/j.coi.2015.11.002; Giacomini A, 2018, BBA-REV CANCER, V1869, P53, DOI 10.1016/j.bbcan.2017.11.004; Holderfield M, 2014, NAT REV CANCER, V14, P455, DOI 10.1038/nrc3760; Hu FQ, 2014, J BIOL REG HOMEOS AG, V28, P649; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kemper K, 2014, CANCER RES, V74, P5937, DOI 10.1158/0008-5472.CAN-14-1174; Kondo S, 2013, BRIT J CANCER, V109, P739, DOI 10.1038/bjc.2013.348; Leali D, 2011, MOL CANCER THER, V10, P1600, DOI 10.1158/1535-7163.MCT-11-0286; Li CW, 2012, CANCER RES, V72, P1290, DOI 10.1158/0008-5472.CAN-11-3123; Locatelli M, 2013, J NEUROIMMUNOL, V260, P99, DOI 10.1016/j.jneuroim.2013.04.009; Magrini E, 2016, TRENDS MOL MED, V22, P497, DOI 10.1016/j.molmed.2016.04.007; Margheri F, 2009, NEOPLASIA, V11, P1106, DOI 10.1593/neo.09934; Muller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6712; Na YR, 2013, MELANOMA RES, V23, P434, DOI 10.1097/CMR.0000000000000021; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Obenauf AC, 2015, TRENDS CANCER, V1, P76, DOI 10.1016/j.trecan.2015.07.009; Ohanna M, 2018, GENE DEV, V32, P448, DOI 10.1101/gad.305854.117; Ravenna L, 2009, PROSTATE, V69, P1245, DOI 10.1002/pros.20966; Riesenberg S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9755; Robert G, 2006, CANCER RES, V66, P7516, DOI 10.1158/0008-5472.CAN-05-3189; Ronca R, 2015, CANCER CELL, V28, P225, DOI 10.1016/j.ccell.2015.07.002; Ronca R, 2013, MOL CANCER THER, V12, P2760, DOI 10.1158/1535-7163.MCT-13-0487; Ronca R, 2013, J PATHOL, V230, P228, DOI 10.1002/path.4181; Rubino M, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1333215; Shaffer SM, 2017, NATURE, V546, P431, DOI 10.1038/nature22794; Shao YP, 2015, J INVEST DERMATOL, V135, P1839, DOI 10.1038/jid.2015.91; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Takazawa Y, 2014, TOHOKU J EXP MED, V234, P57, DOI 10.1620/tjem.234.57; Thomas C, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aah4674; Tichet M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7993; Titz B, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.28; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Tung JN, 2016, J NEURO-ONCOL, V129, P201, DOI 10.1007/s11060-016-2168-z; Verfaillie A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7683; Weiss MB, 2012, CANCER RES, V72, P6382, DOI 10.1158/0008-5472.CAN-12-1033; Widmer DS, 2012, PIGM CELL MELANOMA R, V25, P343, DOI 10.1111/j.1755-148X.2012.00986.x; Ying TH, 2016, SCI REP-UK, V6, DOI 10.1038/srep29385	55	42	44	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 25	2019	38	30					5873	5889		10.1038/s41388-019-0848-9	http://dx.doi.org/10.1038/s41388-019-0848-9			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IT3FY	31253871	Green Published			2022-12-28	WOS:000482739300003
J	Rataj, F; Planel, S; Denis, J; Roelants, C; Filhol, O; Guyon, L; Feige, JJ; Cherradi, N				Rataj, Felicitas; Planel, Severine; Denis, Josiane; Roelants, Caroline; Filhol, Odile; Guyon, Laurent; Feige, Jean-Jacques; Cherradi, Nadia			Targeting AU-rich element-mediated mRNA decay with a truncated active form of the zinc-finger protein TIS11b/BRF1 impairs major hallmarks of mammary tumorigenesis	ONCOGENE			English	Article							BREAST-CANCER; BINDING PROTEIN; CXCR4/CXCL12 AXIS; TRISTETRAPROLIN; EXPRESSION; TTP; DESTABILIZATION; SEQUENCE; TIMP-1; GROWTH	Altered expression of regulatory RNA-binding proteins (RBPs) in cancer leads to abnormal expression of mRNAs encoding many factors involved in cancer hallmarks. While conventional anticancer therapies usually target one pathway at a time, targeting key RBP would affect multiple genes and thus overcome drug resistance. Among the Tristetraprolin family of RBP, TIS11b/BRF1/ZFP36L1 mediates mRNA decay through binding to Adenylate/Uridylate (AU-rich elements) in mRNA 3'-untranslated region and recruitment of mRNA degradation enzymes. Here, we show that TIS11b is markedly underexpressed in three breast cancer cell lines, as well as in breast tumor samples. We hypothesized that restoring intracellular TIS11b levels could impair cancer cell phenotypic traits. We thus generated a derivative of TIS11b called R9-ZnCS334D, by combining N-terminal domain deletion, serine-to-aspartate substitution at position 334 to enhance the function of the protein and fusion to the cell-penetrating peptide polyarginine R9. R9-ZnCS334D not only blunted secretion of vascular endothelial growth factor (VEGF) but also inhibited proliferation, migration, invasion, and anchorage-independent growth of murine 4T1 or human MDA-MB-231 breast cancer cells. Moreover, R9-ZnCS334D prevented endothelial cell organization into vessel-like structures, suggesting that it could potentially target various cell types within the tumor microenvironment. In vivo, injection of R9-ZnCS334D in 4T1 tumors impaired tumor growth, decreased tumor hypoxia, and expression of the epithelial-to-mesenchymal transition (EMT) markers Snail, Vimentin, and N-cadherin. R9-ZnCS334D also hindered the expression of chemokines and proteins involved in cancer-related inflammation and invasion including Fractalkine (CX3CL1), SDF-1 (CXCL12), MCP-1 (CCL2), NOV (CCN3), and Pentraxin-3 (PTX3). Collectively, our data indicate that R9-ZnCS334D counteracts multiple traits of breast cancer cell aggressiveness and suggest that this novel protein could serve as the basis for innovative multi-target therapies in cancer.	[Rataj, Felicitas; Planel, Severine; Denis, Josiane; Filhol, Odile; Guyon, Laurent; Feige, Jean-Jacques; Cherradi, Nadia] Univ Grenoble Alpes, INSERM, Biosci & Biotechnol Inst Grenoble, CEA,Biol Canc & Infect UMR S 1036, F-38000 Grenoble, France; [Roelants, Caroline] Inovarion, Paris, France	CEA; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm)	Cherradi, N (corresponding author), Univ Grenoble Alpes, INSERM, Biosci & Biotechnol Inst Grenoble, CEA,Biol Canc & Infect UMR S 1036, F-38000 Grenoble, France.	nadia.cherradi@cea.fr	Filhol-Cochet, Odile/I-3962-2016; Cherradi, Nadia/K-9695-2016; Feige, Jean-Jacques/F-5534-2013	Cherradi, Nadia/0000-0002-4292-774X; Guyon, Laurent/0000-0002-7674-2348; Filhol, Odile/0000-0003-1964-7958; Feige, Jean-Jacques/0000-0002-1354-7692	Institut National de la Sante et de la Recherche Medicale [INSERM U1036]; Commissariat a l'Energie Atomique; University Grenoble Alpes (UGA); Labex GRAL [ANR-10-LABX-49-01]; Fondation ARC; Fondation pour la Recherche Medicale	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Commissariat a l'Energie Atomique(French Atomic Energy Commission); University Grenoble Alpes (UGA); Labex GRAL; Fondation ARC; Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale)	This work was supported by the Institut National de la Sante et de la Recherche Medicale (INSERM U1036), the Commissariat a l'Energie Atomique (to FR), The University Grenoble Alpes (UGA), the Labex GRAL (ANR-10-LABX-49-01), the Fondation ARC and the Fondation pour la Recherche Medicale (to SP). We thank Dr. Jean-Luc Coll (Institute for Advanced Biosciences, Grenoble, France) and Dr. Olivier Peyruchaud (INSERM U1033, Faculte de Medecine Laennec, Lyon, France) for providing the 4T1-luc and 4T1 cell lines, respectively. We thank the animal facility staff at Biosciences and Biotechnology Institute of Grenoble (BIG) for animal care.	Al-Souhibani N, 2010, ONCOGENE, V29, P4205, DOI 10.1038/onc.2010.168; Al-Souhibani N, 2014, CARCINOGENESIS, V35, P1983, DOI 10.1093/carcin/bgu080; Baklaushev VP, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07851-z; Barcellos-Hoff MH, 2013, NAT REV CANCER, V13, P511, DOI 10.1038/nrc3536; Bell SE, 2006, DEV DYNAM, V235, P3144, DOI 10.1002/dvdy.20949; Benjamin D, 2007, EXPERT OPIN BIOL TH, V7, P1515, DOI 10.1517/14712598.7.10.1515; Bisogno LS, 2018, CURR OPIN GENET DEV, V48, P97, DOI 10.1016/j.gde.2017.11.004; Bleau AM, 2005, FRONT BIOSCI-LANDMRK, V10, P998, DOI 10.2741/1594; Brennan SE, 2009, CANCER RES, V69, P5168, DOI 10.1158/0008-5472.CAN-08-4238; Brooks SA, 2013, BBA-GENE REGUL MECH, V1829, P666, DOI 10.1016/j.bbagrm.2013.02.003; Carrick DM, 2007, ARCH BIOCHEM BIOPHYS, V462, P278, DOI 10.1016/j.abb.2007.04.011; Chamboredon S, 2011, MOL BIOL CELL, V22, P3366, DOI 10.1091/mbc.E10-07-0617; Chen PC, 2014, ONCOTARGET, V5, P1595, DOI 10.18632/oncotarget.1570; Cherradi N, 2006, MOL ENDOCRINOL, V20, P916, DOI 10.1210/me.2005-0121; Choi B, 2014, ONCOTARGET, V5, P481, DOI 10.18632/oncotarget.1664; Ciais D, 2004, ONCOGENE, V23, P8673, DOI 10.1038/sj.onc.1207939; Ciais D, 2013, CELL MOL LIFE SCI, V70, P2031, DOI 10.1007/s00018-012-1150-y; D'Angelo RC, 2014, MOL CANCER RES, V12, P1324, DOI 10.1158/1541-7786.MCR-14-0105; Diamandis EP, 2011, CLIN CANCER RES, V17, P2395, DOI 10.1158/1078-0432.CCR-10-3024; Domanska UM, 2013, EUR J CANCER, V49, P219, DOI 10.1016/j.ejca.2012.05.005; Duan H, 2009, MOL ENDOCRINOL, V23, P497, DOI 10.1210/me.2008-0296; Galloway A, 2016, SCIENCE, V352, P453, DOI 10.1126/science.aad5978; Griseri P, 2011, HUM MOL GENET, V20, P4556, DOI 10.1093/hmg/ddr390; Gruber AR, 2011, NUCLEIC ACIDS RES, V39, pD66, DOI 10.1093/nar/gkq990; Guidotti G, 2017, TRENDS PHARMACOL SCI, V38, P406, DOI 10.1016/j.tips.2017.01.003; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hekmat O, 2013, J PROTEOME RES, V12, P4136, DOI 10.1021/pr400457u; Jamieson-Gladney WL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3016; Johnson BA, 2002, ONCOGENE, V21, P4237, DOI 10.1038/sj.onc.1205526; Khabar KS, 2017, WILEY INTERDISCIP RE, V8, P1; Kondo S, 2013, BRIT J CANCER, V109, P739, DOI 10.1038/bjc.2013.348; LAI WS, 1990, J BIOL CHEM, V265, P16556; Lee HH, 2014, J MICROBIOL BIOTECHN, V24, P287, DOI 10.4014/jmb.1309.09070; Lee SK, 2005, INT J CANCER, V117, P32, DOI 10.1002/ijc.21133; Liang Z, 2007, BIOCHEM BIOPH RES CO, V359, P716, DOI 10.1016/j.bbrc.2007.05.182; Locatelli M, 2013, J NEUROIMMUNOL, V260, P99, DOI 10.1016/j.jneuroim.2013.04.009; Lykke-Andersen J, 2005, GENE DEV, V19, P351, DOI 10.1101/gad.1282305; Milke L, 2013, CARCINOGENESIS, V34, P850, DOI 10.1093/carcin/bgs387; Nagel S, 2017, LEUKEMIA LYMPHOMA, V58, P2196, DOI 10.1080/10428194.2017.1283029; Ouellet V, 2011, AM J PATHOL, V178, P2377, DOI 10.1016/j.ajpath.2011.01.033; Planel S, 2010, ONCOGENE, V29, P5989, DOI 10.1038/onc.2010.341; Planel S, 2014, MOL MECH ANGIOGENESI, P353, DOI 10.1007/978-2-8178-0466-8; Presta M, 2007, J CELL MOL MED, V11, P723, DOI 10.1111/j.1582-4934.2007.00061.x; Rataj F, 2016, MOL BIOL CELL, V27, P3841, DOI 10.1091/mbc.E16-06-0379; Reed JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045877; Sanduja S, 2012, FRONT BIOSCI-LANDMRK, V17, P174, DOI 10.2741/3920; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Soria G, 2008, CANCER LETT, V267, P271, DOI 10.1016/j.canlet.2008.03.018; Tao K, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-228; Wurtz SO, 2008, ACTA ONCOL, V47, P580, DOI 10.1080/02841860802022976; Yoshimura T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058791	51	8	8	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2019	38	26					5174	5190		10.1038/s41388-019-0784-8	http://dx.doi.org/10.1038/s41388-019-0784-8			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IF4AX	30914800				2022-12-28	WOS:000473025300005
J	Nakayama, R; Ueno, Y; Ueda, K; Honda, T				Nakayama, Ryota; Ueno, Yumiko; Ueda, Keiji; Honda, Tomoyuki			Latent infection with Kaposi's sarcoma-associated herpesvirus enhances retrotransposition of long interspersed element-1	ONCOGENE			English	Article							PRIMARY EFFUSION LYMPHOMA; HUMAN L1 ELEMENT; KAPPA-B PATHWAY; DNA-SEQUENCES; ENDOTHELIAL ICAM-1; ACTIVATION; EXPRESSION; CANCER; GENE; VFLIP	Kaposi's sarcoma (KS)-associated herpesvirus (KSHV), a gamma-2 herpesvirus, is the causative agent of KS, primary effusion lymphoma (PEL), and a plasma cell variant of multicentric Castleman's disease. Although KSHV latency is detected in KS-related tumors, oncogenic pathways activated by KSHV latent infection are not fully understood. Here, we found that retrotransposition of long interspersed element-1 (L1), a retrotransposon in the human genome, was enhanced in PEL cells. Among the KSHV latent genes, viral FLICE-inhibitory protein (vFLIP) enhanced L1 retrotransposition in an NF-kappa B-dependent manner. Intracellular cell adhesion molecule-1 (ICAM-1), an NF-kappa B target, regulated the vFLIP-mediated enhancement of L1 retrotransposition. Furthermore, ICAM-1 downregulated the expression of Moloney leukemia virus 10 (MOV10), an L1 restriction factor. Knockdown of ICAM-1 or overexpression of MOV10 relieved the vFLIP-mediated enhancement of L1 retrotransposition. Collectively, during KSHV latency, vFLIP upregulates ICAM-1 in an NF-kappa B-dependent manner, which, in turn, downregulates MOV10 expression and thereby enhances L1 retrotransposition. Because active L1 retrotransposition can lead to genomic instability, which is commonly found in KS and PEL, activation of L1 retrotransposition during KSHV latency may accelerate oncogenic processes through enhancing genomic instability. Our results suggest that L1 retrotransposition may be a novel target for impeding tumor development in KSHV-infected patients.	[Nakayama, Ryota; Ueno, Yumiko; Ueda, Keiji; Honda, Tomoyuki] Osaka Univ, Dept Microbiol & Immunol, Div Virol, Grad Sch Med, Osaka, Japan	Osaka University	Honda, T (corresponding author), Osaka Univ, Dept Microbiol & Immunol, Div Virol, Grad Sch Med, Osaka, Japan.	thonda@virus.med.osaka-u.ac.jp			MEXT/JSPS KAKENHI [15K08496, 18H02664, 18K19449]; Takeda Science Foundation; Senri Life Science Foundation; Suzuken Memorial Foundation; Shimizu Foundation for Immunology and Neuroscience; NOVARTIS Foundation (Japan) for the Promotion of Science	MEXT/JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Takeda Science Foundation(Takeda Science Foundation (TSF)); Senri Life Science Foundation; Suzuken Memorial Foundation; Shimizu Foundation for Immunology and Neuroscience; NOVARTIS Foundation (Japan) for the Promotion of Science(Novartis)	This study was supported in part by the MEXT/JSPS KAKENHI Grant Numbers 15K08496, 18H02664, and 18K19449 (T.H.), and grants from the Takeda Science Foundation, Senri Life Science Foundation, Suzuken Memorial Foundation, The Shimizu Foundation for Immunology and Neuroscience Grant for 2015, and The NOVARTIS Foundation (Japan) for the Promotion of Science (T.H.).	Adamson P, 1999, J IMMUNOL, V162, P2964; Bagneris C, 2008, MOL CELL, V30, P620, DOI 10.1016/j.molcel.2008.04.029; Beck CR, 2010, CELL, V141, P1159, DOI 10.1016/j.cell.2010.05.021; Belancio VP, 2009, GENOME MED, V1, DOI 10.1186/gm97; Boshoff C, 2001, ANNU REV MED, V52, P453, DOI 10.1146/annurev.med.52.1.453; BOVI PD, 1986, CANCER RES, V46, P6333; Brouha B, 2003, P NATL ACAD SCI USA, V100, P5280, DOI 10.1073/pnas.0831042100; Burns KH, 2012, CELL, V149, P740, DOI 10.1016/j.cell.2012.04.019; Burwinkel B, 1998, J MOL BIOL, V277, P513, DOI 10.1006/jmbi.1998.1641; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; Chen JM, 2005, HUM GENET, V117, P411, DOI 10.1007/s00439-005-1321-0; Choi J, 2018, NUCLEIC ACIDS RES, V46, P1912, DOI 10.1093/nar/gkx1312; Coscoy L, 2007, NAT REV IMMUNOL, V7, P391, DOI 10.1038/nri2076; Cost GJ, 2002, EMBO J, V21, P5899, DOI 10.1093/emboj/cdf592; Coufal NG, 2009, NATURE, V460, P1127, DOI 10.1038/nature08248; Dai LX, 2011, BMC BIOCHEM, V12, DOI 10.1186/1471-2091-12-18; Delabesse E, 1997, J CLIN PATHOL, V50, P664, DOI 10.1136/jcp.50.8.664; Denli AM, 2015, CELL, V163, P583, DOI 10.1016/j.cell.2015.09.025; Ding D, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003065; Dittmer DP, 2016, J CLIN INVEST, V126, P3165, DOI 10.1172/JCI84418; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; DOMBROSKI BA, 1991, SCIENCE, V254, P1805, DOI 10.1126/science.1662412; DUPIN N, 1995, NEW ENGL J MED, V333, P798; Dupuy AJ, 2009, CANCER RES, V69, P8150, DOI 10.1158/0008-5472.CAN-09-1135; Ehrlich ES, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091359; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Gaidano G, 1997, HUM PATHOL, V28, P748, DOI 10.1016/S0046-8177(97)90187-8; Ganem D, 2010, J CLIN INVEST, V120, P939, DOI 10.1172/JCI40567; Gill PS, 1998, P NATL ACAD SCI USA, V95, P8257, DOI 10.1073/pnas.95.14.8257; Goodier JL, 2008, CELL, V135, P23, DOI 10.1016/j.cell.2008.09.022; Goodier JL, 2016, MOBILE DNA-UK, V7, DOI 10.1186/s13100-016-0070-z; Goodier JL, 2014, MOBILE DNA-UK, V5, DOI 10.1186/1759-8753-5-11; Goodier JL, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002941; Guasparri I, 2004, J EXP MED, V199, P993, DOI 10.1084/jem.20031467; Hancks DC, 2012, CURR OPIN GENET DEV, V22, P191, DOI 10.1016/j.gde.2012.02.006; Holland J, 1997, J BIOL CHEM, V272, P9108; HOLMES SE, 1994, NAT GENET, V7, P143, DOI 10.1038/ng0694-143; Honda T, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02537; Honda T, 2016, FRONT CHEM, V4, DOI 10.3389/fchem.2016.00021; JAENISCH R, 1981, CELL, V24, P519, DOI 10.1016/0092-8674(81)90343-3; Katano H, 2000, VIROLOGY, V269, P335, DOI 10.1006/viro.2000.0196; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; Kinomoto M, 2007, NUCLEIC ACIDS RES, V35, P2955, DOI 10.1093/nar/gkm181; Lau CC, 2014, CANCER CELL, V25, P335, DOI 10.1016/j.ccr.2014.01.030; Lawson C, 2009, PHARMACOL REP, V61, P22, DOI 10.1016/S1734-1140(09)70004-0; Li XY, 2013, J BIOL CHEM, V288, P21148, DOI 10.1074/jbc.M113.465856; Matta H, 2004, P NATL ACAD SCI USA, V101, P9399, DOI 10.1073/pnas.0308016101; Matta H, 2003, J BIOL CHEM, V278, P52406, DOI 10.1074/jbc.M307308200; Mesri EA, 2014, CELL HOST MICROBE, V15, P266, DOI 10.1016/j.chom.2014.02.011; MIKI Y, 1992, CANCER RES, V52, P643; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; MOOSLEHNER K, 1991, MOL CELL BIOL, V11, P886, DOI 10.1128/MCB.11.2.886; Muro S, 2003, J CELL SCI, V116, P1599, DOI 10.1242/jcs.00367; Nishikawa Y, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103243; Parravicini C, 2000, AM J PATHOL, V156, P743, DOI 10.1016/S0002-9440(10)64940-1; Punj V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037498; Rad R, 2010, SCIENCE, V330, P1104, DOI 10.1126/science.1193004; Radkov SA, 2000, NAT MED, V6, P1121, DOI 10.1038/80459; Scott EC, 2016, GENOME RES, V26, P745, DOI 10.1101/gr.201814.115; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Shukla R, 2013, CELL, V153, P101, DOI 10.1016/j.cell.2013.02.032; Singer T, 2010, TRENDS NEUROSCI, V33, P345, DOI 10.1016/j.tins.2010.04.001; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Staudt Michelle R., 2003, Current Drug Targets - Infectious Disorders, V3, P129, DOI 10.2174/1568005033481150; Sun Q, 2006, ONCOGENE, V25, P2717, DOI 10.1038/sj.onc.1209298; Sun QM, 2003, J BIOL CHEM, V278, P52437, DOI 10.1074/jbc.M304199200; Swanton C, 1997, NATURE, V390, P184, DOI 10.1038/36606; Xie Y, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkq1076	70	13	13	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2019	38	22					4340	4351		10.1038/s41388-019-0726-5	http://dx.doi.org/10.1038/s41388-019-0726-5			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IA1RB	30770900				2022-12-28	WOS:000469339100010
J	Parzych, K; Saavedra-Garcia, P; Valbuena, GN; Al-Sadah, HA; Robinson, ME; Penfold, L; Kuzeva, DM; Ruiz-Tellez, A; Loaiza, S; Holzmann, V; Caputo, V; Johnson, DC; Kaiser, MF; Karadimitris, A; Lam, EWF; Chevet, E; Feldhahn, N; Keun, HC; Auner, HW				Parzych, Katarzyna; Saavedra-Garcia, Paula; Valbuena, Gabriel N.; Al-Sadah, Hibah A.; Robinson, Mark E.; Penfold, Lucy; Kuzeva, Desislava M.; Ruiz-Tellez, Angie; Loaiza, Sandra; Holzmann, Viktoria; Caputo, Valentina; Johnson, David C.; Kaiser, Martin F.; Karadimitris, Anastasios; Lam, Eric W-F; Chevet, Eric; Feldhahn, Niklas; Keun, Hector C.; Auner, Holger W.			The coordinated action of VCP/p97 and GCN2 regulates cancer cell metabolism and proteostasis during nutrient limitation	ONCOGENE			English	Article							VALOSIN-CONTAINING PROTEIN; AMINO-ACID DEPRIVATION; AAA-ATPASE CDC48/P97; ELEVATED EXPRESSION; EIF2-ALPHA KINASE; INDUCED AUTOPHAGY; P97; STRESS; ER; DEGRADATION	VCP/p97 regulates numerous cellular functions by mediating protein degradation through its segregase activity. Its key role in governing protein homoeostasis has made VCP/p97 an appealing anticancer drug target. Here, we provide evidence that VCP/p97 acts as a regulator of cellular metabolism. We found that VCP/p97 was tied to multiple metabolic processes on the gene expression level in a diverse range of cancer cell lines and in patient-derived multiple myeloma cells. Cellular VCP/p97 dependency to maintain proteostasis was increased under conditions of glucose and glutamine limitation in a range of cancer cell lines from different tissues. Moreover, glutamine depletion led to increased VCP/p97 expression, whereas VCP/p97 inhibition perturbed metabolic processes and intracellular amino acid turnover. GCN2, an amino acid-sensing kinase, attenuated stress signalling and cell death triggered by VCP/p97 inhibition and nutrient shortages and modulated ERK activation, autophagy, and glycolytic metabolite turnover. Together, our data point to an interconnected role of VCP/p97 and GCN2 in maintaining cancer cell metabolic and protein homoeostasis.	[Parzych, Katarzyna; Saavedra-Garcia, Paula; Al-Sadah, Hibah A.; Penfold, Lucy; Kuzeva, Desislava M.; Ruiz-Tellez, Angie; Loaiza, Sandra; Holzmann, Viktoria; Auner, Holger W.] Imperial Coll London, Canc Cell Prot Metab Grp, Dept Med, Ctr Haematol, London, England; [Valbuena, Gabriel N.; Lam, Eric W-F; Keun, Hector C.] Imperial Coll London, Hammersmith Hosp, Div Canc, Dept Surg & Canc, London, England; [Robinson, Mark E.; Caputo, Valentina; Karadimitris, Anastasios; Feldhahn, Niklas] Imperial Coll London, Dept Med, Ctr Haematol, London, England; [Johnson, David C.; Kaiser, Martin F.] Inst Canc Res, Div Mol Pathfol, Sutton, Surrey, England; [Chevet, Eric] Univ Rennes 1, INSERM, U1242, Chem,Oncogenesis,Stress,Signaling, Rennes, France; [Chevet, Eric] Ctr Lutte Canc Eugene Marquis Rennes, Rennes, France	Imperial College London; Imperial College London; Imperial College London; University of London; Institute of Cancer Research - UK; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes	Auner, HW (corresponding author), Imperial Coll London, Canc Cell Prot Metab Grp, Dept Med, Ctr Haematol, London, England.	holger.auner04@imperial.ac.uk	Lam, Eric W-F/AAW-8566-2020	Lam, Eric W-F/0000-0003-1274-3576; Holzmann, Viktoria/0000-0001-5168-1289; Kaiser, Martin/0000-0002-3677-4804; Auner, Holger/0000-0003-4040-0642; Penfold, Lucy/0000-0003-0642-4165; Saavedra, Paula/0000-0002-9907-475X; Robinson, Mark/0000-0003-2363-6047; Valbuena, Gabriel/0000-0001-6825-7214; Kuzeva, Desislava/0000-0002-7616-3012	Cancer Research UK Clinician Scientist Fellowship [C41494/A15448]; British Society for Haematology Early Stage Research Start-up Grant; Imperial College London National Institute of Health Research-Biomedical Research Centre (NIHR-BRC); Imperial College London Cancer Research UK Centre; Imperial College Healthcare Charity 'Dorothy Cave Legacy Fund'; Cancer Research UK [A22544]; Saudi Arabian Cultural Bureau in the UK; MRC [MR/N012097/1] Funding Source: UKRI	Cancer Research UK Clinician Scientist Fellowship(Cancer Research UK); British Society for Haematology Early Stage Research Start-up Grant; Imperial College London National Institute of Health Research-Biomedical Research Centre (NIHR-BRC); Imperial College London Cancer Research UK Centre; Imperial College Healthcare Charity 'Dorothy Cave Legacy Fund'; Cancer Research UK(Cancer Research UK); Saudi Arabian Cultural Bureau in the UK; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by a Cancer Research UK Clinician Scientist Fellowship (C41494/A15448) and a British Society for Haematology Early Stage Research Start-up Grant to HWA. The work was also supported by grants from the Imperial College London National Institute of Health Research-Biomedical Research Centre (NIHR-BRC), the Imperial College London Cancer Research UK Centre, and the Imperial College Healthcare Charity 'Dorothy Cave Legacy Fund' to HWA. HCK acknowledges support by Cancer Research UK (A22544) and the Imperial College London Cancer Research UK Centre. HAAS was supported by an award from the Saudi Arabian Cultural Bureau in the UK. The authors also acknowledge the excellent technical flow cytometry support provided by Miss Carme Ripoll Fiol.	Anderson DJ, 2015, CANCER CELL, V28, P653, DOI 10.1016/j.ccell.2015.10.002; Anthony TG, 2004, J BIOL CHEM, V279, P36553, DOI 10.1074/jbc.M404559200; B'chir W, 2013, NUCLEIC ACIDS RES, V41, P7683, DOI 10.1093/nar/gkt563; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Behrends V, 2011, ANAL BIOCHEM, V415, P206, DOI 10.1016/j.ab.2011.04.009; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Birsoy K, 2014, NATURE, V508, P108, DOI 10.1038/nature13110; Bunpo P, 2009, J BIOL CHEM, V284, P32742, DOI 10.1074/jbc.M109.047910; Cao K, 2003, CELL, V115, P355, DOI 10.1016/S0092-8674(03)00815-8; Carvalho P, 2006, CELL, V126, P361, DOI 10.1016/j.cell.2006.05.043; Castilho BA, 2014, BBA-MOL CELL RES, V1843, P1948, DOI 10.1016/j.bbamcr.2014.04.006; Chou TF, 2011, P NATL ACAD SCI USA, V108, P4834, DOI 10.1073/pnas.1015312108; Clarke HJ, 2014, CANCER CELL, V25, P563, DOI 10.1016/j.ccr.2014.03.015; Csardi G., 2006, INTERJOURNALCOMPLEX, V1695, P1, DOI DOI 10.3724/SP.J.1087.2009.02191; Davidson SM, 2016, CELL METAB, V23, P517, DOI 10.1016/j.cmet.2016.01.007; Defenouillere Q, 2013, P NATL ACAD SCI USA, V110, P5046, DOI 10.1073/pnas.1221724110; Deshaies RJ, 2014, BMC BIOL, V12, DOI 10.1186/s12915-014-0094-0; Dickens NJ, 2010, CLIN CANCER RES, V16, P1856, DOI 10.1158/1078-0432.CCR-09-2831; Fessart D, 2013, CANCER LETT, V337, P26, DOI 10.1016/j.canlet.2013.05.030; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hetz C, 2018, MOL CELL, V69, P169, DOI 10.1016/j.molcel.2017.06.017; HILL JM, 1967, J AMER MED ASSOC, V202, P882, DOI 10.1001/jama.202.9.882; Hirayama A, 2009, CANCER RES, V69, P4918, DOI 10.1158/0008-5472.CAN-08-4806; Huber AL, 2013, MOL CELL, V49, P1049, DOI 10.1016/j.molcel.2013.01.009; Ishimura R, 2016, ELIFE, V5, DOI 10.7554/eLife.14295; Janiesch PC, 2007, NAT CELL BIOL, V9, P379, DOI 10.1038/ncb1554; Ju JS, 2008, J BIOL CHEM, V283, P30289, DOI 10.1074/jbc.M805517200; Kamphorst JJ, 2015, CANCER RES, V75, P544, DOI 10.1158/0008-5472.CAN-14-2211; Kind T, 2009, ANAL CHEM, V81, P10038, DOI 10.1021/ac9019522; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; Le Moigne R, 2017, MOL CANCER THER, V16, P2375, DOI 10.1158/1535-7163.MCT-17-0233; Magnaghi P, 2013, NAT CHEM BIOL, V9, P548, DOI [10.1038/nchembio.1313, 10.1038/NCHEMBIO.1313]; Martin R, 2013, J CELL SCI, V126, P3010, DOI 10.1242/jcs.118067; Meyer H, 2014, J CELL SCI, V127, P3877, DOI 10.1242/jcs.093831; Meyer H, 2012, NAT CELL BIOL, V14, P117, DOI 10.1038/ncb2407; Moreau P, 2012, BLOOD, V120, P947, DOI 10.1182/blood-2012-04-403733; Muaddi H, 2010, MOL BIOL CELL, V21, P3220, DOI 10.1091/mbc.E10-01-0023; Muller JMM, 2007, BIOCHEM BIOPH RES CO, V354, P459, DOI 10.1016/j.bbrc.2006.12.206; NEUMAN RE, 1956, SCIENCE, V124, P124, DOI 10.1126/science.124.3212.124; Pan M, 2016, NAT CELL BIOL, V18, P1090, DOI 10.1038/ncb3410; Parzych K, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.373; PASIEKA AE, 1959, NATURE, V183, P1201, DOI 10.1038/1831201a0; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; Radhakrishnan SK, 2014, ELIFE, V3, DOI [10.7554/elife.01856, 10.7554/eLife.01856]; Ravindran R, 2016, NATURE, V531, P523, DOI 10.1038/nature17186; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; Saito Y, 2015, CELL STEM CELL, V17, P585, DOI 10.1016/j.stem.2015.08.019; Sasagawa Y, 2012, J STRUCT BIOL, V179, P104, DOI 10.1016/j.jsb.2012.06.009; Schmidt EK, 2009, NAT METHODS, V6, P275, DOI [10.1038/NMETH.1314, 10.1038/nmeth.1314]; Sha Z, 2014, CURR BIOL, V24, P1573, DOI 10.1016/j.cub.2014.06.004; Shin S, 2015, MOL CELL, V59, P382, DOI 10.1016/j.molcel.2015.06.020; Skrott Z, 2017, NATURE, V552, P194, DOI 10.1038/nature25016; Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040; Steffen J, 2010, MOL CELL, V40, P147, DOI 10.1016/j.molcel.2010.09.012; Sullivan LB, 2016, NAT REV CANCER, V16, P680, DOI 10.1038/nrc.2016.85; Suraweera A, 2012, MOL CELL, V48, P242, DOI 10.1016/j.molcel.2012.08.003; Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299; Nguyen TV, 2017, P NATL ACAD SCI USA, V114, P3565, DOI 10.1073/pnas.1700949114; Tresse E, 2010, AUTOPHAGY, V6, P217, DOI 10.4161/auto.6.2.11014; Tsujimoto Y, 2004, CLIN CANCER RES, V10, P3007, DOI 10.1158/1078-0432.CCR-03-0191; Uchiyama K, 2006, DEV CELL, V11, P803, DOI 10.1016/j.devcel.2006.10.016; Vabulas RM, 2005, SCIENCE, V310, P1960, DOI 10.1126/science.1121925; Vander Heiden MG, 2017, CELL, V168, DOI 10.1016/j.cell.2016.12.039; Verma R, 2013, ELIFE, V2, DOI 10.7554/eLife.00308; Verma R, 2011, MOL CELL, V41, P82, DOI 10.1016/j.molcel.2010.12.017; Vlahakis A, 2014, P NATL ACAD SCI USA, V111, P10586, DOI 10.1073/pnas.1406305111; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Wang YG, 2013, NEOPLASIA, V15, P989, DOI 10.1593/neo.13262; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; WEK SA, 1995, MOL CELL BIOL, V15, P4497; Wengrod J, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa0899; Wilson GJ, 2015, AM J PHYSIOL-ENDOC M, V308, pE283, DOI 10.1152/ajpendo.00361.2014; Wise DR, 2010, TRENDS BIOCHEM SCI, V35, P427, DOI 10.1016/j.tibs.2010.05.003; Yamamoto S, 2003, J CLIN ONCOL, V21, P2537, DOI 10.1200/JCO.2003.12.102; Yamamoto S, 2003, J CLIN ONCOL, V21, P447, DOI 10.1200/JCO.2003.06.068; Ye JB, 2015, GENE DEV, V29, P2331, DOI 10.1101/gad.269324.115; Ye JB, 2010, EMBO J, V29, P2082, DOI 10.1038/emboj.2010.81; Ye YH, 2003, J CELL BIOL, V162, P71, DOI 10.1083/jcb.200302169; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Ye YH, 2005, P NATL ACAD SCI USA, V102, P14132, DOI 10.1073/pnas.0505006102; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhang PC, 2002, MOL CELL BIOL, V22, P6681, DOI 10.1128/MCB.22.19.6681-6688.2002; Zhou HJ, 2015, J MED CHEM, V58, P9480, DOI 10.1021/acs.jmedchem.5b01346	86	24	25	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2019	38	17					3216	3231		10.1038/s41388-018-0651-z	http://dx.doi.org/10.1038/s41388-018-0651-z			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU8RI	30626938	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000465557200008
J	Xie, YQ; Fan, HY; Lu, WF; Yang, Q; Nurkesh, A; Yeleussizov, T; Maipas, A; Lu, J; Manarbek, L; Chen, ZB; Benassi, E				Xie, Yingqiu; Fan, Haiyan; Lu, Wenfu; Yang, Qing; Nurkesh, Ayan; Yeleussizov, Tleubek; Maipas, Aisulu; Lu, Jiang; Manarbek, Limara; Chen, Zhenbang; Benassi, Enrico			Nuclear MET requires ARF and is inhibited by carbon nanodots through binding to phospho-tyrosine in prostate cancer	ONCOGENE			English	Article							KINASE INHIBITORS; TUMOR-SUPPRESSOR; ERK ACTIVATION; C-MET; RECEPTOR; RESISTANCE; DOTS; KEGG; TRANSACTIVATION; NANOPARTICLES	Nuclear receptor tyrosine kinases (nRTKs) are aberrantly upregulated in many types of cancers, but the regulation of nRTK remains unclear. We previously showed androgen deprivation therapy (ADT) induces nMET in castration-resistant prostate cancer (CRPC) specimens. Through gene expression microarray profiles reanalysis, we identified that nMET signaling requires ARF for CRPC growth in Pten/Trp53 conditional knockout mouse model. Accordingly, aberrant MET/nMET elevation correlates with ARF in human prostate cancer (PCa) specimens. Mechanistically, ARF elevates nMET through binding to MET cytoplasmic domain to stabilize MET. Furthermore, carbon nanodots resensitize cancer cells to MET inhibitors through DNA damage response. The inhibition of phosphorylation by carbon nanodots was identified through binding to phosphate group of phospho-tyrosine via computational calculation and experimental assay. Thus, nMET is essential to precision therapy of MET inhibitor. Our findings reveal for the first time that targeting nMET axis by carbon nanodots can be a novel avenue for overcoming drug resistance in cancers especially prostate cancer.	[Xie, Yingqiu; Nurkesh, Ayan; Yeleussizov, Tleubek; Maipas, Aisulu; Manarbek, Limara] Nazarbayev Univ, Dept Biol, Sch Sci & Technol, Astana 010000, Kazakhstan; [Fan, Haiyan; Benassi, Enrico] Nazarbayev Univ, Dept Chem, Sch Sci & Technol, Astana 010000, Kazakhstan; [Lu, Wenfu; Yang, Qing; Chen, Zhenbang] Meharry Med Coll, Dept Biochem Canc Biol Neurosci & Pharmacol, Nashville, TN 37208 USA; [Lu, Jiang] Shenzhen Univ, Luohu Hosp, Dept Urol, Shenzhen 51800, Peoples R China; [Lu, Jiang] Luohu Hosp Grp, Shenzhen Following Precis Med Res Inst, Shenzhen 51800, Peoples R China	Nazarbayev University; Nazarbayev University; Meharry Medical College; Shenzhen University	Xie, YQ (corresponding author), Nazarbayev Univ, Dept Biol, Sch Sci & Technol, Astana 010000, Kazakhstan.; Chen, ZB (corresponding author), Meharry Med Coll, Dept Biochem Canc Biol Neurosci & Pharmacol, Nashville, TN 37208 USA.	xieautumnus@yahoo.com; zchen@mmc.edu	Xie, Yingqiu/C-5346-2011	Nurkesh, Ayan/0000-0001-6418-8223; Manarbek, Limara/0000-0002-6101-5025	NIH [U54 MD007593, G12 MD007586, R24 DA036420, S10RR0254970, CA091408, MD004038, MD007586, CA163069, UL1 RR02497501, UL1 TR000445-06]; NATIONAL CANCER INSTITUTE [U54CA163069] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [U54MD007586, R01MD004038] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	We would like to thank Drs. Simon W. Hayward and LaMonica Stewart for cell lines, Lynn M. Matrisian for providing MMP7-Luc plasmid. This work was supported in part by NIH grants MD004038, MD007586, CA091408 and CA163069, UL1 RR02497501 and UL1 TR000445-06. IF and IHC analysis was performed by Meharry Medical College Morphology Core, which is supported in part by NIH grants U54 MD007593, G12 MD007586, R24 DA036420, and S10RR0254970. We would like to thank Dr. Guoliang Li, Zhanna Alexeyeva, Aigerim Kabulova, Zhibek Keneskhanova, Akerke Altaikyzy for the kind help or assistant on research. Quantum mechanical calculations were performed on the clusters of the Siberian Supercomputer Center (http://www2.sscc.ru) of the Institute of Computational Mathematics and Mathematical Geophysics of the Siberian Branch of the Russian Academy of Sciences.	Ahn SY, 2017, ANTICANCER RES, V37, P1127, DOI 10.21873/anticanres.11426; Chen WY, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aam6826; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Chen ZB, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000053; Ding HM, 2018, NANOSCALE HORIZ, V3, P6, DOI 10.1039/c7nh00138j; Domingo-Domenech J, 2012, CANCER CELL, V22, P373, DOI 10.1016/j.ccr.2012.07.016; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; Guo ZY, 2006, CANCER CELL, V10, P309, DOI 10.1016/j.ccr.2006.08.021; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huggins C, 1972, CA Cancer J Clin, V22, P232, DOI 10.3322/canjclin.22.4.232; Humbey O, 2008, CANCER RES, V68, P9608, DOI 10.1158/0008-5472.CAN-08-2263; Ji HT, 2009, MOL CELL, V36, P547, DOI 10.1016/j.molcel.2009.09.034; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kanehisa M, 2017, NUCLEIC ACIDS RES, V45, pD353, DOI 10.1093/nar/gkw1092; Kanehisa M, 2016, NUCLEIC ACIDS RES, V44, pD457, DOI 10.1093/nar/gkv1070; Katayama R, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003316; Kaur D, 2011, COMPUT THEOR CHEM, V963, P71, DOI 10.1016/j.comptc.2010.09.011; Khoo CM, 2007, P NATL ACAD SCI USA, V104, P3931, DOI 10.1073/pnas.0700093104; Kim SM, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.48; Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003; Klahn M, 2004, J PHYS CHEM A, V108, P6186, DOI 10.1021/jp048617g; Lachat Y, 2004, ONCOGENE, V23, P6854, DOI 10.1038/sj.onc.1207872; Li CL, 2014, J MATER CHEM B, V2, P4564, DOI 10.1039/c4tb00216d; Likos CN, 2001, PHYS REP, V348, P267, DOI 10.1016/S0370-1573(00)00141-1; Liu ST, 2016, SCI REP-UK, V6, DOI 10.1038/srep37761; Lu WF, 2013, MOL ENDOCRINOL, V27, P635, DOI 10.1210/me.2012-1294; Mizrachi A, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14292; Mudryj M, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.AM2015-5051; Petrushev B, 2016, INT J NANOMED, V11, P641, DOI 10.2147/IJN.S94064; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; Pozner-Moulis S, 2006, CANCER RES, V66, P7976, DOI 10.1158/0008-5472.CAN-05-4335; Song A, 2015, CLIN CANCER RES, V21, P2379, DOI 10.1158/1078-0432.CCR-14-1350; Tu WH, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-556; Vacha R, 2011, NANO LETT, V11, P5391, DOI 10.1021/nl2030213; Verras M, 2007, CANCER RES, V67, P967, DOI 10.1158/0008-5472.CAN-06-3552; Vivo M, 2017, ONCOGENE, V36, P4913, DOI 10.1038/onc.2017.104; Wanjala J, 2015, MOL CANCER THER, V14, P278, DOI 10.1158/1535-7163.MCT-14-0542-T; Xie Y, 2008, J BIOL CHEM, V283, P3349, DOI 10.1074/jbc.M707773200; Xie YQ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16441-y; Xie YQ, 2017, CHEMISTRYSELECT, V2, P4079, DOI 10.1002/slct.201700575; Xie YQ, 2016, ONCOTARGET, V7, P47609, DOI 10.18632/oncotarget.10251; Xie YQ, 2016, CURR CANCER DRUG TAR, V16, P572, DOI 10.2174/1568009616666160105105250; Xie YQ, 2014, MOL ONCOL, V8, P1355, DOI 10.1016/j.molonc.2014.05.006; Xie YQ, 2014, MOL ENDOCRINOL, V28, P1629, DOI 10.1210/me.2014-1078; Xie YQ, 2010, MOL PHARMACOL, V78, P310, DOI 10.1124/mol.109.061713; Yu JX, 2009, EMBO J, V28, P21, DOI 10.1038/emboj.2008.238; Yuan YF, 2017, COLLOID SURFACE B, V159, P349, DOI 10.1016/j.colsurfb.2017.07.030; Zhang M, 2017, CANCER BIOL MED, V14, P212, DOI 10.20892/j.issn.2095-3941.2017.0054	50	7	7	0	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2019	38	16					2967	2983		10.1038/s41388-018-0608-2	http://dx.doi.org/10.1038/s41388-018-0608-2			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU3IV	30568225	Green Accepted, Green Submitted			2022-12-28	WOS:000465167600007
J	Yang, XY; Shen, H; Buckley, B; Chen, YM; Yang, N; Mussell, AL; Chernov, M; Kobzik, L; Frangou, C; Han, SX; Zhang, JM				Yang, Xinyuan; Shen, He; Buckley, Brian; Chen, Yanmin; Yang, Nuo; Mussell, Ashley L.; Chernov, Mikhail; Kobzik, Lester; Frangou, Costa; Han, Su-Xia; Zhang, Jianmin			NTRK1 is a positive regulator of YAP oncogenic function	ONCOGENE			English	Article							NERVE GROWTH-FACTOR; HIPPO PATHWAY; CANCER; PROLIFERATION; INHIBITORS; MOLECULE; COMPLEX; YAP/TAZ; CELLS	Multiple cancer signalling networks take part in regulatory crosstalks with the Hippo tumour suppressor pathway through the transcriptional cofactor Yes-associated protein (YAP). Nevertheless, how YAP is controlled by pathway crosstalks in tumourigenesis remains poorly understood. Here, we performed a targeted kinase inhibitor screen in human cancer cells to identify novel Hippo pathway regulators. Notably, we identified the nerve growth factor (NGF) receptor tyrosine kinase (NTRK1), a molecule not previously associated with Hippo signalling. NTRK1 inhibition decreased YAP-driven transcription, cancer cell proliferation and migration. Furthermore, using a complementary functional genomics approach and mouse xenograft models, we show that NTRK1 regulates YAP oncogenic activity in vivo. Mechanistically, NTRK1 inhibition was found to induce large suppressor kinase 1 (LATS1) phosphorylation and to control YAP subcellular localization. Taken together, these results provide compelling evidence of crosstalks between the NGF-NTRK1 and Hippo cancer pathways.	[Yang, Xinyuan; Han, Su-Xia] Xi An Jiao Tong Univ, Dept Oncol, Affiliated Hosp 1, Coll Med, Xian 710061, Shaanxi, Peoples R China; [Yang, Xinyuan; Shen, He; Chen, Yanmin; Mussell, Ashley L.; Zhang, Jianmin] Roswell Pk Canc Inst, Dept Canc Genet & Genom, Buffalo, NY 14263 USA; [Buckley, Brian; Chernov, Mikhail] Roswell Pk Canc Inst, Small Mol Core, Buffalo, NY 14263 USA; [Yang, Nuo] SUNY Buffalo, Dept Anesthesiol, Jacobs Sch Med & Biomed Sci, Buffalo, NY 14214 USA; [Kobzik, Lester; Frangou, Costa] Harvard TH Chan Sch Publ Hlth, Mol & Integrat Physiol Sci, 665 Huntington Ave, Boston, MA 02115 USA	Xi'an Jiaotong University; Roswell Park Cancer Institute; Roswell Park Cancer Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Harvard University; Harvard T.H. Chan School of Public Health	Han, SX (corresponding author), Xi An Jiao Tong Univ, Dept Oncol, Affiliated Hosp 1, Coll Med, Xian 710061, Shaanxi, Peoples R China.; Zhang, JM (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet & Genom, Buffalo, NY 14263 USA.	shan87@mail.xjtu.edu.cn; Jianmin.zhang@roswellpark.org	Zhang, Jianmin/AAN-2931-2020	Han, Suxia/0000-0002-1513-7427	National Natural Science Foundation of China [81672921]; Innovation Capacity Support Plan of Shaanxi Province [2018TD-002]; Roswell Park Cancer Institute; National Cancer Institute (NCI) [P30 CA016056, R01 CA207]; Roswell Park Alliance Foundation; American Cancer Society [RSG-14-214-01-TBE]; NATIONAL CANCER INSTITUTE [R01CA207504, P30CA016056] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Innovation Capacity Support Plan of Shaanxi Province; Roswell Park Cancer Institute; National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Roswell Park Alliance Foundation; American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Dr. Haber who kindly provided us 293AD cells and Dr. Camargo who kindly provided us the CTGF promoter luciferase reporter construct. Also, we thank the Small Molecule Screen, Flow and Image Cytometry, Laboratory Animal and Experimental Tumour Models Shared Resources/Facilities of RPCI. This work was supported by the National Natural Science Foundation of China 81672921; Innovation Capacity Support Plan of Shaanxi Province, Grant/Award Number: 2018TD-002 (to SH). This work was supported by the Roswell Park Cancer Institute and National Cancer Institute (NCI) Grant #P30 CA016056, Roswell Park Alliance Foundation, National Cancer Institute (NCI) R01 CA207504 and the American Cancer Society Research Scholar Grant RSG-14-214-01-TBE (to JZ).	Aloe L, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0395-y; Arash EH, 2017, EMBO REP, V18, P420, DOI 10.15252/embr.201642455; Arkin MR, 2004, NAT REV DRUG DISCOV, V3, P301, DOI 10.1038/nrd1343; Benito-Gutierrez E, 2006, MOL CELL NEUROSCI, V31, P179, DOI 10.1016/j.mcn.2005.09.007; Descamps S, 2001, CANCER RES, V61, P4337; Descamps S, 2001, J BIOL CHEM, V276, P17864, DOI 10.1074/jbc.M010499200; Fiore M, 2009, REV NEUROSCIENCE, V20, P133; Gibault F, 2017, CHEMMEDCHEM, V12, P954, DOI 10.1002/cmdc.201700063; Harvey K, 2007, NAT REV CANCER, V7, P182, DOI 10.1038/nrc2070; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161; Lange AM, 2018, CANCERS, V10, DOI 10.3390/cancers10040105; Li YW, 2016, CELL CYCLE, V15, P2497, DOI 10.1080/15384101.2016.1207836; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Mello SS, 2017, CANCER CELL, V32, P460, DOI 10.1016/j.ccell.2017.09.007; Mohseni M, 2014, NAT CELL BIOL, V16, P108, DOI 10.1038/ncb2884; Nakagawara A, 2001, CANCER LETT, V169, P107, DOI 10.1016/S0304-3835(01)00530-4; Niederhauser O, 2000, J NEUROSCI RES, V61, P263, DOI 10.1002/1097-4547(20000801)61:3<263::AID-JNR4>3.0.CO;2-M; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035; Song SM, 2018, MOL CANCER THER, V17, P443, DOI 10.1158/1535-7163.MCT-17-0560; Wilson KE, 2014, J BIOL CHEM, V289, P23693, DOI 10.1074/jbc.M113.534701; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zhang JM, 2008, CANCER RES, V68, P2789, DOI 10.1158/0008-5472.CAN-07-6205; Zhang JM, 2009, NAT CELL BIOL, V11, P1444, DOI 10.1038/ncb1993; Zhang Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05856-2; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907	30	12	13	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2019	38	15					2778	2787		10.1038/s41388-018-0609-1	http://dx.doi.org/10.1038/s41388-018-0609-1			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HS8LQ	30542115	Green Accepted			2022-12-28	WOS:000464121600008
J	Zhu, JR; Wu, GY; Ke, ZF; Cao, LX; Tang, ML; Li, ZW; Li, QJ; Zhou, JH; Tan, ZY; Song, LB; Li, J				Zhu, Jinrong; Wu, Geyan; Ke, Zunfu; Cao, Lixue; Tang, Miaoling; Li, Ziwen; Li, Qiaojia; Zhou, Junhao; Tan, Zhanyao; Song, Libing; Li, Jun			Targeting TRIM3 deletion-induced tumor-associated lymphangiogenesis prohibits lymphatic metastasis in esophageal squamous cell carcinoma	ONCOGENE			English	Article							NF-KAPPA-B; ACTININ 4 ACTN4; CANCER PROGRESSION; PROGNOSTIC MARKER; C PROMOTES; ALPHA; GROWTH; ENHANCER; SUBUNIT	Tumor-associated lymphangiogenesis has attracted increasing attention because of its potential contribution to lymph node metastasis. However, the molecular mechanisms underlying lymphangiogenesis in cancer remains elusive. In the current study, we demonstrate that tripartite motif-containing 3 (TRIM3) directly interacts with and induces E3 ligase-dependent proteasomal turnover of importin alpha 3 and alpha-Actinin-4 (ACTN4), which controls nuclear factor kappa B (NF-kappa B) activity at a well-ordered level. Heterozygous deletion-mediated TRIM3 downregulation led to NF-kappa B constitutive activation through disruption of the NF-kappa B-I kappa B-alpha negative feedback loop and enhancement of the p65 DNA-binding affinity and transcriptional activity via promoting symmetrical dimethylarginine modification of NF-kappa B/p65 at Arg30 and Arg35, which consequently promoted lymphatic metastasis of esophageal squamous cell carcinoma (ESCC) cells. Treatment with Tecfidera, a medication used to treat multiple sclerosis, restored the negative feedback inhibition of NF-kappa B by reducing the NF-kappa B/ACTN4 interaction and decreasing symmetrically dimethylated NF-kappa B levels, resulting in inhibition of ESCC lymphatic metastasis both in vitro and in vivo. Taken together, our results uncover a novel mechanism for constitutive NF-kappa B activation in cancer and may represent an attractive strategy to treat ESCC lymphatic metastasis.	[Zhu, Jinrong; Wu, Geyan; Cao, Lixue; Li, Ziwen; Li, Qiaojia; Zhou, Junhao; Tan, Zhanyao; Li, Jun] Sun Yat Sen Univ, Key Lab Liver Dis Guangdong Prov, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China; [Zhu, Jinrong; Tang, Miaoling; Li, Jun] Sun Yat Sen Univ, Dept Biochem, Zhongshan Sch Med, Guangzhou, Guangdong, Peoples R China; [Wu, Geyan; Song, Libing] Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Ctr Canc, Guangzhou, Guangdong, Peoples R China; [Ke, Zunfu] Sun Yat Sen Univ, Dept Pathol, Affiliated Hosp 1, Guangzhou 510060, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University	Li, J (corresponding author), Sun Yat Sen Univ, Key Lab Liver Dis Guangdong Prov, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China.; Li, J (corresponding author), Sun Yat Sen Univ, Dept Biochem, Zhongshan Sch Med, Guangzhou, Guangdong, Peoples R China.	lijun37@mail.sysu.edu.cn	wu, ge/ABE-3285-2020; Cao, Lixue/AAM-9316-2020; Song, LB/AAL-1968-2020	Cao, Lixue/0000-0002-0486-6587; 	Natural Science Foundation of China [81830082, 91740119, 91529301, 81621004, 91740118, 81773106, 81530082]; Guangzhou Science and Technology Plan Projects [201803010098]; Natural Science Foundation of Guangdong Province [2018B030311009, 2016A030308002]; Fundamental Research Funds for the Central Universities [17ykjc02]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangzhou Science and Technology Plan Projects; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This work was supported by Natural Science Foundation of China (No. 81830082, 91740119, 91529301, 81621004, 91740118, 81773106 and 81530082); Guangzhou Science and Technology Plan Projects (201803010098); Natural Science Foundation of Guangdong Province (2018B030311009 and 2016A030308002); The Fundamental Research Funds for the Central Universities [No. 17ykjc02].	Agarwal N, 2013, ONCOGENE, V32, P462, DOI 10.1038/onc.2012.69; Aksenova V, 2013, ONCOTARGET, V4, P362, DOI 10.18632/oncotarget.901; Alitalo K, 2005, NATURE, V438, P946, DOI 10.1038/nature04480; An HT, 2014, J BIOL CHEM, V289, P4969, DOI 10.1074/jbc.M113.515395; [Anonymous], 2011, Nat Rev Drug Discov, V10, P404, DOI 10.1038/nrd3465; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; Baud V, 2009, NAT REV DRUG DISCOV, V8, P33, DOI 10.1038/nrd2781; Boulay JL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-71; Carlotti F, 2000, J BIOL CHEM, V275, P41028, DOI 10.1074/jbc.M006179200; Chakraborty S, 2006, J BIOL CHEM, V281, P35070, DOI 10.1074/jbc.M602474200; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Deng W, 2004, ONCOGENE, V23, P9090, DOI 10.1038/sj.onc.1208119; Diaz GM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26519-w; Dieterich LC, 2016, ADV DRUG DELIVER REV, V99, P148, DOI 10.1016/j.addr.2015.12.011; El-Husseini AE, 2001, GENOMICS, V71, P363, DOI 10.1006/geno.2000.6452; Feng YK, 2011, EUR J CANCER, V47, P2353, DOI 10.1016/j.ejca.2011.05.006; Girard C, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1998; He W, 2018, J CLIN INVEST, V128, P861, DOI 10.1172/JCI96218; Hirakawa S, 2007, BLOOD, V109, P1010, DOI 10.1182/blood-2006-05-021758; Hirakawa S, 2011, J DERMATOL SCI, V61, P85, DOI 10.1016/j.jdermsci.2010.11.020; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Karpanen T, 2001, CANCER RES, V61, P1786; Kastrati I, 2016, J BIOL CHEM, V291, P3639, DOI 10.1074/jbc.M115.679704; Khurana S, 2012, J BIOL CHEM, V287, P35418, DOI 10.1074/jbc.M112.401364; Khurana S, 2011, J BIOL CHEM, V286, P1850, DOI 10.1074/jbc.M110.162107; Kumagai Y, 2018, DIS ESOPHAGUS, V31, P1, DOI DOI 10.1093/DOTE/DOY052/5036207; Lam CT, 2002, CANCER LETT, V178, P75, DOI 10.1016/S0304-3835(01)00814-X; Li F, 2010, BBA-REV CANCER, V1805, P167, DOI 10.1016/j.bbcan.2010.01.002; Li J, 2008, CLIN CANCER RES, V14, P3319, DOI 10.1158/1078-0432.CCR-07-4054; Lin C, 2015, ONCOGENE, V34, P332, DOI 10.1038/onc.2013.559; Liu PF, 2011, CYTOKINE, V55, P8, DOI 10.1016/j.cyto.2011.03.008; Lu T, 2015, CANCER RES, V75, P3692, DOI 10.1158/0008-5472.CAN-15-1022; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Moskaluk CA, 1998, CANCER, V83, P232, DOI 10.1002/(SICI)1097-0142(19980715)83:2<232::AID-CNCR5>3.3.CO;2-G; Mukherjee S, 2016, CANCER RES, V76, P2443, DOI 10.1158/0008-5472.CAN-15-2299; Nicolay JP, 2016, BLOOD, V128, P805, DOI 10.1182/blood-2016-01-694117; Peng HY, 2012, J BIOL CHEM, V287, P28017, DOI 10.1074/jbc.M112.383380; Ribatti D, 2018, CURR OPIN IMMUNOL, V53, P161, DOI 10.1016/j.coi.2018.04.027; Saad RS, 2009, AM J CLIN PATHOL, V131, P92, DOI 10.1309/AJCPKWUQSIPVG90H; Schoppmann SF, 2013, SURGERY, V153, P526, DOI 10.1016/j.surg.2012.10.007; Schreiber J, 2015, J CELL BIOL, V211, P569, DOI 10.1083/jcb.201506048; Smith MD, 2018, EUR J IMMUNOL, V48, P380, DOI 10.1002/eji.201747277; Stacker SA, 2014, NAT REV CANCER, V14, P159, DOI 10.1038/nrc3677; Su CH, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-85; Wei H, 2013, P NATL ACAD SCI USA, V110, P13516, DOI 10.1073/pnas.1311784110; Yan Q, 2005, MOL BIOL CELL, V16, P2470, DOI 10.1091/mbc.e04-11-1014; Zhao X, 2017, J BIOL CHEM, V292, P1637, DOI 10.1074/jbc.M116.755546; Zhao X, 2015, J BIOL CHEM, V290, P338, DOI 10.1074/jbc.M114.597260	48	13	13	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2019	38	15					2736	2749		10.1038/s41388-018-0621-5	http://dx.doi.org/10.1038/s41388-018-0621-5			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HS8LQ	30542119				2022-12-28	WOS:000464121600005
